FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Yu, WB
   Xiao, X
   Zhang, JL
   Li, ZF
   Wang, XH
   Tang, FB
   Jiang, XB
   Zhong, YM
AF Yu, Weibo
   Xiao, Xiang
   Zhang, Jiali
   Li, Zhifei
   Wang, Xiaohu
   Tang, Fubo
   Jiang, Xiaobing
   Zhong, Yuanming
TI Cement Distribution Patterns in Osteoporotic Vertebral Compression
   Fractures with Intravertebral Cleft: Effect on Therapeutic Efficacy
SO WORLD NEUROSURGERY
LA English
DT Article
DE Osteoporotic fractures; Relative risk; Treatment outcome; Vertebroplasty
ID VACUUM CLEFT; PERCUTANEOUS VERTEBROPLASTY; BALLOON KYPHOPLASTY;
   KUMMELLS-DISEASE; RISK-FACTORS; SIGN; OSTEONECROSIS; RECOMPRESSION;
   RECOLLAPSE; NECROSIS
AB OBJECTIVE: To determine cement distribution patterns on therapeutic efficacy after percutaneous vertebroplasty treatment of osteoporotic vertebral compression fractures (OVCFs) with intravertebral cleft (IVC).
   METHODS: Patients who were treated with percutaneous vertebroplasty for single OVCFs with IVC and met this study's inclusion criteria were retrospectively reviewed. The follow-up period was at least 2 years. Distribution patterns of cement in the IVC area were respectively specified into 2 groups: group 1: solid lump distribution pattern (n = 22); group 2: the comparatively diffused pattern (n = 90). Radiologic and clinical parameters were analyzed and compared. Then, associations of recollapse with covariates and a risk score were further analyzed and developed to predict recollapse of the augmented vertebrae.
   RESULTS: At the immediate postoperative period, all patients benefited from significant improvement in vertebrae height and kyphotic angle correction. However, significant recollapse was observed at the 2 years postoperative follow-up for the patients in group 1. Furthermore, we found that preoperative severe kyphotic deformity (a cutoff value of 12.5 degrees), solid lump cement distribution pattern, and larger reduction angle (a cutoff value of 8.3 degrees) was significantly associated with increased risk for recollapse. A risk score was developed based on the number of risk factors present in each patient and the receiver operating characteristic curve of the risk score generated an area under the curve of 0.788 (95% confidence interval 0.702-0.873, P = 0.000).
   CONCLUSIONS: The comparatively diffused pattern shows better long-term radiologic and clinical outcomes for the treatment for OVCFs with IVC. A risk score can be used to predict the incidence of recollapse.
C1 [Yu, Weibo; Zhang, Jiali; Li, Zhifei; Wang, Xiaohu; Tang, Fubo; Zhong, Yuanming] Guangxi Univ Chinese Med, Affiliated Hosp 1, Nanning, Guangxi, Peoples R China.
   [Jiang, Xiaobing] Guangzhou Univ Chinese Med, Affiliated Hosp 1, Guangzhou, Guangdong, Peoples R China.
   [Xiao, Xiang] Guangxi Univ Chinese Med, Higher Vocat Technol Coll, Nanning, Guangxi, Peoples R China.
RP Zhong, YM (reprint author), Guangxi Univ Chinese Med, Affiliated Hosp 1, Nanning, Guangxi, Peoples R China.
EM yuweibo0530@163.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [81804113]
FX The authors gratefully acknowledge support from National Natural Science
   Foundation of China (81804113).
CR Becker S, 2008, J Orthop Surg (Hong Kong), V16, P14
   Brown DB, 2004, AM J ROENTGENOL, V182, P319, DOI 10.2214/ajr.182.2.1820319
   Chen YJ, 2012, EUR J RADIOL, V81, P558, DOI 10.1016/j.ejrad.2011.02.034
   Fang XT, 2015, INT J CLIN EXP MED, V8, P16960
   Ha KY, 2013, OSTEOPOROSIS INT, V24, P1207, DOI 10.1007/s00198-012-2065-z
   Heo DH, 2009, OSTEOPOROSIS INT, V20, P473, DOI 10.1007/s00198-008-0682-3
   Ito Yasuo, 2002, Spine J, V2, P101, DOI 10.1016/S1529-9430(01)00165-6
   Jang JS, 2003, SPINE, V28, P1588, DOI 10.1097/00007632-200307150-00021
   Johnell O, 2006, OSTEOPOROSIS INT, V17, P1726, DOI 10.1007/s00198-006-0172-4
   Kang SK, 2011, ANN REHABIL MED-ARM, V35, P844, DOI 10.5535/arm.2011.35.6.844
   Kim DY, 2004, J NEUROSURG, V100, P24, DOI 10.3171/spi.2004.100.1.0024
   Kim MJ, 2006, SPINE, V31, P2079, DOI 10.1097/01.brs.0000231714.15876.76
   Kim YY, 2010, EUR SPINE J, V19, P1907, DOI 10.1007/s00586-010-1479-6
   KungChia L, 2004, J MUSCULOSKELET RES, V8, P43, DOI DOI 10.1142/S0218957704001181
   Libicher M, 2007, EUR RADIOL, V17, P2248, DOI 10.1007/s00330-007-0684-0
   Lin WC, 2010, EUR SPINE J, V19, P1899, DOI 10.1007/s00586-010-1434-6
   Linn J, 2009, SPINE, V34, pE88, DOI 10.1097/BRS.0b013e318193ca06
   MALDAGUE BE, 1978, RADIOLOGY, V129, P23, DOI 10.1148/129.1.23
   MALGHEM J, 1993, RADIOLOGY, V187, P483, DOI 10.1148/radiology.187.2.8475295
   Matzaroglou C, 2013, MED HYPOTHESES, V80, P505, DOI 10.1016/j.mehy.2012.12.003
   McKiernan F, 2003, J BONE MINER RES, V18, P24, DOI 10.1359/jbmr.2003.18.1.24
   Niu JJ, 2015, ACTA RADIOL, V56, P1380, DOI 10.1177/0284185114556016
   RATCLIFFE JF, 1980, J ANAT, V131, P57
   Sarli M, 2005, OSTEOPOROSIS INT, V16, P1210, DOI 10.1007/s00198-005-1833-4
   Sasaki Y, 2013, CASE REP ORTHOP, V2013
   Yang Huilin, 2010, Orthopedics, V33, P479, DOI 10.3928/01477447-20100526-07
   Yu CW, 2007, AM J NEURORADIOL, V28, P42
   Yu Weibo, 2017, Pain Physician, V20, pE979
   Yu WB, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000005675
   Zhang GQ, 2015, INDIAN J ORTHOP, V49, P577, DOI 10.4103/0019-5413.168752
NR 30
TC 1
Z9 1
U1 2
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP E408
EP E415
DI 10.1016/j.wneu.2018.11.181
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400047
PM 30503288
DA 2020-05-12
ER

PT J
AU Yu, ZY
   Zheng, J
   Ma, L
   Guo, R
   You, C
   Li, H
AF Yu, Zhiyuan
   Zheng, Jun
   Ma, Lu
   Guo, Rui
   You, Chao
   Li, Hao
TI Predictive Validity of Hypodensities on Noncontrast Computed Tomography
   for Hematoma Growth in Intracerebral Hemorrhage: a Meta-Analysis
SO WORLD NEUROSURGERY
LA English
DT Article
DE Computed tomography; Hematoma growth; Hypodensities; Intracerebral
   hemorrhage
ID SPOT SIGN; EXPANSION; CT; DENSITY; BRAIN
AB OBJECTIVE: Intracerebral hemorrhage (ICH) is a type of stroke that leads to high mortality. Hematoma growth (HG) happens in about one third of all patients with ICH and is independently related to poor outcome. Previous studies have shown that an indicator on noncontrast computed tomography, called hypodensities, can predict HG in patients with ICH. Thus, this study was done to assess the predictive validity of this marker.
   METHODS: Bibliographic databases were searched, without language restriction, for original investigation on hypodensities and HG in ICH. Data were extracted, and study quality was assessed by 2 reviewers independently. Pooled sensitivity, specificity, positive likelihood ratio (LR), negative LR, diagnostic odds ratio, and their 95% confidence intervals (CIs) were obtained. A summary receiver operating characteristic curve was depicted.
   RESULTS: Five cohorts with 2157 patients in 4 studies were included in the present meta-analysis. The pooled sensitivity was 0.58 (95% CI 0.46-0.68) and the pooled specificity was 0.71 (95% CI 0.62-0.79). In addition, the pooled positive LR was 2.0 (95% CI 1.6-2.5) and the pooled negative LR was 0.60 (95% CI 0.49-0.73). The pooled diagnostic odds ratio was 3 (95% CI 2-5) and the area under summary receiver operating characteristic curve was 0.69 (95% CI 0.65-0.73).
   CONCLUSIONS: This study suggests that hypodensities on noncontrast computed tomography can be helpful in HG prediction, although its pooled predictive values are not very satisfying in the current study. The role of hypodensities in predicting HG should be confirmed by further studies.
C1 [Yu, Zhiyuan; Zheng, Jun; Ma, Lu; Guo, Rui; You, Chao; Li, Hao] Sichuan Univ, West China Hosp, Dept Neurosurg, Chengdu, Sichuan, Peoples R China.
RP Li, H (reprint author), Sichuan Univ, West China Hosp, Dept Neurosurg, Chengdu, Sichuan, Peoples R China.
EM ns_lihao@126.com
FU Outstanding Subject Development 135 Project of West China Hospital,
   Sichuan University [ZY2016102]
FX This work was supported by Outstanding Subject Development 135 Project
   of West China Hospital, Sichuan University [grant number ZY2016102].
CR Barras CD, 2009, STROKE, V40, P1325, DOI 10.1161/STROKEAHA.108.536888
   Boulouis G, 2016, STROKE, V47, P2511, DOI 10.1161/STROKEAHA.116.014425
   Boulouis G, 2016, JAMA NEUROL, V73, P961, DOI 10.1001/jamaneurol.2016.1218
   Brouwers HB, 2014, JAMA NEUROL, V71, P158, DOI 10.1001/jamaneurol.2013.5433
   Brouwers HB, 2013, CEREBROVASC DIS, V35, P195, DOI 10.1159/000346599
   Chang JJ, 2018, ATHEROSCLEROSIS, V269, P14, DOI 10.1016/j.atherosclerosis.2017.12.008
   Fu F, 2018, EUR RADIOL, V28, P4343, DOI 10.1007/s00330-018-5415-1
   Li Q, 2017, STROKE, V48, P3019, DOI 10.1161/STROKEAHA.117.017985
   Li Q, 2016, STROKE, V47, P1777, DOI 10.1161/STROKEAHA.116.013186
   Li Q, 2015, STROKE, V46, P2119, DOI 10.1161/STROKEAHA.115.009185
   Miyahara M, 2018, J STROKE CEREBROVASC, V27, P2543, DOI 10.1016/j.jstrokecerebrovasdis.2018.05.018
   Morotti A, 2018, STROKE, V49, P1163, DOI 10.1161/STROKEAHA.117.020138
   Morotti A, 2017, NEUROLOGY, V89, P548, DOI 10.1212/WNL.0000000000004210
   Morotti A, 2016, STROKE, V47, P1473, DOI 10.1161/STROKEAHA.116.013176
   Qureshi AI, 2016, NEW ENGL J MED, V375, P1033, DOI 10.1056/NEJMoa1603460
   Qureshi AI, 2009, LANCET, V373, P1632, DOI 10.1016/S0140-6736(09)60371-8
   Sprigg N, 2018, LANCET, V391, P2107, DOI 10.1016/S0140-6736(18)31033-X
   Takeda R, 2013, CLIN NEUROL NEUROSUR, V115, P1028, DOI 10.1016/j.clineuro.2012.10.016
   VanDerWerf J, 2018, NEUROCRIT CARE, V29, P40, DOI 10.1007/s12028-018-0507-y
   Wada R, 2007, STROKE, V38, P1257, DOI 10.1161/01.STR.0000259633.59404.f3
   Wang X, 2015, STROKE, V46, P376, DOI 10.1161/STROKEAHA.114.006910
   Xu XH, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000011945
   Yu ZY, 2017, CLIN NEUROL NEUROSUR, V162, P67, DOI 10.1016/j.clineuro.2017.09.008
   Yu ZY, 2017, J NEUROL SCI, V379, P44, DOI 10.1016/j.jns.2017.05.049
   Zhang YB, 2018, WORLD NEUROSURG, V118, pE500, DOI 10.1016/j.wneu.2018.06.223
NR 25
TC 3
Z9 3
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP E639
EP E645
DI 10.1016/j.wneu.2018.11.239
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400075
PM 30554002
DA 2020-05-12
ER

PT J
AU Zheng, CS
   Le, JJ
   Zeng, G
   Wei, Y
   Sun, JC
   Hong, JM
   Li, CH
AF Zheng, Chaoshun
   Le, Jiajun
   Zeng, Gang
   Wei Ye
   Sun, Jianchao
   Hong, Junmin
   Li, Chunhai
TI Development of a Virtual Reality Preoperative Planning System for
   Postlateral Endoscopic Lumbar Discectomy Surgery and Its Clinical
   Application
SO WORLD NEUROSURGERY
LA English
DT Article
DE Computed tomography; Disc herniation; Percutaneous endoscopic lumbar
   discectomy; Preoperative planning; Puncture accuracy; Virtual reality
ID AUGMENTED REALITY; DISC; RADIATION; PATIENT
AB OBJECTIVE: Percutaneous endoscopic lumbar discectomy is an effective way to treat lumbar disc herniation. Traditional preoperative planning based on a 2-dimensional method by magnetic resonance/computed tomography may cause inaccuracy of puncture during surgery. We used virtual reality to stimulate a surgery environment and measured relevant 3-dimensional data. We then explored its applicability for increasing puncture accuracy during actual surgeries.
   METHODS: A prospective randomized trial of lumbar disc herniation was conducted. Both conventional and virtual reality methods were used for preoperative planning and relevant data (planned puncture point and entry angle) were measured. Data were used during surgery and adjusted to complete the operation. The final entry point and entry angle were recorded and compared with relevant planned data statistically. Fluoroscopic times and location time also were included to access the puncture accuracy during surgery.
   RESULTS: Thirty cases were included in our study. Both groups achieved good results after surgery, except for 1 case of postoperative dysesthesia in the traditional planning group and 1 case of residual disc in the virtual reality group. The use of virtual reality can predict a surgeryrelated angle and distance accurately except for depth. Compared with the traditional planning group, the fluoroscopic time (13.18 +/- 4.191 vs. 32.00 +/- 4.52) and location time (17.91 +/- 4.74 vs. 33.22 +/- 3.90) were statistically different, which indicates that this method can increase puncture accuracy.
   CONCLUSIONS: A virtual reality planning system is an accurate preoperative planning method that can significantly improve the puncture accuracy of percutaneous endoscopic lumbar discectomy and reduce fluoroscopic and location times.
C1 [Zheng, Chaoshun; Zeng, Gang; Wei Ye; Sun, Jianchao; Hong, Junmin; Li, Chunhai] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Orthoped, Guangzhou, Guangdong, Peoples R China.
   [Le, Jiajun] Northeastern Univ, Sino Dutch Biomed & Informat Engn Sch, Shenyang, Liaoning, Peoples R China.
RP Li, CH (reprint author), Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Orthoped, Guangzhou, Guangdong, Peoples R China.
EM chunhaili@163.com
CR Abe Y, 2013, J NEUROSURG-SPINE, V19, P492, DOI 10.3171/2013.7.SPINE12917
   Alaraj A, 2013, NEUROSURGERY, V72, pA115, DOI 10.1227/NEU.0b013e3182753093
   Brenner DJ, 2003, P NATL ACAD SCI USA, V100, P13761, DOI 10.1073/pnas.2235592100
   Chen HL, 2015, MED SCI MONITOR, V21, P3948, DOI 10.12659/MSM.895597
   Choi G, 2010, MINIM INVAS NEUROSUR, V53, P147, DOI 10.1055/s-0030-1254145
   Choi KC, 2016, PAIN PHYSICIAN, V19, pE301
   Choi KC, 2015, NEUROSURGERY, V76, P372, DOI 10.1227/NEU.0000000000000628
   Farber M, 2009, METHOD INFORM MED, V48, P493, DOI 10.3414/ME0566
   Fan GX, 2017, INT ORTHOP, V41, P323, DOI 10.1007/s00264-016-3281-5
   Gautschi OP, 2016, CLIN NEUROL NEUROSUR, V150, P33, DOI 10.1016/j.clineuro.2016.08.024
   Gun C, 2009, SPINE, V34, P443
   Hurday Y, 2017, EUR SPINE J, V26, P635, DOI 10.1007/s00586-016-4454-z
   Iprenburg M, 2016, NEUROSURG FOCUS, V40, DOI 10.3171/2015.11.FOCUS15485
   Koerner JD, 2015, CLIN ORTHOP RELAT R, V473, P2000, DOI 10.1007/s11999-014-3671-1
   Mroz TE, 2008, J SPINAL DISORD TECH, V21, P96, DOI 10.1097/BSD.0b013e31805fe9e1
   Mroz TE, 2011, J SPINAL DISORD TECH, V24, P264, DOI 10.1097/BSD.0b013e3181eed618
   Osman SG, 2014, INT J SPINE SURG, V8, DOI 10.14444/1020
   Pfeiffer FM, 2016, J KNEE SURG, V29, P149, DOI 10.1055/s-0035-1570114
   Provaggi E, 2017, P I MECH ENG H, V231, P471, DOI 10.1177/0954411916667761
   Satava RM, 1998, P IEEE, V86, P484, DOI 10.1109/5.662873
   Sheng-Hua HE, 2011, CHINA J ORTHOP TRAUM, V24, P72
NR 21
TC 3
Z9 3
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP E1
EP E8
DI 10.1016/j.wneu.2018.08.082
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400002
PM 30144600
DA 2020-05-12
ER

PT J
AU Zhou, J
   Wang, YL
   Wang, DF
   Chen, QF
   Wang, HC
   Gao, L
AF Zhou, Jiang
   Wang, Yanlong
   Wang, Dongfeng
   Chen, Qifeng
   Wang, Hongcai
   Gao, Liang
TI Endovascular Treatment for Ruptured Aneurysms at Distal Cerebral
   Arteries
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cerebral aneurysm; Distal artery; Endovascular treatment; Rupture
ID MANAGEMENT; EFFICACY; SAFETY
AB OBJECTIVE: To evaluate the feasibility and efficacy of endovascular treatment for ruptured aneurysms at distal cerebral arteries.
   METHODS: A total of 30 ruptured aneurysms at distal cerebral arteries in 30 patients received endovascular treatment (EVT). Distal cerebral arteries were defined as arteries distal to the A2 or M2 segmentations in the anterior circulation, distal to the P2 segmentation in the posterior circulation, or other small branches or perforating arteries. Aneurysm occlusion was assessed using Raymond classification immediately after the procedure and during angiographic follow-up. Clinical follow-up data were retrospectively analyzed and categorized using the modified Rankin scale (MRS).
   RESULTS: Thirty aneurysms were classified as distal anterior circulation in 17 aneurysms and posterior circulation in 13 aneurysms. EVT technically succeeded in all 30 (100%) aneurysms, with stent assistance in 1 aneurysm and coiling only in 29. Aneurysm sac coiling was done in 25 aneurysms, whereas parent artery occlusion was done in 5 aneurysms. Raymond I occlusion were immediately achieved in 19 of 30 (63.3%) aneurysms. Complications occurred in 1 patient because of aneurysm rupture. Angiographic and clinical follow-up data were obtained from 28 patients. Follow-up angiography (mean, 10.14 +/- 5.31 months) revealed Raymond I classification in 22 aneurysms (78.6%). At the end of clinical follow-up (mean, 11.89 +/- 5.07 months), clinical monitoring using the MRS showed a score of 0 in 18 patients, score of 1 in 5 patients, score of 2 in 2 patients, score of 3 in 2 patients, and score of 4 in 1 patient.
   CONCLUSIONS: EVT is a feasible and effective therapy to treat ruptured aneurysms located at distal cerebral arteries.
C1 [Zhou, Jiang; Gao, Liang] Shanghai Tong Ji Univ, Dept Neurosurg, Affiliated Peoples Hosp 10, Shanghai, Peoples R China.
   [Wang, Yanlong] Ningbo Yinzhou 2 Hosp, Dept Neurosurg, Ningbo, Zhejiang, Peoples R China.
   [Wang, Dongfeng; Chen, Qifeng; Wang, Hongcai] Lihuili Hosp, Dept Neurosurg, Ningbo City Med Treatment Ctr, Ningbo, Zhejiang, Peoples R China.
RP Gao, L (reprint author), Shanghai Tong Ji Univ, Dept Neurosurg, Affiliated Peoples Hosp 10, Shanghai, Peoples R China.
EM gaoliang_neurosurgery@hotmail.com
CR Brisman JL, 2005, NEUROSURGERY, V57, P1103, DOI 10.1227/01.NEU.0000185631.20246.1A
   Chalouhi N, 2013, J NEUROSURG, V118, P991, DOI 10.3171/2012.12.JNS121240
   Gallas S, 2005, AM J NEURORADIOL, V26, P1723
   Hui FK, 2011, J NEUROINTERV SURG, V3, P319, DOI 10.1136/jnis.2011.004770
   Husain S, 2017, WORLD NEUROSURG, V107, P588, DOI 10.1016/j.wneu.2017.08.005
   Keston P, 2004, J NEURORADIOLOGY, V31, P384, DOI 10.1016/S0150-9861(04)97021-6
   Li MH, 2006, AM J NEURORADIOL, V27, P1107
   Nievas MNCY, 2010, NEUROL RES, V32, P73, DOI 10.1179/016164110X12556180205951
   Petr O, 2017, WORLD NEUROSURG, V100, P557, DOI 10.1016/j.wneu.2016.11.134
   Petr O, 2016, ACTA NEUROCHIR, V158, P2415, DOI 10.1007/s00701-016-2965-3
   de Aguiar PHP, 2017, TURK NEUROSURG, V27, P725, DOI 10.5137/1019-5149.JTN.17412-16.2
   Rodriguez-Hernandez A, 2013, WORLD NEUROSURG, V80, P103, DOI 10.1016/j.wneu.2012.09.010
   Sturiale CL, 2013, AM J NEURORADIOL, V34, P2317, DOI 10.3174/ajnr.A3629
NR 13
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP E387
EP E392
DI 10.1016/j.wneu.2018.11.178
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400045
PM 30500584
DA 2020-05-12
ER

PT J
AU Zhou, JK
   Zhang, QS
   Chen, YQ
   Li, M
   Xie, Y
   Ke, JJ
   Lin, HZ
   Zhang, YW
AF Zhou, Jin-Kui
   Zhang, Qi-Shuo
   Chen, Yu-Qiang
   Li, Mu
   Xie, Yang
   Ke, Jia-Jie
   Lin, Huan-Zhang
   Zhang, Yao-Wei
TI Use of Hematocrit for Short-Term Prognosis of Patients with Traumatic
   Brain Injury After Decompressive Craniectomy
SO WORLD NEUROSURGERY
LA English
DT Article
DE Decompressive craniectomy; Hematocrit; Prognosis; Traumatic brain injury
ID INTERNATIONAL MISSION; COMPUTED-TOMOGRAPHY; CLINICAL-TRIALS;
   TRANSFUSION; MANAGEMENT; SURGERY; MODELS; ANEMIA; SCORE
AB OBJECTIVE: To discuss the effects of the hematocrit (Hct) in patients with traumatic brain injury after decompressive craniectomy (DC).
   METHODS: Demographic data, inspection and treatment procedures, and 30-day prognosis were obtained for 158 patients with head injury who underwent unilateral DC in our hospital between January 2013 and June 2018. Uni- and multivariate logistic regression was applied to analyze independent risk factors for 30-day outcome. The quantitative analysis of postoperative Hct, DHct (postoperative Hct minus initial Hct), and their combination for the prognosis of patients with TBI was displayed graphically using receiver operating characteristic (ROC) curves. Multiple linear regression was used to explore factors influencing postoperative Hct and Delta Hct.
   RESULTS: Short-term mortality was 29.7%. Uni- and multivariate logistic regression analysis showed that age (odds ratio [OR], 1.064; P = 0.024), Glasgow Coma Scale score (OR, 0.711; P = 0.027), Injury Severity Score (ISS) (OR, 1.156; P = 0.047), midline shift in millimeters (OR, 1.809; P < 0.001), postoperative Hct (OR, 0.743; P = 0.001), and Delta Hct (OR, 1.242; P = 0.048) were independent risk factors for short-term death. In ROC curves, a combination of postoperative Hct and Delta Hct showed the highest sensitivity (77.5%) and highest specificity (89.4%). When using this combination to predict prognosis, we could achieve an accuracy of 94.5%. ISS (beta = -0.172, P = 0.022), initial Hct (beta = 0.243, P = 0.001), principal hematoma location (beta = -2.628, P < 0.001), hours of operation (b = -0.884, P = 0.048), and colloid quantity (beta = -0.002, P = 0.001) were independent contributing factors for Delta Hct, which was similar to postoperative Hct.
   CONCLUSIONS: A combination of postoperative Hct and Delta Hct could better predict short-term survival of patients with TBI. Developing an appropriate treatment strategy to increase postoperative Hct and reduce the Delta Hct may be good for the short-term prognosis of patients with TBI after DC.
C1 [Zhou, Jin-Kui; Zhang, Qi-Shuo; Chen, Yu-Qiang; Xie, Yang; Ke, Jia-Jie; Zhang, Yao-Wei] Shantou Univ, Med Coll, Affiliated Hosp 2, Dept Emergency, Shantou, Guangdong, Peoples R China.
   [Li, Mu] Shantou Univ, Med Coll, Affiliated Hosp 2, Dept Neurosurg, Shantou, Guangdong, Peoples R China.
   [Lin, Huan-Zhang] Sun Yat Sen Univ, Shantou Cent Hosp, Shantou Hosp, Dept Thyroid Surg, Shantou, Guangdong, Peoples R China.
RP Xie, Y (reprint author), Shantou Univ, Med Coll, Affiliated Hosp 2, Dept Emergency, Shantou, Guangdong, Peoples R China.
EM xieyang2626@sina.com
CR Barile L, 2017, ANESTH ANALG, V124, P743, DOI 10.1213/ANE.0000000000001609
   Bellapart J, 2012, J TRAUMA ACUTE CARE, V73, P997, DOI 10.1097/TA.0b013e318265cede
   Carney N, 2017, NEUROSURGERY, V80, P6, DOI 10.1227/NEU.0000000000001432
   Charry JD, 2017, WORLD NEUROSURG, V101, P554, DOI 10.1016/j.wneu.2017.02.051
   Chen KT, 2017, WORLD NEUROSURG, V98, P727, DOI 10.1016/j.wneu.2016.11.090
   Fletcher JJ, 2010, NEUROCRIT CARE, V13, P47, DOI 10.1007/s12028-010-9345-2
   Hardcastle TC, 2017, WORLD J SURG, V41, P1153, DOI 10.1007/s00268-016-3530-1
   Huang YH, 2013, J NEUROSURG, V118, P1329, DOI 10.3171/2013.1.JNS121775
   Jiang JY, 2013, INJURY, V44, P1453, DOI 10.1016/j.injury.2012.08.045
   Khan AD, 2017, AM SURGEON, V83, P836
   Kolias AG, 2016, BRIT J NEUROSURG, V30, P246, DOI 10.3109/02688697.2016.1159655
   Kolias AG, 2013, NAT REV NEUROL, V9, P405, DOI 10.1038/nrneurol.2013.106
   Lubillo ST, 2017, J NEUROSURG, V5, P1
   Maruthappu M, 2015, ANN SURG, V261, P642, DOI 10.1097/SLA.0000000000000852
   Mercier E, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f1757
   Mollayeva T, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-018626
   Montenigro PH, 2015, ANNU REV CLIN PSYCHO, V11, P309, DOI 10.1146/annurev-clinpsy-032814-112814
   Nakae R, 2016, J NEUROTRAUM, V33, P688, DOI 10.1089/neu.2015.4039
   Naqash Imtiaz A, 2011, J Anaesthesiol Clin Pharmacol, V27, P54
   Nyam TTE, 2017, NEUROCRIT CARE, V26, P225, DOI 10.1007/s12028-016-0326-y
   Palmer CS, 2016, INJURY, V47, P109, DOI 10.1016/j.injury.2015.07.003
   Rosenfeld JV, 2012, LANCET, V380, P1088, DOI 10.1016/S0140-6736(12)60864-2
   Seule M, 2015, FACIAL PLAST SURG, V31, P325, DOI 10.1055/s-0035-1562884
   Shutter LA, 2016, NEW ENGL J MED, V375, P1183, DOI 10.1056/NEJMe1609722
   Sun H, 2016, J NEUROTRAUM, V33, P1535, DOI 10.1089/neu.2015.4164
   Thorson CM, 2013, AM SURGEON, V79, P398
   Thorson CM, 2013, J AM COLL SURGEONS, V216, P65, DOI 10.1016/j.jamcollsurg.2012.09.011
   Travers S, 2016, BRAIN INJURY, V30, P1525, DOI 10.1080/02699052.2016.1199907
   Vedantam A, 2017, J NEUROSURG, V1, P1
NR 29
TC 0
Z9 0
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP E141
EP E146
DI 10.1016/j.wneu.2018.11.095
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400017
PM 30468923
DA 2020-05-12
ER

PT J
AU Zhou, KZ
   Maingard, J
   Kok, HK
   Wang, J
   Barras, CD
   O'hare, A
   Looby, S
   Brennan, P
   Thornton, J
   Chandra, RV
   Brooks, DM
   Asadi, H
AF Zhou, Kevin Z.
   Maingard, Julian
   Kok, Hong Kuan
   Wang, Judy
   Barras, Christen D.
   O'hare, Alan
   Looby, Seamus
   Brennan, Paul
   Thornton, John
   Chandra, Ronil V.
   Brooks, Duncan Mark
   Asadi, Hamed
TI Endovascular Retrieval of Dislodged Neurovascular Devices with a
   Stentriever: Case Series and Technical Review
SO WORLD NEUROSURGERY
LA English
DT Review
DE Aneurysm; AVM; Coil; Endovascular; Neurointervention; Retrieval;
   Stentriever
ID INTRACRANIAL STENT; COIL; EMBOLIZATION; TRIAL
AB PURPOSE: Endovascular treatment of neurovascular disorders is now well established as effective and safe; however, the nature of the intracranial vasculature poses unique challenges. The unintentional dislodgement or fracture of a device and its migration within cerebral vessels is a complication with serious potential morbidity that must be managed urgently. In this series, the authors describe 7 cases of a stentriever being used to remove foreign objects from within the cerebral vasculature.
   METHODS: A retrospective search of all interventional neurovascular procedures performed in 2017 at a tertiary metropolitan hospital was performed to identify cases of dislodged devices.
   RESULTS: Five dislodged endovascular coils, 1 microcatheter, and 1 fractured stentriever were technically successfully retrieved. In 6 of the cases, the foreign object was successfully removed with a stentriever alone, whereas 1 case used a J-tip wire and a "J-tip flick" to manipulate the coil and facilitate retrieval.
   Stentrievers, particularly when used alone, confer the advantages of speed, cost, as well as being tailor-made for cerebral vessels. They also allow continuous blood flow when deployed, a critical advantage when considering cerebral perfusion. Critical techniques include the gradual deployment of the stentriever alongside the foreign object to allow its entanglement and partial resheathing, so that the foreign object can become pinned within the microcatheter. Stentrievers do remain limited by vessel caliber and are less able to entangle larger, stiffer devices.
   CONCLUSION: The migration of foreign devices during neurointerventional procedures is a serious complication requiring urgent treatment. This case series highlights the efficacy and advantages of using a stentriever and suggests its consideration as a first-line technique in recovering dislodged foreign bodies in the cerebral vasculature.
C1 [Zhou, Kevin Z.; Chandra, Ronil V.; Asadi, Hamed] Monash Hlth, Intervent Neuroradiol Unit, Monash Imaging, Melbourne, Vic, Australia.
   [Maingard, Julian; Brooks, Duncan Mark; Asadi, Hamed] Austin Hlth, Intervent Radiol Serv, Heidelberg, Vic, Australia.
   [Maingard, Julian; Brooks, Duncan Mark; Asadi, Hamed] Austin Hlth, Dept Radiol, Intervent Neuroradiol Serv, Heidelberg, Vic, Australia.
   [Wang, Judy] Austin Hlth, Dept Surg, Heidelberg, Vic, Australia.
   [Brooks, Duncan Mark] Austin Hlth, Dept Neurol, Heidelberg, Vic, Australia.
   [Kok, Hong Kuan] Northern Hlth, Intervent Radiol Serv, Epping, Vic, Australia.
   [Chandra, Ronil V.] Monash Univ, Dept Imaging, Clayton, Vic, Australia.
   [Brooks, Duncan Mark; Asadi, Hamed] Univ Melbourne, Florey Inst Neurosci & Mental Hlth, Stroke Div, Melbourne, Vic, Australia.
   [Brooks, Duncan Mark; Asadi, Hamed] St Vincents Hlth, Dept Radiol, Intervent Neuroradiol Serv, Melbourne, Vic, Australia.
   [Maingard, Julian] Deakin Univ, Fac Hlth, Sch Med, Waurn Ponds, Vic, Australia.
   [Barras, Christen D.] South Australian Hlth & Med Res Inst, Imaging Div, Adelaide, SA, Australia.
   [Barras, Christen D.] Univ Adelaide, Fac Hlth & Med Sci, Adelaide, SA, Australia.
   [O'hare, Alan; Looby, Seamus; Brennan, Paul; Thornton, John] Beaumont Hosp, Dept Neuroradiol, Dublin, Ireland.
RP Zhou, KZ (reprint author), Monash Hlth, Intervent Neuroradiol Unit, Monash Imaging, Melbourne, Vic, Australia.
EM kevin.zy.zhou@gmail.com
OI Wang, Judy/0000-0002-7355-7542; Chandra, Ronil/0000-0001-7555-2297
CR Berkhemer OA, 2015, NEW ENGL J MED, V372, P11, DOI 10.1056/NEJMoa1411587
   Cerejo R, 2018, INTERV NEURORADIOL, V24, DOI 10.1177/1591019917732287
   Dinc H, 2006, NEURORADIOLOGY, V48, P269, DOI 10.1007/s00234-006-0051-x
   Ding D, 2014, J NEUROINTERV SURG, V6, P428, DOI 10.1136/neurintsurg-2013-010872
   Fessler RD, 2000, NEUROSURGERY, V46, P248
   Floridi C, 2015, SEMIN ULTRASOUND CT, V36, P73, DOI 10.1053/j.sult.2014.11.001
   Henkes H, 2006, AM J NEURORADIOL, V27, P327
   Hopf-Jensen S, 2013, J CLIN NEUROSCI, V20, P884, DOI 10.1016/j.jocn.2012.06.012
   Jagani M, 2018, INTERV NEURORADIOL, V24, DOI 10.1177/1591019917737734
   Kabbani MR, 2015, J NEUROINTERV SURG, V7, pE19, DOI [10.1136/neurintsurg-2014-011181.rep, 10.1136/bcr-2014-011181]
   Lee CY, 2011, NEURORADIOLOGY, V53, P31, DOI 10.1007/s00234-010-0679-4
   Leslie-Mazwi TM, 2013, AM J NEURORADIOL, V34, P1996, DOI 10.3174/ajnr.A3552
   Meyer T, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0178197
   Molyneux A, 2002, LANCET, V360, P1267, DOI 10.1016/S0140-6736(02)11314-6
   Nikoubashman O, 2015, AM J NEURORADIOL, V36, P1162, DOI 10.3174/ajnr.A4240
   Nogueira RG, 2018, NEW ENGL J MED, V378, P11, DOI 10.1056/NEJMoa1706442
   O'Hare AM, 2010, CLIN NEURORADIOL, V20, P251, DOI 10.1007/s00062-010-0020-y
   Singh Devendra Pal, 2016, J Cerebrovasc Endovasc Neurosurg, V18, P48, DOI 10.7461/jcen.2016.18.1.48
   Turek G, 2015, J NEUROSURG, V123, P841, DOI 10.3171/2015.1.JNS132788
   Vora N, 2008, J NEUROIMAGING, V18, P81, DOI 10.1111/j.1552-6569.2007.00165.x
NR 20
TC 0
Z9 0
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP E661
EP E669
DI 10.1016/j.wneu.2018.11.248
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400078
PM 30576823
DA 2020-05-12
ER

PT J
AU Zhou, RP
   Mummaneni, PV
   Chen, KY
   Lau, D
   Cao, K
   Amara, D
   Zhan, C
   Dhall, S
   Chou, D
AF Zhou, Rong Ping
   Mummaneni, Praveen, V
   Chen, Kai-Yuan
   Lau, Darry
   Cao, Kai
   Amara, Dominic
   Zhan, Can
   Dhall, Sanjay
   Chou, Dean
TI Outcomes of Posterior Thoracic Corpectomies for Metastatic Spine Tumors:
   An Analysis of 90 Patients
SO WORLD NEUROSURGERY
LA English
DT Article
DE Complications; Costotransversectomy; Metastatic thoracic tumor;
   Posterior approach; Transpedicular corpectomy
ID SINGLE-FRACTION RADIOSURGERY; QUALITY-OF-LIFE; CORD COMPRESSION;
   TRANSPEDICULAR APPROACH; CAGE RECONSTRUCTION; DENDRITIC CELLS;
   DECOMPRESSION; ANTERIOR; STABILIZATION; VERTEBRECTOMY
AB OBJECTIVE: To retrospectively analyze the outcomes and complications of patients with metastatic thoracic spinal tumors (MTTs) who underwent posterior corpectomies.
   METHODS: Ninety patients with MTTs who underwent posterior corpectomies were retrospectively analyzed. Characteristics evaluated included number of MTTs per year, location, involved vertebrae numbers, sex, histology, pre-and postoperative American Spinal Injury Association (ASIA) grade, visual analog scale (VAS) pain scores, operative time, blood loss, and length of hospital stay.
   RESULTS: The average follow-up was 20.8 +/- 27.9 months (range, 0.5-139.4 months). Of the patients, 76.67% had a single metastasis and 23.33% had multiple metastases. For histology, 16.67% were breast, 15.56% were lung, 12.22% were prostate, and 12.22% were renal cell carcinoma. Of the patients with paraplegia and paraparesis, 74% improved. One patient improved from ASIA grade A to D, 3 patients improved fromgrade B to C, 8 patients improved from grade C to D or E, and 25 patients improved from grade D to E. Three patients (6%) with ASIA grade A and 1 patient (2%) with ASIA grade B had no improvement. One patient with ASIA grade C and 8 patients (16%) with grade D had no improvement. After surgery, VAS pain scores decreased from 8.45 +/- 1.57 to 1.211 +/- 1.81. In terms of complications, 2 patients (2.22%) had deep vein thrombosis and 1 patient had pulmonary embolism (1.11%). Other complications included wound infection (4.44%), cerebrospinal fluid leak (4.44%), pleural effusion (3.33%), wound dehiscence (2.22%), cellulitis (1.11%), epidural hematoma (1.11%), and pneumothorax (1.11%). Of the patients, 2.22% had implant failure and pseudoarthrosis, with 1 patient needing revision surgery. One patient (1.11%) had tumor recurrence.
   CONCLUSIONS: Our results suggest that posterior thoracic corpectomies for MTTs have a reasonable complication rate with favorable outcomes.
C1 [Zhou, Rong Ping; Cao, Kai] Nan Chang Univ, Affiliated Hosp 2, Dept Orthoped, Nanchang, Jiangxi, Peoples R China.
   [Zhou, Rong Ping; Mummaneni, Praveen, V; Chen, Kai-Yuan; Lau, Darry; Amara, Dominic; Zhan, Can; Dhall, Sanjay; Chou, Dean] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA.
   [Chen, Kai-Yuan] Taichung Vet Gen Hosp, Dept Neurosurg, Taichung, Taiwan.
   [Chen, Kai-Yuan] Taichung Vet Gen Hosp, Dept Surg, Puli Branch, Nantou, Taiwan.
   [Zhan, Can] Capital Med Univ, Xuan Wu Hosp, Dept Neurol Surg, Beijing, Peoples R China.
RP Zhou, RP (reprint author), Nan Chang Univ, Affiliated Hosp 2, Dept Orthoped, Nanchang, Jiangxi, Peoples R China.; Zhou, RP (reprint author), Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA.
EM rongg106@163.com
CR Akeyson EW, 1996, J NEUROSURG, V85, P211, DOI 10.3171/jns.1996.85.2.0211
   Amin B. Y., 2013, NEUROSURGICAL FOCU S, V35
   [Anonymous], 1993, J Am Acad Orthop Surg, V1, P76
   Bhatt AD, 2013, CANCER TREAT REV, V39, P142, DOI 10.1016/j.ctrv.2012.08.002
   Bilsky MH, 2000, SPINE, V25, P2240, DOI 10.1097/00007632-200009010-00016
   BYRNE TN, 1992, NEW ENGL J MED, V327, P614
   Cahill DW, 1999, J NEUROSURG, V90, P42, DOI 10.3171/spi.1999.90.1.0042
   Chiu YC, 2015, WORLD J SURG ONCOL, V13, DOI 10.1186/s12957-015-0685-4
   Chou DA, 2011, J NEUROSURG-SPINE, V14, P71, DOI 10.3171/2010.10.SPINE091009
   Cole JS, 2008, LANCET NEUROL, V7, P459, DOI 10.1016/S1474-4422(08)70089-9
   CYBULSKI GR, 1991, SURG NEUROL, V35, P280, DOI 10.1016/0090-3019(91)90005-T
   Falicov A, 2006, SPINE, V31, P2849, DOI 10.1097/01.brs.0000245838.37817.40
   Fong L, 2000, ANNU REV IMMUNOL, V18, P245, DOI 10.1146/annurev.immunol.18.1.245
   Fourney Daryl R, 2003, Neurosurg Focus, V14, pe8
   Gerszten PC, 2005, CANCER, V104, P2244, DOI 10.1002/cncr.21467
   Gerszten PC, 2005, J NEUROSURG-SPINE, V3, P288, DOI 10.3171/spi.2005.3.4.0288
   Gerszten PC, 2005, STEREOT FUNCT NEUROS, V83, P213, DOI 10.1159/000091952
   Gerszten PC, 2007, SPINE, V32, P193, DOI 10.1097/01.brs.0000251863.76595.a2
   Gezercan Y, 2016, WORLD NEUROSURG, V95, P214, DOI 10.1016/j.wneu.2016.08.007
   Gokaslan ZL, 1998, J NEUROSURG, V89, P599, DOI 10.3171/jns.1998.89.4.0599
   GOMEZ JAO, 1995, INT ORTHOP, V19, P309
   Harel R, 2010, EUR J CANCER, V46, P2696, DOI 10.1016/j.ejca.2010.04.025
   HARRINGTON KD, 1984, J NEUROSURG, V61, P107, DOI 10.3171/jns.1984.61.1.0107
   Jacobs W B, 2001, Neurosurg Focus, V11, pe10
   Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43
   Klimo P, 2005, NEURO-ONCOLOGY, V7, P64, DOI 10.1215/S1152851704000262
   Lau D, 2015, J NEUROSURG-SPINE, V23, P217, DOI 10.3171/2014.12.SPINE14543
   Lee BH, 2013, ANN SURG ONCOL, V20, P40, DOI 10.1245/s10434-012-2644-4
   Ljungberg B, 2015, EUR UROL, V67, P913, DOI 10.1016/j.eururo.2015.01.005
   Lu DC, 2010, J NEUROSURG-SPINE, V12, P583, DOI 10.3171/2010.1.SPINE09292
   Maccauro G, 2011, INT J SURG ONCOL, DOI 10.1155/2011/107969
   Metcalfe S, 2012, SPINE, V37, P1375, DOI 10.1097/BRS.0b013e318250a172
   Moulding HD, 2010, J NEUROSURG-SPINE, V13, P87, DOI 10.3171/2010.3.SPINE09639
   Oda I, 1999, SPINE, V24, P1634, DOI 10.1097/00007632-199908150-00003
   OVERBY MC, 1985, J NEUROSURG, V62, P344, DOI 10.3171/jns.1985.62.3.0344
   Patchell RA, 2005, LANCET, V366, P643, DOI 10.1016/S0140-6736(05)66954-1
   Quan GMY, 2011, EUR SPINE J, V20, P1970, DOI 10.1007/s00586-011-1867-6
   Rose PS, 2011, J AM ACAD ORTHOP SUR, V19, P37, DOI 10.5435/00124635-201101000-00005
   Sasani M, 2009, SPINE, V34, pE33, DOI 10.1097/BRS.0b013e318189fcfd
   Schuler G, 2003, CURR OPIN IMMUNOL, V15, P138, DOI 10.1016/S0952-7915(03)00015-3
   Sciubba DM, 2007, EUR SPINE J, V16, P1659, DOI 10.1007/s00586-007-0380-4
   Sciubba DM, 2007, NEUROSURG QUART, V17, P40, DOI 10.1097/WNQ.0b013e31803291cf
   Sciubba DM, 2010, J NEUROSURG-SPINE, V13, P94, DOI 10.3171/2010.3.SPINE09202
   SHIMIZU K, 1992, SPINE, V17, P1400, DOI 10.1097/00007632-199211000-00022
   SIEGAL T, 1982, ANN NEUROL, V11, P28, DOI 10.1002/ana.410110106
   SUNDARESAN N, 1984, J NEUROSURG, V61, P686, DOI 10.3171/jns.1984.61.4.0686
   Sundaresan N, 1996, J NEUROSURG, V85, P438, DOI 10.3171/jns.1996.85.3.0438
   Vahldiek MJ, 1998, SPINE, V23, P543, DOI 10.1097/00007632-199803010-00006
   WELLER SJ, 1995, J NEUROSURG, V82, P739, DOI 10.3171/jns.1995.82.5.0739
   Wilke HJ, 2001, J BONE JOINT SURG BR, V83B, P609, DOI 10.1302/0301-620X.83B4.9072
   Witham TF, 2006, NAT CLIN PRACT NEURO, V2, P87, DOI 10.1038/ncpneuro0116
   WONG DA, 1990, SPINE, V15, P1, DOI 10.1097/00007632-199001000-00001
   Xu RS, 2009, J NEUROSURG-SPINE, V11, P272, DOI 10.3171/2009.3.SPINE08621
   Yao Kevin C, 2003, Neurosurg Focus, V15, pE6
NR 54
TC 1
Z9 1
U1 1
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP E371
EP E378
DI 10.1016/j.wneu.2018.11.172
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400043
PM 30500586
DA 2020-05-12
ER

PT J
AU Benites, BD
   Duarte, ADS
   Longhini, ALF
   Santos, I
   Alvarez, MC
   Ribeiro, LND
   de Paula, E
   Saad, STO
AF Benites, Bruno Deltreggia
   Santos Duarte, Adriana da Silva
   Figueiredo Longhini, Ana Leda
   Santos, Irene
   Alvarez, Marisa Claudia
   de Morais Ribeiro, Ligia Nunes
   de Paula, Eneida
   Olalla Saad, Sara Teresinha
TI Exosomes in the serum of Acute Myeloid Leukemia patients induce
   dendritic cell tolerance: Implications for immunotherapy
SO VACCINE
LA English
DT Article
DE Exosomes; Acute Myeloid Leukemia; 'Dendritic cells; Immunotherapy
ID T-CELL; EXPRESSION; MODULATION; SECRETION
AB Exosomes may represent an interesting antigenic pulse for new forms of anti-tumor immunotherapy. We evaluated exosomes from serum of patients with acute myeloid leukemia (AML) as an antigenic source for dendritic cells (DC) and the effects upon antitumor cytotoxicity, assessed by the percentage of specific lysis of K562 leukemic cells in co-cultures. Surprisingly, incubation of exosomes with DCs decreased lysis of K562, which may correspond to a mechanism of tumor evasion in vivo. However, when immature DCs were pulsed with exosomes purified from K562 culture supernatants, the lysis of target cells was notably enhanced, associated with a substantial increase in the expression of the maturation marker CD83. Thus, the development of vaccines using patients' exosomes would probably add no benefits to the treatment of AML; alternately, exosomes from cultured cells may represent an effective way for maturing DCs into a cytotoxic phenotype, without the immunosuppression observed with patients' exosomes. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Benites, Bruno Deltreggia; Santos Duarte, Adriana da Silva; Figueiredo Longhini, Ana Leda; Santos, Irene; Alvarez, Marisa Claudia; Olalla Saad, Sara Teresinha] Univ Estadual Campinas, Hematol & Transfus Med Ctr, Rua Carlos Chagas 480, BR-13083970 Campinas, SP, Brazil.
   [de Morais Ribeiro, Ligia Nunes; de Paula, Eneida] Univ Estadual Campinas, Dept Biochem & Tissue Biol, Campinas, SP, Brazil.
RP Benites, BD (reprint author), Univ Estadual Campinas, Hematol & Transfus Med Ctr, Rua Carlos Chagas 480, BR-13083970 Campinas, SP, Brazil.
EM benites@unicamp.br
RI de Paula, Eneida/C-3031-2013; Ribeiro, Ligia/AAJ-2820-2020; benites,
   Bruno/W-9207-2019
OI de Paula, Eneida/0000-0003-4504-5723; Ribeiro,
   Ligia/0000-0001-6097-5449; 
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2011/51959-0]
FX This study was supported by Grant no. 2011/51959-0 from the Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP).
CR Aerts-Toegaert C, 2007, EUR J IMMUNOL, V37, P686, DOI 10.1002/eji.200636535
   Anguille S, 2017, BLOOD, V130, P1713, DOI 10.1182/blood-2017-04-780155
   Anguille S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051851
   Bruchhage KL, 2018, ONCOL LETT, V15, P3985, DOI 10.3892/ol.2018.7772
   Coleman BM, 2015, SEMIN CELL DEV BIOL, V40, P89, DOI 10.1016/j.semcdb.2015.02.007
   Ribeiro LND, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-017-18573-7
   Hao SG, 2007, IMMUNOLOGY, V120, P90, DOI 10.1111/j.1365-2567.2006.02483.x
   Hellwinkel JE, 2016, NEURO-ONCOLOGY, V18, P497, DOI 10.1093/neuonc/nov170
   Katsuda T, 2014, BIOL CHEM, V395, P365, DOI 10.1515/hsz-2013-0222
   Liu MF, 1999, SCAND J IMMUNOL, V49, P82, DOI 10.1046/j.1365-3083.1999.00452.x
   Mascanfroni ID, 2013, NAT IMMUNOL, V14, P1054, DOI 10.1038/ni.2695
   R Core Team, 2013, R LANG ENV STAT COMP
   Ruivo CF, 2017, CANCER RES, V77, P6480, DOI 10.1158/0008-5472.CAN-17-0994
   Said EA, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0158265
   Schutz C, 2018, LEUKEMIA, V32, P1053, DOI 10.1038/leu.2017.348
   Tel J, 2014, TRENDS IMMUNOL, V35, P38, DOI 10.1016/j.it.2013.10.007
   Tze LE, 2011, J EXP MED, V208, P149, DOI 10.1084/jem.20092203
   Van Tendeloo VF, 2010, P NATL ACAD SCI USA, V107, P13824, DOI 10.1073/pnas.1008051107
   Whiteside TL, 2013, BIOCHEM SOC T, V41, P245, DOI 10.1042/BST20120265
   Yao Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091463
   Yeh YY, 2015, BLOOD, V125, P3297, DOI 10.1182/blood-2014-12-618470
   Zhao H, 2018, BBA-REV CANCER, V1869, P64, DOI 10.1016/j.bbcan.2017.11.005
NR 22
TC 3
Z9 4
U1 2
U2 14
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 7
PY 2019
VL 37
IS 11
BP 1377
EP 1383
DI 10.1016/j.vaccine.2019.01.079
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HP1DK
UT WOS:000461405400001
PM 30755368
DA 2020-05-12
ER

PT J
AU Hamlet, A
   Jean, K
   Yactayo, S
   Benzler, J
   Cibrelus, L
   Ferguson, N
   Garske, T
AF Hamlet, Arran
   Jean, Kevin
   Yactayo, Sergio
   Benzler, Justus
   Cibrelus, Laurence
   Ferguson, Neil
   Garske, Tini
TI POLICI: A web application for visualising and extracting yellow fever
   vaccination coverage in Africa
SO VACCINE
LA English
DT Article
DE Yellow fever; Vaccination; Africa; Outbreak response; Visualization;
   Shiny
ID DISEASE
AB Recent yellow fever (YF) outbreaks have highlighted the increasing global risk of urban spread of the disease. In context of recurrent vaccine shortages, preventive vaccination activities require accurate estimates of existing population-level immunity. We present POLICI (POpulation-Level Immunization Coverage - Imperial), an interactive online tool for visualising and extracting YF vaccination coverage estimates in Africa.
   We calculated single year age-disaggregated sub-national population-level vaccination coverage for 1950-2050 across the African endemic zone by collating vaccination information and inputting it into a demographic model. This was then implemented on an open interactive web platform.
   POLICI interactively displays age-disaggregated, population-level vaccination coverages at the first sub-national administrative level, through numerous downloadable and customisable visualisations. POLICI is available at https://polici.shinyapps.io/yellow_fever_africa/.
   POLICI offers an accessible platform for relevant stakeholders in global health to access and explore vaccination coverages. These estimates have already been used to inform the WHO strategy to Eliminate Yellow fever Epidemics (EYE). (C) 2019 The Authors. Published by Elsevier Ltd.
C1 [Hamlet, Arran; Jean, Kevin; Ferguson, Neil; Garske, Tini] Imperial Coll London, Dept Infect Dis Epidemiol, MRC Ctr Global Infect Dis Anal, London W2 1PG, England.
   [Jean, Kevin] Conservatoire Natl Arts & Metiers, Lab MESuRS, Paris, France.
   [Yactayo, Sergio; Benzler, Justus; Cibrelus, Laurence] WHO, Infect Hazard Management, Geneva, Switzerland.
RP Hamlet, A (reprint author), Imperial Coll London, Dept Infect Dis Epidemiol, MRC Ctr Global Infect Dis Anal, London W2 1PG, England.
EM arran.hamlet14@imperial.ac.uk; yactayo.s@free.fr; benzlerj@who.int;
   cibrelusl@who.int; neil.ferguson@imperial.ac.uk; t.garske@imperial.ac.uk
RI Ferguson, Neil/B-8578-2008
OI Ferguson, Neil/0000-0002-1154-8093; Hamlet, Arran/0000-0003-0871-0640;
   Jean, Kevin/0000-0001-6462-7185
FU Bill & Melinda Gates foundationGates Foundation [OPP1117543]; UK Medical
   Research Council (Medical Research Council/United Kingdom)
   [MR/K010174/1]
FX This work was supported by the Bill & Melinda Gates foundation
   (OPP1117543 http://www.gatesfoundation.org/) and the UK Medical Research
   Council (MR/K010174/1/Medical Research Council/United Kingdom
   https://mrc.ukri.org/).
CR [Anonymous], WEEKL EP REC WER
   Barrett ADT, 2007, ANNU REV ENTOMOL, V52, P209, DOI 10.1146/annurev.ento.52.110405.091454
   Beeley C., 2013, WEB APPL DEV R USING
   Bright E A, 2015, LANDSCAN 2014
   Carroll LN, 2014, J BIOMED INFORM, V51, P287, DOI 10.1016/j.jbi.2014.04.006
   Dos Santos S, 2017, SCI TOTAL ENVIRON, V607, P497, DOI 10.1016/j.scitotenv.2017.06.157
   Douam F, 2018, TRENDS MICROBIOL, V26, P913, DOI 10.1016/j.tim.2018.05.012
   Durieux C, 1956, MONOGRAPH SERIES WHO, P115
   Garske T, 2014, PLOS MED, V11, DOI 10.1371/journal.pmed.1001638
   Jean K, 2016, AM J TROP MED HYG, V16
   Nigeria Centre For Disease Control (NCDC), 2018, YELL FEV OUTBR NIG
   Organization WH, 2016, WHO UNICEF EST NAT I
   Shearer FM, 2017, LANCET INFECT DIS, V17, P1209, DOI 10.1016/S1473-3099(17)30419-X
   Team RC, 2015, R LANG ENV STAT COMP
   United Nations DoEaSA Population Division Population Estimates and Projections Section, 2016, WORLD POP PROSP 2016
   WHO-World Health Organization, 2016, GLOB STRAT EL YELL F
   World Health Organization, DIS OUTBR NEWS DON
   World Health Organization, 2016, YELL FEV IN INTR
   Zhao S, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/journal.pntd.0006158
NR 19
TC 3
Z9 3
U1 0
U2 5
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 7
PY 2019
VL 37
IS 11
BP 1384
EP 1388
DI 10.1016/j.vaccine.2019.01.074
PG 5
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HP1DK
UT WOS:000461405400002
PM 30770224
OA Green Published, Other Gold
DA 2020-05-12
ER

PT J
AU McCarty, JM
   Lock, MD
   Bennett, S
   Hunt, KM
   Simon, JK
   Gurwith, M
AF McCarty, James M.
   Lock, Michael D.
   Bennett, Sean
   Hunt, Kristin M.
   Simon, Jakub K.
   Gurwith, Marc
TI Age-related immunogenicity and reactogenicity of live oral cholera
   vaccine CVD 103-HgR in a randomized, controlled clinical trial
SO VACCINE
LA English
DT Article
ID B-CELL RESPONSES; HEPATITIS-B; INFLUENZA VACCINATION; ANTIBODY TITER;
   INFECTION; IMMUNOSENESCENCE; CONFIDENCE; OUTBREAK; CONTACTS; SAFETY
AB Aging is accompanied by a decline in immune function which can lead to decreased responses to vaccines. Attenuated recombinant Vibrio cholerae 01 vaccine strain CVD 103-HgR elicits a rapid serum vibriocidal antibody (SVA) response and protects against cholera diarrhea in volunteer challenge studies but has not been studied in older adults. We evaluated CVD 103-HgR (PXVX0200) in adults age 46-64, compared them to previously studied adults age 18-45, and studied age-related immunogenicity across adults 18-64 years of age. Volunteers were randomized to receive a single dose of 1 x 10(9) CFU of PXVX0200 or placebo. Immunogenicity endpoints included SVA and anti-cholera toxin (CT) antibody levels on days 1, 11, 29, 91 and 181 and lipopolysaccharide (LPS) and CT-specific IgA and IgG memory B cells on days 1, 91 and 181. Safety was assessed by comparing solicited signs and symptoms on days 1-8 and other adverse events through day 181. 2979 volunteers received vaccine, including 291 age 45-64. Day 11 seroconversion occurred in 90.4% of older adults vs 93.5%% of younger adults and met the endpoint of demonstrating non-inferiority between the two groups. Significant increases in LPS-specific IgG and IgA and CT-specific memory IgG memory B cells were seen at days 91 and 181. There appeared to be a continuous age-related decline in SVA seroconversion and geometric mean titers, but not memory B cell responses, across the 18-64 year age range. Most reactogenicity was mild and was more common in the placebo group. PXVX0200 appears safe and immunogenic in older adults. (C) 2019 The Authors. Published by Elsevier Ltd.
C1 [McCarty, James M.] Stanford Univ, Sch Med, 291 Campus Dr, Stanford, CA 94305 USA.
   [Lock, Michael D.; Bennett, Sean; Hunt, Kristin M.; Simon, Jakub K.; Gurwith, Marc] PaxVax Inc, 555 Twin Dolphin Dr,Ste 360, Redwood City, CA 94065 USA.
   [Simon, Jakub K.] Merck & Co Inc, 2000 Galloping Hill Rd, Kenilworth, NJ 07033 USA.
RP McCarty, JM (reprint author), Stanford Univ, Sch Med, 291 Campus Dr, Stanford, CA 94305 USA.
EM jmccart2@stanford.edu
OI Hunt, Kristin/0000-0001-6276-7272
FU PaxVax, Inc.
FX This research was funded entirely by PaxVax, Inc., a privately held
   specialty vaccine company. This research did not receive any specific
   grant from funding agencies in the public or not-for-profit sectors.
CR Alam MM, 2011, CLIN VACCINE IMMUNOL, V18, P844, DOI 10.1128/CVI.00562-10
   Averhoff F, 1998, AM J PREV MED, V15, P1, DOI 10.1016/S0749-3797(98)00003-8
   Chen WH, 2016, CLIN INFECT DIS, V62, P1329, DOI 10.1093/cid/ciw145
   Chen WH, 2014, CLIN VACCINE IMMUNOL, V21, P66, DOI 10.1128/CVI.00601-13
   CLEVELAND WS, 1988, J AM STAT ASS, V83
   Clopper CJ, 1934, BIOMETRIKA, V26, P404, DOI 10.1093/biomet/26.4.404
   Dalhat MM, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-1167
   Fagerland MW, 2015, STAT METHODS MED RES, V24, P224, DOI 10.1177/0962280211415469
   Fritzell B, 1998, Dev Biol Stand, V95, P181
   Goodwin K, 2006, VACCINE, V24, P1159, DOI 10.1016/j.vaccine.2005.08.105
   Goronzy JJ, 2013, NAT IMMUNOL, V14, P428, DOI 10.1038/ni.2588
   Gruver AL, 2007, J PATHOL, V211, P144, DOI 10.1002/path.2104
   Haney DJ, 2018, VACCINE, V36, P2768, DOI 10.1016/j.vaccine.2018.04.011
   Haney DJ, 2017, CLIN VACCINE IMMUNOL, V24, DOI [10.1128/CVI.00098-17, 10.1128/cvi.00098-17]
   Haq K, 2014, CURR OPIN IMMUNOL, V29, P38, DOI 10.1016/j.coi.2014.03.008
   Haralambieva IH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122282
   Harris AM, 2009, INFECT IMMUN, V77, P3850, DOI 10.1128/IAI.00369-09
   Havlichek D, 1997, AM J INFECT CONTROL, V25, P418, DOI 10.1016/S0196-6553(97)90090-0
   Hawkes N, 2017, BMJ-BRIT MED J, V358, DOI 10.1136/bmj.j4146
   HOLT PR, 1992, AGE AGEING, V21, P1, DOI 10.1093/ageing/21.1.1
   Islam K, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/journal.pntd.0006376
   Jayasekera CR, 2008, J INFECT DIS, V198, P1055, DOI 10.1086/591500
   LEVINE M M, 1988, Lancet, V2, P467
   LEVINE MM, 1981, J INFECT DIS, V143, P818, DOI 10.1093/infdis/143.6.818
   Levine MM, 1995, B I PASTEUR, V93, P243, DOI 10.1016/0020-2452(96)85758-7
   Levine MM, 2017, EXPERT REV VACCINES, V16, P197, DOI 10.1080/14760584.2017.1291348
   McCarty JM, 2018, VACCINE, V36, P833, DOI 10.1016/j.vaccine.2017.12.062
   MOSLEY WH, 1968, B WORLD HEALTH ORGAN, V38, P777
   MOSLEY WH, 1969, B WORLD HEALTH ORGAN, V40, P187
   Oviedo-Orta E, 2013, CURR OPIN IMMUNOL, V25, P529, DOI 10.1016/j.coi.2013.07.008
   Patel SM, 2012, CLIN VACCINE IMMUNOL, V19, P842, DOI 10.1128/CVI.00037-12
   Reed C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118369
   Romero-Steiner S, 1999, CLIN INFECT DIS, V29, P281, DOI 10.1086/520200
   Sjogren MH, 2005, AM J MED, V118, P34, DOI 10.1016/j.amjmed.2005.07.012
   Solana R, 2012, SEMIN IMMUNOL, V24, P331, DOI 10.1016/j.smim.2012.04.008
   Sule IB, 2017, PAN AFR MED J, V27, DOI 10.11604/pamj.2017.27.172.11925
   Tohme RA, 2011, VACCINE, V29, P9316, DOI 10.1016/j.vaccine.2011.10.011
   Voordouw ACG, 2009, VACCINE, V28, P392, DOI 10.1016/j.vaccine.2009.09.138
   Yang SG, 2016, SCI REP-UK, V6, DOI 10.1038/srep27251
   Young B, 2017, VACCINE, V35, P212, DOI 10.1016/j.vaccine.2016.11.013
   Zarowitz BJ, 2009, GASTROENTEROL CLIN N, V38, P547, DOI 10.1016/j.gtc.2009.06.011
   Zeeshan M, 2007, BMC INFECT DIS, V7, DOI 10.1186/1471-2334-7-120
NR 42
TC 2
Z9 2
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 7
PY 2019
VL 37
IS 11
BP 1389
EP 1397
DI 10.1016/j.vaccine.2019.01.077
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HP1DK
UT WOS:000461405400003
PM 30772070
OA Other Gold
DA 2020-05-12
ER

PT J
AU Harapan, H
   Mudatsir, M
   Yufika, A
   Nawawi, Y
   Wahyuniati, N
   Anwar, S
   Yusri, F
   Haryanti, N
   Wijayanti, NP
   Rizal, R
   Fitriani, D
   Maulida, NF
   Syahriza, M
   Ikram, I
   Fandoko, TP
   Syahadah, M
   Asrizal, FW
   Aletta, A
   Jamil, KF
   Rajamoorthy, Y
   Hadisoemarto, PF
   Wagner, AL
   Groneberg, DA
   Kuch, U
   Sasmono, RT
   Muller, R
   Imrie, A
AF Harapan, Harapan
   Mudatsir, Mudatsir
   Yufika, Amanda
   Nawawi, Yusuf
   Wahyuniati, Nur
   Anwar, Samsul
   Yusri, Fitria
   Haryanti, Novi
   Wijayanti, Nanda Putri
   Rizal, Rizal
   Fitriani, Devi
   Maulida, Nurul Fadhliati
   Syahriza, Muhammad
   Ikram, Ikram
   Fandoko, Try Purwo
   Syahadah, Muniati
   Asrizal, Febrivan Wahyu
   Aletta, Alma
   Jamil, Kurnia Fitri
   Rajamoorthy, Yogambigai
   Hadisoemarto, Panji Fortuna
   Wagner, Abram Luther
   Groneberg, David Alexander
   Kuch, Ulrich
   Sasmono, R. Tedjo
   Mueller, Ruth
   Imrie, Allison
TI Community acceptance and willingness-to-pay for a hypothetical Zika
   vaccine: A cross-sectional study in Indonesia
SO VACCINE
LA English
DT Article
DE Zika virus; Zika vaccine; Zika vaccination; Acceptance;
   Willingness-to-pay
ID DENGUE VACCINE; VIRUS-INFECTION; PARENT ATTITUDES; DETERMINANTS;
   TRANSMISSION; KNOWLEDGE; OUTBREAK
AB Background: Understanding people's perceptions of the economic benefits of a potential Zika vaccine (ZV) is critical to accelerating its introduction into either public sector programs or private market. The aim of this study was to assess the acceptance and willingness-to-pay (WTP) for a hypothetical ZV and the associated explanatory variables in Indonesia.
   Methods: We conducted a health facility-based cross-sectional study in Aceh and West Sumatra province from 1 February to 13 June 2018. Patients who visited outpatient departments, have had children or were expecting their first child, were approached and interviewed to collect information on acceptance, WTP, demographic and socio-economic variables and attitudes towards childhood vaccines. Associations of explanatory variables influencing acceptance and WTP were assessed using logistic regression and linear regression analysis, respectively.
   Results: In total, 956 respondents were included in the final analysis of acceptance, of whom 338 (353%) expressed their WTP. We found that 757 (79.1%) of the respondents were likely to be vaccinated and to recommend their partner to be vaccinated. Higher educational attainment, having a job, having heard about Zika and a good attitude towards childhood vaccination were associated with ZV acceptance in the univariate analyses. In the multivariate analysis, attitude towards childhood vaccination was the strongest predictor for ZV vaccination. We found the geometric mean and median of WTP was US$ 13.1 (95% CI: 11.37-15.09) and US$ 7.0 (95% CI: 4.47-10.98), respectively. In the final model, having heard about Zika, having a job, and higher income were associated with a higher WTP.
   Conclusion: Although the acceptance rate of the ZV is relatively high in Indonesia, less than 40% of respondents are willing to pay, underscoring the need for a low-cost, high-quality vaccine and public sector subsidies for Zika vaccinations in the country. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Harapan, Harapan; Mudatsir, Mudatsir; Wahyuniati, Nur; Ikram, Ikram; Jamil, Kurnia Fitri] Univ Syiah Kuala, Sch Med, Med Res Unit, Banda Aceh, Aceh, Indonesia.
   [Harapan, Harapan; Mudatsir, Mudatsir] Univ Syiah Kuala, Sch Med, Trop Dis Ctr, Banda Aceh, Aceh, Indonesia.
   [Harapan, Harapan; Mudatsir, Mudatsir] Univ Syiah Kuala, Sch Med, Dept Microbiol, Banda Aceh, Aceh, Indonesia.
   [Harapan, Harapan; Imrie, Allison] Univ Western Australia, Sch Biomed Sci, Nedlands, WA, Australia.
   [Yufika, Amanda; Nawawi, Yusuf; Aletta, Alma] Univ Syiah Kuala, Sch Med, Dept Family Med, Banda Aceh, Aceh, Indonesia.
   [Anwar, Samsul] Univ Syiah Kuala, Fac Math & Nat Sci, Dept Stat, Banda Aceh, Aceh, Indonesia.
   [Yusri, Fitria] Malikussaleh Univ, Sch Med, Lhokseumawe, Aceh, Indonesia.
   [Haryanti, Novi] Community Hlth Ctr Meurah Mulia, North Aceh, Aceh, Indonesia.
   [Wijayanti, Nanda Putri] Community Hlth Ctr Tapaktuan, South Aceh, Aceh, Indonesia.
   [Rizal, Rizal] Bunda Hosp, Lhokseumawe, Aceh, Indonesia.
   [Fitriani, Devi] Community Hlth Ctr Teunom, Aceh Jaya, Aceh, Indonesia.
   [Maulida, Nurul Fadhliati] Meuraxa Hosp, Banda Aceh, Aceh, Indonesia.
   [Syahriza, Muhammad] Univ Syiah Kuala, Sch Med, Dept Publ Hlth & Community Med, Banda Aceh, Aceh, Indonesia.
   [Fandoko, Try Purwo] Community Hlth Ctr Gunung, Padang Panjang, West Sumatra, Indonesia.
   [Syahadah, Muniati] Community Hlth Ctr Lima Kaum, Tanah Datar, West Sumatra, Indonesia.
   [Asrizal, Febrivan Wahyu] Community Hlth Ctr Tanjung Paku, Solok, West Sumatra, Indonesia.
   [Jamil, Kurnia Fitri] Univ Syiah Kuala, Sch Med, Dept Internal Med, Banda Aceh, Aceh, Indonesia.
   [Rajamoorthy, Yogambigai] Univ Tunku Abdul Rahman, Dept Econ, Selangor, Malaysia.
   [Hadisoemarto, Panji Fortuna] Univ Padjadjaran, Fac Med, Grad Program Publ Hlth, Bandung, Indonesia.
   [Wagner, Abram Luther] Univ Michigan, Dept Epidemiol, Ann Arbor, MI 48109 USA.
   [Groneberg, David Alexander; Kuch, Ulrich; Mueller, Ruth] Goethe Univ, Inst Occupat Med Social Med & Environm Med, Frankfurt, Germany.
   [Sasmono, R. Tedjo] Eijkman Inst Mol Biol, Jakarta, Indonesia.
   [Mueller, Ruth] Inst Trop Med, Unit Med Entomol, Antwerp, Belgium.
RP Harapan, H (reprint author), Univ Syiah Kuala, Sch Med, Med Res Unit, Jl T Tanoeh Abe, Darussalam 23111, Banda Aceh, Indonesia.
EM harapan@unsyiah.ac.id
RI Wagner, Abram/X-6379-2019; Harapan, Harapan/I-8741-2016; Sasmono,
   Tedjo/H-5680-2016; Imrie, Allison/AAH-2421-2019; Mudatsir,
   Mudatsir/Q-4999-2017
OI Wagner, Abram/0000-0003-4691-7802; Harapan, Harapan/0000-0001-7630-8413;
   Sasmono, Tedjo/0000-0003-0986-2590; Nawawi, Yusuf/0000-0001-8726-0793;
   Mudatsir, Mudatsir/0000-0002-5643-9384
FU Department of Foreign Affairs and Trade; University of Western
   Australia; NHMRC Centre of Research Excellence in Emerging Infectious
   Diseases (CREID)National Health and Medical Research Council of
   Australia; Federal Ministry of Education and ResearchFederal Ministry of
   Education & Research (BMBF) [01KI1717]
FX We would like to thank to the participants of this study. HH is a
   recipient of an Australia Awards Scholarship (AAS) from the Department
   of Foreign Affairs and Trade, Scholarship for International Research
   Fees (SIRF) from The University of Western Australia and NHMRC Centre of
   Research Excellence in Emerging Infectious Diseases (CREID) Scholarship.
   RM, UK and DAG were supported by the Federal Ministry of Education and
   Research under the program "Nationales Forschungsnetz Zoonotische
   Infektionskrankheiten" (01KI1717). The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Ahmed A, 2018, J INFECT PUBLIC HEAL, V11, P153, DOI 10.1016/j.jiph.2017.09.007
   Ajzen I., 1992, J CONSUM PSYCHOL, V1, P297, DOI DOI 10.1016/S1057-7408(08)80057-5
   Azizi FSM, 2017, VACCINE, V35, P2955, DOI 10.1016/j.vaccine.2017.04.010
   Baud D, 2017, LANCET, V390, P2099, DOI [10.1016/S0140-6736(17)31450-2, 10.1016/s0140-6736(17)31450-2]
   Birhane MG, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004486
   Bogoch II, 2016, LANCET INFECT DIS, V16, P1237, DOI 10.1016/S1473-3099(16)30270-5
   Dhimal M, 2018, INFECT DIS POVERTY, V7, DOI 10.1186/s40249-018-0426-3
   DICK GWA, 1952, T ROY SOC TROP MED H, V46, P509, DOI 10.1016/0035-9203(52)90042-4
   Duffy MR, 2009, NEW ENGL J MED, V360, P2536, DOI 10.1056/NEJMoa0805715
   Dyer O., 2016, ZIKA VIRUS IS SET SP, V355, pi5577
   Feng Changyong, 2014, Shanghai Arch Psychiatry, V26, P105, DOI 10.3969/j.issn.1002-0829.2014.02.009
   Fugenschuh A, 2016, OPTIMAL CONTROL INTE
   GLEJSER H, 1969, J AM STAT ASSOC, V64, P316, DOI 10.2307/2283741
   Gregory CJ, 2017, J INFECT DIS, V216, pS875, DOI 10.1093/infdis/jix396
   Gyurech D, 2016, SWISS MED WKLY, V146, DOI 10.4414/smw.2016.14296
   Hadisoemarto PF, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002427
   Hansla A, 2008, ENERG POLICY, V36, P768, DOI 10.1016/j.enpol.2007.10.027
   Harapan H, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10110648
   Harapan H, 2018, BMC INFECT DIS, V18, DOI 10.1186/s12879-018-3006-z
   Harapan H, 2018, J INFECT PUBLIC HEAL, V11, P99, DOI 10.1016/j.jiph.2017.06.013
   Harapan H, 2017, SE ASIAN J TROP MED, V48, P297
   Harapan H, 2017, HUM VACC IMMUNOTHER, V13, P786, DOI 10.1080/21645515.2016.1259045
   Harapan H, 2017, ASIAN PAC J TROP MED, V10, P182, DOI 10.1016/j.apjtm.2017.01.018
   Harapan H, 2017, ACTA TROP, V166, P249, DOI 10.1016/j.actatropica.2016.11.035
   Harapan H, 2016, ASIAN PAC J TROP MED, V9, P1092, DOI 10.1016/j.apjtm.2016.07.036
   Harapan H, 2016, VACCINE, V34, P3670, DOI 10.1016/j.vaccine.2016.05.026
   Ho ZJM, 2017, LANCET INFECT DIS, V17, P813, DOI 10.1016/S1473-3099(17)30249-9
   Kwong JC, 2013, AM J TROP MED HYG, V89, P516, DOI 10.4269/ajtmh.13-0029
   Lee JS, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003810
   Leung GHY, 2015, SE ASIAN J TROP MED, V46, P460
   MACNAMARA FN, 1954, T ROY SOC TROP MED H, V48, P139, DOI 10.1016/0035-9203(54)90006-1
   Musso D, 2014, CLIN MICROBIOL INFEC, V20, pO595, DOI 10.1111/1469-0691.12707
   Noah Norman, 2008, Epidemiol Infect, V136, P865, DOI 10.1017/S0950268808000733
   O'Brien RM, 2007, QUAL QUANT, V41, P673, DOI 10.1007/s11135-006-9018-6
   OLSON JG, 1983, ANN TROP MED PARASIT, V77, P131, DOI 10.1080/00034983.1983.11811687
   OLSON JG, 1981, T ROY SOC TROP MED H, V75, P389, DOI 10.1016/0035-9203(81)90100-0
   Opel DJ, 2013, JAMA PEDIATR, V167, P1065, DOI 10.1001/jamapediatrics.2013.2483
   Opel DJ, 2011, VACCINE, V29, P6598, DOI 10.1016/j.vaccine.2011.06.115
   Opel DJ, 2011, HUM VACCINES, V7, P419, DOI 10.4161/hv.7.4.14120
   Ophir Y, 2018, J PUBLIC HEALTH-UK, P1
   Painter JE, 2017, VACCINE, V35, P960, DOI 10.1016/j.vaccine.2016.12.050
   Palanca-Tan R, 2008, VACCINE, V26, P914, DOI 10.1016/j.vaccine.2007.12.011
   Perkasa A, 2016, EMERG INFECT DIS, V22, P924, DOI 10.3201/eid2205.151915
   Rajamoorthy Y, 2019, BMC PUBLIC HEALTH, V19, DOI 10.1186/s12889-018-6375-8
   Sasmono RT, 2018, EMERG INFECT DIS, V24, P1740, DOI 10.3201/eid2409.180582
   Sauerborn R, 2005, SCAND J PUBLIC HEALT, V33, P146, DOI 10.1080/14034940510005743
   Shoukat A, 2018, BMC MED, V16, DOI 10.1186/s12916-018-1091-x
   Slunge D, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143875
   Vielot NA, 2018, AM J TROP MED HYG, V98, P1848, DOI 10.4269/ajtmh.17-0907
   WHO. UN International children's Emergency Fund, 2017, WHO UNICEF ZIK VIR Z
   Wikan N, 2016, LANCET INFECT DIS, V16, pE119, DOI 10.1016/S1473-3099(16)30010-X
   Wong LP, 2017, VACCINE, V35, P5912, DOI 10.1016/j.vaccine.2017.08.074
   World Health Organization. Fifth meeting of the Emergency Committee under the International Health Regulations, 2005, 5 M EM COMM INT HLTH
   World Health Organization (WHO), 2017, ZIK SIT REP
   Yang J., 2012, INTERPRETING COEFFIC
   Yap BW, 2011, J STAT COMPUT SIM, V81, P2141, DOI 10.1080/00949655.2010.520163
   Yaqub O, 2014, SOC SCI MED, V112, P1, DOI 10.1016/j.socscimed.2014.04.018
NR 57
TC 5
Z9 5
U1 0
U2 6
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 7
PY 2019
VL 37
IS 11
BP 1398
EP 1406
DI 10.1016/j.vaccine.2019.01.062
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HP1DK
UT WOS:000461405400004
PM 30739794
DA 2020-05-12
ER

PT J
AU Ahmed, MLCB
   Heukelbach, J
   Weddih, A
   Filali-Maltouf, A
   Sidatt, M
   Makhalla, K
   Dahdi, S
   Ahmed, ACC
   El-Mami, MV
   Tate, JE
   Parashar, UD
   Benhafid, M
AF Cheikh-brahim Ahmed, Mohamed-Lemine
   Heukelbach, Jorg
   Weddih, Abdellahi
   Filali-Maltouf, Abdelkarim
   Sidatt, Mariem
   Makhalla, Khattry
   Dahdi, Sid'Ahmed
   Ahmed, Aly Cheybany Cheikh
   El-Mami, Mohamed Val
   Tate, Jacqueline E.
   Parashar, Umesh D.
   Benhafid, Mohammed
TI Reduction of hospitalizations with diarrhea among children aged 0-5
   years in Nouakchott, Mauritania, following the introduction of rotavirus
   vaccine
SO VACCINE
LA English
DT Article
DE Diarrhea; Rotavirus; Vaccine; Nouakchott; Mauritania
ID MORTALITY
AB Introduction: Rotavirus vaccine was introduced in Mauritania in December 2014. We investigated hospitalizations with diarrhea during pre and post-vaccination periods among children aged 0-5 years in Nouakchott, the capital of Mauritania.
   Methods: We conducted a retrospective review of hospital admission registries from November 1st 2012 through October 31th 2017 at all referral hospitals in Nouakchott. We described admissions of children aged 0-5 years by diagnosis, data of admission, age and sex, and compared the proportion of all childhood hospitalizations with diarrhea before and after rotavirus vaccine introduction.
   Results: In total, 6552 (19%) of all 34,329 hospitalizations in 0-5 year-olds had diarrhea. Of these, 3523/16,952 (20.7%) were recorded during the pre-vaccine period, 1373/6897 (19.9%) during the transition period (November 2014-October 2015), and 1656/10,480 (15.8%) during the post-vaccination period. The proportion of all childhood hospitalizations with diarrhea during the pre-vaccine period was 22.6% among males and 18.7% among females. Approximately one third (32.3%) of hospitalizations with diarrhea occurred in children aged 6-11 months. During the post-vaccination period, the proportion of hospitalizations with diarrhea declined by 24%, and the highest reduction (74%) was observed in children aged 2 to 5 years (P < 0.001).
   Conclusions: The proportion of childhood hospitalizations with diarrhea in Nouakchott was reduced by about one fourth after introduction of rotavirus vaccination in Mauritania, indicating a major impact for public health for children in the capital city. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Cheikh-brahim Ahmed, Mohamed-Lemine; Filali-Maltouf, Abdelkarim] Univ Mohammed 5, Dept Biol, Lab Microbiol & Mol Biol, Rabat, Morocco.
   [Heukelbach, Jorg] Univ Fed Ceara, Sch Med, Dept Community Hlth, BR-60430140 Fortaleza, Ceara, Brazil.
   [Heukelbach, Jorg] James Cook Univ, Coll Publ Hlth Med & Vet Sci, Div Trop Hlth & Med, Townsville, Qld, Australia.
   [Weddih, Abdellahi; Sidatt, Mariem] Univ Nouakchott El Asriya, Fac Med, Dept Pediat, Nouakchott, Mauritania.
   [Weddih, Abdellahi; Sidatt, Mariem; Makhalla, Khattry] Minist Hlth, Dept Pediat, Nouakchott, Mauritania.
   [Dahdi, Sid'Ahmed] Univ Nouakchott El Asriya, Fac Med, Dept Publ Hlth, Nouakchott, Mauritania.
   [Ahmed, Aly Cheybany Cheikh] Minist Hlth, Dept Mother & Child Hlth, Nouakchott, Mauritania.
   [Cheikh-brahim Ahmed, Mohamed-Lemine; El-Mami, Mohamed Val] Univ Nouakchott El Asriya, Fac Sci & Technol, Dept Biol, Unity Epidemiol & Divers Microorganisms, Nouakchott, Mauritania.
   [Cheikh-brahim Ahmed, Mohamed-Lemine; Tate, Jacqueline E.; Parashar, Umesh D.] CDC Atlanta, Dept Epidemiol Gastroenteritis, Atlanta, GA USA.
   [Benhafid, Mohammed] Natl Inst Hyg, Dept Virol, Unity Gastroenteritis, Rabat, Morocco.
RP Ahmed, MLCB (reprint author), Univ Mohammed 5, Dept Biol, Lab Microbiol & Mol Biol, Rabat, Morocco.; Ahmed, MLCB (reprint author), Univ Nouakchott El Asriya, Fac Sci & Technol, Dept Biol, Unity Epidemiol & Divers Microorganisms, Nouakchott, Mauritania.; Ahmed, MLCB (reprint author), Univ Mohammed 5, Fac Sci, Dept Biol, Lab Microbiol & Mol Biol, Rabat, Morocco.
EM lemine1987@hotmail.fr
RI Ahmed, Mohamed lemine cheikh brahim/X-4569-2019
OI Ahmed, Mohamed lemine cheikh brahim/0000-0003-3904-2809; Heukelbach,
   Jorg/0000-0002-7845-5510; FILALI-MALTOUF, Abdelkarim/0000-0002-2727-3389
CR Ahmed MLCB, 2018, TROP MED INFECT DIS, V17
   [Anonymous], 2014, AFRICA BBC       SEP, P3
   Bado AR, 2016, GLOBAL HEALTH ACTION, V9, P1, DOI 10.3402/gha.v9.30166
   Esparza-Aguilar M, 2013, B WORLD HEALTH ORGAN, V92, P117
   Gastanaduy PA, 2013, PEDIATRICS, V131, pE1115, DOI 10.1542/peds.2012-2797
   Global Burden of Disease Collaborative Network, 2017, GLOB BURD DIS STUD 2
   Gouvea Vera S, 2007, Open Virol J, V1, P47, DOI 10.2174/1874357900701010047
   Groome MJ, 2014, LANCET INFECT DIS, V14, P1096, DOI 10.1016/S1473-3099(14)70940-5
   Hegazi MA, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000006574
   Kotloff KL, 2013, LANCET, V382, P209, DOI 10.1016/S0140-6736(13)60844-2
   Lanata CF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072788
   Liu L, 2015, LANCET, V385, P430, DOI 10.1016/S0140-6736(14)61698-6
   Shah MP, 2017, EXPERT REV VACCINES, V16, P987, DOI 10.1080/14760584.2017.1371595
   Sy I, 2012, MED SANTE TROP, V22, P217, DOI 10.1684/mst.2012.0031
   Sy I, 2017, SANTE PUBLIQUE, V29, P741, DOI 10.3917/spub.175.0741
   Sy Ibrahima, 2010, Sante, V20, P51, DOI 10.1684/san.2010.0187
   Tate JE, 2016, CLIN INFECT DIS, V62, pS96, DOI 10.1093/cid/civ1013
   UNICEF. WHO, 2009, DIARRH WHY CHILDR ST, V1, P58
NR 18
TC 0
Z9 0
U1 1
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 7
PY 2019
VL 37
IS 11
BP 1407
EP 1411
DI 10.1016/j.vaccine.2019.01.078
PG 5
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HP1DK
UT WOS:000461405400005
PM 30765173
DA 2020-05-12
ER

PT J
AU Stasi, C
   Monnini, M
   Cellesi, V
   Salvadori, M
   Marri, D
   Ameglio, M
   Gabbuti, A
   Di Fiandra, T
   Voller, F
   Silvestri, C
AF Stasi, Cristina
   Monnini, Mirko
   Cellesi, Valerio
   Salvadori, Marco
   Marri, Daniele
   Ameglio, Mateo
   Gabbuti, Andrea
   Di Fiandra, Teresa
   Voller, Fabio
   Silvestri, Caterina
TI Screening for hepatitis B virus and accelerated vaccination schedule in
   prison: A pilot multicenter study
SO VACCINE
LA English
DT Article
DE Hepatitis B virus infection; Screening; Vaccination; Prison
ID VIRAL-INFECTIONS; TUBERCULOSIS; HIV
AB Background and Aim: Vaccine against hepatitis B virus (HBV) is highly effective in preventing HBV infection. The aims of this study were to (1) increase the epidemiological knowledge on the impact of HBV in Tuscany region prisons by registering the results of serum screening on a clinical medical record and (2) increase the anti-HBV vaccination using an accelerated schedule.
   Methods: Our study population was composed of all detainees present in prisons and all constrained from freedom or at institutions in the Tuscany region and not vaccinated at these facilities from 1 December 2016 to 31 May 2017.
   Results: Of 17 detention facilities in the Tuscany region, 15 were enrolled in the study. On 28 February 2017, there were 3068 detainees present in these institutions. Considering the 1075 subjects screened for HBV serum markers, 730 (67.9%) were susceptible to infection and needed to be vaccinated. Five hundred and ninety-six agreed to be vaccinated (82%); 27 (2.5%) of our subjects had an isolated anti-HBc, 20 (1.9%) were HBV infected (HBsAg+), 127 (11.8%) had previous HBV infection (anti-HBs+, anti-HBc+ and HBsAg), and 171 had been previously vaccinated. Five hundred and fifty-five inmates (95.1%) received the first vaccine dose, and 404 (83%) underwent the third dose at day 21.
   Conclusion: This study showed that of a high percentage of subjects who underwent screening, more than half needed to be vaccinated. Moreover, our study reached very high levels of vaccination coverage, considering both the entire enrolled population and the new inmates. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Stasi, Cristina; Monnini, Mirko; Voller, Fabio; Silvestri, Caterina] Reg Hlth Agcy Tuscany, Observ Epidemiol, Florence, Italy.
   [Stasi, Cristina] Univ Florence, Dept Expt & Clin Med, Florence, Italy.
   [Cellesi, Valerio] Local Healthcare Tuscany North West, Prison Healthcare Volterra, Volterra, Italy.
   [Salvadori, Marco] Local Healthcare Tuscany Ctr, Sollicciano Dist House, Florence, Italy.
   [Marri, Daniele] Univ Hosp Siena, Infect Dis & Hepatol Unit, Siena, Italy.
   [Ameglio, Mateo] Local Healthcare Tuscany Southest, Dept Operat Units Prison, Siena, Italy.
   [Gabbuti, Andrea] Local Healthcare Tuscany Ctr, Infect Dis Unit, Florence, Italy.
   [Di Fiandra, Teresa] Minist Hlth, Gen Directorate Hlth Prevent, Rome, Italy.
RP Stasi, C (reprint author), Univ Florence, Dept Expt & Clin Med, Florence, Italy.
EM cristina.stasi@gmail.com
OI Stasi, Cristina/0000-0002-9146-9968
FU Ministry of Health, ItalyMinistry of Health, Italy
FX Ministry of Health, Italy funded this study.
CR Almasio PL, 2011, DIGEST LIVER DIS, V43, P589, DOI 10.1016/j.dld.2010.12.004
   BAYAS JM, 1993, VACCINE, V11, P1441, DOI 10.1016/0264-410X(93)90174-V
   Centers for Disease Control and Prevention, 2003, PREV CONTR INF HEP V
   Chang MH, 2015, CSH PERSPECT MED, V5, DOI 10.1101/cshperspect.a021493
   Christensen PB, 2004, VACCINE, V22, P3897, DOI 10.1016/j.vaccine.2004.04.011
   Dolan K, 2016, LANCET, V388, P1089, DOI 10.1016/S0140-6736(16)30466-4
   ECDC Scientific Advice, 2016, SYST REV HEP B C PRE
   Gilbert R L, 2004, Commun Dis Public Health, V7, P306
   Idilman R, 2002, AM J GASTROENTEROL, V97, P435, DOI 10.1111/j.1572-0241.2002.05482.x
   Jacomet C, 2016, EUR J PUBLIC HEALTH, V26, P122, DOI 10.1093/eurpub/ckv183
   OFlanagan D, 2008, VENICE 2 PROJECT HEP
   Sagnelli E, 2012, EUR REV MED PHARMACO, V16, P2142
   Schweitzer A, 2015, LANCET, V386, P1546, DOI 10.1016/S0140-6736(15)61412-X
   Shirani Kiana, 2015, Adv Biomed Res, V4, P17, DOI 10.4103/2277-9175.148675
   Stasi C, 2017, J CLIN TRANSL HEPATO, V5, P272, DOI 10.14218/JCTH.2017.00010
   Stasi C, 2016, EUR J INTERN MED, V34, pE21, DOI 10.1016/j.ejim.2016.04.020
   Van Herck K, 2007, SEX TRANSM INFECT, V83, P426, DOI 10.1136/sti.2006.022111
NR 17
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 7
PY 2019
VL 37
IS 11
BP 1412
EP 1417
DI 10.1016/j.vaccine.2019.01.049
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HP1DK
UT WOS:000461405400006
PM 30733091
DA 2020-05-12
ER

PT J
AU Li, TT
   Zhang, ZY
   Zhang, ZQ
   Qiao, JM
   Rong, R
   Zhang, YY
   Yao, QB
   Li, ZK
   Shen, HL
   Huang, F
   Xue, WH
   Gao, SQ
   Li, SY
   Zheng, QB
   Yu, H
   Zhang, J
   Gu, Y
   Li, SW
   Xia, NS
AF Li, Tingting
   Zhang, Zhenyong
   Zhang, Zhiqing
   Qiao, Jiaming
   Rong, Rui
   Zhang, Yuyun
   Yao, Qiaobin
   Li, Zekai
   Shen, Honglin
   Huang, Fang
   Xue, Wenhui
   Gao, Shuangquan
   Li, Shaoyong
   Zheng, Qingbing
   Yu, Hai
   Zhang, Jun
   Gu, Ying
   Li, Shaowei
   Xia, Ningshao
TI Characterization of native-like HIV-1 gp140 glycoprotein expressed in
   insect cells
SO VACCINE
LA English
DT Article
DE HIV-1; Envelope glycoprotein; Native-like trimer; Vaccine; Insect cell
ID ENVELOPE GLYCOPROTEIN; TRIMERS; VIRUS; ANTIBODY; VACCINE; GLYCOSYLATION;
   PURIFICATION; CLEAVAGE; GP41; NEUTRALIZATION
AB The trimeric HIV-1 envelope glycoprotein (Env) is critical for vaccine development aimed at achieving broadly-neutralizing antibody responses. The use of various recombinant expression systems and construct designs are associated with the resultant nature of produced proteins, especially in terms of glycosylation, antigenicity, and immunogenicity of the glycoprotein. Here, we explored an otherwise baculovirus cassette than classical one designed to express HIV-1 Env protein, including SOSIP mutation and Foldon moiety involvement. This improved design increased the ratio of the Env trimer fraction from similar to 40% to similar to 60% with respect to that of prototypical design, as indicated by high-performance size exclusion chromatography and sedimentation velocity analysis. In addition, the design prolonged cell viability and enhanced the final yield (approximately 13-15 mg/L) after affinity purification. gp140 produced from insect cells mimicked the native-like trimer and mainly adopted glycosylation pattern of oligomannose glycans. The native-like Env proteins conferred cross-clade neutralizing antibody production in BALB/c mice. In summary, the expression of Env in insect cells by optimizing the baculovirus vector provides an alternative strategy for HIV-1 immunogen production and may benefit future Env-based HIV vaccine design. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Li, Tingting; Zhang, Zhenyong; Rong, Rui; Yao, Qiaobin; Shen, Honglin; Huang, Fang; Xue, Wenhui; Gu, Ying; Li, Shaowei; Xia, Ningshao] Xiamen Univ, Sch Life Sci, State Key Lab Mol Vaccinol & Mol Diagnost, Xiamen 361102, Peoples R China.
   [Zhang, Zhiqing; Qiao, Jiaming; Zhang, Yuyun; Li, Zekai; Gao, Shuangquan; Li, Shaoyong; Zheng, Qingbing; Yu, Hai; Zhang, Jun; Gu, Ying; Li, Shaowei; Xia, Ningshao] Xiamen Univ, Sch Publ Hlth, Natl Inst Diagnost & Vaccine Dev Infect Dis, Xiamen 361102, Peoples R China.
RP Gu, Y; Li, SW (reprint author), Xiamen Univ, Sch Life Sci, Natl Inst Diagnost & Vaccine Dev Infect Dis, Xiamen 361102, Peoples R China.
EM guying@xmu.edu.cn; shaowei@xmu.edu.cn
FU Chinese government: National Natural Science Foundation [81671645,
   U1705283, 31670935]; Chinese Scholarship CouncilChina Scholarship
   Council [201706315049]
FX S.L. and Y.G. acknowledge funding support from the Chinese government:
   National Natural Science Foundation (Grants 81671645, U1705283,
   31670935) and Chinese Scholarship Council (Grant No. 201706315049).
CR Binley JM, 2000, J VIROL, V74, P627, DOI 10.1128/JVI.74.2.627-643.2000
   Blattner C, 2014, IMMUNITY, V40, P669, DOI 10.1016/j.immuni.2014.04.008
   Chen B, 2000, J BIOL CHEM, V275, P34946, DOI 10.1074/jbc.M004905200
   Cheng C, 2016, J VIROL, V90, P2740, DOI 10.1128/JVI.02380-15
   Chung NPY, 2014, RETROVIROLOGY, V11, DOI 10.1186/1742-4690-11-33
   EARL PL, 1991, J VIROL, V65, P2047, DOI 10.1128/JVI.65.4.2047-2055.1991
   EARL PL, 1990, P NATL ACAD SCI USA, V87, P648, DOI 10.1073/pnas.87.2.648
   Frey G, 2008, P NATL ACAD SCI USA, V105, P3739, DOI 10.1073/pnas.0800255105
   Gu Y, 2015, CELL RES, V25, P604, DOI 10.1038/cr.2015.34
   Guenaga J, 2016, J VIROL, V90, P2806, DOI 10.1128/JVI.02652-15
   He LL, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12041
   Herrera C, 2005, VIROLOGY, V338, P154, DOI 10.1016/j.virol.2005.05.002
   Hitchman RB, 2010, CELL BIOL TOXICOL, V26, P57, DOI 10.1007/s10565-009-9133-y
   Hom LG, 2000, VIROLOGY, V277, P178, DOI 10.1006/viro.2000.0586
   Hom LG, 1998, BIOTECHNIQUES, V25, P18, DOI 10.2144/98251bm01
   Hu JK, 2015, J VIROL, V89, P10383, DOI 10.1128/JVI.01653-15
   Hu Y-C, 2014, EXP REV VACC, V7, P363
   Hunter E., 1997, HUM RETROVIRUSES AID
   Jarvas G, 2016, ANAL CHEM, V88, P11364, DOI 10.1021/acs.analchem.6b03596
   Jarvis DL, 1998, CURR OPIN BIOTECH, V9, P528, DOI 10.1016/S0958-1669(98)80041-4
   Jarvis DL, 2009, METHOD ENZYMOL, V463, P191, DOI 10.1016/S0076-6879(09)63014-7
   Jefferis R, 2009, NAT REV DRUG DISCOV, V8, P226, DOI 10.1038/nrd2804
   Julien JP, 2013, SCIENCE, V342, P1477, DOI 10.1126/science.1245625
   Kaba SA, 2004, J VIROL METHODS, V122, P113, DOI 10.1016/j.jviromet.2004.07.006
   Khayat R, 2013, J VIROL, V87, P9865, DOI 10.1128/JVI.01222-13
   Klasse PJ, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005864
   Klein F, 2013, SCIENCE, V341, P1199, DOI 10.1126/science.1241144
   Kong L, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12040
   Kong L, 2010, J MOL BIOL, V403, P131, DOI 10.1016/j.jmb.2010.08.033
   Kulp DW, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01549-6
   Liu FX, 2013, PROTEIN EXPRES PURIF, V90, P104, DOI 10.1016/j.pep.2013.05.009
   MCCUNE JM, 1988, CELL, V53, P55, DOI 10.1016/0092-8674(88)90487-4
   Medina-Ramirez M, 2017, CURR OPIN HIV AIDS, V12, P241, DOI 10.1097/COH.0000000000000363
   Moore PL, 2006, J VIROL, V80, P2515, DOI 10.1128/JVI.80.5.2515-2528.2006
   Nkolola JP, 2010, J VIROL, V84, P3270, DOI 10.1128/JVI.02252-09
   Ozorowski G, 2017, NATURE, V547, P360, DOI 10.1038/nature23010
   Pancera M, 2014, NATURE, V514, P455, DOI 10.1038/nature13808
   Parren PWHI, 1997, NAT MED, V3, P366, DOI 10.1038/nm0497-366d
   Pritchard LK, 2015, J VIROL, V89, P8932, DOI 10.1128/JVI.01190-15
   Pritchard LK, 2015, CELL REP, V11, P1604, DOI 10.1016/j.celrep.2015.05.017
   Pugach P, 2015, J VIROL, V89, P3380, DOI 10.1128/JVI.03473-14
   Ringe RP, 2015, J VIROL, V89, P12189, DOI 10.1128/JVI.01768-15
   Sanders RW, 2015, SCIENCE, V349, DOI 10.1126/science.aac4223
   Sanders RW, 2017, IMMUNOL REV, V275, P161, DOI 10.1111/imr.12481
   Sanders RW, 2004, AIDS RES HUM RETROV, V20, P742, DOI 10.1089/0889222041524544
   Sanders RW, 2002, J VIROL, V76, P8875, DOI 10.1128/JVI.76.17.8875-8889.2002
   Sattentau QJ, 2013, VACCINES, V1, DOI 10.3390/vaccines1040497
   Scharf L, 2015, CELL, V162, P1379, DOI 10.1016/j.cell.2015.08.035
   Szabo Z, 2011, ANAL CHEM, V83, P5329, DOI 10.1021/ac2007587
   van Gils MJ, 2013, VIROLOGY, V435, P46, DOI 10.1016/j.virol.2012.10.004
   van Oers MM, 2015, J GEN VIROL, V96, P6, DOI 10.1099/vir.0.067108-0
   Verkerke HP, 2016, J VIROL, V90, P9471, DOI 10.1128/JVI.01351-16
   Wei X, 2003, NATURE, P422
   West AP, 2014, CELL, V156, P633, DOI 10.1016/j.cell.2014.01.052
   Yang C, 2017, ADV WIREL TECHNOL TE, P1, DOI 10.4018/978-1-5225-1712-2
   Yang XZ, 2002, J VIROL, V76, P4634, DOI 10.1128/JVI.76.9.4634-4642.2002
NR 56
TC 0
Z9 0
U1 2
U2 10
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 7
PY 2019
VL 37
IS 11
BP 1418
EP 1427
DI 10.1016/j.vaccine.2019.01.048
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HP1DK
UT WOS:000461405400007
PM 30737044
DA 2020-05-12
ER

PT J
AU Traicoff, D
   Pope, A
   Bloland, P
   Lal, D
   Bahl, J
   Stewart, S
   Ryman, T
   Abbruzzese, M
   Lee, C
   Ahrendts, J
   Shamalla, L
   Sandhu, H
AF Traicoff, Denise
   Pope, Alice
   Bloland, Peter
   Lal, Dharmesh
   Bahl, Jhilmil
   Stewart, Steven
   Ryman, Tove
   Abbruzzese, Molly
   Lee, Carla
   Ahrendts, Johannes
   Shamalla, Lorraine
   Sandhu, Hardeep
TI Developing standardized competencies to strengthen immunization systems
   and workforce
SO VACCINE
LA English
DT Article
DE Immunization competencies; Global health; Health workforce; Workforce
   development; Programme planning; Competency modeling
AB Despite global support for immunization as a core component of the human right to health and the maturity of immunization programs in low- and middle-income countries throughout the world, there is no comprehensive description of the standardized competencies needed for immunization programs at the national, multiple sub-national, and community levels. The lack of defined and standardized competencies means countries have few guidelines to help them address immunization workforce planning, program management, and performance monitoring. Potential consequences resulting from the lack of defined competencies include inadequate or inefficient distribution of resources to support the required functions and difficulties in adequately managing the health workforce. In 2015, an international multi agency working group convened to define standardized competencies that national immunization programs could adapt for their own workforce planning needs. The working group used a stepwise approach to ensure that the competencies would align with immunization programs' objectives. The first step defined the attributes of a successful immunization program. The group then defined the work functions needed to achieve those attributes. Based on the work functions, the working group defined specific competencies. This process resulted in three products: (1) Attributes of an immunization program described within eight technical domains at four levels within a health system: National, Provincial, District/Local, and Community; (2) 229 distinct functions within those eight domains at each of the four levels; and (3) 242 competencies, representing eight technical domains and two foundational domains (Management and Leadership and Vaccine Preventable Diseases and Program). Currently available as a working draft and being tested with immunization projects in several countries, the final document will be published by WHO as normative guidelines. Vertical immunization programs as well as integrated systems can customize the framework to suit their needs. Standardized competencies can support immunization program improvements and help strengthen effective health systems. Published by Elsevier Ltd.
C1 [Traicoff, Denise; Pope, Alice; Bloland, Peter; Stewart, Steven; Lee, Carla; Sandhu, Hardeep] Ctr Dis Control & Prevent, 1600 Clifton Rd,MS A-04, Atlanta, GA 30333 USA.
   [Lal, Dharmesh] Publ Hlth Fdn India, Plot 47,Sect 44, Gurugram 122002, India.
   [Bahl, Jhilmil] World Hlth Org, 20 Ave Appia, CH-1211 Geneva 27, Switzerland.
   [Ryman, Tove; Abbruzzese, Molly] Bill & Melinda Gates Fdn, 500 5th Ave, Seattle, WA 98109 USA.
   [Ahrendts, Johannes] Gavi Vaccine Alliance, Global Hlth Campus,Chemin Pommier 40, CH-1218 Geneva, Switzerland.
   [Shamalla, Lorraine] UNICEF, Programme Div Polio, 3 United Nation Plaza,8th Floor, New York, NY 10017 USA.
   [Stewart, Steven] 40 Shorewood Dr, Asheville, NC 28804 USA.
RP Traicoff, D (reprint author), Ctr Dis Control & Prevent CDC, 1600 Clifton Rd,MS A-04, Atlanta, GA 30333 USA.
EM dtraicoff@cdc.gov; apope@cdc.gov; pbloland@cdc.gov; bahlj@who.int;
   Tove.Ryman@gatesfounda-tion.org; Molly.abbruzzese@gatesfoundation.org;
   CLee@cdc.gov; jahrendts@gavi.org; lshamalla@unicef.org; HSandhu@cdc.gov
FU World Health OrganizationWorld Health Organization [001]; Intramural CDC
   HHS [CC999999]
CR Bill Hansen M., 2002, ROUTINE IMMUNI UNPUB
   Campion MA, 2011, PERS PSYCHOL, V64, P225, DOI 10.1111/j.1744-6570.2010.01207.x
   Gilani S., 2017, SAGE M APR 2017 SESS
   GPEI, 2013, POL ER ENDG STRAT PL
   Liu JX, 2017, HUM RESOUR HEALTH, V15, DOI 10.1186/s12960-017-0193-4
   Murphy GT, 2013, HEALTH POLICY PLANN, V28, P739, DOI 10.1093/heapol/czs115
   Public Health Agency of Canada, 2008, IMM COMP HLTH PROF, P1
   Rummler GA, 2013, IMPROVING PERFORMANC
   Shippmann JS, 2000, PERS PSYCHOL, V53, P703, DOI 10.1111/j.1744-6570.2000.tb00220.x
   United Kingdom Health Protection Agency Department of Health Social Services and Public Safety Royal College of Nursing, 2005, NAT MIN STAND IMM TR
   University of Nebraska-Lincoln Business & Finance Human Resources, 2018, DEF COMP THEIR APPL
   US Agency for International Development, 2003, IMM ESS PRACT FIELD
   VANDELAER J, 2008, B WHO, V86
   WHO, 2015, IMM PRACT PRACT GUID
   World Health Organization, 2016, 2016 MIDT REV GLOB V
   World Health Organization, 2017, WEEKLY EPIDEMIOLOGIC, V22, P315
   World Health Organization, 2008, TRAIN MIDL MAN MLM
   World Health Organization, 2012, DRAFT GLOBAL VACCI A, V65, P1
   World Health Organization, 2016, IMM VACC BIOL RED ST
   World Health Organization African Regional Office. African, 2012, REG EPI REV GUID
   World Health Organization Eastern Mediterranean Regional Office, 2011, DRAFT IMM EPI UNPUB
NR 21
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 7
PY 2019
VL 37
IS 11
BP 1428
EP 1435
DI 10.1016/j.vaccine.2019.01.047
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HP1DK
UT WOS:000461405400008
PM 30765172
OA Other Gold, Green Accepted
DA 2020-05-12
ER

PT J
AU Zhang, TT
   Cui, LL
   Geng, XY
   Yu, XL
   Zhang, J
AF Zhang, Tiantian
   Cui, Liangliang
   Geng, Xingyi
   Yu, Xiaolin
   Zhang, Ji
TI Epidemiology study of pediatric primary intussusception aged <= 24
   months in pre-rotavirus vaccine era of Jinan, China
SO VACCINE
LA English
DT Article
DE Pediatric intussusception; Rotavirus vaccination; Epidemiology
ID HOSPITAL-BASED SURVEILLANCE; CHILDREN; INFANTS; RISK; DISEASE;
   IMMUNIZATION; BENEFITS
AB Introduction: Few studies have reported on the epidemiological characteristics of pediatric primary intussusception in the pre-rotavirus vaccine era of China. It is important to complementary baseline data before rotavirus vaccine introduction in China. This study conduct a retrospective investigation and evaluated the incidence rate, described the epidemiology of pediatric primary intussusception aged <= 24 months.
   Methods: We conducted a retrospective investigation in all secondary- and tertiary-hospitals in Jinan. Pediatric primary intussusception inpatients aged <= 24 months were identified depending on ICD-10 discharge code from a total of 63 hospitals from 2011 to 2015. Demographic and clinical information were extracting from the electronic clinical record systems.
   Results: A total of 575 pediatric primary intussusception inpatients were identified with average annual incidence of 86.5 per 100,000. A significantly higher incidence was observed in males (chi(2) = 13.8, P < 0.01), in the <= 12 months old age group (chi(2) = 19.5, P < 0.01) and from the urban areas (chi(2) = 63.31, P < 0.001). No clear seasonality found. Abdominal pain (80.9%) and vomiting (63.3%) were the most frequently reported. Most intussusception cases occurred in ileo-cecum. Over 92% of intussusception cases were diagnosed by ultrasound alone and 77.4% was successfully treated by air enema. 99.7% were cured. The median time of hospitalization was 2 days (range: 0-35 days).
   Conclusion: This retrospective study provides baseline information of incidence, epidemiologyand clinical characteristics of pediatric primary intussusception in Jinan City during 2011-2016 before the introduction of rotavirus vaccine. It will be important for evaluating safety of rotavirus vaccine if it will be introduced to the routine immunization program in China. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Zhang, Tiantian] Shandong Univ, 44 Culture Western Rd, Jinan 250013, Shandong, Peoples R China.
   [Cui, Liangliang; Geng, Xingyi] Jinan Municipal Ctr Dis Control & Prevent, 2 Weiliu Rd, Jinan 250021, Shandong, Peoples R China.
   [Yu, Xiaolin] Shandong Ctr Dis Control & Prevent, 16992 Qianfo Mt St Jinan, Jinan 250014, Shandong, Peoples R China.
   [Zhang, Ji] Int Ctr Med Sci, Jinan Adm Comm, Xiyuan Bldg, Jinan, Shandong, Peoples R China.
RP Cui, LL; Zhang, J (reprint author), Jinan Ctr Dis Control & Prevent, MPH, Weiliu Rd, Jinan 250021, Shandong, Peoples R China.
EM cll60222@163.com
CR Bines JE, 2004, VACCINE, V22, P569, DOI 10.1016/j.vaccine.2003.09.016
   Bines JE, 2009, J INFECT DIS, V200, pS282, DOI 10.1086/605051
   Blanch AJM, 2007, EMERG MED AUSTRALAS, V19, P45, DOI 10.1111/j.1742-6723.2007.00923.x
   Carlin JB, 2013, CLIN INFECT DIS, V57, P1427, DOI 10.1093/cid/cit520
   Chen SCC, 2010, PEDIATR NEONATOL, V51, P285, DOI 10.1016/S1875-9572(10)60055-1
   Chen YE, 2005, ARCH DIS CHILD, V90, P1077, DOI 10.1136/adc.2005.074104
   Costantino C, 2003, ITAL J PEDIATR, V41, P52
   Cui Pengwei, 2016, Zhonghua Liu Xing Bing Xue Za Zhi, V37, P410, DOI 10.3760/cma.j.issn.0254-6450.2016.03.025
   Cui SH, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-2013-1
   Duan ZJ, 2009, J INFECT DIS, V200, pS167, DOI 10.1086/605039
   Gao ZF, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109997
   Haber P, 2015, VACCINE, V33, P4873, DOI 10.1016/j.vaccine.2015.07.054
   Ho WL, 2005, J FORMOS MED ASSOC, V104, P398
   Hong Kong, 2007, HONG KONG MED J, V13, P279
   Huppertz HI, 2006, PEDIATR INFECT DIS J, V25, pS22, DOI 10.1097/01.inf.0000197713.32880.46
   Jang J, 2017, J KOREAN MED SCI, V32, P1647, DOI 10.3346/jkms.2017.32.10.1647
   Jiang JQ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055729
   Jo DS, 2009, INT J INFECT DIS, V13, pE383, DOI 10.1016/j.ijid.2009.01.011
   Kamdem AF, 2017, EUR J PEDIATR, V176, P301, DOI 10.1007/s00431-016-2838-z
   Kassim P, 2017, VACCINE, V35, P4276, DOI 10.1016/j.vaccine.2017.05.064
   Liu N, 2018, VACCINE, V36, P7862, DOI 10.1016/j.vaccine.2018.02.032
   Lloyd-Johnsen C, 2012, VACCINE, V30, pA190, DOI 10.1016/j.vaccine.2011.11.015
   Muhsen K, 2014, BMC PEDIATR, V14, DOI 10.1186/1471-2431-14-218
   Murphy TV, 2001, NEW ENGL J MED, V344, P564, DOI 10.1056/NEJM200102223440804
   Trang NV, 2014, J PEDIATR-US, V164, P366, DOI 10.1016/j.jpeds.2013.10.006
   Parashar UD, 2016, CLIN INFECT DIS, V62, pS91, DOI 10.1093/cid/civ1015
   Parashar UD, 2009, J INFECT DIS, V200, pS9, DOI 10.1086/605025
   Patel MM, 2011, NEW ENGL J MED, V364, P2283, DOI 10.1056/NEJMoa1012952
   Phua KB, 2013, BMC PEDIATR, V13, DOI 10.1186/1471-2431-13-161
   Rosie B, 2016, NEW ZEAL MED J, V129, P36
   Saez-Llorens X, 2013, BMC GASTROENTEROL, V13, DOI 10.1186/1471-230X-13-95
   Samad L, 2013, VACCINE, V31, P4098, DOI 10.1016/j.vaccine.2013.06.084
   Trotta F, 2016, ITAL J PEDIATR, V42, DOI 10.1186/s13052-016-0298-8
   Vesikari T, 2015, PEDIATR INFECT DIS J, V34, P635, DOI 10.1097/INF.0000000000000683
   Weintraub ES, 2014, NEW ENGL J MED, V370, P513, DOI 10.1056/NEJMoa1311738
   Wu D, 2016, PEDIATR INFECT DIS J, V35, pE392, DOI 10.1097/INF.0000000000001327
   Yen C, 2012, J INFECT DIS, V206, P41, DOI 10.1093/infdis/jis314
   Yousafzai MT, 2018, VACCINE, V36, P7775, DOI 10.1016/j.vaccine.2017.06.073
NR 38
TC 0
Z9 0
U1 1
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 7
PY 2019
VL 37
IS 11
BP 1436
EP 1442
DI 10.1016/j.vaccine.2019.01.060
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HP1DK
UT WOS:000461405400009
PM 30770223
DA 2020-05-12
ER

PT J
AU Malshe, N
   Palkar, S
   Kulkarni, R
   Lalwani, S
   Mishra, AC
   Arankalle, V
AF Malshe, Nandini
   Palkar, Sonali
   Kulkarni, Ruta
   Lalwani, Sanjay
   Mishra, Akhilesh Chandra
   Arankalle, Vidya
TI Early disappearance of maternal anti-measles, mumps, rubella, and
   varicella antibodies in Indian infants
SO VACCINE
LA English
DT Article
DE Measles; Mumps; Rubella; Varicella; Maternal antibody; Vaccination
ID VACCINATION; AGE; IMMUNIZATION; CHILDREN; ZOSTER
AB Background: Immunization of children with vaccines against Measles, Mumps, Rubella, and Varicella (MMRV) is practiced globally with varied recommendations. In India, measles vaccine is administered alone or as MMR at 9 months age. Varicella vaccine is not routinely used. Immunization age is a function of disappearance of maternal antibodies and natural exposure of the children to the pathogens. In view of the measles-WHO-initiative, we aimed to assess if the current immunization age for measles is still valid. In addition, the kinetics of IgG and IgM antibodies against rubella, mumps and varicella viruses was also examined.
   Methods: This cross-sectional study was conducted at a tertiary care hospital in Pune, India. A total of 600 children, 150 each in 6-month/9-month (no vaccination) and 12-month/15-month (minimum 4 weeks post-measles-vaccine) cohorts were included. History of these infections and birth status (term/preterm) was recorded. All serum samples were screened for IgG-anti-MMRV-antibodies while IgG-positives were tested for specific IgM antibodies (ELISA).
   Results: At 6-months, the prevalence of MMRV antibodies was 4.7%, 2.7%, 10.7%, 5.3% respectively depicting disappearance of maternal antibodies in majority of the children. Birth status did not influence antibody positivity. Despite vaccination at similar to 9-months, >25% children were still susceptible to measles virus at the age of 12/15-months. The ratio of clinical:subclinical infections was 4:10 (measles) and 12:1 (varicella). All the mumps/rubella IgM positives (1 and 2 respectively) represented subclinical infections.
   Conclusion: Demonstration of early disappearance of maternal antibodies against MMRV viruses leading to the risk of these infections at an early age emphasize need for early immunization of Indian children. Suboptimal response to measles vaccine needs to be seriously addressed especially in view of the WHO's initiative for measles eradication. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Malshe, Nandini; Palkar, Sonali; Lalwani, Sanjay] Bharati Vidyapeeth Deemed Univ, Coll Med, Dept Pediat, Pune, Maharashtra, India.
   [Kulkarni, Ruta; Mishra, Akhilesh Chandra; Arankalle, Vidya] Bharati Vidyapeeth Deemed Univ, IRSHA, Pune, Maharashtra, India.
RP Arankalle, V (reprint author), Bharati Vidyapeeth Deemed Univ, IRSHA, Dept Communicable Dis, Pune Satara Rd, Pune 411043, Maharashtra, India.
EM varankalle@yahoo.com
FU GlaxoSmithKline Biologicals SAGlaxoSmithKline
FX The study was supported by GlaxoSmithKline Biologicals SA, (GSK study
   identifier: 207269). GlaxoSmithKline Biologicals SA was provided the
   opportunity to review a preliminary version of this manuscript for
   factual accuracy, but the authors are solely responsible for final
   content and interpretation.
CR Aaby P, 2014, CLIN INFECT DIS, V59, P484, DOI 10.1093/cid/ciu354
   Aaby P, 2010, BMJ-BRIT MED J, V341, DOI 10.1136/bmj.c6495
   Atkinson W, 2011, PINK BOOK COURSE TXB
   Awofeso N, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-358
   Begde F, 2015, EUR J PEDIATR, V174, P883, DOI 10.1007/s00431-014-2484-2
   Dehal N, 2015, LANCET, V386, P2389, DOI 10.1016/S0140-6736(15)01190-3
   DEIVANAYAGAM N, 1990, Indian Pediatrics, V27, P919
   Do VA, 2017, J INFECT DIS, V215, P1188, DOI 10.1093/infdis/jiw512
   Helfand RF, 1998, CLIN DIAGN LAB IMMUN, V5, P135, DOI 10.1128/CDLI.5.2.135-138.1998
   Indwar Pallavi, 2016, J Family Med Prim Care, V5, P777, DOI 10.4103/2249-4863.201161
   John S, 2004, J TROP PEDIATRICS, V50, P175, DOI 10.1093/tropej/50.3.175
   Joshi RR, 2003, BOMBAY HOSP J, V45, P40
   Kumari L, 2018, INDIAN J CHILD HLTH, V5, P428
   Lalwani S, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2014-007202
   Leuridan E, 2011, VACCINE, V29, P2222, DOI 10.1016/j.vaccine.2010.06.004
   Leuridan E, 2010, BRIT MED J, V340, DOI 10.1136/bmj.c1626
   Manirakiza A, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-327
   Martins CL, 2014, J INFECT DIS, V209, P1731, DOI 10.1093/infdis/jit804
   Pinquier D, 2011, HUM VACCINES, V7, P534, DOI 10.4161/hv.7.5.14820
   Plans-Rubio Pedro, 2012, Hum Vaccin Immunother, V8, P184, DOI 10.4161/hv.18444
   Singh J, 1999, INDIAN PEDIATR, V35, P1187
   SINGH R, 1994, INDIAN J MED RES, V100, P155
   Sultana R, 2006, SCAND J IMMUNOL, V64, P684, DOI 10.1111/j.1365-3083.2006.01857.x
   van den Berg JP, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094714
   Vashishtha VM, 2015, INDIAN PEDIATR, V52, P505, DOI 10.1007/s13312-015-0666-2
   Vashishtha VM, 2013, INDIAN PEDIATR, V50, P1095, DOI 10.1007/s13312-013-0292-9
   Waaijenborg S, 2013, J INFECT DIS, V208, P10, DOI 10.1093/infdis/jit143
   Yadav S, 2003, INDIAN J MED RES, V118, P183
NR 28
TC 1
Z9 1
U1 2
U2 8
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 7
PY 2019
VL 37
IS 11
BP 1443
EP 1448
DI 10.1016/j.vaccine.2019.01.043
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HP1DK
UT WOS:000461405400010
PM 30765170
DA 2020-05-12
ER

PT J
AU Zeng, YB
   Yuan, ZP
   Yin, JH
   Han, YF
   Chu, CI
   Fang, Y
AF Zeng, Yanbing
   Yuan, Zhipeng
   Yin, Jiahui
   Han, Yaofeng
   Chu, Cheng-I
   Fang, Ya
TI Factors affecting parental intention to vaccinate kindergarten children
   against influenza: A cross-sectional survey in China
SO VACCINE
LA English
DT Article
DE Kindergarten children; Influenza vaccination; Parental vaccination
   intention; Health Belief Model (HBM); Vaccination policy
ID HEALTH BELIEF MODEL; SEASONAL INFLUENZA; COVERAGE; EFFICACY; ADULTS;
   INFORMATION; PERCEPTIONS; POPULATION; HESITANCY; DECISIONS
AB Background: The impact of influenza in children under 5 can be severe and fatal. However, the influenza vaccination uptake in China remains suboptimal. The objectives of this study were to investigate parents' perceptions on influenza vaccination and to assess vaccination promotional factors.
   Methods: A cross-sectional survey among 1506 parents with children in kindergarten was conducted in two areas with different policies: self-paid vaccination and free vaccination. The questionnaire was based on the structure of the Health Belief Model (HBM). Multiple logistic regression was used to analyze the determinants of parental vaccination intention. Odds ratios (OR) and respective 95% confidence intervals (95% CI) are reported.
   Results: Within the free policy group versus the non-free group, vaccination intention rates were 76.3% versus 83.4%, and vaccination rates were 34.2% versus 3.1%. Results from multivariate analysis showed that parents with high scores for perceived susceptibility (OR = 1.44; 95% CI: 1.09-1.91), perceived benefits (OR = 1.80; 95% CI: 130-2.50) and cues to action (OR = 3.32; 95% CI: 2.47-4.46) were more likely to get their children vaccinated, while those perceived more barriers (OR = 0.50; 95% CI: 0.37-0.68) had lower vaccination intention. More knowledge (OR = 1.74; 95% CI: 1.18-2.56) and preferable attitudes (higher perceived necessity: OR = 1.84; 95% CI: 1.53-2.22; less safety worry: OR = 1.35; 95% CI: 1.10-1.66) were associated with significantly higher vaccination intention. Adjusted for parents' gender, age, education, income and children's age, the same significant factors were found. Parental intention was found to be influenced by different vaccination policies. Under a free policy, past influenza vaccination uptake (OR = 4.52; 95% CI: 1.07-19.02) greatly promoted parents' willingness to vaccinate their children.
   Conclusion: Parents had high intention to get their kindergarten children vaccinated with the influenza vaccine in spite of the low uptake rate. Our results indicate that offering free influenza vaccines and parental education over the next years may increase the influenza vaccination rate. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Zeng, Yanbing; Yuan, Zhipeng; Yin, Jiahui; Han, Yaofeng; Fang, Ya] Xiamen Univ, State Key Lab Mol Vaccinol & Mol Diagnost, Xiamen, Fujian, Peoples R China.
   [Zeng, Yanbing; Yuan, Zhipeng; Yin, Jiahui; Han, Yaofeng; Fang, Ya] Xiamen Univ, Sch Publ Hlth, Key Lab Hlth Technol Assessment Fujian Prov, Xiamen, Fujian, Peoples R China.
   [Chu, Cheng-I] Tzu Chi Univ, Dept Publ Hlth, Hualien, Taiwan.
RP Fang, Y (reprint author), Xiamen Univ, Sch Publ Hlth, Key Lab Hlth Technol Assessment Fujian Prov, Xiamen, Fujian, Peoples R China.
EM lyndon@gms.tcu.edu.tw; fangya@xmu.edu.cn
OI Yuan, Zhipeng/0000-0003-0763-9627
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [71874147, 81573257]; Natural Science Fund of Fujian
   ProvinceNatural Science Foundation of Fujian Province [2017101133]
FX This work was supported by National Natural Science Foundation of China
   [Grant Nos. 71874147, 81573257] and the project of Natural Science Fund
   of Fujian Province [Grant 2017101133].
CR Almeida CM, 2012, VACCINE, V30, P3003, DOI 10.1016/j.vaccine.2012.01.079
   [Anonymous], 2007, STAT METHODS BIOMEDI
   BECKER MH, 1977, J HEALTH SOC BEHAV, V18, P348, DOI 10.2307/2955344
   Belshe RB, 2004, CLIN INFECT DIS, V39, P920, DOI 10.1086/423001
   Brotherton J, 2007, COMMUN DIS INTELL S, V31, P51
   Carpenter CJ, 2010, HEALTH COMMUN, V25, P661, DOI 10.1080/10410236.2010.521906
   CDC, 2017, NAT EARL SEAS FLU VA
   Chan Denise P C, 2015, Prev Med Rep, V2, P803, DOI 10.1016/j.pmedr.2015.09.002
   Chi RC, 2004, AM J MED SCI, V327, P113, DOI 10.1097/00000441-200403000-00001
   Flood EM, 2010, CLIN THER, V32, P1448, DOI 10.1016/j.clinthera.2010.06.020
   He L, 2015, CHINESE MED J-PEKING, V128, P327, DOI 10.4103/0366-6999.150099
   JANZ NK, 1984, HEALTH EDUC QUART, V11, P1, DOI 10.1177/109019818401100101
   Jefferson T, 2005, LANCET, V365, P773, DOI 10.1016/S0140-6736(05)17984-7
   Joachim H., 2011, SEASONAL INFLUENZA V
   Jordan R, 2006, VACCINE, V24, P1047, DOI 10.1016/j.vaccine.2005.09.017
   Lafond KE, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1001977
   Larson HJ, 2014, VACCINE, V32, P2150, DOI 10.1016/j.vaccine.2014.01.081
   Lau JTF, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-1026
   Li Y-F, 2011, TAIWAN GONG GONG WEI, V30, P257
   Long Scott, 2006, REGRESSION MODELS CA
   Low MSF, 2017, VACCINE, V35, P6096, DOI 10.1016/j.vaccine.2017.09.060
   Lv M, 2016, VACCINE, V34, P2135, DOI 10.1016/j.vaccine.2016.02.032
   Maurer J, 2010, PREV MED, V51, P185, DOI 10.1016/j.ypmed.2010.05.008
   Mei M., 2017, JIANGSU J PREVENT ME, V28, P439
   Mo PKH, 2015, HEALTH EDUC RES, V30, P706, DOI 10.1093/her/cyv038
   Neuzil KM, 2000, NEW ENGL J MED, V342, P225, DOI 10.1056/NEJM200001273420401
   Neuzil KM, 2002, J INFECT DIS, V185, P147, DOI 10.1086/338363
   Nexoe J, 2009, SCAND J PRIM HEALTH, V17, P105
   Nyqvist MB, 2017, AM ECON REV, V107, P496, DOI 10.1257/aer.p20171103
   Osterholm MT, 2012, LANCET INFECT DIS, V12, P36, DOI 10.1016/S1473-3099(11)70295-X
   Palache A, 2011, VACCINE, V29, P9459, DOI 10.1016/j.vaccine.2011.10.030
   Peduzzi P, 1996, J CLIN EPIDEMIOL, V49, P1373, DOI 10.1016/S0895-4356(96)00236-3
   Restivo V, 2018, INT J ENV RES PUB HE, V15, DOI 10.3390/ijerph15040770
   Roberts JR, 2015, VACCINE, V33, P1748, DOI 10.1016/j.vaccine.2015.01.068
   Rosenstock IM, 2005, MILBANK Q, V83
   Seale H, 2011, VACCINE, V29, P1605, DOI 10.1016/j.vaccine.2010.12.077
   Steiner M, 2002, INFECT CONT HOSP EP, V23, P625, DOI 10.1086/501984
   Su WJ, 2015, INT J INFECT DIS, V30, P115, DOI 10.1016/j.ijid.2014.11.011
   Subramaniam DP, 2016, J COMMUN HEALTH, V41, P697, DOI 10.1007/s10900-015-0144-8
   Teitler-Regev Sharon, 2011, Adv Prev Med, V2011, P353207, DOI 10.4061/2011/353207
   Telford R, 2003, HEALTH EDUC RES, V18, P743, DOI 10.1093/her/cyf059
   Wang HD, 2016, LANCET, V388, P1459, DOI 10.1016/S0140-6736(16)31012-1
   Wu SS, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-017459
   Xinhua, 2018, XINH SURV ONL 2 ITS
   Xu LL, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0181539
   Yang J, 2016, VACCINE, V34, P5724, DOI 10.1016/j.vaccine.2016.10.013
   Yang ZJ, 2015, J HEALTH COMMUN, V20, P69, DOI 10.1080/10810730.2014.904023
   Yuan X, 2018, LANCET, V392, P371, DOI 10.1016/S0140-6736(18)31725-2
   Zhou L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073724
   Zhu DW, 2014, VACCINE, V32, P6705, DOI 10.1016/j.vaccine.2013.06.095
NR 50
TC 0
Z9 0
U1 0
U2 11
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 7
PY 2019
VL 37
IS 11
BP 1449
EP 1456
DI 10.1016/j.vaccine.2019.01.071
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HP1DK
UT WOS:000461405400011
PM 30765168
DA 2020-05-12
ER

PT J
AU Chae, W
   Kim, P
   Hwang, BJ
   Seong, BL
AF Chae, Wonil
   Kim, Paul
   Hwang, Beom Jeung
   Seong, Baik Lin
TI Universal monoclonal antibody-based influenza hemagglutinin quantitative
   enzyme-linked immunosorbent assay
SO VACCINE
LA English
DT Article
DE Influenza vaccine; Potency test; RNA-mediated chaperone; Consensus HA;
   Universal antibodies; ELISA
ID CONFORMATIONAL-CHANGE; VIRUS; QUANTIFICATION; TRANSMISSION; IMMUNOASSAY;
   MECHANISM; SUBTYPES; POTENCY; VACCINE; MICE
AB Seasonal and pandemic influenza infections remain a serious public health concern. Many health authorities recommend annual vaccination as the most effective way to control influenza infection. Accordingly, regulatory guidelines ask vaccine manufacturers to determine vaccine potency at the time of release and throughout shelf-life to ensure vaccine quality. The potency of inactivated influenza vaccine is related to the quantity of hemagglutinin (HA). Since 1970s, single radial immunodiffusion (SRID) assay has been standardly used for the quantitation of HA in influenza vaccine. However, SRID is labor-intensive, inaccurate, and requires standard reference reagents that should be updated annually. Therefore, there have been extensive efforts to develop alternative potency assays. In this study, we developed and tested a new HA quantitative enzyme-linked immunosorbent assay (ELISA) using a universal monoclonal antibody that can bind to HAs from various subtypes in group 1 influenza A virus (IAV). We analyzed the conserved stalk domain of HA via a library approach to design a consensus HA antigen for group 1 IAV. The antigens were expressed as a soluble form in E. coli and were purified by Ni-affinity chromatography. When tested with variety of HAs from lAVs or influenza B viruses (IBVs), the mAbs exhibited specific binding to group 1 HAs, with potential exception to H9 subtype. Among various conditions of pH, urea, and reducing agents, pretreatment of HA at low pH exposing the conserved stalk domain was crucially important for optimal ELISA performance. Calibration curves for various HAs were generated to determine accuracy, specificity, sensitivity, and linear dynamic range. The ELISA method shows high sensitivity and accuracy compared with the SRID assay. The HA group specific universal mAbs against the consensus stalk domain of HA are conducive to establishing an ELISA-based standard procedure for the quantitation of HA antigens for annual vaccination against influenza infection. (C) 2019 The Authors. Published by Elsevier Ltd.
C1 [Chae, Wonil; Hwang, Beom Jeung; Seong, Baik Lin] Yonsei Univ, Coll Life Sci & Biotechnol, Dept Biotechnol, Seoul 03722, South Korea.
   [Kim, Paul] Yonsei Univ, Coll World Class Univ, Dept Integrated OMICS Biomed Sci, Seoul, South Korea.
   [Chae, Wonil; Kim, Paul; Hwang, Beom Jeung; Seong, Baik Lin] Yonsei Univ, Vaccine Translat Res Ctr, Seoul, South Korea.
RP Seong, BL (reprint author), Yonsei Univ, Coll Life Sci & Biotechnol, Dept Biotechnol, Seoul 03722, South Korea.
EM blseong@yonsei.ac.kr
FU Ministry of Food and Drug Safety, Republic of KoreaMinistry of Food &
   Drug Safety (MFDS) [16172MFDS199, 18172MFDS252]; Korean Health
   Technology R&D Project, Ministry of Health & Welfare, Republic of Korea
   [HI13C0826]
FX This research was supported by grants from the Ministry of Food and Drug
   Safety, Republic of Korea (16172MFDS199 and 18172MFDS252) and the Korean
   Health Technology R&D Project, Ministry of Health & Welfare, Republic of
   Korea (HI13C0826). We thank Dr. Dong-wook Kim (Department of Statistics,
   Sungkyunkwan University, Seoul, Korea) for statistical analyses of data.
   The authors declare no conflict of interest.
CR Alexander DJ, 2007, VACCINE, V25, P5637, DOI 10.1016/j.vaccine.2006.10.051
   [Anonymous], 2010, 5 3 STAT AN RES BIOL, P551
   Bodle J, 2013, INFLUENZA OTHER RESP, V7, P191, DOI 10.1111/j.1750-2659.2012.00375.x
   CARR CM, 1993, CELL, V73, P823, DOI 10.1016/0092-8674(93)90260-W
   Chen GL, 2010, J VIROL, V84, P7695, DOI 10.1128/JVI.00511-10
   Choi SI, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002677
   Chun S, 2008, VACCINE, V26, P6068, DOI 10.1016/j.vaccine.2008.09.015
   Combet C, 2000, TRENDS BIOCHEM SCI, V25, P147, DOI 10.1016/S0968-0004(99)01540-6
   Comeau SR, 2004, NUCLEIC ACIDS RES, V32, pW96, DOI 10.1093/nar/gkh354
   Congyu Ke, 2013, Biomed Chromatogr, V27, P433, DOI 10.1002/bmc.2810
   Cox MMJ, 2009, BIOLOGICALS, V37, P182, DOI 10.1016/j.biologicals.2009.02.014
   Gambaryan AS, 1998, VIROLOGY, V247, P170, DOI 10.1006/viro.1998.9224
   Gravel C, 2015, VACCINE, V33, P1129, DOI 10.1016/j.vaccine.2015.01.034
   Guex N, 2009, ELECTROPHORESIS, V30, pS162, DOI 10.1002/elps.200900140
   Hardy Stephanie, 2011, Influenza Other Respir Viruses, V5, P438, DOI 10.1111/j.1750-2659.2011.00250.x
   Harrison SC, 2008, NAT STRUCT MOL BIOL, V15, P690, DOI 10.1038/nsmb.1456
   HOBSON D, 1972, J HYG-CAMBRIDGE, V70, P767, DOI 10.1017/S0022172400022610
   Imai M, 2012, NATURE, V486, P420, DOI 10.1038/nature10831
   Impagliazzo A, 2015, SCIENCE, V349, P1301, DOI 10.1126/science.aac7263
   Jones JC, 2014, J VIROL, V88, P1175, DOI 10.1128/JVI.02526-13
   Khanna M, 2014, BIOMED RES INT, DOI 10.1155/2014/546274
   Kim P, 2018, VIRUSES, P10
   Kim YS, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01093
   Knossow M, 2002, VIROLOGY, V302, P294, DOI 10.1006/viro.2002.1625
   LAMONTAGNE JR, 1983, REV INFECT DIS, V5, P723
   Leikina E, 2002, EMBO J, V21, P5701, DOI 10.1093/emboj/cdf559
   Li CG, 2010, NAT PROTOC, V5, P14, DOI 10.1038/nprot.2009.200
   Lu XS, 2012, J VIROL, V86, P12861, DOI 10.1128/JVI.01606-12
   Ma W, 2007, P NATL ACAD SCI USA, V104, P20949, DOI 10.1073/pnas.0710286104
   Nabel GJ, 2011, NATURE, V471, P157, DOI 10.1038/471157a
   National Research Council Committee on Methods of Producing Monoclonal A, 1999, NAT AC COLL REP FUND
   Poovorawan Y, 2013, PATHOG GLOB HEALTH, V107, P217, DOI 10.1179/2047773213Y.0000000103
   Roh HS, 2015, MOL MED REP, V11, P2819, DOI 10.3892/mmr.2014.3049
   Schmeisser F, 2014, INFLUENZA OTHER RESP, V8, P587, DOI 10.1111/irv.12272
   SHRAKE A, 1973, J MOL BIOL, V79, P351, DOI 10.1016/0022-2836(73)90011-9
   SKEHEL JJ, 1975, P NATL ACAD SCI USA, V72, P93, DOI 10.1073/pnas.72.1.93
   Soria-Guerra RE, 2015, J BIOMED INFORM, V53, P405, DOI 10.1016/j.jbi.2014.11.003
   Suryadevara M, 2014, HUM VACC IMMUNOTHER, V10, P596, DOI 10.4161/hv.27115
   Thomsen MCF, 2012, NUCLEIC ACIDS RES, V40, pW281, DOI 10.1093/nar/gks469
   Vera A, 2007, BIOTECHNOL BIOENG, V96, P1101, DOI 10.1002/bit.21218
   Weir JP, 2016, INFLUENZA OTHER RESP, V10, P354, DOI 10.1111/irv.12383
   WILLIAMS MS, 1993, VET MICROBIOL, V37, P253, DOI 10.1016/0378-1135(93)90027-5
   Williams TL, 2012, VACCINE, V30, P2475, DOI 10.1016/j.vaccine.2011.12.056
   Wohlbold TJ, 2015, VACCINE, V33, P3314, DOI 10.1016/j.vaccine.2015.05.038
   Wood JM, 2018, INFLUENZA OTHER RESP, V12, P195, DOI 10.1111/irv.12543
   World Health Organization, 2018, INFL SEAS FACT SHEET
   Yang SW, 2018, FASEB J, V32, P2658, DOI 10.1096/fj.201700747RR
   Yang Y, 2007, EMERG INFECT DIS, V13, P1348, DOI 10.3201/eid1309.070111
   Yassine HM, 2015, NAT MED, V21, P1065, DOI 10.1038/nm.3927
   2013, WHO TECHN REP SER, V979, P1
NR 50
TC 2
Z9 2
U1 1
U2 5
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 7
PY 2019
VL 37
IS 11
BP 1457
EP 1466
DI 10.1016/j.vaccine.2019.01.068
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HP1DK
UT WOS:000461405400012
PM 30765169
OA Other Gold
DA 2020-05-12
ER

PT J
AU Ramsay, LC
   Anyiwe, K
   Li, M
   Macdonald, L
   Coyte, PC
   Sander, B
AF Ramsay, L. C.
   Anyiwe, K.
   Li, M.
   Macdonald, L.
   Coyte, P. C.
   Sander, B.
TI Economic evaluation of a publicly funded hepatitis A travel vaccination
   program in Ontario, Canada
SO VACCINE
LA English
DT Article
DE Hepatitis A; Economic evaluation; Travel vaccine; Cost-effectiveness
ID COST-EFFECTIVENESS; RISK; PERSISTENCE; CHILDREN; DISEASE; UTILITY;
   ADULTS
AB Background: Hepatitis A virus (HAV) causes acute liver infection and is spread through the fecal-oral route. Travel to countries in HAV-endemic regions (e.g., Asia and Latin America) is a well-described risk factor for infection. Currently, Ontario publicly funds hepatitis A vaccination for some populations at high risk of HAV infection but not for all travellers to endemic countries. The objective of this study was to determine the cost-effectiveness of expanding publicly funded HAV vaccination to people planning travel to HAV-endemic regions, from the Ontario healthcare payer perspective.
   Methods: We conducted a cost-utility analysis comparing an expanded high-risk publicly-funded hepatitis A vaccination program including funded vaccine for travellers to endemic regions to the current high risk program in Ontario. A Markov state transition model was developed, including six possible health states. Model parameters were informed through targeted literature searches and included hepatitis A disease probabilities, utilities associated with health states, health system expenditures, and vaccine costs. Future costs and health outcomes were discounted at 1.5%. Primary outcomes included cost, incremental cost-effectiveness ratio (ICER) and quality adjusted life years (QALYs) over a lifetime time horizon. We conducted one-way, two-way, and probabilistic sensitivity analysis.
   Results: The expanded high risk HAV vaccine program provided few incremental health gains in the travel population (mean 0.000037 QALYs/person), at an incremental cost of $124.31. The ICER of the expanded program compared to status quo is $3,391,504/QALY gained. The conclusion of the model was robust to changes in key parameters across reasonable ranges.
   Conclusions: The expanded vaccination program substantially exceeds commonly accepted cost-effectiveness thresholds. Further research concerning possible cost-effective implementation of high risk travel hepatitis A vaccination should focus on a more integrated understanding of the risk of acquiring hepatitis A during travel to endemic regions (e.g., purpose, length of stay). Crown Copyright (C) 2019 Published by Elsevier Ltd. All rights reserved.
C1 [Ramsay, L. C.; Anyiwe, K.; Coyte, P. C.; Sander, B.] Univ Toronto, Sch Publ Hlth, 155 Coll St, Toronto, ON M5T 1P8, Canada.
   [Ramsay, L. C.; Macdonald, L.; Sander, B.] Univ Hlth Network, Toronto Hlth Econ & Technol Assessment THETA Coll, 200 Elizabeth St, Toronto, ON M5G 2C4, Canada.
   [Li, M.] East China Normal Univ, Zhongshan N Rd, Shanghai 3663, Peoples R China.
   [Macdonald, L.; Sander, B.] Publ Hlth Ontario, 480 Univ Ave, Toronto, ON M5G 1V2, Canada.
   [Coyte, P. C.] Canadian Ctr Hlth Econ, 155 Coll St, Toronto, ON M5T 1P8, Canada.
   [Sander, B.] Inst Clin Evaluat Sci, 2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.
RP Ramsay, LC (reprint author), Univ Hlth Network, Toronto Gen Hosp, Eaton Bldg,10th Floor,Room 248,200 Elizabeth St, Toronto, ON M5G 2C4, Canada.
EM lauren.ramsay@theta.utoronto.ca
CR [Anonymous], 2015, YEARL AV EXCH RAT CU
   [Anonymous], 2017, MEDICINE
   [Anonymous], 2016, TRAV CAN FOR COUNTR
   [Anonymous], 2017, 2016 CENS POP DWELL
   Askling HH, 2009, J TRAVEL MED, V16, P233, DOI 10.1111/j.1708-8305.2009.00307.x
   Bauch CT, 2007, VACCINE, V25, P8536, DOI 10.1016/j.vaccine.2007.10.001
   Bennett WG, 1997, ANN INTERN MED, V127, P855, DOI 10.7326/0003-4819-127-10-199711150-00001
   Bernal W, 2010, LANCET, V376, P190, DOI 10.1016/S0140-6736(10)60274-7
   Bird Y, 2017, INT J PREVENTIVE MED, V8, DOI 10.4103/ijpvm.IJPVM_49_17
   CADTH, 2017, GUID EC EV HLTH TECH
   Canuel M, 2007, BMC INFECT DIS, V7, DOI 10.1186/1471-2334-7-31
   Carlos F, 2016, HUM VACC IMMUNOTHER, V12, P52, DOI 10.1080/21645515.2015.1065362
   Centers for Disease Control and Prevention, 2017, INF DIS REL TRAV HEP
   Crowcroft NS, 2012, EPIDEMIOL INFECT, V140, P1821, DOI 10.1017/S0950268812000064
   Dawson A, 2015, BMC GERIATR, V15, DOI 10.1186/s12877-015-0053-9
   Duval B, 2005, PEDIATR INFECT DIS J, V24, P514, DOI 10.1097/01.inf.0000164705.74498.86
   El Saadany Susie, 2005, Eur J Health Econ, V6, P159
   Franco E, 2012, WORLD J HEPATOL, V4, P68, DOI 10.4254/wjh.v4.i3.68
   Gossner CM, 2015, EURO SURVEILL, V20
   Hens N, 2014, VACCINE, V32, P1507, DOI 10.1016/j.vaccine.2013.10.088
   Heywood P, 2007, Can Commun Dis Rep, V33, P16
   Hsu PC, 2012, J GASTROEN HEPATOL, V27, P149, DOI 10.1111/j.1440-1746.2011.06813.x
   Keystone JS, 2008, INT J INFECT DIS, V12, P3, DOI 10.1016/j.ijid.2007.04.012
   Leung T W, 2006, Can Commun Dis Rep, V32, P287
   Lu PJ, 2013, VACCINE, V31, P2348, DOI 10.1016/j.vaccine.2013.03.011
   Luyten J, 2012, VACCINE, V30, P6070, DOI 10.1016/j.vaccine.2012.07.049
   Ly KN, 2015, J INFECT DIS, V212, P176, DOI 10.1093/infdis/jiu834
   Medical Officer of Health PHO, 2015, MEAS OUTBR SUMM
   Ministry of Health and Long-Term Care, 2017, INF DIS PROT
   Ministry of Health and Long-Term Care, 2017, ONT SCHED BEN PHYS S
   Mittmann N, 1999, PHARMACOECONOMICS, V15, P369, DOI 10.2165/00019053-199915040-00004
   Myers RP, 2000, HEPATOLOGY, V31, P834, DOI 10.1053/he.2000.5719
   Ontario Ministry of Health and Long Term Care, 2016, PUBL FUND IMM SCHED
   Provincial Infectious Diseases Advisory Committee, 2013, HEP A POST PROPH
   Public Health Ontario, 2018, HEP A
   Sane J, MULTISTATE FOODBORNE
   Sartori AMC, 2012, VACCINE, V30, P7489, DOI 10.1016/j.vaccine.2012.10.056
   Savage RD, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1636-6
   Scheifele DW, 2010, VACCINE, V28, P5174, DOI 10.1016/j.vaccine.2010.05.076
   Sharapov UM, FOODBORNE INFECT INT, P279, DOI [10.1016/B978-0-12-416041-500018-4, DOI 10.1016/B978-0-12-416041-500018-4]
   Statistics Canada, 2017, LIF TABL CAN PROV TE
   Stell DA, 2004, LIVER TRANSPLANT, V10, P898, DOI 10.1002/lt.20138
   Suwantika AA, 2014, HUM VACC IMMUNOTHER, V10, P2342, DOI 10.4161/hv.29353
   Taylor MC, 2002, CAN J SURG, V45, P425
   Teitelbaum P, 2004, J TRAVEL MED, V11, P102, DOI 10.2310/7060.2004.17063
   Tricco AC, 2006, BMC HEALTH SERV RES, V6, DOI 10.1186/1472-6963-6-157
   Van Damme P, 2001, VACCINE, V19, P2407, DOI 10.1016/S0264-410X(00)00464-3
   Vrbova L, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-970
   Wu J, 2001, Can J Infect Dis, V12, P341
   Zhang XS, 2016, HUM VACC IMMUNOTHER, V12, P2322, DOI 10.1080/21645515.2015.1134069
NR 50
TC 0
Z9 0
U1 3
U2 11
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 7
PY 2019
VL 37
IS 11
BP 1467
EP 1475
DI 10.1016/j.vaccine.2019.01.070
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HP1DK
UT WOS:000461405400013
PM 30770225
DA 2020-05-12
ER

PT J
AU Doornekamp, L
   de Jong, W
   Wagener, MN
   Goeijenbier, M
   van Gorp, ECM
AF Doornekamp, L.
   de Jong, W.
   Wagener, M. N.
   Goeijenbier, M.
   van Gorp, E. C. M.
TI Dutch healthcare professionals' opinion on vaccination and education to
   prevent infections in immunocompromised patients A mixed-method study
   with recommendations for daily practice
SO VACCINE
LA English
DT Article
DE Immunisation; Immunocompromised host; lmmunosuppression; Mixed method;
   Vaccine uptake
ID INTERNATIONAL TRAVEL; KNOWLEDGE; INFLUENZA; QUALITY; ADVICE; SAFETY
AB Background: The fast-growing population of immunocompromised patients (ICP) is more vulnerable to infectious diseases, demanding strategies to protect them. These strategies seem inconsistent in available guidelines and in practices. We aim to evaluate healthcare professionals' (HCP) opinions on vaccination to reduce the number and severity of infections in ICP.
   Methods: A mixed-method study, with an exploratory sequential design, was performed. Medical specialists from various departments in a tertiary care center in the Netherlands were invited for semi structured interviews to explore their perspective on preventive care of ICP. Topics that play a substantial role in daily practice for ICP were translated into a survey to gain insight into what extent opinions were generalizable to Erasmus Medical Center.
   Results: Surveys were completed by 689 HCP (43% of the invitees), 269 of them treated at least two ICP weekly on average and were considered eligible for further analysis. Quantitative data showed that according to 80 percent of HCP, preventive care for ICP can be improved. Education was chosen by 40 percent as the most important intervention to reduce the number and severity of infections. Vaccinations were valued as important by seventeen percent of HCP. Except for influenza, vaccinations were not regularly discussed during routine consultations. Difficulties to administer vaccinations were experienced by 75 percent of HCP.
   Conclusion: According to our respondents, education is the most promising intervention to reduce the number and severity of infections in ICP. To reach a higher vaccine uptake, we recommend HCP to address vaccinations more frequently during consultations and to search for solutions to alleviate barriers to vaccinate. (C) 2019 The Authors. Published by Elsevier Ltd.
C1 [Doornekamp, L.; de Jong, W.; Goeijenbier, M.; van Gorp, E. C. M.] Erasmus MC, Univ Med Ctr Rotterdam, Dept Virosci, Rotterdam, Netherlands.
   [Wagener, M. N.] Rotterdam Univ Appl Sci, Ctr Expertise Innovat Care, Rotterdam, Netherlands.
   [Goeijenbier, M.] Erasmus MC, Univ Med Ctr Rotterdam, Dept Internal Med, Rotterdam, Netherlands.
   [van Gorp, E. C. M.] Erasmus MC, Univ Med Ctr Rotterdam, Dept Internal Med Infect Dis, Rotterdam, Netherlands.
   [Doornekamp, L.; de Jong, W.; van Gorp, E. C. M.] Erasmus MC, Dept Virosci, Room Ee1726,POB 2040, NL-3000 CA Rotterdam, Netherlands.
RP van Gorp, ECM (reprint author), Erasmus MC, Univ Med Ctr Rotterdam, Dept Virosci, Rotterdam, Netherlands.; van Gorp, ECM (reprint author), Erasmus MC, Univ Med Ctr Rotterdam, Dept Internal Med Infect Dis, Rotterdam, Netherlands.; van Gorp, ECM (reprint author), Erasmus MC, Dept Virosci, Room Ee1726,POB 2040, NL-3000 CA Rotterdam, Netherlands.
EM l.doornekamp@erasmusmc.nl; w.dejong.2@erasmusmc.nl;
   e.vangorp@erasmusmc.nl
FU PfizerPfizer [WP692905]
FX This work was supported by a Pfizer educational grant [WP692905]. There
   was no sponsor involvement in study design, data collection, analysis
   and interpretation of results, writing of the manuscript and decision to
   submit for publication.
CR [Anonymous], 2007, GRAPHPAD PRISM 5
   Balvert F, 2015, AMAZING
   Bialy C, 2015, INTERN MED J, V45, P618, DOI 10.1111/imj.12753
   Boejje H., 2005, ANAL KWALITATIEF OND
   Coignard-Biehler Helene, 2011, J Infect Public Health, V4, P187, DOI 10.1016/j.jiph.2011.06.004
   Croce E, 2017, VACCINE, V35, P1216, DOI 10.1016/j.vaccine.2017.01.048
   Cutrona SL, 2018, J GEN INTERN MED, V33, P659, DOI 10.1007/s11606-017-4266-9
   El-Alfy MS, 2004, HEMATOL J, V5, P77, DOI 10.1038/sj.thj.6200328
   Evans EW, 2017, PUBLIC HEALTH, V153, P25, DOI 10.1016/j.puhe.2017.06.017
   GmbH L, LIMESURVEY OP SOURC
   IBM, 2016, IBM SPSS STAT WINDOW
   Isenor JE, 2016, VACCINE, V34, P5708, DOI 10.1016/j.vaccine.2016.08.085
   James EA, 2013, J VIROL, V87, P12794, DOI 10.1128/JVI.01160-13
   Jung YS, 2014, GUT LIVER, V8, P242, DOI 10.5009/gnl.2014.8.3.242
   Lopez A, 2017, J AUTOIMMUN, V80, P10, DOI 10.1016/j.jaut.2017.03.011
   Loubet P, 2018, DIGEST LIVER DIS, DOI [10.1016/j1:11c12017.12.027, DOI 10.1016/J1:11C12017.12.027]
   Loubet P, 2015, VACCINE, V33, P3703, DOI 10.1016/j.vaccine.2015.06.012
   Malhi G, 2015, J CROHNS COLITIS, V9, P439, DOI 10.1093/ecco-jcc/jjv064
   Martino C, 2016, HUM VACC IMMUNOTHER, V12, P1277, DOI 10.1080/21645515.2015.1138025
   Meidani M, 2014, J RES MED SCI, V19, pS71
   Mikati T, 2015, J TRAVEL MED, V22, P39, DOI 10.1111/jtm.12166
   Moro JA, 2008, TRANSPL P, V40, P3039, DOI 10.1016/j.transproceed.2008.08.101
   Murphey K, 2017, JANEWAYS IMMUNOBIOLO
   Nguyen MTT, 2017, SCAND J RHEUMATOL, V46, P446, DOI 10.1080/03009742.2016.1242774
   O'Cathain A, 2008, J HEALTH SERV RES PO, V13, P92, DOI 10.1258/jhsrp.2007.007074
   Patel RR, 2015, THER CLIN RISK MANAG, V11, P217, DOI 10.2147/TCRM.S52008
   Poil AR, 2018, CASE REP INFECT DIS, DOI 10.1155/2018/8528023
   Posadzki P, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009921.pub2
   Sheth H, 2017, J RHEUMATOL, V44, DOI 10.3899/jrheum.160179
   Sorgdrager W., 1998, WET MEDISCH WETENSCH
   Stine JG, 2010, ARTHRIT CARE RES, V62, P704, DOI 10.1002/acr.20209
   Thirumala R, 2010, CRIT CARE CLIN, V26, P59, DOI 10.1016/j.ccc.2009.09.007
   VSNU, 2014, NETH COD COND AC PRA
   Wasilczuk K, 2017, INT MARIT HEALTH, V68, P229, DOI 10.5603/IMH.2017.0041
   Yeung JH, 2012, INFLAMM BOWEL DIS, V18, P34, DOI 10.1002/ibd.21668
NR 35
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 7
PY 2019
VL 37
IS 11
BP 1476
EP 1483
DI 10.1016/j.vaccine.2019.01.075
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HP1DK
UT WOS:000461405400014
PM 30739793
OA Other Gold, Green Published
DA 2020-05-12
ER

PT J
AU Yinong, YX
   Snider, JT
   van Aalst, R
   Mahmud, SM
   Thommes, EW
   Lee, JKH
   Greenberg, DP
   Chit, A
AF Yinong Young-Xu
   Snider, Julia Thornton
   van Aalst, Robertus
   Mahmud, Salaheddin M.
   Thommes, Edward W.
   Lee, Jason K. H.
   Greenberg, David P.
   Chit, Ayman
TI Analysis of relative effectiveness of high-dose versus standard-dose
   influenza vaccines using an instrumental variable method
SO VACCINE
LA English
DT Article
DE Influenza; High-dose vaccine; Instrumental variable
ID ELECTRONIC HEALTH RECORDS; NURSING-HOME RESIDENTS; MORTALITY BENEFITS;
   ELDERLY-PEOPLE; OLDER; VACCINATION; CARE; HOSPITALIZATIONS; SELECTION;
   FRAILTY
AB Background: Observational studies of the relative effectiveness of influenza vaccines are essential for public health decision making. Their estimates, however, are subject to bias due to unmeasured confounders. Instrumental variable (IV) methods can control for observed and unobserved confounders.
   Methods: We used linked electronic medical record databases in the Veterans Health Administration (VHA) as well as Medicare administrative files to examine the relative vaccine effectiveness (rVE) of high-dose influenza vaccine (HD) versus standard-dose influenza vaccines (SD) in preventing hospitalizations among VHA-enrolled Veterans >= 65 years of age during 5 influenza seasons (2010-2011 through 2014-2015). Using multivariable IV Poisson regression modeling to address unmeasured confounding and bias, we analyzed the data by each season and through longitudinal analysis of all five seasons.
   Findings: We included 3,638,924 person-influenza seasons of observation where 158,636 (4%) were among HD vaccine recipients and 3,480,288 (96%) were among SD vaccine recipients. Of the 1,728,562 Veterans, 1,702,824 (98.5%) were male and 1,299,412 (75%) were non-Hispanic white. Based on the longitudinal analysis of all five seasons, the IV-adjusted rVE estimate of HD vs. SD was 10% (95% CI, 8-12%) against all-cause hospitalization; 18% (95% CI, 15-21%) against cardiorespiratory-associated hospitalization; and 14% (95% CI, 6-22%) against influenza/pneumonia-associated hospitalization. The findings by season were similar.
   Interpretation: Our analysis of VHA clinical data collected from approximately 1.7 million Veterans 65 years and older during five seasons demonstrates that high-dose influenza vaccine is more effective than standard-dose influenza vaccines in preventing influenza- or pneumonia-associated hospitalizations, cardiorespiratory hospitalizations, and all-cause hospitalizations. Published by Elsevier Ltd.
C1 [Yinong Young-Xu] Vet Affairs Med Ctr, Clin Epidemiol Program, White River Jct, VT USA.
   [Yinong Young-Xu] Geisel Sch Med Dartmouth, Dept Psychiat, Hanover, NH USA.
   [Snider, Julia Thornton] Precis Hlth Econ, Oakland, CA USA.
   [van Aalst, Robertus; Thommes, Edward W.; Greenberg, David P.; Chit, Ayman] Sanofi Pasteur, Swiftwater, PA USA.
   [Mahmud, Salaheddin M.] Univ Manitoba, Dept Community Hlth Sci, Coll Med, Winnipeg, MB, Canada.
   [Mahmud, Salaheddin M.] Univ Manitoba, Winnipeg Reg Hlth Author, George & Fay Yee Ctr Healthcare Innovat, Winnipeg, MB, Canada.
   [Thommes, Edward W.] Univ Guelph, Dept Math & Stat, Guelph, ON, Canada.
   [Lee, Jason K. H.; Chit, Ayman] Univ Toronto, Leslie Dan Sch Pharm, Toronto, ON, Canada.
   [Lee, Jason K. H.] Sanofi Pasteur, Toronto, ON, Canada.
RP Yinong, YX (reprint author), VA Med Ctr, 215 North Main St, White River Jct, VT 05009 USA.
EM Yinong.Young-Xu@va.gov; Julia.Snider@precisionhealtheconomics.com;
   Rob.VanAalst@sanofi.com; Salah.Mahmud@umanitoba.ca;
   Edward.Thommes@sanofi.com; Jason.Lee@sanofi.com;
   David.Greenberg@sanofi.com; Ayman.Chit@sanofi.com
RI van Aalst, Robertus/F-8207-2016
OI van Aalst, Robertus/0000-0003-3025-7811
FU Sanofi Pasteur, Inc., Swiftwater, Pennsylvania, US
FX This study was supported with funding from an unrestricted research
   grant from Sanofi Pasteur, Inc., Swiftwater, Pennsylvania, US.
CR Adler-Milstein J, 2014, HEALTH AFFAIR, V33, P1271, DOI 10.1377/hlthaff.2014.0023
   Altonji JG, 2005, J POLIT ECON, V113, P151, DOI 10.1086/426036
   Baum CF, 2003, STATA J, V3, P1, DOI 10.1177/1536867X0300300101
   Collard RM, 2012, J AM GERIATR SOC, V60, P1487, DOI 10.1111/j.1532-5415.2012.04054.x
   DeVoe JE, 2011, ANN FAM MED, V9, P351, DOI 10.1370/afm.1279
   DEYO RA, 1992, J CLIN EPIDEMIOL, V45, P613, DOI 10.1016/0895-4356(92)90133-8
   DiazGranados CA, 2015, VACCINE, V33, P4988, DOI 10.1016/j.vaccine.2015.07.006
   DiazGranados CA, 2014, NEW ENGL J MED, V371, P635, DOI 10.1056/NEJMoa1315727
   Diggle P. J., 2002, ANAL LONGITUDINAL DA
   Fried LP, 2001, J GERONTOL A-BIOL, V56, pM146, DOI 10.1093/gerona/56.3.M146
   Glymour MM, 2012, AM J EPIDEMIOL, V175, P332, DOI 10.1093/aje/kwr323
   Gravenstein S, 2017, LANCET RESP MED, V5, P738, DOI 10.1016/S2213-2600(17)30235-7
   Groenwold RHH, 2010, VALUE HEALTH, V13, P132, DOI 10.1111/j.1524-4733.2009.00584.x
   Izurieta HS, 2015, LANCET INFECT DIS, V15, P293, DOI 10.1016/S1473-3099(14)71087-4
   Jackson LA, 2006, INT J EPIDEMIOL, V35, P337, DOI 10.1093/ije/dyi274
   Jackson ML, 2008, LANCET, V372, P398, DOI 10.1016/S0140-6736(08)61160-5
   Lee J, 2017, OPEN FORUM INFECT S1, V4, pS456
   Lipsitch M, 2010, EPIDEMIOLOGY, V21, P383, DOI 10.1097/EDE.0b013e3181d61eeb
   Marder E, 2013, MMWR-MORBID MORTAL W, V62, P1
   Mazzali C, 2015, INTERN EMERG MED, V10, P517, DOI 10.1007/s11739-015-1213-9
   Monto AS, 2009, VACCINE, V27, P5043, DOI 10.1016/j.vaccine.2009.06.032
   Mullooly JP, 2007, VACCINE, V25, P846, DOI 10.1016/j.vaccine.2006.09.041
   Petersen LA, 2010, HEALTH SERV RES, V45, P762, DOI 10.1111/j.1475-6773.2010.01107.x
   Pizer SD, 2016, HEALTH SERV RES, V51, P790, DOI 10.1111/1475-6773.12355
   Psaty BM, 1999, J AM GERIATR SOC, V47, P749, DOI 10.1111/j.1532-5415.1999.tb01603.x
   Richardson DM, 2015, CLIN INFECT DIS, V61, P171, DOI 10.1093/cid/civ261
   Rogers William H, 2004, J Ambul Care Manage, V27, P249
   Shay DK, 2017, J INFECT DIS, V215, P510, DOI 10.1093/infdis/jiw641
   Simonsen L, 2007, LANCET INFECT DIS, V7, P658, DOI 10.1016/S1473-3099(07)70236-0
   Simonsen L, 2009, VACCINE, V27, P6300, DOI 10.1016/j.vaccine.2009.07.008
   Thompson WW, 2009, AM J PUBLIC HEALTH, V99, pS225, DOI 10.2105/AJPH.2008.151944
   Thompson WW, 2003, JAMA-J AM MED ASSOC, V289, P179, DOI 10.1001/jama.289.2.179
   Thompson WW, 2004, JAMA-J AM MED ASSOC, V292, P1333, DOI 10.1001/jama.292.11.1333
   Widdowson MA, 2017, LANCET RESP MED, V5, P674, DOI 10.1016/S2213-2600(17)30290-4
   Wong K, 2012, ARCH INTERN MED, V172, P484, DOI 10.1001/archinternmed.2011.2038
   Yoo BK, 2006, VALUE HEALTH, V9, P114, DOI 10.1111/j.1524-4733.2006.00089.x
   Young-Xu YN, 2018, J INFECT DIS, V217, P1718, DOI 10.1093/infdis/jiy088
NR 37
TC 5
Z9 5
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 7
PY 2019
VL 37
IS 11
BP 1484
EP 1490
DI 10.1016/j.vaccine.2019.01.063
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HP1DK
UT WOS:000461405400015
PM 30745146
OA Other Gold
DA 2020-05-12
ER

PT J
AU Zuk, P
   Zuk, P
   Lisiewicz-Jakubaszko, J
AF Zuk, Piotr
   Zuk, Pawel
   Lisiewicz-Jakubaszko, Justyna
TI The anti-vaccine movement in Poland: The socio-cultural conditions of
   the opposition to vaccination and threats to public health
SO VACCINE
LA English
DT Article
DE Anti-vaccine movement; Political populism; Social media; Public health;
   Eastern Europe
AB The article analyses the cultural and political contexts of the revival of the anti-vaccine movement in Poland. According to the authors, the attempt to institutionalise and politicise anti-vaccine activists is part of the wider phenomenon of political populism in Eastern Europe. The attempt to abolish compulsory vaccinations, which is supported by right-wing populists, shows that the anti-Enlightenment and anti-Western shift in the public sphere in Eastern Europe can also affect the area of health protection. Western pharmaceutical concerns may be the same target of populist attacks as refugees and migrants. The authors claim that, like in the case of political nationalism, a widespread educational campaign and bottom-up social legal and political measures need to be implemented to combat disinformation about vaccination. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Zuk, Piotr] Univ Wroclaw, Dept Sociol, Wroclaw, Poland.
   [Zuk, Piotr; Zuk, Pawel] Ctr Civil Rights & Democracy Res, Wroclaw, Poland.
   [Lisiewicz-Jakubaszko, Justyna] 4th Mil Clin Hosp, Dept Endocrinol Diabetol & Metab Dis, Wroclaw, Poland.
RP Zuk, P (reprint author), Inst Socjol, Ul Koszarowa 3, PL-51149 Wroclaw, Poland.
EM pzuk@uni.wroc.pl; justyna.jak@interia.pl
CR [Anonymous], 2018, UKRAINA BARDZO NISKA
   Broniatowski DA, 2018, AM J PUBLIC HEALTH, V108, P1378, DOI 10.2105/AJPH.2018.304567
   CBOS [Public Opinion Research Center], 2017, 1002017 CBOS
   Czarkowski MP, 2017, SZCZEPIENIA OCHRONNE
   Dredze M, 2017, VACCINE, V35, P4670, DOI 10.1016/j.vaccine.2017.06.066
   Dredze M, 2016, AM J PREV MED, V50, P550, DOI 10.1016/j.amepre.2015.10.002
   Karwowska A, 2018, PRZEDSZKOLA ZLOBKI T
   Naczelna lzba Lekarska, 2018, STAN PODJ PREZ NRL 2
   Narodowy Instytut Zdrowia Publicznego-Panstwowy Zaklad Higieny, 2019, KAL SZCZEP
   Olive JK, 2018, PLOS MED, V15, DOI 10.1371/journal.pmed.1002578
   Rzeczkowski G, 2018, NIEWYJASNIONA AFERA
   STOP-NOP, 2017, AUT ENC SZCZEP ORZ S
   uk P., 2015, KULTURZE STRACHU PRZ
   WALLERSTEIN I. M., 2004, WORLD SYSTEMS ANAL I
   World Health Organization, 2017, RESP VOC VACC DEN PU
   Zuk P, 2015, DISCOURSE CONTEXT ME, DOI [10.1016/J.dcm2018.07.005, DOI 10.1016/J.DCM2018.07.005]
   Zuk P., 2008, RUCH PRAWNICZY EKONO, V70, P165
   Zuk P, 2019, EC LABOUR RELAT REV
   Zuk P., 2017, J CONT CENTRAL E EUR, V25, P63, DOI DOI 10.1080/0965156X.2017.1339976
   Zuk P, 2018, ECON LABOUR RELAT RE, V29, P97, DOI 10.1177/1035304617739759
   Zuk P, 2017, HEALTH CARE WOMEN IN, V38, P689, DOI 10.1080/07399332.2017.1322595
NR 21
TC 9
Z9 9
U1 8
U2 15
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 7
PY 2019
VL 37
IS 11
BP 1491
EP 1494
DI 10.1016/j.vaccine.2019.01.073
PG 4
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HP1DK
UT WOS:000461405400016
PM 30755366
DA 2020-05-12
ER

PT J
AU Jalloh, MF
   Jalloh, MB
   Albert, A
   Wolff, B
   Callis, A
   Ramakrishnan, A
   Cramer, E
   Sengeh, P
   Abu Pratt, S
   Conteh, L
   Hajjeh, R
   Bunnell, R
   Redd, JT
   Ekstrom, AM
   Nordenstedt, H
AF Jalloh, Mohamed F.
   Jalloh, Mohammad B.
   Albert, Alison
   Wolff, Brent
   Callis, Amy
   Ramakrishnan, Aparna
   Cramer, Emily
   Sengeh, Paul
   Abu Pratt, Samuel
   Conteh, Lansana
   Hajjeh, Rana
   Bunnell, Rebecca
   Redd, John T.
   Ekstrom, Anna Mia
   Nordenstedt, Helena
TI Perceptions and acceptability of an experimental Ebola vaccine among
   health care workers, frontline staff, and the general public during the
   2014-2015 Ebola outbreak in Sierra Leone
SO VACCINE
LA English
DT Article
DE Ebola vaccine; Acceptability; Attitudes; Perceptions; Sierra Leone
ID VIRUS DISEASE; WEST-AFRICA; TRIAL; EPIDEMIC; ATTITUDES; LIBERIA; GUINEA;
   DESIGN; SAFETY
AB Introduction: Experimental Ebola vaccines were introduced during the 2014-2015 Ebola outbreak in West Africa. Planning for the Sierra Leone Trial to Introduce a Vaccine against Ebola (STRIVE) was under-way in late 2014. We examined hypothetical acceptability and perceptions of experimental Ebola vaccines among health care workers (HCWs), frontline workers, and the general public to guide ethical communication of risks and benefits of any experimental Ebola vaccine.
   Methods: Between December 2014 and January 2015, we conducted in-depth interviews with public health leaders (N = 31), focus groups with HCWs and frontline workers (N = 20), and focus groups with members of the general public (N = 15) in Western Area Urban, Western Area Rural, Port Loko, Bombali, and Tonkolili districts. Themes were identified using qualitative content analysis.
   Results: Across all participant groups, not knowing the immediate and long-term effects of an experimental Ebola vaccine was the most serious concern. Some respondents feared that experimental vaccines may cause Ebola, lead to death, or result in other adverse events. Among HCWs, not knowing the level of protection provided by experimental Ebola vaccines was another concern. HCWs and frontline workers were motivated to help find a vaccine for Ebola to help end the outbreak. General public participants cited positive experiences with routine childhood immunization in Sierra Leone.
   Discussion: Our formative assessment prior to STRIVE's implementation in Sierra Leone helped identify concerns, motivations, and information gaps among potential participants of an experimental Ebola vaccine trial, at the time when an unprecedented outbreak was occurring in the country. The findings from this assessment were incorporated early in the process to guide ethical communication of risks and benefits when discussing informed consent for possible participation in the vaccine trial that was launched later in 2015. Published by Elsevier Ltd.
C1 [Jalloh, Mohamed F.; Albert, Alison; Wolff, Brent; Callis, Amy; Ramakrishnan, Aparna; Cramer, Emily; Hajjeh, Rana; Bunnell, Rebecca; Redd, John T.] US Ctr Dis Control & Prevent, Atlanta, GA USA.
   [Jalloh, Mohamed F.; Ekstrom, Anna Mia; Nordenstedt, Helena] Karolinska Inst, Dept Publ Hlth Sci, Stockholm, Sweden.
   [Jalloh, Mohammad B.; Sengeh, Paul; Abu Pratt, Samuel] FOCUS 1000, Freetown, Sierra Leone.
   [Conteh, Lansana] Minist Hlth & Sanitat, Freetown, Sierra Leone.
   [Ekstrom, Anna Mia] Karolinska Univ Hosp, Dept Infect Dis, Stockholm, Sweden.
   [Callis, Amy; Ramakrishnan, Aparna] Devi Partners, San Carlos, CA USA.
   [Hajjeh, Rana] World Hlth Org, Cairo, Egypt.
RP Jalloh, MF (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,MS C18, Atlanta, GA 30329 USA.
EM yum8@cdc.gov
FU CDC FoundationUnited States Department of Health & Human ServicesCenters
   for Disease Control & Prevention - USA
FX CDC Foundation provided financial support to FOCUS 1000.
CR Boisen ML, 2016, ANNU REV VIROL, V3, P147, DOI 10.1146/annurev-virology-110615-040056
   Busta E.R., 2017, INTEGRATING CLIN RES
   Camacho A, 2017, VACCINE, V35, P544, DOI 10.1016/j.vaccine.2016.12.019
   Cohen J, 2014, SCIENCE, V346, P289, DOI 10.1126/science.346.6207.289
   Doe-Anderson J, 2016, CONT CLIN TRIAL COMM, V4, P68, DOI 10.1016/j.conctc.2016.06.008
   Enria L, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889-016-3799-x
   Esangbedo DO, 2016, AM J TROP MED HYG, V95, P654, DOI 10.4269/ajtmh.16-0206
   Frieden TR, 2015, EMERG INFECT DIS, V21, P1897, DOI 10.3201/eid2111.150949
   Getz WM, 2015, COMPUT MATH METHOD M, DOI 10.1155/2015/736507
   Government of Sierra Leone, 2012, HUM RES HLTH STRAT P
   Graneheim UH, 2004, NURS EDUC TODAY, V24, P105, DOI 10.1016/j.nedt.2003.10.001
   Guo ZY, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152438
   Hageman JC, 2016, MMWR-MORBID MORTAL W, V65, P50, DOI 10.15585/mmwr.su6503a8
   Henao-Restrepo AM, 2017, LANCET, V389, P505, DOI 10.1016/S0140-6736(16)32621-6
   Huo X, 2016, VACCINE, V34, P1767, DOI 10.1016/j.vaccine.2016.02.046
   Irwin KL, 2017, VACCINE, V35, P6915, DOI 10.1016/j.vaccine.2017.06.026
   Jones SA, 2016, BMJ GLOB HEALTH, V1, DOI 10.1136/bmjgh-2016-000065
   Kennedy SB, 2016, CLIN TRIALS, V13, P49, DOI 10.1177/1740774515621037
   Kuchar E, 2017, ADV EXP MED BIOL, V980, P27, DOI 10.1007/5584_2016_207
   Merler S, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0005093
   Mooney T, 2018, CLIN TRIALS, V15, P436, DOI 10.1177/1740774518780678
   Moulin A M, 2016, Bull Soc Pathol Exot, V109, P287, DOI 10.1007/s13149-016-0520-3
   Nuriddin A, 2018, BMJ GLOB HEALTH, V3, DOI 10.1136/bmjgh-2017-000410
   Painter JE, 2017, VACCINE, V35, P508, DOI 10.1016/j.vaccine.2016.11.093
   Raheim M, 2016, INT J QUAL STUD HEAL, V11, DOI 10.3402/qhw.v11.30996
   Samai M, 2018, J INFECT DIS, V217, pS6, DOI 10.1093/infdis/jiy020
   Saxena A, 2016, CLIN TRIALS, V13, P96, DOI 10.1177/1740774515621870
   Sesay T, 2017, Public Health Action, V7, pS34, DOI 10.5588/pha.16.0088
   Shukarev G, 2017, HUM VACC IMMUNOTHER, V13, P266, DOI 10.1080/21645515.2017.1264755
   Tengbeh AF, 1982, SOC SCI MED, V2018, P35
   Ughasoro MD, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003838
   WHO, 2016, EB SIT REP
   Widdowson MA, 2016, MMWR-MORBID MORTAL W, V65, P98, DOI 10.15585/mmwr.su6503a14
   World Health Organization, 2015, GUIN RING VACC TRIAL
   World Health Organization, 2012, ANAL SUMM IMM VACC D
   World Health Organization and UNICEF, 2014, EST IMM COV 2014 REV
   Zhu FC, 2017, LANCET, V389, P621, DOI [10.1016/s0140-6736(16)32617-4, 10.1016/S0140-6736(16)32617-4]
NR 37
TC 1
Z9 1
U1 4
U2 10
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 7
PY 2019
VL 37
IS 11
BP 1495
EP 1502
DI 10.1016/j.vaccine.2019.01.046
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HP1DK
UT WOS:000461405400017
PM 30755367
DA 2020-05-12
ER

PT J
AU Wasan, EK
   Syeda, J
   Strom, S
   Cawthray, J
   Hancock, RE
   Wasan, KM
   Gerdts, V
AF Wasan, Ellen K.
   Syeda, Jaweria
   Strom, Stacy
   Cawthray, Jacqueline
   Hancock, Robert E.
   Wasan, Kishor M.
   Gerdts, Volker
TI A lipidic delivery system of a triple vaccine adjuvant enhances mucosal
   immunity following nasal administration in mice
SO VACCINE
LA English
DT Article
DE Liposomes; Vaccine; Adjuvant; Self-assembled systems; Nanoparticles;
   Intranasal delivery
ID DEFENSE REGULATOR PEPTIDE; INTRANASAL IMMUNIZATION; PROTECTIVE IMMUNITY;
   PROVIDES PROTECTION; CELL-LINES; CPG ODN; RESPONSES; COMBINATION;
   NANOPARTICLES; MUCOADHESIVE
AB We previously developed an highly efficacious combination adjuvant comprised of innate defense regulator (IDR)-1002 peptide, poly(I:C) and polyphosphazene (TriAdj). Here we aimed to design and test the in vivo efficacy of a mucoadhesive nasal formulation of this adjuvant. To determine the physical properties of the formulation, the effect of addition of each individual component was characterised by gel electrophoresis and fluorescence quenching using rhodamine-poly(I:C). Cationic liposomes comprised of didodecyl dimethylammonium bromide (DDAB), dioleoyl phosphatidylethanolamine (DOPE) (50:50 or 75:25 mol:mol) and DDAB, L-alpha-phosphatidylcholine (egg PC) and DOPE (40:50:10 mol:mol:mol;) were prepared by the thin-film extrusion method. The liposomes and TriAdj were combined by simple mixing. The formed complex (L-TriAdj) was characterized by dynamic light scattering, zeta potential, and mucin interactions. We found that IDR-1002 peptide, polyphosphazene and poly(I:C) self-assembled in solution forming an anionic complex. Exposure of RAW267.4 mouse macrophage cells to TriAdj alone vs. L-TriAdj indicated that DDAB/DOPE (50:50) and DDAB/EPC/cholesterol (40:50:10) complexation reduced TriAdj toxicity. Next, TriAdj-containing cationic liposomes were prepared at several molar ratios to determine optimal size, stability and desired positive charge. Transmission electron microscopy showed rearrangement of lipid structures on binding of liposomes to TriAdj and to mucin. Stable particles (<200 nm over 24 h) showed mucin binding of DDAB/DOPE + TriAdj was greater than DDAB/EPC/DOPE + TriAdj. To verify in vivo efficacy, mice were administered the DDAB/DOPE + TriAdj complex intranasally with ovalbumin as the antigen, and the immunogenic response was measured by ELISA (serum IgG1 IgG2a, IgA) and ELISpot assays (splenocyte IL-5, IFN-gamma). Mice administered adjuvant showed a significantly greater immune response with L-TriAdj than TriAdj alone, with a dose-response proportionate to the triple adjuvant content, and an overall balanced Th1/Th2 immune response representing both systemic and mucosal immunity. (C) 2019 Published by Elsevier Ltd.
C1 [Wasan, Ellen K.; Syeda, Jaweria; Cawthray, Jacqueline; Wasan, Kishor M.] Univ Saskatchewan, Coll Pharm & Nutr, Saskatoon, SK S7N 5E3, Canada.
   [Strom, Stacy; Gerdts, Volker] Univ Saskatchewan, VIDO InterVac, Vaccine & Infect Dis Org, Int Vaccine Ctr, Saskatoon, SK S7N 5E3, Canada.
   [Hancock, Robert E.] Univ British Columbia, Fac Sci, Dept Microbiol & Immunol, Vancouver, BC V6T 1Z3, Canada.
RP Wasan, EK (reprint author), Univ Saskatchewan, Coll Pharm & Nutr, Hlth Sci 3D01 17, Saskatoon, SK S7N 5E5, Canada.
EM ellen.wasan@usask.ca
RI Hancock, Robert E. W./E-1145-2013
OI Hancock, Robert E. W./0000-0001-5989-8503
FU President's NSERC Fund, University of Saskatchewan; College of Pharmacy
   and Nutrition of the University of Saskatchewan; Agriculture Development
   Fund from the Government of Saskatchewan; Saskatchewan Cattlemen's
   Association; Canadian Institutes for Health ResearchCanadian Institutes
   of Health Research (CIHR) [FDN-154287]
FX The authors acknowledge funding from the President's NSERC Fund,
   University of Saskatchewan, the College of Pharmacy and Nutrition of the
   University of Saskatchewan, the Agriculture Development Fund from the
   Government of Saskatchewan and the Saskatchewan Cattlemen's Association,
   and to REWH from a Canadian Institutes for Health Research grant
   FDN-154287). REWH holds a Canada Research Chair in Health and Genomics
   and is a UBC Killam Professor. In-kind support for the in vivo studies
   was provided by VIDO-InterVac, Saskatoon, SK.
CR Bloomfield VA, 1997, BIOPOLYMERS, V44, P269, DOI 10.1002/(SICI)1097-0282(1997)44:3<269::AID-BIP6>3.0.CO;2-T
   Chen PS, 2002, MICRODETERMINATION P, DOI [10.1021/AC60119A033, DOI 10.1021/AC60119A033]
   Christensen D, 2012, J CONTROL RELEASE, V160, P468, DOI 10.1016/j.jconrel.2012.03.016
   Cui ZR, 2006, CANCER IMMUNOL IMMUN, V55, P1267, DOI 10.1007/s00262-005-0114-6
   De Magistnis MT, 2006, ADV DRUG DELIVER REV, V58, P52, DOI 10.1016/j.addr.2006.01.002
   Desclozeaux M, 2017, VACCINE, V35, P3461, DOI 10.1016/j.vaccine.2017.03.091
   Fuertes Marraco SA, 2011, PLOS ONE, V6, DOI [10.1371/journal.pone.0020189g20189, DOI 10.1371/JOURNAL.PONE.0020189G20189]
   Garg R, 2017, HUM VACC IMMUNOTHER, V13, P2894, DOI 10.1080/21645515.2017.1349584
   Garg R, 2015, VACCINE, V33, P1338, DOI 10.1016/j.vaccine.2015.01.041
   Garg R, 2014, J GEN VIROL, V95, P1043, DOI 10.1099/vir.0.062570-0
   Garg R, 2014, J GEN VIROL, V95, P301, DOI 10.1099/vir.0.058461-0
   Garg R, 2017, VACCINE, V35, P4486, DOI 10.1016/j.vaccine.2017.05.067
   Garg R, 2016, VIROLOGY, V499, P288, DOI 10.1016/j.virol.2016.09.023
   Garlapati S, 2012, VACCINE, V30, P5206, DOI 10.1016/j.vaccine.2012.06.011
   Garlapati S, 2011, VACCINE, V29, P6540, DOI 10.1016/j.vaccine.2011.07.009
   Gracia A, 2011, VACCINE, V29, P1595, DOI 10.1016/j.vaccine.2010.12.083
   Hamborg M, 2014, BBA-BIOMEMBRANES, V1838, P2001, DOI 10.1016/j.bbamem.2014.04.013
   Hamborg M, 2013, PHARM RES-DORDR, V30, P140, DOI 10.1007/s11095-012-0856-8
   Hancock REW, 2016, NAT REV IMMUNOL, V16, P321, DOI 10.1038/nri.2016.29
   Hussain MJ, 2014, J PHARM PHARMACOL, V66, P358, DOI 10.1111/jphp.12173
   Jaganathan KS, 2006, VACCINE, V24, P4201, DOI 10.1016/j.vaccine.2006.01.011
   Jia JB, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00404
   Jiang YH, 2014, PHARM RES-DORDR, V31, P2748, DOI 10.1007/s11095-014-1372-9
   Kastner E, 2015, CORRELATING LIPOSOMA, DOI [10.1111/jphp.12390, DOI 10.1111/JPHP.12390]
   Kaur R, 2014, MOL PHARMACEUT, V11, P197, DOI 10.1021/mp400372j
   Khan SA, 2014, VACCINE, V32, P5781, DOI 10.1016/j.vaccine.2014.08.037
   Madera L, 2012, J INNATE IMMUN, V4, P553, DOI 10.1159/000338648
   Mangal S, 2011, VACCINE, V29, P4953, DOI 10.1016/j.vaccine.2011.04.112
   Milicic A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034255
   Mutwiri G, 2007, VACCINE, V25, P1204, DOI 10.1016/j.vaccine.2006.10.011
   Nijnik A, 2010, J IMMUNOL, V184, P2539, DOI 10.4049/jimmunol.0901813
   Niyonsaba F, 2013, J LEUKOCYTE BIOL, V94, P159, DOI 10.1189/jlb.1012497
   Nyari S, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0200112
   Pawar D, 2016, DRUG DELIV, V23, P185, DOI 10.3109/10717544.2014.908427
   Perrie Y, 2013, HUM VACC IMMUNOTHER, V9, P1374, DOI 10.4161/hv.24694
   Polewicz M, 2013, VACCINE, V31, P3148, DOI 10.1016/j.vaccine.2013.05.008
   Qiao CM, 2017, BIOMATER SCI-UK, V5, P1603, DOI 10.1039/c7bm00244k
   RALPH P, 1977, J IMMUNOL, V119, P950
   RASCHKE WC, 1978, CELL, V15, P261, DOI 10.1016/0092-8674(78)90101-0
   Saini V, 2011, INT J PHARMACEUT, V408, P50, DOI 10.1016/j.ijpharm.2011.01.045
   Schmidt ST, 2016, J CONTROL RELEASE, V239, P107, DOI 10.1016/j.jconrel.2016.08.034
   Snider M, 2014, VACCINE, V32, P6758, DOI 10.1016/j.vaccine.2014.10.010
   Tada R, 2018, INT IMMUNOPHARMACOL, V61, P385, DOI 10.1016/j.intimp.2018.06.027
   Tada Rui, 2017, BMC Res Notes, V10, P68, DOI 10.1186/s13104-017-2380-8
   Tonigold M, 2016, NANOMEDICINE-UK, V11, P2625, DOI 10.2217/nnm-2016-0195
   Wong PT, 2014, MOL PHARMACEUT, V11, P531, DOI 10.1021/mp4005029
NR 46
TC 2
Z9 2
U1 1
U2 18
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 7
PY 2019
VL 37
IS 11
BP 1503
EP 1515
DI 10.1016/j.vaccine.2019.01.058
PG 13
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HP1DK
UT WOS:000461405400018
PM 30739796
DA 2020-05-12
ER

PT J
AU Haber, P
   Moro, PL
   Ng, C
   Dores, GM
   Lewis, P
   Cano, M
AF Haber, Penina
   Moro, Pedro L.
   Ng, Carmen
   Dores, Graca M.
   Lewis, Paige
   Cano, Maria
TI Post-licensure surveillance of trivalent adjuvanted influenza vaccine
   (aIIV3; Fluad), Vaccine Adverse Event Reporting System (VAERS), United
   States, July 2016-June 2018
SO VACCINE
LA English
DT Article
DE Vaccine safety; Post-licensure surveillance; Adjuvanted influenza
   vaccine MF59 (R) (Fluad); Attenuated influenza vaccine; Vaccine adverse
   event reporting system
ID GUILLAIN-BARRE-SYNDROME; SAFETY; GUIDELINES; COLLECTION
AB Background: Trivalent adjuvanted influenza vaccine (aIIV3; Fluad (R)) was approved in the United States (U.S.) in 2015 for adults aged >= 65 years and has been in use since the 2016-17 influenza season.
   Methods: We analyzed U.S. reports for aIIV3 submitted from July 1, 2016 through June 30, 2018 to the Vaccine Adverse Event Reporting System (VAERS), a national spontaneous reporting system. Medical records were reviewed for serious reports. Among individuals >= 65 years of age, the relative frequency of the most commonly reported adverse events (AEs) after aIIV3 were compared with non-adjuvanted inactivated influenza vaccines given to adults aged >= 65 years, high-dose trivalent influenza vaccine (IIV3-HD) and trivalent or quadrivalent vaccines (IIV3/IIV4). Data mining analyses were undertaken to identify whether AEs for aIIV3 occurred disproportionately more than expected compared to all influenza vaccines.
   Results: VAERS received 630 reports after aIIV3, of which 521 (83%) were in adults aged >= 65 years; 79 (13%) in persons <65 years and in 30 (5%) reports age was missing; 19 (3%) reports were serious, including two deaths (0.4%) related to myocardial infarction and Sjogren's syndrome. The most common AEs reported in adults aged >= 65 years were injection site pain (21%) and erythema (18%), with similar proportions reported for IIV3-HD (17% and 19%, respectively) and for IIV3/IIV4 (15%, each). Except for reports related to vaccination of inappropriate age (n = 79) and syringe malfunction (n = 6), data mining did not identify other disproportionately reported AEs.
   Conclusions: Although our review of aIIV3 in VAERS did not identify any unexpected health conditions of concern, we observed more than twice the expected number of reports with administration of the vaccine to persons outside of the age range for which the vaccine is approved in the U.S. Health care providers should be educated on the age groups for whom aIIV3 is recommended. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Haber, Penina; Moro, Pedro L.; Ng, Carmen; Lewis, Paige; Cano, Maria] Ctr Dis Control & Prevent, Immunizat Safety Off, Div Healthcare Qual Promot, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA.
   [Dores, Graca M.] US FDA, Div Epidemiol, Off Biostat & Epidemiol, Ctr Biol Evaluat & Res, Rockville, MD 20857 USA.
RP Haber, P (reprint author), Ctr Dis Control & Prevent, Immunizat Safety Off, Div Healthcare Qual Promot, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA.; Haber, P (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,V18-4, Atlanta, GA 30329 USA.
EM phaber@cdc.gov
OI Dores, Graca/0000-0002-3985-2935
CR Advisory Committee on Immunization Practices (ACIP), 2015, SUMM REP
   Black S, 2015, VACCINE, V33, pB3, DOI 10.1016/j.vaccine.2014.11.062
   DuMouchel W, 1999, AM STAT, V53, P177, DOI 10.2307/2686093
   FLUAD-Seqirus Inc, 2017, US PACK INS MARCH 20
   Food and Drug Administration, 1997, FED REGISTER, V62, P52252
   Frey SE, 2014, VACCINE, V32, P5027, DOI 10.1016/j.vaccine.2014.07.013
   Hibbs BF, 2015, VACCINE, V33, P3171, DOI 10.1016/j.vaccine.2015.05.006
   HURWITZ ES, 1981, NEW ENGL J MED, V304, P1557, DOI 10.1056/NEJM198106253042601
   IOM (Institute of Medicine), 2007, PREV MED ERR QUAL CH
   IOM (Institute of Medicine), 2012, 1 ADV EFF VACC EV CA
   Arias LHM, 2015, VACCINE, V33, P3773, DOI 10.1016/j.vaccine.2015.05.013
   Medical Dictionary for Regulatory Activities, INT C HARM TECHN REQ
   Moro PL, 2018, PEDIATRICS, V142, DOI 10.1542/peds.2017-4171
   Moro PL, 2015, CLIN INFECT DIS, V61, P980, DOI 10.1093/cid/civ423
   Pellegrini M, 2009, VACCINE, V27, P6959, DOI 10.1016/j.vaccine.2009.08.101
   Podda A, 2001, VACCINE, V19, P2673, DOI 10.1016/S0264-410X(00)00499-0
   Polakowski LL, 2013, AM J EPIDEMIOL, V178, P962, DOI 10.1093/aje/kwt051
   Ruggeberg JU, 2007, VACCINE, V25, P5675, DOI 10.1016/j.vaccine.2007.02.064
   SCHONBERGER LB, 1979, AM J EPIDEMIOL, V110, P105, DOI 10.1093/oxfordjournals.aje.a112795
   Sejvar JJ, 2011, VACCINE, V29, P599, DOI 10.1016/j.vaccine.2010.06.003
   Shimabukuro TT, 2015, VACCINE, V33, P4398, DOI 10.1016/j.vaccine.2015.07.035
   Stratton K, 2004, IMMUNIZATION SAFETY
   Szarfman A, 2002, DRUG SAFETY, V25, P381, DOI 10.2165/00002018-200225060-00001
   Vellozzi C, 2010, VACCINE, V28, P7248, DOI 10.1016/j.vaccine.2010.09.021
   Vesikari T, 2011, NEW ENGL J MED, V365, P1406, DOI 10.1056/NEJMoa1010331
   Villa M, 2013, AM J EPIDEMIOL, V178, P1139, DOI 10.1093/aje/kwt078
   Weber JCP, 1984, ADV INFLAMMAT RES, V6, P1
   Zhou Weigong, 2003, MMWR Surveill Summ, V52, P1
NR 28
TC 2
Z9 2
U1 0
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 7
PY 2019
VL 37
IS 11
BP 1516
EP 1520
DI 10.1016/j.vaccine.2019.01.052
PG 5
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HP1DK
UT WOS:000461405400019
PM 30739795
DA 2020-05-12
ER

PT J
AU Sharp, A
   Coles, S
   Pegorie, M
   Harwood, C
   Ngui, SL
   Welfare, W
   Mandal, S
   Balogun, K
   Gent, M
AF Sharp, Ashley
   Coles, Suzi
   Pegorie, Matthieu
   Harwood, Ceryl
   Ngui, Siew-Lin
   Welfare, William
   Mandal, Sema
   Balogun, Koye
   Gent, Mike
TI Vaccination strategies for control of community outbreaks of hepatitis
   A: A comparison of two outbreaks in England
SO VACCINE
LA English
DT Article
DE Hepatitis A; Outbreak; Community; School; Vaccination
ID WIDE OUTBREAK; PREVALENCE; DISEASE
AB In August 2015 two community outbreaks of hepatitis A virus (HAV) occurred in sub-urban communities in Northern England. Each was managed by an independent outbreak control team. In outbreak one, mass vaccination was deployed targeting a residential area and two schools, while in outbreak two, vaccination was reserved for household-type contacts of cases. The highest vaccination uptake was achieved in the school settings (82% and 95%). These case studies illustrate the range of approaches that can be used and the factors that influence decision-making in response to a hepatitis A community outbreak. Both outbreaks likely started from importation(s) of HAV by returning travellers and spread through extended social networks and the local community. Vaccination strategies were selected based on hypotheses about transmission pathways, which were informed by evidence from oral fluid (OF) testing of asymptomatic contacts. More evidence about the effectiveness of mass vaccination in community outbreaks of hepatitis A in low endemicity settings is needed. Hepatitis A guidelines should include recommendations for the use of mass vaccination and OF testing in outbreaks. Crown Copyright (C) 2019 Published by Elsevier Ltd. All rights reserved.
C1 [Sharp, Ashley; Pegorie, Matthieu; Welfare, William] Publ Hlth England North West, Hlth Protect Team, Manchester, Lancs, England.
   [Coles, Suzi; Harwood, Ceryl; Gent, Mike] Publ Hlth England Yorkshire & Humber, Hlth Protect Team, Leeds, W Yorkshire, England.
   [Ngui, Siew-Lin] Publ Hlth England, Natl Infect Serv, Virus Reference Unit, London, England.
   [Welfare, William] Univ Manchester, Manchester Acad Hlth Sci Ctr, Manchester, Lancs, England.
   [Mandal, Sema; Balogun, Koye] Publ Hlth England, Ctr Infect Dis Surveillance & Control, Natl Infect Serv, London, England.
RP Sharp, A (reprint author), Publ Hlth England, Natl Infect Serv, 61 Colindale Ave, London NW9 5EQ, England.
EM Ashley.sharp@phe.gov.uk
OI Welfare, William/0000-0002-8304-1048
CR Brian J, 1996, VACCINE
   Carvalho C, 2012, EURO SURVEILL, V17
   Craig AS, 1998, CLIN INFECT DIS, V27, P531, DOI 10.1086/514700
   ECDC, 2016, HEP A VIR EU EEA
   Edelstein M, 2010, EUR COMMUNICABLE DIS, V15
   GAY NJ, 1994, EPIDEMIOL INFECT, V113, P113, DOI 10.1017/S0950268800051529
   Gilbert R, 2004, COMMUN DIS PUBLIC HL, V7
   Gossner CM, 2015, EUR COMMUNICABLE DIS, V20
   Irving GJ, 2012, COCHRANE DB SYST REV, V7
   Pniazsky V, 1994, J MED VIROL, V44
   Public Health England, 2013, HEP A GREEN BOOK
   Public Health England, 2015, HLTH PROTECTION REPO
   Public Health England, 2017, PUBL HLTH CONTR MAN
   Public Health England, 2016, HLTH PROTECTION REPO
   Public Health England, 2009, GUID PREV CONTR HEP
   Selnikova O, 2008, VACCINE, V26, P3135, DOI 10.1016/j.vaccine.2007.11.016
   Shen YG, 2008, WORLD J GASTROENTERO
   Tjon GMS, 2005, J MED VIROL
   Torner N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031339
   Victor JC, 2007, NEW ENGL J MED, V357, P1685, DOI 10.1056/NEJMoa070546
   Vos T, 2015, LANCET, V386, P743, DOI 10.1016/S0140-6736(15)60692-4
   World Health Organisation, 2012, WEEKLY EPIDEMIOLOGIC, V87, P28
   Zamir C, 2001, EUR J CLIN MICROBIOL, V20, P185, DOI 10.1007/s100960100461
NR 23
TC 0
Z9 0
U1 0
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 7
PY 2019
VL 37
IS 11
BP 1521
EP 1527
DI 10.1016/j.vaccine.2019.01.026
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HP1DK
UT WOS:000461405400020
PM 30770222
DA 2020-05-12
ER

PT J
AU Fortanier, AC
   Venekamp, RP
   Hoes, AW
   Schilder, AGM
AF Fortanier, Alexandre C.
   Venekamp, Roderick P.
   Hoes, Arno W.
   Schilder, Anne G. M.
TI Does pneumococcal conjugate vaccination affect onset and risk of first
   acute otitis media and recurrences? A primary care-based cohort study
SO VACCINE
LA English
DT Article
DE Pneumococcal conjugate vaccine; Acute otitis media; Onset; Children;
   Cohort study
ID PREVENTION; CHILDREN
AB Background: It has been hypothesized that widespread implementation of pneumococcal conjugate vaccination (PCV) in infancy reduces early AOM and thereby prevents further AOM episodes and associated health care resource use.
   Methods: We tested this hypothesis by applying an extension of the original Cox proportional hazards model (Prentice, Williams and Petersons' total time) to individual AOM episodes recorded in pseudonymised primary care electronic health records of 18,237 Dutch children born between 2004 and 2015. Children were assigned to three groups: no-PCV (January 2004-March 2006), PCV7 (April 2006 February 2011) and PCV10 (March 2011-February 2015).
   Results: Of the 18,237 newborns, 6967 (38%) experienced at least one GP-diagnosed AOM episode up to the age of four years (median age at first AOM: 12 months, interquartile range: 12; total number of AOM episodes: 14,689). Time-to-first AOM was longest in the PCV10 group compared with the PCV7 and no-PCV groups (log rank test: P < 0.001); in these groups 30% had experienced a first AOM at 20, 17 and 15 months, respectively. Children in the PCV10 group had a 21% lower risk of experiencing a first AOM episode than those in the no-PCV group (hazard ratio (HR): 0.79, 95% confidence interval (CI): 0.72-0.86), while the effect was less pronounced for the PCV7 group (HR: 0.94, 95% CI: 0.87-1.02). Neither PCV7 nor PCV10 reduced the risk of AOM recurrences. Compared to no-PCV, HRs for overall AOM were 1.00 (95% CI: 0.95-1.06) and 0.89 (95% CI: 0.84-0.95) for PCV7 and PCV10, respectively.
   Conclusion: Our cohort study suggests that PCV postpones the onset and reduces the risk of first AOM without affecting recurrences. The impact of PCV on overall AOM in children up to the age of four years seems therefore largely attributable to the prevention of a first AOM episode. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Fortanier, Alexandre C.; Venekamp, Roderick P.; Hoes, Arno W.; Schilder, Anne G. M.] Univ Utrecht, Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, Stratenum 6-104,POB 85500, NL-3508 GA Utrecht, Netherlands.
   [Schilder, Anne G. M.] UCL, Ear Inst, evidENT, London, England.
   [Schilder, Anne G. M.] NIHR UCLH Biomed Res Ctr, London W1T 7DN, England.
RP Fortanier, AC (reprint author), Univ Utrecht, Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, Stratenum 6-104,POB 85500, NL-3508 GA Utrecht, Netherlands.
EM a.c.fortanier@umcutrecht.nl; r.p.venekam-p@umcutrecht.nl;
   a.w.hoes@umcutrecht.nl; a.schil-der@ucl.ac.uk
FU Department of HealthDiabetes UK [NIHR-RP-011-045]
CR Akkerman A, 2008, HUISARTS WET, V51, P90
   Amorim LDAF, 2015, INT J EPIDEMIOL, V44, P324, DOI 10.1093/ije/dyu222
   Dagan R, 2016, LANCET INFECT DIS, V16, P480, DOI 10.1016/S1473-3099(15)00549-6
   de Hoog MLA, 2016, J PEDIATR-US, V177, P286, DOI 10.1016/j.jpeds.2016.06.066
   Eskola J, 2001, NEW ENGL J MED, V344, P403, DOI 10.1056/NEJM200102083440602
   Fortanier AC, 2014, COCHRANE DB SYST REV, V4, DOI DOI 10.1002/14651858CD001480PUB4
   Fortanier AC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121572
   Hall-Stoodley L, 2006, JAMA-J AM MED ASSOC, V296, P202, DOI 10.1001/jama.296.2.202
   Jokinen J, 2012, CLIN INFECT DIS, V55, P1673, DOI 10.1093/cid/cis799
   Kelly PJ, 2000, STAT MED, V19, P13, DOI 10.1002/(SICI)1097-0258(20000115)19:1&lt;13::AID-SIM279&gt;3.0.CO;2-5
   Kvaerner KJ, 1997, ACTA OTO-LARYNGOL, V117, P578, DOI 10.3109/00016489709113441
   MARCHANT CD, 1984, J PEDIATR-US, V104, P826, DOI 10.1016/S0022-3476(84)80475-8
   Orsini N, 2012, EPIDEMIOLOGY, V23, P770, DOI 10.1097/EDE.0b013e3182625eff
   Prymula R, 2006, LANCET, V367, P740, DOI 10.1016/S0140-6736(06)68304-9
   Sigurdsson S, 2018, CLIN INFECT DIS, DOI [10.1093/cid/civ233, DOI 10.1093/CID/CIV233]
   Smeets HM, 2018, BMC HEALTH SERV RES, V18, DOI 10.1186/s12913-018-3528-5
   TEELE DW, 1989, J INFECT DIS, V160, P83, DOI 10.1093/infdis/160.1.83
   van Lier E, 2017, 20170010 RIVM, DOI [10.21945/RIVM-2017-0010, DOI 10.21945/RIVM-2017-0010]
NR 18
TC 4
Z9 4
U1 0
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 7
PY 2019
VL 37
IS 11
BP 1528
EP 1532
DI 10.1016/j.vaccine.2019.01.064
PG 5
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HP1DK
UT WOS:000461405400021
PM 30738648
OA Other Gold
DA 2020-05-12
ER

PT J
AU Abente, EJ
   Rajao, DS
   Gauger, PC
   Vincent, AL
AF Abente, Eugenio J.
   Rajao, Daniela S.
   Gauger, Phillip C.
   Vincent, Amy L.
TI Alphavirus-vectored hemagglutinin subunit vaccine provides partial
   protection against heterologous challenge in pigs
SO VACCINE
LA English
DT Article
DE Influenza; Replicon particle; Alphavirus; Subunit vaccine
ID INFLUENZA-A VIRUS; PATHOGENICITY AVIAN INFLUENZA; BINDING SITE
   DETERMINE; GENETIC EVOLUTION; IN-VITRO; REPLICON; INFECTION; ANTIBODIES;
   CHICKENS; SUBSTITUTIONS
AB Influenza A virus in swine (IAV-S) is an important pathogen in pigs in the United States, in addition to posing a potential risk to humans through zoonotic events. Intervention strategies continue to be explored to better control virus circulation. Improved surveillance efforts has led to significantly increased sequence data available on circulating strains, vastly improving our understanding of the genetic and antigenic diversity of IAV-S. IAV-S in North America is characterized by repeated spillover events of human viruses into pigs followed by genetic and antigenic diversification. An important gap that needs to be addressed is our understanding of the role that various vaccine platforms have on efficacy against antigenically heterologous challenge. Currently licensed vaccines often update their components to adapt to a dynamic antigenic landscape and newly developed technologies continue to be approved. Hence, it remains critical to test the performance of vaccines against challenge with antigenically distinct viruses. We tested the level of protection conferred by an alphavirus-vectored hemagglutinin (HA) subunit vaccine, delivered as a monovalent or bivalent formulation, against challenge with IAV-S. Monovalent alphavirus-vectored HA vaccines provided efficient protection against challenge with viruses with matched and mismatched HA, although in one mismatched HA challenge group there was a trend for reduced protection. A bivalent vaccine, in which two HA's were simultaneously delivered, was effective in producing antibody response against both antigens and provided protection against challenge. The alphavirus platform is a promising new technology available to swine producers to help reduce the burden of disease caused by IAV-S. (C) 2019 Published by Elsevier Ltd.
C1 [Abente, Eugenio J.; Rajao, Daniela S.; Vincent, Amy L.] ARS, Virus & Prion Res Unit, Natl Anim Dis Ctr, USDA, 1920 Dayton Ave,POB 70, Ames, IA 50010 USA.
   [Gauger, Phillip C.] Iowa State Univ, Dept Vet Diagnost & Prod Anim Med, Coll Vet Med, Ames, IA USA.
   [Rajao, Daniela S.] Univ Georgia, Poultry Diagnost & Res Ctr, Dept Populat Hlth, Coll Vet Med, 953 Coll Stn Rd, Athens, GA 30602 USA.
RP Vincent, AL (reprint author), ARS, Virus & Prion Res Unit, Natl Anim Dis Ctr, USDA, 1920 Dayton Ave,POB 70, Ames, IA 50010 USA.
EM daniela.rajao@uga.edu; amy.vincent@ars.usda.gov
OI Vincent, Amy/0000-0002-4953-7285
FU USDA-ARSUnited States Department of Agriculture (USDA); NIH-National
   Institute of Allergy and Infectious Diseases (NIAID)United States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [R21AI098079]; Center of Research in Influenza Pathogenesis, an NIAID
   [HHSN272201400008C]; U.S. Department of EnergyUnited States Department
   of Energy (DOE) [DE-AC05-06OR23100]; USDAUnited States Department of
   Agriculture (USDA) [DE-AC05-06OR23100]
FX This study was supported by USDA-ARS and by an NIH-National Institute of
   Allergy and Infectious Diseases (NIAID) interagency agreement
   (R21AI098079) associated with Center of Research in Influenza
   Pathogenesis, an NIAID funded Center of Excellence in Influenza Research
   and Surveillance (HHSN272201400008C). EJA was supported in part by an
   appointment to the ARS-USDA Research Participation Program administered
   by the Oak Ridge Institute for Science and Education through an
   interagency agreement between the U.S. Department of Energy and USDA
   under contract number DE-AC05-06OR23100. Mention of trade names or
   commercial products in this article is solely for the purpose of
   providing specific information and does not imply recommendation or
   endorsement by the U.S. Government. USDA is an equal opportunity
   provider and employer.
CR Abente EJ, 2016, J VIROL, V90, P8266, DOI 10.1128/JVI.01002-16
   Bernstein DI, 2009, VACCINE, V28, P484, DOI 10.1016/j.vaccine.2009.09.135
   Bertran K, 2017, VACCINE, V35, P6336, DOI 10.1016/j.vaccine.2017.05.051
   Bertran K, 2013, VACCINE, V31, P3572, DOI 10.1016/j.vaccine.2013.05.039
   Bosworth B, 2010, COMP IMMUNOL MICROB, V33, pE99, DOI 10.1016/j.cimid.2010.05.002
   Chen YQ, 2018, CELL, V173, P417, DOI 10.1016/j.cell.2018.03.030
   Desselberger U, P NATL ACAD SCI US, P3341
   DRAKE JW, 1993, P NATL ACAD SCI USA, V90, P4171, DOI 10.1073/pnas.90.9.4171
   Feng ZX, 2013, J VIROL, V87, P7655, DOI 10.1128/JVI.00804-13
   Gauger PC, 2012, VET PATHOL, V49, P900, DOI 10.1177/0300985812439724
   Gauger PC, 2014, VIROLOGY, V471, P93, DOI 10.1016/j.virol.2014.10.003
   Gauger PC, 2014, METHODS MOL BIOL, V1161, P313, DOI 10.1007/978-1-4939-0758-8_26
   Gauger PC, 2011, VACCINE, V29, P2712, DOI 10.1016/j.vaccine.2011.01.082
   GERHARD W, 1981, NATURE, V290, P713, DOI 10.1038/290713a0
   HALBUR PG, 1995, VET PATHOL, V32, P648, DOI 10.1177/030098589503200606
   Houser K, 2015, CELL HOST MICROBE, V17, P295, DOI 10.1016/j.chom.2015.02.012
   Hubby B, 2007, VACCINE, V25, P8180, DOI 10.1016/j.vaccine.2007.09.038
   Kamrud KI, 2007, VIROLOGY, V360, P376, DOI 10.1016/j.virol.2006.10.049
   Kamrud KI, 2010, J VIROL, V84, P7713, DOI 10.1128/JVI.00310-10
   Khalil SM, 2014, J VIROL, V88, P9182, DOI 10.1128/JVI.00327-14
   Koel BF, 2013, SCIENCE, V342, P976, DOI 10.1126/science.1244730
   Lewis NS, 2011, J VIROL, V85, P12742, DOI 10.1128/JVI.05319-11
   Lewis NS, 2014, J VIROL, V88, P4752, DOI 10.1128/JVI.03805-13
   Memoli M., 2016, MBIO, V7, P1, DOI DOI 10.1128/MBI0.00417-16
   Nachbagauer R, 2017, CLIN MICROBIOL INFEC, V23, P222, DOI 10.1016/j.cmi.2017.02.009
   Paules CI, 2018, NEW ENGL J MED, V378, P7, DOI 10.1056/NEJMp1714916
   Pushko P, 1997, VIROLOGY, V239, P389, DOI 10.1006/viro.1997.8878
   Rayner JO, 2002, REV MED VIROL, V12, P279, DOI 10.1002/rmv.360
   REED L. J., 1938, AMER JOUR HYG, V27, P493
   Santos JJS, 2017, VACCINE, V35, P5637, DOI 10.1016/j.vaccine.2017.08.059
   Schultz-Cherry S, 2000, VIROLOGY, V278, P55, DOI 10.1006/viro.2000.0635
   Scorza FB, 2018, VACCINES-BASEL, P6
   Smith DJ, 2004, SCIENCE, V305, P371, DOI 10.1126/science.1097211
   Souza CK, 2016, CLIN VACCINE IMMUNOL, V23, P470, DOI 10.1128/CVI.00563-15
   Thompson JM, P NATL ACAD SCI US, P3722
   Tripp RA, 2014, VIRUSES-BASEL, V6, P3055, DOI 10.3390/v6083055
   Tsuji M, 1998, J VIROL, V72, P6907, DOI 10.1128/JVI.72.8.6907-6910.1998
   Van Reeth K, 2017, NPJ VACCINES, P2
   Vander Veen R, 2009, PLOS CURR, V1, DOI DOI 10.1371/CURRENTS.RRN1123
   Vander Veen RL, 2013, VET REC, V173, P344, DOI 10.1136/vr.101741
   Vander Veen RL, 2012, VACCINE, V30, P1944, DOI 10.1016/j.vaccine.2012.01.030
   Vincent AL, 2012, J VIROL, V86, P10597, DOI 10.1128/JVI.01439-12
   WILEY DC, 1981, NATURE, V289, P373, DOI 10.1038/289373a0
   WILSON IA, 1981, NATURE, V289, P366, DOI 10.1038/289366a0
   World Health Organization, 2002, WHO MAN AN INFL DIAG
NR 45
TC 2
Z9 3
U1 0
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 7
PY 2019
VL 37
IS 11
BP 1533
EP 1539
DI 10.1016/j.vaccine.2018.12.071
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HP1DK
UT WOS:000461405400022
PM 30723064
OA Green Accepted, Other Gold
DA 2020-05-12
ER

PT J
AU Fry, LM
   Bastos, RG
   Stone, BC
   Williams, LB
   Knowles, DP
   Murphy, SC
AF Fry, Lindsay M.
   Bastos, Reginaldo G.
   Stone, Brad C.
   Williams, Laura B.
   Knowles, Donald P.
   Murphy, Sean C.
TI Gene gun DNA immunization of cattle induces humoral and CD4
   T-cell-mediated immune responses against the Theileria parva polymorphic
   immunodominant molecule
SO VACCINE
LA English
DT Article
DE DNA vaccination; East Coast Fever; Gene gun immunization; Cattle;
   Vaccine
ID EAST-COAST FEVER; ANTIGEN; PARASITE; DIFFERENTIATION; PROLIFERATION;
   SPOROZOITES; EXPRESSION; SEQUENCE; PROGRESS; SURFACE
AB Theileria parva kills over one million cattle annually in sub-Saharan Africa. Parasite genetic complexity, cellular response immunodominance, and bovine MHC diversity have precluded traditional vaccine development. One potential solution is gene gun (GG) immunization, which enables simultaneous administration of one or more DNA-encoded antigens. Although promising in murine, porcine, and human vaccination trials, bovine GG immunization studies are limited. We utilized the model T. parva antigen, polymorphic immunodominant molecule (PIM) to test bovine GG immunization. GG immunization using a mammalian codon optimized PIM sequence elicited significant anti-PIM antibody and cell mediated responses in 7/8 steers, but there was no difference between immunized and control animals following T. parva challenge. The results suggest immunization with PIM, as delivered here, is insufficient to protect cattle from T. parva. Nonetheless, the robust immune responses elicited against this model antigen suggest GG immunization is a promising vaccine platform for T. parva and other bovine pathogens. Published by Elsevier Ltd.
C1 [Fry, Lindsay M.] ARS, Anim Dis Res Unit, USDA, POB 646630, Pullman, WA 99164 USA.
   [Fry, Lindsay M.; Bastos, Reginaldo G.; Williams, Laura B.; Knowles, Donald P.] Washington State Univ, Dept Vet Microbiol & Pathol, POB 647040, Pullman, WA 99164 USA.
   [Stone, Brad C.; Murphy, Sean C.] Univ Washington, Dept Lab Med, Med Ctr, 1959 NE Pacific St, Seattle, WA 98195 USA.
   [Murphy, Sean C.] Univ Washington, Dept Microbiol, 750 Republican St,Box 358070, Seattle, WA 98109 USA.
   [Stone, Brad C.; Murphy, Sean C.] Ctr Emerging & Reemerging Infect Dis, 750 Republican St, Seattle, WA 98109 USA.
RP Fry, LM (reprint author), ARS, Anim Dis Res Unit, USDA, POB 646630, Pullman, WA 99164 USA.
EM Lindsay.Fry@ARS.USDA.gov; reginaldo_bastos@wsu.edu; stoneb4@uw.edu;
   lartz@wsu.edu; dknowles@wsu.edu; murphysc@uw.edu
RI Murphy, Sean C./AAC-7531-2019
OI Murphy, Sean C./0000-0002-2048-0131; Fry, Lindsay/0000-0003-0938-9254
FU USAIDUnited States Agency for International Development (USAID)
   [AID-BFS-P-13-00002]; Bill and Melinda Gates FoundationGates Foundation
   [OPP1078791]
FX This work was supported by USAID (AID-BFS-P-13-00002) and the Bill and
   Melinda Gates Foundation (OPP1078791). The content of this manuscript is
   the sole responsibility of the USDA-ARS-ADRU and Washington State
   University and does not necessarily reflect the views of USAID or the
   United States Government.
CR BALDWIN CL, 1992, EXP PARASITOL, V75, P19, DOI 10.1016/0014-4894(92)90118-T
   Benedictus L, 2012, AM J REPROD IMMUNOL, V67, P224, DOI 10.1111/j.1600-0897.2011.01085.x
   Braun RP, 1999, VIROLOGY, V265, P46, DOI 10.1006/viro.1999.0032
   Chase CCI, 2008, J SWINE HEALTH PROD, V16, P254
   Codner GF, 2012, ANIM GENET, V43, P239, DOI 10.1111/j.1365-2052.2011.02239.x
   Codner GF, 2012, IMMUNOGENETICS, V64, P435, DOI 10.1007/s00251-012-0612-6
   Di Giulio G, 2009, TRENDS PARASITOL, V25, P85, DOI 10.1016/j.pt.2008.11.007
   Ellis SA, 2014, ANNU REV ANIM BIOSCI, V2, P285, DOI 10.1146/annurev-animal-022513-114234
   Engelke L, 2015, VACCINE, V33, P4663, DOI 10.1016/j.vaccine.2015.05.012
   Estes DM, 2002, VET IMMUNOL IMMUNOP, V90, P1, DOI 10.1016/S0165-2427(02)00201-5
   Estes DM, 1998, IMMUNOLOGY, V95, P604
   ESTES DM, 1995, CELL IMMUNOL, V163, P268, DOI 10.1006/cimm.1995.1126
   ESTES DM, 1994, CELL IMMUNOL, V154, P287, DOI 10.1006/cimm.1994.1078
   Fry LM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0156004
   Fuller DH, 2006, METHODS, V40, P86, DOI 10.1016/j.ymeth.2006.05.022
   Gardner MJ, 2005, SCIENCE, V309, P134, DOI 10.1126/science.1110439
   Glass Elizabeth J., 2004, Animal Health Research Reviews, V5, P197, DOI 10.1079/AHR200469
   GODDEERIS BM, 1988, J TISUE CULT METHODS, V11, P101, DOI DOI 10.HTTPS://D0I.0RG/10.1007/BF01404140
   Graham SP, 2008, INFECT IMMUN, V76, P685, DOI 10.1128/IAI.01244-07
   Graham SP, 2006, P NATL ACAD SCI USA, V103, P3286, DOI 10.1073/pnas.0511273103
   Hemmink JD, 2018, INT J PARASITOL, V48, P287, DOI 10.1016/j.ijpara.2017.10.006
   KARIUKI DP, 1995, TROP ANIM HEALTH PRO, V27, P15, DOI 10.1007/BF02236328
   Katende J, 1998, PARASITOL RES, V84, P408, DOI 10.1007/s004360050419
   Lacasta A, 2018, VACCINE, V36, P1389, DOI 10.1016/j.vaccine.2018.01.087
   Littel-van den Hurk SV, 1998, J GEN VIROL, V79, P831
   Loehr BI, 2000, J VIROL, V74, P6077, DOI 10.1128/JVI.74.13.6077-6086.2000
   MacHugh ND, 2009, EUR J IMMUNOL, V39, P2459, DOI 10.1002/eji.200939227
   MCGUIRE TC, 1979, IMMUNOLOGY, V38, P249
   MCKEEVER DJ, 1994, P NATL ACAD SCI USA, V91, P1959, DOI 10.1073/pnas.91.5.1959
   Morrison WI, 2006, PARASITOLOGY, V133, pS169, DOI 10.1017/S0031182006001867
   Morrison WI, 2015, REV SCI TECH OIE, V34, P599, DOI 10.20506/rst.34.2.2383
   Morrison WI, 2015, ANNU REV ANIM BIOSCI, V3, P397, DOI 10.1146/annurev-animal-022513-114152
   MORRISON WI, 1987, PARASITE IMMUNOL, V9, P563, DOI 10.1111/j.1365-3024.1987.tb00530.x
   Mukhebi AW, 1992, EPIDEMIOLOGY THEILER, P378
   Murphy SC, 2013, P NATL ACAD SCI USA, V110, P6055, DOI 10.1073/pnas.1303834110
   Nene V, 2016, PARASITE IMMUNOL, V38, P724, DOI 10.1111/pim.12388
   Nene V, 2016, TICKS TICK-BORNE DIS, V7, P549, DOI 10.1016/j.ttbdis.2016.02.001
   Norling M, 2015, BMC GENOMICS, V16, DOI 10.1186/s12864-015-1910-9
   NORVAL RAI, 1991, PARASITOLOGY, V102, P347, DOI 10.1017/S0031182000064295
   Odongo DO, 2009, J MED ENTOMOL, V46, P888, DOI 10.1603/033.046.0422
   Pelle R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019015
   PERTMER TM, 1995, VACCINE, V13, P1427, DOI 10.1016/0264-410X(95)00069-D
   Stone BC, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153449
   SUGIMOTO C, 1992, PARASITOL RES, V78, P82, DOI 10.1007/BF00936188
   TOYE P, 1995, MOL BIOCHEM PARASIT, V73, P165, DOI 10.1016/0166-6851(95)00110-M
   Toye P, 1996, INFECT IMMUN, V64, P1832, DOI 10.1128/IAI.64.5.1832-1838.1996
   TOYE PG, 1991, PARASITE IMMUNOL, V13, P49, DOI 10.1111/j.1365-3024.1991.tb00262.x
   Toye P, 2014, INFECT IMMUN, V82, P1786, DOI 10.1128/IAI.01029-13
   Trigona WL, 1999, J INTERF CYTOK RES, V19, P1317, DOI 10.1089/107999099312993
   Wise LN, 2018, TICKS TICK-BORNE DIS, V9, P135, DOI 10.1016/j.ttbdis.2017.08.007
   Yager Eric J, 2013, Methods Mol Biol, V940, P223, DOI 10.1007/978-1-62703-110-3_19
NR 51
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 14
PY 2019
VL 37
IS 12
BP 1546
EP 1553
DI 10.1016/j.vaccine.2019.02.009
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HQ0UD
UT WOS:000462109600002
PM 30782490
OA Green Published, Other Gold
DA 2020-05-12
ER

PT J
AU Soh, SH
   Shim, S
   Im, YB
   Park, HT
   Cho, CS
   Yoo, HS
AF Soh, Sang Hee
   Shim, Soojin
   Im, Young Bin
   Park, Hong-Tae
   Cho, Chong-Su
   Yoo, Han Sang
TI Induction of Th2-related immune responses and production of systemic IgA
   in mice intranasally immunized with Brucella abortus malate
   dehydrogenase loaded chitosan nanoparticles
SO VACCINE
LA English
DT Article
DE Mucosal immune response; Malate dehydrogenase; Brucella abortus;
   Chitosan nanoparticles; Nasal immunization
ID PROTECTIVE IMMUNITY; STIMULATING ACTIVITY; NASAL IMMUNIZATION;
   MICROSPHERES; VACCINE; MELITENSIS; INFECTION; DELIVERY; MICROPARTICLES;
   ADJUVANT
AB The aim of this study was to investigate the induction of mucosal immune responses by an important Brucella abortus antigen, malate dehydrogenase (Mdh), loaded in mucoadhesive chitosan nanoparticles (CNs) and immunized intranasally in a BALB/c mouse model. The production of cytokines was investigated in human leukemic monocyte cells (THP-1 cells) after stimulation with the nanoparticles. Mdh-loaded CNs (CNs-Mdh) induced higher interleukin (IL)-6 production than unloaded antigens and TF loaded CNs (CNs-TF). Using ELISpot to quantify cytokines and antibody-secreting cells in the intranasally immunized mice, IL-4 and IgG-secreting cells were found to be significantly increased at 4 weeks and 6 weeks post-immunization in the CNs-Mdh immunized group, respectively. Increases in Mdh-specific IgG, IgG1, and IgG2a antibodies were confirmed at 6 weeks after immunization, indicating a predominant IgG1 response. Analysis of the mucosal immune response in the intranasally immunized mice revealed, Mdh-specific IgA and total IgA in the nasal washes, genital secretions, fecal extracts and sera that were remarkably increased in the CNs-Mdh-immunized group compared to the CNs-TF-immunized group except total IgA of nasal wash. Therefore, the results indicated that the intranasal immunization of CNs-loaded B. abortus Mdh antigen effectively induced antigen-specific mucosal immune responses through the elicitation of Th2-related immune responses. (C) 2019 Published by Elsevier Ltd.
C1 [Soh, Sang Hee; Shim, Soojin; Im, Young Bin; Park, Hong-Tae; Yoo, Han Sang] Seoul Natl Univ, Coll Vet Med, Dept Infect Dis, Seoul 08826, South Korea.
   [Cho, Chong-Su] Seoul Natl Univ, Dept Agr Biotechnol, Seoul 08826, South Korea.
   [Cho, Chong-Su] Seoul Natl Univ, Res Inst Agr & Life Sci, Seoul 08826, South Korea.
RP Yoo, HS (reprint author), Seoul Natl Univ, Coll Vet Med, Dept Infect Dis, Seoul 08826, South Korea.
EM skdy5738@snu.ac.kr; jin08061992@snu.ac.kr; bini@snu.ac.kr;
   twinstar23@snu.ac.kr; chocs@snu.ac.kr; yoohs@snu.ac.kr
FU Korea Health Industry Development Institute (KHIDI) [HI16C2130]; Brain
   Korea (BK) 21 PLUS program for Creative Veterinary Science Research;
   Research Institute of Veterinary Science at Seoul National University in
   the Republic of Korea
FX This work was supported by the Korea Health Industry Development
   Institute (KHIDI) (No. HI16C2130), the Brain Korea (BK) 21 PLUS program
   for Creative Veterinary Science Research and the Research Institute of
   Veterinary Science at Seoul National University in the Republic of
   Korea.
CR Barbari Ghullam Reza, 2017, Int J Nanomedicine, V12, P3471, DOI 10.2147/IJN.S116063
   Ben Mkaddem S, 2013, AUTOIMMUN REV, V12, P666, DOI 10.1016/j.autrev.2012.10.011
   Bin Im Y, 2018, MICROB PATHOGENESIS, V122, P7, DOI 10.1016/j.micpath.2018.06.007
   Brandtzaeg P, 2015, MUCOSAL IMMUNOLOGY, P623
   Cerutti A, 2008, NAT REV IMMUNOL, V8, P421, DOI 10.1038/nri2322
   Aparicio ED, 2013, REV SCI TECH OIE, V32, P53
   Dienz O, 2009, CLIN IMMUNOL, V130, P27, DOI 10.1016/j.clim.2008.08.018
   Dorneles EMS, 2015, VET RES, V46, DOI 10.1186/s13567-015-0199-7
   ELDRIDGE JH, 1990, J CONTROL RELEASE, V11, P205, DOI 10.1016/0168-3659(90)90133-E
   Godfroid J, 2013, REV SCI TECHNIQUE
   Guliyeva U, 2006, EUR J PHARM BIOPHARM, V62, P17, DOI 10.1016/j.ejpb.2005.08.006
   Gwida M, 2010, CROAT MED J, V51, P289, DOI 10.3325/cmj.2010.51.289
   Hop HT, 2015, FEMS MICROBIOL LETT, V362, DOI 10.1093/femsle/fnv003
   Illum L, 2001, ADV DRUG DELIVER REV, V51, P81, DOI 10.1016/S0169-409X(01)00171-5
   Im YB, 2017, MICROB PATHOGENESIS, V110, P7, DOI 10.1016/j.micpath.2017.06.019
   Jacques I, 2007, VACCINE, V25, P794, DOI 10.1016/j.vaccine.2006.09.051
   Jaganathan KS, 2006, VACCINE, V24, P4201, DOI 10.1016/j.vaccine.2006.01.011
   Jiang HL, 2004, EUR J PHARM BIOPHARM, V58, P471, DOI 10.1016/j.ejpb.2004.05.006
   Jiang HL, 2007, POLYM ADVAN TECHNOL, V18, P220, DOI 10.1002/pat.861
   Kang ML, 2007, VACCINE, V25, P4602, DOI 10.1016/j.vaccine.2007.03.038
   Kang ML, 2006, EUR J PHARM BIOPHARM, V63, P215, DOI 10.1016/j.ejpb.2006.01.010
   Kim WS, 2018, CYTOKINE, V104, P14, DOI 10.1016/j.cyto.2018.01.022
   Li HS, 2016, J CONTROL RELEASE, V233, P114, DOI 10.1016/j.jconrel.2016.05.032
   Liu ZZ, 2016, VACCINE, V34, P989, DOI 10.1016/j.vaccine.2015.10.067
   Lowry JE, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017425
   Marttin E, 1998, ADV DRUG DELIVER REV, V29, P13, DOI 10.1016/S0169-409X(97)00059-8
   Mi FL, 1999, J APPL POLYM SCI, V71, P747, DOI 10.1002/(SICI)1097-4628(19990131)71:5<747::AID-APP9>3.0.CO;2-6
   Moller W, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-10
   Neutra MR, 2006, NAT REV IMMUNOL, V6, P148, DOI 10.1038/nri1777
   Oliveira SC, 1996, VACCINE, V14, P959, DOI 10.1016/0264-410X(96)00018-7
   Onate AA, 2003, INFECT IMMUN, V71, P4857, DOI 10.1128/IAI.71.9.4857-4861.2003
   Pappas G, 2005, NEW ENGL J MED, V352, P2325, DOI 10.1056/NEJMra050570
   Pasquevich KA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016203
   Pasquevich KA, 2009, INFECT IMMUN, V77, P436, DOI 10.1128/IAI.01151-08
   Pereswetoff-Morath L, 1998, ADV DRUG DELIVER REV, V29, P185, DOI 10.1016/S0169-409X(97)00069-0
   Phalipon A, 2002, IMMUNITY, V17, P107, DOI 10.1016/S1074-7613(02)00341-2
   Simborio HLT, 2015, MICROB PATHOGENESIS, V83-84, P41, DOI 10.1016/j.micpath.2015.05.004
   Sinha VR, 2004, INT J PHARMACEUT, V274, P1, DOI 10.1016/j.ijpharm.2003.12.026
   Suraud V, 2008, MICROBES INFECT, V10, P1370, DOI 10.1016/j.micinf.2008.08.003
   Tabynov K, 2016, VACCINE, V34, P5049, DOI 10.1016/j.vaccine.2016.08.072
   Tu J, 2016, INT J BIOL MACROMOL, V86, P848, DOI 10.1016/j.ijbiomac.2016.02.015
   van der Lubben IM, 2001, BIOMATERIALS, V22, P687, DOI 10.1016/S0142-9612(00)00231-3
   Yang XH, 2007, VACCINE, V25, P2261, DOI 10.1016/j.vaccine.2006.12.004
   Yang Y, 2007, COMP IMMUNOL MICROB, V30, P19, DOI 10.1016/j.cimid.2006.09.006
   Yin LT, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082765
   Yoon HJ, 2007, BIOCHEM BIOPH RES CO, V358, P954, DOI 10.1016/j.bbrc.2007.05.042
NR 46
TC 3
Z9 3
U1 1
U2 9
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 14
PY 2019
VL 37
IS 12
BP 1554
EP 1564
DI 10.1016/j.vaccine.2019.02.005
PG 11
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HQ0UD
UT WOS:000462109600003
PM 30792035
DA 2020-05-12
ER

PT J
AU Cocozza, F
   Menay, F
   Tsacalian, R
   Elisei, A
   Sampedro, P
   Soria, I
   Waldner, C
   Gravisaco, MJ
   Mongini, C
AF Cocozza, Federico
   Menay, Florencia
   Tsacalian, Rodrigo
   Elisei, Analia
   Sampedro, Pura
   Soria, Ivana
   Waldner, Claudia
   Jose Gravisaco, Maria
   Mongini, Claudia
TI Cyclophosphamide enhances the release of tumor exosomes that elicit a
   specific immune response in vivo in a murine T-cell lymphoma
SO VACCINE
LA English
DT Article
DE Extracellular vesicles; Exosomes; Tumor-vaccine; T-cell lymphoma
ID ASCITES-DERIVED EXOSOMES; EFFICIENT INDUCTION; MICROVESICLES;
   EXPRESSION; VITRO; HEAT-SHOCK-PROTEIN-70; MICROENVIRONMENT;
   PROLIFERATION; BIOGENESIS; ACTIVATION
AB Exosomes are 60-150 nm small extracellular vesicles (EVs) released by most cells. Tumor-cell-derived exosomes, used as a vaccine, elicit a specific cytotoxic response against tumor cells, usually with a greater immunogenicity than tumor-cell lysates. However, the number of exosomes isolated from culture cells is limited. In recent studies, it was observed that cells respond to different stressor stimuli such as cytotoxic drugs, hypoxia, acidosis, or radiation by increasing the release of EVs.
   In this study, using the murine LBC T-cell lymphoma, we found that cyclophosphamide significantly increased EVs yield. These EVs express exosome marker proteins such as TSG-101, CD9, CD81, and CD63. Furthermore, similar humoral and cellular immune responses were induced in vivo by EVs isolated from LBC-tumor cells whether they were grown under normal culture conditions (EVs C) or in the presence of cyclophosphamide (EVs CTX). Mice vaccinated either with EVs C or EVs CTX were similarly protected against an intraperitoneal challenge with LBC tumor cells. CD4+ and CD8+ IFN-gamma secreting cells were induced in immunized mice and a specific cytotoxic cellular immune response was elicited in vitro. These results demonstrate that a Th1 response was induced by immunization with the EVs. Our findings suggest that treatment of tumor cells with cyclophosphamide is a useful method to enhance the secretion of EVs in sensitive cell lines without altering their antitumor properties and thus may be used to produce antigens for future design of cancer vaccines. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Cocozza, Federico; Menay, Florencia; Tsacalian, Rodrigo; Waldner, Claudia; Mongini, Claudia] UBA, CONICET, Ctr Estudios Farmacol & Botan CEFYBO, Buenos Aires, DF, Argentina.
   [Elisei, Analia; Soria, Ivana; Mongini, Claudia] INTA Castelar, Inst Virol, Buenos Aires, DF, Argentina.
   [Sampedro, Pura; Mongini, Claudia] Univ Moron, Fac Ciencias Exactas Quim & Nat, Moron, Argentina.
   [Jose Gravisaco, Maria] INTA Castelar, Inst Biotecnol, Buenos Aires, DF, Argentina.
RP Mongini, C (reprint author), CONICET INTA, Inst Virol & Innovac Tecnol, N Repetto & De Los Reseros S-N,Hurlingham 1686, Buenos Aires, DF, Argentina.
EM mongini.claudia@inta.gob.ar
FU Consejo Nacional de Investigaciones Cientificas y Tecnicas
   (CONICET)Consejo Nacional de Investigaciones Cientificas y Tecnicas
   (CONICET); Facultad de Ciencias Exactas, Quimicas y Naturales de Moron;
   Universidad de Moron, Buenos Aires, Argentina
FX Authors are very grateful to Norma Rizzo, Daniel Gonzalez, Veterinarian
   Marcela Marquez, and Mariela Gammella for their technical assistance. We
   thank the personnel at the Radiation Unit of the Hospital de Oncologia,
   Marie Curie, Buenos Aires, Argentina. We also thank Mrs. Leslie Malek de
   Pasian for proof-reading the manuscript. This work was supported by
   grants from the Consejo Nacional de Investigaciones Cientificas y
   Tecnicas (CONICET) and Facultad de Ciencias Exactas, Quimicas y
   Naturales de Moron; Universidad de Moron, Buenos Aires, Argentina. CM
   and CW are members of the CONICET. FM and FC are fellows of the CONICET.
CR Anand Paras K, 2010, Commun Integr Biol, V3, P405, DOI 10.4161/cib.3.5.12474
   Anand PK, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010136
   Andre F, 2004, ANN ONCOL, V15, P141, DOI 10.1093/annonc/mdh918
   Andre F, 2002, LANCET, V360, P295, DOI 10.1016/S0140-6736(02)09552-1
   Bandari SK, 2018, MATRIX BIOL, V65, P104, DOI 10.1016/j.matbio.2017.09.001
   Bracci L, 2007, CLIN CANCER RES, V13, P644, DOI 10.1158/1078-0432.CCR-06-1209
   Cao LF, 2010, CYTOM PART A, V77A, P534, DOI 10.1002/cyto.a.20887
   Chaput N, 2004, J IMMUNOL, V172, P2137, DOI 10.4049/jimmunol.172.4.2137
   Chaput N, 2006, J LEUKOCYTE BIOL, V80, P471, DOI 10.1189/jlb.0206094
   Chen TY, 2011, J IMMUNOL, V186, P2219, DOI 10.4049/jimmunol.1002991
   Chen TY, 2009, J IMMUNOL, V182, P1449, DOI 10.4049/jimmunol.182.3.1449
   Chen WL, 2006, EUR J IMMUNOL, V36, P1598, DOI 10.1002/eji.200535501
   Clayton A, 2001, J IMMUNOL METHODS, V247, P163, DOI 10.1016/S0022-1759(00)00321-5
   Clayton A, 2005, BLOOD CELL MOL DIS, V34, P206, DOI 10.1016/j.bcmd.2005.03.003
   Clayton A, 2007, CANCER RES, V67, P7458, DOI 10.1158/0008-5472.CAN-06-3456
   Colombo M, 2014, ANNU REV CELL DEV BI, V30, P255, DOI 10.1146/annurev-cellbio-101512-122326
   Dai S, 2008, MOL THER, V16, P782, DOI 10.1038/mt.2008.1
   Dai SM, 2005, CLIN CANCER RES, V11, P7554, DOI 10.1158/1078-0432.CCR-05-0810
   Daillere R, 2016, IMMUNITY, V45, P931, DOI 10.1016/j.immuni.2016.09.009
   de Jonge ME, 2005, CLIN PHARMACOKINET, V44, P1135, DOI 10.2165/00003088-200544110-00003
   De Toro J, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00203
   Delcayre A, 2006, CURR OPIN MOL THER, V8, P31
   EL Andaloussi S, 2013, NAT REV DRUG DISCOV, V12, P348, DOI 10.1038/nrd3978
   Eldh M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015353
   Fernando MR, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0183915
   Fulda Simone, 2010, Int J Cell Biol, V2010, P214074, DOI 10.1155/2010/214074
   Gastpar R, 2005, CANCER RES, V65, P5238, DOI 10.1158/0008-5472.CAN-04-3804
   Ghiringhelli F, 2007, CANCER IMMUNOL IMMUN, V56, P641, DOI 10.1007/s00262-006-0225-8
   Gudbergsson JM, 2016, CYTOTECHNOLOGY, V68, P579, DOI 10.1007/s10616-015-9913-6
   Hamano Y, 2004, CANCER RES, V64, P1570, DOI 10.1158/0008-5472.CAN-03-3126
   Hedlund M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016899
   Hegmans JPJJ, 2004, AM J PATHOL, V164, P1807, DOI 10.1016/S0002-9440(10)63739-X
   Iero M, 2008, CELL DEATH DIFFER, V15, P80, DOI 10.1038/sj.cdd.4402237
   Kim SH, 2006, MOL THER, V13, P289, DOI 10.1016/j.ymthe.2005.09.015
   King HW, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-421
   Kosgodage US, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18051007
   Kowal J, 2016, P NATL ACAD SCI USA, V113, pE968, DOI 10.1073/pnas.1521230113
   Kucharzewska P, 2013, P NATL ACAD SCI USA, V110, P7312, DOI 10.1073/pnas.1220998110
   Lamoreaux L, 2006, NAT PROTOC, V1, P1507, DOI 10.1038/nprot.2006.268
   Lamparski HG, 2002, J IMMUNOL METHODS, V270, P211, DOI 10.1016/S0022-1759(02)00330-7
   Lv LH, 2012, J BIOL CHEM, V287, P15874, DOI 10.1074/jbc.M112.340588
   Menay F, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00286
   Mignot G, 2006, J CELL MOL MED, V10, P376, DOI 10.1111/j.1582-4934.2006.tb00406.x
   Mongini C, 2001, IN VITRO CELL DEV-AN, V37, P499
   Morelli AE, 2004, BLOOD, V104, P3257, DOI 10.1182/blood-2004-03-0824
   Navabi H, 2005, BLOOD CELL MOL DIS, V35, P149, DOI 10.1016/j.bcmd.2005.06.008
   Parolini I, 2009, J BIOL CHEM, V284, P34211, DOI 10.1074/jbc.M109.041152
   Patel GK, 2017, BRIT J CANCER, V116, P609, DOI 10.1038/bjc.2017.18
   Peinado H, 2012, NAT MED, V18, P883, DOI 10.1038/nm.2753
   Pitt JM, 2016, J CLIN INVEST, V126, P1224, DOI 10.1172/JCI81137
   Quah BJC, 2007, NAT PROTOC, V2, P2049, DOI 10.1038/nprot.2007.296
   Raposo G, 2013, J CELL BIOL, V200, P373, DOI 10.1083/jcb.201211138
   Runz S, 2007, GYNECOL ONCOL, V107, P563, DOI 10.1016/j.ygyno.2007.08.064
   Ruybal P, 2005, INT IMMUNOPHARMACOL, V5, P1685, DOI 10.1016/j.intimp.2005.04.016
   Samuel P, 2018, PHILOS T R SOC B, V372, DOI 10.1098/rstb.2017.0065
   Taieb J, 2005, CRIT REV IMMUNOL, V25, P215, DOI 10.1615/CritRevImmunol.v25.i3.30
   Thery C, 2002, NAT REV IMMUNOL, V2, P569, DOI 10.1038/nri855
   Thery Clotilde, 2006, Curr Protoc Cell Biol, VChapter 3, DOI 10.1002/0471143030.cb0322s30
   Tkach M, 2018, PHILOS T R SOC B, V372, DOI 10.1098/rstb.2016.0479
   Tkach M, 2017, EMBO J, V36, P3012, DOI 10.15252/embj.201696003
   Vega VL, 2008, J IMMUNOL, V180, P4299, DOI 10.4049/jimmunol.180.6.4299
   Viaud S, 2013, SCIENCE, V342, P971, DOI 10.1126/science.1240537
   Wang M, 2008, LEUKEMIA, V22, P179, DOI 10.1038/sj.leu.2404959
   Wolfers J, 2001, NAT MED, V7, P297, DOI 10.1038/85438
   Wysoczynski M, 2009, INT J CANCER, V125, P1595, DOI 10.1002/ijc.24479
   Xie YF, 2010, J CELL MOL MED, V14, P2655, DOI 10.1111/j.1582-4934.2009.00851.x
   Yang YS, 2015, INT J HYPERTHER, V31, P498, DOI 10.3109/02656736.2015.1036384
   Zeelenberg IS, 2008, CANCER RES, V68, P1228, DOI 10.1158/0008-5472.CAN-07-3163
   Zhang HC, 2012, STEM CELLS DEV, V21, P3289, DOI 10.1089/scd.2012.0095
   Zitvogel L, 1998, NAT MED, V4, P594, DOI 10.1038/nm0598-594
NR 70
TC 1
Z9 1
U1 4
U2 8
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 14
PY 2019
VL 37
IS 12
BP 1565
EP 1576
DI 10.1016/j.vaccine.2019.02.004
PG 12
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HQ0UD
UT WOS:000462109600004
PM 30777349
DA 2020-05-12
ER

PT J
AU Hsu, CH
   Wannemuehler, KA
   Soofi, S
   Mashal, M
   Hussain, I
   Bhutta, ZA
   McDuffie, L
   Weldon, W
   Farag, NH
AF Hsu, Christopher H.
   Wannemuehler, Kathleen A.
   Soofi, Sajid
   Mashal, Mohd
   Hussain, Imtiaz
   Bhutta, Zulfiqar A.
   McDuffie, Larin
   Weldon, William
   Farag, Noha H.
TI Poliovirus immunity among children under five years-old in accessible
   areas of Afghanistan, 2013
SO VACCINE
LA English
DT Article
DE Afghanistan; Poliovirus; Serosurvey; Eradication; Immunity
ID VACCINE-DERIVED POLIOVIRUS; POLIOMYELITIS ERADICATION; PROGRESS;
   PAKISTAN; SEROPREVALENCE; ANTIBODIES; NIGERIA
AB Background: Afghanistan remains among the three countries with endemic wild poliovirus transmission, and high population immunity levels are required to interrupt transmission and prevent outbreaks. Surveillance and vaccination of children in Afghanistan have been challenging due to security issues limiting accessibility in certain areas.
   Methods: A serosurvey was conducted in 2013 within accessible enumeration areas (EAs) among children aged <5 years using samples collected for a national micronutrient assessment survey to assess poliovirus immunity in Afghanistan. Of 21194 total EAs in Afghanistan, 107 were inaccessible and therefore were excluded from the sampling frame.
   Results: Population immunity was high overall but varied for the poliovirus serotypes, and was lowest for type 3 (95% [95% CI: 93%, 96%]) compared to type 1 (99% [95% CI:97%, 99%]) and type 2 (98% [95% CI:96%, 99%]). The proportion of the population immune to all three types was 93% (95% CI: 91%, 95%), and the proportion seronegative for all three types was 0.5% (95% CI: 0.2%, 1.7%).
   Conclusion: Except for regional differences in immunity to type 3 virus, there were no other apparent differences in seroprevalence by region or by any of the demographic or nutritional characteristics assessed in this study. The study was not powered to provide provincial level seroprevalence estimates, but Paktika Province, in the South region, had the largest proportion of seronegative specimens for type 1 (4 seronegative of 17 serum specimens compared to 14 seronegative of 673 for the remainder of the areas). Among accessible children in Afghanistan, seroprevalence of antibodies to poliovirus was high, with most seroprevalence reported at 95% or greater. Despite high seroprevalence in areas assessed in this study, the continued detection of poliovirus cases in the South and East regions indicate that overall regional vaccination coverage and performance is not sufficient to stop polio transmission. Published by Elsevier Ltd.
C1 [Hsu, Christopher H.; Wannemuehler, Kathleen A.; Farag, Noha H.] Ctr Dis Control & Prevent, Polio Eradicat Branch, Atlanta, GA 30333 USA.
   [Soofi, Sajid; Hussain, Imtiaz; Bhutta, Zulfiqar A.] Aga Khan Univ, Woman & Child Hlth Div, Karachi, Pakistan.
   [Mashal, Mohd] WHO, Amman, Jordan.
   [McDuffie, Larin] IHRC Inc, Atlanta, GA USA.
   [Weldon, William] Ctr Dis Control & Prevent, Div Viral Dis, Atlanta, GA USA.
RP Hsu, CH; Farag, NH (reprint author), Ctr Dis Control & Prevent, Polio Eradicat Branch, Atlanta, GA 30333 USA.
EM ydh2@cdc.gov; iym0@cdc.gov
OI Wannemuehler, Kathleen/0000-0001-9535-6277; soofi,
   sajid/0000-0003-4192-8406
FU United Nations International Children's Emergency Fund grant
   [PCA-2013-003-1]; Centers for Disease Control and Prevention program
   funds
FX This work was supported by the United Nations International Children's
   Emergency Fund grant (PCA-2013-003-1) and the Centers for Disease
   Control and Prevention program funds.
CR Akseer N, 2018, LANCET GLOB HLTH
   Alleman MM, 2018, MMWR-MORBID MORTAL W, V67, P300, DOI 10.15585/mmwr.mm6710a4
   Elhamidi Y, 2017, MMWR-MORBID MORTAL W, V66, P1276, DOI 10.15585/mmwr.mm6646a4
   Etsano A, 2016, MMWR-MORBID MORTAL W, V65, P770, DOI 10.15585/mmwr.mm6530a4
   Farag NH, 2015, MMWR-MORBID MORTAL W, V64, P1271, DOI 10.15585/mmwr.mm6445a4
   Farag NH, 2014, MMWR-MORBID MORTAL W, V63, P973
   Gofama MM, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0185284
   Hsu C, 2018, MMWR-MORBID MORTAL W, V67, P1242, DOI 10.15585/mmwr.mm6744a5
   Hsu CH, 2016, MMWR-MORBID MORTAL W, V65, P1295, DOI 10.15585/mmwr.mm6546a4
   Hussain I, 2018, VACCINE, V36, P1921, DOI 10.1016/j.vaccine.2018.02.055
   Hussain I, 2017, PEDIATR INFECT DIS J, V36, pE230, DOI 10.1097/INF.0000000000001622
   IMB, 2018, REP COMM IND MON BOA
   Jenkins HE, 2010, NEW ENGL J MED, V362, P2360, DOI 10.1056/NEJMoa0910074
   Jorba J, 2016, POLIOVIRUS METHODS M, V1387
   Lumley T., 2010, COMPLEX SURVEYS GUID
   Martinez M, 2018, MMWR-MORBID MORTAL W, V67, P833, DOI 10.15585/mmwr.mm6730a6
   Martinez M, 2017, MMWR-MORBID MORTAL W, V66, P854, DOI 10.15585/mmwr.mm6632a5
   Mbaeyi C, 2016, MMWR-MORBID MORTAL W, V65, P1195, DOI 10.15585/mmwr.mm6543a4
   O'Reilly KM, 2012, LANCET, V380, P491, DOI 10.1016/S0140-6736(12)60648-5
   SteelFisher GK, 2017, LANCET INFECT DIS, V17, P1172, DOI 10.1016/S1473-3099(17)30397-3
   Su YS, 2011, J STAT SOFTW, V45, P1
   Tebbens RJD, 2018, RISK ANAL, V38, P1701, DOI 10.1111/risa.12962
   Wallace GS, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889-016-3386-1
   Wassilak S, 2011, J INFECT DIS, V203, P898, DOI 10.1093/infdis/jiq140
   Weldon WC, 2016, METHODS MOL BIOL, V1387, P145, DOI 10.1007/978-1-4939-3292-4_8
   World Health Organization, 2006, WHO CHILD GROWTH STA, DOI 10.4067/S0370-41062009000400012
NR 26
TC 1
Z9 1
U1 3
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 14
PY 2019
VL 37
IS 12
BP 1577
EP 1583
DI 10.1016/j.vaccine.2019.02.008
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HQ0UD
UT WOS:000462109600005
PM 30782488
OA Green Accepted
DA 2020-05-12
ER

PT J
AU Zeigler, DF
   Roque, R
   Clegg, CH
AF Zeigler, David F.
   Roque, Richard
   Clegg, Christopher H.
TI Optimization of a multivalent peptide vaccine for nicotine addiction
SO VACCINE
LA English
DT Article
DE Addiction; Nicotine vaccine; Hapten; Antibody response; Solid-phase
   protein synthesis
ID SUBSTANCE USE DISORDERS; CARRIER; IMMUNOGENICITY; SUPPRESSION;
   ANTIBODIES; EPITOPES; AFFINITY; DENSITY; ANTIGEN; MICE
AB We have been optimizing the design of a conjugate vaccine for nicotine addiction that employs a peptide-based hapten carrier. This peptide, which is produced by solid-phase protein synthesis, contains B cell and T cell epitope domains and eliminates the non-relevant, but highly immunogenic sequences in microbial carriers. In this report, the amino acid sequences in the T cell domain were optimized for improved vaccine activity and multivalent formulations containing structurally distinct haptens were tested for the induction of additive antibody responses. Trivalent vaccines produced antibody concentrations in mice that were 100 times greater than the amount of nicotine measured in smokers, and significantly reduced acute nicotine toxicity in rats. Two additional features were explored that distinguish the peptide from traditional recombinant carriers. The first is the minimal induction of an anti-carrier response, which can suppress nicotine vaccine activity. The second employs solid-phase synthesis to manufacture haptenated peptide. This approach obviates conventional conjugation chemistries and streamlines production of a more potent vaccine antigen. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Zeigler, David F.; Roque, Richard; Clegg, Christopher H.] TRIA Biosci Corp, Suite 260,1616 Eastlake Ave East, Seattle, WA 98102 USA.
   [Roque, Richard] MedImmune, One MedImmune Way, Gaithersburg, MD 20878 USA.
RP Clegg, CH (reprint author), TRIA Biosci Corp, Suite 260,1616 Eastlake Ave East, Seattle, WA 98102 USA.
EM richard.roque@medimmune.com; cclegg@triabio.com
FU National Institute on Drug Abuse of the National Institutes of
   HealthUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute on Drug Abuse
   (NIDA) [UH2DA041162]
FX Research reported in this publication was supported by the National
   Institute on Drug Abuse of the National Institutes of Health under Award
   Number UH2DA041162.
CR ALEXANDER J, 1994, IMMUNITY, V1, P751, DOI 10.1016/S1074-7613(94)80017-0
   Benowitz Neal L, 2009, Handb Exp Pharmacol, P29, DOI 10.1007/978-3-540-69248-5_2
   Cornish KE, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082557
   de Villiers SHL, 2013, VACCINE, V31, P6185, DOI 10.1016/j.vaccine.2013.10.051
   Degenhardt L, 2017, WORLD PSYCHIATRY, V16, P299, DOI 10.1002/wps.20457
   Falugi F, 2001, EUR J IMMUNOL, V31, P3816, DOI 10.1002/1521-4141(200112)31:12<3816::AID-IMMU3816>3.0.CO;2-K
   Fraser CC, 2014, VACCINE, V32, P2896, DOI 10.1016/j.vaccine.2014.02.024
   Greenbaum J, 2011, IMMUNOGENETICS, V63, P325, DOI 10.1007/s00251-011-0513-0
   GREENSTEIN JL, 1992, J IMMUNOL, V148, P3970
   Hu K, 2012, BIOSCI TRENDS, V6, P52, DOI 10.5582/bst.2012.v6.2.52
   Jacob NT, 2016, J MED CHEM, V59, P2523, DOI 10.1021/acs.jmedchem.5b01676
   Jegerlehner A, 2010, VACCINE, V28, P5503, DOI 10.1016/j.vaccine.2010.02.103
   Kinsey Berma, 2014, Ther Adv Vaccines, V2, P106, DOI 10.1177/2051013614537818
   Liu WL, 2005, EUR J IMMUNOL, V35, P505, DOI 10.1002/eji.200425749
   Made V, 2014, BEILSTEIN J ORG CHEM, V10, P1197, DOI 10.3762/bjoc.10.118
   McCluskie MJ, 2016, IMMUNOPHARM IMMUNOT, V38, P184, DOI 10.3109/08923973.2016.1165246
   McCluskie MJ, 2015, INT IMMUNOPHARMACOL, V25, P518, DOI 10.1016/j.intimp.2015.02.030
   Miller KD, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114366
   NIDA, 2018, MED GUID
   Ohia-Nwoko O, 2016, INT REV NEUROBIOL, V126, P263, DOI 10.1016/bs.irn.2016.02.009
   Pedersen MK, 2006, J IMMUNOL METHODS, V311, P198, DOI 10.1016/j.jim.2006.02.008
   Pentel PR, 2000, PHARMACOL BIOCHEM BE, V65, P191, DOI 10.1016/S0091-3057(99)00206-3
   Pobre K, 2014, VACCINE, V32, P1423, DOI 10.1016/j.vaccine.2014.01.047
   Pravetoni M, 2012, BIOCHEM PHARMACOL, V83, P543, DOI 10.1016/j.bcp.2011.11.004
   Pravetoni M, 2016, HUM VACC IMMUNOTHER, V12, P3005, DOI 10.1080/21645515.2016.1212785
   Pryde DC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076557
   Singh SP, 2016, HUM IMMUNOL, V77, P295, DOI 10.1016/j.humimm.2015.11.012
   Thorn JM, 2017, VACCINES-BASEL, V5, DOI 10.3390/vaccines5020011
   Zeigler DF, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0178835
NR 29
TC 3
Z9 3
U1 1
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 14
PY 2019
VL 37
IS 12
BP 1584
EP 1590
DI 10.1016/j.vaccine.2019.02.003
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HQ0UD
UT WOS:000462109600006
PM 30772068
OA Green Accepted
DA 2020-05-12
ER

PT J
AU Wang, SH
   Smith, D
   Cao, ZY
   Chen, J
   Acosta, H
   Chichester, JA
   Yusibov, V
   Streatfield, SJ
   Fattom, A
   Baker, Jr
AF Wang, Su He
   Smith, Douglas
   Cao, Zhengyi
   Chen, Jesse
   Acosta, Hugo
   Chichester, Jessica A.
   Yusibov, Vidadi
   Streatfield, Stephen J.
   Fattom, Ali
   Baker, James R., Jr.
TI Recombinant H5 hemagglutinin adjuvanted with nanoemulsion protects
   ferrets against pathogenic avian influenza virus challenge
SO VACCINE
LA English
DT Article
DE H5N1; Nanoemulsion; Vaccine; Mice; Ferrets
ID INTRANASAL IMMUNIZATION; IMMUNE-RESPONSE; SPLIT-VIRION; A VIRUS;
   VACCINE; IMMUNOGENICITY; SAFETY; MICE; ANTIBODY; EFFICACY
AB Background: Highly pathogenic H5N1 influenza viruses remain a pandemic risk to the world population. Although vaccines are the best solution to prevent this threat, a more effective vaccine for H5 strains of influenza has yet to be developed. All existing vaccines target only serum antibody against influenza as the primary outcome, while mucosal immunity has not been addressed. To address these shortcomings we have used an effective mucosal adjuvant system to produce a prototype vaccine that provides antibody, cellular and mucosal immunity to multiple serotypes of H5.
   Methods: Plant-derived recombinant H5 (rH5) antigen was mixed with a novel nanoemulsion NE01 adjuvant. The rH5-NE01 vaccine was administered intranasally to CD-1 mice and ferrets. Immunogenicity of this immunization was evaluated through rH5-specific antibody and cellular immune responses. Hemagglutination inhibition (HI) and virus neutralization (VN) assays were performed. Protection against H5N1 virus challenge was evaluated in ferrets.
   Results: Intranasal immunization with rH5-NE01vaccine induced high titers (>10(6)) of rH5-specific IgG in mice. In mice and ferrets this vaccine also achieved titers of >= 40 for both HI and VN. Additionally, the levels of rH5-specific IgA were significantly increased in bronchial secretions in these animals. The rH5-NE01 vaccine enhanced rH5-specific cellular immune responses including IFN-gamma and IL-17. Ten-day survival post challenge was 100% in ferrets that received rH5-NE01 compared to 12.5% in the PBS group. Furthermore, this vaccine prevented weight loss and increases in body temperature after H5N1 challenge as compared to the controls. Moreover, H5N1 virus in nasal wash of rH5-NE01-vaccinated ferrets was significantly decreased compared to controls.
   Conclusion: Intranasal immunization with rH5 antigen formulated with NE01 adjuvant elicited strong, broad and balanced immune responses that effectively protect against H5N1 influenza virus infection in the ferret model. The ease of formulation of rH5-NE01 makes this novel combination a promising mucosal vaccine candidate for pandemic influenza. (C) 2019 Published by Elsevier Ltd.
C1 [Wang, Su He; Cao, Zhengyi; Chen, Jesse; Baker, James R., Jr.] Univ Michigan, Michigan Nanotechnol Inst Med & Biol Sci M NIMBs, Ann Arbor, MI 48109 USA.
   [Smith, Douglas; Acosta, Hugo; Fattom, Ali] BlueWillow Biol, Ann Arbor, MI USA.
   [Chichester, Jessica A.; Yusibov, Vidadi; Streatfield, Stephen J.] Fraunhofer USA Ctr Mol Biotechnol FhCMB, Newark, DE USA.
RP Wang, SH; Baker, Jr (reprint author), Univ Michigan, Michigan Nanotechnol Inst Med & Biol Sci M NIMBs, Ann Arbor, MI 48109 USA.
EM shidasui@umich.edu
RI Yusibov, Vidadi/AAA-7408-2019
FU NIH NIAID Adjuvant Development Program [HHSN272201300028C]; Michigan
   Nanotechnology Institute for Medicine and Biological Sciences
FX This project was funded from the NIH NIAID Adjuvant Development
   ProgramContract #HHSN272201300028C and from Michigan Nanotechnology
   Institute for Medicine and Biological Sciences.
CR Allen JD, 2017, VACCINE, pS0264
   Asanuma H, 2007, VACCINE, V25, P6975, DOI 10.1016/j.vaccine.2007.06.060
   Belshe RB, 2014, JAMA-J AM MED ASSOC, V312, P1420, DOI 10.1001/jama.2014.12609
   Belshe RB, 2011, J INFECT DIS, V203, P666, DOI 10.1093/infdis/jiq093
   Bihari I, 2012, CLIN VACCINE IMMUNOL, V19, P1943, DOI 10.1128/CVI.00373-12
   Bresson JL, 2006, LANCET, V367, P1657, DOI 10.1016/S0140-6736(06)68656-X
   Bretscher PA, 2014, SCAND J IMMUNOL, V79, P361, DOI 10.1111/sji.12175
   Carter NJ, 2008, BIODRUGS, V22, P279, DOI 10.2165/00063030-200822050-00001
   Chichester JA, 2012, VIRUSES-BASEL, V4, P3227, DOI 10.3390/v4113227
   Cox RJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131652
   Das SC, 2012, VACCINE, V30, P6871, DOI 10.1016/j.vaccine.2012.09.007
   Ehrlich HJ, 2008, NEW ENGL J MED, V358, P2573, DOI 10.1056/NEJMoa073121
   Fraternale A, 2010, VACCINE, V28, P7676, DOI 10.1016/j.vaccine.2010.09.033
   Gu ZW, 2017, ONCOTARGET, V8, P22361, DOI 10.18632/oncotarget.15652
   Hamouda T, 2011, CLIN VACCINE IMMUNOL, V18, P1167, DOI 10.1128/CVI.00035-11
   Hamouda T, 2010, HUM VACCINES, V6, P585, DOI 10.4161/hv.6.7.11818
   Hannoun C, 2004, VIRUS RES, V103, P133, DOI 10.1016/j.virusres.2004.02.025
   Harfoot R, 2017, J MICROBIOL, V55, P196, DOI 10.1007/s12275-017-7062-7
   Hellens RP, 2000, PLANT MOL BIOL, V42, P819, DOI 10.1023/A:1006496308160
   Jaffar Z, 2009, J IMMUNOL, V182, P4507, DOI 10.4049/jimmunol.0900237
   Koel BF, 2014, MBIO, V5
   Lai CH, 2015, VACCINE, V33, P4321, DOI 10.1016/j.vaccine.2015.03.082
   Lee G, 2015, PLANT BIOTECHNOL J, V13, P62, DOI 10.1111/pbi.12235
   Leroux-Roels I, 2010, VACCINE, V28, P849, DOI 10.1016/j.vaccine.2009.10.017
   Luczo JM, 2015, REV MED VIROL, V25, P406, DOI 10.1002/rmv.1846
   Major D, 2015, HUM VACC IMMUNOTHER, V11, P1235, DOI 10.4161/21645515.2014.988554
   McKinstry KK, 2009, J IMMUNOL, V182, P7353, DOI 10.4049/jimmunol.0900657
   Myc A, 2003, VACCINE, V21, P3801, DOI 10.1016/S0264-410X(03)00381-5
   Rose MA, 2012, EXPERT REV VACCINES, V11, P595, DOI [10.1586/erv.12.31, 10.1586/ERV.12.31]
   Rowe T, 1999, J CLIN MICROBIOL, V37, P937, DOI 10.1128/JCM.37.4.937-943.1999
   Scurlock AM, 2011, INFECT IMMUN, V79, P1349, DOI 10.1128/IAI.00984-10
   Shoji Y, 2009, VACCINE, V27, P1087, DOI 10.1016/j.vaccine.2008.11.108
   Shoji Y, 2008, VACCINE, V26, P2930, DOI 10.1016/j.vaccine.2008.03.045
   Smith DJ, 2004, SCIENCE, V305, P371, DOI 10.1126/science.1097211
   Stanberry LR, 2012, VACCINE, V30, P307, DOI 10.1016/j.vaccine.2011.10.094
   Swayne DE, 2015, J VIROL, V89, P3746, DOI 10.1128/JVI.00025-15
   Treanor JJ, 2006, NEW ENGL J MED, V354, P1343, DOI 10.1056/NEJMoa055778
   Treanor JJ, 2017, VACCINE, V35, P923, DOI 10.1016/j.vaccine.2016.12.053
   Treanor JJ, 2013, VACCINE, V31, P5760, DOI 10.1016/j.vaccine.2013.08.064
   Trombetta CM, 2014, VACCINES-BASEL, V2, P707, DOI 10.3390/vaccines2040707
   Wang SH, 2012, NANOMEDICINE-UK, V7, P867, DOI [10.2217/NNM.11.187, 10.2217/nnm.11.187]
   Wang XH, 2011, CELL MOL IMMUNOL, V8, P462, DOI 10.1038/cmi.2011.38
   Wong PT, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126120
   Wong PT, 2014, MOL PHARMACEUT, V11, P531, DOI 10.1021/mp4005029
   Wong SS, 2017, SCI REP-UK, V7, DOI 10.1038/srep44727
NR 45
TC 5
Z9 5
U1 2
U2 10
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 14
PY 2019
VL 37
IS 12
BP 1591
EP 1600
DI 10.1016/j.vaccine.2019.02.002
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HQ0UD
UT WOS:000462109600007
PM 30795941
DA 2020-05-12
ER

PT J
AU Abubakar, A
   Melhem, N
   Malik, M
   Dbaibo, G
   Khan, WM
   Zaraket, H
AF Abubakar, Abdinasir
   Melhem, Nada
   Malik, Mamunur
   Dbaibo, Ghassan
   Khan, Wasiq Mehmood
   Zaraket, Hassan
TI Seasonal influenza vaccination policies in the Eastern Mediterranean
   Region: Current status and the way forward
SO VACCINE
LA English
DT Article
DE Influenza (human); Vaccination; Surveys and questionnaires; Policy;
   Eastern Mediterranean Region
ID AVIAN INFLUENZA; MERS-COV; VIRUS-INFECTION; PREGNANT-WOMEN; HAJJ
   PILGRIMS; SURVEILLANCE; IMMUNIZATION; RECOMMENDATIONS; OUTCOMES; POULTRY
AB Background: The World Health Organization recommends annual influenza vaccination, especially in high-risk groups. Little is known about the adoption and implementation of influenza vaccination policies in the Eastern Mediterranean Region.
   Methods: A survey was distributed to country representatives at the ministries of health of the 22 countries of the Region between December 2016 and February 2017 to capture data on influenza immunization policies, recommendations, and practices in place.
   Results: Of the 20 countries that responded to the survey, 14 reported having influenza immunization policies during the 2015/2016 influenza season. All countries with an influenza immunization policy recommended vaccination for people with chronic medical conditions, healthcare workers and pilgrims. Two of the 20 countries did not target pregnant women. Eight countries used the northern hemisphere formulation, one used the southern hemisphere formulation and nine used both. Vaccination coverage was not monitored by all countries and for all target groups. Where reported, coverage of a number of target groups (healthcare workers, children) was generally low. Data on the burden of influenza and vaccine protection are scarce in the Region.
   Conclusions: Despite widespread policy recommendations on influenza vaccination, attaining high coverage rates remains a challenge in the Eastern Mediterranean Region. Tackling disparities in influenza vaccine accessibility and strengthening surveillance systems may increase influenza vaccine introduction and use. (C) 2019 The Authors. Published by Elsevier Ltd.
C1 [Abubakar, Abdinasir; Malik, Mamunur; Khan, Wasiq Mehmood] WHO Reg Off Eastern Mediterranean, Dept WHO Hlth Emergencies Programme, Infect Hazard Management, Cairo, Egypt.
   [Melhem, Nada] Amer Univ Beirut, Fac Hlth Sci, Med Lab Sci Program, 11-0236 Riad El Solh, Beirut 11072020, Lebanon.
   [Melhem, Nada; Dbaibo, Ghassan; Zaraket, Hassan] Amer Univ Beirut, Fac Med, Ctr Infect Dis Res, 11-0236 Riad El Solh, Beirut 11072020, Lebanon.
   [Zaraket, Hassan] Amer Univ Beirut, Fac Med, Dept Expt Pathol Immunol & Microbiol, 11-0236 Riad El Solh, Beirut 11072020, Lebanon.
   [Dbaibo, Ghassan] Amer Univ Beirut, Fac Med, Dept Pediat & Adolescent Med, Div Pediat Infect Dis, 11-0236 Riad El Solh, Beirut 11072020, Lebanon.
RP Zaraket, H (reprint author), Amer Univ Beirut, Fac Med, Ctr Infect Dis Res, 11-0236 Riad El Solh, Beirut 11072020, Lebanon.
EM hz34@aub.edu.lb
RI Dbaibo, Ghassan S./X-2978-2019
OI abubakar, abdinasir/0000-0002-5131-5518; Zaraket,
   Hassan/0000-0003-3807-6409
FU WHO Regional Office for the Eastern Mediterranean, Cairo
FX This research was funded by the WHO Regional Office for the Eastern
   Mediterranean, Cairo.
CR Aberle JH, 2015, EMERG INFECT DIS, V21, P726, DOI 10.3201/eid2104.141745
   Al-Tawfiq JA, 2017, TRAVEL MED INFECT DI, V19, P2, DOI 10.1016/j.tmaid.2017.10.005
   Alzeer AH, 2009, ANN THORAC MED, V4, P50, DOI 10.4103/1817-1737.49412
   [Anonymous], 2017, PEDIATRICS, DOI [10.1542/peds.2017-2550, DOI 10.1542/PEDS.2017-2550]
   [Anonymous], 2015, IR REP H5N1 BIRD FLU
   [Anonymous], 2018, PROT INFL FLU ADV CA
   Balkhy HH, 2004, J TRAVEL MED, V11, P82, DOI 10.2310/7060.2004.17027
   Benowitz I, 2010, CLIN INFECT DIS, V51, P1355, DOI 10.1086/657309
   Bodewes R, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005538
   Brammer L, 2009, INFLUENZA OTHER RESP, V3, P51, DOI 10.1111/j.1750-2659.2009.00077.x
   Centers for Disease Control and Prevention, 2017, VACC WHO SHOULD DO I, P2017
   Gautret P, 2016, TRAVEL MED INFECT DI, V14, P92, DOI 10.1016/j.tmaid.2015.12.008
   Isenor Jennifer E, 2016, J Pharm Policy Pract, V9, P32
   Iuliano AD, 2018, LANCET, V391, P1285, DOI 10.1016/S0140-6736(17)33293-2
   Kammon A, 2015, AVIAN DIS, V59, P422, DOI 10.1637/11068-032215-ResNote.1
   Kandeel A, 2010, EMERG INFECT DIS, V16, P1101, DOI 10.3201/eid1607.091695
   Karve S, 2013, HUM VACC IMMUNOTHER, V9, P841, DOI 10.4161/hv.23413
   Kayali G, 2016, EMERG INFECT DIS, V22, P379, DOI 10.3201/eid2203.150593
   Kayali G, 2014, EMERG INFECT DIS, V20, P542, DOI 10.3201/eid2004.131295
   Khan Wasiq, 2017, Oman Med J, V32, P359, DOI 10.5001/omj.2017.70
   Lai SJ, 2016, LANCET INFECT DIS, V16, pE108, DOI 10.1016/S1473-3099(16)00153-5
   Lang PO, 2012, CLIN INTERV AGING, V7, P55, DOI 10.2147/CIA.S25215
   Macmahon KL, 2008, PUBLIC HEALTH REP, V123, P316, DOI 10.1177/003335490812300311
   Mak PWY, 2012, CLIN CHEM, V58, P1527, DOI 10.1373/clinchem.2012.182626
   Memish ZA, 2014, J INFECT DIS, V210, P1067, DOI 10.1093/infdis/jiu150
   Mertz D, 2017, VACCINE, V35, P521, DOI 10.1016/j.vaccine.2016.12.012
   Moriarty LF, 2014, HUM VACC IMMUNOTHER, V10, P2721, DOI 10.4161/hv.29669
   Olsen SJ, 2016, CLIN INFECT DIS, V63, P487, DOI 10.1093/cid/ciw290
   Ortiz JR, 2016, VACCINE, V34, P5400, DOI 10.1016/j.vaccine.2016.07.045
   Palache A, 2017, VACCINE, V35, P4681, DOI 10.1016/j.vaccine.2017.07.053
   Refaey S, 2017, INFLUENZA OTHER RESP, V11, P57, DOI 10.1111/irv.12429
   Steyer TE, 2004, VACCINE, V22, P1001, DOI 10.1016/j.vaccine.2003.08.045
   Tombari W, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053524
   Ventola C Lee, 2016, P T, V41, P426
   *WHO, WHO GUID PUBL HLTH M
   World Health Organization, INFL SURV REG NEWS E
   World Health Organization, 2018, INFL SEAS
   World Health Organization, 2006, AV INFL SIT IR
   World Health Organization, 2012, INFL POS PAP
   Zaman K, 2008, NEW ENGL J MED, V359, P1555, DOI 10.1056/NEJMoa0708630
NR 40
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 14
PY 2019
VL 37
IS 12
BP 1601
EP 1607
DI 10.1016/j.vaccine.2019.02.001
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HQ0UD
UT WOS:000462109600008
PM 30795940
OA Other Gold
DA 2020-05-12
ER

PT J
AU Fitzwater, SP
   Ramachandran, P
   Kahn, GD
   Nedunchelian, K
   Suresh, S
   Santosham, M
   Chandran, A
AF Fitzwater, Sean Patrick
   Ramachandran, Padmanabhan
   Kahn, Geoffrey D.
   Nedunchelian, Krishnamoorthy
   Suresh, Saradha
   Santosham, Mathuram
   Chandran, Aruna
TI Impact of the introduction of the Haemophilus influenzae type b
   conjugate vaccine in an urban setting in southern India
SO VACCINE
LA English
DT Article
ID CHILDHOOD IMMUNIZATION; BACTERIAL-MENINGITIS; CHILDREN; DISEASE;
   ELIMINATION; PNEUMONIA; BURDEN
AB Introduction: Haemophilus influenzae type b was the leading cause of bacterial meningitis in infants and children below the age of two years prior to the introduction of H. influenzae type b conjugate vaccines. In December 2011, the Indian government introduced H. influenzae b vaccine in the state of Tamilnadu. A prospective surveillance for bacterial meningitis was established at the Institute of Child Health in Chennai to evaluate the etiology of meningitis and impact of the vaccine.
   Material and Methods: Infants aged one to 23 months who were admitted to the hospital with symptoms of suspected bacterial meningitis were enrolled and lumbar puncture was performed. Cerebrospinal fluid samples were analyzed for white blood cells, protein, and glucose. Bacterial culture and a latex agglutination test for common bacterial pathogens were performed.
   Results: Between January 2009 and March 2014, 4,770 children with suspected bacterial meningitis were enrolled. Prior to the introduction of the vaccine, an average of 11.7 cases of H. influenzae b meningitis and 31.1 cases of probable meningitis with no etiology were identified each year. After introduction, the number of cases were reduced by 79% and 44% respectively. The average H. influenzae b vaccine coverage after introduction was 69% among all children with clinically suspected meningitis. In contrast, the mean number of aseptic meningitis and pneumococcal meningitis cases remained stable throughout the pre and post vaccination period; 28.2 and 4.8 per year, respectively.
   Conclusions: H. influenzae b conjugate vaccine reduced the number of cases of H. influenzae b meningitis and probable meningitis within the first two years of its introduction. The impact against meningitis was higher than the vaccination rate, indicating indirect effects of the vaccine. India has recently scaled up the use of Hib conjugate vaccine throughout the country which should substantially reduce childhood meningitis rates further in the country. (C) 2019 The Authors. Published by Elsevier Ltd.
C1 [Fitzwater, Sean Patrick; Kahn, Geoffrey D.; Santosham, Mathuram; Chandran, Aruna] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD 21218 USA.
   [Ramachandran, Padmanabhan; Nedunchelian, Krishnamoorthy; Suresh, Saradha] Inst Child Hlth, Halls Rd, Chennai, Tamil Nadu, India.
   [Ramachandran, Padmanabhan; Nedunchelian, Krishnamoorthy; Suresh, Saradha] Hosp Children, Halls Rd, Chennai, Tamil Nadu, India.
   [Fitzwater, Sean Patrick] Univ Calif Los Angeles, Dept Pediat, Los Angeles, CA 90095 USA.
   [Ramachandran, Padmanabhan] Deemed Univ, Sri Ramachandra Med Coll, Chennai, Tamil Nadu, India.
   [Ramachandran, Padmanabhan] Deemed Univ, Res Inst, Chennai, Tamil Nadu, India.
   [Nedunchelian, Krishnamoorthy] Mehta Multispecialty Hosp India Pvt Ltd, Chennai, Tamil Nadu, India.
RP Fitzwater, SP (reprint author), Univ Calif Los Angeles, Dept Pediat, Div Infect Dis, 10833 Le Conte Ave,Room 22-442, Los Angeles, CA 90095 USA.
EM sfitzwater@mednet.ucla.edu
FU Gavi Hib Initiative - Gavi "Hib" grant
FX This work was supported by The Gavi Hib Initiative, a consortium project
   funded by the Gavi "Hib" grant.
CR Adegbola RA, 2005, LANCET, V366, P144, DOI 10.1016/S0140-6736(05)66788-8
   Bassani DG, 2010, LANCET, V376, P1853, DOI 10.1016/S0140-6736(10)61461-4
   BLACK SB, 1991, PEDIATR INFECT DIS J, V10, P97, DOI 10.1097/00006454-199102000-00004
   Chinchankar Nandita, 2002, Indian Pediatr, V39, P914
   Choudhry A, 2012, INDIAN J MED RES, V135, P534
   Cowgill KD, 2006, JAMA-J AM MED ASSOC, V296, P671, DOI 10.1001/jama.296.6.671
   Deivanayagam N, 1993, Indian Pediatr, V30, P495
   Deonis M, 1997, WHONUT974 DEP NUTR H
   Fitzwater SP, 2013, J PEDIATR-US, V163, pS32, DOI 10.1016/j.jpeds.2013.03.028
   Gallo G, 2002, VACCINE, V20, P993, DOI 10.1016/S0264-410X(01)00449-2
   Gessner BD, 2005, LANCET, V365, P43, DOI 10.1016/S0140-6736(04)17664-2
   *INT VACC ACC CTR, [No title captured]
   International Institute for Population Sciences, 2017, NAT FAM HLTH SURV NF
   International Institute for Population Sciences and Macro International, 2007, NAT FAM HLTH SURV 3
   Lewis RF, 2008, B WORLD HEALTH ORGAN, V86, P292, DOI 10.2471/BLT.07.045336
   Mani R, 2007, J MED MICROBIOL, V25, P108
   Moulton LH, 2000, INT J EPIDEMIOL, V29, P753, DOI 10.1093/ije/29.4.753
   Mulholland K, 1997, LANCET, V349, P1191, DOI 10.1016/S0140-6736(96)09267-7
   Muliyil JP, 2009, INDIAN PEDIATR, V46, P945
   PELTOLA H, 1994, ARCH PEDIAT ADOL MED, V148, P620, DOI 10.1001/archpedi.1994.02170060074015
   Ramachandran P, 2013, INDIAN J MED RES, V137, P712
   Seehusen DA, 2003, AM FAM PHYSICIAN, V68, P1103
   Singhal T, 2008, INDIAN PEDIATR, V45, P635
   Sow SO, 2009, AM J TROP MED HYG, V80, P1033, DOI 10.4269/ajtmh.2009.80.1033
   Sultana NK, 2013, J PEDIATR-US, V163, pS73, DOI 10.1016/j.jpeds.2013.03.033
   Verghese VP, 2009, PEDIATR INFECT DIS J, V28, P738, DOI 10.1097/INF.0b013e318199f2a1
   Watt JP, 2009, LANCET, V374, P903, DOI 10.1016/S0140-6736(09)61203-4
   WHO, 2003, WHOVB0301 DEP VACC B
   1996, [No title captured], V45, P901
NR 29
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 14
PY 2019
VL 37
IS 12
BP 1608
EP 1613
DI 10.1016/j.vaccine.2019.01.080
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HQ0UD
UT WOS:000462109600009
PM 30772069
OA Other Gold
DA 2020-05-12
ER

PT J
AU Durous, L
   Julien, T
   Padey, B
   Traversier, A
   Rosa-Calatrava, M
   Blum, LJ
   Marquette, CA
   Petiot, E
AF Durous, Laurent
   Julien, Thomas
   Padey, Blandine
   Traversier, Aurelien
   Rosa-Calatrava, Manuel
   Blum, Loic J.
   Marquette, Christophe A.
   Petiot, Emma
TI SPRi-based hemagglutinin quantitative assay for influenza vaccine
   production monitoring
SO VACCINE
LA English
DT Article
DE Bioprocess; Hemagglutinin; Influenza vaccine; Surface Plasmon Resonance
   imaging; Influenza virus; Process Analytical Technology
ID VIRUS HEMAGGLUTININ; POTENCY; PROTEIN; QUANTIFICATION; BINDING;
   BIOREACTOR; QUANTIFY; ANTIBODY
AB Influenza vaccine manufacturers lack tools, whatever the involved production bioprocess (egg or cell based), to precisely and accurately evaluate vaccine antigen content from samples. Indeed, the gold standard single-radial immunodiffusion (SRID) assay, which remains the only validated assay for the evaluation of influenza vaccine potency, is criticized by the scientific community and regulatory agencies since a decade for its high variability, lack of flexibility and low sensitivity. We hereby report an imaging surface plasmon resonance (SPRi) assay for the quantification of both inactivated vaccine influenza antigens and viral particles derived from egg- and cell-based production samples, respectively. The assay, based on fetuin-hemagglutinin interactions, presents higher reproducibility (<3%) and a greater analytical range (0.03-20 mu g/mL) than SRID for bulk monovalent and trivalent vaccine and its limit of detection was evaluated to be 100 times lower than the SRID's one. Finally, viral particles production through cell culture based bioprocess was also successfully monitored using our SPRi-based assay and a clear correlation was found between the biosensor response and total virus particle content. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Durous, Laurent; Blum, Loic J.; Marquette, Christophe A.; Petiot, Emma] Univ Claude Bernard Lyon 1, ICBMS, CPE Lyon, Univ Lyon,GEMBAS Team,CNRS UMR 5246,INSA, Villeurbanne, France.
   [Durous, Laurent; Julien, Thomas; Padey, Blandine; Traversier, Aurelien; Rosa-Calatrava, Manuel] Univ Lyon, Univ Claude Bernard Lyon 1, Ecole Normale Super Lyon,Lab Virol & Pathol Humai, Inserm U1111,CNRS UMR5308,CIRI,VirPath Team, Lyon, France.
   [Julien, Thomas; Rosa-Calatrava, Manuel] Univ Lyon, Univ Claude Bernard Lyon 1, VirNext, Fac Med RTH Laennec, F-69008 Lyon, France.
   [Petiot, Emma] LyonTech La Doua, CPE Lyon, Batiment Hubert Curien,43 Bd 11 Novembre 1918, Villeurbanne, France.
RP Marquette, CA (reprint author), Bat Lederer,1 Rue Victor Grignard, F-69100 Villeurbanne, France.
EM christophe.marquette@univ-lyon1.fr
OI PETIOT, Emma/0000-0002-1989-4695; PADEY, Blandine/0000-0002-2159-6507;
   Rosa-calatrava, Manuel/0000-0002-7559-9527; Traversier,
   Aurelien/0000-0003-1874-3075; DUROUS, LAURENT/0000-0002-8809-3023
FU Auvergne Rhone-Alpes Region
FX L. Durous acknowledges the Auvergne Rhone-Alpes Region for his PhD grant
   (ARC 1 Sante). The authors have no other relevant affiliations or
   financial involvement with any organization or entity with a financial
   interest in or financial conflict with the subject matter or materials
   discussed in the manuscript.
CR Bodle J, 2013, INFLUENZA OTHER RESP, V7, P191, DOI 10.1111/j.1750-2659.2012.00375.x
   Brown SW, 2010, AVIAN EB66 CELL LINE
   Buffin S, 2018, J VIROL METHODS, V251, P46, DOI 10.1016/j.jviromet.2017.10.011
   Carvalho SB, 2017, BIOTECHNOL J, V12, DOI 10.1002/biot.201700031
   Chavane N, 2008, ANAL BIOCHEM, V378, P158, DOI 10.1016/j.ab.2008.04.019
   Council of Europe, 2008, EUR PHARM, P867
   EMA/EDQM, 2012, JOINT EMA EDQM WORKS
   Emma P, 2013, BIOTECHNOL PROGR, V29, P275, DOI 10.1002/btpr.1601
   Erickson HP, 2009, BIOL PROCED ONLINE, V11, P32, DOI 10.1007/s12575-009-9008-x
   Frensing T, 2015, BIOTECHNOL J, V10, P681, DOI 10.1002/biot.201400429
   Frensing T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072288
   GE Healthcare, 2005, BIAC SENS SURF HDB
   Genzel Y, 2014, VACCINE, V32, P2770, DOI 10.1016/j.vaccine.2014.02.016
   Genzel Y, 2010, APPL MICROBIOL BIOT, V88, P461, DOI 10.1007/s00253-010-2742-9
   Gerlach JQ, 2014, ANAL METHODS-UK, V6, P440, DOI 10.1039/c3ay40936h
   Heider S, 2014, VIROLOGY, V462, P199, DOI 10.1016/j.virol.2014.06.005
   Jacquemart R, 2008, BIOTECHNOL BIOENG, V100, P184, DOI 10.1002/bit.21725
   Jiang LL, 2015, BIOL PROCED ONLINE, V17, DOI 10.1186/s12575-015-0019-5
   Karlsson Robert, 2016, Biophys Rev, V8, P347, DOI 10.1007/s12551-016-0219-5
   Khurana S, 2014, VACCINE, V32, P2188, DOI 10.1016/j.vaccine.2014.02.049
   Khurana S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011548
   Kon TC, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150700
   Kuck LR, 2017, VACCINE, V35, P1918, DOI 10.1016/j.vaccine.2017.02.028
   Kuck LR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109616
   Lohr V, 2009, VACCINE, V27, P4975, DOI 10.1016/j.vaccine.2009.05.083
   Magadan JG, 2013, J VIROL, V87, P9742, DOI 10.1128/JVI.00471-13
   Masson JF, 2006, ANAL BIOANAL CHEM, V386, P1951, DOI 10.1007/s00216-006-0834-2
   Milian E, 2015, VACCINES, V2015
   Minor PD, 2015, VACCINES-BASEL, V3, P90, DOI 10.3390/vaccines3010090
   Nilsson CE, 2010, VACCINE, V28, P759, DOI 10.1016/j.vaccine.2009.10.070
   Petiot E, 2018, VACCINE, V36, P3101, DOI 10.1016/j.vaccine.2017.03.102
   Pierce CL, 2011, ANAL CHEM, V83, P4729, DOI 10.1021/ac2006526
   Schasfoort RBM, 2017, HANDBOOK OF SURFACE PLASMON RESONANCE, 2ND EDITION, P60
   Takemoto DK, 1996, VIROLOGY, V217, P452, DOI 10.1006/viro.1996.0139
   Thompson CM, 2013, VIROL J, V10, DOI 10.1186/1743-422X-10-141
   Wen YX, 2015, VACCINE, V33, P5342, DOI 10.1016/j.vaccine.2015.08.077
   Whitford W., 2007, BIOPROCESS INT S, V5, P32
   WHO Global Influenza Programme, 2015, INFL VACC RESP START
   WOOD JM, 1977, J BIOL STAND, V5, P237, DOI 10.1016/S0092-1157(77)80008-5
NR 39
TC 0
Z9 0
U1 2
U2 7
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 14
PY 2019
VL 37
IS 12
BP 1614
EP 1621
DI 10.1016/j.vaccine.2019.01.083
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HQ0UD
UT WOS:000462109600010
PM 30773402
DA 2020-05-12
ER

PT J
AU Happe, M
   Samuvel, DJ
   Ohtola, JA
   Korte, JE
   Westerink, MAJ
AF Happe, Myroslawa
   Samuvel, Devadoss J.
   Ohtola, Jennifer A.
   Korte, Jeff E.
   Westerink, M. A. Julie
TI Race-related differences in functional antibody response to pneumococcal
   vaccination in HIV-infected individuals
SO VACCINE
LA English
DT Article
DE HIV infection; B cells; Streptococcus pneumoniae; Pneumococcal conjugate
   vaccine; Pneumococcal polysaccharide vaccine; Racial disparities
ID STREPTOCOCCUS-PNEUMONIAE INFECTIONS; POLYSACCHARIDE VACCINE; BACTERIAL
   PNEUMONIA; RISK-FACTORS; ADULTS; DISEASE; ERA
AB Background: Both HIV positivity and African American (AA) ethnicity are associated with increased incidence of invasive pneumococcal disease (IPD). Poor immune response to pneumococcal polysaccharide-based vaccines may contribute to the race related increased frequency of IPD in African American HIV positive individuals.
   Methods: Caucasian and AA HIV-infected (HIV+) individuals 40-65 years old with CD4(+) T cells/mu l (CD4) >200 on antiretroviral therapy (ART) received either the 13-valent pneumococcal conjugate vaccine (PCV) followed by the 23-valent pneumococcal polysaccharide vaccine (PPV) or PPV only. Serum IgG, IgM and opsonophagocytic antibody responses to serotypes 14 and 23F as well as serum IgG and opsonophagocytic antibody responses to serotype 19A were measured pre- and post-vaccination. We measured serum markers of inflammation in all participants and performed single cell gene expression profiling at the baseline by HD Biomark in Caucasians and African Americans.
   Results: There were no significant differences in pre-immunization inflammatory markers or post-vaccination IgG and IgM concentrations between Caucasian and African American participants. However, we found significantly lower opsonophagocytic activity in response to serotypes 14 and 19A in the AA group compared to the Caucasian group. There was no association between inflammatory markers and immune response to vaccination, however we found extensive biomodal variation in gene expression levels in single IgM+ memory B cells. Differentially expressed genes may be related to differences in the immune response between ethnic groups.
   Conclusions: Distinct racial differences were found in the functional immune response following either PPV and/or PCV/PPV immunization in HIV-positive adults, although these differences were serotype dependent. Decreased ability to respond to vaccination may in part explain racial disparities in pneumococcal disease epidemiology. Published by Elsevier Ltd.
C1 [Happe, Myroslawa] Med Univ South Carolina, Dept Immunol & Microbiol, 96 Jonathan Lucas St,CSB 927, Charleston, SC 29425 USA.
   [Samuvel, Devadoss J.; Westerink, M. A. Julie] Med Univ South Carolina, Dept Med, Div Infect Dis, 96 Jonathan Lucas St,CSB 927, Charleston, SC 29425 USA.
   [Ohtola, Jennifer A.] Univ Toledo, Dept Med, Coll Med & Life Sci, 3000 Arlington Ave, Toledo, OH 43614 USA.
   [Korte, Jeff E.] Dept Publ Hlth Sci, 135 Cannon St, Charleston, SC 29425 USA.
   [Westerink, M. A. Julie] Ralhp H Johnson Vet Adm Med Ctr, Dept Med, 109 Bee St, Charleston, SC 29401 USA.
RP Westerink, MAJ (reprint author), Med Univ South Carolina, 96 Jonathan Lucas St,Clin Sci Bldg Rm 927, Charleston, SC 29425 USA.
EM soloshch@musc.edu; samuvel@musc.edu; ohtolaj@ccf.org; korte@musc.edu;
   westerin@musc.edu
FU National Institute of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [RO1A081558,
   RO1AG045973]; NIH National Center for Advancing Translational Sciences
   (NCATS)United States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Advancing
   Translational Sciences (NCATS) [TL1 TR001451, UL1 TR001450]
FX This work was supported by National Institute of Health [RO1A081558,
   RO1AG045973] and by NIH National Center for Advancing Translational
   Sciences (NCATS) [TL1 TR001451 & UL1 TR001450].
CR ABCs, BACT SURV
   Breiman RF, 2000, ARCH INTERN MED, V160, P2633, DOI 10.1001/archinte.160.17.2633
   Capolunghi F, 2013, IMMUNOL LETT, V152, P114, DOI 10.1016/j.imlet.2013.04.007
   Crum-Cianflone NF, 2010, VACCINE, V28, P7583, DOI 10.1016/j.vaccine.2010.09.056
   Dahl MS, 2001, SCAND J INFECT DIS, V33, P667, DOI 10.1080/00365540110026818
   Dworkin MS, 2001, CLIN INFECT DIS, V32, P794, DOI 10.1086/319218
   Feikin DR, 2004, LANCET INFECT DIS, V4, P445, DOI 10.1016/S1473-3099(04)01060-6
   Franceschi C, 2014, J GERONTOL A-BIOL, V69, pS4, DOI 10.1093/gerona/glu057
   French N, 2000, LANCET, V355, P2106, DOI 10.1016/S0140-6736(00)02377-1
   Fung HB, 2010, AM J GERIATR PHARMAC, V8, P47, DOI 10.1016/j.amjopharm.2010.01.003
   Gant Z, 2014, HIV SURVEILL REP, V3
   Gebo KA, 1996, J INFECT DIS, V173, P857, DOI 10.1093/infdis/173.4.857
   Harrison LH, 2000, ARCH INTERN MED, V160, P89, DOI 10.1001/archinte.160.1.89
   Heffernan RT, 2005, J INFECT DIS, V191, P2038, DOI 10.1086/430356
   Iyer AS, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150261
   Iyer AS, 2015, J AIDS CLIN RES, V6, P421, DOI DOI 10.4172/2155-6113.1000421
   Khaskhely N, 2013, NIH PUBLIC ACCESS, V188, P2455, DOI [10.4049/iimmnunol.1107809.Phenotypic, DOI 10.4049/JIMMUNOL.1102809]
   Khaskhely N, 2012, J IMMUNOL, V188, P2455, DOI 10.4049/jimmunol.1102809
   Kruetzmann S, 2003, J EXP MED, V197, P939, DOI 10.1084/jem.20022020
   Kurupati R, 2016, ONCOTARGET, V7, P62898, DOI 10.18632/oncotarget.11704
   Leggat DJ, 2013, J INFECT DIS, V208, P101, DOI 10.1093/infdis/jit139
   Leggat DJ, 2015, J AIDS CLIN RES, V6, DOI [10.4172/7155-61131000419.Responce, DOI 10.4172/2155-6113.1000419]
   lyer AS, 2015, HHS PUBLIC ACCESS, V6, DOI [10.4172/2155-6113.1000421.Response, DOI 10.4172/2155-6113.1000421]
   MUSHER DM, 1990, J INFECT DIS, V161, P728, DOI 10.1093/infdis/161.4.728
   Nahm MH, 1997, J INFECT DIS, V176, P698, DOI 10.1086/514093
   Ohtola JA, 2016, J AIDS CLIN RES, V7, P556, DOI [10.4172/2155-6113.1000556, DOI 10.4172/2155-6113.1000556]
   Park S, 2011, INFECT IMMUN, V79, P314, DOI 10.1128/IAI.00768-10
   Parmigiani A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079816
   Pastor P, 1998, CLIN INFECT DIS, V26, P590, DOI 10.1086/514589
   Robinson KA, 2001, JAMA-J AM MED ASSOC, V285, P1729, DOI 10.1001/jama.285.13.1729
   Rodriguez-Barradas MC, 2003, CLIN INFECT DIS, V37, P438, DOI 10.1086/375841
   Romero-Steiner S, 2006, CLIN VACCINE IMMUNOL, V13, P165, DOI 10.1128/CVI.13.2.165-169.2006
   Romero-Steiner S, 1999, CLIN INFECT DIS, V29, P281, DOI 10.1086/520200
   Segal Leopoldo N, 2011, Proc Am Thorac Soc, V8, P282, DOI 10.1513/pats.201006-044WR
   Song JY, 2013, J INFECT CHEMOTHER, V19, P412, DOI 10.1007/s10156-013-0601-1
   Watt JP, 2004, CLIN INFECT DIS, V38, P496, DOI 10.1086/381198
   Westerink MAJ, 2012, AGING DIS, V3, P51
   Zandvoort A, 2002, CLIN EXP IMMUNOL, V130, P4, DOI 10.1046/j.1365-2249.2002.01953.x
NR 38
TC 1
Z9 1
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 14
PY 2019
VL 37
IS 12
BP 1622
EP 1629
DI 10.1016/j.vaccine.2019.01.084
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HQ0UD
UT WOS:000462109600011
PM 30797636
OA Green Accepted
DA 2020-05-12
ER

PT J
AU Herrera-Rodriguez, J
   Signorazzi, A
   Holtrop, M
   de Vries-Idema, J
   Huckriede, A
AF Herrera-Rodriguez, Jose
   Signorazzi, Aurora
   Holtrop, Marijke
   de Vries-Idema, Jacqueline
   Huckriede, Anke
TI Inactivated or damaged? Comparing the effect of inactivation methods on
   influenza virions to optimize vaccine production
SO VACCINE
LA English
DT Article
DE beta-propiolactone; Formaldehyde; Vaccine; Influenza; Inactivation
ID BETA-PROPIOLACTONE; VIRUS INACTIVATION; EGG-FLUIDS; A VIRUSES;
   IDENTIFICATION; FORMALDEHYDE; STABILITY; RESPONSES; PROTEINS; DISEASE
AB The vast majority of commercially available inactivated influenza vaccines are produced from egg-grown or cell-grown live influenza virus. The first step in the production process is virus inactivation with beta-propiolactone (BPL) or formaldehyde (FA). Recommendations for production of inactivated vaccines merely define the maximal concentration for both reagents, leaving the optimization of the process to the manufacturers. We assessed the effect of inactivation with BPL and FA on 5 different influenza virus strains. The properties of the viral formulation, such as successful inactivation, preservation of hemagglutinin (HA) binding ability, fusion capacity and the potential to stimulate a Toll-like receptor 7 (TLR7) reporter cell line were then assessed and compared to the properties of the untreated virus. Inactivation with BPL resulted in undetectable infectivity levels, while FA-treated virus retained very low infectious titers. Hemagglutination and fusion ability were highly affected by those treatments that conferred higher inactivation, with BPL-treated virus binding and fusing at a lower degree compared to FA-inactivated samples. On the other hand, BPL-inactivated virus induced higher levels of activation of TLR7 than FA-inactivated virus. The alterations caused by BPL or FA treatments were virus strain dependent. This data shows that the inactivation procedures should be tailored on the virus strain, and that many other elements beside the concentration of the inactivating agent, such as incubation time and temperature, buffer and virus concentration, have to be defined to achieve a functional product. (C) 2019 The Author(s). Published by Elsevier Ltd.
C1 [Herrera-Rodriguez, Jose; Signorazzi, Aurora; Holtrop, Marijke; de Vries-Idema, Jacqueline; Huckriede, Anke] Univ Groningen, Univ Med Ctr Groningen, Dept Med Microbiol, Groningen, Netherlands.
RP Huckriede, A (reprint author), Univ Med Ctr Groningen, Dept Med Microbiol, POB 30001,HPC EB88, NL-9700 RB Groningen, Netherlands.
EM a.l.w.huckriede@umcg.nl
RI Huckriede, Anke/P-3558-2019
OI Huckriede, Anke/0000-0002-2646-5143; Signorazzi,
   Aurora/0000-0001-6757-7523
FU Conacyt grant by the government of Mexico; EU/EFPIA/Innovative Medicines
   Initiative [2] Joint Undertaking 'VAC2-VAC' [115924]
FX We would like to thank Sarah Skeldon, National Institute for Biological
   Standards and Controls, UK, for running SRID assays on the virus
   samples. JHR was supported via a Conacyt grant by the government of
   Mexico. A.S. has received funding from the EU/EFPIA/Innovative Medicines
   Initiative [2] Joint Undertaking 'VAC2-VAC' under grant agreement No
   115924.
CR [Anonymous], 1997, EUROPEAN AGENCY EVAL, P19
   Audouy SAL, 2011, VACCINE, V29, P4345, DOI 10.1016/j.vaccine.2011.04.029
   Bonnafous P, 2014, BBA-BIOMEMBRANES, V1838, P355, DOI 10.1016/j.bbamem.2013.09.021
   Breil C, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18040708
   BROWN F, 1993, DEV BIOL STAND, V81, P103
   Budimir N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030898
   Budimir N, 2010, VACCINE, V28, P8280, DOI 10.1016/j.vaccine.2010.10.007
   BUDOWSKY EI, 1991, VACCINE, V9, P398, DOI 10.1016/0264-410X(91)90125-P
   Costello DA, 2015, J VIROL, V89, P350, DOI 10.1128/JVI.01927-14
   Darnell MER, 2004, J VIROL METHODS, V121, P85, DOI 10.1016/j.jviromet.2004.06.006
   De Benedictis P, 2007, ZOONOSES PUBLIC HLTH, V54, P51, DOI 10.1111/j.1863-2378.2007.01029.x
   Dembinski JL, 2014, J VIROL METHODS, V207, P232, DOI 10.1016/j.jviromet.2014.07.003
   Desbat B, 2011, LANGMUIR, V27, P13675, DOI 10.1021/la2027175
   Edwards K, 2016, 142 VACC REL BIOL PR
   Eftekhari Z, 2016, VACCINE RES, V3, P26, DOI [10.18869/acadpub.varres.3.7.26, DOI 10.18869/ACADPUB.VACRES,3.7.26]
   Furuya Y, 2010, J GEN VIROL, V91, P1450, DOI 10.1099/vir.0.018168-0
   Geeraedts F, 2012, VACCINE, V30, P6501, DOI 10.1016/j.vaccine.2012.07.036
   Geeraedts F, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000138
   Geeraedts F, 2008, INFLUENZA OTHER RESP, V2, P41, DOI 10.1111/j.1750-2659.2008.00038.x
   GOLDSTEI.MA, 1970, APPL MICROBIOL, V19, P290, DOI 10.1128/AEM.19.2.290-294.1970
   Hemmi H, 2002, NAT IMMUNOL, V3, P196, DOI 10.1038/ni758
   Hovden AO, 2005, SCAND J IMMUNOL, V62, P36, DOI 10.1111/j.1365-3083.2005.01633.x
   Iwasaki A, 2004, NAT IMMUNOL, V5, P987, DOI 10.1038/ni1112
   Jonges M, 2010, J CLIN MICROBIOL, V48, P928, DOI 10.1128/JCM.02045-09
   KING AMQ, 1981, NATURE, V293, P479, DOI 10.1038/293479a0
   KING DJ, 1991, AVIAN DIS, V35, P505, DOI 10.2307/1591214
   Kon TC, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150700
   Krammer F, 2015, NAT REV DRUG DISCOV, V14, P167, DOI 10.1038/nrd4529
   Luo M., 2012, INFLUENZA VIRUS ENTR, P201, DOI 10.1007/978-1-4614-0980-9_9
   Marshall D, 1999, J IMMUNOL, V163, P4673
   Metz B, 2006, BIOCONJUGATE CHEM, V17, P815, DOI 10.1021/bc050340f
   Moller L, 2015, VIRUSES-BASEL, V7, P666, DOI 10.3390/v7020666
   Muhmmad K., 2001, International Journal of Agriculture and Biology, V3, P416
   Nicholson KG, 2003, LANCET, V362, P1733, DOI 10.1016/S0140-6736(03)14854-4
   Pawar SD, 2015, J VIROL METHODS, V222, P28, DOI 10.1016/j.jviromet.2015.05.004
   PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4
   Ramakrishnan Muthannan Andavar, 2016, World J Virol, V5, P85, DOI 10.5501/wjv.v5.i2.85
   Salehi B, 2018, ACTA MICROBIOL IMM H, V65, P163, DOI 10.1556/030.65.2018.025
   SCHOLTISSEK C, 1985, VACCINE, V3, P215, DOI 10.1016/0264-410X(85)90109-4
   She YM, 2013, PROTEOMICS, V13, P3537, DOI 10.1002/pmic.201300096
   Taubenberger JK, 2009, REV SCI TECH OIE, V28, P187, DOI 10.20506/rst.28.1.1879
   TIFFANY JM, 1970, P NATL ACAD SCI USA, V65, P1105, DOI 10.1073/pnas.65.4.1105
   Uittenbogaard JP, 2011, J BIOL CHEM, V286, P36198, DOI 10.1074/jbc.M111.279232
   WHO, 2013, ANN 4 REC ASS QUAL S, V977, P189
   WILLIAMS MS, 1993, VET MICROBIOL, V37, P253, DOI 10.1016/0378-1135(93)90027-5
   Wong SS, 2013, CLIN MICROBIOL REV, V26, P476, DOI 10.1128/CMR.00097-12
NR 46
TC 3
Z9 4
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 14
PY 2019
VL 37
IS 12
BP 1630
EP 1637
DI 10.1016/j.vaccine.2019.01.086
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HQ0UD
UT WOS:000462109600012
PM 30765167
OA Green Published, Other Gold
DA 2020-05-12
ER

PT J
AU Takashima, M
   Lambert, SB
   Paynter, S
   Ware, RS
AF Takashima, Mari
   Lambert, Stephen B.
   Paynter, Stuart
   Ware, Robert S.
TI Relative effectiveness of revaccination with 23-valent pneumococcal
   polysaccharide vaccine in preventing invasive pneumococcal disease in
   adult Aboriginal and Torres Strait Islander people, Australia
SO VACCINE
LA English
DT Article
DE Pneumococcal vaccination; Invasive pneumococcal disease; Indigenous;
   Data linkage
AB Background: Aboriginal and Torres Strait Islander (Indigenous) Australians have high rates of invasive pneumococcal disease (IPD), with repeat doses of 23-valent polysaccharide pneumococcal vaccine (PPV23) recommended. We report the relative effectiveness of revaccination using a cohort from linked administrative data.
   Methods: All resident North Queensland Indigenous adults who received any PPV23 vaccination between 2000 and 2012 were identified and linked with IPD cases. IPD rates were compared for individuals revaccinated >five years after initial PPV23 dose against individuals not revaccinated.
   Results: Analysed data included 12,809 individuals and 89,612 person-years. Revaccinated adults had similar rates of IPD as non-revaccinated adults, after adjusting for potential confounders (HR = 0.92; 95%CI: 0.35-2.42). Findings were similar for vaccine-specific serotypes (HR = 1.32; 95%CI: 0.32-5.43).
   Conclusions: Benefits of PPV23 revaccination against IPD in this high-risk population were not demonstrated, although estimates were imprecise. Findings should be validated in other high-risk cohorts, and against all-cause pneumonia as an outcome. Crown Copyright (C) 2019. Published by Elsevier Ltd. All rights reserved.
C1 [Takashima, Mari; Ware, Robert S.] Griffith Univ, Menzies Hlth Inst Queensland, Brisbane, Qld, Australia.
   [Takashima, Mari] Univ Queensland, Sch Publ Hlth, Brisbane, Qld, Australia.
   [Lambert, Stephen B.] Queensland Hlth, Communicable Dis Unit, Brisbane, Qld, Australia.
   [Paynter, Stuart] Curtin Univ, Sch Publ Hlth, Perth, WA, Australia.
RP Takashima, M (reprint author), Griffith Univ, 170 Kessels Rd, Nathan, Qld 4111, Australia.
EM m.takashima@griffith.edu.au
RI Lambert, Stephen/N-7819-2019; Ware, Robert/B-2024-2014
OI Lambert, Stephen/0000-0002-2709-193X; Ware, Robert/0000-0002-6129-6736
CR Australian Bureau of Statistics, 2006, 2039 0 INF PAP INTR
   Australian Bureau of Statistics, 2014, AUSTR STAT GEOGR STA
   Hammitt LL, 2011, VACCINE, V29, P2287, DOI 10.1016/j.vaccine.2011.01.029
   Hanna JN, 2006, MED J AUSTRALIA, V184, P118, DOI 10.5694/j.1326-5377.2006.tb00149.x
   Kantso B, 2015, VACCINE, V33, P5464, DOI 10.1016/j.vaccine.2015.08.011
   Kawakami K, 2010, VACCINE, V28, P7063, DOI 10.1016/j.vaccine.2010.08.010
   Moberley S, 2013, COCHRANE DB SYST REV, V31, DOI DOI 10.1002/14651858.CD000422.PUB3
   Moberley S, 2017, VACCINE, V35, P2908, DOI 10.1016/j.vaccine.2017.04.040
   National Centre For Immunisation Research and Surveillance (NCIRS), 2015, SIGN EV PNEUM VACC P
   National Health and Medical Research Council, 2013, AUSTR IMM HDB
   Remschmidt C, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-2040-y
NR 11
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 14
PY 2019
VL 37
IS 12
BP 1638
EP 1641
DI 10.1016/j.vaccine.2019.01.085
PG 4
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HQ0UD
UT WOS:000462109600013
PM 30782489
DA 2020-05-12
ER

PT J
AU Boumart, Z
   Daouam, S
   Bamouh, Z
   Jazouli, M
   Tadlaoui, KO
   Dungu, B
   Bettinger, G
   Watts, DM
   Elharrak, M
AF Boumart, Z.
   Daouam, S.
   Bamouh, Z.
   Jazouli, M.
   Tadlaoui, K. O.
   Dungu, B.
   Bettinger, G.
   Watts, D. M.
   Elharrak, M.
TI Safety and immunogenicity of a live attenuated Rift Valley Fever
   recombinant arMP-12 Delta NSm21/384 vaccine candidate for sheep, goats
   and calves
SO VACCINE
LA English
DT Article
DE Rift Valley fever (RVF); RVF virus; RVF MP-12 vaccine; arMP-12 Delta
   NSm21/384 vaccine; Sheep; Calves; Goats; Antibody; Morocco
ID MP-12 VACCINE; VIRUS-VACCINE; EFFICACY; IMMUNIZATION; INFECTION;
   SMITHBURN; DELETION; DISEASE; CATTLE
AB Rift Valley fever (RVF) causes serious health and economic losses to the livestock industry as well as a significant cause of human disease. The prevention of RVF in Africa is a global priority, however, available vaccines have only been partially effective. Therefore, the objective of this study was to evaluate the safety and immunogenicity of a live, attenuated recombinant RVFV arMP-12 Delta NSm21/384 nucleotide deletion vaccine candidate in domestic ruminants. Evaluation involved testing to determine the infectivity titer of the vaccine virus in Vero cells for industrial scale up vaccine production. Safety experiments were conducted to determine the potential of the vaccine virus to revert to virulence by serial passages in sheep, the possibility of virus spread from vaccinated sheep and calves to unvaccinated animals, and the potential health effects of administering overdoses of the vaccine to sheep, goats and calves. The immunogenicity of 3 doses of 10(4), 10(5) and 10(6) Tissue Culture Infectious Doses(50%) (TCID50) of the vaccine was assessed in 3 groups of 10 sheep and 3 groups of 10 goats, and doses of 10(5), 10(6) and 10(7) TCID50 was evaluated in 3 groups of 10 calves subcutaenous vaccintation. The results showed that the infectivity titer of the vaccine virus was 10(8.4) TCID50/ml, that the vaccine did not spread from vaccinated to un-vaccinated animals, there was no evidence of reversion to virulence in sheep and the vaccine overdoses did not cause any adverse effects. The immunogenicity among sheep, goats and calves indicated that doses of 10(4)-10(6) TCID50 elicited detectable antibody by day 7 post-vaccination (PV) with antibody titers ranging from 0.6 log to 2.1 log on day 14 PV with sustained titers through day 28 PV. Overall, these findings indicated that the RVFV arMP-12 Delta NSm21/384 vaccine is a promising candidate for the prevention of RVF among domestic ruminants. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Boumart, Z.; Daouam, S.; Bamouh, Z.; Jazouli, M.; Tadlaoui, K. O.; Dungu, B.; Elharrak, M.] Multichem Ind, Res & Dev Dept, Lot 157,ZI Sud Ouest ERAC BP 278, Mohammadia 28810, Morocco.
   [Bettinger, G.; Watts, D. M.] Univ Texas El Paso, Dept Biol Sci, El Paso, TX 79968 USA.
RP Watts, DM (reprint author), Univ Texas El Paso, Dept Biol Sci, El Paso, TX 79968 USA.
EM Z.boumart@mci-santeanimale.com; S.daouam@mci-santeanimale.com;
   Z.bamouh@mci-santeanimale.com; M.jazouli@mci-santeanimale.com;
   K.tadlaou@mci-santea-nimale.com; B.Dungu@mci-santeanimale.com;
   gebettinger@utep.edu; dwattsb@utep.edu; M.Elharrak@mci-santeanimale.com
FU University of Texas at El Paso (UTEP), Texas; United Stated Agency for
   International DevelopmentUnited States Agency for International
   Development (USAID) [AID-OAA-A-13-00084]
FX This study was funded under a subcontract from the University of Texas
   at El Paso (UTEP), Texas, the recipient of a Cooperative Agreement
   (AID-OAA-A-13-00084) from the United Stated Agency for International
   Development.
CR [Anonymous], 2013, PESTE PETITS RUMINAN, V2
   Balkhy HH, 2003, INT J ANTIMICROB AG, V21, P153, DOI 10.1016/S0924-8579(02)00295-9
   Billecocq A, 1996, J GEN VIROL, V77, P3053, DOI 10.1099/0022-1317-77-12-3053
   Bird BH, 2009, JAVMA-J AM VET MED A, V234, P883, DOI 10.2460/javma.234.7.883
   Botros B, 2006, J MED VIROL, V78, P787, DOI 10.1002/jmv.20624
   Busquets N, 2010, VECTOR-BORNE ZOONOT, V10, P689, DOI 10.1089/vbz.2009.0205
   CAPLEN H, 1985, J GEN VIROL, V66, P2271, DOI 10.1099/0022-1317-66-10-2271
   Daouam S., 2015, Journal of Vaccines and Vaccination, V6, P295
   Dar O, 2013, EMERG INFECT DIS, V19, P189, DOI 10.3201/eid1902.120941
   Daubney R, 1931, J PATHOL BACTERIOL, V34, P545, DOI 10.1002/path.1700340418
   Dungu B, 2010, VACCINE, V28, P4581, DOI 10.1016/j.vaccine.2010.04.085
   Gerrard SR, 2007, VIROLOGY, V357, P124, DOI 10.1016/j.virol.2006.08.002
   Himeidan YE, 2014, FRONT PUBLIC HEALTH, V2, DOI 10.3389/fpubh.2014.00169
   Hunter P, 2002, ONDERSTEPOORT J VET, V69, P95
   ICTV Virus Taxonomy, 2017, 10 INT COMM TAX VIR
   Ikegami T, 2017, EXPERT REV VACCINES, V16, P601, DOI 10.1080/14760584.2017.1321482
   Ikegami T, 2015, J VIROL, V89, P7262, DOI 10.1128/JVI.00135-15
   Kalveram B, 2011, JOVE-J VIS EXP, DOI 10.3791/3400
   Lokugamage N, 2017, NPJ VACCINES, V2, DOI 10.1038/s41541-017-0021-9
   Makoschey B, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004550
   MEEGAN JM, 1979, T ROY SOC TROP MED H, V73, P618, DOI 10.1016/0035-9203(79)90004-X
   Morrill JC, 1997, AM J VET RES, V58, P1110
   MORRILL JC, 1987, AM J VET RES, V48, P1042
   MORRILL JC, 1991, VACCINE, V9, P35, DOI 10.1016/0264-410X(91)90314-V
   Morrill JC, 1997, AM J VET RES, V58, P1104
   Morrill JC, 2013, VACCINE, V31, P4988, DOI 10.1016/j.vaccine.2013.08.003
   Morrill JC, 2013, VACCINE, V31, P559, DOI 10.1016/j.vaccine.2012.10.118
   Morrill JC, 2011, J INFECT DIS, V204, P617, DOI 10.1093/infdis/jir354
   MULLER R, 1995, AM J TROP MED HYG, V53, P405, DOI 10.4269/ajtmh.1995.53.405
   Nguku PM, 2010, AM J TROP MED HYG, V83, P5, DOI 10.4269/ajtmh.2010.09-0288
   NIKLASSON BS, 1984, ACTA PATH MICRO IM C, V92, P197
   Pepin M, 2010, VET RES, V41, DOI 10.1051/vetres/2010033
   Pienaar Nicolaas J., 2013, Onderstepoort j. vet. res., V80, P1
   Pittman PR, 2016, VACCINE, V34, P523, DOI 10.1016/j.vaccine.2015.11.078
   Pittman PR, 2016, VACCINE, V34, P424, DOI 10.1016/j.vaccine.2015.12.030
   REED L. J., 1938, AMER JOUR HYG, V27, P493
   Rima B, 2017, J GEN VIROL, V98, P2912, DOI 10.1099/jgv.0.000959
   Saganuwan SA, 2011, AFR J PHARM PHARMACO, V5, P1543
   Tambo E, 2016, LANCET INFECT DIS, V16, P1319, DOI 10.1016/S1473-3099(16)30477-7
   Thompson G. R., 1994, INFECT DIS LIVESTOCK, P825
   von Teichman B, 2011, VACCINE, V29, P5771, DOI 10.1016/j.vaccine.2011.05.055
   Weingartl HM, 2014, VACCINE, V32, P2345, DOI 10.1016/j.vaccine.2013.12.064
   Won SY, 2007, J VIROL, V81, P13335, DOI 10.1128/JVI.01238-07
NR 43
TC 2
Z9 2
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 14
PY 2019
VL 37
IS 12
BP 1642
EP 1650
DI 10.1016/j.vaccine.2019.01.067
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HQ0UD
UT WOS:000462109600014
PM 30773401
DA 2020-05-12
ER

PT J
AU Mikamo, H
   Yamagishi, Y
   Murata, S
   Yokokawa, R
   Han, SR
   Wakana, A
   Sawata, M
   Tanaka, Y
AF Mikamo, Hiroshige
   Yamagishi, Yuka
   Murata, Shinya
   Yokokawa, Ruriko
   Han, Shi Rong
   Wakana, Akira
   Sawata, Miyuki
   Tanaka, Yoshiyuki
TI Efficacy, safety, and immunogenicity of a quadrivalent HPV vaccine in
   Japanese men: A randomized, Phase 3, placebo-controlled study
SO VACCINE
LA English
DT Article
DE Human papillomavirus; Japan; Adult male; Prophylactic efficacy;
   Quadrivalent HPV vaccine; Safety
ID PAPILLOMAVIRUS TYPES 6; CERVICAL-CANCER; INFECTION; BOYS
AB Background: The quadrivalent (q) human papillomavirus (HPV) vaccine protects against infection and disease related to HPV types 6, 11, 16, and 18. We report efficacy, immunogenicity, and safety of qHPV vaccine in a Phase 3 study in Japanese men.
   Methods: In this randomized, double-blind trial (NCT01862874), Japanese men (aged 16-26 years) were randomized in a 1:1 ratio to receive three doses of qHPV vaccine or placebo (Day 1, Month 2, Month 6). The primary efficacy endpoint was the combined incidence of HPV6/11/16/18-related persistent anogenital infection (detected at >= 2 consecutive visits >= 6 months apart), assessed in the per-protocol population of men who received all three vaccinations, and were seronegative at Day 1 and PCR negative from Day 1 to Month 7 to the relevant HPV type. Results are from the interim and final analyses.
   Results: In total, 1124 participants were randomized. The vaccine demonstrated 83.3% (95% confidence interval: 24.9, 98.2; p = 0.007) and 85.9% (95% confidence interval: 52.7, 97.3; p < 0.001) efficacy against HPV6/11/16/18-related persistent infection in the interim and final analyses, respectively. Two cases of HPV6/11/16/18-related external genital lesions (condyloma and PIN 1) were observed in the placebo group and none in the qHPV vaccine group at study end. At Month 7, >97% of participants who received qHPV vaccine seroconverted to each of the vaccine HPV types. Most participants remained seropositive at Month 36, although the seropositivity rate declined between Months 7 and 36. Vaccination-related adverse events were reported in 60.8% and 56.5% of participants in the qHPV vaccine and placebo groups, respectively; most commonly mild to moderate injection-site pain, erythema, and swelling. Injection-site pain and swelling were more common with qHPV vaccine than placebo (each p < 0.05).
   Conclusions: Results suggest qHPV vaccine is efficacious against HPV6/11/16/18-related persistent infections, immunogenic, and well-tolerated in Japanese men. (C) 2019 The Authors. Published by Elsevier Ltd.
C1 [Mikamo, Hiroshige; Yamagishi, Yuka] Akin Med Univ Hosp, Nagakute, Aichi, Japan.
   [Murata, Shinya; Yokokawa, Ruriko; Han, Shi Rong; Wakana, Akira; Sawata, Miyuki; Tanaka, Yoshiyuki] MSD KK, Tokyo, Japan.
RP Murata, S (reprint author), 1-13-12 Kudan Kita,Chiyoda Ku, Tokyo 1028667, Japan.
EM shinya.murata@merck.com
FU Merck Sharp Dohme Corp.Merck & Company
FX This work was supported by Merck Sharp & Dohme Corp., a subsidiary of
   Merck & Co., Inc., Kenilworth, NJ, USA.
CR Alemany L, 2016, EUR UROL, V69, P953, DOI 10.1016/j.eururo.2015.12.007
   Alemany L, 2015, INT J CANCER, V136, P98, DOI 10.1002/ijc.28963
   [Anonymous], 2017, WKLY EPIDEMIOL REC, V92, P241, DOI DOI 10.1016/j.vaccine.2017.05.069
   Castellsague X, 2016, JNCI-J NATL CANCER I, V108, DOI 10.1093/jnci/djv403
   de Martel C, 2017, INT J CANCER, V141, P664, DOI 10.1002/ijc.30716
   de Sanjose S, 2010, LANCET ONCOL, V11, P1048, DOI 10.1016/S1470-2045(10)70230-8
   Dias D, 2005, CLIN DIAGN LAB IMMUN, V12, P959, DOI 10.1128/CDLI.12.8.959-969.2005
   Garland SM, 2007, NEW ENGL J MED, V356, P1928, DOI 10.1056/NEJMoa061760
   Garland SM, 2009, J INFECT DIS, V199, P805, DOI 10.1086/597071
   Giuliano AR, 2011, NEW ENGL J MED, V364, P401, DOI 10.1056/NEJMoa0909537
   Global Advisory Committee on Vaccine Safety World Health Organization., STAT SAF HPV VACC
   GOLDSTONE S, 2018, J CLIN ONCOL S, V36
   Hillman RJ, 2012, CLIN VACCINE IMMUNOL, V19, P261, DOI 10.1128/CVI.05208-11
   Johnson LG, 2004, CANCER-AM CANCER SOC, V101, P281, DOI 10.1002/cncr.20364
   Lehtinen M, 2015, CURR OPIN OBSTET GYN, V27, P326, DOI 10.1097/GCO.0000000000000208
   Moreira ED, 2011, HUM VACCINES, V7, P768, DOI 10.4161/hv.7.7.15579
   Nakashima K, 2014, BMC INFECT DIS, V14, DOI 10.1186/1471-2334-14-43
   Palefsky JM, 2011, NEW ENGL J MED, V365, P1576, DOI 10.1056/NEJMoa1010971
   Schmeler KM, 2016, LANCET, V387, P1798, DOI 10.1016/S0140-6736(16)30314-2
   Stanley M, 2014, HUM VACC IMMUNOTHER, V10, P2106, DOI 10.4161/hv.29137
   Suzuki S, 2018, PAPILLOMAVIRUS RES, V5, P96, DOI 10.1016/j.pvr.2018.02.002
   Tanaka Y, 2016, LANCET ONCOL, V17, P868, DOI 10.1016/S1470-2045(16)00147-9
   Vichnin M, 2015, PEDIATR INFECT DIS J, V34, P983, DOI 10.1097/INF.0000000000000793
   Villa LL, 2007, NEW ENGL J MED, V356, P1915, DOI 10.1056/NEJMoa061741
   Wigle J, 2016, PEDIATR CLIN N AM, V63, P81, DOI 10.1016/j.pcl.2015.08.004
   Yagi A, 2017, HUM VACC IMMUNOTHER, V13, P1700, DOI 10.1080/21645515.2017.1292190
NR 26
TC 2
Z9 2
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 14
PY 2019
VL 37
IS 12
BP 1651
EP 1658
DI 10.1016/j.vaccine.2019.01.069
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HQ0UD
UT WOS:000462109600015
PM 30797638
OA Other Gold
DA 2020-05-12
ER

PT J
AU Iles, RA
   Gatumu, H
   Kagundu, S
   Draheim, C
AF Iles, Richard A.
   Gatumu, Haniel
   Kagundu, Samuel
   Draheim, Christopher
TI Information sharing and willingness-to-pay for CBPP vaccine in rural
   Kenya
SO VACCINE
LA English
DT Article
DE Willingness-to-pay; Contagious bovine pleuropneumonia; Disease risk;
   Information; Kenya Discrete Choice Experiment
ID CONTAGIOUS BOVINE PLEUROPNEUMONIA; ATTRIBUTE NON-ATTENDANCE; CHOICE
   EXPERIMENTS; NAROK DISTRICT; FLUID INTELLIGENCE; IMMUNE-RESPONSES;
   WORKING-MEMORY; IMPACT; FORMULATIONS; PERCEPTIONS
AB The study estimates cattle owners' willingness-to-pay (WTP) for Contagious Bovine Pleuropneumonia (CBPP) vaccine in Samburu county, Kenya. Of particular policy relevance, the study presents findings on WTP for i) improved access to vaccines and ii) timely access to disease-risk information. The mean price for a CBPP vaccine was estimated at KES 66 (USD 0.64). This price relates to a CBPP vaccine that requires a 1.8 h commute, cattle owners' receipt of timely information that the CBPP disease risk is low-moderate and the vaccine lowers the risk of either tail-drop or post-vaccine abortion. The conditional WTP for mean travel duration and high-risk information are similar at KES 53.9 and KES 51.5. The marginal effect on demand for a 1 h additional travel duration and provision of CBPP disease risk information was estimated as a 1.5 per cent reduction and 2.3 increase. The results of this study indicate that cattle owners value greater levels of knowledge concerning the changing risk profile of CBPP in their community and improved access to CBPP vaccination services. Enhanced engagement with cattle owners concerning CBPP would likely result in a greater utilisation of available CBPP vaccines, conditional on the perceived CBPP disease risk. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Iles, Richard A.] Washington State Univ, Sch Econ Sci, Pullman, WA 99164 USA.
   [Iles, Richard A.] Washington State Univ, Paul G Allen Sch Global Anim Hlth, Pullman, WA 99164 USA.
   [Iles, Richard A.; Gatumu, Haniel] Univ Nairobi, Dept Psychol, Nairobi, Kenya.
   [Kagundu, Samuel] Compass Int, Nairobi, Kenya.
   [Draheim, Christopher] Georgia Inst Technol, Dept Psychol, Atlanta, GA 30332 USA.
   [Iles, Richard A.] Washington State Univ, 101 Hulbert Hall, Pullman, WA 99163 USA.
RP Iles, RA (reprint author), Washington State Univ, Sch Econ Sci, Pullman, WA 99164 USA.; Iles, RA (reprint author), Washington State Univ, Paul G Allen Sch Global Anim Hlth, Pullman, WA 99164 USA.; Iles, RA (reprint author), Univ Nairobi, Dept Psychol, Nairobi, Kenya.; Iles, RA (reprint author), Washington State Univ, 101 Hulbert Hall, Pullman, WA 99163 USA.
EM richard.iles@wsu.edu
OI Iles, Richard/0000-0003-4232-783X
FU School of Economic Sciences, Washington State University
FX This research was supported by funding from the School of Economic
   Sciences, Washington State University.
CR Adamowicz W, 1998, AM J AGR ECON, V80, P64, DOI 10.2307/3180269
   Bliemer MCJ, 2005, ITLSWP0508
   Cameron MP, 2013, VACCINE, V31, P3712, DOI 10.1016/j.vaccine.2013.05.089
   Carlsson F, 2003, EC ISSUES J, V83
   Caussade S, 2005, TRANSPORT RES B-METH, V39, P621, DOI 10.1016/j.trb.2004.07.006
   Costenbader V, 2001, SCHOOL PSYCHOL INT, V22, P258, DOI 10.1177/0143034301223003
   Daley TC, 2003, PSYCHOL SCI, V14, P215, DOI 10.1111/1467-9280.02434
   Day B, 2012, J ENVIRON ECON MANAG, V63, P73, DOI 10.1016/j.jeem.2011.09.001
   de Bekker-Grob EW, 2012, HEALTH ECON, V21, P145, DOI 10.1002/hec.1697
   Domencich T. A., 1975, URBAN TRAVEL DEMAND
   Draheim C, 2018, PSYCHOL ASSESSMENT, V30, P116, DOI 10.1037/pas0000444
   Engle RW, 1999, J EXP PSYCHOL GEN, V128, P309, DOI 10.1037/0096-3445.128.3.309
   Fleischer A, 2015, TRANSPORT RES C-EMER, V56, P210, DOI 10.1016/j.trc.2015.03.039
   Frederick S, 2005, J ECON PERSPECT, V19, P25, DOI 10.1257/089533005775196732
   Gracia A, 2009, FOOD QUAL PREFER, V20, P463, DOI 10.1016/j.foodqual.2009.03.010
   GREEN PE, 1990, J MARKETING, V54, P3, DOI 10.2307/1251756
   Hensher DA, 2006, J APPL ECONOMET, V21, P861, DOI 10.1002/jae.877
   Hensher DA, 2010, TRANSPORT RES B-METH, V44, P735, DOI 10.1016/j.trb.2009.12.012
   Hensher DA, 2010, EMPIR ECON, V39, P413, DOI 10.1007/s00181-009-0310-x
   Hoyos D, 2010, ECOL ECON, V69, P1595, DOI 10.1016/j.ecolecon.2010.04.011
   Iles R. A, HLTH EC
   Iles RA, 2014, HEALTH ECON REV, V4, DOI 10.1186/s13561-014-0025-3
   Jores J, 2013, VET RES, V44, DOI 10.1186/1297-9716-44-122
   Kairu-Wanyoike SW, 2017, LIVEST SCI, V197, P61, DOI 10.1016/j.livsci.2017.01.002
   Kairu-Wanyoike SW, 2014, PREV VET MED, V115, P143, DOI 10.1016/j.prevetmed.2014.03.029
   Kairu-Wanyoike SW, 2014, PREV VET MED, V115, P130, DOI 10.1016/j.prevetmed.2014.03.028
   Kairu-Wanyoike SW, 2013, PREV VET MED, V110, P356, DOI 10.1016/j.prevetmed.2013.02.013
   Lagarde M, 2013, HEALTH ECON, V22, P554, DOI 10.1002/hec.2824
   LANCASTER KJ, 1966, J POLIT ECON, V74, P132, DOI 10.1086/259131
   Lancsar E, 2006, HEALTH ECON, V15, P797, DOI 10.1002/hec.1104
   Loureiro ML, 2002, J CONSUM AFF, V36, P203, DOI 10.1111/j.1745-6606.2002.tb00430.x
   Mani A, 2013, SCIENCE, V341, P976, DOI 10.1126/science.1238041
   March JB, 2004, VACCINE, V22, P4358, DOI 10.1016/j.vaccine.2004.03.066
   Markosyan A, 2009, CAN J AGR ECON, V57, P325, DOI 10.1111/j.1744-7976.2009.01154.x
   McFadden D., 1974, FRONTIERS ECONOMETRI
   Muindi P, 2015, DELIVERY CONTAGIOUS
   Nkando I, 2016, VET IMMUNOL IMMUNOP, V171, P103, DOI 10.1016/j.vetimm.2016.02.010
   Nkando I, 2012, RES VET SCI, V93, P568, DOI 10.1016/j.rvsc.2011.08.020
   Onono JO, 2014, PREV VET MED, V115, P122, DOI 10.1016/j.prevetmed.2014.03.022
   Perez-Casal J, 2015, VET IMMUNOL IMMUNOP, V168, P103, DOI 10.1016/j.vetimm.2015.08.013
   Railey AF, 2018, VACCINE, V36, P5077, DOI [10.1016/j.vaccine.2018.06.069, 10.1016/j.va]
   Raven J, 2000, COGNITIVE PSYCHOL, V41, P1, DOI 10.1006/cogp.1999.0735
   Scarpa R, 2009, EUR REV AGRIC ECON, V36, P151, DOI 10.1093/erae/jbp012
   Schniederjans DG, 2014, TRANSPORT RES D-TR E, V31, P116, DOI 10.1016/j.trd.2014.05.024
   Shipstead Z, 2016, PERSPECT PSYCHOL SCI, V11, P771, DOI 10.1177/1745691616650647
   Suleiman A, 2018, PREV VET MED, V149, P67, DOI 10.1016/j.prevetmed.2017.10.011
   Tambi NE, 2006, REV SCI TECH OIE, V25, P999, DOI 10.20506/rst.25.3.1710
   Thaler R. H., 2008, NUDGE IMPROVING DECI
   WFP, 2015, SAMB COUNT CAP GAPS
NR 49
TC 1
Z9 1
U1 3
U2 10
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 14
PY 2019
VL 37
IS 12
BP 1659
EP 1666
DI 10.1016/j.vaccine.2019.01.072
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HQ0UD
UT WOS:000462109600016
PM 30782491
DA 2020-05-12
ER

PT J
AU Enchery, F
   Hamers, C
   Kwiatek, O
   Gaillardet, D
   Montange, C
   Brunel, H
   Goutebroze, S
   Philippe-Reversat, C
   Libeau, G
   Hudelet, P
   Bataille, A
AF Enchery, Francois
   Hamers, Claude
   Kwiatek, Olivier
   Gaillardet, Daniel
   Montange, Camille
   Brunel, Herve
   Goutebroze, Sylvain
   Philippe-Reversat, Corinne
   Libeau, Genevieve
   Hudelet, Pascal
   Bataille, Arnaud
TI Development of a PPRV challenge model in goats and its use to assess the
   efficacy of a PPR vaccine
SO VACCINE
LA English
DT Article
DE Peste des petits ruminants; Goats; Vaccine; Virulence; Strain; Challenge
   model
ID DES-PETITS-RUMINANTS; PESTE; VIRUS; WILD; INFECTION; EXCRETION
AB Peste des Petits Ruminants (PPR) is a severe disease of small ruminants and has high economic impacts in developing countries. Endemic in Africa, the Middle East and Asia, the disease is currently progressing with occurrences reported in North Africa, Turkey and in Georgia, and now threatens Europe. Much remains unknown about the infection dynamics, the virulence of the different strains and species/breed susceptibility. Robust experimental challenge models are needed to explore these fields and to confirm the efficacy of currently sold vaccines. We first assessed virulence of two PPR virus strains (CI89 and MA08) in Saanen goats. Whereas the MA08 strain led to classical severe clinical signs of PPR, the CI89 strain appeared to cause a mild disease in Saanen goats, highlighting the difference in virulence between strains in this animal model. We further demonstrated the importance of the inoculation route in the appearance of clinical signs and that ocular excretion is a better choice than blood for viral detection. After developing a robust challenge model, we assessed the efficacy of a vaccine (PPR-VAC (R), BVI Botswana) against the MA08 strain and demonstrated that this vaccine blocked viral excretion and significantly reduced clinical signs. These results reinforce the paradigm that a strain from one lineage could protect against strains from other lineages. (C) 2019 The Authors. Published by Elsevier Ltd.
C1 [Enchery, Francois; Hamers, Claude; Gaillardet, Daniel; Montange, Camille; Brunel, Herve; Goutebroze, Sylvain; Philippe-Reversat, Corinne; Hudelet, Pascal] Merial SAS, 29 Ave Tony Garnier, F-69007 Lyon, France.
   [Kwiatek, Olivier; Libeau, Genevieve; Bataille, Arnaud] UMR ASTRE, CIRAD, F-34398 Montpellier, France.
   [Enchery, Francois; Hamers, Claude; Kwiatek, Olivier; Gaillardet, Daniel; Montange, Camille; Brunel, Herve; Goutebroze, Sylvain; Philippe-Reversat, Corinne; Libeau, Genevieve; Hudelet, Pascal; Bataille, Arnaud] Univ Montpellier, INRA, CIRAD, ASTRE, Montpellier, France.
RP Enchery, F (reprint author), Merial SAS, 29 Ave Tony Garnier, F-69007 Lyon, France.
EM francois.enchery@boehringer-ingelheim.com
FU CIRAD; Merial/Boehringer-ingelheim
FX The research was completely supported by internal funds from CIRAD and
   Merial/Boehringer-ingelheim.
CR Adombi CM, 2011, J VIROL METHODS, V173, P306, DOI 10.1016/j.jviromet.2011.02.024
   Bardhan D, 2017, REV SCI TECH OIE, V36, P245, DOI 10.20506/rst.36.1.2626
   Baron MD, 2016, ADV VIRUS RES, V95, P1, DOI 10.1016/bs.aivir.2016.02.001
   Couacy-Hymann E, 2007, VET J, V173, P178, DOI 10.1016/j.tvjl.2005.08.020
   Couacy-Hymann E, 2007, PREV VET MED, V78, P85, DOI 10.1016/j.prevetmed.2006.09.003
   Couacy-Hymann E, 2009, RES VET SCI, V87, P332, DOI 10.1016/j.rvsc.2009.03.002
   El Harrak M, 2012, J CLIN MICROBIOL, V50, P3738, DOI 10.1128/JCM.01785-12
   Ezeibe MCO, 2008, TROP ANIM HEALTH PRO, V40, P517, DOI 10.1007/s11250-008-9128-3
   Fakri FZ, 2017, ACTA VET SCAND, V59, DOI 10.1186/s13028-017-0323-y
   FAO, 2013, SUPP LIV BUILD RES P
   FAO and OIE, 2015, GLOB CONTR ER PEST P
   Guo Q, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094412
   Hammouchi M, 2012, VET MICROBIOL, V160, P240, DOI 10.1016/j.vetmic.2012.04.043
   Jaisree S, 2018, TRANSBOUND EMERG DIS, V65, pe198, DOI 10.1111/tbed.12694
   Jones BA, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149982
   Kumar N, 2014, VIRUSES-BASEL, V6, P2287, DOI 10.3390/v6062287
   Kwiatek O, 2010, J VIROL METHODS, V165, P168, DOI 10.1016/j.jviromet.2010.01.014
   Lefere P. C., 1990, Revue Scientifique et Technique - Office International des Epizooties, V9, P935
   Li J, 2017, TRANSBOUND EMERG DIS, V64, pE43, DOI 10.1111/tbed.12600
   Libeau G., 2014, Animal Frontiers, V4, P14, DOI 10.2527/af.2014-0003
   Liu W, 2013, TRANSBOUND EMERG DIS, V60, P63, DOI 10.1111/tbed.12136
   Mahapatra M, 2015, EMERG INFECT DIS, V21, P2230, DOI 10.3201/eid2112.150223
   Marashi M, 2017, EMERG INFECT DIS, V23, P704, DOI 10.3201/eid2304.161218
   Parida S, 2015, VET MICROBIOL, V181, P90, DOI 10.1016/j.vetmic.2015.08.009
   Parida S, 2016, SMALL RUMINANT RES, V142, P16, DOI 10.1016/j.smallrumres.2016.02.018
   Pope RA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055830
NR 26
TC 4
Z9 4
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 14
PY 2019
VL 37
IS 12
BP 1667
EP 1673
DI 10.1016/j.vaccine.2019.01.057
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HQ0UD
UT WOS:000462109600017
PM 30772071
OA Other Gold
DA 2020-05-12
ER

PT J
AU Kingston, NJ
   Kurtovic, L
   Walsh, R
   Joe, C
   Lovrecz, G
   Locarnini, S
   Beeson, JG
   Netter, HJ
AF Kingston, Natalie J.
   Kurtovic, Liriye
   Walsh, Renae
   Joe, Carina
   Lovrecz, George
   Locarnini, Stephen
   Beeson, James G.
   Netter, Hans J.
TI Hepatitis B virus-like particles expressing Plasmodium falciparum
   epitopes induce complement-fixing antibodies against the
   circumsporozoite protein
SO VACCINE
LA English
DT Article
DE Virus-like particle (VLP); Hepatitis B surface antigen; Epitope repeats;
   Plasmodium falciparum
ID SURFACE-ANTIGEN PARTICLES; MONOCLONAL-ANTIBODIES; METHYLOTROPHIC YEAST;
   MALARIA VACCINE; CPG DNA; IMMUNOGENICITY; EFFICACY; SAFETY; IMMUNITY;
   PROTECTION
AB The repetitive structure of compact virus-like particles (VLPs) provides high density displays of antigenic sequences, which trigger key parts of the immune system. The hepatitis B virus (HBV) and human papilloma virus (HPV) vaccines exploit the assembly competence of structural proteins, which are the effective immunogenic components of the prophylactic HBV and HPV vaccines, respectively. To optimize vaccine designs and to promote immune responses against protective epitopes, the "Asp-Ala-Asp-Pro" (NANP)-repeat from the Plasmodium falciparum circumsporozoite protein (CSP) was expressed within the exposed, main antigenic site of the small HBV envelope protein (HBsAgS); this differs from the RTS,S vaccine, in which CSP epitopes are fused to the N-terminus of HBsAgS. The chimeric HBsAgS proteins are assembly competent, produce VLPs, and provide a high antigenic density of the NANP repeat sequence. Chimeric VLPs with four or nine NANP-repeats (NANP4 and NANP9, respectively) were expressed in mammalian cells, the HBsAgS- and CSP-specific antigenicity of the VLPs was determined, and the immunogenicity of the VLPs assessed in relation to the induction of anti-HBsAgS and anti-CSP antibody responses. The chimeric VLPs induced high anti-CSP titres in BALB/c mice independent of the number of the NANP repeats. However, the number of NANP repeats influenced the activity of vaccine-induced antibodies measured by complement fixation to CSP, one of the proposed effector mechanisms for Plasmodium neutralization in vivo. Sera from mice immunized with VLPs containing nine NANP repeats performed better in the complement fixation assay than the group with four NANP repeats. The effect of the epitope-specific density on the antibody quality may instruct VLP platform designs to optimize immunological outcomes and vaccine efficacy. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Kingston, Natalie J.; Beeson, James G.] Monash Univ, Infect & Immun Program, Monash Biomed Discovery Inst, Clayton, Vic 3800, Australia.
   [Kingston, Natalie J.; Beeson, James G.] Monash Univ, Dept Microbiol, Clayton, Vic 3800, Australia.
   [Kingston, Natalie J.] Univ Leeds, Sch Mol & Cellular Biol, Fac Biol Sci, Leeds, W Yorkshire, England.
   [Kingston, Natalie J.] Univ Leeds, Astbury Ctr Struct Mol Biol, Leeds, W Yorkshire, England.
   [Kurtovic, Liriye; Beeson, James G.] Burnet Inst, Commercial Rd, Melbourne, Vic 3004, Australia.
   [Kurtovic, Liriye; Beeson, James G.] Monash Univ, Dept Immunol & Pathol, Melbourne, Vic 2004, Australia.
   [Walsh, Renae; Locarnini, Stephen; Netter, Hans J.] Peter Doherty Inst, Melbourne Hlth, VIDRL, Melbourne, Vic 3000, Australia.
   [Joe, Carina; Netter, Hans J.] Royal Melbourne Inst Technol RMIT Univ, Sch Sci, Melbourne, Vic 3001, Australia.
   [Joe, Carina; Lovrecz, George] Commonwealth Sci & Ind Res Org, Clayton, Vic 3169, Australia.
   [Beeson, James G.] Univ Melbourne, Dept Med, Parkville, Vic 3010, Australia.
RP Netter, HJ (reprint author), Melbourne Hlth, VIDRL, Melbourne, Vic, Australia.
EM hans.netter@mh.org.au
RI Kurtovic, Liriye/AAI-2153-2019
OI Kingston, Natalie/0000-0001-7109-6757; Netter, Hans
   Juergen/0000-0002-2808-3923
FU National Health and Medical Research Council (NHMRC) AustraliaNational
   Health and Medical Research Council of Australia [APP1127538, 1077636,
   1092789]; Australian Government Research Training Program
   ScholarshipAustralian GovernmentDepartment of Industry, Innovation and
   Science; NHMRC Independent Research Institutes Infrastructure Support
   Scheme; State Government of Victoria
FX This study was partly supported by the National Health and Medical
   Research Council (NHMRC) Australia, Research Project Grant APP1127538
   awarded to SL, RW and HJN, Senior Research Fellowship to JGB (1077636)
   and Program Grant to JGB (1092789), and Australian Government Research
   Training Program Scholarship awarded to LK. The Burnet Institute was
   supported by the NHMRC Independent Research Institutes Infrastructure
   Support Scheme and an Operational Infrastructure Grant from the State
   Government of Victoria.
CR Al-Barwani F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104523
   BALLOU WR, 1985, SCIENCE, V228, P996, DOI 10.1126/science.2988126
   Beaumont E, 2013, HEPATOLOGY, V57, P1303, DOI 10.1002/hep.26132
   Behet MC, 2018, INFECT IMMUN, V86, DOI [10.1128/IAI.00920-17, 10.1128/iai.00920-17]
   Boes A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131456
   Boyle MJ, 2015, IMMUNITY, V42, P580, DOI 10.1016/j.immuni.2015.02.012
   Bruss V, 2007, WORLD J GASTROENTERO, V13, P65, DOI 10.3748/wjg.v13.i1.65
   Campo JJ, 2014, VACCINE, V32, P2209, DOI 10.1016/j.vaccine.2014.02.042
   CARROLL RC, 1990, THROMB RES, V59, P831, DOI 10.1016/0049-3848(90)90396-T
   Casares S, 2010, VACCINE, V28, P4880, DOI 10.1016/j.vaccine.2010.05.033
   Chappel JA, 2004, MALARIA J, V3, DOI 10.1186/1475-2875-3-28
   Chaudhury S, 2016, MALARIA J, V15, DOI 10.1186/s12936-016-1348-9
   Cheong WS, 2012, ANTIVIR RES, V93, P209, DOI 10.1016/j.antiviral.2011.11.011
   Cheong WS, 2009, ANTIVIR RES, V81, P113, DOI 10.1016/j.antiviral.2008.10.003
   COHEN S, 1961, NATURE, V192, P733, DOI 10.1038/192733a0
   CREGG JM, 1987, BIO-TECHNOL, V5, P479, DOI 10.1038/nbt0587-479
   Davis HL, 1998, J IMMUNOL, V160, P870
   DELGIUDICE G, 1990, B WORLD HEALTH ORGAN, V68, P191
   DELPEYROUX F, 1986, SCIENCE, V233, P472, DOI 10.1126/science.2425433
   Foquet L, 2014, J CLIN INVEST, V124, P140, DOI 10.1172/JCI70349
   Garland SM, 2016, CLIN INFECT DIS, V63, P519, DOI 10.1093/cid/ciw354
   GAVILANES F, 1982, J BIOL CHEM, V257, P7770
   Gilbert RJC, 2005, P NATL ACAD SCI USA, V102, P14783, DOI 10.1073/pnas.0505062102
   GORDON DM, 1995, J INFECT DIS, V171, P1576, DOI 10.1093/infdis/171.6.1576
   Greenwood BM, 2011, CLIN MICROBIOL INFEC, V17, P1600, DOI 10.1111/j.1469-0691.2011.03612.x
   Harro CD, 2001, J NATL CANCER I, V93, P284, DOI 10.1093/jnci/93.4.284
   Hyakumura M, 2015, J VIROL, V89, P11312, DOI 10.1128/JVI.01123-15
   JANOWICZ ZA, 1991, YEAST, V7, P431, DOI 10.1002/yea.320070502
   Jennings GT, 2009, ANNU REV PHARMACOL, V49, P303, DOI 10.1146/annurev-pharmtox-061008-103129
   JILG W, 1984, LANCET, V2, P1174
   Johannssen T, 2017, TRENDS BIOTECHNOL, V35, P334, DOI 10.1016/j.tibtech.2016.10.002
   John CC, 2005, AM J TROP MED HYG, V73, P222, DOI 10.4269/ajtmh.2005.73.222
   KIM CY, 1973, J CLIN INVEST, V52, P1176, DOI 10.1172/JCI107284
   KOOLWIJK P, 1991, MOL IMMUNOL, V28, P567, DOI 10.1016/0161-5890(91)90125-4
   Kurtovic L, 2018, BMC MED, V16, DOI 10.1186/s12916-018-1054-2
   Lin L, 2004, EUR J IMMUNOL, V34, P1483, DOI 10.1002/eji.200324736
   Malaria Vaccine Funders Group, 2013, MAL VACC TECHN ROADM
   Mangold CMT, 1997, ARCH VIROL, V142, P2257, DOI 10.1007/s007050050240
   Moffat JM, 2013, VACCINE, V31, P2310, DOI 10.1016/j.vaccine.2013.02.042
   Netter HJ, 2001, J VIROL, V75, P2130, DOI 10.1128/JVI.75.5.2130-2141.2001
   Olotu A, 2016, NEW ENGL J MED, V374, P2519, DOI 10.1056/NEJMoa1515257
   Osier FH, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008705
   PETERSON DL, 1987, BIOESSAYS, V6, P258, DOI 10.1002/bies.950060604
   Phogat S, 2008, VIROLOGY, V373, P72, DOI 10.1016/j.virol.2007.11.005
   Pushko P, 2013, INTERVIROLOGY, V56, P141, DOI 10.1159/000346773
   Regules JA, 2016, J INFECT DIS, V214, P762, DOI 10.1093/infdis/jiw237
   RUTGERS T, 1988, BIO-TECHNOL, V6, P1065, DOI 10.1038/nbt0988-1065
   Schwenk R, 2003, PARASITE IMMUNOL, V25, P17, DOI 10.1046/j.1365-3024.2003.00495.x
   Seeger C., 2013, FIELDS VIROLOGY, P2185
   SEINO J, 1993, CLIN EXP IMMUNOL, V94, P291
   STIRK HJ, 1992, INTERVIROLOGY, V33, P148, DOI 10.1159/000150244
   Tinto H, 2015, LANCET, V386, P31, DOI 10.1016/S0140-6736(15)60721-8
   Ungaro F, 2013, EXPERT REV VACCINES, V12, P1173, DOI 10.1586/14760584.2013.836909
   VALENZUELA P, 1982, NATURE, V298, P347, DOI 10.1038/298347a0
   Vietheer PT, 2007, ANTIVIR THER, V12, P477
   White MT, 2014, BMC MED, V12, DOI 10.1186/s12916-014-0117-2
   Yan D, 2015, APPL MICROBIOL BIOT, V99, P10415, DOI 10.1007/s00253-015-7000-8
   YOUNG JF, 1985, SCIENCE, V228, P958, DOI 10.1126/science.2988125
   Zuckerman JN, 2006, J MED VIROL, V78, P169, DOI 10.1002/jmv.20524
NR 59
TC 3
Z9 3
U1 2
U2 5
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 14
PY 2019
VL 37
IS 12
BP 1674
EP 1684
DI 10.1016/j.vaccine.2019.01.056
PG 11
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HQ0UD
UT WOS:000462109600018
PM 30773400
DA 2020-05-12
ER

PT J
AU Awasthi, S
   Vilekar, P
   Conkleton, A
   Rahman, N
AF Awasthi, Shanjana
   Vilekar, Prachi
   Conkleton, Alexandra
   Rahman, Negar
TI Dendritic cell-based immunization induces Coccidioides Ag2/PRA-specific
   immune response
SO VACCINE
LA English
DT Article
DE Dendritic cells; Vaccination; Coccidioides; Immune response
ID MOUSE STRAINS; VACCINE; EXPRESSION; MICE; SUSCEPTIBILITY; INFECTION
AB Valley Fever, or coccidioidomycosis, is caused by a soil-borne, highly virulent fungal pathogen, Coccidioides spp. Infection with Coccidioides can be life-threatening. Since an effective treatment is not available and the T cell-mediated immune response is protective, vaccine development is of interest. In this study, a primary dendritic cell (DC)-vaccine was evaluated for its ability to stimulate Coccidioides antigen-specific immune response in an extremely susceptible BALB/c mouse model. The DC-vaccine (Ag2-DC) was prepared by non-virally transfecting the primary bone marrow-derived DCs with a plasmid DNA encoding Ag2/PRA (protective epitope of Coccidioides). Mice were intranasally immunized with Ag2-DC on days 2 and 10. Immunized mice were necropsied on days 8, 32, and 44. Major organs and blood samples were harvested. The most common indicators of injury (protein, lactate, and albumin), Ag/PRA-specific cytokine-secreting cells, and IgG and its isotypes were determined by biochemical and immunologic assays, respectively. No signs of sickness were noted. Similarly, no significant changes were observed in the levels of total lung protein, lactate, and albumin, in immunized mice compared with healthy control mice. Interferon (IFN-gamma), and interleukin (IL)-4 and IL-17 cytokine-secreting cells were observed in lung and lymph nodes upon Ag2-DC immunization. Our results showed that the levels of serum IgG and its isotypes were increased in Ag2-DC-immunized mice. This report provides evidence of DC immunization-stimulated Ag2/PRA-specific immune responses. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Awasthi, Shanjana; Vilekar, Prachi; Conkleton, Alexandra; Rahman, Negar] Univ Oklahoma, Hlth Sci Ctr, Dept Pharmaceut Sci, Oklahoma City, OK 73117 USA.
RP Awasthi, S (reprint author), Univ Oklahoma, Hlth Sci Ctr, Dept Pharmaceut Sci, Coll Pharm, 1110 N Stonewall Ave, Oklahoma City, OK 73117 USA.
EM Shanjana-Awasthi@ouhsc.edu
FU OHRS award [HR07-119]; Oklahoma Center for the Advancement of Science
   and Technology
FX This work was supported by an OHRS award (#HR07-119) from the Oklahoma
   Center for the Advancement of Science and Technology.
CR Adam RD, 2009, AM J MED, V122, P770, DOI 10.1016/j.amjmed.2008.12.024
   Awasthi S, 1999, AM J RESP CRIT CARE, V160, P942, DOI 10.1164/ajrccm.160.3.9806061
   Awasthi S, 2005, J IMMUNOL, V175, P3900, DOI 10.4049/jimmunol.175.6.3900
   Awasthi S, 2004, CELL IMMUNOL, V231, P49, DOI 10.1016/j.cellimm.2004.11.006
   Awasthi S, 2003, BIOTECHNIQUES, V35, P600, DOI 10.2144/03353dd03
   Awasthi S, 2001, AM J RESP CRIT CARE, V163, P389, DOI 10.1164/ajrccm.163.2.2004168
   Awasthi S, 2007, ANN NY ACAD SCI, V1111, P269, DOI 10.1196/annals.1406.013
   Awasthi S, 2006, CELL IMMUNOL, V240, P31, DOI 10.1016/j.cellimm.2006.06.001
   Awasthi Shanjana, 2017, Methods Mol Biol, V1625, P75, DOI 10.1007/978-1-4939-7104-6_6
   Awasthi S, 2010, MED MYCOL, V48, P470, DOI 10.3109/13693780903226019
   Cox RA, 2004, CLIN MICROBIOL REV, V17, P804, DOI 10.1128/CMR.17.4.804-839.2004
   DeBacker D, 1997, AM J RESP CRIT CARE, V156, P1099, DOI 10.1164/ajrccm.156.4.9701048
   Duplessis CA, 2011, J INFECTION, V63, P223, DOI 10.1016/j.jinf.2011.07.006
   Fierer J, 2006, J INFECT DIS, V193, P1323, DOI 10.1086/502972
   Freedman M, 2018, EMERG INFECT DIS, V24, P417, DOI 10.3201/eid2403.170623
   Galgiani JN, 2016, CLIN INFECT DIS, V63, pE112, DOI 10.1093/cid/ciw360
   Hung CY, 2011, INFECT IMMUN, V79, P4511, DOI 10.1128/IAI.05726-11
   Jiang CY, 1999, INFECT IMMUN, V67, P5848, DOI 10.1128/IAI.67.11.5848-5853.1999
   Jimenez-A MD, 2008, GENES IMMUN, V9, P338, DOI 10.1038/gene.2008.23
   Kirkland TN, 2016, J FUNGI, V2, DOI 10.3390/jof2040034
   KIRKLAND TN, 1983, INFECT IMMUN, V40, P912, DOI 10.1128/IAI.40.3.912-916.1983
   Kuberski TT, 2004, CLIN INFECT DIS, V38, P910, DOI 10.1086/382075
   Lutz MB, 1999, J IMMUNOL METHODS, V223, P77, DOI 10.1016/S0022-1759(98)00204-X
   Magee DM, 2005, INFECT IMMUN, V73, P7011, DOI 10.1128/IAI.73.10.7011-7013.2005
   Metkar S, 2007, INFECT IMMUN, V75, P5415, DOI 10.1128/IAI.00601-07
   Odio CD, 2017, EMERG INFECT DIS, V23, P308, DOI 10.3201/eid2302.160505
   Richards JO, 2002, J IMMUNOL, V169, P2020, DOI 10.4049/jimmunol.169.4.2020
   Richards JO, 2001, J INFECT DIS, V184, P1220, DOI 10.1086/323664
   Sheikh NA, 2013, CANCER IMMUNOL IMMUN, V62, P137, DOI 10.1007/s00262-012-1317-2
   Thompson GR, 2011, SEMIN RESP CRIT CARE, V32, P754, DOI 10.1055/s-0031-1295723
   Vilekar P, 2010, BMC IMMUNOL, V11, DOI 10.1186/1471-2172-11-60
   Vinh DC, 2011, MEDICINE, V90, P87, DOI 10.1097/MD.0b013e3182073ae3
NR 32
TC 2
Z9 2
U1 1
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 14
PY 2019
VL 37
IS 12
BP 1685
EP 1691
DI 10.1016/j.vaccine.2019.01.034
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HQ0UD
UT WOS:000462109600019
PM 30795939
DA 2020-05-12
ER

PT J
AU Scholz, S
   Koerber, F
   Meszaros, K
   Fassbender, RM
   Ultsch, B
   Welte, RR
   Greiner, W
AF Scholz, Stefan
   Koerber, Florian
   Meszaros, Kinga
   Fassbender, Rosa Maya
   Ultsch, Bernhard
   Welte, Robert R.
   Greiner, Wolfgang
TI The cost-of-illness for invasive meningococcal disease caused by
   serogroup B Neisseria meningitidis (MenB) in Germany
SO VACCINE
LA English
DT Article
DE Cost-of-illness; Neisseria meningitidis; Men B; Germany
ID ROTAVIRUS VACCINATION; IMPACT
AB Introduction: Invasive meningococcal disease (IMD) is a severe disease mainly affecting infants and young children. The most common serogroup causing IMD in Germany is the serogroup type B Neisseria meningitidis (MenB). The aim of the present study is to estimate the economic burden of MenB-related IMD in Germany.
   Method: A bottom-up, model-based costing approach has been used to calculate the diagnose- and age-specific yearly lifetime costs of a hypothetical cohort of MenB-related IMD cases. Direct costs contain the treatment cost for the acute phase of the disease, long-term sequelae, costs for rehabilitation, and public health response. Indirect costs are calculated for the human-capital approach and the friction-cost approach considering productivity losses of patients or parents for the acute phase and long-term sequelae. Publicly available databases from the Federal Statistical Office, the SOEP panel data set, literature, and expert opinion were used as data sources. All future costs beyond the reference year of 2015 were discounted at 3%.
   Results: The total costs for the hypothetical cohort (343 patients) from a societal perspective are (sic)19.6 million ((sic)57,100/IMD case) using the friction-cost approach and (sic)58.8 million ((sic)171,000/IMD case) using the human-capital approach. Direct costs amount to (sic)18.6 million or (sic)54,300 (sic)/case. Sequelae are responsible for 81% of the direct costs/case.
   Discussion: The elevated costs/MenB-related IMD case reflect the severity of the disease. The total costs are sensitive to the productivity-loss estimation approach applied. MenB is an uncommon but severe disease; The costs/case reflect the severity of the disease and is within the same magnitude as for human papilloma virus infections. The available literature on sequelae is due to the uncommonness limited and heterogeneous. (C) 2019 GlaxoSmithKline Biologicals SA. Published by Elsevier Ltd.
C1 [Scholz, Stefan; Greiner, Wolfgang] Bielefeld Univ, Univ Str 25, D-33615 Bielefeld, Germany.
   [Koerber, Florian; Fassbender, Rosa Maya; Ultsch, Bernhard; Welte, Robert R.] GSK, Prinzregentenpl 9, D-81675 Munich, Germany.
   [Koerber, Florian] German Res Ctr Environm Hlth GmbH, Helmholtz Ctr Munich, Ingolstadter Landstr 1, D-85764 Neuherberg, Germany.
   [Meszaros, Kinga] GSK, Ave Fleming 20, B-1300 Wavre, Belgium.
RP Scholz, S (reprint author), Univ Bielefeld, Fac Publ Hlth, Dept Hlth Econ & Management, Univ Str 25, D-33615 Bielefeld, Germany.
EM stefan.scholz@uni-bielefeld.de; flokoe1@gmx.de;
   kinga.h.meszaros@gsk.com; rosa-maya.m.fassbender@gsk.com;
   bernhard.a.ultsch@gsk.com; robert.r.welte@gsk.com;
   wolfgang.greiner@uni-bielefeld.de
RI Scholz, Stefan/W-9109-2019
OI Scholz, Stefan/0000-0002-8421-8829
FU GlaxoSmithKline Biologicals SAGlaxoSmithKline [HO-16-17944]
FX GlaxoSmithKline Biologicals SA funded this study (GSK study identifier:
   HO-16-17944) and all costs related to the development of the
   publications.
CR Aidelsburger P, 2014, VACCINE, V32, P1964, DOI 10.1016/j.vaccine.2014.01.061
   Akobundu E, 2006, PHARMACOECONOMICS, V24, P869, DOI 10.2165/00019053-200624090-00005
   Antonova EN, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-968
   Banz K, 2003, VACCINE, V21, P1256, DOI 10.1016/S0264-410X(02)00431-0
   Beck E, 2017, 2017 MRF INT C
   Bock JO, 2015, GESUNDHEITSWESEN, V77, P53, DOI 10.1055/s-0034-1374621
   Bundesagentur fiir Arbeit [Federal Labour Office], 2016, ARB 2015 ARB DEUTSCH, P63
   Bundesministerium fur Gesundheit [Federal Ministry of Health], 2017, PFLEG LEIST NACHSCHL
   Christensen H, 2016, VACCINE, V34, P3412, DOI 10.1016/j.vaccine.2016.04.004
   Dams J, 2017, J AFFECT DISORDERS, V213, P23, DOI 10.1016/j.jad.2017.01.041
   Edmond K, 2010, LANCET INFECT DIS, V10, P317, DOI 10.1016/S1473-3099(10)70048-7
   Ehlken B, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-1885-0
   European Centre for Disease Prevention and Control, 2016, ANN EP REP 2016 INV
   Gasparini R, 2016, HUM VACC IMMUNOTHER, V12, P2148, DOI 10.1080/21645515.2016.1160177
   Giaquinto C, 2007, J INFECT DIS, V195, pS36, DOI 10.1086/516716
   Gottfredsson M, 2011, CLIN INFECT DIS, V53, pE117, DOI 10.1093/cid/cir500
   Hamer HM, 2006, EPILEPSIA, V47, P2165, DOI 10.1111/j.1528-1167.2006.00889.x
   Institute for Quality and Efficiency in Health Care, ALLG METH ENTW VERS
   Jasjeet S. S., 2011, J STAT SOFTW, V42, P1
   Karmann A, 2015, EUR J HEALTH ECON, V16, P719, DOI 10.1007/s10198-014-0624-2
   Kigozi J, 2016, EUR J HEALTH ECON, V17, P31, DOI 10.1007/s10198-014-0652-y
   Kleine-Budde K, 2013, J AFFECT DISORDERS, V147, P137, DOI 10.1016/j.jad.2012.10.024
   Krauth C, 2014, DEPRESS RES TREAT, V2014
   Lundh A, 2008, BMC MED RES METHODOL, V8, DOI 10.1186/1471-2288-8-22
   Murajda L, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-1693-6
   Porz G, 2010, OPHTHALMOLOGE, V107, P216, DOI 10.1007/s00347-009-2036-8
   R Core Team, 2018, R LANG ENV STAT COMP
   Richter T, 2015, VALUE HEALTH, V18, P906, DOI 10.1016/j.jval.2015.05.008
   Robert Koch Institute, 2016, INV MEN DIS CAS 2012
   Robert Koch Institute, 2018, EP B
   Schulze-Gattermann H, 2002, OTOL NEUROTOL, V23, P674, DOI 10.1097/00129492-200209000-00013
   Schupp J, 2009, Z SOZIOL, V38, P350
   Spitzenverband Bund der Krankenkassen [Central Federal Association of Health Insurance Funds], 2009, VER BES MASSN VERB S
   Standing Comittee on Vaccinations (STIKO), 2016, METH DURCHF BER MOD
   Statistical Office Federal, 2017, WIRTSCH LAUF WIRTSCH
   Statistisches Bundesamt [Federal Statistical Office], 2018, HARM VERBR
   Statistisches Bundesamt [Federal Statistical Office], 2017, KRANK DIAGN PAT PAT
   Statistisches Bundesamt [Federal Statistical Office], 2017, TOD
   Statistisches Bundesamt (Federal Statistical Office], 2017, STERB DEUTSCHL JAHR
   Statistisches Bundesamt [Federal Statistical Office], 2017, STAT GEB
   Viner RM, 2012, LANCET NEUROL, V11, P774, DOI 10.1016/S1474-4422(12)70180-1
   Wang B, 2018, PHARMACOECONOMICS, V36, P1201, DOI 10.1007/s40273-018-0679-5
   Wright C, 2013, PEDIATR DRUGS, V15, P49, DOI 10.1007/s40272-012-0006-0
   Zeidler J, 2016, BUNDESGESUNDHEITSBLA, V59, P687, DOI 10.1007/s00103-016-2327-6
   Zeidler J, 2013, BUNDESGESUNDHEITSBLA, V56, P430, DOI 10.1007/s00103-012-1624-y
NR 45
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 14
PY 2019
VL 37
IS 12
BP 1692
EP 1701
DI 10.1016/j.vaccine.2019.01.013
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HQ0UD
UT WOS:000462109600020
PM 30661834
OA Other Gold
DA 2020-05-12
ER

PT J
AU Kim, T
   Hong, JK
   Oem, JK
   Lee, KN
   Lee, HS
   Kim, YJ
   Ryoo, S
   Ko, YJ
   Park, JH
   Choi, J
   Lee, SH
   Jo, HJ
   Lee, MH
   Kim, B
   Kim, J
AF Kim, Taeseong
   Hong, Jang-Kwan
   Oem, Jae-Ku
   Lee, Kwang-Nyeong
   Lee, Hyang-Sim
   Kim, Yong Joo
   Ryoo, Soyoon
   Ko, Young-Joon
   Park, Jong-Hyeon
   Choi, Jida
   Lee, Seung Heon
   Jo, Hye Jun
   Lee, Myoung-Heon
   Kim, Byounghan
   Kim, Jaejo
TI Cross-protective efficacy of the O1 Manisa + O 3039 bivalent vaccine and
   the O 3039 monovalent vaccine against heterologous challenge with FMDV
   O/Jincheon/SKR/2014 in pig
SO VACCINE
LA English
DT Article
ID MOUTH-DISEASE-VIRUS; BETWEEN-PEN TRANSMISSION; VACCINE; PIGS; KOREA;
   EPIDEMIC
AB After massive foot-and-mouth disease (FMD) outbreaks originated from Jincheon County from Dec. 2014 to Apr. 2015, the effectiveness of the previous FMD vaccine containing only the O1 Manisa as the O antigen, O1 Manisa + A Malaysia 97 + Asia 1 Sharmir trivalent vaccine, was questioned in South Korea, and a change in the O antigen in FMD vaccines was demanded to control the FMD caused by FMDV O/Jincheon/ SKR/2014, the O Jincheon strain. Therefore, the efficacies of O1 Manisa + O 3039 bivalent vaccine and O 3039 monovalent vaccine were studied for cross-protection against heterologous challenge with the O Jincheon strain. In this study, the efficacy of the O1 Manisa + O 3039 bivalent vaccine was better than that of the O 3039 monovalent vaccine, even though the serological relationship (r(1) value) between O Jincheon and O 3039 was matched according to the OIE Terrestrial Manual. According to serological test results from vaccinated specific pathogen free pigs, virus neutralization test titers against Jincheon were good estimates for predicting protection against challenge. A field trial of the O1 Manisa + O 3039 bivalent vaccine was performed to estimate the possibility of field application in conventional pig farms, especially due to concerns about the effect of maternally derived antibodies (MDA) in field application of the FMD vaccine. According to the result of the field trial, the O1 Manisa + O 3039 bivalent vaccine was considered to overcome MDA. The results of the efficacy and field trials indicated that the O1 Manisa + O3039 vaccine could be suitable to replace previous FMD vaccines to control the FMD field situation caused by O Jincheon FMDV. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Kim, Taeseong; Lee, Kwang-Nyeong; Lee, Hyang-Sim; Kim, Yong Joo; Ryoo, Soyoon; Ko, Young-Joon; Park, Jong-Hyeon; Choi, Jida; Lee, Seung Heon; Jo, Hye Jun; Lee, Myoung-Heon; Kim, Byounghan; Kim, Jaejo] Anim & Plant Quarantine Agcy, 177,Hyeoksin 8 Ro, Gimcheon City 39660, Gyeongsangbuk D, South Korea.
   [Hong, Jang-Kwan] Daesung Microbiol Lab, 103 Deogyeong Daero, Uiwang City 16103, Gyeonggi Do, South Korea.
   [Oem, Jae-Ku] Chonbuk Natl Univ, Korean Zoonosis Res Inst, 820-120 Hana Ro, Iksan 54531, Jeollabuk Do, South Korea.
RP Kim, J (reprint author), Anim & Plant Quarantine Agcy, 177,Hyeoksin 8 Ro, Gimcheon City 39660, Gyeongsangbuk D, South Korea.
EM jkim1209@korea.kr
OI Park, Jong-Hyeon/0000-0003-0825-8121
FU Animal and Plant Quarantine Agency, Gimcheon, Gyeongsangbuk, Republic of
   Korea
FX Supported by the Animal and Plant Quarantine Agency, Gimcheon,
   Gyeongsangbuk, Republic of Korea.
CR Alves MP, 2009, CLIN VACCINE IMMUNOL, V16, P1151, DOI 10.1128/CVI.00018-09
   Baldridge MT, 2017, J VIROL, V91, DOI 10.1128/JVI.02079-16
   Brito BP, 2017, TRANSBOUND EMERG DIS, V64, P316, DOI 10.1111/tbed.12373
   Eble P, 2006, VET RES, V37, P647, DOI 10.1051/vetres:2006026
   Eble PL, 2004, VACCINE, V22, P1372, DOI 10.1016/j.vaccine.2003.11.003
   FRANCIS MJ, 1986, RES VET SCI, V41, P33, DOI 10.1016/S0034-5288(18)30568-X
   Jamal SM, 2018, INFECT GENET EVOL, V59, P84, DOI 10.1016/j.meegid.2018.01.020
   Liao PC, 2003, VACCINE, V21, P1807, DOI 10.1016/S0264-410X(03)00030-6
   Mattion N, 2009, VACCINE, V27, P741, DOI 10.1016/j.vaccine.2008.11.026
   OIE, 2017, OIE TERR MAN FOOT MO
   Orsel K, 2007, VACCINE, V25, P6381, DOI 10.1016/j.vaccine.2007.06.010
   Park JH, 2013, TRANSBOUND EMERG DIS, V60, P188, DOI 10.1111/j.1865-1682.2012.01333.x
   Park JN, 2014, VACCINE, V32, P1882, DOI 10.1016/j.vaccine.2014.01.067
   Park JH, 2018, J VET SCI, V19, P271, DOI 10.4142/jvs.2018.19.2.271
   Park JH, 2016, CLIN EXP VACCINE RES, V5, P83, DOI 10.7774/cevr.2016.5.1.83
   Park JH, 2014, EMERG INFECT DIS, V20, P2158, DOI 10.3201/eid2012.130518
   Park JH, 2013, EMERG INFECT DIS, V19, P655, DOI 10.3201/eid1904.121320
   Rweyemamu M, 2008, TRANSBOUND EMERG DIS, V55, P57, DOI 10.1111/j.1865-1682.2007.01013.x
   Sangula AK, 2011, EPIDEMIOL INFECT, V139, P189, DOI 10.1017/S0950268810000580
   Sucafusco D, 2014, VACCINE, V32, P6576, DOI 10.1016/j.vaccine.2014.06.056
   van Roermund HJW, 2010, VACCINE, V28, P4452, DOI 10.1016/j.vaccine.2010.04.019
NR 21
TC 3
Z9 3
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 14
PY 2019
VL 37
IS 12
BP 1702
EP 1709
DI 10.1016/j.vaccine.2018.11.080
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HQ0UD
UT WOS:000462109600021
PM 30712811
DA 2020-05-12
ER

PT J
AU Vesikari, T
   Ostergaard, L
   Beeslaar, J
   Absalon, J
   Eiden, JJ
   Jansen, KU
   Jones, TR
   Harris, SL
   Maansson, R
   Munson, S
   O'Neill, RE
   York, LJ
   Perez, JL
AF Vesikari, Timo
   Ostergaard, Lars
   Beeslaar, Johannes
   Absalon, Judith
   Eiden, Joseph J.
   Jansen, Kathrin U.
   Jones, Thomas R.
   Harris, Shannon L.
   Maansson, Roger
   Munson, Samantha
   O'Neill, Robert E.
   York, Laura J.
   Perez, John L.
TI Persistence and 4-year boosting of the bactericidal response elicited by
   two- and three-dose schedules of MenB-FHbp: A phase 3 extension I Cheek
   for updates study in adolescents
SO VACCINE
LA English
DT Article
DE Meningococcal disease; Vaccine; Persistence; Booster; Adolescents;
   Serogroup B
ID MENINGOCOCCAL DISEASE RECOMMENDATIONS; SEROGROUP-B VACCINE; CONJUGATE
   VACCINE; BIVALENT RLP2086; IMMUNIZATION PRACTICES; ANTIBODY PERSISTENCE;
   ADVISORY-COMMITTEE; ACELLULAR PERTUSSIS; IMMUNOGENICITY; TOLERABILITY
AB Background: The period of heightened risk of invasive meningococcal disease in adolescence extends for >10 years. This study aimed to evaluate persistence of the immune response to the serogroup B meningococcal (MenB) vaccine MenB-FHbp (Trumenba (R), Bivalent rLP2086) under two- and three-dose primary vaccination schedules, both of which are approved in the United States and the European Union, and to assess safety and immunogenicity of a booster dose.
   Methods: This was an open-label extension study of a phase 2 randomized MenB-FHbp study (primary study). This interim analysis includes data through 1 month after booster vaccination. In the primary study, adolescents 11-18 years of age were randomized using an interactive voice or web-based response system to receive 120 mu g MenB-FHbp under 0-, 1-, 6-month; 0-, 2-, 6-month; 0-, 6-month; 0-, 2-month; or 0-, 4-month schedules (termed study groups for the current analysis). For the primary study, participants were blinded to their vaccine study group allocation, but investigators and the study sponsor were unblinded. Immune responses in subjects from the primary study were evaluated through 48 months after primary vaccination (persistence stage; 17 sites in Czech Republic, Denmark, Germany, and Sweden). Safety and immunogenicity of a booster dose given at 48 months after primary vaccination (booster stage; 14 sites in Czech Republic, Denmark, and Sweden) were also assessed. Immune responses were evaluated in serum bactericidal assays with human complement (hSBAs) using four MenB test strains representative of disease-causing MenB strains in the United States and Europe and expressing factor H binding proteins (FHbps) heterologous to the vaccine antigens. The primary immunogenicity endpoints were the proportions of subjects with hSBA titers greater than or equal to the assays' lower limit of quantitation (LLOQ: 1:8 or 1:16 depending on strain) at 12, 18, 24, 36, and 48 months after primary vaccination (persistence stage) and 1 and 48 months after the primary vaccination series and 1 month after receipt of the booster dose (booster stage). Safety evaluations during the booster stage included local reactions and systemic events by severity, antipyretic use, adverse events (AEs), immediate AEs, serious AEs (SAES), medically attended AEs (MAEs), newly diagnosed chronic medical conditions (NDCMCs), and missed days of school and work because of AEs. The modified intent-to-treat (mITT) population was used for immunogenicity evaluations in the persistence stage. The booster stage immunogenicity evaluations used the evaluable immunogenicity population; analyses were also performed in the mITT population. For the persistence stage, safety evaluations included subjects with at least one blood draw, whereas for the booster stage, they included subjects who received the booster dose and had available safety data. This trial is registered at ClinicalTrials.gov number NCT01543087.
   Findings: A total of 465 subjects were enrolled in the persistence stage, and 271 subjects were enrolled in the booster stage. Sera for the extension phase of this interim analysis were collected from September 7,2012 to December 7, 2015. One month after primary vaccination, 73.8-100.0% of subjects depending on study group responded with hSBA titers >= LLOQ Response rates declined during the 12 months after last primary vaccination and then remained stable through 48 months, with 18.0-61.3% of subjects depending on study group having hSBA titers >= LLOQ at this time point. One month after receipt of the booster dose, 91.9-100.0% of subjects depending on study group had hSBA titers >= LLOQ against the four primary strains individually and 91.8-98.2% had hSBA titers >= LLOQ against all four strains combined (composite response). Geometric mean titers were higher after booster vaccination than at 1 month after primary vaccination. Immune responses were generally similar across study groups, regardless of whether a two- or three-dose primary series was received. None of the AEs (2.2-6.9% of subjects depending on study group) or NDCMCs (1.8-5.0%) that were reported during the persistence stage were considered related to the investigational product. Local reactions and systemic events were reported by 84.4-93.8% and 68.876.6% of subjects depending on study group, respectively, in the booster stage; these were generally similar across study groups, transient, and less frequent than after any primary vaccination. Additionally, there was no general progressive worsening in severity of reactogenicity events (ie, potentiation; <= 3 subjects per group), and reactogenicity events did not lead to any study withdrawals. No NDCMCs or immediate AEs were reported during the booster stage. AEs were reported by 3.7-12.5% of subjects depending on study group during the booster stage. The two possibly related AEs included a mild worsening of psoriasis and a severe influenza-like illness that resolved in 10 days.
   Interpretation: Immune responses declined after the primary vaccination series; however, a substantially greater number of subjects retained protective responses at 48 months after primary vaccination compared with subjects having protective responses before vaccination. Persistence trends were similar across all 5 study groups regardless of whether a two- or three-dose primary schedule was received. Furthermore, a booster dose given 48 months after primary vaccination was safe, well-tolerated, and elicited robust immune responses indicative of immunologic memory; these responses were similar between two- and three-dose primary schedule study groups. Use of a booster dose may help further extend protection against MenB disease in adolescents. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Vesikari, Timo] Univ Tampere, Vaccine Res Ctr, Med Sch, Biokatu 10, Tampere 33520, Finland.
   [Ostergaard, Lars] Aarhus Univ Hosp, Dept Infect Dis, Palle Juul Jensens Blvd 99, DK-8200 Aarhus N, Denmark.
   [Beeslaar, Johannes] Pfizer UK Vaccine Res & Dev, Horizon Bldg,Honey Lane, Hurley SL6 6RJ, England.
   [Absalon, Judith; Eiden, Joseph J.; Jansen, Kathrin U.; Jones, Thomas R.; Harris, Shannon L.; O'Neill, Robert E.] Pfizer Vaccine Res & Dev, 401 North Middletown Rd, Pearl River, NY 10965 USA.
   [Maansson, Roger; Munson, Samantha; Perez, John L.] Pfizer Vaccine Res & Dev, 500 Arcola Rd, Collegeville, PA 19426 USA.
   [York, Laura J.] Pfizer Vaccine Med Dev Sci & Clin Affairs, 500 Arcola Rd, Collegeville, PA 19426 USA.
RP Beeslaar, J (reprint author), Pfizer UK Vaccine Res & Dev, Horizon Bldg,Honey Lane, Hurley SL6 6RJ, England.
EM Johannes.Beeslaar@pfizer.com
RI Ostergaard, Lars/AAA-3020-2020
OI Ostergaard, Lars/0000-0003-2459-0511; Ostergaard,
   Lars/0000-0002-7619-605X
FU Pfizer Inc.Pfizer
FX This study was funded by Pfizer Inc.
CR Anonymous, 2011, Morbidity and Mortality Weekly Report, V60, P72
   Baxter R, 2015, PEDIATR INFECT DIS J, V34, P1236, DOI 10.1097/INF.0000000000000866
   Baxter R, 2014, PEDIATR INFECT DIS J, V33, P1169, DOI 10.1097/INF.0000000000000438
   Baxter R, 2011, PEDIATR INFECT DIS J, V30, pE41, DOI 10.1097/INF.0b013e3182054ab9
   Borrow R, 2005, VACCINE, V23, P2222, DOI 10.1016/j.vaccine.2005.01.051
   Bruge J, 2004, VACCINE, V22, P1087, DOI 10.1016/j.vaccine.2003.10.005
   Christensen H, 2010, LANCET INFECT DIS, V10, P853, DOI 10.1016/S1473-3099(10)70251-6
   Cohn AC, 2017, PEDIATRICS, V139, DOI 10.1542/peds.2016-2193
   Cohn AC, 2013, MMWR RECOMM REP, V62, P1
   European Centre for Disease Prevention and Control, ANN EP REP 2016 INV
   European Medicines Agency, EPAR SUMM PUBL TRUM
   FINNE J, 1983, LANCET, V2, P355
   Folaranmi T, 2015, MMWR-MORBID MORTAL W, V64, P608
   Frasch CE, 2009, VACCINE, V27, pB112, DOI 10.1016/j.vaccine.2009.04.065
   GOLDSCHNEIDER I, 1969, J EXP MED, V129, P1307, DOI 10.1084/jem.129.6.1307
   Holst J, 2013, HUM VACC IMMUNOTHER, V9, P1241, DOI 10.4161/hv.24129
   Jackson LA, 2009, PEDIATR INFECT DIS J, V28, P86, DOI 10.1097/INF.0b013e31818a0237
   Jacobson RM, 2013, PEDIATR INFECT DIS J, V32, pE170, DOI 10.1097/INF.0b013e318279ac38
   Jafri RZ, 2013, POPUL HEALTH METR, V11, DOI 10.1186/1478-7954-11-17
   Marshall HS, 2017, LANCET INFECT DIS, V17, P58, DOI 10.1016/S1473-3099(16)30314-0
   McQuaid F, 2014, PEDIATR INFECT DIS J, V33, P760, DOI 10.1097/INF.0000000000000327
   Muse D, 2016, PEDIATR INFECT DIS J, V35, P673, DOI 10.1097/INF.0000000000001124
   Ostergaard L, 2017, NEW ENGL J MED, V377, P2349, DOI 10.1056/NEJMoa1614474
   Patton ME, 2017, MMWR-MORBID MORTAL W, V66, P509, DOI 10.15585/mmwr.mm6619a6
   Sadarangani M, 2017, CAN MED ASSOC J, V189, pE1276, DOI 10.1503/cmaj.161288
   Senders S, 2016, PEDIATR INFECT DIS J, V35, P548, DOI 10.1097/INF.0000000000001072
   Sridhar S, 2015, LANCET INFECT DIS, V15, P1334, DOI 10.1016/S1473-3099(15)00217-0
   Stein-Zamir C, 2014, PEDIATR INFECT DIS J, V33, P777, DOI 10.1097/INF.0000000000000282
   Vesikari T, 2016, J PEDIAT INF DIS SOC, V5, P180, DOI 10.1093/jpids/piv064
   Vesikari T, 2016, J PEDIAT INF DIS SOC, V5, P152, DOI 10.1093/jpids/piv039
   Zlotnick GW, 2015, HUM VACC IMMUNOTHER, V11, P5, DOI 10.4161/hv.34293
NR 31
TC 3
Z9 3
U1 0
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 14
PY 2019
VL 37
IS 12
BP 1710
EP 1719
DI 10.1016/j.vaccine.2018.11.073
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HQ0UD
UT WOS:000462109600022
PM 30770221
DA 2020-05-12
ER

PT J
AU Fu, LL
   Zhao, XY
   Ji, LD
   Xu, J
AF Fu, Ling-ling
   Zhao, Xiao-yu
   Ji, Lin-dan
   Xu, Jin
TI Okadaic acid (OA): Toxicity, detection and detoxification
SO TOXICON
LA English
DT Review
DE Okadaic acid; Diarrhetic shellfish poisoning; Protein phosphatase;
   Detection; Detoxification
ID PHOSPHATASE INHIBITION ASSAY; SHELLFISH POISONING TOXINS;
   LINKED-IMMUNOSORBENT-ASSAY; IN-VITRO BIOACCESSIBILITY;
   PROROCENTRUM-LIMA; BLACK SPONGE; PROTEIN PHOSPHATASES; CYTOTOXICITY
   ASSAY; OXIDATIVE STRESS; SMOOTH-MUSCLE
AB Okadaic acid (OA), a potent polyether marine toxin, accumulates in the digestive glands of marine mollusks and therefore can severely threaten the health of humans after ingestion of contaminated shellfish. In vivo and in vitro studies have revealed that exposure of various cells, including human embryonic amniotic cells, hepatocytes, neuroblastoma cells, to OA induces morphological and functional modifications as well as the death of cells. As the number of reports on OA poisoning has increased, this toxin has gradually attracted the public's attention, and researchers are trying to study it. This review summarizes the current literature on the toxicity effects of OA, in addition to its detection and detoxification.
C1 [Fu, Ling-ling; Zhao, Xiao-yu; Xu, Jin] Ningbo Univ, Sch Med, Dept Prevent Med, Ningbo, Zhejiang, Peoples R China.
   [Ji, Lin-dan] Ningbo Univ, Sch Med, Dept Biochem, Ningbo, Zhejiang, Peoples R China.
   [Ji, Lin-dan; Xu, Jin] Ningbo Univ, Sch Med, Zhejiang Prov Key Lab Pathophysiol, Ningbo, Zhejiang, Peoples R China.
RP Xu, J (reprint author), Ningbo Univ, Sch Med, Dept Prevent Med, Ningbo, Zhejiang, Peoples R China.
EM xujin1@nbu.edu.cn
FU Applied Research Project on Nonprofit Technology of Zhejiang Province
   [2017C33151]; Natural Science Foundation of Ningbo [2015A610275]; K.C.
   Wong Magna Fund in Ningbo University
FX This work was supported by the Applied Research Project on Nonprofit
   Technology of Zhejiang Province (No. 2017C33151), the Natural Science
   Foundation of Ningbo (No. 2015A610275), and the K.C. Wong Magna Fund in
   Ningbo University.
CR Bacchiocchi S, 2015, TOXICON, V108, P115, DOI 10.1016/j.toxicon.2015.10.002
   Baker S, 2016, ACTA NEUROPATHOL COM, V4, DOI 10.1186/s40478-016-0300-0
   BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283
   Botelho MJ, 2018, CHEMOSPHERE, V190, P166, DOI 10.1016/j.chemosphere.2017.09.100
   Bouaicha N, 1997, TOXICON, V35, P273, DOI 10.1016/S0041-0101(96)00069-4
   Braga AC, 2016, FOOD CHEM TOXICOL, V89, P54, DOI 10.1016/j.fct.2016.01.008
   Cabado AG, 2004, ARCH TOXICOL, V78, P74, DOI 10.1007/s00204-003-0505-4
   Cakir M, 2017, LIFE SCI, V176, P10, DOI 10.1016/j.lfs.2017.03.022
   Chen L, 2011, TOXICOL IN VITRO, V25, P1796, DOI 10.1016/j.tiv.2011.09.014
   Chen X, 2018, TOXICOL LETT, V284, P96, DOI 10.1016/j.toxlet.2017.12.003
   Chi C, 2017, FISH SHELLFISH IMMUN, V65, P111, DOI 10.1016/j.fsi.2017.03.031
   Christian B, 2008, ANAL BIOANAL CHEM, V391, P117, DOI 10.1007/s00216-007-1778-x
   Ciminiello P, 2006, TOXICON, V47, P174, DOI 10.1016/j.toxicon.2005.10.012
   Danielsen EM, 2014, TOXICON, V88, P77, DOI 10.1016/j.toxicon.2014.06.011
   del Campo M, 2017, TOXICON, V126, P23, DOI 10.1016/j.toxicon.2016.12.005
   Della Loggia R, 1999, NAT TOXINS, V7, P387, DOI 10.1002/1522-7189(199911/12)7:6<387::AID-NT87>3.0.CO;2-N
   Espina B, 2010, BRIT J PHARMACOL, V159, P337, DOI 10.1111/j.1476-5381.2009.00512.x
   Ferron PJ, 2016, TOXICOL IN VITRO, V33, P136, DOI 10.1016/j.tiv.2016.02.021
   Fieber LA, 2012, TOXICOL ENVIRON CHEM, V94, P1805, DOI 10.1080/02772248.2012.730199
   Flanagan AF, 2001, TOXICON, V39, P1021, DOI 10.1016/S0041-0101(00)00241-5
   Franchini A, 2005, EUR J HISTOCHEM, V49, P179
   Fuster-Matanzo A, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19030645
   Garcia C, 2016, FOOD ADDIT CONTAM A, V33, P1711, DOI 10.1080/19440049.2016.1239032
   Harteneck C, 2007, CARDIOVASC DRUG REV, V25, P61, DOI 10.1111/j.1527-3466.2007.00005.x
   Hayat A, 2012, ANAL CHIM ACTA, V724, P92, DOI 10.1016/j.aca.2012.02.035
   Heredia-Tapia A, 2002, TOXICON, V40, P1121, DOI 10.1016/S0041-0101(02)00111-3
   Huang HY, 2013, ENVIRON TOXICOL, V28, P98, DOI 10.1002/tox.20702
   Huynh-Dellerme C, 2003, ENVIRON TOXICOL, V18, P383, DOI 10.1002/tox.10140
   Ikema S, 2015, FOOD CHEM TOXICOL, V83, P229, DOI 10.1016/j.fct.2015.06.006
   Jayaraj R, 2009, TOXICOLOGY, V256, P118, DOI 10.1016/j.tox.2008.11.013
   Jiao YH, 2017, TOXICON, V133, P74, DOI 10.1016/j.toxicon.2017.05.003
   Kamat PK, 2011, PHARMACOL BIOCHEM BE, V100, P311, DOI 10.1016/j.pbb.2011.08.019
   Kamat PK, 2014, MOL NEUROBIOL, V50, P852, DOI 10.1007/s12035-014-8699-4
   Kamat PK, 2013, NEUROTOXICOLOGY, V37, P163, DOI 10.1016/j.neuro.2013.05.002
   KODAMA I, 1986, J PHYSIOL-LONDON, V378, P359, DOI 10.1113/jphysiol.1986.sp016224
   Kolrep F, 2017, TOXICOL IN VITRO, V42, P161, DOI 10.1016/j.tiv.2017.04.009
   Lago J, 2005, TOXICON, V46, P579, DOI 10.1016/j.toxicon.2005.07.007
   Le Berre M, 2015, TOXICON, V103, P169, DOI 10.1016/j.toxicon.2015.06.030
   Le Du J, 2017, AQUAT TOXICOL, V190, P210, DOI 10.1016/j.aquatox.2017.07.012
   Le Hegarat L, 2006, ENVIRON TOXICOL, V21, P55, DOI 10.1002/tox.20154
   Leira F, 2001, TOXICOL IN VITRO, V15, P277, DOI 10.1016/S0887-2333(01)00021-2
   Leonardo S, 2018, MAR ENVIRON RES, V133, P6, DOI 10.1016/j.marenvres.2017.11.004
   Li X, 2014, CHEMOSPHERE, V111, P560, DOI 10.1016/j.chemosphere.2014.05.006
   Louppis AP, 2010, TOXICON, V55, P724, DOI 10.1016/j.toxicon.2009.10.026
   Manita D, 2017, FOOD CHEM TOXICOL, V101, P121, DOI 10.1016/j.fct.2017.01.008
   Matias WG, 1996, J TOXICOL ENV HEALTH, V48, P309, DOI 10.1080/009841096161357
   MAURER HH, 1990, INT J LEGAL MED, V104, P43, DOI 10.1007/BF01816483
   McNamee SE, 2016, HARMFUL ALGAE, V55, P112, DOI 10.1016/j.hal.2016.02.008
   McPartlin DA, 2016, ESSAYS BIOCHEM, V60, P49, DOI 10.1042/EBC20150006
   Mountfort DO, 1999, TOXICON, V37, P909, DOI 10.1016/S0041-0101(98)00222-0
   Mouratidou T, 2006, SCI TOTAL ENVIRON, V366, P894, DOI 10.1016/j.scitotenv.2005.03.002
   Murray I, 2018, ENVIRON SCI POLLUT R, V25, P607, DOI 10.1007/s11356-017-0472-6
   NAM KY, 1990, CARCINOGENESIS, V11, P1171, DOI 10.1093/carcin/11.7.1171
   Nascimento SM, 2005, TOXICON, V45, P633, DOI 10.1016/j.toxicon.2004.12.023
   Nuydens R, 1998, J NEUROCHEM, V70, P1124
   Oliveira JM, 2017, OMICS, V21, P550, DOI 10.1089/omi.2017.0108
   Olivieri G, 2001, J NEUROCHEM, V76, P224, DOI 10.1046/j.1471-4159.2001.00090.x
   Opsahl JA, 2013, MAR DRUGS, V11, P1763, DOI 10.3390/md11061763
   OZAKI H, 1987, N-S ARCH PHARMACOL, V335, P356
   OZAKI H, 1987, J PHARMACOL EXP THER, V243, P1167
   Pan YX, 2017, BIOMED MICRODEVICES, V19, DOI 10.1007/s10544-017-0162-7
   Petroni D, 2013, ENVIRON TOXICOL, V28, P700, DOI 10.1002/tox.20765
   Pollard T. D, 2018, COLD SPRING HARB PER, V10
   Poole CF, 1998, J CHROMATOGR A, V798, P207, DOI 10.1016/S0021-9673(97)01164-3
   Prego-Faraldo MV, 2013, MAR DRUGS, V11, P2829, DOI 10.3390/md11082829
   Ravindran J, 2011, APOPTOSIS, V16, P145, DOI 10.1007/s10495-010-0554-0
   Rodrigues SM, 2010, J APPL TOXICOL, V30, P699, DOI 10.1002/jat.1546
   Rubiolo JA, 2012, LIFE SCI, V90, P416, DOI 10.1016/j.lfs.2011.12.021
   SCHMITZ FJ, 1981, J AM CHEM SOC, V103, P2467, DOI 10.1021/ja00399a081
   Shen XY, 2018, INT J MOL MED, V41, P1138, DOI 10.3892/ijmm.2017.3281
   SHIBATA S, 1987, BLOOD VESSELS, V24, P104
   SIVONEN K, 1992, CHEM RES TOXICOL, V5, P464, DOI 10.1021/tx00028a003
   Smienk H, 2013, J AOAC INT, V96, P77, DOI 10.5740/jaoacint.11-465
   Solino L, 2015, TOXICOL IN VITRO, V29, P59, DOI 10.1016/j.tiv.2014.09.002
   Solter PF, 2013, HASCHEK AND ROUSSEAUX'S HANDBOOK OF TOXICOLOGIC PATHOLOGY, VOL 1-3, 3RD EDITION, P1155, DOI 10.1016/B978-0-12-415759-0.00038-8
   Souid G, 2018, TOXICON, V144, P55, DOI 10.1016/j.toxicon.2018.02.001
   Stewart LD, 2009, ANAL CHEM, V81, P10208, DOI 10.1021/ac902084a
   Subramanian S, 2017, BIOCHEM BIOPH RES CO, V483, P585, DOI 10.1016/j.bbrc.2016.12.101
   Suzuki H, 2013, TOXINS, V5, P9, DOI 10.3390/toxins5010009
   Suzuki T, 2011, ANAL SCI, V27, P571, DOI 10.2116/analsci.27.571
   TACHIBANA K, 1981, J AM CHEM SOC, V103, P2469, DOI 10.1021/ja00399a082
   TAKAI A, 1992, BIOCHEM J, V284, P539, DOI 10.1042/bj2840539
   Ten-Hage L, 2000, TOXICON, V38, P1043, DOI 10.1016/S0041-0101(99)00216-0
   Thompson EJ, 2002, CANCER RES, V62, P3044
   Tubaro A, 1996, TOXICON, V34, P965, DOI 10.1016/0041-0101(96)00073-6
   Turner AD, 2015, TOXICON, V102, P32, DOI 10.1016/j.toxicon.2015.05.010
   Valdiglesias V, 2013, MAR DRUGS, V11, P4328, DOI 10.3390/md11114328
   Valdiglesias V, 2011, J TOXICOL ENV HEAL A, V74, P980, DOI 10.1080/15287394.2011.582026
   Valdiglesias V, 2011, J ENVIRON MONITOR, V13, P1831, DOI 10.1039/c0em00771d
   Valdiglesias V, 2010, MUTAT RES-FUND MOL M, V689, P74, DOI 10.1016/j.mrfmmm.2010.05.004
   Vdovenko MM, 2013, TALANTA, V116, P343, DOI 10.1016/j.talanta.2013.05.057
   Prego-Faraldo MV, 2016, TOXINS, V8, DOI 10.3390/toxins8060159
   Prego-Faraldo MV, 2015, J TOXICOL ENV HEAL A, V78, P814, DOI 10.1080/15287394.2015.1051173
   Vieites JM, 1996, ARCH TOXICOL, V70, P440, DOI 10.1007/s002040050296
   Vilarino N, 2009, SENSORS-BASEL, V9, P9414, DOI 10.3390/s91109414
   Wang JZ, 2001, FEBS LETT, V507, P81, DOI 10.1016/S0014-5793(01)02944-1
   Wang L, 2011, J AOAC INT, V94, P1531, DOI 10.5740/jaoacint.10-412
   Wang RZ, 2017, J HAZARD MATER, V339, P154, DOI 10.1016/j.jhazmat.2017.06.030
   Wang S, 2015, BIORESOURCE TECHNOL, V179, P243, DOI 10.1016/j.biortech.2014.12.019
   Ward MP, 2017, BRIT J PHARMACOL, V174, P1116, DOI 10.1111/bph.13759
   Wu SJ, 2015, ANAL BIOANAL CHEM, V407, P1303, DOI 10.1007/s00216-014-8378-3
   Wu XL, 2017, EUR J PHARM SCI, V110, P101, DOI 10.1016/j.ejps.2017.03.037
   Xing ML, 2009, ENVIRON TOXICOL, V24, P437, DOI 10.1002/tox.20446
   YASUMOTO T, 1978, B JPN SOC SCI FISH, V44, P1249
   Yasumoto T, 1981, FOOD SANIT RES, V31, P515
   Zhang X, 2016, BIOSENS BIOELECTRON, V77, P573, DOI 10.1016/j.bios.2015.07.062
   Zhao L, 2016, EXP BIOL MED, V241, P1825, DOI 10.1177/1535370216650759
NR 107
TC 2
Z9 2
U1 10
U2 31
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD MAR 15
PY 2019
VL 160
BP 1
EP 7
DI 10.1016/j.toxicon.2018.12.007
PG 7
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA HQ4ZR
UT WOS:000462420300001
PM 30639658
DA 2020-05-12
ER

PT J
AU Costa, AG
   de Carvalho, AU
   Melo, MM
   Soto-Blanco, B
AF Costa, Aristoteles G.
   de Carvalho, Antonio Ultimo
   Melo, Marilia M.
   Soto-Blanco, Benito
TI Sequential administrations of trifluoroacetate induce tolerance to
   Palicourea maccgravii, a monofluoroacetate-containing plant, in calves
SO TOXICON
LA English
DT Article
DE Degradation; Dehalogenase; Fluoroacetate; Plant poisoning;
   Trifluoroacetate; Sudden death
ID MASCAGNIA-RIGIDA MALPIGHIACEAE; SODIUM MONOFLUOROACETATE; CATTLE; SHEEP;
   FLUOROACETATE; MARCGRAVII; PROTECT
AB Monofluoroacetate (MFA) is considered one of the most toxic substances known. It is found naturally in plants, and causes sudden death syndrome in ruminants. Due to hyperacute evolution of poisoning and the absence of effective treatment, induction of resistance in animals might be the best tool to control MFA poisoning in ruminants. The objective of this study was to promote resistance in cattle against the toxic effects of MFA through its degradation by the ruminal microbiota after the administration of sodium trifluoroacetate (TFA). Ten calves were distributed into two groups: control group (n = 3) and treated group (n = 7). The calves in the treated group received 0.1 mg/kg live weight of TFA, whereas, those in the control group received water; both for 28 consecutive days. The calves were subjected to daily clinical evaluation and weekly blood biochemical determination to identify any signs of poisoning. After 28 d of administration of TFA or water, 2.0 g/kg body weight of Palicourea marcgravii leaves (containing 0.15% MFA) were administered using a stomach tube to determine the occurrence of resistance. The administration of TFA did not induce any clinical or biochemical changes in blood. The administration of P. marcgravii induced clinical changes in the calves of control group, but there was no change in the calves of the treated group. In conclusion, the administration of TFA to cattle can induce effective resistance against MFA poisoning.
C1 [Costa, Aristoteles G.; de Carvalho, Antonio Ultimo; Melo, Marilia M.; Soto-Blanco, Benito] Univ Fed Minas Gerais, Escola Vet, Dept Clin & Cirurgia Vet, Ave Antonio Carlos 6627, BR-30123970 Belo Horizonte, MG, Brazil.
RP Soto-Blanco, B (reprint author), Univ Fed Minas Gerais, Escola Vet, Dept Clin & Cirurgia Vet, Ave Antonio Carlos 6627, BR-30123970 Belo Horizonte, MG, Brazil.
EM benito.blanco@pq.cnpq.br
CR Barbosa RR, 2008, PESQUI VET BRASIL, V28, P571, DOI 10.1590/S0100-736X2008001200001
   Becker M, 2013, PESQUI VET BRASIL, V33, P1049, DOI 10.1590/S0100-736X2013000900001
   Cahill TM, 2001, ENVIRON SCI TECHNOL, V35, P820, DOI 10.1021/es0013982
   Camboim EKA, 2012, SCI WORLD J, DOI 10.1100/2012/178254
   Cook D, 2014, TOXICON, V80, P9, DOI 10.1016/j.toxicon.2013.12.003
   da Silva IP, 2010, RES VET SCI, V88, P239, DOI 10.1016/j.rvsc.2009.08.012
   da Silva I. Pacifico, 2008, Arqivos do Instituto Biologico Sao Paulo, V75, P229
   da Silva LCA, 2016, TOXICON, V111, P65, DOI 10.1016/j.toxicon.2015.12.016
   Rodrigues JID, 2017, CIENC RURAL, V47, DOI 10.1590/0103-8478cr20151258
   de Oliveira MD, 2013, PESQUI VET BRASIL, V33, P731
   de Vasconcelos JS, 2008, PESQUI VET BRASIL, V28, P521, DOI 10.1590/S0100-736X2008001000013
   Duarte ALL, 2014, J APPL TOXICOL, V34, P220, DOI 10.1002/jat.2860
   Gregg K, 1998, APPL ENVIRON MICROB, V64, P3496
   GREGG K, 1994, BIO-TECHNOL, V12, P1361, DOI 10.1038/nbt1294-1361
   Khristov M, 1998, MONATSH CHEM, V129, P1093, DOI 10.1007/PL00010122
   KREBS HC, 1994, TOXICON, V32, P909, DOI 10.1016/0041-0101(94)90369-7
   Lago E.P., 2009, Arq. Bras. Med. Vet. Zootec., V61, P854, DOI 10.1590/S0102-09352009000400012
   Lee ST, 2012, TOXICON, V60, P791, DOI 10.1016/j.toxicon.2012.05.029
   Leong LEX, 2017, J ANIM SCI BIOTECHNO, V8, DOI 10.1186/s40104-017-0180-6
   Mayer J. J. M, 1994, PLANT ASS TOXINS, P457
   Minnaar PP, 2000, ONDERSTEPOORT J VET, V67, P27
   Minnaar PP, 2000, J CHROMATOGR SCI, V38, P16, DOI 10.1093/chromsci/38.1.16
   Oliveira Carlos Magno C. de, 2004, Pesq. Vet. Bras., V24, P27, DOI 10.1590/S0100-736X2004000100007
   Pavarini SP, 2011, PESQUI VET BRASIL, V31, P291, DOI 10.1590/S0100-736X2011000400004
   Pessoa CRM, 2013, PESQUI VET BRASIL, V33, P752, DOI 10.1590/S0100-736X2013000600011
   PROVENZA FD, 1992, J RANGE MANAGE, V45, P36, DOI 10.2307/4002523
   Santos AC, 2014, PESQUI VET BRASIL, V34, P649, DOI 10.1590/S0100-736X2014000700007
   Schons SV, 2012, CIENC RURAL, V42, P1257, DOI 10.1590/S0103-84782012005000047
   Tavares M. I., 1974, Pesquisa Agropecuaria Brasileira, Veterinaria, V9, P91
   TOKARNIA CH, 1981, PESQUISA VET BRASIL, V1, P7
   TOKARNIA CH, 1986, PESQUISA VET BRASIL, V6, P73
   Vasconcelos Jackson S. de, 2008, Pesq. Vet. Bras., V28, P457, DOI 10.1590/S0100-736X2008001000003
NR 32
TC 1
Z9 1
U1 1
U2 2
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD MAR 15
PY 2019
VL 160
BP 8
EP 11
DI 10.1016/j.toxicon.2019.02.005
PG 4
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA HQ4ZR
UT WOS:000462420300002
PM 30772434
DA 2020-05-12
ER

PT J
AU Ben Taheur, F
   Kouidhi, B
   Al Qurashi, YMA
   Ben Salah-Abbes, J
   Chaieb, K
AF Ben Taheur, Fadia
   Kouidhi, Bochra
   Al Qurashi, Yasir Mohammed A.
   Ben Salah-Abbes, Jalila
   Chaieb, Kamel
TI Review: Biotechnology of mycotoxins detoxification using microorganisms
   and enzymes
SO TOXICON
LA English
DT Review
DE Mycotoxins; Bacteria; Fungi; Yeast; Enzymes; Binding; Detoxification
ID LACTIC-ACID BACTERIA; LACTOBACILLUS-PLANTARUM MON03; AFLATOXIN
   DEGRADATION ENZYME; LC-MS/MS METHOD; OCHRATOXIN-A; IN-VITRO;
   SACCHAROMYCES-CEREVISIAE; FUSARIUM-MYCOTOXINS; RISK-ASSESSMENT;
   OXIDATIVE STRESS
AB Mycotoxins are secondary metabolites produced by various toxigenic fungi belonging to the genera Aspergillus, Fusarium and Penicillium. They have mutagenic, teratogenic, carcinogenic, immunosuppressive and endocrine disrupting effects on both humans and animals. The ubiquitous occurrence and heat stability of these mycotoxins during food and feed processing pose serious health problems in human and animals. Therefore successful biotechnological detoxification tools are in great demand. Recently, the use of bacteria, yeast, moulds and enzymes to mitigate/bind or biodegrade various mycotoxins is a novel strategy used for mycotoxins removal. In this review, recent development in biological control of mycotoxins removal and detoxification will be discussed.
C1 [Ben Taheur, Fadia; Chaieb, Kamel] Monastir Univ, Fac Pharm, Lab Anal Treatment & Valorizat Environm Pollutant, Monastir, Tunisia.
   [Kouidhi, Bochra; Al Qurashi, Yasir Mohammed A.] Taibah Univ, Coll Appl Med Sci, Med Lab Dept, Yanbu El Bahr, Saudi Arabia.
   [Ben Salah-Abbes, Jalila] Monastir Univ, Higher Inst Biotechnol, Lab Genet Biodivers & Bioressources Valorizat, Monastir, Tunisia.
RP Kouidhi, B (reprint author), Taibah Univ, Fac Appl Med Sci, Med Lab Technol Dept, Yanbu, Saudi Arabia.
EM bochrak@yahoo.fr
CR Abbes S, 2007, MUTAT RES-GEN TOX EN, V631, P85, DOI 10.1016/j.mrgentox.2007.01.012
   Abbes S, 2013, J IMMUNOTOXICOL, V10, P279, DOI 10.3109/1547691X.2012.718810
   Abbes S, 2012, IMMUNOPHARM IMMUNOT, V34, P944, DOI 10.3109/08923973.2012.674139
   Abrunhosa L, 2006, FOOD BIOTECHNOL, V20, P231, DOI 10.1080/08905430600904369
   Abrunhosa L, 2014, INT J FOOD MICROBIOL, V188, P45, DOI 10.1016/j.ijfoodmicro.2014.07.019
   Afsharmanesh H, 2018, FOOD CONTROL, V94, P48, DOI 10.1016/j.foodcont.2018.03.002
   Ahangarkani F, 2014, TOXIN REV, V33, P95, DOI 10.3109/15569543.2013.871563
   Alberts JF, 2006, INT J FOOD MICROBIOL, V109, P121, DOI 10.1016/j.ijfoodmicro.2006.01.019
   Alberts JF, 2009, INT J FOOD MICROBIOL, V135, P47, DOI 10.1016/j.ijfoodmicro.2009.07.022
   Alexander J, 2012, EFSA J, V10, DOI 10.2903/j.efsa.2012.2605
   Alexander NJ, 2002, YEAST, V19, P1425, DOI 10.1002/yea.924
   Armando MR, 2012, J APPL MICROBIOL, V113, P256, DOI 10.1111/j.1365-2672.2012.05331.x
   Arumugam T, 2019, MYCOTOXIN RES, V35, P99, DOI 10.1007/s12550-018-0335-0
   BALDWIN NCP, 1986, Z NATURFORSCH C, V41, P845
   Barreira MJ, 2010, FOOD CHEM, V121, P653, DOI 10.1016/j.foodchem.2009.12.085
   Battacone G, 2003, J DAIRY SCI, V86, P2667, DOI 10.3168/jds.S0022-0302(03)73862-4
   BEETON S, 1989, APPL ENVIRON MICROB, V55, P190, DOI 10.1128/AEM.55.1.190-197.1989
   Bejaoui H, 2006, FEMS MICROBIOL LETT, V255, P203, DOI 10.1111/j.1574-6968.2005.00073.x
   Bejaoui H, 2004, J APPL MICROBIOL, V97, P1038, DOI 10.1111/j.1365-2672.2004.02385.x
   Serrano AB, 2015, TOXINS, V7, P3554, DOI 10.3390/toxins7093554
   Ben Salah-Abbes J, 2015, J IMMUNOTOXICOL, V12, P107, DOI 10.3109/1547691X.2014.904025
   Ben Taheur F, 2017, INT J FOOD MICROBIOL, V251, P1, DOI 10.1016/j.ijfoodmicro.2017.03.021
   Bennett JW, 2003, CLIN MICROBIOL REV, V16, P497, DOI 10.1128/CMR.16.3.497-516.2003
   Betina V., 1989, MYCOTOXINS CHEM BIOL
   da Rocha MEB, 2014, FOOD CONTROL, V36, P159, DOI 10.1016/j.foodcont.2013.08.021
   Bhat R, 2010, COMPR REV FOOD SCI F, V9, P57, DOI 10.1111/j.1541-4337.2009.00094.x
   BLANC PJ, 1995, BIOTECHNOL LETT, V17, P291, DOI 10.1007/BF01190639
   Bohm J, 2000, Mycotoxin Res, V16 Suppl 1, P70, DOI 10.1007/BF02942985
   Bragulat MR, 2008, INT J FOOD MICROBIOL, V126, P43, DOI 10.1016/j.ijfoodmicro.2008.04.034
   Calo L, 2003, J APPL GENET, V44, P515
   Cao HW, 2019, TOXICOL IN VITRO, V54, P243, DOI 10.1016/j.tiv.2018.09.020
   Castoria R, 2011, J AGR FOOD CHEM, V59, P11571, DOI 10.1021/jf203098v
   Chang XJ, 2015, FOOD ADDIT CONTAM A, V32, P564, DOI 10.1080/19440049.2014.991948
   Cheeke P, 1998, NATURAL TOXICANTS FE, P7
   Chen CC, 2009, INT J MOL SCI, V10, P3338, DOI 10.3390/ijms10083338
   Chen YP, 2008, J AGR FOOD CHEM, V56, P11767, DOI 10.1021/jf802371b
   Cho KJ, 2010, BIOTECHNOL LETT, V32, P1921, DOI 10.1007/s10529-010-0373-y
   Coelho AR, 2008, WORLD MYCOTOXIN J, V1, P325, DOI 10.3920/WMJ2008.1040
   Cotty P J, 2006, Mycotoxin Res, V22, P110, DOI 10.1007/BF02956774
   Cserhati M, 2013, INT J FOOD MICROBIOL, V166, P176, DOI 10.1016/j.ijfoodmicro.2013.06.002
   Cvek D., 2012, Croatian Journal of Food Technology, Biotechnology and Nutrition, V7, P49
   Da Lozzo EJ, 1998, J BIOCHEM MOL TOXIC, V12, P291, DOI 10.1002/(SICI)1099-0461(1998)12:5<291::AID-JBT5>3.0.CO;2-G
   Dai ML, 2016, ANIM REPROD SCI, V168, P126, DOI 10.1016/j.anireprosci.2016.03.006
   Dalie DKD, 2010, FOOD CONTROL, V21, P370, DOI 10.1016/j.foodcont.2009.07.011
   DALVI RR, 1986, VET RES COMMUN, V10, P429, DOI 10.1007/BF02214006
   Devi P, 2006, MAR BIOTECHNOL, V8, P129, DOI 10.1007/s10126-005-5021-5
   Dobritzsch D, 2014, BIOCHEM J, V462, P441, DOI 10.1042/BJ20140382
   Dong XY, 2015, FOOD ADDIT CONTAM A, V32, P352, DOI 10.1080/19440049.2015.1007090
   Duvick J, 1998, DEV PLANT PATHOL, V13, P369
   EI-Sharkawy S, 1987, J NAT PRODUCTS, V50, P520
   El-Deeb BA, 2005, J BOT, V32, P3
   El-Nezami H, 1998, FOOD CHEM TOXICOL, V36, P321, DOI 10.1016/S0278-6915(97)00160-9
   El-Nezami H, 2000, J FOOD PROTECT, V63, P549, DOI 10.4315/0362-028X-63.4.549
   El-Nezami H, 2002, APPL ENVIRON MICROB, V68, P3545, DOI 10.1128/AEM.68.7.3545-3549.2002
   El-Nezami HS, 2002, FOOD ADDIT CONTAM, V19, P680, DOI 10.1080/02652030210134236
   Elsanhoty RM, 2013, FOOD CONTROL, V33, P287, DOI 10.1016/j.foodcont.2013.03.002
   Eriksen GS, 2004, FOOD CHEM TOXICOL, V42, P619, DOI 10.1016/j.fct.2003.11.006
   Escriva L, 2015, FOOD CHEM TOXICOL, V78, P185, DOI 10.1016/j.fct.2015.02.005
   Eshelli M, 2015, TOXINS, V7, P439, DOI 10.3390/toxins7020439
   Fan Y, 2015, TOXINS, V7, P3330, DOI 10.3390/toxins7083330
   FAO, 2013, MYC FOOD SAF QUAL
   Farbo MG, 2016, INT J FOOD MICROBIOL, V217, P29, DOI 10.1016/j.ijfoodmicro.2015.10.012
   Farzaneh M, 2012, FOOD CONTROL, V23, P100, DOI 10.1016/j.foodcont.2011.06.018
   Fazekas B, 2002, ACTA VET HUNG, V50, P177, DOI 10.1556/AVet.50.2002.2.7
   Flajs D, 2009, ARH HIG RADA TOKSIKO, V60, P457, DOI 10.2478/10004-1254-60-2009-1992
   Fuchs S, 2008, FOOD CHEM TOXICOL, V46, P1398, DOI 10.1016/j.fct.2007.10.008
   Gao XJ, 2018, FOOD CHEM TOXICOL, V112, P310, DOI 10.1016/j.fct.2017.12.066
   Gao X, 2018, J NUTR, V148, P1209, DOI 10.1093/jn/nxy114
   Gao X, 2011, EUR FOOD RES TECHNOL, V232, P957, DOI 10.1007/s00217-011-1463-3
   Gayathri L, 2015, FOOD CHEM TOXICOL, V83, P151, DOI 10.1016/j.fct.2015.06.009
   Glaser N, 2012, FOOD CHEM TOXICOL, V50, P1796, DOI 10.1016/j.fct.2012.02.096
   Gong L, 2019, FOOD CHEM TOXICOL, V123, P374, DOI 10.1016/j.fct.2018.11.015
   Gratz S, 2007, APPL ENVIRON MICROB, V73, P3958, DOI 10.1128/AEM.02944-06
   Gratz S, 2005, J FOOD PROTECT, V68, P2470, DOI 10.4315/0362-028X-68.11.2470
   HAGLER WM, 1979, APPL ENVIRON MICROB, V37, P849, DOI 10.1128/AEM.37.5.849-853.1979
   Hamid AS, 2013, ONCOL LETT, V5, P1087, DOI 10.3892/ol.2013.1169
   Hamidi Adel, 2013, Asian Pacific Journal of Tropical Biomedicine, V3, P732, DOI 10.1016/S2221-1691(13)60147-1
   Harrison L R, 1990, J Vet Diagn Invest, V2, P217
   HARTLEY RD, 1963, NATURE, V198, P1056, DOI 10.1038/1981056a0
   Hassan YI, 2018, TOXINS, V10, DOI 10.3390/toxins10030116
   Hatab S, 2012, J APPL MICROBIOL, V112, P892, DOI 10.1111/j.1365-2672.2012.05279.x
   Hawar S, 2013, FOOD CONTROL, V34, P502, DOI 10.1016/j.foodcont.2013.05.023
   He XX, 2015, FOOD CONTROL, V57, P161, DOI 10.1016/j.foodcont.2015.03.031
   Heidler D, 2003, FEED MIX, V11, P31
   Hernandez-Mendoza A, 2011, FOOD BIOTECHNOL, V25, P140, DOI 10.1080/08905436.2011.576561
   Hormisch D, 2004, SYST APPL MICROBIOL, V27, P653, DOI 10.1078/0723202042369866
   Hsu TC, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0194866
   Huang WW, 2018, J TOXICOL SCI, V43, P377, DOI 10.2131/jts.43.377
   Hussein HS, 2001, TOXICOLOGY, V167, P101, DOI 10.1016/S0300-483X(01)00471-1
   Ianiri G, 2013, APPL ENVIRON MICROB, V79, P3101, DOI 10.1128/AEM.03851-12
   Ikunaga Y, 2011, APPL MICROBIOL BIOT, V89, P419, DOI 10.1007/s00253-010-2857-z
   Islam R, 2012, WORLD J MICROB BIOT, V28, P7, DOI 10.1007/s11274-011-0785-4
   Jany K., 2005, INT J FOOD MICROBIOL, V105, P111
   Jebali R, 2015, J IMMUNOTOXICOL, V12, P290, DOI 10.3109/1547691X.2014.973622
   Jestoi M, 2008, CRIT REV FOOD SCI, V48, P21, DOI 10.1080/10408390601062021
   Jorgensen K, 2005, FOOD ADDIT CONTAM A, V22, P26, DOI 10.1080/02652030500344811
   Juan-Garcia A, 2015, FOOD CHEM TOXICOL, V84, P188, DOI 10.1016/j.fct.2015.08.030
   Juodeikiene G, 2018, LWT-FOOD SCI TECHNOL, V89, P307, DOI 10.1016/j.lwt.2017.10.061
   Kanpiengjai A., 2015, ANN MICROBIOL, P1
   Kim IH, 2003, TOXICOL LETT, V138, P185, DOI 10.1016/S0378-4274(02)00405-8
   Kim S, 2017, J DAIRY SCI, V100, P871, DOI 10.3168/jds.2016-11264
   Klich MA, 2007, MOL PLANT PATHOL, V8, P713, DOI 10.1111/J.1364-3703.2007.00436.X
   Kokkonen M, 2010, INT J FOOD MICROBIOL, V143, P17, DOI 10.1016/j.ijfoodmicro.2010.07.015
   Kowalska A, 2018, FOOD CONTROL, V92, P348, DOI 10.1016/j.foodcont.2018.05.007
   Krol A, 2018, ANAL BIOANAL CHEM, V410, P943, DOI 10.1007/s00216-017-0555-8
   Krska R, 2007, ANIM FEED SCI TECH, V137, P241, DOI 10.1016/j.anifeedsci.2007.06.004
   KUIPERGOODMAN T, 1987, REGUL TOXICOL PHARM, V7, P253, DOI 10.1016/0273-2300(87)90037-7
   Kumar R, 2011, TOXICOL SCI, V122, P557, DOI 10.1093/toxsci/kfr143
   Lagogianni CS, 2018, PHYTOPATHOL MEDITERR, V57, P186, DOI 10.14601/Phytopathol_Mediterr-22492
   LAMPRECHT SC, 1994, PHYTOPATHOLOGY, V84, P383, DOI 10.1094/Phyto-84-383
   Li JL, 2018, FOOD CHEM TOXICOL, V121, P430, DOI 10.1016/j.fct.2018.08.063
   Li XH, 2019, FOOD CONTROL, V96, P47, DOI 10.1016/j.foodcont.2018.08.029
   Liu BH, 2005, J AGR FOOD CHEM, V53, P170, DOI 10.1021/jf048878n
   Liu DL, 1998, FOOD CHEM TOXICOL, V36, P563, DOI 10.1016/S0278-6915(98)00017-9
   Liu DL, 2001, FOOD CHEM TOXICOL, V39, P461, DOI 10.1016/S0278-6915(00)00161-7
   Liuzzi VC, 2017, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.02162
   Llewellyn GC, 1998, FOOD CHEM TOXICOL, V36, P1107, DOI 10.1016/S0278-6915(98)00084-2
   Long M, 2012, J ANIM VET ADV, V11, P2417
   Long XD, 2011, HEPATOL RES, V41, P1085, DOI 10.1111/j.1872-034X.2011.00866.x
   Luo Y, 2018, FOOD CONTROL, V89, P123, DOI 10.1016/j.foodcont.2018.01.016
   MAGAN N, 2004, MYCOTOXINS FOOD DETE
   Maresca M, 2013, TOXINS, V5, P784, DOI 10.3390/toxins5040784
   McCormick SP, 2011, TOXINS, V3, P802, DOI 10.3390/toxins3070802
   McKevith B., 2004, Nutrition Bulletin, V29, P111, DOI 10.1111/j.1467-3010.2004.00418.x
   Meca G, 2013, FOOD CHEM TOXICOL, V59, P334, DOI 10.1016/j.fct.2013.06.010
   Meca G, 2012, FOOD CHEM TOXICOL, V50, P1362, DOI 10.1016/j.fct.2012.02.038
   MIROCHA CJ, 1983, J ASSOC OFF ANA CHEM, V66, P1485
   Moake MM, 2005, COMPR REV FOOD SCI F, V4, P8, DOI 10.1111/j.1541-4337.2005.tb00068.x
   Moretti AF, 2018, J FOOD SCI TECH MYS, V55, P431, DOI 10.1007/s13197-017-2923-y
   Moss MO, 2002, FOOD ADDIT CONTAM, V19, P387, DOI 10.1080/02652030110091163
   Motomura M, 2003, MICROBIOL RES, V158, P237, DOI 10.1078/0944-5013-00199
   Muller G, 1999, MYCOSES, V42, P495, DOI 10.1046/j.1439-0507.1999.00504.x
   NORRED WP, 1992, FOOD CHEM TOXICOL, V30, P233, DOI 10.1016/0278-6915(92)90038-M
   Odhav B, 2008, INT IMMUNOPHARMACOL, V8, P799, DOI 10.1016/j.intimp.2008.01.030
   OVCHINNIKOV YA, 1974, INT J PEPT PROT RES, V6, P465
   Ozkaya S, 2001, THESIS, p86s
   Pereira VL, 2014, TRENDS FOOD SCI TECH, V36, P96, DOI 10.1016/j.tifs.2014.01.005
   Petchkongkaew A, 2008, J APPL MICROBIOL, V104, P1495, DOI 10.1111/j.1365-2672.2007.03700.x
   Petkar H, 2011, J CLIN MICROBIOL, V49, P1175, DOI 10.1128/JCM.01103-10
   Petruzzi L, 2014, FOOD CONTROL, V35, P373, DOI 10.1016/j.foodcont.2013.07.033
   Prettl Z, 2017, ANIM FEED SCI TECH, V224, P104, DOI 10.1016/j.anifeedsci.2016.12.011
   Raju MVLN, 2000, BRIT POULTRY SCI, V41, P640, DOI 10.1080/713654986
   Ricelli A, 2007, APPL ENVIRON MICROB, V73, P785, DOI 10.1128/AEM.02032-06
   Robinson R.K., 2014, ENCY FOOD MICROBIOLO
   Rodriguez H, 2011, J AGR FOOD CHEM, V59, P10755, DOI 10.1021/jf203061p
   Ruiyu Z., 2012, AFR J BIOTECHNOL, V11, P12903
   Samuel MS, 2014, INT BIODETER BIODEGR, V86, P202, DOI 10.1016/j.ibiod.2013.08.026
   Sangi F, 2018, IRAN J TOXICOL, V12
   Sarlak Z, 2017, FOOD CONTROL, V71, P152, DOI 10.1016/j.foodcont.2016.06.037
   Schmidt-Heydt M, 2015, INT J FOOD MICROBIOL, V192, P1, DOI 10.1016/j.ijfoodmicro.2014.09.008
   Schulz MC, 2018, TOXICOL LETT, V291, P149, DOI 10.1016/j.toxlet.2018.04.014
   Serrano AB, 2012, FOOD CONTROL, V28, P178, DOI 10.1016/j.foodcont.2012.04.042
   Serrano AB, 2012, FOOD CHEM, V135, P423, DOI 10.1016/j.foodchem.2012.03.064
   Shafiq S. A., 2015, International Journal of Innovation and Applied Studies, V11, P282
   SHARMA RP, 1993, J DAIRY SCI, V76, P892, DOI 10.3168/jds.S0022-0302(93)77415-9
   Shcherbakova L, 2015, JUNDISHAPUR J MICROB, V8, DOI 10.5812/jjm.24324
   Shetty PH, 2006, TRENDS FOOD SCI TECH, V17, P48, DOI 10.1016/j.tifs.2005.10.004
   Shi HT, 2018, FOOD CONTROL, V91, P202, DOI 10.1016/j.foodcont.2018.03.036
   Shima J, 1997, APPL ENVIRON MICROB, V63, P3825, DOI 10.1128/AEM.63.10.3825-3830.1997
   Shimizu T, 2005, APPL ENVIRON MICROB, V71, P3453, DOI 10.1128/AEM.71.7.3453-3457.2005
   Shu X, 2018, TOXINS, V10, DOI 10.3390/toxins10080330
   Singh N. D., 2013, TOXICOL IND HEALTH
   Slizewska K, 2011, J ANIM FEED SCI, V20, P300
   Slizewska K, 2010, RES VET SCI, V89, P391, DOI 10.1016/j.rvsc.2010.04.004
   Sorensen JL, 2008, J AGR FOOD CHEM, V56, P10439, DOI 10.1021/jf802038b
   SPEIJERS GJA, 1988, FOOD CHEM TOXICOL, V26, P23, DOI 10.1016/0278-6915(88)90037-3
   Stanciu O, 2017, FOOD CONTROL, V73, P147, DOI 10.1016/j.foodcont.2016.07.042
   Stenglein SA, 2009, J PLANT PATHOL, V91, P25
   STORMER FC, 1995, TOXICOLOGY, V95, P45, DOI 10.1016/0300-483X(94)02873-S
   STRONGMAN DB, 1988, J CHEM ECOL, V14, P753, DOI 10.1007/BF01018770
   Sulyok M, 2007, ANAL BIOANAL CHEM, V389, P1505, DOI 10.1007/s00216-007-1542-2
   Sun LH, 2015, MICROB BIOTECHNOL, V8, P490, DOI 10.1111/1751-7915.12244
   Tan H, 2015, FOOD CONTROL, V47, P285, DOI 10.1016/j.foodcont.2014.07.013
   Tanaka T, 2015, TOXICOLOGY, V336, P59, DOI 10.1016/j.tox.2015.08.001
   Tang YL, 2015, FREE RADICAL BIO MED, V89, P944, DOI 10.1016/j.freeradbiomed.2015.09.012
   Tejada-Castaneda ZI, 2008, POULTRY SCI, V87, P1569, DOI 10.3382/ps.2007-00304
   Teniola OD, 2005, INT J FOOD MICROBIOL, V105, P111, DOI 10.1016/j.ijfoodmicro.2005.05.004
   Theumer MG, 2018, TOXICOL LETT, V287, P100, DOI 10.1016/j.toxlet.2018.02.007
   Tomaszewski J, 1998, Ginekol Pol, V69, P363
   TOMODA H, 1992, J ANTIBIOT, V45, P1626, DOI 10.7164/antibiotics.45.1626
   Topcu A, 2010, INT J FOOD MICROBIOL, V139, P202, DOI 10.1016/j.ijfoodmicro.2010.03.006
   Varga J, 2005, ACTA VET HUNG, V53, P189, DOI 10.1556/AVet.53.2005.2.4
   Wang G, 2017, FOOD CONTROL, V77, P57, DOI 10.1016/j.foodcont.2017.01.021
   Wang JQ, 2011, FEMS MICROBIOL LETT, V314, P164, DOI 10.1111/j.1574-6968.2010.02158.x
   Wang J, 2018, WORLD ENVIRONMENTAL AND WATER RESOURCES CONGRESS 2018: HYDRAULICS AND WATERWAYS, WATER DISTRIBUTION SYSTEMS ANALYSIS, AND SMART WATER, P1
   Wang Y, 2018, TOXICON, V146, P69, DOI [10.1016/j.toxicon.2018.04.007, 10]
   Waskiewicz A, 2010, FOOD ADDIT CONTAM A, V27, P608, DOI 10.1080/19440040903551947
   Weidenborner M, 2001, EUR FOOD RES TECHNOL, V212, P262, DOI 10.1007/s002170000259
   Wochner KF, 2018, CRIT REV MICROBIOL, V44, P112, DOI 10.1080/1040841X.2017.1329275
   Wu F, 2004, ENVIRON SCI TECHNOL, V38, P4049, DOI 10.1021/es035353n
   Wu F, 2008, J AGR FOOD CHEM, V56, P3900, DOI 10.1021/jf072697e
   Wu F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045151
   Xia XS, 2017, FOOD CONTROL, V75, P92, DOI 10.1016/j.foodcont.2016.12.036
   Yang G, 2018, CHEM-BIOL INTERACT, V288, P24, DOI 10.1016/j.cbi.2018.03.018
   Yang Q., 2015, WORLD MYCOTOXIN J, P1
   Yao DS, 1998, ANN NY ACAD SCI, V864, P579, DOI 10.1111/j.1749-6632.1998.tb10385.x
   Yi PJ, 2011, WORLD J MICROB BIOT, V27, P1035, DOI 10.1007/s11274-010-0548-7
   Yiannikouris A, 2004, BIOMACROMOLECULES, V5, P2176, DOI 10.1021/bm049775g
   Yiannikouris A, 2004, J FOOD PROTECT, V67, P1195, DOI 10.4315/0362-028X-67.6.1195
   Yu FY, 2006, TOXICOL LETT, V161, P143, DOI 10.1016/j.toxlet.2005.08.009
   Yuan Y, 2014, LETT APPL MICROBIOL, V59, P604, DOI 10.1111/lam.12315
   Zeinvand-Lorestani H, 2015, CHEMOSPHERE, V135, P1, DOI 10.1016/j.chemosphere.2015.03.036
   Zhang X, 2018, ANN APPL BIOL, V173, P164, DOI 10.1111/aab.12452
   Zhao LH, 2011, J APPL MICROBIOL, V110, P147, DOI 10.1111/j.1365-2672.2010.04867.x
   Zhao L, 2015, FOOD CONTROL, V54, P158, DOI 10.1016/j.foodcont.2015.02.003
   Zheng XF, 2018, BIOL CONTROL, V123, P127, DOI 10.1016/j.biocontrol.2018.04.019
   Zhu RY, 2015, FOOD CHEM, V179, P1, DOI 10.1016/j.foodchem.2015.01.066
   Zinedine A, 2007, FOOD CHEM TOXICOL, V45, P1, DOI 10.1016/j.fct.2006.07.030
   Zinedine A, 2017, FOOD CHEM, V214, P440, DOI 10.1016/j.foodchem.2016.07.098
   Zollner P, 2000, J CHROMATOGR B, V738, P233, DOI 10.1016/S0378-4347(99)00521-6
   Zuo RY, 2013, FOOD CHEM TOXICOL, V59, P470, DOI 10.1016/j.fct.2013.06.044
NR 211
TC 8
Z9 8
U1 30
U2 66
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD MAR 15
PY 2019
VL 160
BP 12
EP 22
DI 10.1016/j.toxicon.2019.02.001
PG 11
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA HQ4ZR
UT WOS:000462420300003
PM 30772433
DA 2020-05-12
ER

PT J
AU Peng, XY
   Tang, YK
   Yang, WW
   Chen, YN
   Zhou, Y
   Yuan, Y
   Huang, YF
   Liu, L
AF Peng, Xiao-yu
   Tang, Yan-kui
   Yang, Wei-wei
   Chen, Yu-nong
   Zhou, Yan
   Yuan, Yang
   Huang, Yin-feng
   Liu, Lu
TI Occurrence of microcystin-LR in vegetated lagoons used for urban runoff
   management
SO TOXICON
LA English
DT Article
DE Microcystin-LR; Occurrence; Vegetated lagoons; Phytoremediation;
   Indicator
ID ENVIRONMENTAL-FACTORS; MS/MS METHOD; LC-MS/MS; WATER; EUTROPHICATION;
   LAKE; CYANOBACTERIAL; PERFORMANCE; PHOSPHORUS; CYANOTOXINS
AB Phytoremediation with aquatic macrophyte has been considered as an eco-friendly technique for controlling harmful cyanobacteria outbreak and proven to be effective. The conventional water quality parameters are frequently measured to evaluate the effectiveness of phytoremediation. However, the concentration of microcystin-leucine-arginine (MC-LR) in different vegetated water still remains uncertain. In this study, the contents of MC-LR in four macrophyte-vegetated lagoons were determined by solid phase extraction and ultra-high-performance liquid chromatography with tandem mass spectrometry technology. Results indicated that MC-LR was found in Nymphaea tetragona lagoon (lagoon-S), Vallisneria spiralis lagoon (lagoon-B) and another Vallisneria spiralis lagoon (lagoon-J). Only in lagoon dominated by Pistia stradotes L. (lagoon-D), MC-LR concentration was undiscovered regardless of seasonal variation. The levels of varied seasonally and were affected by the different vegetated aquatic macrophytes. The results suggest that in addition to conventional physicochemical parameters and indicators of water quality, MC-LR levels should be taken into consideration when the effectiveness of phytoremediation is assessed.
C1 [Peng, Xiao-yu; Tang, Yan-kui; Yang, Wei-wei; Chen, Yu-nong; Zhou, Yan; Yuan, Yang; Huang, Yin-feng; Liu, Lu] Guangxi Univ, Sch Resources Environm & Mat, Nanning 530004, Peoples R China.
   [Tang, Yan-kui] Guangxi Univ, Guangxi Key Lab Petrochem Resource Proc & Proc In, Nanning 530004, Peoples R China.
RP Tang, YK (reprint author), Guangxi Univ, Sch Resources Environm & Mat, Nanning 530004, Peoples R China.
EM cindyyktang@gxu.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [51668006, 21507015]; Opening Project of Guangxi Key
   Laboratory of Petrochemical Resource Processing and Process
   Intensification Technology
FX The authors would like to acknowledge financial support provided by the
   National Natural Science Foundation of China (No. 51668006 and No.
   21507015) and the Opening Project of Guangxi Key Laboratory of
   Petrochemical Resource Processing and Process Intensification
   Technology.
CR Beltran E, 2012, J CHROMATOGR A, V1266, P61, DOI 10.1016/j.chroma.2012.10.017
   Cao Q, 2018, ECOTOX ENVIRON SAFE, V156, P141, DOI 10.1016/j.ecoenv.2018.03.030
   Chen AW, 2015, INT BIODETER BIODEGR, V105, P73, DOI 10.1016/j.ibiod.2015.08.017
   Chen C, 2014, INTEGR TRANSF SPEC F, V25, P552, DOI 10.1080/10652469.2014.887073
   Chen JZ, 2012, ECOL ENG, V42, P130, DOI 10.1016/j.ecoleng.2012.02.021
   Chen J, 2018, SENSOR ACTUAT B-CHEM, V254, P778, DOI 10.1016/j.snb.2017.04.070
   Chen L, 2016, J HAZARD MATER, V301, P381, DOI 10.1016/j.jhazmat.2015.08.041
   Dijkman E, 2001, J CHROMATOGR A, V926, P113, DOI 10.1016/S0021-9673(01)01040-8
   Dixit F, 2018, WATER RES, V139, P74, DOI 10.1016/j.watres.2018.03.074
   Dixit F, 2018, CHEMOSPHERE, V192, P113, DOI 10.1016/j.chemosphere.2017.10.135
   Dong JJ, 2017, CHEM ENG J, V330, P596, DOI 10.1016/j.cej.2017.07.174
   Fiore MD, 2005, WATER RES, V39, P5017, DOI 10.1016/j.watres.2005.10.002
   Gao JQ, 2009, DESALINATION, V242, P193, DOI 10.1016/j.desal.2008.04.006
   Geada P, 2017, ALGAL RES, V27, P235, DOI 10.1016/j.algal.2017.09.006
   Gosetti F, 2010, J CHROMATOGR A, V1217, P3929, DOI 10.1016/j.chroma.2009.11.060
   Graham JL, 2004, WATER RES, V38, P4395, DOI 10.1016/j.watres.2004.08.004
   Greer B, 2016, HARMFUL ALGAE, V55, P31, DOI 10.1016/j.hal.2016.01.006
   Grosse Y, 2006, LANCET ONCOL, V7, P628, DOI 10.1016/S1470-2045(06)70789-6
   Han Z, 2016, ECOL ENG, V96, P8, DOI 10.1016/j.ecoleng.2015.10.019
   Hercog K, 2017, CHEMOSPHERE, V189, P319, DOI 10.1016/j.chemosphere.2017.09.075
   Jing H, 2008, ANAL URBAN LAKES EUT
   Lawniczak-Malinska AE, 2018, ECOL ENG, V113, P52, DOI 10.1016/j.ecoleng.2018.02.003
   Li JM, 2017, SCI TOTAL ENVIRON, V595, P615, DOI 10.1016/j.scitotenv.2017.03.285
   Li W, 2015, J CHROMATOGR A, V1389, P76, DOI 10.1016/j.chroma.2015.02.044
   Liu HQ, 2016, BIORESOURCE TECHNOL, V214, P797, DOI 10.1016/j.biortech.2016.05.003
   Liu S. Y, 2016, STUDY AGAL TOXINS PR
   Lu Q, 2009, PHYTOREMEDIATION REM
   Ly J, 2014, J SEA RES, V88, P109, DOI 10.1016/j.seares.2013.12.010
   Madsen JD, 2001, HYDROBIOLOGIA, V444, P71, DOI 10.1023/A:1017520800568
   Martin M, 2013, ECOL ENG, V50, P52, DOI 10.1016/j.ecoleng.2012.04.029
   Minasyan A, 2018, TOXICON, V150, P28, DOI 10.1016/j.toxicon.2018.04.021
   Mohamed ZA, 2010, TOXICON, V55, P1346, DOI 10.1016/j.toxicon.2010.02.007
   Moore KA, 2000, J EXP MAR BIOL ECOL, V244, P1, DOI 10.1016/S0022-0981(99)00135-5
   Ng YS, 2017, J WATER PROCESS ENG, V15, P107, DOI 10.1016/j.jwpe.2016.08.006
   Niu ZG, 2018, CHEMOSPHERE, V193, P403, DOI 10.1016/j.chemosphere.2017.11.037
   Oldekop ML, 2014, J CHROMATOGR B, V967, P147, DOI 10.1016/j.jchromb.2014.07.027
   Pan J, 2015, BIORESOURCE TECHNOL, V191, P327, DOI 10.1016/j.biortech.2015.05.023
   Pei SF, 2018, ESTUAR COAST SHELF S, V202, P103, DOI 10.1016/j.ecss.2017.12.012
   Qian ZY, 2017, TALANTA, V173, P101, DOI 10.1016/j.talanta.2017.05.079
   Qin HJ, 2016, ECOL ENG, V95, P753, DOI 10.1016/j.ecoleng.2016.07.022
   Rivasseau C, 1998, J CHROMATOGR A, V799, P155, DOI 10.1016/S0021-9673(97)01095-9
   Rodrigo MA, 2013, ECOL ENG, V61, P371, DOI 10.1016/j.ecoleng.2013.09.038
   Sondergaard M, 2010, FRESHWATER BIOL, V55, P893, DOI 10.1111/j.1365-2427.2009.02331.x
   Sun Q, 2006, EFFECT ORGANIC CARBO
   Tao YQ, 2017, WATER RES, V122, P512, DOI 10.1016/j.watres.2017.06.026
   Wilde S, 2005, AVIAN VACUOLAR MYELI
   Wu FF, 2012, PROCEDIA ENVIRON SCI, V13, P1030, DOI 10.1016/j.proenv.2012.01.096
   [吴明丽 Wu Mingli], 2012, [生态学报, Acta Ecologica Sinica], V32, P7202
   Wu X, 2013, EFFECTS ALLELOCHEMIC
   [鲜啟鸣 Xian Qiming], 2006, [生态学报, Acta Ecologica Sinica], V26, P3549, DOI 10.1016/S1872-2032(06)60054-1
   Yan HY, 2016, ECOL INDIC, V69, P463, DOI 10.1016/j.ecolind.2016.05.010
   Zervou SK, 2017, J HAZARD MATER, V323, P56, DOI 10.1016/j.jhazmat.2016.07.020
   Zhang H, 2017, TOXICOLOGY, V380, P50, DOI 10.1016/j.tox.2017.02.004
   Zhang Y, 2018, SCI TOTAL ENVIRON, V627, P1294, DOI 10.1016/j.scitotenv.2018.01.327
   Zhang Y, 2015, ENVIRON POLLUT, V206, P705, DOI 10.1016/j.envpol.2015.08.018
   Zheng W, 2018, J CHROMATOGR B, V1072, P60, DOI 10.1016/j.jchromb.2017.11.011
NR 56
TC 0
Z9 0
U1 7
U2 12
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD MAR 15
PY 2019
VL 160
BP 23
EP 28
DI 10.1016/j.toxicon.2019.02.004
PG 6
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA HQ4ZR
UT WOS:000462420300004
PM 30772435
DA 2020-05-12
ER

PT J
AU Aupanun, S
   Phuektes, P
   Poapolathep, S
   Alassane-Kpembi, I
   Oswald, IP
   Poapolathep, A
AF Aupanun, Sawinee
   Phuektes, Patchara
   Poapolathep, Saranya
   Alassane-Kpembi, Imourana
   Oswald, Isabelle P.
   Poapolathep, Amnart
TI Individual and combined cytotoxicity of major trichothecenes type B,
   deoxynivalenol, nivalenol, and fusarenon-X on Jurkat human T cells
SO TOXICON
LA English
DT Article
DE Deoxynivalenol; Nivalenol; Fusarenon-X; Mycotoxin combination; Jurkat T
   cell
ID INDUCED APOPTOSIS; IMMUNE MODULATION; GENE-EXPRESSION; PEYERS-PATCHES;
   MYCOTOXINS; MECHANISMS; 15-ACETYLDEOXYNIVALENOL; 3-ACETYLDEOXYNIVALENOL;
   TOXICOLOGY; RESPONSES
AB Food and feed commodities are often contaminated by more than one mycotoxin. Among the several combinations that frequently occur, fusariotoxins are often mentioned. The multi-mycotoxins contamination is a serious threat for health. In the present study we investigated the toxic interactions between deoxynivalenol (DON), nivalenol (NIV), and fusarenon-X (FX) in Jurkat T cells by using the MTT assay. The tested mycotoxins alone or in combination had a dose dependent effect on proliferating lymphocytes. According to IC50, it could be classified in decreasing order of toxicity: FX > NIV > DON > DON + FX > NIV + FX > DON + NIV > DON + NIV + FX. The type of mycotoxin interactions was assessed by calculating the combination index (CI) and the dose reduction index (DRI). Our data indicate that an antagonistic effect was strongly observed in binary combination between DON and NIV at higher concentrations and ternary mixtures. Meanwhile, the DON and FX mixtures generated moderate antagonism, while NIV and FX provoked different interactions. The effects of tested mycotoxins on apoptosis were also determined using a FACScan flow cytometer. At IC75, the percentages of apoptotic cells in all treatment groups were significantly different when compared to control group but no significant differences among treatment groups was observed. Taken together, our data suggest that immunotoxicity among multi-mycotoxins contamination cannot be predicted based on individual effects but depends on the mixtures, ratio and/or concentrations in the product, as well as type of target cells.
C1 [Aupanun, Sawinee; Poapolathep, Saranya; Poapolathep, Amnart] Kasetsart Univ, Fac Vet Med, Dept Pharmacol, Bangkok 10900, Thailand.
   [Aupanun, Sawinee; Poapolathep, Amnart] Kasetsart Univ, NRU KU, KU Inst Adv Studies, CASAF, Bangkok 10900, Thailand.
   [Phuektes, Patchara] Khonkaen Univ, Fac Vet Med, Dept Pathobiol, Khon Kaen 40002, Thailand.
   [Alassane-Kpembi, Imourana; Oswald, Isabelle P.] Univ Toulouse, INRA, INP Purpan, Toxal Res Ctr Food Toxicol,ENVT, Toulouse, France.
RP Poapolathep, A (reprint author), Kasetsart Univ, Fac Vet Med, Dept Pharmacol, Bangkok 10900, Thailand.
EM fvetamp@ku.ac.th
RI OSWALD, Isabelle/W-9852-2019; OSWALD, Isabelle P/A-8497-2013
OI OSWALD, Isabelle/0000-0001-9918-277X; OSWALD, Isabelle
   P/0000-0001-9918-277X; Alassane-Kpembi, Imourana/0000-0003-0718-2655;
   Poapolathep, Amnart/0000-0001-5322-3281
FU Center for Advanced Studies for Agriculture and Food, Institute for
   Advanced Studies, Kasetsart University under the Higher Education
   Research Promotion and National Research University Project of Thailand,
   Office of the Higher Education Commission, Minist
FX This work was partially supported by the Center for Advanced Studies for
   Agriculture and Food, Institute for Advanced Studies, Kasetsart
   University under the Higher Education Research Promotion and National
   Research University Project of Thailand, Office of the Higher Education
   Commission, Ministry of Education, Thailand.
CR Alassane-Kpembi I, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-07155-2
   Alassane-Kpembi I, 2017, CRIT REV FOOD SCI, V57, P3489, DOI 10.1080/10408398.2016.1140632
   Alassane-Kpembi I, 2015, ARCH TOXICOL, V89, P1337, DOI 10.1007/s00204-014-1309-4
   Alassane-Kpembi I, 2013, TOXICOL APPL PHARM, V272, P191, DOI 10.1016/j.taap.2013.05.023
   Aupanun S, 2016, TOXICON, V123, P15, DOI 10.1016/j.toxicon.2016.10.012
   Aupanun S, 2015, RES VET SCI, V102, P217, DOI 10.1016/j.rvsc.2015.08.012
   Berthiller F, 2007, INT J FOOD MICROBIOL, V119, P33, DOI 10.1016/j.ijfoodmicro.2007.07.022
   Bondy GS, 2000, J TOXICOL ENV HEAL B, V3, P109, DOI 10.1080/109374000281113
   Cavaliere C, 2005, RAPID COMMUN MASS SP, V19, P2085, DOI 10.1002/rcm.2030
   Chou TC, 2006, PHARMACOL REV, V58, P621, DOI 10.1124/pr.58.3.10
   Del Ponte EM, 2012, FOOD CHEM, V132, P1087, DOI 10.1016/j.foodchem.2011.10.108
   [FSCJ] Food Safety Commission of Japan, 2010, RISK ASS REP DEOX NI
   Gouze ME, 2007, VET RES, V38, P635, DOI 10.1051/vetres:2007022
   Grela E, 2018, ACTA HISTOCHEM, V120, P303, DOI 10.1016/j.acthis.2018.03.007
   Hussein HS, 2001, TOXICOLOGY, V167, P101, DOI 10.1016/S0300-483X(01)00471-1
   Islam MR, 2013, TOXICOL LETT, V221, P152, DOI 10.1016/j.toxlet.2013.05.656
   JECFA (Joint FAO/WHO Expert Committee on Food Additives), 2001, SAF EV CERT MYC FOOD, P281
   Katika MR, 2015, J IMMUNOTOXICOL, V12, P206, DOI 10.3109/1547691X.2014.925995
   Kovalsky P, 2016, TOXINS, V8, DOI 10.3390/toxins8120363
   Liao YX, 2018, FOOD CHEM TOXICOL, V112, P342, DOI 10.1016/j.fct.2018.01.013
   Luongo D, 2008, TOXICON, V52, P156, DOI 10.1016/j.toxicon.2008.04.162
   Marin S, 2013, FOOD CHEM TOXICOL, V60, P218, DOI 10.1016/j.fct.2013.07.047
   Marzocco S, 2009, TOXICOL LETT, V189, P21, DOI 10.1016/j.toxlet.2009.04.024
   Matejova I, 2015, VET MED-CZECH, V60, P515, DOI 10.17221/8443-VETMED
   Mayer E, 2017, MYCOTOXIN RES, V33, P297, DOI 10.1007/s12550-017-0289-7
   Mishra S, 2014, FOOD CHEM TOXICOL, V72, P20, DOI 10.1016/j.fct.2014.06.027
   Miura K, 2002, TOXICOLOGY, V172, P103, DOI 10.1016/S0300-483X(01)00586-8
   Montes R, 2012, J FOOD COMPOS ANAL, V27, P38, DOI 10.1016/j.jfca.2012.05.004
   Nielsen Carina, 2009, Mycotoxin Res, V25, P77, DOI 10.1007/s12550-009-0011-5
   Ok HE, 2018, FOOD CONTROL, V87, P53, DOI 10.1016/j.foodcont.2017.12.005
   Pascua-Maestro R, 2018, ACTA HISTOCHEM, V120, P179, DOI 10.1016/j.acthis.2018.01.006
   Payros D, 2016, ARCH TOXICOL, V90, P2931, DOI 10.1007/s00204-016-1826-4
   Pestka JJ, 2008, FOOD ADDIT CONTAM A, V25, P1128, DOI 10.1080/02652030802056626
   Pestka JJ, 2010, WORLD MYCOTOXIN J, V3, P323, DOI 10.3920/WMJ2010.1247
   Pestka JJ, 2005, TOXICOLOGY, V206, P207, DOI 10.1016/j.tox.2004.08.020
   Pestka JJ, 2004, TOXICOL LETT, V153, P61, DOI 10.1016/j.toxlet.2004.04.023
   Pierron A, 2016, SCI REP-UK, V6, DOI 10.1038/srep29105
   Poapolathep A, 2002, EXP TOXICOL PATHOL, V53, P441, DOI 10.1078/0940-2993-00211
   Poapolathep A, 2004, EXP MOL PATHOL, V77, P149, DOI 10.1016/j.yexmp.2004.04.004
   Poapolathep A, 2003, EXP MOL PATHOL, V75, P74, DOI 10.1016/S0014-4800(03)00027-3
   Ruiz MJ, 2011, FOOD CHEM TOXICOL, V49, P2718, DOI 10.1016/j.fct.2011.07.021
   Streit E, 2013, J SCI FOOD AGR, V93, P2892, DOI 10.1002/jsfa.6225
   Streit E, 2012, TOXINS, V4, P788, DOI 10.3390/toxins4100788
   UENO Y, 1983, TRICHOTHECENES CHEM
   van Tonder Alet, 2015, BMC Res Notes, V8, P47, DOI 10.1186/s13104-015-1000-8
   Venkateswaran A, 2000, P NATL ACAD SCI USA, V97, P12097, DOI 10.1073/pnas.200367697
   Wan LYM, 2013, FOOD CHEM TOXICOL, V57, P276, DOI 10.1016/j.fct.2013.03.034
   Wu QH, 2017, ARCH TOXICOL, V91, P3737, DOI 10.1007/s00204-017-2118-3
   Wu WD, 2013, TOXICOL SCI, V131, P279, DOI 10.1093/toxsci/kfs286
   Wu WD, 2012, FOOD CHEM TOXICOL, V50, P2056, DOI 10.1016/j.fct.2012.03.055
NR 50
TC 2
Z9 2
U1 1
U2 18
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD MAR 15
PY 2019
VL 160
BP 29
EP 37
DI 10.1016/j.toxicon.2019.02.006
PG 9
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA HQ4ZR
UT WOS:000462420300005
PM 30776380
DA 2020-05-12
ER

PT J
AU Gomes, M
   Alvarez, MA
   Quellis, LR
   Becher, ML
   Castro, JMD
   Gameiro, J
   Caporrino, MC
   Moura-da-Silva, AM
   Santos, MD
AF Gomes, Marinna
   Alejandra Alvarez, Maria
   Quellis, Leonardo Ramos
   Laguia Becher, Melina
   de Andrade Castro, Juciane Maria
   Gameiro, Jacy
   Caporrino, Maria Cristina
   Moura-da-Silva, Ana Maria
   Santos, Marcelo de Oliveira
TI Expression of an scFv antibody fragment in Nicotiana benthamiana and in
   vitro assessment of its neutralizing potential against the snake venom
   metalloproteinase BaP1 from Bothrops asper
SO TOXICON
LA English
DT Article
DE Bothrops; Molecular farming; scFv; BaP1; In vitro plant cultures;
   Heterologous expression
ID TRANSIENT EXPRESSION; MONOCLONAL-ANTIBODY; COAT PROTEIN; VIRUS; GENE;
   PLANTS
AB Human accidents with venomous snakes represent an overwhelming public health problem, mainly in rural populations of underdeveloped countries. Their high incidence and the severity of the accidents result in 81,000 to 138,000 deaths per year. The treatment is based on the administration of purified antibodies, produced by hyper immunization of animals to generate immunoglobulins (Igs), and then obtained by fractionating hyper immune plasma. The use of recombinant antibodies is an alternative to conventional treatment of snakebite envenoming, particularly the Fv fragment, named the single-chain variable fragment (scFv). We have produced recombinant single chain variable fragment scFv against the venom of the pit viper Bothrops asper at high levels expressed transiently and stably in transgenic plants and in vitro cultures that is reactive to BaP1 (a metalloproteinase from B. asper venom). The yield from stably transformed plants was significantly (p > 0.05) higher than the results in from transient expression. In addition, scFvBaP1 yields from systems derived from stable transformation were: transgenic callus 62 mu g/g (+/- 2); biomass from cell suspension cultures 83 mu g/g (+/- 0.2); culture medium from suspensions 71.75 mg/L (+/- 6.18). The activity of scFvBaP1 was confirmed by binding and neutralization of the fibrin degradation induced by BnP1 toxins from B. neuwiedi and by Atroxlysin Ia from B. atrox venoms. In the present work, we demonstrated the potential use of plant cells to produce scFvBaP1 to be used in the future as a biotechnological alternative to horse immunization protocols to produce anti-venoms to be used in human therapy against snakebites.
C1 [Gomes, Marinna; Quellis, Leonardo Ramos; Santos, Marcelo de Oliveira] Univ Fed Juiz de Fora, Inst Ciencias Biol, Lab Genet, Rua Jose Lourenco Kelmer S-N, BR-36036330 Juiz De Fora, MG, Brazil.
   [Alejandra Alvarez, Maria; Laguia Becher, Melina] Univ Maimonides, CONICET, CEBBAD, Hidalgo 775,Lab 603, Buenos Aires, DF, Argentina.
   [de Andrade Castro, Juciane Maria; Gameiro, Jacy] Univ Fed Juiz de Fora, Inst Ciencias Biol, Lab Imunol, Rua Jose Lourenco Kelmer S-N, BR-36036330 Juiz De Fora, MG, Brazil.
   [Caporrino, Maria Cristina; Moura-da-Silva, Ana Maria] Inst Butantan, Lab Imunopatol, Av Vital Brazil 1500, BR-05503900 Sao Paulo, SP, Brazil.
RP Santos, MD (reprint author), Univ Fed Juiz de Fora, Inst Ciencias Biol, Lab Genet, Rua Jose Lourenco Kelmer S-N, BR-36036330 Juiz De Fora, MG, Brazil.
EM marcelo.santos@ufjf.edu.br
RI Moura-da-Silva, Ana M/A-5247-2008; Alvarez, Maria/W-5654-2019
OI Moura-da-Silva, Ana M/0000-0003-1787-6634; Alvarez,
   Maria/0000-0001-5822-2106
FU Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior - Brasil
   (CAPES)CAPES [001]
FX "This study was financed in part by the Coordenacao de Aperfeicoamento
   de Pessoal de Nivel Superior - Brasil (CAPES) - Finance Code 001".
CR Alape-Giron A, 2009, TOXICON, V54, P938, DOI 10.1016/j.toxicon.2009.06.011
   Alkanaimsh S, 2016, FRONT PLANT SCI, V7, DOI 10.3389/fpls.2016.00743
   Azzazy HME, 2002, CLIN BIOCHEM, V35, P425, DOI 10.1016/S0009-9120(02)00343-0
   Baldo C, 2008, TOXICON, V51, P54, DOI 10.1016/j.toxicon.2007.08.005
   Besufekad Y, 2017, J ADV BIOL BIOTECHNO, V12, P1
   Castro JMA, 2014, TOXICON, V87, P81, DOI 10.1016/j.toxicon.2014.05.017
   Escalante T, 2004, TOXICON, V43, P213, DOI 10.1016/j.toxicon.2003.11.012
   Fernandes CM, 2007, BRIT J PHARMACOL, V151, P1254, DOI 10.1038/sj.bjp.0707351
   Fernandes CM, 2006, TOXICON, V47, P549, DOI 10.1016/j.toxicon.2006.01.009
   Fox J. L., 2012, Nature Biotechnology, V30, P472, DOI 10.1038/nbt0612-472
   Gois PHF, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0006024
   Freitas-de-Sousa LA, 2017, TOXINS, V9, DOI 10.3390/toxins9080239
   Goulet C, 2010, PLANT BIOTECHNOL J, V8, P142, DOI 10.1111/j.1467-7652.2009.00470.x
   Grosse-Holz F, 2018, PLANT BIOTECHNOL J, V16, P1068, DOI 10.1111/pbi.12852
   Gutierrez JM, 2005, T ROY SOC TROP MED H, V99, P468, DOI 10.1016/j.trstmh.2004.09.014
   Gutierrez JM, 1998, TOXICON, V36, P1529, DOI 10.1016/S0041-0101(98)00145-7
   Hallwass M, 2014, MOL PLANT PATHOL, V15, P871, DOI 10.1111/mpp.12144
   Juarez P, 2016, PLANT BIOTECHNOL J, V14, P1791, DOI 10.1111/pbi.12541
   Parreno JMJ, 2018, PLANT BIOTECHNOL J, V16, P727, DOI 10.1111/pbi.12823
   Jutras PV, 2015, BIOTECHNOL J, V10, P1478, DOI 10.1002/biot.201500056
   Lacombe S, 2018, J BIOSCI BIOENG, V125, P116, DOI 10.1016/j.jbiosc.2017.07.008
   Laustsen AH, 2018, TOXICON, V146, P151, DOI 10.1016/j.toxicon.2018.03.004
   Laustsen AH, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005361
   Laustsen AH, 2016, CURR PHARM DESIGN, V22, P5270, DOI 10.2174/1381612822666160623073438
   Laustsen AH, 2016, TOXINS, V8, DOI 10.3390/toxins8080226
   Lee CH, 2016, APPL ENVIRON MICROB, V82, P6973, DOI 10.1128/AEM.01876-16
   Leon G, 2013, TOXICON, V76, P63, DOI 10.1016/j.toxicon.2013.09.010
   Lowry O.H, 1951, J BIOL CHEM, V217, P220
   Ma JKC, 2003, NAT REV GENET, V4, P794, DOI 10.1038/nrg1177
   Magy B, 2014, PLANT BIOTECHNOL J, V12, P457, DOI 10.1111/pbi.12152
   Marusic C, 2016, PLANT BIOTECHNOL J, V14, P240, DOI 10.1111/pbi.12378
   Merlin M, 2014, BIOMED RES INT, DOI 10.1155/2014/136419
   Montero-Morales L, 2017, J PROTEOMICS, V161, P81, DOI 10.1016/j.jprot.2017.04.002
   Moussavou G, 2015, BIOMED RES INT, DOI 10.1155/2015/306164
   MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x
   Muthamilselvan T, 2016, PLANT BIOTECHNOL J, V14, P231, DOI 10.1111/pbi.12377
   Niemer M, 2016, BIOCHIMIE, V122, P119, DOI 10.1016/j.biochi.2015.06.017
   Otero-Patino R, 2009, TOXICON, V54, P998, DOI 10.1016/j.toxicon.2009.07.001
   Pera FFPG, 2015, VIROL J, V12, DOI 10.1186/s12985-015-0436-8
   Pessenda G, 2016, TOXICON, V112, P59, DOI 10.1016/j.toxicon.2016.01.062
   Porebski S, 1997, PLANT MOL BIOL REP, V15, P8, DOI 10.1007/BF02772108
   Qu F, 2003, J VIROL, V77, P511, DOI 10.1128/JVI.77.1.511-522.2003
   Rasool G, 2016, J AGRIC RES-LAHORE, V54, P21
   Robert S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070203
   Rucavado A, 1995, EXP MOL PATHOL, V63, P186, DOI 10.1006/exmp.1995.1042
   Sachett JAG, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005745
   Sack M, 2015, CURR OPIN BIOTECH, V32, P163, DOI 10.1016/j.copbio.2014.12.008
   Stephan A, 2017, INT J MOL SCI, V29, P19
   Tanjoni I, 2003, TOXICON, V42, P809, DOI 10.1016/j.toxicon.2003.10.011
   Watanabe L, 2003, PROTEIN SCI, V12, P2273, DOI 10.1110/ps.03102403
   WHO, 2010, GUID PROD CONTR REG
   WHO, 2012, AN BIT
   Xu J, 2016, ADV PARASIT, V92, P1, DOI 10.1016/bs.apar.2016.02.001
   Yao J, 2015, INT J MOL SCI, V16, P28549, DOI 10.3390/ijms161226122
   Yoshikawa M, 2017, J PLANT RES, V130, P75, DOI 10.1007/s10265-016-0874-4
   Yu F, 2014, MOL IMMUNOL, V59, P100, DOI 10.1016/j.molimm.2014.01.007
   Zhang L, 2014, P NATL ACAD SCI USA, V111, P2656, DOI 10.1073/pnas.1323436111
NR 57
TC 2
Z9 2
U1 1
U2 6
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD MAR 15
PY 2019
VL 160
BP 38
EP 46
DI 10.1016/j.toxicon.2019.02.011
PG 9
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA HQ4ZR
UT WOS:000462420300006
PM 30802471
DA 2020-05-12
ER

PT J
AU de Andrade, IRA
   Candido, MJD
   Pompeu, RCFF
   Feitosa, TS
   Bomfim, MAD
   Salles, HO
   do Egito, AS
AF Albuquerque de Andrade, Igo Renan
   Duarte Candido, Magno Jose
   Fernandes Franco Pompeu, Roberto Claudio
   Feitosa, Tiberio Sousa
   Delmondes Bomfim, Marco Aurelio
   Salles, Hevila Oliveira
   do Egito, Antonio Silvio
TI Inactivation of lectins from castor cake by alternative chemical
   compounds
SO TOXICON
LA English
DT Article
DE Denaturation; Electrophoresis; Hemagglutinating activity; Ricin; Ricinus
   agglutinin; Ricinus communis
ID FED DIETS; RICIN; OIL; TOXICITY; SHEEP; MEAL; DETOXIFICATION;
   PURIFICATION; PROTEINS
AB Enabling the use of castor cake in animal feeding is an excellent alternative strategy to reduce feed costs. The cake is a by-product derived from the extraction of the castor oil by the biodiesel industry whose chemical composition is satisfactory despite the presence of antinutritional factors like toxic lectins, which require detoxification before it can be used as a dietary ingredient. The aim of the present study was to evaluate alternative chemical sources in the degradation and inactivation of ricin and Ricinus communis agglutinin (RCA), two lectins from castor cake. Ten chemical compounds were evaluated: sodium hydroxide, monodicalcium phosphate, dicalcium phosphate, calcium oxide, calcium hydroxide, calcitic limestone, magnesian limestone, urea, potassium chloride, and sodium chloride. Gel electrophoresis indicated 100% lectin degradation only in the cakes treated with 90 g sodium hydroxide and 2500 mL water per kg of cake. The hemagglutination assay was crucial to providing innocuousness to the treated cakes, with total absence of hemagglutinating activity observed in the castor cakes treated with 60 or 90 g sodium hydroxide in water volumes equal to or higher than 1500 mL/kg of castor cake and in the cakes treated with 90 g calcium oxide with 2500 or 3000 mL water/kg castor cake. Thus, though depending on the concentration of the chemical compound and on the volume of water per kilogram of treated cake, sodium hydroxide and calcium oxide showed to be promising chemical products for degradation and complete inactivation of the lectins present in castor cake to allow its use as an ingredient in animal diets.
C1 [Albuquerque de Andrade, Igo Renan] Inst Fed Educ Ciencia & Tecnol Ceara IFCE, Campus Crateus,Av Geraldo Marques Barbosa 567, BR-63708260 Crateus, CE, Brazil.
   [Duarte Candido, Magno Jose] Univ Fed Ceara, Ctr Ciencias Agr, Dept Zootecnia, Av Mister Hulk 2977,Bl 808,Pici Campus, BR-60440554 Fortaleza, Ceara, Brazil.
   [Fernandes Franco Pompeu, Roberto Claudio; Delmondes Bomfim, Marco Aurelio; Salles, Hevila Oliveira] Embrapa Caprinos & Ovinos, Estr Sobral Groairas,Km 04,POB 71, BR-62010970 Sobral, CE, Brazil.
   [Feitosa, Tiberio Sousa] Univ Sao Paulo, ESALQ, Dept Zootecnia, Ave Padua Dias 11, BR-13418900 Piracicaba, SP, Brazil.
   [do Egito, Antonio Silvio] Embrapa Caprinos & Ovinos, Nucl Reg Nordeste, Rua Oswaldo Cruz 1-143, BR-58428095 Campina Grande, PB, Brazil.
RP de Andrade, IRA (reprint author), Inst Fed Educ Ciencia & Tecnol Ceara IFCE, Campus Crateus,Av Geraldo Marques Barbosa 567, BR-63708260 Crateus, CE, Brazil.
EM igo.andrade@ifce.edu.br; magno@ufc.br; antoniosilvio.egito@embrapa.br
RI EGITO, ANTONIO SILVIO/AAC-5929-2019; POMPEU, ROBERTO CLAUDIO FERNANDES
   FRANCO/C-4358-2013; Candido, Magno Jose Duarte/E-2995-2013
OI Candido, Magno Jose Duarte/0000-0003-3573-6053; Pompeu, Roberto Claudio
   Fernandes Franco/0000-0002-4099-3575; Renan Albuquerque de Andrade,
   Igo/0000-0002-3093-4168
FU CAPES through the PROPAG program; FUNCAP [TJP-0072-001320200/12,
   07/2013]; CNPqNational Council for Scientific and Technological
   Development (CNPq) [472322/2013-3]
FX The authors thank the Federal University of Ceara and Embrapa Caprinos e
   Ovinos for the framework for the experiment; Inchistria e Comercio de
   Oleos Vegetais - OLVEQ, for providing the castor cake; CAPES, through
   the PROPAG program, for the fellowship grant; and FUNCAP (case no.
   TJP-0072-001320200/12 notice no. 07/2013) and CNPq (case no.
   472322/2013-3), for financing the project.
CR Akande TO, 2016, J ANIM PHYSIOL AN N, V100, P201, DOI 10.1111/jpn.12360
   Anandan S, 2005, ANIM FEED SCI TECH, V120, P159, DOI 10.1016/j.anifeedsci.2004.10.002
   [Anonymous], 2008, EFSA J, V6, DOI 10.2903/j.efsa.2008.726
   Aslani MR, 2007, TOXICON, V49, P400, DOI 10.1016/j.toxicon.2006.10.010
   Audi J, 2013, AM MED ASS, V294, P2342, DOI [10.1001/jama.294.18.2342, DOI 10.1001/JAMA.294.18.2342]
   Barnes DJ, 2009, IND CROP PROD, V30, P254, DOI 10.1016/j.indcrop.2009.04.003
   Bozza WP, 2015, BIOTECHNOL ADV, V33, P117, DOI 10.1016/j.biotechadv.2014.11.012
   CAWLEY DB, 1978, ARCH BIOCHEM BIOPHYS, V190, P744, DOI 10.1016/0003-9861(78)90335-1
   Cesar AD, 2010, ENERG POLICY, V38, P4031, DOI 10.1016/j.enpol.2010.03.027
   Damodaran S., 2010, FENNEMAS FOOD CHEM
   de Oliveira AS, 2010, ANIM FEED SCI TECH, V158, P15, DOI 10.1016/j.anifeedsci.2010.02.009
   Dib R, 1998, FEBS LETT, V431, P279, DOI 10.1016/S0014-5793(98)00782-0
   Diniz LL, 2011, LIVEST SCI, V135, P153, DOI 10.1016/j.livsci.2010.07.001
   Dubois JL, 2013, IND CROP PROD, V43, P194, DOI 10.1016/j.indcrop.2012.07.012
   Pompeu RCFF, 2012, REV BRAS ZOOTECN, V41, P726, DOI 10.1590/S1516-35982012000300036
   Furtado RN, 2012, ARQ BRAS MED VET ZOO, V64, P155, DOI 10.1590/S0102-09352012000100022
   Garland T, 2006, REV SCI TECH OIE, V25, P341, DOI 10.20506/rst.25.1.1661
   Gowd NKS, 2009, J SCI FOOD AGR, V89, P216, DOI 10.1002/jsfa.3427
   Iyer R, 2011, J AM OIL CHEM SOC, V88, P1271, DOI 10.1007/s11746-011-1775-2
   Kreuzer HW, 2013, J FORENSIC SCI, V58, pS43, DOI 10.1111/1556-4029.12000
   LAEMMLI UK, 1973, J MOL BIOL, V80, P575, DOI 10.1016/0022-2836(73)90198-8
   Lord JM, 2011, TOXINS, V3, P787, DOI 10.3390/toxins3070787
   LYNN KR, 1986, PHYTOCHEMISTRY, V25, P1553, DOI 10.1016/S0031-9422(00)81207-8
   Melo WC, 2008, QUIM NOVA, V31, P1104, DOI 10.1590/S0100-40422008000500031
   Olsnes S, 2001, TOXICON, V39, P1723, DOI 10.1016/S0041-0101(01)00158-1
   Raimondo RFS, 2013, PESQUI VET BRASIL, V33, P119, DOI 10.1590/S0100-736X2013000100022
   Roy CJ, 2015, P NATL ACAD SCI USA, V112, P3782, DOI 10.1073/pnas.1502585112
   SALTVEDT E, 1976, BIOCHIM BIOPHYS ACTA, V451, P536, DOI 10.1016/0304-4165(76)90149-5
   Sanchez R, 2011, IND LUBR TRIBOL, V63, P446, DOI 10.1108/00368791111169034
   Scholza V, 2008, BIOMASS BIOENERG, V32, P95, DOI 10.1016/j.biombioe.2007.08.004
   Sehgal P, 2011, TOXICOLOGY, V282, P56, DOI 10.1016/j.tox.2011.01.012
   Sehgal P, 2010, FOOD CHEM TOXICOL, V48, P3171, DOI 10.1016/j.fct.2010.08.015
   Tunaru S, 2012, P NATL ACAD SCI USA, V109, P9179, DOI 10.1073/pnas.1201627109
   Walsh MJ, 2013, VIRULENCE, V4, P774, DOI 10.4161/viru.26399
   Worbs S, 2011, TOXINS, V3, P1332, DOI 10.3390/toxins3101332
   Zhan JB, 2003, TOXICOLOGY, V186, P119, DOI 10.1016/S0300-483X(02)00726-6
NR 36
TC 0
Z9 0
U1 1
U2 2
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD MAR 15
PY 2019
VL 160
BP 47
EP 54
DI 10.1016/j.toxicon.2019.02.003
PG 8
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA HQ4ZR
UT WOS:000462420300007
PM 30790577
DA 2020-05-12
ER

PT J
AU Tan, KY
   Liew, ST
   Tan, QY
   Abdul-Rahman, FN
   Azmi, NI
   Sim, SM
   Tan, NH
   Khomvilai, S
   Sitprija, V
   Tan, CH
AF Tan, Kae Yi
   Liew, Sin Teng
   Tan, Qian Yi
   Abdul-Rahman, Farah Nadhirah
   Azmi, Nor Izzati
   Sim, Si Mui
   Tan, Nget Hong
   Khomvilai, Sumana
   Sitprija, Visith
   Tan, Choo Hock
TI Evaluating the physicochemical properties and efficacy of recently
   expired and aged antivenom products from Thailand and Taiwan
SO TOXICON
LA English
DT Article
ID CROSS-NEUTRALIZATION; VENOMICS; COBRA; NAJA; LETHALITY; INSIGHTS
AB Gel filtration chromatography and gel electrophoresis revealed minimal protein degradation in lyophilized antivenoms which were 2-year expired (Hemato Polyvalent, Neuro Polyvalent; Thailand) and 18-year expired (Hemato Bivalent, Neuro Bivalent; Taiwan). All expired antivenoms retained immunological binding activity, and were able to neutralize the hemotoxic or neurotoxic as well as lethal effects of the homologous snake venoms. The findings show that antivenoms under proper storage conditions may remain relatively stable beyond the indicated shelf life.
C1 [Tan, Kae Yi; Tan, Nget Hong] Univ Malaya, Fac Med, Dept Mol Med, Kuala Lumpur, Malaysia.
   [Liew, Sin Teng; Tan, Qian Yi; Abdul-Rahman, Farah Nadhirah; Azmi, Nor Izzati] Univ Malaya, Fac Med, Dept Biomed Sci, Kuala Lumpur, Malaysia.
   [Sim, Si Mui; Tan, Choo Hock] Univ Malaya, Fac Med, Dept Pharmacol, Kuala Lumpur, Malaysia.
   [Khomvilai, Sumana; Sitprija, Visith] Thai Red Cross Soc, Queen Saovabha Mem Inst, Rama 4 Rd, Bangkok, Thailand.
RP Tan, CH (reprint author), Univ Malaya, Fac Med, Dept Pharmacol, Kuala Lumpur, Malaysia.
EM tanch@um.edu.my
RI TAN, KAE YI/D-7915-2017; Tan, Choo Hock/B-9905-2010; TAN, KAE
   YI/H-6727-2017; Sim, Debra Si Mui/W-1022-2019
OI TAN, KAE YI/0000-0002-6938-7325; TAN, KAE YI/0000-0002-6938-7325; Tan,
   Choo Hock/0000-0003-1416-077X
FU University of MalayaUniversiti Malaya [RG352-15AFR, BKS003-2017]
FX The authors are grateful to the University of Malaya for the provision
   of research facilities and funding (Grants no. RG352-15AFR and
   BKS003-2017).
CR Arnold C, 2016, NATURE, V537, P26, DOI 10.1038/537026a
   Brown NI, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001670
   Chippaux J. P, 2009, REPTILE VENOMS TOXIN
   Chippaux JP, 2015, T ROY SOC TROP MED H, V109, P747, DOI 10.1093/trstmh/trv088
   Faisal T, 2018, J PROTEOMICS, V183, P1, DOI 10.1016/j.jprot.2018.05.003
   Garcia M, 2002, BIOLOGICALS, V30, P143, DOI 10.1006/biol.2002.0329
   Khomvilai S., 2008, P IN C GLOB ISS CLIN
   Leong PK, 2014, ACTA TROP, V132, P7, DOI 10.1016/j.actatropica.2013.12.015
   Gutierrez JM, 2014, B WORLD HEALTH ORGAN, V92, P526, DOI 10.2471/BLT.13.132431
   O'Leary MA, 2009, T ROY SOC TROP MED H, V103, P937, DOI 10.1016/j.trstmh.2008.11.011
   Oh AMF, 2019, J PROTEOMICS, V193, P243, DOI 10.1016/j.jprot.2018.10.016
   Ratanabanangkoon K, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004565
   Tan C. H., 2019, TOXINS, V11
   Tan Choo Hock, 2019, Methods Mol Biol, V1871, P153, DOI 10.1007/978-1-4939-8814-3_11
   Tan CH, 2017, TOXICON, V140, P32, DOI 10.1016/j.toxicon.2017.10.014
   Tan CH, 2017, J PROTEOMICS, V166, P48, DOI 10.1016/j.jprot.2017.07.002
   Tan CH, 2016, SCI REP-UK, V6, DOI 10.1038/srep37299
   Tan CH, 2011, ACTA TROP, V117, P119, DOI 10.1016/j.actatropica.2010.11.001
   Tan KY, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-25955-y
   Tan KY, 2016, TOXINS, V8, DOI 10.3390/toxins8040086
   Tan KY, 2015, J PROTEOMICS, V120, P105, DOI 10.1016/j.jprot.2015.02.012
   Tan NH, 2017, J PROTEOMICS, V157, P18, DOI 10.1016/j.jprot.2017.01.018
   Villalta M, 2012, J PROTEOMICS, V75, P5628, DOI 10.1016/j.jprot.2012.08.008
   Wong KY, 2016, AM J TROP MED HYG, V94, P1392, DOI 10.4269/ajtmh.15-0871
   World Health Organization W, 2010, WHO GUID PROD CONTR, P134
NR 25
TC 1
Z9 1
U1 0
U2 2
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD MAR 15
PY 2019
VL 160
BP 55
EP 58
DI 10.1016/j.toxicon.2019.02.010
PG 4
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA HQ4ZR
UT WOS:000462420300008
PM 30797900
DA 2020-05-12
ER

PT J
AU Feng, RT
   Li, JG
   Dong, LB
   Hao, ZH
   Ba, ZR
   Zhan, HJ
   Fang, YT
AF Feng Rongtao
   Li Junguo
   Dong Libo
   Hao Zhenhua
   Ba Zhongren
   Zhan Haijuan
   Fang Yitian
TI Gas-solid flow behaviors in a multi-stage circulating fluidized bed
   under elevated pressure
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Fluidization; Circulating fluidized bed; Flow behaviors; Solids holdup;
   Elevated pressure
ID COAL-GASIFICATION; PARTICLE-SIZE; DENSITY; HYDRODYNAMICS; EXPANSION;
   TEMPERATURE; VELOCITY; MINIMUM; RISER
AB Pressurized circulating fluidized bed technology is promising in coal & biomass combustion and gasification. To get more detail information of pressure effects on gas-solids flow behaviors in a circulating fluidized bed reactor, we built a novel pressurized multi-stage circulating fluidized bed (MCFB) reactor a cold pilot setup with 14.5 m height. The experiment was carried out at the elevated pressure up to 0.9 MPa with the use of polystyrene particles (rho(s) = 1020 kg/m(3), d(p) = 400 mu m). We used differential pressure transducers to collect the pressure data and monitor the operating condition. Local solids holdup was measured by the optical fiber probes. Our results showed that the apparent solids holdup presented multi-flow regimes in the axial direction of MCFB. Under the same solids circulation rate and superficial gas velocity, the apparent solids holdup and local solids holdup decreased, and the axial flow structure and radial profiles of solids holdup became more uniform with increasing the pressure. When the fluidized gas mass flow rate and the solids circulation rate were kept the same, the solids holdup at axial and radial directions increased with the pressure. The speed of gas-solids flow development was different at various pressures with a slower speed at high pressure under the same solids circulation rate and superficial gas velocity. As a result, the elevated pressure significantly influences the gas-solids flow behaviors and provides better riser performance with good gas-solids contacting and mixing by the uniform radial and axial distributions than the atmospheric pressure at the same superficial gas velocity. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Feng Rongtao; Li Junguo; Dong Libo; Hao Zhenhua; Ba Zhongren; Fang Yitian] Chinese Acad Sci, Inst Coal Chem, State Key Lab Coal Convers, Taiyuan 030001, Shanxi, Peoples R China.
   [Feng Rongtao] Univ Chinese Acad Sci, Beijing 100039, Peoples R China.
   [Zhan Haijuan] NingXia Univ, State Key Lab High Efficiency Utilizat Coal & Gre, Yinchuan 750021, Peoples R China.
RP Li, JG; Fang, YT (reprint author), Chinese Acad Sci, Inst Coal Chem, State Key Lab Coal Convers, Taiyuan 030001, Shanxi, Peoples R China.
EM lijg@sxicc.ac.cn; fyt@sxicc.ac.cn
RI Li, Junguo/C-7799-2019
OI Li, Junguo/0000-0002-8001-5338
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [21506242]; Foundation of State Key Laboratory of
   High-efficiency Utilization of Coal and Green Chemical Engineering of
   China [2017-K02]
FX The authors gratefully acknowledge the National Natural Science
   Foundation of China (NO. 21506242) and Foundation of State Key
   Laboratory of High-efficiency Utilization of Coal and Green Chemical
   Engineering of China (NO. 2017-K02). Their supports are greatly
   appreciated.
CR CHAN IH, 1987, POWDER TECHNOL, V53, P217, DOI 10.1016/0032-5910(87)80096-7
   DECARVALHO JRFG, 1981, CHEM ENG SCI, V36, P413, DOI 10.1016/0009-2509(81)85022-1
   Duan F, 2010, ENERG FUEL, V24, P3150, DOI 10.1021/ef901596n
   Feng RT, 2017, POWDER TECHNOL, V320, P27, DOI 10.1016/j.powtec.2017.07.024
   Issangya AS, 1999, CHEM ENG SCI, V54, P5451, DOI 10.1016/S0009-2509(99)00283-3
   Jiang XF, 2014, POWDER TECHNOL, V264, P22, DOI 10.1016/j.powtec.2014.05.015
   Kim SW, 2004, CHEM ENG SCI, V59, P3955, DOI 10.1016/j.ces.2004.06.018
   Kwauk M.S., 2007, HDB FLUIDIZATION
   Lackermeier U, 2002, CHEM ENG PROCESS, V41, P771, DOI 10.1016/S0255-2701(02)00008-9
   Li HY, 2013, CAN J CHEM ENG, V91, P760, DOI 10.1002/cjce.21723
   Li J. H., 1993, J CHEM IND ENG, V44, P10
   Li JG, 2018, FUEL, V220, P80, DOI 10.1016/j.fuel.2018.02.005
   Li JG, 2013, FUEL, V110, P153, DOI 10.1016/j.fuel.2012.09.087
   Llop MF, 2000, POWDER TECHNOL, V107, P212, DOI 10.1016/S0032-5910(99)00188-6
   Mastellone ML, 1999, CHEM ENG SCI, V54, P5383
   Monazam ER, 2016, POWDER TECHNOL, V291, P383, DOI 10.1016/j.powtec.2015.12.041
   Qi MZ, 2012, CHEM ENG J, V209, P633, DOI 10.1016/j.cej.2012.08.060
   Richtberg M, 2005, POWDER TECHNOL, V155, P145, DOI 10.1016/j.powtec.2005.05.034
   Shabanian J, 2017, CHEM ENG J, V313, P580, DOI 10.1016/j.cej.2016.12.061
   Song JL, 2018, CHEM ENG RES DES, V138, P21, DOI 10.1016/j.cherd.2018.08.012
   van Ommen JR, 2008, INT J CHEM REACT ENG, V6
   Verma V, 2014, IND ENG CHEM RES, V53, P17487, DOI 10.1021/ie502474k
   Wang ZY, 2013, FUEL PROCESS TECHNOL, V115, P99, DOI 10.1016/j.fuproc.2013.04.011
   YATES JG, 1994, INT J MULTIPHAS FLOW, V20, P297, DOI 10.1016/0301-9322(94)90076-0
   Yin SY, 2014, CHEM ENG COMMUN, V201, P352, DOI 10.1080/00986445.2013.773423
   Yitian F, 2007, COAL CHEM IND, P11
   Zhang H, 1998, POWDER TECHNOL, V100, P260, DOI 10.1016/S0032-5910(98)00147-8
   Zhang YW, 2018, POWDER TECHNOL, V327, P17, DOI 10.1016/j.powtec.2017.12.040
   Zhu H, 2008, AICHE J, V54, P1213, DOI 10.1002/aic.11432
   Zhu JX, 2001, CAN J CHEM ENG, V79, P203, DOI 10.1002/cjce.5450790203
   ZHU JX, 1995, CAN J CHEM ENG, V73, P644, DOI 10.1002/cjce.5450730507
   Zhu XL, 2013, CHEM ENG J, V232, P290, DOI 10.1016/j.cej.2013.06.126
NR 32
TC 6
Z9 6
U1 14
U2 53
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAR 16
PY 2019
VL 196
BP 1
EP 13
DI 10.1016/j.ces.2018.11.057
PG 13
WC Engineering, Chemical
SC Engineering
GA HI9RQ
UT WOS:000456795700001
DA 2020-05-12
ER

PT J
AU Duan, HJ
   Ren, Y
   Zhang, LF
AF Duan, Haojian
   Ren, Ying
   Zhang, Lifeng
TI Initial agglomeration of non-wetted solid particles in high temperature
   melt
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Agglomeration; Bridge cavitation theory; Critical separation distance;
   Equilibrium state
ID DOUBLE-LAYER FORCES; HYDROPHOBIC SURFACES; DISSOLVED-GAS; BRIDGING
   BUBBLES; FREE-ENERGY; ATTRACTION; LONG; ELECTROLYTE; NANOBUBBLES;
   TRANSITION
AB Based on the bridge cavitation theory, the free energy variation during the cavitation between two nonwetted solid particles in a high temperature melt was investigated. The activation state and the stable state were achieved at the maximum and the minimum of the free energy curve varying with the neck radius, respectively. Increasing the separation distance between particles, both the activation energy and the stable energy increased. The activation separation distance was defined as the separation distance at which the extremum of the total free energy with respect to the neck radius had disappeared and the critical separation distance was derived by equaling the free energy before and after the cavitation. When particles were contacting, an equilibrium state was obtained as the system energy reached its minimum value. The equilibrium energy was the energy when the energy drop for the cavitation reached its maximum value. It is novel for the present study to find that both the activation separation distance and the critical separation distance were directly proportional to the radius of particles. Meanwhile, the equilibrium energy was a quadratic function of the particle radius. In the case of the cavitation between two 5.0 mu m alumina particles in the molten steel, the activation separation distance, the critical separation distance and the equilibrium energy were 0.96 mu m, 0.73 mu m and 17.75 x 10(12) J, respectively. Furthermore, a comparison between the calculation and experimental results showed a good agreement. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Duan, Haojian; Ren, Ying; Zhang, Lifeng] Univ Sci & Technol Beijing, Sch Met & Ecol Engn, Beijing 100083, Peoples R China.
RP Ren, Y; Zhang, LF (reprint author), Univ Sci & Technol Beijing, Sch Met & Ecol Engn, Beijing 100083, Peoples R China.
EM renyingfour@163.com; zhanglifeng@ustb.edu.cn
FU National Key R&D Program of China [2017YFB0304000, 2017YFB0304001];
   National Science Foundation ChinaNational Natural Science Foundation of
   China [51725402, 51504020, 51704018]; Fundamental Research Funds for the
   Central UniversitiesFundamental Research Funds for the Central
   Universities [FRF-TP-15-001C2, FRF-TP-15-067A1, FRF-TP-17-039A1];
   Guangxi Key Research and Development Plan [AB17129006]; National
   Postdoctoral Program for Innovative Talents [BX201700028]; Beijing Key
   Laboratory of Green Recycling and Extraction of Metals (GREM); High
   Quality steel Consortium (HQSC) at the School of Metallurgical and
   Ecological Engineering at University of Science and Technology Beijing
   (USTB), China; Green Process Metallurgy and Modeling (GPM2) at the
   School of Metallurgical and Ecological Engineering at University of
   Science and Technology Beijing (USTB), China
FX The authors are grateful for support from the National Key R&D Program
   of China (2017YFB0304000 & 2017YFB0304001), National Science Foundation
   China (Grant No. 51725402, No. 51504020 and No. 51704018), the
   Fundamental Research Funds for the Central Universities (Grant No.
   FRF-TP-15-001C2, No. FRF-TP-15-067A1 and No. FRF-TP-17-039A1), Guangxi
   Key Research and Development Plan (Grant No. AB17129006), National
   Postdoctoral Program for Innovative Talents (Grant No. BX201700028),
   Beijing Key Laboratory of Green Recycling and Extraction of Metals
   (GREM) and the High Quality steel Consortium (HQSC) and Green Process
   Metallurgy and Modeling (GPM<SUP>2</SUP>) at the School of Metallurgical
   and Ecological Engineering at University of Science and Technology
   Beijing (USTB), China.
CR Attard P, 1996, LANGMUIR, V12, P1693, DOI 10.1021/la950866w
   Attard P, 2003, ADV COLLOID INTERFAC, V104, P75, DOI 10.1016/S0001-8686(03)00037-X
   ATTARD P, 1989, J PHYS CHEM-US, V93, P6441, DOI 10.1021/j100354a032
   Attard P, 2000, LANGMUIR, V16, P4455, DOI 10.1021/la991258+
   Attard P., 2013, EUR PHYS J SPEC TOP
   Bostrom M, 2006, ADV COLLOID INTERFAC, V123, P5, DOI 10.1016/j.cis.2006.05.001
   Bratko D, 2001, J CHEM PHYS, V115, P3873, DOI 10.1063/1.1386926
   Carambassis A, 1998, PHYS REV LETT, V80, P5357, DOI 10.1103/PhysRevLett.80.5357
   CHRISTENSON HK, 1990, J PHYS CHEM-US, V94, P8004, DOI 10.1021/j100384a002
   CHRISTENSON HK, 1988, SCIENCE, V239, P390, DOI 10.1126/science.239.4838.390
   Considine RF, 1999, LANGMUIR, V15, P1657, DOI 10.1021/la980900h
   Craig VSJ, 1998, LANGMUIR, V14, P3326, DOI 10.1021/la970591f
   Gooch J. W., 2011, ENCY DICT POLYM, P238
   Hamaker HC, 1937, PHYSICA, V4, P1058, DOI 10.1016/S0031-8914(37)80203-7
   Hampton MA, 2009, J COLLOID INTERF SCI, V333, P800, DOI 10.1016/j.jcis.2009.01.035
   JACQUES MT, 1979, AICHE J, V25, P160, DOI 10.1002/aic.690250118
   Leung K, 2000, J CHEM PHYS, V113, P5845, DOI 10.1063/1.1290479
   LIAN GP, 1993, J COLLOID INTERF SCI, V161, P138, DOI 10.1006/jcis.1993.1452
   Lifshits E.M., 1955, Zhurnal Eksperimental'noi i Teoreticheskoi Fiziki, V29, P94
   Lum K, 1997, PHYS REV E, V56, pR6283, DOI 10.1103/PhysRevE.56.R6283
   Lum K, 1999, J PHYS CHEM B, V103, P4570, DOI 10.1021/jp984327m
   Mahnke J, 1999, PHYS CHEM CHEM PHYS, V1, P2793, DOI 10.1039/a900974d
   MASON G, 1965, CHEM ENG SCI, V20, P859, DOI 10.1016/0009-2509(65)80082-3
   MEAGHER L, 1994, LANGMUIR, V10, P2736, DOI 10.1021/la00020a039
   Meyer EE, 2005, LANGMUIR, V21, P256, DOI 10.1021/la048318i
   MIKLAVCIC SJ, 1995, J CHEM PHYS, V103, P4794, DOI 10.1063/1.470614
   MIKLAVIC SJ, 1994, J PHYS CHEM-US, V98, P9022, DOI 10.1021/j100087a034
   NINHAM BW, 1970, BIOPHYS J, V10, P646, DOI 10.1016/S0006-3495(70)86326-3
   NOGI K, 1983, CAN METALL QUART, V22, P19
   Ogino K, 1973, TETSU TO HAGANE, V59, P1237
   PARKER JL, 1994, J PHYS CHEM-US, V98, P8468, DOI 10.1021/j100085a029
   PASHLEY RM, 1985, SCIENCE, V229, P1088, DOI 10.1126/science.4035349
   PODGORNIK R, 1989, J CHEM PHYS, V91, P5840, DOI 10.1063/1.457535
   Sasai K., 2016, ISIJ INT, V102, P187
   Sasai K, 2014, ISIJ INT, V54, P2780, DOI 10.2355/isijinternational.54.2780
   SIMONS SJR, 1994, CHEM ENG SCI, V49, P2331, DOI 10.1016/0009-2509(94)E0050-Z
   Singh S, 2006, NATURE, V442, P526, DOI 10.1038/442526a
   SPALLA O, 1995, PHYS REV LETT, V74, P2515, DOI 10.1103/PhysRevLett.74.2515
   Stevens H, 2005, LANGMUIR, V21, P6399, DOI 10.1021/la0507535
   Taniguchi S., 1996, ISIJ INT, V36, pS117
   Wood J, 1995, LANGMUIR, V11, P4797, DOI 10.1021/la00012a035
   YAMINSKY VV, 1993, LANGMUIR, V9, P3618, DOI 10.1021/la00036a043
   YAMINSKY VV, 1983, J COLLOID INTERF SCI, V96, P301, DOI 10.1016/0021-9797(83)90034-6
   YAMINSKY VV, 1983, COLLOID SURFACE, V6, P63, DOI 10.1016/0166-6622(83)80007-9
   Zhang XH, 2006, LANGMUIR, V22, P5025, DOI 10.1021/la0601814
   Zheng LC, 2016, ISIJ INT, V56, P926, DOI 10.2355/isijinternational.ISIJINT-2015-561
NR 46
TC 2
Z9 2
U1 5
U2 12
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAR 16
PY 2019
VL 196
BP 14
EP 24
DI 10.1016/j.ces.2018.12.008
PG 11
WC Engineering, Chemical
SC Engineering
GA HI9RQ
UT WOS:000456795700002
DA 2020-05-12
ER

PT J
AU Karampalis, D
   Cao, H
   Caragay, J
   Ding, YL
   Bakalis, S
AF Karampalis, Dimitris
   Cao, Hui
   Caragay, Joel
   Ding, Yulong
   Bakalis, Serafim
TI Understanding dissolution phenomena of spray dried powders using a
   single particle approach
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Dissolution; Single particle approach; Microscopy; Image analysis;
   Porous powder; Inter-particle cohesive effect
ID GUAR GUM POWDERS; EXTENDED DLVO THEORY; INTRINSIC DISSOLUTION; KINETICS;
   BEHAVIOR; DISINTEGRATION; STABILITY; SURFACE; AGGLOMERATION; MECHANISM
AB History studies of particle dissolution have been focused on both "bulk approach" and "single approach". The link between these two approaches can reveal inter-particle cohesive effect but it is rarely reported. The presented work addresses this scientific challenge by investigating individual particle dissolution kinetics, using Monte Carlo analysis to convert results to bulk particle dissolution profiles, and comparing them to experimental results of bulk particle dissolution kinetics. The impact of binder materials on inter-particle cohesive effect has been studied using spray-dried powders with a binary matrix formulation. Dissolution of individual particles across size range was observed under an optical microscope and analysed by Image Processing. The results were used to predict bulk particles dissolution profiles via a Monte Carlo analysis. Meanwhile, chemical measurement (conductivity) of bulk particle dissolution was carried out for the same sample. The comparison between Monte Carlo analysis and chemical measurements showed a good agreement for the samples without binder and with mix binder (Citric Acid + MgSO4 + Zeolite). For the samples with Silicate as binder material, the comparison did not correlate well, chemical measurement shows a generally faster dissolution for bulk particles than Monte Carlo analysis, and higher Silicate concentration in particles results in larger difference. This is mainly due to the polymerization of Silicate that forms a "shell" structure around the particle and slows down dissolution for individual particles. However, in bulk particle dissolution, high salt concentration in the local area around particles breaks polymerization of Silicate and reduces the effect on particle dissolution. Consequently, it is proposed that Monte Carlo analysis of individual particle dissolution can be used to compare to bulk particle dissolution in order to reveal inter-particle cohesive effect on particle dissolution kinetics. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Karampalis, Dimitris; Cao, Hui; Ding, Yulong] Univ Birmingham, Sch Chem Engn, Birmingham B15 2TT, W Midlands, England.
   [Caragay, Joel] Procter & Gamble Newcastle Innovat Ctr, Newcastle Upon Tyne NE12 9TS, Tyne & Wear, England.
   [Bakalis, Serafim] Univ Nottingham, Dept Chem & Environm Engn, Nottingham NG7 2RD, England.
RP Cao, H (reprint author), Univ Birmingham, Sch Chem Engn, Birmingham B15 2TT, W Midlands, England.
EM h.cao@bham.ac.uk
RI Ding, Yulong/AAA-8358-2019
FU Department for Business Innovation Skills; Procter and Gamble Newcastle
   Innovation Centre, United Kingdom; PG
FX Funding for this project is provided by the Department for Business
   Innovation & Skills in collaboration with Procter and Gamble Newcastle
   Innovation Centre, United Kingdom and other partners. The authors would
   also like to thank P&G for their support and contributions to this
   project.
CR Akay G., 1991, EP0534525A2, Patent No. 0534525A2
   ALLEN T, 1997, PARTICLE SIZE MEASUR
   Ansari MA, 2008, POWDER TECHNOL, V181, P104, DOI 10.1016/j.powtec.2006.12.012
   Avdeef A, 2009, CHEM BIODIVERS, V6, P1796, DOI 10.1002/cbdv.200900082
   Bastan FE, 2013, MATER TEHNOL, V47, P303
   Bhandari BR, 2003, CARBOHYD RES, V338, P361, DOI 10.1016/S0008-6215(02)00466-4
   Bhattachar SN, 2002, INT J PHARM, V236, P135, DOI 10.1016/S0378-5173(02)00027-3
   Boerefijn R, 2007, HANDB POWD TECHNOL, V11, P673
   Borjesson E, 2013, DAIRY SCI TECHNOL, V93, P357, DOI 10.1007/s13594-012-0098-x
   Brunner E., 1904, Z PHYS CHEM, V43, P47
   Cao H, 2018, POWDER TECHNOL, V333, P394, DOI 10.1016/j.powtec.2018.04.037
   Chen Y., 2010, FUNDAMENTAL DIFFUSIO, DOI [10.1016/B978-0-12-802447-8.00009-1, DOI 10.1016/B978-0-12-802447-8.00009-1]
   Costa P, 2001, EUR J PHARM SCI, V13, P123, DOI 10.1016/S0928-0987(01)00095-1
   Derjaguin B.V., 1941, ACTA PHYSICOCHIM URS, V14, P633, DOI DOI 10.1016/0079-6816(93)90013-L
   Desai PM, 2016, J PHARM SCI-US, V105, P2545, DOI 10.1016/j.xphs.2015.12.019
   deVilliers MM, 1996, INT J PHARM, V136, P175, DOI 10.1016/0378-5173(95)04380-2
   Edelstein AD, 2014, J BIOL METHODS, V1, pe10, DOI DOI 10.14440/JBM.2014.36
   Forny L, 2011, POWDER TECHNOL, V206, P72, DOI 10.1016/j.powtec.2010.07.022
   Frolov V. F., 1998, THEOR FOUND CHEM ENG, V32, P10474, DOI [10.1021/la904685x, DOI 10.1021/LA904685X]
   Gianfrancesco A, 2011, PROC FOOD SCI, V1, P601, DOI 10.1016/j.profoo.2011.09.091
   Gorrepati EA, 2010, LANGMUIR, V26, P10467, DOI 10.1021/la904685x
   Hamouda AA, 2014, ENERGIES, V7, P568, DOI 10.3390/en7020568
   Handscomb C. S., 2008, THESIS, P237
   HIGUCHI WI, 1963, J PHARM SCI, V52, P67, DOI 10.1002/jps.2600520114
   Hixson AW, 1931, IND ENG CHEM, V23, P923, DOI 10.1021/ie50260a018
   HORN RG, 1989, CHEM PHYS LETT, V162, P404, DOI 10.1016/0009-2614(89)87066-6
   Hsu W. L., 2009, WORLD ACAD SCI ENG T, V3, DOI [10.1016/0166-6622(93)80004-Y.2009-05-21, DOI 10.1016/0166-6622(93)80004-Y.2009-05-21]
   Hulse WL, 2012, INT J PHARMACEUT, V434, P133, DOI 10.1016/j.ijpharm.2012.05.023
   Huntington DH, 2004, DRY TECHNOL, V22, P1261, DOI 10.1081/DRT-120038730
   Israelachvili J, 1996, NATURE, V379, P219, DOI 10.1038/379219a0
   Kaunisto E, 2013, J PHARM SCI-US, V102, P1569, DOI 10.1002/jps.23507
   Kaunisto E, 2009, PHARM DEV TECHNOL, V14, P400, DOI 10.1080/10837450802712641
   Kravtchenko TP, 1999, FOOD HYDROCOLLOID, V13, P219, DOI 10.1016/S0268-005X(99)00002-8
   Larsen CK, 2003, CARBOHYD POLYM, V51, P125, DOI 10.1016/S0144-8617(02)00139-X
   Li CD, 2016, CHINESE J CHEM ENG, V24, P1487, DOI 10.1016/j.cjche.2016.08.001
   Marabi A, 2008, CHEM ENG J, V139, P118, DOI 10.1016/j.cej.2007.07.081
   Marabi A, 2007, FOOD RES INT, V40, P1286, DOI 10.1016/j.foodres.2007.08.007
   Mills PJT, 2000, POWDER TECHNOL, V113, P140, DOI 10.1016/S0032-5910(00)00224-2
   MOSHARRAF M, 1995, INT J PHARM, V122, P35, DOI 10.1016/0378-5173(95)00033-F
   Moshinskii AI, 2004, THEOR FOUND CHEM ENG, V38, P375, DOI 10.1023/B:TFCE.0000036964.87348.0b
   Nernst N, 1904, Z PHYS CHEM-STOCH VE, V47, P52
   NICKLASSON M, 1983, INT J PHARM, V15, P87, DOI 10.1016/0378-5173(83)90069-8
   NIEBERGALL PJ, 1963, J PHARM SCI, V52, P236, DOI 10.1002/jps.2600520310
   NOYES AA, 1897, J AM CHEM SOC, V19, P930, DOI DOI 10.1021/JA02086A003
   Ostergaard J, 2011, J PHARM SCI-US, V100, P3405, DOI 10.1002/jps.22532
   Pillay V, 1999, J PHARM SCI, V88, P843, DOI 10.1021/js990139b
   Prasad KVR, 2002, INT J PHARM, V238, P29, DOI 10.1016/S0378-5173(02)00053-4
   Raghavan SL, 2002, J PHARM SCI, V91, P2166, DOI 10.1002/jps.10208
   Rasband W., 2003, IMAGEJ USER GUIDE IJ, P187, DOI [10.1038/nmeth.2019, DOI 10.1038/NMETH.2019]
   Scheubel E, 2010, PREDICTIVE IN VITRO
   Schubert H., 1987, Journal of Food Engineering, V6, P1, DOI 10.1016/0260-8774(87)90019-7
   Seville J. P. K., 2007, HDB POWDER TECHNOLOG, DOI [10.1002/ejoc.201200111, DOI 10.1002/EJOC.201200111]
   Smrcka D, 2016, EUR J PHARM BIOPHARM, V106, P107, DOI 10.1016/j.ejpb.2016.04.005
   Stepanek F, 2004, CHEM ENG RES DES, V82, P1458, DOI 10.1205/cerd.8211.1458.5235
   Svanback S, 2015, ANAL CHEM, V87, P11058, DOI 10.1021/acs.analchem.5b03067
   Svanback S, 2014, INT J PHARMACEUT, V469, P10, DOI 10.1016/j.ijpharm.2014.04.036
   Thakur SC, 2014, PARTICUOLOGY, V12, P2, DOI 10.1016/j.partic.2013.06.009
   Valmacco V, 2016, NANOSCALE HORIZ, V1, P325, DOI 10.1039/c6nh00070c
   Verwey E.J.W., 1948, THEORY STABILITY LYO
   Wang JZ, 1999, J PHARM SCI, V88, P731, DOI 10.1021/js980236p
   Wang Q, 2003, CARBOHYD POLYM, V53, P75, DOI 10.1016/S0144-8617(03)00009-2
   Wang Q, 2002, CARBOHYD POLYM, V49, P131, DOI 10.1016/S0144-8617(01)00327-7
   Wang Q, 2006, CARBOHYD POLYM, V64, P239, DOI 10.1016/j.carbpol.2005.11.032
   WEBB PA, 2001, INTRO PHYS CHARACTER
   YOKOYAMA A, 1989, LANGMUIR, V5, P534, DOI 10.1021/la00086a043
   YOTSUMOTO H, 1993, J COLLOID INTERF SCI, V157, P434, DOI 10.1006/jcis.1993.1206
   YOTSUMOTO H, 1993, J COLLOID INTERF SCI, V157, P426, DOI 10.1006/jcis.1993.1205
NR 67
TC 1
Z9 1
U1 1
U2 7
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAR 16
PY 2019
VL 196
BP 25
EP 36
DI 10.1016/j.ces.2018.11.046
PG 12
WC Engineering, Chemical
SC Engineering
GA HI9RQ
UT WOS:000456795700003
DA 2020-05-12
ER

PT J
AU Stroh, A
   Daikeler, A
   Nikku, M
   May, J
   Alobaid, F
   von Bohnstein, M
   Strohle, J
   Epple, B
AF Stroh, Alexander
   Daikeler, Alexander
   Nikku, Markku
   May, Jan
   Alobaid, Falah
   von Bohnstein, Maximilian
   Strohle, Jochen
   Epple, Bernd
TI Coarse grain 3D CFD-DEM simulation and validation with capacitance probe
   measurements in a circulating fluidized bed
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE 3D-CFD simulation; Coarse grain discrete element method; EMMS model;
   Capacitance probe measurements; Validation study
ID MWTH PILOT-PLANT; FLOW STRUCTURE; EMMS MODEL; RISER; SOLIDS;
   FORMULATION; COMBUSTION; TFM; EFM
AB A cold flow circulating fluidized bed (CFB) reactor is simulated under three fluidization velocities with the coarse grain discrete element method (DEM) using two different polydisperse particle systems namely glass beads and slightly coarser sand particles of Geldart A-B range. Particle velocities and particle concentration were measured by capacitance probe for the validation of the numerical model. The simulations were carried out using a homogenous drag model and a structure dependent drag model using the theory of energy minimization multiscale method (EMMS). Numerical parameters like grid resolution and computational time were investigated for the coarse grain CFD-DEM model, suggesting a cell uniformity criteria that might lead to more mesh independent results. The simulated macroscopic quantities such as pressure profile are generally in good agreement for all simulated cases using the EMMS model. Microscopic quantities such as particles velocities and solids concentration are partially matched well with the experimental data. The qualitative profiles of particle velocity and particle concentration are in better agreement for the EMMS model than for the homogenous drag model. The simulated reactor outflux using glass beads is well matched with experiment. The simulated reactor outflux with sand material is overestimated with EMMS model, although not that strong as for the Gidaspow model, in comparison to experimental measurements. One reason for the discrepancy is due to the cluster diameter correlation that require further development to be applicable in turbulent fluidization flow regime. Further model improvements are discussed and solutions are provided. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Stroh, Alexander; Daikeler, Alexander; May, Jan; Alobaid, Falah; von Bohnstein, Maximilian; Strohle, Jochen; Epple, Bernd] Tech Univ Darmstadt, Inst Energy Syst & Technol, Otto Berndt Str 2, D-64287 Darmstadt, Germany.
   [Nikku, Markku] Lappeenranta Univ Technol, LUT Energy, PL 20, FI-53851 Lappeenranta, Finland.
RP Stroh, A (reprint author), Tech Univ Darmstadt, Inst Energy Syst & Technol, Otto Berndt Str 2, D-64287 Darmstadt, Germany.
EM alexander.stroh@est.tu-darmstadt.de
OI Strohle, Jochen/0000-0003-2092-326X; Alobaid, Falah/0000-0003-1221-3567
FU European Union's Seventh Framework Programme (FP7/2007-2013)European
   Union (EU) [608578]; German Federal Ministry of Economic Affairs and
   Energy [LISA2 - FKZ: 03ET7018]; GE; RWE; Uniper; Steinmuller Babcock
   Engineering; Rheinkalk
FX The research leading to these results has received funding from the
   European Union's Seventh Framework Programme (FP7/2007-2013) under grant
   agreement No. 608578 (SCARLET-www.project-scarlet.eu) and from the
   German Federal Ministry of Economic Affairs and Energy based on a
   resolution of the German Parliament (LISA2 - FKZ: 03ET7018). The
   financial contribution of GE, RWE, Uniper, Steinmuller Babcock
   Engineering and Rheinkalk is gratefully acknowledged. We thank the
   Hochschulrechenzentrum Darmstadt for providing the infrastructure at the
   Lichtenberg high performance computer of Technical University Darmstadt.
CR Alobaid F, 2013, PARTICUOLOGY, V11, P514, DOI 10.1016/j.partic.2012.05.008
   BI HT, 1995, INT J MULTIPHAS FLOW, V21, P1229, DOI 10.1016/0301-9322(95)00037-X
   Boyer C, 2002, CHEM ENG SCI, V57, P3185, DOI 10.1016/S0009-2509(02)00193-8
   Chu KW, 2016, MINER ENG, V90, P43, DOI 10.1016/j.mineng.2016.01.020
   CUNDALL PA, 1979, GEOTECHNIQUE, V29, P47, DOI 10.1680/geot.1979.29.1.47
   Daikeler A, 2019, CHEM ENG SCI, V195, P921, DOI 10.1016/j.ces.2018.10.037
   Daikeler A., 2018, 23 INT C FLUID BED C
   Daikeler A., 2017, CIRC FLUD BED C KRAK
   Danowitz A, 2012, COMMUN ACM, V55, P55, DOI [10.1145/2133806.2133822, 10.1145/2133806.2133622]
   Du B, 2004, AICHE J, V50, P1386, DOI 10.1002/aic.10168
   Farrusseng D, 2011, METAL-ORGANIC FRAMEWORKS: APPLICATIONS FROM CATALYSIS TO GAS STORAGE, P1, DOI 10.1002/9783527635856
   Fluent A., 2013, 15 THEORY GUIDE
   GIBILARO LG, 1985, CHEM ENG SCI, V40, P1817, DOI 10.1016/0009-2509(85)80116-0
   Gidaspow D., 1994, MULTIPHASE FLOW FLUI
   Gidaspow D., 1991, HYDRODYNAMICS CIRCUL
   Govender N, 2015, MINER ENG, V79, P152, DOI 10.1016/j.mineng.2015.05.010
   Hernandez-Perez V, 2011, J COMPUT MULTIPHASE, V3, P13, DOI DOI 10.1260/1757-482X.3.1.13
   Hong K, 2012, CHEM ENG SCI, V75, P376, DOI 10.1016/j.ces.2012.03.022
   Jajcevic D, 2013, CHEM ENG SCI, V98, P298, DOI 10.1016/j.ces.2013.05.014
   KOLB A, 2004, P ACM SIGGRAPH EUROG, P123
   Kuwagi K, 2004, INT C FLUID ENG 11 I, V160, P243
   Li F, 2012, CHEM ENG SCI, V82, P104, DOI 10.1016/j.ces.2012.07.020
   Li J., 1994, PARTICLE FLUID 2 PHA
   Li JH, 1999, CHEM ENG SCI, V54, P5409, DOI 10.1016/S0009-2509(99)00274-2
   Lu BN, 2011, CHEM ENG SCI, V66, P4624, DOI 10.1016/j.ces.2011.06.026
   Lu LQ, 2018, CHEM ENG SCI, V179, P53, DOI 10.1016/j.ces.2018.01.003
   Lu LQ, 2016, CHEM ENG SCI, V155, P314, DOI 10.1016/j.ces.2016.08.013
   Lu LQ, 2016, IND ENG CHEM RES, V55, P10477, DOI 10.1021/acs.iecr.6b02688
   Lu LQ, 2014, CHEM ENG SCI, V120, P67, DOI 10.1016/j.ces.2014.08.004
   Marzocchella A, 1997, AICHE J, V43, P1458, DOI 10.1002/aic.690430609
   Mostoufi N, 2004, CHEM ENG SCI, V59, P4217, DOI 10.1016/j.ces.2004.06.006
   Nikku M, 2019, CHEM ENG SCI, V195, P39, DOI 10.1016/j.ces.2018.11.031
   Nikolopoulos A, 2017, CHEM ENG SCI, V163, P189, DOI 10.1016/j.ces.2017.01.052
   Nikolopoulos A, 2013, CHEM ENG SCI, V90, P137, DOI 10.1016/j.ces.2012.12.007
   Nikolopoulos A, 2010, CHEM ENG SCI, V65, P4089, DOI 10.1016/j.ces.2010.03.053
   O'Sullivan C, 2004, ENG COMPUTATION, V21, P278, DOI 10.1108/02644400410519794
   Peng ZB, 2014, AICHE J, V60, P2000, DOI 10.1002/aic.14421
   Sakai M, 2014, CHEM ENG J, V244, P33, DOI 10.1016/j.cej.2014.01.029
   Sakano M., 2000, JPN J MULTIPHASE FLO, V14, P66
   Strohle J, 2015, APPL ENERG, V157, P288, DOI 10.1016/j.apenergy.2015.06.035
   Strohle J, 2014, FUEL, V127, P13, DOI 10.1016/j.fuel.2013.12.043
   Stroh A, 2016, PARTICUOLOGY
   Stroh A, 2018, FUEL PROCESS TECHNOL, V169, P84, DOI 10.1016/j.fuproc.2017.09.014
   Stroh A, 2015, ENERGY, V85, P105, DOI 10.1016/j.energy.2015.03.078
   Syamlal M., 1993, DOEMETC951013 NAT EN
   Tang Y, 2015, AICHE J, V61, P688, DOI 10.1002/aic.14645
   Thakur SC, 2016, POWDER TECHNOL, V293, P130, DOI 10.1016/j.powtec.2015.05.051
   Thielicke W., 2014, J OPEN RES SOFTWARE, V2, pe30, DOI [DOI 10.5334/J0RS.BL, 10.5334/jors.bl]
   Vreman B, 2009, FLOW TURBUL COMBUST, V82, P47, DOI 10.1007/s10494-008-9173-z
   Wang JW, 2012, CHEM ENG SCI, V75, P349, DOI 10.1016/j.ces.2012.03.021
   Wang W, 2007, CHEM ENG SCI, V62, P208, DOI 10.1016/j.ces.2006.08.017
   Wen C.Y., 1966, CHEM ENG PROGR S SER, V62, P100, DOI DOI 10.1016/S0032-0633(98)00014-2
   Wiesendorf V., 2000, THESIS
   Yang N, 2004, IND ENG CHEM RES, V43, P5548, DOI 10.1021/ie049773c
   Yang SL, 2015, POWDER TECHNOL, V272, P85, DOI 10.1016/j.powtec.2014.11.035
   Yang W., 2003, HDB FLUIDIZATION FLU
   Zeneli M, 2015, CHEM ENG SCI, V138, P482, DOI 10.1016/j.ces.2015.08.008
NR 57
TC 6
Z9 6
U1 1
U2 23
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAR 16
PY 2019
VL 196
BP 37
EP 53
DI 10.1016/j.ces.2018.11.052
PG 17
WC Engineering, Chemical
SC Engineering
GA HI9RQ
UT WOS:000456795700004
DA 2020-05-12
ER

PT J
AU Li, K
   Xia, J
   Mehmood, MA
   Zhao, XQ
   Liu, CG
   Bai, FW
AF Li, Kai
   Xia, Juan
   Mehmood, Muhammad Aamer
   Zhao, Xin-Qing
   Liu, Chen-Guang
   Bai, Feng-Wu
TI Extracellular redox potential regulation improves yeast tolerance to
   furfural
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Saccharomyces cerevisiae; Furfural; Stress tolerance; Redox potential;
   Ethanol fermentation
ID SACCHAROMYCES-CEREVISIAE; STRESS; PRETREATMENT; HOMEOSTASIS; MECHANISM;
   STATE; ACID
AB Furfural is a major toxic byproduct present in the hydrolysate of lignocellulosic biomass, which inhibits the growth and ethanol fermentation of Saccharomyces cerevisiae. To enhance yeast tolerance to furfural, extracellular redox potential (ORP) regulation was employed for the fermentation system through controlling ORP at -150 mV, -100 mV and -50 mV, respectively, by adjusting its aeration. When ORP was controlled at -100 mV, yeast cells exhibited improved growth, furfural degradation and ethanol production. Analysis of intracellular redox pairs such as NADH/NAD(+) and GSH/GSSG indicated a correlation between extracellular ORP and intracellular redox homeostasis. Moreover, intracellular reactive oxygen species (ROS) caused by furfural stress decreased under the redox control condition, which consequently conferred yeast cells tolerance to furfural. Comparative transcriptome analysis for yeast cells sampling under the ORP control at -100 mV further revealed that the expression of genes for proliferation was up-regulated to degrade furfural more efficiently. These results demonstrated that extracellular ORP regulation would be a strategy for enhancing yeast tolerance to furfural stress during cellulosic ethanol fermentation. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Li, Kai; Xia, Juan; Mehmood, Muhammad Aamer; Zhao, Xin-Qing; Liu, Chen-Guang; Bai, Feng-Wu] Shanghai Jiao Tong Univ, State Key Lab Microbial Metab, Joint Int Res Lab Metab & Dev Sci, Minist Educ,Sch Life Sci & Biotechnol, Shanghai 200240, Peoples R China.
   [Mehmood, Muhammad Aamer] Govt Coll Univ Faisalabad, Dept Bioinformat & Biotechnol, Faisalabad 38000, Pakistan.
RP Liu, CG (reprint author), Shanghai Jiao Tong Univ, State Key Lab Microbial Metab, Joint Int Res Lab Metab & Dev Sci, Minist Educ,Sch Life Sci & Biotechnol, Shanghai 200240, Peoples R China.
EM cg.liu@sjtu.edu.cn
RI Li, Kai/X-4416-2019
FU National Natural Science Foundation of China, ChinaNational Natural
   Science Foundation of China [21536006, 51561145014]; Natural Science
   Foundation of Shanghai, ChinaNatural Science Foundation of Shanghai
   [18ZR1420700]
FX This work was financially supported by the National Natural Science
   Foundation of China, China with grant numbers of 21536006 and
   51561145014 as well as the Natural Science Foundation of Shanghai, China
   with grant number of 18ZR1420700.
CR ALBERTYN J, 1994, MOL CELL BIOL, V14, P4135, DOI 10.1128/MCB.14.6.4135
   Allen SA, 2010, BIOTECHNOL BIOFUELS, V3, DOI 10.1186/1754-6834-3-2
   Ask M, 2013, MICROB CELL FACT, V12, DOI 10.1186/1475-2859-12-87
   Azad GK, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092993
   Bogengruber E, 2003, FEMS YEAST RES, V3, P35, DOI 10.1016/S1567-1356(02)00193-9
   Bonnerot C, 2003, MOL CELL, V12, P1309, DOI 10.1016/S1097-2765(03)00435-0
   Chen HY, 2017, FUEL PROCESS TECHNOL, V160, P196, DOI 10.1016/j.fuproc.2016.12.007
   de Graef MR, 1999, J BACTERIOL, V181, P2351, DOI 10.1128/JB.181.8.2351-2357.1999
   Drakulic T, 2005, FEMS YEAST RES, V5, P1215, DOI 10.1016/j.femsyr.2005.06.001
   Gomez-Pastor R, 2012, APPL MICROBIOL BIOT, V94, P773, DOI 10.1007/s00253-011-3738-9
   Holm AK, 2010, J BIOL CHEM, V285, P17498, DOI 10.1074/jbc.M109.095570
   Jayakody LN, 2014, APPL MICROBIOL BIOT, V98, P6523, DOI 10.1007/s00253-014-5879-0
   Jung YH, 2017, MICROB BIOTECHNOL, V10, P395, DOI 10.1111/1751-7915.12465
   Lau MW, 2009, P NATL ACAD SCI USA, V106, P1368, DOI 10.1073/pnas.0812364106
   Liu CG, 2016, SCI REP-UK, V6, DOI 10.1038/srep25763
   Liu CG, 2013, BIOTECHNOL ADV, V31, P257, DOI 10.1016/j.biotechadv.2012.11.005
   Liu ZL, 2004, J IND MICROBIOL BIOT, V31, P345, DOI 10.1007/s10295-004-0148-3
   Lynd LR, 2017, CURR OPIN BIOTECH, V45, P202, DOI 10.1016/j.copbio.2017.03.008
   Medina VG, 2010, APPL ENVIRON MICROB, V76, P190, DOI 10.1128/AEM.01772-09
   Navarro-Avino JP, 1999, YEAST, V15, P829, DOI 10.1002/(SICI)1097-0061(199907)15:10A<829::AID-YEA423>3.0.CO;2-9
   Nishimoto T, 2015, CURR MICROBIOL, V70, P404, DOI 10.1007/s00284-014-0733-2
   Ohdate T, 2010, FEMS YEAST RES, V10, P787, DOI 10.1111/j.1567-1364.2010.00651.x
   Partow S, 2017, METAB ENG, V43, P64, DOI 10.1016/j.ymben.2017.08.004
   Prieto C, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003911
   Qiu ZL, 2017, BIOTECHNOL BIOFUELS, V10, DOI 10.1186/s13068-017-0806-0
   Rouhier N, 2010, TRENDS BIOCHEM SCI, V35, P43, DOI 10.1016/j.tibs.2009.08.005
   Sato K, 1998, SCIENCE, V281, P1646, DOI 10.1126/science.281.5383.1646
   Schafer FQ, 2001, FREE RADICAL BIO MED, V30, P1191, DOI 10.1016/S0891-5849(01)00480-4
   Schrader S, 2000, ORG PREP PROCED INT, V32, P123, DOI 10.1080/00304940009356279
   Soltanieh S, 2014, NUCLEIC ACIDS RES, V42, P3194, DOI 10.1093/nar/gkt1293
   Taherzadeh MJ, 2000, J BIOSCI BIOENG, V90, P374, DOI 10.1263/jbb.90.374
   Wallace-Salinas V, 2013, BIOTECHNOL BIOFUELS, V6, DOI 10.1186/1754-6834-6-151
   Wang GS, 2011, APPL BIOCHEM BIOTECH, V163, P658, DOI 10.1007/s12010-010-9071-4
   Wang SZ, 2017, CHEM ENG SCI, V158, P37, DOI 10.1016/j.ces.2016.09.026
   Wang XN, 2016, BMC BIOTECHNOL, V16, DOI 10.1186/s12896-016-0264-y
   Zhang Z, 2016, SCI REP-UK, V6, DOI 10.1038/srep27854
   Zhang Z, 2013, ARCH TOXICOL, V87, P1557, DOI 10.1007/s00204-013-1059-8
   Zheng Q, 2008, NUCLEIC ACIDS RES, V36, pW358, DOI 10.1093/nar/gkn276
NR 38
TC 3
Z9 3
U1 12
U2 28
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAR 16
PY 2019
VL 196
BP 54
EP 63
DI 10.1016/j.ces.2018.11.059
PG 10
WC Engineering, Chemical
SC Engineering
GA HI9RQ
UT WOS:000456795700005
DA 2020-05-12
ER

PT J
AU Wang, XL
   Tang, Y
   Wang, YP
   Ke, L
   Ye, XX
   Huang, X
   Shi, B
AF Wang, Xiaoling
   Tang, Yi
   Wang, Yaping
   Ke, Le
   Ye, Xiaoxia
   Huang, Xin
   Shi, Bi
TI Leather enabled multifunctional thermal camouflage armor
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Natural insulation structure; Persistent thermal camouflage; Non-thermal
   functionality; Hydrophobicity
ID COLLAGEN-FIBERS; LIGHTWEIGHT
AB Realizing persistent thermal camouflage of heat objects remains challenging. A variety of biological species have evolved extraordinary thermal insulation strategies that represent an exciting source of inspiration for developing high-performance thermal camouflage materials. However, we are still far from being able to faithfully mimic these natural insulation materials not only because of the difficulty to imitate the intricate structural hierarchy but also due to the challenge to simulate the way used by nature, that is, each level of structural hierarchy collaborates together to achieve efficient insulation. Instead of biomimicing the biological structures, we here make a direct structure editing on the natural insulation structure of cowhide for obtaining multifunctional thermal camouflage armor. SiO2 nanoparticles (SiO(2)NPs) were in situ grown on the 3D hierarchically fibrous scaffold of leather, which played multiple roles in trapping stagnant air as thermal insulator, blocking infrared absorptive groups and reflecting infrared radiation from heat objects. The thermal camouflage armor exhibited a high porosity to 61.4%, as well as low thermal diffusivity (1.24 x 10(7) m(2) s(1)) and thermal conductivity (0.04 W m(1) K-1). The thermal camouflage armor exhibited persistent camouflage performance (1.0 h) and exceptional non-thermal functionalities, including hydrophobicity, flame-resistance, flexibility and arbitrary tailorability. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Wang, Xiaoling; Tang, Yi; Wang, Yaping; Huang, Xin] Sichuan Univ, Dept Biomass Chem & Engn, Chengdu 610065, Sichuan, Peoples R China.
   [Wang, Xiaoling; Tang, Yi; Ke, Le; Ye, Xiaoxia; Huang, Xin; Shi, Bi] Sichuan Univ, Natl Engn Lab Clean Technol Leather Manufacture, Chengdu 610065, Sichuan, Peoples R China.
RP Huang, X (reprint author), Sichuan Univ, Dept Biomass Chem & Engn, Chengdu 610065, Sichuan, Peoples R China.; Huang, X (reprint author), Sichuan Univ, Natl Engn Lab Clean Technol Leather Manufacture, Chengdu 610065, Sichuan, Peoples R China.
EM xhuangscu@163.com
RI Wang, Yaping/B-7350-2017
OI Wang, Yaping/0000-0002-3308-4728
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [21676171, 51507107]; Science and Technology Fund
   for Distinguish Young Scholars of Sichuan Province [2016JQ0002]; Fok
   Ying Tong Education Foundation for Young Teachers in the Higher
   Education Institutions of ChinaFok Ying Tung Education Foundation
   [161099]; 1000 Talents Program of Sichuan Province; National Key R&D
   Program of China [2017YFB0308500]; Science Foundation for Distinguished
   Young Scholars of Sichuan University [2017SCU04A04]
FX Yi Tang has equal contribution to the first author. We thank the
   financial supports provided by the National Natural Science Foundation
   of China (21676171, 51507107), the Science and Technology Fund for
   Distinguish Young Scholars of Sichuan Province (2016JQ0002), the Fok
   Ying Tong Education Foundation for Young Teachers in the Higher
   Education Institutions of China (161099), the 1000 Talents Program of
   Sichuan Province, the National Key R&D Program of China (2017YFB0308500)
   and the Science Foundation for Distinguished Young Scholars of Sichuan
   University (2017SCU04A04).
CR Bonnier F, 2008, J BIOPHOTONICS, V1, P204, DOI 10.1002/jbio.200810020
   BOWES J. H., 1966, J ROY MICROSCOP SOC, V85, P193
   Chu HT, 2016, CARBON, V98, P557, DOI 10.1016/j.carbon.2015.11.036
   Covington AD, 1997, CHEM SOC REV, V26, P111, DOI 10.1039/cs9972600111
   Dawson C, 1999, J THEOR BIOL, V199, P291, DOI 10.1006/jtbi.1999.0959
   Gentleman E, 2003, BIOMATERIALS, V24, P3805, DOI 10.1016/S0142-9612(03)00206-0
   Jin HJ, 2003, NATURE, V424, P1057, DOI 10.1038/nature01809
   Kahl T, 2014, SENSOR REV, V34, P123, DOI 10.1108/SR-10-2012-716
   Liu C, 2016, J MATER CHEM C, V4, P914, DOI 10.1039/c5tc02591e
   Liu XF, 2015, J MATER CHEM C, V3, P345, DOI 10.1039/c4tc01873g
   Liu Y, 2011, BIOMATERIALS, V32, P1291, DOI 10.1016/j.biomaterials.2010.10.018
   Phan L, 2013, ADV MATER, V25, P5621, DOI 10.1002/adma.201301472
   McCafferty DJ, 2013, BIOL LETTERS, V9, DOI 10.1098/rsbl.2012.1192
   Phan L, 2015, J MATER CHEM C, V3, P6493, DOI 10.1039/c5tc00125k
   Salihoglu O, 2018, NANO LETT, V18, P4541, DOI 10.1021/acs.nanolett.8b01746
   Sanderson K, 2015, NATURE, V519, pS14, DOI 10.1038/519S14a
   Sionkowska A, 2004, BIOMATERIALS, V25, P795, DOI 10.1016/S0142-9612(03)00595-7
   SPEER DP, 1980, J BIOMED MATER RES, V14, P753, DOI 10.1002/jbm.820140607
   Stegmaier T, 2009, PHILOS T R SOC A, V367, P1749, DOI 10.1098/rsta.2009.0019
   Sun KW, 2016, INFRARED PHYS TECHN, V78, P156, DOI 10.1016/j.infrared.2016.07.021
   Tao P, 2015, ADV MATER, V27, P428, DOI 10.1002/adma.201401449
   Wang W, 2013, IND ENG CHEM RES, V52, P15066, DOI 10.1021/ie401827s
   Wang XL, 2015, J MATER CHEM C, V3, P10146, DOI 10.1039/c5tc02689j
   Wang ZQ, 2009, APPL SURF SCI, V256, P1404, DOI 10.1016/j.apsusc.2009.08.096
   Wegst UGK, 2015, NAT MATER, V14, P23, DOI [10.1038/NMAT4089, 10.1038/nmat4089]
   Xu CY, 2018, SCIENCE, V359, P1495, DOI 10.1126/science.aar5191
   Yang AK, 2017, NANO LETT, V17, P3506, DOI 10.1021/acs.nanolett.7b00579
   Ye XY, 2008, APPL SURF SCI, V254, P5975, DOI 10.1016/j.apsusc.2008.03.186
NR 28
TC 3
Z9 3
U1 17
U2 68
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAR 16
PY 2019
VL 196
BP 64
EP 71
DI 10.1016/j.ces.2018.12.005
PG 8
WC Engineering, Chemical
SC Engineering
GA HI9RQ
UT WOS:000456795700006
DA 2020-05-12
ER

PT J
AU Radel, B
   Funck, M
   Nguyen, TH
   Nirschl, H
AF Radel, B.
   Funck, M.
   Nguyen, T. H.
   Nirschl, H.
TI Determination of filtration and consolidation properties of protein
   crystal suspensions using analytical photocentrifuges with low volume
   samples
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Centrifugal filtration; Cake filtration; Protein crystals
ID CENTRIFUGAL DRUM FILTRATION; COMPRESSION RHEOLOGY MODEL; EGG-WHITE
   LYSOZYME; BATCH CRYSTALLIZATION; SOLUBILITY
AB Proteins and in particular pharmaceutical proteins like monoclonal antibodies are expensive products. Protein crystallization is an interesting alternative process step to the common purification and formulation of such proteins. The solid-liquid separation of proteins however, is a challenging task because the proteins are sensitive to mechanical stress, which could lead to crystal breakage and often are only available in small amounts for research and development. In this study a newly developed filtration cell for the LUMiSizer (R) centrifuge is used to analyze the filtration behavior with low volume samples. Isometric and needle shaped lysozyme crystals serve as model protein crystals. The needle shaped crystals showed about twice as high compressibility and much higher cake resistance than the isometric lysozyme crystals. After the filtration at maximum pressure in the centrifuge the mean particle diameter decreased compared to the unstressed median diameter. With the filtration cell the cake height and filter cake compression can be monitored in situ and the filter cake resistance and solids volume fraction can be calculated with one experiment using 200-300 ( )mu l sample. (C) 2018 Elsevier Ltd. All rights reserved.
EM benjamin.radel@kit.edu
OI Radel, Benjamin/0000-0001-8479-7288
FU German Research Foundation (DFG)German Research Foundation (DFG) [NI
   414/26-1, SPP 1934/1]
FX The authors thank the German Research Foundation (DFG) for funding the
   project NI 414/26-1, the DiSPBiotech priority program (SPP 1934/1) and
   Prof. Kind and Dipl.-Ing. Michael Barros-Gross from the institute of
   thermal process engineering at the KIT for providing crystalline
   lysozyme. The helpful suggestions for improving the filtration cell and
   the constructive discussions with Prof. Lerche are highly appreciated.
CR Aldabaibeh N, 2009, CRYST GROWTH DES, V9, P3313, DOI 10.1021/cg900113e
   Alles C. M., 2000, THESIS
   Alles CM, 2003, CHEM-ING-TECH, V75, P1221, DOI 10.1002/cite.200303268
   Barr JD, 2006, AICHE J, V52, P545, DOI 10.1002/aic.10678
   Barr JD, 2006, AICHE J, V52, P557, DOI 10.1002/aic.10679
   Basu SK, 2004, EXPERT OPIN BIOL TH, V4, P301, DOI 10.1517/14712598.4.3.301
   Cornehl B, 2014, CHEM ENG SCI, V111, P324, DOI 10.1016/j.ces.2014.02.016
   Cornehl B, 2013, CHEM ENG TECHNOL, V36, P1665, DOI 10.1002/ceat.201300178
   DURBIN SD, 1986, J CRYST GROWTH, V76, P583, DOI 10.1016/0022-0248(86)90175-2
   Eichholz C, 2011, ENG LIFE SCI, V11, P75, DOI 10.1002/elsc.201000121
   Farid SS, 2007, J CHROMATOGR B, V848, P8, DOI 10.1016/j.jchromb.2006.07.037
   Gross M, 2016, CHEM ENG TECHNOL, V39, P1483, DOI 10.1002/ceat.201500582
   Gross MB, 2017, CRYST GROWTH DES, V17, P3491, DOI 10.1021/acs.cgd.7b00456
   Hekmat D, 2007, PROCESS BIOCHEM, V42, P1649, DOI 10.1016/j.procbio.2007.10.001
   HOWARD SB, 1988, J CRYST GROWTH, V90, P94, DOI 10.1016/0022-0248(88)90303-X
   Jen A, 2001, PHARM RES-DORDR, V18, P1483, DOI 10.1023/A:1013057825942
   Kayser O., 2005, PHARM BIOTECHNOLOGY
   Koizumi H, 2004, PHILOS MAG, V84, P2961, DOI 10.1080/14786430410001716791
   Lerche D, 2007, POWDER TECHNOL, V174, P46, DOI 10.1016/j.powtec.2006.10.020
   Liu YX, 2010, CRYST GROWTH DES, V10, P548, DOI 10.1021/cg900919w
   Liu YM, 2016, CRYSTENGCOMM, V18, P1609, DOI 10.1039/c6ce00060f
   Loginov M, 2017, J MEMBRANE SCI, V536, P59, DOI 10.1016/j.memsci.2017.04.064
   Loginov M, 2014, CHEM ENG SCI, V107, P277, DOI 10.1016/j.ces.2013.12.011
   MOROZOV VN, 1981, BIOPOLYMERS, V20, P451, DOI 10.1002/bip.1981.360200304
   Rushton A., 2000, SOLID LIQUID FILTRAT
   SAMBUICHI M, 1987, AICHE J, V33, P109, DOI 10.1002/aic.690330113
   Schmidt S, 2005, ENG LIFE SCI, V5, P273, DOI 10.1002/elsc.200500116
   Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089
   Tait S, 2008, PART PART SYST CHAR, V25, P266, DOI 10.1002/ppsc.200701112
   Tiller FM, 1998, AICHE J, V44, P2159, DOI 10.1002/aic.690441005
   TILLER FM, 1993, WATER SCI TECHNOL, V28, P1
   Walsh G., 2002, PROTEINS BIOCH BIOTE
   Zamiri A, 2010, LANGMUIR, V26, P4251, DOI 10.1021/la9033222
NR 33
TC 0
Z9 0
U1 0
U2 8
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAR 16
PY 2019
VL 196
BP 72
EP 81
DI 10.1016/j.ces.2018.12.019
PG 10
WC Engineering, Chemical
SC Engineering
GA HI9RQ
UT WOS:000456795700007
OA Green Accepted
DA 2020-05-12
ER

PT J
AU Sun, J
   Zhang, CB
   Nan, WH
   Li, DS
   Ke, D
   Lu, WY
AF Sun, Jie
   Zhang, Chuanbo
   Nan, Weihua
   Li, Dashuai
   Ke, Di
   Lu, Wenyu
TI Glycerol improves heterologous biosynthesis of betulinic acid in
   engineered Yarrowia lipolytica
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Betulinic acid; Glycerol; Heterologous biosynthesis; Terpenoids;
   Yarrowia lipolytica
ID SACCHAROMYCES-CEREVISIAE; LIPID-ACCUMULATION; PROTEIN EXPRESSION;
   BETA-CAROTENE; CITRIC-ACID; PATHWAY; OPTIMIZATION; INTEGRATION;
   SECRETION; OXIDASES
AB Glycerol is the main byproduct of the biodiesel production process and can be converted into valuable products by Yarrowia lipolytica. Betulinic acid is a pentacyclic triterpene with a variety of pharmacological properties. Herein we report heterologous biosynthesis of betulinic acid in Y. lipolytica by co-expressing lupeol synthase opAtLUP1, NADPH-cytochrome P450 monooxygenase opCYP716A12, and NADPH-cytochrome P450 reductase opAtCPR1. Initially, the engineered Y. lipolytica produced 0.32 mg/L betulinic acid. This titer was increased to 9.41 mg/L following P450 enzyme fusion and overexpression of key genes from the upstream mevalonate (MVA) pathway. Substitution of glycerol for glucose further enhanced betulinic acid production to 16.98 mg/L, 1.8-fold higher than the titer obtained with glucose. 26.53 mg/L betulinic acid was obtained with 40 g/L glycerol as the sole carbon source, which was comparable to the titer obtained from Saccharomyces cerevisiae with 50 g/L glucose in shake flask cultivation. Glycerol improved betulinic acid titer by increasing the expression of key genes in the MVA pathway, and by increasing the supply of acetyl-CoA. Our study highlights the possible applications of glycerol as carbon source in the production of valuable terpenoids by engineered Y. lipolytica. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Sun, Jie; Zhang, Chuanbo; Nan, Weihua; Li, Dashuai; Ke, Di; Lu, Wenyu] Tianjin Univ, Sch Chem Engn & Technol, Tianjin, Peoples R China.
   [Lu, Wenyu] Tianjin Univ, Minist Educ, Key Lab Syst Bioengn, Tianjin, Peoples R China.
   [Lu, Wenyu] Collaborat Innovat Ctr Chem Sci & Engn Tianjin, SynBio Res Platform, Tianjin, Peoples R China.
RP Lu, WY (reprint author), Tianjin Univ, Sch Chem Engn & Technol, Tianjin, Peoples R China.
EM wenyulu@tju.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [21878220]; Major Research Plan of Tianjin
   [16YFXTSF00460]
FX This work was financially supported by the National Natural Science
   Foundation of China (No. 21878220) and Major Research Plan of Tianjin
   (No. 16YFXTSF00460).
CR Barth G, 1997, FEMS MICROBIOL REV, V19, P219, DOI 10.1016/S0168-6445(97)00002-8
   Blazeck J, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4131
   Cao X, 2016, BIOTECHNOL BIOFUELS, V9, DOI 10.1186/s13068-016-0626-7
   Czarnotta E, 2017, BIOTECHNOL BIOENG, V114, P2528, DOI 10.1002/bit.26377
   Du HX, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146773
   Dulermo T, 2011, METAB ENG, V13, P482, DOI 10.1016/j.ymben.2011.05.002
   Fukushima EO, 2011, PLANT CELL PHYSIOL, V52, P2050, DOI 10.1093/pcp/pcr146
   Gao SL, 2017, BIOTECHNOL LETT, V39, P921, DOI 10.1007/s10529-017-2318-1
   Gao SL, 2017, METAB ENG, V41, P192, DOI 10.1016/j.ymben.2017.04.004
   Gao SL, 2014, BIOTECHNOL LETT, V36, P2523, DOI 10.1007/s10529-014-1634-y
   Gietz RD, 2014, METHODS MOL BIOL, V1163, P33, DOI 10.1007/978-1-4939-0799-1_4
   Huang LL, 2012, PLANTA, V236, P1571, DOI 10.1007/s00425-012-1712-0
   Husselstein-Muller T, 2001, PLANT MOL BIOL, V45, P75, DOI 10.1023/A:1006476123930
   Juretzek T, 2001, YEAST, V18, P97, DOI 10.1002/1097-0061(20010130)18:2<97::AID-YEA652>3.0.CO;2-U
   Karasu-Yalcin S, 2009, ROM BIOTECH LETT, V14, P4870
   Larroude M, 2018, BIOTECHNOL BIOENG, V115, P464, DOI 10.1002/bit.26473
   Ledesma-Amaro R, 2016, PROG LIPID RES, V61, P40, DOI 10.1016/j.plipres.2015.12.001
   Li J, 2015, J BIOSCI BIOENG, V119, P77, DOI 10.1016/j.jbiosc.2014.06.013
   Li J, 2014, APPL MICROBIOL BIOT, V98, P3081, DOI 10.1007/s00253-013-5461-1
   Liu HH, 2015, BIOTECHNOL ADV, V33, P1522, DOI 10.1016/j.biotechadv.2015.07.010
   Liu J, 2011, J APPL MICROBIOL, V110, P90, DOI 10.1111/j.1365-2672.2010.04857.x
   Machado FRS, 2015, INT FOOD RES J, V22, P1253
   Madzak C, 2004, J BIOTECHNOL, V109, P63, DOI 10.1016/j.jbiotec.2003.10.027
   Madzak C, 2000, J MOL MICROB BIOTECH, V2, P207
   Markham K. A., 2018, TRENDS BIOTECHNOL, V1651
   Matthaus F, 2014, APPL ENVIRON MICROB, V80, P1660, DOI 10.1128/AEM.03167-13
   Mlickova K, 2004, APPL ENVIRON MICROB, V70, P3918, DOI 10.1128/AEM.70.7.3918-3924.2004
   Morgunov IG, 2004, PROCESS BIOCHEM, V39, P1469, DOI 10.1016/S0032-9592(03)00259-0
   Nicaud JM, 2002, FEMS YEAST RES, V2, P371, DOI 10.1016/S1567-1356(02)00082-X
   Papanikolaou S, 2002, J APPL MICROBIOL, V92, P737, DOI 10.1046/j.1365-2672.2002.01577.x
   Papanikolaou S, 2008, BIOMASS BIOENERG, V32, P60, DOI 10.1016/j.biombioe.2007.06.007
   PISHA E, 1995, NAT MED, V1, P1046, DOI 10.1038/nm1095-1046
   Rywinska A, 2013, BIOMASS BIOENERG, V48, P148, DOI 10.1016/j.biombioe.2012.11.021
   Rywinska A, 2010, WORLD J MICROB BIOT, V26, P1217, DOI 10.1007/s11274-009-0291-0
   Sabra W., 2017, MICROB CELL FACTOR, V16, P1
   SCHMIDBERGER N, 1994, J BACTERIOL, V176, P2477, DOI 10.1128/JB.176.9.2477-2482.1994
   Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73
   Sestric R, 2014, BIORESOURCE TECHNOL, V164, P41, DOI 10.1016/j.biortech.2014.04.016
   Smith PF, 2007, ANTIMICROB AGENTS CH, V51, P3574, DOI 10.1128/AAC.00152-07
   Tan HW, 2013, RENEW SUST ENERG REV, V27, P118, DOI 10.1016/j.rser.2013.06.035
   VANHEERIKHUIZEN H, 1985, GENE, V39, P213, DOI 10.1016/0378-1119(85)90315-4
   Workman M, 2013, AMB EXPRESS, V3, DOI 10.1186/2191-0855-3-58
   Xue CY, 2013, BIOCHEM ENG J, V81, P47, DOI 10.1016/j.bej.2013.10.004
   Yang X, 2016, BIORESOURCE TECHNOL, V216, P1040, DOI 10.1016/j.biortech.2016.06.028
   Yeh JI, 2008, P NATL ACAD SCI USA, V105, P3280, DOI 10.1073/pnas.0712331105
   Yin S. M., 2017, RES REV J MICROBIOL, V6, P52
   Zhang Y, 2017, BIOTECHNOL LETT, V39, P1033, DOI 10.1007/s10529-017-2331-4
   Zhao FL, 2016, BIOTECHNOL BIOENG, V113, P1787, DOI 10.1002/bit.25934
   Zhou C, 2016, BMC BIOTECHNOL, V16, DOI 10.1186/s12896-016-0290-9
NR 49
TC 7
Z9 7
U1 11
U2 41
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAR 16
PY 2019
VL 196
BP 82
EP 90
DI 10.1016/j.ces.2018.10.052
PG 9
WC Engineering, Chemical
SC Engineering
GA HI9RQ
UT WOS:000456795700008
DA 2020-05-12
ER

PT J
AU Yadav, MD
   Dasgupta, K
   Patwardhan, AW
   Kaushal, A
   Joshi, JB
AF Yadav, Manishkumar D.
   Dasgupta, Kinshuk
   Patwardhan, Ashwin W.
   Kaushal, Amit
   Joshi, Jyeshtharaj B.
TI Kinetic study of single-walled carbon nanotube synthesis by
   thermocatalytic decomposition of methane using floating catalyst
   chemical vapour deposition
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Single wall carbon nanotubes; Floating catalyst; Conductivity; Kinetics;
   Activation energy
ID TEMPERATURE-DEPENDENT GROWTH; FLUIDIZED-BED SYNTHESIS; FIBERS; SULFUR;
   NICKEL; PYROLYSIS; DIAMETER; DYNAMICS; QUALITY; RANGE
AB Single walled carbon nanotubes (SWCNTs) have been synthesized from thermocatalytic decomposition of methane by using ferrocene as the catalyst at atmospheric pressure. Floating catalyst chemical vapour deposition using a horizontal two zone reactor was employed to investigate the kinetics. The effects of temperature of synthesis (800-1000 degrees C), partial pressure (2-40 kPa) of reactant gas and catalyst concentration (0.2-4.6 mol m 3 ) on the rate of formation of SWCNTs have been studied. The rate is proportional to the partial pressure of methane indicating that the surface reaction of methane on the active site is the rate controlling step. The activation energy was found to be 80.16 kJ mol (1). Raman spectroscopy, X-ray photoelectron spectroscopy, transmission electron microscopy, BET, UV-Vis-NIR and thermogravimetry have been used for the characterization of products. UV-Vis-NIR spectroscopy data reveals presence of 78-82% metallic SWCNTs (m-SWCNTs) in the synthesized samples. The BET surface area of purified SWCNTs were found to be 871 m(2) g (1) with pore volume of 0.35 cc g (1) and electrical conductivity of 856-746 S cm (1). (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Yadav, Manishkumar D.; Patwardhan, Ashwin W.; Joshi, Jyeshtharaj B.] Inst Chem Technol, Dept Chem Engn, NP Marg, Mumbai 400019, India.
   [Dasgupta, Kinshuk; Kaushal, Amit] Bhabha Atom Res Ctr, Mat Grp, Mumbai 400085, India.
   [Joshi, Jyeshtharaj B.] Homi Bhabha Natl Inst, Mumbai 400094, India.
RP Patwardhan, AW; Joshi, JB (reprint author), Inst Chem Technol, Dept Chem Engn, NP Marg, Mumbai 400019, India.
EM kdg@barc.gov.in; aw.patwardhan@ictmumbai.edu.in; jbjoshi@gmail.com
RI Dasgupta, Kinshuk/D-7418-2011; YADAV, MANISHKUMAR/Y-3505-2019
OI Dasgupta, Kinshuk/0000-0002-5742-7799; YADAV,
   MANISHKUMAR/0000-0002-6665-7641; Patwardhan, Ashwin/0000-0001-9893-1249
FU DAE-ICT centre; United Phosphorous Limited (UPL) Ltd
FX The authors gratefully acknowledge the financial support from DAE-ICT
   centre and United Phosphorous Limited (UPL) Ltd, to carry out this work.
CR ALSTRUP I, 1993, J CATAL, V139, P513, DOI 10.1006/jcat.1993.1045
   ALSTRUP I, 1992, J CATAL, V135, P147, DOI 10.1016/0021-9517(92)90276-N
   Amama PB, 2008, J PHYS D APPL PHYS, V41, DOI 10.1088/0022-3727/41/16/165306
   Anisimov AS, 2010, CARBON, V48, P380, DOI 10.1016/j.carbon.2009.09.040
   Arepalli S, 2004, J NANOSCI NANOTECHNO, V4, P317, DOI 10.1166/jnn.2004.072
   BAKER RTK, 1989, CARBON, V27, P315, DOI 10.1016/0008-6223(89)90062-6
   Bissett MA, 2011, J APPL PHYS, V110, DOI 10.1063/1.3615945
   BOUDART M, 1956, AICHE J, V2, P62, DOI 10.1002/aic.690020113
   Cao H, 2003, PHYS REV B, V67, DOI [10.1103/PhysRevB.67.161101, 10.1103/PhysRevB.161101]
   Dasgupta K, 2014, AICHE J, V60, P2882, DOI 10.1002/aic.14482
   Dasgupta K, 2011, CHEM ENG J, V171, P841, DOI 10.1016/j.cej.2011.05.038
   Ding EX, 2017, NANOSCALE, V9, P17601, DOI 10.1039/c7nr05554d
   Douven S, 2011, CHEM ENG J, V175, P396, DOI 10.1016/j.cej.2011.08.066
   Dresselhaus MS, 2005, PHYS REP, V409, P47, DOI 10.1016/j.physrep.2004.10.006
   Einarsson E, 2008, CARBON, V46, P923, DOI 10.1016/j.carbon.2008.02.021
   Frossling N., GERLANDS BEITR GEOL, V52
   Fujii S, 2009, APPL PHYS EXPRESS, V2, DOI 10.1143/APEX.2.071601
   Gommes C, 2004, CARBON, V42, P1473, DOI 10.1016/j.carbon.2004.01.063
   Harutyunyan AR, 2002, NANO LETT, V2, P525, DOI 10.1021/nl0255101
   Hoecker C, 2016, CARBON, V96, P116, DOI 10.1016/j.carbon.2015.09.050
   Hou PX, 2014, ACS NANO, V8, P7156, DOI 10.1021/nn502120k
   Hsieh CT, 2009, POWDER TECHNOL, V192, P16, DOI 10.1016/j.powtec.2008.11.004
   Hsieh CT, 2009, MATER CHEM PHYS, V114, P702, DOI 10.1016/j.matchemphys.2008.10.034
   Jeong SW, 2015, CHEM ENG SCI, V134, P496, DOI 10.1016/j.ces.2015.05.051
   Jorio A, 2003, NEW J PHYS, V5, DOI 10.1088/1367-2630/5/1/139
   Jung Y, 2013, CHEM ENG J, V228, P1050, DOI 10.1016/j.cej.2013.05.088
   Kim NS, 2003, J PHYS CHEM B, V107, P9249, DOI 10.1021/jp034895o
   Kuzmany H, 2001, EUR PHYS J B, V22, P307, DOI 10.1007/s100510170108
   Laplaze D, 1998, CARBON, V36, P685, DOI 10.1016/S0008-6223(98)00025-6
   Lee SH, 2015, RSC ADV, V5, P41894, DOI 10.1039/c5ra04691b
   Lee YT, 2003, CHEM PHYS LETT, V372, P853, DOI 10.1016/S0009-2614(03)00529-3
   Lee YT, 2002, J PHYS CHEM B, V106, P7614, DOI 10.1021/jp020488l
   Levenspiel O, 1999, IND ENG CHEM RES, V38, P4140, DOI 10.1021/ie990488g
   LEWIS KE, 1984, J AM CHEM SOC, V106, P4650, DOI 10.1021/ja00328a077
   Li YL, 2004, SCIENCE, V304, P276, DOI 10.1126/science.1094982
   Liu H, 2008, SURF COAT TECH, V202, P4114, DOI 10.1016/j.surfcoat.2008.02.025
   LIU J, 2016, MEAS SCI TECHNOL, V27
   Ma J, 2009, J MATER CHEM, V19, P3033, DOI 10.1039/b820088b
   Maeda Y, 2008, CARBON, V46, P1563, DOI 10.1016/j.carbon.2008.06.057
   Motta MS, 2008, J NANOSCI NANOTECHNO, V8, P2442, DOI 10.1166/jnn.2008.500
   Ni L, 2006, CARBON, V44, P2265, DOI 10.1016/j.carbon.2006.02.031
   Odom TW, 1998, NATURE, V391, P62
   Park JS, 2006, PHYS REV B, V74, DOI 10.1103/PhysRevB.74.165414
   Perego C, 1999, CATAL TODAY, V52, P133, DOI 10.1016/S0920-5861(99)00071-1
   Pirard SL, 2007, CARBON, V45, P1167, DOI 10.1016/j.carbon.2007.02.021
   Reguero V, 2014, CHEM MATER, V26, P3550, DOI 10.1021/cm501187x
   Saraswat SK, 2016, IND ENG CHEM RES, V55, P11672, DOI 10.1021/acs.iecr.6b03145
   Shi ZJ, 1999, CARBON, V37, P1449, DOI 10.1016/S0008-6223(99)00007-X
   Simate GS, 2014, RSC ADV, V4, P9564, DOI 10.1039/c3ra47163b
   SING KSW, 1985, PURE APPL CHEM, V57, P603, DOI 10.1351/pac198557040603
   Snoeck JW, 1997, J CATAL, V169, P250, DOI 10.1006/jcat.1997.1635
   Sundaram RM, 2011, ADV MATER, V23, P5064, DOI 10.1002/adma.201102754
   Wei JQ, 2007, CARBON, V45, P2152, DOI 10.1016/j.carbon.2007.07.001
   Wirth CT, 2009, ACS NANO, V3, P3560, DOI 10.1021/nn900613e
   Xu Y., 2018, J PHYS CHEM C
   Yadav M. D., 2018, CHEM ENG J
   Yoon SW, 2005, J PHYS CHEM B, V109, P20403, DOI 10.1021/jp0546305
   Yoshida H, 2008, NANO LETT, V8, P2082, DOI 10.1021/nl080452q
   Yu B, 2011, J AM CHEM SOC, V133, P5232, DOI 10.1021/ja2008278
   Zein SHS, 2004, IND ENG CHEM RES, V43, P4864, DOI 10.1021/ie034208f
   Zhang Q, 2017, TOPICS CURR CHEM, V375, DOI 10.1007/s41061-017-0178-8
   Zhang Q, 2009, APPL PHYS A-MATER, V94, P853, DOI [10.1007/s00339-008-4904-5, 10.1007/s00339-008-49045]
NR 62
TC 3
Z9 3
U1 8
U2 38
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAR 16
PY 2019
VL 196
BP 91
EP 103
DI 10.1016/j.ces.2018.10.050
PG 13
WC Engineering, Chemical
SC Engineering
GA HI9RQ
UT WOS:000456795700009
DA 2020-05-12
ER

PT J
AU Kok, MDR
   Jervis, R
   Trantet, TG
   Sadeghi, MA
   Brett, DJL
   Shearing, PR
   Gostick, JT
AF Kok, Matthew D. R.
   Jervis, Rhodri
   Trantet, Tom G.
   Sadeghi, Mohammad A.
   Brett, Dan J. L.
   Shearing, Paul R.
   Gostick, Jeff T.
TI Mass transfer in fibrous media with varying anisotropy for flow battery
   electrodes: Direct numerical simulations with 3D X-ray computed
   tomography
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Electrospun electrodes; Numerical modelling; X-ray computed tomography;
   Redox flow battery; Mass transfer coefficient; Fibrous media
ID TRANSPORT-PROPERTIES; TRANSFER RATES; CARBON FELT; PERFORMANCE; HEAT;
   ARCHITECTURE; COMPRESSION; CELL
AB A numerical method for calculating the mass transfer coefficient in fibrous media is presented. First, pressure driven flow was modelled using the Lattice Boltzmann Method. The advection-diffusion equation was solved for convective-reacting porous media flow, and the method is contrasted with experimental methods such as the limiting current diffusion technique, for its ability to determine and simulate mass transfer systems that are operating at low Reynolds number flows. A series of simulations were performed on three materials; specifically, commercially available carbon felts, electrospun carbon fibers and electrospun carbon fibers with anisotropy introduced to the microstructure. Simulations were performed in each principal direction (x,y,z) for each material in order to determine the effects of anisotropy on the mass transfer coefficient. In addition, the simulations spanned multiple Reynolds and Peclet numbers, to fully represent highly advective and highly diffusive systems. The resulting mass transfer coefficients were compared with values predicted by common correlations and a good agreement was found at high Reynolds numbers, but less so at lower Reynolds number typical of cell operation, reinforcing the utility of the numerical approach. Dimensionless mass transfer correlations were determined for each material and each direction in terms of the Sherwood number. These correlations were analyzed with respect to each materials' permeability tensor. It was found that as the permeability of the system increases, the expected mass transfer coefficient decreases. Two general mass transfer correlations are presented, one correlation for isotropic fibrous media and the other for through-plane flow in planar fibrous materials such as electrospun media and carbon paper. The correlations are Sh = 0.879 Re-0.402 Sc-0.390 and Sh = 0.906 Re-0.432 SC0.432 respectively. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Kok, Matthew D. R.; Sadeghi, Mohammad A.] McGill Univ, Dept Chem Engn, Montreal, PQ, Canada.
   [Jervis, Rhodri; Brett, Dan J. L.; Shearing, Paul R.] UCL, Dept Chem Engn, Electrochem Innovat Lab, London, England.
   [Trantet, Tom G.; Gostick, Jeff T.] Univ Waterloo, Dept Chem Engn, Porous Media Engn & Anal Lab, Waterloo, ON, Canada.
RP Gostick, JT (reprint author), Univ Waterloo, Engn 6, 200 Univ Ave West, Waterloo, ON N2L 3G1, Canada.
EM jgostick@uwaterloo.ca
FU EPSRCEngineering & Physical Sciences Research Council (EPSRC)
   [EP/L014289/1, EP/N032888/1]; STFC Extended Network in Batteries and
   Electrochemical Energy Devices [ST/N002385/1]; Royal Academy of
   EngineeringRoyal Academy of Engineering - UK; Natural Science and
   Engineering Research Council (NSERC) of CanadaNatural Sciences and
   Engineering Research Council of Canada; Eugenie Ulmer Lamothe Endowment;
   Vadasz Family Doctoral Fellowship; McGill University's Graduate Mobility
   Award
FX The authors acknowledge support from the EPSRC under grants EP/L014289/1
   and EP/N032888/1, as well as the STFC Extended Network in Batteries and
   Electrochemical Energy Devices (ST/N002385/1) for funding of travel for
   Rhodri Jervis to Canada. Paul R Shearing acknowledges the support of the
   Royal Academy of Engineering. This work was supported by the Natural
   Science and Engineering Research Council (NSERC) of Canada. MDR Kok is
   grateful to the Eugenie Ulmer Lamothe Endowment as well as the Vadasz
   Family Doctoral Fellowship for funding his work, as well the McGill
   University's Graduate Mobility Award for funding his travel to the UK.
CR Arenas LF, 2016, ELECTROCHIM ACTA, V221, P154, DOI 10.1016/j.electacta.2016.10.097
   Bao LH, 2002, CHEM ENG SCI, V57, P125, DOI 10.1016/S0009-2509(01)00368-2
   Brown LD, 2016, J ENERGY STORAGE, V8, P91, DOI 10.1016/j.est.2016.10.003
   Cussler E. L., 2009, DIFFUSION MASS TRANS
   Degruyter W, 2010, GEOSPHERE, V6, P470, DOI 10.1130/GES00555.1
   Eastwood DS, 2014, NUCL INSTRUM METH B, V324, P118, DOI 10.1016/j.nimb.2013.08.066
   Houser J, 2017, J POWER SOURCES, V351, P96, DOI 10.1016/j.jpowsour.2017.03.083
   Januszewski M, 2014, COMPUT PHYS COMMUN, V185, P2350, DOI 10.1016/j.cpc.2014.04.018
   Jervis R, 2018, J ENERGY CHEM, V27, P1353, DOI 10.1016/j.jechem.2018.03.022
   Jervis R, 2016, J PHYS D APPL PHYS, V49, DOI 10.1088/0022-3727/49/43/434002
   KINOSHITA K, 1982, J ELECTROCHEM SOC, V129, P1993, DOI 10.1149/1.2124338
   Kok D. R., 2018, SMALL, V14, DOI 10.1002/smll.201870040
   Kok MDR, 2018, SMALL, V14, DOI 10.1002/smll.201703616
   Kok MDR, 2016, J ELECTROCHEM SOC, V163, pA1408, DOI 10.1149/2.1281607jes
   Kok MDR, 2015, J MEMBRANE SCI, V473, P237, DOI 10.1016/j.memsci.2014.09.017
   Lewis WK, 1924, IND ENG CHEM, V16, P1215, DOI 10.1021/ie50180a002
   Li T, 2005, CHEM ENG SCI, V60, P1837, DOI 10.1016/j.ces.2004.10.032
   Lisboa KM, 2017, J POWER SOURCES, V359, P322, DOI 10.1016/j.jpowsour.2017.05.038
   Liu S, 2017, J ELECTROCHEM SOC, V164, pA2038, DOI 10.1149/2.1301709jes
   Martin H, 2002, CHEM ENG SCI, V57, P3217, DOI 10.1016/S0009-2509(02)00194-X
   Milshtein JD, 2017, J ELECTROCHEM SOC, V164, pE3265, DOI 10.1149/2.0201711jes
   Ohmori H, 2015, J POWER SOURCES, V286, P264, DOI 10.1016/j.jpowsour.2015.03.149
   Oliveira VB, 2008, INT J HYDROGEN ENERG, V33, P3818, DOI 10.1016/j.ijhydene.2008.04.032
   Qiu G, 2012, J POWER SOURCES, V219, P223, DOI 10.1016/j.jpowsour.2012.07.042
   Satofuka N, 1999, COMPUT MECH, V23, P164, DOI 10.1007/s004660050397
   Tomadakis MM, 2005, J COMPOS MATER, V39, P163, DOI 10.1177/00219983050464338
   Torquato S., 2013, RANDOM HETEROGENEOUS
   Trogadas P, 2014, ELECTROCHEM COMMUN, V48, P155, DOI 10.1016/j.elecom.2014.09.010
   Xu A, 2018, J HEAT TRANS-T ASME, V140, DOI 10.1115/1.4038555
   Xu A, 2017, ACTA MECH SINICA-PRC, V33, P555, DOI 10.1007/s10409-017-0667-6
   Xu Q, 2013, PHYS CHEM CHEM PHYS, V15, P10841, DOI 10.1039/c3cp51944a
   YANG MC, 1986, AICHE J, V32, P1910, DOI 10.1002/aic.690321117
   You X, 2017, J ELECTROCHEM SOC, V164, pE3386, DOI 10.1149/2.0401711jes
NR 33
TC 13
Z9 13
U1 7
U2 32
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAR 16
PY 2019
VL 196
BP 104
EP 115
DI 10.1016/j.ces.2018.10.049
PG 12
WC Engineering, Chemical
SC Engineering
GA HI9RQ
UT WOS:000456795700010
DA 2020-05-12
ER

PT J
AU Yen, M
   Magi, V
   Abraham, J
AF Yen, May
   Magi, Vinicio
   Abraham, John
TI Modeling the effects of hydrogen and nitrogen addition on soot formation
   in laminar ethylene jet diffusion flames
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Soot modeling; Semi-empirical models; Laminar sooting flames;
   Ethylene/hydrogen/nitrogen diffusion flames
ID DIESEL; OXIDATION
AB The effects of adding hydrogen and nitrogen on soot concentration in atmospheric laminar ethylene jet flames are studied computationally and computed results are compared with experimental ones. Two sets of flames are studied: one in which the total volumetric injected flow rate is kept fixed and ethylene is substituted with either hydrogen or nitrogen and the other in which the ethylene volumetric flow rate is fixed but varying amounts of hydrogen and nitrogen are added. A two-equation semi-empirical model is employed to model soot. The model is able to qualitatively predict the measured trends of reducing soot concentration as hydrogen or nitrogen is added to ethylene or substituted. Quantitative agreement is within an order of magnitude and the results are found to depend strongly on the coupling between radiation and soot. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Yen, May; Abraham, John] Purdue Univ, Sch Mech Engn, W Lafayette, IN 47907 USA.
   [Magi, Vinicio] Univ Basilicata, Sch Engn, I-85100 Potenza, Italy.
   [Abraham, John] San Diego State Univ, Dept Mech Engn, San Diego, CA 92182 USA.
RP Yen, M (reprint author), Purdue Univ, Sch Mech Engn, W Lafayette, IN 47907 USA.
EM myen@purdue.edu
CR ABRAHAM J, 1985, COMBUST FLAME, V60, P309, DOI 10.1016/0010-2180(85)90036-7
   Appel J, 2000, COMBUST FLAME, V121, P122, DOI 10.1016/S0010-2180(99)00135-2
   Bai XS, 1998, TWENTY-SEVENTH SYMPOSIUM (INTERNATIONAL) ON COMBUSTION, VOLS 1 AND 2, P1623
   Bajaj C, 2013, COMBUST SCI TECHNOL, V185, P454, DOI 10.1080/00102202.2012.726667
   Blacha T, 2012, COMBUST FLAME, V159, P181, DOI 10.1016/j.combustflame.2011.07.006
   Cai G, 2016, CHEM ENG SCI, V144, P249, DOI 10.1016/j.ces.2016.01.039
   Coram A, 2018, ENERG ECON, V70, P179, DOI 10.1016/j.eneco.2017.12.028
   D'Anna A, 2007, COMBUST SCI TECHNOL, V179, P355, DOI 10.1080/00102200600812419
   DU DX, 1995, COMBUST FLAME, V102, P11, DOI 10.1016/0010-2180(95)00043-6
   EPA, 2016, EPA420B16018 US
   FENIMORE CP, 1967, J PHYS CHEM-US, V71, P593, DOI 10.1021/j100862a021
   Flynn P. F., 1999, DIESEL COMBUSTION IN, DOI [10.4271/1999-01-0509, DOI 10.4271/1999-01-0509]
   Frenklach M., 1994, SPRINGER SERIES CHEM, V59, P165, DOI DOI 10.1007/978-3-642-85167-4_10
   Gopalakrishnan V, 2004, COMBUST SCI TECHNOL, V176, P603, DOI 10.1080/00102200490276818
   Gu MY, 2016, COMBUST FLAME, V166, P216, DOI 10.1016/j.combustflame.2016.01.023
   Gulder OL, 1996, TWENTY-SIXTH SYMPOSIUM (INTERNATIONAL) ON COMBUSTION, VOLS 1 AND 2, P2351
   Hiroyasu H., 1976, 760129 SAE, DOI [10.4271/760129, DOI 10.4271/760129]
   Hou Z. - X., 1995, 950608 SAE, DOI [10.4271/950608, DOI 10.4271/950608]
   Howard J.B., 1991, P COMBUST INST, V23, P1107, DOI DOI 10.1016/S0082-0784(06)80371-1
   Ju YG, 1999, J FLUID MECH, V379, P165, DOI 10.1017/S0022112098003231
   Kennedy IM, 1997, PROG ENERG COMBUST, V23, P95, DOI 10.1016/S0360-1285(97)00007-5
   Kennedy IM, 1996, COMBUST FLAME, V107, P368, DOI 10.1016/S0010-2180(96)00092-2
   Kohler M, 2012, COMBUST FLAME, V159, P2620, DOI 10.1016/j.combustflame.2012.01.015
   KOYLU UO, 1992, COMBUST FLAME, V89, P140, DOI 10.1016/0010-2180(92)90024-J
   Kronenburg A, 2000, COMBUST FLAME, V121, P24, DOI 10.1016/S0010-2180(99)00146-7
   LEUNG KM, 1991, COMBUST FLAME, V87, P289, DOI 10.1016/0010-2180(91)90114-Q
   Liu F, 2003, COMBUST THEOR MODEL, V7, P301, DOI 10.1088/1364-7830/7/2/305
   Liu FS, 2002, J QUANT SPECTROSC RA, V73, P409, DOI 10.1016/S0022-4073(01)00205-9
   Mahmoud SM, 2015, P COMBUST INST, V35, P1931, DOI 10.1016/j.proci.2014.06.122
   Mauss F., 1994, SOOT FORMATION COMBU, P325
   McEnally CS, 1998, TWENTY-SEVENTH SYMPOSIUM (INTERNATIONAL) ON COMBUSTION, VOLS 1 AND 2, P1497
   Melillo JM, 2014, CLIMATE CHANGE IMPAC, P841, DOI [10.7930/J0Z31WJ2, DOI 10.7930/J0Z31WJ2, 10.7930/j0z31WJ2]
   MOSS JB, 1995, COMBUST FLAME, V101, P491, DOI 10.1016/0010-2180(94)00233-I
   Nagle J, 1962, P 5 C CARB, VI, P154
   REITZ RD, 1983, COMBUST FLAME, V53, P141, DOI 10.1016/0010-2180(83)90013-5
   SANTORO RJ, 1987, COMBUST SCI TECHNOL, V53, P89, DOI 10.1080/00102208708947022
   SANTORO RJ, 1983, COMBUST FLAME, V51, P203, DOI 10.1016/0010-2180(83)90099-8
   Smooke MD, 2005, COMBUST FLAME, V143, P613, DOI 10.1016/j.combustflame.2005.08.028
   Smooke MD, 2004, COMBUST THEOR MODEL, V8, P593, DOI 10.1088/1364-7830/8/3/009
   Sun ZW, 2017, COMBUST FLAME, V175, P270, DOI 10.1016/j.combustflame.2016.08.031
   Tao F, 2007, P COMBUST INST, V31, P2991, DOI 10.1016/j.proci.2006.08.005
   Toro VV, 2005, P COMBUST INST, V30, P485, DOI 10.1016/j.proci.2004.08.221
   Vishwanathan G., 2008, 2008011331 SAE, DOI [10.4271/2008-01-1331, DOI 10.4271/2008-01-1331]
   WHO, 2014, BURD DIS ASS URB OUT
NR 44
TC 2
Z9 2
U1 5
U2 15
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAR 16
PY 2019
VL 196
BP 116
EP 129
DI 10.1016/j.ces.2018.07.061
PG 14
WC Engineering, Chemical
SC Engineering
GA HI9RQ
UT WOS:000456795700011
DA 2020-05-12
ER

PT J
AU Wang, S
   Luo, K
   Hu, CS
   Fan, JR
AF Wang, Shuai
   Luo, Kun
   Hu, Chenshu
   Fan, Jianren
TI CFD-DEM study of the effect of ring baffles on system performance of a
   full-loop circulating fluidized bed
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE CFD-DEM; Full-loop CFB; Ring baffles; Flow uniformity; Numerical
   simulation
ID GAS-SOLID FLOW; RESIDENCE TIME DISTRIBUTION; DIRECT
   NUMERICAL-SIMULATION; DISCRETE ELEMENT METHOD; HEAT-TRANSFER; SPOUTED
   BED; MODEL; RISER; DISPERSION; DYNAMICS
AB Gas-solid distribution is non-uniform in the circulating fluidized bed (CFB), which deteriorates gas and solid mixing, causing a lower system performance. In this work, the effect of ring baffles on system performance of a full-loop CFB is comprehensively studied using the computational fluid dynamics-discrete element method (CFD-DEM). Detailed information (i.e., solid velocity, solid flux, solid circulation rate, solid inventory height, solid residence time, and solid dispersion) are obtained and analyzed. Meaningful results include: (i) ring baffles improve the inter-particle and inter-phase interactions, and solid particles become more uniformly dispersed in the riser; (ii) introduction of ring baffles increases the solid holdup in local regions of the riser while has a slight influence on pressure drop; (iii) increasing the number of ring baffles and the spacing between ring baffles increases the solid circulation rate and solid inventory height, decreases solid cycle time in the system and SRT in the riser, increases SRT in the dipleg, and has a slight impact on SRT in the cyclone; (iv) the average solid dispersion coefficients in the riser along three directions are 0.675 x 10(-3), 0.522 x 10(-3), and 8.415 x 10(-3) m(2)/s, and the insertion of ring baffles decreases the overall dispersion intensity in the axial direction while has a slight influence in the radial direction. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Wang, Shuai; Luo, Kun; Hu, Chenshu; Fan, Jianren] Zhejiang Univ, State Key Lab Clean Energy Utilizat, Hangzhou 310027, Zhejiang, Peoples R China.
RP Luo, K (reprint author), Zhejiang Univ, State Key Lab Clean Energy Utilizat, Hangzhou 310027, Zhejiang, Peoples R China.
EM zjulk@zju.edu.cn
RI luo, kun/A-8039-2012
OI luo, kun/0000-0003-3644-9400
FU National Key R&D Program of China [2016YFB0600102]; National Natural
   Science Foundation of ChinaNational Natural Science Foundation of China
   [51390493]
FX The authors are sincerely grateful for the National Key R&D Program of
   China (No. 2017YFB0601805), the National Natural Science Foundation of
   China (No. 51390493), and the National Key R&D Program of China (No.
   2016YFB0600102).
CR Alobaid F, 2015, CHEM ENG SCI, V138, P173, DOI 10.1016/j.ces.2015.08.010
   Bachmann P, 2017, POWDER TECHNOL, V308, P378, DOI 10.1016/j.powtec.2016.11.025
   Balasubramanian N, 1998, IND ENG CHEM RES, V37, P2548, DOI 10.1021/ie970358c
   Baltussen M. W., 2018, ADV CHEM ENG, V53, P1
   Bhusarapu S, 2004, CHEM ENG SCI, V59, P5381, DOI 10.1016/j.ces.2004.07.052
   Breault RW, 2006, POWDER TECHNOL, V163, P9, DOI 10.1016/j.powtec.2006.01.009
   Bu JJ, 1999, CAN J CHEM ENG, V77, P26, DOI 10.1002/cjce.5450770106
   Chen K, 2017, PARTICUOLOGY, V34, P134, DOI 10.1016/j.partic.2017.02.003
   CUNDALL PA, 1979, GEOTECHNIQUE, V29, P47, DOI 10.1680/geot.1979.29.1.47
   de Jong JF, 2012, POWDER TECHNOL, V230, P93, DOI 10.1016/j.powtec.2012.06.059
   Fox RO, 2012, ANNU REV FLUID MECH, V44, P47, DOI 10.1146/annurev-fluid-120710-101118
   Gidaspow D., 1994, MULTIPHASE FLOW FLUI
   Grace J. R., 1997, CIRCULATING FLUIDIZE
   Gui N, 2018, POWDER TECHNOL, V330, P174, DOI 10.1016/j.powtec.2018.02.012
   Guio-Perez DC, 2014, CHEM ENG RES DES, V92, P1107, DOI 10.1016/j.cherd.2013.10.018
   Guio-Perez DC, 2013, AICHE J, V59, P3612, DOI 10.1002/aic.14120
   Harris AT, 2003, CHEM ENG SCI, V58, P2181, DOI 10.1016/S0009-2509(03)00082-4
   Hua LN, 2018, CHEM ENG SCI, V186, P168, DOI 10.1016/j.ces.2018.04.027
   Hua LN, 2014, CHEM ENG SCI, V117, P264, DOI 10.1016/j.ces.2014.05.055
   ISSA RI, 1986, J COMPUT PHYS, V62, P40, DOI 10.1016/0021-9991(86)90099-9
   JIANG PJ, 1991, AICHE J, V37, P1392, DOI 10.1002/aic.690370911
   Jiradilok V, 2008, CHEM ENG SCI, V63, P2135, DOI 10.1016/j.ces.2008.01.019
   Kalita P, 2013, INT J HEAT MASS TRAN, V60, P531, DOI 10.1016/j.ijheatmasstransfer.2013.01.043
   Kim JS, 2008, POWDER TECHNOL, V187, P37, DOI 10.1016/j.powtec.2008.01.002
   Li LM, 2017, POWDER TECHNOL, V305, P364, DOI 10.1016/j.powtec.2016.10.005
   Li TW, 2014, CHEM ENG SCI, V120, P10, DOI 10.1016/j.ces.2014.08.041
   Li YJ, 2005, POWDER TECHNOL, V160, P219, DOI 10.1016/j.powtec.2005.09.002
   Liu DY, 2010, COMBUST FLAME, V157, P2116, DOI 10.1016/j.combustflame.2010.04.020
   Liu H, 2015, APPL ENERG, V160, P489, DOI 10.1016/j.apenergy.2015.09.065
   Lu BN, 2013, AICHE J, V59, P1108, DOI 10.1002/aic.13917
   Lu LQ, 2014, CHEM ENG SCI, V120, P67, DOI 10.1016/j.ces.2014.08.004
   Luo CM, 2018, FUEL, V224, P388, DOI 10.1016/j.fuel.2018.03.086
   Luo K, 2017, IND ENG CHEM RES, V56, P799, DOI 10.1021/acs.iecr.6b04047
   Luo K, 2016, AICHE J, V62, P1917, DOI 10.1002/aic.15186
   Luo K, 2015, CHEM ENG SCI, V123, P22, DOI 10.1016/j.ces.2014.10.039
   Moukalled F., 2015, FINITE VOLUME METHOD, V113
   Pallares D, 2006, CHEM ENG SCI, V61, P2710, DOI 10.1016/j.ces.2005.11.030
   Peng ZB, 2015, CHEM ENG RES DES, V95, P262, DOI 10.1016/j.cherd.2014.11.005
   Peng ZB, 2014, AICHE J, V60, P2000, DOI 10.1002/aic.14421
   Raji AO, 2004, J FOOD ENG, V64, P359, DOI 10.1016/j.jfoodeng.2003.11.004
   RHODES MJ, 1991, AICHE J, V37, P1450, DOI 10.1002/aic.690371003
   Rossbach V, 2016, POWDER TECHNOL, V297, P320, DOI 10.1016/j.powtec.2016.04.044
   Samruamphianskun T, 2012, CHEM ENG J, V210, P237, DOI 10.1016/j.cej.2012.08.079
   Sanchez-Prieto J, 2017, CHEM ENG J, V307, P113, DOI 10.1016/j.cej.2016.08.075
   Shi XG, 2015, POWDER TECHNOL, V271, P16, DOI 10.1016/j.powtec.2014.11.011
   Smagorinsky J., 1963, MON WEATHER REV, V91, P99, DOI [10.1175/1520-0493(1963)091<0099:GCEWTP>2.3.CO;2, DOI 10.1175/1520-0493(1963)091<0099:GCEWTP>2.3.CO;2, 10.1175/1520-0493(1963)091, 10.1175/1520-0493(1963)091<less than>0099:GCEWTP<greater than>2.3.CO;2]
   Tenneti S, 2014, ANNU REV FLUID MECH, V46, P199, DOI 10.1146/annurev-fluid-010313-141344
   Therdthianwong A, 2003, POWDER TECHNOL, V133, P1, DOI 10.1016/S0032-5910(03)00120-7
   TSUJI Y, 1993, POWDER TECHNOL, V77, P79, DOI 10.1016/0032-5910(93)85010-7
   Van de Velden M, 2007, CHEM ENG SCI, V62, P2139, DOI 10.1016/j.ces.2006.12.069
   Varas AEC, 2017, CHEM ENG SCI, V169, P246, DOI 10.1016/j.ces.2016.08.030
   Varas AEC, 2017, IND ENG CHEM RES, V56, P5558, DOI 10.1021/acs.iecr.7b00366
   Versteeg H. K., 2007, INTRO COMPUTATIONAL, P16
   Wahyudi H., 2014, 3D CFD DEM STUDY GAS
   Wang CP, 2008, POWDER TECHNOL, V184, P267, DOI 10.1016/j.powtec.2007.08.019
   Wang S, 2018, POWDER TECHNOL, V333, P91, DOI 10.1016/j.powtec.2018.04.011
   Wang S, 2018, IND ENG CHEM RES, V57, P6774, DOI 10.1021/acs.iecr.8b00353
   Wang S, 2017, CHEM ENG SCI, V172, P199, DOI 10.1016/j.ces.2017.05.052
   Wang S, 2017, CHEM ENG J, V313, P858, DOI 10.1016/j.cej.2016.10.130
   Wang S, 2017, APPL THERM ENG, V111, P1523, DOI 10.1016/j.applthermaleng.2016.07.161
   Xu YP, 2018, IND ENG CHEM RES, V57, P740, DOI 10.1021/acs.iecr.7b03817
   Yang SL, 2014, AICHE J, V60, P2788, DOI 10.1002/aic.14494
   Yang SL, 2014, IND ENG CHEM RES, V53, P7043, DOI 10.1021/ie4038399
   Yang SL, 2014, CHEM ENG J, V236, P158, DOI 10.1016/j.cej.2013.09.082
   Zhang YM, 2008, IND ENG CHEM RES, V47, P8484, DOI 10.1021/ie800906n
   Zhong WQ, 2016, CHEM ENG SCI, V140, P16, DOI 10.1016/j.ces.2015.09.035
   Zhu JX, 1997, J CHEM ENG JPN, V30, P928, DOI 10.1252/jcej.30.928
NR 67
TC 6
Z9 6
U1 5
U2 32
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAR 16
PY 2019
VL 196
BP 130
EP 144
DI 10.1016/j.ces.2018.10.056
PG 15
WC Engineering, Chemical
SC Engineering
GA HI9RQ
UT WOS:000456795700012
DA 2020-05-12
ER

PT J
AU Li, P
   Zhang, XH
   Lu, XB
AF Li, Peng
   Zhang, Xuhui
   Lu, Xiaobing
TI Three-dimensional Eulerian modeling of gas-liquid-solid flow with gas
   hydrate dissociation in a vertical pipe
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Marine gas hydrate-bearing sediment; Hydrate dissociation model; CFD;
   Gas-liquid-solid; Eulerian model
ID CIRCULATING FLUIDIZED-BED; OXY-FUEL COMBUSTION; CFD SIMULATIONS;
   MULTIPHASE FLOW; MASS-TRANSFER; HEAT; HYDRODYNAMICS; SENSITIVITY;
   REACTOR; MOTION
AB The pipe transportation of gas hydrate-bearing sediments (GHBS)(1) is one of the key problems in mechanical-thermal exploitation of gas hydrate (GH)(2) in marine stratum. It is a gas-liquid-solid (methane gas-seawater-GHBS particles) three-phase flow, accompanied by GH dissociation. In this study, a three-dimensional Eulerian model combined with the kinetic theory of granular flow (KTGF) was adopted to simulate the gas-liquid-solid flow with GH dissociation. The commercial CFD software FLUENT 16.2 was employed, considering the hydrodynamics, heat and mass transfer, and GH dissociation simultaneously. A kinetic model for GH dissociation in the GHBS particles is presented, considering the influence of multiphase flow on dissociation rate. The model can capture the transition from the initial liquid-solid two-phase flow to gas-liquid-solid three-phase flow, describing the distribution of the phase volume fraction, velocity, temperature, and dissociation rate. The interaction between GH dissociation and multiphase flow is discussed. The simulation results indicate that the continuous production of gas bubbles by GH dissociation leads to more violent fluctuations in the pressure gradient and a more marked elevation of the solid particles compared with the liquid-solid two-phase flow without GH dissociation. In addition, the effect of GH dissociation on the multiphase flow under different hydrate saturations was analyzed. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Zhang, Xuhui] Chinese Acad Sci, Inst Mech, Beijing 100190, Peoples R China.
   Univ Chinese Acad Sci, Sch Engn Sci, Beijing 100049, Peoples R China.
RP Zhang, XH (reprint author), Chinese Acad Sci, Inst Mech, Beijing 100190, Peoples R China.
EM lipeng@imech.ac.cn; zhangxuhui@imech.ac.cn; xblu@imech.ac.cn
OI zhang, xu hui/0000-0001-9614-3679
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [51639008];  [2017027]
FX This study is part of project No. 51639008 funded by the National
   Natural Science Foundation of China, and the Youth Innovation Promotion
   Association of Chinese Academy of Sciences No. 2017027.
CR Adamczyk WP, 2014, APPL THERM ENG, V71, P266, DOI 10.1016/j.applthermaleng.2014.06.063
   ANSYS Inc, 2015, ANSYS FLUENT THEOR G
   Armstrong LM, 2011, CHEM ENG J, V168, P848, DOI 10.1016/j.cej.2011.01.102
   Askaripour H, 2016, INT J MULTIPHAS FLOW, V79, P50, DOI 10.1016/j.ijmultiphaseflow.2015.08.006
   Bai YH, 2007, CHINA OCEAN ENG, V21, P625
   Baltussen MW, 2017, CHEM ENG SCI, V158, P561, DOI 10.1016/j.ces.2016.11.013
   Baniasadi M, 2018, CHEM ENG SCI, V178, P136, DOI 10.1016/j.ces.2017.12.044
   Behjat Y, 2011, CHEM ENG RES DES, V89, P978, DOI 10.1016/j.cherd.2010.10.018
   Cornejo P., 2011, INT J CHEM REACT ENG, V9, P1
   DICKENS GR, 1994, GEOPHYS RES LETT, V21, P2115, DOI 10.1029/94GL01858
   FRIEND DG, 1989, J PHYS CHEM REF DATA, V18, P583, DOI 10.1063/1.555828
   Gerber S, 2010, FUEL, V89, P2903, DOI 10.1016/j.fuel.2010.03.034
   Hamidipour M, 2012, CHEM ENG SCI, V78, P167, DOI 10.1016/j.ces.2012.05.016
   Hong H, 2003, J CAN PETROL TECHNOL, V42, P45, DOI 10.2118/03-11-05
   Jain V, 2017, PARTICUOLOGY, V33, P112, DOI 10.1016/j.partic.2016.07.011
   JOHNSON PC, 1987, J FLUID MECH, V176, P67, DOI 10.1017/S0022112087000570
   Klimanek A, 2015, FUEL, V152, P131, DOI 10.1016/j.fuel.2014.10.058
   KVENVOLDEN KA, 2001, GEOPHYS MONOGR SER, V124, P3, DOI DOI 10.1029/GM124P0003
   Launder B. E., 1974, Computer Methods in Applied Mechanics and Engineering, V3, P269, DOI 10.1016/0045-7825(74)90029-2
   Li P, 2016, INT J GENOMICS, V2016, P1
   Li P, 2018, ENERGIES, V11, DOI 10.3390/en11112896
   Limtrakul S, 2005, CHEM ENG SCI, V60, P1889, DOI 10.1016/j.ces.2004.11.026
   Liu D., 1993, FLUID DYNAMICS 2 PHA
   Liu H, 2013, IND ENG CHEM RES, V52, P18162, DOI 10.1021/ie4024148
   Loha C, 2014, CHEM ENG SCI, V109, P53, DOI 10.1016/j.ces.2014.01.017
   Ma YL, 2018, CHEM ENG SCI, V179, P243, DOI 10.1016/j.ces.2018.01.002
   Makogon YE, 2005, OIL GAS J, V103, P43
   Makogon YF, 1997, HYDRATES HYDROCARBON
   Moridis GJ, 2004, J PETROL SCI ENG, V43, P219, DOI 10.1016/j.petrol.2004.02.015
   Murthy BN, 2007, CHEM ENG SCI, V62, P7184, DOI 10.1016/j.ces.2007.07.005
   Oyama H, 2009, ENERG FUEL, V23, P4995, DOI 10.1021/ef900179y
   Pan H, 2016, POWDER TECHNOL, V299, P235, DOI 10.1016/j.powtec.2016.05.024
   Panneerselvam R, 2007, CHEM ENG J, V132, P159, DOI 10.1016/j.cej.2007.01.042
   Panneerselvam R, 2009, CHEM ENG SCI, V64, P1119, DOI 10.1016/j.ces.2008.10.052
   Qin ZP, 2017, INT J MULTIPHAS FLOW, V96, P34, DOI 10.1016/j.ijmultiphaseflow.2017.07.008
   Rafique M, 2004, REV CHEM ENG, V20, P225
   RUEFF RM, 1988, AICHE J, V34, P1468, DOI 10.1002/aic.690340908
   Sean WY, 2007, AICHE J, V53, P262, DOI 10.1002/aic.11060
   SELIM MS, 1989, AICHE J, V35, P1049, DOI 10.1002/aic.690350620
   Snider D, 2010, POWDER TECHNOL, V199, P100, DOI 10.1016/j.powtec.2009.04.023
   Sokolichin A, 2004, AICHE J, V50, P24, DOI 10.1002/aic.10003
   Wagner W, 2002, J PHYS CHEM REF DATA, V31, P387, DOI 10.1063/1.1461829
   Wang X, 2009, INT J HYDROGEN ENERG, V34, P9686, DOI 10.1016/j.ijhydene.2009.10.027
   Wang ZY, 2009, PETROL SCI, V6, P57, DOI 10.1007/s12182-009-0010-3
   Wei N, 2016, J NAT GAS SCI ENG, V36, P692, DOI 10.1016/j.jngse.2016.11.007
   Wu Y, 2018, FUEL, V216, P596, DOI 10.1016/j.fuel.2017.12.042
   Yin ZY, 2016, J NAT GAS SCI ENG, V35, P1362, DOI 10.1016/j.jngse.2016.04.050
   [张炜 Zhang Wei], 2017, [海洋地质与第四纪地质, Marine Geology & Quaternary Geology], V37, P27
   [张旭辉 Zhang Xuhui], 2016, [力学学报, Chinese Journal of Theoretical and Applied Mechanics], V48, P1238
   [张旭辉 Zhang Xuhui], 2014, [地球物理学进展, Progress in Geophysiscs], V29, P858
   Zhong WQ, 2016, CHEM ENG SCI, V140, P16, DOI 10.1016/j.ces.2015.09.035
NR 51
TC 1
Z9 1
U1 19
U2 83
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAR 16
PY 2019
VL 196
BP 145
EP 165
DI 10.1016/j.ces.2018.10.053
PG 21
WC Engineering, Chemical
SC Engineering
GA HI9RQ
UT WOS:000456795700013
OA Green Published
DA 2020-05-12
ER

PT J
AU Thosar, AU
   Lele, AK
AF Thosar, Aniket U.
   Lele, Ashish K.
TI Analytical solutions of an isothermal two-dimensional model of a cathode
   flow channel in transport limited operational regimes of a proton
   exchange membrane fuel cell
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Proton exchange membrane fuel cells; Polarization curve; Transport
   resistance; Analytical modelling
ID OXYGEN REDUCTION KINETICS
AB In the quest for obtaining accurate closed-form analytical expressions for polarization curve of a proton exchange membrane fuel cell (PEMFC), we have recently presented a two-dimensional model that accounts for oxygen concentration gradient and velocity gradient along the depth of a cathode flow channel. The model was developed for the case when Tafel kinetics of oxygen reduction reaction (ORR) on the cathode governs the overall rate of oxygen consumption. An improved match between predictions of the model and full three-dimensional simulations was obtained over the entire range of current density compared with earlier models which assumed homogenous oxygen concentration in the channel depth and plug flow velocity profile. In reality however, ORR kinetics is often not the rate limiting step for oxygen consumption in the cathode catalyst layer (CCL) at high current density since the Tafel kinetics is modulated by transport resistances in the CCL. In this article, we extend our two-dimensional analytical model to two different transport-limited regimes of CCL operation namely, slow oxygen transport across the CCL and slow proton transport across the CCL. We compare model predictions with results of full three-dimensional simulations in both cases and show that they are in excellent agreement even in these transport limited operational regimes of PEMFC. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Thosar, Aniket U.] Acad Sci & Innovat Res AcSIR, CSIR Natl Chem Lab CSIR NCL Campus, Pune 411008, Maharashtra, India.
   CSIR Natl Chem Lab, Pune 411008, Maharashtra, India.
RP Thosar, AU (reprint author), Acad Sci & Innovat Res AcSIR, CSIR Natl Chem Lab CSIR NCL Campus, Pune 411008, Maharashtra, India.
EM au.thosar@ncl.res.in
FU CSIR-NMITLI program on PEM fuel cells; CSIRCouncil of Scientific &
   Industrial Research (CSIR) - India
FX Authors acknowledge CSIR-NMITLI program on PEM fuel cells for financial
   assistance. AUT thanks CSIR for Senior Research fellowship.
CR Cetinbas FC, 2013, J ELECTROCHEM SOC, V160, pF750, DOI 10.1149/2.017308jes
   Cimenti M, 2010, ECS TRANSACTIONS, V28, P147, DOI 10.1149/1.3502346
   Epting WK, 2012, ADV FUNCT MATER, V22, P555, DOI 10.1002/adfm.201101525
   Harvey D, 2008, J POWER SOURCES, V179, P209, DOI 10.1016/j.jpowsour.2007.12.077
   Khajeh-Hosseini-Dalasm N, 2012, ELECTROCHIM ACTA, V60, P55, DOI 10.1016/j.electacta.2011.10.099
   Kulikovsky AA, 2014, ELECTROCHIM ACTA, V130, P826, DOI 10.1016/j.electacta.2014.03.131
   Kulikovsky AA, 2011, ELECTROCHEM COMMUN, V13, P1395, DOI 10.1016/j.elecom.2011.08.019
   Kulikovsky AA, 2010, ELECTROCHIM ACTA, V55, P6391, DOI 10.1016/j.electacta.2010.06.053
   Kulikovsky AA, 2002, ELECTROCHEM COMMUN, V4, P318, DOI 10.1016/S1388-2481(02)00275-8
   Kulikovsky AA, 2004, ELECTROCHEM COMMUN, V6, P729, DOI 10.1016/j.elecom.2004.05.015
   Larminie James, 2003, FUEL CELL SYSTEMS EX
   Liu YX, 2009, J ELECTROCHEM SOC, V156, pB970, DOI 10.1149/1.3143965
   Makharia R, 2005, J ELECTROCHEM SOC, V152, pA970, DOI 10.1149/1.1888367
   Malek K, 2011, ELECTROCATALYSIS-US, V2, P141, DOI 10.1007/s12678-011-0047-0
   Marquis J, 2013, CHEM ENG SCI, V102, P151, DOI 10.1016/j.ces.2013.08.003
   Neyerlin KC, 2006, J ELECTROCHEM SOC, V153, pA1955, DOI 10.1149/1.2266294
   Neyerlin KC, 2005, J ELECTROCHEM SOC, V152, pA1073, DOI 10.1149/1.1897368
   SRINIVASAN S, 1988, J POWER SOURCES, V22, P359, DOI 10.1016/0378-7753(88)80030-2
   Sun W, 2005, ELECTROCHIM ACTA, V50, P3359, DOI 10.1016/j.electacta.2004.12.009
   Thosar AU, 2018, CHEM ENG SCI, V190, P333, DOI 10.1016/j.ces.2018.06.025
NR 20
TC 1
Z9 1
U1 3
U2 29
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAR 16
PY 2019
VL 196
BP 166
EP 175
DI 10.1016/j.ces.2018.10.048
PG 10
WC Engineering, Chemical
SC Engineering
GA HI9RQ
UT WOS:000456795700014
DA 2020-05-12
ER

PT J
AU Sun, W
   Chen, SL
   Xu, MR
   Wei, YQ
   Fan, TT
   Huang, LX
   Ma, BL
   Guo, JT
AF Sun, Wei
   Chen, Sheng-Li
   Xu, Mingri
   Wei, Yaqian
   Fan, Ting-ting
   Huang, Ling-xiang
   Ma, Baoli
   Guo, Jintao
TI The measurements of the intrinsic diffusivity in pores and surface
   diffusivity inside the porous materials in liquid phase
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Intrinsic surface diffusivity; Intrinsic pore diffusivity; Uniform pore
   structure
ID HINDERED DIFFUSION; RESTRICTIVE DIFFUSION; HEAVY OIL; MICROPOROUS
   MEMBRANES; GAS-CHROMATOGRAPHY; FIXED-BEDS; CATALYST; COEFFICIENT;
   ADSORPTION; PARTICLES
AB In this work, an improved mathematical model was proposed for simulation of the diffusion of dibenzothiophene (DBT) molecules inside the porous materials in liquid phase. The experimental data of the diffusion were obtained in some silica adsorbents with uniform pore structure. The intrinsic pore diffusivity and intrinsic surface diffusivity of molecules were obtained through optimizing the parameters in the mathematical model with the experimental data. The bulk diffusivity of molecules in solution was obtained when the pore size of the silica adsorbents was large enough. The correlation of the intrinsic pore diffusivity with the ratio of diffusion molecular size to pore size of porous materials was established. In addition, the effect of pore size on the ratio of surface mass transfer to total mass transfer was studied and it was found that the smaller the pore size of porous materials, the higher the ratio of surface mass transfer to total mass transfer. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Sun, Wei; Chen, Sheng-Li; Xu, Mingri; Wei, Yaqian; Fan, Ting-ting; Huang, Ling-xiang; Guo, Jintao] China Univ Petr, State Key Lab Heavy Oil Proc, Beijing 102249, Peoples R China.
   [Sun, Wei; Chen, Sheng-Li; Xu, Mingri; Wei, Yaqian; Fan, Ting-ting; Huang, Ling-xiang; Guo, Jintao] China Univ Petr, Dept Chem Engn, Beijing 102249, Peoples R China.
   [Ma, Baoli; Guo, Jintao] CNPC, Daqing Petrochem Res Ctr, Daqing 163741, Heilongjiang, Peoples R China.
RP Chen, SL (reprint author), China Univ Petr, State Key Lab Heavy Oil Proc, Beijing 102249, Peoples R China.; Chen, SL (reprint author), China Univ Petr, Dept Chem Engn, Beijing 102249, Peoples R China.
EM slchen@cup.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [91534120]; China National Petroleum Company
   [DQZX-KY-17-019]
FX The authors acknowledge the financial support by the National Natural
   Science Foundation of China (Grant No: 91534120) and by China National
   Petroleum Company under the contract number of DQZX-KY-17-019.
CR ABSIHALABI M, 1995, FUEL, V74, P1211, DOI 10.1016/0016-2361(94)00042-P
   BALTUS RE, 1983, CHEM ENG SCI, V38, P1959, DOI 10.1016/0009-2509(83)80099-2
   Barrande M, 2007, ANAL CHEM, V79, P9115, DOI 10.1021/ac071377r
   BECK RE, 1972, BIOCHIM BIOPHYS ACTA, V255, P273, DOI 10.1016/0005-2736(72)90028-4
   BECK RE, 1970, SCIENCE, V170, P1302, DOI 10.1126/science.170.3964.1302
   Bhatia SK, 2011, CHEM ENG SCI, V66, P284, DOI 10.1016/j.ces.2010.10.038
   Caravella A, 2016, MICROPOR MESOPOR MAT, V235, P87, DOI 10.1016/j.micromeso.2016.07.049
   CHANTONG A, 1983, AICHE J, V29, P725, DOI 10.1002/aic.690290505
   Chen AC, 2013, CHEM ENG J, V231, P420, DOI 10.1016/j.cej.2013.07.035
   Chen SL, 2007, CATAL TODAY, V125, P143, DOI 10.1016/j.cattod.2007.02.026
   Chen SL, 1996, J COLLOID INTERF SCI, V180, P237, DOI 10.1006/jcis.1996.0295
   Chen SL, 1996, IND ENG CHEM RES, V35, P4487, DOI 10.1021/ie9602217
   CHEN YW, 1994, CAN J CHEM ENG, V72, P854
   Chen ZT, 2010, AICHE J, V56, P2030, DOI 10.1002/aic.12124
   Chung K, 1998, REV PROCESS CHEM ENG, V1, P41
   COMITI J, 1989, CHEM ENG SCI, V44, P1539, DOI 10.1016/0009-2509(89)80031-4
   DEEN WM, 1982, J MEMBRANE SCI, V12, P217, DOI 10.1016/S0376-7388(00)80184-2
   Do D.D., 1998, ADSORPTION ANAL EQUI
   Dogu T, 1998, IND ENG CHEM RES, V37, P2158
   HASHIMOTO N, 1974, IND ENG CHEM FUND, V13, P115, DOI 10.1021/i160050a005
   HAYNES HW, 1975, CHEM ENG SCI, V30, P955, DOI 10.1016/0009-2509(75)80062-5
   HO FG, 1981, CHEM ENG SCI, V36, P253, DOI 10.1016/0009-2509(81)85003-8
   JOHNSON MFL, 1968, J CATAL, V10, P342, DOI 10.1016/0021-9517(68)90149-8
   LEE SY, 1991, IND ENG CHEM RES, V30, P1683, DOI 10.1021/ie00056a002
   Leyva-Ramos R, 2012, CHEM ENG J, V183, P141, DOI 10.1016/j.cej.2011.12.046
   LI CP, 1995, IND ENG CHEM RES, V34, P898, DOI 10.1021/ie00042a024
   Liu Z., 2013, ARCH DERMATOL RES, V306, P173
   Liu Z., 2011, J PETROCHEM U, V24, P1
   Liu ZY, 2010, ENERG FUEL, V24, P2825, DOI 10.1021/ef100064d
   MA YH, 1972, AICHE J, V18, P1148, DOI 10.1002/aic.690180610
   Mauret E, 1997, CHEM ENG SCI, V52, P1807, DOI 10.1016/S0009-2509(96)00499-X
   McKay G, 2001, CHEM ENG J, V81, P213, DOI 10.1016/S1385-8947(00)00191-1
   Medved I, 2011, MICROPOR MESOPOR MAT, V142, P405, DOI 10.1016/j.micromeso.2011.01.015
   MIYAHARA M, 1992, J CHEM ENG JPN, V25, P408, DOI 10.1252/jcej.25.408
   Negrini R, 2012, LANGMUIR, V28, P16455, DOI 10.1021/la303833s
   Pisani L, 2011, TRANSPORT POROUS MED, V88, P193, DOI 10.1007/s11242-011-9734-9
   RENKIN EM, 1954, J GEN PHYSIOL, V38, P225
   RUCKENSTEIN E, 1971, CHEM ENG SCI, V26, P1305, DOI 10.1016/0009-2509(71)80051-9
   SANE RC, 1992, CHEM ENG SCI, V47, P2683, DOI 10.1016/0009-2509(92)87113-5
   SARMAH SK, 1989, AICHE J, V35, P1728, DOI 10.1002/aic.690351018
   Silva VMTM, 1999, IND ENG CHEM RES, V38, P4023, DOI 10.1021/ie990138u
   TSAI CH, 1991, IND ENG CHEM RES, V30, P22, DOI 10.1021/ie00049a004
   TSAI MC, 1993, IND ENG CHEM RES, V32, P1603, DOI 10.1021/ie00020a011
   Wang G, 2011, CHEM ENG SCI, V66, P1200, DOI 10.1016/j.ces.2010.12.026
   Wang ZG, 2014, AICHE J, V60, P3267, DOI 10.1002/aic.14501
   YAKIMCHENKO OE, 1995, J PHYS CHEM-US, V99, P2038, DOI 10.1021/j100007a039
   Yang B, 2016, FUEL, V181, P793, DOI 10.1016/j.fuel.2016.05.069
NR 47
TC 1
Z9 1
U1 8
U2 19
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAR 16
PY 2019
VL 196
BP 176
EP 187
DI 10.1016/j.ces.2018.11.006
PG 12
WC Engineering, Chemical
SC Engineering
GA HI9RQ
UT WOS:000456795700015
DA 2020-05-12
ER

PT J
AU Ma, YL
   Liu, MY
   Zhang, Y
AF Ma, Yongli
   Liu, Mingyan
   Zhang, Yuan
TI Axial meso-scale modeling of gas-liquid-solid fluidized beds
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Model; Gas-liquid-solid; Fluidization; Axial model; Meso-scale
ID DRAG COEFFICIENT; SINGLE BUBBLE; SCALE-UP; HOLDUP; WAKE; HYDRODYNAMICS;
   SIMILITUDE; VELOCITY; REACTORS; SHAPES
AB The meso-scale theory, based on the energy minimization multi-scale principle, has recently inspired the accurate modeling of the multi-phase flow. In this study, an axial meso-scale flow model for the gasliquid-solid fluidized bed is established and verified by the literature models and data. Compared with the reported axial models, this model predicts the axial distribution of all three-phase hydrodynamic parameters with fewer empirical corrections. Predictions of the present model show that the operation conditions and physical properties of solid particles obviously affect the flow behaviors of phases, such as the slip velocity, entrainment of solid particles, wake shedding parameters. Solid particles entrained by bubble wake determine the formation of axial distribution in the gas-liquid-solid fluidized bed. Region with the axial structure is the transition section, length of which depends on the entrainment of solid particles. Furthermore, behaviors of the gas bubbles and the solid particles are mutually influential. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Ma, Yongli; Liu, Mingyan; Zhang, Yuan] Tianjin Univ, Sch Chem Engn & Technol, Tianjin 300350, Peoples R China.
   [Liu, Mingyan] Tianjin Univ, State Key Lab Chem Engn, Tianjin 300350, Peoples R China.
RP Liu, MY (reprint author), Tianjin Univ, Sch Chem Engn & Technol, Tianjin 300350, Peoples R China.
EM myliu@tju.edu.cn
FU National Nature Science Foundation of ChinaNational Natural Science
   Foundation of China [91434204]
FX This work is financially supported by the National Nature Science
   Foundation of China (No. 91434204). Thanks to Xiuhong Zhou for her help
   in modifying the article language.
CR Azzopardi B.J., 2013, THERMOPEDIA
   BATCHELOR GK, 1956, J FLUID MECH, V1, P388, DOI 10.1017/S0022112056000238
   Becker H.A., 1976, DIMENSIONLESS PARAME
   BHAGA D, 1981, J FLUID MECH, V105, P61, DOI 10.1017/S002211208100311X
   CATROS A, 1985, CAN J CHEM ENG, V63, P754, DOI 10.1002/cjce.5450630508
   Cheng C. L., 2002, J CHEM IND ENG, V08, P804
   Clift R., 1978, BUBBLES DROPS PARTIC
   Cova D. R., 1966, CATALYST SUSPENSION, V5
   ELTEMTAMY SA, 1978, INT J MULTIPHAS FLOW, V4, P19, DOI 10.1016/0301-9322(78)90022-8
   Fan L.S., 1989, GAS LIQUID SOLID FLU
   FAN LS, 1990, BUBBLE WAKE DYNAMICS
   FLEMMER RLC, 1986, POWDER TECHNOL, V48, P217, DOI 10.1016/0032-5910(86)80044-4
   GLICKSMAN LR, 1984, CHEM ENG SCI, V39, P1373, DOI 10.1016/0009-2509(84)80070-6
   GOROWARA RL, 1990, IND ENG CHEM RES, V29, P882, DOI 10.1021/ie00101a025
   GRACE JR, 1969, CHEM ENG SCI, V24, P497, DOI 10.1016/0009-2509(69)85021-9
   GRACE JR, 1973, T I CHEM ENG-LOND, V51, P116
   HESKETH RP, 1987, AICHE J, V33, P663, DOI 10.1002/aic.690330414
   HINZE JO, 1955, AICHE J, V1, P289, DOI 10.1002/aic.690010303
   Imafuku K, 1968, J CHEM ENG JAPAN, V1, P153
   Jena HM, 2010, COMPUT CHEM ENG, V34, P476, DOI 10.1016/j.compchemeng.2009.07.003
   Jin GD, 2006, CHEM ENG J, V117, P1, DOI 10.1016/j.cej.2005.12.009
   KATO Y, 1985, J CHEM ENG JPN, V18, P308, DOI 10.1252/jcej.18.308
   Kato Y., 1972, J CHEM ENGINEER JAPA, V5, P112, DOI 10.1252/jcej.5.112
   Kelbaliyev G, 2007, CHEM ENG COMMUN, V194, P1623, DOI 10.1080/00986440701446128
   KOJIMA H, 1980, KAGAKU KOGAKU RONBUN, V6, P46, DOI 10.1252/kakoronbunshu.6.46
   Kreischer B.E., 1989, BUBBLE BUBBLE WAKE C
   KREISCHER BE, 1990, INT J MULTIPHAS FLOW, V16, P187, DOI 10.1016/0301-9322(90)90053-L
   Larachi F, 1996, AICHE J, V42, P2439, DOI 10.1002/aic.690420905
   LEE SLP, 1987, AICHE J, V33, P1359, DOI 10.1002/aic.690330813
   LEVICH VG, 1962, PHYSICOCHEMICAL HYDR
   Li J., 1994, PARTICLE FLUID 2 PHA
   Li J., 1987, THESIS
   Li J, 2014, MESOSCIENCE PRINCIPL
   Li J., 1988, CIRCULATING FLUIDIZE, P89
   Li JH, 2004, CHEM ENG SCI, V59, P1687, DOI 10.1016/j.ces.2004.01.025
   Li JH, 2003, CHEM ENG SCI, V58, P521, DOI 10.1016/S0009-2509(02)00577-8
   Liang W. G., 1993, J CHEM IND ENG, V44, P672
   Liang WG, 1996, CHEM ENG SCI, V51, P2001, DOI 10.1016/0009-2509(96)00057-7
   LINDT JT, 1971, CHEM ENG SCI, V26, P1776, DOI 10.1016/0009-2509(71)86069-4
   Liu M. Y., 1998, THESIS
   Liu MY, 2001, CHEM ENG SCI, V56, P6805, DOI 10.1016/S0009-2509(01)00318-9
   Liu XH, 2015, CHEM ENG J, V278, P492, DOI 10.1016/j.cej.2014.11.093
   Liu XH, 2014, IND ENG CHEM RES, V53, P2800, DOI 10.1021/ie4029335
   Ma YL, 2018, CHEM ENG SCI, V179, P243, DOI 10.1016/j.ces.2018.01.002
   Macchi A, 2001, CHEM ENG SCI, V56, P6039, DOI 10.1016/S0009-2509(01)00207-X
   MATSUMOTO T, 1989, AICHE J, V35, P1701, DOI 10.1002/aic.690351015
   RIGBY GR, 1970, CAN J CHEM ENG, V48, P343, DOI 10.1002/cjce.5450480401
   Rudisuli M, 2012, POWDER TECHNOL, V217, P21, DOI 10.1016/j.powtec.2011.10.004
   Safoniuk M, 1999, CHEM ENG SCI, V54, P4961, DOI 10.1016/S0009-2509(99)00218-3
   Schiller L, 1933, Z VER DTSCH ING, V77, P318
   SONG GH, 1991, CHEM ENG SCI, V46, P2933, DOI 10.1016/0009-2509(91)85162-Q
   TANG WT, 1989, AICHE J, V35, P355, DOI 10.1002/aic.690350303
   Tsuchiya K, 1997, CHEM ENG SCI, V52, P3053, DOI 10.1016/S0009-2509(97)00127-9
   TSUCHIYA K, 1988, CHEM ENG SCI, V43, P1167, DOI 10.1016/0009-2509(88)85077-2
   TSUTSUMI A, 1992, CHEM ENG SCI, V47, P3411, DOI 10.1016/0009-2509(92)85052-D
   WALLIS GB, 1969, ONE DIMENSIONAL 2 PH
   WATKINS SP, 1974, POWDER TECHNOL, V9, P241, DOI 10.1016/0032-5910(74)80048-3
   WEN CY, 1966, AICHE J, V12, P610, DOI 10.1002/aic.690120343
   Yang GQ, 2007, CHEM ENG SCI, V62, P2, DOI 10.1016/j.ces.2006.08.021
NR 59
TC 1
Z9 1
U1 4
U2 27
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAR 16
PY 2019
VL 196
BP 188
EP 201
DI 10.1016/j.ces.2018.11.005
PG 14
WC Engineering, Chemical
SC Engineering
GA HI9RQ
UT WOS:000456795700016
DA 2020-05-12
ER

PT J
AU Li, Y
   Li, H
   Chen, S
   Mbi, E
   Wu, K
AF Li, Ying
   Li, Haitao
   Chen, Shengnan
   Mbi, Ernest
   Wu, Keliu
TI The second critical capillary number for chemical flooding in low
   permeability reservoirs: Experimental and numerical investigations
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Dynamic capillary pressure; Chemical flooding; Capillary number; Low
   permeability; Dynamic contact angle
ID DYNAMIC CONTACT-ANGLE; ENHANCED OIL-RECOVERY; POROUS-MEDIA; 2-PHASE
   FLOW; PRESSURE RELATIONSHIPS; SURFACE-ROUGHNESS; FLUID VISCOSITY; WATER;
   INTERFACE; VELOCITY
AB High capillary numbers are often adopted for chemical flooding in reservoirs to achieve the highest oil recovery. A high capillary number may be disadvantageous for high and medium permeability formations, while no experimental or field data are available for low permeability formations. In this work, through the use of a newly designed experimental apparatus for the measurement of the dynamic capillary pressure in low permeability formations, chemical flooding experiments on sandstone core samples (1-10 mD) were conducted to investigate the effects of high capillary numbers (0.001-2). In addition, these effects were examined through numerical production simulations on a real low permeability reservoir. The dynamic capillary pressure and relative permeability were measured to reveal the dynamic fluid flow characteristics. The dynamic contact angle was investigated to explore the dynamic interface properties. The results show that there is a second critical capillary number (higher than 0.02) that can be used to optimize the chemical flooding performance in low permeability reservoirs. Moreover, the oil relative permeability reaches its highest value at the second critical capillary number, while the water relative permeability always increases with the increase in the capillary number. The dynamic contact angle will reach approximately 180 degrees at a high capillary number, causing an oil film to remain. An optimized capillary number range is proposed for chemical flooding in low permeability reservoirs. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Li, Ying; Li, Haitao] Southwest Petr Univ, State Key Lab Oil & Gas Reservoir Geol & Exploita, Chengdu 610500, Sichuan, Peoples R China.
   [Li, Ying; Chen, Shengnan; Mbi, Ernest; Wu, Keliu] Univ Calgary, Schulich Sch Engn, Dept Chem & Petr Engn, Calgary, AB T2N 1N4, Canada.
RP Li, Y; Li, H (reprint author), Southwest Petr Univ, State Key Lab Oil & Gas Reservoir Geol & Exploita, Chengdu 610500, Sichuan, Peoples R China.; Chen, S (reprint author), Univ Calgary, Schulich Sch Engn, Dept Chem & Petr Engn, Calgary, AB T2N 1N4, Canada.
EM yingingli@163.com; lihaitao@swpu.edu.cn; snchen@ucalgary.ca
RI Wu, Keliu/F-8287-2016
OI Wu, Keliu/0000-0002-0021-5007; Li, Ying/0000-0001-8780-1182
FU State Key Laboratory of Oil and Gas Reservoir Geology and the
   Exploitation Open Foundation Project of China [PLN201625]; Research and
   Demonstration of Intelligent Water Control Technology for High Water-cut
   Horizontal wells in Bohai Oilfield [2016ZX05009003022]
FX This work was supported by the State Key Laboratory of Oil and Gas
   Reservoir Geology and the Exploitation Open Foundation Project of China
   (No. PLN201625) and the Research and Demonstration of Intelligent Water
   Control Technology for High Water-cut Horizontal wells in Bohai Oilfield
   (No. 2016ZX05009003022).
CR ABRAMS A, 1975, SOC PETROL ENG J, V15, P437, DOI 10.2118/5050-PA
   Baoquan Z., 2010, NIG ANN INT C EXH SO
   Blake TD, 2004, J COLLOID INTERF SCI, V279, P198, DOI 10.1016/j.jcis.2004.06.057
   BONN D, 1995, PHYS REV LETT, V75, P2132, DOI 10.1103/PhysRevLett.75.2132
   Bottero S., 2006, P 16 INT C COMP METH, P18
   Bourgeat A, 1998, COMPUTAT GEOSCI, V2, P191, DOI 10.1023/A:1011502303588
   Camps-Roach G, 2010, WATER RESOUR RES, V46, DOI 10.1029/2009WR008881
   CHATZIS I, 1984, SOC PETROL ENG J, V24, P555, DOI 10.2118/10114-PA
   Cottin C, 2010, PHYS REV E, V82, DOI 10.1103/PhysRevE.82.046315
   Dahle HK, 2005, TRANSPORT POROUS MED, V58, P5, DOI 10.1007/s11242-004-5466-4
   Das DB, 2012, AICHE J, V58, P3891, DOI 10.1002/aic.13777
   DiCarlo DA, 2000, WATER RESOUR RES, V36, P2781, DOI 10.1029/2000WR900184
   Friedman SP, 1999, J ADHES SCI TECHNOL, V13, P1495, DOI 10.1163/156856199X00613
   FULCHER RA, 1985, J PETROL TECHNOL, V37, P249, DOI 10.2118/12170-PA
   Goel G, 2016, ENVIRON FLUID MECH, V16, P945, DOI 10.1007/s10652-016-9459-y
   Hassanizadeh SM, 2002, VADOSE ZONE J, V1, P38, DOI 10.2136/vzj2002.3800
   Hassanizadeh SM, 2005, SPRINGER PROC PHYS, V93, P3
   HOFFMAN RL, 1975, J COLLOID INTERF SCI, V50, P228, DOI 10.1016/0021-9797(75)90225-8
   Hsu SY, 2011, VADOSE ZONE J, V10, P642, DOI 10.2136/vzj2010.0069
   International Energy Agency (IEA), 2015, WORLD EN INV OUTL
   Joekar-Niasar V, 2012, CRIT REV ENV SCI TEC, V42, P1895, DOI 10.1080/10643389.2011.574101
   Kalaydjian F.J.M., 1992, SPE ANN TECHN C EXH
   Kandlikar SG, 2005, PHYS FLUIDS, V17, DOI 10.1063/1.1896985
   Korrani AKN, 2016, SPE J, V21, P32
   Kuchin IV, 2016, LANGMUIR, V32, P5333, DOI 10.1021/acs.langmuir.6b00721
   Lee T, 2014, ADV COLLOID INTERFAC, V210, P21, DOI 10.1016/j.cis.2014.02.015
   Li Aifen, 2015, Journal of China University of Petroleum, V39, P92, DOI 10.3969/j.issn.1673-5005.2015.06.012
   LI DM, 1991, J COLLOID INTERF SCI, V143, P382, DOI 10.1016/0021-9797(91)90272-A
   Li HT, 2016, ENERG FUEL, V30, P7082, DOI 10.1021/acs.energyfuels.6b01272
   Li Huabin, 2010, CHEM EOR TECHNOLOGIE, P52
   Li M, 2015, J GEOPHYS RES-SOL EA, V120, P4055, DOI 10.1002/2014JB011799
   [李松泉 LI Songquan], 2008, [石油勘探与开发, Petroleum Exploration and Development], V35, P606
   Li Y, 2017, FUEL, V194, P129, DOI 10.1016/j.fuel.2016.12.088
   Liu D, 2005, PGRE, V12, P40
   Lukyanov AV, 2016, ACS NANO, V10, P6045, DOI 10.1021/acsnano.6b01630
   Manthey S, 2005, TRANSPORT POROUS MED, V58, P121, DOI 10.1007/s11242-004-5472-6
   Melrose J.C., 1974, J CAN PET TECHNOL, V13
   Mirzaei M, 2007, CHEM ENG SCI, V62, P1927, DOI 10.1016/j.ces.2006.12.039
   Moore T, 1956, PROD MON, V20, P20
   Mumford KG, 2011, VADOSE ZONE J, V10, P1162, DOI 10.2136/vzj2010.0125
   NGAN CG, 1982, J FLUID MECH, V118, P27, DOI 10.1017/S0022112082000949
   Oung O, 2005, J POROUS MEDIA, V8, P247, DOI 10.1615/JPorMedia.v8.i3.10
   Ping Lu, 1984, MECH ENG, V6, P44
   Ping Lu, 1987, ACTA PETROLEI SINICA, V8, P49
   Qi Lianqing, 2009, PETROL GEOL OILFIELD, V28, P91
   Qi LQ, 2009, PETROL EXPLOR DEV+, V28, P247
   Sheng J, 2010, MODERN CHEM ENHANCED
   Sofos F, 2010, INT J HEAT MASS TRAN, V53, P3839, DOI 10.1016/j.ijheatmasstransfer.2010.04.037
   STOKES JP, 1988, PHYS REV LETT, V60, P1386, DOI 10.1103/PhysRevLett.60.1386
   TABER JJ, 1969, SOC PETROL ENG J, V9, P3, DOI 10.2118/2098-PA
   Tapia JFD, 2016, APPL ENERG, V184, P337, DOI 10.1016/j.apenergy.2016.09.093
   Thomas S, 2008, OIL GAS SCI TECHNOL, V63, P9, DOI 10.2516/ogst:2007060
   Tian SB, 2012, PETROL EXPLOR DEV+, V39, P405, DOI 10.1016/S1876-3804(12)60057-3
   Vinogradova OI, 1999, INT J MINER PROCESS, V56, P31, DOI 10.1016/S0301-7516(98)00041-6
   Wang XK, 2017, FUEL, V190, P41, DOI 10.1016/j.fuel.2016.11.040
   WEITZ DA, 1987, PHYS REV LETT, V59, P2967, DOI 10.1103/PhysRevLett.59.2967
   Yan C., 2016, ARXIV161007749
   Yang YF, 2016, OPEN PHYS, V14, P610, DOI 10.1515/phys-2016-0069
   Zhang CY, 2011, ENERG FUEL, V25, P3493, DOI 10.1021/ef101732k
   Zhang YB, 2016, INT J HEAT MASS TRAN, V100, P295, DOI 10.1016/j.ijheatmasstransfer.2016.04.097
NR 60
TC 17
Z9 16
U1 13
U2 29
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAR 16
PY 2019
VL 196
BP 202
EP 213
DI 10.1016/j.ces.2018.11.004
PG 12
WC Engineering, Chemical
SC Engineering
GA HI9RQ
UT WOS:000456795700017
DA 2020-05-12
ER

PT J
AU Strasser, W
AF Strasser, Wayne
TI Oxidation-assisted pulsating three-stream non-Newtonian slurry
   atomization for energy production
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Turbulence; CFD
ID FILM THICKNESS; LARGE-EDDY; LIQUID; SIMULATION; INTERFACE; FLOW; SIZE
AB Past work involving validated "cold-flow" CFD modeling of self-generating and self-sustaining pulsating near-sonic non-Newtonian slurry atomization elucidated acoustic signatures, atomization mechanisms, and the effects of numerics and geometric permutations. The numerical method has now been incorporated with exothermic oxidation reaction kinetics relations along with radiation, i.e. no longer cold-flow. These models provide substantially increased model rigor and allow for new pulsing thermal measures which help assess injector thermal stresses. Twelve models have been run for extended periods of time in order to investigate the effects of dramatic changes in gas feed rate and prefilming (retraction) length. Given the new metrics and models, multiple statistically optimized designs are potentially available depending on the objective function(s) and their relative weightings in the overall value proposition to the project. In the case in which all metrics have equal value to the project and are simultaneously considered in a statistical model, the optimum design involves a mid-level of retraction and a mid-level gas feed rate. If, however, more relative weighting is placed on the importance of droplet size minimization and injector thermal management in lieu of feed passage pressure drop minimization, the optimum design involves a similar retraction but a very high level of gas feed rate. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Strasser, Wayne] Eastman Chem Co, POB 511, Kingsport, TN 37660 USA.
RP Strasser, W (reprint author), Eastman Chem Co, POB 511, Kingsport, TN 37660 USA.
EM strasser@eastman.com
RI Strasser, Wayne/F-3994-2019
OI Strasser, Wayne/0000-0001-5913-4132
CR Ahmed M, 2014, CHEM ENG SCI, V107, P149, DOI 10.1016/j.ces.2013.12.004
   Bazdidi-Tehrani F, 2018, CHEM ENG SCI, V189, P233, DOI 10.1016/j.ces.2018.05.046
   Beheshti N, 2007, BIOINSPIR BIOMIM, V2, P57, DOI 10.1088/1748-3182/2/4/001
   Boivin P, 2011, REDUCED KINETIC MECH
   BRACKBILL JU, 1992, J COMPUT PHYS, V100, P335, DOI 10.1016/0021-9991(92)90240-Y
   Chen L, 2016, J ENERG RESOUR-ASME, V138, DOI 10.1115/1.4031835
   Dombrowski N., 1963, AERODYNAMIC INSTABIL
   Hansch S, 2014, PROCEEDINGS OF THE ASME FLUIDS ENGINEERING DIVISION SUMMER MEETING, 2013, VOL 1C: SYMPOSIA
   Howard J, 1973, S INT COMBUST, V14, P975, DOI DOI 10.1016/S0082-0784(73)80089-X
   Hufnagel L, 2018, J FLUID MECH, V835, P86, DOI 10.1017/jfm.2017.749
   Kourmatzis A, 2015, J FLUID MECH, V764, P95, DOI 10.1017/jfm.2014.700
   LING Y, 2018, J FLUID MECH, V859, P268, DOI DOI 10.1017/JFM.2018.825
   Liovic P, 2007, J COMPUT PHYS, V222, P504, DOI 10.1016/j.jcp.2006.07.030
   Liovic P, 2007, INT J HEAT FLUID FL, V28, P127, DOI 10.1016/j.ijheatfluidflow.2006.03.003
   Liovic P, 2012, COMPUT FLUIDS, V63, P27, DOI 10.1016/j.compfluid.2012.03.019
   Mantripragada VT, 2017, CHEM ENG SCI, V158, P227, DOI 10.1016/j.ces.2016.10.027
   MENTER FR, 1994, AIAA J, V32, P1598, DOI 10.2514/3.12149
   Navarro-Martinez S, 2014, INT J MULTIPHAS FLOW, V63, P11, DOI 10.1016/j.ijmultiphaseflow.2014.02.013
   Rajabi A, 2017, CHEM ENG SCI, V165, P89, DOI 10.1016/j.ces.2017.02.024
   Savart  F., 1833, ANN CHIM PHYS, V53, P1833
   Shaikh J, 2018, CHEM ENG SCI, V176, P77, DOI 10.1016/j.ces.2017.10.022
   Steacie E., 1959, SOME PROBLEMS CHEM K
   Strasser W, 2018, ATOMIZATION SPRAY, V28, P643, DOI 10.1615/AtomizSpr.2018026380
   Strasser W., 2015, P P INT MECH ENG C E
   Strasser W, 2018, ASME FLUID ENG DIV
   Strasser W, 2018, J FLUID ENG-T ASME, V140, DOI 10.1115/1.4039234
   Strasser W, 2017, ATOMIZATION SPRAY, V27, P929, DOI 10.1615/AtomizSpr.2017020111
   Strasser W, 2017, CHEM ENG J, V309, P532, DOI 10.1016/j.cej.2016.10.046
   Strasser W, 2016, J FLUID ENG-T ASME, V138, DOI 10.1115/1.4033421
   Strasser W, 2016, J FLUID ENG-T ASME, V138, DOI 10.1115/1.4033422
   Strasser W, 2014, PROG COMPUT FLUID DY, V14, P386, DOI 10.1504/PCFD.2014.065467
   Strasser W, 2011, INT J MULTIPHAS FLOW, V37, P831, DOI 10.1016/j.ijmultiphaseflow.2011.01.011
   Strehlow RA, 1984, COMBUSTION FUNDAMENT
   Tian XW, 2018, CHEM ENG SCI, V183, P13, DOI 10.1016/j.ces.2018.02.040
   Vallee C, 2008, NUCL ENG DES, V238, P637, DOI 10.1016/j.nucengdes.2007.02.051
   WILCOX RL, 1965, AICHE J, V11, P69, DOI 10.1002/aic.690110117
   Xie ZH, 2017, CHEM ENG SCI, V166, P303, DOI 10.1016/j.ces.2017.04.015
   Xue ZC, 2018, CHEM ENG SCI, V190, P248, DOI 10.1016/j.ces.2018.06.039
   Youngs D., 1982, NUMERICAL METHODS FL, P273, DOI DOI 10.1007/S11433-009-0265-0
   Zhang Q, 2017, CHEM ENG SCI, V162, P104, DOI 10.1016/j.ces.2016.12.072
NR 40
TC 3
Z9 3
U1 1
U2 8
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAR 16
PY 2019
VL 196
BP 214
EP 224
DI 10.1016/j.ces.2018.10.055
PG 11
WC Engineering, Chemical
SC Engineering
GA HI9RQ
UT WOS:000456795700018
DA 2020-05-12
ER

PT J
AU Gu, ZY
   Bazant, MZ
AF Gu, Zongyu
   Bazant, Martin Z.
TI Microscopic theory of capillary pressure hysteresis based on pore-space
   accessivity and radius-resolved saturation
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Porous media; Continuum modeling; Upscaling; Capillary pressure;
   Hysteresis; Connectivity
ID POROUS-MEDIA; 2-PHASE FLOW; MULTIPHASE FLOW; INTERFACIAL AREA; MERCURY
   POROSIMETRY; HYDRAULIC CONDUCTIVITY; SIZE DISTRIBUTIONS; DIFFUSION
   LAYERS; SCALE MODELS; VISCOUS-FLOW
AB Continuum models of porous media use macroscopic parameters and state variables to capture essential features of pore-scale physics. We propose a macroscopic property "accessivity" (a) to characterize the network connectivity of different sized pores in a porous medium, and macroscopic state descriptors "radius-resolved saturations" (psi(w)(F), psi(n)(F)) to characterize the distribution of fluid phases within. Small accessivity (alpha -> 0) implies serial connections between different sized pores, while large accessivity (alpha -> 1) corresponds to more parallel arrangements, as the classical capillary bundle model implicitly assumes. Based on these concepts, we develop a statistical theory for quasi-static immiscible drainage-imbibition in arbitrary cycles, and arrive at simple algebraic formulae for updating psi(n)(F) that naturally capture capillary pressure hysteresis, with alpha controlling the amount of hysteresis. These concepts may be used to interpret hysteretic data, upscale pore-scale observations, and formulate new constitutive laws by providing a simple conceptual framework for quantifying connectivity effects, and may have broader utility in continuum modeling of transport, reactions, and phase transformations in porous media. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Gu, Zongyu; Bazant, Martin Z.] MIT, Dept Chem Engn, Cambridge, MA 02139 USA.
   [Bazant, Martin Z.] MIT, Dept Math, Cambridge, MA 02139 USA.
RP Bazant, MZ (reprint author), MIT, Dept Chem Engn, Cambridge, MA 02139 USA.
EM zygu@mit.edu; bazant@mit.edu
OI Gu, Zongyu/0000-0002-6383-8594
FU Saudi Aramco, MIT Energy Initiative
FX The authors wish to acknowledge funding from Saudi Aramco, a Founding
   Member of the MIT Energy Initiative. We are also grateful to Samuel J.
   Cooper for useful discussions.
CR Abell AB, 1999, J COLLOID INTERF SCI, V211, P39, DOI 10.1006/jcis.1998.5986
   Allaire G., 1989, ASYMPTOTIC ANAL, V2, P203
   Arbogast T, 2000, LECT NOTES PHYS, V552, P35
   Bakke S., 1997, SPE J, V2, P136, DOI DOI 10.2118/35479-PA
   Barenblatt GI, 2003, SPE J, V8, P409, DOI 10.2118/87329-PA
   Barenblatt GI, 1971, FLUID DYNAM, V6, P857
   Bear J, 1972, DYNAMICS FLUIDS PORO
   Beliaev AY, 2001, TRANSPORT POROUS MED, V43, P487, DOI 10.1023/A:1010736108256
   Blunt MJ, 2001, CURR OPIN COLLOID IN, V6, P197, DOI 10.1016/S1359-0294(01)00084-X
   Brooks R.H., 1964, T ASAE, V7, P26, DOI DOI 10.13031/2013.40684
   Buckley SE, 1942, T AM I MIN MET ENG, V146, P107, DOI 10.2118/942107-G
   BURDINE NT, 1953, T AM I MIN MET ENG, V198, P71
   Carman P.C., 1937, T I CHEM ENG-LOND, V15, P17, DOI [10.1016/S0263-8762(97)80003-2, DOI 10.1016/S0263-8762(97)80003-2]
   Carson JK, 2005, INT J HEAT MASS TRAN, V48, P2150, DOI 10.1016/j.ijheatmasstransfer.2004.12.032
   CELIA MA, 1995, REV GEOPHYS, V33, P1049, DOI 10.1029/95RG00248
   Chareyre B, 2012, TRANSPORT POROUS MED, V94, P595, DOI 10.1007/s11242-012-0057-2
   Chen Dingfang, 2007, Chinese Journal of Mechanical Engineering, V43, P12, DOI 10.3901/JME.2007.08.012
   Cheng JT, 2004, GEOPHYS RES LETT, V31, DOI 10.1029/2003GL019282
   CHILDS EC, 1950, PROC R SOC LON SER-A, V201, P392, DOI 10.1098/rspa.1950.0068
   Cooper S. J., 2016, SoftwareX, V5, P203, DOI 10.1016/j.softx.2016.09.002
   Corey AT, 1954, PROD MON, V19, P38
   Cushman JH, 2002, ADV WATER RESOUR, V25, P1043, DOI 10.1016/S0309-1708(02)00047-7
   Deen WM, 2011, ANAL TRANSPORT PHENO
   Diamond S, 2000, CEMENT CONCRETE RES, V30, P1517, DOI 10.1016/S0008-8846(00)00370-7
   Do HD, 2001, CHEM ENG J, V84, P295, DOI 10.1016/S1385-8947(00)00383-1
   Doster F, 2010, PHYS REV E, V81, DOI 10.1103/PhysRevE.81.036307
   Dullien F. A. L., 1991, POROUS MEDIA FLUID T
   Durlofsky LJ, 1998, COMPUTAT GEOSCI, V2, P73, DOI 10.1023/A:1011593901771
   EPSTEIN N, 1989, CHEM ENG SCI, V44, P777, DOI 10.1016/0009-2509(89)85053-5
   ESSAID HI, 1993, WATER RESOUR RES, V29, P1753, DOI 10.1029/93WR00370
   Fatt I., 1956, J PETROL TECHNOL, V8, P144
   Forner-Cuenca A, 2016, J ELECTROCHEM SOC, V163, pF1038, DOI 10.1149/2.0511609jes
   Giesche H, 2006, PART PART SYST CHAR, V23, P9, DOI 10.1002/ppsc.200601009
   Gostick JT, 2008, ELECTROCHEM COMMUN, V10, P1520, DOI 10.1016/j.elecom.2008.08.008
   Hassanizadeh SM, 2002, VADOSE ZONE J, V1, P38, DOI 10.2136/vzj2002.3800
   HASSANIZADEH SM, 1993, WATER RESOUR RES, V29, P3389, DOI 10.1029/93WR01495
   HASSANIZADEH SM, 1990, ADV WATER RESOUR, V13, P169, DOI 10.1016/0309-1708(90)90040-B
   Held RJ, 2001, ADV WATER RESOUR, V24, P325, DOI 10.1016/S0309-1708(00)00060-9
   Helland J. O., 2007, WATER RESOUR RES, V43
   Hilfer R, 2006, PHYS REV E, V73, DOI 10.1103/PhysRevE.73.016307
   Hilfer R, 1998, PHYS REV E, V58, P2090, DOI 10.1103/PhysRevE.58.2090
   HILFER R, 1996, ADV CHEM PHYS, V92, P299
   Hill R. D., 1960, BRIT CERAM T, V59, P189
   Holtzman R, 2015, PHYS REV LETT, V115, DOI 10.1103/PhysRevLett.115.164501
   Hornung U., 2012, HOMOGENIZATION POROU, V6
   Hunt AG, 2013, SOIL SCI SOC AM J, V77, P1877, DOI 10.2136/sssaj2013.01.0020
   IRMAY S, 1954, T AM GEOPHYS UNION, V35, P463, DOI DOI 10.1029/TR035I003P00463
   JAGUSTE DN, 1995, CHEM ENG SCI, V50, P167, DOI 10.1016/0009-2509(94)00226-H
   Joekar-Niasar V, 2008, TRANSPORT POROUS MED, V74, P201, DOI 10.1007/s11242-007-9191-7
   Joekar-Niasar V, 2012, CRIT REV ENV SCI TEC, V42, P1895, DOI 10.1080/10643389.2011.574101
   Joekar-Niasar V, 2012, TRANSPORT POROUS MED, V94, P465, DOI 10.1007/s11242-012-9958-3
   Juanes R, 2008, ADV WATER RESOUR, V31, P661, DOI 10.1016/j.advwatres.2007.12.005
   Kadet VV, 2013, J APPL MECH TECH PH+, V54, P423, DOI 10.1134/S0021894413030115
   KALAYDJIAN F, 1987, TRANSPORT POROUS MED, V2, P537
   Karadimitriou NK, 2014, WATER RESOUR RES, V50, P8125, DOI 10.1002/2014WR015388
   KLUTE A, 1952, SOIL SCI SOC AM PRO, V16, P144, DOI 10.2136/sssaj1952.03615995001600020008x
   Kozeny J, 1927, KAPILLARE LEITUNG WA
   Lamibrac A, 2016, J ELECTROCHEM SOC, V163, pF202, DOI 10.1149/2.0401603jes
   LARSON RG, 1981, POWDER TECHNOL, V30, P123, DOI 10.1016/0032-5910(81)80005-8
   LEE KH, 1986, J COLLOID INTERF SCI, V110, P544, DOI 10.1016/0021-9797(86)90407-8
   LENORMAND R, 1983, J FLUID MECH, V135, P337, DOI 10.1017/S0022112083003110
   Li L, 2006, ADV WATER RESOUR, V29, P1351, DOI 10.1016/j.advwatres.2005.10.011
   LOEB AL, 1954, J AM CERAM SOC, V37, P96, DOI 10.1111/j.1551-2916.1954.tb20107.x
   Lowell S., 2012, CHARACTERIZATION POR
   LUCKNER L, 1989, WATER RESOUR RES, V25, P2187, DOI 10.1029/WR025i010p02187
   Masoero E, 2015, CONCREEP 10: MECHANICS AND PHYSICS OF CREEP, SHRINKAGE, AND DURABILITY OF CONCRETE AND CONCRETE STRUCTURES, P306
   MASON G, 1982, J COLLOID INTERF SCI, V88, P36, DOI 10.1016/0021-9797(82)90153-9
   MASON G, 1983, J COLLOID INTERF SCI, V95, P277, DOI 10.1016/0021-9797(83)90100-5
   Meakin P, 2009, REV GEOPHYS, V47, DOI 10.1029/2008RG000263
   Mostaghimi P, 2013, MATH GEOSCI, V45, P103, DOI 10.1007/s11004-012-9431-4
   MUALEM Y, 1976, WATER RESOUR RES, V12, P513, DOI 10.1029/WR012i003p00513
   Neithalath N, 2010, MATER CHARACT, V61, P802, DOI 10.1016/j.matchar.2010.05.004
   Pabst W, 2017, CERAM-SILIKATY, V61, P74, DOI 10.13168/cs.2016.0063
   Pak T, 2015, P NATL ACAD SCI USA, V112, P1947, DOI 10.1073/pnas.1420202112
   PARLAR M, 1988, J COLLOID INTERF SCI, V124, P162, DOI 10.1016/0021-9797(88)90337-2
   Pinder G. F., 2008, ESSENTIALS MULTIPHAS
   Pinson M. B., 2014, ARXIV14023377CONDMAT
   Pinson MB, 2015, PHYS REV APPL, V3, DOI 10.1103/PhysRevApplied.3.064009
   Porter ML, 2009, ADV WATER RESOUR, V32, P1632, DOI 10.1016/j.advwatres.2009.08.009
   Pyrak-Nolte LJ, 2008, WATER RESOUR RES, V44, DOI 10.1029/2007WR006434
   QUIBLIER JA, 1984, J COLLOID INTERF SCI, V98, P84, DOI 10.1016/S0021-9797(84)80012-0
   Ranut P, 2016, APPL THERM ENG, V101, P496, DOI 10.1016/j.applthermaleng.2015.09.094
   Reeves PC, 1996, WATER RESOUR RES, V32, P2345, DOI 10.1029/96WR01105
   Richards LA, 1931, PHYSICS-J GEN APPL P, V1, P318, DOI 10.1063/1.1745010
   Sabharwal M, 2018, J ELECTROCHEM SOC, V165, pF553, DOI 10.1149/2.0921807jes
   Sahimi M, 1994, APPL PERCOLATION THE
   Sahimi M., 2011, FLOW TRANSPORT POROU
   Salmas C, 2001, J COLLOID INTERF SCI, V239, P178, DOI 10.1006/jcis.2001.7531
   SCHEIDEGGER AE, 1974, PHYS FLOW POROUS MED
   SCHEIDEGGER AE, 1953, PRODUCERS MONTHLY, V17, P17
   SEATON NA, 1991, CHEM ENG SCI, V46, P1895, DOI 10.1016/0009-2509(91)80151-N
   Selyakov V.I., 2013, PERCOLATION MODELS T, V9
   Stauffer D., 2014, INTRO PERCOLATION TH
   TAMON H, 1981, AICHE J, V27, P271, DOI 10.1002/aic.690270214
   Thomson W., 1872, P R SOC EDINBURGH, V7, P63, DOI DOI 10.1017/S0370164600041729
   Torquato S., 2013, RANDOM HETEROGENEOUS, V16
   Tranter TG, 2018, TRANSPORT POROUS MED, V121, P597, DOI 10.1007/s11242-017-0973-2
   VANBRAKEL J, 1975, POWDER TECHNOL, V11, P205, DOI 10.1016/0032-5910(75)80049-0
   VANGENUCHTEN MT, 1980, SOIL SCI SOC AM J, V44, P892, DOI 10.2136/sssaj1980.03615995004400050002x
   Washburn EW, 1921, P NATL ACAD SCI USA, V7, P115, DOI 10.1073/pnas.7.4.115
   WILKINSON D, 1983, J PHYS A-MATH GEN, V16, P3365, DOI 10.1088/0305-4470/16/14/028
   Wood BD, 2009, ADV WATER RESOUR, V32, P723, DOI 10.1016/j.advwatres.2008.08.015
   Zhao BZ, 2016, P NATL ACAD SCI USA, V113, P10251, DOI 10.1073/pnas.1603387113
NR 103
TC 0
Z9 0
U1 1
U2 12
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAR 16
PY 2019
VL 196
BP 225
EP 246
DI 10.1016/j.ces.2018.10.054
PG 22
WC Engineering, Chemical
SC Engineering
GA HI9RQ
UT WOS:000456795700019
DA 2020-05-12
ER

PT J
AU Borgogna, A
   Murmura, MA
   Annesini, MC
   Giona, M
   Cerbelli, S
AF Borgogna, A.
   Murmura, M. A.
   Annesini, M. C.
   Giona, M.
   Cerbelli, S.
TI A hybrid numerical approach for predicting mixing length and mixing time
   in microfluidic junctions from moderate to arbitrarily large values of
   the Peclet number
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Monte Carlo; X-junction; Liquid mixing; Stochastic-Lagrangian method;
   Spectral; Inflow-outlfow device
ID MAPPING METHOD; T-JUNCTION; DIFFUSION; SIMULATION; PERFORMANCE;
   MICROMIXER
AB We investigate numerically the homogenization process of a diffusive species in a mixing channel of arbitrary length downstream a microfluidic cross-junction. The channel length, lambda(alpha), necessary to achieve a prescribed level of mixedness, alpha, is targeted as primary quantity of interest, and its dependence on the Reynolds number, Re, on the flow ratio between the impinging currents, R, and on the Schmidt number of the solute, Sc, is analyzed. The accurate numerical solution of the mass transport equations up to values Pe = ReSc similar or equal to 10(6) of the Peclet number is here made possible by a hybrid numerical approach. This approach combines a recently proposed Monte Carlo method, enforced near the impinging zone, with a pseudo-transient 2D formulation of mass transport in the mixing channel, where purely axial (Poiseuille) flow settles in. At values of the flow ratio significantly different from unity (e.g. those used in flash nanoprecipitation) a non-trivial dependence of lambda(alpha) on Re is found at fixed Sc and R. This result is interpreted based on the spectral (eigenvalue/eigenfunction) structure of the 2D generalized Sturm-Liouville pure diffusion problem defined onto the cross-section of the mixing channel. Hinging on this interpretation, we show that for Sc >= 10(3) the dependence of lambda(alpha) on Sc at fixed Re and R can be singled out and theoretically predicted. By this property, universal ready-to-use curves yielding the mixing length for each assigned geometry can be constructed, which could be used to correlate the mixing time with other phenomena (chemical reactions, phase changes) occurring alongside the mass transport. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Borgogna, A.; Murmura, M. A.; Annesini, M. C.; Giona, M.; Cerbelli, S.] Sapienza Univ Roma, Dipartimento Ingn Chim Mat Ambiente, Via Eudossiana 18, I-00184 Rome, Italy.
RP Cerbelli, S (reprint author), Sapienza Univ Roma, Dipartimento Ingn Chim Mat Ambiente, Via Eudossiana 18, I-00184 Rome, Italy.
EM stefano.cerbelli@uniroma1.it
RI BORGOGNA, ALESSIA/AAI-7975-2020
OI BORGOGNA, ALESSIA/0000-0002-5071-1746; GIONA,
   Massimiliano/0000-0001-5875-0160
CR Adeosun JT, 2009, CHEM ENG SCI, V64, P2422, DOI 10.1016/j.ces.2009.02.013
   Alam JM, 2012, INT J HEAT MASS TRAN, V55, P7847, DOI 10.1016/j.ijheatmasstransfer.2012.08.020
   Alvarez MM, 2005, CHEM ENG SCI, V60, P2449, DOI 10.1016/j.ces.2004.11.049
   Andreussi T, 2015, COMPUT CHEM ENG, V76, P150, DOI 10.1016/j.compchemeng.2015.02.017
   Bailey RT, 2017, INT J NUMER METH FL, V83, P940, DOI 10.1002/fld.4335
   Bally F, 2011, CHEM ENG SCI, V66, P1449, DOI 10.1016/j.ces.2010.07.026
   Belytschko T, 1996, COMPUT METHOD APPL M, V139, P3, DOI 10.1016/S0045-7825(96)01078-X
   Borgia A, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2204
   Borgogna A, 2018, MICROFLUID NANOFLUID, V22, DOI 10.1007/s10404-018-2041-9
   Bramosanti M., 2017, ENG ASPECTS
   Cerbelli S, 2008, CHEM ENG SCI, V63, P4396, DOI 10.1016/j.ces.2008.06.003
   Cerbelli S, 2002, AICHE J, V48, P686, DOI 10.1002/aic.690480405
   Cerbelli S., 2017, CHEM ENG T, V57, P853
   Cerbelli S, 2008, CHEM ENG J, V138, P523, DOI 10.1016/j.cej.2007.07.067
   Chronopoulou L, 2014, J NANOPART RES, V16, DOI 10.1007/s11051-014-2703-9
   Cortelezzi L, 2017, MICROFLUID NANOFLUID, V21, DOI 10.1007/s10404-017-1868-9
   Damian IR, 2017, MICROFLUID NANOFLUID, V21, DOI 10.1007/s10404-017-1975-7
   Dashtimoghadam E, 2013, POLYMER, V54, P4972, DOI 10.1016/j.polymer.2013.07.022
   Galletti C, 2015, CHEM ENG SCI, V123, P300, DOI 10.1016/j.ces.2014.11.025
   Galletti C, 2012, CHEM ENG J, V185, P300, DOI 10.1016/j.cej.2012.01.046
   Garofalo F, 2010, AICHE J, V56, P318, DOI 10.1002/aic.11994
   Giona M, 2008, J FLUID MECH, V612, P387, DOI 10.1017/S0022112008003042
   Gorodetskyi O, 2014, CHEM ENG SCI, V107, P30, DOI 10.1016/j.ces.2013.11.045
   Gorodetskyi O, 2012, EPL-EUROPHYS LETT, V97, DOI 10.1209/0295-5075/97/14002
   Gorodetskyi O, 2014, AICHE J, V60, P387, DOI 10.1002/aic.14291
   Helisaz H, 2018, CHEM ENG SCI, V191, P358, DOI 10.1016/j.ces.2018.06.077
   Hou X, 2017, NAT REV MATER, V2, DOI 10.1038/natrevmats.2017.16
   Kerby MB, 2006, ANAL CHEM, V78, P8273, DOI 10.1021/ac061189l
   Lashgari I, 2014, J FLUID MECH, V753, P1, DOI 10.1017/jfm.2014.364
   Lasota A., 2013, CHAOS FRACTALS NOISE, V97
   Leung AKK, 2015, J PHYS CHEM B, V119, P8698, DOI 10.1021/acs.jpcb.5b02891
   Matsunaga T, 2013, LAB CHIP, V13, P1515, DOI 10.1039/c3lc41009a
   McMullen JP, 2011, ORG PROCESS RES DEV, V15, P398, DOI 10.1021/op100300p
   Oliveira MSN, 2012, J FLUID MECH, V711, P171, DOI 10.1017/jfm.2012.386
   Orsi G, 2013, CHEM ENG SCI, V95, P174, DOI 10.1016/j.ces.2013.03.015
   Raynal F, 2007, PHYS FLUIDS, V19, DOI 10.1063/1.2431322
   Reboux S, 2012, J COMPUT PHYS, V231, P3623, DOI 10.1016/j.jcp.2012.01.026
   Russell R, 2002, P NATL ACAD SCI USA, V99, P4266, DOI 10.1073/pnas.072589599
   Saad WS, 2016, NANO TODAY, V11, P212, DOI 10.1016/j.nantod.2016.04.006
   Sadeghi A, 2018, CHEM ENG SCI, V176, P180, DOI 10.1016/j.ces.2017.10.038
   Sarkar S, 2014, CHEM ENG PROCESS, V85, P227, DOI 10.1016/j.cep.2014.08.010
   Singh MK, 2008, MICROFLUID NANOFLUID, V5, P313, DOI 10.1007/s10404-007-0251-7
   Solehati N, 2014, COMPUT FLUIDS, V96, P10, DOI 10.1016/j.compfluid.2014.03.003
   Soleymani A, 2008, CHEM ENG J, V135, pS219, DOI 10.1016/j.cej.2007.07.048
   TOUSSAINT V, 1995, PHYS FLUIDS, V7, P2587, DOI 10.1063/1.868707
   Vikhansky A, 2006, PHYS REV E, V73, DOI 10.1103/PhysRevE.73.056707
   Wu CQ, 2016, MICROFLUID NANOFLUID, V20, DOI 10.1007/s10404-016-1755-9
   Zhao CX, 2011, CHEM ENG SCI, V66, P1463, DOI 10.1016/j.ces.2010.08.039
   Zhu PA, 2017, LAB CHIP, V17, P34, DOI 10.1039/c6lc01018k
NR 49
TC 3
Z9 3
U1 6
U2 14
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAR 16
PY 2019
VL 196
BP 247
EP 264
DI 10.1016/j.ces.2018.10.051
PG 18
WC Engineering, Chemical
SC Engineering
GA HI9RQ
UT WOS:000456795700020
DA 2020-05-12
ER

PT J
AU Cheng, C
   Li, PY
   Zhang, TH
   Wang, XF
   Hsiao, BS
AF Cheng, Cheng
   Li, Peiyun
   Zhang, Tonghui
   Wang, Xuefen
   Hsiao, Benjamin S.
TI Enhanced pervaporation performance of polyamide membrane with
   synergistic effect of porous nanofibrous support and trace graphene
   oxide lamellae
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Graphene oxide skeleton; Nanofibrous composite membrane; Heterogeneous
   polyamide layer; Pervaporation dehydration
ID FILM COMPOSITE MEMBRANES; SEPARATION PERFORMANCE; ISOPROPANOL
   DEHYDRATION; NANOFILTRATION MEMBRANE; HYBRID MEMBRANES; WATER-TRANSPORT;
   BARRIER LAYER; SUBSTRATE; ETHANOL; POLYMERIZATION
AB Electrospun nanofibrous membrane as a supporting layer has attracted great interests in fabricating high performance composite membranes due to its interconnected porous structure. However, it's still a challenge to prepare an ultrathin and integrated skin layer on porous and undulating nanofibrous support, thereby restricting its application in pervaporation. Here, graphene oxide (GO) was introduced into amine aqueous phase to form an integrated and compact polyamide (PA) layer on nanofibrous substrate via interfacial polymerization (IP). Under the synergistic effect of high permeability of the nanofibrous scaffold and flexibility of GO lamellae, tiled GO lamellae acting as a skeleton got involved in the initial reaction for the construction of selective PA layer. By loading trace amount of GO in aqueous phase during IP, the selectivity of PA layer was enhanced significantly compared with that of pristine PA layer on nanofibrous scaffold. High permeate flux of 6593 g/m(2)h with a desirable separation factor of 1491 was achieved using the hybrid membrane with just 0.001 wt% of GO loading for pervaporation dehydrating 90 wt% isopropanol aqueous solution at 70 degrees C. These results indicated the feasibility of constructing a single homogeneous selective layer on nanofibrous support for high-performance pervaporation process. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Cheng, Cheng; Li, Peiyun; Zhang, Tonghui; Wang, Xuefen; Hsiao, Benjamin S.] Donghua Univ, State Key Lab Modificat Chem Fibers & Polymer Mat, Shanghai 201620, Peoples R China.
   [Hsiao, Benjamin S.] SUNY Stony Brook, Dept Chem, Stony Brook, NY 11794 USA.
RP Wang, XF (reprint author), Donghua Univ, State Key Lab Modificat Chem Fibers & Polymer Mat, Shanghai 201620, Peoples R China.
EM wangxf@dhu.edu.cn
RI Hsiao, Benjamin S/E-6944-2013
FU Fundamental Research Funds for the Central UniversitiesFundamental
   Research Funds for the Central Universities; Program of Shanghai Science
   and Technology Innovation International Exchange and Cooperation
   [15230724700]; Program for Innovative Research Team in University of
   Ministry of Education of China [IRT_16R13]
FX This work was supported by the Fundamental Research Funds for the
   Central Universities, Program of Shanghai Science and Technology
   Innovation International Exchange and Cooperation (15230724700) and
   Program for Innovative Research Team in University of Ministry of
   Education of China (IRT_16R13).
CR Ali MEA, 2016, DESALINATION, V386, P67, DOI 10.1016/j.desal.2016.02.034
   Cao KT, 2015, J MEMBRANE SCI, V490, P72, DOI 10.1016/j.memsci.2015.04.050
   Cao KT, 2014, J MEMBRANE SCI, V469, P272, DOI 10.1016/j.memsci.2014.06.053
   Chao WC, 2013, POLYMER, V54, P1381, DOI 10.1016/j.polymer.2013.01.011
   Chao WC, 2011, POLYMER, V52, P2414, DOI 10.1016/j.polymer.2011.03.049
   Cheng C, 2018, J MEMBRANE SCI, V553, P70, DOI 10.1016/j.memsci.2018.02.013
   Cheng C, 2017, J MATER CHEM A, V5, P3558, DOI 10.1039/c6ta09443k
   Cheng XX, 2017, J MEMBRANE SCI, V541, P329, DOI 10.1016/j.memsci.2017.07.009
   Gao BX, 2015, J MEMBRANE SCI, V492, P230, DOI 10.1016/j.memsci.2015.05.035
   Han Y, 2013, ADV FUNCT MATER, V23, P3693, DOI 10.1002/adfm.201202601
   He L, 2015, DESALINATION, V365, P126, DOI 10.1016/j.desal.2015.02.032
   Hua D, 2015, J MEMBRANE SCI, V492, P197, DOI 10.1016/j.memsci.2015.05.056
   Huang K, 2015, ADV FUNCT MATER, V25, P5809, DOI 10.1002/adfm.201502205
   Huang SH, 2008, J MEMBRANE SCI, V307, P73, DOI 10.1016/j.memsci.2007.09.014
   Huang SH, 2014, J MEMBRANE SCI, V470, P411, DOI 10.1016/j.memsci.2014.07.022
   Huang SH, 2009, J APPL POLYM SCI, V114, P1511, DOI 10.1002/app.30661
   Hung WS, 2014, J MEMBRANE SCI, V470, P513, DOI 10.1016/j.memsci.2014.07.066
   Hung WS, 2014, CARBON, V68, P670, DOI 10.1016/j.carbon.2013.11.048
   Karan S, 2015, SCIENCE, V348, P1347, DOI 10.1126/science.aaa5058
   Kim JH, 2000, J MEMBRANE SCI, V169, P81, DOI 10.1016/S0376-7388(99)00335-X
   Lai LF, 2011, CARBON, V49, P3250, DOI 10.1016/j.carbon.2011.03.051
   Li Y, 2017, J MEMBRANE SCI, V537, P42, DOI 10.1016/j.memsci.2017.05.026
   Lind ML, 2009, LANGMUIR, V25, P10139, DOI 10.1021/la900938x
   Lipnizki F, 1999, J MEMBRANE SCI, V153, P183, DOI 10.1016/S0376-7388(98)00253-1
   Sajjan AM, 2015, J IND ENG CHEM, V25, P151, DOI 10.1016/j.jiec.2014.10.027
   Salehian P, 2017, J MEMBRANE SCI, V544, P378, DOI 10.1016/j.memsci.2017.09.038
   Salehian P, 2017, J MEMBRANE SCI, V528, P231, DOI 10.1016/j.memsci.2017.01.038
   Shao P, 2007, J MEMBRANE SCI, V287, P162, DOI 10.1016/j.memsci.2006.10.043
   Smitha B, 2004, J MEMBRANE SCI, V241, P1, DOI 10.1016/j.memsci.2004.03.042
   Song XX, 2011, ADV MATER, V23, P3256, DOI 10.1002/adma.201100510
   Tsai HA, 2018, J MEMBRANE SCI, V551, P261, DOI 10.1016/j.memsci.2018.01.059
   Wang JJ, 2017, J MATER CHEM A, V5, P16289, DOI 10.1039/c7ta00501f
   Wang MR, 2017, J MEMBRANE SCI, V538, P86, DOI 10.1016/j.memsci.2017.05.040
   Wang X, 2017, DESALINATION, V420, P91, DOI 10.1016/j.desal.2017.06.029
   Wang X, 2014, POLYMER, V55, P1358, DOI 10.1016/j.polymer.2013.12.007
   Wang XF, 2016, CURR OPIN CHEM ENG, V12, P62, DOI 10.1016/j.coche.2016.03.001
   Wang XF, 2010, J MEMBRANE SCI, V356, P110, DOI 10.1016/j.memsci.2010.03.039
   Wen P, 2017, J MEMBRANE SCI, V535, P208, DOI 10.1016/j.memsci.2017.04.043
   Wu DH, 2015, J MEMBRANE SCI, V493, P622, DOI 10.1016/j.memsci.2015.07.016
   Wu HQ, 2013, J MEMBRANE SCI, V428, P341, DOI 10.1016/j.memsci.2012.10.053
   Wu MY, 2017, J MEMBRANE SCI, V544, P79, DOI 10.1016/j.memsci.2017.09.016
   Xu GR, 2013, DESALINATION, V328, P31, DOI 10.1016/j.desal.2013.08.012
   Xu J, 2017, J MEMBRANE SCI, V541, P174, DOI 10.1016/j.memsci.2017.06.057
   Xu YX, 2011, J MATER CHEM, V21, P7376, DOI 10.1039/c1jm10768b
   Xue B, 2015, CATAL COMMUN, V64, P105, DOI 10.1016/j.catcom.2015.02.003
   Yang Y, 2017, RSC ADV, V7, P18001, DOI 10.1039/c7ra00621g
   Yin J, 2016, DESALINATION, V379, P93, DOI 10.1016/j.desal.2015.11.001
   Zhang HZ, 2017, DESALINATION, V420, P158, DOI 10.1016/j.desal.2017.07.011
   Zhao J, 2015, J MATER CHEM A, V3, P19980, DOI 10.1039/c5ta04524j
   Zuo J, 2013, J MATER CHEM A, V1, P9814, DOI 10.1039/c3ta11728f
   Zuo J, 2013, J MEMBRANE SCI, V433, P60, DOI 10.1016/j.memsci.2013.01.002
   Zuo J, 2012, J MEMBRANE SCI, V405, P123, DOI 10.1016/j.memsci.2012.02.058
NR 52
TC 6
Z9 6
U1 16
U2 84
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAR 16
PY 2019
VL 196
BP 265
EP 276
DI 10.1016/j.ces.2018.11.019
PG 12
WC Engineering, Chemical
SC Engineering
GA HI9RQ
UT WOS:000456795700021
DA 2020-05-12
ER

PT J
AU Kummer, A
   Varga, T
AF Kummer, Alex
   Varga, Tamas
TI Completion of thermal runaway criteria: Two new criteria to define
   runaway limits
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Critical curves; Place of indication; Safe boundaries; Criteria
   qualification; Feeding trajectory optimisation
ID NITRIC-ACID OXIDATION; REACTOR; BATCH; ACCIDENTS; MODEL; POLYMERIZATION;
   ESTERIFICATION; CONSEQUENCES; SENSITIVITY; SIMULATION
AB Safe operation of thermally sensitive chemical reactors remains a crucial engineering issue. Thermal runaway occurs mainly due to loss of temperature control, and many chemical accidents initiated by thermal runaway can be foreseen by an appropriate analysis of thermal process data. Thermal runaway criteria can be applied to determine the onset of runaway phenomena and safety boundary diagrams can be constructed. However, several runaway criteria exist, which define the runaway-and safe zones differently. In this work nine commonly applied thermal runaway criteria were analyzed and compared based on their critical curves. As a result of this analysis, two new criteria were developed. Reliability of the derived criteria were investigated, where the occurrence of real runaway was determined based on the number of indications applying different criteria. The two new criteria were tested in three general reaction systems and in case a complex problem, where feeding trajectory of fed-batch reactor was optimized applying new criteria as non-linear constraint. One of the new criteria shows the highest reliability in indication of runaway development from all investigated runaway criteria. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Kummer, Alex; Varga, Tamas] Univ Pannonia, Inst Chem & Proc Engn, H-8200 Veszprem, Hungary.
RP Kummer, A (reprint author), Univ Pannonia, Inst Chem & Proc Engn, H-8200 Veszprem, Hungary.
EM kummera@fmt.uni-panaon.hu
OI Varga, Tamas/0000-0002-4730-3784; Alex, Kummer/0000-0002-6550-5101
FU Szechenyi 2020 [GINOP-2.2.1-15-2017-00059]
FX We would like to express our acknowledgement for the financial support
   of Szechenyi 2020 under the GINOP-2.2.1-15-2017-00059.
CR ADLER J, 1964, COMBUST FLAME, V8, P97, DOI 10.1016/0010-2180(64)90035-5
   Adrover A, 2007, CHEM ENG SCI, V62, P1171, DOI 10.1016/j.ces.2006.11.007
   Balasubramanian SG, 2002, PROCESS SAF PROG, V21, P237, DOI 10.1002/prs.680210309
   BASHIR S, 1992, IND ENG CHEM RES, V31, P2164, DOI 10.1021/ie00009a014
   Berty J. M., 1999, EXPT CATALYTIC REACT
   Bosch J, 2004, PROCESS SAF ENVIRON, V82, P18, DOI 10.1205/095758204322777633
   Cardillo P., 1981, ICHEME S SERIES, V68, p3N1
   Casson V, 2012, J LOSS PREVENT PROC, V25, P209, DOI 10.1016/j.jlp.2011.09.002
   Copelli S, 2014, J LOSS PREVENT PROC, V28, P92, DOI 10.1016/j.jlp.2013.05.004
   Dakkoune A, 2018, SAFETY SCI, V105, P77, DOI 10.1016/j.ssci.2018.02.003
   Fabiano B, 2017, J LOSS PREVENT PROC, V49, P18, DOI 10.1016/j.jlp.2017.01.021
   GILLES ED, 1961, CHEM ENG SCI, V15, P328, DOI 10.1016/0009-2509(61)85038-0
   Garcia MAG, 2016, CHEM ENG SCI, V142, P269, DOI 10.1016/j.ces.2015.12.003
   Hwang SW, 2004, CHEM ENG SCI, V59, P4229, DOI 10.1016/j.ces.2004.05.037
   Jiang JJ, 2016, J LOSS PREVENT PROC, V44, P465, DOI 10.1016/j.jlp.2016.10.017
   Kennedy J, 1995, 1995 IEEE INTERNATIONAL CONFERENCE ON NEURAL NETWORKS PROCEEDINGS, VOLS 1-6, P1942, DOI 10.1109/ICNN.1995.488968
   Kummer A, 2017, COMPUT CHEM ENG, V98, P1, DOI 10.1016/j.compchemeng.2016.12.008
   Liu LF, 2018, J LOSS PREVENT PROC, V55, P471, DOI 10.1016/j.jlp.2018.07.017
   Milewska A, 2007, CHEM ENG SCI, V62, P4920, DOI 10.1016/j.ces.2006.12.036
   Milewska A, 2010, CHEM ENG RES DES, V88, P304, DOI 10.1016/j.cherd.2009.10.014
   Ni L, 2016, J LOSS PREVENT PROC, V43, P75, DOI 10.1016/j.jlp.2016.04.004
   Saada R, 2015, PROCESS SAF ENVIRON, V97, P109, DOI 10.1016/j.psep.2015.02.005
   Schweitzer JM, 2010, CHEM ENG SCI, V65, P313, DOI 10.1016/j.ces.2009.07.012
   Semenoff N, 1928, Z PHYS, V48, P571, DOI 10.1007/BF01340021
   Shin MS, 2013, CHEM ENG J, V234, P23, DOI 10.1016/j.cej.2013.08.064
   Sinnott Ray K., 2006, CHEM ENG DESIGN, V6
   Stoessel F., 2008, THERMAL SAFETY CHEM
   Strozzi F, 1999, AICHE J, V45, P2429, DOI 10.1002/aic.690451116
   Szeifert Ferenc, 2006, JOZSEF BERTYM RUNAWA
   van Woezik BAA, 2002, CHEM ENG PROCESS, V41, P59, DOI 10.1016/S0255-2701(01)00106-4
   van Woezik BAA, 2000, CHEM ENG PROCESS, V39, P521, DOI 10.1016/S0255-2701(00)00099-4
   VANHEERDEN C, 1953, IND ENG CHEM, V45, P1242, DOI 10.1021/ie50522a030
   VANWELSE.RJ, 1970, CHEM ENG SCI, V25, P1503, DOI 10.1016/0009-2509(70)85073-4
   Varga T, 2009, ENG APPL ARTIF INTEL, V22, P569, DOI 10.1016/j.engappai.2008.11.001
   Vernieres-Hassimi L, 2017, IND ENG CHEM RES, V56, P13041, DOI 10.1021/acs.iecr.7b01291
   Vianello C, 2018, IND ENG CHEM RES, V57, P4195, DOI 10.1021/acs.iecr.7b05160
   Yuan LM, 2009, J LOSS PREVENT PROC, V22, P426, DOI 10.1016/j.jlp.2009.02.016
   Zaldivar JM, 2003, J LOSS PREVENT PROC, V16, P187, DOI 10.1016/S0950-4230(03)00003-2
   Zhang MG, 2017, PROCESS SAF ENVIRON, V111, P326, DOI 10.1016/j.psep.2017.07.028
NR 39
TC 2
Z9 2
U1 5
U2 20
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAR 16
PY 2019
VL 196
BP 277
EP 290
DI 10.1016/j.ces.2018.11.008
PG 14
WC Engineering, Chemical
SC Engineering
GA HI9RQ
UT WOS:000456795700022
DA 2020-05-12
ER

PT J
AU Ostermeier, P
   DeYoung, S
   Vandersickel, A
   Gleis, S
   Spliethoff, H
AF Ostermeier, Peter
   DeYoung, Stefan
   Vandersickel, Annelies
   Gleis, Stephan
   Spliethoff, Hartmut
TI Comprehensive investigation and comparison of TFM, DenseDPM and CFD-DEM
   for dense fluidized beds
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Fluidization; Numerical simulation; Two fluid model; Dense discrete
   phase model; Computational Fluid Dynamics - Discrete Element Method
ID DISCRETE PARTICLE MODEL; HEAT-TRANSFER; EULERIAN SIMULATION;
   KINETIC-THEORY; DRAG; WALL; HYDRODYNAMICS; DISTRIBUTOR; VALIDATION;
   BEHAVIOR
AB Eulerian-Eulerian and Eulerian-Lagrangian models are widely applied to numerically investigate dense solid-gas fluidized bed systems. However, only a few studies in the existing literature focus on a detailed analysis and comparison of the different modeling approaches. Therefore, the objective of this study is to investigate the Two Fluid Model (TFM), the Dense Discrete Phase Model (DDPM), and the Computational Fluid Dynamics-Discrete Element Method (CFD-DEM) with respect to a comprehensive independency study, a sensitivity analysis of the respective submodels and model parameters, a comparison of the simulation results between the different modeling approaches, as well as their computational demand. The simulations represent a test case of a pilot plant scale reactor (inner diameter up to 387 mm, height 900 mm), which is used within a thermochemical energy storage system (CaO + H2O <--> Ca(OH)(2)). Monodisperse Geldart B powder (particle diameter 200 mu m, particle density 2500 kg/m(3), sphericity factor 0.8) is fluidized with water vapor (ideal gas, temperature 400 degrees C, inlet velocity 0.495 m/s). Grid size, fluid and particle time step, and particle clustering are considered for the independency study. Different wall boundary conditions and calculation methods for the granular temperature are investigated for the TFM. For the DDPM, different wall boundary conditions are analyzed as well, while for the CFD-DEM, simulations with two different DEM submodels (Hertzian and Hookean collision model) and a sensitivity analysis of the respective model parameters are included. Results show that the TFM and the CFD-DEM are able to predict qualitatively and quantitatively similar gas and particle flow fields, if TFM model parameters are set appropriately. However, a quite different pressure drop and bed expansion is observed for each model. The DDPM does not result in realistic flow fields for the investigated test case, despite predicting a pressure drop and bed expansion similar to the TFM. The presented findings lead to the conclusion that model validation should not only be based on global observable values like pressure drop and bed expansion, but also on local particle flow fields and bubbling behavior. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Ostermeier, Peter; DeYoung, Stefan; Vandersickel, Annelies; Gleis, Stephan; Spliethoff, Hartmut] Tech Univ Munich, Lehrstuhl Energiesyst, Boltzmannstr 15, D-85748 Garching, Germany.
   [Spliethoff, Hartmut] ZAE Bayern, Walther Meissner Str 6, D-85748 Garching, Germany.
RP Ostermeier, P (reprint author), Tech Univ Munich, Lehrstuhl Energiesyst, Boltzmannstr 15, D-85748 Garching, Germany.
EM peter.ostermeier@tum.de
OI Spliethoff, Hartmut/0000-0003-3743-2731
FU German Federal Ministry of Economic Affairs and Energy (BMWi) [03ET7025]
FX This research is part of the project "Thermochemischer Energiespeicher
   fur thermische Kraftwerke und industrielle Warme" and is funded by the
   German Federal Ministry of Economic Affairs and Energy (BMWi) under the
   funding code 03ET7025 according to a decision of the German Federal
   Parliament.
CR Akbari V, 2014, POWDER TECHNOL, V267, P398, DOI 10.1016/j.powtec.2014.07.042
   Altantzis C, 2015, POWDER TECHNOL, V270, P256, DOI 10.1016/j.powtec.2014.10.029
   Andrews MJ, 1996, INT J MULTIPHAS FLOW, V22, P379, DOI 10.1016/0301-9322(95)00072-0
   [Anonymous], 2017, ANSYS FLUENT THEORY
   Armstrong LM, 2010, INT J MULTIPHAS FLOW, V36, P916, DOI 10.1016/j.ijmultiphaseflow.2010.07.004
   Armstrong LM, 2010, INT J HEAT MASS TRAN, V53, P4949, DOI 10.1016/j.ijheatmasstransfer.2010.05.047
   Asegehegn TW, 2012, POWDER TECHNOL, V219, P9, DOI 10.1016/j.powtec.2011.11.050
   Bakshi A, 2015, POWDER TECHNOL, V277, P47, DOI 10.1016/j.powtec.2015.02.056
   Bisognin PC, 2016, POWDER TECHNOL, V297, P401, DOI 10.1016/j.powtec.2016.04.028
   Cai RR, 2015, POWDER TECHNOL, V277, P147, DOI 10.1016/j.powtec.2015.02.058
   Chen XZ, 2014, POWDER TECHNOL, V254, P94, DOI 10.1016/j.powtec.2013.12.056
   Chu KW, 2016, MINER ENG, V90, P43, DOI 10.1016/j.mineng.2016.01.020
   Cloete S, 2018, CHEM ENG SCI, V182, P93, DOI 10.1016/j.ces.2018.02.032
   CUNDALL PA, 1979, GEOTECHNIQUE, V29, P47, DOI 10.1680/geot.1979.29.1.47
   DING J, 1990, AICHE J, V36, P523, DOI 10.1002/aic.690360404
   Dong NH, 2013, APPL THERM ENG, V60, P472, DOI 10.1016/j.applthermaleng.2012.08.018
   Gidaspow D, 1992, FLUIDIZATION, P75
   Gu YL, 2016, POWDER TECHNOL, V296, P17, DOI 10.1016/j.powtec.2015.09.037
   Hou BL, 2016, CHEM ENG J, V284, P1224, DOI 10.1016/j.cej.2015.09.073
   JOHNSON PC, 1987, J FLUID MECH, V176, P67, DOI 10.1017/S0022112087000570
   Ku XK, 2015, CHEM ENG SCI, V122, P270, DOI 10.1016/j.ces.2014.08.045
   Kunii D., 1991, FLUIDIZATION ENG
   Lee JL, 2017, POWDER TECHNOL, V318, P193, DOI 10.1016/j.powtec.2017.05.050
   Lichtenegger T, 2018, POWDER TECHNOL, V325, P698, DOI 10.1016/j.powtec.2017.11.058
   Loha C, 2014, CHEM ENG SCI, V109, P53, DOI 10.1016/j.ces.2014.01.017
   Lu HL, 2003, CHEM ENG SCI, V58, P3777, DOI 10.1016/S0009-2509(03)00238-0
   Nikolopoulos A, 2017, CHEM ENG SCI, V163, P189, DOI 10.1016/j.ces.2017.01.052
   Nikolopoulos A, 2010, CHEM ENG SCI, V65, P4080, DOI 10.1016/j.ces.2010.03.054
   Ostermeier P., 2018, INT J COMPUT METHODS, V6, P71
   Ostermeier P, 2018, POWDER TECHNOL, V333, P193, DOI 10.1016/j.powtec.2018.04.028
   Ostermeier P, 2017, POWDER TECHNOL, V312, P89, DOI 10.1016/j.powtec.2017.02.015
   Patankar S.V., 1980, NUMERICAL HEAT TRANS
   Peng ZB, 2014, AICHE J, V60, P2000, DOI 10.1002/aic.14421
   Popoff B, 2007, 6 INT C MULT FLOW LE
   Poschel T., 2005, COMPUTATIONAL GRANUL
   Schneiderbauer S, 2015, CHEM ENG J, V264, P99, DOI 10.1016/j.cej.2014.11.058
   Schneiderbauer S, 2014, AICHE J, V60, P839, DOI 10.1002/aic.14321
   Snider DM, 2001, J COMPUT PHYS, V170, P523, DOI 10.1006/jcph.2001.6747
   Song CX, 2017, POWDER TECHNOL, V314, P346, DOI 10.1016/j.powtec.2016.10.044
   Stroh A, 2018, FUEL PROCESS TECHNOL, V169, P84, DOI 10.1016/j.fuproc.2017.09.014
   Stroh A, 2016, PARTICUOLOGY, V29, P34, DOI 10.1016/j.partic.2015.09.010
   Wang JW, 2013, CHEM-ING-TECH, V85, P290, DOI 10.1002/cite.201200101
   Xu HB, 2017, POWDER TECHNOL, V314, P377, DOI 10.1016/j.powtec.2016.09.006
   Yang S., 2015, POWDER TECHNOL, P296
   Yang W., 2003, HDB FLUIDIZATION FLU
   Ye M, 2005, CHEM ENG RES DES, V83, P833, DOI 10.1205/cherd.04341
   Yusuf R, 2012, INT J MULTIPHAS FLOW, V42, P9, DOI 10.1016/j.ijmultiphaseflow.2012.01.003
   Yusuf R, 2011, CHEM ENG SCI, V66, P1550, DOI 10.1016/j.ces.2010.12.015
   Zhang N, 2010, CHEM ENG J, V162, P821, DOI 10.1016/j.cej.2010.06.033
NR 49
TC 5
Z9 5
U1 8
U2 36
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAR 16
PY 2019
VL 196
BP 291
EP 309
DI 10.1016/j.ces.2018.11.007
PG 19
WC Engineering, Chemical
SC Engineering
GA HI9RQ
UT WOS:000456795700023
DA 2020-05-12
ER

PT J
AU Zachariah, GT
   Panda, D
   Surasani, VK
AF Zachariah, Githin Tom
   Panda, Debashis
   Surasani, Vikranth Kumar
TI Lattice Boltzmann simulations for invasion patterns during drying of
   capillary porous media
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Lattice Boltzmann Method; Capillary porous media; Drying; Pore network
ID IMMISCIBLE DISPLACEMENTS; NUMERICAL-SIMULATION; LIQUID-GAS; NETWORK;
   FLUID; MODEL; EQUATIONS; DYNAMICS; FLOWS
AB Drying of capillary porous media involves coupled heat and mass transfer in complex void space geometry, which makes it very difficult to model and simulate invasion patterns. Thus far, modeling of drying was done using either continuum methods or pore network models (PNM), both of which have some limitations on representing the geometry of void space and underlying transport mechanism. Pore network models were in general applied to reconstructed void space, therefore, dynamic invasion patterns, cluster formations and dependency on drying kinetics may not be accurate. Alternatively, Lattice Boltzmann Method (LBM) is ideal for simulation of drying in capillary porous media as it can incorporate complex effects in a simple and natural way. In this work, the Lattice Boltzmann Method (LBM) using Shan Chen multiphase representation is used to simulate invasion patterns during the drying of four different void space computation domains, differing in both pore and throat geometries.
   The dynamics of invasion patterns and cluster formation were captured in all four computation domains. Due to the complex geometries present in porous media, capillary instabilities are often observed which leads to sudden jumps in the fluid-fluid interface. In this work, the effects of such instabilities on the liquid distribution are studied. The invasion patterns are compared to identify the dependence of capillary instabilities on the pore structure. It was observed that fluid-fluid interface motion could be classified into two types- evaporation-diffusion invasion, which constituted of slow invasion of voids by diffusion, and Haines jumps, which involved fast invasion of voids due to capillary instabilities. It was observed that some types of porous media exhibited an abundance of the former, particularly in irregular pore structures. However, regular pore structures showed a combination of both evaporation-diffusion invasions and Haines jumps. Lastly, it was observed that the rate of invasion of pores depends on its structure. Pores with sharp edges take a considerably longer period to invade due to a liquid holdup at the edges. This work emphasizes the advantages of using the LBM to simulate the drying of porous media for complex regular/irregular geometries. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Zachariah, Githin Tom; Panda, Debashis; Surasani, Vikranth Kumar] Birla Inst Technol & Sci, Dept Chem Engn, Pilani Hyderabad Campus, Hyderabad 500078, India.
RP Surasani, VK (reprint author), Birla Inst Technol & Sci, Dept Chem Engn, Pilani Hyderabad Campus, Hyderabad 500078, India.
EM surasani@hyderabad.bits-pilain.ac.in
RI Zacharaiah, Githin Tom/AAL-6134-2020; Surasani, Vikranth
   Kumar/AAD-3441-2020
OI Surasani, Vikranth Kumar/0000-0003-4987-5695; Panda,
   Debashis/0000-0002-7715-0539
CR Armstrong RT, 2013, PHYS REV E, V88, DOI 10.1103/PhysRevE.88.043010
   Benzi R, 2006, PHYS REV E, V74, DOI 10.1103/PhysRevE.74.021509
   BENZI R, 1992, PHYS REP, V222, P145, DOI 10.1016/0370-1573(92)90090-M
   Berg S, 2013, P NATL ACAD SCI USA, V110, P3755, DOI 10.1073/pnas.1221373110
   BERKOWITZ B, 1993, WATER RESOUR RES, V29, P775, DOI 10.1029/92WR02707
   BHATNAGAR PL, 1954, PHYS REV, V94, P511, DOI 10.1103/PhysRev.94.511
   Blunt MJ, 2013, ADV WATER RESOUR, V51, P197, DOI 10.1016/j.advwatres.2012.03.003
   Broadbent S.R., 1957, Proceedings of the Cambridge Philosophical Society, V53, P629
   Buick JM, 2000, PHYS REV E, V61, P5307, DOI 10.1103/PhysRevE.61.5307
   Chen S, 1998, ANNU REV FLUID MECH, V30, P329, DOI 10.1146/annurev.fluid.30.1.329
   Chopard B, 1999, FUTURE GENER COMP SY, V16, P249, DOI 10.1016/S0167-739X(99)00050-3
   Chopard B, 1998, CELLULAR AUTOMATA MO, DOI [10.1007/978-1-4614-1800-9_27, DOI 10.1007/978-1-4614-1800-9_27]
   Delouei AA, 2016, PHYSICA A, V447, P1, DOI 10.1016/j.physa.2015.11.032
   El Abrach H, 2014, TRANSPORT POROUS MED, V104, P181, DOI 10.1007/s11242-014-0327-2
   El Abrach H, 2013, J POROUS MEDIA, V16, P837, DOI 10.1615/JPorMedia.v16.i9.50
   El Abrach H, 2013, TRANSPORT POROUS MED, V99, P427, DOI 10.1007/s11242-013-0194-2
   El Abrach H, 2013, DRY TECHNOL, V31, P1400, DOI 10.1080/07373937.2013.796485
   Evans I. S., 1970, REV GEOMORPHOLOGIE D, V19, P155
   Gao ML, 2015, PHYS REV E, V91, DOI 10.1103/PhysRevE.91.013308
   Ginzburg I, 2010, J STAT PHYS, V139, P1090, DOI 10.1007/s10955-010-9969-9
   Haines WB, 1930, J AGR SCI, V20, P97, DOI 10.1017/S002185960008864X
   Huang HB, 2014, COMPUT FLUIDS, V93, P164, DOI 10.1016/j.compfluid.2014.01.025
   Huang JW, 2017, COMPUT FLUIDS, V155, P134, DOI 10.1016/j.compfluid.2017.05.027
   Kupershtokh AL, 2009, COMPUT MATH APPL, V58, P965, DOI 10.1016/j.camwa.2009.02.024
   Lallemand P, 2003, PHYS REV E, V68, DOI 10.1103/PhysRevE.68.036706
   Leclaire S, 2017, PHYS REV E, V95, DOI 10.1103/PhysRevE.95.033306
   LENORMAND R, 1983, J FLUID MECH, V135, P337, DOI 10.1017/S0022112083003110
   LENORMAND R, 1988, J FLUID MECH, V189, P165, DOI 10.1017/S0022112088000953
   Li HN, 2005, PHYS REV E, V72, DOI 10.1103/PhysRevE.72.026705
   Lin CL, 2010, FLOW MEAS INSTRUM, V21, P255, DOI 10.1016/j.flowmeasinst.2010.02.008
   Liu HH, 2016, COMPUTAT GEOSCI, V20, P777, DOI 10.1007/s10596-015-9542-3
   Martys NS, 1996, PHYS REV E, V53, P743, DOI 10.1103/PhysRevE.53.743
   Metzger T., 2008, PORE SCALE MODELLING, DOI [10.1007/978-3-540-85715-0_15, DOI 10.1007/978-3-540-85715-0_15]
   Nourgaliev RR, 2003, INT J MULTIPHAS FLOW, V29, P117, DOI 10.1016/S0301-9322(02)00108-8
   Pan C, 2004, WATER RESOUR RES, V40, DOI 10.1029/2003WR002120
   Pereira GG, 2017, APPL MATH MODEL, V44, P160, DOI 10.1016/j.apm.2016.11.009
   PRAT M, 1993, INT J MULTIPHAS FLOW, V19, P691, DOI 10.1016/0301-9322(93)90096-D
   PRAT M, 1995, INT J MULTIPHAS FLOW, V21, P875, DOI 10.1016/0301-9322(95)00022-P
   Prat M, 1999, PHYS REV E, V60, P5647, DOI 10.1103/PhysRevE.60.5647
   Pskovski Z., 1985, DRY TECHNOL, V3, P149, DOI [10.1080/07373938508916261, DOI 10.1080/07373938508916261]
   QIAN YH, 1992, EUROPHYS LETT, V17, P479, DOI 10.1209/0295-5075/17/6/001
   QUINTARD M, 1993, CHEM ENG SCI, V48, P2537, DOI 10.1016/0009-2509(93)80266-S
   Sahimi M., 2011, FLOW TRANSPORT POROU, DOI [10.1002/9783527636693, DOI 10.1002/9783527636693]
   Sanchez-Palencia E., 1980, NONHOMOGENEOUS MEDIA, V129
   SHAN XW, 1995, J STAT PHYS, V81, P379, DOI 10.1007/BF02179985
   SHAN XW, 1993, PHYS REV E, V47, P1815, DOI 10.1103/PhysRevE.47.1815
   SHAN XW, 1994, PHYS REV E, V49, P2941, DOI 10.1103/PhysRevE.49.2941
   Sukop MC, 2004, WATER RESOUR RES, V40, DOI 10.1029/2003WR002333
   Surasani VK, 2008, CHEM ENG SCI, V63, P5218, DOI 10.1016/j.ces.2008.07.011
   Surasani VK, 2008, INT J HEAT MASS TRAN, V51, P2506, DOI 10.1016/j.ijheatmasstransfer.2007.07.033
   Surasani VK, 2010, DRY TECHNOL, V28, P615, DOI 10.1080/07373931003788676
   Surasani VK, 2009, TRANSPORT POROUS MED, V80, P431, DOI 10.1007/s11242-009-9372-7
   Swift MR, 1996, PHYS REV E, V54, P5041, DOI 10.1103/PhysRevE.54.5041
   SWIFT MR, 1995, PHYS REV LETT, V75, P830, DOI 10.1103/PhysRevLett.75.830
   Tsotsas E., 2010, ULLMANNS ENCY IND CH, DOI [10.1002/14356007.b02_04.pub2, DOI 10.1002/14356007.B02_04.PUB2]
   Wu R, 2017, INT J HEAT MASS TRAN, V112, P630, DOI 10.1016/j.ijheatmasstransfer.2017.05.023
   Xiong QR, 2016, J CONTAM HYDROL, V192, P101, DOI 10.1016/j.jconhyd.2016.07.002
   Xu R, 2018, FUEL, V225, P243, DOI 10.1016/j.fuel.2018.03.143
   Yuan P, 2006, PHYS FLUIDS, V18, DOI 10.1063/1.2187070
   Zacharoudiou I, 2016, ADV WATER RESOUR, V92, P43, DOI 10.1016/j.advwatres.2016.03.013
NR 60
TC 1
Z9 1
U1 3
U2 28
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAR 16
PY 2019
VL 196
BP 310
EP 323
DI 10.1016/j.ces.2018.11.003
PG 14
WC Engineering, Chemical
SC Engineering
GA HI9RQ
UT WOS:000456795700024
DA 2020-05-12
ER

PT J
AU Lee, JA
   Ahn, JH
   Kim, I
   Li, S
   Lee, SY
AF Lee, Jong An
   Ahn, Jung Ho
   Kim, Inho
   Li, Sheng
   Lee, Sang Yup
TI Separation and purification of three, four, and five carbon diamines
   from fermentation broth
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE 1,3-diaminopropane; 1,4-diaminobutane; 1,5-diaminopentane; Purification;
   Fermentation broth
ID BIO-BASED PRODUCTION; ESCHERICHIA-COLI; SUCCINIC ACID; EXTRACTION;
   POLYMERS; REMOVAL
AB 1,3-diaminopropane (1,3-DAP), 1,4-diaminobutane (1,4-DAB), and 1,5-diaminopentane (1,5-DAP) are important chemicals due to their wide industrial use including agrochemicals, pharmaceuticals, surfactants, and building blocks for nylon synthesis. Over the last decade, several studies on bio-based production of diamines by metabolically engineered microorganisms have been published. However, development of efficient methods for the recovery of 1,3-DAP, 1,4-DAB, and 1,5-DAP from fermentation broth has not been reported. In this study, an efficient process for the separation and purification of 1,3-DAP, 1,4-DAB, and 1,5-DAP from fermentation broth without using highly flammable or toxic solvents was developed. The optimal process for the recovery and purification of these diamines from fermentation broth comprises several unit operations including removal of cell debris, decolorization of fermentation broth, product concentration, deprotonation of diamines, product separation, and final polishing to obtain pure 1,3-DAP, 1,4-DAB, and 1,5-DAP with yields of 87 +/- 3%, 86 +/- 4%, and 81 +/- 2%, respectively. Process development for the recovery and purification of fermentatively produced diamines reported here is expected to facilitate synthesis of bio-based nylons. Furthermore, the strategy reported here could be similarly applicable in developing downstream processes to recover and purify other diamines and related chemicals from fermentation broth. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Lee, Jong An; Ahn, Jung Ho; Kim, Inho; Li, Sheng; Lee, Sang Yup] Korea Adv Inst Sci & Technol, Dept Chem & Biomol Engn, Plus Program BK21, Daejeon 34141, South Korea.
   [Lee, Jong An; Ahn, Jung Ho; Lee, Sang Yup] Korea Adv Inst Sci & Technol, Metab & Biomol Engn Natl Res Lab, Daejeon 34141, South Korea.
   [Lee, Jong An; Ahn, Jung Ho; Lee, Sang Yup] Korea Adv Inst Sci & Technol, BioCentury, Daejeon 34141, South Korea.
   [Lee, Jong An; Ahn, Jung Ho; Lee, Sang Yup] Korea Adv Inst Sci & Technol, Syst Metab Engn & Syst Healthcare Cross Generat C, Daejeon 34141, South Korea.
   [Lee, Sang Yup] Korea Adv Inst Sci & Technol, BioInformat Res Ctr, Daejeon 34141, South Korea.
   [Lee, Sang Yup] Korea Adv Inst Sci & Technol, BioProc Engn Res Ctr, Daejeon 34141, South Korea.
RP Lee, SY (reprint author), Korea Adv Inst Sci & Technol, Dept Chem & Biomol Engn, Plus Program BK21, Daejeon 34141, South Korea.
EM leesy@kaist.ac.kr
RI Li, Sheng/E-5499-2016; Lee, Sang Yup/C-1526-2011
OI Lee, Sang Yup/0000-0003-0599-3091
FU Ministry of Science and ICT through the National Research Foundation
   (NRF) of Korea [NRF-2012M1A2A2026556, NRF-2012M1A2A2026557]
FX This work was supported by the Technology Development Program to Solve
   Climate Changes on Systems Metabolic Engineering for Biorefineries
   (NRF-2012M1A2A2026556 and NRF-2012M1A2A2026557) from the Ministry of
   Science and ICT through the National Research Foundation (NRF) of Korea.
CR Ahn JH, 2017, IND BIOTECHNOLOGY PR, P505
   Ahn JH, 2016, CURR OPIN BIOTECH, V42, P54, DOI 10.1016/j.copbio.2016.02.034
   Arimi MM, 2014, INT BIODETER BIODEGR, V87, P34, DOI 10.1016/j.ibiod.2013.11.002
   Bednarz A, 2017, J CHEM TECHNOL BIOT, V92, P1817, DOI 10.1002/jctb.5183
   Brehmer B., 2013, BIOBASED PLASTICS MA, P275
   Chae TU, 2015, SCI REP-UK, V5, DOI 10.1038/srep13040
   Cho C, 2015, BIOTECHNOL ADV, V33, P1455, DOI 10.1016/j.biotechadv.2014.11.006
   Choi S, 2016, BIOTECHNOL BIOENG, V113, P2168, DOI 10.1002/bit.25988
   Choi S, 2015, METAB ENG, V28, P223, DOI 10.1016/j.ymben.2014.12.007
   Chung H, 2015, CURR OPIN BIOTECH, V36, P73, DOI 10.1016/j.copbio.2015.07.003
   Froidevaux V, 2016, CHEM REV, V116, P14181, DOI 10.1021/acs.chemrev.6b00486
   Geankoplis C.J., 2003, TRANSPORT PROCESSES
   Harmsen PFH, 2014, BIOFUEL BIOPROD BIOR, V8, P306, DOI 10.1002/bbb.1468
   Jang YS, 2012, BIOTECHNOL BIOENG, V109, P2437, DOI 10.1002/bit.24599
   Kawaguchi H, 2017, BIORESOURCE TECHNOL, V245, P1664, DOI 10.1016/j.biortech.2017.06.135
   Kind S, 2014, METAB ENG, V25, P113, DOI 10.1016/j.ymben.2014.05.007
   Kind S, 2011, APPL MICROBIOL BIOT, V91, P1287, DOI 10.1007/s00253-011-3457-2
   Krzyzaniak A, 2014, J CHEM TECHNOL BIOT, V89, P1015, DOI 10.1002/jctb.4193
   Krzyzaniak A, 2013, J CHEM TECHNOL BIOT, V88, P1937, DOI 10.1002/jctb.4058
   Kurzrock T, 2010, BIOTECHNOL LETT, V32, P331, DOI 10.1007/s10529-009-0163-6
   Lee SY, 2015, NAT BIOTECHNOL, V33, P1061, DOI 10.1038/nbt.3365
   Noh M, 2017, CELL SYST, V5, P418, DOI 10.1016/j.cels.2017.08.016
   Montane D, 2006, IND ENG CHEM RES, V45, P2294, DOI 10.1021/ie051051d
   Oppermann S, 2011, APPL MICROBIOL BIOT, V89, P493, DOI 10.1007/s00253-010-2933-4
   Poole CF, 2010, J CHROMATOGR A, V1217, P2268, DOI 10.1016/j.chroma.2009.09.011
   Qian ZG, 2011, BIOTECHNOL BIOENG, V108, P93, DOI 10.1002/bit.22918
   Qian ZG, 2009, BIOTECHNOL BIOENG, V104, P651, DOI 10.1002/bit.22502
   Qin TT, 2017, RSC ADV, V7, P37112, DOI 10.1039/c7ra04813k
   Song CW, 2015, METAB ENG, V30, P121, DOI 10.1016/j.ymben.2015.05.005
   Vardon DR, 2016, GREEN CHEM, V18, P3397, DOI 10.1039/c5gc02844b
NR 30
TC 3
Z9 3
U1 7
U2 21
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAR 16
PY 2019
VL 196
BP 324
EP 332
DI 10.1016/j.ces.2018.11.018
PG 9
WC Engineering, Chemical
SC Engineering
GA HI9RQ
UT WOS:000456795700025
DA 2020-05-12
ER

PT J
AU Zhu, PA
   Wang, LQ
AF Zhu, Pingan
   Wang, Liqiu
TI Droplet pinch-off with pressure fluctuations
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Pinch-off; Droplet microfluidics; Nonuniversality; Pressure fluctuations
ID MICROFLUIDIC GENERATION; PICOLITER DROPLETS; ATPS DROPLETS; BREAKUP;
   DYNAMICS; PARALLEL
AB Dynamics of Newtonian fluid pinch-off is universal, excluding the possibility of manipulating pinch-off behavior by varying initial and boundary conditions which is desirable in applications such as inkjet printing and microfluidics. Here we show that the dynamics of two-fluid pinch-off with disturbed inlet pressure (such as the profile of the conical liquid neck, cone slope, and neck thinning rate) depends on initial perturbations. The nonuniversality arises from pressure-fluctuation-induced nonlocal flow velocity that stretches the axial length scale of the pinch-off region. We renormalize the disturbed pinch-off using the linear ratio, (1 + beta epsilon), with beta being the empirical constant and epsilon the dimensionless pressure fluctuation. We further apply the pressure fluctuation in engineering pinch-off where the disturbed and undisturbed systems have identical pinch-off dynamics but distinct material properties. Our results could provide useful guidelines for controlling the breakup of liquid threads with extreme physical properties, such as ultrahigh viscosity and ultralow interfacial tension, in inkjet printing and microfluidics for a range of applications. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Wang, Liqiu] Univ Hong Kong, Dept Mech Engn, Hong Kong, Peoples R China.
   HKU ZIRI, Hangzhou 311300, Zhejiang, Peoples R China.
RP Wang, LQ (reprint author), Univ Hong Kong, Dept Mech Engn, Hong Kong, Peoples R China.
EM lqwang@hku.hk
RI Wang, Liqiu/C-1901-2009; Zhu, Pingan/K-4965-2019
OI Zhu, Pingan/0000-0001-5847-1831
FU Research Grants Council of Hong KongHong Kong Research Grants Council
   [CRF C1018-17G, GRF 17204718, 17237316, 17211115, 17207914]; University
   of Hong KongUniversity of Hong Kong [URC 201511159108, 201411159074,
   201311159187]; Zhejiang Provincial Government; Hangzhou Municipal
   Government; Lin'an County Government
FX The financial support from the Research Grants Council of Hong Kong (CRF
   C1018-17G, GRF 17204718, 17237316, 17211115 and 17207914) and the
   University of Hong Kong (URC 201511159108, 201411159074, and
   201311159187) is gratefully acknowledged. This work was also supported
   in part by the Zhejiang Provincial, Hangzhou Municipal, and Lin'an
   County Governments.
CR Arratia PE, 2008, PHYS REV E, V77, DOI 10.1103/PhysRevE.77.036309
   Baccouche A, 2017, NAT PROTOC, V12, P1912, DOI 10.1038/nprot.2017.092
   Barenblatt G. I., 1996, SCALING SELF SIMILAR
   Batchelor G. K., 1967, INTRO FLUID DYNAMICS
   Bransky A, 2009, LAB CHIP, V9, P516, DOI 10.1039/b814810d
   Castrejon-Pita JR, 2015, P NATL ACAD SCI USA, V112, P4582, DOI 10.1073/pnas.1418541112
   Cohen I, 1999, PHYS REV LETT, V83, P1147, DOI 10.1103/PhysRevLett.83.1147
   Cohen I, 2001, PHYS FLUIDS, V13, P3533, DOI 10.1063/1.1409369
   Cole RH, 2017, P NATL ACAD SCI USA, V114, P8728, DOI 10.1073/pnas.1704020114
   Collins DJ, 2013, LAB CHIP, V13, P3225, DOI 10.1039/c3lc50372k
   Delrot P, 2016, PHYS REV APPL, V6, DOI 10.1103/PhysRevApplied.6.024003
   Doshi P, 2003, SCIENCE, V302, P1185, DOI 10.1126/science.1089272
   Du W, 2016, AICHE J, V62, P325, DOI 10.1002/aic.15043
   Eggers J, 2008, REP PROG PHYS, V71, DOI 10.1088/0034-4885/71/3/036601
   Hwang HH, 2018, SMALL METHODS, V2, DOI 10.1002/smtd.201700277
   Javadi A, 2013, PHYS REV LETT, V110, DOI 10.1103/PhysRevLett.110.144501
   Kang ZX, 2016, J MICROMECH MICROENG, V26, DOI 10.1088/0960-1317/26/7/075011
   Lei LY, 2017, J MATER CHEM B, V5, P6034, DOI 10.1039/c7tb01255a
   Li YH, 2015, SOFT MATTER, V11, P3884, DOI 10.1039/c5sm00252d
   Lister JR, 1998, PHYS FLUIDS, V10, P2758, DOI 10.1063/1.869799
   Moon BU, 2015, LAB CHIP, V15, P2437, DOI 10.1039/c5lc00217f
   Petit J, 2012, P NATL ACAD SCI USA, V109, P18327, DOI 10.1073/pnas.1207634109
   Riche CT, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10780
   Tian XW, 2018, CHEM ENG SCI, V183, P13, DOI 10.1016/j.ces.2018.02.040
   Tian Y., 2017, NAT COMMUN, V8
   TJAHJADI M, 1992, J FLUID MECH, V243, P297, DOI 10.1017/S0022112092002738
   Tomotika S., 1935, Proceedings of the Royal Society of London, Series A (Mathematical and Physical Sciences), V150, P322, DOI 10.1098/rspa.1935.0104
   ZHANG M, 2010, APPL PHYS LETT, V97
   Zhang WW, 1999, PHYS REV LETT, V83, P1151, DOI 10.1103/PhysRevLett.83.1151
   Zhang YZ, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12424
   ZHANG YH, 2017, NAT REV MATER, V2
   Zhou CM, 2017, LAB CHIP, V17, P3310, DOI 10.1039/c7lc00696a
   Zhu PA, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15823
   Zhu PA, 2017, LAB CHIP, V17, P34, DOI 10.1039/c6lc01018k
   Zhu PA, 2016, SCI REP-UK, V6, DOI 10.1038/srep31436
   Zhu PG, 2016, MICROFLUID NANOFLUID, V20, DOI 10.1007/s10404-016-1717-2
NR 36
TC 2
Z9 2
U1 3
U2 32
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAR 16
PY 2019
VL 196
BP 333
EP 343
DI 10.1016/j.ces.2018.11.016
PG 11
WC Engineering, Chemical
SC Engineering
GA HI9RQ
UT WOS:000456795700026
DA 2020-05-12
ER

PT J
AU Izurieta, EM
   Pedernera, MN
   Lopez, E
AF Izurieta, Eduardo M.
   Pedernera, Marisa N.
   Lopez, Eduardo
TI Study of a thermally integrated parallel plates reactor for hydrogen
   production
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Ethanol steam reforming; Ethanol combustion; Hydrogen production;
   Thermal coupling; Process intensification; Parallel plates reactor
ID ENDOTHERMIC REACTIONS; ENERGY EFFICIENCY; SYNTHESIS GAS; ETHANOL;
   DESIGN; COMBUSTION; BIOETHANOL; PROCESSOR; CATALYSTS; SYSTEM
AB This paper deals with the study of the integration of ethanol steam reforming and ethanol combustion in a parallel plates reactor aiming a hydrogen production of 1 kW(th) equivalent. The study was performed by means of a mathematical model of a non-adiabatic reactor and the associated heat exchangers used for preheating purposes. Focus is given here to the influence of the insulation of the reactor and heat exchangers, the fuel concentration, fuel distribution policy to the reactor, and reforming flowrate. Thermal coupling between combustion and reforming of ethanol in terms of energetic integration is feasible and an adequate behavior of the reactor and the heat exchangers is predicted. The importance of heat losses to the environment is evidenced since they represent about 35-50% of the heat released by the combustion. Ranges of ethanol fuel concentration (0.6-2.0% of ethanol fuel) and distribution (1 or 2 feed ports), and ethanol reforming load (0.37-0.63 kg/h) were studied to find windows for these variables where a satisfactory operation is possible. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Izurieta, Eduardo M.; Pedernera, Marisa N.] Univ Nacl Sur, Dept Ingn Quim, Bahia Blanca, Buenos Aires, Argentina.
   [Izurieta, Eduardo M.; Pedernera, Marisa N.; Lopez, Eduardo] Univ Nacl Sur, CONICET, Planta Piloto Ingn Quim PLAPIQUI, Bahia Blanca, Buenos Aires, Argentina.
RP Izurieta, EM (reprint author), Univ Nacl Sur, CONICET, Planta Piloto Ingn Quim PLAPIQUI, Bahia Blanca, Buenos Aires, Argentina.
EM eizurieta@plapiqui.edu.ar
OI Izurieta, Eduardo/0000-0002-7012-3992
FU Consejo Nacional de Investigaciones Cientificas y Tecnicas
   (CONICET)Consejo Nacional de Investigaciones Cientificas y Tecnicas
   (CONICET); Universidad Nacional del Sur (UNS); Agencia Nacional de
   Promocion Cientifica y Tecnologica (ANPCyT)ANPCyT
FX The authors acknowledge the financial support of Consejo Nacional de
   Investigaciones Cientificas y Tecnicas (CONICET), Universidad Nacional
   del Sur (UNS), and Agencia Nacional de Promocion Cientifica y
   Tecnologica (ANPCyT).
CR Campesi MA, 2012, FUEL PROCESS TECHNOL, V103, P84, DOI 10.1016/j.fuproc.2011.08.019
   Bergman T. L., 2011, FUNDAMENTALS HEAT MA
   Bruschi Y.M., 2014, THESIS
   Bruschi YM, 2016, CHEM ENG J, V294, P97, DOI 10.1016/j.cej.2016.02.079
   Bruschi YM, 2012, INT J HYDROGEN ENERG, V37, P14887, DOI 10.1016/j.ijhydene.2012.01.175
   Cai WJ, 2010, INT J HYDROGEN ENERG, V35, P1152, DOI 10.1016/j.ijhydene.2009.11.104
   Contreras JL, 2014, INT J HYDROGEN ENERG, V39, P18835, DOI 10.1016/j.ijhydene.2014.08.072
   CYBULSKI A, 1994, CATAL REV, V36, P179, DOI 10.1080/01614949408013925
   DEGROOTE AM, 1995, REV CHEM ENG, V11, P145
   Francesconi JA, 2007, J POWER SOURCES, V173, P467, DOI 10.1016/j.jpowsour.2007.04.048
   Francesconi JA, 2007, J POWER SOURCES, V167, P151, DOI 10.1016/j.jpowsour.2006.12.109
   Francesconi JA, 2017, INT J HYDROGEN ENERG, V42, P2736, DOI 10.1016/j.ijhydene.2016.10.156
   Frauhammer J, 1999, CHEM ENG SCI, V54, P3661, DOI 10.1016/S0009-2509(98)00454-0
   Gardemann U, 2014, INT J HYDROGEN ENERG, V39, P18135, DOI 10.1016/j.ijhydene.2014.05.027
   Hernandez L, 2009, INT J HYDROGEN ENERG, V34, P7041, DOI 10.1016/j.ijhydene.2008.07.089
   Hou TF, 2015, RENEW SUST ENERG REV, V44, P132, DOI 10.1016/j.rser.2014.12.023
   Izurieta EM, 2017, INT J HYDROGEN ENERG, V42, P18794, DOI 10.1016/j.ijhydene.2017.06.134
   Kolios G, 2002, CHEM ENG SCI, V57, P1505, DOI 10.1016/S0009-2509(02)00022-2
   Kolios G, 2001, CHEM ENG SCI, V56, P351, DOI 10.1016/S0009-2509(00)00241-4
   Kolios G, 2007, APPL CATAL B-ENVIRON, V70, P16, DOI 10.1016/j.apcatb.2006.01.030
   Llorca J, 2008, J CATAL, V255, P228, DOI 10.1016/j.jcat.2008.02.006
   Lopez E, 2012, IND ENG CHEM RES, V51, P4143, DOI 10.1021/ie202364y
   Viviente JL, 2017, INT J HYDROGEN ENERG, V42, P13970, DOI 10.1016/j.ijhydene.2017.03.162
   Manzolini G, 2008, INT J HYDROGEN ENERG, V33, P5571, DOI 10.1016/j.ijhydene.2008.06.029
   Mas V, 2006, INT J HYDROGEN ENERG, V31, P21, DOI 10.1016/j.ijhydene.2005.04.004
   Mirvakili A, 2014, J NAT GAS SCI ENG, V16, P18, DOI 10.1016/j.jngse.2013.11.005
   Nabgan W, 2017, RENEW SUST ENERG REV, V79, P347, DOI 10.1016/j.rser.2017.05.069
   Nahar G, 2017, RENEW SUST ENERG REV, V76, P1032, DOI 10.1016/j.rser.2017.02.031
   Nedyalkova R, 2009, INT J HYDROGEN ENERG, V34, P2591, DOI 10.1016/j.ijhydene.2009.01.050
   Oh M, 1996, COMPUT CHEM ENG, V20, P611, DOI 10.1016/0098-1354(95)00196-4
   Pattison RC, 2014, IND ENG CHEM RES, V53, P5028, DOI 10.1021/ie4008997
   Poling B. E, 2001, PROPERTIES GASES LIQ, DOI [10.1036/0070116822, DOI 10.1036/0070116822]
   PSE, 2004, GPROMS INTR US GUID
   Rahimpour MR, 2012, APPL ENERG, V99, P496, DOI 10.1016/j.apenergy.2012.04.003
   Rodriguez ML, 2019, CHEM ENG J, V377, DOI 10.1016/j.cej.2018.10.076
   Saber M, 2010, CHEM ENG SCI, V65, P372, DOI 10.1016/j.ces.2009.06.010
   Uriz I, 2014, CHEM ENG J, V238, P37, DOI 10.1016/j.cej.2013.05.097
   Vaidya PD, 2006, CHEM ENG J, V117, P39, DOI 10.1016/j.cej.2005.12.008
   Warmeintegrierte Gritsch A., 2008, THESIS
   WILKE CR, 1950, J CHEM PHYS, V18, P517, DOI 10.1063/1.1747673
   Yaws C.L., 1999, CHEM PROPERTIES HDB
   Zabed H, 2017, RENEW SUST ENERG REV, V71, P475, DOI 10.1016/j.rser.2016.12.076
   Zanfir M, 2004, CHEM ENG RES DES, V82, P252, DOI 10.1205/026387604772992846
NR 43
TC 5
Z9 5
U1 0
U2 5
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAR 16
PY 2019
VL 196
BP 344
EP 353
DI 10.1016/j.ces.2018.11.011
PG 10
WC Engineering, Chemical
SC Engineering
GA HI9RQ
UT WOS:000456795700027
DA 2020-05-12
ER

PT J
AU Siouris, S
   Blakey, S
AF Siouris, Spiridon
   Blakey, Simon
TI Fitness functions for evolutionary optimization of rate parameters in
   chemically reacting systems
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Reaction rate parameters; Optimization; Fitness functions; Genetic
   algorithms
ID CODED GENETIC ALGORITHMS; RATE CONSTANTS; REACTION-MECHANISMS; ARRHENIUS
   EQUATION; RATE COEFFICIENTS; KINETICS; OPERATORS
AB Evolutionary optimization studies are mainly focused on the type of methodologies and controlling parameters of the algorithms. However, the choice of fitness functions which gives a measure on how well a dataset correlates with reference values is often not justified in a rigorous way. The work in this paper addresses this issue by investigating the performance of a set of fitness functions and their suitability according to the input data used for training the optimization algorithms. A Genetic Algorithm was applied to a chemical kinetics problem with the aim of matching the measured species concentrations through optimization of a set of Arrhenius reaction rate parameters. The challenge with this type of problem lies in the wide range of species concentrations used as the training dataset, where they can be up to fifteen orders in magnitude. This revealed large differences in optimized values arising from the various fitness function formulations, thus highlighting the need for detailed knowledge of fitness functions for a specific optimization problem. Furthermore, the quality of training dataset through error propagation and a scaling parameter were assessed bringing further insight on differences fitness functions. Such information is crucial for the appropriate selection of fitness functions for the effective optimisation of reaction rate parameters. Crown Copyright (C) 2018 Published by Elsevier Ltd. All rights reserved.
C1 [Siouris, Spiridon; Blakey, Simon] Univ Sheffield, Dept Mech Engn, Mappin St, Sheffield S1 3JD, S Yorkshire, England.
RP Siouris, S (reprint author), Univ Sheffield, Dept Mech Engn, Mappin St, Sheffield S1 3JD, S Yorkshire, England.
EM s.siouris@sheffield.ac.uk
RI Blakey, Simon/AAE-2393-2020
OI Blakey, Simon/0000-0001-6478-7170; Siouris, Spiridon/0000-0002-1926-6437
FU EU FP7 ELUBSYS project [233651]; EU Clean Sky FINCAP project [755606]
FX This work was partly supported by the EU FP7 ELUBSYS (grant agreement
   233651) and the EU Clean Sky FINCAP (grant agreement 755606) projects.
CR ATKINSON R, 1986, CHEM REV, V86, P69, DOI 10.1021/cr00071a004
   Balster LM, 2006, ENERG FUEL, V20, P2564, DOI 10.1021/ef060275l
   Bas D, 2007, J FOOD ENG, V79, P622, DOI 10.1016/j.jfoodeng.2006.02.021
   Bernabei M, 2000, J MICROCOLUMN SEP, V12, P585, DOI 10.1002/1520-667X(2000)12:11<585::AID-MCS40>3.0.CO;2-O
   Burgess CJ, 2001, INFORM SOFTWARE TECH, V43, P863, DOI 10.1016/S0950-5849(01)00192-6
   Cantu-Paz E, 2002, INFORM PROCESS LETT, V82, P15, DOI 10.1016/S0020-0190(01)00282-4
   CHEN NH, 1992, AICHE J, V38, P626, DOI 10.1002/aic.690380419
   Cohen S. D., 1996, Computers in Physics, V10, P138
   Dua V, 2011, COMPUT CHEM ENG, V35, P545, DOI 10.1016/j.compchemeng.2010.06.005
   Elliott L, 2003, IND ENG CHEM RES, V42, P1215, DOI 10.1021/ie020501o
   Elliott L, 2004, PROG ENERG COMBUST, V30, P297, DOI 10.1016/j.pecs.2004.02.002
   Goldberg D. E., 1989, GENETIC ALGORITHMS S
   Herrera F, 2003, INT J INTELL SYST, V18, P309, DOI 10.1002/int.10091
   Herrera F, 1998, ARTIF INTELL REV, V12, P265, DOI 10.1023/A:1006504901164
   Hindmarsh A. C., 2016, USED DOCUMENTATION C
   Hindmarsh AC, 2005, ACM T MATH SOFTWARE, V31, P363, DOI 10.1145/1089014.1089020
   Holland J.H., 1975, ADAPTATION NATURAL A
   Hong TP, 2000, J HEURISTICS, V6, P439, DOI 10.1023/A:1009642825198
   Kee RJ, 2003, CHEM REACTING FLOW T
   Kuprowicz NJ, 2007, ENERG FUEL, V21, P530, DOI 10.1021/ef060391o
   LAIDLER KJ, 1984, J CHEM EDUC, V61, P494, DOI 10.1021/ed061p494
   Lemes NH, 2009, CHEMOMETR INTELL LAB, V96, P84, DOI 10.1016/j.chemolab.2009.01.006
   Levine D., 1996, ANL9518
   MAILLARD B, 1983, J AM CHEM SOC, V105, P5095, DOI 10.1021/ja00353a039
   Message Passing Interface Forum, 2009, MPI MESS PASS INT ST
   Mezyk SP, 1997, RADIAT PHYS CHEM, V49, P437, DOI 10.1016/S0969-806X(96)00165-X
   Pilling M. J, 1997, REACTION KINETICS
   Polifke W, 1998, COMBUST FLAME, V113, P119, DOI 10.1016/S0010-2180(97)00212-5
   RANGAIAH GP, 1987, CHEM ENG J BIOCH ENG, V36, P123, DOI 10.1016/0300-9467(87)80050-3
   Rao SK, 2009, IND ENG CHEM RES, V48, P3779, DOI 10.1021/ie801244w
   ROZYCKI C, 1984, J THERM ANAL, V29, P959, DOI 10.1007/BF02188843
   Schwaab M, 2007, CHEM ENG SCI, V62, P2750, DOI 10.1016/j.ces.2007.02.020
   Tadi M, 1998, INT J CHEM KINET, V30, P151, DOI 10.1002/(SICI)1097-4601(1998)30:2<151::AID-KIN7>3.0.CO;2-R
   Tang WY, 2005, IND ENG CHEM RES, V44, P3626, DOI 10.1021/ie048872n
   Taylor J., 1997, INTRO ERROR ANAL STU
   Terry DB, 1998, J CHEM INF COMP SCI, V38, P1232, DOI 10.1021/ci980407b
   Turanyi T, 2012, INT J CHEM KINET, V44, P284, DOI 10.1002/kin.20717
   Vafajoo L., 2011, WORLD ACAD SCI ENG T, V79, P389
   Villaverde AF, 2011, J PHYS CHEM A, V115, P8426, DOI 10.1021/jp203158r
   Von Arx KB, 1998, ENVIRON SCI TECHNOL, V32, P3207, DOI 10.1021/es970947+
   Wright A. H., 1991, FDN GENETIC ALGORITH, P205, DOI DOI 10.1016/B978-0-08-050684-5.50016-1
   Yao RQ, 2003, CHEM ENG J, V94, P113, DOI 10.1016/S1385-8947(03)00025-1
   Zhang BT, 2000, EVOLUTIONARY OPTIMIZ, V2, P55
NR 43
TC 0
Z9 0
U1 1
U2 6
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAR 16
PY 2019
VL 196
BP 354
EP 365
DI 10.1016/j.ces.2018.11.009
PG 12
WC Engineering, Chemical
SC Engineering
GA HI9RQ
UT WOS:000456795700028
DA 2020-05-12
ER

PT J
AU Kurotori, T
   Zahasky, C
   Hejazi, SAH
   Shah, SM
   Benson, SM
   Pini, R
AF Kurotori, Takeshi
   Zahasky, Christopher
   Hejazi, Sayed Alireza Hosseinzadeh
   Shah, Saurabh M.
   Benson, Sally M.
   Pini, Ronny
TI Measuring, imaging and modelling solute transport in a microporous
   limestone
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Porous media; Anomalous transport; Mixing; Fluid flow; Positron Emission
   Tomography
ID POSITRON-EMISSION-TOMOGRAPHY; NON-FICKIAN TRANSPORT; END PORE VOLUME;
   COMPUTED-TOMOGRAPHY; POROUS-MEDIA; HYDRODYNAMIC DISPERSION; PROCESS
   OPTIMIZATION; MASS-TRANSFER; PACKED-BEDS; FLUID-FLOW
AB The analysis of dispersive flows in heterogeneous porous media is complicated by the appearance of anomalous transport. Novel laboratory protocols are needed to probe the mixing process by measuring the spatial structure of the concentration field in the medium. Here, we report on a systematic investigation of miscible displacements in a microporous limestone over the range of Peclet numbers, 20 < Pe < 600. Our approach combines pulse-tracer tests with the simultaneous imaging of the flow by Positron Emission Tomography (PET). Validation of the experimental protocol is achieved by means of control experiments on random beadpacks, as well as by comparing observations with both brine- and radio-tracers (labelled with C-11 or F-18). The application of residence time distribution functions reveals mass transport limitations in the porous rock in the form of a characteristic flow-rate effect. Two transport models, namely the Advection Dispersion Equation (ADE) and the Multi-Rate Mass Transfer (MRMT) model, are thoroughly evaluated with both the experimental breakthrough curves and the internal concentration profiles. We observe that the dispersion coefficient scales linearly with the Peclet number for both porous systems. The tracer profiles acquired on the rock sample are successfully described upon application of the MRMT model that uses two representative grain sizes and a fraction of intra-granular pore space that is independent of the fluid velocity. The analysis of the PET images evidences the presence of macrodispersive spreading caused by subcore-scale heterogeneities, which contribute significantly to the value of the estimated core-scale dispersivity. This effect can be significantly reduced upon application of the 'dispersion-echo' technique, which enables decoupling the effects of spreading and mixing in heterogeneous porous media. These observations are likely to apply to any laboratory-scale rock sample and the approach presented here provides a practical means to study anomalous transport in these systems. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Kurotori, Takeshi; Hejazi, Sayed Alireza Hosseinzadeh; Shah, Saurabh M.; Pini, Ronny] Imperial Coll London, Dept Chem Engn, London, England.
   [Kurotori, Takeshi; Shah, Saurabh M.; Pini, Ronny] Imperial Coll London, Qatar Carbonates & Carbon Storage Res Ctr, London, England.
   [Zahasky, Christopher; Benson, Sally M.] Stanford Univ, Dept Energy Resources Engn, Stanford, CA 94305 USA.
RP Pini, R (reprint author), Imperial Coll London, Dept Chem Engn, London, England.
EM r.pini@imperial.ac.uk
RI ; , Ronny/D-2879-2015
OI Zahasky, Christopher/0000-0002-3427-5622; Kurotori,
   Takeshi/0000-0001-7682-4645; , Ronny/0000-0002-9443-3573; Shah,
   Saurabh/0000-0002-8155-8668
FU QCCSRC by Qatar Petroleum; QCCSRC by Shell; QCCSRC by Qatar Science and
   Technology Park; Natural Environment Research CouncilNERC Natural
   Environment Research Council [NE/N016173/1]; Global Climate Energy
   Project (GCEP); Stanford Center for Carbon Storage (SCCS); Stanford
   Department of Energy Resources Engineering; NIHUnited States Department
   of Health & Human ServicesNational Institutes of Health (NIH) - USA
   [1S10OD018130-01]
FX This work was carried out as part of the Qatar Carbonates and Carbon
   Storage Centre (QCCSRC). TK, SS and RP gratefully acknowledge the
   funding of QCCSRC provided jointly by Qatar Petroleum, Shell, and the
   Qatar Science and Technology Park. SAHH also acknowledges funding by the
   Natural Environment Research Council (grant NE/N016173/1). CZ and SMB
   are funded by the Global Climate Energy Project (GCEP), the Stanford
   Center for Carbon Storage (SCCS), and the Stanford Department of Energy
   Resources Engineering. The Inveon DPET (micro-PET) scanner was funded by
   NIH Grant No. 1S10OD018130-01. The authors thank Nicholas Keat at
   Imanova Ltd. for the support in carrying out the PET experiments on
   beadpacks and reconstructing the associated images. The tomograms
   associated with this work may be obtained from the UKCCSRC data
   repository (data set ID 13607385):
   https://www.bgs.ac.uk/services/ngdc/accessions/index.html#item120009 and
   are associated to the following
   DOI:http://doi.org/10.5285/bac5a5ed-caaa-49e2-845b-9f4a561fd909.
CR Akin S, 2003, GEOL SOC SPEC PUBL, V215, P23, DOI 10.1144/GSL.SP.2003.215.01.03
   Andrew M, 2014, INT J GREENH GAS CON, V22, P1, DOI 10.1016/j.ijggc.2013.12.018
   BAKER LE, 1977, SOC PETROL ENG J, V17, P219, DOI 10.2118/5632-PA
   BATYCKY JP, 1982, SOC PETROL ENG J, V22, P647, DOI 10.2118/9233-PA
   Bear J, 1972, DYNAMICS FLUIDS PORO
   Berkowitz B, 2006, REV GEOPHYS, V44, DOI 10.1029/2005RG000178
   Bijeljic B, 2004, WATER RESOUR RES, V40, DOI 10.1029/2004WR003567
   Bijeljic B, 2013, WATER RESOUR RES, V49, P2714, DOI 10.1002/wrcr.20238
   Bijeljic B, 2011, PHYS REV LETT, V107, DOI 10.1103/PhysRevLett.107.204502
   Boon M, 2017, WATER RESOUR RES, V53, P4624, DOI 10.1002/2016WR019912
   Boutchko R, 2012, J APPL GEOPHYS, V76, P74, DOI 10.1016/j.jappgeo.2011.10.003
   BRETZ RE, 1987, SPE RESERVOIR ENG, V2, P492
   Cirpka OA, 2000, WATER RESOUR RES, V36, P1221, DOI 10.1029/1999WR900354
   COATS KH, 1964, SOC PETROL ENG J, V4, P73, DOI 10.2118/647-PA
   Degueldre C, 1996, EARTH PLANET SC LETT, V140, P213, DOI 10.1016/0012-821X(96)00043-X
   Dentz M, 2011, J CONTAM HYDROL, V120-21, P1, DOI 10.1016/j.jconhyd.2010.05.002
   DULLIEN F, 1992, POROUS MEDIA
   Ferno MA, 2015, WATER RESOUR RES, V51, P7811, DOI 10.1002/2015WR017130
   Ferno MA, 2015, GEOPHYS RES LETT, V42, P7414, DOI 10.1002/2015GL065100
   Fogler HS, 1999, ELEMENTS CHEM REACTI
   GIST GA, 1990, PHYS FLUIDS A-FLUID, V2, P1533, DOI 10.1063/1.857602
   Gjetvaj F, 2015, WATER RESOUR RES, V51, P8273, DOI 10.1002/2015WR017645
   Goethals P, 2009, ENG GEOL, V103, P134, DOI 10.1016/j.enggeo.2008.06.015
   Gouze P, 2008, WATER RESOUR RES, V44, DOI 10.1029/2007WR006278
   Gruendig M, 2007, APPL GEOCHEM, V22, P2334, DOI 10.1016/j.apgeochem.2007.04.024
   HAGGERTY R, 1995, WATER RESOUR RES, V31, P2383, DOI 10.1029/95WR10583
   Hejazi SAH, 2017, IND ENG CHEM RES, V56, P5679, DOI 10.1021/acs.iecr.7b00219
   Honari A, 2016, INT J GREENH GAS CON, V50, P100, DOI 10.1016/j.ijggc.2016.04.004
   Honari A, 2015, INT J GREENH GAS CON, V39, P39, DOI 10.1016/j.ijggc.2015.04.014
   HUDSON HM, 1994, IEEE T MED IMAGING, V13, P601, DOI 10.1109/42.363108
   HULIN JP, 1989, PHYS FLUIDS A-FLUID, V1, P1341, DOI 10.1063/1.857309
   Ilankoon IMSK, 2013, CHEM ENG SCI, V89, P152, DOI 10.1016/j.ces.2012.11.013
   KITANIDIS PK, 1994, WATER RESOUR RES, V30, P2011, DOI 10.1029/94WR00762
   Krause M, 2011, SPE J, V16, P768, DOI 10.2118/126340-PA
   Kulenkampff' J, 2008, PHYS CHEM EARTH, V33, P937, DOI 10.1016/j.pce.2008.05.005
   Kulenkampff J, 2015, CLAY MINER, V50, P369, DOI 10.1180/claymin.2015.050.3.09
   Le Borgne T, 2015, J FLUID MECH, V770, P458, DOI 10.1017/jfm.2015.117
   Le Borgne T, 2010, ADV WATER RESOUR, V33, P1468, DOI 10.1016/j.advwatres.2010.08.006
   Levin CS, 1999, PHYS MED BIOL, V44, P781, DOI 10.1088/0031-9155/44/3/019
   Lippmann-Pipke J, 2017, COMPUT GEOSCI-UK, V101, P21, DOI 10.1016/j.cageo.2017.01.002
   Menke HP, 2015, ENVIRON SCI TECHNOL, V49, P4407, DOI 10.1021/es505789f
   Moses WW, 2011, NUCL INSTRUM METH A, V648, pS236, DOI 10.1016/j.nima.2010.11.092
   MURPHY WF, 1984, GEOPHYS RES LETT, V11, P697, DOI 10.1029/GL011i008p00697
   Neuman SP, 2009, ADV WATER RESOUR, V32, P670, DOI 10.1016/j.advwatres.2008.08.005
   Ogilvie SR, 2001, GEOPHYS RES LETT, V28, P61, DOI 10.1029/2000GL008507
   PERKINS TK, 1963, SOC PETROL ENG J, V3, P70, DOI 10.2118/480-PA
   Perrin JC, 2010, TRANSPORT POROUS MED, V82, P93, DOI 10.1007/s11242-009-9426-x
   Pini R., 2019, SCI CARBON STORAGE D, P350
   Pini R, 2016, J FLUID MECH, V796, DOI 10.1017/jfm.2016.262
   Pini R, 2016, J POROUS MAT, V23, P325, DOI 10.1007/s10934-015-0085-8
   Pini R, 2013, GEOPHYS RES LETT, V40, P3903, DOI 10.1002/grl.50756
   Rajagopalan AK, 2016, INT J GREENH GAS CON, V46, P76, DOI 10.1016/j.ijggc.2015.12.033
   Ringrose PS, 1993, J PETROL SCI ENG, V9, P103, DOI 10.1016/0920-4105(93)90071-L
   SAFFMAN PG, 1959, J FLUID MECH, V6, P321, DOI 10.1017/S0022112059000672
   SAHIMI M, 1986, CHEM ENG SCI, V41, P2103, DOI 10.1016/0009-2509(86)87128-7
   SALLES J, 1993, PHYS FLUIDS A-FLUID, V5, P2348, DOI 10.1063/1.858751
   Shafer J, 2013, PETROPHYSICS, V54, P554
   Steefel CI, 2009, REV MINERAL GEOCHEM, V70, P485, DOI 10.2138/rmg.2009.70.11
   Vogler D, 2018, ADV WATER RESOUR, V114, P149, DOI 10.1016/j.advwatres.2018.02.009
   WAKAO N, 1978, CHEM ENG SCI, V33, P1375, DOI 10.1016/0009-2509(78)85120-3
   WALSH MP, 1994, J CAN PETROL TECHNOL, V33, P36
   YELLIG WF, 1981, J CAN PETROL TECHNOL, V20, P69
   Zahasky C, 2018, ADV WATER RESOUR, V115, P1, DOI 10.1016/j.advwatres.2018.03.002
NR 63
TC 4
Z9 4
U1 4
U2 25
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAR 16
PY 2019
VL 196
BP 366
EP 383
DI 10.1016/j.ces.2018.11.001
PG 18
WC Engineering, Chemical
SC Engineering
GA HI9RQ
UT WOS:000456795700029
DA 2020-05-12
ER

PT J
AU Yablonsky, GS
   Branco, PD
   Marin, GB
   Constales, D
AF Yablonsky, Gregory S.
   Branco, P. Daniel
   Marin, Guy B.
   Constales, Denis
TI Conservatively Perturbed Equilibrium (CPE) in chemical kinetics
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Conservatively Perturbed Equilibrium; Relaxation; Transient behavior;
   Extreme value; Momentary partial equilibrium; Chemical equilibrium
ID COINCIDENCES; INTERSECTIONS; SYSTEMS; EVENTS
AB The phenomenon of "Conservatively Perturbed Equilibrium" (CPE) in chemical kinetics is distinguished using a sequence of first-order reactions (linear mechanism) and non-linear mechanisms as well. In this phenomenon, some, not all initial concentrations of the closed chemical system are replaced by the corresponding equilibrium concentrations at the same total amount of each chemical element.
   Properties of CPE-phenomenon are described:
   1. For the substance which initial concentration is taken as the equilibrium one, the concentration extremum in a way to the equilibrium is unavoidable.
   2. This extremum can be a momentary partial equilibrium for some steps of the chemical mechanism.
   3. Time of occurrence of this extremum is independent of the perturbation.
   Properties 1 and 2 are general properties. Property 3 is specific for the linear mechanism studied. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Yablonsky, Gregory S.] Washington Univ, Dept Energy Environm & Chem Engn, St Louis, MO 63130 USA.
   [Branco, P. Daniel; Constales, Denis] Univ Ghent, Dept Math Anal, Bldg S-8,Krijgslaan 281, B-9000 Ghent, Belgium.
   [Marin, Guy B.] Univ Ghent, Lab Chem Technol, Technol Pk 914, B-9052 Ghent, Belgium.
RP Yablonsky, GS (reprint author), Washington Univ, Dept Energy Environm & Chem Engn, St Louis, MO 63130 USA.
EM gy@wustl.edu; Daniel.BrancoPinto@UGent.be; Guy.Marin@UGent.be;
   Denis.Constales@UGent.be
CR ARIS R, 1968, ARCH RATION MECH AN, V27, P356
   Aris Rutherford, 1965, ARCH RATIONAL MECH A, V19, P81, DOI DOI 10.1007/BF00282276
   Branco PD, 2017, CHEM ENG SCI, V158, P370, DOI 10.1016/j.ces.2016.10.032
   Branco PD, 2018, CHEM ENG SCI, V184, P25, DOI 10.1016/j.ces.2018.02.020
   Branco RD, 2019, COMPUT CHEM ENG, V125, P606, DOI 10.1016/j.compchemeng.2016.06.022
   Constales D, 2013, COMPUT MATH APPL, V65, P1614, DOI 10.1016/j.camwa.2012.11.005
   Constales D., 2018, ADV DATA ANAL MODELL
   Gorban AN, 2013, PHYSICA A, V392, P1318, DOI 10.1016/j.physa.2012.10.009
   Gorban AN, 2011, CHEM ENG SCI, V66, P5388, DOI 10.1016/j.ces.2011.07.054
   GORBANY AN, 1980, REACT KINET CATAL L, V15, P315
   HORN F, 1972, ARCH RATION MECH AN, V47, P81
   Peng BX, 2018, CHEM ENG SCI, V191, P262, DOI 10.1016/j.ces.2018.06.065
   Pinto DB, 2015, ENTROPY-SWITZ, V17, P6783, DOI 10.3390/e17106783
   Rodriguez-Padial N, 2017, COMPLEXITY, DOI 10.1155/2017/3759514
   Rudin W., 2013, PRINCIPLES MATH ANAL, P342
   SHAPIRO NZ, 1965, J SOC IND APPL MATH, V13, P353, DOI 10.1137/0113020
   Vol'pert A. I., 1972, MATH USSR SB, V17, P571, DOI DOI 10.1070/SM1972V017N04ABEH001603
   Vol'pert AI, 1985, ANAL CLASSES DISCONT
   Yablonskii G. S., 1991, COMPREHENSIVE CHEM K, P396
   Yablonsky GS, 2011, EPL-EUROPHYS LETT, V93, DOI 10.1209/0295-5075/93/20004
   Yablonsky GS, 2011, CHEM ENG SCI, V66, P111, DOI 10.1016/j.ces.2010.10.014
   Yablonsky GS, 2010, CHEM ENG SCI, V65, P6065, DOI 10.1016/j.ces.2010.04.007
   Zeldovich Y. B., 2014, SELECTED WORKS YB ZE, P144
NR 23
TC 4
Z9 4
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAR 16
PY 2019
VL 196
BP 384
EP 390
DI 10.1016/j.ces.2018.11.010
PG 7
WC Engineering, Chemical
SC Engineering
GA HI9RQ
UT WOS:000456795700030
DA 2020-05-12
ER

PT J
AU Li, GD
   Deng, SS
   Guan, JF
   Yao, S
AF Li, Guo-Dong
   Deng, Song-Sheng
   Guan, Jin-Fa
   Yao, Su
TI Numerical analysis on cavitation effects in submerged water jet added
   with turbulent drag-reducing additives of CTAC
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Cavitation; Viscosity; Surface tension; Bubble collapse; Simulation
ID SPHERICAL BUBBLE; SIMULATION; DYNAMICS; EROSION; MOTION; MODELS
AB In this paper the cavitation phenomenon and bubble collapse in submerged water jet added with CTAC were studied. The cavitation simulation was based on an improved cavitation model established by introducing coefficients into traditional cavitation model. The coefficients were obtained by fitting the numerical solutions of Rayleigh-Plesset equation in which the viscosity term and surface tension term were not neglected. Cross model was also employed to express the shear-thinning character of the surfactant solution. Simulation results show that the whole cavitation intensity decreased but the scale of cavitation region increased in drag-reducer solution. The submerged water jet added with drag-reducer was less dispersed and the stagnation pressure near the wall was significantly improved. Simulation results of the bubble collapse process show that the bubble collapsed more slowly in drag-reducer solution in comparison with that in pure water. The two pressure peaks near the wall during the collapse process appeared later in drag-reducer solution and the maximum value of the pressure generated in drag-reducer solution was less than that in pure water. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Li, Guo-Dong; Deng, Song-Sheng; Guan, Jin-Fa; Yao, Su] Army Logist Univ PLA, Dept Fuels, Chongqing 401331, Peoples R China.
RP Li, GD (reprint author), Army Logist Univ PLA, Dept Fuels, Chongqing 401331, Peoples R China.
EM lgd341@163.com
FU Basic Science and Advanced Technology Research Special Fund of
   Chongqing, China [cstc2017jcjAX0166]
FX This work is supported by the Basic Science and Advanced Technology
   Research Special Fund of Chongqing, China (cstc2017jcjAX0166).
CR Albernaz DL, 2013, APPL MATH MODEL, V37, P8972, DOI 10.1016/j.apm.2013.03.065
   Annoni M., 2009, INT J MACH MACH MAT, V6
   Asnaghi A, 2017, INT J MULTIPHAS FLOW, V93, P142, DOI 10.1016/j.ijmultiphaseflow.2017.04.005
   Brennen C. E., 1995, CAVITATION BUBBLE DY, V33, P609
   Brujan EA, 1996, ACUSTICA, V82, P423
   Choi JK, 2003, COMPUT MECH, V32, P281, DOI 10.1007/s00466-003-0485-5
   Congedo PM, 2015, EUR J MECH B-FLUID, V53, P190, DOI 10.1016/j.euromechflu.2015.05.005
   Ellis A. T., 1968, SOME EFFECTS MACROMO, P2
   Hosangadi A, 2005, FLUID ENG D, P623
   Howells W. G., 1999, P 10 AM WAT LET C 14
   Jiang C. X., 2015, STUDY MECH SUPERCAVI
   Jiang CX, 2016, APPL THERM ENG, V107, P797, DOI 10.1016/j.applthermaleng.2016.07.040
   Johnsen E, 2009, J FLUID MECH, V629, P231, DOI 10.1017/S0022112009006351
   Klaseboer E, 2005, J FLUID MECH, V537, P387, DOI 10.1017/S0022112005005306
   Koch M, 2016, COMPUT FLUIDS, V126, P71, DOI 10.1016/j.compfluid.2015.11.008
   KUDIN AM, 1973, NATURE-PHYS SCI, V245, P95, DOI 10.1038/physci245095a0
   [李凤臣 Li Fengchen], 2010, [工程热物理学报, Journal of Engineering Thermophysics], V31, P857
   Madadnia J, 2008, ADV MATER RES-SWITZ, V53-54, P357, DOI 10.4028/www.scientific.net/AMR.53-54.357
   MADADNIA J, 1995, INT J MULTIPHAS FLOW, V21, P1253, DOI 10.1016/0301-9322(95)00031-R
   Malvar S, 2016, LAT AM J SOLIDS STRU, V13, P2464, DOI 10.1590/1679-78252923
   Morgut M, 2011, INT J MULTIPHAS FLOW, V37, P620, DOI 10.1016/j.ijmultiphaseflow.2011.03.005
   Osterman A., 2009, J FLUID SCI TECH, V4, P210, DOI DOI 10.1299/JFST.4.210
   Peng GY, 2016, J HYDRODYN, V28, P986, DOI 10.1016/S1001-6058(16)60700-X
   Peng GY, 2013, J HYDRODYN, V25, P502, DOI 10.1016/S1001-6058(11)60389-3
   Philipp A, 1998, J FLUID MECH, V361, P75, DOI 10.1017/S0022112098008738
   Qin Z, 2007, J FLUID MECH, V573, P1, DOI 10.1017/S002211200600351X
   Radvanska A, 2009, STROJARSTVO, V51, P347
   Samiei E., 2010, ASME ESDA, P501
   Schnerr G.H., 2001, 4 INT C MULT FLOW NE
   Shimizu S., 1993, NIPPON KIKAI GAKKAI, V59, P2964
   Singhal AK, 2002, J FLUID ENG-T ASME, V124, P617, DOI 10.1115/1.1486223
   TAN RBH, 1986, CHEM ENG SCI, V41, P3175, DOI 10.1016/0009-2509(86)85054-0
   Wang QX, 2010, J FLUID MECH, V659, P191, DOI 10.1017/S0022112010002430
   Wang R.-H., 1998, J CHINA U PET, V22, P38
   Yang Y.-Y., 2001, PET DRILL TECHNOL, V29, P4
   Zakin J. L., 1976, EFFECT VISCOELASTIC
   Zhang Youyi, 2014, Journal of Sichuan University (Engineering Science Edition), V46, P181
   Zhu H, 2016, APPL OCEAN RES, V58, P118, DOI 10.1016/j.apor.2016.03.017
   Zwart P. J., 2004, 5 INT C MULT FLOW YO
NR 39
TC 0
Z9 0
U1 1
U2 18
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAR 16
PY 2019
VL 196
BP 391
EP 401
DI 10.1016/j.ces.2018.11.025
PG 11
WC Engineering, Chemical
SC Engineering
GA HI9RQ
UT WOS:000456795700031
DA 2020-05-12
ER

PT J
AU Yu, HB
   Tang, WQ
   Li, KJ
   Yin, HF
   Zhao, SL
   Zhou, SH
AF Yu, Hongbo
   Tang, Weiqiang
   Li, Kaijie
   Yin, Hongfeng
   Zhao, Shuangliang
   Zhou, Shenghu
TI Design of Cu-based intermetallic nanocrystals for enhancing
   hydrogenation selectivity
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Intermetallic compounds; Bimetallic; Selective hydrogenation;
   Nitroaromatics; Nanocatalysis
ID RAY PHOTOELECTRON-SPECTROSCOPY; TEMPERATURE SOLUTION SYNTHESIS;
   EFFICIENT CATALYTIC-SYSTEM; PREFERENTIAL OXIDATION; ALLOY NANOPARTICLES;
   CO; REDUCTION; AU; NI; COMPOUND
AB Motivated by the high performance of intermetallic compounds with their ordered structures, developing synthetic methods for preparing intermetallic compounds is highly desired. Herein, we report facile syntheses and rational design of the structurally ordered Cu-based intermetallic compounds (CuM (M = Pt, Pd, Au)). To achieve this, intermetallic nanoparticles were synthesized in solution by a butyllithium co-reduction method at 240 degrees C. The developed wet-chemistry syntheses of ordered intermetallic CuM nanoparticles avoided solid annealing process, and thus relatively small intermetallic nanocrystals were formed. The ordered PtCu nanocatalysts displayed enhanced chemoselectivity relative to the PtCu solid-solution alloy and individual monometallic nanocatalysts for catalytic hydrogenations of a series of substituted nitroaromatics. The DFT-based theoretical calculations for hydrogenations of halonitrobenzenes suggest that the surface geometry of ordered PtCu structures favor the hydrogenation of nitro substituent and disfavor the hydrodechlorination by-reaction, resulting in enhanced chemoselectivity. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Yu, Hongbo; Tang, Weiqiang; Li, Kaijie; Zhao, Shuangliang; Zhou, Shenghu] East China Univ Sci & Technol, State Key Lab Chem Engn, 130 Meilong Rd, Shanghai 200237, Peoples R China.
   [Yu, Hongbo; Tang, Weiqiang; Li, Kaijie; Zhao, Shuangliang; Zhou, Shenghu] East China Univ Sci & Technol, Shanghai Key Lab Multiphase Mat Chem Engn, 130 Meilong Rd, Shanghai 200237, Peoples R China.
   [Yin, Hongfeng] Chinese Acad Sci, Ningbo Inst Mat Technol & Engn, 1219 Zhongguan West Rd, Ningbo 315201, Zhejiang, Peoples R China.
RP Zhao, SL; Zhou, SH (reprint author), East China Univ Sci & Technol, State Key Lab Chem Engn, 130 Meilong Rd, Shanghai 200237, Peoples R China.; Zhao, SL; Zhou, SH (reprint author), East China Univ Sci & Technol, Shanghai Key Lab Multiphase Mat Chem Engn, 130 Meilong Rd, Shanghai 200237, Peoples R China.
EM szhao@ecust.edu.cn; zhoushenghu@ecust.edu.cn
RI Yin, Hong/AAC-5784-2020; Tang, Weiqiang/J-9007-2019; Zhao,
   Shuangliang/B-6139-2017
OI Tang, Weiqiang/0000-0002-7726-4130; Zhao,
   Shuangliang/0000-0002-9547-4860
FU Ningbo Municipal Science and Technology Innovative Research Team
   [2014B81004, 2016B10005]; National Natural Science Foundation of
   ChinaNational Natural Science Foundation of China [21776090, 21571183,
   U1707602]; Fok Ying Tong Education FoundationFok Ying Tung Education
   Foundation [151069]; China Scholarship CouncilChina Scholarship Council;
   British Council
FX S. Zhou and H. Yin thank programs of Ningbo Municipal Science and
   Technology Innovative Research Team (Grant No. 2014B81004 and
   2016B10005). This work is also supported by the National Natural Science
   Foundation of China (Grant No. 21776090, 21571183 and U1707602). S. Zhao
   acknowledges the support of Fok Ying Tong Education Foundation (151069)
   and W. Tang is grateful to the China Scholarship Council and British
   Council for the visiting fellowship.
CR Armbruster M, 2014, SCI TECHNOL ADV MAT, V15, DOI 10.1088/1468-6996/15/3/034803
   BERTOTI I, 1992, SURF INTERFACE ANAL, V19, P453, DOI 10.1002/sia.740190185
   Biesinger MC, 2010, APPL SURF SCI, V257, P887, DOI 10.1016/j.apsusc.2010.07.086
   Cable RE, 2007, CHEM MATER, V19, P4098, DOI 10.1021/cm071214j
   Cardenas-Lizana F, 2009, CATAL LETT, V127, P25, DOI 10.1007/s10562-008-9660-9
   Cen L, 2006, J COLLOID INTERF SCI, V300, P190, DOI 10.1016/j.jcis.2006.03.055
   Chen TL, 2015, CHEM ENG J, V259, P161, DOI 10.1016/j.cej.2014.07.054
   Chen X, 2015, CHEMCATCHEM, V7, P978, DOI 10.1002/cctc.201402957
   Christensen GL, 2013, J PHYS CHEM C, V117, P7039, DOI 10.1021/jp310344r
   Chusuei CC, 1999, LANGMUIR, V15, P2806, DOI 10.1021/la9815446
   Corma A, 2008, J AM CHEM SOC, V130, P8748, DOI 10.1021/ja800959g
   Dosso LA, 2017, INT J HYDROGEN ENERG, V42, P18853, DOI 10.1016/j.ijhydene.2017.06.100
   Friedrich M, 2012, J PHYS CHEM C, V116, P14930, DOI 10.1021/jp303174h
   Furukawa S, 2016, ACS CATAL, V6, P5946, DOI 10.1021/acscatal.6b01677
   Furukawa S, 2016, ACS CATAL, V6, P2121, DOI 10.1021/acscatal.5b02953
   Furukawa S, 2015, CHEMCATCHEM, V7, P3472, DOI 10.1002/cctc.201500808
   Furukawa S, 2014, ACS CATAL, V4, P3533, DOI 10.1021/cs500920p
   Furukawa S, 2014, ACS CATAL, V4, P3581, DOI 10.1021/cs500947d
   Furukawa S, 2014, CHEM COMMUN, V50, P3277, DOI 10.1039/c4cc00024b
   Furukawa S, 2013, RSC ADV, V3, P23269, DOI 10.1039/c3ra43163k
   Garcia-Trenco A, 2017, ACS CATAL, V7, P1186, DOI 10.1021/acscatal.6b02928
   GHIJSEN J, 1988, PHYS REV B, V38, P11322, DOI 10.1103/PhysRevB.38.11322
   Ghodselahi T, 2008, APPL SURF SCI, V255, P2730, DOI 10.1016/j.apsusc.2008.08.110
   Golassa L., 2011, J PHYS SOC JPN, V80
   Grim RJ, 1942, J PHYS CHEM-US, V46, P464, DOI 10.1021/j150418a003
   Iihama S, 2016, ACS CATAL, V6, P742, DOI 10.1021/acscatal.5b02464
   Komatsu T, 2008, J CATAL, V258, P306, DOI 10.1016/j.jcat.2008.06.030
   Komatsu T, 2013, J PHYS CHEM C, V117, P10483, DOI 10.1021/jp4007729
   Krajci M, 2012, J PHYS CHEM C, V116, P6307, DOI 10.1021/jp212317u
   Krajci M, 2016, CHEMCATCHEM, V8, P34, DOI 10.1002/cctc.201500733
   Kruse N, 2011, APPL CATAL A-GEN, V391, P367, DOI 10.1016/j.apcata.2010.05.039
   Kuttiyiel KA, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6185
   Li H, 2011, J MATER CHEM, V21, P18447, DOI 10.1039/c1jm11461a
   Lin MC, 2015, SMALL, V11, P6065, DOI 10.1002/smll.201501871
   Liu MM, 2017, ACS CATAL, V7, P1583, DOI 10.1021/acscatal.6b03109
   Lu P, 2000, B CHEM SOC JPN, V73, P751, DOI 10.1246/bcsj.73.751
   Marakatti VS, 2018, ACS SUSTAIN CHEM ENG, V6, P7325, DOI 10.1021/acssuschemeng.7b04586
   Marakatti VS, 2017, ACS APPL MATER INTER, V9, P3602, DOI 10.1021/acsami.6b12253
   Marakatti VS, 2016, NEW J CHEM, V40, P5448, DOI 10.1039/c5nj03479e
   Nikolaev SA, 2015, APPL CATAL B-ENVIRON, V168, P303, DOI 10.1016/j.apcatb.2014.12.030
   Onda A, 2000, PHYS CHEM CHEM PHYS, V2, P2999, DOI 10.1039/b001381l
   Opalka SM, 2007, J ALLOY COMPD, V446, P583, DOI 10.1016/j.jallcom.2007.01.130
   Ota A., 2011, J PHYS CHEM C, V20, P35
   Ota A, 2011, J PHYS CHEM C, V115, P1368, DOI 10.1021/jp109226r
   Pei GX, 2015, ACS CATAL, V5, P3717, DOI 10.1021/acscatal.5b00700
   Saravanan G, 2016, RSC ADV, V6, P85634, DOI 10.1039/c6ra19602k
   Sarkar A, 2010, J PHYS CHEM C, V114, P4725, DOI 10.1021/jp908933r
   Sarkar S, 2014, J CATAL, V318, P143, DOI 10.1016/j.jcat.2014.07.018
   Schaak RE, 2005, J AM CHEM SOC, V127, P3506, DOI 10.1021/ja043335f
   Serna P, 2015, ACS CATAL, V5, P7114, DOI 10.1021/acscatal.5b01846
   Serna P, 2009, J CATAL, V265, P19, DOI 10.1016/j.jcat.2009.04.004
   Shen K, 2015, ACS CATAL, V5, P5264, DOI 10.1021/acscatal.5b00998
   SHYU JZ, 1989, J CATAL, V115, P16, DOI 10.1016/0021-9517(89)90003-1
   Sra AK, 2004, J AM CHEM SOC, V126, P6667, DOI 10.1021/ja031547r
   Tsai AP, 2004, J PHYS SOC JPN, V73, P3270, DOI 10.1143/JPSJ.73.3270
   Vasquez Y, 2008, J AM CHEM SOC, V130, P11866, DOI 10.1021/ja804858u
   Wang CY, 2016, ACS NANO, V10, P6345, DOI 10.1021/acsnano.6b02669
   Wang DL, 2013, NAT MATER, V12, P81, DOI [10.1038/nmat3458, 10.1038/NMAT3458]
   Wang XD, 2013, J PHYS CHEM C, V117, P7294, DOI 10.1021/jp309548v
   Wei HS, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6634
   Wu CK, 2006, CHEM MATER, V18, P6054, DOI 10.1021/cm061596d
   Zhan WC, 2017, J AM CHEM SOC, V139, P8846, DOI 10.1021/jacs.7b01784
   Zhang B, 2016, ACS CATAL, V6, P6560, DOI 10.1021/acscatal.6b01756
   Zhang JM, 2014, NANOSCALE, V6, P2125, DOI 10.1039/c3nr04715f
   Zhang L, 2014, ACS CATAL, V4, P1546, DOI 10.1021/cs500071c
   Zhang PP, 2015, ACS CATAL, V5, P1335, DOI 10.1021/cs501612g
   Zhou SH, 2007, ADV FUNCT MATER, V17, P3099, DOI 10.1002/adfm.200700216
NR 67
TC 2
Z9 2
U1 18
U2 82
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAR 16
PY 2019
VL 196
BP 402
EP 413
DI 10.1016/j.ces.2018.11.024
PG 12
WC Engineering, Chemical
SC Engineering
GA HI9RQ
UT WOS:000456795700032
DA 2020-05-12
ER

PT J
AU Villanueva-Chavez, JG
   Bizzo, WA
AF Villanueva-Chavez, Juan Grimaldo
   Bizzo, Waldir Antonio
TI Fluid dynamic modeling of a large bubbling fluidized bed for biomass
   combustion: Mass transfer in bubbles
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Mathematical model; Fluid dynamics; Bubbling fluidized bed; Combustion;
   Biomass
ID PARTICLE; HYDRODYNAMICS
AB A one-dimensional mathematical model of the fluid dynamics and combustion process in a bubbling fluidized bed was developed. In the bubble phase, the model includes the throughflow and bypass flow, which crosses the bed without taking part in combustion because of the preferential bubble paths expected in large fluidized-bed systems. Unlike in the classic approach, the emulsion phase was considered not to remain under minimum fluidization conditions, and the influence of downward particles was considered. A correction factor for the equation of the mass transfer coefficient previously described by other authors was therefore proposed to take into account the bypass flow expected in large systems. The main results provided by the model are the velocities and volumetric flows of the gases in the bed (emulsion, visible bubble and throughflow gases), the mass transfer between bed phases and the oxygen profile in the bed. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Villanueva-Chavez, Juan Grimaldo; Bizzo, Waldir Antonio] Univ Campinas UNICAMP, Sch Mech Engn, Cidade Univ Zeferino Vaz, BR-13083860 Campinas, SP, Brazil.
RP Bizzo, WA (reprint author), Univ Campinas UNICAMP, Sch Mech Engn, Cidade Univ Zeferino Vaz, BR-13083860 Campinas, SP, Brazil.
EM bizzo@fem.unicamp.br
RI Bizzo, Waldir A./H-2740-2013
OI Bizzo, Waldir A./0000-0003-1505-4266
CR Cano G, 2007, FUEL PROCESS TECHNOL, V88, P577, DOI 10.1016/j.fuproc.2007.01.008
   CHAVARIE C, 1976, CHEM ENG SCI, V31, P741, DOI 10.1016/0009-2509(76)80046-2
   Clift R., 1985, FLUIDIZATION, P73
   Croxford AJ, 2011, CHEM ENG SCI, V66, P3569, DOI 10.1016/j.ces.2011.04.013
   Darton R., 1979, CHEM ENG RES DES, V57, P134
   Davidson J. F., 1985, FLUIDIZATION
   DELVOSALLE C, 1985, CHEM ENG SCI, V40, P769, DOI 10.1016/0009-2509(85)85030-2
   FITZGERALD T, 1984, POWDER TECHNOL, V38, P107, DOI 10.1016/0032-5910(84)80040-6
   GERA D, 1995, POWDER TECHNOL, V83, P49, DOI 10.1016/0032-5910(94)02924-D
   GLICKSMAN LR, 1987, CHEM ENG SCI, V42, P479, DOI 10.1016/0009-2509(87)80010-6
   GLICKSMAN LR, 1985, POWDER TECHNOL, V42, P159, DOI 10.1016/0032-5910(85)80049-8
   Hernandez-Jimenez F, 2013, CHEM ENG J, V215, P479, DOI 10.1016/j.cej.2012.10.056
   Hilligardt K., 1987, CHEM ENG TECHNOL, V10, P272
   Jakobsen HA, 2008, CHEM REACTOR MODELLI
   Oka S.N., 2004, FLUIDIZED BED COMBUS
   Olsson J., 2010, 13 INT C FLUID NEW P, P1
   Pallares D., 2007, 12 INT C FLUID VANC, P929
   Patankar S.V., 1980, NUMERICAL HEAT TRANS
   Sane SU, 1996, CHEM ENG SCI, V51, P1133, DOI 10.1016/0009-2509(95)00359-2
   Scala F, 2002, CHEM ENG SCI, V57, P1175, DOI 10.1016/S0009-2509(02)00004-0
   Shen LH, 2004, CHEM ENG SCI, V59, P2607, DOI 10.1016/j.ces.2004.01.063
   SIT SP, 1981, CHEM ENG SCI, V36, P327, DOI 10.1016/0009-2509(81)85012-9
   VALENZUELA JA, 1985, POWDER TECHNOL, V44, P103, DOI 10.1016/0032-5910(85)87016-9
   Vepsalainen A, 2014, CHEM ENG SCI, V106, P30, DOI 10.1016/j.ces.2013.11.042
   WERTHER J, 1977, INT J MULTIPHASE FLO, V3, P367
NR 25
TC 1
Z9 1
U1 1
U2 6
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAR 16
PY 2019
VL 196
BP 414
EP 424
DI 10.1016/j.ces.2018.11.023
PG 11
WC Engineering, Chemical
SC Engineering
GA HI9RQ
UT WOS:000456795700033
DA 2020-05-12
ER

PT J
AU Shoji, E
   Yamagiwa, K
   Kubo, M
   Tsukada, T
   Takami, S
   Sugimoto, K
   Ito, D
   Saito, Y
   Teratani, S
AF Shoji, Eita
   Yamagiwa, Koshiro
   Kubo, Masaki
   Tsukada, Takao
   Takami, Seiichi
   Sugimoto, Katsumi
   Ito, Daisuke
   Saito, Yasushi
   Teratani, Shogo
TI Flow visualization of heavy oil in a packed bed using real-time neutron
   radiography
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Neutron radiography; Heavy oil; Flow visualization; Packed bed
ID LIQUID 2-PHASE FLOW; TRICKLE-BED; SUPERCRITICAL-WATER;
   NUMERICAL-SIMULATION; POROUS-MEDIA; MIXING BEHAVIOR; RAY TOMOGRAPHY;
   FLUID-FLOW; REACTOR; GAS
AB Neutron radiography can visualize heavy oil flows in metallic reactors used to upgrade heavy oils. Thus, we visualized heavy oil flows in a packed bed using real-time neutron radiography to support its capability and to offer basic experimental data necessary for verification and validation of numerical simulations. Atmospheric residue was used as the heavy oil sample and heavy oil and N-2 gas were concurrently supplied into a packed bed from above a reactor simulating a trickle bed reactor. Reactor temperatures were set at either 100 degrees C or 250 degrees C to change heavy oil viscosity. The heavy oil flow rate was kept constant at 2.5 mL/min and the N-2 gas flow rate was set at either 1 L/min or 3 L/min at 25 degrees C. A series of neutron radiography experiments was conducted at the B-4 neutron imaging facility in the Kyoto University Research Reactor (KUR) with a thermal neutron flux of 5 x 10(7) n/cm(2).s. We performed image processing for the neutron radiographs to calculate neutron beam attenuation and clarify flow behavior. Visualization results show differences in flow behavior depending on operating factors. Temperature had a particularly substantial effect on flow behavior because heavy oil viscosity depends strongly on temperature. The flows also showed different behaviors for 1 mm and 3 mm packed particle sizes because the void ratios in the packed bed, which were preliminarily observed by X-ray computational tomography (CT), change with particle size. Channeling flow was observed with 3 mm particles and a temperature of 250 degrees C. Furthermore, this work suggests that neutron radiography can be used to investigate heavy oil flows in metallic reactors. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Shoji, Eita; Yamagiwa, Koshiro; Kubo, Masaki; Tsukada, Takao] Tohoku Univ, Dept Chem Engn, Aoba Ku, 6-6-07 Aramaki Aza Aoba, Sendai, Miyagi 9808579, Japan.
   [Takami, Seiichi] Nagoya Univ, Dept Mat Proc Engn, Chikusa Ku, Furo Cho, Nagoya, Aichi 4648603, Japan.
   [Sugimoto, Katsumi] Kobe Univ, Dept Mech Engn, Nada Ku, 1-1 Rokkodai, Kobe, Hyogo 6578501, Japan.
   [Ito, Daisuke; Saito, Yasushi] Kyoto Univ, Inst Integrated Radiat & Nucl Sci, 2-1010 Asashironishi, Kumatori, Sennan 5900494, Japan.
   [Teratani, Shogo] Japan Petr Energy Ctr, Adv Technol & Res Inst, Midori Ku, 1-4-10 Ohnodai, Chiba 2670056, Japan.
RP Shoji, E (reprint author), 6-6-07 Arama Aza Aoba,Aoba Ku, Sendai, Miyagi 9808579, Japan.
EM eita.shoji@tohoku.ac.jp
OI Kubo, Masaki/0000-0002-2182-1508; Shoji, Eita/0000-0003-3846-2633
FU Ministry of Economy, Trade and Industry (METI); Japan Petroleum Energy
   Center (JPEC)
FX This research was supported by Ministry of Economy, Trade and Industry
   (METI) and Japan Petroleum Energy Center (JPEC).
CR Abivin P, 2012, ENERG FUEL, V26, P3448, DOI 10.1021/ef300065h
   Balasko M, 2009, NUCL INSTRUM METH A, V605, P138, DOI 10.1016/j.nima.2009.01.226
   Basavaraj MG, 2005, AICHE J, V51, P2178, DOI 10.1002/aic.10481
   Basavaraj MG, 2004, ISIJ INT, V44, P50, DOI 10.2355/isijinternational.44.50
   Basden M, 2013, IND ENG CHEM RES, V52, P17263, DOI 10.1021/ie402574x
   Boyer C, 2005, CHEM ENG SCI, V60, P6279, DOI 10.1016/j.ces.2005.03.049
   Boyer C, 2002, CHEM ENG SCI, V57, P1079, DOI 10.1016/S0009-2509(01)00361-X
   Deinert MR, 2004, J HYDROL, V290, P192, DOI 10.1016/j.jhydrol.2003.11.018
   DOMANUS JC, 1992, PRACTICAL NEUTRON RA
   Du W, 2017, CHEM ENG SCI, V170, P378, DOI 10.1016/j.ces.2017.02.033
   Finn JR, 2017, CHEM ENG SCI, V172, P722, DOI 10.1016/j.ces.2017.07.022
   Gladden LF, 2003, CATAL TODAY, V79, P203, DOI 10.1016/S0920-5861(03)00006-3
   Guo XY, 2010, PARTICUOLOGY, V8, P293, DOI 10.1016/j.partic.2009.10.005
   Gupta GS, 1997, STEEL RES, V68, P434, DOI 10.1002/srin.199700579
   Harvel GD, 1996, NUCL INSTRUM METH A, V371, P544, DOI 10.1016/0168-9002(95)00807-1
   Harvel GD, 1999, FLOW MEAS INSTRUM, V10, P259, DOI 10.1016/S0955-5986(99)00008-4
   Hassan YA, 2008, NUCL ENG DES, V238, P3080, DOI 10.1016/j.nucengdes.2008.01.027
   Heindel TJ, 2008, FLOW MEAS INSTRUM, V19, P67, DOI 10.1016/j.flowmeasinst.2007.09.003
   IEA, 2017, INT EN OUTL 2017
   Ilyin SO, 2018, ENERG FUEL, V32, P268, DOI 10.1021/acs.energyfuels.7b03058
   Ito D, 2015, PHYSCS PROC, V69, P593, DOI 10.1016/j.phpro.2015.07.084
   Jiang Y, 2002, AICHE J, V48, P701, DOI 10.1002/aic.690480406
   Jiang Y, 1999, CHEM ENG SCI, V54, P2409, DOI 10.1016/S0009-2509(98)00360-1
   Johns ML, 2000, AICHE J, V46, P2151, DOI 10.1002/aic.690461108
   Kaestner AP, 2016, SOLID EARTH, V7, P1281, DOI 10.5194/se-7-1281-2016
   Kang M, 2013, NUCL INSTRUM METH A, V708, P24, DOI 10.1016/j.nima.2012.12.112
   Kashani MN, 2016, CHEM ENG SCI, V145, P71, DOI 10.1016/j.ces.2016.02.003
   Kon T, 2015, ISIJ INT, V55, P1284, DOI 10.2355/isijinternational.55.1284
   Lopes RJG, 2008, CHEM ENG J, V145, P112, DOI 10.1016/j.cej.2008.07.053
   Lu X, 2018, CHEM ENG SCI, V189, P123, DOI 10.1016/j.ces.2018.04.074
   Mantle MD, 2001, CHEM ENG SCI, V56, P523, DOI 10.1016/S0009-2509(00)00256-6
   Meyer R.F., 2007, HEAVY OIL NATURAL BI
   Milczarek JJ, 2005, NUCL INSTRUM METH A, V542, P232, DOI 10.1016/j.nima.2005.01.105
   Mukawa Y., 2016, J JAPAN I ENERGY, V95, P1142
   Natsui S, 2015, ISIJ INT, V55, P1259, DOI 10.2355/isijinternational.55.1259
   Nguyen NL, 2005, CHEM ENG SCI, V60, P6289, DOI 10.1016/j.ces.2005.04.083
   OPEC, 2017, 2017 OPEC WORLD OIL
   PEL L, 1993, INT J HEAT MASS TRAN, V36, P1261, DOI 10.1016/S0017-9310(05)80095-X
   Perfect E, 2014, EARTH-SCI REV, V129, P120, DOI 10.1016/j.earscirev.2013.11.012
   Peterson AA, 2008, J SUPERCRIT FLUID, V43, P490, DOI 10.1016/j.supflu.2007.08.003
   Peterson AA, 2010, J SUPERCRIT FLUID, V54, P250, DOI 10.1016/j.supflu.2010.05.016
   Peterson AA, 2009, J SUPERCRIT FLUID, V49, P71, DOI 10.1016/j.supflu.2008.11.019
   Rong LW, 2014, CHEM ENG SCI, V116, P508, DOI 10.1016/j.ces.2014.05.025
   Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089
   Sederman AJ, 1997, CHEM ENG SCI, V52, P2239, DOI 10.1016/S0009-2509(97)00057-2
   Souraki Y., 2012, ENERGY ENV RES, V2, P140, DOI DOI 10.5539/eer.v2n1p140
   SPOWART AR, 1972, J PHYS E SCI INSTRUM, V5, P497, DOI 10.1088/0022-3735/5/6/001
   Strobl M, 2009, J PHYS D APPL PHYS, V42, DOI 10.1088/0022-3727/42/24/243001
   Suekane T, 2003, AICHE J, V49, P10, DOI 10.1002/aic.690490103
   Sugioka K, 2016, J SUPERCRIT FLUID, V109, P43, DOI 10.1016/j.supflu.2015.11.008
   Sugioka K, 2014, AICHE J, V60, P1168, DOI 10.1002/aic.14313
   Takami S, 2015, PHYSCS PROC, V69, P564, DOI 10.1016/j.phpro.2015.07.080
   Takami S, 2012, J SUPERCRIT FLUID, V63, P46, DOI 10.1016/j.supflu.2011.11.010
   Toukan A, 2017, CHEM ENG SCI, V168, P380, DOI 10.1016/j.ces.2017.04.028
   Toye D, 2005, MEAS SCI TECHNOL, V16, P2213, DOI 10.1088/0957-0233/16/11/012
   Tsaoir MNA, 2012, IND ENG CHEM RES, V51, P8875, DOI 10.1021/ie202023t
   tSaoir MNA, 2012, CHEM ENG J, V189, P383, DOI 10.1016/j.cej.2012.02.037
   tSaoir MNA, 2011, CHEM ENG SCI, V66, P6407, DOI 10.1016/j.ces.2011.08.049
   van der Sman RGM, 2017, CHEM ENG SCI, V158, P154, DOI 10.1016/j.ces.2016.10.008
   Xie P, 2017, CHEM ENG SCI, V172, P216, DOI 10.1016/j.ces.2017.06.040
   Yang WJ, 2010, CHEM ENG J, V156, P582, DOI 10.1016/j.cej.2009.04.013
   Yang YC, 2015, CHEM ENG SCI, V138, P244, DOI 10.1016/j.ces.2015.07.044
NR 62
TC 1
Z9 1
U1 3
U2 13
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAR 16
PY 2019
VL 196
BP 425
EP 432
DI 10.1016/j.ces.2018.11.021
PG 8
WC Engineering, Chemical
SC Engineering
GA HI9RQ
UT WOS:000456795700034
DA 2020-05-12
ER

PT J
AU Booth, CP
   Leggoe, JW
   Aman, ZM
AF Booth, Craig P.
   Leggoe, Jeremy W.
   Aman, Zachary M.
TI The use of computational fluid dynamics to predict the turbulent
   dissipation rate and droplet size in a stirred autoclave
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Computational fluid dynamics; Droplet size; Turbulence modeling; Scaling
ID TANK; FLOW; IMPELLER; MODELS
AB The prediction of droplet sizes in emulsions is important for fields ranging from the chemical process industry to emergency planning in the event of an underwater oil release. Typically scale models have needed to be built and the results scaled up, but as computational resources have grown and turbulence models have matured it has become possible to use computational fluid dynamics (CFD) to simulate the behaviour of the fluid/s. While direct simulation of multiphase breakup at high Reynolds number is currently computationally impractical, this paper looks into the use of CFD along with a correlation function based on maximum turbulent kinetic energy dissipation rate to predict the Sauter mean diameter of droplets in a 1 in. baffle-and-vane type autoclave. The results show that using a RNG-k epsilon turbulence model with a simplified 2D geometry gave droplet sizes within 26.2 mu m of the Sauter mean diameter observed in experiments with no additional tuning of parameters. Correlating pipe and autoclave flows through the Reynolds number and the turbulent kinetic energy dissipation rate was also investigated. Using the traditional definitions of the Reynolds numbers the correlation is poor, the coefficient of determination of the linear fit to the log-log data is 0.64. The first modification replaced the diameter of the blade as characteristic length with the tip swept circumference which increased the coefficient of determination to 0.960. A further modification using data obtained from the turbulent fields of the simulation showed a significant improvement with the coefficient of determination increasing to 0.988. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Booth, Craig P.; Leggoe, Jeremy W.] Univ Western Australia, Sch Mech & Chem Engn, 35 Stirling Hwy, Crawley, WA 6009, Australia.
   [Aman, Zachary M.] Univ Western Australia, Fluid Sci & Resources Div, Sch Mech & Chem Engn, 35 Stirling Hwy, Crawley, WA 6009, Australia.
RP Booth, CP (reprint author), Univ Western Australia, Sch Mech & Chem Engn, 35 Stirling Hwy, Crawley, WA 6009, Australia.
EM craig.booth@uwa.edu.au
RI Aman, Zachary/E-4433-2010
OI Aman, Zachary/0000-0003-4496-3303
FU Gulf of Mexico Research Initiative/C-IMAGE II [SA 12-10]
FX This research was made possible by a grant from The Gulf of Mexico
   Research Initiative/C-IMAGE II, No. SA 12-10. Data are publicly
   available through the Gulf of Mexico Research Initiative Information &
   Data Cooperative (GRIIDC) at https://data.gulfresearchinitiative.org
   (doi: http://dx.doi.org/10.7266/n7-s3m1-x947).
CR Aman ZM, 2015, CHEM ENG SCI, V127, P392, DOI 10.1016/j.ces.2015.01.058
   ANSYS Inc, 2015, ANSYS AC RES REL 16
   BATCHELOR GK, 1951, P CAMB PHILOS SOC, V47, P359, DOI 10.1017/S0305004100026712
   Boxall JA, 2012, LANGMUIR, V28, P104, DOI 10.1021/la202293t
   Brandvik PJ, 2013, MAR POLLUT BULL, V73, P319, DOI 10.1016/j.marpolbul.2013.05.020
   Clay P., 1940, PROC ROY NETHERLANDS, V43
   DONG L, 1994, CHEM ENG SCI, V49, P549, DOI 10.1016/0009-2509(94)80055-3
   Hartmann H, 2004, CHEM ENG SCI, V59, P2419, DOI 10.1016/j.ces.2004.01.065
   HINZE JO, 1955, AICHE J, V1, P289, DOI 10.1002/aic.690010303
   Johansen O, 2013, MAR POLLUT BULL, V73, P327, DOI 10.1016/j.marpolbul.2013.04.012
   Kato M., 1993, 9 S TURB SHEAR FLOWS, P1041
   Li P, 2016, MAR POLLUT BULL, V113, P332, DOI 10.1016/j.marpolbul.2016.10.005
   Menter F. R., 1993, AIAA PAPER, V2906, P1993, DOI DOI 10.2514/6.1993-2906
   Murthy BN, 2008, CHEM ENG SCI, V63, P5468, DOI 10.1016/j.ces.2008.06.019
   Paris CB, 2012, ENVIRON SCI TECHNOL, V46, P13293, DOI 10.1021/es303197h
   Rasband WS, 2011, IMAGEJ
   Reed M., 2000, ENV CAN ARCT MAR OIL, V23, P663
   Singh H, 2011, CHEM ENG SCI, V66, P5976, DOI 10.1016/j.ces.2011.08.018
   Wilcox D. C., 2006, TURBULENCE MODELING
   Yakhot V., 1986, Journal of Scientific Computing, V1, P3, DOI 10.1007/BF01061452
   Zhou GW, 1998, CHEM ENG SCI, V53, P2063, DOI 10.1016/S0009-2509(97)00438-7
NR 21
TC 0
Z9 0
U1 0
U2 14
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAR 16
PY 2019
VL 196
BP 433
EP 443
DI 10.1016/j.ces.2018.11.017
PG 11
WC Engineering, Chemical
SC Engineering
GA HI9RQ
UT WOS:000456795700035
DA 2020-05-12
ER

PT J
AU Perera, K
   Time, RW
   Pradeep, C
   Kumara, AS
AF Perera, Kshanthi
   Time, Rune W.
   Pradeep, Chaminda
   Kumara, Amaranath S.
TI Interfacial wave analysis of low viscous oil-water flow in upwardly
   inclined pipes
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Oil-water interfacial waves; Onset of drop formation; Wave properties;
   Image analysis
ID OIL/WATER FLOW; TRANSITION; STABILITY; INSTABILITIES; PATTERNS
AB The interfacial wave phenomenon in oil-water flow systems is an important area of research, due to its importance in real world applications, especially in oil-water transportation in petroleum industry. The influence of interfacial wavy flow and transition of flow regimes on pressure drop, hold-up and heat transfer has motivated the research on this topic to enhance the understanding, to ensure the process safety and to improve the process economy.
   This paper investigates the interfacial oil-water wavy flow in upwardly inclined pipes. The test fluids are mineral oil (viscosity-1.6 mPa s, density-788 kg/m(3)) and water. The scope of the study covers the upward pipe inclination angles of +3 degrees, +5 degrees, +6 degrees, mixture velocities of 0.2-0.5 m/s, and input water cut (input water volume ratio) 0.1-0.9. Two different flow patterns were observed in wavy flow in upwardly inclined pipes, namely stratified wavy (SW) and stratified wavy and mixed interface (SW&MI). The flow images were recorded using a high-speed video camera through a transparent test section. The image analysis was performed using several Matlab programs to extract wave properties such as wavelength and wave amplitude, as well as the wave speed.
   It is observed that the interfacial instabilities increase with the increasing mixture velocity and with increasing inclinations. Increased instabilities cause interfacial waves to generate and release droplets, while the turbulent intensity in the oil phase also influence droplet formation. An approximately linear relation between wave velocity and mixture velocity was obtained for the wavy flow and a correlation is presented accordingly. Wave energy manifests itself in the combined potential and kinetic energy. The potential energy via the wave amplitude and kinetic energy via the wave speed and wavelength. The overall energy for nonlinear breaking waves is a major source for generation of interfacial droplets. When the flow velocities are increased at a constant input water cut and at a given pipe inclination, the flow regime transition from SW to SW&MI occurs. Meanwhile, the prevailing wavelength decreases and the wave amplitude increases towards the point of transition from SW to SW&MI. The wavelength and the amplitude reach a critical value and remain constant until droplets start to form and release. Once the onset of drop formation occurs at the SW&MI flow regime, the wavelength starts to increase and the wave amplitude decreases with respect to their magnitudes at the point of transition. For a given velocity range, the mean amplitude increases with increasing inclination and decreases with increasing water cut. There is an inverse relation between wavelength and wave amplitude, which means higher amplitude always results in lower wavelength and vice versa.
   The wave velocity was calculated independently by two different analysis techniques applied to high-speed video images. One was carried out in space domain and one in time domain from high-speed image sequences. All data points were within the 7% error margin with respect to 1:1 reference correlation line, assuring the accuracy of analysis techniques and the validity of the correlation derived for relating the wave velocity to the mixture velocity. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Perera, Kshanthi; Time, Rune W.] Univ Stavanger, Dept Energy & Petr Engn, Stavanger, Norway.
   [Pradeep, Chaminda; Kumara, Amaranath S.] Univ South Eastern Norway, Fac Technol Nat Sci & Maritime Sci, Porsgrunn, Norway.
RP Perera, K (reprint author), Univ Stavanger, Dept Energy & Petr Engn, Stavanger, Norway.
EM Kshanthi.perera@uis.no
FU Government of Norway (Kunnskapsdepartementet - KD); 'Statoil
   Akademia-UiS' cooperation project
FX We are grateful to the Government of Norway (Kunnskapsdepartementet -
   KD) and the 'Statoil Akademia-UiS' cooperation project for funding and
   providing support to this research.
CR Al-Wahaibi T, 2012, INT J MULTIPHAS FLOW, V38, P126, DOI 10.1016/j.ijmultiphaseflow.2011.08.007
   Al-Wahaibi T, 2007, CHEM ENG SCI, V62, P2915, DOI 10.1016/j.ces.2007.01.024
   Al-Wahaibi T, 2007, CHEM ENG SCI, V62, P2929, DOI 10.1016/j.ces.2007.01.036
   Al-Wahaibi T, 2011, INT J MULTIPHAS FLOW, V37, P930, DOI 10.1016/j.ijmultiphaseflow.2011.04.003
   ANDRITSOS N, 1987, AICHE J, V33, P444, DOI 10.1002/aic.690330310
   ANDRITSOS N, 1987, INT J MULTIPHAS FLOW, V13, P583, DOI 10.1016/0301-9322(87)90037-1
   Banal AH, 2015, EXP THERM FLUID SCI, V60, P115, DOI 10.1016/j.expthermflusci.2014.08.007
   Boomkamp PAM, 1996, INT J MULTIPHAS FLOW, V22, P67, DOI 10.1016/S0301-9322(97)00013-X
   Bratland O., 2009, PIPE FLOW 1 SINGLE P
   CHARLES ME, 1965, J FLUID MECH, V22, P217, DOI 10.1017/S0022112065000691
   CHARLES ME, 1961, CAN J CHEM ENG, V39, P27
   Chen XT, 1997, J ENERG RESOUR-ASME, V119, P209, DOI 10.1115/1.2794992
   de Castro M.S., 2011, WIT T ENG SCI, P227
   de Castro MS, 2015, EXP THERM FLUID SCI, V62, P85, DOI 10.1016/j.expthermflusci.2014.12.003
   de Castro MS, 2012, EXP THERM FLUID SCI, V37, P171, DOI 10.1016/j.expthermflusci.2011.11.003
   Eklund M, 2015, PROG NUCL ENERG, V85, P548, DOI 10.1016/j.pnucene.2015.05.002
   Fairuzov YV, 2001, SPE PROD FACIL, V16, P14, DOI 10.2118/58934-PA
   FRANCA F, 1992, INT J MULTIPHAS FLOW, V18, P787, DOI 10.1016/0301-9322(92)90059-P
   HANRATTY TJ, 1957, AICHE J, V3, P299, DOI 10.1002/aic.690030303
   Kalaga DV, 2017, AICHE J, V63, P4881, DOI 10.1002/aic.15829
   Kumara WAS, 2010, CHEM ENG SCI, V65, P4332, DOI 10.1016/j.ces.2010.03.045
   Perera K, 2018, INT J COMPUT METHODS, V6, P373
   Perera K, 2018, MEAS SCI TECHNOL, V29, DOI 10.1088/1361-6501/aab054
   Perera K, 2017, FLOW MEAS INSTRUM, V56, P23, DOI 10.1016/j.flowmeasinst.2017.07.002
   PHILLIPS OM, 1957, J FLUID MECH, V2, P417, DOI 10.1017/S0022112057000233
   Rodriguez OMH, 2012, J PETROL SCI ENG, V96-97, P140, DOI 10.1016/j.petrol.2012.09.007
   Rodriguez OMH, 2014, INT J MULTIPHAS FLOW, V58, P114, DOI 10.1016/j.ijmultiphaseflow.2013.09.003
   Sarr S.A., 2003, J ONL MATH APPL, V3, P1
   Taitel Y., 1976, International Journal of Multiphase Flow, V2, P591, DOI 10.1016/0301-9322(76)90019-7
   Trallero JL, 1997, SPE PROD FACIL, V12, P165, DOI 10.2118/36609-PA
   WALLIS GB, 1969, ONE DIMENSIONAL 2 PH
   WHITE FM, 2003, FLUID MECH
   ZUBER N, 1965, J HEAT TRANSF, V87, P453, DOI 10.1115/1.3689137
NR 33
TC 0
Z9 0
U1 1
U2 9
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAR 16
PY 2019
VL 196
BP 444
EP 462
DI 10.1016/j.ces.2018.11.014
PG 19
WC Engineering, Chemical
SC Engineering
GA HI9RQ
UT WOS:000456795700036
DA 2020-05-12
ER

PT J
AU Jiang, K
   Dickinson, JE
   Galvin, KP
AF Jiang, K.
   Dickinson, J. E.
   Galvin, K. P.
TI The kinetics of Fast Flotation using the Reflux Flotation Cell
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Flotation kinetics; Downcomer; Reflux Flotation Cell; Fast Flotation;
   Fine particle flotation
ID SURFACE-AREA FLUX; BUBBLE-SIZE; PARTICLE-SIZE; COAL; GAS; DOWNFLOW
AB This paper examines the kinetics of Fast Flotation of very fine, hydrophobic particles using a rectangularsectioned downcomer in the Reflux Flotation Cell (RFC). Three separate downcomers of equal height and breadth, but different channel widths of 2, 4.5, and 9 mm, were used to investigate the recovery of particles ranging from 1 to 100 mu m in diameter. The RFC utilises parallel inclined channels to enhance the segregation rate of rising bubbles in liquid, a phenomenon known as the Boycott Effect. This work was focused on the contribution of the downcomer kinetics to the Fast Flotation. Feed fluxes over the range of 0.9-8.6 cm/s were examined, with residence times in the downcomer of less than 1 s. Recovery due to entrainment was made consistent by fixing the portion of liquid reporting to the overflow to 10% of the feed volumetric rate, independent of the gas flux employed. Kinetic rate constants for the particle recoveries were analysed by varying flotation parameters such as particle size, gas flux and feed flux, obtaining downcomer kinetic constants of up to 419 min(-1). Distinct kinetic behaviour was found for the 1-10 mu m and 10-100 mu m coarser particles, with the kinetics of finer particles being more dependent on the particle size. The kinetics using the narrower downcomer widths (4.5 mm and 2 mm) relied more on the gas flux than the feed flux, while the kinetics using the wider downcomer width showed more dependence on the feed flux. Scaling laws for the kinetic rate constant were derived empirically based on the downcomer channel width, particle size, gas flux and feed flux. These scaling laws provided insight into the underlying mechanisms and a basis for exploring the potential flotation performance over a wide range of system operational conditions. The narrower downcomers exhibited better performance at the feed fluxes <10 cm/s. Above this feed flux, the wider downcomer of 9 mm performed better, especially for coarser particles above 10 mu m. A basis for downcomer system design is provided based on the kinetic scaling laws. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Jiang, K.; Dickinson, J. E.; Galvin, K. P.] Univ Newcastle, Ctr Adv Particle Proc & Transport, Discipline Chem Engn, Univ Dr, Callaghan, NSW 2308, Australia.
RP Jiang, K (reprint author), Univ Newcastle, Ctr Adv Particle Proc & Transport, Discipline Chem Engn, Univ Dr, Callaghan, NSW 2308, Australia.
EM Kaiqi.Jiang@uon.edu.au
OI Galvin, Kevin/0000-0003-0450-9990
FU Australian Research CouncilAustralian Research Council; Australian Coal
   Association Research Program
FX The authors acknowledge the financial support of the Australian Research
   Council and the Australian Coal Association Research Program.
CR Abkhoshk E, 2010, EXPERT SYST APPL, V37, P5201, DOI 10.1016/j.eswa.2009.12.071
   AHMED N, 1985, INT J MINER PROCESS, V14, P195, DOI 10.1016/0301-7516(85)90003-1
   Atkinson BW, 2003, J CHEM TECHNOL BIOT, V78, P269, DOI 10.1002/jctb.768
   Battersby M. J. G., 2005, ADVANTAGES IMHOFLOT
   Boycott AE, 1920, NATURE, V104, P532, DOI 10.1038/104532b0
   Chen F, 2001, MINER ENG, V14, P427, DOI 10.1016/S0892-6875(01)00023-1
   COLLINS GL, 1976, CHEM ENG SCI, V31, P985, DOI 10.1016/0009-2509(76)87019-4
   Cowburn J, 2006, MINER ENG, V19, P609, DOI 10.1016/j.mineng.2005.09.012
   Dickinson JE, 2015, CHEM ENG RES DES, V101, P74, DOI 10.1016/j.cherd.2015.04.006
   Dickinson JE, 2014, CHEM ENG SCI, V108, P283, DOI 10.1016/j.ces.2013.11.006
   EVANS GM, 1992, CHEM ENG SCI, V47, P3265, DOI 10.1016/0009-2509(92)85034-9
   Finch JA, 2000, MINER ENG, V13, P365, DOI 10.1016/S0892-6875(00)00019-4
   Gorain BK, 1997, MINER ENG, V10, P367, DOI 10.1016/S0892-6875(97)00014-9
   Grau RA, 2003, MINER ENG, V16, P1081, DOI 10.1016/j.mineng.2003.06.007
   Harbort G, 2003, MINER ENG, V16, P1091, DOI 10.1016/j.mineng.2003.06.008
   Harbort G., 2003, 22 INT MIN PROC C P, P715
   Harbort GJ, 2002, T I MIN METALL C, V111, pC1
   Harbort GJ, 1997, AUSTRALAS I MIN MET, V97, P105
   Jiang K, 2016, MINER ENG, V98, P151, DOI 10.1016/j.mineng.2016.08.010
   Jiang K, 2014, ADV POWDER TECHNOL, V25, P1205, DOI 10.1016/j.apt.2014.06.003
   KELSALL DF, 1953, CHEM ENG SCI, V2, P254, DOI 10.1016/0009-2509(53)80044-8
   LEVENSPIEL O, 1999, CHEM REACTION ENG
   Metso, 2006, BAS MIN PROC
   Ofori P, 2014, MINER ENG, V66-68, P77, DOI 10.1016/j.mineng.2014.07.013
   Pyke B, 2003, J COLLOID INTERF SCI, V265, P141, DOI 10.1016/S0021-9797(03)00345-X
   REAY D, 1975, CAN J CHEM ENG, V53, P481, DOI 10.1002/cjce.5450530504
   RICHARDSON JF, 1954, T I CHEM ENG-LOND, V32, P35, DOI DOI 10.1016/S0263-8762(97)80006-8
   SCHUBERT H, 1978, INT J MINER PROCESS, V5, P131, DOI 10.1016/0301-7516(78)90010-8
   Sutherland K. L., 1948, J PHYS CHEM, V52
   Tomlinson H.S., 1963, P 6 IMPC CANN OXF NE, P563
   TRONIEWSKI L, 1987, INT J MULTIPHAS FLOW, V13, P257, DOI 10.1016/0301-9322(87)90033-4
   Vera MA, 1999, MINER ENG, V12, P477, DOI 10.1016/S0892-6875(99)00031-X
   WALLIS GB, 1969, ONE DIMENSIONAL 2 PH
   Wills B.A., 2016, WILLS MINERAL PROCES
   YAMAGIWA K, 1990, J CHEM ENG JPN, V23, P343, DOI 10.1252/jcej.23.343
   Young M. F., 2006, P 38 ANN M CAN MIN P, P311
NR 36
TC 1
Z9 1
U1 4
U2 27
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAR 16
PY 2019
VL 196
BP 463
EP 477
DI 10.1016/j.ces.2018.11.012
PG 15
WC Engineering, Chemical
SC Engineering
GA HI9RQ
UT WOS:000456795700037
DA 2020-05-12
ER

PT J
AU Zhu, LT
   Bin Rashid, TA
   Luo, ZH
AF Zhu, Li-Tao
   Bin Rashid, Taha Abbas
   Luo, Zheng-Hong
TI Comprehensive validation analysis of sub-grid drag and wall corrections
   for coarse-grid two-fluid modeling
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Gas-particle fluidization; Computational fluid dynamics; Two-fluid
   modelling; Sub-grid model; Wall correction; Validation
ID GAS-SOLID FLOWS; COMPUTATIONAL FLUID-DYNAMICS; FILTERED MODEL; PARTICLE
   FLOWS; CFD SIMULATION; HEAT-TRANSFER; GELDART; FLUIDIZATION; PYROLYSIS;
   ARRAYS
AB Development and validation of sub-grid models are of pivotal importance for coarse-grid two-fluid modeling of gas-particle fluidization. In prior study (Zhu et al., 2018, Chem. Eng. Sci. 192, 759-773), we developed an effective three-marker sub-grid drag model to consider the local heterogeneity in gas-particle flows. In this study, we perform a comprehensive 3D hydrodynamic validation analysis of the developed model to its predictability. Specifically, the validation covers more flow situations with respect to rapid, turbulent and bubbling fluidization. Besides, we introduce a simplified wall correction factor for assessing how the bounding walls impact on flow hydrodynamics. Computational results accord well with the experimental data over various flow regimes. The developed model can adequately capture the macroscopic flow properties without an additional wall modification. Compared with the fine-grid two-fluid modeling using the uniform drag model for a lab-scale riser, approximately 44 times speedup in computational time is achieved via the developed model. A much more significant reduction in computational time can be consequently expected for industrial-scale reactors. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Zhu, Li-Tao; Bin Rashid, Taha Abbas; Luo, Zheng-Hong] Shanghai Jiao Tong Univ, Sch Chem & Chem Engn, Dept Chem Engn, State Key Lab Met Matrix Composites, Shanghai 200240, Peoples R China.
RP Luo, ZH (reprint author), Shanghai Jiao Tong Univ, Sch Chem & Chem Engn, Dept Chem Engn, State Key Lab Met Matrix Composites, Shanghai 200240, Peoples R China.
EM luozh@sjtu.edu.cn
RI Zhu, Li-Tao/G-6000-2018
OI Zhu, Li-Tao/0000-0001-6514-8864
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [21776173, 21625603]; Program of Shanghai Subject
   Chief Scientist [18XD1402000]; Center for High Performance Computing,
   Shanghai Jiao Tong University
FX The authors appreciate Dr. Kun Hong at the Huaiyin Institute of
   Technology for providing useful discussions about the solids flux in
   risers. The authors also thank the National Natural Science Foundation
   of China (No. 21776173 and 21625603), the Program of Shanghai Subject
   Chief Scientist (No. 18XD1402000) and the computational support from the
   Center for High Performance Computing, Shanghai Jiao Tong University for
   supporting this work.
CR Ashcraft RW, 2012, CHEM ENG J, V207, P195, DOI 10.1016/j.cej.2012.06.048
   Banaei M, 2018, PARTICUOLOGY, V36, P13, DOI 10.1016/j.partic.2017.01.009
   Beetstra R, 2007, AICHE J, V53, P489, DOI 10.1002/aic.11065
   Benyahia S, 2012, AICHE J, V58, P3589, DOI 10.1002/aic.13826
   Bi HT, 2000, CHEM ENG SCI, V55, P4789, DOI 10.1016/S0009-2509(00)00107-X
   Chen XZ, 2011, POWDER TECHNOL, V205, P276, DOI 10.1016/j.powtec.2010.09.039
   Chen XZ, 2018, CHEM ENG SCI, V192, P864, DOI 10.1016/j.ces.2018.08.019
   Cloete JH, 2018, CHEM ENG SCI, V192, P930, DOI 10.1016/j.ces.2018.06.041
   Cloete S, 2018, CHEM ENG SCI, V182, P93, DOI 10.1016/j.ces.2018.02.032
   Cloete S, 2015, POWDER TECHNOL, V269, P153, DOI 10.1016/j.powtec.2014.08.055
   Das AK, 2003, IND ENG CHEM RES, V42, P2602, DOI 10.1021/ie020744g
   Das S, 2018, CHEM ENG SCI, V183, P260, DOI 10.1016/j.ces.2018.03.022
   Dubrawski K, 2013, POWDER TECHNOL, V235, P203, DOI 10.1016/j.powtec.2012.10.031
   ERGUN S, 1952, CHEM ENG PROG, V48, P89
   Gao X., 2018, AICHE J
   Gao X, 2018, CHEM ENG SCI, V184, P33, DOI 10.1016/j.ces.2018.03.038
   Gao X, 2012, CHEM ENG SCI, V78, P98, DOI 10.1016/j.ces.2012.03.030
   Ghadirian E, 2016, POWDER TECHNOL, V288, P35, DOI 10.1016/j.powtec.2015.10.034
   Herbert P., 1999, ETH CFB MEASUREMENT, P1
   Heynderickx GJ, 2004, IND ENG CHEM RES, V43, P4635, DOI 10.1021/ie034122m
   Hong K, 2013, CHEM ENG SCI, V99, P191, DOI 10.1016/j.ces.2013.05.050
   Horio M., 1988, CIRCULATING FLUIDIZE, P147
   Hou QF, 2017, CHEM ENG SCI, V161, P67, DOI 10.1016/j.ces.2016.12.017
   Igci Y, 2011, AICHE J, V57, P2691, DOI 10.1002/aic.12486
   Imoberdorf GE, 2008, CHEM ENG SCI, V63, P4228, DOI 10.1016/j.ces.2008.05.022
   Joshi JB, 2003, IND ENG CHEM RES, V42, P1115, DOI 10.1021/ie0206608
   Kanki T, 2005, CHEM ENG J, V108, P155, DOI 10.1016/j.cej.2005.01.014
   Kunii D., 1991, FLUIDIZATION ENG
   Lan XY, 2012, CHEM ENG SCI, V69, P419, DOI 10.1016/j.ces.2011.10.064
   Lan XY, 2009, CHEM ENG SCI, V64, P3847, DOI 10.1016/j.ces.2009.05.019
   Lane WA, 2018, CHEM ENG SCI, V176, P409, DOI 10.1016/j.ces.2017.11.018
   Li J., 1994, PARTICLE FLUID 2 PHA
   Li TW, 2017, AICHE J, V63, P1203, DOI 10.1002/aic.15507
   Li TW, 2013, AICHE J, V59, P3624, DOI 10.1002/aic.14132
   Li TW, 2010, POWDER TECHNOL, V203, P447, DOI 10.1016/j.powtec.2010.06.005
   Li XT, 2004, BIOMASS BIOENERG, V26, P171, DOI 10.1016/S0961-9534(03)00084-9
   Li Y., 1980, FLUIDIZATION, P537
   Lim KS, 1995, INT J MULTIPHAS FLOW, V21, P141, DOI 10.1016/0301-9322(95)00038-Y
   Lu BN, 2017, CHEM ENG SCI, V171, P244, DOI 10.1016/j.ces.2017.05.007
   Lu BN, 2011, CHEM ENG SCI, V66, P4624, DOI 10.1016/j.ces.2011.06.026
   Lu LQ, 2018, CHEM ENG SCI, V179, P53, DOI 10.1016/j.ces.2018.01.003
   Lu LQ, 2017, CHEM ENG J, V326, P627, DOI 10.1016/j.cej.2017.06.002
   Luo H, 2017, CHEM ENG J, V326, P47, DOI 10.1016/j.cej.2017.04.145
   Milioli CC, 2013, AICHE J, V59, P3265, DOI 10.1002/aic.14130
   Miller DC, 2014, ANNU REV CHEM BIOMOL, V5, P301, DOI 10.1146/annurev-chembioeng-060713-040321
   Pan H, 2017, IND ENG CHEM RES, V56, P10199, DOI 10.1021/acs.iecr.7b02912
   Sarkar A, 2014, POWDER TECHNOL, V265, P35, DOI 10.1016/j.powtec.2014.01.031
   Schneiderbauer S, 2018, AICHE J, V64, P1591, DOI 10.1002/aic.16142
   Schneiderbauer S, 2017, AICHE J, V63, P3544, DOI 10.1002/aic.15684
   Schneiderbauer S, 2015, CHEM ENG J, V264, P99, DOI 10.1016/j.cej.2014.11.058
   Schneiderbauer S, 2014, AICHE J, V60, P839, DOI 10.1002/aic.14321
   Sundaresan S, 2018, ANNU REV CHEM BIOMOL, V9, P61, DOI 10.1146/annurev-chembioeng-060817-084025
   Tang Y, 2015, AICHE J, V61, P688, DOI 10.1002/aic.14645
   Venderbosch R. H., 1998, ROLE CLUSTERS GAS SO
   Wang JW, 2009, CHEM ENG SCI, V64, P622, DOI 10.1016/j.ces.2008.09.028
   Wang LM, 2010, PARTICUOLOGY, V8, P379, DOI 10.1016/j.partic.2010.07.003
   Wen C.Y., 1966, CHEM ENG PROGR S SER, V62, P100, DOI DOI 10.1016/S0032-0633(98)00014-2
   Xiong QG, 2013, CHEM ENG SCI, V99, P305, DOI 10.1016/j.ces.2013.06.017
   Xiong QG, 2012, CHEM ENG SCI, V71, P422, DOI 10.1016/j.ces.2011.10.059
   Yan WC, 2018, J CLEAN PROD, V178, P476, DOI 10.1016/j.jclepro.2018.01.009
   Zhou GF, 2014, CHEM ENG SCI, V116, P9, DOI 10.1016/j.ces.2014.04.025
   Zhu LT, 2018, CHEM ENG SCI, V192, P759, DOI 10.1016/j.ces.2018.08.026
   Zhu LT, 2017, IND ENG CHEM RES, V56, P1090, DOI 10.1021/acs.iecr.6b04026
   Zhu LT, 2016, IND ENG CHEM RES, V55, P11887, DOI 10.1021/acs.iecr.6b02819
   Zhu LT, 2016, CHEM ENG SCI, V143, P369, DOI 10.1016/j.ces.2016.01.006
NR 65
TC 9
Z9 11
U1 1
U2 10
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAR 16
PY 2019
VL 196
BP 478
EP 492
DI 10.1016/j.ces.2018.11.026
PG 15
WC Engineering, Chemical
SC Engineering
GA HI9RQ
UT WOS:000456795700038
DA 2020-05-12
ER

PT J
AU Lu, JK
   Corvalan, CM
   Chew, YMJ
   Huang, JY
AF Lu, Jiakai
   Corvalan, Carlos M.
   Chew, Y. M. John
   Huang, Jen-Yi
TI Coalescence of small bubbles with surfactants
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Microbubble; Surfactant; Interface; Simulation; Transport phenomena;
   Coalescence
ID BREAKUP; DROPS
AB Bubble coalescence is central to many important technological processes, such as separations, cleaning of oil spills, microfluidics, emulsification and foaming. It is well known that surfactants, which are frequently present as additives or contaminants, delay coalescence by slowing the drainage of the liquid film separating the approaching bubbles before they make contact. However, the coalescence and surfactant transport mechanisms developed after surfactant-laden bubbles make initial contact remain poorly understood. Here, we characterize these mechanisms using high-fidelity numerical simulations to predict the evolution of bubble interfaces, surfactant spreading, and induced Marangoni flows. Our results show that the surfactant initially accumulates on the tiny meniscus bridge formed between the coalescing bubbles due to the rapid and highly localized contraction of meniscus area. At the same time, a Marangoni-driven convective flow is generated at the interface, which drags the accumulated surfactant away from the joining meniscus and toward the back of the bubbles. Together, these transport mechanisms affect the rate bubble coalescence by dynamically modifying the local pull of surface tension on the bubble interfaces. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Lu, Jiakai; Corvalan, Carlos M.; Huang, Jen-Yi] Purdue Univ, Dept Food Sci, 745 Agr Mall Dr, W Lafayette, IN 47907 USA.
   [Chew, Y. M. John] Univ Bath, Dept Chem Engn, Bldg 9 West, Bath BA2 7AY, Avon, England.
RP Huang, JY (reprint author), Purdue Univ, Dept Food Sci, 745 Agr Mall Dr, W Lafayette, IN 47907 USA.
EM huang874@purdue.edu
OI Lu, Jiakai/0000-0002-6951-841X; Chew, John/0000-0003-2888-834X
FU USDA National Institute of Food and AgricultureUnited States Department
   of Agriculture (USDA) [2017-05024, 1014964, 1008409, 199888]; Purdue
   Research Foundation (PRF)
FX This project was partially supported by the USDA National Institute of
   Food and Agriculture, AFRI project 2017-05024 and Hatch projects
   1014964, 1008409 and 199888, and Purdue Research Foundation (PRF).
CR Alke A., 2009, FDMP, V1, P1
   Campana D, 2004, INT J MULTIPHAS FLOW, V30, P431, DOI 10.1016/j.ijmultiphaseflow.2004.03.007
   Ceniceros HD, 2003, PHYS FLUIDS, V15, P245, DOI 10.1063/1.1528940
   Chan DYC, 2011, SOFT MATTER, V7, P2235, DOI 10.1039/c0sm00812e
   Chhabra R.P., 1999, NONNEWTONIAN FLOW FU
   Clift R., 1978, BUBBLES DROPS PARTIC
   CORVALAN CM, 1991, COMPUT CHEM ENG, V15, P729, DOI 10.1016/0098-1354(91)85018-P
   Dravid V, 2006, CHEM ENG SCI, V61, P3577, DOI 10.1016/j.ces.2005.12.026
   Hansen S, 1999, J FLUID MECH, V382, P331, DOI 10.1017/S0022112098003991
   James AJ, 2004, J COMPUT PHYS, V201, P685, DOI 10.1016/j.jcp.2004.06.013
   Kandlikar SG, 2013, APPL PHYS LETT, V102, DOI 10.1063/1.4791682
   Khuntia S., 2012, MICROBUBBLE AIDED WA
   Kistler S. F., 1983, COATING FLOW COMPUTA
   LESSARD RR, 1971, IND ENG CHEM FUND, V10, P260, DOI 10.1021/i160038a012
   Liu HH, 2018, J FLUID MECH, V837, P381, DOI 10.1017/jfm.2017.859
   Lu J., 2018, LANGMUIR
   Lu JK, 2015, LANGMUIR, V31, P8618, DOI 10.1021/acs.langmuir.5b01484
   Lu JK, 2014, CHEM ENG SCI, V119, P182, DOI 10.1016/j.ces.2014.08.024
   Lu JK, 2012, CHEM ENG SCI, V78, P9, DOI 10.1016/j.ces.2012.04.030
   Mason TJ, 1997, CHEM SOC REV, V26, P443, DOI 10.1039/cs9972600443
   Muddu RJ, 2012, CHEM ENG SCI, V69, P602, DOI 10.1016/j.ces.2011.11.023
   Paulsen JD, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4182
   Samanta S, 2011, CHEM ENG SCI, V66, P4824, DOI 10.1016/j.ces.2011.06.046
   Scardovelli R, 1999, ANNU REV FLUID MECH, V31, P567, DOI 10.1146/annurev.fluid.31.1.567
   Slattery J. C, 1990, INTERFACIAL TRANSPOR
   Wong H, 1996, PHYS FLUIDS, V8, P3203, DOI 10.1063/1.869098
   Xue ZJ, 2008, CHEM ENG SCI, V63, P1842, DOI 10.1016/j.ces.2007.12.011
NR 27
TC 2
Z9 2
U1 9
U2 50
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAR 16
PY 2019
VL 196
BP 493
EP 500
DI 10.1016/j.ces.2018.11.002
PG 8
WC Engineering, Chemical
SC Engineering
GA HI9RQ
UT WOS:000456795700039
DA 2020-05-12
ER

PT J
AU Song, Y
   Zhu, J
   Zhang, C
   Sun, ZN
   Lu, XF
AF Song, Yangfan
   Zhu, Jesse
   Zhang, Chao
   Sun, Zeneng
   Lu, Xiaofeng
TI Comparison of liquid-solid flow characteristics in upward and downward
   circulating fluidized beds by CFD approach
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Liquid-solid flow; Upward circulating fluidized bed; Downward
   circulating fluidized bed; Two-fluid model; Numerical study
ID NUMERICAL-SIMULATION; HYDRODYNAMICS; EXPANSION; PARTICLES; BEHAVIOR
AB The flow behaviors of the particles in the upward and downward liquid-solid circulating fluidized beds were simulated by Eulerian-Eulerian approach incorporating the kinetic theory of granular flow. The Syamlal-O'Brien drag model was used to account for the interphase interaction between the liquid and solids phases. The numerical results agreed well with the experimental data obtained by other group members, successfully validating the numerical approach. The hydrodynamic characteristics of the particles with different densities and sizes in the upward and downward circulating fluidized beds were compared in detail under different liquid velocities and solids flow rates. The results indicated that there were many hydrodynamic similarities in the upward and downward circulating fluidized beds. However, due to the deviation of the standard drag curve, the drag force on the lighter particles in the downward liquid-solid circulating fluidized bed became different, leading to random and irregular particle flow behaviors. The predicted average solids holdups matched well with the results by an empirical model proposed by Sang and Zhu and the matching degree between the numerical results and the model was larger than 85%, further proving that the Sang and Zhu model is widely applicable. (C) 2018 Published by Elsevier Ltd.
C1 [Song, Yangfan; Zhu, Jesse; Sun, Zeneng] Univ Western Ontario, Dept Chem & Biochem Engn, London, ON N6A 5B9, Canada.
   [Zhang, Chao] Univ Western Ontario, Dept Mech & Mat Engn, London, ON N6A 5B9, Canada.
   [Song, Yangfan; Lu, Xiaofeng] Chongqing Univ, Minist Educ, Key Lab Low Grade Energy Utilizat Technol & Syst, Chongqing 400044, Peoples R China.
RP Zhu, J (reprint author), Univ Western Ontario, Dept Chem & Biochem Engn, London, ON N6A 5B9, Canada.
EM jzhu@uwo.ca; czhang@eng.uwo.ca; zsun82@uwo.ca; xfluke@cqu.edu.cn
RI Zhu, Jesse/E-4048-2017
OI Zhu, Jesse/0000-0001-7749-8917
FU National Science and Engineering Research Council of CanadaNatural
   Sciences and Engineering Research Council of Canada; China Scholarship
   CouncilChina Scholarship Council
FX The authors are grateful to the financial support by National Science
   and Engineering Research Council of Canada, and Y.F. Song is grateful to
   China Scholarship Council for sponsoring his study at the University of
   Western Ontario, Canada.
CR Cheng Y, 2005, CAN J CHEM ENG, V83, P177
   Cheng Y, 2008, CHEM ENG SCI, V63, P3201, DOI 10.1016/j.ces.2008.03.036
   Couderc J. P., 1985, FLUIDIZATION, P1
   Dadashi A, 2014, POWDER TECHNOL, V260, P52, DOI 10.1016/j.powtec.2014.03.030
   Drew D.A., 1993, PARTICULATE 2 PHASE
   FAN LS, 1982, CHEM ENG J BIOCH ENG, V24, P143, DOI 10.1016/0300-9467(82)80029-4
   Feng YQ, 2012, POWDER TECHNOL, V219, P78, DOI 10.1016/j.powtec.2011.12.007
   Fluent A.N., 2011, ANSYS FLUENT THEOR G
   Jaberi A., 2014, THESIS
   JOHNSON PC, 1987, J FLUID MECH, V176, P67, DOI 10.1017/S0022112087000570
   KARAMANEV DG, 1992, AICHE J, V38, P1916, DOI 10.1002/aic.690381208
   Karamanev DG, 1996, CHEM ENG COMMUN, V147, P75, DOI 10.1080/00986449608936496
   Liang WG, 1997, POWDER TECHNOL, V90, P95, DOI 10.1016/S0032-5910(96)03198-1
   Liu GD, 2016, POWDER TECHNOL, V304, P186, DOI 10.1016/j.powtec.2016.08.058
   Loha C, 2012, CHEM ENG SCI, V75, P400, DOI 10.1016/j.ces.2012.03.044
   Luo H., 2017, THESIS
   Montastruc L, 2009, CHEM ENG J, V148, P139, DOI 10.1016/j.cej.2008.08.035
   Nan T., 2019, THESIS
   Pan H, 2016, POWDER TECHNOL, V299, P235, DOI 10.1016/j.powtec.2016.05.024
   Razzak SA, 2010, POWDER TECHNOL, V199, P77, DOI 10.1016/j.powtec.2009.05.014
   Razzak S. A., 2009, THESIS
   Renganathan T, 2004, CHEM ENG J, V98, P213, DOI 10.1016/j.cej.2003.08.001
   Renganathan T, 2005, CHEM ENG SCI, V60, P2545, DOI 10.1016/j.ces.2004.11.034
   Richardson JF, 1997, CHEM ENG RES DES, V75, pS82, DOI 10.1016/S0263-8762(97)80006-8
   Roy S, 2005, AICHE J, V51, P802, DOI 10.1002/aic.10447
   Roy S, 2001, IND ENG CHEM RES, V40, P5440, DOI 10.1021/ie010181t
   Sang L., 2013, THESIS
   Sang L, 2012, CHEM ENG J, V197, P322, DOI 10.1016/j.cej.2012.05.048
   Sowmeyan R, 2008, BIORESOURCE TECHNOL, V99, P6280, DOI 10.1016/j.biortech.2007.12.001
   Syamlal M., 1989, AICHE S SER, V85, P22
   Wang SY, 2018, J TAIWAN INST CHEM E, V82, P214, DOI 10.1016/j.jtice.2017.08.049
   Wang SY, 2014, POWDER TECHNOL, V261, P14, DOI 10.1016/j.powtec.2014.04.017
   Zhang K, 2012, POWDER TECHNOL, V227, P104, DOI 10.1016/j.powtec.2012.01.030
   Zheng Y., 1999, THESIS
   Zheng Y, 2003, INT J CHEM REACT ENG, V1
   Zhu JX, 2000, CAN J CHEM ENG, V78, P82, DOI 10.1002/cjce.5450780113
NR 36
TC 0
Z9 0
U1 5
U2 22
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAR 16
PY 2019
VL 196
BP 501
EP 513
DI 10.1016/j.ces.2018.11.022
PG 13
WC Engineering, Chemical
SC Engineering
GA HI9RQ
UT WOS:000456795700040
DA 2020-05-12
ER

PT J
AU Mora, AEM
   Silva, ALFDE
   Silva, SMMDE
AF Malaguera Mora, Angel Edecio
   Fernandes de Lima e Silva, Ana Lucia
   Marcondes de Lima e Silva, Sandro Metrevelle
TI Numerical study of the dynamics of a droplet in a T-junction
   microchannel using OpenFOAM
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Microfluidic; S-CLSVOF methodology; OpenFOAM; Breakup mechanism; Taylor
   droplet
ID SURFACE-TENSION; BUBBLE BREAKUP; LEVEL SET; VOLUME; FLUID; FLOWS
AB The mechanisms of droplet breakup in a Microfluidic T-junction are mainly influenced by the capillary number (Ca) and the ratio between the length of the droplet and the transverse dimension of the microchannel (l(o)/w). This work presents numerical simulations of an isolated Taylor droplet in a rectangular T-junction microchannel in the range of 0.0096 to 0.0904 of capillary numbers and viscosity ratio of the dispersed and continuous phases, that is, mu(d)/mu(c) = 0.125. The numerical simulations were carried out with OpenFOAM 2.4 by using the S-CLSVOF methodology which was implemented for this study. The snappyHexMesh tool was used for grid refinement near the microchannel wall in order to correctly model the thin fluid layer between the wall and the drop. It was verified that in this range of the capillary numbers, parasitic currents could affect the dynamics of the droplet in the microchannel. The use of S-CLSVOF, the time step control and mesh resolution enabled a better capture of the interface dynamics. A mathematical correlation was obtained in the obstructed breakup regime for the dimensionless thickness of the droplet (delta/w) in relation to Ca, dimensionless time (tau* = U(d)t/w) and droplet length (l(o)/w). Two types of non-obstructed breakup were observed in the simulations, namely, partially obstructed, and with permanent tunnel. The results showed that the mechanisms of a droplet breakup inside a T-junction are in good agreement with literature. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Malaguera Mora, Angel Edecio; Fernandes de Lima e Silva, Ana Lucia; Marcondes de Lima e Silva, Sandro Metrevelle] Fed Univ Itajuba UNIFEI, Inst Mech Engn, BPS Av 1303, BR-37500903 Itajuba, MG, Brazil.
RP Silva, ALFDE (reprint author), Fed Univ Itajuba UNIFEI, Inst Mech Engn, BPS Av 1303, BR-37500903 Itajuba, MG, Brazil.
EM alfsilva@unifei.edu.br; metrevel@unifei.edu.br
RI Lima e Silva, Ana Lucia F./B-9164-2019; Lima e Silva, Sandro
   Metrevelle/P-1798-2014
OI Lima e Silva, Ana Lucia F./0000-0002-7731-1355; Lima e Silva, Sandro
   Metrevelle/0000-0002-1295-6208
FU CAPESCAPES; CNPqNational Council for Scientific and Technological
   Development (CNPq); FAPEMIGMinas Gerais State Research Foundation
   (FAPEMIG) [TEC-APQ-00893-17]; FAPEMIGMinas Gerais State Research
   Foundation (FAPEMIG)
FX The authors would like to thank the brazilian foundations CAPES for the
   doctoral scholarship and CNPq and FAPEMIG (TEC-APQ-00893-17) for the
   financial support. This work has made use of the computing facilities
   available at the Laboratory of Computational Astrophysics of the Federal
   University of Itajuba (LAC-UNIFEI). The LAC-UNIFEI is maintained with
   grants from CAPES, CNPq and FAPEMIG.
CR Afkhami S, 2011, PHYS FLUIDS, V23, DOI 10.1063/1.3549266
   Albadawi A, 2013, INT J MULTIPHAS FLOW, V53, P11, DOI 10.1016/j.ijmultiphaseflow.2013.01.005
   Berberovic E, 2009, PHYS REV E, V79, DOI 10.1103/PhysRevE.79.036306
   BRACKBILL JU, 1992, J COMPUT PHYS, V100, P335, DOI 10.1016/0021-9991(92)90240-Y
   Cerne G, 2001, J COMPUT PHYS, V171, P776, DOI 10.1006/jcph.2001.6810
   Engl W, 2008, CURR OPIN COLLOID IN, V13, P206, DOI 10.1016/j.cocis.2007.09.003
   Favero J. L., 2009, THESIS U FED RIO GRA
   Fiates J., 2015, THESIS
   Fu TT, 2011, CHEM ENG SCI, V66, P4184, DOI 10.1016/j.ces.2011.06.003
   Greenshields C. J., 2015, OPENFOAM USER GUIDE
   HIRT CW, 1981, J COMPUT PHYS, V39, P201, DOI 10.1016/0021-9991(81)90145-5
   Hoang DA, 2013, COMPUT FLUIDS, V86, P28, DOI 10.1016/j.compfluid.2013.06.024
   Jullien MC, 2009, PHYS FLUIDS, V21, DOI 10.1063/1.3170983
   LAFAURIE B, 1994, J COMPUT PHYS, V113, P134, DOI 10.1006/jcph.1994.1123
   Leshansky A. M., 2012, PHY REV LETT PRL, V108, P1
   LeVeque R., 2004, CAMBRIDGE TEXTS APPL
   Moreland K., 2015, SAND20157813 TR SAND
   OSHER S, 1988, J COMPUT PHYS, V79, P12, DOI 10.1016/0021-9991(88)90002-2
   Renardy Y, 2002, J COMPUT PHYS, V183, P400, DOI 10.1006/jcph.2002.7190
   Seifollahi M, 2008, EUR J MECH B-FLUID, V27, P1, DOI 10.1016/j.euromechflu.2007.01.002
   Shirani E, 2005, J COMPUT PHYS, V203, P154, DOI 10.1016/j.jcp.2004.08.017
   Silva Wilton Pereira da, 2004, Rev. Bras. Ensino Fís., V26, P419
   Sussman M, 2000, J COMPUT PHYS, V162, P301, DOI 10.1006/jcph.2000.6537
   Wang XD, 2015, CHEM ENG SCI, V132, P128, DOI 10.1016/j.ces.2015.04.038
NR 24
TC 3
Z9 3
U1 2
U2 29
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAR 16
PY 2019
VL 196
BP 514
EP 526
DI 10.1016/j.ces.2018.11.020
PG 13
WC Engineering, Chemical
SC Engineering
GA HI9RQ
UT WOS:000456795700041
DA 2020-05-12
ER

PT J
AU Palumbo, AW
   Bartel, CJ
   Sorli, JC
   Weimer, AW
AF Palumbo, Aaron W.
   Bartel, Christopher J.
   Sorli, Jeni C.
   Weimer, Alan W.
TI Characterization of products derived from the high temperature flash
   pyrolysis of microalgae and rice hulls
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Biochar; Flash pyrolysis; Syngas; Drop-tube
ID BIOMASS PYROLYSIS; FLOW REACTOR; GASIFICATION; WOOD; BIOCHAR; DESIGN;
   ROUTES; FUELS
AB Flash heating and high temperature processing of two biomass feed materials is presented as a sustainable thermochemical technique to leverage the entire carbon content of the starting material for various end-uses. Microalgae and rice hulls were flash pyrolyzed in a drop-tube reactor to form exclusively gas and solid products in the temperature range 1573-1873 K at gas residence times of 3-5 s. Product gas yields and compositions approached thermodynamic equilibrium predictions with increasing temperature, which were used in calculations for a conceptual solarthermal processing framework. The derived carbonaceous residue was further characterized for composition (atomic mass and crystalline structures), morphology (surface area, pore volume, surface roughness), and reactivity (via CO2 thermogravimetry). Solid residues generated under flash conditions tended to become nearly indistinguishable, becoming spherical with high macroporosities and similar apparent reactivities. These results were contrasted with slow-pyrolyzed chars of the same starting materials, whose characteristics were markedly opposite for microalgae and rice hulls, further evidencing the importance of char particle thermal history. Results from solarthermal operation show a high calorific value syngas, especially for microalgae at 1873 K. The applicability of carbonaceous residue in a particular downstream use requires further characterization and study. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Palumbo, Aaron W.; Bartel, Christopher J.; Sorli, Jeni C.; Weimer, Alan W.] Univ Colorado, Dept Chem & Biol Engn, Boulder, CO 80303 USA.
RP Weimer, AW (reprint author), Univ Colorado, Dept Chem & Biol Engn, Boulder, CO 80303 USA.
EM alan.weimer@colorado.edu
RI Sorli, Jeni/G-9495-2018; Bartel, Christopher/AAD-5637-2019
OI Sorli, Jeni/0000-0001-7222-2698; Bartel,
   Christopher/0000-0002-5198-5036; WEIMER, ALAN/0000-0002-2471-349X
FU U.S. Department of Education GAANN Renewable and Sustainable Energy
   Fellowship; National Science Foundation REU ProgramNational Science
   Foundation (NSF); Colorado Center for Biorefining and Biofuels;
   University of Colorado at Boulder UROP
FX The authors wish to thank the following organizations for their
   financial support: U.S. Department of Education GAANN Renewable and
   Sustainable Energy Fellowship, National Science Foundation REU Program,
   University of Colorado at Boulder UROP, and the Colorado Center for
   Biorefining and Biofuels.
CR Aarum I, 2017, J ANAL APPL PYROL, V127, P211, DOI 10.1016/j.jaap.2017.08.003
   Agrawal R., 2010, ANN REV, P343
   Agrawal R, 2012, CURR OPIN CHEM ENG, V1, P201, DOI 10.1016/j.coche.2012.07.002
   Arregi A, 2018, ENERG CONVERS MANAGE, V165, P696, DOI 10.1016/j.enconman.2018.03.089
   Asadullah M, 2010, BIORESOURCE TECHNOL, V101, P7935, DOI 10.1016/j.biortech.2010.05.048
   Babu BV, 2008, BIOFUEL BIOPROD BIOR, V2, P393, DOI 10.1002/bbb.92
   Bahng MK, 2009, ANAL CHIM ACTA, V651, P117, DOI 10.1016/j.aca.2009.08.016
   Biagini E, 2008, FUEL, V87, P177, DOI 10.1016/j.fuel.2007.04.010
   Brewer CE, 2009, ENVIRON PROG SUSTAIN, V28, P386, DOI 10.1002/ep.10378
   Brown RC, 2011, THERMOCHEMICAL PROCE
   Cao XY, 2012, ENERG FUEL, V26, P5983, DOI 10.1021/ef300947s
   Cetin E, 2005, FUEL, V84, P1328, DOI 10.1016/j.fuel.2004.07.016
   Cetin E, 2004, FUEL, V83, P2139, DOI 10.1016/j.fuel.2004.05.008
   Cha JS, 2016, J IND ENG CHEM, V40, P1, DOI 10.1016/j.jiec.2016.06.002
   CHAN WCR, 1985, FUEL, V64, P1505, DOI 10.1016/0016-2361(85)90364-3
   Devi L, 2003, BIOMASS BIOENERG, V24, P125, DOI 10.1016/S0961-9534(02)00102-2
   Di Blasi C, 2000, IND ENG CHEM RES, V39, P873, DOI 10.1021/ie990720i
   Di Blasi C, 2008, PROG ENERG COMBUST, V34, P47, DOI 10.1016/j.pecs.2006.12.001
   Dufour A, 2011, ENERG FUEL, V25, P4182, DOI 10.1021/ef200846g
   Dufour A, 2011, CHEM ENG RES DES, V89, P2136, DOI 10.1016/j.cherd.2011.01.005
   Dupont C, 2009, J ANAL APPL PYROL, V85, P260, DOI 10.1016/j.jaap.2008.11.034
   Garcia-Nunez JA, 2017, ENERG FUEL, V31, P5751, DOI 10.1021/acs.energyfuels.7b00641
   Janse AMC, 2000, CHEM ENG PROCESS, V39, P239, DOI 10.1016/S0255-2701(99)00092-6
   Kaniyal AA, 2013, ENERG FUEL, V27, P3556, DOI 10.1021/ef400217n
   Lede J, 2010, ENERGIES, V3, P886, DOI 10.3390/en3040886
   Lee JW, 2010, ENVIRON SCI TECHNOL, V44, P7970, DOI 10.1021/es101337x
   Maag G, 2010, ENERG FUEL, V24, P6540, DOI 10.1021/ef100936j
   Maliutina K, 2017, ENERG CONVERS MANAGE, V151, P426, DOI 10.1016/j.enconman.2017.09.013
   Mallapragada DS, 2013, IND ENG CHEM RES, V52, P5136, DOI 10.1021/ie301125c
   Manya JJ, 2012, ENVIRON SCI TECHNOL, V46, P7939, DOI 10.1021/es301029g
   Martinek J, 2013, SOL ENERGY, V90, P68, DOI 10.1016/j.solener.2013.01.004
   Milne T. A. E., 1998, BIOMASS GASIFIER TAR, P204
   Palumbo AW, 2015, APPL ENERG, V157, P13, DOI 10.1016/j.apenergy.2015.07.072
   Palumbo AW, 2015, J ANAL APPL PYROL, V113, P474, DOI 10.1016/j.jaap.2015.03.010
   Qin K, 2013, ENERG FUEL, V27, P262, DOI 10.1021/ef301432q
   Qin K, 2012, ENERG FUEL, V26, P5992, DOI 10.1021/ef300960x
   Qureshi KM, 2018, J ANAL APPL PYROL, V131, P52, DOI 10.1016/j.jaap.2018.02.010
   SCOTT DS, 1982, CAN J CHEM ENG, V60, P666, DOI 10.1002/cjce.5450600514
   Singh NR, 2010, ENVIRON SCI TECHNOL, V44, P5298, DOI 10.1021/es100316z
   Sun H, 2012, IND ENG CHEM RES, V51, P3587, DOI 10.1021/ie201309r
   Tanger P, 2013, FRONT PLANT SCI, V4, DOI 10.3389/fpls.2013.00218
   Vamvuka D, 2011, INT J ENERG RES, V35, P835, DOI 10.1002/er.1804
   Woodruff RB, 2012, POWDER TECHNOL, V229, P45, DOI 10.1016/j.powtec.2012.06.002
   Zeng K, 2017, SOL ENERGY, V156, P73, DOI 10.1016/j.solener.2017.05.033
NR 44
TC 1
Z9 1
U1 4
U2 37
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAR 16
PY 2019
VL 196
BP 527
EP 537
DI 10.1016/j.ces.2018.11.029
PG 11
WC Engineering, Chemical
SC Engineering
GA HI9RQ
UT WOS:000456795700042
DA 2020-05-12
ER

PT J
AU Ecker, AM
   Thomas, I
   Halele, M
   Wunderlich, B
   Obermeier, A
   Ferstl, J
   Klein, H
   Peschel, A
AF Ecker, Anna-Maria
   Thomas, Ingo
   Haelele, Martin
   Wunderlich, Bernd
   Obermeier, Andreas
   Ferstl, Johann
   Klein, Harald
   Peschel, Andreas
TI Development of a new column shortcut model and its application in
   process optimisation
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Column shortcut model; Process optimisation; Distillation; Edmister
   method; Adapted Edmister Model; Air separation
ID MINIMUM-REFLUX CALCULATIONS; MULTIPLE STEADY-STATES; HOMOGENEOUS
   AZEOTROPIC DISTILLATIONS; NONIDEAL MULTICOMPONENT DISTILLATION;
   OPTIMAL-DESIGN; FRAMEWORK; NUMBER; ABSORPTION; TRAYS
AB Stage-to-stage column models are preferred for accurate process calculation in industry but include many non-linear equations making process optimisation difficult. Further, optimisation of feed and side draw locations or overall column stage numbers introduces integer type optimisation variables and transforms an NLP into an MINLP optimisation problem. We introduce the Adapted Edmister Model (AEM) as a new column shortcut method which is able to overcome the described challenges while satisfying industrial standards of simulation accuracy. The AEM is used in a two-step optimisation approach which consists of initial optimisation with shortcut models and subsequent optimisation with stage-to-stage models. Applying the AEM in two-step optimisation enables NLP optimisation of column stage numbers, feed locations, and side draw locations avoiding an MINLP problem formulation. In addition, using AEM results to initialise stage-to-stage column models improves convergence and gives rise to better optimal solutions. To demonstrate the performance of the AEM, it is applied in the optimisation of an air separation process where high calculation accuracy is crucial. Here, the two-step optimisation approach employing the AEM results in an over 2% better optimum compared to a classical optimisation approach which is high for this process. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Ecker, Anna-Maria; Klein, Harald] Tech Univ Munich, Dept Mech Engn, Inst Plant & Proc Technol, Boltzmannstr 15, D-85748 Garching, Germany.
   [Ecker, Anna-Maria; Thomas, Ingo; Haelele, Martin; Wunderlich, Bernd; Obermeier, Andreas; Ferstl, Johann; Peschel, Andreas] Linde AG, Engn Div, Dr Carl von Linde Str 6-14, D-82049 Pullach, Germany.
RP Ecker, AM (reprint author), Linde AG, Engn Div, Dr Carl von Linde Str 6-14, D-82049 Pullach, Germany.
EM anna.ecker@tum.de
RI ; Klein, Harald/D-7726-2015
OI Obermeier, Andreas/0000-0002-0110-3912; Klein,
   Harald/0000-0002-8973-9906
FU Federal Ministry of Education and Research (BMBF)Federal Ministry of
   Education & Research (BMBF)
FX The authors gratefully acknowledge the financial support of the
   Kopernikus project SynErgie by the Federal Ministry of Education and
   Research (BMBF) and the project supervision by the project management
   organisation Projekttrager Julich (PtJ).; Further, the authors
   gratefully acknowledge the support with Linde OPTISIM (R) given by
   Stephania Hokenmaier (Linde Engineering). The authors would also like to
   thank Johannes Sundberg and Robert Kender (Institute of Plant and
   Process Technology, TUM) as well as Florian Schliebitz (Linde
   Engineering) for fruitful discussions in the context of this work.
CR Agrawal R, 2003, AICHE J, V49, P379, DOI 10.1002/aic.690490210
   Agrawal R, 1996, IND ENG CHEM RES, V35, P1059, DOI 10.1021/ie950323h
   BARBOSA D, 1988, CHEM ENG SCI, V43, P1523, DOI 10.1016/0009-2509(88)85144-3
   BARBOSA D, 1988, CHEM ENG SCI, V43, P2377, DOI 10.1016/0009-2509(88)85172-8
   Bausa J, 1998, AICHE J, V44, P2181, DOI 10.1002/aic.690441008
   Bekiaris N, 1996, IND ENG CHEM RES, V35, P4264, DOI 10.1021/ie950450d
   Bekiaris N, 1996, IND ENG CHEM RES, V35, P207, DOI 10.1021/ie940493e
   BEKIARIS N, 1993, IND ENG CHEM RES, V32, P2023, DOI 10.1021/ie00021a026
   Beneke DA, 2011, AICHE J, V57, P2406, DOI 10.1002/aic.12453
   Biegler LT, 2014, COMPUT CHEM ENG, V60, P17, DOI 10.1016/j.compchemeng.2013.07.009
   Bruggemann S, 2004, COMPUT CHEM ENG, V29, P165, DOI 10.1016/j.compchemeng.2004.07.009
   Burger J, 2013, CHEM ENG SCI, V99, P118, DOI 10.1016/j.ces.2013.05.049
   Caballero JA, 2001, IND ENG CHEM RES, V40, P2260, DOI 10.1021/ie000761a
   Dowling AW, 2015, COMPUT CHEM ENG, V72, P3, DOI 10.1016/j.compchemeng.2014.05.013
   Edmister WC, 1943, IND ENG CHEM, V35, P837, DOI 10.1021/ie50404a003
   EDMISTER WC, 1957, AICHE J, V3, P165, DOI 10.1002/aic.690030207
   Eich-Soellner E., 1997, Surveys on Mathematics for Industry, V7, P1
   Fenske MR, 1932, IND ENG CHEM, V24, P482, DOI 10.1021/ie50269a003
   FIDKOWSKI ZT, 1993, AICHE J, V39, P1303, DOI 10.1002/aic.690390806
   Gilliland ER, 1940, IND ENG CHEM, V32, P1220, DOI 10.1021/ie50369a035
   Grossmann IE, 2005, COMPUT CHEM ENG, V29, P1203, DOI 10.1016/j.compchemeng.2005.02.030
   Haring H. W., 2008, IND GASES PROCESSING
   Hausen H, 1985, TIEFTEMPERATURTECHNI
   Horton G, 1940, IND ENG CHEM, V32, P1384, DOI 10.1021/ie50370a023
   JULKA V, 1990, CHEM ENG SCI, V45, P1801, DOI 10.1016/0009-2509(90)87057-Y
   Kamath RS, 2010, COMPUT CHEM ENG, V34, P1312, DOI 10.1016/j.compchemeng.2010.02.029
   Karuppiah R, 2008, AICHE J, V54, P1499, DOI 10.1002/aic.11480
   Kraemer K, 2009, IND ENG CHEM RES, V48, P6749, DOI 10.1021/ie900143e
   Kramer K., 2012, THESIS
   Kremser A., 1930, NATL PET NEWS, V22, P43
   Landes S. H., 1960, PETROL REFINER, V39, P201
   LEVY SG, 1985, IND ENG CHEM FUND, V24, P463, DOI 10.1021/i100020a011
   Linninger AA, 2009, COMPUT CHEM ENG, V33, P2018, DOI 10.1016/j.compchemeng.2009.06.022
   Marquardt W, 2008, CHINESE J CHEM ENG, V16, P333, DOI 10.1016/S1004-9541(08)60084-1
   OWENS WR, 1968, IND ENG CHEM, V60, P14, DOI 10.1021/ie50708a005
   Peschel A, 2012, CHEM ENG J, V207, P656, DOI 10.1016/j.cej.2012.07.029
   Petlyuk FB, 1971, THEOR FOUND CHEM ENG, V5, P499
   Rooks RE, 1996, IND ENG CHEM RES, V35, P3653, DOI 10.1021/ie960036t
   Ruiz GJ, 2010, COMPUT CHEM ENG, V34, P1556, DOI 10.1016/j.compchemeng.2010.02.008
   Ryll O, 2014, CHEM ENG SCI, V109, P284, DOI 10.1016/j.ces.2014.01.024
   Ryll O, 2012, CHEM ENG SCI, V84, P315, DOI 10.1016/j.ces.2012.08.018
   Sounders M., 1932, IND ENG CHEM, V24, P519
   Thomas I, 2011, COMPUT-AIDED CHEM EN, V29, P31
   Underwood A.J.V., 1946, J I PET, V32, P598
   Underwood A. J. V., 1946, J I PETROL, V32, P614
   UNDERWOOD AJV, 1932, T I CHEM ENG-LOND, V10, P112
   VANDONGEN DB, 1985, IND ENG CHEM FUND, V24, P454, DOI 10.1021/i100020a010
   VISWANATHAN J, 1993, COMPUT CHEM ENG, V17, P949, DOI 10.1016/0098-1354(93)80076-Y
   VISWANATHAN J, 1993, IND ENG CHEM RES, V32, P2942, DOI 10.1021/ie00023a069
   von Watzdorf R, 1999, AICHE J, V45, P1615, DOI 10.1002/aic.690450803
   Windmeier C., 2013, ULLMANNS ENCY IND CH, P1
   Yeomans H, 2000, IND ENG CHEM RES, V39, P4326, DOI 10.1021/ie0001974
   Yeomans H, 2000, IND ENG CHEM RES, V39, P1637, DOI 10.1021/ie9906520
   Zhang LB, 2004, IND ENG CHEM RES, V43, P3163, DOI 10.1021/ie034223k
NR 54
TC 0
Z9 0
U1 1
U2 5
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAR 16
PY 2019
VL 196
BP 538
EP 551
DI 10.1016/j.ces.2018.10.035
PG 14
WC Engineering, Chemical
SC Engineering
GA HI9RQ
UT WOS:000456795700043
DA 2020-05-12
ER

PT J
AU Behrensdorf-Nicol, HA
   Kramer, B
AF Behrensdorf-Nicol, Heike A.
   Kraemer, Beate
TI Is the test for irreversibility of tetanus toxoids still relevant?
SO VACCINE
LA English
DT Article
DE Tetanus vaccines; Toxoids; Test for irreversibility of toxoid; European
   Pharmacopoeia
ID TOXICITY; REVERSION; BINDING
AB Tetanus vaccines for human and veterinary use are based on toxoids resulting from a formaldehyde mediated inactivation of tetanus neurotoxin (TeNT). Due to the high toxicity of TeNT, safety tests are mandatory for each batch of these toxoids. One of the tests addresses the irreversibility of inactivation: The toxoid is stored at 37 degrees C for 6 weeks and then subjected to in vivo toxicity testing.
   However, we found that TeNT solutions rapidly lose their activity at 37 degrees C. Accordingly, any active TeNT molecules arising in the toxoid due to reversion events may no longer be detectable after the 37 degrees C storage period. Furthermore, there is no evidence that a "reversion to toxicity" has ever been observed for tetanus toxoids during vaccine production. Thus, we conclude that the irreversibility test that is prescribed for human and veterinary vaccines has no relevance for vaccine safety. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Behrensdorf-Nicol, Heike A.; Kraemer, Beate] Paul Ehrlich Inst, Fed Inst Vaccines & Biomed, Div Vet Med, Paul Ehrlich Str 51-59, D-63225 Langen, Germany.
RP Behrensdorf-Nicol, HA (reprint author), Paul Ehrlich Inst, Fed Inst Vaccines & Biomed, Div Vet Med, Paul Ehrlich Str 51-59, D-63225 Langen, Germany.
EM Heike.Behrensdorf-Nicol@pei.de
CR AKAMA K, 1971, JPN J MED SCI BIOL, V24, P183, DOI 10.7883/yoken1952.24.183
   AKAMA K, 1971, JPN J MED SCI BIOL, V24, P181, DOI 10.7883/yoken1952.24.181
   Barton J., 1979, BIOCHEM EDUC, V7, P13, DOI DOI 10.1016/0307-4412(79)90013-X
   Behrensdorf-Nicol HA, 2013, VACCINE, V31, P6247, DOI 10.1016/j.vaccine.2013.10.028
   Behrensdorf-Nicol HA, 2010, TOXICOL IN VITRO, V24, P988, DOI 10.1016/j.tiv.2009.12.018
   Corbel MJ, NEW APPROACHES STABI, P113
   Council of Europe, 2018, MONOGRAPH, V697
   Council of Europe, 2018, MONOGRAPH, V452
   GILL DM, 1982, MICROBIOL REV, V46, P86, DOI 10.1128/MMBR.46.1.86-94.1982
   KNIGHT PA, 1993, BIOLOGICALS, V21, P183, DOI 10.1006/biol.1993.1072
   Latham WC, 1988, P INF CONS WHO REQ D, P12
   LINGGOOD FV, 1963, BRIT J EXP PATHOL, V44, P177
   Stainer D W, 1977, Dev Biol Stand, V34, P149
NR 13
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 22
PY 2019
VL 37
IS 13
BP 1721
EP 1724
DI 10.1016/j.vaccine.2019.02.054
PG 4
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HQ8QZ
UT WOS:000462691700001
PM 30826145
DA 2020-05-12
ER

PT J
AU Walker, EJ
   MacDonald, NE
   Islam, N
   Le Saux, N
   Top, KA
   Fell, DB
AF Walker, Emma J.
   MacDonald, Noni E.
   Islam, Nehal
   Le Saux, Nicole
   Top, Karina A.
   Fell, Deshayne B.
TI Completeness and timeliness of diphtheria-tetanus-pertussis,
   measles-mumps-rubella, and polio vaccines in young children with chronic
   health conditions: A systematic review
SO VACCINE
LA English
DT Review
DE Immunization; Coverage; Timeliness; Immunization; Coverage; Timeliness
ID BIRTH-WEIGHT INFANTS; VACCINATION COVERAGE; PREMATURE-INFANTS;
   DATA-COLLECTION; CASE-DEFINITION; INBORN-ERRORS; IMMUNIZATION; PRETERM;
   GUIDELINES; ATTITUDES
AB Objective: To systematically review literature on uptake and timeliness of diphtheria-tetanus-pertussis, measles-mumps-rubella, and/or polio-containing vaccines in infants who were born preterm, with a low birth weight, and/or with chronic health conditions that were diagnosed within the first 6 months of life.
   Methods: Using a standardized search strategy developed by a medical librarian, records were extracted from MEDLINE, Embase, Database of Abstracts of Reviews of Effects, and CINAHL up to May 8, 2018.
   Results: Out of the 1997 records that were screened, we identified 21 studies that met inclusion criteria. Eleven studies assessed vaccine coverage and/or timeliness in preterm infants, 6 in low birth weight infants, and 7 in children with chronic health conditions. Estimates of coverage in these populations were highly variable, ranging from 40% to 100% across the vaccines and population groups.
   Conclusions: There is a lack of studies reporting coverage and timeliness of routine immunizations in special populations of children.
   Policy implications: Our review suggests a need for improved surveillance of immunization status in special populations of infants, as well as a need for standardization of reporting practices. (C) 2019 The Authors. Published by Elsevier Ltd.
C1 [Walker, Emma J.] Queens Univ, Kingston, ON, Canada.
   [MacDonald, Noni E.; Top, Karina A.] Dalhousie Univ, Halifax, NS, Canada.
   [MacDonald, Noni E.; Top, Karina A.] Canadian Ctr Vaccinol, Halifax, NS, Canada.
   [Islam, Nehal] Univ Ottawa, Ottawa, ON, Canada.
   [Le Saux, Nicole] Univ Ottawa, Div Infect Dis, Ottawa, ON, Canada.
   [Le Saux, Nicole; Fell, Deshayne B.] Childrens Hosp Eastern Ontario, Res Inst, Ottawa, ON, Canada.
   [Fell, Deshayne B.] Univ Ottawa, Sch Epidemiol & Publ Hlth, Ottawa, ON, Canada.
RP Fell, DB (reprint author), Univ Ottawa, Sch Epidemiol & Publ Hlth, Ctr Practice Changing Res, 401 Smyth Rd,Room L-1154, Ottawa, ON K1H 8L1, Canada.
EM dfell@cheo.on.ca
RI ; Fell, Deshayne/N-7106-2017
OI Top, Karina/0000-0002-9981-368X; Fell, Deshayne/0000-0002-5548-3228
CR [Anonymous], 2016, ICD 10 CLASS PREGN C
   [Anonymous], CONTR
   Atkinson William L, 2002, MMWR Recomm Rep, V51, P1
   Batra JS, 2009, PEDIATRICS, V123, P951, DOI 10.1542/peds.2008-0231
   Bramer WM de JG, 2015, IMPROVING EFFICIENCY
   Centers for Disease Control and Prevention, 2018, REC IMM SCHED CHILDR
   Cerutti M, 2015, VACCINE, V33, P6520, DOI 10.1016/j.vaccine.2015.10.073
   Crawford NW, 2009, J PAEDIATR CHILD H, V45, P602, DOI 10.1111/j.1440-1754.2009.01573.x
   Cremer R, 2002, ACTA PAEDIATR, V91, P724
   Cutland CL, 2017, VACCINE, V35, P6492, DOI 10.1016/j.vaccine.2017.01.049
   Denizot S, 2011, VACCINE, V29, P382, DOI 10.1016/j.vaccine.2010.11.006
   Doherty M, 2016, VACCINE, V34, P6681, DOI 10.1016/j.vaccine.2016.11.015
   Esposito S, 2016, HUM VACC IMMUNOTHER, V12, P801, DOI 10.1080/21645515.2015.1086046
   Esposito S, 2014, VACCINE, V32, P6601, DOI 10.1016/j.vaccine.2014.09.038
   Fell DWE, PROSPERO 2017
   Funk S, 2017, CRITICAL IMMUNITY TH
   Klein NP, 2011, PEDIATRICS, V127, pE1139, DOI 10.1542/peds.2010-3706
   Kroger AT, 2017, GEN BEST PRACTICE GU
   Laforgia N, 2018, HUM VACC IMMUNOTHER, V14, P1398, DOI 10.1080/21645515.2018.1428509
   Luman ET, 2002, PEDIATRICS, V110, P935, DOI 10.1542/peds.110.5.935
   Magoon M W, 1995, J Perinatol, V15, P222
   Masson A, 2015, J CYST FIBROS, V14, P615, DOI 10.1016/j.jcf.2015.04.006
   Miller Michael A, 2012, Adv Pediatr, V59, P95, DOI 10.1016/j.yapd.2012.04.017
   Moher D, 2010, INT J SURG, V8, P336, DOI 10.1016/j.ijsu.2010.02.007
   Moran T., OBJECTIVE 2 IMMUNIZA
   Nacoulma Eric W C, 2006, Sante, V16, P155
   O'Leary M, 2016, B WORLD HEALTH ORGAN, V94, P442, DOI 10.2471/BLT.15.159699
   Ochoa TJ, 2015, VACCINE, V33, P354, DOI 10.1016/j.vaccine.2014.11.014
   Pinquier D, 2009, ARCH PEDIATRIE, V16, P1533, DOI 10.1016/j.arcped.2009.09.009
   Plotkin SA, 2011, HISTORY OF VACCINE DEVELOPMENT, P1, DOI 10.1007/978-1-4419-1339-5
   Prevots D R, 2000, MMWR Recomm Rep, V49, P1
   Public Health Agency of Canada, 2018, CAN IMM GUID
   Quinn JA, 2016, VACCINE, V34, P6047, DOI 10.1016/j.vaccine.2016.03.045
   RADDISH M, 1993, AM J DIS CHILD, V147, P849, DOI 10.1001/archpedi.1993.02160320051018
   The Joanna Briggs Institute, CRIT APPR TOOLS US J
   Tillmann BU, 2005, EUR J PEDIATR, V164, P320, DOI 10.1007/s00431-005-1627-x
   Tillmann BU, 2001, ACTA PAEDIATR, V90, P1421, DOI 10.1080/08035250152708842
   Tozzi AE, 2014, VACCINE, V32, P793, DOI 10.1016/j.vaccine.2013.12.044
   Upadhyay RP, 2017, J GLOB HEALTH, V7, DOI 10.7189/jogh.07.020415
   WHO, 2018, TABL 2 SUMM WHO POS
   WHO/UNICEF, 2017, WHO UNICEF JOINT REP
   Wilson K, 2012, CAN J PUBLIC HEALTH, V103, pE359, DOI 10.1007/BF03404441
   Woestenberg PJ, 2014, PEDIATR INFECT DIS J, V33, P190, DOI 10.1097/INF.0000000000000106
   World Health Organization, TABL 1 SUMM WHO POS
NR 44
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 22
PY 2019
VL 37
IS 13
BP 1725
EP 1735
DI 10.1016/j.vaccine.2019.02.031
PG 11
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HQ8QZ
UT WOS:000462691700002
PM 30814030
OA Other Gold
DA 2020-05-12
ER

PT J
AU Wang, ZY
   Li, ZT
   Su, X
   Qiao, YY
   Fan, WF
   Li, HB
   Shi, BL
   Qin, T
   Chen, SJ
   Peng, DX
   Liu, XF
AF Wang, Zeyuan
   Li, Zhuotian
   Su, Xiang
   Qiao, Yiyi
   Fan, Weifeng
   Li, Haibin
   Shi, Baolan
   Qin, Tao
   Chen, Sujuan
   Peng, Daxin
   Liu, Xiufan
TI Enhanced cross-lineage protection induced by recombinant H9N2 avian
   influenza virus inactivated vaccine
SO VACCINE
LA English
DT Article
DE H9N2; Avian influenza virus; Inactivated vaccine; Cross-lineage
   protection
ID HEMAGGLUTININ GLYCOSYLATION; HUMAN INFECTION; STALK-LENGTH; A VIRUS;
   NEURAMINIDASE; ANTIGENICITY; GENERATION; VIRULENCE; EVOLUTION; PROTEIN
AB Background: Antigenic drift of H9N2 low pathogenic avian influenza viruses (AIV) may result in vaccination failure in the poultry industry and thus a cross-protective vaccine against H9N2 AIV is highly desirable.
   Methods: A series of H9N2 recombinant viruses with the internal genes of A/Puerto Rico/8/34 (H1N1, PR8) were generated, based on the compatibility between HA and NA, the effect of HA deglycosylation, and protective antigenic epitopes in HA. After evaluation of their biological and immunological characteristics, three recombinant AIVs with the internal genes of the Y280-like strain SN were selected for protective efficacy studies.
   Results: The recombinant viruses rHA(SN)NA(3), rHA(SN)-Delta 200, rHA(SN)-Delta 287, and rHA(SN)-R92G-E93K displayed good cross reactivity and induced higher neutralization antibody titers against both SN and the F98-like strain YZ4. Furthermore, those recombinant viruses had a higher EID50 in chicken embryos after the replacement of internal-gene backbone from PR8 to SN. The rSNHA-Delta 200 induced better protection in immunized chickens against challenge of homologous and heterologous H9N2 avian influenza viruses when compared with the wild type strain.
   Conclusion: The recombinant virus rSNHA-Delta 200 can be used as a potential broad-spectrum vaccine against H9N2 avian influenza. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Wang, Zeyuan; Li, Zhuotian; Su, Xiang; Qiao, Yiyi; Fan, Weifeng; Li, Haibin; Qin, Tao; Chen, Sujuan; Peng, Daxin; Liu, Xiufan] Yangzhou Univ, Coll Vet Med, Yangzhou, Jiangsu, Peoples R China.
   [Qiao, Yiyi; Fan, Weifeng; Li, Haibin; Qin, Tao; Chen, Sujuan; Peng, Daxin; Liu, Xiufan] Jiangsu Coinnovat Ctr Prevent & Control Important, Yangzhou, Jiangsu, Peoples R China.
   [Qiao, Yiyi; Fan, Weifeng; Li, Haibin; Qin, Tao; Chen, Sujuan; Peng, Daxin; Liu, Xiufan] Jiangsu Res Ctr Engn & Technol Prevent & Control, Yangzhou, Jiangsu, Peoples R China.
   [Shi, Baolan] Sinopharm Yangzhou Vac Biol Engn Co LtD, Yangzhou 225009, Jiangsu, Peoples R China.
   [Peng, Daxin] Minist Educ, Int Joint Lab Cooperat Agr & Agr Prod Safety, Yangzhou 225009, Jiangsu, Peoples R China.
RP Peng, DX (reprint author), 48 East Wenhui Rd, Yangzhou 225009, Jiangsu, Peoples R China.
EM pengdx@yzu.edu.cn
OI Peng, Daxin/0000-0001-6773-5149
FU National Key Research and Development Program of China [2017YFD0500701,
   2016YFD0500202]; Program of Green Yang Golden Phoenix (Grant Yangzhou
   talent office [2017]) [6]; High Level Talent Support Plan of Yangzhou
   University; Priority Academic Program Development of Jiangsu Higher
   Education (PAPD)
FX This work was supported by the National Key Research and Development
   Program of China (2017YFD0500701, 2016YFD0500202), the Program of Green
   Yang Golden Phoenix (Grant Yangzhou talent office [2017] NO. 6.), the
   High Level Talent Support Plan of Yangzhou University, and a project
   funded by the Priority Academic Program Development of Jiangsu Higher
   Education (PAPD).
CR AYTAY S, 1991, J VIROL, V65, P3022, DOI 10.1128/JVI.65.6.3022-3028.1991
   Baigent SJ, 2001, VIRUS RES, V79, P177, DOI 10.1016/S0168-1702(01)00272-6
   Butt KM, 2005, J CLIN MICROBIOL, V43, P5760, DOI 10.1128/JCM.43.11.5760-5767.2005
   Chen SJ, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.01086
   Chen Z, 2004, CHINESE MED J-PEKING, V117, P125
   DESHPANDE KL, 1987, P NATL ACAD SCI USA, V84, P36, DOI 10.1073/pnas.84.1.36
   Hoffmann E, 2000, P NATL ACAD SCI USA, V97, P6108, DOI 10.1073/pnas.100133697
   Hoffmann E, 2002, VACCINE, V20, P3165, DOI 10.1016/S0264-410X(02)00268-2
   Kaverin NV, 2004, J VIROL, V78, P240, DOI 10.1128/JVI.78.1.240-249.2004
   Li CJ, 2005, VIROLOGY, V340, P70, DOI 10.1016/j.virol.2005.06.025
   Li YF, 2013, VET MICROBIOL, V162, P614, DOI 10.1016/j.vetmic.2012.11.033
   Matrosovich M, 1999, J VIROL, V73, P1146, DOI 10.1128/JVI.73.2.1146-1155.1999
   Matsuoka Y, 2009, J VIROL, V83, P4704, DOI 10.1128/JVI.01987-08
   Okamatsu M, 2008, ARCH VIROL, V153, P2189, DOI 10.1007/s00705-008-0243-2
   Pan Q, 2012, BMC VET RES, V8, DOI 10.1186/1746-6148-8-104
   Peacock TP, 2018, EMERG MICROBES INFEC, V7, DOI 10.1038/s41426-018-0178-y
   Peiris M, 1999, LANCET, V354, P916, DOI 10.1016/S0140-6736(99)03311-5
   Pu J, 2015, P NATL ACAD SCI USA, V112, P548, DOI 10.1073/pnas.1422456112
   Qin T, 2018, TRANSBOUND EMERG DIS
   Santiago FW, 2012, VACCINE, V30, P4606, DOI 10.1016/j.vaccine.2012.05.005
   Shi SH, 2016, VACCINE, V34, P350, DOI 10.1016/j.vaccine.2015.11.045
   Steel J, 2009, J VIROL, V83, P1742, DOI 10.1128/JVI.01920-08
   Sun YP, 2015, PROTEIN CELL, V6, P18, DOI 10.1007/s13238-014-0111-7
   Sun YP, 2010, VET MICROBIOL, V146, P215, DOI 10.1016/j.vetmic.2010.05.010
   Vigerust DJ, 2007, TRENDS MICROBIOL, V15, P211, DOI 10.1016/j.tim.2007.03.003
   Wagner R, 2000, J VIROL, V74, P6316, DOI 10.1128/JVI.74.14.6316-6323.2000
   Wang WJ, 2010, J VIROL, V84, P6570, DOI 10.1128/JVI.00221-10
   Yin YC, 2017, VET RES, V48, DOI 10.1186/s13567-017-0484-8
   Zhang PH, 2008, J GEN VIROL, V89, P3102, DOI 10.1099/vir.0.2008/005652-0
   Zhang XJ, 2015, J GEN VIROL, V96, P1248, DOI 10.1099/vir.0.000082
   Zhang XJ, 2015, VET MICROBIOL, V175, P244, DOI 10.1016/j.vetmic.2014.12.011
   Zhang Y, 2012, VET MICROBIOL, V156, P285, DOI 10.1016/j.vetmic.2011.11.014
   Zhu YB, 2015, VET MICROBIOL, V178, P144, DOI 10.1016/j.vetmic.2015.04.012
NR 33
TC 1
Z9 1
U1 2
U2 6
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 22
PY 2019
VL 37
IS 13
BP 1736
EP 1742
DI 10.1016/j.vaccine.2019.02.012
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HQ8QZ
UT WOS:000462691700003
PM 30797637
DA 2020-05-12
ER

PT J
AU Munyaka, PM
   Kommadath, A
   Fouhse, J
   Wilkinson, J
   Diether, N
   Stothard, P
   Estelle, J
   Rogel-Gaillard, C
   Plastow, G
   Willing, BP
AF Munyaka, Peris M.
   Kommadath, Arun
   Fouhse, Janelle
   Wilkinson, Jamie
   Diether, Natalie
   Stothard, Paul
   Estelle, Jordi
   Rogel-Gaillard, Claire
   Plastow, Graham
   Willing, Benjamin P.
TI Characterization of whole blood transcriptome and early-life fecal
   microbiota in high and low responder pigs before, and after vaccination
   for Mycoplasma hyopneumoniae
SO VACCINE
LA English
DT Article
DE Vaccination; Transcriptome; Microbiota; Pig; Prediction; Mycoplasma
   hyopneumoniae
ID PERIPHERAL-BLOOD; GUT MICROBIOTA; ANTIBODY-RESPONSES; GENE-EXPRESSION;
   LEAN GROWTH; INFECTION; BIOMARKER; ADJUVANT; BACTERIA; DISEASE
AB We investigated gene expression patterns in whole blood and fecal microbiota profile as potential predictors of immune response to vaccination, using healthy M. hyopneumoniae infection free piglets (n = 120). Eighty piglets received a dose of prophylactic antibiotics during the first two days of life, whereas the remaining 40 did not. Blood samples for RNA-Seq analysis were collected on experimental Day 0 (D0; 28 days of age) just prior to vaccination, D2, and D6 post-vaccination. A booster vaccine was given at D24. Fecal samples for microbial 16SrRNA sequencing were collected at 7 days of age, and at D0 and D35 post-vaccination. Pigs were ranked based on the levels of M. hyopneumoniae-specific antibodies in serum samples collected at D35, and groups of 'high' (HR) and 'low' (LR) responder pigs (n =15 each) were selected. Prophylactic antibiotics did not influence antibody titer levels and differential expression analysis did not reveal differences between HR and LR at any time-point (FOR > 0.05); however, based on functional annotation with Ingenuity Pathway Analysis, D2 post-vaccination, HR pigs were enriched for biological terms relating to increased activation of immune cells. In contrast, the immune activation decreased in HR, 6 days post-vaccination. No significant differences were observed prior to vaccination (D0). Two days post-vaccination, multivariate analysis revealed that ADAM8, PROSER3, B4GALNT1, MAP7D1, SPP1, HTRA4, and ENO3 genes were the most promising potential biomarkers. At D0, OTUs annotated to Prevotella, CF21, Bacteroidales and S24-7 were more abundant in HR, whereas Fibrobacter, Paraprevotella, Anaerovibrio, [Prevotella], YRC22, and Helicobacter positively correlated with the antibody titer as well as MYL1, SPPI, and ENO3 genes. Our study integrates gene differential expression and gut microbiota to predict vaccine response in pigs. The results indicate that post-vaccination gene-expression and early-life gut microbiota profile could potentially predict vaccine response in pigs, and inform a direction for future research. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Munyaka, Peris M.; Kommadath, Arun; Fouhse, Janelle; Wilkinson, Jamie; Diether, Natalie; Stothard, Paul; Plastow, Graham; Willing, Benjamin P.] Univ Alberta, Dept Agr Food & Nutr Sci, Room 310D Ag Ctr, Edmonton, AB T6G 2P5, Canada.
   [Kommadath, Arun; Wilkinson, Jamie; Stothard, Paul; Plastow, Graham] Univ Alberta, Livestock Gentec, Edmonton, AB, Canada.
   [Estelle, Jordi; Rogel-Gaillard, Claire] Univ Paris Saclay, AgroParisTech, GABI, INRA, F-78350 Jouy En Josas, France.
RP Willing, BP (reprint author), Univ Alberta, Dept Agr Food & Nutr Sci, Room 310D Ag Ctr, Edmonton, AB T6G 2P5, Canada.
EM willing@ualberta.ca
RI Kommadath, Arun/I-4644-2019; Estelle, Jordi/A-7976-2008; Willing,
   Benjamin/AAA-9650-2019
OI Kommadath, Arun/0000-0003-3587-6670; Estelle, Jordi/0000-0002-6241-1732;
   
FU Alberta Agriculture and Forestry project [2014F034R]; Genome Canada
   (2014 Genome Canada LSARP - Application of Genomics to Improve Disease
   Resilience and Sustainability in Pork Production); Canada Research
   Chairs ProgramCanada Research Chairs
FX The authors thank the University of Alberta Swine Research and
   Technology Centre, facility staff for their help with the animal trial
   (Animal care and monitoring, vaccination and sample collection). The
   authors also thank Yan Meng for her help with processing of blood
   samples. This work was financially supported by the Alberta Agriculture
   and Forestry project (2014F034R); and Genome Canada (2014 Genome Canada
   LSARP - Application of Genomics to Improve Disease Resilience and
   Sustainability in Pork Production). B.P.W. is supported by the Canada
   Research Chairs Program.
CR Adler M, 2015, PHYSIOL GENOMICS, V47, P470, DOI 10.1152/physiolgenomics.00015.2015
   Adler M, 2013, INT J BIOL SCI, V9, P907, DOI 10.7150/ijbs.6769
   Adler M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058306
   Ahlberg V, 2012, DEV COMP IMMUNOL, V38, P17, DOI 10.1016/j.dci.2012.03.005
   Anders S, 2015, BIOINFORMATICS, V31, P166, DOI 10.1093/bioinformatics/btu638
   Andre FE, 2008, B WORLD HEALTH ORGAN, V86, P140, DOI 10.2471/BLT.07.040089
   Arumugam M, 2011, NATURE, V473, P174, DOI 10.1038/nature09944
   Bearson SMD, 2013, INFECT GENET EVOL, V16, P330, DOI 10.1016/j.meegid.2013.03.022
   Caporaso JG, 2010, NAT METHODS, V7, P335, DOI 10.1038/nmeth.f.303
   Chien J, 2009, CURR CANCER DRUG TAR, V9, P451, DOI 10.2174/156800909788486704
   Chilton PM, 2013, INFECT IMMUN, DOI [10.1128/IAL01150-12, DOI 10.1128/JAI.01150-12]
   Choi I, 2013, PROCEEDINGS OF THE I, pP0595
   Conesa A, 2006, BIOINFORMATICS, DOI [10.1093/bioinformatics/bt1056, DOI 10.1093/BIOINFORMATICS/BT1056]
   Di Pasquale A, 2015, VACCINES-BASEL, V3, P320, DOI 10.3390/vaccines3020320
   Djordjevic SP, 1997, AUST VET J, V75, P504, DOI 10.1111/j.1751-0813.1997.tb14383.x
   Edgar R. C., 2016, BIORXIV, DOI [10.1101/074252, 10.1101/074252., DOI 10.1101/074252]
   Eloe-Fadrosh EA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062026
   Flint HJ, 2012, GUT MICROBES, V3, P289, DOI 10.4161/gmic.19897
   Gensollen T, 2016, SCIENCE, DOI [10.1126/science:aad9378, DOI 10.1126/SCIENCE:AAD937A]
   Gimsa U, 2018, ANIMAL, V12, P116, DOI 10.1017/S1751731117001197
   Gomez-Gaviro M, 2007, J IMMUNOL, V178, P8053, DOI 10.4049/jimmunol.178.12.8053
   Gonzalez I, 2008, J STAT SOFTW, DOI [10.1359/IBMR.0301229, DOI 10.1359/IBMR.0301229]
   Groenen MAM, 2012, NATURE, DOI [10.103/nature11622, DOI 10.1038/NATURE116722]
   Hall JA, 2008, IMMUNITY, V29, P637, DOI 10.1016/j.immuni.2008.08.009
   Hamer HM, 2008, ALIMENT PHARM THER, V27, P104, DOI 10.1111/j.1365-2036.2007.03562.x
   Han M, 2008, CLIN CANCER RES, V14, P455, DOI 10.1158/1078-0432.CCR-07-1801
   Hayashi H, 2007, INT J SYST EVOL MICR, V57, P1323, DOI 10.1099/ijs.0.64979-0
   He F, 2012, MOL SYST BIOL, V8, DOI 10.1038/msb.2012.56
   Henn AD, 2013, SCI REP-UK, V3, DOI 10.1038/srep02327
   Huang TH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028768
   Huda MN, 2014, PEDIATRICS, V134, pE362, DOI 10.1542/peds.2013-3937
   Huda MN, 2017, J IMMUNOL, V198
   Isolauri E, 2015, BENEF MICROBES, V6, P167, DOI 10.3920/BM2014.0114
   Karst SM, 2016, NAT REV MICROBIOL, V14, P197, DOI 10.1038/nrmicro.2015.25
   Knap PW, 2000, OCCASIONAL PUBLICATI, V27, P65
   Kommadath A, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-452
   Lamendella R, 2011, BMC MICROBIOL, V11, DOI 10.1186/1471-2180-11-103
   Le Cao KA, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-34
   Le Cao KA, 2008, STAT APPL GENET MOL, V7, DOI 10.2202/1544-6115.1390
   Lozupone C, 2005, APPL ENVIRON MICROB, V71, P8228, DOI 10.1128/AEM.71.12.8228-8235.2005
   Lynn DJ, 2018, J LEUKOCYTE BIOL, V103, P225, DOI 10.1189/jlb.5MR0617-216R
   Mach N, 2015, ENV MICROBIOL REP, V7, P554, DOI 10.1111/1758-2229.12285
   Mach N, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-894
   Maes D, 2008, VET MICROBIOL, V126, P297, DOI 10.1016/j.vetmic.2007.09.008
   Masella AP, 2012, BMC BIOINFORMATICS, V13, DOI 10.1186/1471-2105-13-31
   Rodriguez JM, 2015, MICROB ECOL HEALTH D, V26, DOI 10.3402/mehd.v26.26050
   Mohr S, 2007, TRENDS MOL MED, V13, P422, DOI 10.1016/j.molmed.2007.08.003
   Oh JZ, 2014, IMMUNITY, V41, P478, DOI 10.1016/j.immuni.2014.08.009
   Pennings JLA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002596
   Ponomareva A A, 2011, Vopr Onkol, V57, P302
   Ramayo-Caldas Y, 2016, ISME J, V10, P2973, DOI 10.1038/ismej.2016.77
   Ransom-Jones E, 2012, MICROB ECOL, V63, P267, DOI 10.1007/s00248-011-9998-1
   Regnstrom K., 2002, Pharmacogenomics Journal, V2, P57, DOI 10.1038/sj.tpj.6500080
   Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616
   Rohart F, 2017, PLOS COMPUT BIOL, V13, DOI 10.1371/journal.pcbi.1005752
   Ropka-Molik K, 2014, ANIM GENET, V45, P674, DOI 10.1111/age.12184
   Salk HM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0162803
   Seekatz AM, 2013, PLOS ONE, DOI [10.1371/journal.pone.0064217, DOI 10.1371/JOURNAL.PONE.0064217]
   Segata N, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-6-r60
   Singh H, 2015, J CLIN ENDOCR METAB, V100, pE936, DOI 10.1210/jc.2014-3969
   Thacker EL, 1998, SWINE HEAL PROD
   Toth Kinga, 2009, Orvosi Hetilap, V150, P969, DOI 10.1556/OH.2009.28625
   van Leeuwen DM, 2008, ENVIRON HEALTH PERSP, V116, P1519, DOI 10.1289/ehp.11401
   Vazquez-Baeza Y, 2013, GIGASCIENCE, V2, DOI 10.1186/2047-217X-2-16
   Wang Y, 2016, PLACENTA, V47, P46, DOI 10.1016/j.placenta.2016.09.003
   Wesemann DR, 2015, ADV IMMUNOL, V125, P155, DOI 10.1016/bs.ai.2014.09.005
   Wilkie B, 1999, VET IMMUNOL IMMUNOP, DOI [10.1016/s0165-2427(99)00136-1, DOI 10.1016/50165-2427/99100136-1]
   Willing BP, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026988
   Yatsunenko T, 2012, NATURE, V486, P222, DOI 10.1038/nature11053
   Zeng MY, 2016, IMMUNITY, V44, P647, DOI 10.1016/j.immuni.2016.02.006
NR 70
TC 0
Z9 0
U1 4
U2 17
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 22
PY 2019
VL 37
IS 13
BP 1743
EP 1755
DI 10.1016/j.vaccine.2019.02.016
PG 13
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HQ8QZ
UT WOS:000462691700004
PM 30808565
DA 2020-05-12
ER

PT J
AU Watanabe, A
   Shimada, T
   Takahashi, T
   Arima, Y
   Kinoshita, H
   Saitoh, T
   Kanou, K
   Matsui, T
   Sunagawa, T
   Tanaka-Taya, K
   Oishi, K
AF Watanabe, Aika
   Shimada, Tomoe
   Takahashi, Takuri
   Arima, Yuzo
   Kinoshita, Hitomi
   Saitoh, Takehiko
   Kanou, Kazuhiko
   Matsui, Tamano
   Sunagawa, Tomimasa
   Tanaka-Taya, Keiko
   Oishi, Kazunori
TI Correlates of laboratory-confirmed measles in Japan, 2011-2015
SO VACCINE
LA English
DT Article
DE Correlates of measles; Vaccination; Surveillance; Measles elimination;
   Laboratory diagnosis
ID ELIMINATION; VIRUS
AB Background: With the progressive decline in the incidence of measles in Japan, its diagnosis has become challenging, with fewer physicians having experience in examining measles patients. We aimed to determine the correlates of laboratory-confirmed measles to help physicians improve their measles diagnosis.
   Methods: This study was conducted using the National Epidemiological Surveillance of Infectious Disease (NESID) system data during 2011-2015. Among clinically suspected measles patients reported to NESID, measles virus (MV)-positive patients were compared with MV-negative patients. The odds ratios (OR) and associated 95% confidence intervals (CI) were determined using logistic regression.
   Results: A total of 4168 laboratory-tested patients were notified to NESID. We analysed 618 MV-positive patients (median age, 17 years; interquartile range [IQR], 4-30 years) and 600 MV-negative (median age, 10 years; IQR, 1-29 years) patients after excluding those that met the exclusion criteria or were reported during the rubella epidemic period (the 18th epidemiological week of 2012 to the 46th week of 2013). Having an epidemiological link with a measles patient within 14 days of onset (OR, 14.9; 95% CI, 10.0-23.3), a history of recent international travel (OR, 11.7; 95% CI, 6.9-19.9), and unvaccinated/unknown vaccination status for measles-containing vaccine (MCV; OR, 3.7; 95% CI, 2.3-5.7) were significantly associated with MV-positive status. International travel (adjusted OR, 10.2; 95% CI, 5.9-17.7) and unvaccinated/unknown MCV vaccination status (adjusted OR, 5.8; 95% CI, 3.5-9.8) remained significantly associated with MV-positive status after adjusting for age, sex, and each other.
   Conclusion: In low-incidence Japan, having an epidemiological link, international travel, and lack of MCV vaccination were correlates of laboratory-confirmed measles. The findings of this study could potentially improve the clinical diagnosis of measles, which can lead to more efficient testing and earlier laboratory confirmation. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Watanabe, Aika; Shimada, Tomoe; Takahashi, Takuri; Arima, Yuzo; Kinoshita, Hitomi; Saitoh, Takehiko; Kanou, Kazuhiko; Matsui, Tamano; Sunagawa, Tomimasa; Tanaka-Taya, Keiko; Oishi, Kazunori] Natl Inst Infect Dis, Infect Dis Surveillance Ctr, Shinjuku Ku, 1-23-1 Toyama, Tokyo 1628640, Japan.
   [Watanabe, Aika] Osaka Univ, Dept Epidemiol Infect Dis, Grad Sch Med, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.
RP Shimada, T (reprint author), Natl Inst Infect Dis, Infect Dis Surveillance Ctr, Shinjuku Ku, 1-23-1 Toyama, Tokyo 1628640, Japan.
EM tomoes@niid.go.jp
OI Arima, Yuzo/0000-0002-8711-7636; Watanabe, Aika/0000-0002-0891-593X
FU Grant of National Center for Global Health and Medicine [26-101]; Japan
   Agency for Medical Research and DevelopmentJapan Agency for Medical
   Research and Development (AMED) [JP18fk0108066]
FX This work was supported by The Grant of National Center for Global
   Health and Medicine (grant number 26-101) and the Japan Agency for
   Medical Research and Development (grant number JP18fk0108066). These
   funding sources had no involvement in the study design, data collection,
   analysis and interpretation of data, writing of the report, or decision
   to submit the article for publication.
CR Botelho-Nevers E, 2012, VACCINE, V30, P3996, DOI 10.1016/j.vaccine.2012.04.023
   Eom H, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0188957
   Griffin DE, 2012, FEMS MICROBIOL REV, V36, P649, DOI 10.1111/j.1574-6976.2012.00330.x
   Japan National Tourism Organization, VIS ARR JAP OV TRAV
   Japan National Tourism Organization, 2018, JAP TOUR STAT
   Kohira S, 2014, IASR, V35, P179
   Komabayashi K, 2018, JPN J INFECT DIS, V29, P1, DOI [10.07883/yoken.lIlD.2018.083, DOI 10.07883/YOKEN.LILD.2018.083]
   MacIntyre CR, 2018, VACCINE, V36, P4393, DOI 10.1016/j.vaccine.2018.06.022
   Maltezou HC, 2013, AM J INFECT CONTROL, V41, P661, DOI 10.1016/j.ajic.2012.09.017
   Minagawa H, 2015, VACCINE, V33, P6043, DOI 10.1016/j.vaccine.2015.08.070
   Ministry of Health Labour and Welfare, LAB WELF COND LAB DI
   Ministry of Health Labour and Welfare, IMPL MAN NAT EP SURV
   Ministry of Health Labour and Welfare, NOT MEAS
   Ministry of Health Labour and Welfare National Institute of Infectious Diseases, 2018, IASR, V39, P29
   Ministry of Health Labour and Welfare National Institute of Infectious Diseases, 2018, INF DIS WEEKL REP
   Ministry of Health Labour and Welfare National Institute of Infectious Diseases, REP CRIT MEASL INF A
   Mizumoto K, 2018, EUROSURVEILLANCE, V23, P8, DOI 10.2807/1560-7917.ES.2018.23.24.1800239
   Najjar Z, 2014, WEST PAC SURVEILL RE, V5, DOI [10.5365/wpsar.2013.4.4.002, 10.5365/WPSAR.2013.4.4.002]
   Perry RT, 2004, J INFECT DIS, V189, pS4, DOI 10.1086/377712
   SIMPSON REH, 1952, LANCET, V263, P549
   Sunagawa T., 2008, Morbidity and Mortality Weekly Report, V57, P1049
   Takahashi T, 2014, WEST PAC SURVEILL RE, V5, P31, DOI [10.5365/WPSAR.2014.5.2.001, 10.5365/wpsar.2014.5.2.001]
   Tanaka-Taya Keiko, 2017, Virus (Nagoya), V67, P17, DOI 10.2222/jsv.67.17
   Watanabe A, 2017, WEST PAC SURVEILL RE, V8, DOI 10.5365/wpsar.2016.7.4.007
   WHO, 2007, MAN LAB DIAGN MEASL
   World Health Organization, 2018, MEASL
   World Health Organization and UNICEF, 2016, JAP WHO UNICEF EST I
   World Health Organization Western Pacific Region, 2013, GUID VER MEASL EL W
   World Health Organization Western Pacific Region, 2015, BRUN DAR CAMB
   Yang TU, 2015, INT J INFECT DIS, V33, P12, DOI 10.1016/j.ijid.2014.09.016
   Zipprich J, 2015, MMWR-MORBID MORTAL W, V64, P153
NR 31
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 22
PY 2019
VL 37
IS 13
BP 1756
EP 1762
DI 10.1016/j.vaccine.2019.02.011
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HQ8QZ
UT WOS:000462691700005
PM 30803842
DA 2020-05-12
ER

PT J
AU Krogsgaard, LW
   Bech, BH
   Plana-Ripoll, O
   Thomsen, RW
   Rytter, D
AF Krogsgaard, Lene Wulff
   Bech, Bodil Hammer
   Plana-Ripoll, Oleguer
   Thomsen, Reimar Wernich
   Rytter, Dorte
TI Hospital contacts and diagnoses five years prior to HPV vaccination
   among females referred for suspected adverse vaccine effects: A Danish
   nationwide case-control study
SO VACCINE
LA English
DT Article
DE HPV vaccine; Suspected adverse effects; Diagnoses; Hospital contacts;
   Register based; Matched case-control study
ID HUMAN-PAPILLOMAVIRUS VACCINATION; RISK; REGISTER
AB Background: High health care utilization before Human Papilloma Virus (HPV) vaccination might be associated with increased risk of suspected adverse effects (AE's) after vaccination. We investigated the association between hospital contacts and diagnoses before HPV vaccination and risk of later referral to a specialized hospital setting (HPV center) for suspected AE's.
   Methods: The study was a Danish register-based matched case-control study. Cases were females referred to an HPV center. Five controls per case were randomly selected in the source population of HPV vaccinated females. Information on hospital contacts and diagnoses was obtained from the Danish National Patient Registry. Conditional logistic regression analyses were used to investigate the association between having one or more diagnoses in each specific International Classification of Diseases 10th version (ICD-10) chapter five years before the HPV vaccination and subsequent referral to an HPV center.
   Results: We identified 1496 cases and 7480 controls. In total, 80% of the cases versus 65% of the controls had at least one hospital contact prior to HPV vaccination (Prevalence Proportion Ratio - PPR: 1.24 (95% Confidence Interval - CI: 1.21-1.27)), with 24% vs 12% (PPR: 1.97 (95% CI: 1.76-2.19)) having six or more contacts. Cases were more likely to have had a diagnosis in 15 out of 19 ICD-10 chapters before the vaccination, with ORs larger than 1.8 for infectious diseases, psychiatric diseases, diseases of the nervous, circulatory, digestive and musculoskeletal system, unspecific symptoms and unspecific contacts.
   Conclusion: Pre-vaccination morbidity and health care utilization seem to play a role in the path leading to suspected AE's after HPV vaccination. Since many of the diagnoses that were particularly increased before vaccination in referred females are overlapping with the most frequent symptoms reported, we cannot exclude that for some of the females, the suspected AE's might have been existing already before the vaccination. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Krogsgaard, Lene Wulff; Bech, Bodil Hammer; Rytter, Dorte] Aarhus Univ, Dept Publ Hlth, Bartholins Alle 2, Aarhus C, Denmark.
   [Plana-Ripoll, Oleguer] Aarhus Univ, Natl Ctr Register Based Res, Fuglesangs Alle 26, Aarhus V, Denmark.
   [Thomsen, Reimar Wernich] Aarhus Univ Hosp, Dept Clin Epidemiol, Palle Juul Jensens Blvd 99, Aarhus N, Denmark.
RP Krogsgaard, LW (reprint author), Aarhus Univ, Dept Publ Hlth, Bartholins Alle 2, Aarhus C, Denmark.
EM L.krogsgaard@ph.au.dk; bhb@ph.au.dk; opr@econ.au.dk; rwt@clin.au.dk;
   dr@ph.au.dk
RI Plana-Ripoll, Oleguer/E-1448-2015
OI Plana-Ripoll, Oleguer/0000-0002-6470-7465; Rytter,
   Dorte/0000-0003-1518-0975; Thomsen, Reimar/0000-0001-9135-3474; Bech,
   Bodil Hammer/0000-0002-0287-3687
FU Danish Cancer SocietyDanish Cancer Society [R183-A11333]; Helsefonden
   [17-B-0094]
FX This work was supported by Danish Cancer Society [R183-A11333 to D.R]
   and by Helsefonden [17-B-0094 to D.R]. The funding agencies had no role
   in study design, data collection, data analysis and interpretation of
   data, writing of the article or decision of submission for publication.
CR Amdisen L, 2018, VACCINE, V36, P5747, DOI 10.1016/j.vaccine.2018.08.006
   Andersen JS, 2011, SCAND J PUBLIC HEALT, V39, P34, DOI 10.1177/1403494810394718
   Andersen TF, 1999, DAN MED BULL, V46, P263
   Arbyn M, 2018, COCHRANE DB SYST REV, V5, DOI [10.1002/14651858.CD009069.pub3.29740819, DOI 10.1002/14651858.CD009069.PUB3.29740819]
   Baldur-Felskov B, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/djt460
   Brinth L, 2015, DAN MED J, V62
   Brinth LS, 2015, VACCINE, V33, P2602, DOI 10.1016/j.vaccine.2015.03.098
   Feiring B, 2017, VACCINE, V35, P4203, DOI 10.1016/j.vaccine.2017.06.031
   Garland SM, 2016, CLIN INFECT DIS, V63, P519, DOI 10.1093/cid/ciw354
   Herweijer E, 2016, INT J CANCER, V138, P2867, DOI 10.1002/ijc.30035
   Hviid A, 2018, J INTERN MED, V283, P154, DOI 10.1111/joim.12694
   Kildemoes HW, 2011, SCAND J PUBLIC HEALT, V39, P38, DOI 10.1177/1403494810394717
   Lu BB, 2011, BMC INFECT DIS, V11, DOI 10.1186/1471-2334-11-13
   Lutzen TH, 2017, CLIN EPIDEMIOL, V9, P465, DOI 10.2147/CLEP.S135318
   Molbak K, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0162520
   Nielsen SS, 2012, SCAND J PUBLIC HEALT, V40, P260, DOI 10.1177/1403494812443602
   Pedersen CB, 2011, SCAND J PUBLIC HEALT, V39, P22, DOI 10.1177/1403494810387965
   Rasmussen L, 2016, BASIC CLIN PHARMACOL, V119, P376, DOI 10.1111/bcpt.12610
   Scheller NM, 2015, JAMA-J AM MED ASSOC, V313, P54, DOI 10.1001/jama.2014.16946
   Scheller NM, 2014, JAMA-J AM MED ASSOC, V312, P187, DOI 10.1001/jama.2014.2198
   Schmidt M, 2015, CLIN EPIDEMIOL, V7, P449, DOI 10.2147/CLEP.S91125
   Schreiber SMS, 2015, J ADOLESCENT HEALTH, V56, P402, DOI 10.1016/j.jadohealth.2014.12.008
   Signorelli C, 2017, EPIDEMIOL INFECT, V145, P1962, DOI [10.1017/s0950268817000747, 10.1017/S0950268817000747]
   Sundhedsstyrelsen, 2018, ARSR BORN 2017
   Suppli CH, 2018, BMC PUBLIC HEALTH, V18, DOI 10.1186/s12889-018-6268-x
   Vichnin M, 2015, PEDIATR INFECT DIS J, V34, P983, DOI 10.1097/INF.0000000000000793
   Weye N, 2018, EUR J PUBLIC HLTH
   WHO, 2016, GLOB ADV COMM VACC S
   Willame C, 2016, HUM VACCIN IMMUNOTHE
   World Health Organisation Human papillomavirus (HPV) and cervical cancer, 2018, HUM PAP HPV CERV CAN
   World Health Organization, 2016, HUM PAP HPV CERV CAN
   World Health Organization, 2016, WKLY EPIDEMIOL REC, V91, P21
   World Health Organization (WHO), 2015, GLOB ADV COMM VACC S
NR 33
TC 1
Z9 1
U1 0
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 22
PY 2019
VL 37
IS 13
BP 1763
EP 1768
DI 10.1016/j.vaccine.2019.02.029
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HQ8QZ
UT WOS:000462691700006
PM 30803841
DA 2020-05-12
ER

PT J
AU Meyer, SB
   Violette, R
   Aggarwal, R
   Simeoni, M
   Macdougall, H
   Waite, N
AF Meyer, Samantha B.
   Violette, Richard
   Aggarwal, Reenika
   Simeoni, Michelle
   Macdougall, Heather
   Waite, Nancy
TI Vaccine hesitancy and Web 2.0: Exploring how attitudes and beliefs about
   influenza vaccination are exchanged in online threaded user comments
SO VACCINE
LA English
DT Article
DE Influenza vaccine; Scraping software; Web 2.0; Vaccine hesitancy; Health
   communication
ID PARENTS; CANADA; CONTROVERSY; ONTARIO; REFUSAL
AB The growth of Web 2.0 has been particularly impactful in shaping information assessment in decision-making with regards to vaccination. The aim of the present study was to explore how attitudes and beliefs about influenza vaccination are exchanged in Web 2.0 through an analysis of user comment threads in response to related news reports on the Canadian Broadcasting Corporation national news website (average of 5.8 million unique visitors per month). User comments (n = 2042) were extracted using a Google Chrome data mining extension, from 33 articles reporting on the seasonal influenza vaccine between September 2015 and October 2016. User comments were analyzed using thematic discourse analysis to identify themes within the data, and also identify how information is exchanged, including identifying the rhetorical devices and tactics used. Mostly unrelated to article content, user comments were extremely polarized with only those with strong positions at either end of the vaccination spectrum (for or against) engaging actively in online debates. Observed exchanges, and the use of rhetorical devices and tactics employed by users are identified as furthering or reinforcing polarization. In addition to exchanging information, forums served as 'echo chambers' where individuals connect with likeminded users and collect additional information to reinforce pre-existing beliefs, rather than encouraging the enrichment of user knowledge. Our data lead us to question existing calls for public health engagement in such online forums, as doing so may actually reduce the intention to vaccinate among individuals against vaccination. Rather, we identify a greater need to observe online platforms to better understand the social mechanisms that may contribute to, or reinforce, attitudes and beliefs related to influenza vaccine refusal. Further research may also explore the effect that such dialogue has on the attitudes and beliefs of passively observing individuals who have yet to decide whether to receive the flu vaccine. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Meyer, Samantha B.; Aggarwal, Reenika; Simeoni, Michelle] Univ Waterloo, Sch Publ Hlth & Hlth Syst, LHN 1722, Waterloo, ON N2L 3G1, Canada.
   [Violette, Richard; Waite, Nancy] Univ Waterloo, Sch Pharm, Waterloo, ON, Canada.
   [Macdougall, Heather] Univ Waterloo, Dept Hist, Waterloo, ON, Canada.
RP Meyer, SB (reprint author), Univ Waterloo, Sch Publ Hlth & Hlth Syst, LHN 1722, Waterloo, ON N2L 3G1, Canada.
EM Samantha.meyer@uwaterloo.ca
OI Violette, Richard/0000-0002-7773-1202; Waite, Nancy/0000-0003-3440-9843
CR Betsch C, 2012, VACCINE, V30, P3727, DOI 10.1016/j.vaccine.2012.02.025
   Betsch C, 2010, J HEALTH PSYCHOL, V15, P446, DOI 10.1177/1359105309353647
   Braun V., 2006, QUALITATIVE RES PSYC, V3, P77, DOI DOI 10.1191/1478088706QP0630A
   Broniatowski DA, 2018, AM J PUBLIC HEALTH, V108, P1378, DOI 10.2105/AJPH.2018.304567
   Brown KF, 2012, VACCINE, V30, P1855, DOI 10.1016/j.vaccine.2011.12.127
   Brunson EK, 2017, HUM ORGAN, V76, P38, DOI 10.17730/0018-7259.76.1.38
   Brunson EK, 2013, VACCINE, V31, P5466, DOI 10.1016/j.vaccine.2013.08.104
   CBC Radio, 2018, OUR HIST
   Corporation CB, 2017, CBC POL
   Dixon G, 2013, HEALTH EDUC RES, V28, P352, DOI 10.1093/her/cys110
   Dube E, 2016, Can Commun Dis Rep, V42, P246
   Dube E, 2014, AM J INFECT CONTROL, V42, pE55, DOI 10.1016/j.ajic.2014.01.006
   Faasse K, 2016, VACCINE, V34, P5808, DOI 10.1016/j.vaccine.2016.09.029
   Kata A, 2012, VACCINE, V30, P3778, DOI 10.1016/j.vaccine.2011.11.112
   Kata A, 2010, VACCINE, V28, P1709, DOI 10.1016/j.vaccine.2009.12.022
   Kaufman SR, 2010, ETHOS, V38, P8, DOI 10.1111/j.1548-1352.2009.01079.x
   LLC SIL, 2018, DAT MIN
   MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036
   Mercer R., 2012, RMR RICKS RANT FLU S
   Meyer SB, 2017, J HEALTH COMMUN, V22, P506, DOI 10.1080/10810730.2017.1312720
   Meyer SB, 2016, J HEALTH COMMUN, V21, P1088, DOI 10.1080/10810730.2016.1222038
   Nicholson MS, 2012, VACCINE, V30, P3806, DOI 10.1016/j.vaccine.2011.10.072
   Nonnecke B, 2000, P CHI 2000
   Nyhan B, 2014, PEDIATRICS, V133, pE835, DOI 10.1542/peds.2013-2365
   Peretti-Watel P, 2015, PLOS CURRENT OUTBREA, DOI [10.1371/currents.outbreaks.6844c80ff9f5b273f34c91f71h7fe789, DOI 10.1371/CURRENTS.OUTBREAKS6844C80FF9F5B273F34C91F71B7FE789]
   Reich JA, 2014, GENDER SOC, V28, P679, DOI 10.1177/0891243214532711
   Salathe M, 2011, PLOS COMPUT BIOL, V7, DOI 10.1371/journal.pcbi.1002199
   Schmid P, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170550
   Singer D, 1996, J REPROD INFANT PSYC, V17, P63, DOI [10.1080/02646839908404585, DOI 10.1080/02646839908404585]
   Sobo EJ, 2016, MED ANTHROPOL, V35, P529, DOI 10.1080/01459740.2016.1145219
   Sobo EJ, 2015, MED ANTHROPOL Q, V29, P381, DOI 10.1111/maq.12214
   Ward PR, 2018, J RISK RES, V21, P1117, DOI 10.1080/13669877.2017.1391318
   Wise AF, 2013, INSTR SCI, V41, P323, DOI 10.1007/s11251-012-9230-9
   Witteman HO, 2012, VACCINE, V30, P3734, DOI 10.1016/j.vaccine.2011.12.039
   Zimmerman RK, 2005, J MED INTERNET RES, V7, DOI 10.2196/jmir.7.2.e17
NR 35
TC 2
Z9 2
U1 2
U2 9
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 22
PY 2019
VL 37
IS 13
BP 1769
EP 1774
DI 10.1016/j.vaccine.2019.02.028
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HQ8QZ
UT WOS:000462691700007
PM 30826142
DA 2020-05-12
ER

PT J
AU Kennedy, RB
   Ovsyannikova, IG
   Thomas, A
   Larrabee, BR
   Rubin, S
   Poland, GA
AF Kennedy, Richard B.
   Ovsyannikova, Inna G.
   Thomas, Antonia
   Larrabee, Beth R.
   Rubin, Steven
   Poland, Gregory A.
TI Differential durability of immune responses to measles and mumps
   following MMR vaccination
SO VACCINE
LA English
DT Article
DE Mumps; Mumps vaccine; Mumps virus; Measles; Measles vaccine; Measles
   virus; MMR-II vaccine; Antibodies; Humoral immunity; T cell ELISPOT;
   Cell-mediated immunity
ID RUBELLA VACCINE; VIRUS VACCINE; ANTIBODIES; ASSAY; IMMUNIZATION;
   OUTBREAK; PERSISTENCE; UNIVERSITY; STABILITY; CELLS
AB The development and wide-spread use of mumps vaccine resulted in a dramatic and sustained decrease in the incidence of mumps disease; however, since 2000, an increase in the size and number of mumps outbreaks in the United States and other countries has sparked renewed interest in the durability of mumps-specific immunity elicited by mumps vaccination. The most likely explanation for mumps cases in previously immunized persons may be secondary vaccine failure, or waning immunity. In the current study, we examined changes in markers of measles and mumps immunity at two timepoints, approximately 7 and 17 years after two-dose MMR-II (R) vaccination, in a cohort of 98 healthy adults.
   Our results indicate that mumps IgG titers exhibited a large and significant decline during this time period, while mumps neutralizing Ab titers were relatively stable. There was a similar discrepancy with measles-specific immune responses. For both pathogens, neutralizing antibody titers were fairly low and, given the length of time since vaccination, may have already declined. These data suggest that specific immune outcomes may wane at different rates and highlight our currently incomplete understanding of protective immune responses to mumps and measles. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Kennedy, Richard B.; Ovsyannikova, Inna G.; Poland, Gregory A.] Mayo Clin, Vaccine Res Grp, Rochester, MN 55905 USA.
   [Thomas, Antonia; Rubin, Steven] US Dept Hlth & Human Serv, Ctr Biol Evaluat & Res, US FDA, Silver Spring, MD 20993 USA.
   [Larrabee, Beth R.] Mayo Clin, Div Biomed Stat & Informat, Dept Hlth Sci Res, Rochester, MN 55905 USA.
RP Kennedy, RB (reprint author), Mayo Clin, Mayo Vaccine Res Grp, Guggenheim 611D,200 First St SW, Rochester, MN 55905 USA.
EM kennedy.rick@mayo.edu
FU Merck Investigator Studies Program; National Institute of Allergy And
   Infectious Diseases of the National Institutes of HealthUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [R01AI33144, R01AI127365, R01AI121054]
FX Research reported in this publication was supported by a grant to Dr.
   Kennedy from the Merck Investigator Studies Program. Additional support
   was provided by the National Institute of Allergy And Infectious
   Diseases of the National Institutes of Health through grants R01AI33144,
   R01AI127365, and R01AI121054. The content is solely the responsibility
   of the authors and does not necessarily represent the official views of
   Merck Laboratories or the National Institutes of Health.
CR Abedi GR, 2012, VACCINE, V30, P7052, DOI 10.1016/j.vaccine.2012.09.053
   Albertson JP, 2016, MMWR-MORBID MORTAL W, V65, P731, DOI 10.15585/mmwr.mm6529a2
   BOULIANNE N, 1995, VACCINE, V13, P1611, DOI 10.1016/0264-410X(95)00098-L
   BUYNAK EB, 1966, P SOC EXP BIOL MED, V123, P768, DOI 10.3181/00379727-123-31599
   Cardemil CV, 2017, NEW ENGL J MED, V377, P947, DOI 10.1056/NEJMoa1703309
   CHRISTENSON B, 1990, BIOLOGICALS, V18, P213, DOI 10.1016/1045-1056(90)90009-O
   Cohen BJ, 2007, VACCINE, V26, P59, DOI 10.1016/j.vaccine.2007.10.046
   Date AA, 2008, J INFECT DIS, V197, P1662, DOI 10.1086/588197
   Deeks SL, 2011, CAN MED ASSOC J, V183, P1014, DOI 10.1503/cmaj.101371
   ENDERS JF, 1946, J IMMUNOL, V54, P283
   FEDOVA D, 1987, Journal of Hygiene Epidemiology Microbiology and Immunology (Prague), V31, P409
   Fiebelkorn AP, 2013, EMERG INFECT DIS, V19, P1411, DOI 10.3201/eid1909.130299
   HABEL K, 1945, PUBLIC HEALTH REP, V60, P201, DOI 10.2307/4585189
   Haralambieva IH, 2008, CLIN VACCINE IMMUNOL, V15, P1054, DOI 10.1128/CVI.00008-08
   Haralambieva IH, 2013, HUM IMMUNOL, V74, P1263, DOI 10.1016/j.humimm.2013.06.031
   Haralambieva LH, 2014, VACCINE, V32, P1946, DOI 10.1016/j.vaccine.2014.01.090
   HARMSEN T, 1992, J CLIN MICROBIOL, V30, P2139, DOI 10.1128/JCM.30.8.2139-2144.1992
   Hendriks J, 2014, BIOANALYSIS, V6, P1385, DOI 10.4155/bio.14.96
   Johnson CD, 1934, J EXP MED, V59, P1, DOI 10.1084/jem.59.1.1
   Kennedy RB, 2009, VACCINE, V27, P3319, DOI 10.1016/j.vaccine.2009.01.086
   Klein SL, 2010, LANCET INFECT DIS, V10, P338, DOI 10.1016/S1473-3099(10)70049-9
   KOMADA H, 1991, ARCH VIROL, V116, P277, DOI 10.1007/BF01319249
   Latner DR, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004791
   Latner DR, 2014, CLIN VACCINE IMMUNOL, V21, P286, DOI 10.1128/CVI.00621-13
   LeBaron CW, 2009, J INFECT DIS, V199, P552, DOI 10.1086/596207
   Mauldin J, 2005, J CLIN MICROBIOL, V43, P4847, DOI 10.1128/JCM.43.9.4847-4851.2005
   Michaut L, 2014, BIOANALYSIS, V6, P1395, DOI 10.4155/bio.14.97
   MILLER E, 1995, VACCINE, V13, P799, DOI 10.1016/0264-410X(94)00086-3
   Muhlemann K, 2004, INFECT GENET EVOL, V4, P215, DOI 10.1016/j.meegid.2004.02.003
   NIGRO G, 1986, J VIROL METHODS, V13, P91, DOI 10.1016/0166-0934(86)90077-7
   Ovsyannikova IG, 2015, IMMUNOGENETICS, V67, P547, DOI 10.1007/s00251-015-0864-z
   Pinsky NA, 2003, CLIN DIAGN LAB IMMUN, V10, P19, DOI 10.1128/CDLI.10.1.19-21.2003
   Pipkin PA, 1999, J VIROL METHODS, V79, P219, DOI 10.1016/S0166-0934(99)00019-1
   Rubin S, 2017, PLOTKINS VACCINES, P663
   Rubin S, 2016, PEDIATR INFECT DIS J, V35, P799, DOI 10.1097/INF.0000000000001182
   Rubin S, 2015, J PATHOL, V235, P242, DOI 10.1002/path.4445
   Rubin SA, 2008, J INFECT DIS, V198, P508, DOI 10.1086/590115
   Rubin SA, 2012, J VIROL, V86, P615, DOI 10.1128/JVI.06125-11
   Tabatabaei SR, 2013, ARCH IRAN MED, V16, P38, DOI 013161/AIM.0012
   Umlauf BJ, 2012, METHODS MOL BIOL, V792, P199, DOI 10.1007/978-1-61779-325-7_16
   Vandermeulen C, 2010, IMMUNOLOGY, V131, P33, DOI 10.1111/j.1365-2567.2010.03263.x
   Voysey M, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-011680
   WEIBEL RE, 1967, NEW ENGL J MED, V276, P245, DOI 10.1056/NEJM196702022760501
NR 43
TC 5
Z9 5
U1 2
U2 9
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 22
PY 2019
VL 37
IS 13
BP 1775
EP 1784
DI 10.1016/j.vaccine.2019.02.030
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HQ8QZ
UT WOS:000462691700008
PM 30797639
OA Green Accepted
DA 2020-05-12
ER

PT J
AU Getahun, D
   Fassett, MJ
   Peltier, MR
   Takhar, HS
   Shaw, SF
   Im, TM
   Chiu, VY
   Jacobsen, SJ
AF Getahun, Darios
   Fassett, Michael J.
   Peltier, Morgan R.
   Takhar, Harpreet S.
   Shaw, Sally F.
   Im, Theresa M.
   Chiu, Vicki Y.
   Jacobsen, Steven J.
TI Association between seasonal influenza vaccination with pre- and
   postnatal outcomes
SO VACCINE
LA English
DT Article
DE Perinatal outcome; Vaccination; Influenza; Race; Ethnicity
ID CHRONIC RESPIRATORY-DISEASES; PREGNANT-WOMEN; BIRTH; ILLNESS; RISK;
   HOSPITALIZATION
AB Objective: Influenza vaccination during pregnancy is known to prevent severe influenza illness but its effects on other outcomes and the extent to which its safety is affected by timing of vaccination, maternal race/ethnicity and the type of vaccine is less clear. Therefore, we examined this in a large retrospective cohort.
   Methods: We analyzed medical and vaccination records from the Kaiser Permanente Southern California (KPSC) records and from the Kaiser Immunization Tracking System (2008-2016). The study included women who were pregnant with singletons during the influenza season. Odds ratios (OR) and their 95% confidence intervals (CI) were used to quantify the associations between immunization status during pregnancy and prenatal and postnatal outcomes after adjusting for confounders.
   Results: Of the 247,036 women in these analyses, 53% were vaccinated during their pregnancy. No association between influenza vaccination during pregnancy and adverse prenatal and neonatal outcomes were observed. Influenza vaccination is associated with reduced risk of influenza (OR: 0.49, 95% CI: 0.39-0.62), maternal fever (OR: 0.40, 95% CI: 0.35-0.45), preeclampsia (OR: 0.93, 95% CI: 0.90-0.96), placental abruption (OR: 0.89, 95% CI: 0.82-0.96), stillbirth (OR: 0.88, 95% CI: 0.78-0.99), and NICU admission (OR: 0.89, 95% CI: 0.87-0.92). Both active and inactive vaccines were found to be safe in vaccinated pregnant women regardless of timing of vaccination.
   Conclusions: This study found no evidence of adverse maternal and infant outcomes associated with seasonal influenza vaccine during pregnancy. On the contrary, vaccinated women were less likely to have adverse outcomes than unvaccinated women. The lack of increased adverse outcomes associated with influenza vaccination suggests that the benefits of vaccination during pregnancy to the woman and her child far outweigh any risk, if there is one, from the vaccination. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Getahun, Darios; Takhar, Harpreet S.; Shaw, Sally F.; Im, Theresa M.; Chiu, Vicki Y.; Jacobsen, Steven J.] Kaiser Permanente Southern Calif, Dept Res & Evaluat, Pasadena, CA USA.
   [Getahun, Darios] Rutgers Robert Wood Johnson Med Sch, Dept Obstet Gynecol & Reprod Sci, New Brunswick, NJ USA.
   [Fassett, Michael J.] Kaiser Permanente Southern Calif, West Los Angeles Med Ctr, Obstet & Gynecol, West Los Angeles, CA USA.
   [Peltier, Morgan R.] NYU, Dept Biomed Res, Winthrop Hosp, Mineola, NY USA.
RP Getahun, D (reprint author), Kaiser Permanente Southern Calif Med Grp, Dept Res & Evaluat, 100 Los Robles Ave,2nd Floor, Pasadena, CA 91101 USA.
EM Darios.T.Getahun@kp.org
OI Jacobsen, Steven/0000-0002-8174-8533
FU Kaiser Permanente Direct Community Benefit Funds; NIH/NICHDUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH Eunice Kennedy Shriver National Institute of Child Health &
   Human Development (NICHD); NIH/NIEHSUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Environmental Health Sciences (NIEHS); Centers for Disease
   Control and PreventionUnited States Department of Health & Human
   ServicesCenters for Disease Control & Prevention - USA; Bayer Pharma AG;
   Dynavax Technologies, Berkeley CA
FX This study was supported by Kaiser Permanente Direct Community Benefit
   Funds. The opinions expressed are solely the responsibility of the
   authors and do not necessarily reflect the official views of the Kaiser
   Permanente Community Benefit Funds.; Dr. Getahun has received research
   support from NIH/NICHD, NIH/NIEHS, Centers for Disease Control and
   Prevention, Bayer Pharma AG. Dr. Fassett has received research support
   from NIH/NIEHS and Bayer Pharma AG. Dr. Peltier has received research
   support from NIH/NIEHS. Dr. Jacobsen has received research support from
   Centers for Disease Control and Prevention and Dynavax Technologies,
   Berkeley CA. All authors report no conflicts of interest.
CR Advisory Committee on Immunization Practices (ACIP), 2016, SUMM REP JUN 22 23 2
   Ahluwalia IB, 2014, PUBLIC HEALTH REP, V129, P408, DOI 10.1177/003335491412900504
   Andrade SE, 2013, PHARMACOEPIDEM DR S, V22, P7, DOI 10.1002/pds.3319
   Benowitz I, 2010, CLIN INFECT DIS, V51, P1355, DOI 10.1086/657309
   Berlutti F, 2011, MOLECULES, V16, P6992, DOI 10.3390/molecules16086992
   Bradley-Stewart A, 2013, J CLIN VIROL, V58, P100, DOI 10.1016/j.jcv.2013.05.011
   Brown AS, 2004, ARCH GEN PSYCHIAT, V61, P774, DOI 10.1001/archpsyc.61.8.774
   Buka SL, 2003, AM J PSYCHIAT, V160, P1978, DOI 10.1176/appi.ajp.160.11.1978
   COX RJ, 1994, VACCINE, V12, P993, DOI 10.1016/0264-410X(94)90334-4
   Cox S, 2006, OBSTET GYNECOL, V107, P1315, DOI 10.1097/01.AOG.0000218702.92005.bb
   Cunney RJ, 2000, INFECT CONT HOSP EP, V21, P449, DOI 10.1086/501786
   Fell DB, 2017, BJOG-INT J OBSTET GY, V124, P48, DOI 10.1111/1471-0528.14143
   Fell Deshayne B, 2012, Am J Public Health, V102, pe33, DOI 10.2105/AJPH.2011.300606
   Gerardin P, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010896
   Getahun D, 2013, J MED STAT INFORM, V1, P1
   Getahun D, 2007, J MATERN-FETAL NEO M, V20, P669, DOI 10.1080/14767050701516063
   Getahun D, 2006, AM J OBSTET GYNECOL, V195, P1180, DOI 10.1016/j.ajog.2006.07.027
   Goodnight William H, 2005, Crit Care Med, V33, pS390, DOI 10.1097/01.CCM.0000182483.24836.66
   Jamieson DJ, 2009, LANCET, V374, P451, DOI 10.1016/S0140-6736(09)61304-0
   Kharbanda EO, 2013, OBSTET GYNECOL, V122, P659, DOI 10.1097/AOG.0b013e3182a1118a
   Kierans William J, 2008, BMC Pregnancy Childbirth, V8, P1, DOI 10.1186/1471-2393-8-1
   Lisonkova S, 2011, BMC PREGNANCY CHILDB, V11, DOI 10.1186/1471-2393-11-39
   Louie JK, 2009, NEW ENGL J MED, V2010, P27, DOI DOI 10.1056/NEJM0A0910444
   Luteijn JM, 2014, HUM REPROD, V29, P809, DOI 10.1093/humrep/det455
   Madhi SA, 2014, NEW ENGL J MED, V371, P918, DOI 10.1056/NEJMoa1401480
   Mazumder B, 2010, J DEV ORIG HLTH DIS, V1, P26, DOI 10.1017/S2040174409990031
   Meijer WJ, 2014, INFECT DIS OBSTET GY, V2014, P1, DOI 10. 1155/2014/768380
   Melendi GA, 2010, ACTA PAEDIATR, V99, P1517, DOI 10.1111/j.1651-2227.2010.01862.x
   MELNIKOVA VF, 1987, ARK PATOL, V49, P19
   MONTO AS, 1975, AM J EPIDEMIOL, V102, P553, DOI 10.1093/oxfordjournals.aje.a112193
   Mor G, 2010, AM J REPROD IMMUNOL, V63, P425, DOI 10.1111/j.1600-0897.2010.00836.x
   Moretti ME, 2005, EPIDEMIOLOGY, V16, P216, DOI 10.1097/01.ede.0000152903.55579.15
   Munoz Flor M, 2003, Paediatr Respir Rev, V4, P99, DOI 10.1016/S1526-0542(03)00027-7
   Naleway AL, 2014, VACCINE, V32, P3122, DOI 10.1016/j.vaccine.2014.04.021
   Okubo H, 2011, PUBLIC HEALTH NUTR, V14, P611, DOI 10.1017/S1368980010002521
   Pierce M, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.d3214
   Rolland-Harris E, 2012, EPIDEMIOL INFECT, V140, P1316, DOI 10.1017/S0950268811001737
   Santry HP, 2005, JAMA-J AM MED ASSOC, V294, P1909, DOI 10.1001/jama.294.15.1909
   Savitz DA, 2015, VACCINE, V33, P6430, DOI 10.1016/j.vaccine.2015.08.041
   Schlaudecker EP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070867
   Siston AM, 2010, JAMA-J AM MED ASSOC, V303, P1517, DOI 10.1001/jama.2010.479
   Sokolow LZ, 2015, AM J OBSTET GYNECOL, V212, DOI 10.1016/j.ajog.2014.08.004
   Steinhoff MC, 2012, JAMA-J AM MED ASSOC, V308, P184, DOI 10.1001/jama.2012.7911
   Takei N, 1996, SCHIZOPHRENIA BULL, V22, P521, DOI 10.1093/schbul/22.3.521
   Uchide N, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/270670
   Uyeki TM, 2003, PEDIATR INFECT DIS J, V22, P164
   Vazquez-Benitez G, 2016, AM J EPIDEMIOL, V184, P176, DOI 10.1093/aje/kww043
   Wen LM, 2010, INT J BEHAV NUTR PHY, V7, DOI 10.1186/1479-5868-7-13
   Yen CJ, 2012, PEDIATR INFECT DIS J, V31, pE52, DOI 10.1097/INF.0b013e318247f094
   Zerbo O, 2017, VACCINE, V35, P3186, DOI 10.1016/j.vaccine.2017.04.074
NR 50
TC 4
Z9 4
U1 1
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 22
PY 2019
VL 37
IS 13
BP 1785
EP 1791
DI 10.1016/j.vaccine.2019.02.019
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HQ8QZ
UT WOS:000462691700009
PM 30799158
DA 2020-05-12
ER

PT J
AU Lefevre, H
   Samain, S
   Ibrahim, N
   Fourmaux, C
   Tonelli, A
   Rouget, S
   Mimoun, E
   De Tournemire, R
   Devernay, M
   Moro, MR
   Lachal, J
AF Lefevre, Herve
   Samain, Stephanie
   Ibrahim, Nour
   Fourmaux, Christine
   Tonelli, Anne
   Rouget, Sebastien
   Mimoun, Emmanuelle
   De Tournemire, Renaud
   Devernay, Marie
   Moro, Marie Rose
   Lachal, Jonathan
TI HPV vaccination and sexual health in France: Empowering girls to decide
SO VACCINE
LA English
DT Article
DE HPV; Human papillomavirus; Vaccines; Adolescent; Qualitative research;
   Attitudes
ID HUMAN-PAPILLOMAVIRUS VACCINATION; ADOLESCENT GIRLS; PARENTS; DECISION;
   BARRIERS; FACILITATORS; PERCEPTIONS; PROGRAM; VIEWS
AB Objective: Vaccination coverage against HPV in France is among the lowest in the industrialized world, although the public authorities have recently become aware of this issue. Few studies have looked at teenaged girls' representations of this vaccination, even though they are the most concerned by it. This qualitative study explored the experiences and representations of HPV vaccination by adolescent girls seeing doctors at least occasionally.
   Study Design: We used a written essay question to explore this issue among 101 adolescent girls at six urban medical centers and a semi-structured interview to discuss it in further depth with five of them. The analysis was lexicometric (ALCESTE (R)) and phenomenological (Interpretative Phenomenological Analysis).
   Results: These results are organized around four superordinate themes: the teenage girls' factual knowledge about this vaccine, their motives for and obstacles to vaccination, their involvement in this decision, and finally the need for information about and solutions to this issue.
   Conclusions: Teenage girls know little about this vaccine and are more sensitive to the emotional discourse that surrounds it than to rational knowledge about it. The requirement for parental authorization for this vaccine reinforces the girls' lack of investment. Vaccination programs should integrate the HPV vaccine more thoroughly into general prevention concerning sexual health and should send a strong signal by offering minors anonymous vaccination free of charge, as is already the case in France for requests for contraception, the morning-after pill, elective abortion, and screening and treatment of sexually transmitted infections. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Lefevre, Herve; Samain, Stephanie; Ibrahim, Nour; Moro, Marie Rose; Lachal, Jonathan] Cochin Hosp, AP HP, Paris, France.
   [Lefevre, Herve; Ibrahim, Nour; Moro, Marie Rose; Lachal, Jonathan] Univ Paris Saclay, INSERM, UVSQ, CESP,Fac Med,Univ Paris Sud, F-94805 Villejuif, France.
   [Lefevre, Herve; Ibrahim, Nour; Fourmaux, Christine; Tonelli, Anne; Rouget, Sebastien; Mimoun, Emmanuelle; De Tournemire, Renaud; Devernay, Marie] French Clin Res Grp Adolescent Med & Hlth, Paris, France.
   [Samain, Stephanie; Ibrahim, Nour; Moro, Marie Rose; Lachal, Jonathan] Univ Paris 05, Sorbonne Paris Cite, Paris, France.
   [Fourmaux, Christine] CHI Creteil, Unite Med Adolescent, Creteil, France.
   [Tonelli, Anne] Clinque E Rist, Serv Med Interne Adolescence, Paris, France.
   [Rouget, Sebastien] Ctr Hosp Sud Francilien, Serv Pediat, Corbeil Essonnes, France.
   [Mimoun, Emmanuelle] CH Marchant, Toulouse, France.
   [De Tournemire, Renaud] CHI Poissy St Germain Laye, Unite Med Adolescents, Conflans St Honorine, France.
   [Devernay, Marie] Trousseau Hosp, AP HP, Unite Adolescents, Paris, France.
RP Lachal, J (reprint author), CESP INSERM 1178, 97 Blvd Port Royal, F-75679 Paris 14, France.
EM herve.lefevre@aphp.fr; nour.ibrahim@aphp.fr;
   christine.Fourmaux@chicreteil.fr; anne.tonelli@fsef.net;
   sebastien.rouget@chsf.fr; emmanuelle.mimoun@ch-marchant.fr;
   rdetournemire@chi-poissy-st-germain.fr; marie.devernay@aphp.fr;
   marie-rose.moro@aphp.fr; jonathan.lachal@gmail.com
CR Amsellem-Mainguy Y, 2011, INFORM SOCIALES, V165-166, P156
   Bernard DM, 2011, MED J AUSTRALIA, V194, P297, DOI 10.5694/j.1326-5377.2011.tb02978.x
   Blume S, 2006, SOC SCI MED, V62, P628, DOI 10.1016/j.socscimed.2005.06.020
   Bonanni Paolo, 2015, Ther Adv Vaccines, V3, P3, DOI 10.1177/2051013614557476
   Chang J, 2018, J PEDIATR ADOL GYNEC, V31, P28, DOI 10.1016/j.jpag.2017.10.003
   de Martel C, 2017, INT J CANCER, V141, P664, DOI 10.1002/ijc.30716
   Ferrer HB, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-700
   Gordon D, 2011, VACCINE, V29, P7350, DOI 10.1016/j.vaccine.2011.07.083
   Gottvall M, 2011, VACCINE, V29, P4576, DOI 10.1016/j.vaccine.2011.04.054
   Gras-Le Guen C, 2017, VACCINE, V35, P4707, DOI 10.1016/j.vaccine.2017.07.042
   Hendry M, 2013, VACCINE, V31, P5152, DOI 10.1016/j.vaccine.2013.08.091
   Hilton S, 2011, VACCINE, V29, P4409, DOI 10.1016/j.vaccine.2011.03.101
   Hofman R, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104772
   Holman DM, 2014, JAMA PEDIATR, V168, P76, DOI 10.1001/jamapediatrics.2013.2752
   Hopfer S, 2011, QUAL HEALTH RES, V21, P262, DOI 10.1177/1049732310383868
   Hughes CC, 2011, BMC PEDIATR, V11, DOI 10.1186/1471-2431-11-74
   Javanbakht M, 2012, VACCINE, V30, P4511, DOI 10.1016/j.vaccine.2012.04.062
   Kata A, 2010, VACCINE, V28, P1709, DOI 10.1016/j.vaccine.2009.12.022
   Katz ML, 2009, VACCINE, V27, P3945, DOI 10.1016/j.vaccine.2009.04.040
   Kennedy C, 2014, INT J BEHAV MED, V21, P3, DOI 10.1007/s12529-013-9356-4
   Lefevre H, 2018, ARCH DIS CHILD, V103, P740, DOI 10.1136/archdischild-2017-313887
   Lefevre H, 2018, NEW ENGL J MED, V378, P1160, DOI 10.1056/NEJMc1801036
   Leone N, 2015, PROJECTION INCIDENCE
   Munoz N, 2003, NEW ENGL J MED, V348, P518, DOI 10.1056/NEJMoa021641
   Perkins RB, 2016, HUM VACC IMMUNOTHER, V12, P1528, DOI 10.1080/21645515.2015.1118594
   Rambout L, 2014, PREV MED, V58, P22, DOI 10.1016/j.ypmed.2013.10.009
   Rey C, 2002, ARCH PEDIATRIE, V9, P88
   Riethmuller D, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-1779-1
   Robbins SCC, 2010, HEALTH PSYCHOL, V29, P618, DOI 10.1037/a0021449
   Rondy M, 2010, VACCINE, V28, P2070, DOI 10.1016/j.vaccine.2009.12.042
   Schiffman M, 2007, LANCET, V370, P890, DOI 10.1016/S0140-6736(07)61416-0
   Schulein S, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889-016-3663-z
   Smith JA, 2008, QUAL PSYCHOL PRACT G
   Viens LJ, 2016, MMWR-MORBID MORTAL W, V65, P661, DOI 10.15585/mmwr.mm6526a1
   World Health Organization, 2006, DEF SEX HLTH REP TEC
NR 35
TC 1
Z9 1
U1 1
U2 6
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 22
PY 2019
VL 37
IS 13
BP 1792
EP 1798
DI 10.1016/j.vaccine.2019.02.020
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HQ8QZ
UT WOS:000462691700010
PM 30808568
DA 2020-05-12
ER

PT J
AU Tachibana, M
   Miura, K
   Takashima, E
   Morita, M
   Nagaoka, H
   Zhou, L
   Long, CA
   King, CR
   Torii, M
   Tsuboi, T
   Ishino, T
AF Tachibana, Mayumi
   Miura, Kazutoyo
   Takashima, Eizo
   Morita, Masayuki
   Nagaoka, Hikaru
   Zhou, Luwen
   Long, Carole A.
   King, C. Richter
   Torii, Motomi
   Tsuboi, Takafumi
   Ishino, Tomoko
TI Identification of domains within Pfs230 that elicit transmission
   blocking antibody responses
SO VACCINE
LA English
DT Article
DE Malaria; Pfs230; Plasmodium falciparum; Transmission-blocking vaccine;
   Wheat germ cell-free system
ID GAMETE-SURFACE PROTEIN; CELL-FREE SYSTEM; PLASMODIUM-FALCIPARUM; VACCINE
   CANDIDATES; ANTIGEN
AB A transmission-blocking vaccine (TBV) against Plasmodium falciparum is likely to be a valuable tool in a malaria eradication program. Pfs230 is one of the major TBV candidates, and multiple Pfs230-based vaccines induced antibodies, which prevented oocyst formation in mosquitoes as determined by a standard membrane-feeding assay (SMFA). Pfs230 is a >300 kDa protein consisting of 14 cysteine motif (CM) domains, and the size and cysteine-rich nature of the molecule have hampered its production as an intact protein. Except for one early study with maltose-binding protein fusion Pfs230 constructs expressed in Esherichia coli, all other studies have focused on only the first four CM domains in the Pfs230 molecule. To identify all possible TBV candidate domains, we systematically produced either single-CM-domain (a total of 14), 2-CM-domain (7), or 4-CM-domain (6) recombinant protein fragments using a eukaryotic wheat germ cell-free expression system (WGCFS). In addition, two more constructs which covered previously published regions, and an N-terminal prodomain construct spanning the natural cleavage site of Pfs230 were produced. Antisera against each fragment were generated in mice and we evaluated the reactivity to native Pfs230 protein by Western blots and immunofluorescence assay (IFA), and functionality by SMFA. All 30 WGCFS-produced Pfs230 constructs were immunogenic in mice. Approximately half of the mouse antibodies specifically recognized native Pfs230 by Western blots with variable band intensities. Among them, seven antibodies showed higher reactivities against native Pfs230 determined by IFA. Interestingly, antibodies against all protein fragments containing CM domain 1 displayed strong inhibitions in SMFA, while antibodies generated using constructs without CM domain 1 showed no inhibition. The results strongly support the concept that future Pfs230-based vaccine development should focus on the Pfs230 CM domain 1. (C) 2019 The Authors. Published by Elsevier Ltd.
C1 [Tachibana, Mayumi; Torii, Motomi; Ishino, Tomoko] Ehime Univ, Proteosci Ctr, Div Mol Parasitol, Toon, Ehime 7910295, Japan.
   [Miura, Kazutoyo; Zhou, Luwen; Long, Carole A.] NIAID, Lab Malaria & Vector Res, NIH, 12735 Twinbrook Pkwy, Rockville, MD 20852 USA.
   [Takashima, Eizo; Morita, Masayuki; Nagaoka, Hikaru; Tsuboi, Takafumi] Ehime Univ, Proteosci Ctr, Div Malaria Res, Bukyo Cho, Matsuyama, Ehime 7908577, Japan.
   [King, C. Richter] PATHs Malaria Vaccine Initiat MVI, Washington, DC 20001 USA.
RP Ishino, T (reprint author), Ehime Univ, Proteosci Ctr, Div Mol Parasitol, Toon, Ehime 7910295, Japan.; Tsuboi, T (reprint author), Ehime Univ, Proteosci Ctr, Div Malaria Res, Bukyo Cho, Matsuyama, Ehime 7908577, Japan.
EM mtachi@m.ehime-u.ac.jp; kmiura@niaid.nih.gov;
   takashima.eizo.mz@ehime-u.ac.jp; morita.masayuki.ls@ehime-u.ac.jp;
   nagaoka.hikaru.ys@ehime-u.ac.jp; luwen.zhou@nih.gov;
   clong@niaid.nih.gov; cking@path.org.jp; torii@m.ehime-u.ac.jp;
   tsuboi.takafumi.mb@ehime-u.ac.jp; tishino@m.ehime-u.ac.jp
OI Takashima, Eizo/0000-0001-9070-8499; Ishino, Tomoko/0000-0003-2466-711X;
   Tsuboi, Takafumi/0000-0002-7415-1325
FU JSPS KAKENHI GrantMinistry of Education, Culture, Sports, Science and
   Technology, Japan (MEXT)Japan Society for the Promotion of
   ScienceGrants-in-Aid for Scientific Research (KAKENHI) [JP15H04725];
   Intramural Research Program of NIAID, NIHUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Allergy & Infectious Diseases (NIAID); PATH's
   Malaria Vaccine Initiative; Bill & Melinda Gates FoundationGates
   Foundation; Global Health Innovative Technology Fund [GHIT T2016-207]
FX This research was partially supported by JSPS KAKENHI Grant (grant
   number JP15H04725). The works performed at National Institute of Allergy
   and Infectious Diseases (NIAID) were supported in part by the Intramural
   Research Program of NIAID, NIH. The research was also supported by
   PATH's Malaria Vaccine Initiative, with funding from both the Bill &
   Melinda Gates Foundation and the Global Health Innovative Technology
   Fund (grant number GHIT T2016-207). The funding sources had no role in
   study design, collection, analysis, interpretation of data, and
   publication.
CR Arredondo SA, 2017, INT J PARASITOL, V47, P409, DOI 10.1016/j.ijpara.2016.10.002
   Arumugam TU, 2014, EXPERT REV VACCINES, V13, P75, DOI 10.1586/14760584.2014.861747
   Bustamante PJ, 2000, PARASITE IMMUNOL, V22, P373, DOI 10.1046/j.1365-3024.2000.00315.x
   CARTER R, 1995, MOL BIOCHEM PARASIT, V71, P203, DOI 10.1016/0166-6851(94)00054-Q
   Eksi S, 2006, MOL MICROBIOL, V61, P991, DOI 10.1111/j.1365-2958.2006.05284.x
   Farrance CE, 2011, CLIN VACCINE IMMUNOL, V18, P1351, DOI 10.1128/CVI.05105-11
   Gerloff DL, 2005, P NATL ACAD SCI USA, V102, P13598, DOI 10.1073/pnas.0502378102
   Harbers M, 2014, FEBS LETT, V588, P2762, DOI 10.1016/j.febslet.2014.05.061
   Kapulu MC, 2015, SCI REP-UK, V5, DOI 10.1038/srep11193
   Lee SM, 2017, CLIN VACCINE IMMUNOL, V24, DOI [10.1128/CVI.00140-17, 10.1128/cvi.00140-17]
   MacDonald NJ, 2016, J BIOL CHEM, V291, P19913, DOI 10.1074/jbc.M116.732305
   Miura K, 2016, VACCINE, V34, P4145, DOI 10.1016/j.vaccine.2016.06.066
   Miura K, 2013, INFECT IMMUN, V81, P4377, DOI 10.1128/IAI.01056-13
   Miura K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057909
   Nikolaeva D, 2015, EXPERT REV VACCINES, V14, P653, DOI 10.1586/14760584.2015.993383
   Ntege EH, 2017, EXPERT REV VACCINES, V16, P769, DOI 10.1080/14760584.2017.1341317
   QUAKYI IA, 1987, J IMMUNOL, V139, P4213
   Simon N, 2016, PARASITOL INT, V65, P27, DOI 10.1016/j.parint.2015.09.007
   Stone WJR, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02646-2
   Stone WJR, 2016, PARASITOLOGY, V143, P187, DOI 10.1017/S0031182015001341
   Tachibana M, 2011, CLIN VACCINE IMMUNOL, V18, P1343, DOI 10.1128/CVI.05104-11
   Tsuboi T, 2008, INFECT IMMUN, V76, P1702, DOI 10.1128/IAI.01539-07
   van Dijk MR, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000853
   Williamson KC, 1995, MOL BIOCHEM PARASIT, V75, P33, DOI 10.1016/0166-6851(95)02507-3
   World Health Organization, 2017, WORLD MALARIA REPORT
   Wu YM, 2015, ADV PARASIT, V89, P109, DOI 10.1016/bs.apar.2015.04.001
NR 26
TC 7
Z9 7
U1 0
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 22
PY 2019
VL 37
IS 13
BP 1799
EP 1806
DI 10.1016/j.vaccine.2019.02.021
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HQ8QZ
UT WOS:000462691700011
PM 30824357
OA Green Accepted, Other Gold
DA 2020-05-12
ER

PT J
AU Parveen, N
   Fernandez, MC
   Haynes, AM
   Zhang, RL
   Godornes, BC
   Centurion-Lara, A
   Giacani, L
AF Parveen, Nikhat
   Fernandez, Mark C.
   Haynes, Austin M.
   Zhang, Rui-Li
   Godornes, B. Charmie
   Centurion-Lara, Arturo
   Giacani, Lorenzo
TI Non-pathogenic Borrelia burgdorferi expressing Treponema pallidum TprK
   and Tp0435 antigens as a novel approach to evaluate syphilis vaccine
   candidates
SO VACCINE
LA English
DT Article
DE Syphilis; Treponema pallidum; Borrelia burgdorferi; TprK; Tp0435
ID REPEAT PROTEIN-K; SEQUENCE DIVERSITY; OUTER-MEMBRANE; CELL; GENE;
   RESPONSIVENESS; INFECTIVITY; PROTECTION; REGIONS; RABBITS
AB Background: Syphilis is resurgent in many developed countries and still prevalent in developing nations. Current and future control campaigns would benefit from the development of a vaccine, but although promising vaccine candidates were identified among the putative surface-exposed integral outer membrane proteins of the syphilis spirochete, immunization experiments in the rabbit model using recombinant antigens have failed to fully protect animals upon infectious challenge. We speculated that such recombinant immunogens, purified under denaturing conditions from Escherichia coli prior to immunization might not necessarily harbor their original structure, and hypothesized that enhanced protection would result from performing similar immunization/challenge experiments with native antigens.
   Methods: To test our hypothesis, we engineered non-infectious Borrelia burgdorferi strains to express the tp0897 (tprK) and tp0435 genes of Treponema pallidum subsp. pallidum and immunized two groups of rabbits by injecting recombinant strains intramuscularly with no adjuvant. TprK is a putative integral outer membrane protein of the syphilis agent, while tp0435 encodes the highly immunogenic T. pallidum 17-kDa lipoprotein, a periplasmic antigen that was also shown on the pathogen surface. Following development of a specific host immune response to these antigens as the result of immunization, animals were challenged by intradermal inoculation of T. pallidum. Cutaneous lesion development was monitored and treponemal burden within lesions were assessed by dark-field microscopy and RT-qPCR, in comparison to control rabbits.
   Results: Partial protection was observed in rabbits immunized with B. burgdorferi expressing TprK while immunity to Tp0435 was not protective. Analysis of the humoral response to TprK antigen suggested reactivity to conformational epitopes.
   Conclusions: Immunization with native antigens might not be sufficient to obtain complete protection to infection. Nonetheless we showed that non-infectious B. burgdorferi can be an effective carrier to deliver and elicit a specific host response to T. pallidum antigens to assess the efficacy of syphilis vaccine candidates. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Parveen, Nikhat] Rutgers New Jersey Med Sch, Dept Microbiol Biochem & Mol Genet, Newark, NJ 07103 USA.
   [Fernandez, Mark C.; Haynes, Austin M.; Zhang, Rui-Li; Godornes, B. Charmie; Giacani, Lorenzo] Univ Washington, Dept Med, Div Allergy & Infect Dis, Harborview Med Ctr, Seattle, WA 98104 USA.
   [Zhang, Rui-Li] Nanjing Med Univ, Affiliated Wuxi Peoples Hosp 2, Dept Dermatol, Wuxi 214002, Peoples R China.
   [Centurion-Lara, Arturo] Univ Peruana Cayetano Heredia, Sch Publ Hlth, Lima 30, Peru.
   [Fernandez, Mark C.; Giacani, Lorenzo] Univ Washington, Dept Global Hlth, Seattle, WA 98104 USA.
RP Giacani, L (reprint author), Univ Washington, Dept Med, Harborview Med Ctr, 325 9th Ave, Seattle, WA 98104 USA.
EM giacal@u.washington.edu
OI Giacani, Lorenzo/0000-0003-3889-7274
FU National Institute for Allergy and Infectious Diseases of the National
   Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [U01AI115497]
FX We thank student interns, Thayer Nasreddin, and Ghayoor Mir in the
   Parveen's laboratory for cloning tprK and tp0435 genes in the pJSB175
   vector. The authors wish to thank Barbara Molini for help with rabbit
   inoculation procedures, and Martin Sadilek for help with analysis of the
   MS data. This work was supported by the National Institute for Allergy
   and Infectious Diseases of the National Institutes of Health grant
   numbers U01AI115497 (to L.G, N.P, and A.C.L.). The content is solely the
   responsibility of the authors and does not necessarily represent the
   official views of the National Institutes of Health.
CR Arroll TW, 1999, INFECT IMMUN, V67, P4757, DOI 10.1128/IAI.67.9.4757-4763.1999
   BAKERZANDER SA, 1993, FEMS IMMUNOL MED MIC, V6, P273
   Blanco DR, 1997, EMERG INFECT DIS, V3, P11, DOI 10.3201/eid0301.970102
   Blevins JS, 2007, APPL ENVIRON MICROB, V73, P1501, DOI 10.1128/AEM.02454-06
   Brisson D, 2012, ANNU REV GENET, V46, P515, DOI 10.1146/annurev-genet-011112-112140
   *CDC, 1999, NAT PLAN EL SYPH US
   CDC, 2018, 2016 SEX TRANSM DIS
   Centurion-Lara A, 2004, MOL MICROBIOL, V52, P1579, DOI 10.1111/j.1365-2958.2004.04086.x
   Centurion-Lara A, 1999, J EXP MED, V189, P647, DOI 10.1084/jem.189.4.647
   Centurion-Lara A, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002222
   Chan KF, 2016, SCI REP-UK, V6, DOI 10.1038/srep25593
   [Anonymous], 2007, Can Commun Dis Rep, V33, P1
   Cox DL, 2010, INFECT IMMUN, V78, P5178, DOI 10.1128/IAI.00834-10
   Djokic V, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02891
   Edmondson DG, 2018, MBIO, V9, DOI 10.1128/mBio.01153-18
   Fletcher MA, 2002, INT J STD AIDS, V13, P38, DOI 10.1258/095646202762226155
   Galen JE, 2015, INFECT IMMUN, V83, P161, DOI 10.1128/IAI.02443-14
   Gerbase AC, 1998, SEX TRANSM INFECT, V74, pS12
   Giacani L, 2007, INFECT IMMUN, V75, P104, DOI 10.1128/IAI.01124-06
   Giacani L, 2013, J BACTERIOL, V195, P896, DOI 10.1128/JB.01973-12
   Giacani L, 2009, VACCINES FOR BIODEFENSE AND EMERGING AND NEGLECTED DISEASES, P1193, DOI 10.1016/B978-0-12-369408-9.00059-7
   Giacani L, 2010, J BACTERIOL, V192, P2645, DOI 10.1128/JB.00159-10
   Giacani L, 2010, J IMMUNOL, V184, P3822, DOI 10.4049/jimmunol.0902788
   Goldenberg RL, 2003, AM J OBSTET GYNECOL, V189, P861, DOI 10.1067/S0002-9378(03)00470-8
   Gomez-Duarte OG, 1999, VACCINE, V17, P1667, DOI 10.1016/S0264-410X(98)00436-8
   Herbert Liam J, 2012, J Glob Health, V2, P010402, DOI 10.7189/jogh.02.010402
   Ke W, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003662
   LaFond RE, 2006, INFECT IMMUN, V74, P1896, DOI 10.1128/IAI.74.3.1896-1906.2006
   LaFond RE, 2003, J BACTERIOL, V185, P6262, DOI 10.1128/JB.185.21.6262-6268.2003
   Lithgow KV, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14273
   Lithgow KV, 2017, EXPERT REV VACCINES, V16, P37, DOI 10.1080/14760584.2016.1203262
   LUKEHART SA, 1980, J IMMUNOL, V124, P454
   Lukehart SA, 2007, CURT PROTOC MICROBIO, DOI DOI 10.1002/9780471729259.MC12A01S7
   MILLER JN, 1973, J IMMUNOL, V110, P1206
   Morgan CA, 2003, INFECT IMMUN, V71, P5605, DOI 10.1128/IAI.71.10.5605-5612.2003
   Morgan CA, 2002, J IMMUNOL, V169, P952, DOI 10.4049/jimmunol.169.2.952
   Morgan CA, 2002, INFECT IMMUN, V70, P6811, DOI 10.1128/IAI.70.12.6811-6816.2002
   Newcombe J, 2004, INFECT IMMUN, V72, P338, DOI 10.1128/IAI.72.1.338-344.2004
   Newman L, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001396
   PENN CW, 1985, J GEN MICROBIOL, V131, P2349
   Purser JE, 2000, P NATL ACAD SCI USA, V97, P13865, DOI 10.1073/pnas.97.25.13865
   Purser JE, 2003, MOL MICROBIOL, V48, P753, DOI 10.1046/j.1365-2958.2003.03452.x
   Roche AM, 2007, INFECT IMMUN, V75, P2469, DOI 10.1128/IAI.01972-06
   Savage EJ, 2012, EURO SURVEILL, V17
   Sheridan SL, 2012, JAMA-J AM MED ASSOC, V308, P454, DOI 10.1001/jama.2012.6364
   Tucker JD, 2011, CURR OPIN INFECT DIS, V24, P50, DOI 10.1097/QCO.0b013e32834204bf
   White RG, 2004, JAIDS-J ACQ IMM DEF, V37, P1500, DOI 10.1097/01.qai.0000127062.94627.31
   World Health Organisation, 2007, GLOB EL CONG SYPH RA
   World Health Organization Department of Reproductive Health and Research, 2011, PREV INC SEL SEX TRA
   Zuckert Wolfram R, 2007, Curr Protoc Microbiol, VChapter 12, DOI 10.1002/9780471729259.mc12c01s4
NR 50
TC 1
Z9 1
U1 5
U2 9
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 22
PY 2019
VL 37
IS 13
BP 1807
EP 1818
DI 10.1016/j.vaccine.2019.02.022
PG 12
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HQ8QZ
UT WOS:000462691700012
PM 30797635
OA Green Accepted
DA 2020-05-12
ER

PT J
AU Doener, F
   Hong, HS
   Meyer, I
   Tadjalli-Mehr, K
   Daehling, A
   Heidenreich, R
   Koch, SD
   Fotin-Mleczek, M
   Gnad-Vogt, U
AF Doener, Fatma
   Hong, Henoch S.
   Meyer, Ingo
   Tadjalli-Mehr, Keyvan
   Daehling, Angelika
   Heidenreich, Regina
   Koch, Sven D.
   Fotin-Mleczek, Mariola
   Gnad-Vogt, Ulrike
TI RNA-based adjuvant CV8102 enhances the immunogenicity of a licensed
   rabies vaccine in a first-in-human trial
SO VACCINE
LA English
DT Article
DE Adjuvant; RNA; Rabies; Prophylactic vaccines; Safety; Immunostimulatory
ID RESPONSES; SINGLE; RECOGNITION; SAFETY
AB Background: We report the first-in-concept human trial of the safety, tolerability and immunogenicity when a novel TLR 7/8/RIG 1 agonist RNA-based adjuvant, CV8102, was administered alone or mixed with fractional doses of a licensed rabies vaccine (Rabipur (R)) as model antigen.
   Methods: The primary objective was to assess the safety and reactogenicity of various dose levels of CV8102 alone or mixed with Rabipur (R) in healthy 18-40 year-old male volunteers. A secondary objective was to assess the immune-enhancing potential of bedside-mixes of CV8102 with fractional doses of Rabipur (R) by measuring induction of rabies virus neutralising titres (VNTs).
   Results: Fifty-six volunteers received 50-100 mu g CV8102 alone (n = 11), bedside-mixed CV8102 and Rabipur (R) (n = 20), or Rabipur (R) alone (n = 25; control). When given alone or mixed with Rabipur (R) CV8102 caused mostly Grade 1 or 2 local or systemic reactogenicity, but no related SAEs. As 100 mu g CV8102 was associated with marked CRP increases further dose escalation was stopped. Combining 25-50 mu g of CV8102 with fractional doses of Rabipur (R) significantly improved the kinetics of VNT responses; 50 mu g CV8102 also improved the magnitude of VNT responses to 1/10 Rabipur (R) but caused severe but self-limiting influenza-like symptoms in 2 of 14 subjects.
   Conclusions: Doses of 25 and 50 mu g CV8102 appeared safe and with an acceptable reactogenicity profile while significantly enhancing the immunogenicity of fractional doses of rabies vaccine. (C) 2019 The Authors. Published by Elsevier Ltd.
C1 [Doener, Fatma; Hong, Henoch S.; Heidenreich, Regina; Koch, Sven D.; Fotin-Mleczek, Mariola] Curevac AG, Paul Ehrlich Str 15, D-72076 Tubingen, Germany.
   [Meyer, Ingo] CRS Clin Res Serv Monchengladbach GmbH, D-41061 Monchengladbach, Germany.
   [Tadjalli-Mehr, Keyvan; Daehling, Angelika; Gnad-Vogt, Ulrike] Curevac AG, Schumannstr 27, D-60325 Frankfurt, Germany.
RP Gnad-Vogt, U (reprint author), Curevac AG, Schumannstr 27, D-60325 Frankfurt, Germany.
EM Ulrike.Gnad-Vogt@curevac.com
FU CureVac AG, Tiibingen, Germany
FX This study and editorial support for the preparation of this manuscript
   were funded by CureVac AG, Tiibingen, Germany.
CR [Anonymous], 2007, Wkly Epidemiol Rec, V82, P425
   Buonaguro L, 2016, CANCER IMMUNOL IMMUN, V65, P93, DOI 10.1007/s00262-015-1728-y
   Celik IH, 2013, EUR J PEDIATR, V172, P839, DOI 10.1007/s00431-013-1946-2
   Circelli L, 2017, CANCER IMMUNOL IMMUN, V66, P103, DOI 10.1007/s00262-016-1923-5
   Coffman RL, 2010, IMMUNITY, V33, P492, DOI 10.1016/j.immuni.2010.10.002
   Di Pasquale A, 2015, VACCINES-BASEL, V3, P320, DOI 10.3390/vaccines3020320
   Diebold SS, 2004, SCIENCE, V303, P1529, DOI 10.1126/science.1093616
   Guy B, 2007, NAT REV MICROBIOL, V5, P505, DOI 10.1038/nrmicro1681
   Heidenreich R, 2015, INT J CANCER, V137, P372, DOI 10.1002/ijc.29402
   Heil F, 2004, SCIENCE, V303, P1526, DOI 10.1126/science.1093620
   Heinzerling L, 2018, J IMMUNOTHERAP CA S1, V6, P172, DOI [10.1186/s40425-018-0422-y, DOI 10.1186/S40425-018-0422-Y]
   Hopkins RJ, 2013, VACCINE, V31, P3051, DOI 10.1016/j.vaccine.2013.04.063
   Jackson S, 2018, VACCINE, V36, P668, DOI 10.1016/j.vaccine.2017.12.038
   Lanza GA, 2011, J INTERN MED, V269, P118, DOI 10.1111/j.1365-2796.2010.02285.x
   Leroux-Roels G, 2010, VACCINE, V28, pC25, DOI 10.1016/j.vaccine.2010.07.021
   Pourcyrous M, 2007, J PEDIATR-US, V151, P167, DOI 10.1016/j.jpeds.2007.02.059
   Tinto H, 2015, LANCET, V386, P31, DOI 10.1016/S0140-6736(15)60721-8
   Toussi DN, 2014, VACCINES, V2, P323, DOI 10.3390/vaccines2020323
   Treanor JJ, 2010, VACCINE, V28, P8268, DOI 10.1016/j.vaccine.2010.10.009
   Vasilakos JP, 2013, EXPERT REV VACCINES, V12, P809, DOI 10.1586/14760584.2013.811208
   WHO Expert Committee on Biological Standardization, 64 REP GUID NONCL EV
   Ziegler A, 2017, J IMMUNOL, V198, P1595, DOI 10.4049/jimmunol.1601129
NR 22
TC 5
Z9 5
U1 0
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 22
PY 2019
VL 37
IS 13
BP 1819
EP 1826
DI 10.1016/j.vaccine.2019.02.024
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HQ8QZ
UT WOS:000462691700013
PM 30797640
OA Other Gold
DA 2020-05-12
ER

PT J
AU Huang, LM
   Chiu, CH
   Chiu, NC
   Lin, CY
   Li, MT
   Kuo, TY
   Weng, YJ
   Hsieh, EF
   Tai, IC
AF Huang, Li-Min
   Chiu, Cheng-Hsun
   Chiu, Nan-Chang
   Lin, Chien-Yu
   Li, Ming-Ta
   Kuo, Tsun-Yung
   Weng, Yi-Jen
   Hsieh, Erh-Fang
   Tai, I-Chen
TI Immunogenicity, safety, cross-reaction, and immune persistence of an
   inactivated enterovirus A71 vaccine in children aged from two months to
   11 years in Taiwan
SO VACCINE
LA English
DT Article
DE Two-month-old infant; EV-A71 vaccine; Immunogenicity; Immune
   persistence; Cross-reaction
ID MOUTH-DISEASE; 71 INFECTION; CLINICAL-FEATURES; SOUTHERN VIETNAM;
   PULMONARY-EDEMA; RISK-FACTORS; FOOT; HAND; EPIDEMIC; CHINA
AB Background: To fight against enterovirus A71 (EV-A71)-associated diseases, vaccine development was initiated in Taiwan focusing on two-month-old infants.
   Methods: We conducted a phase II, double-blind, randomised, placebo-controlled study on infants and children aged two months to 11 years. This study was conducted in 4 parts (2a, 2b, 2c, and 2d) with age de-escalation sequentially. <Two doses were administered with a 28-day or 56-day interval. Participants aged two months to two years received a booster dose at one year after the first dose. During the surveillance period, solicited adverse events (AEs) and unsolicited AEs were recorded for safety evaluation. Blood samples were collected for neutralising antibody assay at various times. Immune persistence and booster effects were also assessed.
   Results: A total of 363 children completed the study. Most AEs were mild and unrelated to treatment. No vaccine-related serious adverse events (SAES) were reported. Geometric mean titres (GMTs) of serum neutralising antibody titres increased profoundly. Most participants in the vaccine groups achieved defined seroprotection (neutralization titre >= 1:32) after the second vaccination and persisted for two years. Furthermore, the EV-A71 vaccine could provide a cross-reaction against other EV-A71 strain genotypes: B5, C4a, C4b, and C5.
   Conclusions: The mid dose of the EV-A71 vaccine elicited high immune response and were tolerable in participants aged between two months and 11 years in all dosing groups. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Huang, Li-Min] Natl Taiwan Univ, Dept Pediat, Childrens Hosp, Taipei, Taiwan.
   [Chiu, Cheng-Hsun] Chang Gung Univ, Chang Gung Childrens Hosp, Dept Pediat, Coll Med, Taoyuan, Taiwan.
   [Chiu, Nan-Chang] MacKay Childrens Hosp, Dept Pediat, Taipei, Taiwan.
   [Chiu, Nan-Chang] Mackay Med Coll, Dept Med, New Taipei, Taiwan.
   [Lin, Chien-Yu; Li, Ming-Ta] Hsinchu MacKay Mem Hosp, Dept Pediat, Hsinchu, Taiwan.
   [Kuo, Tsun-Yung] Natl Ilan Univ, Dept Biotechnol & Anim Sci, Ilan, Taiwan.
   [Weng, Yi-Jen; Hsieh, Erh-Fang; Tai, I-Chen] Medigen Vaccine Biol Corp, Clin Dev Dept, Taipei, Taiwan.
RP Tai, IC (reprint author), Clin Dev Dept, 7F,16,Ln 120,Sec 1 Neihu Rd, Taipei 11493, Taiwan.
EM kathytai@medigenvac.com
OI HUANG, LI-MIN/0000-0002-9291-260X
FU Medigen Vaccine Biologics Corp.
FX The Medigen Vaccine Biologics Corp. sponsored the study and manufacture
   of the investigational vaccine, and was involved in the trial design,
   management and analysis of the data, and preparation and publication of
   the manuscript.
CR Bible JM, 2007, REV MED VIROL, V17, P371, DOI 10.1002/rmv.538
   Centers for Disease Control and Prevention (CDC), 1998, MMWR Morb Mortal Wkly Rep, V47, P629
   Chang LY, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.6.e88
   Chang LY, 1999, LANCET, V354, P1682, DOI 10.1016/S0140-6736(99)04434-7
   Chang PC, 2016, INT J ENV RES PUB HE, V13, DOI 10.3390/ijerph13090890
   Cheng A, 2013, VACCINE, V31, P2471, DOI 10.1016/j.vaccine.2013.03.015
   Chua Kaw Bing, 2011, Virologica Sinica, V26, P221, DOI 10.1007/s12250-011-3195-8
   Donato C, 2016, VIROLOGY, V495, P1, DOI 10.1016/j.virol.2016.04.026
   Fu CX, 2016, SCI REP-UK, V6, DOI 10.1038/srep38874
   Gantt S, 2013, J PEDIATR INFECT DIS, V2, P162, DOI 10.1093/jpids/pit017
   Ho MT, 1999, NEW ENGL J MED, V341, P929, DOI 10.1056/NEJM199909233411301
   Huang CC, 1999, NEW ENGL J MED, V341, P936, DOI 10.1056/NEJM199909233411302
   Lee MS, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001476
   Li RC, 2014, NEW ENGL J MED, V370, P829, DOI 10.1056/NEJMoa1303224
   Lin TY, 2003, EMERG INFECT DIS, V9, P291, DOI 10.3201/eid0903.020285
   Lin TY, 2002, CLIN INFECT DIS, V34, pS52, DOI 10.1086/338819
   Lum LCS, 1998, LANCET, V352, P1391, DOI 10.1016/S0140-6736(05)60789-1
   McMinn PC, 2014, NEW ENGL J MED, V370, P792, DOI 10.1056/NEJMp1400601
   NAGY G, 1982, ARCH VIROL, V71, P217, DOI 10.1007/BF01314873
   Nguyen NTB, 2014, BMC INFECT DIS, V14, DOI 10.1186/1471-2334-14-341
   Ooi EE, 2002, EMERG INFECT DIS, V8, P995, DOI 10.3201/eid0809.010397
   Ooi MH, 2010, LANCET NEUROL, V9, P1097, DOI 10.1016/S1474-4422(10)70209-X
   Sea KH, 2005, CDC TAIWAN 2005 ANN, P53
   Shimizu H, 1999, JPN J INFECT DIS, V52, P12
   Solomon T, 2010, LANCET INFECT DIS, V10, P778, DOI 10.1016/S1473-3099(10)70194-8
   Khanh TH, 2012, EMERG INFECT DIS, V18, P2002, DOI 10.3201/eid1812.120929
   Van Tu P, 2007, EMERG INFECT DIS, V13, P1733, DOI 10.3201/eid1311.070632
   Wang Y, 2011, EPIDEMIOLOGY, V22, P781, DOI 10.1097/EDE.0b013e318231d67a
   Yang F, 2009, J CLIN MICROBIOL, V47, P2351, DOI 10.1128/JCM.00563-09
   Yi EJ, 2017, CLIN EXP VACCINE RES, V6, P4, DOI [10.7774/cevr.2017.6.1.4., 10.7774/cevr.2017.6.1.4]
   Yu CK, 2000, J BIOMED SCI, V7, P523, DOI 10.1007/BF02253368
   Zhang Y, 2010, VIROL J, V7, DOI 10.1186/1743-422X-7-94
   Zhu FC, 2013, LANCET, V381, P2024, DOI 10.1016/S0140-6736(13)61049-1
   Zhu FC, 2014, NEW ENGL J MED, V370, P818, DOI 10.1056/NEJMoa1304923
NR 34
TC 5
Z9 5
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 22
PY 2019
VL 37
IS 13
BP 1827
EP 1835
DI 10.1016/j.vaccine.2019.02.023
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HQ8QZ
UT WOS:000462691700014
PM 30803843
DA 2020-05-12
ER

PT J
AU Mo, ZJ
   Ma, X
   Luo, P
   Mo, Y
   Kaplan, SS
   Shou, Q
   Zheng, MH
   Hille, DA
   Arnold, BA
   Liao, XY
   Li, MQ
   Tao, JH
   Yang, X
   Qiao, DB
   Wei, DK
   Fu, BT
AF Mo, Zhaojun
   Ma, Xiao
   Luo, Peng
   Mo, Yi
   Kaplan, Susan S.
   Shou, Qiong
   Zheng, Minghuan
   Hille, Darcy A.
   Arnold, Beth A.
   Liao, Xueyan
   Li, Mingqiang
   Tao, Junhui
   Yang, Xu
   Qiao, Debiao
   Wei, Ding-Kai
   Fu, Botao
CA V260-024 Study Grp
TI Immunogenicity of pentavalent rotavirus vaccine in Chinese infants
SO VACCINE
LA English
DT Article
DE Immunogenicity; Pentavalent rotavirus vaccine; China
ID CONCOMITANT USE; ACELLULAR PERTUSSIS; POLIOVIRUS VACCINE; CHILDREN
   YOUNGER; HEALTHY INFANTS; SAFETY; GASTROENTERITIS; DIPHTHERIA; EFFICACY;
   ANTIBODY
AB Background: A phase III, randomized, double-blind, placebo-controlled clinical study was conducted in China to assess the efficacy, safety, and immunogenicity of the pentavalent rotavirus vaccine (RotaTeq (TM), RV5) among Chinese infants. The efficacy and safety data have been previously reported. This report presents the immunogenicity data of the study.
   Methods: 4,040 infants aged 6-12 weeks were randomly assigned in a 1:1 ratio to receive 3 oral doses of RV5 or placebo. Trivalent oral poliovirus vaccine (tOPV) and diphtheria, tetanus, and acellular pertussis vaccine (DTaP) were administered in a staggered-use (N = 3,240) or concomitant-use (N = 800) schedule. Immunogenicity of RV5 was evaluated in 800 participants (400 participants from each staggered- and concomitant-use immunogenicity subgroup). Geometric mean titers (GMTs) and seroresponse rates (>= 3-fold rise from baseline to PD3) were measured for anti-rotavirus IgA in the staggered- and concomitant-use subgroups and measured for serum neutralizing antibodies (SNAs) to human rotavirus serotypes G1, G2, G3, G4, PIA[8] in the staggered-use subgroup. Immune responses to tOPV and DTaP coadministered with RV5 were also evaluated in the concomitant-use immunogenicity subgroup. (ClinicalTrials.gov registry: NCT02062385)
   Results: The PD3 GMT and seroresponse rate of anti-rotavirus IgA were higher in the RV5 group (82.42 units/mL, 89.4%) compared to the placebo group (0.33 units/mL, 10.1%). Rotavirus type-specific SNA responses were also higher in the RV5 group compared to the placebo group. In the concomitant-use subgroup, the seroprotection rates of anti-poliovirus type 1, 2, 3 in the participants who received RV5 were non-inferior to those who received placebo, and the antibody responses to DTaP antigens were comparable between the two vaccination groups.
   Conclusions: RV5 was immunogenic in Chinese infants. Immune responses induced by tOPV and DTaP were not affected by the concomitant use of RV5. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Mo, Zhaojun; Mo, Yi] Guangxi Ctr Dis Control & Prevent, Guangxi, Peoples R China.
   [Ma, Xiao; Luo, Peng] Natl Inst Food & Drug Control, Beijing, Peoples R China.
   [Kaplan, Susan S.; Hille, Darcy A.; Arnold, Beth A.] Merck & Co Inc, Kenilworth, NJ USA.
   [Shou, Qiong; Zheng, Minghuan; Liao, Xueyan] MSD R&D China Co Ltd, Beijing, Peoples R China.
   [Li, Mingqiang] Liuzhou City Ctr Dis Control & Prevent, Liuzhou, Peoples R China.
   [Tao, Junhui] Liujiang Cty Ctr Dis Control & Prevent, Beijing, Peoples R China.
   [Yang, Xu] Sanjiang Cty Ctr Dis Control & Prevent, Liuzhou, Peoples R China.
   [Qiao, Debiao] Liucheng Cty Ctr Dis Control & Prevent, Beijing, Peoples R China.
   [Wei, Ding-Kai] Rongan Cty Ctr Dis Control & Prevent, Beijing, Peoples R China.
   [Fu, Botao] Luzhai Cty Ctr Dis Control & Prevent, Beijing, Peoples R China.
RP Liao, XY (reprint author), MSD R&D China Co Ltd, Clin Res, Bldg 21 Rongda Rd, Beijing 100012, Peoples R China.
EM xue.yan.liao@merck.com
FU Merck Sharp Dohme Corp.Merck & Company
FX This study was sponsored and funded by Merck Sharp & Dohme Corp., a
   Subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA, which was involved
   in the study design, conduct, data analysis and interpretation, and also
   in the writing of the report and development of manuscript.
CR Armah GE, 2012, VACCINE, V30, pA86, DOI 10.1016/j.vaccine.2011.10.006
   Block SL, 2007, PEDIATRICS, V119, P11, DOI 10.1542/peds.2006-2058
   Chang CC, 2009, J FORMOS MED ASSOC, V108, P280, DOI 10.1016/S0929-6646(09)60067-X
   Cheuvart B, 2014, HUM VACC IMMUNOTHER, V10, P505, DOI 10.4161/hv.27097
   Ciarlet M, 2008, PEDIATR INFECT DIS J, V27, P874, DOI 10.1097/INF.0b013e3181782780
   Ciarlet M, 2009, VACCINE, V27, pG72, DOI 10.1016/j.vaccine.2009.09.107
   Ciarlet M, 2009, PEDIATR INFECT DIS J, V28, P177, DOI 10.1097/INF.0b013e31818c0161
   Fu C., 2018, ADV MECH ENG, V10, P1
   Fu CX, 2012, VACCINE, V31, P154, DOI 10.1016/j.vaccine.2012.10.078
   Fu CX, 2010, HUM VACCINES, V6, P953, DOI 10.4161/hv.6.11.12847
   Gurung S, 2017, J INFECT DIS, V216, pS101, DOI 10.1093/infdis/jiw574
   Jin H, 2011, VACCINE, V29, P7801, DOI 10.1016/j.vaccine.2011.07.104
   Kim DS, 2008, PEDIATR INFECT DIS J, V27, P177, DOI 10.1097/INF.0b013e31815aba79
   Li Dandi, 2015, Bing Du Xue Bao, V31, P170
   Li RC, 2016, HUM VACC IMMUNOTHER, V12, P785, DOI 10.1080/21645515.2015.1085143
   Liu GF, 2017, HUM VACC IMMUNOTHER, V13, P2357, DOI [10.1080/21645515.2017.1365208, 10.1080/21645515.2017.1356522]
   [刘娜 Liu Na], 2015, [中华实验和临床病毒学杂志, Chinese Journal of Experimental and Clinical Virology], V29, P256
   MIETTINEN O, 1985, STAT MED, V4, P213, DOI 10.1002/sim.4780040211
   Mo ZJ, 2017, VACCINE, V35, P5897, DOI 10.1016/j.vaccine.2017.08.081
   Patel M, 2013, J INFECT DIS, V208, P284, DOI 10.1093/infdis/jit166
   PATH, 2018, GLOB INTR STAT
   Rodriguez ZM, 2007, PEDIATR INFECT DIS J, V26, P221, DOI 10.1097/01.inf.0000254391.71103.e8
   Shin S, 2012, VACCINE, V30, pA106, DOI 10.1016/j.vaccine.2011.11.091
   SOARES KV, 2000, [No title captured], DOI [10.1002/14651858, DOI 10.1002/14651858]
   Tanaka Y, 2017, HUM VACC IMMUNOTHER, V13, P1352, DOI 10.1080/21645515.2017.1279769
   Tate JE, 2016, CLIN INFECT DIS, V62, pS96, DOI 10.1093/cid/civ1013
   Tregnaghi MW, 2011, PEDIATR INFECT DIS J, V30, pE103, DOI 10.1097/INF.0b013e3182138278
   Vesikari T, 2017, HUM VACC IMMUNOTHER, V13, P1505, DOI 10.1080/21645515.2017.1294294
   Ward RL, 1997, J INFECT DIS, V176, P570, DOI 10.1086/514076
   WHO, 2009, WKLY EPIDEMIOL REC, V84, P517
   Wu D, 2016, PEDIATR INFECT DIS J, V35, pE392, DOI 10.1097/INF.0000000000001327
   Zaman K, 2010, LANCET, V376, P615, DOI 10.1016/S0140-6736(10)60755-6
   Zaman K, 2009, VACCINE, V27, P1333, DOI 10.1016/j.vaccine.2008.12.059
   Zhang J, 2015, PEDIATR INFECT DIS J, V34, pE233, DOI 10.1097/INF.0000000000000799
   Zhen SS, 2015, EMERG MICROBES INFEC, V4, DOI 10.1038/emi.2015.64
   2009, [No title captured], V84, P220
NR 36
TC 0
Z9 0
U1 2
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 22
PY 2019
VL 37
IS 13
BP 1836
EP 1843
DI 10.1016/j.vaccine.2019.02.018
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HQ8QZ
UT WOS:000462691700015
PM 30808567
DA 2020-05-12
ER

PT J
AU da Cunha, CEP
   Bettin, EB
   Bakry, AFAAY
   Neto, ACPS
   Amaral, MG
   Dellagostin, OA
AF Pouey da Cunha, Carlos Eduardo
   Bettin, Everton Burlamarque
   Aziz Yousef Bakry, Aisha Farid Abdel
   Pinto Seixas Neto, Amilton Clair
   Amaral, Marta Goncalves
   Dellagostin, Odir Antonio
TI Evaluation of different strategies to promote a protective immune
   response against leptospirosis using a recombinant LigA and LigB chimera
SO VACCINE
LA English
DT Article
DE Leptospira; Leptospiral Immunoglobulin-like; Subunit vaccine; DNA
   vaccine; Protection
ID OUTER-MEMBRANE PROTEINS; IMMUNOGLOBULIN-LIKE; CONSERVED REGION; B
   PROTEINS; INTERROGANS; DNA; VACCINATION; HAMSTERS; VACCINES; LIPL32
AB Leptospirosis is a zoonosis of worldwide distribution, caused by infection with pathogenic Leptospira species. The vaccines that are currently available are bacterins, with limited human use, that confer shortterm, serovar-specific immunity. Lig proteins are considered to be the best vaccine candidates to date. Here, we aimed to construct a recombinant Lig chimera (LC) comprised of LigAni and LigBrep fragments, and to evaluate it as subunit or DNA vaccine using different administration strategies. Vaccines were formulated with 50 mu g of recombinant LC associated with different adjuvants or with 100 mu g of pTARGET/LC. Four-week-old hamsters received two doses of vaccine with different strategies and were challenged with 5 x DL50 Leptospira interrogans serovar Copenhageni strain Fiocruz L1-130. The immune response generated by Lig chimera conferred 100% protection to hamsters treated with at least one dose of recombinant LC. Despite the high levels of antibodies that vaccinated animals produced, a sterilizing immunity was not achieved. The lack of a sterilizing immunity could indicate the importance of a mixed humoral and cellular immune response. The present study generated insights that will be useful in the future development of improved subunit vaccines against leptospirosis. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Pouey da Cunha, Carlos Eduardo; Bettin, Everton Burlamarque; Aziz Yousef Bakry, Aisha Farid Abdel; Pinto Seixas Neto, Amilton Clair; Amaral, Marta Goncalves; Dellagostin, Odir Antonio] Univ Fed Pelotas, Ctr Desenvolvimento Tecnol, Biotecnol, Pelotas, Brazil.
RP Dellagostin, OA (reprint author), Ctr Desenvolvimento Tecnol, Nucleo Biotecnol, Campus Univ S-N,Caixa Postal 354, BR-96010900 Pelotas, RS, Brazil.
EM odir@ufpel.edu.br
OI Bettin, Everton/0000-0001-5095-2198
FU CNPqNational Council for Scientific and Technological Development
   (CNPq); CAPESCAPES; FAPERGSFoundation for Research Support of the State
   of Rio Grande do Sul (FAPERGS)
FX The authors are grateful to animal care facility staff and lab support
   staff for their help to make this study a reality and to the funding
   agencies, namely CNPq, CAPES, and FAPERGS, for the grants and
   scholarships that were provided.
CR Adler B, 2015, CURR TOP MICROBIOL, V387, P1, DOI 10.1007/978-3-662-45059-8
   Adler B, 2010, VET MICROBIOL, V140, P287, DOI 10.1016/j.vetmic.2009.03.012
   [Anonymous], 2011, Wkly Epidemiol Rec, V86, P45
   [Anonymous], 1999, Wkly Epidemiol Rec, V74, P237
   Barocchi MA, 2002, INFECT IMMUN, V70, P6926, DOI 10.1128/IAI.70.12.6926-6932.2002
   Breda LCD, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0004192
   Conrad NL, 2017, PLOS NEGLECT TROP D, V11
   Costa F, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003898
   Coutinho ML, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001422
   Cunha CEP, 2014, VACCINE, V32, P214, DOI 10.1016/j.vaccine.2013.11.025
   Dellagostin OA, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18010158
   Dellagostin OA, 2011, HUM VACCINES, V7, P1215, DOI 10.4161/hv.7.11.17944
   Evangelista KV, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0180004
   Faisal SM, 2009, VACCINE, V27, P378, DOI 10.1016/j.vaccine.2008.10.089
   Fernandes LGV, 2017, INT J INFECT DIS, V57, P61, DOI 10.1016/j.ijid.2017.01.032
   Forster KM, 2015, MEM I OSWALDO CRUZ, V110, P989, DOI 10.1590/0074-02760150222
   Forster KM, 2013, CLIN VACCINE IMMUNOL, V20, P725, DOI 10.1128/CVI.00601-12
   Gil LAF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069692
   Gomes-Solecki M, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00058
   Grassmann AA, 2017, FRONT IMMUNOL, V8
   Grassmann AA, 2012, CLIN VACCINE IMMUNOL, V19, P740, DOI 10.1128/CVI.05720-11
   Green M.R., 2012, MOL CLONING LAB MANU
   Haake DA, 1999, INFECT IMMUN, V67, P6572
   Habjanec L, 2008, INT IMMUNOPHARMACOL, V8, P717, DOI 10.1016/j.intimp.2008.01.017
   Hartwig DD, 2014, CURR MICROBIOL, V68, P524, DOI 10.1007/s00284-013-0505-4
   Hartwig DD, 2013, CLIN VACCINE IMMUNOL, V20, P747, DOI 10.1128/CVI.00034-13
   Hartwig DD, 2011, CURR MICROBIOL, V62, P1337, DOI 10.1007/s00284-010-9865-1
   Hsieh CL, 2017, FRONT CELL INFECT MI, V7, DOI 10.3389/fcimb.2017.00163
   Li L, 2007, ARCH MICROBIOL, V188, P591, DOI 10.1007/s00203-007-0280-3
   Lin X, 2016, BMC MICROBIOL, V16, DOI 10.1186/s12866-016-0852-y
   Lourdault K, 2014, INFECT IMMUN, V82, P893, DOI 10.1128/IAI.01533-13
   Lucas DSD, 2011, VACCINE, V29, P3413, DOI 10.1016/j.vaccine.2011.02.084
   McBride AJA, 2005, CURR OPIN INFECT DIS, V18, P376, DOI 10.1097/01.qco.0000178824.05715.2c
   McBride AJA, 2009, INFECT GENET EVOL, V9, P196, DOI 10.1016/j.meegid.2008.10.012
   Merien F, 1997, INFECT IMMUN, V65, P729, DOI 10.1128/IAI.65.2.729-738.1997
   Monaris D, 2015, CLIN VACCINE IMMUNOL, V22, P965, DOI 10.1128/CVI.00285-15
   Monte LG, 2011, COMP IMMUNOL MICROB, V34, P441, DOI 10.1016/j.cimid.2011.08.003
   Murray GL, 2013, VACCINE, V31, P495, DOI 10.1016/j.vaccine.2012.11.028
   Oliveira TL, 2016, MEM I OSWALDO CRUZ, V111, P712, DOI 10.1590/0074-02760160214
   Oliveira TL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142821
   Silva EF, 2007, VACCINE, V25, P6277, DOI 10.1016/j.vaccine.2007.05.053
   Silveira MM, 2017, VACCINE, V35, P5559, DOI 10.1016/j.vaccine.2017.08.067
   Srikram A, 2011, J INFECT DIS, V203, P870, DOI 10.1093/infdis/jiq127
   Umthong S, 2015, J MICROBIOL BIOTECHN, V25, P526, DOI 10.4014/jmb.1408.08007
   Yan WW, 2009, MICROBES INFECT, V11, P230, DOI 10.1016/j.micinf.2008.11.008
   Yang HY, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0004105
NR 46
TC 2
Z9 2
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 22
PY 2019
VL 37
IS 13
BP 1844
EP 1852
DI 10.1016/j.vaccine.2019.02.010
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HQ8QZ
UT WOS:000462691700016
PM 30826147
DA 2020-05-12
ER

PT J
AU Zhang, DT
   Zhang, Y
   Wang, QY
   Lock, J
   Pan, Y
   Cui, SJ
   Yang, P
   Hu, YH
AF Zhang, Daitao
   Zhang, Yi
   Wang, Quanyi
   Lock, Jerome
   Pan, Yang
   Cui, Shujuan
   Yang, Peng
   Hu, Yonghua
TI The effectiveness of influenza vaccination in preventing
   hospitalizations in elderly in Beijing, 2016-18
SO VACCINE
LA English
DT Article
DE Influenza; Vaccine effectiveness; Test-negative; Hospitalization
ID SEASONAL INFLUENZA; UNITED-STATES; CHINA; PROTECTION; A(H3N2); VIRUSES
AB Background: Influenza vaccinations play an important role in preventing influenza related hospitalizations. The objective of this study was to estimate the effectiveness of vaccination in protecting Beijing residents aged >= 60 years from influenza related hospitalizations during the 2016/17 and 2017/18 influenza seasons.
   Methods: Patients who met the definition of severe acute respiratory infection (SARI) and were hospitalized in the nine sentinel hospitals in Beijing during the 2016/17 and 2017/18 influenza seasons were identified as the study population. The vaccination status of patients was obtained from a vaccination registry. Real-time reverse transcription polymerase chain reaction (RT-PCR) experiments were conducted to test pharyngeal or lower respiratory tract samples collected from SARI patients for influenza A and B viruses. Vaccine effectiveness (VE) was examined using a test-negative design that compare the odds of vaccination among influenza positives and negatives, adjusting for calendar week of illness onset, age, and underlying medical conditions.
   Results: We identified 50,364 patients in the study, in which there were 145 influenza cases and 528 influenza-negative controls aged >= 60 years in 2016/17 season and 149 cases and 358 controls aged >= 60 years in 2017/18 season. The most commonly identified subtype among participants was influenza A(H3N2) in 2016/17 and 2017/18 season (78.5% and 70.6%). Among the adults aged >= 60 years, the adjusted VE of vaccination against any influenza virus for serious acute respiratory infection (SARI) patients was 32.8% (95% confidence interval ICI]: -22.0 to 63.0%) in 2016/17 season. While the adjusted VE in 2017/18 season were 4.6% (95% CI: -72.4 to 47.2%) against any types of influenza, 29.2% (95% CI: -92.9 to 74%) against influenza A(H1N1)pdm09, -37.7% (95% Cl: -293.8; 51.9%) against influenza A (H3N2) viruses, and 3.6% (95% CI: -113.8 to 56.5%) against influenza B.
   Conclusion: The influenza vaccine provided moderate protection in 2016/17 season and mild protection in 2017/18 season for influenza related inpatients of adults aged >= 60 years in Beijing. (C) 2019 Published by Elsevier Ltd.
C1 [Zhang, Daitao; Hu, Yonghua] Peking Univ, Dept Epidemiol & Biostat, Sch Publ Hlth, 38 Xueyuan Rd, Beijing 100191, Peoples R China.
   [Zhang, Daitao; Zhang, Yi; Wang, Quanyi; Pan, Yang; Cui, Shujuan; Yang, Peng] Beijing Municipal Ctr Dis Prevent & Control, Inst Infect Dis & Endem Dis Control, 16 Hepingli Middle St, Beijing 100013, Peoples R China.
   [Zhang, Daitao; Zhang, Yi; Wang, Quanyi; Pan, Yang; Cui, Shujuan; Yang, Peng] Beijing Res Ctr Prevent Med, 16 Hepingli Middle St, Beijing 100013, Peoples R China.
   [Lock, Jerome] Maastricht Univ, Fac Hlth Med & Life Sci, Dept Hlth Eth & Soc, Maastricht, Netherlands.
RP Hu, YH (reprint author), Peking Univ, Dept Epidemiol & Biostat, Sch Publ Hlth, 38 Xueyuan Rd, Beijing 100191, Peoples R China.
EM yhhu@bjmu.edu.cn
FU Capital's Funds for Health Improvement and Research [2018-2-1013]
FX This work was supported by the Capital's Funds for Health Improvement
   and Research (grant number 2018-2-1013).
CR 56th World Health Assembly, 2003, PREV CONTR INFL PAND
   Belongia Edward A, 2017, Expert Rev Vaccines, V16, P1, DOI 10.1080/14760584.2017.1334554
   Belongia EA, 2016, LANCET INFECT DIS, V16, P942, DOI 10.1016/S1473-3099(16)00129-8
   Castilla J, 2017, EUROSURVEILLANCE, V22, P11, DOI 10.2807/1560-7917.ES.2017.22.7.30465
   European Centre for Disease Prevention and Control, 2017, RISK ASS SEAS INFL E
   Feng LZ, 2010, VACCINE, V28, P6778, DOI 10.1016/j.vaccine.2010.07.064
   Flannery B, 2018, MMWR-MORBID MORTAL W, V67, P180, DOI 10.15585/mmwr.mm6706a2
   Flannery B, 2017, MMWR-MORBID MORTAL W, V66, P167, DOI 10.15585/mmwr.mm6606a3
   Fry AM, 2014, CLIN INFECT DIS, V59, P406, DOI 10.1093/cid/ciu328
   Grohskopf LA, 2017, AM J TRANSPLANT, V17, P2970, DOI 10.1111/ajt.14511
   Jimenez-Jorge S, 2015, EUROSURVEILLANCE, V20, DOI 10.2807/1560-7917.ES2015.20.28.21187
   Kim JH, 2009, J IMMUNOL, V183, P3294, DOI 10.4049/jimmunol.0900398
   Kissling E, 2017, EUROSURVEILLANCE, V22, P2, DOI 10.2807/1560-7917.ES.2017.22.7.30464
   Lv M, 2016, VACCINE, V34, P2135, DOI 10.1016/j.vaccine.2016.02.032
   Martinez-Baz I, 2017, J INFECT DIS, V215, P847, DOI 10.1093/infdis/jix055
   McLean HQ, 2014, CLIN INFECT DIS, V59, P1375, DOI 10.1093/cid/ciu680
   Ohmit SE, 2014, CLIN INFECT DIS, V58, P319, DOI 10.1093/cid/cit736
   Paessler Slobodan, 2017, F1000Res, V6, P2067, DOI 10.12688/f1000research.13198.1
   Qin Y, 2016, VACCINE, V34, P2329, DOI 10.1016/j.vaccine.2016.03.068
   Radin JM, 2016, VACCINE, V34, P3907, DOI 10.1016/j.vaccine.2016.05.034
   Skowronski DM, 2017, EUROSURVEILLANCE, V22, P2, DOI [10.2807/1560-7917.es.2017.22.6.30460, 10.2807/1560-7917.ES.2017.22.6.30460]
   Skowronski DM, 2018, EUROSURVEILLANCE, V23, P2, DOI 10.2807/1560-7917.ES.2018.23.5.18-00035
   Skowronski DM, 2017, J INFECT DIS, V215, P1059, DOI 10.1093/infdis/jix074
   Sullivan SG, 2017, EUROSURVEILLANCE, V22, P2, DOI 10.2807/1560-7917.ES.2017.22.43.17-00707
   Sullivan SG, 2014, EXPERT REV VACCINES, V13, P1571, DOI 10.1586/14760584.2014.966695
   The Francis Crick Institute, 2017, REP PREP WHO ANN CON
   Veljkovic V, 2015, FRONT MICROBIOL, V6, DOI 10.3389/fmicb.2015.01456
   World Health Organization, 2018, INFL SEAS
   World Health Organization, 2018, REC COMP INFL VIR VA
   Wu NC, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006682
   Zhang Y, 2017, VACCINE, V35, P3129, DOI 10.1016/j.vaccine.2017.03.084
   Zimmerman RK, 2016, CLIN INFECT DIS, V63, P1564, DOI 10.1093/cid/ciw635
   Zost SJ, 2017, P NATL ACAD SCI USA, V114, P12578, DOI 10.1073/pnas.1712377114
NR 33
TC 0
Z9 1
U1 1
U2 5
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 22
PY 2019
VL 37
IS 13
BP 1853
EP 1858
DI 10.1016/j.vaccine.2019.02.013
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HQ8QZ
UT WOS:000462691700017
PM 30827734
DA 2020-05-12
ER

PT J
AU Dolan, SB
   Carnahan, E
   Shearer, JC
   Beylerian, EN
   Thompson, J
   Gilbert, SS
   Werner, L
   Ryman, TK
AF Dolan, Samantha B.
   Carnahan, Emily
   Shearer, Jessica C.
   Beylerian, Emily N.
   Thompson, Jenny
   Gilbert, Skye S.
   Werner, Laurie
   Ryman, Tove K.
TI Redefining vaccination coverage and timeliness measures using electronic
   immunization registry data in low- and middle-income countries
SO VACCINE
LA English
DT Article
DE Immunization; Vaccine; Measures; Routine health information system;
   Individual-level data; Electronic immunization registry
ID INFORMATION-SYSTEMS; CHILDHOOD IMMUNIZATION; UNITED-STATES; PROGRESS;
   QUALITY
AB Vaccine coverage is routinely used as a performance indicator for immunization programs both at local and global levels. For many national immunization programs, there are challenges with accurately estimating vaccination coverage based on available data sources, however an increasing number of low- and middle-income countries (LMICs) have begun implementing electronic immunization registries to replace health facilities' paper-based tools and aggregate reporting systems. These systems allow for more efficient capture and use of routinely reported individual-level data that can be used to calculate dose-specific and cohort vaccination coverage, replacing the commonly used aggregate routine health information system data. With these individual-level data immunization programs have the opportunity to redefine performance measures to enhance programmatic decision-making at all levels of the health system. In this commentary, we discuss how measures for assessing vaccination status and program performance can be redefined and recalculated using these data when generated at the health facility level and the implications of the use and availability of electronic individual-level data. (C) 2019 The Authors. Published by Elsevier Ltd.
C1 [Dolan, Samantha B.] Dolan Consulting LLC, Seattle, WA USA.
   [Dolan, Samantha B.; Carnahan, Emily; Shearer, Jessica C.; Beylerian, Emily N.; Thompson, Jenny; Gilbert, Skye S.; Werner, Laurie] PATH, Seattle, WA USA.
   [Dolan, Samantha B.] Univ Washington, Dept Global Hlth, Seattle, WA 98195 USA.
   [Ryman, Tove K.] Bill & Melinda Gates Fdn, Seattle, WA USA.
RP Dolan, SB (reprint author), 2201 Westlake Ave, Seattle, WA 98121 USA.
EM sdolan11@uw.edu
OI Dolan, Samantha/0000-0001-8088-6611
FU Bill & Melinda Gates Foundation, Seattle, WAGates Foundation
   [OPP1042273]
FX This work was supported by the Bill & Melinda Gates Foundation, Seattle,
   WA. [grant number OPP1042273].
CR Adetifa IMO, 2018, VACCINE, V36, P7965, DOI 10.1016/j.vaccine.2018.11.005
   American Immunization Registry Association, 2015, AN GUID ASS VACC COV
   American Immunization Registry Association, 2018, ISS DAT QUAL PRACT M
   American Immunization Registry Association, 2015, AFIX IIS INT OP TECH
   [Anonymous], 2012, Wkly Epidemiol Rec, V87, P1
   Bilous J, 2006, LANCET, V367, P1464, DOI 10.1016/S0140-6736(06)68625-X
   Bosch-Capblanch X, 2009, TROP MED INT HEALTH, V14, P2, DOI 10.1111/j.1365-3156.2008.02181.x
   Brown D. W., 2014, WORLD J VACCINES, V4, P42546, DOI [10.4236/wjv.2014.41004, DOI 10.4236/WJV.2014.41004]
   Brown DW, 2014, WORLD J VACCINES, V4, P97, DOI DOI 10.4236/wjv.2014.43012
   Burton A, 2009, B WORLD HEALTH ORGAN, V87, P535, DOI 10.2471/BLT.08.053819
   Canavan B. C., 2006, Morbidity and Mortality Weekly Report, V55, P1327
   Danovaro-Holliday MC, 2014, REV PANAM SALUD PUBL, V35, P453
   Centers for Disease Control and Prevention, 2018, IMM INF SYST IIS FUN
   Curran EA, 2013, HUM VACC IMMUNOTHER, V9, P1346, DOI 10.4161/hv.24033
   Cutts FT, 2016, VACCINE, V34, P4103, DOI 10.1016/j.vaccine.2016.06.053
   Cutts FT, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001404
   Dumit EM, 2018, VACCINE, V36, P7923, DOI 10.1016/j.vaccine.2018.06.076
   Eastern Mediterranean Region. World Health Organization, 2016, E MED VACC ACT PLAN
   Finlayson Teresa J., 2011, Morbidity and Mortality Weekly Report, V60, P1
   Freeman VA, 2003, ANNU REV PUBL HEALTH, V24, P227, DOI 10.1146/annurev.publhealth.24.100901.140831
   Fuller JE, 2017, MATERN CHILD HLTH J, V21, P29, DOI 10.1007/s10995-016-2090-1
   Gavi The Vaccine Alliance, 2016, 2016 2020 IND
   Gowda C, 2013, PUBLIC HEALTH REP, V128, P489, DOI 10.1177/003335491312800608
   Hanson CM, 2018, VACCINE, V36, P3260, DOI 10.1016/j.vaccine.2018.04.070
   Hu Y, 2017, INT J ENV RES PUBLIC, V14
   Lim SS, 2008, LANCET, V372, P2031, DOI 10.1016/S0140-6736(08)61869-3
   MacDonald SE, 2018, HUM VACCIN IMMUNOTHE
   Murray CJL, 2003, LANCET, V362, P1022, DOI 10.1016/S0140-6736(03)14411-X
   Murthy N, 2017, MMWR-MORBID MORTAL W, V66, P1178, DOI 10.15585/mmwr.mm6643a4
   Namageyo-Funa A, 2018, BMC HEALTH SERV RES, V18, DOI 10.1186/s12913-018-3435-9
   Nguyen Nga Tuyet, 2017, Mhealth, V3, P26, DOI 10.21037/mhealth.2017.06.03
   Pan American Health Organization, 2018, EL IMM REG PRACT CON
   Pan American Health Organization, 2014, METH EV MISS OPP VAC
   Papania M, 2006, LANCET, V367, P965, DOI 10.1016/S0140-6736(06)68403-1
   Police Rachel L, 2010, Inform Prim Care, V18, P245
   Regional Office for Africa World Health Organization, 2015, REG STRAT PLAN IMM 2
   Regional Office for Europe World Health Organization, 2014, EUR VACC ACT PLAN 20
   Regional Office for South-East Asia World Health Organization, 2017, S E AS REG VACC ACT
   Regional Office for the Americas World Health Organization, 2015, PLAN ACT IMM
   Robinson S, 2018, OREGON IMMUNIZATION
   Ronveaux O, 2005, B WORLD HEALTH ORGAN, V83, P503
   Scott C, 2017, MMWR-MORBID MORTAL W, V66, P1226, DOI 10.15585/mmwr.mm6644a5
   Stein-Zamir C, 2017, HUM VACC IMMUNOTHER, V13, P2102, DOI 10.1080/21645515.2017.1341028
   Trumbo SP, 2018, VACCINE, V36, P7674, DOI 10.1016/j.vaccine.2018.10.083
   United Nations, SUST DEV GOALS
   Wagenaar BH, 2016, HEALTH POLICY PLANN, V31, P129, DOI 10.1093/heapol/czv029
   Western Pacific Region World Health Organization, 2015, REG FRAM IMPL GLOB V
   WHO, 2018, LIM REL GLOB REP IMM
   World Health Organization, 2013, GLOB VACC ACT PLAN 2
   World Health Organization, REG VACC ACT PLANS
   World Health Organization, 2015, ASS IMPR ACC TARG PO
NR 51
TC 5
Z9 5
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 22
PY 2019
VL 37
IS 13
BP 1859
EP 1867
DI 10.1016/j.vaccine.2019.02.017
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HQ8QZ
UT WOS:000462691700018
PM 30808566
OA Other Gold, Green Published
DA 2020-05-12
ER

PT J
AU Cohen, C
   Moreira, ED
   Nanez, H
   Nachiappan, JP
   Arvinder-Singh, HS
   Huoi, C
   Nealon, J
   Sarti, E
   Puentes-Rosas, E
   Moureau, A
   Khromava, A
   Ab Rahman, R
   Moy, FS
   Ismail, NIB
   Gee, LH
   Chung, LW
   Ling, YH
   Majawit, EM
   Fu, GW
   Win, MZ
   Morfin, MD
   Hernandez, AL
   Rodriguez, E
   Vazquez, M
   Benuelos, MA
   Correa, SK
   Nanez, M
   Nangullasmu, T
   Ribeiro, G
   Moreira, S
   Lobo, V
   Celestino, C
   Santana, P
   Tavares, V
   Zocchetti, C
   Oh, YH
   Rochon, J
   Gailhardou, S
   Panozzo, C
   Moreira, T
   Gripenberg, M
   Ojeda, J
   Shinohara, E
   Becerra, A
   Calingaert, B
   Harding, A
   Johannes, C
   Pladevall-Vila, M
AF Cohen, Carine
   Moreira Jr, Edson D.
   Nanez, Homero
   Nachiappan, Jeyaseelan P.
   Arvinder-Singh, H. S.
   Huoi, Catherine
   Nealon, Joshua
   Sarti, Elsa
   Puentes-Rosas, Esteban
   Moureau, Annick
   Khromava, Alena
   Ab Rahman, Rusnah
   Moy, Fong Siew
   Ismail, Nahla Irtiza Binti
   Gee, Lee Heng
   Chung, Law Wan
   Ling, Yap Huey
   Majawit, Elyssa Milus
   Fu, Gan Wee
   Win, Moe Zaw
   del Rayo Morfin, Maria
   Leon Hernandez, Alfonso
   Rodriguez, Eduardo
   Vazquez, Marisela
   Alfonso Benuelos, Manuel
   Kristell Correa, Silvia
   Nanez, Melissa
   Nangullasmu, Tomas
   Ribeiro, Guillherme
   Moreira, Sandra
   Lobo, Victor
   Celestino, Cristina
   Santana, Perla
   Tavares, Vitoria
   Zocchetti, Celine
   Oh, Yong Ho
   Rochon, Julie
   Gailhardou, Sophia
   Panozzo, Catherine
   Moreira, Thais
   Gripenberg, Marissa
   Ojeda, Joyce
   Shinohara, Erica
   Becerra, Amalia
   Calingaert, Brian
   Harding, Abenah
   Johannes, Catherine
   Pladevall-Vila, Mane
CA Study Team
TI Incidence rates of neurotropic-like and viscerotropic-like disease in
   three dengue-endemic countries: Mexico, Brazil, and Malaysia
SO VACCINE
LA English
DT Article
DE Tetravalent dengue vaccine; Viscerotropic; Neurotropic; Dengue-endemic
ID GUILLAIN-BARRE-SYNDROME; ADVERSE EVENTS; VACCINE; SAFETY; VIRUS;
   IMMUNIZATION
AB Background: The background incidence of viscerotropic- (VLD) and neurotropic-like disease (NLD) unrelated to immunization in dengue-endemic countries is currently unknown.
   Methods: This retrospective population-based analysis estimated crude and standardized incidences of VLD and NLD in twelve hospitals in Brazil (n = 3), Mexico (n = 3), and Malaysia (n = 6) over a 1-year period before the introduction of the tetravalent dengue vaccine. Catchment areas were estimated using publicly available population census information and administrative data. The denominator population for incidence rates was calculated, and sensitivity analyses assessed the impact of important assumptions.
   Results: Total cases adjudicated as definite VLD were 5, 57, and 56 in Brazil, Mexico, and Malaysia, respectively. Total cases adjudicated as definite NLD were 103, 29, and 26 in Brazil, Mexico, and Malaysia, respectively. Crude incidence rates of cases adjudicated as definite VLD in Brazil, Mexico, and Malaysia were 1.17, 2.60, and 1.48 per 100,000 person-years, respectively. Crude incidence rates of cases adjudicated as definite NLD in Brazil, Mexico, and Malaysia were 4.45, 1.32, and 0.69 per 100,000 person-years, respectively.
   Conclusions: Background incidence estimates of VLD and NLD obtained in Mexico, Brazil, and Malaysia could provide context for cases occurring after the introduction of the tetravalent dengue vaccine. (C) 2019 Published by Elsevier Ltd.
C1 [Cohen, Carine; Huoi, Catherine; Zocchetti, Celine; Oh, Yong Ho; Rochon, Julie; Gailhardou, Sophia; Panozzo, Catherine; Moreira, Thais; Gripenberg, Marissa; Ojeda, Joyce; Shinohara, Erica; Becerra, Amalia] Sanofi Pasteur, 14 Espace Henry Vallee, F-69007 Lyon, France.
   [Moreira Jr, Edson D.] Brazilian Minist Hlth, Assoc Obras Sociais Irma Dulce, Salvador, BA, Brazil.
   [Moreira Jr, Edson D.] Brazilian Minist Hlth, Oswaldo Cruz Fdn, Salvador, BA, Brazil.
   [Nanez, Homero] Univ Autonoma Nuevo Lean, Fac Med, Univ Hosp Dr Jose E Gonzalez, Monterrey, NL, Mexico.
   [Nachiappan, Jeyaseelan P.] Hosp Raja Permaisuri Bainun, Ipoh, Perak, Malaysia.
   [Arvinder-Singh, H. S.] Clin Res Ctr, Kuala Lumpur, Malaysia.
   [Nealon, Joshua] Sanofi Pasteur, Asia & JPAC Reg, Singapore, Singapore.
   [Sarti, Elsa; Puentes-Rosas, Esteban] Sanofi Pasteur LATAM, Coyoacan, Cdmx, Mexico.
   [Moureau, Annick] Sanofi Pasteur, Clin Dev, Lyon, France.
   [Khromava, Alena] Sanofi Pasteur, Toronto, ON, Canada.
   [Calingaert, Brian; Harding, Abenah; Johannes, Catherine; Pladevall-Vila, Mane] RTI Hlth Solut, Res Triangle Pk, NC USA.
RP Cohen, C (reprint author), Sanofi Pasteur, 14 Espace Henry Vallee, F-69007 Lyon, France.
EM Carine.Cohen@sanofi.com; edson@bahia.fiocruz.br; homnan@gmail.com;
   jaynachi@gmail.com; arvinder.crc@gmail.com; Catherine.Huoi@sano-fi.com;
   Joshua.Nealon@sanofi.com; Elsa.Sarti@sanofi.com;
   Esteban.Puentes@sanofi.com; Annick.Moureau@sanofi.com;
   Alena.Khromava@sanofi.com
RI Moreira, Edson D/J-1758-2012; Moreira, Edson/W-7437-2019;
   Harbaksh-Singh, Arvinder-Singh/A-5670-2017
OI Moreira, Edson D/0000-0002-7081-8348; Moreira,
   Edson/0000-0002-7081-8348; Harbaksh-Singh,
   Arvinder-Singh/0000-0001-9543-4036
FU Sanofi Pasteur
FX This study was funded by Sanofi Pasteur.
CR Amanna IJ, 2016, EXPERT REV VACCINES, V15, P1519, DOI 10.1080/14760584.2016.1198259
   BEGHI E, 1984, ANN NEUROL, V16, P283, DOI 10.1002/ana.410160304
   Biscayart C, 2014, VACCINE, V32, P1266, DOI 10.1016/j.vaccine.2014.01.015
   Brinkhoff T., 2015, MEXICO METROPOLITAN
   Daffis S, 2005, VIROLOGY, V337, P262, DOI 10.1016/j.virol.2005.04.031
   Fay MP, 1997, STAT MED, V16, P791
   Fokke C, 2014, BRAIN, V137, P33, DOI 10.1093/brain/awt285
   Gailhardou S, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004821
   Gershman MD, 2012, VACCINE, V30, P5038, DOI 10.1016/j.vaccine.2012.04.067
   Guirakhoo F, 2004, J VIROL, V78, P4761, DOI 10.1128/JVI.78.9.4761-4775.2004
   Guy B, 2015, VACCINE, V33, P7100, DOI 10.1016/j.vaccine.2015.09.108
   Jentes ES, 2016, J TRAVEL MED, V23, DOI 10.1093/jtm/taw062
   Kohl K S, BRIGHTON COLLABORATI
   L'Azou M, 2018, T ROY SOC TROP MED H, V112, P158, DOI 10.1093/trstmh/try037
   L'Azou M, 2016, NEW ENGL J MED, V374, P1155, DOI 10.1056/NEJMoa1503877
   Lindsey NP, 2016, J TRAVEL MED, V23, DOI 10.1093/jtm/taw045
   Mahaux O, 2016, PHARMACOEPIDEM DR S, V25, P215, DOI 10.1002/pds.3918
   Martins RD, 2010, PROCEDIA VACCINOL, V2, P178, DOI 10.1016/j.provac.2010.07.012
   McGrogan A, 2009, NEUROEPIDEMIOLOGY, V32, P150, DOI 10.1159/000184748
   Monath TP, 2015, VACCINE, V33, P62, DOI 10.1016/j.vaccine.2014.10.004
   Rocha MSG, 2004, ARQ NEURO-PSIQUIAT, V62, P33, DOI 10.1590/S0004-282X2004000100006
   Scott LJ, 2016, DRUGS, V76, P1301, DOI 10.1007/s40265-016-0626-8
   Sejvar JJ, 2011, NEUROEPIDEMIOLOGY, V36, P123, DOI 10.1159/000324710
   Seligman SJ, 2014, VACCINE, V32, P5769, DOI 10.1016/j.vaccine.2014.08.051
   Sridhar S, 2018, NEW ENGL J MED, V379, P327, DOI 10.1056/NEJMoa1800820
   Thomas RE, 2016, DRUG DES DEV THER, V10, P3345, DOI 10.2147/DDDT.S99600
   Thomas RE, 2013, VACCINE, V31, P6201, DOI 10.1016/j.vaccine.2013.10.050
   ULM K, 1990, AM J EPIDEMIOL, V131, P373, DOI 10.1093/oxfordjournals.aje.a115507
   Wilder-Smith A, 2019, LANCET INFECT DIS, V19, pE31, DOI 10.1016/S1473-3099(18)30494-8
   World Health Organization, 2018, DENG VACC WHO POS PA, V2018, P457, DOI [10.1016/j.vaccine.2018.09.063, DOI 10.1016/J.VACCINE.2018.09.063]
NR 30
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 22
PY 2019
VL 37
IS 13
BP 1868
EP 1875
DI 10.1016/j.vaccine.2019.01.087
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HQ8QZ
UT WOS:000462691700019
PM 30826144
DA 2020-05-12
ER

PT J
AU Pepin, S
   Dupuy, M
   Borja-Tabora, CFC
   Montellano, M
   Bravo, L
   Santos, J
   de Castro, JA
   Rivera-Medina, DM
   Cutland, C
   Ariza, M
   Diez-Domingo, J
   Gonzalez, CD
   Martinon-Torres, F
   Papadopoulou-Alataki, E
   Theodoriado, M
   Kazek-Duret, MP
   Gurunathan, S
   De Bruijn, I
   Abalos, K
   Aurell, H
   Baldo, JM
   Bona, G
   Angel, M
   Cadorna-Carlos, J
   Cangrejo, M
   Capilna, BR
   Cara, AC
   Martinez, AC
   Chemin, F
   Closa, R
   Cots, MB
   Coux, F
   Diez-Domingo, J
   Dracea, LL
   Emporiadou, M
   Espiau, M
   Esposito, S
   Pecurariu, OAF
   Garces-Sanchez, M
   Garg, S
   Gil, A
   Gonzales, L
   Guevel, R
   Guillen, S
   Icardi, G
   Laot, T
   Lacroix, I
   Mares, J
   Pons, MM
   Moreau, C
   Neamtu, ML
   Neculau, AE
   Ojeda, J
   Papaevangelou, V
   Penon, MG
   Petit, C
   Philibert, M
   Cantarino, VP
   Py, ML
   Ramos, JT
   Rivas, E
   Roilides, E
   Rosich, A
   Salamand, C
   Suarez, E
   Surdu, GD
   Vera, TC
   Tsolia, M
   Vicedo, M
   Woods, A
AF Pepin, Stephanie
   Dupuy, Martin
   Corazon Borja-Tabora, Charissa Fay
   Montellano, May
   Bravo, Lulu
   Santos, Jaime
   de Castro, Jo-Anne
   Rivera-Medina, Doris Maribel
   Cutland, Clare
   Ariza, Miguel
   Diez-Domingo, Javier
   Diaz Gonzalez, Celia
   Martinon-Torres, Federico
   Papadopoulou-Alataki, Efimia
   Theodoriado, Maria
   Kazek-Duret, Marie Pierre
   Gurunathan, Sanjay
   De Bruijn, Iris
   Abalos, Karina
   Aurell, Helena
   Maria Baldo, Jose
   Bona, Gianni
   Angel, Miguel
   Cadorna-Carlos, Josefina
   Cangrejo, Marcela
   Capilna, Brindusa Ruxandra
   Cara, Alexandra Carmen
   Carmona Martinez, Alfonso
   Chemin, Frederic
   Closa, Ricardo
   Cots, Manuel Baca
   Coux, Florence
   Diez-Domingo, Javier
   Dracea, Laura Larisa
   Emporiadou, Maria
   Espiau, Maria
   Esposito, Susanna
   Pecurariu, Oana Asso Falup
   Garces-Sanchez, Maria
   Garg, Sanjay
   Gil, Amparo
   Gonzales, Laurie
   Guevel, Ronan
   Guillen, Sara
   Icardi, Giancarlo
   Laot, Thelma
   Lacroix, Isabelle
   Mares, Josep
   Martinez Pons, Manuel
   Moreau, Catherine
   Neamtu, Mihai Leonida
   Neculau, Andrea Elena
   Ojeda, Joyce
   Papaevangelou, Vana
   Penon, Maria Gabriella
   Petit, Celine
   Philibert, Marie
   Planelles Cantarino, Victoria
   Py, Marie-Laure
   Ramos, Jose T.
   Rivas, Enrique
   Roilides, Emmanouel
   Rosich, Angels
   Salamand, Camille
   Suarez, Eva
   Surdu, Gabriel Doru
   Cerdan Vera, Teresa
   Tsolia, Mariza
   Vicedo, Mira
   Woods, Anne
CA GQM05 Study Grp
TI Efficacy, immunogenicity, and safety of a quadrivalent inactivated
   influenza vaccine in children aged 6-35 months: A multi-season
   randomised placebo-controlled trial in the Northern and Southern
   Hemispheres
SO VACCINE
LA English
DT Article
DE Quadrivalent inactivated influenza vaccine; Children; Efficacy; Safety;
   Immunogenicity
ID PHASE-III; BURDEN; VIRUS; ADULTS; IMPACT
AB Background: A quadrivalent split-virion inactivated influenza vaccine (VaxigripTetre (TM), Sanofi Pasteur; IIV4) containing two A strains (H1N1 and H3N2) and B strains from both lineages (Victoria and Yamagata) was approved in Europe in 2016 for individuals aged >= 3 years. This study examined the efficacy and safety of IIV4 in children aged 6-35 months.
   Methods: This was a phase III randomised controlled trial conducted in Latin America, Asia, Africa, and Europe during the Northern Hemisphere 2014/2015 and 2015/2016 and Southern Hemisphere 2014 and 2015 influenza seasons. Healthy children aged 6-35 months not previously vaccinated against influenza were randomised to receive two full doses 28 days apart of IIV4, placebo, the licensed trivalent splitvirion inactivated vaccine (IIV3), an investigational IIV3 containing a B strain from the alternate lineage. The primary objective was to demonstrate efficacy against influenza illness caused by any strain or vaccine-similar strains.
   Results: The study enrolled 5806 participants. Efficacy, assessed in 4980 participants completing the study according to protocol, was demonstrated for IIV4. Vaccine efficacy was 50.98% (97% CI, 37.36-61.86%) against influenza caused by any A or B type and 68.40% (97% CI, 47.07-81.92%) against influenza caused by vaccine-like strains. Safety profiles were similar for IIV4, placebo, and the IIV3s, although injection-site reactions were slightly more frequent for IIV4 than placebo.
   Conclusions: IIV4 was safe and effective for protecting children aged 6-35 months against influenza illness caused by vaccine-similar or any circulating strains. (C) 2018 The Authors. Published by Elsevier Ltd.
C1 [Pepin, Stephanie; Dupuy, Martin; Kazek-Duret, Marie Pierre; De Bruijn, Iris; Aurell, Helena; Coux, Florence; Garg, Sanjay; Gonzales, Laurie; Guevel, Ronan; Lacroix, Isabelle; Moreau, Catherine; Petit, Celine; Philibert, Marie; Py, Marie-Laure; Salamand, Camille; Woods, Anne] Sanofi Pasteur, 1541 Ave Marcel Merieux, F-69280 Marcy Letoile, France.
   [Corazon Borja-Tabora, Charissa Fay] Res Inst Trop Med, Muntinlupa, Philippines.
   [Montellano, May] Mary Chiles Gen Hosp, Manila, Philippines.
   [Bravo, Lulu] Univ Philippines Manila, Natl Inst Hlth, Manila, Philippines.
   [Santos, Jaime] Philippine Childrens Med Ctr, Quezon City, Philippines.
   [de Castro, Jo-Anne] DLSUMC De La Salle Hlth Sci Inst, Dasmarinas, Cavite, Philippines.
   [Rivera-Medina, Doris Maribel] Invers Invest Med SA, Tegucigalpa, Honduras.
   [Cutland, Clare] Chris Hani Baragwanath Hosp, Johannesburg, South Africa.
   [Ariza, Miguel] Caimed Dominicana AS Invest Salud, Santo Domingo, Dominican Rep.
   [Diez-Domingo, Javier] FISABIO Publ Hlth, Valencia, Spain.
   [Diaz Gonzalez, Celia] Hosp Infanta La Paz, Madrid, Spain.
   [Martinon-Torres, Federico] Univ Santiago de Compostela, Translat Pediat & Infect Dis, Santiago De Compostela, Spain.
   [Martinon-Torres, Federico] Univ Santiago, Inst Invest Sanitaria Santiago, Genet Vaccines & Infect Dis Res Grp GENVIP, Santiago, Spain.
   [Papadopoulou-Alataki, Efimia] Aristotle Univ Thessaloniki, Sch Med, Thessaloniki, Greece.
   [Theodoriado, Maria] Childrens Hosp Aghia Sofia, Athens, Greece.
   [Gurunathan, Sanjay] Sanofi Pasteur, Swiftwater, PA USA.
   [Abalos, Karina] Sanofi Pasteur, Taguig City, Philippines.
   [Maria Baldo, Jose] Ctr Salud Quart de Poblet, Valencia, Spain.
   [Bona, Gianni] Univ Piemonte Orientale, Novara, Italy.
   [Angel, Miguel] Ctr Salud Illes Columbretes, Castellon De La Plana, Castellon, Spain.
   [Cadorna-Carlos, Josefina] Univ East Ramon Magsaysay, Quezon City, Philippines.
   [Cangrejo, Marcela] Sanofi Pasteur, Bogota, Colombia.
   [Capilna, Brindusa Ruxandra] Ultratest SRL, Targu Mures, Romania.
   [Carmona Martinez, Alfonso] Inst Hispalense Pediat Sevilla, Seville, Spain.
   [Closa, Ricardo] Univ Rovira & Virgili, Tarragona, Spain.
   [Cots, Manuel Baca] Hosp Quiron Salud, Madrid, Spain.
   [Diez-Domingo, Javier; Garces-Sanchez, Maria; Planelles Cantarino, Victoria] Ctr Super Invest Salud Publ, Valencia, Spain.
   [Emporiadou, Maria] Aristotle Univ Thessaloniki, Thessaloniki, Greece.
   [Espiau, Maria] Univ Hosp Vall dHebron, Barcelona, Spain.
   [Esposito, Susanna; Icardi, Giancarlo] Univ Genoa, Genoa, Italy.
   [Pecurariu, Oana Asso Falup] Transylvania Univ, Brasov, Romania.
   [Gil, Amparo; Rosich, Angels] Ctr Salud Malvarrosa, Valencia, Spain.
   [Guillen, Sara] Hosp Univ Getafe, Madrid, Spain.
   [Laot, Thelma] Sanofi Pasteur, Manila, Philippines.
   [Mares, Josep] Inst Pediat Mares Riera, Girona, Spain.
   [Martinez Pons, Manuel] CS Republ Argentina, Valencia, Spain.
   [Neamtu, Mihai Leonida] Lucian Blaga Univ Sibiu, Sibiu, Romania.
   [Ojeda, Joyce; Rivas, Enrique] Sanofi Pasteur, Mexico City, DF, Mexico.
   [Papaevangelou, Vana; Tsolia, Mariza] Univ Athens, Sch Med, Athens, Greece.
   [Penon, Maria Gabriella] ULSS179 Presidio Osped Este Dipartimento PD, Este, Italy.
   [Ramos, Jose T.] Hosp Clin San Carlos, Madrid, Spain.
   [Roilides, Emmanouel] Aristotle Univ Thessaloniki, Thessaloniki, Greece.
   [Suarez, Eva] Ctr Salud Burriana 2, Borriana, Castello, Spain.
   [Vicedo, Mira] Ctr Salud Petrer 1, Petrer, Alacant, Spain.
RP Pepin, S (reprint author), Sanofi Pasteur, 1541 Ave Marcel Merieux, F-69280 Marcy Letoile, France.
EM Stephanie.Pepin@sanofipasteur.com; Martin.Dupuy@sanofi.com;
   jimson2@me.com; cutlandc@rmpru.co.za; celiac.diaz@salud.madrid.org;
   Federico.Martinon.Torres@sergas.es; efiala@otenet.gr;
   mpapagrig@med.uoa.gr; Marie-Pierre.Kazek-Duret@sanofi.com;
   Sanjay.Gurunathan@sanofi.com; Iris.DeBruijn@sanofi.com
RI Martinon-Torres, Federico/E-4982-2016; Domingo, Javier Diez/B-7293-2015
OI Martinon-Torres, Federico/0000-0002-9023-581X; Domingo, Javier
   Diez/0000-0003-1008-3922
FU Sanofi Pasteur
FX The study was funded by Sanofi Pasteur. Medical writing was provided by
   Dr. Phillip Leventhal (4Clinics, Paris, France) and paid for by Sanofi
   Pasteur. Employees of Sanofi Pasteur participated in conceiving and
   designing the study, drafting and editing the article, deciding to
   submit the article for publication, and approving the final, submitted
   version.
CR Ambrose CS, 2012, HUM VACC IMMUNOTHER, V8, P81, DOI 10.4161/hv.8.1.17623
   [Anonymous], 2011, Wkly Epidemiol Rec, V86, P222
   Cadorna-Carlos JB, 2015, VACCINE, V33, P2485, DOI 10.1016/j.vaccine.2015.03.065
   Choi WS, 2017, HUMAN VACC IMMUNOTHE
   Claeys C, 2017, 35 ANN M EUR SOC PED
   Cox RJ, 2013, HUM VACC IMMUNOTHER, V9, P405, DOI 10.4161/hv.22908
   Crepey P, 2015, INFLUENZA OTHER RESP, V9, P39, DOI 10.1111/irv.12318
   DiazGranados CA, 2012, VACCINE, V31, P49, DOI 10.1016/j.vaccine.2012.10.084
   Fraaij PLA, 2011, VACCINE, V29, P7524, DOI 10.1016/j.vaccine.2011.08.010
   Glezen WP, 2013, AM J PUBLIC HEALTH, V103, pE43, DOI 10.2105/AJPH.2012.301137
   Heikkinen T, 2014, CLIN INFECT DIS, V59, P1519, DOI 10.1093/cid/ciu664
   Iskander M, 2007, CURR OPIN INFECT DIS, V20, P259, DOI 10.1097/QCO.0b013e3280ad4687
   Jain VK, 2017, J PEDIATR INFECT DIS, V6, P9, DOI 10.1093/jpids/piw068
   Langley JM, 2012, J PEDIATR INFECT DIS, V1, P55, DOI [10.1093/jpids/pis012, 10.1093/JPIDS/PIS012]
   LEVANDOWSKI RA, 1991, PEDIATRICS, V88, P1031
   Lu ChunYi, 2016, Trials in Vaccinology, V5, P48
   Ohmit SE, 2011, J INFECT DIS, V204, P1879, DOI 10.1093/infdis/jir661
   Pavia-Ruz N, 2013, HUM VACC IMMUNOTHER, V9, P1978, DOI 10.4161/hv.25363
   Pepin S, 2016, HUM VACC IMMUNOTHER, V12, P3072, DOI 10.1080/21645515.2016.1212143
   Pepin S, 2013, VACCINE, V31, P5572, DOI 10.1016/j.vaccine.2013.08.069
   ROTA PA, 1990, VIROLOGY, V175, P59, DOI 10.1016/0042-6822(90)90186-U
   SAGE Working Group, 2012, BACKGR PAP INFL VACC
   Sesay S, 2017, HUMAN VAC IMMUNOTHER
   Skowronski DM, 2011, PEDIATRICS, V128, pE276, DOI 10.1542/peds.2010-2777
   Smith Nicole M., 2006, Morbidity and Mortality Weekly Report, V55, P1
   Thompson WW, 2003, JAMA-J AM MED ASSOC, V289, P179, DOI 10.1001/jama.289.2.179
   Tricco AC, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-153
   World Health Organization, 2012, TABL 2A TIV VACC CHI
   WRIGHT PF, 1976, J INFECT DIS, V134, P633, DOI 10.1093/infdis/134.6.633
NR 29
TC 6
Z9 6
U1 2
U2 10
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 22
PY 2019
VL 37
IS 13
BP 1876
EP 1884
DI 10.1016/j.vaccine.2018.11.074
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HQ8QZ
UT WOS:000462691700020
PM 30558818
OA Other Gold
DA 2020-05-12
ER

PT J
AU Pepin, S
   Samson, SI
   Alvarez, FP
   Dupuy, M
   Gresset-Bourgeois, V
   De Bruijn, I
AF Pepin, Stephanie
   Samson, Sandrine, I
   Alvarez, Fabian P.
   Dupuy, Martin
   Gresset-Bourgeois, Viviane
   De Bruijn, Iris
TI Impact of a quadrivalent inactivated influenza vaccine on
   influenza-associated complications and health care use in children aged
   6 to 35 months: Analysis of data from a phase III trial in the Northern
   and Southern Hemispheres
SO VACCINE
LA English
DT Article
DE Quadrivalent influenza vaccine; Children; Vaccine efficacy; Health care
   utilisation; Clinical trial
ID SEASONAL INFLUENZA; BURDEN; RATIONALE; LINEAGES; VIRUSES
AB Background: A multi-season phase III trial conducted in the Northern and Southern Hemispheres demonstrated the efficacy of a quadrivalent split-virion inactivated influenza vaccine (IIV4) in children 6-35 months of age.
   Methods: Data collected during the phase III trial were analysed to examine the vaccine efficacy (VE) of IIV4 in preventing laboratory-confirmed influenza in age subgroups and to determine the relative risk for IIV4 vs. placebo for severe outcomes, healthcare use, and parental absenteeism from work associated with laboratory-confirmed influenza.
   Results: VE (95% confidence interval [CI]) to prevent laboratory-confirmed influenza due to any A or B strain was 54.76% (40.24-66.03%) for participants aged 6-23 months and 46.91% (23.57-63.53%) for participants aged 24-35 months. VE (95% CI) to prevent laboratory-confirmed influenza due to vaccine-similar strains was 74.51% (53.55-86.91%) for participants aged 6-23 months and 59.78% (19.11-81.25%) for participants aged 24-35 months. Compared to placebo, IIV4 reduced the risk (95% CI) by 31.28% (8.96-89.34%) for acute otitis media, 21.76% (6.46-58.51%) for acute lower respiratory infection, 40.80% (29.62-55.59%) for healthcare medical visits, 29.71% (11.66-67.23%) for parent absenteeism from work, and 39.20% (26.89-56.24%) for antibiotic use.
   Conclusion: In children aged 6-35 months, vaccination with IIV4 reduces severe outcomes of influenza as well as the associated burden for their parents and the healthcare system. In addition, vaccination with IIV4 is effective at preventing against influenza in children aged 6-23 and 24-35 months. (C) 2019 The Authors. Published by Elsevier Ltd.
C1 [Pepin, Stephanie; Dupuy, Martin; De Bruijn, Iris] Sanofi Pasteur, 1541 Ave Marcel Merieux, F-69820 Marcy Letoile, France.
   [Samson, Sandrine, I] Sanofi Pasteur, 1 Discovery Dr, Swiftwater, PA 18370 USA.
   [Alvarez, Fabian P.; Gresset-Bourgeois, Viviane] Sanofi Pasteur, 14 Espace Henry Vallee, F-69007 Lyon, France.
RP Pepin, S (reprint author), Sanofi Pasteur, Global Clin Sci, Campus Merieux,Batiment 10 Ouest, F-69820 Marcy Letoile, France.
EM stephanie.pepin@sanofi.com; Sandrine.Samson@sanofi.com;
   Fabian.Alvarez@sanofi.com; Martin.Dupuy@sanofi.com;
   Bourgeois@sanofi.com; Iris.DeBruijn@sanofi.com
OI Alvarez, Fabian P./0000-0003-3085-6275
FU Sanofi Pasteur
FX This work was supported by Sanofi Pasteur. The sponsor participated in
   study design, the collection, analysis and interpretation of data; in
   the writing of the report; and in the decision to submit the article for
   publication.
CR Ambrose CS, 2012, HUM VACC IMMUNOTHER, V8, P81, DOI 10.4161/hv.8.1.17623
   Antonova EN, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-968
   Beyer WEP, 2017, VACCINE, V35, P4167, DOI 10.1016/j.vaccine.2017.06.038
   Claeys C, 2017, 35 ANN M EUR SOC PED
   Crepey P, 2015, INFLUENZA OTHER RESP, V9, P39, DOI 10.1111/irv.12318
   DiazGranados CA, 2012, VACCINE, V31, P49, DOI 10.1016/j.vaccine.2012.10.084
   Fraaij PLA, 2011, VACCINE, V29, P7524, DOI 10.1016/j.vaccine.2011.08.010
   Glezen WP, 2013, AM J PUBLIC HEALTH, V103, pE43, DOI 10.2105/AJPH.2012.301137
   Heikkinen T, 2004, J INFECT DIS, V190, P1369, DOI 10.1086/424527
   Heikkinen T, 2006, ACTA PAEDIATR, V95, P778, DOI 10.1080/08035250600612272
   Heikkinen T, 2014, CLIN INFECT DIS, V59, P1519, DOI 10.1093/cid/ciu664
   Lafond KE, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1001977
   LEVANDOWSKI RA, 1991, PEDIATRICS, V88, P1031
   Linder JA, 2009, J GEN INTERN MED, V24, P504, DOI 10.1007/s11606-009-0933-9
   Misurski DA, 2011, AM J MANAG CARE, V17, P601
   Nair H, 2011, LANCET, V378, P1917, DOI 10.1016/S0140-6736(11)61051-9
   Pepin S, 2018, VACCINE
   ROTA PA, 1990, VIROLOGY, V175, P59, DOI 10.1016/0042-6822(90)90186-U
   SAGE Working Group, 2012, BACKGR PAP INFL VACC
   Thompson WW, 2003, JAMA-J AM MED ASSOC, V289, P179, DOI 10.1001/jama.289.2.179
   Tricco AC, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-153
   World Health Organization, 2012, TABL 2A TIV VACC CHI
NR 22
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 22
PY 2019
VL 37
IS 13
BP 1885
EP 1888
DI 10.1016/j.vaccine.2019.01.059
PG 4
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HQ8QZ
UT WOS:000462691700021
PM 30745147
OA Other Gold
DA 2020-05-12
ER

PT J
AU Perdrizet, JA
   Shiau, DS
   Xie, HS
AF Perdrizet, John A.
   Shiau, Deng-Shan
   Xie, Huisheng
TI The serological response in dogs inoculated with canine distemper virus
   vaccine at the acupuncture point governing vessel-14: A randomized
   controlled trial
SO VACCINE
LA English
DT Article
DE Acupuncture; Canine distemper virus vaccine; Randomized controlled
   trial; Serum Neutralization (SN) titers
ID IMMUNE; THROMBOCYTOPENIA; STRATEGIES; PARVOVIRUS
AB The improvement of immunity to vaccination has historically focused on manipulation of antigen presentation rather than the host. Immune modulation by stimulating specific acupuncture points along the Meridian System has been practiced in Traditional Chinese Medicine. The purpose , of this study was to quantitatively determine whether acupoint vaccination, in which vaccine is administered at an acupuncture point in dogs, has the potential to enhance the immune response.
   A randomized controlled trial was conducted to compare the effectiveness of acupoint vaccination versus a conventional method, based on humoral immune response in dogs given Canine Distemper Vaccine (CDV). One hundred client-owned dogs were admitted to the study with following characteristics: (1) passed a routine physical exam, (2) aged between 1 and 10 years old, (3) had no history of chronic disease, and (4) were not on immunomodulating medications. Dogs were randomly assigned to either the Acupuncture group inoculated at the acupoint Governing Vessel (GV)-14, or to the Control group inoculated conventionally at a non-acupuncture site. Mean changes from Day0 to Day14 of the response to CDV vaccination, measured by serum neutralization (SN) titers with log-transformation for reducing outlier effects, were compared between groups. No significant difference was found between groups in age, weight, or sex (all p >0.2). Both groups had significant increases of CDV SN titer post-vaccination (p < 0.001). The mean increase in Acupuncture group (0.72; SD = 0.79) was significantly greater than that of the Control group (0.36; SD = 0.67); p = 0.019. Inference on percentage of change in raw SN titer data further revealed that the effects in the Acupuncture group was significantly greater than the Control group (242% vs. 83%; p = 0.02).
   This study demonstrated that Acupoint vaccination at GV-14 resulted in a significantly elevated humoral immune response to CDV vaccine compared to Controls, which suggests the potential of acupoint vaccination to enhance the immune response. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Perdrizet, John A.] Sanctuary Anim Clin, 210 Linden St, Holyoke, MA 01040 USA.
   [Shiau, Deng-Shan; Xie, Huisheng] Chi Inst Tradit Chinese Vet Med, Reddick, FL 32686 USA.
   [Xie, Huisheng] Univ Florida, Dept Comparat Diagnost & Populat Med, Gainesville, FL 32610 USA.
RP Perdrizet, JA (reprint author), Sanctuary Anim Clin, 210 Linden St, Holyoke, MA 01040 USA.
EM jperd@verizon.net; xieh@ufl.edu
CR Abdelmagid OY, 2004, VET THER, V5, P173
   APPEL M, 1973, AM J VET RES, V34, P1459
   AXTHELM MK, 1987, AM J VET RES, V48, P1269
   Beeler J, 1996, PEDIATR INFECT DIS J, V15, P88, DOI 10.1097/00006454-199601000-00020
   BLIXENKRONEMOLLER M, 1993, VET MICROBIOL, V37, P163, DOI 10.1016/0378-1135(93)90190-I
   Cabioglu MT, 2008, AM J CHINESE MED, V36, P25, DOI 10.1142/S0192415X08005552
   CITRON ML, 1982, JAMA-J AM MED ASSOC, V248, P1178
   Cui M, 1992, J Tradit Chin Med, V12, P211
   Davis-Wurzler GM, 2014, VET CLIN N AM-SMALL, V44, P235, DOI 10.1016/j.cvsm.2013.11.006
   Deem SL, 2000, J ZOO WILDLIFE MED, V31, P441, DOI 10.1638/1042-7260(2000)031[0441:CDITCA]2.0.CO;2
   del Rey A, 2017, FRONT HORM RES, V48, P1, DOI 10.1159/000452902
   Diao X, 2002, CHIN J VET MED, V38, P38
   Ding SS, 2014, QJM-INT J MED, V107, P341, DOI 10.1093/qjmed/hct196
   Duval D, 1996, J VET INTERN MED, V10, P290, DOI 10.1111/j.1939-1676.1996.tb02064.x
   FUJIWARA R, 1991, INT J NEUROSCI, V57, P141, DOI 10.3109/00207459109150354
   Galan A, 2014, CAN VET J, V55, P373
   Gao SD, 1995, CHIN J VET SCI TECH, V1, P7
   GREEN EC, 1990, INFECT DIS DOG CAT, P226
   Guo Yuanyuan, 2011, THESIS
   Habacher G, 2006, J VET INTERN MED, V20, P480, DOI 10.1892/0891-6640(2006)20[480:EOAIVM]2.0.CO;2
   Hu S, P 18 ANN INT TCVM C, P86
   Jiang Wen, 2014, Zhen Ci Yan Jiu, V39, P63
   Joos S, 2007, J ALTERN COMPLEM MED, V6, P519
   Karafillakis E, 2017, VACCINE, V35, P4840, DOI 10.1016/j.vaccine.2017.07.061
   Kim SK, 2010, AUTON NEUROSCI-BASIC, V157, P38, DOI 10.1016/j.autneu.2010.03.010
   Kou W, 2005, BRAIN BEHAV IMMUN, V19, P318, DOI 10.1016/j.bbi.2004.10.001
   Leroux-Roels G, 2010, VACCINE, V28, pC25, DOI 10.1016/j.vaccine.2010.07.021
   Li Hui, 2009, Zhen Ci Yan Jiu, V34, P225
   Ling JY, 2013, J TRADIT CHIN MED, V33, P1061
   Ma S. Q., 1994, CHIN ANIM INFECT DIS, V2, P15
   Martella V, 2008, VET CLIN N AM-SMALL, V38, P787, DOI 10.1016/j.cvsm.2008.02.007
   MCANULTY JF, 1985, J AM VET MED ASSOC, V186, P1217
   Meyer EK, 2001, VET CLIN N AM-SMALL, V31, P493, DOI 10.1016/S0195-5616(01)50604-X
   Moore GE, 2005, JAVMA-J AM VET MED A, V227, P1102, DOI 10.2460/javma.2005.227.1102
   Mouzin DE, 2004, JAVMA-J AM VET MED A, V224, P55, DOI 10.2460/javma.2004.224.55
   NEIDERUD J, 1983, ACTA PAEDIATR SCAND, V72, P613, DOI 10.1111/j.1651-2227.1983.tb09780.x
   Plotkin SA, 2003, J INFECT DIS, V187, P1349, DOI 10.1086/374419
   Pulendran B, 2010, IMMUNITY, V33, P516, DOI 10.1016/j.immuni.2010.10.006
   REED L. J., 1938, AMER JOUR HYG, V27, P493
   Rogers P A, 1992, Probl Vet Med, V4, P162
   Sciesinski K., 1990, Scientifur, V14, P274
   Shams H, 2005, VET J, V170, P289, DOI 10.1016/j.tvjl.2004.07.004
   Singh M, 1999, NAT BIOTECHNOL, V17, P1075, DOI 10.1038/15058
   Souayah Nizar, 2009, J Clin Neuromuscul Dis, V11, P1, DOI 10.1097/CND.0b013e3181aaa968
   STRAW B, 1978, VET MED SM ANIM CLIN, V73, P725
   Sun DB, 2016, J VET MED SCI, V78, P355, DOI 10.1292/jvms.15-0446
   Takahashi T., 2009, J EXPT CLIN MED, V1, P17
   Tan Y, 2007, THESIS
   Tizard I, 1998, J AM VET MED ASSOC, V213, P54
   Tong Y. E., 1998, CHIN ANIM INFECT DIS, V20, P329
   Twark L, 2000, J AM VET MED ASSOC, V217, P1021, DOI 10.2460/javma.2000.217.1021
   Wang M., 1993, CHIN ANIM INFECT DIS, V5, P17
   Wang XM, 1995, CHIN J VET SCI TECH, V2, P21
   Wang Yujie, 2016, Zhongguo Zhen Jiu, V36, P6
   Xiao L, 2012, J TRADIT CHIN MED, V32, P1124
   Xiao Lei, 2007, Zhongguo Zhen Jiu, V27, P169
   Xie H, 2013, TRADITIONAL CHINESE, P157
   Ye Fang, 2007, J Tradit Chin Med, V27, P19
   Zhou Dan, 2009, Zhongguo Zhen Jiu, V29, P32
NR 59
TC 0
Z9 0
U1 1
U2 5
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 22
PY 2019
VL 37
IS 13
BP 1889
EP 1896
DI 10.1016/j.vaccine.2018.10.076
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HQ8QZ
UT WOS:000462691700022
PM 30799157
DA 2020-05-12
ER

PT J
AU Ting-Hui-Lin
   Chia, MY
   Lin, CY
   Yeh, YQ
   Jeng, US
   Wu, WG
   Lee, MS
AF Ting-Hui-Lin
   Chia, Min-Yuan
   Lin, Chun-Yang
   Yeh, Yi-Qi
   Jeng, U-Ser
   Wu, Wen-Guey
   Lee, Min-Shi
TI Improving immunogenicity of influenza virus H7N9 recombinant
   hemagglutinin for vaccine development
SO VACCINE
LA English
DT Article
DE H7N9; Hemagglutinin; Influenza vaccine; Transmembrane domain
ID LIPID RAFT MICRODOMAINS; INSECT CELLS; ORIGIN; EXPRESSION; MICE;
   SPECIFICITY; FLUBLOK(R); PROTECTION; COMPLEXES; INFECTION
AB Human infections of novel avian influenza A virus (H7N9) emerged in early 2013 and caused about 40% case-fatality through 2017. Therefore, development of influenza H7N9 vaccines is critical for pandemic preparedness. Currently, there are three means of production of commercial influenza vaccines: egg-based, mammalian cell-based, and insect cell-based platforms. The insect cell-based platform has the advantage of high speed in producing recombinant protein. In this study, we evaluate the stability and immunogenicity of two different influenza H7 HA expression constructs generated using the baculovirus system, including membrane-based full-length HA (mH7) and secreted ectodomain-based H7 (sH7). The mH7 construct could form an oligomer-rosette structure and had a high hemagglutinin (HA) titer 8192. In contrast to mH7, the sH7 construct could not form an oligomer-rosette structure and did not have HA titer before cross-linking with anti-His antibody. Thermal stability tests showed that the sH7 and mH7 constructs were unstable at 43 degrees C and 52 degrees C, respectively. In a mice immunization study, the mH7 construct but not the sH7 construct could induce robust HI and neutralizing antibody titers. In conclusion, further development of the mH7 vaccine candidate is desirable. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Ting-Hui-Lin; Chia, Min-Yuan; Lin, Chun-Yang; Lee, Min-Shi] Natl Hlth Res Inst, Natl Inst Infect Dis & Vaccinol, Zhunan, Miaoli County, Taiwan.
   [Ting-Hui-Lin; Wu, Wen-Guey] Natl Tsing Hua Univ, Coll Life Sci, Hsinchu, Taiwan.
   [Chia, Min-Yuan] Natl Chung Hsing Univ, Dept Vet Med, Taichung, Taiwan.
   [Yeh, Yi-Qi; Jeng, U-Ser] Natl Synchrotron Radiat Res Ctr, Hsinchu, Taiwan.
   [Jeng, U-Ser] Natl Tsing Hua Univ, Dept Chem Engn, Hsinchu, Taiwan.
RP Lee, MS (reprint author), Natl Hlth Res Inst, R1-7F,35 Keyan Rd, Zhunan 35053, Miaoli County, Taiwan.
EM Minshi@nhri.org.tw
RI Lin, Chun-Yang/AAH-1897-2020
OI Lin, Chun-Yang/0000-0002-3064-0178
FU Ministry of Science and Technology [106-3114-Y404-002]; National Health
   Research InstitutesNational Health Research Institutes, Japan
FX We appreciate funding from the Ministry of Science and Technology
   (106-3114-Y404-002) and the National Health Research Institutes.
CR Blanchfield K, 2014, INFLUENZA OTHER RESP, V8, P628, DOI 10.1111/irv.12285
   Bottcher C, 1999, FEBS LETT, V463, P255, DOI 10.1016/S0014-5793(99)01475-1
   Buckland B, 2014, VACCINE, V32, P5496, DOI 10.1016/j.vaccine.2014.07.074
   Chang SY, 2013, LANCET, V381, P1621, DOI 10.1016/S0140-6736(13)60943-5
   Chen BJ, 2005, J VIROL, V79, P13673, DOI 10.1128/JVI.79.21.13673-13684.2005
   Cox Manon M J, 2015, Ther Adv Vaccines, V3, P97, DOI 10.1177/2051013615595595
   Cox MMJ, 2009, BIOLOGICALS, V37, P182, DOI 10.1016/j.biologicals.2009.02.014
   Crawford J, 1999, VACCINE, V17, P2265, DOI 10.1016/S0264-410X(98)00494-0
   Feshchenko E, 2012, BMC BIOTECHNOL, V12, DOI 10.1186/1472-6750-12-77
   Frank S, 2001, J MOL BIOL, V308, P1081, DOI 10.1006/jmbi.2001.4644
   Gao RB, 2013, NEW ENGL J MED, V368, P1888, DOI 10.1056/NEJMoa1304459
   Groftehauge MK, 2015, ACTA CRYSTALLOGR D, V71, P36, DOI 10.1107/S1399004714016617
   Holtz KM, 2014, BMC BIOTECHNOL, V14, DOI 10.1186/s12896-014-0111-y
   Izikson R, 2015, VACCINE, V33, P6622, DOI 10.1016/j.vaccine.2015.10.097
   Jeng US, 2010, J APPL CRYSTALLOGR, V43, P110, DOI 10.1107/S0021889809043271
   Kamal RP, 2017, J VIROL, V91, DOI 10.1128/JVI.01202-17
   KAWAOKA Y, 1989, VIROLOGY, V169, P283, DOI 10.1016/0042-6822(89)90153-0
   Klausberger M, 2014, VACCINE, V32, P355, DOI 10.1016/j.vaccine.2013.11.036
   Kordyukova L, 2017, VIRUS RES, V227, P183, DOI 10.1016/j.virusres.2016.09.014
   Kreijtz JHCM, 2015, J INFECT DIS, V211, P791, DOI 10.1093/infdis/jiu528
   KURODA K, 1986, EMBO J, V5, P1359, DOI 10.1002/j.1460-2075.1986.tb04367.x
   Leser GP, 2017, J VIROL, V91, DOI 10.1128/JVI.02104-16
   Lin SC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020052
   Liu SH, 2010, J SYNCHROTRON RADIAT, V17, P761, DOI 10.1107/S0909049510034308
   Liu YV, 2015, VACCINE, V33, P2152, DOI 10.1016/j.vaccine.2015.03.009
   Partridge J, 2010, VACCINE, V28, P4709, DOI 10.1016/j.vaccine.2010.04.083
   Petoukhov MV, 2012, J APPL CRYSTALLOGR, V45, P342, DOI 10.1107/S0021889812007662
   Petoukhov MV, 2005, BIOPHYS J, V89, P1237, DOI 10.1529/biophysj.105.064154
   Reid AH, 1999, P NATL ACAD SCI USA, V96, P1651, DOI 10.1073/pnas.96.4.1651
   Rossman JS, 2011, VIROLOGY, V411, P229, DOI 10.1016/j.virol.2010.12.003
   SCHOLTISSEK C, 1978, VIROLOGY, V87, P13, DOI 10.1016/0042-6822(78)90153-8
   Shih O, 2017, PHYS CHEM CHEM PHYS, V19, P7947, DOI 10.1039/c6cp08820a
   Smith GE, 2013, VACCINE, V31, P4305, DOI 10.1016/j.vaccine.2013.07.043
   Smith GJD, 2009, NATURE, V459, P1122, DOI 10.1038/nature08182
   Stevens J, 2006, SCIENCE, V312, P404, DOI 10.1126/science.1124513
   Stevens J, 2004, SCIENCE, V303, P1866, DOI 10.1126/science.1093373
   Takeda M, 2003, P NATL ACAD SCI USA, V100, P14610, DOI 10.1073/pnas.2235620100
   Tall RD, 2003, TRAFFIC, V4, P838, DOI 10.1046/j.1398-9219.2003.0138.x
   Treanor JJ, 1996, J INFECT DIS, V173, P1467, DOI 10.1093/infdis/173.6.1467
   van Oers MM, 2015, J GEN VIROL, V96, P6, DOI 10.1099/vir.0.067108-0
   Wang K, 2006, VACCINE, V24, P2176, DOI 10.1016/j.vaccine.2005.11.005
   Watanabe T, 2014, TRENDS MICROBIOL, V22, P623, DOI 10.1016/j.tim.2014.08.008
   Wei CJ, 2008, J VIROL, V82, P6200, DOI 10.1128/JVI.00187-08
   Wood JM, 2002, VACCINE, V20, pB40, DOI 10.1016/S0264-410X(02)00509-1
   Wood JMaW M.S., 1998, HIST INACTIVATED INF
   World Health Organization, 2002, WHO MAN AN INFL DIAG
   Yang H, 2014, J VIROL, V88, P4828, DOI 10.1128/JVI.02278-13
   Yang H, 2013, J VIROL, V87, P12433, DOI 10.1128/JVI.01854-13
   Yang H, 2012, J VIROL, V86, P8645, DOI 10.1128/JVI.00281-12
   Yang J, 2015, 2015 11TH INTERNATIONAL CONFERENCE ON COMPUTATIONAL INTELLIGENCE AND SECURITY (CIS), P10, DOI 10.1109/CIS.2015.11
   Yeh YQ, 2017, J PHYS CHEM LETT, V8, P470, DOI 10.1021/acs.jpclett.6b02722
   Zhang J, 2000, J VIROL, V74, P4634, DOI 10.1128/JVI.74.10.4634-4644.2000
NR 52
TC 1
Z9 1
U1 0
U2 11
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 22
PY 2019
VL 37
IS 13
BP 1897
EP 1903
DI 10.1016/j.vaccine.2018.09.034
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HQ8QZ
UT WOS:000462691700023
PM 30857635
DA 2020-05-12
ER

PT J
AU Hiller, U
   Mankertz, A
   Koneke, N
   Wicker, S
AF Hiller, Ute
   Mankertz, Annette
   Koeneke, Norbert
   Wicker, Sabine
TI Hospital outbreak of measles - Evaluation and costs of 10 occupational
   cases among healthcare worker in Germany, February to March 2017
SO VACCINE
LA English
DT Article
DE Healthcare personnel; Healthcare worker; Measles; Occupational
   infection; Nosocomial infection; Vaccination
ID TRANSMISSION; EXPOSURE
AB After treatment of an inpatient with measles, an outbreak occurred within the unprotected healthcare workers (HCW) of a regional hospital in Hesse, Germany in February and March 2017. Overall, 10 HCW contracted measles. Remarkably, none of the affected HCW had direct contact to the index patient. One nosocomial transmission to a patient occurred. The economic impact of the outbreak is estimated to approximately 700,000(sic).
   Medical institutions play a major role in the management of measles outbreaks, since the risk of exposure as well as nosocomial transmission to vulnerable patients and HCW is very high. To avoid outbreaks it is essential to have an easily accessible documentation of the immune-status of all HCW. The role of occupational medicine in identifying and closing vaccination gaps is of particular importance. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Hiller, Ute] Lahn Dill Kliniken GmbH, Infect Prevent & Control Team, Forsthausstr 1-3, D-35578 Wetzlar, Germany.
   [Mankertz, Annette] Robert Koch Inst, Natl Reference Ctr Measles Mumps Rubella, Seestr 10, D-13353 Berlin, Germany.
   [Koeneke, Norbert] Lahn Dill Kliniken GmbH, Forsthausstr 1-3, D-35578 Wetzlar, Germany.
   [Wicker, Sabine] Univ Hosp Frankfurt, Occupat Hlth Serv, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.
   [Wicker, Sabine] Natl Verificat Comm Measles & Rubella Eliminat Ge, Berlin, Germany.
   [Wicker, Sabine] Robert Koch Inst, German Standing Comm Vaccinat STIKO, Berlin, Germany.
RP Wicker, S (reprint author), Univ Hosp Frankfurt, Occupat Hlth Serv, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.; Wicker, S (reprint author), Natl Verificat Comm Measles & Rubella Eliminat Ge, Berlin, Germany.; Wicker, S (reprint author), Robert Koch Inst, German Standing Comm Vaccinat STIKO, Berlin, Germany.
EM ute.hiller@lahn-dill-kliniken.de; Sabine.Wicker@kgu.de
OI Wicker, Sabine/0000-0002-6726-1614; Hiller, Ute/0000-0003-2544-8680
CR Amendola A, 2017, EUROSURVEILLANCE, V22, P8, DOI 10.2807/1560-7917.ES.2017.22.33.30596
   Botelho-Nevers E, 2012, VACCINE, V30, P3996, DOI 10.1016/j.vaccine.2012.04.023
   Bundesministerium fur Gesundheit. Federal Ministry of Health, NAT ACT PLAN 2015 20
   Fiebelkorn AP, 2014, VACCINE, V32, P4823, DOI 10.1016/j.vaccine.2013.11.005
   Gerike E, 2000, BUNDESGESUNDHBL, V43, P11, DOI http://dx.doi.org/10.1007/s001030050004
   Gohil SK, 2016, CLIN INFECT DIS, V62, P166, DOI 10.1093/cid/civ802
   Lo NC, 2017, JAMA PEDIATR, V171, P887, DOI 10.1001/jamapediatrics.2017.1695
   Maltezou HC, 2018, HOSP INFECT
   Maltezou HC, 2013, AM J INFECT CONTROL, V41, P661, DOI 10.1016/j.ajic.2012.09.017
   Matysiak-Klose D, 2017, DEUT MED WOCHENSCHR, V142, P1767, DOI 10.1055/s-0043-117973
   Paunio M, 1998, AM J EPIDEMIOL, V148, P1103, DOI 10.1093/oxfordjournals.aje.a009588
   Porretta A, 2017, EUROSURVEILLANCE, V22, P12, DOI 10.2807/1560-7917.ES.2017.22.33.30597
   Public Law: Infection Protection Act, PUBL LAW INF PROT AC
   Robert Koch-Institut (RKI), 2018, SURVSTAT RKI 2 0
   Robert Koch-Institut (RKI), EMPF STAND IMPFK STI
   Robert Koch -Institute (RKI), 2015, CAS DEF MEAS
   Rosen JB, 2014, CLIN INFECT DIS, V58, P1205, DOI 10.1093/cid/ciu105
   Siegel JD, 2017, 2007 GUIDELINE ISOLA
   Steingart KR, 1999, INFECT CONT HOSP EP, V20, P115, DOI 10.1086/501595
   Strebel PM, 2012, VACCINES
   World Health Organization, GLOB MEASL RUB STRAT
NR 21
TC 6
Z9 6
U1 0
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 28
PY 2019
VL 37
IS 14
BP 1905
EP 1909
DI 10.1016/j.vaccine.2019.02.068
PG 5
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HR6VD
UT WOS:000463290400001
PM 30850241
DA 2020-05-12
ER

PT J
AU Giduthuri, JG
   Purohit, V
   Maire, N
   Kudale, A
   Utzinger, J
   Schindler, C
   Weiss, MG
AF Giduthuri, Joseph G.
   Purohit, Vidula
   Maire, Nicolas
   Kudale, Abhay
   Utzinger, Jurg
   Schindler, Christian
   Weiss, Mitchell G.
TI Influenza vaccination of pregnant women: Engaging clinicians to reduce
   missed opportunities for vaccination
SO VACCINE
LA English
DT Article
DE Antenatal care; Antenatal influenza vaccination; Clinician engagement;
   Clinician hesitancy to vaccinate; India; Maternal vaccination; Missed
   opportunities for vaccination
ID PANDEMIC INFLUENZA; SPONTANEOUS-ABORTION; FETAL-DEATH; IMMUNIZATION;
   RATES; COVERAGE; MOTHERS; POLICY
AB Background: Antenatal influenza vaccination (AIV) is an effective intervention for protecting pregnant women and their newborns against influenza. Although the World Health Organization recommends AIV at any stage of pregnancy, in low- and middle-income countries, including India, it is rarely provided. Research suggests that antenatal care (ANC) provider practices explain much of this limited coverage. Our study in urban Pune, India, assessed the feasibility of a two-stage clinician-engagement strategy to reduce missed opportunities for AIV in urban private-practice ANC clinics.
   Methods: Clinicians were randomized to intervention and control groups in slum and middle-class study sites. Intervention-group clinicians (active clinicians) were assessed on vaccination-related views and practices, and were presented with authoritative AIV recommendations from global, academic and professional medical organizations. In a second meeting after a community survey, findings concerning vaccination-related views and experiences were explained to active clinicians. Assessments of community vaccination views were not provided to control-group clinicians. Both groups maintained logs of ANC clinic visit vaccination status throughout the 11-month study period to enable identification of missed and taken opportunities for vaccination. Analyses were restricted to visits of women in their third trimester without previous AIV in the current pregnancy.
   Results: Overall, 30 clinicians participated. After first and second interactions, active clinicians in middleclass communities vaccinated at 12.2% and 37.8%, respectively. Middle-class control clinicians vaccinated at <0.2% throughout the study. This difference in AIV taken opportunities between middle-class active and control clinics was statistically significant (p < 0.05) after first and second interactions. In slum-community sites, active clinicians' AIV activity was minimal throughout.
   Conclusions: Our approach for engaging clinicians effectively reduced missed opportunities for AIV in urban middle-class settings of Pune. It may also improve maternal vaccination for other conditions. The absence of any similar effect in slum-based clinics likely reflects critical limitations of vaccine access. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Giduthuri, Joseph G.; Maire, Nicolas; Utzinger, Jurg; Schindler, Christian; Weiss, Mitchell G.] Swiss Trop & Publ Hlth Inst, CH-4002 Basel, Switzerland.
   [Giduthuri, Joseph G.; Maire, Nicolas; Utzinger, Jurg; Schindler, Christian; Weiss, Mitchell G.] Univ Basel, Basel, Switzerland.
   [Purohit, Vidula; Kudale, Abhay] Maharashtra Assoc Anthropol Sci, Ctr Hlth Res & Dev, Pune, Maharashtra, India.
   [Purohit, Vidula; Kudale, Abhay] Savitribai Phule Pune Univ, Pune, Maharashtra, India.
RP Giduthuri, JG (reprint author), Swiss Trop & Publ Hlth Inst, CH-4002 Basel, Switzerland.
EM joseph.giduthuri@swisstph.ch
RI Kudale, Abhay/A-2822-2013
OI Kudale, Abhay/0000-0003-2887-1636; Giduthuri, Joseph/0000-0003-1654-0389
FU World Health Organization's Initiative for Vaccine Research; Centers for
   Disease Control and Prevention (CDC)United States Department of Health &
   Human ServicesCenters for Disease Control & Prevention - USA [U50
   CK000431]; Swiss Government Excellence Fellowship; State Secretariat for
   Education, Research and Innovation (ESKAS) [2016.0408]
FX This study was funded by a grant from the World Health Organization's
   Initiative for Vaccine Research. The authors would like to acknowledge
   the contributions of the Centers for Disease Control and Prevention
   (CDC), which provides financial support to the World Health Organization
   Initiative for Vaccine Research (U50 CK000431). Joseph G. Giduthuri is
   the recipient of a Swiss Government Excellence Fellowship, granted by
   the State Secretariat for Education, Research and Innovation (ESKAS,
   2016.0408).
CR [Anonymous], 2012, Wkly Epidemiol Rec, V87, P461
   [Anonymous], WHO REC SEAS INFL VA
   Bhalerao-Gandhi Ashwini, 2015, Infect Dis Obstet Gynecol, V2015, P867587, DOI 10.1155/2015/867587
   Bhaskar E, 2012, LUNG INDIA, V29, P232, DOI 10.4103/0970-2113.99105
   Bodeker B, 2015, BMC PUBLIC HEALTH, V15, DOI [10.1186/S12889-015-2621-5, 10.1186/s12889-015-2621-5]
   Bratton KN, 2015, CLIN INFECT DIS, V60, pE11, DOI 10.1093/cid/ciu915
   Creanga AA, 2010, OBSTET GYNECOL, V115, P717, DOI 10.1097/AOG.0b013e3181d57947
   Ding HL, 2015, MMWR-MORBID MORTAL W, V64, P1000, DOI 10.3201/mmwr.mm6436a2
   Fell DB, 2015, BJOG-INT J OBSTET GY, V122, P17, DOI 10.1111/1471-0528.12977
   Fell DB, 2017, VACCINE, V35, P5738, DOI 10.1016/j.vaccine.2017.08.037
   Hirve S, 2016, INFLUENZA OTHER RESP, V10, P254, DOI 10.1111/irv.12374
   Iuliano AD, 2018, LANCET, V391, P1285, DOI 10.1016/S0140-6736(17)33293-2
   Keller-Stanislawski B, 2014, VACCINE, V32, P7057, DOI 10.1016/j.vaccine.2014.09.052
   Klatt TE, 2012, OBSTET GYNECOL, V119, P301, DOI 10.1097/AOG.0b013e318242032a
   Koul PA, 2014, INT J GYNECOL OBSTET, V127, P234, DOI 10.1016/j.ijgo.2014.05.021
   Lotter K, 2018, AUST NZ J OBSTET GYN, V58, P417, DOI 10.1111/ajo.12739
   Madhi SA, 2014, NEW ENGL J MED, V371, P918, DOI 10.1056/NEJMoa1401480
   Mak DB, 2015, AUST NZ J OBSTET GYN, V55, P131, DOI 10.1111/ajo.12292
   Mak TK, 2008, LANCET INFECT DIS, V8, P44, DOI 10.1016/S1473-3099(07)70311-0
   McCarthy EA, 2012, AUST NZ J OBSTET GYN, V52, P334, DOI 10.1111/j.1479-828X.2012.01428.x
   McMillan M, 2015, VACCINE, V33, P2108, DOI 10.1016/j.vaccine.2015.02.068
   Meharry PM, 2014, MATERN CHILD HLTH J, V18, P1205, DOI 10.1007/s10995-013-1352-4
   Moniz MH, 2013, OBSTET GYNECOL, V121, P734, DOI 10.1097/AOG.0b013e31828642b1
   Mosby LG, 2011, AM J OBSTET GYNECOL, V205, P10, DOI 10.1016/j.ajog.2010.12.033
   Mouzoon ME, 2010, AM J MANAG CARE, V16, P209
   Neuzil KM, 1998, AM J EPIDEMIOL, V148, P1094, DOI 10.1093/oxfordjournals.aje.a009587
   Omer SB, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1000441
   Ortiz JR, 2016, VACCINE, V34, P5400, DOI 10.1016/j.vaccine.2016.07.045
   Ortiz JR, 2011, VACCINE, V29, P4439, DOI 10.1016/j.vaccine.2011.04.048
   Praphasiri P, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169221
   Schmid P, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170550
   Sherman MJ, 2012, J REPROD MED, V57, P371
   Stockwell MS, 2014, AM J PUBLIC HEALTH, V104, pE7, DOI 10.2105/AJPH.2013.301620
   Sundaram N, 2015, HUM VACC IMMUNOTHER, V11, P2376, DOI 10.1080/21645515.2015.1062956
   Wallis DH, 2006, J AM BOARD FAM MED, V19, P345, DOI 10.3122/jabfm.19.4.345
   WHO, METH ASS MISS OPP VA
   WHO, MISS OPP VACC MOV ST
   WHO, PLANN GUID RED MISS
   WHO, MAT INFL IMM GUID IN
   Wilson RJ, 2015, VACCINE, V33, P6420, DOI 10.1016/j.vaccine.2015.08.046
   World Health Organization, REP SAGE WORK GROUP
   Yuen CYS, 2014, VACCINE, V32, P4602, DOI 10.1016/j.vaccine.2014.06.067
   Zaman K, 2008, NEW ENGL J MED, V359, P1555, DOI 10.1056/NEJMoa0708630
NR 43
TC 0
Z9 0
U1 2
U2 5
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 28
PY 2019
VL 37
IS 14
BP 1910
EP 1917
DI 10.1016/j.vaccine.2019.02.035
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HR6VD
UT WOS:000463290400002
PM 30827735
DA 2020-05-12
ER

PT J
AU Ndawula, C
   Sabadin, GA
   Parizi, LF
   Vaz, ID
AF Ndawula Jr, Charles
   Sabadin, Gabriela Alves
   Parizi, Luis Fernando
   Vaz Jr, Itabajara da Silva
TI Constituting a glutathione S-transferase-cocktail vaccine against tick
   infestation
SO VACCINE
LA English
DT Article
DE GST; Rhipicephalus appendiculatus; African ticks; Broad-spectrum vaccine
ID RHIPICEPHALUS BOOPHILUS MICROPLUS; HAEMAPHYSALIS-LONGICORNIS; CANDIDATE
   ANTIGENS; ANTIBODY AVIDITY; CATTLE; EXPRESSION; STRATEGIES; PROTEINS;
   DIFFERENTIATION; APPENDICULATUS
AB Cocktail vaccines are proposed as an attractive way to increase protection efficacy against specific tick species. Furthermore, such vaccines made with different tick antigens have the potential of cross-protecting against a broad range of tick species. However, there are still limitations to the selection of immunogen candidates. Acknowledging that glutathione S-transferases (GSTs) have been exploited as vaccines against ticks and other parasites, this study aimed to analyze a GST-cocktail vaccine as a potential broad-spectrum tick vaccine. To constitute the GST-cocktail vaccine, five tick species of economic importance for livestock industry were studied (Rhipicephalus appendiculatus, Rhipicephalus decoloratus, Rhipicephalus microplus, Amblyomma variegatum, and Haemaphysalis longicornis). Tick GST ORF sequences were cloned, and the recombinant GSTs were produced in Escherichia coli. rGSTs were purified and inoculated into rabbits, and the immunological response was characterized. The humoral response against rGST-Rd and rGST-Av showed a stronger cross-reactivity against heterologous rGSTs compared to rGST-HI, rGST-Ra, and rGST-Rm. Therefore, rGST-Rd and rGST-Av were selected for constituting an experimental rGST-cocktail vaccine. Vaccination experiment in rabbits showed that rGST-cocktail caused 35% reduction in female numbers in a Rhipicephalus sanguineus infestation. This study brings forward an approach to selecting immunogens for cocktail vaccines, and the results highlight rGST-Rd and rGST-Av as potentially useful tools for the development of a broad-spectrum tick vaccine. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Ndawula Jr, Charles; Sabadin, Gabriela Alves; Parizi, Luis Fernando; Vaz Jr, Itabajara da Silva] Univ Fed Rio Grande do Sul, Ctr Biotecnol, Ave Bento Goncalves 9500, BR-91501970 Porto Alegre, RS, Brazil.
   [Vaz Jr, Itabajara da Silva] Univ Fed Rio Grande do Sul, Fac Vet, Ave Bento Goncalves 9090, BR-91540000 Porto Alegre, RS, Brazil.
   [Vaz Jr, Itabajara da Silva] Inst Nacl Ciencia & Tecnol Entomol Mol, Ave Bento Goncalves 9090, BR-91501970 Porto Alegre, RS, Brazil.
RP Vaz, ID (reprint author), Univ Fed Rio Grande do Sul, Ctr Biotecnol, Ave Bento Goncalves 9500, BR-91501970 Porto Alegre, RS, Brazil.
EM itabajara.vaz@ufrgs.br
RI Silva Vaz, I/A-5943-2009
OI Silva Vaz, I/0000-0003-0309-9328
FU CNPqNational Council for Scientific and Technological Development
   (CNPq); CAPES from BrazilCAPES
FX This research was supported by CNPq and CAPES from Brazil. Charles
   Ndawula Jr is a TWAS-CNPq PhD Fellow and staff of the National Livestock
   Resources Research Institute, and was granted a full-time study leave by
   the National Agricultural Research Organization, Uganda, to undertake
   the PhD fellowship.
CR Almazan C, 2005, VACCINE, V23, P5294, DOI 10.1016/j.vaccine.2005.08.004
   Artigas-Jeronimo S, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.01612
   Bartley K, 2015, PARASITE VECTOR, V8, DOI 10.1186/s13071-015-0960-9
   BOULANGER D, 1991, PARASITE IMMUNOL, V13, P473, DOI 10.1111/j.1365-3024.1991.tb00545.x
   Bustamante LY, 2017, P NATL ACAD SCI USA, V114, P12045, DOI 10.1073/pnas.1702944114
   Canales M, 2009, BMC BIOTECHNOL, V9, DOI 10.1186/1472-6750-9-29
   Chasseaud L F, 1979, Adv Cancer Res, V29, P175, DOI 10.1016/S0065-230X(08)60848-9
   Cunha NC, 2009, PESQUI VET BRASIL, V29, P105, DOI 10.1590/S0100-736X2009000200003
   De Freitas DRJ, 2008, REV BRAS PARASITOL V, V17, P99, DOI 10.1590/S1984-29612008000200007
   De la Fuente J, 2006, PARASITE IMMUNOL, V28, P275, DOI 10.1111/j.1365-3024.2006.00828.x
   De La Fuente J, 2000, ANN NY ACAD SCI, V916, P617
   de la Fuente J, 2015, EXPERT REV VACCINES, V14, P1367, DOI 10.1586/14760584.2015.1076339
   de Lima MFR, 2002, INSECT BIOCHEM MOLEC, V32, P747, DOI 10.1016/S0965-1748(01)00157-6
   De Vos S, 2001, EXP APPL ACAROL, V25, P245, DOI 10.1023/A:1010609007009
   Doria-Rose NA, 2015, CURR OPIN VIROL, V11, P137, DOI 10.1016/j.coviro.2015.04.002
   DUNN SD, 1986, ANAL BIOCHEM, V157, P144, DOI 10.1016/0003-2697(86)90207-1
   Duscher GG, 2014, TICKS TICK-BORNE DIS, V5, P225, DOI 10.1016/j.ttbdis.2013.11.006
   Duthie MS, 2016, VACCINE, V34, P2779, DOI 10.1016/j.vaccine.2016.04.067
   Edwards K.T., 2009, Midsouth Entomologist, V2, P28
   Enayati AA, 2010, PESTIC BIOCHEM PHYS, V97, P243, DOI 10.1016/j.pestbp.2010.03.003
   FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x
   Fox JL, 2006, CLIN VACCINE IMMUNOL, V13, P33, DOI 10.1128/CVI.13.1.33-36.2006
   Fragoso H, 1998, VACCINE, V16, P1990, DOI 10.1016/S0264-410X(98)00116-9
   Freeman JM, 2010, PARASITE VECTOR, V3, DOI 10.1186/1756-3305-3-101
   Gassmann C, 1997, J MED VIROL, V51, P242, DOI 10.1002/(SICI)1096-9071(199703)51:3&lt;242::AID-JMV17&gt;3.0.CO;2-M
   Ghosh S., 2007, Journal of Vector Borne Diseases, V44, P79
   Guerrero FD, 2012, INT J PARASITOL, V42, P421, DOI 10.1016/j.ijpara.2012.04.003
   Hall AT, 1999, NUCL ACIDS S SER, V41, P95, DOI DOI 10.1021/BK-1999-0734.CH008
   He F, 2011, BIOPROTOCOL BIO, V1, pe80, DOI DOI 10.21769/BIOPROTOC.80
   Hernandez EP, 2018, PARASITE VECTOR, V11, DOI 10.1186/s13071-018-2667-1
   Jongejan F, 2004, PARASITOLOGY, V129, pS3, DOI 10.1017/S0031182004005967
   Kamani J, 2017, EXP APPL ACAROL, V73, P283, DOI 10.1007/s10493-017-0177-z
   Klasse PJ, 2016, EXPERT REV VACCINES, V15, P295, DOI 10.1586/14760584.2016.1128831
   Kumar S, 2016, MOL BIOL EVOL, V33, P1870, DOI [10.1093/molbev/msw054, 10.1093/molbev/msv279]
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   Madder M, 2012, EXP APPL ACAROL, V56, P385, DOI 10.1007/s10493-012-9522-4
   Manjunathachar H V, 2014, ASIAN PACIFIC J TROP, V4, P770
   Mannervik B, 1985, Adv Enzymol Relat Areas Mol Biol, V57, P357
   Merino O, 2013, VACCINE, V31, P5889, DOI 10.1016/j.vaccine.2013.09.037
   Merino O, 2013, FRONT CELL INFECT MI, V3, DOI 10.3389/fcimb.2013.00030
   Mounsey KE, 2010, PARASITE VECTOR, V3, DOI 10.1186/1756-3305-3-43
   Mulcahy G, 1998, VACCINE, V16, P932, DOI 10.1016/S0264-410X(97)00289-2
   Nijhof AM, 2009, BMC MOL BIOL, V10, DOI 10.1186/1471-2199-10-112
   Olds CL, 2016, PARASITE VECTOR, V9, DOI 10.1186/s13071-016-1774-0
   OMEARA TJ, 1993, IMMUNOL CELL BIOL, V71, P473, DOI 10.1038/icb.1993.53
   PABST MJ, 1974, J BIOL CHEM, V249, P7140
   Parizi LF, 2012, VACCINE, V30, P6912, DOI 10.1016/j.vaccine.2012.08.078
   Parizi LF, 2011, EXP PARASITOL, V127, P113, DOI 10.1016/j.exppara.2010.07.001
   Perciani CT, 2007, J CLIN LAB ANAL, V21, P201, DOI 10.1002/jcla.20172
   Perner J, 2018, INSECT BIOCHEM MOLEC, V95, P44, DOI 10.1016/j.ibmb.2018.02.002
   Preyavichyapugdee N, 2008, EXP PARASITOL, V119, P229, DOI 10.1016/j.exppara.2008.01.014
   RAADSMA HW, 1994, VET IMMUNOL IMMUNOP, V40, P253, DOI 10.1016/0165-2427(94)90024-8
   Rasband W. S., 2016, IMAGEJ
   Sabadin GA, 2017, VACCINE, V35, P6649, DOI 10.1016/j.vaccine.2017.10.026
   SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454
   Sambrook J., 1989, MOL CLONING LAB MANU
   SCHWARTZKOFF CL, 1993, AUST VET J, V70, P123, DOI 10.1111/j.1751-0813.1993.tb06101.x
   Shi YP, 1999, P NATL ACAD SCI USA, V96, P1615, DOI 10.1073/pnas.96.4.1615
   Tayebwa DS, 2018, TICKS TICK-BORNE DIS, V9, P1475, DOI 10.1016/j.ttbdis.2018.06.012
   Trager W., 1939, J PARASITOL, V25, P137, DOI DOI 10.2307/3272354
   Trimnell AR, 2005, VACCINE, V23, P4329, DOI 10.1016/j.vaccine.2005.03.041
   Valle Manuel Rodriguez, 2018, Front Biosci (Elite Ed), V10, P122
   van Dalen J, 2006, EDUC HEALTH, V19, P117, DOI 10.1080/13576280500510065
   Vaz ID, 2004, INSECT MOL BIOL, V13, P329
   Vaz ID, 2004, VET PARASITOL, V119, P237, DOI 10.1016/j.vetpar.2003.11.004
   Veerapathran A, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000457
   Ward KN, 2001, J CLIN MICROBIOL, V39, P959, DOI 10.1128/JCM.39.3.959-963.2001
   Willadsen P, 1996, PARASITE IMMUNOL, V18, P241, DOI 10.1046/j.1365-3024.1996.d01-90.x
   Willadsen P, 2008, TRENDS PARASITOL, V24, P164, DOI 10.1016/j.pt.2008.01.005
   Zhan B, 2005, INFECT IMMUN, V73, P6903, DOI 10.1128/IAI.73.10.6903-6911.2005
NR 70
TC 3
Z9 3
U1 1
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 28
PY 2019
VL 37
IS 14
BP 1918
EP 1927
DI 10.1016/j.vaccine.2019.02.039
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HR6VD
UT WOS:000463290400003
PM 30824358
DA 2020-05-12
ER

PT J
AU Zepeda-Cervantes, J
   Cruz-Resendiz, A
   Sampieri, A
   Carreon-Napoles, R
   Sanchez-Betancourt, JI
   Vaca, L
AF Zepeda-Cervantes, Jesus
   Cruz-Resendiz, Adolfo
   Sampieri, Alicia
   Carreon-Napoles, Rosalba
   Ivan Sanchez-Betancourt, Jose
   Vaca, Luis
TI Incorporation of ORF2 from Porcine Circovirus Type 2(PCV2) into
   genetically encoded nanoparticles as a novel vaccine using a
   self-aggregating peptide
SO VACCINE
LA English
DT Article
DE Nanoparticles; Subunit vaccine; Porcine Circovirus Type 2; Polyhedrin;
   Self-aggregating peptide
ID WASTING SYNDROME PMWS; VIRUS-LIKE PARTICLES; PCV2 VACCINES;
   PURIFICATION; EXPRESSION; RESPONSES; ADJUVANT; SWINE; INFECTION; SYSTEM
AB Porcine Circovirus Type 2 (PCV2) is one of the most important pathogens in pigs around the world. PCV2 is a non-enveloped virus and its capsid is formed by a single protein known as open reading frame 2 (ORF2). The aim of this study was to evaluate the antigenicity and immunogenicity of genetically-encoded protein nanoparticles (NPs) containing ORF2 from PCV2 fused to the first 110 amino acids of the N-terminus of polyhedrin from the insect virus Autographa californica nucleopolyhedrovirus (PH (1 -1 1 0)). Our group has previously described that some polyhedrin fragments self-aggregate forming polyhedra-like particles. We identified a self-aggregating signal within the first 110 amino acids from polyhedrin (PH(1 -1 1 0)). Fusing the ORF2 from PCV2 to the carboxyl terminus from PH(1 -1 1 0) results in the formation of NPs which incorporate the antigen of interest. Using this system we synthesized NPs containing PH(1 -1 1 0) fused to ORF2 (PH(1 -1 1 0)PCV2) and purify them to immunize pigs and evaluate the humoral immune response generated by these NPs comparing them to a commercially available vaccine. Pigs immunized with PH(1 -1 1 0)PCV2 NPs produced antibodies against ORF2 from PCV2 as indicated by western blot and ELISA analysis. Antibodies obtained with PH(1 -1 1 0)PCV2 NPs were comparable to those obtained using a commercial PCV2 vaccine. These antibodies neutralized the infection of a recombinant PCV2 expressing the green fluorescent protein (GFP). These results together suggest that the self-aggregating peptide PH(1 -1 1 0) can be used for the synthesis of subunit vaccines against PCV2. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Zepeda-Cervantes, Jesus; Cruz-Resendiz, Adolfo; Sampieri, Alicia; Vaca, Luis] Univ Nacl Autonoma Mexico, Inst Fisiol Celular, Ciudad Univ, Cdmx 04510, Coyoacan, Mexico.
   [Zepeda-Cervantes, Jesus] Univ Nacl Autonoma Mexico, Programa Doctorado Ciencias Biomed, Ciudad Univ, Cdmx 04510, Coyoacan, Mexico.
   [Carreon-Napoles, Rosalba; Ivan Sanchez-Betancourt, Jose] Univ Nacl Autonoma Mexico, Dept Med & Zootecnia Cerdos, Fac Med Vet & Zootecnia, Ciudad Univ, Cdmx 04510, Coyoacan, Mexico.
RP Vaca, L (reprint author), Univ Nacl Autonoma Mexico, Inst Fisiol Celular, Ciudad Univ, Cdmx 04510, Coyoacan, Mexico.
EM asampier@ifc.unam.mx; rcarreonn@prodigy.net.mx; lvaca@ifc.unam.mx
OI Cruz-Resendiz, Adolfo/0000-0002-0275-3204; Vaca,
   Luis/0000-0003-2266-4847; Zepeda-Cervantes, Jesus/0000-0003-2069-2027;
   SANCHEZ BETANCOURT, JOSE IVAN/0000-0001-8201-9669
FU Laboratorios Sanfer (Boulevard Adolfo Lopez Mateos) [314]; grant
   Secretaria de Ciencia y Tecnologia e Innovacion de la Ciudad de Mexico;
   Consejo Nacional de Ciencia y Tecnologia (CONACyT), MexicoConsejo
   Nacional de Ciencia y Tecnologia (CONACyT) [282604]
FX This work was partially supported by Laboratorios Sanfer (Boulevard
   Adolfo Lopez Mateos No 314. 2nd floor, Tlacopac, Alvaro Obregon, 01049,
   Mexico City). Luis Vaca received the grant Secretaria de Ciencia y
   Tecnologia e Innovacion de la Ciudad de Mexico. Jesus Zepeda-Cervantes
   is a doctoral student from Programa de Doctorado en Ciencias Biomedicas,
   Universidad Nacional Autonoma de Mexico (UNAM) and received fellowship
   282604 from Consejo Nacional de Ciencia y Tecnologia (CONACyT), Mexico.
   We would like to thank M.Sc. Liliana Suarez Ramirez from Facultad de
   Medicina Veterinaria y Zootecnia-UNAM and Dr. Josue Orlando Ramirez
   Jarquin from Institute de Fisiologia Celular-UNAM for his critical
   review of this manuscript and valuable comments.
CR Afghah Z, 2017, VET MICROBIOL, V206, P21, DOI 10.1016/j.vetmic.2016.10.002
   An DJ, 2009, VET RES COMMUN, V33, P139, DOI 10.1007/s11259-008-9080-8
   Bachmann MF, 2010, NAT REV IMMUNOL, V10, P787, DOI 10.1038/nri2868
   Blanchard P, 2003, VACCINE, V21, P4565, DOI 10.1016/S0264-410X(03)00503-6
   Bucarey SA, 2009, VACCINE, V27, P5781, DOI 10.1016/j.vaccine.2009.07.061
   Castro-Acosta RM, 2010, ELECTROPHORESIS, V31, P1376, DOI 10.1002/elps.200900558
   Chae C, 2005, VET J, V169, P326, DOI 10.1016/j.tvjl.2004.01.012
   Chae C, 2012, VET J, V194, P151, DOI 10.1016/j.tvjl.2012.06.031
   Chen JJ, 2013, BIOMATERIALS, V34, P8776, DOI 10.1016/j.biomaterials.2013.07.063
   Chesson CB, 2014, VACCINE, V32, P1174, DOI 10.1016/j.vaccine.2013.11.047
   Chung YC, 2006, WORLD J GASTROENTERO, V12, P921, DOI 10.3748/wjg.v12.i6.921
   Cook JC, 1999, PROTEIN EXPRES PURIF, V17, P477, DOI 10.1006/prep.1999.1155
   Faccini S, 2017, TRANSBOUND EMERG DIS, V64, P1661, DOI 10.1111/tbed.12714
   Fort M, 2007, VET MICROBIOL, V125, P244, DOI 10.1016/j.vetmic.2007.06.004
   Franzo G, 2016, SCI REP-UK, V6, DOI 10.1038/srep39458
   Grau-Roma L, 2011, VET J, V187, P23, DOI 10.1016/j.tvjl.2010.01.018
   Hamley IW, 2014, CHEM COMMUN, V50, P15948, DOI 10.1039/c4cc07511k
   Harrison RL, 2006, ADV VIRUS RES, V68, P159, DOI 10.1016/S0065-3527(06)68005-6
   Hegde VL, 2007, IMMUNOBIOLOGY, V212, P119, DOI 10.1016/j.imbio.2006.10.002
   Jeong J, 2015, VET MICROBIOL, V177, P43, DOI 10.1016/j.vetmic.2015.02.027
   Karuppannan A. K, 2017, VIRUS, V9, P1, DOI DOI 10.3390/V9050099
   Krakowka S, 2007, CAN VET J, V48, P716
   Kristensen CS, 2011, PREV VET MED, V98, P250, DOI 10.1016/j.prevetmed.2010.11.015
   Ku X, 2017, TRANSBOUND EMERG DIS, V64, P703, DOI 10.1111/tbed.12638
   Lee KS, 2012, MOL BIOTECHNOL, V50, P211, DOI 10.1007/s12033-011-9431-5
   Li TC, 1997, J VIROL, V71, P7207, DOI 10.1128/JVI.71.10.7207-7213.1997
   Mandal D, 2014, ORG BIOMOL CHEM, V12, P3544, DOI 10.1039/c4ob00447g
   Meng XJ, 2013, ANNU REV ANIM BIOSCI, V1, P43, DOI 10.1146/annurev-animal-031412-103720
   Misinzo G, 2009, VIRUS RES, V139, P1, DOI 10.1016/j.virusres.2008.09.005
   Misinzo G, 2006, J VIROL, V80, P3487, DOI 10.1128/JVI.80.7.3487-3494.2006
   Molina GN, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0168939
   Morenweiser R, 2005, GENE THER, V12, pS103, DOI 10.1038/sj.gt.3302624
   Nauwynck HJ, 2012, VIRUS RES, V164, P43, DOI 10.1016/j.virusres.2011.11.003
   Nawagitgul P, 2000, J GEN VIROL, V81, P2281, DOI 10.1099/0022-1317-81-9-2281
   Nazli-Huda I., 2012, African Journal of Biotechnology, V11, P3877
   Pijlman GP, 2015, BIOTECHNOL J, V10, P659, DOI 10.1002/biot.201400427
   Resendes A, 2004, VET RES, V35, P83, DOI 10.1051/vetres:2003039
   Rudra JS, 2012, BIOMATERIALS, V33, P6476, DOI 10.1016/j.biomaterials.2012.05.041
   Rudra JS, 2010, BIOMATERIALS, V31, P8475, DOI 10.1016/j.biomaterials.2010.07.068
   Rudra JS, 2010, P NATL ACAD SCI USA, V107, P622, DOI 10.1073/pnas.0912124107
   Sampieri A, 2015, BMC BIOCHEM, V16, DOI 10.1186/s12858-015-0034-9
   Segales J, 2004, VET MICROBIOL, V98, P137, DOI 10.1016/j.vetmic.2003.10.006
   Segales Joaquim, 2005, Animal Health Research Reviews, V6, P119, DOI 10.1079/AHR2005106
   Segales J, 2012, VIRUS RES, V164, P10, DOI 10.1016/j.virusres.2011.10.007
   Slack J, 2007, ADV VIRUS RES, V69, P99, DOI 10.1016/S0065-3527(06)69003-9
   Stadejek T, 2017, TRANSBOUND EMERG DIS, V64, P1350, DOI 10.1111/tbed.12672
   Tian XS, 2016, J PHARM SCI-US, V105, P3366, DOI 10.1016/j.xphs.2016.08.009
   TISCHER I, 1982, NATURE, V295, P64, DOI 10.1038/295064a0
   Trent A, 2015, AAPS J, V17, P380, DOI 10.1208/s12248-014-9707-3
   Vicente T, 2011, J INVERTEBR PATHOL, V107, pS42, DOI 10.1016/j.jip.2011.05.004
   Zepeda-Cervantes J, 2018, EXPERT REV VACCINES, V17, P723, DOI 10.1080/14760584.2018.1507742
   Zhao L, 2014, VACCINE, V32, P327, DOI 10.1016/j.vaccine.2013.11.069
NR 52
TC 1
Z9 1
U1 2
U2 11
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 28
PY 2019
VL 37
IS 14
BP 1928
EP 1937
DI 10.1016/j.vaccine.2019.02.044
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HR6VD
UT WOS:000463290400004
PM 30824359
DA 2020-05-12
ER

PT J
AU Klein, NP
   Goddard, K
   Lewis, E
   Ross, P
   Gee, J
   DeStefano, F
   Baxter, R
AF Klein, Nicola P.
   Goddard, Kristin
   Lewis, Edwin
   Ross, Pat
   Gee, Julianne
   DeStefano, Frank
   Baxter, Roger
TI Long term risk of developing type 1 diabetes after HPV vaccination in
   males and females
SO VACCINE
LA English
DT Article
DE HPV vaccine; Diabetes; Vaccine safety; DM1
ID HUMAN-PAPILLOMAVIRUS VACCINATION; AUTOIMMUNE-DISEASES; SAFETY;
   SURVEILLANCE; ADOLESCENTS
AB Introduction: Despite minimal evidence, public concerns that the human papillomavirus (HPV) vaccine can cause autoimmune diseases (AD) persist. We evaluated whether HPV vaccine is associated with a long-term increased risk of diabetes mellitus type 1 (DM1).
   Methods: This was a retrospective cohort study in which we identified all potential DM1 cases from Kaiser Permanente Northern California (KPNC) members who were between 11 and 26 years old any time after June 2006 through December 2015. We chart reviewed a random sample of 100 DM1 cases to confirm diagnosis and to develop a computer algorithm that reliably determined symptom onset date. Our DM1 Analysis Population comprised all individuals who met membership criteria and who were age and sex eligible to have received HPV vaccine. We adjusted for age, sex, race, Medicaid, and years of prior KPNC membership by stratification using a Cox multiplicative hazards model with a calendar timeline.
   Results: Our DM1 analysis included 911,648 individuals. Of 2613 DM1 cases identified, 338 remained in the analysis after applying our algorithm, HPV vaccine eligibility and membership criteria. Over the 10 years of the study period, comparing vaccinated with unvaccinated persons, we did not find an increased risk of DM1 associated with HPV vaccine receipt (hazard ratio 1.21, 95% Confidence Interval 0.94, 1.57).
   Conclusions: We found no increased risk for development of DM1 following HPV vaccination. Our study provides reassurance that during the 10-year time period after HPV vaccine was introduced, there was no substantial increased risk for DM1 following HPV vaccination. (C) 2019 Published by Elsevier Ltd.
C1 [Klein, Nicola P.; Goddard, Kristin; Lewis, Edwin; Ross, Pat; Baxter, Roger] Kaiser Permanente Vaccine Study Ctr, 1 Kaiser Plaza,16th Floor, Oakland, CA 94612 USA.
   [Gee, Julianne; DeStefano, Frank] Immunizat Safety Off, Ctr Dis Control & Prevent, Atlanta, GA USA.
RP Klein, NP (reprint author), Kaiser Permanente Vaccine Study Ctr, 1 Kaiser Plaza,16th Floor, Oakland, CA 94612 USA.
EM nicola.klein@kp.org
FU Centers for Disease Control and Prevention (CDC)United States Department
   of Health & Human ServicesCenters for Disease Control & Prevention - USA
   [200-2012-53581/0008]
FX This work was supported by grant funding from the Centers for Disease
   Control and Prevention (CDC). Contract Number: 200-2012-53581/0008.
CR [Anonymous], 2011, MMWR-MORBID MORTAL W, V60, P1705
   [Anonymous], 2018, PRESCRIBING INFORM G
   [Anonymous], 2015, PRESCRIBING INFORM G
   Arnheim-Dahlstom L, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f5906
   *CDC, 2007, MMWR, V56
   Chao C, 2012, J INTERN MED, V271, P193, DOI 10.1111/j.1365-2796.2011.02467.x
   Frisch M, 2018, INT J EPIDEMIOL, V47, P634, DOI 10.1093/ije/dyx273
   Gee J, 2011, VACCINE, V29, P8279, DOI 10.1016/j.vaccine.2011.08.106
   Grimaldi-Bensouda L, 2014, J INTERN MED, V275, P398, DOI 10.1111/joim.12155
   Holman DM, 2014, JAMA PEDIATR, V168, P76, DOI 10.1001/jamapediatrics.2013.2752
   Jacobson DL, 1997, CLIN IMMUNOL IMMUNOP, V84, P223, DOI 10.1006/clin.1997.4412
   Karussis D, 2014, AUTOIMMUN REV, V13, P215, DOI 10.1016/j.autrev.2013.10.003
   Klein NP, 2012, ARCH PEDIAT ADOL MED, V166, P1140, DOI 10.1001/archpediatrics.2012.1451
   Klein NP, 2010, VACCINE, V28, P1062, DOI 10.1016/j.vaccine.2009.10.115
   Merger SR, 2013, DIABETIC MED, V30, P170, DOI 10.1111/dme.12048
   Miranda S, 2017, VACCINE, V35, P4761, DOI 10.1016/j.vaccine.2017.06.030
   Pellegrino P, 2014, AUTOIMMUN REV, V13, P736, DOI 10.1016/j.autrev.2014.01.054
   Slade BA, 2009, JAMA-J AM MED ASSOC, V302, P750, DOI 10.1001/jama.2009.1201
   Stokley S, 2014, MMWR-MORBID MORTAL W, V63, P620
NR 19
TC 2
Z9 2
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 28
PY 2019
VL 37
IS 14
BP 1938
EP 1944
DI 10.1016/j.vaccine.2019.02.051
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HR6VD
UT WOS:000463290400005
PM 30827738
OA Green Accepted
DA 2020-05-12
ER

PT J
AU Lu, FJ
   Mosley, YYC
   Carmichael, B
   Brown, DD
   HogenEsch, H
AF Lu, Fangjia
   Mosley, Yung-Yi C.
   Carmichael, Brooke
   Brown, Devonte D.
   HogenEsch, Harm
TI Formulation of aluminum hydroxide adjuvant with TLR agonists poly(I:C)
   and CpG enhances the magnitude and avidity of the humoral immune
   response
SO VACCINE
LA English
DT Article
DE Vaccines; Adjuvants; Toll-like receptors; Cytokines; Inflammation
ID DOUBLE-STRANDED-RNA; DENDRITIC CELLS; ANTIGEN PRESENTATION; NLRP3
   INFLAMMASOME; NALP3 INFLAMMASOME; MANNOSE RECEPTOR; NEXT-GENERATION;
   ACTIVATION; MOUSE; IL-1-BETA
AB Subunit vaccines generally require adjuvants to achieve optimal immune responses. Toll-like receptor (TLR) agonists are promising immune potentiators, but rapid diffusion from the injection site reduces their local effective concentration and may cause systemic reactions. In this study, we investigated the potential of aluminum hydroxide adjuvant (AH) to adsorb the TLR3 agonist poly(I:C) and TLR9 agonist CpG and compared the effect of the combination adjuvant on the immune response with either the TLR agonists or AH alone in mice. Poly(I:C) and CpG readily adsorbed onto AH and this combination adjuvant induced a stronger IgG1 and IgG2a immune response with a significant increase of antibody avidity. The combination adjuvant enhanced antigen uptake and activation of dendritic cells in vitro. It induced an inflammatory response at the injection site similar to AH but without eosinophils which are typically observed with AH. A distinctive antigen-containing monocyte/macrophage population with an intermediate level of CD11c expression was identified in the draining lymph nodes after immunization with TLR agonists and the combination adjuvant. Injection of the combination adjuvant did not induce an increase of TNF alpha and CXCL10 in serum in contrast to the injection of soluble TLR agonists. These results indicate that this combination adjuvant is a promising formulation to solve some of the unmet needs of current vaccines. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Lu, Fangjia; Mosley, Yung-Yi C.; Carmichael, Brooke; Brown, Devonte D.; HogenEsch, Harm] Purdue Univ, Coll Vet Med, Dept Comparat Pathobiol, 725 Harrison St, W Lafayette, IN 47907 USA.
   [HogenEsch, Harm] Purdue Univ, Purdue Inst Inflammat Immunol & Infect Dis, W Lafayette, IN 47907 USA.
RP HogenEsch, H (reprint author), Purdue Univ, Coll Vet Med, Dept Comparat Pathobiol, 725 Harrison St, W Lafayette, IN 47907 USA.
EM hogenesch@purdue.edu
OI HogenEsch, Harm/0000-0002-2738-9189
FU USDA-NIFAUnited States Department of Agriculture (USDA) [IND020164H]
FX This research was supported in part by Hatch formula funds from
   USDA-NIFA (Project No. IND020164H).
CR Aebig JA, 2007, J IMMUNOL METHODS, V323, P139, DOI 10.1016/j.jim.2007.04.003
   Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391
   Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560
   Allen JD, 2017, VACCINE, V35, P5209, DOI 10.1016/j.vaccine.2017.07.107
   Bagchi A, 2007, J IMMUNOL, V178, P1164, DOI 10.4049/jimmunol.178.2.1164
   Bannard O, 2017, CURR OPIN IMMUNOL, V45, P21, DOI 10.1016/j.coi.2016.12.004
   Blander JM, 2006, NATURE, V440, P808, DOI 10.1038/nature04596
   Brito LA, 2014, J CONTROL RELEASE, V190, P563, DOI 10.1016/j.jconrel.2014.06.027
   Bruhns P, 2015, IMMUNOL REV, V268, P25, DOI 10.1111/imr.12350
   Burgdorf S, 2007, SCIENCE, V316, P612, DOI 10.1126/science.1137971
   Burgdorf S, 2006, J IMMUNOL, V176, P6770, DOI 10.4049/jimmunol.176.11.6770
   Calabro S, 2011, VACCINE, V29, P1812, DOI 10.1016/j.vaccine.2010.12.090
   Chakarov S, 2014, EMBO MOL MED, V6, P590, DOI 10.1002/emmm.201403841
   Comoy EE, 1997, INT IMMUNOL, V9, P523, DOI 10.1093/intimm/9.4.523
   Didierlaurent AM, 2009, J IMMUNOL, V183, P6186, DOI 10.4049/jimmunol.0901474
   Eisenbarth SC, 2008, NATURE, V453, P1122, DOI 10.1038/nature06939
   EZEKOWITZ RAB, 1981, J EXP MED, V154, P60, DOI 10.1084/jem.154.1.60
   FINKELMAN FD, 1990, ANNU REV IMMUNOL, V8, P303, DOI 10.1146/annurev.immunol.8.1.303
   Flach TL, 2011, NAT MED, V17, P479, DOI 10.1038/nm.2306
   Franchi L, 2008, EUR J IMMUNOL, V38, P2085, DOI 10.1002/eji.200838549
   GERMANN T, 1995, EUR J IMMUNOL, V25, P823, DOI 10.1002/eji.1830250329
   Ghimire TR, 2012, IMMUNOL LETT, V147, P55, DOI 10.1016/j.imlet.2012.06.002
   Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123
   HO MK, 1982, J IMMUNOL, V128, P1221
   HogenEsch H, 2018, NPJ VACCINES, V3, DOI 10.1038/s41541-018-0089-x
   HogenEsch H, 2013, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00406
   Hornung V, 2008, NAT IMMUNOL, V9, P847, DOI 10.1038/ni.1631
   Ilyinskii PO, 2014, VACCINE, V32, P2882, DOI 10.1016/j.vaccine.2014.02.027
   Kasturi SP, 2011, NATURE, V470, P543, DOI 10.1038/nature09737
   Kool M, 2008, J IMMUNOL, V181, P3755, DOI 10.4049/jimmunol.181.6.3755
   Langlet C, 2012, J IMMUNOL, V188, P1751, DOI 10.4049/jimmunol.1102744
   Leleux JA, 2017, CELL REP, V18, P700, DOI 10.1016/j.celrep.2016.12.073
   Li HF, 2008, J IMMUNOL, V181, P17, DOI 10.4049/jimmunol.181.1.17
   Li HF, 2007, J IMMUNOL, V178, P5271, DOI 10.4049/jimmunol.178.8.5271
   Lindblad EB, 2004, IMMUNOL CELL BIOL, V82, P497, DOI 10.1111/j.0818-9641.2004.01286.x
   Lopez-Castejon G, 2011, CYTOKINE GROWTH F R, V22, P189, DOI 10.1016/j.cytogfr.2011.10.001
   Lu FJ, 2017, NPJ VACCINES, V2, DOI 10.1038/s41541-017-0007-7
   Lu FJ, 2015, J CONTROL RELEASE, V204, P51, DOI 10.1016/j.jconrel.2015.03.002
   Lu FJ, 2013, VACCINE, V31, P3979, DOI 10.1016/j.vaccine.2013.05.107
   Ma YF, 2009, CLIN VACCINE IMMUNOL, V16, P1476, DOI 10.1128/CVI.00282-09
   Maisonneuve C, 2014, P NATL ACAD SCI USA, V111, P12294, DOI 10.1073/pnas.1400478111
   Marrack P, 2009, NAT REV IMMUNOL, V9, P287, DOI 10.1038/nri2510
   Michaelsen TE, 2004, SCAND J IMMUNOL, V59, P34, DOI 10.1111/j.0300-9475.2004.01362.x
   Morefield GL, 2005, VACCINE, V23, P1588, DOI 10.1016/j.vaccine.2004.07.050
   Mori A, 2012, EUR J IMMUNOL, V42, P2709, DOI 10.1002/eji.201242372
   Mosca F, 2008, P NATL ACAD SCI USA, V105, P10501, DOI 10.1073/pnas.0804699105
   Mutwiri G, 2011, EXPERT REV VACCINES, V10, P95, DOI 10.1586/ERV.10.154
   Napolitani G, 2005, NAT IMMUNOL, V6, P769, DOI 10.1038/ni1223
   OI VT, 1984, NATURE, V307, P136, DOI 10.1038/307136a0
   Orr MT, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0083884
   Reed SG, 2013, NAT MED, V19, P1597, DOI 10.1038/nm.3409
   SALLUSTO F, 1995, J EXP MED, V182, P389, DOI 10.1084/jem.182.2.389
   Sokolovska A, 2007, VACCINE, V25, P4575, DOI 10.1016/j.vaccine.2007.03.045
   Sun HF, 2003, VACCINE, V21, P849, DOI 10.1016/S0264-410X(02)00531-5
   Tirapu I, 2009, INT IMMUNOL, V21, P871, DOI 10.1093/intimm/dxp053
   Watts C, 2010, CURR OPIN IMMUNOL, V22, P124, DOI 10.1016/j.coi.2009.12.005
   Wu TYH, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3009980
   Yu M, 2011, CYTOKINE GROWTH F R, V22, P63, DOI 10.1016/j.cytogfr.2011.02.001
   Zhu Q, 2008, P NATL ACAD SCI USA, V105, P16260, DOI 10.1073/pnas.0805325105
NR 59
TC 3
Z9 3
U1 2
U2 11
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 28
PY 2019
VL 37
IS 14
BP 1945
EP 1953
DI 10.1016/j.vaccine.2019.02.033
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HR6VD
UT WOS:000463290400006
PM 30803844
DA 2020-05-12
ER

PT J
AU Rosso, A
   Massimi, A
   De Vito, C
   Adamo, G
   Baccolini, V
   Marzuillo, C
   Vacchio, MR
   Villari, P
AF Rosso, Annalisa
   Massimi, Azzurra
   De Vito, Corrado
   Adamo, Giovanna
   Baccolini, Valentina
   Marzuillo, Carolina
   Vacchio, Maria Rosaria
   Villari, Paolo
TI Knowledge and attitudes on pediatric vaccinations and intention to
   vaccinate in a sample of pregnant women from the City of Rome
SO VACCINE
LA English
DT Article
DE Vaccine hesitancy; Vaccination; Attitudes; Knowledge; Pregnancy;
   Pregnant women
ID TEACHABLE MOMENT; HESITANCY; PARENTS; CONFIDENCE; STRATEGIES; REFUSAL;
   MEASLES; MMR
AB Background: In recent years, pediatric immunization rates in Italy have decreased well below the recommended thresholds, largely due to an increase in scepticism about the efficacy and safety of vaccines. We aimed to identify the degree of such scepticism, and the factors driving it, among a sample of pregnant women in the City of Rome.
   Methods: We conducted a cross-sectional survey on a sample of pregnant women attending antenatal classes (CANs) in Rome through distribution of a self-administered questionnaire. Multiple logistic regression models were built to analyze the determinants of knowledge, attitudes and intention to vaccinate in this population.
   Results: A total of 458 pregnant women attending CANs in 36 family health centers and two hospitals in Rome answered the survey. Mean age was 32.9 (+/- 5.0) years, and over 90% of women were in their first pregnancy. More than 26% of respondents showed a good level of knowledge of the safety and efficacy of vaccines, but there were high rates of uncertainty or agreement with some of the most common antivaccination sentiments. Only 75% of women were sure about vaccinating their children with the hexavalent vaccine, and 64.3% with MMR. A good level of knowledge was the strongest predictor of positive attitudes towards vaccination (OR 11.61, 95% CI 6.43-20.96), which, in turn, influenced the intention to vaccinate for most vaccines with the perception of the benefit of immunization for protection against disease.
   Conclusions: Scepticism about the safety, efficacy and importance of vaccines is associated to pregnant women's hesitancy to vaccinate their children, suggesting the need to develop strategies to increase vaccine acceptance in the antenatal period. The capacity of health care professionals, particularly midwives, to correctly deliver information to future parents should be strengthened in order to reduce the spread of misinformation and fear of vaccine safety. (C) 2019 The Authors. Published by Elsevier Ltd.
C1 [Rosso, Annalisa; Massimi, Azzurra; De Vito, Corrado; Adamo, Giovanna; Baccolini, Valentina; Marzuillo, Carolina; Vacchio, Maria Rosaria; Villari, Paolo] Sapienza Univ Rome, Dept Publ Hlth & Infect Dis, Ple Aldo Moro 5, I-00185 Rome, Italy.
RP Rosso, A (reprint author), Sapienza Univ Rome, Dept Publ Hlth & Infect Dis, Ple Aldo Moro 5, I-00185 Rome, Italy.
EM annalisa.rosso@uniroma1.it; azzurra.massimi@uniroma1.it;
   corrado.devito@uniroma1.it; giovanna.adamo@uniroma1.it;
   valentina.baccolini@uniroma1.it; carolina.marzuillo@uniroma1.it;
   rosaria.vacchio@uniroma1.it; paolo.villari@uniroma1.it
RI Adamo, Giovanna/AAB-6922-2019
OI Adamo, Giovanna/0000-0001-8983-1924; Massimi,
   Azzurra/0000-0001-6612-2949; Rosso, Annalisa/0000-0002-0537-5130; DE
   VITO, CORRADO/0000-0002-7846-672X
FU Sapienza University of Rome [RM116154F1C1C6AF]
FX This work was supported by Sapienza University of Rome [University
   Research Projects 2016 (Progetti di Ricerca di Ateneo 2016), protocol n.
   RM116154F1C1C6AF]
CR Adamo G, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0205147
   Adamo Giovanna, 2017, Ig Sanita Pubbl, V73, P429
   Adamo G, 2016, EPIDEMIOL BIOSTAT PU, V13, DOI 10.2427/12075
   Aquino F, 2017, VACCINE, V35, P4494, DOI 10.1016/j.vaccine.2017.07.029
   Atkinson L, 2016, BRIT J HEALTH PSYCH, V21, P842, DOI 10.1111/bjhp.12200
   Attwell K, 2018, VACCINE, V36, P6531, DOI 10.1016/j.vaccine.2018.02.028
   Brown KF, 2010, VACCINE, V28, P4235, DOI 10.1016/j.vaccine.2010.04.052
   Corben P, 2018, BMC PUBLIC HEALTH, V18, DOI 10.1186/s12889-018-5389-6
   Cunningham RM, 2018, ACAD PEDIATR, V18, P154, DOI 10.1016/j.acap.2017.08.003
   D'Alessandro A, 2018, HUM VACC IMMUNOTHER, V14, P1573, DOI 10.1080/21645515.2018.1483809
   D'Ancona F, 2018, EUROSURVEILLANCE, V23, P2, DOI 10.2807/1560-7917.ES.2018.23.22.1800238
   Danchin MH, 2018, VACCINE, V36, P6473, DOI 10.1016/j.vaccine.2017.08.003
   De Vito C, 2007, VACCINE, V25, P8794, DOI 10.1016/j.vaccine.2007.10.034
   Dempsey AF, 2011, PEDIATRICS, V128, P848, DOI 10.1542/peds.2011-0400
   Dube E, 2018, VACCINE, V36, P545, DOI 10.1016/j.vaccine.2017.12.005
   Dube E, 2015, VACCINE, V33, P4191, DOI 10.1016/j.vaccine.2015.04.041
   European Centre for Disease Prevention and Control, 2018, MEASL RUB SURV 2017
   European Centre for Disease Prevention and Control, 2015, VACC HES HEALTHC THE
   Giambi C, 2018, VACCINE, V36, P779, DOI 10.1016/j.vaccine.2017.12.074
   Gualano MR, 2018, VACCINE, V36, P3368, DOI 10.1016/j.vaccine.2018.04.029
   Heininger U, 2006, VACCINE, V24, P6351, DOI 10.1016/j.vaccine.2006.05.029
   Hosmer DW, 2000, APPL LOGISTIC REGRES
   Istituto Superiore di Sanita (National Health Institute), COP VACC IT
   Jarrett C, 2015, VACCINE, V33, P4180, DOI 10.1016/j.vaccine.2015.04.040
   Larson HJ, 2016, EBIOMEDICINE, V12, P295, DOI 10.1016/j.ebiom.2016.08.042
   Larson HJ, 2014, VACCINE, V32, P2150, DOI 10.1016/j.vaccine.2014.01.081
   Larson HJ, 2011, LANCET, V378, P526, DOI 10.1016/S0140-6736(11)60678-8
   Liu FC, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-1766-6
   MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036
   Manzoli L, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.g3058
   Marti M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0172310
   Massimi A, 2017, EPIDEMIOL BIOSTAT PU, V14, P1, DOI [10.2427/12625, DOI 10.2427/12625]
   Morrone T, 2017, HUM VACC IMMUNOTHER, V13, P1921, DOI 10.1080/21645515.2017.1313940
   Napolitano F, 2018, HUM VACC IMMUNOTHER, V14, P1558, DOI 10.1080/21645515.2018.1463943
   Napolitano F, 2016, HUM VACC IMMUNOTHER, V12, P1504, DOI 10.1080/21645515.2016.1156271
   Olander EK, 2016, WOMEN BIRTH, V29, pE67, DOI 10.1016/j.wombi.2015.11.005
   Opel DJ, 2011, VACCINE, V29, P6598, DOI 10.1016/j.vaccine.2011.06.115
   Opel DJ, 2011, HUM VACCINES, V7, P419, DOI 10.4161/hv.7.4.14120
   Pelullo CP, 2018, HUM VACC IMMUNOTHER, V14, P1566, DOI 10.1080/21645515.2017.1421877
   Phadke VK, 2016, JAMA-J AM MED ASSOC, V315, P1149, DOI 10.1001/jama.2016.1353
   Phelan S, 2010, AM J OBSTET GYNECOL, V203, pE13, DOI [10.1016/j.ajog.2010.06.051, 10.1016/j.ajog.2009.06.008]
   Raude J, 2016, EXPERT REV VACCINES, V15, P937, DOI 10.1080/14760584.2016.1184092
   Regione Veneto ASL Verona., 2011, IND DET RIF OFF VACC
   Sadaf A, 2013, VACCINE, V31, P4293, DOI 10.1016/j.vaccine.2013.07.013
   Salmon DA, 2015, AM J PREV MED, V49, pS391, DOI 10.1016/j.amepre.2015.06.009
   Spinelli A, 2003, J Matern Fetal Neonatal Med, V13, P94, DOI 10.1080/713605803
   Ward JK, 2018, VACCINE, V36, P1801, DOI 10.1016/j.vaccine.2018.02.095
   Williams SE, 2014, HUM VACC IMMUNOTHER, V10, P2584, DOI 10.4161/hv.28596
   Yaqub O, 2014, SOC SCI MED, V112, P1, DOI 10.1016/j.socscimed.2014.04.018
NR 49
TC 4
Z9 4
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 28
PY 2019
VL 37
IS 14
BP 1954
EP 1963
DI 10.1016/j.vaccine.2019.02.049
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HR6VD
UT WOS:000463290400007
PM 30827733
OA Other Gold, Green Published
DA 2020-05-12
ER

PT J
AU Satoh, H
   Tanaka-Taya, K
   Shimizu, H
   Goto, A
   Tanaka, S
   Nakano, T
   Hotta, C
   Okazaki, T
   Itamochi, M
   Ito, M
   Okamoto-Nakagaw, R
   Yamashita, Y
   Arai, S
   Okuno, H
   Morino, S
   Oishi, K
AF Satoh, Hiroshi
   Tanaka-Taya, Keiko
   Shimizu, Hiroyuki
   Goto, Akiko
   Tanaka, Shizuka
   Nakano, Tsuyoshi
   Hotta, Chiemi
   Okazaki, Terue
   Itamochi, Masae
   Ito, Miyabi
   Okamoto-Nakagaw, Reiko
   Yamashita, Yasutaka
   Arai, Satoru
   Okuno, Hideo
   Morino, Saeko
   Oishi, Kazunori
TI Polio vaccination coverage and seroprevalence of poliovirus antibodies
   after the introduction of inactivated poliovirus vaccines for routine
   immunization in Japan
SO VACCINE
LA English
DT Article
DE Polio; Sabin-derived inactivated poliovirus vaccine; Routine
   immunization; Vaccination coverage; Seroprevalence
ID PARALYTIC POLIOMYELITIS; SABIN STRAINS
AB In Japan, the oral poliovirus vaccine (OPV) was changed to 2 types of inactivated poliovirus vaccine (IPV), the standalone conventional IPV (cIPV) and the Sabin-derived IPV combined with diphtheria-tetanus-acellular pertussis vaccine (DTaP-sIPV), for routine immunization in 2012. We evaluated polio vaccination coverage and the seroprevalence of poliovirus antibodies using data from the National Epidemiological Surveillance of Vaccine-Preventable Diseases (NESVPD) from 2011 to 2015. Several years before the introduction of IPV in 2012, OPV administration for children was refused by some parents because of concerns about the risk of vaccine-associated paralytic poliomyelitis. Consequently, in children aged <1 years who were surveyed in 2011-2012, polio vaccination coverage (45.0-48.8%) and seropositivity rates for poliovirus (type 1: 51.7-65.9%, type 2: 48.3-53.7%, and type 3: 15.0-29.3%) were decreased compared to those surveyed in 2009. However, after IPV introduction, the vaccination coverage (95.5-100%) and seropositivity rates (type 1: 93.2-96.6%, type 2: 93.1-100%, and type 3: 88.6-93.9%) increased among children aged <1 years in 2013-2015. In particular, seropositivity rates and geometric mean titers (GMTs) for poliovirus type 3 in <5-year-old children who received 4 doses of IPV (98.5% and 247.4, respectively) were significantly higher than in those who received 2 doses of OPV (72.5% and 22.9, respectively). Furthermore, in <5-year-old children who received 4 doses of either DTaP-sIPV or cIPV, the seropositivity rates and the GMTs for all 3 types of poliovirus were similarly high (96.5-100% and 170.3-368.8, respectively). Our findings from the NESVPD demonstrate that both the vaccination coverage and seropositivity rates for polio remained high in children after IPV introduction. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Satoh, Hiroshi; Tanaka-Taya, Keiko; Arai, Satoru; Okuno, Hideo; Morino, Saeko; Oishi, Kazunori] Natl Inst Infect Dis, Surveillance Ctr, Dept Infect Dis, Shinjuku Ku, 1-23-1 Toyama, Tokyo 1628640, Japan.
   [Shimizu, Hiroyuki] Natl Inst Infect Dis, Dept Virol 2, 4-7-1 Gakuen, Tokyo 2080011, Japan.
   [Goto, Akiko] Hokkaido Inst Publ Hlth, Kita Ku, North 19,West 12, Sapporo, Hokkaido 0600819, Japan.
   [Tanaka, Shizuka] Yamagata Prefectural Inst Publ Hlth, 1-6-6 Tokamachi, Yamagata 9900031, Japan.
   [Nakano, Tsuyoshi] Gunma Prefectural Inst Publ Hlth & Environm Sci, 378 Kamiokimachi, Maebashi, Gunma 3710052, Japan.
   [Hotta, Chiemi] Chiba Prefectural Inst Publ Hlth, Chuo Ku, 666-2 Nitonacho, Chiba 2608715, Japan.
   [Okazaki, Terue] Tokyo Metropolitan Inst Publ Hlth, Shinjuku Ku, 3-24-1 Hyakunincho, Tokyo 1690073, Japan.
   [Itamochi, Masae] Toyama Inst Hlth, 17-1 Nakataikoyama, Imizu, Toyama 9390363, Japan.
   [Ito, Miyabi] Aichi Prefectural Inst Publ Hlth, Kita Ku, 7-6 Nagare,Tsujicho, Nagoya, Aichi 4628576, Japan.
   [Okamoto-Nakagaw, Reiko] Yamaguchi Prefectural Inst Publ Hlth & Environm, 2-5-67 Aoi, Yamaguchi 7530821, Japan.
   [Yamashita, Yasutaka] Ehime Prefectural Inst Publ Hlth & Environm Sci, 8-234 Sanbancho, Matsuyama, Ehime 7900003, Japan.
RP Tanaka-Taya, K (reprint author), Natl Inst Infect Dis, Infect Dis Surveillance Ctr, Shinjuku Ku, 1-23-1 Toyama, Tokyo 1628640, Japan.
EM ktaya@niid.go.jp
FU Japan Agency for Medical Research and Development (AMED), JapanJapan
   Agency for Medical Research and Development (AMED) [JP18fk0108004,
   JP18fk0108066]
FX This study was supported by the Japan Agency for Medical Research and
   Development (AMED), Japan under Grant Number JP18fk0108004 and
   JP18fk0108066.
CR Asahina N, 2010, PEDIATR INT, V52, P838, DOI 10.1111/j.1442-200X.2010.03132.x
   HARA M, 1983, MICROBIOL IMMUNOL, V27, P1057, DOI 10.1111/j.1348-0421.1983.tb02939.x
   Higashigawa M, 2010, J INFECT CHEMOTHER, V16, P356, DOI 10.1007/s10156-010-0065-5
   Jee YM, 2004, EPIDEMIOL INFECT, V132, P351, DOI 10.1017/S0950268803001663
   Kaliappan SP, 2016, VACCINE, V34, P4979, DOI 10.1016/j.vaccine.2016.08.032
   Kim HJ, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-0894-z
   Ministry of Health Labour and Welfare, 2012, POL VACC COV ROUT IM
   Ministry of Health Labour and Welfare, 2016, POL POL VACC Q A
   Ministry of Health Labour and Welfare, 2011, 1 C SMOOTH PROM IPV
   Ministry of Health Labour and Welfare, 2014, SURV VACC STAT ROUT
   Miyoshi M, 2010, JPN J INFECT DIS, V63, P216
   National Institute of Infectious Diseases, 1980, ANN REP NESVPD POL
   National Institute of Infectious Diseases, 2011, PROT NESVPD
   National Institute of Infectious Diseases, 2002, PROC NESVPD POL
   Okada K, 2013, J INFECT DIS, V208, P275, DOI 10.1093/infdis/jit155
   Okayasu H, 2016, BIOLOGICALS, V44, P581, DOI 10.1016/j.biologicals.2016.08.005
   PATRIARCA PA, 1991, REV INFECT DIS, V13, P926
   Shimizu H, 2016, VACCINE, V34, P1975, DOI 10.1016/j.vaccine.2014.11.015
   Sun MB, 2017, CLIN INFECT DIS, V64, P1317, DOI 10.1093/cid/cix110
   Wallace GS, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889-016-3386-1
   WHO, 2014, VACCINE, V32, P4117, DOI 10.1016/j.vaccine.2014.04.023
   World Health Organization (WHO), 2013, POL ER ENDG STRAT PL
NR 22
TC 2
Z9 2
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 28
PY 2019
VL 37
IS 14
BP 1964
EP 1971
DI 10.1016/j.vaccine.2019.02.034
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HR6VD
UT WOS:000463290400008
PM 30827736
DA 2020-05-12
ER

PT J
AU Zhou, FJ
   Xu, J
   Black, CL
   Ding, H
   Cho, BH
   Lu, PJ
   Lindley, MC
AF Zhou, Fangjun
   Xu, Jing
   Black, Carla L.
   Ding, Helen
   Cho, Bo-Hyun
   Lu, Peng-Jun
   Lindley, Megan C.
TI Trends in Tdap vaccination among privately insured pregnant women in the
   United States, 2009-2016
SO VACCINE
LA English
DT Article
DE MarketScan data; Pregnant women; Tetanus; Diphtheria and acellular
   pertussis vaccine (Tdap); Vaccination coverage
ID ACELLULAR PERTUSSIS VACCINATION; IMMUNIZATION PRACTICES; INFLUENZA
   VACCINATION; CHILDHOOD INFECTIONS; HEALTH-INSURANCE; SAFETY DATALINK;
   DIPHTHERIA; TETANUS; COVERAGE; INFANTS
AB Background: Infants younger than 6 months are at increased risk of complications and mortality from pertussis infection. In October 2012, the Advisory Committee on Immunization Practices revised its recommendation to include a Tdap dose during each pregnancy, ideally between 27 and 36 weeks gestation.
   Objective: Assess trends in Tdap vaccination coverage among privately insured pregnant women from 2009 to 2016 including timing of Tdap vaccination (before, during, or after pregnancy), trimester of vaccination for women vaccinated during pregnancy, and missed vaccination opportunities for unvaccinated women. Identify factors associated with vaccination during the optimal period of 27-36 weeks gestation.
   Study design: Retrospective analysis of privately insured women 15-49 years who delivered live births during 2009-2016 conducted using 2009-2016 MarketScan data. Tdap vaccination coverage and the timing of Tdap vaccine administration were assessed for women continuously enrolled from 6 months before pregnancy to 1 month after delivery. Multivariable logistic regression was performed to identify factors independently associated with receipt of Tdap vaccine at 27-36 weeks gestation.
   Results: Tdap vaccination coverage during pregnancy increased from 0.4% in 2009 to 6.2% in 2012 and to 53.2% in 2016. The proportion of vaccinated women receiving Tdap at 27-36 weeks gestation increased from <10% in 2009 to nearly 90% in 2016, with most vaccination occurring at 27-32 weeks gestation. Women of older age, residing in a metropolitan statistical area, residing outside the South, and having a capitated health insurance plan were more likely to receive Tdap at 27-36 weeks gestation than their counterparts. Among women not vaccinated during pregnancy, 77.7% had a pregnancy-related medical claim between 27 and 36 weeks gestation.
   Conclusion: Tdap vaccination coverage during pregnancy increased significantly from 2009 to 2016, with the greatest increase occurring after the revised Advisory Committee on Immunization Practices recommendation. Most women who did not receive Tdap vaccine had a missed vaccination opportunity during pregnancy, indicating potential for much higher vaccination coverage and consequent infant protection against pertussis. Published by Elsevier Ltd.
C1 [Zhou, Fangjun; Xu, Jing; Black, Carla L.; Ding, Helen; Cho, Bo-Hyun; Lu, Peng-Jun; Lindley, Megan C.] Ctr Dis Control & Prevent CDC, Immunizat Serv Div, NCIRD, Atlanta, GA 30329 USA.
   [Ding, Helen] CFD Res Corp, Huntsville, AL 35806 USA.
   [Xu, Jing] US FDA, Off Publ Hlth Strategy & Anal, Silver Spring, MD 20993 USA.
RP Zhou, FJ (reprint author), Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, 1600 Clifton Rd NE,Mail Stop A19, Atlanta, GA 30333 USA.
EM faz1@cdc.gov
OI Cho, Bo-Hyun/0000-0002-9690-0489
FU Intramural CDC HHS [CC999999]
CR Abu Raya B, 2014, VACCINE, V32, P5787, DOI 10.1016/j.vaccine.2014.08.038
   Ahluwalia IB, 2015, MMWR-MORBID MORTAL W, V64, P522
   Amirthalingam G, 2014, LANCET, V384, P1521, DOI 10.1016/S0140-6736(14)60686-3
   Anonymous, 2011, Morbidity and Mortality Weekly Report, V60, P1424
   [Anonymous], 2012 FIN PERT SURV R
   Baxter R, 2017, PEDIATRICS, V139, DOI 10.1542/peds.2016-4091
   Bhatt A, 2014, PUBLIC HEALTH REP, V129, P115
   Bonville CA, 2015, HUM VACC IMMUNOTHER, V11, P713, DOI 10.1080/21645515.2015.1011999
   Buchmueller TC, 2009, INQUIRY-J HEALTH CAR, V46, P187, DOI 10.5034/inquiryjrnl_46.02.187
   Butler AM, 2017, OBSTET GYNECOL, V129, P629, DOI 10.1097/AOG.0000000000001927
   Dabrera G, 2015, CLIN INFECT DIS, V60, P333, DOI 10.1093/cid/ciu821
   Ding H, 2017, MMWR-MORBID MORTAL W, V66, P1016, DOI 10.15585/mmwr.mm6638a2
   Eberhardt CS, 2016, CLIN INFECT DIS, V62, P829, DOI 10.1093/cid/ciw027
   Hamilton BE, 2015, NCHS DATA BRIEF, V2016, P1
   Healy CM, 2006, CURR OPIN INFECT DIS, V19, P271, DOI 10.1097/01.qco.0000224822.65599.5b
   Healy CM, 2018, JAMA-J AM MED ASSOC, V320, P1464, DOI 10.1001/jama.2018.14298
   Healy CM, 2013, CLIN INFECT DIS, V56, P539, DOI 10.1093/cid/cis923
   Housey M, 2014, MMWR-MORBID MORTAL W, V63, P839
   Kharbanda EO, 2014, PREV MED, V67, P316, DOI 10.1016/j.ypmed.2014.05.025
   Kharbanda EO, 2016, VACCINE, V34, P968, DOI 10.1016/j.vaccine.2015.12.046
   Kim DK, 2018, MMWR-MORBID MORTAL W, V67, P158, DOI 10.15585/mmwr.mm6705e3
   Kozhimannil KB, 2012, WOMEN HEALTH ISS, V22, pE135, DOI 10.1016/j.whi.2011.12.002
   Lopez Michelle A, 2014, Hosp Pediatr, V4, P269, DOI 10.1542/hpeds.2013-0093
   Martin Joyce A, 2018, Natl Vital Stat Rep, V67, P1
   Miller BL, 2011, VACCINE, V29, P3850, DOI 10.1016/j.vaccine.2011.03.058
   Munoz FM, 2014, JAMA-J AM MED ASSOC, V311, P1760, DOI 10.1001/jama.2014.3633
   Naidu MA, 2016, AM J OBSTET GYNECOL, V215, DOI 10.1016/j.ajog.2016.03.002
   O'Halloran AC, 2016, AM J INFECT CONTROL, V44, P786, DOI 10.1016/j.ajic.2016.03.048
   O'Leary ST, 2018, AM J PREV MED, V54, P205, DOI 10.1016/j.amepre.2017.10.016
   Pool V, 2018, VACCINE, V36, P2282, DOI 10.1016/j.vaccine.2018.03.029
   Sawyer M, 2013, MMWR-MORBID MORTAL W, V62, P131
   Skoff TH, 2017, CLIN INFECT DIS, V65, P1977, DOI 10.1093/cid/cix724
   Suryadevara M, 2014, VACCINE, V32, P7000, DOI 10.1016/j.vaccine.2014.10.018
   Terranella A, 2013, PEDIATRICS, V131, pE1748, DOI 10.1542/peds.2012-3144
   The Guide to Community Preventive Services, INCR APPR VACC
   Weston W, 2011, VACCINE, V29, P8483, DOI 10.1016/j.vaccine.2011.09.063
   Williams WW, 2016, MMWR SURVEILL SUMM, V65, P1, DOI 10.15585/mmwr.ss6501a1
   Yuen CYS, 2014, VACCINE, V32, P4602, DOI 10.1016/j.vaccine.2014.06.067
   Zinkernagel RM, 2001, NEW ENGL J MED, V345, P1331, DOI 10.1056/NEJMra012493
NR 39
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 28
PY 2019
VL 37
IS 14
BP 1972
EP 1977
DI 10.1016/j.vaccine.2019.02.042
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HR6VD
UT WOS:000463290400009
PM 30826146
OA Green Accepted
DA 2020-05-12
ER

PT J
AU Harro, C
   Bourgeois, AL
   Sack, D
   Walker, R
   DeNearing, B
   Brubaker, J
   Maier, N
   Fix, A
   Dally, L
   Chakraborty, S
   Clements, JD
   Saunders, I
   Darsley, MJ
AF Harro, Clayton
   Bourgeois, A. Louis
   Sack, David
   Walker, Richard
   DeNearing, Barbara
   Brubaker, Jessica
   Maier, Nicole
   Fix, Alan
   Dally, Len
   Chakraborty, Subhra
   Clements, John D.
   Saunders, Ingelise
   Darsley, Michael J.
TI Live attenuated enterotoxigenic Escherichia coli (ETEC) vaccine with
   dmLT adjuvant protects human volunteers against virulent experimental
   ETEC challenge
SO VACCINE
LA English
DT Article
ID MUCOSAL IMMUNE-RESPONSES; HEAT-LABILE ENTEROTOXIN; COLONIZATION FACTORS;
   COMBINATION VACCINE; CHOLERA-TOXIN; DOUBLE-BLIND; IMMUNOGENICITY;
   SAFETY; ANTIGEN; MUTANT
AB Background: There is no licensed vaccine against enterotoxigenic Escherichia coli (ETEC), a major cause of diarrhea-associated morbidity and mortality among infants and children in low-income countries and travelers. The results of this vaccination/challenge study demonstrate strong protection by an attenuated ETEC vaccine candidate, ACE527, when co-administered with a mucosal adjuvant, the double-mutant heat-labile toxin (dmLT) of ETEC.
   Methods: Sixty healthy adults participated in a randomized, placebo-controlled, double-blind study with three doses of lyophilized ACE527 (similar to 3 x 10(9 )of each strain per dose) administered orally with or without dmLT adjuvant (25 mu g/dose). Six months later, 36 of these volunteers and a control group of 21 unvaccinated volunteers were challenged with virulent ETEC strain H10407. The primary outcome was severe diarrhea, defined as passing >800 g of unformed stools during the inpatient period following challenge.
   Findings: The vaccine was well tolerated and induced robust immune responses to key antigens. The protective efficacy (PE) against the primary outcome of severe diarrhea was 65.9% (95% confidence interval [CI] 5.4-87.7, p = 0.003). Among subjects receiving the adjuvanted vaccine, the attack rate of severe diarrhea was 23.1, while in unimmunized controls it was 67.7%. The PE against diarrhea of any severity was 58.5% (95% CI 3.8- 82.1, p = 0.016). There was a strong inverse correlation between shedding of the vaccine strain after either of the first two doses and absence of severe diarrhea upon challenge (RR = 0.29, 95% CI 0.08-1.05, p = 0.041). Challenge strain shedding was 10-fold lower in those receiving the adjuvant than in those receiving vaccine alone. The unadjuvanted vaccine was not protective (PE = 23.1%).
   Interpretation: The results of this study support further development of ACE527 + dmLT as a vaccine for children in endemic countries and travelers. This is the first clinical demonstration that dmLT can contribute significantly to vaccine efficacy and may warrant testing with other oral vaccines. (C) 2019 The Authors. Published Published by Elsevier Ltd.
C1 [Harro, Clayton; Sack, David; DeNearing, Barbara; Brubaker, Jessica; Chakraborty, Subhra] Johns Hopkins Bloomberg Sch Publ Hlth, Ctr Immunizat Res, Baltimore, MD USA.
   [Bourgeois, A. Louis; Walker, Richard; Maier, Nicole; Fix, Alan] PATH, Washington, DC USA.
   [Dally, Len] Emmes Corp, Rockville, MD USA.
   [Clements, John D.] Tulane Univ, Sch Med, 1430 Tulane Ave, New Orleans, LA 70112 USA.
   [Saunders, Ingelise] TDVaccines, Odense, Denmark.
   [Darsley, Michael J.] MD Biol Ltd, Cambridge, England.
RP Bourgeois, AL (reprint author), 455 Massachusetts Ave NW,Suite 1000, Washington, DC 20001 USA.
EM lbourgeois@path.org
RI Sack, David/Y-4267-2019
OI Sack, David/0000-0002-9338-5119
FU JHU; PATH through its enteric vaccine project (Bill & Melinda Gates
   Foundation) [OPP44127, OPP1054302, OPP1112376]
FX The work was supported by JHU with funding from PATH through its enteric
   vaccine project (grant nos. OPP44127, OPP1054302, and OPP1112376 from
   the Bill & Melinda Gates Foundation). PATH participated in the design of
   the studies, interpretation of results, and review of the manuscript.
CR Bergqvist P, 2013, MUCOSAL IMMUNOL, V6, P122, DOI 10.1038/mi.2012.56
   Bourgeois AL, 2016, VACCINE, V34, P2880, DOI 10.1016/j.vaccine.2016.02.076
   Cardeno A, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-20740-3
   Chakraborty S, 2016, CLIN VACCINE IMMUNOL, V23, P55, DOI 10.1128/CVI.00617-15
   Darsley MJ, 2012, CLIN VACCINE IMMUNOL, V19, P1921, DOI 10.1128/CVI.00364-12
   El-Kamary SS, 2013, CLIN VACCINE IMMUNOL, V20, P1764, DOI 10.1128/CVI.00464-13
   Guillobel HCR, 2000, INFECT IMMUN, V68, P4349, DOI 10.1128/IAI.68.7.4349-4353.2000
   Harro C, 2011, CLIN VACCINE IMMUNOL, V18, P2118, DOI 10.1128/CVI.05342-11
   Harro C, 2011, CLIN VACCINE IMMUNOL, V18, P1719, DOI 10.1128/CVI.05194-11
   Hartman AB, 1999, INFECT IMMUN, V67, P5841, DOI 10.1128/IAI.67.11.5841-5847.1999
   Holmgren J, 2013, VACCINE, V31, P2457, DOI 10.1016/j.vaccine.2013.03.027
   Hosangadi D, 2019, VACCINE, V37, P7372, DOI 10.1016/j.vaccine.2017.09.083
   Isidean SD, 2011, VACCINE, V29, P6167, DOI 10.1016/j.vaccine.2011.06.084
   Kotloff KL, 2017, VACCINE, V35, P6783, DOI 10.1016/j.vaccine.2017.07.036
   Leach S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051718
   Lundgren A, 2014, VACCINE, V32, P7077, DOI 10.1016/j.vaccine.2014.10.069
   McArthur MA, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005291
   Norton EB, 2015, VACCINE, V33, P1909, DOI 10.1016/j.vaccine.2015.02.069
   Norton EB, 2011, CLIN VACCINE IMMUNOL, V18, P546, DOI 10.1128/CVI.00538-10
   Qadri F, 2006, VACCINE, V24, P1726, DOI 10.1016/j.vaccine.2005.08.110
   Rao MR, 2005, J INFECT DIS, V191, P562, DOI 10.1086/427662
   Turner AK, 2006, INFECT IMMUN, V74, P1062, DOI 10.1128/IAI.74.2.1062-1071.2006
   Turner AK, 2001, INFECT IMMUN, V69, P4969, DOI 10.1128/IAI.69.8.4969-4979.2001
   Turner AK, 2011, CLIN VACCINE IMMUNOL, V18, P2128, DOI 10.1128/CVI.05345-11
   Wolf MK, 1997, CLIN MICROBIOL REV, V10, P569, DOI 10.1128/CMR.10.4.569
NR 25
TC 4
Z9 4
U1 0
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 28
PY 2019
VL 37
IS 14
BP 1978
EP 1986
DI 10.1016/j.vaccine.2019.02.025
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HR6VD
UT WOS:000463290400010
PM 30797634
OA Green Published, Other Gold
DA 2020-05-12
ER

PT J
AU Ainslie, KEC
   Haber, M
   Orenstein, WA
AF Ainslie, Kylie E. C.
   Haber, Michael
   Orenstein, Walter A.
TI Bias of influenza vaccine effectiveness estimates from test-negative
   studies conducted during an influenza pandemic
SO VACCINE
LA English
DT Article
DE Influenza; Test-negative; Pandemic; Vaccine effectiveness; Bias
ID DESIGN; VIRUS
AB Test-negative (TN) studies have become the most widely used study design for the estimation of influenza vaccine effectiveness (VE) and are easily incorporated into existing influenza surveillance networks. We seek to determine the bias of TN-based VE estimates during a pandemic using a dynamic probability model. The model is used to evaluate and compare the bias of VE estimates under various sources of bias when vaccination occurs after the beginning of an outbreak, such as during a pandemic. The model includes two covariates (health status and health awareness), which may affect the probabilities of vaccination, developing influenza and non-influenza acute respiratory illness (ARI), and seeking medical care. Specifically, we evaluate the bias of VE estimates when (1) vaccination affects the probability of developing a non-influenza ARI; (2) vaccination affects the probability of seeking medical care; (3) a covariate (e.g. health status) is related to both the probabilities of vaccination and developing an ARI; and (4) a covariate (e.g. health awareness) is related to both the probabilities of vaccination and of seeking medical care. We considered two outcomes against which the vaccine is supposed to protect: symptomatic influenza and medically-attended influenza.
   When vaccination begins during an outbreak, we found that the effect of delayed onset of vaccination is unpredictable. VE estimates from TN studies were biased regardless of the source of bias present. However, if the core assumption of the TN design is satisfied, that is, if vaccination does not affect the probability of non-influenza ARI, then TN-based VE estimates against medically-attended influenza will only suffer from small (<0.05) to moderate bias (>= 0.05 and <0.10). These results suggest that if sources of bias listed above are ruled out, TN studies are a valid study design for the estimation of VE during a pandemic. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Ainslie, Kylie E. C.; Haber, Michael] Emory Univ, Dept Biostat & Bioinformat, Rollins Sch Publ Hlth, 1518 Clifton Rd, Atlanta, GA 30322 USA.
   [Ainslie, Kylie E. C.] Imperial Coll London, MRC Ctr Global Infect Dis Anal, Sch Publ Hlth, Dept Infect Dis Epidemiol, Norfolk Pl, London W2 1PG, England.
   [Orenstein, Walter A.] Emory Univ, Div Infect Dis, Dept Med, Sch Med, 1462 Clifton Rd, Atlanta, GA 30322 USA.
RP Ainslie, KEC (reprint author), Imperial Coll London, MRC Ctr Global Infect Dis Anal, Sch Publ Hlth, Dept Infect Dis Epidemiol, Norfolk Pl, London W2 1PG, England.
EM k.ainslie@imperial.ac.uk
OI Ainslie, Kylie/0000-0001-5419-7206
FU National Institute of Allergies and Infectious Diseases of the National
   Institutes of Health (NIH) [R01AI110474]
FX This research was supported by the National Institute of Allergies and
   Infectious Diseases of the National Institutes of Health (NIH) under
   Award R01AI110474. The content is solely the responsibility of the
   authors and does not necessarily represent the official views of the
   NIH.
CR Ainslie KEC, 2019, AM J EPIDEMIOL, V188, P451, DOI 10.1093/aje/kwy240
   Ainslie KEC, 2017, VACCINE, V35, P7297, DOI 10.1016/j.vaccine.2017.10.107
   Bond HS, 2016, EPIDEMIOL INFECT, V144, P1601, DOI 10.1017/S095026881500309X
   Borse RH, 2013, EMERG INFECT DIS, V19, P439, DOI 10.3201/eid1903.120394
   Castilla J, 2013, CLIN INFECT DIS, V57, P167, DOI 10.1093/cid/cit194
   Centers for Disease Control and Prevention, 2017, INFL FLU
   Dawood FS, 2012, LANCET INFECT DIS, V12, P687, DOI 10.1016/S1473-3099(12)70121-4
   Deiss RG, 2015, VACCINE, V33, P7160, DOI 10.1016/j.vaccine.2015.11.004
   Fiore AE, 2009, VACCINES PANDEMIC IN
   Foppa IM, 2015, VACCINE, V33, P3003, DOI 10.1016/j.vaccine.2015.02.042
   Foppa IM, 2013, VACCINE, V31, P3104, DOI 10.1016/j.vaccine.2013.04.026
   Fukushima W, 2017, VACCINE, V35, P4796, DOI 10.1016/j.vaccine.2017.07.003
   Haber M, 2015, EPIDEMIOL INFECT, V143, P1417, DOI 10.1017/S0950268814002179
   HABER M, 1995, AM J EPIDEMIOL, V141, P980, DOI 10.1093/oxfordjournals.aje.a117365
   Jackson ML, 2015, VACCINE, V33, P1313, DOI 10.1016/j.vaccine.2015.01.069
   Jackson ML, 2013, VACCINE, V31, P2165, DOI 10.1016/j.vaccine.2013.02.053
   Lipsitch M, 2016, INT J EPIDEMIOL, V45, P2060, DOI 10.1093/ije/dyw124
   Orenstein EW, 2007, INT J EPIDEMIOL, V36, P623, DOI 10.1093/ije/dym021
   R Core Team, 2016, R LANG ENV STAT COMP
   Reed C, 2009, EMERG INFECT DIS, V15, P2004, DOI 10.3201/eid1512.091413
   Serres G. de, 2013, Eurosurveillance, V18, P20585
   Shi M, 2017, BMC INFECT DIS, V17, DOI 10.1186/s12879-017-2838-2
   Skowronski DM, 2007, VACCINE, V25, P2842, DOI 10.1016/j.vaccine.2006.10.002
   Sullivan SG, 2016, AM J EPIDEMIOL, V184, P345, DOI 10.1093/aje/kww064
   VanWormer JJ, 2014, BMC INFECT DIS, V14, DOI 10.1186/1471-2334-14-231
NR 25
TC 1
Z9 1
U1 0
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 28
PY 2019
VL 37
IS 14
BP 1987
EP 1993
DI 10.1016/j.vaccine.2019.02.036
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HR6VD
UT WOS:000463290400011
PM 30833155
OA Green Accepted
DA 2020-05-12
ER

PT J
AU Pan, SC
   Hsieh, SM
   Lin, CF
   Hsu, YS
   Chang, MG
   Chang, SC
AF Pan, Sung-Ching
   Hsieh, Szu-Min
   Lin, Chih-Feng
   Hsu, Yu-Shen
   Chang, Mingi
   Chang, Shan-Chwen
TI A randomized, double-blind, controlled clinical trial to evaluate the
   safety and immunogenicity of an intranasally administered trivalent
   inactivated influenza vaccine with adjuvant LTh(alpha K): A phase I
   study
SO VACCINE
LA English
DT Article
DE Influenza vaccine; Intranasal; Adjuvant; LTh(alpha K)
ID HEAT-LABILE TOXIN; ANTIBODY-RESPONSES; SEASONAL INFLUENZA; BIVALENT
   VACCINE; UNITED-STATES; B-SUBUNIT; DELIVERY; IMMUNIZATION; NASAL; IGA
AB Background: A nasal influenza vaccine has been available only in a live attenuated form, which limits the range of recipients to immune-competent individuals. The present study evaluated a newly developed intranasal inactivated influenza vaccine with a novel adjuvant, heat-labile enterotoxin (LT) derived from E. coli (LTh(alpha K)).
   Methods: The study was a randomized, double-blind, controlled phase I trial to evaluate the safety and immunogenicity of an intranasal vaccine containing the trivalent influenza HA antigen (7.5 mu g each of A/California/7/09 (H1N1)-like virus, A/Victoria/210/2009 (H3N2) virus, and B/Brisbane/60/2008-like virus) in combination with 4 different doses of adjuvant LTh(alpha K) (7.5, 15, 30 or 45 mu g) and 22.5 mu of influenza HA antigen alone (control vaccine). The vaccine was intranasally administered on Days 0 and 7. A safety evaluation commenced for 180 days, and hemagglutination inhibition (HI) antibody titers and nasal HA-specific IgA titers on Day 0 and Day 28 were assessed to determine whether an immunogenic response was elicited.
   Results: From November 2012 to September 2013, a total of 36 subjects were enrolled. Twenty-four subjects received an adjuvanted vaccine, and 12 subjects received a control vaccine. The most common adverse event (AE) was mild nasal discomfort, and systemic AEs were mild fatigue and headache. Only two subjects discontinued the study because of an AE (one had grade 3 fever, and one had nodal arrhythmia). In the group with 45 mu g of LTh(alpha K), the seroprotection rates were 100%, 100% and 80%, and the nasal IgA conversion factors were 7.90, 7.46 and 12.27 for the A/H3N2, A/H1N1 and split B strains, respectively. Adjuvant LTh(alpha K) vaccine showed a significant enhancement in mucosal immunity in split B -specific IgA.
   Conclusion: The intranasal inactivated influenza vaccine is generally safe, and the LTh(alpha K)-adjuvanted vaccine is more immunogenic than non-adjuvanted control vaccine. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Pan, Sung-Ching; Hsieh, Szu-Min; Chang, Shan-Chwen] Natl Taiwan Univ Hosp, Dept Internal Med, 7 Chung Shan South Rd, Taipei 100, Taiwan.
   [Lin, Chih-Feng] Natl Taiwan Univ Hosp, Dept Otolaryngol Head & Neck Surg, Taipei, Taiwan.
   [Hsu, Yu-Shen; Chang, Mingi] Advagene Biopharma Co Ltd, Taipei, Taiwan.
   [Hsu, Yu-Shen; Chang, Mingi] Dev Ctr Biotechnol, New Taipei, Taiwan.
   [Chang, Shan-Chwen] Natl Taiwan Univ, Coll Med, Taipei, Taiwan.
RP Chang, SC (reprint author), Natl Taiwan Univ Hosp, Dept Internal Med, 7 Chung Shan South Rd, Taipei 100, Taiwan.
EM changsc@ntu.edu.tw
FU National Science Committee, Taiwan [NSC 101-2325-B-002-089, NSC
   99-3113-Y-462-002]
FX The present study was financially supported through grants from the
   National Science Committee, Taiwan [NSC 101-2325-B-002-089 and NSC
   99-3113-Y-462-002].
CR ALEXANDROVA GI, 1986, VACCINE, V4, P114, DOI 10.1016/0264-410X(86)90049-6
   Auewarakul P, 2007, VACCINE, V25, P659, DOI 10.1016/j.vaccine.2006.08.026
   Belshe RB, 2004, NEW ENGL J MED, V351, P2286, DOI 10.1056/NEJMoa043555
   Bibolini MJ, 2012, CELL IMMUNOL, V280, P50, DOI 10.1016/j.cellimm.2012.11.012
   Centers for Disease Control and Prevention, 2015, VACC INF STAT
   Chiou CJ, 2009, BIOMATERIALS, V30, P5862, DOI 10.1016/j.biomaterials.2009.06.046
   CLEMENTS JD, 1984, INFECT IMMUN, V46, P564, DOI 10.1128/IAI.46.2.564-569.1984
   Coulter A, 2003, VACCINE, V21, P946, DOI 10.1016/S0264-410X(02)00545-5
   de Haan L, 2001, VACCINE, V19, P2898, DOI 10.1016/S0264-410X(00)00556-9
   Durrer P, 2003, VACCINE, V21, P4328, DOI 10.1016/S0264-410X(03)00457-2
   Gemmill I, 2016, Can Commun Dis Rep, V42, P188
   Gluck R, 2000, J INFECT DIS, V181, P1129, DOI 10.1086/315337
   Glueck R, 2001, ADV DRUG DELIVER REV, V51, P203, DOI 10.1016/S0169-409X(01)00174-0
   Grohskopf LA, 2016, MMWR RECOMM REP, V65, P1, DOI 10.15585/mmwr.rr6505a1
   Harmon MW, 1989, DIAGNOSTIC PROCEDURE, P631
   Lewis DJM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006999
   Lu PJ, 2013, AM J EPIDEMIOL, V178, P1478, DOI 10.1093/aje/kwt158
   Muramatsu M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085582
   Mutsch M, 2004, NEW ENGL J MED, V350, P896, DOI 10.1056/NEJMoa030595
   Nakahashi-Ouchida R, 2017, EXPERT REV VACCINES, V16, P1231, DOI 10.1080/14760584.2017.1395702
   Ogra PL, 1984, IMMUNOLOGY LUNG UPPE
   Renegar KB, 2004, J IMMUNOL, V173, P1978, DOI 10.4049/jimmunol.173.3.1978
   Rouphael NG, 2017, LANCET, V390, P649, DOI 10.1016/S0140-6736(17)30575-5
   Rudenko L, 2016, VACCINE, V34, P5436, DOI 10.1016/j.vaccine.2016.08.018
   Saluja V, 2010, AAPS J, V12, P109, DOI 10.1208/s12248-009-9168-2
   Sanders MT, 2009, VACCINE, V27, P2475, DOI 10.1016/j.vaccine.2009.02.054
   Stephenson I, 2006, J VIROL, V80, P4962, DOI 10.1128/JVI.80.10.4962-4970.2006
   STROM J, 1976, SCAND J INFECT DIS, V8, P21
   Suzuki T, 2015, P NATL ACAD SCI USA, V112, P7809, DOI 10.1073/pnas.1503885112
   Tamura S, 2016, JPN J INFECT DIS, V69, P165, DOI 10.7883/yoken.JJID.2015.560
   Tumpey TM, 2001, J VIROL, V75, P5141, DOI 10.1128/JVI.75.11.5141-5150.2001
   U.S. Department of Health and Human Services, 2011, HLTH PEOPL 2020 TOP
   Wacheck V, 2010, J INFECT DIS, V201, P354, DOI 10.1086/649428
   World Health Organization, 2018, INFL SEAS
   World health Organization, 2012, WEEKLY EPIDEMIOLOGIC
   WRIGHT PF, 1983, INFECT IMMUN, V40, P1092, DOI 10.1128/IAI.40.3.1092-1095.1983
   Yalich B, 2006, SPECIMEN COLLECTION
NR 37
TC 1
Z9 1
U1 2
U2 9
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 28
PY 2019
VL 37
IS 14
BP 1994
EP 2003
DI 10.1016/j.vaccine.2019.02.006
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HR6VD
UT WOS:000463290400012
PM 30837170
DA 2020-05-12
ER

PT J
AU Burny, W
   Marchant, A
   Herve, C
   Callegaro, A
   Caubet, M
   Fissette, L
   Gheyle, L
   Legrand, C
   Ndour, C
   da Silva, FT
   van der Most, R
   Willems, F
   Didierlaurent, AM
   Yarzabal, J
   Bosmans, S
   Bourguignon, P
   Brouwer, M
   Carletti, I
   Danloy, S
   Didierlaurent, A
   Druart, X
   Fis-Sette, L
   Gavrilovic, L
   Herve, C
   Saliez, J
   Yarzabal, JP
AF Burny, Wivine
   Marchant, Arnaud
   Herve, Caroline
   Callegaro, Andrea
   Caubet, Magalie
   Fissette, Laurence
   Gheyle, Lien
   Legrand, Catherine
   Ndour, Cheikh
   da Silva, Fernanda Tavares
   van der Most, Robbert
   Willems, Fabienne
   Didierlaurent, Arnaud M.
   Yarzabal, Juan
   Bosmans, Stephane
   Bourguignon, Patricia
   Brouwer, Margreet
   Carletti, Isabelle
   Danloy, Sophie
   Didierlaurent, Arnaud
   Druart, Xavier
   Fis-Sette, Laurence
   Gavrilovic, Lydia
   Herve, Caroline
   Saliez, Julie
   Yarzabal, Juan Pablo
CA ECR-008 Study Grp
TI Inflammatory parameters associated with systemic reactogenicity
   following vaccination with adjuvanted hepatitis B vaccines in humans
SO VACCINE
LA English
DT Article
DE HBsAg-AS01B adjuvanted vaccine; Reactogenicity; Innate response;
   Association with systemic symptoms; IFN gamma signals; IL-6 signals
ID ZOSTER SUBUNIT VACCINE; SAFETY; EFFICACY; TRIAL; EXPRESSION; RESPONSES
AB Background: Adjuvants like AS01(B) increase the immunogenicity of vaccines and generally cause increased transient reactogenicity compared with Alum. A phase H randomized trial was conducted to characterize the response to AS01(B) and Alum adjuvanted vaccines. A post-hoc analysis was performed to examine the associations between reactogenicity and innate immune parameters.
   Methods: The trial involved 60 hepatitis 13-naive adults aged 18-45 years randomized 1:1 to receive either two doses of HBsAg-AS01(B) on Day (D)0 and D30, or three doses of HBsAg-Alum on D0, D30, D180. Prior to vaccination, all subjects received placebo injection in order to differentiate the impact of injection process and the vaccination. Main outcomes included reactogenicity symptoms, vital signs, blood cytokines, biochemical and hematological parameters after vaccination. Associations were explored using linear regression.
   Findings: The vaccine with AS01(B) induced higher HBsAg-specific antibody levels than Alum. Local and systemic symptoms were more frequent in individuals who received HBsAg AS01(B)/Alum vaccine or placebo, but were mild and short-lived. Blood levels of C-reactive protein (CRP), bilirubin, leukocyte, monocyte and neutrophil counts increased rapidly and transiently after AS01(B) but not after Alum or placebo. Lymphocyte counts decreased in the AS01(B) group and lactate dehydrogenase levels decreased after Alum. Modelling revealed associations between systemic symptoms and increased levels of CRP and IL-6 after the first HBsAg-AS01(B) or HBsAg-Alum immunization. Following the second vaccine dose, CRP, IL-6, IP-10, IFN-gamma, MIP-1 beta and MCP-2 were identified as key parameters associated with systemic symptoms. These observations were confirmed using an independent data set extracted from a previous study of the immune response to HBsAg-adjuvanted vaccines (NCT00805389).
   Conclusions: IL-6 and IFN-gamma signals were associated with systemic reactogenicity following administration of AS01(B)-adjuvanted vaccine. These signals were similar to those previously associated with antibody and T-cell responses induced by HBsAg-adjuvanted vaccines, suggesting that similar innate immune signals may underlie adjuvant reactogenicity and immunogenicity. (C) 2019 GlaxoSmithKline Biologicals SA. Published by Elsevier Ltd.
C1 [Burny, Wivine; Herve, Caroline; Callegaro, Andrea; Caubet, Magalie; Fissette, Laurence; da Silva, Fernanda Tavares; van der Most, Robbert; Didierlaurent, Arnaud M.; Yarzabal, Juan] GSK, Rue Inst 89, B-1330 Rixensart, Belgium.
   [Marchant, Arnaud; Willems, Fabienne] Univ Libre Bruxelles, Inst Med Immunol, Charleroi, Belgium.
   [Gheyle, Lien] SGS Life Sci Serv, Antwerp, Belgium.
   [Legrand, Catherine; Ndour, Cheikh] Catholic Univ Louvain, Inst Stat Biostat & Actuarial Sci ISBA, Louvain La Neuve, Belgium.
RP Burny, W (reprint author), GSK, Rue Inst 89, B-1330 Rixensart, Belgium.
EM Wivine.Burny@GSK.com
RI Cerveto, Thomas/S-2584-2019
FU GlaxoSmithKline Biologicals SAGlaxoSmithKline; programme "BEWARE
   fellowship Academia", Belgium from Region Wallonne - Belgium [1510396]
FX GlaxoSmithKline Biologicals SA was the funding source and was involved
   in all stages of the study conduct and analysis. GlaxoSmithKline
   Biologicals SA also took responsibility for all costs associated with
   the development and publishing of the present manuscript. CN has
   received funding under the programme "BEWARE fellowship Academia",
   Belgium from Region Wallonne - Belgium (Convention STADOC no 1510396).
CR Burny W, 2017, FRONT IMMUNOL, V8, P14, DOI 10.3389/fimmu.2017.00943
   Center for Biologics Evaluation and Research, 2007, GUID IND TOX GRAD SC
   Chan CYY, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.96031
   Coccia M, 2017, NPJ VACCINES, V2, DOI 10.1038/s41541-017-0027-3
   Cunningham AL, 2016, NEW ENGL J MED, V375, P1019, DOI 10.1056/NEJMoa1603800
   Destexhe E, 2013, J PHARMACOL TOX MET, V68, P367, DOI 10.1016/j.vascn.2013.04.003
   Detienne S, 2016, SCI REP-UK, V6, DOI 10.1038/srep39475
   Di Pasquale A, 2016, VACCINE, V34, P6672, DOI 10.1016/j.vaccine.2016.10.039
   Di Pasquale A, 2015, VACCINES-BASEL, V3, P320, DOI 10.3390/vaccines3020320
   Didierlaurent AM, 2014, J IMMUNOL, V193, P1920, DOI 10.4049/jimmunol.1400948
   Farinde A, LAB REFERENCE RANGES
   Garcon N, 2007, EXPERT REV VACCINES, V6, P723, DOI 10.1586/14760584.6.5.723
   Garcon N, 2017, HUM VACC IMMUNOTHER, V13, P19, DOI 10.1080/21645515.2016.1225635
   Giordano G, 2017, J APPL TOXICOL, V37, P132, DOI 10.1002/jat.3329
   KAPLAN G, 1987, J EXP MED, V166, P1098, DOI 10.1084/jem.166.4.1098
   Kester KE, 2009, J INFECT DIS, V200, P337, DOI 10.1086/600120
   Lal H, 2015, NEW ENGL J MED, V372, P2087, DOI 10.1056/NEJMoa1501184
   Lee S, 2015, IMMUNE NETW, V15, P51, DOI 10.4110/in.2015.15.2.51
   Leroux-Roels G, 2016, CLIN IMMUNOL, V169, P16, DOI 10.1016/j.clim.2016.05.007
   Leroux-Roels I, 2012, J INFECT DIS, V206, P1280, DOI 10.1093/infdis/jis497
   Lewis DJM, 2015, J IMMUNOL RES, DOI 10.1155/2015/909406
   McKee AS, 2017, CURR OPIN IMMUNOL, V47, P44, DOI 10.1016/j.coi.2017.06.005
   Mian-McCarthy S, 2012, NEW ENGL J MED, V367, P2284, DOI 10.1056/NEJMoa1208394
   Netea MG, 2016, SCIENCE, V352, DOI 10.1126/science.aaf1098
   Sallusto F, 1998, J EXP MED, V187, P875, DOI 10.1084/jem.187.6.875
   VANDAMME J, 1994, J IMMUNOL, V152, P5495
   Wright KP, 2002, AM J PHYSIOL-REG I, V283, pR1370, DOI 10.1152/ajpregu.00205.2002
NR 27
TC 4
Z9 4
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 28
PY 2019
VL 37
IS 14
BP 2004
EP 2015
DI 10.1016/j.vaccine.2019.02.015
PG 12
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HR6VD
UT WOS:000463290400013
PM 30850240
OA Other Gold
DA 2020-05-12
ER

PT J
AU Xie, YL
   Li, HT
   Qi, XC
   Ma, YJ
   Yang, B
   Zhang, SM
   Chang, HY
   Yin, XP
   Li, ZY
AF Xie, Yinli
   Li, Haitao
   Qi, Xingcai
   Ma, Youji
   Yang, Bo
   Zhang, Shumin
   Chang, Huiyun
   Yin, Xiangping
   Li, Zhiyong
TI Immunogenicity and protective efficacy of a novel foot-and-mouth disease
   virus empty-capsid-like particle with improved acid stability
SO VACCINE
LA English
DT Article
DE FMDV serotype O; Empty-capsid-like particles; Acid stability Recombinant
   baculovirus; Immunogenicity
ID PRECURSOR POLYPEPTIDE P1; ANTIBODY-RESPONSE; INSECT CELLS; SUBSTITUTION;
   RESISTANCE; INCREASE; IMMUNITY; SUBUNIT; SYSTEM; CATTLE
AB Foot-and-mouth disease virus (FMDV) is the etiological agent of a highly contagious disease that affects cloven-hoofed animal species. The FMDV capsid is highly acid labile and viral particles lose their immunogenicity when they disassemble at mildly acidic pHs. The viral capsid of FMDV serotype O is more sensitive than those of other serotypes, making it more difficult to acquire enough emptycapsid-like particles in the acidic insect cell environment for research. In this study, novel FMDV mutants with increased acid resistance were isolated using BHK-21 cell cultured under low-pH conditions. Amino acid substitutions Q25R, K41E, and N85A in the VP1 capsid protein and K154Q in the VP3 capsid protein were detected in all six mutants. Based on these amino acid replacements, empty-capsid-like particles of FMDV serotype O, which were resistant to the acid-induced dissociation of the capsid into pentameric subunits, were produced in insect cells. We characterized the protective immunity induced by these acid-resistant empty capsid particles. Significant humoral and cellular immune responses were elicited in mice after immunization with the acid-resistant empty capsid particles. The acid-resistant emptycapsid-like particles also induced strong neutralizing antibodies in guinea pigs and protected all the guinea pigs from FMDV challenge. Our results suggest that these acid-resistant empty-capsid-like particles have potential utility as a vaccine against serotype O FMDV infection. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Xie, Yinli; Zhang, Shumin; Chang, Huiyun; Yin, Xiangping; Li, Zhiyong] Chinese Acad Agr Sci, State Key Lab Vet Etiol Biol, Key Lab Grazing Anim Dis, Minist Agr,Lanzhou Vet Res Inst, Lanzhou, Gansu, Peoples R China.
   [Xie, Yinli; Yang, Bo] Northwest A&F Univ, Coll Vet Med, Yangling, Shaanxi, Peoples R China.
   [Li, Haitao; Qi, Xingcai; Ma, Youji] Gansu Agr Univ, Coll Anim Sci & Technol, Lanzhou, Gansu, Peoples R China.
RP Li, ZY (reprint author), Chinese Acad Agr Sci, Lanzhou Vet Res Inst, 1 Xujiaping Rd, Lanzhou 730046, Gansu, Peoples R China.
EM lizhiyong02@caas.cn
FU National Key R&D Program of China [2017YFD0500902]; National Natural
   Science Foundation of ChinaNational Natural Science Foundation of China
   [31201943, 31572522]; Fundamental Research Funds of the Chinese Academy
   of Agricultural Sciences [1610312016026]
FX This work was supported by National Key R&D Program of China
   (2017YFD0500902), National Natural Science Foundation of China (No.
   31201943 and No. 31572522) and Fundamental Research Funds of the Chinese
   Academy of Agricultural Sciences (1610312016026).
CR Abubakar M, 2018, REV MED VIROL, V28, DOI 10.1002/rmv.1966
   Bhat SA, 2013, RES VET SCI, V95, P1217, DOI 10.1016/j.rvsc.2013.07.007
   BROWN F, 1961, NATURE, V192, P1163, DOI 10.1038/1921163a0
   Brown F, 1950, J IMMUNOL, V1959, P444
   Caridi F, 2017, VET MICROBIOL, V203, P275, DOI 10.1016/j.vetmic.2017.03.031
   Caridi F, 2015, J VIROL, V89, P5633, DOI 10.1128/JVI.03358-14
   Carrillo C, 2005, J VIROL, V79, P6487, DOI 10.1128/JVI.79.10.6487-6504.2005
   CURRY S, 1995, J VIROL, V69, P430, DOI 10.1128/JVI.69.1.430-438.1995
   DOEL TR, 1994, VACCINE, V12, P592, DOI 10.1016/0264-410X(94)90262-3
   DOEL TR, 1981, ARCH VIROL, V70, P21, DOI 10.1007/BF01320790
   DOEL TR, 1982, ARCH VIROL, V73, P185, DOI 10.1007/BF01314726
   Doel TR, 2003, VIRUS RES, V91, P81, DOI 10.1016/S0168-1702(02)00261-7
   Domingo E, 2003, VIRUS RES, V91, P47, DOI 10.1016/S0168-1702(02)00259-9
   Fernandes F, 2013, EXPERT REV VACCINES, V12, P225, DOI [10.1586/erv.12.153, 10.1586/ERV.12.153]
   Fry EE, 2005, CURR TOP MICROBIOL, V288, P71
   Grubman MJ, 2004, CLIN MICROBIOL REV, V17, P465, DOI 10.1128/CMR.17.2.465-493.2004
   Harmsen MM, 2011, VACCINE, V29, P2682, DOI 10.1016/j.vaccine.2011.01.069
   Harmsen MM, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00960
   Knight-Jones TJD, 2013, PREV VET MED, V112, P161, DOI 10.1016/j.prevetmed.2013.07.013
   Li ZY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043849
   Li ZY, 2011, VET MICROBIOL, V149, P99, DOI 10.1016/j.vetmic.2010.10.022
   Li ZY, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002273
   Liang T, 2014, ARCH VIROL, V159, P657, DOI 10.1007/s00705-013-1872-7
   Liu FX, 2013, PROTEIN EXPRES PURIF, V90, P104, DOI 10.1016/j.pep.2013.05.009
   Martin-Acebes MA, 2011, J VIROL, V85, P2733, DOI 10.1128/JVI.02245-10
   Martin-Acebes MA, 2010, J VIROL, V84, P2902, DOI 10.1128/JVI.02311-09
   Mateo R, 2008, J VIROL, V82, P12232, DOI 10.1128/JVI.01553-08
   MELOEN RH, 1979, J GEN VIROL, V45, P761, DOI 10.1099/0022-1317-45-3-761
   Moraes MP, 2011, VACCINE, V29, P9431, DOI 10.1016/j.vaccine.2011.10.037
   PAY TWF, 1987, VACCINE, V5, P60, DOI 10.1016/0264-410X(87)90011-9
   Porta C, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003255
   RAO MG, 1994, VET MICROBIOL, V39, P135, DOI 10.1016/0378-1135(94)90094-9
   Rweyemamu M, 2014, J VET MED RES REP
   Sanz-Parra A, 1999, VIROLOGY, V259, P129, DOI 10.1006/viro.1999.9717
   Sanz-Parra A, 1999, J GEN VIROL, V80, P671, DOI 10.1099/0022-1317-80-3-671
   Sari D, 2016, ADV EXP MED BIOL, V896, P199, DOI 10.1007/978-3-319-27216-0_13
   Scott KA, 2017, J VIROL, P91
   Sobrino F, 2001, VET RES, V32, P1, DOI 10.1051/vetres:2001106
   van Vlijmen HWT, 1998, J MOL BIOL, V275, P295, DOI 10.1006/jmbi.1997.1418
   Vazquez-Calvo A, 2014, J VIROL, V88, P3039, DOI 10.1128/JVI.03222-13
   Wang Haiwei, 2014, Virologica Sinica, V29, P103, DOI 10.1007/s12250-014-3426-x
   Xie Y., 2016, BIOMED RES INT, V2016
   Yamaji H, 2014, APPL MICROBIOL BIOT, V98, P1963, DOI 10.1007/s00253-013-5474-9
   Yamayoshi S, 2014, EMERG MICROBES INFEC, V3, DOI 10.1038/emi.2014.49
NR 44
TC 4
Z9 4
U1 4
U2 8
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 28
PY 2019
VL 37
IS 14
BP 2016
EP 2025
DI 10.1016/j.vaccine.2019.02.032
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HR6VD
UT WOS:000463290400014
PM 30808570
DA 2020-05-12
ER

PT J
AU Wateska, AR
   Nowalk, MP
   Lin, CJ
   Harrison, LH
   Schaffner, W
   Zimmerman, RK
   Smith, KJ
AF Wateska, Angela R.
   Nowalk, Mary Patricia
   Lin, Chyongchiou J.
   Harrison, Lee H.
   Schaffner, William
   Zimmerman, Richard K.
   Smith, Kenneth J.
TI Cost-effectiveness of adult pneumococcal vaccination policies in
   underserved minorities aged 50-64 years compared to the US general
   population
SO VACCINE
LA English
DT Article
DE Adult pneumococcal vaccination; Cost-effectiveness analysis; Decision
   analysis; Underserved minorities
ID CONJUGATE VACCINE; UNITED-STATES; DISEASE; PNEUMONIA; INFLUENZA;
   COVERAGE; IMMUNIZATION; DISPARITIES; STRATEGIES; CHILDREN
AB Background: Changing pneumococcal disease epidemiology due to childhood vaccination has prompted re-examination of US adult pneumococcal vaccination policies, as have considerations of greater pneumococcal disease incidence and higher prevalence of conditions that increase risk in underserved minority populations. Prior analyses suggest routine pneumococcal vaccination at age 50 could be considered, which could disproportionately benefit underserved populations.
   Methods: A Markov cohort model estimated the cost-effectiveness of US pneumococcal vaccination policies in hypothetical 50-year-old underserved minority and general population cohorts. Strategies included receiving one or both available pneumococcal vaccines based on age- or chronic condition-specific criteria. US databases and medical literature data calibrated pneumococcal illness incidence, vaccine serotype distributions, age- and race-specific chronic condition distributions, and costs. Black population data were used as a proxy for underserved minorities. We took a US healthcare perspective, discounting at 3%/year. One-way and probabilistic sensitivity analyses were performed and scenarios modeling differing vaccine assumptions were examined.
   Results: In both black and general population 50-year-olds, giving both pneumococcal vaccines to all 50-year-olds prevented the most disease, but cost >$250,000 per quality adjusted life year (QALY) gained. Current CDC recommendations (both vaccines for the immunocompromised, polysaccharide vaccine for other high-risk conditions) were economically favorable in either population when analyses assumed polysaccharide vaccine was ineffective against nonbacteremic pneumococcal pneumonia (NBP). If polysaccharide vaccine is effective against NBP or if less complex age-based vaccination recommendations result in increased vaccine uptake, giving polysaccharide vaccine to all 50-year-olds cost < $100,000/QALY; this effect was more pronounced in black cohorts. Results were robust in 1-way and probabilistic sensitivity analyses.
   Conclusions: Despite changes in pneumococcal epidemiology, current CDC recommendations were favored in underserved minority and general population cohorts. Polysaccharide vaccine for all 50-year-olds could be considered under some vaccine uptake and effectiveness assumptions, particularly if mitigating racial health disparities in pneumococcal disease is a priority. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Wateska, Angela R.; Nowalk, Mary Patricia; Lin, Chyongchiou J.; Harrison, Lee H.; Zimmerman, Richard K.; Smith, Kenneth J.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA.
   [Schaffner, William] Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA.
RP Smith, KJ (reprint author), 200 Meyran Ave,Suite 200, Pittsburgh, PA 15213 USA.
EM arw74@pitt.edu; tnowalk@pitt.edu; cjlin@pitt.edu; lharriso@edc.pitt.edu;
   william.schaffner@vanderbilt.edu; zimmer@pitt.edu; smithkj2@upmc.edu
OI Zimmerman, Richard/0000-0001-5941-6092; Lin,
   Chyongchiou/0000-0001-9441-3508; Smith, Kenneth J/0000-0001-8088-566X
FU National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [R01 AI11657503]
FX This work was supported by the National Institutes of Health (grant
   number R01 AI11657503).
CR Anderson WL, 2010, PUBLIC HEALTH REP, V125, P44, DOI 10.1177/003335491012500107
   [Anonymous], 2018, HCUP DAT HEALTHC COS
   [Anonymous], 2017, HLTH US 2016 CHARTB
   Blommaert A, 2016, VACCINE, V34, P2106, DOI 10.1016/j.vaccine.2016.03.003
   Bonten MJM, 2015, NEW ENGL J MED, V372, P1114, DOI 10.1056/NEJMoa1408544
   Briggs AH, 2012, MED DECIS MAKING, V32, P722, DOI 10.1177/0272989X12458348
   Burton DC, 2010, AM J PUBLIC HEALTH, V100, P1904, DOI 10.2105/AJPH.2009.181313
   *CDCP, CDC VACC PRIC LIST
   Centers for Disease Contol and Prevention (CDC), 2016, AD COND IMM SCHED
   Fiore Anthony E., 2010, Morbidity and Mortality Weekly Report, V59, P1
   Gold MR, 1998, MED CARE, V36, P778, DOI 10.1097/00005650-199806000-00002
   Grabenstein JD, 2012, CLIN INFECT DIS, V55, P255, DOI 10.1093/cid/cis354
   Grijalva CG, 2007, LANCET, V369, P1179, DOI 10.1016/S0140-6736(07)60564-9
   Hebert PL, 2005, HEALTH SERV RES, V40, P517, DOI 10.1111/j.1475-6773.2005.0e371.x
   Hill HA, 2017, MMWR-MORBID MORTAL W, V66, P1171, DOI 10.15585/mmwr.mm6643a3
   Hurley LP, 2018, J AM BOARD FAM MED, V31, P94, DOI 10.3122/jabfm.2018.01.170216
   Hurley LP, 2014, ANN INTERN MED, V160, P161, DOI 10.7326/M13-2332
   Jackson L, 1999, JAMA-J AM MED ASSOC, V281, P243, DOI 10.1001/jama.281.3.243
   Kim EJ, 2018, J GEN INT MED
   Lee G., ACIP PRESENTATION PN
   Lexau CA, 2005, JAMA-J AM MED ASSOC, V294, P2043, DOI 10.1001/jama.294.16.2043
   Mangen MJJ, 2017, BMC INFECT DIS, V17, DOI 10.1186/s12879-017-2302-3
   Matanock A., INVASIVE PNEUMOCOCCA
   Moore MR, 2015, LANCET INFECT DIS, V15, P301, DOI 10.1016/S1473-3099(14)71081-3
   Musher DM, 2012, CLIN INFECT DIS, V55, P265, DOI 10.1093/cid/cis364
   Neumann PJ, 2014, NEW ENGL J MED, V371, P796, DOI 10.1056/NEJMp1405158
   Neumann PJ, COST EFFECTIVENESS H
   Paradiso PR, 2012, CLIN INFECT DIS, V55, P259, DOI 10.1093/cid/cis359
   Pilishvili T, 2017, OPEN FORUM INFECT DI, V4, pS66, DOI DOI 10.1093/ofid/ofx162.158
   Pilishvili T., 2018, ACIP M ATL GA OCT 24
   Said MA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060273
   See I, 2017, CLIN INFECT DIS, V64, P597, DOI 10.1093/cid/ciw808
   Sisk JE, 2003, ANN INTERN MED, V138, P960, DOI 10.7326/0003-4819-138-12-200306170-00007
   Smith KJ, 2008, VACCINE, V26, P1420, DOI 10.1016/j.vaccine.2008.01.007
   Smith KJ, 2012, JAMA-J AM MED ASSOC, V307, P804, DOI 10.1001/jama.2012.169
   Stoecker C, 2016, J GEN INTERN MED, V31, P901, DOI 10.1007/s11606-016-3651-0
   Thorpe RJ, 2016, J URBAN HEALTH, V93, P808, DOI 10.1007/s11524-016-0075-4
   Waight PA, 2015, LANCET INFECT DIS, V15, P535, DOI 10.1016/S1473-3099(15)70044-7
   Williams WW, 2017, MMWR SURVEILL SUMM, V66, P1, DOI 10.15585/mmwr.ss6611a1
   Zimmerman RK, 2010, VACCINE, V28, P6470, DOI 10.1016/j.vaccine.2010.07.037
NR 40
TC 4
Z9 4
U1 0
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 28
PY 2019
VL 37
IS 14
BP 2026
EP 2033
DI 10.1016/j.vaccine.2019.01.002
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HR6VD
UT WOS:000463290400015
PM 30846259
OA Green Accepted
DA 2020-05-12
ER

PT J
AU Muangchana, C
   Thanormwat, Y
   Kongsiang, A
AF Muangchana, Charung
   Thanormwat, Yothin
   Kongsiang, Apichat
TI Workshops advocating ASEAN Vaccine Security and Self-Reliance (AVSSR): A
   regional initiative
SO VACCINE
LA English
DT Article
DE National Vaccine Institute (Thailand); NVI; ASEAN Vaccine Security and
   Self-Reliance; AVSSR Vaccine; Shortage of vaccine; ASEAN Post-2015
   Health Development; Agenda
AB The concept of ASEAN Vaccine Security and Self-Reliance (AVSSR) has recently been advocated for by the National Vaccine Institute (NVI), a public organization of Thailand, through two workshops in 2014 and 2015 organized in cooperation with the World Health Organization (WHO) for the ASEAN Collaboration Initiatives for Regional Vaccine Security and Self-Reliance (VSSR). In both workshops relevant policy makers, Expanded Programme on Immunization (EPI) managers, and experts from government and partner agencies involved in the vaccine life cycle actively participated. A paradigm shift in leveraging the initiatives of VSSR from national to regional levels was noted and reiterated.
   The first workshop's objective was to understand the perspectives and identify the needs of ASEAN countries regarding vaccine security, and to list potential areas for further collaboration. The existing vaccine-related capacities, collaborations, and networks in ASEAN were discussed based on findings from a pre-workshop, self-administered questionnaire survey. The workshop ended with four key areas unanimously recommended for regional collaboration strengthening: (1) system development for vaccine security; (2) human resource development; (3) ASEAN price policy for vaccine (APPV) and pooled procurement; and (4) communication and coordination. A call for immediate action was made, prompting the second workshop to focus only on "communication and coordination" to identify concrete, actionable collaborative models for effective communication and coordination. At the second workshop, a five-year Communication and Coordination Action Plan (CCAP) was developed to foster long-term AVSSR.
   The AVSSR's ultimate goal is to avoid incidental vaccine shortage and ensure sufficient supply of affordable, quality vaccines for normal and urgent situations both at the national and ASEAN-wide levels. To date, collaboration for AVSSR is being strengthened according to the ASEAN post-2015 Health Development Agenda and its collaborative framework among concerned countries and development partners. Nevertheless, to achieve the goal, integration of multiple strategies based upon strong policy commitment and uninterrupted engagement among relevant partners are required. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Muangchana, Charung] Natl Vaccine Inst Publ Org, Barasnaradura Infect Dis Inst, Bldg 4,Flr 5,Bldg Barasnaradura Infect Dis Inst, Muang 11000, Nonthaburi, Thailand.
   [Thanormwat, Yothin; Kongsiang, Apichat] Natl Vaccine Inst Publ Org, Bur Vaccine Policy Dev, Bldg 4,Flr 5,Bldg Barasnaradura Infect Dis Inst, Muang 11000, Nonthaburi, Thailand.
RP Muangchana, C (reprint author), Natl Vaccine Inst Publ Org, Barasnaradura Infect Dis Inst, Bldg 4,Flr 5,Bldg Barasnaradura Infect Dis Inst, Muang 11000, Nonthaburi, Thailand.
EM charung.m@nvi.mail.go.th; yothin.t@nvi.mail.go.th;
   apichat.k@nvi.mail.go.th
FU WHOWorld Health Organization; ASEAN Secretariat Office; ASEAN-NDI;
   DCVMN; IVI South Korea; NRA Alliance; NCL Network; Thailand MOPH and
   affiliated departments; Department of Medical Sciences (DMSc); Food and
   Drug Administration (FDA)
FX We are grateful to all speakers, chairs, co-chairs and workshop
   participants from ASEAN countries, whose active participation and
   contribution made both workshops possible. We would like to express
   sincere gratitude to all contributing institutions and organizations,
   including WHO, ASEAN Secretariat Office, ASEAN-NDI, DCVMN, IVI South
   Korea, NRA Alliance, NCL Network, Thailand MOPH and affiliated
   departments, especially the Department of Medical Sciences (DMSc) and
   the Food and Drug Administration (FDA) for their financial and/or
   technical supports. We are indebted to Mr. Stephane Guichard for his
   assistance and contribution to the events; Ms. Lois Privor-Dumm as a
   native English speaker for her proofreading and grammar editing of this
   manuscript; and, Ms. Tasnim Partapurand Dr. Jessada Salathong for their
   invaluable suggestions in developing the Communication and Coordination
   Action Plan (CCAP). We thank the Thailand Center of Excellence Life
   Sciences (TCELS) for the first workshop operation on Foresight technique
   and Dr. Somchai Peerapakorn for his kind guidance in the manuscript
   preparation.
CR [Anonymous], 2015, ASEAN POST 2016 HLTH
   [Anonymous], 2016, PREEMP RESP VACC SUP
   ASEAN Secretariat, 2014, ASEAN COMM MAST PLAN
   ASEAN Secretariat, 2015, ASEAN EC COMM 2015 P
   Costa A, 2003, J INFECT DIS, V187, pS22, DOI 10.1086/368274
   GAVI the Vaccine Alliance, 2016, COUNTR EL SUPP
   NVI and WHO, 2016, COMM COORD ACT PLAN
   NVI and WHO, 2014, FULL M WORKSH ASEAN
   Pan American Health Organization and World Health Organization Regional Office for the Americas, PAHO STRAT FUND
   UNICEF, 2012, SUPPL LOG VACC SEC
   UNICEF Supply Division Vaccine Procurement, 2015, VACC EC HLTH CHECK A
   United Nations, 2015, MILL DEV GOALS REP 2
   World Health Organization, 2016, VACC PROD PRIC PROC
   World Health Organization Regional Office for South -East Asia, 2016, WHO S E AS REG IMM T
NR 14
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 28
PY 2019
VL 37
IS 14
BP 2034
EP 2041
DI 10.1016/j.vaccine.2018.05.017
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HR6VD
UT WOS:000463290400016
PM 30033115
DA 2020-05-12
ER

PT J
AU Koether, K
   Lee, ST
   Belluci, RS
   Garcia, R
   Pfister, JA
   Cunha, PHJ
   Rocha, NS
   Borges, AS
   Oliveira, JP
AF Koether, Karoline
   Lee, Stephen T.
   Belluci, Renata S.
   Garcia, Rodrigo
   Pfister, James A.
   Cunha, Paulo Henrique J.
   Rocha, Noeme S.
   Borges, Alexandre S.
   Oliveira-Filho, Jose P.
TI Spontaneous poisoning by Palicourea marcgravii (Rubiaceae) in a sheep
   herd in southeastern Brazil
SO TOXICON
LA English
DT Article
DE Monofluoracetate; Poisoning; Palicourea; Sheep; Sudden death
ID SODIUM MONOFLUOROACETATE; CATTLE; PLANTS; REGION; STATE; ACID
AB Palicourea marcgravii (Rubiaceae) is considered the most important toxic plant affecting livestock farming in Brazil. This study describes an outbreak of spontaneous poisoning by P. marcgravii in sheep. Forty-nine sheep died while showing clinical signs of sudden death after having access to the plant. During the necropsy, P. marcgravii leaves were observed in the rumens of the animals. Histopathological analysis demonstrated hydropic degeneration of the kidneys. Monofluoracetate concentration obtained in Palicourea samples was 0.53% (5.3 mu g/mg). These findings collectively indicate that the affected animals died from poisoning due to P. marcgravii.
C1 [Koether, Karoline; Belluci, Renata S.; Garcia, Rodrigo; Rocha, Noeme S.; Borges, Alexandre S.; Oliveira-Filho, Jose P.] Sao Paulo State Univ Unesp, Sch Vet Med & Anim Sci, BR-18607400 Botucatu, SP, Brazil.
   [Lee, Stephen T.; Pfister, James A.] ARS, USDA, Poisonous Plant Res Lab, 1150 E 1400 N, Logan, UT 84341 USA.
   [Cunha, Paulo Henrique J.] Univ Fed Goias, Escola Vet & Zootecnia, BR-74001970 Goiania, Go, Brazil.
RP Oliveira, JP (reprint author), Sao Paulo State Univ Unesp, Sch Vet Med & Anim Sci, BR-18607400 Botucatu, SP, Brazil.
EM jose.oliveira-filho@unesp.br
RI de Oliveira-Filho, Jose Paes/A-2140-2013; da Cunha, Paulo Henrique
   Jorge/E-7107-2019; Rocha, Noeme/G-1264-2012
OI de Oliveira-Filho, Jose Paes/0000-0001-9890-2640; da Cunha, Paulo
   Henrique Jorge/0000-0002-1478-3670; Rocha, Noeme/0000-0001-9676-116X
CR Barbosa EDG, 2015, PESQUI VET BRASIL, V35, P209, DOI 10.1590/S0100-736X2015000300001
   Barbosa JD, 2003, PESQUI VET BRASIL, V23, P167, DOI 10.1590/S0100-736X2003000400005
   Carvalho FKDL, 2016, TOXICON, V109, P42, DOI 10.1016/j.toxicon.2015.11.009
   de Arruda FP, 2017, CIENC RURAL, V47, DOI 10.1590/0103-8478cr20160761
   Neto TSD, 2017, TOXICON, V135, P12, DOI 10.1016/j.toxicon.2017.05.025
   DOBEREINER J., 1959, ARQ INST BIOL ANIMAL, V2, P83
   KREBS HC, 1994, TOXICON, V32, P909, DOI 10.1016/0041-0101(94)90369-7
   Lee ST, 2014, J AGR FOOD CHEM, V62, P7345, DOI 10.1021/jf500563h
   Lee ST, 2012, TOXICON, V60, P791, DOI 10.1016/j.toxicon.2012.05.029
   Nogueira VA, 2010, PESQUI VET BRASIL, V30, P533, DOI 10.1590/S0100-736X2010000700004
   Nogueira VA, 2011, PESQUI VET BRASIL, V31, P823, DOI 10.1590/S0100-736X2011001000001
   OLIVEIRA MM, 1963, EXPERIENTIA, V19, P586, DOI 10.1007/BF02151004
   Peixoto T. C., 2012, PESQUI VET BRASIL, V32, P219
   Peixoto TC, 2010, PESQUI VET BRASIL, V30, P1021, DOI 10.1590/S0100-736X2010001200004
   Pessoa CRM, 2013, PESQUI VET BRASIL, V33, P752, DOI 10.1590/S0100-736X2013000600011
   Santos AC, 2014, PESQUI VET BRASIL, V34, P649, DOI 10.1590/S0100-736X2014000700007
   Schons SV, 2012, CIENC RURAL, V42, P1257, DOI 10.1590/S0103-84782012005000047
   Shokry E, 2017, TOXICON, V137, P54, DOI 10.1016/j.toxicon.2017.07.014
   Soto-Blanco b, 2004, REVTA CAATINGA MOSSO, P52
   Tokarnia C.H., 2012, PLANTAS TOXICAS BRAS, P27
   Tokarnia Carlos Hubinger, 1991, Pesquisa Veterinaria Brasileira, V11, P65
   TOKARNIA CH, 1983, PESQUISA VET BRASIL, V3, P75
   TOKARNIA CH, 1986, PESQUISA VET BRASIL, V6, P121
   TOKARNIA CH, 1986, PESQUISA VET BRASIL, V6, P73
   TOKARNIA CH, 1990, PESQUISA VET BRASIL, V10, P1
   Vasconcelos Jackson S. de, 2008, Pesq. Vet. Bras., V28, P457, DOI 10.1590/S0100-736X2008001000003
NR 26
TC 0
Z9 0
U1 0
U2 3
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD APR 1
PY 2019
VL 161
BP 1
EP 3
DI 10.1016/j.toxicon.2019.02.015
PG 3
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA HR0EY
UT WOS:000462802300001
PM 30825462
DA 2020-05-12
ER

PT J
AU Kocyigit, A
   Guler, EM
   Kaleli, S
AF Kocyigit, Abdurrahim
   Guler, Eray Metin
   Kaleli, Suleyman
TI Anti-inflammatory and antioxidative properties of honey bee venom on
   Freund's Complete Adjuvant-induced arthritis model in rats
SO TOXICON
LA English
DT Article
DE Apitherapy; Honey bee venom; Inflammation; DNA damage; Immunomodulation;
   Arthritis
ID RHEUMATOID-ARTHRITIS; INFLAMMATORY ACTIVITY; LIPID-PEROXIDATION;
   DNA-DAMAGE; INTERFERON; EPIDEMIOLOGY; MELITTIN; GAMMA
AB The aim of this study was to assess anti-inflammatory, anti-oxidant, anti-genotoxic and immunomodulatory effects of honey bee venom (HBV) on adjuvant-induced arthritis in rats. Thirty-five rats were equally divided into a negative control (NC), a positive control (PC) and low, moderate and high doses (2, 4 and 20 mg/kg, respectively) of HBV treatment groups. Freund's Complete Adjuvant (FCA) was given to the rats to form arthritis. The treatment groups were treated with HBV for 3 consecutive weeks. After the treatment, plasma IL-1 beta, IL-6, TNF-alpha, IFN-gamma and TGF-beta 1, total oxidant status (TOS), total antioxidant status (TAS) and myeloperoxidase (MPO) activities and mononuclear leukocyte (MNL) DNA damage levels were measured. Oxidative stress index (OSI) was calculated. IL-beta, IL-6, TNF-alpha, TGF-beta 1, IFN-gamma, TOS, OSI, DNA damage levels and MPO activities were significantly higher and TAS levels were lower in the PC group than the NC. After low-doses of HBV treatment IL-1 beta, IL-6, TNF-alpha, TGF-beta 1, TOS, OSI, MPO and MNL-DNA damage levels significantly decreased according to the PC, while IFN-gamma and TAS levels increased. The differences in moderate and high-dose HBV treatment groups were not as significant as low HBV doses. Low-doses of HBV has been shown to treat RA with anti-inflammatory and antioxidant effects, by preventing DNA damage. However, these effects have not been observed as strong at higher doses of HBV. In summary, HBV may be an effective option to ameliorate RA, but the optimization of the therapeutic dose has a crucial role.
C1 [Kocyigit, Abdurrahim; Guler, Eray Metin] Bezmialem Vakif Univ, Med Fac, Dept Med Biochem, Istanbul, Turkey.
   [Kocyigit, Abdurrahim; Guler, Eray Metin] Bezmialem Vakif Univ, Adv Res & Applicat Ctr Tradit & Complementary Med, Istanbul, Turkey.
   [Kaleli, Suleyman] Sakarya Univ, Med Fac, Dept Med Biol, Sakarya, Turkey.
RP Kocyigit, A (reprint author), Bezmialem Vakif Univ, Med Fac, Dept Med Biochem, Istanbul, Turkey.
EM akocyigit@bezmialem.edu.tr
RI Guler, Eray Metin/AAC-6551-2020; Kocyigit, Abdurrahim/P-8685-2019;
   Kaleli, Suleyman/F-2072-2018
OI Guler, Eray Metin/0000-0003-4351-1719; Kocyigit,
   Abdurrahim/0000-0003-2335-412X; Kaleli, Suleyman/0000-0002-6043-2521
CR Abhari K, 2016, FOOD NUTR RES, V60, DOI 10.3402/fnr.v60.30876
   Altindag O, 2007, CLIN BIOCHEM, V40, P167, DOI 10.1016/j.clinbiochem.2006.10.006
   Baskol G, 2006, CELL BIOCHEM FUNCT, V24, P307, DOI 10.1002/cbf.1257
   BRADLEY PP, 1982, J INVEST DERMATOL, V78, P206, DOI 10.1111/1523-1747.ep12506462
   Cascao R, 2010, AUTOIMMUN REV, V9, P531, DOI 10.1016/j.autrev.2009.12.013
   CHANG YH, 1979, AGENTS ACTIONS, V9, P205, DOI 10.1007/BF02024736
   Cheon H, 2002, CLIN EXP IMMUNOL, V127, P547, DOI 10.1046/j.1365-2249.2002.01785.x
   Dossey AT, 2010, NAT PROD REP, V27, P1737, DOI 10.1039/c005319h
   EISEMAN JL, 1982, BIOCHEM PHARMACOL, V31, P1139, DOI 10.1016/0006-2952(82)90354-9
   Erel O, 2004, CLIN BIOCHEM, V37, P112, DOI 10.1016/j.clinbiochem.2003.10.014
   Erel O, 2005, CLIN BIOCHEM, V38, P1103, DOI 10.1016/j.clinbiochem.2005.08.008
   FAVA R, 1989, J EXP MED, V169, P291, DOI 10.1084/jem.169.1.291
   Gomes A, 2011, ETHNO BIOL USAGE ZOO
   Gomes A, 2014, TOXICON, V90, P106, DOI 10.1016/j.toxicon.2014.07.002
   Im E. J., 2016, EVID BASED COMPLEMEN, V2016
   Jung HJ, 2005, J ETHNOPHARMACOL, V97, P359, DOI 10.1016/j.jep.2004.11.026
   Karimi A, 2012, IRAN J PHARM RES, V11, P671
   Kim EY, 2017, CYTOKINE, V98, P87, DOI 10.1016/j.cyto.2017.04.012
   Kim SJ, 2010, AM J CHINESE MED, V38, P921, DOI 10.1142/S0192415X10008354
   Kim WU, 2000, CLIN EXP IMMUNOL, V119, P175, DOI 10.1046/j.1365-2249.2000.01095.x
   Kvien TK, 2004, PHARMACOECONOMICS, V22, P1
   Kwon YB, 2001, PAIN, V90, P271, DOI 10.1016/S0304-3959(00)00412-7
   Lee JY, 2005, IN VIVO, V19, P801
   LEMMEL EM, 1988, RHEUMATOL INT, V8, P87, DOI 10.1007/BF00271840
   Majithia V, 2007, AM J MED, V120, P936, DOI 10.1016/j.amjmed.2007.04.005
   Martin-Sanchez F, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.390
   MCGAHON AJ, 1995, METHOD CELL BIOL, V46, P153
   Milovanovic A, 2004, CLIN CHIM ACTA, V343, P237, DOI 10.1016/j.cccn.2003.12.030
   Moreno M, 2015, TOXINS, V7, P1126, DOI 10.3390/toxins7041126
   NAKAJIMA H, 1991, AGENTS ACTIONS, V34, P63, DOI 10.1007/BF01993239
   Neergheen-Bhujun VS, 2014, J HERB MED, V4, P1, DOI 10.1016/j.hermed.2013.11.002
   NEWBOULD BB, 1963, BRIT J PHARM CHEMOTH, V21, P127, DOI 10.1111/j.1476-5381.1963.tb01508.x
   Nipate SS, 2015, IMMUNOPHARM IMMUNOT, V37, P171, DOI 10.3109/08923973.2015.1009996
   Pohlers D, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2217
   Rajaiah R., 2010, J BIOL CHEM JBC M, VM110
   Saini SS, 1997, BIOCHEM BIOPH RES CO, V238, P436, DOI 10.1006/bbrc.1997.7295
   Sangha O, 2000, RHEUMATOLOGY, V39, P3, DOI 10.1093/rheumatology/39.suppl_2.3
   Sarban S, 2005, CLIN BIOCHEM, V38, P981, DOI 10.1016/j.clinbiochem.2005.08.003
   Schroder K, 2004, J LEUKOCYTE BIOL, V75, P163, DOI 10.1189/jlb.0603252
   SINGH NP, 1988, EXP CELL RES, V175, P184, DOI 10.1016/0014-4827(88)90265-0
   Smolen JS, 2003, NAT REV DRUG DISCOV, V2, P473, DOI 10.1038/nrd1109
   Son DJ, 2007, PHARMACOL THERAPEUT, V115, P246, DOI 10.1016/j.pharmthera.2007.04.004
   Tuncel J, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155936
   van de Putte BA, 2004, ANN RHEUM DIS, V63, P508, DOI 10.1136/ard.2003.013052
   van der Linden MPM, 2009, ARTHRITIS RHEUM, V60, P2242, DOI 10.1002/art.24721
   van der Poll T, 2008, LANCET INFECT DIS, V8, P32, DOI 10.1016/S1473-3099(07)70265-7
   VANDENBERG WB, 1994, CLIN EXP IMMUNOL, V95, P237
   Xie JG, 2018, EUR J INTEGR MED, V20, P200, DOI 10.1016/j.eujim.2018.05.008
   Zhang S., 2018, BEE VENOM THERAPY PO
NR 49
TC 1
Z9 1
U1 2
U2 8
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD APR 1
PY 2019
VL 161
BP 4
EP 11
DI 10.1016/j.toxicon.2019.02.016
PG 8
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA HR0EY
UT WOS:000462802300002
PM 30825463
DA 2020-05-12
ER

PT J
AU Sun, J
   Zhang, HS
   Li, HJ
   Zhang, YZ
   He, Q
   Lu, JJ
   Yin, Y
   Sun, CY
AF Sun, Jian
   Zhang, Hong-Shun
   Li, Hai-Jiao
   Zhang, Yi-Zhe
   He, Qian
   Lu, Jun-Jia
   Yin, Yu
   Sun, Cheng-Ye
TI A case study of Lepiota brunneoincarnata poisoning with endoscopic
   nasobiliary drainage in Shandong, China
SO TOXICON
LA English
DT Review
DE Lepiota brunneoincarnata; Poisoning; Endoscopic nasobiliary drainage;
   Amatoxins
ID CYCLOPEPTIDE TOXINS; AMANITA-PHALLOIDES; MUSHROOM; AMATOXINS; LETHAL;
   INGESTION; KINETICS
AB The most frequently reported fatal Lepiota ingestions are due to L. brunneoincarnata. We present a case of L. brunneoincarnata poisoning with endoscopic nasobiliary drainage known to be the first in China. The patient suffered gastrointestinal symptoms 9 h post ingestion of mushrooms. The patient was hospitalized 4 days after eating the mushrooms with jaundice. The peak ALT, AST, APTT, TBIL and DBIL values of the patient were as follow: ALT, 2980 U/L (day 4 post ingestion); AST, 1910 U/L (day 4 post ingestion); APTT, 92.8 seconds (day 8 post ingestion), TBIL, 136 mu mol/L (day 10 post ingestion), DBIL 74 mu mol/L (day 10 post ingestion). UPLC-ESI-MS/MS was used to detect the peptide toxins in the mushroom and biological samples from the patient. We calculated that the patient may have ingested a total of 29.05 mg amatoxin from 300 g mushrooms, consisting of 19.91 mg alpha-amanitin, 9.1 mg beta-amanitin, and 0.044 mg gamma-amanitin. Amatoxins could be detected in bile even on day 6 after ingestion of L. brunneoincarnata. With rehydration, endoscopic nasobiliary drainage and intravenous infusion of Legalon SIL, the patient recovered after serious hepatotoxicity developed.
C1 [Sun, Jian] Ningxia Med Univ, Inst Publ Hlth & Management, Ningxia 750004, Peoples R China.
   [Zhang, Hong-Shun; Li, Hai-Jiao; Zhang, Yi-Zhe; He, Qian; Lu, Jun-Jia; Yin, Yu; Sun, Cheng-Ye] Chinese Ctr Dis Control & Prevent, Natl Inst Occupat Hlth & Poison Control, Room 318,29th Bldg,Nan Wei Rd, Beijing 100050, Peoples R China.
RP Yin, Y (reprint author), Chinese Ctr Dis Control & Prevent, Natl Inst Occupat Hlth & Poison Control, Room 318,29th Bldg,Nan Wei Rd, Beijing 100050, Peoples R China.; Sun, CY (reprint author), Chinese Ctr Dis Control & Prevent, Natl Inst Occupat Hlth & Poison Control, Room 502,27th Bldg,Nan Wei Rd, Beijing 100050, Peoples R China.
EM yymssyn@126.com; suncy@chinacdc.cn
FU Scientific Basic Research Foundation of the Ministry of Science and
   Technology, China [2015FY111400]; National Nature Science Foundation of
   China Youth Science Foundation [31501814]
FX We are very thankful to Scientific Basic Research Foundation of the
   Ministry of Science and Technology, China (2015FY111400) and National
   Nature Science Foundation of China Youth Science Foundation
   (No.31501814) for providing the necessary fund for this research.
CR BUSI C, 1979, NEW ENGL J MED, V300, P800
   Cai Q, 2016, MYCOLOGIA, V108, P993, DOI 10.3852/16-008
   Chen Z, 2003, MYCOSYSTEMA
   Chen ZH, 2014, FUNGAL DIVERS, V64, P123, DOI 10.1007/s13225-013-0260-7
   Diaz J. H, 2017, WILDERNESS ENV MED
   Diaz JH, 2005, CRIT CARE MED, V33, P427, DOI 10.1097/01.CCM.0000153531.69448.49
   Enjalbert F, 2002, J TOXICOL-CLIN TOXIC, V40, P715, DOI 10.1081/CLT-120014646
   FAULSTICH H, 1985, ARCH TOXICOL, V56, P190, DOI 10.1007/BF00333425
   FAULSTICH H, 1973, DEUT MED WOCHENSCHR, V98, P2258
   JAEGER A, 1993, J TOXICOL-CLIN TOXIC, V31, P63, DOI 10.3109/15563659309000374
   Jander S, 2000, TREATMENT AMANITA PH
   Karlson-Stiber C, 2003, TOXICON, V42, P339, DOI 10.1016/S0041-0101(03)00238-1
   Kaya E, 2013, TOXICON, V76, P225, DOI 10.1016/j.toxicon.2013.10.008
   Kervegant M, 2013, WILD ENVIRON MED, V24, P170, DOI 10.1016/j.wem.2012.11.002
   Kose M, 2015, WILD ENVIRON MED, V26, P350, DOI 10.1016/j.wem.2014.12.025
   Letschert K, 2006, TOXICOL SCI, V91, P140, DOI 10.1093/toxsci/kfj141
   Madhok M, 2006, PEDIATR EMERG CARE, V22, P177, DOI 10.1097/01.pec.0000202459.49731.33
   Magdalan J, 2011, HUM EXP TOXICOL, V30, P38, DOI 10.1177/0960327110368418
   Parnmen S, 2016, J TOXICOL SCI, V41, P65, DOI 10.2131/jts.41.65
   Patowary B. S, 2010, J COLL MED SCI NEPAL, V6
   PAYDAS S, 1990, BRIT J CLIN PRACT, V44, P450
   RAMIREZ P, 1993, J HEPATOL, V19, P51, DOI 10.1016/S0168-8278(05)80175-8
   Santi L, 2012, INT J HEPATOL, DOI 10.1155/2012/487480
   Sgambelluri RM, 2014, TOXINS, V6, P2336, DOI 10.3390/toxins6082336
   Sun J, 2017, HUM EXP TOXICOL
   Sun J, 2017, TOXICON
   Tang SS, 2016, TOXICON, V120, P78, DOI 10.1016/j.toxicon.2016.07.018
   Thiel C, 2011, TOXICOL LETT, V203, P142, DOI 10.1016/j.toxlet.2011.03.016
   Ulrich M, 2012, CURR PHARM BIOTECHNO, V13
   Ward J, 2013, J EMERG MED, V44, P116, DOI 10.1016/j.jemermed.2012.02.020
   Watling M. I. R, 1991, EDINB J BOT, V48, P91
   Wei JH, 2017, TOXICON, V133, P26, DOI 10.1016/j.toxicon.2017.04.012
   Yilmaz I, 2015, WILD ENVIRON MED, V26, P491, DOI 10.1016/j.wem.2015.08.002
   Yilmaz I, 2014, TOXICON, V87, P68, DOI 10.1016/j.toxicon.2014.05.019
   Yimaz A, 2006, SAUDI MED J, V27, P858
   Zhou Jing, 2016, Chinese Journal of Emergency Medicine, V25, P724
NR 36
TC 0
Z9 1
U1 7
U2 10
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD APR 1
PY 2019
VL 161
BP 12
EP 16
DI 10.1016/j.toxicon.2019.02.017
PG 5
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA HR0EY
UT WOS:000462802300003
PM 30831147
DA 2020-05-12
ER

PT J
AU Yu, M
   Peng, Z
   Liao, YX
   Wang, LL
   Li, D
   Qin, CY
   Hu, JW
   Wang, ZT
   Cai, MY
   Cai, Q
   Zhou, F
   Shi, SJ
   Yang, W
AF Yu, Miao
   Peng, Zhao
   Liao, Yuxiao
   Wang, Liangliang
   Li, Dan
   Qin, Chenyuan
   Hu, Jiawei
   Wang, Zhenting
   Cai, Mengyao
   Cai, Qiang
   Zhou, Feng
   Shi, Shaojun
   Yang, Wei
TI Deoxynivalenol-induced oxidative stress and Nrf2 translocation in
   maternal liver on gestation day 12.5 d and 18.5 d
SO TOXICON
LA English
DT Article
DE Deoxynivalenol (DON); Hepatotoxicity; Oxidative stress; HO-1; Nrf2
   translocation
ID NF-KAPPA-B; FUSARIUM MYCOTOXINS; NRF2/HO-1 PATHWAY; UP-REGULATION;
   SYSTEM; MOUSE; ANTIOXIDANTS; ACTIVATION; EXPOSURE; TOXIN
AB Deoxynivalenol (DON) contamination is indicated as a worldwide problem since it causes economic losses for the grain and is a potential threat to both animal and human health. This study concentrated on DON-induced oxidative damage and the accompanying nuclear factor erythroid 2-related factor 2 (Nrf2) translocation during DON-induced maternal hepatotoxicity. The 0, 1.0 and 2.5 mg/kg/day of DON were used as doses for the experiment during gestation days. DON slightly increased the levels of ALT and AST in GD12.5 d instead of GD18.5 d. Oxidative stress and anti-oxidization system were both found to be activated in the experiment which marked by ROS, MDA and GSH increasing, especially on GD12.5 d. The levels of HO-1 were significantly increased by DON exposure at different two time points. Moreover, Nrf2 translocation appeared both in GD 12.5 d and GD 18.5 d. In conclusion, DON-induced ROS accumulation may cause maternal liver damage in the initial stages, but the related stimulation of Nrf2/HO-1 pathway improves the removal of ROS and decreases the level of oxidative stress thereby protecting the liver damage. Therefore, upregulating the Nrf2-dependent response is one of the potential methods that protects maternal liver from DON-induced oxidative damage.
C1 [Yu, Miao] Jiangnan Univ, Wuxi Sch Med, Dept Publ Hlth & Prevent Med, 1800 Lihu Rd, Wuxi 214122, Peoples R China.
   [Peng, Zhao; Liao, Yuxiao; Wang, Liangliang; Li, Dan; Qin, Chenyuan; Hu, Jiawei; Wang, Zhenting; Cai, Mengyao; Yang, Wei] Huazhong Univ Sci & Technol, Hubei Key Lab Food Nutr & Safety, Dept Nutr & Food Hyg, Sch Publ Hlth,Tongji Med Coll, 13 Hangkong Rd, Wuhan 430030, Hubei, Peoples R China.
   [Cai, Qiang] Suzhou Octech Co Ltd, SND, 8 Jinfeng Rd, Suzhou 215163, Peoples R China.
   [Zhou, Feng] Suzhou Globalpeak High Tech Co Ltd, SND, 8 Jinfeng Rd, Suzhou 215163, Peoples R China.
   [Shi, Shaojun] Huazhong Univ Sci & Technol, Union Hosp, Dept Pharm, Tongji Med Coll, Wuhan 430022, Hubei, Peoples R China.
RP Yang, W (reprint author), Huazhong Univ Sci & Technol, Hubei Key Lab Food Nutr & Safety, Dept Nutr & Food Hyg, Sch Publ Hlth,Tongji Med Coll, 13 Hangkong Rd, Wuhan 430030, Hubei, Peoples R China.
EM yw8278@hotmail.com
FU National Natural Science Foundation of China (NSFC)National Natural
   Science Foundation of China [81741018, 81502811, 81803199, 81874326];
   Fundamental Research Funds for the Central UniversitiesFundamental
   Research Funds for the Central Universities [JUSRP11752]; Wuxi National
   Health and Family Planning Commission [Z201813]; Department of Public
   Health and Preventive Medicine, Wuxi School of Medicine, Jiangnan
   University [JUGW201803]; Natural Science Foundation of Hubei
   ProvinceNatural Science Foundation of Hubei Province [ZRMS2017000504]
FX This study was supported by the National Natural Science Foundation of
   China (NSFC No. 81741018, 81502811, 81803199 and 81874326), Fundamental
   Research Funds for the Central Universities (JUSRP11752), Wuxi National
   Health and Family Planning Commission (Major scientific projects,
   Z201813), Department of Public Health and Preventive Medicine, Wuxi
   School of Medicine, Jiangnan University (JUGW201803) and Natural Science
   Foundation of Hubei Province (ZRMS2017000504). We also would like to
   thank all the participants for their contribution to this study.
CR Bellezza I, 2012, J NUTR BIOCHEM, V23, P1583, DOI 10.1016/j.jnutbio.2011.10.012
   Thanh BVL, 2016, MYCOTOXIN RES, V32, P99, DOI 10.1007/s12550-016-0245-y
   Chen LK, 2017, J APPL TOXICOL, V37, P60, DOI 10.1002/jat.3359
   Danicke S, 2006, TOXICOL LETT, V165, P297, DOI 10.1016/j.toxlet.2006.05.006
   Del Favero G, 2018, TOXICOL LETT, V295, P424, DOI 10.1016/j.toxlet.2018.07.007
   Ding Y, 2015, MOL NEUROBIOL, V52, P1430, DOI 10.1007/s12035-014-8929-9
   Ficheux AS, 2012, TOXICON, V60, P1171, DOI 10.1016/j.toxicon.2012.08.001
   FORSELL JH, 1986, FOOD CHEM TOXICOL, V24, P213, DOI 10.1016/0278-6915(86)90231-0
   Frankic T, 2006, FOOD CHEM TOXICOL, V44, P1838, DOI 10.1016/j.fct.2006.06.002
   Hou YJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060374
   Jiang X, 2013, TOXICOL LETT, V219, P65, DOI 10.1016/j.toxlet.2013.02.022
   Jung KA, 2010, MOLECULES, V15, P7266, DOI 10.3390/molecules15107266
   Kelsey NA, 2010, MOLECULES, V15, P7792, DOI 10.3390/molecules15117792
   Li F, 2018, BIOMED PHARMACOTHER, V108, P1216, DOI 10.1016/j.biopha.2018.09.144
   Liao YX, 2018, FOOD CHEM TOXICOL, V112, P342, DOI 10.1016/j.fct.2018.01.013
   Park SY, 2011, IMMUNOL LETT, V139, P93, DOI 10.1016/j.imlet.2011.05.007
   Pedruzzi LM, 2012, BIOCHIMIE, V94, P2461, DOI 10.1016/j.biochi.2012.07.015
   Pestka JJ, 2010, ARCH TOXICOL, V84, P663, DOI 10.1007/s00204-010-0579-8
   RIZZO AF, 1994, J VET MED A, V41, P81, DOI 10.1111/j.1439-0442.1994.tb00070.x
   Sahu SC, 2010, J APPL TOXICOL, V30, P566, DOI 10.1002/jat.1527
   Schipper HM, 2004, FREE RADICAL BIO MED, V37, P1995, DOI 10.1016/j.freeradbiomed.2004.09.015
   Singh S, 2010, FREE RADICAL RES, V44, P1267, DOI 10.3109/10715762.2010.507670
   Suzuki Mikiko, 2016, Current Opinion in Toxicology, V1, P29, DOI 10.1016/j.cotox.2016.10.001
   Thomas NS, 2019, TOXICOL IN VITRO, V54, P317, DOI 10.1016/j.tiv.2018.10.018
   Tsai J. J, 2018, BLOOD
   Wang LL, 2019, TRENDS FOOD SCI TECH, V83, P41, DOI 10.1016/j.tifs.2018.11.003
   Wu SC, 2015, MOL NUTR FOOD RES, V59, P1930, DOI 10.1002/mnfr.201500181
   Xu LL, 2018, FOOD CHEM, V266, P557, DOI 10.1016/j.foodchem.2018.05.111
   Yu M, 2018, TOXINS, V10, DOI 10.3390/toxins10090370
   Yu M, 2015, J FUNCT FOODS, V14, P767, DOI 10.1016/j.jff.2015.03.004
   Yu M, 2013, REGUL TOXICOL PHARM, V66, P279, DOI 10.1016/j.yrtph.2013.04.005
NR 31
TC 3
Z9 3
U1 5
U2 12
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD APR 1
PY 2019
VL 161
BP 17
EP 22
DI 10.1016/j.toxicon.2019.02.018
PG 6
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA HR0EY
UT WOS:000462802300004
PM 30826469
DA 2020-05-12
ER

PT J
AU Zheng, RJ
   Guan, QM
   Zheng, M
   Huang, ZX
   Huang, HN
   Fu, WS
   Lin, SE
   Yang, Y
AF Zheng, Renjin
   Guan, Qiumei
   Zheng, Mi
   Huang, Zongxiu
   Huang, Hongnan
   Fu, Wusheng
   Lin, Shouer
   Yang, Yan
TI Toxin and toxicity identification of mangrove horseshoe crab
   Carcinoscorpius rotundicauda collected from South China
SO TOXICON
LA English
DT Article
DE Mangrove horseshoe crab; Carcinoscorpius rotundicauda; Tetrodotoxin;
   Paralytic shellfish poisoning; LC-MS/MS1
ID TETRODOTOXIN; BACTERIA
AB The presence of paralytic shellfish poisoning (PSP), diarrhetic Shellfish Poisoning (DSP), tetrodotoxin gm and its analogues (11-oxoTTX, 4.9-anhydro-11-oxoTTX, 4.9-anhydroTTX, 5-deoxyTTX, 5.11-dideoxyTTX, 5.6.11-trideoxyTTX and 4.9-anhydro-5.6.11-trideoxy TTX) were initially investigated in Carcinoscorpius rotundicauda collected from south China with Liquid chromatography-tandem mass spectrometry (LC-MS-MS) and mouse bioassay. The TTX toxicity was 10.8 +/- 3.9 MU/g muscle, 6.3 +/- 0.6 MU/g viscera and 6.3 +/- 0.6 MU/g eggs in mean value. Merely dcGTX2 and dcSTX were detected in ten Specimens, ranging from 0.01 to 0.77 mu g/g. Analyses suggested that these Carcinoscorpius rotundicauda contain TTX and its analogues as the major toxin and PSPs as the minor, respectively. Besides, no DSPs were found.
C1 [Zheng, Renjin; Huang, Zongxiu; Huang, Hongnan; Fu, Wusheng; Lin, Shouer; Yang, Yan] Fujian Ctr Dis Control & Prevent, Fujian Prov Key Lab Zoonosis Res, Phys & Chem Anal Dept, Fuzhou 350001, Fujian, Peoples R China.
   [Guan, Qiumei] Fujian Med Univ, Fuzhou 350004, Fujian, Peoples R China.
   [Zheng, Mi] Second Peoples Hosp Fujian, Fuzhou 350001, Fujian, Peoples R China.
RP Zheng, RJ (reprint author), Fujian Ctr Dis Control & Prevent, Fujian Prov Key Lab Zoonosis Res, Phys & Chem Anal Dept, Fuzhou 350001, Fujian, Peoples R China.
EM 402109842@qq.com
OI Zheng, Renjin/0000-0001-7242-9621
FU Natural Science Foundation of Fujian ProvinceNatural Science Foundation
   of Fujian Province [2015J01296]; Youth Scientific Research Project of
   Fujian Health and Family Planning Commission [2014-1-27]
FX This study was supported by the fund of the Natural Science Foundation
   of Fujian Province (grant no. 2015J01296), Youth Scientific Research
   Project of Fujian Health and Family Planning Commission (grant no.
   2014-1-27).
CR Dao H, 2009, FISHERIES SCI, V75, P435, DOI 10.1007/s12562-008-0041-5
   Gu M. X., 2015, ZHE JIANG PREV MED, P1152
   Huang HN, 2016, ANAL LETT, V49, P2377, DOI 10.1080/00032719.2016.1149484
   HWANG DF, 1991, MAR BIOL, V111, P65, DOI 10.1007/BF01986347
   KUNGSUWAN A, 1988, NIPPON SUISAN GAKK, V54, P1799
   KUNGSUWAN A, 1987, B JPN SOC SCI FISH, V53, P261
   Liao Y, 2000, Wei Sheng Yan Jiu, V29, P184
   Liao Yong-yan, 2006, Journal of Tropical Oceanography, V25, P85
   Liu L. L., 2016, CHIN PREV MED, P414
   Ngy L, 2007, TOXICON, V49, P843, DOI 10.1016/j.toxicon.2006.12.004
   NOGUCHI T, 1987, MAR BIOL, V94, P625, DOI 10.1007/BF00431409
   Rodriguez P, 2012, FOOD CHEM, V132, P1103, DOI 10.1016/j.foodchem.2011.11.081
   SIMIDU U, 1987, APPL ENVIRON MICROB, V53, P1714, DOI 10.1128/AEM.53.7.1714-1715.1987
   Tanu MB, 1999, J FOOD HYG SOC JPN, V40, P426
   Wu H, 2010, J GUANGDONG MED COLL, V28, P88
   Zhuo LY, 2013, FOOD CHEM, V137, P115, DOI 10.1016/j.foodchem.2012.10.010
NR 16
TC 1
Z9 1
U1 0
U2 5
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD APR 1
PY 2019
VL 161
BP 23
EP 27
DI 10.1016/j.toxicon.2019.02.002
PG 5
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA HR0EY
UT WOS:000462802300005
PM 30796930
DA 2020-05-12
ER

PT J
AU Boucaud-Maitre, D
   Cachet, X
   Bouzidi, C
   Riffault-Valois, L
   Dupuy, C
   Garnier, R
   Langrand, J
AF Boucaud-Maitre, Denis
   Cachet, Xavier
   Bouzidi, Chouaha
   Riffault-Valois, Ludivine
   Dupuy, Caroline
   Garnier, Robert
   Langrand, Jerome
TI Severity of manchineel fruit (Hippomane mancinella) poisoning: A
   retrospective case series of 97 patients from French Poison Control
   Centers
SO TOXICON
LA English
DT Article
DE Hippomane mancinella; Manchineel fruit; Bradycardia; Physostigmine
ID TOXIC PRINCIPLES
AB In this retrospective series of 97 cases of manchineel fruit ingestion reported to French Poison Control Centers between 2009 and 2017, we investigated cases of poisoning due to manchineel fruit (from the Hippomane mancinella tree). This fruit is known to be responsible for oropharyngeal and gastrointestinal tract lesions and possibly hypotension and bradycardia (previously attributed to the presence of physostigmine). The most commonly observed clinical signs were oropharyngeal pain, abdominal pain, diarrhea and oropharyngeal irritation. No major gastrointestinal tract lesions were observed in the five cases in which upper gastrointestinal (GI) endoscopy was performed. One case of laryngeal edema and one case of bradycardia were observed, but analysis of the harvested fruits did not confirm the presence of physostigmine. Ingestion of manchineel fruit can cause mild abdominal pain and digestive irritation, requiring medical attention. Rarely, when several fruits have been ingested, severe oropharyngeal injury or hemodynamic disorders may require otorhinolaryngological consultation or cardiac monitoring for several hours, respectively.
C1 [Boucaud-Maitre, Denis] Ctr Hosp BasseTerre, Dispositif Toxicovigilance, Basse Terre, Guadeloupe, France.
   [Boucaud-Maitre, Denis] CHU Guadeloupe, Direct Rech Clin & Innovat, Pointe a Pitre, Guadeloupe, France.
   [Cachet, Xavier; Bouzidi, Chouaha] Univ Paris 05, Sorbonne Paris Cite, CNRS, Lab Pharmacognosie,Fac Pharm Paris,COMETE,UMR 863, Paris, France.
   [Riffault-Valois, Ludivine] Fac Pharm Strasbourg, Equipe Chim Analyt Mol BioAct & Pharmacognosie, UMR7178, IPHC, Illkirch Graffenstaden, France.
   [Dupuy, Caroline] CHU Guadeloupe, SMUR 971, SAMU, Pointe a Pitre, Guadeloupe, France.
   [Garnier, Robert; Langrand, Jerome] Hop Fernand Widal, Ctr Antipoison Paris, Paris, France.
   [Garnier, Robert; Langrand, Jerome] Hop Lariboisiere Femand Widal, AP HP, Federat Toxicol FeTox, Paris, France.
   [Garnier, Robert; Langrand, Jerome] INSERM, UMRS 1144, Paris, France.
RP Boucaud-Maitre, D (reprint author), CHU Guadeloupe, Route Chauvel, F-97159 Pointe a Pitre, Guadeloupe, France.
EM denis.boucaud@gmail.com
RI Garnier, Robert/AAJ-2294-2020
CR Blanc-Brisset I, 2007, Med Trop (Mars), V67, P311
   Blue LM, 2011, J TRAVEL MED, V18, P422, DOI 10.1111/j.1708-8305.2011.00568.x
   Botterel F, 2000, PRESSE MED, V29, P81
   Bygbjerg I C, 1991, Ugeskr Laeger, V154, P27
   Dupuy C, 2018, REV PRATICIEN, V4, P407
   LAUTER WM, 1955, J AM PHARM ASSOC, V44, P361, DOI 10.1002/jps.3030440616
   MERLE H, 1995, J FR OPHTALMOL, V18, P461
   Persson HE, 1998, J TOXICOL-CLIN TOXIC, V36, P205, DOI 10.3109/15563659809028940
   PITTS JF, 1993, BRIT J OPHTHALMOL, V77, P284, DOI 10.1136/bjo.77.5.284
   RAO KV, 1974, PLANTA MED, V25, P166, DOI 10.1055/s-0028-1097927
   Sparman A, 2009, W INDIAN MED J, V58, P65
   Strickland, 2000, BMJ, V321, P428, DOI 10.1136/bmj.321.7258.428
   ZARGAR SA, 1992, AM J GASTROENTEROL, V87, P337
NR 13
TC 0
Z9 1
U1 3
U2 7
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD APR 1
PY 2019
VL 161
BP 28
EP 32
DI 10.1016/j.toxicon.2019.02.014
PG 5
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA HR0EY
UT WOS:000462802300006
PM 30826471
DA 2020-05-12
ER

PT J
AU Stonecipher, CA
   Lee, ST
   Green, BT
   Cook, D
   Welch, KD
   Pfister, JA
   Gardner, DR
AF Stonecipher, Clinton A.
   Lee, Stephen T.
   Green, Benedict T.
   Cook, Daniel
   Welch, Kevin D.
   Pfister, James A.
   Gardner, Dale R.
TI Evaluation of noninvasive specimens to diagnose livestock exposure to
   toxic larkspur (Delphinium spp.)
SO TOXICON
LA English
DT Article
DE Earwax; Nasal mucus; Oral fluid; Methyllycaconitine; Deltaline;
   Delphinium
ID NORDITERPENOID ALKALOIDS; TALL LARKSPUR; DITERPENOID ALKALOIDS;
   METHYLLYCACONITINE; SAMPLES; EARWAX
AB Larkspurs (Delphinium spp.) are native perennial plants that have a serious toxic potential to cattle on foothill and mountain rangelands in the western United States. Livestock death due to larkspur toxicity is attributed to norditerpenoid alkaloids. Diagnosing plant poisonings in livestock is often challenging. The objective of this study was to evaluate the use of three matrices; earwax, oral fluid, and nasal mucus, as noninvasive specimens to determine livestock exposure to larkspurs. Reversed phase high performance liquid chromatography high resolution mass spectrometry was used to analyze for norditerpene alkaloids, in all three matrices, in cattle administered a single dose of larkspur. Earwax, oral fluid, and nasal mucus were collected over 6 days post dosing. Methyllycaconitine (MLA) and deltaline concentrations in earwax ranged from 0.4 +/- 0.1 to 0.2 +/- 0.06 and 0.6 +/- 0.5 to 0.11 +/- 0.08 ng/mg, respectively. MLA and deltaline concentrations in oral fluid ranged from 0.08 +/- 0.03 to 0.01 +/- 0.002 ng/mg and 0.07 +/- 0.03 ng/mg to not detected (ND), respectively. MLA and deltaline concentrations in nasal mucus ranged from 0.2 +/- 0.13 to 0.03 +/- 0.01 ng/mg and 0.2 +/- 0.12 ng/mg to ND, respectively. The ability to detect differing norditerpene alkaloid chemotypes from two different Delphinium spp. was also possible in the three matrices. This study demonstrates the potential of earwax, oral fluid, and nasal mucus as noninvasive specimens for chemical analyses to aid in the diagnosis of livestock that may have been exposed to and poisoned by larkspur plants.
C1 [Stonecipher, Clinton A.; Lee, Stephen T.; Green, Benedict T.; Cook, Daniel; Welch, Kevin D.; Pfister, James A.; Gardner, Dale R.] ARS, Poisonous Plant Res Lab, USDA, 1150 E 1400 N, Logan, UT 84341 USA.
RP Stonecipher, CA (reprint author), ARS, Poisonous Plant Res Lab, USDA, 1150 E 1400 N, Logan, UT 84341 USA.
EM Clint.Stonecipher@ars.usda.gov
FU U.S. Department of Agriculture, Agricultural Research ServiceUnited
   States Department of Agriculture (USDA)
FX Authors would like to thank Charles Hailes, Scott Larsen, and Rex Probst
   for technical assistance. This research was supported by U.S. Department
   of Agriculture, Agricultural Research Service.
CR Alvord L S, 1997, J Am Acad Audiol, V8, P383
   Cone EJ, 2007, ANN NY ACAD SCI, V1098, P51, DOI 10.1196/annals.1384.037
   Cook D, 2017, BIOCHEM SYST ECOL, V75, P1, DOI 10.1016/j.bse.2017.09.002
   Cook D, 2011, AM J VET RES, V72, P706, DOI 10.2460/ajvr.72.5.706
   Cook D, 2009, J CHEM ECOL, V35, P643, DOI 10.1007/s10886-009-9637-1
   Drummer Olaf H, 2006, Clin Biochem Rev, V27, P147
   Ewan Joseph, 1945, UNIV COLO STUDIES SERIES D, V2, P55
   Gardner DR, 2009, PHYTOCHEM ANALYSIS, V20, P104, DOI 10.1002/pca.1104
   Gardner DR, 2002, BIOCHEM SYST ECOL, V30, P77, DOI 10.1016/S0305-1978(01)00120-X
   Gardner DR, 2000, J NAT PROD, V63, P1127, DOI 10.1021/np0000116
   Gardner DR, 1997, PHYTOCHEM ANALYSIS, V8, P55, DOI 10.1002/(SICI)1099-1565(199703)8:2<55::AID-PCA338>3.0.CO;2-Q
   Green B. T., 2014, Rangelands, V36, P10, DOI 10.2111/RANGELANDS-D-13-00031.1
   Green BT, 2009, AM J VET RES, V70, P926, DOI 10.2460/ajvr.70.7.926
   Green BT, 2009, AM J VET RES, V70, P539, DOI 10.2460/ajvr.70.4.539
   Horner M W, 1976, Br J Sports Med, V10, P133, DOI 10.1136/bjsm.10.3.133
   Hotzel H, 1996, J APPL BACTERIOL, V80, P505, DOI 10.1111/j.1365-2672.1996.tb03249.x
   Langel K, 2014, DRUG TEST ANAL, V6, P461, DOI 10.1002/dta.1532
   Lee ST, 2019, J AGR FOOD CHEM, V67, P43, DOI 10.1021/acs.jafc.8b05673
   MANNERS GD, 1995, J NAT PRODUCTS, V58, P863, DOI 10.1021/np50120a007
   MANNERS GD, 1993, J AGR FOOD CHEM, V41, P96, DOI 10.1021/jf00025a020
   MORGAN CE, 1947, ANAL CHEM, V19, P806, DOI 10.1021/ac60010a014
   Nielsen D. B., 1988, The ecology and economic impact of poisonous plants on livestock production., P119
   NIELSEN DB, 1994, J RANGE MANAGE, V47, P369, DOI 10.2307/4002332
   Panter KE, 2002, BIOCHEM SYST ECOL, V30, P113, DOI 10.1016/S0305-1978(01)00123-5
   PELLETIER SW, 1989, PHYTOCHEMISTRY, V28, P1521, DOI 10.1016/S0031-9422(00)97779-3
   Pfister J. A., 1993, Rangelands, V15, P157
   Pfister JA, 1999, J NAT TOXINS, V8, P81
   Prickett J, 2008, J VET DIAGN INVEST, V20, P156, DOI 10.1177/104063870802000203
   RALPHS MH, 1988, J ANIM SCI, V66, P2334
   Shokry E, 2017, TOXICON, V137, P54, DOI 10.1016/j.toxicon.2017.07.014
   Shokry E, 2017, FORENSIC TOXICOL, V35, P348, DOI 10.1007/s11419-017-0363-z
   STEGELMEIER BL, 2009, RANGELANDS, V31, P5, DOI DOI 10.2111/1551-501X-31.1.5
   Stegelmeier BL, 2013, HASCHEK AND ROUSSEAUX'S HANDBOOK OF TOXICOLOGIC PATHOLOGY, VOL 1-3, 3RD EDITION, P1259, DOI 10.1016/B978-0-12-415759-0.00040-6
   United Nations Office on Drugs and Crime, GUID TEST DRUGS INT
   WARNOCK M.J, 1997, FLORA N AM N MEXICO, V3, P196
   Warnock Michael J., 1995, Phytologia, V78, P73
   Welch KD, 2008, J ANIM SCI, V86, P2761, DOI 10.2527/jas.2008-1025
   Welch KD, 2012, J ANIM SCI, V90, P2394, DOI 10.2527/jas.2011-4560
   Welch KD, 2010, AM J VET RES, V71, P487, DOI 10.2460/ajvr.71.4.487
NR 39
TC 2
Z9 2
U1 1
U2 3
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD APR 1
PY 2019
VL 161
BP 33
EP 39
DI 10.1016/j.toxicon.2019.02.013
PG 7
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA HR0EY
UT WOS:000462802300007
PM 30826472
DA 2020-05-12
ER

PT J
AU Saporito, RA
   Russell, MW
   Richards-Zawacki, CL
   Dugas, MB
AF Saporito, Ralph A.
   Russell, Matthew W.
   Richards-Zawacki, Corinne L.
   Dugas, Matthew B.
TI Experimental evidence for maternal provisioning of alkaloid defenses in
   a dendrobatid frog
SO TOXICON
LA English
DT Article
DE Chemical defense; Dendrobatid; Feeding experiment; Oophaga; Poison frog;
   Sequestration
ID POISON FROG; OOPHAGA-PUMILIO; SEQUESTRATION; CARE; SKIN; PATTERNS;
   GLANDS
AB Dendrobatid frogs sequester alkaloid defenses from dietary arthropods. Here, we provide experimental evidence that mother strawberry poison frogs (Oophaga pumilio) provision alkaloids to tadpoles. Captive-raised females were fed the synthetic alkaloid decahydroquinoline (DHQ), which we subsequently quantified in their skin, eggs, and developing tadpoles. DHQ quantity was positively associated with tadpole mass/development, suggesting high sequestration rates by tadpoles. These data confirm that tadpoles obtain nutrition and alkaloids by feeding exclusively on maternally provisioned eggs.
C1 [Saporito, Ralph A.; Russell, Matthew W.] John Carroll Univ, Dept Biol, 1 John Carroll Blvd, Cleveland, OH 44118 USA.
   [Richards-Zawacki, Corinne L.; Dugas, Matthew B.] Tulane Univ, Dept Ecol & Evolutionary Biol, 400 Lindy Boggs Bldg, New Orleans, LA 70118 USA.
   [Dugas, Matthew B.] Illinois State Univ, Sch Biol Sci, Normal, IL 61790 USA.
   [Richards-Zawacki, Corinne L.] Univ Pittsburgh, Dept Biol Sci, 4249 Fifth Ave, Pittsburgh, PA 15260 USA.
RP Saporito, RA (reprint author), John Carroll Univ, Dept Biol, 1 John Carroll Blvd, Cleveland, OH 44118 USA.
EM rsaporito@jcu.edu
FU Kresge Challenge Grant
FX We thank the Panama for providing collecting (SE/A-112-08, SE/A-27-09)
   and export permission (SEX/A-58-09) for frogs used to establish the
   colony. Several Tulane undergraduate students, in particular Allison
   Killius, assisted with frog care, and M.A. Nichols assisted in
   maintaining the GC -MS. Funding for this project was partially supported
   by a Kresge Challenge Grant awarded to JCU. Tulane University's IACUC
   (0382; 0382R) approved the methods used in this study.
CR Bolton SK, 2017, J CHEM ECOL, V43, P273, DOI [10.1007/s10886-017-0827-Y, 10.1007/s10886-017-0827-y]
   BRUST DG, 1993, J HERPETOL, V27, P96, DOI 10.2307/1564914
   Daly JW, 2005, J NAT PROD, V68, P1556, DOI 10.1021/np0580560
   Dugas MB, 2016, J EVOLUTION BIOL, V29, P1977, DOI 10.1111/jeb.12921
   Dugas MB, 2016, BEHAV ECOL, V27, P476, DOI 10.1093/beheco/arv173
   Eisner T, 2000, P NATL ACAD SCI USA, V97, P1634, DOI 10.1073/pnas.030532797
   Frost D., 2018, AMPHIBIAN SPECIES WO
   Gosner K. L., 1960, Herpetologica, V16, P183
   Grant T, 2006, B AM MUS NAT HIST, V299, P1, DOI DOI 10.1206/0003-0090(2006)299[
   Hanifin CT, 2003, J CHEM ECOL, V29, P1729, DOI 10.1023/A:1024885824823
   Hantak MM, 2013, J CHEM ECOL, V39, P1400, DOI 10.1007/s10886-013-0361-5
   Hayes RA, 2009, J CHEM ECOL, V35, P391, DOI 10.1007/s10886-009-9608-6
   Hovey KJ, 2018, J CHEM ECOL, V44, P312, DOI 10.1007/s10886-018-0930-8
   Hutchinson DA, 2007, P NATL ACAD SCI USA, V104, P2265, DOI 10.1073/pnas.0610785104
   Mebs D, 2001, TOXICON, V39, P87, DOI 10.1016/S0041-0101(00)00155-0
   Myers C.W., 1978, B AM MUS NAT HIST, V161, P307
   Nishida R, 2002, ANNU REV ENTOMOL, V47, P57, DOI 10.1146/annurev.ento.47.091201.145121
   Saporito RA, 2007, TOXICON, V50, P757, DOI 10.1016/j.toxicon.2007.06.022
   Saporito RA, 2015, EXP APPL ACAROL, V67, P317, DOI 10.1007/s10493-015-9962-8
   Saporito RA, 2012, CHEMOECOLOGY, V22, P159, DOI 10.1007/s00049-011-0088-0
   Savitzky AH, 2012, CHEMOECOLOGY, V22, P141, DOI 10.1007/s00049-012-0112-z
   Stynoski JL, 2017, ZOOMORPHOLOGY, V136, P219, DOI 10.1007/s00435-017-0344-0
   Stynoski JL, 2014, ECOLOGY, V95, P587, DOI 10.1890/13-0927.1
   Stynoski JL, 2009, ANIM BEHAV, V78, P1351, DOI 10.1016/j.anbehav.2009.09.002
   Williams BL, 2011, J CHEM ECOL, V37, P10, DOI 10.1007/s10886-010-9901-4
NR 25
TC 1
Z9 1
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD APR 1
PY 2019
VL 161
BP 40
EP 43
DI 10.1016/j.toxicon.2019.02.008
PG 4
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA HR0EY
UT WOS:000462802300008
PM 30790578
DA 2020-05-12
ER

PT J
AU Sitprija, V
   Sitprija, S
AF Sitprija, Visith
   Sitprija, Siravit
TI Marine toxins and nephrotoxicity:Mechanism of injury
SO TOXICON
LA English
DT Review
DE Marine toxins; Sea snake; Cnidarian; Plankton; PLA(2); Protein
   phosphatase inhibitor; Renal injury
ID PROTEIN PHOSPHATASE 2A; ACUTE-RENAL-FAILURE; OKADAIC ACID;
   MICROCYSTIN-LR; SEA-SNAKE; DOMOIC ACID; CELL-DEATH; PHOSPHOLIPASE A(2);
   VENOM; PALYTOXIN
AB Marine toxins are known among several causes of toxin induced renal injury. Enzymatic mechanism by phospholipase A(2) is responsible for acute kidney injury (AKI) in sea snake envenoming without any change in cardiac output and systemic vascular resistance. Cnidarian toxins form pores in the cell membrane with Ca influx storm resulting in cell death. Among plankton toxins domoic acid, palytoxin and maitotoxin cause renal injury by ion transport into the cell through ion channels resulting in renal cell swelling and lysis. Okadaic acid, calyculin A, microcystin LR and nodularin cause AM by serine threonine phosphatase inhibition and hyperphosphorylation with increased activity of Ca2+/calmodulin - dependent protein kinase II, increased cytosolic Ca2+, reactive oxygen species, caspase and P53. Renal injury by plankons is mostly subclinical and requires sensitive biomarker for diagnosis. In this respect repeated consumption of plankton toxin contaminated seafood is a risk of developing chronic renal disease. The subject deserves more clinical study and scientific attention.
C1 [Sitprija, Visith] Thai Red Cross Soc, Queen Saovabha Mem Inst, Rama 4 Rd, Bangkok 10330, Thailand.
   [Sitprija, Siravit] Mahidol Univ, Dept Biol, Rama 6 Rd, Bangkok 10400, Thailand.
RP Sitprija, V (reprint author), Thai Red Cross Soc, Queen Saovabha Mem Inst, Rama 4 Rd, Bangkok 10330, Thailand.
EM visithstprj@yahoo.com; siravit.sit@mahidol.ac.th
CR Ali SA, 2000, TOXICON, V38, P687, DOI 10.1016/S0041-0101(99)00184-1
   Ardito F, 2017, INT J MOL MED, V40, P271, DOI 10.3892/ijmm.2017.3036
   Bakrac B, 2010, J BIOL CHEM, V285, P22186, DOI 10.1074/jbc.M110.105122
   Bashford CL, 2001, CELL MOL BIOL LETT, V6, P328
   Bavastrelli M, 2001, J TRAVEL MED, V8, P139, DOI 10.2310/7060.2001.24387
   Beasley VR, 2000, J TOXICOL ENV HEAL A, V61, P281, DOI 10.1080/00984100050136599
   BOE R, 1991, EXP CELL RES, V195, P237, DOI 10.1016/0014-4827(91)90523-W
   BOTTINGER H, 1984, N-S ARCH PHARMACOL, V325, P85, DOI 10.1007/BF00507059
   Bruschetta G, 2014, MAR DRUGS, V12, P2182, DOI 10.3390/md12042182
   Louzao MC, 2011, TOXICON, V57, P460, DOI 10.1016/j.toxicon.2010.09.017
   Chen Y, 2013, CLIN CHIM ACTA, V425, P18, DOI 10.1016/j.cca.2013.07.005
   Cross TG, 2000, EXP CELL RES, V256, P34, DOI 10.1006/excr.2000.4836
   DAVIS MA, 1994, TOXICOL PATHOL, V22, P595, DOI 10.1177/019262339402200604
   Deekajorndech Tawatchai, 2004, Journal of the Medical Association of Thailand, V87, pS292
   Desouza M, 2012, BIOARCHITECTURE, V2, P75, DOI DOI 10.4161/BI0A.20975
   Diakov A, 2010, CELL PHYSIOL BIOCHEM, V26, P913, DOI 10.1159/000324000
   DIETL P, 1994, MOL PHARMACOL, V45, P300
   Drevensek G, 2002, J NAT TOXINS, V11, P231
   Dynia DW, 2010, AM J PHYSIOL-RENAL, V298, pF745, DOI 10.1152/ajprenal.00182.2009
   Fenner PJ, 2010, J TRAVEL MED, V17, P133, DOI 10.1111/j.1708-8305.2009.00390.x
   Fladmark KE, 1999, CELL DEATH DIFFER, V6, P1099, DOI 10.1038/sj.cdd.4400590
   Frazao B, 2012, MAR DRUGS, V10, P1812, DOI 10.3390/md10081812
   Funk JA, 2014, J AM SOC NEPHROL, V25, P1187, DOI 10.1681/ASN.2013080836
   Gagnon KB, 2010, J BIOL CHEM, V285, P14115, DOI 10.1074/jbc.M110.112672
   GARCIA PJ, 1994, ANN INTERN MED, V120, P665, DOI 10.7326/0003-4819-120-8-199404150-00007
   Gehringer MM, 2004, FEBS LETT, V557, P1, DOI 10.1016/S0014-5793(03)01447-9
   Gill SS, 2001, TOXICOL PATHOL, V29, P208, DOI 10.1080/019262301317052486
   GRANTHAM J, 1984, CIRC RES, V54, P483, DOI 10.1161/01.RES.54.5.483
   Gu L, 2003, CELL MOTIL CYTOSKEL, V54, P286, DOI 10.1002/cm.10099
   GUESS HA, 1982, PEDIATRICS, V70, P979
   Ito Emiko, 1994, Natural Toxins, V2, P371
   JENNINGS ML, 1991, J GEN PHYSIOL, V97, P799, DOI 10.1085/jgp.97.4.799
   Jouiaei M, 2015, TOXINS, V7, P2251, DOI 10.3390/toxins7062251
   Kan T, 2016, INT J ENV RES PUB HE, V13, P1
   Kleppe R, 2015, MAR DRUGS, V13, P6505, DOI 10.3390/md13106505
   Kubokawa M., 2011, ENZYM RES, V5, DOI [10.4061/2011/587359.587359, DOI 10.4061/2011/587359.587359]
   La-Salete R, 2008, J APPL TOXICOL, V28, P55, DOI 10.1002/jat.1251
   Li DL, 1998, AM J PHYSIOL-RENAL, V275, pF863
   Liedtke CM, 2005, J BIOL CHEM, V280, P25491, DOI 10.1074/jbc.M504473200
   Lowe J, 2012, TOXICON, V59, P601, DOI 10.1016/j.toxicon.2012.02.003
   Lu XZ, 2013, WORLD J DIABETES, V4, P70, DOI 10.4239/wjd.v4.i3.70
   Mallari RQ, 1996, PEDIATRICS, V98, P458
   MERCER HP, 1981, MED J AUSTRALIA, V1, P130, DOI 10.5694/j.1326-5377.1981.tb135383.x
   Mitrmoonpitak C, 2013, TOXICON, V61, P47, DOI 10.1016/j.toxicon.2012.10.017
   Mizuno M, 2012, MAR DRUGS, V10, P1582, DOI 10.3390/md10071582
   Mos L, 2001, ENVIRON TOXICOL PHAR, V9, P79, DOI 10.1016/S1382-6689(00)00065-X
   Nevalainen TJ, 2004, COMP BIOCHEM PHYS B, V139, P731, DOI 10.1016/j.cbpc.2004.09.006
   Nijjar MS, 2000, INT J MOL MED, V6, P377
   Nobre ACL, 1999, BRAZ J MED BIOL RES, V32, P985, DOI 10.1590/S0100-879X1999000800008
   Okano H, 1998, INTERNAL MED, V37, P330, DOI 10.2169/internalmedicine.37.330
   Papakonstanti EA, 2000, CELL PHYSIOL BIOCHEM, V10, P257, DOI 10.1159/000016366
   Perez-Gomez A, 2010, J NEUROCHEM, V114, P28, DOI 10.1111/j.1471-4159.2010.06602.x
   PERL TM, 1990, NEW ENGL J MED, V322, P1775, DOI 10.1056/NEJM199006213222504
   Pouria S, 1998, LANCET, V352, P21, DOI 10.1016/S0140-6736(97)12285-1
   Prasad GVR, 2006, AM J KIDNEY DIS, V47, DOI 10.1053/j.ajkd.2005.09.025
   Pulido OM, 2008, MAR DRUGS, V6, P180, DOI 10.3390/md20080010
   Ravindran VS, 2010, INDIAN J EXP BIOL, V48, P1225
   Rosado CJ, 2008, CELL MICROBIOL, V10, P1765, DOI 10.1111/j.1462-5822.2008.01191.x
   Sakwiwatkul K, 2002, J NAT TOXINS, V11, P111
   Scheiner-Bobis G, 2002, EUR J BIOCHEM, V269, P3905, DOI 10.1046/j.1432-1033.2002.03056.x
   Schilling WP, 1999, AM J PHYSIOL-CELL PH, V277, pC766
   Shinzato T, 2008, INTERNAL MED, V47, P853, DOI 10.2169/internalmedicine.47.0847
   Simola O, 2012, VET PATHOL, V49, P755, DOI 10.1177/0300985811415703
   Sinkins WG, 2009, AM J PHYSIOL-CELL PH, V297, pC1533, DOI 10.1152/ajpcell.00252.2009
   SITPRIJA V, 1971, BMJ-BRIT MED J, V3, P218, DOI 10.1136/bmj.3.5768.218
   Sitprija V, 2016, INT J NEPHROL THERAP, V2, P1
   Sitprija V, 2012, TOXICON, V60, P943, DOI 10.1016/j.toxicon.2012.06.012
   Sobel J, 2005, CLIN INFECT DIS, V41, P1290, DOI 10.1086/496926
   SPIELMAN FJ, 1982, SOUTHERN MED J, V75, P1425, DOI 10.1097/00007611-198211000-00033
   Sun HP, 2012, PHYSIOLOGY, V27, P43, DOI 10.1152/physiol.00034.2011
   Takahashi M., 1989, TOXICON, V27, P979
   Tamiya N, 2011, P JPN ACAD B-PHYS, V87, P41, DOI 10.2183/pjab.87.41
   Taniyama S, 2003, TOXICON, V42, P29, DOI 10.1016/S0041-0101(03)00097-7
   Thomas SG, 2006, J CELL BIOL, V174, P221, DOI 10.1083/jcb.200604011
   Tsao CC, 2007, CELL CYCLE, V6, P2377, DOI 10.4161/cc.6.19.4737
   TUNGTHANATHANICH P, 1986, TOXICON, V24, P365, DOI 10.1016/0041-0101(86)90196-0
   Valdiglesias V, 2013, MAR DRUGS, V11, P4328, DOI 10.3390/md11114328
   Valenti G, 2000, J CELL SCI, V113, P1985
   Verhoef PA, 2004, MOL PHARMACOL, V66, P909, DOI 10.1124/mol.66.4.909
   Vieira AC, 2013, TOXINS, V5, P2093, DOI 10.3390/toxins5112093
   Wakimoto T, 2016, NAT PROD REP, V33, P751, DOI 10.1039/c5np00123d
   Weiser Douglas C, 2003, Curr Protoc Mol Biol, VChapter 18, DOI 10.1002/0471142727.mb1810s62
   Wu ML, 2014, ANN EMERG MED, V64, P633, DOI 10.1016/j.annemergmed.2014.06.001
   Yanagihara AA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051368
   ZAGER RA, 1993, P NATL ACAD SCI USA, V90, P8297, DOI 10.1073/pnas.90.17.8297
NR 85
TC 1
Z9 1
U1 10
U2 21
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD APR 1
PY 2019
VL 161
BP 44
EP 49
DI 10.1016/j.toxicon.2019.02.012
PG 6
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA HR0EY
UT WOS:000462802300009
PM 30826470
DA 2020-05-12
ER

PT J
AU Kovesi, B
   Pelyhe, C
   Zandoki, E
   Mezes, M
   Balogh, K
AF Kovesi, Benjamin
   Pelyhe, Csilla
   Zandoki, Erika
   Mezes, Miklos
   Balogh, Krisztian
TI Effect of short-term sterigmatocystin exposure on lipid peroxidation and
   glutathione redox system and expression of glutathione redox system
   regulatory genes in common carp liver
SO TOXICON
LA English
DT Article
DE Sterigmatocystin; Common carp; Antioxidant defence system; Glutathione
   peroxidase; Gene expression
ID AFLATOXIN B-1; ACUTE TOXICITY; CELLS; ANTIOXIDANT; PATHWAY;
   IDENTIFICATION; ACTIVATION; GROWTH; LEVEL
AB Sterigmatocystin (STC) is structurally close to the mycotoxin aflatoxin B-1 as it shares its biosynthetic pathway with aflatoxins. The purpose of the present study was to investigate the short-term (24 h) effects of STC contaminated diet at different doses (1 mg, 2 mg and 4 mg STC kg(-1) feed) in one year old common carp juveniles. Liver samples were taken in 8-h intervals. The markers of the lipid peroxidation showed moderate changes after the application of sterigmatocystin-contaminated diet, significant elevations were only observed in the lowest applied dose group of sterigmatocystin after 16 h of exposure. Reduced glutathione content showed higher levels than control group after 16 h of exposure as effect of low dose of sterigmatocystin. Glutathione peroxidase (GPX4) activity was lower than control in the group treated with 2 mg STC kg(-1) feed after 24 h of exposure. Gene expression measurements of keap1, nrf2, gpx4a, gpx4b and gss genes revealed a dual response. Down regulation or near control values were observed 8 h after exposure which was followed by an induction 16 and 24 h after exposure. In case of gsr, gene expression values returned to control levels by the 24th hour. In summary, these results suggest that lower doses of STC caused oxidative stress earlier than higher doses, which efficiently activated the Keap1-Nrf2 pathway, while higher doses revealed long-drawn activation of this pathway.
C1 [Kovesi, Benjamin; Mezes, Miklos; Balogh, Krisztian] Szent Istvan Univ, Dept Nutr, Pater Karoly 1, H-2103 Godollo, Hungary.
   [Pelyhe, Csilla; Zandoki, Erika; Mezes, Miklos; Balogh, Krisztian] Szent Istvan Univ, Kaposvar Univ, Hungarian Acad Sci, Mycotoxins Food Chain Res Grp, Guba Sdndor 40, H-7400 Kaposvar, Hungary.
RP Mezes, M (reprint author), Szent Istvan Univ, Dept Nutr, Pater Karoly 1, H-2103 Godollo, Hungary.
EM Mezes.Miklos@mkk.szie.hu
FU New National Excellence Program of the Ministry of Human Capacities,
   Hungary [UNKP-17-3]; European UnionEuropean Union (EU); European Social
   FundEuropean Social Fund (ESF);  [EFOP-3.6.3-VEKOP-16-2017-00008]
FX This study was supported by the UNKP-17-3. New National Excellence
   Program of the Ministry of Human Capacities, Hungary to BK, and
   EFOP-3.6.3-VEKOP-16-2017-00008 project, co-financed by the European
   Union and the European Social Fund to BK, KB and MM.
CR Abdel-Wahhab MA, 2005, MUTAT RES-GEN TOX EN, V582, P20, DOI 10.1016/j.mrgentox.2004.12.009
   ABDELHAMID AM, 1988, ARCH TIERERNAHR, V38, P833, DOI 10.1080/17450398809430911
   Association of Official Analytical Chemists (AOAC), 1984, OFFICIAL METHODS ANA, P13, DOI [10.5962/bhl.title.44636, DOI 10.5962/BHL.TITLE.44636]
   BAERTSCHI SW, 1989, CHEM RES TOXICOL, V2, P114, DOI 10.1021/tx00008a008
   BOTSOGLOU NA, 1994, J AGR FOOD CHEM, V42, P1931, DOI 10.1021/jf00045a019
   Bunger J, 2004, TOXICOLOGY, V202, P199, DOI 10.1016/j.tox.2004.05.007
   BUTLER WH, 1964, BRIT J CANCER, V18, P756, DOI 10.1038/bjc.1964.87
   CURRY PT, 1984, MUTAT RES, V137, P111, DOI 10.1016/0165-1218(84)90099-5
   El-Barbary MI, 2016, FISH PHYSIOL BIOCHEM, V42, P617, DOI 10.1007/s10695-015-0164-4
   ENGELBRECHT JC, 1972, JNCI-J NATL CANCER I, V48, P1647
   ESSIGMANN JM, 1979, P NATL ACAD SCI USA, V76, P179, DOI 10.1073/pnas.76.1.179
   ESSIGMANN JM, 1980, CANCER RES, V40, P4085
   Gloire G, 2006, BIOCHEM PHARMACOL, V72, P1493, DOI 10.1016/j.bcp.2006.04.011
   HATANAKA J, 1982, JPN J EXP MED, V52, P243
   Heinonen JT, 1996, TOXICOL APPL PHARM, V136, P1, DOI 10.1006/taap.1996.0001
   HENDRICKS JD, 1980, J NATL CANCER I, V64, P1503, DOI 10.1093/jnci/64.6.1503
   Hermesz E, 2009, COMP BIOCHEM PHYS C, V150, P101, DOI 10.1016/j.cbpc.2009.03.007
   Huang SJ, 2014, FOOD CHEM TOXICOL, V66, P89, DOI 10.1016/j.fct.2014.01.024
   IARC, 1987, IARC MON EV CARC RIS, V1-42, DOI [10.1002/food.19890330516, DOI 10.1002/FOOD.19890330516]
   Jaramillo MC, 2013, GENE DEV, V27, P2179, DOI 10.1101/gad.225680.113
   Jiang J, 2015, FISH PHYSIOL BIOCHEM, V41, P1143, DOI 10.1007/s10695-015-0076-3
   Kovesi B, 2018, TOXICON, V144, P103, DOI 10.1016/j.toxicon.2018.02.003
   LAWRENCE RA, 1976, BIOCHEM BIOPH RES CO, V71, P952, DOI 10.1016/0006-291X(76)90747-6
   Liu YL, 2012, FOOD CHEM TOXICOL, V50, P1920, DOI 10.1016/j.fct.2012.03.005
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   Mahrous KF, 2006, AFR J BIOTECHNOL, V5, P1180
   NODA K, 1981, CARCINOGENESIS, V2, P945, DOI 10.1093/carcin/2.10.945
   PURCHASE IF, 1969, FOOD COSMET TOXICOL, V7, P135, DOI 10.1016/S0015-6264(69)80295-6
   Rahman I, 2006, NAT PROTOC, V1, P3159, DOI 10.1038/nprot.2006.378
   Safari R, 2016, FISH SHELLFISH IMMUN, V55, P242, DOI 10.1016/j.fsi.2016.05.038
   Shen HM, 1996, FREE RADICAL BIO MED, V21, P139, DOI 10.1016/0891-5849(96)00019-6
   Sivakumar V, 2001, HUM EXP TOXICOL, V20, P398, DOI 10.1191/096032701682692955
   Suzuki T, 2015, FREE RADICAL BIO MED, V88, P93, DOI 10.1016/j.freeradbiomed.2015.06.006
   Sweeney MJ, 1999, FEMS MICROBIOL LETT, V175, P149, DOI 10.1111/j.1574-6968.1999.tb13614.x
   Taguchi K, 2011, GENES CELLS, V16, P123, DOI 10.1111/j.1365-2443.2010.01473.x
   TERAO K, 1983, J TOXICOL-TOXIN REV, V2, P77, DOI 10.3109/15569548309006494
   UEDA N, 1984, MUTAT RES, V139, P203, DOI 10.1016/0165-7992(84)90129-5
   Versilovskis A, 2010, MOL NUTR FOOD RES, V54, P136, DOI 10.1002/mnfr.200900345
   Wang ST, 1997, J NUTR, V127, P2135
   Xing Ling-Xiao, 2005, Wei Sheng Yan Jiu, V34, P454
   Xing X, 2011, MOL NUTR FOOD RES, V55, P749, DOI 10.1002/mnfr.201000344
   YAMAZAKI H, 1995, CARCINOGENESIS, V16, P2167, DOI 10.1093/carcin/16.9.2167
   Yu JJ, 2004, APPL ENVIRON MICROB, V70, P1253, DOI 10.1128/AEM.70.3.1253-1262.2004
   Zhang Y, 2012, MOL MED REP, V5, P1318, DOI 10.3892/mmr.2012.788
   Zouaoui N, 2016, FOOD CHEM TOXICOL, V89, P92, DOI 10.1016/j.fct.2016.01.010
NR 46
TC 3
Z9 3
U1 2
U2 9
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD APR 1
PY 2019
VL 161
BP 50
EP 56
DI 10.1016/j.toxicon.2019.03.001
PG 7
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA HR0EY
UT WOS:000462802300010
PM 30849453
DA 2020-05-12
ER

PT J
AU Siebert, AL
   Doucette, LA
   Simpson-Haidaris, PJ
   Werren, JH
AF Siebert, Aisha L.
   Doucette, Luticha A.
   Simpson-Haidaris, P. J.
   Werren, John H.
TI Parasitoid wasp venom elevates sorbitol and alters expression of
   metabolic genes in human kidney cells
SO TOXICON
LA English
DT Article
ID ALDOSE REDUCTASE INHIBITORS; RAT MESANGIAL CELLS; NASONIA-VITRIPENNIS;
   OXIDATIVE STRESS; EVOLUTION; FAMILY; PHYLOGENY; GLOMERULI; INSIGHTS;
   ENZYMES
AB Venom from the parasitoid wasp Nasonia vitripennis dramatically elevates sorbitol levels in its natural fly hosts. In humans, sorbitol elevation is associated with complications of diabetes. Here we demonstrate that venom also induces this disease-relevant phenotype in human cells, and investigate possible pathways involved. Key findings are that (a) low doses of Nasonia venom elevate sorbitol levels in human renal mesangial cells (HRMCs) without changing glucose or fructose levels; (b) venom is a much more potent inducer of sorbitol elevation than glucose; (c) low venom doses significantly alter expression of genes involved in sterol and alcohol metabolism, transcriptional regulation, and chemical/stimulus response; (d) although venom treatment does not alter expression of the key sorbitol pathway gene aldose reductase (AR); (e) venom elevates expression of a related gene implicated in diabetes complications (AKR1C3) as well as the fructose metabolic gene (GFPT2). Although elevated sorbitol is accepted as a major contributor to secondary complications of diabetes, the molecular mechanism of sorbitol regulation and its contribution to diabetes complications are not fully understood. Our findings suggest that genes other than AR could contribute to sorbitol regulation, and more broadly illustrate the potential of parasitoid venoms for medical application.
C1 [Siebert, Aisha L.; Simpson-Haidaris, P. J.] Univ Rochester, Sch Med & Dent, Translat Biomed Sci Dept, Rochester, NY 14642 USA.
   [Siebert, Aisha L.] Northwestern Univ, Feinberg Sch Med, Dept Urol, Chicago, IL 60611 USA.
   [Doucette, Luticha A.; Werren, John H.] Univ Rochester, Biol Dept, Rochester, NY 14627 USA.
RP Siebert, AL (reprint author), Northwestern Univ, Feinberg Sch Med, Dept Urol, Chicago, IL 60611 USA.
EM aisha.siebert@northwestern.edu
RI Siebert, Aisha/AAF-3411-2020
OI Siebert, Aisha/0000-0001-6954-9163; , PJ/0000-0003-2778-2500
FU National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [F31DK108658,
   RO1GM098667]; University of Rochester Drug Development Delivery Pilot
   Award; Helen Wisch Chair
FX We would like to thank A. Dolan, R. Edwards, M. He, E. Martinson, and
   Mrinalini for comments and discussion. This research was supported by
   the National Institutes of Health (F31DK108658 to ALS, RO1GM098667 to
   JHW), University of Rochester Drug Development Delivery Pilot Award to
   JHW and PJSH, and Helen Wisch Chair to JHW.
CR Anders S, 2015, BIOINFORMATICS, V31, P166, DOI 10.1093/bioinformatics/btu638
   Anders S, 2013, NAT PROTOC, V8, P1765, DOI 10.1038/nprot.2013.099
   Baelde HJ, 2004, AM J KIDNEY DIS, V43, P636, DOI 10.1053/j.ajkd.2003.12.028
   Blair JE, 2005, MOL BIOL EVOL, V22, P2275, DOI 10.1093/molbev/msi225
   BOEL E, 1995, J DIABETES COMPLICAT, V9, P104, DOI 10.1016/1056-8727(94)00025-J
   Brownlee M, 2001, NATURE, V414, P813, DOI 10.1038/414813a
   Centers for Disease Control and Prevention, DIAB DAT STAT
   Danneels EL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096825
   Danneels EL, 2013, INSECT BIOCHEM MOLEC, V43, P1189, DOI 10.1016/j.ibmb.2013.10.003
   Danneels EL, 2010, TOXINS, V2, P494, DOI 10.3390/toxins2040494
   de Graaf DC, 2010, INSECT MOL BIOL, V19, P11, DOI 10.1111/j.1365-2583.2009.00914.x
   de la Fuente JA, 2003, NAT PROD REP, V20, P243, DOI 10.1039/b204709h
   El-Kabbani O, 1999, MOL VIS, V5, pU1
   Feng ZK, 2004, BIOINFORMATICS, V20, P2153, DOI 10.1093/bioinformatics/bth214
   Forbes JM, 2008, DIABETES, V57, P1446, DOI 10.2337/db08-0057
   Forbes JM, 2013, PHYSIOL REV, V93, P137, DOI 10.1152/physrev.00045.2011
   Goecks J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064125
   GROND J, 1990, CONTRIB NEPHROL, V81, P229
   HEILIG CW, 1995, J CLIN INVEST, V96, P1802, DOI 10.1172/JCI118226
   Heraty J, 2009, INSECT BIODIVERSITY
   Hsu KC, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-S1-S33
   Kelley LA, 2009, NAT PROTOC, V4, P363, DOI 10.1038/nprot.2009.2
   Lewko B, 2011, EXP DIABETES RES, DOI 10.1155/2011/278963
   Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324
   Lv JL, 2015, BIOCHEM BIOPH RES CO, V459, P264, DOI 10.1016/j.bbrc.2015.02.096
   Lynch JA, 2015, GENETICS, V199, P897, DOI 10.1534/genetics.112.147512
   Martinson E. O, 2015, MOL BIOL EVOL
   Martinson EO, 2018, ECOL ENTOMOL, V43, P146, DOI 10.1111/een.12480
   Martinson EO, 2017, CURR BIOL, V27, P2007, DOI 10.1016/j.cub.2017.05.032
   Martinson EO, 2014, MOL ECOL, V23, P5918, DOI 10.1111/mec.12967
   McCarthy DJ, 2012, NUCLEIC ACIDS RES, V40, P4288, DOI 10.1093/nar/gks042
   Mitsiades N, 2012, CANCER RES, V72, P6142, DOI 10.1158/0008-5472.CAN-12-1335
   Mrinalini, 2015, METABOLOMICS, V11, P350, DOI 10.1007/s11306-014-0697-z
   Mrinalini Werren, 2015, HDB TOXINOLOGY
   Oates PJ, 2008, CURR DRUG TARGETS, V9, P14, DOI 10.2174/138945008783431781
   Ota A, 2013, J DIABETES RES, DOI 10.1155/2013/175901
   Pennacchio F, 2006, ANNU REV ENTOMOL, V51, P233, DOI 10.1146/annurev.ento.51.110104.151029
   Petrash JM, 2004, CELL MOL LIFE SCI, V61, P737, DOI 10.1007/s00018-003-3402-3
   QUICKE D, 1997, PARASITIC WASPS
   Reddy GB, 2008, MOL VIS, V14, P593
   Rivers David B., 2008, P259
   Rizner TL, 2014, STEROIDS, V79, P49, DOI 10.1016/j.steroids.2013.10.012
   Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616
   Rodriguez-Barbero A, 2000, CELL BIOL TOXICOL, V16, P145, DOI 10.1023/A:1007683320660
   Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089
   Seery LT, 1998, J MOL EVOL, V46, P139, DOI 10.1007/PL00006288
   Shaw N, 2014, CELL STRESS CHAPERON, V19, P281, DOI 10.1007/s12192-013-0455-6
   Siebert A. L, 2015, TOXICON OFFICIAL J I
   Sreekumar PG, 2016, INVEST OPHTH VIS SCI, V57, P1238, DOI 10.1167/iovs.15-17053
   Stockand JD, 1997, AM J KIDNEY DIS, V29, P971, DOI 10.1016/S0272-6386(97)90476-5
   Team R. C. R, 2012, LANG ENV STAT COMP V
   Wada Jun, 2002, Kidney Int, V61, pS73
   Wallner EI, 2001, RENAL FAILURE, V23, P311, DOI 10.1081/JDI-100104715
   Werren J.H., 2009, COLD SPRING HARB PRO, V2009
   Werren J.H., 2009, COLD SPRING HARB PRO, V2009
   Werren JH, 2009, COLD SPRING HARB PRO, V2009
   Werren JH, 2010, SCIENCE, V327, P343, DOI 10.1126/science.1178028
   Whitfield JB, 1998, ANNU REV ENTOMOL, V43, P129, DOI 10.1146/annurev.ento.43.1.129
   Yabe-Nishimura C, 1998, PHARMACOL REV, V50, P21
   Yang JM, 2004, J COMPUT CHEM, V25, P843, DOI 10.1002/jcc.20013
   Zhao ST, 2012, NEUROCHEM RES, V37, P153, DOI 10.1007/s11064-011-0593-0
NR 61
TC 0
Z9 1
U1 2
U2 4
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD APR 1
PY 2019
VL 161
BP 57
EP 64
DI 10.1016/j.toxicon.2018.11.308
PG 8
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA HR0EY
UT WOS:000462802300011
PM 30831148
DA 2020-05-12
ER

PT J
AU Ottenhausen, M
   Kalasauskas, D
   Kramer, A
   Neuhoff, J
   Serrano, L
   Schwandt, E
   Ringel, F
AF Ottenhausen, Malte
   Kalasauskas, Darius
   Kramer, Andreas
   Neuhoff, Jonathan
   Serrano, Lucas
   Schwandt, Eike
   Ringel, Florian
TI Bone Flap Necrosis Due to Low-Grade Infection with Propionibacterium
   acnes
SO WORLD NEUROSURGERY
LA English
DT Article
DE Aseptic; Bone flap necrosis; Cranioplasty; Low-grade infection;
   Osteonecrosis; Propionibacterium acnes
ID TRAUMATIC BRAIN-INJURY; DECOMPRESSIVE CRANIECTOMY;
   MICROBIAL-CONTAMINATION; CRANIOPLASTY; SURGERY; HIP
AB BACKGROUND: Osteonecrosis of bone flaps after cranioplasty with autologous cryoconserved bone flaps is a common phenomenon. The exact reason for it remains unknown.
   CASE DESCRIPTION: We present a case of a 67-year-old patient who had a bone flap necrosis after elective craniotomy and underwent secondary cranioplasty. A low-grade infection with Propionibacterium acnes was detected in microbiologic samples from the bone flap as the cause of the lysis. We discuss similarities with aseptic implant loosening and present recent evidence that low-grade infections might be the underlying reason in several cases.
   CONCLUSIONS: We conclude that low-grade infections play an underestimated role in bone flap necrosis after cranioplasty as well and encourage routine microbiologic sampling (extended culture and polymerase chain reaction) to rule out infection in all similar cases and suggest a routine antibiotic therapy until final microbiologic results.
C1 [Ottenhausen, Malte; Kalasauskas, Darius; Kramer, Andreas; Neuhoff, Jonathan; Serrano, Lucas; Schwandt, Eike; Ringel, Florian] Univ Med Ctr Mainz, Dept Neurol Surg, Mainz, Germany.
RP Ottenhausen, M (reprint author), Univ Med Ctr Mainz, Dept Neurol Surg, Mainz, Germany.
EM Malte.Ottenhausen@unimedizin-mainz.de
RI Ringel, Florian/E-4933-2014; Ottenhausen, Malte/Z-4121-2019
OI Ottenhausen, Malte/0000-0003-0797-1101
CR Bhaskar IP, 2013, ACTA NEUROCHIR, V155, P367, DOI 10.1007/s00701-012-1517-8
   Chan DYC, 2017, J CLIN NEUROSCI, V42, P81, DOI 10.1016/j.jocn.2017.04.016
   Chiang HY, 2011, J NEUROSURG, V114, P1746, DOI 10.3171/2011.1.JNS10782
   Dapunt U, 2016, MATERIALS BASEL, P9
   Kempthorne JT, 2015, BIOMED RES INT, DOI 10.1155/2015/946215
   Kim JH, 2018, WORLD NEUROSURG, V115, pE111, DOI 10.1016/j.wneu.2018.03.197
   Lange N, 2018, ACTA NEUROCHIR, V160, P199, DOI 10.1007/s00701-017-3371-1
   Martin KD, 2014, ACTA NEUROCHIR, V156, P813, DOI 10.1007/s00701-014-2021-0
   Moojen DJF, 2010, ACTA ORTHOP, V81, P667, DOI 10.3109/17453674.2010.525201
   Nisbet M, 2007, J ANTIMICROB CHEMOTH, V60, P1097, DOI 10.1093/jac/dkm351
   Schoekler B, 2014, CLIN NEUROL NEUROSUR, V120, P64, DOI 10.1016/j.clineuro.2014.02.014
   Schwarz F, 2016, J NEUROSURG, V124, P710, DOI 10.3171/2015.4.JNS159
   SMOLL NR, 2013, SCHWEIZ RUNDSCH MED, V102, P809, DOI DOI 10.1024/1661-8157/a001341
   Strom JO, 2011, BRAIN INJURY, V25, P250, DOI 10.3109/02699052.2010.542431
   Trampuz A, 2007, NEW ENGL J MED, V357, P654, DOI 10.1056/NEJMoa061588
   von der Brelie C, 2016, J NEUROL SURG PART A, V77, P19, DOI 10.1055/s-0035-1558410
   Zarate MS, 2009, MEDICINA-BUENOS AIRE, V69, P170
NR 17
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP 1
EP 3
DI 10.1016/j.wneu.2018.12.055
PG 3
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800105
PM 30590219
DA 2020-05-12
ER

PT J
AU Omura, T
   Fukushima, Y
   Yoshikawa, G
   Matsuhashi, A
   Sato, D
   Endo, T
   Sato, K
   Inoue, M
   Saito, A
   Tsutsumi, K
AF Omura, Takaki
   Fukushima, Yuta
   Yoshikawa, Gakushi
   Matsuhashi, Ako
   Sato, Daisuke
   Endo, Takeaki
   Sato, Katsuya
   Inoue, Mizuho
   Saito, Akira
   Tsutsumi, Kazuo
TI Cerebral Hyperperfusion Syndrome After a Burr Hole Drainage Surgery for
   Chronic Subdural Hematoma
SO WORLD NEUROSURGERY
LA English
DT Article
DE Arterial spin labeling; Burr hole surgery; Cerebral hyperperfusion
   syndrome; Chronic subdural hematoma; Fluid attenuated inversion recovery
ID BLOOD-FLOW; MANAGEMENT
AB BACKGROUND: Although chronic subdural hematoma (CSDH) has a good prognosis after classical minimally-invasive drainage surgery, severe complications still occur at a substantial rate. Cerebral hyperperfusion syndrome (CHS), which is a common severe complication after carotid endarterectomy or carotid artery stenting for cervical carotid artery stenosis, is rare after drainage surgery for a CSDH.
   CASE DESCRIPTION: We describe the case of an 82-year-old woman who presented with ipsilesional symptoms including contralateral hemiparesis and dysarthria, progressively worsening consciousness, and status epilepticus after a burr hole drainage surgery for CSDH. Magnetic resonance fluid-attenuated inversion recovery imaging showed diffuse subcortical low intensity in the ipsilesional hemisphere almost simultaneously with the appearance of the symptoms. Arterial spin labeling magnetic resonance perfusion imaging showed the abnormal increase of cerebral blood flow in the hemisphere. Continuous propofol administration and blood pressure management improved the symptoms.
   CONCLUSIONS: CHS can cause severe postoperative complications after drainage surgery for CSDH. Subcortical low-intensity fluid-attenuated inversion recovery imaging is a useful investigation for early detection of CHS in CSDH, and arterial spin labeling imaging is an effective minimally-invasive modality for confirming the diagnosis.
C1 [Omura, Takaki; Fukushima, Yuta; Yoshikawa, Gakushi; Matsuhashi, Ako; Sato, Daisuke; Endo, Takeaki; Sato, Katsuya; Inoue, Mizuho; Saito, Akira; Tsutsumi, Kazuo] Showa Gen Hosp, Dept Neurosurg, Kodaira, Tokyo, Japan.
   [Omura, Takaki; Fukushima, Yuta] Univ Tokyo Hosp, Dept Neurosurg, Tokyo, Japan.
RP Fukushima, Y (reprint author), Showa Gen Hosp, Dept Neurosurg, Kodaira, Tokyo, Japan.; Fukushima, Y (reprint author), Univ Tokyo Hosp, Dept Neurosurg, Tokyo, Japan.
EM fukushima-tky@umin.ac.jp
CR Almenawer SA, 2014, ANN SURG, V259, P449, DOI 10.1097/SLA.0000000000000255
   Bartek J, 2017, WORLD NEUROSURG, V106, P609, DOI 10.1016/j.wneu.2017.07.044
   D'Abbondanza JA, 2014, NEUROL RES, V36, P176, DOI 10.1179/1743132813Y.0000000279
   Ducruet AF, 2012, NEUROSURG REV, V35, P155, DOI 10.1007/s10143-011-0349-y
   Ivens S, 2010, J NEUROL, V257, P615, DOI 10.1007/s00415-009-5384-z
   Kolias AG, 2014, NAT REV NEUROL, V10, P570, DOI 10.1038/nrneurol.2014.163
   Lega BC, 2010, J NEUROSURG, V113, P615, DOI 10.3171/2009.9.JNS08825
   Mehta V, 2018, J CLIN NEUROSCI, V50, P7, DOI 10.1016/j.jocn.2018.01.050
   Ogasawara K, 2000, SURG NEUROL, V54, P155, DOI 10.1016/S0090-3019(00)00281-0
   Ogasawara K, 1999, NEUROSURGERY, V45, P484, DOI 10.1097/00006123-199909000-00014
   Santarius T, 2009, LANCET, V374, P1067, DOI 10.1016/S0140-6736(09)61115-6
   Shiba M, 2018, CLIN NEUROL NEUROSUR, V167, P70, DOI 10.1016/j.clineuro.2018.02.019
   Tanaka A, 1997, SURG NEUROL, V47, P346, DOI 10.1016/S0090-3019(96)00369-2
   Tanioka S, 2017, WORLD NEUROSURG, V101, DOI 10.1016/j.wneu.2017.03.089
   Uchihashi Y, 2011, AM J NEURORADIOL, V32, P1545, DOI 10.3174/ajnr.A2525
   van Mook WNKA, 2005, LANCET NEUROL, V4, P877, DOI 10.1016/S1474-4422(05)70251-9
   Weigel R, 2003, J NEUROL NEUROSUR PS, V74, P937, DOI 10.1136/jnnp.74.7.937
   Yoshimoto T, 1997, SURG NEUROL, V48, P132
NR 18
TC 2
Z9 2
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP 5
EP 8
DI 10.1016/j.wneu.2018.12.100
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800107
PM 30610989
DA 2020-05-12
ER

PT J
AU Nishimura, F
   Park, YS
   Motoyama, Y
   Nakagawa, I
   Yamada, S
   Tamura, K
   Matsuda, R
   Takeshima, Y
   Takamura, Y
   Nakase, H
AF Nishimura, Fumihiko
   Park, Yong-Soo
   Motoyama, Yasushi
   Nakagawa, Ichiro
   Yamada, Shuichi
   Tamura, Kentaro
   Matsuda, Ryosuke
   Takeshima, Yasuhiro
   Takamura, Yoshiaki
   Nakase, Hiroyuki
TI Intractable Rathke Cleft Cyst Hidden Behind Coexisting Giant Pituitary
   Adenoma
SO WORLD NEUROSURGERY
LA English
DT Article
DE Endoscopic endonasal surgery; Ethanol cauterization; Pituitary adenoma;
   Rathke cleft cyst
AB BACKGROUND: Although pituitary adenoma (PA) and Rathke cleft cyst (RCC) share a common embryologic origin, concurrent appearances have rarely been reported. We present a case of intractable RCC hidden behind a coexisting giant PA.
   CASE DESCRIPTION: A 39-year-old woman presented to an ophthalmologist with visual disturbance. Brain magnetic resonance imaging findings showed a giant mass in the intrasellar and suprasellar portion, with a cystic portion contained in the posterior part. Endoscopic endonasal surgery was performed to remove the tumor, and histopathologic findings revealed a nonfunctioning PA. Further brain magnetic resonance imaging showed the appearance of a residual cyst. A second endonasal endoscopic surgery was performed to relieve compression of the optic chiasm by the growing cyst, followed by cyst drainage and irrigation, and portions of the cyst walls were obtained. The histopathologic diagnosis was RCC with inflammation. Over the course of 1 year, 3 separate recurrences of the growing cyst were noted, with cyst drainage and irrigation performed each time. Finally, ethanol cauterization was performed, which stopped the symptomatic RCC recurrence. Eight years after the final procedure, there was no cyst recurrence, and the patient's condition was good with improved visual acuity and normal pituitary function.
   CONCLUSIONS: The presence of a nonenhanced cyst with a PA on magnetic resonance imaging suggests the possibility of coexisting RCC and PA.
C1 [Nishimura, Fumihiko; Park, Yong-Soo; Motoyama, Yasushi; Nakagawa, Ichiro; Yamada, Shuichi; Tamura, Kentaro; Matsuda, Ryosuke; Takeshima, Yasuhiro; Takamura, Yoshiaki; Nakase, Hiroyuki] Nara Med Univ, Dept Neurosurg, Kashihara, Nara, Japan.
RP Nishimura, F (reprint author), Nara Med Univ, Dept Neurosurg, Kashihara, Nara, Japan.
EM fnishi@naramed-u.ac.jp
CR Babu Ranjith, 2013, Asian J Neurosurg, V8, P183, DOI 10.4103/1793-5482.125662
   Bader Lucas J, 2004, Pituitary, V7, P39, DOI 10.1023/B:PITU.0000044632.15978.44
   Gao Y, 2014, WORLD J SURG ONCOL, V12, DOI 10.1186/1477-7819-12-94
   Kasliwal MK, 2012, ACTA NEUROCHIR, V154, P665, DOI 10.1007/s00701-012-1284-6
   Miyagi Atsushi, 1993, Neurologia Medico-Chirurgica, V33, P643, DOI 10.2176/nmc.33.643
   NAKASU S, 1989, SURG NEUROL, V31, P41, DOI 10.1016/0090-3019(89)90216-4
   NAYLOR MF, 1995, J COMPUT ASSIST TOMO, V19, P853, DOI 10.1097/00004728-199511000-00003
   NISHIO S, 1987, NEUROSURGERY, V21, P371, DOI 10.1227/00006123-198709000-00016
   Noh SJ, 2007, ACTA NEUROCHIR, V149, P1223, DOI 10.1007/s00701-007-1295-x
   Radhakrishnan N, 2011, INDIAN J PATHOL MICR, V54, P649, DOI 10.4103/0377-4929.85135
   SHANKLIN WM, 1951, ANAT REC, V109, P217, DOI 10.1002/ar.1091090206
   Sumida M, 2001, NEURORADIOLOGY, V43, P755, DOI 10.1007/s002340100559
   Tamura R, 2015, CASE REP NEUROL MED, DOI 10.1155/2015/948025
   TROKOUDES KM, 1978, JAMA-J AM MED ASSOC, V240, P471, DOI 10.1001/jama.240.5.471
   Vancura RW, 2006, ARCH PATHOL LAB MED, V130, P403
NR 15
TC 0
Z9 0
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP 9
EP 11
DI 10.1016/j.wneu.2018.12.105
PG 3
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800108
PM 30610983
DA 2020-05-12
ER

PT J
AU Lin, B
   Yang, HY
   Yang, HJ
   Shen, SY
AF Lin, Bo
   Yang, Hongyu
   Yang, Huijun
   Shen, Shiyue
TI A Rare Case of Bilateral Malignant Paragangliomas
SO WORLD NEUROSURGERY
LA English
DT Article
DE Angiography; Head and neck; Malignant paraganglioma; Treatment
ID CAROTID-BODY TUMOR; NECK PARAGANGLIOMAS; SURGICAL-TREATMENT; HEAD;
   MANAGEMENT; EMBOLIZATION; DIAGNOSIS
AB BACKGROUND: Paragangliomas are neuroendocrine neoplasms that arise from the extra-adrenal paraganglia of the autonomic nervous system. Approximately 3% of all paragangliomas occur in the head and neck region. Most reported cases are benign and unilateral. We present a rare case of bilateral malignant paragangliomas.
   CASE DESCRIPTION: A 28-year-old woman presented with a 10-year history of bilateral neck swelling. Physical examination showed bilateral neck masses with obvious pulsation. Enhanced computed tomography revealed 2 irregular solid nodules, located in the left and right carotid artery bifurcation, respectively. Carotid artery angiography showed compression of the internal and external carotid arteries by the tumors on both sides. On diagnosis of the bilateral carotid body tumors, preoperative embolization was performed. The left-side lesion and lymph nodes were resected and a diagnosis of malignant paraganglioma with lymph node metastasis was made. She was treated with 50-Gy radiotherapy, and computed tomography performed 2 years later showed that the right-side lesion was unchanged. She was symptom-free as of the last follow-up.
   CONCLUSIONS: The rarity of bilateral malignant paragangliomas makes their management clinically challenging. The primary management of a recognized malignancy should be directed toward complete surgical removal of the primary tumor and regional lymph nodes. Postoperative radiation is beneficial in slowing the progression of residual disease. Genetic studies have shown that familial paragangliomas are associated with germline mutation of SDHD on 11q23.
C1 [Lin, Bo; Yang, Hongyu; Yang, Huijun; Shen, Shiyue] Peking Univ, Dept Oral & Maxillofacial Surg, Shenzhen Hosp, Shenzhen, Peoples R China.
RP Yang, HY (reprint author), Peking Univ, Dept Oral & Maxillofacial Surg, Shenzhen Hosp, Shenzhen, Peoples R China.
EM yanghongyu0520@163.com
CR Abu-Ghanem S, 2016, HEAD NECK-J SCI SPEC, V38, pE2386, DOI 10.1002/hed.24381
   ARRIAGA MA, 1992, ANN OTO RHINOL LARYN, V101, P955, DOI 10.1177/000348949210101114
   Ayala-Ramirez M, 2011, J CLIN ENDOCR METAB, V96, P717, DOI 10.1210/jc.2010-1946
   Bastounis E, 1999, EUR J SURG, V165, P198
   Baysal BE, 2008, J MED GENET, V45, P689, DOI 10.1136/jmg.2008.058560
   BHANSALI SA, 1991, OTOLARYNG HEAD NECK, V104, P132, DOI 10.1177/019459989110400126
   Boedeker CC, 2005, OTOLARYNG HEAD NECK, V132, P467, DOI 10.1016/j.otohns.2004.09.024
   Boedeker CC, 2005, FAM CANCER, V4, P55, DOI 10.1007/s10689-004-2154-z
   BRANHAM GH, 1989, OTOLARYNG HEAD NECK, V101, P99, DOI 10.1177/019459988910100117
   Burnichon N, 2009, J CLIN ENDOCR METAB, V94, P2817, DOI 10.1210/jc.2008-2504
   Carroll W, 2004, HEAD NECK-J SCI SPEC, V26, P301, DOI 10.1002/hed.20017
   Chan Wing-Sze, 2007, Int J Cardiol, V118, pe81, DOI 10.1016/j.ijcard.2007.01.024
   Chino JP, 2009, AM J CLIN ONCOL-CANC, V32, P304, DOI 10.1097/COC.0b013e318187dd94
   Cvjetko I, 2013, J CRANIOFAC SURG, V24, pE242, DOI 10.1097/SCS.0b013e31828607ef
   Dardik Alan, 2002, Vasc Endovascular Surg, V36, P277, DOI 10.1177/153857440203600405
   Ghali MGZ, 2017, WORLD NEUROSURG, V101, P559, DOI 10.1016/j.wneu.2017.02.073
   Harrington SW, 1941, ANN SURG, V114, P820, DOI 10.1097/00000658-194111000-00003
   Hinerman RW, 2008, HEAD NECK-J SCI SPEC, V30, P1431, DOI 10.1002/hed.20885
   Torrealba JI, 2016, ANN VASC SURG, V34, P200, DOI 10.1016/j.avsg.2015.12.029
   Isik ACU, 2007, MED PRIN PRACT, V16, P209, DOI 10.1159/000100392
   Isik ACU, 2006, EUR ARCH OTO-RHINO-L, V263, P23, DOI 10.1007/s00405-004-0885-y
   Jansen JC, 2000, CANCER-AM CANCER SOC, V88, P2811, DOI 10.1002/1097-0142(20000615)88:12<2811::AID-CNCR21>3.3.CO;2-Z
   Karatas E, 2008, AURIS NASUS LARYNX, V35, P171, DOI 10.1016/j.anl.2007.05.007
   KLIEWER KE, 1989, HUM PATHOL, V20, P29, DOI 10.1016/0046-8177(89)90199-8
   Konishi M, 2011, EUR ARCH OTO-RHINO-L, V268, P1535, DOI 10.1007/s00405-011-1731-7
   Krych AJ, 2006, INT J RADIAT ONCOL, V65, P1063, DOI 10.1016/j.ijrobp.2006.02.020
   Kupferman ME, 2008, CURR ONCOL REP, V10, P156, DOI 10.1007/s11912-008-0024-9
   LACK EE, 1979, HUM PATHOL, V10, P191, DOI 10.1016/S0046-8177(79)80008-8
   LAMURAGLIA GM, 1992, J VASC SURG, V15, P1038, DOI 10.1016/0741-5214(92)90461-G
   LaMuraglia GM, 1992, J VASC SURG, V15, P1044
   Lee JH, 2002, CANCER, V94, P730, DOI 10.1002/cncr.10252
   Luna-Ortiz K, 2005, ORAL ONCOL, V41, P56, DOI 10.1016/j.oraloncology.2004.06.006
   McDougall CM, 2012, NEUROSURGERY, V71, pE182, DOI 10.1227/NEU.0b013e31824b131b
   Moskovic DJ, 2010, HEAD NECK ONCOL, V2, DOI 10.1186/1758-3284-2-23
   Nishijima H, 2011, ANN OTO RHINOL LARYN, V120, P381, DOI 10.1177/000348941112000606
   Pacheco-Ojeda L, 2001, ANN OTO RHINOL LARYN, V110, P36, DOI 10.1177/000348940111000107
   Patlola R, 2010, INT J CARDIOL, V143, pE7, DOI 10.1016/j.ijcard.2008.12.020
   Persky MS, 2002, HEAD NECK-J SCI SPEC, V24, P423, DOI 10.1002/hed.10068
   Rosa M, 2008, DIAGN CYTOPATHOL, V36, P178, DOI 10.1002/dc.20775
   Sethi RV, 2013, AM J OTOLARYNG, V34, P431, DOI 10.1016/j.amjoto.2013.03.010
   Smeds M, 2013, VASCULAR, V21, P396, DOI 10.1177/1708538112472286
NR 41
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP 12
EP 16
DI 10.1016/j.wneu.2018.12.131
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800109
PM 30611952
DA 2020-05-12
ER

PT J
AU Xu, T
   Liang, RS
AF Xu, Tao
   Liang, Risheng
TI Cerebral Venous Thrombosis with Tumor-Like Features: A Case Report and
   Review of the Literature
SO WORLD NEUROSURGERY
LA English
DT Review
DE Anticoagulation; Brain angiography; Case report; Cerebral venous
   thrombosis; Magnetic resonance venography; Sigmoid sinus venous
   thrombosis
ID SINUS; MIMICKING; DIAGNOSIS; MRI
AB BACKGROUND: Cerebral venous thrombosis (CVT), a rare cerebrovascular condition, is induced by blocked cerebral venous reflux, often presenting nonspecific symptoms. Magnetic resonance imaging (MRI) of the brain may improve the often elusive diagnosis of CVT. However, the sensitivity, specificity, and full spectrum of such MRI findings are poorly understood.
   CASE DESCRIPTION: We report the case of a 53-year-old male patient with CVT. The patient complained of a severe headache in addition to an enhanced lesion on contrasted T1-weighted MR images, which was originally considered an angiogenic tumor. However, surgery and pathology confirmed the case to be CVT. After surgery and administration of an anticoagulation agent, the patient's symptoms alleviated, and cranial MRI and computed tomography 1 month after surgery showed no abnormalities.
   CONCLUSIONS: We conclude that such cases may occur where CVT appears tumor-like on MRI, including mass effect and abnormal contrast enhancement. Therefore, for young and middle-aged adults with episodic and progressive headaches presenting such MRI findings, the possibility of CVT should always be considered. MRI combined with MR venography should be used as the preferred strategy for early diagnosis of CVT.
C1 [Xu, Tao; Liang, Risheng] Fujian Med Univ, Union Hosp, Dept Neurosurg, Fuzhou, Fujian, Peoples R China.
RP Liang, RS (reprint author), Fujian Med Univ, Union Hosp, Dept Neurosurg, Fuzhou, Fujian, Peoples R China.
EM doctorlr123@126.com
CR Alons IME, 2015, BMC NEUROL, V15, DOI 10.1186/s12883-015-0389-y
   Bakshi R, 1998, J NEUROIMAGING, V8, P210, DOI 10.1111/jon199884210
   Boucelma M, 2013, J NEUROSCI RURAL PRA, V4, P381, DOI 10.4103/0976-3147.120193
   Coutinho JM, 2012, STROKE, V43, P3375, DOI 10.1161/STROKEAHA.112.671453
   Dentali F, 2012, J THROMB HAEMOST, V10, P582, DOI 10.1111/j.1538-7836.2012.04637.x
   Ganeshan D, 2010, EUR J RADIOL, V74, P110, DOI 10.1016/j.ejrad.2009.02.007
   Gao LS, 2018, THROMB RES, V167, P64, DOI 10.1016/j.thromres.2018.05.012
   Gradinscak DJ, 2004, CLIN NUCL MED, V29, P68, DOI 10.1097/01.rlu.0000103233.31619.d1
   Issar Pratibha, 2017, J Assoc Physicians India, V65, P16
   Luo YX, 2018, FRONT AGING NEUROSCI, V10, DOI 10.3389/fnagi.2018.00002
   Masuoka J, 2009, NEUROL MED-CHIR, V49, P359, DOI 10.2176/nmc.49.359
   Meng R, 2014, INT J STROKE, V9, P166, DOI 10.1111/ijs.12034
   Smith E, 2018, EMERG MED J, V35, P396, DOI 10.1136/emermed-2018-207777.1
   Stam J, 2005, NEW ENGL J MED, V352, P1791, DOI 10.1056/NEJMra042354
   Wang XT, 2012, EXP THER MED, V4, P923, DOI 10.3892/etm.2012.697
   Wei Y, 2018, NEUROSCI LETT, V662, P205, DOI 10.1016/j.neulet.2017.10.041
   Xu WL, 2018, THROMB HAEMOSTASIS, V118, P1067, DOI 10.1055/s-0038-1642636
   Yu YX, 2016, ONCOL LETT, V11, P649, DOI 10.3892/ol.2015.3931
   Zhou G, 2016, EUR NEUROL, V75, P257, DOI 10.1159/000446649
NR 19
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP 17
EP 21
DI 10.1016/j.wneu.2018.12.109
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800110
PM 30610975
DA 2020-05-12
ER

PT J
AU Goto, S
   Izumi, T
   Nishihori, M
   Ishida, M
   Ishida, T
   Otawa, M
   Kawaguchi, T
   Oshima, R
   Kropp, A
   Ikezawa, M
   Wakabayashi, T
AF Goto, Shunsaku
   Izumi, Takashi
   Nishihori, Masahiro
   Ishida, Mamoru
   Ishida, Tetsuya
   Otawa, Masato
   Kawaguchi, Tomoki
   Oshima, Ryosuke
   Kropp, Asuka
   Ikezawa, Mizuka
   Wakabayashi, Toshihiko
TI Cardiac Arrest Induced by Carotid Sinus Reflex Activation During
   Flow-Diverter Stent Deployment
SO WORLD NEUROSURGERY
LA English
DT Article
DE Carotid sinus reflex; Complication; Flow diverter stent
ID ANEURYSMS; PIPELINE
AB BACKGROUND: A 60-year-old female with multiple carotid aneurysms underwent endovascular treatment with a Pipeline Flex embolization device (PED) under local anesthesia via femoral puncture.
   CASE DESCRIPTION: Cardiac arrest occurred when the delivery systems were pushed to promote adequate opening and apposition of the PED against the vessel wall and was recovered to sinus rhythm in approximately 30 seconds by pulling down the microcatheter. The carotid sinus reflex was suspected as the cause of this temporary asystole. Delivery of the PED was accompanied by application of forward pressure on the delivery system. This resulted in buckling of the delivery systems in the neck and likely excessive pressure on the carotid sinus. The procedure was continued and successfully completed with care not to excessively push the system and with the additional use of atropine.
   CONCLUSIONS: Although it was a rare complication, the phenomenon and its mechanisms were known in the carotid artery stenting procedure. To the best of our knowledge, this is the first report of cardiac arrest induced by a carotid sinus reflex during PED deployment. It is important for an operator of PED deployment to recognize its possibility. Vital signs should be closely checked during PED deployment, particularly while pushing the catheter.
C1 [Goto, Shunsaku; Izumi, Takashi; Nishihori, Masahiro; Ishida, Mamoru; Ishida, Tetsuya; Otawa, Masato; Kawaguchi, Tomoki; Oshima, Ryosuke; Kropp, Asuka; Ikezawa, Mizuka; Wakabayashi, Toshihiko] Nagoya Univ, Dept Neurosurg, Grad Sch Med, Nagoya, Aichi, Japan.
RP Izumi, T (reprint author), Nagoya Univ, Dept Neurosurg, Grad Sch Med, Nagoya, Aichi, Japan.
EM panda_aichi@yahoo.co.jp
CR Becske T, 2013, RADIOLOGY, V267, P858, DOI 10.1148/radiol.13120099
   Brinjikji W, 2013, STROKE, V44, P442, DOI 10.1161/STROKEAHA.112.678151
   Bujak M, 2015, CATHETER CARDIO INTE, V85, P282, DOI 10.1002/ccd.25622
   Cayne NS, 2005, J VASC SURG, V41, P956, DOI 10.1016/j.jvs.2005.02.038
   Kallmes DF, 2015, AM J NEURORADIOL, V36, P108, DOI 10.3174/ajnr.A4111
   Mas J, 2006, NEW ENGL J MED, V355, P1660, DOI 10.1056/NEJMoa061752
   Mylonas SN, 2013, J ENDOVASC THER, V20, P48, DOI 10.1583/12-4015.1
   Zhou G, 2017, NEUROSURG FOCUS, V42, DOI 10.3171/2017.3.FOCUS16450
NR 8
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP 22
EP 24
DI 10.1016/j.wneu.2018.12.136
PG 3
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800111
PM 30615992
DA 2020-05-12
ER

PT J
AU Ren, YQ
   Wu, YQ
   Guo, G
AF Ren, Yeqing
   Wu, Yongqiang
   Guo, Geng
TI Terson Syndrome Secondary to Subarachnoid Hemorrhage: A Case Report
SO WORLD NEUROSURGERY
LA English
DT Article
DE Subarachnoid hemorrhage; Terson syndrome; Vitreous hemorrhage
AB BACKGROUND: Terson syndrome is a serious complication of subarachnoid hemorrhage (SAH) that includes any intraocular hemorrhage and may result in blurred vision or even blindness. However, it is often overlooked clinically.
   CASE DESCRIPTION: A 42-year-old man presented with coma due to rupture of a left posterior communicating artery aneurysm. A preoperative computed tomography scan demonstrated SAH and bilateral fundus hemorrhage. Visual evoked potential and B-scan ocular ultrasound revealed vitreous hemorrhages, features consistent with Terson syndrome. Pars plana vitrectomy was performed 2 weeks after SAH with a subsequent improvement of visual acuity.
   CONCLUSIONS: Early identification is important for the recovery of the patient's nervous system and ophthalmology. Neurosurgeons should be aware of the pathology and pay attention to it to maximize patient's benefit.
C1 [Ren, Yeqing; Wu, Yongqiang; Guo, Geng] Shanxi Med Univ, Hosp 1, Dept Neurosurg, Taiyuan, Shanxi, Peoples R China.
RP Guo, G (reprint author), Shanxi Med Univ, Hosp 1, Dept Neurosurg, Taiyuan, Shanxi, Peoples R China.
EM guogeng973@163.com
OI Ren, Yeqing/0000-0003-4030-3404
CR Baker ML, 2008, J CLIN NEUROSCI, V15, P313, DOI 10.1016/j.jocn.2006.09.011
   Czorlich P, 2016, J CLIN NEUROSCI, V33, P182, DOI 10.1016/j.jocn.2016.04.015
   Czorlich P, 2015, NEUROSURG REV, V38, P129, DOI 10.1007/s10143-014-0564-4
   Czorlich P, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114907
   Garweg JG, 2009, ACTA OPHTHALMOL, V87, P222, DOI 10.1111/j.1755-3768.2008.01200.x
   Hoving EW, 2009, J NEUROSURG, V110, P858, DOI 10.3171/2008.6.17610
   Iuliano L, 2014, CASE REP OPHTHALMOL, DOI 10.1155/2014/689793
   Joswig H, 2016, ACTA NEUROCHIR, V158, P1027, DOI 10.1007/s00701-016-2766-8
   Kim HS, 2012, J KOREAN NEUROSURG S, V51, P367, DOI 10.3340/jkns.2012.51.6.367
   Kunle-Hassan Feyi, 2018, Retin Cases Brief Rep, V12, P216, DOI 10.1097/ICB.0000000000000458
   Litten M, 1881, BERL KLIN WOCHENSCHR, V18, P23
   Michalewska Zofia, 2010, Ophthalmic Surg Lasers Imaging, V41 Suppl, pS42, DOI 10.3928/15428877-20101031-15
   Moteki Y, 2018, WORLD NEUROSURG, V116, pE505, DOI 10.1016/j.wneu.2018.05.021
   Munteanu M, 2019, INT OPHTHALMOL, V39, P461, DOI 10.1007/s10792-018-0822-5
   Naseri A, 2001, NEUROLOGY, V57, P364, DOI 10.1212/WNL.57.2.364
   Ogawa T, 2001, OPHTHALMOLOGY, V108, P1654, DOI 10.1016/S0161-6420(01)00673-X
   Pagani-Estevez GL, 2016, REGION ANESTH PAIN M, V41, P164, DOI 10.1097/AAP.0000000000000352
   Seif GI, 2014, CAN J NEUROL SCI, V41, P572, DOI 10.1017/cjn.2014.7
   Stienen MN, 2012, CLIN NEUROL NEUROSUR, V114, P535, DOI 10.1016/j.clineuro.2011.10.034
   Swallow CE, 1998, AM J NEURORADIOL, V19, P743
   Terson A, 1900, CLIN OPHTHALMOL, V6, P309
NR 21
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP 25
EP 28
DI 10.1016/j.wneu.2018.12.084
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800112
PM 30599249
DA 2020-05-12
ER

PT J
AU Guida, L
   Roux, FE
   Massimino, M
   Marras, CE
   Sganzerla, E
   Giussani, C
AF Guida, Lelio
   Roux, Frank-Emmanuel
   Massimino, Maura
   Marras, Carlo E.
   Sganzerla, Erik
   Giussani, Carlo
TI Safety and Efficacy of Endoscopic Third Ventriculostomy in Diffuse
   Intrinsic Pontine Glioma Related Hydrocephalus: A Systematic Review
SO WORLD NEUROSURGERY
LA English
DT Review
DE Diffuse intrinsic pontine glioma; Endoscopic third ventriculostomy;
   Hydrocephalus; Torkildsen shunt; Ventriculocisternal shunt;
   Ventriculoperitoneal shunt
ID BRAIN-STEM GLIOMAS; VENTRICULOPERITONEAL SHUNT; EXTRANEURAL METASTASES;
   METAANALYSES; CHILDHOOD; RADIATION; BIOPSY
AB OBJECTIVE: Diffuse intrinsic pontine glioma (DIPG) related hydrocephalus occurs as the result of tumor growth and sylvian aqueduct obstruction. There is no consensus about the best surgical option; thus, a review has been performed to clarify the rate of success, complications, and possible issues of endoscopic third ventriculostomy (ETV) in comparison to other available techniques.
   METHODS: This systematic review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement, and was registered with the International Prospective Register of Systematic Reviews (PROSPERO) (registration number CRD42018089001). MEDLINE, Web of Knowledge, and EMBASE were searched for published series in which ETV was performed to treat hydrocephalus in DIPG patients.
   RESULTS: Six studies were included. Two further cases from our experience were added for a total amount of 55 patients treated through either ETV, ventriculoperitoneal shunt (VPS), or ventriculocisternal shunt according to Torkildsen. Eighty-six percent of patients who underwent ETV experienced clinical improvement after surgery (P value 0.03). Torkildsen shunt placement was associated with a 50% failure rate. Two patients implanted with VPS developed symptoms of shunt malfunction and increased ventricular sizes (10%). The Fisher exact test was applied to compare efficacy of VPS and ETV with no statistical difference between the 2 groups (P value 0.17). Patients who underwent ETV did not experience major complications, and no procedural termination was observed.
   CONCLUSIONS: ETV is an effective and safe treatment option, associated with a low complication rate and a high success rate. Evidences from this review suggest considering ETV as the first-line treatment of hydrocephalus in DIPG patients.
C1 [Guida, Lelio; Sganzerla, Erik; Giussani, Carlo] Univ Milano Bicocca, Sch Med, Dept Neurosurg, Osped San Gerardo, Monza, Italy.
   [Roux, Frank-Emmanuel] Univ Toulouse, CHU Toulouse, Pole Neurosci Neurochirurg, UPS, Toulouse, France.
   [Massimino, Maura] Fdn IRCCS Ist Nazl Tumori, Dept Pediat Oncol, Milan, Italy.
   [Marras, Carlo E.] Bambino Gesu Childrens Hosp IRCCS, Dept Neurosurg, Rome, Italy.
RP Giussani, C (reprint author), Univ Milano Bicocca, Sch Med, Dept Neurosurg, Osped San Gerardo, Monza, Italy.
EM carlo.giussani@unimib.it
RI Marras, Carlo Efisio/AAA-4964-2020; Massimino, Maura/K-7310-2016
OI Marras, Carlo Efisio/0000-0003-0790-8903; Massimino,
   Maura/0000-0002-5506-2001; Guida, Lelio/0000-0001-6981-6698
CR Amano T, 2002, CHILD NERV SYST, V18, P599, DOI 10.1007/s00381-002-0637-5
   Barajas RF, 2015, J NEUROL SURG REP, V76, P91, DOI 10.1055/s-0035-1547365
   BOURAS T, 2013, [No title captured], V79, pE9
   Carai A, 2017, WORLD NEUROSURG, V101, P584, DOI 10.1016/j.wneu.2017.02.088
   Choux M, 1999, PEDIAT NEUROSURGERY
   Donahue B, 1998, INT J RADIAT ONCOL, V40, P677, DOI 10.1016/S0360-3016(97)00846-8
   Drake JM, 2009, CHILD NERV SYST, V25, P467, DOI 10.1007/s00381-008-0761-y
   DUFFNER PK, 1981, ANN NEUROL, V10, P261, DOI 10.1002/ana.410100311
   EPSTEIN F, 1986, J NEUROSURG, V64, P11, DOI 10.3171/jns.1986.64.1.0011
   Giussani C, 2017, WORLD NEUROSURG, V103, P257, DOI 10.1016/j.wneu.2017.03.143
   Hellwig D, 2005, NEUROSURG REV, V28, P1, DOI 10.1007/s10143-004-036-2
   Jacques TS, 2008, CYTOPATHOLOGY, V19, P264, DOI 10.1111/j.1365-2303.2007.00510.x
   JIMENEZJIMENEZ FJ, 1991, J NEUROL NEUROSUR PS, V54, P281, DOI 10.1136/jnnp.54.3.281
   Jones C, 2017, NEURO-ONCOLOGY, V19, P153, DOI 10.1093/neuonc/now101
   KEATING RF, 2001, TUMORS PEDIAT CENTRA
   Khatua S, 2011, CHILD NERV SYST, V27, P1391, DOI 10.1007/s00381-011-1468-z
   Kieran MW, 2016, J NEUROSURG-PEDIATR, V18, P390, DOI 10.3171/2015.6.PEDS15374
   Klimo P, 2006, J NEUROSURG, V105, P271, DOI 10.3171/ped.2006.105.4.271
   Kobayashi N, 2016, CHILD NERV SYST, V32, P1251, DOI 10.1007/s00381-016-3065-7
   Liberati A, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000100
   Massimino M, 2014, J NEURO-ONCOL, V118, P305, DOI 10.1007/s11060-014-1428-z
   Moher D, 2000, ONKOLOGIE, V23, P597, DOI 10.1159/000055014
   Moher D, 2010, INT J SURG, V8, P336, DOI 10.1016/j.ijsu.2010.02.007
   Morota N, 2010, CHILD NERV SYST, V26, P1705, DOI 10.1007/s00381-010-1182-2
   Packer RJ, 1996, PEDIATR NEUROSURG, V24, P211, DOI 10.1159/000121040
   PACKER RJ, 1993, CANCER-AM CANCER SOC, V72, P1414, DOI 10.1002/1097-0142(19930815)72:4<1414::AID-CNCR2820720442>3.0.CO;2-C
   Packer RJ, 2017, NEURO-ONCOLOGY, V19, P750, DOI 10.1093/neuonc/now209
   Raja AI, 2007, J NEUROSURG, V106, P44, DOI 10.3171/ped.2007.106.1.44
   Ray Pulak, 2005, Neurosurg Focus, V19, pE8
   Rekate HL, 2004, NEUROSURG CLIN N AM, V15, P39, DOI 10.1016/S1042-3680(03)00074-3
   Roujeau T, 2011, CHILD NERV SYST, V27, P1735, DOI 10.1007/s00381-011-1538-2
   Sacko O, 2010, J NEUROSURG-PEDIATR, V5, P68, DOI 10.3171/2009.8.PEDS08108
   Souweidane MM, 2010, J NEUROS-PEDIATR, V5, P250, DOI 10.3171/2009.10.PEDS09187
   Torkildsen A, 1939, ACTA PSYCH NEUROL, V14, P221, DOI 10.1111/j.1600-0447.1939.tb06636.x
   Tuli S, 1999, PEDIATR NEUROSURG, V30, P11, DOI 10.1159/000028753
NR 35
TC 3
Z9 3
U1 1
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP 29
EP 35
DI 10.1016/j.wneu.2018.12.096
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800113
PM 30599251
DA 2020-05-12
ER

PT J
AU Furtado, SV
   Berenstein, A
AF Furtado, Sunil, V
   Berenstein, Alejandro
TI Distal Microcatheter Placement Using the ASAHI CHIKAI 008 Microguidewire
   for Liquid Embolic Material Delivery
SO WORLD NEUROSURGERY
LA English
DT Article
DE Embolization; Microcatheter; Microguidewire; Vascular malformations
ID DETACHABLE TIP MICROCATHETER; ARTERIOVENOUS-MALFORMATIONS; ENDOVASCULAR
   TREATMENT; EMBOLIZATION
AB BACKGROUND: Management of vascular malformations requires microcatheter manipulation through distal tortuous arterial feeders <1 mm in diameter to permit safe and effective embolization at the fistula or nidus location. The ASAHI CHIKAI 008 microguidewire (ACM) recently introduced in the United States was used to evaluate microcatheter torque, support, and safety in distal microcatheter navigation.
   METHODS: The use of the ACM in conjunction with flow-directed and over-the-wire microcatheters was evaluated in 25 neuroendovascular cases performed by a single operator for endovascular microcatheter embolization of intracranial vascular malformations over a 1-year period. The study evaluated angiographic evidence of distal microcatheter positioning, subsequent obliteration of the fistula at the location, and any complications.
   RESULTS: The microguidewire was used in microcatheter embolization of 10 vein of Galen malformations, 11 brain and head and neck arteriovenous malformations, 2 spinal dural arteriovenous fistulas, and 2 cranial dural arteriovenous fistulas. Good flow-directed and over-the-wire microcatheter placement using the ACM was possible across the spectrum of cases achieving optimal catheterization and safe embolization in all. There were no microguidewire- or microcatheter-related vessel spasms, dissections, or perforations during combined or individual manipulation and no contrast or embolic extravasation on fluoroscopy or postembolization angiography.
   CONCLUSIONS: The ACM is a safe, sturdy microguidewire that provides good torque in distal arterial anatomy, while providing microcatheter support and maintaining tip configuration on repeated use.
C1 [Furtado, Sunil, V] Ramaiah Med Coll & Hosp, Dept Neurosurg, Bangalore, Karnataka, India.
   [Berenstein, Alejandro] Icahn Sch Med, Mt Sinai Hlth Care Syst, Dept Neurosurg, New York, NY 10029 USA.
RP Furtado, SV (reprint author), Ramaiah Med Coll & Hosp, Dept Neurosurg, Bangalore, Karnataka, India.
EM sunilvf@gmail.com
CR Aletich VA, 1997, AM J NEURORADIOL, V18, P929
   Altschul D, 2014, CHILD NERV SYST, V30, P1099, DOI 10.1007/s00381-014-2404-9
   Baharvahdat H, 2014, AM J NEURORADIOL, V35, P978, DOI 10.3174/ajnr.A3906
   Berenstein A, 2010, CHILD NERV SYST, V26, P1345, DOI 10.1007/s00381-010-1206-y
   Gailloud Philippe, 2005, J Perinatol, V25, P542
   Guimaraes Marcelo, 2011, Semin Intervent Radiol, V28, P350, DOI 10.1055/s-0031-1284462
   Lin N, 2015, J NEUROINTERV SURG, V7, P835, DOI 10.1136/neurintsurg-2014-011352
   Paramasivam S, 2015, J NEUROINTERV SURG, V7, P458, DOI 10.1136/neurintsurg-2014-011165
   To CY, 2013, J NEUROINTERV SURG, V5, pE50, DOI 10.1136/neurintsurg-2012-010519.rep
   Weber W, 2007, AM J NEURORADIOL, V28, P371
NR 10
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP 36
EP 43
DI 10.1016/j.wneu.2018.12.132
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800114
PM 30615991
DA 2020-05-12
ER

PT J
AU Michiwaki, Y
   Nakamizo, A
   Kawano, Y
   Tsumoto, T
AF Michiwaki, Yuhei
   Nakamizo, Akira
   Kawano, Yosuke
   Tsumoto, Tomoyuki
TI Ruptured Cerebral Arteriovenous Malformation During Fifth Pregnancy:
   Case Report and Literature Review
SO WORLD NEUROSURGERY
LA English
DT Review
DE Cerebral arteriovenous malformation; Hemorrhage; Pregnancy; Stroke
ID INTRACRANIAL HEMORRHAGE; RISK
AB BACKGROUND: Whether the risk of rupture of a cerebral arteriovenous malformation (AVM) increases during pregnancy remains controversial. Moreover, it is unclear whether the number of pregnancies correlates with AVM rupture risk. We report a case of ruptured AVM during the fifth pregnancy.
   CASE DESCRIPTION: A 34-year-old woman presenting sudden headache and vomiting was admitted to our hospital. Neuroimaging revealed a subarachnoid hemorrhage due to a ruptured AVM in the right temporal lobe. She was pregnant (9 weeks and 1 day), and she had previously experienced 4 normal vaginal deliveries (gravidity and parity G4P4) without complications. Elective treatment including neuroendovascular and direct surgery was performed, and the AVM was safely resected (at 15 weeks, 6 days of pregnancy). She underwent elective caesarean section without complications 151 days after the AVM resection (at 37 weeks, 1 day of pregnancy), and the baby was healthy.
   CONCLUSIONS: This report suggests that the risk of AVM rupture persists even after multiple deliveries. Intracranial hemorrhage should be suspected in pregnant patients who underwent multiple deliveries, and a rapid diagnosis and appropriate treatment are necessary.
C1 [Michiwaki, Yuhei] Kyushu Univ, Grad Sch Med Sci, Dept Neurosurg, Fukuoka, Fukuoka, Japan.
   [Michiwaki, Yuhei; Nakamizo, Akira; Kawano, Yosuke] Natl Hosp Org Kyushu Med Ctr, Dept Neurosurg, Clin Res Inst, Fukuoka, Fukuoka, Japan.
   [Tsumoto, Tomoyuki] Natl Hosp Org Kyushu Med Ctr, Dept Neuroendovasc Surg, Clin Res Inst, Fukuoka, Fukuoka, Japan.
RP Michiwaki, Y (reprint author), Kyushu Univ, Grad Sch Med Sci, Dept Neurosurg, Fukuoka, Fukuoka, Japan.; Michiwaki, Y (reprint author), Natl Hosp Org Kyushu Med Ctr, Dept Neurosurg, Clin Res Inst, Fukuoka, Fukuoka, Japan.
EM wayside.bamboo@gmail.com
CR DIAS MS, 1990, NEUROSURGERY, V27, P855, DOI 10.1227/00006123-199012000-00001
   Fukuda K, 2013, NEUROL MED-CHIR, V53, P565, DOI 10.2176/nmc.53.565
   Gross BA, 2013, J NEUROSURG, V118, P437, DOI 10.3171/2012.10.JNS121280
   Gross BA, 2012, NEUROSURGERY, V71, P349, DOI 10.1227/NEU.0b013e318256c34b
   Karnad Dilip R, 2005, Crit Care Med, V33, pS362, DOI 10.1097/01.CCM.0000182790.35728.F7
   Liu XJ, 2014, NEUROLOGY, V82, P1798, DOI 10.1212/WNL.0000000000000436
   Porras JL, 2017, STROKE, V48, P1507, DOI 10.1161/STROKEAHA.117.016828
   Takahashi JC, 2014, J STROKE CEREBROVASC, V23, pE65, DOI 10.1016/j.jstrokecerebrovasdis.2013.08.017
   Zhu DY, 2018, WORLD NEUROSURG, V111, pE301, DOI 10.1016/j.wneu.2017.12.056
NR 9
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP 45
EP 47
DI 10.1016/j.wneu.2018.12.130
PG 3
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800116
PM 30611953
DA 2020-05-12
ER

PT J
AU Kim, KH
   Chong, SJ
   Lee, JY
   Kim, SK
   Cho, BK
   Wang, KC
AF Kim, Kyung Hyun
   Chong, Sangjoon
   Lee, Ji Yeoun
   Kim, Seung-Ki
   Cho, Byung-Kyu
   Wang, Kyu-Chang
TI A Method of Untethering by Skipping the Area of Positive Responses on
   Electrical Stimulation During Surgery of Lumbosacral Lipomatous
   Malformation: "Hopping on a Stepping Stone"
SO WORLD NEUROSURGERY
LA English
DT Article
DE Intraoperative electrical stimulation; Lumbosacral lipomatous
   malformation; Root; Untethering
AB OBJECTIVE: In complex lumbosacral lipomatous malformation or retethering, "crotch" dissection, an incision on the dura or lipoma at the site lateral to the lipoma-cord fusion line saving underlying roots, is often not easy. Attempts of this dissection in complex and obscured conditions may cause damage to the spinal cord or nerve roots. A method for caudal extension of untethering while positive areas on electrical stimulation were encountered during the crotch dissection of lumbosacral lipomatous malformation is described.
   METHODS: After thinning out the negative-response area just caudal to the positive-response area, a small perforation is made at the negative-response area skipping the positive-response area with probing the dissection direction through the subarachnoid space by an inside-out fashion. Subsequently, the procedure is continued caudally from the perforation site.
   RESULTS: Safe caudal extension of untethering is possible using this method. Illustrative operative photographs are shown.
   CONCLUSIONS: By using this method, safe untethering can be achieved avoiding root injuries in complicated lipomas such as chaotic or retethering cases.
C1 [Kim, Kyung Hyun; Lee, Ji Yeoun; Kim, Seung-Ki; Wang, Kyu-Chang] Seoul Natl Univ, Div Pediat Neurosurg, Childrens Hosp, Seoul, South Korea.
   [Chong, Sangjoon] Asan Med Ctr, Dept Neurosurg, Seoul, South Korea.
   [Lee, Ji Yeoun] Seoul Natl Univ, Dept Anat, Coll Med, Seoul, South Korea.
   [Cho, Byung-Kyu] Armed Forces Capital Hosp, Dept Neurosurg, Gyeonggi Do, South Korea.
RP Wang, KC (reprint author), Seoul Natl Univ, Div Pediat Neurosurg, Childrens Hosp, Seoul, South Korea.
EM kcwang@snu.ac.kr
OI Kim, Kyung Hyun/0000-0002-8238-2043
FU Mid-career Researcher Program through NRF - Korea government (Ministry
   of Science and ICT) [2015R1A2A1A15055781]
FX This work (2015R1A2A1A15055781) was supported by Mid-career Researcher
   Program through NRF grant funded by the Korea government (Ministry of
   Science and ICT).
CR FUJIWARA F, 1995, NEUROSURGERY, V37, P1212, DOI 10.1227/00006123-199512000-00024
   Krassioukov AV, 2004, J NEUROSURG-SPINE, V1, P243, DOI 10.3171/spi.2004.1.3.0243
   Pang D, 2009, NEUROSURGERY, V65, P511, DOI 10.1227/01.NEU.0000350879.02128.80
NR 3
TC 0
Z9 0
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP 48
EP 51
DI 10.1016/j.wneu.2018.12.137
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800117
PM 30615990
DA 2020-05-12
ER

PT J
AU Nakajo, K
   Uda, T
   Sasaki, T
   Tanaka, S
   Nishijima, S
   Watanabe, Y
   Yamanaka, K
   Ohata, K
AF Nakajo, Kosuke
   Uda, Takehiro
   Sasaki, Tsuyoshi
   Tanaka, Sayaka
   Nishijima, Shugo
   Watanabe, Yusuke
   Yamanaka, Kazuhiro
   Ohata, Kenji
TI Case Report and Review of the Literature of Schwannomas That Originate
   from Falx Cerebri
SO WORLD NEUROSURGERY
LA English
DT Review
DE Falx cerebri; Schwannoma
ID INTRACEREBRAL SCHWANNOMA
AB BACKGROUND: Schwannomas not related to cranial nerves are rare. Here, we present a case of a schwannoma that originated from the falx cerebri and review reported cases in the literature.
   CASE DESCRIPTION: A 36-year-old male experienced generalized seizures following right hemiparesis predominantly in his lower extremity. Magnetic resonance imaging revealed a round tumor attached to the falx cerebri on the left side. Radiologically, the tumor appeared to be a falx meningioma. We performed gross total removal of the tumor. Pathology showed a schwannoma that originated from the falx cerebri. Right hemiparesis disappeared soon after surgery.
   CONCLUSION: Although distinguishing a schwannoma of the falx cerebri from a falx meningioma and metastasis is difficult preoperatively, inclusion of schwannoma of the falx cerebri in the differential diagnosis is important, especially when the patient is relatively young and/or the tumor lacks a dural tail sign.
C1 [Nakajo, Kosuke; Uda, Takehiro; Sasaki, Tsuyoshi; Nishijima, Shugo; Watanabe, Yusuke; Yamanaka, Kazuhiro; Ohata, Kenji] Osaka City Univ, Grad Sch Med, Dept Neurosurg, Osaka, Japan.
   [Tanaka, Sayaka] Osaka City Univ, Grad Sch Med, Dept Pathol, Osaka, Japan.
RP Nakajo, K (reprint author), Osaka City Univ, Grad Sch Med, Dept Neurosurg, Osaka, Japan.
EM kousuke19841984@yahoo.co.jp
OI Uda, Takehiro/0000-0001-6422-4140
CR BRUNI P, 1984, SURG NEUROL, V22, P360, DOI 10.1016/0090-3019(84)90140-X
   Celikoglu E, 2007, J CLIN NEUROSCI, V14, P589, DOI 10.1016/j.jocn.2006.04.014
   GHOSH S, 1992, BRIT J NEUROSURG, V6, P163, DOI 10.3109/02688699209002921
   Horgan MA, 1998, J NEUROSURG, V89, P490, DOI 10.3171/jns.1998.89.3.0490
   Ma L, 2013, J CRANIOFAC SURG, V24, pE541, DOI 10.1097/SCS.0b013e31828601bf
   Nagata T, 2011, NEUROL MED-CHIR, V51, P382, DOI 10.2176/nmc.51.382
   Nyberg G, 1997, ACTA OTO-LARYNGOL, V117, P482, DOI 10.3109/00016489709113425
   Raswan Uday S, 2017, Surg Neurol Int, V8, P228, DOI 10.4103/sni.sni_374_16
   Russels DS, 1989, PATHOL TUMOURS NER, P776
   Sakamoto H, 2000, ACTA OTO-LARYNGOL, P18
   VAQUERO J, 1990, SURG NEUROL, V34, P160, DOI 10.1016/0090-3019(90)90066-X
   Zagardo MT, 1998, AM J NEURORADIOL, V19, P1290
NR 12
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP 52
EP 55
DI 10.1016/j.wneu.2018.12.122
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800118
PM 30611950
DA 2020-05-12
ER

PT J
AU Lee, JJ
   Ryu, G
   Kim, HY
   Dhong, HJ
   Chung, SK
   Hong, SD
AF Lee, Jung Joo
   Ryu, Gwanghui
   Kim, Hyo Yeol
   Dhong, Hun-Jong
   Chung, Seung-Kyu
   Hong, Sang Duk
TI Endoscopic 2-Port Technique for Infratemporal Fossa Tumors: Using
   Prelacrimal Medial Maxillectomy and Caldwell-Luc Approach
SO WORLD NEUROSURGERY
LA English
DT Article
DE Caldwell-Luc; Endoscopic; Infratemporal fossa; Prelacrimal
ID PTERYGOPALATINE FOSSA; ENDONASAL APPROACH; RECESS APPROACH; SCHWANNOMA;
   WALL
AB BACKGROUND: The endoscopic endonasal approach to the infratemporal fossa (ITF) has gained popularity. However, the inferior turbinate and/or lacrimal duct are often removed when performing endoscopic medial maxillectomy for ITF approach, and there is potential risk for empty nose syndrome or epiphora. Although the endoscopic prelacrimal recess approach was introduced to avoid these complications, there were some limitations associated with surgical freedom. We report a 2-port endoscopic technique using both prelacrimal recess and antral window as a means to preserve the inferior turbinate and lacrimal duct, while facilitating instrument availability during ITF tumor resection. -
   METHODS: We retrospectively reviewed 3 patients between September 2016 and May 2018 who were treated with a modified 2-port technique for ITF tumors.
   RESULTS: There was 1 case of trigeminal schwannoma originating in the mandibular nerve, 1 recurrent meningioma, and 1 paraganglioma. The 2-port technique was not initially planned in these 3 cases, but it was decided to use the technique during surgery because tumors were extensively attached to surrounding muscles and had profuse bleeding. After tumor resection, sinonasal anatomy including inferior turbinate and lacrimal duct was well preserved.
   CONCLUSIONS: We propose a hybrid endoscopic surgical procedure for ITF tumors using both endoscopic prelacrimal recess approach and transantral window. This technique provides surgeons an adequate working space via a bimanual technique through 2 different ports, while preserving normal sinonasal structures.
C1 [Lee, Jung Joo; Ryu, Gwanghui; Kim, Hyo Yeol; Dhong, Hun-Jong; Chung, Seung-Kyu; Hong, Sang Duk] Sungkyunkwan Univ, Sch Med, Dept Otorhinolaryngol Head & Neck Surg, Samsung Med Ctr, Seoul, South Korea.
RP Hong, SD (reprint author), Sungkyunkwan Univ, Sch Med, Dept Otorhinolaryngol Head & Neck Surg, Samsung Med Ctr, Seoul, South Korea.
EM kkam97@gmail.com
CR Alfieri A, 2003, NEUROSURGERY, V52, P374, DOI 10.1227/01.NEU.0000044562.73763.00
   Attia M, 2013, WORLD NEUROSURG, V80, pE367, DOI 10.1016/j.wneu.2012.10.016
   Bao S, 2006, SURG NEUROL S1, V66, pS17
   Gao L, 2017, J CRANIOFAC SURG, V28, P1589, DOI 10.1097/SCS.0000000000003419
   He HY, 2018, WORLD NEUROSURG, V118, P172, DOI 10.1016/j.wneu.2018.07.087
   Kasemsiri P, 2013, LARYNGOSCOPE, V123, P811, DOI 10.1002/lary.23697
   Lin YT, 2018, INT FORUM ALLERGY RH, V8, P530, DOI 10.1002/alr.22062
   OSGUTHORPE JD, 1991, ARCH OTOLARYNGOL, V117, P751
   Pasquini E, 2002, AM J RHINOL, V16, P113, DOI 10.1177/194589240201600208
   Simmen D, 2017, RHINOLOGY, V55, P170, DOI [10.4193/Rhino16.318, 10.4193/Rhin16.318]
   Truong HQ, 2019, J NEUROSURG, V131, P154, DOI 10.3171/2018.2.JNS172959
   Zhou B, 2016, J NEUROSURG, V124, P1068, DOI 10.3171/2015.3.JNS132702
   Zhou B, 2013, CHINESE MED J-PEKING, V126, P1276, DOI 10.3760/cma.j.issn.0366-6999.20121754
   Zhou Bing, 2007, Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi, V42, P743
NR 14
TC 2
Z9 2
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP 56
EP 61
DI 10.1016/j.wneu.2018.12.134
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800119
PM 30611951
DA 2020-05-12
ER

PT J
AU Rocca, G
   Caputo, F
   Terranova, C
   Alice, S
   Ventura, F
AF Rocca, Gabriele
   Caputo, Fiorella
   Terranova, Claudio
   Alice, Stefano
   Ventura, Francesco
TI Myelopathy Due to Intracranial Dural Arteriovenous Fistula with
   Perimedullary Venous Drainage: Clinical and Medicolegal Aspects in a
   Case of Diagnostic Pitfall
SO WORLD NEUROSURGERY
LA English
DT Article
DE Diagnostic delay; Dural arteriovenous fistula; Myelopathy
ID CLASSIFICATION; MALFORMATIONS; SINUS; RISK
AB BACKGROUND: Intracranial dural arteriovenous fistula (DAVF) consists of a meshwork of arteriovenous shunts. Drainage of the fistula may be into a dural sinus or directly into cortical veins. Rarely, dural arteriovenous fistulas drain exclusively into perimedullary veins. Prompt diagnosis is important, as the clinical course is potentially life threatening.
   CASE DESCRIPTION: A 67-year-old man presented with difficulties in walking and bladder retention. Magnetic resonance imaging showed central myelopathy, edema from C6 to T8, and dilated posterior medullary veins. Spinal angiography showed no abnormalities. The diagnostic impression was one of inflammatory demyelinating disease, and the patient was treated with corticosteroids. Three days later, the patient had become paraparetic. Brain magnetic resonance imaging showed abnormal vascular structures around the lower brainstem and cervical cord. Cerebral angiography showed a dural fistula at the skull base supplied by the neuromeningeal branch of the ascending pharyngeal artery and draining into the posterior medullary veins. Following neurosurgical referral, the draining vein was clipped just beyond the arterial feeders. At that time, the patient was wheelchair-bound and needed assistance in daily activities.
   CONCLUSIONS: Early diagnosis of this rare vascular malformation is challenging; angiographic studies must include the cranial vasculature when spinal studies are normal or if the abnormality on magnetic resonance imaging is maximal in the upper spinal cord. In the case described, as only medullary angiography was performed, the intracranial dural arteriovenous fistula with perimedullary venous drainage was not diagnosed. Delayed diagnosis is likely to lead to severe neurologic consequences.
C1 [Rocca, Gabriele; Caputo, Fiorella; Alice, Stefano; Ventura, Francesco] Univ Genoa, Dept Legal & Forens Med, Genoa, Italy.
   [Terranova, Claudio] Univ Padua, Sect Legal Med, Padua, Italy.
RP Ventura, F (reprint author), Univ Genoa, Dept Legal & Forens Med, Genoa, Italy.
EM francesco.ventura@unige.it
OI Caputo, Fiorella/0000-0002-4263-9203; TERRANOVA,
   CLAUDIO/0000-0002-7499-7232
CR Asakawa H, 2002, SURG NEUROL, V58, P251, DOI 10.1016/S0090-3019(02)00861-3
   Atkinson JLD, 2001, MAYO CLIN PROC, V76, P1120, DOI 10.4065/76.11.1120
   BARNWELL SL, 1989, J NEUROSURG, V71, P352, DOI 10.3171/jns.1989.71.3.0352
   BORDEN JA, 1995, J NEUROSURG, V82, P166, DOI 10.3171/jns.1995.82.2.0166
   Chen CJ, 1998, NEURORADIOLOGY, V40, P393, DOI 10.1007/s002340050609
   COGNARD C, 1995, RADIOLOGY, V194, P671, DOI 10.1148/radiology.194.3.7862961
   Collice M, 2000, NEUROSURGERY, V47, P56
   El Asri AC, 2013, WORLD NEUROSURG, V79, P182, DOI 10.1016/j.wneu.2012.09.012
   Giorgetti A, 2001, J HEADACHE PAIN, V2, P45
   Gomez J, 2012, NEUROSURG CLIN N AM, V23, P55, DOI 10.1016/j.nec.2011.09.003
   Goto K, 1999, J NEUROSURG, V90, P289, DOI 10.3171/jns.1999.90.2.0289
   Gupta Ak, 2009, Indian J Radiol Imaging, V19, P43, DOI 10.4103/0971-3026.45344
   Kalamangalam GP, 2002, J NEUROL NEUROSUR PS, V72, P816, DOI 10.1136/jnnp.72.6.816
   Katsaridis V, 2009, CURR TREAT OPTION NE, V11, P35, DOI 10.1007/s11940-009-0005-9
   Kim MS, 2002, J CLIN NEUROSCI, V9, P147, DOI 10.1054/jocn.2001.1029
   Kim NH, 2011, J NEUROSURG, V114, P830, DOI 10.3171/2010.5.JNS10128
   Kwon BJ, 2005, AM J NEURORADIOL, V26, P2500
   Milhaud D, 2000, EUR J NEUROL, V7, P123, DOI 10.1046/j.1468-1331.2000.00003.x
   Ricolfi F, 1999, NEURORADIOLOGY, V41, P803, DOI 10.1007/s002340050846
   Stolz E, 2003, EUR NEUROL, V49, P247, DOI 10.1159/000070197
   SUNDT TM, 1983, J NEUROSURG, V59, P32, DOI 10.3171/jns.1983.59.1.0032
   van Rooij WJ, 2007, AM J NEURORADIOL, V28, P348
   VERSARI PP, 1993, NEUROSURGERY, V33, P914
   Zipfel GJ, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.2.FOCUS0928
NR 24
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP 62
EP 66
DI 10.1016/j.wneu.2018.12.150
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800120
PM 30639497
DA 2020-05-12
ER

PT J
AU Muhammad, S
   Tanikawa, R
   Niemela, M
AF Muhammad, Sajjad
   Tanikawa, Rokuya
   Niemela, Mika
TI Surgical Treatment of Pediatric Unilateral Tinnitus Due to
   Cochleovestibular Nerve Compression by Intrameatal Anterior Inferior
   Cerebellar Artery Loop
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cochleovestibular nerve; Intrameatal anterior inferior cerebellar
   artery; Pediatrics; Surgery; Tinnitus
ID MICROVASCULAR DECOMPRESSION; VASCULAR LOOPS; CRANIAL NERVE
AB OBJECTIVES: Cochleovestibular nerve compression syndrome due to intra-meatal anterior inferior cerebellar artery (AICA) that causes tinnitus is an extremely rare condition with special therapeutic challenges and implications. Here we present the first surgically treated pediatric case of tinnitus showing microvascular conflict of the cochleovestibular nerve and intrameatal AICA loop.
   METHODS: A pediatric case of tinnitus is described, and a surgical technique is elaborated with video material. A PubMed literature search was performed to identify surgically treated pediatric cases of intrameatal compression of the eighth nerve with an AICA loop.
   RESULTS: Tinnitus was completely resolved and hearing was intact immediately after surgical decompression. The patient was free from further symptoms after a short follow-up of 12 weeks. Microsurgical decompression including opening of the internal auditory canal and transposition of the AICA was an effective treatment option in this case.
   CONCLUSION: Decompression of the cochleovestibular nerve including opening of the internal auditory canal and transposition of the AICA appears to be an effective treatment option for cases with radiologically confirmed intrameatal vascular compression of the eighth nerve causing unilateral pulsatile tinnitus.
C1 [Muhammad, Sajjad; Niemela, Mika] Univ Helsinki, Dept Neurosurg, Helsinki, Finland.
   [Muhammad, Sajjad; Niemela, Mika] Helsinki Univ Hosp, Helsinki, Finland.
   [Tanikawa, Rokuya] Sapporo Teishinkai Hosp, Sapporo, Hokkaido, Japan.
RP Muhammad, S (reprint author), Univ Helsinki, Dept Neurosurg, Helsinki, Finland.; Muhammad, S (reprint author), Helsinki Univ Hosp, Helsinki, Finland.
EM ext-sajjad.muhammad@hus.fi
OI Muhammad, Sajjad/0000-0002-6734-7979
CR Capelle HH, 2010, J HEADACHE PAIN, V11, P339, DOI 10.1007/s10194-010-0213-4
   Chadha NK, 2008, CLIN OTOLARYNGOL, V33, P5, DOI 10.1111/j.1749-4486.2007.01597.x
   Daneshi Ahmad, 2004, Int Tinnitus J, V10, P161
   Esposito G, 2016, WORLD NEUROSURG, V96, P556, DOI 10.1016/j.wneu.2016.09.030
   Gultelkin S, 2008, AM J NEURORADIOL, V29, P1746, DOI 10.3174/ajnr.A1212
   Islamian AP, 2014, CLIN NEUROL NEUROSUR, V117, P102, DOI 10.1016/j.clineuro.2013.11.031
   JANNETTA PJ, 1980, ANN SURG, V192, P518, DOI 10.1097/00000658-198010000-00010
   Kim DK, 2012, CLIN EXP OTORHINOLAR, V5, P170, DOI 10.3342/ceo.2012.5.3.170
   LAHA RK, 1977, J NEUROSURG, V47, P316, DOI 10.3171/jns.1977.47.3.0316
   SILA CA, 1987, STROKE, V18, P252, DOI 10.1161/01.STR.18.1.252
   Zhang L, 2012, NEUROL INDIA, V60, P495, DOI 10.4103/0028-3886.103194
NR 11
TC 0
Z9 0
U1 4
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP 67
EP 70
DI 10.1016/j.wneu.2018.12.154
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800121
PM 30639499
OA Green Accepted
DA 2020-05-12
ER

PT J
AU Miki, K
   Kai, Y
   Hiraki, Y
   Kamano, H
   Oka, K
   Natori, Y
AF Miki, Kenji
   Kai, Yasutoshi
   Hiraki, Yuka
   Kamano, Hironori
   Oka, Kazunari
   Natori, Yoshihiro
TI Malignant Meningioma Mimicking Chronic Subdural Hematoma
SO WORLD NEUROSURGERY
LA English
DT Article
DE Chronic subdural hematoma; Meningioma
ID PLASMINOGEN-ACTIVATOR
AB BACKGROUND: Chronic subdural hematoma (CSDH) is the most common disease encountered in neurosurgery. Diagnoses of CSDH are usually made on the basis of computed tomography (CT) images. In this report, we discuss the case of a patient with meningioma whose findings instead suggested CSDH.
   CASE DESCRIPTION: A 91-year-old woman complained of dizziness. Brain CT imaging revealed a low-density subdural space, following which we diagnosed her with CSDH. On the same day, we performed burr hole surgery. However, when opening the burr hole and cutting the dura, a light yellowish tumor was observed under the dura. After the operation, her condition deteriorated and she died 2 days later. After 10 days, pathologic examination of the tumor specimen led to a diagnosis of atypical meningioma.
   CONCLUSIONS: In almost all cases, CSDH can be diagnosed using CT images only. However, our patient's true diagnosis was meningioma, rather than CSDH. We rouse attention not to take it for CSDH with a CT image easily.
C1 [Miki, Kenji; Kai, Yasutoshi; Oka, Kazunari; Natori, Yoshihiro] Aso Iizuka Hosp, Dept Neurosurg, Yoshio Machi, Iizuka, Fukuoka, Japan.
   [Hiraki, Yuka] Aso Iizuka Hosp, Dept Pathol, Yoshio Machi, Iizuka, Fukuoka, Japan.
   [Kamano, Hironori] Aso Iizuka Hosp, Dept Radiol, Yoshio Machi, Iizuka, Fukuoka, Japan.
RP Miki, K (reprint author), Aso Iizuka Hosp, Dept Neurosurg, Yoshio Machi, Iizuka, Fukuoka, Japan.
EM KenjiMiki-mickeydreamk@yahoo.co.jp
CR Abramovich CM, 1998, HUM PATHOL, V29, P1420, DOI 10.1016/S0046-8177(98)90010-7
   Brecknell JE, 2006, BRIT J NEUROSURG, V20, P239, DOI 10.1080/02688690600852647
   Levi M, 2004, BRIT J HAEMATOL, V124, P567, DOI 10.1046/j.1365-2141.2003.04790.x
   OKA K, 1988, J NEUROSURG, V69, P356, DOI 10.3171/jns.1988.69.3.0356
   OKA K, 1994, J NEURO-ONCOL, V22, P183, DOI 10.1007/BF01052893
   Oka K, 1995, ADV CLIN NEUROSCI, V5, P269
   SAKAI N, 1981, Neurologia Medico-Chirurgica, V21, P329
   SCOTT M, 1975, J NEUROSURG, V42, P338, DOI 10.3171/jns.1975.42.3.0338
   Stanisic M, 2013, ACTA NEUROCHIR, V155, P323, DOI 10.1007/s00701-012-1565-0
   TSUDA H, 1988, THROMB HAEMOSTASIS, V60, P508
   Velez AM, 2011, NEUROSURGERY, V68, pE1165, DOI 10.1227/NEU.0b013e31820a181a
   Zhou YS, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116095
NR 12
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP 71
EP 74
DI 10.1016/j.wneu.2018.12.129
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800122
PM 30611944
DA 2020-05-12
ER

PT J
AU Matsuoka, G
   Eguchi, S
   Ryu, B
   Tominaga, T
   Ishikawa, T
   Yamaguchi, K
   Kawamata, T
AF Matsuoka, Go
   Eguchi, Seiichiro
   Ryu, Bikei
   Tominaga, Tadasuke
   Ishikawa, Tatsuya
   Yamaguchi, Koji
   Kawamata, Takakazu
TI Treatment Strategy for Recurrent Hemorrhage from Meningioma: Case Report
   and Literature Review
SO WORLD NEUROSURGERY
LA English
DT Review
DE Hemorrhage; Intratumoral hemorrhage; Meningioma; Recurrence; Subdural
   hematoma
ID SUBDURAL-HEMATOMA; SUBARACHNOID HEMORRHAGE
AB BACKGROUND: We came across a rare case of recurrent hemorrhage from a meningioma. Here, we describe this case and discuss the treatment strategies for recurrent hemorrhage from a meningioma using a literature review.
   CASE DESCRIPTION: A 61-year-old woman with a history of 2 episodes of hemorrhage from a meningioma originating from the left falx cerebri presented to our outpatient clinic. She was asymptomatic, and magnetic resonance imaging revealed a small tumor along the falx cerebri. However, we decided to remove the hemorrhagic meningioma. No abnormal vascular structures were recognized on preoperative angiography and intraoperative evaluation. The tumor was easily removed along the falx cerebri (Simpson grade I). The pathologic diagnosis was transitional meningioma, World Health Organization grade I. The patient experienced no recurrence of tumor or hemorrhage for up to 15 months after surgery.
   CONCLUSIONS: The incidence of repeated bleeding from meningiomas is very rare and is seldom reported because the mortality associated with hemorrhage in meningiomas is high (28%-50%). Immediate diagnosis and surgical treatment with both hematoma evacuation and tumor removal are crucial to avoid inadequate and delayed treatment that may cause mortality.
C1 [Matsuoka, Go; Eguchi, Seiichiro; Ryu, Bikei; Tominaga, Tadasuke; Ishikawa, Tatsuya; Yamaguchi, Koji; Kawamata, Takakazu] Tokyo Womens Med Univ, Dept Neurosurg, Tokyo, Japan.
RP Matsuoka, G (reprint author), Tokyo Womens Med Univ, Dept Neurosurg, Tokyo, Japan.
EM matsuoka.go@twmu.ac.jp
OI Bikei, Ryu/0000-0003-0323-6628
CR Bellut D, 2011, J CLIN NEUROSCI, V18, P992, DOI 10.1016/j.jocn.2011.01.007
   Bosnjak R, 2005, J NEUROSURG, V103, P473, DOI 10.3171/jns.2005.103.3.0473
   CHASKIS C, 1992, CLIN NEUROL NEUROSUR, V94, P269, DOI 10.1016/0303-8467(92)90103-A
   Coombs JB, 2014, J EMERG MED, V47, pE63, DOI 10.1016/j.jemermed.2014.04.026
   Deprez FC, 2012, JBR-BTR, V95, P309, DOI 10.5334/jbr-btr.660
   HAMER J, 1979, NEUROCHIRURGIA, V22, P189
   HELLE TL, 1980, J NEUROL NEUROSUR PS, V43, P725, DOI 10.1136/jnnp.43.8.725
   JONES N R, 1989, British Journal of Neurosurgery, V3, P691, DOI 10.3109/02688698908992693
   KONDZIOLKA D, 1987, J NEUROSURG, V67, P852, DOI 10.3171/jns.1987.67.6.0852
   Krishnan P, 2015, J NEUROSCI RURAL PRA, V6, P91, DOI 10.4103/0976-3147.143210
   Kumar R, 1997, J NEUROL NEUROSUR PS, V62, P649, DOI 10.1136/jnnp.62.6.649
   LATCHAW JP, 1981, NEUROSURGERY, V9, P433, DOI 10.1227/00006123-198110000-00017
   Lefranc F, 2001, ACTA NEUROCHIR, V143, P977, DOI 10.1007/s007010170002
   Marder CP, 2014, AM J ROENTGENOL, V202, P25, DOI 10.2214/AJR.12.9749
   MARTINEZLAGE JF, 1991, ACTA NEUROCHIR, V110, P129, DOI 10.1007/BF01400680
   MODESTI LM, 1976, J NEUROSURG, V45, P437, DOI 10.3171/jns.1976.45.4.0437
   Niiro M, 2003, ACTA NEUROCHIR, V145, P767, DOI 10.1007/s00701-003-0089-z
   Nishi T, 1999, CANCER, V86, P1354, DOI 10.1002/(SICI)1097-0142(19991001)86:7<1354::AID-CNCR35>3.0.CO;2-R
   SCOTTI G, 1987, J NEUROSURG, V66, P779, DOI 10.3171/jns.1987.66.5.0779
   Sunada I, 1998, Radiat Med, V16, P483
   Timothy J, 1999, J NEUROSURG, V91, P496, DOI 10.3171/jns.1999.91.3.0496
   WAKAI S, 1981, J NEUROSURG, V55, P187, DOI 10.3171/jns.1981.55.2.0187
   Worm PV, 2009, ARQ NEURO-PSIQUIAT, V67, P308, DOI 10.1590/S0004-282X2009000200028
NR 23
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP 75
EP 80
DI 10.1016/j.wneu.2018.12.124
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800123
PM 30620893
DA 2020-05-12
ER

PT J
AU Benichi, S
   Consoli, A
   Coskun, O
   Boulin, A
   Wang, A
   Rodesch, G
   Di Maria, F
AF Benichi, Sandro
   Consoli, Arturo
   Coskun, Oguzhan
   Boulin, Anne
   Wang, Adrien
   Rodesch, Georges
   Di Maria, Federico
TI Thrombectomy by Direct Cervical Access in Case of Common Carotid
   Occlusion with Collateral Supply to Internal Carotid Artery: Uncommon
   Anatomic Variant
SO WORLD NEUROSURGERY
LA English
DT Article
DE Acute ischemic stroke; Cervical vessels; Collateral supply; Direct
   cervical access; MR angiography; Stroke; Thrombectomy
ID ACUTE ISCHEMIC-STROKE; ENDOVASCULAR TREATMENT; INTRACRANIAL ANEURYSM;
   PUNCTURE
AB BACKGROUND: Mechanical thrombectomy for acute ischemic stroke recently proved its superiority to standard medical management alone. With the increasing number of procedures, practitioners are exposed to unexpected situations that may lead to failure of access and significantly worse clinical outcome. Being able to plan the procedure and use alternative techniques may be useful in case of peculiar anatomy.
   CASE DESCRIPTION: We report here the case of a 60-year-old man referred to our institution for an acute ischemic stroke. The patient had an initial National Institutes of Health Stroke Scale score of 19. The patient's medical history revealed an unspecified cervical treatment at the level of C5-C6 20 years previously. Magnetic resonance imaging showed a left M1 occlusion and the absence of ipsilateral common carotid. The digital subtraction angiography revealed an anastomosis through the left inferior and superior thyroid artery. Mechanical thrombectomy was performed through direct cervical access with a TICI 3 recanalization score.
   CONCLUSIONS: Absence of viable access to perform mechanical thrombectomy during acute ischemic stroke is a rare but pejorative event. Direct common carotid puncture, even in its distal segment, when necessary is a feasible technique to perform internal carotid catheterization.
C1 [Benichi, Sandro] Necker Enfants Malad Hosp, Dept Pediat Neurosurg, Paris, France.
   [Consoli, Arturo; Coskun, Oguzhan; Boulin, Anne; Rodesch, Georges; Di Maria, Federico] Foch Hosp, Dept Diagnost & Intervent Neuroradiol, Suresnes, France.
   [Wang, Adrien] Foch Hosp, Dept Neurol, Suresnes, France.
RP Benichi, S (reprint author), Necker Enfants Malad Hosp, Dept Pediat Neurosurg, Paris, France.
EM sandro.benichi@gmail.com
CR Balami JS, 2015, INT J STROKE, V10, P1168, DOI 10.1111/ijs.12618
   Blanc R, 2006, NEURORADIOLOGY, V48, P925, DOI 10.1007/s00234-006-0157-1
   Blanc R, 2002, AM J NEURORADIOL, V23, P978
   BOSNIAK MA, 1963, RADIOLOGY, V81, P89, DOI 10.1148/81.1.89
   Brunser AM, 2016, J NEUROIMAGING, V26, P420, DOI 10.1111/jon.12334
   Hassan AE, 2013, AM J NEURORADIOL, V34, P354, DOI 10.3174/ajnr.A3202
   Iosif C, 2013, J NEURORADIOLOGY, V40, P130, DOI 10.1016/j.neurad.2012.05.002
   LASJAUNIAS P, 1978, NEURORADIOLOGY, V15, P31, DOI 10.1007/BF00327443
   Meyne JK, 2015, ROFO-FORTSCHR RONTG, V187, P555, DOI 10.1055/s-0034-1399222
   PAPON X, 1995, SURG RADIOL ANAT, V17, P335, DOI 10.1007/BF01795193
   Ribo M, 2013, J NEUROINTERV SURG, V5, P70, DOI 10.1136/neurintsurg-2012-010438
NR 11
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP 84
EP 86
DI 10.1016/j.wneu.2018.12.133
PG 3
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800011
PM 30611947
DA 2020-05-12
ER

PT J
AU El Ahmadieh, TY
   Plitt, A
   Kafka, B
   Aoun, SG
   Raisanen, JM
   Orr, B
   Pan, E
   Wardak, Z
   Nedzi, LA
   Patel, TR
AF El Ahmadieh, Tarek Y.
   Plitt, Aaron
   Kafka, Benjamin
   Aoun, Salah G.
   Raisanen, Jack M.
   Orr, Brent
   Pan, Edward
   Wardak, Zabi
   Nedzi, Lucien A.
   Patel, Toral R.
TI H3 K27M Mutations in Thalamic Pilocytic Astrocytomas with Anaplasia
SO WORLD NEUROSURGERY
LA English
DT Article
DE Anaplasia; Chemotherapy; H3 K27M mutation; Pilocytic astrocytoma;
   Radiation; Surgery; Thalamic
ID GLIOMAS; TUMOR
AB BACKGROUND: The revised World Health Organization classification of central nervous system tumors, published in 2016, has recognized the H3 K27M mutation as a critical genetic signature defining a new group of infiltrative astrocytomas designated as diffuse midline glioma, H3 K27M mutant. Although most H3 K27M mutations arise in the setting of diffusely infiltrative tumors, there are rare reports of compact tumors with low-grade histologic features harboring this mutation. The prevalence and clinical significance of this mutation in pilocytic astrocytomas remain unclear.
   CASE DESCRIPTION: We report 2 young adult patients with H3 K27M-mutated thalamic pilocytic astrocytomas who presented to medical attention with symptomatic hydrocephalus requiring urgent intervention. We present our experience with this unusual tumor and recommend a treatment paradigm of maximal safe surgical resection followed by chemotherapy and radiation.
   CONCLUSIONS: Stereotactic biopsies may undergrade some adult thalamic pilocytic astrocytomas. Therefore, we recommend that all these tumors be evaluated for the H3 K27M mutation. Further, we think H3 K27M-mutant thalamic pilocytic astrocytomas require aggressive multimodality treatment and these treatments should be guided by the molecular findings, as opposed to the histologic ones.
C1 [El Ahmadieh, Tarek Y.; Plitt, Aaron; Kafka, Benjamin; Aoun, Salah G.; Patel, Toral R.] Univ Texas Southwestern Med Ctr Dallas, Dept Neurol Surg, Dallas, TX 75390 USA.
   [Raisanen, Jack M.] Univ Texas Southwestern Med Ctr Dallas, Dept Pathol, Dallas, TX USA.
   [Pan, Edward] Univ Texas Southwestern Med Ctr Dallas, Dept Neurol & Neurotherapeut, Dallas, TX 75390 USA.
   [Wardak, Zabi; Nedzi, Lucien A.] Univ Texas Southwestern Med Ctr Dallas, Dept Radiat Oncol, Dallas, TX 75390 USA.
   [Orr, Brent] St Jude Childrens Res Hosp, Dept Pathol, 332 N Lauderdale St, Memphis, TN 38105 USA.
RP Patel, TR (reprint author), Univ Texas Southwestern Med Ctr Dallas, Dept Neurol Surg, Dallas, TX 75390 USA.
EM toral.patel@utsouthwestern.edu
RI Aoun, Salah G./J-2406-2019
OI Aoun, Salah G./0000-0003-3499-7569; El Ahmadieh,
   Tarek/0000-0002-7122-4349
CR Aihara K, 2014, NEURO-ONCOLOGY, V16, P140, DOI 10.1093/neuonc/not144
   Bechet D, 2014, ACTA NEUROPATHOL, V128, P733, DOI 10.1007/s00401-014-1337-4
   Brown PD, 2004, INT J RADIAT ONCOL, V58, P1153, DOI 10.1016/j.ijrobp.2003.09.020
   Collins VP, 2015, ACTA NEUROPATHOL, V129, P775, DOI 10.1007/s00401-015-1410-7
   FORSYTH PA, 1993, CANCER-AM CANCER SOC, V72, P1335, DOI 10.1002/1097-0142(19930815)72:4<1335::AID-CNCR2820720431>3.0.CO;2-E
   Hochart A, 2015, ANN CLIN TRANSL NEUR, V2, P439, DOI 10.1002/acn3.184
   Karremann M, 2018, NEURO-ONCOLOGY, V20, P123, DOI 10.1093/neuonc/nox149
   Louis DN, 2016, ACTA NEUROPATHOL, V131, P803, DOI 10.1007/s00401-016-1545-1
   Meyronet D, 2017, NEURO-ONCOLOGY, V19, P1127, DOI 10.1093/neuonc/now274
   Morita S, 2018, J NEUROSURG, V129, P593, DOI 10.3171/2017.4.JNS162443
   Orillac C, 2016, ACTA NEUROPATHOL COM, V4, DOI 10.1186/s40478-016-0361-0
   Rodriguez FJ, 2010, AM J SURG PATHOL, V34, P147, DOI 10.1097/PAS.0b013e3181c75238
   SCHWARTZ AM, 1990, CANCER, V65, P333, DOI 10.1002/1097-0142(19900115)65:2<333::AID-CNCR2820650225>3.0.CO;2-3
   Solomon DA, 2016, BRAIN PATHOL, V26, P569, DOI 10.1111/bpa.12336
   STEINBERG GK, 1985, J NEUROSURG, V62, P9, DOI 10.3171/jns.1985.62.1.0009
   Yong EXZ, 2014, J CLIN NEUROSCI, V21, P1993, DOI 10.1016/j.jocn.2014.02.014
NR 16
TC 2
Z9 2
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP 87
EP 92
DI 10.1016/j.wneu.2018.12.147
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800124
PM 30639498
DA 2020-05-12
ER

PT J
AU Ohshima, T
   Miyachi, S
   Joko, M
   Matsuo, N
   Kawaguchi, R
   Maejima, R
   Takayasu, M
AF Ohshima, Tomotaka
   Miyachi, Shigeru
   Joko, Masahiro
   Matsuo, Naoki
   Kawaguchi, Reo
   Maejima, Ryuya
   Takayasu, Masakazu
TI Endovascular Embolization of Sinus Pericranii Using Plastic Cup During
   Glue Injection
SO WORLD NEUROSURGERY
LA English
DT Article
DE Endovascular treatment; Sinus pericranii; Transvenous embolization
ID TRANSVENOUS EMBOLIZATION
AB BACKGROUND: Sinus pericranii (SP) is a rare abnormal connection between the intracranial and extracranial venous drainage pathways through the osseous channels. Herein we present the case of a patient with growing SP, which was successfully treated using endovascular transvenous embolization through external compression with a plastic cup for preventing glue migration into subcutaneous veins.
   CASE DESCRIPTION: A 9-month-old boy presented with a gradually growing mass on the midline cranial vertex after his birth, for which transvenous embolization was performed. A microcatheter was successfully navigated into the SP from the superior sagittal sinus. Because the subcutaneous drainages were confirmed to be multidirectional, we compressed the drainages through the skin using a plastic cup during the glue injection step for preventing glue migration. Subsequently, the SP was completely obliterated. The postoperative course was uneventful.
   CONCLUSIONS: Manual compression using a plastic cup was useful not only for embolization but also for reducing the physician's exposure to radiation as compared with that in the finger compression method. When a direct puncture is required, a plastic cylinder can also be used.
C1 [Ohshima, Tomotaka; Miyachi, Shigeru] Aichi Med Univ, Neuroendovasc Therapy Ctr, Nagakute, Aichi, Japan.
   [Joko, Masahiro; Matsuo, Naoki; Kawaguchi, Reo; Maejima, Ryuya; Takayasu, Masakazu] Aichi Med Univ, Dept Neurosurg, Nagakute, Aichi, Japan.
RP Ohshima, T (reprint author), Aichi Med Univ, Neuroendovasc Therapy Ctr, Nagakute, Aichi, Japan.
EM tmtkoh@gmail.com
CR Baek Hye Jin, 2011, Neurointervention, V6, P84, DOI 10.5469/neuroint.2011.6.2.84
   Brook AL, 2009, J NEUROSURG-PEDIATR, V3, P220, DOI 10.3171/2008.10.PEDS08267
   David LR, 1998, J CRANIOFAC SURG, V9, P3, DOI 10.1097/00001665-199801000-00003
   Kessler IM, 2009, INTERV NEURORADIOL, V15, P429, DOI 10.1177/159101990901500410
   Lasjaunias P, 2001, SURG NEUROANGIOGRAPH, P702
   Pavanello M, 2015, J NEUROSURG-PEDIATR, V15, P60, DOI 10.3171/2014.9.PEDS13641
   Rangel-Castilla L, 2009, NEUROSURG FOCUS, V27, DOI 10.3171/2009.8.FOCUS09170
NR 7
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP 93
EP 97
DI 10.1016/j.wneu.2018.12.176
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800125
PM 30639487
DA 2020-05-12
ER

PT J
AU Beuriat, PA
   Cattiaux, L
   Guibaud, L
   Szathmari, A
   Sabatier, I
   Rousselle, C
   Mottolese, C
   Di Rocco, F
AF Beuriat, Pierre-Aurelien
   Cattiaux, Lucile
   Guibaud, Laurent
   Szathmari, Alexandru
   Sabatier, Isabelle
   Rousselle, Christophe
   Mottolese, Carmine
   Di Rocco, Federico
TI Isolated Antenatal Hydrocephalus After Fetal Exposure to Misoprostol:
   Teratogenic Effect of the Cytotec?
SO WORLD NEUROSURGERY
LA English
DT Article
DE Antenatal; Endoscopic third ventriculostomy; Hydrocephalus; Misoprostol;
   Teratogenic effect
AB BACKGROUND: Misoprostol is often used for termination of pregnancy in France and other countries. However, some pregnancies are continued after taking the drug and congenital malformations are known to be the consequence of fetal exposure to misoprostol, among them hydrocephalus. The type of hydrocephalus in case of misoprostol exposure is not known.
   CASE DESCRIPTION: We report the first case in the literature of an obstructive hydrocephalus due to an aqueduct of Sylvius stenosis diagnosed during pregnancy after misoprostol intake.
   CONCLUSIONS: The possible physiopathologic implications of the drug regarding the genesis of this malformation are discussed.
C1 [Beuriat, Pierre-Aurelien; Cattiaux, Lucile; Szathmari, Alexandru; Sabatier, Isabelle; Rousselle, Christophe; Mottolese, Carmine; Di Rocco, Federico] Claude Bernard Univ, Hop Femme Mere Enfant, Pediat Neurosurg Unit, Villeurbanne, France.
   [Guibaud, Laurent] Claude Bernard Univ, Hop Femme Mere Enfant, Serv Imagerie Pediat & Foetale, Villeurbanne, France.
   [Sabatier, Isabelle; Rousselle, Christophe] Hop Femme Mere Enfant, Pediat Neurol Unit, Lyon, France.
RP Mottolese, C (reprint author), Claude Bernard Univ, Hop Femme Mere Enfant, Pediat Neurosurg Unit, Villeurbanne, France.
EM pierre-aurelien.beuriat@neurochirurgie.fr
OI Di Rocco, Federico/0000-0003-2145-5533
CR CASTILLA EE, 1994, AM J MED GENET, V51, P161, DOI 10.1002/ajmg.1320510217
   COLLINS FS, 1983, J PEDIATR-US, V102, P620, DOI 10.1016/S0022-3476(83)80204-2
   Gonzalez CH, 1998, LANCET, V351, P1624, DOI 10.1016/S0140-6736(97)12363-7
   Kozma C, 2011, AM J MED GENET A, V155A, P1723, DOI 10.1002/ajmg.a.34037
   Orioli IM, 2000, BRIT J OBSTET GYNAEC, V107, P519, DOI 10.1111/j.1471-0528.2000.tb13272.x
   Persaud T., 1979, REPROD TERATOLOGICAL
   Tang OS, 2007, INT J GYNECOL OBSTET, V99, pS160, DOI 10.1016/j.ijgo.2007.09.004
NR 7
TC 0
Z9 0
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP 98
EP 100
DI 10.1016/j.wneu.2018.12.177
PG 3
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800126
PM 30639481
DA 2020-05-12
ER

PT J
AU Goodarzi, A
   Thaci, B
   Toussi, A
   Karnati, T
   Kim, K
   Fragoso, R
AF Goodarzi, Amir
   Thaci, Bart
   Toussi, Atrin
   Karnati, Tejas
   Kim, Kee
   Fragoso, Ruben
TI Glioblastoma Multiforme of the Conus Medullaris-Management Strategies
   and Complications
SO WORLD NEUROSURGERY
LA English
DT Review
DE Conus medullaris; Glioblastoma multiforme; Intramedullary tumor; Spinal
   glioma; Spinal tumor
ID SPINAL-CORD; MALIGNANT ASTROCYTOMAS; K27M MUTATION; HISTONE H3.3;
   SURVIVAL; RADIOTHERAPY; TEMOZOLOMIDE; PROGNOSIS; CHILD
AB Primary spinal glioblastoma multiforme (GBM) of the conus medullaris is a rare and devastating pathologic entity. The presenting symptoms commonly include progressive neurologic deficits in the lower extremities, bowel and bladder dysfunction, and low back pain. Histologically, these tumors have high-grade features similar to their intracranial counterparts. However, recent advancements in the field of molecular oncology have been beginning to elucidate a unique molecular blueprint for these spinal gliomas. Given the lack of standardized treatment strategies, we have presented our institutional experience in treating a small series of patients with conus medullaris GBM and have reviewed the reported data on the relevant molecular markers, management strategies, and complication avoidance for this malignant pathologic entity.
C1 [Goodarzi, Amir; Thaci, Bart; Toussi, Atrin; Karnati, Tejas; Kim, Kee] Univ Calif Davis, Sch Med, Dept Neurol Surg, Sacramento, CA 95817 USA.
   [Fragoso, Ruben] Univ Calif Davis, Sch Med, Dept Radiat Oncol, Sacramento, CA 95817 USA.
RP Goodarzi, A (reprint author), Univ Calif Davis, Sch Med, Dept Neurol Surg, Sacramento, CA 95817 USA.
EM agoodarzi@ucdavis.edu
CR Adams H, 2012, SPINE, V37, pE727, DOI 10.1097/BRS.0b013e31824584c0
   ANDREWS AA, 1978, ARCH NEUROL-CHICAGO, V35, P244, DOI 10.1001/archneur.1978.00500280062013
   Cacchione A, 2016, CHIN J CANCER, V35, DOI 10.1186/s40880-016-0107-1
   Chen JC, 2016, INT J HEAT MASS TRAN, V95, P1, DOI 10.1016/j.ijheatmasstransfer.2015.11.067
   Choi WC, 2009, SURG NEUROL, V71, P234, DOI 10.1016/j.surneu.2007.07.059
   Khuong-Quang DA, 2012, ACTA NEUROPATHOL, V124, P439, DOI 10.1007/s00401-012-0998-0
   Gee Teak Sheng, 2012, Med J Malaysia, V67, P438
   Gielen GH, 2013, AM J CLIN PATHOL, V139, P345, DOI 10.1309/AJCPABOHBC33FVMO
   Govindan A, 2011, BRAIN TUMOR PATHOL, V28, P297, DOI 10.1007/s10014-011-0041-5
   Hegi ME, 2005, NEW ENGL J MED, V352, P997, DOI 10.1056/NEJMoa043331
   Jallo GI, 2004, J NEURO-ONCOL, V68, P71, DOI 10.1023/B:NEON.0000024747.66993.26
   Karremann M, 2018, NEURO-ONCOLOGY, V20, P123, DOI 10.1093/neuonc/nox149
   Konar SK, 2016, WORLD NEUROSURG, V86, P341, DOI 10.1016/j.wneu.2015.08.078
   Lee A, 2018, CLIN NEUROL NEUROSUR, V170, P127, DOI 10.1016/j.clineuro.2018.05.014
   Marchan EM, 2007, J NEUROSURG-SPINE, V7, P656, DOI 10.3171/SPI-07/12/656
   Mayer RR, 2012, CLIN NEUROL NEUROSUR, V114, P275, DOI 10.1016/j.clineuro.2011.10.017
   McGirt MJ, 2008, NEUROSURGERY, V63, P55, DOI 10.1227/01.NEU.0000335070.37943.09
   Medhkour A, 2005, SURG NEUROL, V63, P576, DOI 10.1016/j.surneu.2004.08.044
   Minehan KJ, 2009, INT J RADIAT ONCOL, V73, P727, DOI 10.1016/j.ijrobp.2008.04.060
   Mori K, 2012, SPINE J, V12, pE1, DOI 10.1016/j.spinee.2011.12.005
   Parsons DW, 2008, SCIENCE, V321, P1807, DOI 10.1126/science.1164382
   Rizzo D, 2015, BIOMED RES INT, DOI 10.1155/2015/215135
   Sanborn MR, 2011, J CLIN NEUROSCI, V18, P842, DOI 10.1016/j.jocn.2010.08.037
   Scarrow AM, 2000, CLIN NEUROL NEUROSUR, V102, P166, DOI 10.1016/S0303-8467(00)00086-X
   Schwartzentruber J, 2012, NATURE, V482, P226, DOI 10.1038/nature10833
   Shen CX, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000006634
   SHIRATO H, 1995, INT J RADIAT ONCOL, V33, P323, DOI 10.1016/0360-3016(95)00179-3
   Singh PK, 2009, J SPINAL CORD MED, V32, P583, DOI 10.1080/10790268.2009.11754565
   Stecco A, 2005, AM J NEURORADIOL, V26, P2157
   Strik HM, 2000, J NEURO-ONCOL, V50, P239, DOI 10.1023/A:1006415703881
   Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330
   Voldborg BR, 1997, ANN ONCOL, V8, P1197, DOI 10.1023/A:1008209720526
   Yan CR, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000006500
   Yi S, 2019, NEUROSURGERY, V84, P1072, DOI 10.1093/neuros/nyy150
NR 34
TC 0
Z9 0
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP 101
EP 109
DI 10.1016/j.wneu.2018.12.164
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800127
PM 30639501
DA 2020-05-12
ER

PT J
AU Meybodi, AT
   Moreira, LB
   Zhao, XC
   Lawton, MT
   Preul, MC
AF Meybodi, Ali Tayebi
   Moreira, Leandro Borba
   Zhao, Xiaochun
   Lawton, Michael T.
   Preul, Mark C.
TI Double Origin of the Posterior Inferior Cerebellar Artery: Anatomic Case
   Report
SO WORLD NEUROSURGERY
LA English
DT Article
DE Lateral spinal artery; Posterior inferior cerebellar artery; Posterior
   spinal artery; Vertebral artery fenestration; Vertebrobasilar system
ID RUPTURED ANEURYSM; ENDOVASCULAR TREATMENT; COILING
AB BACKGROUND: Double origin of the posterior inferior cerebellar artery is rare. It has important clinical implications especially in cases of aneurysms of the vertebral artery or the posterior inferior cerebellar artery. Several radiologic reports of this variant exist. However, no anatomic illustration of this rarity exists in the literature. This brief report provides the first anatomic illustration of this important variation of the vertebrobasilar system.
   CASE DESCRIPTION: A cadaveric specimen was prepared for dissection. A far lateral craniotomy was performed on the right side. While exploring the right cerebellomedullary cistern, 2 separate origins of the posterior inferior cerebellar artery were found from the vertebral artery as the caudal and rostral trunks that joined to form the distal posterior inferior cerebellar artery trunk at the tonsillomedullary segment. Microscopic and endoscopic illustrations are provided.
   CONCLUSIONS: To the best of our knowledge, this is the first anatomic report on the double origin of the posterior inferior cerebellar artery. Cadaveric illustration of this variant helps with understanding its anatomic relationship with adjacent neurovascular structures of the cerebellomedullary cistern including the perforating arteries and the lower cranial nerves.
C1 [Meybodi, Ali Tayebi; Moreira, Leandro Borba; Zhao, Xiaochun; Lawton, Michael T.; Preul, Mark C.] Barrow Neurol Inst, Div Neurol Surg, 350 W Thomas Rd, Phoenix, AZ 85013 USA.
RP Preul, MC (reprint author), Barrow Neurol Inst, Div Neurol Surg, 350 W Thomas Rd, Phoenix, AZ 85013 USA.
EM Mark.Preul@DignityHealth.org
FU Barrow Neurological Foundation; Newsome Chair in Neurosurgery Research
FX This work was supported by Barrow Neurological Foundation and the
   Newsome Chair in Neurosurgery Research held by Dr. Preul.
CR Akgun V, 2013, SCI WORLD J, DOI 10.1155/2013/620162
   Cho YD, 2011, SURG RADIOL ANAT, V33, P271, DOI 10.1007/s00276-010-0747-9
   Fan F, 2011, CATHETER CARDIO INTE, V77, P150, DOI 10.1002/ccd.22685
   Koh JS, 2012, J KOREAN NEUROSURG S, V51, P40, DOI 10.3340/jkns.2012.51.1.40
   Kwon BJ, 2007, NEUROSURGERY, V61, P242, DOI [10.1227/01.neu.0000303976.22054.9d, 10.1227/01.NEU.0000280120.36270.37]
   LASJAUNIAS P, 1985, J NEUROSURG, V63, P235, DOI 10.3171/jns.1985.63.2.0235
   Lawton MT, 2010, 7 ANEURYSMS TENETS T
   Lee SH, 2011, INTERV NEURORADIOL, V17, P183, DOI 10.1177/159101991101700207
   Lee SH, 2009, CEREBELLUM, V8, P382, DOI 10.1007/s12311-009-0108-6
   Lesley WS, 2007, AM J ROENTGENOL, V189, P893, DOI 10.2214/AJR.07.2453
   Lesley WS, 2004, AM J NEURORADIOL, V25, P425
   Meybodi AT, 2016, J NEUROSURG, V125, P909, DOI 10.3171/2015.8.JNS151411
   Trivelato FP, 2011, INTERV NEURORADIOL, V17, P351, DOI 10.1177/159101991101700312
   Pasco A, 2002, J NEUROSURG, V96, P127, DOI 10.3171/jns.2002.96.1.0127
   Pekcevik Y, 2014, SURG RADIOL ANAT, V36, P455, DOI 10.1007/s00276-013-1208-z
   Plumb AA, 2009, SURG RADIOL ANAT, V31, P393, DOI 10.1007/s00276-008-0448-9
   Rhoton AL, 2000, NEUROSURGERY, V47, pS29, DOI 10.1097/00006123-200009001-00010
   Stopford JSB, 1916, J ANAT PHYSIOL, V50, P131
   Uchino A, 2015, NEURORADIOL J, V28, P187, DOI 10.1177/1971400915576659
   Uchiyama T, 2015, INTERV NEURORADIOL, V21, P451, DOI 10.1177/1591019915590363
   Vora N, 2009, J NEUROIMAGING, V19, P65, DOI 10.1111/j.1552-6569.2008.00243.x
NR 21
TC 3
Z9 3
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP 110
EP 115
DI 10.1016/j.wneu.2018.12.127
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800128
PM 30611945
DA 2020-05-12
ER

PT J
AU Abu Arja, MH
   Stalling, M
   Governale, LS
   Pierson, CR
   Rusin, JA
   Palmer, JD
   Finlay, JL
   Olshefski, R
   Boue, DR
AF Abu Arja, Mohammad H.
   Stalling, Melissa
   Governale, Lance S.
   Pierson, Christopher R.
   Rusin, Jerome A.
   Palmer, Joshua D.
   Finlay, Jonathan L.
   Olshefski, Randal
   Boue, Daniel R.
TI Germinoma Involving the Retina: An Unusual Presentation of Recurrent
   Intracranial Mixed Germ Cell Tumor
SO WORLD NEUROSURGERY
LA English
DT Article
DE Central nervous system tumors; Germ cell tumor; Germinoma; Mixed
   malignant germ cell tumor; Optic pathway; Relapse; Retinal infiltration
ID OPTIC NEUROPATHY; RADIATION; CHEMOTHERAPY; IRRADIATION
AB BACKGROUND: We report a patient with primary central nervous system mixed malignant germ cell tumor (GCT) who presented with recurrent malignant germinomatous infiltration of the retina.
   CASE DESCRIPTION: A 10-year-old girl initially presented with a large suprasellar mixed malignant GCT with a near-complete response after initial induction of chemotherapy and irradiation. Three and a half years after initial therapy, she presented with progressively worsening vision in her left eye. Magnetic resonance imaging showed infiltrative changes within the left optic nerve but no discrete mass. Serum and cerebrospinal fluid tumor markers were not elevated and cerebrospinal fluid cytology was negative. Left optic nerve biopsy confirmed the presence of mature teratoma and pure germinoma components. She was treated with gross-total resection of the left eye and optic nerve and chemotherapy. Histopathologic evaluation of the optic nerve showed only mature teratoma elements, but with pure germinoma cells infiltrating the inner layers of the retina.
   CONCLUSIONS: Loco-regional extension of suprasellar GCT to the optic nerve is not uncommon; however, to the best of our knowledge, infiltration of the tumor into the retina is not reported in the literature. Early detection of optic pathway involvement and proper delineation of the irradiation field may prevent GCT infiltration of the retina with subsequent vision loss.
C1 [Abu Arja, Mohammad H.; Finlay, Jonathan L.; Olshefski, Randal] Nationwide Childrens Hosp, Dept Pediat, Div Hematol Oncol & Blood & Marrow Transplant, Columbus, OH 43205 USA.
   [Stalling, Melissa; Pierson, Christopher R.; Boue, Daniel R.] Nationwide Childrens Hosp, Dept Pathol & Lab Med, Columbus, OH USA.
   [Stalling, Melissa; Pierson, Christopher R.; Boue, Daniel R.] Ohio State Univ, Dept Pathol, James Canc Hosp, Columbus, OH 43210 USA.
   [Governale, Lance S.] Univ Florida, Dept Neurosurg, Gainesville, FL USA.
   [Pierson, Christopher R.] Ohio State Univ, James Canc Hosp, Dept Biomed Educ & Anat, Columbus, OH 43210 USA.
   [Rusin, Jerome A.] Nationwide Childrens Hosp, Dept Radiol, Columbus, OH USA.
   [Palmer, Joshua D.] Ohio State Univ, James Canc Hosp, Dept Radiat Oncol, Columbus, OH 43210 USA.
RP Abu Arja, MH (reprint author), Nationwide Childrens Hosp, Dept Pediat, Div Hematol Oncol & Blood & Marrow Transplant, Columbus, OH 43205 USA.
EM mha9008@nyp.org
OI Palmer, Joshua/0000-0003-3311-0129
CR Alapetite C, 2010, NEURO-ONCOLOGY, V12, P1318, DOI 10.1093/neuonc/noq093
   Bouffet E, 1999, BRIT J CANCER, V79, P1199, DOI 10.1038/sj.bjc.6690192
   Calaminus G, 2013, NEURO-ONCOLOGY, V15, P788, DOI 10.1093/neuonc/not019
   Danesh-Meyer HV, 2008, J CLIN NEUROSCI, V15, P95, DOI 10.1016/j.jocn.2007.09.004
   Duron L, 2018, NEURORADIOLOGY, V60, P27, DOI 10.1007/s00234-017-1928-6
   Ferguson I, 2017, CLIN EXP OPHTHALMOL, V45, P592, DOI 10.1111/ceo.12927
   Frappaz D, 2017, PEDIATR BLOOD CANCER, V64, DOI 10.1002/pbc.26543
   JENNINGS MT, 1985, J NEUROSURG, V63, P155, DOI 10.3171/jns.1985.63.2.0155
   Kenjo M, 2015, JPN J RADIOL, V33, P336, DOI 10.1007/s11604-015-0424-3
   Khatua S, 2010, PEDIATR BLOOD CANCER, V55, P42, DOI 10.1002/pbc.22468
   Loius D, 2016, WHO CLASSIFICATION T
   Matsutani M, 1997, J NEUROSURG, V86, P446, DOI 10.3171/jns.1997.86.3.0446
   Nakajima T, 2001, NEUROSURGERY, V48, P214, DOI 10.1097/00006123-200101000-00041
   PARSONS JT, 1994, INT J RADIAT ONCOL, V30, P755, DOI 10.1016/0360-3016(94)90346-8
   Pereira LS, 2008, EUR J OPHTHALMOL, V18, P159
   Sonoda Y, 2008, J NEUROSURG-PEDIATR, V2, P118, DOI 10.3171/PED/2008/2/8/118
NR 16
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP 116
EP 120
DI 10.1016/j.wneu.2018.12.143
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800129
PM 30630044
DA 2020-05-12
ER

PT J
AU Zhang, YW
   Xiao, Q
   Zeng, JH
   Deng, L
AF Zhang, Yuan-Wei
   Xiao, Qiang
   Zeng, Ji-Huan
   Deng, Liang
TI Solitary Fibrous Tumor of the Lumbar Spine Resembling Schwannoma: Case
   Report and Review of the Literature
SO WORLD NEUROSURGERY
LA English
DT Review
DE Immunohistochemistry; Schwannoma; Solitary fibrous tumor; Spinal canal
ID DIAGNOSIS
AB BACKGROUND: Solitary fibrous tumors (SFTs) are rare tumors derived from mesenchymal tissues. Notably, despite the widespread reports of SFT in various parts of the body, it is extremely rare in the spine, especially the lumbosacral spine, with only 4 previously reported cases.
   CASE PRESENTATION: A 40-year-old Chinese man had experienced low back and right leg pain for 11 years. Magnetic resonance imaging of the lumbar spine indicated a dumbbell-shaped mass at the right L4 vertebra. After the first surgical resection, the tumor was diagnosed as schwannoma pathologically. Three years later, he presented with low back pain, numbness in both legs, and defecation incontinence. Imaging examination suggested tumor recurrence. Pathologic examination of the second surgical specimen revealed features of SFT. So far, the patient has recovered well through the second extended resection and postoperative radiotherapy.
   CONCLUSION: To our knowledge, this is the fifth reported case of lumbar spine SFT, and its diagnosis is a difficult challenge. However, accurate diagnosis and complete resection of SFT in a patient suspected of having SFT could extend life or improve quality of life.
C1 [Zhang, Yuan-Wei; Xiao, Qiang; Zeng, Ji-Huan; Deng, Liang] Jiangxi Prov Peoples Hosp, Dept Orthoped, Nanchang, Jiangxi, Peoples R China.
   [Zhang, Yuan-Wei] Nanchang Univ, Grad Sch, Med Dept, Nanchang, Jiangxi, Peoples R China.
RP Deng, L (reprint author), Jiangxi Prov Peoples Hosp, Dept Orthoped, Nanchang, Jiangxi, Peoples R China.
EM dengliang001137@163.com
OI Deng, Liang/0000-0002-7221-9146
CR Bisceglia M, 2011, INT J SURG PATHOL, V19, P476, DOI 10.1177/1066896911405655
   Chick JFB, 2013, AM J ROENTGENOL, V200, pW238, DOI 10.2214/AJR.11.8430
   Doyle LA, 2014, MODERN PATHOL, V27, P390, DOI 10.1038/modpathol.2013.164
   Esteves C, 2017, RADIOGRAPHICS, V37, P2018, DOI 10.1148/rg.2017160200
   Klemperer P, 1931, ARCH PATHOL, V11, P387
   Lang N, 2018, EUR RADIOL, V28, P3986, DOI 10.1007/s00330-018-5349-7
   Louis DN, 2016, ACTA NEUROPATHOL, V131, P803, DOI 10.1007/s00401-016-1545-1
   Munoz E, 2008, SPINE, V33, pE397, DOI 10.1097/BRS.0b013e31817343dc
   Nagano A, 2014, SPINE J, V14, pE17, DOI 10.1016/j.spinee.2013.07.463
   Pasquali S, 2016, EJSO-EUR J SURG ONC, V42, P1064, DOI 10.1016/j.ejso.2016.01.023
   Robinson DR, 2013, NAT GENET, V45, P180, DOI 10.1038/ng.2509
   Shen JQ, 2018, CANCER MANAG RES, V10, P1069, DOI 10.2147/CMAR.S165218
   Stout AP, 1942, ANN SURG, V116, P26, DOI 10.1097/00000658-194207000-00004
   Tan JHY, 2016, BMC PULM MED, V16, DOI 10.1186/s12890-016-0279-0
   Wang CH, 2016, J NEURORADIOLOGY, V43, P325, DOI 10.1016/j.neurad.2016.06.003
NR 15
TC 0
Z9 0
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP 121
EP 124
DI 10.1016/j.wneu.2019.01.004
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800130
PM 30654157
DA 2020-05-12
ER

PT J
AU Nguyen, KD
   Reddy, V
   Rahimi, SY
AF Nguyen, Khoi D.
   Reddy, Vamsi
   Rahimi, Scott Y.
TI Dural Sandwich Technique for Hemicraniectomy and Benefits During
   Cranioplasty
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cranial defect; Cranial trauma; Craniectomy; Cranioplasty; Dural
   sandwich
ID DECOMPRESSIVE CRANIECTOMY
AB OBJECTIVE: Hemicraniectomy is a commonly performed neurosurgical procedure used in the setting of medically refractory malignant intracranial hypertension. Complications from cranioplasty after hemicraniectomy can be significant, including infection and wound issues. Difficulty with scar tissue during exposure for cranioplasty can be challenging and can lead to prolonged surgical time and increased bleeding. We describe a surgical technique, termed the "dural sandwich," that could provide a significant benefit during cranioplasty as compared with traditional single-layered dural closure.
   METHODS: A retrospective analysis was conducted that included 14 patients who underwent a hemicraniectomy procedure over a 4-year period. Seven patients were identified who received a cranioplasty after dural sandwich technique during craniectomy. They were compared with a similar patient group of 7 patients who received a cranioplasty after conventional hemicraniectomy with single-layered dural closure. Surgical time, estimated blood loss, and complication rates were compared between the 2 groups. Analysis of variance measures were performed to assess for statistically significant differences in blood loss and operative time between the dural sandwich and control groups. Statistical significance was defined as P < 0.05.
   RESULTS: The mean estimated blood loss was 82.1 mL in the dural sandwich craniectomy group versus 150 mL in the conventional hemicraniectomy group (P < 0.05). The mean estimated surgical time was 91.7 minutes in the dural sandwich craniectomy group versus 127.5 minutes in the conventional craniectomy group (P < 0.05). There was no evidence of neurologic deterioration, cerebral spinal fluid leak, or postoperative hematoma requiring evacuation in either group. In the conventional craniectomy group, a single report of a wound infection was noted that was treated conservatively with antibiotics.
   CONCLUSIONS: By layering bovine pericardium above and below the dura during initial hemicraniectomy, an artificial plane is created that improves ease of exposure during cranioplasty. This technique could reduce surgical time and blood loss during subsequent cranioplasty, and potentially reduce recovery time and postoperative complications.
C1 [Nguyen, Khoi D.; Reddy, Vamsi; Rahimi, Scott Y.] Augusta Univ, Med Ctr, Dept Neurosurg, Augusta, GA 30912 USA.
RP Nguyen, KD (reprint author), Augusta Univ, Med Ctr, Dept Neurosurg, Augusta, GA 30912 USA.
EM khnguyen@augusta.edu
OI Reddy, Vamsi/0000-0003-2302-936X
CR Aarabi B, 2006, J NEUROSURG, V104, P469, DOI 10.3171/jns.2006.104.4.469
   Adamo MA, 2009, J NEUROSURG-PEDIATR, V3, P334, DOI 10.3171/2008.12.PEDS08310
   Buang S S, 2012, Med J Malaysia, V67, P393
   Chang V, 2010, J NEUROSURG, V112, P1120, DOI 10.3171/2009.6.JNS09133
   Gooch MR, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.3.FOCUS0962
   Kakar V, 2009, BRIT J NEUROSURG, V23, P147, DOI 10.1080/02688690902756702
   Kan P, 2006, J NEUROSURG, V105, P337, DOI 10.3171/ped.2006.105.5.337
   Quinones-Hinojosa A, 2012, SCHMIDEK SWEET OPERA
   Raghavan A, 2018, WORLD NEUROSURG, V119, P282, DOI 10.1016/j.wneu.2018.08.024
   Schuss P, 2012, J NEUROTRAUM, V29, P1090, DOI 10.1089/neu.2011.2176
   Sobani Zain A, 2011, Surg Neurol Int, V2, P123, DOI 10.4103/2152-7806.85055
   Stephens FL, 2010, NEUROSURG FOCUS, V28, DOI 10.3171/2010.2.FOCUS1026
   Yadla S, 2011, NEUROSURGERY, V68, P1124, DOI 10.1227/NEU.0b013e31820a5470
NR 13
TC 4
Z9 4
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP 125
EP 128
DI 10.1016/j.wneu.2018.12.162
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800131
PM 30641235
DA 2020-05-12
ER

PT J
AU Ricciardi, L
   Chaichana, KL
   Cardia, A
   Stifano, V
   Rossini, Z
   Olivi, A
   Sturiale, CL
AF Ricciardi, Luca
   Chaichana, Kaisorn L.
   Cardia, Andrea
   Stifano, Vito
   Rossini, Zefferino
   Olivi, Alessandro
   Sturiale, Carmelo Lucio
TI The Exoscope in Neurosurgery: An Innovative "Point of View". A
   Systematic Review of the Technical, Surgical, and Educational Aspects
SO WORLD NEUROSURGERY
LA English
DT Review
DE Exoscope; Microscope; Surgical video telescope; VITOM
ID HIGH-DEFINITION EXOSCOPE; OPERATING MICROSCOPE; CLINICAL-EXPERIENCE;
   VISUALIZATION TOOL; TUBULAR RETRACTORS; SURGERY; DEEP;
   MICRONEUROSURGERY; RESECTION; VITOM
AB BACKGROUND: The introduction of operative microscopes (OMs) is the most important revolution in modern microneurosurgery, as a result of the implementation of lighting and magnification of the surgical field and of the capability to dissect the microneurovascular structures. Recently, the advent of video telescopic intraoperative microscopes or exoscopes (EX) has enlarged these perspectives in neurosurgery.
   OBJECTIVE: To systematically review all the pertinent literature.
   METHODS: We systematically reviewed the pertinent literature and collected all the reported experience with EX use in neurosurgery. Quantitative and qualitative data, along with the authors' opinions and concerns, were recorded and analyzed. A comparison with the OM was also considered.
   RESULTS: Twenty-nine studies reporting surgical procedures on 574 patients were included in the study. Data analysis was categorized in 3 groups, representing technical, surgical, and educational aspects. The EX is largely considered superior or equivalent to OM in many features, such as the surgeon's ergonomic comfort, educational opportunities, image quality, magnification, lighting, and costs. However, some surgeons still prefer the OM, especially for its better stereoscopic vision.
   CONCLUSIONS: The EX has been emerging as an alternative to the OM for performing many cranial, spinal, and peripheral neurosurgical procedures. Despite some limitations, this new optical device presents many features that can be considered as an evolution of the OM. In future years, larger studies will confirm these preliminary impressions.
C1 [Ricciardi, Luca; Stifano, Vito; Olivi, Alessandro; Sturiale, Carmelo Lucio] Fdn Policlin Univ Agostino Gemelli IRCCS, Dept Neurosurg, Rome, Italy.
   [Ricciardi, Luca; Chaichana, Kaisorn L.; Stifano, Vito; Olivi, Alessandro] Univ Cattolica Sacro Cuore, Dept Neurosurg, Rome, Italy.
   [Ricciardi, Luca] Mayo Clin, Coll Med, Dept Neurosurg, Jacksonville, FL 32224 USA.
   [Cardia, Andrea; Rossini, Zefferino] Humanitas Clin & Res Ctr, Div Neurosurg, Milan, Italy.
RP Sturiale, CL (reprint author), Fdn Policlin Univ Agostino Gemelli IRCCS, Dept Neurosurg, Rome, Italy.
EM cropcircle.2000@virgilio.it
RI Sturiale, Carmelo Lucio/K-6412-2016; Ricciardi, Luca/L-5405-2019;
   Stifano, Vito/I-9032-2019
OI Sturiale, Carmelo Lucio/0000-0002-4080-2492; Ricciardi,
   Luca/0000-0001-5110-8386; Stifano, Vito/0000-0002-5509-9592; CARDIA,
   Andrea/0000-0002-7349-3753
CR Akbari SHA, 2019, OPER NEUROSURG, V16, P292, DOI 10.1093/ons/opy108
   Bakhsheshian J, 2019, OPER NEUROSURG, V16, P159, DOI 10.1093/ons/opy079
   Bauer AM, 2017, OPER NEUROSURG, V13, P69, DOI 10.1227/NEU.0000000000001258
   Beez T, 2018, CUREUS, V10, DOI 10.7759/cureus.2108
   Belloch JP, 2014, ACTA NEUROCHIR, V156, P653, DOI 10.1007/s00701-013-1976-6
   Birch K, 2014, J CLIN NEUROSCI, V21, P1245, DOI 10.1016/j.jocn.2013.10.026
   Day JD, 2017, NEUROSURGERY, V64, P151, DOI 10.1093/neuros/nyx324
   Di Ieva A, 2012, NEUROSURG REV, V35, P341, DOI 10.1007/s10143-011-0371-0
   Gassie K, 2018, J NEUROSURG SCI, V62, P682, DOI 10.23736/S0390-5616.18.04466-1
   Gonen L, 2017, NEUROSURG FOCUS, V42, DOI 10.3171/2017.3.FOCUS1712
   Iyer R, 2018, J NEUROL SURG PART A, V79, P330, DOI 10.1055/s-0038-1641738
   Jackson C, 2017, J NEUROL SURG PART A, V78, P588, DOI 10.1055/s-0037-1602698
   Jannetta P J, 1968, Am Surg, V34, P31
   Klinger DR, 2018, OPER NEUROSURG, V14, P26, DOI 10.1093/ons/opx081
   Krishnan KG, 2017, WORLD NEUROSURG, V97, P652, DOI 10.1016/j.wneu.2016.09.037
   Labib MA, 2017, NEUROSURGERY, V80, P515, DOI 10.1227/NEU.0000000000001316
   Mamelak AN, 2008, SURG INNOV, V15, P38, DOI 10.1177/1553350608315954
   Mamelak AN, 2012, J CLIN NEUROSCI, V19, P306, DOI 10.1016/j.jocn.2011.07.014
   Mamelak AN, 2010, NEUROSURGERY, V67, P476, DOI 10.1227/01.NEU.0000372204.85227.BF
   Moisi MD, 2017, WORLD NEUROSURG, V98, P273, DOI 10.1016/j.wneu.2016.11.003
   Nagata Y, 2017, WORLD NEUROSURG, V103, P310, DOI 10.1016/j.wneu.2017.04.059
   Oertel JM, 2017, WORLD NEUROSURG, V105, P153, DOI 10.1016/j.wneu.2017.05.109
   Parihar Vijay, 2016, Asian J Neurosurg, V11, P421
   Piquer J, 2014, BIOMED RES INT, DOI 10.1155/2014/207974
   Postacchini F, 2011, ACTA NEUROCHIR SUPPL, V108, P17, DOI 10.1007/978-3-211-99370-5_4
   Rand R W, 1968, Clin Neurosurg, V15, P319
   Read JCA, 2014, ERGONOMICS, V57, P1140, DOI 10.1080/00140139.2014.914581
   Ritsma B, 2014, CASE REP NEUROL MED, DOI 10.1155/2014/102307
   Rossini Z, 2017, WORLD NEUROSURG, V107, P663, DOI 10.1016/j.wneu.2017.08.083
   RUNNELS JB, 1974, J KANSAS MED SOC, V75, P40
   Sack J, 2018, OPER NEUROSURG, V14, P395, DOI 10.1093/ons/opx145
   Scranton RA, 2016, J NEUROSURG, V125, P1360, DOI 10.3171/2015.12.JNS152185
   Shirzadi A, 2012, SPINE, V37, pE1517, DOI 10.1097/BRS.0b013e3182709cef
   Uluc K, 2009, NEUROSURG FOCUS, V27, DOI 10.3171/2009.6.FOCUS09120
   Wanibuchi M, 2018, WORLD NEUROSURG, V109, pE105, DOI 10.1016/j.wneu.2017.09.113
   Yasargil MG, 1999, NEUROSURGERY, V45, P1025
   YASARGIL MG, 1970, BIBL OPHTHALMOL, P62
   Zhu XB, 2012, NEURAL REGEN RES, V7, P912, DOI 10.3969/j.issn.1673-5374.2012.12.006
NR 38
TC 8
Z9 8
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP 136
EP 144
DI 10.1016/j.wneu.2018.12.202
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800135
PM 30660891
DA 2020-05-12
ER

PT J
AU An, JW
   Lee, CW
AF An, Jin-Woo
   Lee, Chul-Woo
TI Surgical Treatment of Extraforaminal Gas-Containing Pseudocyst
   Compressing L5 Nerve Root by Using Unilateral Biportal Endoscopy
SO WORLD NEUROSURGERY
LA English
DT Article
DE Gas pseudocyst; Lumbar foramen; Percutaneous endoscopic; Unilateral
   biportal endoscopy
ID LUMBAR INTRASPINAL GAS; EPIDURAL GAS; RADICULAR COMPRESSION; SPINAL
   STENOSIS; TECHNICAL NOTE; DECOMPRESSION; RADICULOPATHY; DISKECTOMY;
   SURGERY; CT
AB BACKGROUND: Most gaseous lumbar pseudocysts have been previously reported to be located in the spinal canal and successfully treated by several therapeutic methods. By comparison, a gas-containing pseudocyst in the lumbar extraforaminal area is rare. Here, the authors report a case of symptomatic gas-containing cyst located in the lumbar foramen. It was successfully treated with unilateral biportal endoscopic (UBE) surgery.
   CASE DESCRIPTION: A 75-year-old man presented with severe left leg pain and tingling sensation refractory to conservative treatment that aggravated with weight bearing and position change. Computed tomography and magnetic resonance imaging showed a gas-containing cyst compressing the left L5 nerve root ganglion in the foramina area at the L5-S1 level. Gaseous extraforaminal pseudocyst was successfully removed by UBE surgery via the paraspinal approach. Vivid and clear endoscopic operative imaging of pseudocyst in detail was obtained during the operation. The patient's symptom was significantly improved after the operation.
   CONCLUSIONS: A gas-containing pseudocyst in the lumbar foraminal area is not common. Combined use of preoperative magnetic resonance imaging and computed tomography can help diagnose a gaseous pseudocyst and differentiate other pathologies. A UBE technique that provides good operative visualization and delicate operative manipulation is a less invasive therapeutic method to treat a foraminal gas-containing pseudocyst.
C1 [An, Jin-Woo] Bur Team Hosp, Dept Orthoped Surg, Suwon, South Korea.
   [Lee, Chul-Woo] St Peters Hosp, Dept Neurosurg, Seoul, South Korea.
RP Lee, CW (reprint author), St Peters Hosp, Dept Neurosurg, Seoul, South Korea.
EM mannitol240@gmail.com
OI Lee, Chul-Woo/0000-0002-6562-977X
CR Akbary K, 2018, WORLD NEUROSURG, V117, P153, DOI 10.1016/j.wneu.2018.05.111
   Akhaddar A, 2010, INTERNAL MED, V49, P2647, DOI 10.2169/internalmedicine.49.4474
   BOSSER V, 1990, NEURORADIOLOGY, V31, P552, DOI 10.1007/BF00340142
   Charles RW, 1989, SPINE, V27, P998
   Choi DJ, 2016, CLIN ORTHOP SURG, V8, P325, DOI 10.4055/cios.2016.8.3.325
   Choi KC, 2017, WORLD NEUROSURG, V99, P259, DOI 10.1016/j.wneu.2016.12.052
   DEMIERRE B, 1988, NEUROSURGERY, V22, P731, DOI 10.1227/00006123-198804000-00018
   Eum JH, 2016, J NEUROSURG-SPINE, V24, P602, DOI 10.3171/2015.7.SPINE15304
   GULATI AN, 1980, NEURORADIOLOGY, V20, P191, DOI 10.1007/BF00336681
   Heo DH, 2017, NEUROSURG FOCUS, V43, DOI 10.3171/2017.5.FOCUS17146
   Hwang JH, 2017, WORLD NEUROSURG, V101, P33, DOI 10.1016/j.wneu.2017.01.079
   Ilica AT, 2006, AM J NEURORADIOL, V27, P998
   Kim HS, 2017, WORLD NEUROSURG, V108, P763, DOI 10.1016/j.wneu.2017.09.018
   Kim HS, 2017, WORLD NEUROSURG, V103, P201, DOI 10.1016/j.wneu.2017.03.130
   Kim HS, 2011, J KOREAN NEUROSURG S, V49, P384, DOI 10.3340/jkns.2011.49.6.384
   Lee CW, 2018, WORLD NEUROSURG, V113, pE129, DOI 10.1016/j.wneu.2018.01.195
   Lee CW, 2016, J KOREAN NEUROSURG S, V59, P172, DOI 10.3340/jkns.2016.59.2.172
   Lee CW, 2014, J KOREAN NEUROSURG S, V56, P521, DOI 10.3340/jkns.2014.56.6.521
   Lee DY, 2010, J KOREAN NEUROSURG S, V47, P232, DOI 10.3340/jkns.2010.47.3.232
   MORTENSEN WW, 1991, SPINE, V16, P190, DOI 10.1097/00007632-199102000-00017
   Oertel JM, 2017, WORLD NEUROSURG, V103, P122, DOI 10.1016/j.wneu.2017.02.075
   Pak Kevin I, 2011, HSS J, V7, P89, DOI 10.1007/s11420-010-9168-x
   Righini A, 1999, J NEUROSURG, V91, P133, DOI 10.3171/spi.1999.91.1.0133
   Sasani M, 2007, SPINE, V32, pE320, DOI 10.1097/01.brs.0000261565.76537.ea
   Seo HY, 2014, J ORTHOP SCI, V19, P507, DOI 10.1007/s00776-012-0313-x
   TSUJI H, 1990, J NEUROSURG, V73, P785, DOI 10.3171/jns.1990.73.5.0785
   Vaquero J, 2011, J RHEUMATOL, V38, P2264, DOI 10.3899/jrheum.110564
   Yasuoka H, 2010, J R Army Med Corps, V156, P47
   Yoshida H, 1997, SPINE, V22, P348, DOI 10.1097/00007632-199702010-00021
   Yun Sung Min, 2012, Korean J Spine, V9, P365, DOI 10.14245/kjs.2012.9.4.365
   Zhu B, 2017, PAIN PHYSICIAN, V20, pE445
NR 31
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP 145
EP 150
DI 10.1016/j.wneu.2018.12.186
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800136
PM 30659964
DA 2020-05-12
ER

PT J
AU Luo, N
   He, X
   Li, GZ
   Liao, YH
   Tang, Q
   Ye, RP
   Zhong, DJ
AF Luo, Ning
   He, Xia
   Li, Guangzhou
   Liao, Yehui
   Tang, Qiang
   Ye, Rupei
   Zhong, Dejun
TI Desmoid Tumor Presenting as a Typical Cervical Dumbbell Tumor: Case
   Report and Review of the Literature
SO WORLD NEUROSURGERY
LA English
DT Review
DE Case report; Desmoid tumor; Dumbbell-shaped tumor; Head and neck
   neoplasm; Spinal tumor
ID FAMILIAL ADENOMATOUS POLYPOSIS; AGGRESSIVE FIBROMATOSIS;
   SURGICAL-TREATMENT; STRATEGY; SURGERY; HEAD; NECK
AB BACKGROUND: Dumbbell-shaped tumor is a type of inner and outer cervical spinal canal tumor, and most of these are neurogenic. Desmoid tumors are rare, and, to the best of our knowledge, no case of desmoid tumors involving intervertebral foramen formed dumbbell-shaped tumors in the cervical spine have been reported before in English literature. Here we report a case of a desmoid tumor occurring in the cervical spine that is presented as a typical dumbbell-shaped tumor.
   CASE DESCRIPTION: A 47-year-old woman was admitted to our department with a mass in the left side of her neck. The tumor was initially thought to be a neurogenic cervical dumbbell tumor based on physical and radiologic examination. Postoperative hematoxylin-eosin staining and immunohistochemical staining verified the diagnosis of a cervical dumbbell desmoid tumor, which, to our knowledge, had never been reported before. We report our experience and reviewed literature regarding desmoid tumor to share our experience and explore proper treatment options of such lesions.
   CONCLUSIONS: Desmoid tumors in the head and neck may present as cervical dumbbell-shaped tumors. Before the treatment plan was made, thorough examinations, including surgical pathology, were necessary.
C1 [Luo, Ning; Li, Guangzhou; Liao, Yehui; Tang, Qiang; Zhong, Dejun] Southwest Med Univ, Affiliated Hosp, Dept Spinal Surg, Luzhou, Peoples R China.
   [He, Xia] Southwest Med Univ, Affiliated Hosp, Dept Pediat Surg, Luzhou, Peoples R China.
   [Ye, Rupei] Southwest Med Univ, Affiliated Hosp, Dept Pathol, Luzhou, Peoples R China.
RP Zhong, DJ (reprint author), Southwest Med Univ, Affiliated Hosp, Dept Spinal Surg, Luzhou, Peoples R China.
EM zdj_1974@163.com
CR Aicher B, 2012, CEPHALALGIA, V32, P185, DOI 10.1177/0333102411430856
   Ando K, 2014, J ORTHOP SURG RES, V9, DOI 10.1186/1749-799X-9-2
   Asazuma T, 2004, SPINE, V29, pE10, DOI 10.1097/01.BRS.0000103662.13689.76
   Avincsal OM, 2018, BALK MED J, V35, P278, DOI 10.4274/balkanmedj.2017.0509
   BERNSTEIN KE, 1982, CANCER-AM CANCER SOC, V48, P1668, DOI 10.1002/1097-0142(19820415)49:8<1668::AID-CNCR2820490823>3.0.CO;2-9
   Binatli O, 1999, J Neurosurg Sci, V43, P163
   Buitendijk S, 2005, CANCER-AM CANCER SOC, V104, P1090, DOI 10.1002/cncr.21275
   Church J, 2005, DIS COLON RECTUM, V48, P1528, DOI 10.1007/s10350-005-0018-8
   COFFIN CM, 1995, AM J SURG PATHOL, V19, P859, DOI 10.1097/00000478-199508000-00001
   Dempke W, 2001, J CANCER RES CLIN, V127, P411, DOI 10.1007/s004320000225
   Eastley N, 2014, EJSO-EUR J SURG ONC, V40, P1125, DOI 10.1016/j.ejso.2014.02.226
   Eden K, 1941, BRIT J SURG, V28, P549, DOI 10.1002/bjs.18002811205
   El-Mahdy W, 1999, BRIT J NEUROSURG, V13, P550, DOI 10.1080/02688699943042
   Fletcher CDM, 2013, WHO CLASSIFICATION T
   Gega M, 2006, J CLIN ONCOL, V24, P102, DOI 10.1200/JCO.2005.02.1923
   Goldstein A, 2018, CUREUS, V10, DOI 10.7759/cureus.3145
   Grabowski Leszek, 2008, Otolaryngol Pol, V62, P191, DOI 10.1016/S0030-6657(08)70239-7
   Guo W, 2009, SPINE, V34, P2587, DOI 10.1097/BRS.0b013e3181bd4a2b
   GURBUZ AK, 1994, GUT, V35, P377, DOI 10.1136/gut.35.3.377
   GUTMANN DH, 1993, ARCH NEUROL-CHICAGO, V50, P1185, DOI 10.1001/archneur.1993.00540110065007
   Hansmann A, 2004, CANCER-AM CANCER SOC, V100, P612, DOI 10.1002/cncr.11937
   Hendriks MP, 2013, HEAD NECK-J SCI SPEC, V35, pE246, DOI 10.1002/hed.23092
   Jain Paresh, 2010, Ann R Coll Surg Engl, V92, pW19, DOI 10.1308/147870810X12822015504365
   Jelinek JA, 2001, INT J RADIAT ONCOL, V50, P121, DOI 10.1016/S0360-3016(00)01570-4
   Jiang L, 2009, SPINE, V34, P1307, DOI 10.1097/BRS.0b013e3181a27a32
   KATSUMI Y, 1989, SPINE, V14, P1171, DOI 10.1097/00007632-198911000-00007
   KONWALER BE, 1955, AM J CLIN PATHOL, V25, P241
   Kruk-Zagajewska A, 2000, Otolaryngol Pol, V54, P75
   Latchford AR, 2006, BRIT J SURG, V93, P1258, DOI 10.1002/bjs.5425
   Lewis JJ, 1999, ANN SURG, V229, P866, DOI 10.1097/00000658-199906000-00014
   Li C, 1998, AM J PATHOL, V153, P709, DOI 10.1016/S0002-9440(10)65614-3
   Muller J., 1838, UEBER FEINEN BAU FOR
   Nagata T, 2016, WORLD J SURG ONCOL, V14, DOI 10.1186/s12957-016-1000-8
   Nair Keerthi Krishnankutty, 2017, Pan Afr Med J, V27, P47, DOI 10.11604/pamj.2017.27.47.11739
   NAYLOR EW, 1979, ARCH SURG-CHICAGO, V114, P1181
   Neumaier CE, 1997, CLIN RADIOL, V52, P310, DOI 10.1016/S0009-9260(97)80062-1
   Nuyttens JJ, 2000, CANCER, V88, P1517, DOI 10.1002/(SICI)1097-0142(20000401)88:7<1517::AID-CNCR3>3.0.CO;2-9
   Ozawa H, 2007, J NEUROSURG-SPINE, V7, P587, DOI 10.3171/SPI-07/12/587
   Pikaar A, 2002, Ned Tijdschr Geneeskd, V146, P1355
   Pospiech J, 1995, Eur Spine J, V4, P213, DOI 10.1007/BF00303413
   REITAMO JJ, 1982, AM J CLIN PATHOL, V77, P665
   Sakorafas GH, 2007, SURG ONCOL, V16, P131, DOI 10.1016/j.suronc.2007.07.009
   Shinohara S, 2017, AURIS NASUS LARYNX, V44, P365, DOI 10.1016/j.anl.2016.07.006
   Skubitz KM, 2017, MAYO CLIN PROC, V92, P947, DOI 10.1016/j.mayocp.2017.02.012
   Tan MS, 2003, SPINE, V28, P888, DOI 10.1097/00007632-200305010-00010
   Tejpar S, 2005, ACTA GASTRO-ENT BELG, V68, P5
   Tejpar S, 1999, ONCOGENE, V18, P6615, DOI 10.1038/sj.onc.1203041
   Vandevenne JE, 1997, EUR RADIOL, V7, P1013, DOI 10.1007/s003300050243
   Wang CP, 2006, HEAD NECK-J SCI SPEC, V28, P1008, DOI 10.1002/hed.20467
   [肖建如 XIAO Jianru], 2006, [中华骨科杂志, Chinese Journal of Orthopedics], V26, P798
   Yasargil MG, 1996, J NEUROSURG, V84, P891
NR 51
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP 151
EP 156
DI 10.1016/j.wneu.2019.01.001
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800137
PM 30639503
DA 2020-05-12
ER

PT J
AU Kitagawa, T
   Ishikawa, H
   Yamamoto, J
   Ota, S
AF Kitagawa, Takehiro
   Ishikawa, Hisashi
   Yamamoto, Junkoh
   Ota, Shinzo
TI Takotsubo Cardiomyopathy and Neurogenic Pulmonary Edema After Carotid
   Endarterectomy
SO WORLD NEUROSURGERY
LA English
DT Article
DE Carotid endarterectomy; Insular cortex; Neurogenic pulmonary edema;
   Postoperative complication; Takotsubo cardiomyopathy
ID INSULAR CORTEX; BRAIN; PATHOGENESIS; STRESS
AB BACKGROUND: Takotsubo cardiomyopathy (TCM) and neurogenic pulmonary edema (NPE) are rare complications of an acute ischemic stroke. In particular, TCM and NPE following carotid endarterectomy (CEA) are extremely rare. In general, TCM- and NPE-associated ischemic strokes are caused by excess catecholamine release after sympathetic nervous stimulation following stroke onset, but the mechanism triggering this stimulation is still unknown.
   CASE DESCRIPTION: An 88-year-old man underwent left CEA for symptomatic carotid artery stenosis (North American Symptomatic Carotid Endarterectomy Trial, 65%). After the surgery, his respiratory condition rapidly worsened, and chest radiography revealed an infiltrative shadow on both lung fields. Transthoracic echocardiography revealed left ventricular dysfunction, suggesting TCM. Postoperative magnetic resonance imaging revealed a small infarction in the left anterior insular cortex. Eventually, his respiratory and cardiac functions gradually improved. He was finally discharged on his own from the hospital on postoperative day 9.
   CONCLUSIONS: We described a very rare case of TCM and NPE following CEA. The mechanisms of TCM and NPE involve excess catecholamine release after sympathetic nervous stimulation. Our findings suggest that surgery-associated transient ischemia and reperfusion injury to the left insular cortex stimulate sympathetic nerves.
C1 [Kitagawa, Takehiro; Yamamoto, Junkoh] Univ Occupat & Environm Hlth, Dept Neurosurg, Kitakyushu, Fukuoka, Japan.
   [Ishikawa, Hisashi; Ota, Shinzo] Ota Mem Hosp, Brain Attack Ctr, Dept Neurosurg, Fukuyama, Hiroshima, Japan.
RP Kitagawa, T (reprint author), Univ Occupat & Environm Hlth, Dept Neurosurg, Kitakyushu, Fukuoka, Japan.
EM tkitagawa0626@gmail.com
CR Akashi YJ, 2008, CIRCULATION, V118, P2754, DOI 10.1161/CIRCULATIONAHA.108.767012
   Ako J, 2006, AM J MED, V119, P10, DOI 10.1016/j.amjmed.2005.08.022
   Augustine JR, 1996, BRAIN RES REV, V22, P229, DOI 10.1016/S0165-0173(96)00011-2
   Baumann A, 2007, ACTA ANAESTH SCAND, V51, P447, DOI 10.1111/j.1399-6576.2007.01276.x
   Beissner F, 2013, J NEUROSCI, V33, P10503, DOI 10.1523/JNEUROSCI.1103-13.2013
   Bybee KA, 2008, CIRCULATION, V118, P397, DOI 10.1161/CIRCULATIONAHA.106.677625
   Cho HJ, 2010, J CLIN NEUROL, V6, P152, DOI 10.3988/jcn.2010.6.3.152
   Chouchani ET, 2014, NATURE, V515, P431, DOI 10.1038/nature13909
   Inamasu J, 2012, ACTA NEUROCHIR, V154, P2179, DOI 10.1007/s00701-012-1515-x
   Kitagawa T, 2017, NO SHINKEI GEKA, V46, P21
   Nagai M, 2017, CURR PHARM DESIGN, V23, P879, DOI 10.2174/1381612822666161006123530
   Nagai M, 2010, J AM SOC HYPERTENS, V4, P174, DOI 10.1016/j.jash.2010.05.001
   OPPENHEIMER SM, 1992, NEUROLOGY, V42, P1727, DOI 10.1212/WNL.42.9.1727
   THEODORE J, 1975, LANCET, V2, P749
   Yoshimura S, 2008, ANN NEUROL, V64, P547, DOI 10.1002/ana.21459
   박무석, 2016, [Journal of Neurocritical Care, 대한신경집중치료학회지], V9, P171, DOI 10.18700/jnc.160051
NR 16
TC 2
Z9 2
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP 157
EP 160
DI 10.1016/j.wneu.2018.12.206
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800138
PM 30660883
DA 2020-05-12
ER

PT J
AU Yan, YW
   Li, YJ
   Huang, LJ
   Zhang, SM
AF Yan, Yawei
   Li, Yunjie
   Huang, Liangjiang
   Zhang, Suming
TI A Comprehensive Meta-Analysis for Bypass Surgery in Adult Moyamoya
SO WORLD NEUROSURGERY
LA English
DT Review
DE Adult moyamoya; Bypass; Conservative treatment; Meta-analysis; Recurrent
   stroke
ID EXTRACRANIAL-INTRACRANIAL BYPASS; CEREBRAL-ARTERY ANASTOMOSIS; LONG-TERM
   OUTCOMES; SURGICAL REVASCULARIZATION; INTRACEREBRAL HEMORRHAGE;
   CLINICAL-FEATURES; DISEASE; MANAGEMENT; HYPERPERFUSION; RECURRENCE
AB OBJECTIVE: To evaluate the outcomes of bypass surgery for adult moyamoya and compare different surgical modalities by performing a comprehensive meta-analysis of relevant studies.
   METHODS: A systematic literature search was performed and articles regarding different treatments for adult patients with moyamoya were included. Odds ratios (ORs) were calculated to evaluate stroke recurrence, mortality, perioperative complications, and angiographic revascularization among different surgical methods and conservative treatment (CT).
   RESULTS: A total of 17 studies with 2224 adult patients with moyamoya were included in the meta-analysis. Compared with CT, surgical revascularization significantly decreased the future stroke events in the total population ([OR] 0.404; 95% confidence interval [CI] 0.279-0.585; P < 0.001) and in the hemorrhagic-onset patients as well (OR 0.259; 95% CI 0.138-0.486; P < 0.001). However, for those patients with moyamoya and ischemia, there was no significant difference for future stroke events between the bypass and CT groups (OR 0.470; 95% CI 0.140-1.579; P = 0.222). Bypass also showed no mortality reduction compared with CT (OR 0.372; 95% CI 0.120-1.154; P = 0.087). For different surgical techniques, no differences for future stroke events, mortality, and perioperative complications were found between direct bypass and indirect bypass, whereas the degree of angiographic revascularization was better in the direct bypass group than in the indirect group (OR 4.720; 95% CI 1.222-18.230; P = 0.024).
   CONCLUSIONS: The bypass treatment was superior to conservative treatment in preventing recurrent stroke in adult patients with moyamoya, especially in those with a hemorrhagic onset. Direct bypass is associated with better revascularization results compared with indirect bypass.
C1 [Yan, Yawei; Li, Yunjie; Huang, Liangjiang; Zhang, Suming] Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Neurol, Wuhan, Hubei, Peoples R China.
RP Zhang, SM (reprint author), Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Neurol, Wuhan, Hubei, Peoples R China.
EM suming_zhang@hust.edu.cn
OI liangjiang, huang/0000-0002-5434-4357
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [81371292]
FX This study was supported by the National Natural Science Foundation of
   China (81371292).
CR Abla AA, 2013, NEUROSURGERY, V73, P430, DOI 10.1227/NEU.0000000000000017
   Acker G, 2018, STROKE, V49, P476, DOI 10.1161/STROKEAHA.117.018563
   [Anonymous], 2012, NEUROL MED CHIR TOKY, V52, P245, DOI DOI 10.2176/NMC.52.245
   AOKI N, 1993, SURG NEUROL, V40, P372, DOI 10.1016/0090-3019(93)90215-M
   Arias EJ, 2015, J STROKE CEREBROVASC, V24, P1597, DOI 10.1016/j.jstrokecerebrovasdis.2015.03.053
   Arias EJ, 2014, NEUROSURGERY, V74, pS116, DOI 10.1227/NEU.0000000000000229
   Bang JS, 2012, NEUROSURGERY, V70, P625, DOI 10.1227/NEU.0b013e3182333c47
   Cho WS, 2014, STROKE, V45, P3025, DOI 10.1161/STROKEAHA.114.005624
   Choi JU, 1997, CLIN NEUROL NEUROSUR, V99, pS11, DOI 10.1016/S0303-8467(97)00033-4
   Choi Won-Seo, 2013, J Cerebrovasc Endovasc Neurosurg, V15, P191, DOI 10.7461/jcen.2013.15.3.191
   Deng XF, 2018, J NEUROSURG, V128, P1785, DOI 10.3171/2017.2.JNS162405
   Deng XF, 2018, J NEUROSURG, V128, P1327, DOI 10.3171/2016.12.JNS162626
   Donaghy R M, 1968, Prog Brain Res, V30, P263
   Esposito G, 2016, STROKE, V47, P282, DOI 10.1161/STROKEAHA.115.008220
   Fujii K, 1997, CLIN NEUROL NEUROSUR, V99, pS194
   Fujimura M, 2009, SURG NEUROL, V71, P442, DOI 10.1016/j.surneu.2008.02.031
   Fujimura M, 2009, SURG NEUROL, V71, P223, DOI 10.1016/j.surneu.2007.07.077
   Funaki T, 2018, J NEUROSURG, V128, P777, DOI 10.3171/2016.11.JNS161650
   Ge PC, 2017, WORLD NEUROSURG, V100, P459, DOI 10.1016/j.wneu.2017.01.055
   Gross BA, 2013, ACTA NEUROCHIR, V155, P247, DOI 10.1007/s00701-012-1545-4
   Guey S, 2015, APPL CLIN GENET, V8, P49, DOI 10.2147/TACG.S42772
   Guzman R, 2009, J NEUROSURG, V111, P927, DOI 10.3171/2009.4.JNS081649
   Han JS, 2011, STROKE, V42, P3047, DOI 10.1161/STROKEAHA.111.615955
   Houkin K, 1996, STROKE, V27, P1342, DOI 10.1161/01.STR.27.8.1342
   Huang Z, 2015, NEUROL RES, V37, P886, DOI 10.1179/1743132815Y.0000000073
   Hyun SJ, 2010, ACTA NEUROCHIR, V152, P1181, DOI 10.1007/s00701-010-0638-1
   Imai H, 2015, WORLD NEUROSURG, V83, P691, DOI 10.1016/j.wneu.2015.01.016
   Jang DK, 2017, J NEUROSURG, V127, P492, DOI 10.3171/2016.8.JNS152875
   Jeon JP, 2018, J NEUROSURG, V128, P793, DOI 10.3171/2016.11.JNS161688
   Jeon JP, 2016, J KOREAN NEUROSURG S, V59, P537, DOI 10.3340/jkns.2016.59.6.537
   Jiang HQ, 2014, J NEUROSURG, V121, P1048, DOI 10.3171/2014.7.JNS132434
   Kashiwagi S, 1996, ACTA NEUROL SCAND, V93, P85, DOI 10.1111/j.1600-0404.1996.tb00557.x
   Kawaguchi S, 2000, J NEUROSURG, V93, P397, DOI 10.3171/jns.2000.93.3.0397
   Kawaguchi T, 1996, J NEUROSURG, V84, P468, DOI 10.3171/jns.1996.84.3.0468
   Kim DS, 2012, NEUROL MED-CHIR, V52, P333, DOI 10.2176/nmc.52.333
   Kim H, 2016, WORLD NEUROSURG, V94, P273, DOI 10.1016/j.wneu.2016.07.009
   Kim T, 2016, J NEUROSURG, V124, P1788, DOI 10.3171/2015.6.JNS151105
   Kronenburg A, 2014, CURR NEUROL NEUROSCI, V14, DOI 10.1007/s11910-013-0423-7
   Lee SB, 2012, ACTA NEUROCHIR, V154, P1179, DOI 10.1007/s00701-012-1325-1
   Lee SU, 2018, CURR TREAT OPTION NE, V20, DOI 10.1007/s11940-018-0511-8
   Liu L, 2017, J CRANIOFAC SURG, V28, pE522, DOI 10.1097/SCS.0000000000003390
   Miyamoto S, 2014, STROKE, V45, P1415, DOI 10.1161/STROKEAHA.113.004386
   Mizoi K, 1996, SURG NEUROL, V45, P541, DOI 10.1016/0090-3019(95)00475-0
   Morimoto M, 1999, ACTA NEUROCHIR, V141, P377, DOI 10.1007/s007010050313
   Ohue S, 2008, SURG NEUROL, V69, P281, DOI 10.1016/j.surneu.2007.01.047
   Oyama H, 2013, NAGOYA J MED SCI, V75, P37
   Roach ES, 2008, STROKE, V39, P2644, DOI 10.1161/STROKEAHA.108.189696
   Rodriguez-Hernandez A, 2011, WORLD NEUROSURG, V76, pS72, DOI 10.1016/j.wneu.2011.06.032
   Smith ER, 2012, J NEUROSURG-PEDIATR, V9, P353, DOI 10.3171/2011.12.PEDS1172
   Sun H, 2016, WORLD NEUROSURG, V92, P179, DOI 10.1016/j.wneu.2016.04.083
   SUZUKI J, 1969, ARCH NEUROL-CHICAGO, V20, P288, DOI 10.1001/archneur.1969.00480090076012
   Yao Z, 2019, TURK NEUROSURG, V29, P171, DOI 10.5137/1019-5149.JTN.22598-18.3
   Yoshida Y, 1999, STROKE, V30, P2272, DOI 10.1161/01.STR.30.11.2272
   Zhao M, 2019, J NEUROSURG, V130, P531, DOI 10.3171/2017.10.JNS171749
NR 54
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP 161
EP 170
DI 10.1016/j.wneu.2018.12.183
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800139
PM 30654155
DA 2020-05-12
ER

PT J
AU Tanioka, S
   Ishida, F
   Kuraishi, K
   Tanaka, K
   Shimosaka, S
   Suzuki, H
   Mizuno, M
AF Tanioka, Satoru
   Ishida, Fujimaro
   Kuraishi, Keita
   Tanaka, Katsuhiro
   Shimosaka, Shinichi
   Suzuki, Hidenori
   Mizuno, Masaki
TI A Novel Radiologic Assessment of Screw Loosening Focusing on Spatial
   Position Change of Screws Using an Iterative Closest Point Algorithm
   with Stereolithography Data: Technical Note
SO WORLD NEUROSURGERY
LA English
DT Article
DE Iterative closest point algorithm; Screw loosening; Spatial position
   change of screws; Spinal instrumentation surgery; Stereolithography
ID FINITE-ELEMENT; PEDICLE SCREWS; REDUCTION; STRENGTH
AB OBJECTIVE: In thoracolumbar spinal instrumentation surgery, pedicle screw fixation is widely used, whereas screw loosening occurs only occasionally over time. It is common to evaluate screw loosening by the radiographic lucent zone around screws, which can neither evaluate loosening quantitatively nor detect slight screw loosening. In the present technical note, we describe a novel assessment technique of screw loosening by generating 3-dimensional screw images from computed tomography data and superposing them in time series.
   METHODS: Computed tomography data were exported in digital imaging and communications in medicine dataset and imported to the 3-dimensional computer-aided designing software, by which screws and rods were segmented and outputted in stereolithography (STL) format. The STL files were imported to the software, and registration based on iterative closest point algorithm was performed to assess screw position changes.
   RESULTS: Positional changes on STL in time series were classified into 3 types: 1) no position changes existed in the entire system of screws and rods; 2) position changes existed in the entire system of screws and rods, but no position changes were shown when the left-sided and right-sided screws and rod were separately evaluated; and 3) position changes existed in the left and/or right-sided screws and rods even when evaluated separately.
   CONCLUSIONS: This technique enables the quantitative evaluation of screw loosening and loosening between screws and rods. In conjunction with conventional methods of assessing radiographic lucent zone, we are able to obtain more accurate information regarding screw loosening after spinal instrumentation surgery.
C1 [Tanioka, Satoru; Ishida, Fujimaro; Tanaka, Katsuhiro; Shimosaka, Shinichi] Mie Chuo Med Ctr, Dept Neurosurg, Tsu, Mie, Japan.
   [Kuraishi, Keita; Suzuki, Hidenori; Mizuno, Masaki] Mie Univ, Dept Neurosurg, Grad Sch Med, Tsu, Mie, Japan.
RP Tanioka, S (reprint author), Mie Chuo Med Ctr, Dept Neurosurg, Tsu, Mie, Japan.
EM satoru-tanioka@umin.net
OI Tanioka, Satoru/0000-0002-4678-6163; Suzuki,
   Hidenori/0000-0002-8555-5448
CR Aghayev E, 2014, EUR SPINE J, V23, P689, DOI 10.1007/s00586-013-3080-2
   BESL PJ, 1992, IEEE T PATTERN ANAL, V14, P239, DOI 10.1109/34.121791
   Bianco RJ, 2017, CLIN SPINE SURG, V30, pE226, DOI 10.1097/BSD.0000000000000151
   Chao CK, 2008, J SPINAL DISORD TECH, V21, P130, DOI 10.1097/BSD.0b013e318073cc4b
   Dakhil-Jerew F, 2009, EUR SPINE J, V18, P1486, DOI 10.1007/s00586-009-1071-0
   Funama Y, 2015, PHYS MEDICA, V31, P66, DOI 10.1016/j.ejmp.2014.10.003
   Galbusera F, 2015, EUR SPINE J, V24, P1005, DOI 10.1007/s00586-015-3768-6
   Haase K, 2013, COMPUT BIOL MED, V43, P1748, DOI 10.1016/j.compbiomed.2013.07.032
   Imai K, 2006, SPINE, V31, P1789, DOI 10.1097/01.brs.0000225993.57349.df
   Kidoh M, 2016, EUR RADIOL, V26, P1378, DOI 10.1007/s00330-015-3950-6
   Mora H, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0164694
   Ohtori S, 2013, SPINE, V38, P487
   Okuyama K, 2001, Spine J, V1, P402, DOI 10.1016/S1529-9430(01)00078-X
   Rohlmann A, 2012, EUR SPINE J, V21, P666, DOI 10.1007/s00586-011-2047-4
   Rohlmann A, 2010, J BIOMECH, V43, P2963, DOI 10.1016/j.jbiomech.2010.07.018
   Sanden B, 2004, J BONE JOINT SURG BR, V86B, P457, DOI 10.1302/0301-620X.86B3.14323
   Shi L, 2012, J SPINAL DISORD TECH, V25, P123, DOI 10.1097/BSD.0b013e31820ef9f7
NR 17
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP 171
EP 177
DI 10.1016/j.wneu.2018.12.209
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800140
PM 30660886
DA 2020-05-12
ER

PT J
AU Doi, K
   Toyooka, T
   Wada, K
   Otani, N
   Takeuchi, S
   Tomiyama, A
   Nakatogawa, H
   Tanaka, T
   Shimazaki, H
   Hayashi, K
   Mori, K
AF Doi, Kazuma
   Toyooka, Terushige
   Wada, Kojiro
   Otani, Naoki
   Takeuchi, Satoru
   Tomiyama, Arata
   Nakatogawa, Hirokazu
   Tanaka, Tokutaro
   Shimazaki, Hideyuki
   Hayashi, Katsumi
   Mori, Kentaro
TI Spontaneous Regression of Germinomas After Salvage Surgery and Possible
   Mechanism of Induced Apoptosis
SO WORLD NEUROSURGERY
LA English
DT Article
DE Apoplexy; Apoptosis; Endoscopic third ventriculostomy; Germinoma;
   Spontaneous regression; T lymphocyte
ID PRIMARY INTRACRANIAL GERMINOMA; TUMOR
AB BACKGROUND: A few cases of spontaneous regression of germ cell tumors have been reported. Possible mechanisms include steroid medication, surgical intervention, diagnostic radiation exposure, and immune response. None of these hypotheses has been supported by sufficient data.
   CASE DESCRIPTION: Two cases of germinoma demonstrated spontaneous regression before antitumor therapy. In the first case, a 19-year-old man presented with acute hydrocephalus due to a pineal mass and underwent emergent endoscopic third ventriculostomy. The pineal tumor started to regress on the 4th postoperative day after endoscopic third ventriculostomy. In the second case, a 22-year-old man presented with acute hydrocephalus and panhypopituitarism due to a suprasellar mass and underwent emergent external ventricular drainage, biopsy, and septostomy on the day of admission. Apparent regression of the tumor was discovered on the 5th day after initial surgery. Pathologic diagnosis was pure germinoma in both cases. Remarkable accumulations of CD4-positive lymphocytes and some apoptotic cells positive for terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end labeling staining were detected in both cases. Diagnostic radiation exposure is the only common condition in all reported cases.
   CONCLUSIONS: This unusual phenomenon of spontaneous regression of germinoma may be caused by a combination of pathognomonic characteristics of anatomic location with paraventricular development and stress induction as a trigger, such as salvage surgery or diagnostic radiation, including at extremely low dosage.
C1 [Doi, Kazuma; Toyooka, Terushige; Wada, Kojiro; Otani, Naoki; Takeuchi, Satoru; Tomiyama, Arata; Mori, Kentaro] Natl Def Med Coll, Dept Neurosurg, Tokorozawa, Saitama, Japan.
   [Shimazaki, Hideyuki] Natl Def Med Coll, Dept Pathol, Tokorozawa, Saitama, Japan.
   [Hayashi, Katsumi] Natl Def Med Coll, Dept Radiol, Tokorozawa, Saitama, Japan.
   [Nakatogawa, Hirokazu; Tanaka, Tokutaro] Seirei Hamamatsu Gen Hosp, Dept Neurosurg, Hamamatsu, Shizuoka, Japan.
RP Doi, K (reprint author), Natl Def Med Coll, Dept Neurosurg, Tokorozawa, Saitama, Japan.
EM mogulaiko1987@yahoo.co.jp
RI Tomiyama, Arata/H-9851-2019
CR Aoyama H, 2002, J CLIN ONCOL, V20, P857, DOI 10.1200/JCO.20.3.857
   Aoyama H, 2009, PROG NEUROL SURG, V23, P96, DOI 10.1159/000210056
   COLE WH, 1981, J SURG ONCOL, V17, P201, DOI 10.1002/jso.2930170302
   Frassanito P, 2015, WORLD NEUROSURG, V84, DOI 10.1016/j.wneu.2015.03.063
   Fujimaki T, 1999, J NEURO-ONCOL, V41, P65, DOI 10.1023/A:1006155120191
   Hu MM, 2016, EUR J MED RES, V21, DOI 10.1186/s40001-016-0204-2
   Ide M, 1997, CANCER, V79, P558, DOI 10.1002/(SICI)1097-0142(19970201)79:3<558::AID-CNCR19>3.0.CO;2-2
   Inoue A, 2018, NEUROSURG REV, V41, P557, DOI 10.1007/s10143-017-0891-3
   Jorsal T, 2012, ACTA ONCOL, V51, P3, DOI 10.3109/0284186X.2011.586000
   Kelder W, 1998, ANN NEUROL, V44, P831, DOI 10.1002/ana.410440521
   Kuwayama Kazuyuki, 2014, No Shinkei Geka, V42, P859
   Mascalchi M, 1998, J NEUROL NEUROSUR PS, V64, P670, DOI 10.1136/jnnp.64.5.670
   Masoudi A, 2008, PEDIATR BLOOD CANCER, V50, P1079, DOI 10.1002/pbc.21421
   Mattogno PP, 2016, WORLD NEUROSURG, V88, P64, DOI 10.1016/j.wneu.2015.12.080
   Murai Y, 2000, J NEUROSURG, V93, P884, DOI 10.3171/jns.2000.93.5.0884
   Ono H, 2011, J NEURO-ONCOL, V103, P755, DOI 10.1007/s11060-010-0432-1
   Ransohoff RM, 2003, NAT REV IMMUNOL, V3, P569, DOI 10.1038/nri1130
   Sato A, 2009, NEUROL SURG TOKYO, V37, P277
   Shimizu J, 2008, NEUROL MED-CHIR, V48, P227, DOI 10.2176/nmc.48.227
   Si SJ, 2010, PEDIATR HEMAT ONCOL, V27, P237, DOI 10.3109/08880010903544866
   Strazielle N, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150945
   Ubogu EE, 2006, TRENDS PHARMACOL SCI, V27, P48, DOI 10.1016/j.tips.2005.11.002
   Yamamoto Shusuke, 2016, No Shinkei Geka, V44, P851
   Yoneoka Yuichiro, 2011, J Med Case Rep, V5, P39, DOI 10.1186/1752-1947-5-39
NR 24
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP 178
EP 183
DI 10.1016/j.wneu.2018.12.165
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800141
PM 30659974
DA 2020-05-12
ER

PT J
AU Low, JCM
   Maratos, E
   Kumar, A
   King, A
   Al-Sarraj, S
   Barazi, S
AF Low, Jacob Chen Ming
   Maratos, Eleni
   Kumar, Atul
   King, Andrew
   Al-Sarraj, Safa
   Barazi, Sinan
TI Adult Parasellar Capillary Hemangioma with Intrasellar Extension
SO WORLD NEUROSURGERY
LA English
DT Article
DE Capillary hemangioma; Parasellar; Pituitary; Sella
ID CAVERNOUS SINUS; STEREOTACTIC RADIOSURGERY; HEAD
AB BACKGROUND: Capillary hemangiomata are benign vascular tumors that typically occur in children. They rarely occur in the central nervous system. Intracranial capillary hemangiomata in adults are very rare entities with only 18 cases reported in the literature. We report a case of parasellar capillary hemangiomata that extended into the sella in a 64-year-old woman as well as a review of the literature in adults.
   CASE DESCRIPTION: We report a 64-year-old patient who presented with a headache, left-sided paresthesia, and weakness. Initial computed tomography of her brain showed a left-sided 3 cm x 2.5 cm parasellar lesion with intrasellar extension and no mass effect. Subsequent magnetic resonance imaging (MRI) showed a lesion that was homogenously hyperintense on T2-weighted MRI and fluid-attenuated inversion recovery, isointense with adjacent brain parenchyma on T1-weighted MRI, and which demonstrated enhancement after contrast administration. The patient initially underwent an endoscopic transsphenoidal biopsy, which was inconclusive, followed by a craniotomy, biopsy, and debulking. Histologic examination showed fibrous tissue containing numerous thin-walled and irregular vascular channels of varying sizes. There was a very mild associated inflammatory infiltrate, mainly formed of small mononuclear chronic inflammatory cells and occasional histiocytes. The histologic appearances were in keeping with capillary hemangiomata.
   CONCLUSIONS: Capillary hemangiomata related to the sella are very rare and can easily be misdiagnosed on imaging alone. The present case highlights capillary hemangiomata as an important, albeit rare, differential when considering a sellar or parasellar mass.
C1 [Low, Jacob Chen Ming; Maratos, Eleni; Barazi, Sinan] Kings Coll Hosp London, Dept Neurosurg, London, England.
   [Kumar, Atul; King, Andrew; Al-Sarraj, Safa] Kings Coll Hosp London, Dept Neuropathol, London, England.
RP Low, JCM (reprint author), Kings Coll Hosp London, Dept Neurosurg, London, England.
EM Jacob.CM.Low@doctors.org.uk
CR Abe M, 2004, J NEUROSURG, V101, P73, DOI 10.3171/jns.2004.101.1.0073
   Badinand B, 2003, AM J NEURORADIOL, V24, P190
   BATSAKIS JG, 1981, HEAD NECK SURG, V3, P231, DOI 10.1002/hed.2890030311
   Chang AR, 2017, RADIAT ONCOL J, V35, P25, DOI 10.3857/roj.2016.01984
   Daenekindt T, 2008, J NEUROSURG-PEDIATR, V1, P488, DOI 10.3171/PED/2008/1/6/488
   Hasan A, 2011, NEUROSURGERY, V68, pE850, DOI 10.1227/NEU.0b013e3182093320
   Holtzman RNN, 1999, J NEUROSURG, V90, P239, DOI 10.3171/spi.1999.90.2.0239
   Jalloh I, 2014, ACTA NEUROCHIR, V156, P1151, DOI 10.1007/s00701-014-2007-y
   John SG, 2012, CLINICS PRACT, V2, DOI 10.4081/cp.2012.e35
   Lee YH, 2010, BRAIN PATHOL, V20, P257, DOI 10.1111/j.1750-3639.2009.00345.x
   Liu Jonathan J, 2015, Surg Neurol Int, V6, pS127, DOI 10.4103/2152-7806.155701
   Marchuk DA, 2001, J CLIN INVEST, V107, P665, DOI 10.1172/JCI12470
   Maurer GD, 2010, J NEUROL, V257, P484, DOI 10.1007/s00415-009-5398-6
   Mayo C, 2010, INT J RADIAT ONCOL, V76, pS28, DOI 10.1016/j.ijrobp.2009.07.1753
   Mirza B, 2013, WORLD NEUROSURG, V80, DOI 10.1016/j.wneu.2012.12.013
   Morace R, 2012, WORLD NEUROSURG, V78, DOI 10.1016/j.wneu.2011.09.017
   Nepute J, 2016, CASE REP RADIOL, V2016
   Okamoto Ai, 2015, Surg Neurol Int, V6, pS539, DOI 10.4103/2152-7806.168066
   Ooi KH, 2018, CUREUS, V10, DOI 10.7759/cureus.2285
   Phi JH, 2012, J NEURO-ONCOL, V109, P177, DOI 10.1007/s11060-012-0884-6
   Simon SL, 2005, SURG NEUROL, V64, P154, DOI 10.1016/j.surneu.2004.10.025
   Smith IF, 2007, INT J OBSTET ANESTH, V16, P82, DOI 10.1016/j.ijoa.2006.04.016
   Song SW, 2014, J NEURO-ONCOL, V118, P163, DOI 10.1007/s11060-014-1414-5
   Tsao MN, 2003, J NEUROSURG, V98, P169, DOI 10.3171/jns.2003.98.1.0169
   Wang X, 2012, J NEURO-ONCOL, V107, P239, DOI 10.1007/s11060-011-0753-8
   WILLING SJ, 1993, AM J NEURORADIOL, V14, P529
   Xia XY, 2017, EXP THER MED, V14, P2007, DOI 10.3892/etm.2017.4780
   Yamamoto M, 2010, J NEUROSURG, V112, P772, DOI 10.3171/2009.6.JNS08271
   Younas F, 2011, NEUROL SCI, V32, P963, DOI 10.1007/s10072-011-0569-5
NR 29
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP 184
EP 191
DI 10.1016/j.wneu.2018.12.185
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800142
DA 2020-05-12
ER

PT J
AU Graul, I
   Zippelius, T
   Holzl, A
   Strube, P
AF Graul, Isabel
   Zippelius, Timo
   Hoelzl, Alexander
   Strube, Patrick
TI Elongated Conus Medullaris, Sacral Agenesis, and Scoliosis: A Case
   Report of a Patient with Trisomy 19q and Monosomy 7q
SO WORLD NEUROSURGERY
LA English
DT Article
DE Conus medullaris elongation; Monosomy 7q; Sacral agenesis; Trisomy 19q
ID TETHERED CORD SURGERY; TERMINAL DELETION; CHROMOSOME-7
AB BACKGROUND: Progression of scoliosis following completion of growth, and the combination of low mental retardation and the conspicuous sagittal clinical and radiographic abnormalities suggest a secondary genesis of the scoliosis according to a genetic aberration.
   CASE DESCRIPTION: In the outpatient department, an 18-year-old woman presents with scoliosis and mild mental retardation. Radiography findings demonstrate a sacral agenesis and then consecutively performed magnetic resonance imaging on a conus depression. Because of the symptom constellation, a genetic syndrome was suspected. Genetic diagnostics revealed a trisomy 19q and monosomy 7q. Typically, deletions of the subtelomere 7q show a phenotype with growth retardation, facial anomalies, and intellectual deficit; trisomy of the subtelomere 19q shows growth retardation, atypical ears, short neck, and intellectual deficit with delayed development. The further clinical radiologic and neurologic examination showed no evidence of a tethered cord syndrome. The correction of scoliosis was performed under intraoperative neurophysiological monitoring without neurologic complications.
   CONCLUSIONS: In the presence of dysplastic sacral changes and accompanying elongated conus medullaris in patients with scoliosis, it is always necessary to think of rare chromosome aberrations and to initiate appropriate diagnostics before surgery. The intraoperative neurophysiological monitoring is strongly recommended, owing to a morphologically, and not fully-excludable, tethered cord syndrome.
C1 [Graul, Isabel; Zippelius, Timo; Hoelzl, Alexander; Strube, Patrick] Univ Hosp Jena, Orthoped Dept, Campus Eisenberg, Jena, Germany.
RP Graul, I (reprint author), Univ Hosp Jena, Orthoped Dept, Campus Eisenberg, Jena, Germany.
EM isabel.graul@med.uni-jena.de
RI Strube, Patrick/AAH-5408-2019
OI Strube, Patrick/0000-0003-3210-5301
CR Ayub S, 2016, AM J MED GENET A, V170, P896, DOI 10.1002/ajmg.a.37428
   Carvalheira G, 2014, META GENE, V2, P799, DOI 10.1016/j.mgene.2014.09.004
   Dorn T, 2001, EPILEPSY RES, V47, P119, DOI 10.1016/S0920-1211(01)00303-5
   Fang Yuan, 2015, Zhonghua Yi Xue Za Zhi, V95, P1659
   Fruhmesser A, 2012, AM J MED GENET A, V158A, P2239, DOI 10.1002/ajmg.a.35450
   Hempfing A, 2011, ORTHOPADE, V40, P690, DOI 10.1007/s00132-011-1796-4
   Jackson EM, 2014, J NEUROSURG-PEDIATR, V13, P355, DOI 10.3171/2014.1.PEDS11336
   Jahangiri Faisal R, 2017, Neurodiagn J, V57, P295, DOI 10.1080/21646821.2017.1396780
   Khealani B, 2009, J CLIN NEUROPHYSIOL, V26, P76, DOI 10.1097/WNP.0b013e31819f9067
   Lenzini E, 2010, GENET TEST MOL BIOMA, V14, P695, DOI 10.1089/gtmb.2010.0079
   LYNCH SA, 1995, NAT GENET, V11, P93, DOI 10.1038/ng0995-93
   Mottet N, 2017, FETAL DIAGN THER, V42, P137, DOI 10.1159/000451080
   Nasr AY, 2018, FOLIA MORPHOL, V77, P609, DOI 10.5603/FM.a2018.0041
   Pavone P, 2010, EUR J PEDIATR, V169, P475, DOI 10.1007/s00431-009-1061-6
   RENSHAW TS, 1978, J BONE JOINT SURG AM, V60, P373, DOI 10.2106/00004623-197860030-00020
   Sala F, 2013, CHILD NERV SYST, V29, P1611, DOI 10.1007/s00381-013-2188-3
   Su Pen-Hua, 2008, Pediatrics and Neonatology, V49, P189, DOI 10.1016/S1875-9572(09)60007-3
   Zen PRG, 2010, EUR J MED GENET, V53, P333, DOI 10.1016/j.ejmg.2010.06.008
NR 18
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP 192
EP 196
DI 10.1016/j.wneu.2018.12.178
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800143
PM 30641238
DA 2020-05-12
ER

PT J
AU Kumar, A
   Parihar, V
   Yadav, YR
   Shrivastava, V
   Patel, NK
AF Kumar, Ambuj
   Parihar, Vijay
   Yadav, Yad Ram
   Shrivastava, Vijay
   Patel, Neha K.
TI A Rare Case of Giant Primary Orbital Hydatid Cyst
SO WORLD NEUROSURGERY
LA English
DT Article
DE Giant; Hydatid cyst; Primary orbital
AB BACKGROUND: Primary orbital involvement is extremely rare in echinococcosis. We report a case of giant orbital hydatid cyst in a 15-year-old boy.
   CASE DESCRIPTION: A 15-year-old boy presented with left-side proptosis and gradual painless vision loss. Computed tomography and magnetic resonance imaging revealed a giant multilocular cystic orbital lesion extending into sub-frontal region. Surgical excision was done. Histopathology was suggestive of hydatid cyst. Postoperatively, an antiparasitic agent was administered for 3 months.
   CONCLUSIONS: Hydatic cyst should be kept in differential diagnosis of orbital cystic lesions, especially in pediatric population and endemic areas.
C1 [Kumar, Ambuj; Parihar, Vijay; Yadav, Yad Ram] NSCB Med Coll, Dept Neurosurg, Jabalpur, India.
   [Shrivastava, Vijay; Patel, Neha K.] NSCB Med Coll, Dept Pathol, Jabalpur, India.
RP Kumar, A (reprint author), NSCB Med Coll, Dept Neurosurg, Jabalpur, India.
EM drambuj21@gmail.com
CR Altinors N, 2000, J NEUROSURG, V93, P1, DOI 10.3171/jns.2000.93.1.0001
   Benazzou S, 2010, J CRANIO MAXILL SURG, V38, P274, DOI 10.1016/j.jcms.2009.10.001
   Ergun R, 1997, NEUROSURG REV, V20, P33, DOI 10.1007/BF01390523
   Jimenez-Mejias ME, 2000, J INFECTION, V41, P105, DOI 10.1053/jinf.2000.0687
   ONERCI M, 1991, J CRANIO MAXILL SURG, V19, P359, DOI 10.1016/S1010-5182(05)80279-3
   Oztekin PS, 2014, SINGAP MED J, V55, pE184, DOI 10.11622/smedj.2014167
   Somay H, 2012, J CLIN NEUROSCI, V19, P898, DOI 10.1016/j.jocn.2011.09.018
NR 7
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP 197
EP 200
DI 10.1016/j.wneu.2018.12.208
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800144
PM 30660876
DA 2020-05-12
ER

PT J
AU Tanweer, O
   Mureb, MC
   Pacione, D
   Sen, R
   Jafar, JJ
   Riina, HA
   Huang, PP
AF Tanweer, Omar
   Mureb, Monica C.
   Pacione, Donato
   Sen, Rajeev
   Jafar, Jafar J.
   Riina, Howard A.
   Huang, Paul P.
TI Endovascular and Microsurgical Aneurysm Training in a Chicken Thigh and
   Leg Pulsatile Model
SO WORLD NEUROSURGERY
LA English
DT Article
DE Aneurysm; Chicken vascular anatomy; Education; Endovascular treatment;
   Microsurgical clipping; Microvascular anastomosis; Training
AB BACKGROUND: Neurovascular training models include animal models, synthetics, or computer simulation. In vivo models are expensive and require significant resources. Synthetic/computer models do not reflect the elasticity of fresh vessels. We describe an endovascular and microsurgical training model using a chicken thigh/leg.
   METHODS: A total of 20 chicken thigh/leg models were obtained. Angiography was used to understand the anatomy. Proximal cannulation with a 5-French catheter was achieved and connected to a hemostatic valve with a pump to simulate pulsatile flow. Aneurysms were created at the thigh-leg junction. For clipping training, 3 types of aneurysms were created to reproduce anatomy seen in middle cerebral, anterior communicating, and posterior communicating aneurysms.
   RESULTS: The average cost per specimen was $1.70 +/- $0.30. The diameter of the proximal femoral artery was 2.4 mm +/- 0.2 mm. The length from the proximal femoral artery to the aneurysm was 9.5 cm +/- 0.7 cm. Distal catheterization was successful in all cases (n = 6). Successful deployment of coils and a stent was achieved under fluoroscopic guidance. Gross oversizing of coils and other mistakes led to aneurysm rupture. Each examiner performed an exploration of the pulsatile aneurysm, application and reapplication of a variety of clips, and then the final inspection of branching vessels to confirm patency.
   CONCLUSIONS: The chicken thigh/leg model provides training opportunities in microsurgical suturing, endovascular techniques for aneurysm obliteration, and microsurgical reconstruction of aneurysms. It combines affordability, time efficiency, and reproducibility. Further studies measuring improvement in technical aneurysm management and comparison with other training models are warranted.
C1 [Tanweer, Omar; Mureb, Monica C.; Pacione, Donato; Jafar, Jafar J.; Riina, Howard A.; Huang, Paul P.] NYU, Dept Neurosurg, Sch Med, 550 1St Ave, New York, NY 10016 USA.
   [Sen, Rajeev] Univ Washington, Dept Neurosurg, Seattle, WA 98195 USA.
RP Tanweer, O (reprint author), NYU, Dept Neurosurg, Sch Med, 550 1St Ave, New York, NY 10016 USA.
EM omar.tanweer@nyumc.org
OI Mureb, Monica/0000-0002-7634-0584; Jafar, Jafar/0000-0002-9401-5507;
   Huang, Paul/0000-0003-0563-921X
CR Chen WF, 2014, J PLAST RECONSTR AES, V67, P973, DOI 10.1016/j.bjps.2014.03.024
   Chueh JY, 2009, AM J NEURORADIOL, V30, P1159, DOI 10.3174/ajnr.A1543
   GERMAN WJ, 1954, NEW ENGL J MED, V250, P104, DOI 10.1056/NEJM195401212500303
   GIBO H, 1981, J NEUROSURG, V54, P151, DOI 10.3171/jns.1981.54.2.0151
   Jeong HS, 2011, ANN PLAST SURG, V70, P57
   Kim Byeong Jin, 2013, J Cerebrovasc Endovasc Neurosurg, V15, P20, DOI 10.7461/jcen.2013.15.1.20
   Magaldi M Oliveira, 2014, NEUROSURGERY S4, V10, P600
   Magaldi MO, 2014, OPER NEUROSURG, V10, P592, DOI 10.1227/NEU.0000000000000553
   Olabe J, 2009, SURG NEUROL, V72, P695, DOI 10.1016/j.surneu.2008.12.008
   Raymond J, 2007, AM J NEURORADIOL, V28, P401
   Sidhu RS, 2007, J VASC SURG, V45, P343, DOI 10.1016/j.jvs.2006.09.040
   Yatomi K, 2012, J NEUROL SURG PART A, V73, P397, DOI 10.1055/s-0032-1322592
NR 12
TC 0
Z9 0
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP 201
EP 207
DI 10.1016/j.wneu.2018.12.166
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800145
PM 30641239
DA 2020-05-12
ER

PT J
AU Barthelemy, EJ
   Gabriel, PJ
   Lafortune, Y
   Clervius, H
   Pyda, J
   Park, KB
AF Barthelemy, Ernest J.
   Gabriel, Phabinly J.
   Lafortune, Yudy
   Clervius, Helene
   Pyda, Jordan
   Park, Kee B.
TI The Current State of Neurosurgery in Haiti
SO WORLD NEUROSURGERY
LA English
DT Article
DE Global health; Global neurosurgery; Global surgery; Haiti; International
   development
ID PORT-AU-PRINCE; GLOBAL HEALTH; DEVELOPING-WORLD; SURGERY; EPIDEMIOLOGY
AB BACKGROUND: Even though surgical conditions account for as much as 32% of the global burden of disease, 5 billion people worldwide do not have access to timely, affordable surgical and anesthetic care. Access to surgical care is separated along socioeconomic divides, and these disparities are most pronounced in low-and middle-income countries, such as the Caribbean nation of Haiti, where the availability of specialty surgical services like neurosurgery are scant, or completely absent.
   METHODS: This paper provides a narrative account of current neurosurgery-related activity in Haiti, a nation whose social, political, and economic context is unique in the Americas.
   RESULTS: After some background information and a bibliometric analysis of recent research efforts, we provide brief biographical sketches of Haiti's local neurosurgical leaders and an overview of recent initiatives in Haitian neurosurgical capacity building.
   CONCLUSIONS: The paper concludes with recommendations to guide the international neurosurgery community in future contributions.
C1 [Barthelemy, Ernest J.; Pyda, Jordan] Harvard Med Sch, Program Global Surg & Social Change, Dept Global Hlth & Social Med, Boston, MA 02115 USA.
   [Barthelemy, Ernest J.; Park, Kee B.] Icahn Sch Med Mt Sinai, Dept Neurosurg, New York, NY 10029 USA.
   [Gabriel, Phabinly J.] Rutgers New Jersey Med Sch, Newark, NJ USA.
   [Lafortune, Yudy] Hosp Bernard Mevs Project Medishare, Serv Neurochirurg, Port Au Prince, Haiti.
   [Lafortune, Yudy] Univ Etat Haiti, Fac Med & Pharm, Format Neurochirurg, Port Au Prince, Haiti.
   [Clervius, Helene] Univ Quisqueya, Fac Med, Port Au Prince, Haiti.
   [Pyda, Jordan] Beth Israel Deaconess Med Ctr, Dept Surg, 330 Brookline Ave, Boston, MA 02215 USA.
RP Barthelemy, EJ (reprint author), Harvard Med Sch, Program Global Surg & Social Change, Dept Global Hlth & Social Med, Boston, MA 02115 USA.; Barthelemy, EJ (reprint author), Icahn Sch Med Mt Sinai, Dept Neurosurg, New York, NY 10029 USA.
EM globalneurosurgeon@gmail.com
CR [Anonymous], 2018, LE NOUVELLISTE
   Barthelemy EJ, 2018, WORLD NEUROSURG, V120, P143, DOI 10.1016/j.wneu.2018.08.070
   Barthelemy EJ, 2018, WORLD NEUROSURG, V119, P257, DOI 10.1016/j.wneu.2018.07.277
   Barthelemy EJ, 2014, WORLD NEUROSURG, V82, DOI 10.1016/j.wneu.2013.10.012
   Berkowitz AL, 2016, J NEUROL SCI, V360, P158, DOI 10.1016/j.jns.2015.12.003
   Cohen SP, 2012, SPINE J, V12, P833, DOI 10.1016/j.spinee.2011.10.010
   Comstock S, 2011, J TRAUMA, V71, pS413, DOI 10.1097/TA.0b013e318232e575
   Conaboy C., 2012, BOSTON NEUROSURGEON
   Corley JA, 2016, NEUROSURGERY, V79, pE544, DOI 10.1227/NEU.0000000000001351
   Dare AJ, 2014, LANCET, V384, P2245, DOI 10.1016/S0140-6736(14)60237-3
   Davies JI, 2015, LANCET, V386, P507, DOI 10.1016/S0140-6736(15)60465-2
   DeGennaro VA, 2012, J CRANIOFAC SURG, V23, P2028, DOI 10.1097/SCS.0b013e3182597e2d
   Devries CR, 2012, GLOBAL SURG PUBLIC H
   Dewan MC, 2019, J NEUROSURG, V130, P1055, DOI 10.3171/2017.11.JNS171500
   Dodard M, 2000, ACAD MED, V75, P397, DOI 10.1097/00001888-200004000-00023
   Ellegala DB, 2014, J NEUROSURG, V121, P1526, DOI 10.3171/2014.7.JNS122153
   Farmer PE, 2008, WORLD J SURG, V32, P533, DOI 10.1007/s00268-008-9525-9
   Hill K, 2007, LANCET, V370, P1726, DOI 10.1016/S0140-6736(07)61309-9
   Joseph FJ, 2017, WORLD NEUROSURG, V103, P386, DOI 10.1016/j.wneu.2017.04.073
   Klooster W, 2011, CARIB SER, V30, P57
   Le Nouvelliste. Ariel Henry 5e ministre de l'Interieur sous la presidence de Martelly, 2015, LE NOUVELLISTE
   Levi AD, 2011, C Q, V12, P4
   Meara JG, 2015, LANCET, V386, P569, DOI 10.1016/S0140-6736(15)60160-X
   Meara JG, 2014, LANCET, V383, P12, DOI 10.1016/S0140-6736(13)62345-4
   Miller School of Medicine/ University of Miami, 2012, 2 YEARS LAT UMS HOSP
   Park KB, 2016, WORLD NEUROSURG, V88, P32, DOI 10.1016/j.wneu.2015.12.048
   Payton CA., 2017, NACLA REP AM, V49, P64
   Project Medishare, 2017, M NEUR FELL DR LAF
   Schoneberg JM, 2017, THIRD WORLD Q, V38, P604, DOI 10.1080/01436597.2016.1199946
   Shah AH, 2018, NEUROSURG FOCUS, V45, DOI 10.3171/2018.7.FOCUS18279
   Taira B, 2009, WORLD J SURG, V33, P893, DOI 10.1007/s00268-009-9981-x
   Valtis YK, 2017, J NEUROL SCI, V379, P327, DOI 10.1016/j.jns.2017.06.029
   Vanderpool D, 2017, VASCULAR SURG, P341
   Weil AG, 2015, J CRANIOFAC SURG, V26, P1061, DOI 10.1097/SCS.0000000000001681
   World Health Organisation, 2017, GLOB ATL MED DEV
   Zuraik C, 2017, WORLD J SURG, V41, P2674, DOI 10.1007/s00268-017-4088-2
NR 36
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP 208
EP 213
DI 10.1016/j.wneu.2018.12.205
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800146
PM 30660896
DA 2020-05-12
ER

PT J
AU Mirone, G
   Russo, C
   Spennato, P
   Mazio, F
   Nastro, A
   Cinalli, G
AF Mirone, Giuseppe
   Russo, Carmela
   Spennato, Pietro
   Mazio, Federica
   Nastro, Anna
   Cinalli, Giuseppe
TI Interhypothalamic Adhesion as Cause of Aborted Third Ventriculostomy:
   Neuroradiologic and Neuroendoscopic Considerations in Pediatric Case
SO WORLD NEUROSURGERY
LA English
DT Article
DE Endoscopic third ventriculostomy; Interhypothalamic adhesions; MRI
AB BACKGROUND: Interhypothalamic adhesions (IHAs) are horizontally oriented parenchymal bands of tissue connecting the medial hypothalamic regions across the third ventricle. They can be assessed with high-resolution magnetic resonance (MR) techniques.
   CASE DESCRIPTION: We report MR and neuroendoscopic features of IHA in a 3-year-old boy without symptoms referable to the hypothalamus. He presented with obstructive hydrocephalus secondary to posterior fossa tumor. An endoscopic third ventriculostomy (ETV) was attempted but not performed because of the presence of a thick IHA, which prevented an approach to the floor of the third ventricle. During the procedure the patient also experienced supraventricular tachycardia. The procedure was aborted, and an external ventricular drainage was left in the ventricles until resolution of hydrocephalus after posterior fossa surgery. To the best of our knowledge, no study has previously described in detail endoscopic images of IHA.
   CONCLUSIONS: MR imaging allows one to preoperatively identify most anatomic anomalies of the ventricular system and the floor of the third ventricle. However, an IHA that may prevent an approach to the floor of the third ventricle due to his thickness may be missed. This can be recognized only on direct vision, underlining the importance of endoscopy in neurosurgery.
C1 [Mirone, Giuseppe; Spennato, Pietro; Cinalli, Giuseppe] Santobono Pausilipon Childrens Hosp, Dept Neurosurg, Naples, Italy.
   [Russo, Carmela; Mazio, Federica; Nastro, Anna] Santobono Pausilipon Childrens Hosp, Dept Neuroradiol, Naples, Italy.
RP Spennato, P (reprint author), Santobono Pausilipon Childrens Hosp, Dept Neurosurg, Naples, Italy.
EM pierospen@gmail.com
CR Ahmed FN, 2016, AM J NEURORADIOL, V37, P726, DOI 10.3174/ajnr.A4602
   Di Rocco C, 2006, CHILD NERV SYST, V22, P1573, DOI 10.1007/s00381-006-0194-4
   Giussani C, 2017, WORLD NEUROSURG, V103, P257, DOI 10.1016/j.wneu.2017.03.143
   Loubet A, 2017, J NEURORADIOLOGY, V44, P63, DOI 10.1016/j.neurad.2016.09.001
   Miller E, 2008, CHILD NERV SYST, V24, P563, DOI 10.1007/s00381-007-0528-x
   Rohde V, 2000, MINIM INVAS NEUROSUR, V43, P111, DOI 10.1055/s-2000-8330
   Simon EM, 2000, AM J NEURORADIOL, V21, P1955
   Sughrue ME, 2016, WORLD NEUROSURG, V90, P211, DOI 10.1016/j.wneu.2016.02.037
   Whitehead MT, 2016, AM J NEURORADIOL, V37, pE35, DOI 10.3174/ajnr.A4703
   Whitehead MT, 2014, AM J NEURORADIOL, V35, P2002, DOI 10.3174/ajnr.A3987
   Whitehead Matthew T, 2015, Case Rep Radiol, V2015, P748413, DOI 10.1155/2015/748413
   Whitehead Matthew T, 2013, Case Rep Radiol, V2013, P197415, DOI 10.1155/2013/197415
NR 12
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP 214
EP 218
DI 10.1016/j.wneu.2019.01.018
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800147
PM 30677576
DA 2020-05-12
ER

PT J
AU Carminucci, A
   Parr, M
   Bitar, M
   Danish, SF
AF Carminucci, Arthur
   Parr, Matthew
   Bitar, Mireille
   Danish, Shabbar F.
TI Delayed-Onset Cyst Formation After Laser Interstitial Thermal Therapy:
   Unreported Long-Term Complication
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cyst formation; LITT; Long-term complications
ID GAMMA-KNIFE RADIOSURGERY; STEREOTACTIC RADIOSURGERY; ABLATION; LESIONS
AB BACKGROUND: The majority of complications following (LITT) therapy occur in the early postoperative period, with few long-term complications being reported.
   CASE DESCRIPTION: Here we present 2 cases of delayed-onset cyst formation occurring more than 1 year following ablation, a previously unreported complication. In the first case, a 59-year-old female who previously underwent LITT for a radiation-induced cavernoma developed a 2-cm cystic lesion 18 months after ablation, resulting in recurrent seizures. In the second case, a 53-year-old female with a recurrent left frontal cerebral metastasis developed a large cystic lesion 30 months post ablation. Both patients required craniotomies and resection of their cystic lesions. In both cases pathology demonstrated reactive gliosis and blood vessel sclerosis.
   CONCLUSIONS: We hypothesize chronic gliosis following LITT therapy results in blood vessel sclerosis leading to blood-brain barrier-breakdown and delayed cyst formation. These findings support the need for long-term surveillance of patients treated with LITT.
C1 [Carminucci, Arthur; Parr, Matthew; Danish, Shabbar F.] Rutgers State Univ, Dept Neurol Surg, New Brunswick, NJ 08901 USA.
   [Bitar, Mireille] Rutgers RWJMS, Dept Pathol, New Brunswick, NJ USA.
RP Danish, SF (reprint author), Rutgers State Univ, Dept Neurol Surg, New Brunswick, NJ 08901 USA.
EM danishsh@cinj.rutgers.edu
CR Alattar AA, 2018, WORLD NEUROSURG, DOI [10.1227/01.NEU.0000351771.46273.22, DOI 10.1227/01.NEU.0000351771.46273.22]
   Ashraf O, 2018, WORLD NEUROSURG, V112, P166, DOI [10.1016/j.wneu.2018.01.123, 10.1016/J.WNEU.2018.01.123]
   Atsina KB, 2017, AM J ROENTGENOL, V208, P48, DOI 10.2214/AJR.16.16144
   Beechar VB, 2018, J NEURO-ONCOL, V137, P57, DOI 10.1007/s11060-017-2694-3
   Chaunzwa TL, 2018, NEUROSURGERY, V82, P56, DOI 10.1093/neuros/nyx142
   Ilyas A, 2018, J NEUROSURG, V128, P1354, DOI 10.3171/2016.12.JNS162478
   Ishikawa E, 2009, NEUROSURGERY, V65, P689, DOI 10.1227/01.NEU.0000351771.46273.22
   Jethwa PR, 2011, J NEUROSURG-PEDIATR, V8, P468, DOI 10.3171/2011.8.PEDS11148
   Patel NV, 2013, LASER SURG MED, V45, P362, DOI 10.1002/lsm.22151
   Patel P, 2016, J NEUROSURG, V125, P853, DOI 10.3171/2015.7.JNS15244
   Pollock BE, 2001, NEUROSURGERY, V49, P259, DOI 10.1097/00006123-200108000-00004
   Pomeraniec IJ, 2018, J NEUROSURG, V129, P937, DOI 10.3171/2017.6.JNS17559
   Pruitt R, 2017, J NEUROSURG, V126, P1238, DOI 10.3171/2016.3.JNS152147
   Rao MS, 2014, NEUROSURGERY, V74, P658, DOI 10.1227/NEU.0000000000000332
   Schwabe B, 1997, J COMPUT ASSIST TOMO, V21, P818, DOI 10.1097/00004728-199709000-00031
   Schwarzmaier HJ, 2006, EUR J RADIOL, V59, P208, DOI 10.1016/j.ejrad.2006.05.010
   Shuto T, 2005, J NEUROSURG, V102, P134, DOI 10.3171/jns.2005.102.s_supplement.0134
   Shuto T, 2016, J CLIN NEUROSCI, V33, P239, DOI 10.1016/j.jocn.2016.05.022
   Silva D, 2017, NEUROSURG CLIN N AM, V28, P525, DOI 10.1016/j.nec.2017.05.015
   Yamamoto M, 1998, STEREOT FUNCT NEUROS, V70, P166, DOI 10.1159/000056419
   Yamamoto M, 1998, SURG NEUROL, V49, P385, DOI 10.1016/S0090-3019(97)00531-4
   Yamamoto M, 2013, INT J RADIAT ONCOL, V85, P53, DOI 10.1016/j.ijrobp.2012.04.018
NR 22
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP 219
EP 223
DI 10.1016/j.wneu.2018.12.148
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800148
PM 30639484
DA 2020-05-12
ER

PT J
AU Hiroshima, S
   Saga, T
   Saito, M
   Tamura, Y
   Ogawa, H
   Anei, R
   Kamada, K
AF Hiroshima, Satoru
   Saga, Takehiro
   Saito, Masato
   Tamura, Yukie
   Ogawa, Hiroshi
   Anei, Ryogo
   Kamada, Kyousuke
TI Treatment of Fourth Ventricle Arachnoid Cyst via Anterior Hone of
   Lateral Ventricle Using Flexible Endoscope
SO WORLD NEUROSURGERY
LA English
DT Article
DE Arachnoid cyst; Endoscopic third ventriculostomy; Flexible endoscopy;
   Fourth ventricle
ID 4TH VENTRICLE
AB BACKGROUND: Arachnoid cysts are common anomalies in the intracranial region. However, an intraventricular arachnoid cyst is rare, and occurrence within the fourth ventricle is especially uncommon; only 16 cases have been described in the literature. Arachnoid cysts in the fourth ventricle may cause obstructive hydrocephalus or cerebellar ataxia or cranial nerve palsy. Treatment of a fourth ventricular arachnoid cyst is complete or partial resection via a midline suboccipital approach. Recently, endoscopic fenestration has become the procedure of choice in the treatment of arachnoid cysts in supratentorial locations, but as yet there has been no report of treating a fourth ventricle arachnoid cyst using a flexible endoscope.
   CASE DESCRIPTION: We present the case of a 43-year-old man who suffered a recurrence of an arachnoid cyst in the fourth ventricle that had been partially excised 8 years previously using midline suboccipital craniectomy. Because of concerns of adhesions following the previous craniectomy, we decided to perform endoscopic treatment via the anterior horn of the lateral ventricle.
   CONCLUSIONS: As per our knowledge, this is the first case reporting the treatment of an arachnoid cyst of the fourth ventricle using a flexible endoscope via the anterior horn of the lateral ventricle. This method can be used to treat arachnoid cysts of the fourth ventricle.
C1 [Hiroshima, Satoru; Saga, Takehiro; Saito, Masato; Tamura, Yukie; Ogawa, Hiroshi; Anei, Ryogo; Kamada, Kyousuke] Asahikawa Med Univ, Dept Neurosurg, Asahikawa, Hokkaido, Japan.
RP Kamada, K (reprint author), Asahikawa Med Univ, Dept Neurosurg, Asahikawa, Hokkaido, Japan.
EM kamadyk@gmail.com
OI Hiroshima, Satoru/0000-0001-9868-7557; Ogawa,
   Hiroshi/0000-0002-5887-4021
CR Alhohani H, 2018, ASIAN J NEUROSURG, V13, P184
   Azzimondi G, 1995, NEUROSURG REV, V18, P269, DOI 10.1007/BF00383879
   BECKER T, 1991, NEURORADIOLOGY, V33, P341, DOI 10.1007/BF00587820
   Bonde V, 2008, J CLIN NEUROSCI, V15, P26, DOI 10.1016/j.jocn.2006.12.010
   DIROCCO C, 1979, SURG NEUROL, V12, P467
   Gaab MR, 2013, WORLD NEUROSURG, V79, DOI 10.1016/j.wneu.2012.02.032
   Helland CA, 2010, J NEUROSURG, V113, P934, DOI 10.3171/2009.11.JNS081663
   Kirollos RW, 2001, CHILD NERV SYST, V17, P713, DOI 10.1007/s003810100494
   KOROSUE K, 1983, NEUROSURGERY, V12, P108, DOI 10.1227/00006123-198301000-00018
   Martinoni M, 2014, OPER NEUROSURG, V10, pE374, DOI 10.1227/NEU.0000000000000335
   NADKARNI T, 1995, BRIT J NEUROSURG, V9, P675, DOI 10.1080/02688699550040972
   Nomura S, 2002, NEUROL MED-CHIR, V42, P452, DOI 10.2176/nmc.42.452
   Prezerakos GK, 2011, IRISH J MED SCI, V180, P769, DOI 10.1007/s11845-011-0681-9
   Schroeder HWS, 1996, J NEUROSURG, V85, P293, DOI 10.3171/jns.1996.85.2.0293
   Sugimoto T, 2016, WORLD NEUROSURG, V85, DOI 10.1016/j.wneu.2015.08.061
   Vernooij MW, 2007, NEW ENGL J MED, V357, P1821, DOI 10.1056/NEJMoa070972
   Westermaier T, 2010, ACTA NEUROCHIR, V152, P119, DOI 10.1007/s00701-009-0309-2
NR 17
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP 224
EP 227
DI 10.1016/j.wneu.2018.12.226
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800149
PM 30677578
DA 2020-05-12
ER

PT J
AU Kinnen, F
   Fleck, SK
   Baldauf, J
   Hans, V
   Daeschlein, G
   Rathmann, E
   Schroeder, HWS
   Marx, S
AF Kinnen, Frederik
   Fleck, Steffen K.
   Baldauf, Joerg
   Hans, Volkmar
   Daeschlein, Georg
   Rathmann, Eiko
   Schroeder, Henry W. S.
   Marx, Sascha
TI Primary Leptomeningeal Melanocytic Tumors of the Spine: Report of Two
   Cases and Review of the Literature
SO WORLD NEUROSURGERY
LA English
DT Review
DE Case report; Primary leptomeningeal melanocytoma; Primary leptomeningeal
   melanoma; Rare CNS diseases
ID CENTRAL-NERVOUS-SYSTEM; MENINGEAL MELANOCYTOMA; MALIGNANT-MELANOMA;
   PARASPINAL EXTENSION; CERVICAL-SPINE; MIMICKING; CLASSIFICATION; ROOT
AB BACKGROUND: Primary leptomeningeal melanocytic tumors of the central nervous system are rare and, especially in the spine, less frequent compared with other entities. There is no consensus regarding the best care of these tumors.
   CASE DESCRIPTION: We report 2 cases of primary leptomeningeal melanocytic tumors, 1 primary leptomeningeal melanoma (PLM) and 1 primary leptomeningeal melanocytoma (PLMC) of the upper cervical spine, and emphasize different surgical findings and clinical courses of these patients. A review of the literature according to primary leptomeningeal melanocytic tumors of the spine was done, especially to compare different treatment modalities in the younger history.
   CONCLUSIONS: Primary melanocytic tumors of the spine are exceedingly rare. Before surgery it is difficult to make a correct diagnosis. Usually an unexpected intraoperative finding with consecutive histopathologic analyses leads to the final diagnosis. An accurate search for melanocytic tumors outside the central nervous system as a primary source is mandatory. PLMC has a better prognosis than PLM. There is no consensus regarding the adjuvant therapy, but patients with PLM should be given radiotherapy, chemotherapy, and immunotherapeutic approaches as immune checkpoint blockade after surgery. Communicating hydrocephalus is highly associated with PLM, but may occur in PLMC as well.
C1 [Kinnen, Frederik; Fleck, Steffen K.; Baldauf, Joerg; Schroeder, Henry W. S.; Marx, Sascha] Univ Med Greifswald, Dept Neurosurg, Greifswald, Germany.
   [Daeschlein, Georg] Univ Med Greifswald, Dept Dermatol, Greifswald, Germany.
   [Rathmann, Eiko] Univ Med Greifswald, Inst Radiol, Greifswald, Germany.
   [Hans, Volkmar] Sozialstiftung Bamberg, Inst Pathol, Bamberg, Germany.
RP Marx, S (reprint author), Univ Med Greifswald, Dept Neurosurg, Greifswald, Germany.
EM marxs@uni-greifswald.de
CR Bhargava P, 2013, TURK NEUROSURG, V23, P539, DOI 10.5137/1019-5149.JTN.5272-11.0
   Chang Warren, 2013, Radiol Case Rep, V8, P857, DOI 10.2484/rcr.v8i3.857
   CLIFFORD JH, 1968, J NEUROSURG, V29, P410, DOI 10.3171/jns.1968.29.4.0410
   El-Khashab M, 2009, CHILD NERV SYST, V25, P407, DOI 10.1007/s00381-008-0782-6
   Eun SS, 2011, WORLD NEUROSURG, V75, P303, DOI 10.1016/j.wneu.2010.06.034
   Foit NA, 2013, EUR SPINE J, V22, pS521, DOI 10.1007/s00586-013-2773-x
   Goyal A, 2003, SPINE, V28, pE140, DOI 10.1097/00007632-200304010-00025
   HAYWARD RD, 1976, J NEUROL NEUROSUR PS, V39, P526, DOI 10.1136/jnnp.39.6.526
   Hering K, 2016, CASE REP ONCOL MED, DOI 10.1155/2016/3815280
   Jeong Dong Hwan, 2013, Brain Tumor Res Treat, V1, P116, DOI 10.14791/btrt.2013.1.2.116
   Kim OH, 2013, KOREAN J RADIOL, V14, P470, DOI 10.3348/kjr.2013.14.3.470
   Kounin GK, 2005, CLIN NEUROL NEUROSUR, V107, P525, DOI 10.1016/j.clineuro.2004.10.013
   Lee CH, 2010, SPINE, V35, pE303, DOI 10.1097/BRS.0b013e3181ccb1b3
   Lee NK, 2010, EUR SPINE J, V19, pS174, DOI 10.1007/s00586-010-1285-1
   Li YP, 2014, ONCOL LETT, V8, P339, DOI 10.3892/ol.2014.2099
   Liubinas SV, 2010, J CLIN NEUROSCI, V17, P1227, DOI 10.1016/j.jocn.2010.01.017
   Louis DN, 2016, ACTA NEUROPATHOL, V131, P803, DOI 10.1007/s00401-016-1545-1
   Marx S, 2014, J NEUROL SURG REP, V75, pE93, DOI 10.1055/s-0034-1372474
   Merciadri P, 2011, ACTA NEUROCHIR, V153, P2283, DOI 10.1007/s00701-011-1143-x
   Ottenhausen M, 2018, NEUROSURG REV
   Schneider Frank, 2002, Spine (Phila Pa 1976), V27, pE545, DOI 10.1097/00007632-200212150-00026
   Shownkeen HN, 2002, NEURORADIOLOGY, V44, P1008, DOI 10.1007/s00234-002-0875-y
   SILBERT SW, 1978, CANCER, V41, P519, DOI 10.1002/1097-0142(197802)41:2<519::AID-CNCR2820410219>3.0.CO;2-3
   Tosaka M, 2001, J NEUROSURG, V94, P528, DOI 10.3171/jns.2001.94.3.0528
   van de Nes J, 2016, J NEURO-ONCOL, V127, P435, DOI 10.1007/s11060-015-2052-2
   Virchow R, 1859, ARCH PATHOL ANAT, V16, P180, DOI DOI 10.1007/BF01945262
   Wang FL, 2007, J NEUROSURG-SPINE, V6, P451, DOI 10.3171/spi.2007.6.5.451
   Wang YB, 2016, SPINE J, V16, pE59, DOI 10.1016/j.spinee.2015.09.036
   Yang CL, 2016, SPINE J, V16, pE553, DOI 10.1016/j.spinee.2016.03.007
   Yu J, 2012, J INT MED RES, V40, P1207, DOI 10.1177/147323001204000341
NR 30
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP 228
EP 236
DI 10.1016/j.wneu.2019.01.015
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800150
PM 30660881
DA 2020-05-12
ER

PT J
AU Paulo, D
   Semonche, A
   Choudhry, O
   Al-Mufti, F
   Prestigiacomo, CJ
   Roychowdhury, S
   Nanda, A
   Gupta, G
AF Paulo, Danika
   Semonche, Alexa
   Choudhry, Osamah
   Al-Mufti, Fawaz
   Prestigiacomo, Charles J.
   Roychowdhury, Sudipta
   Nanda, Anil
   Gupta, Gaurav
TI History of Hemostasis in Neurosurgery
SO WORLD NEUROSURGERY
LA English
DT Article
DE Hemostasis; Historical vignette; Literature review; Neurosurgery
ID PROTHROMBIN COMPLEX CONCENTRATE; TRANEXAMIC ACID; BONE WAX;
   BRAIN-TUMORS; INTRACEREBRAL HEMORRHAGE; MICROFIBRILLAR COLLAGEN;
   INTRATHECAL INJECTION; HYDROGEN-PEROXIDE; FLOSEAL MATRIX; SILVER CLIPS
AB Control of bleeding in the confined area of the skull is imperative for successful neurosurgery and the prevention of devastating complications such as postoperative hemorrhage. This paper reviews the historical evolution of methods to achieve successful hemostasis in neurosurgery from the early 1800s to today. The major categories of hemostatic agents (mechanical, chemical, and thermal) are delineated and discussed in chronologic order. The significance of this article is in its detailed history of the kinds of hemostatic methods that have evolved with our accumulating medical and surgical knowledge, which may inform future innovations and improvements.
C1 [Paulo, Danika; Semonche, Alexa; Nanda, Anil; Gupta, Gaurav] Rutgers Robert Wood Johnson Med Sch, Dept Neurosurg, New Brunswick, NJ 08901 USA.
   [Choudhry, Osamah] NYU, Dept Neurol Surg, New York, NY USA.
   [Al-Mufti, Fawaz] Univ Hosp, Dept Neurol, Newark, NJ USA.
   [Prestigiacomo, Charles J.] Rutgers New Jersey Med Sch, Dept Neurosurg, Newark, NJ USA.
   [Roychowdhury, Sudipta] Robert Wood Johnson Univ Hosp, Dept Radiol, New Brunswick, NJ USA.
RP Gupta, G (reprint author), Rutgers Robert Wood Johnson Med Sch, Dept Neurosurg, New Brunswick, NJ 08901 USA.
EM guptaga@rwjms.rutgers.edu
RI Gupta, Gaurav/AAL-3349-2020
OI Gupta, Gaurav/0000-0002-9442-6007; Choudhry, Osamah/0000-0002-2790-2894
CR Agnew DH, 1891, T AM SURG ASS, V9, P15
   Arand AG, 1996, NEUROSURGERY, P615
   Arthus M, 1890, ARCH PHYSL, V5, P739
   Ashraf O, 2018, WORLD NEUROSURG, V112, P166, DOI [10.1016/j.wneu.2018.01.123, 10.1016/J.WNEU.2018.01.123]
   AURELIO J, 1984, ORAL SURG ORAL MED O, V58, P98, DOI 10.1016/0030-4220(84)90371-2
   Baker GT, 1899, INT DENT J, V20, P776
   BATES JI, 1948, J NEUROSURG, V5, P349, DOI 10.3171/jns.1948.5.4.0349
   Baxter Healthcare Corporation, FLOSEAL HEM MATR INS
   Baxter Healthcare Corporation, IMP RISK INF FLOSEAL
   Beynon C, 2014, ACTA NEUROCHIR, V156, P741, DOI 10.1007/s00701-014-2032-x
   Bharath K, 2011, J NEUROSURG ANESTH, V23, P376, DOI 10.1097/ANA.0b013e31822c804f
   Black PML, 1993, HARVEY CUSHING BRIGH
   Braun H, 1909, BEITRAGE KLIN CHIR, V62, P641
   Brightmore T G, 1975, Langenbecks Arch Chir, VSuppl, P39
   Buchanan A, 1879, J PHYSL, V2, P158
   BUCHANAN A, 1845, LONDON MED GAZ, V1, P617
   BUCY PC, 1985, J NEUROL NEUROSUR PS, V48, P965, DOI 10.1136/jnnp.48.10.965
   Cartmill M, 2000, BRIT J NEUROSURG, V14, P458
   Chivukula S, 2014, NEUROSURG FOCUS, V36, DOI 10.3171/2014.1.FOCUS13565
   Clark W, 1911, J ADV THER, P169
   Cohen-Gadol AA, 2004, J NEUROSURG, V100, P225, DOI 10.3171/ped.2004.100.2.0225
   CORRELL JT, 1945, P SOC EXP BIOL MED, V58, P233
   Cox S, 2003, J NEUROSCI RES, V72, P734, DOI 10.1002/jnr.10623
   Crile G, 1902, ANN SURG, V35, P441
   Crile GW, 1900, MED REC, V57, P270
   Cushing H, 1918, Br Med J, V1, P221
   Cushing H, 1927, LANCET, V1, P1329
   Cushing H, 1911, ANN SURG, V54, P1, DOI 10.1097/00000658-191107000-00002
   Cushing H, 1915, J AMER MED ASSOC, V64, P189
   Cushing H, 1931, SURG GYNECOL OBSTET, V52, P129
   Cushing H, 1904, MED NEWS NY, V84, P577
   Cushing H, 1917, TUMOURS NERVUS ACUST, P296
   CUSHING HARVEY, 1930, ACTA PATH ET MICROBIOL SCANDINAVICA, V7, P1
   Cushing Harvey, 2001, Yale Journal of Biology and Medicine, V74, P399
   D'Arsonval MA, 1891, CR SOC BIOL, V43, P283
   Dadure C, 2011, ANESTHESIOLOGY, V114, P856, DOI 10.1097/ALN.0b013e318210f9e3
   Dandy W, 1966, THE BRAIN
   Dandy WE, 1925, ANN SURG, V82, P513, DOI 10.1097/00000658-192510010-00001
   Dawbarn RHM, 1907, ANN SURG, V45, P161, DOI 10.1097/00000658-190702000-00001
   DeBlaineville H, 1834, GAZETTE MED PARIS, P524
   Diaz R, 2016, NEUROSURGERY, V79, pS3, DOI 10.1227/NEU.0000000000001435
   Dormandy T, 2006, WORST EVILS FIGHT PA
   EARLE KM, 1965, FED PROC, V24, pS129
   Ellegala DB, 2002, NEUROSURGERY, V51, P513, DOI 10.1097/00006123-200208000-00041
   Ellis H., 2001, A HIST OF SURG
   EPSTEIN JA, 1987, NEUROSURGERY, V20, P63, DOI 10.1097/00006123-198701000-00018
   Faivre P, 2015, VALUE HEALTH, V18, pA370, DOI 10.1016/j.jval.2015.09.748
   Fay T, 1927, JAMA-J AM MED ASSOC, V89, P25
   Fergusson DA, 2008, NEW ENGL J MED, V358, P2319, DOI 10.1056/NEJMoa0802395
   FINE SAMUEL, 1965, ADVANCE BIOL MED PHYS, V10, P149
   Frazier C, 1906, U PENNSYLVANIA MED B, V19, P49
   French KF, 2012, NEUROCRIT CARE, V17, P107, DOI 10.1007/s12028-012-9681-5
   Garcha PS, 2007, ANESTH ANALG, V104, P241, DOI 10.1213/01.ane.0000250436.17786.72
   Gazzeri Roberto, 2014, Surg Technol Int, V25, P280
   Gazzeri Roberto, 2012, Surg Technol Int, V22, P49
   Gazzeri R, 2011, ACTA NEUROCHIR, V153, P148, DOI 10.1007/s00701-010-0762-y
   GEARY JR, 1950, J NEUROSURG, V7, P383, DOI 10.3171/jns.1950.7.5.0383
   Germans MR, 2013, TRIALS, V14, DOI 10.1186/1745-6215-14-143
   GIBBLE JW, 1990, TRANSFUSION, V30, P741, DOI 10.1046/j.1537-2995.1990.30891020337.x
   Gifford H, 1893, OMAHA CLIN, V6, P393
   Goldwyn R M, 1979, Ann Plast Surg, V2, P135, DOI 10.1097/00000637-197902000-00008
   Graham H, 1939, DEATH OF PAIN
   Graham H, 1939, THE STORY OF SURG
   Grasso G, 2014, MED SCI MONITOR, V20, P538, DOI 10.12659/MSM.890583
   Green R, 1967, HIST NEUROLOGICAL SU
   Grey E.G., 1915, SURG GYNECOL OBSTET, V21, P452
   HADEISHI H, 1995, NEUROSURGERY, V36, P1220, DOI 10.1227/00006123-199506000-00028
   HAIT MR, 1970, AM J SURG, V120, P330
   Hammersten O, 1879, PFLUG ARCH EUR J PHY, P563
   Hare HA, 1899, PROGR MED Q DIGEST A
   HARRIS WH, 1978, J BONE JOINT SURG AM, V60, P454, DOI 10.2106/00004623-197860040-00004
   Harvey S., 1916, BOSTON MED SURG J, V174, P658
   Harvey S.C., 1929, HIST HEMOSTASIS
   Heidenhain L, 1904, ZENTRALBL F CHIR, V9
   Heyl H, 1940, ANN SURG, V111, P159
   Hillman J, 2002, J NEUROSURG, V97, P771, DOI 10.3171/jns.2002.97.4.0771
   Horsley V, 1914, J NEUROSURG, V21, P713
   Horsley V., 1886, BRIT MED J, Vii, P670
   Horsley V, 1906, BMJ-BRIT MED J, V2, P411
   Horsley V, 1892, BMJ-BRIT MED J, V1, P1165
   Horsley V, 1893, BMJ-BRIT MED J, V2, P1365
   HOWARD TC, 1969, CLIN ORTHOP RELAT R, P226
   Howell WH, 1918, AM J PHYSIOL, P328
   Kenyon JH, 1915, ANN SURG, V61, P17, DOI 10.1097/00000658-191501000-00005
   Kinoshita M, 2015, J NEUROSURG, V122, P1180, DOI 10.3171/2014.9.JNS14347
   KOOS W, 1970, NEURO-CHIR, V16, P548
   Krause F, 1909, SURG BRAIN SPINAL CO, V1
   Kredel L., 1906, ZENTRALBL CHIR, V33, P1137
   KUDRYASHOV B A, 1975, Biokhimiya, V40, P452
   Landi A, 2016, J NEUROL SURG PART A, V77, P139, DOI 10.1055/s-0035-1558413
   Lanphear E, 1895, JAMA-J AM MED ASSOC, P24
   LEE K-C, 1991, Yonsei Medical Journal, V32, P53
   LIGHT RU, 1945, J NEUROSURG, V2, P414, DOI 10.3171/jns.1945.2.5.0414
   Low WK, 2002, ORL J OTO-RHINO-LARY, V64, P38, DOI 10.1159/000049267
   Lozner EL, 1941, AM J MED SCI, V202, P593
   Luhmann SJ, 2013, J PEDIATR ORTHOPED, V33, pE58, DOI 10.1097/BPO.0b013e3182857d88
   Lyons AE, 1997, HIST NEUROSURGERY
   MACFARLANE RG, 1964, NATURE, V202, P498, DOI 10.1038/202498a0
   Malgaigne J, 1851, OPERATIVE SURG BASED, P96
   Malis LI, 1996, J NEUROSURG, V85, P970, DOI 10.3171/jns.1996.85.5.0970
   Malpighi M, 1686, DE POLYPO CORDIS
   Mangano DT, 2006, NEW ENGL J MED, V354, P353, DOI 10.1056/NEJMoa051379
   Mankin KP, 2012, J SPINAL DISORD TECH, V25, P259, DOI 10.1097/BSD.0b013e3182334ec5
   MATRAS H, 1985, J ORAL MAXIL SURG, V43, P605, DOI 10.1016/0278-2391(85)90129-6
   MAWK JR, 1986, NEUROSURGERY, V18, P827, DOI 10.1097/00006123-198606000-00027
   Mayers E., 1901, PHILA MED J, V7, P819
   McKenzie K, 1927, SURG GYNECOL OBSTET, V45, P549
   Mebel D, 2016, ANESTH ANALG, V122, P503, DOI 10.1213/ANE.0000000000001065
   Mellanby J, 1933, P R SOC LOND B-CONTA, V113, P93, DOI 10.1098/rspb.1933.0033
   Merriman B, 2013, CAN J ANESTH, V60, P506, DOI 10.1007/s12630-013-9910-1
   Miller J, 1845, HEMORRHAGE PRINCIPLE, P367
   Milne AA, 2004, VOX SANG, V87, P29, DOI 10.1111/j.1741-6892.2004.00450.x
   Milne J.S., 1907, SURG INSTRUMENTS GRE
   Miyamoto K, 2006, SPINE, V31, pE91, DOI 10.1097/01.brs.0000199902.80607.ce
   Morawitz P, 1904, BEITR CHEM PHYSIOL P, V5, P133
   NAPPI JF, 1980, CLEFT PALATE J, V17, P291
   Orgill DP, 1998, J BIOMED MATER RES, V39, P358, DOI 10.1002/(SICI)1097-4636(19980305)39:3<358::AID-JBM3>3.0.CO;2-I
   Ortmann E, 2013, BRIT J ANAESTH, V111, P549, DOI 10.1093/bja/aet154
   OWEN CA, 1990, AM J CLIN PATHOL, V93, pS3
   Oz MC, 2003, J CARDIAC SURG, V18, P486, DOI 10.1046/j.0886-0440.2003.00302.x
   Oz MC, 2000, ANN THORAC SURG, V69, P1376, DOI 10.1016/S0003-4975(00)01194-2
   Paget S, 1919, SIR VICTOR HORSLEY A, V1
   Palmer JD, 2003, J NEUROSURG, V98, P1208, DOI 10.3171/jns.2003.98.6.1208
   Pare A, 1969, 10 BOOKS SURG MAGAZI
   Park R, 1896, TREATISE ON SURG, P671
   Parker R, 1892, BMJ-BRIT MED J, P1076
   PILCHER C, 1945, SURG GYNECOL OBSTET, V81, P365
   Price JS, 2015, J MED ECON, V18, P777, DOI 10.3111/13696998.2015.1046879
   Renkens KL, 2001, SPINE, V26, P1645, DOI 10.1097/00007632-200108010-00002
   Reuthebuch O, 2000, VASA-J VASCULAR DIS, V29, P204, DOI 10.1024/0301-1526.29.3.204
   Richet C, 1871, B ACAD MED, V36, P564
   Robicsek F, 2001, J Med Biogr, V9, P16
   ROBICSEK F, 1980, SURG GYNECOL OBSTET, V150, P579
   ROCKWOOD CA, 1968, J BONE JOINT SURG AM, VA 50, P837
   ROGERS BO, 1970, PLAST RECONSTR SURG, V46, P554, DOI 10.1097/00006534-197012000-00004
   Sachs E, 1925, ANN SURG, V81, P1053, DOI 10.1097/00000658-192506010-00002
   Sachs M, 1998, ZBL CHIR, V123, P950
   SCHER KS, 1982, SURGERY, V91, P301
   Schwartz S, 1999, PRINCIPLES SURG, P77
   Schwartz SI, 2009, GIFTED HANDS AM MOST
   Seegers WH, 1938, J BIOL CHEM, V126, P91
   Seegers WH, 1940, J BIOL CHEM, V136, P103
   SHAFFREY CI, 1990, NEUROSURGERY, V26, P207, DOI 10.1227/00006123-199002000-00004
   SORRENTI SJ, 1984, CLIN ORTHOP RELAT R, P293
   Sprigg N, 2014, J STROKE CEREBROVASC, V23, P1312, DOI 10.1016/j.jstrokecerebrovasdis.2013.11.007
   Starin WA, 1918, J INFECT DIS, V23, P139, DOI 10.1086/infdis/23.2.139
   Starr M, 1893, BRAIN SURG, P284
   Thackrah C, 1834, INQUIRY NATURE PROPE
   Thomson J, 1831, LECT INFLAMMATION EX
   Tiffany L M, 1897, Ann Surg, V26, P307
   Vigue B, 2007, INTENS CARE MED, V33, P721, DOI 10.1007/s00134-007-0528-z
   Wagner W, 1889, ZENTRALBL CHIR, P833
   Wangensteen O. W., 1979, RISE SURG EMPIRIC CR
   Wardrop D, 2013, COCHRANE DB SYST REV, V7
   Williams HS, HIST SCI GALEN THE L
   Woo CH, 2014, WORLD NEUROSURG, V81, P110, DOI 10.1016/j.wneu.2012.12.002
   Yackel EC, 1942, J AM CHEM SOC, V64, P121, DOI 10.1021/ja01253a032
   Yeh HM, 2003, ANESTHESIOLOGY, V98, P270, DOI 10.1097/00000542-200301000-00042
   Young JZ, 1940, LANCET, V2, P126
NR 159
TC 1
Z9 1
U1 3
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP 237
EP 250
DI 10.1016/j.wneu.2018.12.015
PG 14
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800151
PM 30579020
DA 2020-05-12
ER

PT J
AU Samadian, M
   Omidbeigi, M
   Bakhtevari, MH
   Asaadi, S
   Jafari, A
   Rezaei, O
AF Samadian, Mohammad
   Omidbeigi, Mahmoud
   Bakhtevari, Mehrdad Hosseinzadeh
   Asaadi, Sina
   Jafari, Armin
   Rezaei, Omidvar
TI Nerve-Sheath-Risen Neuroglial Cyst: Case Report and Review of the
   Literature
SO WORLD NEUROSURGERY
LA English
DT Review
DE Cranial nerve; Nerve sheath tumor; Neuroglial cyst; Trigeminal
ID ARACHNOID CYSTS; CEREBELLOPONTINE ANGLE; GLIOEPENDYMAL CYST;
   INTRACRANIAL CYSTS; FOSSA; PATHOGENESIS
AB BACKGROUND: Neuroglial cysts are rare intracranial lesions that are believed to originate from the sequestration of neural tube lining during embryogenesis. They can present anywhere within the neuraxis; however, their most common location is the frontal lobe. Cerebellopontine angle (CPA) neuroglial cysts are extremely rare and, to the best of our knowledge, there are no previous reports of a neuroglial cyst arising from cranial nerves.
   CASE DESCRIPTION: The current study presented a male adolescent with the reoccurrence of an intracranial cyst with symptoms of diplopia and facial numbness primarily treated as CPA arachnoid cyst with fenestration of the cyst 12 months prior to admission to our center. Different magnetic resonance imaging sequences showed a thin-walled extra-axial cyst at the right CPA without gadolinium enhancement. Direct visualization of the lesion revealed a cyst arising from the fifth cranial nerve sheath compressing the surrounding structures. The cyst was fenestrated, and a biopsy was taken from the cyst wall. The pathological analysis, along with specified histological markers, indicated the neuroglial nature of the cyst.
   CONCLUSIONS: The rising of a neuroglial cyst from the nerve sheath is a finding that brings other possible origins of neuroglial cysts into consideration.
C1 [Samadian, Mohammad; Omidbeigi, Mahmoud; Bakhtevari, Mehrdad Hosseinzadeh; Asaadi, Sina; Jafari, Armin; Rezaei, Omidvar] Shahid Beheshti Univ Med Sci, Loghman E Hakim Hosp, Dept Neurosurg, Skull Base Res Ctr, Tehran, Iran.
RP Bakhtevari, MH (reprint author), Shahid Beheshti Univ Med Sci, Loghman E Hakim Hosp, Dept Neurosurg, Skull Base Res Ctr, Tehran, Iran.
EM mehrdaada@yahoo.com
OI Hosseinzadeh Bakhtevari, Mehrdad/0000-0001-9185-4359
CR ANDREWS BT, 1984, NEUROSURGERY, V15, P91, DOI 10.1227/00006123-198407000-00017
   Chibbaro S, 2008, ACTA NEUROCHIR, V150, P599, DOI 10.1007/s00701-008-1563-4
   DEVOLDER AG, 1994, J NEUROL NEUROSUR PS, V57, P296, DOI 10.1136/jnnp.57.3.296
   Gosalakkal JA, 2002, PEDIATR NEUROL, V26, P93, DOI 10.1016/S0887-8994(01)00329-0
   Gupta G, 2007, NEUROSURG FOCUS, V22, P1
   HO KL, 1987, ACTA NEUROPATHOL, V74, P382, DOI 10.1007/BF00687216
   Hund-Georgiadis M, 2002, NEUROLOGY, V59, P1935, DOI 10.1212/01.WNL.0000038745.98689.6B
   JENG CM, 1995, J FORMOS MED ASSOC, V94, P487
   Lee EJ, 2012, J KOREAN NEUROSURG S, V52, P325, DOI 10.3340/jkns.2012.52.4.325
   MONACO P, 1995, J NEUROL NEUROSUR PS, V58, P109, DOI 10.1136/jnnp.58.1.109-a
   OSBORN A, 1994, DIAGNOSTIC NEURORADI
   Osborn AG, 2015, DIAGNOSTIC IMAGING B
   Pierre-Kahn A, 2000, CHILD NERV SYST, V16, P618, DOI 10.1007/s003810000316
   Samadian M, 2015, INTERDISCIP NEUROSUR, V2, P111, DOI 10.1016/j.inat.2015.03.006
   Samadian M, 2012, TURK NEUROSURG, V22, P242, DOI 10.5137/1019-5149.JTN.2902-10.1
   SATO H, 1991, CHILD NERV SYST, V7, P375, DOI 10.1007/BF00304201
   Sgouros S, 2001, PEDIATR NEUROSURG, V35, P188, DOI 10.1159/000050420
   Sharifi G, 2015, WORLD NEUROSURG, V84, P398, DOI 10.1016/j.wneu.2015.03.033
   Shenouda EF, 2005, ACTA NEUROCHIR, V147, P787, DOI 10.1007/s00701-005-0514-6
   Verma A, 2012, NEPALESE J RADIOL, V2, P35
   WESTER K, 1995, J NEUROL NEUROSUR PS, V59, P293, DOI 10.1136/jnnp.59.3.293
   Westermaier T, 2012, ADV EXP MED BIOL, V724, P37, DOI 10.1007/978-1-4614-0653-2_3
NR 22
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP 251
EP 255
DI 10.1016/j.wneu.2018.12.203
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800152
PM 30660890
DA 2020-05-12
ER

PT J
AU Caro-Osorio, E
   Alcazar-Felix, RJ
   Martinez, HR
   Figueroa-Sanchez, JA
   Herrera-Castro, JC
   Barbosa-Quintana, A
AF Caro-Osorio, Enrique
   Alcazar-Felix, Roberto J.
   Martinez, Hector R.
   Figueroa-Sanchez, Jose A.
   Herrera-Castro, Jose C.
   Barbosa-Quintana, Alvaro
TI Ectopic Germinoma in the Corpus Callosum with Severe Restrictive
   Anorexia: Case Report and Review of Literature
SO WORLD NEUROSURGERY
LA English
DT Review
DE Corpus callosum; Germinoma; Unspecified eating disorder
ID GERM-CELL TUMORS; MRI
AB BACKGROUND: Intracranial germ cell tumors are a rare group of neoplasms constituting 1% to 2% of primary intracranial tumors in North America and Europe. Germinomas of the corpus callosum are exceedingly rare, accounting for only 0.7% of all intracranial germ cell tumors.
   CASE DESCRIPTION: We report a case of germinoma in the corpus callosum of a 17-year-old woman with a 2-year history of personality change, anorexia, amnesia, hypersomnia, and depression. Magnetic resonance imaging showed a well-circumscribed, heterogeneous mass measuring 2.9 x 5 x 3.1 cm, with multiple cystic areas and heterogeneous enhancement with gadolinium. It arose in the corpus callosum and extended to the fornix and frontal lobes. There was mild perilesional edema but no evidence of hypothalamus or hippocampus involvement. No spinal drop metastases were visualized on magnetic resonance imaging. Cerebrospinal fluid and serum levels of alpha-fetoprotein, beta-human chorionic gonadotropin, carcinoembryonic antigen, and placental alkaline phosphatase were all normal. Immunohistologic staining of tumor cells was positive for OCT3/4, placental alkaline phosphatase, and CD117 and negative for CD30 and GPC3. Radiotherapy led to a substantial decrease in tumor size.
   CONCLUSION: This is a case of germinoma arising in the corpus callosum that presented clinically with an eating disorder manifested as restrictive anorexia.
C1 [Caro-Osorio, Enrique; Martinez, Hector R.; Figueroa-Sanchez, Jose A.; Herrera-Castro, Jose C.; Barbosa-Quintana, Alvaro] TecSalud Tecnol Monterrey, Hosp Zambrano Hellion, Neurol & Neurosurg Inst, San Pedro Garza Garcia, Mexico.
   [Alcazar-Felix, Roberto J.] TecSalud Tecnol Monterrey, Escuela Med & Ciencias Salud, Chapter Tec Monterrey, Monterrey, Nuevo Leon, Mexico.
RP Caro-Osorio, E (reprint author), TecSalud Tecnol Monterrey, Hosp Zambrano Hellion, Neurol & Neurosurg Inst, San Pedro Garza Garcia, Mexico.
EM ecaro@itesm.mx
OI Figueroa-Sanchez, Jose Antonio/0000-0003-1427-9471
FU AANS Medical Student Chapter Tec de Monterrey
FX We are grateful to the AANS Medical Student Chapter Tec de Monterrey for
   their support and guidance in this project.
CR Allen J, 2012, PEDIATR BLOOD CANCER, V59, P1180, DOI 10.1002/pbc.24097
   Gul Niflioglu G, 2011, TURK J PATHOL, V27, P87, DOI 10.5146/tjpath.2011.01019
   Huo L, 2015, MOL CLIN ONCOL, V3, P430, DOI 10.3892/mco.2014.461
   JENNINGS MT, 1985, J NEUROSURG, V63, P155, DOI 10.3171/jns.1985.63.2.0155
   Kamoshima Y, 2008, J NEUROSURG, V109, P126, DOI 10.3171/JNS/2008/109/7/0126
   Liang L, 2002, NEURORADIOLOGY, V44, P382, DOI 10.1007/s00234-001-0752-0
   Margolin E, 2011, NEURO-OPHTHALMOLOGY, V35, P15, DOI 10.3109/01658107.2010.540366
   ONO N, 1994, NEUROSURGERY, V35, P615, DOI 10.1227/00006123-199410000-00006
   Sano K, 1999, J NEUROSURG, V90, P258, DOI 10.3171/jns.1999.90.2.0258
   SOEJIMA T, 1987, NEURORADIOLOGY, V29, P366, DOI 10.1007/BF00348916
   SUMIDA M, 1995, NEURORADIOLOGY, V37, P32, DOI 10.1007/BF00588516
   Uher R, 2005, J NEUROL NEUROSUR PS, V76, P852, DOI 10.1136/jnnp.2004.048819
   Wenger M, 2002, SURG NEUROL, V57, P34, DOI 10.1016/S0090-3019(01)00652-8
   WILSON JT, 1995, PEDIATR NEUROSURG, V23, P1, DOI 10.1159/000120927
   Yonezawa H, 2010, NEUROL MED-CHIR, V50, P588, DOI 10.2176/nmc.50.588
NR 15
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP 256
EP 258
DI 10.1016/j.wneu.2019.01.026
PG 3
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800153
PM 30682514
DA 2020-05-12
ER

PT J
AU Uno, T
   Hayashi, Y
   Sasagawa, Y
   Miyamori, T
   Oishi, M
   Nakada, M
AF Uno, Takehiro
   Hayashi, Yasuhiko
   Sasagawa, Yasuo
   Miyamori, Tadao
   Oishi, Masahiro
   Nakada, Mitsutoshi
TI Suprasellar Colloid Cyst over 11-Year Follow-up: Case Report and
   Literature Review
SO WORLD NEUROSURGERY
LA English
DT Review
DE Colloid cyst; Growth analysis; Suprasellar cystic lesion
ID SELLAR REGION; NEURENTERIC CYST; IMAGING FINDINGS; CLEFT CYST
AB BACKGROUND: Colloid cysts (CCs) are rare cystic lesions derived from the endoderm of the central nervous system. Although they appear most commonly in the anterior roof of the third ventricle, there are only a few reports of CCs located in the suprasellar region. Although CCs are considered to be slow-growing benign tumors, their developmental process remains unclear.
   CASE DESCRIPTION: A 6-year-old boy was referred to our hospital for a mild head injury. Head computed tomography scan revealed a round, hyperdense suprasellar lesion, while magnetic resonance imaging depicted the mass as an isointense lesion with multiple highly hypointense spots on T2-weighted imaging. Although this lesion had been managed conservatively with annual magnetic resonance imaging follow-up, its size gradually increased, resulting in an increase in diameter by a factor of 1.5 over an 11-year period. The doubling time of this tumor was estimated to be approximately 7 years. Despite its asymptomatic nature, the cystic lesion was totally resected when the patient was 17 years of age using an endoscopic endonasal approach to make a definitive histologic diagnosis and prevent the occurrence of neurologic symptoms. The postoperative course was uneventful, and the histologic diagnosis of the surgical specimen was consistent with CC.
   CONCLUSIONS: This case suggests that CC may be one of several possible diagnoses in patients who present with suprasellar cystic lesions. Even if CCs in the suprasellar region remain asymptomatic, radiological follow-up is required due to possible progressive enlargement of the cyst.
C1 [Uno, Takehiro; Hayashi, Yasuhiko; Sasagawa, Yasuo; Oishi, Masahiro; Nakada, Mitsutoshi] Kanazawa Univ, Grad Sch Med Sci, Dept Neurosurg, Kanazawa, Ishikawa, Japan.
   [Miyamori, Tadao] Toyama Municipal Hosp, Dept Neurosurg, Toyama, Japan.
RP Hayashi, Y (reprint author), Kanazawa Univ, Grad Sch Med Sci, Dept Neurosurg, Kanazawa, Ishikawa, Japan.
EM yahayashi@med.kanazawa-u.ac.jp
OI Uno, Takehiro/0000-0001-5530-3859; Oishi, Masahiro/0000-0002-9776-2399
CR BASKIN DS, 1984, J NEUROSURG, V60, P8, DOI 10.3171/jns.1984.60.1.0008
   Bender B, 2013, ACAD RADIOL, V20, P1457, DOI 10.1016/j.acra.2013.08.014
   Bladowska J, 2010, POL J RADIOL, V75, P29
   Brekelmans CT, 1996, CANCER, V78, P1220, DOI 10.1002/(SICI)1097-0142(19960915)78:6<1220::AID-CNCR8>3.3.CO;2-J
   Gauden AJ, 2012, J CLIN NEUROSCI, V19, P352, DOI 10.1016/j.jocn.2011.10.005
   GRAZIANI N, 1995, ACTA NEUROCHIR, V133, P174, DOI 10.1007/BF01420070
   Guduk M, 2017, J CRANIOFAC SURG, V28, pE166, DOI 10.1097/SCS.0000000000003142
   Iqbal J, 1999, ACTA NEUROCHIR, V141, P389, DOI 10.1007/s007010050315
   Kimura H, 2006, ACTA NEUROCHIR, V148, P347, DOI 10.1007/s00701-005-0714-0
   Miyagi Atsushi, 2007, Neurosurgery, V60, pE203
   Nomikos P, 1999, Pituitary, V2, P123, DOI 10.1023/A:1009983414014
   Paniraj GL, 2014, WORLD NEUROSURG, V81, DOI 10.1016/j.wneu.2013.07.073
   Petrakakis I, 2016, CLIN NEUROL NEUROSUR, V149, P154, DOI 10.1016/j.clineuro.2016.08.011
   Saeger W, 2003, PATHOLOGE, V24, P247, DOI 10.1007/s00292-003-0626-9
   Temiz C, 2017, WORLD NEUROSURG, V98, DOI 10.1016/j.wneu.2016.12.040
   Wenger M, 2001, J CLIN NEUROSCI, V8, P564, DOI 10.1054/jocn.2000.0925
NR 16
TC 1
Z9 1
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP 261
EP 266
DI 10.1016/j.wneu.2018.11.258
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800155
PM 30664960
DA 2020-05-12
ER

PT J
AU Skandalakis, GP
   Koutsarnakis, C
   Pantazis, N
   Kalyvas, A
   Komaitis, S
   Lani, E
   Drosos, E
   Kalamatianos, T
   Hadjipanayis, CG
   Natsis, K
   Stranjalis, G
   Piagkou, M
AF Skandalakis, Georgios P.
   Koutsarnakis, Christos
   Pantazis, Nikos
   Kalyvas, Aristotelis
   Komaitis, Spyridon
   Lani, Evgenia
   Drosos, Evangelos
   Kalamatianos, Theodosis
   Hadjipanayis, Constantinos G.
   Natsis, Konstantinos
   Stranjalis, George
   Piagkou, Maria
TI Caroticoclinoid Bar: A Systematic Review and Meta-Analysis of Its
   Prevalence and Potential Implications in Cerebrovascular and Skull Base
   Surgery
SO WORLD NEUROSURGERY
LA English
DT Review
DE Caroticoclinoid bar; Caroticoclinoid foramen; Caroticoclinoid ring;
   Clinoidectomy
ID ANTERIOR CLINOID PROCESS; OPTIC STRUT; ANATOMICAL VARIATIONS; CAVERNOUS
   SINUS; FORAMEN; MORPHOMETRY; EMPHASIS; REGION
AB BACKGROUND: The presence of a caroticoclinoid bar (CCB) has been implicated in both transcranial and endonasal surgery. Its morphology reflects differences in the microsurgical anatomy of the parasellar area and its manipulation during anterior or middle clinoidectomy can result in internal carotid artery injury. Although adjustment of the surgical technique according to the CCB anatomic variants is required for safe surgical access to the paraclinoid region, a review indicated the lack of a systematic assortment of reported data regarding the prevalence of the CCB. Thus, our objective was to systematically review and document the prevalence of the CCB and its anatomic variations.
   METHODS: Three databases were systematically reviewed using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement through August 2018 to identify relevant studies.
   RESULTS: A total of 27 reports (7521 subjects or specimens, 14,449 sides) were included in the present meta-analysis. The overall pooled prevalence of the CCB was 32.6% (95% confidence interval [CI], 26.6%-38.8%) when measured in the subjects or specimens and 23.6% (95% CI, 19.7%-27.6%) when measured in each side. The overall prevalence of the CCB reported from imaging studies was 23.1% (95% CI, 8.9%-41.4%) for the subjects/specimens and 18.7% (95% CI, 12.6%-25.7%) for each side. The presence of the CCB was slightly more prevalent (P = 0.050) on the right side.
   CONCLUSIONS: Our results showed a considerable prevalence of the CCB, with lower prevalence rates found among imaging studies. Although meticulous preoperative investigation is mandatory, surgeons treating patients with parasellar pathologic entities should always be vigilant regarding the CCB.
C1 [Skandalakis, Georgios P.; Koutsarnakis, Christos; Kalyvas, Aristotelis; Komaitis, Spyridon; Lani, Evgenia; Drosos, Evangelos; Kalamatianos, Theodosis; Stranjalis, George; Piagkou, Maria] Athens Microneurosurg Lab, Athens, Greece.
   [Skandalakis, Georgios P.; Koutsarnakis, Christos; Kalyvas, Aristotelis; Komaitis, Spyridon; Lani, Evgenia; Drosos, Evangelos; Stranjalis, George] Natl & Kapodistrian Univ Athens, Sch Med, Dept Neurosurg, Athens, Greece.
   [Skandalakis, Georgios P.; Koutsarnakis, Christos; Kalyvas, Aristotelis; Komaitis, Spyridon; Lani, Evgenia; Piagkou, Maria] Natl & Kapodistrian Univ Athens, Sch Med, Dept Anat & Surg Anat, Athens, Greece.
   [Pantazis, Nikos] Natl & Kapodistrian Univ Athens, Sch Med, Dept Hyg Epidemiol & Med Stat, Athens, Greece.
   [Hadjipanayis, Constantinos G.] Icahn Sch Med Mt Sinai, Dept Neurosurg, New York, NY 10029 USA.
   [Hadjipanayis, Constantinos G.] Mt Sinai Hlth Syst, Mt Sinai Beth Israel, New York, NY USA.
   [Natsis, Konstantinos] Aristotle Univ Thessaloniki, Dept Anat & Surg Anat, Fac Hlth Sci, Thessaloniki, Greece.
RP Skandalakis, GP (reprint author), Athens Microneurosurg Lab, Athens, Greece.; Skandalakis, GP (reprint author), Natl & Kapodistrian Univ Athens, Sch Med, Dept Neurosurg, Athens, Greece.; Skandalakis, GP (reprint author), Natl & Kapodistrian Univ Athens, Sch Med, Dept Anat & Surg Anat, Athens, Greece.
EM gskandalakis@med.uoa.gr
RI Kalyvas, Aristotelis/AAI-4966-2020; Piagkou, Maria/AAK-6109-2020
OI Piagkou, Maria/0000-0002-4831-8005
CR Aggarwal B, 2012, J ANAT SOC INDIA, V61, P37
   ALMEFTY O, 1988, SURG NEUROL, V30, P370, DOI 10.1016/0090-3019(88)90200-5
   Beer-Furlan A, 2014, J CLIN NEUROSCI, V21, P836, DOI 10.1016/j.jocn.2013.10.006
   Boyan N, 2011, NEUROSURG QUART, V21, P133, DOI 10.1097/WNQ.0b013e31820f1929
   Brahmbhatt RJ, 2015, INDIAN J SURG, V77, pS299, DOI 10.1007/s12262-012-0800-5
   Burkhardt JK, 2018, OPER NEUROSURG, V15, pE63, DOI 10.1093/ons/opy018
   Catala M, 2003, J NEURORADIOLOGY, V30, P196
   Dagtekin A, 2014, TURK NEUROSURG, V24, P484, DOI 10.5137/1019-5149.JTN.8738-13.1
   Desai SD, 2010, NJBMS, V1, P60
   Dolenc V V, 1987, Br J Neurosurg, V1, P251, DOI 10.3109/02688698709035309
   DOLENC VV, 1985, J NEUROSURG, V62, P667, DOI 10.3171/jns.1985.62.5.0667
   Efthymiou E, 2018, ACTA NEUROCHIR, V160, P1979, DOI 10.1007/s00701-018-3607-8
   Erturk M, 2004, NEUROSURG REV, V27, P22, DOI 10.1007/s10143-003-0265-x
   Fernandez-Miranda JC, 2012, NEUROSURGERY, V71, P233, DOI 10.1227/NEU.0b013e3182690b6b
   Figueiredo EG, 2006, J NEUROSURG, V104, P957, DOI 10.3171/jns.2006.104.6.957
   FREEMAN MF, 1950, ANN MATH STAT, V21, P607, DOI 10.1214/aoms/1177729756
   Freire AR, 2011, INT J MORPHOL, V29, P427, DOI 10.4067/S0717-95022011000200021
   Gibelli D, 2018, NEURORADIOL J, V31, P299, DOI 10.1177/1971400917751036
   Gupta Nirupima, 2005, Nepal Med Coll J, V7, P141
   Harris R, 2017, STAT J, V8, P3
   Henle J, 1855, HDB SYSTEMATISCHEN A
   Henry BM, 2018, CLIN ANAT, V31, P364, DOI 10.1002/ca.23042
   Hunter JP, 2014, J CLIN EPIDEMIOL, V67, P897, DOI 10.1016/j.jclinepi.2014.03.003
   INOUE T, 1990, NEUROSURGERY, V26, P903, DOI 10.1227/00006123-199006000-00001
   Jha S., 2017, Morphologie, V101, P47, DOI 10.1016/j.morpho.2016.07.160
   Kamide T, 2018, J NEUROSURG, V129, P1511, DOI 10.3171/2017.7.JNS17673
   Kamide T, 2018, WORLD NEUROSURG, V109, pE493, DOI 10.1016/j.wneu.2017.10.007
   Kanjiya D, 2012, INT J BIOMED ADV RES, V03, P874
   Kapur E, 2012, BOSNIAN J BASIC MED, V12, P88
   Kerr RG, 2012, J NEUROL SURG PART B, V73, P424, DOI 10.1055/s-0032-1329626
   Keyes JEL, 1935, ARCH OPHTHALMOL-CHIC, V13, P538
   Kier E L, 1966, Invest Radiol, V1, P346, DOI 10.1097/00004424-196609000-00023
   Krisht AF, 2007, NEUROSURGERY, V60, P242, DOI 10.1227/01.NEU.0000249265.88203.DF
   LANG J, 1977, ACTA ANAT, V99, P121, DOI 10.1159/000144840
   Lawton MT, 2003, NEUROSURGERY, V52, P263, DOI 10.1227/01.NEU.0000043642.46308.D1
   Lawton MT, 2011, 7 ANEURYSMS TENETS T
   Lee Hye Yeon, 1997, Yonsei Medical Journal, V38, P151
   Mascitelli JR, 2019, J NEUROSURG, V130, P1435, DOI 10.3171/2018.2.JNS173141
   Meybodi AT, 2019, J NEUROSURG, V130, P1426, DOI 10.3171/2018.1.JNS173139
   Meybodi AT, 2018, WORLD NEUROSURG, V119, pE607, DOI 10.1016/j.wneu.2018.07.217
   Miller C, 2017, OPER NEUROSURG, V13, P124, DOI 10.1227/NEU.0000000000001310
   Moher D, 2010, INT J SURG, V8, P336, DOI 10.1016/j.ijsu.2010.02.007
   Natsis K, 2018, J CRANIO MAXILL SURG, V46, P635, DOI 10.1016/j.jcms.2018.01.008
   Nyaga VN, 2014, ARCH PUBLIC HEALTH, V72, DOI 10.1186/2049-3258-72-39
   Ota N, 2015, WORLD NEUROSURG, V83, P635, DOI 10.1016/j.wneu.2014.12.014
   Ozdogmus O, 2003, SURG RADIOL ANAT, V25, P241, DOI 10.1007/s00276-003-0111-4
   Peris-Celda M, 2013, NEUROSURGERY, V73, P117, DOI 10.1227/NEU.0000000000000184
   PERNECZKY A, 1988, ACTA NEUROCHIR, V92, P76, DOI 10.1007/BF01401976
   Rhoton AL, 2002, NEUROSURGERY, V51, pS375, DOI 10.1227/01.NEU.0000028833.01529.E7
   Rigante L, 2015, J NEUROL SURG PART B, V76, P239, DOI 10.1055/s-0034-1543964
   Sanai N, 2012, NEUROSURGERY, V71, P285, DOI 10.1227/NEU.0b013e318256c3eb
   Shaikh SI, 2012, IJBMS, V3, P148
   Sharma A, 2018, J NEUROSURG, V129, P60, DOI 10.3171/2017.2.JNS162114
   Skrzat J., 2006, Folia Morphologica, V65, P242
   Skrzat Janusz, 2012, Folia Med Cracov, V52, P97
   Souza AD, 2016, J CLIN DIAGN RES, V10, pAC5, DOI 10.7860/JCDR/2016/19316.7520
   Suprasanna K, 2017, J NEUROSCI RURAL PRA, V8, P330, DOI 10.4103/jnrp.jnrp_416_16
   Suprasanna K, 2015, J Clin Diagn Res, V9, pTC06, DOI 10.7860/JCDR/2015/15698.6615
   Tabani H, 2017, WORLD NEUROSURG, V104, DOI 10.1016/j.wneu.2017.05.049
   Tayebi Meybodi A, 2018, J NEUROSURG, P1
   Truong HQ, 2019, J NEUROSURG, V131, P122, DOI 10.3171/2018.3.JNS18596
   Zdilla Matthew J, 2015, Surg Neurol Int, V6, P13, DOI 10.4103/2152-7806.150456
   Zuckerman S, 1955, AM J PHYS ANTHROP-NE, V13, P521, DOI 10.1002/ajpa.1330130311
NR 63
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP 267
EP 276
DI 10.1016/j.wneu.2019.01.017
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800156
PM 30677570
DA 2020-05-12
ER

PT J
AU San-Juan, D
   Alvarez-Perera, LA
   Davila-Rodriguez, DO
   Ramos-Jimenez, C
   Alcocer-Barradas, V
   Lilia-Tena, M
   Anschel, DJ
   Cruz, JP
   Martinez-Juarez, IE
AF San-Juan, Daniel
   Angel Alvarez-Perera, Luis
   Oswaldo Davila-Rodriguez, Daniel
   Ramos-Jimenez, Christian
   Alcocer-Barradas, Victor
   Lilia-Tena, Martha
   Anschel, David J.
   Perez Cruz, Jocelyn
   Enriqueta Martinez-Juarez, Iris
TI Neurosurgical Therapy for Status Epilepticus in Oligoastrocytoma
   Patients
SO WORLD NEUROSURGERY
LA English
DT Article
DE Brain neoplasms; EcoG; Epilepsy; Oligoastrocytoma; Status epilepticus
ID EPILEPSY SURGERY; UNITED-STATES; 1ST EPISODE; MORTALITY; BRAIN
AB BACKGROUND: Super-refractory status epilepticus (SRSE) is a life-threatening neurologic emergency defined as "status epilepticus (SE) that continues 24 hours or more after the onset of anesthesia, including those cases in which the SE recurs on the reduction or withdrawal of anesthesia," which occurs in 10% to 15% of patients with SE and rarely has been resolved surgically.
   CASE DESCRIPTIONS: A 20-year-old man with SRSE and a long history of left parieto-occipital oligoastrocytoma was admitted for convulsive SE that became SRSE and underwent lesionectomy guided by electrocorticography and neuronavigation for local tumor recurrence. Histopathologic diagnosis was oligoastrocytoma. SRSE was aborted and the patient recovered fully without any functional deficits.
   CONCLUSIONS: The lesionectomy guided by electrocorticography and neuronavigation should be considered as a treatment option for patients with SRSE.
C1 [San-Juan, Daniel; Angel Alvarez-Perera, Luis; Oswaldo Davila-Rodriguez, Daniel] Natl Inst Neurol & Neurosurg, Dept Clin Res, Mexico City, DF, Mexico.
   [Alcocer-Barradas, Victor] Natl Inst Neurol & Neurosurg, Dept Neurosurg, Mexico City, DF, Mexico.
   [Lilia-Tena, Martha] Natl Inst Neurol & Neurosurg, Dept Pathol, Mexico City, DF, Mexico.
   [Perez Cruz, Jocelyn] Natl Inst Neurol & Neurosurg, Neurointens Care Unit, Mexico City, DF, Mexico.
   [Enriqueta Martinez-Juarez, Iris] Natl Inst Neurol & Neurosurg, Epilepsy Clin, Mexico City, DF, Mexico.
   [Ramos-Jimenez, Christian] Autonomous Univ State Mexico, Fac Med, Toluca, State Of Mexico, Mexico.
   [Anschel, David J.] St Charles Hosp, Comprehens Epilepsy Ctr Long Isl, Port Jefferson, NY USA.
RP San-Juan, D (reprint author), Natl Inst Neurol & Neurosurg, Dept Clin Res, Mexico City, DF, Mexico.
EM pegaso31@yahoo.com
OI Martinez-Juarez, Iris E./0000-0001-6512-5312
CR Basha MM, 2017, NEUROCRIT CARE, V27, P370, DOI 10.1007/s12028-017-0381-z
   Dubey Deepanshu, 2017, Neurol India, V65, pS12, DOI 10.4103/neuroindia.NI_958_16
   Goonawardena J, 2015, J CLIN NEUROSCI, V22, P29, DOI 10.1016/j.jocn.2014.03.038
   Hocker S, 2014, CURR NEUROL NEUROSCI, V14, DOI 10.1007/s11910-014-0452-x
   Knudsen-Baas KM, 2016, SEIZURE-EUR J EPILEP, V40, P76, DOI 10.1016/j.seizure.2016.06.013
   Krsek P, 2002, EPILEPTIC DISORD, V4, P203
   Lanman TA, 2018, INTERDISCIP NEUROSUR, V11, P70, DOI 10.1016/j.inat.2017.07.017
   Lhatoo SD, 2007, EPILEPSIA, V48, P61, DOI 10.1111/j.1528-1167.2007.01353.x
   Logroscino G, 2005, EPILEPSIA, V46, P46, DOI 10.1111/j.1528-1167.2005.00409.x
   Logroscino G, 2002, NEUROLOGY, V58, P537, DOI 10.1212/WNL.58.4.537
   Ma XP, 2001, EPILEPSY RES, V46, P33, DOI 10.1016/S0920-1211(01)00252-2
   Ostrom QT, 2016, NEURO-ONCOLOGY, V18, pv1, DOI 10.1093/neuonc/now207
   Prabhu VC, 2010, NEUROL CLIN, V28, P1037, DOI 10.1016/j.ncl.2010.03.022
   Rai S, 2018, NEUROTHERAPEUTICS, V15, P697, DOI 10.1007/s13311-018-0640-5
   Ristic AJ, 2012, EPILEPTIC DISORD, V14, P22, DOI 10.1684/epd.2012.0484
   Sahm F, 2014, ACTA NEUROPATHOL, V128, P551, DOI 10.1007/s00401-014-1326-7
   San-Juan D, 2017, J CLIN NEUROPHYSIOL, V34, P520, DOI 10.1097/WNP.0000000000000407
   Sanchez S, 2016, J CLIN MED, V5, DOI 10.3390/jcm5080071
   Shorvon S, 2011, BRAIN, V134, P2802, DOI 10.1093/brain/awr215
NR 19
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP 277
EP 281
DI 10.1016/j.wneu.2019.01.027
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800157
PM 30682510
DA 2020-05-12
ER

PT J
AU Piitulainen, JM
   Posti, JP
   Vallittu, PK
   Aitasalo, KM
   Serlo, W
AF Piitulainen, Jaakko M.
   Posti, Jussi P.
   Vallittu, Pekka K.
   Aitasalo, Kalle M.
   Serlo, Willy
TI A Large Calvarial Bone Defect in a Child: Osseointegration of an Implant
SO WORLD NEUROSURGERY
LA English
DT Article
DE Bioactive glass; Cranioplasty; Fiber-reinforced composite; Pediatric
ID FIBER-REINFORCED COMPOSITE; TRAUMATIC BRAIN-INJURY; DECOMPRESSIVE
   CRANIECTOMY; EARLY CRANIOPLASTY; STEM-CELLS; RECONSTRUCTION;
   HYDROXYAPATITE; TITANIUM; DURA
AB BACKGROUND: This original report describes the outcome of a cranioplasty at long-term follow-up. A large calvarial bone defect of a child was reconstructed with a bioactive and biostable nonmetallic implant.
   CASE DESCRIPTION: In a child with infantile fibrosarcoma of occipital bone, the malignancy was removed at 2.5 years of age, and the defect site was reconstructed with an onlay glass fiber-reinforced composite-bioactive glass implant. The follow-up examination at 5 years 7 months showed no signs of tumor recurrence. During the follow-up period, the contour of the reconstructed area followed skull anatomic development. Computed tomography demonstrated considerably large areas (approximately 70% of the total area) of bone ongrowth to the peridural surface of the implant.
   CONCLUSIONS: In the future, a synthetic cranioplasty material that is able to integrate with cranial bone may be considered superior to cryopreserved bone grafts in younger age groups.
C1 [Piitulainen, Jaakko M.; Aitasalo, Kalle M.] Univ Turku, Turku Univ Hosp, Dept Otorhinolaryngol Head & Neck Surg, Div Surg & Canc Dis, Turku, Finland.
   [Posti, Jussi P.] Univ Turku, Turku Univ Hosp, Dept Neurosurg, Div Clin Neurosci, Turku, Finland.
   [Posti, Jussi P.] Univ Turku, Turku Brain Injury Ctr, Turku Univ Hosp, Turku, Finland.
   [Piitulainen, Jaakko M.; Posti, Jussi P.; Vallittu, Pekka K.; Aitasalo, Kalle M.] Univ Turku, Dept Biomat Sci, Inst Dent, Turku, Finland.
   [Piitulainen, Jaakko M.; Posti, Jussi P.; Vallittu, Pekka K.; Aitasalo, Kalle M.] Univ Turku, Turku Clin Biomat Ctr, Inst Dent, Turku, Finland.
   [Vallittu, Pekka K.] City Turku Welf Div, Turku, Finland.
   [Serlo, Willy] Oulu Univ Hosp, Dept Children & Adolescents, Oulu, Finland.
   [Serlo, Willy] Univ Oulu, Med Res Ctr Oulu, Oulu, Finland.
   [Serlo, Willy] Univ Oulu, PEDEGO Res Unit, Oulu, Finland.
RP Piitulainen, JM (reprint author), Univ Turku, Turku Univ Hosp, Dept Otorhinolaryngol Head & Neck Surg, Div Surg & Canc Dis, Turku, Finland.; Piitulainen, JM (reprint author), Univ Turku, Dept Biomat Sci, Inst Dent, Turku, Finland.; Piitulainen, JM (reprint author), Univ Turku, Turku Clin Biomat Ctr, Inst Dent, Turku, Finland.
EM jaakko.piitulainen@utu.fi
RI Posti, Jussi P./Y-2908-2019
OI Posti, Jussi P./0000-0002-5925-5193; Piitulainen,
   Jaakko/0000-0001-9788-8904
CR Aitasalo KMJ, 2014, HEAD NECK-J SCI SPEC, V36, P722, DOI 10.1002/hed.23370
   Chan DYC, 2017, J CLIN NEUROSCI, V42, P81, DOI 10.1016/j.jocn.2017.04.016
   Fong KD, 2003, PLAST RECONSTR SURG, V112, P1312, DOI 10.1097/01.PRS.0000079860.14734.D6
   Frassanito P, 2017, CHILD NERV SYST, V33, P1759, DOI 10.1007/s00381-017-3541-8
   Fu KJ, 2016, J CRANIOFAC SURG, V27, P593, DOI 10.1097/SCS.0000000000002491
   Gosain AK, 2003, PLAST RECONSTR SURG, V112, P515, DOI 10.1097/01.PRS.0000070728.56716.51
   Grant GA, 2004, J NEUROSURG, V100, P163, DOI 10.3171/ped.2004.100.2.0163
   Honeybul S, 2017, J NEUROSURG, V126, P81, DOI 10.3171/2015.12.JNS152004
   Jin SW, 2016, J KOREAN NEUROSURG S, V59, P192, DOI 10.3340/jkns.2016.59.3.192
   Kim BW, 2017, ANN REHABIL MED-ARM, V41, P354, DOI 10.5535/arm.2017.41.3.354
   Korhonen TK, 2019, J NEUROSURG, V130, P312, DOI 10.3171/2017.8.JNS171857
   Lindfors NC, 2010, BONE, V47, P212, DOI 10.1016/j.bone.2010.05.030
   Lindner D, 2017, J NEUROSURG, V126, P175, DOI 10.3171/2015.10.JNS151245
   Malcolm JG, 2018, NEUROSURGERY, V82, P278, DOI 10.1093/neuros/nyx182
   Martin KD, 2014, ACTA NEUROCHIR, V156, P813, DOI 10.1007/s00701-014-2021-0
   Piitulainen JM, 2015, WORLD NEUROSURG, V83, P708, DOI 10.1016/j.wneu.2015.01.014
   Piitulainen JM, 2015, ACTA NEUROCHIR, V157, P681, DOI 10.1007/s00701-015-2363-2
   Posti JP, 2016, J MECH BEHAV BIOMED, V55, P191, DOI 10.1016/j.jmbbm.2015.10.030
   Sarin J, 2012, ANN OTO RHINOL LARYN, V121, P563, DOI 10.1177/000348941212100901
   Schwarz F, 2016, J NEUROSURG, V124, P710, DOI 10.3171/2015.4.JNS159
   Shahid AH, 2018, J NEUROSURG, V128, P229, DOI 10.3171/2016.10.JNS16678
   Shih YRV, 2014, P NATL ACAD SCI USA, V111, P990, DOI 10.1073/pnas.1321717111
   Stoor P, 1998, ACTA ODONTOL SCAND, V56, P161, DOI 10.1080/000163598422901
   Thesleff T, 2017, STEM CELL TRANSL MED, V6, P1576, DOI 10.1002/sctm.16-0410
   Tuusa SMR, 2008, J BIOMED MATER RES B, V84B, P510, DOI 10.1002/jbm.b.30898
   Vallittu PK, 2017, J MATER SCI, V52, P8772, DOI 10.1007/s10853-017-0888-x
   Zaccaria L, 2017, CHILD NERV SYST, V33, P343, DOI 10.1007/s00381-016-3327-4
   Zegers T, 2017, J CRANIO MAXILL SURG, V45, P82, DOI 10.1016/j.jcms.2016.10.016
NR 28
TC 0
Z9 0
U1 4
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP 282
EP 286
DI 10.1016/j.wneu.2019.01.028
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800158
PM 30684720
DA 2020-05-12
ER

PT J
AU Sarkiss, CA
   Germano, IM
AF Sarkiss, Christopher A.
   Germano, Isabelle M.
TI Machine Learning in Neuro-Oncology: Can Data Analysis From 5346 Patients
   Change Decision-Making Paradigms?
SO WORLD NEUROSURGERY
LA English
DT Review
DE Glioma; Machine learning; Neuro-oncology; Neurosurgery; Support vector
   machine
ID GRADE GLIOMAS; SURVIVAL; GLIOBLASTOMA; CLASSIFICATION; RADIOSURGERY;
   TUMOR
AB BACKGROUND: Machine learning (ML) is an application of artificial intelligence (AI) that gives computer systems the ability to learn data, without being explicitly programmed. Currently, ML has been successfully used for optical character recognition, spam filtering, and face recognition. The aim of the present study was to review the current applications of ML in the field of neuro-oncology.
   METHODS: We conducted a systematic literature review using the PubMed and Cochrane databases using a keyword search for January 30, 2000 to March 31, 2018. The data were clustered for neuro-oncology scope of ML into 3 categories: patient outcome predictors, imaging analysis, and gene expression.
   RESULTS: Data from 5346 patients in 29 studies were used to develop ML-based algorithms (MLBAs) in neuro-oncology. MLBAs were used to predict the outcomes for 2483 patients, with a sensitivity range of 78%-98% and specificity range of 76%-95%. In all studies, the MLBAs had greater accuracy than the conventional ones. MLBAs for image analysis showed accuracy in diagnosing low-grade versus high-grade gliomas, ranging from 80% to 93% and 90% for diagnosing high-grade glioma versus lymphoma. Seven studies used MLBAs to analyze gene expression in neuro-oncology.
   CONCLUSIONS: MLBAs in neuro-oncology have been shown to predict patients' outcomes more accurately than conventional parameters in a retrospective analysis. If their high diagnostic accuracy in imaging analysis and detection of somatic mutations are corroborated in prospective studies, the use of tissue diagnosis or liquid biopsy might be curtailed. Finally, MLBAs are promising to help guide targeted therapy, can lead to personalized medicine, and open areas of study in the cancer cellular signaling system, not otherwise known.
C1 [Sarkiss, Christopher A.; Germano, Isabelle M.] Mt Sinai Hlth Syst, Icahn Sch Med Mt Sinai, Dept Neurosurg, New York, NY 10019 USA.
   [Germano, Isabelle M.] NYU, Dept Econ, Leonard N Stern Sch Business, New York, NY 10003 USA.
RP Germano, IM (reprint author), Mt Sinai Hlth Syst, Icahn Sch Med Mt Sinai, Dept Neurosurg, New York, NY 10019 USA.; Germano, IM (reprint author), NYU, Dept Econ, Leonard N Stern Sch Business, New York, NY 10003 USA.
EM isabelle.germano@mountsinai.org
CR Akkus Z, 2017, J DIGIT IMAGING, V30, P469, DOI 10.1007/s10278-017-9984-3
   Alcaide-Leon P, 2017, AM J NEURORADIOL, V38, P1145, DOI 10.3174/ajnr.A5173
   Blumenthal DT, 2017, AM J NEURORADIOL, V38, P908, DOI 10.3174/ajnr.A5127
   Celejewska A, 2014, J OVARIAN RES, V7, DOI 10.1186/s13048-014-0079-1
   Celtikci E, 2018, TURK NEUROSURG, V28, P167, DOI 10.5137/1019-5149.JTN.20059-17.1
   Deo RC, 2015, CIRCULATION, V132, P1920, DOI 10.1161/CIRCULATIONAHA.115.001593
   Emblem KE, 2015, RADIOLOGY, V275, P228, DOI 10.1148/radiol.14140770
   Hu JS, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153369
   Kellner-Weldon F, 2017, EUR J RADIOL, V95, P75, DOI 10.1016/j.ejrad.2017.07.028
   Kickingereder P, 2016, RADIOLOGY, V281, P907, DOI 10.1148/radiol.2016161382
   Knoll MA, 2018, AM J CLIN ONCOL-CANC, V41, P425, DOI 10.1097/COC.0000000000000299
   Lao JW, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-10649-8
   Lee S, 2016, CANCER MED-US, V5, P3615, DOI 10.1002/cam4.955
   Li QH, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-14753-7
   Li YM, 2018, NEUROIMAGE-CLIN, V17, P306, DOI 10.1016/j.nicl.2017.10.030
   Li ZC, 2018, EUR RADIOL, V28, P3640, DOI 10.1007/s00330-017-5302-1
   Liu Luyan, 2016, Med Image Comput Comput Assist Interv, V9901, P26, DOI 10.1007/978-3-319-46723-8_4
   Macyszyn L, 2016, NEURO-ONCOLOGY, V18, P417, DOI 10.1093/neuonc/nov127
   Malhotra K, 2016, J BIOMED INFORM, V61, P267, DOI 10.1016/j.jbi.2016.03.020
   Moher D, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2535
   Nie Dong, 2016, Med Image Comput Comput Assist Interv, V9901, P212, DOI 10.1007/978-3-319-46723-8_25
   Papp L, 2018, J NUCL MED, V59, P892, DOI 10.2967/jnumed.117.202267
   Perez-Ramirez U, 2016, J MAGN RESON IMAGING, V44, P642, DOI 10.1002/jmri.25207
   Ranjith G, 2015, NEURORADIOL J, V28, P106, DOI 10.1177/1971400915576637
   Scherer M, 2016, NEUROSURG FOCUS, V40, DOI 10.3171/2015.11.FOCUS15542
   Shu C, 2018, J MOL NEUROSCI, V64, P491, DOI 10.1007/s12031-018-1049-7
   Suh HB, 2018, EUR RADIOL, V28, P3832, DOI 10.1007/s00330-018-5368-4
   Way GP, 2017, BMC GENOMICS, V18, DOI 10.1186/s12864-017-3519-7
   Wu JF, 2015, INT J COMPUT ASS RAD, V10, P1167, DOI 10.1007/s11548-014-1111-z
   Young JD, 2017, BMC BIOINFORMATICS, V18, DOI 10.1186/s12859-017-1798-2
   Zacharaki EI, 2012, AM J NEURORADIOL, V33, P1065, DOI 10.3174/ajnr.A2939
   Zhang X, 2017, ONCOTARGET, V8, P47816, DOI 10.18632/oncotarget.18001
NR 32
TC 7
Z9 7
U1 5
U2 11
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP 287
EP 294
DI 10.1016/j.wneu.2019.01.046
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800159
PM 30684706
DA 2020-05-12
ER

PT J
AU Ritzenthaler, T
   Gobert, F
   Dailler, F
AF Ritzenthaler, Thomas
   Gobert, Florent
   Dailler, Frederic
TI "Vasospasm Mimic" After Aneurysmal Subarachnoid Hemorrhage
SO WORLD NEUROSURGERY
LA English
DT Article
DE Computed tomography; Continuous EEG; Delayed cerebral ischemia;
   Subarachnoid hemorrhage; Transcranial Doppler; Vasospasm
ID DELAYED CEREBRAL-ISCHEMIA; NONCONVULSIVE STATUS EPILEPTICUS;
   TRANSCRANIAL DOPPLER; PERFUSION-CT; EEG
AB BACKGROUND: Secondary brain injuries, such as delayed cerebral infarction (DCI), are the leading causes of disability after subarachnoid hemorrhage (SAH). Detecting DCI may be challenging, especially for patients presenting an altered level of consciousness.
   CASE DESCRIPTION: We describe herein the case of a patient who developed acute hemiplegia 4 days after SAH, with raised blood flow velocities on transcranial Doppler, compatible with vasospasm. Finally, full work-up, using computed tomography (CT) scan with perfusion CT and continuous electroencephalography, was consistent with nonconvulsive seizures.
   CONCLUSIONS: Multiple secondary complications (DCI, seizures, hydrocephalus) may occur after SAH but are clinically difficult to diagnose. A multimodal evaluation (transcranial Doppler, CT or magnetic resonance imaging, electroencephalography) is useful in order to detect and treat late complications.
C1 [Ritzenthaler, Thomas; Gobert, Florent; Dailler, Frederic] Civil Hosp Lyon, Neurol Intens Care Unit, Bron, France.
RP Ritzenthaler, T (reprint author), Civil Hosp Lyon, Neurol Intens Care Unit, Bron, France.
EM thomas.ritzenthaler@chu-lyon.fr
OI Ritzenthaler, Thomas/0000-0002-0920-7759
CR Balanca B, 2018, CLIN NEUROPHYSIOL, V129, P1926, DOI 10.1016/j.clinph.2018.06.013
   Binaghi S, 2007, AM J NEURORADIOL, V28, P750
   Claassen J, 2005, J CLIN NEUROPHYSIOL, V22, P92, DOI 10.1097/01.WNP.0000145006.02048.3A
   Connolly ES, 2012, STROKE, V43, P1711, DOI 10.1161/STR.0b013e3182587839
   Cremers CHP, 2014, J CEREBR BLOOD F MET, V34, P200, DOI 10.1038/jcbfm.2013.208
   Foreman B, 2016, J CLIN NEUROPHYSIOL, V33, P174, DOI 10.1097/WNP.0000000000000273
   Francoeur CL, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1447-6
   Hauf M, 2009, AM J NEURORADIOL, V30, P693, DOI 10.3174/ajnr.A1456
   Macdonald RL, 2014, NAT REV NEUROL, V10, P44, DOI 10.1038/nrneurol.2013.246
   Marshall SA, 2010, NEUROSURG CLIN N AM, V21, P291, DOI 10.1016/j.nec.2009.10.010
   Merceron S, 2014, SEIZURE-EUR J EPILEP, V23, P284, DOI 10.1016/j.seizure.2014.01.001
   Payabvash S, 2015, CLIN RADIOL, V70, P1136, DOI 10.1016/j.crad.2015.06.078
   Vergouwen MDI, 2010, STROKE, V41, P2391, DOI 10.1161/STROKEAHA.110.589275
   Westermaier T, 2014, NEUROCRIT CARE, V20, P406, DOI 10.1007/s12028-013-9896-0
   Wilson CD, 2014, CAN J NEUROL SCI, V41, P314, DOI 10.1017/S031716710001725X
NR 15
TC 3
Z9 3
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP 295
EP 297
DI 10.1016/j.wneu.2019.01.034
PG 3
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800160
PM 30684699
DA 2020-05-12
ER

PT J
AU Chaskis, E
   Sadeghi, N
   De Witte, O
   Lefranc, F
AF Chaskis, Elly
   Sadeghi, Niloufar
   De Witte, Olivier
   Lefranc, Florence
TI Neurosurgical Device Implantation for Neurooncologic Patients: What To
   Avoid?
SO WORLD NEUROSURGERY
LA English
DT Article
DE Brain tumor; Cranioplasty; Hydroxyapatite; MRI artifacts;
   Ventriculoperitoneal shunt
ID MAGNETIC-FIELD INTERACTIONS; ARTIFACTS
AB BACKGROUND: Neurooncologic patients frequently require surgery, and neurosurgical devices are often implanted during neurosurgery. These devices could disturb oncologic follow-up by magnetic resonance imaging.
   METHODS: The authors describe the use of neurosurgical devices, such as bone substitutes, ventriculoperitoneal shunts, and titanium skull fixations, in neurooncologic patients.
   RESULTS: Acrylic cement cranioplasty, valve of ventriculoperitoneal shunt, and titanium skull fixations produced magnetic artifacts disturbing postoperative magnetic resonance imaging.
   CONCLUSIONS: The authors highlight the fact that all these neurosurgical devices implanted during surgery should be carefully evaluated to allow appropriate imaging follow-up for neurooncologic patients, which is a problem that remains underreported in the literature.
C1 [Chaskis, Elly; De Witte, Olivier; Lefranc, Florence] Free Univ Brussels, Erasme Hosp, Dept Neurosurg, Brussels, Belgium.
   [Sadeghi, Niloufar] Free Univ Brussels, Erasme Hosp, Dept Radiol, Brussels, Belgium.
RP Lefranc, F (reprint author), Free Univ Brussels, Erasme Hosp, Dept Neurosurg, Brussels, Belgium.
EM Florence.lefranc@erasme.ulb.ac.be
CR Cunningham AS, 2005, BRIT J NEUROSURG, V19, P167, DOI 10.1080/02688690500145720
   Feroze AH, 2015, J NEUROSURG, V123, P1098, DOI 10.3171/2014.11.JNS14622
   Matsuura H, 2002, J NEUROSURG, V97, P1472, DOI 10.3171/jns.2002.97.6.1472
   Shah AM, 2014, NEUROSURG FOCUS, V36, DOI 10.3171/2014.2.FOCUS13561
   Shellock FG, 2001, J MAGN RESON IMAGING, V14, P295, DOI 10.1002/jmri.1185
   Zanotti B, 2016, J CRANIOFAC SURG, V27, P2061, DOI 10.1097/SCS.0000000000003025
NR 6
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP 298
EP 303
DI 10.1016/j.wneu.2019.01.035
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800161
PM 30684711
OA Bronze
DA 2020-05-12
ER

PT J
AU Strickland, B
   Lewis, CS
   Pham, MH
AF Strickland, Ben
   Lewis, Courtney S.
   Pham, Martin H.
TI Bilateral Vertebral Artery Occlusion After Cervical Spine Fracture
   Dislocation
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cervical spine injury; Spine fracture; Trauma; Vertebral artery
ID INJURY; TRAUMA; INFARCTION; STROKE; NECK
AB BACKGROUND: Vertebral artery injury is known to potentially occur in conjunction with blunt cervical spine trauma. Rarely, these injuries present bilaterally as complete occlusions. Twelve cases of bilateral vertebral artery occlusions after closed cervical spine trauma have been described in the reported data, nearly all of which demonstrated signs and symptoms of vertebrobasilar insufficiency and ischemia.
   CASE DESCRIPTION: Our patient presented after a traumatic C5-C6 flexion-distraction injury that had resulted in bilateral locked facets and spinal cord injury and bilateral vertebral artery occlusions at the V1 segment. However, our patient did not show any cranial symptoms despite his neurovascular injury.
   CONCLUSIONS: We present our patient's case as a rare illustration of a bilateral vertebral artery occlusion after blunt cervical spine trauma without clinical vertebrobasilar ischemic sequelae.
C1 [Strickland, Ben; Lewis, Courtney S.; Pham, Martin H.] Univ Southern Calif, Keck Sch Med, Dept Neurosurg, Los Angeles, CA 90007 USA.
RP Pham, MH (reprint author), Univ Southern Calif, Keck Sch Med, Dept Neurosurg, Los Angeles, CA 90007 USA.
EM martinpham@gmail.com
OI Lewis, Courtney/0000-0003-4393-1940
CR CARPENTER S, 1961, J NEUROSURG, V18, P849, DOI 10.3171/jns.1961.18.6.0849
   Foreman PM, 2015, J NEUROSURG-SPINE, V23, P665, DOI 10.3171/2015.1.SPINE141174
   Giacobetti FB, 1997, SPINE, V22, P188, DOI 10.1097/00007632-199701150-00011
   Golinvaux NS, 2015, ORTHOP SURG, V7, P281, DOI 10.1111/os.12187
   Hartkamp MJ, 1999, STROKE, V30, P2671, DOI 10.1161/01.STR.30.12.2671
   Jang D, 2014, J KOREAN NEUROSURG S, V56, P141, DOI 10.3340/jkns.2014.56.2.141
   Jang Jae-Won, 2011, Surg Neurol Int, V2, P39, DOI 10.4103/2152-7806.78255
   Kikuchi Kenji, 1993, Neurologia Medico-Chirurgica, V33, P769, DOI 10.2176/nmc.33.769
   Komatsu Miki, 2016, Spinal Cord Ser Cases, V2, P16031, DOI 10.1038/scsandc.2016.31
   LYNESS SS, 1978, ORTHOP CLIN N AM, V9, P1029
   Matsumoto T, 2014, EUR J ORTHOP SURG TR, V24, P311
   MIYACHI S, 1994, SPINE, V19, P83, DOI 10.1097/00007632-199401000-00019
   Muratsu H, 2005, J SPINAL DISORD TECH, V18, P293
   Ozveren F, 1999, NEUROL MED-CHIR, V39, P28, DOI 10.2176/nmc.39.28
   SIMEONE FA, 1968, J NEUROSURG, V29, P540, DOI 10.3171/jns.1968.29.5.0540
   SIX EG, 1981, J NEUROSURG, V54, P814, DOI 10.3171/jns.1981.54.6.0814
   Taneichi H, 2005, SPINE, V30, P1955, DOI 10.1097/01.brs.0000176186.64276.d4
   Vaccaro AR, 1998, SPINE, V23, P789, DOI 10.1097/00007632-199804010-00009
   Veras LM, 2000, SPINE, V25, P1171, DOI 10.1097/00007632-200005010-00019
   Weller SJ, 1999, J TRAUMA, V46, P660, DOI 10.1097/00005373-199904000-00017
   WENTZ KU, 1994, RADIOLOGY, V190, P105, DOI 10.1148/radiology.190.1.8259384
   WILLIS BK, 1994, NEUROSURGERY, V34, P435, DOI 10.1227/00006123-199403000-00008
   Yoshihara H, 2011, PATIENT SAF SURG, V5, DOI 10.1186/1754-9493-5-18
NR 23
TC 2
Z9 2
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP 304
EP 309
DI 10.1016/j.wneu.2019.01.033
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800162
PM 30684719
DA 2020-05-12
ER

PT J
AU Alvarez-Pinzon, AM
   Valerio, JE
   Swedberg, HN
   Elwasila, SM
   Wolf, A
   Alonso, JR
AF Alvarez-Pinzon, Andres M.
   Valerio, Jose E.
   Swedberg, Heather N.
   Elwasila, Sammer M.
   Wolf, Aizik
   Alonso, Jose R.
TI Highly Active Antiretroviral Therapy and Gamma Knife Radiosurgery for
   the Treatment of AIDS-Related Primary Central Nervous System Lymphoma
SO WORLD NEUROSURGERY
LA English
DT Article
DE AIDS; CD4; Lymphoma; Oncology; Primary central nervous system lymphoma;
   Radiosurgery; Retrovirals
AB BACKGROUND: The criterion standard for the treatment of newly diagnosed primary central nervous system lymphoma (PCNSL) remains high-dose chemotherapy in conjunction with palliative whole-brain radiotherapy; however, there may be a role for novel combined approaches in immunocompromised patients.
   CASE DESCRIPTION: A 66-year-old man presented with acute cephalalgia, disorientation, and lethargy. His condition was evaluated in the emergency department, and he was admitted with probable hydrocephalus. Magnetic resonance imaging (MRI) of the brain revealed multiple nonspecific brain lesions, predominantly involving the right temporal lobe, which on biopsy led to a diagnosis of PCNSL. Subsequent laboratory studies demonstrated active human immunodeficiency virus (HIV) infection, with a CD4 count of 21 cells/mu L and an HIV viral load (VL) of >400,000 copies/mL. The patient was eventually given highly active antiretroviral therapy (HAART). He declined palliative whole-brain radiotherapy but was amenable to gamma knife radiosurgery (GKRS) for treatment of the right temporal brain lesions. Three months later, the patient's neurologic symptoms had improved; similarly, his CD4 count increased to 176 cells/mL, and his HIV viral load was <90 copies/mL. By the 12-month follow-up visit, the patient was asymptomatic, and at 36 months, MRI of the brain demonstrated total remission without new brain lesions.
   CONCLUSIONS: The criterion standard for treatment of newly diagnosed PCNSL remains high-dose chemotherapy in conjunction with palliative whole-brain radiotherapy; however, there may be a role for novel combined approaches using chemotherapy, HAART, and GKRS to have a positive impact on survival rates of PCNSL related to AIDS.
C1 [Alvarez-Pinzon, Andres M.; Alonso, Jose R.] Univ Salamanca, Lab Neural Plast & Neurorepair, Inst Neurosci Castile & Leon INCyL, E-37007 Salamanca, Spain.
   [Alvarez-Pinzon, Andres M.; Valerio, Jose E.; Wolf, Aizik] Miami Neurosci Ctr, Neurosurg Oncol & Neuroimmunol, Neurol Surg Dept, South Miami, FL 33143 USA.
   [Swedberg, Heather N.; Elwasila, Sammer M.] Florida Atlantic Univ, Charles E Schmidt Coll Med, Boca Raton, FL 33431 USA.
RP Alvarez-Pinzon, AM (reprint author), Univ Salamanca, Lab Neural Plast & Neurorepair, Inst Neurosci Castile & Leon INCyL, E-37007 Salamanca, Spain.; Alvarez-Pinzon, AM (reprint author), Miami Neurosci Ctr, Neurosurg Oncol & Neuroimmunol, Neurol Surg Dept, South Miami, FL 33143 USA.
EM andresmauricioalvarez07@gmail.com
RI Alonso, J. R./B-2523-2017
OI Alonso, J. R./0000-0001-5235-7616; ALVAREZ PINZON,
   ANDRES/0000-0003-3488-8020
CR Alvarez-Pinzon A. M., 2016, OBSERVATIONAL STUDY, V8, pe697, DOI DOI 10.7759/CUREU
   Karia SJ, 2017, LANCET, V389, P2238, DOI 10.1016/S0140-6736(17)30056-9
   Kenai H, 2006, J NEUROSURG, V105, P133, DOI 10.3171/sup.2006.105.7.133
   Matinella A, 2015, J NEUROL, V262, P1317, DOI 10.1007/s00415-015-7713-8
   Moulignier A, 2017, NEUROLOGY, V89, P796, DOI [10.1212/WNL.0000000000004265, 10.1212/wnl.0000000000004265]
NR 5
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP 310
EP 312
DI 10.1016/j.wneu.2018.12.182
PG 3
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800163
PM 30654158
DA 2020-05-12
ER

PT J
AU Hou, K
   Ji, TF
   Guo, YB
   Xu, K
   Yu, J
AF Hou, Kun
   Ji, Tiefeng
   Guo, Yunbao
   Xu, Kan
   Yu, Jinlu
TI Coexistence of Persistent Primitive Trigeminal Artery, Moyamoya Disease,
   and Multiple Intracranial Aneurysms: A Case Report and Literature Review
SO WORLD NEUROSURGERY
LA English
DT Review
DE Intracranial aneurysm; Moyamoya disease; Persistent primitive trigeminal
   artery; Subarachnoid hemorrhage
AB BACKGROUND: Persistent primitive trigeminal artery (PPTA) is a rare abnormal carotid-basilar anastomosis. In rare circumstances, PPTA can be associated with some cerebrovascular anomalies, including arteriovenous malformation, intracranial aneurysm, carotid cavernous fistula, and moyamoya disease (MMD).
   CASE DESCRIPTION: In this report, we present an extremely rare case with simultaneous occurrence of PPTA, MMD, and multiple intracranial aneurysms. The patient was admitted for subarachnoid hemorrhage. Endovascular coiling of the multiple aneurysms was successfully performed. The patient experienced an uneventful recovery, and no recurrence of the intracranial aneurysms was noted during the 1-year follow-up.
   CONCLUSIONS: The pathogenesis of the coexistence of PPTA and MMD, PPTA and intracranial aneurysm, and MMD and intracranial aneurysm is still unknown. According to the literature, congenital factor and hemodynamic stress may play an important role in the formation of these vascular anomalies. In case of hypoplasia of the vertebrobasilar system, PPTA could also be used as a route for endovascular coiling for some specific aneurysms in the posterior circulation. To our knowledge, this is the first report of such a case.
C1 [Hou, Kun; Guo, Yunbao; Xu, Kan; Yu, Jinlu] Jilin Univ, Hosp 1, Dept Neurosurg, Changchun, Jilin, Peoples R China.
   [Ji, Tiefeng] Jilin Univ, Hosp 1, Dept Radiol, Changchun, Jilin, Peoples R China.
RP Yu, J (reprint author), Jilin Univ, Hosp 1, Dept Neurosurg, Changchun, Jilin, Peoples R China.
EM jlyu@jlu.edu.cn
RI Yu, Jinlu/S-7854-2019
OI Yu, Jinlu/0000-0003-2329-7946; Hou, Kun/0000-0001-7112-7883; Xu,
   Kan/0000-0001-8947-1172
CR Arai Y, 2011, NEUROL MED-CHIR, V51, P774
   Chen Sien-Tsong, 1993, Journal of the Formosan Medical Association, V92, P385
   Kai Y, 2011, NEUROL MED-CHIR, V51, P361, DOI 10.2176/nmc.51.361
   Kim JE, 2012, NEUROL MED-CHIR, V52, P311, DOI 10.2176/nmc.52.311
   KINJO T, 1988, Neurological Surgery, V16, P1107
   Komiyama M, 1998, ACTA NEUROCHIR, V140, P1037, DOI 10.1007/s007010050212
   Komiyama M, 1999, NEUROL MED-CHIR, V39, P416, DOI 10.2176/nmc.39.416
   Komiyama M, 1999, NEUROL MED CHIR TOKY, V39, P20
   Li MH, 2004, ACTA RADIOL, V45, P664, DOI 10.1080/02841850410001196
   SALTZMAN GF, 1959, ACTA RADIOL, V51, P329, DOI 10.3109/00016925909171103
   Vasovic L, 2012, CHILD NERV SYST, V28, P33, DOI 10.1007/s00381-011-1622-7
   Zenteno Marco, 2018, Asian J Neurosurg, V13, P861, DOI 10.4103/1793-5482.238078
   Zhang L, 2015, INT J MED SCI, V12, P234, DOI 10.7150/ijms.10837
NR 13
TC 2
Z9 2
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP 313
EP 318
DI 10.1016/j.wneu.2019.01.030
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800164
PM 30684717
DA 2020-05-12
ER

PT J
AU Wang, Y
   He, QW
   Meng, XJ
   Zhou, SZ
   Zhu, YF
   Xu, J
   Tao, RJ
AF Wang, Yong
   He, Qiaowei
   Meng, Xiangji
   Zhou, Shizhen
   Zhu, Yufang
   Xu, Jun
   Tao, Rongjie
TI Apatinib (YN968D1) and Temozolomide in Recurrent Invasive Pituitary
   Adenoma: Case Report and Literature Review
SO WORLD NEUROSURGERY
LA English
DT Review
DE Antiangiogenic therapy; Apatinib; Chemotherapy; Invasive pituitary
   adenomas; Temozolomide
ID ENDOTHELIAL GROWTH-FACTOR; THERAPY; VEGF
AB BACKGROUND: Invasive pituitary adenomas often recurred after postoperative radiotherapy and are difficult to treat. Temozolomide is an alkylating cytostaticum and has been reported to reduce pituitary tumor size and hormone hypersecretion. However, this is far from enough. Pituitary adenomas have relatively high expression of vascular endothelial growth factor. Therefore an antiangiogenic agent has been used in a small number of aggressive or malignant pituitary tumors after recurrence. Apatinib (YN968D1) is a small-molecule antiangiogenic agent that selectively inhibits VEGFR-2 and also mildly inhibits c-Kit and c-Src tyrosine kinases, abundant in invasive pituitary adenomas.
   CASE DESCRIPTION: We present a 41-year-old female with a growth hormone (GH)-secreting invasive pituitary adenoma causing menstrual disorder and headache symptoms. Over 3 years, she underwent 4 surgeries and a stereotactic radiosurgery, but the results were poor. Two months after the fourth operation, she started treatment with temozolomide (200 mg/m(2), days 1-5, 28 days, orally) and apatinib (0.425 g, daily, orally). Her GH level dropped to normal with a >90% decrease in tumor size, after 1-year treatment. There was no evidence of recurrence by imaging or by serum GH levels over 31.5 months of follow-up.
   CONCLUSIONS: We successfully treated this patient with recurrent invasive pituitary adenoma with temozolomide and apatinib for 31.5 months without recurrence. Angiogenesis is an active process in the cases of invasive pituitary adenomas that cannot be controlled by conventional therapy.
C1 [Wang, Yong; Meng, Xiangji; Zhou, Shizhen; Zhu, Yufang; Xu, Jun; Tao, Rongjie] Shandong Univ, Shandong Acad Med Sci, Shandong Canc Hosp, Dept Neurosurg, Jinan, Shandong, Peoples R China.
   [He, Qiaowei] Qingdao Univ, Yantai Yuhuangding Hosp, Dept Neurosurg, Yantai, Peoples R China.
RP Tao, RJ (reprint author), Shandong Univ, Shandong Acad Med Sci, Shandong Canc Hosp, Dept Neurosurg, Jinan, Shandong, Peoples R China.
EM rongjietao@163.com
CR Barkhoudarian G, 2018, WORLD NEUROSURG, V118, P118, DOI 10.1016/j.wneu.2018.07.082
   Cristina C, 2014, INT J ENDOCRINOL, DOI 10.1155/2014/608497
   Hoeben A, 2004, PHARMACOL REV, V56, P549, DOI 10.1124/pr.56.4.3
   Hu XC, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-820
   Jia W, 2013, ANTICANCER RES, V33, P3815
   Lasolle H, 2017, EUR J ENDOCRINOL, V176, P769, DOI 10.1530/EJE-16-0979
   Li J, 2016, J CLIN ONCOL, V34, P1448, DOI 10.1200/JCO.2015.63.5995
   Luque GM, 2011, J PHARMACOL EXP THER, V337, P766, DOI 10.1124/jpet.110.177790
   Onofri C, 2006, J ENDOCRINOL, V191, P249, DOI 10.1677/joe.1.06992
   Ortiz LD, 2012, PITUITARY, V15, P445, DOI 10.1007/s11102-011-0346-8
   Roviello G, 2016, EXPERT REV GASTROENT, V10, P887, DOI 10.1080/17474124.2016.1209407
   Scott AJ, 2015, DRUG TODAY, V51, P223, DOI 10.1358/dot.2015.51.4.2320599
   Touma W, 2017, J CLIN NEUROSCI, V41, P75, DOI 10.1016/j.jocn.2017.02.052
   Xie L, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4303-z
   Zhang HJ, 2015, DRUG DES DEV THER, V9, P6075, DOI 10.2147/DDDT.S97235
NR 15
TC 2
Z9 2
U1 1
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP 319
EP 322
DI 10.1016/j.wneu.2018.12.174
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800165
PM 30639490
DA 2020-05-12
ER

PT J
AU Chihara, H
   Hatano, T
   Ando, M
   Takita, W
   Tokunaga, K
   Hashikawa, T
   Funakoshi, Y
   Kamata, T
   Higashi, E
   Nagata, I
AF Chihara, Hideo
   Hatano, Taketo
   Ando, Mitsusige
   Takita, Wataru
   Tokunaga, Keisuke
   Hashikawa, Takuro
   Funakoshi, Yusuke
   Kamata, Takahiko
   Higashi, Eiji
   Nagata, Izumi
TI A Case of Posterior Reversible Encephalopathy Syndrome After Surgical
   Clipping of Unruptured Cerebral Aneurysm
SO WORLD NEUROSURGERY
LA English
DT Article
DE Clipping; General anesthesia; PRES; Unruptured cerebral aneurysm
ID VASOSPASM; THERAPY; COMPLICATION; PERFUSION
AB BACKGROUND: Posterior reversible encephalopathy syndrome (PRES) is characterized by reversible edematous lesions on imaging examinations, along with symptoms of altered consciousness disorder and seizures. Various factors associated with PRES have been reported. However, we encountered a very rare case that developed after clipping surgery for unruptured cerebral aneurysm.
   CASE DESCRIPTION: A 74-year-old man with a history of hypertension presented with an unruptured right middle cerebral artery aneurysm and underwent cranial clipping surgery. After surgery, he developed consciousness disorder and epilepsy after delayed awakening from general anesthesia. Radiological examinations revealed multiple edematous lesions, strongly suggesting PRES, and excluding asymmetry consistent with the area of craniotomy. With conservative treatment, symptoms and radiological findings almost disappeared. Symptoms and imaging findings remaining at the area of craniotomy were attributed to the severe difference in cerebral perfusion pressure due to craniotomy.
   CONCLUSIONS: Based on the literature, this case was considered to represent PRES caused by rapid blood pressure fluctuations accompanying general anesthesia for clipping surgery. Practitioners must keep PRES in mind as a rare complication after clipping for unruptured cerebral aneurysms. PRES developing after craniotomy shows unilaterality and may become severe in the craniotomy area and leave sequelae.
C1 [Chihara, Hideo; Hatano, Taketo; Ando, Mitsusige; Takita, Wataru; Tokunaga, Keisuke; Hashikawa, Takuro; Funakoshi, Yusuke; Kamata, Takahiko; Higashi, Eiji; Nagata, Izumi] Kokura Mem Hosp, Dept Neurosurg, Kitakyushu, Fukuoka, Japan.
RP Chihara, H (reprint author), Kokura Mem Hosp, Dept Neurosurg, Kitakyushu, Fukuoka, Japan.
EM dollmaster213@yahoo.co.jp
OI Chihara, Hideo/0000-0001-8767-6617; Tokunaga,
   Keisuke/0000-0002-0701-3635
CR Amin-Hanjani S, 1999, NEUROSURGERY, V44, P1113, DOI 10.1097/00006123-199905000-00097
   Awori J, 2016, J CLIN NEUROSCI, V26, P33, DOI 10.1016/j.jocn.2015.11.001
   Bartynski WS, 2008, AM J NEURORADIOL, V29, P1043, DOI 10.3174/ajnr.A0929
   Bartynski WS, 2007, AM J NEURORADIOL, V28, P1320, DOI 10.3174/ajnr.A0549
   Camlidag I, 2015, KOREAN J RADIOL, V16, P1104, DOI 10.3348/kjr.2015.16.5.1104
   Dhar R, 2011, NEUROSURGERY, V69, pE1176, DOI 10.1227/NEU.0b013e318223b995
   Fugate JE, 2010, MAYO CLIN PROC, V85, P427, DOI 10.4065/mcp.2009.0590
   Giraldo EA, 2011, NEUROCRIT CARE, V14, P427, DOI 10.1007/s12028-011-9515-x
   Hammad T, 2015, CASE REP NEUROL MED, DOI 10.1155/2015/538523
   Jang HW, 2010, J CLIN NEUROSCI, V17, P1059, DOI 10.1016/j.jocn.2009.10.006
   Muhammad S, 2016, STROKE, V47, P519, DOI 10.1161/STROKEAHA.115.011697
   Niwa Ryoko, 2017, Surg Neurol Int, V8, P103, DOI 10.4103/sni.sni_55_17
   Pugliese S, 2010, J HEADACHE PAIN, V11, P437, DOI 10.1007/s10194-010-0226-z
   Sanelli PC, 2005, NEUROCRIT CARE, V3, P46, DOI 10.1385/NCC:3:1:046
   Sato Hiroyuki, 2016, No Shinkei Geka, V44, P507, DOI 10.11477/mf.1436203320
   Voetsch B, 2011, NEUROCRIT CARE, V15, P542, DOI 10.1007/s12028-011-9635-3
   Walder B, 2002, NEUROLOGY, V58, P1327, DOI 10.1212/WNL.58.9.1327
   Wartenberg KE, 2006, J NEUROIMAGING, V16, P170, DOI 10.1111/j.1552-6569.2006.00031.x
NR 18
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP 323
EP 327
DI 10.1016/j.wneu.2019.01.014
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800166
PM 30660882
DA 2020-05-12
ER

PT J
AU Sahin, A
   Dalgic, N
AF Sahin, Ayse
   Dalgic, Nazan
TI Intravenous and Intraventricular Daptomycin Plus Intravenous Linezolid
   Treatment of an Infant with Vancomycin-Resistant Enterococci-Induced
   Ventriculoperitoneal Shunt Infection
SO WORLD NEUROSURGERY
LA English
DT Article
DE Daptomycin; Infant; Shunt infection
ID CASE SERIES; CHILDREN; VENTRICULITIS; MENINGITIS; FAECALIS
AB BACKGROUND: The rate of ventriculoperitoneal (VP) shunt infection is reported between 3% and 20%. Vancomycin-resistant enterococci (VRE) are increasingly prevalent nosocomial pathogens worldwide, and they rarely cause infections to the central nervous system. Daptomycin is a cyclic lipopeptide effective antibiotic because of its rapid bactericidal effect. It is a life-saving treatment option for meningitis, bacteremia, sepsis, endocarditis, and urinary system infections caused by VRE.
   CASE DESCRIPTION: Here, we present a 2.5-month-old infant boy with a ventriculoperitoneal shunt infection caused by vancomycin-resistant Enterococcus faecium. This is the first report of a pediatric VP shunt infection caused by VRE and treated with a combination of intravenous (IV) linezolid IV and intraventricular (IVT) daptomycin.
   CONCLUSION: The patient was admitted to the medical center with umbilical discharge, and shunt revision was applied with the thought of shunt dysfunction. Intermittent umbilical cerebrospinal fluid (CSF) leakage continued, and the patient experienced a fever 2 weeks after the operation. VRE growth in his CSF culture was treated by meropenem and linezolid. Upon continuation of the growth afterwards, the patient was referred to our hospital and underwent extraventricular drainage, and IV linezolid, IV daptomycin (8 mg/kg per day), and IVT daptomycin (2.5 mg/kg per day) was scheduled as treatment. On the fifth day of treatment, there was no growth in the culture, and no side effects were observed during the treatment. A VP shunt was placed in the patient for the 15 days of IV daptomycin plus IVT treatment, and 36 days of linezolid. No infection was observed in the 8-month follow-up period.
C1 [Sahin, Ayse; Dalgic, Nazan] Univ Hlth Sci, Sisli Hamidiye Etfal Res & Educ Hosp, Dept Pediat Infect Dis, Istanbul, Turkey.
RP Sahin, A (reprint author), Univ Hlth Sci, Sisli Hamidiye Etfal Res & Educ Hosp, Dept Pediat Infect Dis, Istanbul, Turkey.
EM ayseturgutsahin@gmail.com
CR Adams DJ, 2014, CURR INFECT DIS REP, V16, DOI 10.1007/s11908-014-0427-8
   Antachopoulos C, 2018, ANTIMICROB AGENTS CH, V62, DOI 10.1128/AAC.02462-17
   Denetclaw TH, 2014, ANN PHARMACOTHER, V48, P1376, DOI 10.1177/1060028014542634
   Elvy J, 2008, J ANTIMICROB CHEMOTH, V61, P461, DOI 10.1093/jac/dkm501
   Jaspan HB, 2010, PEDIATR INFECT DIS J, V29, P379, DOI 10.1097/INF.0b013e3181c806d8
   Knoll BM, 2013, SCAND J INFECT DIS, V45, P131, DOI 10.3109/00365548.2012.717711
   Lee JK, 2012, J KOREAN MED SCI, V27, P1563, DOI 10.3346/jkms.2012.27.12.1563
   Lich BF, 2016, J NEUROL SURG REP, V77, pE160, DOI 10.1055/s-0036-1593439
   Miller WR, 2016, CSH PERSPECT MED, V6, DOI 10.1101/cshperspect.a026997
   O'Driscoll T, 2015, INFECT DRUG RESIST, V8, P217, DOI 10.2147/IDR.S54125
   Sullins AK, 2013, PEDIATR DRUGS, V15, P93, DOI 10.1007/s40272-013-0017-5
   Syrogiannopoulos GA, 2017, PEDIATR INFECT DIS J, V36, P962, DOI [10.1097/INF.0000000000001629, 10.1097/inf.0000000000001629]
   Tamma PD, 2014, CURR OPIN INFECT DIS, V27, P517, DOI 10.1097/QCO.0000000000000115
   Tunkel AR, 2017, CLIN INFECT DIS, V64, pE34, DOI 10.1093/cid/ciw861
   Wang JS, 2014, INT J INFECT DIS, V25, P26, DOI 10.1016/j.ijid.2014.01.009
NR 15
TC 2
Z9 2
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP 328
EP 330
DI 10.1016/j.wneu.2019.01.065
PG 3
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800167
PM 30685371
DA 2020-05-12
ER

PT J
AU Sharma, M
   Aljuboori, Z
   Clouse, JW
   Rodgers, R
   Altstadt, T
AF Sharma, Mayur
   Aljuboori, Zaid
   Clouse, Jared William
   Rodgers, Richard
   Altstadt, Thomas
TI Sacroiliac Joint Fusion System for High-Grade Spondylolisthesis Using
   "Reverse Bohlman Technique": A Technical Report and Overview of the
   Literature
SO WORLD NEUROSURGERY
LA English
DT Article
DE High-grade spondylolisthesis; Novel technique; Reverse Bohlman technique
ID LUMBAR INTERBODY FUSION; ISTHMIC SPONDYLOLISTHESIS; PARTIAL REDUCTION;
   SCREW FIXATION; IN-SITU; ANTERIOR; L5-S1; DECOMPRESSION; CHILDREN;
   SPONDYLOLYSIS
AB OBJECTIVE/BACKGROUND: High-grade spondylolisthesis (HGS) is a complex clinical problem that poses significant challenges to the treating physician. Contentious debate has continued regarding the most optimal surgical approach for these patients. A variety of transsacral and transvertebral techniques have been described in reported studies.
   METHODS AND RESULTS: We present 2 cases of low back pain and radicular symptoms. Our 2 patients were a 35-year-old woman and a 26-year-old white woman. The computed tomography and magnetic resonance imaging scans revealed progressive HGS (grade III) that had not been relieved by conservative measures. Both patients underwent transsacral fixation using the reverse Bohlman technique (RBT) at L5-S1 and L4-L5 anterior lumbar interbody fusion combined with posterolateral fusion. At the 9- and 10-month follow-up visits, the patients reported minimal back pain with no radicular symptoms, and the imaging studies showed satisfactory fusion in both patients.
   CONCLUSIONS: To the best of our knowledge, this is the first report to demonstrate the utility of the sacroiliac joint fusion cage using RBT in patients with HGS with successful clinical outcome. The RBT is safe, feasible, and effective in carefully selected patients.
C1 [Sharma, Mayur; Aljuboori, Zaid; Altstadt, Thomas] Univ Louisville, Sch Med, Dept Neurol Surg, Louisville, KY 40292 USA.
   [Clouse, Jared William; Rodgers, Richard] Indianapolis Univ, Sch Med, Dept Neurol Surg, Indianapolis, IN USA.
RP Altstadt, T (reprint author), Univ Louisville, Sch Med, Dept Neurol Surg, Louisville, KY 40292 USA.
EM Thomas.altstadt@louisville.edu
RI Sharma, Mayur/B-3228-2018
OI Sharma, Mayur/0000-0001-6481-7819
CR ABDU WA, 1994, SPINE, V19, P710, DOI 10.1097/00007632-199403001-00011
   Bartolozzi P, 2003, SPINE, V28, P1135, DOI 10.1097/00007632-200306010-00010
   BOHLMAN HH, 1982, J BONE JOINT SURG AM, V64, P415, DOI 10.2106/00004623-198264030-00012
   Bollini G, 2011, ORTHOP TRAUMATOL-SUR, V97, P179, DOI 10.1016/j.otsr.2010.11.003
   Bouyer B, 2014, CHILD NERV SYST, V30, P505, DOI 10.1007/s00381-013-2260-z
   Bozkus H, 2004, J NEUROSURG, V100, P62, DOI 10.3171/spi.2004.100.1.0062
   Cheung EV, 2006, J AM ACAD ORTHOP SUR, V14, P488, DOI 10.5435/00124635-200608000-00006
   Harroud A, 2013, EUR SPINE J, V22, P849, DOI 10.1007/s00586-012-2591-6
   Hart RA, 2014, J NEUROSURG-SPINE, V20, P523, DOI 10.3171/2014.1.SPINE12904
   Hire JM, 2015, J NEUROSURG-SPINE, V22, P80, DOI 10.3171/2014.10.SPINE14138
   Ishihara H, 2001, J SPINAL DISORD, V14, P91, DOI 10.1097/00002517-200104000-00001
   Kasliwal MK, 2013, NEUROSURG CLIN N AM, V24, P275, DOI 10.1016/j.nec.2012.12.002
   Labelle H, 2005, SPINE, V30, pS27, DOI 10.1097/01.brs.0000155560.92580.90
   Labelle H, 2011, EUR SPINE J S, VS5, P641
   Lakshmanan P, 2009, SPINE J, V9, P1024, DOI 10.1016/j.spinee.2009.08.456
   LAURENT LE, 1976, CLIN ORTHOP RELAT R, P85
   Macagno AE, 2016, J ORTHOP, V13, P1, DOI 10.1016/j.jor.2015.12.004
   MEYERDING H W, 1956, J Int Coll Surg, V26, P566
   Mobbs RJ, 2016, GLOB SPINE J, V6, P147, DOI 10.1055/s-0035-1557141
   Passias PG, 2015, INT J SPINE SURG, V9, DOI 10.14444/2050
   Pawar A, 2012, EUR SPINE J, V21, P2122, DOI 10.1007/s00586-012-2181-7
   PIZZUTILLO PD, 1989, J PEDIATR ORTHOPED, V9, P538, DOI 10.1097/01241398-198909010-00007
   Remes V, 2006, SPINE, V31, P2491, DOI 10.1097/01.brs.0000239218.38489.db
   Rindler RS, 2016, WORLD NEUROSURG, V95, DOI 10.1016/j.wneu.2016.05.030
   Sasso RC, 2008, J SPINAL DISORD TECH, V21, P328, DOI 10.1097/BSD.0b013e318149e7ea
   Smith JA, 2001, SPINE, V26, P2227, DOI 10.1097/00007632-200110150-00014
   SMITH MD, 1990, J BONE JOINT SURG AM, V72A, P415, DOI 10.2106/00004623-199072030-00015
   Speed K, 1938, ARCH SURG-CHICAGO, V37, P175, DOI 10.1001/archsurg.1938.01200020003001
   Stoker GE, 2011, ARGOSPINE NEWS J, V23, P33
   Transfeldt EE, 2007, SPINE, V32, pS126, DOI 10.1097/BRS.0b013e318145b353
   Vanhoutte EK, 2012, BRAIN, V135, P1639, DOI 10.1093/brain/awr318
NR 31
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP 331
EP 339
DI 10.1016/j.wneu.2019.01.041
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800168
PM 30684713
DA 2020-05-12
ER

PT J
AU Chen, LZ
   Jiang, Y
   Hu, FY
   Zhou, MK
   Li, GZ
   Wang, Y
   He, L
   Zheng, HB
AF Chen, Lizhang
   Jiang, Yi
   Hu, Fayun
   Zhou, Muke
   Li, Guangzong
   Wang, Yan
   He, Li
   Zheng, Hongbo
TI Femoral-Long Sheath-Reshape-Anchoring-Stenting (FLRAS) Technique in
   Venous Sinus Stenting for Idiopathic Intracranial Hypertension
SO WORLD NEUROSURGERY
LA English
DT Article
DE FLRAS; Idiopathic intracranial hypertension; Procedure duration;
   Technique; Venous sinus stenting
ID PSEUDOTUMOR CEREBRI; ANGIOPLASTY
AB OBJECTIVE: To evaluate efficacy and safety of the novel femoral-long sheath-reshape-anchoring-stenting (FLRAS) technique for venous sinus stenting in patients with idiopathic intracranial hypertension.
   METHODS: In a retrospective, single-center study, we comparatively analyzed clinical and imaging data from consecutive patients with idiopathic intracranial hypertension who underwent venous sinus stenting using either traditional technique from June 2013 to May 2015 or FLRAS technique from May 2015 to May 2018.
   RESULTS: The study enrolled 20 patients (mean age 36.7 years; range, 17-50 years; 15 women). In the FLRAS group (n = 12) versus traditional stenting group (n = 8), mean procedure duration was significantly shorter (48.3 minutes vs. 92.5 minutes, P < 0.001), and procedure success rate was higher (100% vs. 87.5%, P > 0.05), with no complications versus 2 complications.
   CONCLUSIONS: Use of FLRAS technique for venous sinus stenting in patients with idiopathic intracranial hypertension appeared to yield favorable outcomes relative to use of traditional stenting technique. A large, multi-center, randomized study is warranted to confirm these findings.
C1 [Chen, Lizhang; Jiang, Yi; Hu, Fayun; Zhou, Muke; He, Li; Zheng, Hongbo] Sichuan Univ, West China Hosp, Chengdu, Sichuan, Peoples R China.
   [Li, Guangzong] Cent Hosp Panzhihua City, Panzhihua, Peoples R China.
   [Wang, Yan] Chengdu Fifth Peoples Hosp, Chengdu, Sichuan, Peoples R China.
RP Zheng, HB (reprint author), Sichuan Univ, West China Hosp, Chengdu, Sichuan, Peoples R China.
EM drzhenghb@126.com
OI zheng, hongbo/0000-0001-6635-5494; Chen, Lizhang/0000-0002-8170-8494;
   wang, yan/0000-0001-5451-6799
CR Burchiel KJ, 2012, J NEUROSURG, V116, P536, DOI 10.3171/2011.4.JNS11752
   Bussiere M, 2010, AM J NEURORADIOL, V31, P645, DOI 10.3174/ajnr.A1890
   Corbett JJ, 2002, NEUROLOGY, V58, P5, DOI 10.1212/WNL.58.1.5
   El Mekabaty A, 2017, J NEUROINTERV SURG, V9, P1228, DOI 10.1136/neurintsurg-2016-012803
   Elder BD, 2015, J CLIN NEUROSCI, V22, P685, DOI 10.1016/j.jocn.2014.10.012
   Fargen KM, 2018, J NEUROINTERV SURG, V10, P1203, DOI 10.1136/neurintsurg-2018-014042
   Fields JD, 2013, J NEUROINTERV SURG, V5, P62, DOI 10.1136/neurintsurg-2011-010156
   Friedman DI, 2013, NEUROLOGY, V81, P1159, DOI 10.1212/WNL.0b013e3182a55f17
   Harrigan MR, 2018, HDB CEREBROVASCULAR, P588
   Higgins JNP, 2003, J NEUROL NEUROSUR PS, V74, P1662, DOI 10.1136/jnnp.74.12.1662
   Kanagalingam S, 2015, SAUDI J OPHTHALMOL, V29, P3, DOI 10.1016/j.sjopt.2014.09.007
   King JO, 1995, NEUROLOGY, V45, P2224, DOI 10.1212/WNL.45.12.2224
   Kumpe DA, 2017, J NEUROINTERV SURG, V9, P867, DOI 10.1136/neurintsurg-2016-012810
   Lenck S, 2017, NEUROSURGERY, V80, P393, DOI 10.1227/NEU.0000000000001261
   Oliver WC, 1997, J CARDIOTHOR VASC AN, V11, P851, DOI 10.1016/S1053-0770(97)90119-1
   Qureshi Adnan I, 2016, J Vasc Interv Neurol, V9, P55
   Raper DMS, 2018, NEUROSURGERY, V82, P555, DOI 10.1093/neuros/nyx186
   Satti SR, 2017, INTERV NEURORADIOL, V23, P186, DOI 10.1177/1591019916680110
   Shazly TA, 2018, J NEUROINTERV SURG, V10, P310, DOI 10.1136/neurintsurg-2017-013103
   SMITH JL, 1985, J CLIN NEURO-OPHTHAL, V5, P55
   Starke Robert M, 2015, ScientificWorldJournal, V2015, P140408, DOI 10.1155/2015/140408
   Teleb MS, 2015, J NEUROIMAGING, V25, P72, DOI 10.1111/jon.12072
   Wall M, 2010, NEUROL CLIN, V28, P593, DOI 10.1016/j.ncl.2010.03.003
NR 23
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP 340
EP 344
DI 10.1016/j.wneu.2018.12.052
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800169
PM 30590216
DA 2020-05-12
ER

PT J
AU Nam, HGW
   Lim, KT
   Park, JS
   Park, CK
   Kim, HS
AF Nam, Han Ga Wi
   Lim, Kang Taek
   Park, Jin Soo
   Park, Chun-Kun
   Kim, Hyung Suk
TI Endoscopic Rescue Technique for Iatrogenic Sacroiliac Joint Syndrome
   Caused by Sextant Percutaneous Pedicle Screw Fixation System
SO WORLD NEUROSURGERY
LA English
DT Article
DE Endoscopic spinal surgery; Pedicle screw; Percutaneous; Sacroiliac
   joint; Sextant
ID LUMBAR FUSION; MOTION; PAIN
AB BACKGROUND: The Sextant percutaneous pedicle screw fixation system is a commonly used technique. In this system, the pedicle screw and the sharp rod are placed through stab incisions. The unique mechanism of action of this system may cause unprecedented adverse effects, such as iatrogenic sacroiliac (SI) joint syndrome.
   CASE DESCRIPTION: A patient presented with iatrogenic SI joint syndrome caused by the rod of the Sextant system at the L4-L6 level causing ilium irritation and dynamic SI joint instability. The patient was treated with an endoscopy-based technique. This is the first report of endoscopic treatment for iatrogenic SI joint syndrome as an adverse effect resulting from use of the Sextant system.
   CONCLUSIONS: Surgeons need to be aware of iatrogenic SI joint syndrome using the Sextant system when performing percutaneous pedicle screw fixation. An endoscopy-based technique may be an effective alternative to conventional corrective surgery when treating iatrogenic SI joint syndrome using the Sextant system.
C1 [Nam, Han Ga Wi; Lim, Kang Taek; Park, Jin Soo; Park, Chun-Kun; Kim, Hyung Suk] Good Doctor Teun Teun Hosp, Dept Neurosurg, Anyang, South Korea.
RP Kim, HS (reprint author), Good Doctor Teun Teun Hosp, Dept Neurosurg, Anyang, South Korea.
EM hskim6903@hanmail.net
CR Ahn Y, 2010, NEUROSURGERY, V67, pE865, DOI 10.1227/01.NEU.0000374856.26808.80
   Axelsson P, 1997, SPINE, V22, P414, DOI 10.1097/00007632-199702150-00012
   Balderston RA, 1998, SPINE, V23, P54, DOI 10.1097/00007632-199801010-00011
   Foley K T, 2001, Neurosurg Focus, V10, pE10
   Foley KT, 2002, J NEUROSURG, V97, P7, DOI 10.3171/spi.2002.97.1.0007
   Ha KY, 2008, SPINE, V33, P1192, DOI 10.1097/BRS.0b013e318170fd35
   Ivanov AA, 2009, SPINE, V34, pE162, DOI 10.1097/BRS.0b013e3181978ea3
   Kambin P, 2004, SPINE, V29, P598, DOI 10.1097/01.BRS.0000112066.78935.74
   Khoo LT, 2002, NEUROSURGERY, V51, pS166, DOI 10.1227/01.NEU.0000031068.83783.7B
   Kotani Y, 2012, EUR SPINE J, V21, P1171, DOI 10.1007/s00586-011-2114-x
   Lim KT, 2019, ASIAN SPINE J, V13, P272, DOI 10.31616/asj.2018.0228
   Maigne JY, 2005, EUR SPINE J, V14, P654, DOI 10.1007/s00586-004-0692-6
   Nam HGW, 2018, WORLD NEUROSURG, V120, P448, DOI 10.1016/j.wneu.2018.09.040
   Schwender JD, 2005, J SPINAL DISORD TECH, V18, pS1, DOI 10.1097/01.bsd.0000132291.50455.d0
   Shono Y, 1998, SPINE, V23, P1550, DOI 10.1097/00007632-199807150-00009
   Yoshihara H, 2012, EUR SPINE J, V21, P1788, DOI 10.1007/s00586-012-2350-8
NR 16
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP 345
EP 349
DI 10.1016/j.wneu.2019.01.073
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800170
DA 2020-05-12
ER

PT J
AU Lin, YP
   Rao, SY
   Li, YJ
   Zhao, S
   Chen, BL
AF Lin, Yongpeng
   Rao, Siyuan
   Li, Yongjin
   Zhao, Shuai
   Chen, Bolai
TI Posterior Percutaneous Full-Endoscopic Cervical Laminectomy and
   Decompression for Cervical Stenosis with Myelopathy: A Technical Note
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cervical diskectomy; Cervical myelopathy; Cervical ossified ligamentum
   flavum; Cervical spinal canal stenosis; Endoscopes; Minimally invasive
   surgery
ID DISC ARTHROPLASTY; FORAMINOTOMY; DISKECTOMY; OUTCOMES
AB OBJECTIVE: Cervical stenosis with myelopathy caused by ossification of the ligamentum flavum is relatively rare. Surgical treatment is the preferred option. Previous surgical procedures usually require assisted internal fixation, and some problems may occur, such as large trauma, intraoperative bleeding, wound infection, and internal fixation failure. The aim of this paper is to introduce a new minimally invasive surgical procedure for the treatment of upper cervical spinal stenosis complicated with myelopathy.
   METHODS: A 56-year-old man with cervical myelopathy (C2-3) caused by calcification of the ligamentum flavum underwent posterior percutaneous full-endoscopic cervical laminectomy and decompression (PECLD) and achieved good clinical efficacy.
   RESULTS: A surgical incision just 1 cm in size was made, and there was little bleeding during the operation. The patient was hospitalized for 2 days and returned to work after 4 weeks. The patient's postoperative recovery of neurologic function was significantly improved, pain was obviously reduced, and quality of life was remarkably improved. No intra- or postoperative surgical complications were encountered.
   CONCLUSIONS: PECLD is an effective method for treating cervical stenosis associated with myelopathy because of ossification of the ligamentum flavum. It has the advantages of smaller trauma, less bleeding, shorter postoperative hospital stay, and faster recovery. Taken together, this minimally technique can be considered as a good alternative to traditional open surgery.
C1 [Lin, Yongpeng; Li, Yongjin; Zhao, Shuai; Chen, Bolai] Guangdong Prov Hosp Tradit Chinese Med, Div Spine Surg Ctr, Guangzhou, Guangdong, Peoples R China.
   [Rao, Siyuan] Guangzhou Univ Chinese Med, Clin Coll 2, Guangzhou, Guangdong, Peoples R China.
RP Chen, BL (reprint author), Guangdong Prov Hosp Tradit Chinese Med, Div Spine Surg Ctr, Guangzhou, Guangdong, Peoples R China.
EM chenbolai337@163.com
FU Guangdong Provincial Medical Research Fund [2017460]
FX This work was partially supported by a grant from the Guangdong
   Provincial Medical Research Fund (2017460 for Y. Lin).
CR Aghayev E, 2013, EUR SPINE J, V22, P1723, DOI 10.1007/s00586-013-2770-0
   Bucknall V, 2018, J ORTHOP SURG-HONG K, V26, DOI 10.1177/2309499018758520
   Choi G, 2017, J KOREAN NEUROSURG S, V60, P485, DOI 10.3340/jkns.2017.0203.004
   Chung JY, 2016, ASIAN SPINE J, V10, P582, DOI 10.4184/asj.2016.10.3.582
   Davies BM, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0172564
   Hashiguchi A, 2018, ASIAN SPINE J, V12, P391, DOI 10.4184/asj.2018.12.3.391
   Heary RF, 2019, J SPINAL CORD MED, V42, P407, DOI 10.1080/10790268.2018.1471780
   Jin YJ, 2013, SPINE J, V13, P408, DOI 10.1016/j.spinee.2012.11.048
   Lee U, 2018, WORLD NEUROSURG, V115, pE532, DOI 10.1016/j.wneu.2018.04.090
   Liu XZ, 2014, ORTHOPEDICS, V37, pE117, DOI 10.3928/01477447-20140124-12
   Ma L, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000011542
   Nadkarni SM, 2017, INDIAN J ORTHOP, V51, P653, DOI 10.4103/ortho.IJOrtho_283_16
   Passias PG, 2017, J CLIN NEUROSCI, V42, P75, DOI 10.1016/j.jocn.2017.04.017
   Puvanesarajah V, 2017, SPINE, V42, P1, DOI 10.1097/BRS.0000000000001639
   Ruetten S, 2008, SPINE, V33, P940, DOI 10.1097/BRS.0b013e31816c8b67
   Song ZJ, 2016, INT ORTHOP, V40, P1335, DOI 10.1007/s00264-016-3193-4
   Tracey RW, 2014, J CLIN NEUROSCI, V21, P1905, DOI 10.1016/j.jocn.2014.05.007
   Wan Q, 2018, J NEUROSURG-SPINE, V29, P351, DOI 10.3171/2018.1.SPINE17795
   Wang HJ, 2020, INT J NEUROSCI, V130, P19, DOI 10.1080/00207454.2018.1495632
   Wang T, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000006421
   Won S, 2017, PAIN PHYSICIAN, V20, P77
   Zhang C, 2018, PAIN PHYSICIAN, V21, pE215
NR 22
TC 1
Z9 1
U1 1
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP 350
EP 357
DI 10.1016/j.wneu.2018.12.180
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800171
PM 30648610
DA 2020-05-12
ER

PT J
AU Preet, K
   Udawatta, M
   Romiyo, P
   Gopen, Q
   Yang, I
AF Preet, Komal
   Udawatta, Methma
   Romiyo, Prasanth
   Gopen, Quinton
   Yang, Isaac
TI Spontaneous Shrinkage of Cystic Acoustic Neuroma
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cerebellopontine angle; Schwannoma
ID VESTIBULAR SCHWANNOMA; CONSERVATIVE MANAGEMENT; GROWTH;
   NEURORADIOLOGIST; NEUROPATHOLOGY; SURGERY; SERIES
AB BACKGROUND: Cystic acoustic neuromas typically present with more rapid growth and shorter symptomatic periods when compared with solid tumors.
   CASE PRESENTATION: We present the case of a 70-year-old man unilateral sensorineural hearing loss, frequent falls, and worsening ataxia. Magnetic resonance imaging (MRI) confirmed a 33.9-cm(3) cystic acoustic neuroma with mass effect on the brainstem and cerebellum. Subsequent MRI scans revealed tumor measurements of 38.2 cm(3), 37.6 cm(3), 23.8 cm(3), and 14.3 cm(3) at 3, 6, 9, and 15 months after initial presentation, respectively.
   CONCLUSIONS: Spontaneous tumor regression was accompanied with reduced mass effect on neighboring structures and improved symptoms. Owing to their unpredictable growth patterns, early surgical resection has been recommended for cystic acoustic neuromas. However, this patient experienced spontaneous tumor involution after conservative management. Further research on the growth patterns of cystic schwannomas is imperative for them proper counseling of patients and improvement of treatment strategies.
C1 [Preet, Komal; Udawatta, Methma; Romiyo, Prasanth; Yang, Isaac] Univ Calif Los Angeles, Harbor UCLA Med Ctr, Ronald Reagan UCLA Med Ctr, Dept Neurosurg, Los Angeles, CA 90095 USA.
   [Yang, Isaac] Univ Calif Los Angeles, Harbor UCLA Med Ctr, Ronald Reagan UCLA Med Ctr, Off Patient Experience, Los Angeles, CA 90095 USA.
   [Yang, Isaac] Univ Calif Los Angeles, Harbor UCLA Med Ctr, Ronald Reagan UCLA Med Ctr, David Geffen Sch Med, Los Angeles, CA 90095 USA.
   [Gopen, Quinton; Yang, Isaac] Univ Calif Los Angeles, Harbor UCLA Med Ctr, Ronald Reagan UCLA Med Ctr, Dept Head & Neck Surg, Los Angeles, CA 90095 USA.
   [Yang, Isaac] Univ Calif Los Angeles, Harbor UCLA Med Ctr, Ronald Reagan UCLA Med Ctr, Dept Radiat Oncol, Los Angeles, CA 90095 USA.
   [Yang, Isaac] Univ Calif Los Angeles, Harbor UCLA Med Ctr, Ronald Reagan UCLA Med Ctr, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA.
   [Yang, Isaac] Univ Calif Los Angeles, Harbor UCLA Med Ctr, Los Angeles Biomed Res Inst LA BioMed, Los Angeles, CA 90095 USA.
RP Yang, I (reprint author), Univ Calif Los Angeles, Harbor UCLA Med Ctr, Ronald Reagan UCLA Med Ctr, Dept Neurosurg, Los Angeles, CA 90095 USA.; Yang, I (reprint author), Univ Calif Los Angeles, Harbor UCLA Med Ctr, Ronald Reagan UCLA Med Ctr, Off Patient Experience, Los Angeles, CA 90095 USA.; Yang, I (reprint author), Univ Calif Los Angeles, Harbor UCLA Med Ctr, Ronald Reagan UCLA Med Ctr, David Geffen Sch Med, Los Angeles, CA 90095 USA.; Yang, I (reprint author), Univ Calif Los Angeles, Harbor UCLA Med Ctr, Ronald Reagan UCLA Med Ctr, Dept Head & Neck Surg, Los Angeles, CA 90095 USA.; Yang, I (reprint author), Univ Calif Los Angeles, Harbor UCLA Med Ctr, Ronald Reagan UCLA Med Ctr, Dept Radiat Oncol, Los Angeles, CA 90095 USA.; Yang, I (reprint author), Univ Calif Los Angeles, Harbor UCLA Med Ctr, Ronald Reagan UCLA Med Ctr, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA.; Yang, I (reprint author), Univ Calif Los Angeles, Harbor UCLA Med Ctr, Los Angeles Biomed Res Inst LA BioMed, Los Angeles, CA 90095 USA.
EM iyang@medne.ucla.edu
OI Udawatta, Methma/0000-0002-5225-7006
FU David Geffen Medical Scholarship; Tina and Fred Segal Benign Brain Tumor
   and Skull Base Research Fellowship; AUA Carolyn L. Kuckein Student
   Research Fellowship; Neurosurgery Research & Education Foundation
   Medical Student Grant; UCLA Visionary Ball Fund Grant; Eli and Edythe
   Broad Center of Regenerative Medicine and Stem Cell Research UCLA
   Scholars in Translational Medicine Program Award; UCLA Honberger
   Endowment Brain Tumor Research Seed Grant; Stryker Technology
   Development Grant; Stop Cancer (US) Research Career Development Award;
   Jason Dessel Memorial Seed Grant
FX Methma Udawatta is a recipient of the David Geffen Medical Scholarship.
   Prasanth Romiyo is supported by the Tina and Fred Segal Benign Brain
   Tumor and Skull Base Research Fellowship, AUA Carolyn L. Kuckein Student
   Research Fellowship, and Neurosurgery Research & Education Foundation
   Medical Student Grant. Isaac Yang is supported by the UCLA Visionary
   Ball Fund Grant, Eli and Edythe Broad Center of Regenerative Medicine
   and Stem Cell Research UCLA Scholars in Translational Medicine Program
   Award, Jason Dessel Memorial Seed Grant, UCLA Honberger Endowment Brain
   Tumor Research Seed Grant, Stryker Technology Development Grant, and
   Stop Cancer (US) Research Career Development Award.
CR Bakkouri Wissame El, 2009, J Neurosurg, V110, P662, DOI 10.3171/2007.5.16836
   Benech F, 2005, NEUROSURG REV, V28, P209, DOI 10.1007/s10143-005-0380-y
   Bowden G, 2017, NEUROSURGERY, V81, P490, DOI 10.1093/neuros/nyx027
   CHARABI S, 1995, OTOLARYNG HEAD NECK, V113, P5, DOI 10.1016/S0194-5998(95)70138-9
   CHARABI S, 1994, LARYNGOSCOPE, V104, P1348
   CHARABI S, 1994, J LARYNGOL OTOL, V108, P375, DOI 10.1017/S0022215100126854
   Frisch CD, 2017, NEUROSURGERY, V80, P112, DOI 10.1227/NEU.0000000000001376
   Fucci MJ, 1999, AM J OTOL, V20, P495
   Fundova P, 2000, J LARYNGOL OTOL, V114, P935
   Harati Ali, 2017, Surg Neurol Int, V8, P45, DOI 10.4103/sni.sni_129_16
   Hassan AU, 2013, INT J RES MED SCI, V1, P178
   KAMEYAMA S, 1994, ACTA NEUROCHIR, V129, P127, DOI 10.1007/BF01406491
   Luetje CM, 2000, AM J OTOL, V21, P393, DOI 10.1016/S0196-0709(00)80050-2
   Oliveira Penido Norma de, 2007, Braz J Otorhinolaryngol, V73, P867, DOI 10.1016/S1808-8694(15)31189-7
   Piccirillo E, 2009, OTOL NEUROTOL, V30, P826, DOI 10.1097/MAO.0b013e3181b04e18
   Rahmathulla Gazanfar, 2011, Surg Neurol Int, V2, P187, DOI 10.4103/2152-7806.91142
   ROBBINS B, 1978, RADIOLOGY, V128, P367, DOI 10.1148/128.2.367
   Sinha S, 2008, J CLIN NEUROSCI, V15, P511, DOI 10.1016/j.jocn.2007.01.007
   Smouha EE, 2005, LARYNGOSCOPE, V115, P450, DOI 10.1097/00005537-200503000-00011
   Stangerup SE, 2006, OTOL NEUROTOL, V27, P547, DOI 10.1097/00129492-200606000-00018
   Su WD, 2005, J CLIN NEUROSCI, V12, P253, DOI 10.1016/j.jocn.2004.03.040
   Sylvester MJ, 2017, OTOLARYNG HEAD NECK, V156, P166, DOI 10.1177/0194599816677522
   TALI ET, 1993, AM J NEURORADIOL, V14, P1241
   Thakur JD, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.6.FOCUS12200
   Tschudi DC, 2000, AM J OTOL, V21, P722
   WALLACE CJ, 1993, CAN ASSOC RADIOL J, V44, P453
   Wang MQ, 2013, TURK NEUROSURG, V23, P161, DOI 10.5137/1019-5149.JTN.5910-12.1
   Wippold FJ, 2007, AM J NEURORADIOL, V28, P1633, DOI 10.3174/ajnr.A0682
   Wippold FJ, 2006, AM J NEURORADIOL, V27, P2037
NR 29
TC 0
Z9 0
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP 358
EP 360
DI 10.1016/j.wneu.2019.01.003
PG 3
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800172
PM 30685372
DA 2020-05-12
ER

PT J
AU Lin, CM
   Chang, CH
   Chen, SW
   Huang, YH
   Wang, AYC
   Chen, CC
AF Lin, Chuan-Min
   Chang, Chien-Hung
   Chen, Shao-Wei
   Huang, Yu-Hsuan
   Wang, Alvin Yi-Chou
   Chen, Ching-Chang
TI Direct Neck Exposure for Rescue Endovascular Mechanical Thrombectomy in
   a Patient with Acute Common Carotid Occlusion Concurrent with Type A
   Aortic Dissection
SO WORLD NEUROSURGERY
LA English
DT Article
DE Carotid dissection; Hybrid angiography suite; Mechanical thrombectomy;
   Neck exposure; Type A aortic dissection
ID ACUTE ISCHEMIC-STROKE; ARTERY PUNCTURE; ACCESS; VESSEL
AB BACKGROUND: Mechanical thrombectomy is an effective treatment of acute large vessel occlusion. However, when difficult anatomy is encountered in which the reperfusion catheter cannot be positioned well, the outcomes can be suboptimal. We present a patient with right common carotid artery (CCA) and internal carotid artery occlusion after repair of an acute type A aortic dissection. Successful mechanical thrombectomy and stenting through direct neck exposure and puncture was performed.
   CASE DESCRIPTION: A 45-year-old man with a type A aortic dissection presented with sudden onset of neck pain and cold sweating. Aortic valve resuspension, proximal anastomosis of ascending aortic graft, partial aortic arch graft replacement, and innominate artery reimplantation was performed. After aortic surgery, left limb weakness was noted in the intensive care unit. Computed tomography angiography of the brain showed right CCA occlusion up to the internal carotid artery. The right CCA was exposed and directly punctured. A thrombus was successfully removed, and 5 stents were deployed to treat the internal carotid artery and CCA dissection. Angiography showed a final Thrombolysis In Cerebral Infarction 3 result, and the patient had an excellent clinical recovery.
   CONCLUSIONS: Acute mechanical thrombectomy through open direct neck puncture to treat an acute type A aortic dissection and concurrent CCA dissection and occlusion is an effective and optimal method.
C1 [Lin, Chuan-Min; Chang, Chien-Hung] Chang Gung Univ, Linkou Chang Gung Mem Hosp, Stroke Ctr, Dept Neurol, Taoyuan, Taiwan.
   [Chen, Shao-Wei] Chang Gung Univ, Linkou Chang Gung Mem Hosp, Div Thorac & Cardiovasc Surg, Taoyuan, Taiwan.
   [Wang, Alvin Yi-Chou; Chen, Ching-Chang] Chang Gung Univ, Linkou Chang Gung Mem Hosp, Dept Neurosurg, Taoyuan, Taiwan.
   [Huang, Yu-Hsuan] Natl Taiwan Univ Hosp, Dept Ophthalmol, Taipei, Taiwan.
RP Chen, CC (reprint author), Chang Gung Univ, Linkou Chang Gung Mem Hosp, Dept Neurosurg, Taoyuan, Taiwan.
EM 8702047@cgmh.org.rw
OI Wang, Alvin Yi-Chou/0000-0003-4831-3607
CR Ashour R, 2016, WORLD NEUROSURG, V91, P6, DOI 10.1016/j.wneu.2016.03.055
   Berkhemer OA, 2015, NEW ENGL J MED, V372, P11, DOI 10.1056/NEJMoa1411587
   Campbell BCV, 2015, NEW ENGL J MED, V372, P1009, DOI 10.1056/NEJMoa1414792
   Dorfer C, 2012, WORLD NEUROSURG, V77, P192, DOI 10.1016/j.wneu.2010.11.007
   Goyal M, 2015, NEW ENGL J MED, V372, P1019, DOI 10.1056/NEJMoa1414905
   Jovin TG, 2015, NEW ENGL J MED, V372, P2296, DOI 10.1056/NEJMoa1503780
   Lee JY, 2018, NEURORADIOLOGY, V60, P565, DOI 10.1007/s00234-018-1994-4
   Mokin M, 2015, J NEUROINTERV SURG, V7, P108, DOI 10.1136/neurintsurg-2013-011007
   Ribo M, 2013, J NEUROINTERV SURG, V5, P70, DOI 10.1136/neurintsurg-2012-010438
   Roche AD, 2017, J STROKE CEREBROVASC, V26, pE211, DOI 10.1016/j.jstrokecerebrovasdis.2017.07.017
   Ross IB, 2006, SURG NEUROL, V65, P207, DOI 10.1016/j.surneu.2005.06.023
   Saver JL, 2015, NEW ENGL J MED, V372, P2285, DOI 10.1056/NEJMoa1415061
   Sfyroeras GS, 2013, J VASC SURG, V58, P1402, DOI 10.1016/j.jvs.2013.07.111
   Spiotta AM, 2014, J NEUROINTERV SURG, V6, P511, DOI 10.1136/neurintsurg-2013-010726
NR 14
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP 361
EP 365
DI 10.1016/j.wneu.2019.01.081
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800173
PM 30703603
DA 2020-05-12
ER

PT J
AU Kim, JK
   Lieberman, E
   Stein, EG
   Betchen, SA
AF Kim, Joseph K.
   Lieberman, Evan
   Stein, Evan G.
   Betchen, Simone A.
TI Spontaneous Hemorrhage Followed by Paraparesis in a Patient with a
   Spinal Meningioma
SO WORLD NEUROSURGERY
LA English
DT Article
DE Paraparesis; Spinal meningioma; Tumor hemorrhage
ID SUBDURAL-HEMATOMA
AB BACKGROUND: Although rare, spinal meningiomas may cause motor and sensory deficits or difficulty with bladder or bowel function due to spinal cord compression. Although hemorrhage of intracranial meningiomas is well documented, there are very few cases of hemorrhage or hematoma associated with spinal meningiomas in the literature. Spinal meningiomas have been reported to be associated with subdural, epidural, intratumoral, and subarachnoid hemorrhage, and usually in the setting of an inciting event such as lumbar puncture or anticoagulation therapy.
   CASE DESCRIPTION: A 68-year-old women presented to the emergency room with acute onset of paraparesis in the lower extremities. Magnetic resonance imaging findings were inconclusive for cause but showed spinal cord compression. Intraoperative findings demonstrated an intratumoral hemorrhage and pathology was consistent with meningioma.
   CONCLUSIONS: To the best of our knowledge, this is the first report in English literature of a patient who first develops symptoms from a spinal meningioma with spontaneous intratumoral hemorrhage presenting with acute paraparesis. Magnetic resonance imaging findings in retrospect match surgical intraoperative findings. Prompt surgical intervention can result in complete resolution of neurologic deficits.
C1 [Lieberman, Evan; Stein, Evan G.] Maimonides Hosp, Dept Radiol, Brooklyn, NY 11219 USA.
   [Betchen, Simone A.] Maimonides Hosp, Div Neurosurg, Brooklyn, NY 11219 USA.
   [Kim, Joseph K.] Suny Downstate Med Ctr, Dept Radiat Oncol, Brooklyn, NY 11203 USA.
RP Betchen, SA (reprint author), Maimonides Hosp, Div Neurosurg, Brooklyn, NY 11219 USA.
EM sbetchen@hotmail.com
CR Bosnjak R, 2005, J NEUROSURG, V103, P473, DOI 10.3171/jns.2005.103.3.0473
   Galgano MA, 2014, J SPINE, V3, P157
   Gonzalez-Vargas P, 2018, INTERDISCIP NEUROSUR, V14, P142, DOI 10.1016/j.inat.2018.08.001
   Haegelen C, 2005, EUR SPINE J, V14, P440, DOI 10.1007/s00586-004-0809-y
   Hambra Di Vitantonio, 2014, Surg Neurol Int, V5, pS469, DOI 10.4103/2152-7806.143724
   Lee Heui Seung, 2013, Korean J Spine, V10, P255, DOI 10.14245/kjs.2013.10.4.255
   Morimoto T, 1996, ACTA NEUROCHIR, V138, P886, DOI 10.1007/BF01411269
   Ogawa Y, 2013, SPINE, V38, P1405, DOI 10.1097/BRS.0b013e3182987495
   Sandalcioglu IE, 2008, EUR SPINE J, V17, P1035, DOI 10.1007/s00586-008-0685-y
   SCHROTH G, 1987, J NEUROSURG, V66, P695, DOI 10.3171/jns.1987.66.5.0695
   Setzer Matthias, 2007, Neurosurg Focus, V23, pE14, DOI 10.3171/FOC-07/10/E14
   SWANN KW, 1984, J NEUROSURG, V61, P975, DOI 10.3171/jns.1984.61.5.0975
   TOLEDO E, 1981, NEUROSURGERY, V8, P600, DOI 10.1227/00006123-198105000-00018
   Vij M, 2012, J CANCER RES THER, V8, P145, DOI 10.4103/0973-1482.95198
NR 14
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP 366
EP 369
DI 10.1016/j.wneu.2019.01.031
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800174
PM 30684702
DA 2020-05-12
ER

PT J
AU Puffer, RC
   Bishop, AT
   Spinner, RJ
   Shin, AY
AF Puffer, Ross C.
   Bishop, Allen T.
   Spinner, Robert J.
   Shin, Alexander Y.
TI Bilateral Brachial Plexus Injury After MiraDry Procedure for Axillary
   Hyperhidrosis
SO WORLD NEUROSURGERY
LA English
DT Article
DE Axillary hyperhidrosis; Bilateral brachia plexus injury; MiraDry
ID MICROWAVE DEVICE; CLINICAL-EVALUATION
AB BACKGROUND: Multiple treatments are available for primary axillary hyperhidrosis including noninvasive, microwave-based thermal treatments designed to destroy sweat glands in the axilla. Often these procedures involve local anesthetic injection to the axilla, followed by placement of the microwave emitter onto the skin and applying the heat treatment to varying depths of the subcutaneous tissues.
   CASE DESCRIPTION: A 49-year-old, thin, active woman (body mass index 19.6) underwent microwave-based treatment to the bilateral axillary regions. She experienced an electric sensation into the ulnar digits of the right hand during anesthetic injection and then underwent the microwave thermal treatment. She suffered a bilateral brachial plexus injury with imaging evidence of severe, subcutaneous edema surrounding the nerves of the plexus in the axilla, as well as denervation atrophy of the arm and forearm muscles bilaterally. At the time of evaluation and electromyography, 8 months after treatment, she had recovered significant strength in the left upper extremity but continued to have evidence of a severe radial nerve injury on the right. Electromyography demonstrated some recovery, and observation was recommended followed by secondary reconstruction if required. It is likely that the patient sustained thermal injury to the nerves in the axilla bilaterally, given the close proximity to the skin surface in a patient with a low body mass index.
   CONCLUSIONS: In thin patients undergoing treatment of primary axillary hyperhidrosis, consideration should be given to the distal brachial plexus, which may be at risk of damage with high-powered microwave-based therapy.
C1 [Puffer, Ross C.; Spinner, Robert J.] Mayo Clin, Dept Neurosurg, Rochester, MN USA.
   [Bishop, Allen T.; Shin, Alexander Y.] Mayo Clin, Dept Orthoped Surg, Rochester, MN 55905 USA.
RP Shin, AY (reprint author), Mayo Clin, Dept Orthoped Surg, Rochester, MN 55905 USA.
EM Shin.alexander@mayo.edu
CR Chang CK, 2017, J COSMET LASER THER, V19, P439, DOI 10.1080/14764172.2017.1342039
   Glaser DA, 2012, DERMATOL SURG, V38, P185, DOI 10.1111/j.1524-4725.2011.02250.x
   Hong HCH, 2012, DERMATOL SURG, V38, P728, DOI 10.1111/j.1524-4725.2012.02375.x
   Johnson JE, 2012, LASER SURG MED, V44, P20, DOI 10.1002/lsm.21142
   Lupin M, 2014, DERMATOL SURG, V40, P805, DOI 10.1111/DSU.0000000000000041
   Malet A, 2015, ANESTH ANALG, V120, P589, DOI 10.1213/ANE.0000000000000562
   Strutton DR, 2004, J AM ACAD DERMATOL, V51, P241, DOI 10.1016/j.jaad.2003.12.040
   Suh DH, 2014, DERMATOL SURG, V40, P482, DOI 10.1111/dsu.12425
NR 8
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP 370
EP 372
DI 10.1016/j.wneu.2019.01.093
PG 3
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800175
PM 30703585
DA 2020-05-12
ER

PT J
AU Brimley, C
   Griessenauer, CJ
   Dalal, S
   Schirmer, CM
   Goren, O
AF Brimley, Cameron
   Griessenauer, Christoph J.
   Dalal, Shamsher
   Schirmer, Clemens M.
   Goren, Oded
TI Acute Development and Rupture of a Basilar Tip Mycotic Aneurysm
SO WORLD NEUROSURGERY
LA English
DT Article
DE Aneurysm rupture; Digital subtraction angiography; Infective
   endocarditis; Mycotic aneurysm
AB BACKGROUND: Infectious intracranial aneurysms are rare but encountered when associated with rupture or detected on screening of high-risk patients. The time course of the development of these aneurysms is unknown. Ultimately, the data published on mycotic aneurysms are in the form of case series, retrospective studies, with one recent systematic review, all of which have difficulty defining specifics regarding aneurysmal formation in these patients. We present a case that may help define the time frame of mycotic aneurysm growth.
   CASE DESCRIPTION: A patient with endocarditis, first identified to have a distal middle cerebral artery aneurysm treated with Onyx embolization, and an otherwise-unremarkable cerebral angiogram experienced significant subarachnoid hemorrhage 5 days later. Within that short time frame on appropriate antibiotic therapy, she developed and ruptured a basilar tip aneurysm, which was subsequently treated with coil embolization.
   CONCLSUSIONS: The time course of infectious intracranial aneurysm development is not known and difficult to define. This case illustrates an example of the development of a new infectious intracranial aneurysm and subsequent rupture over the course of 5 days, showing that these types of aneurysms and subsequent neurologic sequelae can happen acutely.
C1 [Brimley, Cameron; Griessenauer, Christoph J.; Schirmer, Clemens M.; Goren, Oded] Geisinger, Dept Neurosurg, Danville, PA 17822 USA.
   [Dalal, Shamsher] Geisinger, Dept Radiol, Danville, PA USA.
   [Griessenauer, Christoph J.] Paracelsus Med Univ, Res Inst Neurointervent, Salzburg, Austria.
RP Brimley, C (reprint author), Geisinger, Dept Neurosurg, Danville, PA 17822 USA.
EM cjbrimley@geisinger.edu
CR Alawieh A, 2018, J NEUROINTERV SURG, V10, P713, DOI 10.1136/neurintsurg-2017-013603
   Baddour, 2016, CIRCULATION, V134, pE113, DOI 10.1161/CIR.0000000000000427
   Clare C E, 1992, Neurosurg Clin N Am, V3, P551
   Hamisch CA, 2016, CEREBROVASC DIS, V42, P493, DOI 10.1159/000448406
   Hui FK, 2015, J NEUROINTERV SURG, V7, P449, DOI 10.1136/neurintsurg-2014-011124
   Samaniego EA, 2017, NEUROL-CLIN PRACT, V7, P449, DOI 10.1212/CPJ.0000000000000315
NR 6
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP 373
EP 377
DI 10.1016/j.wneu.2018.12.211
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800176
PM 30660878
DA 2020-05-12
ER

PT J
AU Adekanmbi, A
   Peters, KB
   Razis, E
   Adeolu, AA
   Lukas, RV
   Balogun, JA
AF Adekanmbi, Adefisayo
   Peters, Katherine B.
   Razis, Evangelia
   Adeolu, Augustine A.
   Lukas, Rimas, V
   Balogun, James A.
TI Neurooncology Research in Nigeria: Great Untapped Potential
SO WORLD NEUROSURGERY
LA English
DT Article
DE Academic; Africa; Brain tumor; Neuro-oncology; Nigeria; Publications;
   Scholarship
ID CHALLENGES; CARE
AB BACKGROUND: Nigeria has the largest population in Africa and has suboptimal access to neurooncology care. It has been estimated that there is approximately 1 neurosurgeon for every 2.4 million people in the country, with only few of these trained in the neurooncology subspecialty and no dedicated medical or radiation neurooncologists. There is a paucity of information on the field of neurooncology in Nigeria. This manuscript aims to provide an overview of the current state of neurooncology literature in Nigeria.
   METHODS: A systematic literature review was performed, using Google Scholar, PubMed, and African Journals Online, to search for articles related to neurooncology in Nigeria, from 1963-2018. Articles were reviewed and categorized.
   RESULTS: Sixty-three relevant articles were identified. They comprised original research in basic science (N = 1), clinical science (N = 59), and reviews (N = 3). Retrospective case series were the most common type of publication. Categorizing according to histology, articles focused on meningioma (N = 12), pituitary tumors (N = 10), glioma (N = 7), central nervous system metastases (N = 6), multiple histologic types (N = 25), and other types of tumors (N = 3). Eight pediatric neurooncology publications were among these. Two manuscripts, focusing on surgical subjects, specifically addressed issues on neurooncology clinical practice in Nigeria. Of the total manuscripts, 26 were published in Nigerian-based journals and 37 in journals outside Nigeria. The majority of the journals were low-impact factor journals. An increasing number of publications over time was noted.
   CONCLUSIONS: There is a small but growing amount of scholarly literature on neurooncology from Nigeria. However, there continues to be room for growth in neurooncology research output. With Nigeria's large patient population, there is potential to learn and add to the academic literature. Although there are logistical obstacles to both patient care and research in neurooncology in Nigeria, there is promise for favorable advancement.
C1 [Adekanmbi, Adefisayo; Adeolu, Augustine A.; Balogun, James A.] Univ Ibadan, Coll Med, Dept Surg, Div Neurosurg, Ibadan, Nigeria.
   [Peters, Katherine B.] Duke Univ, Dept Neurol, Durham, NC USA.
   [Razis, Evangelia] Hygeia Hosp, Contemporary Oncol Team, Oncol Dept 3, Athens, Greece.
   [Lukas, Rimas, V] Northwestern Univ, Lurie Comprehens Canc Ctr, Dept Neurol, Lou & Jean Malnati Brain Tumor Inst, Chicago, IL 60611 USA.
RP Balogun, JA (reprint author), Univ Ibadan, Coll Med, Dept Surg, Div Neurosurg, Ibadan, Nigeria.
EM jabalogun@comui.edu.ng
FU American Society for Clinical Oncology Virtual Mentor program
   [P50CA221747]
FX A. A. is supported by the American Society for Clinical Oncology Virtual
   Mentor program. RVL is supported by P50CA221747. The article content was
   composed in the absence of any commercial or financial relationships
   that could be construed as a potential conflict of interest.
CR Adeleye AO, 2016, SURG NEUROL INT, V7
   ADELOYE A, 1969, BRIT J CANCER, V23, P340, DOI 10.1038/bjc.1969.44
   Adewole DA, 2015, AM J TROP MED HYG, V93, P648, DOI 10.4269/ajtmh.14-0245
   Al-Adawi SH, 2010, SAUDI MED J, V31, P1093
   [Anonymous], 2018, GLOB CANC OBS
   Chan MH, 2015, CHILD NERV SYST, V31, P1227, DOI 10.1007/s00381-015-2771-x
   Dempsey RJ, 2018, WORLD NEUROSURG, V112, P325, DOI 10.1016/j.wneu.2018.02.099
   Hannan Abdul, 2016, J Glob Oncol, V2, P97, DOI 10.1200/JGO.2016.003244
   Irabor OC, 2016, INT J RADIAT ONCOL, V95, P1327, DOI 10.1016/j.ijrobp.2016.04.026
   McClelland S, 2007, NEUROSURGERY, V60, P769, DOI 10.1227/01.NEU.0000255410.69022.E8
   Mezue Wilfred C, 2012, Surg Neurol Int, V3, P110, DOI 10.4103/2152-7806.101788
   Ndubuisi CA, 2017, J NEUROSCI RURAL PRA, V8, P407, DOI 10.4103/jnrp.jnrp_18_17
   Ngulde SI, 2015, CUREUS, V7, DOI 10.7759/cureus.372
   Ohaegbulam SC, 1999, NEUROL RES, V21, P161, DOI 10.1080/01616412.1999.11740912
   OHAEGBULAM SC, 1980, CANCER, V46, P2322, DOI 10.1002/1097-0142(19801115)46:10<2322::AID-CNCR2820461034>3.0.CO;2-F
   Rahman M, 2003, PUBLIC HEALTH, V117, P274, DOI 10.1016/S0033-3506(03)00068-4
   Servadei F, 2018, WORLD NEUROSURG, V112, P315, DOI 10.1016/j.wneu.2018.01.047
   Stefan Daniela Cristina, 2015, J Glob Oncol, V1, P30, DOI 10.1200/JGO.2015.000406
   Victora CG, 2006, REV SAUDE PUBL, V40, P36, DOI 10.1590/s0034-89102006000400006
NR 19
TC 1
Z9 1
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP 381
EP 385
DI 10.1016/j.wneu.2018.12.192
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800178
PM 30659966
DA 2020-05-12
ER

PT J
AU Sun, SW
   Li, YP
   Zhang, HZ
   Wang, XD
   She, L
   Yan, ZC
   Lu, GY
AF Sun, Shuwen
   Li, Yuping
   Zhang, Hengzhu
   Wang, Xiaodong
   She, Lei
   Yan, Zhengcun
   Lu, Guangyu
TI The Effect of Mannitol in the Early Stage of Supratentorial Hypertensive
   Intracerebral Hemorrhage: A Systematic Review and Meta-Analysis
SO WORLD NEUROSURGERY
LA English
DT Review
DE Hypertensive intracerebral hemorrhage; Mannitol; Meta-analysis
ID HEMATOMA ENLARGEMENT; STROKE
AB BACKGROUND: Mannitol has been widely applied as a priority drug in the clinical treatment for brain edema and increased intracranial pressure after intracerebral hemorrhage. However, no consensus on the efficacy and safety of mannitol has been achieved. Our meta-analysis was conducted to assess the effect of mannitol in the early stage of supratentorial hypertensive intracerebral hemorrhage (HICH) and provided a treatment reference for clinicians.
   METHODS: All relevant studies on mannitol treatment of supratentorial HICH were identified from the databases including PubMed, EMBASE, Cochrane Library, VIP, CNKI, and Wan Fang. Our outcome measures included the incidence of hematoma enlargement, the neurologic function improvement rate, mortality, and the incidence of aggravated brain edema. The subgroup analysis was performed to explore the impact of study type, year of publication, intervention time, and dose on the outcome measures. Publication bias was assessed by the funnel plot.
   RESULTS: Thirty-four studies consisting of 3627 patients with supratentorial HICH were included in this study (from 2000 to 2018). Significant statistical difference was found between the mannitol and nonmannitol group in terms of all the outcome measures, including the incidence of hematoma enlargement (P < 0.00001), the neurologic function improvement rate (P < 0.00001), mortality (P < 0.00001), and the incidence of aggravated cerebral edema (P = 0.0002). In subgroup analysis, the results showed that study type and intervention time did not significantly affect the outcome measures. No significant statistical difference was found in the subgroups of publication time (after 2010) (P = 0.08) and half-dose of mannitol (P = 0.20) on mortality. In addition, the further analysis showed that whatever the dose (250 mL or 125 mL) and intervention time (<24, <12, or <6 hours), mannitol could lead to hematoma enlargement.
   CONCLUSIONS: For patients without obvious symptoms of intracranial hypertension or cerebral palsy, it is not recommended to use mannitol routinely in the early stage of supratentorial HICH. More high-quality trials should be included to confirm our conclusion and to ascertain the best time and dose of mannitol to use.
C1 [Sun, Shuwen; Li, Yuping; Zhang, Hengzhu; Wang, Xiaodong; She, Lei; Yan, Zhengcun] Yangzhou Univ, Clin Med Coll, Dept Neurosurg, Yangzhou, Jiangsu, Peoples R China.
   [Lu, Guangyu] Yangzhou Univ, Yangzhou, Jiangsu, Peoples R China.
RP Zhang, HZ (reprint author), Yangzhou Univ, Clin Med Coll, Dept Neurosurg, Yangzhou, Jiangsu, Peoples R China.
EM zhanghengzhu@sina.com
OI Sun, Shuwen/0000-0002-2492-1483
CR Alvarez B, 1998, FREE RADICAL BIO MED, V24, P1331, DOI 10.1016/S0891-5849(98)00005-7
   [Anonymous], 1995, CHIN J NEUROL, V6, P62
   Bereczki D, 2007, COCHRANE DB SYST REV, V7
   Brott T, 1997, STROKE, V28, P1, DOI 10.1161/01.STR.28.1.1
   Chinese Stroke Society of the Chinese Society of Neurology, 2015, CHINESE J NEUROLOGY, V48, P435, DOI 10.3760/cma.j.issn.1006-7876.2015.06.002
   Dai HF, 2015, CHIN J PRACT NERV DI, P112
   DONAHUE RP, 1986, JAMA-J AM MED ASSOC, V255, P2311, DOI 10.1001/jama.255.17.2311
   Fang LW, 2013, CHIN J PRACT NERV DI, V16, P65
   Fujii Y, 1998, STROKE, V29, P1160, DOI 10.1161/01.STR.29.6.1160
   FUJII Y, 1994, J NEUROSURG, V80, P51, DOI 10.3171/jns.1994.80.1.0051
   Gan JP, 2006, PRACT J CARD CEREB P, V14, P805
   Gao Y, 2011, CHIN J DIFFIC COMPL, V10, P735
   Helbok R, 2011, J NEUROL NEUROSUR PS, V82, P378, DOI 10.1136/jnnp.2009.198754
   Higgins JPT, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5928
   Huang ZC, 2002, CLIN NEUROPHYSIOL, V113, P454, DOI 10.1016/S1388-2457(02)00015-9
   Inamura K, 1992, No To Shinkei, V44, P779
   Kalita J, 2004, J NEUROL SCI, V224, P19, DOI 10.1016/j.jns.2004.05.019
   Kazui S, 1997, STROKE, V28, P2370, DOI 10.1161/01.STR.28.12.2370
   Korenkov AI, 2000, NEUROSURG REV, V23, P145, DOI 10.1007/PL00011946
   Li C, 2015, J NONGKEN MED, V37, P481
   Li L, 2008, J NINGXIA MED U, V30, P657
   Liang XY, 2006, PREV TREAT CARD CERE, V6, P175
   Liu L, 2015, CHIN FOREIGN MED TRE, V34, P127
   Liu ML, 2006, SICHUAN MED J, V27, P632
   Lu GJ, 2003, CHIN J PRACT NERV DI, V6, P70
   Ma ZC, 2016, HLTH WORLD, V6, P37
   Mao LY, 2010, MED INFORM, V23, P94
   [苗青 Miao Qing], 2015, [中华疾病控制杂志, Chinese Journal of Disease Control & Prevention], V19, P1072
   Misra UK, 2005, J NEUROL SCI, V234, P41, DOI 10.1016/j.jns.2005.03.038
   Murthy SB, 2015, STROKE, V46, P3088, DOI 10.1161/STROKEAHA.115.010054
   Nau R, 2000, CLIN PHARMACOKINET, V38, P23, DOI 10.2165/00003088-200038010-00002
   Rabinstein AA, 2006, NEUROLOGIST, V12, P59, DOI 10.1097/01.nrl.0000186810.62736.f0
   SANTAMBROGIO S, 1978, STROKE, V9, P130, DOI 10.1161/01.STR.9.2.130
   Shi Y, 2000, Zhonghua Yi Xue Za Zhi, V80, P849
   Si FM, 2008, CHIN J MISDIAGN, V8, P1545
   Su XY, 2007, CHIN J DIFFIC COMPL, V6, P680
   Sun QJ, 2012, CHIN J PRIM MED PHAR, P1139
   Sun SJ, 2005, CHIN J DIFFIC COMPL, V4, P208
   Sun WY, 2006, PRACT J CARD CEREB P, V14, P448
   Sun XB, 2006, CLIN MED CHIN, V22, P335
   Tai GY, 2016, XINXUEGUANBING FANGZ, P11
   Tang GC, 2013, PRACT J CARD CEREB P, V21, P48
   Tian Y, 2013, J NEUROL SCI, V330, P38, DOI 10.1016/j.jns.2013.04.001
   van Asch CJJ, 2010, LANCET NEUROL, V9, P167, DOI 10.1016/S1474-4422(09)70340-0
   WAKAI A, 2007, LANCET
   Wang AP, 2005, CHIN J PRACT NERV DI, V8, P73
   Wang MZ, 2002, SHANDONG MED J, V42, P8
   Wang XL, 2006, CHIN J INTEGR MED, V4, P1009
   Wells GA, 2014, APPL ENG AGRIC, V18, P727
   Xi GH, 2006, LANCET NEUROL, V5, P53, DOI 10.1016/S1474-4422(05)70283-0
   Xiao Y, 2013, LAB MED CLIN, V10, P456
   [谢思明 Xie Siming], 2005, [中国急救医学, Chinese Journal of Critical Care Medicine], V25, P52
   Xu Q, 2005, CHIN J PRACT MED, V32, P28
   Yang G, 2016, PAK J MED SCI, V32, P677, DOI 10.12669/pjms.323.9533
   Yang S, 2018, CHINA PRACT MED, DOI [10.14163/j.cnki.11-5547/r.2018.09.066, DOI 10.14163/J.CNKI.11-5547/R.2018.09.066]
   Yu J, 2015, J N SICHUAN MED COLL, V30, P509
   Zhang J, 2007, HAINAN MED J, V18, P12
   Zhang JH, 2009, HERALD MED, V28, P744
   Zhang JK, 2010, SHAANXI MED J, V39, P481
   Zhang L, 2009, J MED PHARM CHIN MIN, V15, P13
   Zhu JS, 2008, CHONGQING MED, V37, P1601
   Zhu XC, 2005, CLIN FOCUS, V20, P31
   Zong BY, 2005, CHIN J EMERG MED, V14, P1038
   肖桂荣, 2003, [中国康复医学杂志, Chinese Journal of Rehabilitation Medicine], V18, P618
NR 64
TC 1
Z9 1
U1 2
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP 386
EP 396
DI 10.1016/j.wneu.2018.11.249
PG 11
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800179
PM 30576817
DA 2020-05-12
ER

PT J
AU Young, JS
   Dayani, F
   Morshed, RA
   Okada, H
   Aghi, MK
AF Young, Jacob S.
   Dayani, Fara
   Morshed, Ramin A.
   Okada, Hideho
   Aghi, Manish K.
TI Immunotherapy for High-Grade Gliomas: A Clinical Update and Practical
   Considerations for Neurosurgeons
SO WORLD NEUROSURGERY
LA English
DT Review
DE Adoptive T cell therapy; Cerebral edema; Checkpoint inhibitors;
   Corticosteroids; Dendritic cell vaccines; Peptide vaccines
ID NEWLY-DIAGNOSED GLIOBLASTOMA; DENDRITIC CELL VACCINATION; LONG-TERM
   SURVIVAL; PHASE-II TRIAL; T-CELLS; RECURRENT GLIOBLASTOMA; ADVERSE
   EVENTS; MALIGNANT PROGRESSION; PEPTIDE VACCINATION; COMBINED NIVOLUMAB
AB BACKGROUND: The current standard of care for patients with high-grade gliomas includes surgical resection, chemotherapy, and radiation; but even still most patients experience disease progression and succumb to their illness within a few years of diagnosis. Immunotherapy, which stimulates an anti-tumor immune response, has been revolutionary in the treatment of some hematologic and solid malignancies, generating substantial excitement for its potential for patients with glioblastoma. However, to date, the preclinical success of these approaches against high-grade glioma models has not been replicated in human clinical trials. Moreover, the complex response to these biologically active treatments can complicate management decisions, and the neurosurgical oncology community needs to be actively involved in and up to date on the use of these agents in patients with high-grade glioma. In this review, we discuss the challenges immunotherapy faces for high-grade gliomas, the completed and ongoing clinical trials for the major immunotherapies, and the nuances in management for patients being actively treated with one of these agents.
   METHODS: We reviewed the literature to summarize the current immunotherapy strategies for high-grade gliomas.
   RESULTS: Preclinical and clinical trials investigating dendritic cell and peptide vaccines, checkpoint inhibitors, and adoptive T cell therapy are highlighted in this review.
   CONCLUSIONS: Although immunotherapy has yet to fully fulfill its promise for patients with glioblastoma and improve patient outcomes, there is still excitement that these approaches will eventually lead to durable anti-tumor responses. As neurosurgeons, an understanding of the complex interactions between the standard of care therapies and the other medications used in the treatment arsenal for patients with high-grade brain tumors is crucial to the management of these patients.
C1 [Young, Jacob S.; Morshed, Ramin A.; Okada, Hideho; Aghi, Manish K.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA.
   [Dayani, Fara] Univ Calif San Francisco, Sch Med, San Francisco, CA USA.
RP Young, JS (reprint author), Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA.
EM jacob.young@ucsf.edu
RI Young, Jacob/AAE-6194-2020
OI Dayani, Fara/0000-0002-1426-4328
FU NCI NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R01
   CA227136]; NINDS NIH HHSUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Neurological Disorders & Stroke (NINDS) [R01 NS079697]
CR Abdel-Wahab N, 2017, ADV EXP MED BIOL, V995, P155, DOI 10.1007/978-3-319-53156-4_8
   Ahmed N, 2017, JAMA ONCOL, V3, P1094, DOI 10.1001/jamaoncol.2017.0184
   Antonios JP, 2017, P NATL ACAD SCI USA
   Aquino D, 2017, J IMMUNOL RES, DOI 10.1155/2017/5813951
   Batich KA, 2017, CLIN CANCER RES, V23, P1898, DOI 10.1158/1078-0432.CCR-16-2057
   Batlevi CL, 2016, NAT REV CLIN ONCOL, V13, P25, DOI 10.1038/nrclinonc.2015.187
   Bertrand F, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-02358-7
   Bloch O, 2017, NEURO-ONCOLOGY, V19, P29
   Bloch O, 2014, NEURO-ONCOLOGY, V16, P274, DOI 10.1093/neuonc/not203
   Brown CE, 2016, NEW ENGL J MED, V375, P2561, DOI 10.1056/NEJMoa1610497
   Brown CE, 2015, CLIN CANCER RES, V21, P4062, DOI 10.1158/1078-0432.CCR-15-0428
   Buerki RA, 2018, CLIN CANCER RES, V24, P5198, DOI 10.1158/1078-0432.CCR-17-2769
   Cacciavillano W, 2015, PEDIATR BLOOD CANCER, V62, P2120, DOI 10.1002/pbc.25631
   Cao Q, 2010, CANCER LETT, V295, P17, DOI 10.1016/j.canlet.2010.02.009
   Carter T, 2016, CLIN ONCOL-UK, V28, P622, DOI 10.1016/j.clon.2016.04.042
   Chang CN, 2011, J CLIN NEUROSCI, V18, P1048, DOI 10.1016/j.jocn.2010.11.034
   Chistiakov DA, 2017, EUR J PHARMACOL, V810, P70, DOI 10.1016/j.ejphar.2017.05.064
   Crane CA, 2013, CLIN CANCER RES, V19, P205, DOI 10.1158/1078-0432.CCR-11-3358
   Curry WT, 2016, CLIN CANCER RES, V22, P2885, DOI 10.1158/1078-0432.CCR-15-2163
   Dix AR, 1999, J NEUROIMMUNOL, V100, P216, DOI 10.1016/S0165-5728(99)00203-9
   Ellingson BM, 2017, J NEURO-ONCOL, V134, P495, DOI 10.1007/s11060-017-2375-2
   Fecci PE, 2006, CANCER RES, V66, P3294, DOI 10.1158/0008-5472.CAN-05-3773
   Fecci PE, 2007, CLIN CANCER RES, V13, P2158, DOI 10.1158/1078-0432.CCR-06-2070
   Fecci PE, 2014, CLIN CANCER RES, V20, P5620, DOI 10.1158/1078-0432.CCR-14-0832
   Fenstermaker RA, 2016, CANCER IMMUNOL IMMUN, V65, P1339, DOI 10.1007/s00262-016-1890-x
   Filley AC, 2017, ONCOTARGET, V8, P91779, DOI 10.18632/oncotarget.21586
   Finocchiaro G, 2017, DISCOV MED, V23, P113
   Giles AJ, 2018, J IMMUNOTHER CANCER, V6, DOI 10.1186/s40425-018-0371-5
   Gramatzki D, 2017, NEUROLOGY, V88, P1422, DOI 10.1212/WNL.0000000000003809
   Guo G, 2015, J IMMUNOTHER CANCER, V3, DOI 10.1186/s40425-015-0053-5
   Hazarika M, 2017, CLIN CANCER RES, V23, P3484, DOI 10.1158/1078-0432.CCR-16-0712
   Heiland DH, 2017, ONCOTARGET, V8, P42214, DOI 10.18632/oncotarget.15031
   Herbst RS, 2014, NATURE, V515, P563, DOI 10.1038/nature14011
   Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466
   Hu Z, 2018, NAT REV IMMUNOL, V18, P168, DOI 10.1038/nri.2017.131
   Hunn MK, 2015, J NEURO-ONCOL, V121, P319, DOI 10.1007/s11060-014-1635-7
   Inoges S, 2017, J TRANSL MED, V15, DOI 10.1186/s12967-017-1202-z
   Ishikawa E, 2014, J NEUROSURG, V121, P543, DOI 10.3171/2014.5.JNS132392
   Izumoto S, 2008, J NEUROSURG, V108, P963, DOI 10.3171/JNS/2008/108/5/0963
   Johnson BE, 2014, SCIENCE, V343, P189, DOI 10.1126/science.1239947
   Kalbasi A, 2013, J CLIN INVEST, V123, P2756, DOI 10.1172/JCI69219
   Kirner A, 2014, HUM VACC IMMUNOTHER, V10, P3179, DOI 10.4161/21645515.2014.983857
   Kong DS, 2017, ONCOTARGET, V8, P7003, DOI 10.18632/oncotarget.12273
   Lamberti G, 2018, FUTUR NEUROL, V13, P1, DOI 10.2217/fnl-2017-0033
   LAMPSON LA, 1995, MICROSC RES TECHNIQ, V32, P267, DOI 10.1002/jemt.1070320402
   Larkin J, 2015, NEW ENGL J MED, V373, P23, DOI [10.1056/NEJMoa1504030, 10.1056/NEJMc1509660]
   Lawrence MS, 2013, NATURE, V499, P214, DOI 10.1038/nature12213
   Liau LM, 2005, CLIN CANCER RES, V11, P5515, DOI 10.1158/1078-0432.CCR-05-0464
   Lu CY, 2017, BRIT J HAEMATOL, V178, P413, DOI 10.1111/bjh.14686
   Lynes J, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00578
   Lyon JG, 2017, ADV DRUG DELIVER REV, V114, P19, DOI 10.1016/j.addr.2017.06.006
   Margolin K, 2012, ONCOIMMUNOLOGY, V1, P1197, DOI 10.4161/onci.20687
   Margolin K, 2012, LANCET ONCOL, V13, P459, DOI 10.1016/S1470-2045(12)70090-6
   Matsumura S, 2008, J IMMUNOL, V181, P3099, DOI 10.4049/jimmunol.181.5.3099
   Maude SL, 2014, NEW ENGL J MED, V371, P1507, DOI 10.1056/NEJMoa1407222
   Maus MV, 2014, BLOOD, V123, P2625, DOI 10.1182/blood-2013-11-492231
   Maxwell R, 2018, INT J RADIAT ONCOL, V102, pS170, DOI 10.1016/j.ijrobp.2018.07.035
   Michot JM, 2016, EUR J CANCER, V54, P139, DOI 10.1016/j.ejca.2015.11.016
   Mitchell DA, 2015, NATURE, V519, P366, DOI 10.1038/nature14320
   Mu LY, 2017, J CANCER, V8, P2704, DOI 10.7150/jca.20665
   Nduom EK, 2016, NEURO-ONCOLOGY, V18, P195, DOI 10.1093/neuonc/nov172
   Nduom EK, 2015, NEURO-ONCOLOGY, V17, P9, DOI 10.1093/neuonc/nov151
   Neyns B, 2010, CANCER-AM CANCER SOC, V116, P2868, DOI 10.1002/cncr.25035
   O'Rourke DM, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aaa0984
   Oji Y, 2016, INT J CANCER, V139, P1391, DOI 10.1002/ijc.30182
   Oka Y, 2008, CURR OPIN IMMUNOL, V20, P211, DOI 10.1016/j.coi.2008.04.009
   Okada Hideho, 2015, Lancet Oncol, V16, pe534, DOI 10.1016/S1470-2045(15)00088-1
   Okada H, 2015, CLIN CANCER RES, V21, P286, DOI 10.1158/1078-0432.CCR-14-1790
   Okada H, 2011, J CLIN ONCOL, V29, P330, DOI 10.1200/JCO.2010.30.7744
   Omuro A, 2018, NEURO-ONCOLOGY, V20, P674, DOI 10.1093/neuonc/nox208
   Parney IF, 2000, NEUROSURGERY, V46, P1169, DOI 10.1097/00006123-200005000-00030
   Patel MA, 2014, CANCERS, V6, P1953, DOI 10.3390/cancers6041953
   Phuphanich S, 2013, CANCER IMMUNOL IMMUN, V62, P125, DOI 10.1007/s00262-012-1319-0
   Platten M, 2016, CANCER IMMUNOL IMMUN, V65, P1269, DOI 10.1007/s00262-016-1874-x
   Pollack IF, 2016, NEURO-ONCOLOGY, V18, P1157, DOI 10.1093/neuonc/now026
   Pollack IF, 2014, J CLIN ONCOL, V32, P2050, DOI 10.1200/JCO.2013.54.0526
   Postow MA, 2018, NEW ENGL J MED, V378, P158, DOI 10.1056/NEJMra1703481
   Prins RM, 2011, CLIN CANCER RES, V17, P1603, DOI 10.1158/1078-0432.CCR-10-2563
   Pule MA, 2008, NAT MED, V14, P1264, DOI 10.1038/nm.1882
   Ramos CA, 2014, CANCER J, V20, P112, DOI 10.1097/PPO.0000000000000031
   Rampling R, 2016, CLIN CANCER RES, V22, P4776, DOI 10.1158/1078-0432.CCR-16-0506
   Ranjan S, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4131-1
   Reap EA, 2018, CANCER RES, V78, P256, DOI 10.1158/0008-5472.CAN-17-0469
   Reardon DA, 2015, J CLIN ONCOL S, V33, P2009, DOI DOI 10.1227/01.NEU.0000467069.86811.3F
   Reardon DA, 2017, DISCOV MED, V24, P201
   Reardon DA, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.2042
   Reardon DA, 2016, J CLIN ONCOL, V34, DOI 10.1200/JCO.2016.34.15_suppl.2014
   Reardona DA, 2017, NEURO-ONCOLOGY, V19, P21, DOI 10.1093/neuonc/nox036.071
   Rizvi NA, 2015, SCIENCE, V348, P124, DOI 10.1126/science.aaa1348
   Robert C, 2015, NEW ENGL J MED, V372, P320, DOI 10.1056/NEJMoa1412082
   Sakai K, 2015, J NEUROSURG, V123, P989, DOI 10.3171/2015.1.JNS141554
   Sampson JH, 2010, J CLIN ONCOL, V28, P4722, DOI 10.1200/JCO.2010.28.6963
   Sanchez-Perez LA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059082
   Schaller TH, 2017, EXPERT REV CLIN IMMU, V13, P1049, DOI 10.1080/1744666X.2017.1384313
   Schuessler A, 2014, CANCER RES, V74, P3466, DOI 10.1158/0008-5472.CAN-14-0296
   Schumacher T, 2014, ONCOIMMUNOLOGY, V3, DOI 10.4161/2162402X.2014.974392
   Schuster J, 2015, NEURO-ONCOLOGY, V17, P854, DOI 10.1093/neuonc/nou348
   Sengupta S, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/831090
   Slingluff CL, 2007, CLIN CANCER RES, V13, P6386, DOI 10.1158/1078-0432.CCR-07-0486
   Stepanenko AA, 2016, CANCER CELL INT, V16, DOI 10.1186/s12935-016-0311-8
   Takeshima T, 2010, CANCER RES, V70, P2697, DOI 10.1158/0008-5472.CAN-09-2982
   van Thuijl HF, 2015, ACTA NEUROPATHOL, V129, P597, DOI 10.1007/s00401-015-1403-6
   Vik-Mo EO, 2013, CANCER IMMUNOL IMMUN, V62, P1499, DOI 10.1007/s00262-013-1453-3
   Villanueva-Meyer JE, 2017, NEUROSURGERY, V81, P397, DOI 10.1093/neuros/nyx103
   Vlahovic G, 2015, NEURO-ONCOLOGY, V17, P1043, DOI 10.1093/neuonc/nov071
   Wainwright DA, 2014, CLIN CANCER RES, V20, P5290, DOI 10.1158/1078-0432.CCR-14-0514
   Walter S, 2012, NAT MED, V18, P1254, DOI 10.1038/nm.2883
   Weller M, 2017, LANCET ONCOL, V18, P1373, DOI 10.1016/S1470-2045(17)30517-X
   Wen PY, 2014, NEURO-ONCOLOGY, V16
   Wolchok JD, 2017, NEW ENGL J MED, V377, P1345, DOI 10.1056/NEJMoa1709684
   Yeku OO, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-10940-8
   Yeung JT, 2013, CLIN CANCER RES, V19, P1816, DOI 10.1158/1078-0432.CCR-12-2861
   Yonemori K, 2010, CANCER-AM CANCER SOC, V116, P302, DOI 10.1002/cncr.24735
   Yovino S, 2013, CANCER INVEST, V31, P140, DOI 10.3109/07357907.2012.762780
   Zeng J, 2013, INT J RADIAT ONCOL, V86, P343, DOI 10.1016/j.ijrobp.2012.12.025
   Zhu X, 2017, J NEUROSURG-PEDIATR, V19, P249, DOI 10.3171/2016.8.PEDS16326
   Zou WP, 2005, NAT REV CANCER, V5, P263, DOI 10.1038/nrc1586
NR 117
TC 4
Z9 4
U1 2
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP 397
EP 409
DI 10.1016/j.wneu.2018.12.222
PG 13
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800180
PM 30677574
DA 2020-05-12
ER

PT J
AU Darwazeh, R
   Darwazeh, M
   Kato, Y
   Sbeih, I
   Bakhti, S
   El Abbadi, N
   Sun, XC
   Chao, Y
AF Darwazeh, Rami
   Darwazeh, Mazhar
   Kato, Yoko
   Sbeih, Ibrahim
   Bakhti, Souad
   El Abbadi, Najia
   Sun, Xiaochuan
   Chao, You
TI Georgette Kidess, the First Female Neurosurgeon in Palestine
SO WORLD NEUROSURGERY
LA English
DT Article
DE First female neurosurgeon; Georgette Kidess; History; Neurosurgery;
   Palestine; Women in neurosurgery
ID WOMEN; GENDER; HISTORY; COMMUNICATION; PRODUCTIVITY; FUTURE; WOMAN
AB OBJECTIVE: The aim of this study is to detail the background, training, and career of Dr. Georgette Kidess, the first and still the only female neurosurgeon in Palestine. In addition, we mention the obstacles that women face during their neurosurgical career and how to overcome them. Also, we discuss different methods to attract female medical students to neurosurgery.
   METHODS: Information was gathered only from direct face-to-face interviews with Dr. Kidess.
   RESULTS: Georgette Kidess was born on May 2, 1952, in Nablus, Palestine. She received the degree of Doctor of Medicine (M.D.) at Eberhard Karls Universitat, Tubingen, Germany in 1979. She worked as a neurosurgeon at the Hadassah EinKarem Hospital in Jerusalem and subsequently established the first neurosurgical department at the Ramallah Governmental Hospital in Ramallah in 1986. Thereafter, she has continued a career in private practice, currently at Saint Luke's Hospital, Nablus. Dr. Kidess played a major part in establishing neurosurgery in Palestine. She was among the founders of the Palestinian Neurosurgical Society in 2014.
   CONCLUSIONS: In this article, we recount Dr. Kidess's contributions and achievements to neurosurgery in Palestine. Her commitment, persistence, and diligence enabled her to overcome great odds and become the first female neurosurgeon in Palestine. We hope that her story will inspire and open the doors for subsequent women to enter and enhance neurosurgery, especially in the Middle East.
C1 [Darwazeh, Rami; Chao, You] Sichuan Univ, West China Hosp, Dept Neurosurg, Chengdu, Sichuan, Peoples R China.
   [Darwazeh, Rami; Darwazeh, Mazhar] Arab Womens Union Hosp, Dept Neurosurg, Nablus, Palestine.
   [Kato, Yoko] Fujita Hlth Univ, Dept Neurosurg, Sch Med, Aichi, Japan.
   [Sbeih, Ibrahim] Dept Neurosurg, Farah Med Campus, Amman, Jordan.
   [Bakhti, Souad] Acad Hosp Mustapha Pacha, Pediat Neurosurg Div, Algiers, Algeria.
   [El Abbadi, Najia] Univ Mohammed 5, Hop IbnSina, Fac Med & Pharm, Dept Neurosurg, Rabat, Morocco.
   [Sun, Xiaochuan] Chongqing Med Univ, Affiliated Hosp 1, Dept Neurosurg, Chongqing, Peoples R China.
RP Chao, Y (reprint author), Sichuan Univ, West China Hosp, Dept Neurosurg, Chengdu, Sichuan, Peoples R China.
EM 823882243@qq.com
OI sun, xiao chuan/0000-0001-6992-332X
CR Abosch A, 2018, J NEUROSURG, V129, P277, DOI 10.3171/2018.4.JNS172878
   Awad AJ, 2014, WORLD NEUROSURG, V82, DOI 10.1016/j.wneu.2014.09.022
   Balak N, 2007, ACTA NEUROCHIR, V149, P943, DOI 10.1007/s00701-007-1252-8
   Bean J, 2008, J NEUROSURG, V109, P377, DOI 10.3171/JNS/2008/109/9/0377
   Benzil DL, 2008, J NEUROSURG, V109, P378, DOI 10.3171/JNS/2008/109/9/0378
   Bertakis KD, 2009, PATIENT EDUC COUNS, V76, P356, DOI 10.1016/j.pec.2009.07.022
   Ciurea AV, 2013, WORLD NEUROSURG, V80, P650, DOI 10.1016/j.wneu.2013.02.031
   Corley J, 2018, WORLD NEUROSURG, V111, P130, DOI 10.1016/j.wneu.2017.12.086
   Darwazeh R, 2017, WORLD NEUROSURG, V104, P39, DOI 10.1016/j.wneu.2017.04.150
   Derose KP, 2001, J GEN INTERN MED, V16, P218, DOI 10.1046/j.1525-1497.2001.016004218.x
   Eagly AH, 2003, PSYCHOL BULL, V129, P569, DOI 10.1037/0033-2909.129.4.569
   Gilkes CE, 2008, NEUROSURGERY, V62, P738, DOI 10.1227/01.neu.0000317324.71483.e5
   Jackson VA, 2003, ACAD MED, V78, P328, DOI 10.1097/00001888-200303000-00020
   Julie KS, 2018, JAMA NETW OPEN, V1
   Kato Y, 2004, MINIM INVAS NEUROSUR, V47, P65, DOI 10.1055/s-2004-818470
   Khan NR, 2014, J NEUROSURG, V120, P746, DOI 10.3171/2013.11.JNS131708
   Kitagawa R, 2016, WORLD NEUROSURG, V90, DOI 10.1016/j.wneu.2015.09.102
   Koven S, 2017, NEW ENGL J MED, V376, P1907, DOI 10.1056/NEJMp1702010
   LEVINSON W, 1991, WESTERN J MED, V154, P423
   Mejia-Perez SL, 2017, GAC MED MEX, V153, P279
   McClelland S, 2008, J NATL MED ASSOC, V100, P439, DOI 10.1016/S0027-9684(15)31279-7
   McClelland S, 2007, J NATL MED ASSOC, V99, P1193
   McDermott M, 2018, JAMA NEUROL, V75, P956, DOI 10.1001/jamaneurol.2018.0275
   Renfrow JJ, 2018, NEUROSURGERY, V82, P576, DOI 10.1093/neuros/nyx251
   Renfrow JJ, 2016, J NEUROSURG, V124, P834, DOI 10.3171/2015.3.JNS142313
   Roter DL, 1999, OBSTET GYNECOL, V93, P635, DOI 10.1016/S0029-7844(98)00542-0
   Roter DL, 2002, JAMA-J AM MED ASSOC, V288, P756, DOI 10.1001/jama.288.6.756
   Spetzler Robert F, 2011, Asian J Neurosurg, V6, P6, DOI 10.4103/1793-5482.85627
   Tomei KL, 2014, J CLIN NEUROSCI, V21, P1102, DOI 10.1016/j.jocn.2013.11.006
   Venes JL, 2006, J NEUROSURG, V104, P227, DOI 10.3171/ped.2006.104.4.227
   Woodrow SI, 2006, NEUROSURGERY, V59, P749, DOI 10.1227/01.NEU.0000232671.44297.DF
   Zanon N, 2011, CHILD NERV SYST, V27, P337, DOI 10.1007/s00381-010-1380-y
NR 32
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP 414
EP 422
DI 10.1016/j.wneu.2018.12.163
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800182
PM 30639486
DA 2020-05-12
ER

PT J
AU Karikari, I
   Ghogawala, Z
   Ropper, AE
   Yavin, D
   Gabr, M
   Goodwin, CR
   Abd-El-Barr, M
   Veeravagu, A
   Wang, MC
AF Karikari, Isaac
   Ghogawala, Zoher
   Ropper, Alexander E.
   Yavin, Daniel
   Gabr, Mostafa
   Goodwin, C. Rory
   Abd-El-Barr, Muhammad
   Veeravagu, Anand
   Wang, Marjorie C.
TI Utility of Cervical Collars Following Cervical Fusion Surgery. Does It
   Improve Fusion Rates or Outcomes? A Systematic Review
SO WORLD NEUROSURGERY
LA English
DT Review
DE Anterior cervical; Cervical collar; Cervical fusion; Posterior cervical
ID DISKECTOMY; ORTHOSES
AB BACKGROUND: The use of postoperative cervical collars following cervical fusions is common practice. Its use has been purported to improve fusion rates and outcomes. There is a paucity in the strength of evidence to support its clinical benefit. Our objective is to critically evaluate the published literature to determine the strength of evidence supporting the use of postoperative cervical collar use following cervical fusions.
   METHODS: A systematic review using Preferred Reporting Items for Systematic Reviews and Meta-Analyses (also known as PRISMA) was performed. An online search using Medline and Cochrane Central Register of Controlled Trials databases was used to query prospective and retrospective clinical trials evaluating cervical fusions with or without postoperative collar.
   RESULTS: The search identified 894 articles in Medline and 65 articles in the Cochrane database. From these articles, 130 were selected based on procedure and collar use. Only 3 studies directly compared between collar use and no collar use. Our analysis of the mean improvement in neck disability index scores and improvement over time intervals did not show a statistically significant difference between collar versus no collar (P = 0.86).
   CONCLUSIONS: We found no strong evidence to support the use of cervical collars after 1- and 2-level anterior cervical discectomy and fusion procedures, and no studies comparing collar use and no collar use after posterior cervical fusions. Given the cost and likely impact of collar use on driving and the return to work, our study shows that currently there is no proven benefit to routine use of postoperative cervical collar in patients undergoing 1- and 2-level anterior cervical discectomy and fusion for degenerative cervical pathologies.
C1 [Karikari, Isaac; Gabr, Mostafa; Goodwin, C. Rory; Abd-El-Barr, Muhammad] Duke Univ, Med Ctr, Div Neurosurg, Durham, NC 27710 USA.
   [Ghogawala, Zoher] Yale New Haven Med Ctr, Div Neurosurg, 20 York St, New Haven, CT 06504 USA.
   [Ropper, Alexander E.] Baylor St Lukes Med Ctr, Div Neurosurg, Houston, TX USA.
   [Yavin, Daniel] Univ Calgary, Cumming Sch Med, Div Neurosurg, Calgary, AB, Canada.
   [Veeravagu, Anand] Stanford Univ, Med Ctr, Div Neurosurg, Stanford, CA 94305 USA.
   [Wang, Marjorie C.] Med Coll Wisconsin, Dept Neurosurg, Milwaukee, WI 53226 USA.
RP Karikari, I (reprint author), Duke Univ, Med Ctr, Div Neurosurg, Durham, NC 27710 USA.
EM Isaac.karikari@duke.edu
OI Gabr, Mostafa/0000-0003-2058-2098
CR Abbott A, 2013, PHYSIOTHER THEOR PR, V29, P290, DOI 10.3109/09593985.2012.731627
   Barry CJ, 2003, NEUROSURGERY, V53, P98, DOI 10.1227/01.NEU.0000068703.08923.40
   Benzel EC, 2001, BIOMECHANICS SPINE S, P437
   Bernardo WM, 2017, INT BRAZ J UROL, V43, P383, DOI [10.1590/S1677-5538.IBJU.2017.03.02, 10.1590/s1677-5538.ibju.2017.03.02]
   Bible JE, 2009, SPINE J, V9, P309, DOI 10.1016/j.spinee.2008.06.453
   Camara R, 2016, CUREUS, V8, DOI 10.7759/cureus.688
   Campbell MJ, 2009, SPINE, V34, P43, DOI 10.1097/BRS.0b013e318191895d
   Cauthen JC, 1998, SPINE, V23, P188, DOI 10.1097/00007632-199801150-00008
   Gavin TM, 2003, J REHABIL RES DEV, V40, P527, DOI 10.1682/JRRD.2003.11.0527
   GRIFFITH SL, 1995, J SPINAL DISORD, V8, P429
   Grubb MR, 1998, SPINE, V23, P886, DOI 10.1097/00007632-199804150-00009
   Higgins JP, 2011, COCHRANE COLLABORATI, DOI DOI 10.1002/9780470712184
   Jagannathan J, 2008, J NEUROSURG-SPINE, V8, P420, DOI 10.3171/SPI/2008/8/5/420
   Liberati A, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000100
   LOWERY GL, 1995, SPINE, V20, P2436, DOI 10.1097/00007632-199511001-00012
   Overley SC, 2018, GLOB SPINE J, V8, P40, DOI 10.1177/2192568217697318
   Sandler AJ, 1996, SPINE, V21, P1624, DOI 10.1097/00007632-199607150-00002
   Schneider AM, 2007, SPINE, V32, pE1, DOI 10.1097/01.brs.0000251019.24917.44
   Stambolis V, 2003, DYSPHAGIA, V18, P39, DOI 10.1007/s00455-002-0083-2
   Totten V Y, 1999, Prehosp Emerg Care, V3, P347, DOI 10.1080/10903129908958967
   Webber-Jones Joan E, 2002, Orthop Nurs, V21, P19, DOI 10.1097/00006416-200207000-00004
   Zhang SN, 2005, CLIN BIOMECH, V20, P264, DOI 10.1016/j.clinbiomech.2004.09.015
NR 22
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP 423
EP 429
DI 10.1016/j.wneu.2018.12.066
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800183
PM 30593959
DA 2020-05-12
ER

PT J
AU Kim, J
   Chang, C
   Jung, Y
AF Kim, Jonghoon
   Chang, Chuihoon
   Jung, Youngjin
TI Technical Trick of Combined Embolization of Inaccessible Dural
   Arteriovenous Fistula by Endovascular Route Only
SO WORLD NEUROSURGERY
LA English
DT Article
DE Craniotomy; Dural arteriovenous fistula; Embolization; Therapeutic
ID SINUS; CLASSIFICATION
AB OBJECTIVE: Endovascular embolization of dural arteriovenous fistula may not be a feasible approach depending on the location and/or surrounding structures.
   METHODS: Combined embolization comprising endovascular embolization by direct puncture of the sinus after small craniotomy under fluoroscopic guidance is a good treatment option for lesions that cannot be treated by endovascular embolization alone.
   RESULTS: We presented 2 cases of dural arteriovenous fistula that could not be treated by endovascular embolization alone. Treatment included direct puncture of the sinus after small craniotomy to access and completely block the lesion.
   CONCLUSIONS: Combined techniques are required for the management of complex dural arteriovenous fistula. We report a treatment method that can be used for lesions that cannot be treated by endovascular embolization alone along with some technical pitfalls.
C1 [Kim, Jonghoon; Chang, Chuihoon; Jung, Youngjin] Yeungnam Univ, Med Ctr & Med Sch, Dept Neurosurg, Daegu, South Korea.
RP Jung, Y (reprint author), Yeungnam Univ, Med Ctr & Med Sch, Dept Neurosurg, Daegu, South Korea.
EM jyjns@yu.ac.kr
OI JUNG, Youngjin/0000-0002-9659-2607
FU Yeungnam University
FX This work was supported by the 2014 Yeungnam University Research Grant.
CR BORDEN JA, 1995, J NEUROSURG, V82, P166, DOI 10.3171/jns.1995.82.2.0166
   Cognard C, 2008, AM J NEURORADIOL, V29, P235, DOI 10.3174/ajnr.A0817
   COGNARD C, 1995, RADIOLOGY, V194, P671, DOI 10.1148/radiology.194.3.7862961
   Endo S, 1998, J NEUROSURG, V88, P449, DOI 10.3171/jns.1998.88.3.0449
   Houdart E, 2002, J NEUROSURG, V97, P280, DOI 10.3171/jns.2002.97.2.0280
   Lasjaunias P, 2004, SURG NEUROANGIOGRAPH
   Luo CB, 2007, ACTA NEUROCHIR, V149, P197, DOI 10.1007/s00701-006-0910-6
   Lv X, 2009, AM J NEURORADIOL, V30, P462, DOI 10.3174/ajnr.A1419
   Natarajan SK, 2010, WORLD NEUROSURG, V73, P365, DOI 10.1016/j.wneu.2010.01.009
   Pierot L, 1998, NEUROSURGERY, V42, P194, DOI 10.1097/00006123-199801000-00044
   Pollock BE, 1999, NEUROSURGERY, V45, P459, DOI 10.1097/00006123-199909000-00008
NR 11
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP 430
EP 434
DI 10.1016/j.wneu.2018.09.122
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800184
PM 30266699
DA 2020-05-12
ER

PT J
AU Chen, MG
   Yu, WS
   Sun, SJ
   Dong, CL
   Huang, N
   Mao, L
   Wang, HD
AF Chen, Maogang
   Yu, Wensu
   Sun, Shujie
   Dong, Chenglong
   Huang, Na
   Mao, Lei
   Wang, Handong
TI Stereotactic Aspiration of Necrotic Brain Tissue for Treating Malignant
   Middle Cerebral Artery Infarction: A Report of 13 Consecutive Cases
SO WORLD NEUROSURGERY
LA English
DT Article
DE Decompressive hemicraniectomy; Large hemispheric infarction; Malignant
   middle cerebral artery infarction; Stereotactic aspiration
ID SPONTANEOUS HEMORRHAGIC TRANSFORMATION; HEALTH-CARE PROFESSIONALS;
   DECOMPRESSIVE CRANIECTOMY; ISCHEMIC-STROKE; CONTROLLED-TRIAL;
   HEMICRANIECTOMY; MULTICENTER; PREDICTION; MANAGEMENT; SURGERY
AB BACKGROUND: This study aimed to evaluate the efficacy and safety of stereotactic aspiration of necrotic brain tissue for treating malignant middle cerebral artery infarction (MMI) in patients older than 60 years of age.
   CASE DESCRIPTION: A total of 13 consecutive patients with MMI (mean age, 67 +/- 6.62 years) were enrolled in the study. These patients were treated with stereotactic aspiration of necrotic brain tissue within 72 hours from stroke onset between January 2016 and June 2017. The surgical results and clinical outcomes were evaluated in response to stereotactic aspiration of necrotic brain tissue. The mean preoperative infarction volume in the patients was found to be 153.46 +/- 9.39 mL according to the latest computed tomography scan. The 30-day mortality was 2 out of 13 patients (15.4%). Patients were followed-up for 6 months to evaluate the efficacy of stereotactic aspiration of necrotic brain tissue using the modified Rankin Scale (mRS). Among the 11 surviving surgical patients, 6 (54.5%) had an mRS score of 3 (defined as moderate disability), 4 (36.4%) had an mRS score of 4 (defined as moderate to severe disability), and 1 (9.1%) had an mRS score of 5 (defined as severe disability). The probability of 6-month unfavorable outcome, defined as an mRS score of 5 or 6 (death), was 3 out of 13 (23.1%).
   CONCLUSIONS: Our results suggest the stereotactic aspiration of necrotic brain tissue is an effective and safe method in patients with MMI who are over 60 years of age.
C1 [Chen, Maogang; Mao, Lei; Wang, Handong] Nanjing Univ, Sch Med, Jinling Hosp, Dept Neurosurg, Nanjing, Jiangsu, Peoples R China.
   [Chen, Maogang; Dong, Chenglong; Huang, Na] Xuzhou Med Univ, Yancheng City Peoples Hosp 1, Yancheng Clin Inst, Dept Emergency, Yancheng, Jiangsu, Peoples R China.
   [Yu, Wensu] Xuzhou Med Univ, Yancheng City Peoples Hosp 1, Yancheng Clin Inst, Dept Neurol, Yancheng, Jiangsu, Peoples R China.
   [Sun, Shujie] Chinese Acad Sci, Shanghai Clin Ctr, Neurosurg Dept, Shanghai, Peoples R China.
RP Wang, HD (reprint author), Nanjing Univ, Sch Med, Jinling Hosp, Dept Neurosurg, Nanjing, Jiangsu, Peoples R China.
EM njhdwang@hotmail.com
CR Albers GW, 2016, ANN NEUROL, V79, P76, DOI 10.1002/ana.24543
   Arnaout OM, 2011, NEUROSURG FOCUS, V30, DOI 10.3171/2011.3.FOCUS1160
   Back L, 2015, INTERN MED J, V45, P711, DOI 10.1111/imj.12724
   Bernotas G, 2017, MEDICINA-LITHUANIA, V53, P303, DOI 10.1016/j.medici.2017.07.006
   Chen GJ, 2016, NEUROL RES, V38, P538, DOI 10.1080/01616412.2016.1187864
   Hofmeijer J, 2009, LANCET NEUROL, V8, P326, DOI 10.1016/S1474-4422(09)70047-X
   Huttner HB, 2009, LANCET NEUROL, V8, P949, DOI 10.1016/S1474-4422(09)70224-8
   Juttler E, 2011, INT J STROKE, V6, P79, DOI 10.1111/j.1747-4949.2010.00544.x
   Juttler E, 2007, STROKE, V38, P2518, DOI 10.1161/STROKEAHA.107.485649
   Kurland DB, 2015, NEUROCRIT CARE, V23, P292, DOI 10.1007/s12028-015-0144-7
   Landreneau MM, 2017, SEMIN RESP CRIT CARE, V38, P737, DOI 10.1055/s-0037-1607992
   Neugebauer H, 2014, INT J STROKE, V9, P460, DOI 10.1111/ijs.12211
   Oppenheim C, 2000, STROKE, V31, P2175, DOI 10.1161/01.STR.31.9.2175
   Park J, 2012, ACTA NEUROCHIR, V154, P79, DOI 10.1007/s00701-011-1178-z
   Powers WJ, 2018, STROKE, V49, pE46, DOI 10.1161/STR.0000000000000158
   Staykov D, 2011, STROKE, V42, P513, DOI 10.1161/STROKEAHA.110.605642
   Tan S, 2014, J NEUROL, V261, P905, DOI 10.1007/s00415-014-7297-8
   Thomalla GJ, 2003, STROKE, V34, P1892, DOI 10.1161/01.STR.0000081985.44625.B6
   Thomalla G, 2010, ANN NEUROL, V68, P435, DOI 10.1002/ana.22125
   Torbey MT, 2015, NEUROCRIT CARE, V22, P146, DOI 10.1007/s12028-014-0085-6
   Vahedi K, 2007, STROKE, V38, P2506, DOI 10.1161/STROKEAHA.107.485235
   Vahedi K, 2007, LANCET NEUROL, V6, P215, DOI 10.1016/S1474-4422(07)70036-4
   Wijdicks EFM, 2014, STROKE, V45, P1222, DOI 10.1161/01.str.0000441965.15164.d6
   Zhao JW, 2012, NEUROCRIT CARE, V17, P161, DOI 10.1007/s12028-012-9703-3
NR 24
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP 435
EP 444
DI 10.1016/j.wneu.2018.10.190
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800185
PM 30404052
DA 2020-05-12
ER

PT J
AU Cai, H
   Liu, WJ
   Feng, TD
   Li, Z
   Liu, YH
AF Cai, Heng
   Liu, Wenjing
   Feng, Tianda
   Li, Zhen
   Liu, Yunhui
TI Clinical Presentation and Pathologic Characteristics of Pituitary
   Metastasis from Breast Carcinoma: Cases and a Systematic Review of the
   Literature
SO WORLD NEUROSURGERY
LA English
DT Review
DE Breast cancer; Hyperprolactinemia; Pituitary metastasis; Surgery;
   Treatment
ID CANCER METASTASIS; TUMORS; LESIONS; GLAND
AB BACKGROUND: It is rare for breast carcinoma to metastasize to the pituitary gland; this finding indicates extensive metastasis of the primary tumor.
   CASE DESCRIPTION: Herein, we present a 57-year-old patient with pituitary gland metastasis from breast cancer that was treated with extensive radical mastectomy 16 years prior. The pituitary was the sole site of metastasis. The patient was admitted with the chief complaint of blurred vision for 1 year and episodic headaches for 1 month. Magnetic resonance imaging revealed a solid mass in the sellar region with heterogenous contrast enhancement. The preoperative diagnosis was a pituitary adenoma. Neuroendoscopy-assisted tumor resection was conducted through a single-nostril sphenoid sinus approach. A pinkish-white, firm neoplasm was found, with an abundant blood supply and an indistinct boundary between the neoplasm and normal pituitary tissue; complete resection was achieved. The results of immunohistochemical analysis were positive for cytokeratin, Ki-67 antigen, estrogen receptors, progesterone receptors, and prolactin-induced protein. The neoplasm was negative for spalt-like transcription factor 4, mammaglobin, and the alpha subunit of the glycoprotein hormones. These results were used to reach a final diagnosis of pituitary gland metastasis from a primary breast carcinoma. The patient's vision improved significantly after surgery, and no recurrence was detected during 1 year of follow-up.
   CONCLUSIONS: Pituitary gland metastasis is rare and difficult to differentiate from a pituitary adenoma without a pathologic diagnosis. Surgery is the first choice for treatment. Surgery, radiotherapy, and chemotherapy are combined with endocrine therapy to tailor treatment to the results of immunohistochemistry.
C1 [Cai, Heng; Feng, Tianda; Li, Zhen; Liu, Yunhui] China Med Univ, Shengjing Hosp, Dept Neurosurg, Shenyang, Liaoning, Peoples R China.
   [Liu, Wenjing] China Med Univ, Affiliated Hosp 1, Dept Geriatr, Shenyang, Liaoning, Peoples R China.
RP Liu, YH (reprint author), China Med Univ, Shengjing Hosp, Dept Neurosurg, Shenyang, Liaoning, Peoples R China.
EM sj_neurosurgery@126.com
OI Liu, Yun-hui/0000-0002-6121-2037
FU Natural Science Foundation of ChinaNational Natural Science Foundation
   of China [81702488, 81502181]; Doctoral Research Startup Fund Guidance
   Program Projects of Liaoning Province [20170520020]
FX This work is supported by grants from the Natural Science Foundation of
   China (81702488 and 81502181) and Doctoral Research Startup Fund
   Guidance Program Projects of Liaoning Province (20170520020).
CR Barbaro D, 2013, ENDOCRINE, V43, P485, DOI 10.1007/s12020-012-9806-9
   BRANCH CL, 1987, J CLIN ENDOCR METAB, V65, P469, DOI 10.1210/jcem-65-3-469
   CHIANA MF, 1990, NEUROCHIRURGIA, V33, P127
   Dogan M., 2008, Experimental Oncology, V30, P324
   DUCHEN LW, 1966, J PATHOL BACTERIOL, V91, P347, DOI 10.1002/path.1700910208
   Fortunati N, 2015, ONCOL LETT, V9, P2762, DOI 10.3892/ol.2015.3149
   Gilard V, 2016, J NEURO-ONCOL, V126, P219, DOI 10.1007/s11060-015-1967-y
   Gormally JF, 2014, BMJ CASE REP
   GURLING KJ, 1957, BRIT J CANCER, V11, P519, DOI 10.1038/bjc.1957.63
   He WZ, 2015, PITUITARY, V18, P159, DOI 10.1007/s11102-014-0552-2
   Javanbakht A, 2018, ENDOCR CONNECT, V7, P1049, DOI 10.1530/EC-18-0338
   Kam J, 2017, ASIA-PAC J CLIN ONCO, V13, pE181, DOI 10.1111/ajco.12353
   Lin EY, 2008, MINIM INVAS NEUROSUR, V51, P222, DOI 10.1055/s-2008-1062742
   Magalhaes JF, 2014, ARQ BRAS ENDOCRINOL, V58, P869, DOI 10.1590/0004-2730000002950
   Mao JF, 2011, J POSTGRAD MED, V57, P302, DOI 10.4103/0022-3859.90080
   Naqi R, 2012, J PAK MED ASSOC, V62, P169
   Park Y, 2016, CANCER RES TREAT, V48, P403, DOI 10.4143/crt.2014.165
   Peppa Melpomeni, 2009, Clin Breast Cancer, V9, pE4, DOI 10.3816/CBC.2009.n.047
   Ravnik J, 2016, NEUROL NEUROCHIR POL, V50, P511, DOI 10.1016/j.pjnns.2016.08.007
   Saeger W, 2007, EUR J ENDOCRINOL, V156, P203, DOI 10.1530/eje.1.02326
   Spinelli GP, 2012, WORLD J SURG ONCOL, V10, DOI 10.1186/1477-7819-10-137
   Tanaka T, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1831-7
   Turaka Aruna, 2012, Tumori, V98, pe1, DOI 10.1700/1053.11520
   Vianello F, 2011, THYROID, V21, P921, DOI 10.1089/thy.2010.0335
   Wendel C, 2017, AM J CASE REP, V18, P7, DOI 10.12659/AJCR.901032
   Zacharia BE, 2015, WORLD NEUROSURG, V84, P1267, DOI 10.1016/j.wneu.2015.05.061
NR 26
TC 1
Z9 1
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP 445
EP +
DI 10.1016/j.wneu.2018.12.126
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800186
PM 30630045
DA 2020-05-12
ER

PT J
AU Mobbs, RJ
   Parr, WCH
   Choy, WJ
   McEvoy, A
   Walsh, WR
   Phan, K
AF Mobbs, Ralph J.
   Parr, William C. H.
   Choy, Wen Jie
   McEvoy, Aidan
   Walsh, William R.
   Phan, Kevin
TI Anterior Lumbar Interbody Fusion Using a Personalized Approach: Is
   Custom the Future of Implants for Anterior Lumbar Interbody Fusion
   Surgery?
SO WORLD NEUROSURGERY
LA English
DT Article
DE 3D printed spine implant; Additive manufacturing; ALIF; Custom device;
   Patient-specific implant; Spine surgery
ID FINITE-ELEMENT-ANALYSIS; 3D; BONE; MODEL; RECONSTRUCTION; INTEGRATION;
   BEHAVIOR; DESIGN; END
AB BACKGROUND: Spine surgery has the potential to benefit from the use of three-dimensional (3D) printing technology (additive manufacturing), particularly in cases of complex anatomic diseases. Custom devices have the potential to reduce operative times, reduce blood loss, provide immediate stability, and improve fusion rates.
   CASE DESCRIPTION: A 34-year-old man presented with 3-year history of bilateral L5 radiculopathy caused by bilateral L5 pars defect, L5/S1 degenerative disc disease, and severe foraminal stenosis. Anterior lumbar interbody fusion surgery was determined to be the most efficacious method for distraction of the disc space to increase the foraminal volume and stabilization of the motion segment. Surgical decompression and reconstruction was performed in combination with a 3D printed custom interbody implant. Custom design features included corrective angulation to restore lumbar lordosis, preplanned screw holes in the 3D implant, and device end plate interface geometry designed to shape-match with the patient's end plate anatomy.
   CONCLUSIONS: The use of patient-specific implants has reduced operative time significantly, which may offset costs of increased time spent preplanning the procedure. Surgical procedures can be preplanned using 3D models reconstructed from patient computed tomography and/or magnetic resonance imaging scans. Planning can be aided by 3D printed models of patient anatomy, which surgeons can use in training before performing complex procedures. When considering implants and prostheses, the use of 3D printing allows a superior anatomic fit for the patient compared with generic devices, with the potential to improve restoration of nonpathologic anatomy.
C1 [Mobbs, Ralph J.; Parr, William C. H.; Choy, Wen Jie; Walsh, William R.; Phan, Kevin] UNSW, Fac Med, Sydney, NSW, Australia.
   [Mobbs, Ralph J.; Choy, Wen Jie; Phan, Kevin] NeuroSpine Surg Res Grp NSURG, Sydney, NSW, Australia.
   [Mobbs, Ralph J.; Phan, Kevin] Prince Wales Hosp, Dept Neurosurg, Sydney, NSW, Australia.
   [Parr, William C. H.; Choy, Wen Jie; Walsh, William R.] UNSW, Surg & Orthopaed Res Labs S&ORL, Sydney, NSW, Australia.
   [Parr, William C. H.] 3DMorphic, Sydney, NSW, Australia.
   [McEvoy, Aidan] Matrix Med Innovat, Sydney, NSW, Australia.
   [Phan, Kevin] Univ Sydney, Fac Med, Sydney, NSW, Australia.
RP Mobbs, RJ (reprint author), UNSW, Fac Med, Sydney, NSW, Australia.; Mobbs, RJ (reprint author), NeuroSpine Surg Res Grp NSURG, Sydney, NSW, Australia.; Mobbs, RJ (reprint author), Prince Wales Hosp, Dept Neurosurg, Sydney, NSW, Australia.
EM r.mobbs@unsw.edu.au
OI Choy, Wen Jie/0000-0001-8929-8170
CR 3DSystems, SOLUTIONS
   American Society for Testing and Materials, 2011, F226704 AM SOC TEST
   Aquilina P, 2015, CRANIOMAX TRAUM REC, V8, P111, DOI 10.1055/s-0034-1395385
   Ayoub AF, 2014, INT J ORAL MAX SURG, V43, P454, DOI 10.1016/j.ijom.2013.08.016
   Birnbaum K, 2001, SPINE, V26, P365, DOI 10.1097/00007632-200102150-00012
   Brentel Aline Scalone, 2006, J. Appl. Oral Sci., V14, P213, DOI 10.1590/S1678-77572006000300013
   Choy WJ, 2017, WORLD NEUROSURG, V105, DOI 10.1016/j.wneu.2017.05.133
   D'Urso PS, 1999, J CRANIO MAXILL SURG, V27, P30, DOI 10.1016/S1010-5182(99)80007-9
   D'Urso PS, 2005, SPINE, V30, P2841, DOI 10.1097/01.brs.0000190886.56895.3d
   D'Urso PS, 1999, SPINE, V24, P1247, DOI 10.1097/00007632-199906150-00013
   DALTON JE, 1995, J BONE JOINT SURG AM, V77A, P97, DOI 10.2106/00004623-199501000-00012
   Dean D, 2003, J CRANIOFAC SURG, V14, P819, DOI 10.1097/00001665-200311000-00002
   Denoziere G, 2006, J BIOMECH, V39, P766, DOI 10.1016/j.jbiomech.2004.07.039
   Ernstberger T, 2007, EUR SPINE J, V16, P179, DOI 10.1007/s00586-006-0064-5
   Evans SP, 2012, J BIOMECH, V45, P2702, DOI 10.1016/j.jbiomech.2012.08.003
   Giang G, 2017, WORLD NEUROSURG, V104, P259, DOI 10.1016/j.wneu.2017.05.011
   Grant JP, 2001, SPINE, V26, P889, DOI 10.1097/00007632-200104150-00012
   Gross BC, 2014, ANAL CHEM, V86, P3240, DOI 10.1021/ac403397r
   Hull C. W, 1986, Patent, Patent No. [4575330, 4575330A]
   Izatt MT, 2007, EUR SPINE J, V16, P1507, DOI 10.1007/s00586-006-0289-3
   Kim BJ, 2012, J KOREAN NEUROSURG S, V52, P541, DOI 10.3340/jkns.2012.52.6.541
   Klein GT, 2013, WORLD NEUROSURG, V80, P233, DOI 10.1016/j.wneu.2013.07.009
   Knox K, 2005, CATHETER CARDIO INTE, V65, P47, DOI 10.1002/ccd.20333
   Kurtz SM, 2007, BIOMATERIALS, V28, P4845, DOI 10.1016/j.biomaterials.2007.07.013
   Long M, 1998, BIOMATERIALS, V19, P1621, DOI 10.1016/S0142-9612(97)00146-4
   Malik HH, 2015, J SURG RES, V199, P512, DOI 10.1016/j.jss.2015.06.051
   Martelli N, 2016, SURGERY, V159, P1485, DOI 10.1016/j.surg.2015.12.017
   Mironov V, 2003, TRENDS BIOTECHNOL, V21, P157, DOI 10.1016/S0167-7799(03)00033-7
   Mobbs Ralph J, 2017, J Spine Surg, V3, P429, DOI 10.21037/jss.2017.09.02
   Mobbs RJ, 2017, J NEUROSURG-SPINE, V26, P513, DOI 10.3171/2016.9.SPINE16371
   Morgan EF, 2001, J BIOMECH, V34, P569, DOI 10.1016/S0021-9290(01)00011-2
   Mower TM, 2016, MAT SCI ENG A-STRUCT, V651, P198, DOI 10.1016/j.msea.2015.10.068
   Niinomi M, 1998, MAT SCI ENG A-STRUCT, V243, P231, DOI 10.1016/S0921-5093(97)00806-X
   Olivares-Navarrete R, 2012, SPINE J, V12, P265, DOI 10.1016/j.spinee.2012.02.002
   Parr WCH, 2013, J BIOMECH, V46, P200, DOI 10.1016/j.jbiomech.2012.11.011
   Parr WCH, 2012, J THEOR BIOL, V301, P1, DOI 10.1016/j.jtbi.2012.01.030
   Parr WCH, 2016, EVOL BIOL, V43, P171, DOI 10.1007/s11692-016-9371-x
   Phan Kevin, 2016, J Spine Surg, V2, P314, DOI 10.21037/jss.2016.12.06
   Phan K, 2016, J CLIN NEUROSCI, V24, P138, DOI 10.1016/j.jocn.2015.07.017
   Rao Prashanth J, 2017, J Spine Surg, V3, P168, DOI 10.21037/jss.2017.05.03
   Roy ME, 1999, J BIOMED MATER RES, V44, P191, DOI 10.1002/(SICI)1097-4636(199902)44:2<191::AID-JBM9>3.3.CO;2-7
   Ruffo M, 2006, P I MECH ENG B-J ENG, V220, P1417, DOI 10.1243/09544054JEM517
   Schubert C, 2014, BRIT J OPHTHALMOL, V98, P159, DOI 10.1136/bjophthalmol-2013-304446
   Sidambe AT, 2014, MATERIALS, V7, P8168, DOI 10.3390/ma7128168
   Simmons CA, 1999, J BIOMED MATER RES, V47, P127, DOI 10.1002/(SICI)1097-4636(199911)47:2<127::AID-JBM3>3.0.CO;2-C
   Suh PB, 2015, SPINE J, V15, pS178
   Tack P, 2016, BIOMED ENG ONLINE, V15, DOI 10.1186/s12938-016-0236-4
   TAKATSUKA K, 1995, J BIOMED MATER RES, V29, P157, DOI 10.1002/jbm.820290204
   Tan CJ, 2017, J BIOMECH ENG-T ASME, V139, DOI 10.1115/1.4037558
   Teng I, 2017, J CLIN NEUROSCI, V44, P11, DOI 10.1016/j.jocn.2017.06.013
   ter Gunne AFP, 2009, SPINE, V34, P1422, DOI 10.1097/BRS.0b013e3181a03013
   Therapeutic Goods Administration, 2002, THER GOODS MED DEV R
   Turney BW, 2014, J ENDOUROL, V28, P360, DOI 10.1089/end.2013.0616
   Ventola C Lee, 2014, P T, V39, P704
   Wilcox Ben, 2017, J Spine Surg, V3, P433, DOI 10.21037/jss.2017.09.01
   Xu NF, 2016, SPINE, V41, pE50, DOI 10.1097/BRS.0000000000001179
NR 56
TC 6
Z9 6
U1 4
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP 452
EP +
DI 10.1016/j.wneu.2018.12.144
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800187
PM 30633990
DA 2020-05-12
ER

PT J
AU Orlov, K
   Arat, A
   Osiev, A
   Berestov, V
   Aytemir, K
   Topcuoglu, MA
   Arsava, EM
AF Orlov, Kirill
   Arat, Anil
   Osiev, Alexander
   Berestov, Vadim
   Aytemir, Kudret
   Topcuoglu, Mehmet Akif
   Arsava, Ethem Murat
TI Transvenous Treatment of Carotid Aneurysms Through Transseptal Access
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cerebral aneurysm; Dissecting aneurysm; Endovascular treatment; Flow
   diverter; Transseptal access; Transvenous approach
ID CEREBROVASCULAR INJURY; ARTERY DISSECTION; PUNCTURE
AB BACKGROUND: Transseptal puncture has been widely used by cardiologists to reach the left side of the heart through a transvenous access. Rarely, it also can be used to pass into the supra-aortic arteries from the venous side when conventional transarterial access pathways (transfemoral, transradial/brachial routes, or direct carotid puncture) are likely to fail.
   CASE DESCRIPTION: We report 2 cases of transvenous femoral access followed by transseptal access to aorta to treat dissecting carotid artery aneurysms at the level of the skull base with flow diverters. In one case, multiple cervical arterial bypass operations and in the other a rare anomaly of the aortic arch precluded endovascular treatment through conventional routes.
   CONCLUSIONS: Transvenous-transseptal access enabled treatment of both cases easily and without complications. On follow-up computed tomography angiograms, both flow diverters were patent, there were no residual aneurysms, and no neurologic or cardiac adverse events in either patient.
C1 [Orlov, Kirill; Berestov, Vadim] EN Meshalkin Siberian Fed Biomed Res Ctr, Novosibirsk, Russia.
   [Orlov, Kirill] Novosibirsk State Med Univ, Novosibirsk, Russia.
   [Arat, Anil] Hacettepe Univ Hosp, Dept Radiol, Ankara, Turkey.
   [Osiev, Alexander] Moscow Reg Res & Clin Inst MONIKI, Moscow, Russia.
   [Aytemir, Kudret] Hacettepe Univ Hosp, Dept Cardiol, HUTF Kardiyol ABD, Ankara, Turkey.
   [Topcuoglu, Mehmet Akif; Arsava, Ethem Murat] Hacettepe Univ Hosp, Dept Neurol, HUTF Norol ABD, Ankara, Turkey.
RP Arat, A (reprint author), Hacettepe Univ Hosp, Dept Radiol, Ankara, Turkey.
EM anilarat@hotmail.com
OI arat, anil/0000-0001-7122-4675
CR Brzezicki G, 2016, J NEUROINTERV SURG, V8, DOI 10.1136/neurintsurg-2015-011653
   Das R, 2011, CARDIOVASC INTER RAD, V34, P723, DOI 10.1007/s00270-010-9981-0
   Dorfer C, 2012, WORLD NEUROSURG, V77, P192, DOI 10.1016/j.wneu.2010.11.007
   Foreman PM, 2017, CEREBROVASC DIS EXTR, V7, P72, DOI 10.1159/000455391
   Foreman PM, 2014, J NEUROSURG, V120, P1437, DOI 10.3171/2014.3.JNS131959
   Galyfos George, 2016, Vasc Specialist Int, V32, P1, DOI 10.5758/vsi.2016.32.1.1
   Iosif C, 2013, J NEURORADIOLOGY, V40, P130, DOI 10.1016/j.neurad.2012.05.002
   Jolly SS, 2011, LANCET, V377, P1409, DOI 10.1016/S0140-6736(11)60404-2
   Joseph G, 1997, CATHETER CARDIO DIAG, V40, P416
   Joseph G, 2015, J ENDOVASC THER, V22, P385, DOI 10.1177/1526602815583647
   Kataria V, 2017, BIOMED RES INT, DOI 10.1155/2017/2351925
   Lehrmann H, 2014, J CARDIOVASC ELECTR, V25, P479, DOI 10.1111/jce.12356
   Peitz Geoffrey W, 2017, J Vasc Interv Neurol, V9, P42
   Razak A, 2014, J NEUROIMAGING, V24, P298, DOI 10.1111/j.1552-6569.2012.00759.x
   Seth R, 2013, AM J NEURORADIOL, V34, P1219, DOI 10.3174/ajnr.A3337
   Shin DS, 2016, J NEUROL SURG PART A, V77, P505, DOI 10.1055/s-0036-1584511
   Spanos K, 2016, INJURY, V47, P307, DOI 10.1016/j.injury.2015.09.015
   Todo T, 2012, ANN VASC SURG, V26, DOI 10.1016/j.avsg.2011.12.005
   Xianjun Huang, 2013, Interv Neurol, V1, P164, DOI 10.1159/000353124
   Yilbas AA, 2018, REV BRAS ANESTESIOL, V68, P194, DOI [10.1016/j.bjane.2015.09.004, 10.1016/j.bjan.2016.12.003]
   Yoon YS, 2000, J INVASIVE CARDIOL, V12, P70
NR 21
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP 459
EP +
DI 10.1016/j.wneu.2018.12.207
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800188
PM 30660893
DA 2020-05-12
ER

PT J
AU Morgenstern, PF
   Ivasyk, I
   Anand, VK
   Schwartz, TH
AF Morgenstern, Peter F.
   Ivasyk, Iryna
   Anand, Vijay K.
   Schwartz, Theodore H.
TI The Evolution of Endoscopic Skull Base Surgery Outcomes: Defining the
   Edge of the Envelope
SO WORLD NEUROSURGERY
LA English
DT Article
DE Craniotomy; Endoscopic endonasal approach; Skull base surgery; Skull
   base tumor
ID TUBERCULUM SELLAE MENINGIOMA; SINGLE-CENTER EXPERIENCE; EXTENDED
   TRANSSPHENOIDAL APPROACH; OPEN TRANSCRANIAL RESECTION; ENDONASAL
   APPROACH; OLFACTORY NEUROBLASTOMA; SURGICAL TECHNIQUE; MICROSURGICAL
   RESECTION; PEDIATRIC CRANIOPHARYNGIOMA; CRANIOFACIAL RESECTION
AB BACKGROUND: Endoscopic skull base surgery is a relatively new approach in the neurosurgical armamentarium and its usefulness is still being explored. As the field has evolved, so too have the results. For this reason, it is important to re-examine the outcomes of surgery for a variety of diseases individually over time to determine the appropriate indications for these approaches.
   METHODS: We performed a systematic review of recent literature (since 2012) of all studies using the endoscopic endonasal approach (EEA) for craniopharyngioma, olfactory groove, planum sphenoidale, tuberculum sellae meningioma, esthesioneuroblastoma, chordoma, and chondrosarcoma and discuss outcomes compared with a transcranial approach (TCA). These results are also compared with a series of reviews of the literature that were performed before 2012 to see how results have evolved over time.
   RESULTS: For chordomas, craniopharyngioma and planum sphenoidale/tuberculum sellae meningiomas, EEA has shown superior outcomes to TCA for well-selected cases. Olfactory groove meningiomas still have a better outcome when performed using TCA. Esthesioneuroblastoma requires consideration of tumor stage and extent to select the appropriate approach, although with time, more advanced tumors have become approachable with EEA. Chondrosarcoma is a rare lesion that may be resectable by EEA when anatomy is favorable, although its rarity makes comparison difficult.
   CONCLUSIONS: Advances in EEA make it a useful tool that is at times superior to TCA for specific diseases based on recently published literature reporting rates of resection and complications. Ongoing re-evaluation of outcomes is essential to providing the best information to surgeons choosing an approach in each patient.
C1 [Morgenstern, Peter F.; Ivasyk, Iryna; Anand, Vijay K.; Schwartz, Theodore H.] New York Presbyterian Weill Cornell Med, Dept Neurol Surg, New York, NY 10065 USA.
RP Schwartz, TH (reprint author), New York Presbyterian Weill Cornell Med, Dept Neurol Surg, New York, NY 10065 USA.
EM schwarh@med.cornell.edu
RI Schwartz, Theodore/AAK-3320-2020
CR Abou-Al-Shaar H, 2016, WORLD NEUROSURG, V95, DOI 10.1016/j.wneu.2016.08.044
   Ali ZS, 2013, CHILD NERV SYST, V29, P2065, DOI 10.1007/s00381-013-2153-1
   Alli S, 2016, J NEURO-ONCOL, V130, P299, DOI 10.1007/s11060-016-2147-4
   Almefty K, 2007, CANCER-AM CANCER SOC, V110, P2457, DOI 10.1002/cncr.23073
   Arifin Muhammad Zafrullah, 2012, Asian J Neurosurg, V7, P21, DOI 10.4103/1793-5482.95691
   Attia M, 2012, NEUROSURGERY, V71, P58, DOI 10.1227/NEU.0b013e318258e23d
   Bakhsheshian J, 2016, NEUROSURG FOCUS, V41, DOI 10.3171/2016.8.FOCUS16268
   Bal E, 2016, WORLD NEUROSURG, V94, P375, DOI 10.1016/j.wneu.2016.07.004
   Baldauf J, 2015, NEUROSURG CLIN N AM, V26, P363, DOI 10.1016/j.nec.2015.03.013
   Bander ED, 2018, J NEUROSURG, V128, P40, DOI 10.3171/2016.9.JNS16823
   Banu MA, 2016, J NEUROSURG, V124, P605, DOI 10.3171/2015.1.JNS141884
   Barkhoudarian G, 2014, WORLD NEUROSURG, V82, pS138, DOI 10.1016/j.wneu.2014.07.017
   Barzo P, 2018, WORLD NEUROSURG, V109, P1, DOI 10.1016/j.wneu.2017.08.162
   Bosnjak R, 2013, RADIOL ONCOL, V47, P266, DOI 10.2478/raon-2013-0036
   Bowers CA, 2011, NEUROSURG FOCUS, V30, DOI 10.3171/2011.2.FOCUS1115
   Candido DNC, 2018, J NEUROL SURG PART B, V79, pS221, DOI 10.1055/s-0038-1623528
   Cavallo LM, 2014, J NEUROSURG, V121, P100, DOI 10.3171/2014.3.JNS131521
   Chang Chin-Fang, 2015, Ear Nose Throat J, V94, pE30
   Chen LH, 2011, CLIN NEUROL NEUROSUR, V113, P39, DOI 10.1016/j.clineuro.2010.08.019
   Chen X, 2017, EJSO-EUR J SURG ONC, V43, P1718, DOI 10.1016/j.ejso.2017.05.022
   Cheng J, 2017, J CRANIOFAC SURG, V28, pE591, DOI 10.1097/SCS.0000000000003920
   Chibbaro S, 2014, NEUROSURG REV, V37, P224
   Chibbaro S, 2014, NEUROSURG REV, V37, P217, DOI 10.1007/s10143-013-0503-9
   Chowdhury FH, 2012, BRIT J NEUROSURG, V26, P692, DOI 10.3109/02688697.2012.673648
   Conger AR, 2014, NEUROSURG FOCUS, V37, DOI 10.3171/2014.7.FOCUS14364
   Cote DJ, 2015, WORLD NEUROSURG, V84, P899, DOI 10.1016/j.wneu.2015.05.019
   Curey S, 2012, J NEUROSURG, V117, P1013, DOI 10.3171/2012.9.JNS12167
   de Divitiis E, 2008, NEUROSURGERY, V62, P556, DOI 10.1227/01.neu.0000317303.93460.24
   de Gabory L, 2018, HEAD NECK S1, V22, P1
   Dhandapani S, 2017, J NEUROSURG, V126, P418, DOI 10.3171/2016.1.JNS152238
   Dhandapani S, 2015, CUREUS, V7, DOI 10.7759/cureus.311
   Dho YS, 2018, J NEUROSURG, V129, P611, DOI 10.3171/2017.4.JNS162143
   Ditzel LFS, 2015, NEUROSURG CLIN N AM, V26, P453, DOI 10.1016/j.nec.2015.03.008
   Dogan I, 2018, J NEUROL SURG PART B, V79, pS218, DOI 10.1055/s-0037-1620254
   Feng L, 2015, CLIN NEUROL NEUROSUR, V138, P94, DOI 10.1016/j.clineuro.2015.08.006
   Fernandez-Miranda Juan C, 2012, J Neurosurg, V32 Suppl, pE8
   Frank G, 2006, NEUROSURGERY, V59, P50, DOI 10.1227/01.NEU.0000219914.17221.55
   Frank G, 2010, WORLD NEUROSURG, V73, P625, DOI 10.1016/j.wneu.2010.05.031
   Fu TS, 2016, HEAD NECK-J SCI SPEC, V38, pE2306, DOI 10.1002/hed.24233
   Gallia GL, 2012, J CLIN NEUROSCI, V19, P1478, DOI 10.1016/j.jocn.2012.03.011
   Gerganov V, 2014, J NEUROSURG, V120, P559, DOI 10.3171/2013.9.JNS122133
   Graffeo CS, 2014, PITUITARY, V17, P349, DOI 10.1007/s11102-013-0508-y
   Gu Y, 2015, J NEUROSURG, V122, P1166, DOI 10.3171/2015.1.JNS132842
   Gui SB, 2016, NEUROSURG REV, V39, P321, DOI 10.1007/s10143-015-0696-1
   Hannequin P, 2015, NEUROCHIRURGIE, V61, P318, DOI 10.1016/j.neuchi.2015.06.002
   Harvey RJ, 2017, HEAD NECK-J SCI SPEC, V39, P2425, DOI 10.1002/hed.24912
   Hasegawa H, 2017, J NEUROSURG, V19, P1
   Hayhurst C, 2016, TURK NEUROSURG, V26, P662, DOI 10.5137/1019-5149.JTN.16105-15.3
   Heery CR, 2016, ONCOL THER, V4, P35, DOI 10.1007/s40487-016-0016-0
   Herr MW, 2014, J NEUROL SURG PART B, V75, P58, DOI 10.1055/s-0033-1356493
   Higgins TS, 2011, INT FORUM ALLERGY RH, V1, P255, DOI 10.1002/alr.20051
   Hwang CS, 2017, J CRANIO MAXILL SURG, V45, P120, DOI 10.1016/j.jcms.2016.10.004
   Hyun SJ, 2018, OPER NEUROSURG, V14, P112, DOI 10.1093/ons/opx082
   Jahangiri A, 2015, NEUROSURGERY, V76, P179, DOI 10.1227/NEU.0000000000000611
   Jahangiri A, 2014, J NEUROSURG, V121, P67, DOI 10.3171/2014.3.JNS131532
   Jeswani S, 2016, J NEUROSURG, V124, P627, DOI 10.3171/2015.3.JNS142254
   Khan OH, 2014, NEUROSURG FOCUS, V37, DOI 10.3171/2014.7.FOCUS14321
   Kim SK, 2014, ACTA NEUROCHIR, V156, P1917, DOI 10.1007/s00701-014-2150-5
   Kim Y, 2018, J THERM ANAL CALORIM, V133, P737, DOI 10.1007/s10973-017-6778-2
   Komotar RJ, 2013, WORLD NEUROSURG, V80, P148, DOI 10.1016/j.wneu.2012.12.003
   Komotar RJ, 2012, WORLD NEUROSURG, V77, P713, DOI 10.1016/j.wneu.2011.08.025
   Komotar RJ, 2012, WORLD NEUROSURG, V77, P329, DOI 10.1016/j.wneu.2011.07.011
   Komotar RJ, 2011, WORLD NEUROSURG, V76, P318, DOI 10.1016/j.wneu.2011.02.026
   Konig M, 2018, NEUROSURG REV, V41, P323, DOI 10.1007/s10143-017-0859-3
   Koutourousiou M, 2014, NEUROSURG FOCUS, V37, DOI 10.3171/2014.7.FOCUS14330
   Koutourousiou M, 2013, J NEUROSURG, V119, P1194, DOI 10.3171/2013.6.JNS122259
   Koutourousiou M, 2012, NEUROSURGERY, V71, P614, DOI 10.1227/NEU.0b013e31825ea3e0
   Kshettry VR, 2016, NEUROSURG FOCUS, V41, DOI 10.3171/2016.9.FOCUS16292
   Labidi M, 2016, J NEUROSURG SCI, V60, P476
   Li D, 2018, WORLD NEUROSURG, V109, pE517, DOI 10.1016/j.wneu.2017.10.013
   Lin Y, 2017, PEDIATR NEUROSURG, V52, P155, DOI 10.1159/000455919
   Liu JK, 2018, J NEUROL SURG PART B, V79, pS213, DOI 10.1055/s-0037-1606553
   Liu JK, 2016, NEUROSURG FOCUS, V41, DOI 10.3171/2016.9.FOCUS16284
   Lobo Bjorn, 2015, Surg Neurol Int, V6, P82, DOI 10.4103/2152-7806.157442
   Lund VJ, 2015, RHINOLOGY, V53, P204, DOI [10.4193/Rhin14.318, 10.4193/Rhino14.318]
   Makarenko S, 2017, J NEUROSURG, V126, P1191, DOI 10.3171/2016.3.JNS152307
   Mangussi-Gomes J, 2016, OTOLARYNG CLIN N AM, V49, P167, DOI 10.1016/j.otc.2015.09.011
   Manthuruthil C, 2016, WORLD NEUROSURG, V90, P1, DOI 10.1016/j.wneu.2016.02.035
   Margalit N, 2013, J NEUROL SURG PART B, V74, P247, DOI 10.1055/s-0033-1342920
   Pascual JM, 2014, NEUROSURG FOCUS, V36, DOI 10.3171/2014.2.FOCUS13567
   Marx S, 2018, J NEUROSURG, V128, P32, DOI 10.3171/2016.11.JNS16713
   Matsuo T, 2014, NEUROL MED-CHIR, V54, P974, DOI 10.2176/nmc.oa.2014-0038
   Maurer AJ, 2015, J NEUROL SURG REP, V76, P113, DOI 10.1055/s-0035-1549222
   Mays AC, 2017, LARYNGOSCOPE, V9, P317
   McMaster ML, 2001, CANCER CAUSE CONTROL, V12, P1, DOI 10.1023/A:1008947301735
   Mehta GU, 2018, ACTA NEUROCHIR, V160, P361, DOI 10.1007/s00701-017-3437-0
   Mesquita PM, 2014, NEUROSURG FOCUS, V37, DOI 10.3171/2014.7.FOCUS14349
   Messerer M, 2016, NEUROCHIRURGIE, V62, P136, DOI 10.1016/j.neuchi.2015.12.003
   Mohindra S, 2014, INDIAN J OTOLARYNGOL, V66, P241, DOI 10.1007/s12070-013-0633-y
   Mortazavi MM, 2016, WORLD NEUROSURG, V86, P270, DOI [10.1016/J.WNEU.2015.09.043, 10.1016/j.wneu.2015.09.043]
   Moussazadeh N, 2016, NEUROSURG FOCUS, V41, DOI 10.3171/2016.9.FOCUS16299
   Moussazadeh N, 2015, J NEUROSURG, V122, P735, DOI 10.3171/2014.11.JNS14827
   Nishioka H, 2016, WORLD NEUROSURG, V91, P266, DOI 10.1016/j.wneu.2016.04.042
   Ogawa Y, 2012, ACTA NEUROCHIR, V154, P621, DOI 10.1007/s00701-011-1266-0
   Omay SB, 2018, J NEUROSURG, V129, P642, DOI 10.3171/2017.6.JNS163188
   Ottenhausen M, 2018, NEUROSURG FOCUS, V44, DOI 10.3171/2018.1.FOCUS17734
   Ottenhausen M, 2014, WORLD NEUROSURG, V82, P442, DOI 10.1016/j.wneu.2014.03.032
   Park HR, 2017, WORLD NEUROSURG, V103, P465, DOI 10.1016/j.wneu.2017.04.047
   Patel SG, 2012, J NEUROL SURG PART B, V73, P208, DOI 10.1055/s-0032-1311754
   Patel VS, 2017, WORLD NEUROSURG, V108, P6, DOI 10.1016/j.wneu.2017.08.058
   Rahme RJ, 2018, WORLD NEUROSURG, V110, pE231, DOI 10.1016/j.wneu.2017.10.146
   Raza SM, 2017, OPER NEUROSURG HAGER, V40, P818
   Rimmer J, 2014, LARYNGOSCOPE, V124, P1542, DOI 10.1002/lary.24562
   Rogers EM, 2003, DIFFUSION INNOVATION
   Ruggeri AG, 2016, WORLD NEUROSURG, V88, P374, DOI 10.1016/j.wneu.2015.11.002
   Rustemi O, 2018, J NEUROL SURG PART B, V79, pS225, DOI 10.1055/s-0037-1620245
   Sakata K, 2016, WORLD NEUROSURG, V89, P240, DOI 10.1016/j.wneu.2016.02.019
   Samii A, 2009, NEUROSURG REV, V32, P67, DOI 10.1007/s10143-008-0170-4
   Sankhla SK, 2015, J PEDIATR NEUROSCI, V10, P308, DOI 10.4103/1817-1745.174457
   Sbaihat A, 2013, ANN OTO RHINOL LARYN, V122, P763, DOI 10.1177/000348941312201206
   Schroeder HWS, 2014, WORLD NEUROSURG, V82, pS81, DOI 10.1016/j.wneu.2014.07.030
   Shetty SR, 2017, ACTA NEUROCHIR, V159, P1875, DOI 10.1007/s00701-017-3303-0
   Shidoh S, 2014, NEUROL MED-CHIR, V54, P991, DOI 10.2176/nmc.st.2014-0135
   Shimony N, 2017, ACTA NEUROCHIR, V159, P1835, DOI 10.1007/s00701-016-3032-9
   Solari D, 2016, J NEUROSURG SCI, V60, P454
   Stapleton AL, 2017, INT J PEDIATR OTORHI, V93, P163, DOI 10.1016/j.ijporl.2016.12.019
   Straus D, 2017, NEUROSURGERY, V26, P437
   Su SY, 2014, CURR ONCOL REP, V16, DOI 10.1007/s11912-013-0369-6
   Sughrue ME, 2010, J NEUROSURG, V113, P1029, DOI 10.3171/2010.3.JNS091971
   Tajudeen BA, 2015, J NEUROL SURG PART B, V76, P43, DOI 10.1055/s-0034-1390011
   Tamasauskas A, 2014, TURK NEUROSURG, V24, P174, DOI 10.5137/1019-5149.JTN.6995-12.2
   Tan NCW, 2012, J NEUROL SURG PART B, V73, P379, DOI 10.1055/s-0032-1321508
   Tan TSE, 2017, EUR J ENDOCRINOL, V176, P359, DOI 10.1530/EJE-16-0812
   Taniguchi M, 2016, J NEUROSURG, V124, P1032, DOI 10.3171/2015.1.JNS142526
   Tawk RG, 2014, J NEUROL SURG PART A, V75, P354, DOI 10.1055/s-0033-1358609
   TERASAKA S, 2011, NEUROSURGERY S1, V68, pNIL86, DOI DOI 10.1227/NEU.0b013e31820781e1
   Tsang RK, 2015, CLIN OTOLARYNGOL, V40, P274, DOI 10.1111/coa.12364
   Tsitouras V, 2016, J CLIN NEUROSCI, V34, P169, DOI 10.1016/j.jocn.2016.06.003
   Turri-Zanoni M, 2017, ORAL ONCOL, V74, P21, DOI 10.1016/j.oraloncology.2017.09.010
   Walcott BP, 2012, LANCET ONCOL, V13, pE69, DOI 10.1016/S1470-2045(11)70337-0
   Wang K, 2015, CLIN NEUROL NEUROSUR, V130, P20, DOI 10.1016/j.clineuro.2014.12.016
   Wannemuehler TJ, 2016, NEUROSURG FOCUS, V41, DOI 10.3171/2016.9.FOCUS16314
   Wessell A, 2014, J NEUROL SURG REP, V75, pE149, DOI 10.1055/s-0034-1376427
   Wilk A, 2016, TURK NEUROSURG, V26, P824, DOI 10.5137/1019-5149.JTN.14160-15.1
   Wilson DA, 2014, WORLD NEUROSURG, V82, pE243, DOI 10.1016/j.wneu.2013.02.002
   Yang A, 2018, J NEUROL SURG PART B, V79, pS219, DOI 10.1055/s-0037-1618599
   Yano S, 2017, WORLD NEUROSURG, V100, P288, DOI 10.1016/j.wneu.2017.01.005
   Yokoi H, 2015, CASE REP OTOLARYNGOL, V2015
   Zaidi HA, 2014, NEUROSURG FOCUS, V37, DOI 10.3171/2014.8.FOCUS14366
   Zanation AM, 2009, LARYNGOSCOPE, V119, P19, DOI 10.1002/lary.20027
   Zhang HK, 2016, J CRANIOFAC SURG, V27, pE709, DOI 10.1097/SCS.0000000000003031
   Zhang LY, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166046
   Zhang QH, 2008, ORL-J OTO-RHIN-LARYN, V70, P124, DOI 10.1159/000114536
   Zoli M, 2018, J NEUROSURG, V128, P329, DOI 10.3171/2016.11.JNS162082
   Zou MX, 2018, WORLD NEUROSURG, V109, P307, DOI 10.1016/j.wneu.2017.10.010
   Zygourakis CC, 2014, J CLIN NEUROSCI, V21, P1558, DOI 10.1016/j.jocn.2014.03.005
NR 146
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP 491
EP 501
DI 10.1016/j.wneu.2019.01.119
PG 11
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800206
DA 2020-05-12
ER

PT J
AU Soneru, CP
   Riley, CA
   Tabaee, A
   Kacker, A
   Anand, VK
   Schwartz, TH
AF Soneru, Christian P.
   Riley, Charles A.
   Tabaee, Abtin
   Kacker, Ashutosh
   Anand, Vijay K.
   Schwartz, Theodore H.
TI The Challenge of Skull Base Closure: Methods for Reducing Postoperative
   Cerebrospinal Fluid Leak
SO WORLD NEUROSURGERY
LA English
DT Article
DE Autologous free tissue grafts; Cerebrospinal fluid leak; Endoscopic
   skull base surgery; Gasket-seal closure; Lumbar drain; Nasoseptal flap;
   Tissue sealants
ID ENDOSCOPIC ENDONASAL APPROACH; POSTLUMBAR PUNCTURE HEADACHE; SELLAR
   FLOOR RECONSTRUCTION; PEDICLED NASOSEPTAL FLAP; INFERIOR TURBINATE FLAP;
   LARGE DURAL DEFECTS; CRANIAL BASE; TRANSSPHENOIDAL SURGERY; LUMBAR
   DRAINS; RISK-FACTORS
AB BACKGROUND: With recent advances in endoscopic skull base surgery, larger and more complex skull base defects are encountered and many possible reconstructive methods and materials are available. The purpose of this review is to summarize the possible causes of skull base defects, to describe the challenges associated with skull base reconstruction, and to detail the techniques and materials that may be used.
   METHODS: Literature review.
   RESULTS: Although skull base defects may be caused by traumatic or nontraumatic causes, this review focuses on the endoscopic reconstruction of defects. Many materials are available for endoscopic reconstruction and several techniques have been described for repair of skull base defects. With these advances, the outcomes of endoscopic skull base reconstruction have improved greatly over the past 20 years.
   CONCLUSIONS: Given the complexity of skull base defects and the multiple materials and techniques available for endoscopic reconstruction, a thorough understanding of the challenges associated with skull base repair is crucial for the endoscopic skull base surgeon.
C1 [Soneru, Christian P.; Riley, Charles A.; Tabaee, Abtin; Kacker, Ashutosh; Anand, Vijay K.; Schwartz, Theodore H.] Weill Cornell Med Coll, Dept Otolaryngol Head & Neck Surg, New York, NY 10065 USA.
   [Schwartz, Theodore H.] Weill Cornell Med Coll, Dept Neurosurg, New York, NY 10065 USA.
   [Schwartz, Theodore H.] Weill Cornell Med Coll, Dept Neurosci, New York, NY 10065 USA.
RP Schwartz, TH (reprint author), Weill Cornell Med Coll, Dept Otolaryngol Head & Neck Surg, New York, NY 10065 USA.; Schwartz, TH (reprint author), Weill Cornell Med Coll, Dept Neurosurg, New York, NY 10065 USA.; Schwartz, TH (reprint author), Weill Cornell Med Coll, Dept Neurosci, New York, NY 10065 USA.
EM sschwarh@med.cornell.edu
RI Schwartz, Theodore/AAK-3320-2020
CR Ahmed SV, 2006, POSTGRAD MED J, V82, P713, DOI 10.1136/pgmj.2006.044792
   Amorim JA, 2012, CEPHALALGIA, V32, P916, DOI 10.1177/0333102412453951
   Baban MIA, 2017, EUR ARCH OTO-RHINO-L, V274, P2827, DOI 10.1007/s00405-017-4587-7
   Bassett E, 2016, INT FORUM ALLERGY RH, V6, P1113, DOI 10.1002/alr.21778
   Bedrosian JC, 2014, WORLD NEUROSURG, V82, pS86, DOI 10.1016/j.wneu.2014.07.018
   Bleier BS, 2011, AM J RHINOL ALLERGY, V25, P186, DOI 10.2500/ajra.2011.25.3587
   Burns JA, 1996, LARYNGOSCOPE, V106, P1080, DOI 10.1097/00005537-199609000-00007
   Campbell RG, 2016, AM J RHINOL ALLERGY, V30, P294, DOI 10.2500/ajra.2016.30.4319
   Cappabianca P, 2004, SURG NEUROL, V62, P227, DOI 10.1016/j.surneu.2004.01.016
   Chaaban MR, 2014, LARYNGOSCOPE, V124, P70, DOI 10.1002/lary.24160
   Chaaban MR, 2013, INT FORUM ALLERGY RH, V3, P718, DOI 10.1002/alr.21188
   Chauvet D, 2011, ACTA NEUROCHIR, V153, P2465, DOI 10.1007/s00701-011-1197-9
   Cherubino M, 2017, J CRANIO MAXILL SURG, V45, P87, DOI 10.1016/j.jcms.2016.10.017
   Cohen S, 2018, OPER NEUROSURG, V14, P66, DOI 10.1093/ons/opx070
   D'Anza B, 2016, AM J RHINOL ALLERGY, V30, P430, DOI 10.2500/ajra.2016.30.4377
   Dadgostar A, 2017, AM J RHINOL ALLERGY, V31, P196, DOI 10.2500/ajra.2017.31.4430
   de Almeida JR, 2009, J OTOLARYNGOL-HEAD N, V38, P106, DOI 10.2310/7070.2008.OA0216
   Dehdashti AR, 2009, NEUROSURGERY, V64, P677, DOI 10.1227/01.NEU.0000339121.20101.85
   Dusick JR, 2006, SURG NEUROL, V66, P371, DOI 10.1016/j.surneu.2006.06.043
   Dusick JR, 2005, J NEUROSURG, V102, P832, DOI 10.3171/jns.2005.102.5.0832
   Eloy JA, 2012, INT FORUM ALLERGY RH, V2, P397, DOI 10.1002/alr.21040
   Eloy JA, 2012, OTOLARYNG HEAD NECK, V147, P161, DOI 10.1177/0194599812437530
   Esposito F, 2007, NEUROSURGERY, V60, P295, DOI 10.1227/01.NEU.0000255354.64077.66
   Fortes FSG, 2007, LARYNGOSCOPE, V117, P1329, DOI 10.1097/mlg.0b013e318062111f
   Fortes FSG, 2007, LARYNGOSCOPE, V117, P970, DOI 10.1097/MLG.0b013e3180471482
   Fraser S, 2018, J NEUROSURG, V128, P1066, DOI 10.3171/2016.12.JNS1694
   Garcia-Navarro V, 2013, WORLD NEUROSURG, V80, P563, DOI 10.1016/j.wneu.2011.08.034
   Gil Z, 2012, OTOLARYNG HEAD NECK, V146, P842, DOI 10.1177/0194599811434516
   Governale LS, 2008, NEUROSURGERY, V63, P379, DOI 10.1227/01.NEU.0000327023.18220.88
   Gray ST, 2013, ADV OTO-RHINO-LARYNG, V74, P12, DOI 10.1159/000342264
   Greenfield JP, 2010, NEUROSURGERY, V66, P883, DOI 10.1227/01.NEU.0000368395.82329.C4
   Hadad G, 2006, LARYNGOSCOPE, V116, P1882, DOI 10.1097/01.mlg.0000234933.37779.e4
   Hammond ER, 2011, J NEUROL SCI, V306, P24, DOI 10.1016/j.jns.2011.04.004
   Harvey RJ, 2012, LARYNGOSCOPE, V122, P452, DOI 10.1002/lary.22475
   Heaton CM, 2012, LARYNGOSCOPE, V122, P1446, DOI 10.1002/lary.23305
   Hirono S, 2015, J NEUROL SURG REP, V76, P83, DOI 10.1055/s-0035-1547369
   Hosemann W., 1999, Rhinology (Utrecht), V37, P108
   Huntley C, 2015, INT FORUM ALLERGY RH, V5, P353, DOI 10.1002/alr.21480
   Ibrahim AA, 2016, EUR ARCH OTO-RHINO-L, V273, P921, DOI 10.1007/s00405-015-3681-y
   Ivan ME, 2015, J CLIN NEUROSCI, V22, P48, DOI 10.1016/j.jocn.2014.08.009
   Kassam A B, 2008, NEUROSURGERY S1, V63, pONS44
   Kassam AB, 2008, NEUROSURGERY, V63, P44, DOI 10.1227/01.NEU.0000297074.13423.F5
   Kitano M, 2004, NEUROSURGERY, V54, P653, DOI 10.1227/01.NEU.0000108780.72365.DC
   Komotar RJ, 2013, J NEUROL SURG PART A, V74, P239, DOI 10.1055/s-0032-1325636
   Komotar RJ, 2012, WORLD NEUROSURG, V77, P329, DOI 10.1016/j.wneu.2011.07.011
   Kumar A, 2003, J CLIN NEUROSCI, V10, P92, DOI 10.1016/S0967-5868(02)00262-X
   Leng LZ, 2008, NEUROSURGERY, V62, P342, DOI [10.1227/01.NEU.0000312720.93685.17, 10.1227/01.neu.0000326017.84315.1f]
   Leng LZ, 2012, NEUROSURGERY, V70, P110, DOI 10.1227/NEU.0b013e31822e8ffc
   Liang BQ, 2017, ACTA NEUROCHIR, V159, P1379, DOI 10.1007/s00701-017-3247-4
   Liebelt BD, 2015, WORLD NEUROSURG, V84, P240, DOI 10.1016/j.wneu.2015.02.025
   Luginbuhl AJ, 2010, LARYNGOSCOPE, V120, P876, DOI 10.1002/lary.20861
   Macia G, 2016, INT J ORAL MAX SURG, V45, P158, DOI 10.1016/j.ijom.2015.09.001
   Marks SC, 1998, AM J RHINOL, V12, P417, DOI 10.2500/105065898780707900
   McCoul ED, 2014, WORLD NEUROSURG, V81, P136, DOI 10.1016/j.wneu.2012.08.011
   Mehta GU, 2012, J NEUROSURG, V116, P1299, DOI 10.3171/2012.3.JNS112160
   Murray RD, 2017, J NEUROSURG, V126, P1720, DOI 10.3171/2016.4.JNS152975
   NELIGAN PC, 1995, CLIN PLAST SURG, V22, P71
   Nyquist GG, 2010, J NEUROSURG, V113, P961, DOI 10.3171/2009.10.JNS08986
   Nyquist GG, 2010, OTOLARYNG HEAD NECK, V142, P327, DOI 10.1016/j.otohns.2009.12.020
   Ommaya A K, 1976, Clin Neurosurg, V23, P363
   Oshino S, 2010, WORLD NEUROSURG, V73, P701, DOI 10.1016/j.wneu.2010.04.001
   Paldino M, 2003, NEUROSURG FOCUS, V15, P2
   Patel KS, 2013, J NEUROSURG, V119, P661, DOI 10.3171/2013.4.JNS13124
   Patel MR, 2010, SKULL BASE-INTERD AP, V20, P397, DOI 10.1055/s-0030-1253573
   Patel MR, 2010, NEUROSURGERY, V66, P506, DOI 10.1227/01.NEU.0000365620.59677.FF
   Peris-Celda M, 2013, J NEUROL SURG PART B, V74, P369, DOI 10.1055/s-0033-1347368
   Pinheiro-Neto CD, 2010, LARYNGOSCOPE, V120, P1798, DOI 10.1002/lary.20996
   Prevedello DM, 2009, LARYNGOSCOPE, V119, P2094, DOI 10.1002/lary.20226
   Ramakrishnan VR, 2012, INT FORUM ALLERGY RH, V2, P34, DOI 10.1002/alr.20101
   Rawal RB, 2012, OTOLARYNG HEAD NECK, V147, P434, DOI 10.1177/0194599812443042
   Reyes C, 2017, J NEUROL SURG PART B, V78, P393, DOI 10.1055/s-0037-1602245
   Rivera-Serrano CM, 2010, LARYNGOSCOPE, V120, P1922, DOI 10.1002/lary.21049
   Roxbury CR, 2016, AM J RHINOL ALLERGY, V30, P367, DOI 10.2500/ajra.2016.30.4356
   Saitoh Y, 2013, NEUROL MED-CHIR, V53, P65, DOI 10.2176/nmc.53.65
   Schlosser RJ, 2004, LARYNGOSCOPE, V114, P255, DOI 10.1097/00005537-200402000-00015
   Seda L, 2006, SURG NEUROL, V66, P46, DOI 10.1016/j.surneu.2005.10.021
   Soudry E, 2014, OTOLARYNG HEAD NECK, V150, P730, DOI 10.1177/0194599814520685
   Stokken J, 2015, CURR OPIN OTOLARYNGO, V23, P78, DOI 10.1097/MOO.0000000000000119
   Tabaee A, 2007, LARYNGOSCOPE, V117, P1133, DOI 10.1097/MLG.0b013e31805c08c5
   Thorp BD, 2014, NEUROSURG FOCUS, V37, DOI 10.3171/2014.7.FOCUS14350
   Ting JY, 2013, ADV OTO-RHINO-LARYNG, V74, P33, DOI 10.1159/000342266
   Upadhyay S, 2017, LARYNGOSCOPE, V127, P1970, DOI 10.1002/lary.26546
   Wiedermann JP, 2017, INT J PEDIATR OTORHI, V92, P143, DOI 10.1016/j.ijporl.2016.11.014
   Wormald PJ, 2003, AM J RHINOL, V17, P299, DOI 10.1177/194589240301700508
   Wormald PJ, 1997, J LARYNGOL OTOL, V111, P1042, DOI 10.1017/S0022215100139295
   Yano S, 2007, SURG NEUROL, V67, P59, DOI 10.1016/j.surneu.2006.05.049
   Zanation AM, 2009, AM J RHINOL ALLERGY, V23, P518, DOI 10.2500/ajra.2009.23.3378
   Ziu MT, 2013, WORLD NEUROSURG, V80, P554, DOI 10.1016/j.wneu.2012.08.001
   Zwagerman NT, 2019, J NEUROSURG, V131, P1172, DOI 10.3171/2018.4.JNS172447
NR 89
TC 0
Z9 0
U1 2
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP 502
EP 512
DI 10.1016/j.wneu.2019.01.121
PG 11
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800207
DA 2020-05-12
ER

PT J
AU Riley, CA
   Soneru, CP
   Tabaee, A
   Kacker, A
   Anand, VK
   Schwartz, TH
AF Riley, Charles A.
   Soneru, Christian P.
   Tabaee, Abtin
   Kacker, Ashutosh
   Anand, Vijay K.
   Schwartz, Theodore H.
TI Technological and Ideological Innovations in Endoscopic Skull Base
   Surgery
SO WORLD NEUROSURGERY
LA English
DT Article
DE 3-Dimensional endoscope; 5-Aminolevulinic acid; Endoscopic skull base
   surgery; Fluorescein; Fluorescent dyes; High-definition endoscope;
   Indocyanine green; Intraoperative magnetic resonance imaging; Quality of
   life
ID QUALITY-OF-LIFE; CEREBROSPINAL-FLUID LEAK; INDOCYANINE GREEN
   FLUORESCENCE; DOSE INTRATHECAL FLUORESCEIN; TRANSORAL ROBOTIC SURGERY;
   5-AMINOLEVULINIC ACID; ENDONASAL APPROACH; TRANSSPHENOIDAL SURGERY;
   PHOTODYNAMIC THERAPY; EXPANDED ENDONASAL
AB BACKGROUND: Endoscopic skull base surgery has evolved over the last several decades due to technological advances and operative techniques. Several innovations that are not yet mainstream may have significant impact on the future of endoscopic skull base surgery.
   METHODS: Current literature pertaining to innovations in endoscopic skull base surgery was retrieved using PubMed, Embase, Web of Science, and Google Scholar.
   RESULTS: Several recent innovations may play an influential role in the advancement of endoscopic skull base surgery, including fluorescent dyes such as indocyanine green fluorescence, fluorescein, and 5-aminolevulinic acid, 3-dimensional endoscopes, robotic surgery, and intraoperative magnetic resonance imaging.
   CONCLUSIONS: Several technologies are under current investigation with the hope to improve future outcomes in endoscopic skull base surgery. Additional research and evolution are necessary and will require intense scrutiny before becoming standard of care.
C1 [Riley, Charles A.; Soneru, Christian P.; Tabaee, Abtin; Kacker, Ashutosh; Anand, Vijay K.; Schwartz, Theodore H.] Weill Cornell Med Coll, Dept Otolaryngol Head & Neck Surg, New York, NY 10065 USA.
   [Schwartz, Theodore H.] Weill Cornell Med Coll, Dept Neurosurg, New York, NY 10065 USA.
   [Schwartz, Theodore H.] Weill Cornell Med Coll, Dept Neurosci, New York, NY 10065 USA.
RP Schwartz, TH (reprint author), Weill Cornell Med Coll, Dept Otolaryngol Head & Neck Surg, New York, NY 10065 USA.; Schwartz, TH (reprint author), Weill Cornell Med Coll, Dept Neurosurg, New York, NY 10065 USA.; Schwartz, TH (reprint author), Weill Cornell Med Coll, Dept Neurosci, New York, NY 10065 USA.
EM schwarh@med.cornell.edu
RI Schwartz, Theodore/AAK-3320-2020
CR Alobid I, 2013, AM J RHINOL ALLERGY, V27, P426, DOI 10.2500/ajra.2013.27.3932
   Banu MA, 2014, CLIN NEUROL NEUROSUR, V116, P28, DOI 10.1016/j.clineuro.2013.11.006
   Barkhoudarian G, 2013, NEUROSURGERY, V73, P74, DOI 10.1227/NEU.0b013e31828ba962
   Bedrosian JC, 2013, INT FORUM ALLERGY RH, V3, P664, DOI 10.1002/alr.21161
   Bekelis K, 2011, NEUROSURG FOCUS, V30, DOI 10.3171/2011.2.FOCUS1112
   Berkmann S, 2012, ACTA NEUROCHIR, V154, P639, DOI 10.1007/s00701-012-1285-5
   Brown SM, 2008, OTOLARYNG HEAD NECK, V138, P400, DOI 10.1016/j.otohns.2007.12.007
   Castelnuovo P, 2012, ACTA OTORHINOLARYNGO, V32, P189
   Castelnuovo P, 2013, J NEUROSURG, V119, P1401, DOI 10.3171/2013.8.JNS13296
   Chauvet D, 2017, J NEUROSURG, V127, P941, DOI 10.3171/2016.9.JNS161638
   Cho SS, 2019, OPER NEUROSURG, V16, P59, DOI 10.1093/ons/opy034
   Cornelius JF, 2014, PHOTODIAGN PHOTODYN, V11, P481, DOI 10.1016/j.pdpdt.2014.07.008
   Cornelius JF, 2017, PHOTODIAGN PHOTODYN, V20, P111, DOI 10.1016/j.pdpdt.2017.09.011
   Cornelius JF, 2019, WORLD NEUROSURG, V122, pE890, DOI 10.1016/j.wneu.2018.10.171
   Cornelius JF, 2014, J NEUROSURG, V121, P766, DOI 10.3171/2014.4.JNS14775
   Cornelius JF, 2014, PHOTODIAGN PHOTODYN, V11, P1, DOI 10.1016/j.pdpdt.2014.01.001
   Cornelius JF, 2013, J NEUROL SURG PART B, V74, P211, DOI 10.1055/s-0033-1342918
   Della Puppa A, 2014, J NEUROSURG, V120, P840, DOI 10.3171/2013.12.JNS131642
   Derousseau T, 2015, INT FORUM ALLERGY RH, V5, P1129, DOI 10.1002/alr.21608
   Emanuelli E, 2015, CLIN NEUROL NEUROSUR, V132, P21, DOI 10.1016/j.clineuro.2015.02.013
   Evans CO, 2008, VITAM HORM, V79, P235, DOI 10.1016/S0083-6729(08)00408-1
   Evans CO, 2003, CANCER RES, V63, P4218
   Felisati G, 2013, EUR ARCH OTO-RHINO-L, V270, P2249, DOI 10.1007/s00405-012-2328-5
   Felisati G, 2008, ACTA OTORHINOLARYNGO, V28, P159
   Fraser JF, 2009, MINIM INVAS NEUROSUR, V52, P25, DOI 10.1055/s-0028-1104567
   Gil Z, 2004, J NEUROSURG, V100, P813, DOI 10.3171/jns.2004.100.5.0813
   Glicksman JT, 2018, LARYNGOSCOPE, V128, P789, DOI 10.1002/lary.26833
   Green JM, 2013, J ORAL MAXIL SURG, V71, P1439, DOI 10.1016/j.joms.2013.01.019
   Hide T, 2015, J NEUROSURG, V122, P1185, DOI 10.3171/2014.9.JNS14599
   Jakimovski D, 2014, WORLD NEUROSURG, V82, pE513, DOI 10.1016/j.wneu.2013.06.005
   Jalessi M, 2016, EUR ARCH OTO-RHINO-L, V273, P1199, DOI 10.1007/s00405-015-3729-z
   Jones ME, 2000, AM J RHINOL, V14, P93, DOI 10.2500/105065800781692859
   Jones SH, 2016, NEUROSURGERY, V79, P736, DOI 10.1227/NEU.0000000000001360
   Kerr EE, 2017, J NEUROL SURG PART B, V78, P408, DOI 10.1055/s-0037-1602777
   Khanna A, 2018, CURR OPIN OTOLARYNGO, V26, P13, DOI 10.1097/MOO.0000000000000433
   Komotar RJ, 2013, J NEUROL SURG PART A, V74, P239, DOI 10.1055/s-0032-1325636
   Larysz D, 2012, FOLIA NEUROPATHOL, V50, P277, DOI 10.5114/fn.2012.30528
   Lee DD, 2017, WORLD NEUROSURG, V98, P303, DOI 10.1016/j.wneu.2016.10.114
   Lee JYK, 2018, J NEUROSURG, V129, P390, DOI 10.3171/2017.2.JNS163191
   Little AS, 2015, J NEUROSURG, V123, P799, DOI 10.3171/2014.10.JNS14921
   MAHALEY MS, 1966, J NEUROSURG, V25, P298, DOI 10.3171/jns.1966.25.3.0298
   Manes RP, 2011, INT FORUM ALLERGY RH, V1, P191, DOI 10.1002/alr.20012
   Manthuruthil C, 2016, WORLD NEUROSURG, V90, P1, DOI 10.1016/j.wneu.2016.02.035
   Marcus HJ, 2014, NEUROSURGERY, V74, P375, DOI 10.1227/NEU.0000000000000249
   McCoul ED, 2015, J NEUROSURG, V123, P813, DOI 10.3171/2014.11.JNS14559
   McCoul ED, 2012, J NEUROSURG, V117, P498, DOI 10.3171/2012.6.JNS111066
   McCoul ED, 2012, INT FORUM ALLERGY RH, V2, P174, DOI 10.1002/alr.21008
   Oertel J, 2016, CLIN NEUROL NEUROSUR, V146, P29, DOI 10.1016/j.clineuro.2016.04.016
   Patel KS, 2015, J NEUROSURG, V123, P571, DOI 10.3171/2014.12.JNS141591
   Piccirillo JF, 2002, OTOLARYNG HEAD NECK, V126, P41, DOI 10.1067/mhn.2002.121022
   Placantonakis DG, 2007, NEUROSURGERY, V61, P161, DOI 10.1227/01.NEU.0000279993.65459.7B
   Pledger CL, 2016, J NEUROSURG, V125, P323, DOI 10.3171/2015.6.JNS142695
   Potapov AA, 2016, NEUROSURG REV, V39, P437, DOI 10.1007/s10143-015-0697-0
   Raithatha R, 2012, INT FORUM ALLERGY RH, V2, P9, DOI 10.1002/alr.20097
   Raza SM, 2016, J NEUROSURG, V124, P621, DOI 10.3171/2014.12.JNS14995
   Rigante M, 2017, ACTA OTORHINOLARYNGO, V37, P237, DOI 10.14639/0392-100X-1684
   Roth J, 2011, ORBIT-ABINGDON, V30, P43, DOI 10.3109/01676830.2010.543004
   Roth J, 2009, NEUROSURGERY, V65, P1116, DOI 10.1227/01.NEU.0000360340.85186.7A
   Schaberg MR, 2010, CURR OPIN OTOLARYNGO, V18, P8, DOI 10.1097/MOO.0b013e328334db5b
   Schneider JS, 2013, CURR OPIN OTOLARYNGO, V21, P11, DOI 10.1097/MOO.0b013e32835bc650
   Schwartz TH, 2006, NEUROSURGERY, V58, P44, DOI 10.1227/01.NEU.0000193927.49862.B6
   Senior BA, 2001, AM J RHINOL, V15, P21, DOI 10.2500/105065801781329356
   Seth R, 2010, OTOLARYNG HEAD NECK, V143, P626, DOI 10.1016/j.otohns.2010.07.011
   Shah RN, 2011, AM J RHINOL ALLERGY, V25, P141, DOI 10.2500/ajra.2011.25.3593
   Silva D, 2014, WORLD NEUROSURG, V81, P374, DOI 10.1016/j.wneu.2012.08.013
   Julian JAS, 2016, ACTA NEUROCHIR, V158, P1351, DOI 10.1007/s00701-016-2830-4
   Singh H, 2016, J NEURO-ONCOL, V130, P309, DOI 10.1007/s11060-016-2124-y
   Szerlip NJ, 2011, SKULL BASE-INTERD AP, V21, P223, DOI 10.1055/s-0031-1277262
   Tabaee A, 2007, OTOLARYNG HEAD NECK, V137, P316, DOI 10.1016/j.otohns.2006.11.012
   Tabaee A, 2009, NEUROSURGERY, V64, P288, DOI 10.1227/01.NEU.0000338069.51023.3C
   Tabani H, 2017, WORLD NEUROSURG, V104, DOI 10.1016/j.wneu.2017.05.049
   Theodosopoulos PV, 2010, J NEUROSURG, V112, P736, DOI 10.3171/2009.6.JNS08916
   Villaret AB, 2017, WORLD NEUROSURG, V105, P875, DOI 10.1016/j.wneu.2017.06.089
   Wang SS, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000000465
   White DR, 2003, AM J OTOLARYNG, V24, P213, DOI 10.1016/S0196-0709(03)00031-0
   Yang T, 2015, CUREUS, V7, DOI 10.7759/cureus.357
   Yano T, 2016, ANN PLAS SURG, V76, P198, DOI 10.1097/SAP.0000000000000519
   Yeh DH, 2015, EJSO-EUR J SURG ONC, V41, P1603, DOI 10.1016/j.ejso.2015.09.007
   Yokoyama J, 2016, ANTICANCER RES, V36, P3419
   Zacharia BE, 2015, WORLD NEUROSURG, V84, P1267, DOI 10.1016/j.wneu.2015.05.061
   Zaidi HA, 2016, NEUROSURG FOCUS, V40, DOI 10.3171/2016.1.FOCUS15515
   Zaidi HA, 2016, WORLD NEUROSURG, V86, P419, DOI 10.1016/j.wneu.2015.10.004
   Zhang HP, 2017, WORLD NEUROSURG, V104, P802, DOI 10.1016/j.wneu.2017.04.056
   Zhang RR, 2016, NEUROSURGERY, V79, pN12, DOI 10.1227/NEU.0000000000001291
NR 84
TC 1
Z9 1
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP 513
EP 521
DI 10.1016/j.wneu.2019.01.120
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800208
PM 30708082
DA 2020-05-12
ER

PT J
AU Caporlingua, A
   Prior, A
   Cavagnaro, MJ
   Winston, G
   Oliveira, DLC
   Sadwhani, SD
   Arias, GA
   Schwalb, JN
   Akhbari, M
   Evins, AI
   Bernardo, A
AF Caporlingua, Alessandro
   Prior, Alessandro
   Cavagnaro, Maria Jose
   Winston, Graham
   Oliveira, Dayvid L. C.
   Sadwhani, Shaan D.
   Arias, Glenn Alvarez
   Schwalb, Jesse N.
   Akhbari, Melika
   Evins, Alexander, I
   Bernardo, Antonio
TI The Intracranial and Intracanalicular Optic Nerve as Seen Through
   Different Surgical Windows: Endoscopic Versus Transcranial
SO WORLD NEUROSURGERY
LA English
DT Article
DE Approaches; Decompression; Endoscopic; Optic canal; Optic nerve; Skull
   base; Surgical anatomy
ID TUBERCULUM SELLAE MENINGIOMAS; SUPERIOR ORBITAL FISSURE; MICROSURGICAL
   ANATOMY; SUPRAORBITAL KEYHOLE; OPHTHALMIC ARTERY; TRANSSPHENOIDAL
   APPROACH; ANTERIOR CLINOIDECTOMY; SKULL BASE; DECOMPRESSION; SERIES
AB BACKGROUND: Surgically manageable lesions involving the intracranial or intracanalicular portions of the optic nerve (cranial nerve II) can be approached through several different operative windows. Given the complex anatomy of the optic nerve and its surrounding neurovascular structures, it is essential to understand the conventional and topographic anatomy of the optic nerve from different surgical perspectives as well as its relationship with surrounding structures. We describe the intracranial and intracanalicular course of the optic nerve and present an analytical evaluation of the degree of exposure provided by several different transcranial and endoscopic surgical approaches.
   METHODS: Using 12 cadaveric specimens (24 sides), pterional, frontotemporal-orbital, supraorbital, unilateral subfrontal, and extended endonasal approaches were performed. The transcranial approaches were extended by removing the anterior clinoid process, unroofing the optic canal, and/or cutting the falciform ligament. The endonasal approach was extended using the transplanum transtuberculum, transmedial optic carotid recess, and transcanalicular modifications. The optic nerve was divided into proximal intracranial, distal intracranial, and intracanalicular segments, which were each divided coronally into quadrants and subquadrants, to evaluate their degree of exposure in each approach.
   RESULTS: The pterional approach provided 135 degrees of exposure along the superolateral aspects of the entire intracranial optic nerve, and 225 degrees of exposure of the intracanalicular optic nerve. The supraorbital and subfrontal approaches provided similar degrees of exposure, with 225 degrees-270 degrees of superolateral and superomedial exposure of the nerve along its intracranial and intracanalicular segments, depending on the approach extension used, with the subfrontal approach allowing for more medial control of the nerve. The endoscopic endonasal approach provided access to the inferior and medial quadrants of the optic nerve, allowing for 180 degrees of exposure.
   CONCLUSIONS: Although the pterional approach provides the widest degree of surgical exposure of all optic nerve segments, the inferior and medial quadrants of the nerve can be adequately exposed only through an endoscopic endonasal approach. Optimal approach selection based on the intended target quadrant is essential for safe surgical exposure of the optic nerve.
C1 [Caporlingua, Alessandro; Prior, Alessandro; Cavagnaro, Maria Jose; Winston, Graham; Oliveira, Dayvid L. C.; Sadwhani, Shaan D.; Arias, Glenn Alvarez; Schwalb, Jesse N.; Akhbari, Melika; Evins, Alexander, I; Bernardo, Antonio] Weill Cornell Med, Neurol Surg, New York, NY 10065 USA.
RP Bernardo, A (reprint author), Weill Cornell Med, Neurol Surg, New York, NY 10065 USA.
EM anb2029@med.cornell.edu
RI bernardo, Antonio/AAB-9474-2020; Evins, Alexander I./K-1022-2018
OI Evins, Alexander I./0000-0002-6309-6922; Caporlingua,
   Alessandro/0000-0003-2776-5399; Alvarez Arias,
   Glenn/0000-0002-4497-980X; Akhbari, Melika/0000-0001-7634-2515
CR Abhinav K, 2015, OPER NEUROSURG, V11, P431, DOI 10.1227/NEU.0000000000000900
   Arai H, 2000, ACTA NEUROCHIR, V142, P751, DOI 10.1007/s007010070089
   Attia M, 2012, NEUROSURGERY, V71, P58, DOI 10.1227/NEU.0b013e318258e23d
   Beer-Furlan A, 2014, J NEUROL SURG PART B, V75, P187, DOI 10.1055/s-0033-1364165
   Beer-Furlan A, 2014, J CLIN NEUROSCI, V21, P836, DOI 10.1016/j.jocn.2013.10.006
   Berhouma M, 2014, NEUROSURG FOCUS, V37, DOI 10.3171/2014.7.FOCUS14303
   Bernardo A, 2017, WORLD NEUROSURG, V106, P1030, DOI [10.1016/J.WNEU.2017.06.158, 10.1016/j.wneu.2017.06.158]
   Bernardo A, 2014, NEUROSURG REV, V37, P597, DOI 10.1007/s10143-014-0552-8
   Bernardo A, 2013, NEUROSURGERY, V72, P194, DOI 10.1227/NEU.0b013e31827e5844
   Cascone P, 2012, J CRANIOFAC SURG, V23, P1430, DOI 10.1097/SCS.0b013e31825e3acf
   Chang DJ, 2009, NEUROSURGERY S, V64
   Chang HS, 2006, J NEUROSURG, V104, P621, DOI 10.3171/jns.2006.104.4.621
   Chen YH, 2004, J NEUROTRAUM, V21, P976, DOI 10.1089/0897715041526140
   Cheng CM, 2013, J NEUROSURG, V118, P264, DOI 10.3171/2012.9.JNS09186
   CHOU PI, 1995, J NEURO-OPHTHALMOL, V15, P186
   Coscarella E, 2003, NEUROSURGERY, V53, P162, DOI 10.1227/01.NEU.0000068866.22176.07
   de Divitiis E, 2008, NEUROSURGERY, V62, P556, DOI 10.1227/01.neu.0000317303.93460.24
   de Divitiis E, 2007, NEUROSURGERY, V60, P46, DOI 10.1227/01.NEU.0000249211.89096.25
   DOLENC VV, 1985, J NEUROSURG, V62, P667, DOI 10.3171/jns.1985.62.5.0667
   Erdogmus S, 2006, NEUROSURG REV, V29, P213, DOI 10.1007/s10143-006-0028-6
   Fukuda H, 2014, J NEUROL SURG PART B, V75, P125, DOI 10.1055/s-0033-1359302
   Gogela SL, 2018, OPER NEUROSURG, V14, P295, DOI 10.1093/ons/opx093
   Hart CK, 2009, ANN OTO RHINOL LARYN, V118, P839, DOI 10.1177/000348940911801203
   HAUSER MJ, 1952, AMA ARCH OPHTHALMOL, V48, P627, DOI 10.1001/archopht.1952.00920010638011
   Horiguchi K, 2010, NEUROL MED-CHIR, V50, P518, DOI 10.2176/nmc.50.518
   Horiuchi T, 2015, J NEUROSURG, V123, P460, DOI 10.3171/2014.12.JNS141218
   Hwang JM, 2000, PEDIATR NEUROSURG, V33, P328, DOI 10.1159/000055980
   Inoue K, 2009, NEUROSURGERY, V65, P644, DOI 10.1227/01.NEU.0000351774.81674.32
   Joo W, 2012, NEUROSURGERY, V70, P300, DOI 10.1227/NEU.0b013e3182431767
   Kakizawa Y, 2000, NEUROSURGERY, V47, P1130, DOI 10.1097/00006123-200011000-00022
   Karppinen A, 2015, WORLD NEUROSURG, V84, P48, DOI 10.1016/j.wneu.2015.02.024
   Kasperbauer JL, 2005, AM J RHINOL, V19, P603, DOI 10.1177/194589240501900613
   Kassam Amin, 2005, Neurosurg Focus, V19, pE3
   KRISHT AF, 1994, NEUROSURGERY, V35, P899, DOI 10.1227/00006123-199411000-00014
   Krisht AF, 2007, NEUROSURGERY, V60, P242, DOI 10.1227/01.NEU.0000249265.88203.DF
   Labib MA, 2013, NEUROSURGERY, V72, P66, DOI 10.1227/NEU.0b013e318271f614
   Liu JK, 2011, NEUROSURG FOCUS, V30, DOI 10.3171/2011.3.FOCUS115
   Mahmoud M, 2010, NEUROSURGERY, V67, P108, DOI 10.1227/01.NEU.0000383153.75695.24
   Margalit NS, 2003, NEUROSURGERY, V53, P523, DOI 10.1227/01.NEU.0000079506.75164.F4
   Mathiesen T, 2006, NEUROSURGERY, V59, P570, DOI 10.1227/01.NEU.0000228683.79123.F9
   Mesquita PM, 2017, WORLD NEUROSURG, V104, P745, DOI 10.1016/j.wneu.2017.04.171
   NISHIO S, 1985, ACTA NEUROCHIR, V76, P82, DOI 10.1007/BF01418465
   Norris JH, 2012, ORBIT, V31, P34, DOI 10.3109/01676830.2011.605500
   Nozaki K, 2008, NEUROSURGERY, V62, P839, DOI 10.1227/01.neu.0000318169.75095.cb
   Ota N, 2015, WORLD NEUROSURG, V83, P635, DOI 10.1016/j.wneu.2014.12.014
   Otani N, 2016, WORLD NEUROSURG, V90, P357, DOI 10.1016/j.wneu.2016.03.013
   Peris-Celda M, 2013, NEUROSURGERY, V73, P117, DOI 10.1227/NEU.0000000000000184
   Puchner MJA, 1998, ACTA NEUROCHIR, V140, P1231, DOI 10.1007/s007010050243
   Raza SM, 2010, MINIM INVAS NEUROSUR, V53, P1, DOI 10.1055/s-0030-1247504
   RENN WH, 1975, J NEUROSURG, V43, P288, DOI 10.3171/jns.1975.43.3.0288
   Rigante L, 2015, J NEUROL SURG PART B, V76, P239, DOI 10.1055/s-0034-1543964
   Ringel F, 2007, NEUROSURGERY, V60, P214, DOI 10.1227/01.NEU.0000255415.4793/.IA
   Sade B, 2009, SURG NEUROL, V72, P118, DOI 10.1016/j.surneu.2008.08.007
   Seoane E, 1998, NEUROSURGERY, V42, P869, DOI 10.1097/00006123-199804000-00108
   Shoakazemi A, 2015, J NEUROSURG, V122, P564, DOI 10.3171/2014.11.JNS14341
   Singh H, 2017, J NEUROSURG, V126, P940, DOI 10.3171/2016.3.JNS1634
   Taha ANM, 2011, NEUROSURG FOCUS, V30, DOI 10.3171/2011.2.FOCUS1118
   Tayebi Meybodi A, 2018, J NEUROSURG, P1
   van Overbeeke J, 2003, Orbit, V22, P81
   Wang XD, 2017, TURK NEUROSURG, V27, P212, DOI 10.5137/1019-5149.JTN.15298-15.1
   Zoli M, 2016, ACTA NEUROCHIR, V158, P1343, DOI 10.1007/s00701-016-2797-1
NR 61
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP 522
EP 538
DI 10.1016/j.wneu.2019.01.122
PG 17
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800209
PM 31002303
DA 2020-05-12
ER

PT J
AU Al-Afif, S
   Majernik, GH
   Al Krinawe, Y
   Esmaeilzadeh, M
   Hartmann, C
   Krauss, JK
AF Al-Afif, Shadi
   Majernik, Goekce Hatipoglu
   Al Krinawe, Yazeed
   Esmaeilzadeh, Majid
   Hartmann, Christian
   Krauss, Joachim K.
TI The Role of Neurosurgery in the Treatment of Intracranial Tumor-Like
   Inflammatory Lesions
SO WORLD NEUROSURGERY
LA English
DT Article
DE Inflammatory lesion; Intracranial; Tumor; Pseudotumor
ID CENTRAL-NERVOUS-SYSTEM; ORBITOFRONTAL CHOLESTEROL GRANULOMA;
   ANGIOTENSIN-CONVERTING ENZYME; CHESTER-DISEASE MIMICKING; STEREOTACTIC
   BIOPSY; IMAGING FINDINGS; CEREBROSPINAL-FLUID; BRAIN-ABSCESS; CRANIAL
   FOSSA; FOLLOW-UP
AB BACKGROUND: Different inflammatory diseases can manifest as intracranial lesions. They may be indistinguishable from intracranial neoplasms in the clinical setting, imaging studies, or laboratory studies. The value of surgery in the diagnosis and the treatment of such lesions is still unclear.
   METHODS: A total of 3066 reports of histopathologic examinations over a 10-year period were reviewed. Forty patients with an inflammatory intracranial lesion were identified. Clinical, radiologic, and follow-up data were analyzed and the diagnostic and therapeutic value of surgery was assessed.
   RESULTS: We identified 24 women and 16 men (mean age, 47 years). The diameter of the lesion varied between 1 and 5.5 cm (mean, 2.6 cm). The location of the inflammatory lesion was intracerebral supratentorial (n = 18, 45%), intrasellar/suprasellar (n = 5, 12.5%), cerebellar (n = 5, 12.5%), in the brainstem (n = 4, 10%), in the cerebellopontine angle (n = 3, 7.5%), meningeal (n = 3, 7.5%), and at other locations (n[6, 15%). Seventeen patients underwent surgical removal of the mass lesion, whereas in 23 patients a biopsy was taken. The lesions were classified into 7 groups: specific (infectious) granuloma (n = 10, 25%), unspecific granuloma (n = 7, 17.5%), idiopathic inflammatory pseudotumor (n = 5, 12.5%), demyelinating lesions (n = 5, 12.5%) encapsulated hematoma (n = 4, 10%), organized cerebral infarction (n = 3, 7.5%), and vasculitis (n = 4, 10%). Surgery was judged as valuable in 35 patients (87.5%).
   CONCLUSIONS: The differential diagnosis of intracranial inflammatory lesions involves a wide spectrum. Surgery has a diagnostic and/or therapeutic value in most entities and clinical circumstances. However, attention must be taken to avoid surgery without a therapeutic or diagnostic value for the patient.
C1 [Al-Afif, Shadi; Majernik, Goekce Hatipoglu; Al Krinawe, Yazeed; Esmaeilzadeh, Majid; Krauss, Joachim K.] Hannover Med Sch, Inst Pathol, Dept Neurosurg, Hannover, Germany.
   [Hartmann, Christian] Hannover Med Sch, Inst Pathol, Dept Neuropathol, Hannover, Germany.
RP Al-Afif, S (reprint author), Hannover Med Sch, Inst Pathol, Dept Neurosurg, Hannover, Germany.
EM al-afif.shadi@mh-hannover.de
CR Alapatt JP, 2006, SURG NEUROL, V66, P75, DOI 10.1016/j.surneu.2005.11.061
   Annesley-Williams D, 2000, J NEUROPATH EXP NEUR, V59, P477, DOI 10.1093/jnen/59.6.477
   Arat YO, 2003, OPHTHALMIC PLAST REC, V19, P382, DOI 10.1097/01.IOP.0000083644.62765.70
   ARRIAGA MA, 1991, AM J OTOL, V12, P470
   BEAMAN BL, 1994, CLIN MICROBIOL REV, V7, P213, DOI 10.1128/CMR.7.2.213-264.1994
   Burger PC, 1997, CANCER-AM CANCER SOC, V80, P2040, DOI 10.1002/(SICI)1097-0142(19971201)80:11<2040::AID-CNCR2>3.0.CO;2-0
   Disease EC, 2015, EUR J INTERN MED, V26, P223, DOI 10.1016/j.ejim.2015.03.004
   Capelle HH, 2010, J HEADACHE PAIN, V11, P339, DOI 10.1007/s10194-010-0213-4
   Chu CT, 1998, J NEUROPATH EXP NEUR, V57, P30, DOI 10.1097/00005072-199801000-00005
   COFFIN CM, 1995, AM J SURG PATHOL, V19, P859, DOI 10.1097/00000478-199508000-00001
   COLLI BO, 1986, J NEUROSURG, V65, P309, DOI 10.3171/jns.1986.65.3.0309
   Cunliffe CH, 2009, ARCH PATHOL LAB MED, V133, P101, DOI 10.1043/1543-2165-133.1.101
   da Rocha Antonio Jose, 2005, Top Magn Reson Imaging, V16, P155, DOI 10.1097/01.rmr.0000189109.62899.a1
   Dagher AP, 1996, NEURORADIOLOGY, V38, P560
   Dale JC, 1999, MAYO CLIN PROC, V74, P535
   Del Brutto OH, 2012, J NEUROL SCI, V319, P32, DOI 10.1016/j.jns.2012.05.027
   Dubey A, 2005, SURG NEUROL, V63, P254, DOI 10.1016/j.surneu.2004.04.020
   Dumas JL, 1997, NEURORADIOLOGY, V39, P12, DOI 10.1007/s002340050358
   Edlow JA, 2011, LANCET NEUROL, V10, P550, DOI 10.1016/S1474-4422(11)70069-2
   Eksi MS, 2013, PEDIATR NEUROSURG, V49, P179, DOI 10.1159/000360424
   Fritz D, 2016, BMC NEUROL, V16, DOI 10.1186/s12883-016-0741-x
   Garcia HH, 2003, ACTA TROP, V87, P71, DOI 10.1016/S0001-706X(03)00057-3
   Garcia HH, 2002, CLIN MICROBIOL REV, V15, P747, DOI 10.1128/CMR.15.4.747-756.2002
   Garg RK, 1999, POSTGRAD MED J, V75, P133, DOI 10.1136/pgmj.75.881.133
   Greiner-Perth R, 1997, NEUROSURG REV, V20, P231, DOI 10.1007/BF01105893
   Hajj-Ali RA, 2014, J AUTOIMMUN, V48-49, P149, DOI 10.1016/j.jaut.2014.01.007
   Haroche J, 2013, RHEUM DIS CLIN N AM, V39, P299, DOI 10.1016/j.rdc.2013.02.011
   Harris DE, 1997, NEUROIMAG CLIN N AM, V7, P187
   Hausler M, 2003, HUM PATHOL, V34, P253, DOI 10.1053/hupa.2003.35
   Hermann EJ, 2015, ACTA NEUROCHIR, V157, P1229, DOI 10.1007/s00701-015-2452-2
   HIRSH LF, 1981, NEUROSURGERY, V9, P169, DOI 10.1227/00006123-198108000-00011
   Hong BJ, 2010, CLIN NEUROL NEUROSUR, V112, P865, DOI 10.1016/j.clineuro.2010.07.010
   HUNTER SB, 1987, ARCH PATHOL LAB MED, V111, P464
   Iannotti CA, 2009, SURG NEUROL, V72, P74, DOI 10.1016/j.surneu.2008.02.025
   Ionita C, 2004, AM J NEURORADIOL, V25, P270
   Jackler RK, 2003, OTOL NEUROTOL, V24, P96, DOI 10.1097/00129492-200301000-00020
   JINKINS JR, 1991, NEURORADIOLOGY, V33, P126, DOI 10.1007/BF00588250
   Kelley RE, 2004, FRONT BIOSCI-LANDMRK, V9, P946, DOI 10.2741/1259
   Kennedy KJ, 2007, SURG NEUROL, V68, P43, DOI 10.1016/j.surneu.2006.08.067
   Khalatbari MR, 2012, CHILD NERV SYST, V28, P291, DOI 10.1007/s00381-011-1611-x
   Khoury J, 2009, NEUROLOGIST, V15, P108, DOI 10.1097/NRL.0b013e31819bcf84
   Kilincer C, 2006, J CLIN NEUROSCI, V13, P481, DOI 10.1016/j.jocn.2005.04.031
   Kim JE, 2003, ACTA NEUROCHIR, V145, P547, DOI 10.1007/s00701-003-0048-8
   Kumar GGS, 2010, J MAGN RESON IMAGING, V31, P1469, DOI 10.1002/jmri.22192
   Kumar V., 2013, ROBBINS BASIC PATHOL, P29
   Lie J T, 1991, Curr Opin Rheumatol, V3, P36, DOI 10.1097/00002281-199102000-00008
   Lucchinetti CF, 2008, BRAIN, V131, P1759, DOI 10.1093/brain/awn098
   Lui PCW, 2009, HUM PATHOL, V40, P1611, DOI 10.1016/j.humpath.2009.04.016
   Mackert BM, 2008, NERVENARZT, V79, P153, DOI 10.1007/s00115-007-2322-0
   Masdeu JC, 2000, NEUROLOGY, V54, P1427, DOI 10.1212/WNL.54.7.1427
   McNab AA, 2015, OPHTHAL PLAST RECONS, V31, P83, DOI 10.1097/IOP.0000000000000363
   MIAUX Y, 1995, AM J NEURORADIOL, V16, P555
   Middelhof CA, 2005, J NEUROSURG, V103, P374, DOI 10.3171/ped.2005.103.4.0374
   Montoya JG, 2002, J INFECT DIS, V185, pS73, DOI 10.1086/338827
   MORIOKA T, 1995, NEURORADIOLOGY, V37, P564
   Mosnier I, 2002, OTOL NEUROTOL, V23, P522, DOI 10.1097/00129492-200207000-00022
   Nagappa M, 2013, ACTA NEUROL SCAND, V128, P39, DOI 10.1111/ane.12071
   Nakamura M, 2010, EJSO-EUR J SURG ONC, V36, P208, DOI 10.1016/j.ejso.2009.07.004
   Newton CR, 2012, LANCET, V380, P1193, DOI 10.1016/S0140-6736(12)61381-6
   Nishiyama Akira, 2014, Surg Neurol Int, V5, P88, DOI 10.4103/2152-7806.134076
   Nozaki K, 2012, NEUROLOGIST, V18, P373, DOI 10.1097/NRL.0b013e3182704d04
   Okamoto K, 1998, CLIN IMAG, V22, P333, DOI 10.1016/S0899-7071(98)00025-4
   Omuro AMP, 2006, LANCET NEUROL, V5, P937, DOI 10.1016/S1474-4422(06)70597-X
   Pakos EE, 2005, CLIN NEUROL NEUROSUR, V107, P152, DOI 10.1016/j.clineuro.2004.06.003
   Park SB, 2009, AM J ROENTGENOL, V193, P1180, DOI 10.2214/AJR.09.2398
   Patnana M, 2012, AM J ROENTGENOL, V198, pW217, DOI 10.2214/AJR.11.7288
   PATY DW, 1988, NEUROLOGY, V38, P180, DOI 10.1212/WNL.38.2.180
   Petrakakis I, 2016, CLIN NEUROL NEUROSUR, V149, P154, DOI 10.1016/j.clineuro.2016.08.011
   Polo R, 2013, OTOL NEUROTOL, V34, pE103, DOI 10.1097/MAO.0b013e318287f0ef
   POSER S, 1992, ACTA NEUROL SCAND, V86, P579, DOI 10.1111/j.1600-0404.1992.tb05490.x
   Prabhakaran V, 2004, T ROY SOC TROP MED H, V98, P478, DOI 10.1016/j.trstmh.2003.12.006
   Qu SB, 2009, RHEUMATOL INT, V30, P127, DOI 10.1007/s00296-009-0914-7
   Ramsey RG, 1997, NEUROIMAG CLIN N AM, V7, P171
   Rapalino O, 2017, NEUROSURGERY, V81, P10, DOI 10.1093/neuros/nyx201
   Royer Mark C, 2007, Curr Opin Otolaryngol Head Neck Surg, V15, P319, DOI 10.1097/MOO.0b013e3282a08f74
   Rushing EJ, 2004, J NEUROSURG, V100, P1115, DOI 10.3171/jns.2004.100.6.1115
   Salvarani C, 2007, ANN NEUROL, V62, P442, DOI 10.1002/ana.21226
   Scolding NJ, 2002, EUR J NEUROL, V9, P343, DOI 10.1046/j.1468-1331.2002.00422.x
   Sharma OP, 1997, CHEST, V112, P220, DOI 10.1378/chest.112.1.220
   Singh KK, 1999, J CLIN MICROBIOL, V37, P467, DOI 10.1128/JCM.37.2.467-470.1999
   Sonmez G, 2008, CLIN IMAG, V32, P88, DOI 10.1016/j.clinimag.2007.08.024
   SOTELO J, 1985, ARCH INTERN MED, V145, P442, DOI 10.1001/archinte.145.3.442
   SOTELO J, 1984, NEW ENGL J MED, V310, P1001, DOI 10.1056/NEJM198404193101601
   Spagnolo P, 2018, LANCET RESP MED, V6, P389, DOI 10.1016/S2213-2600(18)30064-X
   Stenzel W, 2004, J NEUROL, V251, P764, DOI 10.1007/s00415-004-0440-1
   Stranjalis G, 2003, MINIM INVAS NEUROSUR, V46, P90, DOI 10.1055/s-2003-39346
   Takeuchi S, 2011, NEUROL INDIA, V59, P135, DOI 10.4103/0028-3886.84352
   Tan HM, 2004, BRIT J RADIOL, V77, P153, DOI 10.1259/bjr/26682607
   Turatti M, 2013, J NEUROL SCI, V324, P156, DOI 10.1016/j.jns.2012.10.026
   Vuorinen V, 2003, ACTA NEUROCHIR, V145, P5, DOI 10.1007/s00701-002-1030-6
   Wegener S, 2015, EUR NEUROL, V73, P71, DOI 10.1159/000366199
   Whiteman MLH, 1997, NEUROIMAG CLIN N AM, V7, P199
   Wilkinson RJ, 2017, NAT REV NEUROL, V13, P581, DOI 10.1038/nrneurol.2017.120
   Wurm G, 2004, ACTA NEUROCHIR, V146, P19, DOI 10.1007/s00701-003-0151-x
   Yaldizli O, 2005, EUR J MED RES, V10, P400
   Yanardag H., 2005, SMJ Singapore Medical Journal, V46, P731
   Zhang JB, 2017, WORLD NEUROSURG, V98, P790, DOI 10.1016/j.wneu.2016.11.151
NR 97
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP E81
EP E95
DI 10.1016/j.wneu.2018.12.003
PG 15
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800012
PM 30554001
DA 2020-05-12
ER

PT J
AU Bach, K
   Ford, J
   Foley, R
   Januszewski, J
   Murtagh, R
   Decker, S
   Uribe, JS
AF Bach, Konrad
   Ford, Jonathan
   Foley, Robert
   Januszewski, Jacob
   Murtagh, Ryan
   Decker, Summer
   Uribe, Juan S.
TI Morphometric Analysis of Lumbar Intervertebral Disc Height: An Imaging
   Study
SO WORLD NEUROSURGERY
LA English
DT Article
DE Intervertebral disc; Intervertebral disc degeneration; Lumbar
   intervertebral disc height; Lumbar vertebrae; Spinal fusion; Spine
ID DEGENERATION; SUBSIDENCE; FRACTURE; CAGES
AB BACKGROUND: Little published data exist regarding normal values of disc height. Current literature relies on plain radiographs making accurate measurements of individual lumbar disc height difficult.
   OBJECTIVE: We seek to establish normal values for lumbar intervertebral discs in different age groups using computed tomography scans in healthy individuals.
   METHODS: Two hundred forty anonymized abdominal computed tomography scans (131 women) were prospectively collected once institutional review board approval was obtained. Individuals with spinal pathologies were excluded. Disc height measurements were obtained at the anterior edge, center, and posterior edge of each vertebra in the midsagittal plane, averaged, and compared against age and sex.
   RESULTS: Average age was 45 (14-83) years for women and 48 (14-89) years for men. Average lumbar disc height was 5.6 +/- 1.1 mm for men and 4.8 +/- 0.8 mm for women at T12/L1, 6.9 +/- 1.3 mm for men and 5.8 +/- 0.9 mm for women at L1/2, 8.1 +/- 1.4 mm for men and 6.9 +/- 1.1 mm for women at L2/3, 8.7 +/- 1.5 mm for men and 7.6 +/- 1.2 mm for women at L3/4, 9.2 +/- 1.6 mm for men and 8.5 +/- 1.6 mm for women at L4/5, and 8.8 +/- 1.6 mm for men and 8.6 +/- 1.8 mm for women at L5/S1. Disc height was significantly smaller for women than men (P < 0.001), except at L5/S1.
   CONCLUSIONS: Variation in disc height is determined much more by sex than age. The maximum height of the interbody space in the adult lumbar spine was at the L4/5 level (8.9 +/- 1.7 mm [men], 8.6 +/- 1.8 mm [women]). Based on our findings, >10 mm cage height will result in supraphysiologic interbody space restoration and potentially predispose to complications.
C1 [Bach, Konrad; Januszewski, Jacob] Univ S Florida, Morsani Coll Med, Dept Neurol Surg, Tampa, FL 33620 USA.
   [Ford, Jonathan; Foley, Robert; Murtagh, Ryan; Decker, Summer] Univ S Florida, Morsani Coll Med, Dept Radiol, Tampa, FL USA.
   [Uribe, Juan S.] Barrow Neurol Inst, Dept Neurosurg, Phoenix, AZ 85013 USA.
RP Bach, K (reprint author), Univ S Florida, Morsani Coll Med, Dept Neurol Surg, Tampa, FL 33620 USA.
EM kbach@health.usf.edu
OI Decker, Summer/0000-0002-9256-5708; Ford, Jonathan/0000-0003-4367-9044
CR Albietz JS, 2012, EUR SPINE J, V21, P145, DOI 10.1007/s00586-011-1970-8
   BRINCKMANN P, 1983, SPINE, V8, P851, DOI 10.1097/00007632-198311000-00007
   Brinckmann P, 2004, SPINE, V29, P108, DOI 10.1097/01.BRS.0000102680.61791.5B
   Evans JD, 1996, STRAIGHTFORWARD STAT
   Frobin W, 2001, EUR RADIOL, V11, P263, DOI 10.1007/s003300000556
   Jackman TM, 2014, J ORTHOP RES, V32, P880, DOI 10.1002/jor.22620
   Le TV, 2012, SPINE, V37, P1268, DOI 10.1097/BRS.0b013e3182458b2f
   Luoma K, 2001, SPINE, V26, P680, DOI 10.1097/00007632-200103150-00026
   Marchi L, 2013, J NEUROSURG-SPINE, V19, P110, DOI 10.3171/2013.4.SPINE12319
   Morgan Elise F., 2005, European Journal of Morphology, V42, P13, DOI 10.1080/09243860500095273
   Oliveira L, 2010, SPINE, V35, pS331, DOI 10.1097/BRS.0b013e3182022db0
   Pfirrmann CWA, 2006, J ORTHOP RES, V24, P1086, DOI 10.1002/jor.20113
   Roberts N, 1997, J MAGN RESON IMAGING, V7, P880, DOI 10.1002/jmri.1880070517
   Rousseau MA, 2007, J SPINAL DISORD TECH, V20, P278, DOI 10.1097/01.bsd.0000211284.14143.63
   Shao Z, 2002, SPINE, V27, P263, DOI 10.1097/00007632-200202010-00013
   Tempel ZJ, 2015, EUR SPINE J, V24, pS409, DOI 10.1007/s00586-015-3845-x
   Truumees E, 2002, SPINE, V27, P2441, DOI 10.1097/00007632-200211150-00005
   TWOMEY L, 1985, ACTA ORTHOP SCAND, V56, P496, DOI 10.3109/17453678508993043
   Vadapalli S, 2006, SPINE, V31, P2189, DOI 10.1097/01.brs.0000232720.23748.ce
   Wang HL, 2016, BMC MUSCULOSKEL DIS, V17, DOI 10.1186/s12891-016-0866-5
NR 20
TC 0
Z9 0
U1 1
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP E106
EP E118
DI 10.1016/j.wneu.2018.12.014
PG 13
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800014
PM 30579030
DA 2020-05-12
ER

PT J
AU Campero, A
   Villalonga, JF
   Basso, A
AF Campero, Alvaro
   Villalonga, Juan F.
   Basso, Armando
TI Anatomical Risk Factors for Intraoperative Cerebrospinal Fluid Leaks
   During Transsphenoidal Surgery for Pituitary Adenomas
SO WORLD NEUROSURGERY
LA English
DT Article
DE CSF leak; Pituitary adenoma; Pituitary fossa; Risk factors;
   Transsphenoidal approach
ID RECONSTRUCTION; EXPERIENCE; COMPLICATIONS; REPAIR; RHINORRHEA;
   PREVENTION
AB BACKGROUND: Cerebrospinal fluid (CSF) fistulas are among the most clinically important and frequent complications of transsphenoidal surgery for pituitary adenomas. Between the adenoma and the CSF, a "barrier" exists that consists of <= 3 elements. These, from cephalad to caudad, are the arachnoid, dura mater (sellar diaphragm), and pituitary glandular tissue. The objective of the present study was to determine whether the presence or absence of any of these 3 anatomical elements would be associated with the development of an intraoperative CSF fistula.
   METHODS: From November 2016 to June 2018, 40 patients with pituitary adenomas underwent surgery, by transsphenoidal endonasal access, under a microscope. All procedures were filmed in 3 dimensions. The intraoperative findings and preoperative magnetic resonance images were analyzed and compared. The patients who had developed a fistula were compared against those who had not.
   RESULTS: In 20 patients, glandular tissue was identified between the tumor and subarachnoid space. In 13, dura mater was evident, and in 7, only the arachnoid was noted. An intraoperative CSF fistula occurred in 6 patients, all of whom had the arachnoid as the only barrier. The presence of a fistula was significantly more likely statistically for patients with an arachnoid-only barrier than for those with any other barrier composition (P < 0.001).
   CONCLUSIONS: The anatomical architecture forming the roof of the pituitary fossa is an important determinant of intraoperative CSF fistula risk. When the barrier consists of only the arachnoid, the risk will be significantly greater than when the barrier contains additional elements. Preoperative magnetic resonance imaging would be useful to determine the type of the existing barrier.
C1 [Campero, Alvaro] Univ Nacl Tucuman, Fac Med, LINT, San Miguel De Tucuman, Argentina.
   [Campero, Alvaro; Villalonga, Juan F.] Hosp Padilla, Jefe Serv Neurocirugia, San Miguel De Tucuman, Argentina.
   [Villalonga, Juan F.] FLENI, Dept Neurocirugia, Buenos Aires, DF, Argentina.
   [Basso, Armando] Univ Nacl Buenos Aires, Hosp Clin, Buenos Aires, DF, Argentina.
RP Villalonga, JF (reprint author), Hosp Padilla, Jefe Serv Neurocirugia, San Miguel De Tucuman, Argentina.; Villalonga, JF (reprint author), FLENI, Dept Neurocirugia, Buenos Aires, DF, Argentina.
EM jfvillalonga@gmail.com
CR Banu MA, 2014, J NEUROSURG, V121, P961, DOI 10.3171/2014.5.JNS132028
   Bergsneider M, 2011, OPER NEUROSURG, V71, P68
   Berker M, 2012, PITUITARY, V15, P288, DOI 10.1007/s11102-011-0368-2
   Campero A, 2008, NEUROSURGERY, V62, P717, DOI 10.1227/01.neu.0000317321.79106.37
   Cappabianca P, 1998, MINIM INVAS NEUROSUR, V41, P66, DOI 10.1055/s-2008-1052019
   Cappabianca P, 2004, NEUROSURGERY, V55, P933, DOI 10.1227/01.NEU.0000137330.02549.0D
   Cappabianca P, 2010, ACTA NEUROCHIR, V152, P897, DOI 10.1007/s00701-009-0580-2
   Cavallo LM, 2012, ACTA NEUROCHIR, V154, P2251, DOI 10.1007/s00701-012-1493-z
   Cho JM, 2011, NEUROSURGERY, V68, DOI 10.1227/NEU.0b013e318207b4ea
   Chung SB, 2012, ACTA NEUROCHIR, V154, P1499, DOI 10.1007/s00701-012-1404-3
   Dlouhy BJ, 2012, J NEUROSURG, V116, P1311, DOI 10.3171/2012.2.JNS111837
   Duntze J, 2012, NEUROCHIRURGIE, V58, P241, DOI 10.1016/j.neuchi.2012.02.005
   Fishpool SJC, 2017, EUR ARCH OTO-RHINO-L, V274, P837, DOI 10.1007/s00405-016-4287-8
   Freyschlag CF, 2016, J NEUROL SURG PART A, V77, P229, DOI 10.1055/s-0035-1547357
   Gaynor BG, 2013, J NEUROL SURG PART B, V74, P155, DOI 10.1055/s-0033-1338263
   Goljo E, 2018, AM J OTOLARYNG, V39, P253, DOI 10.1016/j.amjoto.2017.12.015
   Gondim JA, 2015, J NEUROSURG, V123, P31, DOI 10.3171/2014.10.JNS14372
   Gondim JA, 2011, PITUITARY, V14, P174, DOI 10.1007/s11102-010-0280-1
   Hadad G, 2006, LARYNGOSCOPE, V116, P1882, DOI 10.1097/01.mlg.0000234933.37779.e4
   Hardy J, 1969, Clin Neurosurg, V16, P185
   Jakimovski D, 2014, WORLD NEUROSURG, V82, pE513, DOI 10.1016/j.wneu.2013.06.005
   Jho HD, 1996, ACTA NEUROCHIR, V138, P1416, DOI 10.1007/BF01411120
   Jho HD, 1997, J NEUROSURG, V87, P44, DOI 10.3171/jns.1997.87.1.0044
   Lobatto DJ, 2018, PITUITARY, V21, P84, DOI 10.1007/s11102-017-0839-1
   Luginbuhl AJ, 2010, LARYNGOSCOPE, V120, P876, DOI 10.1002/lary.20861
   Magro E, 2016, WORLD NEUROSURG, V89, P442, DOI 10.1016/j.wneu.2016.02.059
   Nishioka H, 2009, ACTA NEUROCHIR, V151, P1427, DOI 10.1007/s00701-009-0406-2
   Nix P, 2016, BRIT J NEUROSURG, V30, P422, DOI 10.3109/02688697.2016.1161176
   Patel MR, 2010, SKULL BASE-INTERD AP, V20, P397, DOI 10.1055/s-0030-1253573
   Pereira EAC, 2017, J CLIN NEUROSCI, V44, P6, DOI 10.1016/j.jocn.2017.06.016
   Rabadan AT, 2009, J NEURO-ONCOL, V93, P127, DOI 10.1007/s11060-009-9858-8
   Rivera-Serrano CM, 2011, LARYNGOSCOPE, V121, P990, DOI 10.1002/lary.21419
   Sanders-Taylor C, 2015, J NEUROL SURG PART B, V76, P281, DOI 10.1055/s-0034-1544118
   Shikary T, 2017, WORLD NEUROSURG, V102, P608, DOI 10.1016/j.wneu.2017.03.008
   Strickland BA, 2018, J NEUROSURG, V129, P425, DOI 10.3171/2017.4.JNS162451
   Tien DA, 2016, OTOLARYNG CLIN N AM, V49, P119, DOI 10.1016/j.otc.2015.09.007
   Zhou QY, 2017, WORLD NEUROSURG, V101, P390, DOI 10.1016/j.wneu.2017.01.119
NR 37
TC 2
Z9 2
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP E346
EP E355
DI 10.1016/j.wneu.2018.12.094
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800045
PM 30615995
DA 2020-05-12
ER

PT J
AU Carl, B
   Bopp, M
   Gjorgjevski, M
   Oehrn, C
   Timmermann, L
   Nimsky, C
AF Carl, Barbara
   Bopp, Miriam
   Gjorgjevski, Marko
   Oehrn, Carina
   Timmermann, Lars
   Nimsky, Christopher
TI Implementation of Intraoperative Computed Tomography for Deep Brain
   Stimulation: Pitfalls and Optimization of Workflow, Accuracy, and
   Radiation Exposure
SO WORLD NEUROSURGERY
LA English
DT Article
DE Deep brain stimulation; Effective radiation dose; Intraoperative
   computed tomography imaging; Lead localization; Microelectrode imaging;
   Registration accuracy
ID DOSE-LENGTH PRODUCT; O-ARM; STEREOTACTIC ACCURACY; SUBTHALAMIC NUCLEUS;
   CT; PLACEMENT; FRAME; MRI; ELECTRODES; NEXFRAME
AB OBJECTIVE: Deep brain stimulation (DBS) is an effective treatment for movement disorders. Stereotactic electrode placement can be guided by intraoperative imaging, which also allows for immediate intraoperative quality control. This article is about implementation and refining a workflow applying intraoperative computed tomography (iCT) for DBS.
   METHODS: Eighteen patients underwent DBS with bilateral implantation of directional electrodes applying a 32-slice movable computed tomography scanner in combination with microelectrode recording.
   RESULTS: iCT led to a significant decrease in overall procedural time, despite performing multiple scans. In 3 of the initial 5 cases, iCT caused an adjustment of the final electrodes demonstrating the learning curve and the necessity to integrate road mapping for the exchange of microelectrode to final electrode. Implementation of low-dose computed tomography protocols added microelectrode iCT to the refined workflow, resulting in an intraoperative adjustment of a trajectory in 1 patient. Low-dose protocols lowered the total effective dose to 1.15 mSv, that is, a reduction by a factor of 3.5 compared to a standard non-iCT DBS procedure, despite repeated iCTs. Intraoperative lead detection based on final iCT revealed a radial error of 1.04 +/- 0.58 mm and a vector error of 2.28 +/- 0.97 mm compared to the preoperative planning, adjusted by the findings of microelectrode recording.
   CONCLUSIONS: iCT can be easily integrated into the surgical workflow resulting in an overall efficient timesaving procedure. Repeated intraoperative scanning ensures reliable electrode placement, although low-dose scanning protocols prevent extensive radiation exposure. iCT of microelectrodes is feasible and led to the adjustment of 1 electrode.
C1 [Carl, Barbara; Bopp, Miriam; Gjorgjevski, Marko; Nimsky, Christopher] Univ Marburg, Dept Neurosurg, Marburg, Germany.
   [Oehrn, Carina; Timmermann, Lars] Univ Marburg, Dept Neurol, Marburg, Germany.
   [Bopp, Miriam; Timmermann, Lars; Nimsky, Christopher] MCMBB, Marburg, Germany.
RP Carl, B (reprint author), Univ Marburg, Dept Neurosurg, Marburg, Germany.
EM carlb@med.uni-marburg.de
RI Nimsky, Christopher/E-3702-2014
OI Nimsky, Christopher/0000-0002-8216-9410; Oehrn, Carina
   Renate/0000-0001-8451-7960; Carl, Barbara/0000-0003-3661-9908; Bopp,
   Miriam H. A./0000-0003-1574-7572
CR Abul-Kasim K, 2012, J SPINAL DISORD TECH, V25, P52, DOI 10.1097/BSD.0b013e318211fdea
   [Anonymous], 2007, Ann ICRP, V37, P1, DOI 10.1016/j.icrp.2008.08.001
   Bot M, 2017, STEREOT FUNCT NEUROS, V95, P183, DOI 10.1159/000475672
   Bot M, 2015, STEREOT FUNCT NEUROS, V93, P316, DOI 10.1159/000375178
   Brahimaj B, 2018, J CLIN NEUROSCI, V50, P58, DOI 10.1016/j.jocn.2018.01.020
   Burchiel KJ, 2013, J NEUROSURG, V119, P301, DOI 10.3171/2013.4.JNS122324
   Bus S, 2018, ACTA NEUROCHIR, V160, P373, DOI 10.1007/s00701-017-3432-5
   Caire F, 2010, STEREOT FUNCT NEUROS, V88, P109, DOI 10.1159/000280823
   Carl B, 2018, WORLD NEUROSURG, V118, pE584, DOI 10.1016/j.wneu.2018.06.246
   Carl B, 2018, WORLD NEUROSURG, V113, pE414, DOI 10.1016/j.wneu.2018.02.045
   De Salles AAF, 2004, MINIM INVAS NEUROSUR, V47, P284, DOI 10.1055/s-2004-830094
   Fiegele T, 2008, PARKINSONISM RELAT D, V14, P595, DOI 10.1016/j.parkreldis.2008.01.008
   Hall Walter A, 2005, Magn Reson Imaging Clin N Am, V13, P533, DOI 10.1016/j.mric.2005.04.001
   Holloway K, 2013, NEUROSURGERY, V72, P47, DOI 10.1227/NEU.0b013e318273a090
   Huda W, 2008, RADIOLOGY, V248, P995, DOI 10.1148/radiol.2483071964
   Huda W, 2011, MED PHYS, V38, P1261, DOI 10.1118/1.3544350
   Hyam JA, 2015, OPER NEUROSURG, V11, P412, DOI 10.1227/NEU.0000000000000848
   Kelman C, 2010, STEREOT FUNCT NEUROS, V88, P288, DOI 10.1159/000316761
   Ketcha MD, 2017, P SPIE INT SOC OPT E, V10135
   Kochanski RB, 2018, BRAIN SCI, V8, DOI 10.3390/brainsci8010017
   Kochanski RB, 2017, WORLD NEUROSURG, V103, P168, DOI 10.1016/j.wneu.2017.04.003
   Kochanski RB, 2016, CLIN NEUROL NEUROSUR, V150, P164, DOI 10.1016/j.clineuro.2016.09.014
   Lefranc M, 2014, STEREOT FUNCT NEUROS, V92, P242, DOI 10.1159/000362936
   Li Z, 2016, STEREOT FUNCT NEUROS, V94, P351, DOI 10.1159/000449206
   Lin EC, 2010, MAYO CLIN PROC, V85, P1142, DOI 10.4065/mcp.2010.0260
   Manninen AL, 2012, AM J NEURORADIOL, V33, P2038, DOI 10.3174/ajnr.A3123
   Martin AJ, 2005, MAGN RESON MED, V54, P1107, DOI 10.1002/mrm.20675
   Mirzadeh Z, 2016, J NEUROSURG, V124, P902, DOI 10.3171/2015.4.JNS1550
   Mirzadeh Z, 2014, MOVEMENT DISORD, V29, P1788, DOI 10.1002/mds.26056
   Okun MS, 2005, ARCH NEUROL-CHICAGO, V62, P1250, DOI 10.1001/archneur.62.8.noc40425
   Pezeshkian P, 2011, NEUROSURGERY, V69, P1299, DOI 10.1227/NEU.0b013e31822b7069
   Richardson RM, 2009, STEREOT FUNCT NEUROS, V87, P297, DOI 10.1159/000230692
   Saleh C, 2016, NEURORADIOL J, V29, P244, DOI 10.1177/1971400916639960
   Sarwahi V, 2017, SPINE, V42, pE1311, DOI 10.1097/BRS.0000000000002154
   Schrader B, 2002, MOVEMENT DISORD, V17, pS167, DOI 10.1002/mds.10160
   Seijo F, 2014, ACTA NEUROCHIR, V156, P1505, DOI 10.1007/s00701-014-2082-0
   Servello Domenico, 2016, Surg Neurol Int, V7, pS551, DOI 10.4103/2152-7806.187534
   Shahlaie K, 2011, NEUROSURGERY, V68, P114, DOI 10.1227/NEU.0b013e31820781bc
   SHALIT MN, 1979, SURG NEUROL, V11, P382
   Smith AP, 2011, J NEUROSURG, V115, P301, DOI 10.3171/2011.3.JNS101642
   Starr PA, 2010, J NEUROSURG, V112, P479, DOI 10.3171/2009.6.JNS081161
   Starr PA, 2009, NEUROSURG CLIN N AM, V20, P207, DOI 10.1016/j.nec.2009.04.010
   von Langsdorff D, 2015, J NEUROSURG, V122, P191, DOI 10.3171/2014.9.JNS14256
   Weise LM, 2014, ACTA NEUROCHIR, V156, P581, DOI 10.1007/s00701-013-1897-4
NR 44
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP E252
EP E265
DI 10.1016/j.wneu.2018.12.079
PG 14
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800033
PM 30593970
DA 2020-05-12
ER

PT J
AU Chen, D
   Li, XY
   Zhu, XQ
   Wu, LX
   Ma, SQ
   Yan, J
   Yan, DM
AF Chen, Di
   Li, Xueyuan
   Zhu, Xuqiang
   Wu, Lixin
   Ma, Siqi
   Yan, Jing
   Yan, Dongming
TI Diffusion Tensor Imaging with Fluorescein Sodium Staining in the
   Resection of High-Grade Gliomas in Functional Brain Areas
SO WORLD NEUROSURGERY
LA English
DT Article
DE Brain functional areas; Diffusion tensor imaging; Fluorescein sodium;
   Glioma; Neurosurgical procedures
ID WHITE-MATTER; GUIDED SURGERY; GLIOBLASTOMA-MULTIFORME; TRACTOGRAPHY;
   TRACKING; ANATOMY; FILTER
AB OBJECTIVE: To evaluate the feasibility and clinical value of magnetic resonance diffusion tensor imaging (DTI) with fluorescein sodium staining (FLS) in the resection of high-grade glioma (HGG) in functional brain areas.
   METHODS: Retrospective cohort study design. The data of 95 patients who underwent surgery at the First Affiliated Hospital of Zhengzhou University for HGG in functional brain areas from October 2014 to December 2017 were investigated. In the observation group, 49 patients underwent DTI preoperatively and received FLS for the removal of tumor during the operation. In the control group, 46 patients received the routine method. All patients were subjected to enhanced magnetic resonance imaging to assess the extent of tumor resection within 72 hours after operation. The changes in muscle strength and Karnofsky Performance Status Scale (KPS) scores were evaluated 1 month after surgery.
   RESULTS: The extent of resection was significantly higher in the observation group than in the control group (83.7% vs. 45.7%, respectively; P < 0.001). The rate of muscle strength reduction after surgery was remarkably lower in the observation group than in the control group (20.4% vs. 47.8%, respectively; P = 0.005). KPS scores were higher in the observation group than in the control group (73.5% vs. 47.8%, respectively; P = 0.029). In the observation group, the sensitivity of FLS in identifying tumor tissue was 91.7% (44/48), with a specificity of 90.0% (45/50).
   CONCLUSIONS: The application of DTI with FLS can facilitate the maximum resection of HGG in functional brain areas with minimum loss of fiber tracts, reduce the disability rate, and improve quality of postoperative life compared with traditional glioma surgery.
C1 [Chen, Di; Li, Xueyuan; Zhu, Xuqiang; Wu, Lixin; Ma, Siqi; Yan, Dongming] Zhengzhou Univ, Affiliated Hosp 1, Dept Neurosurg, Zhengzhou, Henan, Peoples R China.
   [Yan, Jing] Zhengzhou Univ, Affiliated Hosp 1, Dept Magnet Resonance Imaging, Zhengzhou, Henan, Peoples R China.
RP Yan, DM (reprint author), Zhengzhou Univ, Affiliated Hosp 1, Dept Neurosurg, Zhengzhou, Henan, Peoples R China.
EM mrdmyan@163.com
FU Science and Technology Key Fund Project of Henan Province [17210241001];
   Major Scientific Research Project of Henan Province Higher College
   [18A320077]
FX This work was supported by grants from the Science and Technology Key
   Fund Project of Henan Province (17210241001) and Major Scientific
   Research Project of Henan Province Higher College (18A320077).
CR Acerbi F, 2014, NEUROSURG FOCUS, V36, DOI 10.3171/2013.11.FOCUS13487
   Acerbi F, 2013, ACTA NEUROCHIR, V155, P1277, DOI 10.1007/s00701-013-1734-9
   Arfanakis K, 2006, ONCOL REP, V15, P1061
   Berman J, 2009, MAGN RESON IMAGING C, V17, P205, DOI 10.1016/j.mric.2009.02.002
   Craig SEL, 2016, WORLD NEUROSURG, V90, P154, DOI 10.1016/j.wneu.2016.02.060
   De Bonis P, 2013, CLIN NEUROL NEUROSUR, V115, P37, DOI 10.1016/j.clineuro.2012.04.005
   Dilek O, 2011, J CLIN NEUROSCI, V18, P430, DOI 10.1016/j.jocn.2010.06.012
   Feiden S, 2008, PATHOLOGE, V29, P411, DOI 10.1007/s00292-008-1064-5
   Feigl GC, 2014, WORLD NEUROSURG, V81, P144, DOI 10.1016/j.wneu.2013.01.004
   Jellison BJ, 2004, AM J NEURORADIOL, V25, P356
   Jung H, 2014, CURR SURG REP, V2, DOI 10.1007/s40137-014-0069-7
   Koc K, 2008, BRIT J NEUROSURG, V22, P99, DOI 10.1080/02688690701765524
   Kwan ASL, 2006, CLIN EXP OPHTHALMOL, V34, P33, DOI 10.1111/j.1442-9071.2006.01136.x
   Li YP, 2014, WORLD NEUROSURG, V82, P175, DOI 10.1016/j.wneu.2013.06.014
   Liu JTC, 2014, NEUROSURGERY, V75, P61, DOI 10.1227/NEU.0000000000000344
   McGirt MJ, 2009, NEUROSURGERY, V65, P463, DOI 10.1227/01.NEU.0000349763.42238.E9
   Mori S, 1999, ANN NEUROL, V45, P265, DOI 10.1002/1531-8249(199902)45:2<265::AID-ANA21>3.0.CO;2-3
   Mori S, 2002, ANN NEUROL, V51, P377, DOI 10.1002/ana.10137
   Romano A, 2010, INT J MED RADIOL, V19, P2798
   Schebesch KM, 2013, ACTA NEUROCHIR, V155, P693, DOI 10.1007/s00701-013-1643-y
   Shinoda J, 2003, J NEUROSURG, V99, P597, DOI 10.3171/jns.2003.99.3.0597
   Stummer W, 2012, J NEURO-ONCOL, V108, P89, DOI 10.1007/s11060-012-0798-3
   Stupp R, 2005, NEUROCHIRURGIE, V51, P50
   Tanahashi S, 2006, ANESTH ANALG, V103, P503, DOI 10.1213/01.ANE.0000227205.37935.10
   Tonn Jorg-Christian, 2008, Clin Neurosurg, V55, P20
   Witwer BP, 2002, J NEUROSURG, V97, P568, DOI 10.3171/jns.2002.97.3.0568
   Wu JS, 2007, NEUROSURGERY, V61, P935, DOI 10.1227/01.neu.0000303189.80049.ab
   Xu JL, 2010, NEURORADIOLOGY, V52, P1193, DOI 10.1007/s00234-010-0731-4
NR 28
TC 2
Z9 2
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP E595
EP E603
DI 10.1016/j.wneu.2018.12.160
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800076
PM 30639485
DA 2020-05-12
ER

PT J
AU Chen, SF
   Luo, M
   Wang, YK
   Liu, HJ
AF Chen, Songfeng
   Luo, Ming
   Wang, Yongkui
   Liu, Hongjian
TI Stopping at Sacrum Versus Nonsacral Vertebra in Long Fusion Surgery for
   Adult Spinal Deformity: Meta-Analysis of Revision with Minimum 2-Year
   Follow-Up
SO WORLD NEUROSURGERY
LA English
DT Article
DE Adult spinal deformity; Meta-analysis; Nonsacrum; Revision; Sacrum
ID PROXIMAL JUNCTIONAL KYPHOSIS; ADJACENT SEGMENT PATHOLOGY; RISK-FACTORS;
   L5; L5-S1; ARTHRODESIS; FATE; S1; INSTRUMENTATION; REOPERATION
AB OBJECTIVE: A pooled comparison was conducted on a revision to the sacrum (S) versus a nonsacral (NS) surgical strategy in adult spinal deformity (ASD).
   METHODS: Strictly following the PRISMA 2009 guidelines, the MEDLINE, EMBASE, and Cochrane Library databases were used to search for studies published in English up to March 2018 that addressed the S versus NS surgical approach for a long fusion to treat ASD. Data on total revisions and revision reasons were extracted from the included studies and were pooled analyzed.
   RESULTS: Eight retrospective studies with a total of 1846 ASD patients (528 S and 1318 NS) were included. The total revision rate was 11.38% (S: 17.80% and NS: 8.80%), and implant failure, pseudarthrosis, adjacent segment degeneration, and proximal junctional kyphosis (PJK) were common reasons for revision. The pooled results indicated that the NS group had decreased incident rates of total revision (95% confidence interval [CI] 1.20-2.32, P = 0.002; I-2 = 0%) and pseudarthrosis (95% CI 2.16-15.44, P = 0.0005; I-2 = 0%) compared with the S group. No significant differences were observed in implant failure (95% CI 0.86-3.90, P = 0.12; I-2 = 0%), adjacent segment degeneration (95% CI 0.08-1.25, P = 0.10; I-2 = 0%), and PJK (95% CI 0.54-6.88, P = 0.35; I-2 = 0%) between the 2 groups.
   CONCLUSIONS: Revision in ASD patients is a serious problem with a total rate of 11.38%, and implant failure, pseudarthrosis, adjacent segment degeneration, and PJK are common reasons for revision. Stopping at the sacrum vertebra in long fusion surgery on ASD patients seems to increase the incidence rates of total revision and pseudarthrosis.
C1 [Chen, Songfeng; Luo, Ming; Wang, Yongkui; Liu, Hongjian] Zhengzhou Univ, Dept Orthoped Surg, Affiliated Hosp 1, Zhengzhou, Henan, Peoples R China.
RP Liu, HJ (reprint author), Zhengzhou Univ, Dept Orthoped Surg, Affiliated Hosp 1, Zhengzhou, Henan, Peoples R China.
EM hongjianmd@sina.com
CR Bess S, 2016, CLIN SPINE SURG, V29, P6, DOI 10.1097/BSD.0000000000000352
   Bridwell KH, 2013, NEUROSURGERY, V72, P899, DOI 10.1227/NEU.0b013e31828bacd8
   Brown KM, 2004, J SPINAL DISORD TECH, V17, P358, DOI 10.1097/01.bsd.0000112080.04960.67
   Caridi J, 2011, SPINE J S10, V11, p172S, DOI [10.1016/j.spinee.2011.08.411, DOI 10.1016/J.SPINEE.2011.08.411]
   Cho KJ, 2009, EUR SPINE J, V18, P531, DOI 10.1007/s00586-009-0883-2
   Crawford CH, 2012, EUR SPINE J, V21, P2165, DOI 10.1007/s00586-012-2310-3
   Drazin D, 2011, NEUROSURG FOCUS, V31, DOI 10.3171/2011.7.FOCUS11145
   Eck K R, 2001, Spine (Phila Pa 1976), V26, pE182, DOI 10.1097/00007632-200105010-00012
   Edwards CC, 2004, SPINE, V29, P1996, DOI 10.1097/01.brs.0000138272.54896.33
   Edwards CC, 2003, SPINE, V28, P2122, DOI 10.1097/01.BRS.0000084266.37210.85
   Emami A, 2002, SPINE, V27, P776, DOI 10.1097/00007632-200204010-00017
   Faloon Michael J, 2015, Spine Deform, V3, P367, DOI 10.1016/j.jspd.2015.02.005
   Glassman Steven D, 2015, Spine Deform, V3, P199, DOI 10.1016/j.jspd.2014.08.005
   Harding IJ, 2008, EUR SPINE J, V17, P250, DOI 10.1007/s00586-007-0539-z
   Horton WC, 1996, SPINE, V21, P2520, DOI 10.1097/00007632-199611010-00024
   Kasliwal MK, 2012, SPINE, V37, pS165, DOI 10.1097/BRS.0b013e31826d62c9
   Kim HJ, 2016, J AM ACAD ORTHOP SUR, V24, P318, DOI 10.5435/JAAOS-D-14-00393
   Kim HJ, 2012, SPINE, V37, pS144, DOI 10.1097/BRS.0b013e31826d611b
   Kuhns CA, 2007, SPINE, V32, P2771, DOI 10.1097/BRS.0b013e31815a7ece
   Lau D, 2016, SPINE, V41, P213, DOI 10.1097/BRS.0000000000001326
   Liu FY, 2016, EUR SPINE J, V25, P2376, DOI 10.1007/s00586-016-4534-0
   Maruo K, 2013, SPINE, V38, pE1469, DOI 10.1097/BRS.0b013e3182a51d43
   Mok JM, 2009, SPINE, V34, P832, DOI 10.1097/BRS.0b013e31819f2080
   Park SJ, 2017, NEUROSURGERY, V80, P279, DOI 10.1227/NEU.0000000000001240
   Paxinos O, 2010, J NEUROSURG-SPINE, V13, P469, DOI 10.3171/2010.4.SPINE09764
   Pichelmann MA, 2010, SPINE, V35, P219, DOI 10.1097/BRS.0b013e3181c91180
   Polly DW, 2006, SPINE, V31, pS179, DOI 10.1097/01.brs.0000234761.87368.ee
   Puvanesarajah V, 2016, J NEUROSURG-SPINE, V25, P486, DOI 10.3171/2016.2.SPINE151345
   Scheer JK, 2018, SPINE, V43, P339, DOI 10.1097/BRS.0000000000001626
   Scheer JK, 2015, SPINE, V40, P1505, DOI 10.1097/BRS.0000000000001062
   Scheer JK, 2013, J NEUROSURG-SPINE, V19, P464, DOI 10.3171/2013.7.SPINE12901
   Schlenk Richard P, 2003, Neurosurg Focus, V15, pE2
   Sciubba Daniel M, 2015, Spine Deform, V3, P575, DOI 10.1016/j.jspd.2015.04.005
   Smith JS, 2016, NEUROSURGERY, V78, P851, DOI 10.1227/NEU.0000000000001116
   Swamy G, 2007, NEUROSURG CLIN N AM, V18, P281, DOI 10.1016/j.nec.2007.01.010
   Tsuchiya K, 2006, SPINE, V31, P303, DOI 10.1097/01.brs.0000197193.81296.f1
   Xu LL, 2013, EUR SPINE J, V22, P1326, DOI 10.1007/s00586-013-2678-8
   Yasuda Tatsuya, 2016, Spine Deform, V4, P378, DOI 10.1016/j.jspd.2016.03.001
   Zhu F, 2014, SPINE, V39, pB36, DOI 10.1097/BRS.0000000000000463
NR 39
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP E380
EP E386
DI 10.1016/j.wneu.2018.12.102
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800049
PM 30605759
DA 2020-05-12
ER

PT J
AU Davison, MA
   Desai, SA
   Lilly, DT
   Vuong, VD
   Moreno, J
   Bagley, C
   Adogwa, O
AF Davison, Mark A.
   Desai, Shyam A.
   Lilly, Daniel T.
   Vuong, Victoria D.
   Moreno, Jessica
   Bagley, Carlos
   Adogwa, Owoicho
TI A Two-Year Cost Analysis of Maximum Nonoperative Treatments in Patients
   with Cervical Stenosis that Ultimately Required Surgery
SO WORLD NEUROSURGERY
LA English
DT Article
DE Anterior cervical discectomy and fusion; Cervical stenosis; Cervical
   surgery; Cost analysis; Nonoperative therapy; Opioid use; Symptomatic
   upper back pain
ID MULTICENTER; MYELOPATHY; TRENDS; NECK
AB OBJECTIVE: The aim of this study is to characterize the use and associated costs of maximal nonoperative therapy (MNT) received within 2-years before anterior cervical discectomy and fusion (ACDF) surgery in patients with symptomatic cervical stenosis.
   METHODS: An insurance database, including private/commercially insured and Medicare Advantage beneficiaries, was queried for patients undergoing 1-level, 2-level, or 3-level ACDF procedures between 2007 and 2016. Research records were searchable by International Classification of Diseases diagnosis and procedure, Current Procedural Terminology, and generic drug codes. The use of MNTs within 2 years before index ACDF surgery was assessed by cost billed to patients, prescriptions written, and number of units billed.
   RESULTS: Of 220,902 (7.16%) eligible patients, 15,825 underwent index surgery. Patient breakdown of the use of MNT modalities was as follows: 5731 (36.2%) used nonsteroidal antiinflammatory drugs; 9827 (62.1%) used opioids; 7383 (46.7%) used muscle relaxants; 3609 (22.8%) received cervical epidural steroid injection; 5504 (34.8%) attended physical therapy/occupational therapy; 1663 (10.5%) received chiropractor treatments; and 200 (1.3%) presented to the emergency department. During the 2-year preoperative period, there were 51,675 prescriptions for diagnostic cervical imaging. The total direct cost associated with all MNTs before ACDF was $16,056,556. Cervical spine imaging comprised the largest portion of the total MNT cost ($8,677,110; 54.0%), followed by cervical epidural steroid injection ($3,315,913; 20.7%) and opioids ($2,228,221; 13.9%). Opiates were the most frequently prescribed therapy (71,602 prescriptions).
   DISCUSSION: Opioids are the most frequently prescribed and most used therapy in the preoperative period for cervical stenosis. Further studies and improved guidelines are necessary to determine which patients may benefit from ACDF earlier in the course of nonoperative therapies.
C1 [Davison, Mark A.; Desai, Shyam A.; Lilly, Daniel T.; Vuong, Victoria D.; Adogwa, Owoicho] Rush Univ, Med Ctr, Dept Neurosurg, Chicago, IL 60612 USA.
   [Moreno, Jessica; Bagley, Carlos] Univ Texas Southwestern Med Ctr Dallas, Dept Neurosurg, Dallas, TX 75390 USA.
RP Adogwa, O (reprint author), Rush Univ, Med Ctr, Dept Neurosurg, Chicago, IL 60612 USA.
EM owoicho.adogwa@gmail.com
OI Desai, Shyam/0000-0001-5823-8546
CR Boogaarts HD, 2015, EUR SPINE J, V24, pS139, DOI 10.1007/s00586-013-2781-x
   Chiles BW, 1999, NEUROSURGERY, V44, P762, DOI 10.1097/00006123-199904000-00041
   Cohen SP, 2014, ANESTHESIOLOGY, V121, P1045, DOI 10.1097/ALN.0000000000000409
   Cummins J, 2006, SPINE, V31, P806, DOI 10.1097/01.brs.0000207473.09030.0d
   Faour M, 2017, ORTHOPEDICS, V40, P25, DOI 10.3928/01477447-20161013-02
   Faour M, 2017, SPINE, V42, pE104, DOI 10.1097/BRS.0000000000001715
   Gerling MC, 2018, INT J SPINE SURG, V12, P250, DOI 10.14444/5031
   Hoy D, 2014, ANN RHEUM DIS, V73, P1309, DOI 10.1136/annrheumdis-2013-204431
   Jain N, 2018, SPINE J, V18, P1989, DOI 10.1016/j.spinee.2018.03.015
   Lawrence JTR, 2008, SPINE, V33, P2074, DOI 10.1097/BRS.0b013e3181809f07
   Lee Dennis, 2014, J Bone Joint Surg Am, V96, pe89
   Michaleff ZA, 2012, EUR SPINE J, V21, P1283, DOI 10.1007/s00586-011-2135-5
   Murray CJL, 2013, JAMA-J AM MED ASSOC, V310, P591, DOI 10.1001/jama.2013.13805
   Pugely AJ, 2018, SPINE J, V18, P1974, DOI 10.1016/j.spinee.2018.03.018
   Sampath P, 2000, SPINE, V25, P670, DOI 10.1097/00007632-200003150-00004
NR 15
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP E616
EP E625
DI 10.1016/j.wneu.2018.12.167
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800079
PM 30641237
DA 2020-05-12
ER

PT J
AU Ding, ZM
   Lu, XJ
   Wang, Q
   Li, B
   Qian, XW
   Liu, XY
AF Ding, Zhemin
   Lu, Xiaojie
   Wang, Qing
   Li, Bing
   Qian, Xinwei
   Liu, Xiaoyong
TI Intradural Subtemporal Keyhole Approach with Neuronavigational
   Assistance to the Petroclival and Ventrolateral Brainstem Regions:
   Quantitative Analysis of Anatomic Exposure and Surgical Freedom
SO WORLD NEUROSURGERY
LA English
DT Article
DE Endoscopy; Keyhole; Kawase; Navigational assistance; Subtemporal
   approach; Surgical freedom
ID TRIGEMINAL SCHWANNOMAS; TRANSPETROSAL APPROACH; MENINGIOMAS; SURGERY;
   FOSSA; EVOLUTION; PROPOSAL; LESIONS; TUMORS; CAVE
AB OBJECTIVE: The purpose of this study was to evaluate the advantages of endoscopy and navigational assistance in the intradural subtemporal keyhole approach and the intradural Kawase approach by studying anatomic exposure and surgical freedom in the posterior cranial fossa.
   METHODS: Twenty endoscopic intradural subtemporal keyhole approaches (EISKA) were performed on 10 cadaveric heads. An intradural Kawase approach and a navigation-assisted intradural Kawase approach were then carried out on a random side of each specimen. Related anatomic structures were observed through a 0 degrees endoscope and a microscope. Anatomic exposure and surgical freedom were measured by transparent graph paper and analyzed.
   RESULTS: Compared with themicrosurgical technique, the superior, inferior, and medial limits of the endoscopic anatomic exposure increased by 2.9, 15.65, and 10.2 mm, whereas the surgical freedom increased by 2.9, 7.55, and 6mm (P < 0.05) in the intradural subtemporal keyhole approach. In the intradural Kawase approach and the navigation-assisted intradural Kawase approach, the endoscopic anatomic exposure and surgical freedom also increased (P < 0.05). Using a frameless navigational device, the inferior limit of the anatomic exposure increased 3.8 mm by endoscopy and 3.5 mm by microscopy, whereas the surgical freedom increased by 2.7 and 2.2 mm, respectively (P < 0.05).
   CONCLUSIONS: The EISKA provides greater anatomic exposure and surgical freedom primarily in the superior, inferior, and medial directions of the brainstem region. Maximum anatomic exposure and surgical freedom of the posterior cranial fossa was obtained by navigational assistance with fewer complications.
C1 [Ding, Zhemin; Qian, Xinwei; Liu, Xiaoyong] Jiangnan Univ, Dept Neurosurg, Affiliated Hosp, Wuxi, Jiangsu, Peoples R China.
   [Ding, Zhemin; Qian, Xinwei; Liu, Xiaoyong] Fourth Peoples Hosp Wuxi, Wuxi, Peoples R China.
   [Lu, Xiaojie; Wang, Qing; Li, Bing] Nanjing Med Univ, Dept Neurosurg, Affiliated Wuxi Peoples Hosp 2, Nanjing, Jiangsu, Peoples R China.
   [Lu, Xiaojie] Jiangnan Univ, Dept Neurosci Ctr, Wuxi, Jiangsu, Peoples R China.
RP Ding, ZM (reprint author), Jiangnan Univ, Dept Neurosurg, Affiliated Hosp, Wuxi, Jiangsu, Peoples R China.; Ding, ZM (reprint author), Fourth Peoples Hosp Wuxi, Wuxi, Peoples R China.
EM zheminding@163.com
FU Health and Planning Commission Fund of Wuxi City [Q201838]; Clinical
   Special Science Fund of Science and Technology of Jiangsu Province
   [BL2013006]; Six-Talent Peak Fund of Jiangsu Province [WSW-063]; 333
   High-level Personnel Training Project Fund of Jiangsu Province
   [BRA2015051]
FX This work was supported by the Health and Planning Commission Fund of
   Wuxi City (grant number Q201838), Clinical Special Science Fund of
   Science and Technology of Jiangsu Province (grant number BL2013006),
   Six-Talent Peak Fund of Jiangsu Province (grant number WSW-063), and 333
   High-level Personnel Training Project Fund of Jiangsu Province (grant
   number BRA2015051).
CR Al-Mefty O, 2002, J NEUROSURG, V96, P453, DOI 10.3171/jns.2002.96.3.0453
   ALMEFTY O, 1988, NEUROSURGERY, V22, P510, DOI 10.1227/00006123-198803000-00010
   Anik I, 2018, WORLD NEUROSURG, V112, pE691, DOI 10.1016/j.wneu.2018.01.134
   Bambakidis NC, 2007, NEUROSURGERY, V61, P202, DOI [10.1227/01.NIEU.0000280119.36270.BA, 10.1227/01.neu.0000303218.61230.39]
   Ding ZM, 2017, WORLD NEUROSURG, V101, P606, DOI 10.1016/j.wneu.2017.02.052
   Dogan Ihsan, 2017, Neurosurg Focus, V43, pV12, DOI 10.3171/2017.10.FocusVid.17379
   Fries G, 1998, NEUROSURGERY, V42, P226, DOI 10.1097/00006123-199802000-00008
   Goehre F, 2015, WORLD NEUROSURG, V83, P842, DOI 10.1016/j.wneu.2015.01.042
   Goel A, 2003, NEUROSURGERY, V52, P783, DOI 10.1227/01.NEU.0000053365.05795.03
   Goel A, 2018, WORLD NEUROSURG, V110, pE835, DOI 10.1016/j.wneu.2017.11.127
   Guan MW, 2013, CHINESE MED J-PEKING, V126, P1707, DOI 10.3760/cma.j.issn.0366-6999.20122844
   Hunter JB, 2015, OTOLARYNG CLIN N AM, V48, P477, DOI 10.1016/j.otc.2015.02.007
   Ito CJ, 2016, J NEUROL SURG REP, V77, pE56, DOI 10.1055/s-0035-1570389
   KAWASE T, 1991, NEUROSURGERY, V28, P869, DOI 10.1227/00006123-199106000-00014
   KAWASE T, 1985, J NEUROSURG, V63, P857, DOI 10.3171/jns.1985.63.6.0857
   MILLER CG, 1993, NEUROSURGERY, V33, P461
   Nagata Y, 2018, J NEUROSURG, V128, P685, DOI 10.3171/2016.11.JNS161833
   Nakov Vladimir S, 2017, Surg Neurol Int, V8, P15, DOI 10.4103/2152-7806.199555
   ODONOGHUE GM, 1993, AM J OTOL, V14, P122
   Perneczky A, 1998, NEUROSURGERY, V42, P219, DOI 10.1097/00006123-199802000-00001
   Pichierri A, 2010, NEUROSURGERY, V67, P29, DOI 10.1227/01.NEU.0000383131.72001.9E
   Sabatino G, 2012, ACTA NEUROCHIR, V154, P2009, DOI 10.1007/s00701-012-1496-9
   Samii M, 2000, J NEUROSURG, V92, P235, DOI 10.3171/jns.2000.92.2.0235
   Sanusi O, 2018, WORLD NEUROSURG, V115, pE13, DOI 10.1016/j.wneu.2018.02.127
   Sassun TE, 2016, WORLD NEUROSURG, V96, P111, DOI 10.1016/j.wneu.2016.08.023
   Sato Y, 2018, WORLD NEUROSURG, V110, P93, DOI 10.1016/j.wneu.2017.10.176
   Sekhar L N, 1991, Acta Neurochir Suppl (Wien), V53, P183
   Spetzler R F, 1994, Clin Neurosurg, V41, P62
   Sure U, 2000, SURG NEUROL, V53, P563, DOI 10.1016/S0090-3019(00)00243-3
   TAHA JM, 1995, J NEUROSURG, V82, P719, DOI 10.3171/jns.1995.82.5.0719
   Tatagiba M, 2015, WORLD NEUROSURG, V84, P1708, DOI 10.1016/j.wneu.2015.07.033
   Tripathi M, 2015, J NEUROSURG, V123, P14, DOI 10.3171/2015.2.JNS132876
   Vega-Basulto S, 2003, REV NEUROLOGIA, V37, P711, DOI 10.33588/rn.3708.2003168
   Wang Q, 2016, WORLD NEUROSURG, V95, DOI 10.1016/j.wneu.2016.08.062
   Wang Q, 2010, WORLD NEUROSURG, V73, P694, DOI 10.1016/j.wneu.2010.04.007
   Watanabe T, 2014, ACTA NEUROCHIR, V156, P1145, DOI 10.1007/s00701-014-2085-x
   Yoshida K, 1999, J NEUROSURG, V91, P202, DOI 10.3171/jns.1999.91.2.0202
   Yoshida K, 2009, NEUROL MED-CHIR, V49, P580, DOI 10.2176/nmc.49.580
   Youssef S, 2006, NEUROSURGERY, V59, P270, DOI 10.1227/01.NEU.0000227580.70254.02
NR 39
TC 0
Z9 0
U1 0
U2 11
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP E682
EP E692
DI 10.1016/j.wneu.2019.01.006
PG 11
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800087
PM 30659968
DA 2020-05-12
ER

PT J
AU Dones, F
   Kournoutas, I
   Vigo, V
   Di Bonaventura, R
   Raygor, K
   El-Sayed, IH
   Abla, AA
   Rubio, RR
AF Dones, Flavia
   Kournoutas, Ioannis
   Vigo, Vera
   Di Bonaventura, Rina
   Raygor, Kunal
   El-Sayed, Ivan H.
   Abla, Adib A.
   Rubio, Roberto Rodriguez
TI A Combined Extradural-Intradural Technique for an En Bloc Anterior
   Petrosectomy: A Cadaveric Feasibility Study
SO WORLD NEUROSURGERY
LA English
DT Article
DE Extradural-intradural drilling; Internal acoustic canal; Kawase
   approach; Middle fossa; One-piece; Petroclival region; Trigeminal
   landmarks
ID CRANIAL FOSSA APPROACH; TRANSPETROSAL-TRANSTENTORIAL APPROACH;
   SUPERFICIAL PETROSAL NERVE; PETROCLIVAL MENINGIOMAS; HEARING
   PRESERVATION; SURGICAL TECHNIQUE; MIDDLE; ANATOMY; DISSECTION; SURGERY
AB INTRODUCTION: The anterior petrosectomy approach is among the most popular for exposure of the petroclival region. However, the complexity of the anatomy, drilling time required, and risk of injury to neurovascular structures have made this procedure especially challenging. We have proposed a novel combined extradural-intradural technique for en bloc anterior petrosectomy-or one-piece Kawase-and have charted the landmarks that define its surgical boundaries.
   METHODS: The approach was performed on 14 embalmed specimens. The one-piece Kawase approach consists of 3 extradural drilling steps, followed by incision of the dura and skeletonization of the superior petrosal sinus. The procedure culminates with 2 intradural drilling steps. The bone piece was then removed en bloc, and the maximum anteroposterior, superoinferior, and mediolateral lengths were recorded. The linear distances between the main neurovascular landmarks were also measured using a stereotactic navigation system.
   RESULTS: The mean measurements were 17.6 +/- 2.6 mm for the anteroposterior distance, 10.5 +/- 2.3 mm for the superoinferior distance, and 9.5 +/- 2.6 mm for the mediolateral distance. The medial linear distance from the mandibular nerve/greater superficial petrosal nerve to the internal carotid artery was 6.8 +/- 1.3 mm, to the facial hiatus was 11.6 +/- 2.2 mm, and to the lateral internal acoustic canal was 17.9 +/- 1.8 mm. The average distance from the porus trigeminus to the medial internal acoustic canal was 19.4 mm.
   CONCLUSIONS: The advantages of this technique include the wide exposure of the petroclival region, extensive visualization of critical structures via extradural and intradural corridors, and minimization of bone drilling, which could reduce heat damage. Clinical application of the illustrated technique is required to test its reliability in different pathological subsets.
C1 [Dones, Flavia; Kournoutas, Ioannis; Vigo, Vera; Di Bonaventura, Rina; El-Sayed, Ivan H.; Abla, Adib A.; Rubio, Roberto Rodriguez] Univ Calif San Francisco, Skull Base & Cerebrovasc Lab, San Francisco, CA 94143 USA.
   [Raygor, Kunal; Abla, Adib A.; Rubio, Roberto Rodriguez] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA.
   [El-Sayed, Ivan H.; Rubio, Roberto Rodriguez] Univ Calif San Francisco, Dept Otolaryngol Head & Neck Surg, San Francisco, CA 94143 USA.
RP Rubio, RR (reprint author), Univ Calif San Francisco, Skull Base & Cerebrovasc Lab, San Francisco, CA 94143 USA.; Rubio, RR (reprint author), Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA.; Rubio, RR (reprint author), Univ Calif San Francisco, Dept Otolaryngol Head & Neck Surg, San Francisco, CA 94143 USA.
EM neurodriguez@gmail.com
OI Rodriguez-Rubio, Roberto/0000-0002-7206-309X
CR Altieri R, 2017, NEUROSURG REV, V40, P231, DOI 10.1007/s10143-016-0754-3
   Benet A, 2014, J NEUROSURG, V120, P1229, DOI 10.3171/2014.1.JNS131857
   BERTALANFFY H, 1991, NEUROSURGERY, V29, P815, DOI 10.1227/00006123-199112000-00002
   CATALANO PJ, 1993, OTOLARYNG HEAD NECK, V108, P111, DOI 10.1177/019459989310800202
   Chang SW, 2009, NEUROSURGERY, V64, pS44, DOI 10.1227/01.NEU.0000334410.24984.DD
   Cokkeser Y, 2001, OTOLARYNG HEAD NECK, V124, P94, DOI 10.1067/mhn.2001.111712
   DAY JD, 1994, NEUROSURGERY, V34, P1009, DOI 10.1227/00006123-199406000-00009
   Djahlian HR, 2007, ENT-EAR NOSE THROAT, V86, P474, DOI 10.1177/014556130708600813
   FISCH U, 1970, ADV OTO-RHINO-LARYNG, V17, P203
   FOURNIER HD, 1994, SURG RADIOL ANAT, V16, P143, DOI 10.1007/BF01627587
   Fukuda H, 2014, WORLD NEUROSURG, V82, DOI 10.1016/j.wneu.2014.03.034
   GARCIAIBANEZ E, 1980, OTOLARYNG HEAD NECK, V88, P486, DOI 10.1177/019459988008800430
   Guo XM, 2017, WORLD NEUROSURG, V99, P618, DOI 10.1016/j.wneu.2016.11.019
   Gupta SK, 2012, J NEUROSURG, V117, P1007, DOI 10.3171/2012.9.JNS12429
   HAKUBA A, 1988, SURG NEUROL, V30, P108, DOI 10.1016/0090-3019(88)90095-X
   House W F, 1968, Arch Otolaryngol, V88, P631
   HOUSE W F, 1961, Laryngoscope, V71, P1363
   HOUSE WF, 1986, AM J OTOL, V7, P1
   Ichimura S, 2016, NEUROSURG REV, V39, P625, DOI 10.1007/s10143-016-0711-1
   Jittapiromsak P, 2009, NEUROSURGERY, V64, P253, DOI 10.1227/01.NEU.0000343522.79764.15
   KANZAKI J, 1977, ARCH OTO-RHINO-LARYN, V217, P119, DOI 10.1007/BF00453899
   KAWASE T, 1994, ACTA NEUROCHIR, V129, P113, DOI 10.1007/BF01406489
   KAWASE T, 1991, NEUROSURGERY, V28, P869, DOI 10.1227/00006123-199106000-00014
   KAWASE T, 1985, J NEUROSURG, V63, P857, DOI 10.3171/jns.1985.63.6.0857
   Kim SM, 2015, J NEUROSURG, V123, P9, DOI 10.3171/2014.12.JNS132840
   Lan MY, 2010, EUR ARCH OTO-RHINO-L, V267, P1867, DOI 10.1007/s00405-010-1328-6
   Le Shaw M, 2012, OPHTHAL PLAST RECONS, V28, P328, DOI 10.1097/IOP.0b013e31825ca5b2
   MILLER CG, 1993, NEUROSURGERY, V33, P461
   PARISIER SC, 1977, LARYNGOSCOPE, V87, P1, DOI 10.1288/00005537-197704001-00001
   Pensak ML, 2009, LARYNGOSCOPE, V119, P1060, DOI 10.1002/lary.20235
   Rigante L, 2016, WORLD NEUROSURG, V86, P93, DOI 10.1016/j.wneu.2015.08.083
   Sennaroglu L, 2003, LARYNGOSCOPE, V113, P332, DOI 10.1097/00005537-200302000-00025
   Shibao S, 2016, J NEUROSURG, V124, P432, DOI 10.3171/2015.1.JNS141854
   Simon MV, 2011, J CLIN NEUROPHYSIOL, V28, P566, DOI 10.1097/WNP.0b013e31823da494
   Slater PW, 1998, LARYNGOSCOPE, V108, P1408, DOI 10.1097/00005537-199809000-00030
   Steiger HJ, 2006, J NEUROSURG, V104, P38, DOI 10.3171/jns.2006.104.1.38
   Tanriover N, 2009, SURG NEUROL, V71, P586, DOI 10.1016/j.surneu.2008.04.009
   Thumfart W, 1988, Arch Otorhinolaryngol Suppl, V1, P81
   Tomio R, 2014, ACTA NEUROCHIR, V156, P1847, DOI 10.1007/s00701-014-2162-1
   Tripathi M, 2015, J NEUROSURG, V123, P14, DOI 10.3171/2015.2.JNS132876
   Van Gompel JJ, 2015, J NEUROL SURG PART B, V76, P379, DOI 10.1055/s-0034-1543971
   Wang J, 2016, J NEUROSURG, V125, P1094, DOI 10.3171/2015.8.JNS151325
NR 42
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP E315
EP E323
DI 10.1016/j.wneu.2018.12.089
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800041
PM 30639606
DA 2020-05-12
ER

PT J
AU Du, YQ
   Duan, WR
   Chen, Z
   Wu, H
   Jian, FZ
AF Du, Yue-Qi
   Duan, Wan-Ru
   Chen, Zan
   Wu, Hao
   Jian, Feng-Zeng
TI Predictors for Development of Symptomatic Myelopathy in Patients with
   Radiculopathy Caused by Cervical Ossification of Posterior Longitudinal
   Ligament
SO WORLD NEUROSURGERY
LA English
DT Article
DE Development of myelopathy; Occupying ratio; Ossification of the
   posterior longitudinal ligament; Predictors; Radiculopathy
ID SPINAL-CORD; SPONDYLOTIC MYELOPATHY; COMPRESSION; MANAGEMENT; SURGERY;
   TRAUMA; RISK
AB OBJECTIVE: To identify clinical factors predicting the development of myelopathy in cervical ossification of the posterior longitudinal ligament (OPLL) patients with radiculopathy.
   METHODS: We retrospectively reviewed 83 cervical OPLL patients who presented with radiculopathy. On the basis of the symptoms and physical findings, we divided patients into 2 groups: myelopathy group and non-myelopathy group. Demographic, clinical, and radiologic characteristics were reviewed and analyzed among the 2 groups. Predictors for the development of myelopathy were assessed via univariate and multivariate analysis.
   RESULTS: Univariate analysis demonstrated that a high occupying ratio and the presence of an intramedullary high signal were risk factors for development of myelopathy from radiculopathy in OPLL patients. Multivariate analysis further identified that a high occupying ratio was the only independent predictor (odds ratio 1.05, 95% confidence interval 1.003-1.091, P = 0.035). The cervical range of motion and minor trauma were not related to the development of myelopathy in our study.
   CONCLUSIONS: Nonmyelopathic OPLL patients with radiculopathy and a high occupying ratio were at higher risk of developing myelopathy, and surgical intervention should be recommended in these cases. However, for elderly patients with significant comorbid conditions, the risks and benefits of surgery should be carefully considered.
C1 [Du, Yue-Qi; Duan, Wan-Ru; Chen, Zan; Wu, Hao; Jian, Feng-Zeng] Capital Med Univ, Xuanwu Hosp, Dept Neurosurg, Beijing, Peoples R China.
RP Jian, FZ (reprint author), Capital Med Univ, Xuanwu Hosp, Dept Neurosurg, Beijing, Peoples R China.
EM fengzengjian@hotmail.com
CR Bednarik J, 2004, SPINE, V29, P2260, DOI 10.1097/01.brs.0000142434.02579.84
   Bednarik J, 2008, EUR SPINE J, V17, P421, DOI 10.1007/s00586-008-0585-1
   Chang H, 2012, J BONE JOINT SURG BR, V94B, P946, DOI 10.1302/0301-620X.94B7.29018
   Chang V, 2015, NEUROSURGERY, V77, P561, DOI 10.1227/NEU.0000000000000888
   Choi BW, 2015, CLIN ORTHOP SURG, V7, P465, DOI 10.4055/cios.2015.7.4.465
   Du YQ, 2019, J STROKE CEREBROVASC, V28, P458, DOI 10.1016/j.jstrokecerebrovasdis.2018.10.024
   Du YQ, 2018, WORLD NEUROSURG, V111, pE527, DOI 10.1016/j.wneu.2017.12.113
   Fehlings MG, 2013, SPINE, V38, pS19, DOI 10.1097/BRS.0b013e3182a7f4de
   Fujiyoshi T, 2008, SPINE, V33, pE990, DOI 10.1097/BRS.0b013e318188b300
   FUKUSHIMA T, 1991, SPINE, V16, pS534, DOI 10.1097/00007632-199110001-00016
   Kadanka Z, 2017, BRAIN BEHAV, V7, DOI 10.1002/brb3.797
   Kameyama T, 1995, Rinsho Byori, V43, P886
   KAMEYAMA T, 1995, BRAIN, V118, P263, DOI 10.1093/brain/118.1.263
   Lee SE, 2016, J CLIN NEUROSCI, V33, P163, DOI 10.1016/j.jocn.2016.03.040
   Matsunaga S, 2002, J NEUROSURG, V97, P172, DOI 10.3171/spi.2002.97.2.0172
   Matsunaga S, 2008, SPINE, V33, P2648, DOI 10.1097/BRS.0b013e31817f988c
   MEHALIC TF, 1990, NEUROSURGERY, V26, P217, DOI 10.1227/00006123-199002000-00006
   PENNING L, 1978, AM J ROENTGENOL, V130, P317, DOI 10.2214/ajr.130.2.317
   Rao R, 2002, J BONE JOINT SURG AM, V84A, P1872, DOI 10.2106/00004623-200210000-00021
   Shigematsu H, 2010, EUR SPINE J, V19, P720, DOI 10.1007/s00586-010-1338-5
   Smith ZA, 2011, NEUROSURG FOCUS, V30, DOI 10.3171/2011.1.FOCUS10256
   TSUYAMA N, 1984, CLIN ORTHOP RELAT R, P71
   Uchida K, 2014, SPINE J, V14, P1601, DOI 10.1016/j.spinee.2013.09.038
   Vedantam A, 2013, EUR SPINE J, V22, P96, DOI 10.1007/s00586-012-2483-9
   WADA E, 1995, SPINE, V20, P2226, DOI 10.1097/00007632-199510001-00009
   Wilson JR, 2013, SPINE, V38, pS37, DOI 10.1097/BRS.0b013e3182a7f2e7
   Yonenobu K, 2012, SPINE, V37, pE315, DOI 10.1097/BRS.0b013e318239ccbd
   Yue WM, 2001, SPINE, V26, P1760, DOI 10.1097/00007632-200108150-00006
NR 28
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP E710
EP E714
DI 10.1016/j.wneu.2018.12.199
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800091
PM 30660887
DA 2020-05-12
ER

PT J
AU Eagles, ME
   Tso, MK
   Macdonald, RL
AF Eagles, Matthew E.
   Tso, Michael K.
   Macdonald, R. Loch
TI Cognitive Impairment, Functional Outcome, and Delayed Cerebral Ischemia
   After Aneurysmal Subarachnoid Hemorrhage
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cognitive impairment; Delayed cerebral ischemia; Outcome measures;
   Subarachnoid hemorrhage
ID MINI-MENTAL-STATE; PREDICTION
AB BACKGROUND: Measures such as modified Rankin Scale (mRS) may not reflect cognitive outcome following aneurysmal subarachnoid hemorrhage. The aim of this study was to assess the relationship between functional outcome, measured by mRS, and cognition, measured by mini-mental state examination (MMSE), after aSAH. A secondary analysis evaluated the impact of delayed cerebral ischemia (DCI) on the proportion of patients who had cognitive impairment.
   METHODS: We performed a post hoc analysis of the Clazosentan to Overcome Neurological Ischemia and Infarction Occurring After Subarachnoid Hemorrhage (CONSCIOUS-1) trial data. MMSE and mRS scores were compared using Kruskal-Wallis equality-of-populations rank test with pairwise comparison post hoc analysis. Cognitive impairment was defined as MMSE score <27. A stepwise logistic regression model evaluated whether DCI was a predictor of cognitive impairment.
   RESULTS: CONSCIOUS-1 comprised 413 patients. Of these, 337 took an MMSE at their 12-week follow-up. Mean MMSE score was 27 with a median of 29 (range, 0-30; SD 5.4). There were no significant differences between MMSE scores of patients who had 12-week mRS scores of 0-2. On multivariate analysis, DCI was independently associated with cognitive impairment after aSAH.
   CONCLUSIONS: Patients considered to have a good outcome on mRS had varying degrees of cognitive function on MMSE, whereas development of DCI was an independent predictor of cognitive impairment after aSAH. MMSE may not be sensitive enough to discern subtle defects in cognition, as the median score was 29 out of 30.
C1 [Eagles, Matthew E.] Univ Calgary, Dept Clin Neurosci, Sect Neurosurg, Calgary, AB, Canada.
   [Tso, Michael K.; Macdonald, R. Loch] Univ Buffalo Neurosurg, Dept Neurosurg, Buffalo, NY USA.
   [Macdonald, R. Loch] St Michaels Hosp, Keenan Res Ctr Biomed Sci, Div Neurosurg, Toronto, ON, Canada.
   [Macdonald, R. Loch] St Michaels Hosp, Keenan Res Ctr Biomed Sci, Labatt Family Ctr Excellence Brain Injury & Traum, Toronto, ON, Canada.
   [Macdonald, R. Loch] St Michaels Hosp, Li Ka Shing Knowledge Inst, Toronto, ON, Canada.
   [Macdonald, R. Loch] Univ Toronto, Dept Physiol, Toronto, ON, Canada.
   [Macdonald, R. Loch] Univ Toronto, Dept Surg, Toronto, ON, Canada.
   [Macdonald, R. Loch] Univ Toronto, Inst Med Sci, Toronto, ON, Canada.
RP Eagles, ME (reprint author), Univ Calgary, Dept Clin Neurosci, Sect Neurosurg, Calgary, AB, Canada.
EM matthew.eagles@ucalgary.ca
OI Tso, Michael/0000-0002-9629-3092
CR Al-Khindi T, 2010, STROKE, V41, pE519, DOI 10.1161/STROKEAHA.110.581975
   Andersen CR, 2019, NEUROCRIT CARE, V30, P534, DOI 10.1007/s12028-018-0566-0
   Brand C, 2014, BRIT J NEUROSURG, V28, P68, DOI 10.3109/02688697.2013.815314
   Chu Alberto Chi Ho, 2015, Acta Neurochir Suppl, V120, P303, DOI 10.1007/978-3-319-04981-6_51
   Eagles ME, 2018, NEUROSURGERY, V82, P299, DOI 10.1093/neuros/nyx165
   FARRELL B, 1991, J NEUROL NEUROSUR PS, V54, P1044, DOI 10.1136/jnnp.54.12.1044
   FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6
   Franceschini M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0165165
   Frontera JA, 2006, NEUROSURGERY, V59, P21, DOI 10.1227/01.NEU.0000218821.34014.1B
   Gupta SK, 2014, WORLD NEUROSURG, V81, P316, DOI 10.1016/j.wneu.2013.01.034
   JENNETT B, 1975, LANCET, V1, P480
   Kramer AH, 2008, J NEUROSURG, V109, P199, DOI 10.3171/JNS/2008/109/8/0199
   Macdonald RL, 2008, STROKE, V39, P3015, DOI 10.1161/STROKEAHA.108.519942
   Macdonald RL, 2014, NAT REV NEUROL, V10, P44, DOI 10.1038/nrneurol.2013.246
   Macdonald RL, 2013, TRANSL STROKE RES, V4, P286, DOI 10.1007/s12975-012-0242-1
   Macdonald RL, 2013, WORLD NEUROSURG, V79, P418, DOI 10.1016/j.wneu.2013.01.006
   Naidech AM, 2015, CRIT CARE MED, V43, P1654, DOI 10.1097/CCM.0000000000001082
   O'Bryant SE, 2008, ARCH NEUROL-CHICAGO, V65, P963, DOI 10.1001/archneur.65.7.963
   Orbo M, 2008, J NEUROL, V255, P1770, DOI 10.1007/s00415-008-0047-z
   Pace A, 2018, BRAIN, V141, DOI 10.1093/brain/awy003
   Rosengart AJ, 2007, STROKE, V38, P2315, DOI 10.1161/STROKEAHA.107.484360
   Schweizer TA, 2012, J NEUROL SCI, V316, P137, DOI 10.1016/j.jns.2012.01.003
   Schweizer TA, 2010, NAT REV NEUROL, V6, P427, DOI 10.1038/nrneurol.2010.94
   Stienen MN, 2019, NEUROSURGERY, V84, P1124, DOI 10.1093/neuros/nyy155
   Stienen MN, 2014, WORLD NEUROSURG, V82, pE599, DOI 10.1016/j.wneu.2014.05.011
   Tso M, 2014, WORLD NEUROSURG, V81, P252, DOI 10.1016/j.wneu.2013.03.020
   Wong GK, 2015, J NEUROL SCI, V358, P58, DOI 10.1016/j.jns.2015.08.013
   Wong GKC, 2012, J NEUROL NEUROSUR PS, V83, P1112, DOI 10.1136/jnnp-2012-302217
NR 28
TC 5
Z9 5
U1 1
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP E558
EP E562
DI 10.1016/j.wneu.2018.12.152
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800072
PM 30639483
DA 2020-05-12
ER

PT J
AU Elkholy, AR
   Farid, AM
   Shamhoot, EA
AF Elkholy, Ahmed Rizk
   Farid, Ashraf Mohamed
   Shamhoot, Ebrahim Ahmed
TI Spontaneous Resorption of Herniated Lumbar Disk: Observational
   Retrospective Study in 9 Patients
SO WORLD NEUROSURGERY
LA English
DT Article
DE Herniated lumbar disk; Spontaneous resorption
ID INTERVERTEBRAL DISC; SPONTANEOUS REGRESSION; NATURAL-HISTORY; MANAGEMENT
AB BACKGROUND: Spontaneous resorption of herniated lumbar disk was explained in the literature by different mechanisms, and multiple predictive factors for resorption were reported in numerous studies. The purpose of this study was to evaluate the phenomena of spontaneous resorption of herniated lumbar disk without surgery (mechanisms, predictive factors, expected time for resorption, and proper time for conservative treatment).
   METHODS: This retrospective clinical case series included 9 patients with herniated lumbar disk on initial magnetic resonance imaging (MRI). The mean age was 39 +/- 6.3 years, and the male to female ratio was 2:1. All patients presented with back pain and sciatica without motor deficit. All patients refused surgical intervention; therefore, they were treated conservatively. Patients were followed-up clinically and radiologically (MRI) in the outpatient clinic on regular visits (for 18 months).
   RESULTS: Spontaneous resorption of herniated disk was found in all patients in a mean time of 8.7 +/- 3.2 months. All patients recovered clinically in a mean time of 5.7 +/- 1.6 weeks by conservative treatment. Large and/or sequestrated disks were associated with rapid resorption. Early recovery patients showed early spontaneous resorption of the disk.
   CONCLUSIONS: Spontaneous resorption of herniated lumbar disk can occur by different mechanisms (retraction, dehydration, and inflammatory mediated mechanism). Large and/or sequestrated disks are essential predictive factors for rapid spontaneous resorption. Furthermore, early clinical recovery is usually associated with quick resorption of the herniated disk.
C1 [Elkholy, Ahmed Rizk; Farid, Ashraf Mohamed; Shamhoot, Ebrahim Ahmed] Tanta Univ, Fac Med, Neurosurg Dept, Tanta, Egypt.
RP Elkholy, AR (reprint author), Tanta Univ, Fac Med, Neurosurg Dept, Tanta, Egypt.
EM elkholyneurosurgery@yahoo.com
CR Ahn SH, 2000, SPINE, V25, P475, DOI 10.1097/00007632-200002150-00014
   Alentado VJ, 2014, GLOB SPINE J, V4, P279, DOI 10.1055/s-0034-1387807
   Atlas SJ, 2001, SPINE, V26, P1179, DOI 10.1097/00007632-200105150-00017
   Autio RA, 2006, SPINE, V31, P1247, DOI 10.1097/01.brs.0000217681.83524.4a
   Autio RA, 2002, SPINE, V27, P1433, DOI 10.1097/00007632-200207010-00012
   Borota L, 2008, SPINE J, V8, P397, DOI 10.1016/j.spinee.2006.11.004
   BOZZAO A, 1992, RADIOLOGY, V185, P135, DOI 10.1148/radiology.185.1.1523297
   Buttermann GR, 2002, J SPINAL DISORD TECH, V15, P469, DOI 10.1097/00024720-200212000-00007
   Chiu CC, 2015, CLIN REHABIL, V29, P184, DOI 10.1177/0269215514540919
   DELAUCHECAVALLIER MC, 1992, SPINE, V17, P927, DOI 10.1097/00007632-199208000-00010
   Ding LZ, 2015, CELL BIOCHEM BIOPHYS, V71, P1357, DOI 10.1007/s12013-014-0357-y
   Doita M, 2001, SPINE, V26, P1522, DOI 10.1097/00007632-200107150-00004
   GUINTO FC, 1984, AM J NEURORADIOL, V5, P632
   Haro H, 1999, J SPINAL DISORD, V12, P245
   Henmi Tatsuhiko, 2002, Journal of Medical Investigation, V49, P40
   HIRABAYASHI S, 1990, SPINE, V15, P1231, DOI 10.1097/00007632-199011010-00026
   Ito T, 1996, SPINE, V21, P230, DOI 10.1097/00007632-199601150-00014
   KEY JA, 1945, ANN SURG, V121, P534, DOI 10.1097/00000658-194504000-00013
   Komori H, 1996, SPINE, V21, P225, DOI 10.1097/00007632-199601150-00013
   MARSHALL LL, 1977, CLIN ORTHOP RELAT R, P61
   Minamide A, 1999, SPINE, V24, P940, DOI 10.1097/00007632-199905150-00003
   Mysliwiec LW, 2010, EUR SPINE J, V19, P1087, DOI 10.1007/s00586-009-1274-4
   Orief T, 2012, WORLD NEUROSURG, V77, P146, DOI 10.1016/j.wneu.2011.04.021
   Reyentovich A, 2002, SPINE, V27, P549, DOI 10.1097/00007632-200203010-00024
   Rothoerl RD, 2002, NEUROSURG REV, V25, P162, DOI 10.1007/s101430100184
   Sakai T, 2007, J NEUROSURG-SPINE, V6, P574, DOI 10.3171/spi.2007.6.6.574
   Seo JY, 2016, EUR SPINE J, V25, P1393, DOI 10.1007/s00586-014-3587-1
   Slavin KV, 2001, SURG NEUROL, V56, P333, DOI 10.1016/S0090-3019(01)00607-3
   TEPLICK JG, 1985, AM J NEURORADIOL, V6, P331
   YAMASHITA K, 1994, SPINE, V19, P479, DOI 10.1097/00007632-199402001-00021
NR 30
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP E453
EP E459
DI 10.1016/j.wneu.2018.12.115
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800059
PM 30610984
DA 2020-05-12
ER

PT J
AU Eroglu, U
   Shah, K
   Bozkurt, M
   Kahilogullari, G
   Yakar, F
   Dogan, I
   Ozgural, O
   Attar, A
   Unlu, A
   Caglar, S
   Gadol, AAC
   Ugur, HC
AF Eroglu, Umit
   Shah, Kushal
   Bozkurt, Melih
   Kahilogullari, Gokmen
   Yakar, Fatih
   Dogan, Ihsan
   Ozgural, Onur
   Attar, Ayhan
   Unlu, Agahan
   Caglar, Sukrud
   Gadol, Aaron A. Cohen
   Ugur, Hasan Caglar
TI Supraorbital Keyhole Approach: Lessons Learned from 106 Operative Cases
SO WORLD NEUROSURGERY
LA English
DT Article
DE Aneurysm; Anterior skull base; Eyebrow incision; Meningioma; Minimally
   invasive; Supraorbital keyhole
ID ASSISTED BRAIN SURGERY; CRANIOTOMY; LESIONS; 3RD-VENTRICLE; EXPERIENCE;
   ANEURYSMS; REMOVAL; TUMORS
AB OBJECTIVE: The supraorbital keyhole approach through an eyebrow incision has been a potentially less invasive approach as an alternative to the standard pterional craniotomy. We aimed to review procedures for anterior and middle cranial fossa lesions and identify lessons learned from addressing various pathologies through this approach.
   METHODS: We retrospectively reviewed 106 consecutive patients who underwent this approach. We documented patients' age, sex, pathology, clinical results, extent of tumor resection, complications, use of endoscope, and cosmetic results.
   RESULTS: Our series addressed a variety of pathologies. Male patients accounted for 55% of the cohort and mean age was 51.7 (2-79) years. Notably, 52% of patients underwent resection of extra-axial masses. Gross total resection was achieved in 74.4% of intra-axial lesions according to postoperative imaging. Two (1.9%) patients developed transient ptosis. One (0.9%) patient developed an allergic reaction to titanium. No cerebrospinal fluid fistula or rhinorrhea occurred. Three patients developed temporary diabetes insipidus after resection of parasellar lesions (2 craniopharyngiomas and 1 pituitary adenoma). In 14 patients with olfactory groove meningiomas, 6 (42.8%) suffered from absence or diminished olfaction postoperatively, and 2 (14.2%) developed postoperative anosmia. Five (38.5%) patients underwent a subsequent resection of recurrent glial tumors. Four weeks postoperatively, 95% of patients demonstrated acceptable cosmetic results. Cosmetic results for 6 (5%) patients were unavailable.
   CONCLUSIONS: The supraorbital keyhole approach may be safely used for various lesions within the anterior and middle cranial fossa. The effectiveness and limitations of this approach and possible complications are discussed. This is a valuable approach for selected patients.
C1 [Eroglu, Umit; Bozkurt, Melih; Kahilogullari, Gokmen; Yakar, Fatih; Dogan, Ihsan; Ozgural, Onur; Attar, Ayhan; Unlu, Agahan; Caglar, Sukrud; Ugur, Hasan Caglar] Ankara Univ, Ibn I Sina Hosp, Sch Med, Dept Neurosurg, Ankara, Turkey.
   [Shah, Kushal] Univ Kansas, Dept Neurosurg, Kansas City, KS USA.
   [Gadol, Aaron A. Cohen] Indiana Univ, Dept Neurol Surg, Goodman Campbell Brain & Spine, Indianapolis, IN 46204 USA.
RP Gadol, AAC (reprint author), Indiana Univ, Dept Neurol Surg, Goodman Campbell Brain & Spine, Indianapolis, IN 46204 USA.
EM acohenmd@gmail.com
RI eroglu, umit/P-2500-2017; Yakar, Fatih/V-6116-2017
OI Yakar, Fatih/0000-0001-7414-3766; Cohen-Gadol,
   Aaron/0000-0002-4946-1524; Eroglu, Umit/0000-0001-8623-071X; dogan,
   ihsan/0000-0002-1985-719X
CR Abdou MS, 2000, MINIM INVAS NEUROSUR, V43, P208, DOI 10.1055/s-2000-11379
   Chalouhi N, 2013, NEUROSURGERY, P441
   Chalouhi N, 2013, NEUROSURGERY, V72, P437, DOI 10.1227/NEU.0b013e3182804e9c
   Charalampaki P, 2008, NEUROSURGERY, V62, P1049, DOI [10.1227/01.NEU.0000176638.86772.2D, 10.1227/01.neu.0000333770.58693.ed]
   Chen HC, 2010, J CLIN NEUROSCI, V17, P1510, DOI 10.1016/j.jocn.2010.04.025
   Czirjak S, 2001, NEUROSURGERY, V48, P145, DOI 10.1097/00006123-200101000-00025
   de Paiva-Neto MA, 2010, ARQ NEURO-PSIQUIAT, V68, P418, DOI 10.1590/S0004-282X2010000300018
   DELASHAW JB, 1992, NEUROSURGERY, V30, P954, DOI 10.1227/00006123-199206000-00028
   DELFINI R, 1992, J NEUROSURG, V77, P959, DOI 10.3171/jns.1992.77.6.0959
   Eroglu U, 2018, WORLD NEUROSURG, V114, pE60, DOI 10.1016/j.wneu.2018.02.056
   Fries G, 1998, NEUROSURGERY, V42, P226, DOI 10.1097/00006123-199802000-00008
   Fries G, 1998, NEUROSURGERY, V42, P231, DOI DOI 10.1097/00006123-199802000-00008
   Heros RC, 2011, J NEUROSURG, V114, P850, DOI 10.3171/2010.6.JNS10878
   Iacoangeli M, 2017, ACTA NEUROCHIR, V159, P645, DOI 10.1007/s00701-017-3117-0
   Iacoangeli M, 2015, J NEUROL SURG PART A, V76, P112, DOI 10.1055/s-0034-1368685
   JANE JA, 1982, NEUROSURGERY, V11, P537, DOI 10.1227/00006123-198210000-00016
   KAPLAN MJ, 1984, LARYNGOSCOPE, V94, P1137
   Krause F., 1908, CHIRURG GEHIRNS RUCK
   Ormond DR, 2013, MINIM INVASIVE SURG, V2013, DOI 10.1155/2013/296469
   Perneczky A, 1998, NEUROSURGERY, V42, P219, DOI 10.1097/00006123-199802000-00001
   Perneczky A, 2009, KEYHOLE APPROACHES N, V1
   Reisch R, 2003, SURG NEUROL, V59, P223, DOI 10.1016/S0090-3019(02)01037-6
   Reisch R, 2005, NEUROSURGERY, V57, P242, DOI 10.1227/01.NEU.0000178353.42777.2C
   Reisch R, 2014, J NEUROSURG, V121, P730, DOI 10.3171/2014.4.JNS13787
   Singh H, 2017, J NEUROSURG, V126, P940, DOI 10.3171/2016.3.JNS1634
   Steiger HJ, 2001, NEUROSURGERY, V48, P347, DOI 10.1097/00006123-200102000-00021
   Teo C, 2005, CHILD NERV SYST, V21, P696, DOI 10.1007/s00381-005-1204-7
   Thaher F, 2015, J NEUROL SURG PART A, V76, P433, DOI 10.1055/s-0034-1389368
   van Lindert E, 1998, SURG NEUROL, V49, P481, DOI 10.1016/S0090-3019(96)00539-3
   Warren WL, 2009, NEUROSURGERY, V64, P324, DOI 10.1227/01.NEU.0000338951.29171.07
   Wilson DA, 2014, WORLD NEUROSURG, V82, pE243, DOI 10.1016/j.wneu.2013.02.002
   WILSON DH, 1971, J NEUROSURG, V34, P102, DOI 10.3171/jns.1971.34.1.0102
   Zhang SG, 2017, ONCOTARGET, V8, P48343, DOI 10.18632/oncotarget.15983
NR 33
TC 3
Z9 3
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP E667
EP E674
DI 10.1016/j.wneu.2018.12.188
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800085
PM 30659969
DA 2020-05-12
ER

PT J
AU Godzik, J
   Dalton, JF
   Martinez-del-Campo, E
   Newcomb, AGUS
   Dominguez, F
   Reyes, PM
   Theodor, N
   Kelly, BP
   Crawford, NR
AF Godzik, Jakub
   Dalton, Jonathan F.
   Martinez-del-Campo, Eduardo
   Newcomb, Anna G. U. S.
   Dominguez, Felix
   Reyes, Phillip M.
   Theodor, Nicholas
   Kelly, Brian P.
   Crawford, Neil R.
TI Biomechanical Evaluation of Cervicothoracic Junction Fusion Constructs
SO WORLD NEUROSURGERY
LA English
DT Article
DE Biomechanics; Cervical spine; Cervicothoracic junction; Instrumentation;
   Interlaminar hooks; Lateral mass screw; Pedicle screw; Range of motion;
   Rod diameter; Thoracic spine
ID SPINAL FIXATION DEVICES; CERVICAL STABILIZATION; IN-VITRO; SYSTEMS
AB OBJECTIVE: We studied the effect of different cervicothoracic construct design variables on biomechanical stability in vitro.
   METHODS: Six fresh-frozen human cadaveric spines (C5-T4) were used. After intact analysis, each specimen was destabilized and reconstructed, with all groups having 4.0-mm pedicle screws placed at T1-T3. The 2 hook-rod constructs included interlaminar hooks at C6 and C7, with either 3.5-mm or 4.0-mm rods (C6-T3). The 2 screw-rod constructs tested included lateral mass screws at C6 and C7, with either 3.5-mm or 4.0-mm rods (C6-T3). The 2 screw-connector-rod constructs tested included lateral mass screws at C6 and C7, with either 3.5-mm or 4.0-mm rods; 1 rod spanned C6-C7 with a connector to a second rod of the same size spanning T1-T3. Global (C6-T3) and intervertebral (C6-C7, C7-T1, T1-T2, and T2-T3) ranges of motion were compared for each construct.
   RESULTS: In terms of global (C6-T3) stability, 3.5-mm versus 4.0-mm rod constructs were not significantly different, regardless of whether the construct was hook-rod, screw-rod, or screw-connector-rod. The hook-rod constructs provided less stability compared with the screw-rod and screw-connector-rod constructs in lateral bending (P < 0.04) and axial rotation (P < 0.001). The screw-rod constructs demonstrated a similar range of motion to that of the screw-connector-rod constructs, except for significantly less axial rotation at the C6-C7 level with 3.5-mm rods (P = 0.04).
   CONCLUSIONS: We found that the rod diameter of a construct does not appear to significantly influence the biomechanical stability of subaxial constructs. The screw-rod construct resulted in certain biomechanical advantages compared with the screw-connector-rod construct, and both were significantly superior to the hook-rod construct.
C1 [Godzik, Jakub] St Josephs Hosp, Barrow Neurol Inst, Dept Neurosurg, Phoenix, AZ USA.
   [Martinez-del-Campo, Eduardo; Newcomb, Anna G. U. S.; Dominguez, Felix; Reyes, Phillip M.; Kelly, Brian P.; Crawford, Neil R.] St Josephs Hosp, Spinal Biomech Lab, Dept Neurosurg Res, Phoenix, AZ 85013 USA.
   [Dalton, Jonathan F.] Washington Univ, Sch Med, St Louis, MO USA.
   [Theodor, Nicholas] Johns Hopkins Univ, Dept Neurosurg, Baltimore, MD USA.
RP Kelly, BP (reprint author), St Josephs Hosp, Spinal Biomech Lab, Dept Neurosurg Res, Phoenix, AZ 85013 USA.
EM Neuropub@dignityhealth.org
FU DePuy Synthes Spine, Inc.
FX This study was funded by grant support from DePuy Synthes Spine, Inc.
CR Crawford NR, 1999, CLIN BIOMECH, V14, P153, DOI 10.1016/S0268-0033(98)00080-1
   CRAWFORD NR, 1995, SPINE, V20, P2097, DOI 10.1097/00007632-199510000-00005
   Crawford NR, 1997, SPINE, V22, P559, DOI 10.1097/00007632-199703010-00020
   Eleraky M, 2010, J NEUROSURG-SPINE, V13, P622, DOI 10.3171/2010.5.SPINE09848
   Espinoza-Larios A, 2007, SPINE J, V7, P194, DOI 10.1016/j.spinee.2006.04.015
   Grubb MR, 1997, SPINE, V22, P1948, DOI 10.1097/00007632-199709010-00002
   Jonas R, 2018, SPINE J, V18, P515, DOI 10.1016/j.spinee.2017.10.065
   KOTANI Y, 1994, SPINE, V19, P2529, DOI 10.1097/00007632-199411001-00007
   Molina C, 2014, J SPINAL DISORD TECH, V27, P40, DOI 10.1097/BSD.0b013e31824e1f86
   PANJABI MM, 1988, SPINE, V13, P1135, DOI 10.1097/00007632-198810000-00014
   PANJABI MM, 1988, SPINE, V13, P1129, DOI 10.1097/00007632-198810000-00013
   Perez-Orribo L, 2012, SPINE, V38, P635
   Scheer JK, 2011, SPINE, V36, pE519, DOI 10.1097/BRS.0b013e3181f65de1
   Scheer JK, 2011, J NEUROSURG-SPINE, V14, P330, DOI 10.3171/2010.10.SPINE1059
   Tatsumi RL, 2007, SPINE, V32, P1072, DOI 10.1097/01.brs.0000261490.90956.2b
   Voronov LI, 2016, MED DEVICES-EVID RES, V9, P223, DOI 10.2147/MDER.S109588
   Wang VY, 2007, NEUROSURG CLIN N AM, V18, P365, DOI 10.1016/j.nec.2007.02.012
NR 17
TC 2
Z9 2
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP E139
EP E146
DI 10.1016/j.wneu.2018.12.040
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800018
PM 30579021
DA 2020-05-12
ER

PT J
AU Gokcen, HB
   Gumussuyu, G
AF Gokcen, H. Bahadir
   Gumussuyu, Gurkan
TI A Quality Analysis of Disc Herniation Videos on YouTube
SO WORLD NEUROSURGERY
LA English
DT Article
DE Disc; Hernia; Herniation; Internet; Quality; Video; YouTube
ID HEALTH INFORMATION; INTERNET
AB BACKGROUND: An increasing number of patients are investigating health information by using the Internet because of its exponential growth. Therefore, it is important to test the accuracy of the information presented to determine which information should not be shared. This study investigated the information available on YouTube with regard to disc herniation.
   METHODS: The first 50 videos found after the keyword "disc herniation" was used in the YouTube search engine were included in the study. Video popularity was evaluated with an index called the video power index (VPI). The quality and accuracy of the information were evaluated by 2 independent spinal surgeons using the Journal of American Medical Association (JAMA) score and the DISCERN scoring system. Interobserver agreement and individual correlations of the data of each video were statistically analyzed.
   RESULTS: Of the 50 videos evaluated, 16 (32%) contained animation and 34 (64%) contained real images. The mean duration was 6.587 minutes, and the mean view was 423.472. The mean DISCERN score was 30.7 (+/- 10.3), and the mean JAMA score was 1.8 (+/- 0.5). There was good agreement between the 2 researchers in terms of DISCERN and JAMA scores. No statistically significant correlation was found between the JAMA and DISCERN scores of both researchers and VPI values, video lengths, animation, or real images.
   CONCLUSIONS: The quality of the disc herniation information offered on YouTube is low. The evaluation of medical information obtained from the Internet by health professionals is an important step in guiding the correct flow of medical information to patients.
C1 [Gokcen, H. Bahadir; Gumussuyu, Gurkan] Istinye Univ, Orthoped & Traumatol Dept, Med Sch, Istanbul, Turkey.
RP Gokcen, HB (reprint author), Istinye Univ, Orthoped & Traumatol Dept, Med Sch, Istanbul, Turkey.
EM bahadrgokcen@gmail.com
CR AbouZahr C, 2005, B WORLD HEALTH ORGAN, V83, P578
   Benetoli A, 2017, J MED INTERNET RES, V19, DOI 10.2196/jmir.7656
   Brooks FM, 2014, ANN ROY COLL SURG, V96, P144, DOI 10.1308/003588414X13814021676396
   Cassidy JT, 2018, KNEE SURG SPORT TR A, V26, P840, DOI 10.1007/s00167-017-4514-x
   Charnock D, 1999, J EPIDEMIOL COMMUN H, V53, P105, DOI 10.1136/jech.53.2.105
   Desai T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082469
   Drozd Brandy, 2018, JMIR Med Educ, V4, pe3, DOI 10.2196/mededu.8527
   Erdem MN, 2018, SPINE, V43, pE1334, DOI 10.1097/BRS.0000000000002691
   Fat MJL, 2011, J CHILD NEUROL, V26, P804, DOI 10.1177/0883073811402345
   Fischer J, 2013, JCR-J CLIN RHEUMATOL, V19, P373, DOI 10.1097/RHU.0b013e3182a69fb2
   Gonzalez-Estrada A, 2015, ALLERGY ASTHMA PROC, V36, pE121, DOI 10.2500/aap.2015.36.3890
   Haymes AT, 2016, J LARYNGOL OTOL, V130, P749, DOI 10.1017/S0022215116008410
   Hertwig R, 2004, PSYCHOL SCI, V15, P534, DOI 10.1111/j.0956-7976.2004.00715.x
   Kunst H, 2002, BRIT MED J, V324, P581, DOI 10.1136/bmj.324.7337.581
   Lagan BM, 2010, BIRTH-ISS PERINAT C, V37, P106, DOI 10.1111/j.1523-536X.2010.00390.x
   MacLeod MG, 2015, ARTHROSCOPY, V31, P136, DOI 10.1016/j.arthro.2014.06.009
   Madathil KC, 2015, HEALTH INFORM J, V21, P173, DOI 10.1177/1460458213512220
   Morahan-Martin JM, 2004, CYBERPSYCHOL BEHAV, V7, P497, DOI 10.1089/1094931042403082
   Mukewar S, 2013, J CROHNS COLITIS, V7, P392, DOI 10.1016/j.crohns.2012.07.011
   Ovenden CD, 2018, ASIAN SPINE J, V12, P987, DOI 10.31616/asj.2018.12.6.987
   Postacchini F, 2011, ACTA NEUROCHIR SUPPL, V108, P17, DOI 10.1007/978-3-211-99370-5_4
   Pouriesa M, 2013, SPINE J, V13, P402, DOI 10.1016/j.spinee.2012.11.047
   Powell J, 2011, J MED INTERNET RES, V13, DOI 10.2196/jmir.1600
   Samuel N, 2017, WORLD NEUROSURG, V105, P394, DOI 10.1016/j.wneu.2017.05.111
   Silberg WM, 1997, JAMA-J AM MED ASSOC, V277, P1244, DOI 10.1001/jama.1997.03540390074039
   Sood A, 2011, UROLOGY, V77, P558, DOI 10.1016/j.urology.2010.07.536
   Staunton PF, 2015, SPINE, V40, P1857, DOI 10.1097/BRS.0000000000001137
   Tackett S, 2018, ACAD MED, V93, P1150, DOI 10.1097/ACM.0000000000002118
   Tartaglione Jason P, 2016, Foot Ankle Spec, V9, P17, DOI 10.1177/1938640015592840
   Ullrich Peter F Jr, 2002, Spine (Phila Pa 1976), V27, pE185, DOI 10.1097/00007632-200204010-00019
   Weil AG, 2014, WORLD NEUROSURG, V82, P31, DOI DOI 10.1016/J.WNEU.2012.11.003
NR 31
TC 6
Z9 6
U1 2
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP E799
EP E804
DI 10.1016/j.wneu.2019.01.146
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800104
PM 30721774
DA 2020-05-12
ER

PT J
AU Goldschmidt, E
   Fellows-Mayle, W
   Paschel, EE
   Niranjan, A
   Flickinger, JC
   Lunsford, LD
   Gerszteren, PC
AF Goldschmidt, Ezequiel
   Fellows-Mayle, Wendy
   Paschel, Erin E.
   Niranjan, Ajay
   Flickinger, John C.
   Lunsford, L. Dade
   Gerszteren, Peter C.
TI Evaluation of Clinical and Histologic Effects of High-Dose Radiosurgery
   on Rat Dorsal Root Ganglion
SO WORLD NEUROSURGERY
LA English
DT Article
DE Dorsal root ganglion; Neuromodulation; Pain; Radiosurgery
ID CERVICAL RADICULAR PAIN; MODEL
AB BACKGROUND: Stereotactic radiosurgery (SRS) is an effective technique to create lesions of the trigeminal nerve to treat refractory trigeminal neuralgia. In the lumbar spine, the dorsal root ganglion (DRG) contains the body of the sensory neurons responsible for pain sensitivity. Neuromodulation of the DRG might therefore improve chronic peripheral pain. This study was performed to determine the feasibility, clinical, and histologic effects of delivering high-dose SRS targeted to the lumbar DRG in a rat model.
   METHODS: Four Sprague Dawley male rats underwent 80 Gy maximum-dose single-fraction SRS to the left L5 and L6 DRG using the Leksell Gamma Knife Icon (Elekta, Atlanta, Georgia, USA). The right L5 and L6 DRGs served as controls. The animals were evaluated for motor and sensory deficits every 2 weeks and were sacrificed at 3 and 6 months after SRS. Common histologic techniques were used to assess for fibrosis and demyelination at the target levels.
   RESULTS: No detectable motor or sensory deficits were seen in any animal. Histologic changes including fibrosis and loss of myelin were noted to the left L5 and L6 DRGs, but not the right side control DRGs. Fibrotic changes within the vertebral body were also evident on the treated sides of the vertebral bodies.
   CONCLUSIONS: We were able to detect a demyelinating response from SRS delivered to the DRG in rats. Because such changes mimic those seen after trigeminal SRS in experimental animals, we hypothesize that radiosurgery may be a potential option in chronic spinal radicular pain amenable to neuromodulation.
C1 [Goldschmidt, Ezequiel; Fellows-Mayle, Wendy; Paschel, Erin E.; Niranjan, Ajay; Lunsford, L. Dade; Gerszteren, Peter C.] Univ Pittsburgh, Med Ctr, Dept Neurosurg, Pittsburgh, PA 15213 USA.
   [Flickinger, John C.] Univ Pittsburgh, Med Ctr, Dept Radiat Oncol, Pittsburgh, PA 15213 USA.
RP Gerszteren, PC (reprint author), Univ Pittsburgh, Med Ctr, Dept Neurosurg, Pittsburgh, PA 15213 USA.
EM gerszteren@upmc.edu
FU Copeland Grant from the Department of Neurosurgery of the University of
   Pittsburgh
FX This work was supported by a Copeland Grant from the Department of
   Neurosurgery of the University of Pittsburgh.
CR Bilsky MH, 2017, NEUROSURG FOCUS, V42, DOI 10.3171/2016.10.FOCUS16433
   Calvo-Lobo C, 2017, J PAIN RES, V10, P129, DOI 10.2147/JPR.S122255
   De Salles AAF, 2013, NEUROSURG CLIN N AM, V24, P491, DOI 10.1016/j.nec.2013.07.001
   Gianola S, 2016, PHYSIOTHER CAN, V68, P267, DOI 10.3138/ptc.2015-30
   Gu XP, 2008, ANESTHESIOLOGY, V108, P113, DOI 10.1097/01.anes.0000296073.16972.13
   KINSELLA TJ, 1991, INT J RADIAT ONCOL, V20, P697, DOI 10.1016/0360-3016(91)90011-R
   Kondziolka D, 2000, NEUROSURGERY, V46, P971, DOI 10.1097/00006123-200004000-00038
   Li Gordon, 2007, Neurosurg Focus, V23, pE2
   Monserrate A, 2017, NEUROSURG FOCUS, V42, DOI 10.3171/2016.9.FOCUS16356
   Moradi-Lakeh M, 2017, ANN RHEUM DIS, V76, P1365, DOI 10.1136/annrheumdis-2016-210146
   RAND RW, 1993, STEREOT FUNCT NEUROS, V61, P93, DOI 10.1159/000100663
   Sapunar Damir, 2012, J Pain Res, V5, P31, DOI 10.2147/JPR.S26603
   Van Zundert J, 2006, REGION ANESTH PAIN M, V31, P152, DOI 10.1016/j.rapm.2005.11.014
   Van Zundert J, 2007, PAIN, V127, P173, DOI 10.1016/j.pain.2006.09.002
   Wang DD, 2018, J NEUROSURG, V128, P68, DOI 10.3171/2016.9.JNS16149
NR 15
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP E276
EP E280
DI 10.1016/j.wneu.2018.12.082
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800035
PM 30593969
DA 2020-05-12
ER

PT J
AU Grebala, P
   Helenius, I
   Buchowski, JM
   Larson, AN
   Shah, SA
AF Grebala, Pawel
   Helenius, Ilkka
   Buchowski, Jacob M.
   Larson, Annalise Noelle
   Shah, Suken A.
TI Back Pain and Outcomes of Pregnancy After Instrumented Spinal Fusion for
   Adolescent Idiopathic Scoliosis
SO WORLD NEUROSURGERY
LA English
DT Article
DE AIS; Back pain; Cesarean section; Scoliosis and pregnancy; Scoliosis
   surgery
ID FEMALE SEXUAL FUNCTION; PREVALENCE; POPULATION; INDEX
AB OBJECTIVE: We hypothesized that women undergoing scoliosis surgery who became pregnant would go to full term, have uncomplicated pregnancies, and similar patient-reported outcome measures than non-pregnant patients and healthy controls.
   METHODS: Two hundred five women with adolescent idiopathic scoliosis (AIS) undergoing scoliosis surgery between 1998 and 2015 at several institutions in 1 country and 173 healthy women, without AIS, parous and nulliparous, were selected at random.
   RESULTS: One hundred eight women with scoliosis surgery and no pregnancy (SNP), 97 women with scoliosis surgery and pregnancy (SP), 91 healthy controls and no pregnancy, and 82 healthy controls and pregnancy (HP) were reviewed. Mean follow-up was 5 years in the SNP, 6 years in the SP, 5 years in the healthy controls and no pregnancy, and 5 years in the HP. The average time from surgery to childbirth was 5 years. Back pain (BP) during pregnancy was observed in 48% of the SP and 34% of the HP. BP after childbirth was present in 43% of the SP and 42% of the HP. Patients fused to L3 or L4 experienced more frequent low BP during pregnancy (40%) than those fused above L3 (P < 0.05). Cesarean section (CS) was performed for 64% and 33% in SP and HP, respectively (P < 0.05). As the lowest instrumented vertebra moved caudal to L4, the frequency of CS increased (P < 0.05; R = 0.8). The majority of CS in SP were performed in patients fused to L4 (55%) versus patients fused above and to L3 (45%) (P < 0.05). The most common analgesia for CS was spinal block (75% in SP and 86% in HP). Patients fused to L4 required general anesthesia significantly more often (7%) versus those fused above L4 (4%, P < 0.05). The health-related quality of life after spinal fusion showed general satisfaction and were similar for SNP and SP (mean 3.84 and 3.91, respectively). No sexual dysfunction was reported.
   CONCLUSIONS: Women with a history of spinal fusion for AIS fused to L3 or L4 reported a higher incidence of low BP, and CSs are more frequently required. This risk increased to 55% when spinal fusion to L4 was performed. The quality of life and sexual function were at the same level in women after scoliosis surgery than in healthy controls.
C1 [Grebala, Pawel] Med Univ Bialystok, Fac Med, Dept Pediat Orthopaed & Traumatol, Bialystok, Poland.
   [Grebala, Pawel] Reg Specialized Childrens Hosp, Dept Pediat Orthopaed, Scoliosis Serv, Olsztyn, Poland.
   [Helenius, Ilkka] Univ Turku, Dept Paediat Orthopaed Surg, Turku, Finland.
   [Helenius, Ilkka] Turku Univ Hosp, Turku, Finland.
   [Buchowski, Jacob M.] Washington Univ, Sch Med, Dept Orthoped Surg, St Louis, MO USA.
   [Larson, Annalise Noelle] Mayo Clin, Dept Orthopaed Surg, Rochester, MN USA.
   [Shah, Suken A.] Nemours Alfred I duPont Hosp Children, Wilmington, DE USA.
RP Grebala, P (reprint author), Med Univ Bialystok, Fac Med, Dept Pediat Orthopaed & Traumatol, Bialystok, Poland.; Grebala, P (reprint author), Reg Specialized Childrens Hosp, Dept Pediat Orthopaed, Scoliosis Serv, Olsztyn, Poland.
EM pgrabala@wp.pl
RI Helenius, Ilkka/AAM-5803-2020; Larson, A. Noelle/AAC-7158-2019
OI Buchowski, Jacob/0000-0001-8880-8490; Grabala,
   Pawel/0000-0001-7059-2935; Helenius, Ilkka/0000-0001-5200-3279
CR Asher MA, 2006, SCOLIOSIS SPINAL DIS, V1, DOI 10.1186/1748-7161-1-2
   Azar F, 2017, CAMPBELLS OPERATIVE
   BETZ RR, 1987, J BONE JOINT SURG AM, V69A, P90, DOI 10.2106/00004623-198769010-00015
   Chia YY, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000003468
   Crawford CH, 2015, SPINE, V40, P377, DOI 10.1097/BRS.0000000000000761
   Danielsson AJ, 2003, SPINE, V28, pE373, DOI 10.1097/01.BRS.0000084267.41183.75
   Danielsson AJ, 2001, SPINE, V26, P1449, DOI 10.1097/00007632-200107010-00015
   Falick-Michaeli T, 2015, GLOB SPINE J, V5, P179, DOI 10.1055/s-0035-1552987
   Glowacki M, 2009, SPINE, V34, P1060, DOI 10.1097/BRS.0b013e31819c1ec3
   Hasler CC, 2013, SWISS MED WKLY, V143, DOI 10.4414/smw.2013.13714
   Katonis P, 2011, HIPPOKRATIA, V15, P205
   Konieczny MR, 2013, J CHILD ORTHOP, V7, P3, DOI 10.1007/s11832-012-0457-4
   Lavelle WF, 2009, SPINE J, V9, P271, DOI 10.1016/j.spinee.2008.05.007
   Lenke LG, 2001, J BONE JOINT SURG AM, V83A, P1169, DOI 10.2106/00004623-200108000-00006
   Nowosielski K, 2013, J SEX MED, V10, P386, DOI 10.1111/jsm.12012
   Orvomaa E, 2007, EUR SPINE J, V6, P304
   Padua R, 2001, SPINE, V26, P1268, DOI 10.1097/00007632-200106010-00019
   Reamy BV, 2001, AM FAM PHYSICIAN, V64, P111
   Rosen R, 2000, J SEX MARITAL THER, V26, P191, DOI 10.1080/009262300278597
   Sabino J, 2008, CURR REV MUSCULOSKE, V1, P137, DOI 10.1007/s12178-008-9021-8
   Stapleton DB, 2002, AUST NZ J OBSTET GYN, V42, P482, DOI 10.1111/j.0004-8666.2002.00482.x
   Theroux J, 2015, PAIN RES MANAG, V20, P153, DOI 10.1155/2015/674354
   Vadivelu R, 2005, POSTGRAD MED J, V81, P65, DOI 10.1136/pgmj.2003.015370
   VISSCHER W, 1988, SPINE, V13, P1096, DOI 10.1097/00007632-198810000-00006
   Wang SM, 2004, OBSTET GYNECOL, V104, P65, DOI 10.1097/01.AOG.0000129403.54061.0e
   Young G L, 2002, Cochrane Database Syst Rev, pCD000121
NR 26
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP E404
EP E410
DI 10.1016/j.wneu.2018.12.106
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800052
PM 30610987
DA 2020-05-12
ER

PT J
AU Gultekin, GD
   Gulmen, V
   Ars, E
   Dilbaz, S
   Zileli, M
AF Gultekin, Guliz D.
   Gulmen, Vehbi
   Ars, Eda
   Dilbaz, Suna
   Zileli, Mehmet
TI Transverse Process Fractures: A Clinical Series and Coronal Injury of
   the Spine
SO WORLD NEUROSURGERY
LA English
DT Article
DE Coronal injury of the spine; MLF; Myofascial injury; Psoas; Quadratus
   lumborum; Thoracolumbar fascia; Transverse process fracture
ID LUMBAR SPINE; CLASSIFICATION; ANATOMY; FASCIA; MARKER; L5
AB BACKGROUND: Transverse process fractures in trauma patients frequently are diagnosed using computed tomography and result in severe pain and limitation of motion. However, there is no accepted standard of care. Thus, these fractures can be treated with excessive measures or inadequately treated. In this study, diagnosis and treatment of transverse process fractures are examined.
   METHODS: The mechanisms of trauma, findings, and associated organ injuries of 50 patients with transverse process fractures and no other spinal injuries treated between 2013 and 2015 were recorded. The same treatment protocol was applied to each patient. The results of the treatments were examined retrospectively and recorded.
   RESULTS: Deformation and edema of the fascia and muscles around the transverse process fractures were detected by computed tomography and magnetic resonance imaging. The average pain intensity of the patients before treatment was 8.8 of 10 on a visual analog scale and 5.2 of 10 after treatment with nonsteroidal anti-inflammatory drugs, muscle relaxants, flexible support corsets, and mobilization. Patients hospitalized for additional pathologies were primarily treated in thoracic surgery wards (11 of 15 patients). Transverse process fractures were caused by backward falls or blows to the back in 49 patients.
   CONCLUSIONS: Transverse process fractures can be treated quickly and effectively with the recommended protocol after excluding any accompanying organ injuries or other spinal injuries. Transverse process fractures most often occur during backward falls or blows to the back, commonly low-energy injuries. This trauma mechanism can be described as a "coronal injury of the spine."
C1 [Gultekin, Guliz D.] Istanbul Medeniyet Univ, Neurosurg Dept, Goztepe Educ & Res Hosp, Istanbul, Turkey.
   [Gulmen, Vehbi; Zileli, Mehmet] Gazi Hosp, Neurosurg Dept, Izmir, Turkey.
   [Ars, Eda] Koc Univ Hosp, Emergency Med Dept, Istanbul, Turkey.
   [Dilbaz, Suna] Istanbul Hlth Sci Univ, Kanuni Sultan Suleyman Educ & Res Hosp, Neurosurg Dept, Istanbul, Turkey.
RP Gultekin, GD (reprint author), Istanbul Medeniyet Univ, Neurosurg Dept, Goztepe Educ & Res Hosp, Istanbul, Turkey.
EM op.drgulizgultekin@yahoo.com
CR Akinpelu BJ, 2016, J NEUROSURG-PEDIATR, V17, P639, DOI 10.3171/2015.10.PEDS15377
   Armstrong JR, 1958, LUMBAR DISC LESIONS
   Bali Kamal, 2011, Sports Med Arthrosc Rehabil Ther Technol, V3, P8, DOI 10.1186/1758-2555-3-8
   Barker PJ, 2004, SPINE, V29, P129, DOI 10.1097/01.BRS.0000107005.62513.32
   Barker PJ, 2007, EUR SPINE J, V16, P2232, DOI 10.1007/s00586-007-0502-z
   Barker PJ, 2010, CLIN BIOMECH, V25, P505, DOI 10.1016/j.clinbiomech.2010.02.008
   BILLET FPJ, 1991, ROFO FORTSCHR RONTG, V155, P171, DOI 10.1055/s-2008-1033240
   Boulter JH, 2016, WORLD NEUROSURG, V95, P285, DOI 10.1016/j.wneu.2016.08.027
   Bradley LH, 2008, J TRAUMA, V65, P832, DOI 10.1097/TA.0b013e318184d30e
   Brynin R, 2001, J MANIP PHYSIOL THER, V24, P123, DOI 10.1067/mmt.2001.112562
   Bui TT, 2017, WORLD NEUROSURG, V104, P82, DOI 10.1016/j.wneu.2017.04.137
   Chmelova J, 2011, ACTA CHIR ORTHOP TR, V78, P46
   D'Alessandro MP, 1841, HDB ANATOMIE MENSCHE
   Daglar Bulent, 2005, Ulus Travma Acil Cerrahi Derg, V11, P58
   DENIS F, 1983, SPINE, V8, P817, DOI 10.1097/00007632-198311000-00003
   Dutson SCM, 2006, BRIT J SPORT MED, V40, DOI 10.1136/bjsm.2005.017947
   Elenburg JL, 2016, J MAN MANIP THER, V24, DOI 10.1179/2042618614Y.0000000101
   Gertzbein SD, 2012, AM J SPORT MED, V40, P1750, DOI 10.1177/0363546512449814
   Gray M, 2015, OXF MED CASE REP, V2015, P8
   Homnick A, 2007, J TRAUMA, V63, P1292, DOI 10.1097/TA.0b013e31812eed3c
   Inaba K, 2011, J TRAUMA, V70, P174, DOI 10.1097/TA.0b013e3181d3cc6e
   Ishimaru D, 2016, CLIN J SPORT MED, V26, P405, DOI 10.1097/JSM.0000000000000267
   Jarvinen TAHJ, 2005, AM J SPORT MED, V33, P745, DOI 10.1177/0363546505274714
   Kiel J, 2018, STRESS REACTION FRAC
   Krueger MA, 1996, CLIN ORTHOP RELAT R, P191
   Lee JY, 2005, J ORTHOP SCI, V10, P671, DOI 10.1007/s00776-005-0956-y
   Leidholt J D, 1973, Orthop Clin North Am, V4, P691
   Lombardo G, 2017, EUR J TRAUMA EMERG S, V43, P657, DOI 10.1007/s00068-016-0745-7
   Marshall R, 2001, LIVING ANATOMY STRUC
   Miller CD, 2000, INJURY, V31, P773, DOI 10.1016/S0020-1383(00)00111-X
   Nagasawa DT, 2017, WORLD NEUROSURG, V100, P336, DOI 10.1016/j.wneu.2017.01.032
   OTTE D, 1990, UNFALLCHIRURG, V93, P418
   Park JM, 2014, PAIN PRACT, V14, P752, DOI 10.1111/papr.12213
   Phillips S, 2008, P I MECH ENG H, V222, P151, DOI 10.1243/09544119JEIM266
   REIS ND, 1985, INJURY, V16, P421, DOI 10.1016/0020-1383(85)90063-4
   Shah JP, 2008, ARCH PHYS MED REHAB, V89, P16, DOI 10.1016/j.apmr.2007.10.018
   Starks I, 2011, J BONE JOINT SURG BR, V93B, P967, DOI 10.1302/0301-620X.93B7.26772
   TEWES DP, 1995, AM J SPORT MED, V23, P507, DOI 10.1177/036354659502300423
   Torrance David Allen, 2011, J Can Chiropr Assoc, V55, P240
   Tosun O, 2015, MED PROBL PERFORM AR, V30, P111, DOI 10.21091/mppa.2015.2019
   Vaccaro AR, 2013, SPINE, V38, P2028, DOI 10.1097/BRS.0b013e3182a8a381
   van Dijke GAH, 1999, J BIOMECH, V32, P927, DOI 10.1016/S0021-9290(99)00085-8
   Wang B, 2016, SKELETAL RADIOL, V45, P1687, DOI 10.1007/s00256-016-2493-5
   Willard FH, 2012, J ANAT, V221, P507, DOI 10.1111/j.1469-7580.2012.01511.x
   Winterstein J, 2003, J MANIP PHYSIOL THER, V26, P53, DOI 10.1067/mmt.2003.22
   Xia T, 2013, J TRAUMA ACUTE CARE, V74, P1108, DOI 10.1097/TA.0b013e318282745d
NR 46
TC 1
Z9 1
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP E25
EP E38
DI 10.1016/j.wneu.2018.11.147
PG 14
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800005
PM 30502476
DA 2020-05-12
ER

PT J
AU Guo, R
   Chen, RQ
   Yu, ZY
   Tian, R
   Ren, YM
   You, C
   Ma, L
AF Guo, Rui
   Chen, Ruiqi
   Yu, Zhiyuan
   Tian, Rui
   Ren, Yanming
   You, Chao
   Ma, Lu
TI Clinical Features and Prognosis of Primary Intraventricular Hemorrhage
   in Elderly: Single-Center Experience
SO WORLD NEUROSURGERY
LA English
DT Article
DE Elderly; Primary intraventricular hemorrhage; Surgery; Vascular
   disorders
ID INTRACEREBRAL HEMORRHAGE; ETIOLOGY; YIELD
AB OBJECTIVE: Primary intraventricular hemorrhage (PIVH) is rare in the aging population and remains a challenge for cerebrovascular surgeons. In the present study, the authors reviewed the patient characteristics, angiographic results, and treatments and determined clinical outcomes in 34 patients older than 60 years of age who were treated at West China Hospital between 2010 and 2014.
   METHODS: The medical records of elderly patients were queried. The parameters regarding patient demographics, presenting symptoms, treatment modalities, angiographic results, and clinical outcomes were assessed and analyzed.
   RESULTS: There were 19 male (55.9%) and 15 female (44.1%) patients, with an average age (+/- SD) of 67.9 +/- 7.7 years in our study. The most common symptoms on presentation were headache (50%), followed by disturbance of consciousness (26.5%). Only 5 patients (14.3%) were diagnosed with underlying cerebrovascular etiologies including Moyamoya disease (5.9%), arteriovenous malformations (2.9%), and aneurysms (5.9%). Idiopathic PIVH was diagnosed in 29 patients (85.7%). Thirteen patients (38.2%) underwent surgical intervention, while 21 patients (61.8%) received conservative treatment. Twelve patients (35.3%) had an unfavorable outcome at discharge, and an unfavorable outcome was observed in 14 patients (41.2%) at the 3-month follow-up. Patients with higher Graeb score might be associated with an unfavorable outcome both in shortterm and long-term follow-up.
   CONCLUSIONS: Most PIVH patients were diagnosed with idiopathic PIVH in the elderly. Surgical treatment of aging patients should be optimized to improve clinical outcomes. The admission Graeb scores were considered to be the independent prognostic factors for both short-term and long-term outcomes.
C1 [Guo, Rui; Chen, Ruiqi; Yu, Zhiyuan; Tian, Rui; Ren, Yanming; You, Chao; Ma, Lu] Sichuan Univ, West China Hosp, Dept Neurosurg, Chengdu, Sichuan, Peoples R China.
RP Ma, L (reprint author), Sichuan Univ, West China Hosp, Dept Neurosurg, Chengdu, Sichuan, Peoples R China.
EM huaxi_ma1u@163.com
FU National Science and Technology Pillar Program in the 12th Five-Year
   Plan [2011BAI08B05]
FX Our study was funded by the National Science and Technology Pillar
   Program in the 12th Five-Year Plan (2011BAI08B05). The authors report no
   other conflict of interest concerning the materials or methods used in
   this study or the findings specified in this paper.
CR Arboix A, 2012, ISRN NEUROL, V2012
   Chen CC, 2011, WORLD NEUROSURG, V75, P264, DOI 10.1016/j.wneu.2010.07.041
   Chiquete E, 2007, CEREBROVASC DIS, V24, P196, DOI 10.1159/000104477
   Dey M, 2012, CURR NEUROL NEUROSCI, V12, P24, DOI 10.1007/s11910-011-0231-x
   Feigin VL, 2003, LANCET NEUROL, V2, P43, DOI 10.1016/S1474-4422(03)00266-7
   Flint AC, 2008, NEUROCRIT CARE, V8, P330, DOI 10.1007/s12028-008-9070-2
   Gaberel T, 2011, STROKE, V42, P2776, DOI 10.1161/STROKEAHA.111.615724
   GATES PC, 1986, STROKE, V17, P872, DOI 10.1161/01.STR.17.5.872
   Giray S, 2009, TURK NEUROSURG, V19, P338
   GRAEB DA, 1982, RADIOLOGY, V143, P91, DOI 10.1148/radiology.143.1.6977795
   Guo R, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000005089
   Hameed Bilal, 2005, JPMA Journal of the Pakistan Medical Association, V55, P315
   Hanley DF, 2017, LANCET, V389, P603, DOI 10.1016/S0140-6736(16)32410-2
   Inoue Y, 2018, J STROKE CEREBROVASC, V27, P97, DOI 10.1016/j.jstrokecerebrovasdis.2017.08.006
   JAYAKUMAR PN, 1989, ACTA NEUROL SCAND, V80, P1, DOI 10.1111/j.1600-0404.1989.tb03833.x
   Kiymaz N, 2005, ADV THER, V22, P447, DOI 10.1007/BF02849864
   Lee WC, 2007, ADV THER, V24, P258, DOI 10.1007/BF02849893
   Liu M, 2007, LANCET NEUROL, V6, P456, DOI 10.1016/S1474-4422(07)70004-2
   Maniker AH, 2006, NEUROSURGERY, V59, P419, DOI 10.1227/01.NEU.0000222817.99752.E6
   McCarron MO, 2004, LANCET NEUROL, V3, P484, DOI 10.1016/S1474-4422(04)00825-7
   Ngo QN, 2009, PEDIATR CRIT CARE ME, V10, P346, DOI 10.1097/PCC.0b013e3181a320cd
   OJEMANN RG, 1983, STROKE, V14, P468, DOI 10.1161/01.STR.14.4.468
   Passero S, 2002, ACTA NEUROL SCAND, V105, P115, DOI 10.1034/j.1600-0404.2002.1o118.x
   Sanossian N, 2016, STROKE, V47, P2737, DOI 10.1161/STROKEAHA.116.013318
   Sia S F, 2007, Med J Malaysia, V62, P308
   Srivastava T, 2014, NEUROL INDIA, V62, P144, DOI 10.4103/0028-3886.132333
   Zhang S, 2017, J NEUROL, V264, P382, DOI 10.1007/s00415-016-8367-x
   Zhou HG, 2011, J NEUROL, V258, P661, DOI 10.1007/s00415-011-5902-7
NR 28
TC 1
Z9 1
U1 1
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP E445
EP E452
DI 10.1016/j.wneu.2018.12.114
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800058
PM 30610977
DA 2020-05-12
ER

PT J
AU Guo, TM
   Lu, J
   Xing, YL
   Liu, GX
   Zhu, HY
   Yang, L
   Qiao, XM
AF Guo, Tuan-Mao
   Lu, Jian
   Xing, Yan-Li
   Liu, Guo-Xiong
   Zhu, Hai-Yun
   Yang, Lan
   Qiao, Xi-Min
TI A 3-Dimensional Finite Element Analysis of Adjacent Segment Disk
   Degeneration Induced by Transforaminal Lumbar Interbody Fusion After
   Pedicle Screw Fixation
SO WORLD NEUROSURGERY
LA English
DT Article
DE 3-dimensional finite element analysis; Adjacent segment disk
   degeneration; Annulus fibrosis; Biomechanical study; Intervertebral
   disk; Transforaminal lumbar interbody fusion
AB BACKGROUND: Transforaminal lumbar interbody fusion (TLIF) is an effective treatment of upper lumbar intervertebral disk herniation. However, its clinical efficacy for adjacent segment disk degeneration (ASDD) remains undefined. Therefore, the biomechanical evaluation of ASDD caused by TLIF after pedicle screw fixation (PSF) was explored via a 3-dimensional (3D) finite element analysis.
   METHODS: Computed tomography images of a healthy male adult volunteer were used in this study. A L3-4 3D finite element model (model) was successfully constructed using Pro/E software, which was also used to establish the L4-5 of the TLIF, PSF, and PSF + TLIF models. Under the same loading conditions, the protrusion and retraction of the adjacent intervertebral disk and the stress distribution of the annulus fibrosis, facet joint, and articular process in the TLIF, PSF, and PSF + TLIF models were all compared.
   RESULTS: Protrusion and retraction of the adjacent intervertebral disk were more notable in the PSF + TLIF model than in the PSF model under the same loading conditions. The stress of the annulus fibrosis of the PSF + TLIF model was stronger relative to that of the PSF model under flexion, extension, or lateral bending. The stress of the articular process of the PSF + TLIF model was also stronger than that of the PSF model under extension or lateral bending.
   CONCLUSIONS: This study provides evidence that TLIF may aggravate ASDD after PSF. Furthermore, the findings provided in this report represent the theoretic basis for the clinical analysis of ASDD caused by TLIF after PSF.
C1 [Guo, Tuan-Mao; Lu, Jian; Xing, Yan-Li; Liu, Guo-Xiong; Zhu, Hai-Yun; Yang, Lan; Qiao, Xi-Min] Xianyang Cent Hosp, Dept Orthoped, Xianyang, Peoples R China.
RP Qiao, XM (reprint author), Xianyang Cent Hosp, Dept Orthoped, Xianyang, Peoples R China.
EM gtm0619@163.com
FU Project of Scientific and Technological Innovation Team of Spinal
   Degeneration of Xianyang in 2014 [2014-8]; Research Fund of Provincial
   Health Department in 2016 [2016D071]; Project of Xianyang Science and
   Technology Bureau in 2016 [2016K02-99]
FX This work was supported by the Project of Scientific and Technological
   Innovation Team of Spinal Degeneration of Xianyang in 2014 (2014-8), the
   Research Fund of Provincial Health Department in 2016 (2016D071), and
   the Project of Xianyang Science and Technology Bureau in 2016
   (2016K02-99).
CR Anandjiwala J, 2011, EUR SPINE J, V20, P1951, DOI 10.1007/s00586-011-1917-0
   Bae JS, 2010, NEUROSURGERY, V67, P1600, DOI 10.1227/NEU.0b013e3181f91697
   Chen WJ, 2004, CLIN BIOMECH, V19, P763, DOI 10.1016/j.clinbiomech.2004.05.010
   Chow DHK, 1996, SPINE, V21, P549, DOI 10.1097/00007632-199603010-00004
   Chrastil J, 2012, J AM ACAD ORTHOP SUR, V20, P283, DOI 10.5435/JAAOS-20-05-283
   Erwin WM, 2015, ARTHRITIS RES THER, V17, DOI 10.1186/s13075-015-0733-z
   Hua Yong-Jun, 2014, Zhongguo Gu Shang, V27, P722
   Iatridis JC, 1997, J ORTHOP RES, V15, P318, DOI 10.1002/jor.1100150224
   Jackson AR, 2011, J BIOMECH ENG-T ASME, V133, DOI 10.1115/1.4004944
   Kim J, 2012, ANN BIOMED ENG, V40, P1996, DOI 10.1007/s10439-012-0570-z
   LEE CK, 1984, SPINE, V9, P574, DOI 10.1097/00007632-198409000-00007
   LEE CK, 1988, SPINE, V13, P375, DOI 10.1097/00007632-198803000-00029
   Millecamps M, 2012, PAIN, V153, P1167, DOI 10.1016/j.pain.2012.01.027
   Shin JK, 2017, BIOMED RES, V29, P464
   Taghiabadi E, 2015, CELL J, V17, P49
   Tao Y, 2016, CHINESE J TISSUE ENG, V20, P1932
   Tiaden AN, 2012, J BIOL CHEM, V287, P21335, DOI 10.1074/jbc.M112.341032
   Tian NF, 2013, EUR SPINE J, V22, P1741, DOI 10.1007/s00586-013-2747-z
   Turgut M, 2006, EUR SPINE J, V15, P605, DOI 10.1007/s00586-005-0972-9
   Villavicencio Alan T, 2010, Surg Neurol Int, V1, P12, DOI 10.4103/2152-7806.63905
   Wang Lei, 2012, Zhonghua Yi Xue Za Zhi, V92, P2781
   Xu H, 2013, NEUROSURGERY, V72, P21, DOI 10.1227/NEU.0b013e3182742a69
   Yan DL, 2008, EUR SPINE J, V17, P1311, DOI 10.1007/s00586-008-0739-1
   Yan JZ, 2011, INT J MED ROBOT COMP, V7, P96, DOI 10.1002/rcs.374
NR 24
TC 0
Z9 0
U1 0
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP E51
EP E57
DI 10.1016/j.wneu.2018.11.195
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800007
PM 30503290
DA 2020-05-12
ER

PT J
AU Han, S
   Hyun, SJ
   Kim, KJ
   Jahng, TA
   Jeon, SI
   Wui, SH
   Lee, JY
   Lee, S
   Rhim, SC
   Chung, S
   Jang, J
   Lee, BH
AF Han, Sanghyun
   Hyun, Seung-Jae
   Kim, Ki-Jeong
   Jahng, Tae-Ahn
   Jeon, Se-Il
   Wui, Seong-Hyun
   Lee, Jin Young
   Lee, Subum
   Rhim, Seung-Chul
   Chung, Sungkyun
   Jang, Jeesoo
   Lee, Byoung Hun
TI Effect of Vertebroplasty at the Upper Instrumented Vertebra and Upper
   Instrumented Vertebra+1 for Prevention of Proximal Junctional Failure in
   Adult Spinal Deformity Surgery: A Comparative Matched-Cohort Study
SO WORLD NEUROSURGERY
LA English
DT Article
DE Adult spinal deformity surgery; Proximal junctional failure; Proximal
   junctional fracture; Proximal junctional kyphosis; Vertebroplasty
ID ADOLESCENT IDIOPATHIC SCOLIOSIS; PEDICLE SCREW CONSTRUCTS; RISK-FACTORS;
   SURGICAL-TREATMENT; PERCUTANEOUS VERTEBROPLASTY; CEMENT AUGMENTATION;
   CLINICAL-OUTCOMES; KYPHOSIS; FUSION; SACRUM
AB BACKGROUND: This study aimed to compare radiographic outcomes of adult spinal deformity (ASD) surgery with or without 2-level prophylactic vertebroplasty (PVP) at the uppermost instrumented vertebra (UIV) and the vertebra 1 level proximal to the UIV.
   METHODS: This retrospective 1: 2 matched-cohort comparative study enrolled 2 groups of patients undergoing ASD surgery, including 28 patients with PVP (PVP group) and 56 patients without PVP (non-PVP group), in 3 institutes between 2012 and 2015. The primary outcome measure was the incidence of proximal junctional kyphosis (PJK), proximal junctional failure (PJF), and proximal junctional fracture (PJFX). The secondary outcome measure were radiologic outcomes between PVP segments and non-PVP segments.
   RESULTS: Between the PVP group and non-PVP group, no significant differences were found in the incidence of PJK (13 = 46.4%] vs. 26 = 46.4%]; P = 1.000), PJF (11 = 39.3%] vs. 18 = 32.1%]; P = 0.516), and PJFX (11 = 39.3%] vs. 18 = 32.1%]; P = 0.516). The number of the PJFX segments was 16 and 33 in PVP segments and non-PVP segments, respectively. Until revision surgery or final follow-up, the PJFX had progressed in 24 non-PVP segments (82.7%), but not in PVP segments. The PJFX progression in all PVP segments stopped near the PVP mass at the final follow-up. Reoperation as a result of PJFX was performed in 1 patient (3.6%) and 8 patients (14.3%) in the PVP and non-PVP groups, respectively.
   CONCLUSIONS: PVP at UIV and vertebra 1 level proximal to the UIV cannot prevent PJK, PJF, and PJFX; however, it plays a positive role by delaying their progression. Furthermore, PVP tends to lower the reoperation rate after PJFX in ASD surgery.
C1 [Han, Sanghyun] Chungnam Natl Univ, Coll Med, Chungnam Natl Univ Hosp, Dept Neurosurg, Daejeon, South Korea.
   [Hyun, Seung-Jae; Kim, Ki-Jeong; Jahng, Tae-Ahn; Jeon, Se-Il; Wui, Seong-Hyun] Seoul Natl Univ, Coll Med, Bundang Hosp, Dept Neurosurg,Spine Ctr, Seongnam, South Korea.
   [Lee, Jin Young; Lee, Subum; Rhim, Seung-Chul] Univ Ulsan, Asan Med Ctr, Dept Neurosurg, Coll Med, Seoul, South Korea.
   [Chung, Sungkyun; Jang, Jeesoo] Nanoori Suwon Hosp, Dept Neurosurg, Suwon, South Korea.
   [Lee, Byoung Hun] Hallym Univ, Dept Neurosurg, Hangang Sacred Heart Hosp, Seoul, South Korea.
RP Hyun, SJ (reprint author), Seoul Natl Univ, Coll Med, Bundang Hosp, Dept Neurosurg,Spine Ctr, Seongnam, South Korea.; Jang, J (reprint author), Nanoori Suwon Hosp, Dept Neurosurg, Suwon, South Korea.
EM hyunsj@snu.ac.kr; spinejjs@naver.com
CR Annis Prokopis, 2014, Evid Based Spine Care J, V5, P160, DOI 10.1055/s-0034-1386755
   Bae J, 2018, NEUROSPINE, V15, P18, DOI 10.14245/ns.1836022.011
   Baroud G, 2003, EUR SPINE J, V12, P421, DOI 10.1007/s00586-002-0512-9
   Belkoff SM, 2000, SPINE, V25, P1061, DOI 10.1097/00007632-200005010-00004
   Bridwell KH, 2004, J BONE JOINT SURG AM, V86A, P1587, DOI 10.2106/00004623-200407000-00033
   Denis F, 2009, SPINE, V34, pE729, DOI 10.1097/BRS.0b013e3181ae2ab2
   Fujimori T, 2014, NEUROSURG FOCUS, V36, DOI 10.3171/2014.3.FOCUS13541
   Ha Y, 2013, J NEUROSURG-SPINE, V19, P360, DOI 10.3171/2013.5.SPINE12737
   Han SL, 2011, INT ORTHOP, V35, P1349, DOI 10.1007/s00264-011-1283-x
   Hart R, 2013, SPINE, V38, pE1223, DOI 10.1097/BRS.0b013e31829fedde
   Heini PF, 2001, EUR SPINE J, V10, P164, DOI 10.1007/s005860000204
   Helgeson MD, 2010, SPINE, V35, P177, DOI 10.1097/BRS.0b013e3181c77f8c
   Hostin R, 2013, SPINE, V38, P1008, DOI 10.1097/BRS.0b013e318271319c
   Hyun SJ, 2018, J KOREAN NEUROSURG S, V61, P661, DOI 10.3340/jkns.2018.0150
   Hyun Seung-Jae, 2017, Korean J Spine, V14, P126, DOI 10.14245/kjs.2017.14.4.126
   Hyun SJ, 2010, J KOREAN NEUROSURG S, V47, P95, DOI 10.3340/jkns.2010.47.2.95
   Ikegami D, 2015, SPINE, V40, pE740, DOI 10.1097/BRS.0000000000000894
   Kim HJ, 2013, SPINE, V38, P896, DOI 10.1097/BRS.0b013e3182815b42
   Kim HJ, 2012, CLIN ORTHOP RELAT R, V470, P1633, DOI 10.1007/s11999-011-2179-1
   Kim YJ, 2008, SPINE, V33, P2179, DOI 10.1097/BRS.0b013e31817c0428
   Kim YJ, 2006, SPINE, V31, P2329, DOI 10.1097/01.brs.0000238968.82799.d9
   Kwon Ji-Woong, 2017, Korean J Spine, V14, P27, DOI 10.14245/kjs.2017.14.2.27
   Lau D, 2014, SPINE, V39, P2093, DOI 10.1097/BRS.0000000000000627
   Lee Byoung Hun, 2017, Korean J Spine, V14, P89, DOI 10.14245/kjs.2017.14.3.89
   Liu FY, 2016, EUR SPINE J, V25, P2376, DOI 10.1007/s00586-016-4534-0
   Makhni MC, 2018, J KOREAN NEUROSURG S, V61, P167, DOI 10.3340/jkns.2017.0404.013
   Martin Christopher T, 2013, Spine Deform, V1, P132, DOI 10.1016/j.jspd.2013.01.005
   Maruo K, 2013, SPINE, V38, pE1469, DOI 10.1097/BRS.0b013e3182a51d43
   Mummaneni PV, 2016, NEUROSURGERY, V78, P101, DOI 10.1227/NEU.0000000000001002
   O'Leary PT, 2009, SPINE, V34, P2134, DOI 10.1097/BRS.0b013e3181b2e17e
   Ohrt-Nissen S, 2018, NEUROSPINE, V15, P123, DOI 10.14245/ns.1836050.025
   Park SJ, 2017, NEUROSURGERY, V80, P279, DOI 10.1227/NEU.0000000000001240
   Peh WCG, 2003, BRIT J RADIOL, V76, P69, DOI 10.1259/bjr/10254271
   Ploumis A, 2009, SPINE, V34, P1581, DOI 10.1097/BRS.0b013e31819c94cc
   Polikeit A, 2003, SPINE, V28, P991, DOI 10.1097/00007632-200305150-00006
   Rose PS, 2009, SPINE, V34, P785, DOI 10.1097/BRS.0b013e31819d0c86
   Smith JS, 2013, SPINE, V38, P1663, DOI 10.1097/BRS.0b013e31829ec563
   Smith MW, 2015, SPINE J, V15, P2142, DOI 10.1016/j.spinee.2015.05.028
   Smith Micah W, 2013, Evid Based Spine Care J, V4, P163, DOI 10.1055/s-0033-1357366
   Tanigawa N, 2011, AM J ROENTGENOL, V196, P1415, DOI 10.2214/AJR.10.5586
   Theologis AA, 2015, SPINE, V40, P1516, DOI 10.1097/BRS.0000000000001043
   Watanabe K, 2010, SPINE, V35, P138, DOI 10.1097/BRS.0b013e3181c8f35d
   Yagi M, 2014, SPINE, V39, pE607, DOI 10.1097/BRS.0000000000000266
   Yagi M, 2012, SPINE, V37, P1479, DOI 10.1097/BRS.0b013e31824e4888
   Yagi M, 2011, SPINE, V36, pE60, DOI 10.1097/BRS.0b013e3181eeaee2
NR 45
TC 1
Z9 1
U1 2
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP E436
EP E444
DI 10.1016/j.wneu.2018.12.113
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800057
PM 30610979
DA 2020-05-12
ER

PT J
AU Heino, I
   Frantzen, J
   Rinne, J
   Girard, R
   Cao, Y
   Sajanti, A
   Katila, AJ
   Posti, JP
   Takala, RSK
   Tenovuo, O
   Koskimaki, J
AF Heino, Iiro
   Frantzen, Janek
   Rinne, Jaakko
   Girard, Romuald
   Cao, Ying
   Sajanti, Antti
   Katila, Ari J.
   Posti, Jussi P.
   Takala, Riikka S. K.
   Tenovuo, Olli
   Koskimaki, Janne
TI Risk Factors for Recurrent Hematoma After Surgery for Acute Traumatic
   Subdural Hematoma
SO WORLD NEUROSURGERY
LA English
DT Article
DE Acute subdural hematoma; Multivariate analysis; Postcraniotomy hematoma;
   Risk factor; Surgery; Traumatic brain injury
ID BRAIN-INJURY; POSTOPERATIVE HEMATOMA; HYPONATREMIA; HEMORRHAGE;
   REDUCTION; MORTALITY; ETHANOL
AB OBJECTIVE: The development of postcraniotomy hematoma (PCH) after surgery for acute traumatic subdural hematoma (aSDH) has been associated with an increased risk of a poor outcome. The risk factors contributing to PCH remain poorly understood. Our aim was to study the potential risk factors for PCH in a consecutive series of surgically evacuated patients with aSDH.
   METHODS: A total of 132 patients with aSDH treated at Turku University Hospital (Turku, Finland) from 2008 to 2012 were enrolled in the present retrospective cohort study. The demographic, clinical, laboratory, and imaging data were collected from the medical records. A comprehensive analysis of the data using 6 different univariate methods, including machine learning and multivariate analyses, was conducted to identify the factors related to PCH.
   RESULTS: The incidence of PCH after primary surgery for traumatic aSDH was 10.6%. The patients experiencing PCH were younger (P = 0.04). No difference was found in the use of anticoagulant or antiplatelet medication for the patients with and without PCH. Multivariate analyses identified alcohol inebriation at the time of injury (odds ratio [OR], 12.67; P = 0.041) and hypocapnia (OR, 26.09; P = 0.003) as independent risk factors for PCH. The patients with PCH had had hyponatremia (OR, 0.08; P = 0.018) less often, and their maximal systolic blood pressure was lower (OR, 0.94; P = 0.009). The area under the curve for the multivariate model was 0.96 (P = 0.049), with a Youden index of 0.88.
   CONCLUSIONS: The results suggest that alcohol inebriation at the time of injury and hypocapnia during hospitalization are risk factors for the development of PCH.
C1 [Heino, Iiro; Sajanti, Antti] Univ Turku, Fac Med, Turku, Finland.
   [Frantzen, Janek; Rinne, Jaakko; Posti, Jussi P.; Koskimaki, Janne] Turku Univ Hosp, Div Clin Neurosci, Dept Neurosurg, Turku Brain Injury Ctr, Turku, Finland.
   [Katila, Ari J.; Takala, Riikka S. K.] Turku Univ Hosp, Perioperat Serv Intens Care Med & Pain Management, Turku Brain Injury Ctr, Turku, Finland.
   [Posti, Jussi P.; Tenovuo, Olli] Turku Univ Hosp, Div Clin Neurosci, Turku Brain Injury Ctr, Turku, Finland.
   [Posti, Jussi P.; Tenovuo, Olli] Univ Turku, Turku, Finland.
   [Girard, Romuald; Cao, Ying; Koskimaki, Janne] Univ Chicago Med & Biol Sci, Neurovasc Surg Program, Sect Neurosurg, Chicago, IL 60637 USA.
   [Posti, Jussi P.; Tenovuo, Olli] Univ Turku, Dept Neurol, Turku, Finland.
RP Koskimaki, J (reprint author), Turku Univ Hosp, Div Clin Neurosci, Dept Neurosurg, Turku Brain Injury Ctr, Turku, Finland.; Koskimaki, J (reprint author), Univ Chicago Med & Biol Sci, Neurovasc Surg Program, Sect Neurosurg, Chicago, IL 60637 USA.
EM koskimaki@uchicago.edu
RI Posti, Jussi P./Y-2908-2019
OI Posti, Jussi P./0000-0002-5925-5193; Koskimaki,
   Janne/0000-0002-2311-6327; Heino, Iiro/0000-0002-5293-9859
CR ALBRECHT RF, 1987, STROKE, V18, P649, DOI 10.1161/01.STR.18.3.649
   Basali A, 2000, ANESTHESIOLOGY, V93, P48, DOI 10.1097/00000542-200007000-00012
   BULLOCK R, 1990, J NEUROSURG, V72, P9, DOI 10.3171/jns.1990.72.1.0009
   Carney N, 2017, NEUROSURGERY, V80, P6, DOI 10.1227/NEU.0000000000001432
   Curley G, 2010, CRIT CARE MED, V38, P1348, DOI 10.1097/CCM.0b013e3181d8cf2b
   DAVIS JW, 1970, ATHEROSCLEROSIS, V11, P473, DOI 10.1016/0021-9150(70)90025-0
   FIRTH D, 1993, BIOMETRIKA, V80, P27, DOI 10.2307/2336755
   Glaser N, 2014, PEDIATR DIABETES, V15, P484, DOI 10.1111/pedi.12114
   Hannon MJ, 2013, J CLIN ENDOCR METAB, V98, P3229, DOI 10.1210/jc.2013-1555
   Hannon MJ, 2012, J CLIN ENDOCR METAB, V97, P1423, DOI 10.1210/jc.2011-3201
   HAUT MJ, 1974, AM J MED, V56, P22, DOI 10.1016/0002-9343(74)90747-5
   Huang KT, 2016, NEUROCRIT CARE, V24, P294, DOI 10.1007/s12028-015-0194-x
   JENNETT B, 1975, LANCET, V1, P480
   Jolliffe IT, 2016, PHILOS T R SOC A, V374, DOI 10.1098/rsta.2015.0202
   KALFAS IH, 1988, NEUROSURGERY, V23, P343, DOI 10.1227/00006123-198809000-00010
   KOTWICA Z, 1993, ACTA NEUROCHIR, V121, P95, DOI 10.1007/BF01809257
   Krishnamoorthy V, 2017, CRIT CARE MED, V45, P1028, DOI 10.1097/CCM.0000000000002404
   Kursa MB, 2010, J STAT SOFTW, V36, P1, DOI 10.18637/jss.v036.i11
   LUNDBERG N, 1959, Acta Psychiatr Scand Suppl, V34, P1
   Maegele M, 2017, LANCET NEUROL, V16, P630, DOI 10.1016/S1474-4422(17)30197-7
   Massaro F, 1996, ACTA NEUROCHIR, V138, P185, DOI 10.1007/BF01411359
   MATHEW P, 1993, ACTA NEUROCHIR, V121, P100, DOI 10.1007/BF01809258
   McGuire LC, 2006, EMERG MED J, V23, P417, DOI 10.1136/emj.2004.017590
   MERRIMAN E, 1979, J NEUROSURG, V50, P682, DOI 10.3171/jns.1979.50.5.0682
   Moro N, 2007, SURG NEUROL, V68, P387, DOI 10.1016/j.surneu.2006.11.052
   PALMER JD, 1994, NEUROSURGERY, V35, P1061, DOI 10.1227/00006123-199412000-00007
   Prathep S, 2014, CRIT CARE MED, V42, P142, DOI 10.1097/CCM.0b013e318298a890
   RAICHLE M E, 1972, Stroke, V3, P566
   RAICHLE ME, 1970, ARCH NEUROL-CHICAGO, V23, P394, DOI 10.1001/archneur.1970.00480290014002
   Renaud SC, 1996, CLIN CHIM ACTA, V246, P77, DOI 10.1016/0009-8981(96)06228-6
   RICHARDS T, 1974, SURGERY, V75, P253
   Schisterman EF, 2005, EPIDEMIOLOGY, V16, P73, DOI 10.1097/01.ede.0000147512.81966.ba
   SEELIG JM, 1981, NEW ENGL J MED, V304, P1511, DOI 10.1056/NEJM198106183042503
   Seifman MA, 2011, NEUROSURG REV, V34, P393, DOI 10.1007/s10143-010-0304-3
   Servadei F, 1998, J TRAUMA, V44, P868, DOI 10.1097/00005373-199805000-00021
   Sturdik I, 2014, EUR J INTERN MED, V25, P379, DOI 10.1016/j.ejim.2014.02.002
   Tamaki T, 2006, NEUROL MED-CHIR, V46, P219, DOI 10.2176/nmc.46.219
   Tzoulis P, 2014, CLIN ENDOCRINOL, V81, P401, DOI 10.1111/cen.12429
   Urdaneta AE, 2017, J INTENSIVE CARE MED, V32, P151, DOI 10.1177/0885066615616907
   Vassilouthis J, 1999, BRIT J NEUROSURG, V13, P154, DOI 10.1080/02688699943916
   Vega RA, 2017, NEUROSURG CLIN N AM, V28, P247, DOI 10.1016/j.nec.2016.11.007
   WILBERGER JE, 1991, J NEUROSURG, V74, P212, DOI 10.3171/jns.1991.74.2.0212
   Zetterling M, 2004, J NEUROSURG ANESTH, V16, P151, DOI 10.1097/00008506-200404000-00008
NR 43
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP E563
EP E571
DI 10.1016/j.wneu.2018.12.155
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800073
PM 30639489
DA 2020-05-12
ER

PT J
AU Hou, BL
   Wen, SJ
   Katsevman, GA
   Liuz, H
   Urhie, O
   Turner, RC
   Carpenter, J
   Bhatia, S
AF Hou, Bob L.
   Wen, Sijin
   Katsevman, Gennadiy A.
   Liuz, Hui
   Urhie, Ogaga
   Turner, Ryan C.
   Carpenter, Jeffrey
   Bhatia, Sanjay
TI Magnetic Resonance Imaging Parameters and Their Impact on Survival of
   Patients with Glioblastoma: Tumor Perfusion Predicts Survival
SO WORLD NEUROSURGERY
LA English
DT Article
DE Anatomic MRI; Diffusion MRI; Glioblastoma; OS; Overall survival;
   Perfusion MRI; TBF; TBV; Tumor blood flow; Tumor blood volume
ID SUSCEPTIBILITY CONTRAST MRI; STRATIFIES PROGRESSION-FREE; HIGH-GRADE
   ASTROCYTOMAS; CEREBRAL BLOOD-VOLUME; DIFFUSION; PERMEABILITY;
   PSEUDOPROGRESSION; MULTIFORME; BIOMARKER; RESECTION
AB BACKGROUND: Many prognostic factors influence overall survival (OS) of patients with glioblastoma. Despite gross total resection and Stupp protocol adherence, many patients have poor survival. Perfusion magnetic resonance imaging may assist in diagnosis, treatment monitoring, and prognostication.
   METHODS: This retrospective study of 36 patients with glioblastoma assessed influence of preoperative magnetic resonance imaging parameters reflecting tumor cell density and vascularity and patient age on OS.
   RESULTS: The area under curve based on optimal receiver operating characteristic curves for the perfusion parameters normalized relative tumor blood volume (n_rTBV) and normalized relative tumor blood flow (n_rTBF) were 0.92 and 0.89, respectively, and the highest among all imaging parameters and age. OS showed strongly negative correlations with corrected n_rTBV (R = -0.70; P < 0.001) and n_rTBF (R = -0.67; P < 0.001). The Cox model, which included age and imaging parameters, demonstrated that n_rTBV and n_rTBF were most predictive of OS, with hazard ratios of 5.97 (P = 0.0001) and 8.76 (P = 0.0001), respectively, compared with 1.63 (P = 0.19) for age. Eighteen patients with corrected n_rTBV <= 2.5 (best cutoff value) had a median OS of 15.1 months (95% confidence interval (CI), 11.34-21.25) compared with 2.8 months (95% CI, 1.48-4.03; P < 0.001) for 18 patients with corrected n_rTBV >2.5. Twenty-four patients with n_rTBF <= 2.79 had a median OS of 12 months (95% CI, 10.46-17.9) compared with 2.8 months for 12 patients with n_rTBF >2.79 (95% CI, 1.31-4.2; P < 0.001).
   CONCLUSIONS: The dominant predictors of OS are normalized perfusion parameters n_rTBV and n_rTBF. Preoperative perfusion imaging may be used as a surrogate to predict glioblastoma aggressiveness and survival independent of treatment.
C1 [Hou, Bob L.; Carpenter, Jeffrey] West Virginia Univ, Dept Radiol, Morgantown, WV 26506 USA.
   [Wen, Sijin; Liuz, Hui] West Virginia Univ, Dept Biostat, Morgantown, WV 26506 USA.
   [Katsevman, Gennadiy A.; Turner, Ryan C.; Bhatia, Sanjay] West Virginia Univ, Dept Neurosurg, Morgantown, WV 26506 USA.
   [Urhie, Ogaga] West Virginia Univ, Sch Med, Morgantown, WV 26506 USA.
RP Katsevman, GA (reprint author), West Virginia Univ, Dept Neurosurg, Morgantown, WV 26506 USA.
EM gkatsev@gmail.com
OI Urhie, Ogaga/0000-0001-5245-3296
FU NIGMS NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of General
   Medical Sciences (NIGMS) [U54 GM104942]
CR AXEL L, 1980, RADIOLOGY, V137, P679, DOI 10.1148/radiology.137.3.7003648
   Barajas RF, 2015, CLIN RADIOL, V70, P1087, DOI 10.1016/j.crad.2015.03.006
   Bonekamp D, 2015, J MAGN RESON IMAGING, V42, P87, DOI 10.1002/jmri.24756
   Chang W, 2015, TOMOGRAPHY, V1, P37, DOI 10.18383/j.tom.2015.00115
   Chaudhry NS, 2013, CANCER INVEST, V31, P287, DOI 10.3109/07357907.2013.789899
   Dehkordi ANV, 2017, NMR BIOMED, V30
   Guo AC, 2002, RADIOLOGY, V224, P177, DOI 10.1148/radiol.2241010637
   Gupta A, 2015, CLIN NEURORADIOL, V25, P143, DOI 10.1007/s00062-014-0289-3
   Harris RJ, 2015, J NEURO-ONCOL, V122, P497, DOI 10.1007/s11060-015-1755-8
   Hegi ME, 2005, NEW ENGL J MED, V352, P997, DOI 10.1056/NEJMoa043331
   Hirai T, 2008, AM J NEURORADIOL, V29, P1505, DOI 10.3174/ajnr.A1121
   Hou ZG, 2018, WORLD NEUROSURG, V113, pE561, DOI 10.1016/j.wneu.2018.02.095
   Jafari-Khouzani K, 2015, TRANSL ONCOL, V8, P137, DOI 10.1016/j.tranon.2015.03.002
   Jain R, 2013, RADIOLOGY, V267, P212, DOI 10.1148/radiol.12120846
   Kalpathy-Cranner J, 2014, CANCER RES, V74, P4622, DOI 10.1158/0008-5472.CAN-14-0383
   Khalifa J, 2016, EUR RADIOL, V26, P4194, DOI 10.1007/s00330-016-4234-5
   Lacerda S, 2009, NEUROIMAG CLIN N AM, V19, P527, DOI 10.1016/j.nic.2009.08.007
   Lacroix M, 2001, J NEUROSURG, V95, P190, DOI 10.3171/jns.2001.95.2.0190
   Law M, 2004, AM J NEURORADIOL, V25, P746
   Law M, 2008, RADIOLOGY, V247, P490, DOI 10.1148/radiol.2472070898
   Lee J, 2016, AM J NEURORADIOL, V37, P37, DOI 10.3174/ajnr.A4534
   Marko NF, 2014, J CLIN ONCOL, V32, P774, DOI 10.1200/JCO.2013.51.8886
   O'Neill AF, 2016, J NEURO-ONCOL, V130, P495, DOI 10.1007/s11060-016-2243-5
   Parker G J, 1999, Top Magn Reson Imaging, V10, P130, DOI 10.1097/00002142-199904000-00006
   Pope WB, 2012, J NEURO-ONCOL, V108, P491, DOI 10.1007/s11060-012-0847-y
   Price SJ, 2016, J MAGN RESON IMAGING, V43, P487, DOI 10.1002/jmri.24996
   Qiao XJ, 2015, AM J NEURORADIOL, V36, P672, DOI 10.3174/ajnr.A4196
   Ricard D, 2012, LANCET, V379, P1984, DOI 10.1016/S0140-6736(11)61346-9
   Ryoo I, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071704
   Sinha S, 2002, AM J NEURORADIOL, V23, P520
   Thomas AA, 2015, J NEURO-ONCOL, V125, P183, DOI 10.1007/s11060-015-1893-z
   Thomas DL, 2000, PHYS MED BIOL, V45, pR97, DOI 10.1088/0031-9155/45/8/201
   TOFTS PS, 1991, MAGNET RESON MED, V17, P357, DOI 10.1002/mrm.1910170208
   Young RJ, 2013, CLIN IMAG, V37, P41, DOI 10.1016/j.clinimag.2012.02.016
NR 34
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP E285
EP E295
DI 10.1016/j.wneu.2018.12.085
PG 11
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800037
PM 30593971
DA 2020-05-12
ER

PT J
AU Hsu, YC
   Huang, APH
   Xiao, FR
   Kuo, LT
   Tsai, JC
   Lai, DM
AF Hsu, Yung-Chun
   Huang, Abel Po-Hao
   Xiao, Fu-Ren
   Kuo, Lu-Ting
   Tsai, Jui-Chang
   Lai, Dar-Ming
TI Decompressive Cranioplasty (Osteoplastic Hinged Craniectomy): A Novel
   Technique for Increased Intracranial Pressure-Initial Experience and
   Outcome
SO WORLD NEUROSURGERY
LA English
DT Article
DE Complications; Cranioplasty; Decompressive craniectomy; Decompressive
   cranioplasty; Decompressive volume
ID CRANIOTOMY; HEMICRANIECTOMY; MORBIDITY
AB BACKGROUND: We redesigned decompressive craniectomy and cranioplasty procedures to decrease the inherent risk of complications. This novel technique, called decompressive cranioplasty, not only may decrease the complication rate but also may improve the cosmetic result, obviate the need for artificial skull implant, and increase the decompressive volume compared with traditional craniectomy.
   METHODS: In decompressive cranioplasty, the Agnes Fast craniotomy was adopted without cutting the temporalis muscle from the underlying bone flap. After opening the dura with or without removal of intracranial hematomas, duraplasty was performed with an intracranial pressure monitor inserted. Four miniplates were bent into a "Z" shape, and the vascularized bone flap was elevated approximately 1.2-1.5 cm above the outer cortex of the skull and fixed with the miniplates. Subsequent cranioplasty was done with a mini-incision on the miniplate sites and reshaping of the miniplate to align the outer cortex of the bone flap.
   RESULTS: We successfully performed decompressive cranioplasty in 3 emergent cases-2 traumatic subdural hematomas and 1 malignant middle cerebral artery infarction. Postoperative brain computed tomography demonstrated adequate decompression in all cases. Cosmetic outcome was excellent, and there was no temporal hallowing. Mastication function was not affected. At 6-month follow-up, there was no bone flap shrinkage and no hydrocephalus.
   CONCLUSIONS: Decompressive cranioplasty is a safe and effective method in the management of patients with brain edema and intracranial hypertension. It is simple to perform and may reduce the morbidity associated with traditional decompressive craniectomy and subsequent cranioplasty.
C1 [Hsu, Yung-Chun; Huang, Abel Po-Hao; Xiao, Fu-Ren; Kuo, Lu-Ting; Tsai, Jui-Chang; Lai, Dar-Ming] Natl Taiwan Univ Hosp, Dept Surg, Div Neurosurg, Taipei, Taiwan.
RP Lai, DM (reprint author), Natl Taiwan Univ Hosp, Dept Surg, Div Neurosurg, Taipei, Taiwan.
EM dmlai@ntu.edu.tw
OI Kuo, Lu-Ting/0000-0002-1405-8700; Xiao, Furen/0000-0001-9683-3979; TSAI,
   JUI-CHANG/0000-0003-2723-6841
CR Adeleye AO, 2016, J NEUROL SURG PART A, V77, P167, DOI 10.1055/s-0035-1566115
   Ban SP, 2010, J KOREAN NEUROSURG S, V48, P244, DOI 10.3340/jkns.2010.48.3.244
   Brondani R, 2017, CEREBROVASC DIS EXTR, V7, P51, DOI 10.1159/000458730
   Ezer H, 2011, SKULL BASE-INTERD AP, V21, P159, DOI 10.1055/s-0031-1275247
   Goettler CE, 2007, J TRAUMA, V62, P777, DOI 10.1097/TA.0b013e31802ee55e
   Grant GA, 2004, J NEUROSURG, V100, P163, DOI 10.3171/ped.2004.100.2.0163
   Honeybul S, 2016, BRIT J NEUROSURG, V30, P523, DOI 10.1080/02688697.2016.1187259
   Kan P, 2006, J NEUROSURG, V105, P337, DOI 10.3171/ped.2006.105.5.337
   Kenning TJ, 2012, J NEUROSURG, V116, P1289, DOI 10.3171/2012.2.JNS111772
   Kenning TJ, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.4.FOCUS0960
   Khanna R, 2016, J NEUROSURG, V125, P674, DOI 10.3171/2015.6.JNS15706
   Ko K, 2007, NEUROSURGERY, V60, P255, DOI 10.1227/01.NEU.0000255380.64969.81
   Nagatani Kimihiro, 2013, Acta Neurochir Suppl, V118, P285, DOI 10.1007/978-3-7091-1434-6_55
   Pillai A, 2007, J NEUROSURG, V106, P59, DOI 10.3171/jns.2007.106.1.59
   Schmidt JH, 2007, J NEUROSURG, V107, P678, DOI 10.3171/JNS-07/09/0678
   Stiver SI, 2008, J NEUROSURG, V109, P245, DOI 10.3171/JNS/2008/109/8/0245
   Valenca MM, 2010, J NEUROSURG, V113, P982, DOI 10.3171/2009.11.JNS09674
   Zanaty M, 2015, J NEUROSURG, V123, P182, DOI 10.3171/2014.9.JNS14405
NR 18
TC 2
Z9 2
U1 4
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP E431
EP E435
DI 10.1016/j.wneu.2018.12.112
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800056
PM 30610974
DA 2020-05-12
ER

PT J
AU Huang, QL
   Cao, X
   Chai, X
   Wang, X
   Xiao, CY
   Wang, J
AF Huang, Qing-ling
   Cao, Xuan
   Chai, Xue
   Wang, Xiao
   Xiao, Chaoyong
   Wang, Juan
TI The Radiological Imaging Features of Easily Misdiagnosed Epithelioid
   Glioblastoma in Seven Patients
SO WORLD NEUROSURGERY
LA English
DT Article
DE Epithelioid glioblastoma; Misdiagnosed; Radiological imaging features
ID BRAF V600E; TERT PROMOTER; GRADE
AB OBJECTIVE: We review the radiological imaging features and report histopathological findings of 7 adult patients with epithelioid glioblastoma (eGBM), which was a newly revised subtype of glioblastoma.
   METHODS: Seven adult patients with a diagnosis of eGBM on a brain tissue specimen were retrospectively confirmed by pathology. The tumor magnetic resonance imaging characteristics such as location, number, edema, necrosis, hemorrhage, enhancement, diffusion-weighted image, apparent diffusion coefficient, magnetic resonance spectroscopy, dynamic susceptibility contrast-perfusione-weighted imaging, and histopathological findings were documented.
   RESULTS: The tumors of these patients exhibited iso-hyperintensive signal on the T2-weighted image and iso-hypointensive signal on the T1-weighted image. All the lesions manifested iso-hypointensive signal on the diffusion-weighted image, and 2 cases showed significantly restricted hyperintensive signal (2/7). Peritumoral edema in all cases was mild. Five cases were located in the cortical lobe (5/7) and the other 2 were multifocal (2/7). Four cases showed white matter collapse sign (4/7). These tumors revealed apparent enhancement after contrast injection. In particular, 4 cases displayed capsuled sign (4/7), 2 cases showed dura mater tail sign (2/7), and 1 case showed hemorrhage (1/7). The mean value of apparent diffusion coefficient in 6 cases was 1.09 x 10(-3) mm(2)/s. The mean value of relative cerebral blood volume in 3 cases was 2.84 x 10(-3) mm(2)/s on dynamic susceptibility contrast-perfusione-weighted imaging. The average value of the choline/N-acetyl aspartate ratio in 4 cases was 6.47 x 10(-3) mm(2)/s on magnetic resonance spectroscopy. All cases expressed a BRAF V600E mutation according to molecular characteristics.
   CONCLUSIONS: eGBMs that were predominantly located in cortex with mild peritumoral edema, white matter collapse, encapsular sign, and dura mater tail sign could be easily misdiagnosed as cortex-involved intracranial brain tumor such as meningioma, whereas multifocal tumors could be easily misdiagnosed as metastatic tumor and lymphoma. Multimodal images were helpful for the differential diagnosis.
C1 [Huang, Qing-ling; Chai, Xue; Wang, Xiao; Xiao, Chaoyong] Nanjing Med Univ, Affiliated Nanjing Brain Hosp, Dept Radiol, Nanjing, Jiangsu, Peoples R China.
   [Wang, Juan] Nanjing Med Univ, Affiliated Nanjing Brain Hosp, Dept Pathol, Nanjing, Jiangsu, Peoples R China.
   [Cao, Xuan] Univ Cincinnati, Dept Math Sci, Cincinnati, OH USA.
RP Huang, QL (reprint author), Nanjing Med Univ, Affiliated Nanjing Brain Hosp, Dept Radiol, Nanjing, Jiangsu, Peoples R China.
EM hql_nju@163.com
OI Cao, Xuan/0000-0002-6859-0030
CR Broniscer A, 2014, NEUROPATH APPL NEURO, V40, P327, DOI 10.1111/nan.12093
   Fudaba H, 2014, AM J NEURORADIOL, V35, P2091, DOI 10.3174/ajnr.A4018
   Funata N, 2016, BRAIN TUMOR PATHOL, V33, P57, DOI 10.1007/s10014-015-0239-z
   Furuta T, 2018, NEUROPATHOLOGY, V38, P218, DOI 10.1111/neup.12459
   Gasco J, 2009, NEUROCIRUGIA, V20, P550
   Gokden M, 2017, ADV ANAT PATHOL, V24, P379, DOI 10.1097/PAP.0000000000000170
   Higano S, 2006, RADIOLOGY, V241, P839, DOI 10.1148/radiol.2413051276
   Khanna G, 2018, PATHOL RES PRACT, V214, P679, DOI 10.1016/j.prp.2018.03.019
   Korshunov A, 2018, BRAIN PATHOL, V28, P656, DOI 10.1111/bpa.12566
   Kwee TC, 2010, J MAGN RESON IMAGING, V31, P531, DOI 10.1002/jmri.22070
   Matsumura N, 2017, NEUROPATHOLOGY, V37, P58, DOI 10.1111/neup.12318
   Murakami C, 2018, NEUROPATHOLOGY, V38, P498, DOI 10.1111/neup.12479
   Nakajima S, 2015, CLIN RADIOL, V70, P1393, DOI 10.1016/j.crad.2015.08.004
   Nitta N, 2018, WORLD NEUROSURG, V112, P257, DOI 10.1016/j.wneu.2018.01.200
   ROSENBLUM MK, 1991, AM J SURG PATHOL, V15, P925, DOI 10.1097/00000478-199110000-00002
   Shibahara I, 2018, BRAIN TUMOR PATHOL, V35, P10, DOI 10.1007/s10014-017-0302-z
   Sugimoto K, 2016, BRAIN TUMOR PATHOL, V33, P137, DOI 10.1007/s10014-015-0243-3
   Svajdler M, 2017, CESK PATOL, V53, P12
   Wu CC, 2018, AM J NEURORADIOL, V39, P1814, DOI 10.3174/ajnr.A5794
NR 19
TC 4
Z9 4
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP E527
EP E532
DI 10.1016/j.wneu.2018.12.128
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800068
PM 30611946
DA 2020-05-12
ER

PT J
AU Imahori, T
   Okamura, Y
   Sakata, J
   Shose, H
   Yokote, A
   Matsushima, K
   Matsui, D
   Kobayashi, M
   Hosoda, K
   Tanaka, K
   Fujita, A
   Kohmura, E
AF Imahori, Taichiro
   Okamura, Yusuke
   Sakata, Junichi
   Shose, Hiroyasu
   Yokote, Akiyoshi
   Matsushima, Kazushi
   Matsui, Daisaku
   Kobayashi, Makoto
   Hosoda, Kohkichi
   Tanaka, Kazuhiro
   Fujita, Atsushi
   Kohmura, Eiji
TI Stent Expansion and In-Stent Thrombus Sign in the Trevo Stent Retriever
   Predict Recanalization and Possible Etiology During Mechanical
   Thrombectomy: A Case Series of 50 Patients with Acute Middle Cerebral
   Artery Occlusion
SO WORLD NEUROSURGERY
LA English
DT Article
DE Acute ischemic stroke; Mechanical thrombectomy; Stent retriever; Stroke;
   Trevo
ID ACUTE ISCHEMIC-STROKE; ENDOVASCULAR TREATMENT; DEVICE; THERAPY; PROVUE;
   CT
AB BACKGROUND: Interaction between the stent retriever and clot is a key factor for recanalization during mechanical thrombectomy. The aim of this study was to evaluate the association between radiographically apparent features during thrombectomy and angiographic outcomes using the Trevo stent retriever with a fully radiopaque strut.
   METHODS: We retrospectively reviewed 50 patients with acute middle cerebral artery occlusion who were treated with the Trevo. Patients were divided into groups that achieved (first-pass recanalization group, n = 21) or did not achieve (non-first-pass recanalization group, n = 29) a modified Thrombolysis in Cerebral Ischemia score of 2b or 3 with the first-pass procedure. Patients were also divided into a thromboembolic (n = 39) and atherosclerotic (n = 11) group by occlusion etiology. We evaluated radiographic findings of the Trevo's strut (e.g., degree of stent expansion and filling defect of the thrombus in the strut [in-stent thrombus sign]) during the first-pass procedure.
   RESULTS: Median stent expansion was significantly greater in the first-pass recanalization group than in the non-first-pass recanalization group (60% vs. 34%; P < 0.01) and in the thromboembolic group than in the atherosclerotic group (45% vs. 31%; P < 0.01). The receiver operator characteristic curve showed moderate capacity for prediction of recanalization and etiology, with an area under the curve of 0.83 and 0.73, respectively. In-stent thrombus sign was significantly more common in the thromboembolic group than in the atherosclerotic group (86% vs. 10%; P < 0.01).
   CONCLUSIONS: Greater stent expansion was associated with recanalization after thrombectomy. The in-stent thrombus sign may be useful for etiology prediction. These radiographic findings could provide useful real-time feedback during procedures, reflecting clot-stent interaction.
C1 [Imahori, Taichiro; Okamura, Yusuke; Sakata, Junichi; Shose, Hiroyasu] Toyooka Hosp, Dept Neurosurg, Toyooka, Hyogo, Japan.
   [Yokote, Akiyoshi; Matsushima, Kazushi] Toyooka Hosp, Dept Neurol, Toyooka, Hyogo, Japan.
   [Matsui, Daisaku; Kobayashi, Makoto] Toyooka Hosp, Tajima Emergency & Crit Care Med Ctr, Toyooka, Hyogo, Japan.
   [Hosoda, Kohkichi] Kobe City Nishi Kobe Med Ctr, Dept Neurosurg, Kobe, Hyogo, Japan.
   [Imahori, Taichiro; Tanaka, Kazuhiro; Fujita, Atsushi; Kohmura, Eiji] Kobe Univ, Dept Neurosurg, Grad Sch Med, Kobe, Hyogo, Japan.
RP Imahori, T (reprint author), Toyooka Hosp, Dept Neurosurg, Toyooka, Hyogo, Japan.; Imahori, T (reprint author), Kobe Univ, Dept Neurosurg, Grad Sch Med, Kobe, Hyogo, Japan.
EM taichiro.imahori@gmail.com
RI Hosoda, Kohkichi/AAF-1949-2020
OI Imahori, Taichiro/0000-0002-8744-3044; Hosoda,
   Kohkichi/0000-0002-0419-9497
FU Medical Research Fund of Hyogo Medical Association
FX part of this research was supported by Grants-in-Aid for Scientific
   Research, Medical Research Fund of Hyogo Medical Association (Grant No.
   MRF-H-04-17).
CR ADAMS HP, 1993, STROKE, V24, P35, DOI 10.1161/01.STR.24.1.35
   Berkhemer OA, 2015, NEW ENGL J MED, V372, P11, DOI 10.1056/NEJMoa1411587
   Campbell BCV, 2015, NEW ENGL J MED, V372, P1009, DOI 10.1056/NEJMoa1414792
   Chimowitz MI, 2005, NEW ENGL J MED, V352, P1305, DOI 10.1056/NEJMoa043033
   Goyal M, 2015, NEW ENGL J MED, V372, P1019, DOI 10.1056/NEJMoa1414905
   Haussen DC, 2015, STROKE, V46, P2838, DOI 10.1161/STROKEAHA.115.010044
   Imahori T, 2017, J STROKE CEREBROVASC, V26, P2793, DOI 10.1016/j.jstrokecerebrovasdis.2017.06.060
   Imahori T, 2017, NEUROL MED-CHIR, V57, P128, DOI 10.2176/nmc.oa.2016-0215
   Jovin TG, 2015, NEW ENGL J MED, V372, P2296, DOI 10.1056/NEJMoa1503780
   Kabbasch C, 2016, J NEUROINTERV SURG, V8, P778, DOI 10.1136/neurintsurg-2015-011861
   Lee JS, 2015, J STROKE CEREBROVASC, V24, P2074, DOI 10.1016/j.jstrokecerebrovasdis.2015.05.003
   Mitchell BD, 2015, AM J NEURORADIOL, V36, P1317, DOI 10.3174/ajnr.A4256
   Saver JL, 2015, NEW ENGL J MED, V372, P2285, DOI 10.1056/NEJMoa1415061
   Shi ZS, 2010, STROKE, V41, P2775, DOI 10.1161/STROKEAHA.110.587063
   Shinohara Y, 2008, INT J STROKE, V3, P55, DOI 10.1111/j.1747-4949.2008.00178.x
   Tsumoto T, 2017, J NEUROINTERV SURG, V9, P843, DOI 10.1136/neurintsurg-2016-012492
   van der Marel K, 2016, J NEUROINTERV SURG, V8, P1278, DOI 10.1136/neurintsurg-2015-012209
   Yi TY, 2017, WORLD NEUROSURG, V103, P65, DOI 10.1016/j.wneu.2017.03.108
NR 18
TC 0
Z9 0
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP E303
EP E311
DI 10.1016/j.wneu.2018.12.087
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800039
PM 30597281
DA 2020-05-12
ER

PT J
AU Ishak, B
   Gnanadev, R
   Dupont, G
   Kikuta, S
   Altafulla, J
   Iwanaga, J
   Tubbs, RS
AF Ishak, Basem
   Gnanadev, Raja
   Dupont, Graham
   Kikuta, Shogo
   Altafulla, Juan
   Iwanaga, Joe
   Tubbs, R. Shane
TI Gerber's Ligament-A Forgotten Structure of the Craniocervical Junction
SO WORLD NEUROSURGERY
LA English
DT Article
DE Accessory band; Anatomy; Craniocervical junction; Cruciform ligament;
   Transverse ligament
ID SURFACE ANATOMY; MEMBRANE; ALAR
AB BACKGROUND: Ligaments of the craniocervical junction play a critical role in stabilizing this region. Gerber's ligament has more or less been forgotten and, to our knowledge, never studied.
   METHODS: Dissection of the craniocervical junction was performed in 15 fresh frozen cadavers. In the prone position, the posterior elements of the upper cervical vertebrae and occiput were removed. After removing the contents of the spinal canal and posterior cranial fossa, the dura mater and tectorial membrane were reflected. The superior band of the cruciform ligament was reflected. When Gerber's ligament was identified, its attachments and morphometry were recorded. Lastly, Gerber's ligament was observed while range of motion of the craniocervical junction was performed.
   RESULTS: Gerber's ligament was identified in 7 specimens (46.7%). This structure arose anteriorly from the junction of the superior band and transverse part of the cruciform ligament. Gerber's ligament was always found to be just deep to the superior band of the cruciform ligament but traveled more anteriorly to attach onto the posterior aspect of the dens approaching, but not attaching onto, its apex. Mean length was 11 mm, and mean width was 7 mm. Thickness of the ligament was 0.5-1.1 mm. The ligament was found to become taut with minimal rotation of the atlantoaxial joint and extension of the craniocervical junction.
   CONCLUSIONS: A good understanding of all ligaments of the craniocervical junction is important to surgeons and physicians treating patients with injury to the upper cervical spine.
C1 [Ishak, Basem; Gnanadev, Raja; Dupont, Graham; Kikuta, Shogo; Altafulla, Juan; Iwanaga, Joe; Tubbs, R. Shane] Seattle Sci Fdn, Washington, DC 98122 USA.
   [Ishak, Basem] Swedish Med Ctr, Swedish Neurosci Inst, Washington, DC USA.
   [Ishak, Basem] Heidelberg Univ Hosp, Dept Neurosurg, Heidelberg, Germany.
   [Tubbs, R. Shane] St Georges Univ, Dept Anat Sci, St Georges, Grenada.
RP Iwanaga, J (reprint author), Seattle Sci Fdn, Washington, DC 98122 USA.
EM joei@seattlesciencefoundation.org
OI Altafulla, Juan/0000-0002-2110-8665; Kikuta, Shogo/0000-0002-2236-2884;
   GnanaDev, Raja/0000-0002-8220-1353
CR Badshah M, 2017, CLIN ANAT, V30, P781, DOI 10.1002/ca.22907
   DVORAK J, 1988, J ORTHOP RES, V6, P452, DOI 10.1002/jor.1100060317
   DVORAK J, 1987, SPINE, V12, P183, DOI 10.1097/00007632-198703000-00016
   Horning B, 1973, Schweiz Arch Tierheilkd, V115, P107
   Oakes PC, 2017, CLIN ANAT, V30, P322, DOI 10.1002/ca.22853
   ODA T, 1992, CLIN BIOMECH, V7, P201, DOI 10.1016/S0268-0033(92)90002-L
   Sharif K, 2018, CLIN ANAT, V31, P216, DOI 10.1002/ca.22980
   Shen XH, 2017, CLIN ANAT, V30, P330, DOI 10.1002/ca.22847
   Shoja MM, 2018, CLIN ANAT, V31, P466, DOI 10.1002/ca.23049
   Shoja MM, 2018, CLIN ANAT, V31, P488, DOI 10.1002/ca.23048
   Tubbs RS, 2007, CLIN ANAT, V20, P382, DOI 10.1002/ca.20334
   Tubbs RS, 2007, SURG RADIOL ANAT, V29, P219, DOI 10.1007/s00276-007-0196-2
   Tubbs RS, 2012, WORLD NEUROSURG, V77, P775, DOI 10.1016/j.wneu.2011.09.048
   Tubbs RS, 2011, J NEUROSURG-SPINE, V14, P697, DOI 10.3171/2011.1.SPINE10612
   Tubbs RS, 2010, J NEUROSURG-SPINE, V12, P619, DOI 10.3171/2009.12.SPINE09671
   Tubbs RS, 2004, NEUROSURGERY, V55, P400, DOI 10.1227/01.NEU.0000129699.37854.77
   Vangilder J C, 1983, Clin Neurosurg, V30, P514
   Yoon SY, 2018, CLIN ANAT, V31, P710, DOI 10.1002/ca.23074
   Yuksel M, 2006, NEUROSURGERY, V59, P888, DOI 10.1227/01.NEU.0000232661.24547.06
NR 19
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP E707
EP E709
DI 10.1016/j.wneu.2018.12.198
PG 3
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800090
PM 30660889
DA 2020-05-12
ER

PT J
AU Jacobs, R
   Kano, H
   Gross, BA
   Niranjan, A
   Monaco, EA
   Lunsford, LD
AF Jacobs, Rachel
   Kano, Hideyuki
   Gross, Bradley A.
   Niranjan, Ajay
   Monaco, Edward A., III
   Lunsford, L. Dade
TI Defining Long-Term Clinical Outcomes and Risks of Stereotactic
   Radiosurgery for Brainstem Cavernous Malformations
SO WORLD NEUROSURGERY
LA English
DT Article; Proceedings Paper
CT Annual Scientific Meeting of the
   American-Association-of-Neurological-Surgeons (AANS)
CY APR 29-MAY 02, 2018
CL New Orleans, LA
SP Amer Assoc Neurol Surg
DE Adverse radiation effect; Brainstem; Cavernoma; Cavernous malformation;
   Gamma knife; Hemorrhage; Stereotactic radiosurgery
ID SURGICAL-MANAGEMENT; HEMORRHAGE RISK
AB BACKGROUND: We evaluated clinical outcomes in patients with symptomatic brainstem cavernous malformations (CMs) treated by stereotactic radiosurgery (SRS).
   METHODS: Between 1988 and 2016, Gamma Knife SRS was performed in 76 evaluable patients with solitary symptomatic brainstem CMs. Forty-nine (66%) were intrinsic (not reaching a pial or ependymal surface). Most patients (91%) had experienced 2 or more hemorrhages associated with new neurologic deficits. Fourteen patients (18%) underwent resection before radiosurgery. The median CM volume was 0.66 cm(3) (range, 0.05-6.8), and the median margin dose was 15.0 Gy.
   RESULTS: After SRS, 15 patients (20%) had an imaging confirmed new hemorrhage at a median follow-up of 48 months. The hemorrhage-free survival after SRS for brainstem CMs was 92% at 1 year, 87% at 3 years, and 85% at 5 years. The annual hemorrhage rate was 31% before and 4% after SRS. In univariate analysis, CM volume, previous surgical resection, and increased number of hemorrhages before SRS were significantly associated with a higher rate of hemorrhage after SRS. In multivariate analysis, only number of previous hemorrhages was significant (P < 0.0005; hazard ratio, 1.51, 95% confidence interval, 1.23-1.85). Symptomatic adverse radiation effects developed in 7 patients (9%). The rate of symptom deterioration related to hemorrhage or symptomatic adverse radiation effects was 10% at 1 year, 18% at 3 years, and 20% at 5 years.
   CONCLUSIONS: Patients with an increased rate of hemorrhage before SRS had an increased risk of repeat hemorrhage and symptom deterioration rate after SRS. Intrinsic CM location did not significantly affect rates of symptom deterioration or rebleeding.
C1 [Jacobs, Rachel; Kano, Hideyuki; Gross, Bradley A.; Niranjan, Ajay; Monaco, Edward A., III; Lunsford, L. Dade] Univ Pittsburgh, Dept Neurol Surg, Med Ctr, Pittsburgh, PA 15260 USA.
RP Kano, H (reprint author), Univ Pittsburgh, Dept Neurol Surg, Med Ctr, Pittsburgh, PA 15260 USA.
EM kanoh@upmc.edu
FU AB Elekta, Stockholm, Sweden
FX The work described in this report was funded by a research grant to H.K.
   from AB Elekta, Stockholm, Sweden. L.D.L. is an AB Elekta stockholder.
CR Abla AA, 2011, NEUROSURGERY, V68, P403, DOI 10.1227/NEU.0b013e3181ff9cde
   Akers A, 2017, NEUROSURGERY, V80, P665, DOI 10.1093/neuros/nyx091
   Al-Shahi SR, 2012, LANCET NEUROL, V11, P217, DOI DOI 10.1016/S1474-4422(12)70004-2
   Barker FG, 2001, NEUROSURGERY, V49, P15, DOI 10.1097/00006123-200107000-00002
   Choudhri Omar, 2014, Surg Neurol Int, V5, pS148, DOI 10.4103/2152-7806.134810
   Flemming KD, 2012, NEUROLOGY, V78, P632, DOI 10.1212/WNL.0b013e318248de9b
   FRITSCHI JA, 1994, ACTA NEUROCHIR, V130, P35, DOI 10.1007/BF01405501
   Garcia RM, 2015, NEUROSURGERY, V76, P265, DOI 10.1227/NEU.0000000000000602
   Garrett M, 2009, SURG NEUROL S2, V72
   Garrett M, 2009, SURG NEUROL, V72, P3, DOI 10.1016/j.surneu.2009.05.031
   Gross BA, 2017, J NEUROSURG, V126, P1079, DOI 10.3171/2016.3.JNS152419
   Gross BA, 2016, J NEUROSURG-PEDIATR, V17, P123, DOI 10.3171/2015.2.PEDS14541
   Gross BA, 2013, WORLD NEUROSURG, V80, P89, DOI 10.1016/j.wneu.2012.04.002
   Gross BA, 2009, NEUROSURGERY, V64, P805, DOI [10.1227/01.NEU.0000343667.14177.72, 10.1227/01.NEU.0000343668.44288.18]
   Hasegawa T, 2002, NEUROSURGERY, V50, P1190, DOI 10.1097/00006123-200206000-00003
   Jeon JS, 2014, J NEUROL NEUROSUR PS, V85, P1366, DOI 10.1136/jnnp-2013-306844
   Kano H, 2013, NEUROSURGERY, V73, P401, DOI 10.1227/01.neu.0000431471.64289.3d
   Kida Yoshihisa, 2015, Surg Neurol Int, V6, pS249, DOI 10.4103/2152-7806.157071
   KONDZIOLKA D, 1995, J NEUROSURG, V83, P825, DOI 10.3171/jns.1995.83.5.0825
   Li D, 2014, J NEUROSURG, V121, P32, DOI 10.3171/2014.3.JNS132537
   Li D, 2013, J NEUROSURG, V119, P996, DOI 10.3171/2013.7.JNS13462
   Lunsford LD, 2010, J NEUROSURG, V113, P23, DOI 10.3171/2010.1.JNS081626
   Monaco EA, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.7.FOCUS10151
   Park SH, 2013, WORLD NEUROSURG, V80, pE261, DOI 10.1016/j.wneu.2012.09.013
   Porter PJ, 1997, J NEUROSURG, V87, P190, DOI 10.3171/jns.1997.87.2.0190
   Samii M, 2001, J NEUROSURG, V95, P825, DOI 10.3171/jns.2001.95.5.0825
   Shin SS, 2015, J NEUROSURG, V123, P938, DOI 10.3171/2014.10.JNS14499
   Wang CC, 2003, SURG NEUROL, V59, P444, DOI 10.1016/S0090-3019(03)00187-3
NR 28
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP E58
EP E64
DI 10.1016/j.wneu.2018.11.226
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800008
PM 30529525
DA 2020-05-12
ER

PT J
AU Jiang, JF
   Diaz, AN
   Campbell, M
   Boulis, NM
   Keifer, OP
AF Jiang, James F.
   Diaz, Ashley N.
   Campbell, Melissa
   Boulis, Nicholas M.
   Keifer, Orion P., Jr.
TI Supraorbital Occipital Circumferential Stimulation for the Treatment of
   Refractory Chronic Primary Headache: A Case Series
SO WORLD NEUROSURGERY
LA English
DT Article
DE Headache; Migraine; Pain; Supraorbital occipital stimulation treatment
ID NERVE-STIMULATION; CHRONIC MIGRAINE; PREVALENCE; DISABILITY
AB BACKGROUND: Patients with refractory chronic primary headache disorders have extremely debilitating symptoms, severe comorbidities (e.g., anxiety, depression), and a significant reduction in quality of life. The headaches are extremely difficult to treat, as they are often refractory to pharmacologic and procedural interventions. Neuromodulation with stimulation of the occipital and supraorbital nerves has been proposed as a viable treatment for these refractory headaches. We retrospectively review the long-term (33.5 +/- 20 months) results of supraorbital occipital nerve circumferential stimulation (SOCS) in patients with chronic primary headache disorders.
   METHODS: We retrospectively review 25 patients who were evaluated for SOCS for chronic primary headache disorders from 2010 to 2017 at a single institution with a single neurosurgeon.
   RESULTS: Of these 25 patients, 14 saw benefits to their trial stage of stimulation and underwent full implantation. A total 3 patients were excluded from further analysis because of having < 2 months of follow-up or discordant data. Of the 11 patients analyzed, there was an overall response rate (>= 50% pain reduction) of 82%. The average preoperative 10-point pain score dropped from 7.1 +/- 1.6 to a postoperative score of 3.3 +/- 2.1. However, there was a high rate of complications including infection, erosion, and loss of effect.
   CONCLUSIONS: The results (82% response) suggest that SOCS may be an effective treatment and should be studied more extensively. Occipital nerve stimulation alone has shown 40% to 50% response rate in published studies. However, the relatively high complication rate highlights an obstacle for the approach for the treatment of refractory headache disorders and room for device optimization.
C1 [Jiang, James F.; Diaz, Ashley N.; Campbell, Melissa; Boulis, Nicholas M.; Keifer, Orion P., Jr.] Emory Univ, Dept Neurosurg, Sch Med, Atlanta, GA 30322 USA.
RP Boulis, NM (reprint author), Emory Univ, Dept Neurosurg, Sch Med, Atlanta, GA 30322 USA.
EM nboulis@emory.edu
OI Boulis, Nicholas/0000-0002-7271-3953
CR Buse DC, 2012, HEADACHE, V52, P1456, DOI 10.1111/j.1526-4610.2012.02223.x
   Clark SW, 2016, NEUROMODULATION, V19, P507, DOI 10.1111/ner.12400
   D'Ostilio K, 2016, CURR PAIN HEADACHE R, V20, DOI 10.1007/s11916-016-0589-1
   Hann S, 2013, NEUROSURG FOCUS, V35, DOI 10.3171/2013.6.FOCUS13233
   Headache Classification Committee of the International Headache Society, 2013, INT CLASS HEAD DIS
   Jasper JF, 2008, PAIN PHYSICIAN, V11, P187
   Jenkins B, 2011, HEADACHE, V51, P1254, DOI 10.1111/j.1526-4610.2011.01966.x
   Keifer OP, 2017, WORLD NEUROSURG, V105, P599, DOI 10.1016/j.wneu.2017.06.064
   Lipton RB, 2009, CEPHALALGIA, V29, P30
   Messali A, 2016, HEADACHE, V56, P306, DOI 10.1111/head.12755
   Narouze SN, 2007, HEADACHE, V47, P1100, DOI 10.1111/j.1526-4610.2007.00869.x
   Reed KL, 2010, CEPHALALGIA, V30, P260, DOI 10.1111/j.1468-2982.2009.01996.x
   Reed KL, 2011, CEPHALALGIA S1, P98
   Saper JR, 2011, CEPHALALGIA, V31, P271, DOI 10.1177/0333102410381142
   Stewart WF, 2010, J OCCUP ENVIRON MED, V52, P8, DOI 10.1097/JOM.0b013e3181c1dc56
   Stovner LJ, 2007, CEPHALALGIA, V27, P193, DOI 10.1111/j.1468-2982.2007.01288.x
   Vaisman J, 2012, NEUROMODULATION, V15, P374, DOI 10.1111/j.1525-1403.2012.00455.x
NR 17
TC 0
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP E417
EP E423
DI 10.1016/j.wneu.2018.12.108
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800054
PM 30610973
DA 2020-05-12
ER

PT J
AU Jin, XQ
   Du, XF
   Yang, MF
   Zhang, Q
AF Jin, Xiao-Qing
   Du, Xiao-Feng
   Yang, Ming-Fei
   Zhang, Qiang
TI Development and Validation of Prognostic Model for Patients with Acute
   Subdural Hematoma-Reliable Nomogram
SO WORLD NEUROSURGERY
LA English
DT Article
DE Acute subdural hematoma; Brainstem; CT value; Gray-white matter ratio;
   Prognosis
ID GLASGOW COMA SCALE; OUTCOME PREDICTION; BRAIN-INJURY; HEAD-INJURY;
   TRAUMA; CLASSIFICATION; CRANIECTOMY; TOMOGRAPHY; HEMORRHAGE; MORTALITY
AB OBJECTIVE: By extracting clinical and computed tomography imaging data of patients with acute subdural hematoma (ASDH), factors that were significantly associated with poor prognosis were screened and a nomogram model was established and validated.
   METHODS: All patients with ASDH who underwent subdural hematoma removal and decompressive craniectomy from January 2014 to March 2018 in Qinghai Provincial People's Hospital were continuously collected. Finally, 124 patients were included in the study. According to the Glasgow Outcome Scale at 3 months after operation, patients were divided into a good prognosis group and a poor prognosis group.
   RESULTS: Univariate and binary logistic regression analysis were performed to screen out independent predictors that were significantly associated with poor prognosis of ASDH. On the basis of these factors, a nomogram model was established.
   CONCLUSIONS: The nomogram model had high accuracy for predicting poor prognosis in patients with ASDH, and it was easy to promote. In the future, large sample and multicenter prospective studies are necessary to complement and identify the results.
C1 [Jin, Xiao-Qing] Qinghai Univ, Dept Grad Sch, Xining, Qinghai, Peoples R China.
   [Du, Xiao-Feng] Qinghai Inst Hlth Sci, Dept Nursing, Xining, Qinghai, Peoples R China.
   [Yang, Ming-Fei; Zhang, Qiang] Qinghai Prov Peoples Hosp, Dept Neurosurg, Xining, Qinghai, Peoples R China.
RP Yang, MF (reprint author), Qinghai Prov Peoples Hosp, Dept Neurosurg, Xining, Qinghai, Peoples R China.
EM iloveyoucmu@163.com
CR Balestreri M, 2004, J NEUROL NEUROSUR PS, V75, P161
   Bledsoe BE, 2015, PREHOSP DISASTER MED, V30, P46, DOI 10.1017/S1049023X14001289
   Chen SH, 2011, J TRAUMA, V71, P1632, DOI 10.1097/TA.0b013e3182367b3c
   Donkin JJ, 2010, CURR OPIN NEUROL, V23, P293, DOI 10.1097/WCO.0b013e328337f451
   Gentsch A, 2015, CLIN NEURORADIOL, V25, P49, DOI 10.1007/s00062-013-0281-3
   Gurer B, 2017, TURK NEUROSURG, V27, P37, DOI 10.5137/1019-5149.JTN.14809-15.0
   Nguyen HS, 2016, NEURORADIOL J, V29, P372, DOI 10.1177/1971400916658795
   HASELSBERGER K, 1988, ACTA NEUROCHIR, V90, P111, DOI 10.1007/BF01560563
   Hopp S, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0815-8
   Jin XQ, 2018, WORLD NEUROSURG, V116, pE759, DOI 10.1016/j.wneu.2018.05.086
   Kim Hyunjun, 2018, Korean J Neurotrauma, V14, P14, DOI 10.13004/kjnt.2018.14.1.14
   Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668
   Mangel L, 2002, NEOPLASMA, V49, P237
   Marion DW, 2006, NEUROSURGERY, V58, P655
   MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14
   Moussa WMM, 2018, NEUROSURG REV, V41, P483, DOI 10.1007/s10143-017-0873-5
   Oertel M, 2002, J NEUROSURG, V96, P109, DOI 10.3171/jns.2002.96.1.0109
   Perel P, 2007, J EVAL CLIN PRACT, V13, P464, DOI 10.1111/j.1365-2753.2006.00713.x
   ROZSA L, 1989, NEUROSURG REV, V12, P133, DOI 10.1007/BF01741486
   SHENKIN HA, 1982, J NEUROSURG, V57, P254, DOI 10.3171/jns.1982.57.2.0254
   Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165
   Stocchetti N, 2004, J NEUROTRAUM, V21, P1131, DOI 10.1089/neu.2004.21.1131
   STONE JL, 1986, J TRAUMA, V26, P445, DOI 10.1097/00005373-198605000-00006
   Thelin EP, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002368
   Tien HCN, 2011, ANN SURG, V253, P1178, DOI 10.1097/SLA.0b013e318217e339
   Wen L, 2011, BRAIN INJURY, V25, P1318, DOI 10.3109/02699052.2011.608214
   WILBERGER JE, 1991, J NEUROSURG, V74, P212, DOI 10.3171/jns.1991.74.2.0212
   Wu JJ, 1999, J TRAUMA, V47, P39, DOI 10.1097/00005373-199907000-00009
   Yamamura H, 2016, SCAND J TRAUMA RESUS, V24, DOI 10.1186/s13049-016-0271-y
   Yuh EL, 2012, J NEUROTRAUM, V29, P735, DOI 10.1089/neu.2011.2008
NR 30
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP E266
EP E275
DI 10.1016/j.wneu.2018.12.081
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800034
PM 30593962
DA 2020-05-12
ER

PT J
AU Kahraman, S
   Gocmen, S
   Gokmen, MHA
   Acka, G
   Pusat, S
AF Kahraman, Serdar
   Gocmen, Selcuk
   Gokmen, Meltem Hale Alpsan
   Acka, Gokhan
   Pusat, Serhat
TI Intraoperative Neurophysiologic Monitoring for Lumbar Intradural
   Schwannomas: Does It Affect Clinical Outcome?
SO WORLD NEUROSURGERY
LA English
DT Article
DE Intraoperative multimodal neuromonitoring; Schwannomas; Spinal surgery;
   Spinal tumor; Total laminectomy; Unilateral minimal invasive laminectomy
AB OBJECTIVE: Intraoperative multimodal neuromonitoring (IONM) is considered valuable for the early detection and prevention of any neurologic compromise during spine surgery. It has also become the standard of care at many institutions to improve the surgical outcome and be a safety net for both clinical and medicolegal concerns.
   METHODS: Our experience and outcomes in 46 consecutive cases of lumbar intradural schwannoma resection were reviewed with respect to clinical outcomes and patient safety, before and after the integration of IONM into our clinical practice.
   RESULTS: Total surgical resection of schwannomas in the lumbar spine led to improved health-related quality of life for patients. The standard technique for microsurgical resection of schwannomas requires identifying and resecting the fiber of origin for the schwannoma, guided with triggered electromyographic monitoring. However, whether this changed the surgical strategy, because spinal roots that gave rise to the schwannoma were frequently found to be nonfunctional during surgery, remains unclear. In our series of 46 patients, we did not recognize any additional motor deficit after the surgery, regardless of the use of IONM.
   CONCLUSIONS: Despite our analysis proving no difference in clinical outcomes with or without the use of IONM during surgical excision of lumbar schwannomas, we still prefer using IONM as a standard approach. It adds to the confidence and ease of mind of the surgeon during resection and also provides valuable data in cases of medicolegal disputes. However, it comes with an increased cost and lengthened surgical procedure.
C1 [Kahraman, Serdar; Gocmen, Selcuk; Acka, Gokhan] Anadolu Med Ctr, Dept Neurosurg, Kocaeli, Turkey.
   [Gokmen, Meltem Hale Alpsan] Anadolu Med Ctr, Dept Neurol, Kocaeli, Turkey.
   [Pusat, Serhat] Sultan Abdulhamithan Hosp, Neurosurg, Istanbul, Turkey.
RP Gocmen, S (reprint author), Anadolu Med Ctr, Dept Neurosurg, Kocaeli, Turkey.
EM s_gocmen@yahoo.com
CR Fehlings MG, 2010, SPINE, V35, pS37, DOI 10.1097/BRS.0b013e3181d8338e
   Ghadirpour R, 2015, CLIN NEUROL NEUROSUR, V130, P140, DOI 10.1016/j.clineuro.2015.01.007
   Korn A, 2015, ACTA NEUROCHIR, V157, P819, DOI 10.1007/s00701-014-2307-2
   Nuwer MR, 2012, NEUROLOGY, V78, P585, DOI 10.1212/WNL.0b013e318247fa0e
   Oya J, 2017, WORLD NEUROSURG, V106, P17, DOI 10.1016/j.wneu.2017.06.026
   Rho YJ, 2016, SPINAL CORD, V54, P1121, DOI 10.1038/sc.2016.65
   Sutter M, 2007, EUR SPINE J, V16, pS153, DOI 10.1007/s00586-007-0417-8
   Wiedemayer H, 2002, J NEUROSURG, V96, P255, DOI 10.3171/jns.2002.96.2.0255
NR 8
TC 0
Z9 0
U1 1
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP E789
EP E792
DI 10.1016/j.wneu.2019.01.054
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800102
PM 30684697
DA 2020-05-12
ER

PT J
AU Kamamoto, D
   Saga, I
   Ohara, K
   Yoshida, K
   Sasaki, H
AF Kamamoto, Dai
   Saga, Isako
   Ohara, Kentaro
   Yoshida, Kazunari
   Sasaki, Hikaru
TI Association Between CD133, CD44, and Nestin Expression and Prognostic
   Factors in High-Grade Meningioma
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cancer stem cells; CD133; CD44; High-grade meningioma; Nestin;
   Prognosis; Simpson grade
ID CANCER STEM-CELLS; MALIGNANT PROGRESSION; IDENTIFICATION; RECURRENCE;
   THERAPIES
AB BACKGROUND: Meningioma is the most common primary brain tumor. It is graded as I, II, or III based on the World Health Organization (WHO) classification of central nervous system tumors. Meningiomas, especially those classified as grade II-III, have an aggressive history and a high recurrence rate. Cancer stem cells (CSCs) represent a small subset of tumor cells and are considered to be involved in tumor initiation, growth, and/or recurrence. To date, the CSCs of meningioma have not been well established.
   METHODS: We assessed 51 grade II/III meningiomas using immunohistochemistry to determine if a correlation exists with the prognosis by investigating CD133, CD44, and nestin expression as possible CSC markers and age, gender, initial WHO tumor grade, Simpson grade, and the use of adjuvant radiation therapy.
   RESULTS: The median overall survival was 7.1 years, and the median progression-free survival (PFS) was 1.8 years. Univariate analysis using Cox proportional hazards regression revealed a negative correlation between CD133 and nestin expression and PFS (P = 0.0176 and P = 0.0138, respectively), and high expression of CD44 demonstrated a tendency toward a shorter PFS (P [0.0563), as did the initial WHO grade and Simpson grade found at the initial operation (P = 0.0166 and P 0.0333, respectively). Multivariate analysis showed relevance between CD133 and nestin expression and PFS.
   CONCLUSIONS: CD133 and nestin expression, initial WHO grade and Simpson grade were associated with PFS in patients with grade II/III meningioma. These findings might suggest that these molecules are representative of CSCs in meningioma regarding the aspect of clinical course.
C1 [Kamamoto, Dai; Saga, Isako; Yoshida, Kazunari; Sasaki, Hikaru] Keio Univ, Sch Med, Dept Neurosurg, Tokyo, Japan.
   [Ohara, Kentaro] Keio Univ, Sch Med, Dept Pathol, Tokyo, Japan.
RP Kamamoto, D (reprint author), Keio Univ, Sch Med, Dept Neurosurg, Tokyo, Japan.
EM daikamamoto@hotmail.com
CR Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100
   Al-Mefty O, 2004, J NEUROSURG, V101, P210, DOI 10.3171/jns.2004.101.2.0210
   Alamir H, 2018, CANCER CELL INT, V18, DOI 10.1186/s12935-018-0571-6
   Baumgarten P, 2016, ACTA NEUROPATHOL, V132, P479, DOI 10.1007/s00401-016-1598-1
   Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730
   Champeaux C, 2015, BRIT J NEUROSURG, V29, P693, DOI 10.3109/02688697.2015.1054350
   Cherciu Irina, 2014, Curr Health Sci J, V40, P153, DOI 10.12865/CHSJ.40.03.01
   Cimino PJ, 2015, EXP MOL PATHOL, V99, P354, DOI 10.1016/j.yexmp.2015.08.007
   Committee of Brain Tumor Registry of Japan, 2003, NEUROL MED CHIR TO S, V49, pS1
   Dragu DL, 2015, WORLD J STEM CELLS, V7, P1185, DOI 10.4252/wjsc.v7.i9.1185
   Durand A, 2009, J NEURO-ONCOL, V95, P367, DOI 10.1007/s11060-009-9934-0
   Freitag D, 2017, MOL CARCINOGEN, V56, P1953, DOI 10.1002/mc.22653
   Galani V, 2015, TURK NEUROSURG, V25, P574, DOI 10.5137/1019-5149.JTN.10800-14.2
   Han J, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-173
   Heald JB, 2014, ACTA NEUROCHIR, V156, P383, DOI 10.1007/s00701-013-1923-6
   Holohan C, 2013, NAT REV CANCER, V13, P714, DOI 10.1038/nrc3599
   Hueng DY, 2011, J NEURO-ONCOL, V104, P45, DOI 10.1007/s11060-010-0469-1
   Jenkinson MD, 2016, J CLIN NEUROSCI, V28, P87, DOI 10.1016/j.jocn.2015.09.021
   Kaley T, 2014, NEURO-ONCOLOGY, V16, P829, DOI 10.1093/neuonc/not330
   Khan I, 2017, CANCER CELL INT, V17, DOI 10.1186/s12935-017-0441-7
   KLEIHUES P, 2000, PATHOLOGY GENETICS T
   Krayenbuhl N, 2007, NEUROSURGERY, V61, P495, DOI 10.1227/01.NEU.0000280009.79813.DE
   LEMAY DR, 1989, SURG NEUROL, V31, P365, DOI 10.1016/0090-3019(89)90068-2
   Li L, 2014, GASTROENTEROLOGY, V146, P1108, DOI 10.1053/j.gastro.2013.12.035
   Li Z, 2013, EXP HEMATOL ONCOL, V2, DOI 10.1186/2162-3619-2-17
   Louis DN, 2016, WHO CLASSIFICATION T
   Moliterno J, 2015, J NEUROSURG, V123, P23, DOI 10.3171/2014.10.JNS14502
   Mostafa RR, 2017, J CLIN DIAGN RES, V11, pEC12, DOI 10.7860/JCDR/2017/28438.10379
   Omary MB, 2004, NEW ENGL J MED, V351, P2087, DOI 10.1056/NEJMra040319
   Rath P, 2011, EXP MOL PATHOL, V90, P179, DOI 10.1016/j.yexmp.2010.12.003
   ROHRINGER M, 1989, J NEUROSURG, V71, P665, DOI 10.3171/jns.1989.71.5.0665
   Salvati M, 1997, SURG NEUROL, V47, P435, DOI 10.1016/S0090-3019(96)00360-6
   Shivapathasundram G, 2018, J CLIN NEUROSCI, V47, P66, DOI 10.1016/j.jocn.2017.10.059
   SIMPSON D, 1957, J NEUROL NEUROSUR PS, V20, P22, DOI 10.1136/jnnp.20.1.22
   Singh SK, 2003, CANCER RES, V63, P5821
   Sun SQ, 2015, NEUROSURG FOCUS, V38, DOI 10.3171/2015.1.FOCUS14757
   Vaiopoulos AG, 2012, STEM CELLS, V30, P363, DOI 10.1002/stem.1031
   Wen PY, 2010, J NEURO-ONCOL, V99, P365, DOI 10.1007/s11060-010-0349-8
   Whittle IR, 2004, LANCET, V363, P1535, DOI 10.1016/S0140-6736(04)16153-9
   Wiemels J, 2010, J NEURO-ONCOL, V99, P307, DOI 10.1007/s11060-010-0386-3
   Xiao ZY, 2018, TURK NEUROSURG, V28, P910, DOI 10.5137/1019-5149.JTN.21234-17.2
   Zhao P, 2015, NEUROSURG REV, V38, P101, DOI 10.1007/s10143-014-0558-2
NR 42
TC 1
Z9 1
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP E188
EP E196
DI 10.1016/j.wneu.2018.12.067
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800025
PM 30593958
DA 2020-05-12
ER

PT J
AU Karatas, Y
   Erdi, MF
   Kaya, B
   Keskin, F
   Cuce, G
   Kilinc, I
   Uyar, M
   Izci, EK
   Kalkan, E
AF Karatas, Yasar
   Erdi, Mehmet Fatih
   Kaya, Bulent
   Keskin, Fatih
   Cuce, Gokhan
   Kilinc, Ibrahim
   Uyar, Mehmet
   Izci, Emir Kaan
   Kalkan, Erdal
TI Neuroprotective Effects of Tocilizumab on Experimentally-Induced Spinal
   Cord Ischemia-Reperfusion Injury
SO WORLD NEUROSURGERY
LA English
DT Article
DE Ischemia-reperfusion; Neuroprotective; Spinal; Tocilizumab
ID CELL APOPTOSIS; CYTOKINES
AB OBJECTIVES: We aimed to evaluate neuroprotective effects of tocilizumab on spinal cord ischemia-reperfusion (I/R) injury. Our study design was an experimental rabbit spinal cord I/R injury model, and the setting was at the Animal Research Laboratory, Necmettin Erbakan University, Meram School of Medicine, Konya, Turkey.
   METHODS: Twenty-four adult New Zealand rabbits were randomly divided into 3 groups: Group 1, control group (n = 8); Group 2, I/R group, and Group 3 (n = 8) I/R injury D tocilizumab (4 mg/kg, ip) treatment group. Spinal cord I/R injury repair was performed by infrarenal aortic cross clamping.
   On neurologic evaluation, spinal cord tissue plasma tumor necrosis factor alpha (TNFa), total antioxidant status (TAS), total oxidant status (TOS), thiobarbituric acid reactive substances (TBARS), interleukin 6 (IL-6), interleukin 10 (IL-10) levels were analyzed. Spinal cord neuronal damage score and apoptotic cell count were also investigated.
   RESULTS: I/R injury significantly increases the plasma and spinal cord tissue TNFa, TOS, TBARS, and IL-6 levels and decreases the plasma and spinal cord tissue TAS and IL-10 levels. Tocilizumab treatment significantly reduces the plasma and spinal cord tissue TNF alpha, TOS, TBARS, IL-6 levels and increases plasma and tissue TAS and IL-10 levels.
   I/R injury significantly increases spinal cord neuronal damage score and apoptotic cell count. Tocilizumab treatment significantly reduces spinal cord neuronal damage score and apoptotic cell count. Neurologic examination scores at 24, 48, and 72 hours were significantly better in the treatment group when compared with the I/R group.
   CONCLUSIONS: This study shows significant neuroprotective effects of tocilizumab on rabbit spinal cord I/R injury.
C1 [Karatas, Yasar; Kaya, Bulent; Kalkan, Erdal] Medova Hosp, Neurosurg Dept, Konya, Turkey.
   [Erdi, Mehmet Fatih; Keskin, Fatih] Necmettin Erbakan Univ, Meram Med Fac, Neurosurg Dept, Konya, Turkey.
   [Cuce, Gokhan] Necmettin Erbakan Univ, Meram Med Fac, Histol & Embriol Dept, Konya, Turkey.
   [Kilinc, Ibrahim] Necmettin Erbakan Univ, Meram Med Fac, Med Biochem Dept, Konya, Turkey.
   [Uyar, Mehmet] Necmettin Erbakan Univ, Meram Med Fac, Publ Hlth Dept, Konya, Turkey.
   [Izci, Emir Kaan] Meram Educ Res Hosp, Neurosurg Dept, Konya, Turkey.
RP Karatas, Y (reprint author), Medova Hosp, Neurosurg Dept, Konya, Turkey.
EM yasarkrts@gmail.com
RI Karatas, Yasar/AAG-4719-2020; Cuce, Gokhan/AAE-6966-2020
OI Karatas, Yasar/0000-0003-3163-2345
CR Ash Z, 2012, EXPERT OPIN BIOL TH, V12, P1277, DOI 10.1517/14712598.2012.707178
   Chan PH, 1996, STROKE, V27, P1124, DOI 10.1161/01.STR.27.6.1124
   Coselli JS, 2002, ANN THORAC SURG, V73, P1107, DOI 10.1016/S0003-4975(02)03370-2
   CRAWFORD ES, 1986, J VASC SURG, V3, P389, DOI 10.1067/mva.1986.avs0030389
   De Benedetti F, 2012, NEW ENGL J MED, V367, P2385, DOI 10.1056/NEJMoa1112802
   Dhillon S, 2014, BIODRUGS, V28, P75, DOI 10.1007/s40259-013-0076-8
   Gurer B, 2015, INJURY, V46, P240, DOI 10.1016/j.injury.2014.11.002
   Hancerli Y, 2017, TURK J GASTROENTEROL, V28, P485, DOI 10.5152/tjg.2017.16738
   Junk AK, 2002, P NATL ACAD SCI USA, V99, P10659, DOI 10.1073/pnas.152321399
   Juttler E, 2002, NEUROSCIENTIST, V8, P268, DOI 10.1177/1073858402008003012
   KISHIMOTO T, 1995, BLOOD, V86, P1243, DOI 10.1182/blood.V86.4.1243.bloodjournal8641243
   Klune JR, 2010, SURG CLIN N AM, V90, P665, DOI 10.1016/j.suc.2010.04.003
   Klusman I, 1997, BRAIN RES, V762, P173, DOI 10.1016/S0006-8993(97)00381-8
   Kocogullari CU, 2008, SURG TODAY, V38, P237, DOI 10.1007/s00595-007-3614-5
   Liang Y, 2011, SPINAL CORD, V49, P302, DOI 10.1038/sc.2010.113
   Mukaino M, 2010, EXP NEUROL, V224, P403, DOI 10.1016/j.expneurol.2010.04.020
   Okada S, 2004, J NEUROSCI RES, V76, P265, DOI 10.1002/jnr.20044
   Robey RC, 2014, IMMUNOTHERAPY-UK, V6, P211, DOI [10.2217/IMT.13.167, 10.2217/imt.13.167]
   Sahin MA, 2011, HEART SURG FORUM, V14, pE171, DOI 10.1532/HSF98.20101126
   Shechter R, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000113
   Wang LM, 2005, CELL RES, V15, P387, DOI 10.1038/sj.cr.7290306
   Wang SJ, 2016, BOSNIAN J BASIC MED, V16, P145, DOI 10.17305/bjbms.2016.853
NR 22
TC 3
Z9 2
U1 3
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP E208
EP E213
DI 10.1016/j.wneu.2018.12.069
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800027
PM 30593966
DA 2020-05-12
ER

PT J
AU Khan, KN
   Jain, SK
   Sinha, VD
   Sinha, J
AF Khan, Khursheed Nam
   Jain, Shashi Kant
   Sinha, Virendra Deo
   Sinha, Jyotsna
TI Preoperative Diffusion Tensor Imaging: A Landmark Modality for
   Predicting the Outcome and Characterization of Supratentorial
   Intra-Axial Brain Tumors
SO WORLD NEUROSURGERY
LA English
DT Article
DE Neurologic and surgical outcome; Preoperative diffusion tensor imaging;
   Safe surgical corridor; Supratentorial intra-axial brain tumors
ID MAGNETIC-RESONANCE TRACTOGRAPHY; CEREBRAL WHITE-MATTER; RESECTION;
   EXTENT; GLIOMAS; SURVIVAL; TRACTS
AB BACKGROUND AND OBJECTIVE: In view of the few large prospective studies available on the role of preoperative diffusion tensor imaging (DTI), and the potential of DTI in showing the relationship between tumor and white matter tracts, we studied the role of preoperative DTI in planning a safe surgical corridor, predicting the neurologic and surgical outcome and tumor characterization in supratentorial intra-axial brain tumors.
   METHODS: We included 128 cases. Preoperative neurologic status and tumor volume were assessed. A magnetic resonance imaging (MRI)-based surgical plan was decided and reviewed for changes after DTI (site of corticotomy or limit of resection) by senior faculty of neurosurgery and neuroradiologist. Tracts were classified as displaced, infiltrated, or disrupted. Postoperative neurologic and surgical outcome was assessed along with evaluation of association of DTI with tumor type.
   RESULTS: DTI-based change in surgical corridor was seen in 60 patients (47%). Sixty-six patients harbored low-grade gliomas, 48 had high-grade gliomas, and 14 had metastastic lesions. Resectability (maximum safe resection) was higher in patients with displaced fibers and lower in those with disrupted/infiltrated fibers, which was statistically significant. Fewer patients had neurologic deterioration in the displaced category (7.1%) compared with the disrupted/infiltrated category (13.9%). Although no significant association could be established between neurologic outcome and fiber type, displaced fibers were associated mainly with low-grade glioma (71%), whereas disrupted/infiltrated fibers were associated mainly with high-grade glioma (66%); this correlation was significant.
   CONCLUSIONS: Preoperative DTI is a landmark tool for planning a safe surgical corridor and predicting the tumor type along with neurologic and surgical outcome of patients.
C1 [Khan, Khursheed Nam; Jain, Shashi Kant; Sinha, Virendra Deo] Sawai Maan Singh Med Coll, Dept Neurosurg, Jaipur, Rajasthan, India.
   [Sinha, Jyotsna] Getwell Clin, Dept Radiol, Jaipur, Rajasthan, India.
RP Jain, SK (reprint author), Sawai Maan Singh Med Coll, Dept Neurosurg, Jaipur, Rajasthan, India.
EM shashi_neelu@yahoo.com
CR Abdullah KG, 2013, NEUROSURG FOCUS, V34, DOI 10.3171/2013.1.FOCUS12412
   AMMIRATI M, 1987, NEUROSURGERY, V21, P201, DOI 10.1227/00006123-198708000-00012
   Bello L, 2007, NEUROSURGERY, V60, P67, DOI 10.1227/01.NEU.0000249206.58601.DE
   BERGER MS, 1994, CANCER, V74, P1784, DOI 10.1002/1097-0142(19940915)74:6<1784::AID-CNCR2820740622>3.0.CO;2-D
   Berger MS, 1997, J NEURO-ONCOL, V34, P85, DOI 10.1023/A:1005715405413
   Berman J, 2009, MAGN RESON IMAGING C, V17, P205, DOI 10.1016/j.mric.2009.02.002
   Cao Zhikai, 2010, Neurol India, V58, P886, DOI 10.4103/0028-3886.73736
   Castellano A, 2012, NEURO-ONCOLOGY, V14, P192, DOI 10.1093/neuonc/nor188
   Chanraud S, 2010, NEUROPSYCHOL REV, V20, P209, DOI 10.1007/s11065-010-9129-7
   Dolecek TA, 2012, NEURO-ONCOLOGY, V14, pv1, DOI 10.1093/neuonc/nos218
   Dubey Amitesh, 2018, Asian J Neurosurg, V13, P302, DOI 10.4103/ajns.AJNS_226_16
   Field AS, 2004, J MAGN RESON IMAGING, V20, P555, DOI 10.1002/jmri.20169
   Giese A, 1996, NEUROSURGERY, V39, P235, DOI 10.1097/00006123-199608000-00001
   Hirsch BS, 2012, JHN J, V7, DOI [10.29046/JHNJ.007.1.002, DOI 10.29046/JHNJ.007.1.002]
   Ibrahim AS, 2013, EGYPT J RADIOL NUC M, V44, P297, DOI 10.1016/j.ejrnm.2013.02.011
   Jellison BJ, 2004, AM J NEURORADIOL, V25, P356
   Jones DK, 2003, MAGNET RESON MED, V49, P7, DOI 10.1002/mrm.10331
   Karimi S, 2006, APPL RAD, V35, P9
   Keles GE, 2001, J NEUROSURG, V95, P735, DOI 10.3171/jns.2001.95.5.0735
   Maesawa S, 2010, WORLD NEUROSURG, V74, P153, DOI 10.1016/j.wneu.2010.03.022
   Mandonnet E, 2007, NEURO-ONCOLOGY, V9, P63, DOI 10.1215/15228517-2006-015
   Nimsky C, 2005, RADIOLOGY, V234, P218, DOI 10.1148/radiol.2341031984
   Nimsky C, 2005, NEUROSURGERY, V56, P130, DOI 10.1227/01.NEU.0000144842.18771.30
   Romano A, 2007, RADIOL MED, V112, P906, DOI 10.1007/s11547-007-0181-1
   Romano A, 2009, EUR RADIOL, V19, P2798, DOI 10.1007/s00330-009-1483-6
   Sanai N, 2008, NEUROSURGERY, V62, P753, DOI 10.1227/01.neu.0000318159.21731.cf
   Sinha S, 2002, AM J NEURORADIOL, V23, P520
   Smith JS, 2008, J CLIN ONCOL, V26, P1338, DOI 10.1200/JCO.2007.13.9337
   Soni N, 2017, CUREUS, V9, DOI 10.7759/cureus.1739
   Stummer W, 2008, NEUROSURGERY, V62, P564, DOI [10.1227/01.NEU.0000297118.47076.5F, 10.1227/01.neu.0000317304.31579.17, 10.1227/01.NEU.0000346230.80425.3A]
   Talos IF, 2006, RADIOLOGY, V239, P506, DOI 10.1148/radiol.2392050661
NR 31
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP E540
EP E551
DI 10.1016/j.wneu.2018.12.146
PG 12
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800070
PM 30639605
DA 2020-05-12
ER

PT J
AU Kim, DB
   Shin, MH
   Kim, JT
AF Kim, Dong-Bin
   Shin, Myung-Hoon
   Kim, Jong-Tae
TI Vertebral Body Rotation in Patients with Lumbar Degenerative Scoliosis:
   Surgical Implication for Oblique Lumbar Interbody Fusion
SO WORLD NEUROSURGERY
LA English
DT Article
DE Coupled axial rotation; Lumbar degenerative scoliosis; Oblique lumbar
   interbody fusion; Orthogonal maneuver
ID AXIAL ROTATION; SPINE
AB BACKGROUND: To investigate changes of oblique corridor in patients with lumbar degenerative scoliosis and determine proper working angle with respect to the direction of vertebral axial rotation during the oblique lumbar interbody fusion procedure.
   METHODS: The distance of oblique corridor and the rotational angle of the left or right apex group were measured on axial T2 magnetic resonance images and then compared with those of the propensity score-matched control group.
   RESULTS: Fifty-five patients of the left apex group and 57 patients of the right apex groupwere compared with the equal number of patients of the propensity score-matched control group. The distance of oblique corridor in the left apex group was shorter than that in the control group at the levels of L1-2 and L2-3. In contrast, the distance of oblique corridor in the right apex group was longer than that of the control group at the level of L2-3. Patients of the left apex group showed the vertebral body rotating to the left side from L1-2 to L5-S1, whereas in the right apex group, the vertebral body rotated to the right side at the levels of L1-2, L2-3, and L3-4.
   CONCLUSIONS: In the left apex group, the oblique corridor was decreased from psoas overlap, and coupled axial rotation to the left side might increase the risk of contralateral nerve root injury during orthogonally working. Thus, surgeons should pay attention to the state of coupled vertebral axial rotation of lumbar degenerative scoliosis for the oblique lumbar interbody fusion procedure.
C1 [Kim, Dong-Bin; Shin, Myung-Hoon; Kim, Jong-Tae] Catholic Univ, Incheon St Marys Hosp, Coll Med, Dept Neurosurg, Incheon, South Korea.
RP Shin, MH (reprint author), Catholic Univ, Incheon St Marys Hosp, Coll Med, Dept Neurosurg, Incheon, South Korea.
EM novice97@naver.com
FU Catholic Medical Center Research Foundation [5-2018-B0001-00216]
FX The authors wish to acknowledge the financial support of the Catholic
   Medical Center Research Foundation made by The Catholic University of
   Korea in 2018 and its grant number is 5-2018-B0001-00216.
CR Anand N, 2010, NEUROSURG FOCUS, V28, DOI 10.3171/2010.1.FOCUS09278
   Chang J, 2017, WORLD NEUROSURG, V98, DOI 10.1016/j.wneu.2016.11.028
   Davis TT, 2014, J NEUROSURG-SPINE, V21, P785, DOI 10.3171/2014.7.SPINE13564
   Deukmedjian AR, 2012, J NEUROSURG-SPINE, V16, P615, DOI 10.3171/2012.3.SPINE1210
   Jin J, 2018, CLIN SPINE SURG, V31, P31, DOI 10.1097/BSD.0000000000000474
   Kim H, 2013, EUR SPINE J, V22, P1332, DOI 10.1007/s00586-013-2740-6
   Kim KT, 2018, NEUROSURG REV, V41, P355, DOI 10.1007/s10143-017-0927-8
   Li GA, 2009, EUR SPINE J, V18, P1013, DOI 10.1007/s00586-009-0936-6
   Molinares DM, 2016, J NEUROSURG-SPINE, V24, P248, DOI 10.3171/2015.3.SPINE13976
   PANJABI MM, 1994, J BONE JOINT SURG AM, V76A, P413, DOI 10.2106/00004623-199403000-00012
   PEARCY MJ, 1984, SPINE, V9, P582, DOI 10.1097/00007632-198409000-00008
   Regev GJ, 2009, SPINE, V34, P1330, DOI 10.1097/BRS.0b013e3181a029e1
   Sharma AK, 2011, J SPINAL DISORD TECH, V24, P242, DOI 10.1097/BSD.0b013e3181ecf995
   Shin JH, 2013, EUR SPINE J, V22, P2671, DOI 10.1007/s00586-013-2777-6
   Silva FE, 2010, NEUROSURG FOCUS, V28, DOI 10.3171/2010.1.FOCUS09271
   Zhang BL, 2017, BMC MUSCULOSKEL DIS, V18, DOI 10.1186/s12891-017-1504-6
NR 16
TC 0
Z9 0
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP E226
EP E232
DI 10.1016/j.wneu.2018.12.073
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800030
PM 30593961
DA 2020-05-12
ER

PT J
AU Kim, IS
   Kim, YI
   Hong, JT
   Lee, DS
AF Kim, Il Sup
   Kim, Young Il
   Hong, Jae Taek
   Lee, Dong Sup
TI Rationales for a Urodynamic Study in Patients with Cervical Spondylotic
   Myelopathy
SO WORLD NEUROSURGERY
LA English
DT Article
DE Myelopathy; Neurogenic bladder; Urodynamics
ID NEUROGENIC BLADDER; URINARY-BLADDER; INJURY; QUESTIONNAIRE;
   CONTRACTILITY; ASSOCIATION; EFFICACY; INDEX
AB BACKGROUND: Detrusor sphincter dyssynergia, involuntary detrusor contractions (IDCs), and poor bladder compliance are common urodynamic findings in cervical spondylotic myelopathy (CSM). There is little information regarding the role of a urodynamic study after decompression surgery for CSM.
   METHODS: Urodynamic study was performed before and 6 months after decompression of CSM. Japanese Orthopaedic Association score for cervical myelopathy and Neck Disability Index functional score were applied. International Prostate Symptom Score was applied in male patients, and 6-item Urogenital Distress Inventory was applied in female patients.
   RESULTS: Mean patient age was 61.3 years. Final follow-up was obtained in 17 of 32 patients. Neurogenic bladder was confirmed in 11 (64.7%) patients, with 7 patients having poor bladder compliance, 3 patients having IDCs, and 6 patients having detrusor sphincter dyssynergia. Poor bladder compliance was normalized in 4 of 7 patients. IDCs disappeared in 2 (phasic IDCs) of 3 patients and improved in 1 (terminal IDC) patient. Detrusor sphincter dyssynergia markedly improved in 4 of 6 patients. Bladder compliance in 17 patients was 45.52 +/- 23.71 before decompression surgery and 77.07 +/- 39.85 after decompression surgery (P = 0.004). Both Japanese Orthopaedic Association and Neck Disability Index scores improved (P = 0.007 and P = 0.001, respectively). International Prostate Symptom Score and 6-item Urogenital Distress Inventory were not changed 6 months after surgery.
   CONCLUSIONS: Neurogenic bladder could be partially controlled in patients with CSM after surgical decompression. The neurogenic component in the urodynamic study findings varied. Depending on the findings, further appropriate urologic treatments after neurologic decompression surgery should be considered.
C1 [Kim, Il Sup; Kim, Young Il; Hong, Jae Taek] Catholic Univ Korea, St Vincents Hosp, Dept Neurosurg, Suwon, South Korea.
   [Lee, Dong Sup] Catholic Univ Korea, St Vincents Hosp, Dept Urol, Suwon, South Korea.
RP Lee, DS (reprint author), Catholic Univ Korea, St Vincents Hosp, Dept Urol, Suwon, South Korea.
EM LDS@catholic.ac.kr
OI Lee, Dong Sup/0000-0003-0862-3205
CR Abarbanel J, 2007, UROLOGY, V69, P436, DOI 10.1016/j.urology.2006.11.019
   Abrams P, 1999, BJU INT, V84, P14
   Chancellor M B, 1993, J Am Paraplegia Soc, V16, P207
   Chen H, 2018, WORLD NEUROSURG, V116, pE1007, DOI 10.1016/j.wneu.2018.05.150
   DEGROAT WC, 1975, BRAIN RES, V87, P201, DOI 10.1016/0006-8993(75)90417-5
   Edwards Charles C 2nd, 2003, Spine J, V3, P68, DOI 10.1016/S1529-9430(02)00566-1
   Fukuda K, 2013, SPINE, V38, P104, DOI 10.1097/BRS.0b013e318267af02
   GERRIDZEN RG, 1992, J UROLOGY, V147, P416, DOI 10.1016/S0022-5347(17)37254-3
   Giannantoni A, 1998, SPINAL CORD, V36, P29, DOI 10.1038/sj.sc.3100509
   Gibson J, 2018, YALE J BIOL MED, V91, P43
   Haylen BT, 2010, NEUROUROL URODYNAM, V29, P4, DOI 10.1002/nau.20798
   Japanese Orthopaedic Association, 1994, NIPPON SEIKEIGEKA GA, V68, P490
   Japanese Orthopaedic Association, 1976, NIPPON SEIKEIGEKA GA, V50, P18
   Jeong SL, 2010, UROL CLIN N AM, V37, P537, DOI 10.1016/j.ucl.2010.06.005
   Khan MS, 2004, BJOG-INT J OBSTET GY, V111, P468, DOI 10.1111/j.1471-0528.2004.00126.x
   Kuo HC, 2012, J FORMOS MED ASSOC, V111, P386, DOI 10.1016/j.jfma.2011.05.014
   Madersbacher H, 2013, SPINAL CORD, V51, P432, DOI 10.1038/sc.2013.19
   Manack A, 2011, NEUROUROL URODYNAM, V30, P395, DOI 10.1002/nau.21003
   Menon N, 2014, J NEUROSCI RURAL PRA, V5, pS13, DOI 10.4103/0976-3147.145194
   Misawa T, 2005, J SPINAL DISORD TECH, V18, P315, DOI 10.1097/01.bsd.0000166638.31398.14
   Miyake M, 2017, BMC UROL, V17, DOI 10.1186/s12894-017-0251-1
   Nagata K, 2012, SPINE, V37, P1892, DOI 10.1097/BRS.0b013e31825a2619
   Nouri A, 2017, WORLD NEUROSURG, V105, P864, DOI 10.1016/j.wneu.2017.06.025
   Samson Gregory, 2007, Phys Med Rehabil Clin N Am, V18, P255
   Santos-Silva A, 2013, INT J UROL, V20, P956, DOI 10.1111/iju.12188
   Shedid D, 2007, NEUROSURGERY, V60, P7, DOI 10.1227/01.NEU.0000215430.86569.C4
   Shefchyk SJ, 2002, PROG BRAIN RES, V137, P71
   Tai CF, 2006, RESTOR NEUROL NEUROS, V24, P69
   UEBERSAX JS, 1995, NEUROUROL URODYNAM, V14, P131, DOI 10.1002/nau.1930140206
   Vainrib M, 2014, UROLOGY, V84, P940, DOI 10.1016/j.urology.2014.06.009
   VERNON H, 1991, J MANIP PHYSIOL THER, V14, P409
   Wahl EF, 2004, BJU INT, V94, P898, DOI 10.1111/j.1464-410X.2004.05055.x
   Wein AJ, 2012, CAMPBELL WALSH UROLO, P1847
   Wu JC, 2013, NEUROSURG FOCUS, V35, DOI 10.3171/2013.4.FOCUS13122
   Yamanishi T, 2011, UROL SCI, V22, P120, DOI 10.1016/j.urols.2011.08.007
NR 35
TC 0
Z9 0
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP E147
EP E155
DI 10.1016/j.wneu.2018.12.049
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800019
PM 30583129
DA 2020-05-12
ER

PT J
AU Ko, CC
   Chen, TY
   Lim, SW
   Kuo, YT
   Wu, TC
   Chen, JH
AF Ko, Ching-Chung
   Chen, Tai-Yuan
   Lim, Sher-Wei
   Kuo, Yu-Ting
   Wu, Te-Chang
   Chen, Jeon-Hor
TI Prediction of Recurrence in Parasagittal and Parafalcine Meningiomas:
   Added Value of Diffusion-Weighted Magnetic Resonance Imaging
SO WORLD NEUROSURGERY
LA English
DT Article
DE ADC; DWI; Meningioma; Parafalcine; Parasagittal; Recurrence
ID SKULL BASE MENINGIOMAS; STEREOTACTIC RADIOSURGERY; INTRACRANIAL
   MENINGIOMAS; MALIGNANT MENINGIOMAS; POSTOPERATIVE MUTISM; COEFFICIENT;
   TUMORS; GRADE; COMPLICATIONS; RADIOTHERAPY
AB BACKGROUND: Parasagittal and parafalcine (PSPF) meningiomas recur more frequently than other intracranial meningiomas owing to the difficulty in achieving gross total resection. The present study investigated the preoperative magnetic resonance imaging (MRI) features for the prediction of progression/recurrence (P/R) in benign PSPF meningiomas with an emphasis on the apparent diffusion coefficient (ADC) values.
   METHODS: We retrospectively investigated the preoperative MRI features for the prediction of P/R in benign (World Health Organization grade I) PSPF meningiomas. Only patients who had undergone preoperative and postoperative MRI follow-up studies for >= 1 year were included. From October 2006 to December 2015, 48 patients with a diagnosis of benign PSPF meningioma were included (median follow-up period, 42.5 months). Of these 48 patients, 12 (25%) developed P/R (median time to P/R, 23 months).
   RESULTS: PSPF meningiomas in male patients, subtotal resection, large tumor diameter, high diffusion-weighted imaging signal, and lower ADC values or ratios were significantly associated with P/R (P < 0.05). The cutoff points of the ADC value and ADC ratio for the prediction of P/R were 0.83 3 10-3 mm(2)/second and 0.99, with an area under the curve of 0.82 and 0.83, respectively (P = 0.001). On multivariate Cox proportional hazards analysis, male sex and low ADC values (< 0.83 3 10-3 mm(2)/second) were high-risk factors for P/R, with a hazard ratio of 12.37 and 30.2, respectively (P < 0.05). Kaplan-Meier analysis showed that lower ADC values and ratios predicted for significantly shorter progression-free survival (P < 0.05).
   CONCLUSIONS: The preoperative ADC values and ratios for the prediction of P/R offer additional valuable information for the treatment planning for PSPF meningiomas.
C1 [Ko, Ching-Chung; Chen, Tai-Yuan; Kuo, Yu-Ting; Wu, Te-Chang] Chi Mei Med Ctr, Dept Med Imaging, Sect Neuroradiol, Tainan, Taiwan.
   [Chen, Tai-Yuan] Chang Jung Christian Univ, Grad Inst Med Sci, Tainan, Taiwan.
   [Lim, Sher-Wei] Chi Mei Med Ctr, Dept Neurosurg, Tainan, Taiwan.
   [Lim, Sher-Wei] Min Hwei Coll Hlth Care Management, Dept Nursing, Tainan, Taiwan.
   [Kuo, Yu-Ting] Kaohsiung Med Univ, Coll Med, Fac Med, Dept Radiol, Kaohsiung, Taiwan.
   [Wu, Te-Chang] Natl Yang Ming Univ, Dept Biomed Imaging & Radiol Sci, Taipei, Taiwan.
   [Chen, Jeon-Hor] I Shou Univ, E DA Canc Hosp, Dept Radiol, Kaohsiung, Taiwan.
   [Chen, Jeon-Hor] Univ Calif Irvine, Sch Med, Ctr Funct Oncoimaging Radiol Sci, Irvine, CA 92717 USA.
RP Ko, CC (reprint author), Chi Mei Med Ctr, Dept Med Imaging, Sect Neuroradiol, Tainan, Taiwan.
EM crazyboy0729@gmail.com
CR [Anonymous], 2009, NEOPLASIA, V11, P102, DOI 10.1593/neo.81328
   Aslan K, 2018, BRIT J RADIOL, V91, DOI [10.1259/bjr.201810088, 10.1259/bjr.20180088]
   Baskan O, 2016, BRIT J RADIOL, V89, DOI 10.1259/bjr.20140842
   Chung SB, 2007, J KOREAN NEUROSURG S, V42, P276, DOI 10.3340/jkns.2007.42.4.276
   Clark VE, 2013, SCIENCE, V339, P1077, DOI 10.1126/science.1233009
   Colli BO, 2006, SURG NEUROL, V66, pS20, DOI 10.1016/j.surneu.2006.08.023
   Conti A, 2016, CUREUS, V8, DOI 10.7759/cureus.605
   Conti A, 2009, NEUROSURG FOCUS, V27, DOI 10.3171/2009.8.FOCUS09-157
   CRUTCHFIELD JS, 1994, J NEUROSURG, V81, P115, DOI 10.3171/jns.1994.81.1.0115
   Mesa JAE, 2018, WORLD NEUROSURG, V110, pE112, DOI 10.1016/j.wneu.2017.10.087
   Gass A, 2001, J NEUROL SCI, V186, pS15, DOI 10.1016/S0022-510X(01)00487-7
   Gihr GA, 2018, MOL IMAGING BIOL, V20, P632, DOI 10.1007/s11307-018-1166-2
   Girvigian MR, 2008, NEUROSURGERY, V62, pA19, DOI 10.1227/01.neu.0000325933.34154.cb
   Higano S, 2006, RADIOLOGY, V241, P839, DOI 10.1148/radiol.2413051276
   Huo WY, 2004, INT CONGR SER, V1259, P53, DOI 10.1016/S0531-5131(03)01711-4
   Hwang WL, 2016, NEURO-ONCOLOGY, V18, P863, DOI 10.1093/neuonc/nov285
   Ildan F, 2007, SKULL BASE-INTERD AP, V17, P157, DOI 10.1055/s-2007-970554
   Kalapurakal JA, 1997, RADIOLOGY, V204, P461, DOI 10.1148/radiology.204.2.9240536
   Kaur G, 2014, NEURO-ONCOLOGY, V16, P628, DOI 10.1093/neuonc/nou025
   Ko CC, 2018, J NEURO-ONCOL, V138, P63, DOI 10.1007/s11060-018-2769-9
   LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310
   Le Bihan D, 2006, J MAGN RESON IMAGING, V24, P478, DOI 10.1002/jmri.20683
   Lin L, 2018, AM J NEURORADIOL, V39, P1032, DOI 10.3174/ajnr.A5662
   Louis DN, 2016, ACTA NEUROPATHOL, V131, P803, DOI 10.1007/s00401-016-1545-1
   Maclean J, 2014, CLIN ONCOL-UK, V26, P51, DOI 10.1016/j.clon.2013.10.001
   Maillo A, 2007, NEURO-ONCOLOGY, V9, P438, DOI 10.1215/15228517-2007-026
   Mansouri A, 2016, J NEUROSURG, V125, P431, DOI 10.3171/2015.7.JNS15546
   Mathiesen T, 2003, SURG NEUROL, V60, P193, DOI 10.1016/S0090-3019(03)00377-X
   McGovern SL, 2010, J NEUROSURG, V112, P925, DOI 10.3171/2009.9.JNS09617
   MELAMED S, 1979, NEUROCHIRURGIA, V22, P47
   Nagar VA, 2008, AM J NEURORADIOL, V29, P1147, DOI 10.3174/ajnr.A0996
   Nanda A, 2017, J NEUROSURG, V126, P201, DOI 10.3171/2016.1.JNS151842
   Nowak A, 2007, NEUROL NEUROCHIR POL, V41, P306
   Oyama H, 2012, NAGOYA J MED SCI, V74, P211
   Perry A, 1997, AM J SURG PATHOL, V21, P1455, DOI 10.1097/00000478-199712000-00008
   Raza SM, 2010, NEUROSURGERY, V67, P885, DOI 10.1227/NEU.0b013e3181ef2a18
   Sade B, 2007, NEUROSURGERY, V61, P1194, DOI 10.1227/01.neu.0000306097.38141.65
   Server A, 2009, ACTA RADIOL, V50, P682, DOI 10.1080/02841850902933123
   SIMPSON D, 1957, J NEUROL NEUROSUR PS, V20, P22, DOI 10.1136/jnnp.20.1.22
   Sindou M, 2005, ACT NEUR S, V94, P167
   Skudas Gintautas, 2002, Medicina (Kaunas), V38, P1089
   Stafford SL, 2001, NEUROSURGERY, V49, P1029, DOI 10.1097/00006123-200111000-00001
   STEJSKAL EO, 1965, J CHEM PHYS, V42, P288, DOI 10.1063/1.1695690
   Surov A, 2016, WORLD NEUROSURG, V88, P598, DOI 10.1016/j.wneu.2015.10.049
   Surov A, 2015, TRANSL ONCOL, V8, P517, DOI 10.1016/j.tranon.2015.11.012
   Tahta K, 2007, J CLIN NEUROSCI, V14, P793, DOI 10.1016/j.jocn.2006.05.010
   Tang Y, 2014, AM J ROENTGENOL, V202, P1303, DOI 10.2214/AJR.13.11637
   Toh CH, 2008, AM J NEURORADIOL, V29, P471, DOI 10.3174/ajnr.A0872
   Wiemels J, 2010, J NEURO-ONCOL, V99, P307, DOI 10.1007/s11060-010-0386-3
NR 49
TC 1
Z9 1
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP E470
EP E479
DI 10.1016/j.wneu.2018.12.117
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800061
PM 30610981
DA 2020-05-12
ER

PT J
AU Li, DD
   Huang, H
   Fang, JH
   Fu, FW
   Lin, J
   Bai, GH
   Xu, SY
   Sheng, HS
   Zhou, Q
   Zhang, N
   Yin, B
AF Li, Dan-Dong
   Huang, Huan
   Fang, Jun-Hao
   Fu, Fang-Wang
   Lin, Jian
   Bai, Guang-Hui
   Xu, Shang-Yu
   Sheng, Han-Song
   Zhou, Qian
   Zhang, Nu
   Yin, Bo
TI Solitaire Stent Permanent Implantation as an Effective Rescue Treatment
   for Emergency Large Artery Occlusion
SO WORLD NEUROSURGERY
LA English
DT Article
DE Acute ischemic stroke; Intracranial atherosclerotic stenosis; Large
   artery occlusion; Mechanical thrombectomy; Stent implantation
ID ACUTE ISCHEMIC-STROKE; SYMPTOMATIC ATHEROSCLEROTIC STENOSIS;
   GLYCOPROTEIN IIB/IIIA INHIBITORS; MECHANICAL THROMBECTOMY; ENDOVASCULAR
   TREATMENT; WINGSPAN STENTS; TIROFIBAN; OUTCOMES; GUIDELINES; THERAPY
AB BACKGROUND: In this study, we present our experiences on the feasibility of rescue permanent Solitaire stent placement for failed mechanical thrombectomy (MT) and our protocol to avoid ineffective stent placement.
   METHODS: We retrospectively evaluated the data for consecutive patients admitted into the Second Affiliated Hospital of Wenzhou Medical University and 2 collaboration hospitals from August 2014 to May 2018 for emergency large artery occlusion. The baseline clinical characteristics and radiologic assessment, interventional data, clinical outcome, and angiographic follow-up data were assessed. Notably, we introduced our protocol for antegrade flow assessment before Solitaire stent detachment to ensure an effective stent implantation.
   RESULTS: Thirty-nine patients (mean age, 68.1 years, mean preprocedural National Institute of Health Scale Score, 22.1) were included, in which 34 patients had anterior circulation large artery occlusion and 5 patients had posterior circulation large artery occlusion. The MT attempts ranged from 1-5 (3.6 on average). The mean onset-to-puncture time was 4.8 hours (ranging from 2.1-7.8 hours) and the mean procedure time was 87.4 minutes (ranging from 32-124 minutes). Modified thrombolysis in cerebral infarction 2b-3 reperfusions were noted in all cases. The immediate, average postprocedure stenosis rate was 25.3%, and the average stenosis rate at the 3-month angiographic follow-up was 34.7% (data from 15 patients). Three patients died. Nineteen (48.7%) patients had good outcome (modified Rankin Scale, mRS <= 2) at the 3-month follow-up.
   CONCLUSIONS: Permanent Solitaire stent placement might be a feasible therapy for patients with MT-failed emergency large artery occlusion. For a successful revascularization, careful antegrade flow assessment before stent detachment is critical.
C1 [Li, Dan-Dong; Fang, Jun-Hao; Lin, Jian; Xu, Shang-Yu; Sheng, Han-Song; Zhang, Nu; Yin, Bo] Wenzhou Med Univ, Affiliated Hosp 2, Dept Neurosurg, Wenzhou, Zhejiang, Peoples R China.
   [Huang, Huan; Bai, Guang-Hui] Wenzhou Med Univ, Affiliated Hosp 2, Dept Radiol, Wenzhou, Zhejiang, Peoples R China.
   [Fu, Fang-Wang] Wenzhou Med Univ, Affiliated Hosp 2, Dept Neurol, Wenzhou, Zhejiang, Peoples R China.
   [Fu, Fang-Wang] Wenzhou Med Univ, Yuying Childrens Hosp, Wenzhou, Zhejiang, Peoples R China.
   [Zhou, Qian] Wenzhou Med Univ, Sch Med 2, Wenzhou, Zhejiang, Peoples R China.
RP Yin, B (reprint author), Wenzhou Med Univ, Affiliated Hosp 2, Dept Neurosurg, Wenzhou, Zhejiang, Peoples R China.
EM 76yinbo@163.com
FU Science and Technology Program of Wenzhou, China [Y20170090]
FX This study was supported by the Science and Technology Program of
   Wenzhou, China (Y20170090) to Dan-Dong Li.
CR Alexander KP, 2006, CIRCULATION, V114, P1380, DOI 10.1161/CIRCULATIONAHA.106.620815
   Baek JH, 2016, STROKE, V47, P2360, DOI 10.1161/STROKEAHA.116.014073
   Baracchini C, 2017, WORLD NEUROSURG, V103, P57, DOI 10.1016/j.wneu.2017.03.070
   Chang Y, 2018, STROKE, V49, P958, DOI 10.1161/STROKEAHA.117.020072
   Ciccone A, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005208.pub3
   Duan GL, 2016, J NEUROINTERV SURG, V8, DOI 10.1136/neurintsurg-2015-011734
   FELDMANN E, 1990, NEUROLOGY, V40, P1541, DOI 10.1212/wnl.40.10.1540
   Freeman JW, 2010, CONNECT TISSUE RES, V51, P314, DOI 10.3109/03008200903329771
   Ganti L, 2015, ANN EMERG MED, V66, P65, DOI 10.1016/j.annemergmed.2015.02.002
   Goyal M, 2016, LANCET, V387, P1723, DOI 10.1016/S0140-6736(16)00163-X
   Horie N, 2016, J CLIN NEUROSCI, V32, P24, DOI 10.1016/j.jocn.2015.12.043
   Jia BX, 2018, J NEUROINTERV SURG, V10, P746, DOI 10.1136/neurintsurg-2017-013489
   Junghans U, 2003, CIRCULATION, V107, P2717, DOI 10.1161/01.CIR.0000070544.15890.0E
   Kellert L, 2013, STROKE, V44, P1453, DOI 10.1161/STROKEAHA.111.000502
   Kim JS, 2014, J STROKE, V16, P105, DOI 10.5853/jos.2014.16.3.105
   Powers WJ, 2018, STROKE, V49, pE46, DOI 10.1161/STR.0000000000000158
   Seitz RJ, 2008, CURR VASC PHARMACOL, V6, P29, DOI 10.2174/157016108783331303
   Seo Jung Hwa, 2015, Neurointervention, V10, P22, DOI 10.5469/neuroint.2015.10.1.22
   Siebler M, 2011, STROKE, V42, P2388, DOI 10.1161/STROKEAHA.110.599662
   Tian C., 2017, NEUROLOGY, V2, P244
   Vajda Z, 2012, NEUROSURGERY, V70, P91, DOI 10.1227/NEU.0b013e31822dff0f
   Woo HG, 2018, AM J NEURORADIOL, V39, P331, DOI 10.3174/ajnr.A5477
   Yoon W, 2015, NEUROSURGERY, V76, P680, DOI 10.1227/NEU.0000000000000694
   Zhang L, 2012, AM J NEURORADIOL, V33, P343, DOI 10.3174/ajnr.A2772
   Zhang L, 2013, J CLIN NEUROSCI, V20, P362, DOI 10.1016/j.jocn.2012.03.033
NR 25
TC 0
Z9 0
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP E533
EP E539
DI 10.1016/j.wneu.2018.12.145
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800069
PM 30664959
DA 2020-05-12
ER

PT J
AU Li, GW
   Wang, ND
   Li, X
   Ma, N
   Li, TH
   Sun, YJ
   Liu, P
   Miao, ZR
   Zhang, Y
AF Li, Guangwen
   Wang, Naidong
   Li, Xin
   Ma, Ning
   Li, Tonghui
   Sun, Yujie
   Liu, Peng
   Miao, Zhongrong
   Zhang, Yong
TI Balloon-Mounted versus Self-Expanding Stent Outcomes in Symptomatic
   Middle Cerebral Artery Stenosis Combined with Poor Collaterals in China:
   A Multicenter Registry Study
SO WORLD NEUROSURGERY
LA English
DT Article
DE Atherosclerosis; Middle cerebral artery; Stent; Stroke
ID AGGRESSIVE MEDICAL-MANAGEMENT; PREVENTING RECURRENT STROKE; INTRACRANIAL
   STENOSIS; DISEASE; RISK
AB OBJECTIVE: To compare the technical and 1-year clinical outcome in balloon-mounted versus self-expanding stenting for symptomatic severe stenosis of the middle cerebral artery combined with poor collaterals in China.
   METHODS: Ninety-one patients with severe middle cerebral artery atherosclerotic stenosis combined with poor collaterals were recruited in the study. Balloon-mounted stent or self-expanding stent were selected to treat patients following a guideline. The baseline characteristics, cerebral angiography, and outcomes were compared between the patients treated with balloon-mounted stent and self-expanding stent.
   RESULTS: The mean degree of stenosis was 85.5% +/- 6.37% in the balloon-mounted stenting group and 85.4% +/- 7.73% in the self-expanding stenting group before treatment (P = 0.930). A longer operative time occurred in patients treated with self-expanding stent than in those treated with balloon-mounted stent (96.7 vs. 68.6 minutes, respectively; P = 0.002). Patients with self-expanding stent had a higher rate of residual stenosis than those with balloon-mounted stent (67.3% vs. 38.9%, respectively; P = 0.014). The patients in balloon-mounted stenting group was less likely to have restenosis (6.1% vs. 26.5%, P = 0.019) and had a lower degree of stenosis (5.0% +/- 0.0% vs. 26.9% +/- 29.2%, P = 0.019) compared with patients in the selfexpanding stenting group. During the 1-year follow-up, the recurrence rate of ischemic stroke, transient ischemic attack, hemorrhage stroke, and death was not significantly different between the 2 groups (1/33 vs. 2/49, P = 0.804; 1/33 vs. 1/49, P = 0.776; 0/33 vs. 2/49, P = 0.240; 1/33 vs. 0/49, P = 0.220, respectively).
   CONCLUSIONS: Balloon-mounted stents may have a shorter operative time and lower restenosis occurrence than self-expanding stents. No significant difference in 1-year outcome was observed between the 2 groups.
C1 [Li, Guangwen; Wang, Naidong; Li, Xin; Li, Tonghui; Sun, Yujie; Liu, Peng; Zhang, Yong] Qingdao Univ, Dept Neurol, Affiliated Hosp, Qingdao, Shandong, Peoples R China.
   [Li, Guangwen; Wang, Naidong; Li, Xin; Li, Tonghui; Sun, Yujie; Liu, Peng; Zhang, Yong] Qingdao Univ, Dept Intervent Neurol, Affiliated Hosp, Qingdao, Shandong, Peoples R China.
   [Ma, Ning; Miao, Zhongrong] Capital Med Univ, Intervent Neurol, Beijing Tiantan Hosp, Qingdao, Shandong, Peoples R China.
RP Zhang, Y (reprint author), Qingdao Univ, Dept Neurol, Affiliated Hosp, Qingdao, Shandong, Peoples R China.; Zhang, Y (reprint author), Qingdao Univ, Dept Intervent Neurol, Affiliated Hosp, Qingdao, Shandong, Peoples R China.
EM bravezhang@126.com
RI Li, Guangwen/AAD-5859-2020
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [81371290]; Beijing High-level Personnel Funds
   (2013-2019)
FX This project was supported by the National Natural Science Foundation of
   China (81371290) and Beijing High-level Personnel Funds (2013-2019).
CR Aketa S, 2017, WORLD NEUROSURG, V105, DOI 10.1016/j.wneu.2017.06.154
   Baik SH, 2018, INTERV NEURORADIOL, V24, P666, DOI 10.1177/1591019918786515
   Che WQ, 2018, J VASC SURG, V68, P1406, DOI 10.1016/j.jvs.2018.02.042
   Chimowitz MI, 2011, NEW ENGL J MED, V365, P993, DOI 10.1056/NEJMoa1105335
   Chimowitz MI, 2005, NEW ENGL J MED, V352, P1305, DOI 10.1056/NEJMoa043033
   Djulejic V, 2015, ACTA NEUROCHIR, V157, P743, DOI 10.1007/s00701-015-2378-8
   Fiorella D, 2012, STROKE, V43, P2682, DOI 10.1161/STROKEAHA.112.661173
   Gruber P, 2018, J NEUROINTERV SURG, V10, pE32, DOI 10.1136/neurintsurg-2017-013699
   Hafeez A, 2016, NEUROL RES, V38, P477, DOI 10.1080/01616412.2016.1192264
   Kurre W, 2012, NEURORADIOLOGY, V54, P43, DOI 10.1007/s00234-010-0826-y
   Kwon HM, 2016, JAMA NEUROL, V73, P36, DOI 10.1001/jamaneurol.2015.3145
   Li GW, 2018, PROG NEUROBIOL, V163, P59, DOI 10.1016/j.pneurobio.2017.08.002
   Liu JR, 2013, NEURORADIOLOGY, V55, P57, DOI 10.1007/s00234-012-1064-2
   Ma Y, 2017, WORLD NEUROSURG, V104, P74, DOI 10.1016/j.wneu.2017.04.057
   Miao ZR, 2015, STROKE, V46, P2822, DOI 10.1161/STROKEAHA.115.010549
   Miao ZR, 2015, J NEUROINTERV SURG, V7, P331, DOI 10.1136/neurintsurg-2014-011109
   Rohde S, 2013, INT J STROKE, V8, P87, DOI 10.1111/j.1747-4949.2011.00715.x
   Shuaib A, 2011, LANCET NEUROL, V10, P909, DOI 10.1016/S1474-4422(11)70195-8
   Wu D, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-006431
   Yue XY, 2011, CARDIOVASC INTER RAD, V34, P54, DOI 10.1007/s00270-010-9885-z
   Zaidat OO, 2008, NEUROLOGY, V70, P1518, DOI 10.1212/01.wnl.0000306308.08229.a3
   Zaidat OO, 2015, JAMA-J AM MED ASSOC, V313, P1240, DOI 10.1001/jama.2015.1693
   Zhao J, 2018, J STROKE CEREBROVASC, V27, P479, DOI 10.1016/j.jstrokecerebrovasdis.2017.09.032
NR 23
TC 2
Z9 2
U1 1
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP E675
EP E681
DI 10.1016/j.wneu.2018.12.189
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800086
PM 30659967
DA 2020-05-12
ER

PT J
AU Li, L
   Zhang, L
   Zhang, Y
AF Li, Li
   Zhang, Lei
   Zhang, Yan
TI Roles of miR-494 in Intervertebral Disk Degeneration and the Related
   Mechanism
SO WORLD NEUROSURGERY
LA English
DT Article
DE Apoptosis; Intervertebral disk degeneration; MicroRNA-494;
   Neuro-oncological ventral antigen 1; Proliferation
ID NUCLEUS PULPOSUS CELL; MATRIX DEGRADATION; APOPTOSIS
AB OBJECTIVE: In this study, we focused on the regulatory roles of miR-494 in the pathogenesis of intervertebral disk degeneration (IDD) and the related mechanism.
   METHODS: First, rat IDD models were established, and the expression levels of miR-494 in IDDs of the rats were examined. Next, human nucleus pulposus (NP) cells were cultured and transfected with miR-494 mimics and inhibitors, and the roles of miR-494 on the proliferation and apoptosis of cells were determined using MTT cell proliferation assay and flow cytometry methods. Furthermore, the targeting relationship between miR-494 and neuro-oncological ventral antigen 1 (NOVA1) was examined by dual luciferase reporter assay. Finally, the expression of NOVA1, Caspase-3, Bcl-2eassociated X protein (BAX), and B-cell lymphoma-2 (BCL-2) was examined using real-time quantitative polymerase chain reaction and western blot methods.
   RESULTS: The results demonstrated that the expression of miR-494 was significantly upregulated in IDD rats. Moreover, transfection of miR-494 inhibitors induced a significant increase in the proliferation and marked decrease in the apoptosis of the degenerated human NP cells. Transfection of miR-494 mimics has shown the opposite effects. Furthermore, NOVA1 has been confirmed as a target of miR-494, and the expressions of NOVA1 were significantly downregulated in IDD rats. In addition, transfection of miR-494 inhibitors significantly decreased the expression of Caspase-3 and BAX and markedly increased the expression of NOVA1 and BCL-2. Transfection of miR-494 mimics has shown the opposite effects.
   CONCLUSIONS: miR-494 was upregulated in IDD, and miR-494 might regulate the proliferation and apoptosis of NP cells through targeting NOVA1.
C1 [Li, Li] Zhengzhou Univ, Luoyang Cent Hosp, Nursing Dept, Zhengzhou, Henan, Peoples R China.
   [Zhang, Lei] Zhengzhou Univ, Luoyang Cent Hosp, Cardial Surg Dept, Zhengzhou, Henan, Peoples R China.
   [Zhang, Yan] Zhengzhou Univ, Coll Nursing, Zhengzhou, Henan, Peoples R China.
RP Zhang, Y (reprint author), Zhengzhou Univ, Coll Nursing, Zhengzhou, Henan, Peoples R China.
EM zhangyan6987@outlook.com
CR Cao ZG, 2017, EXP THER MED, V14, P4572, DOI 10.3892/etm.2017.5053
   Epstein Nancy E, 2017, Surg Neurol Int, V8, P301, DOI 10.4103/sni.sni_151_17
   Kang L, 2017, ONCOTARGET, V8, P27868, DOI 10.18632/oncotarget.15838
   Leggio L, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18122698
   Li HL, 2017, INT J MOL MED, V40, P1125, DOI 10.3892/ijmm.2017.3089
   Lin JC, 2016, BBA-GENE REGUL MECH, V1859, P1368, DOI 10.1016/j.bbagrm.2016.08.006
   Liu HY, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01043
   Liu SK, 2017, ONCOTARGET, V8, P112720, DOI 10.18632/oncotarget.22746
   Liu W, 2017, EXP CELL RES, V359, P39, DOI 10.1016/j.yexcr.2017.08.011
   Menezes-Reis R, 2016, SPINE, V41, pE1081, DOI 10.1097/BRS.0000000000001568
   Meng XT, 2018, EXP THER MED, V15, P2627, DOI 10.3892/etm.2018.5715
   Molinos M, 2015, J R SOC INTERFACE, V12, DOI 10.1098/rsif.2015.0429
   Nanoudis S, 2017, FRONT GENET, V8, DOI 10.3389/fgene.2017.00209
   Rasheed Z, 2018, EUR J NUTR, V57, P917, DOI 10.1007/s00394-016-1375-x
   Shan Z, 2017, ONCOTARGET, V8, P40276, DOI 10.18632/oncotarget.16831
   Shen B, 2015, FEBS LETT, V589, P3205, DOI 10.1016/j.febslet.2015.09.009
   Wei WF, 2017, CELL DEATH DIS, V8, DOI 10.1038/s41419-017-0077-5
   Xin Y, 2017, CELL PROLIF, V50
   Yan HB, 2018, ANTI-CANCER DRUG, V29, P440, DOI 10.1097/CAD.0000000000000614
   Yu X, 2018, J CELL MOL MED, V22, P2622, DOI 10.1111/jcmm.13527
   Zhang B, 2018, CELL PHYSIOL BIOCHEM, V45, P2506, DOI 10.1159/000488269
NR 21
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP E365
EP E372
DI 10.1016/j.wneu.2018.12.098
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800047
PM 30599248
DA 2020-05-12
ER

PT J
AU Li, XY
   Kong, C
   Sun, XY
   Guo, MC
   Ding, JZ
   Yang, YM
   Lu, SB
AF Li, Xiang-Yu
   Kong, Chao
   Sun, Xiang-Yao
   Guo, Ma-Chao
   Ding, Jun-Zhe
   Yang, Yi-Ming
   Lu, Shi-Bao
TI Influence of the Ratio of C2-C7 Cobb Angle to T1 Slope on Cervical
   Alignment After Laminoplasty
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cervical spondylotic myelopathy; Kyphotic alignment change;
   Laminoplasty; Sagittal alignment; Sagittal balance
ID POSTERIOR LONGITUDINAL LIGAMENT; OPEN-DOOR LAMINOPLASTY; SAGITTAL
   IMBALANCE; OSSIFICATION; PREDICTOR; LORDOSIS; OUTCOMES; BALANCE; MOTION;
   RANGE
AB PURPOSE: To assess the relationship between the ratio of C2-C7 Cobb angle to T1 slope (CL/T1S) and cervical alignment changes after laminoplasty.
   METHODS: 78 consecutive patients with cervical myelopathy who underwent laminoplasty were enrolled. All patients with preoperative and follow-up cervical spine lateral x-ray images available for review were recruited in this study. Imaging data included C2-C7 Cobb angle, T1 slope, and cervical sagittal vertical axis (cSVA). All patients were classified into low-ratio group (bottom 25% of CL/T1S), fair-ratio group (middle 50% of CL/T1S), and high ratio group (top 25% of CL/T1S) according to CL/T1S ratio. The recovery rate was calculated based on the Japanese Orthopedic Association score.
   RESULTS: The preoperative C2-C7 Cobb angle had significant correlations with the T1 slope (r=0.528). Kyphotic alignment changes in the group with a high ratio of CL/T1S was greater than that of the other 2 groups (P < 0.001). The incidence of postoperative kyphosis in the group with a low ratio of CL/T1S was higher than that of the other 2 groups (P < 0.001). There was no postoperative kyphosis in the fair-ratio group. The surgical outcome in the low-ratio CL/T1S group and the high-ratio CL/T1S group was poorer than that in the fair-ratio CL/T1S group (P = 0.005).
   CONCLUSIONS: The cervical alignment was kept well in the mid-range CL/T1S ratio group after laminoplasty. Patients with a high CL/T1S ratio were more likely to present with kyphotic alignment changes. Patients with a low CL/T1S ratio were more likely to have postoperative kyphosis.
C1 [Li, Xiang-Yu; Kong, Chao; Sun, Xiang-Yao; Guo, Ma-Chao; Ding, Jun-Zhe; Yang, Yi-Ming; Lu, Shi-Bao] Capital Med Univ, Xuanwu Hosp, Dept Orthoped, Beijing, Peoples R China.
   [Kong, Chao; Lu, Shi-Bao] Natl Clin Res Ctr Geriatr Dis, Beijing, Peoples R China.
RP Lu, SB (reprint author), Capital Med Univ, Xuanwu Hosp, Dept Orthoped, Beijing, Peoples R China.; Lu, SB (reprint author), Natl Clin Res Ctr Geriatr Dis, Beijing, Peoples R China.
EM spinelu@163.com
OI Kong, Chao/0000-0001-7611-2648
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [81672201, 81871794]
FX This research was supported by the National Natural Science Foundation
   of China (No. 81672201 and 81871794).
CR Aita I, 2000, J BONE JOINT SURG AM, V82A, P1743, DOI 10.2106/00004623-200012000-00008
   Ames CP, 2013, SPINE, V38, pS149, DOI 10.1097/BRS.0b013e3182a7f449
   Cho JH, 2014, SPINE, V39, pE1575, DOI 10.1097/BRS.0000000000000614
   Fujiyoshi T, 2008, SPINE, V33, pE990, DOI 10.1097/BRS.0b013e318188b300
   HIRABAYASHI K, 1981, SPINE, V6, P354, DOI 10.1097/00007632-198107000-00005
   Hosono N, 2005, J NEUROSURG-SPINE, V3, P29, DOI 10.3171/spi.2005.3.1.0029
   Kim B, 2016, SPINE J, V16, P219, DOI 10.1016/j.spinee.2015.10.042
   Kim TH, 2013, SPINE, V38, pE992, DOI 10.1097/BRS.0b013e3182972e1b
   Lamartina C, 2014, EUR SPINE J, V23, P1177, DOI 10.1007/s00586-014-3227-9
   Lee SH, 2012, J SPINAL DISORD TECH, V25, pE41, DOI 10.1097/BSD.0b013e3182396301
   Lin SR, 2015, EUR SPINE J, V24, P127, DOI 10.1007/s00586-014-3605-3
   Liu XW, 2017, EUR SPINE J, V26, P1173, DOI 10.1007/s00586-016-4912-7
   Machino M, 2012, SPINE, V37, pE1243, DOI 10.1097/BRS.0b013e3182659d3e
   Matsuoka Y, 2018, SPINE SURG RELAT RES, P2017
   Nori S, 2018, EUR SPINE J, V27, P2029, DOI 10.1007/s00586-018-5588-y
   Nori S, 2018, SPINE, V43, P542, DOI 10.1097/BRS.0000000000002359
   Sakai K, 2016, SPINE, V41, P299, DOI 10.1097/BRS.0000000000001206
   SATOMI K, 1994, SPINE, V19, P507, DOI 10.1097/00007632-199403000-00003
   Sodeyama T, 1999, SPINE, V24, P1527, DOI 10.1097/00007632-199908010-00005
   Suda K, 2003, SPINE, V28, P1258, DOI 10.1097/00007632-200306150-00008
   Suk KS, 2007, SPINE, V32, pE656, DOI 10.1097/BRS.0b013e318158c573
   Tang JA, 2012, NEUROSURGERY, V76, pS14
   Zhang JT, 2017, EUR SPINE J, V26, P1205, DOI 10.1007/s00586-017-4971-4
NR 23
TC 1
Z9 1
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP E659
EP E666
DI 10.1016/j.wneu.2018.12.181
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800084
PM 30654159
DA 2020-05-12
ER

PT J
AU Lieber, AC
   Mcneill, IT
   Scaggiante, J
   Nistal, DA
   Fowkes, M
   Umphlett, M
   Pan, J
   Roussos, P
   Mobbs, CV
   Mocco, J
   Kellner, CP
AF Lieber, Adam C.
   Mcneill, Ian T.
   Scaggiante, Jacopo
   Nistal, Dominic A.
   Fowkes, Mary
   Umphlett, Melissa
   Pan, Jonathan
   Roussos, Panos
   Mobbs, Charles, V
   Mocco, J.
   Kellner, Christopher P.
TI Biopsy During Minimally Invasive Intracerebral Hemorrhage Clot
   Evacuation
SO WORLD NEUROSURGERY
LA English
DT Article
DE Biopsies; Cerebral amyloid angiopathy; Intracerebral hemorrhage;
   Minimally invasive surgery
ID CEREBRAL AMYLOID ANGIOPATHY; COMPLICATIONS; MORTALITY; HEMATOMA;
   PROGRESS; SURGERY; STROKE
AB BACKGROUND: The safety and efficacy of brain parenchyma biopsy during minimally invasive (MIS) intracerebral hemorrhage (ICH) clot evacuation has not been previously reported. The objective of this study was to establish the safety and diagnostic efficacy of brain biopsy during MIS ICH clot evacuation and to validate the modified Boston criteria as a predictor of cerebral amyloid angiopathy (CAA) in this cohort.
   METHODS: From October 2016 to March 2018, superficial and perihematomal biopsies were collected for 40 patients undergoing MIS ICH clot evacuation and analyzed by the pathology department to assess for various ICH etiologies. Additionally, the admission magnetic resonance imaging or computed tomography scan of each patient was analyzed and evaluated for the likelihood of a CAA etiology based on the modified Boston criteria. Student t test was used to analyze intergroup differences in continuous variables, and a 2-tailed Fisher exact test was used to determine intergroup differences of categorical variables, with significance set at P < 0.05.
   RESULTS: Two of the 40 patients (5%) experienced postoperative rebleed. Four of the 40 patients (10%) had evidence of CAA on biopsy. Patients with CAA on biopsy were older (P = 0.005) and had a higher prevalence of parietal lobe (P = 0.02) and occipital lobe (P = 0.001) hemorrhage. The modified Boston criteria had a sensitivity of 100% (95% confidence interval [CI], 39.6%-100%) and a specificity of 72.2% (95% CI, 54.6%-84.2%) for predicting CAA on biopsy.
   CONCLUSIONS: Brain biopsy in MIS ICH clot evacuation is safe and allows for the diagnosis of various ICH etiologies.
C1 [Lieber, Adam C.; Mcneill, Ian T.; Scaggiante, Jacopo; Nistal, Dominic A.; Pan, Jonathan; Mocco, J.; Kellner, Christopher P.] Mt Sinai Hosp, Dept Neurosurg, New York, NY 10029 USA.
   [Fowkes, Mary; Umphlett, Melissa] Mt Sinai Hosp, Dept Pathol, New York, NY 10029 USA.
   [Roussos, Panos] Mt Sinai Hosp, Dept Genet & Genom Sci, New York, NY 10029 USA.
   [Roussos, Panos] Mt Sinai Hosp, Dept Psychiat, New York, NY 10029 USA.
   [Mobbs, Charles, V] Mt Sinai Hosp, Dept Neurosci, New York, NY 10029 USA.
   [Roussos, Panos] James J Peters VA Med Ctr, Mental Illness Res Educ & Clin Ctr VISN 2 South, Bronx, NY USA.
RP Kellner, CP (reprint author), Mt Sinai Hosp, Dept Neurosurg, New York, NY 10029 USA.
EM christopher.kellner@gmail.com
RI Scaggiante, Jacopo/AAJ-4748-2020
OI Scaggiante, Jacopo/0000-0002-9531-9131
CR Ariesen MJ, 2003, STROKE, V34, P2060, DOI 10.1161/01.STR.0000080678.09344.8D
   Attems J, 2011, NEUROPATH APPL NEURO, V37, P75, DOI 10.1111/j.1365-2990.2010.01137.x
   BERNSTEIN M, 1994, J NEUROSURG, V81, P165, DOI 10.3171/jns.1994.81.2.0165
   Davis SM, 2006, NEUROLOGY, V66, P1175, DOI 10.1212/01.wnl.0000208408.98482.99
   Depreitere B, 2007, J NEUROSURG, V106, P340, DOI 10.3171/ped.2007.106.5.340
   Filippi M, 2005, MR IMAGING WHITE MAT
   Gonzalez-Perez A, 2013, NEUROLOGY, V81, P559, DOI 10.1212/WNL.0b013e31829e6eff
   Greenberg SM, 1996, NEUROLOGY, V46, P1751, DOI 10.1212/WNL.46.6.1751
   Hanley DF, 2016, LANCET NEUROL, V15, P1226, DOI 10.1016/S1474-4422(16)30234-4
   Hirohata M, 2010, EUR J NEUROL, V17, P823, DOI 10.1111/j.1468-1331.2009.02940.x
   Ikram MA, 2012, CURR ATHEROSCLER REP, V14, P300, DOI 10.1007/s11883-012-0252-1
   KASE CS, 1986, STROKE, V17, P590, DOI 10.1161/01.STR.17.4.590
   Kellner CP, 2018, J NEUROINTERV SURG, V10, P771, DOI 10.1136/neurintsurg-2017-013719
   Knudsen KA, 2001, NEUROLOGY, V56, P537, DOI 10.1212/WNL.56.4.537
   Leclerc JL, 2015, BMC NEUROSCI, V16, DOI 10.1186/s12868-015-0182-2
   Li XQ, 2015, J KOREAN NEUROSURG S, V58, P30, DOI 10.3340/jkns.2015.58.1.30
   Linn J, 2008, AM J NEURORADIOL, V29, P184, DOI 10.3174/ajnr.A0783
   Lively S, 2011, J NEUROPATH EXP NEUR, V70, P913, DOI 10.1097/NEN.0b013e318231151e
   Meretoja A, 2012, STROKE, V43, P2592, DOI 10.1161/STROKEAHA.112.661603
   Miller CM, 2008, SURG NEUROL, V69, P441, DOI 10.1016/j.surneu.2007.12.016
   Morgenstern LB, 2001, NEUROLOGY, V56, P1294, DOI 10.1212/WNL.56.10.1294
   Nolte KB, 1996, NEUROLOGY, V46, P1291, DOI 10.1212/WNL.46.5.1291
   Peretta P, 2006, J NEUROSURG, V105, P187, DOI 10.3171/ped.2006.105.3.187
   Qureshi AI, 2001, NEW ENGL J MED, V344, P1450, DOI 10.1056/NEJM200105103441907
   Sacco S, 2009, STROKE, V40, P394, DOI 10.1161/STROKEAHA.108.523209
   Samarasekera N, 2012, J NEUROL NEUROSUR PS, V83, P275, DOI 10.1136/jnnp-2011-300371
   Schroeder HWS, 2004, CHILD NERV SYST, V20, P878, DOI 10.1007/s00381-004-0946-y
   Sukumari-Ramesh S, 2012, J NEUROTRAUM, V29, P2798, DOI 10.1089/neu.2011.2243
   Teernstra OPM, 2003, STROKE, V34, P968, DOI 10.1161/01.STR.0000063367.52044.40
   Tseng JH, 2012, FORMOS J SURG, V45, P25, DOI 10.1016/j.fjs.2011.11.005
   van Asch CJJ, 2010, LANCET NEUROL, V9, P167, DOI 10.1016/S1474-4422(09)70340-0
   van Rooden S, 2009, STROKE, V40, P3022, DOI 10.1161/STROKEAHA.109.554378
   Vespa P, 2016, STROKE, V47, P2749, DOI 10.1161/STROKEAHA.116.013837
   Xi GH, 2006, LANCET NEUROL, V5, P53, DOI 10.1016/S1474-4422(05)70283-0
   Zhan Ren-ya, 2004, J Zhejiang Univ Sci, V5, P1262, DOI 10.1631/jzus.2004.1262
NR 35
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP E169
EP E175
DI 10.1016/j.wneu.2018.12.058
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800022
PM 30590212
DA 2020-05-12
ER

PT J
AU Lin, JM
   Cao, ZY
   Peng, AF
   Chen, T
   Zhou, Y
   Huang, SH
   Liu, JM
   Liu, ZL
AF Lin, Jun-Ming
   Cao, Zhi-Yuan
   Peng, Ai-Fen
   Chen, Tao
   Zhou, Yang
   Huang, Shan-Hu
   Liu, Jia-Ming
   Liu, Zhi-Li
TI Are Routine Postoperative Laboratory Tests Really Necessary After Lumbar
   Spinal Surgery?
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cost effectiveness; Lumbar spinal surgery; Risk factors; Routine
   laboratory test
ID UTILIZATION MANAGEMENT; BLOOD-TRANSFUSION; PREVALENCE; FUSION; RISK;
   COMPLICATIONS; ELECTROLYTE; PHYSICIANS
AB BACKGROUND: For patients undergoing lumbar spinal surgery, many surgeons routinely perform laboratory tests within 3 days after surgery. However, few studies have reported the necessity for routine laboratory tests for patients with uncomplicated cases within 3 days after surgery.
   METHODS: We performed a retrospective study of patients with lumbar degenerative disease who had undergone lumbar spinal surgery from May 2014 to May 2017. The perioperative patient information was recorded. The abnormal postoperative laboratory tests were recorded. Finally, the incidence and risk factors for patients requiring postoperative clinical treatment were analyzed.
   RESULTS: A total of 1915 patients were included in the present study. Postoperative laboratory tests had been ordered for 870 patients (45.43%). Of these patients, only a small proportion had required postoperative clinical intervention to treat abnormal serum hemoglobin (2.53%), albumin (1.95%), serum potassium (0.92%), or serum calcium (6.55%) levels. Multivariate logistic regression analysis showed that female gender and operative time were risk factors for the need for blood transfusion after lumbar spinal surgery. Age and operative time were risk factors for patients requiring albumin supplementation after lumbar spinal surgery. Finally, intraoperative blood loss and operative time were independent risk factors for patients requiring calcium supplementation after surgery.
   CONCLUSIONS: Owing to the small number of postoperative clinical interventions for abnormal laboratory test results, we believe that the use of routine laboratory tests within 3 days after lumbar spinal surgery for patients with uncomplicated cases are unnecessary. Our results showed that operative time is a potential risk factor for the necessity for clinical treatment after lumbar spinal surgery.
C1 [Lin, Jun-Ming; Cao, Zhi-Yuan; Chen, Tao; Zhou, Yang; Huang, Shan-Hu; Liu, Jia-Ming; Liu, Zhi-Li] Nanchang Univ, Dept Orthopaed Surg, Affiliated Hosp 1, Nanchang, Jiangxi, Peoples R China.
   [Peng, Ai-Fen] Jiangxi Univ Tradit Chinese Med, Sch Humanities, Nanchang, Jiangxi, Peoples R China.
RP Liu, ZL (reprint author), Nanchang Univ, Dept Orthopaed Surg, Affiliated Hosp 1, Nanchang, Jiangxi, Peoples R China.
EM liuzhiliyfy@163.com
FU Department of Science and Technology Program of Jiangxi Province, China
   [20162BCB22022, 20162BCB23057]; Graduate Innovation Special Fund Project
   of Jiangxi Provincial, China [YC2017-S084]
FX This work was supported by the Department of Science and Technology
   Program of Jiangxi Province, China (grants 20162BCB22022 and
   20162BCB23057) and the Graduate Innovation Special Fund Project of
   Jiangxi Provincial, China (grant YC2017-S084).
CR Baird G, 2014, BIOCHEM MEDICA, V24, P223, DOI 10.11613/BM.2014.025
   Ball CG, 2010, HPB, V12, P465, DOI 10.1111/j.1477-2574.2010.00209.x
   Bennett S, 2018, ANN SURG, V267, P766, DOI 10.1097/SLA.0000000000002205
   Carabini LM, 2014, J NEUROSURG ANESTH, V26, P205, DOI 10.1097/ANA.0000000000000014
   Chernew ME, 2011, HEALTH AFFAIR, V30, P51, DOI 10.1377/hlthaff.2010.0980
   Dexter SPL, 1997, BRIT J SURG, V84, P464, DOI 10.1002/bjs.1800840410
   Dzankic S, 2001, ANESTH ANALG, V93, P301, DOI 10.1097/00000539-200108000-00013
   Feliciano DV, 2011, J AM COLL SURGEONS, V212, P714, DOI 10.1016/j.jamcollsurg.2010.12.036
   Gille O, 2014, ORTHOP TRAUMATOL-SUR, V100, P311, DOI 10.1016/j.otsr.2014.07.006
   Hart A, 2014, J BONE JOINT SURG AM, V96A, P1945, DOI [10.2106/JBJS.N.0077, 10.2106/JBJS.N.00077]
   Haug RH, 1999, J ORAL MAXIL SURG, V57, P16, DOI 10.1016/S0278-2391(99)90623-7
   HILL GL, 1993, WORLD J SURG, V17, P146, DOI 10.1007/BF01658920
   Hohensinner PJ, 2016, BBA-MOL CELL RES, V1863, P360, DOI 10.1016/j.bbamcr.2015.11.034
   Huck A, 2014, CLIN CHIM ACTA, V427, P111, DOI 10.1016/j.cca.2013.09.021
   Kalichman L, 2009, SPINE J, V9, P545, DOI 10.1016/j.spinee.2009.03.005
   Kim BD, 2014, SPINE, V39, P510, DOI 10.1097/BRS.0000000000000163
   Kim JY, 2011, AM J CLIN PATHOL, V135, P108, DOI 10.1309/AJCP4GS7KSBDBACF
   Kusumi E, 2006, INT J HEMATOL, V84, P217, DOI 10.1532/IJH97.06097
   LINKO K, 1986, ACTA ANAESTH SCAND, V30, P139, DOI 10.1111/j.1399-6576.1986.tb02384.x
   Mommsen P, 2011, PATHOL RES PRACT, V207, P142, DOI 10.1016/j.prp.2010.12.003
   Munro J, 1997, HEALTH TECHNOL ASSES, V1, P1
   Myburgh JA, 2009, CRIT CARE RESUSC, V11, P67
   NARR BJ, 1991, MAYO CLIN PROC, V66, P155, DOI 10.1016/S0025-6196(12)60487-X
   Okada N, 2018, CLIN THER, V40, P252, DOI 10.1016/j.clinthera.2017.12.006
   Olson RP, 2005, ANESTH ANALG, V101, P1337, DOI 10.1213/01.ANE.0000180836.02142.E6
   Peersman G, 2006, HSS J, V2, P70, DOI 10.1007/s11420-005-0130-2
   PEREZ A, 1995, BRIT J ANAESTH, V74, P250, DOI 10.1093/bja/74.3.250
   Qaseem A, 2012, ANN INTERN MED, V156, P147, DOI 10.7326/0003-4819-156-2-201201170-00011
   Roizen MF, 2000, NEW ENGL J MED, V342, P204, DOI 10.1056/NEJM200001203420311
   Sisko A, 2009, HEALTH AFFAIR, V28, pW346, DOI 10.1377/hlthaff.28.2.w346
   Smetana GW, 2003, MED CLIN N AM, V87, P7, DOI 10.1016/S0025-7125(02)00147-5
   Sood R, 2007, NETH J MED, V65, P167
   WILSON RF, 1992, AM SURGEON, V58, P535
   Yang Y, 2015, CLIN NEUROL NEUROSUR, V136, P100, DOI 10.1016/j.clineuro.2015.06.003
NR 34
TC 0
Z9 0
U1 0
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP E748
EP E754
DI 10.1016/j.wneu.2018.12.214
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800096
PM 30677571
DA 2020-05-12
ER

PT J
AU Liu, JJ
   Nielsen, TH
   Abhinav, K
   Lee, J
   Han, SS
   Marks, MP
   Do, HM
   Dodd, RL
   Steinberg, GK
AF Liu, Jonathan J.
   Nielsen, Troels H.
   Abhinav, Kumar
   Lee, Justin
   Han, Summer S.
   Marks, Michael P.
   Do, Huy M.
   Dodd, Robert L.
   Steinberg, Gary K.
TI Surgical Treatment of Recurrent Previously Coiled and/or Stent-Coiled
   Intracerebral Aneurysms: A Single-Center Experience in a Series of 75
   Patients
SO WORLD NEUROSURGERY
LA English
DT Article
DE Clip ligation; Previously coiled aneurysms; Recurrent aneurysms;
   Stent-assisted coil
ID RUPTURED INTRACRANIAL ANEURYSMS; CEREBRAL-ARTERY ANEURYSMS; ENDOVASCULAR
   TREATMENT; NEUROSURGICAL MANAGEMENT; MICROSURGICAL TREATMENT;
   BYPASS-SURGERY; EMBOLIZATION; COILING; PREDICTORS; EFFICACY
AB BACKGROUND: Endovascular treated cerebral aneurysms have a greater recurrence rate compared with microsurgical clip ligation. Despite recent endovascular advances, microsurgical clip ligation might be the treatment of choice for certain previously endovascular treated recurrent aneurysms. We report on our single-center experience with 76 previously coiled and/or stent-coiled aneurysms.
   OBJECTIVE: To analyze the surgical and radiologic outcome after clipping of previous endovascular treated recurrent cerebral aneurysms.
   METHODS: Patients were retrospectively identified. Demographic data, aneurysm size, location, perioperative coil extraction, occlusion rate, and complication rate were recorded. Patients were divided into a previously coiled-only group (COG) and a previously stent-assisted coiled group (SAC).
   RESULTS: Seventy-five patients with 76 aneurysms were included. Sixty-nine patients were included in the COG, 7 patients in the SAC group. Complete or acceptable near-complete occlusion was obtained in 95% of patients in the COG and 57% in the SAC group. Two patients in the COG (2.9%) died postoperatively of a major stroke. One patient died of rehemorrhage after wrapping of an aneurysm. Minor complications occurred in 8.7%. In the SAC group, the mortality was 0%, with 1 major stroke (14.2%), 1 minor stroke (14.2%), and 1 cranial nerve palsy (14.2%). Intraoperative coil extraction and previous stent-assisted coiling were significant predictors of complication rate (P = 0.025 and P = 0.0036 respectively). Previous stent-assisted coiling was a significant predictor of incomplete occlusion (P = 0.036).
   CONCLUSIONS: Microsurgical clipping of previously endovascular treated recurrent aneurysms is an effective treatment with high obliteration rates. Previously stent-assisted coiling and intraoperative coil extraction are predictors of worse outcome and incomplete occlusion.
C1 [Liu, Jonathan J.; Nielsen, Troels H.; Abhinav, Kumar; Han, Summer S.; Marks, Michael P.; Do, Huy M.; Dodd, Robert L.; Steinberg, Gary K.] Stanford Univ, Sch Med, Dept Neurosurg, Stanford, CA 94305 USA.
   [Liu, Jonathan J.; Nielsen, Troels H.; Abhinav, Kumar; Lee, Justin; Han, Summer S.; Marks, Michael P.; Do, Huy M.; Dodd, Robert L.; Steinberg, Gary K.] Stanford Univ, Sch Med, Stanford Stroke Ctr, Stanford, CA 94305 USA.
   [Lee, Justin; Han, Summer S.] Stanford Univ, Sch Med, Dept Med, Stanford, CA 94305 USA.
   [Marks, Michael P.; Do, Huy M.; Dodd, Robert L.] Stanford Univ, Sch Med, Dept Radiol, Stanford, CA 94305 USA.
RP Steinberg, GK (reprint author), Stanford Univ, Sch Med, Dept Neurosurg, Stanford, CA 94305 USA.; Steinberg, GK (reprint author), Stanford Univ, Sch Med, Stanford Stroke Ctr, Stanford, CA 94305 USA.
EM gsteinberg@stanford.edu
FU Bernard and Ronni Lacroute; William Randolph Hearst Foundation; Russell
   and Elizabeth Siegelman
FX This work was supported in part by funding from Bernard and Ronni
   Lacroute, the William Randolph Hearst Foundation, and Russell and
   Elizabeth Siegelman (G.K.S.). G.K.S. is a consultant for Qool
   Therapeutics, Peter Lazic US, Inc., and NeuroSave.
CR Arnaout OM, 2015, WORLD NEUROSURG, V84, P246, DOI 10.1016/j.wneu.2015.02.027
   Ban Seung Pil, 2017, Oper Neurosurg (Hagerstown), V13, P679, DOI 10.1093/ons/opx039
   Benaissa A, 2015, J NEUROINTERV SURG, V7, P44, DOI 10.1136/neurintsurg-2013-011046
   Boet R, 2001, ACTA NEUROCHIR, V143, P1093, DOI 10.1007/s007010100001
   Byrne JV, 1999, J NEUROSURG, V90, P656, DOI 10.3171/jns.1999.90.4.0656
   Chalouhi N, 2014, J NEUROINTERV SURG, V6, P19, DOI 10.1136/neurintsurg-2012-010612
   Daou B, 2019, J NEUROSURG, V130, P1376, DOI 10.3171/2017.12.JNS163090
   Daou B, 2016, J NEUROSURG, V125, P1337, DOI 10.3171/2015.10.JNS151544
   Daou B, 2015, NEUROSURGERY, V77, P692, DOI 10.1227/NEU.0000000000000901
   GUGLIELMI G, 1991, J NEUROSURG, V75, P8, DOI 10.3171/jns.1991.75.1.0008
   GURIAN JH, 1995, J NEUROSURG, V83, P843, DOI 10.3171/jns.1995.83.5.0843
   Johnston SC, 2008, STROKE, V39, P120, DOI 10.1161/STROKEAHA.107.495747
   Johnston SC, 2006, STROKE, V37, P1437, DOI 10.1161/01.STR.0000221331.01830.ce
   Kang HS, 2006, NEUROSURGERY, V58, P60, DOI 10.1227/01.NEU.0000194188.51731.13
   Kivipelto L, 2014, J NEUROSURG, V120, P398, DOI 10.3171/2013.10.JNS13738
   Lawson MF, 2011, NEUROSURGERY, V69, P598, DOI 10.1227/NEU.0b013e3182181c2b
   Lawton MT, 2008, NEUROSURGERY, V62, P1503, DOI [10.1227/01.NEU.0000043642.46308.D1, 10.1227/01.neu.0000333814.02649.a0]
   Lee J, 2018, WORLD NEUROSURG, V114, pE508, DOI 10.1016/j.wneu.2018.03.017
   Meybodi AT, 2017, J NEUROSURG, V127, P463, DOI 10.3171/2016.7.JNS16772
   Molyneux AJ, 2005, LANCET, V366, P809, DOI 10.1016/S0140-6736(05)67214-5
   Nguyen TN, 2007, SURG NEUROL, V68, P19, DOI 10.1016/j.surneu.2006.10.021
   Petr O, 2015, ACTA NEUROCHIR, V157, P1623, DOI 10.1007/s00701-015-2500-y
   Pillai Promod, 2007, J Med Case Rep, V1, P168, DOI 10.1186/1752-1947-1-168
   Raymond J, 2003, STROKE, V34, P1398, DOI 10.1161/01.STR.0000073841.88563.E9
   Romani R, 2011, NEUROSURGERY, V68, P140, DOI 10.1227/NEU.0b013e3181fd860e
   Slob MJ, 2004, AM J NEURORADIOL, V25, P1373
   Thornton J, 2000, SURG NEUROL, V54, P352, DOI 10.1016/S0090-3019(00)00337-2
   Waldron JS, 2009, NEUROSURGERY, V64, P301, DOI 10.1227/01.NEU.0000335178.15274.B4
   Zhang YJ, 2003, NEUROSURGERY, V52, P283, DOI 10.1227/01.NEU.0000043643.93767.86
NR 29
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP E649
EP E658
DI 10.1016/j.wneu.2018.12.171
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800083
PM 30639494
DA 2020-05-12
ER

PT J
AU Luzzi, S
   Elia, A
   Del Maestro, M
   Morotti, A
   Elbabaa, SK
   Cavallini, A
   Galzio, R
AF Luzzi, Sabino
   Elia, Angela
   Del Maestro, Mattia
   Morotti, Andrea
   Elbabaa, Samer K.
   Cavallini, Anna
   Galzio, Renato
TI Indication, Timing, and Surgical Treatment of Spontaneous Intracerebral
   Hemorrhage: Systematic Review and Proposal of a Management Algorithm
SO WORLD NEUROSURGERY
LA English
DT Review
DE Hemorrhagic stroke; Intracerebral hematoma; Intracerebral hemorrhage;
   Minimal invasive surgery; Stroke management
ID BASAL GANGLIA HEMORRHAGE; STEREOTACTIC-GUIDED EVACUATION; ENDOSCOPIC
   HEMATOMA EVACUATION; INITIAL CONSERVATIVE TREATMENT; RANDOMIZED
   CONTROLLED-TRIAL; MINIMALLY-INVASIVE SURGERY; DECOMPRESSIVE CRANIECTOMY;
   CEREBRAL-HEMORRHAGE; PUTAMINAL HEMORRHAGE; STICH
AB OBJECTIVE: To delineate the most recommendable treatment of spontaneous intracerebral hemorrhages and the indication for surgery, its timing, and the best surgical technique to be adopted case by case.
   METHODS: Based on PubMed/MEDLINE, Embase, and the Cochrane Library databases, a systematic review of the literature was performed using as keywords the terms "spontaneous intracerebral hemorrhage," "surgical management," "medical management," "supratentorial," and "infratentorial." Because of the highest level of evidence, only randomized and nonrandomized clinical trials, meta-analyses, and comparative cohort studies reported within the last 12 years were selected. An updated and evidence-based treatment algorithm was reported also.
   RESULTS: The search initially returned 255 articles. After application of the exclusion criteria, only 19 studies were selected. According to the site and volume of the hematoma, admission Glasgow Coma Scale (GCS) score, and progressive neurologic decline, specific subgroups were identified. Surgery must be considered in patients with an admission GCS score ranging between 5 and 12 and a hematoma volume >30 mL. The best time-window has been reported to be 7-24 hours after ictus. Endoscopic surgery is recommendable for patients with a supratentorial hematoma >60 mL and with a poor GCS score (4-8). Alternative techniques, such as minimally invasive puncture and thrombolysis, may be considered for deeper hematoma.
   CONCLUSIONS: Careful selection of patients eligible for surgery is mandatory. The optimal timing falls into a time-window ranging between 7 and 24 hours after ictus. Minimal invasive techniques are valuable surgical options for patients in a poor GCS score or harboring large deep-seated hemorrhages.
C1 [Luzzi, Sabino; Del Maestro, Mattia; Galzio, Renato] Fdn IRCCS Policlin San Matteo, Neurosurg Unit, Dept Surg Sci, Pavia, Italy.
   [Luzzi, Sabino] Univ Bari Aldo Moro, DEOT, PhD Course Tissues & Organs Transplantat & Cellul, Bari, Italy.
   [Elia, Angela; Galzio, Renato] Univ Pavia, Polo Didatt CesareBrusotti, Dept Clin Surg Diagnost & Pediat Sci, Neurosurg Unit, Pavia, Italy.
   [Del Maestro, Mattia] Univ Pavia, Polo Didatt CesareBrusotti, Dept Clin Surg Diagnost & Pediat Sci, PhD Sch Expt Med, Pavia, Italy.
   [Morotti, Andrea; Cavallini, Anna] Fdn IRCCS C Mondino, Stroke Unit, Dept Neurol Emergencies, Pavia, Italy.
   [Elbabaa, Samer K.] Arnold Palmer Hosp Children, Dept Pediat Neurosurg, Pediat Neurosci Ctr Excellence, Orlando, FL USA.
RP Luzzi, S (reprint author), Fdn IRCCS Policlin San Matteo, Neurosurg Unit, Dept Surg Sci, Pavia, Italy.; Luzzi, S (reprint author), Univ Bari Aldo Moro, DEOT, PhD Course Tissues & Organs Transplantat & Cellul, Bari, Italy.
EM sabino.luzzi@gmail.com
RI Elbabaa, Samer/X-4709-2019
OI Elbabaa, Samer/0000-0003-1733-1941; Luzzi, Sabino/0000-0002-1381-8528
CR Akhigbe T, 2015, WORLD NEUROSURG, V84, P451, DOI 10.1016/j.wneu.2015.03.051
   AUER LM, 1989, J NEUROSURG, V70, P530, DOI 10.3171/jns.1989.70.4.0530
   Baharoglu MI, 2016, LANCET, V387, P2605, DOI 10.1016/S0140-6736(16)30392-0
   BATJER HH, 1990, ARCH NEUROL-CHICAGO, V47, P1103, DOI 10.1001/archneur.1990.00530100071015
   Bhaskar MK, 2017, NEUROL INDIA, V65, P752, DOI 10.4103/neuroindia.NI_151_16
   CAI Q, 2017, MEDICINE, V96, DOI DOI 10.1097/MD.0000000000008435
   CHEN X, 1992, ACTA ACAD MED SHANGH, V19, P237
   CHENG XC, 2001, CHIN J CLIN NEUROSCI, V9, P365
   Chi FL, 2014, WORLD J EMERG MED, V5, P203, DOI [10.5847/wjem.j.issn.1920-8642.2014.03.008, 10.5847/wjem.j.1920-8642.2014.03.008]
   Cho DY, 2006, SURG NEUROL, V65, P547, DOI 10.1016/j.surneu.2005.09.032
   DIERSSEN G, 1983, ACTA NEUROCHIR, V69, P53, DOI 10.1007/BF02055853
   Eroglu U, 2018, WORLD NEUROSURG, V114, pE60, DOI 10.1016/j.wneu.2018.02.056
   Feng Y, 2016, TURK NEUROSURG, V26, P84, DOI 10.5137/1019-5149.JTN.12669-14.0
   Ghani ARI, 2008, MALAYS J MED SCI, V15, P48
   Gregson BA, 2012, STROKE, V43, P1496, DOI 10.1161/STROKEAHA.111.640284
   Hattori N, 2004, J NEUROSURG, V101, P417, DOI 10.3171/jns.2004.101.3.0417
   Hayes SB, 2013, NEUROSURG FOCUS, V34, DOI 10.3171/2013.2.FOCUS12422
   Hemphill JC, 2015, STROKE, V46, P2032, DOI 10.1161/STR.0000000000000069
   HOSSEINI H, 2003, CEREBROVASC DIS, V16, P57
   JUVELA S, 1989, J NEUROSURG, V70, P755, DOI 10.3171/jns.1989.70.5.0755
   Keep RF, 2012, LANCET NEUROL, V11, P720, DOI 10.1016/S1474-4422(12)70104-7
   Kim YZ, 2009, J KOREAN NEUROSURG S, V46, P109, DOI 10.3340/jkns.2009.46.2.109
   Li Q, 2013, BRIT J NEUROSURG, V27, P617, DOI 10.3109/02688697.2013.765938
   Li YQ, 2017, WORLD NEUROSURG, V105, P332, DOI 10.1016/j.wneu.2017.05.134
   Li ZH, 2017, NEUROPSYCH DIS TREAT, V13, P213, DOI 10.2147/NDT.S120368
   Lo YT, 2017, WORLD NEUROSURG, V103, P815, DOI 10.1016/j.wneu.2017.04.025
   Ma L, 2010, J STROKE CEREBROVASC, V19, P294, DOI 10.1016/j.jstrokecerebrovasdis.2009.07.002
   Maira G, 2002, NEUROL RES, V24, P54, DOI 10.1179/016164102101199549
   Matsumoto J, 2006, SURG NEUROL, V65, P74, DOI 10.1016/j.surneu.2005.04.036
   MCKISSOCK W, 1961, LANCET, V2, P221
   Mendelow AD, 2013, LANCET, V382, P397, DOI 10.1016/S0140-6736(13)60986-1
   Mendelow AD, 2005, LANCET, V365, P387
   Miller CM, 2008, SURG NEUROL, V69, P441, DOI 10.1016/j.surneu.2007.12.016
   Morgan T, 2008, ACTA NEUROCHIR SUPPL, V105, P147
   Morgenstern LB, 1998, NEUROLOGY, V51, P1359, DOI 10.1212/WNL.51.5.1359
   Morioka J, 2006, SURG NEUROL, V65, P67, DOI 10.1016/j.surneu.2005.03.023
   Moussa WMM, 2017, NEUROSURG REV, V40, P115, DOI 10.1007/s10143-016-0743-6
   Nagasaka T, 2011, J STROKE CEREBROVASC, V20, P208, DOI 10.1016/j.jstrokecerebrovasdis.2009.11.021
   Nakano T, 2003, MINIM INVAS NEUROSUR, V46, P278
   Nishihara T, 2007, CHILD NERV SYST, V23, P677, DOI 10.1007/s00381-007-0325-6
   Pantazis G, 2006, SURG NEUROL, V66, P492, DOI 10.1016/j.surneu.2006.05.054
   Pantoni L, 2010, LANCET NEUROL, V9, P689, DOI 10.1016/S1474-4422(10)70104-6
   Prasad K, 2008, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD000200.pub2, 10.1002/14651858.CD002244.pub3]
   Qiu YM, 2003, CHINESE MED J-PEKING, V116, P195
   Segal R, 2006, ISRAEL MED ASSOC J, V8, P815
   Sun HX, 2010, NEUROL RES, V32, P371, DOI 10.1179/016164110X12670144526147
   Tan SH, 2001, SURG NEUROL, V56, P287, DOI 10.1016/S0090-3019(01)00561-4
   Teernstra OPM, 2006, ACTA NEUROCHIR, V148, P521, DOI 10.1007/s00701-005-0713-1
   Teernstra OPM, 2003, STROKE, V34, P968, DOI 10.1161/01.STR.0000063367.52044.40
   van Asch CJJ, 2010, LANCET NEUROL, V9, P167, DOI 10.1016/S1474-4422(09)70340-0
   Vespa P, 2016, STROKE, V47, P2749, DOI 10.1161/STROKEAHA.116.013837
   Wang GQ, 2014, MILITARY MED RES, V1, DOI 10.1186/2054-9369-1-10
   Wang WH, 2015, J CHIN MED ASSOC, V78, P101, DOI 10.1016/j.jcma.2014.08.013
   Wang WZ, 2009, INT J STROKE, V4, P11, DOI 10.1111/j.1747-4949.2009.00239.x
   Wang YF, 2008, ACTA NEUROCHIR SUPPL, V105, P141
   Xia ZW, 2018, WORLD NEUROSURG, V115, P266, DOI 10.1016/j.wneu.2018.04.181
   Xu XH, 2018, J NEUROSURG, V128, P553, DOI 10.3171/2016.10.JNS161589
   Yamashiro S, 2015, NEUROL MED-CHIR, V55, P819, DOI 10.2176/nmc.oa.2014-0136
   Yao Z, 2018, WORLD NEUROSURG, V113, P348, DOI 10.1016/j.wneu.2018.02.022
   Yao Z, 2018, WORLD NEUROSURG, V110, P121, DOI 10.1016/j.wneu.2017.10.167
   Zhang HZ, 2014, BIOMED RES INT, DOI 10.1155/2014/898762
   Zhou HG, 2011, BMC NEUROL, V11, DOI 10.1186/1471-2377-11-76
   Zhou XY, 2012, STROKE, V43, P2923, DOI 10.1161/STROKEAHA.112.667535
   Zhu HW, 2012, TURK NEUROSURG, V22, P294, DOI 10.5137/1019-5149.JTN.5136-11.1
   Zuccarello M, 1999, STROKE, V30, P1833, DOI 10.1161/01.STR.30.9.1833
NR 65
TC 3
Z9 3
U1 1
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP E769
EP E778
DI 10.1016/j.wneu.2019.01.016
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800099
PM 30677572
DA 2020-05-12
ER

PT J
AU Matsumoto, M
   Mizutani, T
   Sugiyama, T
   Sumi, K
   Nakajo, T
   Arai, S
AF Matsumoto, Masaki
   Mizutani, Tohru
   Sugiyama, Tatsuya
   Sumi, Kenji
   Nakajo, Takato
   Arai, Shintaro
TI Distance Between the Falciform Ligament and Distal Dural Ring as a
   Surgical Landmark for the Treatment of Paraclinoid Aneurysms
SO WORLD NEUROSURGERY
LA English
DT Article
DE 3D-CT angiography; Distal dural ring; Falciform ligament; Paraclinoid
   aneurysms
ID CAVERNOUS SINUS ANEURYSMS; ANATOMIC FEATURES; LOCATION; DIFFERENTIATION;
   CISTERNOGRAPHY; ANGIOGRAPHY; CT
AB OBJECTIVE: It is difficult to completely comprehend the anatomy of the structures surrounding the paraclinoid region before aneurysm and tumor treatment therein. When treating paraclinoid aneurysms, it is important to determine the location of the aneurysm as intradural or extradural. Thus, accurate prediction of the position of the distal dural ring (DDR) is necessary. To this end, we focused on the falciform ligament (FL), which is easily visualized on images based on its anatomic features. We measured the distance between the FL and the DDR in patients undergoing paraclinoid aneurysm operations.
   METHODS: Between January 2017 and July 2018, 15 patients who underwent clipping for paraclinoid aneurysm treatment were retrospectively identified. The distance between the FL and the DDR was measured using a microscale at the time of the operation.
   RESULTS: The patients comprised 14 women and 1 man. The mean aneurysm diameter was 7.29 +/- 2.21 mm and the median size was 6.5 mm. Eleven of the aneurysms were on the left and 4 were on the right side. The mean distance between the FL and the DDR was 3.50 +/- 0.17 mm and the median distance was 3.50 mm. The distance between the FL and the DDR was almost the same across cases (3.5 mm).
   CONCLUSIONS: The position of the FL can be easily predicted using preoperative three-dimensional computed tomography angiography based on its anatomic features. In this study, the DDR was located 3.5 mm proximal to the FL along the internal carotid artery. This information is useful for predicting the position of the DDR.
C1 [Matsumoto, Masaki; Mizutani, Tohru; Sugiyama, Tatsuya; Sumi, Kenji] Showa Univ, Dept Neurosurg, Sch Med, Tokyo, Japan.
   [Nakajo, Takato] Showa Univ, Dept Neurosurg, Fujigaoka Hosp, Yokohama, Kanagawa, Japan.
   [Arai, Shintaro] Showa Univ, Dept Neurosurg, Koto Toyosu Hosp, Tokyo, Japan.
RP Matsumoto, M (reprint author), Showa Univ, Dept Neurosurg, Sch Med, Tokyo, Japan.
EM mmatsumoto-oka@umin.ac.jp
CR Beretta F, 2005, SKULL BASE-INTERD AP, V15, P253, DOI 10.1055/s-2005-918886
   Gonzalez LF, 2003, NEUROSURGERY, V52, P1131, DOI 10.1227/01.NEU.0000058465.98426.2E
   Hashimoto K, 2006, NEUROSURGERY, V59, P880, DOI 10.1227/01.NEU.0000232664.02190.E1
   Hirai T, 2008, AM J NEURORADIOL, V29, P130, DOI 10.3174/ajnr.A0756
   Hitotsumatsu T, 1997, ACTA NEUROCHIR, V139, P869, DOI 10.1007/BF01411405
   Inoue S, 2014, ACTA NEUROCHIR, V156, P505, DOI 10.1007/s00701-014-1996-x
   Kanayama S, 2015, NEURORADIOLOGY, V57, P155, DOI 10.1007/s00234-014-1447-7
   Kawashima A, 2009, NEUROSURGERY, V65, P1188, DOI 10.1227/01.NEU.0000350875.34638.1A
   Kim JM, 2000, NEUROSURGERY, V46, P670, DOI 10.1097/00006123-200003000-00029
   KOBAYASHI S, 1989, J NEUROSURG, V70, P216, DOI 10.3171/jns.1989.70.2.0216
   Liao CH, 2016, J NEUROSURG, V125, P275, DOI 10.3171/2015.7.JNS151046
   Oikawa S, 1998, J NEUROSURG, V89, P250, DOI 10.3171/jns.1998.89.2.0250
   PUNT J, 1979, J NEUROSURG, V51, P151, DOI 10.3171/jns.1979.51.2.0151
   Rafiei A, 2017, NEUROSURGERY, V81, P949, DOI 10.1093/neuros/nyx157
   Seoane E, 1998, NEUROSURGERY, V42, P869, DOI 10.1097/00006123-199804000-00108
   Thines L, 2008, AM J NEURORADIOL, V29, P125, DOI 10.3174/ajnr.A0734
   Thines L, 2006, EUR RADIOL, V16, P479, DOI 10.1007/s00330-005-2879-6
   Thines L, 2009, NEUROSURGERY, V64, P1059, DOI 10.1227/01.NEU.0000343523.67272.34
   Tsuboi T, 2007, SURG NEUROL, V67, P381, DOI 10.1016/j.surneu.2006.08.006
   Watanabe Y, 2009, AM J NEURORADIOL, V30, P845, DOI 10.3174/ajnr.A1440
   Watanabe Y, 2011, MAGN RESON MED SCI, V10, P29, DOI 10.2463/mrms.10.29
NR 21
TC 2
Z9 2
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP E498
EP E502
DI 10.1016/j.wneu.2018.12.120
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800064
PM 30615993
DA 2020-05-12
ER

PT J
AU Matsuura, J
   Otsuka, T
   Nakagawa, T
   Kai, K
AF Matsuura, Jin
   Otsuka, Tadahiro
   Nakagawa, Takashi
   Kai, Keitaro
TI Frontal Sinus Repair Using Polymethyl Methacrylate After Bifrontal
   Craniotomy
SO WORLD NEUROSURGERY
LA English
DT Article
DE Bifrontal craniotomy; Complication; Frontal sinus; Polymethyl
   methacrylate
ID RECONSTRUCTION; CRANIOPLASTY; EXPERIENCE; VASOSPASM; SURGERY; FLAP
AB BACKGROUND: In many cases in which bifrontal craniotomy is performed, the frontal sinus is opened, and postoperative complications occur. Various methods to close the frontal sinus have been reported. However, all these methods require skill to perform and take time. The aim of this study was to report results obtained with closure of the frontal sinus using polymethyl methacrylate, which is a simpler method.
   METHODS: From December 2008 to June 2018, 122 patients with a ruptured anterior communicating aneurysm were transported to the authors' facility, and 52 patients consecutively underwent bifrontal craniotomy with opening of the frontal sinuses, which were then filled with polymethyl methacrylate.
   RESULTS: Mean follow-up period was 21.8 months; the longest follow-up was 116 months. No cerebrospinal fluid leakage or other complications were observed.
   CONCLUSIONS: The method of filling the frontal sinus with polymethyl methacrylate reported in this study was safe and had no complications. This method should be considered as a method of frontal sinus closure.
C1 [Matsuura, Jin; Otsuka, Tadahiro; Nakagawa, Takashi; Kai, Keitaro] Natl Hosp Org Kumamoto Med Ctr, Dept Neurosurg, Kumamoto, Japan.
RP Matsuura, J (reprint author), Natl Hosp Org Kumamoto Med Ctr, Dept Neurosurg, Kumamoto, Japan.
EM mj.1593_mj@yahoo.co.jp
CR Delaney SW, 2016, J PLAST RECONSTR AES, V69, P1037, DOI 10.1016/j.bjps.2016.06.006
   Donath A, 2006, LARYNGOSCOPE, V116, P1585, DOI 10.1097/01.mlg.0000232514.31101.39
   Eppley BL, 2005, J CRANIOFAC SURG, V16, P140, DOI 10.1097/00001665-200501000-00028
   Ito S, 2003, SURG NEUROL, V60, P155, DOI 10.1016/S0090-3019(03)00207-6
   KASSELL NF, 1982, NEUROSURGERY, V11, P337, DOI 10.1227/00006123-198209000-00001
   KLINGELHOFER J, 1991, J NEUROSURG, V75, P752, DOI 10.3171/jns.1991.75.5.0752
   Kwinta BM, 2017, WORLD NEUROSURG, V105, P749, DOI 10.1016/j.wneu.2017.06.090
   Lustica I, 2001, COLLEGIUM ANTROPOL, V25, P137
   Marchac D, 2008, J PLAST RECONSTR AES, V61, P744, DOI 10.1016/j.bjps.2007.10.055
   Meetze K, 2004, LARYNGOSCOPE, V114, P945, DOI 10.1097/00005537-200405000-00031
   Mori K, 2003, SURG NEUROL, V60, P326, DOI 10.1016/S0090-3019(03)00240-4
   Sakarunchai I, 2016, INTERDISCIP NEUROSUR, V4, P6, DOI 10.1016/j.inat.2016.01.003
   Sharavanan GM, 2015, J MAXILLOFAC ORAL SU, V14, P378, DOI 10.1007/s12663-014-0670-4
   Takeuchi S, 2015, WORLD NEUROSURG, V83, P907, DOI 10.1016/j.wneu.2015.01.030
   Xu G, 2008, ORL-J OTO-RHIN-LARYN, V70, P118, DOI 10.1159/000114535
   Yu Huanxin, 2015, Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi, V29, P2154
   Zhou HJ, 2013, J CRANIO MAXILL SURG, V41, P665, DOI 10.1016/j.jcms.2013.01.006
NR 17
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP E281
EP E284
DI 10.1016/j.wneu.2018.12.083
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800036
PM 30593968
DA 2020-05-12
ER

PT J
AU Mijderwijk, HJ
   Fischer, I
   Zhivotovskaya, A
   Bostelmann, R
   Steiger, HJ
   Cornelius, JF
   Petridis, AK
AF Mijderwijk, Hendrik-Jan
   Fischer, Igor
   Zhivotovskaya, Angelika
   Bostelmann, Richard
   Steiger, Hans-Jakob
   Cornelius, Jan F.
   Petridis, Athanasios K.
TI Prognostic Model for Chronic Shunt-Dependent Hydrocephalus After
   Aneurysmal Subarachnoid Hemorrhage
SO WORLD NEUROSURGERY
LA English
DT Article
DE Aneurysm; Basal/peripheral CSF spaces; Blood clearance; Hydrocephalus;
   Shunt dependency; Subarachnoid bleeding
ID STEREOTACTIC CATHETER VENTRICULOCISTERNOSTOMY; RUPTURED INTRACRANIAL
   ANEURYSMS; ENDOVASCULAR COILING; CEREBROSPINAL-FLUID; LUMBAR DRAINAGE;
   PREDICTORS; RISK; TRIAL; CLEARANCE; SCORE
AB BACKGROUND: Patients with aneurysmal subarachnoid hemorrhage (aSAH) are at risk of the development of chronic shunt-dependent hydrocephalus. However, identification of shunt-dependent patients remains challenging. We sought to develop a prognostic model to identify patients with aSAH at risk of chronic shunt-dependent hydrocephalus. In addition to the well-known prognostic variables, blood clearance in the cerebrospinal fluid (CSF) spaces was considered.
   METHODS: We retrospectively analyzed the data from 227 patients treated at our institution from January 2012 to January 2016. The outcome was ventriculoperitoneal shunt placement within 30 days after aSAH. The candidate prognostic variables were patient age, World Federation of Neurological Surgeons grade and Fisher grade, external ventricular drainage, ventricular and intracerebral hemorrhage, and interval to blood clearance in the peripheral/basal CSF spaces. Adjustment for multiple testing was performed. Multivariable logistic regression analysis was used for model development. Bootstrapping was applied for internal validation. The model performance measures included indexes for explained variance (R-2), calibration (graphic plot, Hosmer-Lemeshow test), and discrimination (c-statistic).
   RESULTS: Of the 227 patients, 90 (39.6%) required a ventriculoperitoneal shunt. The constructed prognostic model combined external ventricular drainage placement, the presence of ventricular blood, and the duration of blood clearance in the basal cisterns. The model performance was promising, with an R-2 of 33% (20% after bootstrapping), the calibration plot was adequate, the Hosmer-Lemeshow test result was not significant, and the c-statistic was 0.85 (0.84 as assessed after bootstrapping) indicating a good discriminating prognostic model.
   CONCLUSIONS: Our prognostic model could help identify patients requiring permanent CSF diversion after aSAH, although additional modification and external validation are needed. Interventions aimed at accelerating the clearance of blood in the basal cisterns might have the potential to prevent the development of chronic hydrocephalus after aSAH.
C1 [Mijderwijk, Hendrik-Jan; Zhivotovskaya, Angelika; Bostelmann, Richard; Steiger, Hans-Jakob; Cornelius, Jan F.; Petridis, Athanasios K.] Heinrich Heine Univ, Dept Neurosurg, Dusseldorf, Germany.
   [Fischer, Igor] Heinrich Heine Univ, Dept Neurosurg, Div Informat & Data Sci, Dusseldorf, Germany.
RP Mijderwijk, HJ (reprint author), Heinrich Heine Univ, Dept Neurosurg, Dusseldorf, Germany.
EM Hendrik-Jan.Mijderwijk@med.uni-duesseldorf.de
RI Bostelmann, Richard/AAI-7162-2020
OI Mijderwijk, Hendrik-Jan/0000-0002-9516-8257; Bostelmann,
   Richard/0000-0002-0286-5724
CR Al-Tamimi YZ, 2012, STROKE, V43, P677, DOI 10.1161/STROKEAHA.111.625731
   BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x
   Chan M, 2009, J NEUROSURG, V110, P44, DOI 10.3171/2008.5.17560
   Connolly ES, 2012, STROKE, V43, P1711, DOI 10.1161/STR.0b013e3182587839
   Czorlich P, 2015, ACTA NEUROCHIR, V157, P409, DOI 10.1007/s00701-014-2334-z
   de Oliveira JG, 2007, NEUROSURGERY, V61, P924, DOI 10.1227/01.neu.0000303188.72425.24
   Dehdashti AR, 2004, J NEUROSURG, V101, P402, DOI 10.3171/jns.2004.101.3.0402
   Diesing D, 2018, J NEUROSURG, V128, P1273, DOI 10.3171/2016.12.JNS162400
   Dorai Z, 2003, NEUROSURGERY, V52, P763, DOI 10.1227/01.NEU.0000053222.74852.2D
   Erixon HO, 2014, ACTA NEUROCHIR, V156, P2059, DOI 10.1007/s00701-014-2200-z
   Gruber A, 1999, NEUROSURGERY, V44, P503, DOI 10.1097/00006123-199903000-00039
   Hanggi D, 2009, CENT EUR NEUROSURG, V70, P61, DOI 10.1055/s-0028-1087214
   Hirashima Y, 2003, CEREBROVASC DIS, V16, P205, DOI 10.1159/000071117
   Hoh BL, 2011, WORLD NEUROSURG, V76, P548, DOI 10.1016/j.wneu.2011.05.054
   Jabbarli R, 2016, EUR J NEUROL, V23, P912, DOI 10.1111/ene.12962
   Jovanovi Vladimir, 2005, Srp Arh Celok Lek, V133, P401
   Klimo P, 2004, J NEUROSURG, V100, P215, DOI 10.3171/jns.2004.100.2.0215
   Klopfenstein JD, 2004, J NEUROSURG, V100, P225, DOI 10.3171/jns.2004.100.2.0225
   Komotar RJ, 2009, J NEUROSURG, V111, P147, DOI 10.3171/2009.1.JNS0821
   Kwon OY, 2008, J KOREAN NEUROSURG S, V43, P281, DOI 10.3340/jkns.2008.43.6.281
   Moons KGM, 2009, BRIT MED J, V338, DOI 10.1136/bmj.b606
   O'Kelly CJ, 2009, J NEUROSURG, V111, P1029, DOI 10.3171/2008.9.JNS08881
   Paisan GM, 2018, NEUROSURGERY, V83, P393, DOI 10.1093/neuros/nyx393
   Park YK, 2018, ACTA NEUROCHIR, V160, P1407, DOI 10.1007/s00701-018-3560-6
   Rios JMV, 2018, PATIENT SAF SURG, V12, DOI 10.1186/s13037-018-0160-6
   Roelz R, 2018, OPER NEUROSURG, V14, P231, DOI 10.1093/ons/opx129
   Roelz R, 2017, STROKE, V48, P2704, DOI 10.1161/STROKEAHA.117.018397
   Shirao S, 2011, NEUROSURGERY, V68, P966, DOI 10.1227/NEU.0b013e318208f1ba
   Steyerberg E, 2009, CLIN PREDICTION MODE
   TAPANINAHO A, 1993, ACTA NEUROCHIR, V123, P118, DOI 10.1007/BF01401866
   Vale FL, 1997, J NEUROSURG, V86, P462, DOI 10.3171/jns.1997.86.3.0462
   van Lieshout JH, 2018, J NEUROSURG, V128, P1778, DOI 10.3171/2017.2.JNS162748
   Wessell AP, 2019, J NEUROSURG, V130, P1984, DOI 10.3171/2018.1.JNS172925
   Wilson CD, 2017, J NEUROSURG, V126, P586, DOI 10.3171/2015.11.JNS152094
   Winkler EA, 2018, J NEUROSURG, V129, P1166, DOI 10.3171/2017.5.JNS163271
   Wolf S, 2015, CURR OPIN CRIT CARE, V21, P120, DOI 10.1097/MCC.0000000000000183
   Xie ZY, 2017, WORLD NEUROSURG, V106, P844, DOI 10.1016/j.wneu.2017.06.119
   Zaidi HA, 2015, NEUROSURGERY, V76, P608, DOI 10.1227/NEU.0000000000000677
NR 38
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP E572
EP E579
DI 10.1016/j.wneu.2018.12.156
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800074
PM 30639492
DA 2020-05-12
ER

PT J
AU Monsivais, D
   Morales, M
   Day, A
   Kim, D
   Hoh, B
   Blackburn, S
AF Monsivais, Daniel
   Morales, Miriam
   Day, Arthur
   Kim, Dong
   Hoh, Brian
   Blackburn, Spiros
TI Cost Analysis of Endovascular Coiling and Surgical Clipping for the
   Treatment of Ruptured Intracranial Aneurysms
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cost-effective analysis; Endovascular coil; Intracranial aneurysm;
   Neurosurgical clipping; Quality adjusted life years; Subarachnoid
   hemorrhage
ID UNRUPTURED CEREBRAL ANEURYSMS; LENGTH-OF-STAY; SUBARACHNOID HEMORRHAGE;
   UNITED-STATES
AB BACKGROUND: Cost-effectiveness analyses for the treatment of aneurysmal subarachnoid hemorrhage are necessary to determine health policy, treatment guidelines, and screening protocols for cerebral aneurysms. To perform these modeling studies, detailed cost data are necessary and are currently lacking.
   OBJECTIVE: The goal of this study was to determine detailed inpatient cost of aneurysmal subarachnoid hemorrhage.
   METHODS: A retrospective review of our ruptured subarachnoid hemorrhage database was performed to identify consecutive patients between January 2013 and December 2015. Patients were searched by International Classification of Disease 9 diagnosis and procedure codes. Patient demographics and clinical characteristics were acquired. The cost breakdown was compiled into a comprehensive itemized list encompassing all aspects of hospitalization. A mean cost based on resource used per patient was obtained.
   RESULTS: There were 269 patients treated, 209 were coiled and 60 were clipped. Mean age in the clipping group was 49 years and 55 years in the coil group (P = 0.006). Other patient demographics and clinical characteristics were found to be statistically similar for both groups. Total cost per patient for treatment and hospital stay was $74,192 for clipping and $85,553 for coiling (P = 0.06). Cost amplified with increasing Hunt and Hess grade in both clipping and coiling groups.
   CONCLUSIONS: The detailed cost information reported in this article can be used to help establish appropriate, standardized costs nationally by improving transparency. It can also help provide critical information necessary to develop cost-effective treatment algorithms and screening protocols.
C1 [Monsivais, Daniel; Morales, Miriam; Day, Arthur; Kim, Dong; Blackburn, Spiros] Univ Texas Hlth Sci Ctr Houston, Dept Neurosurg, Houston, TX 77030 USA.
   [Hoh, Brian] Univ Florida, Lillian S Wells Dept Neurosurg, Gainesville, FL USA.
RP Monsivais, D (reprint author), Univ Texas Hlth Sci Ctr Houston, Dept Neurosurg, Houston, TX 77030 USA.
EM Daniel.R.Monsivais@uth.tmc.edu
CR Bairstow Phillip, 2002, Australas Radiol, V46, P249, DOI 10.1046/j.1440-1673.2002.01053.x
   Bekelis K, 2017, J NEUROSURG, V126, P805, DOI 10.3171/2016.2.JNS152994
   Bekelis K, 2016, J NEUROINTERV SURG, V8, P316, DOI 10.1136/neurintsurg-2014-011575
   Brinjikji W, 2012, AM J NEURORADIOL, V33, P1037, DOI 10.3174/ajnr.A2938
   Chang Hyuk Won, 2016, Neurointervention, V11, P86, DOI 10.5469/neuroint.2016.11.2.86
   de Rooij NK, 2007, J NEUROL NEUROSUR PS, V78, P1365, DOI 10.1136/jnnp.2007.117655
   FINKLER SA, 1982, ANN INTERN MED, V96, P102, DOI 10.7326/0003-4819-96-1-102
   Hoh BL, 2010, STROKE, V41, P337, DOI 10.1161/STROKEAHA.109.569269
   Hoh BL, 2009, NEUROSURGERY, V64, P614, DOI 10.1227/01.NEU.0000340784.75352.A4
   Johnston SC, 1999, NEUROLOGY, V52, P1799, DOI 10.1212/WNL.52.9.1799
   Ryttlefors M, 2008, STROKE, V39, P2720, DOI 10.1161/STROKEAHA.107.506030
   Shea AM, 2007, NEUROSURGERY, V61, P1131, DOI 10.1227/01.neu.0000306090.30517.ae
   Siegel J, 1996, J AM MED, V276, P16
   Wiebers D, 2003, LANCET, V362, P103, DOI 10.1016/S0140-6736(03)13860-3
   Wolstenholme J, 2008, STROKE, V39, P111, DOI 10.1161/STROKEAHA.107.482570
   Zygourakis CC, 2015, NEUROSURG CLIN N AM, V26, P189, DOI 10.1016/j.nec.2014.11.008
NR 16
TC 1
Z9 1
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP E125
EP E130
DI 10.1016/j.wneu.2018.12.028
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800016
PM 30579007
DA 2020-05-12
ER

PT J
AU Mou, JM
   Wang, XS
   Huo, G
   Ruan, LL
   Jin, K
   Tan, S
   Wang, FC
   Hua, H
   Yang, G
AF Mou, Jiamin
   Wang, Xiaoshu
   Huo, Gang
   Ruan, Lunliang
   Jin, Kai
   Tan, Song
   Wang, Fuchao
   Hua, Huang
   Yang, Gang
TI Endoscopic Endonasal Surgery for Craniopharyngiomas: A Series of 60
   Patients
SO WORLD NEUROSURGERY
LA English
DT Article
DE Craniopharyngiomas; Endoscopy extended endonasal approach; In situ bone
   flap
ID TRANSSPHENOIDAL APPROACH; PEDIATRIC CRANIOPHARYNGIOMAS;
   SURGICAL-TREATMENT; CRANIAL BASE; RESECTION; EXPERIENCE
AB OBJECTIVE: To report our experience of the management of 60 patients with craniopharyngioma with endoscopic endonasal surgery (EES) and evaluate the feasibility and safety of EES for craniopharyngiomas.
   METHODS: The clinical data of 60 patients with craniopharyngioma who underwent EES between November 2014 and December 2017 were analyzed retrospectively. All patients had vascularized nasoseptal flaps, and the most recent 4 patients had "in situ bone flaps" for better skull base reconstruction. Visual improvements, tumor resection extents, recurrence rates, endocrine functional changes, and surgical complications were evaluated.
   RESULTS: The resection rates were as follows: gross total, 68.3% (41 patients); near total (> 95% of tumor removed), 15% (9 patients); subtotal (>= 80% of tumor removed), 10% (6 patients); and partial (partial resection <80% of tumor removed), 6.7% (4 patients). Fifty-two patients presented with visual impairment; of these, 46 (88.5%) improved or returned to normal after surgery. Regarding the 32 patients with hypopituitarism before surgery, pituitary function was unchanged in 15 (46.8%), improved or normalized in 4 (12.5%), and deteriorated in 13 (40.6%). Eleven patients (18.3%) suffered from diabetes insipidus before treatment, and 27 more patients had this condition after surgery. Twenty-two patients had hyposmia postoperatively, and 17 patients experienced significant weight gain. Four patients had recent memory loss, and 2 of them had a temporary recent mental disorder. Three (5%) patients had cerebro-spinal fluid leakage after surgery. Three patients (5%) contracted meningitis and were cured with antibiotic treatment. One patient showed recurrence by magnetic resonance imaging re-examination, at the mean follow-up time of 22 months (range, 8-45 months; standard deviation, 11 months).
   CONCLUSIONS: EES can provide surgeons with excellent exposure and can achieve a high extent of removal of most craniopharyngiomas, even those with intraventricular extensions, In our view, vascularized pedicled septal flaps and in situ bony flaps were used in skull base reconstruction.
C1 [Mou, Jiamin; Wang, Xiaoshu; Huo, Gang; Ruan, Lunliang; Jin, Kai; Tan, Song; Wang, Fuchao; Hua, Huang; Yang, Gang] Chongqing Med Univ, Affiliated Hosp 1, Dept Neurosurg, Chongqing, Peoples R China.
RP Yang, G (reprint author), Chongqing Med Univ, Affiliated Hosp 1, Dept Neurosurg, Chongqing, Peoples R China.
EM yg_angcq@163.com
CR Bunin GR, 1998, J NEUROSURG, V89, P547, DOI 10.3171/jns.1998.89.4.0547
   Cavallo LM, 2009, J NEUROSURG, V111, P578, DOI 10.3171/2009.2.JNS081026
   Cavallo LM, 2014, J NEUROSURG, V121, P100, DOI 10.3171/2014.3.JNS131521
   Chakrabarti I, 2005, J NEUROSURG, V102, P650, DOI 10.3171/jns.2005.102.4.0650
   De Divitiis E, 2007, NEUROSURGERY, V61, P219, DOI 10.1227/01.neu.0000303220.55393.73
   Dehdashti AR, 2009, NEUROSURGERY, V64, P677, DOI 10.1227/01.NEU.0000339121.20101.85
   Dusick JR, 2005, J NEUROSURG, V102, P832, DOI 10.3171/jns.2005.102.5.0832
   Fahlbusch R, 1999, J NEUROSURG, V90, P237, DOI 10.3171/jns.1999.90.2.0237
   Frank G, 2006, NEUROSURGERY, V59, P75, DOI 10.1227/01.NEU.0000219897.98238.A3
   Gardner PA, 2008, J NEUROSURG, V109, P6, DOI 10.3171/JNS/2008/109/7/0006
   Gardner PA, 2008, J NEUROSURG, V108, P1043, DOI 10.3171/JNS/2008/108/5/1043
   Hadad G, 2006, LARYNGOSCOPE, V116, P1882, DOI 10.1097/01.mlg.0000234933.37779.e4
   Honegger J, 1999, J NEUROSURG, V90, P251, DOI 10.3171/jns.1999.90.2.0251
   Jane JA, 2010, NEUROSURG FOCUS, V28, DOI 10.3171/2010.1.FOCUS09319
   Jane JA, 2010, J NEUROSURG-PEDIATR, V5, P49, DOI 10.3171/2009.7.PEDS09252
   Karavitaki N, 2005, CLIN ENDOCRINOL, V62, P397, DOI 10.1111/j.1365-2265.2005.02231.x
   Karavitaki N, 2006, ENDOCR REV, V27, P371, DOI 10.1210/er.2006-0002
   Kassam AB, 2008, NEUROSURGERY, V63, P44, DOI 10.1227/01.NEU.0000297074.13423.F5
   Kim EH, 2011, J NEUROSURG, V114, P1338, DOI 10.3171/2010.11.JNS10612
   Komotar RJ, 2012, WORLD NEUROSURG, V77, P329, DOI 10.1016/j.wneu.2011.07.011
   Koutourousiou M, 2013, J NEUROSURG, V119, P1194, DOI 10.3171/2013.6.JNS122259
   Laufer I, 2007, J NEUROSURG, V106, P400, DOI 10.3171/jns.2007.106.3.400
   Leng LZ, 2012, NEUROSURGERY, V70, P110, DOI 10.1227/NEU.0b013e31822e8ffc
   Liubinas SV, 2011, J CLIN NEUROSCI, V18, P451, DOI 10.1016/j.jocn.2010.10.004
   Maira G, 2004, J NEUROSURG, V100, P445, DOI 10.3171/jns.2004.100.3.0445
   Menon G, 2009, J CLIN NEUROSCI, V16, P160, DOI 10.1016/j.jocn.2008.04.012
   Merchant TE, 2002, INT J RADIAT ONCOL, V53, P533, DOI 10.1016/S0360-3016(02)02799-2
   Muller HL, 2004, J CLIN ENDOCR METAB, V89, P3298, DOI 10.1210/jc.2003-031751
   Prabhu VC, 2005, CHILD NERV SYST, V21, P622, DOI 10.1007/s00381-005-1190-9
   Puget S, 2007, J NEUROSURG, V106, P3, DOI 10.3171/ped.2007.106.1.3
   Yadav YR, 2012, J NEUROSCI RURAL PRA, V3, P328, DOI 10.4103/0976-3147.102615
   Yadav Yad Ram, 2015, Asian J Neurosurg, V10, P10, DOI 10.4103/1793-5482.151502
   Yamada S, 2010, WORLD NEUROSURG, V74, P320, DOI 10.1016/j.wneu.2010.06.014
   YASARGIL MG, 1990, J NEUROSURG, V73, P3, DOI 10.3171/jns.1990.73.1.0003
NR 34
TC 5
Z9 5
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP E424
EP E430
DI 10.1016/j.wneu.2018.12.110
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800055
PM 30610976
DA 2020-05-12
ER

PT J
AU Nguyen, B
   Blasco, M
   Svider, PF
   Lin, HS
   Liu, JK
   Eloy, JA
   Folbe, AJ
AF Nguyen, Brandon
   Blasco, Michael
   Svider, Peter F.
   Lin, Ho-Sheng
   Liu, James K.
   Eloy, Jean Anderson
   Folbe, Adam J.
TI Recurrence of Ventral Skull Base Lesions Attributed to Tumor Seeding: A
   Systematic Review
SO WORLD NEUROSURGERY
LA English
DT Review
DE Chordoma; Craniopharyngioma; Ectopic recurrence; Iatrogenic; Sinonasal;
   Skull base; Tumor seeding
ID ECTOPIC RECURRENCE; SURGICAL PATHWAY; CLIVAL CHORDOMA;
   CRANIOPHARYNGIOMA; RESECTION; METASTASIS; SURGERY; IMPLANTATION;
   MANAGEMENT; CARCINOMA
AB OBJECTIVE: To evaluate ventral skull base lesion recurrences along surgical access pathways attributed to iatrogenic seeding.
   METHODS: A systematic review of the literature was performed searching for recurrence of ventral skull base lesions attributed to iatrogenic implantation. Studies were assessed for level of evidence. Primary intervention, pathology, and other clinical factors were reported following Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines.
   RESULTS: Among 69 patients with recurrent skull base lesions attributed to seeding, the most common pathologies were craniopharyngioma (52.2%), chordoma (33.3%), adenocarcinoma (4.3%), adenoid cystic carcinoma (2.9%), and squamous cell carcinoma (2.9%). Median time to recurrence was 36 months. Time to recurrence was significantly longer for craniopharyngiomas than for chordomas (42 months vs. 24 months, P <= 0.05). Surgical approaches included craniotomy (62.0%), transseptal (11.3%), transfacial (12.7%), and transpalatal (4.2%). Mean time to recurrence after craniotomy was 69 months. Endoscopic/endoscopic-assisted approaches were used in 5 cases (7.0%). Commonly reported recurrence sites included subarachnoid (29.6%), dura (21.1%), incision (12.7%), septum (7.0%), and ethmoid sinuses (4.2%).
   CONCLUSIONS: The potential for iatrogenic tumor seeding exists for numerous skull base lesions, most notably craniopharyngioma and chordomas. Routine surveillance may be necessary owing to significant latency intervals to ectopic recurrence. Although transnasal endoscopic techniques have been extensively employed in recent decades, only a handful of reported cases involve lesions originally treated with this approach. Further direct comparison of traditional approaches with endoscopic approaches may be invaluable in further elucidating the role of surgical technique in tumor implantation and recurrence.
C1 [Nguyen, Brandon; Folbe, Adam J.] William Beaumont Hosp, Dept Otolaryngol, Royal Oak, MI 48072 USA.
   [Nguyen, Brandon; Blasco, Michael; Lin, Ho-Sheng] Wayne State Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, Detroit, MI 48202 USA.
   [Lin, Ho-Sheng] John D Dingell VA Med Ctr, Detroit, MI USA.
   [Lin, Ho-Sheng; Folbe, Adam J.] Barbara Ann Karmanos Canc Inst, Detroit, MI USA.
   [Svider, Peter F.; Liu, James K.; Eloy, Jean Anderson] Rutgers New Jersey Med Sch, Dept Otolaryngol Head & Neck Surg, Newark, NJ USA.
   [Liu, James K.; Eloy, Jean Anderson] Rutgers New Jersey Med Sch, Ctr Skull Base & Pituitary Surg, Newark, NJ USA.
   [Eloy, Jean Anderson] Rutgers New Jersey Med Sch, Neurol Inst New Jersey, Newark, NJ USA.
   [Liu, James K.; Eloy, Jean Anderson] Rutgers New Jersey Med Sch, Dept Neurol Surg, Newark, NJ USA.
   [Eloy, Jean Anderson] Rutgers New Jersey Med Sch, Dept Ophthalmol & Visual Sci, Newark, NJ USA.
RP Nguyen, B (reprint author), William Beaumont Hosp, Dept Otolaryngol, Royal Oak, MI 48072 USA.; Nguyen, B (reprint author), Wayne State Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, Detroit, MI 48202 USA.
EM bknguyen@oakland.edu
CR Al Mahdi MM, 2018, TURK NEUROSURG, V28, P313, DOI 10.5137/1019-5149.JTN.17215-16.1
   Arnautovic K I, 2001, Neurosurg Focus, V10, pE7
   Asano S, 2003, ACTA NEUROCHIR, V145, P599, DOI 10.1007/s00701-003-0057-7
   BARLOON TJ, 1988, AM J NEURORADIOL, V9, P406
   Bianco AD, 2006, SURG NEUROL, V66, P437, DOI 10.1016/j.surneu.2005.12.027
   Bikmaz K, 2009, NEUROSURGERY, V64, P382, DOI [10.1227/01.NEU.0000337128.67045.70, 10.1227/01.NEU.0000337078.60998.98]
   Boyette JR, 2008, ENT-EAR NOSE THROAT, V87, P106, DOI 10.1177/014556130808700214
   Cabral DTF, 2018, J NEUROSURG, V129, P947, DOI 10.3171/2017.6.JNS17111
   Chibbaro S, 2014, NEUROSURG REV, V37, P217, DOI 10.1007/s10143-013-0503-9
   Clark SW, 2015, NAGOYA J MED SCI, V77, P297
   Du C, 2016, CHILD NERV SYST, V32, P1523, DOI 10.1007/s00381-016-3050-1
   Elfving M, 2011, CHILD NERV SYST, V27, P845, DOI 10.1007/s00381-010-1375-8
   Elliott RE, 2009, J NEUROSURG-PEDIATR, V4, P105, DOI 10.3171/2009.3.PEDS0948
   Elmaci L, 2002, NEURO-ONCOLOGY, V4, P123, DOI 10.1093/neuonc/4.2.123
   Erdem AF, 2016, J CLIN MONIT COMPUT, V30, P655, DOI 10.1007/s10877-015-9768-6
   Fischbein NJ, 2000, AM J NEURORADIOL, V21, P578
   Freitag SK, 2001, BRIT J NEUROSURG, V15, P511, DOI 10.1080/02688690120097723
   Golbin D, 2015, CUREUS, V7, DOI 10.7759/cureus.437
   Goncalves CB, 2014, PITUITARY, V17, P214, DOI 10.1007/s11102-013-0490-4
   Hines JP, 2014, AM J OTOLARYNG, V35, P431, DOI 10.1016/j.amjoto.2013.12.018
   Ichikawa M, 2010, NEUROL MED-CHIR, V50, P70, DOI 10.2176/nmc.50.70
   Iloreta AMC, 2014, J NEUROL SURG REP, V75, pE246, DOI 10.1055/s-0034-1387184
   ISRAEL ZH, 1995, PEDIATR NEUROSURG, V22, P210, DOI 10.1159/000120903
   Ito M, 2001, NEUROSURGERY, V48, P933
   Jakobs M, 2012, J NEUROSURG, V117, P490, DOI 10.3171/2012.6.JNS111885
   Jeong IH, 2006, J NEURO-ONCOL, V79, P191, DOI 10.1007/s11060-006-9124-2
   Jian XD, 2017, TURK NEUROSURG, V27, P160, DOI 10.5137/1019-5149.JTN.12386-14.2
   Joshi SC, 2003, INT J GYNECOL CANCER, V13, P901, DOI 10.1111/j.1525-1438.2003.13376.x
   KAMPHORST W, 1992, J NEUROL NEUROSUR PS, V55, P73, DOI 10.1136/jnnp.55.1.73
   Karavitaki N, 2006, ENDOCR REV, V27, P371, DOI 10.1210/er.2006-0002
   Kawaguchi T, 2005, J CLIN NEUROSCI, V12, P307, DOI 10.1016/j.jocn.2004.01.009
   Keerthi R, 2016, J MAXILLOFAC ORAL SU, V15, pS343, DOI 10.1007/s12663-015-0876-0
   Kordes U, 2011, KLIN PADIATR, V223, P176, DOI 10.1055/s-0031-1273743
   Krengli M, 2016, REP PRACT ONCOL RADI, V21, P407, DOI 10.1016/j.rpor.2016.02.005
   Krueger EM, 2017, CUREUS, V9, DOI 10.7759/cureus.1211
   Lee DK, 2001, J NEUROSURG, V94, P617, DOI 10.3171/jns.2001.94.4.0617
   Lee JH, 1999, J NEUROSURG, V90, P796, DOI 10.3171/jns.1999.90.4.0796
   Liu JM, 2002, NEUROSURGERY, V50, P639, DOI 10.1097/00006123-200203000-00041
   MALIK JM, 1992, J NEUROSURG, V77, P804, DOI 10.3171/jns.1992.77.5.0804
   McMaster ML, 2001, CANCER CAUSE CONTROL, V12, P1, DOI 10.1023/A:1008947301735
   Miller TC, 2006, LARYNGOSCOPE, V116, P661, DOI 10.1097/01.mlg.0000201987.41904.6c
   Moore MG, 2011, SKULL BASE-INTERD AP, V21, P87, DOI 10.1055/s-0030-1266762
   Nielsen EH, 2011, J NEURO-ONCOL, V104, P755, DOI 10.1007/s11060-011-0540-6
   Nomura H, 2002, NEUROL MED-CHIR, V42, P268, DOI 10.2176/nmc.42.268
   Novegno F, 2002, CHILD NERV SYST, V18, P468, DOI 10.1007/s00381-002-0641-9
   RAGOOWANSI AT, 1991, J NEUROSURG, V74, P653, DOI 10.3171/jns.1991.74.4.0653
   Rangel-Castilla L, 2016, REP PRACT ONCOL RADI, V21, P325, DOI 10.1016/j.rpor.2014.09.002
   Reddy Gaddum D, 2016, Surg Neurol Int, V7, pS174, DOI 10.4103/2152-7806.178570
   Reilly WT, 1996, DIS COLON RECTUM, V39, P200
   Romani R, 2010, ACTA NEUROCHIR, V152, P297, DOI 10.1007/s00701-009-0415-1
   Sakashita T, 2009, SKULL BASE-INTERD AP, V19, P127, DOI 10.1055/s-0028-1096201
   Salunke P, 2011, NEUROL INDIA, V59, P137, DOI 10.4103/0028-3886.76881
   Sanusi O, 2018, WORLD NEUROSURG, V115, pE13, DOI 10.1016/j.wneu.2018.02.127
   Schmalisch K, 2010, ACTA NEUROCHIR, V152, P313, DOI 10.1007/s00701-009-0538-4
   Shyamala K, 2014, J INT SOC PREV COMMU, V4, P5, DOI 10.4103/2231-0762.129446
   Stacchiotti S, 2015, LANCET ONCOL, V16, pE71, DOI 10.1016/S1470-2045(14)71190-8
   TONNER D, 1992, J ENDOCRINOL INVEST, V15, P387, DOI 10.1007/BF03348759
   Tsuboi Y, 2007, NEUROL MED-CHIR, V47, P479, DOI 10.2176/nmc.47.479
   van Lierop AC, 2008, AURIS NASUS LARYNX, V35, P447, DOI 10.1016/j.anl.2007.09.006
   Vaquero J, 2003, J NEURO-ONCOL, V64, P255, DOI 10.1023/A:1025672617249
   Vogin G, 2016, HEAD NECK-J SCI SPEC, V38, pE1238, DOI 10.1002/hed.24199
   Wang XY, 2010, J INT MED RES, V38, P1876, DOI 10.1177/147323001003800536
   Yang Y, 2015, BRIT J NEUROSURG, V29, P295, DOI 10.3109/02688697.2014.967751
   Zemmoura I, 2012, BRIT J NEUROSURG, V26, P102, DOI 10.3109/02688697.2011.595844
   Zener R, 2011, J SURG CASE REP
   Zoicas Flavius, 2012, Front Endocrinol (Lausanne), V3, P46, DOI 10.3389/fendo.2012.00046
NR 66
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP E395
EP E403
DI 10.1016/j.wneu.2018.12.104
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800051
PM 30605757
DA 2020-05-12
ER

PT J
AU Omran, K
   Ibrahim, AH
AF Omran, Khaled
   Ibrahim, Al Hassan
TI Outcome of Transforminal Lumbar Thorough Debridement, Decompression, and
   Spondylodesis Technique in Treatment of 25 Patients with Pyogenic
   Spondylodiscitis
SO WORLD NEUROSURGERY
LA English
DT Article
DE Lumbar pyogenic spondylodiscitis; Spinal infection; Transforminal lumbar
   thorough debridement, decompression, and spondylodesis
ID CREST BONE-GRAFT; INTERBODY FUSION; POSTERIOR INSTRUMENTATION; SPINAL
   INFECTION; SURGICAL-MANAGEMENT; TUBERCULOSIS; SURGERY; CLASSIFICATION;
   SAFETY
AB BACKGROUND: Lumbar pyogenic spondylodiscitis (LPS) is still a tangled problem in its management, especially with increasing rates of cases who underwent different spinal procedures and in patients with chronic medical disease. One-stage posterior direct transforminal lumbar thorough debridement of septic lesion, decompression, and spondylodesis (TLTDDS) are the main goals in treatment of complicated LPS without additional morbidity of anterior surgery. This is a retrospective assessment of the clinical, laboratory, functional, and radiologic outcomes in 25 patients with LPS who underwent the TLTDDS procedure.
   METHODS: Twenty-nine patients with complicated LPS were treated surgically by TLTDDS surgery from January 2014 to August 2017. Complete records of 25 patients were available for evaluation. All patients were examined clinically for back or leg pain using a visual analog scale (VAS) and neurological assessment by the American Spine Injury Association. Perioperative outcome and complications were documented. All patients were serially followed up between 12 and 32 months as regard pain (VAS), functional status by Kirkaldy Willis criteria, and Oswestry disability index, laboratory, and radiologic outcomes (angle of segmental kyphosis, lumbar lordosis correction, and fusion criteria).
   RESULTS: Definitive solid bony fusion was seen between 6 and 14 months, except in 3 cases, which showed probable fusion. There was significant improvement in VAS, American Spine Injury Association index, laboratory investigations, and Oswestry disability index. One patient (5%) had transient neurological deficit, which resolved completely within 2 months.
   CONCLUSIONS: TLTDDS surgery is an effective procedure in the treatment of symptomatic LPS and allows abscess evacuation with adequate neural decompression, segmental kyphosis correction, and functional improvement.
C1 [Omran, Khaled; Ibrahim, Al Hassan] Menia Univ, Spine Unit, Dept Orthoped Surg & Traumatol, Minia Univ Hosp, El Minia, Egypt.
RP Omran, K (reprint author), Menia Univ, Spine Unit, Dept Orthoped Surg & Traumatol, Minia Univ Hosp, El Minia, Egypt.
EM drkhaledthabet80@yahoo.com
OI omran, khaled/0000-0002-5024-8165
CR Adam D, 2014, CHIRURGIA-BUCHAREST, V109, P90
   Akbar M, 2012, ORTHOPADE, V41, P749, DOI 10.1007/s00132-012-1998-4
   An KC, 2012, ASIAN SPINE J, V6, P15, DOI 10.4184/asj.2012.6.1.15
   Blizzard DJ, 2015, J CLIN NEUROSCI, V22, P1758, DOI 10.1016/j.jocn.2015.05.021
   Butler JS, 2006, SPINE, V31, P2695, DOI 10.1097/01.brs.0000244662.78725.37
   Endres S, 2012, J ORTHOP SURG-HONG K, V20, P1
   Fantoni M, 2012, EUR REV MED PHARMACO, V16, P2
   Frangen TM, 2006, UNFALLCHIRURG, V109, P743, DOI 10.1007/s00113-006-1084-7
   Ha KY, 2007, SPINE, V32, P1856, DOI 10.1097/BRS.0b013e318108b804
   Ito M, 2007, SPINE, V32, P200, DOI 10.1097/01.brs.0000251645.58076.96
   Iwata A, 2014, J NEUROL SURG PART A, V75, P170, DOI 10.1055/s-0032-1329268
   Jensen AG, 1997, J INFECTION, V34, P113, DOI 10.1016/S0163-4453(97)92395-1
   Kapsalaki E, 2009, INT J INFECT DIS, V13, P564, DOI 10.1016/j.ijid.2008.08.025
   Kim CJ, 2010, SPINE, V35, pE1096, DOI 10.1097/BRS.0b013e3181e04dd3
   KIRKALDYWILLIS WH, 1974, CLIN ORTHOP RELAT R, P30
   KONSTAM PG, 1962, BRIT J SURG, V50, P26, DOI 10.1002/bjs.18005021908
   Krishnan A, 2018, J ORTHOP ALLIED SCI, V6, P16
   Kuklo TR, 2006, J SPINAL DISORD TECH, V19, P376, DOI 10.1097/01.bsd.0000203945.03922.f6
   Lee JS, 2006, J BONE JOINT SURG BR, V88B, P765, DOI 10.1302/0301-620X.88B6
   Lu ML, 2015, EUR SPINE J, V24, P555, DOI 10.1007/s00586-014-3585-3
   Mehta JS, 2001, J BONE JOINT SURG BR, V83B, P859, DOI 10.1302/0301-620X.83B6.11142
   Moon MS, 2012, J ORTHOP SURG-HONG K, V20, P11, DOI 10.1177/230949901202000103
   Omran K, 2017, CLIN SPINE SURG, V30, pE1211, DOI 10.1097/BSD.0000000000000485
   Pang XY, 2013, ARCH ORTHOP TRAUM SU, V133, P765, DOI 10.1007/s00402-013-1722-9
   Pee YH, 2008, J NEUROSURG-SPINE, V8, P405, DOI 10.3171/SPI/2008/8/5/405
   Sasso RC, 2005, J SPINAL DISORD TECH, V18, pS77, DOI 10.1097/01.bsd.0000112045.36255.83
   Shetty AP, 2016, INT ORTHOP, V40, P1163, DOI 10.1007/s00264-015-3063-5
   Tschoke SK, 2015, PATIENT SAF SURG, V9, DOI 10.1186/s13037-015-0083-4
   Viezens L, 2017, WORLD NEUROSURG, V102, P18, DOI 10.1016/j.wneu.2017.02.129
   Zarghooni K, 2012, INT ORTHOP, V36, P405, DOI 10.1007/s00264-011-1425-1
   Zeng H, 2014, EUR J TRAUMA EMERG S, V40, P607, DOI 10.1007/s00068-013-0367-2
NR 31
TC 0
Z9 0
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP E197
EP E207
DI 10.1016/j.wneu.2018.12.068
PG 11
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800026
PM 30610978
DA 2020-05-12
ER

PT J
AU Orrego-Gonzalez, E
   Enriquez-Marulanda, A
   Ravindran, K
   Celin-Varcalcel, D
   Parrado-Sanchez, L
   Lobato-Polo, J
AF Orrego-Gonzalez, Eduardo
   Enriquez-Marulanda, Alejandro
   Ravindran, Krishnan
   Celin-Varcalcel, Daniel
   Parrado-Sanchez, Laura
   Lobato-Polo, Javier
TI Factors Associated with Ventriculoperitoneal Shunt Failures in the First
   30 Postoperative Days in Pediatric Patients
SO WORLD NEUROSURGERY
LA English
DT Article
DE External ventricular drain; Hydrocephalus; Intraventricular hemorrhage
   of the premature; Pediatrics; Shunt infection; VP shunt failure
ID CEREBROSPINAL-FLUID; RISK-FACTORS; HYDROCEPHALUS; SURVIVAL; OUTCOMES;
   SECONDARY; SURGERY; DESIGN
AB OBJECTIVE: Placing of a ventriculoperitoneal shunt (VPS) is one of the most common procedures performed by neurosurgeons. Surgical revision of VPS is a significant cause of patient morbidity and mortality. This study was aimed to provide an analysis of factors related to VPS failures in the first 30 postoperative days in a pediatric cohort.
   METHODS: This was a retrospective cohort study of 83 pediatric patients (<18 years old), shunted for the first time at a referral care center, between January 2012 and December 2016. Univariate analysis was used to detect potential predictors of VPS failures within the first 30 postoperative days and in the first 6 months of follow-up. Kaplan-Meier survival curves were used to examine the occurrence of VPS failures over time.
   RESULTS: During the first 30 postoperative days, VPS failures occurred in 21 patients (25.3%). Intraventricular hemorrhage (IVH) (odds ratio [OR], 4.41; 95% confidence interval [CI], 1.44-13.48), cerebrospinal fluid (CSF) alterations (OR, 5.11; 95% CI, 1.37-19.1), and previous external ventricular drain (EVD) (OR, 7.05; 95% CI, 1.18-41.8) were significantly associated with shunt failure during the first postoperative month. Kaplan-Meier survival analysis showed decreased shunt survival for patients with IVH, both during the first 30 days after surgery (P = 0.005, log-rank), and during the 6 months after surgery (P = 0.005, log-rank).
   CONCLUSIONS: In this study, we found that in pediatric patients, IVH was associated with VPS failure within the first 30 postoperative days and decreased shunt survival over time. Further larger prospective randomized studies are needed to better understand these results.
C1 [Orrego-Gonzalez, Eduardo; Enriquez-Marulanda, Alejandro; Celin-Varcalcel, Daniel; Parrado-Sanchez, Laura; Lobato-Polo, Javier] Fdn Valle Lili, Cali, Colombia.
   [Orrego-Gonzalez, Eduardo; Parrado-Sanchez, Laura; Lobato-Polo, Javier] Univ ICESI, Cali, Colombia.
   [Enriquez-Marulanda, Alejandro; Celin-Varcalcel, Daniel; Lobato-Polo, Javier] Ctr Invest Clin, Cali, Colombia.
   [Enriquez-Marulanda, Alejandro; Ravindran, Krishnan] Harvard Med Sch, Neurosurg Serv, Beth Israel Deaconess Med Ctr, Boston, MA 02115 USA.
RP Lobato-Polo, J (reprint author), Fdn Valle Lili, Cali, Colombia.; Lobato-Polo, J (reprint author), Univ ICESI, Cali, Colombia.; Lobato-Polo, J (reprint author), Ctr Invest Clin, Cali, Colombia.
EM jmlobatop@yahoo.com
OI Lobato-Polo, Javier/0000-0002-0588-5093; Enriquez-Marulanda,
   Alejandro/0000-0001-6091-390X; Orrego Gonzalez, Eduardo
   Esteban/0000-0002-8406-4153
CR Agarwal A, 2016, SEMIN ULTRASOUND CT, V37, P100, DOI 10.1053/j.sult.2016.02.007
   Al-Tamimi YZ, 2014, NEUROSURGERY, V74, P29, DOI 10.1227/NEU.0000000000000196
   ALBRIGHT AL, 1988, J NEUROSURG, V69, P883, DOI 10.3171/jns.1988.69.6.0883
   Anderson IA, 2019, J NEUROSURG, V130, P145, DOI 10.3171/2017.8.JNS17399
   BIERBRAUER KS, 1991, PEDIATR NEUROSURG, V16, P287, DOI 10.1159/000120544
   Buster BE, 2016, J CLIN NEUROSCI, V24, P94, DOI 10.1016/j.jocn.2015.08.024
   Chittiboina P, 2013, J NEUROSURG-PEDIATR, V11, P37, DOI 10.3171/2012.8.PEDS11296
   Del Bigio MR, 1998, NEUROSURGERY, V42, P319, DOI 10.1097/00006123-199802000-00064
   Drake JM, 1998, NEUROSURGERY, V43, P294, DOI 10.1097/00006123-199808000-00068
   Drake JM, 1998, NEUROSURGERY, V43, P303, DOI DOI 10.1097/00006123-199808000-00068
   FERNELL E, 1985, Z KINDERCHIR, V40, P12
   Fulkerson DH, 2011, J NEUROSURG-PEDIATR, V7, P147, DOI 10.3171/2010.11.PEDS10244
   Godek ML, 2006, PLASMA PROCESS POLYM, V3, P485, DOI 10.1002/ppap.200600007
   Hamidu AU, 2015, J NEUROSCI RURAL PRA, V6, P55, DOI 10.4103/0976-3147.143195
   HASE U, 1981, Z KINDERCHIR, V34, P135
   Hayhurst C, 2010, J NEUROSURG, V113, P1273, DOI 10.3171/2010.3.JNS091237
   Heep A, 2002, ARCH DIS CHILD-FETAL, V87, pF34, DOI 10.1136/fn.87.1.F34
   Iglesias S, 2017, NEUROCIRUGIA, V28, P159, DOI 10.1016/j.neucir.2016.12.004
   Kestle J, 2000, PEDIATR NEUROSURG, V33, P230, DOI 10.1159/000055960
   Kestle JRW, 2003, J NEUROSURG, V98, P284, DOI 10.3171/jns.2003.98.2.0284
   Kulkarni AV, 2013, J NEUROSURG-PEDIATR, V12, P334, DOI 10.3171/2013.7.PEDS12637
   Notarianni C, 2009, J NEUROSURG-PEDIATR, V4, P547, DOI 10.3171/2009.7.PEDS08371
   Park MK, 2015, J KOREAN NEUROSURG S, V57, P359, DOI 10.3340/jkns.2015.57.5.359
   Paulsen AH, 2015, J NEUROSURG-PEDIATR, V16, P633, DOI 10.3171/2015.5.PEDS14532
   Piatt JH, 2014, J NEUROSURG-PEDIATR, V14, P179, DOI 10.3171/2014.5.PEDS1421
   Prajapati BS, 2015, PEDIAT INFECT DIS, V7, P22
   Rashid QTA, 2012, CHILD NERV SYST, V28, P221, DOI 10.1007/s00381-011-1527-5
   Riva-Cambrin J, 2016, J NEUROSURG-PEDIATR, V17, P382, DOI 10.3171/2015.6.PEDS14670
   Shannon CN, 2012, CHILD NERV SYST, V28, P2093, DOI 10.1007/s00381-012-1830-9
   Shannon CN, 2011, J NEUROSURG-PEDIATR, V8, P593, DOI 10.3171/2011.9.PEDS11192
   Simon TD, 2012, J NEUROSURG-PEDIATR, V9, P54, DOI 10.3171/2011.10.PEDS11307
   Simon TD, 2009, J NEUROS-PEDIATR, V4, P156, DOI 10.3171/2009.3.PEDS08215
   Stein SC, 2008, J NEUROSURG-PEDIATR, V1, P40, DOI 10.3171/PED-08/01/040
   Tuli S, 2000, J NEUROSURG, V92, P31, DOI 10.3171/jns.2000.92.1.0031
   Wagshul ME, 2006, J NEUROSURG, V104, P810, DOI 10.3171/jns.2006.104.5.810
   Whitehead WE, 2017, J NEUROSURG-PEDIATR, V19, P157, DOI 10.3171/2016.8.PEDS16229
NR 36
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP E517
EP E526
DI 10.1016/j.wneu.2018.12.125
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800067
PM 30611949
DA 2020-05-12
ER

PT J
AU Ozsoy-Unubol, T
   Ercalik, T
   Gunduz, OH
AF Ozsoy-Unubol, Tugba
   Ercalik, Tulay
   Gunduz, Osman Hakan
TI Comparison of Epidural Steroid Injection Efficiency with Two Different
   Doses in Radiculopathies Associated with Lumbar Disc Herniation
SO WORLD NEUROSURGERY
LA English
DT Article
DE Epidural; Injection; Methylprednisolone; Radiculopathy; Transforaminal
ID CHRONIC LOW-BACK; RADICULAR PAIN; NONPARTICULATE CORTICOSTEROIDS;
   DOUBLE-BLIND; EFFICACY; METHYLPREDNISOLONE; DEXAMETHASONE; INTERLAMINAR;
   PARTICULATE
AB OBJECTIVE: Transforaminal epidural steroid injections (TFESIs) have been increasingly used in the treatment of lumbar radicular pain resistant to conservative modalities. Although different steroids can be used at different doses, the minimally effective steroid dose should be used to reduce side effects. The present retrospective study examined and compared the efficacy of 40 mg and 80 mg of methylprednisolone in TFESIs.
   METHODS: We included 67 patients who had undergone unilateral L5-S1 TFESIs under fluoroscopic guidance in the present study. Assessments were conducted at baseline and at 1 hour, 3 weeks, and 3 months after the TFESIs. The Short-Form 36-item Health Survey, Numeric Rating Scale, Oswestry Disability Index, and Istanbul Low Back Pain Disability Index were used as outcome measures.
   RESULTS: The present study evaluated 33 patients who had undergone TFESIs with 40 mg of methylprednisolone and 34 patients who had undergone TFESIs with 80 mg of methylprednisolone. Although no statistically significant differences were found between the 2 groups' outcome measures, both groups showed significant improvements in pain, disability, and quality of life at 3 weeks and 3 months after treatment.
   CONCLUSIONS: TFESIs with 40 mg and 80 mg are effective for the treatment of pain that results from lumbar disc herniation. They also positively affect patients' disability and quality of life. However, neither steroid dose was more efficient than the other dose. Therefore, we believe the smaller dose should be preferred to reduce the potential side effects of steroids.
C1 [Ozsoy-Unubol, Tugba; Ercalik, Tulay; Gunduz, Osman Hakan] Marmara Univ, Sch Med, Dept Phys Med & Rehabil, Istanbul, Turkey.
   [Ercalik, Tulay; Gunduz, Osman Hakan] Marmara Univ, Sch Med, Dept Phys Med & Rehabil, Sect Pain Med, Istanbul, Turkey.
RP Ozsoy-Unubol, T (reprint author), Marmara Univ, Sch Med, Dept Phys Med & Rehabil, Istanbul, Turkey.
EM tugbaozsoyy@gmail.com
RI GUNDUZ, Osman H/L-1464-2015
OI GUNDUZ, Osman H/0000-0002-3214-803X
CR Ahadian FM, 2011, REGION ANESTH PAIN M, V36, P572, DOI 10.1097/AAP.0b013e318232e843
   Chou R, 2015, ANN INTERN MED, V163, P373, DOI 10.7326/M15-0934
   Duruoz MT, 2013, J BACK MUSCULOSKELET, V26, P45, DOI 10.3233/BMR-2012-00349
   Fairbank JCT, 2000, SPINE, V25, P2940, DOI 10.1097/00007632-200011150-00017
   Friedly JL, 2018, PAIN, V159, P876, DOI 10.1097/j.pain.0000000000001158
   Friedly JL, 2014, NEW ENGL J MED, V371, P11, DOI 10.1056/NEJMoa1313265
   Ghahreman A, 2010, PAIN MED, V11, P1149, DOI 10.1111/j.1526-4637.2010.00908.x
   Gharibo CG, 2011, PAIN PHYSICIAN, V14, P499
   Habib G, 2013, J CLIN ANESTH, V25, P629, DOI 10.1016/j.jclinane.2013.07.002
   Hawker GA, 2011, ARTHRIT CARE RES, V63, pS240, DOI 10.1002/acr.20543
   Iannuccilli JD, 2013, SEMIN INTERVENT RAD, V30, P307, DOI 10.1055/s-0033-1353484
   Joswig H, 2017, WORLD NEUROSURG, V107, P764, DOI 10.1016/j.wneu.2017.08.055
   Kang SS, 2011, PAIN PHYSICIAN, V14, P361
   Kennedy DJ, 2018, SPINE J, V18, P29, DOI 10.1016/j.spinee.2017.08.264
   Kennedy DJ, 2014, PAIN MED, V15, P548, DOI 10.1111/pme.12325
   Kim WH, 2013, PAIN PHYSICIAN, V16, P557
   Lee JH, 2018, PAIN PHYSICIAN, V21, P449
   McCahon RA, 2011, ANAESTHESIA, V66, P595, DOI 10.1111/j.1365-2044.2011.06764.x
   McCormick Z, 2015, AM J PHYS MED REHAB, V94, P1058, DOI 10.1097/PHM.0000000000000296
   Mehta P, 2017, PM&R, V9, P502, DOI 10.1016/j.pmrj.2016.11.008
   Okmen K, 2017, SPINE J, V17, P168, DOI 10.1016/j.spinee.2016.08.024
   Owlia M. B., 2007, SMJ Singapore Medical Journal, V48, P241
   Palmer WE, 2016, RADIOLOGY, V281, P669, DOI 10.1148/radiol.2016152055
   Shakir A, 2013, AM J PHYS MED REHAB, V92, P768, DOI 10.1097/PHM.0b013e318282c9f2
   Shim E, 2017, RADIOGRAPHICS, V37, P537, DOI 10.1148/rg.2017160043
   Taskaynatan MA, 2015, J BACK MUSCULOSKELET, V28, P447, DOI 10.3233/BMR-140539
   WARE JE, 1993, SF 36 HLTH SURVEY MA
   Wong WL, 2015, PAIN PHYSICIAN, V18, pE355
   Zhai JS, 2017, AM J THER, V24, pE259, DOI 10.1097/MJT.0000000000000265
NR 29
TC 0
Z9 0
U1 3
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP E163
EP E168
DI 10.1016/j.wneu.2018.12.056
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800021
PM 30590213
DA 2020-05-12
ER

PT J
AU Pandey, SK
   Mani, SE
   Sudhakar, SV
   Panwar, J
   Joseph, BV
   Rajshekhar, V
AF Pandey, Sanjeev Kumar
   Mani, Sunithi Elizabeth
   Sudhakar, Sniya Valsa
   Panwar, Jyoti
   Joseph, Baylis Vivek
   Rajshekhar, Vedantam
TI Reliability of Imaging-Based Diagnosis of Lateral Ventricular Masses in
   Children
SO WORLD NEUROSURGERY
LA English
DT Article
DE Brain tumor; Children; Diagnosis; Lateral ventricle; Radiology
ID COMPUTED-TOMOGRAPHY; TUMORS; MENINGIOMAS; NEOPLASMS; FEATURES; CT
AB OBJECTIVE: We studied the accuracy of the radiologic diagnosis of lateral ventricular masses in children (<20 years of age).
   METHODS: In this retrospective study, data were collected from children with lateral ventricular masses managed in our unit between 2001 and 2016. There were 43 patients (26 boys and 17 girls; mean age, 12.1 years; range, 8 months to 20 years). Magnetic resonance imaging was available for 36 patients, whereas in 7 patients only a contrast-enhanced computed tomography scan was available. The images were read independently by 3 radiologists, who were blinded to the pathology. Two differential diagnoses were offered for each patient. The agreement between the 3 radiologists was calculated using the Fleiss kappa statistic.
   RESULTS: The common pathologic diagnoses were subependymal giant cell astrocytoma (SEGA) (20.9%), low-grade astrocytoma (16.3%), high-grade astrocytoma (9.3%), choroid plexus papilloma (9.3%), and meningioma (9.3%). The sensitivity, specificity, and accuracy of the radiologic diagnoses were 62%, 96.7%, and 94.2%, respectively. Low-grade tumors such as low-grade gliomas, SEGAs, choroid plexus papillomas, and meningiomas were diagnosed with a high level of accuracy. High-grade gliomas, choroid plexus carcinomas, and other malignant neoplasms were difficult to diagnose on imaging. Cavernous angiomas were also difficult to diagnose. There was only fair agreement between the 3 radiologists (Fleiss kappa = 0.24).
   CONCLUSIONS: The pathologic spectrum of lateral ventricular tumors in children is wide, and identifying the pathology on imaging is difficult for malignant tumors. Benign tumors such as SEGAs, low-grade astrocytomas, and choroid plexus papillomas are relatively easier to diagnose. There is significant interobserver variability in the radiologic diagnosis of these tumors.
C1 [Pandey, Sanjeev Kumar; Joseph, Baylis Vivek; Rajshekhar, Vedantam] Christian Med Coll & Hosp, Dept Neurol Sci, Vellore, Tamil Nadu, India.
   [Mani, Sunithi Elizabeth; Sudhakar, Sniya Valsa; Panwar, Jyoti] Christian Med Coll & Hosp, Dept Radiodiag, Vellore, Tamil Nadu, India.
RP Rajshekhar, V (reprint author), Christian Med Coll & Hosp, Dept Neurol Sci, Vellore, Tamil Nadu, India.
EM rajshekhar@cmcvallore.ac.in
CR Aguzzi A, 2000, PATHOLOGY GENETICS T, P84
   Apuzzo MLJ, 1998, SURG 3 VENTRICLE, P421
   DEEN HG, 1982, J NEUROSURG, V56, P317, DOI 10.3171/jns.1982.56.3.0317
   FERRANTE L, 1989, CHILD NERV SYST, V5, P83, DOI 10.1007/BF00571115
   Fisher PG, 2008, PEDIATR BLOOD CANCER, V51, P245, DOI 10.1002/pbc.21563
   Han S, 2015, J NEURO-ONCOL, V124, P45, DOI 10.1007/s11060-015-1818-x
   HOPE JKA, 1992, AM J NEURORADIOL, V13, P1353
   JELINEK J, 1990, AM J NEURORADIOL, V11, P567
   Koeller KK, 2002, RADIOGRAPHICS, V22, P1473, DOI 10.1148/rg.226025118
   KOOS WT, 1971, INTRACRANIAL TUMORS
   Kumar GSS, 2006, SURG NEUROL, V65, P367, DOI 10.1016/j.surneu.2005.09.015
   LEMAY M, 1979, NEURORADIOLOGY, V17, P191, DOI 10.1007/BF00342746
   Mallucci CL, 1996, CHILD NERV SYST, V12, P582
   MCCONACHIE NS, 1994, BRIT J RADIOL, V67, P223, DOI 10.1259/0007-1285-67-795-223
   PENDL G, 1992, ACTA NEUROCHIR, V116, P128, DOI 10.1007/BF01540865
   Secer HI, 2008, TURK NEUROSURG, V18, P345
   SILVER AJ, 1982, RADIOLOGY, V145, P71, DOI 10.1148/radiology.145.1.7122900
   Suh D Y, 2001, Neurosurg Focus, V10, pE4, DOI 10.3171/foc.2001.10.6.5
   Suri V, 2015, J PEDIATR NEUROSCI, V10, P393, DOI 10.4103/1817-1745.174433
   Wang MQ, 2013, J CLIN NEUROSCI, V20, P679, DOI 10.1016/j.jocn.2012.05.053
   Xia JG, 2016, CLIN NEURORADIOL, V26, P341, DOI 10.1007/s00062-015-0370-6
   Zuccaro G, 1999, CHILD NERV SYST, V15, P774, DOI 10.1007/s003810050470
NR 22
TC 0
Z9 0
U1 1
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP E693
EP E701
DI 10.1016/j.wneu.2018.12.196
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800088
PM 30660880
DA 2020-05-12
ER

PT J
AU Patil, H
   Garg, N
   Navakar, D
   Banabokade, L
AF Patil, Harshad
   Garg, Nitin
   Navakar, Deepa
   Banabokade, Laxmikant
TI Lumbar Spine Surgeries Under Spinal Anesthesia in High-Risk Patients: A
   Retrospective Analysis
SO WORLD NEUROSURGERY
LA English
DT Article
DE General anesthesia; High-risk patients; Lumbar surgery; Spinal
   anesthesia
ID PERIOPERATIVE OUTCOME VARIABLES; GENERAL-ANESTHESIA; REGIONAL
   ANESTHESIA; LAMINECTOMY; COMPLICATIONS
AB OBJECTIVE: To determine outcomes of spinal anesthesia (SA) in high-risk patients undergoing lumbar spine surgery in whom general anesthesia (GA) was contraindicated.
   METHODS: A retrospective study was conducted in Bansal Hospital, Bhopal, India. SA was achieved with a heavy spinal dose of bupivacaine administered in the sitting position. After assessing sensory level, patients were placed into prone position. Throughout surgery, hemodynamic parameters were monitored. At the end of surgery, patients were placed into supine position and taken out of the operating room for monitoring in the recovery room. Postoperatively, time spent in the post-anesthesia care unit, hemodynamic changes, incidence of nausea and vomiting, urinary retention, spinal headache, analgesic use, regression of sensory block, and length of hospital stay were documented. Patient and surgeon satisfaction was also assessed.
   RESULTS: The study included 18 high-risk patients with lumbar spine disease. Twelve patients were classified as American Society of Anesthesiologists IV, and 6 were classified as American Society of Anesthesiologists III. Ten patients underwent microdiscectomy, and 8 patients underwent canal and lateral recess decompression. None of the patients had anesthetic or surgical complications. Postoperative pain relief was excellent. There were no incidences of postoperative vomiting or urinary retention. Only 2 patients (11.11%) developed nausea. Both surgeons and patients reported a high level of satisfaction. SA was 12% cheaper than general anesthesia.
   CONCLUSIONS: SA is a safe, reliable, and satisfactory alternative to general anesthesia in high-risk lumbar spine surgeries. Postoperative morbidity and mortality can be reduced by SA and spinal analgesia techniques. SA allows good perioperative hemodynamic stability. It is also more cost-effective.
C1 [Patil, Harshad; Garg, Nitin] Bansal Hosp, Dept Neurosurg, Bhopal, India.
   [Navakar, Deepa; Banabokade, Laxmikant] Bansal Hosp, Dept Anaesthesia, Bhopal, India.
RP Patil, H (reprint author), Bansal Hosp, Dept Neurosurg, Bhopal, India.
EM dr_harshadpatil@yahoo.com
CR Attari MA, 2011, J RES MED SCI, V16, P524
   Blichfeldt-Lauridsen L, 2012, ACTA ANAESTH SCAND, V56, P17, DOI 10.1111/j.1399-6576.2011.02558.x
   Breucking E, 2000, ANAESTHESIST, V49, P187, DOI 10.1007/s001010050813
   Brown DL, 2010, MILLERS ANESTHESIA, P1611
   COVINO BG, 1989, INT ANESTHESIOL CLIN, V27, P8, DOI 10.1097/00004311-198902710-00003
   Dagher Christine, 2002, J Med Liban, V50, P206
   De Rojas JO, 2014, CLIN NEUROL NEUROSUR, V119, P39, DOI 10.1016/j.clineuro.2014.01.016
   Demirel CB, 2003, J NEUROSURG ANESTH, V15, P185, DOI 10.1097/00008506-200307000-00005
   Duggappa DR, 2015, INDIAN J ANAESTH, V59, P574, DOI 10.4103/0019-5049.165859
   Erbas YC, 2015, TURK NEUROSURG, V25, P771, DOI 10.5137/1019-5149.JTN.14772-15.1
   Ezhevskaya AA, 2013, SPINE, V38, P1324, DOI 10.1097/BRS.0b013e318290ff26
   Finsterwald M, 2018, J CLIN ANESTH, V46, P3, DOI 10.1016/j.jclinane.2018.01.004
   Hassi N, 1995, Cah Anesthesiol, V43, P21
   Jellish WS, 1996, ANESTH ANALG, V83, P559, DOI 10.1097/00000539-199609000-00021
   Kahveci K, 2014, NEUROL NEUROCHIR POL, V48, P167, DOI 10.1016/j.pjnns.2014.05.005
   Kaul TK, 2007, INDIAN J ANAESTH, V51, P280
   Laakso E, 1997, BRIT J ANAESTH, V79, P609
   McLain RF, 2005, J NEUROSURG-SPINE, V2, P17, DOI 10.3171/spi.2005.2.1.0017
   McLain RF, 2004, SPINE, V29, P2542, DOI 10.1097/01.brs.0000144834.43115.38
   Maman AFOB, 2007, ANN FR ANESTH, V26, P465, DOI 10.1016/j.annfar.2007.02.010
   Raw DA, 2003, BRIT J ANAESTH, V91, P886, DOI 10.1093/bja/aeg253
   Rodgers A, 2000, BMJ-BRIT MED J, V321, P1493, DOI 10.1136/bmj.321.7275.1493
   Smrcka M, 2001, ACTA NEUROCHIR, V143, P377, DOI 10.1007/s007010170093
   Tetzlaff JE, 1998, J CLIN ANESTH, V10, P666, DOI 10.1016/S0952-8180(98)00112-3
NR 24
TC 2
Z9 2
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP E779
EP E782
DI 10.1016/j.wneu.2019.01.023
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800100
PM 30682512
DA 2020-05-12
ER

PT J
AU Pedro, MT
   Eissler, A
   Schmidberger, J
   Kratzer, W
   Wirtz, CR
   Antoniadis, G
   Koenig, RW
AF Pedro, Maria Teresa
   Eissler, Alexandra
   Schmidberger, Julian
   Kratzer, Wolfgang
   Wirtz, Christian Rainer
   Antoniadis, Gregor
   Koenig, Ralph Werner
TI Sodium Fluorescein-Guided Surgery in Peripheral Nerve Sheath Tumors:
   First Experience in 10 Cases of Schwannoma
SO WORLD NEUROSURGERY
LA English
DT Article
DE Peripheral nerve sheath tumors; Schwannoma; Sodium fluorescein; Yellow
ID RESECTION; MICROSCOPE; BRAIN; GLIOMA; SERIES; ANGIOGRAPHY; FILTER
AB BACKGROUND: The intravenous application of sodium fluorescein (SF) for brain tumor surgery goes back to the late 1940s. The development of specific fluorophore filters significantly reduced the required dosage of SF and therefore diminished possible side effects. This study investigates the application of SF in benign peripheral nerve sheath tumors (PNSTs), concentrating on its feasibility during microsurgical removal.
   METHODS: The single-center study includes 10 consecutive schwannoma cases operated on between September 2016 and March 2017. Inclusion criteria were defined as age >= 18 years, preoperative magnetic resonance imaging with suspicion of schwannoma, and final histopathologic confirmation of schwannoma. Exclusion criteria were a history of intolerance to SF and renal insufficiency. The microsurgical part of each surgery was video recorded, and the collected material was retrospectively analyzed. Red, green, and blue values of various regions of interest set on tumor and normal nerve of each patient were evaluated using ImageJ, an open platform for scientific image analysis.
   RESULTS: Digital video analysis confirmed the intra-operative impression of increased fluorescence of the tumor in contrast with normal nerve tissue. Because the color yellow is predominantly a mixture of red and green, values of these colors were significantly increased in schwannomas compared with normal nerve tissue ( P = 0.0003 and P = 0.0023, respectively).
   CONCLUSIONS: SF reveals increased fluorescence in schwannomas compared with normal nerve tissue. Intraoperative differentiation of tumor and normal nerve tissue becomes possible using a low dose of SF (0.5-1 mg/kg). No side effects occurred. Secure microsurgical preparation is feasible during application of the YELLOW 560 nm filter.
C1 [Pedro, Maria Teresa; Wirtz, Christian Rainer; Antoniadis, Gregor; Koenig, Ralph Werner] Univ Ulm, Dept Neurosurg, Peripheral Nerve Surg Unit, Gunzburg, Germany.
   [Eissler, Alexandra; Schmidberger, Julian; Kratzer, Wolfgang] Univ Ulm, Dept Internal Med 1, Gunzburg, Germany.
RP Pedro, MT (reprint author), Univ Ulm, Dept Neurosurg, Peripheral Nerve Surg Unit, Gunzburg, Germany.
EM maria-teresa.pedro@uni-ulm.de
CR Acerbi F, 2016, CLIN NEUROL NEUROSUR, V146, P123, DOI 10.1016/j.clineuro.2016.05.003
   Acerbi F, 2013, ACTA NEUROCHIR, V155, P1277, DOI 10.1007/s00701-013-1734-9
   Chen B, 2012, INT J MED SCI, V9, P708, DOI 10.7150/ijms.4843
   da Silva Carlos Eduardo, 2010, Surg Neurol Int, V1, P70, DOI 10.4103/2152-7806.72247
   Diaz RJ, 2015, J NEUROSURG, V122, P1360, DOI 10.3171/2015.2.JNS132507
   Doyle PJ, 2015, OBSTET GYNECOL, V125, P548, DOI 10.1097/AOG.0000000000000675
   Ganju A, 2001, J NEUROSURG, V95, P51, DOI 10.3171/jns.2001.95.1.0051
   Gass J D, 1972, Int Ophthalmol Clin, V12, P85, DOI 10.1097/00004397-197201210-00007
   Kim DH, 2005, J NEUROSURG, V102, P246, DOI 10.3171/jns.2005.102.2.0246
   KRANSDORF MJ, 1995, AM J ROENTGENOL, V164, P395, DOI 10.2214/ajr.164.2.7839977
   Kretschmer Thomas, 2007, Neurosurg Focus, V22, pE19
   Kuroiwa T, 1998, SURG NEUROL, V50, P41, DOI 10.1016/S0090-3019(98)00055-X
   Liu JG, 2013, CHINESE MED J-PEKING, V126, P2418, DOI 10.3760/cma.j.issn.0366-6999.20122939
   Moiyadi AV, 2015, NEUROL INDIA, V63, P155, DOI 10.4103/0028-3886.156275
   Montano N, 2016, J NEUROSURG, V125, P363, DOI 10.3171/2015.6.JNS15596
   MOORE GE, 1948, J NEUROSURG, V5, P392, DOI 10.3171/jns.1948.5.4.0392
   RABB MF, 1978, SURV OPHTHALMOL, V22, P387, DOI 10.1016/0039-6257(78)90134-0
   Rey-Dios R, 2013, ACTA NEUROCHIR, V155, P701, DOI 10.1007/s00701-013-1635-y
   Schebesch KM, 2016, TURK NEUROSURG, V26, P185, DOI 10.5137/1019-5149.JTN.16952-16.0
   Schebesch KM, 2015, CLIN NEUROL NEUROSUR, V139, P125, DOI 10.1016/j.clineuro.2015.09.015
   Schebesch KM, 2015, ACTA NEUROCHIR, V157, P899, DOI 10.1007/s00701-015-2395-7
   Schebesch KM, 2013, ACTA NEUROCHIR, V155, P693, DOI 10.1007/s00701-013-1643-y
   Shinoda J, 2003, J NEUROSURG, V99, P597, DOI 10.3171/jns.2003.99.3.0597
   Stummer W, 2015, ACTA NEUROCHIR, V157, P1379, DOI 10.1007/s00701-015-2471-z
   ZIMMERN PE, 1995, J UROLOGY, V154, P62, DOI 10.1016/S0022-5347(01)67225-2
NR 25
TC 4
Z9 4
U1 1
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP E724
EP E732
DI 10.1016/j.wneu.2019.01.010
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800093
PM 30660884
DA 2020-05-12
ER

PT J
AU Peters, PA
   Kaszuba, MC
   Raghunathan, A
   Puffer, RC
   Spinner, RJ
AF Peters, Pierce A.
   Kaszuba, Megan C.
   Raghunathan, Aditya
   Puffer, Ross C.
   Spinner, Robert J.
TI Synchronous Development of Multicentric Malignant Peripheral Nerve
   Sheath Tumors: Institutional Review
SO WORLD NEUROSURGERY
LA English
DT Review
DE Malignant peripheral nerve sheath tumor; MPNST; Multicentric;
   Synchronous
ID PREVALENCE
AB BACKGROUND: Malignant peripheral nerve sheath tumors (MPNSTs) are rare soft tissue sarcomas, with approximately 50% occurring in patients diagnosed with neurofibromatosis type 1 (NF-1). NF-1 occurs in approximately 1/3000 individuals, and given that the lifetime prevalence of MPNST is estimated at 8%-13%, synchronous development of separate MPNSTs is plausible. We sought to report the incidence of synchronous MPNST in a cohort of pathology-proven cases since 1994.
   METHODS: Records since 1994 were queried and identified 192 patients with pathology-proven MPNST. Medical records of these patients were reviewed to search for patients with synchronous MPNSTs.
   RESULTS: Retrospective review of 192 patients treated for MPNST at our institution (including 71 patients with NF-1) revealed only 1 patient with synchronous MPNSTs. A 48-year-old woman with NF-1 presented with progressive right upper and lower extremity pain and radicular symptoms. Biopsies of right sciatic and median nerve lesions revealed high-grade MPNST, and she underwent radiotherapy and complete resection of both masses. Due to initial nonspecific biopsy results and patient preference, treatment of the median nerve lesion was delayed by 8 months. She did not have recurrence of her disease at the 18-month follow-up.
   CONCLUSIONS: Synchronous development of MPNST is unusual, with an incidence of 1.4% in our cohort of NF-1 patients with MPNSTs. Given the reported incidence of synchronous MPNST, the rate of malignant transformation in NF-1 may be overestimated. However, heightened suspicion for malignant transformation should continue in patients harboring a diagnosis of MPNST.
C1 [Peters, Pierce A.; Kaszuba, Megan C.; Raghunathan, Aditya; Puffer, Ross C.; Spinner, Robert J.] Mayo Clin, Dept Neurol Surg, Rochester, MN 55905 USA.
RP Spinner, RJ (reprint author), Mayo Clin, Dept Neurol Surg, Rochester, MN 55905 USA.
EM Spinner.Robert@Mayo.edu
OI Raghunathan, Aditya/0000-0001-6198-7441
CR Benz MR, 2010, CANCER-AM CANCER SOC, V116, P451, DOI 10.1002/cncr.24755
   Doorn P F, 1995, Eur J Surg Oncol, V21, P78, DOI 10.1016/S0748-7983(05)80073-3
   DUCATMAN BS, 1986, CANCER-AM CANCER SOC, V57, P2006, DOI 10.1002/1097-0142(19860515)57:10<2006::AID-CNCR2820571022>3.0.CO;2-6
   Evans DG, 2010, AM J MED GENET A, V152A, P327, DOI 10.1002/ajmg.a.33139
   Evans DGR, 2002, J MED GENET, V39, P311, DOI 10.1136/jmg.39.5.311
   Lammert M, 2005, ARCH DERMATOL, V141, P71, DOI 10.1001/archderm.141.1.71
   Leena JB, 2013, INDIAN J SURG, V75, pS25, DOI 10.1007/s12262-011-0302-x
   Ozturk E, 2007, CLIN IMAG, V31, P363, DOI 10.1016/j.clinimag.2007.04.028
   Tovmassian D, 2016, INT J SURG ONCOL, DOI 10.1155/2016/6162182
NR 9
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP E312
EP E314
DI 10.1016/j.wneu.2018.12.088
PG 3
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800040
PM 30597282
DA 2020-05-12
ER

PT J
AU Polak, J
   Ciuk, S
   Kucybala, I
   Giliavas, J
   Gajdosz, A
   Urbanik, A
AF Polak, Jakub
   Ciuk, Szymon
   Kucybala, Iwona
   Giliavas, Jakub
   Gajdosz, Anna
   Urbanik, Andrzej
TI Cerebral Aneurysms: Are They Associated with Anatomic Variations of
   Carotid and Main Cerebral Arteries?
SO WORLD NEUROSURGERY
LA English
DT Article
DE Anatomic variants; Carotid arteries; Cerebral aneurysms; Cerebral
   arteries
ID INTRACRANIAL ANEURYSMS; HYPOPLASIA; COILING; KINKING
AB OBJECTIVE: Vascular anatomic variations are very common in the population, but their coexistence with life-threating vascular malformations remains unclear. The objective of the study was to assess the correlation between the presence of anatomic variants of both carotid and main cerebral arteries and the occurrence of cerebral aneurysms.
   METHODS: We analyzed examinations of 194 patients who underwent computed tomography angiography of the head and neck between September of 2016 and November of 2017. The assessed parameters were: the variation of the common carotid arteries origin, hypoplasia or duplication of any of the main cerebral arteries, carotid artery kinking, and the presence of cerebral aneurysms.
   RESULTS: We found 5.7% of patients had a cerebral aneurysm. Hypoplasia of at least 1 main cerebral artery occurred in 34.5% of patients, with the most frequent being the vertebral artery (21.6%). Duplication of at least 1 main cerebral artery was detected in 2.6%. Cerebral aneurysms occurred more often together with hypoplasia (P = 0.041; OR = 3.175) or duplication (P < 0.001; OR = 18.500) of at least 1 main cerebral artery. In 7.2% of cases, the origin of common carotid arteries created a true bovine arch, and in 4.1% the so-called bovine arch. Patients with alternative variants of aortic arch branching were more likely to have cerebral aneurysms (P = 0.002; OR = 5.903). We found 27.3% of patients had internal carotid arteries affected by kinking. Carotid kinking did not predispose the patient to the formation of a cerebral aneurysm (P = 0.378).
   CONCLUSIONS: There is an evident correspondence between the presence of vascular anatomic variants (abnormal origin of the carotid arteries, hypoplasia, or duplication of the main cerebral artery) and the occurrence of cerebral aneurysms.
C1 [Polak, Jakub; Kucybala, Iwona; Giliavas, Jakub; Gajdosz, Anna; Urbanik, Andrzej] Jagiellonian Univ, Dept Radiol, Med Coll, Krakow, Poland.
   [Ciuk, Szymon] Wroclaw Med Univ, Dept Gen & Intervent Radiol & Neuroradiol, Wroclaw, Poland.
RP Polak, J (reprint author), Jagiellonian Univ, Dept Radiol, Med Coll, Krakow, Poland.
EM jpolak@outlook.com
RI Kucybala, Iwona/AAF-3010-2020
OI Polak, Jakub/0000-0001-9805-8267; Kucybala, Iwona/0000-0002-5823-4390
CR Ahn SS, 2014, ANN VASC SURG, V28, P381, DOI 10.1016/j.avsg.2013.06.010
   Beigelman R, 2010, ANGIOLOGY, V61, P107, DOI 10.1177/0003319709336417
   Bouthillier A, 1996, NEUROSURGERY, V38, P425, DOI 10.1097/00006123-199603000-00001
   Brisman JL, 2006, NEW ENGL J MED, V355, P928, DOI 10.1056/NEJMra052760
   Cebral JR, 2013, ANN BIOMED ENG, V41, P1366, DOI 10.1007/s10439-012-0723-0
   Chalouhi N, 2013, STROKE, V44, P3613, DOI 10.1161/STROKEAHA.113.002390
   CHARBEL F T, 1991, Neurological Research, V13, P253
   Chen H, 2014, SURG RADIOL ANAT, V36, P353, DOI 10.1007/s00276-013-1182-5
   Dumfarth J, 2015, J THORAC CARDIOV SUR, V149, P1586, DOI 10.1016/j.jtcvs.2015.02.019
   Gunnal Sandhya Arvind, 2018, Asian J Neurosurg, V13, P363, DOI 10.4103/ajns.AJNS_152_16
   Kendi A T K, 2009, Br J Radiol, V82, pe216, DOI 10.1259/bjr/26005109
   Kovac JD, 2014, MED SCI MONITOR, V20, P420, DOI 10.12659/MSM.890265
   Labeyrie PE, 2017, INT J STROKE, V12, P549, DOI 10.1177/1747493016687577
   Lauric A, 2014, J NEUROINTERV SURG, V6, P733, DOI 10.1136/neurintsurg-2013-010987
   Layton KF, 2006, AM J NEURORADIOL, V27, P1541
   Lazzaro MA, 2012, J NEUROINTERV SURG, V4, P22, DOI 10.1136/jnis.2010.004358
   Meila D, 2012, CLIN NEURORADIOL, V22, P327, DOI 10.1007/s00062-012-0171-0
   Pancera P, 1998, INT ANGIOL, V17, P22
   Pellegrino L, 1998, Minerva Cardioangiol, V46, P69
   Schievink WI, 2010, NEUROLOGY, V74, P1430, DOI 10.1212/WNL.0b013e3181dc1acf
   SPALLONE A, 1981, J NEUROSURG, V55, P693, DOI 10.3171/jns.1981.55.5.0693
   WEIBEL J, 1965, NEUROLOGY, V15, P7, DOI 10.1212/WNL.15.1.7
   Williams Lindsy N, 2013, Neurol Clin Pract, V3, P99
   Xu LY, 2012, J COMPUT ASSIST TOMO, V36, P421, DOI 10.1097/RCT.0b013e3182574dea
   Zhou MK, 2015, NEUROLOGY, V84, P818, DOI 10.1212/WNL.0000000000001284
NR 25
TC 0
Z9 0
U1 1
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP E604
EP E608
DI 10.1016/j.wneu.2018.12.161
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800077
PM 30639500
DA 2020-05-12
ER

PT J
AU Raymond, SB
   Koch, MJ
   Rabinov, JD
   Leslie-Mazwi, TM
   Torok, CM
   Stapleton, CJ
   Patel, AB
AF Raymond, Scott B.
   Koch, Matthew J.
   Rabinov, James D.
   Leslie-Mazwi, Thabele M.
   Torok, Collin M.
   Stapleton, Christopher J.
   Patel, Aman B.
TI The Role of Collateral Circulation in Branch Vessel Occlusion After Flow
   Diversion
SO WORLD NEUROSURGERY
LA English
DT Article
DE Aneurysm; Branch vessel; Collateral circulation; Flow diverter
ID ANTERIOR CHOROIDAL ARTERY; PIPELINE EMBOLIZATION DEVICE; PARENT ARTERY;
   ANEURYSMS; DIVERTORS; PATENCY; EXPERIENCE
AB BACKGROUND: Flow diversion for treatment of intracranial aneurysms frequently necessitates covering adjacent branch vessels. Although branch vessel occlusion is common, associated clinical deficits are rare. It has been hypothesized that clinically silent branch vessel occlusion is due to underlying collateral circulation. To study the role of collateral circulation in covered branch vessel occlusion, we assessed collateral vessels and altered branch vessel flow on transfemoral catheter angiography in patients undergoing flow diversion of intracranial aneurysms.
   METHODS: Angiograms obtained before treatment, immediately after treatment, and during follow-up were evaluated for branch vessel flow patterns and associated collateral circulation in a consecutive retrospective cohort of 84 patients from 2011 to 2017 with branch vessel coverage related to aneurysm flow diversion using the Pipeline embolization device.
   RESULTS: We identified 142 branch vessels covered by the Pipeline device construct for treatment of 89 aneurysms, predominately in the anterior circulation (>90%). Collateral circulation was observed in approximately one third of these vessels and was associated with diminished (P < 0.001) or absent (P < 0.001) flow on follow-up angiography. Only 2 of 80 terminal branch vessels (no collaterals) were occluded, and these occurred in a patient with Pipeline device construct thrombosis. Altered branch vessel flow was not associated with vascular risk factors, treatment technique, or outcome measures, including new or worsening neurologic deficit.
   CONCLUSIONS: Altered flow in branch vessels covered during flow diversion reflects underlying collateral circulation and is not associated with downstream ischemic deficits.
C1 [Raymond, Scott B.] Massachusetts Gen Hosp, Dept Radiol, 32 Fruit St, Boston, MA 02114 USA.
   [Koch, Matthew J.; Rabinov, James D.; Leslie-Mazwi, Thabele M.; Stapleton, Christopher J.; Patel, Aman B.] Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA 02114 USA.
   [Leslie-Mazwi, Thabele M.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.
   [Torok, Collin M.] St Paul Radiol, St Paul, MN USA.
RP Raymond, SB (reprint author), Massachusetts Gen Hosp, Dept Radiol, 32 Fruit St, Boston, MA 02114 USA.
EM scott.raymond@mgh.harvard.edu
OI Raymond, Scott/0000-0001-7008-8974
CR Berge J, 2011, AM J NEURORADIOL, V32, P1930, DOI 10.3174/ajnr.A2710
   Bhogal P, 2017, J NEUROINTERV SURG, V9, P471, DOI 10.1136/neurintsurg-2016-012781
   Bhogal P, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00381
   Bhogal P, 2017, WORLD NEUROSURG, V103, P789, DOI 10.1016/j.wneu.2017.04.092
   Bhogal P, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00020
   BONITA R, 1988, STROKE, V19, P1497, DOI 10.1161/01.STR.19.12.1497
   Brinjikji W, 2015, AM J NEURORADIOL, V36, P537, DOI 10.3174/ajnr.A4139
   Burrows AM, 2016, AM J NEURORADIOL, V37, P1866, DOI 10.3174/ajnr.A4835
   Chalouhi N, 2014, AM J NEURORADIOL, V35, P1562, DOI 10.3174/ajnr.A3957
   Daou B, 2017, J NEUROSURG, V126, P564, DOI 10.3171/2016.2.JNS152544
   Fanning NF, 2008, J NEUROSURG, V108, P1074, DOI 10.3171/JNS/2008/108/6/1074
   Griessenauer CJ, 2017, NEUROSURGERY, V80, P726, DOI 10.1093/neuros/nyw110
   Jevsek M, 2016, RADIOL ONCOL, V50, P378, DOI 10.1515/raon-2016-0049
   Kabbasch Christoph, 2016, J Vasc Interv Neurol, V9, P14
   Mattingly T, 2015, J NEUROINTERV SURG, V7, pE13, DOI 10.1136/neurintsurg-2013-011062
   Neki H, 2015, J NEUROSURG, V123, P1540, DOI 10.3171/2014.11.JNS141603
   Park MS, 2016, AM J NEURORADIOL, V37, P1127, DOI 10.3174/ajnr.A4678
   Puffer RC, 2012, J NEUROSURG, V116, P892, DOI 10.3171/2011.11.JNS111612
   R Core Team, 2013, R LANG ENV STAT COMP
   Rangel-Castilla L, 2017, J NEUROSURG, V126, P1064, DOI 10.3171/2016.4.JNS16147
   Raz E, 2015, AM J NEURORADIOL, V36, P937, DOI 10.3174/ajnr.A4217
   Saleme S, 2014, NEUROSURGERY, V75, P623, DOI 10.1227/NEU.0000000000000522
   Siddiqui AH, 2012, J NEUROSURG, V116, P1258, DOI 10.3171/2012.2.JNS111942
   Srinivasan VM, 2018, J NEUROINTERV SURG, V10, P634, DOI 10.1136/neurintsurg-2017-013466
   Szikora I, 2010, AM J NEURORADIOL, V31, P1139, DOI 10.3174/ajnr.A2023
   Tsang Anderson Chun On, 2015, Neurointervention, V10, P60, DOI 10.5469/neuroint.2015.10.2.60
   Walcott BP, 2016, JAMA NEUROL, V73, P1002, DOI 10.1001/jamaneurol.2016.0609
   Yavuz K, 2014, AM J NEURORADIOL, V35, P529, DOI 10.3174/ajnr.A3692
NR 28
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP E182
EP E187
DI 10.1016/j.wneu.2018.12.064
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800024
PM 30593960
DA 2020-05-12
ER

PT J
AU Reid, DBC
   Haglin, JM
   Durand, WM
   Daniels, AH
AF Reid, Daniel B. C.
   Haglin, Jack M.
   Durand, Wesley M.
   Daniels, Alan H.
TI Operative Management of Spinal Infection Among Intravenous Drug Abusers
SO WORLD NEUROSURGERY
LA English
DT Article
DE IV drug abuse; Spinal decompression; Spinal fusion; Spinal infection
ID VERTEBRAL OSTEOMYELITIS
AB OBJECTIVE: Recent population-level increases in intravenous drug abuse (IVDA) may contribute to incidence of spinal infection. The aim of this study was to evaluate national trends of spinal infections and evaluate effect of IVDA on outcomes in operative management of spinal infection.
   METHODS: Using the National (Nationwide) Inpatient Sample database for 2002-2014, all patients undergoing spinal decompression or fusion for treatment of spinal infection were evaluated. Inpatient outcomes included length of stay, total cost, complications, discharge to facility, reoperations, and inpatient mortality. Bivariate and multivariate logistic regression analyses were performed to compare patients with IVDA and patients without IVDA.
   RESULTS: A total of 60,964 patients undergoing surgical management of spinal infection were identified. Number of surgically managed spine infections increased from 2002 to 2014 (P < 0.0001). Proportion of surgically managed spine infections associated with IVDA increased from 3.3% in 2002 to 14.0% in 2014 (P < 0.0001). IVDA was associated with increased hospital length of stay (odds ratio = 1.38; 95% confidence interval, 1.32-1.45; P < 0.0001) and greater total charges (odds ratio = 1.23; 95% confidence interval, 1.17-1.29; P < 0.0001). No other significant differences between groups were noted.
   CONCLUSIONS: From 2002 to 2014 in the United States, the incidence of operatively treated spine infections increased 227.9%, and the proportion of cases associated with IVDA significantly increased. Patients with IVDA had a longer mean length of stay and increased inpatient cost of care but were not at increased risk for complication, reoperation, or mortality. These findings are important for surgeons, internists, hospitals, and insurers to ensure proper resource allocation in treating these at-risk patients.
C1 [Reid, Daniel B. C.; Durand, Wesley M.; Daniels, Alan H.] Brown Univ, Warren Alpert Med Sch, Providence, RI 02912 USA.
   [Reid, Daniel B. C.; Daniels, Alan H.] Rhode Isl Hosp, Dept Orthoped Surg, Spine Div, Providence, RI USA.
   [Haglin, Jack M.] Mayo Clin, Sch Med, Scottsdale, AZ 85259 USA.
RP Haglin, JM (reprint author), Mayo Clin, Sch Med, Scottsdale, AZ 85259 USA.
EM jackhaglin@gmail.com
CR Agency for Healthcare Research and Quality, 2016, OV NAT NAT INP SAMPL
   Agency for Healthcare Research and Quality, 2018, CLIN CLASS SOFTW CCS
   Beronius M, 2001, SCAND J INFECT DIS, V33, P527, DOI 10.1080/00365540110026566
   Butler JS, 2006, SPINE, V31, P2695, DOI 10.1097/01.brs.0000244662.78725.37
   Centers for Disease Control and Prevention, 2017, HER OV DAT
   Chelsom J, 1998, SCAND J INFECT DIS, V30, P147, DOI 10.1080/003655498750003537
   Chuo CY, 2007, J SPINAL DISORD TECH, V20, P324, DOI 10.1097/BSD.0b013e31802c144a
   Cruse J M, 2000, J Spinal Cord Med, V23, P129
   Durand Wesley M, 2018, AMIA Jt Summits Transl Sci Proc, V2017, P349
   Hopf C, 1998, NEUROSURG REV, V21, P217, DOI 10.1007/BF01105775
   HORSBURGH CR, 1989, INFECT CONT HOSP EP, V10, P211
   KOPPEL BS, 1988, ARCH NEUROL-CHICAGO, V45, P1331, DOI 10.1001/archneur.1988.00520360049011
   KRODEL A, 1991, ARCH ORTHOP TRAUM SU, V110, P78, DOI 10.1007/BF00393878
   Krogsgaard MR, 1998, ACTA ORTHOP SCAND, V69, P513, DOI 10.3109/17453679808997789
   Lansky A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097596
   LIFESO RM, 1990, SPINE, V15, P1265, DOI 10.1097/00007632-199012000-00007
   Mann Sascha, 2004, Neurosurg Focus, V17, pE3
   Nolla JM, 2002, SEMIN ARTHRITIS RHEU, V31, P271, DOI 10.1053/sarh.2002.29492
   Oh DHW, 2018, CLIN ORTHOP RELAT R, V476, P1557, DOI 10.1097/01.blo.0000534682.68856.d8
   Quinones-Hinojosa Alfredo, 2004, Neurosurg Focus, V17, pE1, DOI 10.3171/foc.2004.17.6.1
   Rezai AR, 1999, NEUROSURGERY, V44, P1018, DOI 10.1097/00006123-199905000-00047
   Robinson BHB, 1972, GUYS HOSP REP, V110, P303
   Sapico FL, 1996, ORTHOP CLIN N AM, V27, P9
   Schinkel Christian, 2003, Surg Infect (Larchmt), V4, P387, DOI 10.1089/109629603322761445
   Wang Z, 2012, SPINE, V37, P685, DOI 10.1097/BRS.0b013e31823b01b8
   Wurcel AG, 2016, OPEN FORUM INFECT DI, V3, DOI 10.1093/ofid/ofw157
   Ziu M, 2014, NEUROSURG FOCUS, V37, DOI 10.3171/2014.6.FOCUS14148
NR 27
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP E552
EP E557
DI 10.1016/j.wneu.2018.12.151
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800071
PM 30639488
DA 2020-05-12
ER

PT J
AU Rodriguez-Trivino, CY
   Castro, IT
   Duenas, Z
AF Rodriguez-Trivino, Claudia Yaneth
   Castro, Isidro Torres
   Duenas, Zulma
TI Hypochloremia in Patients with Severe Traumatic Brain Injury: A Possible
   Risk Factor for Increased Mortality
SO WORLD NEUROSURGERY
LA English
DT Article
DE Mortality; Risk factor; Traumatic brain injury
ID HYPERNATREMIA; CARE; EPIDEMIOLOGY; BARRIER; SODIUM; DEATH
AB OBJECTIVE: To determine association between electrolyte disturbances and mortality in patients with severe traumatic brain injury.
   METHODS: Medical records of patients with severe traumatic brain injury and Glasgow Coma Scale score <8 and electrolyte alterations were reviewed in a retrospective cohort study. Electrolyte levels were analyzed to establish an association between patients who died and patients who survived. Bivariate analysis was performed using chi(2) test with a statistical reliability of 95% for categorical variables. Analysis for electrolyte changes to determine association with mortality was performed using chi(2) test with multiple comparisons. Logistic regression was performed between the electrolyte alterations and their association with mortality. The reliability of statistical tests was 95%.
   RESULTS: There was a significant relationship between hypochloremia and increased risk of mortality in 23.1% of deceased patients (P = 0.03). Furthermore, there was a significant correlation with age (P < 0.01) and with the Acute Physiology and Chronic Health Evaluation APACHE II (P < 0.01).
   CONCLUSIONS: Hypochloremia could be an important prognostic factor to determine mortality risk and to improve treatment in patients with severe traumatic brain injury.
C1 [Rodriguez-Trivino, Claudia Yaneth; Castro, Isidro Torres] Fdn Univ Navarra UNINAVARRA, Grp Navarra Med, Fac Ciencias Salud, Dept Ciencias Fisiol, Neiva, Huila, Colombia.
   [Rodriguez-Trivino, Claudia Yaneth; Duenas, Zulma] Univ Nacl Colombia, Dept Ciencias Fisiol, Grp Neurobiol & Comportamiento, Fac Med, Bogota, Bogota Dc, Colombia.
RP Rodriguez-Trivino, CY (reprint author), Fdn Univ Navarra UNINAVARRA, Grp Navarra Med, Fac Ciencias Salud, Dept Ciencias Fisiol, Neiva, Huila, Colombia.; Rodriguez-Trivino, CY (reprint author), Univ Nacl Colombia, Dept Ciencias Fisiol, Grp Neurobiol & Comportamiento, Fac Med, Bogota, Bogota Dc, Colombia.
EM claur3@gmail.com
OI Rodriguez, Claudia/0000-0002-6884-3931; Duenas,
   Zulma/0000-0001-6068-4174
CR Audibert G, 2012, Ann Fr Anesth Reanim, V31, pe109, DOI 10.1016/j.annfar.2012.04.014
   Ballabh P, 2004, NEUROBIOL DIS, V16, P1, DOI 10.1016/j.nbd.2003.12.016
   Beal AL, 2002, SHOCK, V18, P107, DOI 10.1097/00024382-200208000-00002
   BERGER MM, 1992, CRIT CARE MED, V20, P1681, DOI 10.1097/00003246-199212000-00014
   Brazinova A, 2016, J NEUROTRAUM, DOI 10.1089/neu.2015.4126
   Carney N, 2017, NEUROSURGERY, V80, P6, DOI 10.1227/NEU.0000000000001432
   Colantonio A, 2015, J HEAD TRAUMA REHAB, V30, pE18, DOI 10.1097/HTR.0000000000000112
   Duran C, 2010, ANNU REV PHYSIOL, V72, P95, DOI 10.1146/annurev-physiol-021909-135811
   Elmore S, 2007, TOXICOL PATHOL, V35, P495, DOI 10.1080/01926230701320337
   Gong YF, 2017, PFLUG ARCH EUR J PHY, V469, P105, DOI 10.1007/s00424-016-1906-6
   Guzman F, 2008, COLOMB MEDICA, V39, P25
   Hoffman H, 2018, WORLD NEUROSURG, V118, pE880, DOI 10.1016/j.wneu.2018.07.089
   Isomura Y, 2003, J NEUROPHYSIOL, V90, P2752, DOI 10.1152/jn.00142.2003
   Kovesdy CP, 2012, CIRCULATION, V125, P677, DOI 10.1161/CIRCULATIONAHA.111.065391
   Li M, 2013, INJURY, V44, P1213, DOI 10.1016/j.injury.2012.05.021
   Liu Y, 2013, P NATL ACAD SCI USA, V110, P20364, DOI 10.1073/pnas.1319661110
   Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668
   McHugh GS, 2007, J NEUROTRAUM, V24, P287, DOI 10.1089/neu.2006.0031
   Moreno A, 2011, ACTA MED COLOMB, V36, P162
   Paiva WS, 2011, THER CLIN RISK MANAG, V7, P345, DOI 10.2147/TCRM.S17692
   Palmer CS, 2016, INJURY, V47, P109, DOI 10.1016/j.injury.2015.07.003
   Polderman KH, 2000, CRIT CARE MED, V28, P2022, DOI 10.1097/00003246-200006000-00057
   Polderman KH, 1999, CRIT CARE MED, V27, P1105, DOI 10.1097/00003246-199906000-00029
   Puvanachandra P, 2008, SALUD PUBLICA MEXICO, V50, pS3, DOI 10.1590/s0036-36342008000700002
   Rodriguez C, 2018, IATREIA, V31, pS28
   Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22
   Rubiano AM, 2017, 26 INT EUR S MARCH 3
   Rubiano AM, 2015, NATURE, V527, pS193, DOI 10.1038/nature16035
   Stein DM, 2017, CRIT CARE CLIN, V33, P1, DOI 10.1016/j.ccc.2016.08.008
   Tisdall M, 2006, J NEUROSURG ANESTH, V18, P57, DOI 10.1097/01.ana.0000191280.05170.0f
   Upadhyay A, 2009, SEMIN NEPHROL, V29, P227, DOI 10.1016/j.semnephrol.2009.03.004
   Yumoto T, 2015, ACTA MED OKAYAMA, V69, P213
NR 32
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP E783
EP E788
DI 10.1016/j.wneu.2019.01.025
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800101
PM 30682506
DA 2020-05-12
ER

PT J
AU Romano, A
   D'Andrea, G
   Pesce, A
   Olivieri, G
   Rossi-Espagnet, MC
   Picotti, V
   Raco, A
   Bozzao, A
AF Romano, Andrea
   D'Andrea, Giancarlo
   Pesce, Alessandro
   Olivieri, Giorgia
   Rossi-Espagnet, Maria Camilla
   Picotti, Veronica
   Raco, Antonino
   Bozzao, Alessandro
TI Trigonal and Peritrigonal Lesions of the Lateral Ventricle: Presurgical
   Tractographic Planning and Clinic Outcome Evaluation
SO WORLD NEUROSURGERY
LA English
DT Article
DE MRI; Presurgical planning; Tractography; Trigonal lesions
ID MAGNETIC-RESONANCE TRACTOGRAPHY; CEREBRAL WHITE-MATTER; INTRAVENTRICULAR
   MENINGIOMAS; BRAIN SHIFT; SURGICAL CONSIDERATIONS; CORTICOSPINAL TRACT;
   FIBER-TRACKING; TUMORS; NEURONAVIGATION; DEFORMATION
AB BACKGROUND: Surgery of lesions within the atrium of the lateral ventricle remains a challenging procedure because of the deep location and the relationship to vascular structures. The aim of this study was to determine the usefulness of tractography to evaluate the position of white matter tracts located along the course of the surgical access to trigonal and peritrigonal lesions.
   METHODS: Diffusion tensor imaging (DTI) was acquired in 19 patients. All patients underwent surgical resection of brain tumors. Pre- and postoperative clinical conditions were evaluated by a neurosurgeon, using the Karnofsky Performance Status Scale. The corticospinal tract, optic radiation, and arcuate fasciculum were reconstructed because of their location close to the trigonal region. Two neurosurgeons were asked to assess the surgical approach with and without tractography.
   RESULTS: According to the tractographic reconstructions, the surgical access was chosen from the middle temporal gyrus in 12 patients (63%) and the posterior parietal gyrus in 7 patients (37%), leading to an a priori change in the surgical approach in 14 patients (73%). Six patients (31%) showed new postsurgical transient symptoms, whereas in 2 patients (10%) the deficits were permanent. After 30 days, the Karnofsky Performance Status Scale evaluation showed an improvement or a substantial stability of symptoms in 90% of cases. In 2 patients, a worsening of 30% of clinical performance was appreciable.
   CONCLUSIONS: The use of DTI in preoperative planning of trigonal and peritrigonal lesions may help in description of the best surgical approach for patient; this technique allows to reach the tumors, saving the white matter tracts, when it is possible.
C1 [Romano, Andrea] Umberto I Hosp, Dept Odontostomatol & Maxillofacial Sci, Rome, Italy.
   [Romano, Andrea; Rossi-Espagnet, Maria Camilla; Bozzao, Alessandro] S Andrea Hosp, Dept Neuroradiol, NESMOS, Rome, Italy.
   [Pesce, Alessandro; Picotti, Veronica; Raco, Antonino] S Andrea Hosp, Dept Neurosurg, NESMOS, Rome, Italy.
   [Olivieri, Giorgia] Univ Sapienza, S Andrea Hosp, Dept Clin Pathol, Rome, Italy.
   [D'Andrea, Giancarlo] Fabrizio Spaziani Hosp, Dept Neurosurg, Frosinone, Italy.
   [Rossi-Espagnet, Maria Camilla] Bambino Gesu Pediat Hosp, Imaging Dept, Neuroradiol Unit, Rome, Italy.
RP Romano, A (reprint author), Umberto I Hosp, Dept Odontostomatol & Maxillofacial Sci, Rome, Italy.; Romano, A (reprint author), S Andrea Hosp, Dept Neuroradiol, NESMOS, Rome, Italy.
EM andrea.romano@uniroma1.it
RI D'Andrea, Giancarlo/L-1039-2017; Pesce, Alessandro/AAC-2223-2020
OI D'Andrea, Giancarlo/0000-0001-7861-0587; Romano,
   Andrea/0000-0003-0254-9665; Rossi Espagnet, Maria
   Camilla/0000-0002-2991-5840
CR Basser PJ, 2000, MAGNET RESON MED, V44, P625, DOI 10.1002/1522-2594(200010)44:4<625::AID-MRM17>3.0.CO;2-O
   BATJER H, 1987, J NEUROSURG, V67, P511, DOI 10.3171/jns.1987.67.4.0511
   Bertalanffy A, 2006, NEUROSURG REV, V29, P30, DOI 10.1007/s10143-005-0414-5
   Bertani GA, 2018, WORLD NEUROSURG, V117, pE42, DOI 10.1016/j.wneu.2018.05.131
   Bhatoe Harjinder S, 2006, Neurosurg Focus, V20, pE9, DOI 10.3171/foc.2006.20.3.10
   Bozzao A, 2010, EUR RADIOL, V20, P2475, DOI 10.1007/s00330-010-1806-7
   D'Angelo Vincenzo A, 2005, Neurosurgery, V56, P36
   DELATORRE E, 1963, J Neurosurg, V20, P461
   Field AS, 2004, J MAGN RESON IMAGING, V20, P555, DOI 10.1002/jmri.20169
   FORNARI M, 1981, J NEUROSURG, V54, P64, DOI 10.3171/jns.1981.54.1.0064
   Gelabert-Gonzalez M, 2008, NEUROCIRUGIA, V19, P427
   Gokalp HZ, 1998, NEUROSURG REV, V21, P126, DOI 10.1007/BF02389318
   Hartkens T, 2003, IEEE T MED IMAGING, V22, P82, DOI 10.1109/TMI.2002.806596
   Hastreiter P, 2004, MED IMAGE ANAL, V8, P447, DOI 10.1016/j.media.2004.02.001
   JEEVES MA, 1979, J NEUROL NEUROSUR PS, V42, P134, DOI 10.1136/jnnp.42.2.134
   Jellison BJ, 2004, AM J NEURORADIOL, V25, P356
   Juretschke FR, 2010, NEUROSURG REV, V33, P457, DOI 10.1007/s10143-010-0271-8
   Kamada K, 2005, NEUROSURGERY, V57, P121, DOI 10.1227/01.NEU.0000163526.60240.B6
   Kawashima M, 2006, SURG NEUROL, V65, P436, DOI 10.1016/j.surneu.2005.09.033
   KEMPE LG, 1976, ACTA NEUROCHIR, V35, P233, DOI 10.1007/BF01406119
   Kinoshita M, 2005, NEUROIMAGE, V25, P424, DOI 10.1016/j.neuroimage.2004.07.076
   Liu M, 2006, NEUROSURG REV, V29, P36, DOI 10.1007/s10143-005-0418-1
   Lyngdoh BT, 2007, J CLIN NEUROSCI, V14, P442, DOI 10.1016/j.jocn.2006.01.005
   Mastronardi Luciano, 2008, Clin Neurosurg, V55, P160
   Menon G, 2009, BRIT J NEUROSURG, V23, P297, DOI 10.1080/02688690902721862
   Mormina E, 2015, AM J NEURORADIOL, V36, P1853, DOI 10.3174/ajnr.A4368
   Nabavi A, 2001, NEUROSURGERY, V48, P787, DOI 10.1097/00006123-200104000-00019
   Nakamura M, 2003, SURG NEUROL, V59, P491, DOI 10.1016/S0090-3019(03)00082-X
   Nayar VV, 2010, CLIN NEUROL NEUROSUR, V112, P400, DOI 10.1016/j.clineuro.2010.02.005
   Nimsky C, 2006, NEUROSURGERY, V58, P292, DOI 10.1227/01.NEU.0000204726.00088.6D
   Nimsky C, 2005, NEUROSURGERY, V56, P130, DOI 10.1227/01.NEU.0000144842.18771.30
   Odegaard KM, 2013, NEUROSURG REV, V36, P57, DOI 10.1007/s10143-012-0410-5
   PENDL G, 1992, ACTA NEUROCHIR, V116, P128, DOI 10.1007/BF01540865
   Pescatori L, 2017, WORLD NEUROSURG, V100, P144, DOI 10.1016/j.wneu.2016.12.120
   Reinges MHT, 2004, ACTA NEUROCHIR, V146, P369, DOI 10.1007/s00701-003-0204-1
   Roberts DW, 1998, NEUROSURGERY, V43, P749, DOI 10.1097/00006123-199810000-00010
   Romano A, 2007, RADIOL MED, V112, P906, DOI 10.1007/s11547-007-0181-1
   Romano A, 2009, EUR RADIOL, V19, P2798, DOI 10.1007/s00330-009-1483-6
   Romano A, 2011, NEUROSURGERY, V69, P696, DOI 10.1227/NEU.0b013e31821a8555
   Schonberg T, 2006, NEUROIMAGE, V30, P1100, DOI 10.1016/j.neuroimage.2005.11.015
   Secer HI, 2008, TURK NEUROSURG, V18, P345
   Sun GC, 2011, NEUROSURGERY, V69, P1070, DOI 10.1227/NEU.0b013e3182274841
   Sunaert S, 2006, J MAGN RESON IMAGING, V23, P887, DOI 10.1002/jmri.20582
   Winkler PA, 2009, MENINGIOMAS DIAGNOSI, P491
   Yasargil MG, 1996, MICRONEUROSURGERY, P56
   Yu CS, 2005, EUR J RADIOL, V56, P197, DOI 10.1016/j.ejrad.2005.04.010
NR 46
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP E296
EP E302
DI 10.1016/j.wneu.2018.12.086
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800038
PM 30599250
DA 2020-05-12
ER

PT J
AU Rotman, LE
   Kicielinski, KP
   Broadwater, DR
   Davis, MC
   Vaughan, TB
   Woodworth, BA
   Riley, KO
AF Rotman, Lauren E.
   Kicielinski, Kimberly P.
   Broadwater, Devin R.
   Davis, Matthew C.
   Vaughan, T. Brooks
   Woodworth, Bradford A.
   Riley, Kristen O.
TI Predictors of Nasoseptal Flap Use After Endoscopic Transsphenoidal
   Pituitary Mass Resection
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cerebrospinal fluid leak; Endoscopic cerebrospinal fluid leak repair;
   Nasoseptal flap; Pituitary adenoma; Sella turcica; Sphenoid sinus
ID CEREBROSPINAL-FLUID LEAKS; SKULL-BASE RECONSTRUCTION; REPAIR; ADENOMAS;
   OUTCOMES; MANAGEMENT; SURGERY; OPTIONS
AB OBJECTIVE: The pedicled nasoseptal flap (NSF) is the widely accepted reconstructive technique of choice for repair of larger skull base defects after endoscopic endonasal approaches. There is a dearth of literature examining the decision-making process regarding flap harvest. The objective of this study is to evaluate preoperative characteristics that predict the use of NSF reconstruction after endoscopic transsphenoidal resection of pituitary tumors.
   METHODS: In this retrospective case control study, demographic, clinical, imaging, and procedural details were gathered on all patients undergoing endoscopic transsphenoidal pituitary adenoma resection at a single academic center since January 2009. Characteristics were compared for patients receiving an NSF and those not undergoing NSF repair. A multivariate model that best predicted the use of an NSF was built and a risk score was developed.
   RESULTS: Two hundred thirty-eight patients were included, and 39 underwent NSF placement. Tumor size and anatomic characteristics were the predominant factors that significantly differed between cases and controls. Patients with transsellar tumor extension had 6.3 higher odds of requiring NSF, each millimeter increase in tumor height on coronal T1 magnetic resonance imaging increased the odds of NSF use by 1.2. The flap risk score (FRS) is calculated by adding tumor height (mm) to 6 if there is transsellar extension. At an FRS of >35, the FRS is 87% specific and 85% sensitive for flap placement.
   CONCLUSIONS: Preoperative imaging characteristics can predict NSF use. The FRS can be applied by surgical teams and referring physicians to determine which patients are more likely to undergo NSF repair.
C1 [Rotman, Lauren E.; Kicielinski, Kimberly P.; Broadwater, Devin R.; Davis, Matthew C.; Riley, Kristen O.] Univ Alabama Birmingham, Dept Neurosurg, Birmingham, AL 35487 USA.
   [Vaughan, T. Brooks] Univ Alabama Birmingham, Dept Endocrinol, Birmingham, AL USA.
   [Woodworth, Bradford A.] Univ Alabama Birmingham, Dept Otolaryngol, Birmingham, AL USA.
RP Rotman, LE (reprint author), Univ Alabama Birmingham, Dept Neurosurg, Birmingham, AL 35487 USA.
EM lerotman@uabmc.edu
CR Banks CA, 2009, OTOLARYNG HEAD NECK, V140, P826, DOI 10.1016/j.otohns.2008.12.060
   Cavallo Luigi M, 2005, Neurosurg Focus, V19, pE2
   Davies BM, 2016, ACTA NEUROCHIR, V158, P677, DOI 10.1007/s00701-015-2699-7
   Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026
   Hadad G, 2006, LARYNGOSCOPE, V116, P1882, DOI 10.1097/01.mlg.0000234933.37779.e4
   Harvey RJ, 2012, LARYNGOSCOPE, V122, P452, DOI 10.1002/lary.22475
   Hegazy HM, 2000, LARYNGOSCOPE, V110, P1166, DOI 10.1097/00005537-200007000-00019
   Hwang YC, 2009, J KOREAN MED SCI, V24, P46, DOI 10.3346/jkms.2009.24.1.46
   Illing E, 2013, INT FORUM ALLERGY RH, V3, P928, DOI 10.1002/alr.21206
   Karnezis TT, 2016, INT FORUM ALLERGY RH, V6, P1117, DOI 10.1002/alr.21783
   Kassam Amin, 2005, Neurosurg Focus, V19, pE8
   Kuan EC, 2018, J NEUROL SURG PART B, V79, P177, DOI 10.1055/s-0037-1606293
   Liu JK, 2012, NEUROSURG FOCUS, V32, DOI 10.3171/2012.5.FOCUS1255
   Liu JF, 2015, J AM GERIATR SOC, V63, P1924, DOI 10.1111/jgs.13590
   Lund V, 2011, RHINOLOGY, P1
   Mooney MA, 2017, J NEUROL SURG PART B, V78, P413, DOI 10.1055/s-0037-1603649
   Nawar Rita N, 2008, J Intensive Care Med, V23, P75, DOI 10.1177/0885066607312992
   Nayak JV, 2018, INT FORUM ALLERGY RH, V8, P1162, DOI 10.1002/alr.22156
   Ostrom QT, 2014, NEURO-ONCOLOGY, V16, P1, DOI 10.1093/neuonc/nou223
   Park J, 2004, SURG NEUROL, V61, P488, DOI 10.1016/S0090-3019(03)00581-0
   Patel MR, 2014, LARYNGOSCOPE, V124, P846, DOI 10.1002/lary.24319
   Patel MR, 2010, SKULL BASE-INTERD AP, V20, P397, DOI 10.1055/s-0030-1253573
   Patel MR, 2010, NEUROSURGERY, V66, P506, DOI 10.1227/01.NEU.0000365620.59677.FF
   Rivera-Serrano CM, 2011, LARYNGOSCOPE, V121, P990, DOI 10.1002/lary.21419
   Schmalisch K, 2012, CLIN ENDOCRINOL, V77, P728, DOI 10.1111/j.1365-2265.2012.04457.x
   Senior BA, 2001, AM J RHINOL, V15, P21, DOI 10.2500/105065801781329356
   Shahangian A, 2017, INT FORUM ALLERGY RH, V7, P80, DOI 10.1002/alr.21845
   Shiley SG, 2003, LARYNGOSCOPE, V113, P1283, DOI 10.1097/00005537-200308000-00003
   SNYDERMAN CH, 1990, LARYNGOSCOPE, V100, P607
   Strickland BA, 2018, J NEUROSURG, V129, P425, DOI 10.3171/2017.4.JNS162451
   Thorp BD, 2014, NEUROSURG FOCUS, V37, DOI 10.3171/2014.7.FOCUS14350
   WIENER SN, 1985, AM J NEURORADIOL, V6, P717
   Zanation AM, 2011, OTOLARYNG CLIN N AM, V44, P1201, DOI 10.1016/j.otc.2011.06.016
   Zhou QY, 2017, WORLD NEUROSURG, V101, P390, DOI 10.1016/j.wneu.2017.01.119
   Zweig JL, 2000, OTOLARYNG HEAD NECK, V123, P195, DOI 10.1067/mhn.2000.107452
NR 35
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP E356
EP E364
DI 10.1016/j.wneu.2018.12.097
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800046
PM 30599246
DA 2020-05-12
ER

PT J
AU Ryu, SM
   Lee, SH
   Kim, ES
   Eoh, W
AF Ryu, Sung Mo
   Lee, Sun-Ho
   Kim, Eun-Sang
   Eoh, Whan
TI Predicting Survival of Patients with Spinal Ependymoma Using Machine
   Learning Algorithms with the SEER Database
SO WORLD NEUROSURGERY
LA English
DT Article
DE Ependymoma; Machine learning; Random forest; Spinal; Spine; Survival
ID ADJUVANT RADIATION-THERAPY; ANDERSON CANCER CENTER; MYXOPAPILLARY
   EPENDYMOMA; EPIDEMIOLOGY; RADIOTHERAPY; OUTCOMES; RESECTION; SURGERY;
   TUMORS; CORD
AB OBJECTIVE: This study was conducted to understand the clinical and demographic factors influencing the overall survival (OS) of patients with spinal ependymoma and to predict the OS with machine learning (ML) algorithms.
   METHODS: We compiled spinal ependymoma cases diagnosed between 1973 and 2014 from the Surveillance, Epidemiology, and End Results (SEER) registry. To identify the factors influencing survival, statistical analyses were performed using the Kaplan-Meier method and Cox proportional hazards regression model. In addition, we implemented ML algorithms to predict the OS of patients with spinal ependymoma.
   RESULTS: In the multivariate analysis model, age >= 65 years, histologic subtype, extraneural metastasis, multiple lesions, surgery, radiation therapy, and gross total resection (GTR) were found to be independent predictors for OS. Our ML model achieved an area under the receiver operating characteristic curve (AUC) of 0.74 (95% confidence interval [CI], 0.72-0.75) for predicting a 5-year OS of spinal ependymoma and an AUC of 0.81 (95% CI, 0.80-0.83) for predicting a 10-year OS. The stepwise logistic regression model showed poorer performance by an AUC of 0.71 (95% CI, 0.70-0.72) for predicting a 5-year OS and an AUC of 0.75 (95% CI, 0.73-0.77) for predicting a 10-year OS.
   CONCLUSIONS: With SEER data, we reaffirmed that therapeutic factors, such as surgery and GTR, were associated with improved OS. Compared with statistical methods, ML techniques showed satisfactory results in predicting OS; however, the dataset was heterogeneous and complex with numerous missing values.
C1 [Ryu, Sung Mo; Lee, Sun-Ho; Kim, Eun-Sang] Sungkyunkwan Univ, Samsung Med Ctr, Dept Neurosurg, Sch Med, Seoul, South Korea.
   [Eoh, Whan] Sungkyunkwan Univ, Sch Med, Samsung Changwon Hosp, Dept Neurosurg, Chang Won, South Korea.
RP Lee, SH (reprint author), Sungkyunkwan Univ, Samsung Med Ctr, Dept Neurosurg, Sch Med, Seoul, South Korea.
EM sunho72.lee@samsung.com
CR Ahmad LG, 2013, J HLTH MED INFORM, V4, P2, DOI DOI 10.4172/2157-7420.1000124
   Akyurek S, 2006, J NEURO-ONCOL, V80, P177, DOI 10.1007/s11060-006-9169-2
   Amirian ES, 2012, NEUROEPIDEMIOLOGY, V39, P116, DOI 10.1159/000339320
   Bates JE, 2016, J NEURO-ONCOL, V129, P251, DOI 10.1007/s11060-016-2167-0
   Benesch M, 2012, CHILD NERV SYST, V28, P2017, DOI 10.1007/s00381-012-1908-4
   Cha UJ, 2017, PRACTICAL ARTIFICIAL
   Chamberlain Marc C, 2003, Curr Neurol Neurosci Rep, V3, P193, DOI 10.1007/s11910-003-0078-x
   Chang UK, 2002, J NEURO-ONCOL, V57, P133
   Chao ST, 2011, J NEUROSURG-SPINE, V14, P59, DOI 10.3171/2010.9.SPINE09920
   Cristianini N., 2000, INTRO SUPPORT VECTOR
   Cruz JA, 2006, CANCER INFORM, V2, P59
   Duong LM, 2012, CANCER-AM CANCER SOC, V118, P4220, DOI 10.1002/cncr.27390
   Gareth J., 2015, INTRO STAT LEARNING
   Gelman A., 2006, DATA ANAL USING REGR, P529, DOI DOI 10.3200/GNTP.168.4.465-469
   Gilbert MR, 2010, CURR NEUROL NEUROSCI, V10, P240, DOI 10.1007/s11910-010-0109-3
   Halvorsen CM, 2010, NEUROSURGERY, V67, P1622, DOI 10.1227/NEU.0b013e3181f96d41
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   HELSETH A, 1989, J NEUROSURG, V71, P842, DOI 10.3171/jns.1989.71.6.0842
   Klekamp J, 2013, J NEUROSURG-SPINE, V19, P12, DOI 10.3171/2013.3.SPINE121063
   Kourou K, 2015, COMPUT STRUCT BIOTEC, V13, P8, DOI 10.1016/j.csbj.2014.11.005
   Kukreja S, 2015, WORLD NEUROSURG, V83, P852, DOI 10.1016/j.wneu.2014.08.006
   Lee SH, 2013, NEURO-ONCOLOGY, V15, P921, DOI 10.1093/neuonc/not038
   Li WT, 2001, GENET EPIDEMIOL, V21, pS272, DOI 10.1002/gepi.2001.21.s1.s272
   Lin YM, 2015, NEUROL RES, V37, P650, DOI 10.1179/1743132815Y.0000000041
   Mandal U, 2008, CHEM PHARM BULL, V56, P150, DOI 10.1248/cpb.56.150
   Nagasawa DT, 2011, NEUROSURG FOCUS, V31, DOI 10.3171/2011.7.FOCUS11158
   Nathoo N, 2011, WORLD NEUROSURG, V76, P531, DOI 10.1016/j.wneu.2011.06.043
   Obermeyer Z, 2016, NEW ENGL J MED, V375, P1216, DOI 10.1056/NEJMp1606181
   Oermann EK, 2013, NEUROSURGERY, V72, P944, DOI 10.1227/NEU.0b013e31828ea04b
   Pica A, 2009, INT J RADIAT ONCOL, V74, P1114, DOI 10.1016/j.ijrobp.2008.09.034
   Reni M, 2007, CRIT REV ONCOL HEMAT, V63, P81, DOI 10.1016/j.critrevonc.2007.03.004
   Ruda R, 2008, CURR OPIN NEUROL, V21, P754, DOI 10.1097/WCO.0b013e328317efe8
   Schmitt P., 2015, J BIOMETRICS BIOSTAT, V6, P224, DOI DOI 10.4172/2155-6180.1000224
   Sgouros S, 1996, BRIT J NEUROSURG, V10, P559, DOI 10.1080/02688699646862
   Tsai CJ, 2014, NEUROSURGERY, V75, P205, DOI 10.1227/NEU.0000000000000408
   Wahab SH, 2007, J NEURO-ONCOL, V83, P85, DOI 10.1007/s11060-006-9310-2
   Weber DC, 2015, NEURO-ONCOLOGY, V17, P588, DOI 10.1093/neuonc/nou293
NR 37
TC 2
Z9 2
U1 1
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP E331
EP E339
DI 10.1016/j.wneu.2018.12.091
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800043
PM 30597279
DA 2020-05-12
ER

PT J
AU Salunke, P
   Singh, A
   Rekhapalli, R
AF Salunke, Pravin
   Singh, Apinderpreet
   Rekhapalli, Rajasekhar
TI Dural Artery from Supraclinoid Internal Carotid Artery to Anterior
   Clinoid Process: Origin, Course, and Clinical Implications
SO WORLD NEUROSURGERY
LA English
DT Article
DE Anterior clinoid process; Dural blood supply; ICA branches; Meningioma;
   Supraclinoid ICA
ID MENINGIOMAS
AB BACKGROUND: Dura of the anterior clinoid process (ACP) is presumably supplied by the ophthalmic and external carotid artery branches. There is a less recognized artery described by Yasargil that arises directly from the supraclinoid internal carotid artery (ICA) and supplies the ACP dura. We studied the origin and course of this direct branch in patients in whom the carotid cistern was dissected for lesions not involving the carotid cistern and ACP dura. The management implications of this arterial twig have been described.
   METHODS: Thirty patients operated through the transsylvian route for suprasellar lesions were included. The arterial branch from the supraclinoid ICA to the clinoidal dura was dissected and studied under high magnification.
   RESULTS: A thin solitary artery could be delineated in 21 patients. In 14 patients, it originated from the dorsomedial surface of the ICA at its bifurcation close to the A1 origin. In the remaining 7, it was seen arising from the dorsomedial surface of the ICA, 2-4 mm proximal to bifurcation. The artery coursed from medial to lateral and pierced the clinoidal dura, 1-3 mm lateral to the entry of the carotid artery. The artery had no branches.
   CONCLUSIONS: The knowledge of this arterial twig to the clinoidal dura is important as this supply may be responsible for feeding the tumor arising from the dura arising from the anterior clinoid, making preoperative embolization impossible. In addition, the tumor may grow along with this vessel and infiltrate the adventitia of the ICA at the origin of this vessel.
C1 [Salunke, Pravin; Singh, Apinderpreet; Rekhapalli, Rajasekhar] PGIMER, Dept Neurosurg, Chandigarh, India.
RP Singh, A (reprint author), PGIMER, Dept Neurosurg, Chandigarh, India.
EM apinderpreetsingh@gmail.com
OI Rekapalli, Rajasekhar/0000-0003-0428-5042
CR Cecchini G, 2015, WORLD NEUROSURG, V84, P1161, DOI 10.1016/j.wneu.2015.06.005
   KOTAPKA MJ, 1994, J NEUROSURG, V81, P252, DOI 10.3171/jns.1994.81.2.0252
   Martins Carolina, 2005, Neurosurgery, V56, P211, DOI 10.1227/01.NEU.0000144823.94402.3D
   McCracken DJ, 2017, NEUROSURGERY, V80, P957, DOI 10.1093/neuros/nyw134
   Perrini P, 2007, J NEUROSURG, V106, P142, DOI 10.3171/jns.2007.106.1.142
   Rim NJ, 2008, KOREAN J RADIOL, V9, pS10, DOI 10.3348/kjr.2008.9.s.s10
   Signorelli F, 2010, ACTA NEUROCHIR, V152, P1807, DOI 10.1007/s00701-010-0716-4
   Terada T, 1996, SURG NEUROL, V45, P161, DOI 10.1016/S0090-3019(96)80010-3
   Yasargil MG, 1984, MICRONEUROSURGERY, P70
NR 9
TC 2
Z9 2
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP E222
EP E225
DI 10.1016/j.wneu.2018.12.071
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800029
PM 30593957
DA 2020-05-12
ER

PT J
AU Salvati, M
   Pesce, A
   Palmieri, M
   Brunetto, GMF
   Santoro, A
   Frati, A
AF Salvati, Maurizio
   Pesce, Alessandro
   Palmieri, Mauro
   Brunetto, Giacoma Maria Floriana
   Santoro, Antonio
   Frati, Alessandro
TI The Role and Real Effect of an Iterative Surgical Approach for the
   Management of Recurrent High-Grade Glioma: An Observational Analytic
   Cohort Study
SO WORLD NEUROSURGERY
LA English
DT Article
DE Extent of resection; Glioma; Overall survival; Progression-free
   survival; Recurrence; Reoperation
ID SAFE RESECTION; SURGERY; SURVIVAL; OUTCOMES; REOPERATION; EXPERIENCES;
   DIAGNOSIS
AB BACKGROUND: The benefits of multiple interventions on the recurrence of high-grade gliomas are renowned. However, the real effect of repeated operations on the survival parameters does not seem to have been assessed. The aim of the present study was to determine whether reoperation for selected patients is safe and feasible.
   METHODS: A total of 78 patients with high-grade glioma had undergone surgery from 2004 to 2014. All the patients had met the following inclusion criteria: American Society of Anesthesiologists score 1-3, Karnofsky performance scale score > 60, and reintervention >= 4 months after the first surgery. The following parameters were evaluated: overall survival (OS) after diagnosis and reintervention, progression-free survival (PFS) after reintervention, number of surgical procedures, and OS of patients who had undergone surgery > 2 times. The results were compared with those of 78 patients with high-grade glioma who had undergone adjuvant chemotherapy.
   RESULTS: OS at 1 year was 100%. At 2 years, OS was 39.4% for those with glioblastoma and 58.3% for those with anaplastic astrocytoma. PFS after 6 months was 53.03% for glioblastoma and 75.0% for anaplastic astrocytoma. Of the 78 patients, 55 had undergone reoperation, with 15 requiring a third intervention and 8 requiring 4. Major complications developed in only 2 patients. Statistical analysis revealed no significant differences in complications or worsening neurological status.
   CONCLUSIONS: These data showed excellent outcomes in terms of OS and PFS and clinical conditions after multiple surgical procedures. Therefore, reintervention appears to be a feasible and safe solution for selected patients.
C1 [Salvati, Maurizio; Frati, Alessandro] Sapienza Univ Rome, Dept Neurosurg, IRCCS, Neuromed, Pozzilli, Italy.
   [Pesce, Alessandro; Palmieri, Mauro] Azienda Osped St Andrea, Rome, Italy.
   [Pesce, Alessandro; Palmieri, Mauro] Sapienza Univ Rome, Dept Neurosci Mental Hlth & Sense Organs, Div Neurosurg, Rome, Italy.
   [Brunetto, Giacoma Maria Floriana; Santoro, Antonio] Sapienza Univ Rome, Dept Human Neurosci, Div Neurosurg, Rome, Italy.
RP Salvati, M (reprint author), Sapienza Univ Rome, Dept Neurosurg, IRCCS, Neuromed, Pozzilli, Italy.
EM salvati.maurizio@libero.it
RI Pesce, Alessandro/AAC-2223-2020; Frati, Alessandro/AAC-2204-2020
OI Palmieri, Mauro/0000-0001-5131-1392
CR BERGER MS, 1989, NEUROSURGERY, V25, P786, DOI 10.1227/00006123-198911000-00015
   Butowski NA, 2006, J CLIN ONCOL, V24, P1273, DOI 10.1200/JCO.2005.04.7522
   Camand E, 2012, J CELL SCI, V125, P844, DOI 10.1242/jcs.087668
   Chang SM, 2003, J NEUROSURG, V98, P1175, DOI 10.3171/jns.2003.98.6.1175
   D'Andrea G, 2016, WORLD NEUROSURG, V87, P627, DOI 10.1016/j.wneu.2015.10.076
   Duffau H, 2007, NEUROPHYSIOL CLIN, V37, P373, DOI 10.1016/j.neucli.2007.09.003
   Frati A, 2019, WORLD NEUROSURG, V121, pE882, DOI 10.1016/j.wneu.2018.10.004
   Frati A, 2018, WORLD NEUROSURG, V114, pE565, DOI 10.1016/j.wneu.2018.03.034
   Hervey-Jumper SL, 2016, J NEURO-ONCOL, V130, P269, DOI 10.1007/s11060-016-2110-4
   Keles GE, 2004, J NEUROSURG, V100, P369, DOI 10.3171/jns.2004.100.3.0369
   Lara-Velazquez M, 2017, BRAIN SCI, V7, DOI 10.3390/brainsci7120166
   Laws ER, 2003, J NEUROSURG, V99, P467, DOI 10.3171/jns.2003.99.3.0467
   Louis DN, 2016, WHO CLASSIFICATION T
   Martinez-Garcia M, 2018, CLIN TRANSL ONCOL, V20, P22, DOI 10.1007/s12094-017-1763-6
   McGirt MJ, 2009, J NEUROSURG, V110, P156, DOI 10.3171/2008.4.17536
   Miceli G, 1994, BATTERIA ANALISI DEF
   Noell S, 2015, CLIN NEUROL NEUROSUR, V136, P41, DOI 10.1016/j.clineuro.2015.05.021
   Park JK, 2010, J CLIN ONCOL, V28, P3838, DOI 10.1200/JCO.2010.30.0582
   Pinsker M, 2001, ZBL NEUROCHIR, V62, P43, DOI 10.1055/s-2002-19477
   Quick J, 2014, J NEURO-ONCOL, V117, P365, DOI 10.1007/s11060-014-1397-2
   Raco A, 2017, WORLD NEUROSURG, V103, P748, DOI 10.1016/j.wneu.2017.04.063
   Ryken TC, 2014, J NEURO-ONCOL, V118, P479, DOI 10.1007/s11060-013-1336-7
   Sanai N, 2011, J NEUROSURG, V115, P3, DOI 10.3171/2011.2.JNS10998
   Southwell DG, 2018, J NEUROSURG, V129, P567, DOI 10.3171/2017.5.JNS17166
   Spena G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080916
   Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330
   Yasargil MG, 1994, MICRONEUROSURGERY IV
   Yong RL, 2014, J NEUROSURG, V121, P802, DOI 10.3171/2014.6.JNS132038
NR 28
TC 3
Z9 3
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP E480
EP E488
DI 10.1016/j.wneu.2018.12.118
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800062
PM 30610982
DA 2020-05-12
ER

PT J
AU Shen, M
   Tang, YF
   Shou, XF
   Wang, M
   Zhang, QL
   Qiao, ND
   Ma, ZY
   Ye, Z
   He, WQ
   Zhang, YC
   Chen, ZY
   Zhang, ZY
   Ye, HY
   Li, YM
   Li, SQ
   Zhao, Y
   Zhou, X
   Wang, YF
AF Shen, Ming
   Tang, Yifan
   Shou, Xuefei
   Wang, Meng
   Zhang, Qilin
   Qiao, Nidan
   Ma, Zengyi
   Ye, Zhao
   He, Wenqiang
   Zhang, Yichao
   Chen, Zhengyuan
   Zhang, Zhaoyun
   Ye, Hongying
   Li, Yiming
   Li, Shiqi
   Zhao, Yao
   Zhou, Xiang
   Wang, Yongfei
TI Surgical Results and Predictors of Initial and Delayed Remission for
   Growth Hormone-Secreting Pituitary Adenomas Using the 2010 Consensus
   Criteria in 162 Patients from a Single Center
SO WORLD NEUROSURGERY
LA English
DT Article
DE Acromegaly; Delayed remission; Initial remission; Pituitary adenoma
ID ENDOSCOPIC TRANSSPHENOIDAL SURGERY; OUTCOMES; RATES; CURE; GUIDELINES;
   EXPERIENCE; INVASION; IMPACT
AB BACKGROUND: The factors associated with initial and delayed remission after growth hormone (GH)-secreting pituitary adenoma excision have not been completely elucidated.
   METHODS: We recruited 185 consecutive patients who had undergone resection of GH-secreting pituitary adenomas from January 2013 to December 2014 and assessed their tumor characteristics and surgical outcomes. The criteria for initial or delayed remission (using the 2010 consensus criteria) were normalized insulin-like growth factor 1 (IGF-1) levels, GH levels <0.4 mu g/L with an oral glucose tolerance test, and/or random GH levels <1.0 mu g/L at or after the postoperative 3-month (PO3M) follow-up, without adjuvant therapy.
   RESULTS: Remission was achieved in 92 of 162 patients (56.8%) after surgery alone and was associated with a lower Knosp grade of 0-2 and lower postoperative day 1 GH level on multivariate regression analysis. A baseline IGF-1 index (IGF-1 level/upper limit of normal) of <2.835 predicted for initial remission at the PO3M follow-up (positive predictive value, 95.3%; negative predictive value, 36.6%; P < 0.001). The PO3M IGF-1 index was significantly lower in the delayed remission group than in the nonremission group. Furthermore, the former had had fewer invasive tumors (1.23 +/- 0.21 vs. 1.77 +/- 0.37 [9.52% vs. 76.47%]; P < 0.001). A PO3M IGF-1 index of <1.485 predicted for delayed remission during subsequent follow-up (positive predictive value, 84.6%; negative predictive value, 92.3%; P < 0.001).
   CONCLUSIONS: A lower Knosp grade of 0-2 and lower postoperative day 1 GH level were independent predictors of surgical remission. The baseline IGF-1 and PO3M IGF-1 indexes might predict for initial and delayed remission, respectively.
C1 [Shen, Ming; Tang, Yifan; Shou, Xuefei; Zhang, Qilin; Qiao, Nidan; Ma, Zengyi; Ye, Zhao; He, Wenqiang; Zhang, Yichao; Chen, Zhengyuan; Li, Shiqi; Zhao, Yao; Zhou, Xiang; Wang, Yongfei] Fudan Univ, Huashan Hosp, Shanghai Med Coll, Dept Neurosurg, Shanghai, Peoples R China.
   [Wang, Meng; Zhang, Zhaoyun; Ye, Hongying; Li, Yiming] Fudan Univ, Huashan Hosp, Shanghai Med Coll, Dept Endocrinol & Metab, Shanghai, Peoples R China.
   [Shen, Ming; Tang, Yifan; Shou, Xuefei; Wang, Meng; Zhang, Qilin; Qiao, Nidan; Ma, Zengyi; Ye, Zhao; He, Wenqiang; Zhang, Yichao; Chen, Zhengyuan; Zhang, Zhaoyun; Ye, Hongying; Li, Yiming; Li, Shiqi; Zhao, Yao; Zhou, Xiang; Wang, Yongfei] Shanghai Pituitary Tumor Ctr, Shanghai, Peoples R China.
RP Wang, YF (reprint author), Fudan Univ, Huashan Hosp, Shanghai Med Coll, Dept Neurosurg, Shanghai, Peoples R China.; Wang, YF (reprint author), Shanghai Pituitary Tumor Ctr, Shanghai, Peoples R China.
EM eamns@hotmail.com
OI Qiao, Nidan/0000-0001-5478-3555
CR Albarel F, 2013, CLIN ENDOCRINOL, V78, P263, DOI 10.1111/j.1365-2265.2012.04492.x
   ALEXANDER L, 1980, CLIN ENDOCRINOL, V12, P71, DOI 10.1111/j.1365-2265.1980.tb03135.x
   ALTMAN DG, 1999, PRACTICAL STAT MED R
   Anik I, 2017, WORLD NEUROSURG, V108, P278, DOI 10.1016/j.wneu.2017.08.182
   Annamalai AK, 2013, J CLIN ENDOCR METAB, V98, P1040, DOI 10.1210/jc.2012-3072
   Arafat AM, 2008, J CLIN ENDOCR METAB, V93, P1254, DOI 10.1210/jc.2007-2084
   Babu H, 2017, NEUROSURGERY, V81, P357, DOI 10.1093/neuros/nyx020
   Berkmann S, 2013, J NEUROSURG, V119, P1447, DOI 10.3171/2013.8.JNS13790
   Briceno V, 2017, NEUROL RES, V39, P387, DOI 10.1080/01616412.2017.1296653
   De P, 2003, J CLIN ENDOCR METAB, V88, P3567, DOI 10.1210/jc.2002-021822
   Dekkers OM, 2008, J CLIN ENDOCR METAB, V93, P61, DOI 10.1210/jc.2007-1191
   Demir O, 2012, TURK NEUROSURG, V22, P645, DOI 10.5137/1019-5149.JTN.6045-12.0
   DICHIRO G, 1962, AMER J ROENTGENOL RA, V87, P989
   Fathalla H, 2015, NEUROSURG REV, V38, P541, DOI 10.1007/s10143-015-0613-7
   Giustina A, 2010, J CLIN ENDOCR METAB, V95, P3141, DOI 10.1210/jc.2009-2670
   Gondim JA, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.7.FOCUS10167
   Haliloglu O, 2016, WORLD NEUROSURG, V88, P270, DOI 10.1016/j.wneu.2015.12.092
   Hardy J, 1976, Adv Neurol, V15, P261
   Hazer DB, 2013, J NEUROSURG, V119, P1467, DOI 10.3171/2013.8.JNS13224
   Hofstetter CP, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.7.FOCUS10173
   Jane JA, 2011, J CLIN ENDOCR METAB, V96, P2732, DOI 10.1210/jc.2011-0554
   Kim MS, 2009, J KOREAN NEUROSURG S, V45, P271, DOI 10.3340/jkns.2009.45.5.271
   Kinoshita Y, 2016, NEUROSURG REV, V39, P313, DOI 10.1007/s10143-015-0692-5
   KNOSP E, 1993, NEUROSURGERY, V33, P610, DOI 10.1227/00006123-199310000-00008
   Ku CR, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000003808
   Li SQ, 2004, CHIN J NEUROSURG DIS, V3, P39
   Melmed S, 2009, J CLIN ENDOCR METAB, V94, P1509, DOI 10.1210/jc.2008-2421
   Netuka D, 2016, WORLD NEUROSURG, V91, P490, DOI [10.1016/J.WNEU.2016.04.094, 10.1016/j.wneu.2016.04.094]
   Nishioka H, 2017, ENDOCR J, V64, P1073, DOI 10.1507/endocrj.EJ17-0261
   Nishioka Hiroshi, 2014, J Neurosurg, V121, P505, DOI 10.3171/2014.3.JNS132214
   Sarkar S, 2014, CLIN NEUROL NEUROSUR, V126, P190, DOI 10.1016/j.clineuro.2014.09.004
   Sarkar S, 2014, ACTA NEUROCHIR, V156, P1379, DOI 10.1007/s00701-014-2098-5
   Sasagawa Y, 2017, PITUITARY, V20, P403, DOI 10.1007/s11102-017-0798-6
   Shin MS, 2013, NEUROSURGERY, V73, P473, DOI 10.1227/01.neu.0000431480.87160.84
   Shirvani M, 2014, WORLD NEUROSURG, V81, P125, DOI 10.1016/j.wneu.2013.01.021
   Shou XF, 2005, NEUROSURGERY, V56, P249, DOI 10.1227/01.neu.0000147976.06937.1D
   Shou XF, 2016, BMC NEUROL, V16, DOI 10.1186/s12883-016-0767-0
   Starke RM, 2013, J CLIN ENDOCR METAB, V98, P3190, DOI 10.1210/jc.2013-1036
   Starnoni D, 2016, ACTA NEUROCHIR, V158, P2109, DOI 10.1007/s00701-016-2903-4
   Sun H, 2014, J NEUROL SURG PART B, V75, P47, DOI 10.1055/s-0033-1354578
   Wang YY, 2012, CLIN ENDOCRINOL, V76, P399, DOI 10.1111/j.1365-2265.2011.04193.x
   WILSON CB, 1984, J NEUROSURG, V61, P814, DOI 10.3171/jns.1984.61.5.0814
   Yano S, 2017, WORLD NEUROSURG, V105, P375, DOI 10.1016/j.wneu.2017.05.162
   Yildirim AE, 2014, TURK NEUROSURG, V24, P906, DOI [10.5137/1019-5149JTN.11288-14.1, 10.5137/1019-5149.JTN.11288-14.1]
NR 44
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP E39
EP E50
DI 10.1016/j.wneu.2018.11.179
PG 12
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800006
PM 30500578
DA 2020-05-12
ER

PT J
AU Shkarubo, AN
   Chernov, IV
   Andreev, DN
AF Shkarubo, Alexey N.
   Chernov, Ilia, V
   Andreev, Dmitriy N.
TI Transoral Removal of Ventrally Located Meningiomas of the
   Craniovertebral Junction
SO WORLD NEUROSURGERY
LA English
DT Article
DE Craniovertebral junction meningiomas; Dura plastic; Transoral approach
ID UPPER CERVICAL-SPINE; CRANIOCERVICAL JUNCTION; INTRADURAL LESIONS;
   BASILAR IMPRESSION; ANTERIOR; MANAGEMENT; SURGERY; STABILIZATION;
   MALFORMATIONS; DECOMPRESSION
AB BACKGROUND: Surgical treatment of ventral pathologic lesions of the craniovertebral junction and upper cervical spine is extremely difficult due to limited accessibility, as well as the difficulty of performing surgical manipulations in a deep, narrow wound in conditions of restricted surgical freedom and angle of attack.
   METHODS: In this article we present 2 clinical cases in which the transoral approach was used to treat ventral meningiomas of the craniovertebral junction. Endoscopic assistance and an original method of anterior atlantooccipital stabilization were used.
   RESULTS: Subtotal removal in the first case and complete removal of the tumor in the second case were achieved. In the first case, an unsuccessful attempt of anterior stabilization was made. In the second case, there were no indications for instrumentation (anterior or posterior) as local bone autograft fusion between the condyles and lateral masses of C1 was effectively carried out.
   CONCLUSIONS: Previously, the transoral approach garnered interest only from a historical point of view, but with technical progress it has acquired a "second life." Novel surgical techniques allow for a more radical resection of named tumors, as well as lower morbidity and invasiveness of the surgical procedures, which, in the long term, leads to lower complication rates.
C1 [Shkarubo, Alexey N.; Chernov, Ilia, V; Andreev, Dmitriy N.] NN Burdenko Natl Sci & Pract Ctr Neurosurg, Dept Neurooncol, Moscow, Russia.
RP Chernov, IV (reprint author), NN Burdenko Natl Sci & Pract Ctr Neurosurg, Dept Neurooncol, Moscow, Russia.
EM ilch@list.ru
OI Cernov, Il'a/0000-0002-9789-3452
CR APUZZO MLJ, 1978, NEUROSURGERY, V3, P201, DOI 10.1227/00006123-197809000-00012
   Balasingam V, 2006, J NEUROSURG, V105, P301, DOI 10.3171/jns.2006.105.2.301
   Choi D, 2013, NEUROSURGERY, V73, P296, DOI 10.1227/01.neu.0000430324.24623.10
   Choi D, 2010, NEUROSURGERY, V66, P59, DOI 10.1227/01.NEU.0000362000.35742.3D
   CROCKARD HA, 1985, J NEUROSURG, V62, P293, DOI 10.3171/jns.1985.62.2.0293
   CROCKARD HA, 1995, BRIT J NEUROSURG, V9, P283, DOI 10.1080/02688699550041304
   CROCKARD HA, 1991, NEUROSURGERY, V28, P88
   DICKMAN CA, 1992, J NEUROSURG, V77, P525, DOI 10.3171/jns.1992.77.4.0525
   DILORENZO N, 1992, ACTA NEUROCHIR, V118, P112, DOI 10.1007/BF01401296
   DILORENZO N, 1989, NEUROSURGERY, V24, P37, DOI 10.1227/00006123-198901000-00006
   DILORENZO N, 1982, J NEUROSURG, V57, P603, DOI 10.3171/jns.1982.57.5.0603
   Eicker SO, 2013, NEUROSURG REV, V36, P487, DOI 10.1007/s10143-013-0457-y
   Eicker SO, 2015, NEUROSURG FOCUS, V38, DOI 10.3171/2015.2.FOCUS14799
   Fong S, 2005, J SPINAL DISORD TECH, V18, P321, DOI 10.1097/01.bsd.0000169062.77005.78
   George B, 1997, SURG NEUROL, V47, P371, DOI 10.1016/S0090-3019(96)00204-2
   Goel A, 1998, J NEUROSURG, V88, P962, DOI 10.3171/jns.1998.88.6.0962
   HADLEY MN, 1989, J NEUROSURG, V71, P16, DOI 10.3171/jns.1989.71.1.0016
   HARKEY HL, 1990, NEUROSURGERY, V27, P782
   HARRIS JP, 1989, LARYNGOSCOPE, V99, P467
   Ikuma Hisanori, 2012, Eur Spine J, V21 Suppl 4, pS509, DOI 10.1007/s00586-011-2138-2
   JAMES D, 1991, NEUROSURGERY, V29, P411, DOI 10.1227/00006123-199109000-00012
   Mei-Hua L, 2013, TURK NEUROSURG, V23, P202, DOI 10.5137/1019-5149.JTN.6744-12.1
   MENEZES AH, 1988, J NEUROSURG, V69, P895, DOI 10.3171/jns.1988.69.6.0895
   MENEZES AH, 1980, J NEUROSURG, V53, P444, DOI 10.3171/jns.1980.53.4.0444
   PASZTOR E, 1984, J NEUROSURG, V60, P276, DOI 10.3171/jns.1984.60.2.0276
   Perrini P, 2014, ACTA NEUROCHIR, V156, P1231, DOI 10.1007/s00701-014-2057-1
   Perrini P, 2009, NEUROSURGERY, V64, P331, DOI 10.1227/01.NEU.0000334430.25626.DC
   SEN CN, 1991, ACTA NEUROCHIR, V108, P70, DOI 10.1007/BF01407670
   Shkarubo AN, 2018, WORLD NEUROSURG, V109, pE155, DOI 10.1016/j.wneu.2017.09.124
   Shkarubo AN, 2017, WORLD NEUROSURG, V102, P181, DOI 10.1016/j.wneu.2017.02.113
   Shkarubo AN, 2017, WORLD NEUROSURG, V99, P47, DOI 10.1016/j.wneu.2016.11.147
   Zozulya Yuri P, 2011, Asian J Neurosurg, V6, P18, DOI 10.4103/1793-5482.85629
NR 32
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP E387
EP E394
DI 10.1016/j.wneu.2018.12.103
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800050
PM 30605758
DA 2020-05-12
ER

PT J
AU Silva, NA
   Taylor, BES
   Herendeen, JS
   Reddy, R
   Eloy, JA
   Liu, JK
AF Silva, Nicole A.
   Taylor, Blake E. S.
   Herendeen, John S.
   Reddy, Renuka
   Eloy, Jean Anderson
   Liu, James K.
TI Return to the Emergency Room with or without Readmission After
   Endoscopic Transsphenoidal Surgery in Socioeconomically Disadvantaged
   Patients at an Urban Medical Center
SO WORLD NEUROSURGERY
LA English
DT Article
DE Emergency room; Endoscopic transsphenoidal surgery; Hyponatremia;
   Medicaid; Postoperative; Readmission; Socioeconomic status
ID 30-DAY UNPLANNED READMISSION; DELAYED HYPONATREMIA; RISK-FACTORS; CARE;
   IMPLEMENTATION; DISPARITIES; PREVALENCE; MANAGEMENT; PREDICTORS; RATES
AB BACKGROUND: Although reducing 30-day hospital readmissions is now a priority in neurosurgical quality improvement, postoperative emergency room (ER) visits have remained poorly understood, in particular, in populations with limited access to outpatient care. After endoscopic transsphenoidal surgery, the unique pathologic entities treated can engender a variety of surgical and metabolic complications-often dangerous, delayed, and nonspecific in presentation. We sought to characterize the causes and timing of ER visits-with or without readmission-in a socioeconomically disadvantaged population.
   METHODS: We reviewed all the patients undergoing ETS by our skull base team from 2009 to 2017 to determine their socioeconomic profile and causes of ER visits. For external validation, we compared our results with national data from the American College of Surgeons National Surgical Quality Improvement Program.
   RESULTS: Of the 229 patients, 35 (15.3%) had visited the ER within 30 days of discharge. Of these 229 patients, 21 (9.2%) were readmitted, and 109 (47.6%) were insured by Medicaid. The most common reasons for the ER visits were headache (8 of 35 [22.9%]), hyponatremia (7 of 35 [20.0%]), and epistaxis (5 of 35 [14.3%]). The most common cause for readmission was symptomatic hyponatremia (6 of 21 [28.6%]). The other reasons for readmission included meningitis (2 of 21 [9.5%]), adrenal crisis (2 of 21 [9.5%]), and cerebrospinal fluid leakage (1 of 21 [4.8%]). The average time to readmission was 10.9 days. According to the National Surgical Quality Improvement Program database, the 30-day readmission rate was 5.5%, of which 22.2% were for hyponatremia.
   CONCLUSION: Delayed hyponatremia accounts for a large proportion of ER visits and unplanned readmissions. Close follow-up with diligent, multidisciplinary care might reduce the number of ER visits and readmission in this population.
C1 [Silva, Nicole A.; Taylor, Blake E. S.; Herendeen, John S.; Reddy, Renuka; Eloy, Jean Anderson; Liu, James K.] Neurol Inst New Jersey, Dept Neurol Surg, Newark, NJ 07103 USA.
   [Eloy, Jean Anderson; Liu, James K.] Neurol Inst New Jersey, Ctr Skull Base & Pituitary Surg, Newark, NJ 07103 USA.
   [Eloy, Jean Anderson; Liu, James K.] Rutgers New Jersey Med Sch, Dept Otolaryngol Head & Neck Surg, Newark, NJ 07103 USA.
   [Eloy, Jean Anderson] Rutgers New Jersey Med Sch, Dept Ophthalmol & Visual Sci, Newark, NJ USA.
RP Liu, JK (reprint author), Neurol Inst New Jersey, Dept Neurol Surg, Newark, NJ 07103 USA.; Liu, JK (reprint author), Neurol Inst New Jersey, Ctr Skull Base & Pituitary Surg, Newark, NJ 07103 USA.; Liu, JK (reprint author), Rutgers New Jersey Med Sch, Dept Otolaryngol Head & Neck Surg, Newark, NJ 07103 USA.
EM james.liu.md@rutgers.edu
CR Ammirati M, 2013, J NEUROL NEUROSUR PS, V84, P843, DOI 10.1136/jnnp-2012-303194
   Basu J, 2018, INQUIRY-J HEALTH CAR, V55, DOI 10.1177/0046958018774180
   Bohl MA, 2018, NEUROSURGERY, V82, P110, DOI 10.1093/neuros/nyx151
   Bohl MA, 2016, NEUROSURGERY, V78, P84, DOI 10.1227/NEU.0000000000001003
   Bur AM, 2016, OTOLARYNG HEAD NECK, V155, P688, DOI 10.1177/0194599816652379
   Carminucci AS, 2016, ENDOCR PRACT, V22, P36, DOI 10.4158/EP15894.OR
   Cote DJ, 2017, J AM COLL SURGEONS, V224, P971, DOI 10.1016/j.jamcollsurg.2017.02.015
   Cote DJ, 2016, WORLD NEUROSURG, V88, P1, DOI 10.1016/j.wneu.2016.01.022
   Goljo E, 2016, LARYNGOSCOPE, V126, P808, DOI 10.1002/lary.25771
   Graboyes EM, 2017, LARYNGOSCOPE, V127, P337, DOI 10.1002/lary.25997
   Hendricks BL, 2016, OTOLARYNG HEAD NECK, V154, P359, DOI 10.1177/0194599815617130
   Hensen J, 1999, CLIN ENDOCRINOL, V50, P431, DOI 10.1046/j.1365-2265.1999.00666.x
   Ingraham Angela M, 2010, Adv Surg, V44, P251
   Jahangiri A, 2013, J NEUROSURG, V119, P1478, DOI 10.3171/2013.7.JNS13273
   Kalanithi PSA, 2014, NEUROMODULATION, V17, P60, DOI 10.1111/ner.12051
   MacKinney T, 2013, J PRIM CARE COMMUNIT, V4, P135, DOI 10.1177/2150131913478981
   McKee S, 2018, INT FORUM ALLERGY RH, V8, P1145, DOI 10.1002/alr.22148
   McLaughlin N, 2014, NEUROSURG FOCUS, V37, DOI 10.3171/2014.8.FOCUS14445
   Mukherjee D, 2013, J CLIN NEUROSCI, V20, P57, DOI 10.1016/j.jocn.2012.05.014
   Purger DA, 2018, NEUROSURGERY, V82, P454, DOI 10.1093/neuros/nyx215
   Rolston JD, 2016, PITUITARY, V19, P248, DOI 10.1007/s11102-015-0685-y
   Su AW, 2016, SPINE, V41, P1523, DOI 10.1097/BRS.0000000000001558
   Taylor BES, 2016, NEUROSURGERY, V79, P356, DOI 10.1227/NEU.0000000000001110
   Thomas JG, 2014, WORLD NEUROSURG, V81, P576, DOI 10.1016/j.wneu.2013.11.014
   Thompson CF, 2012, ORL J OTO-RHINO-LARY, V74, P315, DOI 10.1159/000345500
NR 25
TC 2
Z9 2
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP E131
EP E138
DI 10.1016/j.wneu.2018.12.039
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800017
PM 30579010
DA 2020-05-12
ER

PT J
AU Son, SM
   Choi, SH
   Goh, TS
   Park, W
   Lee, JS
AF Son, Seung Min
   Choi, Sung Hoon
   Goh, Tae Sik
   Park, Wonseok
   Lee, Jung Sub
TI Efficacy and Safety of Direct Vertebral Rotation in the Surgical
   Correction of Scoliosis: A Meta-Analysis
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cobb angle; Direct vertebral rotation; Meta-analysis; Scoliosis
ID ADOLESCENT IDIOPATHIC SCOLIOSIS; PEDICLE SCREW FIXATION; DEROTATION;
   SURGERY; THORACOPLASTY; OUTCOMES; CURVE; HOOK
AB OBJECTIVE: To compare outcomes of scoliosis correction with direct vertebral rotation (DVR) and without DVR (no direct vertebral rotation [N-DVR]) through meta-analysis.
   METHODS: MEDLINE and Embase databases were searched from the earliest available date of indexing through April 10, 2018, for studies evaluating outcomes of DVR and N-DVR in scoliosis. Two researchers performed the data extraction independently. Any discrepancies were resolved by a consensus.
   RESULTS: Seven comparative studies were identified. There were no significant differences between DVR and N-DVR for apical vertebral translation, thoracic kyphosis, lumbar lordosis, coronal balance, sagittal balance, complication rate, and preoperative major Cobb angles. DVR was more effective than N-DVR for correction of thoracic Cobb angle (P = 0.02, weighted mean difference = -3.46 degrees [95% confidence interval, -5.57 degrees, -1.35 degrees]), lumbar Cobb angle (P < 0.0001, weighted mean difference = -4.37 degrees [95% confidence interval, -6.31 degrees, -2.42 degrees]), and apical vertebral rotation (P < 0.0001, weighted mean difference = -3.28 degrees [95% confidence interval, -4.85 degrees, -1.72 degrees]).
   CONCLUSIONS: This meta-analysis showed that postoperative thoracic Cobb angle, postoperative lumbar Cobb angle, and postoperative apical vertebral rotation were better with DVR compared with N-DVR. Further large multicenter studies will be necessary to substantiate these results.
C1 [Son, Seung Min; Choi, Sung Hoon] Pusan Natl Univ, Dept Orthopaed Surg, Biomed Res Inst, Yangsan Hosp, Yangsan, South Korea.
   [Goh, Tae Sik; Park, Wonseok; Lee, Jung Sub] Pusan Natl Univ Hosp, Biomed Res Inst, Dept Orthopaed Surg, Busan, South Korea.
RP Lee, JS (reprint author), Pusan Natl Univ Hosp, Biomed Res Inst, Dept Orthopaed Surg, Busan, South Korea.
EM jungsublee@pusan.ac.kr
FU Basic Science Research Program through a National Research Foundation of
   Korea - Government of Korea Ministry of Science and ICT and Future
   Planning [2018R1A2B6007351]
FX This research was supported by the Basic Science Research Program
   through a National Research Foundation of Korea grant funded by the
   Government of Korea Ministry of Science and ICT and Future Planning
   (Grant No. 2018R1A2B6007351).
CR Abul-Kasim K, 2011, SCOLIOSIS SPINAL DIS, V6, DOI 10.1186/1748-7161-6-13
   Asghar J, 2009, SPINE, V34, P804, DOI 10.1097/BRS.0b013e3181996c1b
   Badve SA, 2015, SPINE J, V15, P1034, DOI 10.1016/j.spinee.2014.12.002
   Chang DG, 2014, SPINE, V39, pE1359, DOI 10.1097/BRS.0000000000000578
   Clements DH, 2009, SPINE, V34, P2147, DOI 10.1097/BRS.0b013e3181adb35d
   D'Andrea LP, 2000, SPINE, V25, P1795, DOI 10.1097/00007632-200007150-00010
   Deeks JJ, 2005, J CLIN EPIDEMIOL, V58, P882, DOI 10.1016/j.jclinepi.2005.01.016
   Di Silvestre M, 2013, EUR SPINE J, V22, P313, DOI 10.1007/s00586-012-2372-2
   Egger M, 2002, INT J EPIDEMIOL, V31, P1, DOI 10.1093/ije/31.1.1
   Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P1283, DOI 10.1016/j.jclinepi.2011.01.012
   Helgeson MD, 2010, SPINE, V35, P177, DOI 10.1097/BRS.0b013e3181c77f8c
   Hicks JM, 2010, SPINE, V35, pE465, DOI 10.1097/BRS.0b013e3181d1021a
   Huang ZF, 2016, CLIN SPINE SURG, V29, pE157, DOI 10.1097/BSD.0000000000000123
   Kadoury S, 2009, EUR SPINE J, V18, P23, DOI 10.1007/s00586-008-0817-4
   Kim SS, 2017, ASIAN SPINE J, V11, P127, DOI 10.4184/asj.2017.11.1.127
   Lee SM, 2004, SPINE, V29, P343, DOI 10.1097/01.BRS.0000109991.88149.19
   Mattila M, 2013, SPINE, V38, P1576, DOI 10.1097/BRS.0b013e31829a6d37
   Mladenov KV, 2011, EUR SPINE J, V20, P1114, DOI 10.1007/s00586-011-1740-7
   Pankowski R, 2016, SPINE, V41, P864, DOI 10.1097/BRS.0000000000001363
   Rushton PRP, 2014, EUR SPINE J, V23, P1166, DOI 10.1007/s00586-014-3242-x
   Samdani AF, 2012, SPINE, V37, pE849, DOI 10.1097/BRS.0b013e31824a4911
   Seki S, 2016, SPINE J, V16, P365, DOI 10.1016/j.spinee.2015.11.032
   Suk SI, 2008, SPINE, V33, P1061, DOI 10.1097/BRS.0b013e31816f2888
   Sun L, 2013, BMC MUSCULOSKEL DIS, V14, DOI 10.1186/1471-2474-14-175
   THOMPSON SG, 1994, BMJ-BRIT MED J, V309, P1351, DOI 10.1136/bmj.309.6965.1351
   Urbanski W, 2017, ARCH ORTHOP TRAUM SU, V137, P879, DOI 10.1007/s00402-017-2700-4
   Watanabe K, 2012, BMC MUSCULOSKEL DIS, V13, DOI 10.1186/1471-2474-13-99
NR 27
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP E641
EP E648
DI 10.1016/j.wneu.2018.12.170
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800082
PM 30639493
DA 2020-05-12
ER

PT J
AU Su, K
   Luan, JY
   Wang, QD
   Yang, Y
   Mei, W
   Zhang, ZM
AF Su, Kai
   Luan, Jiyao
   Wang, Qingde
   Yang, Yong
   Mei, Wei
   Zhang, Zhongmin
TI Radiographic Analysis of Minimally Invasive Transforaminal Lumbar
   Interbody Fusion versus Conventional Open Surgery on Sagittal
   Lumbar-Pelvic Alignment for Degenerative Spondylolisthesis
SO WORLD NEUROSURGERY
LA English
DT Article
DE Comparison; Degenerative spondylolisthesis; Minimally invasive; Open;
   Sagittal lumbar-pelvic alignment; Sagittal parameters
ID SPINOPELVIC ALIGNMENT; IN-SITU; BALANCE; SPINE; INSTRUMENTATION;
   ANTERIOR
AB OBJECTIVE: To compare the impact of minimally invasive transforaminal lumbar interbody fusion (MIS-TLIF) with open posterior lumbar interbody fusion (PLIF) on sagittal lumbar-pelvic radiographic parameters for degenerative spondylolisthesis (DS).
   METHODS: Of 48 patients with L4 single segmental DS, 25 underwent MIS-TLIF with Quadrant system and 23 underwent conventional open PLIF. Comparisons of data from the preoperative and final follow-up standing lateral lumbar x-rays, with the bilateral femoral heads, of the 2 groups were conducted using the following parameters: slip percentage (SP), lumbar lordosis (LL), pelvic incidence, pelvic tilt (PT), sacral slope, lumbosacral angle, slip angle (SA), and the L1 axis and S1 distance (LASD).
   RESULTS: The slip reduction rate (Delta SP) in the OPEN group was significantly higher than in the MIS group (67 +/- 34% vs. 37 +/- 51%, P = 0.018). The change of SA (Delta SA) in the OPEN group was significantly higher than in the MIS group (3 +/- 7 degrees vs. -3 +/- 5 degrees, P = 0.003). The change of LASD (Delta LASD) in the OPEN group was significantly lower than in the MIS group (-4 +/- 15 mm vs. 4 +/- 9 mm, P = 0.033). There were positive correlations between the preoperative SP and LASD, and Delta SA and the change of LL (Delta LL), and a negative correlation between DLL and the change of PT (Delta PT).
   CONCLUSIONS: For low-grade DS, open PLIF has a higher rate of slip reduction compared to MIS-TLIF, and significantly reduces LASD, therefore, it is more conducive to improving lumbar sagittal balance.
C1 [Su, Kai; Wang, Qingde; Yang, Yong; Mei, Wei] Zhengzhou Orthoped Hosp, Dept Spine Surg, Zhengzhou, Henan, Peoples R China.
   [Luan, Jiyao] Henan Univ Chinese Med, Grad Sch, Zhengzhou, Henan, Peoples R China.
   [Zhang, Zhongmin] Southern Med Univ, Affiliated Hosp 3, Dept Spine Surg, Guangzhou, Guangdong, Peoples R China.
RP Mei, W (reprint author), Zhengzhou Orthoped Hosp, Dept Spine Surg, Zhengzhou, Henan, Peoples R China.
EM 465993014@qq.com
CR Barrey C, 2007, NEUROSURGERY, V61, P981, DOI 10.1227/01.neu.0000303194.02921.30
   BRADFORD DS, 1987, J BONE JOINT SURG AM, V69A, P191, DOI 10.2106/00004623-198769020-00005
   Chaleat-Valayer Emmanuelle, 2011, Eur Spine J, V20 Suppl 5, P634, DOI 10.1007/s00586-011-1931-2
   GELB DE, 1995, SPINE, V20, P1351, DOI 10.1097/00007632-199506000-00005
   Godde S, 2003, SPINE, V28, P1693, DOI 10.1097/00007632-200308010-00012
   Hresko MT, 2007, SPINE, V32, P2208, DOI 10.1097/BRS.0b013e31814b2cee
   Hresko MT, 2009, J PEDIATR ORTHOPED, V29, P157, DOI 10.1097/BPO.0b013e3181977de8
   JACKSON RP, 1994, SPINE, V19, P1611, DOI 10.1097/00007632-199407001-00010
   Kawakami M, 2002, SPINE, V27, P59, DOI 10.1097/00007632-200201010-00014
   Kepler Christopher K, 2012, Orthop Surg, V4, P15, DOI 10.1111/j.1757-7861.2011.00165.x
   Kim JS, 2009, J KOREAN NEUROSURG S, V45, P74, DOI 10.3340/jkns.2009.45.2.74
   Kim KH, 2010, SPINE, V35, P625, DOI 10.1097/BRS.0b013e3181bb8168
   Kong LD, 2016, CLIN SPINE SURG, V29, pE87, DOI 10.1097/BSD.0000000000000104
   Kumar MN, 2001, EUR SPINE J, V10, P314, DOI 10.1007/s005860000239
   Labelle H, 2008, EUR SPINE J, V17, P1170, DOI 10.1007/s00586-008-0713-y
   Lafage V, 2009, SPINE, V34, pE599, DOI 10.1097/BRS.0b013e3181aad219
   Lamberg T, 2007, J BONE JOINT SURG AM, V89A, P512, DOI 10.2106/JBJS.E.00545
   Le Huec JC, 2015, INT ORTHOP, V39, P87, DOI 10.1007/s00264-014-2516-6
   Legaye J, 1998, Eur Spine J, V7, P99, DOI 10.1007/s005860050038
   Lim JK, 2013, J KOREAN NEUROSURG S, V53, P96, DOI 10.3340/jkns.2013.53.2.96
   Liu H, 2015, EUR SPINE J, V24, P1204, DOI 10.1007/s00586-014-3395-7
   Muschik M, 1997, SPINE, V22, P2036, DOI 10.1097/00007632-199709010-00020
   Parker SL, 2014, WORLD NEUROSURG, V82, P230, DOI 10.1016/j.wneu.2013.01.041
   Roussouly P, 2006, SPINE, V31, P2484, DOI 10.1097/01.brs.0000239155.37261.69
   Thiong JMM, 2004, SPINE, V29, P1642, DOI 10.1097/01.BRS.0000132312.78469.7B
   Tokuhashi Y, 2008, SPINE, V33, P786, DOI 10.1097/BRS.0b013e31816956f7
   Vialle R, 2005, J BONE JOINT SURG AM, V87A, P260, DOI 10.2106/JBJS.D.02043
   Watkins RG, 2014, J SPINAL DISORD TECH, V27, P253, DOI 10.1097/BSD.0b013e31828a8447
NR 28
TC 1
Z9 1
U1 1
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP E733
EP E739
DI 10.1016/j.wneu.2019.01.011
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800094
PM 30660874
DA 2020-05-12
ER

PT J
AU Sun, SB
   Liu, A
   Zhang, Y
AF Sun, Shibin
   Liu, Ali
   Zhang, YaZhuo
TI Long-Term Follow-Up Studies of Gamma Knife Radiosurgery for Postsurgical
   Nonfunctioning Pituitary Adenomas
SO WORLD NEUROSURGERY
LA English
DT Article
DE Gamma Knife radiosurgery; Long-term follow-up; Multimodality imaging
   confusion; Nonfunctioning pituitary adenoma
ID TRANSSPHENOIDAL RESECTION; STEREOTACTIC RADIOSURGERY; MACROADENOMAS;
   RADIOTHERAPY; SURGERY; OUTCOMES
AB OBJECTIVE: The aim of this study was to evaluate the long-term clinical outcomes of Gamma Knife radiosurgery (GKRS) for residual and recurrent nonfunctioning pituitary adenomas (NFPAs) after surgery and the role of GKRS in the management of NFPAs.
   METHODS: Between January 2000 and December 2010, 204 patients with residual or recurrent NFPAs undergoing GKRS were enrolled in this study according to the inclusion criteria. The median age of the patients was 48 years (mean, 48 years; range, 14-79 years). The median tumor volume was 3.3 mL (mean, 5.2 mL; range, 0.3-26.4 mL). The median margin dose was 14 Gy (mean, 14 Gy; range, 9-18 Gy). The median maximum dose was 31 Gy (mean, 30 Gy; 20-40 Gy). The median duration of follow-up was 86 months (mean, 88 months; range, 12-213 months).
   RESULTS: Of these 204 patients, the latest follow-up magnetic resonance imaging studies showed tumor regression in 102 patients (50%), tumor stability in 81 patients (40%), and tumor enlargement in 21 patients (10%). The tumor control rate of this cohort was 90%. The cumulative progression-free survival at 3, 5, 8, 10, and 15 years was 97%, 95%, 92%, 92%, and 81%, respectively. Thirty-seven patients (18%) developed new-onset hypopituitarism, with 1 patient experiencing panhypopituitarism. Five patients (2.5%) presented with new or worsening visual dysfunction without tumor growth. No new cranial nerve dysfunction was shown and no second brain tumor was identified.
   CONCLUSIONS: GKRS provided high tumor control and a low complication rate in our long-term follow-up. We recommend that early GKRS should be considered the routine adjuvant treatment for residual NFPAs approximately 6 months after subtotal surgical resection.
C1 [Sun, Shibin; Liu, Ali] Capital Med Univ, Beijing Neurosurg Inst, Beijing Tiantan Hosp, Gamma Knife Ctr, Beijing, Peoples R China.
   [Zhang, YaZhuo] Capital Med Univ, Beijing Neurosurg Inst, Beijing Tiantan Hosp,Key Lab Cent Nervous Syst In, Beijing Inst Brain Disorders,Brain Tumor Ctr,Chin, Beijing, Peoples R China.
RP Zhang, Y (reprint author), Capital Med Univ, Beijing Neurosurg Inst, Beijing Tiantan Hosp,Key Lab Cent Nervous Syst In, Beijing Inst Brain Disorders,Brain Tumor Ctr,Chin, Beijing, Peoples R China.
EM 13901303474@163.com
FU National Science Foundation of ChinaNational Natural Science Foundation
   of China [81771489]; Beijing Municipal Science and Technology
   CommissionBeijing Municipal Science & Technology Commission
   [Z171100000117002]
FX This study was supported by the National Science Foundation of China
   (81771489) and supported by Beijing Municipal Science and Technology
   Commission (Z171100000117002).
CR Bir SC, 2015, J NEUROL SURG PART B, V76, P351, DOI 10.1055/s-0035-1549309
   Breen P, 1998, J NEUROSURG, V89, P933, DOI 10.3171/jns.1998.89.6.0933
   Chen Y, 2012, NEUROENDOCRINOLOGY, V96, P333, DOI 10.1159/000339823
   Cohen-Inbar O, 2017, J NEURO-ONCOL, V135, P67, DOI 10.1007/s11060-017-2520-y
   ELLIS F, 1949, P ROY SOC MED, V42, P853, DOI 10.1177/003591574904201018
   Feigl GC, 2002, J NEUROSURG, V97, P415, DOI 10.3171/jns.2002.97.supplement_5.0415
   Gittoes NJL, 1998, CLIN ENDOCRINOL, V48, P331
   Gopalan R, 2011, NEUROSURGERY, V69, P284, DOI 10.1227/NEU.0b013e31821bc44e
   Hasegawa T, 2015, WORLD NEUROSURG, V83, P1173, DOI 10.1016/j.wneu.2015.01.054
   Iwata H, 2011, NEURO-ONCOLOGY, V13, P916, DOI 10.1093/neuonc/nor055
   Lee CC, 2014, J NEUROSURG, V120, P647, DOI 10.3171/2013.11.JNS131757
   LEKSELL L, 1983, J NEUROL NEUROSUR PS, V46, P797, DOI 10.1136/jnnp.46.9.797
   Levy MJ, 2018, CLIN ENDOCRINOL, V89, P354, DOI 10.1111/cen.13791
   Li ZY, 2015, PITUITARY, V18, P42, DOI 10.1007/s11102-014-0554-0
   Losa M, 2004, J NEUROSURG, V100, P438, DOI 10.3171/jns.2004.100.3.0438
   Mingione V, 2006, J NEUROSURG, V104, P876, DOI 10.3171/jns.2006.104.6.876
   Minniti G, 2018, PITUITARY, V21, P154, DOI 10.1007/s11102-018-0868-4
   Park KJ, 2011, NEUROSURGERY, V69, P1188, DOI 10.1227/NEU.0b013e318222afed
   Pollock BE, 2008, INT J RADIAT ONCOL, V70, P1325, DOI 10.1016/j.ijrobp.2007.08.018
   Pomeraniec IJ, 2016, J NEUROSURG, V125, P202, DOI 10.3171/2015.5.JNS15581
   Przybylowski CJ, 2017, J NEUROSURG, V126, P889, DOI [10.3171/2016.3.JNS152735, 10.3171/2016.11.JNS16976]
   Runge MJR, 2012, STRAHLENTHER ONKOL, V188, P319, DOI 10.1007/s00066-011-0052-5
   Sadik ZHA, 2017, WORLD NEUROSURG, V100, P361, DOI 10.1016/j.wneu.2017.01.028
   Sheehan JP, 2013, J NEUROSURG, V119, P446, DOI 10.3171/2013.3.JNS12766
   Sheehan JP, 2002, J NEUROSURG, V97, P408, DOI 10.3171/jns.2002.97.supplement_5.0408
   Starke RM, 2012, J NEUROSURG, V117, P129, DOI 10.3171/2012.4.JNS112250
   Syro LV, 2018, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00318
   Tomsic KZ, 2017, ENDOCR RES, V7, P1
   TSANG RW, 1994, INT J RADIAT ONCOL, V30, P557, DOI 10.1016/0360-3016(92)90941-A
   Wowra B, 2002, J NEUROSURG, V97, P429, DOI 10.3171/jns.2002.97.supplement_5.0429
   Xu ZY, 2014, INT J RADIAT ONCOL, V90, P903, DOI 10.1016/j.ijrobp.2014.07.013
   Zhang YH, 2008, NEUROL RES, V30, P581, DOI 10.1179/174313208X298110
   Zhao XB, 2014, CLIN NUCL MED, V39, P605, DOI 10.1097/RLU.0000000000000457
NR 33
TC 1
Z9 1
U1 1
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP E715
EP E723
DI 10.1016/j.wneu.2019.01.009
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800092
PM 30660894
DA 2020-05-12
ER

PT J
AU Tawfik-Helika, M
   Mertens, P
   Ribas, G
   Cusimano, MD
   Catala, M
   Kirollos, R
   Jacquesson, T
AF Tawfik-Helika, Mamdouh
   Mertens, Patrick
   Ribas, Guilherme
   Cusimano, Michael D.
   Catala, Martin
   Kirollos, Ramez
   Jacquesson, Timothee
TI Understanding Anatomy of the Petrous Pyramid-A New Compartmental
   Approach
SO WORLD NEUROSURGERY
LA English
DT Article
DE Anatomy; Middle ear; Petrous; Pyramid; Segmentation; Space; Temporal
   bone
ID TEMPORAL BONE PNEUMATIZATION; AIR CELLS
AB BACKGROUND: Learning surgical anatomy of the petrous pyramid can be a challenge, especially in the beginning of the training process. Providing an easier, holistic approach can be of help to everyone with interest in learning and teaching skull base anatomy. We present the complex organization of petrous pyramid anatomy using a new compartmental approach that is simple to understand and remember.
   METHODS: The surfaces of the petrous pyramid of two temporal bones were examined; and the contents of the petrous pyramid of 8 temporal bones were exposed through progressive drilling of the superior surface.
   RESULTS: The petrous pyramid is made up of a bony container, and its contents were grouped into 4 compartments (mucosal, cutaneous, neural, and vascular). Two reference lines were identified (mucosal and external-internal auditory canal lines) intersecting at the level of the middle ear. The localization of contents relative to these reference lines was then described, and 2 methods of segmentation (the X method and the V method) were then proposed. This description was then used to describe middle ear relationships, facial nerve anatomy, and air cell distribution.
   CONCLUSIONS: This new compartmental approach allows a comprehensive understanding of the distribution of petrous pyramid contents. Dividing it into anatomic compartments, and then navigating this mental map along specific reference points, lines, spaces, and segments, could create a useful tool to teach or learn its complex tridimensional anatomy.
C1 [Tawfik-Helika, Mamdouh] Beaujon Univ Hosp, AP HP, Dept Neurosurg, Clichy, France.
   [Mertens, Patrick; Jacquesson, Timothee] Univ Lyon 1, Dept Anat, Lyon, France.
   [Ribas, Guilherme] Univ Sao Paulo, Dept Surg, Med Sch, Sao Paulo, Brazil.
   [Cusimano, Michael D.] Univ Toronto, St Michaels Hosp, Div Neurosurg, Toronto, ON, Canada.
   [Catala, Martin] Sorbonne Univ, IBPS, CNRS UMR 7622, INSERM ERL 1156, Paris, France.
   [Kirollos, Ramez] Natl Neurosci Inst, Singapore, Singapore.
   [Jacquesson, Timothee] Hosp Civils Lyon, Neurol Hosp Pierre Wertheimer, Skull Base Multidisciplinary Unit, Dept Neurosurg B, Lyon, France.
RP Tawfik-Helika, M (reprint author), Beaujon Univ Hosp, AP HP, Dept Neurosurg, Clichy, France.
EM drmamdoh@hotimail.com
RI Cusimano, Michael/X-4059-2019
CR ALLAM AF, 1969, ANN OTO RHINOL LARYN, V78, P49, DOI 10.1177/000348946907800105
   Altieri R, 2017, NEUROSURG REV, V40, P231, DOI 10.1007/s10143-016-0754-3
   Banerjee AD, 2011, SKULL BASE-INTERD AP, V21, P329, DOI 10.1055/s-0031-1284215
   Fournier HD, 2007, ADV TECH STAND NEURO, V32, P91, DOI 10.1007/978-3-211-47423-5_5
   Gulya AJ, 2007, ANATOMY TEMPORAL BON
   Harnsberger H., 2003, POCKETRADIOLOGIST TE
   Hindi K, 2014, INDIAN J OTOLARYNGOL, V66, P429, DOI 10.1007/s12070-014-0745-z
   Jadhav AB, 2014, OR SURG OR MED OR PA, V117, P376, DOI 10.1016/j.oooo.2013.12.398
   Jen A, 2004, LARYNGOSCOPE, V114, P656, DOI 10.1097/00005537-200404000-00011
   Kiris T, 1996, BARROW Q, P12
   Ladril J-P, 2008, ATLAS RAISONNE ANATO
   Lang J., 1999, SKULL BASE RELATED S
   Mansour S, 2013, COMPREHENSIVE CLIN A
   Pellet W, 2012, OTONEUROSURGERY
   Proctor B, 1989, SURG ANATOMY EAR TEM
   Quigley AJ, 2013, J RADIOL CASE REP, V7, P27, DOI 10.3941/jrcr.v7i8.1444
   Rayappa C, 2012, ESSENTIALS HEAD NECK
   Rhoton AL, 2000, NEUROSURGERY, V47, pS211, DOI 10.1097/00006123-200009001-00023
   Ribas GC, 2007, J NEUROSURG, V106, P449, DOI 10.3171/jns.2007.106.3.449
   Roche PH, 2011, NEUROSURG FOCUS, V30, DOI 10.3171/2011.2.FOCUS1119
   Santini JJ, 1980, ATLAS OSTEOLOGIE CRA
   Sennaroglu L, 2003, LARYNGOSCOPE, V113, P332, DOI 10.1097/00005537-200302000-00025
   Standring S, 2016, GRAYS ANATOMY ANATOM
   WILSON DF, 1991, SKULL BASE SURG, V1, P188, DOI 10.1055/s-2008-1057005
   Yamakami I, 2003, NEUROL MED-CHIR, V43, P334, DOI 10.2176/nmc.43.334
NR 25
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP E65
EP E80
DI 10.1016/j.wneu.2018.11.234
PG 16
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800009
PM 30620892
DA 2020-05-12
ER

PT J
AU Thomas, PAW
   Mitchell, PS
   Marshman, LAG
AF Thomas, Piers A. W.
   Mitchell, Paul S.
   Marshman, Laurence A. G.
TI Early Postoperative Morbidity After Chronic Subdural Hematoma:
   Predictive Usefulness of the Physiological and Operative Severity Score
   for Enumeration of Mortality and Morbidity, American College of Surgeons
   National Surgical Quality Improvement Program, and American Society of
   Anesthesiologists Grade in a Prospective Cohort
SO WORLD NEUROSURGERY
LA English
DT Article
DE ACS-NQSIP; ASA; Chronic; Morbidity; POSSUM; Subdural hematoma
ID RISK CALCULATOR; POSSUM; SYSTEMS; COMPLICATIONS; SURVIVAL
AB BACKGROUND: Although chronic subdural hematoma (CSDH) is generally benign, long-term survival (LTS) after CSDH is poor in a significant subgroup. This dichotomy has been compared to fractured neck of femur. However, although early postoperative mortality (within 30 days of CSDH) is well recorded with CSDH and similar to fractured neck of femur (4%-8%), scant accurate data exist regarding early postoperative morbidity (POMB). POMB, which prolongs length of stay (LOS) after major nonneurosurgery, is associated with decreased LTS. One recent CSDH study suggested a POMB standard of 10% i.e., notably less than with fractured neck of femur (45%).
   METHODS: POMB was recorded in a novel prospective single-center cohort after CSDH. The POSSUM(Physiological and Operative Severity Score for Enumeration ofMortality and Morbidity), American College of Surgeons National Surgical Quality Improvement Program (ACS-NSQIP) score, and American Society of Anesthesiologists (ASA) grade were assessed as tools for potentially predicting POMB. Receiver operating characteristic (ROC) curves were calculated.
   RESULTS: Early postoperative mortality (within 30 days of CSDH) occurred in 3 of 114 patients (3%). Seventy-one POMB events occurred in 54 of 114 patients (47%), with 27 of 54 (50%) having a Clavien-Dindo grade >= 2. Most POMBwas neurologic (n= 47/71, 66%). Age (P= 0.01), Glasgow Coma Scale (GCS) score (P = 0.001), Markwalder grade (P= 0.01), hypertension (P = 0.047), and/or >= 1 preexistent comorbidity (P = 0.041) were predictive. LOS (P = 0.01) and discharge modified Rankin Scale score (P < 0.001) were significantly associated. Predicted and observed POMB with POSSUM were significantly disparate (chi(2)= 15.23; P = 0.001): POSSUMarea under ROC (AUROC = 0.611) was also nondiscriminatory. ACS-NSQIP (chi(2) = 18.51; P < 0.001; AUROC = 0.629) and ASA grades (P= 0.25) were also nonpredictive.
   CONCLUSIONS: POMB was frequently disabling, mostly neurologic, and as frequent and diverse as with fractured neck of femur. POMB was significantly correlated with LOS and discharge modified Rankin Scale score. Surprisingly, POSSUM, ACS-NSQIP, and ASA grades were not predictive and would not aid consent. Simple parameters (age, Glasgow Coma Scale, Markwalder grade, hypertension, and/or >= 1 other comorbidity) were instead predictive. Longitudinal follow-up will determine whether POMB affects LTS. CSDH, like fractured neck of femur, is distinct.
C1 [Thomas, Piers A. W.; Mitchell, Paul S.; Marshman, Laurence A. G.] Townsville Hosp, Dept Neurosurg, Townsville, Qld, Australia.
   [Thomas, Piers A. W.; Marshman, Laurence A. G.] James Cook Univ, Sch Med & Dent, Townsville, Qld, Australia.
RP Marshman, LAG (reprint author), Townsville Hosp, Dept Neurosurg, Townsville, Qld, Australia.; Marshman, LAG (reprint author), James Cook Univ, Sch Med & Dent, Townsville, Qld, Australia.
EM l.a.g.marshman@btinternet.com
FU Townsville Hospital Research fund [SERTA RG00513]
FX This research received an internal grant from the Townsville Hospital
   Research fund (SERTA RG00513).
CR Baechli H, 2004, NEUROSURG REV, V27, P263, DOI 10.1007/s10143-004-0337-6
   Bilimoria KY, 2013, J AM COLL SURGEONS, V217, P833, DOI 10.1016/j.jamcollsurg.2013.07.385
   Brennan PM, 2017, J NEUROSURG, V127, P732, DOI 10.3171/2016.8.JNS16134
   Chari A, 2016, J NEUROTRAUM, V33, P1212, DOI 10.1089/neu.2015.3983
   Chen JCT, 2000, NEUROSURG CLIN N AM, V11, P399, DOI 10.1016/S1042-3680(18)30101-3
   Chen W, 2010, J CLIN NEUROSCI, V17, P567, DOI 10.1016/j.jocn.2009.09.020
   Chia PH, 2013, BONE JOINT RES, V2, P162, DOI 10.1302/2046-3758.28.2000177
   Clavien PA, 2009, ANN SURG, V250, P187, DOI 10.1097/SLA.0b013e3181b13ca2
   COPELAND GP, 1991, BRIT J SURG, V78, P356
   Duckett S, 2018, ALL COMPLICATIONS SH
   Hackett NJ, 2015, INT J SURG, V18, P184, DOI 10.1016/j.ijsu.2015.04.079
   Hopkins TJ, 2016, PERIOPER MED, V5, DOI 10.1186/s13741-016-0054-z
   Johnson C, 2017, J INVEST MED, V65, P722, DOI 10.1136/jim-2016-000224
   Madhavan S, 2016, HPB, V18, pe157
   Manickam A, 2016, J CLIN NEUROSCI, V34, P100, DOI 10.1016/j.jocn.2016.05.026
   Manickam A, 2012, J NEUROSURG, V117, P186, DOI 10.3171/2011.10.JNS111316
   MARKWALDER TM, 1981, J NEUROSURG, V55, P390, DOI 10.3171/jns.1981.55.3.0390
   Marshman LAG., 2013, PROSPECTIVE RANDOMIZ
   Marshman LAG, 2015, CLIN NEUROL NEUROSUR, V131, P1, DOI 10.1016/j.clineuro.2015.01.009
   Mercer SJ, 2013, INDIAN J ANAESTH, V57, P587, DOI 10.4103/0019-5049.123332
   Miranda LB, 2011, J NEUROSURG, V114, P72, DOI 10.3171/2010.8.JNS10298
   Moonesinghe SR, 2014, BRIT J ANAESTH, V113, P977, DOI 10.1093/bja/aeu224
   Prytherch DR, 1998, BRIT J SURG, V85, P1217
   Ramanathan TS, 2005, BRIT J ANAESTH, V94, P430, DOI 10.1093/bja/aei064
   Ramesh VJ, 2008, BRIT J NEUROSURG, V22, P275, DOI 10.1080/02688690701784905
   Reponen E, 2015, J NEUROSURG, V123, P594, DOI 10.3171/2014.11.JNS141970
   Santarius T, 2004, BRIT J NEUROSURG, V18, P328, DOI 10.1080/02688690400004845
   Santarius T, 2009, LANCET, V374, P1067, DOI 10.1016/S0140-6736(09)61115-6
   Squier W, 2009, FORENSIC SCI INT, V187, P6, DOI 10.1016/j.forsciint.2009.02.005
   Tekkis PP, 2004, BRIT J SURG, V91, P1174, DOI 10.1002/bjs.4430
   Tekkis PP, 2004, BRIT J SURG, V91, P288, DOI 10.1002/bjs.4414
   Tekkis PP, 2003, BRIT J SURG, V90, P340, DOI 10.1002/bjs.4037
   Trotter W, 1914, BRIT J SURG, V2, P271, DOI 10.1002/bjs.1800020608
   Vaziri S, 2018, J NEUROSURG, V128, P942, DOI 10.3171/2016.11.JNS161377
   Wijesinghe LD, 1998, BRIT J SURG, V85, P209
NR 35
TC 4
Z9 4
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP E489
EP E497
DI 10.1016/j.wneu.2018.12.119
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800063
PM 30610985
DA 2020-05-12
ER

PT J
AU Troberg, E
   Kronvall, E
   Hansen, BM
   Nilsson, OG
AF Troberg, Ebba
   Kronvall, Erik
   Hansen, Bjorn M.
   Nilsson, Ola G.
TI Prediction of Long-Term Outcome After Intracerebral Hemorrhage Surgery
SO WORLD NEUROSURGERY
LA English
DT Article
DE Intracerebral hemorrhage; Long-term outcome; Prognosis; Risk factors;
   Surgery
ID INITIAL CONSERVATIVE TREATMENT; HEALTH-CARE PROFESSIONALS; REACTION
   LEVEL SCALE; QUALITY-OF-LIFE; INTRAVENTRICULAR HEMORRHAGE;
   SURGICAL-TREATMENT; CONTROLLED-TRIAL; STROKE; MANAGEMENT; HEMATOMA
AB BACKGROUND: Surgery for spontaneous primary intracerebral hemorrhage (ICH) remains controversial. Previous surgical trials have primarily focused on short-term mortality while studies on long-term functional outcome are rare. We therefore conducted this retrospective study of long-term outcome on all ICH patients who underwent craniotomy at a single neurosurgical center during a 10-year period.
   METHODS: We included all patients >15 years of age who underwent evacuation of spontaneous ICH at Skane University Hospital between 2003 and 2012. Case fatality at 30 days, 1 year, and long-term follow-up (up to 10 years) were analyzed in relation to potential predictors of outcome. Long-term functional outcome was assessed in 2013 by telephone interview using the modified Rankin Scale (mRS).
   RESULTS: Of 229 operated patients, overall case fatality was 20% at 30 days and 31% at 1 year. For patients with supratentorial ICH, the case fatality was 16% at 30 days and 27% at 1 year, and 29% at 30 days and 41% at 1 year for patients with cerebellar ICH. The most consistent independent predictors of mortality were preictal heart disease and level of consciousness on admission. Of 185 patients with long-term functional outcome available (median follow-up 6.14 years), 44 of them (24%) had a good outcome (mRS score 0-3) and 141 (76%) were severely disabled or dead (mRS score 4-6).
   CONCLUSIONS: The case fatality in our study was comparatively low, but most survivors lived dependently several years after surgery. Heart disease and level of consciousness were the most consistent predictors of mortality.
C1 [Troberg, Ebba] Lund Univ, Skane Univ Hosp, Dept Clin Sci, Lund, Sweden.
   Lund Univ, Skane Univ Hosp, Dept Neurosurg, Lund, Sweden.
RP Troberg, E (reprint author), Lund Univ, Skane Univ Hosp, Dept Clin Sci, Lund, Sweden.
EM ebba.troberg@med.lu.se
OI Kronvall, Erik/0000-0003-2329-1608
CR Andaluz N, 2009, J NEUROSURG, V110, P403, DOI 10.3171/2008.5.17559
   Appelros P, 2009, STROKE, V40, P1082, DOI 10.1161/STROKEAHA.108.540781
   AUER LM, 1989, J NEUROSURG, V70, P530, DOI 10.3171/jns.1989.70.4.0530
   BRODERICK JP, 1993, STROKE, V24, P987, DOI 10.1161/01.STR.24.7.987
   Choy DKS, 2010, SINGAP MED J, V51, P320
   Dammann P, 2011, NEUROSURG REV, V34, P77, DOI 10.1007/s10143-010-0279-0
   Dandaleh NS, 2012, J CLIN NEUROSCI, V19, P1236, DOI 10.1016/j.jocn.2011.11.025
   Dolderer S, 2004, EUR NEUROL, V52, P112, DOI 10.1159/000080268
   Eriksson M, 2007, STROKE, V38, P1384, DOI 10.1161/01.STR.0000260102.97954.9c
   Flaherty ML, 2006, NEUROCRIT CARE, V5, P197, DOI 10.1385/NCC:5:3:197
   Fogelholm R, 2005, J NEUROL NEUROSUR PS, V76, P1534, DOI 10.1136/jnnp.2004.055145
   Gaberel T, 2012, NEUROSURG REV, V35, P485, DOI 10.1007/s10143-012-0399-9
   GRAEB DA, 1982, RADIOLOGY, V143, P91, DOI 10.1148/radiology.143.1.6977795
   Gregson BA, 2012, STROKE, V43, P1496, DOI 10.1161/STROKEAHA.111.640284
   Hai J, 2010, NEUROL INDIA, V58, P74, DOI 10.4103/0028-3886.60403
   Hanley DF, 2009, STROKE, V40, P1533, DOI 10.1161/STROKEAHA.108.535419
   Hansen BM, 2016, STROKE, V47, P2634, DOI 10.1161/STROKEAHA.116.014203
   Hansen BM, 2016, NEUROEPIDEMIOLOGY, V46, P43, DOI 10.1159/000442575
   Hansen BM, 2013, J NEUROL NEUROSUR PS, V84, P1150, DOI 10.1136/jnnp-2013-305200
   Hattori N, 2004, J NEUROSURG, V101, P417, DOI 10.3171/jns.2004.101.3.0417
   Hemphill JC, 2015, STROKE, V46, P2032, DOI 10.1161/STR.0000000000000069
   Hwang BY, 2012, J NEUROSURG, V116, P185, DOI 10.3171/2011.9.JNS10850
   JUVELA S, 1989, J NEUROSURG, V70, P755, DOI 10.3171/jns.1989.70.5.0755
   Kothari U, 1996, STROKE, V27, P1304, DOI 10.1161/01.STR.27.8.1304
   Last J, 2015, J STROKE CEREBROVASC, V24, P925, DOI 10.1016/j.jstrokecerebrovasdis.2014.12.001
   MATHEW P, 1995, J NEUROL NEUROSUR PS, V59, P287, DOI 10.1136/jnnp.59.3.287
   MCKISSOCK W, 1961, LANCET, V2, P221
   Mendelow AD, 2013, LANCET, V382, P397, DOI 10.1016/S0140-6736(13)60986-1
   Mendelow AD, 2005, LANCET, V365, P387
   Morgenstern LB, 2010, STROKE, V41, P2108, DOI 10.1161/STR.0b013e3181ec611b
   Nilsson OG, 2002, J NEUROSURG, V97, P531, DOI 10.3171/jns.2002.97.3.0531
   Qureshi AI, 2009, LANCET, V373, P1632, DOI 10.1016/S0140-6736(09)60371-8
   Samarasekera N, 2015, STROKE, V46, P361, DOI 10.1161/STROKEAHA.114.007953
   STARMARK JE, 1988, ACTA NEUROCHIR, V91, P12, DOI 10.1007/BF01400521
   Steiner T, 2014, INT J STROKE, V9, P840, DOI 10.1111/ijs.12309
   Teernstra OPM, 2003, STROKE, V34, P968, DOI 10.1161/01.STR.0000063367.52044.40
   van Asch CJJ, 2010, LANCET NEUROL, V9, P167, DOI 10.1016/S1474-4422(09)70340-0
   Walther SM, 2003, INTENS CARE MED, V29, P933, DOI 10.1007/s00134-003-1757-4
   Zia E, 2009, STROKE, V40, P3567, DOI 10.1161/STROKEAHA.109.556324
   Zuccarello M, 1999, STROKE, V30, P1833, DOI 10.1161/01.STR.30.9.1833
NR 40
TC 1
Z9 1
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP E96
EP E105
DI 10.1016/j.wneu.2018.12.012
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800013
PM 30579029
DA 2020-05-12
ER

PT J
AU Vargas, J
   Spiotta, A
   Chatterjee, AR
AF Vargas, Jan
   Spiotta, Alejandro
   Chatterjee, Arindram Rano
TI Initial Experiences with Artificial Neural Networks in the Detection of
   Computed Tomography Perfusion Deficits
SO WORLD NEUROSURGERY
LA English
DT Article
DE Acute ischemic stroke; Artificial neural networks; CT perfusion; Machine
   learning
ID FINAL INFARCT VOLUME; LUNG-CANCER; ENDOVASCULAR THERAPY;
   ISCHEMIC-STROKE; CT PERFUSION; MRI; SEGMENTATION; CLASSIFICATION;
   THROMBECTOMY; CNN
AB BACKGROUND: Head computed tomography (CT) with perfusion imaging has become crucial in the selection of patients for mechanical thrombectomy. In recent years, machine learning has rapidly evolved and found applications in a wide variety of health care tasks. We report our initial experiences with training a neural network to predict the presence and laterality of a perfusion deficit in patients with acute ischemic stroke.
   METHODS: CT perfusion images of patients with suspicion for acute ischemic stroke were obtained. The data were split into training and validation sets. A long-term, recurrent convolutional network was constructed, which consisted of a convolutional neural network stacked on top of a long short-term memory layer.
   RESULTS: Of the 396 patients, 139 (35.1%) had a right-sided perfusion deficit, 199 (50.3%) had a left-sided deficit, and 58 (14.6%) had no evidence of a deficit. The best model was able to achieve an accuracy of 85.8% on validation data. Receiver operating characteristic curves were generated for each class, and an area under the curve (AUC) was calculated for each class. For right-sided deficits, the AUC was 0.90, for left-sided deficits, the AUC was 0.96, and for no deficit, the AUC was 0.93.
   CONCLUSIONS: The field of machine learning, powered by convolutional neural networks for the task of image recognition and processing, has quickly developed in recent years. We constructed an artificial neural network that can identify and classify the presence and laterality of a perfusion deficit on CT perfusion imaging.
C1 [Vargas, Jan] Greenville Hlth Syst, Div Neuroendovasc Surg, Greenville, SC 29615 USA.
   [Spiotta, Alejandro] Med Univ South Carolina, Dept Neurosurg, Charleston, SC 29425 USA.
   [Chatterjee, Arindram Rano] Med Univ South Carolina, Dept Radiol, Charleston, SC 29425 USA.
RP Vargas, J (reprint author), Greenville Hlth Syst, Div Neuroendovasc Surg, Greenville, SC 29615 USA.
EM j.vargas.machaj@gmail.com
OI Chatterjee, Arindam/0000-0002-6172-2010
CR Akkus Z, 2017, J DIGIT IMAGING, V30, P449, DOI 10.1007/s10278-017-9983-4
   Alvarez JM, 2012, LECT NOTES COMPUT SC, V7578, P376, DOI 10.1007/978-3-642-33786-4_28
   Asadi H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088225
   Austein F, 2016, STROKE, V47, P2311, DOI 10.1161/STROKEAHA.116.013147
   Badrinarayanan V, 2017, IEEE T PATTERN ANAL, V39, P2481, DOI 10.1109/TPAMI.2016.2644615
   Bagher-Ebadian H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022626
   Bouslama M, 2017, STROKE, V48, P1271, DOI 10.1161/STROKEAHA.116.015636
   Campbell BCV, 2015, NEW ENGL J MED, V372, P1009, DOI 10.1056/NEJMoa1414792
   Campbell BCV, 2014, INT J STROKE, V10, P51
   Chadha A, 2017, ARXIV171005112V2CSCV
   Cuingnet R, 2010, LECT NOTES COMPUT SC, V6361, P316
   Dusenberry MW, 2017, AM J EMERG MED, V35, P260, DOI 10.1016/j.ajem.2016.10.065
   Georgiadis P, 2008, COMPUT METH PROG BIO, V89, P24, DOI 10.1016/j.cmpb.2007.10.007
   Girshick R, 2014, ARXIV13112524CSCV
   Goldberg Y, 2016, J ARTIF INTELL RES, V57, P345, DOI 10.1613/jair.4992
   Graves A, 2005, NEURAL NETWORKS, V18, P602, DOI 10.1016/j.neunet.2005.06.042
   Haussen DC, 2016, INTERV NEUROL, V5, P81, DOI 10.1159/000445763
   He K, 2015, DEEP RESIDUAL LEARNI, P1512
   He K, 2016, IDENTITY MAPPINGS DE, P1603
   He KM, 2017, IEEE I CONF COMP VIS, P2980, DOI 10.1109/ICCV.2017.322
   Hegde V, 2018, ARXIV170706719V2CSCV
   Huang FJ, 2006, C COMP VIS PATT REC, P284, DOI DOI 10.1109/CVPR.2006.164
   Huang SL, 2010, J CEREBR BLOOD F MET, V30, P1661, DOI 10.1038/jcbfm.2010.56
   Huynh BQ, 2016, J MED IMAGING, V3, DOI 10.1117/1.JMI.3.3.034501
   Ibragimov B, 2017, MED PHYS, V44, P547, DOI 10.1002/mp.12045
   Ishii T, 2015, 2015 14TH IAPR INTERNATIONAL CONFERENCE ON MACHINE VISION APPLICATIONS (MVA), P341, DOI 10.1109/MVA.2015.7153200
   Jerebko AK, 2003, MED PHYS, V30, P52, DOI 10.1118/1.1528178
   Ji SW, 2013, IEEE T PATTERN ANAL, V35, P221, DOI 10.1109/TPAMI.2012.59
   Kamnitsas K., 2015, ISCHEMIC STROKE LESI, V13, P13, DOI DOI 10.1016/J.MEDIA.2016.10.004
   Kamnitsas K, 2017, MED IMAGE ANAL, V36, P61, DOI 10.1016/j.media.2016.10.004
   Karpathy A, 2014, PROC CVPR IEEE, P1725, DOI 10.1109/CVPR.2014.223
   Kleesiek J, 2016, NEUROIMAGE, V129, P460, DOI 10.1016/j.neuroimage.2016.01.024
   Krizhevsky A, 2017, COMMUN ACM, V60, P84, DOI 10.1145/3065386
   Kuruvilla J, 2014, COMPUT METH PROG BIO, V113, P202, DOI 10.1016/j.cmpb.2013.10.011
   Lansberg MG, 2012, LANCET NEUROL, V11, P860, DOI 10.1016/S1474-4422(12)70203-X
   Lecun Y, 1998, P IEEE, V86, P2278, DOI 10.1109/5.726791
   Maji D, 2016, ARXIV160304833 CORR
   Mikolov T, 2014, ARXIV14127753CSNE
   Milletari F, 2017, COMPUT VIS IMAGE UND, V164, P92, DOI 10.1016/j.cviu.2017.04.002
   Mokin M, 2017, STROKE, V48, P932, DOI 10.1161/STROKEAHA.116.015472
   Nogueira MA, 2017, BMC MED IMAGING, V17, DOI 10.1186/s12880-017-0181-0
   Patel A, 2017, INT SOC OPT PHOTON
   Payan A., 2015, ARXIV150202506
   Ren S, 2015, ARXIV150601497CSCV C
   Saver JL, 2015, INT J STROKE, V10, P439, DOI 10.1111/ijs.12459
   Sedaghat N, 2016, ARXIV160403351CSCV
   Shin HC, 2016, IEEE T MED IMAGING, V35, P1285, DOI 10.1109/TMI.2016.2528162
   Srivastava N, 2014, J MACH LEARN RES, V15, P1929
   Straka M, 2010, J MAGN RESON IMAGING, V32, P1024, DOI 10.1002/jmri.22338
   Sundermeyer M, 2015, IEEE-ACM T AUDIO SPE, V23, P517, DOI 10.1109/TASLP.2015.2400218
   Toney LK, 2014, RADIOLOGY, V270, P91, DOI 10.1148/radiol.13122427
   Turk AS, 2013, J NEUROINTERV SURG, V5, P523, DOI 10.1136/neurintsurg-2012-010491
   Turk AS, 2013, J NEUROINTERV SURG, V5, P518, DOI 10.1136/neurintsurg-2012-010452
   van Opbroek A, 2015, IEEE T MED IMAGING, V34, P1018, DOI 10.1109/TMI.2014.2366792
   Wolterink JM, 2016, MED IMAGE ANAL, V34, P123, DOI 10.1016/j.media.2016.04.004
   Xiong W, 2016, ARXIV16005256
   Ye H, 2015, ARXIV150401920CSCV C
   Zagoruyko S, 2016, WIDE RESIDUAL NETWOR, P1605
   Zhang WL, 2015, NEUROIMAGE, V108, P214, DOI 10.1016/j.neuroimage.2014.12.061
   Zhou ZH, 2002, ARTIF INTELL MED, V24, P25, DOI 10.1016/S0933-3657(01)00094-X
NR 60
TC 2
Z9 2
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP E10
EP E16
DI 10.1016/j.wneu.2018.10.084
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800003
PM 30366140
DA 2020-05-12
ER

PT J
AU Volovici, V
   van Dijk, EJ
   van der Lugt, A
   Koudstaal, PJ
   Vincent, AJ
AF Volovici, Victor
   van Dijk, Ewoud J.
   van der Lugt, Aad
   Koudstaal, Peter J.
   Vincent, Arnaud J.
TI A Modified Encephalo-Duro-Synangiosis Technique Induced
   Neovascularization in Symptomatic Atherosclerotic Carotid Artery
   Occlusion: A Phase I trial
SO WORLD NEUROSURGERY
LA English
DT Article
DE Atherosclerosis; Carotid artery occlusion; Collateral circulation;
   Critical perfusion; Encephalo-duro-galeo-synangiosis; Hypoperfusion
ID EXTRACRANIAL-INTRACRANIAL BYPASS; MOYAMOYA-DISEASE; CEREBRAL-ISCHEMIA;
   BURR-HOLE; STROKE; TRANSPLANTATION; CELLS; REVASCULARIZATION;
   ANGIOGENESIS; PERFUSION
AB OBJECTIVE: To the best of our knowledge, the present study is the first to assess the safety and feasibility of a modified encephalo-galeo-duro-synangiosis operation in patients with atherosclerotic carotid artery occlusion.
   METHODS: Eight patients who had experienced new ipsilateral cerebrovascular events after the diagnosis of carotid artery occlusion were recruited. To facilitate extracranial-to-intracranial collateralization, 5 or 6 burr holes were made, and the dura mater and arachnoid were opened. The patients were closely monitored for complications and underwent conventional angiography, magnetic resonance imaging, and perfusion-weighted magnetic resonance imaging at baseline and 1 year of follow-up. After 10 years, the patients who were still alive were interviewed and assessed for functional outcomes and neurological status.
   RESULTS: No surgery-related adverse events were observed, apart from temporary headache and subcutaneous effusion. Four of six patients had developed an extracranial-to-intracranial collateral blood vessels on angiography, and these patients had no incident ischemic events during the follow-up period. During the long-term follow-up period (10 years), 3 patients had died. Of those living, 4 of the 5 patients reported total resolution of the symptoms, with no incident ischemic events. One patient still experienced disability from an ischemic stroke that occurred as a result of the 1-year follow-up angiography.
   CONCLUSIONS: Encephalo-duro-galeo-synangiosis for symptomatic carotid occlusion seems to be safe and feasible and might be able to induce extracranial-to-intracranial collaterals in patients with carotid artery occlusion. Further studies are needed to define the optimal therapeutic window and yield of burr hole surgery in the treatment of symptomatic carotid occlusive disease as an adjuvant to extracranial-intracranial bypass.
C1 [van Dijk, Ewoud J.] Erasmus Univ, Med Ctr, Dept Neurol, Rotterdam, Netherlands.
   [Volovici, Victor; Vincent, Arnaud J.] Erasmus Univ, Med Ctr, Dept Neurosurg, Rotterdam, Netherlands.
   [van der Lugt, Aad] Erasmus Univ, Med Ctr, Dept Radiol, Rotterdam, Netherlands.
   [Volovici, Victor; Koudstaal, Peter J.] Erasmus Univ, Med Ctr, Dept Publ Hlth, Rotterdam, Netherlands.
   [Volovici, Victor; Koudstaal, Peter J.] Erasmus, Int Stroke Ctr, Rotterdam, Netherlands.
   [van Dijk, Ewoud J.] Radboud Univ Nijmegen, Med Ctr, Dept Neurol, Nijmegen, Netherlands.
RP Volovici, V (reprint author), Erasmus Univ, Med Ctr, Dept Neurosurg, Rotterdam, Netherlands.; Volovici, V (reprint author), Erasmus Univ, Med Ctr, Dept Publ Hlth, Rotterdam, Netherlands.; Volovici, V (reprint author), Erasmus, Int Stroke Ctr, Rotterdam, Netherlands.
EM v.volovici@erasmusmc.nl
RI van Dijk, Ewoud J/J-7951-2012
CR Assmus B, 2006, NEW ENGL J MED, V355, P1222, DOI 10.1056/NEJMoa051779
   BARNETT HJM, 1985, NEW ENGL J MED, V313, P1191, DOI 10.1056/nejm198511073131904
   Ceradini DJ, 2004, NAT MED, V10, P858, DOI 10.1038/nm1075
   Chang EI, 2007, CIRCULATION, V116, P2818, DOI 10.1161/CIRCULATIONAHA.107.715847
   Czabanka M, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.1.FOCUS08298
   ENDO M, 1989, J NEUROSURG, V71, P180, DOI 10.3171/jns.1989.71.2.0180
   Kaga A, 1997, NEUROL SURG TOKYO, V25, P803
   Kawaguchi T, 1996, J NEUROSURG, V84, P468, DOI 10.3171/jns.1996.84.3.0468
   Klijn CJM, 2002, STROKE, V33, P2451, DOI 10.1161/01.STR.0000030319.78212.51
   Klijn CJM, 1997, STROKE, V28, P2084, DOI 10.1161/01.STR.28.10.2084
   Komotar RJ, 2009, J NEUROSURG, V110, P896, DOI 10.3171/2008.9.JNS17658
   Losordo DW, 2007, CIRCULATION, V115, P3165, DOI 10.1161/CIRCULATIONAHA.106.687376
   Manoonkitiwongsa PS, 2001, J CEREBR BLOOD F MET, V21, P1223, DOI 10.1097/00004647-200110000-00011
   Matoba S, 2008, AM HEART J, V156, P1010, DOI 10.1016/j.ahj.2008.06.025
   MATSUSHIMA Y, 1985, CHILD NERV SYST, V1, P363, DOI 10.1007/BF00270826
   Mukawa M, 2016, J NEUROSURG, V124, P1211, DOI 10.3171/2015.4.JNS15155
   Ni L, 2017, SCI REP-UK, V7, DOI 10.1038/srep41586
   Powers WJ, 2011, JAMA-J AM MED ASSOC, V306, P1983, DOI 10.1001/jama.2011.1610
   Rafat N, 2009, STROKE, V40, P432, DOI 10.1161/STROKEAHA.108.529420
   Rouhl RPW, 2008, STROKE, V39, P2158, DOI 10.1161/STROKEAHA.107.507251
   Sadashiva N, 2016, NEUROL INDIA, V64, P78, DOI 10.4103/0028-3886.178046
   Sainte-Rose C, 2006, J NEUROSURG, V105, P437, DOI 10.3171/ped.2006.105.6.437
   van Laar PJ, 2008, STROKE, V39, P3003, DOI 10.1161/STROKEAHA.108.514265
   Xiao QZ, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000975
NR 24
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP E176
EP E181
DI 10.1016/j.wneu.2018.12.063
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800023
PM 30615994
DA 2020-05-12
ER

PT J
AU Wakuta, N
   Abe, H
   Nonaka, M
   Morishita, T
   Higashi, T
   Arima, H
   Inoue, T
AF Wakuta, Naoki
   Abe, Hiroshi
   Nonaka, Masani
   Morishita, Takashi
   Higashi, Toshio
   Arima, Hisatomi
   Inoue, Tooru
TI Analysis of Endoscopic Findings in the Chronic Subdural Hematoma Cavity:
   Bleeding Factors in Chronic Subdural Hematoma Natural History and as
   Predictors of Recurrence
SO WORLD NEUROSURGERY
LA English
DT Article
DE Bleeding factors; Chronic subdural hematoma; Endoscopic findings;
   Natural history; Recurrent predictor
ID INDEPENDENT PREDICTORS; LOCAL HYPERFIBRINOLYSIS; INFLAMMATORY CYTOKINES;
   SURGICAL-TREATMENT; RISK-FACTORS; MANAGEMENT; THROMBOMODULIN;
   COMPLICATIONS; DRAINAGE; OUTCOMES
AB OBJECTIVE: Possible factors associated with bleeding from endoscopy-detected chronic subdural hematomas (CSDHs) have rarely been analyzed. We therefore evaluated intraoperative endoscopic findings to elucidate the clinical course and assess predictors of CSDH recurrence.
   METHODS: Altogether, 540 CSDHs were reviewed in this retrospective study. Six possible signs of bleeding were detected in the cavity: spotty bleeding on the outer membrane, hematoma clots, cerebral parenchymal suspension, stretched cortical vessels, intraluminal trabecular structures, and septa separating the cavity. We evaluated the association of each with the radiologic findings, endoscopic features, and interval from trauma to surgery and then assessed the correlation between each endoscopic feature and CSDH recurrence.
   RESULTS: Spotty bleeding, cerebral parenchymal suspension, and stretched cortical vessels occurred during every period. Hematoma clots exhibited a 2-peak pattern with significant resurgence during the chronic phase. Trabecular structures significantly increased 61 days after the trauma, reaching 71.2% of patients on day 91. Septa were found in the cavity in only 12.5% during the initial 30 days but subsequently increased significantly to 37.3%. At 2 months, an exacerbation stage was inferred. The multivariable analysis revealed that trabecular structures and residual septa were significant independent risk factors for recurrence. We opened most septa intraoperatively. Their recurrence rate was 7.5%, which is lower than has been previously reported.
   CONCLUSIONS: Evaluation of the changes in the endoscopic findings and their association with recurrence was useful for clarifying the mechanism of CSDH enlargement, the risk of recurrence, and the potential for endoscopic surgery.
C1 [Wakuta, Naoki; Abe, Hiroshi; Nonaka, Masani; Morishita, Takashi; Higashi, Toshio; Inoue, Tooru] Fukuoka Univ, Dept Neurosurg, Fukuoka Univ Hosp, Fukuoka, Fukuoka, Japan.
   [Wakuta, Naoki; Abe, Hiroshi; Nonaka, Masani; Morishita, Takashi; Higashi, Toshio; Inoue, Tooru] Fukuoka Univ, Sch Med, Fukuoka, Fukuoka, Japan.
   [Arima, Hisatomi] Fukuoka Univ, Dept Prevent Med & Publ Hlth, Fac Med, Fukuoka, Fukuoka, Japan.
RP Wakuta, N (reprint author), Fukuoka Univ, Dept Neurosurg, Fukuoka Univ Hosp, Fukuoka, Fukuoka, Japan.; Wakuta, N (reprint author), Fukuoka Univ, Sch Med, Fukuoka, Fukuoka, Japan.
EM nwakuta@fukuoka-u.ac.jp
OI Morishita, Takashi/0000-0002-0789-7776
CR Abouzari M, 2007, NEUROSURGERY, V61, P794, DOI 10.1227/01.NEU.0000298908.94129.67
   Adhiyaman V, 2002, POSTGRAD MED J, V78, P71, DOI 10.1136/pmj.78.916.71
   Asano Y, 1992, No To Shinkei, V44, P827
   Bartek J, 2017, WORLD NEUROSURG, V106, P609, DOI 10.1016/j.wneu.2017.07.044
   Berhouma M, 2014, ACTA NEUROCHIR, V156, P2359, DOI 10.1007/s00701-014-2219-1
   Chari A, 2016, J NEUROTRAUM, V33, P1212, DOI 10.1089/neu.2015.3983
   Delgado-Lopez PD, 2009, NEUROCIRUGIA, V20, P346
   El-Kadi H, 2000, NEUROSURG CLIN N AM, V11, P553, DOI 10.1016/S1042-3680(18)30122-0
   Frati A, 2004, J NEUROSURG, V100, P24, DOI 10.3171/jns.2004.100.1.0024
   Fukuhara T, 1996, SURG NEUROL, V45, P570, DOI 10.1016/0090-3019(95)00471-8
   Gelabert-Gonzalez M, 2005, CLIN NEUROL NEUROSUR, V107, P223, DOI 10.1016/j.clineuro.2004.09.015
   Han MH, 2017, J NEUROSURG, V127, P1117, DOI 10.3171/2016.8.JNS16867
   Hellwig D, 1996, SURG NEUROL, V45, P272, DOI 10.1016/0090-3019(95)00417-3
   HOSODA K, 1987, J NEUROSURG, V67, P677, DOI 10.3171/jns.1987.67.5.0677
   Ishikawa Toshihito, 2017, No Shinkei Geka, V45, P667, DOI 10.11477/mf.1436203572
   ITO H, 1976, J NEUROSURG, V45, P26, DOI 10.3171/jns.1976.45.1.0026
   ITO H, 1978, J NEUROSURG, V48, P197, DOI 10.3171/jns.1978.48.2.0197
   Jung YG, 2015, J KOREAN NEUROSURG S, V57, P266, DOI 10.3340/jkns.2015.57.4.266
   Killeffer JA, 2000, NEUROSURG CLIN N AM, V11, P407, DOI 10.1016/S1042-3680(18)30102-5
   Kitazono M, 2012, NEUROL MED-CHIR, V52, P810, DOI 10.2176/nmc.52.810
   Kristof RA, 2008, J NEUROSURG, V108, P275, DOI 10.3171/JNS/2008/108/2/0275
   Kwon TH, 2000, J NEUROSURG, V93, P796, DOI 10.3171/jns.2000.93.5.0796
   Lindvall P, 2009, J CLIN NEUROSCI, V16, P1287, DOI 10.1016/j.jocn.2009.01.001
   Mobbs R, 2009, J CLIN NEUROSCI, V16, P701, DOI 10.1016/j.jocn.2008.06.023
   Murakami H, 2002, J NEUROSURG, V96, P877, DOI 10.3171/jns.2002.96.5.0877
   Nagahori Takeshi, 1993, Neurological Surgery, V21, P697
   NAGANUMA H, 1986, NEUROSURGERY, V19, P794, DOI 10.1227/00006123-198611000-00013
   Nakaguchi H, 2001, J NEUROSURG, V95, P256, DOI 10.3171/jns.2001.95.2.0256
   NOMURA S, 1994, J NEUROSURG, V81, P910, DOI 10.3171/jns.1994.81.6.0910
   Park SH, 2011, CLIN NEUROL NEUROSUR, V113, P272, DOI 10.1016/j.clineuro.2010.11.014
   Pont LMEB, 2012, NEUROSURGERY, V70, P873, DOI 10.1227/NEU.0b013e31823672ad
   ROBINSON RG, 1984, J NEUROSURG, V61, P263, DOI 10.3171/jns.1984.61.2.0263
   SAITO K, 1989, J NEUROSURG, V70, P68, DOI 10.3171/jns.1989.70.1.0068
   Sakakibara Fumihiro, 2011, Brain and Nerve (Tokyo), V63, P69
   Schwarz F, 2015, CLIN NEUROL NEUROSUR, V138, P66, DOI 10.1016/j.clineuro.2015.08.002
   Shiomi N, 2002, NEUROL SURG TOKYO, V30, P717
   Stanisic M, 2005, ACTA NEUROCHIR, V147, P1249, DOI 10.1007/s00701-005-0616-1
   Suzuki M, 1998, ACTA NEUROCHIR, V140, P51, DOI 10.1007/s007010050057
   TAKAHASHI Y, 1985, Neurologia Medico-Chirurgica, V25, P998, DOI 10.2176/nmc.25.998
   Takahashi Yoshihiko, 1996, Neurologia Medico-Chirurgica, V36, P627, DOI 10.2176/nmc.36.627
   Tanikawa M, 2001, ACTA NEUROCHIR, V143, P613, DOI 10.1007/s007010170067
   Tao ZQ, 2016, MED HYPOTHESES, V86, P43, DOI 10.1016/j.mehy.2015.11.027
   Teo C, 1996, CHILD NERV SYST, V12, P248
   Toi H, 2018, J NEUROSURG, V128, P222, DOI 10.3171/2016.9.JNS16623
   Torihashi K, 2008, NEUROSURGERY, V63, P1125, DOI 10.1227/01.NEU.0000335782.60059.17
   VICTORATOS GC, 1981, SURG NEUROL, V15, P158, DOI 10.1016/0090-3019(81)90041-0
   WAKAI S, 1990, NEUROSURGERY, V26, P771, DOI 10.1227/00006123-199005000-00006
   Yamamoto H, 2003, J NEUROSURG, V98, P1217, DOI 10.3171/jns.2003.98.6.1217
   Yasargil MG, 1984, MICRONEUROSURGERY, V1, P14
NR 49
TC 3
Z9 3
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP E241
EP E251
DI 10.1016/j.wneu.2018.12.078
PG 11
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800032
PM 30593956
DA 2020-05-12
ER

PT J
AU Wallace, AN
   Madaelil, TP
   Kamran, M
   Miller, TR
   Almandoz, JED
   Grossberg, JA
   Kansagra, AP
   Gandhi, D
   Kayan, Y
   Cawley, CM
   Moran, CJ
   Jindal, G
   Crevecoeur, T
   Howard, BM
   Cross, DT
   Kole, MJ
   Roy, AK
   Dion, JE
   Osbun, JW
AF Wallace, Adam N.
   Madaelil, Thomas P.
   Kamran, Mudassar
   Miller, Timothy R.
   Almandoz, Josser E. Delgado
   Grossberg, Jonathan A.
   Kansagra, Akash P.
   Gandhi, Dheeraj
   Kayan, Yasha
   Cawley, C. Michael
   Moran, Christopher J.
   Jindal, Gaurav
   Crevecoeur, Travis
   Howard, Brian M.
   Cross, Dewitte T.
   Kole, Matthew J.
   Roy, Anil K.
   Dion, Jacques E.
   Osbun, Joshua W.
TI Pipeline Embolization of Vertebrobasilar Aneurysms-A Multicenter Case
   Series
SO WORLD NEUROSURGERY
LA English
DT Article
DE Aneurysm; Pipeline embolization; Posterior circulation; Vertebrobasilar
ID UNRUPTURED INTRACRANIAL ANEURYSMS; SINGLE-CENTER EXPERIENCE;
   TERM-FOLLOW-UP; ENDOVASCULAR TREATMENT; FLOW DIVERTORS; ARTERY
   ANEURYSMS; DEVICE; PREDICTION; OCCLUSION; COILING
AB BACKGROUND: The Pipeline Embolization Device (PED) has been increasingly used for the treatment of posterior circulation aneurysms. The purpose of the present study was to examine the clinical and angiographic outcomes of patients with vertebrobasilar aneurysms treated with the PED.
   METHODS: We performed a retrospective review of vertebrobasilar aneurysms treated with the PED at 4 highvolume neurovascular centers. Patient, aneurysm, and procedural data were collected, including perioperative and delayed complications. Aneurysm occlusion on followup imaging studies was defined as complete (100%), near-complete (>90%), or incomplete (<90%) occlusion.
   RESULTS: The cohort included 35 patients with 37 vertebrobasilar aneurysms who underwent 36 treatment sessions. Of the 35 patients, 10 were men (29%), and the mean patient age was 54.1 years (range, 32-75). Eight patients (23%) underwent urgent treatment because of a ruptured aneurysm (n = 6), brainstem perforator stroke (n = 1), or posttraumatic pseudoaneurysm (n = 1). Of the 37 aneurysms, 22 arose from the vertebral artery (59%) and 15 from the basilar artery (41%). Also, 19 were saccular aneurysms (51%), with a mean size of 7.7 mm (range, 1.7-38.0); 17 were fusiform aneurysms (46%), with a mean size of 11.0 mm (range, 4.3-34); and 1 was a 2.9-mm blister aneurysm. The overall procedural complication rate was 14% (5 of 36), including 3 neurologically symptomatic complications. At a mean follow-up period of 14 months (range, 3-59), 24 of 34 aneurysms (71%) were completely occluded and 29 of 34 (85%) were completely or near-completely occluded.
   CONCLUSION: Our results show that Pipeline embolization of vertebrobasilar aneurysms is associated with acceptable occlusion and complication rates.
C1 [Wallace, Adam N.; Almandoz, Josser E. Delgado; Kayan, Yasha] Abbott NW Hosp, Neurosci Inst, Div Neurointervent Radiol, Minneapolis, MN 55407 USA.
   [Wallace, Adam N.] Univ Iowa, Dept Radiol, Iowa City, IA 52242 USA.
   [Madaelil, Thomas P.; Dion, Jacques E.] Emory Univ, Dept Radiol, Atlanta, GA 30322 USA.
   [Kamran, Mudassar; Kansagra, Akash P.; Moran, Christopher J.; Cross, Dewitte T.; Osbun, Joshua W.] Washington Univ, Mallinckrodt Inst Radiol, St Louis, MO USA.
   [Miller, Timothy R.; Gandhi, Dheeraj] Univ Maryland, Dept Radiol, Baltimore, MD 21201 USA.
   [Grossberg, Jonathan A.; Cawley, C. Michael; Howard, Brian M.; Roy, Anil K.] Emory Univ, Dept Neurosurg, Atlanta, GA 30322 USA.
   [Kansagra, Akash P.; Moran, Christopher J.; Crevecoeur, Travis; Cross, Dewitte T.; Osbun, Joshua W.] Washington Univ, Dept Neurosurg, St Louis, MO USA.
   [Kansagra, Akash P.; Osbun, Joshua W.] Washington Univ, Dept Neurol, St Louis, MO USA.
   [Jindal, Gaurav] Univ Maryland, Dept Neurol, Baltimore, MD 21201 USA.
   [Jindal, Gaurav; Kole, Matthew J.] Univ Maryland, Dept Neurosurg, Baltimore, MD 21201 USA.
RP Wallace, AN (reprint author), Abbott NW Hosp, Neurosci Inst, Div Neurointervent Radiol, Minneapolis, MN 55407 USA.; Wallace, AN (reprint author), Univ Iowa, Dept Radiol, Iowa City, IA 52242 USA.
EM adam.wallace@crlmed.com
CR Almandoz JED, 2017, NEURORADIOLOGY, V59, P1291, DOI 10.1007/s00234-017-1930-z
   Bhogal P, 2017, J NEUROINTERV SURG, V9, P471, DOI 10.1136/neurintsurg-2016-012781
   Brinjikji W, 2015, AM J NEURORADIOL, V36, P2308, DOI 10.3174/ajnr.A4443
   Brinjikji W, 2013, STROKE, V44, P442, DOI 10.1161/STROKEAHA.112.678151
   Chalouhi N, 2015, J NEUROSURG, V122, P1498, DOI 10.3171/2014.12.JNS14411
   Coert BA, 2007, J NEUROSURG, V106, P855, DOI 10.3171/jns.2007.106.5.855
   Ferns SP, 2009, STROKE, V40, pE523, DOI 10.1161/STROKEAHA.109.553099
   Greving JP, 2014, LANCET NEUROL, V13, P59, DOI 10.1016/S1474-4422(13)70263-1
   Griessenauer CJ, 2019, J NEUROSURG, V130, P923, DOI 10.3171/2017.9.JNS171376
   Griessenauer CJ, 2017, NEUROSURGERY, V80, P579, DOI 10.1227/NEU.0000000000001377
   Kallmes DF, 2015, AM J NEURORADIOL, V36, P108, DOI 10.3174/ajnr.A4111
   Liang F, 2018, WORLD NEUROSURG, V112, pE683, DOI 10.1016/j.wneu.2018.01.129
   Lin Li-Mei, 2013, Surg Neurol Int, V4, P114, DOI 10.4103/2152-7806.117711
   Lopes DK, 2018, NEUROSURGERY, V83, P488, DOI 10.1093/neuros/nyx467
   Lozier AP, 2002, STROKE, V33, P2509, DOI 10.1161/01.STR.0000031928.71695.A9
   Lusseveld E, 2002, J NEUROL NEUROSUR PS, V73, P591, DOI 10.1136/jnnp.73.5.591
   Phillips TJ, 2012, AM J NEURORADIOL, V33, P1225, DOI 10.3174/ajnr.A3166
   Rangel-Castilla L, 2017, J NEUROSURG, V126, P1064, DOI 10.3171/2016.4.JNS16147
   Raymond J, 2003, STROKE, V34, P1398, DOI 10.1161/01.STR.0000073841.88563.E9
   Ries T, 2007, AM J NEURORADIOL, V28, P1755, DOI 10.3174/ajnr.A0649
   Saatci I, 2012, AM J NEURORADIOL, V33, P1436, DOI 10.3174/ajnr.A3246
   Shapiro M, 2014, J NEUROINTERV SURG, V6, P389, DOI 10.1136/neurintsurg-2013-010793
   Siddiqui AH, 2012, J NEUROSURG, V116, P1258, DOI 10.3171/2012.2.JNS111942
   Spetzler RF, 2015, J NEUROSURG, V123, P609, DOI 10.3171/2014.9.JNS141749
   Vedantam A, 2015, NEUROSURGERY, V76, P173, DOI 10.1227/NEU.0000000000000595
   Wallace AN, 2018, NEUROSURGERY, V83, P790, DOI 10.1093/neuros/nyx561
   Wang CB, 2016, NEURORADIOLOGY, V58, P391, DOI 10.1007/s00234-016-1649-2
   Wermer MJH, 2007, STROKE, V38, P1404, DOI 10.1161/01.STR.0000260955.51401.cd
   Wiebers D, 2003, LANCET, V362, P103, DOI 10.1016/S0140-6736(03)13860-3
   Yavuz K, 2014, AM J NEURORADIOL, V35, P529, DOI 10.3174/ajnr.A3692
   Yu SCH, 2012, RADIOLOGY, V265, P893, DOI 10.1148/radiol.12120422
NR 31
TC 2
Z9 2
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP E460
EP E469
DI 10.1016/j.wneu.2018.12.116
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800060
PM 30610980
DA 2020-05-12
ER

PT J
AU Wanderer, S
   Coluccia, D
   Anon, J
   Fandino, J
   Berkmann, S
AF Wanderer, Stefan
   Coluccia, Daniel
   Anon, Javier
   Fandino, Javier
   Berkmann, Sven
TI Intraoperative Computed Tomography Versus Fluoroscopy for
   Ventriculoperitoneal Shunt Placement
SO WORLD NEUROSURGERY
LA English
DT Article
DE Hydrocephalus; Intraoperative cranial fluoroscopy; Intraoperative CT;
   Ventriculoperitoneal shunt
ID CATHETER PLACEMENT; VENTRICULAR CATHETERS; ACCURACY; INSERTION;
   GUIDANCE; CHILDHOOD; PARIETAL; CHILDREN
AB OBJECTIVE: Catheter malposition represents one of the major causes of ventriculoperitoneal (VP) shunt dysfunction. The usefulness of intraoperative fluoroscopy using skull landmarks has already been proved to decrease catheter malposition and surgical revision rates. After introducing intraoperative computed tomography (iCT) in our department, our objective was to evaluate the accuracy of this imaging modality to decrease cranial catheter misplacement compared with intraoperative fluoroscopy.
   METHODS: In our retrospective analysis of 152 patients, catheter placement was evaluated by iCT (n = 48) and biplane fluoroscopy (n = 57). A control group (n = 47) had no intraoperative imaging. Outcome measures included accuracy of ventricular catheter position, revision surgeries, and clinical outcomes.
   RESULTS: Ventricular catheter placement was accurate in 24/48 patients with iCT and 45/57 patients with fluoroscopy (P = 0.002) versus 23/47 patients in the control group. Sensitivity and positive predictive value for estimating optimal catheter position with iCT were 100% and 54%. The specificity and negative predictive value were 50% and 100%. After intraoperative revision, 4 catheters remained malpositioned in the iCT group, whereas the fluoroscopy group had none (P = 0.03); 2 of these 4 catheters were revised postoperatively.
   CONCLUSIONS: Fluoroscopy may be the method of choice to intraoperatively assess ventricular catheter positioning. In our experience, iCT shows a tendency to be more time consuming and, in the beginning, was not associated with a steeper learning curve. Another consideration was the significant higher radiation exposure per patient. iCT did not improve the accuracy of catheter placement and did not decrease early revisions for VP placement patients.
C1 [Wanderer, Stefan; Coluccia, Daniel; Fandino, Javier; Berkmann, Sven] Kantonsspital Aarau, Dept Neurosurg, Aarau, Switzerland.
   [Anon, Javier] Kantonsspital Aarau, Div Neuroradiol, Dept Radiol, Aarau, Switzerland.
RP Wanderer, S (reprint author), Kantonsspital Aarau, Dept Neurosurg, Aarau, Switzerland.
EM stefan.wanderer@ksa.ch
RI Coluccia, Daniel/L-4612-2018
OI Coluccia, Daniel/0000-0002-0260-5834
CR ALBRIGHT AL, 1988, J NEUROSURG, V69, P883, DOI 10.3171/jns.1988.69.6.0883
   BIERBRAUER KS, 1991, PEDIATR NEUROSURG, V16, P287, DOI 10.1159/000120544
   Coluccia D, 2016, WORLD NEUROSURG, V86, P71, DOI 10.1016/j.wneu.2015.08.072
   Cooke D L, 2011, AJNR Am J Neuroradiol, V32, pE69, DOI 10.3174/ajnr.A2066
   Dickerman RD, 2005, J CLIN NEUROSCI, V12, P781, DOI 10.1016/j.jocn.2004.12.005
   Fandino J, 2013, ACTA NEUROCHIR SUPPL, V115, P113, DOI 10.1007/978-3-7091-1192-5_24
   Garell PC, 1998, J NEUROSURG, V89, P157, DOI 10.3171/jns.1998.89.1.0157
   Gruter BE, 2018, WORLD NEUROSURG, V117, pE204, DOI 10.1016/j.wneu.2018.05.241
   Hart D, 2009, BRIT J RADIOL, V82, P1, DOI 10.1259/bjr/12568539
   HOWARD MA, 1995, J NEUROSURG, V82, P300, DOI 10.3171/jns.1995.82.2.0300
   Huda W., 2010, REV RADIOLOGIC PHYS
   Huyette DR, 2008, J NEUROSURG, V108, P88, DOI 10.3171/JNS/2008/108/01/0088
   Janson CG, 2014, J NEUROSURG, V120, P684, DOI 10.3171/2013.8.JNS13250
   Keen WW, 1890, LANCET, V136, P553, DOI [DOI 10.1016/S0140-6736(00)48676-9, 10.1016/S0140-6736(00)48676-9]
   Kestle JRW, 2003, J NEUROSURG, V98, P284, DOI 10.3171/jns.2003.98.2.0284
   Kim YB, 2006, J CLIN NEUROSCI, V13, P50, DOI 10.1016/j.jocn.2004.12.010
   Kobayashi Shinya, 2012, Surg Neurol Int, V3, P119, DOI 10.4103/2152-7806.102330
   Kono K, 2014, TURK NEUROSURG, V24, P123, DOI 10.5137/1019-5149.JTN.7928-13.0
   Kotecha R, 2011, J INVEST SURG, V24, P195, DOI 10.3109/02713683.2011.615210
   Krettek C, 2012, UNFALLCHIRURG, V115, P100, DOI 10.1007/s00113-011-2126-3
   Levitt MR, 2012, J NEUROSURG-PEDIATR, V10, P112, DOI 10.3171/2012.3.PEDS122
   Lind CRP, 2009, J CLIN NEUROSCI, V16, P918, DOI 10.1016/j.jocn.2008.09.015
   Mavridis IN, 2017, CASE REP MED, DOI 10.1155/2017/3953248
   Nesvick CL, 2015, NEUROSURGERY, V77, P321, DOI 10.1227/NEU.0000000000000849
   Nevzati E, 2017, BRIT J NEUROSURG, V31, P741, DOI 10.1080/02688697.2017.1297764
   Patwardhan RV, 2005, NEUROSURGERY, V56, P139, DOI 10.1227/01.NEU.0000146206.40375.41
   Pearce MS, 2012, LANCET, V380, P499, DOI 10.1016/S0140-6736(12)60815-0
   Saladino A, 2009, NEUROCRIT CARE, V10, P248, DOI 10.1007/s12028-008-9154-z
   Theodosopoulos PV, 2001, CAN J NEUROL SCI, V28, P56
   Toma AK, 2009, NEUROSURGERY, V65, P1197, DOI 10.1227/01.NEU.0000356973.39913.0B
   Villavicencio AT, 2003, SURG NEUROL, V59, P375, DOI 10.1016/S0090-3019(03)00070-3
   Whitehead WE, 2007, J NEUROSURG, V107, P406, DOI 10.3171/PED-07/11/406
   Wilson TJ, 2013, J NEUROSURG, V119, P66, DOI 10.3171/2012.11.JNS111384
   Wu Y, 2007, NEUROSURGERY, V61, P557, DOI 10.1227/01.NEU.0000290903.07943.AF
   Yamada SM, 2012, CLIN NEUROL NEUROSUR, V114, P622, DOI 10.1016/j.clineuro.2011.12.025
NR 35
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP E609
EP E615
DI 10.1016/j.wneu.2019.01.002
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800078
PM 30639491
DA 2020-05-12
ER

PT J
AU Wang, HB
   Sun, JC
   Sun, KQ
   Li, X
   Wang, Y
   Xu, XM
   Zhang, B
   Guo, YF
   Shi, JG
AF Wang, Haibo
   Sun, Jingchuan
   Sun, Kaiqiang
   Li, Xin
   Wang, Yuan
   Xu, Ximing
   Zhang, Bin
   Guo, Yongfei
   Shi, Jiangang
TI Anterior Controllable Antedisplacement Fusion for Multilevel Cervical
   Spondylotic Myelopathy with Spinal Stenosis: Comparison with Anterior
   Cervical Corpectomy and Fusion
SO WORLD NEUROSURGERY
LA English
DT Article
DE Anterior cervical corpectomy and fusion (ACCF); Anterior controllable
   antedisplacement fusion (ACAF); Cervical spondylotic myelopathy;
   Complication; Stenosis; Surgery
ID POSTERIOR LONGITUDINAL LIGAMENT; OSSIFICATION; SURGERY
AB OBJECTIVE: To introduce anterior controllable ante-displacement fusion (ACAF), a new surgical technique, to treat multilevel cervical spondylotic myelopathy with spinal stenosis and compare ACAF with anterior cervical corpectomy and fusion (ACCF).
   METHODS: Patients with multilevel cervical spondylotic myelopathy with spinal stenosis who underwent ACAF (36 cases) and ACCF (45 cases) from January 2016 to June 2017 were enrolled in this study. Japanese Orthopaedic Association score was analyzed before the operation and at each scheduled follow-up during the follow-up period after surgery to evaluate neurologic function. Clinical and radiologic outcomes and perioperative complications were analyzed.
   RESULTS: At the final follow-up, mean Japanese Orthopaedic Association scores of the 2 groups were significantly improved compared with preoperatively (P < 0.01 and P < 0.01). However, mean Japanese Orthopaedic Association scores between the 2 groups were not statistically significant (13.7 +/- 1.9 vs. 13.5 +/- 1.8, P = 0.66). Operative duration was longer and blood loss was greater in the ACAF group compared with the ACCF group. Overall occurrence of complications in the ACAF group was significantly lower compared with the ACCF group (P < 0.05).
   CONCLUSIONS: ACAF has similar clinical and radiologic outcomes and fewer complications compared with ACCF in treatment of multilevel cervical spondylotic myelopathy with spinal stenosis. ACAF can be used as an alternative treatment for cervical stenosis.
C1 [Wang, Haibo; Sun, Jingchuan; Sun, Kaiqiang; Li, Xin; Wang, Yuan; Xu, Ximing; Zhang, Bin; Guo, Yongfei; Shi, Jiangang] Second Mil Med Univ, Changzheng Hosp, Spine Ctr, Dept Orthoped Surg, Shanghai, Peoples R China.
RP Shi, JG (reprint author), Second Mil Med Univ, Changzheng Hosp, Spine Ctr, Dept Orthoped Surg, Shanghai, Peoples R China.
EM czyyshijiangang@163.com
FU Shanghai Science and Technology Commission Technology Support Project
   [18441905800]; National Nature Science Foundation of ChinaNational
   Natural Science Foundation of China [81802218]
FX This study was supported by the Shanghai Science and Technology
   Commission Technology Support Project (Grant No. 18441905800) and
   National Nature Science Foundation of China (Grant No. 81802218).
CR Grasso G, 2015, EUR SPINE J, V24, pS842, DOI 10.1007/s00586-015-4281-7
   Hackel M, 2001, Rozhl Chir, V80, P163
   Hey HWD, 2013, EUR SPINE J, V22, P116, DOI 10.1007/s00586-012-2486-6
   Iwasaki M, 2007, SPINE, V32, P654, DOI 10.1097/01.brs.0000257566.91177.cb
   Iwasaki Motoki, 2009, Clin Calcium, V19, P1486, DOI CliCa091014861492
   Kimura H, 2014, EUR SPINE J, V23, P1491, DOI 10.1007/s00586-014-3253-7
   Li H, 2011, SPINE J, V11, P1049, DOI 10.1016/j.spinee.2011.09.008
   Li ZH, 2014, EUR SPINE J, V23, P1472, DOI 10.1007/s00586-014-3208-z
   Liu T, 2011, EUR SPINE J, V20, P224, DOI 10.1007/s00586-010-1486-7
   Mitsunaga LK, 2012, ADV ORTHOP, V2012, DOI 10.1155/2012/307916
   Qin RQ, 2018, EUR SPINE J, V27, P1375, DOI 10.1007/s00586-017-5451-6
   WANG T, 2016, MEDICINE, V95, DOI DOI 10.1097/MD.0000000000005437
   Wang T, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000006421
   Yang HS, 2018, WORLD NEUROSURG, V118, pE562, DOI 10.1016/j.wneu.2018.06.239
   Yilmaz M, 2017, CLIN SPINE SURG, V30, pE152, DOI 10.1097/BSD.0b013e318268d30a
NR 15
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP E740
EP E747
DI 10.1016/j.wneu.2018.12.212
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800095
PM 30660892
DA 2020-05-12
ER

PT J
AU Wang, HB
   Xu, T
   Sun, JC
   Wang, Y
   Sun, KK
   Xu, XM
   Zhang, B
   Guo, YF
   Shi, JG
AF Wang, Haibo
   Xu, Tao
   Sun, Jingchuan
   Wang, Yuan
   Sun, Kakiang
   Xu, Ximing
   Zhang, Bin
   Guo, Yongfei
   Shi, Jiangang
TI Homogeneous Spinal-Shortening Axial Decompression as a Revision Surgery
   After Untethering Surgery in Pediatric Patients with Tethered Cord
   Syndrome
SO WORLD NEUROSURGERY
LA English
DT Article
DE Homogeneous spinal-shortening axial decompression; Revision; Tethered
   cord syndrome; Untethering; Urodynamic
ID SURGICAL-MANAGEMENT; OUTCOMES; CHILDREN; MYELOMENINGOCELE; EXPERIENCE;
   ADULTS
AB OBJECTIVE: To evaluate surgical outcomes of homogeneous spinal-shortening axial decompression (HSAD) for reoperation in pediatric patients with tethered cord syndrome.
   METHODS: Twenty consecutive pediatric patients (<= 18 years old, 7 boys, 13 girls) who underwent HSAD after untethering surgery between June 2012 and May 2015 were included. The Japanese Orthopaedic Association score and visual analog scale were used to evaluate preoperative and postoperative neurologic function and pain. The International Consultation on Incontinence Questionnairee-Short Form and urodynamics were used to evaluate urinary function. The Rintala score was used to evaluate stool function.
   RESULTS: Mean age of patients was 13.4 +/- 3.6 years (range, 7 -18 years). The mean duration of follow-up was 31.2 +/- 12.7 months (range, 12-48 months). The Japanese Orthopaedic Association score was increased from 13.31 +/- 4.03 preoperatively to 19.15 +/- 4.17 at final follow-up (P < 0.01). The visual analog scale score was decreased from 5.25 +/- 1.78 preoperatively to 2.21 +/- 1.63 at final follow-up (P < 0.01). The International Consultation on Incontinence Questionnairee Short Form score was decreased from 14.94 +/- 4.15 preoperatively to 7.63 +/- 4.40 at final follow-up (P < 0.01). All urodynamics parameters improved compared with before the operation. The Rintala score improved from 5.26 +/- 3.45 preoperatively to 12.32 +/- 3.43 at final follow-up (P < 0.01).
   CONCLUSIONS: Outcomes of HSAD for revision surgery of tethered cord syndrome were satisfactory. HSAD improved neurologic function of patients significantly. HSAD could become an alternative surgical treatment of reoperation for tethered cord syndrome.
C1 [Wang, Haibo; Sun, Jingchuan; Wang, Yuan; Sun, Kakiang; Xu, Ximing; Zhang, Bin; Guo, Yongfei; Shi, Jiangang] Second Mil Med Univ, Changzheng Hosp, Spine Ctr, Dept Orthoped Surg, Shanghai, Peoples R China.
   [Xu, Tao] Peoples Liberat Army, Hosp 906, Dept Orthoped Surg, Ningbo, Zhejiang, Peoples R China.
RP Shi, JG (reprint author), Second Mil Med Univ, Changzheng Hosp, Spine Ctr, Dept Orthoped Surg, Shanghai, Peoples R China.
EM czyyshijianggang@163.com
FU Shanghai Science and Technology Commission Technology Support Project
   [18441905800]; National Nature Science Foundation of ChinaNational
   Natural Science Foundation of China [81802218]
FX This study was supported by the Shanghai Science and Technology
   Commission Technology Support Project (Grant No. 18441905800) and
   National Nature Science Foundation of China (Grant No. 81802218).
CR Abdallah A, 2018, NEUROSURG REV, V41, P229, DOI 10.1007/s10143-017-0842-z
   Aldave G, 2017, J NEUROSURG-PEDIATR, V19, P703, DOI 10.3171/2017.1.PEDS16533
   Alsowayan O, 2016, J PEDIAT UROL, V12, pe281
   Alsowayan O, 2016, J PEDIAT UROL, V12, P285
   George TM, 2005, J NEUROSURG, V102, P150, DOI 10.3171/jns.2005.102.2.0150
   Geyik M, 2016, CHILD NERV SYST, V32, P1079, DOI 10.1007/s00381-016-3053-y
   Geyik M, 2015, CHILD NERV SYST, V31, P1559, DOI 10.1007/s00381-015-2748-9
   Guerra LA, 2006, J UROLOGY, V176, P1729, DOI 10.1016/j.juro.2006.03.116
   Kokubun S, 2011, J NEUROSURG-SPINE, V15, P21, DOI 10.3171/2011.2.SPINE10114
   Lee GYF, 2006, J NEUROSURG-SPINE, V4, P123, DOI 10.3171/spi.2006.4.2.123
   Safain MG, 2015, J NEUROSURG-SPINE, V23, P120, DOI 10.3171/2014.11.SPINE14877
   Samuels R, 2009, CHILD NERV SYST, V25, P1085, DOI 10.1007/s00381-009-0895-6
   Steinbok P, 2006, J NEUROSURG, V104, P309, DOI 10.3171/ped.2006.104.5.309
   Sun JC, 2018, WORLD NEUROSURG, V116, pE66, DOI 10.1016/j.wneu.2018.03.221
   Sysoev K, 2018, CHILD NERV SYST, V34, P305, DOI 10.1007/s00381-017-3630-8
   Wang Haibo, 2015, Zhonghua Yi Xue Za Zhi, V95, P1801
   YAMADA S, 1981, J NEUROSURG, V54, P494, DOI 10.3171/jns.1981.54.4.0494
NR 17
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP E702
EP E706
DI 10.1016/j.wneu.2018.12.197
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800089
PM 30660897
DA 2020-05-12
ER

PT J
AU Wang, QP
   Yuan, Y
   Xiong, NX
   Fu, P
   Huang, T
   Yang, B
   Liu, J
   Chu, X
   Zhao, HY
AF Wang, Qiang-ping
   Yuan, Ye
   Xiong, Nan-xiang
   Fu, Peng
   Huang, Tao
   Yang, Bo
   Liu, Jia
   Chu, Xi
   Zhao, Hong-yang
TI Anatomic Variation and Hemodynamic Evolution of Vertebrobasilar Arterial
   System May Contribute to the Development of Vascular Compression in
   Hemifacial Spasm
SO WORLD NEUROSURGERY
LA English
DT Article
DE ANSYS; Computational fluid dynamics; Hemifacial spasm; Vertebral artery
ID MICROVASCULAR DECOMPRESSION; POSTERIOR-FOSSA; MECHANISM
AB BACKGROUND: Hemifacial spasm (HFS) is caused by vascular compression of the facial nerve. The definitive mechanism of offending vessel formation remains unclear. The aim of this study was to explore whether the anatomic and hemodynamic characteristics of the vertebrobasilar artery play a role in problematic vessel formation in HFS.
   METHODS: Imaging data of 341 patients with HFS who underwent microvascular decompression were reviewed retrospectively and compared with 360 control subjects. Hemodynamics of typical anatomic variations of the vertebral artery (VA) were analyzed using computational fluid dynamics software.
   RESULTS: Asymmetry of the left and right VAs was prevalent, and the left VA was the most dominant VA. A dominant VA was more prevalent in the HFS group than in the control group (P = 0.026). Left HFS had a significantly higher proportion of a left dominant VA, and right HFS had a significantly higher proportion of a right dominant VA (P < 0.001). Computational fluid dynamics models showed that angulation and tortuosity of vessels caused remarkable pressure difference between vascular walls of opposite sides. Dynamic clinical observations showed the mode of vessel transposition coincided with biomechanical characteristics.
   CONCLUSIONS: Anatomic variations and hemodynamics of the vertebrobasilar arterial system are likely to contribute to vascular compression formation in HFS.
C1 [Wang, Qiang-ping; Yuan, Ye; Xiong, Nan-xiang; Fu, Peng; Huang, Tao; Zhao, Hong-yang] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Neurosurg, Wuhan, Hubei, Peoples R China.
   [Yang, Bo; Liu, Jia] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Radiol, Wuhan, Hubei, Peoples R China.
   [Chu, Xi] Naval Univ Engn, Inst Nucl Sci & Engn, Wuhan, Hubei, Peoples R China.
RP Xiong, NX (reprint author), Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Neurosurg, Wuhan, Hubei, Peoples R China.
EM mozhuoxiong@163.com
CR Abas A, 2016, COMPUT MATH METHOD M, DOI 10.1155/2016/6143126
   Batla A, 2012, J NEUROL, V259, P1561, DOI 10.1007/s00415-011-6376-3
   Chan LL, 2009, NEUROLOGY, V73, P1054, DOI 10.1212/WNL.0b013e3181b9c8ce
   Dehgani Mobaraki P, 2017, BMJ CASE REP, V12, P2017
   Doenitz C, 2010, NEUROSURGERY, V67, P1213, DOI 10.1227/NEU.0b013e3181f34def
   Finlay HM, 1998, STROKE, V29, P1595, DOI 10.1161/01.STR.29.8.1595
   GARDNER WJ, 1962, J NEUROSURG, V19, P947, DOI 10.3171/jns.1962.19.11.0947
   Garibaldi DC, 2003, ARCH NEUROL-CHICAGO, V60, P626, DOI 10.1001/archneur.60.4.626
   Han IB, 2009, NEUROSURGERY, V65, P130, DOI 10.1227/01.NEU.0000348548.62440.42
   Hyun SJ, 2010, NEUROSURG REV, V33, P325, DOI 10.1007/s10143-010-0254-9
   Jou LD, 2005, AM J NEURORADIOL, V26, P2357
   Mao BY, 2016, BIOMED ENG ONLINE, V15, DOI 10.1186/s12938-016-0260-4
   Metaxa E, 2008, AM J PHYSIOL-HEART C, V295, pH736, DOI 10.1152/ajpheart.01156.2007
   Nagashima H, 2001, J CLIN NEUROSCI, V8, P43, DOI 10.1054/jocn.2000.0814
   Naraghi R, 2004, J NEUROSURG, V100, P1025, DOI 10.3171/jns.2004.100.6.1025
   Nixon AM, 2010, J NEUROSURG, V112, P1240, DOI 10.3171/2009.10.JNS09759
   Park JS, 2015, ACTA NEUROCHIR, V157, P449, DOI 10.1007/s00701-014-2338-8
   Sharma R, 2017, NEUROL INDIA, V65, P493, DOI 10.4103/neuroindia.NI_1166_16
   Swiatnicki W, 2014, Bull Soc Sci Med Grand Duche Luxemb, P73
   von Elm E, 2014, INT J SURG, V12, P1495, DOI 10.1016/j.ijsu.2014.07.013
   Wu YC, 2010, J NEUROL SCI, V298, P61, DOI 10.1016/j.jns.2010.08.017
   Xu BN, 2011, NEUROSURG REV, V34, P39, DOI 10.1007/s10143-010-0282-5
   Zaidi HA, 2015, J CLIN NEUROSCI, V22, P62, DOI 10.1016/j.jocn.2014.09.008
NR 23
TC 1
Z9 1
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP E233
EP E240
DI 10.1016/j.wneu.2018.12.074
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800031
PM 30593967
DA 2020-05-12
ER

PT J
AU Weaver, DJ
   Malik, AT
   Jain, N
   Yu, E
   Kim, J
   Khan, SN
AF Weaver, Douglas J.
   Malik, Azeem Tariq
   Jain, Nikhil
   Yu, Elizabeth
   Kim, Jeffery
   Khan, Safdar N.
TI The Modified 5-Item Frailty Index: A Concise and Useful Tool for
   Assessing the Impact of Frailty on Postoperative Morbidity Following
   Elective Posterior Lumbar Fusions
SO WORLD NEUROSURGERY
LA English
DT Article
DE Frailty; Index; Morbidity; NSQIP; Outcomes; Posterior lumbar fusions
ID CHARLSON COMORBIDITY INDEX; INTERBODY FUSION; OUTCOMES; MORTALITY;
   COMPLICATIONS; PREDICTOR; SURGERY; DATABASE; PROGRAM; ALIF
AB BACKGROUND: The modified 5-item frailty index (mFI-5) is a concise comorbidity-based risk stratification tool that has been shown to predict the occurrence of adverse outcomes following various orthopedic surgeries.
   METHODS: The 2012-2016 American College of Surgeons - National Surgical Quality Improvement Program (ACS-NSQIP) dataset was used to identify patients undergoing an elective 1- to 2-level posterior lumbar fusion for degenerative lumbar pathology. The mFI-5 score was calculated based on the presence of the 5 co-morbidities: congestive heart failure within 30 days prior to surgery, insulin-dependent or noninsulin-dependent diabetes mellitus, chronic obstructive pulmonary disease or pneumonia, partially dependent or totally dependent functional health status at time of surgery, and hypertension requiring medication. Multivariate analysis was used to assess the independent impact of increasing mFI-5 score on postoperative morbidity while controlling for baseline clinical characteristics.
   RESULTS: Increasing mFI-5 score versus mFI-5 = 0 was associated with higher odds of any complication (mFI-5 >= 2: odds ratio [OR] 1.45; mFI-5 = 1: OR 1.22), 30-day readmissions (mFI-5 >= 2: OR 1.46; mFI-5 = 1: OR 1.18), and nonhome discharge (mFI-5 >= 2: OR 1.80; mFI-5 = 1: OR 1.16). Higher mFI-5 score was significantly associated with increased risks of superficial surgical site infection, deep surgical site infection, unplanned reoperation, any medical complication, pneumonia, unplanned intubation, postoperative ventilator use, progressive renal insufficiency, acute renal failure, urinary tract infection, stroke, myocardial infarction, bleeding requiring transfusion, sepsis, and septic shock.
   CONCLUSIONS: Higher mFI-5 scores were associated with increased postoperative morbidity following elective 1- to 2-level posterior lumbar fusions.
C1 [Weaver, Douglas J.; Malik, Azeem Tariq; Jain, Nikhil; Yu, Elizabeth; Kim, Jeffery; Khan, Safdar N.] Ohio State Univ, Wexner Med Ctr, Dept Orthopaed, Columbus, OH 43210 USA.
RP Khan, SN (reprint author), Ohio State Univ, Wexner Med Ctr, Dept Orthopaed, Columbus, OH 43210 USA.
EM Safdar.Khan@osumc.edu
RI Jain, Nikhil/R-5904-2019
OI Jain, Nikhil/0000-0002-8699-9630
CR Ali R, 2016, J NEUROSURG-SPINE, V25, P537, DOI 10.3171/2015.10.SPINE14582
   Anderson JT, 2015, SPINE, V40, P748, DOI 10.1097/BRS.0000000000000863
   Barnes B, 2001, J NEUROSURG, V95, P1, DOI 10.3171/spi.2001.95.1.0001
   Cheung NK, 2013, NEUROSURGERY, V72, P443, DOI 10.1227/NEU.0b013e31827fce96
   Chimukangara M, 2017, SURG ENDOSC, V31, P2509, DOI 10.1007/s00464-016-5253-7
   DiPaola CP, 2008, J AM ACAD ORTHOP SUR, V16, P130, DOI 10.5435/00124635-200803000-00004
   Duplantier N, 2015, J ARTHROPLASTY, V30, P1485, DOI 10.1016/j.arth.2015.04.014
   Flexman AM, 2016, SPINE J, V16, P1315, DOI 10.1016/j.spinee.2016.06.017
   Hoy D, 2014, ANN RHEUM DIS, V73, P968, DOI 10.1136/annrheumdis-2013-204428
   Leven DM, 2017, GLOB SPINE J, V7, P529, DOI 10.1177/2192568217700099
   Leven DM, 2016, SPINE, V41, pE1394, DOI 10.1097/BRS.0000000000001886
   McGirt MJ, 2017, J NEUROSURG-SPINE, V27, P357, DOI 10.3171/2016.11.SPINE16526
   Mokdad AH, 2018, JAMA-J AM MED ASSOC, V319, P1444, DOI 10.1001/jama.2018.0158
   Molinari R W, 2001, Spine J, V1, P215
   Okuda S, 2006, J NEUROSURG-SPINE, V4, P304, DOI 10.3171/spi.2006.4.4.304
   Ondeck NT, 2018, SPINE J, V18, P44, DOI 10.1016/j.spinee.2017.05.028
   Patel KV, 2014, CLIN ORTHOP RELAT R, V472, P1010, DOI 10.1007/s11999-013-3334-7
   Phan K, 2017, SPINE J, V17, P538, DOI 10.1016/j.spinee.2016.10.023
   Runner RP, 2017, J ARTHROPLASTY, V32, pS177, DOI 10.1016/j.arth.2017.03.046
   Segal DN, 2018, WORLD NEUROSURG, V116, pE225, DOI 10.1016/j.wneu.2018.04.172
   Shin JI, 2017, SPINE, V42, P304, DOI 10.1097/BRS.0000000000001755
   Shultz BN, 2018, SPINE, V43, P798, DOI 10.1097/BRS.0000000000002418
   Subramaniam S, 2018, J AM COLL SURGEONS, V226, P173, DOI 10.1016/j.jamcollsurg.2017.11.005
   Talia AJ, 2015, J CLIN NEUROSCI, V22, P243, DOI 10.1016/j.jocn.2014.08.008
   Teng I, 2017, J CLIN NEUROSCI, V44, P11, DOI 10.1016/j.jocn.2017.06.013
   Velanovich V, 2013, J SURG RES, V183, P104, DOI 10.1016/j.jss.2013.01.021
   Vu CCL, 2017, INJURY, V48, P2443, DOI 10.1016/j.injury.2017.08.026
   Wilson JM, 2018, J HAND SURG-AM, V43, P701, DOI 10.1016/j.jhsa.2018.05.029
NR 28
TC 4
Z9 4
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP E626
EP E632
DI 10.1016/j.wneu.2018.12.168
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800080
PM 30639495
DA 2020-05-12
ER

PT J
AU Whiting, AC
   Catapano, JS
   Walker, CT
   Godzik, J
   Lambert, M
   Ponce, FA
AF Whiting, Alexander C.
   Catapano, Joshua S.
   Walker, Corey T.
   Godzik, Jakub
   Lambert, Margaret
   Ponce, Francisco A.
TI Peri-Lead Edema After Deep Brain Stimulation Surgery: A Poorly
   Understood but Frequent Complication
SO WORLD NEUROSURGERY
LA English
DT Article
DE Complications; Deep brain stimulation; Functional neurosurgery;
   Peri-lead edema
ID HARDWARE-RELATED COMPLICATIONS; ELECTRODE; MANAGEMENT; TRANSIENT
AB OBJECTIVE: Postoperative peri-lead edema (PLE) is a poorly understood complication of deep brain stimulation (DBS), which has been described sporadically in patients presenting with profound and often delayed symptoms. We performed a prospective evaluation of patients undergoing DBS to determine the frequency of and identify risk factors for PLE.
   METHODS: Patients underwent DBS electrode placement by a single physician. Postoperative magnetic resonance imaging (MRI) was performed approximately 6 weeks after the operation in asymptomatic subjects and analyzed for presence of PLE. All symptomatic subjects underwent MRI at the time of presentation. Data regarding index disease, preoperative medical issues, operative technique, and intraoperative variables were collected and statistically analyzed.
   RESULTS: A total of 191 leads were placed in 102 subjects; 15 patients (14.7%) demonstrated PLE. Seven patients (6.9%) presented with symptoms related to PLE, most often altered mental status or neurologic deficit. Many of the MRI findings were profound, with PLE sometimes several centimeters in diameter. No statistically significant difference was found between PLE-positive and normal subjects when analyzing multiple variables, including presence of vascular disease, hypertension, anticoagulant/antiplatelet use, electrode target, index disease, unilateral versus bilateral lead placement, number of brain penetrations, and presence or absence of microelectrode recording.
   CONCLUSIONS: Patients with postoperative PLE can present with severe symptoms or can be asymptomatic and go undiagnosed. Because of the delayed-onset potential, PLE may be more common than previously reported. No clear risk factors have been identified; therefore, further studies and increased clinical vigilance are paramount for improving comprehension and possible prevention of PLE.
C1 [Whiting, Alexander C.; Catapano, Joshua S.; Walker, Corey T.; Godzik, Jakub; Lambert, Margaret; Ponce, Francisco A.] St Josephs Hosp, Barrow Neurol Inst, Dept Neurosurg, Phoenix, AZ 85013 USA.
RP Ponce, FA (reprint author), St Josephs Hosp, Barrow Neurol Inst, Dept Neurosurg, Phoenix, AZ 85013 USA.
EM Neuropub@barrowneuro.org
OI Whiting, Alexander/0000-0002-4585-5219
CR Arocho-Quinones EV, 2016, NEUROMODULATION, V19, P872, DOI 10.1111/ner.12432
   Blomstedt P, 2005, ACTA NEUROCHIR, V147, P1061, DOI 10.1007/s00701-005-0576-5
   Boockvar JA, 2000, J NEUROSURG, V93, P140, DOI 10.3171/jns.2000.93.1.0140
   Boviatsis EJ, 2010, ACTA NEUROCHIR, V152, P2053, DOI 10.1007/s00701-010-0749-8
   Deogaonkar M, 2011, J CLIN NEUROSCI, V18, P910, DOI 10.1016/j.jocn.2010.11.020
   Englot DJ, 2011, STEREOT FUNCT NEUROS, V89, P311, DOI 10.1159/000329365
   Fenoy AJ, 2017, STEREOT FUNCT NEUROS, V95, P86, DOI 10.1159/000454892
   Fenoy AJ, 2014, J NEUROSURG, V120, P132, DOI 10.3171/2013.10.JNS131225
   Haberler C, 2000, ANN NEUROL, V48, P372, DOI 10.1002/1531-8249(200009)48:3<372::AID-ANA12>3.0.CO;2-0
   Jagid Jonathan, 2015, BMJ Case Rep, V2015, DOI 10.1136/bcr-2015-211470
   Kimmelman J, 2011, MOVEMENT DISORD, V26, P1415, DOI 10.1002/mds.23770
   Kleiner-Fisman G, 2006, MOVEMENT DISORD, V21, pS290, DOI 10.1002/mds.20962
   Kuroda R, 1991, Acta Neurochir Suppl (Wien), V52, P140
   Lefaucheur R, 2013, BRAIN STIMUL, V6, P459, DOI 10.1016/j.brs.2012.05.012
   Mirzadeh Z, 2014, MOVEMENT DISORD, V29, P1788, DOI 10.1002/mds.26056
   Oh MY, 2002, NEUROSURGERY, V50, P1268
   Ryu SI, 2004, STEREOT FUNCT NEUROS, V82, P65, DOI 10.1159/000077402
   Sillay KA, 2008, NEUROSURGERY, V62, P360, DOI 10.1227/01.neu.0000316002.03765.33
   Tong FM, 2015, NEUROSURG REV, V38, P245, DOI 10.1007/s10143-014-0588-9
   Uitti RJ, 2002, NEUROSURGERY, V51, P1423, DOI 10.1097/00006123-200212000-00012
   Umemura A, 2003, J NEUROSURG, V98, P779, DOI 10.3171/jns.2003.98.4.0779
   Videnovic A, 2008, MOVEMENT DISORD, V23, P343, DOI 10.1002/mds.21753
   Voges J, 2006, J NEUROL NEUROSUR PS, V77, DOI 10.1136/jnnp.2005.081232
   Voges J, 2007, MOVEMENT DISORD, V22, P1486, DOI 10.1002/mds.21481
NR 24
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP E340
EP E345
DI 10.1016/j.wneu.2018.12.092
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800044
PM 30594699
DA 2020-05-12
ER

PT J
AU Wu, RH
   Deng, DH
   Huang, XQ
   Shi, CL
   Liao, XQ
AF Wu, Rui-Hui
   Deng, Dong-Hai
   Huang, Xing-Qiu
   Shi, Cheng-Long
   Liao, Xu-Qiang
TI Radiation Exposure Reduction in Ultrasound-Guided Transforaminal
   Percutaneous Endoscopic Lumbar Discectomy for Lumbar Disc Herniation: A
   Randomized Controlled Trial
SO WORLD NEUROSURGERY
LA English
DT Article
DE Lumbar disc herniation; Radiation exposure; Transforaminal percutaneous
   endoscopic lumbar discectomy; Ultrasound
ID OUTCOMES; SCIATICA; SURGEON
AB BACKGROUND: Transforaminal percutaneous endoscopic lumbar discectomy (TF-PELD) is a minimally invasive technique with high radiation exposure. The purpose of this study was to compare radiation exposure of ultrasound-guided TF-PELD with fluoroscopy-guided TF-PELD.
   METHODS: In this prospective randomized controlled clinical trial, 60 patients with lumbar disc herniation were enrolled and randomly assigned to 2 groups (30 cases in each group): the ultrasound-guided group or the fluoroscopy-guided group. The radiation exposure, fluoroscopy time, and visual analog scale score were recorded. The number of possible operations per year within the yearly occupational exposure limit (OEL) was calculated. We also recorded the adverse events to evaluate the safety of ultrasound-guided TF-PELD.
   RESULTS: In 30 patients from the ultrasound-guided group, the lumbar disc structure was clearly visible under ultrasound guidance. The effective dose to surgeons and radiation dose to patients were 1.7 +/- 0.4 and 25.2 +/- 4.9 mu Sv in the ultrasound-guided group and 9.0 +/- 2.5 and 127.4 +/- 27.1 mu Sv in the fluoroscopy-guided group (P < 0.05), respectively. The fluoroscopy time was 2.6 +/- 0.5 seconds in the ultrasound-guided group and 127.3 +/- 29.5 seconds in the fluoroscopy-guided group (P < 0.05). A surgeon with shielding devices could treat 5556 cases per year in the fluoroscopy-guided group before exceeding the OEL for whole-body radiation, whereas they could treat 29,412 cases in the ultrasound-guided group. No difference between groups was detected in postoperative visual analog scale score (P > 0.58). No serious adverse event was found in any patient.
   CONCLUSIONS: Ultrasound-guided TF-PELD could decrease radiation exposure to surgeons and patients, without serious adverse events. It seems to be an acceptable alternative to fluoroscopy-guided TF-PELD.
C1 [Wu, Rui-Hui; Deng, Dong-Hai; Huang, Xing-Qiu; Shi, Cheng-Long; Liao, Xu-Qiang] First Peoples Hosp Foshan, Dept Orthoped, Foshan, Guangdong, Peoples R China.
RP Liao, XQ (reprint author), First Peoples Hosp Foshan, Dept Orthoped, Foshan, Guangdong, Peoples R China.
EM lxqiang100@hotmail.com
FU Guangdong Medical Research Foundation [B2017114]
FX This study was supported by Guangdong Medical Research Foundation(2017)
   (number B2017114).
CR Ahn Y, 2004, SPINE, V29, pE326, DOI 10.1097/01.BRS.0000134591.32462.98
   Ahn Y, 2013, SPINE, V38, P617, DOI 10.1097/BRS.0b013e318275ca58
   Ahn Y, 2012, EXPERT REV MED DEVIC, V9, P361, DOI [10.1586/erd.12.23, 10.1586/ERD.12.23]
   Alvi MA, 2018, WORLD NEUROSURG, V11
   Atlas SJ, 2005, SPINE, V30, P927, DOI 10.1097/01.brs.0000158954.68522.2a
   BROSS IDJ, 1979, AM J PUBLIC HEALTH, V69, P130, DOI 10.2105/AJPH.69.2.130
   Carragee EJ, 1997, SPINE, V22, P1650, DOI 10.1097/00007632-199707150-00025
   Fan GX, 2015, J SPINAL DISORD TECH, V28, pE173, DOI 10.1097/BSD.0000000000000210
   Galiano K, 2007, REGION ANESTH PAIN M, V32, P317, DOI 10.1016/j.rapm.2007.03.010
   Gangi A, 1996, RADIOGRAPHICS, V16, P89, DOI 10.1148/radiographics.16.1.89
   Kamper SJ, 2014, EUR SPINE J, V23, P1021, DOI 10.1007/s00586-013-3161-2
   Khoo LT, 2002, NEUROSURGERY, V51, pS166, DOI 10.1227/01.NEU.0000031068.83783.7B
   Klein LW, 2009, CATHETER CARDIO INTE, V73, P432, DOI 10.1002/ccd.21801
   Lau D, 2011, J CLIN NEUROSCI, V18, P81, DOI 10.1016/j.jocn.2010.04.040
   Lee KH, 2012, EUR SPINE J, V21, P2265, DOI 10.1007/s00586-012-2281-4
   Luhmann Dagmar, 2005, GMS Health Technol Assess, V1, pDoc07
   Mariscalco MW, 2011, SPINE, V36, P255, DOI 10.1097/BRS.0b013e3181ceb976
   Maroon JC, 2002, NEUROSURGERY, V51, pS137, DOI 10.1227/01.NEU.0000031066.08137.64
   PACK GT, 1965, RADIOLOGY, V84, P436, DOI 10.1148/84.3.436
   Peltier E, 2013, J NEUROSURG SCI, V57, P123
   Sairyo K, 2018, J ORTHOP SCI, V23, P229, DOI 10.1016/j.jos.2017.10.015
   Srinivasan D, 2014, WORLD NEUROSURG, V82, DOI 10.1016/j.wneu.2014.07.041
   Tzaan Wen-Ching, 2007, Chang Gung Med J, V30, P226
   Wang JA, 2011, EUR SPINE J, V20, P623, DOI 10.1007/s00586-010-1578-4
   Wu XT, 2006, SPINE, V31, P2689, DOI 10.1097/01.brs.0000244615.43199.07
   Yoon WW, 2015, EUR SPINE J, V24, P1422, DOI 10.1007/s00586-014-3589-z
   Young M, 2015, EUR SPINE J, V24, P1427, DOI 10.1007/s00586-015-3855-8
NR 27
TC 0
Z9 0
U1 1
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP E633
EP E640
DI 10.1016/j.wneu.2018.12.169
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800081
PM 30648611
DA 2020-05-12
ER

PT J
AU Wu, XH
   Zang, D
   Wu, X
   Sun, YR
   Yu, J
   Hu, J
AF Wu, Xuehai
   Zang, Di
   Wu, Xing
   Sun, Yirui
   Yu, Jian
   Hu, Jin
TI Diagnosis and Management for Secondary Low- or Negative-Pressure
   Hydrocephalus and a New Hydrocephalus Classification Based on
   Ventricular Pressure
SO WORLD NEUROSURGERY
LA English
DT Article
DE Classification; Diagnosis; Low pressure hydrocephalus; Management;
   Negative pressure hydrocephalus; Ventricular pressure
AB BACKGROUND: Low-pressure hydrocephalus (LPH) and negative-pressure hydrocephalus (NegPH), secondary to traumatic brain injury, cerebral hemorrhage, tumor resection, and central nervous system (CNS) infection in adults, are seldom reported. They have not been recognized enough pathophysiologically in previous clinical practice. They used to have poor prognosis, and routine shunt surgery has unsatisfactory outcomes. The current classifications of hydrocephalus do not provide proper guidance for clinical practice, especially for LPH and NegPH.
   METHODS: Thirty-nine cases of LPH and NegPH were included from January 2013 to March 2018. Clinical features and image characteristics were reviewed. The prognosis of these patients were evaluated by Glasgow Outcome Scale-Extended (GOS-E) within 3 months after external ventricular drainage or ventriculoperitoneal (VP) shunt accepted. Management strategies were discussed in detail.
   RESULTS: Ventricular pressure was lower than 70 mm H2O in all 39 patients, and the lowest value was -10 cm H2O. About an average of 3.5 operations were completed for every patient. Eighteen cases had CNS infection. Eight patients died. Besides 2 patients lost to follow-up, all patients had a poor prognosis with an average GOS-E score of 2.7. For the 29 surviving patients, the time interval from onset to last VP shunt achieved was 31-3880 days, with an average of 376 days.
   CONCLUSIONS: Both LPH and NegPH used to have poor prognosis. However, a good prognosis can be achieved by proper management with a further understanding of the pathophysiology. A new classification for hydrocephalus was proposed according to ventricular pressure, which is necessary and reasonable.
C1 [Wu, Xuehai; Zang, Di; Wu, Xing; Sun, Yirui; Yu, Jian; Hu, Jin] Fudan Univ, Huashan Hosp, Dept Neurosurg, Shanghai, Peoples R China.
RP Wu, XH (reprint author), Fudan Univ, Huashan Hosp, Dept Neurosurg, Shanghai, Peoples R China.
EM wuxuehai2013@163.com
FU Natural Science Foundation of ChinaNational Natural Science Foundation
   of China [81571025]; International Cooperation Project from Shanghai
   Science Foundation [18410711300]
FX This work was supported by the Natural Science Foundation of China
   (81571025) and International Cooperation Project from Shanghai Science
   Foundation (18410711300).
CR Akins PT, 2011, NEUROCRIT CARE, V15, P461, DOI 10.1007/s12028-011-9543-6
   Clarke MJ, 2006, J NEUROSURG, V105, P475, DOI 10.3171/jns.2006.105.3.475
   Cohen AR, 2011, J NEUROSURG, V115, P1029, DOI 10.3171/2011.5.JNS11703
   Filippidis AS, 2011, J NEUROSURG, V115, P1031, DOI 10.3171/2011.6.JNS101504
   Hunn BHM, 2014, CLIN NEUROL NEUROSUR, V116, P67, DOI 10.1016/j.clineuro.2013.10.019
   Kalani MYS, 2013, J CLIN NEUROSCI, V20, P462, DOI 10.1016/j.jocn.2012.04.027
   Lesniak MS, 2002, BRIT J NEUROSURG, V16, P555
   Levine DN, 2008, J NEUROL SCI, V269, P1, DOI 10.1016/j.jns.2007.12.022
   Lin B-J, 2016, NEUROSURG QUART, V26, P256
   Miller J D, 1975, Clin Neurosurg, V22, P76
   Owler BK, 2001, BRIT J NEUROSURG, V15, P353
   Pandey S, 2017, WORLD NEUROSURG, V99, DOI 10.1016/j.wneu.2016.12.049
   PANG DL, 1994, NEUROSURGERY, V35, P643, DOI 10.1227/00006123-199410000-00010
   Rekate HL, 2008, J NEUROSURG-PEDIATR, V2, P1, DOI 10.3171/PED/2008/2/7/001
   Smalley ZS, 2017, NEUROSURGERY, V80, P439, DOI 10.1093/neuros/nyw046
   Strand A, 2018, WORLD NEUROSURG, V109, pE131, DOI 10.1016/j.wneu.2017.09.120
   Suarez-Rivera O, 1998, SURG NEUROL, V49, P563, DOI 10.1016/S0090-3019(97)00342-X
   VASSILYADI M, 1995, J NEUROSURG, V83, P486, DOI 10.3171/jns.1995.83.3.0486
NR 18
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP E510
EP E516
DI 10.1016/j.wneu.2018.12.123
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800066
PM 30611954
DA 2020-05-12
ER

PT J
AU Xin, BQ
   Chen, GH
   Wang, Y
   Bai, GJ
   Gao, X
   Chu, JJ
   Xiao, JR
   Liu, TL
AF Xin, Baoquan
   Chen, Guanghui
   Wang, Yang
   Bai, Guangjian
   Gao, Xin
   Chu, Jianjun
   Xiao, Jianru
   Liu, Tielong
TI The Efficacy of Immersive Virtual Reality Surgical Simulator Training
   for Pedicle Screw Placement: A Randomized Double-Blind Controlled Trial
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cadaver study; Pedicle screw placement; Simulator training; Virtual
   reality
ID SPINE SURGERY; NAVIGATION; INSERTION; ACCURACY; SAFETY
AB PURPOSE: To assess efficacy of immersive virtual reality (VR) surgical simulator training for pedicle screw placement (PSP) in surgical graduate students.
   METHODS: Sixteen inexperienced surgical graduate students were equally randomly assigned to an experimental group (VR group) and a control group (non-VR group). Students in the VR group performed PSP on the immersive VR surgical simulator, and students in the non-VR group were given a traditional introductory teaching session before a cadaver test. Eight adult fresh cadavers, 6 male and 2 female, were collected and randomly allocated to the 2 groups. Each group performed bilateral T11-L4 PSP on the cadavers independently, and the outcomes of PSP in terms of accuracy, success rate, and efficiency were assessed by computed tomography and compared between the 2 groups statistically.
   RESULTS: Accuracy rate of PSP in the VR group was 89.6% versus 60.4% in the non-VR group (P < 0.05), success rate was 100% versus 79.2% (P < 0.05), and mean time was 2.8 +/- 1 minutes versus 4.9 +/- 1 minutes (P < 0.05), all showing significant differences between the 2 groups.
   CONCLUSIONS: The immersive VR surgical simulator for PSP training model is superior to the traditional training model in terms of accuracy, success rate, and efficiency, showing potential in training new orthopedic spine surgeons.
C1 [Xin, Baoquan; Bai, Guangjian] Taishan Med Univ, Tai An, Shandong, Peoples R China.
   [Chen, Guanghui] Peking Univ, Hosp 3, Dept Orthoped, Beijing, Peoples R China.
   [Wang, Yang; Chu, Jianjun] Hefei Orthopaed Hosp, Dept Spine, Hefei, Anhui, Peoples R China.
   [Gao, Xin; Xiao, Jianru; Liu, Tielong] Changzheng Hosp, Orthopaed Oncol Ctr, Dept Orthopaed, Shanghai, Peoples R China.
RP Liu, TL (reprint author), Changzheng Hosp, Orthopaed Oncol Ctr, Dept Orthopaed, Shanghai, Peoples R China.
EM liuteilongvip@163.com
CR Alaker M, 2016, INT J SURG, V29, P85, DOI 10.1016/j.ijsu.2016.03.034
   Bernardo A, 2017, WORLD NEUROSURG, V106, P1015, DOI 10.1016/j.wneu.2017.06.140
   Choque-Velasquez J, 2018, WORLD NEUROSURG, V112, P126, DOI 10.1016/j.wneu.2018.01.067
   Fan Y, 2017, MED SCI MONITOR, V23, P5960, DOI 10.12659/MSM.905713
   Gao ST, 2018, EUR SPINE J, V27, P921, DOI 10.1007/s00586-017-5333-y
   Gasco J, 2014, NEUROL RES, V36, P968, DOI 10.1179/1743132814Y.0000000388
   Gebhard F, 2004, INJURY, V35, P35, DOI 10.1016/j.injury.2004.05.009
   Gonzalvo A, 2009, SPINE, V34, pE761, DOI 10.1097/BRS.0b013e3181b2f928
   Heng PA, 2004, ST HEAL T, V98, P130
   Hlubek RJ, 2018, SPINE J, V18, P1374, DOI 10.1016/j.spinee.2017.12.003
   Incekara F, 2018, WORLD NEUROSURG, V118, pE422, DOI 10.1016/j.wneu.2018.06.208
   Keric N, 2017, NEUROSURG FOCUS, V42, DOI 10.3171/2017.2.FOCUS16552
   Lee SH, 2012, SPINE, V37, P280, DOI 10.1097/BRS.0b013e31822338ad
   Luciano CJ, 2013, NEUROSURGERY, V72, pA89, DOI 10.1227/NEU.0b013e3182750a8d
   Luciano CJ, 2011, NEUROSURGERY, V69, P14, DOI 10.1227/NEU.0b013e31821954ed
   Manbachi A, 2014, SPINE J, V14, P165, DOI 10.1016/j.spinee.2013.03.029
   Maytin M, 2015, PACE, V38, P319, DOI 10.1111/pace.12546
   Mazur T, 2018, WORLD NEUROSURG, V110, P414, DOI 10.1016/j.wneu.2017.11.132
   Pfandler M, 2017, SPINE J, V17, P1352, DOI 10.1016/j.spinee.2017.05.016
   Podolsky DJ, 2010, J SPINAL DISORD TECH, V23, pE70, DOI 10.1097/BSD.0b013e3181d345cb
   Shi JG, 2018, WORLD NEUROSURG, V111, pE98, DOI 10.1016/j.wneu.2017.12.015
   Shimokawa N, 2017, NEUROSURG REV, V40, P251, DOI 10.1007/s10143-016-0757-0
   Tanner Gregory, 2017, BMC Res Notes, V10, P678, DOI 10.1186/s13104-017-3029-3
   Theologou Marios, 2017, Surg Neurol Int, V8, P131, DOI 10.4103/sni.sni_85_17
   Willis RE, 2014, J SURG EDUC, V71, P426, DOI 10.1016/j.jsurg.2013.11.003
NR 25
TC 3
Z9 3
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP E324
EP E330
DI 10.1016/j.wneu.2018.12.090
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800042
PM 30597280
DA 2020-05-12
ER

PT J
AU Xiong, CX
   Luo, JL
   Yin, D
   Zhan, XL
   Liu, HJ
AF Xiong, Chunxiang
   Luo, Juli
   Yin, Dong
   Zhan, Xinli
   Liu, Huijiang
TI Biomechanical Evaluation of an Anterior Upper Thoracic Plate Fixation
   System: An In Vitro Human Cadaveric Study
SO WORLD NEUROSURGERY
LA English
DT Article
DE Anterior approach; Biomechanical; Fixation system; Plate; Thoracic
   vertebra
ID CERVICOTHORACIC JUNCTION; SPINE; STERNOTOMY; VERTEBRAE; SCREWS
AB OBJECTIVE: This study aimed to evaluate the biomechanical characteristics of the anterior upper thoracic plate fixation system (AUTP).
   METHODS: Twelve specimens were divided into 2 groups: the AUTP group and the anterior cervical locking plate (ACLP) group. Bone mineral density was assessed in all specimens. The specimens were loaded with pure bending moments of +/- 4 Nm to move toward extension/flexion, right/left lateral tilt, and right/left axial rotation. Each specimen was tested in 3 load cycles under 3 conditions (native, destabilized, and torsion). The tightening moments were assessed in every screw using a torsion meter.
   RESULTS: The tightening moment of the AUTP screws was more pronounced than the ACLP (P < 0.05). Significant decreases after stabilization with the AUTP compared with the native situation were observed in the AUTP group (P < 0.05). In terms of the direction of lateral tilt and torsion, the neutral zone increased significantly after stabilization with the AUTP compared with the native situation (P < 0.05).
   CONCLUSIONS: The AUTP was shown to provide more rigidity to the destabilized spine than the ACLP.
C1 [Xiong, Chunxiang] Shanxi Med Univ, Co Culture Post Doctoral Res Ctr, Peoples Hosp Guangxi Zhuang Autonomous Reg, Nanning, Guangxi, Peoples R China.
   [Xiong, Chunxiang] Shanxi Med Univ, Postdoctoral Mobile Stn Clin Med, Nanning, Guangxi, Peoples R China.
   [Xiong, Chunxiang; Yin, Dong] Peoples Hosp Guangxi Zhuang Autonomous Reg, Dept Orthoped, Nanning, Guangxi, Peoples R China.
   [Luo, Juli] Hunan Univ Tradit Chinese Med, Dept Orthoped, Affiliated Hosp 1, Changsha, Hunan, Peoples R China.
   [Zhan, Xinli] Guangxi Med Univ, Spine & Osteopathy Ward, Affiliated Hosp 1, Nanning, Guangxi, Peoples R China.
   [Liu, Huijiang] First Peoples Hosp Nanning, Spine Ward, Nanning, Guangxi, Peoples R China.
RP Zhan, XL (reprint author), Guangxi Med Univ, Spine & Osteopathy Ward, Affiliated Hosp 1, Nanning, Guangxi, Peoples R China.
EM gxqyyxcx@163.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [30960386]; Guangxi Natural Science
   FoundationNational Natural Science Foundation of Guangxi Province
   [2015GXNSFAA139200]; Guangxi Medical and Health Self-financing Plan
   Project [Z2016609]
FX This work was supported by the National Natural Science Foundation of
   China (30960386), Guangxi Natural Science Foundation (Guikeji
   2015GXNSFAA139200), and Guangxi Medical and Health Self-financing Plan
   Project (Z2016609).
CR Agarwala A, 2012, CLIN BIOMECH, V27, P64, DOI 10.1016/j.clinbiomech.2011.07.007
   Cho J, 2017, BMC MUSCULOSKEL DIS, V18, DOI 10.1186/s12891-017-1889-2
   Cohen ZR, 2004, J SPINAL DISORD TECH, V17, P543, DOI 10.1097/01.bsd.0000117541.10843.c9
   Cusick JF, 2018, CLIN BIOMECH, V55, P18, DOI 10.1016/j.clinbiomech.2018.04.001
   Grechenig S, 2015, INJURY, V46, pS125, DOI 10.1016/S0020-1383(15)30031-0
   Huang YX, 2010, EUR SPINE J, V19, P1936, DOI 10.1007/s00586-010-1478-7
   Le HV, 2015, CUREUS, V7, DOI 10.7759/cureus.324
   Lee DH, 2011, SPINE J, V11, P1146, DOI 10.1016/j.spinee.2011.11.006
   Lee Jae Ho, 2017, Korean J Spine, V14, P57, DOI 10.14245/kjs.2017.14.2.57
   Liu YL, 2009, CLIN ORTHOP RELAT R, V467, P2018, DOI 10.1007/s11999-008-0469-z
   Mihir B, 2006, SPINE, V31, pE244, DOI 10.1097/01.brs.0000214883.11874.80
   Nel JJ, 2017, VET SURG, V46, P789, DOI 10.1111/vsu.12673
   Park J, 2011, J NEUROSURG-SPINE, V14, P639, DOI 10.3171/2011.1.SPINE10446
   Radek A, 1999, Neurol Neurochir Pol, V33, P1201
   Rovlias A, 2017, J NEUROSCI RURAL PRA, V8, P120, DOI 10.4103/jnrp.jnrp_99_17
   Sharan AD, 2000, SPINE, V25, P910, DOI 10.1097/00007632-200004150-00003
   Teng HL, 2009, J NEUROSURG-SPINE, V10, P531, DOI 10.3171/2009.2.SPINE08372
   Ward J, 2015, J MAN MANIP THER, V23, P43, DOI 10.1179/1066981714Z.000000000106
   Wilke H J, 1998, Eur Spine J, V7, P148, DOI 10.1007/s005860050045
   Xiao ZM, 2007, EUR SPINE J, V16, P439, DOI 10.1007/s00586-006-0239-0
   Xu TM, 2016, WORLD NEUROSURG, V92, P133, DOI 10.1016/j.wneu.2016.04.126
NR 21
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP E503
EP E509
DI 10.1016/j.wneu.2018.12.121
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800065
PM 30611948
DA 2020-05-12
ER

PT J
AU Xu, HM
   Hu, F
   Wang, XY
   Tong, SL
AF Xu, Hong-Ming
   Hu, Fei
   Wang, Xiang-Yang
   Tong, Song-Lin
TI Magnetic Resonance-Based Morphological Features of the Manubrium and the
   Surgeons' View Line: When to Use Manubriotomy?
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cervicothoracic junction; CTJ; Magnetic resonance imaging; Manubriotomy;
   Surgeons' view line; Surgical approach
ID MODIFIED ANTERIOR APPROACH; CERVICOTHORACIC JUNCTION; SPINE; SELECTION;
   TUMORS
AB OBJECTIVE: We sought to identify the morphological features of the relationship between the manubrium and vertebrae of the cervicothoracic junction for use in guidelines for the selection of the appropriate surgical approach.
   METHODS: We performed a review of 222 midsagittal section magnetic resonance imaging scans. The surgeons' view line was parallel to the inferior caudal vertebral endplate. Morphometric measurement of the manubrium and the cervicothoracic junction's vertebral body included the distance from the highest point of the manubrium to the surgeons' view line and the angle between that line to the horizontal line.
   RESULTS: A significant difference was found with regard to the distance between the groups (P < 0.001). A significant difference between males and females was also identified. The lowest level above the manubrium was the T1. Between the groups, the angles were significantly different (P <= 0.01). Males had a larger angle than females with respect to groups C6, C7, T1 (P < 0.001), and T2 (P = 0.007). In terms of both the distance and the angle, no significant difference was found according to age (P > 0.05).
   CONCLUSION: Our results have provided insight into the anatomy of the manubrium and vertebrae of the cervicothoracic junction. Furthermore, our results have shown that, for most people, the T1 forms the boundary of the manubriotomy. We found that both the distance and angle differed significantly according to sex. A better understanding of the radiological anatomy of the surgeons' view line will help in the preoperative assessment of patients and in indicating an appropriate surgical approach.
C1 [Xu, Hong-Ming; Tong, Song-Lin] Wenzhou Med Univ, Affiliated Cixi Hosp, Dept Orthopaed Surg, Ningbo, Zhejiang, Peoples R China.
   [Hu, Fei] Ningbo Univ, Sch Med, Diabet Res Ctr, Ningbo, Zhejiang, Peoples R China.
   [Wang, Xiang-Yang] Wenzhou Med Univ, Dept Orthopaed Surg, Affiliated Hosp 2, Wenzhou, Peoples R China.
RP Wang, XY (reprint author), Wenzhou Med Univ, Dept Orthopaed Surg, Affiliated Hosp 2, Wenzhou, Peoples R China.
EM xiangyangwang@126.com
FU Medical and Health Science and Technology Program of Zhejiang Province
   [2018KY740]; Major Scientific and Technological Project of Medical and
   Health of Zhejiang Province [WKJ-ZJ-1527]; Zhejiang Public Service
   Technology Research Program/Social Development [LGF18H060008]
FX The present study was supported by the Medical and Health Science and
   Technology Program of Zhejiang Province (grant 2018KY740), the Major
   Scientific and Technological Project of Medical and Health of Zhejiang
   Province (grant WKJ-ZJ-1527), and the Zhejiang Public Service Technology
   Research Program/Social Development (grant LGF18H060008).
CR An HS, 1999, J SPINAL DISORD, V12, P519
   Cauchoix J, 1957, Ann R Coll Surg Engl, V21, P237
   DARLING GE, 1995, SPINE, V20, P1519, DOI 10.1097/00007632-199507000-00015
   Falavigna Asdrubal, 2009, Coluna/Columna, V8, P153, DOI 10.1590/S1808-18512009000200010
   Falavigna A, 2011, J NEUROSURG-SPINE, V15, P38, DOI 10.3171/2011.3.SPINE10342
   Fuentes S, 2010, J NEUROSURG-SPINE, V12, P160, DOI 10.3171/2009.9.SPINE09471
   GIEGER M, 1995, NEUROSURGERY, V37, P704, DOI 10.1227/00006123-199510000-00014
   HODGSON AR, 1960, J BONE JOINT SURG AM, V42, P295, DOI 10.2106/00004623-196042020-00009
   Huang YX, 2013, EUR SPINE J, V22, P1533, DOI 10.1007/s00586-013-2766-9
   Jain S, 2008, J NEUROSURG-SPINE, V9, P71, DOI 10.3171/SPI/2008/9/7/071
   Karikari IO, 2009, NEUROSURGERY, V65, P165, DOI 10.1227/01.NEU.0000347472.07670.EB
   Kaya RA, 2006, SURG NEUROL, V65, P454, DOI 10.1016/j.surneu.2005.08.017
   KURZ LT, 1991, SPINE, V16, pS542, DOI 10.1097/00007632-199110001-00018
   Le Hoang, 2003, Neurosurg Focus, V15, pE3
   Luk KDK, 2002, J BONE JOINT SURG AM, V84A, P1013, DOI 10.2106/00004623-200206000-00017
   Sar C, 1999, J SPINAL DISORD, V12, P102
   SIEGAL T, 1985, NEUROSURGERY, V17, P424, DOI 10.1227/00006123-198509000-00005
   SMITH GW, 1958, J BONE JOINT SURG AM, V40, P607, DOI 10.2106/00004623-195840030-00009
   SOUTHWICK WO, 1957, J BONE JOINT SURG AM, V39, P631, DOI 10.2106/00004623-195739030-00017
   Teng HL, 2009, J NEUROSURG-SPINE, V10, P531, DOI 10.3171/2009.2.SPINE08372
NR 20
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP E793
EP E798
DI 10.1016/j.wneu.2019.01.055
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800103
PM 30684721
DA 2020-05-12
ER

PT J
AU Xu, J
   Yu, BF
   Liu, CH
   Zheng, W
   Xiao, YH
   Lin, Y
AF Xu, Jie
   Yu, Bo-Fei
   Liu, Chun-Hua
   Zheng, Wu
   Xiao, Yu-Hua
   Lin, Yuan
TI Microscopic Keyhole Technique for Surgical Removal of Thoracic Spinal
   Meningiomas
SO WORLD NEUROSURGERY
LA English
DT Article
DE Keyhole technique; Minimally invasive surgery; Thoracic spinal
   meningiomas; Tubular retractor
ID POSTERIOR APPROACH; ELDERLY-PATIENTS; SURGERY; LAMINECTOMY; RESECTION;
   TUMORS; EXPERIENCE; FUSION
AB OBJECTIVE: The aim of this study was to evaluate the safety and efficacy of the microscopic minimally invasive keyhole technique for surgical resection of thoracic spinal meningiomas.
   METHODS: Seventeen consecutive patients with thoracic spinal meningiomas were included in the series from May 2015 to August 2017. All patients were treated using a microscopic keyhole technique through a tubular retractor system. The demographic data and perioperative variables were recorded. At last follow-up, clinical outcome was assessed using the visual analog scale for pain and the American Spinal Injury Association scale for motor and sensory outcome.
   RESULTS: All patients underwent microscopic keyhole surgery and complete resection was achieved. Mean operative time was 153.2 minutes (range 115-300 minutes). Mean blood loss during surgery was 110.3 mL (range 50-175 mL). No infection or aggravation of spinal cord injury occurred after operation, except for 2 patients who had postoperative cerebrospinal fluid leakage that recovered after conservative treatment. The mean duration of hospital stay was 6.8 days (range 5-10 days). At the last follow-up, all patients had a reduced level of pain as suggested by an average visual analog scale score that improved from 7.6 to 0.2. The American Spinal Injury Association grade improved or remained normal in all patients except 1. No evidence of tumor recurrence or secondary spinal deformity was observed in any patients during the postoperative follow-up period, and spinal stabilities were found to be satisfactory.
   CONCLUSIONS: Based on our results, the microscopic minimally invasive keyhole technique can be used safely and effectively for resection of thoracic spinal meningiomas.
C1 [Xu, Jie; Yu, Bo-Fei; Zheng, Wu; Xiao, Yu-Hua; Lin, Yuan] Fujian Med Univ, Fujian Prov Hosp, Dept Orthoped, Div Spine Surg, Fuzhou, Fujian, Peoples R China.
   [Xu, Jie; Yu, Bo-Fei; Zheng, Wu; Xiao, Yu-Hua; Lin, Yuan] Fujian Med Univ, Fujian Prov Hosp, Dept Orthoped, Electrophysiol Ctr, Fuzhou, Fujian, Peoples R China.
   [Liu, Chun-Hua] Fujian Univ Tradit Chinese Med, Quanzhou Orthoped Traumatol Hosp, Dept Spinal Surg, Quanzhou, Fujian, Peoples R China.
RP Xu, J (reprint author), Fujian Med Univ, Fujian Prov Hosp, Dept Orthoped, Div Spine Surg, Fuzhou, Fujian, Peoples R China.; Xu, J (reprint author), Fujian Med Univ, Fujian Prov Hosp, Dept Orthoped, Electrophysiol Ctr, Fuzhou, Fujian, Peoples R China.
EM Jiexu1520@163.com
CR Afathi M, 2015, NEUROCHIRURGIE, V61, P333, DOI 10.1016/j.neuchi.2015.05.001
   Arora N, 2013, J ELECTROMYOGR KINES, V23, P394, DOI 10.1016/j.jelekin.2012.10.018
   CHIOU SM, 1989, ACTA NEUROCHIR, V100, P127, DOI 10.1007/BF01403599
   Cohen-Gadol AA, 2003, J NEUROSURG, V98, P258, DOI 10.3171/spi.2003.98.3.0258
   Cramer P, 2005, J NEUROSURG-SPINE, V3, P153, DOI 10.3171/spi.2005.3.2.0153
   Fessler RG, 2002, NEUROSURGERY, V51, pS37, DOI 10.1227/01.NEU.0000030928.34393.63
   Foley K T, 1999, Neurosurg Focus, V7, pe5
   Gandhi RH, 2013, NEUROSURG FOCUS, V35, DOI 10.3171/2013.5.FOCUS13163
   Gautschi Oliver P, 2014, Praxis (Bern 1994), V103, P1323, DOI 10.1024/1661-8157/a001832
   Ghahreman A, 2010, NEUROSURGERY, V66, P296, DOI 10.1227/01.NEU.0000363600.24074.D0
   Haegelen C, 2005, EUR SPINE J, V14, P440, DOI 10.1007/s00586-004-0809-y
   Iacoangeli M, 2012, CLIN INTERV AGING, V7, P557, DOI 10.2147/CIA.S38923
   Kelley BJ, 2012, J NEUROSURG-PEDIATR, V10, P334, DOI 10.3171/2012.7.PEDS11526
   Kim CH, 2011, SPINE, V36, pE531, DOI 10.1097/BRS.0b013e3181dc8426
   Kim CW, 2010, SPINE, V35, pS281, DOI 10.1097/BRS.0b013e3182022d32
   Kleihues P, 2002, J NEUROPATH EXP NEUR, V61, P215, DOI 10.1093/jnen/61.3.215
   Kwak YS, 2012, J KOREAN NEUROSURG S, V52, P427, DOI 10.3340/jkns.2012.52.4.427
   Lee Gun Woo, 2014, Eur J Orthop Surg Traumatol, V24 Suppl 1, pS145, DOI 10.1007/s00590-013-1287-x
   McGirt MJ, 2010, NEUROSURGERY, V66, P1005, DOI 10.1227/01.NEU.0000367721.73220.C9
   Mesfin A, 2015, J AM ACAD ORTHOP SUR, V23, P38, DOI 10.5435/JAAOS-23-01-38
   Morandi X, 2004, SPINE, V29, P2191, DOI 10.1097/01.brs.0000141173.79572.40
   Nadkarni B, 2005, J Orthop Surg (Hong Kong), V13, P326
   Ozkan N, 2013, NEUROSURG REV, V36, P611, DOI 10.1007/s10143-013-0462-1
   Ogden AT, 2009, CLIN BIOMECH, V24, P143, DOI 10.1016/j.clinbiomech.2008.11.005
   Raygor KP, 2015, NEUROSURG FOCUS, V39, DOI 10.3171/2015.5.FOCUS15187
   Schaller B, 2005, J NEURO-ONCOL, V75, P157, DOI 10.1007/s11060-005-1469-4
   Sciubba DM, 2008, J NEUROSURG-SPINE, V8, P413, DOI 10.3171/SPI/2008/8/5/413
   SOLERO CL, 1989, NEUROSURGERY, V25, P153, DOI 10.1227/00006123-198908000-00001
   Voulgaris S, 2010, EUR SPINE J, V19, P1195, DOI 10.1007/s00586-010-1295-z
   Xu J, 2018, WORLD NEUROSURG, V109, pE110, DOI 10.1016/j.wneu.2017.09.114
   Yu Y, 2011, J CLIN NEUROSCI, V18, P1168, DOI 10.1016/j.jocn.2010.12.043
   Zhu YJ, 2015, NEUROSURG FOCUS, V39, DOI 10.3171/2015.5.FOCUS15182
   Zhuang YD, 2017, ONCOL LETT, V14, P7873, DOI 10.3892/ol.2017.7203
NR 33
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP E373
EP E379
DI 10.1016/j.wneu.2018.12.099
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800048
PM 30610972
DA 2020-05-12
ER

PT J
AU Yeboa, DN
   Liao, KP
   Guadagnolo, BA
   Rao, G
   Bishop, A
   Chung, C
   Li, J
   Tatsui, CE
   Rhines, LD
   Ferguson, S
   Paulino, AD
   Ghia, AJ
AF Yeboa, Debra Nana
   Liao, Kia-ping
   Guadagnolo, Beverly Ashleigh
   Rao, Ganesh
   Bishop, Andrew
   Chung, Caroline
   Li, Jing
   Tatsui, Claudio Esteves
   Rhines, Laurence D.
   Ferguson, Sherise
   Paulino, Arnold de la Cruz
   Ghia, Amol Jitendra
TI National Patterns of Care in the Management of World Health Organization
   Grade II and III Spinal Ependymomas
SO WORLD NEUROSURGERY
LA English
DT Article
DE Ependymoma; Grade; Radiation therapy; Spinal ependymoma; Spine; Survival
ID INTRAMEDULLARY EPENDYMOMA; MYXOPAPILLARY; GUIDELINES; DISTANCE;
   FACILITY; TUMORS
AB BACKGROUND: Spinal ependymomas are rare, with an incidence of 1 per 100,000. Given the paucity of data for higher grade II and III disease, the management and patterns of care require further investigation.
   METHODS: Our study of 1345 patients with higher-grade spinal ependymoma used chi(2) tests and simple and multivariable logistic regression models to assess demographic and clinical factors associated with therapy. Kaplan-Meier and log-rank tests were used to assess overall survival (OS).
   RESULTS: Most grade II patients received surgery alone (81.1%) compared with 36.8% of grade III. Approximately 60% of patients with grade III ependymomas received radiotherapy (RT) versus 15.3% of grade II (P < 0.001). Patients living <= 32 km (20 miles) from a facility were more likely to receive RT (P < 0.001) than were those living further away. On multivariable logistic regression, grade (grade III, odds ratio, 8.6; P < 0.001) and facility distance were significantly associated with receipt of RT (P < 0.0001). The 5-year and 10-year OS was 94.7%/85.1% for patients with grade II disease and 58.2%/46.4% for grade III disease (P < 0.0001). OS was highest at facilities treating an average of 15 patients over 10 years, corresponding to the top 81st percentile in volume. The 10-year OS was 92.6% at facilities treating at least 15 patients and 88.0% at facilities treating 6-14 patients.
   CONCLUSIONS: Approximately 40% of patients with grade III ependymomas do not receive immediate adjuvant therapy, which may be related to distance from a facility. Patients with this rare tumor may benefit from multidisciplinary care at facilities with a larger volume.
C1 [Yeboa, Debra Nana; Guadagnolo, Beverly Ashleigh; Bishop, Andrew; Chung, Caroline; Li, Jing; Paulino, Arnold de la Cruz; Ghia, Amol Jitendra] Univ Texas Houston, MD Anderson Canc Ctr, Dept Radiat Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.
   [Yeboa, Debra Nana; Liao, Kia-ping; Guadagnolo, Beverly Ashleigh] Univ Texas Houston, MD Anderson Canc Ctr, Dept Hlth Serv Res, 1515 Holcombe Blvd, Houston, TX 77030 USA.
   [Rao, Ganesh; Tatsui, Claudio Esteves; Rhines, Laurence D.; Ferguson, Sherise] Univ Texas Houston, MD Anderson Canc Ctr, Dept Neurosurg, 1515 Holcombe Blvd, Houston, TX 77030 USA.
RP Yeboa, DN (reprint author), Univ Texas Houston, MD Anderson Canc Ctr, Dept Radiat Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.
EM dnyeboa@mdanderson.org
OI Bishop, Andrew/0000-0002-7737-8023
CR Acharya S, 2016, INT J RADIAT ONCOL, V94, P691, DOI 10.1016/j.ijrobp.2015.12.020
   Akyurek S, 2006, J NEURO-ONCOL, V80, P177, DOI 10.1007/s11060-006-9169-2
   Borges LF, 2018, J NEUROSURG SCI, V62, P51, DOI 10.23736/S0390-5616.17.04162-5
   Chang UK, 2002, J NEURO-ONCOL, V57, P133
   COOPER PR, 1989, NEUROSURGERY, V25, P855, DOI 10.1227/00006123-198912000-00001
   Figueiredo N, 2013, J NEUROSURG SCI, V57, P327
   Harrop JS, 2009, SPINE, V34, pS69, DOI 10.1097/BRS.0b013e3181b95c6f
   Khalid SI, 2018, WORLD NEUROSURG, V111, pE53, DOI 10.1016/j.wneu.2017.11.165
   Kobayashi K, 2018, SPINE, V43, pE525, DOI 10.1097/BRS.0000000000002496
   MCCORMICK PC, 1990, J NEUROSURG, V72, P523, DOI 10.3171/jns.1990.72.4.0523
   Milano MT, 2010, J NEURO-ONCOL, V98, P83, DOI 10.1007/s11060-009-0054-7
   National Comprehensive Cancer Network, 2018, NAT COMPR CANC NETW
   Ruda R, 2018, NEURO-ONCOLOGY, V20, P445, DOI 10.1093/neuonc/nox166
   Vetterlein MW, 2017, CANCER-AM CANCER SOC, V123, P3241, DOI 10.1002/cncr.30744
   WALDRON JN, 1993, INT J RADIAT ONCOL, V27, P223, DOI 10.1016/0360-3016(93)90231-J
   Weber DC, 2015, NEURO-ONCOLOGY, V17, P588, DOI 10.1093/neuonc/nou293
   WEN BC, 1991, INT J RADIAT ONCOL, V20, P781, DOI 10.1016/0360-3016(91)90023-W
   Wostrack M, 2018, J NEUROSURG-SPINE, V28, P654, DOI 10.3171/2017.9.SPINE17494
NR 18
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP E580
EP E594
DI 10.1016/j.wneu.2018.12.159
PG 15
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800075
PM 30641236
DA 2020-05-12
ER

PT J
AU Yilmaz, H
   Yilmaz, O
AF Yilmaz, Hakan
   Yilmaz, Ozlem
TI Follow-Up Computed Tomography Requirement of Pediatric Head Trauma
   Patients with Abnormal Imaging Findings
SO WORLD NEUROSURGERY
LA English
DT Article
DE Brain computed tomography scan; Glasgow Coma Scale; Head trauma;
   Pediatric
ID CLINICAL DECISION RULE; CHILDREN; PREDICTION; INJURY; CT; RISK; SEX; AGE
AB OBJECTIVE: We investigated pediatric patients presenting with isolated head trauma to emergency service. Where abnormal findings were detected on brain computed tomography (CT) scan, we evaluated the follow-up scan rate and whether follow-up scans affected the treatment protocol.
   METHODS: Pediatric patients who presented to emergency service between 2014 and 2017 with isolated head trauma and were later found to have abnormal findings on CT scan were evaluated. The patients were evaluated in terms of age, sex, pediatric Glasgow Coma Scale score at emergency service, trauma mechanism, and abnormal findings on CT scan. We also documented whether follow-up CT scan altered the treatment decision in patients as to whether they underwent surgery or received conservative treatment.
   RESULTS: The 105 head trauma patients with abnormal findings on CT scan consisted of 58 boys (55.2%) and 47 girls (44.8%). After the first brain CT examination, 5 of the patients (4.7%) underwent emergency surgery. For patients with linear fractures, the number of follow-up CT scans was 2.3. For patients with linear fractures, vomiting was found to be a symptom with statistical meaning as a sign of additional cranial pathology compared with headache, drowsiness, and irritability. A total of 280 follow-up CT scans with a mean number of 2.66 per patient were performed.
   CONCLUSIONS: Follow-up CT scan for patients with abnormal findings on the initial CT scan after head trauma does not influence the decision to choose clinical observation or surgery except in patients with neurologic deterioration.
C1 [Yilmaz, Hakan] Usak Univ, Educ & Res Hosp, Dept Neurosurg, Duzce, Turkey.
   [Yilmaz, Hakan] Duzce State Hosp, Dept Neurosurg, Duzce, Turkey.
   [Yilmaz, Ozlem] Usak Univ, Dept Pediat, Educ & Res Hosp, Usak, Turkey.
RP Yilmaz, H (reprint author), Usak Univ, Educ & Res Hosp, Dept Neurosurg, Duzce, Turkey.; Yilmaz, H (reprint author), Duzce State Hosp, Dept Neurosurg, Duzce, Turkey.
EM dr_hakanyilmaz@hotmail.com
CR BERNEY J, 1994, CHILD NERV SYST, V10, P509, DOI 10.1007/BF00335073
   BERNEY J, 1994, CHILD NERV SYST, V10, P517, DOI 10.1007/BF00335074
   Brody AS, 2007, PEDIATRICS, V120, P677, DOI 10.1542/peds.2007-1910
   Davis T, 2014, HEAD INJURY TRIAGE A
   Donnelly LF, 2001, AM J ROENTGENOL, V176, P303, DOI 10.2214/ajr.176.2.1760303
   Dunning J, 2006, ARCH DIS CHILD, V91, P885, DOI 10.1136/adc.2005.083980
   Gerdung C, 2012, CAN J EMERG MED, V14, P243, DOI 10.2310/8000.2012.110387
   KISSOON N, 1990, CAN MED ASSOC J, V142, P27
   Lee Christoph I, 2008, J Am Coll Radiol, V5, P78, DOI 10.1016/j.jacr.2007.06.013
   Lorton F, 2016, SCAND J TRAUMA RESUS, V24, DOI 10.1186/s13049-016-0287-3
   Maguire JL, 2009, PEDIATRICS, V124, pE145, DOI 10.1542/peds.2009-0075
   Osmond MH, 2010, CAN MED ASSOC J, V182, P341, DOI 10.1503/cmaj.091421
   Parkin PC, 2009, LANCET, V374, P1127, DOI 10.1016/S0140-6736(09)61634-2
   Pearce MS, 2012, LANCET, V380, P499, DOI 10.1016/S0140-6736(12)60815-0
   Schonfeld D, 2014, ARCH DIS CHILD, V99, P427, DOI 10.1136/archdischild-2013-305004
   Schutzman SA, 2001, PEDIATRICS, V107, P983, DOI 10.1542/peds.107.5.983
   Slovis TL, 2003, PEDIATRICS, V112, P971, DOI 10.1542/peds.112.4.971
NR 17
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP E764
EP E768
DI 10.1016/j.wneu.2018.12.219
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800098
PM 30677573
DA 2020-05-12
ER

PT J
AU Yoshino, M
   Kin, T
   Hara, T
AF Yoshino, Masanori
   Kin, Taichi
   Hara, Takayuki
TI Usefulness of High-Resolution Three-Dimensional Multifusion Medical
   Imaging for Preoperative Planning in Patients with Cerebral
   Arteriovenous Malformation
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cerebral arteriovenous malformation; Draining vein; Feeding artery;
   High-resolution three-dimensional multi-fusion medical imaging
ID DIGITAL-SUBTRACTION-ANGIOGRAPHY; MR-ANGIOGRAPHY; SYSTEM; SIMULATION;
   DIAGNOSIS; ARTERIES; DISPLAY
AB BACKGROUND: Successful resection of arteriovenous malformation (AVM) depends on preoperative assessment of the detailed morphology of the AVM. Simultaneous detailed three-dimensional visualization of the feeding arteries, draining veins, and surrounding structures is needed. The aim of this study was to evaluate the usefulness of high-resolution three-dimensional multifusion medical imaging (HR-3DMMI) for preoperative planning of AVM resection.
   METHODS: HR-3DMMI combined magnetic resonance imaging, magnetic resonance angiography, thin-slice computed tomography, and three-dimensional rotational angiography. Surface rendering was mainly used for creation of HR-3DMMI using multiple thresholds to create three-dimensional models. HR-3DMMI technique was used in 8 patients for preoperative planning, and imaging findings were compared with operative findings.
   RESULTS: All feeding arteries and draining veins were found intraoperatively at the same position as estimated preoperatively and were occluded as planned preoperatively.
   CONCLUSIONS: HR-3DMMI technique demonstrated the precise locations of feeding arteries, draining veins, and surrounding important tissues, such as corticospinal tract and arcuate fiber, preoperatively and estimated the appropriate route for resection of the AVM. HR-3DMMI is expected to be a very useful support tool for surgery of AVM.
C1 [Yoshino, Masanori; Hara, Takayuki] Toranomon Gen Hosp, Dept Neurosurg, Tokyo, Japan.
   [Kin, Taichi] Univ Tokyo, Dept Neurosurg, Grad Sch Med, Tokyo, Japan.
RP Yoshino, M (reprint author), Toranomon Gen Hosp, Dept Neurosurg, Tokyo, Japan.
EM ymasa-tky@umin.ac.jp
OI Yoshino, Masanori/0000-0003-3799-7775
CR Bekelis K, 2012, NEUROSURG FOCUS, V32, DOI 10.3171/2012.1.FOCUS127
   Bendok BR, 2014, NEUROSURGERY, V74, pS60, DOI 10.1227/NEU.0000000000000230
   Chappell ET, 2003, NEUROSURGERY, V52, P624, DOI 10.1227/01.NEU.0000047895.82857.EB
   Crowley RW, 2014, NEUROSURGERY, V74, pS74, DOI 10.1227/NEU.0000000000000176
   Kakizawa Y, 2002, J NEUROSURG, V96, P770, DOI 10.3171/jns.2002.96.4.0770
   Kin T, 2012, J NEUROSURG, V117, P78, DOI 10.3171/2012.3.JNS111541
   Kin T, 2011, NEUROSURGERY, V69, P40, DOI 10.1227/NEU.0b013e318211019a
   Kin T, 2009, NEUROSURGERY, V65, P121, DOI 10.1227/01.NEU.0000347890.19718.0A
   Lescher S, 2017, J NEUROINTERV SURG, V9, P887, DOI 10.1136/neurintsurg-2016-012462
   Malone HR, 2010, NEUROSURGERY, V67, P1105, DOI 10.1227/NEU.0b013e3181ee46d0
   McGee KP, 2006, J MAGN RESON IMAGING, V23, P361, DOI 10.1002/jmri.20519
   Mikami T, 2012, NEUROSURG REV, V35, P393, DOI 10.1007/s10143-012-0383-4
   Natarajan SK, 2008, NEUROSURGERY, V62, P1213, DOI 10.1227/01.neu.0000333293.74986.e5
   Ng I, 2009, ACTA NEUROCHIR, V151, P453, DOI 10.1007/s00701-009-0278-5
   Oishi M, 2011, NEUROSURGERY, V68, DOI 10.1227/NEU.0b013e318207b3ad
   Rubin BA, 2014, NEUROSURGERY, V74, pS50, DOI 10.1227/NEU.0000000000000219
   SPETZLER RF, 1986, J NEUROSURG, V65, P476, DOI 10.3171/jns.1986.65.4.0476
   Stadie AT, 2008, J NEUROSURG, V108, P382, DOI 10.3171/JNS/2008/108/2/0382
   STOCK KW, 1995, RADIOLOGY, V195, P451, DOI 10.1148/radiology.195.2.7724765
   Tsuchiya K, 2003, ACTA RADIOL, V44, P675, DOI 10.1046/j.1600-0455.2003.00133.x
   Wong GKC, 2009, SURG NEUROL, V72, P69, DOI 10.1016/j.surneu.2008.01.049
   Yoshino M, 2017, J NEUROSURG, V127, P139, DOI 10.3171/2016.5.JNS152646
   Yoshino M, 2015, NEUROL MED-CHIR, V55, P674, DOI 10.2176/nmc.tn.2014-0278
   Yoshino M, 2013, ACTA NEUROCHIR, V155, P1391, DOI 10.1007/s00701-013-1761-6
   Yoshino M, 2012, BRIT J NEUROSURG, V26, P927, DOI 10.3109/02688697.2012.692840
NR 25
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP E755
EP E763
DI 10.1016/j.wneu.2018.12.217
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800097
PM 30677580
DA 2020-05-12
ER

PT J
AU Zhang, C
   Wang, K
   Jian, FZ
   Wu, H
AF Zhang, Can
   Wang, Kai
   Jian, Fengzeng
   Wu, Hao
TI Efficacy of Oblique Lateral Interbody Fusion in Treatment of
   Degenerative Lumbar Disease
SO WORLD NEUROSURGERY
LA English
DT Article
DE Decompression; Disk degeneration; Nerve injury; Oblique lateral
   interbody fusion
ID FOLLOW-UP; COMPLICATIONS; DECOMPRESSION
AB OBJECTIVE: This study aimed to analyze the efficacy of oblique lumbar interbody fusion (OLIF) in the treatment of degenerative lumbar disease.
   METHODS: Twenty-two patients with degenerative lumbar disease who underwent OLIF between October 2016 and January 2017 were included. Radiography, computed tomography, and magnetic resonance imaging were performed pre-operatively and postoperatively. The cross-sectional area (CSA) of the dural sac, disk height, cross-sectional height of the intervertebral foramina, and intervertebral foramina CSA were measured. Scores from the visual analog scale, Oswestry Disability Index, and Medical Outcome Study 36-Item Short-Form Health Survey, obtained preoperatively, 1 week and 3 months postoperatively, and at the final follow-up, were compared.
   RESULTS: Forty-five segments were fused in 22 patients using OLIF. Postoperatively, CSA increased from 0.79 +/- 0.32 cm(2) to 1.40 +/- 0.37 cm(2), disk height increased from 0.67 +/- 0.24 cm to 1.15 +/- 0.31 cm, cross-sectional height increased from 1.51 +/- 0.25 cm to 2.01 +/- 0.31 cm, and intervertebral foramina increased from 1.11 +/- 0.28 cm(2) to 1.86 +/- 0.38 cm(2) (P < 0.01). The visual analog scale, Oswestry Disability Index, and 36-Item Short-Form Health Survey scores of all patients significantly improved postoperatively (P < 0.05). There were no complications involving injuries to spinal nerves, great vessels, abdominal viscera, or ureters. Only 1 patient experienced injury to the psoas major.
   CONCLUSIONS: OLIF is a safe and effective minimally invasive procedure for the treatment of degenerative lumbar disease.
C1 [Zhang, Can; Wang, Kai; Jian, Fengzeng; Wu, Hao] Capital Med Univ, Dept Neurosurg, Xuanwu Hosp, China INI, Beijing, Peoples R China.
RP Wu, H (reprint author), Capital Med Univ, Dept Neurosurg, Xuanwu Hosp, China INI, Beijing, Peoples R China.
EM 13901397527@139.com
CR Acosta FL, 2011, J NEUROSURG-SPINE, V15, P92, DOI 10.3171/2011.3.SPINE10425
   Bergey DL, 2004, SPINE, V29, P1681, DOI 10.1097/01.BRS.0000133643.75795.EF
   Chastain CA, 2007, ORTHOPEDICS, V30, P389, DOI 10.3928/01477447-20070501-18
   Cummock MD, 2011, J NEUROSURG-SPINE, V15, P11, DOI 10.3171/2011.2.SPINE10374
   Fujibayashi S, 2015, SPINE, V40, pE175, DOI 10.1097/BRS.0000000000000703
   GILL K, 1993, ACTA ORTHOP SCAND, V64, P108, DOI 10.3109/17453679309160137
   Ishihara H, 2001, J SPINAL DISORD, V14, P91, DOI 10.1097/00002517-200104000-00001
   Lee SH, 2011, SPINE, V36, pE538, DOI 10.1097/BRS.0b013e3181f45a17
   Manwaring JC, 2014, J NEUROSURG-SPINE, V20, P515, DOI 10.3171/2014.2.SPINE1347
   Mayer HM, 1997, SPINE, V22, P691, DOI 10.1097/00007632-199703150-00023
   Ohtori S, 2015, ASIAN SPINE J, V9, P565, DOI 10.4184/asj.2015.9.4.565
   Ohtori S, 2015, YONSEI MED J, V56, P1051, DOI 10.3349/ymj.2015.56.4.1051
   Okuda S, 2006, J NEUROSURG-SPINE, V4, P304, DOI 10.3171/spi.2006.4.4.304
   Oliveira L, 2010, SPINE, V35, pS331, DOI 10.1097/BRS.0b013e3182022db0
   Ozgur Burak M, 2006, Spine J, V6, P435, DOI 10.1016/j.spinee.2005.08.012
   Sasso RC, 2005, SPINE, V30, P670, DOI 10.1097/01.brs.0000155423.18218.75
   Sato J, 2017, EUR SPINE J, V26, P671, DOI 10.1007/s00586-015-4170-0
   Silvestre C, 2012, ASIAN SPINE J, V6, P89, DOI 10.4184/asj.2012.6.2.89
   TAKAHASHI K, 1990, SPINE, V15, P1211, DOI 10.1097/00007632-199011010-00022
   Youssef JA, 2010, SPINE, V35, pS302, DOI 10.1097/BRS.0b013e3182023438
NR 20
TC 2
Z9 2
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP E17
EP E24
DI 10.1016/j.wneu.2018.11.139
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800004
PM 30481626
DA 2020-05-12
ER

PT J
AU Zhang, L
   Wang, JC
   Feng, XM
   Tao, YP
   Yang, JD
   Wang, YX
   Zhang, SF
   Cai, J
AF Zhang, Liang
   Wang, Jingcheng
   Feng, Xinmin
   Tao, Yuping
   Yang, Jiandong
   Wang, Yongxiang
   Zhang, Shengfei
   Cai, Jun
TI Outcome Evaluation of Zero-Profile Device Used for Single-Level Anterior
   Cervical Discectomy and Fusion with Osteoporosis Compared without
   Osteoporosis: A Minimum Three-Year Follow-Up Study
SO WORLD NEUROSURGERY
LA English
DT Article
DE Anterior cervical discectomy and fusion; Cervical degenerative disc
   disease; Dysphagia; Fusion; Osteoporosis; Subsidence; Zero-Profile
   device
ID ALONE ANCHORED SPACER; SPINE SURGERY; CLINICAL-OUTCOMES; INTERBODY
   FUSION; ZOLEDRONIC ACID; PLATE; DYSPHAGIA; IMPLANT; CAGE; FIXATION
AB OBJECTIVE: We compared the mid-term efficacy and safety of anterior cervical discectomy and fusion (ACDF) using a Zero-Profile device for cervical degenerative disc disease (CDDD) with and without osteoporosis.
   METHODS: We performed a retrospective study of elderly patients with CDDD treated by single-level ACDF with a Zero-Profile device. The patients were divided into group A (osteoporosis) and group B (no osteoporosis) according to the bone mineral density. The clinical outcomes (Japanese Orthopaedic Association, neck disability index, visual analog scale, and short-form 36 scores), radiological outcomes (cervical lordosis and fusion rate), and complications were reviewed at each follow-up examination.
   RESULTS: All procedures were successfully performed in all patients. The Japanese Orthopaedic Association, neck disability index, visual analog scale, and short-form 36 scores and cervical lordosis were significantly improved postoperatively in both groups (P < 0.05). However, no significant difference was found between the 2 groups at each follow-up point (P > 0.05). No significant difference was found in the fusion rate at 3 months postoperatively (group A, 88.9%; group B, 90.0%), dysphagia rate at 1 month postoperatively (group A, 11.1%; group B, 15.0%), or cage subsidence rate at the final follow-up visit (group A, 11.1%; group B, 10.0%; P > 0.05). All patients achieved solid fusion, and no patient had dysphagia at the final follow-up examination.
   CONCLUSIONS: ACDF with the Zero-Profile device can be used as an effective and reliable treatment for single-level CDDD with osteoporosis.
C1 [Zhang, Liang; Wang, Jingcheng; Feng, Xinmin; Tao, Yuping; Yang, Jiandong; Wang, Yongxiang; Zhang, Shengfei; Cai, Jun] Yangzhou Univ, Clin Med Coll, Dept Orthoped, Yangzhou, Jiangsu, Peoples R China.
   [Zhang, Liang; Wang, Jingcheng; Feng, Xinmin; Tao, Yuping; Yang, Jiandong; Wang, Yongxiang; Zhang, Shengfei; Cai, Jun] Northern Peoples Hosp Jiangsu Prov, Inst Orthoped, Yangzhou, Jiangsu, Peoples R China.
RP Feng, XM (reprint author), Yangzhou Univ, Clin Med Coll, Dept Orthoped, Yangzhou, Jiangsu, Peoples R China.; Feng, XM (reprint author), Northern Peoples Hosp Jiangsu Prov, Inst Orthoped, Yangzhou, Jiangsu, Peoples R China.
EM fxmspine@sina.com
OI FENG, Xinmin/0000-0001-9287-858X
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [81401830]; Young Medical Scholars Major Program of
   Jiangsu Province [QNRC2016342]
FX This study was supported by grants from the National Natural Science
   Foundation of China (grant 81401830) and Young Medical Scholars Major
   Program of Jiangsu Province (grant QNRC2016342).
CR Albanese V, 2017, WORLD NEUROSURG, V106, P724, DOI 10.1016/j.wneu.2017.06.051
   Bazaz R, 2002, SPINE, V27, P2453, DOI 10.1097/00007632-200211150-00007
   Chen F, 2016, OSTEOPOROSIS INT, V27, P1469, DOI 10.1007/s00198-015-3398-1
   Chen Y, 2016, CLIN NEUROL NEUROSUR, V144, P72, DOI 10.1016/j.clineuro.2016.03.010
   Chin DK, 2007, OSTEOPOROSIS INT, V18, P1219, DOI 10.1007/s00198-007-0370-8
   Fisahn C, 2018, WORLD NEUROSURG, V109, pE382, DOI 10.1016/j.wneu.2017.09.188
   Guzman JZ, 2016, SPINE, V41, P662, DOI 10.1097/BRS.0000000000001347
   He SH, 2018, SPINE, V43, pE259, DOI 10.1097/BRS.0000000000002323
   He YX, 2011, BONE, V48, P1388, DOI 10.1016/j.bone.2011.03.720
   Kaiser MG, 2002, NEUROSURGERY, V50, P229, DOI 10.1097/00006123-200202000-00001
   Kalb S, 2012, WORLD NEUROSURG, V77, P183, DOI 10.1016/j.wneu.2011.07.004
   Korinth MC, 2008, ZBL NEUROCHIR, V69, P113, DOI 10.1055/s-2008-1081201
   Lan T, 2018, J BACK MUSCULOSKELET, V31, P299, DOI 10.3233/BMR-169708
   Lehman RA, 2015, J AM ACAD ORTHOP SUR, V23, P253, DOI 10.5435/JAAOS-D-14-00042
   Oppenlander ME, 2014, J SPINAL DISORD TECH, V27, P185, DOI 10.1097/BSD.0000000000000052
   Pang J, 2015, REJUV RES, V18, P356, DOI 10.1089/rej.2015.1682
   Park JB, 2005, J BONE JOINT SURG AM, V87A, P558, DOI 10.2106/JBJS.C.01555
   Park SB, 2011, J KOREAN NEUROSURG S, V49, P317, DOI 10.3340/jkns.2011.49.6.317
   Pitzen TR, 2009, SPINE, V34, P641, DOI 10.1097/BRS.0b013e318198ce10
   Ponnusamy KE, 2011, SPINE J, V11, P54, DOI 10.1016/j.spinee.2010.09.024
   Reinhold M, 2006, SPINE, V31, P406, DOI 10.1097/01.brs.0000199894.63450.70
   Scholz M, 2011, CLIN ORTHOP RELAT R, V469, P666, DOI 10.1007/s11999-010-1597-9
   Scholz M, 2009, SPINE, V34, P156, DOI 10.1097/BRS.0b013e31818ff9c4
   Shen Y, 2018, WORLD NEUROSURG, V115, pE226, DOI 10.1016/j.wneu.2018.04.019
   Shi L, 2012, J ORTHOP RES, V30, P1296, DOI 10.1002/jor.22072
   Shi S, 2016, WORLD NEUROSURG, V89, P285, DOI 10.1016/j.wneu.2016.02.009
   Shi S, 2016, J CLIN NEUROSCI, V25, P69, DOI 10.1016/j.jocn.2015.05.050
   SMITH GW, 1958, J BONE JOINT SURG AM, V40, P607, DOI 10.2106/00004623-195840030-00009
   Song KJ, 2009, SPINE, V34, P2886, DOI 10.1097/BRS.0b013e3181b64f2c
   Tu CW, 2014, J SURG RES, V192, P112, DOI 10.1016/j.jss.2014.05.034
   Wang KF, 2018, WORLD NEUROSURG, V113, pE70, DOI 10.1016/j.wneu.2018.01.157
   Wang MB, 2016, ACTA ORTHOP TRAUMATO, V50, P186, DOI 10.3944/AOTT.2015.15.0073
   Wang Y, 2009, OSTEOPOROSIS INT, V20, P1651, DOI 10.1007/s00198-009-0925-y
   Waschke A, 2013, J SPINAL DISORD TECH, V26, pE112, DOI 10.1097/BSD.0b013e3182764b37
   World Health Organization, 2003, PREV MAN OST REP WHO
   Yan DL, 2011, ARCH ORTHOP TRAUM SU, V131, P1369, DOI 10.1007/s00402-011-1317-2
   Yang Y, 2016, CLIN NEUROL NEUROSUR, V148, P72, DOI 10.1016/j.clineuro.2016.07.020
   Yang Y, 2016, DYSPHAGIA, V31, P134, DOI 10.1007/s00455-015-9681-7
   Yun DJ, 2017, WORLD NEUROSURG, V97, P189, DOI 10.1016/j.wneu.2016.09.065
   Zhang L, 2016, TURK NEUROSURG, V26, P416, DOI 10.5137/1019-5149.JTN.12017-14.1
NR 40
TC 1
Z9 1
U1 0
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP E1
EP E9
DI 10.1016/j.wneu.2018.10.024
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800002
PM 30321681
DA 2020-05-12
ER

PT J
AU Zhang, XR
   Gao, K
   Xie, HQ
   Gao, YZ
AF Zhang, Xiuru
   Gao, Kun
   Xie, Huiqi
   Gao, Yanzheng
TI Characteristics of Cervical Sagittal Alignment at Different C0-C2
   Correcting Angles in Fusion Treatment of Atlantoaxial Dislocations
SO WORLD NEUROSURGERY
LA English
DT Article
DE Atlantoaxial dislocations; C0-C2 angle; Cervical degenerative disc
   disease; Cervical sagittal alignment; Cervical sagittal vertical axis
ID SPINE ALIGNMENT; SPONDYLOTIC MYELOPATHY; CLINICAL-IMPLICATIONS; SUBAXIAL
   SUBLUXATION; DISC DEGENERATION; O-C2 ANGLE; PREDICTOR; ANTERIOR;
   SURGERY; CLASSIFICATION
AB OBJECTIVE: To explore the appropriate range of C0-C2 correction angles by analyzing cervical sagittal alignment parameters and evaluating clinical outcomes.
   METHODS: The preoperative and postoperative radiographs, visual analogue scale, Japanese Orthopedic Association score, and neck disability index of 65 atlantoaxial dislocation patients were retrospectively collected. The C0-C2 angle, C2-C7 angle, and cervical sagittal vertical axis (cSVA) were measured from the radiographs, and an assessment of cervical degenerative disc disease was made. According to the 2-year postoperative C0-C2 angles, all patients were categorized into a <10 degrees subgroup, 10 degrees-20 degrees subgroup, and >20 degrees subgroups.
   RESULTS: The postoperative C2-C7 angles and cSVA of the 10 degrees-20 degrees subgroup were significantly different from those of the <10 degrees subgroup. The Japanese Orthopedic Association score of the 10 degrees-20 degrees subgroup was significantly different from those of the <10 degrees and >20 degrees subgroups. All patients (26/26) in the 10 degrees-20 degrees subgroup exhibited a cSVA 0-40 mm, 25% of patients (6/24) in the >20 degrees subgroup exhibited a cSVA >40 mm, and 40% of patients (6/15) in the <10 degrees subgroup showed a cSVA <0 mm. The postoperative incidence of cervical degenerative disc disease did not increase in the 10 degrees-20 degrees subgroup.
   CONCLUSIONS: Atlantoaxial dislocation patients with different C0-C2 postoperative angles had different cervical sagittal alignments and clinical outcomes. In our study, the patients within the C0-C2 10 degrees-20 degrees subgroup exhibited superior clinical outcomes and cervical sagittal alignment.
C1 [Zhang, Xiuru; Xie, Huiqi] Sichuan Univ, West China Hosp, Dept Stem Cell & Tissue Engn, Chengdu, Sichuan, Peoples R China.
   [Zhang, Xiuru] Sichuan Univ, West China Hosp, Dept Orthoped, Chengdu, Sichuan, Peoples R China.
   [Zhang, Xiuru; Gao, Kun; Gao, Yanzheng] Henan Prov People Hosp, Surg Spine & Spinal Cord, Zhengzhou, Henan, Peoples R China.
RP Gao, YZ (reprint author), Henan Prov People Hosp, Surg Spine & Spinal Cord, Zhengzhou, Henan, Peoples R China.
EM Gaospine@126.com
OI Xie, Hui-Qi/0000-0003-0760-0853
CR Abelin-Genevois K, 2014, EUR SPINE J, V23, P1442, DOI 10.1007/s00586-013-3150-5
   Ames CP, 2015, J NEUROSURG-SPINE, V23, P673, DOI 10.3171/2014.12.SPINE14780
   Ames CP, 2013, SPINE, V38, pS149, DOI 10.1097/BRS.0b013e3182a7f449
   Benlidayi IC, 2015, AGING CLIN EXP RES, V27, P297, DOI 10.1007/s40520-014-0274-3
   BORDEN AGB, 1960, RADIOLOGY, V74, P806, DOI 10.1148/74.5.806
   Cote P, 1997, SPINE, V22, P859, DOI 10.1097/00007632-199704150-00007
   Goel A, 2005, J NEUROSURG-SPINE, V2, P505, DOI 10.3171/spi.2005.2.4.0505
   Goel A, 2019, WORLD NEUROSURG, V121, pE908, DOI 10.1016/j.wneu.2018.10.009
   Hardacker JW, 1997, SPINE, V22, P1472, DOI 10.1097/00007632-199707010-00009
   Harrison DD, 2004, SPINE, V29, P2485, DOI 10.1097/01.brs.0000144449.90741.7c
   Hey HWD, 2017, SPINE, V42, P1614, DOI 10.1097/BRS.0000000000002160
   Hyun SJ, 2016, SPINE, V41, pE396, DOI 10.1097/BRS.0000000000001264
   Ito H, 2009, EUR SPINE J, V18, P869, DOI 10.1007/s00586-009-0945-5
   Iyer S, 2016, SPINE, V41, P1826, DOI 10.1097/BRS.0000000000001642
   Izeki M, 2014, EUR SPINE J, V23, P328, DOI 10.1007/s00586-013-2963-6
   Kwon WK, 2017, SPINE, V42, P318, DOI 10.1097/BRS.0000000000001776
   Lan SB, 2018, WORLD NEUROSURG, V111, pE135, DOI 10.1016/j.wneu.2017.12.013
   Le Huec JC, 2015, EUR SPINE J, V24, P63, DOI 10.1007/s00586-014-3632-0
   Lee SH, 2012, J SPINAL DISORD TECH, V25, pE41, DOI 10.1097/BSD.0b013e3182396301
   Liu Q, 2016, WORLD NEUROSURG, V87, P521, DOI 10.1016/j.wneu.2015.09.025
   Liu W, 2018, J PAIN RES, V11, P1359, DOI 10.2147/JPR.S160472
   Machino M, 2016, SPINE, V41, P476, DOI 10.1097/BRS.0000000000001237
   Matsunaga S, 1997, SPINE, V22, P765, DOI 10.1097/00007632-199704010-00011
   Matsunaga S, 2001, SPINE, V26, P161, DOI 10.1097/00007632-200101150-00010
   MCGREGOR M, 1948, BRIT J RADIOL, V21, P171, DOI 10.1259/0007-1285-21-244-171
   Miyata M, 2009, SPINE, V34, P184, DOI [10.1097/BRS.0b013e31818ff64e, 10.1097/BRS.0b013e3181ab3ce8]
   Miyazaki M, 2008, SPINE, V33, pE870, DOI 10.1097/BRS.0b013e3181839733
   Okada E, 2009, EUR SPINE J, V18, P1644, DOI 10.1007/s00586-009-1095-5
   Ota M, 2011, SPINE, V36, pE720, DOI 10.1097/BRS.0b013e3181f9f714
   Park MS, 2014, SPINE J, V14, P1228, DOI 10.1016/j.spinee.2013.09.043
   Passias PG, 2013, J SPINAL DISORD TECH, V26, P15, DOI 10.1097/BSD.0b013e31823097f9
   Roguski M, 2014, SPINE, V39, P2070, DOI 10.1097/BRS.0000000000000641
   Scheer JK, 2013, J NEUROSURG-SPINE, V19, P141, DOI 10.3171/2013.4.SPINE12838
   Sherekar SK, 2006, NEUROL INDIA, V54, P264
   Sun LQ, 2016, WORLD NEUROSURG, V94, P89, DOI 10.1016/j.wneu.2016.06.092
   Takeshima Toshichika, 2002, Spine (Phila Pa 1976), V27, pE348, DOI 10.1097/00007632-200208010-00014
   Tamai K, 2018, SPINE J, V18, P1505, DOI 10.1016/j.spinee.2018.01.012
   Tang Jessica A, 2015, Neurosurgery, V76 Suppl 1, pS14, DOI 10.1227/01.neu.0000462074.66077.2b
   Uchida K, 2009, J NEUROSURG-SPINE, V11, P521, DOI 10.3171/2009.2.SPINE08385
   Villavicencio AT, 2011, NEUROSURGERY, V68, P1309, DOI 10.1227/NEU.0b013e31820b51f3
   Yang CW, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000001198
   Yu M, 2015, EUR SPINE J, V24, P1265, DOI 10.1007/s00586-015-3832-2
   Zhao WL, 2019, SPINE, V44, pE60, DOI 10.1097/BRS.0000000000002754
NR 43
TC 0
Z9 0
U1 2
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP E119
EP E124
DI 10.1016/j.wneu.2018.12.017
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800015
PM 30583133
DA 2020-05-12
ER

PT J
AU Zhao, JL
   Du, ZY
   Yuan, Q
   Yu, J
   Sun, YR
   Wu, X
   Li, ZQ
   Wu, XH
   Hu, J
AF Zhao, Jian-Lan
   Du, Zhuo-Ying
   Yuan, Qiang
   Yu, Jian
   Sun, Yi-Rui
   Wu, Xing
   Li, Zhi-Qi
   Wu, Xue-Hai
   Hu, Jin
TI Prognostic Value of Neutrophil-to-Lymphocyte Ratio in Predicting the
   6-Month Outcome of Patients with Traumatic Brain Injury: A Retrospective
   Study
SO WORLD NEUROSURGERY
LA English
DT Article
DE 6-Month outcome; Neutrophil-to-lymphocyte ratio; Prediction model;
   Traumatic brain injury
ID INFLAMMATION; MECHANISMS
AB BACKGROUND: Peripheral white blood cells are regularly analyzed on admission for patients with traumatic brain injury (TBI). The prognostic value of the neutrophil-to-lymphocyte ratio (NLR) in predicting the 6-month outcome of patients with TBI is unclear.
   METHODS: We designed a single-center retrospective cohort study. Patients admitted to Fudan University Huashan Hospital within 6 hours after TBI were identified between December 2004 and December 2017. The primary outcome was 6-month Glasgow Outcome Scale score. Independent predictors of 6-month outcome were assessed using uni- and multivariate analyses. Three models based on admission characteristics were built to evaluate the prognostic value of the NLR in predicting the outcome of patients with TBI. The discriminative ability of predictive models was evaluated by the area under the curve (AUC).
   RESULTS: A total of 1291 patients with TBI were included. Multivariate analysis showed age, Glasgow Coma Scale scores at admission, subdural hematoma, intraparenchymal hemorrhage, traumatic subarachnoid hemorrhage, NLR (P < 0.001), and coagulopathy (P = 0.028) were independent predictors of 6-month outcome. The model combining the NLR and standard variables (AUC = 0.936; 95% confidence interval [CI], 0.923-0.949) was more favorable in predicting 6-month outcome of patients with TBI than the model without the NLR (AUC = 0.901; 95% CI, 0.883-0.919) and the model based only on the NLR (AUC = 0.827; 95% CI, 0.802-0.852).
   CONCLUSIONS: NLR is an independent prognostic factor of predicting 6-month outcome of patients with TBI. A high NLR in patients with TBI is associated with poor outcome. The prognostic value of the NLR in predicting 6-month outcome of patients with TBI is favorable.
C1 [Zhao, Jian-Lan; Du, Zhuo-Ying; Yuan, Qiang; Yu, Jian; Sun, Yi-Rui; Wu, Xing; Li, Zhi-Qi; Wu, Xue-Hai; Hu, Jin] Fudan Univ, Huashan Hosp, Dept Neurosurg, Shanghai, Peoples R China.
   [Yu, Jian] Shigatse Peoples Hosp, Dept Neurosurg, Shigatse, Tibet Autonomou, Peoples R China.
   [Sun, Yi-Rui] Fudan Univ, Zhongshan Hosp, Minhang Branch, Dept Neurosurg, Shanghai, Peoples R China.
RP Hu, J (reprint author), Fudan Univ, Huashan Hosp, Dept Neurosurg, Shanghai, Peoples R China.
EM 286644104@qq.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [81471241, 81271375, 81701206, 81671200, 81171133];
   Shanghai Municipal Science and Technology Commission project
   [16411955300, 18441903300, 18695841300]; Shanghai Municipal Commission
   of Health and Family Planning project [201840063, 201801075]; Major and
   Develop Project of Chinese Ministry of Science and Technology
   [2017ZX09304005]; Public Medical Artificial Intelligence Training
   Platform [XX-RGZN-01-17-4684]; Shanghai Minhang Natural Science
   Foundation [2014MHZ001]
FX This work was supported by the National Natural Science Foundation of
   China (81471241, 81271375, 81701206, 81671200, and 81171133), Shanghai
   Municipal Science and Technology Commission project (16411955300,
   18441903300, and 18695841300), Shanghai Municipal Commission of Health
   and Family Planning project (201840063 and 201801075), The Major and
   Develop Project of Chinese Ministry of Science and Technology
   (2017ZX09304005), the Public Medical Artificial Intelligence Training
   Platform (XX-RGZN-01-17-4684), and Shanghai Minhang Natural Science
   Foundation (2014MHZ001).
CR Balu R, 2014, CURR NEUROL NEUROSCI, V14, DOI 10.1007/s11910-014-0484-2
   Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998
   Carney N, 2017, NEUROSURGERY, V80, P6, DOI 10.1227/NEU.0000000000001432
   Chen WQ, 2018, J HEAD TRAUMA REHAB, V33, pE53, DOI 10.1097/HTR.0000000000000320
   Corps KN, 2015, JAMA NEUROL, V72, P355, DOI 10.1001/jamaneurol.2014.3558
   Dewall Jeremy, 2010, JEMS, V35, P54, DOI 10.1016/S0197-2510(10)70095-4
   Eltzschig HK, 2012, NEW ENGL J MED, V367, P2322, DOI 10.1056/NEJMra1205750
   Helmy A, 2011, PROG NEUROBIOL, V95, P352, DOI 10.1016/j.pneurobio.2011.09.003
   Keep RF, 2012, LANCET NEUROL, V11, P720, DOI 10.1016/S1474-4422(12)70104-7
   Kenne E, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-17
   Kinoshita K, 2016, J INTENSIVE CARE, V4, DOI 10.1186/s40560-016-0138-3
   Kolaczkowska E, 2013, NAT REV IMMUNOL, V13, P159, DOI 10.1038/nri3399
   Lattanzi S, 2016, STROKE, V47, P1654, DOI 10.1161/STROKEAHA.116.013627
   Liao YL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068963
   Lotze MT, 2005, NAT REV IMMUNOL, V5, P331, DOI 10.1038/nri1594
   Maas Andrew I R, 2015, Handb Clin Neurol, V128, P455, DOI 10.1016/B978-0-444-63521-1.00029-7
   Nguyen HX, 2007, J NEUROCHEM, V102, P900, DOI 10.1111/j.1471-4159.2007.04643.x
   Roth TL, 2014, NATURE, V505, P223, DOI 10.1038/nature12808
   Scholz M, 2007, MED RES REV, V27, P401, DOI 10.1002/med.20064
   Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74
   Sun YM, 2017, AM J EMERG MED, V35, P429, DOI 10.1016/j.ajem.2016.11.037
   Szmydynger-Chodobska J, 2009, J CEREBR BLOOD F MET, V29, P1503, DOI 10.1038/jcbfm.2009.71
   Tamhane UU, 2008, AM J CARDIOL, V102, P653, DOI 10.1016/j.amjcard.2008.05.006
   Wang F, 2018, NEUROTOX RES, V34, P347, DOI 10.1007/s12640-018-9890-6
   Wang J, 2007, J CEREBR BLOOD F MET, V27, P894, DOI 10.1038/sj.jcbfm.9600403
   West KL, 2011, J NEUROSURG, V114, P9, DOI 10.3171/2010.7.JNS091857
   Yuan F, 2012, J TRAUMA ACUTE CARE, V73, P137, DOI 10.1097/TA.0b013e31824b00ac
   Yuan Q, 2018, SCAND J TRAUMA RESUS, V26, DOI 10.1186/s13049-017-0471-0
NR 28
TC 2
Z9 2
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP E411
EP E416
DI 10.1016/j.wneu.2018.12.107
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800053
PM 30610986
DA 2020-05-12
ER

PT J
AU Zheng, ZZ
   Tu, ZM
   Li, YW
   Dai, YL
   Wu, PF
   Jiang, B
   Xu, JT
   Xiao, SP
   Li, L
   Lv, GH
   Wang, B
AF Zheng, Zhen-Zhong
   Tu, Zhiming
   Li, Yawei
   Dai, Yuliang
   Wu, Peng-Fei
   Jiang, Bing
   Xu, Jietao
   Xiao, Shipeng
   Li, Lei
   Lv, Guo-Hua
   Wang, Bing
TI Full-Endoscopic Lumbar Discectomy for Lumbar Disc Herniation with
   Posterior Ring Apophysis Fracture: A Retrospective Study
SO WORLD NEUROSURGERY
LA English
DT Article
DE Adolescents; Clinical outcomes; Full-endoscopic lumbar discectomy;
   Lumbar disc herniation; Ring apophysis fracture
ID INTERLAMINAR DISKECTOMY; VERTEBRAL RIM; LIMBUS LUMBAR; ADOLESCENT; PLATE
AB OBJECTIVE: The present retrospective study evaluated the clinical results of full-endoscopic lumbar discectomy (FELD) for the treatment of lumbar disc herniation (LDH) with lumbar posterior ring apophysis fracture (PRAF) using an interlaminar or a transforaminal approach at an inpatient surgery center.
   METHODS: Patients with single-level LDH with type III PRAF who had undergone FELD using an interlaminar or a transforaminal approach from January 2010 to December 2015 were enrolled. The general data recorded included sex, age, location, surgical approach, operative time, hospital stay, perioperative complications, and recurrence. The presence of mobile and immobile fragments was documented. The clinical outcomes were evaluated using a visual analog scale for low back and leg pain. The Oswestry Disability Index was used for the functional assessment and the modified MacNab criteria for patient satisfaction.
   RESULTS: FELD was performed successfully in all cases and no serious perioperative complications were observed. A mobile fragment of PRAS was present in 18 patients and an immobile fragment in 15 patients. Complications occurred in 2 of the 33 included patients; 1 dual tear (3.0%) and 1 transient dysesthesia (3.0%) that did not require further treatment. Recurrence developed in 1 patient (3.0%) and required reoperation. The visual analog scale and Oswestry Disability Index scores had significantly improved postoperatively at 3, 6, and 12 months and the final follow-up visit (P < 0.05). Using the modified MacNab criteria, an excellent or good rate of 93.4% was achieved.
   CONCLUSIONS: FELD is a safe and effective minimally invasive approach for the treatment of LDH with type III PRAF. Sufficient preparation and experience are required to achieve satisfactory results.
C1 [Zheng, Zhen-Zhong; Tu, Zhiming; Li, Yawei; Dai, Yuliang; Jiang, Bing; Xu, Jietao; Xiao, Shipeng; Li, Lei; Lv, Guo-Hua; Wang, Bing] Cent S Univ, Xiangya Hosp 2, Dept Spine Surg, Changsha, Hunan, Peoples R China.
   [Wu, Peng-Fei] Cent S Univ, Ctr Med Genet, Sch Life Sci, Changsha, Hunan, Peoples R China.
RP Wang, B (reprint author), Cent S Univ, Xiangya Hosp 2, Dept Spine Surg, Changsha, Hunan, Peoples R China.
EM wbxyeyy@csu.edu.cn
FU Hunan Provincial Natural Science Foundation of ChinaNatural Science
   Foundation of Hunan Province [2018JJ3752]
FX This research was supported by Hunan Provincial Natural Science
   Foundation of China (2018JJ3752).
CR Akhaddar A, 2011, J NEUROSURG-SPINE, V14, P475, DOI 10.3171/2010.11.SPINE10392
   Baba H, 1996, SPINAL CORD, V34, P427, DOI 10.1038/sc.1996.76
   BANERIAN KG, 1990, RADIOLOGY, V177, P763, DOI 10.1148/radiology.177.3.2243985
   Chang CH, 2008, SPINE, V33, P1750, DOI 10.1097/BRS.0b013e31817d1d12
   Chen Lih-Huei, 2004, Chang Gung Med J, V27, P22
   EPSTEIN NE, 1991, SPINE, V16, P962, DOI 10.1097/00007632-199108000-00017
   EPSTEIN NE, 1992, SPINE, V17, P1489, DOI 10.1097/00007632-199212000-00008
   EPSTEIN NE, 1989, NEUROSURGERY, V24, P595, DOI 10.1227/00006123-198904000-00019
   Fairbank JCT, 2000, SPINE, V25, P2940, DOI 10.1097/00007632-200011150-00017
   Farrokhi MR, 2009, J RES MED SCI, V14, P63
   FUJITA K, 1986, AM J SPORT MED, V14, P243, DOI 10.1177/036354658601400313
   KELLER RH, 1974, RADIOLOGY, V110, P21, DOI 10.1148/110.1.21
   LAREDO JD, 1986, SKELETAL RADIOL, V15, P201, DOI 10.1007/BF00354061
   Lavelle WF, 2011, J AM ACAD ORTHOP SUR, V19, P649, DOI 10.5435/00124635-201111000-00001
   MACNAB I, 1971, J BONE JOINT SURG AM, VA 53, P891, DOI 10.2106/00004623-197153050-00004
   Martinez-Lage JF, 1998, CHILD NERV SYST, V14, P131, DOI 10.1007/s003810050195
   Matsumoto M, 2007, MINIM INVAS NEUROSUR, V50, P335, DOI 10.1055/s-2007-993202
   Mendez JS, 2002, NEUROL RES, V24, P139, DOI 10.1179/016164102101199675
   Peh W C, 1998, Australas Radiol, V42, P34
   Ruetten S, 2006, MINIM INVAS NEUROSUR, V49, P80, DOI 10.1055/s-2006-932172
   Ruetten S, 2008, SPINE, V33, P931, DOI 10.1097/BRS.0b013e31816c8af7
   SAVINI R, 1991, SPINE, V16, P1118, DOI 10.1097/00007632-199109000-00018
   Scarfo GB, 1996, SURG NEUROL, V46, P205
   Shirado O, 2005, CLIN ORTHOP RELAT R, P120, DOI 10.1097/01.blo.0000150457.47232.fd
   TAKATA K, 1988, J BONE JOINT SURG AM, V70A, P589, DOI 10.2106/00004623-198870040-00016
   Talha A, 1997, Eur Spine J, V6, P347, DOI 10.1007/BF01142684
   Tu ZM, 2018, PAIN PHYSICIAN, V21, pE63
   Wang XD, 2014, CHILD NERV SYST, V30, P897, DOI 10.1007/s00381-013-2320-4
   Wu XY, 2013, EUR SPINE J, V22, P475, DOI 10.1007/s00586-012-2580-9
   YANG IK, 1994, NEURORADIOLOGY, V36, P453
NR 30
TC 0
Z9 0
U1 2
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP E156
EP E162
DI 10.1016/j.wneu.2018.12.054
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800020
PM 30590214
DA 2020-05-12
ER

PT J
AU Zhou, HY
   Liu, QQ
   Zhao, CJ
   Ma, JF
   Ye, XL
   Xu, JW
AF Zhou, Hongyu
   Liu, Qiangqiang
   Zhao, Chenjie
   Ma, Junfeng
   Ye, Xiaolai
   Xu, Jiwen
TI Lead Failure After Vagus Nerve Stimulation Implantation: Radiographic
   Examination and Revision Surgery
SO WORLD NEUROSURGERY
LA English
DT Article
DE Lead damage; Lead failure; Lead pin disengagement; Radiographic
   examination; Revision; Vagus nerve stimulation
ID RESISTANT EPILEPSY; ELECTRODES; PACEMAKER; REMOVAL
AB OBJECTIVE: The present study assessed the most common types of lead failures, identified the causes, and discussed the potential procedures for revision surgery after vagus nerve stimulator implantation in patients with epilepsy.
   METHODS: In a retrospective study during an 8-year period, 13 patients had undergone revision surgery because of lead failure. Lead failure was classified as either lead intrinsic damage or lead pin disengagement from the generator header. On the radiographic image, we defined a rear lead connector (RC) ratio that represented the portion of the rear lead connector in the header receptacle. It was used to quantitatively evaluate the mechanical failure of the lead-header interface. The optimal procedures to identify and manage lead failure were established.
   RESULTS: All 13 patients presented with high lead impedance of >= 9 kOhms at the time of revision. Of 10 patients with lead damage, 7 had presented with an increased seizure frequency after a period of seizure remission. In contrast to lead damage occurring relatively late (>15 months), lead pin disengagement was usually found within the early months after device implantation. A significant association was found between an elevated RC ratio (>= 35%) and lead pin disengagement. The microsurgical technique permitted removal or replacement of the lead without adverse effects.
   CONCLUSIONS: The method of measuring the RC ratio developed in the present study is feasible for identifying lead disengagement at the generator level. Lead revision was an effective and safe procedure for patients experiencing lead failure.
C1 [Zhou, Hongyu; Liu, Qiangqiang; Zhao, Chenjie; Ma, Junfeng; Ye, Xiaolai; Xu, Jiwen] Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Dept Funct Neurosurg, Shanghai, Peoples R China.
RP Zhou, HY (reprint author), Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Dept Funct Neurosurg, Shanghai, Peoples R China.
EM iamrains@hotmail.com
CR Aalbers MW, 2015, ACTA NEUROCHIR, V157, P1917, DOI 10.1007/s00701-015-2547-9
   Agarwal G, 2011, OTOLARYNG HEAD NECK, V144, P123, DOI 10.1177/0194599810390896
   Coleman AE, 2012, J VET CARDIOL, V14, P519, DOI 10.1016/j.jvc.2012.07.003
   Couch JD, 2016, NEUROSURGERY, V78, P42, DOI 10.1227/NEU.0000000000000985
   Dlouhy BJ, 2012, NEUROSURG FOCUS, V32, DOI 10.3171/2012.1.FOCUS11333
   Elliott RE, 2011, J NEUROSURG-PEDIATR, V7, P491, DOI 10.3171/2011.2.PEDS10505
   Espinosa J, 1999, SURG NEUROL, V51, P659, DOI 10.1016/S0090-3019(99)00046-4
   Kahlow H, 2013, SEIZURE-EUR J EPILEP, V22, P827, DOI 10.1016/j.seizure.2013.06.011
   Kuruvilla C, 2002, PACE, V25, P115, DOI 10.1046/j.1460-9592.2002.00115.x
   Lam S, 2016, J CLIN NEUROSCI, V30, P83, DOI 10.1016/j.jocn.2016.01.024
   LivaNova, 2018, VNS THER SYST PHYS M, P269
   LivaNova, 2018, VNS THER SYST PHYS M, P266
   MacDonald J, 2004, ACTA NEUROCHIR, V146, P567, DOI 10.1007/s00701-004-0246-z
   Ng WH, 2010, CHILD NERV SYST, V26, P1081, DOI 10.1007/s00381-010-1121-2
   O'Neill BR, 2010, NEUROSURGERY, V67, DOI 10.1227/NEU.0b013e3181f825a3
   Sondhi S, 2018, IHJ CARDIOVASCULAR C, V2, P196
   Spuck S, 2010, NEUROSURGERY, V67, DOI 10.1227/NEU.0b013e3181f88867
   Vale FL, 2011, SEIZURE-EUR J EPILEP, V20, P244, DOI 10.1016/j.seizure.2010.12.003
   Waseem H, 2014, EPILEPSY BEHAV, V31, P110, DOI 10.1016/j.yebeh.2013.12.002
NR 19
TC 0
Z9 0
U1 2
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP E214
EP E221
DI 10.1016/j.wneu.2018.12.070
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800028
PM 30593965
DA 2020-05-12
ER

PT J
AU Pratt, R
   Njau, SW
   Ndagire, C
   Chaisson, N
   Toor, S
   Ahmed, N
   Mohamed, S
   Dirks, J
AF Pratt, Rebekah
   Njau, Sharon W.
   Ndagire, Channelle
   Chaisson, Nicole
   Toor, Sharondeep
   Ahmed, Nimo
   Mohamed, Saida
   Dirks, Jay
TI "We are Muslims and these diseases don't happen to us": A qualitative
   study of the views of young Somali men and women concerning HPV
   immunization
SO VACCINE
LA English
DT Article
DE HPV; Vaccine; Somali; Immigrant; Qualitative
ID HUMAN-PAPILLOMAVIRUS VACCINATION; CANCER; BARRIERS; IMMIGRANT; BREAST;
   ADOLESCENTS; COMPLETION; INFECTION; KNOWLEDGE; ATTITUDES
AB Background: Minnesota is home to the largest Somali immigrant population in the United States. Despite high rates of cervical cancer in this population, immunization rates for the human papillomavirus (HPV) are among the lowest in the nation. Targeting Somali young adults for catch-up vaccinations may be an important strategy for addressing these low rates. This study sought to understand the views of Somali young adults regarding HPV immunization.
   Methods: Four focus groups (N = 34; 21 women) were conducted at an urban clinic in Minnesota. Two groups were all female, one all male, and one mixed gender. Participants in each group discussed their views on immunization in general, and then their views on HPV immunization.
   Findings: Most participants had prior negative experiences with immunization and were skeptical concerning its value. In general, participants had low knowledge about HPV, though they expressed interest in knowing more. Views about HPV were influenced by culture, with risk perceived as low due to interpretations of religious beliefs and expectations around sexual behavior. Low levels of trust in doctors and other healthcare providers influenced participants' perceptions of the benefits of immunization. Participants also valued autonomy highly and resented having received required vaccinations without much choice, such as through their immigration experience or by school authorities. Participants suggested making more opportunities available for learning about HPV and how to prevent it, including via web-based platforms.
   Conclusion: An important opportunity exists to address low HPV immunization rates in the Somali American population by offering vaccination to young adults, who are interested in learning more about HPV. However, key barriers around HPV needs to be addressed in ways that respect the need for autonomy in this age group and that build trust with providers, which may mean avoiding authoritative approaches. (C) 2019 Published by Elsevier Ltd.
C1 [Pratt, Rebekah; Njau, Sharon W.; Ndagire, Channelle; Chaisson, Nicole; Toor, Sharondeep; Ahmed, Nimo; Dirks, Jay] Univ Minnesota, Dept Family Med & Community Hlth, 717 Delaware St, Minneapolis, MN 55414 USA.
   [Chaisson, Nicole; Toor, Sharondeep; Mohamed, Saida; Dirks, Jay] Univ Minnesota, Phys Smileys Clin, 2020 E 28th St, Minneapolis, MN 55407 USA.
RP Pratt, R (reprint author), Univ Minnesota, Dept Family Med & Community Hlth, 717 Delaware St, Minneapolis, MN 55414 USA.
EM rjpratt@umn.edu; njaux003@umn.edu; cndagire@macalester.edu;
   chai0027@umn.edu; stoor@umn.edu; nimoa@umn.edu;
   smohamed10@umphysicians.umn.edu; dirks007@umn.edu
OI Pratt, Rebekah/0000-0003-3561-8276
FU American Academy of Family Practice Foundation Immunization Award
FX This work was supported by an American Academy of Family Practice
   Foundation Immunization Award (PI Jay Dirks).
CR Abakporo U, 2018, J IMMIGR MINOR HEALT, V20, P1230, DOI 10.1007/s10903-017-0642-0
   Al-Amoudi S., 2013, HEALTH CARE WOMEN IN, V36, P608, DOI DOI 10.1080/07399337
   Allen EM, 2019, J TRANSCULT NURS, V30, P55, DOI 10.1177/1043659618796909
   Ben Morrison T, 2012, J IMMIGR MINOR HEALT, V14, P968, DOI 10.1007/s10903-012-9632-4
   Bigby J, 2003, PUBLIC HEALTH REP, V118, P338, DOI 10.1093/phr/118.4.338
   Bonville CA, 2017, HUM VACC IMMUNOTHER, V13, P2646, DOI 10.1080/21645515.2017.1371380
   Calonge N, 2009, ANN INTERN MED, V151, P716, DOI 10.7326/0003-4819-151-10-200911170-00008
   Carroll Jennifer, 2007, Health Care Women Int, V28, P360, DOI 10.1080/07399330601179935
   CDC, 2016, PAR TOP QUEST HPV VA
   Chandra A, 2011, SEXUAL BEHAV SEXUAL, V19, DOI [10.1007/978-94-007-5512-3, DOI 10.1007/978-94-007-5512-3]
   Charmaz K., 1995, RETHINKING METHODS P, P27, DOI DOI 10.4135/9781446221792
   Charmaz K., 2014, CONSTRUCTING GROUNDE, P416
   Dailey P., 2013, COMMUNICATION SOMALI
   Dailey PM, 2017, J CANCER EDUC, V32, P516, DOI 10.1007/s13187-015-0959-0
   Degni F, 2012, J IMMIGR MINOR HEALT, V14, P330, DOI 10.1007/s10903-011-9465-6
   DiClemente RJ, 2015, HUM VACC IMMUNOTHER, V11, P2883, DOI 10.1080/21645515.2015.1070996
   Dunne EF, 2006, J INFECT DIS, V194, P1044, DOI 10.1086/507432
   Ferrer HB, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-700
   Fu LY, 2014, VACCINE, V32, P1901, DOI 10.1016/j.vaccine.2014.01.091
   Garbutt JM, 2018, IMPLEMENT SCI, V13, DOI 10.1186/s13012-018-0729-6
   Gillison ML, 2015, J CLIN ONCOL, V33, P3235, DOI 10.1200/JCO.2015.61.6995
   Goldie SJ, 2005, NEW ENGL J MED, V353, P2158, DOI 10.1056/NEJMsa044278
   Hariri S, 2013, J ADOLESCENT HEALTH, V53, P679, DOI 10.1016/j.jadohealth.2013.09.018
   Henninger Michelle L, 2017, Perm J, V21, P16, DOI 10.7812/TPP/16-191
   Holman DM, 2014, JAMA PEDIATR, V168, P76, DOI 10.1001/jamapediatrics.2013.2752
   Hughes CC, 2011, BMC PEDIATR, V11, DOI 10.1186/1471-2431-11-74
   Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI 10.3322/caac.20115
   Jemal A, 2013, JNCI-J NATL CANCER I, V105, P175, DOI 10.1093/jnci/djs491
   Johnson CE, 2009, AM J PREV MED, V37, pS230, DOI 10.1016/j.amepre.2009.09.036
   Joura EA, 2015, NEW ENGL J MED, V372, P711, DOI 10.1056/NEJMoa1405044
   Khaja K, 2010, HEALTH CARE WOMEN IN, V31, P686, DOI 10.1080/07399332.2010.490313
   McComb E, 2018, J IMMIGR MINOR HEALT, V20, P1424, DOI 10.1007/s10903-018-0709-6
   NPR, 2017, UND HIST COMM VACC
   Pavlish CL, 2010, SOC SCI MED, V71, P353, DOI 10.1016/j.socscimed.2010.04.010
   Peirson L, 2013, SYST REV, V2, DOI 10.1186/2046-4053-2-35
   Pratt R, 2017, BMC PUBLIC HEALTH, V17, DOI 10.1186/s12889-017-4182-2
   Pruitt CN, 2013, J LOW GENIT TRACT DI, V17, P280, DOI 10.1097/LGT.0b013e3182759a64
   QSRIP, 2012, NVIVO QUAL DAT AN SO
   Raymond NC, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-1188
   Rickert VI, 2015, HUM VACC IMMUNOTHER, V11, P315, DOI 10.1080/21645515.2014.1004022
   Rutten LJF, 2017, VACCINE, V35, P6122, DOI 10.1016/j.vaccine.2017.09.056
   Rutten LJF, 2017, VACCINE, V35, P164, DOI 10.1016/j.vaccine.2016.11.012
   Salad J, 2015, INT J EQUITY HEALTH, V14, DOI 10.1186/s12939-015-0198-3
   Serrano B, 2012, INFECT AGENTS CANCER, V7, DOI 10.1186/1750-9378-7-38
   Skull SA, 2008, J IMMIGR MINOR HEALT, V10, P263, DOI 10.1007/s10903-007-9071-9
   Social Omar YS, 2013, BILDHAAN INT J SOMAL, V12, P9
   Spencer AM, 2014, J EPIDEMIOL COMMUN H, V68, P571, DOI 10.1136/jech-2013-202629
   Wolff ER, 2014, J AM BOARD FAM MED, V27, P458, DOI 10.3122/jabfm.2014.04.130275
NR 48
TC 0
Z9 0
U1 2
U2 6
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD APR 3
PY 2019
VL 37
IS 15
BP 2043
EP 2050
DI 10.1016/j.vaccine.2019.03.006
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HR9EW
UT WOS:000463463000001
PM 30871929
DA 2020-05-12
ER

PT J
AU Thorrington, D
   van Leeuwen, E
   Ramsay, M
   Pebody, R
   Baguelin, M
AF Thorrington, Dominic
   van Leeuwen, Edwin
   Ramsay, Mary
   Pebody, Richard
   Baguelin, Marc
TI Assessing optimal use of the standard dose adjuvanted trivalent seasonal
   influenza vaccine in the elderly
SO VACCINE
LA English
DT Article
DE Influenza; Vaccination; Trivalent vaccines; Adjuvanted vaccines; Cost
   effectiveness; QALY; LAIV
ID COST-EFFECTIVENESS; ENGLAND; IMMUNOGENICITY; SAFETY; WALES
AB Background: Despite a long-standing vaccination programme, seasonal influenza remains a major public health problem in England, in particular for the elderly where a significant disease burden remains despite vaccine coverage approaching the WHO target of 75%. The recently licensed adjuvanted trivalent vaccines (TIV-ADJ) have been shown to offer greater protection for the elderly compared to the standarddose non-adjuvanted trivalent vaccines (TIV), particularly for those individuals 75 years old and above for whom the TIV has limited effectiveness. We assessed the cost-effectiveness of the TIV-ADJ for use in the elderly.
   Methods: We used a dynamic SEIR-type transmission model coupled with an economic evaluation framework, estimating the reduction in GP consultations, hospitalisations and influenza-attributable mortality. We assessed the optimal use of the TIV-ADJ by estimating the cost-effectiveness of programmes that used this vaccine in the 65+ and 75+ age groups.
   Findings: The use of TIV-ADJ is highly cost-effective for both target age cohorts with incremental costeffectiveness ratios well below the 20,000 pound per quality-adjusted life year (QALY) with over 90% probability that the vaccine is cost-effective at a cost-effectiveness threshold of 30,000 pound per QALY.
   Interpretation: The increased protection provided across all three influenza vaccine sub-types makes TIV-ADJ a more attractive option than TIV from the perspective of the healthcare provider, driven by the increased efficacy against A(H3N2). When deciding on the optimal use of the newly available vaccine it is important to consider the fact that TIV has very limited effectiveness for the 75+ age group, who would therefore get the greatest benefit from a more effective vaccine. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Thorrington, Dominic; van Leeuwen, Edwin; Ramsay, Mary; Pebody, Richard; Baguelin, Marc] Publ Hlth England, Immunisat & Countermeasures Div, 61 Colindale Ave, London NW9 5EQ, England.
   [van Leeuwen, Edwin] Imperial Coll, Fac Med, London SW7 2AZ, England.
   [Baguelin, Marc] London Sch Hyg & Trop Med, Dept Infect Dis Epidemiol, Keppel St, London WC7E 7HT, England.
RP Pebody, R (reprint author), Publ Hlth England, Immunisat & Countermeasures Div, 61 Colindale Ave, London NW9 5EQ, England.
EM richard.pebody@phe.gov.uk
RI ; ramsay, mary elizabeth/S-8281-2016
OI Baguelin, Marc/0000-0003-3867-1953; ramsay, mary
   elizabeth/0000-0002-7156-7640
FU European Union's Horizon 2020 research and innovation programme
   [634446]; National Institute for Health Research Health Protection
   Research Unit (NIHR HPRU) in Respiratory Infections at Imperial College
   London; NIHR HPRU in Immunisation at LSHTM; Public Health England (PHE)
FX DT's position at Public Health England is funded by the I-MOVE+
   (Integrated Monitoring of Vaccines in Europe) project that received
   funding from the European Union's Horizon 2020 research and innovation
   programme under grant agreement #634446, EvL's position at Public Health
   England is funded by the National Institute for Health Research Health
   Protection Research Unit (NIHR HPRU) in Respiratory Infections at
   Imperial College London in partnership with Public Health England (PHE),
   MB's position at London School of Hygiene & Tropical Medicine (LSHTM) is
   funded by the NIHR HPRU in Immunisation at LSHTM.
CR [Anonymous], 2018, SUMM DAT SUPP CHOIC
   Baguelin M, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001527
   Baguelin M, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0452-y
   Belongia EA, 2016, LANCET INFECT DIS, V16, P942, DOI 10.1016/S1473-3099(16)00129-8
   Cromer D, 2014, J INFECTION, V68, P363, DOI 10.1016/j.jinf.2013.11.013
   De Donato S, 1999, VACCINE, V17, P3094, DOI 10.1016/S0264-410X(99)00138-3
   Frey SE, 2014, VACCINE, V32, P5027, DOI 10.1016/j.vaccine.2014.07.013
   Hodgson D, 2017, LANCET PUBLIC HEALTH, V2, pE74, DOI 10.1016/S2468-2667(16)30044-5
   Lee BY, 2011, AM J KIDNEY DIS, V57, P724, DOI 10.1053/j.ajkd.2010.12.016
   Mossong J, 2008, PLOS MED, V5, P381, DOI 10.1371/journal.pmed.0050074
   NICE, 2013, GUID METH TECHN APPR
   Pebody RG, 2018, EUROSURVEILLANCE, V23, P20, DOI 10.2807/1560-7917.ES.2018.23.39.1800092
   Pitman RJ, 2013, VACCINE, V31, P927, DOI 10.1016/j.vaccine.2012.12.010
   Public Health England, 2016, VACC UPT GUID LAT CO
   Public Health England, 2017, SEAS INFL VACC UPT G
   Thorrington D, 2017, BMC MED, V15, DOI 10.1186/s12916-017-0932-3
   Van Buynder PG, 2013, VACCINE, V31, P6122, DOI 10.1016/j.vaccine.2013.07.059
   van Leeuwen E, 2017, PLOS COMPUT BIOL, V13, DOI 10.1371/journal.pcbi.1005838
NR 18
TC 1
Z9 1
U1 1
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD APR 3
PY 2019
VL 37
IS 15
BP 2051
EP 2056
DI 10.1016/j.vaccine.2019.03.002
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HR9EW
UT WOS:000463463000002
PM 30871927
DA 2020-05-12
ER

PT J
AU Yiannakoulias, N
   Slavik, CE
   Chase, M
AF Yiannakoulias, Nikolaos
   Slavik, Catherine E.
   Chase, Monika
TI Expressions of pro- and anti-vaccine sentiment on YouTube
SO VACCINE
LA English
DT Article
DE YouTube; Vaccine hesitancy; Participatory Internet; Text analysis
ID HEALTH-CARE WORKERS; WEB 2.0; INFORMATION; CONTROVERSIES; VACCINATIONS;
   PERCEPTIONS; ATTITUDES; ONLINE; VIDEOS; MEDIA
AB Billions of hours of YouTube content are viewed every day. Much of this content is aimed at entertainment, some of it is educational, and a considerable quantity is meant to influence or reinforce public opinion on a variety of matters, including health. Most of the content on YouTube is not created by professionals, public institutions or the traditional media, and instead is authored by private individual content creators. Given the potential impact of this medium for communicating health information, it is important for researchers and public health practitioners to understand the nature of health information as it is shared on YouTube. The primary objective of this research is to describe expressions of vaccine hesitancy content on YouTube, and specifically, compare the expression of pro- and anti immunization sentiments. We do this by not only analyzing a systematic sample of influenza and measles immunization videos in terms of viewer analytics, but also by choice of language. We find that pro- and anti-immunization videos are common, but that videos with anti-immunization sentiment tend to be more 'liked'. We also find that a small number of words can be effectively used to identify anti immunization content, an observation that could be useful for identifying trends in anti-immunization sentiment on social media. Our results suggest that public health experts may need to increase the profile of their content on YouTube, and that there may be some useful strategies for improving the public's disposition towards pro-immunization messaging. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Yiannakoulias, Nikolaos; Slavik, Catherine E.] McMaster Univ, Sch Geog & Earth Sci, Hamilton, ON, Canada.
   [Chase, Monika] McMaster Univ, Sch Interdisciplinary Sci, Hamilton, ON, Canada.
RP Yiannakoulias, N (reprint author), McMaster Univ, Sch Geog & Earth Sci, Hamilton, ON, Canada.
EM yiannan@mcmaster.ca
CR Arnold T, 2017, R J, V9, P1
   Baker JP, 2003, VACCINE, V21, P4003, DOI 10.1016/S0264-410X(03)00302-5
   Butler DP, 2013, BURNS, V39, P856, DOI 10.1016/j.burns.2012.10.017
   Colgrove J, 2005, HEALTH AFFAIR, V24, P729, DOI 10.1377/hlthaff.24.3.729
   Cormode G, 2008, 1 MONDAY, V13, P1, DOI DOI 10.5210/FM.V13I6.2125
   Dickson-Spillmann M, 2009, RISK ANAL, V29, P1170, DOI 10.1111/j.1539-6924.2009.01233.x
   Dixon G, 2013, HEALTH EDUC RES, V28, P352, DOI 10.1093/her/cys110
   Dube E, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0156118
   Eskola J, 2015, VACCINE, V33, P4215, DOI 10.1016/j.vaccine.2015.04.043
   Gonzalez-Estrada A, ALL ASTHM P, P121
   Hak E, 2005, VACCINE, V23, P3103, DOI 10.1016/j.vaccine.2005.01.074
   Heininger U, 2006, VACCINE, V24, P6351, DOI 10.1016/j.vaccine.2006.05.029
   Hussin M, 2011, BODY IMAGE, V8, P90, DOI 10.1016/j.bodyim.2010.10.003
   Kang GJ, 2017, VACCINE, V35, P3621, DOI 10.1016/j.vaccine.2017.05.052
   Kata A, 2012, VACCINE, V30, P3778, DOI 10.1016/j.vaccine.2011.11.112
   Keelan J, 2007, JAMA-J AM MED ASSOC, V298, P2482, DOI 10.1001/jama.298.21.2482
   Larson HJ, 2014, VACCINE, V32, P2150, DOI 10.1016/j.vaccine.2014.01.081
   Lewis SP, 2012, J ADOLESCENT HEALTH, V51, P380, DOI 10.1016/j.jadohealth.2012.01.013
   Little KE, 2015, PUBLIC HEALTH, V129, P755, DOI 10.1016/j.puhe.2015.02.031
   Meyer SB, 2017, J HEALTH COMMUN, V22, P506, DOI 10.1080/10810730.2017.1312720
   Moran M. B., 2016, Journal of Communication in Healthcare, V9, P151, DOI 10.1080/17538068.2016.1235531
   Murugiah K, 2011, RESUSCITATION, V82, P332, DOI 10.1016/j.resuscitation.2010.11.015
   Nerghes A, 2018, WEBSCI'18: PROCEEDINGS OF THE 10TH ACM CONFERENCE ON WEB SCIENCE, P127, DOI 10.1145/3201064.3201086
   Oyeyemi SO, 2014, BMJ-BRIT MED J, V349, DOI 10.1136/bmj.g6178
   Prymula R, 2013, EUR REV, V21, pS56, DOI 10.1017/S1062798713000227
   Sharma M, 2017, AM J INFECT CONTROL, V45, P301, DOI 10.1016/j.ajic.2016.08.022
   SLOVIC P, 1987, SCIENCE, V236, P280, DOI 10.1126/science.3563507
   Song G, 2014, RISK ANAL, V34, P541, DOI 10.1111/risa.12114
   Venkatraman A, 2015, VACCINE, V33, P1422, DOI 10.1016/j.vaccine.2015.01.078
   Yaqub O, 2014, SOC SCI MED, V112, P1, DOI 10.1016/j.socscimed.2014.04.018
   Yiannakoulias N, 2017, SOC SCI MED, V191, P57, DOI 10.1016/j.socscimed.2017.08.042
   Yoo JH, 2012, HEALTH COMMUN, V27, P86, DOI 10.1080/10410236.2011.569003
   Zipprich J, 2015, MMWR-MORBID MORTAL W, V64, P153
NR 33
TC 4
Z9 4
U1 7
U2 27
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD APR 3
PY 2019
VL 37
IS 15
BP 2057
EP 2064
DI 10.1016/j.vaccine.2019.03.001
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HR9EW
UT WOS:000463463000003
PM 30862365
DA 2020-05-12
ER

PT J
AU Abaasa, A
   Nash, S
   Mayanja, Y
   Price, M
   Fast, PE
   Kamali, A
   Kaleebu, P
   Todd, J
AF Abaasa, Andrew
   Nash, Stephen
   Mayanja, Yunia
   Price, Matt
   Fast, Patricia E.
   Kamali, Anatoli
   Kaleebu, Pontiano
   Todd, Jim
TI Simulated vaccine efficacy trials to estimate HIV incidence for actual
   vaccine clinical trials in key populations in Uganda
SO VACCINE
LA English
DT Article
DE HIV-incidence vaccine trials key- populations
ID FISHING COMMUNITIES; LAKE VICTORIA; OBSERVATIONAL COHORT; RISK-FACTORS;
   PREVENTION; PREVALENCE; MEN
AB Background: Fisherfolks (FF) and female sex workers (FSW) in Uganda could be suitable key populations for HIV vaccine efficacy trials because of the high HIV incidence and good retention in observational cohorts. However, the observed HIV incidence may differ in participants who enroll into a trial. We used simulated vaccine efficacy trials (SiVET) nested within observational cohorts in these populations to evaluate this difference.
   Methods: SiVETs were nested in two observational cohorts (Jul 2012-Apr 2014 in FF and Aug 2014-Apr 2017 in FSW). From Jan 2012 all observational cohort participants (aged 18-49 years) presenting for quarterly visits were screened for enrolment into SiVETs, until 572 were enrolled. Those not enrolled (screened-out or not screened) in SiVET continued participation in the observational cohorts. In addition to procedures in the observational cohorts (HIV testing & risk assessment), SiVET participants were given a licensed Hepatitis B vaccine mimicking a schedule of a possible HIV vaccine, and followed-up for 12 months.
   Findings: In total, 3989 participants were enrolled into observational cohorts (1575 FF prior to Jul 2012 and 2414 FSW prior to Aug 2014). Of these 3622 (90.8%) returned at least once, 672 (44.1%) were screened and 572 enrolled in the SiVETs. HIV incidence pre SIVETs was 4.5/100 person years-at-risk (pyar), 95%CI (3.8-5.5). HIV incidence in SiVET was 3.5/100 pyar, (2.2-5.6) and higher in those not enrolled in the SiVET, 5.9/100 pyar, (4.3-8.1). This difference was greatest among FF. In the 12 months post-SIVET period (FF, May 2014-Apr 2015 and FSW, May 2017-Apr 2018), the HIV incidence was 3.7/100 pyar, (2.5-5.8).
   Interpretation: HIV incidence was lower in SiVET participants compared to non-SiVET. This difference was different for the two populations. Researchers designing HIV efficacy trials using observational cohort data need to consider the potential for lower than expected HIV incidence following screening and enrolment. (C) 2019 The Authors. Published by Elsevier Ltd.
C1 [Abaasa, Andrew; Mayanja, Yunia; Kaleebu, Pontiano] MRC UVRI, Entebbe, Uganda.
   [Abaasa, Andrew; Mayanja, Yunia; Kaleebu, Pontiano] LSTHM Uganda Res Unit, Entebbe, Uganda.
   [Abaasa, Andrew; Nash, Stephen; Todd, Jim] London Sch Hyg & Trop Med, London, England.
   [Price, Matt; Fast, Patricia E.; Kamali, Anatoli] Int AIDS Vaccine Initiat, New York, NY USA.
   [Price, Matt] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA.
   [Fast, Patricia E.] Stanford Univ, Sch Med, Pediat Infect Dis, Stanford, CA 94305 USA.
RP Abaasa, A (reprint author), MRC UVRI, Entebbe, Uganda.; Abaasa, A (reprint author), LSTHM Uganda Res Unit, Entebbe, Uganda.
EM Andrew.Abaasa@mrcuganda.org
FU IAVI; Global HIV vaccine Enterprise; USAIDUnited States Agency for
   International Development (USAID); UK, Medical Research CouncilMedical
   Research Council UK (MRC); UK Medical Research Council (MRC)Medical
   Research Council UK (MRC); UK Department for International Development
   (DFID) under the MRC/DFID Concordat agreement; European UnionEuropean
   Union (EU) [MR/K012126/1]
FX The OBSC1 and SiVET<INF>2</INF> were fully funded by IAVI. The SiVET,
   work was partially funded by the Global HIV vaccine Enterprise as a
   pilot grant. The SiVET<INF>1</INF> work was also co-funded by IAVI with
   the generous support of USAID and other donors; a full list of IAVI
   donors is available at www.iavi.org.The contents of this manuscript are
   the responsibility of IAVI and co-authors and do not necessarily reflect
   the views of USAID or the US Government. OBSC<INF>2</INF> was funded by
   the UK, Medical Research Council. For this manuscript, the funders had
   no role in data analysis and its interpretation. Stephen Nash is
   supported by an award which is jointly funded by the UK Medical Research
   Council (MRC) and the UK Department for International Development (DFID)
   under the MRC/DFID Concordat agreement, and part of the EDCTP2 programme
   supported by the European Union. Grant Reference MR/K012126/1.
CR Abaasa A, 2016, VACCINE, V34, P1778, DOI 10.1016/j.vaccine.2016.02.048
   Abaasa Andrew, 2015, BMC Res Notes, V8, P815, DOI 10.1186/s13104-015-1804-6
   Asiki G, 2013, VACCINE, V31, P5055, DOI 10.1016/j.vaccine.2013.08.080
   Asiki G, 2011, SEX TRANSM INFECT, V87, P511, DOI 10.1136/sti.2010.046805
   Baeten JM, 2016, NEW ENGL J MED, V375, P2121, DOI 10.1056/NEJMoa1506110
   Baeten JM, 2012, NEW ENGL J MED, V367, P399, DOI 10.1056/NEJMoa1108524
   Benoit A, 2015, PHARM STAT, V14, P294, DOI 10.1002/pst.1685
   Chhim S, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2016-015390
   Cuadros DF, 2014, COMPUT BIOL MED, V50, P1, DOI 10.1016/j.compbiomed.2014.03.008
   Development IcoAa, 2010, UND RES PROC HIV PRE
   Feldblum PJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001474
   Grant RM, 2010, NEW ENGL J MED, V363, P2587, DOI 10.1056/NEJMoa1011205
   Hitchings MDT, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005470
   Hladik W, 2017, BMC PUBLIC HEALTH, V17, DOI 10.1186/s12889-017-4428-z
   Janes H, 2013, AIDS RES HUM RETROV, V29, P1513, DOI [10.1089/AID.2012.0385, 10.1089/aid.2012.0385]
   Kiwanuka N, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-986
   Kiwanuka N, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094932
   Mutagoma M, 2017, INT J STD AIDS, V28, P1082, DOI 10.1177/0956462416688137
   Padian NS, 2010, AIDS, V24, P621, DOI 10.1097/QAD.0b013e328337798a
   Peterson Leigh, 2007, PLoS Clin Trials, V2, pe27, DOI 10.1371/journal.pctr.0020027
   Peterson L, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001312
   Pinsky PF, 2007, AM J EPIDEMIOL, V165, P874, DOI 10.1093/aje/kwk075
   Ruzagira E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024037
   Ruzagira E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020684
   Seeley J, 2012, SEX TRANSM DIS, V39, P433, DOI 10.1097/OLQ.0b013e318251555d
   Szwarcwald CL, 2018, MEDICINE S, V97
   UAC, 2007, NAT STRAT PLAN HIV A
   Vandepitte J, 2011, SEX TRANSM DIS, V38, P316, DOI 10.1097/OLQ.0b013e3182099545
   Wallace M, 2018, SAMJ S AFR MED J, V108, P291, DOI [10.7196/SAMJ.2017.v108i4.12909, 10.7196/SAMJ.2018.v108i4.12909, 10.7196/samj.2018.v108i4.12909]
NR 29
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD APR 3
PY 2019
VL 37
IS 15
BP 2065
EP 2072
DI 10.1016/j.vaccine.2019.02.072
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HR9EW
UT WOS:000463463000004
PM 30857933
OA Other Gold, Green Accepted
DA 2020-05-12
ER

PT J
AU Miura, K
   Deng, BB
   Wu, YM
   Zhou, LW
   Pham, TP
   Diouf, A
   Wu, CK
   Lee, SM
   Plieskatt, JL
   Morin, MJ
   Long, CA
AF Miura, Kazutoyo
   Deng, Bingbing
   Wu, Yimin
   Zhou, Luwen
   Pham, Thao P.
   Diouf, Ababacar
   Wu, Chia-Kuei
   Lee, Shwu-Maan
   Plieskatt, Jordan L.
   Morin, Merribeth J.
   Long, Carole A.
TI ELISA units, IgG subclass ratio and avidity determined functional
   activity of mouse anti-Pfs230 antibodies judged by a standard
   membrane-feeding assay with Plasmodium falciparum
SO VACCINE
LA English
DT Article
DE Plasmodium falciparum; Pfs230; Transmission-blocking vaccine; Standard
   membrane-feeding assay; IgG subclass; Avidity
ID BLOCKING VACCINE CANDIDATES; TRANSMISSION; MALARIA; PFS230; PROTEIN;
   ANTIGEN
AB The standard membrane-feeding assay (SMFA) is a functional assay that has been used to inform the development of transmission-blocking vaccines (TBV) against Plasmodium falciparum malaria. For Pfs230, a lead target antigen for TBV development, a few studies have tested either a single anti-Pfs230 poly-clonal or monoclonal antibody (one antibody per study) at serial dilutions and showed a dose-dependent response. Further, there have been reports that the SMFA activity of anti-Pfs230 poly-clonal and monoclonal antibodies were enhanced in the presence of complement. However, no analysis has been performed with multiple samples, and the impact of anti-Pfs230 antibody titers, IgG subclass profile and avidity were evaluated together in relation to transmission-reducing activity (TRA) by SMFA. In this report, a total of 39 unique anti-Pfs230 IgGs from five different mouse immunization studies were assessed for their ELISA units (EU), IgG2/IgG1 ratio and avidity by ELISA, and the functionality (% transmission-reducing activity, %TRA) by SMFA. The mice were immunized with Pfs230 alone, Pfs230 conjugated to CRM197, or a mixture of unconjugated Pfs230 and CRM 197 proteins using Alhydrogel or Montanide ISA720 adjuvants. In all studies, the Pfs230 antigen was from the same source. There was a significant correlation between EU and %TRA (p < 0.0001 by a Spearman rank test) for the anti-Pfs230 lgGs. Notably, multiple linear regression analyses showed that both IgG2/IgG1 ratio and avidity significantly affected %TRA (p = 0.003 to p = 0.014, depending on the models) after adjusting for EU. The results suggest that in addition to antibody titers, IgG2/IgG1 ratio and avidity should each be evaluated to predict the biological activity of anti-Pfs230 antibodies for future vaccine development. (C) 2019 Published by Elsevier Ltd.
C1 [Miura, Kazutoyo; Deng, Bingbing; Zhou, Luwen; Pham, Thao P.; Diouf, Ababacar; Long, Carole A.] NIAID, Lab Malaria & Vector Res, NIH, Rockville, MD 20852 USA.
   [Wu, Yimin; Wu, Chia-Kuei; Lee, Shwu-Maan; Plieskatt, Jordan L.; Morin, Merribeth J.] PATHs Malaria Vaccine Initiat MVI, Washington, DC 20001 USA.
RP Miura, K (reprint author), 12735 Twinbrook Pkwy, Rockville, MD 20852 USA.
EM kmiura@niaid.nih.gov
OI Lee, Shwu-Maan/0000-0003-0819-0569
FU PATH's Malaria Vaccine Initiative; National Institute of Allergy and
   infectious Disease/NIHUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID)
FX The study was supported by PATH's Malaria Vaccine Initiative, and the
   intramural program of the National Institute of Allergy and infectious
   Disease/NIH. The funders had no role in study design, data collection
   and analysis, decision to publish, or preparation of the manuscript.
CR Bustamante PJ, 2000, PARASITE IMMUNOL, V22, P373, DOI 10.1046/j.1365-3024.2000.00315.x
   Cheru L, 2010, VACCINE, V28, P4423, DOI 10.1016/j.vaccine.2010.04.036
   Collins AM, 2016, IMMUNOL CELL BIOL, V94, P949, DOI 10.1038/icb.2016.65
   Eksi S, 2006, MOL MICROBIOL, V61, P991, DOI 10.1111/j.1365-2958.2006.05284.x
   Farrance CE, 2011, CLIN VACCINE IMMUNOL, V18, P1351, DOI 10.1128/CVI.05105-11
   Hickey JM, 2018, J PHARM SCI-US, V107, P1806, DOI 10.1016/j.xphs.2018.03.002
   Jones DS, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0138761
   Kapulu MC, 2015, SCI REP-UK, V5, DOI 10.1038/srep11193
   Lee SM, 2017, CLIN VACCINE IMMUNOL, V24, DOI [10.1128/CVI.00140-17, 10.1128/cvi.00140-17]
   MacDonald NJ, 2016, J BIOL CHEM, V291, P19913, DOI 10.1074/jbc.M116.732305
   Menon V, 2018, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01998
   Miura K, 2008, VACCINE, V26, P193, DOI 10.1016/j.vaccine.2007.10.064
   Miura K, 2007, MALARIA J, V6, DOI 10.1186/1475-2875-6-107
   Miura K, 2016, MALARIA J, V15, DOI 10.1186/s12936-016-1515-z
   Miura K, 2013, INFECT IMMUN, V81, P4377, DOI 10.1128/IAI.01056-13
   Miura K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057909
   Nikolaeva D, 2015, EXPERT REV VACCINES, P1, DOI DOI 10.1586/14760584.2015.993383
   Organization WH, 2017, WORLD MALARIA REPORT
   QUAKYI IA, 1987, J IMMUNOL, V139, P4213
   ROEFFEN W, 1995, INFECT IMMUN, V63, P467, DOI 10.1128/IAI.63.2.467-471.1995
   Tachibana M, 2011, CLIN VACCINE IMMUNOL, V18, P1343, DOI 10.1128/CVI.05104-11
   Thompson EA, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.120692
   van Dijk MR, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000853
   Williamson KC, 1995, MOL BIOCHEM PARASIT, V75, P33, DOI 10.1016/0166-6851(95)02507-3
   Wu YM, 2015, ADV PARASIT, V89, P109, DOI 10.1016/bs.apar.2015.04.001
NR 25
TC 3
Z9 3
U1 0
U2 7
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD APR 3
PY 2019
VL 37
IS 15
BP 2073
EP 2078
DI 10.1016/j.vaccine.2019.02.071
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HR9EW
UT WOS:000463463000005
PM 30850239
OA Green Accepted
DA 2020-05-12
ER

PT J
AU Verelst, F
   Kessels, R
   Delva, W
   Beutels, P
   Willem, L
AF Verelst, Frederik
   Kessels, Roselinde
   Delva, Wim
   Beutels, Philippe
   Willem, Lander
TI Drivers of vaccine decision-making in South Africa: A discrete choice
   experiment
SO VACCINE
LA English
DT Article
DE Vaccination; Discrete choice experiment; Behavior; Free-riding;
   Decision-making criteria; South Africa
ID BAYESIAN OPTIMAL DESIGNS; UNINFECTED CHILDREN; MEASLES; HIV; HESITANCY;
   PREFERENCES; ANTIBODY; IMMUNITY; PARENTS
AB To increase vaccination coverage, it is essential to understand the vaccine decision-making process. High population coverage is required to obtain herd immunity and to protect vulnerable groups in terms of age (e.g. the very young) or health (e.g. immunodeficiency). Vaccine confidence and coverage in South Africa are relatively low, opening the window for sustained outbreaks of vaccine-preventable diseases in a country facing one of the most severe HIV epidemics in the world, To capture the vaccine-related decision-making process in South Africa, we performed a discrete choice experiment with 1200 participants in December 2017. We asked for their preferences with respect to (1) vaccine effectiveness, (2) vaccine-preventable burden of disease, (3) accessibility of the vaccine in terms of co-payment and prescription requirements, (4) frequency of mild vaccine-related side-effects, (5) population vaccination coverage and (6) local vaccination coverage. We distinguished between decision-making for vaccines administered to the participant, and for vaccines administered to their youngest child. We analyzed the data for each of these groups using a panel mixed logit model and found similar results for decisions to vaccinate oneself or one's child. Vaccine effectiveness was the most important attribute followed by population coverage and burden of disease. Local coverage and accessibility were also important determinants of vaccination behavior, but to a lesser extent. Regarding population and local coverage, we observed a positive effect on vaccine utility indicating the potential of peer influence. As such, social normative influence could be exploited to increase vaccination confidence and coverage. With respect to vaccine-preventable burden of the disease, the marginal utilities showed disease severity to be more important than frequency of disease. Policymakers and health care workers should stress the effectiveness of vaccines together with the severity of vaccine-preventable diseases. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Verelst, Frederik; Beutels, Philippe; Willem, Lander] Univ Antwerp, Vaccine & Infect Dis Inst, Ctr Hlth Econ Res & Modelling Infect Dis, Univ Pl 1, B-2610 Antwerp, Antwerp, Belgium.
   [Kessels, Roselinde] Univ Antwerp, Dept Econ, Prinsstr 13, B-2000 Antwerp, Belgium.
   [Kessels, Roselinde] Univ Antwerp, Flemish Res Fdn FWO, Prinsstr 13, B-2000 Antwerp, Belgium.
   [Kessels, Roselinde] Univ Amsterdam, Sch Econ, POB 15867, NL-1001 NJ Amsterdam, Netherlands.
   [Delva, Wim] Univ Ghent, Int Ctr Reprod Hlth, C Heymanslaan 10, B-9000 Ghent, Belgium.
   [Delva, Wim] Stellenbosch Univ, South African Dept Sci & Technol, Nat Res Fdn DST NRF, Ctr Excellence Epidemiol Modelling & Anal SACEMA, ZA-7602 Stellenbosch, South Africa.
   [Delva, Wim] Hasselt Univ, Ctr Stat, Martelarenlaan 42, B-3500 Hasselt, Belgium.
   [Delva, Wim] Katholieke Univ Leuven, Rega Inst Med Res, Herestr 49, B-3000 Leuven, Belgium.
   [Delva, Wim] Stellenbosch Univ, Fac Med & Hlth Sci, Dept Global Hlth, ZA-7602 Stellenbosch, South Africa.
   [Beutels, Philippe] UNSW Med, Univ New South Wales, Sch Publ Hlth & Community Med, Sydney, NSW 2052, Australia.
RP Verelst, F (reprint author), Univ Antwerp, Vaccine & Infect Dis Inst VAXINFECTIO, CHERMID, Campus Drie Eiken,Room R2-08,Univ Pl 1, B-2610 Antwerp, Antwerpen, Belgium.
EM frederik.verelst@uantwerp.be
RI Kessels, Roselinde/N-8479-2016; Beutels, Philippe/A-1919-2010; Willem,
   Lander/AAC-4658-2019
OI Kessels, Roselinde/0000-0002-4534-0047; Beutels,
   Philippe/0000-0001-5034-3595; Willem, Lander/0000-0002-9210-1196; Delva,
   Wim/0000-0001-8054-1904
FU Antwerp Study Centre for Infectious Diseases (ASCID) at the University
   of Antwerp; Research Foundation FlandersFWO [G043815N]; Global Minds
   initiative at the University of Antwerp
FX FV, PB and LW acknowledge support of the Antwerp Study Centre for
   Infectious Diseases (ASCID) at the University of Antwerp. PB, FV, LW and
   RK acknowledge support by the Research Foundation Flanders (research
   project no. G043815N and a postdoctoral fellowship (RK)). Funding for
   the data collection was provided by the Global Minds initiative at the
   University of Antwerp. We thank all respondents who participated in the
   study. We also thank Viilyen Motaze for providing background information
   with respect to the South African immunization programme, and two
   anonymous referees for providing constructive comments that
   substantially improved our manuscript. The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript. Conflicts of interest: none.
CR Bishai D, 2007, PHARMACOECONOMICS, V25, P143, DOI 10.2165/00019053-200725020-00006
   Brunson EK, 2013, VACCINE, V31, P5466, DOI 10.1016/j.vaccine.2013.08.104
   Bults M, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-2
   Clark MD, 2014, PHARMACOECONOMICS, V32, P883, DOI 10.1007/s40273-014-0170-x
   Coast J, 2012, HEALTH ECON, V21, P730, DOI 10.1002/hec.1739
   Cuervo DP, 2016, TRANSPORT RES B-METH, V93, P648, DOI 10.1016/j.trb.2016.08.010
   de Bekker-Grob EW, 2012, HEALTH ECON, V21, P145, DOI 10.1002/hec.1697
   de Bekker-Grob EW, 2010, VACCINE, V28, P6692, DOI 10.1016/j.vaccine.2010.08.001
   Determann D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102505
   Dube E, 2015, EXPERT REV VACCINES, V14, P99, DOI 10.1586/14760584.2015.964212
   Fine P, 2011, CLIN INFECT DIS, V52, P911, DOI 10.1093/cid/cir007
   Fowlkes AL, 2016, VACCINE, V34, P1459, DOI 10.1016/j.vaccine.2016.01.055
   Gidengil C, 2012, VACCINE, V30, P3445, DOI 10.1016/j.vaccine.2012.03.022
   Godlee Fiona, 2011, BMJ, V342, pc7452, DOI 10.1136/bmj.c7452
   Grabenstein JD, 2013, VACCINE, V31, P2011, DOI 10.1016/j.vaccine.2013.02.026
   Hall J, 2002, HEALTH ECON, V11, P457, DOI 10.1002/hec.694
   JMP, 1989, VERS PRO 13
   Kata A, 2012, VACCINE, V30, P3778, DOI 10.1016/j.vaccine.2011.11.112
   Kessels R, 2015, APPL STOCH MODEL BUS, V31, P626, DOI 10.1002/asmb.2065
   Kessels R, 2015, BMC HEALTH SERV RES, V15, DOI 10.1186/s12913-015-0847-7
   Kessels R, 2011, J CHOICE MODEL, V4, P52
   Kessels R, 2011, APPL STOCH MODEL BUS, V27, P173, DOI 10.1002/asmb.906
   Lancsar E, 2008, PHARMACOECONOMICS, V26, P661, DOI 10.2165/00019053-200826080-00004
   Larson H. J., 2016, EBIOMEDICINE, DOI [10.1016/j.ebiom.2016.08.042, DOI 10.1016/J.EBI0M.2016.08.042]
   Larson HJ, 2014, VACCINE, V32, P2150, DOI 10.1016/j.vaccine.2014.01.081
   Luyten J, 2015, VALUE HEALTH, V18, P224, DOI 10.1016/j.jval.2014.12.007
   MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036
   Melinda Suchard, 2016, VACCINE INFORM PAREN
   Moss WJ, 2002, CLIN INFECT DIS, V35, P189, DOI 10.1086/341248
   National Institute for Communicable Diseases, 2017, AL MEASL OUTBR DECL
   Oteng B, 2011, SEX TRANSM INFECT, V87, P52, DOI 10.1136/sti.2009.041392
   Sadique MZ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054149
   Scott S, 2005, J INFECT DIS, V191, P1854, DOI 10.1086/429963
   van Boven M, 2010, J R SOC INTERFACE, V7, P1537, DOI 10.1098/rsif.2010.0086
   Verelst F, 2018, SOC SCI MED, V207, P106, DOI 10.1016/j.socscimed.2018.04.038
   Verelst F, 2016, J R SOC INTERFACE, V13, DOI 10.1098/rsif.2016.0820
   World Health Organization, 2013, GLOB VACC ACT PLAN 2
   World Health Organization, 2017, IMM COV WHO UNICEF E
   Zuma K, 2016, AJAR-AFR J AIDS RES, V15, P67, DOI 10.2989/16085906.2016.1153491
NR 39
TC 2
Z9 2
U1 2
U2 12
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD APR 3
PY 2019
VL 37
IS 15
BP 2079
EP 2089
DI 10.1016/j.vaccine.2019.02.056
PG 11
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HR9EW
UT WOS:000463463000006
PM 30857931
DA 2020-05-12
ER

PT J
AU Zhang, HY
   Jia, EC
   Xia, WJ
   Lv, TY
   Lu, CG
   Xu, ZP
   Zhu, WL
AF Zhang Huiyong
   Jia Enchao
   Xia Wenjiao
   Lv Tanyu
   Lu Chengui
   Xu Zhenping
   Zhu Wuling
TI Utilizing VEGF165b mutant as an effective immunization adjunct to
   augment antitumor immune response
SO VACCINE
LA English
DT Article
DE Breast cancer; Immunization; VEGF; T regulatory cell; Tumor vaccine;
   Mucin 1
ID ENDOTHELIAL GROWTH-FACTOR; DIRECTLY SUPPRESSES ACTIVATION; T-CELLS;
   ADENOCARCINOMA RECOGNIZE; PEPTIDE VACCINES; OVARIAN-CANCER; BREAST;
   MULTIPLE; TUMORS; MUC1
AB Compelling evidence has shown that blocking VEGF via monoclonal antibodies may be beneficial in that it not only inhibits tumor angiogenesis but also reduces immune suppression and promotes T cell infiltration into tumors. Herein, we determined whether our recently generated VEGF165b mutant could be used as a co-immunization adjunct to augment the peptide cancer-vaccine-induced immune response in a mouse model of breast cancer. When co-immunized mVEGF165b with the peptide-based cancer vaccine (MUC1, a T-cell epitope dominant peptide vaccine from Mucin1), the VEGF antibody titers increased approximately 600,000-fold in mice. Moreover, the anti-VEGF antibody also reduced the frequency of regulatory T cells (Tregs) in both preventive and therapeutic scenarios. Mechanistically, the decrease of the Tregs population was associated with a remarkably increased MUC-1-specific IFN-gamma-producing CD8(+) T cells and anti-MUC1 humoral response. Finally, this combination co-immunization produced a superior antitumor response and significantly prolonged survival of tumor-bearing mice. In conclusion, our findings suggest that mVEGF165b may be an ideal immunization adjunct to enhance the immune efficacy of peptide-based tumor vaccines by overcoming immune tolerance. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Zhang Huiyong; Xia Wenjiao; Lv Tanyu; Lu Chengui; Xu Zhenping; Zhu Wuling] Xinxiang Med Univ, Sch Life Sci & Technol, Synthet Biol Engn Lab Henan Prov, Xinxiang 453003, Peoples R China.
   [Jia Enchao] Luohe Med Coll, Affiliated Hosp 1, Luohe Cent Hosp, Dept Pathol, Luohe 462000, Peoples R China.
RP Zhu, WL (reprint author), Xinxiang Med Univ, Sch Life Sci & Technol, Synthet Biol Engn Lab Henan Prov, Xinxiang 453003, Peoples R China.
EM zhuwuling1@163.com
OI zhang, huiyong/0000-0002-1982-8137
FU Henan Province Science and Technology Key Project [182102310337]; Major
   Science and Technology Projects of Henan Province [161100310900]
FX This work was funded in part by the Henan Province Science and
   Technology Key Project [Grant No. 182102310337] and Major Science and
   Technology Projects of Henan Province [Grant No. 161100310900]; We would
   like to thank LetPub (www.letpub.com) for providing linguistic
   assistance during the preparation of this manuscript.
CR Aparicio-Gallego G, 2011, MOL CANCER THER, V10, P2215, DOI 10.1158/1535-7163.MCT-10-1124
   Beatson RE, 2010, IMMUNOTHERAPY-UK, V2, P305, DOI 10.2217/IMT.10.17
   Butts C, 2011, J CANCER RES CLIN, V137, P1337, DOI 10.1007/s00432-011-1003-3
   Carmon L, 2015, BRIT J HAEMATOL, V169, P44, DOI 10.1111/bjh.13245
   Duraiswamy J, 2014, CANCER RES, V74, P633, DOI 10.1158/0008-5472.CAN-13-2752
   Gabrilovich D, 1998, BLOOD, V92, P4150, DOI 10.1182/blood.V92.11.4150.423k45_4150_4166
   Gabrilovich DI, 1996, NAT MED, V2, P1096, DOI 10.1038/nm1096-1096
   Gavalas NG, 2012, BRIT J CANCER, V107, P1869, DOI 10.1038/bjc.2012.468
   Gendler SJ, 2001, J MAMMARY GLAND BIOL, V6, P339, DOI 10.1023/A:1011379725811
   JEROME KR, 1993, J IMMUNOL, V151, P1654
   JEROME KR, 1991, CANCER RES, V51, P2908
   Kaumaya PTP, 2012, FUTURE ONCOL, V8, P961, DOI [10.2217/FON.12.95, 10.2217/fon.12.95]
   Kobayashi M, 2013, MED ONCOL, V30, DOI 10.1007/s12032-013-0556-1
   Lapeyre-Prost A, 2017, INT REV CEL MOL BIO, V330, P295, DOI 10.1016/bs.ircmb.2016.09.007
   Lau SK, 2004, AM J CLIN PATHOL, V122, P61, DOI 10.1309/9R6673QEC06D86Y4
   Mannan S, 2016, IMMUNOTHERAPY-UK, V8, P1263, DOI 10.2217/imt-2016-0126
   Melief CJM, 2008, NAT REV CANCER, V8, P351, DOI 10.1038/nrc2373
   Moynihan KD, 2016, NAT MED, V22, P1402, DOI 10.1038/nm.4200
   Neufeld G, 1999, FASEB J, V13, P9
   Oh DS, 2017, ONCOTARGET, V8, P47440, DOI 10.18632/oncotarget.17663
   Ohm JE, 2003, BLOOD, V101, P4878, DOI 10.1182/blood-2002-07-1956
   Robinson CJ, 2001, J CELL SCI, V114, P853
   Roland CL, 2009, MOL CANCER THER, V8, P1761, DOI 10.1158/1535-7163.MCT-09-0280
   Sangha R, 2007, CLIN CANCER RES, V13, p4652S, DOI 10.1158/1078-0432.CCR-07-0213
   Singh R, 2013, EXP MOL MED, V45, DOI 10.1038/emm.2013.111
   Slingluff CL, 2011, CANCER J, V17, P343, DOI 10.1097/PPO.0b013e318233e5b2
   Terme M, 2013, CANCER RES, V73, P539, DOI 10.1158/0008-5472.CAN-12-2325
   Toes REM, 1996, P NATL ACAD SCI USA, V93, P7855, DOI 10.1073/pnas.93.15.7855
   van der Burg SH, 2016, NAT REV CANCER, V16, P219, DOI 10.1038/nrc.2016.16
   Voron T, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00070
   Wada J, 2009, ANTICANCER RES, V29, P881
   Woolard J, 2004, CANCER RES, V64, P7822, DOI 10.1158/0008-5472.CAN-04-0934
   Yankai Z, 2006, BIOCHEM BIOPH RES CO, V345, P1365, DOI 10.1016/j.bbrc.2006.05.022
   Zhang HY, 2018, J BIOTECHNOL, V284, P84, DOI 10.1016/j.jbiotec.2018.08.002
   Zhang HY, 2015, TUMOR BIOL, V36, P3871, DOI 10.1007/s13277-014-3029-z
   Ziogas AC, 2012, INT J CANCER, V130, P857, DOI 10.1002/ijc.26094
NR 36
TC 0
Z9 0
U1 2
U2 7
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD APR 3
PY 2019
VL 37
IS 15
BP 2090
EP 2098
DI 10.1016/j.vaccine.2019.02.055
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HR9EW
UT WOS:000463463000007
PM 30837171
DA 2020-05-12
ER

PT J
AU Mercaldo, RA
   Bellan, SE
AF Mercaldo, Rachel A.
   Bellan, Steven E.
TI Evaluation of alternative endpoints for ZIKV vaccine efficacy trials
SO VACCINE
LA English
DT Article
DE Zika virus; Teratogen; Clinical trial; Vaccine efficacy; Simulation
   study
ID VIRUS-INFECTION
AB Zika virus (ZIKV) infection during pregnancy is associated with microcephaly and other birth defects, collectively termed Congenital Zika Syndrome (CZS). During the epidemic in 2015-16, ZIKV spread through the Americas and quickly joined the list of other known teratogenic pathogens, TORCH. Multiple ZIKV vaccines have been developed for protection of pregnant women and women of childbearing age. However, ZIKV infection incidence has since waned substantially, and adverse birth outcomes are rare outcomes of infection. Studying a vaccine's protective efficacy against CZS in a large phase III clinical trial may be infeasible in such times of low incidence. Should trials be initiated, researchers may resort to alternative clinical endpoints.
   In this study, we simulate a variety of vaccine clinical trial scenarios to evaluate the feasibility of the CZS endpoint in vaccine studies and compare CZS to other potential outcomes: ZIKV infection detected through weekly, biweekly, or monthly testing and laboratory-confirmed, symptomatic Zika Virus Disease. We compare the sample size required for 80% statistical power to detect vaccine efficacy and trial duration for each scenario. Our results show the feasibility of CZS clinical endpoints depends on the timing of simulated clinical trials in the course of a seasonal epidemic, due to CZS risk varying with trimester of infection. This result highlights additional considerations needed when designing vaccine efficacy trials of protection against teratogenic pathogens. Published by Elsevier Ltd.
C1 [Mercaldo, Rachel A.; Bellan, Steven E.] Univ Georgia, Coll Publ Hlth, Dept Epidemiol & Biostat, Athens, GA 30602 USA.
   [Bellan, Steven E.] Univ Georgia, Ctr Ecol Infect Dis, Athens, GA 30602 USA.
   [Bellan, Steven E.] Univ Stellenbosch, South African Ctr Epidemiol Modelling & Anal, Stellenbosch, South Africa.
RP Mercaldo, RA (reprint author), Univ Georgia, Coll Publ Hlth, Dept Epidemiol & Biostat, Athens, GA 30602 USA.
EM mercaldo@uga.edu
OI Mercaldo, Rachel/0000-0003-2021-6020
FU National Institute of Allergy and Infectious Diseases K01 award
   [K01AI125830]
FX This work was supported by a National Institute of Allergy and
   Infectious Diseases K01 award (K01AI125830) (SEB). The authors thank
   Andreas Handel, Christopher Whalen, and Michael Welton for their time
   and comments.
CR Andersen K, 2018, ZIKA CASE NUMBERS PA
   Asher J., 2017, BIORXIV, DOI [10.1101/187591, DOI 10.1101/187591]
   Barouch DH, 2017, IMMUNITY, V46, P176, DOI 10.1016/j.immuni.2017.02.005
   Cao-Lormeau VM, 2016, LANCET, V387, P1531, DOI 10.1016/S0140-6736(16)00562-6
   CDC, 2018, TEST GUID
   CDC, 2017, GUID EV PUBL HLTH MA, P1
   Eppes C, 2017, AM J OBSTET GYNECOL, V216, P209, DOI 10.1016/j.ajog.2017.01.020
   European Union, 2014, REP CRIT RAW MAT EU, P1
   Justus CG, 1978, J APPL METEOROL, DOI [10.1175/1520-0450(1978)017<0350:MFEWSF>2.0.CO:2, DOI 10.1175/1520-0450(1978)017<0350:MFEWSF>2.0.CO:2]
   Lessler J, 2016, BIORXIV, DOI [10.1101/041913, DOI 10.1101/041913]
   Mehrjardi Mohammad Zare, 2017, Virology (Auckl), V8, p1178122X17708993, DOI [10.1177/1178122X17708993, 10.1177/1178122x17708993]
   Pan American Health Organization, 2018, COUNTR TERR AUT TRAN, P41696
   Pardi N, 2017, NATURE, V543, P248, DOI 10.1038/nature21428
   Pass RF, 2014, J PEDIATR INFECT DIS, V3, pS2, DOI 10.1093/jpids/piu069
   Petersen LR, 2016, NEW ENGL J MED, V374, P1552, DOI 10.1056/NEJMra1602113
   Rasmussen SA, 2016, NEW ENGL J MED, V374, P1981, DOI 10.1056/NEJMsr1604338
   Reynolds MR, 2017, MMWR-MORBID MORTAL W, V66, P366, DOI 10.15585/mmwr.mm6613e1
   SEVER JL, 1985, REV INFECT DIS, V7, pS164
   Taylor A, 2003, BRIT MED J, V327, P434, DOI 10.1136/bmj.327.7412.434
   Theel ES, 2018, J CLIN MICROBIOL, V56, DOI [10.1128/JCM.01972-17, 10.1128/jcm.01972-17]
   [United Nation Department of Economic and Social Affairs PD], 2015, TRENDS CONTR US WORL, DOI [10.1016/j.contraception.2012.08.029, DOI 10.1016/J.CONTRACEPTION.2012.08.029]
   van der Linden V, 2016, MMWR-MORBID MORTAL W, V65, P1343, DOI 10.15585/mmwr.mm6547e2
   WHO, 2016, WHO DIR GEN SUMM OUT
   World Health Organization, 2017, WHO WORKSH M GEN
   Zorrilla CD, 2017, J INFECT DIS, V216, pS891, DOI 10.1093/infdis/jix448
NR 25
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD APR 3
PY 2019
VL 37
IS 15
BP 2099
EP 2105
DI 10.1016/j.vaccine.2019.02.066
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HR9EW
UT WOS:000463463000008
PM 30871928
OA Green Accepted
DA 2020-05-12
ER

PT J
AU Porth, JM
   Wagner, AL
   Teklie, H
   Abeje, Y
   Moges, B
   Boulton, ML
AF Porth, Julia M.
   Wagner, Abram L.
   Teklie, Habtamu
   Abeje, Yemesrach
   Moges, Beyene
   Boulton, Matthew L.
TI Vaccine non-receipt and refusal in Ethiopia: The expanded program on
   immunization coverage survey, 2012
SO VACCINE
LA English
DT Article
DE Vaccine refusal; Vaccine non-receipt; Missed opportunities; Ethiopia;
   Expanded program on immunization
ID CHILD IMMUNIZATION; POLIO ERADICATION; HESITANCY; DISTRICT;
   ACCEPTABILITY; ZONE
AB Introduction: Rates of full childhood immunization in Ethiopia are well below the WHO global goal of 90% coverage by 2020. This study explores associations between sociodemographic characteristics and healthcare services utilization with experiences of not receiving a vaccine in Ethiopia.
   Methods: This analysis uses data from Ethiopia's 2012 Expanded Program on Immunization Coverage Survey. The relationships between explanatory variables, including sociodemographic and healthcare utilization factors, and various reasons a child was not vaccinated were assessed with Rao-Scott chi-square tests. Multivariable logistic regression analyses examined significant predictors of these experiences.
   Results: The sample includes the caregivers of 2,722 children. Experiences of not receiving a vaccine were characterized overall and by type of experience: whether a caregiver ever refused vaccination for their child (2.9%), ever decided to not take their child to a health center for vaccination (3.6%), and ever went to a health facility for vaccination but child was not vaccinated (12.0%). Region of residence, possession of a vaccination card, and the setting of the child's last routine vaccination were predictors of not receiving a vaccine. Caregivers reported negative perceptions of vaccines were among their reasons for refusing a vaccine or declining to take their child to a health facility for vaccination.
   Conclusion: Prior experiences with health facilities, such as where a child received their last routine vaccine, play a key role in future vaccination. Vaccine receipt at an outreach event is associated with not bringing a child to a health facility for vaccination, which may indicate an unwillingness to visit or difficulty accessing health centers. Further, negative perceptions of vaccines may result in vaccine refusal or delay. Findings of this study provide public health officials with a better understanding of factors related to vaccination experiences and can inform development of interventions that will improve childhood vaccination rates in Ethiopia. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Porth, Julia M.; Wagner, Abram L.; Boulton, Matthew L.] Univ Michigan, Sch Publ Hlth, Dept Epidemiol, Ann Arbor, MI 48109 USA.
   [Teklie, Habtamu; Moges, Beyene] Ethiopian Publ Hlth Inst, Addis Ababa, Ethiopia.
   [Abeje, Yemesrach] St Pauls Hosp, Millennium Med Coll, Dept Publ Hlth, Addis Ababa, Ethiopia.
   [Boulton, Matthew L.] Univ Michigan, Med Sch, Div Infect Dis, Dept Internal Med, Ann Arbor, MI USA.
RP Porth, JM (reprint author), 1415 Washington Hts, Ann Arbor, MI 48109 USA.
EM jmporth@umich.edu
RI Wagner, Abram/X-6379-2019
OI Wagner, Abram/0000-0003-4691-7802; Porth, Julia/0000-0001-6407-5579
FU Ethiopian Public Health Institute
FX The data collection was funded through the Ethiopian Public Health
   Institute. We are deeply grateful to the data collectors who gathered
   the data.
CR Ababu Yohannes, 2017, Pan Afr Med J, V27, P2, DOI 10.11604/pamj.supp.2017.27.2.10635
   Abadura SA, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-2315-z
   Ahmed A, 2018, J INFECT PUBLIC HEAL, V11, P153, DOI 10.1016/j.jiph.2017.09.007
   Animaw W, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-464
   Bedford H, 2018, VACCINE, V36, P6556, DOI 10.1016/j.vaccine.2017.08.004
   Closser S, 2016, MED ANTHROPOL Q, V30, P321, DOI 10.1111/maq.12254
   Succi RCD, 2018, J PEDIAT-BRAZIL, V94, P574, DOI 10.1016/j.jped.2018.01.008
   de Sousa A, 2012, TROP MED INT HEALTH, V17, P308, DOI 10.1111/j.1365-3156.2011.02915.x
   Douba A, 2016, ANAL RISK FACTORS IN, V17, P1
   Dube E, 2015, VACCINE, V33, P4191, DOI 10.1016/j.vaccine.2015.04.041
   Dube E, 2015, EXPERT REV VACCINES, V14, P99, DOI 10.1586/14760584.2015.964212
   Dube E, 2014, VACCINE, V32, P6649, DOI 10.1016/j.vaccine.2014.09.039
   Ebrahim Y, 2015, CHILDHOOD IMMUNIZATI, P4
   Etana B, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-566
   Favin M, 2012, INT HEALTH, V4, P229, DOI 10.1016/j.inhe.2012.07.004
   Ghinai I, 2013, GLOB PUBLIC HEALTH, V8, P1138, DOI 10.1080/17441692.2013.859720
   Giambi C, 2018, VACCINE, V36, P779, DOI 10.1016/j.vaccine.2017.12.074
   Heeringa S.G, 2017, APPL SURVEY DATA ANA
   Hussen M, 2013, SCI TECHNOLOGY ARTS, V7522, P36
   Kassahun Melkamu Beyene, 2015, BMC Res Notes, V8, P239, DOI 10.1186/s13104-015-1192-y
   Lakew Y, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-2078-6
   Larson HJ, 2014, VACCINE, V32, P2150, DOI 10.1016/j.vaccine.2014.01.081
   Larson HJ, 2013, LANCET INFECT DIS, V13, P606, DOI 10.1016/S1473-3099(13)70108-7
   Legesse E, 2015, BMC PEDIATR, V15, DOI 10.1186/s12887-015-0345-4
   Luyten J, 2014, EUR J PUBLIC HEALTH, V24, P310, DOI 10.1093/eurpub/ckt080
   MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036
   Masters NB, 2018, HUM VACC IMMUNOTHER, V14, P2340, DOI 10.1080/21645515.2018.1480242
   Mohamud AN, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-865
   Negussie A, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889-015-2678-1
   Peiffer-Smadja N, 2017, VACCINE, V35, P2569, DOI 10.1016/j.vaccine.2017.03.068
   Peprah D, 2016, VACCINE, V34, P3823, DOI 10.1016/j.vaccine.2016.05.038
   Phadke VK, 2016, JAMA-J AM MED ASSOC, V315, P1149, DOI 10.1001/jama.2016.1353
   Ropeik D, 2013, HUM VACC IMMUNOTHER, V9, P1815, DOI 10.4161/hv.25250
   Schmid P, 2018, VACCINE, V36, P196, DOI 10.1016/j.vaccine.2016.09.065
   Sridhar S, 2014, VACCINE, V32, P6870, DOI 10.1016/j.vaccine.2014.10.063
   Streefland PH, 2001, HEALTH POLICY, V55, P159, DOI 10.1016/S0168-8510(00)00132-9
   Tadesse H, 2009, ARCH MED SCI, V5, P233
   Taylor S, 2017, VACCINE, V35, P6438, DOI 10.1016/j.vaccine.2017.09.075
   The DHS program central statistical agency [Ethiopia], 2017, ETH DEM HLTH SURV 20
   Wiyeh AB, 2018, EXPERT REV VACCINES, V17, P1063, DOI 10.1080/14760584.2018.1549994
   World Health Organization, 2014, REP SAG WORK GROUP V, DOI [10.4172/2155-9821.1000161, DOI 10.4172/2155-9821.1000161]
   World Health Organization (WHO), 2014, REG HEAL PLAN, V7
   Yenit MK, 2015, FACTORS ASS INCOMPLE, V2, P2, DOI [10.4172/2376-127X.1000180, DOI 10.4172/2376-127X.1000180]
   Zewdie A, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889-016-3904-1
NR 44
TC 2
Z9 2
U1 1
U2 5
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD APR 3
PY 2019
VL 37
IS 15
BP 2106
EP 2121
DI 10.1016/j.vaccine.2019.02.045
PG 16
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HR9EW
UT WOS:000463463000009
PM 30826143
DA 2020-05-12
ER

PT J
AU Zhan, Y
   Deng, Y
   Huang, BY
   Song, QQ
   Wang, W
   Yang, Y
   Dai, LP
   Wang, WL
   Yan, JH
   Gao, GF
   Tan, WJ
AF Zhan, Ying
   Deng, Yao
   Huang, Baoying
   Song, Qianqian
   Wang, Wen
   Yang, Yang
   Dai, Lianpan
   Wang, Wenling
   Yan, Jinghua
   Gao, Gorge F.
   Tan, Wenjie
TI Humoral and cellular immunity against both ZIKV and poxvirus is elicited
   by a two-dose regimen using DNA and non-replicating vaccinia virus-based
   vaccine candidates
SO VACCINE
LA English
DT Article
DE Zika virus; Poxvirus; Vaccine; DNA; Non-replicating vaccinia virus;
   Immunity; Mice; T-cell epitope; Prime-boost
ID DENGUE VIRUS; IMMUNOGENICITY; ANTIBODY; ENHANCEMENT; ROBUST
AB The Zika virus (ZIKV) and poxvirus infection are considered as public health emergencies, necessitating the development of effective vaccines. Here, we report novel recombinant DNA-based and non-replicating vaccinia virus (NTV)-based vaccine candidates that express the precursor membrane-envelope (prME) or envelope (E) glycoproteins of ZIKV. After immunization of BABL/c mice with the vaccines using a homologous protocol (DNA/DNA, NTV/NTV) or heterogeneous (DNAJNTV) protocol, a similar level of anti-E IgG and neutralizing antibodies (microneutralization test) were detected in the mice. However, a significantly higher level of E-specific T cell responses was elicited in mice when a heterogeneous prime-boost protocol was used (DNA/NTV) with either the DNA-based or NTV-based vaccines. Furthermore, neutralizing antibodies and a T cell immune response against the vaccinia virus (W) were detected in mice that were subjected to the prime-boost protocol (DNA/NTV), whereas those subjected to a homologous NTV/NTV protocol had higher levels of anti-VV IgG and neutralizing antibodies. Lastly, a novel H-2d-restricted CD8 T-cell epitope, VRSYCYEASISDMAS, was identified in the ZIKV E protein. These data demonstrate proof of concept of a bivalent vaccine candidate against ZIKV and orthopoxvirus, and support the use of DNA-prME prime and NTV-E boost protocols to protect against ZIKV and orthopoxvirus infections. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Zhan, Ying; Song, Qianqian; Tan, Wenjie] Wenzhou Med Univ, Minist Educ, Wenzhou, Zhejiang, Peoples R China.
   [Zhan, Ying; Song, Qianqian; Tan, Wenjie] Wenzhou Med Univ, Zhejiang Prov Key Lab Med Genet, Inst Med Virol, Sch Lab Med & Life Sci, Wenzhou, Zhejiang, Peoples R China.
   [Zhan, Ying; Deng, Yao; Huang, Baoying; Song, Qianqian; Wang, Wen; Wang, Wenling; Gao, Gorge F.; Tan, Wenjie] China CDC, Natl Inst Viral Dis Control & Prevent, 155 Changbai Rd, Beijing 102206, Peoples R China.
   [Yang, Yang; Gao, Gorge F.] Shenzhen Third Peoples Hosp, Shenzhen Key Lab Pathogen & Immun, Shenzhen, Guangdong, Peoples R China.
   [Dai, Lianpan; Yan, Jinghua; Gao, Gorge F.] Chinese Acad Sci, Beijing Inst Life Sci, Res Network Immun & Hlth, Beijing, Peoples R China.
RP Tan, WJ (reprint author), China CDC, Natl Inst Viral Dis Control & Prevent, 155 Changbai Rd, Beijing 102206, Peoples R China.; Tan, WJ (reprint author), Wenzhou Med Univ, Minist Educ, Shenzhen 325035, Zhejiang, Peoples R China.; Tan, WJ (reprint author), Wenzhou Med Univ, Zhejiang Prov Key Lab Med Genet, Inst Med Virol, Shenzhen 325035, Zhejiang, Peoples R China.
EM tanwj28@163.com
OI HUANG, Baoying/0000-0001-9516-1146
FU National Key Research and Development Program of China [2016YFD0500301,
   2016YFC1200901, 2016YFC1200200]; National Major Project for Control and
   Prevention of Infectious Disease in China [2016ZX10004001-003]
FX This work was supported by the National Key Research and Development
   Program of China (2016YFD0500301, 2016YFC1200901 and 2016YFC1200200) and
   the National Major Project for Control and Prevention of Infectious
   Disease in China (2016ZX10004001-003). The funding agencies had no role
   in the study design, data collection, data analysis, decision to
   publish, or preparation of the manuscript. We thank LetPub
   (www.letpub.com) for providing linguistic assistance during the
   preparation of this manuscript.
CR Bardina SV, 2017, SCIENCE, V356, P175, DOI 10.1126/science.aal4365
   Barouch DH, 2005, J VIROL, V79, P8828, DOI 10.1128/JVI.79.14.8828-8834.2005
   Besnard M, 2014, EUROSURVEILLANCE, V19, P13, DOI 10.2807/1560-7917.ES2014.19.13.20751
   Boigard H, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005608
   Brasil P, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004636
   Brault AC, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-15039-8
   Chattopadhyay A, 2018, VACCINE, V36, P3894, DOI 10.1016/j.vaccine.2018.05.095
   Chen H, 2011, CLIN VACCINE IMMUNOL, V18, P1789, DOI 10.1128/CVI.05113-11
   Chuai X, 2018, VACCINE, V36, P3740, DOI 10.1016/j.vaccine.2018.05.061
   Dai LP, 2016, IUBMB LIFE, V68, P783, DOI 10.1002/iub.1556
   Dejnirattisai W, 2016, NAT IMMUNOL, V17, P1102, DOI 10.1038/ni.3515
   Deng Y, 2017, VACCINE, V35, P3347, DOI 10.1016/j.vaccine.2017.04.059
   Diamond MS, 2018, ANN REV MED
   DICK GWA, 1952, T ROY SOC TROP MED H, V46, P509, DOI 10.1016/0035-9203(52)90042-4
   Dowd KA, 2016, SCIENCE, V354, P237, DOI 10.1126/science.aai9137
   Dowd KA, 2016, CELL REP, V16, P1485, DOI 10.1016/j.celrep.2016.07.049
   Duffy MR, 2009, NEW ENGL J MED, V360, P2536, DOI 10.1056/NEJMoa0805715
   Fang Q, 2005, VIROLOGY, V335, P242, DOI 10.1016/j.virol.2005.02.014
   Garg H, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10110631
   Gaudinski MR, 2018, LANCET, V391, P552, DOI 10.1016/S0140-6736(17)33105-7
   Hazin AN, 2016, NEW ENGL J MED, V374, P2193, DOI 10.1056/NEJMc1603617
   Huang HR, 2017, J VIROL, V91, DOI [10.1128/JVI.00900-17, 10.1128/jvi.00900-17]
   Lazear HM, 2016, CELL HOST MICROBE, V19, P720, DOI 10.1016/j.chom.2016.03.010
   Li XF, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-02975-w
   Liu Q, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033392
   Liu XL, 2018, NPJ VACCINES, V3, DOI 10.1038/s41541-018-0072-6
   Ma WQ, 2016, CELL, V167, P1511, DOI 10.1016/j.cell.2016.11.016
   Melamed S, 2018, VACCINES-BASEL, V6, DOI 10.3390/vaccines6010008
   Perkus ME, 2010, ANN NY ACAD SCI, V754, P222
   Poon VK, 2018, J INFECT DIS
   Prow NA, 2018, EXPERT REV VACCINES, V17, P925, DOI 10.1080/14760584.2018.1522255
   Quinan BR, 2016, VACCINE, V34, P6120, DOI 10.1016/j.vaccine.2016.10.058
   Quinan BR, 2014, VACCINE, V32, P2972, DOI 10.1016/j.vaccine.2014.03.093
   Richner JM, 2017, CELL
   Roth A, 2014, EUR COMMUN DIS B, V19
   Shan C, 2017, NAT MED
   Shankar A, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.01761
   Sun GY, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170462
   Sutter Gerd, 2003, Current Drug Targets - Infectious Disorders, V3, P263, DOI 10.2174/1568005033481123
   Wen B, 2013, MOL THER, V21, P1787, DOI 10.1038/mt.2013.122
   Wen J, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01669-z
   Xu K, 2018, J VIROL, V92, DOI [10.1128/JVI.01722-17, 10.1128/jvi.01722-17]
NR 42
TC 3
Z9 3
U1 1
U2 8
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD APR 3
PY 2019
VL 37
IS 15
BP 2122
EP 2130
DI 10.1016/j.vaccine.2019.02.063
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HR9EW
UT WOS:000463463000010
PM 30851967
DA 2020-05-12
ER

PT J
AU Wui, SR
   Kim, KS
   Ryu, JI
   Ko, A
   Do, HTT
   Lee, YJ
   Kim, HJ
   Lim, SJ
   Park, SA
   Cho, YJ
   Kim, CG
   Lee, NG
AF Wui, Seo Ri
   Kim, Kwang Sung
   Ryu, Ji In
   Ko, Ara
   Hien Thi Thu Do
   Lee, Yeon Jung
   Kim, Hark Jun
   Lim, Soo Jeong
   Park, Shin Ae
   Cho, Yang Je
   Kim, Chang-Gyeom
   Lee, Na Gyong
TI Efficient induction of cell-mediated immunity to varicella-zoster virus
   glycoprotein E co-lyophilized with a cationic liposome-based adjuvant in
   mice
SO VACCINE
LA English
DT Article
DE Cationic liposome adjuvant; Co-lyophilization; Herpes zoster vaccine;
   Varicella-zoster virus glycoprotein E
ID O-ACYLATED LIPOOLIGOSACCHARIDE; ANTHRACIS PROTECTIVE ANTIGEN; CD4(+)
   T-CELLS; HERPES-ZOSTER; SUBUNIT VACCINE; VESICLE SIZE; RESPONSES;
   EFFICACY; LIPOPOLYSACCHARIDES; IMMUNOGENICITY
AB Varicella zoster virus (VZV) is a neurotropic and lymphotropic alpha herpesvirus that causes varicella and herpes zoster (HZ). At a primary infection, VZV causes varicella in young children. Reactivation of latent VZV in sensory ganglia causes painful HZ in elderly people, occasionally leading to a serious complication, postherpetic neuralgia (PHN). A live attenuated VZV vaccine, the first vaccine licensed for the prevention of HZ and PHN is not very effective, while a recombinant subunit vaccine provides higher and longer protection against HZ. In the present study, we developed a new adjuvant system CIA09A, which is composed of cationic liposomes, the Toll-like receptor 4 (TLR4) agonist de-O-acylated lipooligosaccharide, and Quillaja saponin fraction QS-21. We then determined its adjuvant activity for recombinant VZV glycoprotein E (gE) in mice. Co-lyophilization of the liposomal adjuvant formulation with gE did not abolish the immune-stimulating activity. In fact, the CIA09A-adjuvanted gE vaccine was highly effective in eliciting both humoral and cellular immune responses to the recombinant gE protein and VZV in a VZV-primed mouse model. Furthermore, the frequency of gE-specific polyfunctional CD4(+) T cells expressing interferon (IFN)-gamma, tumor necrosis factor (TNF)-alpha, and interleukin (IL)-2 was significantly increased in mice immunized with the adjuvanted vaccine. These data indicate that co-lyophilization of protein antigens with CIA09A enables development of a liposome-adjuvanted vaccine in a single vial to induce strong cell-mediated immunity required for vaccine efficacy. Thus, the CIA09A-adjuvanted gE vaccine warrants further development as a new prophylactic vaccine against HZ. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Wui, Seo Ri; Kim, Kwang Sung; Ryu, Ji In; Ko, Ara; Hien Thi Thu Do; Lee, Yeon Jung; Kim, Hark Jun; Lim, Soo Jeong; Lee, Na Gyong] Sejong Univ, Dept Integrated Biosci & Biotechnol, 209 Neungdong Ro, Seoul 05006, South Korea.
   [Kim, Kwang Sung; Park, Shin Ae; Cho, Yang Je] EyeGene, R & D Ctr, Goyang 10551, South Korea.
   [Kim, Chang-Gyeom] Korea Polytech Univ, Seongnam 13122, South Korea.
RP Lee, NG (reprint author), Sejong Univ, Dept Integrated Biosci & Biotechnol, 209 Neungdong Ro, Seoul 05006, South Korea.
EM nglee@sejong.ac.kr
FU Korean Health Technology R&D Project, Ministry of Health & Welfare,
   Republic of Korea [HI14C2664/HI17C0175]; Ministry of Food and Drug
   Administration [16172MFDS261]
FX This study was supported by grants from the Korean Health Technology R&D
   Project, Ministry of Health & Welfare, Republic of Korea (No.
   HI14C2664/HI17C0175) and the Ministry of Food and Drug Administration
   (No. 16172MFDS261).
CR Alving CR, 2016, EXPERT OPIN DRUG DEL, V13, P807, DOI 10.1517/17425247.2016.1151871
   Badiee A, 2012, EXP PARASITOL, V132, P403, DOI 10.1016/j.exppara.2012.09.001
   Berkowitz EM, 2015, J INFECT DIS, V211, P1279, DOI 10.1093/infdis/jiu606
   Brewer JM, 2004, J IMMUNOL, V173, P6143, DOI 10.4049/jimmunol.173.10.6143
   Brewer JM, 1998, J IMMUNOL, V161, P4000
   Brito LA, 2014, J CONTROL RELEASE, V190, P563, DOI 10.1016/j.jconrel.2014.06.027
   Chen CJ, 2010, J CONTROL RELEASE, V142, P299, DOI 10.1016/j.jconrel.2009.10.024
   Chlibek R, 2016, VACCINE, V34, P863, DOI 10.1016/j.vaccine.2015.09.073
   Cho YJ, 2006, VACCINE, V24, P5862, DOI 10.1016/j.vaccine.2006.04.048
   Coccia M, 2017, NPJ VACCINES, V2, DOI 10.1038/s41541-017-0027-3
   Cunningham AL, 2016, NEW ENGL J MED, V375, P1019, DOI 10.1056/NEJMoa1603800
   Cunningham AL, 2018, J INFECT DIS, V218, pS127, DOI 10.1093/infdis/jiy382
   Cunningham AL, 2018, J INFECT DIS, V217, P1750, DOI 10.1093/infdis/jiy095
   Dendouga N, 2012, VACCINE, V30, P3126, DOI 10.1016/j.vaccine.2012.01.088
   Didierlaurent AM, 2017, EXPERT REV VACCINES, V16, P55, DOI 10.1080/14760584.2016.1213632
   Hales Craig M, 2014, MMWR Morb Mortal Wkly Rep, V63, P729
   Han JE, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085838
   Han JE, 2012, VACCINE, V30, P4127, DOI 10.1016/j.vaccine.2012.04.079
   Henriksen-Lacey M, 2011, J CONTROL RELEASE, V154, P131, DOI 10.1016/j.jconrel.2011.05.019
   Henriksen-Lacey M, 2010, J CONTROL RELEASE, V145, P102, DOI 10.1016/j.jconrel.2010.03.027
   Khademi F, 2018, REV PHYSIOL BIOCH P, V175, P47, DOI 10.1007/112_2018_9
   Ko A, 2018, ARCH PHARM RES, V41, P219, DOI 10.1007/s12272-017-0985-z
   Korsholm KS, 2007, IMMUNOLOGY, V121, P216, DOI 10.1111/j.1365-2567.2007.02560.x
   Laing KJ, 2015, J INFECT DIS, V212, P1022, DOI 10.1093/infdis/jiv164
   Lal H, 2015, NEW ENGL J MED, V372, P2087, DOI 10.1056/NEJMoa1501184
   Lee CH, 1999, ANAL BIOCHEM, V267, P161, DOI 10.1006/abio.1998.2961
   Levin MJ, 2008, J INFECT DIS, V197, P825, DOI 10.1086/528696
   LEVIN MJ, 1992, J INFECT DIS, V166, P253, DOI 10.1093/infdis/166.2.253
   Liu J, 2016, SCI REP-UK, V6, DOI 10.1038/srep20577
   Ma YF, 2011, NANOSCALE, V3, P2307, DOI 10.1039/c1nr10166h
   Mozafari MR, 2005, CELL MOL BIOL LETT, V10, P711
   Nisini R, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00155
   Oxman MN, 2010, CLIN INFECT DIS, V51, P197, DOI 10.1086/653605
   Oxman MN, 2005, NEW ENGL J MED, V352, P2271, DOI 10.1056/NEJMoa051016
   Ryu JI, 2017, J MICROBIOL BIOTECHN, V27, P1539, DOI 10.4014/jmb.1706.06009
   Ryu JI, 2016, BIOMED RES INT, DOI 10.1155/2016/3713656
   Schmidt ST, 2016, PHARMACEUTICS, V8, DOI 10.3390/pharmaceutics8010007
   Schub D, 2015, J INFECT DIS, V211, P600, DOI 10.1093/infdis/jiu500
   Stadtmauer EA, 2014, BLOOD, V124, P2921, DOI 10.1182/blood-2014-04-573048
   Steain M, 2014, J VIROL, V88, P2704, DOI 10.1128/JVI.03445-13
   Van der Meeren O, 2018, NEW ENGL J MED, V379, P1621, DOI 10.1056/NEJMoa1803484
   Vangasseri DP, 2006, MOL MEMBR BIOL, V23, P385, DOI 10.1080/09687860600790537
   Vossen MTM, 2004, J INFECT DIS, V190, P72, DOI 10.1086/421277
   Wang C, 2014, ACCIDENT ANAL PREV, V71, P82, DOI 10.1016/j.aap.2014.05.004
   Wang W, 2000, INT J PHARMACEUT, V203, P1, DOI 10.1016/S0378-5173(00)00423-3
   Weinberg A, 2010, CURR TOP MICROBIOL, V342, P341, DOI 10.1007/82_2010_31
   Welsby I, 2017, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00663
   Wui SR, 2013, ARCH PHARM RES, V36, P464, DOI 10.1007/s12272-013-0034-5
   Wui SR, 2011, INT IMMUNOPHARMACOL, V11, P1195, DOI 10.1016/j.intimp.2011.03.020
   Yan WL, 2007, MOL IMMUNOL, V44, P3672, DOI 10.1016/j.molimm.2007.04.009
   Zerboni L, 2014, NAT REV MICROBIOL, V12, P197, DOI 10.1038/nrmicro3215
   Zhang HW, 2017, METHODS MOL BIOL, V1522, P17, DOI 10.1007/978-1-4939-6591-5_2
NR 52
TC 0
Z9 0
U1 2
U2 16
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD APR 3
PY 2019
VL 37
IS 15
BP 2131
EP 2141
DI 10.1016/j.vaccine.2019.02.048
PG 11
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HR9EW
UT WOS:000463463000011
PM 30827737
DA 2020-05-12
ER

PT J
AU Mouchet, J
   Begaud, B
AF Mouchet, Julie
   Begaud, Bernard
TI Hepatitis B vaccination and central demyelination - History, description
   and observed/expected analyses of 624 cases reported to the French
   pharmacovigilance over a 20-year period
SO VACCINE
LA English
DT Article
DE Hepatitis B vaccine; Multiple sclerosis; Demyelination; Vaccination;
   Risk
ID ADVERSE DRUG-REACTIONS; MULTIPLE-SCLEROSIS; RISK; DISEASES
AB Background: Confidence in vaccines is essential for achieving targeted immunization coverage. The current skepticism about vaccine safety feeds on controversies such as the suspicion about a link between hepatitis B (HB) vaccination and central demyelination (CD) after the massive HB immunization campaign in France in 1994-2000. This study assesses the robustness of this signal by analysing all validated cases reported in 1980-2000 and by conducting observed-to-expected (OE) comparisons.
   Methods: After characterizing case profiles, reporting rates per 1,000,000 vaccine doses sold were computed for the period and per year. OE comparisons were conducted by using individual-based and person-year approaches and were stratified by gender.
   Finding: A total of 624CD cases including 422 incident cases of multiple sclerosis (MS) were reported over 20 years. Women accounted for 73.2% (n = 457). Mean age was 29.8 years (SD = 11.1). Incidence of events peaked in 1995-1996 and 1997, these years accounting for 59.8% (n = 373) of cases. Events were mainly reported after booster doses (46.3%, n = 289). The overall reporting rate was 6.5 per 1,000,000 doses sold. The OE analyses produced inconclusive results, the number of observed cases remaining below the expected number.
   Conclusions: The complete disjunction between target and joint populations in the 1990s French HB immunization campaign created an unpreceded situation with similar to 26 million of adults exposed at the age of MS onset. Two findings are noteworthy: the non-random distribution of reports according to the rank of vaccination or years of survey, and the fact that the number of reports sometimes approached the baseline incidence of MS, irrespective of underreporting. While the nature of the link remains unclear, our results are not consistent with a strong association between HB vaccine and MS. Current recommendations targeting newborns with a possible catch-up of at-risk adults should remain the preferred strategy in low-endemic countries. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Mouchet, Julie; Begaud, Bernard] Univ Bordeaux, INSERM, Bordeaux Populat Hlth Res Ctr, Team Pharmacoepidemiol,UMR 1219, F-33000 Bordeaux, France.
RP Mouchet, J (reprint author), Univ Bordeaux, INSERM, Bordeaux Populat Hlth Res Ctr, Team Pharmacoepidemiol,UMR 1219, F-33000 Bordeaux, France.
EM julie.le-moal@u-bordeaux.fr
FU University of Bordeaux, France; INSERMInstitut National de la Sante et
   de la Recherche Medicale (Inserm)
FX University of Bordeaux, France and INSERM. The funding source had no
   role in the study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR Alvarez-Requejo A, 1998, EUR J CLIN PHARMACOL, V54, P483, DOI 10.1007/s002280050498
   Ascherio A, 2001, NEW ENGL J MED, V344, P327, DOI 10.1056/NEJM200102013440502
   BEGAUD B, 2000, DICT PHARMACOEPIDEMI
   DeStefano F, 2003, ARCH NEUROL-CHICAGO, V60, P504, DOI 10.1001/archneur.60.4.504
   Eftekharian Mohammad Mahdi, 2014, Human Antibodies, V23, P31, DOI 10.3233/HAB-150281
   European Medicine Agency, 2000, SUMM PROD CHAR ENG B
   Fourrier A, 2001, BRIT J CLIN PHARMACO, V51, P489, DOI 10.1046/j.1365-2125.2001.01364.x
   Fromont A, 2012, MULT SCLER J, V18, P1108, DOI 10.1177/1352458511433305
   Gaudelus J, 2010, ARCH PEDIATRIE, V17, P955, DOI 10.1016/S0929-693X(10)70196-2
   Hernan MA, 2004, NEUROLOGY, V63, P838, DOI 10.1212/01.WNL.0000138433.61870.82
   Hocine MN, 2007, VACCINE, V25, P5938, DOI 10.1016/j.vaccine.2007.05.032
   Langer-Gould A, 2014, JAMA NEUROL, V71, P1506, DOI 10.1001/jamaneurol.2014.2633
   Larson HJ, 2016, EBIOMEDICINE, V12, P295, DOI 10.1016/j.ebiom.2016.08.042
   Levy-Bruhl D, 1999, B EPIDEMIL HEBD, V9, P1
   Mahaux O, 2016, PHARMACOEPIDEM DR S, V25, P215, DOI 10.1002/pds.3918
   Mikaeloff Y, 2007, ARCH PEDIAT ADOL MED, V161, P1176, DOI 10.1001/archpedi.161.12.1176
   Mikaeloff Y, 2009, NEUROLOGY, V72, P873, DOI 10.1212/01.wnl.0000335762.42177.07
   Moride Y, 1997, BRIT J CLIN PHARMACO, V43, P177, DOI 10.1046/j.1365-2125.1997.05417.x
   Observatoire Francais de la Sclerose en Plaque, 2017, DESCR COH OFSEN 15 D
   Ramagopalan SV, 2009, NEUROEPIDEMIOLOGY, V32, P257, DOI 10.1159/000201564
   Sturkenboom MCJM, 1999, PHARMACOEPIDEMIOL S, V8, pS170
   Touze E, 2000, REV NEUROL, V156, P242
   Touze E, 2002, NEUROEPIDEMIOLOGY, V21, P180, DOI 10.1159/000059520
   Zipp F, 1999, NAT MED, V5, P964, DOI 10.1038/12376
NR 24
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD APR 3
PY 2019
VL 37
IS 15
BP 2142
EP 2148
DI 10.1016/j.vaccine.2019.02.046
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HR9EW
UT WOS:000463463000012
PM 30851966
DA 2020-05-12
ER

PT J
AU Jacobs, AAC
   Harks, F
   Hazenberg, L
   Hoeijmakers, MJH
   Nell, T
   Pel, S
   Segers, RPAM
AF Jacobs, A. A. C.
   Harks, F.
   Hazenberg, L.
   Hoeijmakers, M. J. H.
   Nell, T.
   Pel, S.
   Segers, R. P. A. M.
TI Efficacy of a novel inactivated Lawsonia intracellularis vaccine in pigs
   against experimental infection and under field conditions
SO VACCINE
LA English
DT Article
DE Swine; Ileitis; Porcine proliferative enteropathy; Adenomatosis;
   Protection; Immunity
ID REDUCTION; IMMUNITY
AB The efficacy of a novel inactivated Lawsonia intracellularis vaccine, Porcilis (R) Lawsonia, was compared to that of a commercially available live attenuated vaccine in three experimental vaccination-challenge studies in pigs. The efficacy of the new vaccine was further tested under field conditions on a farm with a history of acute ileitis.
   The novel inactivated vaccine consists of a freeze-dried antigen fraction that is dissolved just prior to use in either the adjuvant or in Porcilis (R) PCV M Hyo; an existing combination vaccine against porcine circovirus type 2 and Mycoplasma hyopneumoniae.
   The three experimental vaccination-challenge trials had a similar design and for each trial 75 piglets were used, randomly allotted to three groups of 25 piglets. The pigs were vaccinated at 4 or 5 weeks of age with either Porcilis (R) Lawsonia in adjuvant or in associated mixed use with Porcilis (R) PCV M Hyo (group 1), with the live vaccine (group 2), or left as unvaccinated controls (group 3). The pigs were challenged with virulent Lawsonia intracellularis 3, 4 or 17 weeks after vaccination. Post-challenge the pigs were evaluated for clinical signs, average daily weight gain, shedding and macroscopic as well as microscopic immuno-histological ileum lesion scores. In the field study, the mortality and key performance parameters were evaluated over a period of 8 months.
   The results of all three experimental vaccination-challenge trials showed that Porcilis (R) Lawsonia induced statistically significant protection against experimental Lawsonia intracellularis infection. This was demonstrated by lower clinical scores, improved weight gain, reduction of Lawsonia intracellularis shedding and reduction of macroscopic as well as microscopic ileum lesion scores when compared to the controls. The protection induced was superior to that of the commercially available live vaccine. In the field study, Porcilis (R) Lawsonia proved to be highly efficacious; reducing Lawsonia associated mortality to zero and improving key production parameters. (C) 2019 Merck Sharp and Dohm Animal Health. Published by Elsevier Ltd.
C1 [Jacobs, A. A. C.; Harks, F.; Hazenberg, L.; Hoeijmakers, M. J. H.; Nell, T.; Pel, S.; Segers, R. P. A. M.] MSD Anim Hlth, Wim Korverstr 35,POB 31, NL-5830 AA Boxmeer, Netherlands.
RP Jacobs, AAC (reprint author), MSD Anim Hlth, Wim Korverstr 35,POB 31, NL-5830 AA Boxmeer, Netherlands.
EM ton.jacobs@merck.com; frans.harks@merck.com; leonie.hazenberg@merck.com;
   mathieu.hoeijmakers@merck.com; tom.nell@merck.com;
   suzanne.pel@merck.com; ruud.segers@merck.com
CR Agresti A., 2002, CATEGORICAL DATA ANA
   Clark L. K., 1993, JSHAP, V1, P10
   Goldsby RA, 2000, KUBY IMMUNOLOGY, P380
   Guedes RMC, 2010, CAN J VET RES, V74, P97
   Haake M, 2014, VET MICROBIOL, V168, P272, DOI 10.1016/j.vetmic.2013.11.012
   Jacobson M, 2003, RES VET SCI, V74, P163, DOI 10.1016/S0034-5288(02)00187-X
   JONES GF, 1993, INFECT IMMUN, V61, P5237, DOI 10.1128/IAI.61.12.5237-5244.1993
   Knight-Jones TJD, 2014, P ROY SOC B-BIOL SCI, V281, DOI 10.1098/rspb.2013.2839
   Lawson GHK, 2000, J COMP PATHOL, V122, P77, DOI 10.1053/jcpa.1999.0347
   McOrist S., 2003, Pig Journal, V51, P26
   Riber U, 2015, VACCINE, V33, P156, DOI 10.1016/j.vaccine.2014.10.084
   Roerink F, 2018, VACCINE, V36, P1500, DOI 10.1016/j.vaccine.2017.12.049
   Segales J, 2012, VIRUS RES, V164, P10, DOI 10.1016/j.virusres.2011.10.007
   Vannucci FA, 2014, VET PATHOL, V51, P465, DOI 10.1177/0300985813520249
NR 14
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD APR 3
PY 2019
VL 37
IS 15
BP 2149
EP 2157
DI 10.1016/j.vaccine.2019.02.067
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HR9EW
UT WOS:000463463000013
PM 30867100
OA Other Gold
DA 2020-05-12
ER

PT J
AU Sekiya, T
   Mifsud, EJ
   Ohno, M
   Nomura, N
   Sasada, M
   Fujikura, D
   Daito, T
   Shingai, M
   Ohara, Y
   Nishimura, T
   Endo, M
   Mitsumata, R
   Ikeda, T
   Hatanaka, H
   Kitayama, H
   Motokawa, K
   Sobue, T
   Suzuki, S
   Itoh, Y
   Brown, LE
   Ogasawara, K
   Kino, Y
   Kida, H
AF Sekiya, Toshiki
   Mifsud, Edin J.
   Ohno, Marumi
   Nomura, Naoki
   Sasada, Mayumi
   Fujikura, Daisuke
   Daito, Takuji
   Shingai, Masashi
   Ohara, Yuki
   Nishimura, Tomohiro
   Endo, Masafumi
   Mitsumata, Ryotarou
   Ikeda, Tomio
   Hatanaka, Hironori
   Kitayama, Hiroki
   Motokawa, Kenji
   Sobue, Tomoyoshi
   Suzuki, Saori
   Itoh, Yasushi
   Brown, Lorena E.
   Ogasawara, Kazumasa
   Kino, Yoichiro
   Kida, Hiroshi
TI Inactivated whole virus particle vaccine with potent immunogenicity and
   limited IL-6 induction is ideal for influenza
SO VACCINE
LA English
DT Article
DE Inactivated whole influenza virus particle vaccine; Seasonal and
   pandemic influenza
ID LIPOPOLYSACCHARIDE-INDUCED FEVER; BRAIN ENDOTHELIAL-CELLS; EXPRESS
   CYCLOOXYGENASE-2; IMMUNE-RESPONSES; CHILDREN; RECOGNITION; SPLIT; RNA;
   HEMAGGLUTININ; INFECTION
AB In contrast to current ether- or detergent-disrupted "split" vaccines (SVs) for influenza, inactivated whole influenza virus particle vaccines (WPVs) retain the original virus structure and components and as such may confer similar immunity to natural infection. In a collaboration between academia and industry, the potential of WPV as a new seasonal influenza vaccine was investigated. Each of the four seasonal influenza vaccine manufacturers in Japan prepared WPVs and SVs from the same batches of purified influenza virus. Both mice and monkeys vaccinated with the WPVs exhibited superior immune responses to those vaccinated with the corresponding SVs. Vaccination with A/California/07/2009 (H1N1) WPV enabled mice to survive a lethal challenge dose of homologous virus whereas those vaccinated with SV succumbed to infection within 6 days. Furthermore, mice vaccinated with WPV induced substantial numbers of multifunctional CD8(+) T cells, important for control of antigenically drifted influenza virus strains. In addition, cytokines and chemokines were detected at early time points in the sera of mice vaccinated with WPV but not in those animals vaccinated with SV. These results indicate that WPVs induce enhanced innate and adaptive immune responses compared to equivalent doses of SVs. Notably, WPV at one fifth of the dose of SV was able to induce potent immunity with limited production of IL-6, one of the pyrogenic cytokines. We thus propose that WPVs with balanced immunogenicity and safety may set a new global standard for seasonal influenza vaccines. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Sekiya, Toshiki; Mifsud, Edin J.; Ohno, Marumi; Nomura, Naoki; Sasada, Mayumi; Fujikura, Daisuke; Daito, Takuji; Shingai, Masashi; Kida, Hiroshi] Hokkaido Univ, Res Ctr Zoonosis Control, Sapporo, Hokkaido, Japan.
   [Sekiya, Toshiki; Mifsud, Edin J.; Shingai, Masashi; Brown, Lorena E.; Kida, Hiroshi] Hokkaido Univ, Global Stn Zoonosis Control, Global Inst Collaborat Res & Educ GI CoRE, Sapporo, Hokkaido, Japan.
   [Sekiya, Toshiki; Mifsud, Edin J.; Brown, Lorena E.] Univ Melbourne, Peter Doherty Inst Infect & Immun, Dept Microbiol & Immunol, Melbourne, Vic, Australia.
   [Ohara, Yuki; Nishimura, Tomohiro; Endo, Masafumi] KM Biol Co Ltd, Kumamoto, Japan.
   [Mitsumata, Ryotarou; Ikeda, Tomio] Denka Seiken Co Ltd, R&D Ctr, Niigata, Japan.
   [Hatanaka, Hironori; Kitayama, Hiroki] Osaka Univ, Res Fdn Microbial Dis, Kannonji, Kagawa, Japan.
   [Motokawa, Kenji] Kitasato Daiichi Sankyo Vaccine Co Ltd, Mfg Dept 3, Saitama, Japan.
   [Sobue, Tomoyoshi] Kitasato Daiichi Sankyo Vaccine Co Ltd, CMC Res Labs, Saitama, Japan.
   [Suzuki, Saori; Itoh, Yasushi; Ogasawara, Kazumasa] Shiga Univ Med Sci, Dept Pathol, Div Pathol & Dis Regulat, Otsu, Shiga, Japan.
   [Ogasawara, Kazumasa] Shiga Univ Med Sci, Res Ctr Anim Life Sci, Otsu, Shiga, Japan.
   [Kino, Yoichiro] Kino Consulting, Kumamoto, Japan.
   [Kida, Hiroshi] Nagasaki Univ, Collaborating Res Ctr Control Infect Dis, Nagasaki, Japan.
RP Kida, H (reprint author), Hokkaido Univ, Res Ctr Zoonosis Control, Kita Ku, Kita-20 Nishi-10, Sapporo, Hokkaido 0010020, Japan.
EM kida@vetmed.hokudai.ac.jp
FU Japan Initiative for Global Research Network on Infectious Diseases
   (J-GRID) from Japan Agency for Medical Research and Development
   (AMED)Japan Agency for Medical Research and Development (AMED)
   [JP18fm0108008]; GI-CoRE program of Hokkaido University; Program for
   Leading Graduate Schools from the Japan Society for the Promotion of
   Science [F01]; Japan Science and Technology Agency Basic Research
   Programs, JSPS KAKENHI [17K15367, 16K18792, 18K07135]
FX We thank Dr. Watanabe (National Institute of Infectious Disease in
   Japan) for kindly providing influenza virus strains,
   A/California/07/2009 (H1N1) and B/Texas/2/2013 (Victoria). The project
   was supported by the Japan Initiative for Global Research Network on
   Infectious Diseases (J-GRID) from Japan Agency for Medical Research and
   Development (AMED) JP18fm0108008, the GI-CoRE program of Hokkaido
   University and the Program for Leading Graduate Schools (F01) from the
   Japan Society for the Promotion of Science. M Ohno, T Daito, and M
   Shingai were supported by grants from the Japan Science and Technology
   Agency Basic Research Programs, JSPS KAKENHI (grant numbers 17K15367,
   16K18792 and 18K07135, respectively).
CR Arikata M, 2012, PLOS ONE, V2009, P7
   BACHMAYER H, 1976, POSTGRAD MED J, V52, P360, DOI 10.1136/pgmj.52.608.360
   BARRY DW, 1976, AM J EPIDEMIOL, V104, P47, DOI 10.1093/oxfordjournals.aje.a112273
   BERNSTEIN DI, 1982, PEDIATRICS, V69, P404
   BRADY MI, 1976, J HYG-CAMBRIDGE, V77, P161, DOI 10.1017/S002217240002458X
   BRADY MI, 1976, J HYG-CAMBRIDGE, V77, P173, DOI 10.1017/S0022172400024591
   Cao CY, 1996, BRAIN RES, V733, P263, DOI 10.1016/0006-8993(96)00575-6
   Chai Z, 1996, J EXP MED, V183, P311, DOI 10.1084/jem.183.1.311
   Cox RJ, 2006, VACCINE, V24, P6585, DOI 10.1016/j.vaccine.2006.05.040
   de Jong MD, 2006, NAT MED, V12, P1203, DOI 10.1038/nm1477
   Diebold SS, 2004, SCIENCE, V303, P1529, DOI 10.1126/science.1093616
   Engstrom L, 2012, ENDOCRINOLOGY, V153, P4849, DOI 10.1210/en.2012-1375
   Evans SS, 2015, NAT REV IMMUNOL, V15, P335, DOI 10.1038/nri3843
   Geeraedts F, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000138
   Geeraedts F, 2008, INFLUENZA OTHER RESP, V2, P41, DOI 10.1111/j.1750-2659.2008.00038.x
   Goodwin K, 2006, VACCINE, V24, P1159, DOI 10.1016/j.vaccine.2005.08.105
   Hanada R, 2009, NATURE, V462, P505, DOI 10.1038/nature08596
   Hasday JD, 2014, COMPR PHYSIOL, V4, P109, DOI 10.1002/cphy.c130019
   Hayden FG, 1998, J CLIN INVEST, V101, P643, DOI 10.1172/JCI1355
   Hornung V, 2004, J IMMUNOL, V173, P5935, DOI 10.4049/jimmunol.173.10.5935
   Itoh Y, 2010, VACCINE, V28, P780, DOI 10.1016/j.vaccine.2009.10.067
   KIDA H, 1982, VIROLOGY, V122, P38, DOI 10.1016/0042-6822(82)90375-0
   Konsman JP, 2004, J COMP NEUROL, V472, P113, DOI 10.1002/cne.20052
   Kumagai T, 2004, VACCINE, V22, P3404, DOI 10.1016/j.vaccine.2004.02.030
   Lin JT, 2006, LANCET, V368, P991, DOI 10.1016/S0140-6736(06)69294-5
   Loo YM, 2011, IMMUNITY, V34, P680, DOI 10.1016/j.immuni.2011.05.003
   Lund JM, 2004, P NATL ACAD SCI USA, V101, P5598, DOI 10.1073/pnas.0400937101
   Matsumura K, 1998, J NEUROSCI, V18, P6279
   Miyake T, 2010, J MED PRIMATOL, V39, P58, DOI 10.1111/j.1600-0684.2009.00395.x
   Nakayama T, 2016, VACCINE, V34, P5815, DOI 10.1016/j.vaccine.2016.08.051
   Netea MG, 2000, CLIN INFECT DIS, V31, pS178, DOI 10.1086/317513
   Onodera T, 2016, J IMMUNOL, V196, P4172, DOI 10.4049/jimmunol.1600046
   Osterholm MT, 2012, LANCET INFECT DIS, V12, P36, DOI 10.1016/S1473-3099(11)70295-X
   Palm NW, 2009, IMMUNOL REV, V227, P221, DOI 10.1111/j.1600-065X.2008.00731.x
   PARKMAN PD, 1977, J INFECT DIS, V136, pS722, DOI 10.1093/infdis/136.Supplement_3.S722
   PECK FB, 1968, J AMER MED ASSOC, V206, P2277
   Petrova VN, 2018, NAT REV MICROBIOL, V16, P47, DOI 10.1038/nrmicro.2017.118
   Reber AJ, 2012, AGING DIS, V3, P68
   Sawai T, 2008, IMMUNOLOGY, V124, P155, DOI 10.1111/j.1365-2567.2007.02745.x
   Stephenson I, 2003, LANCET, V362, P1959, DOI 10.1016/S0140-6736(03)15014-3
   Stohr K, 2006, NAT REV MICROBIOL, V4, P565, DOI 10.1038/nrmicro1482
   Vesikari T, 2009, PEDIATR INFECT DIS J, V28, P563, DOI 10.1097/INF.0b013e31819d6394
   Wu JA, 2010, VACCINE, V28, P6221, DOI 10.1016/j.vaccine.2010.07.008
   Yamagata K, 2001, J NEUROSCI, V21, P2669, DOI 10.1523/JNEUROSCI.21-08-02669.2001
   Zetterstrom M, 1998, ANN NY ACAD SCI, V856, P48, DOI 10.1111/j.1749-6632.1998.tb08311.x
NR 45
TC 0
Z9 0
U1 0
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD APR 3
PY 2019
VL 37
IS 15
BP 2158
EP 2166
DI 10.1016/j.vaccine.2019.02.057
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HR9EW
UT WOS:000463463000014
PM 30857932
DA 2020-05-12
ER

PT J
AU Liu, J
   Wang, H
   Wang, LD
   Xing, L
   Zhang, SH
   Xiao, HN
   Ma, YL
AF Liu, Jie
   Wang, Hao
   Wang, Lidong
   Xing, Lei
   Zhang, Shihan
   Xiao, Huining
   Ma, Yongliang
TI Defect-engineered cobalt-based solid catalyst for high efficiency
   oxidation of sulfite
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE CO3O4 NCs/g-C3N4 hybrids; Defect engineering; Oxygen vacancies; Size
   effect; Catalytic oxidation of sulfite
ID QUANTUM DOTS; PHOTOCATALYTIC ACTIVITY; OXYGEN VACANCIES;
   ELECTRONIC-STRUCTURE; CO2 HYDROGENATION; SULFATE RECOVERY; NANOSHEETS;
   PERFORMANCE; CEO2; ACTIVATION
AB We report a defect-engineered Co-based solid catalyst, namely the CO3O4 nanocubes (NCs)/graphitic C3N4(g-C3N4) hybrid, for enhancing the oxidation of magnesium sulfite (MgSO3) in the desulfurization of wet magnesia. Abundant oxygen vacancies were induced successfully on the CO3O4 NCs/g-C3N4 hybrid. The creation of oxygen vacancies promoted MgSO3 oxidation by enhancing the adsorption of reactant MgSO3 and accelerating the striping of product MgSO4 to refresh the Co active sites. The oxygen vacancies also promoted the transfer of oxygen molecules and subsequent activation of oxygen molecules to active oxygen species. The size effect of CO3O4 NCs, which may be a crucial factor for improving the catalytic activity, considerably enhanced the efficiency of Co species. Moreover, because the g-C3N4 support had a large surface area and large number of unpaired electrons, the coupling of CO3O4 NCs and g-C3N4 improved the dispersion of CO3O4 NCs, which substantially decreased the usage of Co species. During the MgSO3 oxidation reaction, the hybrid catalyst exhibited an unprecedented MgSO4 yield per Co site of 1678.9 mmol/mmol Co at 30 min and a rapid MgSO3 oxidation rate of 0.068 mmol.L (1).s (1). (C) 2018 Published by Elsevier Ltd.
C1 [Liu, Jie; Wang, Hao; Wang, Lidong; Xing, Lei; Xiao, Huining] MOE, Key Lab Resources & Environm Syst Optimizat, Beijing 102206, Peoples R China.
   [Liu, Jie; Wang, Hao; Wang, Lidong; Xing, Lei; Xiao, Huining] North China Elect Power Univ, Sch Environm Sci & Engn, Baoding 071003, Peoples R China.
   [Zhang, Shihan] Zhejiang Univ Technol, Coll Environm, Hangzhou 310014, Zhejiang, Peoples R China.
   [Ma, Yongliang] Tsinghua Univ, Sch Environm, Beijing 100085, Peoples R China.
RP Wang, LD (reprint author), North China Elect Power Univ, Sch Environm Sci & Engn, Baoding 071003, Peoples R China.
EM wld@tsinghua.edu.cn
RI Zhang, Shihan/Q-1585-2019
FU National Key Research and Development Program of China [2017YFC0210201,
   2016YFC0204100]; Natural Science Foundation of Hebei ProvinceNatural
   Science Foundation of Hebei Province [E2016502096, B2016502063];
   Fundamental Research Funds for the Central UniversitiesFundamental
   Research Funds for the Central Universities [2017XS130]; National Nature
   Science Foundation of ChinaNational Natural Science Foundation of China
   [21507029]
FX The present work is supported by the National Key Research and
   Development Program of China (No. 2017YFC0210201 and 2016YFC0204100),
   the Natural Science Foundation of Hebei Province (No. E2016502096,
   B2016502063), the Fundamental Research Funds for the Central
   Universities (No. 2017XS130), and the National Nature Science Foundation
   of China (No. 21507029). This manuscript was edited by Wallace Academic
   Editing.
CR Ali A, 2018, J ALLOY COMPD, V731, P181, DOI 10.1016/j.jallcom.2017.10.032
   Bai XJ, 2014, APPL CATAL B-ENVIRON, V147, P82, DOI 10.1016/j.apcatb.2013.08.007
   Cai T, 2015, APPL CATAL B-ENVIRON, V166, P393, DOI 10.1016/j.apcatb.2014.10.047
   Carrasco J, 2014, J PHYS CHEM C, V118, P5352, DOI 10.1021/jp410478c
   Chen C, 2017, ELECTROCHIM ACTA, V245, P672, DOI 10.1016/j.electacta.2017.05.179
   Cui YJ, 2012, ANGEW CHEM INT EDIT, V51, P11814, DOI 10.1002/anie.201206534
   Deng KX, 2017, CATAL COMMUN, V100, P81, DOI 10.1016/j.catcom.2017.06.041
   Fang WJ, 2017, APPL CATAL B-ENVIRON, V209, P631, DOI 10.1016/j.apcatb.2017.03.041
   Garcia T, 2010, APPL CATAL A-GEN, V386, P16, DOI 10.1016/j.apcata.2010.07.018
   Ge YR, 2017, SENSOR ACTUAT B-CHEM, V244, P983, DOI 10.1016/j.snb.2017.01.092
   Gomez LE, 2016, INT J HYDROGEN ENERG, V41, P4993, DOI 10.1016/j.ijhydene.2016.01.099
   Gu H, 2015, TALANTA, V132, P871, DOI 10.1016/j.talanta.2014.09.042
   Hong W., 2017, ACS SUSTAIN CHEM ENG, V6, P889
   Jaffari GH, 2017, APPL SURF SCI, V396, P547, DOI 10.1016/j.apsusc.2016.10.193
   Jiang JZ, 2014, CARBON, V80, P213, DOI 10.1016/j.carbon.2014.08.059
   Jongsomjit B, 2001, J CATAL, V204, P98, DOI 10.1006/jcat.2001.3387
   Ke J, 2018, NANO-MICRO LETT, V10, DOI 10.1007/s40820-018-0222-4
   Lan ZA, 2016, APPL CATAL B-ENVIRON, V192, P116, DOI 10.1016/j.apcatb.2016.03.062
   Lee J, 2011, J AM CHEM SOC, V133, P10066, DOI 10.1021/ja204077e
   Li N, 2018, ELECTROCHIM ACTA, V270, P330, DOI 10.1016/j.electacta.2018.03.083
   Li QW, 2017, APPL CATAL B-ENVIRON, V203, P851, DOI 10.1016/j.apcatb.2016.10.076
   Li QW, 2014, ENVIRON SCI TECHNOL, V48, P4145, DOI 10.1021/es404872w
   Li Y, 2015, ACS CATAL, V5, P3006, DOI 10.1021/cs502084g
   Lian SC, 2018, ACS NANO, V12, P568, DOI 10.1021/acsnano.7b07377
   Liu HR, 2018, FUEL, V217, P570, DOI 10.1016/j.fuel.2017.12.112
   Liu J, 2019, J HAZARD MATER, V365, P531, DOI 10.1016/j.jhazmat.2018.11.040
   Liu J, 2018, APPL CATAL B-ENVIRON, V236, P396, DOI 10.1016/j.apcatb.2018.05.042
   Liu J, 2018, APPL CATAL B-ENVIRON, V224, P705, DOI 10.1016/j.apcatb.2017.11.028
   Liu J, 2018, APPL CATAL A-GEN, V549, P289, DOI 10.1016/j.apcata.2017.10.010
   Liu J, 2017, APPL CATAL B-ENVIRON, V200, P297, DOI 10.1016/j.apcatb.2016.07.020
   Lu YF, 2018, APPL CATAL B-ENVIRON, V231, P357, DOI 10.1016/j.apcatb.2018.01.008
   Luo S, 2018, APPL CATAL B-ENVIRON, V221, P215, DOI 10.1016/j.apcatb.2017.09.028
   Mei J, 2018, J IND ENG CHEM, V57, P208, DOI 10.1016/j.jiec.2017.08.025
   Patel A, 2011, CATAL TODAY, V166, P188, DOI 10.1016/j.cattod.2010.05.040
   Rokicinska A, 2016, APPL CATAL B-ENVIRON, V195, P59, DOI 10.1016/j.apcatb.2016.05.008
   Samanta S, 2017, APPL CATAL B-ENVIRON, V218, P621, DOI 10.1016/j.apcatb.2017.06.043
   Shang Z, 2017, APPL CATAL B-ENVIRON, V209, P33, DOI 10.1016/j.apcatb.2017.02.074
   Shi AY, 2017, APPL CATAL B-ENVIRON, V218, P137, DOI 10.1016/j.apcatb.2017.06.017
   Shi N, 2015, CHEM COMMUN, V51, P1338, DOI 10.1039/c4cc08179j
   Tang SF, 2019, PLASMA SCI TECHNOL, V21, DOI 10.1088/2058-6272/aaeba6
   Vile G, 2014, ANGEW CHEM INT EDIT, V53, P12069, DOI 10.1002/anie.201406637
   Wang CJ, 2011, J MATER CHEM, V21, P13452, DOI 10.1039/c1jm12367j
   Wang GS, 2017, NANO ENERGY, V35, P17, DOI 10.1016/j.nanoen.2017.03.008
   Wang LD, 2018, CHEM ENG J, V331, P416, DOI 10.1016/j.cej.2017.08.127
   Wang LD, 2018, J HAZARD MATER, V342, P579, DOI 10.1016/j.jhazmat.2017.08.080
   Wang LD, 2017, ENVIRON SCI TECHNOL, V51, P11346, DOI 10.1021/acs.est.7b03364
   Wang LD, 2017, J MATER CHEM A, V5, P8018, DOI 10.1039/c7ta01513e
   Wang LD, 2016, APPL CATAL A-GEN, V511, P16, DOI 10.1016/j.apcata.2015.11.028
   Wang WJ, 2017, APPL CATAL B-ENVIRON, V217, P570, DOI 10.1016/j.apcatb.2017.06.027
   Xie QH, 2018, ACS CATAL, V8, P4902, DOI 10.1021/acscatal.8b00650
   Xiong J, 2018, ELECTROCHIM ACTA, V268, P503, DOI 10.1016/j.electacta.2018.02.090
   Xu L, 2016, ANGEW CHEM INT EDIT, V55, P5277, DOI 10.1002/anie.201600687
   Ye JL, 2018, CHEMCATCHEM, V10, P259, DOI 10.1002/cctc.201701148
   Ye JY, 2013, ACS CATAL, V3, P1296, DOI 10.1021/cs400132a
   Ye MY, 2017, ANGEW CHEM INT EDIT, V56, P8407, DOI 10.1002/anie.201611127
   Zalfani M, 2016, APPL CATAL B-ENVIRON, V199, P187, DOI 10.1016/j.apcatb.2016.06.016
   Zeng L, 2014, APPL CATAL B-ENVIRON, V147, P490, DOI 10.1016/j.apcatb.2013.09.013
   Zhang GG, 2014, ADV MATER, V26, P805, DOI 10.1002/adma.201303611
   Zhang HY, 2018, APPL CATAL B-ENVIRON, V223, P2, DOI 10.1016/j.apcatb.2017.03.028
   Zhang LM, 2013, CRYSTENGCOMM, V15, P1389, DOI 10.1039/c2ce26374b
   Zhang Q, 2018, APPL CATAL B-ENVIRON, V239, P1, DOI 10.1016/j.apcatb.2018.07.076
   Zhang ZJ, 2011, J HAZARD MATER, V196, P255, DOI 10.1016/j.jhazmat.2011.09.017
   Zheng Y, 2014, ANGEW CHEM INT EDIT, V53, P11926, DOI 10.1002/anie.201407319
   Zheng Z, 2017, ADV FUNCT MATER, V27, DOI 10.1002/adfm.201703115
   Zhou HR, 2019, APPL CATAL B-ENVIRON, V242, P76, DOI 10.1016/j.apcatb.2018.09.090
   Zhou MJ, 2015, ACS CATAL, V5, P4485, DOI 10.1021/acscatal.5b00488
   Zhu T, 2015, CATAL TODAY, V258, P70, DOI 10.1016/j.cattod.2015.03.046
   Zyla M, 2016, CORROS SCI, V112, P536, DOI 10.1016/j.corsci.2016.08.016
NR 68
TC 2
Z9 2
U1 16
U2 94
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD APR 6
PY 2019
VL 197
BP 1
EP 10
DI 10.1016/j.ces.2018.12.011
PG 10
WC Engineering, Chemical
SC Engineering
GA HK0ZQ
UT WOS:000457634000001
DA 2020-05-12
ER

PT J
AU Dechet, MA
   Goblirsch, A
   Romeis, S
   Zhao, M
   Lanyi, FJ
   Kaschta, J
   Schubert, DW
   Drummer, D
   Peukert, W
   Schmidt, J
AF Dechet, Maximilian A.
   Goblirsch, Anja
   Romeis, Stefan
   Zhao, Meng
   Lanyi, Franz J.
   Kaschta, Joachim
   Schubert, Dirk W.
   Drummer, Dietmar
   Peukert, Wolfgang
   Schmidt, Jochen
TI Production of polyamide 11 microparticles for Additive Manufacturing by
   liquid-liquid phase separation and precipitation
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Liquid-liquid phase separation (LLPS); Polymer precipitation; Polyamide
   11 (PA11); Additive Manufacturing (AM); Selective laser sintering (SLS)
ID POLYMER-SOLUTIONS; RHEOLOGICAL BEHAVIOR; POWDERS; SIZE; CRYSTALLIZATION;
   MORPHOLOGY; MICROSPHERES; PARTICLES; DISTRIBUTIONS; FLOWABILITY
AB Within this contribution liquid-liquid phase separation (LLPS) and precipitation from ethanol was studied as an approach to produce polyamide 11 (PA11) powders for selective laser sintering (SLS). To this end, the cloud point and solution temperature curve of the PAll-ethanol system was determined experimentally via turbidity measurements. The proper range of system composition and temperature for particle formation was deduced. The dependence of particle characteristics on process parameters (polymer concentration, stirring conditions and temperature regime) during LLPS and precipitation was assessed and the products were characterized with respect to their size and morphology. Furthermore, structural, rheological and thermal characteristics were analyzed and correlated with process parameters. Molecular weight distributions were determined. After removal of fines and dry coating with hydrophobic fumed silica, an optimized PA11 powder with mean particle size of 91 mu m showing good flowability for SLS was obtained. SLS processability of this optimized PA11 powder was demonstrated by building multilayered test specimens in a laser sintering machine. With this contribution, we present a comprehensive workflow for the process development, product characterization and product application of a SLS powder manufactured via precipitation. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Dechet, Maximilian A.; Goblirsch, Anja; Romeis, Stefan; Peukert, Wolfgang; Schmidt, Jochen] Friedrich Alexander Univ Erlangen Nurnberg, Inst Particle Technol, Cauerstr 4, D-91058 Erlangen, Germany.
   [Dechet, Maximilian A.; Goblirsch, Anja; Romeis, Stefan; Drummer, Dietmar; Peukert, Wolfgang; Schmidt, Jochen] Friedrich Alexander Univ Erlangen Nurnberg, Interdisciplinary Ctr Funct Particle Syst, Haberstr 9a, D-91058 Erlangen, Germany.
   [Dechet, Maximilian A.; Zhao, Meng; Drummer, Dietmar; Peukert, Wolfgang; Schmidt, Jochen] Collaborat Res Ctr 814 Addit Mfg, Weichselgarten 9, D-91058 Erlangen, Germany.
   [Zhao, Meng; Drummer, Dietmar] Friedrich Alexander Univ Erlangen Nurnberg, Inst Polymer Technol, Weichselgarten 9, D-91058 Erlangen, Germany.
   [Lanyi, Franz J.; Kaschta, Joachim; Schubert, Dirk W.] Friedrich Alexander Univ Erlangen Nurnberg, Inst Polymer Mat, Martensstr 7, D-91058 Erlangen, Germany.
   [Schubert, Dirk W.; Drummer, Dietmar] BPI, Dr Mack Str 77, D-90762 Furth, Germany.
RP Schmidt, J (reprint author), Friedrich Alexander Univ Erlangen Nurnberg, Inst Particle Technol, Cauerstr 4, D-91058 Erlangen, Germany.
EM maximilian.dechet@fau.de; anja.goblirsch@fau.de; stefan.romeis@fau.de;
   zhao@lkt.uni-erlangen.de; franz.lanyi@fau.de; joachim.kaschta@fau.de;
   dirk.schubert@fau.de; drummer@lkt.uni-erlangen.de;
   wolfgang.peukert@fau.de; jochen.schmidt@fau.de
RI Schmidt, Jochen/N-2608-2016
OI Schmidt, Jochen/0000-0002-9056-2749; Lanyi, Franz
   Josef/0000-0002-8095-6939; Dechet, Maximilian/0000-0002-3649-0019
FU Deutsche Forschungsgemeinschaft (DFG)German Research Foundation (DFG)
   [CRC 814]
FX This study has been supported by Deutsche Forschungsgemeinschaft (DFG)
   in the framework of the CRC 814 "Additive Manufacturing" (projects A1,
   A3 and B3). Financial support is gratefully acknowledged.
CR AERTS L, 1993, MAKROMOL CHEM, V194, P2697
   BARRETT EP, 1951, J AM CHEM SOC, V73, P373, DOI 10.1021/ja01145a126
   Baumann F. E., 1998, HERSTELLUNG POLYAMID, DOI [10.1016/j.polymer.2007.08.058, DOI 10.1016/J.POLYMER.2007.08.058], Patent No. 19708946. 6621
   Behler K, 2007, POLYMER, V48, P6617, DOI 10.1016/j.polymer.2007.08.058
   Berretta S, 2014, EUR POLYM J, V59, P218, DOI 10.1016/j.eurpolymj.2014.08.004
   Blumel C, 2015, RAPID PROTOTYPING J, V21, P697, DOI 10.1108/RPJ-07-2013-0074
   Brunauer S, 1938, J AM CHEM SOC, V60, P309, DOI 10.1021/ja01269a023
   BURGHARDT WR, 1989, MACROMOLECULES, V22, P2482, DOI 10.1021/ma00195a082
   CARREAU PJ, 1972, T SOC RHEOL, V16, P99, DOI 10.1122/1.549276
   Dadbakhsh S, 2016, PHYSCS PROC, V83, P971, DOI 10.1016/j.phpro.2016.08.102
   Dauwe C., 2003, HDB SIZE EXCLUSION C, p[xvi, 694]
   Dijkstra DJ, 2009, PURE APPL CHEM, V81, P339, DOI 10.1351/PAC-REP-08-07-22
   Drummer D, 2010, PHYSCS PROC, V5, P533, DOI 10.1016/j.phpro.2010.08.081
   EMMERIK PTV, 1973, EUR POLYM J, V9, P309
   Fanselow S, 2016, CHEM ENG SCI, V141, P282, DOI 10.1016/j.ces.2015.11.019
   Feng W, 2015, RSC ADV, V5, P61580, DOI 10.1039/c5ra11525f
   Flory P.J., 1953, PRINCIPLES POLYM CHE
   Frubing P, 2006, J CHEM PHYS, V125, DOI 10.1063/1.2360266
   Funk CV, 2016, J APPL POLYM SCI, V133, DOI [10.1002/APP.43237, 10.1002/app.43237]
   GOGOLEWSKI S, 1979, COLLOID POLYM SCI, V257, P811, DOI 10.1007/BF01383352
   Goodridge RD, 2012, PROG MATER SCI, V57, P229, DOI 10.1016/j.pmatsci.2011.04.001
   Gotzinger M, 2004, LANGMUIR, V20, P5298, DOI 10.1021/la049914f
   Gotzinger M, 2003, POWDER TECHNOL, V130, P102, DOI 10.1016/S0032-5910(02)00234-6
   Haworth B, 2013, RAPID PROTOTYPING J, V19, P28, DOI 10.1108/13552541311292709
   Hilaire Jean-Claude, 1986, PROCESS PRODUCTION P, Patent No. 0192515
   Incarnato L, 2004, POLYMER, V45, P3487, DOI 10.1016/j.polymer.2004.03.005
   JENIKE AW, 1970, STORAGE FLOW SOLIDS
   Kloos  S., 2016, P 6 INT C ADD TECHN, P147
   Kloos S, 2018, POWDER TECHNOL, V335, P275, DOI 10.1016/j.powtec.2018.05.005
   KONINGSVELD R, 1985, POLYM ENG SCI, V25, P1118, DOI 10.1002/pen.760251712
   KONINGSVELD R, 1967, KOLLOID Z Z POLYM, V220, P31, DOI 10.1007/BF02086054
   Laun S, 2008, POLYMER, V49, P4502, DOI 10.1016/j.polymer.2008.08.017
   Lexow M.M., 2016, J POWDER TECHNOLOGY, V2016, P1
   Liu SY, 1998, J APPL POLYM SCI, V70, P2371, DOI 10.1002/(SICI)1097-4628(19981219)70:12<2371::AID-APP9>3.0.CO;2-4
   Loyen Karine, 2011, US, Patent No. 2011052649
   Matsuyama H, 2001, J APPL POLYM SCI, V82, P169, DOI 10.1002/app.1836
   Matsuyama H, 2000, POLYMER, V41, P8673, DOI 10.1016/S0032-3861(00)00268-8
   McGuire KS, 1995, POLYMER, V36, P4951, DOI 10.1016/0032-3861(96)81620-X
   Meyer K.-R., 1980, EP, Patent No. 0014772
   Monsheimer S., 2013, DE, Patent No. 102011078719
   Mumcu S. D., 1986, DE, Patent No. [3510687, 3510687DE]
   Mys N, 2016, AIP CONF PROC, V1779, DOI 10.1063/1.4965570
   MYS N, 2016, POLYMERS-BASEL, V8, DOI DOI 10.3390/polym8110383
   Nair SS, 2006, MACROMOLECULES, V39, P2841, DOI 10.1021/ma052597e
   NEWMAN BA, 1977, J APPL PHYS, V48, P4092, DOI 10.1063/1.323435
   NICHOLS ME, 1994, J POLYM SCI POL PHYS, V32, P573, DOI 10.1002/polb.1994.090320319
   Nie TT, 2017, J APPL POLYM SCI, V134, DOI [10.1002/app.44885, 10.1002/APP.44885]
   Pfeffer R, 2001, POWDER TECHNOL, V117, P40, DOI 10.1016/S0032-5910(01)00314-X
   REHAGE G, 1965, MAKROMOLEKUL CHEM, V88, P232
   RICHARDS RB, 1946, T FARADAY SOC, V42, P10, DOI 10.1039/tf9464200010
   Rulkens R, 2012, POLYM SCI COMPREHENS, P431, DOI DOI 10.1016/B978-0-444-53349-4.00147-3
   Rumpf H., 1975, MECH VERFAHRENSTECHN
   Sachs M, 2017, POWDER TECHNOL, V316, P357, DOI 10.1016/j.powtec.2017.01.006
   Sachs M, 2015, PROCEDIA ENGINEER, V102, P542, DOI 10.1016/j.proeng.2015.01.119
   SCHAAF P, 1987, POLYMER, V28, P193, DOI 10.1016/0032-3861(87)90403-4
   Schmid M., 2018, LASER SINTERING PLAS
   Schmid M, 2015, AIP CONF PROC, V1664, DOI 10.1063/1.4918516
   Schmidt J., 2016, CHEM-ING-TECH, V88, P1208, DOI DOI 10.1002/CITE.201650354
   Schmidt J, 2016, CHEM ENG SCI, V156, P1, DOI 10.1016/j.ces.2016.09.009
   Schmidt J, 2014, POWDER TECHNOL, V261, P78, DOI 10.1016/j.powtec.2014.04.003
   Schmidt J, 2012, POWDER TECHNOL, V228, P84, DOI 10.1016/j.powtec.2012.04.064
   Schubert H., 2010, EMULGIERTECHNIK GRUN
   Schulze Dietmar, 2008, POWDERS BULK SOLIDS, DOI [10.1007/978-3-540-73768-1, DOI 10.1007/978-3-540-73768-1]
   SLICHTER WP, 1959, J POLYM SCI, V36, P259, DOI 10.1002/pol.1959.1203613020
   Strobbe D, 2018, PLAST RUBBER COMPOS, V47, P2, DOI 10.1080/14658011.2017.1399532
   vandeWitte P, 1996, J MEMBRANE SCI, V117, P1, DOI 10.1016/0376-7388(96)00088-9
   VANEMMERICK PT, 1973, EUR POLYM J, V9, P157, DOI 10.1016/0014-3057(73)90138-9
   VANEMMERIK PT, 1973, EUR POLYM J, V9, P931, DOI 10.1016/0014-3057(73)90056-6
   Wang GX, 2018, EXPRESS POLYM LETT, V12, P13, DOI 10.3144/expresspolymlett.2018.3
   Wang GX, 2015, MATER DESIGN, V87, P656, DOI 10.1016/j.matdes.2015.08.083
   Wang SJ, 2017, J POLYM SCI POL PHYS, V55, P320, DOI 10.1002/polb.24275
   Wohlers T.T., 2016, WOHLERS REPORT 2016
   Wudy K., 2016, ANN INT SOL FREEF FA, P770
   Yan CZ, 2009, J MATER PROCESS TECH, V209, P5785, DOI 10.1016/j.jmatprotec.2009.06.010
   Yang J, 2005, POWDER TECHNOL, V158, P21, DOI 10.1016/j.powtec.2005.04.032
   Zhang QZ, 2000, MACROMOLECULES, V33, P5999, DOI 10.1021/ma000298d
   Zhao CX, 2008, J CENT SOUTH UNIV T, V15, P76, DOI 10.1007/s11771-008-0318-y
   Zhao M, 2018, POLYMERS-BASEL, V10, DOI 10.3390/polym10020168
   Ziegelmeier S, 2015, J MATER PROCESS TECH, V215, P239, DOI 10.1016/j.jmatprotec.2014.07.029
   Ziegmann A, 2016, MACROMOL SYMP, V365, P203, DOI 10.1002/masy.201650030
NR 80
TC 6
Z9 6
U1 8
U2 48
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD APR 6
PY 2019
VL 197
BP 11
EP 25
DI 10.1016/j.ces.2018.11.051
PG 15
WC Engineering, Chemical
SC Engineering
GA HK0ZQ
UT WOS:000457634000002
DA 2020-05-12
ER

PT J
AU Yamamoto, T
   Fang, Y
   Komarov, SV
AF Yamamoto, Takuya
   Fang, Yu
   Komarov, Sergey, V
TI Mechanism of small bubble breakup in an unbaffled stirred vessel
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Stirring; Volume of Fluid (VOF) method; OpenFOAM; Bubble breakup;
   Trailing vortex; Large Eddy Simulation (LES)
ID ROTATING IMPELLER DEGASSER; GAS-LIQUID FLOW; DROP SIZE;
   COMPUTER-SIMULATION; MASS-TRANSFER; TANK; MODEL; BIOREACTORS;
   DISPERSION; SYSTEMS
AB The present study investigated the mechanism of small bubble breakup in an unbaffled vessel stirred by a 4-blade paddle impeller. Bubbles were injected underneath the rotating blades. Numerical simulation and experimental observations were performed to investigate the related phenomena. The Volume of Fluid (VOF) method was utilized to simulate a gas-liquid multiphase flow. The injected bubbles were broken behind the impeller blade, where they were transported due to a decreasing pressure gradient caused by the impeller rotation. At the behind of the blade, bubbles were elongated and fragmented due to the trailing vortices developing from the rear surface of blade. The fragmented bubbles were entrapped at the cores of trailing vortices, and then floated up in the space where the trailing vortices became weak. The size of the broken bubbles was dependent on the impeller rotation rate. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Yamamoto, Takuya; Fang, Yu; Komarov, Sergey, V] Tohoku Univ, Grad Sch Environm Studies, Sendai, Miyagi 9808579, Japan.
RP Yamamoto, T (reprint author), Tohoku Univ, Grad Sch Environm Studies, Sendai, Miyagi 9808579, Japan.
EM t-yamamoto@tohoku.ac.jp
FU Initiative on Promotion of Supercomputing for Young or Women
   Researchers, Information Technology Center, The University of Tokyo;
   Collaborative Research Program for Young Scientists of ACCMS, Kyoto
   University; IIMV, Kyoto University
FX This research is partially supported by Initiative on Promotion of
   Supercomputing for Young or Women Researchers, Information Technology
   Center, The University of Tokyo, and partly by Collaborative Research
   Program for Young Scientists of ACCMS and IIMV, Kyoto University.
CR Abdullah B, 2011, CHEM ENG SCI, V66, P5648, DOI 10.1016/j.ces.2011.07.048
   Andersson R, 2006, AICHE J, V52, P2031, DOI 10.1002/aic.10832
   BARIGOU M, 1991, MEAS SCI TECHNOL, V2, P318, DOI 10.1088/0957-0233/2/4/009
   Buffo A, 2012, CHEM ENG SCI, V70, P31, DOI 10.1016/j.ces.2011.04.042
   CHEN HT, 1967, AICHE J, V13, P989, DOI 10.1002/aic.690130529
   Devi TT, 2015, J ENG PHYS THERMOPH+, V88, P76, DOI 10.1007/s10891-015-1169-7
   Dotto GL, 2011, J HAZARD MATER, V187, P164, DOI 10.1016/j.jhazmat.2011.01.016
   Galaction AI, 2004, BIOCHEM ENG J, V20, P85, DOI 10.1016/j.bej.2004.02.005
   Galinat S, 2005, CHEM ENG SCI, V60, P6511, DOI 10.1016/j.ces.2005.05.012
   Hasan BO, 2018, EXP THERM FLUID SCI, V96, P48, DOI 10.1016/j.expthermflusci.2018.02.013
   Hasan BO, 2017, INT J MULTIPHAS FLOW, V97, P94, DOI 10.1016/j.ijmultiphaseflow.2017.08.006
   Hasan BO, 2017, CHINESE J CHEM ENG, V25, P698, DOI 10.1016/j.cjche.2017.03.008
   Hashemi N, 2016, CHEM ENG J, V289, P402, DOI 10.1016/j.cej.2015.12.077
   HESKETH RP, 1991, IND ENG CHEM RES, V30, P835, DOI 10.1021/ie00053a005
   HINZE JO, 1955, AICHE J, V1, P289, DOI 10.1002/aic.690010303
   JOSHI JB, 1982, CHEM ENG SCI, V37, P813, DOI 10.1016/0009-2509(82)80171-1
   Kerdouss F, 2006, CHEM ENG SCI, V61, P3313, DOI 10.1016/j.ces.2005.11.061
   Khopkar AR, 2005, CHEM ENG SCI, V60, P2215, DOI 10.1016/j.ces.2004.11.044
   Khopkar AR, 2008, CHEM ENG SCI, V63, P3810, DOI 10.1016/j.ces.2008.04.039
   KIM HC, 1987, CHEM ENG SCI, V42, P1645, DOI 10.1016/0009-2509(87)80169-0
   KONNO M, 1983, J CHEM ENG JPN, V16, P312, DOI 10.1252/jcej.16.312
   KUMAR S, 1991, CHEM ENG SCI, V46, P2483, DOI 10.1016/0009-2509(91)80041-V
   Lane GL, 2005, CHEM ENG SCI, V60, P2203, DOI 10.1016/j.ces.2004.11.046
   Lee BW, 2014, CHEM ENG SCI, V116, P623, DOI 10.1016/j.ces.2014.05.048
   Lee BW, 2014, CHEM ENG SCI, V109, P264, DOI 10.1016/j.ces.2014.01.032
   Liao YX, 2009, CHEM ENG SCI, V64, P3389, DOI 10.1016/j.ces.2009.04.026
   Maass S, 2007, CHEM ENG RES DES, V85, P703, DOI 10.1205/cherd06187
   Maass S, 2012, CHEM ENG SCI, V70, P146, DOI 10.1016/j.ces.2011.08.027
   Machon V, 1997, CHEM ENG RES DES, V75, P339, DOI 10.1205/026387697523651
   Martin M, 2008, IND ENG CHEM RES, V47, P6251, DOI 10.1021/ie800063v
   Martinez-Bazan C, 1999, J FLUID MECH, V401, P157, DOI 10.1017/S0022112099006680
   Murthy BN, 2008, CHEM ENG SCI, V63, P5468, DOI 10.1016/j.ces.2008.06.019
   NISHIKAWA M, 1987, J CHEM ENG JPN, V20, P82, DOI 10.1252/jcej.20.82
   OpenFOAM, OP SOURC SOFTW
   Petitti M, 2013, CHEM ENG J, V228, P1182, DOI 10.1016/j.cej.2013.05.047
   Rusche H., 2002, THESIS
   Scargiali F, 2007, CHEM ENG RES DES, V85, P637, DOI 10.1205/cherd06243
   Selma B, 2010, CHEM ENG SCI, V65, P1925, DOI 10.1016/j.ces.2009.11.018
   Solsvik J, 2016, IND ENG CHEM RES, V55, P2872, DOI 10.1021/acs.iecr.6b00591
   Solsvik J, 2015, INT J CHEM REACT ENG, V13, P477, DOI 10.1515/ijcre-2014-0154
   Solsvik J, 2015, CHEM ENG SCI, V131, P219, DOI 10.1016/j.ces.2015.03.059
   SPROW FB, 1967, CHEM ENG SCI, V22, P435, DOI 10.1016/0009-2509(67)80130-1
   Venneker BCH, 2002, AICHE J, V48, P673, DOI 10.1002/aic.690480404
   Wan BB, 2018, J MATER PROCESS TECH, V251, P330, DOI 10.1016/j.jmatprotec.2017.09.001
   Wang TF, 2006, AICHE J, V52, P125, DOI 10.1002/aic.10611
   Warke VS, 2005, J MATER PROCESS TECH, V168, P112, DOI 10.1016/j.jmatprotec.2004.10.017
   Warke VS, 2005, J MATER PROCESS TECH, V168, P119, DOI 10.1016/j.jmatprotec.2004.10.016
   Weller H.G., 2008, TECHNICAL REPORT
   Yamamoto T., CHEM ENG J
   Yamamoto T, 2018, J MATER PROCESS TECH, V261, P164, DOI 10.1016/j.jmatprotec.2018.06.012
   Yamamoto T, 2018, J MATER PROCESS TECH, V259, P409, DOI 10.1016/j.jmatprotec.2018.04.025
   Yamamoto T, 2018, J CHEM ENG JPN, V51, P423, DOI 10.1252/jcej.17we112
   Yamamoto T, 2017, INT J NUMER METH FL, V83, P223, DOI 10.1002/fld.4267
   Yano M, 2017, AJCHE, V1, P73
   Yuan G, 2003, CHEM ENG SCI, V58, P257, DOI 10.1016/S0009-2509(02)00476-1
   Zhou GW, 1998, CHEM ENG SCI, V53, P2063, DOI 10.1016/S0009-2509(97)00438-7
NR 56
TC 5
Z9 5
U1 8
U2 34
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD APR 6
PY 2019
VL 197
BP 26
EP 36
DI 10.1016/j.ces.2018.12.007
PG 11
WC Engineering, Chemical
SC Engineering
GA HK0ZQ
UT WOS:000457634000003
DA 2020-05-12
ER

PT J
AU Mobini, S
   Meshkani, F
   Rezaei, M
AF Mobini, Sajad
   Meshkani, Fereshteh
   Rezaei, Mehran
TI Supported Mn catalysts and the role of different supports in the
   catalytic oxidation of carbon monoxide
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE CO oxidation; Supported catalyst; Ceria; Stability
ID TEMPERATURE CO OXIDATION; HYDROTHERMAL SYNTHESIS; PARTICLE-SIZE;
   PREFERENTIAL OXIDATION; REDOX PROPERTIES; OXIDE; PERFORMANCE; GOLD;
   NANOCATALYSTS; COMBUSTION
AB The effects of the carrier and the content of the active species were studied in the carbon monoxide oxidation process. MnOx catalysts supported on ZrO2, CeO2, MgO, SiO2, and Al2O3 were prepared and characterized by XRD, BET-BJH, FE-SEM, EDX, TPR, and CO2-TPD analyses. The relation between the textural properties of the catalysts and the catalytic performance was investigated. The results showed that Mn/CeO2 catalyst despite of its lowest surface area (55.5 m(2)/g) possessed the highest activity among other catalysts. High ability to supply oxygen through the support during the reaction is the most important reason for the proper performance of this catalyst. The investigation of the Mn content indicated that the 20 wt% Mn/CeO2 showed high dispersion, appropriate reducibility and the highest concentration of active sites compared to other catalysts with various Mn contents. The temperature corresponding to 50% of the CO conversion (T-50) was about 142 degrees C, which was 20 degrees C lower than the other samples. In addition, the influence of different parameters including pretreatment condition, feed ratio, and GHSV was examined on the catalytic performance. The results showed that the catalytic stability declined with the incorporation of water vapor and CO2 in the feed mixture. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Mobini, Sajad; Meshkani, Fereshteh; Rezaei, Mehran] Univ Kashan, Fac Engn, Chem Engn Dept, Catalyst & Adv Mat Res Lab, Kashan, Iran.
   [Meshkani, Fereshteh; Rezaei, Mehran] Univ Kashan, Inst Nanosci & Nanotechnol, Kashan, Iran.
RP Meshkani, F (reprint author), Univ Kashan, Catalyst & Adv Mat Res Lab, Chem Engn Dept, Km 6 Ravand Rd, Kashan, Iran.
EM meshkani@kashanu.ac.ir
RI Rezaei, Mehran/E-3600-2014
OI Rezaei, Mehran/0000-0001-5669-4089
FU Iran National Science Foundation (INSF)Iran National Science Foundation
   (INSF); University of Kashan [842077/06]
FX The authors deeply appreciate the financial support provided by Iran
   National Science Foundation (INSF) and University of Kashan (Grant No.
   842077/06)
CR Akbari B., 2011, IRAN J MAT SCI ENG, V8, P48
   Almana N, 2016, J CATAL, V340, P368, DOI 10.1016/j.jcat.2016.06.002
   Arandiyan H, 2014, J PHYS CHEM C, V118, P14913, DOI 10.1021/jp502256t
   Arena F, 2001, PHYS CHEM CHEM PHYS, V3, P1911, DOI 10.1039/b100091h
   Basahel SN, 2016, CATALYSTS, V6, DOI 10.3390/catal6040057
   Bowen P, 2002, J DISPER SCI TECHNOL, V23, P631, DOI 10.1081/DIS-120015368
   Carno J, 1997, APPL CATAL A-GEN, V155, P265, DOI 10.1016/S0926-860X(97)80129-9
   Chen AM, 2003, J MOL CATAL A-CHEM, V203, P299, DOI 10.1016/S1381-1169(03)00380-7
   Choong CKS, 2017, PHYS CHEM CHEM PHYS, V19, P4199, DOI 10.1039/c6cp05934a
   Diez VK, 2011, CATAL TODAY, V173, P21, DOI 10.1016/j.cattod.2011.02.060
   Ding JC, 2016, SENSOR ACTUAT B-CHEM, V222, P517, DOI 10.1016/j.snb.2015.08.099
   Dong L, 2016, APPL CATAL B-ENVIRON, V180, P451, DOI 10.1016/j.apcatb.2015.06.034
   Dong YM, 2014, RSC ADV, V4, P39167, DOI 10.1039/c4ra02654c
   Einaga H, 2009, J HAZARD MATER, V164, P1236, DOI 10.1016/j.jhazmat.2008.09.032
   Ganiyu SA, 2017, IND ENG CHEM RES, V56, P5201, DOI 10.1021/acs.iecr.7b00719
   Pintos DG, 2013, J PHYS CHEM C, V117, P18063, DOI 10.1021/jp403911b
   Gomez-Garcia MA, 2015, CHEM ENG J, V282, P20, DOI 10.1016/j.cej.2015.03.015
   Gu D, 2016, J AM CHEM SOC, V138, P9572, DOI 10.1021/jacs.6b04251
   Guo XL, 2016, FUEL, V163, P56, DOI 10.1016/j.fuel.2015.09.043
   Han SW, 2016, CHEM ENG J, V283, P992, DOI 10.1016/j.cej.2015.08.021
   Hassanpour M, 2017, J MATER SCI-MATER EL, V28, P10830, DOI 10.1007/s10854-017-6860-3
   Huang K, 2015, APPL CATAL B-ENVIRON, V179, P395, DOI 10.1016/j.apcatb.2015.05.044
   Ivanov K. I., 2015, INT J CHEM MOL NUCL, V9, P298
   Ivanova S, 2010, CHEMCATCHEM, V2, P556, DOI 10.1002/cctc.200900302
   Jia CJ, 2011, J AM CHEM SOC, V133, P11279, DOI 10.1021/ja2028926
   Khedr MH, 2006, MAT SCI ENG A-STRUCT, V430, P40, DOI 10.1016/j.msea.2006.05.119
   Kim SC, 2010, APPL CATAL B-ENVIRON, V98, P180, DOI 10.1016/j.apcatb.2010.05.027
   Lan L, 2017, APPL CATAL B-ENVIRON, V203, P494, DOI 10.1016/j.apcatb.2016.10.047
   Lashina EA, 2012, CHEM ENG SCI, V83, P149, DOI 10.1016/j.ces.2012.03.020
   Lee C, 2017, CATAL TODAY, V281, P460, DOI 10.1016/j.cattod.2016.05.050
   Leofanti G, 1998, CATAL TODAY, V41, P207, DOI 10.1016/S0920-5861(98)00050-9
   Li J, 2014, CATAL SCI TECHNOL, V4, P1268, DOI 10.1039/c3cy01004j
   Li SN, 2014, APPL CATAL B-ENVIRON, V144, P498, DOI 10.1016/j.apcatb.2013.07.049
   Li X, 2016, ANGEW CHEM INT EDIT, V55, P4092, DOI 10.1002/anie.201510201
   Li ZX, 2017, APPL SURF SCI, V403, P335, DOI 10.1016/j.apsusc.2017.01.169
   Liang YL, 2017, ENVIRON SCI POLLUT R, V24, P9314, DOI 10.1007/s11356-017-8645-x
   Lin SY, 2015, APPL SURF SCI, V327, P335, DOI 10.1016/j.apsusc.2014.11.176
   Liu LJ, 2010, J MOL CATAL A-CHEM, V327, P1, DOI 10.1016/j.molcata.2010.05.002
   Liu XY, 2012, J AM CHEM SOC, V134, P10251, DOI 10.1021/ja3033235
   Liu YX, 2013, J CATAL, V305, P146, DOI 10.1016/j.jcat.2013.04.025
   Lu XP, 2015, IND ENG CHEM RES, V54, P12516, DOI 10.1021/acs.iecr.5b03327
   Mandapaka RK, 2015, CHEM ENG SCI, V131, P271, DOI 10.1016/j.ces.2015.03.056
   Mobini S, 2017, J ENVIRON CHEM ENG, V5, P4906, DOI 10.1016/j.jece.2017.09.027
   Mobini S, 2017, PROCESS SAF ENVIRON, V107, P181, DOI 10.1016/j.psep.2017.02.009
   Morfin F, 2015, J CATAL, V331, P210, DOI 10.1016/j.jcat.2015.08.022
   Nematoliahi B, 2015, INT J HYDROGEN ENERG, V40, P8539, DOI 10.1016/j.ijhydene.2015.04.127
   Panagiotopoulou P, 2006, J CATAL, V240, P114, DOI 10.1016/j.jcat.2006.03.012
   Pappas DK, 2016, J CATAL, V334, P1, DOI 10.1016/j.jcat.2015.11.013
   Piumetti M, 2016, APPL CATAL B-ENVIRON, V197, P35, DOI 10.1016/j.apcatb.2016.02.023
   Rahmani S, 2014, J IND ENG CHEM, V20, P1346, DOI 10.1016/j.jiec.2013.07.017
   Rezaei P, 2018, PROCESS SAF ENVIRON, V119, P379, DOI 10.1016/j.psep.2018.08.024
   Rico-Frances S, 2016, APPL CATAL B-ENVIRON, V180, P169, DOI 10.1016/j.apcatb.2015.06.031
   Roldan Cuenya B, 2010, THIN SOLID FILMS, V518, P3127, DOI 10.1016/j.tsf.2010.01.018
   Ryou Y, 2015, CATAL TODAY, V258, P518, DOI 10.1016/j.cattod.2015.02.009
   Santos RCR, 2016, CATAL SCI TECHNOL, V6, P4986, DOI 10.1039/c6cy00096g
   Shen MQ, 2015, J RARE EARTH, V33, P56, DOI 10.1016/S1002-0721(14)60383-5
   Shin H, 2018, APPL SURF SCI, V429, P102, DOI 10.1016/j.apsusc.2017.05.198
   Simanjuntak FSH, 2014, APPL CATAL A-GEN, V484, P33, DOI 10.1016/j.apcata.2014.06.028
   Su D, 2013, J MATER CHEM A, V1, P4845, DOI 10.1039/c3ta00031a
   Trawczynski J, 2005, APPL CATAL B-ENVIRON, V55, P277, DOI 10.1016/j.apcatb.2004.09.005
   Vasilchenko DB, 2016, CATAL COMMUN, V73, P34, DOI 10.1016/j.catcom.2015.10.012
   Venkataswamy P, 2015, APPL CATAL B-ENVIRON, V162, P122, DOI 10.1016/j.apcatb.2014.06.038
   Wang CB, 2006, CATAL LETT, V107, P223, DOI 10.1007/s10562-005-0002-x
   Wang LG, 2017, CATAL TODAY, V281, P360, DOI 10.1016/j.cattod.2016.02.052
   Wang LC, 2009, APPL CATAL B-ENVIRON, V88, P204, DOI 10.1016/j.apcatb.2008.09.031
   Wang X, 2002, J AM CHEM SOC, V124, P2880, DOI 10.1021/ja0177105
   Wang XY, 2009, APPL CATAL B-ENVIRON, V86, P166, DOI 10.1016/j.apcatb.2008.08.009
   Wang Y, 2014, APPL CATAL B-ENVIRON, V160, P542, DOI 10.1016/j.apcatb.2014.06.011
   Wongkaew A, 2013, ADV MATER SCI ENG, V2013, DOI 10.1155/2013/374080
   Wu GJ, 2011, CATAL SCI TECHNOL, V1, P601, DOI 10.1039/c1cy00036e
   Wu YS, 2017, CATAL TODAY, V281, P500, DOI 10.1016/j.cattod.2016.05.024
   Xu J, 2014, ACS CATAL, V4, P4106, DOI 10.1021/cs5011376
   Yang ZG, 2014, J RARE EARTH, V32, P117, DOI 10.1016/S1002-0721(14)60040-5
   Yao XJ, 2014, CATAL SCI TECHNOL, V4, P2814, DOI 10.1039/c4cy00397g
   Yen HA, 2015, ACS CATAL, V5, P5505, DOI 10.1021/acscatal.5b00869
   Zhang DS, 2012, CATAL COMMUN, V26, P164, DOI 10.1016/j.catcom.2012.05.001
   Zhang HW, 2017, CHEM ENG J, V324, P279, DOI 10.1016/j.cej.2017.05.013
   Zhang LL, 2011, J COLLOID INTERF SCI, V355, P464, DOI 10.1016/j.jcis.2010.11.076
   Zhou JF, 2017, APPL PHYS B-LASERS O, V123, DOI 10.1007/s00340-017-6681-3
NR 79
TC 6
Z9 6
U1 8
U2 66
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD APR 6
PY 2019
VL 197
BP 37
EP 51
DI 10.1016/j.ces.2018.12.006
PG 15
WC Engineering, Chemical
SC Engineering
GA HK0ZQ
UT WOS:000457634000004
DA 2020-05-12
ER

PT J
AU Ge, XL
   Liu, BT
   Liu, BT
   Wang, HX
   Yuan, XG
AF Ge, Xiaolong
   Liu, Botong
   Liu, Botan
   Wang, Hongxing
   Yuan, Xigang
TI Three-dimensional numerical simulation of gas-liquid interfacial mass
   transfer with Rayleigh convection using hybrid LBM-FDM and its mass
   transfer coefficient model
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Rayleigh convection; Interfacial mass transfer; Lattice Boltzmann
   method; Mass transfer model; Dissipation rate of concentration variance
ID LATTICE BOLTZMANN METHOD; BENARD-MARANGONI CONVECTION;
   NATURAL-CONVECTION; STABILITY ANALYSIS; CARBON-DIOXIDE; POROUS-MEDIA;
   ABSORPTION; ONSET; DIFFUSION; FLUID
AB Rayleigh convection has a significant effect on gas-liquid interfacial mass transfer. However, its intensified mechanism has not been clarified so far. In the present work, three-dimensional hybrid Lattice Boltzmann Method-Finite Difference Method (LBM-FDM) was employed to simulate the Rayleigh convection emerging in the CO2-ethanol absorption process. A gas phase random disturbance model was applied to represent the disturbances on the gas-liquid interface which effectively induces Rayleigh convection. Then the front view images obtained by three-dimensional simulation were compared to the Schlieren observations for validation. Finally, a theoretical mass transfer coefficient model based on dissipation rate of concentration variance was proposed, by analyzing the overhead view of concentration contour and dissipation rate of concentration variance contour. Compared to the small eddy model and surface divergence model, the proposed model shows its strength in determining molecular diffusion stage and convective mass transfer stage of Rayleigh convection process, as well as eliminating the phase difference in model prediction. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Ge, Xiaolong; Liu, Botan; Wang, Hongxing] Tianjin Univ Sci & Technol, Coll Chem Engn & Mat Sci, Tianjin Key Lab Marine Resources & Chem, Tianjin 300457, Peoples R China.
   [Liu, Botong] Tsinghua Univ, Dept Chem Engn, Beijing 100084, Peoples R China.
   [Ge, Xiaolong; Yuan, Xigang] Tianjin Univ, Sch Chem Engn & Technol, Tianjin 300072, Peoples R China.
RP Liu, BT (reprint author), Tianjin Univ Sci & Technol, Coll Chem Engn & Mat Sci, Tianjin Key Lab Marine Resources & Chem, Tianjin 300457, Peoples R China.; Liu, BT (reprint author), Tsinghua Univ, Dept Chem Engn, Beijing 100084, Peoples R China.
EM lbt18@mails.tsinghua.edu.cn; liubotan@tust.edu.cn
OI Jia, Shengkun/0000-0003-4524-0588
FU Open Research Project of State Key Laboratory of Chemical Engineering
   [SKL-ChE-16B06, SKL-ChE-18B02]; Yangtze Scholars and Innovative Research
   Team in Chinese University [IRT-17R81]; Tianjin Higher Education
   Innovation Team Development Program [TD13-5008]; National Natural
   Science Foundation of ChinaNational Natural Science Foundation of China
   [91634117, U1862119]; China Postdoctoral Science FoundationChina
   Postdoctoral Science Foundation [2018M631742]
FX The research work is supported by Open Research Project of State Key
   Laboratory of Chemical Engineering (Grant No. SKL-ChE-16B06,
   SKL-ChE-18B02), Yangtze Scholars and Innovative Research Team in Chinese
   University (IRT-17R81), Tianjin Higher Education Innovation Team
   Development Program (TD13-5008), the National Natural Science Foundation
   of China (91634117, U1862119) and China Postdoctoral Science Foundation
   (2018M631742).
CR Alberto Arce, 2000, J CHEM ENG DATA, V45, P536, DOI [10.1021/je000009g, DOI 10.1021/JE000009G]
   Arendt B, 2004, INT J HEAT MASS TRAN, V47, P3649, DOI 10.1016/j.ijheatmasstransfer.2004.04.011
   Banerjee S, 2004, INT J MULTIPHAS FLOW, V30, P963, DOI 10.1016/j.ijmultiphaseflow.2004.05.004
   Chang QM, 2006, J COMPUT PHYS, V212, P473, DOI 10.1016/j.jcp.2005.05.031
   Chen S, 1998, ANNU REV FLUID MECH, V30, P329, DOI 10.1146/annurev.fluid.30.1.329
   Chen SY, 2012, IND ENG CHEM RES, V51, P10955, DOI 10.1021/ie3018912
   Chevalier S, 2015, HEAT MASS TRANSFER, V51, P941, DOI 10.1007/s00231-014-1466-2
   Danckwerts P. V., 1981, IND ENG CHEM, V43, P51, DOI DOI 10.1016/B978-0-08-026250-5.50016-2
   Dittmar D, 2003, CHEM ENG SCI, V58, P1223, DOI 10.1016/S0009-2509(02)00626-7
   Farajzadeh R, 2009, IND ENG CHEM RES, V48, P6423, DOI 10.1021/ie801521u
   Farajzadeh R, 2007, INT J HEAT MASS TRAN, V50, P5054, DOI 10.1016/j.ijheatmasstransfer.2007.08.019
   Fontana E, 2016, CHEM ENG SCI, V155, P99, DOI 10.1016/j.ces.2016.07.045
   Fontana E, 2015, CHEM ENG SCI, V126, P67, DOI 10.1016/j.ces.2014.12.005
   FORTESCUE GE, 1967, CHEM ENG SCI, V22, P1163, DOI 10.1016/0009-2509(67)80183-0
   Fu B, 2013, CHEM ENG RES DES, V91, P437, DOI 10.1016/j.cherd.2012.11.006
   Fu YH, 2018, CHEM ENG SCI, V181, P79, DOI 10.1016/j.ces.2018.02.010
   GOLDSTEIN RJ, 1990, J FLUID MECH, V213, P111, DOI 10.1017/S0022112090002245
   Guo K, 2015, CHEM ENG SCI, V135, P33, DOI 10.1016/j.ces.2015.07.017
   Guo K, 2015, CHEM ENG TECHNOL, V38, P23, DOI 10.1002/ceat.201400335
   Guo Y, 2006, CHINESE J CHEM ENG, V14, P747, DOI 10.1016/S1004-9541(07)60006-8
   He XY, 1997, PHYS REV E, V55, pR6333, DOI 10.1103/PhysRevE.55.R6333
   He XY, 1997, J STAT PHYS, V87, P115, DOI 10.1007/BF02181482
   Higbie R, 1935, T AM INST CHEM ENG, V31, P365
   Huang XJ, 2018, INT J HEAT MASS TRAN, V116, P185, DOI 10.1016/j.ijheatmasstransfer.2017.09.021
   Jia SK, 2018, CHEM ENG SCI, V182, P44, DOI 10.1016/j.ces.2018.02.017
   LAMONT JC, 1970, AICHE J, V16, P513, DOI 10.1002/aic.690160403
   Li XP, 2013, CHEM ENG SCI, V102, P209, DOI 10.1016/j.ces.2013.06.037
   Liu BT, 2017, CHEM ENG TECHNOL, V40, P1059, DOI 10.1002/ceat.201600553
   Liu BT, 2003, THESIS
   LUK S, 1986, AICHE J, V32, P1546, DOI 10.1002/aic.690320915
   Massman WJ, 1998, ATMOS ENVIRON, V32, P1111, DOI 10.1016/S1352-2310(97)00391-9
   Mei RW, 1998, J COMPUT PHYS, V143, P426, DOI 10.1006/jcph.1998.5984
   Okhotsimskii A, 1998, CHEM ENG SCI, V53, P2547, DOI 10.1016/S0009-2509(98)00092-X
   Premnath KN, 2007, J COMPUT PHYS, V224, P539, DOI 10.1016/j.jcp.2006.10.023
   QIAN YH, 1993, EUROPHYS LETT, V21, P255, DOI 10.1209/0295-5075/21/3/001
   Rahman SU, 2001, CHEM ENG J, V84, P587, DOI 10.1016/S1385-8947(01)00174-7
   Rahman SU, 2000, IND ENG CHEM RES, V39, P214, DOI 10.1021/ie990357f
   Rayleigh L, 1916, PHILOS MAG, V32, P529, DOI 10.1080/14786441608635602
   Rongy L, 2012, AICHE J, V58, P1336, DOI 10.1002/aic.12685
   Servan-Camas B, 2008, ADV WATER RESOUR, V31, P1113, DOI 10.1016/j.advwatres.2008.05.001
   Shi Y, 2006, COMPUT FLUIDS, V35, P1, DOI 10.1016/j.compfluid.2004.11.003
   Skartlien R, 2011, PHYSICA A, V390, P2291, DOI 10.1016/j.physa.2011.02.022
   STERNLING CV, 1959, AICHE J, V5, P514, DOI 10.1002/aic.690050421
   Sukop M.C., 2007, LATTICE BOLTZMANN MO
   Sun DK, 2011, COMPUT MATH APPL, V61, P3585, DOI 10.1016/j.camwa.2010.11.001
   Sun ZF, 2012, CHEM ENG SCI, V68, P579, DOI 10.1016/j.ces.2011.10.023
   Sun ZF, 2006, IND ENG CHEM RES, V45, P3293, DOI 10.1021/ie051185r
   Sun ZF, 2002, IND ENG CHEM RES, V41, P1905, DOI 10.1021/ie010707+
   Takahashi M., 1982, CHEM INFORMATIONSDIE, V13, DOI [10.1021/je00029a029, DOI 10.1021/JE00029A029]
   Tan KK, 2010, ENG APPL COMP FLUID, V4, P475, DOI 10.1080/19942060.2010.11015334
   TAN KK, 1992, CHEM ENG SCI, V47, P3565, DOI 10.1016/0009-2509(92)85071-I
   Tan KK, 1999, CHEM ENG SCI, V54, P4179, DOI 10.1016/S0009-2509(99)00089-5
   Whitman W.G., 1962, INT J HEAT MASS TRAN, V5, P429, DOI DOI 10.1016/0017-9310(62)90032-7
   Xu ZF, 2006, AICHE J, V52, P3363, DOI 10.1002/aic.10972
   Yu LM, 2006, IND ENG CHEM RES, V45, P1201, DOI 10.1021/ie050855q
NR 55
TC 0
Z9 0
U1 10
U2 45
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD APR 6
PY 2019
VL 197
BP 52
EP 68
DI 10.1016/j.ces.2018.12.001
PG 17
WC Engineering, Chemical
SC Engineering
GA HK0ZQ
UT WOS:000457634000005
DA 2020-05-12
ER

PT J
AU Zhao, BD
   Wang, JW
AF Zhao, Bidan
   Wang, Junwu
TI Topography analysis of particle velocity distribution function in
   gas-solid flow
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Fluidization; Gas-solid flow; Kinetic theory; Granular flow; Particle
   velocity distribution function; Topography analysis
ID MOTT-SMITH METHOD; NUMERICAL-SIMULATION; 2-FLUID MODEL; SHOCK; EXTENSION
AB Particle velocity distribution function (PVDF) is key to kinetic theory of granular flow. Studies have shown that the PVDFs in gas-solid flow can be Maxwellian, bimodal and/or non-Maxwellian with an overpopulated high-energy tail. In this short communication, topography analysis was carried out to elucidate the mathematical nature of bimodal distribution. It was shown that both of the non-Maxwellian distribution with an overpopulated high-energy tail and the Maxwellian distribution are special cases of bimodal distribution, therefore, bimodal distribution can be used as the starting point of developing a unified kinetic theory for gas-solid flow. Furthermore, the constrained conditions for the transition from bimodal distribution to the non-Maxwellian distribution with an overpopulated high-energy tail were identified. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Zhao, Bidan; Wang, Junwu] Chinese Acad Sci, Inst Proc Engn, State Key Lab Multiphase Complex Syst, POB 353, Beijing 100190, Peoples R China.
   [Zhao, Bidan] Univ Chinese Acad Sci, Sch Chem Engn, Beijing 100049, Peoples R China.
RP Wang, JW (reprint author), Chinese Acad Sci, Inst Proc Engn, State Key Lab Multiphase Complex Syst, POB 353, Beijing 100190, Peoples R China.
EM jwwang@ipe.ac.cn
RI Wang, Junwu/C-6591-2009; Wang, Junwu/P-5040-2019
OI Wang, Junwu/0000-0003-3988-1477; Wang, Junwu/0000-0003-3988-1477
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [21422608]; Key Research Program of Frontier
   Sciences, Chinese Academy of Sciences [QYZDJ-SSW-JSC029]; Strategic
   Priority Research Program, Chinese Academy of Sciences [XDA21030700];
   State Key Laboratory of Multiphase Complex Systems Facility Upgradation
   Program
FX This study is financially supported by the National Natural Science
   Foundation of China (21422608), the Key Research Program of Frontier
   Sciences, Chinese Academy of Sciences (QYZDJ-SSW-JSC029), the Strategic
   Priority Research Program, Chinese Academy of Sciences under grant
   XDA21030700 and the State Key Laboratory of Multiphase Complex Systems
   Facility Upgradation Program.
CR Brilliantov N.V., 2004, KINETIC THEORY GRANU
   Feng H. S.-H, 2016, THESIS
   Fiedler O, 1997, POWDER TECHNOL, V94, P51, DOI 10.1016/S0032-5910(97)03287-7
   Gidaspow D., 1994, MULTIPHASE FLOW FLUI
   Glansdorff P., 1961, Proceedings of the 2nd International Symposium on Rarefied Gas Dynamics, P475
   GLANSDORFF P, 1962, PHYS FLUIDS, V5, P371, DOI 10.1063/1.1706628
   Lampis M., 1977, Meccanica, V12, P171, DOI 10.1007/BF02179931
   Leszczynski JS, 2002, POWDER TECHNOL, V128, P22, DOI 10.1016/S0032-5910(02)00150-X
   Liu XW, 2017, AICHE J, V63, P3, DOI 10.1002/aic.15489
   Lu H., 2017, KINETIC THEORY DENSE
   Lu HL, 2008, POWDER TECHNOL, V182, P282, DOI 10.1016/j.powtec.2007.09.003
   LUN CKK, 1984, J FLUID MECH, V140, P223, DOI 10.1017/S0022112084000586
   MOTTSMITH HM, 1951, PHYS REV, V82, P885, DOI 10.1103/PhysRev.82.885
   ORLOV AV, 1992, PHYS FLUIDS A-FLUID, V4, P1856, DOI 10.1063/1.858358
   Ozarkar SS, 2008, PHYS FLUIDS, V20, DOI 10.1063/1.3035943
   Rao K., 2008, INTRO GRANULAR FLOW
   Ray S, 2005, ANN STAT, V33, P2042, DOI 10.1214/009053605000000417
   Robfftson C.A., 1969, SKANDINAVIAN AKTUARI, V52, P137, DOI DOI 10.1080/03461238.1969.10404590
   SAKURAI A, 1957, J FLUID MECH, V3, P255, DOI 10.1017/S0022112057000622
   SALWEN H, 1964, PHYS FLUIDS, V7, P180, DOI 10.1063/1.1711131
   Solovchuk MA, 2011, PHYS REV E, V83, DOI 10.1103/PhysRevE.83.026301
   Solovchuk MA, 2010, PHYS REV E, V81, DOI 10.1103/PhysRevE.81.056314
   TOBA K, 1965, PHYS FLUIDS, V8, P2153, DOI 10.1063/1.1761174
   Wang HF, 2018, AICHE J, V64, P2364, DOI 10.1002/aic.16163
   Wang JW, 2016, AICHE J, V62, P2649, DOI 10.1002/aic.15244
   Zel'Dovich Y. B., 2012, PHYS SHOCK WAVES HIG
   Zhao BD, 2018, CHEM ENG SCI, V177, P333, DOI 10.1016/j.ces.2017.11.047
   ZIERING S, 1961, PHYS FLUIDS, V4, P975, DOI 10.1063/1.1706448
NR 28
TC 1
Z9 1
U1 0
U2 7
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD APR 6
PY 2019
VL 197
BP 69
EP 73
DI 10.1016/j.ces.2018.11.054
PG 5
WC Engineering, Chemical
SC Engineering
GA HK0ZQ
UT WOS:000457634000006
DA 2020-05-12
ER

PT J
AU Acar, C
   Dincer, I
AF Acar, Canan
   Dincer, Ibrahim
TI Investigation of a novel photoelectrochemical hydrogen production system
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Photoelectrochemical process; Hydrogen production; Solar energy;
   Sustainability; Efficiency
ID THERMODYNAMIC ANALYSIS; ENERGY SOLUTIONS
AB The primary aim of this study us to develop an integrated PV/T-photoelectrochemical-chloralkali (PEC-chloralkali) system with multigeneration benefits and evaluate its thermodynamic performance. The key component of the integrated system is the continuous type hybrid H-2 generation reactor, which is also referred to as PEC-chloralkali reactor. The hybrid reactor is capable of converting the byproducts of H-2 production into valuable products for the industry. In addition to hydrogen, the hybrid reactor can produce Cl-2 and NaOH simultaneously. The reason behind using the hybrid reactor together with PV/T in an integrated system is to maximize solar spectrum utilization by combining the advantages of the photoelectrochemical system and PV/T. The electrodes are used as electron donors to drive the photoelectrochemical reaction in the hybrid reactor. As a result, the need for additional chemicals is eliminated and the risk of any potentially harmful waste streams is minimized. The integrated system has five useful products which are hydrogen and chlorine gases, sodium hydroxide solution, heat, and electricity. The performance of the system is evaluated based on hydrogen, chlorine, heat, and electricity production rates, energy and exergy efficiencies, and exergy destruction rates at different ambient temperatures and with different total photoactive area sizes. It is seen that the present innovative hybrid multigenerational system is capable of producing 8.9 g/h H-2 and 244 g/h Cl-2 at energy and exergy efficiencies about 86% and 29%, respectively. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Acar, Canan] Bahcesehir Univ, Fac Engn & Nat Sci, Ciragan Caddesi 4-6, TR-34353 Istanbul, Turkey.
   [Acar, Canan; Dincer, Ibrahim] Univ Ontario Inst Technol, Fac Engn & Appl Sci, Clean Energy Res Lab, 2000 Simcoe St North, Oshawa, ON L1H 7K4, Canada.
RP Acar, C (reprint author), Bahcesehir Univ, Fac Engn & Nat Sci, Ciragan Caddesi 4-6, TR-34353 Istanbul, Turkey.; Acar, C (reprint author), Univ Ontario Inst Technol, Fac Engn & Appl Sci, Clean Energy Res Lab, 2000 Simcoe St North, Oshawa, ON L1H 7K4, Canada.
EM Canan.Acar@eng.bau.edu.tr
CR Acar C, 2018, INT J HYDROGEN ENERG, V43, P10249, DOI 10.1016/j.ijhydene.2017.08.117
   Acar C, 2018, INT J HYDROGEN ENERG, V43, P4223, DOI 10.1016/j.ijhydene.2017.07.043
   Acar C, 2017, INT J HYDROGEN ENERG, V42, P30550, DOI 10.1016/j.ijhydene.2017.10.008
   Acar C, 2017, INT J HYDROGEN ENERG, V42, P3605, DOI 10.1016/j.ijhydene.2016.11.044
   Acar C, 2017, INT J HYDROGEN ENERG, V42, P2504, DOI 10.1016/j.ijhydene.2016.03.099
   Acar C, 2016, J POWER SOURCES, V331, P189, DOI 10.1016/j.jpowsour.2016.09.026
   Acar C, 2016, INT J HYDROGEN ENERG, V41, P7950, DOI 10.1016/j.ijhydene.2015.11.160
   Acar C, 2015, INT J HYDROGEN ENERG, V40, P11112, DOI 10.1016/j.ijhydene.2014.12.036
   Acar C, 2014, INT J HYDROGEN ENERG, V39, P15362, DOI 10.1016/j.ijhydene.2014.07.146
   Belarb E, 2016, CHEM ENG SCI, V154, P143, DOI 10.1016/j.ces.2016.06.055
   Bicer Y, 2016, ENERG CONVERS MANAGE, V123, P218, DOI 10.1016/j.enconman.2016.05.090
   Choi SK, 2016, J MATER CHEM A, V4, P14008, DOI 10.1039/c6ta05200b
   DeNora O., 1982, U. S. Patent No., Patent No. 4,340,452
   Dincer I, 2018, INT J HYDROGEN ENERG, V43, P8579, DOI 10.1016/j.ijhydene.2018.03.120
   Dincer I, 2016, INT J SUST AVIAT, V2, P74, DOI 10.1504/IJSA.2016.076077
   Dincer I, 2015, INT J ENERG RES, V39, P585, DOI 10.1002/er.3329
   Fan WQ, 2016, APPL CATAL B-ENVIRON, V181, P7, DOI 10.1016/j.apcatb.2015.07.032
   Friedlingstein P, 2014, NAT GEOSCI, V7, P709, DOI [10.1038/ngeo2248, 10.1038/NGEO2248]
   Gao CT, 2015, SOL ENERG MAT SOL C, V141, P101, DOI 10.1016/j.solmat.2015.05.026
   Gao L, 2014, NANO LETT, V14, P3715, DOI 10.1021/nl404540f
   Garcia-Herrero I, 2017, SCI TOTAL ENVIRON, V580, P147, DOI 10.1016/j.scitotenv.2016.10.202
   Gross MA, 2016, CHEM SCI, V7, P5537, DOI 10.1039/c6sc00715e
   International Energy Agency (IEA), 2017, TECHN REP 2017 KEY W
   Jalali AA, 2009, DESALINATION, V237, P126, DOI 10.1016/j.desal.2007.11.056
   Kwon KC, 2016, ENERG ENVIRON SCI, V9, P2240, DOI 10.1039/c6ee00144k
   Li SP, 2015, ACS APPL MATER INTER, V7, P18560, DOI 10.1021/acsami.5b04936
   Lu XH, 2014, CHEM SOC REV, V43, P7581, DOI 10.1039/c3cs60392j
   Mendoza PG, 2017, CHEM ENG RES DES, V128, P120, DOI 10.1016/j.cherd.2017.10.001
   Morales-Guio CG, 2015, ANGEW CHEM INT EDIT, V54, P664, DOI 10.1002/anie.201410569
   Suzuki TM, 2017, APPL CATAL B-ENVIRON, V202, P597, DOI 10.1016/j.apcatb.2016.09.066
   Tsai KA, 2015, APPL CATAL B-ENVIRON, V164, P271, DOI 10.1016/j.apcatb.2014.09.034
   Turner JA, 2004, SCIENCE, V305, P972, DOI 10.1126/science.1103197
   Ulleberg O, 2003, INT J HYDROGEN ENERG, V28, P21, DOI 10.1016/S0360-3199(02)00033-2
   Wang P, 2015, J PHYS CHEM C, V119, P26275, DOI 10.1021/acs.jpcc.5b07276
   Yu Z, 2015, ENERG ENVIRON SCI, V8, P760, DOI 10.1039/c4ee03565h
   Zamfirescu C, 2014, SOL ENERGY, V107, P700, DOI 10.1016/j.solener.2014.05.036
   Zhang HX, 2016, ENERG ENVIRON SCI, V9, P3113, DOI 10.1039/c6ee02215d
NR 37
TC 4
Z9 4
U1 7
U2 26
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD APR 6
PY 2019
VL 197
BP 74
EP 86
DI 10.1016/j.ces.2018.12.014
PG 13
WC Engineering, Chemical
SC Engineering
GA HK0ZQ
UT WOS:000457634000007
DA 2020-05-12
ER

PT J
AU Heinonen, J
   Sainio, T
AF Heinonen, Jari
   Sainio, Tuomo
TI Novel chromatographic process for the recovery and purification of
   hydroxy acids from alkaline spent pulping liquors
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Black liquor; Hydroxy carboxylic acids; Lignin; Pulping chemicals;
   Chromatographic separation
ID ALPHA-ISOSACCHARINIC ACID; LACTIC-ACID; PHENOLIC-COMPOUNDS;
   CARBOXYLIC-ACIDS; SODIUM-HYDROXIDE; BLACK LIQUOR; KRAFT; SEPARATION;
   LIGNIN; CELLULOSE
AB In this study, an efficient sequential chromatographic process for recovering hydroxy acids (HAs) from soda and kraft black liquors (BLs) has been developed. Lignin and pulping chemicals are also recovered and can be recycled back to the pulping process. A weak cation exchange resin in Na+ form separates lignin from BL. Up to 95% lignin yield was obtained, with over 50% yield for HAs as Na salts. A cellulosebased resin is used to separate HAs from NaOH. Complete separation, and thus 100% yield for HAs and NaOH, was achieved. The HAs in soda BL are liberated by ion exchange. In case of kraft BL, the solution is acidified with H2SO4 and subjected to ion exchange and ion exclusion chromatography to recover the remaining pulping chemicals. It was found that fouling, which limits the efficiency of membrane-based processing of BLs, is avoided with the appropriate choice of chromatographic separation materials. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Heinonen, Jari; Sainio, Tuomo] Lappeenranta Univ Technol, Sch Engn Sci, Skinnarilankatu 34, FIN-53850 Lappeenranta, Finland.
RP Heinonen, J (reprint author), Lappeenranta Univ Technol, Sch Engn Sci, Skinnarilankatu 34, FIN-53850 Lappeenranta, Finland.
EM jari.heinonen@lut.fi
OI Sainio, Tuomo/0000-0002-4951-8711; Heinonen, Jari/0000-0002-1308-4755
FU Academy of FinlandAcademy of Finland [SA/298548]
FX Financial support from the Academy of Finland (grant SA/298548) is
   gratefully acknowledged.
CR ALEN R, 1981, PAP PUU-PAP TIM, V63, P5
   ALEN R, 1980, PAP PUU-PAP TIM, V62, P469
   ALEN R, 1991, J CHEM TECHNOL BIOT, V51, P225
   Alen R., 1980, PAP PUU-PAP TIM, V62, P328
   Barralet JE, 2005, CHEM MATER, V17, P1313, DOI 10.1021/cm048803z
   da Silva EAB, 2009, CHEM ENG RES DES, V87, P1276, DOI 10.1016/j.cherd.2009.05.008
   Brunow G, 1999, SPRINGER SER WOOD, P77
   Draefis Z.D., 2000, DERMATOL THER, V13, P154
   Dusselier M, 2014, TOP CURR CHEM, V353, P85, DOI 10.1007/128_2014_540
   Dusselier M, 2013, ENERG ENVIRON SCI, V6, P1415, DOI 10.1039/c3ee00069a
   Ekberg S, 2004, J SOLUTION CHEM, V33, P465, DOI 10.1023/B:JOSL.0000037771.45926.f2
   Faustino H, 2010, MOLECULES, V15, P9308, DOI 10.3390/molecules15129308
   Ghaffar T, 2014, J RADIAT RES APPL SC, V7, P222, DOI 10.1016/j.jrras.2014.03.002
   Gomes ED, 2018, SEP PURIF TECHNOL, V194, P256, DOI 10.1016/j.seppur.2017.11.050
   Gustafsson J., 2011, PAPERMAK SCI TECHN 6, P187
   Heinonen J, 2018, CHEM ENG TECHNOL, V41, P2402, DOI 10.1002/ceat.201800412
   Heinonen J, 2019, SEP PURIF TECHNOL, V210, P670, DOI 10.1016/j.seppur.2018.08.064
   Heinonen J, 2018, SEP PURIF TECHNOL, V193, P317, DOI 10.1016/j.seppur.2017.10.049
   Heinonen J, 2014, SEP PURIF TECHNOL, V129, P137, DOI 10.1016/j.seppur.2014.03.031
   Heinonen J, 2010, IND ENG CHEM RES, V49, P2907, DOI 10.1021/ie901598z
   Helfferich F.G., 1995, ION EXCHANGE
   Hellsten S, 2013, CHEM ENG RES DES, V91, P2765, DOI 10.1016/j.cherd.2013.06.001
   Hellsten S, 2013, SEP PURIF TECHNOL, V118, P234, DOI 10.1016/j.seppur.2013.06.027
   Holladay J., 2007, TOP VALUE ADDED CHEM, DOI [DOI 10.2172/921839, 10.2172/921839.]
   IEA Bioenergy, 2011, BIOB CHEM VAL ADD PR
   IEA Energy Technology Network, 2015, EN TECHN SYST AN PRO
   Jang YS, 2012, BIOTECHNOL BIOENG, V109, P2437, DOI 10.1002/bit.24599
   Kessler E, 2008, DERMATOL SURG, V34, P45, DOI 10.1111/j.1524-4725.2007.34007.x
   Koivistoinen OM, 2013, MICROB CELL FACT, V12, DOI 10.1186/1475-2859-12-82
   Kornhauser A, 2010, CLIN COSMET INVESTI, V3, P135, DOI 10.2147/CCID.S9042
   Kumar H, 2015, SEP PURIF TECHNOL, V142, P293, DOI 10.1016/j.seppur.2014.12.038
   Kumar H, 2014, IND ENG CHEM RES, V53, P9464, DOI 10.1021/ie5006004
   Laatikainen M, 2018, CHEM ENG J, V341, P578, DOI 10.1016/j.cej.2018.02.070
   Lignimatch, 2010, FUT US LIGN VAL ADD
   LOWENDAHL L, 1978, SVEN PAPPERSTIDN, V81, P392
   Manttari M, 2015, J MEMBRANE SCI, V490, P84, DOI 10.1016/j.memsci.2015.04.048
   McMurry J., 2008, ORGANIC CHEM
   Mehtio T, 2012, EUR POLYM J, V48, P774, DOI 10.1016/j.eurpolymj.2012.01.010
   Mota MIF, 2016, CHEM ENG J, V288, P869, DOI 10.1016/j.cej.2015.12.041
   Motomura H, 1998, DYES PIGMENTS, V39, P243, DOI 10.1016/S0143-7208(98)00014-X
   NEDDERMEYER PA, 1968, ANAL CHEM, V40, P755, DOI 10.1021/ac60260a015
   Niemela K, 1999, SPRINGER SER WOOD, P193
   Shaw PB, 2012, CARBOHYD RES, V349, P6, DOI 10.1016/j.carres.2011.11.022
   Shelia T.C., 2011, ADV IND BIOTECHNOL, P56
   Svensson M, 2007, J HAZARD MATER, V144, P477, DOI 10.1016/j.jhazmat.2006.10.054
   Upton BM, 2016, CHEM REV, V116, P2275, DOI 10.1021/acs.chemrev.5b00345
   Vahii-Savo N., 2014, BEHAV BLACK LIQUOR N
   Vakkilainen E., 2008, PAPERMAKING SCI TE 6, P85
   Vakkilainen E. K., 2005, KRAFT RECOVERY BOILE
   Van Heiningen A, 2006, PULP PAP-CANADA, V107, P38
   Vercammen K, 1999, ACTA CHEM SCAND, V53, P241, DOI 10.3891/acta.chem.scand.53-0241
   Wang S., 2008, Patent No. [WO/2008036049 Al, 2008036049]
   Werpy T., 2004, TOP VALUE ADDED CHEM, V1, DOI [10.2172/15008859, DOI 10.2172/15008859]
NR 53
TC 2
Z9 2
U1 2
U2 19
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD APR 6
PY 2019
VL 197
BP 87
EP 97
DI 10.1016/j.ces.2018.12.013
PG 11
WC Engineering, Chemical
SC Engineering
GA HK0ZQ
UT WOS:000457634000008
DA 2020-05-12
ER

PT J
AU Herrera-Hernandez, EC
   Aguilar-Madera, CG
   Ocampo-Perez, R
   Espinosa-Paredes, G
   Nunez-Lopez, M
AF Herrera-Hernandez, E. C.
   Aguilar-Madera, C. G.
   Ocampo-Perez, R.
   Espinosa-Paredes, G.
   Nunez-Lopez, M.
TI Fractal continuum model for the adsorption-diffusion process
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Adsorption-diffusion model; Porous activated carbon; Fractal continuum;
   Fractal dimensions
ID ACTIVATED CARBON; HYDROGEN-PRODUCTION; PORE VOLUME; PARTICLES; SURFACES;
   REMOVAL
AB In this work, we present a mathematical model to describe the adsorption-diffusion process on fractal porous materials. This model is based on the fractal continuum approach and considers the scale-invariant properties of the surface and volume of adsorbent particles, which are well-represented by their fractal dimensions. The method of lines was used to solve the nonlinear fractal model, and the numerical predictions were compared with experimental data to determine the fractal dimensions through an optimization algorithm. The intraparticle mass flux and the mean square displacement dynamics as a function of fractal dimensions were analyzed. The results suggest that they can be potentially used to characterize the intraparticle mass transport processes. The fractal model demonstrated to be able to predict adsorption-diffusion experiments and jointly can be used to estimate fractal parameters of porous adsorbents. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Herrera-Hernandez, E. C.] CONACYT Ctr Ingn & Desarrollo Ind, Av Playa Pie Cuesta 702, Queretaro 76125, Qro, Mexico.
   [Aguilar-Madera, C. G.] Univ Autonoma Nuevo Leon, Fac Ciencias Tierra, Linares 67700, NL, Mexico.
   [Ocampo-Perez, R.] Univ Autonoma San Luis Potosi, Fac Ciencias Quim, San Luis Potosi 78260, Mexico.
   [Espinosa-Paredes, G.] Univ Autonoma Metropolitana Iztapalapa, Area Ingn Recursos Energet, Cd Mexico 09340, Mexico.
   [Nunez-Lopez, M.] ITAM, Dept Math, Rio Hondo 1, Ciudad De Mexico 01080, Mexico.
RP Herrera-Hernandez, EC (reprint author), CONACYT Ctr Ingn & Desarrollo Ind, Av Playa Pie Cuesta 702, Queretaro 76125, Qro, Mexico.
EM erik.herrera@cidesi.edu.mx
RI Aguilar-Madera, Carlos/AAF-2057-2020
OI OCAMPO PEREZ, RAUL/0000-0003-2033-7527; Herrera-Hernandez, Erik
   Cesar/0000-0002-9006-5013
FU CONACYT Mexico trough catedra at CIDESI; Asociacion Mexicana de Cultura
   A.C, Mexico
FX ECH-H acknowledges the support from CONACYT Mexico trough catedra at
   CIDESI. MN-L acknowledges the financial support from the Asociacion
   Mexicana de Cultura A.C, Mexico.
CR Aguerre RJ, 1996, J FOOD ENG, V30, P227, DOI 10.1016/S0260-8774(97)89377-6
   Ardi MS, 2015, RENEW SUST ENERG REV, V42, P1164, DOI 10.1016/j.rser.2014.10.091
   AVNIR D, 1984, NATURE, V308, P261, DOI 10.1038/308261a0
   Balankin A. S., 2012, PHYS REV E, V85, P1
   Baumann G, 2013, FRACT CALC APPL ANAL, V16, P737, DOI 10.2478/s13540-013-0046-3
   Bui TD, 2017, J MEMBRANE SCI, V539, P76, DOI 10.1016/j.memsci.2017.05.067
   Burnett MD, 2015, DRY TECHNOL, V33, P455, DOI [10.1080/07373937.2014.958161, 10.]
   Cuerda-Correa EM, 2006, APPL SURF SCI, V252, P6102, DOI 10.1016/j.apsusc.2005.11.012
   Dabrowski A, 2001, ADV COLLOID INTERFAC, V93, P135, DOI 10.1016/S0001-8686(00)00082-8
   Dincer I, 2015, INT J HYDROGEN ENERG, V40, P11094, DOI 10.1016/j.ijhydene.2014.12.035
   dos Santos M. A., 2017, ADV MATH PHYS, V2017, P1
   Foo KY, 2010, CHEM ENG J, V156, P2, DOI 10.1016/j.cej.2009.09.013
   Herrera-Hernandez EC, 2013, PHYS REV E, V88, DOI 10.1103/PhysRevE.88.063004
   Jiang HN, 2013, CHAOS, V23, DOI 10.1063/1.4813597
   Kang JH, 2015, AIP ADV, V5, DOI 10.1063/1.4938518
   Kano F, 2000, SURF SCI, V467, P131, DOI 10.1016/S0039-6028(00)00730-5
   Khalili N. R., 1997, CONF970962 ARG NAT L, P859
   Kyzas GZ, 2015, J MOL LIQ, V203, P159, DOI 10.1016/j.molliq.2015.01.004
   Langmuir I, 1918, J AM CHEM SOC, V40, P1361, DOI 10.1021/ja02242a004
   Latimer AA, 2017, NAT MATER, V16, P225, DOI [10.1038/nmat4760, 10.1038/NMAT4760]
   LEYVARAMOS R, 1994, CAN J CHEM ENG, V72, P262, DOI 10.1002/cjce.5450720213
   Montagnaro F, 2014, FUEL PROCESS TECHNOL, V128, P412, DOI 10.1016/j.fuproc.2014.07.021
   Nikolaidis P, 2017, RENEW SUST ENERG REV, V67, P597, DOI 10.1016/j.rser.2016.09.044
   Ocampo-Perez R, 2017, CHEM ENG J, V321, P510, DOI 10.1016/j.cej.2017.03.137
   Ocampo-Perez R, 2013, ADSORPTION, V19, P945, DOI 10.1007/s10450-013-9502-y
   Ocampo-Perez R, 2010, CHEM ENG J, V165, P133, DOI 10.1016/j.cej.2010.09.002
   Oh WD, 2016, APPL CATAL B-ENVIRON, V194, P169, DOI 10.1016/j.apcatb.2016.04.003
   Papathanasiou MM, 2016, AICHE J, V62, P2341, DOI 10.1002/aic.15203
   PFEIFER P, 1984, J CHEM PHYS, V80, P4573, DOI 10.1063/1.447307
   Qiu H, 2009, J ZHEJIANG UNIV-SC A, V10, P716, DOI 10.1631/jzus.A0820524
   Rezaei-Shouroki M, 2017, INT J HYDROGEN ENERG, V42, P9500, DOI 10.1016/j.ijhydene.2017.02.072
   Sakaguchi H, 2005, J PHYS SOC JPN, V74, P2703, DOI 10.1143/JPSJ.74.2703
   Segars R, 1996, MATER RES SOC SYMP P, V407, P349
   Selmi T, 2018, ADSORPTION, V24, P11, DOI 10.1007/s10450-017-9927-9
   Sun WJ, 2015, FUEL, V155, P7, DOI 10.1016/j.fuel.2015.03.083
   Tarasov V. E., 2010, PHYS LETT A, V336, P167
   Tarasov VE, 2015, COMMUN NONLINEAR SCI, V20, P360, DOI 10.1016/j.cnsns.2014.05.025
   Tarasov VE, 2005, ANN PHYS-NEW YORK, V318, P286, DOI 10.1016/j.aop.2005.01.004
   Tarasov VE, 2011, NONLINEAR PHYS SCI, P1
   Wang YL, 2007, COLLOID SURFACE A, V299, P224, DOI 10.1016/j.colsurfa.2006.11.044
   Xu LJ, 2008, ACTA GEOCHIM, V27, P126, DOI 10.1007/s11631-008-0126-y
   Xu WJ, 2017, VACUUM, V141, P307, DOI 10.1016/j.vacuum.2017.04.031
NR 42
TC 2
Z9 2
U1 2
U2 16
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD APR 6
PY 2019
VL 197
BP 98
EP 108
DI 10.1016/j.ces.2018.11.058
PG 11
WC Engineering, Chemical
SC Engineering
GA HK0ZQ
UT WOS:000457634000009
DA 2020-05-12
ER

PT J
AU Cai, RR
   Lu, H
   Zhang, LZ
AF Cai, Rong-Rong
   Lu, Hao
   Zhang, Li-Zhi
TI Evaluation the effect of fiber alignment on particle collection
   performance of mechanical/electret filters based on Voronoi
   tessellations
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Filtration performance; Electret filter; Voronoi tessellation; 3D fiber
   orientation
ID LATTICE-BOLTZMANN; FIBROUS FILTERS; FILTRATION PERFORMANCE; HYDRAULIC
   PERMEABILITY; AEROSOL-PARTICLES; COLLAGEN GELS; FLOW; SIMULATION;
   DEPOSITION; CAPTURE
AB The effect of fiber alignment on particle collection performance of mechanical/electret filters are investigated numerically. Four sets of fiber networks, namely, nearly isotropic, aligned, highly aligned and layered orientations are constructed using Voronoi tessellations. The particle transport and deposition process in these fiber networks under the coupling of flow field and electrostatic field are modeled using hybrid lattice Boltzmann Lagrangian method. The particle collection efficiencies and pressure drops of the mechanical/electret filters are calculated and compared. Results indicate that the mechanical filter with layered networks has the best filtration performance for large particles, and then the aligned networks has the next best performance. However, the sequence reverses when filtering the nanoparticles. In contrast to a mechanical filter, the electret filter with isotropic networks exhibits the best performance for full range of particles size, indicating that the dielectric attraction is less impacted by the 3D fiber orientations. Increasing fibers orientations in the airflow direction and constructing 3D pores of high sphericity are recommended to improve the performance of an electret filter. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Cai, Rong-Rong; Lu, Hao; Zhang, Li-Zhi] South China Univ Technol, Sch Chem & Chem Engn, Educ Minist, Key Lab Enhanced Heat Transfer & Energy Conservat, Guangzhou 510640, Guangdong, Peoples R China.
   [Zhang, Li-Zhi] South China Univ Technol, State Key Lab Subtrop Bldg Sci, Guangzhou 510640, Guangdong, Peoples R China.
RP Zhang, LZ (reprint author), South China Univ Technol, Sch Chem & Chem Engn, Educ Minist, Key Lab Enhanced Heat Transfer & Energy Conservat, Guangzhou 510640, Guangdong, Peoples R China.
EM lzzhang@scut.edu.cn
RI Zhang, Li-Zhi/A-7195-2012
OI Zhang, Li-Zhi/0000-0001-5768-2119
FU Natural Science Foundation of ChinaNational Natural Science Foundation
   of China [51506058]; National Science Fund for Distinguished Young
   Scholars of ChinaNational Natural Science Foundation of ChinaNational
   Science Fund for Distinguished Young Scholars [51425601]; Science and
   Technology Planning Projects of Guangdong Province: GDST-Innovate UK
   (Newton Project, UK) International Cooperation Project [2018A050501005];
   Guangdong - Hong Kong Technology Cooperation Funding Scheme (TCFS)
   [2017B050506005]
FX The current work is supported by the Natural Science Foundation of
   China, No. 51506058. The Project is also supported by National Science
   Fund for Distinguished Young Scholars of China, No. 51425601; and by the
   Science and Technology Planning Projects of Guangdong Province:
   GDST-Innovate UK (Newton Project, UK) International Cooperation Project
   No. 2018A050501005, Guangdong - Hong Kong Technology Cooperation Funding
   Scheme (TCFS), No. 2017B050506005.
CR Al-Attabi R, 2018, SCI TOTAL ENVIRON, V625, P706, DOI 10.1016/j.scitotenv.2017.12.342
   BANKS DO, 1991, AEROSOL SCI TECH, V14, P224, DOI 10.1080/02786829108959485
   Baumgartner H, 1987, FILTR SEPARAT, V24, P346
   Cai RR, 2017, APPL THERM ENG, V111, P1536, DOI 10.1016/j.applthermaleng.2016.07.162
   Cai RR, 2016, BUILD ENVIRON, V106, P274, DOI 10.1016/j.buildenv.2016.07.001
   Chai ZH, 2008, APPL MATH MODEL, V32, P2050, DOI 10.1016/j.apm.2007.06.033
   Chen S, 2015, POWDER TECHNOL, V274, P431, DOI 10.1016/j.powtec.2015.01.051
   Chen XM, 2007, COMPOS SCI TECHNOL, V67, P1286, DOI 10.1016/j.compscitech.2006.10.011
   Clague DS, 1997, PHYS FLUIDS, V9, P1562, DOI 10.1063/1.869278
   Clague DS, 2000, PHYS REV E, V61, P616, DOI 10.1103/PhysRevE.61.616
   Coles ME, 1998, SPE RESERV EVAL ENG, V1, P288, DOI 10.2118/50985-PA
   DAHNEKE B, 1995, AEROSOL SCI TECH, V23, P25, DOI 10.1080/02786829508965292
   Davies C.N., 1973, AIR FILTRATION
   DAVIES CN, 1945, P PHYS SOC LOND, V57, P259, DOI 10.1088/0959-5309/57/4/301
   Diogenes A N, 2009, THERM ENG, V8, P35
   DRUMMOND JE, 1984, INT J MULTIPHAS FLOW, V10, P515, DOI 10.1016/0301-9322(84)90079-X
   Erikson A, 2008, BIOPOLYMERS, V89, P135, DOI 10.1002/bip.20874
   Fan JH, 2018, COMMUN COMPUT PHYS, V23, P932, DOI 10.4208/cicp.OA-2016-0236
   Filippova O, 1997, COMPUT FLUIDS, V26, P697, DOI 10.1016/S0045-7930(97)00009-1
   Fotovati S, 2010, CHEM ENG SCI, V65, P5285, DOI 10.1016/j.ces.2010.06.032
   Gervais PC, 2014, SEP PURIF TECHNOL, V126, P52, DOI 10.1016/j.seppur.2014.02.011
   Guo ZL, 2002, CHINESE PHYS, V11, P366, DOI 10.1088/1009-1963/11/4/310
   Hinds W., 2012, AEROSOL TECHNOLOGY P
   Huang HK, 2016, POWDER TECHNOL, V292, P232, DOI 10.1016/j.powtec.2016.02.012
   JACKSON GW, 1986, CAN J CHEM ENG, V64, P364, DOI 10.1002/cjce.5450640302
   Jaganathan S, 2008, CHEM ENG SCI, V63, P244, DOI 10.1016/j.ces.2007.09.020
   Jones TB, 2005, ELECTROMECHANICS PAR
   Lantermann U, 2007, COMPUT FLUIDS, V36, P407, DOI 10.1016/j.compfluid.2005.10.005
   Lehmann M.J., 2013, F S INT ED, V13, P69
   Li SQ, 2007, J AEROSOL SCI, V38, P1031, DOI 10.1016/j.jaerosci.2007.08.004
   Li SQ, 2011, PROG ENERG COMBUST, V37, P633, DOI 10.1016/j.pecs.2011.02.001
   Li W, 2016, ADV POWDER TECHNOL, V27, P638, DOI 10.1016/j.apt.2016.02.018
   Lin KC, 2017, COMPUT FLUIDS, V156, P534, DOI 10.1016/j.compfluid.2017.08.011
   Marshall JS, 2009, J COMPUT PHYS, V228, P1541, DOI 10.1016/j.jcp.2008.10.035
   Maynard A. D., 2007, NANOPARTICLES OCCUPA
   Mecke K. R., 2008, MORPHOLOGY CONDENSED
   OUNIS H, 1990, AEROSOL SCI TECH, V13, P47, DOI 10.1080/02786829008959423
   Pradhan AK, 2012, POWDER TECHNOL, V221, P101, DOI 10.1016/j.powtec.2011.12.027
   Przekop R, 2003, J AEROSOL SCI, V34, P133, DOI 10.1016/S0021-8502(02)00153-2
   Przekop R, 2014, INT J NUMER METH FL, V76, P779, DOI 10.1002/fld.3952
   QIAN YH, 1992, EUROPHYS LETT, V17, P479, DOI 10.1209/0295-5075/17/6/001
   Rabiee MB, 2015, PARTICUOLOGY, V21, P90, DOI 10.1016/j.partic.2014.11.010
   Romay FJ, 1999, FILTR SEPARAT, V36, P51, DOI 10.1016/S0015-1882(99)80080-9
   Saleh AM, 2015, SEP PURIF TECHNOL, V149, P295, DOI 10.1016/j.seppur.2015.06.005
   Sambaer W, 2012, CHEM ENG SCI, V82, P299, DOI 10.1016/j.ces.2012.07.031
   Sanchez AL, 2013, AEROSOL SCI TECH, V47, P606, DOI 10.1080/02786826.2013.778384
   SANGANI AS, 1982, INT J MULTIPHAS FLOW, V8, P193, DOI 10.1016/0301-9322(82)90029-5
   Sbragaglia M, 2005, PHYS FLUIDS, V17, DOI 10.1063/1.2044829
   Schwarzkopf J. D., 2011, MULTIPHASE FLOWS DRO
   SCHWEERS E, 1994, POWDER TECHNOL, V80, P191, DOI 10.1016/0032-5910(94)02850-8
   Soltani P, 2014, POWDER TECHNOL, V254, P44, DOI 10.1016/j.powtec.2014.01.001
   Spielman L., 1968, ENVIRON SCI TECHNOL, V2, P279, DOI [10.1021/es60016a003, DOI 10.1021/ES60016A003]
   Stylianopoulos T, 2007, COMPUT METHOD APPL M, V196, P2981, DOI 10.1016/j.cma.2006.06.019
   Stylianopoulos T, 2010, BIOPHYS J, V99, P3119, DOI 10.1016/j.bpj.2010.08.065
   Stylianopoulos T, 2008, PHYS FLUIDS, V20, DOI 10.1063/1.3021477
   Tahir MA, 2009, PHYS FLUIDS, V21, DOI 10.1063/1.3211192
   Thomas D, 2001, CHEM ENG SCI, V56, P3549, DOI 10.1016/S0009-2509(01)00041-0
   Thompson KE, 2002, AICHE J, V48, P1369, DOI 10.1002/aic.690480703
   Voronoi G, 1908, J REINE ANGEW MATH, V134, P198, DOI 10.1515/crll.1908.134.198
   Wang CS, 2013, IND ENG CHEM RES, V52, P5, DOI 10.1021/ie300574m
   Wang HM, 2014, AEROSOL SCI TECH, V48, P207, DOI 10.1080/02786826.2013.868595
   Wang HM, 2013, J AEROSOL SCI, V66, P164, DOI 10.1016/j.jaerosci.2013.08.016
   Wang HM, 2012, POWDER TECHNOL, V227, P111, DOI 10.1016/j.powtec.2011.12.057
   Wang M, 2008, INT J HEAT MASS TRAN, V51, P1325, DOI 10.1016/j.ijheatmasstransfer.2007.11.031
   Wu GJ, 2016, AEROSOL SCI TECH, V50, P1033, DOI 10.1080/02786826.2016.1218437
   Wu MB, 2013, J AEROSOL SCI, V57, P96, DOI 10.1016/j.jaerosci.2012.09.002
   Xiao F, 2016, COMPUT MATH APPL, V72, P328, DOI 10.1016/j.camwa.2015.09.009
   Yang YJ, 2015, SEP PURIF TECHNOL, V152, P14, DOI 10.1016/j.seppur.2015.08.005
   Zhao XL, 2016, SCI REP-UK, V6, DOI 10.1038/srep35472
NR 69
TC 1
Z9 1
U1 11
U2 43
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD APR 6
PY 2019
VL 197
BP 109
EP 119
DI 10.1016/j.ces.2018.12.015
PG 11
WC Engineering, Chemical
SC Engineering
GA HK0ZQ
UT WOS:000457634000010
DA 2020-05-12
ER

PT J
AU Diao, R
   Zhang, HY
   Zhao, DF
   Li, S
AF Diao, Rui
   Zhang, Hongyang
   Zhao, Dongfeng
   Li, Shi
TI Adsorption and structure of benzene, toluene, and p-xylene in carbon
   slit pores: A Monte Carlo simulation study
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Adsorption; BTX; Monte Carlo simulation; Carbon slit pores
ID ACTIVATED CARBON; COMPUTER-SIMULATIONS; AROMATIC-COMPOUNDS; VOCS;
   VAPORS; FIBER; HYDROPHOBICITY; QUADRUPOLE; EQUILIBRIA; DESORPTION
AB The adsorption of benzene (B), toluene (T), and p-xylene (X) at ambient temperature in carbon slit pores was studied using the grand canonical Monte Carlo simulation. We focused on how the structure of the adsorbed B, T, and X molecules is influenced by pore size, in particular the effects of the methyl groups in the cases of toluene and p-xylene. The packing density of the compounds in the pores was found to follow the order B < T < X at low loadings but X < T < B at high loadings. Furthermore, various molecular orientations were observed in the different pore sizes, including parallel, perpendicular, and parallel combined with perpendicular, and the nearest neighboring molecules assumed to undergo an edge-wise or T-shaped interaction. For parallel molecules, two adjacent molecules were aligned in an edge-wise interaction, which is the most favorable for solid-fluid interactions. However, for perpendicular molecules, two adjacent molecules were arranged in a T-shape, which is more favorable for fluid-fluid interactions. For the perpendicular toluene and p-xylene molecules, the angle between the methyl group and the pore walls was found to be 30 degrees. In the smallest pore studied, the benzene molecules were found to adopt a 2D hexagonally packed solid-like state, whereas the toluene and p-xylene molecules were in a liquid-like state. Consequently, the microscopic structures of B, T, X in various sized pores were investigated. The molecular models showed that the fluid-fluid interactions were significant for B, T, X adsorption, except for the cases of toluene and p-xylene in pores that can accommodate more than one molecular layer, where the solid-fluid interactions play a more dominant role because of the enhanced solid-fluid interactions of the toluene and p-xylene molecules oriented in parallel to each other. In addition, we have compared the results of our simulation with experimental data from previous research. The simulated isotherm agrees reasonably well with the experimentally obtained isotherm, and the simulated nearest-neighbor distance between the adsorbed molecules is almost the same as the experimental value. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Diao, Rui; Zhao, Dongfeng; Li, Shi] China Univ Petr East China, Coll Chem Engn, Qingdao 266580, Shandong, Peoples R China.
   [Zhang, Hongyang] Curtin Univ Technol, Dept Petr Engn, Bentley, WA 6102, Australia.
RP Zhao, DF (reprint author), China Univ Petr East China, Coll Chem Engn, Qingdao 266580, Shandong, Peoples R China.
EM zhaodongfeng@upc.edu.cn
FU China Postdoctoral Science FoundationChina Postdoctoral Science
   Foundation [2018M632747]; Natural Science Foundation of Shandong
   ProvinceNatural Science Foundation of Shandong Province
   [ZR201702150018]; Fundamental Research Funds for the Central
   UniversitiesFundamental Research Funds for the Central Universities
   [18CX02143A, 17CX05017]; China University of Petroleum [YJ20170019]
FX This work was supported under the China Postdoctoral Science Foundation
   funding scheme (2018M632747), the Natural Science Foundation of Shandong
   Province (ZR201702150018), the Fundamental Research Funds for the
   Central Universities (18CX02143A, 17CX05017), new faculty start-up
   funding from China University of Petroleum (YJ20170019), and was
   supported by resources provided by the National Supercomputer Centre in
   Tianjin, where the calculations were performed on TianHe-1 (A).
CR Ahnert F, 2003, ADSORPTION, V9, P311, DOI 10.1023/A:1026271830072
   Coasne B, 2011, PHYS CHEM CHEM PHYS, V13, P3748, DOI 10.1039/e0cp02205e
   COX EG, 1958, PROC R SOC LON SER-A, V247, P1, DOI 10.1098/rspa.1958.0167
   Do DD, 2006, LANGMUIR, V22, P1121, DOI 10.1021/la052545i
   Frenkel D., 2002, UNDERSTANDING MOL SI
   Ghoshal AK, 2002, J LOSS PREVENT PROC, V15, P413, DOI 10.1016/S0950-4230(02)00042-6
   Gil RR, 2014, CHEM ENG J, V245, P80, DOI 10.1016/j.cej.2014.02.012
   Giraudet S, 2014, ENERG FUEL, V28, P3924, DOI 10.1021/ef500600b
   Guillot A, 2000, ADSORPT SCI TECHNOL, V18, P1, DOI 10.1260/0263617001493233
   Haghseresht F, 2002, LANGMUIR, V18, P6193, DOI 10.1021/la025541b
   Kim KJ, 2006, CATAL TODAY, V111, P223, DOI 10.1016/j.cattod.2005.10.030
   Klomkliang N, 2012, IND ENG CHEM RES, V51, P5320, DOI 10.1021/ie300121p
   Klomkliang N, 2012, CHEM ENG SCI, V69, P472, DOI 10.1016/j.ces.2011.11.001
   Li L, 2011, J HAZARD MATER, V192, P683, DOI 10.1016/j.jhazmat.2011.05.069
   Lillo-Rodenas MA, 2006, CARBON, V44, P1455, DOI 10.1016/j.carbon.2005.12.001
   Lillo-Rodenas MA, 2011, ADSORPTION, V17, P473, DOI 10.1007/s10450-010-9301-7
   Lillo-Rodenas MA, 2005, CARBON, V43, P1758, DOI 10.1016/j.carbon.2005.02.023
   Liu HB, 2016, J HAZARD MATER, V318, P425, DOI 10.1016/j.jhazmat.2016.07.026
   MEEHAN P, 1980, J CHEM SOC FARAD T 1, V76, P2011, DOI 10.1039/f19807602011
   Oh GY, 2008, SCI TOTAL ENVIRON, V393, P341, DOI 10.1016/j.scitotenv.2008.01.005
   STEELE WA, 1973, SURF SCI, V36, P317, DOI 10.1016/0039-6028(73)90264-1
   VERNOV A, 1991, LANGMUIR, V7, P2817, DOI 10.1021/la00059a066
   VERNOV A, 1991, LANGMUIR, V7, P3110, DOI 10.1021/la00060a034
   Wang CM, 2004, J CHEM ENG DATA, V49, P527, DOI 10.1021/je0302102
   Wick CD, 2002, J CHROMATOGR A, V954, P181, DOI 10.1016/S0021-9673(02)00171-1
   Yun JH, 1997, J CHEM ENG DATA, V42, P894, DOI 10.1021/je970066i
   Yun JH, 1998, J CHEM ENG DATA, V43, P843, DOI 10.1021/je980069a
   Yun JH, 1999, AICHE J, V45, P751, DOI 10.1002/aic.690450410
   Zhang XY, 2017, J HAZARD MATER, V338, P102, DOI 10.1016/j.jhazmat.2017.05.013
NR 29
TC 3
Z9 3
U1 11
U2 81
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD APR 6
PY 2019
VL 197
BP 120
EP 134
DI 10.1016/j.ces.2018.12.004
PG 15
WC Engineering, Chemical
SC Engineering
GA HK0ZQ
UT WOS:000457634000011
DA 2020-05-12
ER

PT J
AU Oskooei, AB
   Koohsorkhi, J
   Mehrpooya, M
AF Oskooei, Araz Belali
   Koohsorkhi, Javad
   Mehrpooya, Mehdi
TI Simulation of plasma-assisted catalytic reduction of NOx, CO, and HC
   from diesel engine exhaust with COMSOL
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Diesel fuel; NOx; CO; HC; Plasma-assisted catalyst; COMSOL
ID NONTHERMAL PLASMA; REMOVAL
AB In the present paper, computational fluid dynamic (CFD) model was applied to simulate for the first time a synergetic application of a hybrid plasma and catalyst comprising DOC (Diesel Oxidation Catalyst) with Pt/CeO2 -Al2O3 and SCR (Selective Catalytic Reaction) with V2O5/TiO2. Plasma-catalytic can be used in cold start diesel engine exhaust to reduce pollutants when catalyst is not hot enough. Plasma system was a pulsed corona consisting of the coaxial wire-cylinder reactor. NOx and C3H6  reduction, NO2, NO, and radical produced concentration dependence of the electric field intensity were achieved. Transient temperature and CO distribution at catalyst channel, catalyst back pressure, and NO distribution all over the CC (catalytic converter) concentration were investigated to determine the steady state reduction efficiency of NO, CO, CH4, and C3H6 with respect to inlet velocities and temperatures. In velocity 3 m/s, temperature 600 K, highest electric field before sparkover at 17 kV/cm, and 80 s engine cold start time, the reduction efficiencies of NO and C3H6 got about 9% and 99% respectively. In steady state condition CO, NO, and C3H6 reduction in catalyst are about 98%, 29%, and 95% in order. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Oskooei, Araz Belali; Koohsorkhi, Javad; Mehrpooya, Mehdi] Univ Tehran, Fac New Sci & Technol, Tehran, Iran.
RP Koohsorkhi, J (reprint author), Univ Tehran, Fac New Sci & Technol, Tehran, Iran.
EM koohsorkhi@ut.ac.ir
RI Mehrpooya, Mehdi/AAH-1617-2019
CR Agrawal G, 2012, CHEM ENG SCI, V71, P310, DOI 10.1016/j.ces.2011.12.041
   Braun J., 2000, INFLUENCE PHYS CHEM
   Chae JO, 2003, J ELECTROSTAT, V57, P251, DOI 10.1016/S0304-3886(02)00165-1
   Eddy Melissa, 2017, AS EUROPE SOURS DIES
   Francke KP, 2000, CATAL TODAY, V59, P411, DOI 10.1016/S0920-5861(00)00306-0
   Gomez-Ramirez A, 2014, ACS CATAL, V4, P402, DOI 10.1021/cs4008528
   Jo Jin-Oh, 2017, INT J ADV SCI ENG TE, V5
   Liu B, 2001, CHEM ENG SCI, V56, P2641, DOI 10.1016/S0009-2509(00)00535-2
   McLarnon C. R., 1998, EFFECT REACTOR DESIG
   Miessner H, 2002, CATAL TODAY, V75, P325, DOI 10.1016/S0920-5861(02)00085-8
   Mok YS, 2002, CHEM ENG J, V85, P87, DOI 10.1016/S1385-8947(01)00221-2
   Mok YS, 1998, CHEM ENG SCI, V53, P1667, DOI 10.1016/S0009-2509(97)00441-7
   Mourimune T., 2005, 5 ASIA PACIFIC C COM
   Penetrante B. M., 2001, AIR FORCE RES LAB TY
   Penetrante B. M, 1997, FUNDAMENTAL LIMITS N
   Penetrante BM, 1999, PURE APPL CHEM, V71, P1829, DOI 10.1351/pac199971101829
   Phaily MKA, 2014, INT J CHEM ENG, DOI 10.1155/2014/350185
   Rezaei M., 2003, 44 SCAND C SIM MOD S
   Royer Sebastien, 2011, CATALYTIC OXIDATION, P24
   Santos H, 2008, INT J HEAT MASS TRAN, V51, P41, DOI 10.1016/j.ijheatmasstransfer.2007.04.044
   Steffens D., 2003, DIESEL ENGINE ENV
   Stere CE, 2014, ACS CATAL, V4, P666, DOI 10.1021/cs4009286
   Tsinoglou DN, 2004, APPL MATH MODEL, V28, P775, DOI 10.1016/j.apm.2003.12.006
   Wu GJ, 2005, ENERG CONVERS MANAGE, V46, P2010, DOI 10.1016/j.enconman.2004.11.001
NR 24
TC 5
Z9 5
U1 9
U2 76
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD APR 6
PY 2019
VL 197
BP 135
EP 149
DI 10.1016/j.ces.2018.12.009
PG 15
WC Engineering, Chemical
SC Engineering
GA HK0ZQ
UT WOS:000457634000012
DA 2020-05-12
ER

PT J
AU Turchi, M
   Cai, Q
   Lian, GP
AF Turchi, Mattia
   Cai, Qiong
   Lian, Guoping
TI An evaluation of in-silico methods for predicting solute partition in
   multiphase complex fluids - A case study of octanol/water partition
   coefficient
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Partition coefficient; Complex formulations; MD simulations; COSMOmic;
   Octanol-water
ID MOLECULAR-DYNAMICS SIMULATIONS; LIMITING ACTIVITY-COEFFICIENTS;
   STRATUM-CORNEUM PERMEABILITY; MICROSCOPIC DIFFUSION-MODEL; AUXILIARY
   BASIS-SETS; COSMO-RS; DRUG-DELIVERY; FORCE-FIELD; WATER; UNIFAC
AB Solute partition in multiphase fluids is an important thermodynamic phenomenon and performance attribute for a wide range of product formulations of foods, pharmaceuticals and cosmetics. Experimental evaluation of partition coefficients in complex product formulations is empirical, difficult and time consuming. In-silico methods such as fragment constant method and group contribution method require parameter fitting to the experimental data and are limited to relatively simple fluids. Recently, a method combining molecular dynamics (MD) and quantum chemical (QC) calculation of screening charge density function has been reported. The method does not only use fundamental properties of intermolecular force and charge density function, which does not require parameter fitting to the experimental data, but also applies to complex fluid structures such as micelles. In this work, the predictive accuracy of the combined method of MD and QC is evaluated. Using widely available octanol-water partition coefficients as a case study, the performance of the combined MD and COSMOmic for predicting octanol/water partition coefficients has been compared with those of the EPI Suite' fragment constant method, UNIFAC group contribution method and COSMOtherm. The prediction of the combined MD/COSMOmic method is the closest to the best performing fragment constant method which was specifically designed for the octanol-water system. The combined MD/QC method proves to be the most promising and robust method applicable to a wide range of complex structures of multiphase fluid systems. (C) 2018 Published by Elsevier Ltd. All rights reserved.
C1 [Turchi, Mattia; Lian, Guoping] Unilever Res Colworth, Colworth Pk, Sharnbrook MK44 1LQ, Beds, England.
   [Turchi, Mattia; Cai, Qiong; Lian, Guoping] Univ Surrey, Dept Chem & Proc Engn, Guildford GU2 7XH, Surrey, England.
RP Lian, GP (reprint author), Unilever Res Colworth, Colworth Pk, Sharnbrook MK44 1LQ, Beds, England.
EM guoping.lian@unilever.com
RI Cai, Qiong/Q-1751-2018
OI Cai, Qiong/0000-0002-1677-0515
FU EU Hori-zon 2020 research and innovation programme under the Marie
   Sklo-dowska-Curie grant [675251]
FX The authors appreciate the financial support provided by the EU Hori-zon
   2020 research and innovation programme under the Marie Sklo-dowska-Curie
   grant agreement No 675251. Computational resources have been provided by
   Unilever Research & Development Port Sunlight Laboratory. MACRO-EXCEL
   script for UNIFAC calculations has been provided by prof. Jens
   Abildskov. (DTU CHEMICAL ENGINEERING Department of Chemical and
   Biochemical Engineering).
CR [Anonymous], 2014, TURBOMOLE VERS 6 6
   [Anonymous], 2006, U S EPI SUITE REV PA
   Arp HPH, 2006, ENVIRON SCI TECHNOL, V40, P7298, DOI 10.1021/es060744y
   BECKE AD, 1988, PHYS REV A, V38, P3098, DOI 10.1103/PhysRevA.38.3098
   Bittermann K, 2016, CHEMOSPHERE, V144, P382, DOI 10.1016/j.chemosphere.2015.08.065
   Bittermann K, 2014, J PHYS CHEM B, V118, P14833, DOI 10.1021/jp509348a
   Bonomi M, 2009, COMPUT PHYS COMMUN, V180, P1961, DOI 10.1016/j.cpc.2009.05.011
   Chen CS, 2016, IND ENG CHEM RES, V55, P9284, DOI 10.1021/acs.iecr.6b02040
   Chen LJ, 2015, PHARM RES-DORDR, V32, P1779, DOI 10.1007/s11095-014-1575-0
   Cock PJA, 2009, BIOINFORMATICS, V25, P1422, DOI 10.1093/bioinformatics/btp163
   Dhakal P, 2018, J CHEM ENG DATA, V63, P2586, DOI 10.1021/acs.jced.7b01080
   Dhakal P, 2018, J CHEM ENG DATA, V63, P352, DOI 10.1021/acs.jced.7b00748
   Dhakal P, 2018, FLUID PHASE EQUILIBR, V470, P232, DOI 10.1016/j.fluid.2017.11.024
   Eckert F, 2002, AICHE J, V48, P369, DOI 10.1002/aic.690480220
   Eichkorn K, 1997, THEOR CHEM ACC, V97, P119, DOI 10.1007/s002140050244
   EICHKORN K, 1995, CHEM PHYS LETT, V240, P283, DOI 10.1016/0009-2614(95)00621-A
   FREDENSLUND A, 1977, IND ENG CHEM PROC DD, V16, P450, DOI 10.1021/i260064a004
   FREDENSLUND A, 1975, AICHE J, V21, P1086, DOI 10.1002/aic.690210607
   Gmehling J, 1998, IND ENG CHEM RES, V37, P4876, DOI 10.1021/ie980347z
   Gnap M, 2018, FLUID PHASE EQUILIBR, V470, P241, DOI 10.1016/j.fluid.2018.01.032
   Gonzalez HE, 2007, AICHE J, V53, P1620, DOI 10.1002/aic.11171
   Hansch C., 1995, EXPLORING QSAR HYDRO
   Hansen N, 2013, J CHEM THEORY COMPUT, V9, P1334, DOI 10.1021/ct300933y
   Hess B, 2008, J CHEM THEORY COMPUT, V4, P435, DOI 10.1021/ct700301q
   Heynderickx PM, 2014, FLUID PHASE EQUILIBR, V367, P22, DOI 10.1016/j.fluid.2014.01.017
   Hsieh CM, 2010, FLUID PHASE EQUILIBR, V297, P90, DOI 10.1016/j.fluid.2010.06.011
   Huang WJ, 2015, J PHYS CHEM B, V119, P5588, DOI 10.1021/acs.jpcb.5b01291
   Ingram T, 2013, LANGMUIR, V29, P3527, DOI 10.1021/la305035b
   Itoh SG, 2011, PROTEINS, V79, P3420, DOI 10.1002/prot.23176
   Jakobtorweihen S, 2014, J CHEM PHYS, V141, DOI 10.1063/1.4890877
   Jakobtorweihen S, 2013, J COMPUT CHEM, V34, P1332, DOI 10.1002/jcc.23262
   Jo S, 2009, BIOPHYS J, V97, P50, DOI 10.1016/j.bpj.2009.04.013
   KLAMT A, 1995, J PHYS CHEM-US, V99, P2224, DOI 10.1021/j100007a062
   Klamt A, 1998, J PHYS CHEM A, V102, P5074, DOI 10.1021/jp980017s
   Klamt A, 2008, J PHYS CHEM B, V112, P12148, DOI 10.1021/jp801736k
   Klamt A, 2009, FLUID PHASE EQUILIBR, V285, P15, DOI 10.1016/j.fluid.2009.05.010
   Klauda JB, 2010, J PHYS CHEM B, V114, P7830, DOI 10.1021/jp101759q
   Kwon JH, 2006, ENVIRON TOXICOL CHEM, V25, P1984, DOI 10.1897/05-550R.1
   Lang BE, 2012, J CHEM ENG DATA, V57, P2221, DOI 10.1021/je3001427
   LARSEN BL, 1987, IND ENG CHEM RES, V26, P2274, DOI 10.1021/ie00071a018
   Lian GP, 2004, J CONTROL RELEASE, V98, P139, DOI 10.1016/j.jconrel.2004.04.017
   Lian GP, 2008, J PHARM SCI-US, V97, P584, DOI 10.1002/jps.21074
   MacKerell AD, 1998, J PHYS CHEM B, V102, P3586, DOI 10.1021/jp973084f
   Madene A, 2006, INT J FOOD SCI TECH, V41, P1, DOI 10.1111/j.1365-2621.2005.00980.x
   Martinez L, 2009, J COMPUT CHEM, V30, P2157, DOI 10.1002/jcc.21224
   Martyna GJ, 1996, MOL PHYS, V87, P1117, DOI 10.1080/00268979650027054
   Mitragotri S, 2003, J CONTROL RELEASE, V86, P69, DOI 10.1016/S0168-3659(02)00321-8
   Mokrushina L, 2007, IND ENG CHEM RES, V46, P6501, DOI 10.1021/ie0704849
   Morrow BH, 2013, LANGMUIR, V29, P14823, DOI 10.1021/la403398n
   Mulqueen P, 2003, ADV COLLOID INTERFAC, V106, P83, DOI 10.1016/S0001-8686(03)00106-4
   NOSE S, 1983, MOL PHYS, V50, P1055, DOI 10.1080/00268978300102851
   Okamoto Y, 2004, J MOL GRAPH MODEL, V22, P425, DOI 10.1016/j.jmgm.2003.12.009
   Ostergaard J, 2003, ELECTROPHORESIS, V24, P1038, DOI 10.1002/elps.200390120
   PARRINELLO M, 1981, J APPL PHYS, V52, P7182, DOI 10.1063/1.328693
   PERDEW JP, 1986, PHYS REV B, V33, P8822, DOI 10.1103/PhysRevB.33.8822
   Poole SK, 2000, J CHROMATOGR B, V745, P117, DOI 10.1016/S0378-4347(00)00072-4
   Rai VK, 2018, J CONTROL RELEASE, V270, P203, DOI 10.1016/j.jconrel.2017.11.049
   Sangster J., 1993, LOGKOW DATABANK EVAL
   SCHAFER A, 1994, J CHEM PHYS, V100, P5829, DOI 10.1063/1.467146
   Simoni LD, 2008, IND ENG CHEM RES, V47, P256, DOI 10.1021/ie070956j
   Storm S, 2014, J PHYS CHEM B, V118, P3593, DOI 10.1021/jp410636w
   Storrn S, 2013, LANGMUIR, V29, P11582, DOI 10.1021/la402415b
   TOMASI J, 1994, CHEM REV, V94, P2027, DOI 10.1021/cr00031a013
   Turchi M, 2017, COMPUT-AIDED CHEM EN, V40C, P2773, DOI 10.1016/B978-0-444-63965-3.50464-5
   Valko K, 2003, J PHARM SCI-US, V92, P2236, DOI 10.1002/jps.10494
   Valko K, 1997, ANAL CHEM, V69, P2022, DOI 10.1021/ac961242d
   Vogt A, 2016, J CONTROL RELEASE, V242, P3, DOI 10.1016/j.jconrel.2016.07.027
   Wang TF, 2006, J PHARM SCI-US, V95, P620, DOI 10.1002/jps.20509
   Wang TF, 2007, J PHARM SCI-US, V96, P3024, DOI 10.1002/jps.20883
   Yordanova D, 2017, J PHYS CHEM B, V121, P5794, DOI 10.1021/acs.jpcb.7b03147
   Yordanova D, 2015, J CHEM THEORY COMPUT, V11, P2329, DOI 10.1021/acs.jctc.5b00026
NR 71
TC 4
Z9 4
U1 4
U2 22
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD APR 6
PY 2019
VL 197
BP 150
EP 158
DI 10.1016/j.ces.2018.12.003
PG 9
WC Engineering, Chemical
SC Engineering
GA HK0ZQ
UT WOS:000457634000013
DA 2020-05-12
ER

PT J
AU Islam, ASMA
   Bergstrom, DJ
AF Islam, A. S. M. Atiqul
   Bergstrom, D. J.
TI Modelling bubble induced turbulence for gas-liquid bubbly flow in a
   vertical pipe
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Two-fluid model; Gas-liquid bubbly flow; Turbulence modulation; Gas
   volume fraction; Low Reynolds number model
ID PHASE DISTRIBUTION; SIMULATION; PREDICTION; WALL; COLUMN; VALIDATION;
   UNIFORM; FORCES
AB A two-fluid model in the Eulerian-Eulerian framework has been implemented for the turbulent gas-liquid bubbly upward flow in a vertical pipe. The transport equations, i.e. Reynolds-Averaged Navier-Stokes equations for the two-fluid model, are discretized using the finite volume method. The effect of the disperse gas phase on the liquid phase turbulence, referred to as turbulence modulation, was accounted for through source terms in the transport equations for a low Reynolds number k - epsilon turbulence closure. The model was used to predict the turbulence kinetic energy and its dissipation rate, mean phasic velocities and volume fraction distribution for a set of test cases selected from the available literature. The focus of the present study was on assessing the model predictions using measurements of the turbulence kinetic energy of the liquid phase. A relatively novel aspect of the present analysis is the use of the budgets of the transport equations for the turbulence kinetic energy and dissipation rate to assess the effect of the turbulence modulation on the liquid turbulence field. Although the present model formulation is shown to adequately predict the effect of bubbles in some flows and perform better than some of the other model formulations, the overall conclusion is that the present approaches for incorporating turbulence modulation are at best partially successful and still need further development. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Islam, A. S. M. Atiqul; Bergstrom, D. J.] Univ Saskatchewan, Dept Mech Engn, Saskatoon, SK S7N 5A9, Canada.
RP Bergstrom, DJ (reprint author), Dept Mech Engn, Room 1A06,Engn Bldg,57 Campus Dr, Saskatoon, SK S7N 5A9, Canada.
EM don.bergstrom@usask.ca
FU Natural Sciences and Engineering Research Council of Canada
   (NSERC)Natural Sciences and Engineering Research Council of Canada
FX The authors are grateful to the Natural Sciences and Engineering
   Research Council of Canada (NSERC) for providing financial assistance
   for this research project.
CR ANTAL SP, 1991, INT J MULTIPHAS FLOW, V17, P635, DOI 10.1016/0301-9322(91)90029-3
   Brennen C. E., 2005, FUNDAMENTALS MULTIPH
   Colombo M, 2015, INT J MULTIPHAS FLOW, V77, P222, DOI 10.1016/j.ijmultiphaseflow.2015.09.003
   Dhotre MT, 2007, CHEM ENG SCI, V62, P7140, DOI 10.1016/j.ces.2007.08.016
   Drew D.A., 1998, THEORY MULTICOMPONEN
   Ekambara K, 2005, CHEM ENG SCI, V60, P6733, DOI 10.1016/j.ces.2005.05.047
   Frank T, 2008, NUCL ENG DES, V238, P647, DOI 10.1016/j.nucengdes.2007.02.056
   Hibiki T, 2001, INT J HEAT MASS TRAN, V44, P1869, DOI 10.1016/S0017-9310(00)00232-5
   Hosokawa S, 2009, CHEM ENG SCI, V64, P5308, DOI 10.1016/j.ces.2009.09.017
   Islam ASMA, 2016, INT J MULTIPHAS FLOW, V85, P236, DOI 10.1016/j.ijmultiphaseflow.2016.06.010
   Krepper E, 2005, NUCL ENG DES, V235, P597, DOI 10.1016/j.nucengdes.2004.09.006
   LAHEY RT, 1993, NUCL ENG DES, V141, P177, DOI 10.1016/0029-5493(93)90101-E
   Liao Y.S., 2013, THESIS
   Liu T. J., 1998, P 3 INT C MULT FLOW
   Liu TJ, 1997, INT J MULTIPHAS FLOW, V23, P1085, DOI 10.1016/S0301-9322(97)00030-X
   Lucas D, 2007, CHEM ENG SCI, V62, P4146, DOI 10.1016/j.ces.2007.04.035
   Lucas D, 2005, INT J MULTIPHAS FLOW, V31, P1304, DOI 10.1016/j.ijmultiphaseflow.2005.07.004
   Lucas D, 2001, INT J THERM SCI, V40, P217, DOI 10.1016/S1290-0729(00)01211-4
   Ma T, 2017, PHYS REV FLUIDS, V2, DOI 10.1103/PhysRevFluids.2.034301
   Masood RMA, 2014, CHEM ENG SCI, V108, P154, DOI 10.1016/j.ces.2014.01.004
   Monahan SM, 2009, IND ENG CHEM RES, V48, P8134, DOI 10.1021/ie801202x
   MYONG HK, 1990, JSME INT J II-FLUID, V33, P63, DOI 10.1299/jsmeb1988.33.1_63
   Patankar S.V., 1980, NUMERICAL HEAT TRANS
   Pfleger D, 2001, CHEM ENG SCI, V56, P1737, DOI 10.1016/S0009-2509(00)00403-6
   Prasser HM, 2007, NUCL ENG DES, V237, P1848, DOI 10.1016/j.nucengdes.2007.02.018
   Rzehak R, 2013, INT J MULTIPHAS FLOW, V55, P138, DOI 10.1016/j.ijmultiphaseflow.2013.04.007
   Rzehak R, 2012, NUCL ENG DES, V253, P41, DOI 10.1016/j.nucengdes.2012.07.009
   Santarelli C, 2016, CHEM ENG SCI, V141, P46, DOI 10.1016/j.ces.2015.10.013
   Sato Y., 1975, International Journal of Multiphase Flow, V2, P79, DOI 10.1016/0301-9322(75)90030-0
   Shawkat ME, 2008, INT J MULTIPHAS FLOW, V34, P767, DOI 10.1016/j.ijmultiphaseflow.2008.01.007
   Tomiyama A, 1995, MULTIPHASE FLOW 1995, P3
   Tomiyama A., 1998, 3 INT C MULT FLOW LY
   Troshko AA, 2001, INT J MULTIPHAS FLOW, V27, P1965, DOI 10.1016/S0301-9322(01)00043-X
   Vitankar VS, 2002, CHEM ENG SCI, V57, P3235, DOI 10.1016/S0009-2509(02)00196-3
   WELLEK RM, 1966, AICHE J, V12, P854, DOI 10.1002/aic.690120506
   Yao W, 2004, INT J HEAT MASS TRAN, V47, P307, DOI 10.1016/j.ijheatmasstransfer.2003.06.004
   Ziegenhein T, 2015, CHEM ENG SCI, V122, P1, DOI 10.1016/j.ces.2014.09.022
   Ziegenhein T, 2017, CAN J CHEM ENG, V95, P170, DOI 10.1002/cjce.22647
   Ziegenhein T, 2013, CHEM-ING-TECH, V85, P1080, DOI 10.1002/cite.201200223
   ZUN I, 1980, INT J MULTIPHAS FLOW, V6, P583, DOI 10.1016/0301-9322(80)90053-1
NR 40
TC 0
Z9 0
U1 1
U2 7
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD APR 6
PY 2019
VL 197
BP 159
EP 171
DI 10.1016/j.ces.2018.11.061
PG 13
WC Engineering, Chemical
SC Engineering
GA HK0ZQ
UT WOS:000457634000014
DA 2020-05-12
ER

PT J
AU Zhou, H
   Jing, S
   Yu, X
   Zhou, H
   Lan, WJ
   Li, SW
AF Zhou, Hao
   Jing, Shan
   Yu, Xiong
   Zhou, Han
   Lan, Wenjie
   Li, Shaowei
TI Study of droplet breakage in a pulsed disc and doughnut column-Part I:
   Experiments and correlations
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Population balance model; Pulsed disc and doughnut column; Droplet
   breakup; Physical properties
ID SIMULATION; SIZE; HYDRODYNAMICS; PERFORMANCE; VISCOSITY; MODEL
AB We have developed a direct measurement method for the breakage of droplet swarm in our previous work. However, experimental data for droplet breakage is still extremely indispensable for the development and employment of population balance model (PBM). In this paper, the direct measurement of droplet breakage for a series of liquid-liquid systems has been carried out in a pulsed disc and doughnut column (PDDC) to meet the requirement. The data together with that in our previous work cover the main factors affecting the droplet breakage in the PDDC and are sufficient to support the establishment of useful empirical correlations for breakup frequency and daughter droplet size distribution. The experimental results and correlations all indicate that the breakup frequency function increases as the dispersed-phase viscosity or the interfacial tension decreases. The daughter droplet size distribution broadens considerably with decreasing interfacial tension. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Zhou, Hao; Jing, Shan; Yu, Xiong; Zhou, Han; Li, Shaowei] Tsinghua Univ, Inst Nucl & New Energy Technol, Collaborat Innovat Ctr Adv Nucl Energy Technol, Beijing 100084, Peoples R China.
   [Lan, Wenjie] China Univ Petr, State Key Lab Heavy Oil Proc, Beijing 102249, Peoples R China.
   [Li, Shaowei] Tsinghua Univ, State Key Lab Chem Engn, Beijing 100084, Peoples R China.
RP Jing, S; Li, SW (reprint author), Tsinghua Univ, Inst Nucl & New Energy Technol, Collaborat Innovat Ctr Adv Nucl Energy Technol, Beijing 100084, Peoples R China.
EM s-jing@tsinghua.edu.cn; lsw@tsinghua.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [21576147, 21776151, 21376132]
FX We gratefully acknowledge the support of the National Natural Science
   Foundation of China (21576147, 21776151, 21376132).
CR Abidin MIIZ, 2015, AICHE J, V61, P1129, DOI 10.1002/aic.14751
   Andersson R, 2006, AICHE J, V52, P2020, DOI 10.1002/aic.10831
   ANGELOV G, 1990, CHEM ENG J BIOCH ENG, V45, P87, DOI 10.1016/0300-9467(90)80031-7
   Angelov G, 1998, CHEM ENG J, V71, P1, DOI 10.1016/S1385-8947(98)00111-9
   Becker PJ, 2014, CHEM ENG SCI, V109, P326, DOI 10.1016/j.ces.2014.02.008
   Becker PJ, 2014, CAN J CHEM ENG, V92, P296, DOI 10.1002/cjce.21885
   BILLERBECK CJ, 1956, IND ENG CHEM, V48, P183, DOI 10.1021/ie50554a012
   CALABRESE RV, 1986, AICHE J, V32, P657, DOI 10.1002/aic.690320416
   COULALOGLOU CA, 1977, CHEM ENG SCI, V32, P1289, DOI 10.1016/0009-2509(77)85023-9
   Han LC, 2015, AICHE J, V61, P2147, DOI 10.1002/aic.14830
   Jahya AB, 2009, SOLVENT EXTR ION EXC, V27, P63, DOI 10.1080/07366290802544734
   Kumar A, 1996, IND ENG CHEM RES, V35, P2682, DOI 10.1021/ie950674w
   Kumar R., 2013, ISRN CHEM ENG, V2013
   Liu HQ, 2016, IND ENG CHEM RES, V55, P2242, DOI 10.1021/acs.iecr.5b04661
   Luo H, 1996, AICHE J, V42, P1225, DOI 10.1002/aic.690420505
   Maass S, 2012, CHEM ENG SCI, V70, P146, DOI 10.1016/j.ces.2011.08.027
   MILOT JF, 1990, CHEM ENG J BIOCH ENG, V45, P111, DOI 10.1016/0300-9467(90)80033-9
   Sathyagal AN, 1996, CHEM ENG SCI, V51, P1377, DOI 10.1016/0009-2509(95)00311-8
   Schmidt SA, 2006, CHEM ENG SCI, V61, P246, DOI 10.1016/j.ces.2005.02.075
   Solsvik J, 2015, CHEM ENG SCI, V131, P219, DOI 10.1016/j.ces.2015.03.059
   Solsvik J, 2013, REV CHEM ENG, V29, P241, DOI 10.1515/revce-2013-0009
   Torab-Mostaedi M, 2011, BRAZ J CHEM ENG, V28, P447, DOI 10.1590/S0104-66322011000300010
   Torab-Mostaedi M, 2011, BRAZ J CHEM ENG, V28, P313, DOI 10.1590/S0104-66322011000200016
   Torab-Mostaedi M, 2011, CHEM ENG RES DES, V89, P2742, DOI 10.1016/j.cherd.2011.06.006
   Torab-Mostaedi M, 2011, CHEM IND CHEM ENG Q, V17, P333, DOI 10.2298/CICEQ110123019T
   WANG CY, 1986, AICHE J, V32, P667, DOI 10.1002/aic.690320417
   Zhao L, 2014, CHEM ENG J, V253, P93, DOI 10.1016/j.cej.2014.04.082
   Zhou H, 2017, AICHE J, V63, P4188, DOI 10.1002/aic.15742
NR 28
TC 2
Z9 2
U1 2
U2 13
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD APR 6
PY 2019
VL 197
BP 172
EP 183
DI 10.1016/j.ces.2018.12.017
PG 12
WC Engineering, Chemical
SC Engineering
GA HK0ZQ
UT WOS:000457634000015
DA 2020-05-12
ER

PT J
AU Sui, H
   Liu, JJ
   He, L
   Li, XG
   Jani, A
AF Sui, Hong
   Liu, Jijiang
   He, Lin
   Li, Xingang
   Jani, Ammi
TI Adsorption and desorption of binary mixture of acetone and ethyl acetate
   on silica gel
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE VSA-TSA combined process; Bi-component competitive adsorption; Acetone;
   Ethyl acetate; Silica gel
ID PRESSURE SWING ADSORPTION; VOLATILE ORGANIC-COMPOUNDS; VOCS; REMOVAL;
   TEMPERATURE; RECOVERY; EMISSIONS; OXIDATION; NITROGEN; TOLUENE
AB Adsorption and desorption of acetone and ethyl acetate (two typical oxygenated VOCs) on silica gel have been systematically studied by vacuum swing adsorption (VSA) combined with temperature swing adsorption (TSA) process. It is found that the adsorption of both the oxygenated VOC compounds on silica gel could be well described by the Langmuir-Freundlich model. Although highly dependent on the operational parameters, the adsorption of both the oxygenated VOC compounds on silica gel is found to be controlled by external diffusion. When the two compounds are mixed, the adsorbed acetone is found to be partially replaced by the ethyl acetate when the adsorption approaches the saturation due to the stronger affinity of ethyl acetate to silica gel. It also suggests that there is a competitive adsorption between ethyl acetate and acetone. Further modeling demonstrates that the whole kinetic adsorption of binary oxygenated components could be divided into three steps: the free adsorption, the competitive adsorption and the equilibrium state. The final ratio of adsorbed acetone to ethyl acetate on silica gel is dependent on the adsorption bed height. The adsorbed oxygenated VOCs on silica gel are observed to be desorbed by vacuum pumping, which is also found to be significantly enhanced by increasing temperature (by similar to 30 degrees C), achieving over 2.5 times of concentration increase in the desorbed gas stream. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Sui, Hong; Liu, Jijiang; He, Lin; Li, Xingang] Tianjin Univ, Sch Chem Engn & Technol, Tianjin 300072, Peoples R China.
   [Sui, Hong; Liu, Jijiang; Li, Xingang] Natl Engn Res Ctr Distillat Technol, Tianjin 300072, Peoples R China.
   [Sui, Hong; Liu, Jijiang; He, Lin; Li, Xingang] Collaborat Innovat Ctr Chem Sci & Engn Tianjin, Tianjin 300072, Peoples R China.
   [Jani, Ammi] Univ Western Ontario, Dept Chem & Biochem Engn, London, ON N6A 3K7, Canada.
RP He, L (reprint author), Tianjin Univ, Sch Chem Engn & Technol, Tianjin 300072, Peoples R China.
EM linhe@tju.edu.cn
OI He, Lin/0000-0002-0125-7401
FU Science and Technology Program of Tianjin, China [17ZXSTSF00070];
   International S&T Cooperation Program of China, ISTCP [2015DFR40910]
FX This work was financially supported by Science and Technology Program of
   Tianjin, China (No. 17ZXSTSF00070) and International S&T Cooperation
   Program of China, ISTCP (No. 2015DFR40910).
CR Acharya J, 2009, CHEM ENG J, V150, P25, DOI 10.1016/j.cej.2008.11.035
   Alonso C, 1998, ENVIRON SCI TECHNOL, V32, P3118, DOI 10.1021/es9711021
   Bernstein JA, 2008, J ALLERGY CLIN IMMUN, V121, P585, DOI 10.1016/j.jaci.2007.10.045
   Blasin-Aube V, 2003, APPL CATAL B-ENVIRON, V43, P175, DOI 10.1016/S0926-3373(02)00302-8
   Chen YS, 2002, IND ENG CHEM RES, V41, P1583, DOI 10.1021/ie010752h
   Chiang YC, 2001, CARBON, V39, P523, DOI 10.1016/S0008-6223(00)00161-5
   Chuang CL, 2003, CHEMOSPHERE, V53, P17, DOI 10.1016/S0045-6535(03)00357-6
   DIJT JC, 1990, COLLOID SURFACE, V51, P141, DOI 10.1016/0166-6622(90)80138-T
   Grande CA, 2005, IND ENG CHEM RES, V44, P8815, DOI 10.1021/ie050671b
   Gupta VK, 2002, CHEM ENG SCI, V57, P2679, DOI 10.1016/S0009-2509(02)00158-6
   Ho YS, 1999, PROCESS BIOCHEM, V34, P451, DOI 10.1016/S0032-9592(98)00112-5
   JOYNER LG, 1951, J AM CHEM SOC, V73, P3155, DOI 10.1021/ja01151a046
   Liu YJ, 1998, SEPAR SCI TECHNOL, V33, P2431, DOI 10.1080/01496399808545313
   Mason JA, 2011, ENERG ENVIRON SCI, V4, P3030, DOI 10.1039/c1ee01720a
   Namba S., 2000, STUD SURF SCI CATAL, V129, P757, DOI [10.1016/S0167-2991(00)80280-3, DOI 10.1016/S0167-2991(00)80280-3]
   Novoa JJ, 1998, CHEM PHYS LETT, V290, P519, DOI 10.1016/S0009-2614(98)00525-9
   Parida SK, 2006, ADV COLLOID INTERFAC, V121, P77, DOI 10.1016/j.cis.2006.05.028
   Ramalingam SG, 2011, J HAZARD MATER, V198, P95, DOI 10.1016/j.jhazmat.2011.10.019
   Ravikovitch PI, 2002, LANGMUIR, V18, P1550, DOI 10.1021/la0107594
   Saldarriaga JF, 2014, ENVIRON ENG SCI, V31, P300, DOI 10.1089/ees.2013.0475
   Serbezov A, 1998, ADSORPTION, V4, P93, DOI 10.1023/A:1008819001197
   Simo M, 2008, COMPUT CHEM ENG, V32, P1635, DOI 10.1016/j.compchemeng.2007.07.011
   SING KSW, 1985, PURE APPL CHEM, V57, P603, DOI 10.1351/pac198557040603
   Sivasankar V, 2013, CHEM ENG J, V214, P45, DOI 10.1016/j.cej.2012.10.023
   Steiner T, 1998, CHEM COMMUN, P891, DOI 10.1039/a708099i
   Stout R.L., 2000, APPL POLYM SCI 21 CE, DOI DOI 10.1016/B978-008043417-9/50030-1
   Sui H, 2017, J TAIWAN INST CHEM E, V74, P218, DOI 10.1016/j.jtice.2017.02.019
   Sui H, 2017, CHEM ENG J, V316, P232, DOI 10.1016/j.cej.2017.01.061
   Swetha G, 2017, CHEM ENG RES DES, V117, P725, DOI 10.1016/j.cherd.2016.11.036
   Thommes M, 2006, LANGMUIR, V22, P756, DOI 10.1021/la051686h
   Thommes M, 2015, PURE APPL CHEM, V87, P1051, DOI 10.1515/pac-2014-1117
   Wei W, 2014, FRONT ENV SCI ENG, V8, P27, DOI 10.1007/s11783-012-0461-4
   Zhang XP, 2010, CARBON, V48, P2317, DOI 10.1016/j.carbon.2010.03.008
   Zhang XY, 2017, J HAZARD MATER, V338, P102, DOI 10.1016/j.jhazmat.2017.05.013
NR 34
TC 7
Z9 7
U1 11
U2 84
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD APR 6
PY 2019
VL 197
BP 185
EP 194
DI 10.1016/j.ces.2018.12.010
PG 10
WC Engineering, Chemical
SC Engineering
GA HK0ZQ
UT WOS:000457634000017
DA 2020-05-12
ER

PT J
AU Basu, S
   Sarkar, J
AF Basu, Surita
   Sarkar, Jayati
TI Miniaturization of surface patterns in soft elastic film over patterned
   substrates
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Miniaturization; Patterned substrates; Waterlily leaf replica; CD
   replica; Pattern formation; Adhesion and debonding
ID CONTACT INSTABILITY; THIN-FILMS; LITHOGRAPHY; ADHESION; FABRICATION;
   TOPOGRAPHY; CAST
AB In this experimental study results reveal the formation of miniaturized surface morphologies over a soft thin elastic film of micron range thickness (h), when cast on various patterned substrates created from: naturally available intrinsically rough water lily leaves, commercially available sinusoidally patterned compact disks and cubic boxes created by electron beam lithography. The evolving surface patterns formed had varying structures of columns to labyrinth to cavities during the adhesion and debonding cycle, irrespective of which the engendered dominant wavelength (lambda) remained at a minuscule length scale that was found to be much less than that obtained on flat substrates. It was observed experimentally that the length scales of the patterns formed decreased linearly with increase in substrate amplitude and regardless of the substrate pattern geometry used depended solely on its RMS roughness such that lambda/h = 2.96-18.2*(RMS/h). The study indicates the redundancy in creating very costly regular geometrical patterned substrates for miniaturization and instead advocates the use of intrinsically rough natural surface replicas to be used as patterned substrates for cost-effective fabrication of miniaturized surface patterns at such soft interfaces. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Basu, Surita; Sarkar, Jayati] Indian Inst Technol, Dept Chem Engn, Hauz Khas, New Delhi, India.
RP Sarkar, J (reprint author), Indian Inst Technol, Dept Chem Engn, Hauz Khas, New Delhi, India.
EM jayati@chemical.iitd.ac.in
CR Annepu H, 2014, LANGMUIR, V30, P12278, DOI 10.1021/la502933c
   Annepu H, 2014, MODEL SIMUL MATER SC, V22, DOI 10.1088/0965-0393/22/5/055003
   Annepu H, 2012, PHYS REV E, V86, DOI 10.1103/PhysRevE.86.051604
   Arun N, 2007, J ADHESION, V83, P513, DOI 10.1080/00218460701453486
   Arun N, 2006, ADV MATER, V18, P660, DOI 10.1002/adma.200502199
   Chung JY, 2006, EUR PHYS J E, V20, P47, DOI 10.1140/epje/i2005-10080-0
   Das AL, 2007, ADV MATER, V19, P1943, DOI 10.1002/adma.200602681
   Findenegg G. H., 1986, CHEMIE, V90, P1241
   Gao LC, 2006, LANGMUIR, V22, P2966, DOI 10.1021/la0532149
   Ghatak A, 2000, PHYS REV LETT, V85, P4329, DOI 10.1103/PhysRevLett.85.4329
   Ghatak A, 2006, PHYS REV E, V73, DOI 10.1103/PhysRevE.73.041601
   Ghatak A, 2004, P ROY SOC A-MATH PHY, V460, P2725, DOI 10.1098/rspa.2004.1313
   Ghatak A, 2003, LANGMUIR, V19, P2621, DOI 10.1021/la026932t
   Gonuguntla M., 2006, PHYS REV LETT, V97, P1
   Gonuguntla M, 2006, LANGMUIR, V22, P7066, DOI 10.1021/la0600696
   Guo LJ, 2007, ADV MATER, V19, P495, DOI 10.1002/adma.200600882
   Kotni TR, 2017, J PHYS-CONDENS MAT, V29, DOI 10.1088/1361-648X/aa62d9
   Kotni TR, 2014, PHYS REV E, V90, DOI 10.1103/PhysRevE.90.020401
   Lahiri J, 1999, LANGMUIR, V15, P2055, DOI 10.1021/la9811970
   Lee KJ, 2005, ADV FUNCT MATER, V15, P557, DOI 10.1002/adfm.200400189
   Mishra S, 2017, INT J ADHES ADHES, V79, P102, DOI 10.1016/j.ijadhadh.2017.09.013
   Monch W, 2001, EUROPHYS LETT, V53, P525, DOI 10.1209/epl/i2001-00184-7
   Moore GE, 1998, P IEEE, V86, P82, DOI 10.1109/JPROC.1998.658762
   Mukherjee R, 2007, J CHEM PHYS, V127, DOI 10.1063/1.2752499
   Mukherjee R, 2008, B MATER SCI, V31, P249, DOI 10.1007/s12034-008-0043-z
   Mukherjee R, 2007, ADV FUNCT MATER, V17, P2356, DOI 10.1002/adfm.200600896
   Norman J, 2006, ANN BIOMED ENG, V34, P89, DOI 10.1007/s10439-005-9005-4
   Park SI, 2015, NAT BIOTECHNOL, V33, P1280, DOI 10.1038/nbt.3415
   Rajurkar KP, 2006, CIRP ANN-MANUF TECHN, V55, P643, DOI 10.1016/j.cirp.2006.10.002
   Sarkar J, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.018302
   Sarkar J, 2003, PHYS REV E, V67, DOI 10.1103/PhysRevE.67.031607
   Sarkar J, 2005, LANGMUIR, V21, P1457, DOI 10.1021/la048061o
   Sarkar J., 2016, SIMULATING CONTACT I
   Sarkar J., 2005, J ADHESION, V81, P1
   Sarkar J, 2011, J ADHESION, V87, P214, DOI 10.1080/00218464.2011.557332
   Sarkar J, 2010, LANGMUIR, V26, P8464, DOI 10.1021/la9049007
   Sarkar J, 2008, PHYS REV E, V77, DOI 10.1103/PhysRevE.77.031604
   Shenhar R., 2004, Introduction to nanoscale science and technology, P41, DOI 10.1007/1-4020-7757-2_3
   Shenoy V, 2002, J MECH PHYS SOLIDS, V50, P1155, DOI 10.1016/S0022-5096(01)00109-0
   Shenoy V, 2001, PHYS REV LETT, V86, P119, DOI 10.1103/PhysRevLett.86.119
   Spanhel L, 2006, J SOL-GEL SCI TECHN, V39, P7, DOI 10.1007/s10971-006-7302-5
   Tomar G, 2007, PHYS REV E, V76, DOI 10.1103/PhysRevE.76.011607
   Ueda E., 2013, ADV MATER, V25, P1368
   Wu MC, 1997, P IEEE, V85, P1833, DOI 10.1109/5.649660
   Xia YN, 1996, SCIENCE, V273, P347, DOI 10.1126/science.273.5273.347
   Yabu H, 2008, POLYM J, V40, P534, DOI 10.1295/polymj.PJ2008022
NR 46
TC 1
Z9 1
U1 1
U2 2
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD APR 6
PY 2019
VL 197
BP 195
EP 203
DI 10.1016/j.ces.2018.12.012
PG 9
WC Engineering, Chemical
SC Engineering
GA HK0ZQ
UT WOS:000457634000018
DA 2020-05-12
ER

PT J
AU Fang, TM
   Wang, MH
   Gao, Y
   Zhang, YN
   Yan, YG
   Zhang, J
AF Fang, Timing
   Wang, Muhan
   Gao, Yang
   Zhang, Yingnan
   Yan, Youguo
   Zhang, Jun
TI Enhanced oil recovery with CO2/N-2 slug in low permeability reservoir:
   Molecular dynamics simulation
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Carbon dioxide; Nitrogen; Molecular dynamics simulation; Slug injection;
   Nanoslit
ID SUPERCRITICAL CARBON-DIOXIDE; INORGANIC NANOPORES; EXTRACTION;
   MECHANISM; VOLUME; SHALE
AB Slug injection of CO2/N-2 has proven to be a promising technology for the enhancement of oil recovery in low/ultra-low permeability reservoirs. In spite of this, the detailed displacement process and interaction mechanisms remain unclear. Adopting molecular dynamic simulations, the displacement behavior of CO2/N-2 flooding was investigated at the molecular and atomic level. It was found that CO2 and N-2 play varying roles: the solubility of CO2 is strong, and the propel effect of N-2 provides an obvious advantage. Furthermore, the synergistic effect of the CO2 slug and N-2 slug was found to be better than single phase injection and even better than mixture gas (flue gas) flooding. Particularly, it shows the best displacement efficiency when CO2 is used as a front slug. This study unveils the underlying mechanism of gas flooding in low permeability reservoirs, and the results may be proved helpfully in providing theoretical support for the optimization of the injection mode. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Fang, Timing; Wang, Muhan; Zhang, Yingnan; Yan, Youguo; Zhang, Jun] China Univ Petr, Sch Mat Sci & Engn, Qingdao 266580, Shandong, Peoples R China.
   [Yan, Youguo; Zhang, Jun] China Univ Petr, Inst Adv Mat, Qingdao 266580, Shandong, Peoples R China.
   [Gao, Yang] Petrochina, Xinjiang Oilfield Co, Res Inst Explorat & Dev, Beijing, Peoples R China.
RP Yan, YG; Zhang, J (reprint author), China Univ Petr, Sch Mat Sci & Engn, Qingdao 266580, Shandong, Peoples R China.
EM zhangjun.upc@gmail.com
OI Wang, Muhan/0000-0001-7786-4825
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [51874332, U1663206, U1762212, 51622405];
   Fundamental Research Funds for the Central UniversitiesFundamental
   Research Funds for the Central Universities [15CX08003A, YCX2017067,
   18CX06006A]
FX This work is financially supported by the National Natural Science
   Foundation of China (51874332, U1663206, U1762212, 51622405), and
   Fundamental Research Funds for the Central Universities (15CX08003A,
   YCX2017067 and 18CX06006A).
CR BOCQUET L, 1994, PHYS REV E, V49, P3079, DOI 10.1103/PhysRevE.49.3079
   Bourg IC, 2012, J PHYS CHEM C, V116, P11556, DOI 10.1021/jp301299a
   Chae K, 2011, J CHEM PHYS, V134, DOI 10.1063/1.3512918
   Crolet J. L., 1990, OFFSH TECHN C OFFSH
   Cygan RT, 2004, J PHYS CHEM B, V108, P1255, DOI 10.1021/jp0363287
   Dai Z, 2013, ENVIRON SCI TECH LET, V1, P49
   Dong T., 2013, AAPG MEMOIR, V102, P67, DOI DOI 10.1306/13391706M1023584
   Du BJ, 2014, GEOSYSTEM ENG, V17, P279, DOI 10.1080/12269328.2014.988297
   Fang TM, 2016, J SUPERCRIT FLUID, V113, P10, DOI 10.1016/j.supflu.2015.09.016
   FISCHER DD, 1984, J PETROL TECHNOL, V36, P96, DOI 10.2118/9719-PA
   GARDNER JW, 1981, J PETROL TECHNOL, V33, P2067, DOI 10.2118/8367-PA
   Gereben O, 2013, J PHYS-CONDENS MAT, V25, DOI 10.1088/0953-8984/25/45/454211
   Gholizadeh R, 2018, CHEM ENG SCI, V184, P62, DOI 10.1016/j.ces.2018.03.045
   Hu HX, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-05758-3
   Karim F, 1992, SPE ROCK MOUNT REG M
   Koretsky CM, 1998, AM J SCI, V298, P349, DOI 10.2475/ajs.298.5.349
   La H, 2015, J SUPERCRIT FLUID, V100, P146, DOI 10.1016/j.supflu.2015.01.020
   Le T, 2016, MOL SIMULAT, V42, P745, DOI 10.1080/08927022.2015.1089991
   Leary J. P., 1979, PETROL ENG INT, V51, P20
   Lee T, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11890
   Liu B, 2017, ENERG FUEL, V31, P738, DOI 10.1021/acs.energyfuels.6b02377
   Liu B, 2015, FUEL, V143, P194, DOI 10.1016/j.fuel.2014.11.046
   Macintyre K. J., 1986, J CANADIAN PETROLEUM, V25, P160
   Manrique E., 2006, SPE DOE S IMPR OIL R
   Mejia A, 2014, J CHEM ENG DATA, V59, P2928, DOI 10.1021/je5000764
   National Institute of Standards and Technology, 2011, THERMOPHYSICAL PROPE
   NOSE S, 1984, MOL PHYS, V52, P255, DOI 10.1080/00268978400101201
   Petzetakis N, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8529
   PLIMPTON S, 1995, J COMPUT PHYS, V117, P1, DOI 10.1006/jcph.1995.1039
   Potoff JJ, 2001, AICHE J, V47, P1676, DOI 10.1002/aic.690470719
   Ronova IA, 2003, MACROMOL THEOR SIMUL, V12, P425, DOI 10.1002/mats.200350002
   Santos MS, 2018, ENERG FUEL, V32, P1934, DOI 10.1021/acs.energyfuels.7b02451
   Sinanan BS, 2012, SPETT 2012 EN C EXH
   Siregar S, 2007, J ENG TECHNOL SCI, V39, P20
   Song C., 2012, SPE CAN UNC RES C
   van Bergen F, 2004, ENERGY, V29, P1611, DOI 10.1016/j.energy.2004.03.063
   Vorobyov I, 2007, J CHEM THEORY COMPUT, V3, P1120, DOI 10.1021/ct600350s
   Wang JY, 2011, J SUPERCRIT FLUID, V58, P272, DOI 10.1016/j.supflu.2011.06.008
   Wang S, 2016, FUEL, V171, P74, DOI 10.1016/j.fuel.2015.12.071
   Whorton LP, 1952, United States patent US, Patent No. [US 2623596 A, 2623596]
   Wu TT, 2016, J SUPERCRIT FLUID, V107, P499, DOI 10.1016/j.supflu.2015.07.005
   Xiao T, 2017, ENERG FUEL, V31, P12487, DOI 10.1021/acs.energyfuels.7b01720
   Xu Z, 2011, COLLOID SURFACE A, V380, P135, DOI 10.1016/j.colsurfa.2011.02.046
   Yan YG, 2017, FUEL, V190, P253, DOI 10.1016/j.fuel.2016.11.019
   Zhang C., 2014, SPE HEAV OIL C CAN
   Zhang JF, 2013, ENERG FUEL, V27, P2741, DOI 10.1021/ef400283n
   Zoete V, 2011, J COMPUT CHEM, V32, P2359, DOI 10.1002/jcc.21816
NR 47
TC 10
Z9 11
U1 7
U2 38
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD APR 6
PY 2019
VL 197
BP 204
EP 211
DI 10.1016/j.ces.2018.12.016
PG 8
WC Engineering, Chemical
SC Engineering
GA HK0ZQ
UT WOS:000457634000019
DA 2020-05-12
ER

PT J
AU Jan, O
   Song, KL
   Dichiara, A
   Resende, FLP
AF Jan, Oliver
   Song, Kunlin
   Dichiara, Anthony
   Resende, Fernando L. P.
TI Oligomerization of supercritical ethylene over nickel-based
   silica-alumina catalysts
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Oligomerization; Ethylene; Supercritical; Nickel; Silica-alumina
ID HETEROGENEOUS OLIGOMERIZATION; NI; ZEOLITE; REACTIVATION; MAINTENANCE;
   EFFICIENT; SITES
AB We used supercritical ethylene as both a solvent and reactant for ethylene oligomerization over silica-alumina catalysts with different pore structures and decorated with Ni nanoparticles namely Ni-H beta and Ni-Al-SBA-15. The catalysts were characterized by electron microscopy, X-ray diffraction, nitrogen physisorption, and Fourier transformed infrared spectroscopy. The effect of pressure and temperature on the overall conversion and product selectivity over Ni-H beta were evaluated in the range from 0.0 to 52.5 bar (partial pressure of ethylene) and 30 to 120 degrees C. At subcritical conditions over Ni-H beta (120 degrees C and 11.2/22.4 bar), the ethylene conversion reached a plateau of around 50% after six hours. By increasing the pressure past the critical point of ethylene, the steady-state conversion significantly increased to 71%. The drastic increase in conversion can be attributed to the high butene and hexene solubilities in supercritical ethylene, promoting the desorption of di- and trimerization products from the catalytic active sites and making those sites available for incoming ethylene molecules. At supercritical conditions, high ethylene conversion (85%) and C4 selectivity (74%) was achieved using Ni-Al-SBA-15 (impregnated mesoporous catalyst), while Ni-H beta (the microporous catalyst) yielded less C4 (32 wt%) and more C6 (22 wt%) possibly because of confinement effects of the micropore channels. We also examined the influence of the reaction temperature over Ni-H beta. The catalytic activity increased with temperature from 30 to 120 degrees C. Even though there was little activity at 30 degrees C for ethylene oligomerization, the solvation abilities at this condition provide opportunities for in-situ removal of heavy molecular weight species from the catalyst for regeneration purposes, provided that the catalyst does not strongly adsorb ethylene molecules at low temperature. This work shows for the first time that supercritical ethylene conditions have great potential for practical catalytic applications. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Jan, Oliver; Song, Kunlin; Dichiara, Anthony; Resende, Fernando L. P.] Univ Washington, Sch Environm & Forest Sci, Seattle, WA 98195 USA.
RP Resende, FLP (reprint author), 290 Bloedel Hall,4000 15th Ave NE, Seattle, WA 98195 USA.
EM fresende@uw.edu
FU Agriculture and Food Research Initiative Competitive Grant from the USDA
   National Institute of Food and Agriculture [2011-68005-30407]; National
   Science FoundationNational Science Foundation (NSF) [ECC-1542101];
   University of WashingtonUniversity of Washington; Molecular Engineering
   & Sciences Institute; National Institutes of HealthUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USA; Weyerhaeuser Endowment in Paper Science and Engineering; Clean
   Energy Institute
FX The authors are appreciative of the funding provided by the Agriculture
   and Food Research Initiative Competitive Grant no. 2011-68005-30407 from
   the USDA National Institute of Food and Agriculture and the Weyerhaeuser
   Endowment in Paper Science and Engineering. We gratefully acknowledge
   Noah Ferguson and Heather Wise for TEM and SEM observations,
   respectively. Part of this work was conducted at the Molecular Analysis
   Facility, a National Nanotechnology Coordinated Infrastructure site at
   the University of Washington which is supported in part by the National
   Science Foundation (grant ECC-1542101), the University of Washington,
   the Molecular Engineering & Sciences Institute, the Clean Energy
   Institute, and the National Institutes of Health.
CR Andrei RD, 2015, J CATAL, V323, P76, DOI 10.1016/j.jcat.2014.12.027
   Ethylene S., 1948, J AM CHEM SOC, V4085, P5
   Finiels A, 2014, CATAL SCI TECHNOL, V4, P2412, DOI 10.1039/c4cy00305e
   Ganji S, 2013, CATAL SCI TECHNOL, V3, P409, DOI 10.1039/c2cy20627g
   Harvey BG, 2015, ENERG FUEL, V29, P2431, DOI 10.1021/ef5027746
   Hassan F, 2012, CHEM ENG J, V207, P133, DOI 10.1016/j.cej.2012.06.031
   Heveling J, 2003, APPL CATAL A-GEN, V248, P239, DOI 10.1016/S0926-860X(03)00160-1
   Hulea V, 2004, J CATAL, V225, P213, DOI 10.1016/j.jcat.2004.04.018
   Hulea V, 2018, ACS CATAL, V8, P3263, DOI 10.1021/acscatal.7b04294
   Komatsu T., 2001, J AM CHEM SOC, P4085, DOI [10.1039/b102415a, DOI 10.1039/B102415A]
   Lallemand M, 2008, APPL CATAL A-GEN, V338, P37, DOI 10.1016/j.apcata.2007.12.024
   Lallemand M, 2011, CHEM ENG J, V172, P1078, DOI 10.1016/j.cej.2011.06.064
   Lallemand M, 2009, J PHYS CHEM C, V113, P20360, DOI 10.1021/jp9082932
   Li A, 2017, RSC ADV, V7, P9551, DOI 10.1039/c6ra26736j
   Martinez A, 2013, APPL CATAL A-GEN, V467, P509, DOI 10.1016/j.apcata.2013.08.021
   NG FTT, 1994, APPL CATAL A-GEN, V119, P327, DOI 10.1016/0926-860X(94)85200-6
   O'Connor C.T., 1990, CATAL TODAY, V6, P329
   Ochoa-Hernandez C, 2013, CATAL TODAY, V210, P81, DOI 10.1016/j.cattod.2012.12.002
   Piovano A, 2016, ANGEW CHEM INT EDIT, V55, P11203, DOI 10.1002/anie.201604136
   SAIM S, 1988, CHEM ENG SCI, V43, P1837, DOI 10.1016/0009-2509(88)87050-7
   Saim S., 1990, J SUPERCRIT FLUIDS, V3
   SAVAGE PE, 1995, AICHE J, V41, P1723, DOI 10.1002/aic.690410712
   Sirkar K. K., 2014, SEPARATION MOLECULES
   SUBRAMANIAM B, 1994, IND ENG CHEM RES, V33, P504, DOI 10.1021/ie00027a005
   TILTSCHER H, 1981, ANGEW CHEM INT EDIT, V20, P892, DOI 10.1002/anie.198108921
   Toulhoat H, 2011, J AM CHEM SOC, V133, P2481, DOI 10.1021/ja105950z
   Trabelsi F, 2000, IND ENG CHEM RES, V39, P3666, DOI 10.1021/ie000314v
   Wang XY, 2016, CATAL TODAY, V269, P48, DOI 10.1016/j.cattod.2015.11.047
   Wang Z, 2017, COORDIN CHEM REV, V350, P68, DOI 10.1016/j.ccr.2017.06.003
   Yu K, 2014, RSC ADV, V4, P33120, DOI 10.1039/c4ra03864a
NR 30
TC 2
Z9 2
U1 6
U2 31
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD APR 6
PY 2019
VL 197
BP 212
EP 222
DI 10.1016/j.ces.2018.12.018
PG 11
WC Engineering, Chemical
SC Engineering
GA HK0ZQ
UT WOS:000457634000020
DA 2020-05-12
ER

PT J
AU Bednarek, X
   Martin, S
   Ndiaye, A
   Peres, V
   Bonnefoy, O
AF Bednarek, X.
   Martin, S.
   Ndiaye, A.
   Peres, V
   Bonnefoy, O.
TI Extrapolation of DEM simulations to large time scale. Application to the
   mixing of powder in a conical screw mixer
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Mixing powders; DEM; Large time scale simulation; Extrapolation
ID V-BLENDER; PARTICLES; FLOW; SEGREGATION; BEHAVIOR; MODELS
AB The paper proposes an original algorithm which allows a long time scale extrapolation of DEM results at a very low computational cost. This algorithm can be adapted to any periodic processes. In this study, it is applied to the mixing process of powders within a conical screw mixer. The results are then compared with long time DEM simulations. It appears that this method is able to predict the DEM results with a very good accuracy. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Bednarek, X.; Martin, S.; Bonnefoy, O.] Univ Lyon, Ctr SPIN, CNRS, Mines St Etienne,UMR 5307 LGF, F-42023 St Etienne, France.
   [Ndiaye, A.; Peres, V] MELOX ORANO, Chusclan, France.
RP Martin, S (reprint author), Univ Lyon, Ctr SPIN, CNRS, Mines St Etienne,UMR 5307 LGF, F-42023 St Etienne, France.
EM sylvain.martin@emse.fr
OI Martin, Sylvain/0000-0002-6681-0079
CR ASHTON MD, 1966, TRANS INST CHEM ENG, V44, pT166
   Bertrand F, 2005, CHEM ENG SCI, V60, P2517, DOI 10.1016/j.ces.2004.11.048
   Chen XZ, 2016, POWDER TECHNOL, V304, P177, DOI 10.1016/j.powtec.2016.08.017
   CUNDALL PA, 1979, GEOTECHNIQUE, V29, P47, DOI 10.1680/geot.1979.29.1.47
   Doucet J, 2008, COMPUT CHEM ENG, V32, P1334, DOI 10.1016/j.compchemeng.2007.06.017
   Fan Y, 2014, J FLUID MECH, V741, P252, DOI 10.1017/jfm.2013.680
   Golshan S, 2017, POWDER TECHNOL, V305, P279, DOI 10.1016/j.powtec.2016.09.059
   Hou QF, 2014, POWDER TECHNOL, V256, P529, DOI 10.1016/j.powtec.2014.01.062
   Kloss C, 2012, PROG COMPUT FLUID DY, V12, P140, DOI 10.1504/PCFD.2012.047457
   Kuhn H. W., 1955, NAV RES LOG, V2, P83, DOI DOI 10.1002/NAV.3800020109
   Kuo HP, 2002, CHEM ENG SCI, V57, P3621, DOI 10.1016/S0009-2509(02)00086-6
   LACEY PMC, 1954, J APPL CHEM, V4, P257
   Lemieux A, 2008, POWDER TECHNOL, V181, P205, DOI 10.1016/j.powtec.2006.12.009
   Lemieux M, 2007, CHEM ENG SCI, V62, P1783, DOI 10.1016/j.ces.2006.12.012
   Liu PY, 2013, CHEM ENG SCI, V86, P99, DOI 10.1016/j.ces.2012.06.015
   Marigo M, 2011, POWDER TECHNOL, V212, P17, DOI 10.1016/j.powtec.2011.04.009
   Mishra BK, 2002, MINER ENG, V15, P27, DOI 10.1016/S0892-6875(01)00194-7
   Pezo L, 2015, ADV POWDER TECHNOL, V26, P1391, DOI 10.1016/j.apt.2015.07.016
   Pezo M, 2016, CHEM ENG RES DES, V109, P317, DOI 10.1016/j.cherd.2016.02.003
   Radeke CA, 2010, CHEM ENG SCI, V65, P6435, DOI 10.1016/j.ces.2010.09.035
   RENDL F, 1988, J COMPUT APPL MATH, V23, P257, DOI 10.1016/0377-0427(88)90001-5
   Sakai M, 2009, CHEM ENG SCI, V64, P533, DOI 10.1016/j.ces.2008.10.003
   Schlick CP, 2016, J FLUID MECH, V797, P95, DOI 10.1017/jfm.2016.260
   Schlick CP, 2015, AICHE J, V61, P1524, DOI 10.1002/aic.14780
   Yang RY, 2008, POWDER TECHNOL, V188, P170, DOI 10.1016/j.powtec.2008.04.081
   Zhu HP, 2007, CHEM ENG SCI, V62, P3378, DOI 10.1016/j.ces.2006.12.089
NR 26
TC 5
Z9 5
U1 2
U2 13
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD APR 6
PY 2019
VL 197
BP 223
EP 234
DI 10.1016/j.ces.2018.12.022
PG 12
WC Engineering, Chemical
SC Engineering
GA HK0ZQ
UT WOS:000457634000021
DA 2020-05-12
ER

PT J
AU Kessler, T
   Kunde, C
   McBride, K
   Mertens, N
   Michaels, D
   Sundmacher, K
   Kienle, A
AF Kessler, Tobias
   Kunde, Christian
   McBride, Kevin
   Mertens, Nick
   Michaels, Dennis
   Sundmacher, Kai
   Kienle, Achim
TI Global optimization of distillation columns using explicit and implicit
   surrogate models
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Global optimization; Distillation; Surrogate models; Kriging; Output
   multiplicities
ID HYDROFORMYLATION; DESIGN; 1-DODECENE
AB Surrogate-based optimization of distillation columns using an iterative Kriging approach is investigated. To avoid suboptimal local minima the focus lies on deterministic global optimization. The determination of optimal setups and operating conditions for ideal and non-ideal distillation columns, leading to mixed-integer nonlinear programming (MINLP) problems, serve as case studies. To cope with output multiplicities of the model an implicit surrogate formulation is proposed. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Kessler, Tobias; Kunde, Christian; Sundmacher, Kai; Kienle, Achim] Otto von Guericke Univ, Univ Pl 2, D-39106 Magdeburg, Germany.
   [McBride, Kevin; Sundmacher, Kai; Kienle, Achim] Max Planck Inst Dynam Complex Tech Syst, Sandtorstr 1, D-39106 Magdeburg, Germany.
   [Mertens, Nick] TU Dortmund, Vogelpothsweg 87, D-44227 Dortmund, Germany.
RP Kessler, T (reprint author), Otto von Guericke Univ, Univ Pl 2, D-39106 Magdeburg, Germany.
EM tobias.kessler@ovgu.de; christian.kunde@ovgu.de;
   mcbride@mpi-magdeburg.mpg.de; nick.mertens@math.tu-dortmund.de;
   kai.sundmacher@ovgu.de; achim.kienle@ovgu.de
RI KeSSler, Tobias/AAG-1369-2020
OI KeSSler, Tobias/0000-0003-3618-713X; Kienle, Achim/0000-0002-9011-0451;
   Kunde, Christian/0000-0002-7311-3060
FU Deutsche Forschungsgemeinschaft (DFG)German Research Foundation (DFG)
   [SFB/TRR 63]
FX This work is part of the Collaborative Research Center "Integrated
   Chemical Processes in Liquid Multiphase Systems - InPROMPT". Financial
   support by the Deutsche Forschungsgemeinschaft (DFG) is gratefully
   acknowledged through SFB/TRR 63.
CR Audet C, 2018, J GLOBAL OPTIM, V70, P645, DOI 10.1007/s10898-017-0574-1
   Ballerstein M, 2015, OPTIM ENG, V16, P409, DOI 10.1007/s11081-014-9267-5
   Bennett K.P., 2000, SIGKDD EXPLOR, V2, P1, DOI DOI 10.1145/380995.380999
   Bhosekar A, 2018, COMPUT CHEM ENG, V108, P250, DOI 10.1016/j.compchemeng.2017.09.017
   Boukouvala F, 2016, EUR J OPER RES, V252, P701, DOI 10.1016/j.ejor.2015.12.018
   Caballero JA, 2008, AICHE J, V54, P2633, DOI 10.1002/aic.11579
   Cozad A, 2014, AICHE J, V60, P2211, DOI 10.1002/aic.14418
   Dorn C, 1998, IND ENG CHEM RES, V37, P506, DOI 10.1021/ie9703447
   Eason JP, 2016, AICHE J, V62, P3124, DOI 10.1002/aic.15325
   Forrester AIJ, 2009, PROG AEROSP SCI, V45, P50, DOI 10.1016/j.paerosci.2008.11.001
   Gleixner A., 2017, 1761 ZIB
   Ibrahim D, 2018, CHEM ENG RES DES, V134, P212, DOI 10.1016/j.cherd.2018.03.006
   Kessler T., 2019, SN APPL SCI, V1
   Kessler T, 2017, COMPUT-AIDED CHEM EN, V40C, P2113, DOI 10.1016/B978-0-444-63965-3.50354-8
   Kieslich C. A., 2018, J GLOBAL OPTIM
   Kocis L, 1997, ACM T MATH SOFTWARE, V23, P266, DOI 10.1145/264029.264064
   Locatelli M., 2013, MOS SIAM SERIES OPTI
   McBride K, 2017, COMPUT CHEM ENG, V105, P212, DOI 10.1016/j.compchemeng.2016.11.019
   McBride K, 2015, IND ENG CHEM RES, V54, P6761, DOI 10.1021/acs.iecr.5b00795
   Mertens N, 2018, OPTIM ENG, V19, P479, DOI 10.1007/s11081-018-9377-6
   Nallasivam U, 2016, AICHE J, V62, P2071, DOI 10.1002/aic.15204
   Nentwich C, 2016, IEEE IJCNN, P1291, DOI 10.1109/IJCNN.2016.7727346
   PAPALAMBROS PY, 2000, PRINCIPLES OPTIMAL D
   POLING BE, 2000, PROPERTIES GASES LIQ
   Quirante N, 2015, AICHE J, V61, P2169, DOI 10.1002/aic.14798
   Rheinboldt WC., 1986, NUMERICAL ANAL PARAM
   Saman R., 2012, WATER RESOUR RES, V48
   Schafer E, 2012, IND ENG CHEM RES, V51, P10296, DOI 10.1021/ie300484q
   Scheuerer M, 2013, EUR J APPL MATH, V24, P601, DOI 10.1017/S0956792513000016
   Seydel R, 2009, PRACTICAL BIFURCATIO
   Steimel J, 2013, COMPUT CHEM ENG, V59, P63, DOI 10.1016/j.compchemeng.2013.06.017
   Tawarmalani M, 2005, MATH PROGRAM, V103, P225, DOI 10.1007/s10107-005-0581-8
   Upton BGJ, 2004, GEOL SOC SPEC PUBL, V223, P195, DOI 10.1144/GSL.SP.2004.223.01.09
   WEIDLICH U, 1987, IND ENG CHEM RES, V26, P1372, DOI 10.1021/ie00067a018
   Zhang Y, 2013, IND ENG CHEM RES, V52, P3121, DOI 10.1021/ie300856p
NR 35
TC 8
Z9 8
U1 4
U2 19
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD APR 6
PY 2019
VL 197
BP 235
EP 245
DI 10.1016/j.ces.2018.12.002
PG 11
WC Engineering, Chemical
SC Engineering
GA HK0ZQ
UT WOS:000457634000022
DA 2020-05-12
ER

PT J
AU Ouattara, Z
   Magnin, A
   Bleses, D
   Jay, P
AF Ouattara, Ziemihori
   Magnin, Albert
   Bleses, Didier
   Jay, Pascal
TI Influence of the inclination of a plate on forces generated in flows of
   Newtonian and yield stress fluids
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Yield stress fluid; Newtonian fluid; Inclined plate; Drag; Lift
ID FLAT-PLATE; VISCOPLASTIC FLUID; REYNOLDS-NUMBER; BOUNDARY-LAYER;
   BEHAVIOR; SPHERES; STABILITY; RHEOMETRY; CYLINDER; ANCHORS
AB The aim of this article is to study experimentally and numerically the influence of the inclination of a plate placed near a wall on flows of Newtonian and yield stress fluids. The drag and lift forces were particularly studied. The inclination of the plate varies between 0 degrees and 90 degrees. The inertia of the fluid is considered negligible. The effects of the Oldroyd number, the shear-thinning index and the inclination of the plate on drag and lift are shown. Experimentally, an instrumented flume was used with a Carbopol gel as a yield stress fluid model. The measured lift and drag forces are compared to the numerical results and the literature data. The elasticity and plasticity effects are discussed. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Jay, Pascal] Univ Grenoble Alpes, LRP, F-38000 Grenoble, France.
   CNRS, LRP, F-38000 Grenoble, France.
RP Jay, P (reprint author), Univ Grenoble Alpes, LRP, F-38000 Grenoble, France.
EM pascal.jay@univ-grenoble-alpes.fr
FU LabEx Tec 21 (Investissements d'Avenir-grant)French National Research
   Agency (ANR) [ANR-11-LABX-0030]; PolyNat Carnot Institute
   (Investissements d'Avenir)French National Research Agency (ANR)
   [ANR-11-CARN-030-01]; Ivory Coast Scholarship
FX The Laboratoire Rheologie et Procedes is part of the LabEx Tec 21
   (Investissements d'Avenir-grant agreement no ANR-11-LABX-0030) and of
   the PolyNat Carnot Institute (Investissements d'Avenir -grant agreement
   no ANR-11-CARN-030-01).; The PhD Research project of Z. Ouattara has
   been made possible thanks to an Ivory Coast Scholarship.
CR Ahonguio F, 2016, J NON-NEWTON FLUID, V238, P131, DOI 10.1016/j.jnnfm.2016.07.010
   Ahonguio F, 2014, J NON-NEWTON FLUID, V206, P57, DOI 10.1016/j.jnnfm.2014.03.002
   Anderson K. H., 2003, PHASE 2 REPORT API D
   ATAPATTU DD, 1990, J NON-NEWTON FLUID, V38, P31, DOI 10.1016/0377-0257(90)85031-S
   Aubeny CP, 2010, J GEOTECH GEOENVIRON, V136, P57, DOI 10.1061/(ASCE)GT.1943-5606.0000198
   Balmforth NJ, 2017, J FLUID MECH, V813, P929, DOI 10.1017/jfm.2016.878
   Balmforth NJ, 2010, J NON-NEWTON FLUID, V165, P1139, DOI 10.1016/j.jnnfm.2010.05.012
   Balmforth NJ, 2010, J NON-NEWTON FLUID, V165, P1147, DOI 10.1016/j.jnnfm.2010.06.004
   Bemben S. M., 1973, OFFSH TECHN C
   Boujlel J, 2012, J RHEOL, V56, P1083, DOI 10.1122/1.4720387
   BROOKES G. F., 1969, RHEOL ACTA, V8, P472
   Brookes GF, 1968, RHEOL ACTA, V7, P189
   Burgos GR, 1999, J RHEOL, V43, P463, DOI 10.1122/1.550992
   Caton F, 2008, RHEOL ACTA, V47, P601, DOI 10.1007/s00397-008-0267-2
   Coussot P, 2006, J RHEOL, V50, P975, DOI 10.1122/1.2337259
   Dhanvi Vengre Raghavendra, 2016, THESIS
   Dimitriou CJ, 2013, J RHEOL, V57, P27, DOI 10.1122/1.4754023
   Divoux T, 2011, SOFT MATTER, V7, P8409, DOI 10.1039/c1sm05607g
   Divoux T, 2010, PHYS REV LETT, V104, DOI 10.1103/PhysRevLett.104.208301
   Ferreira M. R., 2014, P ENCIT, V15, P10
   Fraggedakis D, 2016, SOFT MATTER, V12, P5378, DOI 10.1039/c6sm00480f
   Goodrich B, 1997, PRODUCT LIT
   Hariharaputhiran M, 1998, J NON-NEWTON FLUID, V79, P87, DOI 10.1016/S0377-0257(98)00084-6
   HUDSON JD, 1985, J FLUID MECH, V160, P369, DOI 10.1017/S0022112085003524
   IN KM, 1995, FLUID DYN RES, V15, P13, DOI 10.1016/0169-5983(95)90438-8
   JANSSEN E, 1958, J FLUID MECH, V3, P329, DOI 10.1017/S002211205800001X
   Lidon P, 2017, RHEOL ACTA, V56, P307, DOI 10.1007/s00397-016-0961-4
   MAGNIN A, 1987, J NON-NEWTON FLUID, V23, P91, DOI 10.1016/0377-0257(87)80012-5
   MAGNIN A, 1990, J NON-NEWTON FLUID, V36, P85, DOI 10.1016/0377-0257(90)85005-J
   Martinie L, 2013, J RHEOL, V57, P627, DOI 10.1122/1.4789785
   Meeker SP, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.198302
   Merifield RS, 2003, J GEOTECH GEOENVIRON, V129, P243, DOI 10.1061/(ASCE)1090-0241(2003)129:3(243)
   Merifield RS, 2001, GEOTECHNIQUE, V51, P141, DOI 10.1680/geot.51.2.141.40290
   Merkak O, 2006, J NON-NEWTON FLUID, V133, P99, DOI 10.1016/j.jnnfm.2005.10.012
   Mitsoulis E, 2004, CHEM ENG SCI, V59, P789, DOI 10.1016/j.ces.2003.09.041
   Mougin N, 2012, J NON-NEWTON FLUID, V171, P42, DOI 10.1016/j.jnnfm.2012.01.003
   Ovarlez G, 2010, NAT MATER, V9, P115, DOI [10.1038/nmat2615, 10.1038/NMAT2615]
   PAPANASTASIOU TC, 1987, J RHEOL, V31, P385, DOI 10.1122/1.549926
   Patel SA, 2016, NUMER HEAT TR A-APPL, V70, P917, DOI 10.1080/10407782.2016.1214493
   Patel SA, 2013, J NON-NEWTON FLUID, V202, P32, DOI 10.1016/j.jnnfm.2013.09.006
   Piau JM, 2007, J NON-NEWTON FLUID, V144, P1, DOI 10.1016/j.jnnfm.2007.02.011
   Piau JM, 2004, J NON-NEWTON FLUID, V117, P97, DOI 10.1016/j.jnnfm.2004.01.002
   Piau JM, 2002, J NON-NEWTON FLUID, V102, P193, DOI 10.1016/S0377-0257(01)00178-1
   Savreux F, 2005, AICHE J, V51, P750, DOI 10.1002/aic.10488
   TAMADA K, 1983, J FLUID MECH, V132, P445, DOI 10.1017/S0022112083001718
   Tokpavi DL, 2008, J NON-NEWTON FLUID, V154, P65, DOI 10.1016/j.jnnfm.2008.02.006
   Tokpavi DL, 2009, J NON-NEWTON FLUID, V164, P35, DOI 10.1016/j.jnnfm.2009.08.002
   TOMOTIKA S, 1953, Q J MECH APPL MATH, V6, P290, DOI 10.1093/qjmam/6.3.290
   Wu J, 1996, J NON-NEWTON FLUID, V66, P127, DOI 10.1016/S0377-0257(96)01476-0
   Yarin AL, 2004, J RHEOL, V48, P101, DOI 10.1122/1.1631423
NR 50
TC 0
Z9 0
U1 0
U2 4
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD APR 6
PY 2019
VL 197
BP 246
EP 257
DI 10.1016/j.ces.2018.12.026
PG 12
WC Engineering, Chemical
SC Engineering
GA HK0ZQ
UT WOS:000457634000023
DA 2020-05-12
ER

PT J
AU Wang, X
   Liu, ZM
   Pang, Y
AF Wang, Xiang
   Liu, Zhaomiao
   Pang, Yan
TI Breakup dynamics of droplets in an asymmetric bifurcation by mu PIV and
   theoretical investigations
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Microfluidics; Droplet; Breakup; mu PIV; Theoretical prediction
ID BUBBLE BREAKUP; MICROCHANNEL; PLUGS
AB Dynamics of the three breakup regimes of droplets in an asymmetric bifurcation is experimentally studied by a high-speed microscope system and a micro-particle image velocimetry (mu PIV) system. Effects of the droplet length and the capillary number on the evolution of the neck thickness are analyzed. For droplets that obstruct the microchannel, the pressure drop across the droplet during the breakup process is theoretically calculated and its relationship with the neck shrinkage is discussed. Based on mass conservation law, the theoretical prediction on the geometric shape of droplets can be constructed and both the radius of droplet rear cap and the neck thickness agree well with experimental results. It is proven that the theoretical model could also be successfully constructed for asymmetric bifurcations and the model in this paper could be applied to bifurcations with arbitrary angles. If gaps are present between the droplet and channel sidewalls, it is found that the thinning process of the neck and variations of the flow field of droplets are distinctly different from the obstructed breakup. For no breakup regime, the vortex flow accompanies the backflow of the droplet tip and two different vortex distributions within the droplet are disclosed for the first time, which are separated by the droplet length. The critical neck thickness that determines whether droplets break after flowing through the bifurcation is revealed and compared with other works. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Wang, Xiang; Liu, Zhaomiao; Pang, Yan] Beijing Univ Technol, Coll Mech Engn & Appl Elect Technol, Beijing 100124, Peoples R China.
RP Liu, ZM (reprint author), Beijing Univ Technol, Coll Mech Engn & Appl Elect Technol, Beijing 100124, Peoples R China.
EM lzm@bjut.edu.cn
RI Wang, Xiang/K-5106-2016
OI Wang, Xiang/0000-0001-6144-9301; Liu, Zhaomiao/0000-0002-3408-595X
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [11572013, 11872083, 11702007]
FX The authors are grateful for the support of the National Natural Science
   Foundation of China (11572013, 11872083 and 11702007).
CR Aboutalebi M, 2018, J MAGN MAGN MATER, V447, P139, DOI 10.1016/j.jmmm.2017.09.053
   Adamson DN, 2006, LAB CHIP, V6, P1178, DOI 10.1039/b604993a
   Anna SL, 2016, ANNU REV FLUID MECH, V48, P285, DOI 10.1146/annurev-fluid-122414-034425
   Bedram A, 2015, PHYS REV E, V91, DOI 10.1103/PhysRevE.91.053012
   Carlson A, 2010, INT J MULTIPHAS FLOW, V36, P397, DOI 10.1016/j.ijmultiphaseflow.2010.01.002
   Chabert M, 2008, P NATL ACAD SCI USA, V105, P3191, DOI 10.1073/pnas.0708321105
   Chen YP, 2017, J FLUID MECH, V819, P401, DOI 10.1017/jfm.2017.181
   Choi W, 2011, LAB CHIP, V11, P3970, DOI 10.1039/c1lc20444k
   Chong ZZ, 2016, LAB CHIP, V16, P35, DOI 10.1039/c5lc01012h
   Fu TT, 2011, CHEM ENG SCI, V66, P4184, DOI 10.1016/j.ces.2011.06.003
   Fu YH, 2017, PHYS FLUIDS, V29, DOI 10.1063/1.4978300
   Garstecki P, 2006, LAB CHIP, V6, P693
   Hoang DA, 2013, J FLUID MECH, V717, DOI 10.1017/jfm.2013.18
   Hoang DA, 2014, CHEM ENG J, V236, P545, DOI 10.1016/j.cej.2013.08.066
   Jullien MC, 2009, PHYS FLUIDS, V21, DOI 10.1063/1.3170983
   Leshansky AM, 2012, PHYS REV LETT, V108, DOI 10.1103/PhysRevLett.108.264502
   Leshansky AM, 2009, PHYS FLUIDS, V21, DOI 10.1063/1.3078515
   Link D. R., 2004, PHYS REV LETT, V92, DOI [10.1103/PhysRevLett.92.054503054503, DOI 10.1103/PHYSREVLETT.92.054503054503]
   Liu ZM, 2017, MICROFLUID NANOFLUID, V21, DOI 10.1007/s10404-017-2019-z
   Ma SH, 2015, LAB CHIP, V15, P2327, DOI 10.1039/c5lc00346f
   Menetrier-Deremble L, 2006, PHYS REV E, V74, DOI 10.1103/PhysRevE.74.035303
   Nie J, 2010, ANAL CHEM, V82, P7852, DOI 10.1021/ac101723x
   Pang Y, 2014, LAB CHIP, V14, P4029, DOI 10.1039/c4lc00871e
   Parthiban P, 2013, BIOMICROFLUIDICS, V7, DOI 10.1063/1.4819276
   Protiere S, 2010, EPL-EUROPHYS LETT, V92, DOI 10.1209/0295-5075/92/54002
   Salkin L, 2013, LAB CHIP, V13, P3022, DOI 10.1039/c3lc00040k
   Salkin L, 2012, PHYS REV E, V86, DOI 10.1103/PhysRevE.86.036317
   Samie M, 2013, PHYS REV E, V87, DOI 10.1103/PhysRevE.87.053003
   Shang LR, 2017, CHEM REV, V117, P7964, DOI 10.1021/acs.chemrev.6b00848
   Stone HA, 2004, ANNU REV FLUID MECH, V36, P381, DOI 10.1146/annurev.fluid.36.050802.122124
   Sun X, 2018, CHEM ENG SCI, V188, P158, DOI 10.1016/j.ces.2018.05.027
   Tan YC, 2008, MICROFLUID NANOFLUID, V4, P343, DOI 10.1007/s10404-007-0184-1
   van Steijn V, 2007, CHEM ENG SCI, V62, P7505, DOI 10.1016/j.ces.2007.08.068
   van Steijn V, 2009, PHYS REV LETT, V103, DOI 10.1103/PhysRevLett.103.214501
   Wang X, 2018, CHEM ENG SCI, V188, P11, DOI 10.1016/j.ces.2018.05.003
   Wang X, 2017, RSC ADV, V7, P29966, DOI 10.1039/c7ra04494a
   Wang XD, 2015, AICHE J, V61, P1081, DOI 10.1002/aic.14704
   Wen H, 2015, LAB CHIP, V15, P1905, DOI 10.1039/c4lc01377h
   Yamada M, 2008, J COLLOID INTERF SCI, V321, P401, DOI 10.1016/j.jcis.2008.01.036
NR 39
TC 3
Z9 3
U1 17
U2 48
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD APR 6
PY 2019
VL 197
BP 258
EP 268
DI 10.1016/j.ces.2018.12.030
PG 11
WC Engineering, Chemical
SC Engineering
GA HK0ZQ
UT WOS:000457634000024
DA 2020-05-12
ER

PT J
AU Chao, C
   Xu, GW
   Fan, XF
AF Chao, Cong
   Xu, Guangwen
   Fan, Xianfeng
TI Effect of surface tension, viscosity, pore geometry and pore contact
   angle on effective pore throat
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Capillary resistance; Two-phase flows; Pore throat; Surface tension;
   Constricted capillary; Pore contact angle
ID PRESSURE-DROP; 2-PHASE FLOWS; INTERFACIAL-TENSION; CHANNEL DIAMETER;
   WATER MANAGEMENT; BEREA SANDSTONE; CARBON-DIOXIDE; WETTABILITY; MOTION;
   MICROCHANNELS
AB Through experimental measurement and theoretical calculation, we have investigated the effect of surface tension, liquid viscosity and the capillary geometry (capillary gradient and tip diameter) on the effective pore throat, and the impact of the effective pore throat on pore resistance to two-phase interfaces formed from fluids with different viscosities and surface tensions. When a two-phase interface flows in channels with varied pore diameter, capillary force is insignificant in the section of the channel with an inner pore diameter greater than the effective pore throat, and the pressure drops in this section depend on capillary tip diameter, rather than the surface tension. Capillary force takes significant effect on the interface only when the pore diameter in a tapered capillary is smaller than the effective pore throat. Effective pore throat depends on fluid surface tension and the capillary geometry, but not on liquid viscosity. The higher the fluid surface tension, the larger the diameter of the effective pore throat. A channel with a large tip diameter or gradient will give a large effective pore throat diameter. Fluid viscosity only affects the magnitude of the resistant pressure drops of fluid flows in constricted capillaries, but does not affect the effective pore throat diameter. The effective pore throat and the pressure profile measured in this study can be explained by the pore contact angle, but cannot be explained by the contact angle on a flat surface of the same materials. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Chao, Cong; Fan, Xianfeng] Univ Edinburgh, Sch Engn, Inst Mat & Proc, Edinburgh EH9 3JL, Midlothian, Scotland.
   [Xu, Guangwen] Shenyang Univ Chem Technol, Inst Ind Chem & Energy Technol, Shenyang, Liaoning, Peoples R China.
RP Fan, XF (reprint author), Univ Edinburgh, Sch Engn, Inst Mat & Proc, Edinburgh EH9 3JL, Midlothian, Scotland.
EM x.fan@ed.ac.uk
RI CHAO, CONG/P-4390-2017; Fan, Xianfeng/E-4381-2016
OI CHAO, CONG/0000-0001-6738-5732; Fan, Xianfeng/0000-0002-6811-953X
CR Andrade J. D., 1985, SURFACE INTERFACIAL, V1, P249
   Andrew M, 2014, INT J GREENH GAS CON, V22, P1, DOI 10.1016/j.ijggc.2013.12.018
   Blunt MJ, 2001, CURR OPIN COLLOID IN, V6, P197, DOI 10.1016/S1359-0294(01)00084-X
   BRETHERTON FP, 1961, J FLUID MECH, V10, P166, DOI 10.1017/S0022112061000160
   Chan WK, 2005, J MICROMECH MICROENG, V15, P1722, DOI 10.1088/0960-1317/15/9/014
   Chao C, 2018, CHEM ENG SCI, V192, P114, DOI 10.1016/j.ces.2018.07.026
   Cho H, 2007, J COLLOID INTERF SCI, V306, P379, DOI 10.1016/j.jcis.2006.10.077
   Choi C, 2011, EXP THERM FLUID SCI, V35, P1086, DOI 10.1016/j.expthermflusci.2011.03.003
   Chung PMY, 2004, INT J MULTIPHAS FLOW, V30, P735, DOI 10.1016/j.ijmultiphaseflow.2004.05.002
   Cobos S, 2009, INT J MULTIPHAS FLOW, V35, P507, DOI 10.1016/j.ijmultiphaseflow.2009.02.018
   Dong H, 2009, PHYS REV E, V80, DOI 10.1103/PhysRevE.80.036307
   Dullien F. A. L., 1992, POROUS MEDIA FLUID T
   Giordano GG, 1998, PROG POLYM SCI, V23, P509, DOI 10.1016/S0079-6700(97)00046-4
   Golparvar A., 2018, ADV GEOENERGY RES, V2, P418, DOI DOI 10.26804/AGER.2018.04.07
   Green D. W., 1998, MEMORIAL FUND AIME
   Hebach A, 2002, J CHEM ENG DATA, V47, P1540, DOI 10.1021/je025569p
   HOUGH EW, 1951, T AM I MIN MET ENG, V192, P57
   Ichikawa N, 2004, J COLLOID INTERF SCI, V280, P155, DOI 10.1016/j.jcis.2004.07.017
   JENNINGS HY, 1971, SOC PETROL ENG J, V11, P171, DOI 10.2118/3071-PA
   Kreutzer MT, 2005, AICHE J, V51, P2428, DOI 10.1002/aic.10495
   Lee CY, 2008, EXP THERM FLUID SCI, V32, P1716, DOI 10.1016/j.expthermflusci.2008.06.007
   Li XX, 2014, CHEM ENG SCI, V117, P137, DOI 10.1016/j.ces.2014.06.024
   Li XX, 2013, CHEM ENG SCI, V104, P988, DOI 10.1016/j.ces.2013.10.026
   Liang MC, 2018, INT J HYDROGEN ENERG, V43, P17880, DOI 10.1016/j.ijhydene.2018.07.186
   Liang MC, 2015, MICROFLUID NANOFLUID, V19, P1, DOI 10.1007/s10404-014-1541-5
   LIN S, 1991, INT J MULTIPHAS FLOW, V17, P95, DOI 10.1016/0301-9322(91)90072-B
   Lindquist WB, 2000, J GEOPHYS RES-SOL EA, V105, P21509, DOI 10.1029/2000JB900208
   Liu Z., 2017, ADV GEOENERGY RES, V1, P171, DOI DOI 10.26804/AGER.2017.03.04
   MARTINEZ MJ, 1990, J FLUID MECH, V210, P565, DOI 10.1017/S0022112090001409
   MCAULIFFE CD, 1973, J PETROL TECHNOL, V25, P727, DOI 10.2118/4369-PA
   Metz T, 2010, MICROFLUID NANOFLUID, V9, P341, DOI 10.1007/s10404-009-0551-1
   MORROW NR, 1970, IND ENG CHEM, V62, P32, DOI 10.1021/ie50726a006
   Nabawy BS, 2009, AAPG BULL, V93, P719, DOI 10.1306/03160908131
   Nelson PH, 2009, AAPG BULL, V93, P329, DOI 10.1306/10240808059
   Olbricht WL, 1996, ANNU REV FLUID MECH, V28, P187, DOI 10.1146/annurev.fl.28.010196.001155
   Oren PE, 2003, J PETROL SCI ENG, V39, P177, DOI 10.1016/S0920-4105(03)00062-7
   Pang FM, 2007, J MOL LIQ, V136, P71, DOI 10.1016/j.molliq.2007.01.003
   Parmar R, 2013, CHEM ENG PROCESS, V64, P79, DOI 10.1016/j.cep.2012.12.002
   Peng S, 2012, J HYDROL, V472, P254, DOI 10.1016/j.jhydrol.2012.09.034
   PETERSON JW, 1986, IND ENG CHEM FUND, V25, P668, DOI 10.1021/i100024a032
   Quan P, 2007, J POWER SOURCES, V164, P222, DOI 10.1016/j.jpowsour.2006.09.110
   Ramstad T, 2012, TRANSPORT POROUS MED, V94, P487, DOI 10.1007/s11242-011-9877-8
   Reeves PC, 1996, WATER RESOUR RES, V32, P2345, DOI 10.1029/96WR01105
   Ringrose PS, 1993, J PETROL SCI ENG, V9, P103, DOI 10.1016/0920-4105(93)90071-L
   Roca JF, 2013, COMPUT FLUIDS, V87, P50, DOI 10.1016/j.compfluid.2012.11.020
   Roman S, 2017, J COLLOID INTERF SCI, V507, P279, DOI 10.1016/j.jcis.2017.07.092
   ROSSEN WR, 1990, AICHE J, V36, P1176, DOI 10.1002/aic.690360807
   Sahimi M., 2011, CHARACTERIZATION POR, P15
   Saisorn S, 2010, EXP THERM FLUID SCI, V34, P454, DOI 10.1016/j.expthermflusci.2009.02.006
   Sarma HK, 1998, J CAN PETROL TECHNOL, V37, P55, DOI 10.2118/98-07-06
   Sharan M, 2001, BIORHEOLOGY, V38, P415
   Sinha PK, 2007, J MATER CHEM, V17, P3089, DOI 10.1039/b703485g
   Smith WO, 1930, J AM CHEM SOC, V52, P1345, DOI 10.1021/ja01367a007
   Tanimu A, 2017, CHEM ENG J, V327, P792, DOI 10.1016/j.cej.2017.06.161
   VAZQUEZ G, 1995, J CHEM ENG DATA, V40, P611, DOI 10.1021/je00019a016
   Warnier MJF, 2010, MICROFLUID NANOFLUID, V8, P33, DOI 10.1007/s10404-009-0448-z
   Washburn EW, 1921, PHYS REV, V17, P273, DOI 10.1103/PhysRev.17.273
   Wright R., 1933, AAPG BULL, V17, P1521, DOI DOI 10.1306/3D932BDC-16B1-11D7-8645000102C1865D
   Yue J, 2004, CHEM ENG J, V102, P11, DOI 10.1016/j.cej.2004.02.001
   Zhang L, 2002, J MICROELECTROMECH S, V11, P12, DOI 10.1109/84.982858
   Zou CN, 2012, J PETROL SCI ENG, V88-89, P82, DOI 10.1016/j.petrol.2012.02.001
NR 61
TC 2
Z9 2
U1 3
U2 31
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD APR 6
PY 2019
VL 197
BP 269
EP 279
DI 10.1016/j.ces.2018.12.029
PG 11
WC Engineering, Chemical
SC Engineering
GA HK0ZQ
UT WOS:000457634000025
DA 2020-05-12
ER

PT J
AU Wang, S
   Luo, K
   Hu, CS
   Lin, JJ
   Fan, JR
AF Wang, Shuai
   Luo, Kun
   Hu, Chenshu
   Lin, Junjie
   Fan, Jianren
TI CFD-DEM simulation of heat transfer in fluidized beds: Model
   verification, validation, and application
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE CFD-DEM; Heat transfer; Verification and validation; Circulating
   fluidized bed; Numerical simulation
ID DISCRETE PARTICLE SIMULATION; GAS-SOLID FLOW; FULL-LOOP;
   NUMERICAL-SIMULATION; PARTICULATE SYSTEMS; MINIMUM FLUIDIZATION;
   IMMERSED TUBES; SCALE; HYDRODYNAMICS; VELOCITY
AB For a single isolated particle, the effect of overlap displacement on conduction and the effect of particle diameter/fluid velocity on convection are comprehensively studied using a CFD-DEM method coupled with heat exchange. Moreover, the model is further validated in a pseudo-2D bubbling fluidized bed and the influence of operating parameters (i.e., fluid velocity, particle diameter, and mass loading) on heat transfer contribution is deeply revealed. The results show that the fluid velocity and particle diameter have a more remarkable influence on convective heat transfer than conductive heat transfer. Besides, the particle-fluid convection dominates the heat transfer while the particle-particle conduction is almost negligible. The particle-fluid-particle conduction occupies about 10% of the total heat transfer. Finally, the model is successfully applied in a circulating fluidized bed. The average mass fractions of solid materials in the riser, cyclone, and dipleg are 0.737, 0.023, and 0.240, respectively. Solid internal circulations and lower solid velocities in the horizontal part of dipleg lead to a two-peak histogram distribution of particles temperature in the riser and the system. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Wang, Shuai; Luo, Kun; Hu, Chenshu; Lin, Junjie; Fan, Jianren] Zhejiang Univ, State Key Lab Clean Energy Utilizat, Hangzhou 310027, Zhejiang, Peoples R China.
RP Luo, K (reprint author), Zhejiang Univ, State Key Lab Clean Energy Utilizat, Hangzhou 310027, Zhejiang, Peoples R China.
EM zjulk@zju.edu.cn
RI luo, kun/A-8039-2012
OI luo, kun/0000-0003-3644-9400
FU National Key R&D Program of China [2016YFB0600102, 2017YFB0601805];
   National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [51390493]
FX The present work is supported by the National Key R&D Program of China
   (No. 2017YFB0601805), the National Natural Science Foundation of China
   (No. 51390493), and the National Key R&D Program of China (No.
   2016YFB0600102), which should be sincerely acknowledged.
CR Abdelmotalib HM, 2015, INT J HEAT MASS TRAN, V89, P567, DOI 10.1016/j.ijheatmasstransfer.2015.05.085
   Adamczyk WP, 2016, PARTICUOLOGY, V29, P69, DOI 10.1016/j.partic.2015.12.006
   Alobaid F, 2015, CHEM ENG SCI, V138, P173, DOI 10.1016/j.ces.2015.08.010
   Anantharaman A, 2018, POWDER TECHNOL, V323, P454, DOI 10.1016/j.powtec.2017.10.016
   Baltussen MW, 2018, ADV CHEM ENG, V53, P1, DOI 10.1016/bs.ache.2018.02.001
   Baniasadi M, 2018, CHEM ENG SCI, V178, P136, DOI 10.1016/j.ces.2017.12.044
   Basu P., 2015, CIRCULATING FLUIDIZE
   Bellan S, 2018, INT J HEAT MASS TRAN, V116, P377, DOI 10.1016/j.ijheatmasstransfer.2017.09.015
   Clarke DA, 2018, IND ENG CHEM RES, V57, P3002, DOI 10.1021/acs.iecr.7b04638
   Deen NG, 2007, CHEM ENG SCI, V62, P28, DOI 10.1016/j.ces.2006.08.014
   DELVOSALLE C, 1985, CHEM ENG SCI, V40, P769, DOI 10.1016/0009-2509(85)85030-2
   Diggs A, 2016, J COMPUT PHYS, V313, P775, DOI 10.1016/j.jcp.2016.02.066
   Fattahi M, 2016, APPL THERM ENG, V105, P385, DOI 10.1016/j.applthermaleng.2015.05.071
   Gan JQ, 2016, CHEM ENG SCI, V144, P201, DOI 10.1016/j.ces.2016.01.041
   Ge W, 2002, CHEM ENG SCI, V57, P3993, DOI 10.1016/S0009-2509(02)00234-8
   Gidaspow D., 1994, MULTIPHASE FLOW FLUI
   Gu JR, 2018, CHEM ENG SCI, V192, P619, DOI 10.1016/j.ces.2018.08.008
   Guio-Perez DC, 2013, AICHE J, V59, P3612, DOI 10.1002/aic.14120
   Hau ZY, 2016, IND ENG CHEM RES, V55, P9040, DOI 10.1021/acs.iecr.6b01682
   He YR, 2004, POWDER TECHNOL, V145, P88, DOI 10.1016/j.powtec.2004.04.047
   Hou QF, 2012, AICHE J, V58, P1422, DOI 10.1002/aic.12700
   Hou QF, 2012, IND ENG CHEM RES, V51, P11572, DOI 10.1021/ie3015999
   Kafui KD, 2002, CHEM ENG SCI, V57, P2395, DOI 10.1016/S0009-2509(02)00140-9
   Kraft S, 2018, PARTICUOLOGY, V36, P70, DOI 10.1016/j.partic.2017.04.009
   Ku XK, 2015, CHEM ENG SCI, V122, P270, DOI 10.1016/j.ces.2014.08.045
   Li D, 2018, J FLUID MECH, V845, P417, DOI 10.1017/jfm.2018.231
   Li DY, 2017, CHINESE J CHEM ENG, V25, P1369, DOI 10.1016/j.cjche.2017.01.014
   Li J, 2000, POWDER TECHNOL, V112, P273, DOI 10.1016/S0032-5910(00)00302-8
   Li LM, 2017, POWDER TECHNOL, V305, P364, DOI 10.1016/j.powtec.2016.10.005
   Li TW, 2014, CHEM ENG SCI, V120, P10, DOI 10.1016/j.ces.2014.08.041
   Li YJ, 2005, POWDER TECHNOL, V160, P219, DOI 10.1016/j.powtec.2005.09.002
   Li Z, 2017, CHEM ENG J, V317, P242, DOI 10.1016/j.cej.2017.02.055
   Li Z, 2017, CHEM ENG SCI, V169, P299, DOI 10.1016/j.ces.2016.04.046
   Li Z, 2016, CHEM ENG SCI, V140, P279, DOI 10.1016/j.ces.2015.10.020
   Loha C, 2014, RENEW SUST ENERG REV, V40, P688, DOI 10.1016/j.rser.2014.07.199
   Lu LQ, 2017, INT J HEAT MASS TRAN, V111, P723, DOI 10.1016/j.ijheatmasstransfer.2017.04.040
   Ma Q, 2017, POWDER TECHNOL, V320, P574, DOI 10.1016/j.powtec.2017.07.094
   Patil AV, 2015, CHEM ENG J, V277, P388, DOI 10.1016/j.cej.2015.04.131
   Patil AV, 2015, CHEM ENG J, V259, P90, DOI 10.1016/j.cej.2014.07.107
   Patil DJ, 2006, AICHE J, V52, P58, DOI 10.1002/aic.10590
   Peng ZB, 2014, AICHE J, V60, P2000, DOI 10.1002/aic.14421
   Qiu KZ, 2016, INT J THERM SCI, V100, P357, DOI 10.1016/j.ijthermalsci.2015.10.001
   Sin EML, 2018, POWDER TECHNOL, V327, P500, DOI 10.1016/j.powtec.2017.12.095
   TSUJI Y, 1993, POWDER TECHNOL, V77, P79, DOI 10.1016/0032-5910(93)85010-7
   van der Hoef MA, 2008, ANNU REV FLUID MECH, V40, P47, DOI 10.1146/annurev.fluid.40.111406.102130
   Wahyudi H., 2014, 3D CFD STUDY GAS SOL
   Wang S, 2018, POWDER TECHNOL, V333, P91, DOI 10.1016/j.powtec.2018.04.011
   Wang S, 2018, IND ENG CHEM RES, V57, P6774, DOI 10.1021/acs.iecr.8b00353
   Wang S, 2017, CHEM ENG J, V313, P858, DOI 10.1016/j.cej.2016.10.130
   Wang S, 2017, APPL THERM ENG, V111, P1523, DOI 10.1016/j.applthermaleng.2016.07.161
   WEN CY, 1966, AICHE J, V12, P610, DOI 10.1002/aic.690120343
   Xie J, 2017, ENERG FUEL, V31, P14248, DOI 10.1021/acs.energyfuels.7b02693
   Xu YP, 2018, IND ENG CHEM RES, V57, P740, DOI 10.1021/acs.iecr.7b03817
   Yang N, 2003, CHEM ENG J, V96, P71, DOI 10.1016/j.cej.2003.08.006
   Yang SL, 2014, AICHE J, V60, P2788, DOI 10.1002/aic.14494
   Yang SL, 2014, IND ENG CHEM RES, V53, P6896, DOI 10.1021/ie403046q
   Zhao JD, 2013, POWDER TECHNOL, V239, P248, DOI 10.1016/j.powtec.2013.02.003
   Zhao YZ, 2009, AICHE J, V55, P3109, DOI 10.1002/aic.11956
   Zhong WQ, 2016, POWDER TECHNOL, V302, P108, DOI 10.1016/j.powtec.2016.07.010
   Zhong WQ, 2016, CHEM ENG SCI, V140, P16, DOI 10.1016/j.ces.2015.09.035
   Zhou ZY, 2010, J FLUID MECH, V661, P482, DOI 10.1017/S002211201000306X
   Zhou ZY, 2009, AICHE J, V55, P868, DOI 10.1002/aic.11823
   Zhu HP, 2007, CHEM ENG SCI, V62, P3378, DOI 10.1016/j.ces.2006.12.089
   Zhu HP, 2008, CHEM ENG SCI, V63, P5728, DOI 10.1016/j.ces.2008.08.006
NR 64
TC 10
Z9 10
U1 12
U2 82
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD APR 6
PY 2019
VL 197
BP 280
EP 295
DI 10.1016/j.ces.2018.12.031
PG 16
WC Engineering, Chemical
SC Engineering
GA HK0ZQ
UT WOS:000457634000026
DA 2020-05-12
ER

PT J
AU Marek, M
AF Marek, M.
TI Gas flow maldistribution in random packed beds of non-spherical
   particles - A CFD study
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE CFD; Gas maldistribution; Fixed bed; Particle-resolved direct numerical;
   simulation; Raschig ring
ID PACKING COLUMN; HEAT-TRANSFER; SIMULATION; LIQUID; MODEL; PATTERNS
AB In this work, gas maldistribution in random packings of cylinders and Raschig rings is studied with particle-resolved direct numerical simulation (PRDNS) employing a finite volume solver for Cartesian grids and the immersed boundary method for the treatment of complex geometries. The geometry of the random packed bed has been obtained in a separate simulation based on a sequential deposition of particles in a cylindrical column and a simplified mechanics with additional radial force allowing for higher packing densities. The first part of the work focuses on comparison of the packings of cylinders and rings with respect to their ability to distribute the flow uniformly over the cross-section of the column when the gas in the form of a narrow jet enters along the column axis and impinges on the bed directly. The second part is devoted to analysis of three different inlet configurations and their influence on gas maldistribution in the packing of Raschig rings. It has been found that the random packing of rings has comparable properties of flow uniformisation to the same arrangement of full cylinders with significantly lower pressure drop and much less pronounced effect of formation of localised jets at the bed outlet. Among the considered inlet configurations the most beneficial is the one in which the gas duct is tangential to the walls of the distribution chamber. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Marek, M.] Czestochowa Tech Univ, Fac Mech Engn & Comp Sci, Al Armii Krajowej 21, PL-42200 Czestochowa, Poland.
RP Marek, M (reprint author), Czestochowa Tech Univ, Fac Mech Engn & Comp Sci, Al Armii Krajowej 21, PL-42200 Czestochowa, Poland.
EM marekm@imc.pcz.czest.pl
FU National Centre of Science [UMO-2014/15/B/ST8/04762]; 
   [BS-1-103-301/04/P]
FX The work partially supported by the Statutory Research grant
   BS-1-103-301/04/P and National Centre of Science research grant
   UMO-2014/15/B/ST8/04762.
CR Asendrych D, 2017, CHEM ENG COMMUN, V204, P580, DOI 10.1080/00986445.2017.1292258
   Augier F, 2010, CHEM ENG SCI, V65, P1055, DOI 10.1016/j.ces.2009.09.059
   Bazmi M, 2012, INT COMMUN HEAT MASS, V39, P736, DOI 10.1016/j.icheatmasstransfer.2012.03.005
   BILLET R, 1995, PACKED TOWERS
   Boccardo G, 2015, CHEM ENG J, V279, P809, DOI 10.1016/j.cej.2015.05.032
   Caulkin R, 2009, IND ENG CHEM RES, V48, P202, DOI 10.1021/ie800033a
   CHORIN AJ, 1968, MATH COMPUT, V22, P745, DOI 10.2307/2004575
   Darakchiev SR, 2010, BULG CHEM COMMUN, V42, P323
   Dixon AG, 2013, COMPUT CHEM ENG, V48, P135, DOI 10.1016/j.compchemeng.2012.08.011
   Dong Y, 2017, CHEM ENG J, V317, P204, DOI 10.1016/j.cej.2017.02.063
   Du W, 2015, PARTICUOLOGY, V23, P90, DOI 10.1016/j.partic.2014.10.013
   Edwards DP, 1999, CHEM ENG RES DES, V77, P656, DOI 10.1205/026387699526593
   Ferziger J.H., 2002, COMPUTATIONAL METHOD
   Fourati M, 2012, CHEM ENG SCI, V80, P1, DOI 10.1016/j.ces.2012.05.031
   Giese M, 1998, AICHE J, V44, P484, DOI 10.1002/aic.690440225
   Green D. W., 2007, EQUIPMENT DISTILLATI
   Guardo A, 2005, CHEM ENG SCI, V60, P1733, DOI 10.1016/j.ces.2004.10.034
   Haghshenasfard M, 2007, CHEM ENG TECHNOL, V30, P1176, DOI 10.1002/ceat.200700102
   Iaccarino G., 2003, Applied Mechanics Review, V56, P331, DOI 10.1115/1.1563627
   Iliuta I, 2012, CHEM ENG SCI, V73, P299, DOI 10.1016/j.ces.2012.02.007
   Jurtz N, 2019, REV CHEM ENG, V35, P139, DOI 10.1515/revce-2017-0059
   Kolev N., 2006, PACKED BED COLUMNS A
   Kouri RJ, 1996, CHEM ENG J BIOCH ENG, V61, P95, DOI 10.1016/0923-0467(95)03032-8
   Mackowiak J, 2010, FLUID DYNAMICS OF PACKED COLUMNS: PRINCIPLES OF THE FLUID DYNAMIC DESIGN OF COLUMNS FOR GAS/LIQUID AND LIQUID/LIQUID SYSTEMS, P1, DOI 10.1007/b98397
   Marek M, 2017, CHEM ENG SCI, V161, P382, DOI 10.1016/j.ces.2016.12.030
   Marek M, 2013, CHEM PROCESS ENG-INZ, V34, P347, DOI 10.2478/cpe-2013-0028
   Mittal R, 2005, ANNU REV FLUID MECH, V37, P239, DOI 10.1146/annurev.fluid.37.061903.175743
   Mohd-Yusof J., 1997, CTR TURBULENCE RES A, P317
   MUIR LA, 1986, CAN J CHEM ENG, V64, P1027, DOI 10.1002/cjce.5450640623
   Niegodajew P, 2018, EXP THERM FLUID SCI, V96, P162, DOI 10.1016/j.expthermflusci.2018.03.008
   Niegodajew P, 2016, APPL MATH MODEL, V40, P10222, DOI 10.1016/j.apm.2016.07.003
   Niegodajew P, 2016, POWDER TECHNOL, V297, P193, DOI 10.1016/j.powtec.2016.04.024
   Nijemeisland M, 2004, CHEM ENG SCI, V59, P5185, DOI 10.1016/j.ces.2004.07.088
   Olujic Z., 1991, GAS SEP PURIF, V5, P59
   Olujic Z, 2011, CHINESE J CHEM ENG, V19, P726
   Owens SA, 2013, IND ENG CHEM RES, V52, P2032, DOI 10.1021/ie3016889
   Parsons I. M, 1992, GAS SEP PURIF, V6, P221
   Partopour B, 2017, POWDER TECHNOL, V322, P258, DOI 10.1016/j.powtec.2017.09.009
   Patel AK, 2008, POWDER TECHNOL, V185, P239, DOI 10.1016/j.powtec.2007.10.019
   Paterson WR, 2000, CHEM ENG SCI, V55, P3515, DOI 10.1016/S0009-2509(99)00598-9
   PESKIN CS, 1972, J COMPUT PHYS, V10, P252, DOI 10.1016/0021-9991(72)90065-4
   Petrova T, 2008, CHEM ENG TECHNOL, V31, P1723, DOI 10.1002/ceat.200800321
   PORTER KE, 1993, IND ENG CHEM RES, V32, P2408, DOI 10.1021/ie00022a026
   Robbins DJ, 2012, AICHE J, V58, P3904, DOI 10.1002/aic.13767
   Siiria S, 2007, POWDER TECHNOL, V174, P82, DOI 10.1016/j.powtec.2007.01.001
   Sosnowski M, 2018, J PHYS CONF SER, V1101, DOI 10.1088/1742-6596/1101/1/012036
   STIKKELMAN R, 1989, CHEM ENG TECHNOL, V12, P445, DOI DOI 10.1002/ceat.270120164
   Suekane T, 2003, AICHE J, V49, P10, DOI 10.1002/aic.690490103
   Sullivan SP, 2005, CHEM ENG SCI, V60, P3405, DOI 10.1016/j.ces.2005.01.038
   Tryggvason G., 2011, DIRECT NUMERICAL SIM
   Yang XF, 2013, APPL MATH MODEL, V37, P9052, DOI 10.1016/j.apm.2013.04.021
NR 51
TC 0
Z9 0
U1 0
U2 28
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD APR 6
PY 2019
VL 197
BP 296
EP 305
DI 10.1016/j.ces.2018.12.032
PG 10
WC Engineering, Chemical
SC Engineering
GA HK0ZQ
UT WOS:000457634000027
DA 2020-05-12
ER

PT J
AU Pan, F
   Chen, XD
   Mercade-Prieto, R
   Xiao, J
AF Pan, Fei
   Chen, Xiao Dong
   Mercade-Prieto, Ruben
   Xiao, Jie
TI Numerical simulation of milk fouling: Taking fouling layer domain and
   localized surface reaction kinetics into account
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Milk fouling; beta- LG; Fouling kinetics; Fouling layer structure; Heat
   exchanger
ID PLATE HEAT-EXCHANGERS; BETA-LACTOGLOBULIN DENATURATION; WHEY-PROTEIN
   DEPOSIT; DYNAMIC-MODEL; CALCIUM; AGGREGATION; TEMPERATURE; ADSORPTION;
   GROWTH
AB Numerous theoretical and numerical models have been developed to characterize milk fouling in heat exchangers. Though they helped us understand the fouling process, they lack consideration of fouling layer structure and its evolution. In this work, aiming at a more reliable predictive tool, milk fouling is modeled in a simplified 2D heat exchanger. A unique feature of this fully-coupled multi-domain multi-physics model is that the dynamic change of fouling layer structure can be explicitly taken into account while bulk and surface reaction kinetics for beta-lactoglobulin (beta-LG) are coupled with momentum, mass and heat transfer. The structural evolution of the deposit is expressed via a continuously varying geometry of the fouling layer domain. Protein fouling deposition can then be modeled based on local information along the deposit surface. Model based analyses revealed a two-stage growth behavior with diffident dominant control factors. The role of different deposition kinetics on the overall fouling of the heat exchanger was also considered as a test case. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Pan, Fei; Chen, Xiao Dong; Mercade-Prieto, Ruben; Xiao, Jie] Soochow Univ, Coll Chem Chem Engn & Mat Sci, Sch Chem & Environm Engn, China Australia Joint Res Ctr Future Dairy Mfg, Suzhou 215123, Jiangsu, Peoples R China.
   [Mercade-Prieto, Ruben] Nazarbayev Univ, Sch Engn, Dept Chem & Mat Engn, Astana, Kazakhstan.
RP Mercade-Prieto, R; Xiao, J (reprint author), Soochow Univ, Coll Chem Chem Engn & Mat Sci, Sch Chem & Environm Engn, China Australia Joint Res Ctr Future Dairy Mfg, Suzhou 215123, Jiangsu, Peoples R China.; Mercade-Prieto, R (reprint author), Nazarbayev Univ, Sch Engn, Dept Chem & Mat Engn, Astana, Kazakhstan.
EM ruben.mercade@nu.edu.kz; jie.xiao@suda.edu.cn
OI Chen, xiao dong/0000-0002-0150-0491
FU Natural Science Foundation of Jiangsu ProvinceJiangsu Planned Projects
   for Postdoctoral Research FundsNatural Science Foundation of Jiangsu
   Province [BK20170062]; National Key Research and Development Program of
   China (International S& T Cooperation Program, ISTCP) [2016YFE0101200];
   National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [21406148]; Jiangsu Specially-Appointed Professors
   Program; Jiangsu Innovation and Entrepreneurship (Shuang Chuang)
   Program; Priority Academic Program Development (PAPD) of Jiangsu Higher
   Education Institutions
FX This work was supported by the research funds from the Natural Science
   Foundation of Jiangsu Province (BK20170062), the National Key Research
   and Development Program of China (International S& T Cooperation
   Program, ISTCP, No. 2016YFE0101200), the National Natural Science
   Foundation of China (No. 21406148) and the "Jiangsu Specially-Appointed
   Professors Program", "Jiangsu Innovation and Entrepreneurship (Shuang
   Chuang) Program", "Priority Academic Program Development (PAPD) of
   Jiangsu Higher Education Institutions".
CR BELMARBEINY MT, 1993, J FOOD ENG, V19, P119, DOI 10.1016/0260-8774(93)90038-L
   Bouvier L, 2014, J FOOD ENG, V136, P56, DOI 10.1016/j.jfoodeng.2014.03.025
   Boxler C, 2014, J FOOD ENG, V121, P1, DOI 10.1016/j.jfoodeng.2013.08.003
   Brahim F., 2003, NUMERICAL SIMULATION
   BURTON H, 1968, J DAIRY RES, V35, P317, DOI 10.1017/S0022029900019038
   Changani SD, 1997, EXP THERM FLUID SCI, V14, P392, DOI 10.1016/S0894-1777(96)00141-0
   Choi W, 2013, J FOOD PROCESS ENG, V36, P439, DOI 10.1111/j.1745-4530.2012.00684.x
   Davies TJ, 1997, FOOD BIOPROD PROCESS, V75, P106, DOI 10.1205/096030897531414
   De Bonis MV, 2009, INT J THERM SCI, V48, P2006, DOI 10.1016/j.ijthermalsci.2009.03.010
   de Jong P, 1997, TRENDS FOOD SCI TECH, V8, P401, DOI 10.1016/S0924-2244(97)01089-3
   Delplace F., 1994, Food and Bioproducts Processing, V72, P163, DOI 10.1205/096030802760309188
   Deplace F., 1995, FOOD BIOPROD PROCESS, V73, P112
   Donato L, 2009, DAIRY SCI TECHNOL, V89, P3, DOI 10.1051/dst:2008033
   FRYER PJ, 1989, J SOC DAIRY TECHNOL, V42, P23
   Gandhi G, 2017, LWT-FOOD SCI TECHNOL, V81, P170, DOI 10.1016/j.lwt.2017.03.063
   Georgiadis MC, 2000, CHEM ENG SCI, V55, P1605, DOI 10.1016/S0009-2509(99)00429-7
   Guerin R, 2007, CHEM ENG SCI, V62, P1948, DOI 10.1016/j.ces.2006.12.038
   ITOH H, 1995, BIOSCI BIOTECH BIOCH, V59, P1648, DOI 10.1271/bbb.59.1648
   Jimenez M, 2013, J COLLOID INTERF SCI, V404, P192, DOI 10.1016/j.jcis.2013.04.021
   Jong P. D., 1996, APPL SCI, V1, P194
   Jun S, 2006, J FOOD ENG, V75, P364, DOI 10.1016/j.jfoodeng.2005.03.064
   Jun S, 2005, INT J DAIRY TECHNOL, V58, P214, DOI 10.1111/j.1471-0307.2005.00213.x
   Kehoe JJ, 2014, FOOD HYDROCOLLOID, V39, P264, DOI 10.1016/j.foodhyd.2014.01.019
   Khaldi M, 2015, J FOOD ENG, V147, P68, DOI 10.1016/j.jfoodeng.2014.09.020
   Kroslak M, 2007, BIOMACROMOLECULES, V8, P963, DOI 10.1021/bm060293+
   LALANDE M, 1985, BIOTECHNOL PROGR, V1, P131, DOI 10.1002/btpr.5420010210
   Loveday SM, 2016, INT DAIRY J, V52, P92, DOI 10.1016/j.idairyj.2015.08.001
   Mahdi Y, 2009, APPL MATH MODEL, V33, P648, DOI 10.1016/j.apm.2007.11.030
   Perry R H., 2007, PERRYS CHEM ENG HDB
   Petit J, 2011, J DAIRY SCI, V94, P5794, DOI 10.3168/jds.2011-4470
   Santos O, 2006, J FOOD ENG, V73, P174, DOI 10.1016/j.jfoodeng.2005.01.018
   SKUDDER PJ, 1981, J DAIRY RES, V48, P99, DOI 10.1017/S0022029900021518
   Xiao J, 2017, CHEM ENG SCI, V168, P137, DOI 10.1016/j.ces.2017.04.043
   Xiao J, 2017, HEAT TRANSFER ENG, V38, P775, DOI 10.1080/01457632.2016.1206419
   Yang W, 2018, CHEM ENG SCI, V177, P501, DOI 10.1016/j.ces.2017.12.004
   Zhang F, 2015, FOOD BIOPROD PROCESS, V93, P188, DOI 10.1016/j.fbp.2014.10.017
NR 36
TC 2
Z9 2
U1 2
U2 14
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD APR 6
PY 2019
VL 197
BP 306
EP 316
DI 10.1016/j.ces.2018.12.021
PG 11
WC Engineering, Chemical
SC Engineering
GA HK0ZQ
UT WOS:000457634000028
DA 2020-05-12
ER

PT J
AU Ermolaev, VS
   Mordkovich, VZ
AF Ermolaev, Vadim S.
   Mordkovich, V. Z.
TI Method for recovery of complete molecular composition of the
   Fischer-Tropsch synthesis products on the basis of incomplete
   experimental data
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Fischer-Tropsch synthesis; Vapor-liquid-liquid equilibrium; Product
   distribution; Selectivity
ID GROUP-CONTRIBUTION EQUATION; PHASE-EQUILIBRIA; CUBIC EQUATION;
   ALPHA-FUNCTION; STATE; VTPR; PREDICTION
AB A method for calculational recovery of complete molecular composition of the Fischer-Tropsch synthesis products on the basis of incomplete experimental data is proposed. The method employs VTPR equation of state for analysing the available data on the composition of gaseous and liquid phases at the exit of a Fischer-Tropsch reactor. It is shown that in most cases such data are incomplete and misleading due to both instrumental limitations and inevitable losses at phase separation manipulations. The critical thermodynamic properties of the synthesis products, as well as the parameters of the equation of state for the calculation of multicomponent equilibrium using the group contribution method are determined. The results of the calculations are displayed along with experimental data from the literature and data obtained in the laboratory and industrial scale reactors. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Ermolaev, Vadim S.] Technol Inst Superhard & Novel Carbon Mat FSBI TI, Moscow, Russia.
   INFRA Ltd, Moscow, Russia.
RP Ermolaev, VS (reprint author), Technol Inst Superhard & Novel Carbon Mat FSBI TI, Moscow, Russia.
EM ermolaev@infratechnology.com
RI Mordkovich, Vladimir Z/L-2077-2013
OI Mordkovich, Vladimir Z/0000-0002-9553-7657
FU Ministry of Education and Science of the Russian FederationMinistry of
   Education and Science, Russian Federation
FX This work was supported by the Ministry of Education and Science of the
   Russian Federation in terms of state assignment to FSBI TISNCM.
CR Ahlers J, 2002, IND ENG CHEM RES, V41, P5890, DOI 10.1021/ie0203734
   Asalieva E, 2015, APPL CATAL A-GEN, V505, P260, DOI 10.1016/j.apcata.2015.08.006
   Collinet E, 2006, FLUID PHASE EQUILIBR, V246, P111, DOI 10.1016/j.fluid.2006.05.033
   Derevich IV, 2008, THEOR FOUND CHEM EN+, V42, P216, DOI 10.1134/S0040579508020152
   Diedrichs A, 2006, FLUID PHASE EQUILIBR, V248, P56, DOI 10.1016/j.fluid.2006.07.009
   Ermolaev VS, 2015, CHEM ENG SCI, V138, P1, DOI 10.1016/j.ces.2015.07.036
   Gernert J, 2014, FLUID PHASE EQUILIBR, V375, P209, DOI 10.1016/j.fluid.2014.05.012
   Gmehling J., 2012, CHEM THERMODYNAMICS
   Li ZD, 2012, FLUID PHASE EQUILIBR, V332, P21, DOI 10.1016/j.fluid.2012.06.021
   MICHELSEN ML, 1980, FLUID PHASE EQUILIBR, V4, P1, DOI 10.1016/0378-3812(80)80001-X
   MICHELSEN ML, 1994, FLUID PHASE EQUILIBR, V98, P1, DOI 10.1016/0378-3812(94)80104-5
   Mordkovich VZ, 2015, CATAL IND, V15, P23, DOI DOI 10.18412/1816-0387-2015-5-23-45
   Poling B. E., 2001, PROPERTIES GASES LIQ
   Schmid B, 2012, FLUID PHASE EQUILIBR, V317, P110, DOI 10.1016/j.fluid.2012.01.006
   Schmid B, 2011, FLUID PHASE EQUILIBR, V302, P213, DOI 10.1016/j.fluid.2010.09.009
   Schmid B, 2010, J SUPERCRIT FLUID, V55, P438, DOI 10.1016/j.supflu.2010.10.018
   SOAVE G, 1986, FLUID PHASE EQUILIBR, V31, P203, DOI 10.1016/0378-3812(86)90013-0
   TWU CH, 1991, FLUID PHASE EQUILIBR, V69, P33, DOI 10.1016/0378-3812(91)90024-2
   TWU CH, 1995, FLUID PHASE EQUILIBR, V105, P49, DOI 10.1016/0378-3812(94)02601-V
   Wilson G. M. A, 1968, AICHE 65 NAT M CLEV
NR 20
TC 0
Z9 0
U1 2
U2 7
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD APR 6
PY 2019
VL 197
BP 317
EP 325
DI 10.1016/j.ces.2018.12.020
PG 9
WC Engineering, Chemical
SC Engineering
GA HK0ZQ
UT WOS:000457634000029
DA 2020-05-12
ER

PT J
AU Ray, M
   Chowdhury, F
   Sowinski, A
   Mehrani, P
   Passalacqua, A
AF Ray, M.
   Chowdhury, F.
   Sowinski, A.
   Mehrani, P.
   Passalacqua, A.
TI An Euler-Euler model for mono-dispersed gas-particle flows incorporating
   electrostatic charging due to particle-wall and particle-particle
   collisions
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Electrostatic charging; Contact charging; Fluidized bed; Polyethylene
   particles; Computational fluid dynamics; Eulerian model
ID SOLID FLUIDIZED-BED; CONTACT ELECTRIFICATION; AVERAGED EQUATIONS; BUBBLE
   FORMATION; DEM SIMULATION; KINETIC-THEORY; GRANULAR FLOW; CFD;
   GENERATION; IMPLEMENTATION
AB A computational model for the prediction of triboelectric charging in gas-solid fluidized beds is developed in the context of the Euler-Euler two-fluid model with kinetic theory closures for the description of the particulate phase. Sub-model for charge transfer due to particle-wall collisions is obtained consistently with the boundary conditions of Johnson and Jackson (1987), and assuming the model of Matsusaka et al. (2000) for charge transfer during a single collision. Similarly, a sub-model for charge diffusion due to particle-particle collisions is developed based on the kinetic theory of granular flow of Jenkins and Savage (1983), and the aforementioned charging model. The Eulerian charging model is then coupled to the two-fluid model, with kinetic theory closures which are available in the OpenFOAM (R) computational toolbox for fluid dynamics. The model is tested to simulate the effect of polyethylene particle size (362, 462, 550 mu m) in the electrification process, and is validated against experimental findings (Sowinski, 2012; Sowinski et al., 2012). The order of magnitude of charge densities in different regions of the bed, predicted by the model, was coherent with the experimental results. The model also predicted that particles larger than 425 mu m would not stick to the column wall, which acceptably agreed with the experimental observation that particles larger than 600 mu m did not adhere to the wall surface. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Ray, M.; Passalacqua, A.] Iowa State Univ, Dept Mech Engn, 2025 Black Engn Bldg, Ames, IA 50011 USA.
   [Chowdhury, F.; Sowinski, A.; Mehrani, P.] Univ Ottawa, Dept Chem & Biol Engn, 161 Louis Pasteur, Ottawa, ON K1N 6N5, Canada.
RP Passalacqua, A (reprint author), Iowa State Univ, Dept Mech Engn, 2025 Black Engn Bldg, Ames, IA 50011 USA.
EM albertop@iastate.edu
RI Passalacqua, Alberto/L-9483-2016
OI Passalacqua, Alberto/0000-0001-9368-9393; Chowdhury,
   Fahad/0000-0002-0737-6057; Sowinski, Andrew/0000-0001-9162-6743; Ray,
   Manjil/0000-0001-8026-8047
CR Bakshi A, 2018, POWDER TECHNOL, V332, P114, DOI 10.1016/j.powtec.2018.03.048
   Benyahia S, 2008, CHEM ENG SCI, V63, P5672, DOI 10.1016/j.ces.2008.08.016
   Boemer A, 1997, INT J MULTIPHAS FLOW, V23, P927, DOI 10.1016/S0301-9322(97)00018-9
   Boemer A, 1998, CHEM ENG SCI, V53, P1835, DOI 10.1016/S0009-2509(98)00044-X
   Bokkers GA, 2004, POWDER TECHNOL, V140, P176, DOI 10.1016/j.powtec.2004.01.018
   CAMMARATA L, 2003, INT J CHEM REACTOR E, V1
   CHAPMAN SC, 1961, MATH THEORY NONUNIFO
   Chowdhury F, 2018, J ELECTROSTAT, V91, P9, DOI 10.1016/j.elstat.2017.11.004
   Cross J., 1987, ELECTROSTATICS PRINC
   Drew D. A., 1983, Theory of Dispersed Multiphase Flow. Proceedings of an Advanced Seminar, P173
   DREW DA, 1971, STUD APPL MATH, V50, P205
   Garg R, 2009, INT J MULTIPHAS FLOW, V35, P376, DOI 10.1016/j.ijmultiphaseflow.2008.12.004
   Garzo V, 2012, J FLUID MECH, V712, P129, DOI 10.1017/jfm.2012.404
   GIDASPOW D, 1983, IND ENG CHEM FUND, V22, P193, DOI 10.1021/i100010a008
   Gidaspow D., 1994, MULTIPHASE FLOW FLUI
   Giffin A, 2010, J ELECTROSTAT, V68, P492, DOI 10.1016/j.elstat.2010.06.013
   Hassani MA, 2013, POWDER TECHNOL, V246, P16, DOI 10.1016/j.powtec.2013.05.007
   Hjertager BH, 2007, CISM COUR L, P125
   HSIAU SS, 1993, J HEAT TRANS-T ASME, V115, P541, DOI 10.1115/1.2910720
   Ireland PM, 2010, POWDER TECHNOL, V198, P189, DOI 10.1016/j.powtec.2009.11.017
   Ishii M., 1975, THERMOFLUID DYNAMIC
   ISSA RI, 1986, J COMPUT PHYS, V62, P40, DOI 10.1016/0021-9991(86)90099-9
   Jackson R, 1997, CHEM ENG SCI, V52, P2457, DOI 10.1016/S0009-2509(97)00065-1
   Jalalinejad F, 2015, INT J MULTIPHAS FLOW, V70, P104, DOI 10.1016/j.ijmultiphaseflow.2014.11.007
   Jenkins JT, 1997, PHYS FLUIDS, V9, P2835, DOI 10.1063/1.869396
   JENKINS JT, 1992, J APPL MECH-T ASME, V59, P120, DOI 10.1115/1.2899416
   JENKINS JT, 1983, J FLUID MECH, V130, P187, DOI 10.1017/S0022112083001044
   JOHNSON PC, 1987, J FLUID MECH, V176, P67, DOI 10.1017/S0022112087000570
   Kaneko Y, 1999, CHEM ENG SCI, V54, P5809, DOI 10.1016/S0009-2509(99)00153-0
   Kolehmainen J, 2018, J FLUID MECH, V848, P340, DOI 10.1017/jfm.2018.361
   Kolehmainen J, 2017, AICHE J, V63, P1872, DOI 10.1002/aic.15541
   Kolehmainen J, 2016, AICHE J, V62, P2282, DOI 10.1002/aic.15279
   Korevaar MW, 2014, POWDER TECHNOL, V258, P144, DOI 10.1016/j.powtec.2014.03.020
   Kunii D., 1991, FLUIDIZATION ENG
   Lahey RT, 2005, NUCL ENG DES, V235, P1043, DOI 10.1016/j.nucengdes.2005.02.020
   Laurentie JC, 2013, J ELECTROSTAT, V71, P951, DOI 10.1016/j.elstat.2013.08.001
   Lindborg H, 2007, CHEM ENG SCI, V62, P5854, DOI 10.1016/j.ces.2007.06.011
   Liu XD, 2014, CHEM ENG PROCESS, V79, P14, DOI 10.1016/j.cep.2014.02.006
   LOWELL J, 1980, ADV PHYS, V29, P947, DOI 10.1080/00018738000101466
   LOWELL J, 1975, J PHYS D APPL PHYS, V8, P53, DOI 10.1088/0022-3727/8/1/013
   Lun C. K. K., 1986, EFFECTS IMPACT VELOC, P14
   LUN CKK, 1984, J FLUID MECH, V140, P223, DOI 10.1017/S0022112084000586
   Mathiesen V, 2000, POWDER TECHNOL, V112, P34, DOI 10.1016/S0032-5910(99)00303-4
   Matsusaka S, 2003, ADV POWDER TECHNOL, V14, P143, DOI 10.1163/156855203763593958
   Matsusaka S, 2010, CHEM ENG SCI, V65, P5781, DOI 10.1016/j.ces.2010.07.005
   Matsusaka S, 2000, J PHYS D APPL PHYS, V33, P2311, DOI 10.1088/0022-3727/33/18/316
   Matsusyama T, 2006, CHEM ENG SCI, V61, P2230, DOI 10.1016/j.ces.2005.05.003
   Mehrani P, 2005, J ELECTROSTAT, V63, P165, DOI 10.1016/j.elstat.2004.10.003
   Mountain JR, 2001, IEEE T IND APPL, V37, P778, DOI 10.1109/28.924759
   Muhle M. E., 2010, J COMPUTATIONAL MULT, V2, P189, DOI DOI 10.1260/1757-482X.2.4.189
   OGAWA S, 1980, Z ANGEW MATH PHYS, V31, P483, DOI 10.1007/BF01590859
   Oliveira PJ, 2003, INT J NUMER METH FL, V43, P1177, DOI 10.1002/fld.508
   Passalacqua A, 2011, POWDER TECHNOL, V213, P174, DOI 10.1016/j.powtec.2011.07.030
   Passalacqua A, 2009, CHEM ENG SCI, V64, P2795, DOI 10.1016/j.ces.2009.03.005
   Patankar S.V., 1980, NUMERICAL HEAT TRANS
   Pei C, 2016, POWDER TECHNOL, V304, P208, DOI 10.1016/j.powtec.2016.08.030
   Pei CL, 2015, AICHE J, V61, P1792, DOI 10.1002/aic.14768
   Pei CL, 2013, POWDER TECHNOL, V248, P34, DOI 10.1016/j.powtec.2013.04.014
   Rakotonirina AD, 2018, POWDER TECHNOL, V324, P18, DOI 10.1016/j.powtec.2017.10.033
   Rokkam RG, 2013, CHEM ENG SCI, V92, P146, DOI 10.1016/j.ces.2013.01.023
   Rokkam RG, 2010, POWDER TECHNOL, V203, P109, DOI 10.1016/j.powtec.2010.04.002
   SCHAEFFER DG, 1987, J DIFFER EQUATIONS, V66, P19, DOI 10.1016/0022-0396(87)90038-6
   SCHEIN LB, 1992, PHYS LETT A, V167, P79, DOI 10.1016/0375-9601(92)90630-5
   Shen WZ, 2001, AIAA J, V39, P2406, DOI 10.2514/2.1252
   Simonin O., 1996, CONTINUUM MODELLING
   Song CX, 2017, POWDER TECHNOL, V314, P346, DOI 10.1016/j.powtec.2016.10.044
   Sowinski A., 2012, THESIS
   Sowinski A, 2012, CHEM ENG SCI, V71, P552, DOI 10.1016/j.ces.2011.11.031
   Sowinski A, 2010, CHEM ENG SCI, V65, P2771, DOI 10.1016/j.ces.2010.01.008
   Spalding D., 1980, RECENT ADV NUMERICAL
   Srivastava A, 2003, POWDER TECHNOL, V129, P72, DOI 10.1016/S0032-5910(02)00132-8
   SWEBY PK, 1984, SIAM J NUMER ANAL, V21, P995, DOI 10.1137/0721062
   Taghipour F, 2005, CHEM ENG SCI, V60, P6857, DOI 10.1016/j.ces.2005.05.044
   TSUO YP, 1990, AICHE J, V36, P885, DOI 10.1002/aic.690360610
   Weller H. G., 2006, BOUNDED EXPLICIT IMP
   WILSON RG, 1966, J APPL PHYS, V37, P2261, DOI 10.1063/1.1708797
   Yang Y, 2017, POWDER TECHNOL, V308, P422, DOI 10.1016/j.powtec.2016.12.032
   Ye M, 2008, PARTICUOLOGY, V6, P540, DOI 10.1016/j.partic.2008.07.005
NR 78
TC 6
Z9 6
U1 4
U2 23
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD APR 6
PY 2019
VL 197
BP 327
EP 344
DI 10.1016/j.ces.2018.12.028
PG 18
WC Engineering, Chemical
SC Engineering
GA HK0ZQ
UT WOS:000457634000031
DA 2020-05-12
ER

PT J
AU Olayiwola, SO
   Dejam, M
AF Olayiwola, Saheed Olawale
   Dejam, Morteza
TI Mathematical modelling of surface tension of nanoparticles in
   electrolyte solutions
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Nanoparticles; Surface tension; Electrolytes; Dipole-dipole interaction;
   Structural effect
ID AQUEOUS-SOLUTIONS; WATER; ADSORPTION; SILICA; DISSOLUTION; SOLUBILITY;
   KINETICS; HYDRATION; ALUMINA; FORCES
AB Nanoparticles (NPs) have been successfully applied to reservoirs for enhanced oil recovery and fines migration mitigation at laboratory scale. Despite the successful implementation at laboratory scale, it is rarely applied at field scale. One of the major reasons for the delay in implementation is the lack of an appropriate model to predict the fluid-particles behaviour in the reservoir. An accurate prediction of the surface tension of the fluid system is particularly important in field design and development in the petroleum sector.
   The surface tension of NPs in deionized water increases with increase in concentration of NPs. This study exploits the Debye-Hilckel constants to calculate the mean activity coefficients of NPs in solution combined with the equation proposed by Li and Lu (2001) for single electrolyte solutions to estimate the change in surface tension.
   However, NPs behaviour in brine (electrolyte solution) is different from the behaviour of mixture of different electrolytes. In deionized water, the surface tension of the fluid increases with increase in the NPs concentration, but NPs in electrolyte solutions behave as surface active agent decreasing the surface tension with increase in NPs concentration. This work includes the dipole-dipole interaction and structural effects along with the equation developed by Borwanker and Wasan (1988) for surface excess adsorption. This surface excess adsorption is applied to Li and Lu's equation for mixed electrolyte solutions to estimate the change in surface tension.
   This study is able to model the surface tension of NPs with or without electrolyte. Here, the molecular interaction of NPs in deionized water and electrolyte solutions is considered to predict the fluid-surface tension. The free energy at the interface is affected by the intermolecular interaction of the NPs. This intermolecular interaction includes electrical double layer, dipole-dipole interaction, and structural effects. The proposed model shows a good agreement with the experimental data from previous studies. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Olayiwola, Saheed Olawale; Dejam, Morteza] Univ Wyoming, Coll Engn & Appl Sci, Dept Petr Engn, 1000 E Univ Ave, Laramie, WY 82071 USA.
RP Dejam, M (reprint author), Univ Wyoming, Coll Engn & Appl Sci, Dept Petr Engn, 1000 E Univ Ave, Laramie, WY 82071 USA.
EM mdejam@uwyo.edu
RI Dejam, Morteza/F-5313-2011
OI Dejam, Morteza/0000-0002-3435-3838; Olayiwola, Saheed
   Olawale/0000-0003-3921-1043
FU Department of Petroleum Engineering in the College of Engineering and
   Applied Science at the University of Wyoming
FX The financial support from the Department of Petroleum Engineering in
   the College of Engineering and Applied Science at the University of
   Wyoming is gratefully appreciated.
CR Adamson A.W., 1997, PHYS CHEM SURFACES
   ALEXANDER GB, 1954, J PHYS CHEM-US, V58, P453, DOI 10.1021/j150516a002
   Andreev M, 2018, J PHYS CHEM B, V122, P4029, DOI 10.1021/acs.jpcb.8b00518
   Ariyama K., 1937, Bulletin of the Chemical Society of Japan, V12, P109, DOI 10.1246/bcsj.12.109
   Bassett R. L., 1973, GEOCHEMICAL INVESTIG
   Bera A, 2016, J NAT GAS SCI ENG, V34, P1284, DOI 10.1016/j.jngse.2016.08.023
   Bhuiyan MHU, 2015, PROCEDIA ENGINEER, V105, P431, DOI 10.1016/j.proeng.2015.05.030
   Bolhuis PG, 1997, NATURE, V388, P235, DOI 10.1038/40779
   BORWANKAR RP, 1988, CHEM ENG SCI, V43, P1323, DOI 10.1016/0009-2509(88)85106-6
   BUFF FP, 1956, J CHEM PHYS, V25, P312, DOI 10.1063/1.1742878
   Chapman DL, 1913, PHILOS MAG, V25, P475, DOI 10.1080/14786440408634187
   Chen HL, 2017, CHEM ENG SCI, V162, P10, DOI 10.1016/j.ces.2016.12.028
   Cheng HP, 2002, J CHEM PHYS, V116, P9300, DOI 10.1063/1.1473808
   Cho KS, 2005, J AM CHEM SOC, V127, P7140, DOI 10.1021/ja050107s
   CHRISTOFFERSEN J, 1991, J CRYST GROWTH, V113, P599, DOI 10.1016/0022-0248(91)90096-N
   Debye P, 1923, PHYS Z, V24, P185
   Drelich J., 2016, J NANOMATER MOL NANO, V2013
   Drzymala J, 2012, J PHYS CHEM A, V116, P6465, DOI 10.1021/jp211034y
   Engeset B, 2012, THESIS
   ERIKSSON P, 1988, ENVIRON PROG, V7, P58, DOI 10.1002/ep.3300070116
   Fan H, 2012, PHYS REV E, V86, DOI 10.1103/PhysRevE.86.051610
   Fawcett W. R., 2004, LIQUIDS SOLUTIONS IN
   Ferdous S, 2012, J NANOPART RES, V14, DOI 10.1007/s11051-012-0850-4
   FOWKES FM, 1964, IND ENG CHEM, V56, P40, DOI 10.1021/ie50660a008
   FOWKES FM, 1968, J COLLOID INTERF SCI, V28, P493, DOI 10.1016/0021-9797(68)90082-9
   FRANKE MD, 1987, AICHE J, V33, P267, DOI 10.1002/aic.690330213
   Gibbs J.W., 1906, SCI PAPERS JW GIBBS
   Gouy M., 1910, J PHYS-PARIS, V9, P457, DOI DOI 10.1051/JPHYSTAP:019100090045700
   HACHISU S, 1973, J COLLOID INTERF SCI, V42, P342, DOI 10.1016/0021-9797(73)90298-1
   Harikrishnan AR, 2017, EUR PHYS J E, V40, DOI 10.1140/epje/i2017-11541-5
   HEY MJ, 1981, J CHEM SOC FARAD T 1, V77, P123, DOI 10.1039/f19817700123
   HORN RG, 1980, CHEM PHYS LETT, V71, P192, DOI 10.1016/0009-2614(80)80144-8
   JAMES RO, 1982, SURF COLLOID SCI, V12, P119
   JARVIS NL, 1968, J PHYS CHEM-US, V72, P74, DOI 10.1021/j100847a014
   Jiang LH, 2018, CHEM ENG J, V343, P371, DOI 10.1016/j.cej.2018.03.026
   Kamal MS, 2017, J NANOMATER, DOI 10.1155/2017/2473175
   KHILAR KC, 1984, J COLLOID INTERF SCI, V101, P214, DOI 10.1016/0021-9797(84)90021-3
   Kobayashi M, 2007, CHEM MATER, V19, P5373, DOI 10.1021/cm071370q
   KRALCHEVSKY PA, 1995, CHEM PHYS LETT, V240, P385, DOI 10.1016/0009-2614(95)00539-G
   Kruyt H., 1952, COLLOID SCI, V1, P1
   Langmuir I, 1918, J AM CHEM SOC, V40, P1361, DOI 10.1021/ja02242a004
   Laysandra L, 2017, HELIYON, V3, DOI 10.1016/j.heliyon.2017.e00488
   Lefevre G, 2002, LANGMUIR, V18, P7530, DOI 10.1021/la025651i
   Li ZB, 1999, IND ENG CHEM RES, V38, P1133, DOI 10.1021/ie980465m
   Li ZB, 2001, CHEM ENG SCI, V56, P2879, DOI 10.1016/S0009-2509(00)00525-X
   LORENZ PB, 1950, J PHYS COLLOID CHEM, V54, P685, DOI 10.1021/j150479a014
   Lucassen-Reynders E. H., 1976, PROG SURF MEMBRANE S, V10, P253
   Markovich T, 2015, J CHEM PHYS, V142, DOI 10.1063/1.4905954
   McCabe C., 2010, SAFT ASS FLUIDS FLUI
   Metin CO, 2012, J NANOPART RES, V14, DOI 10.1007/s11051-012-1246-1
   Moosavi M, 2010, INT J HEAT FLUID FL, V31, P599, DOI 10.1016/j.ijheatfluidflow.2010.01.011
   Muller HSP, 2013, J PHYS CHEM A, V117, P13868, DOI 10.1021/jp4083807
   Negin Chegenizadeh, 2016, Petroleum, V2, P324, DOI 10.1016/j.petlm.2016.10.002
   Newton RC, 2003, CONTRIB MINERAL PETR, V146, P135, DOI 10.1007/s00410-003-0483-9
   NIKOLOV AD, 1990, PROG COLL POL SCI S, V82, P87
   NIKOLOV AD, 1989, J COLLOID INTERF SCI, V133, P1, DOI 10.1016/0021-9797(89)90278-6
   Nowotny J, 2010, J PHYS CHEM C, V114, P18215, DOI 10.1021/jp105735x
   OCONNOR TL, 1958, J PHYS CHEM-US, V62, P1195, DOI 10.1021/j150568a008
   Olayiwola SO, 2019, FUEL, V241, P1045, DOI 10.1016/j.fuel.2018.12.122
   Onsager L, 1934, J CHEM PHYS, V2, DOI 10.1063/1.1749522
   Petersen PB, 2006, ANNU REV PHYS CHEM, V57, P333, DOI 10.1146/annurev.physchem.57.032905.104609
   Randles J. E. B., 1977, Physics and Chemistry of Liquids, V7, P107, DOI 10.1080/00319107708084730
   RIMSTIDT JD, 1980, GEOCHIM COSMOCHIM AC, V44, P1683, DOI 10.1016/0016-7037(80)90220-3
   Shevchenko EV, 2006, NATURE, V439, P55, DOI 10.1038/nature04414
   Shim M, 1999, J CHEM PHYS, V111, P6955, DOI 10.1063/1.479988
   SIRACUSA PA, 1987, COLLOID SURFACE, V26, P55, DOI 10.1016/0166-6622(87)80106-3
   Smith AM, 2017, PHYS REV LETT, V118, DOI 10.1103/PhysRevLett.118.096002
   STAIRS RA, 1995, CAN J CHEM, V73, P781, DOI 10.1139/v95-098
   STILLINGS LL, 1995, GEOCHIM COSMOCHIM AC, V59, P1483, DOI 10.1016/0016-7037(95)00057-7
   Sulaiman W. R. W., 2015, ADV MAT RES
   Talapin DV, 2007, NANO LETT, V7, P1213, DOI 10.1021/nl070058c
   Tang ZY, 2006, ADV MATER, V18, P3203, DOI 10.1002/adma.200600113
   Tang ZY, 2002, SCIENCE, V297, P237, DOI 10.1126/science.1072086
   Tanvir Saad, 2012, Nanoscale Res Lett, V7, P226, DOI 10.1186/1556-276X-7-226
   Vafaei S, 2009, NANOTECHNOLOGY, V20, DOI 10.1088/0957-4484/20/18/185702
   VANMEGEN W, 1976, J COLLOID INTERF SCI, V57, P40, DOI 10.1016/0021-9797(76)90172-7
   Wasan DT, 2003, NATURE, V423, P156, DOI 10.1038/nature01591
   WASAN DT, 1992, COLLOID SURFACE, V67, P139, DOI 10.1016/0166-6622(92)80293-B
   Weissenborn PK, 1996, J COLLOID INTERF SCI, V184, P550, DOI 10.1006/jcis.1996.0651
   Zallaghi M, 2018, J PET EXPLOR PROD TE, V8, P259, DOI 10.1007/s13202-017-0347-x
   Zargartalebi M, 2014, J PETROL SCI ENG, V119, P36, DOI 10.1016/j.petrol.2014.04.010
   Zhang Y, 2008, WATER RES, V42, P2204, DOI 10.1016/j.watres.2007.11.036
NR 82
TC 23
Z9 23
U1 11
U2 21
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD APR 6
PY 2019
VL 197
BP 345
EP 356
DI 10.1016/j.ces.2018.11.047
PG 12
WC Engineering, Chemical
SC Engineering
GA HK0ZQ
UT WOS:000457634000032
HC Y
HP N
DA 2020-05-12
ER

PT J
AU Guo, ZH
   Sun, ZN
   Zhang, N
   Ding, M
   Shi, S
AF Guo, Zehua
   Sun, Zhongning
   Zhang, Nan
   Ding, Ming
   Shi, Shuai
TI CFD analysis of fluid flow and particle-to-fluid heat transfer in packed
   bed with radial layered configuration
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Packed bed; CFD; Radial layered configuration; Convective heat transfer;
   Pressure drop
ID VOID FRACTION DISTRIBUTION; PRESSURE-DROP; SMALL TUBE; EXPERIMENTAL
   VALIDATION; NUMERICAL SIMULATIONS; FIXED-BEDS; REACTORS; WALL;
   COEFFICIENTS; TRANSPORT
AB The channeling effect at the container wall results in difficulties for heat transfer in the central part of packed beds with small tube-to-particle diameter ratios. To overcome this shortcoming, a new kind of packed bed is developed with radial layered configuration: a fluid-penetrable wire mesh is used to divide the container into two parts in the radial direction, which allows particles of different sizes for regional loading. Therefore, following the general rule of fluid flow distribution in packed beds, small particles could be filled in the zone at the container wall to restrain the channeling effect and large particles in the center to promote local heat transfer capacity. In the present work, to facilitate the proper functionality of new equipment using the novel method, a CFD simulation combined with the DEM method for random packing generation is conducted to study the characteristics of the new packed bed on the packing structure, fluid flow, and particles-to-fluid convective heat transfer under a high fluid velocity regime (Re similar to 10(4)). It finds that the new packing method could exhibit a much regular structure than the conventional packed beds. And outstanding performance is observed in pressure drop reduction and heat transfer efficiency improvement. Moreover, the well-known equations for pressure drop and convective heat transfer predictions are found not applicable to the new bed and distinctive features of fluid velocity and temperature distribution are identified. These findings are helpful for the design of high efficiency reactors. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Guo, Zehua; Sun, Zhongning; Zhang, Nan; Ding, Ming] Harbin Engn Univ, Fundamental Sci Nucl Safety & Simulat Technol Lab, Harbin 150001, Heilongjiang, Peoples R China.
   [Guo, Zehua; Sun, Zhongning; Zhang, Nan; Ding, Ming] Harbin Engn Univ, Coll Nucl Sci & Technol, Harbin 150001, Heilongjiang, Peoples R China.
   [Shi, Shuai] China Ship Dev & Design Ctr, Wuhan 430064, Hubei, Peoples R China.
RP Zhang, N (reprint author), Harbin Engn Univ, Fundamental Sci Nucl Safety & Simulat Technol Lab, Harbin 150001, Heilongjiang, Peoples R China.
EM gzh0391@hrbeu.edu.cn; zhangnan11@hrbeu.edu.cn
FU Student Research and Innovation Fund of the Fundamental Research Funds
   for the Central Universities [HEUGIP2018021]; Fundamental Research Funds
   for the Central UniversitiesFundamental Research Funds for the Central
   Universities [HEUCF181503]; National Natural Science Foundation of
   ChinaNational Natural Science Foundation of China [11705036]
FX The authors acknowledge the financial support provided by the Ph.D.
   Student Research and Innovation Fund of the Fundamental Research Funds
   for the Central Universities (HEUGIP2018021), the Fundamental Research
   Funds for the Central Universities (HEUCF181503), and the National
   Natural Science Foundation of China (No. 11705036).
CR Bagci O, 2014, TRANSPORT POROUS MED, V104, P501, DOI 10.1007/s11242-014-0345-0
   BENENATI RF, 1962, AICHE J, V8, P359, DOI 10.1002/aic.690080319
   Bey O, 2001, INT J THERM SCI, V40, P152, DOI 10.1016/S1290-0729(00)01204-7
   Bird R. B., 2002, TRANSPORT PHENOMENA
   Bu SS, 2014, NUCL ENG DES, V270, P21, DOI 10.1016/j.nucengdes.2014.01.001
   Calis HPA, 2001, CHEM ENG SCI, V56, P1713, DOI 10.1016/S0009-2509(00)00400-0
   Carman P.C., 1937, T I CHEM ENG-LOND, V15, P17, DOI [10.1016/S0263-8762(97)80003-2, DOI 10.1016/S0263-8762(97)80003-2]
   Chikhi N, 2014, ANN NUCL ENERGY, V74, P24, DOI 10.1016/j.anucene.2014.05.009
   Das S, 2017, CHEM ENG SCI, V160, P1, DOI 10.1016/j.ces.2016.11.008
   de Klerk A, 2003, AICHE J, V49, P2022, DOI 10.1002/aic.690490812
   DIXON AG, 1988, CAN J CHEM ENG, V66, P705, DOI 10.1002/cjce.5450660501
   Dixon AG, 1997, IND ENG CHEM RES, V36, P3053, DOI 10.1021/ie9605950
   Dixon AG, 2013, COMPUT CHEM ENG, V48, P135, DOI 10.1016/j.compchemeng.2012.08.011
   Dixon AG, 2012, CHEM ENG J, V200, P344, DOI 10.1016/j.cej.2012.06.065
   Dong Y, 2017, CHEM ENG J, V317, P204, DOI 10.1016/j.cej.2017.02.063
   Eppinger T, 2011, CHEM ENG J, V166, P324, DOI 10.1016/j.cej.2010.10.053
   Erdim E, 2015, POWDER TECHNOL, V283, P488, DOI 10.1016/j.powtec.2015.06.017
   ERGUN S, 1952, CHEM ENG PROG, V48, P89
   Freund H, 2003, CHEM ENG SCI, V58, P903, DOI 10.1016/S0009-2509(02)00622-X
   Giese M, 1998, AICHE J, V44, P484, DOI 10.1002/aic.690440225
   Guo XY, 2014, CHEM ENG SCI, V107, P266, DOI 10.1016/j.ces.2013.12.032
   Guo ZH, 2017, CHEM ENG SCI, V173, P578, DOI 10.1016/j.ces.2017.08.022
   Guo ZH, 2017, POWDER TECHNOL, V319, P445, DOI 10.1016/j.powtec.2017.06.061
   Hu Y., 2017, CIESC J, V68, P54
   Magnico P, 2003, CHEM ENG SCI, V58, P5005, DOI 10.1016/S0009-2509(03)00282-3
   Ookawara S., 2007, P EUR C CHEM ENG ECC
   Singhal A, 2017, CHEM ENG SCI, V172, P1, DOI 10.1016/j.ces.2017.06.003
   WAKAO N, 1979, CHEM ENG SCI, V34, P325, DOI 10.1016/0009-2509(79)85064-2
   Wang LB, 2001, INT J HEAT FLUID FL, V22, P603, DOI 10.1016/S0142-727X(01)00127-8
   Wehinger GD, 2015, CHEM ENG SCI, V122, P197, DOI 10.1016/j.ces.2014.09.007
   WHITE SM, 1987, WARME STOFFUBERTRAG, V21, P291, DOI 10.1007/BF01009290
   Winterberg M, 2000, CHEM ENG SCI, V55, P967, DOI 10.1016/S0009-2509(99)00379-6
   Yang J, 2016, NUCL ENG DES, V300, P85, DOI 10.1016/j.nucengdes.2015.10.030
   Zobel N, 2012, CHEM ENG SCI, V71, P212, DOI 10.1016/j.ces.2011.12.029
NR 34
TC 4
Z9 4
U1 11
U2 30
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD APR 6
PY 2019
VL 197
BP 357
EP 370
DI 10.1016/j.ces.2018.12.034
PG 14
WC Engineering, Chemical
SC Engineering
GA HK0ZQ
UT WOS:000457634000033
DA 2020-05-12
ER

PT J
AU Kumar, A
   Bhan, A
AF Kumar, Anurag
   Bhan, Aditya
TI Oxygen content as a variable to control product selectivity in
   hydrodeoxygenation reactions on molybdenum carbide catalysts
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Molybdenum carbide; Oxygen treatment; Hydrodeoxygenation; Anisole
ID VAPOR-PHASE HYDRODEOXYGENATION; TRANSITION-METAL CARBIDES; TUNGSTEN
   CARBIDES; SURFACE-CHEMISTRY; DEOXYGENATION; ADSORPTION; ISOMERIZATION;
   NITRIDES; INSIGHTS; BENZENE
AB Oxygen-treatment of as-synthesized molybdenum carbide at 296 K-423 K and subsequent temperature-programmed-surface-reaction with hydrogen was utilized to obtain oxygen-modified Mo2C (O:Mo-bulk = 0.002 for Fresh-Mo2C to O:Mo-bulk = 0.276 for Mo2C oxygen treated at 423 K) formulations. Benzene selectivity decreased from 97% at O:Mo-bulk = 0.002 to 18% at O:Mo-bulk = 0.276 while phenol selectivity concurrently increased from 0.2% at O:Mo-bulk = 0.002 to 81% at O:Mo-bulk = 0.276 in reactions of anisole/hydrogen mixtures at atmospheric pressure and 423 K showing that O* content can be used to tune the product selectivity in hydrodeoxygenation reactions on transition metal carbides. This change in selectivity can plausibly be ascribed to the formation of MoOx/MoOxCy species that disrupts ensembles required for selective aromatic C-O bond cleavage. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Kumar, Anurag; Bhan, Aditya] Univ Minnesota, Dept Chem Engn & Mat Sci, Minneapolis, MN 55455 USA.
RP Bhan, A (reprint author), Univ Minnesota, Dept Chem Engn & Mat Sci, Minneapolis, MN 55455 USA.
EM abhan@umn.edu
FU National Science Foundation Catalysis and Biocatalysis Program (CBET
   Award) [1510661]
FX This research was supported by National Science Foundation Catalysis and
   Biocatalysis Program (CBET Award No. 1510661). Prof. Rakesh Agrawal's
   extensive research in the area of sustainable energy development has
   provided us the motivation and encouragement to pursue fundamental
   catalysis research in the utilization of biomass as an alternate carbon
   and energy source.
CR Bej SK, 2004, APPL CATAL A-GEN, V264, P141, DOI 10.1016/j.apcata.2003.12.051
   BLEKKAN EA, 1994, IND ENG CHEM RES, V33, P1657, DOI 10.1021/ie00031a003
   Bouchy C, 2000, J CATAL, V190, P92, DOI 10.1006/jcat.1999.2741
   Boullosa-Eiras S, 2014, CATAL TODAY, V223, P44, DOI 10.1016/j.cattod.2013.09.044
   Chen C. J., 1998, J MOL CATAL-A CHEM, V131, P285
   Chen CJ, 2017, ACS CATAL, V7, P1113, DOI 10.1021/acscatal.6b02762
   Chen CJ, 2016, APPL CATAL A-GEN, V510, P42, DOI 10.1016/j.apcata.2015.10.043
   Chen JGG, 1996, CHEM REV, V96, P1477, DOI 10.1021/cr950232u
   Choi JS, 2000, J CATAL, V193, P238, DOI 10.1006/jcat.2000.2894
   Choi JS, 2002, CATAL LETT, V81, P175, DOI 10.1023/A:1016568804706
   Choudhary TV, 2011, APPL CATAL A-GEN, V397, P1, DOI 10.1016/j.apcata.2011.02.025
   Eng J, 1998, J PHYS CHEM B, V102, P9687, DOI 10.1021/jp9826120
   Eng J, 1997, J PHYS CHEM B, V101, P4044, DOI 10.1021/jp9633355
   Fernandez-Rodriguez J, 2017, J ENERGY CHEM, V26, P622, DOI 10.1016/j.jechem.2017.02.007
   Furimsky E, 2003, APPL CATAL A-GEN, V240, P1, DOI 10.1016/S0926-860X(02)00428-3
   Furimsky E, 2000, APPL CATAL A-GEN, V199, P147, DOI 10.1016/S0926-860X(99)00555-4
   Garin F., 1997, REACTION MECH KINETI, V166, P125
   HURFF SJ, 1983, IND ENG CHEM FUND, V22, P426, DOI 10.1021/i100012a012
   Hwu HH, 2005, CHEM REV, V105, P185, DOI 10.1021/cr0204606
   IGLESIA E, 1992, CATAL TODAY, V15, P307, DOI 10.1016/0920-5861(92)80181-L
   IGLESIA E, 1992, CATAL TODAY, V15, P455, DOI 10.1016/0920-5861(92)85010-J
   IGLESIA E, 1991, J CATAL, V131, P523, DOI 10.1016/0021-9517(91)90284-B
   Jin W, 2019, CHEMCATCHEM, V11, P924, DOI 10.1002/cctc.201801722
   Kelly TG, 2014, GREEN CHEM, V16, P777, DOI 10.1039/c3gc41259h
   Kelly TG, 2012, CHEM SOC REV, V41, P8021, DOI 10.1039/c2cs35165j
   Ko CH, 2012, KOREAN J CHEM ENG, V29, P1657, DOI 10.1007/s11814-012-0199-5
   KO EI, 1980, SURF SCI, V100, pL449
   KO EI, 1981, SURF SCI, V109, P221, DOI 10.1016/0039-6028(81)90521-5
   KO EI, 1981, SURF SCI, V112, P373, DOI 10.1016/0039-6028(81)90381-2
   Kumar A, 2018, CATAL SCI TECHNOL, V8, P2938, DOI 10.1039/c8cy00358k
   Lamic AF, 2005, J MOL CATAL A-CHEM, V237, P109, DOI 10.1016/j.molcata.2005.03.041
   Lee WS, 2015, ACS CATAL, V5, P4104, DOI 10.1021/acscatal.5b00713
   Lee WS, 2014, J CATAL, V319, P44, DOI 10.1016/j.jcat.2014.07.025
   Lee WS, 2014, CATAL SCI TECHNOL, V4, P2340, DOI 10.1039/c4cy00286e
   Lin ZX, 2018, GREEN CHEM, V20, P2679, DOI 10.1039/c8gc00239h
   Liu P, 2006, J PHYS CHEM B, V110, P19418, DOI 10.1021/jp0621629
   Mai EF, 2014, GREEN CHEM, V16, P4092, DOI 10.1039/c4gc00920g
   Medford AJ, 2012, J CATAL, V290, P108, DOI 10.1016/j.jcat.2012.03.007
   Murugappan K, 2018, NAT CATAL, V1, P960, DOI 10.1038/s41929-018-0171-9
   Neylon MK, 1999, APPL CATAL A-GEN, V183, P253, DOI 10.1016/S0926-860X(99)00053-8
   OYAMA ST, 1992, CATAL TODAY, V15, P179, DOI 10.1016/0920-5861(92)80175-M
   Prasomsri T, 2014, ENERG ENVIRON SCI, V7, P2660, DOI 10.1039/c4ee00890a
   Prasomsri T, 2013, ENERG ENVIRON SCI, V6, P1732, DOI 10.1039/c3ee24360e
   RANHOTRA GS, 1987, J CATAL, V108, P40, DOI 10.1016/0021-9517(87)90153-9
   Ren H, 2014, GREEN CHEM, V16, P761, DOI 10.1039/c3gc41256c
   Ren XR, 2017, ACS SUSTAIN CHEM ENG, V5, P6548, DOI 10.1021/acssuschemeng.7b00732
   RIBEIRO FH, 1991, CHEM MATER, V3, P805, DOI 10.1021/cm00017a015
   RIBEIRO FH, 1991, J CATAL, V130, P86, DOI 10.1016/0021-9517(91)90094-K
   RIBEIRO FH, 1991, J CATAL, V130, P498, DOI 10.1016/0021-9517(91)90131-M
   Saidi M, 2014, ENERG ENVIRON SCI, V7, P103, DOI [10.1039/c3ee43081b, 10.1039/C3EE43081B]
   Schaidle JA, 2016, ACS CATAL, V6, P1181, DOI 10.1021/acscatal.5b01930
   Schaidle JA, 2012, J CATAL, V289, P210, DOI 10.1016/j.jcat.2012.02.012
   Shetty M, 2015, J CATAL, V331, P86, DOI 10.1016/j.jcat.2015.07.034
   Shi XR, 2016, J MOL CATAL A-CHEM, V417, P53, DOI 10.1016/j.molcata.2016.03.007
   SINFELT JH, 1971, NATURE-PHYS SCI, V229, P27, DOI 10.1038/physci229027b0
   Stellwagen DR, 2015, GREEN CHEM, V17, P582, DOI 10.1039/c4gc01831a
   Stottlemyer AL, 2012, SURF SCI REP, V67, P201, DOI 10.1016/j.surfrep.2012.07.001
   Sullivan MM, 2018, J CATAL, V357, P195, DOI 10.1016/j.jcat.2017.11.004
   Sullivan MM, 2016, J CATAL, V344, P53, DOI 10.1016/j.jcat.2016.09.012
   Sullivan MM, 2016, ACS CATAL, V6, P1145, DOI 10.1021/acscatal.5b02656
   Sullivan MM, 2016, CATAL SCI TECHNOL, V6, P602, DOI 10.1039/c5cy01665g
   Sullivan MM, 2015, J CATAL, V326, P82, DOI 10.1016/j.jcat.2015.03.011
   Vitale G, 2011, APPL CATAL A-GEN, V408, P178, DOI 10.1016/j.apcata.2011.09.026
   Wang T, 2014, J PHYS CHEM C, V118, P8079, DOI 10.1021/jp501471u
   Wang T, 2014, J PHYS CHEM C, V118, P3162, DOI 10.1021/jp412067x
   Xiong K, 2014, APPL SURF SCI, V323, P88, DOI 10.1016/j.apsusc.2014.06.100
   Zhang YY, 2018, ACS SUSTAIN CHEM ENG, V6, P5349, DOI 10.1021/acssuschemeng.8b00129
NR 67
TC 2
Z9 2
U1 6
U2 34
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD APR 6
PY 2019
VL 197
BP 371
EP 378
DI 10.1016/j.ces.2018.12.027
PG 8
WC Engineering, Chemical
SC Engineering
GA HK0ZQ
UT WOS:000457634000034
DA 2020-05-12
ER

PT J
AU Graca, NS
   Ribeiro, AM
   Rodrigues, AE
AF Graca, Nuno S.
   Ribeiro, Ana M.
   Rodrigues, Alirio E.
TI Modeling the electrocoagulation process for the treatment of
   contaminated water
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Electrocoagulation; Mathematical model; Aluminum electrodes; Arsenic;
   Water treatment
ID ALUMINUM; REMOVAL; COAGULATION; IRON; GROUNDWATER; DISSOLUTION;
   SUSPENSIONS; HYDROLYSIS
AB The study of the electro-dissolution of aluminum electrodes during the electrocoagulation process is important for understanding the mechanisms involved in the process. This study involved the experimental determination of both total and dissolved aluminum concentrations during the electrocoagulation processes operation. The total aluminum concentration was fitted with the Faraday's equation and was obtained 1.6 of current efficiency, indicating a super-faradaic behavior of the electrochemical process at the given operating conditions. Additionally, a mathematical model was developed considering the electrochemical dissolution of the Al anode, water electrolysis, hydrolysis of dissolved Al and water dissociation reaction involved in the electrocoagulation process. The simulated results showed a good prediction of the evolution of both concentration of dissolved aluminum and pH during the electrocoagulation process operation. The model was also employed to simulate the removal of arsenic from water by electrocoagulation showing a good prediction of the experimental results at the operating conditions considered. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Graca, Nuno S.; Ribeiro, Ana M.; Rodrigues, Alirio E.] Univ Porto, Dept Chem Engn, LSRE, LCM, Rua Dr Roberto Frias S-N, P-4200465 Porto, Portugal.
RP Graca, NS (reprint author), Univ Porto, Dept Chem Engn, LSRE, LCM, Rua Dr Roberto Frias S-N, P-4200465 Porto, Portugal.
RI Rodrigues, Alirio E./L-5515-2015; Ribeiro, Ana/C-9502-2011
OI Rodrigues, Alirio E./0000-0002-0715-4761; Graca,
   Nuno/0000-0002-4397-6578; Ribeiro, Ana/0000-0003-4269-1420
FU FEDER through COMPETE2020 - Programa Operacional Competitividade e
   Internacionalizacao (POCI) [POCI-01-0145-FEDER-006984]; FCT - Fundacao
   para a Ciencia e a TecnologiaPortuguese Foundation for Science and
   Technology [INDIGO/0003/2014]
FX This work was financially supported by: Project
   POCI-01-0145-FEDER-006984 - Associate Laboratory LSRE-LCM funded by
   FEDER through COMPETE2020 - Programa Operacional Competitividade e
   Internacionalizacao (POCI) -and by national funds through FCT - Fundacao
   para a Ciencia e a Tecnologia; Project INDIGO/0003/2014 funded by FCT -
   Fundacao para a Ciencia e a Tecnologia.
CR Abodi LC, 2012, ELECTROCHIM ACTA, V63, P169, DOI 10.1016/j.electacta.2011.12.074
   Benefield L. D., 1982, PROCESS CHEM WATER W, P359, DOI [10.1016/j.ces.2013.03.016, DOI 10.1016/J.CES.2013.03.016]
   Canizares P, 2008, SEP PURIF TECHNOL, V60, P155, DOI 10.1016/j.seppur.2007.08.003
   Canizares P, 2008, J HAZARD MATER, V151, P44, DOI 10.1016/j.jhazmat.2007.05.043
   Canizares P, 2007, IND ENG CHEM RES, V46, P6189, DOI 10.1021/ie070059f
   Carmona M, 2006, CHEM ENG SCI, V61, P1237, DOI 10.1016/j.ces.2005.08.030
   Chen XM, 2002, ENVIRON SCI TECHNOL, V36, P778, DOI 10.1021/es011003u
   Duan JM, 2003, ADV COLLOID INTERFAC, V100, P475, DOI 10.1016/S0001-8686(02)00067-2
   Fajardo AS, 2015, CHEM ENG J, V275, P331, DOI 10.1016/j.cej.2015.03.116
   Flores OJ, 2014, INT J ELECTROCHEM SC, V9, P6658
   Guseva O, 2009, ELECTROCHIM ACTA, V54, P4514, DOI 10.1016/j.electacta.2009.03.048
   Jimenez C, 2012, SEP PURIF TECHNOL, V98, P102, DOI 10.1016/j.seppur.2012.07.005
   Khemis M, 2006, CHEM ENG SCI, V61, P3602, DOI 10.1016/j.ces.2005.12.034
   Lacasa E, 2013, SEP PURIF TECHNOL, V107, P219, DOI 10.1016/j.seppur.2013.01.035
   Lakshmanan D, 2010, WATER RES, V44, P5641, DOI 10.1016/j.watres.2010.06.018
   Lu J, 2017, CHEM ENG SCI, V165, P165, DOI 10.1016/j.ces.2017.03.001
   Lu J, 2015, CHEM ENG J, V267, P86, DOI 10.1016/j.cej.2015.01.011
   MATTESON MJ, 1995, COLLOID SURFACE A, V104, P101, DOI 10.1016/0927-7757(95)03259-G
   Mechelhoff M, 2013, CHEM ENG SCI, V95, P353, DOI 10.1016/j.ces.2013.03.016
   Mechelhoff M, 2013, CHEM ENG SCI, V95, P301, DOI 10.1016/j.ces.2013.03.010
   Miwa DW, 2006, WATER RES, V40, P3281, DOI 10.1016/j.watres.2006.06.033
   Hakizimana JN, 2017, DESALINATION, V404, P1, DOI 10.1016/j.desal.2016.10.011
   Onder E, 2007, SEP PURIF TECHNOL, V52, P527, DOI 10.1016/j.seppur.2006.06.006
   Sadeddin K, 2011, DESALINATION, V268, P204, DOI 10.1016/j.desal.2010.10.027
   Silva JFA, 2018, SEP PURIF TECHNOL, V197, P237, DOI 10.1016/j.seppur.2017.12.055
   van Genuchten CM, 2012, ENVIRON SCI TECHNOL, V46, P986, DOI 10.1021/es201913a
   Xiao F, 2008, J ENVIRON SCI, V20, P907, DOI 10.1016/S1001-0742(08)62185-3
NR 27
TC 6
Z9 6
U1 4
U2 22
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD APR 6
PY 2019
VL 197
BP 379
EP 385
DI 10.1016/j.ces.2018.12.038
PG 7
WC Engineering, Chemical
SC Engineering
GA HK0ZQ
UT WOS:000457634000035
DA 2020-05-12
ER

PT J
AU Ludwig, W
   Zajac, D
   Ligus, G
   Korman, P
AF Ludwig, Wojciech
   Zajac, Daniel
   Ligus, Grzegorz
   Korman, Piotr
TI Analysis of pneumatic nozzle operation with the stochastic
   Euler-Lagrange model
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE CFD; Spraying; Sheet constant; Ligament constant; Secondary phenomena
ID SPRAY CONE ANGLE; LIQUID; CFD; FLOW; SIMULATION; AIR; DISINTEGRATION;
   ATOMIZATION; DEPOSITION; APPARATUS
AB The aim of this study was to develop a CFD model for initial qualitative analysis of the operation of the pneumatic nozzle used for dry coating. The calibration consisted in comparing the droplets velocity yielded by the model with our own experimental data. The impact of the sheet and ligament constants as well as of the application of secondary coalescence and breakup models on dispersed phase velocity were taken into consideration. It turned out that the secondary phenomena had the largest impact on the dispersed phase velocity. Only after they had been taken into consideration was the agreement between the computation results and empirical data satisfactory.
   Afterwards, the best set-up of the model was used for describing the plasticizer atomization in a draft tube of a spout-fluid bed apparatus. It was concluded that this process should be carried out with the atomizing gas at a pressure of 2 . 10(5) Pa. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Ludwig, Wojciech; Korman, Piotr] Wroclaw Univ Sci & Technol, Fac Chem, Dept Chem Engn, Norw 4-6, PL-50373 Wroclaw, Poland.
   [Zajac, Daniel] Kelvion, Engn & R&D Dept, Kobaltowa 2, PL-45641 Opole, Poland.
   [Ligus, Grzegorz] Opole Univ Technol, Fac Mech Engn, Dept Environm Engn, Proszkowska 76, PL-45758 Opole, Poland.
RP Ludwig, W (reprint author), Wroclaw Univ Sci & Technol, Fac Chem, Dept Chem Engn, Norw 4-6, PL-50373 Wroclaw, Poland.
EM wojciech.ludwig@pwr.edu.pl; daniel.zajac@kelvion.com;
   g.ligus@po.opole.pl; piotr.korman@pwr.edu.pl
OI Ligus, Grzegorz/0000-0002-3426-3074; Ludwig,
   Wojciech/0000-0002-8101-3481; Korman, Piotr Kamil/0000-0002-0603-8742
FU Polish National Science Centre [UMO-2013/09/B/ST8/00157]; Polish
   Ministry for Science and Higher EducationMinistry of Science and Higher
   Education, Poland
FX The studies were funded by the Polish National Science Centre within the
   framework of the research grant UMO-2013/09/B/ST8/00157. The work has
   been partly supported by statutory funds from Polish Ministry for
   Science and Higher Education.
CR Abboud AW, 2018, POWDER TECHNOL, V334, P36, DOI 10.1016/j.powtec.2018.04.065
   Bayvel L., 1993, LIQUID ATOMIZATION
   BERLEMONT A, 1990, INT J MULTIPHAS FLOW, V16, P19, DOI 10.1016/0301-9322(90)90034-G
   Case WR, 2016, CHEM ENG SCI, V156, P229, DOI 10.1016/j.ces.2016.09.014
   Chen Y, 2017, IND ROBOT, V44, P629, DOI 10.1108/IR-07-2016-0205
   DALY BJ, 1970, PHYS FLUIDS, V13, P2634, DOI 10.1063/1.1692845
   Delele MA, 2009, J FOOD ENG, V91, P228, DOI 10.1016/j.jfoodeng.2008.08.027
   Dernotte J, 2012, ATOMIZATION SPRAY, V22, P461, DOI 10.1615/AtomizSpr.2012004401
   DOMBROWSKI N, 1963, CHEM ENG SCI, V18, P203, DOI 10.1016/0009-2509(63)85005-8
   Duangkhamchan W, 2012, CHEM ENG SCI, V68, P555, DOI 10.1016/j.ces.2011.10.022
   Fries L, 2013, CHEM ENG SCI, V86, P108, DOI 10.1016/j.ces.2012.06.026
   GOSMAN AD, 1983, J ENERGY, V7, P482, DOI 10.2514/3.62687
   Halder MR, 2004, EXP THERM FLUID SCI, V28, P297, DOI 10.1016/S0894-1777(03)00110-9
   Hede PD, 2008, CHEM ENG SCI, V63, P3821, DOI 10.1016/j.ces.2008.04.014
   Jiang X, 2010, PROG ENERG COMBUST, V36, P131, DOI 10.1016/j.pecs.2009.09.002
   Jiang ZC, 2018, DRY TECHNOL, V36, P638, DOI 10.1080/07373937.2017.1319852
   Keshani S, 2015, J FOOD ENG, V146, P152, DOI 10.1016/j.jfoodeng.2014.09.004
   Khan S, 2018, FUEL, V225, P203, DOI 10.1016/j.fuel.2018.03.139
   Ko GH, 2005, J AEROSOL SCI, V36, P1300, DOI 10.1016/j.jaerosci.2005.02.005
   Lamb H., 1945, HYDRODYNAMICS
   Lee MW, 2012, APPL MATH MODEL, V36, P4512, DOI 10.1016/j.apm.2012.02.015
   Lefebvre A. H., 1989, ATOMIZATION SPRAYS
   Liu A., 1993, 930072 SAE, DOI [10.4271/930072., DOI 10.4271/930072]
   Ludwig W, 2012, PROCEDIA ENGINEER, V42, P437, DOI 10.1016/j.proeng.2012.07.435
   Ludwig W, 2012, PROCEDIA ENGINEER, V42, P1157, DOI 10.1016/j.proeng.2012.07.508
   Ludwig W, 2017, POWDER TECHNOL, V319, P332, DOI 10.1016/j.powtec.2017.07.001
   Masters K., 1972, SPRAY DRYING
   Miller P. C. H., 2009, T ASABE, V52, P1471
   MOSTAFA AA, 1987, INT J HEAT MASS TRAN, V30, P2583, DOI 10.1016/0017-9310(87)90139-6
   Muller R, 2006, PHARM DEV TECHNOL, V11, P425, DOI 10.1080/10837450600770205
   Nijdam JJ, 2006, APPL MATH MODEL, V30, P1196, DOI 10.1016/j.apm.2006.02.001
   Nuyttens D, 2009, T ASABE, V52, P1471, DOI 10.13031/2013.29127
   O'Rourke P.J., 1981, THESIS
   ORourke P. J., 1987, 872089 SAE, DOI [10.4271/872089, DOI 10.4271/872089]
   Orzechowski Z., 1991, SPRAYING OF LIQUIDS
   Pandey P, 2006, AAPS PHARMSCITECH, V7
   Pawar SK, 2014, CAN J CHEM ENG, V92, P2013, DOI 10.1002/cjce.22065
   Quiroz-Perez E, 2016, FUEL, V186, P100, DOI 10.1016/j.fuel.2016.08.067
   RIZKALLA AA, 1975, J FLUID ENG-T ASME, V97, P316, DOI 10.1115/1.3447309
   Rodriguez-Rivero C, 2013, POWDER TECHNOL, V246, P617, DOI 10.1016/j.powtec.2013.05.050
   Ruger M, 2000, ATOMIZATION SPRAY, V10, P47
   Schick R. J., 2006, SPRAY TECHNOLOGY REF
   Schmidt D. P., 1999, 3 ASME JSME JOINT EN
   Schmidt D. P., 1999, 010496 SAE, DOI [10.4271/1999-01-0496, DOI 10.4271/1999-01-0496]
   Senecal PK, 1999, INT J MULTIPHAS FLOW, V25, P1073, DOI 10.1016/S0301-9322(99)00057-9
   Seyedin SH, 2017, PERIOD POLYTECH-CHEM, V61, P117, DOI 10.3311/PPch.8611
   Shafaee M, 2011, J MECH SCI TECHNOL, V25, P365, DOI 10.1007/s12206-010-1215-5
   Sharqawy MH, 2017, APPL THERM ENG, V117, P584, DOI 10.1016/j.applthermaleng.2017.02.061
   Sirignano WA, 2000, PROG ENERG COMBUST, V26, P609, DOI 10.1016/S0360-1285(00)00014-9
   SMITH PG, 1982, CHEM ENG SCI, V37, P950, DOI 10.1016/0009-2509(82)80186-3
   SMITH PG, 1983, CHEM ENG SCI, V38, P1223, DOI 10.1016/0009-2509(83)80042-6
   Spray Drying Systems Co, 2006, ENG GUID SPRAY DRYIN
   Suzzi D, 2010, CHEM ENG SCI, V65, P5699, DOI 10.1016/j.ces.2010.07.007
   Szafran RG, 2012, POWDER TECHNOL, V225, P52, DOI 10.1016/j.powtec.2012.03.031
   Taylor G.I., 1963, SCI PAPERS GI TAYLOR
   Turton R, 2008, POWDER TECHNOL, V181, P186, DOI 10.1016/j.powtec.2006.12.006
   Turton R, 2010, DRUG DEV IND PHARM, V36, P143, DOI 10.3109/03639040903452278
   van Wachem BGM, 2003, CHEM ENG J, V96, P81, DOI 10.1016/j.cej.2003.08.025
   Walzel P., 1993, INT CHEM ENG, V33, P46
   Weber C, 1931, Z ANGEW MATH MECH, V11, P136, DOI 10.1002/zamm.19310110207
   Yoo SY, 2004, KSME INT J, V18, P1002, DOI 10.1007/BF02990872
   Zabihi F, 2015, J COAT TECHNOL RES, V12, P489, DOI 10.1007/s11998-015-9656-5
   Zbicinski I, 2017, J CHEM ENG JPN, V50, P757, DOI 10.1252/jcej.16we350
NR 63
TC 3
Z9 3
U1 1
U2 28
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD APR 6
PY 2019
VL 197
BP 386
EP 403
DI 10.1016/j.ces.2019.01.002
PG 18
WC Engineering, Chemical
SC Engineering
GA HK0ZQ
UT WOS:000457634000036
DA 2020-05-12
ER

PT J
AU Liu, ZY
   Li, YQ
   Luan, HX
   Gao, WB
   Guo, Y
   Chen, YH
AF Liu, Zheyu
   Li, Yiqiang
   Luan, Huoxin
   Gao, Wenbin
   Guo, Yang
   Chen, Yihang
TI Pore scale and macroscopic visual displacement of oil-in-water emulsions
   for enhanced oil recovery
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Emulsion; Pore scale; Macroscopic visualization; Transport in porous
   media; Enhanced oil recovery
ID MOBILITY CONTROL; RESIDUAL OIL; CRUDE-OIL; FLOW; MODEL; EMULSIFICATION;
   OPTIMIZATION; SURFACTANTS; MECHANISM; DESIGN
AB In-situ formation of emulsions has been observed in a large amount of chemical flooding pilots, and their effect on oil recovery is of great interest to petroleum engineers and researchers. In this study, microfluidic and transparent sand pack models were used to investigate mechanisms of emulsion propagation and plugging in both pore and macro scales. A microfluidic chip consisting of high- and lowpermeability areas was fabricated to represent a heterogeneous area. Another chip was created with the same throat width but enlarged pore sizes (1.5 times larger) and reduced throat lengths. Two microscopic displacement experiments were conducted to compare the effect of pore structure on residual oil displacement after surfactant/polymer (SP) flooding by injecting the same emulsion slug. Meanwhile, the macroscopic flow path of the displacing fluid in the emulsion flooding was investigated using a relatively homogeneous transparent 2D sand pack. The emulsion plugging was proved to be a complicated process, and it could be strongly affected by pore throat structures. Fluid division and high oil recovery could only be achieved during the emulsion flooding in the condition with properly matched sizes of emulsion droplets and pore throats. For a relatively homogeneous 2D sand pack model, oil bank formation and enlarged sweep volume were observed in the emulsion flooding even though it was conducted after SP flooding. As suggested by results of this study, the in-situ formation of emulsion might significantly contribute to the oil recovery in reservoirs with tortuous pore structures, while making little difference in those with large pore throat channels that emulsion couldn't be trapped in. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Liu, Zheyu; Li, Yiqiang; Gao, Wenbin; Guo, Yang] China Univ Petr, Coll Petr Engn, Beijing 102249, Peoples R China.
   [Luan, Huoxin] Petro China, Xinjiang Oilfield Co, Res Inst Expt & Detect, Karamay 834000, Peoples R China.
   [Chen, Yihang] Petro China, Res Inst Petr Explorat & Dev, Beijing 100083, Peoples R China.
RP Liu, ZY; Li, YQ (reprint author), China Univ Petr, Coll Petr Engn, Beijing 102249, Peoples R China.
EM zheyu-liu@outlook.com; lyq89731007@163.com
OI liu, Zheyu/0000-0002-1564-7486; LI, Yiqiang/0000-0001-5926-8229
FU Major National Science and Technology Project of China
   [2016ZX05025-003-010]; China University of Petroleum, Beijing [01JB0585]
FX The authors would like to thank the Major National Science and
   Technology Project of China (Grant No. 2016ZX05025-003-010) and the
   grant from China University of Petroleum, Beijing (No. 01JB0585) for the
   financial support during this research.
CR Aitkulov A., 2018, SPE IMPR OIL REC C T, DOI [10.2118/190271-MS, DOI 10.2118/190271-MS]
   Alvarado V, 2010, ENERGIES, V3, P1529, DOI 10.3390/en3091529
   [Anonymous], 2018, BP EN OUTL 2018
   Bai YR, 2014, ENERG FUEL, V28, P1829, DOI 10.1021/ef402313n
   Baldygin A, 2014, J PETROL SCI ENG, V121, P167, DOI 10.1016/j.petrol.2014.06.021
   CHATENEVER A, 1959, J PETROL TECHNOL, V11, P13
   Chatenever A, 1952, J PET TECHNOL, V4, P149, DOI [10.2118/135-G, DOI 10.2118/135-G]
   Chen Z, 2018, IND ENG CHEM RES, V57, P7301, DOI 10.1021/acs.iecr.8b00889
   Cobos S, 2009, INT J MULTIPHAS FLOW, V35, P507, DOI 10.1016/j.ijmultiphaseflow.2009.02.018
   de Farias MLR, 2016, TRANSPORT POROUS MED, V113, P267, DOI 10.1007/s11242-016-0692-0
   Demikhova II, 2016, J PETROL SCI ENG, V143, P235, DOI 10.1016/j.petrol.2016.02.018
   Destefanis M. F., 2011, Journal of Physics: Conference Series, V296, DOI 10.1088/1742-6596/296/1/012014
   Dresselhaus MS, 2001, NATURE, V414, P332, DOI 10.1038/35104599
   Engelke B, 2013, ENERG FUEL, V27, P1967, DOI 10.1021/ef301429v
   Fanun M., 2009, MICROEMULSIONS PROPE, P349
   Fortenberry R, 2015, SPE J, V20, P255, DOI 10.2118/166478-PA
   Gogarty W. B., 1967, SPE J, V7, P161, DOI [10.2118/1566-b, DOI 10.2118/1566-B]
   GOGARTY WB, 1970, J PETROL TECHNOL, V22, P141, DOI 10.2118/1847-E-PA
   Guillen VR, 2012, TRANSPORT POROUS MED, V94, P197, DOI 10.1007/s11242-012-9997-9
   Guillen VR, 2012, INT J MULTIPHAS FLOW, V43, P62, DOI 10.1016/j.ijmultiphaseflow.2012.03.001
   Guo H., 2017, SPE RES CHAR SIM C E, DOI [10.2118/186036-MS, DOI 10.2118/186036-MS]
   Guo H, 2018, SPE PROD OPER, V33, P353, DOI 10.2118/179661-PA
   Hou Q., 2012, SOC PETROLEUM ENG, DOI [10.2118/152010-MS, DOI 10.2118/152010-MS]
   Karambeigi MS, 2013, PETROL SCI TECHNOL, V31, P923, DOI 10.1080/10916466.2010.506461
   Karambeigi MS, 2015, J IND ENG CHEM, V29, P382, DOI 10.1016/j.jiec.2015.04.019
   Khanamiri HH, 2016, ENERG FUEL, V30, P8114, DOI 10.1021/acs.energyfuels.6b01236
   Khorsandi S, 2016, J SURFACTANTS DETERG, V19, P1273, DOI 10.1007/s11743-016-1877-9
   Kobayashi I, 2003, COLLOID SURFACE A, V229, P33, DOI 10.1016/j.colsurfa.2003.08.005
   Lake LW, 1989, ENHANCED OIL RECOVER
   Li JJ, 2017, PARTICUL SCI TECHNOL, V35, P355, DOI 10.1080/02726351.2016.1160461
   Liu ZY, 2016, PETROL SCI, V13, P91, DOI 10.1007/s12182-015-0070-5
   Liu ZY, 2017, J PETROL SCI ENG, V152, P267, DOI 10.1016/j.petrol.2017.03.010
   [栾和鑫 Luan Huoxin], 2017, [油田化学, Oilfield Chemistry], V34, P528
   MCAULIFFE CD, 1973, J PETROL TECHNOL, V25, P721, DOI 10.2118/4370-PA
   MILLER CA, 1993, COLLOID SURFACE A, V74, P169, DOI 10.1016/0927-7757(93)80263-E
   Nogueira GL, 2013, TRANSPORT POROUS MED, V98, P427, DOI 10.1007/s11242-013-0151-0
   Pal R, 1996, AICHE J, V42, P3181, DOI 10.1002/aic.690421119
   Panthi K, 2013, ENERG FUEL, V27, P764, DOI 10.1021/ef301847z
   Ponce RV, 2014, J PETROL SCI ENG, V119, P112, DOI 10.1016/j.petrol.2014.04.020
   Pope G. A., 2011, J PET TECHNOL, V63, P65, DOI DOI 10.2118/0711-0065-JPT
   Rocha De Farias M.L., 2012, LAT AM CAR PETR ENG, DOI [10.2118/152290-MS, DOI 10.2118/152290-MS]
   Romero L, 1996, SPE DOE IMPR OIL REC, DOI [10.2118/35461-MS, DOI 10.2118/35461-MS]
   Romero MI, 2011, PHYS REV E, V84, DOI 10.1103/PhysRevE.84.046305
   Shen PP, 2009, SPE J, V14, P237, DOI 10.2118/126128-PA
   STOKES JP, 1986, PHYS REV LETT, V57, P1718, DOI 10.1103/PhysRevLett.57.1718
   Tagavifar M, 2018, SPE J, V23, P66
   Walker D., 2012, SPE IMPR OIL REC S T, DOI [10.2118/154275-MS, DOI 10.2118/154275-MS]
   Wang ZH, 2013, J PETROL SCI ENG, V111, P178, DOI 10.1016/j.petrol.2013.09.010
   Xu K, 2017, SPE J, V22, P459, DOI 10.2118/179691-PA
   Yin SL, 2018, ARAB J GEOSCI, V11, DOI 10.1007/s12517-018-3992-6
   Yu L, 2018, CHEM ENG SCI, V178, P335, DOI 10.1016/j.ces.2017.12.043
   Zhang G, 2015, SPE INT S OILF CHEM, DOI [10.2118/173728-MS, DOI 10.2118/173728-MS]
   Zhang H, 2011, SPE J, V16, P388, DOI 10.2118/129908-PA
   Zhou YZ, 2018, J PETROL SCI ENG, V163, P519, DOI 10.1016/j.petrol.2018.01.027
   Zhou YZ, 2017, PETROL EXPLOR DEV+, V44, P111, DOI 10.1016/S1876-3804(17)30014-9
   Zhou ZH, 2014, ENERG FUEL, V28, P1020, DOI 10.1021/ef402416j
NR 56
TC 12
Z9 12
U1 4
U2 42
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD APR 6
PY 2019
VL 197
BP 404
EP 414
DI 10.1016/j.ces.2019.01.001
PG 11
WC Engineering, Chemical
SC Engineering
GA HK0ZQ
UT WOS:000457634000037
DA 2020-05-12
ER

PT J
AU Gu, GH
   Wittreich, GR
   Vlachos, DG
AF Gu, Geun Ho
   Wittreich, Gerhard R.
   Vlachos, Dionisios G.
TI Microkinetic modeling of aqueous phase biomass conversion:Application to
   ethylene glycol reforming
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Group additivity; Aqueous phase reforming; Ethylene glycol; Hydrogen;
   Biomass
ID CONVERSION; CELLULOSE; ACID
AB In this communication, we develop automatically a reaction network for ethylene glycol reforming on Pt. We employ a recently introduced group additivity scheme for estimation of thermochemistry over metal catalysts in vapor phase and in solution along with Bronsted-Evans-Polanyi (BEP) relations for vapor phase kinetics to parameterize microkinetic models for vapor and aqueous phases. Unlike vapor-phase reforming, we show that solvent occupies a significant fraction of surface sites and by doing this, it shifts the water-gas shift reaction to CO2 and H-2 and avoids poisoning of the catalyst by CO. The model is found to be in reasonable agreement with the experimental data. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Gu, Geun Ho; Wittreich, Gerhard R.; Vlachos, Dionisios G.] Univ Delaware, Catalysis Ctr Energy Innovat, Dept Chem & Biomol Engn, Newark, DE 19716 USA.
   [Gu, Geun Ho] Korea Adv Inst Sci & Technol, Daejeon, South Korea.
RP Vlachos, DG (reprint author), Univ Delaware, Catalysis Ctr Energy Innovat, Dept Chem & Biomol Engn, Newark, DE 19716 USA.
EM vlachos@udel.edu
OI Vlachos, Dionisios/0000-0002-6795-8403
FU Catalysis Center for Energy Innovation, an Energy Frontier Research
   Center - U.S. Department of Energy, Office of Science, Office of Basic
   Energy SciencesUnited States Department of Energy (DOE) [DE-SC0001004]
FX We acknowledge support from the Catalysis Center for Energy Innovation,
   an Energy Frontier Research Center funded by the U.S. Department of
   Energy, Office of Science, Office of Basic Energy Sciences under Award
   number DE-SC0001004. We would like to dedicate this article in honor of
   UD alum and inspirational leader and friend, Professor Rakesh Agrawal of
   Purdue University.
CR Behtash S, 2014, GREEN CHEM, V16, P605, DOI 10.1039/c3gc41368c
   Brodeur Gary, 2011, Enzyme Res, V2011, P787532, DOI 10.4061/2011/787532
   Coltrin M. E., 1991, SURFACE CHEMKIN VERS
   Cortright RD, 2002, NATURE, V418, P964, DOI 10.1038/nature01009
   Deng WH, 2015, IND ENG CHEM RES, V54, P5226, DOI 10.1021/acs.iecr.5b00757
   Einvall J, 2007, ENERG FUEL, V21, P2481, DOI 10.1021/ef060633k
   Faheem M, 2016, CATAL SCI TECHNOL, V6, P8242, DOI 10.1039/c6cy02111e
   Gu GH, 2017, J PHYS CHEM C, V121, P21510, DOI 10.1021/acs.jpcc.7b07340
   Huber GW, 2006, APPL CATAL B-ENVIRON, V62, P226, DOI 10.1016/j.apcatb.2005.07.010
   Ji N, 2009, CATAL TODAY, V147, P77, DOI 10.1016/j.cattod.2009.03.012
   Lohmann J, 2001, IND ENG CHEM RES, V40, P957, DOI 10.1021/ie0005710
   Mettler MS, 2014, CATAL SCI TECHNOL, V4, P3822, DOI 10.1039/c4cy00676c
   Mhadeshwar AB, 2003, J PHYS CHEM B, V107, P12721, DOI 10.1021/jp034954y
   Rangarajan S, 2012, COMPUT CHEM ENG, V46, P141, DOI 10.1016/j.compchemeng.2012.06.003
   Saha B, 2014, GREEN CHEM, V16, P24, DOI 10.1039/c3gc41324a
   Salciccioli M, 2011, ACS CATAL, V1, P1246, DOI 10.1021/cs2003593
   Salciccioli M, 2011, CHEM ENG SCI, V66, P4319, DOI 10.1016/j.ces.2011.05.050
   Shabaker JW, 2003, J CATAL, V215, P344, DOI 10.1016/S0021-9517(03)00032-0
   Sutton D, 2001, FUEL PROCESS TECHNOL, V73, P155, DOI 10.1016/S0378-3820(01)00208-9
   Sutton JE, 2013, J PHYS CHEM C, V117, P4691, DOI 10.1021/jp312593u
   Sutton JE, 2012, ACS CATAL, V2, P1624, DOI 10.1021/cs3003269
   Swift TD, 2016, J CATAL, V333, P149, DOI 10.1016/j.jcat.2015.10.009
NR 22
TC 4
Z9 4
U1 3
U2 23
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD APR 6
PY 2019
VL 197
BP 415
EP 418
DI 10.1016/j.ces.2018.12.036
PG 4
WC Engineering, Chemical
SC Engineering
GA HK0ZQ
UT WOS:000457634000038
DA 2020-05-12
ER

PT J
AU Glass, M
   Mitsos, A
AF Glass, Moll
   Mitsos, Alexander
TI Parameter estimation in reactive systems subject to sufficient criteria
   for thermodynamic stability
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Reactive tangent plane; Chemical equilibrium constant; Bilevel program;
   Gibbs free energy; Data regression; Extent-of-reaction
ID LIQUID-LIQUID EQUILIBRIUM; BILEVEL OPTIMIZATION FORMULATION;
   ELECTROLYTE-NRTL MODEL; CHEMICAL-EQUILIBRIUM; PHASE-EQUILIBRIA;
   COMPUTATION; NONUNIQUENESS; PREDICTION; RETRIEVAL; VLE
AB For process simulation involving chemical reactions, thermodynamically accurate model parameters for chemical equilibrium are indispensable. We demonstrate that regression subject to the well-known chemical equilibrium constant entails violation of the sufficient conditions for thermodynamic stability. As a consequence, erroneous values of the equilibrium conversion are obtained upon use of the respective parameter values in, e.g., process simulation. In order to alleviate the problem, we propose a methodology for estimating parameters subject to necessary and sufficient criteria for thermodynamic stability. In particular, we propose an extension of Mitsos et al. (2009) to parameter estimation in reactive systems; an upper-level model-experiment mismatch is minimized subject to several lower-level minimization problems (LLP), which ensure the fulfilment of the reactive tangent plane criterion (RTPC) of Smith et al. (1993), along with other desired behavior of the Gibbs free energy. A fictitious single-phase dimerization reaction employing Margules and NRTL as Gibbs free energy models illustrates the thermodynamic guarantees provided by the proposed formulation, when the conventional ones fail. Our formulation conceptually allows any type of phase equilibrium, e.g., VLLE, as well as any type of activity coefficient model. The subproblems of the bilevel algorithm pose challenges to state-of-the-art commercial solvers. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Glass, Moll; Mitsos, Alexander] Rhein Westfal TH Aachen, AVT Aachener Verfahrenstechn, Proc Syst Engn, Forckenbeckstr 51, D-52074 Aachen, Germany.
RP Mitsos, A (reprint author), Rhein Westfal TH Aachen, AVT Aachener Verfahrenstechn, Proc Syst Engn, Forckenbeckstr 51, D-52074 Aachen, Germany.
EM moll.glass@avt.rwth-aachen.de; amitsos@alum.mit.edu
RI Mitsos, Alexander/D-5873-2011
OI Mitsos, Alexander/0000-0003-0335-6566
FU Excellence Initiative by the German federal and state governments
   [EXC236]
FX This work was performed as part of the Cluster of Excellence "Tailor
   Made Fuels from Biomass" which is funded by the Excellence Initiative by
   the German federal and state governments (EXC236) to promote science and
   research at German universities. Moll Glass wishes to thank
   "Studienstiftung des deutschen Volkes" for her PhD scholarship. Finally,
   we would like to thank Pablo Valero Cabeza, M.Sc. and Johannes-Robert
   Bruch, M.Sc. for assisting with the literature review, and Jeffrey
   Cumpston for carefully proofreading the manuscript. The authors declare
   no competing financial interests.
CR [Anonymous], 2017, CHEMCAD 7 1
   [Anonymous], 2016, ASP PROP 8 8
   BAKER LE, 1982, SOC PETROL ENG J, V22, P731, DOI 10.2118/9806-PA
   BARBOSA D, 1988, CHEM ENG SCI, V43, P529, DOI 10.1016/0009-2509(88)87014-3
   Beightler C. S., 1976, APPL GEOMETRIC PROGR
   Bellot JC, 1999, AICHE J, V45, P1329, DOI 10.1002/aic.690450617
   Bertsekas D., 1995, NONLINEAR PROGRAMMIN
   Biegler LT, 2010, NONLINEAR PROGRAMMIN
   Bollas GM, 2008, AICHE J, V54, P1608, DOI 10.1002/aic.11485
   Bollas GM, 2009, CHEM ENG SCI, V64, P1768, DOI 10.1016/j.ces.2009.01.003
   Bonilla-Petriciolet A, 2012, INT J CHEM REACT ENG, V10, DOI 10.1515/1542-6580.2894
   CARAM HS, 1976, CHEM ENG SCI, V31, P163, DOI 10.1016/0009-2509(76)85051-8
   Chen CC, 2004, AICHE J, V50, P1928, DOI 10.1002/aic.10151
   Cherif M, 2000, FLUID PHASE EQUILIBR, V175, P197, DOI 10.1016/S0378-3812(00)00458-1
   Cisneros ESP, 1997, CHEM ENG SCI, V52, P527
   Dortmund Data Bank Software Package (DDBSP), 2016, DDBST GMBH 2016
   Fingerhut R, 2017, IND ENG CHEM RES, V56, P9868, DOI 10.1021/acs.iecr.7b01360
   Gau CY, 2000, FLUID PHASE EQUILIBR, V168, P1, DOI 10.1016/S0378-3812(99)00332-5
   GAUTAM R, 1979, AICHE J, V25, P991, DOI 10.1002/aic.690250610
   GAUTAM R, 1979, AICHE J, V25, P1006, DOI 10.1002/aic.690250612
   Glass M, 2017, FLUID PHASE EQUILIBR, V433, P212, DOI 10.1016/j.fluid.2016.11.004
   Gmehling J., 1991, DEV THERMODYNAMIC MO, P1
   Gumus ZH, 1997, COMPUT CHEM ENG, V21, pS983, DOI 10.1016/S0098-1354(97)87630-2
   GUPTA AK, 1991, FLUID PHASE EQUILIBR, V63, P65, DOI 10.1016/0378-3812(91)80021-M
   Harding ST, 2000, IND ENG CHEM RES, V39, P1576, DOI 10.1021/ie990527o
   HEIDEMANN RA, 1978, CHEM ENG SCI, V33, P1517, DOI 10.1016/0009-2509(78)85202-6
   JIANG Y, 1995, SIAM J OPTIMIZ, V5, P813, DOI 10.1137/0805039
   Jiang Y, 1996, FLUID PHASE EQUILIBR, V118, P77, DOI 10.1016/0378-3812(95)02828-5
   Lemonidis P, 2008, THESIS
   MATHER AE, 1986, FLUID PHASE EQUILIBR, V30, P83, DOI 10.1016/0378-3812(86)80044-9
   McDonald CM, 1997, COMPUT CHEM ENG, V21, P1
   Michelsen M, 2007, THERMODYNAMIC MODELS
   MICHELSEN ML, 1994, COMPUT CHEM ENG, V18, P545, DOI 10.1016/0098-1354(93)E0017-4
   Mitsos A, 2008, J GLOBAL OPTIM, V42, P475, DOI 10.1007/s10898-007-9260-z
   Mitsos A, 2009, CHEM ENG SCI, V64, P548, DOI 10.1016/j.ces.2008.09.034
   Mitsos Alexander, 2018, BILEVEL OPTIMIZATION
   Mitsos Alexander, 2009, 19 EUR S COMP AID PR
   ONKEN U, 1989, INT J THERMOPHYS, V10, P739, DOI 10.1007/BF00507993
   OTHMER HG, 1976, CHEM ENG SCI, V31, P993, DOI 10.1016/0009-2509(76)87020-0
   PITZER KS, 1973, J PHYS CHEM-US, V77, P2300, DOI 10.1021/j100638a009
   PITZER KS, 1973, J PHYS CHEM-US, V77, P268, DOI 10.1021/j100621a026
   Que HL, 2011, J CHEM ENG DATA, V56, P963, DOI 10.1021/je100930y
   SCHOTT GL, 1964, J CHEM PHYS, V40, P2065, DOI 10.1063/1.1725470
   Simoni LD, 2008, IND ENG CHEM RES, V47, P256, DOI 10.1021/ie070956j
   Simoni LD, 2007, FLUID PHASE EQUILIBR, V255, P138, DOI 10.1016/j.fluid.2007.04.005
   Simoni LD, 2009, IND ENG CHEM RES, V48, P7246, DOI 10.1021/ie900461j
   SMITH JV, 1993, AICHE J, V39, P707, DOI 10.1002/aic.690390421
   Smith W, 1982, CHEM REACTION EQUILI
   SORENSEN JM, 1979, FLUID PHASE EQUILIBR, V3, P47, DOI 10.1016/0378-3812(79)80027-8
   Tawarmalani M, 2005, MATH PROGRAM, V103, P225, DOI 10.1007/s10107-005-0581-8
   Tester SW, 1997, THERMODYNAMICS ITS A
   Turner CH, 2008, MOL SIMULAT, V34, P119, DOI 10.1080/08927020801986564
   van Bochove GH, 2000, FLUID PHASE EQUILIBR, V171, P45, DOI 10.1016/S0378-3812(00)00347-2
   van Bochove GH, 2002, FLUID PHASE EQUILIBR, V194, P1029, DOI 10.1016/S0378-3812(01)00706-3
   Weber G. W., 2003, GEN SEMIINFINITE OPT
   WHITE CW, 1981, AICHE J, V27, P466, DOI 10.1002/aic.690270316
NR 56
TC 0
Z9 0
U1 0
U2 3
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD APR 6
PY 2019
VL 197
BP 420
EP 431
DI 10.1016/j.ces.2018.08.035
PG 12
WC Engineering, Chemical
SC Engineering
GA HK0ZQ
UT WOS:000457634000040
DA 2020-05-12
ER

PT J
AU Nemet, A
   Isafiade, AJ
   Klemes, JJ
   Kravanja, Z
AF Nemet, Andreja
   Isafiade, Adeniyi Jide
   Klemes, Jiri Jaromir
   Kravanja, Zdravko
TI Two-step MILP/MINLP approach for the synthesis of large-scale HENs
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Large-scale HEN; Mathematical programming; Total site; HEN design;
   Two-step MILP/MINLP approach
ID HEAT-EXCHANGER NETWORKS; SIMULTANEOUS-OPTIMIZATION MODELS; TOTAL SITE;
   SUPERSTRUCTURE SYNTHESIS; GLOBAL OPTIMIZATION; INTEGRATION; ALGORITHM;
   ENTRANSY; STRATEGY; DESIGN
AB Although different methodologies for the synthesis of heat exchanger network (HEN) problems have been introduced in the last forty years, there are still significant challenges to be addressed, such as solving large-scale problems. This study focuses on synthesizing large-scale HENs using mathematical programming to achieve near globally optimal solutions based on a two-step MILP/MINLP approach. In the first step a mixed-integer linear programming (MILP) model, TransHEN, is used that obtains a globally optimal solution at selected Delta T-min. By utilisation of this model, the most promising matches are selected based on feasibility and viability. The second step entails using the matches selected in the TransHEN of Step 1 in a mixed-integer nonlinear programming (MINLP) model, HENsyn, using a reduced superstructure, to generate a feasible HEN. This study presents also a simultaneous Total Site synthesis with direct heat transfer between processes, and is the first step in the wider project of synthesising an entire Total Site with direct and indirect heat transfer; and is the first step in the wider scope of synthesising an entire Total Site with direct and indirect heat transfer; however, in order to attain this goal, a tool capable of an appropriately handling large number of streams is required. The newly developed procedure has been tested on several case studies, two of which are presented in this paper. For Case study 1 the results obtained lie within the range of best solutions obtained by other authors. Case study 2, consisting of 173 process stream and involving multiple hot utilities, shows the applicability of the developed method to handle large-scale HEN problems. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Nemet, Andreja; Klemes, Jiri Jaromir] Brno Univ Technol VUT BRNO, Fac Mech Engn, NETME Ctr, SPIL,Tech 2896 2, Brno 61669, Czech Republic.
   [Isafiade, Adeniyi Jide] Univ Cape Town, Dept Chem Engn, Private Bag X3, ZA-7701 Rondebosch, South Africa.
   [Kravanja, Zdravko] Univ Maribor, Fac Chem & Chem Engn, Smetanova Ulica 17, Maribor 2000, Slovenia.
RP Nemet, A (reprint author), Brno Univ Technol VUT BRNO, Fac Mech Engn, NETME Ctr, SPIL,Tech 2896 2, Brno 61669, Czech Republic.
EM nemet@vutbr.fme.cz
RI Klemes, Jiri Jaromir/B-7291-2009; Isafiade, Adeniyi Jide/AAF-6481-2020
OI Klemes, Jiri Jaromir/0000-0002-7450-7029; Isafiade, Adeniyi
   Jide/0000-0002-6918-312X
FU EU "CZ Operational Programme Research and Development, Education",
   Priority 1: Strengthening capacity for quality research [CZ.02.1.
   01/0.0/0.0/15_003/0000456]; Slovenian Research AgencySlovenian Research
   Agency - Slovenia [P2-0032, L2-7633]; National Research Foundation of
   South AfricaNational Research Foundation - South Africa [105780]
FX This research has benefited from the collaboration agreement between
   Brno University of Technology -VUT Brno Czech Republic, and University
   of Maribor, Slovenia under the project "Sustainable Process Integration
   Laboratory - SPIL" funded by EU "CZ Operational Programme Research and
   Development, Education", Priority 1: Strengthening capacity for quality
   research (Grant No. CZ.02.1. 01/0.0/0.0/15_003/0000456) and was
   financially supported by Slovenian Research Agency (program P2-0032 and
   project L2-7633) as well. Research has also benefited from the National
   Research Foundation of South Africa's research development grants for
   Y-rated researchers (Grant No: 105780).
CR Agarwal A, 2008, IND ENG CHEM RES, V47, P3489, DOI 10.1021/ie070805g
   Anantharaman R, 2010, COMPUT CHEM ENG, V34, P1822, DOI 10.1016/j.compchemeng.2009.12.002
   Azeez OS, 2013, COMPUT CHEM ENG, V56, P184, DOI 10.1016/j.compchemeng.2013.05.010
   Bao ZK, 2018, ENERGY, V152, P694, DOI 10.1016/j.energy.2018.03.170
   Barbaro A, 2005, COMPUT CHEM ENG, V29, P1945, DOI 10.1016/j.compchemeng.2005.04.006
   Bjork K.-M., 2003, P IASTED INT C MOD S
   Bjork KM, 2002, COMPUT CHEM ENG, V26, P1581, DOI 10.1016/S0098-1354(02)00129-1
   Bogataj M, 2012, APPL THERM ENG, V43, P75, DOI 10.1016/j.applthermaleng.2011.12.015
   Briones V, 1999, CHEM ENG SCI, V54, P519, DOI 10.1016/S0009-2509(98)00235-8
   CERDA J, 1983, CHEM ENG SCI, V38, P373, DOI 10.1016/0009-2509(83)80156-0
   Chen Y, 2015, COMPUT CHEM ENG, V82, P68, DOI 10.1016/j.compchemeng.2015.05.015
   Chew KH, 2013, APPL THERM ENG, V61, P17, DOI 10.1016/j.applthermaleng.2013.03.014
   DHOLE VR, 1993, COMPUT CHEM ENG, V17, pS101, DOI 10.1016/0098-1354(93)85015-E
   DURAN MA, 1986, AICHE J, V32, P123, DOI 10.1002/aic.690320114
   Ernst P, 2010, HEAT MASS TRANSFER, V46, P1087, DOI 10.1007/s00231-010-0685-4
   Escobar M, 2013, APPL THERM ENG, V51, P801, DOI 10.1016/j.applthermaleng.2012.10.022
   Fieg G, 2009, CHEM ENG PROCESS, V48, P1506, DOI 10.1016/j.cep.2009.10.003
   Furman KC, 2001, COMPUT CHEM ENG, V25, P1371, DOI 10.1016/S0098-1354(01)00681-0
   GUNDERSEN T, 1990, COMPUT CHEM ENG, V14, P925, DOI 10.1016/0098-1354(90)87050-Y
   Gundersen T, 1997, COMPUT CHEM ENG, V21, pS59
   Guo ZY, 2007, INT J HEAT MASS TRAN, V50, P2545, DOI 10.1016/j.ijheatmasstransfer.2006.11.034
   Huang KF, 2014, CHEM ENG SCI, V105, P53, DOI 10.1016/j.ces.2013.10.040
   Isafiade AJ, 2008, CHEM ENG RES DES, V86, P245, DOI 10.1016/j.cherd.2007.11.001
   Isafiade A, 2015, CHEM ENG SCI, V127, P175, DOI 10.1016/j.ces.2014.12.037
   Hipolito-Valencia BJ, 2014, AICHE J, V60, P213, DOI 10.1002/aic.14292
   Jezowski JM, 2003, IND ENG CHEM RES, V42, P1723, DOI 10.1021/ie020643i
   Laukkanen T, 2012, CHEM ENG RES DES, V90, P1129, DOI 10.1016/j.cherd.2011.12.010
   Li JL, 2014, J TAIWAN INST CHEM E, V45, P508, DOI 10.1016/j.jtice.2013.06.033
   Liew PY, 2014, APPL THERM ENG, V70, P1073, DOI 10.1016/j.applthermaleng.2014.03.014
   LINNHOFF B, 1978, AICHE J, V24, P633, DOI 10.1002/aic.690240411
   Luo X, 2009, COMPUT CHEM ENG, V33, P1169, DOI 10.1016/j.compchemeng.2008.12.003
   Nemet A, 2015, COMPUT CHEM ENG, V72, P159, DOI 10.1016/j.compchemeng.2014.07.004
   Thuy NTP, 2014, APPL MECH MATER, V564, P292, DOI 10.4028/www.scientific.net/AMM.564.292
   PAPOULIAS SA, 1983, COMPUT CHEM ENG, V7, P707, DOI 10.1016/0098-1354(83)85023-6
   Pavao LV, 2017, AICHE J, V63, P1582, DOI 10.1002/aic.15524
   Pavao LV, 2017, CHEM ENG SCI, V158, P96, DOI 10.1016/j.ces.2016.09.030
   Pettersson F, 2005, COMPUT CHEM ENG, V29, P993, DOI 10.1016/j.compchemeng.2004.11.001
   Ponce-Ortega JM, 2010, IND ENG CHEM RES, V49, P2849, DOI 10.1021/ie901750a
   Pouransari N, 2015, ENERG CONVERS MANAGE, V89, P985, DOI 10.1016/j.enconman.2014.11.006
   Sekulic DP, 2015, ENERGY, V80, P251, DOI 10.1016/j.energy.2014.11.067
   Shethna HK, 2006, IND ENG CHEM RES, V45, P4629, DOI 10.1021/ie0504250
   Shethna HK, 2000, APPL THERM ENG, V20, P1577, DOI 10.1016/S1359-4311(00)00024-7
   Song RR, 2017, ENERGY, V135, P382, DOI 10.1016/j.energy.2017.06.136
   Wang YF, 2015, INT J HEAT MASS TRAN, V90, P627, DOI 10.1016/j.ijheatmasstransfer.2015.06.064
   Wang YF, 2015, ENERGY, V90, P56, DOI 10.1016/j.energy.2015.04.015
   Xiao Y, 2018, APPL THERM ENG, V128, P861, DOI 10.1016/j.applthermaleng.2017.09.075
   Xu YC, 2015, ENERGY, V86, P696, DOI 10.1016/j.energy.2015.04.024
   YEE TF, 1990, COMPUT CHEM ENG, V14, P1151, DOI 10.1016/0098-1354(90)85009-Y
   YEE TF, 1990, COMPUT CHEM ENG, V14, P1185, DOI 10.1016/0098-1354(90)80001-R
   YEE TF, 1990, COMPUT CHEM ENG, V14, P1165, DOI 10.1016/0098-1354(90)85010-8
   Zhang CW, 2016, APPL THERM ENG, V107, P565, DOI 10.1016/j.applthermaleng.2016.07.009
   Zhang CW, 2016, APPL THERM ENG, V104, P707, DOI 10.1016/j.applthermaleng.2016.05.103
   Zhang HL, 2018, CHEM ENG RES DES, V134, P62, DOI 10.1016/j.cherd.2018.03.046
NR 53
TC 4
Z9 4
U1 9
U2 19
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD APR 6
PY 2019
VL 197
BP 432
EP 448
DI 10.1016/j.ces.2018.06.036
PG 17
WC Engineering, Chemical
SC Engineering
GA HK0ZQ
UT WOS:000457634000041
DA 2020-05-12
ER

PT J
AU Kasereka, MC
   Sawatzky, J
   Hawkes, MT
AF Kasereka, Masumbuko Claude
   Sawatzky, Julia
   Hawkes, Michael T.
TI Ebola epidemic in war-torn Democratic Republic of Congo, 2018:
   Acceptability and patient satisfaction of the recombinant Vesicular
   Stomatitis Virus - Zaire Ebolavirus Vaccine
SO VACCINE
LA English
DT Article
DE rVSV-ZEBOV; Ebola; Vaccine acceptability; Vaccine hesitancy; Vaccine
   satisfaction
ID RING VACCINATION; DISEASE; GUINEA; ATTITUDES; SAFETY; END
AB Background: The current Ebola outbreak in Eastern Democratic Republic of the Congo (DRC) is the second largest in history and the first in which the recombinant Vesicular Stomatitis Virus - Zaire Ebolavirus (rVSV-ZEBOV) vaccine has been used at scale. We assessed side-effects, satisfaction, and attitudes toward the new vaccine.
   Methods: Cross-sectional survey questionnaire from a convenience sample of 90 vaccine recipients and 96 community controls in Eastern DRC.
   Results: Side-effects were reported in 75/90 (83%) vaccine recipients but only 5 (7%) and 4 (5%) reported arthralgia and rash, respectively. 76/90 (84%) vaccinees were classified as "promoters" (would recommend vaccine to others) and 6/90 (7%) as "detractors." 69/96 (72%) of unvaccinated community controls would wish to be vaccinated if supply were available. 153/186 (82%) would accept vaccination for family members.
   Conclusions: The rVSV-ZEBOV vaccine was well tolerated, with high acceptability in the community during the current outbreak in the DRC. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Kasereka, Masumbuko Claude] Univ Catholique Graben, Butembo, DEM REP CONGO.
   [Sawatzky, Julia] Univ Alberta, Edmonton, AB, Canada.
   [Hawkes, Michael T.] Univ Alberta, Dept Pediat, 3-588D Edmonton Clin Hlth Acad,11405 87 Ave NW, Edmonton, AB T6G 1C9, Canada.
   [Hawkes, Michael T.] Univ Alberta, Dept Med Microbiol & Immunol, Edmonton, AB, Canada.
   [Hawkes, Michael T.] Univ Alberta, Sch Publ Hlth, Edmonton, AB, Canada.
RP Hawkes, MT (reprint author), Univ Alberta, Dept Pediat, 3-588D Edmonton Clin Hlth Acad,11405 87 Ave NW, Edmonton, AB T6G 1C9, Canada.
EM mthawkes@ualberta.ca
OI Hawkes, Michael/0000-0002-4122-0937; Kasereka,
   Masumbuko/0000-0003-1367-3426
FU Association for Health Innovation in Africa [20180-3]
FX We thank all the patients and their families and the community health
   workers and research assistants who cared for the patients and collected
   study data. This study was supported by Association for Health
   Innovation in Africa (grant number 20180-3 [KMC]). The funder had no
   role in study design, data collection, data analysis, data
   interpretation, writing of the report, or decision to submit the article
   for publication.
CR AP News, AP NEWS
   APNews, 2018, APNEWS
   Buli Benti Geleta, 2015, Pan Afr Med J, V22 Suppl 1, P11, DOI 10.11694/pamj.supp.2015.22.1.6269
   CDC, 2016, 2014 2016 EB OUTBR W
   Claude KM, 2018, LANCET, V392, P1399, DOI 10.1016/S0140-6736(18)32419-X
   Coghlan B, 2006, LANCET, V367, P44, DOI 10.1016/S0140-6736(06)67923-3
   Gsell PS, 2017, LANCET INFECT DIS, V17, P1276, DOI 10.1016/S1473-3099(17)30541-8
   Henao-Restrepo AM, 2017, LANCET, V389, P505, DOI 10.1016/S0140-6736(16)32621-6
   Huttner A, 2015, LANCET INFECT DIS, V15, P1156, DOI 10.1016/S1473-3099(15)00154-1
   Irwin KL, 2017, VACCINE, V35, P6915, DOI 10.1016/j.vaccine.2017.06.026
   Jalloh MF, 2017, MMWR-MORBID MORTAL W, V66, P1109, DOI 10.15585/mmwr.mm6641a4
   Kpanake L, 2018, HUM VACC IMMUNOTHER, V14, P2391, DOI 10.1080/21645515.2018.1480236
   Obenauer J, 2018, BMC PUBLIC HEALTH, V18, DOI 10.1186/s12889-018-5543-1
   Reichheld F. F., 2003, HARVARD BUS REV, V81, P124
   Ughasoro MD, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003838
   WHO, 2017, M STRAT ADV GROUP EX
   World Health Organisation, 2016, EB VIR DIS FACT SHEE
NR 17
TC 5
Z9 5
U1 2
U2 5
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD APR 10
PY 2019
VL 37
IS 16
BP 2174
EP 2178
DI 10.1016/j.vaccine.2019.03.004
PG 5
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HV8TO
UT WOS:000466257200003
PM 30878249
DA 2020-05-12
ER

PT J
AU Fabiani, M
   Fano, V
   Spadea, T
   Piovesan, C
   Bianconi, E
   Rusciani, R
   Salamina, G
   Greco, G
   Ramigni, M
   Declich, S
   Petrelli, A
   Pezzotti, P
AF Fabiani, Massimo
   Fano, Valeria
   Spadea, Teresa
   Piovesan, Cinzia
   Bianconi, Egisto
   Rusciani, Raffaella
   Salamina, Giuseppe
   Greco, Gregorio
   Ramigni, Mauro
   Declich, Silvia
   Petrelli, Alessio
   Pezzotti, Patrizio
TI Comparison of early childhood vaccination coverage and timeliness
   between children born to Italian women and those born to foreign women
   residing in Italy: A multi-centre retrospective cohort study
SO VACCINE
LA English
DT Article
DE Immigrants; Vaccination coverage; Childhood
ID IMMIGRANT CHILDREN; HEALTH; AGE; POPULATION; MIGRATION; HESITANCY;
   MIGRANTS
AB Background: Compared to hosting populations, immigrants are usually considered more vulnerable to communicable diseases, many of which are vaccine-preventable. This study aims to estimate vaccination coverage (VC) and timeliness in children born to women from high migratory pressure countries (HMPC) and to evaluate factors affecting differences with children born to Italian women or women from advanced development countries (ITA + ADC).
   Methods: We retrospectively analysed data of children born in 2009-2014 and resident in areas served by three local health units in the cities of Rome (n = 40,284), Turin (n = 49,600), and Treviso (n = 20,080). Data were retrieved through record-linkage of the population, vaccination, and birth registries. We used the Kaplan-Meier method to estimate VCs at different ages for the 3rd dose of vaccine against tetanus and the 1st dose of vaccines against measles and meningococcal group C. Factors affecting differences in VCs by citizenship were evaluated using log-binomial models.
   Results: In Rome, VCs at 2 years of age were consistently higher in children born to ITA + ADC women than in children born to HMPC women, while differences in VCs by citizenship varied according to antigen and birth-cohort in Turin and Treviso, respectively. Where differences were observed, these were only partially explained by the mother's socio-demographic characteristics, level of utilisation of health-services during pregnancy, and maternal, perinatal, and neonatal outcomes. Finally, we observed a reduction of VCs in recent birth cohorts (2012-14 vs. 2009-11), especially in children born to ITA + ADC women.
   Conclusions: Differences in VCs by citizenship were not homogeneous and varied according to geographical context, antigen, and birth-cohort. These differences are likely to be also affected by informal barriers (e.g., linguistic and cultural barriers), which should be addressed in implementing strategies to increase vaccine uptake in foreign children. Moreover, our results suggest that effective strategies to promote vaccinations in the autochthonous population are also needed. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Fabiani, Massimo; Pezzotti, Patrizio] Italian Natl Inst Hlth ISS, Infect Dis Dept, Viale Regina Elena 299, I-00161 Rome, Italy.
   [Fano, Valeria; Bianconi, Egisto] Asl RM2, Local Hlth Unit 2, Via Filippo Meda 35, I-00157 Rome, Italy.
   [Spadea, Teresa; Rusciani, Raffaella] Asl TO3, Epidemiol Unit, Local Hlth Unit 3, Via Sabaudia 164, I-10095 Turin, Italy.
   [Piovesan, Cinzia; Ramigni, Mauro] Ulss 2 Marca Trevigiana, Dept Prevent, Local Hlth Unit 2, Via S Ambrogio Fiera 37, I-31100 Treviso, Italy.
   [Salamina, Giuseppe; Greco, Gregorio] Asl Citta Torino, Local Hlth Unit, Via San Secondo 29, I-10128 Turin, Italy.
   [Declich, Silvia] Italian Natl Inst Hlth ISS, Natl Ctr Global Hlth, Viale Regina Elena 299, I-00161 Rome, Italy.
   [Petrelli, Alessio] Natl Inst Hlth Migrat & Poverty INMP, Via S Gallicano 25, I-00153 Rome, Italy.
RP Fabiani, M (reprint author), Italian Natl Inst Hlth, Infect Dis Dept, Viale Regina Elena 299, I-00161 Rome, Italy.
EM massimo.fabiani@iss.it
OI Fabiani, Massimo/0000-0002-5893-7117; Declich,
   Silvia/0000-0002-5916-3889
CR Barsanti S, 042013 SCUOL SUP SAN
   Bielicki JA, 2012, PEDIATRICS, V130, pE600, DOI 10.1542/peds.2012-0132
   Borras E, 2007, VACCINE, V25, P3240, DOI 10.1016/j.vaccine.2007.01.026
   Canova C, 2013, 38 C IT EP ASS AIE 4
   Castelli F, 2017, CLIN MICROBIOL INFEC, V23, P283, DOI 10.1016/j.cmi.2017.03.012
   Chiaradia G, 2011, ITAL J PUBLIC HLTH, V8, P268
   Dayan GH, 2006, AM J EPIDEMIOL, V163, P561, DOI 10.1093/aje/kwj074
   De Franco F, 2010, MED BAMBINO PAGINE E, V13
   Ferrara P, 2016, MINERVA PEDIATR, V68, P121
   Flores G, 2005, MED CARE RES REV, V62, P255, DOI 10.1177/1077558705275416
   Giambi C, 2018, VACCINE, V36, P779, DOI 10.1016/j.vaccine.2017.12.074
   Italian Ministry of Health, VACC ET PED AD COP V
   Italian Ministry of Health, 2017, PIAN NAZ PREV VACC P
   Italian National Institute of Statistics (ISTAT), 2020, DEM FIG
   Kentikelenis A, 2015, EUR J PUBLIC HEALTH, V25, P937, DOI 10.1093/eurpub/ckv151
   Larson HJ, 2016, EBIOMEDICINE, V12, P295, DOI 10.1016/j.ebiom.2016.08.042
   MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036
   Mladovsky P, 2012, CLIN MED, V12, P248, DOI 10.7861/clinmedicine.12-3-248
   Osservatorio Nazionale sulla Salute delle Regioni Italian, 2009, RAPP OSS 2009 STAT S
   Pallasch G, 2005, GESUNDHEITSWESEN, V67, P33, DOI 10.1055/s-2004-813912
   Pavlopoulou ID, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-908
   Poethko-Muller C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042867
   Rechel B, 2013, LANCET, V381, P1235, DOI 10.1016/S0140-6736(12)62086-8
   Servizio Sanitario Nazionale-Regione Veneto Azienda Unity Locale Socio-Sanitaria N. 13 Dipartimento di Prevenzione, 2016, AZ UN LOC SOC N 13
   Spadea T, 2018, SPRBRIEF PUB HEALT, P57, DOI 10.1007/978-3-319-73630-3_6
   UNDP, 2007, HUMAN DEV REPORT 200
   United Nations, 2017, INT MIGR REP 2017
   Vandermeulen C, 2008, EUR J PEDIATR, V167, P1161, DOI 10.1007/s00431-007-0652-3
   World Health Organization, 2013, GLOB VACC ACT PLAN 2
   Wormann T., 2011, Migration and health in the European Union, P121
   2009, VACCINE, V27, P2563, DOI DOI 10.1016/J.VACCINE.2009.02.009
NR 31
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD APR 10
PY 2019
VL 37
IS 16
BP 2179
EP 2187
DI 10.1016/j.vaccine.2019.03.023
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HV8TO
UT WOS:000466257200004
PM 30902479
DA 2020-05-12
ER

PT J
AU Harris, AM
   Millman, AJ
   Lora, M
   Osinubi, A
   Lom, J
   Miller, LS
AF Harris, Aaron M.
   Millman, Alexander J.
   Lora, Meredith
   Osinubi, Ademola
   Lom, Jennifer
   Miller, Lesley S.
TI Hepatitis B testing, care linkage, and vaccination coverage within a
   registry of hepatitis C infected patients
SO VACCINE
LA English
DT Article
DE Hepatitis B; Hepatitis C; Testing; Registry; Vaccination
ID UNITED-STATES COHORT; VIRUS COINFECTION; REACTIVATION; THERAPY
AB Background: Hepatitis B virus (HBV) infection testing among persons with hepatitis C virus (HCV) infection is necessary to appropriately care for these patients, yet uptake of HBV testing and vaccination in this population is suboptimal.
   Methods: In a retrospective cohort analysis, we describe the prevalence of hepatitis B testing, linkage to hepatitis B care, and hepatitis B vaccination in patients with HCV infection within a large urban safety-net health system. Using a registry of HCV-infected patients with patient-level electronic health record data, that included demographic, clinical, and laboratory information from 2004 to 2016 from Grady Health System in Atlanta, GA, we describe (1) The prevalence of hepatitis B testing (hepatitis B surface antigen [HBsAg], core antibody [anti-HBc] surface antibody [anti-HBs]); (2) The proportion of HBsAg-positive persons receiving HBV DNA and e-antigen (HBeAg) as indicators for linkage to hepatitis B-directed care; and (3) The proportion of persons receiving hepatitis B vaccine.
   Results: Of 4224 HCV-infected patients, 3629 (86%) had test results for HBsAg and 43 (1.2%) were HBsAg positive. Of 2342 (55%) with test results for all three HBV serological markers, median age was 60 years, 67% were male, and 83% were African-American, 789 (34%) anti-HBc positive only, 678 (29%) anti-HBc/anti-HBs positive, 190 (8.1%) anti-HBs positive only, and 642 (27%) were HBV-susceptible. Of HBsAg positive patients, 21% received HBV DNA and 40% HBeAg testing. The proportion of HBV-susceptible patients receiving at least 1 dose of hepatitis B vaccine was 322/642 (50%).
   Conclusions: In a large cohort of HCV-infected patients, we found a high prevalence of current or past HBV infection, but there were gaps in complete hepatitis B testing, hepatitis B-directed care, and hepatitis B vaccination. Strategies are needed to increase hepatitis B testing, linkage to care, and administration of the hepatitis B vaccine for HCV-infected persons in this healthcare system. Published by Elsevier Ltd.
C1 [Harris, Aaron M.; Millman, Alexander J.; Osinubi, Ademola] Ctr Dis Control & Prevent, Div Viral Hepatitis, 1600 Clifton Rd NE,MS US12-3, Atlanta, GA 30329 USA.
   [Lora, Meredith; Lom, Jennifer; Miller, Lesley S.] Emory Univ, Sch Med, Atlanta, GA USA.
   [Lora, Meredith; Lom, Jennifer; Miller, Lesley S.] Emory Univ, Sch Med, Div Gen Med, 49 Jesse Hill Jr Dr SE, Atlanta, GA 30303 USA.
RP Harris, AM (reprint author), Ctr Dis Control & Prevent, Div Viral Hepatitis, 1600 Clifton Rd NE,MS US12-3, Atlanta, GA 30329 USA.
EM amharris@cdc.gov; irm6@cdc.gov; Meredith.lora@emory.edu; nkg5@cdc.gov;
   Jennifer.elizabeth.lom@emory.edu; lesley.miller@emory.edu
FU Centers for Disease Control and PreventionUnited States Department of
   Health & Human ServicesCenters for Disease Control & Prevention - USA
   [HHSD2002013M53955B]
FX This evaluation was supported by a contract award from the Centers for
   Disease Control and Prevention (Contract No. HHSD2002013M53955B) to
   NORC.
CR Abara WE, 2017, ANN INTERN MED, V167, P794, DOI 10.7326/M17-1106
   Allison RD, 2015, J HEPATOL, V63, P822, DOI 10.1016/j.jhep.2015.04.021
   [Anonymous], REC TEST MAN TREAT H
   Bersoff-Matcha SJ, 2017, ANN INTERN MED, V166, P792, DOI 10.7326/M17-0377
   Bruce MG, 2016, J INFECT DIS, V214, P16, DOI 10.1093/infdis/jiv748
   Cohen C, 2011, J VIRAL HEPATITIS, V18, P377, DOI 10.1111/j.1365-2893.2010.01401.x
   Hachem CY, 2008, ALIMENT PHARM THER, V28, P1078, DOI 10.1111/j.1365-2036.2008.03827.x
   Hofmeister MG, 2018, HEPATOLOGY
   Hsu L, 2013, DIGEST DIS SCI, V58, P807, DOI 10.1007/s10620-012-2396-9
   Jackson S, 2018, VACCINE, V36, P668, DOI 10.1016/j.vaccine.2017.12.038
   Jacobs RJ, 2005, DIGEST DIS SCI, V50, P1525, DOI 10.1007/s10620-005-2873-5
   Kruse RL, 2014, HEPATOLOGY, V60, P1871, DOI 10.1002/hep.27337
   Lok ASF, 2007, HEPATOLOGY, V45, P507, DOI 10.1002/hep.21513
   Lok ASF, 2012, ANN INTERN MED, V156, P743, DOI 10.7326/0003-4819-156-10-201205150-00013
   Ly KN, 2016, CLIN INFECT DIS, V62, P1287, DOI 10.1093/cid/ciw111
   Miller LS, 2017, HEPATOLOGY, V66, p537A
   Moorman AC, 2018, GASTROENTEROLOGY, V154, P754, DOI 10.1053/j.gastro.2017.12.002
   Ponde RAA, 2010, ARCH VIROL, V155, P149, DOI 10.1007/s00705-009-0559-6
   Roberts H, 2015, HEPATOLOGY
   Schillie S, 2018, MMWR RECOMM REP, V67, P1, DOI 10.15585/mmwr.rr6701a1
   Terrault NA, 2018, HEPATOLOGY, V67, P1560, DOI 10.1002/hep.29800
   Tyson GL, 2013, HEPATOLOGY, V58, P538, DOI 10.1002/hep.26400
   Wang C, 2017, CLIN GASTROENTEROL H, V15, P132, DOI 10.1016/j.cgh.2016.06.023
   Williams WW, 2017, MMWR SURVEILL SUMM, V66, P1, DOI 10.15585/mmwr.ss6611a1
   Yue X, 2018, VACCINE, V36, P1183, DOI 10.1016/j.vaccine.2018.01.033
NR 25
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD APR 10
PY 2019
VL 37
IS 16
BP 2188
EP 2193
DI 10.1016/j.vaccine.2019.03.012
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HV8TO
UT WOS:000466257200005
PM 30902481
DA 2020-05-12
ER

PT J
AU Hu, J
   Xu, JL
   Liu, F
   Tan, C
   Yuan, FY
   Chen, HC
   Bei, WC
AF Hu, Jin
   Xu, Jiali
   Liu, Feng
   Tan, Chen
   Yuan, Fangyan
   Chen, Huanchun
   Bei, Weicheng
TI Immunogenicity and cross-protective efficacy of double-mutant
   Streptococcus suis Delta SspepO/Delta SspspC serotypes 2 and 7
SO VACCINE
LA English
DT Article
DE Streptococcus suis; Delta SspepO/Delta SspspC; Vaccine; Immunogenicity;
   Cross-protection
ID VIRULENCE; CONSTRUCTION; CANDIDATE; PROTEINS; STRAINS
AB Streptococcus suis serotype 2 (S. suis 2) is a major pathogen causing streptococcosis in swine, resulting in significant losses in swine breeding worldwide. We previously reported that the non-antibiotic-resistant double-mutant strain Delta SspepO/Delta SspspC can be used as a live vaccine, providing effective protection against S. suis 2 infections in mice. This study aimed to understand the characteristics of streptococcosis and develop vaccine candidates for immunization. Intramuscular injection of live S. suis Delta SspepO/Delta SspspC in pigs induced discernable antibody production and provided cross-protection against challenges by a type 2 strain (100% protection) and a type 7 strain (60% protection). Protection was evaluated via clinical, bacteriological, serological, and post-mortem examinations. Furthermore, vaccination induced the production of opsonizing antibodies against serotypes 2 and 7. Analysis of IgG subclasses (IgG1 and IgG2a) revealed that both Th1 and Th2 responses were induced by S. suis Delta SspepO/Delta SspspC, although the IgG2a (Thl) response predominated over the IgG1 (Th2) response. This study is the first, to our knowledge, to establish a live vaccine candidate to protect against two major S. suis serotypes. Further studies are required to assess these candidate vaccines and examine their feasibility in providing cross-protection against S. suis. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Hu, Jin; Xu, Jiali; Liu, Feng; Tan, Chen; Chen, Huanchun; Bei, Weicheng] Huazhong Agr Univ, State Key Lab Agr Microbiol, Wuhan, Hubei, Peoples R China.
   [Hu, Jin; Xu, Jiali; Liu, Feng; Tan, Chen; Chen, Huanchun; Bei, Weicheng] Huazhong Agr Univ, Cooperat Innovat Ctr Sustainable Pig Prod, Wuhan, Hubei, Peoples R China.
   [Xu, Jiali; Liu, Feng; Tan, Chen; Chen, Huanchun; Bei, Weicheng] Huazhong Agr Univ, Coll Anim Sci Ea Vet Med, Wuhan, Hubei, Peoples R China.
   [Yuan, Fangyan] Hubei Acad Agr Sci, Inst Anim Husb & Vet Sci, Key Lab Prevent & Control Agents Anim Bacteriosis, Minist Agr,Hubei Key Lab Anim Embryo & Mol Breedi, Wuhan, Hubei, Peoples R China.
RP Bei, WC (reprint author), Huazhong Agr Univ, State Key Lab Agr Microbiol, Coll Anim Sci & Vet Med, Wuhan 430070, Hubei, Peoples R China.
EM beiwc@mail.hzau.edu.cn
FU National Nature Science Foundation of ChinaNational Natural Science
   Foundation of China [31702239, 31672560]; National Key Research and
   Development Program of China [2017YFD0501001]; Fundamental Research
   Funds for the Central UniversitiesFundamental Research Funds for the
   Central Universities [22662018PY042]; Competitive planning project from
   Hubei Academy of Agricultural Sciences [2015jzxjh03]; Natural Science
   Foundation of Hubei ProvinceNatural Science Foundation of Hubei Province
   [2016CFA015]; China Agriculture Research System [CARS-35]
FX This research is supported by the National Nature Science Foundation of
   China (No. 31702239 and 31672560), the National Key Research and
   Development Program of China (2017YFD0501001), the Fundamental Research
   Funds for the Central Universities (No. 22662018PY042), Competitive
   planning project from Hubei Academy of Agricultural Sciences
   (2015jzxjh03), the Natural Science Foundation of Hubei Province
   (2016CFA015) and China Agriculture Research System (CARS-35)
CR Baing A, 2015, FRONT MICROBIOL, V6, P1191
   Baums CG, 2009, CLIN VACCINE IMMUNOL, V16, P200, DOI 10.1128/CVI.00371-08
   Feng LP, 2018, VACCINE, V36, P2581, DOI 10.1016/j.vaccine.2018.03.079
   Fu SL, 2012, VACCINE, V30, P6839, DOI 10.1016/j.vaccine.2012.09.014
   Gottschalk M, 2000, VET MICROBIOL, V76, P259, DOI 10.1016/S0378-1135(00)00250-9
   Gottschalk M, 2010, FUTURE MICROBIOL, V5, P371, DOI 10.2217/FMB.10.2
   Hu J, 2015, MICROBIOL RES, V170, P87, DOI 10.1016/j.micres.2014.08.010
   Jiang XW, 2016, VACCINE, V34, P6529, DOI 10.1016/j.vaccine.2016.05.003
   Li JQ, 2011, VACCINE, V29, P6514, DOI 10.1016/j.vaccine.2011.07.010
   Liu F, 2018, J INFECT DIS, V217, P973, DOI 10.1093/infdis/jix523
   Segura M, 2015, EXPERT REV VACCINES, V14, P1587, DOI 10.1586/14760584.2015.1101349
   Silva LMG, 2006, VET MICROBIOL, V115, P117, DOI 10.1016/j.vetmic.2005.12.013
   Tan C, 2011, MICROB PATHOGENESIS, V51, P319, DOI 10.1016/j.micpath.2011.07.008
   Teng L, 2017, GENOME ANNOUNCEMENTS, V5
   Wei ZG, 2009, VET MICROBIOL, V137, P196, DOI 10.1016/j.vetmic.2008.12.015
   Yuan ZZ, 2013, J BIOL CHEM, V288, P956, DOI 10.1074/jbc.M112.388686
   Zhang AD, 2008, PROTEOMICS, V8, P3506, DOI 10.1002/pmic.200800007
   Zhang AD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050987
   Zhang W, 2007, PROTEOMICS, V7, P4468, DOI 10.1002/pmic.200700294
   Zheng CK, 2017, VIRULENCE, V8, P53, DOI 10.1080/21505594.2016.1201256
   Zheng CK, 2016, MICROB PATHOGENESIS, V98, P149, DOI 10.1016/j.micpath.2016.07.009
   Zheng CK, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108197
   2013, CLIN VACCINE IMMUNOL, V20, P134, DOI DOI 10.1128/CVI.00458-12
NR 23
TC 0
Z9 0
U1 0
U2 5
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD APR 10
PY 2019
VL 37
IS 16
BP 2194
EP 2199
DI 10.1016/j.vaccine.2019.03.028
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HV8TO
UT WOS:000466257200006
PM 30902483
DA 2020-05-12
ER

PT J
AU Picazo, JJ
   Ruiz-Contreras, J
   Casado-Flores, J
   Negreira, S
   Baquero-Artigao, F
   Hernandez-Sampelayo, T
   Otheo, E
   del Amo, M
   Mendez, C
   Ramos, JT
   Betriu, C
   Culebras, E
   Gonzalez, F
   Rodriguez-Avial, I
   Ruiz-Contreras, J
   Negreira, S
   Orellana, MA
   Delgado-Iribarren, A
   Bueno, M
   Alhambra, A
   Garcia, MT
   Gonzalez, MJ
   Cobos, J
   Baquero, F
   Garcia, A
   Casado, J
   Hernandez, B
   Zafra, M
   Jaqueti, J
   Calvo, C
   Wilhelmi, I
   Serrano, C
   Garcia-Penuela, E
   Cercenado, E
   Hernandez-Sampelayo, T
   Otheo, E
   Ruiz, P
   Dominguez, N
   Gadea, I
   Romero, I
   Gomez-Garces, JL
   Roa, MA
   Ruiz, M
   Cacho, J
   Garcia-Picazo, ML
   Gallego, S
   Cilleruelo, MJ
   Sanchez, MI
   Penin, M
   Gomez, P
   Salso, S
   Corcino, M
   Rodriguez, A
   Clemente, J
   Ruibal, JL
   Agundez, B
   Canete, A
   Garcia-Vao, C
   Sanchez, A
   Sanz, JC
   Mendez, C
   del Amo, M
   Balseiro, C
   Samaniego, ML
AF Picazo, Juan J.
   Ruiz-Contreras, Jesus
   Casado-Flores, Juan
   Negreira, Sagrario
   Baquero-Artigao, Fernando
   Hernandez-Sampelayo, Teresa
   Otheo, Enrique
   del Amo, Maria
   Mendez, Cristina
   Ramos, J. T.
   Betriu, C.
   Culebras, E.
   Gonzalez, F.
   Rodriguez-Avial, I
   Ruiz-Contreras, J.
   Negreira, S.
   Orellana, M. A.
   Delgado-Iribarren, A.
   Bueno, M.
   Alhambra, A.
   Garcia, M. T.
   Gonzalez, M. J.
   Cobos, J.
   Baquero, F.
   Garcia, A.
   Casado, J.
   Hernandez, B.
   Zafra, M.
   Jaqueti, J.
   Calvo, C.
   Wilhelmi, I
   Serrano, C.
   Garcia-Penuela, E.
   Cercenado, E.
   Hernandez-Sampelayo, T.
   Otheo, E.
   Ruiz, P.
   Dominguez, N.
   Gadea, I
   Romero, I
   Gomez-Garces, J. L.
   Roa, M. A.
   Ruiz, M.
   Cacho, J.
   Garcia-Picazo, M. L.
   Gallego, S.
   Cilleruelo, M. J.
   Sanchez, M., I
   Penin, M.
   Gomez, P.
   Salso, S.
   Corcino, M.
   Rodriguez, A.
   Clemente, J.
   Ruibal, J. L.
   Agundez, B.
   Canete, A.
   Garcia-Vao, C.
   Sanchez, A.
   Sanz, J. C.
   Mendez, C.
   del Amo, M.
   Balseiro, C.
   Samaniego, M. L.
CA Heracles Study Grp
TI Impact of 13-valent pneumococcal conjugate vaccination on invasive
   pneumococcal disease in children under 15 years old in Madrid, Spain,
   2007 to 2016: The HERACLES clinical surveillance study
SO VACCINE
LA English
DT Article
DE Streptococcus pneumoniae; Invasive pneumococcal disease (IPD); PCV13;
   Regional Immunization Programme (RIP); Serotype 19A; Antibiotic
   resistance
ID STREPTOCOCCUS-PNEUMONIAE; UNITED-STATES; SEROTYPE 19A; EPIDEMIOLOGY;
   TRENDS
AB Streptococcus pneumoniae is a major cause of morbidity and mortality worldwide. Using the data from the HERACLES clinical surveillance study (2007-2016), we describe the population impact of the 13-valent pneumococcal conjugate vaccine (PVC13) on invasive pneumococcal disease (IPD) in children <15 years of age in the Community of Madrid, Spain. After six years of the inclusion of PCV13 in the vaccination calendar (2010-2016), and despite changes in the Regional Immunization Programme that limited its availability, the net benefit incidence rate (IR) of IPD fell by 70.1% (IRR 0.3 [95% CI: 0.22-0.4]; p <= 0.001), mainly due to a significant reduction (91%) in the PCV13 serotypes (IRR 0.09 [95% CI: 0.05-0.16], p <= 0.001). Furthermore, no significant changes were detected in the IR of IPD caused by non-PCV13 serotypes. The IRs of the aggressive, resistant and most prevalent serotype in the analysed population, the 19A serotype, dramatically decreased from the beginning to the end of the study (98%) [IRR 0.03 (95% CI: 0.00-0.19), p <= 0.001], to its almost total disappearance. Remarkably, this reduction led to a pronounced decline in the percentage of cefotaxime-resistant isolates and the incidence of meningitis cases. Assessment of the clinical impact revealed a reduction in the number of all clinical presentations of IPD, confirming the effectiveness of the PCV13. Finally, PCV13 detected by PCR is predicted to have a stronger impact than the one based on culture methods, which can overlook more than 20% of cases of IPD, mainly pleural empyemas. (C) 2019 Published by Elsevier Ltd.
C1 [Picazo, Juan J.] Univ Complutense, Sch Med, Med Dept, Madrid, Spain.
   [Ruiz-Contreras, Jesus; Negreira, Sagrario] Hosp Univ 12 Octubre, Pediat Dept, Madrid, Spain.
   [Ruiz-Contreras, Jesus; Negreira, Sagrario; Hernandez-Sampelayo, Teresa] Univ Complutense, Sch Med, Pediat Dept, Madrid, Spain.
   [Casado-Flores, Juan] Hosp Univ Infantil Nino Jesus, Pediat ICU, Madrid, Spain.
   [Casado-Flores, Juan; Baquero-Artigao, Fernando] Univ Autonoma, Sch Med, Pediat Dept, Madrid, Spain.
   [Baquero-Artigao, Fernando] Hosp Univ La Paz, Pediat Dept, Madrid, Spain.
   [Hernandez-Sampelayo, Teresa] Hosp Gen Univ Gregorio Marafran, Pediat Dept, Madrid, Spain.
   [Hernandez-Sampelayo, Teresa] CIBERES, CIBER Resp Dis, Madrid, Spain.
   [Otheo, Enrique] Hosp Univ Ramon & Cajal, Pediat Dept, Madrid, Spain.
   [Otheo, Enrique] Univ Alcala De Henares, Fac Med, Madrid, Spain.
   [del Amo, Maria; Mendez, Cristina] Pfizer SLU, Med Dept, Madrid, Spain.
   [Picazo, Juan J.; Ramos, J. T.; Betriu, C.; Culebras, E.; Gonzalez, F.; Rodriguez-Avial, I] Hosp Univ Clin San Carlos, Madrid, Spain.
   [Ruiz-Contreras, J.; Negreira, S.; Orellana, M. A.] Hosp Univ 12 Octubre, Madrid, Spain.
   [Delgado-Iribarren, A.; Bueno, M.] Hosp Univ Fdn Alcorcon, Madrid, Spain.
   [Alhambra, A.; Garcia, M. T.] Hosp Univ HM Sanchinarro, Madrid, Spain.
   [Gonzalez, M. J.; Cobos, J.] Hosp San Rafael, Madrid, Spain.
   [Baquero, F.; Garcia, A.] Hosp Univ La Paz, Madrid, Spain.
   [Casado, J.; Hernandez, B.] Hosp Univ Infantil Nino Jesus, Madrid, Spain.
   [Zafra, M.; Jaqueti, J.] Hosp Univ Fuenlabrada, Madrid, Spain.
   [Calvo, C.; Wilhelmi, I] Hosp Univ Severo Ochoa, Madrid, Spain.
   [Serrano, C.; Garcia-Penuela, E.] Hosp Univ Sanitas La Zarzuela, Madrid, Spain.
   [Cercenado, E.; Hernandez-Sampelayo, T.] Hosp Gen Univ Gregorio Maranon, Madrid, Spain.
   [Otheo, E.; Ruiz, P.] Hosp Univ Ramon & Cajal, Madrid, Spain.
   [Dominguez, N.; Gadea, I] Fdn Jimenez Diaz, Madrid, Spain.
   [Romero, I] Hosp Univ HM Torrelodones, Madrid, Spain.
   [Gomez-Garces, J. L.; Roa, M. A.] Hosp Univ Mostoles, Madrid, Spain.
   [Ruiz, M.; Cacho, J.] Hosp Univ Getafe, Madrid, Spain.
   [Garcia-Picazo, M. L.; Gallego, S.] Hosp Escorial, Madrid, Spain.
   [Cilleruelo, M. J.; Sanchez, M., I] Hosp Univ Puerta Hierro, Madrid, Spain.
   [Penin, M.; Gomez, P.] Hosp Univ Principe Asturias, Madrid, Spain.
   [Salso, S.; Corcino, M.] Hosp Univ HM Monteprincipe, Madrid, Spain.
   [Rodriguez, A.] Hosp Univ Sureste, Madrid, Spain.
   [Clemente, J.] Hosp Henares, Madrid, Spain.
   [Ruibal, J. L.] Hosp Univ Infanta Cristina, Madrid, Spain.
   [Agundez, B.] Hosp Univ Infanta Leonor, Madrid, Spain.
   [Canete, A.] Hosp Univ Infanta Sofia, Madrid, Spain.
   [Garcia-Vao, C.] Hosp Univ Tajo, Madrid, Spain.
   [Sanchez, A.] BR Salud, Madrid, Spain.
   [Sanz, J. C.] LRSP, Madrid, Spain.
   [Mendez, C.; del Amo, M.; Balseiro, C.; Samaniego, M. L.] Pfizer SLU, Madrid, Spain.
RP Picazo, JJ (reprint author), Univ Complutense, Sch Med, Med Dept, Fac Med, Pabellon 1,1 Planta Ciudad Univ, E-28040 Madrid, Spain.
EM jpicazo@picazo.net
RI Miguel, M Angeles Orellana/AAF-4500-2020; Culebras,
   ESTHER/AAA-3865-2019; rodriguez-avial, iciar/AAA-6968-2019
OI Miguel, M Angeles Orellana/0000-0002-2696-8613; Baquero,
   Fernando/0000-0002-6903-3826
FU Pfizer, SpainPfizer
FX Study Sponsored by Pfizer, Spain.
CR Aguiar SI, 2014, EUROSURVEILLANCE, V19, P18, DOI 10.2807/1560-7917.ES2014.19.12.20750
   [Anonymous], 2012, Wkly Epidemiol Rec, V87, P129
   [Anonymous], 2018, EUR COUNTR POP
   Bamgbola O, 2016, THER ADV ENDOCRINOL, V7, P136, DOI 10.1177/2042018816638223
   Beall BW, 2011, SHIFTING GENETIC STR
   (CLSI) CaLl, 2014, M100S24 CLSI CALI
   (CLSI) CaLSI, 2006, M7A CLSI CALSI
   Fenoll A, 2009, J CLIN MICROBIOL, V47, P1012, DOI 10.1128/JCM.01454-08
   Gervaix A, 2014, CLIN THER, V36, P802, DOI 10.1016/j.clinthera.2014.03.001
   Hicks LA, 2007, INCIDENCE PNEUMOCOCC
   Horacio AN, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073704
   Klugman K, 2013, VACCINES, P504
   Kwambana-Adams B, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-08717-0
   Kyaw MH, 2006, EFFECT INTRO PNEUMOC
   Link-Gelles R, 2013, VACCINE, V31, P2572, DOI 10.1016/j.vaccine.2013.03.049
   Michelow IC, 2002, CLIN INFECT DIS, V34, pE1, DOI 10.1086/324358
   MOINE P, 1994, CHEST, V105, P1487, DOI 10.1378/chest.105.5.1487
   Moore MR, 2008, J INFECT DIS, V197, P1016, DOI 10.1086/528996
   O'Brien KL, 2009, LANCET, V374, P893, DOI 10.1016/S0140-6736(09)61204-6
   Pai R, 2005, POSTVACCINE GENETIC
   Picazo J, 2011, VACCINE, V29, P1770, DOI 10.1016/j.vaccine.2010.12.114
   Picazo J, 2011, CLIN VACCINE IMMUNOL, V18, P89, DOI 10.1128/CVI.00317-10
   Picazo J, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0172222
   Reinert RR, 2010, VACCINE, V28, P4249, DOI 10.1016/j.vaccine.2010.04.020
   Robinson KA, 2001, JAMA-J AM MED ASSOC, V285, P1729, DOI 10.1001/jama.285.13.1729
   Whitney CG, 2003, DECLINE INVASIVE PNE
   2012, MMWR MORBID MORTAL W, V61, P394
NR 27
TC 1
Z9 1
U1 0
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD APR 10
PY 2019
VL 37
IS 16
BP 2200
EP 2207
DI 10.1016/j.vaccine.2019.03.015
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HV8TO
UT WOS:000466257200007
PM 30902478
DA 2020-05-12
ER

PT J
AU Feyssaguet, M
   Bellanger, A
   Nozay, F
   Friel, D
   Merck, E
   Verlant, V
   Maleve, M
   Lallemand, S
   El Moussaoui, A
   D'Argoeuves, PD
   Jones, T
   Goldblatt, D
   Schoonbroodt, S
AF Feyssaguet, Muriel
   Bellanger, Aurelie
   Nozay, Florence
   Friel, Damien
   Merck, Estelle
   Verlant, Vincent
   Maleve, Michel
   Lallemand, Stephane
   El Moussaoui, Abdelkarim
   D'Argoeuves, Polly De Gorguette
   Jones, Tessa
   Goldblatt, David
   Schoonbroodt, Sonia
TI Comparison between a new multiplex electrochemiluminescence assay and
   the WHO reference enzyme-linked immunosorbent assay to Chock for measure
   serum antibodies against pneumococcal serotype-specific polysaccharides
SO VACCINE
LA English
DT Article
DE Electrochemiluminescence assay; Enzyme-linked immunosorbent assay;
   Pneumococcal polysaccharides; Threshold; Bridging; Concordance
ID CONJUGATE VACCINE; IMMUNOGENICITY; EFFICACY; SAFETY
AB Background: Two electrochemiluminescence (ECL) assays were developed which, together, can simultaneously measure serum antibodies against pneumococcal capsular polysaccharides (PnPS) for 17 sero-types. The assays were validated for the 13 PnPS included in the 13-valent pneumococcal conjugate vaccine (PCV13). As recommended by the World Health Organization (WHO), we compared the ECL assays with the WHO reference enzyme-linked immunosorbent assay (ELISA) and derived a threshold corresponding to the 0.35 mu g/mL threshold established for the WHO reference ELISA for the non-inferiority comparison and licensure of new PCVs against invasive pneumococcal disease.
   Methods: A panel of 452 serum samples from children vaccinated with one of the three licensed PCVs was assessed with the ECL assays and the WHO reference ELISA. The ECL assay threshold for the aggregated seven PnPS included in the 7-valent PCV (PCV7) and serotype-specific thresholds were determined using a receiver operating characteristics (ROC) curve-based approach and Deming regression. To evaluate concordance between the ECL assays and the WHO reference ELISA, serostatus agreement rates between both assays and geometric means of the ratios (GMRs) of concentrations obtained with both assays were calculated.
   Results: The thresholds for the seven aggregated PCV7 serotypes obtained with the ROC curve-based approach and Deming regression approximated 0.35 mu g/mL (0.38 and 0.34 mu g/mL, respectively). Individual thresholds for the PCV13 serotypes ranged between 0.24 and 0.51 mu g/mL across both approaches. Serostatus agreement rates using a 0.35 mu g/mL threshold for both assays were >= 86.9% for all PCV13 serotypes. GMRs ranged between 0.85 and 1.25 for 11/13 serotypes and were <1.29 for the two remaining serotypes.
   Conclusion: The ECL assays were comparable to the WHO reference ELISA and offer a sensitive, time- and serum volume-saving method to quantify serotype-specific anti-PnPS antibodies in pediatric sera. A 035 mu g/mL threshold will be used for each PCV13 serotype to assess PCV immunogenicity in clinical trials. (C) 2019 GlaxoSmithKline Biologicals SA. Published by Elsevier Ltd.
C1 [Feyssaguet, Muriel; Bellanger, Aurelie; Nozay, Florence; Maleve, Michel; Lallemand, Stephane; El Moussaoui, Abdelkarim; Schoonbroodt, Sonia] GSK, Rue Inst 89, B-1330 Rixensart, Belgium.
   [Friel, Damien; Merck, Estelle; Verlant, Vincent] GSK, Ave Fleming 20, B-1300 Wavre, Belgium.
   [D'Argoeuves, Polly De Gorguette; Jones, Tessa; Goldblatt, David] UCL Great Ormond St Inst Child Hlth, 30 Guilford St, London WC1N 1EH, England.
RP Feyssaguet, M (reprint author), GSK, Rue Inst 89, B-1330 Rixensart, Belgium.
EM muriel.m.feyssaguet@gsk.com; aurelie.m.bellanger@gsk.com;
   florence.nozay@gsk.com; damien.j.friel@gsk.com; estelle.x.merck@gsk.com;
   vincent.verlant@gsk.com; michel.maleve@gsk.com;
   stephane.lallemand@gsk.com; abdelkarim.x.el-moussaoui@gsk.com;
   p.dargoeuves@ucl.ac.uk; tessajones.09@ucl.ac.uk; d.goldblatt@ucl.ac.uk;
   sonia.j.schoonbroodt@gsk.com
FU GlaxoSmithKline Biologicals SAGlaxoSmithKline
FX This work was supported by GlaxoSmithKline Biologicals SA, who was
   involved in all stages of the analyses and paid for all costs associated
   with the development and publishing of this manuscript.
CR [Anonymous], 2012, Wkly Epidemiol Rec, V87, P129
   [Anonymous], 2018, MSD TECHN PLATF
   Biagini RE, 2003, CLIN DIAGN LAB IMMUN, V10, P744, DOI 10.1128/CDLI.10.5.744-750.2003
   Black S, 2000, PEDIATR INFECT DIS J, V19, P187, DOI 10.1097/00006454-200003000-00003
   Cohen O, 2017, PNEUMOCOCCAL CONJUGA
   DEAVER DR, 1995, NATURE, V377, P758, DOI 10.1038/377758a0
   Eskola J, 2001, NEW ENGL J MED, V344, P403, DOI 10.1056/NEJM200102083440602
   Goldblatt D, 2011, CLIN VACCINE IMMUNOL, V18, P1728, DOI 10.1128/CVI.05252-11
   Henckaerts I, 2006, CLIN VACCINE IMMUNOL, V13, P356, DOI 10.1128/CVI.13.3.356-360.2006
   ICH, 2005, VAL AN PROC TEXT MET
   Jodar L, 2003, VACCINE, V21, P3265, DOI 10.1016/S0264-410X(03)00230-5
   LINNET K, 1993, CLIN CHEM, V39, P424
   Meso Scale Discovery, 2013, MSD TECHN PLATF
   Nolan K, 2018, 11 INT S PNEUM PNEUM
   Pickering JW, 2002, AM J CLIN PATHOL, V117, P589
   Siber GR, 2007, VACCINE, V25, P3816, DOI 10.1016/j.vaccine.2007.01.119
   US Dept of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research Center for Veterinary Medicine, 2013, BIOAN METH VAL GUID
   Vesikari T, 2009, PEDIATR INFECT DIS J, V28, pS66, DOI 10.1097/INF.0b013e318199f8ef
   Wernette CM, 2003, CLIN DIAGN LAB IMMUN, V10, P514, DOI 10.1128/CDLI.10.4.514-519.2003
   WHO Expert Committee on Biological Standardization, 2013, WHO TECHN REP SER
   World Health Organization, TRAIN MAN ENZ LINK I
   World Health Organization Expert Committee on Biological Standardization, 2013, WHO TECHN REP SER
   Yeh SH, 2010, PEDIATRICS, V126, pE493, DOI 10.1542/peds.2009-3027
   2005, J IMMUNOL METHODS, V296, P135, DOI DOI 10.1016/IJIM.2004.11.006
   2014, LANCET INFECT DIS, V14, P839, DOI DOI 10.1016/1473-3099(14)70822-9
   2009, EXPERT REV VACCINES, V8, P1479, DOI DOI 10.1586/ERV.09.113
   2002, PEDIATR INFECT DIS J, V21, P810, DOI DOI 10.1097/01.INF0000027417699356.4R
   2010, PEDIATRICS, V125, P866, DOI DOI 10.1542/PEDS2009-1405
   2006, J IMMUNOL METHODS, V309, P75, DOI DOI 10.1016/JJIM.2005.11.019
   2007, AM J CLIN PATHOL, V128, P23, DOI DOI 10.1309/7131K5W6QH7J112TMA
   2015, CLIN MICROBIOL REV, V28, P871, DOI DOI 10.1128/RMR00074-15
   2010, CLIN VACCINE IMMUNOL, V17, P134, DOI DOI 10.1128/RVI00289-09
   2009, CLIN VACCINE IMMUNOL, V16, P387, DOI DOI 10.1128/CVI00415-08
NR 33
TC 3
Z9 3
U1 0
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD APR 10
PY 2019
VL 37
IS 16
BP 2208
EP 2215
DI 10.1016/j.vaccine.2019.03.011
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HV8TO
UT WOS:000466257200008
PM 30879829
OA Other Gold, Green Published
DA 2020-05-12
ER

PT J
AU Hoffman, BL
   Fetter, EM
   Chu, KH
   Shensa, A
   Hermann, C
   Wolynn, T
   Williams, D
   Primack, BA
AF Hoffman, Beth L.
   Fetter, Elizabeth M.
   Chu, Kar-Hai
   Shensa, Ariel
   Hermann, Chad
   Wolynn, Todd
   Williams, Dania
   Primack, Brian A.
TI It's not all about autism: The emerging landscape of anti-vaccination
   sentiment on Facebook
SO VACCINE
LA English
DT Article
DE Facebook; Social media; Anti-vaccination; Health communication
ID UNITED-STATES; SOCIAL MEDIA; WEB 2.0; OPPORTUNITIES; IMMUNIZATION;
   CHALLENGES; ONLINE; IMPACT
AB Background: Due in part to declining vaccination rates, in 2018 over 20 states reported at least one case of measles, and over 40,000 cases were confirmed in Europe. Anti-vaccine posts on social media may be facilitating anti-vaccination behaviour. This study aimed to systematically characterize (1) individuals known to publicly post anti-vaccination content on Facebook, (2) the information they convey, and (3) the spread of this content.
   Methods: Our data set consisted of 197 individuals who posted anti-vaccination comments in response to a message promoting vaccination. We systematically analysed publicly-available content using quantitative coding, descriptive analysis, social network analysis, and an in-depth qualitative assessment. The final codebook consisted of 26 codes; Cohen's kappa ranged 0.71-1.0 after double-coding.
   Results: The majority (89%) of individuals identified as female. Among 136 individuals who divulged their location, 36 states and 8 other countries were represented. In a 2-mode network of individuals and topics, modularity analysis revealed 4 distinct sub-groups labelled as "trust," "alternatives," "safety," and "conspiracy." For example, a comment representative of "conspiracy" is that poliovirus does not exist and that pesticides caused clinical symptoms of polio. An example from the "alternatives" sub-group is that eating yogurt cures human papillomavirus. Deeper qualitative analysis of all 197 individuals' profiles found that these individuals also tended to post material against other health-related practices such as water fluoridation and circumcision.
   Conclusions: Social media outlets may facilitate anti-vaccination connections and organization by facilitating the diffusion of centuries old arguments and techniques. Arguments against vaccination are diverse but remain consistent within sub-groups of individuals. It would be valuable for health professionals to leverage social networks to deliver more effective, targeted messages to different constituencies. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Hoffman, Beth L.; Chu, Kar-Hai; Shensa, Ariel; Primack, Brian A.] Univ Pittsburgh, Sch Med, Dept Med, Div Gen Internal Med, 1218 Scaife Hall,35505 Terrace St, Pittsburgh, PA 15261 USA.
   [Hoffman, Beth L.; Chu, Kar-Hai; Shensa, Ariel; Williams, Dania; Primack, Brian A.] Univ Pittsburgh, Sch Med, Ctr Res Media Technol & Hlth, 230 McKee Pl,Suite 600, Pittsburgh, PA 15213 USA.
   [Hoffman, Beth L.; Fetter, Elizabeth M.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Behav & Community Hlth Sci, 130 De Soto St, Pittsburgh, PA 15261 USA.
   [Hermann, Chad; Wolynn, Todd] Kids Plus Pediat, 4070 Beechwood Blvd, Pittsburgh, PA 15217 USA.
   [Primack, Brian A.] Univ Pittsburgh, Hlth Policy Inst, 311 Scaife Hall,3550 Terrace St, Pittsburgh, PA 15261 USA.
   [Chu, Kar-Hai; Primack, Brian A.] Univ Pittsburgh, Sch Med, Dept Pediat, Div Adolescent Med, 311 Scaife Hall,35505 Terrace St, Pittsburgh, PA 15261 USA.
RP Primack, BA (reprint author), Univ Pittsburgh, Sch Med, Ctr Res Media Technol & Hlth, 230 McKee Pl,Suite 600, Pittsburgh, PA 15213 USA.
EM blh72@pitt.edu; emfelter@pitt.edu; chuk@pitt.edu; ariel.shensa@pitt.edu;
   chad@kidspluspgh.com; todd@kidspluspgh.com; dcw36@pitt.edu;
   bprimack@pitt.edu
OI Hoffman, Beth/0000-0001-6576-8748; Primack, Brian/0000-0002-5962-0939;
   Felter, Elizabeth/0000-0002-0567-0623
CR Amin AB, 2017, NAT HUM BEHAV, V1, P873, DOI 10.1038/s41562-017-0256-5
   Baker JP, 2003, VACCINE, V21, P4003, DOI 10.1016/S0264-410X(03)00302-5
   Bastian M., 2009, P INT AAAI C WEBL SO, P361, DOI DOI 10.1136/QSHC.2004.010033
   Bauch CT, 2013, SCIENCE, V342, P47, DOI 10.1126/science.1244492
   Berezow A., 2016, AM COUNC SCI HEAL
   Berezow A. B., 2012, SCI LEFT FEEL GOOD F
   Betsch C, 2012, VACCINE, V30, P3727, DOI 10.1016/j.vaccine.2012.02.025
   Betsch C, 2010, J HEALTH PSYCHOL, V15, P446, DOI 10.1177/1359105309353647
   Borgatti SP, 2012, COMPUT COMPLEX, P2912, DOI [10.1007/978-1-4614-1800-9_179., DOI 10.1007/978-1-4614-1800-9_179, 10.1007/978-1-4614-1800-9_179]
   BUCKINGHAM D, 2003, MEDIA ED LITERACY LE
   Centers for Disease Control and Prevention, 2018, MEASL CAS OUTBR
   Centers For Disease Control (Usa), 1999, Morbidity and Mortality Weekly Report, V48, P241
   Chakraborty P, 2017, COGENT MED, DOI [10.1080/12331205X2017139085, DOI 10.1080/12331205X2017139085]
   Chu K-H, 2013, J SOC STRUCT JOSS, V14
   Colditz JB, 2018, AM J PUBLIC HEALTH, V108, P1009, DOI 10.2105/AJPH.2018.304497
   Colditz JB, 2017, AM J HEALTH PROMOT, V31, P302, DOI [10.4278/ajhp.150218-QUAL-736, 10.4278/ajhp.150218-qual-736]
   Diethelm P, 2009, EUR J PUBLIC HEALTH, V19, P2, DOI 10.1093/eurpub/ckn139
   Doherty M, 2016, VACCINE, V34, P6707, DOI 10.1016/j.vaccine.2016.10.025
   Dredze M, 2016, AM J PREV MED, V50, P550, DOI 10.1016/j.amepre.2015.10.002
   Dunn AG, 2017, VACCINE, V35, P3033, DOI 10.1016/j.vaccine.2017.04.060
   Faasse K, 2016, VACCINE, V34, P5808, DOI 10.1016/j.vaccine.2016.09.029
   FREEMAN LC, 1977, SOCIOMETRY, V40, P35, DOI 10.2307/3033543
   Gilkey MB, 2018, CANCER EPIDEM BIOMAR, V27, P762, DOI 10.1158/1055-9965.EPI-17-1067
   Girvan M, 2002, P NATL ACAD SCI USA, V99, P7821, DOI 10.1073/pnas.122653799
   HOFFMAN BL, 2017, HLTH ED RES, V12, P551, DOI DOI 10.1093/HER/CYX034
   Hornsey MJ, 2018, HLTH PSCYCHOL, DOI [10.1037/heA00005R6, DOI 10.1037/HEA00005R6]
   Hunter RF, 2018, AM J PUBLIC HEALTH, V108, P343, DOI [10.2105/AJPH.2017.304249, 10.2105/ajph.2017.304249]
   Jones DS, 2012, NEW ENGL J MED, V366, P2333, DOI 10.1056/NEJMp1113569
   Kahan D.M., 2014, 17 CCP RISK PERC STU, DOI [DOI 10.2139/SSRN.2386034, 10.2139/ssrn.2386034]
   Kata A, 2012, VACCINE, V30, P3778, DOI 10.1016/j.vaccine.2011.11.112
   Kinch M., 2018, HOPE FEAR HIST VACCI
   Krippendorff K, 2004, HUM COMMUN RES, V30, P411, DOI 10.1111/j.1468-2958.2004.tb00738.x
   Moorhead SA, 2013, J MED INTERNET RES, V15, DOI 10.2196/jmir.1933
   Nicholson MS, 2012, VACCINE, V30, P3806, DOI 10.1016/j.vaccine.2011.10.072
   Nyhan B, 2014, PEDIATRICS, V133, pE835, DOI 10.1542/peds.2013-2365
   Omer SB, 2012, NEW ENGL J MED, V367, P1170, DOI 10.1056/NEJMc1209037
   Orr D, 2016, ISR J HEALTH POLICY, V5, DOI 10.1186/s13584-016-0093-4
   Schmidt AL, 2018, VACCINE, V36, P3606, DOI 10.1016/j.vaccine.2018.05.040
   Smith N, 2019, INFORM COMMUN SOC, V22, P1310, DOI 10.1080/1369118X.2017.1418406
   Stahl JP, 2016, MED MALADIES INFECT, V46, P117, DOI 10.1016/j.medmal.2016.02.002
   StataCorp, 2018, STAT STAT SOFTW VERS
   Statista, 2018, MOST POP MOB SOC NET
   Strauss A., 2007, BASICS QUALITATIVE R
   Wasserman S., 1994, SOCIAL NETWORK ANAL
   Wolfe RM, 2002, JAMA-J AM MED ASSOC, V287, P3245, DOI 10.1001/jama.287.24.3245
   World Health Organization, 2017, RESP VOC VACC DEN PU
   World Health Organization, 2018, MEASL CAS HIT REC HI
   Zhou FJ, 2014, PEDIATRICS, V133, P577, DOI 10.1542/peds.2013-0698
NR 48
TC 13
Z9 13
U1 12
U2 29
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD APR 10
PY 2019
VL 37
IS 16
BP 2216
EP 2223
DI 10.1016/j.vaccine.2019.03.003
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HV8TO
UT WOS:000466257200009
PM 30905530
OA Green Accepted
DA 2020-05-12
ER

PT J
AU Chen, T
   Zhou, XT
   Qi, Y
   Mi, LJ
   Sun, XF
   Zhang, SF
   Liu, Y
   Olson, V
   Qiu, W
   Wu, XF
   Hu, RL
AF Chen, Teng
   Zhou, Xintao
   Qi, Yu
   Mi, Lijuan
   Sun, Xuefei
   Zhang, Shoufeng
   Liu, Ye
   Olson, Victoria
   Qiu, Wei
   Wu, Xianfu
   Hu, Rongliang
TI Feline herpesvirus vectored-rabies vaccine in cats: A dual protection
SO VACCINE
LA English
DT Article
DE Rabies virus glycoprotein; Feline herpesvirus; Recombinant vaccine; Cats
ID GLYCOPROTEINS GI; IMMUNE-RESPONSES; STRIPED SKUNKS; VIRUS; RECOMBINANT;
   GENES; SURVEILLANCE; EXPRESSION; ONRAB(R); RACCOONS
AB In China, cats cause about 5% of human rabies cases. Rabies control in cats plays a role in achieving the ultimate goal of elimination of dog rabies-mediated human deaths. However, there is no cat-specific rabies vaccine in China yet. In this study, we constructed a recombinant rabies vaccine by using a felid herpesvirus 1 (FHV-1) isolate, and deleted the gl/E in the FHV-1 and replaced the region with a glycoprotein (G) of rabies virus (RABV) strain BD06 through homologous recombination. The recombinant virus FHV-RVG was recovered and purified, and the expression of RABV glycoprotein was verified by indirect immunofluorescent assay. For potency in cats, each animal was inoculated intranasally with 1 ml FHV-RVG at 10(6.5) TCID50. Blood samples were collected at defined intervals for antibody titration. The animals were challenged by herpes and rabies after completion of vaccination on day 180 and day 194, respectively. Our results demonstrated all vaccinated cats generated antibodies against both FHV-1 and RABV, and reached an arbitrary protective titer > 0.5 IU/ml for rabies viral neutralizing antibody (VNA) by day 14 post inoculation (dpi) and titer peaked on 30 dpi with VNA at 24.5 +/- 10.23 IU/ml. All vaccinated cats presented no clinical signs of FHV-1 infection and survived rabies challenge, while the control cats had severe rhinotracheitis and died from rabies after challenge. All this demonstrated that the FHV-based recombinant vaccine is effective in protection against both FHV-1 and RABV infections. (C) 2019 Published by Elsevier Ltd.
C1 [Chen, Teng; Zhou, Xintao; Qi, Yu; Mi, Lijuan; Sun, Xuefei; Zhang, Shoufeng; Liu, Ye; Hu, Rongliang] Acad Mil Med Sci, Mil Vet Res Inst, Changchun, Jilin, Peoples R China.
   [Qiu, Wei] Ctr Dis Control & Prevent Chengdu Mil Reg, Chengdu, Sichuan, Peoples R China.
   [Olson, Victoria; Wu, Xianfu] Ctr Dis Control & Prevent, Poxvirus & Rabies Branch, Atlanta, GA 30333 USA.
RP Hu, RL (reprint author), Acad Mil Med Sci, Mil Vet Res Inst, Changchun, Jilin, Peoples R China.; Qiu, W (reprint author), Ctr Dis Control & Prevent Chengdu Mil Reg, Chengdu, Sichuan, Peoples R China.; Wu, XF (reprint author), Ctr Dis Control & Prevent, Poxvirus & Rabies Branch, Atlanta, GA 30333 USA.
EM qiuwei1971@126.com; xaw6@cdc.gov; ronglianghu@hotmail.com
FU National Key Research and Development Program [2016YFD0501000]
FX This program is supported by the "National Key Research and Development
   Program" (Approval No. 2016YFD0501000).
CR Amann R, 2013, J VIROL, V87, P1618, DOI 10.1128/JVI.02470-12
   Astray RM, 2017, ARCH VIROL, V162, P323, DOI 10.1007/s00705-016-3128-9
   BENMANSOUR A, 1991, J VIROL, V65, P4198, DOI 10.1128/JVI.65.8.4198-4203.1991
   Card JP, 1997, J NEUROVIROL, V3, P49, DOI 10.3109/13550289709015792
   Castilho JG, 2017, ZOONOSES PUBLIC HLTH, V64, P423, DOI 10.1111/zph.12320
   Cliquet F, 1998, J IMMUNOL METHODS, V212, P79, DOI 10.1016/S0022-1759(97)00212-3
   De Lucca T, 2013, PREV VET MED, V111, P126, DOI 10.1016/j.prevetmed.2013.03.007
   Dyer JL, 2014, JAVMA-J AM VET MED A, V245, P1111, DOI 10.2460/javma.245.10.1111
   Fehlner-Gardiner C, 2012, J WILDLIFE DIS, V48, P157, DOI 10.7589/0090-3558-48.1.157
   Fooks AR, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.91
   Gilbert AT, 2018, J WILD DIS, DOI [10.7589/201.7-09-242, DOI 10.7589/201.7-09-242]
   HAMPSON K, 2015, PLOS NEGLECT TROP D, V9
   Huang Y, 2015, J VIROL, V89, P3427, DOI 10.1128/JVI.03656-14
   Kruger JM, 1996, VIROLOGY, V220, P299, DOI 10.1006/viro.1996.0318
   Li ZL, 2015, VIRUS GENES, V50, P434, DOI 10.1007/s11262-015-1169-x
   Liu Y, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004890
   Liu Ye, 2014, Virologica Sinica, V29, P308, DOI 10.1007/s12250-014-3484-0
   Liu Y, 2013, J CLIN MICROBIOL, V51, P3499, DOI 10.1128/JCM.01565-13
   Liu Y, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002097
   Mainguy J, 2012, J WILDLIFE DIS, V48, P979, DOI 10.7589/2011-12-316
   Meslin FX, 2013, ANTIVIR RES, V98, P291, DOI 10.1016/j.antiviral.2013.03.011
   Morikawa VM, 2012, REV SOC BRAS MED TRO, V45, P255, DOI 10.1590/S0037-86822012000200022
   QI L, 2018, BMC INFECT DIS, V18, DOI DOI 10.1186/02879-017-2830-X
   Shwiff S, 2013, TRANSBOUND EMERG DIS, V60, P330, DOI 10.1111/j.1865-1682.2012.01351.x
   Shwiff S, 2013, ANTIVIR RES, V98, P352, DOI 10.1016/j.antiviral.2013.03.004
   Singh AJ, 2018, MMWR-MORBID MORTAL W, V67, P1174, DOI 10.15585/mmwr.mm6742a2
   Song M, 2014, BMC INFECT DIS, V14, DOI 10.1186/1471-2334-14-212
   SPATZ SJ, 1994, J GEN VIROL, V75, P1235, DOI 10.1099/0022-1317-75-6-1235
   SUSSMAN MD, 1995, VIROLOGY, V214, P12, DOI 10.1006/viro.1995.9959
   Taylor LH, 2017, ACTA TROP, V165, P133, DOI 10.1016/j.actatropica.2015.12.007
   Wang SC, 2015, ARCH VIROL, V160, P2315, DOI 10.1007/s00705-015-2512-1
   Woldehiwet Z, 2005, CLIN CHIM ACTA, V351, P49, DOI 10.1016/j.cccn.2004.09.018
   WUNNER WH, 1988, REV INFECT DIS, V10, pS771
   Zhang Shoufeng, 2013, Virologica Sinica, V28, P146, DOI 10.1007/s12250-013-3316-7
   Zhao J, 2013, GENOME ANNOUNCEMENTS, P1, DOI [10.11213/genomeA.00192-11, DOI 10.11213/GENOMEA.00192-11]
   Zhao JH, 2014, ARCH VIROL, V159, P2059, DOI 10.1007/s00705-014-2044-0
NR 36
TC 0
Z9 0
U1 0
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD APR 10
PY 2019
VL 37
IS 16
BP 2224
EP 2231
DI 10.1016/j.vaccine.2019.03.008
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HV8TO
UT WOS:000466257200010
PM 30878247
DA 2020-05-12
ER

PT J
AU Criado, MF
   Bertran, K
   Lee, DH
   Killmaster, L
   Stephens, CB
   Spackman, E
   Silva, MSE
   Atkins, E
   Mebatsion, T
   Widener, J
   Pritchard, N
   King, H
   Swayne, DE
AF Criado, Miria Ferreira
   Bertran, Kateri
   Lee, Dong-Hun
   Killmaster, Lindsay
   Stephens, Christopher B.
   Spackman, Erica
   Sa e Silva, Mariana
   Atkins, Emily
   Mebatsion, Teshome
   Widener, Justin
   Pritchard, Nikki
   King, Hallie
   Swayne, David E.
TI Efficacy of novel recombinant fowlpox vaccine against recent Mexican
   H7N3 highly pathogenic avian influenza virus
SO VACCINE
LA English
DT Article
DE Chickens; High pathogenicity avian influenza; H7N3; Immunity;
   Recombinant fowlpox virus vaccine; Vaccine
ID T-CELL RECOGNITION; GLYCOSYLATION SITES; N-GLYCOSYLATION; HEMAGGLUTININ;
   H5; PROTECTION; EVOLUTION; MODULATE; POULTRY; PCR
AB Since 2012, H7N3 highly pathogenic avian influenza (HPAI) has produced negative economic and animal welfare impacts on poultry in central Mexico. In the present study, chickens were vaccinated with two different recombinant fowlpox virus vaccines (rFPV-H7/3002 with 2015 H7 hemagglutinin [HA] gene insert, and rFPV-H7/2155 with 2002 H7 HA gene insert), and were then challenged three weeks later with H7N3 HPAI virus (A/chicken/Jalisco/CPA-37905/2015). The rEPV-H7/3002 vaccine conferred 100% protection against mortality and morbidity, and significantly reduced virus shed titers from the respiratory and gastrointestinal tracts. In contrast, 100% of sham and rEPV-H7/2155 vaccinated birds shed virus at higher titers and died within 4 days. Pre- (15/20) and post- (20/20) challenge serum of birds vaccinated with rFPV-H7/3002 had antibodies detectable by hemagglutination inhibition (HI) assay using challenge virus antigen. However, only a few birds (3/20) in the rFPV-H7/2155 vaccinated group had antibodies that reacted against the challenge strain but all birds had antibodies that reacted against the homologous vaccine antigen (A/turkey/Virginia/SEP-66/2002) (20/20). One possible explanation for differences in vaccines efficacy is the antigenic drift between circulating viruses and vaccines. Molecular analysis demonstrated that the Mexican H7N3 strains have continued to rapidly evolve since 2012. In addition, we identified in silico three potential new N-glycosylation sites on the globular head of the H7 HA of A/chicken/Jalisco/CPA-37905/2015 challenge virus, which were absent in 2012 H7N3 outbreak virus. Our results suggested that mutations in the HA antigenic sites including increased glycosylation sites, accumulated in the new circulating Mexican H7 HPAIV strains, altered the recognition of neutralizing antibodies from the older vaccine strain rFPV-H7/2155. Therefore, the protective efficacy of novel rFPV-H7/3002 against recent outbreak Mexican H7N3 HPAIV confirms the importance of frequent updating of vaccines seed strains for long-term effective control of H7 HPAI virus. Published by Elsevier Ltd.
C1 [Criado, Miria Ferreira; Bertran, Kateri; Lee, Dong-Hun; Killmaster, Lindsay; Stephens, Christopher B.; Spackman, Erica; Swayne, David E.] ARS, Exot & Emerging Avian Viral Dis Res Unit, Southeast Poultry Res Lab, US Natl Poultry Res Ctr,USDA, Athens, GA 30604 USA.
   [Sa e Silva, Mariana; Atkins, Emily; Mebatsion, Teshome; Widener, Justin; King, Hallie] Boehringer Ingelheim Anim Hlth, Athens, GA 30601 USA.
   [Pritchard, Nikki] Boehringer Ingelheim Anim Hlth, Gainesville, GA 30503 USA.
   [Bertran, Kateri] Inst Agrifood Res & Technol, Ctr Recerca Sanitat Anim, Campus Univ Autonoma Barcelona, Bellaterra 08193, Spain.
   [Lee, Dong-Hun] Univ Connecticut, Dept Pathobiol & Vet Sci, Storrs, CT 06269 USA.
RP Swayne, DE (reprint author), ARS, Exot & Emerging Avian Viral Dis Res Unit, Southeast Poultry Res Lab, US Natl Poultry Res Ctr,USDA, Athens, GA 30604 USA.
EM Miria.Criado@ars.usda.gov; kateri.bertran@gmail.com;
   dong-hun.lee@uconn.edu; Lindsay.Killmaster@ars.usda.gov;
   Chris.Stephens@ars.usda.gov; Erica.Spackman@ars.usda.gov;
   mariana.saesilva@boehringer-ingelheim.com;
   Teshome.Mebatsion@boehringer-ingelheim.com;
   Justin.Widener@boehringer-ingelheim.com;
   Nikki.Pritchard@boehringer-ingelheim.com;
   Hallie.King@boehringer-ingelheim.com; David.Swayne@ars.usda.gov
RI Bertran, Kateri/H-3458-2019; Lee, Dong-hun/H-5082-2019
OI Bertran, Kateri/0000-0002-6920-4154; Spackman,
   Erica/0000-0002-4935-2360; Swayne, David/0000-0001-7472-1992
FU Agricutural Research Service project [6040-32000-066-00D]; Boehringer
   Ingelheim Animal Health, Inc. [58-6040-7-002]
FX This research was supported by Agricutural Research Service project
   6040-32000-066-00D and Boehringer Ingelheim Animal Health, Inc., trust
   agreement 58-6040-7-002.
CR Alvarado-Facundo E, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149149
   Arnold K, 2006, BIOINFORMATICS, V22, P195, DOI 10.1093/bioinformatics/bti770
   Bertran K, 2013, VACCINE, V31, P3572, DOI 10.1016/j.vaccine.2013.05.039
   Biasini M, 2014, NUCLEIC ACIDS RES, V42, pW252, DOI 10.1093/nar/gku340
   Blom N, 2004, PROTEOMICS, V4, P1633, DOI 10.1002/pmic.200300771
   Bordoli L, 2009, NAT PROTOC, V4, P1, DOI 10.1038/nprot.2008.197
   Bosworth B, 2010, COMP IMMUNOL MICROB, V33, pE99, DOI 10.1016/j.cimid.2010.05.002
   Bublot M, 2006, ANN NY ACAD SCI, V1081, P193, DOI 10.1196/annals.1373.023
   Cattoli G, 2011, VACCINE, V29, P9368, DOI 10.1016/j.vaccine.2011.09.127
   DASSR, 2011, P NATL ACAD SCI USA, V108, pE1417, DOI DOI 10.1073/PNAS.1108754108
   de Vries E, 2015, EMERG INFECT DIS, V21, P842, DOI 10.3201/eid2105.141927
   DRUMMER HE, 1993, VIROLOGY, V192, P282, DOI 10.1006/viro.1993.1031
   FAO, 2012, HIGHL PATH AV INFL M, P26
   Herve PL, 2015, VIROLOGY, V486, P134, DOI 10.1016/j.virol.2015.08.033
   Huang Y, 2010, BIOINFORMATICS, V26, P680, DOI 10.1093/bioinformatics/btq003
   Hutter J, 2013, J IMMUNOL, V190, P220, DOI 10.4049/jimmunol.1201060
   JACKSON DC, 1994, VIROLOGY, V199, P422, DOI 10.1006/viro.1994.1140
   Johannssen T, 2017, TRENDS BIOTECHNOL, V35, P334, DOI 10.1016/j.tibtech.2016.10.002
   Kapczynski DR, 2013, J VIROL, V87, P9086, DOI 10.1128/JVI.00666-13
   Kearse M, 2012, BIOINFORMATICS, V28, P1647, DOI 10.1093/bioinformatics/bts199
   Koel BF, 2014, MBIO, V5
   Krauss S, 2015, EMERG MICROBES INFEC, V4, DOI 10.1038/emi.2015.35
   Lee CW, 2004, J VIROL METHODS, V119, P151, DOI 10.1016/j.jviromet.2004.03.014
   Lee DH, 2017, J VET SCI, V18, P269, DOI [10.4142/jvs.2017.18.s1.269, 10.4142/jvs.2017.18.S1.269]
   Lee DH, 2016, EMERG INFECT DIS, V22, P1283, DOI 10.3201/eid2207.160048
   Liu WC, 2016, J VIROL, V90, P6085, DOI 10.1128/JVI.00452-16
   OIE, 2018, HIGHL PATH AV INFL
   OIE, 2017, HIGHL PATH AV INFL
   OIE-World Organisation for Animal Health, 2017, UPD AV INFL AN TYP H
   Olsen B, 2006, SCIENCE, V312, P384, DOI 10.1126/science.1122438
   Olsen CW, 2003, VIRUS RES, V93, P115, DOI 10.1016/S0168-1702(03)00073-X
   Schmeisser F, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117108
   Spackman E, 2002, J CLIN MICROBIOL, V40, P3256, DOI 10.1128/JCM.40.9.3256-3260.2002
   Spackman E, 2014, AVIAN DIS, V58, P359, DOI 10.1637/10751-121913-Reg.1
   Spackman E, 2013, VIRUS RES, V178, P121, DOI 10.1016/j.virusres.2013.03.004
   Stamatakis A, 2014, BIOINFORMATICS, V30, P1312, DOI 10.1093/bioinformatics/btu033
   Suzuki Y, 2011, GENES GENET SYST, V86, P287, DOI 10.1266/ggs.86.287
   Swayne D. E., 2016, Animal influenza, P378
   Swayne DE, 2015, J VIROL, V89, P3746, DOI 10.1128/JVI.00025-15
   Swayne DE, 2012, EXPERT REV VACCINES, V11, P877, DOI 10.1586/ERV.12.60
   Swayne DE, 2013, DIS POULTRY, P153
   Swayne DE, 1998, ISOLATION IDENTIFICA, P150
   Tate MD, 2014, VIRUSES-BASEL, V6, P1294, DOI 10.3390/v6031294
   THOMAS DB, 1990, J IMMUNOL, V144, P2789
   Vander Veen RL, 2013, VET REC, V173, P344, DOI 10.1136/vr.101741
   Wei CJ, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000799
   Wu CY, 2017, P NATL ACAD SCI USA, V114, P280, DOI 10.1073/pnas.1617174114
   Wu NC, 2017, J MOL BIOL, V429, P2694, DOI 10.1016/j.jmb.2017.06.015
   Xu YF, 2016, SCI REP-UK, V6, DOI 10.1038/srep20688
   Zost SJ, 2017, P NATL ACAD SCI USA, V114, P12578, DOI 10.1073/pnas.1712377114
   1987, ANN REV BIOCH, V56, P365
   2013, J IMMUNOL, V190, P220
NR 52
TC 4
Z9 4
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD APR 10
PY 2019
VL 37
IS 16
BP 2232
EP 2243
DI 10.1016/j.vaccine.2019.03.009
PG 12
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HV8TO
UT WOS:000466257200011
PM 30885512
OA Green Published, Other Gold
DA 2020-05-12
ER

PT J
AU Norman, DA
   Danchin, M
   Van Buynder, P
   Moore, HC
   Blyth, CC
   Seale, H
AF Norman, Daniel A.
   Danchin, Margie
   Van Buynder, Paul
   Moore, Hannah C.
   Blyth, Christopher C.
   Seale, Holly
TI Caregiver's attitudes, beliefs, and experiences for influenza
   vaccination in Australian children with medical comorbidities
SO VACCINE
LA English
DT Article
DE Influenza vaccine; Children; Medical comorbidity; Survey
ID COVERAGE
AB Background: Influenza vaccination is recommended and funded for Australian children with medical comorbidities that increase their risk of severe influenza. Despite this, influenza vaccine coverage remains low within this population. We examined caregivers' attitudes and practices for influenza vaccination in children with medical comorbidities.
   Methods: Cross-sectional surveys were conducted with caregivers of children (6 months to <18 years old) with medical comorbidities attending sub-speciality paediatric outpatient clinics at the Royal Children's Hospital (Melbourne), Princess Margaret Hospital (Perth), and Leading Steps private paediatric clinic (Gold Coast). Multivariate linear regression was used to identify surveys responses predictive of receipt of influenza vaccination in 2017.
   Results: From the 611 surveys collected, 556 were suitable for analysis. Caregiver reported 2017 influenza vaccine coverage was 52.2% in children with medical comorbidities. Caregivers who believed influenza vaccines to be >= 50% effective were more likely to vaccinate their children (adjusted Odds Ratio [a043.79 (2.41; 5.96). Those who expressed concerns about vaccine side effects were less likely to vaccinate their children (aOR: 0.49 [95% CI: 0.30; 0.80]). Influenza vaccine uptake was significantly more likely for children who had been previously recommended influenza vaccination by their hospital-based physician (aOR: 4.33 [95% CI: 2.58; 7.27]) and had previously received a hospital-based vaccination (aOR: 3.11 [95% CI 1.79; 5.40]). Hospital-based physicians were also caregivers' most commonly reported source of trusted vaccination information (63.5%). Whilst only 29.3% of caregivers reported their child had been recommended influenza vaccination during a previous admission, 80.1% of caregivers stated they were receptive to their child receiving potential future influenza vaccinations during hospitalisations.
   Conclusions: Reported influenza vaccination coverage in children with medical comorbidities remains inadequate. An important finding of this study is that influenza vaccination recommendation by children's hospital physicians and previous vaccine receipt in hospital was associated with vaccine uptake. Opportunities for vaccination, especially during hospitalisation, must be examined. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Norman, Daniel A.; Moore, Hannah C.; Blyth, Christopher C.] Univ Western Australia, Wesfarmers Ctr Vaccines & Infect Dis, Telethon Kids Inst, Nedlands, WA, Australia.
   [Norman, Daniel A.; Blyth, Christopher C.] Univ Western Australia, Sch Med, Nedlands, WA, Australia.
   [Danchin, Margie] Royal Childrens Hosp, Dept Gen Med, Melbourne, Vic, Australia.
   [Danchin, Margie] Univ Melbourne, Dept Paediat, Melbourne, Vic, Australia.
   [Danchin, Margie] Murdoch Childrens Res Inst, Vaccine & Immunisat Res Grp, Parkville, Vic, Australia.
   [Van Buynder, Paul] Griffith Univ, Southport, Qld, Australia.
   [Van Buynder, Paul] Gold Coast Hosp & Hlth Serv, Southport, Qld, Australia.
   [Blyth, Christopher C.] Perth Childrens Hosp, Dept Infect Dis, Perth, WA, Australia.
   [Blyth, Christopher C.] Path West Lab Med, Dept Microbiol, Perth, WA, Australia.
   [Seale, Holly] Univ New South Wales, Sch Publ Hlth & Community Med, Samuels Ave, Kensington, NSW 2033, Australia.
RP Seale, H (reprint author), Univ New South Wales, Sch Publ Hlth & Community Med, Samuels Ave, Kensington, NSW 2033, Australia.
EM h.seale@unsw.edu.au
RI Moore, Hannah/AAA-4107-2019
OI Moore, Hannah/0000-0001-6434-8290; Seale, Holly/0000-0002-1877-5395
CR [Anonymous], 2017, 2016 CENS QUICKSTATS
   Armstrong P, BMJ OPEN
   Blyth CC, 2018, CLIN INFECT DIS, DOI [10.1093/cid/ciy597.ciy597-ciy, DOI 10.1093/CID/CIY597.CIY597-CIY]
   Blyth CC, 2014, EUROSURVEILLANCE, V2016, P21, DOI DOI 10.2807/1560-7917
   Blyth CC, 2016, PEDIATR INFECT DIS J, V35, P309, DOI 10.1097/INF.0000000000000999
   CDC, 2016, FLU VACC COV US 2016
   Cheng AC, 2014, COMMUN DIS INTELL, V38, pE143
   Department of Health A, 2017, 24 DEP HLTH HUM SERV, P1
   Department of Health AG, 2017, AUSTR INFL SURV REP
   FREEDMAN JL, 2015, PEDIATRICS, V135, pE54, DOI DOI 10.1542/PEDS.2014-0941
   Grohskopf LA, 2017, AM J TRANSPLANT, V17, P2970, DOI 10.1111/ajt.14511
   Hesitancy WSWGoV, REP SAGE WORK GROUP
   [Immunisation ATAGo Health Do], 2013, AUSTR IMM HDB
   Li-Kim-Moy J, 2017, EPIDEMIOL INFECT, V145, P1451, DOI 10.1017/S0950268816003381
   Newcombe J, 2014, VACCINE, V32, P6364, DOI 10.1016/j.vaccine.2014.06.044
   Rao S, 2018, INFLUENZA OTHER RESP, V12, P416, DOI 10.1111/irv.12482
   Rhodes A., 2017, FLU VACCINATION PERS
NR 17
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD APR 10
PY 2019
VL 37
IS 16
BP 2244
EP 2248
DI 10.1016/j.vaccine.2019.02.077
PG 5
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HV8TO
UT WOS:000466257200012
PM 30885511
DA 2020-05-12
ER

PT J
AU Zerva, L
   Katsoni, E
   Simitzi, C
   Stratakis, E
   Athanassakis, I
AF Zerva, Loanna
   Katsoni, Eleni
   Simitzi, Chara
   Stratakis, Emmanuel
   Athanassakis, Irene
TI Laser micro-structured Si scaffold-implantable vaccines against
   Salmonella Typhimurium
SO VACCINE
LA English
DT Article
DE Silicon scaffold; Laser manufacturing; Immune response; Scaffold
   implantation; Salmonella Typhimurium; Peptidoglycan
AB Salmonella Typhi is responsible for typhoid fever in humans. Despite the efforts, the development of longlasting vaccines has failed and the available vaccines display only moderate activity, being considered as "international traveler's" vaccines. Taking advantage of the previously described implantable vaccine technology consisting on 3D laser-microstructured Si scaffolds loaded with antigen-seeded macrophages, the present study aimed to apply an antigenic stimulus of whole extracts of S. Typhimurium, which is the mouse analogue of the human Salmonella Typhi, and examine its ability to mount specific antibody response. After defining the experimental conditions for specific anti-S. Typhimurium IgG production in vitro, antigen-seeded macrophages loaded onto the 3D Si-scaffolds were implanted to mice, while parallel experiments used conventional Freund-complete-adjuvant vaccination protocols. The results showed that only the implantable vaccine protocol could mount a specific antibody response 14 days after implantation. The cytokine profile showed increase of IL-10 and IFN-gamma in the case of implantable and conventional vaccination respectively, 7 days after implantation. Morphological studies on the excised scaffolds 14 days after implantation, showed the development of a well-structured adherent monolayer, establishing multiple contacts with lymphocytes in favor to immune response development. Based on the hypothesis that both stimulatory and suppressive components in the vaccination preparation, could affect the overall activity, peptidoglycan was applied as an antigen to the vaccination protocols. Surprisingly, peptidoglycan was shown to induce a mitogenic rather than specific immunogenic response. In this case, histological analysis of the excised scaffolds showed a restricted layer of adherent cells with cytoplasmic extensions, but hard to distinguish cell contacts with lymphocytes. Finally, the presented results showed a differential behavior of antigen presenting cells in accordance to the antigenic stimulus and consequently the activation state of the cells. Tailoring the micro/sub-micron 3D structures and chemistry of Si scaffolds, could control cell behavior according to the user's needs. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Zerva, Loanna; Katsoni, Eleni; Simitzi, Chara; Athanassakis, Irene] Univ Crete, Dept Biol, Iraklion 71409, Crete, Greece.
   [Simitzi, Chara; Stratakis, Emmanuel] Fdn Res & Technol, IESL, Iraklion 71409, Crete, Greece.
RP Athanassakis, I (reprint author), Univ Crete, Dept Biol, Iraklion 71409, Crete, Greece.
EM athanire@uoc.gr
RI Stratakis, Emmanuel/M-8290-2019
OI Stratakis, Emmanuel/0000-0002-1908-8618; Athanassakis,
   Irene/0000-0003-4762-119X
FU Special Account for Research Resources of the University of Crete
   [KA4063]
FX This work was partially funded by the Special Account for Research
   Resources of the University of Crete (KA4063) and through services to
   the private sector. The authors would like to thank Alexandra
   Siakouli-Galanopoulou for performing SEM analysis. I.Z. was responsible
   for the experimental work and supervised E.K. who performed some of the
   experiments as part of her undergraduate thesis. C.S. constructed all Si
   scaffolds under the supervision of E.S. I.A. conceived and supervised
   the project and wrote the paper. All co-authors helped in editing the
   present manuscript. The idea of implantable vaccines has been deposited
   to the Greek patent office (#). Except from this local patent, the
   authors declare no commercial or financial conflict of interest.
CR Garai P, 2012, VIRULENCE, V3, P377, DOI 10.4161/viru.21087
   GarciadelPortillo F, 1997, INFECT IMMUN, V65, P24, DOI 10.1128/IAI.65.1.24-34.1997
   Garmory HS, 2002, FEMS MICROBIOL REV, V26, P339, DOI 10.1111/j.1574-6976.2002.tb00619.x
   House D, 2001, CURR OPIN INFECT DIS, V14, P573, DOI 10.1097/00001432-200110000-00011
   Makela PH, 1997, HOST RESPONSE INTRAC, P143
   MASTROENI P, 1993, INFECT IMMUN, V61, P3981, DOI 10.1128/IAI.61.9.3981-3984.1993
   Mittrucker HW, 2000, J LEUKOCYTE BIOL, V67, P457
   Pham OH, 2015, FUTURE MICROBIOL, V10, P101, DOI 10.2217/fmb.14.98
   Quintela JC, 1997, MOL MICROBIOL, V23, P693, DOI 10.1046/j.1365-2958.1997.2561621.x
   Ranella A, 2010, ACTA BIOMATER, V6, P2711, DOI 10.1016/j.actbio.2010.01.016
   Simitzi C, 2015, BIOMATERIALS, V67, P115, DOI 10.1016/j.biomaterials.2015.07.008
   Van Goethem E, 2010, J IMMUNOL, V184, P1049, DOI 10.4049/jimmunol.0902223
   Zerva I, 2013, PROCEDIA ENGINEER, V59, P211, DOI 10.1016/j.proeng.2013.05.113
   Zerva I, 2015, VACCINE, V33, P3142, DOI 10.1016/j.vaccine.2015.04.017
   2017, VACCINE, V35, P5081, DOI DOI 10.1016/J.VACCINE.2017.08.001
NR 15
TC 0
Z9 0
U1 1
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD APR 10
PY 2019
VL 37
IS 16
BP 2249
EP 2257
DI 10.1016/j.vaccine.2019.02.080
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HV8TO
UT WOS:000466257200013
PM 30885513
DA 2020-05-12
ER

PT J
AU Selinger, C
   Bershteyn, A
   Dimitrov, DT
   Adamson, BJS
   Revill, P
   Hallett, TB
   Phillips, AN
   Bekker, LG
   Rees, H
   Gray, G
AF Selinger, Christian
   Bershteyn, Anna
   Dimitrov, Dobromir T.
   Adamson, Blythe J. S.
   Revill, Paul
   Hallett, Timothy B.
   Phillips, Andrew N.
   Bekker, Linda-Gail
   Rees, Helen
   Gray, Glenda
TI Targeting and vaccine durability are key for population-level impact and
   cost-effectiveness of a pox-protein HIV vaccine regimen in South Africa
SO VACCINE
LA English
DT Article
DE HIV vaccine; Agent-based modeling; Cost-effectiveness; South Africa
ID RV144-LIKE VACCINES; POTENTIAL IMPACT; TRIAL; CHALLENGES; EFFICACY;
   AIDSVAX; ALVAC
AB Background: RV144 is to date the only HIV vaccine trial to demonstrate efficacy, albeit rapidly waning over time. The HVTN 702 trial is currently evaluating in South Africa a similar vaccine formulation to that of RV144 for subtype C HIV with additional boosters (pox-protein regimen). Using a detailed stochastic individual-based network model of disease transmission calibrated to the HIV epidemic, we investigate population-level impact and maximum cost of an HIV vaccine to remain cost-effective.
   Methods: Consistent with the original pox-protein regimen, we model a primary series of five vaccinations meeting the goal of 50% cumulative efficacy 24 months after the first dose and include two-yearly boosters that maintain durable efficacy over 10 years. We simulate vaccination programs in South Africa starting in 2027 under various vaccine targeting and HIV treatment and prevention assumptions.
   Results: Our analysis shows that this partially effective vaccine could prevent, at catch-up vaccination with 60% coverage, up to 941,000 (15.6%) new infections between 2027 and 2047 assuming current trends of antiretroviral treatment. An impact of up to 697,000 (11.5%) infections prevented could be achieved by targeting age cohorts of highest incidence. Economic evaluation indicates that, if treatment scale-up was achieved, vaccination could be cost-effective at a total cost of less than $385 and $62 per 10year series (cost-effectiveness thresholds of $5,691 and $750).
   Conclusions: While a partially effective, rapidly waning vaccine could help to prevent HIV infections, it will not eliminate HIV as a public health priority in sub-Saharan Africa. Vaccination is expected to be most effective under targeted delivery to age groups of highest HIV incidence. Awaiting results of trial, the introduction of vaccination should go in parallel with continued innovation in HIV prevention, including studies to determine the costs of delivery and feasibility and further research into products with greater efficacy and durability. (C) 2019 The Author(s). Published by Elsevier Ltd.
C1 [Selinger, Christian; Bershteyn, Anna] Inst Dis Modeling, Bellevue, WA 98005 USA.
   [Dimitrov, Dobromir T.; Adamson, Blythe J. S.] Fred Hutchinson Canc Res Ctr, Vaccine & Infect Dis Div, 1124 Columbia St, Seattle, WA 98104 USA.
   [Adamson, Blythe J. S.] Univ Washington, Comparat Hlth Outcomes Policy & Econ CHOICE Inst, Seattle, WA 98195 USA.
   [Revill, Paul] Univ York, York, N Yorkshire, England.
   [Hallett, Timothy B.] Imperial Coll, London, England.
   [Phillips, Andrew N.] UCL, London, England.
   [Bekker, Linda-Gail] Desmond Tutu HIV Ctr, Cape Town, South Africa.
   [Rees, Helen] Univ Witwatersrand, Fac Hlth Sci, Wits RHI, Johannesburg, South Africa.
   [Gray, Glenda] Univ Witwatersrand, Fac Hlth Sci, Perinatal HIV Res Unit, Johannesburg, South Africa.
   [Gray, Glenda] South African Med Res Council, Cape Town, South Africa.
RP Selinger, C (reprint author), Inst Dis Modeling, Bellevue, WA 98005 USA.
EM christian.selinger@gmail.com
RI Phillips, Andrew N/B-4427-2008
OI Phillips, Andrew N/0000-0003-2384-4807; Rees, Helen/0000-0003-1442-6734;
   Hallett, Timothy/0000-0002-9681-0424; Selinger,
   Christian/0000-0002-4361-549X
FU Bill and Melinda Gates through the Global Good Fund
FX We acknowledge productive discussions with Dan Klein, Dan Bridenbecker,
   and Mandy Izzo (all Institute for Disease Modeling), Peter Gilbert (Fred
   Hutchinson Cancer Research Center), Leigh Johnson (University of Cape
   Town), the Vaccine Research Program at the National Institutes of
   Allergy and Infectious Disease (US National Institutes of Health),
   members of the P5 Global Access Committee (comprised of representatives
   from the Bill & Melinda Gates Foundation, National Institutes of Health
   (DAIDS/NIAID), Sanofi Pasteur, GlaxoSmithKline and the South African
   Medical Research Council) and Shift Health (Toronto, Canada) and the HIV
   Modelling Consortium which facilitated the Modelling workshop convened
   by the PS GAC. This work was supported by Bill and Melinda Gates through
   the Global Good Fund.
CR Adamson B, 2017, PHARMACOECON-OPEN, V1, P1, DOI 10.1007/s41669-016-0009-9
   Akapirat S, 2014, CROI2014
   Andersson KM, 2011, VACCINE, V29, P6092, DOI 10.1016/j.vaccine.2011.06.060
   [Anonymous], 2003, MAKING CHOICES HLTH
   Bershteyn A, EPRINTSARXIV12063720
   Bershteyn A, 2013, J R SOC INTERFACE, V10, DOI 10.1098/rsif.2013.0613
   Cooper CJ, 2010, JAMA-J AM MED ASSOC, V304, P275, DOI 10.1001/jama.2010.926
   Corey L, 2017, P NATL ACAD SCI USA, V114, P3798, DOI 10.1073/pnas.1703236114
   Davison AC, 2013, CAMBRIDGE SERIES STA
   de Montigny S, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-24268-4
   de Oliveira IV, 2016, ARGUMENTOS, P21
   de Oliveira T, 2017, LANCET HIV, V4, pE41, DOI 10.1016/S2352-3018(16)30186-2
   Eaton JW, 2014, LANCET GLOB HEALTH, V2, pE23, DOI 10.1016/S2214-109X(13)70172-4
   Gilbert Peter B, 2016, Epidemiol Methods, V5, P93, DOI 10.1515/em-2015-0007
   Gregson N, 2005, NAT REV DRUG DISCOV, V4, P121, DOI 10.1038/nrd1633
   Hankins CA, 2011, VACCINE, V29, P6069, DOI 10.1016/j.vaccine.2011.07.001
   Harmon TM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146387
   Harper KN, 2017, AIDS, V31, pN1, DOI 10.1097/QAD.0000000000001296
   Hontelez JAC, 2011, VACCINE, V29, P6100, DOI 10.1016/j.vaccine.2011.06.059
   Jit M, 2015, VACCINE, V33, P3788, DOI 10.1016/j.vaccine.2015.06.084
   Johnson L, ASSESSMENT HIV VACCI
   Klein DJ, 2014, AIDS, V28, pS47, DOI 10.1097/QAD.0000000000000081
   Larson Bruce A, 2013, Cost Eff Resour Alloc, V11, P18, DOI 10.1186/1478-7547-11-18
   Medlock J, 2017, P NATL ACAD SCI USA, V114, P4017, DOI 10.1073/pnas.1620788114
   Moodley I, 2013, SAMJ S AFR MED J, V103, P318, DOI 10.7196/SAMJ.6414
   Moodley N, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889-016-2959-3
   Moodley N, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000002528
   Neumann PJ, 2015, NEW ENGL J MED, V373, P2595, DOI 10.1056/NEJMp1512009
   Ochalek CK, COST DALY AVERTED TH
   Phillips AN, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107214
   Plazy M, 2016, J INT AIDS SOC, V19, DOI 10.7448/IAS.19.1.20913
   Rehle T, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133255
   Rerks-Ngarm S, 2017, J INFECT DIS, V215, P1255, DOI 10.1093/infdis/jix099
   Rerks-Ngarm S, 2009, NEW ENGL J MED, V361, P2209, DOI 10.1056/NEJMoa0908492
   Robb ML, 2012, LANCET INFECT DIS, V12, P531, DOI 10.1016/S1473-3099(12)70088-9
   Russell ND, 2016, CURR OPIN HIV AIDS, V11, P614, DOI 10.1097/COH.0000000000000322
   Salomon JA, 2015, LANCET GLOB HEALTH, V3, pE712, DOI 10.1016/S2214-109X(15)00069-8
   Shisana O, 2014, S AFRICAN NATL HIV P
   Smith JA, 2016, LANCET HIV, V3, pE289, DOI 10.1016/S2352-3018(16)30036-4
   South African National AIDS Council, S AFR HIV TB INV CAS
   Unaids, 2016, GLOB AIDS UPD 2016
   Unaids, FAST TRACK COMB PREV
   Vickerman P, 2012, DRUG ALCOHOL DEPEN, V123, P122, DOI 10.1016/j.drugalcdep.2011.10.032
   Voronin Y, 2015, VACCINE, V33, P1243, DOI 10.1016/j.vaccine.2014.10.040
   Woods B, 2016, VALUE HEALTH, V19, P929, DOI 10.1016/j.jval.2016.02.017
   Zuma K, 2011, AJAR-AFR J AIDS RES, V10, P189, DOI 10.2989/16085906.2011.626283
NR 46
TC 3
Z9 3
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD APR 10
PY 2019
VL 37
IS 16
BP 2258
EP 2267
DI 10.1016/j.vaccine.2019.02.073
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HV8TO
UT WOS:000466257200014
PM 30890385
OA Green Published, Green Accepted, Other Gold
DA 2020-05-12
ER

PT J
AU Quiambao, BP
   Ambas, C
   Diego, S
   Castells, VB
   Korejwo, J
   Petit, C
   Houillon, G
AF Quiambao, Beatriz P.
   Ambas, Cristina
   Diego, Sherylle
   Castells, Valerie Bosch
   Korejwo, Joanna
   Petit, Celine
   Houillon, Guy
TI Intradermal post-exposure rabies vaccination with purified Vero cell
   rabies vaccine: Comparison of a one-week, 4-site regimen versus updated
   Thai Red Cross regimen in a randomized non-inferiority trial in the
   Philippines
SO VACCINE
LA English
DT Article
DE Verorab (R); Purified Vero cell rabies vaccine; Philippines; Rabies
   post-exposure prophylaxis; Intradermal regimen
ID DOG BITES
AB Background: Rabies post-exposure prophylaxis (PEP) via intradermal (ID) administration is standard practice in Asia. Accumulating evidence suggests that PEP shortened to 3 visits in one week does not adversely affect seroconversion rates or immune memory.
   Objective: To determine whether the seroconversion rate at Day14 with a 1-week, 4-site (4-4-4-0-0) ID vaccination regimen with or without rabies immunoglobulin (RIG) was non-inferior to the updated Thai Red Cross (TRC) 28-day, 2-site (2-2-2-0-2) ID regimen with RIG during rabies PEP. We also assessed one-year antibody persistence.
   Methods: This phase III, mono-center, open-label, randomized-controlled trial assigned participants aged <= 50 years (n = 600) exposed to suspected rabid animals and sustaining WHO Category II injuries (automatic allocation to G1) or Category III injuries (randomized to G2 or G3) to the following groups (1:1:1 ratio): G1 (n = 200), 1-week 4-site ID regimen with the purified Vero cell rabies vaccine (PVRV; Verorab (R)) without RIG; G2 (n = 201), 1-week 4-site ID regimen with PVRV, and purified equine rabies immunoglobulin (pERIG); G3 (n = 199), TRC 28-day, 2-site ID regimen with PVRV, and pERIG. Non-inferiority tests compared G1 vs. G3 and G2 vs. G3. Seroconversion rate was the proportion (%) of vaccinees with rabies virus neutralizing antibodies (RVNA) titers >= 0.5 IU/mL measured by rapid fluorescent focus inhibition test.
   Results: On Day14, after the third vaccine administration, seroconversion rates were non-inferior in both comparisons and were, respectively, 100%, 99.4%, 98.8% in G1, G2, G3 with a decrease to 97.6%, 89%, 79.8% at Year 1. At Day14, RVNA geometric mean titers were 11.3 IU/mL; 9.89 IU/mL; 6.15 IU/mL, respectively, decreasing to 2.96 IU/mL, 1.37 IU/mL, 0.97 IU/mL at Year1. Safety and tolerability were similar between the three groups.
   Conclusion: The seroconversion rate at Day 14 with the 1-week 4-site ID regimen, both with and without pERIG, was non-inferior to the reference TRC 28-day 2-site ID regimen with pERIG during rabies PEP with PVRV. (C) 2019 The Authors. Published by Elsevier Ltd.
C1 [Quiambao, Beatriz P.; Ambas, Cristina; Diego, Sherylle] Res Inst Trop Med, Muntinlupa, Philippines.
   [Castells, Valerie Bosch; Korejwo, Joanna; Petit, Celine; Houillon, Guy] Sanofi Pasteur, 14 Espace Henry Vallee, F-69007 Lyon, France.
RP Houillon, G (reprint author), Sanofi Pasteur, 14 Espace Henry Vallee, F-69007 Lyon, France.
EM Guy.Houillon@sanofi.com
FU Sanofi Pasteur
FX This study was sponsored by Sanofi Pasteur. The sponsor participated in
   operational aspects of the study including data collection and
   statistical analyses.
CR [Anonymous], 2005, INT C HARM TECHN REQ, P1, DOI DOI 10.1007/S11095-007-9511-1
   Briggs DJ, 2000, B WORLD HEALTH ORGAN, V78, P693
   Gilchrist J, 2008, INJURY PREV, V14, P296, DOI 10.1136/ip.2007.016220
   Hampson K, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003709
   Kerdpanich P, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/journal.pntd.0006340
   Luo P, 2016, RAB AM RITA C OCT 23
   Narayana A, 2015, HUM VACC IMMUNOTHER, V11, P1748, DOI 10.1080/21645515.2015.1048938
   Newcombe RG, 1998, STAT MED, V17, P873, DOI 10.1002/(SICI)1097-0258(19980430)17:8<873::AID-SIM779>3.0.CO;2-I
   Novartis Vaccines and Diagnostics, 2016, CLIN TRIALS RES DAT
   Ponsich A, 2016, ACTA TROP, V160, P62, DOI 10.1016/j.actatropica.2016.04.015
   REED L. J., 1938, AMER JOUR HYG, V27, P493
   Shantavasinkul P, 2010, CLIN INFECT DIS, V51, P1070, DOI 10.1086/656585
   Shi JF, 2010, VACCINE, V28, P2573, DOI [10.1016/j.vaccine.2010.08.082, 10.1016/j.vaccine.2010.01.051]
   Sudarshan MK, 2012, HUM VACC IMMUNOTHER, V8, P1077, DOI 10.4161/hv.20471
   SUNTHARASAMAI P, 1994, VACCINE, V12, P508, DOI 10.1016/0264-410X(94)90308-5
   Suwansrinon K, 2007, T ROY SOC TROP MED H, V101, P206, DOI 10.1016/j.trstmh.2006.04.009
   Timiryasova T, 2016, RAB AM RITA C OCT 23
   Westgarth C, 2018, J EPIDEMIOL COMMUN H, V72, P331, DOI 10.1136/jech-2017-209330
   WHO/Department of control of neglected tropical diseases, 2018, LAB TECHNIQUES RABIE
   World Health Organization, 2009, HUM DOG RAB PREV CON
   World Health Organization (WHO), 2018, WKLY EPIDEMIOL REC, V93, P201, DOI DOI 10.1016/J.VACCINE.2010.08.082
   2002, CLIN INFECT DIS, V35, P1562, DOI DOI 10.1086/344954
   2016, HUM VACC IMMUNOTHER, V12, P837, DOI DOI 10.1080/21645515.2015.1085142
   2011, J TRAVEL MED, V18, P327, DOI DOI 10.1111/J.1708-8305.2011.00540.X
   2017, ACTA TROP, V165, P133, DOI DOI 10.1016/JACTATROPICA.2015.12.007
   2015, HUM VACC IMMUNOTHER, V11, P435, DOI DOI 10.4161/21645515.2014.994460
   2017, HUM VACC IMMUNOTHER, V13, P762, DOI DOI 10.1080/21645515.2016.1255834
NR 27
TC 4
Z9 4
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD APR 10
PY 2019
VL 37
IS 16
BP 2268
EP 2277
DI 10.1016/j.vaccine.2019.02.083
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HV8TO
UT WOS:000466257200015
PM 30890382
OA Other Gold
DA 2020-05-12
ER

PT J
AU Fritzsche, C
   Bergmann, L
   Loebermann, M
   Glass, A
   Reisinger, EC
AF Fritzsche, Carlos
   Bergmann, Lisa
   Loebermann, Micha
   Glass, Aenne
   Reisinger, Emil C.
TI Immune response to hepatitis A vaccine in patients with HIV
SO VACCINE
LA English
DT Article
DE HIV; Hepatitis A; Vaccine; Seroconversion rate; Hepatitis B
ID INFECTED PATIENTS; B VACCINATION; IMMUNOGENICITY; DURABILITY;
   PREDICTORS; SAFETY; MEN
AB Objectives: The aim of this study was to evaluate the impact of various factors that may influence the immunologic response to hepatitis A mono-vaccine or hepatitis A/B co-vaccine (Twinrix (R)) in HIV-infected patients.
   Design: Retrospective cross-sectional study.
   Methods: HIV positive patients with a full course of hepatitis A vaccine were tested for HAV antibodies. The seroconversion rates were determined, and the influence of several factors including CD4 cell counts, CD4/CD8 ratio, plasma viral load, type of vaccine, and antiretroviral therapy at the time of vaccine, was evaluated.
   Results: After vaccination, 80.2% of the patients developed anti-HAV antibodies, 81.5% in the mono-vaccine group and 79.2% in the hepatitis A/B co-vaccine group. In the mono-vaccine group, factors significantly associated with a better response to the vaccine were higher CD4 cell count, higher CD4/CD8 ratio, and shorter time interval from vaccine to serological control. In patients who received the hepatitis A/B co-vaccine, younger age and female sex were significantly associated with better vaccine response. Multivariable logistic regression analysis revealed time interval from vaccine to serological control of more than 5 years vs. less than 1 year to be significantly associated with decrease of seroconversion after HAV vaccine.
   Conclusions: The response to hepatitis A vaccine is impaired in HIV positive patients. HIV patients, at least those older than 30, should be tested for seroconversion after receiving the hepatitis A vaccine. As hepatitis A titers may rapidly decline, control serology during follow-up should be proposed, possibly within two years. However, vaccine type does not play a role in vaccine response. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Fritzsche, Carlos; Bergmann, Lisa; Loebermann, Micha; Reisinger, Emil C.] All Univ Med Sch Rostock, Dept Med, Div Trop Med & Infect Dis, Rostock, Germany.
   [Glass, Aenne] All Univ Med Sch Rostock, Inst Biostat & Informat Med & Ageing Res, Rostock, Germany.
RP Fritzsche, C (reprint author), Univ Rostock, Dept Med, Div Trop Med & Infect Dis, Med Sch, Ernst Heydemann Str 6, D-18057 Rostock, Germany.
EM Carlos.Fritzsche@med.uni-rostock.de
OI Loebermann, Micha/0000-0002-3453-8998
CR Aberg JA, 2009, CLIN INFECT DIS, V49, P651, DOI 10.1086/605292
   Armstrong Kia E, 2010, J Int Assoc Physicians AIDS Care (Chic), V9, P179, DOI 10.1177/1545109710368721
   Belderok SM, 2013, VACCINE, V31, P4156, DOI 10.1016/j.vaccine.2013.06.086
   Beran J, 2007, EXPERT REV VACCINES, V6, P891, DOI 10.1586/14760584.6.6.891
   Bodsworth NJ, 1997, AIDS, V11, P747, DOI 10.1097/00002030-199706000-00007
   Bordi L, 2012, J CLIN VIROL, V54, P26, DOI 10.1016/j.jcv.2012.01.009
   Catherine FX, 2017, HUM VACC IMMUNOTHER, V13, P1304, DOI 10.1080/21645515.2016.1277844
   Cheng A, 2017, J INFECT DIS, V215, P606, DOI 10.1093/infdis/jiw605
   Ciabattini A, 2018, SEMIN IMMUNOL, V40, P83, DOI 10.1016/j.smim.2018.10.010
   CLEMENS R, 1995, J INFECT DIS, V171, pS44, DOI 10.1093/infdis/171.Supplement_1.S44
   Crum-Cianflone NF, 2011, J INFECT DIS, V203, P1815, DOI 10.1093/infdis/jir180
   Fonquernie L, 2001, CLIN INFECT DIS, V32, P297, DOI 10.1086/318478
   Fritzsche C, 2018, INFECTION, V46, P565, DOI 10.1007/s15010-018-1129-1
   HESS G, 1995, J MED VIROL, V46, P40, DOI 10.1002/jmv.1890460109
   Huang SH, 2019, HEPATOLOGY BALTIMORE
   Jablonowska E, 2014, INT J STD AIDS, V25, P745, DOI 10.1177/0956462413518902
   Jimenez HR, 2013, VACCINE, V31, P1328, DOI 10.1016/j.vaccine.2012.12.045
   Kim HN, 2008, INT J STD AIDS, V19, P600, DOI 10.1258/ijsa.2007.007197
   Kourkounti S, 2012, INT J STD AIDS, V23, P464, DOI 10.1258/ijsa.2011.011297
   Loebermann M, 2004, CLIN THER, V26, P1084, DOI 10.1016/S0149-2918(04)90180-4
   Mena G, 2015, HUM VACC IMMUNOTHER, V11, P2582, DOI 10.1080/21645515.2015.1055424
   Mena G, 2013, VACCINE, V31, P3668, DOI 10.1016/j.vaccine.2013.06.012
   Mena G, 2012, VACCINE, V30, P3703, DOI 10.1016/j.vaccine.2012.03.018
   Mor Z, 2012, INT J STD AIDS, V23, P529, DOI 10.1258/ijsa.2010.010269
   Neilsen GA, 1997, J INFECT DIS, V176, P1064, DOI 10.1086/516512
   Overton ET, 2007, J VIRAL HEPATITIS, V14, P189, DOI 10.1111/j.1365-2893.2006.00822.x
   Rimland D, 2005, AIDS, V19, P1702, DOI 10.1097/01.aids.0000186815.99993.55
   Shire NJ, 2006, VACCINE, V24, P272, DOI 10.1016/j.vaccine.2005.07.102
   Shive CL, 2018, VACCINE, V36, P453, DOI 10.1016/j.vaccine.2017.12.018
   Sokoya T, 2017, MEDIAT INFLAMM, V2017, DOI 10.1155/2017/6825493
   Vento S, 1998, NEW ENGL J MED, V338, P286, DOI 10.1056/NEJM199801293380503
   Wallace MR, 2004, CLIN INFECT DIS, V39, P1207, DOI 10.1086/424666
   Weinberg A, 2012, JAIDS-J ACQ IMM DEF, V60, pE15, DOI 10.1097/QAI.0b013e31824d30bd
   Weissman S, 2006, J VIRAL HEPATITIS, V13, P81, DOI 10.1111/j.1365-2893.2005.00658.x
   2003, J INFECT DIS, V187, P1327
NR 35
TC 1
Z9 1
U1 1
U2 5
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD APR 10
PY 2019
VL 37
IS 16
BP 2278
EP 2283
DI 10.1016/j.vaccine.2019.02.064
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HV8TO
UT WOS:000466257200016
PM 30890384
DA 2020-05-12
ER

PT J
AU Clarke, JD
   Dzierlenga, A
   Arman, T
   Toth, E
   Li, H
   Lynch, KD
   Tian, DD
   Goedken, M
   Paine, MF
   Cherrington, N
AF Clarke, John D.
   Dzierlenga, Anika
   Arman, Tarana
   Toth, Erica
   Li, Hui
   Lynch, Katherine D.
   Tian, Dan-Dan
   Goedken, Michael
   Paine, Mary F.
   Cherrington, Nathan
TI Nonalcoholic fatty liver disease alters microcystin-LR toxicokinetics
   and acute toxicity
SO TOXICON
LA English
DT Article
DE Acute toxicity; Microcystin-LR; Nonalcoholic steatohepatitis;
   Toxicokinetics
ID CHRONIC KIDNEY-DISEASE; ANIMAL-MODELS; HEPATOCELLULAR-CARCINOMA;
   RAT-LIVER; STEATOHEPATITIS; EXPOSURE; IDENTIFICATION; CYANOBACTERIA;
   HEPATOTOXIN; MICE
AB Microcystin-LR (MCLR) is a cyanotoxin produced by blue-green algae that causes liver and kidney toxicities. MCLR toxicity is dependent on cellular uptake through the organic anion transporting polypeptide (OATP) transporters. Nonalcoholic fatty liver disease (NAFLD) progresses through multiple stages, alters expression of hepatic OATPs, and is associated with chronic kidney disease. The purpose of this study was to determine whether NAFLD increases systemic exposure to MCLR and influences acute liver and kidney toxicities. Rats were fed a control diet or two dietary models of NAFLD; methionine and choline deficient (MCD) or high fat/high cholesterol (HFHC). Two studies were performed in these groups: 1) a single dose intravenous toxicokinetic study (20 pg/kg), and 2) a single dose intraperitoneal toxicity study (60 mu g/kg). Compared to control rats, plasma MCLR area under the concentration-time curve (AUC) in MCD rats doubled, whereas biliary clearance (Cl-bil) was unchanged; in contrast, plasma AUC in HFHC rats was unchanged, whereas Cl-bil approximately doubled. Less MCLR bound to PP2A was observed in the liver of MCD rats. This shift in exposure decreased the severity of liver pathology only in the MCD rats after a single toxic dose of MCLR (60 mu g/kg). In contrast, the single toxic dose of MCLR increased hepatic inflammation, plasma cholesterol, proteinuria, and urinary KIM1 in HFHC rats more than MCLR exposed control rats. In conclusion, rodent models of NAFLD alter MCLR toxicokinetics and acute toxicity and may have implications for liver and kidney pathologies in NAFLD patients.
C1 [Clarke, John D.; Arman, Tarana; Lynch, Katherine D.; Tian, Dan-Dan; Paine, Mary F.] Washington State Univ, Dept Pharmaceut Sci, Spokane, WA 99202 USA.
   [Dzierlenga, Anika; Toth, Erica; Li, Hui; Cherrington, Nathan] Univ Arizona, Dept Pharmacol & Toxicol, Tucson, AZ 85721 USA.
   [Goedken, Michael] Rutgers State Univ, Rutgers Translat Sci, Piscataway, NJ 08901 USA.
RP Clarke, JD (reprint author), POB 1495, Spokane, WA 99210 USA.
EM j.clarke@wsu.edu
OI Tian, Dan-Dan/0000-0002-8270-7119; Clarke, John/0000-0003-3835-7761
FU National Institute of Environmental Health SciencesUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Environmental Health Sciences (NIEHS)
   [K99/R00ES024455]; Washington State University
FX This work was supported by the National Institute of Environmental
   Health Sciences [grant number K99/R00ES024455] and Washington State
   University.
CR Ahmed M, 2015, WORLD J HEPATOL, V7, P1450, DOI 10.4254/wjh.v7.i11.1450
   Al-Eryani L, 2015, TOXICOL PATHOL, V43, P482, DOI 10.1177/0192623314549960
   Andrinolo D, 2008, TOXICON, V51, P457, DOI 10.1016/j.toxicon.2007.11.012
   Armstrong MJ, 2014, HEPATOLOGY, V59, P1174, DOI 10.1002/hep.26717
   Bhattacharya R., 1997, Biomedical and Environmental Sciences, V10, P93
   Canet MJ, 2014, DRUG METAB DISPOS, V42, P586, DOI 10.1124/dmd.113.055996
   Cave M, 2010, ENVIRON HEALTH PERSP, V118, P1735, DOI 10.1289/ehp.1002720
   Chen J, 2009, TOXICOL SCI, V108, P81, DOI 10.1093/toxsci/kfp009
   Cichocki JA, 2017, TOXICOL SCI, V159, P102, DOI 10.1093/toxsci/kfx120
   Clarke JD, 2015, PHARMACOL THERAPEUT, V151, P99, DOI 10.1016/j.pharmthera.2015.03.005
   Clarke JD, 2014, J HEPATOL, V61, P139, DOI 10.1016/j.jhep.2014.02.021
   Clarke JD, 2014, J PHARMACOL EXP THER, V348, P452, DOI 10.1124/jpet.113.211284
   Delgado LF, 2012, SCI TOTAL ENVIRON, V435, P509, DOI 10.1016/j.scitotenv.2012.07.046
   El-Shehawy R, 2012, WATER RES, V46, P1420, DOI 10.1016/j.watres.2011.11.021
   Elmore SA, 2017, TOXICOL PATHOL, V45, P799, DOI 10.1177/0192623317733924
   ERIKSSON JE, 1988, COMP BIOCHEM PHYS C, V89, P207, DOI 10.1016/0742-8413(88)90211-3
   Ferslew BC, 2015, CLIN PHARMACOL THER, V97, P419, DOI 10.1002/cpt.66
   Fischer WJ, 2005, TOXICOL APPL PHARM, V203, P257, DOI 10.1016/j.taap.2004.08.012
   Fleming Lora E., 2002, Harmful Algae, V1, P157, DOI 10.1016/S1568-9883(02)00026-4
   Guo XC, 2014, J CHROMATOGR B, V963, P54, DOI 10.1016/j.jchromb.2014.05.046
   Hamad Asma A, 2012, Arab J Gastroenterol, V13, P161, DOI 10.1016/j.ajg.2012.06.010
   Haque JA, 2010, LAB INVEST, V90, P1704, DOI 10.1038/labinvest.2010.112
   He J, 2017, ARCH TOXICOL, V91, P465, DOI 10.1007/s00204-016-1681-3
   Hebbard L, 2010, NAT PUBL GR, V8, P34
   Ibrahim SH, 2016, DIGEST DIS SCI, V61, P1325, DOI 10.1007/s10620-015-3977-1
   Jha V, 2013, LANCET, V382, P260, DOI 10.1016/S0140-6736(13)60687-X
   Lau JKC, 2017, J PATHOL, V241, P36, DOI 10.1002/path.4829
   LAVOIE L, 1991, ENDOCRINOLOGY, V129, P2674, DOI 10.1210/endo-129-5-2674
   Lehman EM, 2007, WATER RES, V41, P795, DOI 10.1016/j.watres.2006.09.030
   Li Y, 2011, ENVIRON HEALTH PERSP, V119, P1483, DOI 10.1289/ehp.1002412
   Liu JH, 2018, ENVIRON TOXICOL, V33, P16, DOI 10.1002/tox.22456
   Lowe J, 2012, TOXICON, V59, P601, DOI 10.1016/j.toxicon.2012.02.003
   Lu H, 2008, TOXICOL SCI, V103, P35, DOI 10.1093/toxsci/kfn038
   MERILUOTO JAO, 1989, TOXICON, V27, P1021, DOI 10.1016/0041-0101(89)90153-0
   Mikolasevic I, 2013, KIDNEY BLOOD PRESS R, V37, P305, DOI 10.1159/000350158
   Milutinovic A, 2003, TOXICON, V42, P281, DOI 10.1016/S0041-0101(03)00143-0
   Milutinovic A, 2002, CELL MOL BIOL LETT, V7, P139
   Milutinovic A, 2013, MAR DRUGS, V11, P2785, DOI 10.3390/md11082785
   Nobre ACL, 1999, BRAZ J MED BIOL RES, V32, P985, DOI 10.1590/S0100-879X1999000800008
   Nobre ACL, 2001, TOXICON, V39, P721, DOI 10.1016/S0041-0101(00)00193-8
   Poste AE, 2011, ENVIRON SCI TECHNOL, V45, P5806, DOI 10.1021/es200285c
   Ramani A, 2012, BIODEGRADATION, V23, P35, DOI 10.1007/s10532-011-9484-y
   Rinella ME, 2008, J LIPID RES, V49, P1068, DOI 10.1194/jlr.M800042-JLR200
   Sedan D, 2015, TOXICON, V104, P26, DOI 10.1016/j.toxicon.2015.07.011
   Sedan D, 2010, TOXICON, V55, P333, DOI 10.1016/j.toxicon.2009.08.008
   Seth RK, 2013, TOXICOL SCI, V134, P291, DOI 10.1093/toxsci/kft104
   Sinclair JL, 2008, ADV EXP MED BIOL, V619, P45
   Streba LAM, 2015, WORLD J GASTROENTERO, V21, P4103, DOI 10.3748/wjg.v21.i14.4103
   Svircev Z, 2009, J ENVIRON SCI HEAL C, V27, P36, DOI 10.1080/10590500802668016
   Takahashi Y, 2012, WORLD J GASTROENTERO, V18, P2300, DOI 10.3748/wjg.v18.i19.2300
   Targher G, 2014, DIABETES CARE, V37, P1729, DOI 10.2337/dc13-2704
   Targher G, 2011, J HEPATOL, V54, P1020, DOI 10.1016/j.jhep.2010.11.007
   TOIVOLA DM, 1994, FEBS LETT, V344, P175, DOI 10.1016/0014-5793(94)00382-3
   Ueno Y, 1996, CARCINOGENESIS, V17, P1317, DOI 10.1093/carcin/17.6.1317
   Wahlang B, 2014, TOXICOL APPL PHARM, V279, P380, DOI 10.1016/j.taap.2014.06.019
   Wahlang B, 2013, J NUTR BIOCHEM, V24, P1587, DOI 10.1016/j.jnutbio.2013.01.009
   Wu LY, 2010, J CHROMATOGR A, V1217, P1455, DOI 10.1016/j.chroma.2009.12.068
   Yasui K, 2011, METABOLISM, V60, P735, DOI 10.1016/j.metabol.2010.07.022
   Younossi ZM, 2016, HEPATOLOGY, V64, P73, DOI 10.1002/hep.28431
   Zhang F, 2015, ENVIRON HEALTH-GLOB, V14, DOI 10.1186/s12940-015-0026-7
   Zhang ZY, 2016, J HAZARD MATER, V315, P126, DOI 10.1016/j.jhazmat.2016.05.011
   Zheng CF, 2017, HEPATOLOGY, V66, P1519, DOI 10.1002/hep.29310
   Zou YH, 2006, LIFE SCI, V79, P1100, DOI 10.1016/j.lfs.2006.03.021
NR 63
TC 2
Z9 2
U1 2
U2 7
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD APR 15
PY 2019
VL 162
BP 1
EP 8
DI 10.1016/j.toxicon.2019.03.002
PG 8
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA HU3SC
UT WOS:000465193300001
PM 30849452
OA Green Accepted
DA 2020-05-12
ER

PT J
AU Prezoto, BC
   Kato, EE
   Goncalves, LRC
   Sampaio, SC
   Sano-Martins, IS
AF Prezoto, B. C.
   Kato, E. E.
   Goncalves, L. R. C.
   Sampaio, S. C.
   Sano-Martins, I. S.
TI Elevated plasma levels of hepatocyte growth factor in rats
   experimentally envenomated with Bothrops jararaca venom: Role of snake
   venom metalloproteases
SO TOXICON
LA English
DT Article
DE Bothrops jararaca snake venom; Hepatocyte growth factor activator;
   Hepatocyte growth factor; Venom-induced consumption coagulopathy; Snake
   venom metalloproteases; Snake venom serine proteinases
ID FACTOR ACTIVATOR; PROTEOLYTIC ACTIVATION; PATIENTS BITTEN; CELL BIOLOGY;
   FACTOR HGF; NEUTRALIZATION; PATHOGENESIS; COAGULATION; DAMAGE; INJURY
AB The hepatocyte growth factor (HGF)/c-met pathway, which mainly consists of HGF activator (HGFA) and its substrate HGF, protects various types of cells via anti-apoptotic and anti-inflammatory signals. Thrombin is the main physiological activator of such plasmatic pathway, and increased plasma concentrations of HGF have been considered as a molecular marker for some pathological conditions, such as disseminated intravascular coagulation. Since thrombin generation is often linked to tissue injury, and these events are common during snake venom-induced consumption coagulopathies (VICC), our goals were to examine whether Bothrops jararaca venom (Bjv), which induces VICC in vivo: (i) activates the HGF/c-met pathway in vivo and (ii) cleaves zymogen forms of HGFA and HGF (proHGFA and proHGF, respectively) in vitro. Two experimental groups (n = 6, each) of male adult Wistar rats were subcutaneously injected with 500 mu L of 0.9% NaCl solution (control) or sub-lethal doses (1.6 mg/kg) of Bjv. Three hours after envenomation, whole blood samples were collected from the carotid arteries to evaluate relevant coagulation parameters using rotational thromboelastometry and fibrinogen level (colorimetric assay). Additionally, the plasma concentration of HGF was assayed (ELISA). Thromboelastometric assays showed that blood clotting and fibrin polymerization were severely impaired 3 h after Bjv injection. Total plasma HGF concentrations were almost 6-fold higher in the Bjv-injected group (410.0 +/- 91) compared with control values (68 +/- 18 pg/mL, p < 0.05). Western blotting assay showed that Bjv processed proHGFA and proHGF, generating bands resembling those generated by thrombin and kallikrein, respectively. In contrast to the serine protease inhibitor 4-(2-aminoethyl)benzenesulfonyl fluoride hydrochloride (AEBSF), the metalloprotease inhibitor ethylenediaminetetraacetic acid disodium salt (Na-2-EDTA) strongly reduced the ability of Bjv to process proHGFA and generated one active band similar to that of thrombin. Since Bjv contains prothrombin and factor X activators, increased intravascular thrombin formation might partly explain the increased HGF levels after bothropic envenomation. In conclusion, these findings suggest that snake venom metalloproteases may be determinant for elevation of plasma levels of HGF in rats experimentally envenomated with Bjv.
C1 [Prezoto, B. C.] Butantan Inst, Lab Pharmacol, Av Dr Vital Brazil 1500, BR-05503900 Sao Paulo, Brazil.
   [Kato, E. E.; Goncalves, L. R. C.; Sampaio, S. C.; Sano-Martins, I. S.] Butantan Inst, Lab Pathophysiol, Av Dr Vital Brazil 1500, BR-05503900 Sao Paulo, Brazil.
RP Prezoto, BC (reprint author), Butantan Inst, Lab Pharmacol, Av Dr Vital Brazil 1500, BR-05503900 Sao Paulo, Brazil.
EM benedito.prezoto@butantan.gov.br
RI Prezoto, Benedito C/A-5488-2018; Goncalves, Luis R. C./A-4233-2009
OI Goncalves, Luis R. C./0000-0001-8395-9150
FU FAPESPFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
   [2016/00211-0]
FX This study was supported by FAPESP (Proc. number 2016/00211-0). The
   funder had no role in the study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR AMARAL CFS, 1985, TOXICON, V23, P877, DOI 10.1016/0041-0101(85)90379-4
   Antunes TC, 2010, TOXICON, V56, P1443, DOI 10.1016/j.toxicon.2010.08.011
   Berger M, 2008, TOXICON, V51, P488, DOI [10.1016/j.toxicon.2007.09.005, 10.1016/j.toxicon.2007-09.005]
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629
   Carneiro AS, 2008, TOXICON, V52, P619, DOI 10.1016/j.toxicon.2008.07.012
   Chippaux JP, 2015, J VENOM ANIM TOXINS, V21, DOI 10.1186/s40409-015-0011-1
   Chung S, 2010, THROMB RES, V125, pE285, DOI 10.1016/j.thromres.2010.01.046
   Cidade DAP, 2006, TOXICON, V48, P590, DOI 10.1016/j.toxicon.2006.07.010
   Clissa PB, 2001, TOXICON, V39, P1567, DOI 10.1016/S0041-0101(01)00131-3
   Coudriet GM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015384
   da Silva NMV, 2007, TOXICON, V50, P196, DOI 10.1016/j.toxicon.2007.03.010
   DASILVA OA, 1979, AM J TROP MED HYG, V28, P401, DOI 10.4269/ajtmh.1979.28.401
   DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001
   Escalante T, 2006, ARCH BIOCHEM BIOPHYS, V455, P144, DOI 10.1016/j.abb.2006.09.018
   Fox JW, 2005, TOXICON, V45, P969, DOI 10.1016/j.toxicon.2005.02.012
   Funakoshi H, 2003, CLIN CHIM ACTA, V327, P1, DOI 10.1016/S0009-8981(02)00302-9
   Gherardi E, 1997, CIBA F SYMP, V212, P24
   Gong RJ, 2008, CURR OPIN INVEST DR, V9, P1163
   GRANT DS, 1993, P NATL ACAD SCI USA, V90, P1937, DOI 10.1073/pnas.90.5.1937
   Gutierrez JM, 2005, TOXICON, V45, P997, DOI 10.1016/j.toxicon.2005.02.029
   GUTIERREZ JM, 1981, TOXICON, V19, P493, DOI 10.1016/0041-0101(81)90007-6
   Gutierrez JM, 1998, TOXICON, V36, P1529, DOI 10.1016/S0041-0101(98)00145-7
   Gutierrez JM, 2018, TOXICON, V148, P123, DOI 10.1016/j.toxicon.2018.04.016
   Ito W, 2010, INT ARCH ALLERGY IMM, V152, P96, DOI 10.1159/000312133
   KAMIGUTI AS, 1991, TOXICON, V29, P961, DOI 10.1016/0041-0101(91)90079-7
   KAMIGUTI AS, 1989, TOXICON, V27, P955, DOI 10.1016/0041-0101(89)90146-3
   Kataoka H, 2003, CANCER METAST REV, V22, P223, DOI 10.1023/A:1023051500010
   Kataoka H, 2010, FEBS J, V277, P2230, DOI 10.1111/j.1742-4658.2010.07640.x
   lekushi K., 2010, J HYPERTENS, V28, P2454
   Liu YH, 2006, KIDNEY INT, V69, P213, DOI 10.1038/sj.ki.5000054
   MARUYAMA M, 1990, THROMB HAEMOSTASIS, V63, P449
   Matsui T, 2000, BBA-PROTEIN STRUCT M, V1477, P146, DOI 10.1016/S0167-4838(99)00268-X
   McClain SA, 1996, AM J PATHOL, V149, P1257
   MEBS D, 1986, TOXICON, V24, P1001, DOI 10.1016/0041-0101(86)90006-1
   Miyazawa K, 1996, J BIOL CHEM, V271, P3615
   MIYAZAWA K, 1994, J BIOL CHEM, V269, P8966
   Miyazawa K, 2010, FEBS J, V277, P2208, DOI 10.1111/j.1742-4658.2010.07637.x
   Mizuno S, 2008, FRONT BIOSCI-LANDMRK, V13, P7072, DOI 10.2741/3211
   Molnarfi N, 2015, AUTOIMMUN REV, V14, P293, DOI 10.1016/j.autrev.2014.11.013
   Moura-Da-Silva AM, 2007, CURR PHARM DESIGN, V13, P2893, DOI 10.2174/138161207782023711
   Mukai S, 2008, FEBS J, V275, P1003, DOI 10.1111/j.1742-4658.2008.06265.x
   Nakamura T, 2011, J GASTROEN HEPATOL, V26, P188, DOI 10.1111/j.1440-1746.2010.06549.x
   Nakamura T, 2010, P JPN ACAD B-PHYS, V86, P588, DOI 10.2183/pjab.86.588
   Ohnishi T, 2006, J IMMUNOL, V176, P6945, DOI 10.4049/jimmunol.176.11.6945
   Pediaditakis P, 2002, J BIOL CHEM, V277, P14109, DOI 10.1074/jbc.M112196200
   Peek M, 2002, J BIOL CHEM, V277, P47804, DOI 10.1074/jbc.M209778200
   Petricevich VL, 2000, TOXICON, V38, P1253, DOI 10.1016/S0041-0101(99)00227-5
   RATNOFF OD, 1951, J LAB CLIN MED, V37, P316
   Rodgers JT, 2017, CELL REP, V19, P479, DOI 10.1016/j.celrep.2017.03.066
   Rosario M, 2003, TRENDS CELL BIOL, V13, P328, DOI 10.1016/S0962-8924(03)00104-1
   Rosen EM, 1997, CIBA F SYMP, V212, P215
   Santoro ML, 2008, TOXICON, V51, P1440, DOI 10.1016/j.toxicon.2008.03.018
   Santoro ML, 2004, THROMB HAEMOSTASIS, V92, P369, DOI 10.1160/TH04-02-0120
   SANTORO ML, 1993, TOXICON, V31, P733, DOI 10.1016/0041-0101(93)90379-W
   Schaffner F, 2008, SEMIN THROMB HEMOST, V34, P147, DOI 10.1055/s-2008-1079254
   Senise LV, 2015, EXP BIOL MED, V240, P1528, DOI 10.1177/1535370215590818
   Sgrignolli LR, 2011, NEPHRON CLIN PRACT, V119, pC131, DOI 10.1159/000324228
   SHIMOMURA T, 1993, J BIOL CHEM, V268, P22927
   Takeda S, 2012, BBA-PROTEINS PROTEOM, V1824, P164, DOI 10.1016/j.bbapap.2011.04.009
   Trusolino L, 1998, FASEB J, V12, P1267
   Tsai PC, 2016, J BIOCHEM MOL TOXIC, V30, P12, DOI 10.1002/jbt.21735
   Tsai PC, 2014, CELL BIOCHEM FUNCT, V32, P485, DOI 10.1002/cbf.3041
   Whiting D, 2014, AM J HEMATOL, V89, P228, DOI 10.1002/ajh.23599
   Yamashita KM, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002814
   Zamuner SR, 2004, TOXICON, V44, P259, DOI 10.1016/j.toxicon.2004.05.029
   Zychar BC, 2010, TOXICON, V55, P227, DOI 10.1016/j.toxicon.2009.07.025
NR 67
TC 1
Z9 2
U1 0
U2 2
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD APR 15
PY 2019
VL 162
BP 9
EP 14
DI 10.1016/j.toxicon.2019.03.003
PG 6
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA HU3SC
UT WOS:000465193300002
PM 30849454
DA 2020-05-12
ER

PT J
AU Kramer, J
   Pohl, H
   Predel, R
AF Kraemer, Jonas
   Pohl, Hans
   Predel, Reinhard
TI Venom collection and analysis in the pseudoscorpion Chelifer cancroides
   (Pseudoscorpiones: Cheliferidae)
SO TOXICON
LA English
DT Article
DE Pseudoscorpion; Chelifer cancroides; Lamina defensor; Venom collection;
   Transcriptome; Mass spectrometry fingerprints; Antimicrobial peptides
ID MOLECULAR EVOLUTION
AB Pseudoscorpions are very small arthropods with almost worldwide distribution. They possess a unique venom delivery system in the chelal hands of their pedipalps that has evolved independently from that of scorpions and spiders. Studies on the venom composition of pseudoscorpions are very rare. Recently, the potential venom composition of the pseudoscorpion Synsphyronus apimelus Harvey, 1987 (Pseudoscorpiones: Garypidae) has been studied by transcriptome analysis. However, a proteome analysis of venom to identify the genuine venom compounds of pseudoscorpions has not yet been performed. In our study, we have developed a non-invasive approach for extracting minute amounts of venom, which for the first time allowed collecting pure venom samples of pseudoscorpions with minimal contaminations and high reproducibility. These experiments first required a morphological investigation of the venom delivery system with a focus on the role of the lamina defensor in the release of venom. Likely, the venom delivery system of pseudoscorpions has a mechanism that prevents the release of venom if the prey is not successfully penetrated by a venom tooth. Electrical stimulation of a gland-containing chelal hand in combination with a mechanical stimulation of the lamina defensor at the base of the venom tooth resulted in an average of 5 nl of collected venom. The utility of the method was then validated by repeated venom extractions and subsequent analysis of the venom composition using MALDI-TOF mass fingerprinting. Subsequent proteomics analysis in combination with transcriptome analyses of chelal hand tissue has identified the first genuine venom compounds of pseudoscorpions with putative antimicrobial peptides. For our experiments, we used the house pseudoscorpion Chelifer cancroides (Linnaeus, 1758) (Pseudoscorpiones: Cheliferidae).
C1 [Kraemer, Jonas; Predel, Reinhard] Univ Cologne, Inst Zool, D-50674 Cologne, Germany.
   [Pohl, Hans] Friedrich Schiller Univ Jena, Inst Zool & Evolut Forsch, D-07743 Jena, Germany.
RP Kramer, J; Predel, R (reprint author), Univ Cologne, Inst Zool, D-50674 Cologne, Germany.
EM j.krae12@gmail.com; rpredel@uni-koeln.de
OI Pohl, Hans/0000-0002-7090-6612
FU German Research FoundationGerman Research Foundation (DFG) [PR766/11-1]
FX We thank Christian Frese, Corinna Klein, Astrid Wilbrand-Hennes, Ursula
   Cullman (CECAD Proteomics Facility, University of Cologne) and Lapo
   Ragionieri (Institute for Zoology, Cologne) for excellent support with
   Quadrupole Orbitrap analysis. We also thank Leo Leson and the staff of
   the workshop of the Cologne Institute for Zoology for helping with the
   construction of the milking apparatus, Janine Altmfiller and Marek
   Franitza (Cologne Center for Genomics) for transcriptome sequencing and
   the German Research Foundation for funding (PR766/11-1).
CR Binford GJ, 2009, MOL BIOL EVOL, V26, P547, DOI 10.1093/molbev/msn274
   Casewell NR, 2013, TRENDS ECOL EVOL, V28, P219, DOI 10.1016/j.tree.2012.10.020
   Chamberlin J. C., 1924, Entomological News Philadelphia, V35, P205
   CHAMBERLIN JOSEPH CONRAD, 1931, STANFORD UNIV PUB I UNIV SER BIOL SCI, V7, P1
   Croneberg A, 1888, B SOC IMP NATURALIST, V2, P416
   De Lima ME, 2007, COMP BIOCHEM PHYS C, V146, P264, DOI 10.1016/j.cbpc.2006.10.010
   Diego-Garcia E, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-295
   dos Santos WF, 2006, J BIOCHEM MOL TOXIC, V20, P27, DOI 10.1002/jbt.20113
   Fratini F, 2017, TOXICON, V130, P91, DOI 10.1016/j.toxicon.2017.02.020
   Garb JE, 2014, JOVE-J VIS EXP, DOI 10.3791/51618
   Garb JE, 2013, MOL BIOL EVOL, V30, P999, DOI 10.1093/molbev/mst011
   Grabherr MG, 2011, NAT BIOTECHNOL, V29, P644, DOI 10.1038/nbt.1883
   Harvey MS, 2014, J ARACHNOL, V42, P86, DOI 10.1636/K13-57.1
   Harvey Mark S., 1992, Invertebrate Taxonomy, V6, P1373, DOI 10.1071/IT9921373
   Judson MLI, 2016, B SOC GEOL MEX, V68, P57
   Li RL, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-766
   McCue MD, 2006, COPEIA, P818, DOI 10.1643/0045-8511(2006)6[818:COPVIT]2.0.CO;2
   Morgenstern D, 2013, TOXICON, V63, P120, DOI 10.1016/j.toxicon.2012.11.022
   MUCHMORE WB, 1981, J ARACHNOL, V9, P47
   MUELLER U, 1981, J ALLERGY CLIN IMMUN, V68, P254, DOI 10.1016/0091-6749(81)90148-2
   Murienne J, 2008, MOL PHYLOGENET EVOL, V49, P170, DOI 10.1016/j.ympev.2008.06.002
   Nabi G, 2014, J BIOL LIFE SCI, V6, P57, DOI [10.5296/jbls.v6i1.6418, DOI 10.5296/JBLS.V6I1.6418]
   Pohl H, 2010, MICROSC RES TECHNIQ, V73, P1073, DOI 10.1002/jemt.20835
   Santibanez-Lopez CE, 2018, TOXINS, V10, DOI 10.3390/toxins10050207
   Schaffrath S., 2014, EUPA OPEN PROTEOMICS, V3, P239, DOI DOI 10.1016/J.EUPR0T.2014.02.017
   Schiffer T, 2017, HANDLUNGSANLEITUNG A
   Schneeberg K, 2017, MICROSC RES TECHNIQ, V80, P1199, DOI 10.1002/jemt.22917
   Smith JJ, 2018, TOXINS, V10, DOI 10.3390/toxins10030096
   TOKI T, 1988, BIOMED RES-TOKYO, V9, P421
   von Reumont BM, 2014, TOXINS, V6, P3488, DOI 10.3390/toxins6123488
   Young BA, 2001, ANAT REC, V264, P415, DOI 10.1002/ar.10015
NR 31
TC 2
Z9 2
U1 2
U2 5
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD APR 15
PY 2019
VL 162
BP 15
EP 23
DI 10.1016/j.toxicon.2019.02.009
PG 9
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA HU3SC
UT WOS:000465193300003
PM 30796931
DA 2020-05-12
ER

PT J
AU Taranu, I
   Marin, DE
   Palade, M
   Pistol, GC
   Chedea, VS
   Gras, MA
   Rotar, C
AF Taranu, Ionelia
   Marin, Daniela Eliza
   Palade, Mihai
   Pistol, Gina Cecilia
   Chedea, Veronica Sanda
   Gras, Mihail Alexandru
   Rotar, Catalin
TI Assessment of the efficacy of a grape seed waste in counteracting the
   changes induced by aflatoxin B1 contaminated diet on performance,
   plasma, liver and intestinal tissues of pigs after weaning
SO TOXICON
LA English
DT Article
DE AFB1; Grape seed waste; Pig; Inflammation; Antioxidative response
ID GROWTH-PERFORMANCE; GENE-EXPRESSION; NUTRIENT DIGESTIBILITY; RED-WINE;
   METABOLISM; EXPOSURE; EXTRACT; INJURY; B-1; ANTIOXIDANTS
AB The aim of this study was to investigate the potential of a grape seed byproduct to mitigate the harmful damage produced by aflatoxin B1 (AFB1) at systemic level in plasma and liver as well as at local level in the gastrointestinal tract in weaned piglets. Twenty four crossbred pigs (TOPIG) were randomly assigned to one of four experimental diets: 1)- control diet (normal compound feed for starter piglets without mycotoxin), 2)- AFB1 diet (compound feed contaminated with 320 ppb pure AFB1), 3)- GS diet (compound feed including 8% of grape seed meal), 4)- AFB1 + GS diet (compound feed containing 8% of grape seed meal contaminated with 320 ppb AFB1) for 30 days. The results showed that pigs fed AFB1 diet had altered performance (-25.1%), increased the thiobarbituric substances (TBARS) concentration wile reduced total antioxidant capacity and activity of antioxidant enzymes (CAT, SOD and GPx) in plasma and organs. AFB1 produced a dual effect on inflammatory response by increasing the level of pro-inflammatory cytokines in liver and colon and decreasing these cytokines in duodenum. The inclusion of grape seed in the diet of AFB1 intoxicated pigs enhanced the antioxidant enzymes activity, decreased the pro-inflammatory cytokines and TBARS level and ameliorated the growth performance of AFB1-treated animals. These findings suggest that grape waste is a promising feed source in counteracting the harmful effect of aflatoxin B1.
C1 [Taranu, Ionelia; Marin, Daniela Eliza; Palade, Mihai; Pistol, Gina Cecilia; Chedea, Veronica Sanda; Gras, Mihail Alexandru; Rotar, Catalin] Natl Inst Res & Dev Biol & Anim Nutr, Lab Anim Biol, Calea Bucuresti 1, Balotesti 077015, Ilfov, Romania.
RP Taranu, I (reprint author), Natl Inst Res & Dev Biol & Anim Nutr, Lab Anim Biol, Calea Bucuresti 1, Balotesti 077015, Ilfov, Romania.
EM ionelia.taranu@ibna.ro
RI GRAS, MIHAIL ALEXANDRU C/B-7134-2012; Rotar, Mircea
   Catalin/AAC-6682-2020; Pistol, Gina Cecilia/B-5801-2011
OI Chedea, Veronica/0000-0002-7075-8867; Pistol, Gina/0000-0003-1139-604X
FU Romanian Ministry of Research [189/2017-2018]
FX This work was financed through the project PN-III-PED-contract
   189/2017-2018 financed by Romanian Ministry of Research. The authors
   thanks to Dr. Catarina Gosh for proof reading this manuscript.
CR Adilah ZN, 2018, BIOMED RES INT, DOI 10.1155/2018/9568351
   Akinrinmade FJ, 2016, MYCOTOXIN RES, V32, P53, DOI 10.1007/s12550-016-0239-9
   Ali Rajput S, 2017, LIVER HISTOPATHOLOGY, P9
   Avantaggiato G, 2014, J AGR FOOD CHEM, V62, P497, DOI 10.1021/jf404179h
   Bagchi D, 2000, TOXICOLOGY, V148, P187, DOI 10.1016/S0300-483X(00)00210-9
   Belguendouz L, 1997, BIOCHEM PHARMACOL, V53, P1347, DOI 10.1016/S0006-2952(96)00820-9
   Brunton PJ, 2013, REPRODUCTION, V146, pR175, DOI 10.1530/REP-13-0258
   Chedea V. S, 2018, INTESTINAL ABSORPTIO, P10
   Chuang CC, 2011, J NUTR BIOCHEM, V22, P89, DOI 10.1016/j.jnutbio.2009.12.002
   Clarke LC, 2018, ANIM FEED SCI TECH, V240, P52, DOI 10.1016/j.anifeedsci.2018.03.013
   del Rio Garcia Juan Carlos, 2007, Revista Iberoamericana de Micologia, V24, P136
   Doshi P, 2015, J FOOD SCI TECH MYS, V52, P181, DOI 10.1007/s13197-013-0991-1
   EFSA, 2009, EFSA J, V6, P123
   Fiesel A, 2014, BMC VET RES, V10, DOI 10.1186/s12917-014-0196-5
   Fox EM, 2008, CURR OPIN MICROBIOL, V11, P481, DOI 10.1016/j.mib.2008.10.007
   Galvano F, 2001, J FOOD PROTECT, V64, P120, DOI 10.4315/0362-028X-64.1.120
   Gambacorta L, 2016, J AGR FOOD CHEM, V64, P6762, DOI 10.1021/acs.jafc.6b02146
   Gessner DK, 2013, ACTA VET SCAND, V55, DOI 10.1186/1751-0147-55-18
   Giriwono P, 2010, EXTRACT FERMENTED BA
   Grenier B, 2012, BIOCHEM PHARMACOL, V83, P1465, DOI 10.1016/j.bcp.2012.02.007
   Hogan S, 2010, J AGR FOOD CHEM, V58, P11250, DOI 10.1021/jf102759e
   Hou X, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108314
   Hussein HS, 2001, TOXICOLOGY, V167, P101, DOI 10.1016/S0300-483X(01)00471-1
   Iora SRF, 2015, INT J FOOD SCI TECH, V50, P62, DOI 10.1111/ijfs.12583
   Jager AV, 2016, INT J HYG ENVIR HEAL, V219, P294, DOI 10.1016/j.ijheh.2015.12.003
   Jard G, 2011, FOOD ADDIT CONTAM A, V28, P1590, DOI 10.1080/19440049.2011.595377
   Jebali R, 2018, TOXICON, V146, P13, DOI 10.1016/j.toxicon.2018.03.008
   Jiang M, 2015, IMMUNOPHARM IMMUNOT, V37, P450, DOI 10.3109/08923973.2015.1081933
   Kos J, 2013, FOOD CONTROL, V34, P31, DOI 10.1016/j.foodcont.2013.04.004
   Kucukcakan Basak, 2015, Open Access Maced J Med Sci, V3, P363, DOI 10.3889/oamjms.2015.032
   LINDEMANN MD, 1993, J ANIM SCI, V71, P171, DOI 10.2527/1993.711171x
   Ling KH, 2016, CHEM RES TOXICOL, V29, P823, DOI 10.1021/acs.chemrestox.6b00001
   Liu BY, 2018, J NUTR BIOCHEM, V52, P115, DOI 10.1016/j.jnutbio.2017.09.025
   Long M., 2016, INT J MOL SCI, V17
   Long XD, 2014, AFLATOXINS FOOD SOUR
   Lu T, 2014, J ANIM SCI, V92, P5455, DOI 10.2527/jas.2013-7109
   Magrone T, 2010, P NUTR SOC, V69, P279, DOI 10.1017/S0029665110000121
   Marin DE, 2002, J ANIM SCI, V80, P1250
   Meissonnier GM, 2007, FOOD CHEM TOXICOL, V45, P2145, DOI 10.1016/j.fct.2007.05.012
   Melo PS, 2015, FOOD CHEM, V181, P160, DOI 10.1016/j.foodchem.2015.02.087
   Muhammad I, 2018, CURCUMIN CONFERS HEP
   Muhammad I, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00554
   Ohlsson C, 2009, ENDOCR REV, V30, P494, DOI 10.1210/er.2009-0010
   Peng X, 2014, INT J ENV RES PUB HE, V11, P13130, DOI 10.3390/ijerph111213130
   Perez-Jimenez J, 2008, NUTR RES REV, V21, P158, DOI 10.1017/S0954422408125124
   Pinton P, 2014, TOXINS, V6, P1615, DOI 10.3390/toxins6051615
   Pistol GC, 2014, BRIT J NUTR, V111, P452, DOI 10.1017/S0007114513002675
   Pluske JR, 2013, J ANIM SCI BIOTECHNO, V4, DOI 10.1186/2049-1891-4-1
   Romero A, 2016, TOXICOLOGY, V353, P21, DOI 10.1016/j.tox.2016.05.003
   Salem R, 2018, ENVIRON TOXICOL PHAR, V60, P118, DOI 10.1016/j.etap.2018.04.015
   Sehm J, 2007, J ANIM PHYSIOL AN N, V91, P289, DOI 10.1111/j.1439-0396.2006.00650.x
   SHEN HM, 1995, TOXICOLOGY, V99, P115, DOI 10.1016/0300-483X(94)03008-P
   Taranu I, 2018, J ANIM PHYSIOL AN N, V102, pE30, DOI 10.1111/jpn.12697
   Taranu I, 2015, TOXICOL LETT, V232, P310, DOI 10.1016/j.toxlet.2014.10.022
   Taranu I, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110186
   Tulayakul P, 2007, TOXICON, V50, P339, DOI 10.1016/j.toxicon.2007.04.005
   Wang DF, 2012, J ANIM PHYSIOL AN N, V96, P939, DOI 10.1111/j.1439-0396.2011.01212.x
   Wang XH, 2019, POULTRY SCI, V98, P136, DOI 10.3382/ps/pey358
   Watson S, 2018, BMC PUBLIC HEALTH, V18, DOI 10.1186/s12889-018-6164-4
   World Health Organization, 2012, INT SCI M NODD SYNDR, P1
   Yener Z, 2009, FOOD CHEM TOXICOL, V47, P418, DOI 10.1016/j.fct.2008.11.031
   Yilmaz S, 2018, RES VET SCI, V119, P268, DOI 10.1016/j.rvsc.2018.07.007
   Zheng N, 2018, TOXICON, V150, P77, DOI 10.1016/j.toxicon.2018.04.017
   Zhu Y, 2017, TRANSPORT RES REC, P9, DOI 10.3141/2604-02
NR 64
TC 3
Z9 3
U1 7
U2 16
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD APR 15
PY 2019
VL 162
BP 24
EP 31
DI 10.1016/j.toxicon.2019.02.020
PG 8
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA HU3SC
UT WOS:000465193300004
PM 30849456
DA 2020-05-12
ER

PT J
AU Bernardi, L
   Pinto, AFM
   Mendes, E
   Yates, III
   Lamers, ML
AF Bernardi, L.
   Pinto, A. F. M.
   Mendes, E.
   Yates, J. R., III
   Lamers, M. L.
TI Lonomia obliqua bristle extract modulates Rac1 activation, membrane
   dynamics and cell adhesion properties
SO TOXICON
LA English
DT Article
DE RhoGTPases; Paxillin; Vinculin; Focal adhesion kinase; Actin
ID MOLECULAR-MECHANISMS; ADHERENS JUNCTIONS; ENDOTHELIAL-CELL; VENOM;
   TOXINS; ACTIN; EXPRESSION; CADHERIN; GTPASES; PROLIFERATION
AB Lonomia obliqua is a caterpillar of potential therapeutic interest whose venom is able to induce severe blood leakage and modulate leukocyte migration. Since both phenotypes are associated with changes in cytoskeleton dynamics and cell adhesion properties, the aim of this study was to analyze the effects of Lonomia obliqua bristle extract (LOBE) in cell adhesion and migration signaling. Proteomic analysis revealed that epithelial cells (CHO-K1) exposed to LOBE (30 mu g/mL, 30 min) exhibited changes in levels of actin regulatory proteins, including RhoGTPases. These changes correlated with an increase in the activity of the RhoGTPase family member Rac as measured by Forster resonance energy transfer (FRET). When plated in migration promoting conditions, CHO-Kl cells exposed to LOBE (10 mu g/mL) showed an increase in membrane ruffling after short (30 min) period of incubation that was accompanied by changes in the distribution of the adhesion markers paxillin, vinculin and an increase of focal adhesion kinase autophosphorylation levels (Y397), suggesting changes in cell-extracellular matrix (ECM) adhesion properties and signaling. These data suggest that LOBE possesses bioactive molecules that are capable to modulated cell migration signaling, cytoskeletal dynamics and cell-ECM properties of several cell types.
C1 [Bernardi, L.; Mendes, E.; Lamers, M. L.] Univ Fed Rio Grande do Sul, Basic Res Ctr, Dent Sch, Porto Alegre, RS, Brazil.
   [Pinto, A. F. M.] Salk Inst Biol Studies, Peptide Biol Lab, Clayton Fdn, San Diego, CA 92138 USA.
   [Yates, J. R., III] Scripps Res Inst, Dept Mol Med, San Diego, CA USA.
   [Bernardi, L.; Lamers, M. L.] Univ Fed Rio Grande do Sul, Inst Basic Hlth Sci, Dept Morphol Sci, Rua Sarmento Leite 500, BR-90050170 Porto Alegre, RS, Brazil.
RP Lamers, ML (reprint author), Univ Fed Rio Grande do Sul, Inst Basic Hlth Sci, Dept Morphol Sci, Rua Sarmento Leite 500, BR-90050170 Porto Alegre, RS, Brazil.
EM marcelo.lamers@ufrgs.br
RI LAMERS, MARCELO/A-5291-2013
OI LAMERS, MARCELO/0000-0001-5296-5662; Pinto, Antonio/0000-0002-1573-8011
FU Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES,
   Brazil)CAPES [9748-13-0, 9513-11-6, 1519/2011]; National Center for
   Research ResourcesUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Center for
   Research Resources (NCRR) [5P41RR011823]; National Institute of General
   Medical SciencesUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of General Medical Sciences (NIGMS) [8 P41 GM103533, GM23244];
   CAPESCAPES [001]
FX This project was supported by the Coordenacao de Aperfeicoamento de
   Pessoal de Nivel Superior (CAPES, Brazil, #9748-13-0, #9513-11-6,
   #1519/2011), National Center for Research Resources (5P41RR011823),
   National Institute of General Medical Sciences (8 P41 GM103533 and
   GM23244). We acknowledge the Mass Spectrometry Facility at Brazilian
   Biosciences National Laboratory (LNBio, CNPEM, Campinas, Brazil, for
   their support on preliminary mass spectrometry analysis. Additionally,
   this study was financed in part by CAPES Finance Code 001.
CR Abety AN, 2012, J INVEST DERMATOL, V132, P2451, DOI 10.1038/jid.2012.153
   Arocha-Pinango CL, 2000, BIOCHIMIE, V82, P937, DOI 10.1016/S0300-9084(00)01164-0
   Berger M, 2015, ARCH TOXICOL, V89, P459, DOI 10.1007/s00204-014-1264-0
   Berger M, 2010, J THROMB THROMBOLYS, V30, P300, DOI 10.1007/s11239-010-0449-5
   Brazilian Ministry of Health, 2016, INC AC LAG BRAS GRAN
   Carvalho PC, 2016, NAT PROTOC, V11, P102, DOI 10.1038/nprot.2015.133
   Carvalho Paulo C, 2012, Curr Protoc Bioinformatics, VChapter 13, DOI 10.1002/0471250953.bi1319s40
   Choi CK, 2008, NAT CELL BIOL, V10, P1039, DOI 10.1038/ncb1763
   Collares-Buzato CB, 2014, TOXICON, V78, P41, DOI 10.1016/j.toxicon.2013.11.013
   Coopman P, 2016, CELL MOL LIFE SCI, V73, P3535, DOI 10.1007/s00018-016-2260-8
   Costa EP, 2008, TOXICON, V52, P380, DOI 10.1016/j.toxicon.2008.04.165
   Deakin NO, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037990
   Devreotes P, 2015, CSH PERSPECT BIOL, V7, DOI 10.1101/cshperspect.a005959
   Ding J, 2014, EXP BIOL MED, V239, P387, DOI 10.1177/1535370213513991
   Escalante T, 2011, J PROTEOMICS, V74, P1781, DOI 10.1016/j.jprot.2011.03.026
   Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148
   Fukata M, 2001, NAT REV MOL CELL BIO, V2, P887, DOI 10.1038/35103068
   Giannotta M, 2013, DEV CELL, V26, P441, DOI 10.1016/j.devcel.2013.08.020
   Hansen MDH, 2002, J BIOL CHEM, V277, P45371, DOI 10.1074/jbc.M207747200
   Harvey AL, 2014, TOXICON, V92, P193, DOI 10.1016/j.toxicon.2014.10.020
   Heinen TE, 2014, CYTOTECHNOLOGY, V66, P63, DOI 10.1007/s10616-013-9537-7
   Hodgson L, 2010, CURR PROTOC CELL BIO, V14, P11
   Itoh RE, 2002, MOL CELL BIOL, V22, P6582, DOI 10.1128/MCB.22.18.6582-6591.2002
   Koh CY, 2012, TOXICON, V59, P497, DOI 10.1016/j.toxicon.2011.03.017
   Kowacs PA, 2006, ARQ NEURO-PSIQUIAT, V64, P1030, DOI 10.1590/S0004-282X2006000600029
   Lamers ML, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022865
   Lawson Campbell D, 2014, Small GTPases, V5, pe27958, DOI 10.4161/sgtp.27958
   Macara IG, 2014, CURR BIOL, V24, pR815, DOI 10.1016/j.cub.2014.06.068
   McDonald WH, 2004, RAPID COMMUN MASS SP, V18, P2162, DOI 10.1002/rcm.1603
   Moon SY, 2003, TRENDS CELL BIOL, V13, P13, DOI 10.1016/S0962-8924(02)00004-1
   Morgenstern D, 2013, TOXICON, V63, P120, DOI 10.1016/j.toxicon.2012.11.022
   Murphy G, 2008, NAT REV CANCER, V8, P929, DOI 10.1038/nrc2459
   Nascimento-Silva V, 2012, TOXICON, V60, P50, DOI 10.1016/j.toxicon.2012.03.016
   Nolte S, 2012, TOXICON, V59, P81, DOI 10.1016/j.toxicon.2011.10.012
   Olofsson B, 1999, CELL SIGNAL, V11, P545, DOI 10.1016/S0898-6568(98)00063-1
   Parsons JT, 2010, NAT REV MOL CELL BIO, V11, P633, DOI 10.1038/nrm2957
   Pinto AFM, 2006, TOXICON, V47, P113, DOI 10.1016/j.toxicon.2005.10.004
   Pinto AFM, 2008, TOXICON, V51, P1119, DOI 10.1016/j.toxicon.2008.01.010
   Pinto AFM, 2010, TOXICON, V56, P1103, DOI 10.1016/j.toxicon.2010.01.013
   Portes-Junior JA, 2014, J PROTEOME RES, V13, P3338, DOI 10.1021/pr500185a
   Reis CV, 2006, BIOCHEM J, V398, P295, DOI 10.1042/BJ20060325
   Ricci-Silva ME, 2008, TOXICON, V51, P1017, DOI 10.1016/j.toxicon.2008.01.013
   RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8
   Ridley AJ, 2003, SCIENCE, V302, P1704, DOI 10.1126/science.1092053
   Ridley AJ, 2015, CURR OPIN CELL BIOL, V36, P103, DOI 10.1016/j.ceb.2015.08.005
   Sampaio SC, 2006, TOXICON, V47, P909, DOI 10.1016/j.toxicon.2006.03.004
   Samy RP, 2016, BIOCHEM PHARMACOL, V115, P1, DOI 10.1016/j.bcp.2016.03.006
   Schaller MD, 2010, J CELL SCI, V123, P1007, DOI 10.1242/jcs.045112
   Selistre-de-Araujo HS, 2010, TOXINS, V2, P2606, DOI 10.3390/toxins2112606
   Spindler V, 2010, CARDIOVASC RES, V87, P243, DOI 10.1093/cvr/cvq086
   Sumida GM, 2011, BMC CELL BIOL, V12, DOI 10.1186/1471-2121-12-48
   Takeichi M, 2014, NAT REV MOL CELL BIO, V15, P397, DOI 10.1038/nrm3802
   van Buul JD, 2014, CELL ADHES MIGR, V8, P108, DOI 10.4161/cam.27599
   Veiga ABG, 2005, GENE, V355, P11, DOI 10.1016/j.gene.2005.05.002
   Vicente-Manzanares M, 2005, J CELL SCI, V118, DOI 10.1242/jcs.02662
   WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6
   Wu YI, 2009, NATURE, V461, P104, DOI 10.1038/nature08241
   Xu T, 2015, J PROTEOMICS, V129, P16, DOI 10.1016/j.jprot.2015.07.001
   Yau TW, 2012, CELL BIOL INT, V36, P87, DOI 10.1042/CBI20110012
   Yuan SY, 2012, MICROVASC RES, V83, P82, DOI 10.1016/j.mvr.2011.06.015
   Zaidel-Bar R, 2003, J CELL SCI, V116, P4605, DOI 10.1242/jcs.00792
   Zamir E, 1999, J CELL SCI, V112, P1655
   Zybailov B, 2006, J PROTEOME RES, V5, P2339, DOI 10.1021/pr060161n
NR 63
TC 0
Z9 0
U1 0
U2 4
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD APR 15
PY 2019
VL 162
BP 32
EP 39
DI 10.1016/j.toxicon.2019.02.019
PG 8
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA HU3SC
UT WOS:000465193300005
PM 30849455
DA 2020-05-12
ER

PT J
AU de Medeiros, CR
   de Souza, SN
   da Silva, MC
   Ventura, JD
   Piorelli, RD
   Puorto, G
AF de Medeiros, Carlos Roberto
   de Souza, Solange Nogueira
   da Silva, Milene Cirino
   Ventura, Janaina de Souza
   Piorelli, Roberta de Oliveira
   Puorto, Giuseppe
TI Bites by Tomodon dorsatus (serpentes, dipsadidae): Clinical and
   epidemiological study of 86 cases
SO TOXICON
LA English
DT Article
DE Tomodon dorsatus; Dipsadidae: non-front-fanged colubroid; Envenomation;
   Snakebite
ID SNAKES; REPRODUCTION
AB A total of 86 proven cases of Tomodon dorsatus bites admitted to Hospital Vital Brazil (HVB) of Butantan Institute, in Sao Paulo, Brazil, between 1945 and 2018, were retrospectively analyzed. The cases included were those in which the snake was brought to HVB and was correctly identified. Of the 86 cases of snake bites, it was possible to describe the sex of the snake in 52 cases; 31 (59.6%) snakes were male. Only 52 snakes out of 86 could be studied because of their preservation status. The length of snakes (snout-vent length) ranged from 180 to 770 mm. Of the 86 snakes, 72 could be distinguished as adults (n = 63, 87.5%) or juveniles (n = 9, 12.5%). Most bites occurred in the spring and summer seasons (n = 57, 66.3%) and during warmer periods of the day (n = 61, 72.6%), between 9 A.M. and 3 P.M.
   The mean (+/- standard deviation) age of the victims was 26.9 +/- 17.2 years, and 60 (69.8%) were men. Approximately 90% of the patients sought medical care within 6 h after the bite. Both upper (n = 45, 52.3%) and lower (n = 37, 43.0%) limbs were the most frequently bitten, particularly the feet and hands (n = 54, 62.8%). The local clinical manifestations were pain (n = 55, 64.0%), transitory bleeding (n = 23, 26.7%), erythema (n = 22, 25.6%), edema (n = 14, 16.3%), paresthesia (n = 9, 10.5%), and ecchymosis (n = 3, 3.5%). Only 10 (11.6%) patients reported non-specific systemic symptoms characterized by transient dizziness or mild headache, and 21 (24.4%) patients showed no evidence of envenomation. A 20 min whole blood clotting test was performed in 31 (36.0%) patients on admission and all of them had coagulable blood. Supportive treatment was offered to 38 (44.2%) patients, namely, antiseptic (n = 20, 23.3%), antihistamines (n = 12, 14.0%), and analgesics (n = 9, 10.5%). Four (4.7%) patients were inappropriately treated with Bothrops antivenom before their admission to HVB. No sequelae or relevant complications were observed in patients, and the prognosis was benign. Therefore, although T. dorsatus bites can cause mild local symptomatology, it is important that health professionals know how to make the correct diagnosis to avoid unnecessary use of antivenom.
C1 [de Medeiros, Carlos Roberto; de Souza, Solange Nogueira; da Silva, Milene Cirino; Ventura, Janaina de Souza; Piorelli, Roberta de Oliveira] Inst Butantan, Hosp Vital Brazil, Sao Paulo, SP, Brazil.
   [Puorto, Giuseppe] Inst Butantan, Museu Biol, Sao Paulo, SP, Brazil.
RP de Medeiros, CR (reprint author), Av Dr Vital Brasil 1500, BR-05503900 Sao Paulo, SP, Brazil.
EM carlos.medeiros@butantan.gov.br
OI Medeiros, Carlos Roberto de/0000-0001-9533-0819
CR ALDRIDGE RD, 1995, J HERPETOL, V29, P399, DOI 10.2307/1564990
   Barbo Fausto E., 2011, South American Journal of Herpetology, V6, P135
   Bizerra A, 2005, AMPHIBIA-REPTILIA, V26, P33, DOI 10.1163/1568538053693350
   Bizerra A. F., 1998, THESIS
   Campbell J.A, 1989, VENOMOUS REPTILES LA, P380
   Citadini JM, 2013, BEHAV PROCESS, V97, P11, DOI 10.1016/j.beproc.2013.03.008
   de Lema T., 1978, NAT REV, V4, P38
   de Medeiros CR, 2010, TOXICON, V56, P1018, DOI 10.1016/j.toxicon.2010.07.006
   DUMERIL AMC, 1854, ERPETOLOGIE GEN HIST, V9
   GIBSON AR, 1979, OECOLOGIA, V43, P79
   JORGE MT, 1992, REV INST MED TROP SP, V34, P347, DOI 10.1590/S0036-46651992000400013
   Jorge MT, 1999, ANN TROP MED PARASIT, V93, P401, DOI 10.1080/00034989958393
   Junqueira-de-Azevedo ILM, 2016, TOXINS, V8, DOI 10.3390/toxins8080230
   Kaji AH, 2014, ANN EMERG MED, V64, P292, DOI 10.1016/j.annemergmed.2014.03.025
   Kardong KV, 2002, J TOXICOL-TOXIN REV, V21, P1
   *MIN SAUD, 1998, MAN DIAGN TRAT AC AN
   MINTON SA, 1990, J WILDERNESS MED, V1, P119, DOI 10.1580/0953-9859-1.2.119
   Nicoleti AF, 2010, REV SOC BRAS MED TRO, V43, P657, DOI 10.1590/S0037-86822010000600011
   Nishioka Sergio De Andrade, 1994, Revista do Instituto de Medicina Tropical de Sao Paulo, V36, P279
   OLIVEIRA R.B., 2003, REV SOC BRAS MED TRO, V36, P657
   Prado-Franceschi J, 2002, J TOXICOL-TOXIN REV, V21, P117, DOI 10.1081/TXR-120004744
   Puorto G, 2009, ANIMAIS PECONHENTOS, P125
   RIBEIRO L A, 1989, Revista do Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo, V44, P143
   Ribeiro L.A, 1994, REV SOC BRAS MED S1, V27, P87
   RIBEIRO LA, 1990, REV I MED TROP, V32, P436, DOI 10.1590/S0036-46651990000600008
   Salomao Maria da Graca, 2003, Herpetological Review, V34, P307
   Saviola AJ, 2014, TOXIN REV, V33, P185, DOI 10.3109/15569543.2014.942040
   SAZIMA I, 1992, HIST NATURAL SERRA J, P212
   SINAN, 2017, ANIMAIS PECONHENTOS
   Warrell D.A, 2004, VENOMOUS REPTILES W, P718
   Weatherall D.J, 1992, OXFORD TRATADO MED I, P675
   Weinstein SA, 2011, ELSEV INSIGHT, P1
   Weinstein SA, 2013, TOXICON, V69, P103, DOI 10.1016/j.toxicon.2013.02.003
   Zelanis A, 2010, TOXICON, V55, P666, DOI 10.1016/j.toxicon.2009.09.015
NR 34
TC 0
Z9 0
U1 0
U2 1
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD APR 15
PY 2019
VL 162
BP 40
EP 45
DI 10.1016/j.toxicon.2019.03.005
PG 6
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA HU3SC
UT WOS:000465193300006
PM 30853409
DA 2020-05-12
ER

PT J
AU Rogowska, A
   Pomastowski, P
   Sagandykova, G
   Buszewski, B
AF Rogowska, A.
   Pomastowski, P.
   Sagandykova, G.
   Buszewski, B.
TI Zearalenone and its metabolites: Effect on human health, metabolism and
   neutralisation methods
SO TOXICON
LA English
DT Review
DE Metabolism; Mycotoxins; Xenoestrogens; Zearalenone
ID LACTIC-ACID BACTERIA; BETA-D-GLUCANS; AFLATOXIN B-1; MYCOTOXIN
   ZEARALENONE; SACCHAROMYCES-CEREVISIAE; FUSARIUM MYCOTOXINS;
   ALPHA-ZEARALENOL; IN-VITRO; MICROBIAL TRANSFORMATION; ESTROGENIC
   MYCOTOXIN
AB Mycotoxins are natural compounds produced as secondary metabolites by mold fungi belonging mainly to the Fusarium family, commonly found on plants such as corn or small grains in the temperate climate zone. One of these mycotoxins is zearalenone, which is classified as a xenoestrogen, an exogenous compound which resembles the structure of naturally occurring estrogens with its chemical structure. This property of zearalenone determines its ability to bind to estrogen receptors of cell and its bioaccumulation. This leads to disorders of the hormonal balance of the body, which in consequence may lead to numerous diseases of reproductive system such as prostate, ovarian, cervical or breast cancers. High risk posed by long-term exposure to contaminated food forces the modem science to develop and implement effective methods of zearalenone neutralisation. This work is a review of current state of knowledge on toxic effects of zearalenone, its metabolism in biological systems and proposed methods of its neutralisation.
C1 [Rogowska, A.; Pomastowski, P.; Sagandykova, G.; Buszewski, B.] Nicolaus Copernicus Univ, Ctr Modern Interdisciplinary Technol, Wilenska 4, PL-87100 Torun, Poland.
   [Rogowska, A.; Buszewski, B.] Nicolaus Copernicus Univ, Fac Chem, Dept Environm Chem & Bioanalyt, Gagarina 7, PL-87100 Torun, Poland.
RP Buszewski, B (reprint author), Nicolaus Copernicus Univ, Ctr Modern Interdisciplinary Technol, Wilenska 4, PL-87100 Torun, Poland.
EM bbusz@chem.umk.pl
OI Pomastowski, Pawel/0000-0002-1594-0623; Sagandykova,
   Gulyaim/0000-0001-6778-4653
FU Maestro-6 [2014/14/A/ST4/00641]; National Science Centre, Poland
FX This work was supported by Maestro-6, No. 2014/14/A/ST4/00641
   (2015-2017) from the National Science Centre, Poland.
CR Abbasian N, 2018, TOXICON, V154, P7, DOI 10.1016/j.toxicon.2018.07.022
   Abd A., 1997, NAHRUNG, V41, P362, DOI DOI 10.1002/F00D
   Amelin VG, 2013, J ANAL CHEM+, V68, P61, DOI 10.1134/S1061934813010036
   Andreoletti O, 2011, EFSA J, V9, DOI 10.2903/j.efsa.2011.2105
   Appell M, 2017, J LUMIN, V188, P551, DOI 10.1016/j.jlumin.2017.04.062
   Bai XJ, 2018, APPL SURF SCI, V430, P198, DOI 10.1016/j.apsusc.2017.06.055
   Baptista AS, 2004, WORLD J MICROB BIOT, V20, P475, DOI 10.1023/B:WIBI.0000040397.48873.3b
   Barkai-Golan R, 2008, WORLD MYCOTOXIN J, V1, P147, DOI 10.3920/WMJ2008.x018
   Bejaoui H, 2004, J APPL MICROBIOL, V97, P1038, DOI 10.1111/j.1365-2672.2004.02385.x
   Beloglazova N, 2019, TALANTA, V192, P169, DOI 10.1016/j.talanta.2018.09.042
   Ben Taheur F, 2017, INT J FOOD MICROBIOL, V251, P1, DOI 10.1016/j.ijfoodmicro.2017.03.021
   BENNETT GA, 1981, J AM OIL CHEM SOC, V58, P974, DOI 10.1007/BF02659774
   Bennett JW, 2003, CLIN MICROBIOL REV, V16, P497, DOI 10.1128/CMR.16.3.497-516.2003
   Berthiller F, 2006, FOOD ADDIT CONTAM, V23, P1194, DOI 10.1080/02652030600778728
   BIEHL ML, 1993, TOXICOL APPL PHARM, V121, P152, DOI 10.1006/taap.1993.1140
   Binder EM, 2007, ANIM FEED SCI TECH, V137, P265, DOI 10.1016/j.anifeedsci.2007.06.005
   Binder SB, 2017, TOXINS, V9, DOI 10.3390/toxins9020056
   Boswald C, 1995, Nat Toxins, V3, P138, DOI 10.1002/nt.2620030304
   Brodehl A, 2014, FEMS MICROBIOL LETT, V359, P124, DOI 10.1111/1574-6968.12586
   Bronowicka-Klys DE, 2016, BIOMED PHARMACOTHER, V84, P1945, DOI 10.1016/j.biopha.2016.11.007
   Cao HW, 2019, TOXICOL IN VITRO, V54, P243, DOI 10.1016/j.tiv.2018.09.020
   *CAST, 2003, MYC RISKS PLANT AN H
   CHANG WM, 1984, FOOD CHEM TOXICOL, V22, P887, DOI 10.1016/0278-6915(84)90171-6
   COALLIERASCAH J, 1985, APPL ENVIRON MICROB, V49, P163, DOI 10.1128/AEM.49.1.163-167.1985
   Council for Agricultural Science and Technology, 1989, 116 CAST, P91
   Dall'Erta A, 2013, CHEM RES TOXICOL, V26, P305, DOI 10.1021/tx300438c
   De Boevre M, 2012, WORLD MYCOTOXIN J, V5, P207, DOI 10.3920/WMJ2012.1410
   Dellafiora L, 2017, FOOD CHEM TOXICOL, V108, P257, DOI 10.1016/j.fct.2017.07.062
   Devegowda G., 1996, P AUST POULT SCI S, V8, P103
   EI-Sharkawy S.H., 1989, ACTA PHANN JUGOSL, V39, P303
   El Darra N, 2019, FOOD CONTROL, V95, P63, DOI 10.1016/j.foodcont.2018.07.033
   El-Nezami H, 1998, FOOD CHEM TOXICOL, V36, P321, DOI 10.1016/S0278-6915(97)00160-9
   El-Nezami H, 2002, APPL ENVIRON MICROB, V68, P3545, DOI 10.1128/AEM.68.7.3545-3549.2002
   El-Nezami H, 2002, BRIT J NUTR, V88, P119
   El-Nezami HS, 2002, FOOD ADDIT CONTAM, V19, P680, DOI 10.1080/02652030210134236
   ELSHARKAWY SH, 1991, APPL ENVIRON MICROB, V57, P549, DOI 10.1128/AEM.57.2.549-552.1991
   Engler KH, 2000, ARCH MICROBIOL, V174, P381, DOI 10.1007/s002030000215
   Fazekas B, 2001, J AOAC INT, V84, P1453
   Fleck SC, 2017, FOOD CHEM TOXICOL, V106, P193, DOI 10.1016/j.fct.2017.05.048
   Fleck SC, 2016, FOOD CHEM TOXICOL, V95, P19, DOI 10.1016/j.fct.2016.05.021
   Follmann W, 2016, J TOXICOL ENV HEAL A, V79, P1015, DOI 10.1080/15287394.2016.1219540
   Frizzell C, 2015, TOXICOL IN VITRO, V29, P575, DOI 10.1016/j.tiv.2015.01.006
   Gadzala-Kopciuch R, 2011, ANAL BIOANAL CHEM, V401, P2069, DOI 10.1007/s00216-011-5206-x
   Gilbert J, 2009, BIOACTIVE COMPOUNDS
   Goud KY, 2019, J ELECTROANAL CHEM, V832, P336, DOI 10.1016/j.jelechem.2018.10.058
   Hao K, 2018, FOOD AGR IMMUNOL, V29, P498, DOI 10.1080/09540105.2017.1406461
   Harkai P, 2016, INT BIODETER BIODEGR, V108, P48, DOI 10.1016/j.ibiod.2015.12.007
   Haskard CA, 2001, APPL ENVIRON MICROB, V67, P3086, DOI 10.1128/AEM.67.7.3086-3091.2001
   Hleba L, 2017, J MICROB BIOTEC FOOD, V7, P181, DOI 10.15414/jmbfs.2017.7.2.181-185
   Hueza IM, 2014, TOXINS, V6, P1080, DOI 10.3390/toxins6031080
   Huuskonen P, 2015, PLACENTA, V36, P1052, DOI 10.1016/j.placenta.2015.06.014
   Huwig A, 2001, TOXICOL LETT, V122, P179, DOI 10.1016/S0378-4274(01)00360-5
   Iha MH, 2013, FOOD CONTROL, V29, P1, DOI 10.1016/j.foodcont.2012.05.058
   Jard G, 2010, WORLD MYCOTOXIN J, V3, P183, DOI 10.3920/WMJ2009.1184
   Jeyakumar JMJ, 2018, MICROB PATHOGENESIS, V123, P98, DOI 10.1016/j.micpath.2018.06.045
   Joannis-Cassan C, 2011, J FOOD PROTECT, V74, P1175, DOI 10.4315/0362-028X.JFP-11-023
   Jodlbauer J, 2000, Mycotoxin Res, V16 Suppl 2, P174, DOI 10.1007/BF02940030
   Joint FAO/WHO Expert Committee on Food Additives (JECFA), 2000, WHO FOOD ADD SER, V44
   Josephs RD, 2003, J AOAC INT, V86, P50
   Jouany JP, 2007, ANIM FEED SCI TECH, V137, P342, DOI 10.1016/j.anifeedsci.2007.06.009
   Jung EM, 2010, TOXICOL IN VITRO, V24, P1538, DOI 10.1016/j.tiv.2010.06.019
   Juodeikiene G, 2018, LWT-FOOD SCI TECHNOL, V89, P307, DOI 10.1016/j.lwt.2017.10.061
   Kalagatur NK, 2018, FOOD CONTROL, V94, P276, DOI 10.1016/j.foodcont.2018.07.030
   KAMIMURA H, 1986, APPL ENVIRON MICROB, V52, P515, DOI 10.1128/AEM.52.3.515-519.1986
   Keller L, 2015, TOXINS, V7, P3297, DOI 10.3390/toxins7083297
   Kennedy DG, 1998, FOOD ADDIT CONTAM, V15, P393, DOI 10.1080/02652039809374658
   KIESSLING KH, 1984, APPL ENVIRON MICROB, V47, P1070, DOI 10.1128/AEM.47.5.1070-1073.1984
   Kollarczik Birgit, 1994, Natural Toxins, V2, P105, DOI 10.1002/nt.2620020303
   Kowalska K, 2016, ENVIRON TOXICOL PHAR, V48, P141, DOI 10.1016/j.etap.2016.10.015
   Krol A, 2018, ANAL BIOANAL CHEM, V410, P943, DOI 10.1007/s00216-017-0555-8
   KUIPERGOODMAN T, 1987, REGUL TOXICOL PHARM, V7, P253, DOI 10.1016/0273-2300(87)90037-7
   Kumar KN, 2016, LWT-FOOD SCI TECHNOL, V69, P522, DOI 10.1016/j.lwt.2016.02.005
   Lahouar A, 2017, INT J FOOD MICROBIOL, V242, P53, DOI 10.1016/j.ijfoodmicro.2016.11.015
   Lawlor PG, 2001, IRISH VET J, V54, P172
   Lee M, 2016, KOREAN J FOOD SCI AN, V36, P463, DOI 10.5851/kosfa.2016.36.4.463
   LINE JE, 1995, J FOOD PROTECT, V58, P1042, DOI 10.4315/0362-028X-58.9.1042
   Llorent-Martinez EJ, 2019, TALANTA, V191, P89, DOI 10.1016/j.talanta.2018.08.049
   Malekinejad H, 2006, VET J, V172, P96, DOI 10.1016/j.tvjl.2005.03.004
   Malekinejad H, 2006, VET RES COMMUN, V30, P445, DOI 10.1007/s11259-006-3325-1
   Malekinejad H, 2005, ARCH TOXICOL, V79, P547, DOI 10.1007/s00204-005-0664-6
   MANN R, 1976, EUR J APPL MICROBIOL, V2, P297, DOI 10.1007/BF01278613
   Markovic M, 2017, COLLOID SURFACE A, V529, P7, DOI 10.1016/j.colsurfa.2017.05.054
   Markovic M, 2017, COLLOID SURFACE B, V151, P324, DOI 10.1016/j.colsurfb.2016.12.033
   MATSUURA Y, 1985, J FOOD HYG SOC JPN, V26, P24
   Mauro T, 2018, FOOD CHEM TOXICOL, V116, P227, DOI 10.1016/j.fct.2018.04.027
   McKenzie KS, 1997, FOOD CHEM TOXICOL, V35, P807, DOI 10.1016/S0278-6915(97)00052-5
   Miles CO, 1996, J AGR FOOD CHEM, V44, P3244, DOI 10.1021/jf9601325
   Minervini F, 2005, TOXICOL LETT, V159, P272, DOI 10.1016/j.toxlet.2005.05.017
   Minervini F, 2008, INT J MOL SCI, V9, P2570, DOI 10.3390/ijms9122570
   MIROCHA CJ, 1981, FOOD COSMET TOXICOL, V19, P25, DOI 10.1016/0015-6264(81)90299-6
   Mokoena MP, 2005, J FOOD PROTECT, V68, P2095, DOI 10.4315/0362-028X-68.10.2095
   Molina-Molina JM, 2014, FOOD CHEM TOXICOL, V74, P233, DOI 10.1016/j.fct.2014.10.008
   Molnar O, 2004, SYST APPL MICROBIOL, V27, P661, DOI 10.1078/0723202042369947
   Muthulakshmi S, 2018, CHEMOSPHERE, V198, P111, DOI 10.1016/j.chemosphere.2018.01.141
   Nagendra Shah, 1999, Bioscience and Microflora, V18, P43
   Nathanail AV, 2015, ANAL BIOANAL CHEM, V407, P4745, DOI 10.1007/s00216-015-8676-4
   NELSON PE, 1994, CLIN MICROBIOL REV, V7, P479, DOI 10.1128/CMR.7.4.479-504.1994
   Niderkorn V, 2007, FOOD ADDIT CONTAM A, V24, P406, DOI 10.1080/02652030601101110
   Ogunbanwo Samuel T., 2005, Advances in Food Sciences, V27, P189
   Ok HE, 2014, FOOD CHEM, V163, P252, DOI 10.1016/j.foodchem.2014.04.111
   OLSEN M, 1981, ACTA PHARMACOL TOX, V48, P157
   OLSEN M, 1987, FOOD CHEM TOXICOL, V25, P681, DOI 10.1016/0278-6915(87)90101-3
   Pang J, 2017, TOXICOL APPL PHARM, V333, P60, DOI 10.1016/j.taap.2017.08.011
   Paris MPK, 2014, J AGR FOOD CHEM, V62, P1181, DOI 10.1021/jf405627d
   Pascari X, 2018, LWT-FOOD SCI TECHNOL, V92, P87, DOI 10.1016/j.lwt.2018.02.021
   Peltonen K, 2001, J DAIRY SCI, V84, P2152, DOI 10.3168/jds.S0022-0302(01)74660-7
   Pfeiffer E, 2011, MOL NUTR FOOD RES, V55, P560, DOI 10.1002/mnfr.201000381
   Pfeiffer E, 2009, MOL NUTR FOOD RES, V53, P1123, DOI 10.1002/mnfr.200800584
   PLASENCIA J, 1991, APPL ENVIRON MICROB, V57, P146, DOI 10.1128/AEM.57.1.146-150.1991
   Polak M, 2009, POL J VET SCI, V12, P103
   PRELUSKY DB, 1990, J ENVIRON SCI HEAL B, V25, P87, DOI 10.1080/03601239009372678
   Raju MVLN, 2000, BRIT POULTRY SCI, V41, P640, DOI 10.1080/713654986
   Raymond SL, 2003, J ANIM SCI, V81, P2123
   Ryu D, 1999, J FOOD PROTECT, V62, P1482, DOI 10.4315/0362-028X-62.12.1482
   SANCO Directorate-General Health and Consumer Protection, 2003, SCOOP EUR PROJ TASK
   Sangsila A, 2016, FOOD CONTROL, V62, P187, DOI 10.1016/j.foodcont.2015.10.031
   SANTIN E, 2003, INT J POULTRY SCI, V2, P241, DOI DOI 10.3923/IJPS.2003.341.344
   Savi GD, 2018, INT J FOOD MICROBIOL, V270, P5, DOI 10.1016/j.ijfoodmicro.2018.02.004
   Schoevers EJ, 2012, REPROD TOXICOL, V34, P110, DOI 10.1016/j.reprotox.2012.03.004
   SCHWADORF K, 1992, J CHROMATOGR, V595, P259, DOI 10.1016/0021-9673(92)85168-S
   Scott P M, 1992, Mycotoxin Res, V8, P58, DOI 10.1007/BF03192217
   Scott PM, 1996, J AOAC INT, V79, P875
   Shephard GS, 2013, FOOD CHEM TOXICOL, V62, P217, DOI 10.1016/j.fct.2013.08.040
   Shetty PH, 2006, TRENDS FOOD SCI TECH, V17, P48, DOI 10.1016/j.tifs.2005.10.004
   Sirot V, 2013, FOOD CHEM TOXICOL, V52, P1, DOI 10.1016/j.fct.2012.10.036
   Solfrizzo M, 2014, TOXINS, V6, P523, DOI 10.3390/toxins6020523
   Songsermsakul P, 2006, J CHROMATOGR B, V843, P252, DOI 10.1016/j.jchromb.2006.06.012
   Sprynskyy M, 2012, COLLOID SURFACE B, V94, P7, DOI 10.1016/j.colsurfb.2011.12.024
   Su Y, 2018, ECOTOX ENVIRON SAFE, V158, P284, DOI 10.1016/j.ecoenv.2018.04.046
   Sun ZM, 2018, J MOL LIQ, V264, P645, DOI 10.1016/j.molliq.2018.05.091
   SUNJIC V, 1991, ENZYME MICROB TECH, V13, P344, DOI 10.1016/0141-0229(91)90155-4
   THYAGARAJA N, 1994, FOOD CHEM TOXICOL, V32, P805, DOI 10.1016/0278-6915(94)90156-2
   TRENHOLM HL, 1989, ARCH ENVIRON CON TOX, V18, P443, DOI 10.1007/BF01062372
   UENO Y, 1983, FOOD CHEM TOXICOL, V21, P167, DOI 10.1016/0278-6915(83)90232-6
   Vega MF, 2017, BRAZ J MICROBIOL, V48, P715, DOI 10.1016/j.bjm.2017.05.001
   Vendl O, 2010, FOOD ADDIT CONTAM A, V27, P1148, DOI 10.1080/19440041003801166
   Videmann B, 2012, WORLD MYCOTOXIN J, V5, P57, DOI 10.3920/WMJ2011.1319
   Videmann B, 2008, FOOD CHEM TOXICOL, V46, P3279, DOI 10.1016/j.fct.2008.07.011
   Videmann B, 2009, TOXICOL LETT, V190, P215, DOI 10.1016/j.toxlet.2009.07.021
   Wallin S, 2015, FOOD CHEM TOXICOL, V83, P133, DOI 10.1016/j.fct.2015.05.023
   Wang G, 2017, FOOD CONTROL, V77, P57, DOI 10.1016/j.foodcont.2017.01.021
   Wang GF, 2019, J HAZARD MATER, V364, P227, DOI 10.1016/j.jhazmat.2018.09.071
   Wang GF, 2018, J COLLOID INTERF SCI, V518, P48, DOI 10.1016/j.jcis.2018.02.020
   Wang GF, 2018, J COLLOID INTERF SCI, V511, P67, DOI 10.1016/j.jcis.2017.09.074
   Wang Y, 2018, TOXICON, V146, P69, DOI [10.1016/j.toxicon.2018.04.007, 10]
   Wang Y, 2018, TOXICON, V155, P9, DOI 10.1016/j.toxicon.2018.09.005
   Warth B, 2013, TOXICOL LETT, V220, P88, DOI 10.1016/j.toxlet.2013.04.012
   WOOD GE, 1992, J ANIM SCI, V70, P3941
   Xu JH, 2016, FOOD CONTROL, V68, P244, DOI 10.1016/j.foodcont.2016.03.030
   Xu WJ, 2019, FOOD CONTROL, V96, P180, DOI 10.1016/j.foodcont.2018.09.006
   Yiannikouris A, 2004, J AGR FOOD CHEM, V52, P3666, DOI 10.1021/jf035127x
   Yiannikouris A, 2004, J FOOD PROTECT, V67, P1195, DOI 10.4315/0362-028X-67.6.1195
   Zatecka E, 2014, REPROD TOXICOL, V45, P20, DOI 10.1016/j.reprotox.2014.01.003
   Zhang HY, 2016, J PROTEOMICS, V143, P416, DOI 10.1016/j.jprot.2016.04.017
   Zinedine A., 2005, International Journal of Agriculture and Biology, V7, P67
   Zinedine A, 2007, FOOD CHEM TOXICOL, V45, P1, DOI 10.1016/j.fct.2006.07.030
   Zollner P, 2002, J AGR FOOD CHEM, V50, P2494, DOI 10.1021/jf0113631
NR 157
TC 10
Z9 10
U1 15
U2 33
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD APR 15
PY 2019
VL 162
BP 46
EP 56
DI 10.1016/j.toxicon.2019.03.004
PG 11
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA HU3SC
UT WOS:000465193300007
PM 30851274
DA 2020-05-12
ER

PT J
AU Mebs, D
   Wunder, C
   Toennes, SW
AF Mebs, Dietrich
   Wunder, Cora
   Toennes, Stefan W.
TI Coping with noxious effects of quinine by praying mantids (Mantodea) and
   spiders (Araneae)
SO TOXICON
LA English
DT Article
DE Mantids; Spiders; Quinine; Bitter taste; Web-silk
ID PLANT; DISCRIMINATION; SEQUESTRATION; TASTE
AB Because of its bitter taste, quinine elicits strong antifeedant and toxic effects in animals including arthropods. In the present study, two mantis, Sphodromantis viridis, Hierodula membranacea, and two spider species, Nephila edulis, Selenocosmia javanensis, were offered a quinine solution or prey (crickets) contaminated or injected with quinine, which they ingested and survived without apparent toxic symptoms. Analysis of their faeces and, in the case of spiders, of silk from their web revealed that quinine was excreted over a period of 8-12 (mantids) or 7 days (spiders). Interestingly, the silk glands of the spiders served as an additional excretory organ of quinine. Both, mantids and spiders were shown to tolerate high amounts of quinine in their prey. Obviously, the bitter taste of this compound is not perceived by their gustatory receptors and consequently triggers no aversive reactions.
C1 [Mebs, Dietrich; Wunder, Cora; Toennes, Stefan W.] Goethe Univ Frankfurt, Inst Legal Med, Kennedyallee 104, D-60956 Frankfurt, Germany.
RP Mebs, D (reprint author), Goethe Univ Frankfurt, Inst Legal Med, Kennedyallee 104, D-60956 Frankfurt, Germany.
EM mebs@em.uni-frankfurt.de
CR BELITZ H-D, 1985, Food Reviews International, V1, P271, DOI 10.1080/87559128509540773
   BERENBAUM MR, 1984, AM MIDL NAT, V111, P64, DOI 10.2307/2425543
   Chaudhari N, 2010, J CELL BIOL, V190, P285, DOI 10.1083/jcb.201003144
   DUFFEY SS, 1980, ANNU REV ENTOMOL, V25, P447, DOI 10.1146/annurev.en.25.010180.002311
   EISNER T, 1982, BIOSCIENCE, V32, P321, DOI 10.2307/1308848
   Eisner T, 1970, CHEM ECOL, P157
   Erb M, 2016, CURR OPIN INSECT SCI, V14, P8, DOI 10.1016/j.cois.2015.11.005
   FERGUSON JE, 1985, J CHEM ECOL, V11, P311, DOI 10.1007/BF01411417
   French A, 2015, FRONT INTEGR NEUROSC, V9, DOI 10.3389/fnint.2015.00058
   GELPERIN A, 1968, NATURE, V219, P399, DOI 10.1038/219399a0
   Glendinning JI, 2007, BIOL BULL-US, V213, P252, DOI 10.2307/25066643
   Hill DS, 2008, PESTS CROPS WARMER C
   Lunceford BE, 2015, INTEGR COMP BIOL, V55, P507, DOI 10.1093/icb/icv058
   Masek P, 2010, P NATL ACAD SCI USA, V107, P14833, DOI 10.1073/pnas.1009318107
   Mebs D, 2017, TOXICON, V131, P16, DOI 10.1016/j.toxicon.2017.03.010
   Mebs D, 2016, CHEMOECOLOGY, V26, P121, DOI 10.1007/s00049-016-0211-3
   Noge K, 2012, J CHEM ECOL, V38, P1050, DOI 10.1007/s10886-012-0166-y
   Nyffeler M, 2017, WILSON J ORNITHOL, V129, P331, DOI 10.1676/16-100.1
   Opitz SEW, 2009, CHEMOECOLOGY, V19, P117, DOI 10.1007/s00049-009-0018-6
   PARADISE CJ, 1993, J INSECT BEHAV, V6, P155, DOI 10.1007/BF01051501
   Petschenka G, 2016, CURR OPIN INSECT SCI, V14, P17, DOI 10.1016/j.cois.2015.12.004
   Petschenka G, 2011, BASIC APPL ECOL, V12, P260, DOI 10.1016/j.baae.2010.12.005
   REITZE M, 1991, OECOLOGIA, V86, P568, DOI 10.1007/BF00318324
   Schneider M, 2017, TOXICON, V139, P13, DOI 10.1016/j.toxicon.2017.09.011
   VASCONCELLOSNETO J, 1984, ECOL ENTOMOL, V9, P337, DOI 10.1111/j.1365-2311.1984.tb00857.x
   Ventura AK, 2013, CURR BIOL, V23, pR401, DOI 10.1016/j.cub.2013.02.037
   Vizueta J, 2017, GENOME BIOL EVOL, V9, P178, DOI 10.1093/gbe/evw296
   Weiss LA, 2011, NEURON, V69, P258, DOI 10.1016/j.neuron.2011.01.001
   Winterstein E, 1931, ALKALOIDE MONOGRAPHI
NR 29
TC 0
Z9 0
U1 2
U2 8
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD APR 15
PY 2019
VL 162
BP 57
EP 60
DI 10.1016/j.toxicon.2019.03.017
PG 4
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA HU3SC
UT WOS:000465193300008
PM 30904569
DA 2020-05-12
ER

PT J
AU Everett, HE
   Aramouni, M
   Coward, V
   Ramsay, A
   Kelly, M
   Morgan, S
   Tchilian, E
   Canini, L
   Woolhouse, MEJ
   Gilbert, S
   Charleston, B
   Brown, IH
   Brookes, SM
AF Everett, Helen E.
   Aramouni, Mario
   Coward, Vivien
   Ramsay, Andrew
   Kelly, Michael
   Morgan, Sophie
   Tchilian, Elma
   Canini, Laetitia
   Woolhouse, Mark E. J.
   Gilbert, Sarah
   Charleston, Bryan
   Brown, Ian H.
   Brookes, Sharon M.
TI Vaccine-mediated protection of pigs against infection with pandemic H1N1
   2009 swine influenza A virus requires a close antigenic match between
   the vaccine antigen and challenge virus
SO VACCINE
LA English
DT Article
DE Swine influenza A virus; Pandemic 2009 influenza A virus; H1N1; Whole
   inactivated virus vaccine; Immune response
AB Swine influenza A virus (SwIV) infection has considerable economic and animal welfare consequences and, because of the zoonotic potential, can also have public health implications. The 2009 pandemic H1N1 'swine-origin' infection is now endemic in both pigs and humans. In Europe, avian-like H1(av)N1, human-like H1(hu)N2, human-like swine H3N2 and, since 2009, pandemic H1N1 (pH1N1) lineage viruses and reassortants, constitute the dominant subtypes. In this study, we used a swine pH1N1 challenge virus to investigate the efficacy of whole inactivated virus vaccines homologous or heterologous to the challenge virus as well as a commercial vaccine. We found that vaccine-mediated protection was most effective when vaccine antigen and challenge virus were homologous and correlated with the specific production of neutralising antibodies and a cellular response to the challenge virus. We conclude that a conventional whole inactivated SwIV vaccine must be antigenically matched to the challenge strain to be an effective control measure. (C) 2019 Published by Elsevier Ltd.
C1 [Everett, Helen E.; Coward, Vivien; Ramsay, Andrew; Kelly, Michael; Brown, Ian H.; Brookes, Sharon M.] Anim & Plant Hlth Agcy APHA Weybridge, Virol Dept, Addlestone KT15 3NB, Surrey, England.
   [Aramouni, Mario; Gilbert, Sarah] Univ Oxford, Jenner Inst, ORCRB, Roosevelt Dr, Oxford OX3 7DQ, England.
   [Canini, Laetitia; Woolhouse, Mark E. J.] Univ Edinburgh, Charlotte Auerbach Rd, Edinburgh EH9 3FL, Midlothian, Scotland.
   [Morgan, Sophie; Tchilian, Elma; Charleston, Bryan] Pirbright Inst, Ash Rd, Woking GU24 0NF, Surrey, England.
RP Everett, HE (reprint author), Anim & Plant Hlth Agcy APHA Weybridge, Virol Dept, Addlestone KT15 3NB, Surrey, England.
EM helen.everett@apha.gsi.gov.uk
RI Gilbert, Sarah C./H-2857-2019; Brookes, Sharon M/W-2128-2019; Tchilian,
   Elma/Q-5976-2017
OI Gilbert, Sarah C./0000-0002-6823-9750; Brookes, Sharon
   M/0000-0001-9207-6659; Tchilian, Elma/0000-0002-4869-5118; Everett,
   Helen/0000-0002-1233-4265
FU Biotechnology and Biological Sciences Research Council sLoLa Grant
   [BB/L001330/1]
FX This work was funded by the Biotechnology and Biological Sciences
   Research Council sLoLa Grant BB/L001330/1. We are grateful to the Animal
   Sciences Unit staff at the Animal and Plant Health Agency (APHA) for
   ensuring excellent animal care. We wish to thank Dr. Catherine Charreyre
   from Boehringer-Ingleheim for her consultancy. Gripovac (R) 3 vaccine
   and TS6 adjuvant were kindly supplied by Merial Animal Health.
CR [Anonymous], WO, Patent No. [2005009462A3, 2005009462]
   BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x
   Brookes SM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009068
   BUDOWSKY EI, 1991, VACCINE, V9, P398, DOI 10.1016/0264-410X(91)90125-P
   Dilrrwald R, 2010, EMERG INFECT DIS, V16, P1029
   Franzoni G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0084246
   Gauger PC, 2012, VET PATHOL, V49, P900, DOI 10.1177/0300985812439724
   Hemmink JD, 2016, VET RES, V47, DOI 10.1186/s13567-016-0390-5
   Kitikoon P, 2014, METHODS MOL BIOL, V1161, P295, DOI 10.1007/978-1-4939-0758-8_24
   Kyriakis CS, 2010, EMERG INFECT DIS, V16, P96, DOI 10.3201/eid1601.091190
   Lewis NS, 2016, ELIFE, V5, DOI 10.7554/eLife.12217
   Loeffen WLA, 2011, VET MICROBIOL, V152, P304, DOI 10.1016/j.vetmic.2011.05.027
   Mughini-Gras L, 2015, PLOS CURR, V7
   Murcia PR, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002730
   Nagy A, 2010, ARCH VIROL, V155, P665, DOI 10.1007/s00705-010-0636-x
   Souza CK, 2018, VACCINE
   Van Reeth K, 2013, CURR TOP MICROBIOL, V370, P173, DOI 10.1007/82_2012_266
   Vincent AL, 2017, VET MICROBIOL, V206, P35, DOI 10.1016/j.vetmic.2016.11.026
   Vincent AL, 2010, VACCINE, V28, P2782, DOI 10.1016/j.vaccine.2010.01.049
   Watson SJ, 2015, J VIROL, V89, P9920, DOI 10.1128/JVI.00840-15
NR 20
TC 3
Z9 3
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD APR 17
PY 2019
VL 37
IS 17
BP 2288
EP 2293
DI 10.1016/j.vaccine.2019.02.078
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HV8UV
UT WOS:000466260500002
PM 30914224
OA Bronze, Green Published
DA 2020-05-12
ER

PT J
AU Brunelli, L
   Romanese, F
   Benetollo, PP
   Iob, A
   Forgiarini, M
   D'Agaro, P
   Valent, F
   Brusaferro, S
   Arnoldo, L
   Bassetti, M
   Borghi, G
   Brianti, G
   Brunetti, P
   Campagnolo, M
   Cattani, G
   Cogo, P
   Del Negro, M
   Fabbro, A
   Gallo, T
   Lubrano, P
   Marchetti, F
   Miceli, S
   Nocerino, A
   Paravano, L
   Pascolo, P
   Perna, M
   Pischiutti, P
   Plazzotta, A
   Regattin, L
   Sacher, B
   Sigon, M
   Taddio, A
   Tommasini, T
   Vacchiano, E
AF Brunelli, Laura
   Romanese, Federico
   Benetollo, Pier Paolo
   Iob, Andrea
   Forgiarini, MariaRita
   D'Agaro, Pierlanfranco
   Valent, Francesca
   Brusaferro, Silvio
   Arnoldo, Luca
   Bassetti, Matteo
   Borghi, Gianni
   Brianti, Giorgio
   Brunetti, Patrizia
   Campagnolo, Mirella
   Cattani, Giovanni
   Cogo, Paola
   Del Negro, Marco
   Fabbro, Anna
   Gallo, Tolinda
   Lubrano, Paolo
   Marchetti, Fabio
   Miceli, Stefano
   Nocerino, Agostino
   Paravano, Luca
   Pascolo, Piero
   Perna, Maurizio
   Pischiutti, Paolo
   Plazzotta, Andrea
   Regattin, Laura
   Sacher, Bruno
   Sigon, Massimo
   Taddio, Andrea
   Tommasini, Tiziano
   Vacchiano, Erica
CA FVG Preventive Serv Task Force
TI Management of reduced vaccine coverage due to 6 years of failure to
   vaccinate: The Codroipo case, Italy
SO VACCINE
LA English
DT Article
DE Vaccine preventable diseases; Immunization; Failure to vaccinate; Public
   health reaction; Public health policy; Extraordinary vaccination
   campaign
ID HEALTHY-CHILDREN; IMMUNOGENICITY; RUBELLA; MEASLES; SAFETY; MUMPS
AB During 2017 an alert was raised in relation to a possible vaccination failure occurred in Friuli Venezia Giulia Region (Italy) between 2009 and 2015, exposing multiple cohorts of children and the entire community to vaccine preventable diseases outbreak risk. The Codroipo case resulted in 20,441 vaccine doses being in doubt, thus prompting the healthcare system to react in order to revaccinate 5444 children through planning and implementing network actions and multiple channels of communication. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Brunelli, Laura; Romanese, Federico; Brusaferro, Silvio; Cogo, Paola] Univ Udine, Dept Med, Udine, Italy.
   [Benetollo, Pier Paolo; Iob, Andrea; Forgiarini, MariaRita; Brunetti, Patrizia; Cattani, Giovanni; Lubrano, Paolo; Sacher, Bruno; Sigon, Massimo; Tommasini, Tiziano] Azienda Assistenza Sanitaria Friuli Venezia Giuli, Local Hlth Trust 3, Gemona, Italy.
   [D'Agaro, Pierlanfranco] Univ Trieste, Dept Med Surg & Hlth Sci, Trieste, Italy.
   [D'Agaro, Pierlanfranco] Trieste Healthcare, Trieste, Italy.
   [D'Agaro, Pierlanfranco] Univ Integrated Trust, ASUITS, Trieste, Italy.
   [Valent, Francesca; Brusaferro, Silvio; Arnoldo, Luca; Bassetti, Matteo; Brianti, Giorgio; Campagnolo, Mirella; Cogo, Paola; Fabbro, Anna; Gallo, Tolinda; Miceli, Stefano; Nocerino, Agostino; Paravano, Luca; Pascolo, Piero; Perna, Maurizio; Regattin, Laura] Udine Healthcare, Udine, Italy.
   [Valent, Francesca; Brusaferro, Silvio; Arnoldo, Luca; Bassetti, Matteo; Brianti, Giorgio; Campagnolo, Mirella; Cogo, Paola; Fabbro, Anna; Gallo, Tolinda; Miceli, Stefano; Nocerino, Agostino; Paravano, Luca; Pascolo, Piero; Perna, Maurizio; Regattin, Laura] Univ Integrated Trust, ASUIUD, Udine, Italy.
   [Pischiutti, Paolo] FVG Reg Hlth Syst, Udine, Italy.
   [Plazzotta, Andrea; Vacchiano, Erica] Cittadinanzatt Nonprofit Citizen NGO, Tavagnacco, Italy.
   [Taddio, Andrea] Inst Maternal & Child Hlth IRCCS Burlo Garofolo, Trieste, Italy.
   [Brunelli, Laura] Via Colugna 50, I-33100 Udine, Italy.
RP Brunelli, L (reprint author), Univ Udine, Udine, Italy.; Brunelli, L (reprint author), Via Colugna 50, I-33100 Udine, Italy.
EM laura.brunelli@uniud.it
OI Bassetti, Matteo/0000-0002-0145-9740
CR Heininger U, 2012, VACCINE, V30, P1265, DOI 10.1016/j.vaccine.2011.12.048
   Hibbs BF, 2018, VACCINE, V36, P553, DOI 10.1016/j.vaccine.2017.11.083
   Hickler B, 2015, VACCINE, V33, P4155, DOI 10.1016/j.vaccine.2015.04.034
   Kuter BJ, 2016, PEDIATR INFECT DIS J, V35, P1011, DOI 10.1097/INF.0000000000001241
   Leung JHY, 2015, EXPERT REV VACCINES, V14, P1149, DOI 10.1586/14760584.2015.1057572
   Su JR, 2016, MMWR-MORBID MORTAL W, V65, P161, DOI 10.15585/mmwr.mm6506a4
   World Health Organization, 2014, REP SAGE WORK GROUP
   2014, SOC SCI MED, V112, P1, DOI DOI 10.1016/J.SOCSCIMED.2014.04.018
NR 8
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD APR 17
PY 2019
VL 37
IS 17
BP 2294
EP 2297
DI 10.1016/j.vaccine.2019.01.082
PG 4
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HV8UV
UT WOS:000466260500003
PM 30878248
DA 2020-05-12
ER

PT J
AU de Soarez, PC
   Silva, AB
   Randi, BA
   Azevedo, LM
   Novaes, HMD
   Sartori, AMC
AF de Soarez, Patricia Coelho
   Silva, Aline Blumer
   Randi, Bruno Azevedo
   Azevedo, Laura Marques
   Dutilh Novaes, Hillegonda Maria
   Christovam Sartori, Ana Marli
TI Systematic review of health economic evaluation studies of dengue
   vaccines
SO VACCINE
LA English
DT Review
DE Dengue vaccines; Cost-benefit analysis; Cost-utility analysis;
   Cost-effectiveness analysis
ID COST-EFFECTIVENESS; VACCINATION PROGRAMS; EXPANSION FACTORS;
   SURVEILLANCE; DYNAMICS; CHILDREN; UTILITY; BURDEN; SAFETY; ASIA
AB Objectives: To review the literature on economic evaluation of dengue vaccination to produce evidence to support a local cost-effectiveness study and to subsidize the decision to introduce a dengue vaccine in the Brazilian National Immunization Program. Methods: We systematically searched multiple databases (MEDLINE (via PubMed), EMBASE, SCOPUS, NHS Economic Evaluation Database (NHS EED), HTA Database (via Centre for Reviews and Dissemination - CRD) and LILACS), selecting full HEEs of dengue vaccine. Two independent reviewers screened articles for relevance and extracted the data. The methodology for the quality reporting was assessed using CHEERS checklist. We performed a qualitative narrative synthesis. Results: Thirteen studies conducted in Asian and Latin America countries were reviewed. All studies were favorable to the incorporation of the vaccine. However, the assumptions and values assumed for vaccine efficacy, safety and duration of protection, as well as the choice of the study population and the type of model used in the analyses, associated to an insufficient reporting of the methodological steps, affect the validity of the studies' results. The quality reporting appraisal showed that the majority (8/13) of the studies reported less than 55% of the CHEERS checklists' items. Conclusions: This systematic review shows that the economic evaluation of dengue vaccination did not adhere to key recommended general methods for economic evaluation. The presented cost-effectiveness results should not be transferred to other countries. It is recommended to conduct studies with local epidemiological and cost data, as well as assumptions about vaccination that reflect the results observed in clinical trials. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [de Soarez, Patricia Coelho; Silva, Aline Blumer; Azevedo, Laura Marques; Dutilh Novaes, Hillegonda Maria] Univ Sao Paulo, Fac Med, Dept Med Prevent, Sao Paulo, SP, Brazil.
   [Randi, Bruno Azevedo; Christovam Sartori, Ana Marli] Univ Sao Paulo, Fac Med, Dept Molestias Infecciosas & Parasitarias, Sao Paulo, SP, Brazil.
RP de Soarez, PC (reprint author), Av Dr Arnaldo,455 2 Andar,Sala 2228, BR-01246903 Sao Paulo, SP, Brazil.
EM patricia.soarez@usp.br
RI Novaes, Hillegonda M. D./F-7060-2011; Sartori, Ana Marli
   Christovam/I-6663-2012; Soarez, Patricia/D-9710-2012
OI Novaes, Hillegonda M. D./0000-0001-9849-0324; Sartori, Ana Marli
   Christovam/0000-0003-3777-0757; Soarez, Patricia/0000-0001-8383-0728
FU Ministry of HealthMinistry of Health - Turkey [LOA: SCON2017-0247];
   Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq,
   National Counsel of Technological and Scientific Development)National
   Council for Scientific and Technological Development (CNPq)
   [304580/2016-3]
FX This work was supported by the Ministry of Health, No LOA:
   SCON2017-0247, and the Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico (CNPq, National Counsel of Technological and Scientific
   Development) under CNPq Research Grant no. 304580/2016-3). The funding
   source had no involvement in study design; in the collection, analysis
   and interpretation of data; in the writing of the report; and in the
   decision to submit the article for publication.
CR Achee NL, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003655
   Anderson R, 2010, HEALTH ECON, V19, P350, DOI 10.1002/hec.1486
   [Anonymous], 2009, SYST REV EC EV CRDS
   [Anonymous], 2018, WKLY EPIDEMIOL REC, V93, P457
   Bertram MY, 2016, B WORLD HEALTH ORGAN, V94, P925, DOI 10.2471/BLT.15.164418
   Bhatt S, 2013, NATURE, V496, P504, DOI 10.1038/nature12060
   Capeding MR, 2014, LANCET, V384, P1358, DOI 10.1016/S0140-6736(14)61060-6
   Carrasco LR, 2011, PLOS NEGLECT TROP D, P5
   Coelho GE, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004705
   Duarte HHP, 2006, REV SAUDE PUBL, V40, P134, DOI 10.1590/S0034-89102006000100021
   Durand L, 2017, J BRAS EC SAUDE, V9, P12
   Durham DP, 2013, VACCINE, V31, P3957, DOI 10.1016/j.vaccine.2013.06.036
   Endo IC, 2016, VACCINE, V34, P6133, DOI 10.1016/j.vaccine.2016.10.037
   Grifoni A, 2017, J VIROL
   Hadinegoro SR, 2015, NEW ENGL J MED, V373, P1195, DOI 10.1056/NEJMoa1506223
   Husereau D, 2013, VALUE HEALTH, V16, P231, DOI 10.1016/j.jval.2013.02.002
   Koh HL, 2017, ASIAN J PHARM CLIN R, P12
   Larson HJ, 2019, HUM VACC IMMUNOTHER, V15, P625, DOI 10.1080/21645515.2018.1522468
   Lee BY, 2011, AM J TROP MED HYG, V84, P764, DOI 10.4269/ajtmh.2011.10-0624
   Lee JS, 2018, VACCINE, V36, P2346, DOI 10.1016/j.vaccine.2018.03.002
   Moher D, 2009, J CLIN EPIDEMIOL, V62, P1006, DOI 10.1016/j.jclinepi.2009.06.005
   Precioso AR, 2015, VACCINE, V33, P7121, DOI 10.1016/j.vaccine.2015.09.105
   Priyamvada L, 2017, EMERG MICROBES INFEC, V6, DOI 10.1038/emi.2017.42
   Ramakrishnan L, 2015, VIRAL IMMUNOL, V28, P76, DOI 10.1089/vim.2014.0093
   Runge-Ranzinger S, 2014, TROP MED INT HEALTH, V19, P1116, DOI 10.1111/tmi.12333
   Saez-Llorens X, 2018, LANCET INFECT DIS, V18, P162, DOI 10.1016/S1473-3099(17)30632-1
   Shafie AA, 2017, PHARMACOECONOMICS, V35, P575, DOI 10.1007/s40273-017-0487-3
   Shepard DS, 2004, VACCINE, V22, P1275, DOI 10.1016/j.vaccine.2003.09.019
   Shepard DS, 2010, EC EVALUATION CHILD
   Shepard DS, 2010, HDB DIS BURDENS QUAL, V2, P1281
   Shim E, 2017, AM J TROP MED HYG, V96, P1227, DOI 10.4269/ajtmh.16-0810
   Shim E, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0175020
   Shim E, 2016, AM J TROP MED HYG, V95, P1137, DOI 10.4269/ajtmh.16-0194
   Silva MMO, 2016, EMERG INFECT DIS, V22, P336, DOI 10.3201/eid2202.150495
   Sridhar S, 2018, NEW ENGL J MED, V379, P327, DOI 10.1056/NEJMoa1800820
   Stanaway JD, 2016, LANCET INFECT DIS, V16, P712, DOI 10.1016/S1473-3099(16)00026-8
   Toan NT, 2015, TROP MED INT HEALTH, V20, P840, DOI 10.1111/tmi.12498
   Tozan Y, 2016, EXPERT REV VACCINES, V15, P519, DOI 10.1586/14760584.2016.1129278
   Undurraga EA, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002056
   Valido Ezra M, 2018, BMC Res Notes, V11, P661, DOI 10.1186/s13104-018-3766-y
   Velumani S, 2016, HUM VACC IMMUNOTHER, V12, P1265, DOI 10.1080/21645515.2015.1126012
   Villar L, 2015, NEW ENGL J MED, V372, P113, DOI 10.1056/NEJMoa1411037
   Orellano PW, 2016, VACCINE, V34, P616, DOI 10.1016/j.vaccine.2015.12.040
   Zeng W, 2018, VACCINE, V36, P413, DOI 10.1016/j.vaccine.2017.11.064
NR 44
TC 3
Z9 3
U1 0
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD APR 17
PY 2019
VL 37
IS 17
BP 2298
EP 2310
DI 10.1016/j.vaccine.2019.03.026
PG 13
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HV8UV
UT WOS:000466260500004
PM 30910406
DA 2020-05-12
ER

PT J
AU Erondu, NA
   Ferland, L
   Haile, BH
   Abimbola, T
AF Erondu, Ngozi Adaeze
   Ferland, Lisa
   Haile, Betiel Hadgu
   Abimbola, Taiwo
TI A systematic review of vaccine preventable disease surveillance cost
   studies
SO VACCINE
LA English
DT Review
DE Systematic review; Cost analysis; Vaccine preventable diseases; Public
   health surveillance; Low income; Middle income
ID PUBLIC-HEALTH SURVEILLANCE; ROUTINE IMMUNIZATION
AB Background: Planning and monitoring vaccine introduction and effectiveness relies on strong vaccine preventable disease (VPD) surveillance. In low and middle-income countries (LMICs) especially, cost is a commonly reported barrier to VPD surveillance system maintenance and performance; however, it is rarely calculated or assessed. This review describes and compares studies on the availability of cost information for VPD surveillance systems in LMICs to facilitate the design of future cost studies of VPD surveillance.
   Methods: PubMed, Web of Science, and EconLit were used to identify peer-reviewed articles and Google was searched for relevant grey literature. Studies selected described characteristics and results of VPD surveillance systems cost studies performed in LMICs. Studies were categorized according to the type of VPD surveillance system, study aim, the annual cost of the system, and per capita costs.
   Results: Eleven studies were identified that assessed the cost of VPD surveillance systems. The studies assessed systems from six low-income countries, two low-middle-income countries, and three middle income countries. The majority of the studies (n = 7) were conducted in sub-Saharan Africa and fifteen distinct VPD surveillance systems were assessed across the studies. Most studies aimed to estimate incremental costs of additional surveillance components and presented VPD surveillance system costs as mean annual costs per resource category, health structure level, and by VPD surveillance activity. Staff time/personnel cost represents the largest cost driver, ranging from 21% to 61% of total VPD surveillance system costs across nine studies identifying a cost driver.
   Conclusions: This review provides a starting point to guide LMICs to invest and advocate for more robust VPD surveillance systems. Critical gaps were identified including limited information on the cost of laboratory surveillance, challenges with costing shared resources, and missing data on capital costs. Appropriate guidance is needed to guide LMICs conducting studies on VPD surveillance system costs. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Erondu, Ngozi Adaeze] London Sch Hyg & Trop Med, Keppel St, London WC1E 7HT, England.
   [Erondu, Ngozi Adaeze; Ferland, Lisa; Haile, Betiel Hadgu] Global Bridge Grp LLC, Pleasanton, CA 94566 USA.
   [Abimbola, Taiwo] US Ctr Dis Control & Prevent, Atlanta, GA USA.
RP Erondu, NA (reprint author), London Sch Hyg & Trop Med, Keppel St, London WC1E 7HT, England.; Erondu, NA (reprint author), Global Bridge Grp LLC, Pleasanton, CA 94566 USA.
EM ghconsulting@ngozierondu.com; iip2@cdc.gov
OI Erondu, Ngozi/0000-0003-0268-6838
FU World Health OrganizationWorld Health Organization
FX This work was supported by the World Health Organization through an
   Agreement for Performance of Work to NE (Ref: FWC/IVB/EPI).
CR Agence de Medecine Preventive Bill and Melinda Gates Foundation Centers for Disease Control and Prevention (U. S.) Center for Health Decision Science at Harvard School of Public Health, PROVAC PROM EV BAS D
   [Anonymous], 2008, WHO REC STAND SURV S
   Baly A, 2012, TROP MED INT HEALTH, V17, P123, DOI 10.1111/j.1365-3156.2011.02881.x
   Brenzel L, 2015, VACCINE, V33, pA13, DOI 10.1016/j.vaccine.2014.12.066
   Bureau of Labor Statistics, 2017, BLS HIST CONS PRIC I
   Butler D, 2006, NATURE, V440, P6, DOI 10.1038/440006a
   Castaneda-Orjuela C, 2013, VACCINE, P31
   Critical Appraisal Skills Programme, 2017, CRITICAL APPRAISAL S
   Duintjer Tebbens RJ, 2015, BMC INFECT DIS
   Erondu NA, 2015, EVALUATING COMMUNICA
   Herida M, 2016, EUR J PUBLIC HEALTH, V26, P674, DOI 10.1093/eurpub/ckv250
   Irurzun-Lopez M, 2016, VACCINE, V34, P1133, DOI 10.1016/j.vaccine.2015.10.045
   Kaburi BB, 2017, BMC INFECT DIS, V17, DOI 10.1186/s12879-017-2410-0
   Kebede S, 2011, HEALTH RES POLICY SY, V9, DOI 10.1186/1478-4505-9-27
   Le Gargasson JB, 2015, VACCINE, V33, pA40, DOI 10.1016/j.vaccine.2014.12.081
   Lukwago L, 2013, HEALTH POLICY PLANN, V28, P30, DOI 10.1093/heapol/czs022
   Moher D, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000097
   Mueller DH, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-17
   Somda Zana C, 2009, Cost Eff Resour Alloc, V7, P1, DOI 10.1186/1478-7547-7-1
   Somda ZC, 2007, SURVCOST 1 0 MANUAL
   Tandon A, 2010, ASSESSING PUBLIC EXP
   Tebbens RJD, 2006, RISK ANAL, V26, P1507, DOI 10.1111/j.1539-6924.2006.00842.x
   THACKER SB, 1988, EPIDEMIOL REV, V10, P164, DOI 10.1093/oxfordjournals.epirev.a036021
   Toscano CM, 2013, VACCINE, V31, pC88, DOI 10.1016/j.vaccine.2013.05.036
   World Health Organization, 2006, IMM COST FIN TOOL US
   World Health Organization, 2017, A70ACONF1 WHO
   World Health Organization, 2006, COMM DIS SURV RESP S
NR 27
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD APR 17
PY 2019
VL 37
IS 17
BP 2311
EP 2321
DI 10.1016/j.vaccine.2019.02.026
PG 11
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HV8UV
UT WOS:000466260500005
PM 30902482
OA Green Accepted
DA 2020-05-12
ER

PT J
AU Sarkar, S
   Piepenbrink, MS
   Basu, M
   Thakar, J
   Keefer, MC
   Hessell, AJ
   Haigwood, NL
   Kobie, JJ
AF Sarkar, Sanghita
   Piepenbrink, Michael S.
   Basu, Madhubanti
   Thakar, Juilee
   Keefer, Michael C.
   Hessell, Ann J.
   Haigwood, Nancy L.
   Kobie, James J.
TI IL-33 enhances the kinetics and quality of the antibody response to a
   DNA and protein-based HIV-1 Env vaccine
SO VACCINE
LA English
DT Article
DE HIV-1; Envelope; Vaccine; Antibody; IgM; IL-33
ID IMMUNODEFICIENCY-VIRUS TYPE-1; B-CELL RESPONSES; NEUTRALIZING
   ANTIBODIES; MARGINAL ZONE; IMMUNE-RESPONSES; INTERLEUKIN 33; B1B CELLS;
   ADJUVANT; MEMORY; INFECTION
AB Induction of a sustained and broad antibody (Ab) response is a major goal in developing a protective HIV-1 vaccine. DNA priming alone shows reduced levels of immunogenicity; however, when combined with protein boosting is an attractive vaccination strategy for induction of humoral responses. Using the VC10014 DNA and protein-based vaccine consisting of HIV-1 envelope (Env) gp160 plasmids and trimeric gp140 proteins derived from an HIV-1 Glade B infected subject who developed broadly neutralizing serum Abs, and which has been previously demonstrated to induce Tier 2 heterologous neutralizing Abs in rhesus macaques, we evaluated whether MPLA and IL-33 when administered during the DNA priming phase enhances the humoral response in mice. The addition of IL-33 during the gpl60 DNA priming phase resulted in high titer gp120-specific plasma IgG after the first immunization. The IL-33 treated mice had higher plasma IgG Ab avidity, breadth, and durability after DNA and protein co-immunization with alum adjuvant as compared to MPLA and alum only treated mice. IL-33 was also associated with a significant IgM Env-specific response and expansion of peritoneal and splenic B-1b B cells. These results indicate that DNA priming in the presence of exogenous IL-33 qualitatively alters the HIV-1 Env-specific humoral response, improving the kinetics and breadth of potentially protective Ab. (C) 2019 The Authors. Published by Elsevier Ltd.
C1 [Sarkar, Sanghita; Piepenbrink, Michael S.; Basu, Madhubanti; Keefer, Michael C.; Kobie, James J.] Univ Rochester, Med Ctr, Infect Dis Div, Rochester, NY 14642 USA.
   [Thakar, Juilee] Univ Rochester, Med Ctr, Dept Microbiol & Immunol, Rochester, NY 14642 USA.
   [Hessell, Ann J.; Haigwood, Nancy L.] Oregon Hlth & Sci Univ, Oregon Natl Primate Res Ctr, Beaverton, OR USA.
RP Kobie, JJ (reprint author), Univ Rochester, Med Ctr, Infect Dis Div, Rochester, NY 14642 USA.
EM james_kobie@urmc.rochester.edu
OI Haigwood, Nancy/0000-0002-1477-9575
FU National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [5R01AI117787];
   University of Rochester Center for AIDS Research [P30AI078498];
   University of Rochester
FX This work was supported by the National Institutes of Health
   (5R01AI117787 to JJK), the University of Rochester Center for AIDS
   Research P30AI078498 (NIH/NIAID), and institutional funding provided by
   the University of Rochester.
CR Allakhverdi Z, 2007, J IMMUNOL, V179, P2051, DOI 10.4049/jimmunol.179.4.2051
   Alugupalli KR, 2004, IMMUNITY, V21, P379, DOI 10.1016/j.immuni.2004.06.019
   Arima H, 2018, BLOOD ADV, V2, P2282, DOI 10.1182/bloodadvances.2018019919
   Baumgarth N, 2013, IMMUNOL REV, V255, P82, DOI 10.1111/imr.12094
   Baumgarth N, 2011, NAT REV IMMUNOL, V11, P34, DOI 10.1038/nri2901
   Burton DR, 2012, CELL HOST MICROBE, V12, P396, DOI 10.1016/j.chom.2012.09.008
   Carbonari M, 2005, J IMMUNOL, V174, P6532, DOI 10.4049/jimmunol.174.10.6532
   Chan JK, 2012, J CLIN INVEST, V122, P2711, DOI 10.1172/JCI62423
   Choi YS, 2008, J EXP MED, V205, P3053, DOI 10.1084/jem.20080979
   Chukwuma VU, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0209437
   Cristillo AD, 2006, VIROLOGY, V346, P151, DOI 10.1016/j.virol.2005.10.038
   De Becker G, 2000, INT IMMUNOL, V12, P807, DOI 10.1093/intimm/12.6.807
   Defrance T, 2011, CURR OPIN IMMUNOL, V23, P330, DOI 10.1016/j.coi.2011.03.004
   Dimitrov JD, 2011, ANAL BIOCHEM, V418, P149, DOI 10.1016/j.ab.2011.07.007
   Duan LH, 2012, MOL MED, V18, P753, DOI 10.2119/molmed.2011.00428
   Ferraro B, 2011, CLIN INFECT DIS, V53, P296, DOI 10.1093/cid/cir334
   Giannini SL, 2006, VACCINE, V24, P5937, DOI 10.1016/j.vaccine.2006.06.005
   Gong S, 2018, AIDS, V32, pF5, DOI [10.1097/qad.0000000000001857, 10.1097/QAD.0000000000001857]
   Haas KM, 2011, J IMMUNOL, V187, P5183, DOI 10.4049/jimmunol.1101990
   Hessell AJ, 2016, J IMMUNOL, V196, P3064, DOI 10.4049/jimmunol.1500527
   Ismaili J, 2002, J IMMUNOL, V168, P926, DOI 10.4049/jimmunol.168.2.926
   Jardine J, 2013, SCIENCE, V340, P711, DOI 10.1126/science.1234150
   Joint United Nations Programme on HIV/AIDS, 2018, MIL TO GO
   Kayamuro H, 2010, J VIROL, V84, P12703, DOI 10.1128/JVI.01182-10
   Kharsany Ayesha B M, 2016, Open AIDS J, V10, P34, DOI 10.2174/1874613601610010034
   Kim JJ, 1997, J IMMUNOL, V158, P816
   Kim SH, 1996, ANTICANCER RES, V16, P2821
   Komai-Koma M, 2011, J IMMUNOL, V186, P2584, DOI 10.4049/jimmunol.1002103
   Kreslaysky T, 2018, CURR OPIN IMMUNOL, V51, P24, DOI 10.1016/j.coi.2018.01.001
   Kutzler MA, 2008, NAT REV GENET, V9, P776, DOI 10.1038/nrg2432
   Lohning M, 1998, P NATL ACAD SCI USA, V95, P6930, DOI 10.1073/pnas.95.12.6930
   MacGregor RR, 1998, J INFECT DIS, V178, P92, DOI 10.1086/515613
   Malherbe DC, 2014, J VIROL, V88, P12949, DOI 10.1128/JVI.01812-14
   Malherbe DC, 2011, J VIROL, V85, P5262, DOI 10.1128/JVI.02419-10
   Martin F, 2001, IMMUNITY, V14, P617, DOI 10.1016/S1074-7613(01)00129-7
   Martin F, 2000, IMMUNOL REV, V175, P70, DOI 10.1111/j.1600-065X.2000.imr017515.x
   Martin M, 2003, INFECT IMMUN, V71, P2498, DOI 10.1128/IAI.71.5.2498-2507.2003
   Moyron-Quiroz JE, 2009, VACCINE, V28, P140, DOI 10.1016/j.vaccine.2009.09.086
   Mu R, 2010, J RHEUMATOL, V37, P2006, DOI 10.3899/jrheum.100184
   Nogales A, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-22307-8
   O'Ryan M, 2015, HUM VACC IMMUNOTHER, V11, P584, DOI 10.1080/21645515.2015.1011019
   Okuda K, 2014, VACCINES, V2, P89, DOI 10.3390/vaccines2010089
   Oppenheim JJ, 2005, CURR OPIN IMMUNOL, V17, P359, DOI 10.1016/j.coi.2005.06.002
   Peachman KK, 2010, VIRAL IMMUNOL, V23, P627, DOI 10.1089/vim.2010.0061
   Pujanauski LM, 2013, P NATL ACAD SCI USA, V110, P1422, DOI 10.1073/pnas.1213713110
   Puschnik A, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002274
   Rappuoli R, 2018, SEMIN IMMUNOL
   Rose WA, 2015, SCI REP-UK, V5, DOI 10.1038/srep13146
   Sanders RW, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003618
   Sasaki S, 1998, J VIROL, V72, P4931, DOI 10.1128/JVI.72.6.4931-4939.1998
   Sather DN, 2014, J VIROL, V88, P12968, DOI 10.1128/JVI.01816-14
   Sattler S, 2014, J AUTOIMMUN, V50, P107, DOI 10.1016/j.jaut.2014.01.032
   Schmitz J, 2005, IMMUNITY, V23, P479, DOI 10.1016/j.immuni.2005.09.015
   Schneider E, 2009, J IMMUNOL, V183, P3591, DOI 10.4049/jimmunol.0900328
   Sellhorn G, 2009, VACCINE, V28, P430, DOI 10.1016/j.vaccine.2009.10.028
   Sharma SK, 2015, CELL REP, V11, P539, DOI 10.1016/j.celrep.2015.03.047
   Shepherd SJ, 2015, J VIROL METHODS, V217, P42, DOI 10.1016/j.jviromet.2015.02.016
   Smithgall MD, 2008, INT IMMUNOL, V20, P1019, DOI 10.1093/intimm/dxn060
   Srivastava IK, 2003, J VIROL, V77, P2310, DOI 10.1128/JVI.77.4.2310-2320.2003
   Taillardet M, 2009, BLOOD, V114, P4432, DOI 10.1182/blood-2009-01-200014
   Taylor JJ, 2012, J EXP MED, V209, P597, DOI 10.1084/jem.20111696
   Viau M, 2007, MOL IMMUNOL, V44, P2124, DOI 10.1016/j.molimm.2006.07.302
   Villarreal DO, 2015, VACCINE, V33, P4313, DOI 10.1016/j.vaccine.2015.03.086
   Villarreal DO, 2015, HUM VACC IMMUNOTHER, V11, P1954, DOI 10.1080/21645515.2015.1026499
   Villarreal DO, 2014, CURR OPIN IMMUNOL, V28, P102, DOI 10.1016/j.coi.2014.03.004
   Villarreal DO, 2014, CANCER RES, V74, P1789, DOI 10.1158/0008-5472.CAN-13-2729
   Wu XL, 2010, SCIENCE, V329, P856, DOI 10.1126/science.1187659
   Yammani RD, 2013, J IMMUNOL, V190, P3100, DOI 10.4049/jimmunol.1203058
   Yang Y, 2012, P NATL ACAD SCI USA, V109, P5388, DOI 10.1073/pnas.1121627109
NR 69
TC 2
Z9 2
U1 0
U2 5
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD APR 17
PY 2019
VL 37
IS 17
BP 2322
EP 2330
DI 10.1016/j.vaccine.2019.03.044
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HV8UV
UT WOS:000466260500006
PM 30926296
OA Green Accepted, Other Gold
DA 2020-05-12
ER

PT J
AU Choudhary, TS
   Reddy, NS
   Apte, A
   Sinha, B
   Roy, S
   Nair, NP
   Sindhu, KN
   Patil, R
   Upadhyay, RP
   Chowdhury, R
AF Choudhary, Tarun Shankar
   Reddy, N. Samarasimha
   Apte, Aditi
   Sinha, Bireshwar
   Roy, Sudipto
   Nair, Nayana P.
   Sindhu, Kulandaipalayam Natarajan
   Patil, Rutuja
   Upadhyay, Ravi Prakash
   Chowdhury, Ranadip
TI Delayed vaccination and its predictors among children under 2 years in
   India: Insights from the national family health survey-4
SO VACCINE
LA English
DT Article
DE Timeliness; Delayed Vaccination; Measles; DPT; Child health;
   Epidemiology
ID BIRTH-WEIGHT INFANTS; IMMUNIZATION; DETERMINANTS; COVERAGE; MEASLES;
   TIMELINESS; MORTALITY; PERTUSSIS; SCHEDULE; RISK
AB Objective: Delayed vaccination increases the susceptibility window for vaccine preventable diseases. Our analysis estimates the proportion of children between 10 and 23 months of age with delayed vaccination in India and the associated socio-demographic, maternal and child related factors.
   Methods: We used individual level data from the National Family and Health Survey 4, conducted in 2015-2016. The primary outcome of the study was delayed vaccination for BCG, DPT- 1st dose and Measles. Delayed vaccination for each vaccine was defined as administration of the vaccine dose after 28 days of the minimum recommended age, as per the national immunization schedule in India. We estimated the proportion of children with delayed vaccination for each vaccine and used multivariable logistic regression to explore associated factors.
   Findings: In the current analysis, 23.1%, 29.3% and 34.8% of children aged 10 to 23 months had delayed vaccination for BCG, DPT-1st dose and Measles respectively. Children from Muslim families (aOR 1.36 for BCG; aOR 1.45 for DPT-1; aOR 1.26 for Measles); birth weight < 2000 g (aOR 2.33 for BCG; aOR 1.53 for DPT-1; aOR 1.36 for Measles) had higher odds of delayed vaccination. Lower maternal education and belonging to a family from lower wealth quintile had higher odds of delayed vaccination. Children of mothers who had tetanus toxoid immunization during pregnancy had lower odds of delayed vaccination (aOR 0.69 for BCG; aOR 0.76 for DPT-1; aOR 0.78 for Measles).
   Conclusion: The proportion of children with delayed vaccination is high in India. Vaccine timeliness should be a core indicator of the immunization program with greater focus on groups with higher chances of delayed vaccination i.e. home birth, low birth weight new-borns, poorer households, children of mothers with lower education and children from Muslim families. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Choudhary, Tarun Shankar; Sinha, Bireshwar; Upadhyay, Ravi Prakash; Chowdhury, Ranadip] Soc Appl Studies, Ctr Hlth Res & Dev, 45 Kalu Sarai, New Delhi 110016, India.
   [Reddy, N. Samarasimha; Nair, Nayana P.; Sindhu, Kulandaipalayam Natarajan] Christian Med Coll & Hosp, Vellore, Tamil Nadu, India.
   [Apte, Aditi; Roy, Sudipto; Patil, Rutuja] KEM Hosp Res Ctr, Pune, Maharashtra, India.
RP Choudhary, TS (reprint author), Soc Appl Studies, Ctr Hlth Res & Dev, 45 Kalu Sarai, New Delhi 110016, India.
EM tarun.choudhary@sas.org.in
OI Apte, Aditi/0000-0002-9120-2569; Chowdhury, Ranadip/0000-0002-0055-6653
FU Bill and Melinda Gates FoundationGates Foundation [OPP1110191];
   technical advisory group of the PRERNA platform and faculty at Centre
   for Health Research and Development, Society for Applied Studies, Delhi;
   Knowledge Integration and Translational Platform, an initiative of the
   Department of Biotechnology, Government of India; Gates Foundation
   through the Biotechnology Industry Research Assistance Council;
   technical advisory group of the PRERNA platform and faculty at KEM
   Hospital Research Centre, Pune; technical advisory group of the PRERNA
   platform and faculty at Christian Medical College, Vellore
FX The Young investigators acknowledge the core support provided by the
   Bill and Melinda Gates Foundation (Grant ID OPP1110191). We thank the
   technical advisory group of the PRE RNA platform and faculties at Centre
   for Health Research and Development, Society for Applied Studies, Delhi;
   KEM Hospital Research Centre, Pune and Christian Medical College,
   Vellore for their support and guidance. We also acknowledge the support
   of Knowledge Integration and Translational Platform, an initiative of
   the Department of Biotechnology, Government of India and Gates
   Foundation, through the Biotechnology Industry Research Assistance
   Council.
CR Akmatov MK, 2008, VACCINE, V26, P3805, DOI 10.1016/j.vaccine.2008.05.031
   Awofeso N, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-358
   Brown KF, 2010, VACCINE, V28, P4235, DOI 10.1016/j.vaccine.2010.04.052
   Danis K, 2010, VACCINE, V28, P1861, DOI 10.1016/j.vaccine.2009.11.078
   Fadel SA, 2017, LANCET, V390, P1972, DOI 10.1016/S0140-6736(17)32162-1
   Fatiregun AA, 2012, VACCINE, V30, P730, DOI 10.1016/j.vaccine.2011.11.082
   Favin M, 2012, INT HEALTH, V4, P229, DOI 10.1016/j.inhe.2012.07.004
   Gibson DG, 2015, VACCINE, V33, P6778, DOI 10.1016/j.vaccine.2015.10.021
   Grant CC, 2003, BRIT MED J, V326, P852, DOI 10.1136/bmj.326.7394.852
   Guerra Fernando A, 2007, Paediatr Drugs, V9, P143, DOI 10.2165/00148581-200709030-00002
   Hosmer D.W., 2013, APPL LOGISTIC REGRES
   Hughes MM, 2016, VACCINE, V34, P933, DOI 10.1016/j.vaccine.2015.12.061
   IIPS, 2017, NAT FAM HLTH SURV NF
   International Institute for Population Sciences (IIPS) Macro International, 2007, NAT FAM HLTH SURV NF, VI
   Kolos V, 2007, VACCINE, V25, P588, DOI 10.1016/j.vaccine.2006.08.022
   Mathew JL, 2012, INDIAN PEDIATR, V49, P203, DOI 10.1007/s13312-012-0063-z
   McGovern ME, 2015, AM J EPIDEMIOL, V182, P791, DOI 10.1093/aje/kwv125
   Ministry of Health and Family Welfare Govt. of India, 2017, IMM HDB MED OFF
   O'Leary M, 2016, B WORLD HEALTH ORGAN, V94, P442, DOI 10.2471/BLT.15.159699
   Ochoa TJ, 2015, VACCINE, V33, P354, DOI 10.1016/j.vaccine.2014.11.014
   Odutola A, 2015, BMC HEALTH SERV RES, V15, DOI 10.1186/s12913-015-1015-9
   Pati S, 2011, MATERN CHILD HLTH J, V15, P386, DOI 10.1007/s10995-010-0580-0
   Press Information Bureau Government of India Ministry of Health and Family Welfare, INT MISS INDR IMI
   Prinja S, 2010, B WORLD HEALTH ORGAN, V88, P97, DOI 10.2471/BLT.08.059543
   Rejali M, 2015, J RES HEALTH SCI, V15, P54
   SCHAFFER SJ, 1995, ARCH PEDIAT ADOL MED, V149, P792, DOI 10.1001/archpedi.1995.02170200082013
   Schoeps A, 2013, VACCINE, V32, P96, DOI 10.1016/j.vaccine.2013.10.063
   Sharma A, 2016, HEALTH POLICY PLANN, V31, P884, DOI 10.1093/heapol/czw008
   Shrivastwa N, 2016, PEDIATR INFECT DIS J, V35, P955, DOI 10.1097/INF.0000000000001223
   Siedler A, 2002, PEDIATR INFECT DIS J, V21, P826, DOI 10.1097/00006454-200209000-00008
   Singh A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048891
   Singh PK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073102
   Suarez-Castaneda E, 2015, VACCINE, V33, P6865, DOI 10.1016/j.vaccine.2015.07.092
   UN-IGME, 2017, LEV TRENDS CHILD MOR
   UNICEF, CHILD MORT EST COUNT
   Upadhyay RP, 2017, J GLOB HEALTH, V7, DOI 10.7189/jogh.07.020415
   Vashishtha VM, 2013, INDIAN PEDIATR, V50, P111, DOI 10.1007/s13312-013-0025-0
   vonKries R, 1997, EUR J PEDIATR, V156, P282, DOI 10.1007/s004310050601
   World Health Organisation, DAT STAT GRAPH IMM V
   2016, VACCINE, V34, P2635
NR 40
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD APR 17
PY 2019
VL 37
IS 17
BP 2331
EP 2339
DI 10.1016/j.vaccine.2019.03.039
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HV8UV
UT WOS:000466260500007
PM 30914221
OA Green Published, Other Gold
DA 2020-05-12
ER

PT J
AU Xu, YH
   Ma, SZ
   Huang, YB
   Chen, FY
   Chen, LY
   Ding, D
   Zheng, YP
   Li, H
   Xiao, J
   Feng, J
   Peng, T
AF Xu, Yuhua
   Ma, Shuzhi
   Huang, Yangbo
   Chen, Fengying
   Chen, Liyun
   Ding, Dong
   Zheng, Yanping
   Li, Hua
   Xiao, Jing
   Feng, Jin
   Peng, Tao
TI Virus-like particle vaccines for poliovirus types 1, 2, and 3 with
   enhanced thermostability expressed in insect cells
SO VACCINE
LA English
DT Article
DE Poliovirus; Vaccine; Thermostability; Virus-like particle; BEVS; Insect
   cell
ID CLEAVAGE
AB Poliovirus (PV) is a pathogen that causes poliomyelitis, which may lead to paralysis and fatality. Inactivated PV vaccines (IPVs) and live-attenuated oral PV vaccines (OPVs) are currently used to defend against PV worldwide. Vaccines must be developed in a PV-free environment given the biosafety issues associated with OPV and IPV production and to eradicate PV globally. In this study, PV1, PV2, and PV3 virus-like particles with enhanced thermostability (PV-sVLPs) were produced in large quantities by using a baculovirus expression vector system (BEVS). Mice immunized with PV-sVLPs generated antibodies with strong PV-neutralizing response. In addition, splenocytes collected from immunized mice expressed high levels of IFN-gamma, IL-2, GM-CSF, IL-5, and IL-10 upon PV-sVLPs stimulation. These data suggest that PV-sVLPs can serve as vaccines against PV infection. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Xu, Yuhua; Ma, Shuzhi; Li, Hua; Xiao, Jing; Peng, Tao] Guangzhou Med Univ, Coll Basic Med Sci, Sino French Hoffmann Inst Immunol, State Key Lab Resp Dis, Guangzhou, Guangdong, Peoples R China.
   [Xu, Yuhua; Ma, Shuzhi; Huang, Yangbo; Chen, Fengying; Chen, Liyun; Ding, Dong; Zheng, Yanping; Feng, Jin; Peng, Tao] Guangdong South China Vaccine Co Ltd, Guangzhou, Guangdong, Peoples R China.
RP Peng, T (reprint author), Guangzhou Med Univ, Coll Basic Med Sci, Sino French Hoffmann Inst Immunol, State Key Lab Resp Dis, Guangzhou, Guangdong, Peoples R China.; Peng, T (reprint author), Guangdong South China Vaccine Co Ltd, Guangzhou, Guangdong, Peoples R China.
EM peng_tao@gibh.ac.cn
FU Guangdong Province Science and Technology Development Program
   [2011A080502006]; Guangzhou Health & Medical Collaborative Innovation
   Program [201803040007]; Guangzhou Innovation & Entrepreneurship Leading
   Team Program [CYLJTD-201602]; Guangzhou Entrepreneurship Leading Talents
   Program [LYC201315]; Science and Technology Program of Guangzhou
   Development District [2018-L081]; Pearl River Science and Technology
   Nova Program of Guangzhou [201610010156]; National Natural Science
   Foundation of ChinaNational Natural Science Foundation of China
   [31500046]
FX This study was supported by the Guangdong Province Science and
   Technology Development Program (No. 2011A080502006), Guangzhou Health &
   Medical Collaborative Innovation Program (No.201803040007), Guangzhou
   Innovation & Entrepreneurship Leading Team Program (No. CYLJTD-201602),
   Guangzhou Entrepreneurship Leading Talents Program (NO. LYC201315), the
   Science and Technology Program of Guangzhou Development District (No.
   2018-L081). YX was supported by the Pearl River Science and Technology
   Nova Program of Guangzhou (No. 201610010156), and HL was supported by
   the National Natural Science Foundation of China (No. 31500046).
CR ANSARDI DC, 1991, J VIROL, V65, P2088, DOI 10.1128/JVI.65.4.2088-2092.1991
   BRAUTIGAM S, 1993, VIROLOGY, V192, P512, DOI 10.1006/viro.1993.1067
   Cao YM, 2010, BIOTECHNOL LETT, V32, P1223, DOI 10.1007/s10529-010-0295-8
   Chackerian B, 2007, EXPERT REV VACCINES, V6, P381, DOI 10.1586/14760584.6.3.381
   Cutts FT, 2007, B WORLD HEALTH ORGAN, V85, P719, DOI 10.2471/BLT.06.038414
   Helen Fox, 2017, PLOS PATHOG, V13
   Jain NK, 2015, ADV DRUG DELIVER REV, V93, P42, DOI 10.1016/j.addr.2014.10.023
   Kim JH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018556
   Marsian J, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00090-w
   Minor P, 2009, VACCINE, V27, P2649, DOI 10.1016/j.vaccine.2009.02.071
   Bin Park S, 2012, NATURE, V491, P21, DOI 10.1038/491021a
   PATEL V, 1993, VIROLOGY, V192, P361, DOI 10.1006/viro.1993.1044
   Pushko P, 2007, VACCINE, V25, P4283, DOI 10.1016/j.vaccine.2007.02.059
   Racaniello V.R., 2007, FIELDS VIROLOGY, P795
   Rombaut B, 1997, J GEN VIROL, V78, P1829, DOI 10.1099/0022-1317-78-8-1829
   RYAN MD, 1994, EMBO J, V13, P928, DOI 10.1002/j.1460-2075.1994.tb06337.x
   URAKAWA T, 1989, J GEN VIROL, V70, P1453, DOI 10.1099/0022-1317-70-6-1453
   WIEGERS K, 1992, J VIROL, V66, P4597, DOI 10.1128/JVI.66.7.4597-4600.1992
   YPMAWONG MF, 1988, VIROLOGY, V166, P265, DOI 10.1016/0042-6822(88)90172-9
   VIROLOGY, V266, P352
NR 20
TC 0
Z9 0
U1 2
U2 6
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD APR 17
PY 2019
VL 37
IS 17
BP 2340
EP 2347
DI 10.1016/j.vaccine.2019.03.031
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HV8UV
UT WOS:000466260500008
PM 30922699
DA 2020-05-12
ER

PT J
AU Bekele, Y
   Lemma, M
   Bobosha, K
   Yibeltal, D
   Nasi, A
   Gebre, M
   Nilsson, A
   Aseffa, A
   Howe, R
   Chiodi, F
AF Bekele, Yonas
   Lemma, Mahlet
   Bobosha, Kidist
   Yibeltal, Desalegn
   Nasi, Aikaterini
   Gebre, Meseret
   Nilsson, Anna
   Aseffa, Abraham
   Howe, Rawleigh
   Chiodi, Francesca
TI Homing defects of B cells in HIV-1 infected children impair vaccination
   responses
SO VACCINE
LA English
DT Article
DE HIV-1 infection; Children; B cells; Homing; Chemokine receptors; HBV
   vaccine
ID CXCL13; RESPONSIVENESS; CXCR4; LIGHT; DARK; AGE
AB Background: Successful vaccinations rely on antibody responses. Chemokine receptors play an important role in B cell homing to differentiation niches. We assessed CXCR4, CXCR5 and CCR6 expression on B cells during HIV-1 infection and relate it to antibody responses against a HBV vaccine.
   Methods: Blood was obtained from 54 healthy controls and 38 ART-treated HIV-1 infected children, aviremic (n = 25) or viremic (n = 13). Frequency of naive and memory B cell subsets was studied by immunostaining. Homing capacity of blood B cells to lymphoid and inflamed tissues was evaluated through CXCR4, CXCR5 and CCR6 expression. Plasma CXCL12 and CXCL13 levels and antibody titers to HBV antigen were determined by ELISA.
   Results: The frequency of naive and resting memory (RM) B cells in ART treated children was comparable to control subjects. Profound defects in the homing phenotypes of naive and memory B cells were identified, with lower CXCR4 and CXCR5 expression. Increased CXCL13 levels were observed in infected children, inversely correlating to CXCR5 expressing B cell subpopulations. Antibody titers to HBV vaccine correlated with frequency of resting and switched memory B cells in HIV-1 infected children.
   Conclusions: Homing defects of B cells to germinal center may underlie impaired vaccine responses during HIV-1 infection. (C) 2019 The Authors. Published by Elsevier Ltd.
C1 [Bekele, Yonas; Lemma, Mahlet; Nasi, Aikaterini; Chiodi, Francesca] Karolinska Inst, Dept Microbiol Tumor & Cell Biol, Stockholm, Sweden.
   [Bekele, Yonas; Lemma, Mahlet; Bobosha, Kidist; Yibeltal, Desalegn; Aseffa, Abraham; Howe, Rawleigh] Armauer Hansen Res Inst, POB 1005, Addis Ababa, Ethiopia.
   [Lemma, Mahlet] Addis Ababa Univ, Coll Nat Sci, Addis Ababa, Ethiopia.
   [Gebre, Meseret] All Africa Leprosy TB & Rehabil Training ALERT Ct, Addis Ababa, Ethiopia.
   [Nilsson, Anna] Karolinska Inst, Dept Womens & Children Hlth, Stockholm, Sweden.
RP Bekele, Y; Chiodi, F (reprint author), Karolinska Inst, Dept Microbiol Tumor & Cell Biol, Biomedicum, Solna Vagen 9, S-17165 Stockholm, Sweden.
EM yonas.bekele.feyissa@ki.se; francesca.chiodi@ki.se
RI Aseffa, Abraham/J-3248-2016
OI Aseffa, Abraham/0000-0002-8028-1150; Nilsson, Anna/0000-0001-5885-7101;
   Chiodi, Francesca/0000-0002-1385-8343; Bobosha,
   Kidist/0000-0001-8091-7182
FU Swedish Medical Research CouncilSwedish Medical Research Council (SMRC)
   [2016-01165]; Swedish International Development Agency [51080091]
FX The study was supported through grants from the Swedish Medical Research
   Council [grant number 2016-01165] and the research cooperation between
   Sweden and Ethiopia from the Swedish International Development Agency
   [grant number 51080091].
CR Allen CDC, 2004, NAT IMMUNOL, V5, P943, DOI 10.1038/ni1100
   Barinov A, 2017, P NATL ACAD SCI USA, V114, P2319, DOI 10.1073/pnas.1611958114
   Bekele Y, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09165-6
   Bekele Y, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000001125
   Cagigi A, 2008, BLOOD, V112, P4401, DOI 10.1182/blood-2008-02-140426
   Cagigi A, 2010, AIDS, V24, P2075, DOI 10.1097/QAD.0b013e32833c3298
   Chiodi F, 2010, J CLIN INVEST, V120, P3810, DOI 10.1172/JCI44872
   Cohen KW, 2015, J IMMUNOL, V194, P2769, DOI 10.4049/jimmunol.1400952
   Finch DK, 2013, EUR J CLIN INVEST, V43, P501, DOI 10.1111/eci.12063
   Gauvin J, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155868
   Geherin SA, 2012, J IMMUNOL, V188, P6027, DOI 10.4049/jimmunol.1102639
   Hargreaves DC, 2001, J EXP MED, V194, P45, DOI 10.1084/jem.194.1.45
   Havenar-Daughton C, 2016, P NATL ACAD SCI USA, V113, P2702, DOI 10.1073/pnas.1520112113
   Jacquot S, 2000, IMMUNOL RES, V21, P23, DOI 10.1385/IR:21:1:23
   Mabuka JM, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01104
   Moir S, 2008, J EXP MED, V205, P1797, DOI 10.1084/jem.20072683
   Muema DM, 2015, J IMMUNOL, V195, P1082, DOI 10.4049/jimmunol.1500491
   Nie YC, 2004, J EXP MED, V200, P1145, DOI 10.1084/jem.20041185
   Okada T, 2006, CURR OPIN IMMUNOL, V18, P278, DOI 10.1016/j.coi.2006.02.005
   Pensierosoa S, 2009, P NATL ACAD SCI USA, V106, P7939, DOI 10.1073/pnas.0901702106
   Reif K, 2002, NATURE, V416, P94, DOI 10.1038/416094a
   Stein JV, 2005, IMMUNOLOGY, V116, P1, DOI 10.1111/j.1365-2567.2005.02183.x
   Suzuki K, 2009, J EXP MED, V206, P1485, DOI 10.1084/jem.20090209
   van Montfrans JM, 2012, J ALLERGY CLIN IMMUN, V129, P787, DOI 10.1016/j.jaci.2011.11.013
   Victora GD, 2012, BLOOD, V120, P2240, DOI 10.1182/blood-2012-03-415380
   2011, BLOOD, V118, P1560, DOI DOI 10.1182/BLOOD-2011-01-332106
NR 26
TC 3
Z9 3
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD APR 17
PY 2019
VL 37
IS 17
BP 2348
EP 2355
DI 10.1016/j.vaccine.2019.03.027
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HV8UV
UT WOS:000466260500009
PM 30914222
OA Other Gold
DA 2020-05-12
ER

PT J
AU Wedlock, PT
   Mitgang, EA
   Oron, AP
   Hagedorn, BL
   Leonard, J
   Brown, ST
   Bakal, J
   Siegmund, SS
   Lee, BY
AF Wedlock, Patrick T.
   Mitgang, Elizabeth A.
   Oron, Assaf P.
   Hagedorn, Brittany L.
   Leonard, Jim
   Brown, Shawn T.
   Bakal, Jennifer
   Siegmund, Sheryl S.
   Lee, Bruce Y.
TI Modeling the economic impact of different vial-opening thresholds for
   measles-containing vaccines
SO VACCINE
LA English
DT Article
DE Measles vaccine; Vaccine supply chain; Presentation; Policy
ID IMMUNIZATION; BENEFITS; HEALTH
AB Introduction: The lack of specific policies on how many children must be present at a vaccinating location before a healthcare worker can open a measles-containing vaccine (MCV) - i.e. the vial-opening threshold - has led to inconsistent practices, which can have wide-ranging systems effects.
   Methods: Using HERMES-generated simulation models of the routine immunization supply chains of Benin, Mozambique and Niger, we evaluated the impact of different vial-opening thresholds (none, 30% of doses must be used, 60%) and MCV presentations (10-dose, 5-dose) on each supply chain. We linked these outputs to a clinical- and economic-outcomes model which translated the change in vaccine availability to associated infections, medical costs, and DALYs. We calculated the economic impact of each policy from the health system perspective.
   Results: The vial-opening threshold that maximizes vaccine availability while minimizing costs varies between individual countries. In Benin (median session size = 5), implementing a 30% vial-opening threshold and tailoring distribution of 10-dose and 5-dose MCVs to clinics based on session size is the most cost-effective policy, preventing 671 DALYs ($471 /DALY averted) compared to baseline (no threshold, 10-dose MCVs). In Niger (median MCV session size = 9), setting a 60% vial-opening threshold and tailoring MCV presentations is the most cost-effective policy, preventing 2897 DALYs (816.05/ DALY averted). In Mozambique (median session size = 3), setting a 30% vial-opening threshold using 10-dose MCVs is the only beneficial policy compared to baseline, preventing 3081 DALYs ($85.98/DALY averted). Across all three countries, however, a 30% vial-opening threshold using 10-dose MCVs everywhere is the only MCV threshold that consistently benefits each system compared to baseline.
   Conclusion: While the ideal vial-opening threshold policy for MCV varies by supply chain, implementing a 30% vial-opening threshold for 10-dose MCVs benefits each system by improving overall vaccine availability and reducing associated medical costs and DALYs compared to no threshold. (C) 2019 The Authors. Published by Elsevier Ltd.
C1 [Wedlock, Patrick T.; Mitgang, Elizabeth A.; Leonard, Jim; Brown, Shawn T.; Bakal, Jennifer; Siegmund, Sheryl S.; Lee, Bruce Y.] HERMES Logist Modeling Team, Baltimore, MD 21205 USA.
   [Wedlock, Patrick T.; Mitgang, Elizabeth A.; Leonard, Jim; Brown, Shawn T.; Bakal, Jennifer; Siegmund, Sheryl S.; Lee, Bruce Y.] HERMES Logist Modeling Team, Pittsburgh, PA 15213 USA.
   [Wedlock, Patrick T.; Mitgang, Elizabeth A.; Siegmund, Sheryl S.; Lee, Bruce Y.] Johns Hopkins Univ, Global Obes Prevent Ctr, Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA.
   [Oron, Assaf P.; Hagedorn, Brittany L.] Inst Dis Modeling, Bellevue, WA USA.
   [Leonard, Jim; Bakal, Jennifer] Carnegie Mellon Univ, Pittsburgh Supercomp Ctr, Pittsburgh, PA 15213 USA.
   [Brown, Shawn T.] McGill Univ, McGill Neurol Inst, McGill Ctr Integrat Neurosci, Montreal, PQ, Canada.
RP Lee, BY (reprint author), HERMES Logist Modeling Team, Baltimore, MD 21205 USA.; Lee, BY (reprint author), HERMES Logist Modeling Team, Pittsburgh, PA 15213 USA.; Lee, BY (reprint author), Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth Publ Hlth Computat & Operat Res PHI, Int Vaccine Access Ctr, Global Obes Prevent Ctr, 615 N Wolfe St,Room W3501, Baltimore, MD 21205 USA.
EM brucelee@jhu.edu
OI Wedlock, Patrick/0000-0001-7635-5949; Brown, Shawn/0000-0001-6980-8372
FU Bill and Melinda Gates FoundationGates Foundation; Agency for Healthcare
   Research and Quality (AHRQ)United States Department of Health & Human
   ServicesAgency for Healthcare Research & Quality [R01HS023317]; National
   Institute of General Medical Sciences Modeling Infectious Disease Agent
   Study (MIDAS) Informatics Services Group [1U24GM110707]; Global Obesity
   Prevention Center (GOPC) at johns Hopkins; Eunice Kennedy Shriver
   National Institute of Child Health and Human Development (NICHD)United
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child
   Health & Human Development (NICHD); Office of the Director, National
   Institutes of Health (OD)United States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [U54HD070725]
FX This work was supported by the Bill and Melinda Gates Foundation, the
   Agency for Healthcare Research and Quality (AHRQ) via grant R01HS023317,
   National Institute of General Medical Sciences Modeling Infectious
   Disease Agent Study (MIDAS) Informatics Services Group grant
   1U24GM110707, and the Global Obesity Prevention Center (GOPC) at johns
   Hopkins and the Eunice Kennedy Shriver National Institute of Child
   Health and Human Development (NICHD) and the Office of the Director,
   National Institutes of Health (OD) under award number U54HD070725. The
   content is solely the responsibility of the authors and does not
   necessarily represent the official views of the National Institutes of
   Health. The funders had no role in the design and conduct of the study;
   collection, management, analysis, and interpretation of the data; and
   preparation, review, or approval of the manuscript.
CR [Anonymous], 2017, MOZAMBIQUE PROPOSAL
   [Anonymous], 2016, PROPOSAL NVS MENA SU
   [Anonymous], 2017, PROPOSAL NVS ROTA MR
   Armah GE, 2010, LANCET, V376, P606, DOI 10.1016/S0140-6736(10)60889-6
   Assi TM, 2013, VACCINE, V31, P2828, DOI 10.1016/j.vaccine.2013.04.011
   Brown ST, 2014, VACCINE, V32, P4097, DOI 10.1016/j.vaccine.2014.04.090
   Brown ST, 2014, VACCINE, V32, P2518, DOI 10.1016/j.vaccine.2014.02.060
   Byberg S, 2017, GLOBAL HEALTH ACTION, V10, DOI 10.1080/16549716.2017.1329968
   Drain PK, 2003, B WORLD HEALTH ORGAN, V81, P726
   Ewald H, 2016, DTSCH ARZTEBL INT, V113, P139, DOI 10.3238/arztebl.2016.0139
   Fisker AB, 2014, LANCET GLOB HEALTH, V2, pE478, DOI 10.1016/S2214-109X(14)70274-8
   Gavi the vaccine alliance, 2018, GAV ALL EL TRANS POL
   Global Burden of Disease Collaborative Network, 2016, GLOB BURD DIS STUD 2
   Grouzard Veronique, 2018, CLIN GUIDELINES DIAG
   Haidari LA, 2017, VACCINE, V35, P2224, DOI 10.1016/j.vaccine.2016.11.103
   Heaton A, 2017, VACCINE, V35, P2272, DOI 10.1016/j.vaccine.2016.11.066
   HUTCHINS SS, 1993, B WORLD HEALTH ORGAN, V71, P549
   Jamison DT, 2006, DISEASE CONTROL PRIORITIES IN DEVELOPING COUNTRIES, 2ND EDITION, P1
   Lee BY, 2017, VACCINE, V35, P4475, DOI 10.1016/j.vaccine.2017.05.096
   Lee BY, 2017, VACCINE, V35, pA36, DOI 10.1016/j.vaccine.2016.11.033
   PAHO, 2016, EXP PROGR IMM IMM TU
   Patel PB, 2016, INT J HEALTH POLICY, V5, P233, DOI 10.15171/ijhpm.2015.208
   Pillsbury A, 2015, WEST PAC SURVEILL RE, V6, P43, DOI [10.5365/WPSAR.2015.6.2.007, 10.5365/wpsar.2015.6.2.007]
   Robertson SE, 1997, B WORLD HEALTH ORGAN, V75, P69
   Sanders GD, 2016, JAMA-J AM MED ASSOC, V316, P1093, DOI 10.1001/jama.2016.12195
   Simons EA, 2016, RISK ANAL, V36, P1332, DOI 10.1111/risa.12263
   Stenberg K, 2018, COST EFFECT RESOUR A, V16, DOI 10.1186/s12962-018-0095-x
   Stop TB Partnership, 2018, GLOB DRUG FAC MED CA
   Tate JE, 2016, CLIN INFECT DIS, V62, pS96, DOI 10.1093/cid/civ1013
   Thysen SM, 2018, VACCINE, V36, P3406, DOI 10.1016/j.vaccine.2018.05.003
   UNICEF, 2017, DIPTH ANT MARK UPD
   UNICEF, 2018, PROD MEN VACC SUPPL
   Usuf E, 2018, BMC PUBLIC HEALTH, V18, DOI 10.1186/s12889-018-5762-5
   Vynnycky E, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149160
   Walker CLF, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-S3-S16
   Wallace AS, 2017, VACCINE, V35, P6751, DOI 10.1016/j.vaccine.2017.09.082
   Whitney CG, 2014, MMWR-MORBID MORTAL W, V63, P352
   *WHO, 2003, TREATM TUB GUID NAT
   WHO, 2005, MONITORING VACCINE W
   World Health Organization (WHO), 2013, GUID INTR 2 DOS MEAS
   Zaman K, 2010, LANCET, V376, P615, DOI 10.1016/S0140-6736(10)60755-6
   2011, VACCINE, V29, P3811
   2016, VACCINE, V34, P4998
   2012, VACCINE, V30, P5637
   2017, VACCINE, V35, P1817
   2015, VACCINE, V33, P2858
   2015, VACCINE, V33, P4451
NR 47
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD APR 17
PY 2019
VL 37
IS 17
BP 2356
EP 2368
DI 10.1016/j.vaccine.2019.03.017
PG 13
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HV8UV
UT WOS:000466260500010
PM 30914223
OA Green Published, Other Gold
DA 2020-05-12
ER

PT J
AU Ross, TM
   DiNapoli, J
   Giel-Moloney, M
   Bloom, CE
   Bertran, K
   Balzli, C
   Strugnell, T
   Silva, MSE
   Mebatsion, T
   Bublot, M
   Swayne, DE
   Kleanthous, H
AF Ross, Ted M.
   DiNapoli, Joshua
   Giel-Moloney, Maryann
   Bloom, Chalise E.
   Bertran, Kateri
   Balzli, Charles
   Strugnell, Tod
   Sa e Silva, Mariana
   Mebatsion, Teshome
   Bublot, Michel
   Swayne, David E.
   Kleanthous, Harry
TI A computationally designed H5 antigen shows immunological breadth of
   coverage and protects against drifting avian strains
SO VACCINE
LA English
DT Article
DE influenza; H5N1; Universal vaccine; Chickens; COBRA; Pre-pandemic
ID INFLUENZA-A VIRUSES; OPTIMIZED HEMAGGLUTININ; ANTIBODY; EVOLUTION;
   IMMUNOGENICITY; GLYCOSYLATION; PATHOGENICITY; EPIDEMIOLOGY; OUTBREAKS;
   BINDING
AB Since the first identification of the H5N1 Goose/Guangdong lineage in 1996, this highly pathogenic avian influenza virus has spread worldwide, becoming endemic in domestic poultry. Sporadic transmission to humans has raised concerns of a potential pandemic and underscores the need for a broad crossprotective influenza vaccine. Here, we tested our previously described methodology, termed Computationally Optimized Broadly Reactive Antigen (COBRA), to generate a novel hemagglutinin (HA) gene, termed COBRA-2, that was based on H5 HA sequences from 2005 to 2006. The COBRA-2 HA virus-like particle (VLP) vaccines were used to vaccinate chickens and the immune responses were compared to responses elicited by VLP's expressing HA from A/whooper swan/Mongolia/244/2005 (WS/05), a representative 2005 vaccine virus from Glade 2.2. To support this evaluation a hemagglutination inhibition (HAI) breadth panel was developed consisting of phylogenetically and antigenically diverse H5 strains in circulation from 2005 to 2006, as well as recent drift variants (2008 - 2014). We found that the COBRA-2 VLP vaccines elicited robust HAI titers against this entire breadth panel, whereas the VLP vaccine based upon the recommended WS/05 HA only elicited HAI responses against a subset of strains. Furthermore, while all vaccines protected chickens against challenge with the WS/05 virus, only the human COBRA-2 VLP vaccinated birds were protected (80%) against a recent drifted Glade 2.3.2.1B, A/ duck/Vietnam/NCVD-672/2011 (VN/11) virus. This is the first report to demonstrate seroprotective antibody responses against genetically diverse clades and sub-clades of H5 viruses and protective efficacy against a recent drifted variant using a globular head based design strategy. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Ross, Ted M.; Bloom, Chalise E.] Univ Georgia, Ctr Vaccines & Immunol, Dept Infect Dis, Athens, GA 30602 USA.
   [DiNapoli, Joshua; Giel-Moloney, Maryann; Strugnell, Tod; Kleanthous, Harry] Sanofi Pasteur, 38 Sidney St, Cambridge, MA 02139 USA.
   [Bertran, Kateri; Balzli, Charles; Swayne, David E.] ARS, Exot & Emerging Avian Viral Dis Res Unit, Southeast Poultry Res Lab, US Natl Poultry Res Ctr,USDA, Athens, GA 30602 USA.
   [Bublot, Michel] Boehringer Ingelheim SAS, R&D, F-69007 Lyon, France.
   [Sa e Silva, Mariana; Mebatsion, Teshome] Boehringer Ingelheim GmbH & Co KG, R&D, Athens, GA 30601 USA.
RP Giel-Moloney, M (reprint author), Sanofi Pasteur, 38 Sidney St, Cambridge, MA 02139 USA.
EM Maryann.Giel-Moloney@sanofi.com
OI Ross, Ted/0000-0003-1947-7469; Swayne, David/0000-0001-7472-1992
FU Merial, Inc. [58-6612-0-114]; Southeast Poultry Research Laboratory,
   Agricultural Research Service, U.S. Department of Agriculture
   [58-6612-0-114]
FX The research received no specific grant from any funding agency in the
   public, commercial, or not-for-profit sectors. This project was
   partially funded by Trust Fund Cooperative Agreement #58-6612-0-114 in
   collaboration between Merial, Inc. and Southeast Poultry Research
   Laboratory, Agricultural Research Service, U.S. Department of
   Agriculture.
CR [Agency EM CfMPfH], 2014, EMACHMPNWP4572592014
   Bao YM, 2008, J VIROL, V82, P596, DOI 10.1128/JVI.02005-07
   Bright RA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001501
   Chen H, 2005, NATURE, V436, P191, DOI 10.1038/nature03974
   Crevar CJ, 2015, HUM VACC IMMUNOTHER, V11, P572, DOI 10.1080/21645515.2015.1012013
   Giles BM, 2012, J INFECT DIS, V205, P1562, DOI 10.1093/infdis/jis232
   Giles BM, 2012, CLIN VACCINE IMMUNOL, V19, P128, DOI 10.1128/CVI.05533-11
   Giles BM, 2011, VACCINE, V29, P3043, DOI 10.1016/j.vaccine.2011.01.100
   Gillim-Ross L, 2006, CLIN MICROBIOL REV, V19, P614, DOI 10.1128/CMR.00005-06
   Green TD, 2003, J VIROL, V77, P2046, DOI 10.1128/JVI.77.3.2046-2055.2003
   Hoffmann E, 2005, P NATL ACAD SCI USA, V102, P12915, DOI 10.1073/pnas.0506416102
   Hu HX, 2012, J VIROL, V86, P2978, DOI 10.1128/JVI.06665-11
   Huson DH, 2012, SYST BIOL, V61, P1061, DOI 10.1093/sysbio/sys062
   Katoh K, 2013, MOL BIOL EVOL, V30, P772, DOI 10.1093/molbev/mst010
   Lai SJ, 2016, LANCET INFECT DIS, V16, pE108, DOI 10.1016/S1473-3099(16)00153-5
   Lee CW, 2004, J VIROL METHODS, V119, P151, DOI 10.1016/j.jviromet.2004.03.014
   Lee DH, 2017, J VET SCI, V18, P269, DOI [10.4142/jvs.2017.18.s1.269, 10.4142/jvs.2017.18.S1.269]
   Lo CY, 2017, OPEN FORUM INFECT DI, V4, DOI 10.1093/ofid/ofx023
   Misura KMS, 2006, P NATL ACAD SCI USA, V103, P5361, DOI 10.1073/pnas.0509355103
   Price MN, 2009, MOL BIOL EVOL, V26, P1641, DOI 10.1093/molbev/msp077
   Sandbulte MR, 2007, PLOS MED, V4, P265, DOI 10.1371/journal.pmed.0040059
   Schrauwen EJA, 2014, EMERG MICROBES INFEC, V3, DOI 10.1038/emi.2014.9
   Schultz-Cherry S, 2014, MBIO, V5, DOI 10.1128/mBio.02430-14
   Smith GJD, 2015, INFLUENZA OTHER RESP, V9, P271, DOI 10.1111/irv.12324
   Su S, 2015, J VIROL, V89, P8671, DOI 10.1128/JVI.01034-15
   Sun LN, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005476
   Thornburg NJ, 2013, J CLIN INVEST, V123, P4405, DOI 10.1172/JCI69377
   Verhagen JH, 2015, EUROSURVEILLANCE, V20, DOI 10.2807/1560-7917.ES2015.20.12.21069
   Wang WJ, 2010, J VIROL, V84, P6570, DOI 10.1128/JVI.00221-10
   Wang ZF, 2016, FRONT IMMUNOL, V7, P1, DOI 10.3389/fimmu.2016.00060
   *WHO, [No title captured]
   WHO-World Health Organization, 2017, WEEKLY EPIDEMIOLOGIC
   Winarski KL, 2015, P NATL ACAD SCI USA, V112, P9346, DOI 10.1073/pnas.1502762112
   World Health Organization Global Influenza Surveillance Network, 2011, MAN LAB DIAGN VIR SU
   Xu XY, 1999, VIROLOGY, V261, P15, DOI 10.1006/viro.1999.9820
   Yamada S, 2006, NATURE, V444, P378, DOI 10.1038/nature05264
   Zhang XJ, 2015, VET MICROBIOL, V175, P244, DOI 10.1016/j.vetmic.2014.12.011
   Zhong WM, 2016, OPEN FORUM INFECT DI, V3, DOI 10.1093/ofid/ofw102
   Zhu XY, 2013, J VIROL, V87, P12619, DOI 10.1128/JVI.01577-13
   Zuo T, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9855
   2014, J INFECT DIS, V209, P1860, DOI DOI 10.1093/INFDIS/JIU123
   2015, J VIROL, V89, P8806, DOI DOI 10.1128/JVI.00653-15
   2009, EUR J IMMUNOL, V39, P3498, DOI DOI 10.1002/EJI.200939532
   2015, J VIROL, V89, P6521, DOI DOI 10.1128/JVI.00728-15
   2013, VACCINE, V31, P4953, DOI DOI 10.1016/J.VACCINE.2013.08.046
NR 45
TC 4
Z9 4
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD APR 17
PY 2019
VL 37
IS 17
BP 2369
EP 2376
DI 10.1016/j.vaccine.2019.03.018
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HV8UV
UT WOS:000466260500011
PM 30905528
DA 2020-05-12
ER

PT J
AU Lee, BY
   Brown, ST
   Haidari, LA
   Clark, S
   Abimbola, T
   Pallas, SE
   Wallace, AS
   Mitgang, EA
   Leonard, J
   Bartsch, SM
   Yemeke, TT
   Zenkov, E
   Ozawa, S
AF Lee, Bruce Y.
   Brown, Shawn T.
   Haidari, Leila A.
   Clark, Samantha
   Abimbola, Taiwo
   Pallas, Sarah E.
   Wallace, Aaron S.
   Mitgang, Elizabeth A.
   Leonard, Jim
   Bartsch, Sarah M.
   Yemeke, Tatenda T.
   Zenkov, Eli
   Ozawa, Sachiko
TI Economic value of vaccinating geographically hard-to-reach populations
   with measles vaccine: A modeling application in Kenya
SO VACCINE
LA English
DT Article
DE Vaccination; Economic; Hard-to-reach populations
ID IMMUNIZATION; COVERAGE
AB Background: Since special efforts are necessary to vaccinate people living far from fixed vaccination posts, decision makers are interested in knowing the economic value of such efforts.
   Methods: Using our immunization geospatial information system platform and a measles compartment model, we quantified the health and economic value of a 2-dose measles immunization outreach strategy for children <24 months of age in Kenya who are geographically hard-to-reach (i.e., those living outside a specified catchment radius from fixed vaccination posts, which served as a proxy for access to services).
   Findings: When geographically hard-to-reach children were not vaccinated, there were 1427 total measles cases from 2016 to 2020, resulting in $9.5 million ($3.1-$18.1 million) in direct medical costs and productivity losses and 7504 (3338-12,903) disability-adjusted life years (DALYs). The outreach strategy cost $76 ($23-$142)/DALY averted (compared to no outreach) when 25% of geographically hard-to-reach children received MCV1, $122 ($40-$226)/DALY averted when 50% received MCV1, and $274 ($123-$478)/DALY averted when 100% received MCV1.
   Conclusion: Outreach vaccination among geographically hard-to-reach populations was highly cost-effective in a wide variety of scenarios, offering support for investment in an effective outreach vaccination strategy. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Lee, Bruce Y.; Mitgang, Elizabeth A.; Bartsch, Sarah M.] Johns Hopkins Bloomberg Sch Publ Hlth, Publ Hlth Computat & Operat Res PHICOR, Baltimore, MD 21205 USA.
   [Lee, Bruce Y.; Mitgang, Elizabeth A.; Bartsch, Sarah M.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD 21205 USA.
   [Lee, Bruce Y.; Mitgang, Elizabeth A.; Bartsch, Sarah M.] Johns Hopkins Univ, GOPC, Baltimore, MD USA.
   [Brown, Shawn T.; Haidari, Leila A.; Leonard, Jim; Zenkov, Eli] Carnegie Mellon Univ, PSC, Pittsburgh, PA 15213 USA.
   [Brown, Shawn T.] McGill Univ, McGill Ctr Integrat Neurosci, McGill Neurol Inst, Montreal, PQ, Canada.
   [Clark, Samantha] Univ Washington, Comparat Hlth Outcomes Policy & Econ CHOICE Inst, Seattle, WA 98195 USA.
   [Abimbola, Taiwo; Pallas, Sarah E.; Wallace, Aaron S.] Ctr Dis Control & Prevent CDC, Atlanta, GA USA.
   [Yemeke, Tatenda T.; Ozawa, Sachiko] Univ N Carolina, Div Practice Adv & Clin Educ, UNC Eshelman Sch Pharm, Chapel Hill, NC 27515 USA.
   [Ozawa, Sachiko] Univ N Carolina, Dept Maternal & Child Hlth, UNC Gillings Sch Global Publ Hlth, Chapel Hill, NC 27515 USA.
RP Lee, BY (reprint author), Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth Publ Hlth Computat & Operat Res PHI, IVAC, GOPC, 615 N Wolfe St,Room W3501, Baltimore, MD 21205 USA.
EM brucelee@jhu.edu
RI Ozawa, Sachiko/Z-4944-2019
OI Ozawa, Sachiko/0000-0001-7608-9038; Yemeke, Tatenda/0000-0002-1489-627X;
   Pallas, Sarah/0000-0002-9719-6278; Brown, Shawn/0000-0001-6980-8372
FU Centers for Disease Control and Prevention (CDC)United States Department
   of Health & Human ServicesCenters for Disease Control & Prevention - USA
   [200-2015-M-63169]; International Society for Infectious Diseases
   (ISID); Pfizer via the SIGMA grant; Agency for Healthcare Research and
   Quality (AHRQ)United States Department of Health & Human ServicesAgency
   for Healthcare Research & Quality [R01HS023317]; Eunice Kennedy Shriver
   National Institute of Child Health and Human Development (NICHD) Office
   of Behavioral and Social Sciences Research (OBSSR); Global Obesity
   Prevention Center (GOPC) [U54HD070725]; NICHDUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   Eunice Kennedy Shriver National Institute of Child Health & Human
   Development (NICHD) [U01HD086861]; National Institute for General
   Medical Science (NIGMS) via the MIDAS [5U24GM110707]
FX Research reported in this publication was supported by the Centers for
   Disease Control and Prevention (CDC) via contract 200-2015-M-63169, the
   International Society for Infectious Diseases (ISID) and Pfizer via the
   SIGMA grant and the Agency for Healthcare Research and Quality (AHRQ)
   via grant R01HS023317, the Eunice Kennedy Shriver National Institute of
   Child Health and Human Development (NICHD) Office of Behavioral and
   Social Sciences Research (OBSSR) and the Global Obesity Prevention
   Center (GOPC) via grant U54HD070725, NICHD via grant U01HD086861, and
   the National Institute for General Medical Science (NIGMS) via the MIDAS
   5U24GM110707 grant. The funders had no role in the design and conduct of
   the study; collection, management, analysis, and interpretation of the
   data; and preparation, review, or approval of the manuscript.
CR Anderson R. M., 1991, INFECT DIS HUMANS
   [Anonymous], 2017, NAT COUNT HLTH BUDG
   [Anonymous], 2014, GAVI VACC ALL 2016 2
   Antillon M, 2017, VACCINE, V35, P3506, DOI 10.1016/j.vaccine.2017.05.001
   Bertram MY, 2016, B WORLD HEALTH ORGAN, V94, P925, DOI 10.2471/BLT.15.164418
   Centers for Disease Control and Prevention, 2008, MANUAL SURVEILLANCE
   CIESIN (Center for International Earth Science Information Network Columbia University); IFPRI (International Food Policy Research Institute); The World Bank and CIAT (Centro Internacional De Agricultura Tropical), 2000, GLOB RUR URB MAPP PR
   Feldstein LR, 2017, MORBIDITY MORTALITY
   Ferrari MJ, 2008, NATURE, V451, P679, DOI 10.1038/nature06509
   Gold MR, 1996, COST EFFECTIVENESS H
   Haidari LA, 2016, VACCINE, V34, P4161, DOI 10.1016/j.vaccine.2016.06.065
   Kim SY, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-253
   Kisangau N, 2018, PAN AFR MED J, V31, DOI 10.11604/pamj.2018.31.65.16309
   Organization W. H. and UNICEF, 2002, INCR IMM COV HLTH FA
   Ozawa S, 2018, VACCINE, V36, P3641, DOI 10.1016/j.vaccine.2018.05.030
   Rainey JJ, 2011, VACCINE, V29, P8215, DOI 10.1016/j.vaccine.2011.08.096
   Republic of Kenya Ministry of Health Division of Vaccines and Immunization, 2011, KEN COMPR MULT YEAR
   Ryman T, 2010, J PUBLIC HEALTH-UK, V32, P18, DOI 10.1093/pubmed/fdp048
   Salomon JA, 2015, LANCET GLOB HEALTH, V3, pE712, DOI 10.1016/S2214-109X(15)00069-8
   The World Bank, 2015, GNI PER CAP ATL METH
   Thompson KM, 2016, RISK ANAL, V36, P1357, DOI 10.1111/risa.12459
   Toikilik S, 2010, VACCINE, V28, P4673, DOI 10.1016/j.vaccine.2010.04.063
   UNICEF, 2016, VACC PRIC DAT
   United Nations, 2015, WORLD POP PROSP 2015
   US State Department, 2014, COUNTR REP HUM RIGHT
   Uzicanin A, 2011, J INFECT DIS, V204, pS133, DOI 10.1093/infdis/jir102
   van Hoek AJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047511
   Van Malderen C, 2013, INT J EQUITY HEALTH, V12, DOI 10.1186/1475-9276-12-3
   VANDELAER J, 2008, B WHO, V86
   VanderEnde K, 2018, MORBIDITY MORTALITY
   Vijayaraghavan M, 2007, HEALTH POLICY, V83, P27, DOI 10.1016/j.healthpol.2006.11.008
   Webber R., 2012, COMMUNICABLE DIS GLO
   WHO, 2016, WHO PREQ VACC
   WHO, 2012, GLOB HLTH OBS LIF TA
   WHO, 2016, IMM SCHED ANT
   WHO, 2015, GLOB REF LIST 100 CO
   Wolfson LJ, 2009, INT J EPIDEMIOL, V38, P192, DOI 10.1093/ije/dyn224
   Woods B, 2016, VALUE HEALTH, V19, P929, DOI 10.1016/j.jval.2016.02.017
   World Bank, WORLD DEV IND
   World Bank, 2014, 2013 WORLD BANK DEV
   World Health Organization, 2016, THE RED STRAT
   World Health Organization, 2015, WHO UNICEF EST NAT I
   World Health Organization Department of Immunization and Biologicals, IMM PRACT PRACT GUID
   World Health Organization (WHO), 2012, GLOB MEASL RUB STRAT
NR 44
TC 2
Z9 2
U1 3
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD APR 17
PY 2019
VL 37
IS 17
BP 2377
EP 2386
DI 10.1016/j.vaccine.2019.03.007
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HV8UV
UT WOS:000466260500012
PM 30922700
OA Green Accepted
DA 2020-05-12
ER

PT J
AU Hayford, K
   Mutembo, S
   Carcelen, A
   Matakala, HK
   Munachoonga, P
   Winter, A
   Wanyiri, JW
   Searle, K
   Mwansa, FD
   Mwiche, A
   Phiri, C
   Book, C
   Thuma, PE
   Moss, WJ
AF Hayford, Kyla
   Mutembo, Simon
   Carcelen, Andrea
   Matakala, Hellen K.
   Munachoonga, Passwell
   Winter, Amy
   Wanyiri, Jane W.
   Searle, Kelly
   Mwansa, Francis D.
   Mwiche, Angels
   Phiri, Caroline
   Book, Chris
   Thuma, Philip E.
   Moss, William J.
TI Measles and rubella serosurvey identifies rubella immunity gap in young
   adults of childbearing age in Zambia: The added value of nesting a
   serological survey within a post-campaign coverage evaluation survey
SO VACCINE
LA English
DT Article
DE Serology; Serological survey; Immunization coverage; Vaccination;
   Measles; Rubella; Dried blood spots; Surveillance; IgG antibody
ID VACCINATION; PROGRESS; IMMUNOASSAYS; IMMUNIZATION; ELIMINATION
AB Background: Serological surveys can potentially complement vaccine coverage surveys, such as post- vaccination campaign coverage evaluation surveys (PCES), by providing direct information on population immunity within and outside the target age range of the mass vaccination campaign. We estimate age specific population immunity to measles and rubella viruses in Southern Province, Zambia, and assess the value of adding serological data to vaccination coverage estimates by nesting a serological survey within a PCES.
   Methods: Dried blood spots (DBS) from fingerprick blood were collected from all individuals ages nine months or older in households participating in the PCES and tested for measles and rubella virus-specific immunoglobulin G (IgG) by enzyme immunoassay (Siemens Enzygnost, Marburg, Germany).
   Results: Overall seroprevalence was 95.5% (95% CI: 92.8, 97.2) for measles virus-specific IgG and 97.7% (95% CI: 96.0, 98.7) for rubella virus-specific IgG. Rubella seroprevalence was 98.4% (95% CI: 95.9, 99.4) among children eligible for the MR vaccination campaign, significantly higher than the reported measles-rubella (MR) vaccination campaign coverage of 89.8% (p = 0.003), and higher than the 91.3% rubella seroprevalence for adolescents and adults 16-30 years of age (p = 0.049).
   Conclusion: Seroprevalence to measles and rubella viruses in children younger than 16 years of age was significantly higher than expected from vaccination coverage estimates, likely reflecting exposure to wild-type viruses and underreporting of vaccination. The serosurvey revealed rubella immunity gaps among women 16-30 years of age, precisely the age group in which protection from rubella is most important to prevent congenital rubella syndrome. Nesting serological surveys within existing surveys can leverage resources and infrastructure while providing complementary information important to immunization programs. (C) 2019 The Author(s). Published by Elsevier Ltd.
C1 [Hayford, Kyla; Carcelen, Andrea; Wanyiri, Jane W.; Moss, William J.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD USA.
   [Mutembo, Simon; Mwansa, Francis D.; Mwiche, Angels; Phiri, Caroline] Govt Republ Zambia, Minist Hlth, Lusaka, Zambia.
   [Mutembo, Simon] Univ Georgia, Coll Publ Hlth, Dept Epidemiol & Biostat, Athens, GA 30602 USA.
   [Matakala, Hellen K.; Munachoonga, Passwell; Book, Chris; Thuma, Philip E.] Macha Res Trust, Choma, Zambia.
   [Winter, Amy; Searle, Kelly; Moss, William J.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA.
RP Hayford, K (reprint author), Int Vaccine Access Ctr, 415 N Washington St,Floor 5, Baltimore, MD 21231 USA.
EM kylahayford@jhu.edu
FU Bill & Melinda Gates FoundationGates Foundation
FX The study was funded by the Bill & Melinda Gates Foundation.
CR Cutts FT, 2016, TROP MED INT HEALTH, V21, P1086, DOI 10.1111/tmi.12737
   Cutts FT, 2016, VACCINE, V34, P4103, DOI 10.1016/j.vaccine.2016.06.053
   Cutts FT, 2013, EXPERT REV VACCINES, V12, P917, DOI 10.1586/14760584.2013.814847
   Dietz V, 2004, REV PANAM SALUD PUBL, V16, P432, DOI 10.1590/S1020-49892004001200013
   Dimech W, 2008, J CLIN MICROBIOL, V46, P1955, DOI 10.1128/JCM.00231-08
   Gavi, GAV VACC ALL COUNTR
   Huzly D, 2016, J CLIN VIROL, V74, P13, DOI 10.1016/j.jcv.2015.11.022
   Jonas A, 2016, INT J INFECT DIS, V49, P196, DOI 10.1016/j.ijid.2016.05.009
   Lim SS, 2008, LANCET, V372, P2031, DOI 10.1016/S0140-6736(08)61869-3
   Luman ET, 2007, B WORLD HEALTH ORGAN, V85, P651, DOI 10.2471/BLT.07.045328
   Luman ET, 2009, VACCINE, V27, P2534, DOI 10.1016/j.vaccine.2008.10.002
   Moss William J., 2009, IMMUNOLOGICAL BASIS
   Motaze NV, 2019, CLIN INFECT DIS, V68, P1658, DOI 10.1093/cid/ciy758
   Mutembo S, 2018, AM J TROP MED HYG, V99, P1639, DOI 10.4269/ajtmh.18-0320
   Panagiotopoulos T, 1999, BRIT MED J, V319, P1462, DOI 10.1136/bmj.319.7223.1462
   Scobie HM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127105
   Sutcliffe CG, 2017, PEDIATR INFECT DIS J, V36, P301, DOI 10.1097/INF.0000000000001422
   Travassos MA, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149970
   Trentini F, 2017, LANCET INFECT DIS, V17, P1089, DOI 10.1016/S1473-3099(17)30421-8
   WHO, 2018, MEASL CAS COUNTR SLI
   WHO, 2018, VACCINATION COVERAGE
   Winter AK, 2018, J INFECT DIS, V218, P355, DOI 10.1093/infdis/jiy137
   Zuber PLF, 2003, J INFECT DIS, V187, pS86, DOI 10.1086/368052
   2016, LANCET, V388, P728
   2018, VACCINE, V36, P4001
NR 25
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD APR 17
PY 2019
VL 37
IS 17
BP 2387
EP 2393
DI 10.1016/j.vaccine.2019.02.037
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HV8UV
UT WOS:000466260500013
PM 30905529
OA Other Gold, Green Published
DA 2020-05-12
ER

PT J
AU Dasgupta, R
   Sharma, S
   Sharma, N
   Banerjee, K
   Haran, EGP
   Muliyel, JP
   Salunke, S
   Masoodi, MA
   Haldar, P
   Bahl, S
   Bhatnagar, P
   Joshi, S
   Arora, NK
AF Dasgupta, Rajib
   Sharma, Shweta
   Sharma, Nisha
   Banerjee, K.
   Haran, E. G. P.
   Muliyel, J. P.
   Salunke, Subhash
   Masoodi, Muneer Ahmad
   Haldar, Pradeep
   Bahl, Sunil
   Bhatnagar, Pankaj
   Joshi, Sudhir
   Arora, Narendra K.
TI Successful switch (tOPV to bOPV) in India: Tribute to a resilient health
   system
SO VACCINE
LA English
DT Article
DE Switch strategy; Validation; bOPV; tOPV
AB In accordance with the end game strategies for polio eradication a synchronized switch plan from tOPV to bOPV was implemented globally in 2016. The National Committee for Polio Eradication (NCCPE) validated the switch activities in India. An expert group of 104 academics conducted field visits in 25 states and 2 Union territories for independent verification (after an initial round of verification by the National Polio Surveillance Project [NPSP]). The objectives were to validate withdrawal and disposal of tOPV by screening cold chain points in public and private sector health facilities in both rural and urban areas; additionally, availability of bOPV and IPV was also documented. 34 filled tOPV and 5 empty vials were detected inside cold chain equipment and 17 outside. The disposal mechanism was found to be reasonably adequate. The key strategies -- 'throttling' of vaccine supplies well ahead of the switch date while preventing stock outs at various immunization points, simultaneously working with the regulators to delicense the tOPV on the switch date and helping manufacturers to calibrate vaccine production according to national timelines, and strong and persistent advocacy with professional associations to align with national bOPV and IPV policy facilitated successful accomplishment of the switch process. Effective implementation of the switch strategy in India also bears testimony to the resilience of the health system operating under diverse and heterogeneous governance. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Dasgupta, Rajib; Banerjee, K.; Haran, E. G. P.; Muliyel, J. P.; Salunke, Subhash; Masoodi, Muneer Ahmad; Arora, Narendra K.] Natl Certificat Comm Polio Eradicat, F-1-5,Second Floor,Okhla Ind Area Phase 1, New Delhi 110020, India.
   [Sharma, Shweta; Sharma, Nisha] Natl Certificat Comm Polio Eradicat Secretariat, New Delhi, India.
   [Haldar, Pradeep] Minist Hlth & Family Welf, New Delhi, India.
   [Bahl, Sunil] SEARO WHO, New Delhi, India.
   [Bhatnagar, Pankaj; Joshi, Sudhir] Natl Polio Surveillance Project, New Delhi, India.
RP Arora, NK (reprint author), Natl Certificat Comm Polio Eradicat, F-1-5,Second Floor,Okhla Ind Area Phase 1, New Delhi 110020, India.
EM nkarora@inclentrust.org
OI SHARMA, SHWETA/0000-0001-7430-083X
FU Ministry of Health & Family Welfare, Government of India [C-1321]
FX Ministry of Health & Family Welfare, Government of India, Grant ID : DY.
   No. C-1321 dated 22-08-2016.2.
CR [Anonymous], 2008, REPORT INDEPENDENT C
   [Anonymous], 2016, REP NAT VAL TOPV BOP
   Arora NK, 2010, B WORLD HEALTH ORGAN, V88, P232, DOI 10.2471/BLT.09.072058
   Global Polio Eradication Initiative, SWITCH TOPV BOPV GUI
   Haldar Pradeep, 2016, Indian Pediatr, V53 Suppl 1, pS44
   Masten AS, 2001, AM PSYCHOL, V56, P227, DOI 10.1037/0003-066X.56.3.227
   Myers M., 2015, RESILIENT SYSTEMS NE
   Rodin J., 2014, RESILIENCE DIVIDEND
   SEARO WHO, GOV BOD MATT KEY ISS
NR 9
TC 0
Z9 0
U1 0
U2 5
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD APR 17
PY 2019
VL 37
IS 17
BP 2394
EP 2400
DI 10.1016/j.vaccine.2019.02.038
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HV8UV
UT WOS:000466260500014
PM 30879830
DA 2020-05-12
ER

PT J
AU Izac, JR
   Camire, AC
   Earnhart, CG
   Embers, ME
   Funk, RA
   Breitschwerdt, EB
   Marconi, RT
AF Izac, Jerilyn R.
   Camire, Andrew C.
   Earnhart, Christopher G.
   Embers, Monica E.
   Funk, Rebecca A.
   Breitschwerdt, Edward B.
   Marconi, Richard T.
TI Analysis of the antigenic determinants of the OspC protein of the Lyme
   disease spirochetes: Evidence that the C10 motif is not immunodominant
   or required to elicit bactericidal antibody responses
SO VACCINE
LA English
DT Article
DE Borreliella; Lyme disease; OspC; Lyme disease vaccine; Borrelia
ID OUTER SURFACE-PROTEINS; FACTOR-H-BINDING; BORRELIA-BURGDORFERI;
   IXODES-SCAPULARIS; ACARI IXODIDAE; VACCINE; IDENTIFICATION; EPITOPE;
   INFECTION; TICKS
AB As Ixodes ticks spread to new regions, the incidence of Lyme disease (LD) in companion animals and humans will increase. Preventive strategies for LD in canines center on vaccination and tick control (acaricides). Both subunit and bacterin based LD veterinary vaccines are available. Outer surface protein C (OspC), a potent immunogen and dominant early antigen, has been demonstrated to elicit protective antibody (Ab) responses. However, a single OspC protein elicits a relatively narrow range of protection. There are conflicting reports as to whether the immunodominant epitopes of OspC reside within variable or conserved domains. A detailed understanding of the antigenic determinants of OspC is essential for understanding immune responses to this essential virulence factor and vaccinogen. Here, we investigate the contribution of the conserved C-terminal C10 motif in OspC triggered Ab responses. Using a panel of diverse recombinant full length OspC proteins and their corresponding C10 deletion variants (OspC Delta C10), we demonstrate that the C10 motif does not significantly contribute to immunization or infection induced Ab responses in rabbits, rats, canines, horses and non-human primates. Furthermore, the C10 motif is not required to trigger potent bactericidal Ab responses. This study provides insight into the antigenic structure of OspC. The results enhance our understanding of immune responses that develop during infection or upon vaccination and have implications for interpretation of LD diagnostic assays that employ OspC. (C) 2019 The Authors. Published by Elsevier Ltd.
C1 [Marconi, Richard T.] Virginia Commonwealth Univ, Med Ctr, Dept Microbiol & Immunol, 1112 East Clay St,Room 101 McGuire Hall, Richmond, VA 23298 USA.
   Tulane Natl Primate Res Ctr, Div Immunol, Covington, LA 70433 USA.
   Virginia Tech, Dept Large Anim Clin Sci, Virginia Maryland Coll Vet Med, Blacksburg, VA USA.
   North Carolina State Univ, Coll Vet Med, Comparat Med Inst, Raleigh, NC 27607 USA.
RP Marconi, RT (reprint author), Virginia Commonwealth Univ, Med Ctr, Dept Microbiol & Immunol, 1112 East Clay St,Room 101 McGuire Hall, Richmond, VA 23298 USA.
EM Richard.marconi@vcuhealth.org
OI Breitschwerdt, Edward/0000-0002-3506-0279
FU National Institutes of Health, NIAID, Bethesda, MD [R56AI127801]; Steven
   and Alexandra Cohen Foundation, NY, USA
FX Steven and Alexandra Cohen Foundation, NY, USA; National Institutes of
   Health, NIAID, Bethesda, MD, R56AI127801.
CR Adeolu M, 2014, ANTON LEEUW INT J G, V105, P1049, DOI 10.1007/s10482-014-0164-x
   Ball EC, 2016, TECHNICAL B VANGUARD
   Baum E, 2016, PLOS ONE, V8
   BENACH JL, 1983, NEW ENGL J MED, V308, P740, DOI 10.1056/NEJM198303313081302
   Bockenstedt LK, 1997, INFECT IMMUN, V65, P4661, DOI 10.1128/IAI.65.11.4661-4667.1997
   Buckles EL, 2006, CLIN VACCINE IMMUNOL, V13, P1162, DOI 10.1128/CVI.00099-06
   BURGDORFER W, 1982, SCIENCE, V216, P1317, DOI 10.1126/science.7043737
   Divers TJ, 2018, J VET INTERN MED, V32, P617, DOI 10.1111/jvim.15042
   Earnhart CG, 2005, INFECT IMMUN, V73, P7869, DOI 10.1128/IAI.73.12.7869-7877.2005
   Earnhart CG, 2007, HUM VACCINES, V3, P281, DOI 10.4161/hv.4661
   Earnhart CG, 2007, CLIN VACCINE IMMUNOL, V14, P628, DOI 10.1128/CVI.00409-06
   Earnhart CG, 2007, VACCINE, V25, P3419, DOI 10.1016/j.vaccine.2006.12.051
   Earnhart CG, 2007, VACCINE, V25, P466, DOI 10.1016/j.vaccine.2006.07.052
   Earnhart CG, 2014, PATHOG DIS, V70, P176, DOI 10.1111/2049-632X.12119
   Earnhart CG, 2010, MOL MICROBIOL, V76, P393, DOI 10.1111/j.1365-2958.2010.07103.x
   Edmondson DG, 2017, CLIN VACCINE IMMUNOL, V24, DOI [10.1128/CVI.00306-16, 10.1128/cvi.00306-16]
   Eisen RJ, 2016, J MED ENTOMOL, V53, P349, DOI 10.1093/jme/tjv237
   Embers ME, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0189071
   Embers ME, 2016, CLIN VACCINE IMMUNOL, V23, P294, DOI 10.1128/CVI.00685-15
   FIKRIG E, 1992, P NATL ACAD SCI USA, V89, P5418, DOI 10.1073/pnas.89.12.5418
   Fraser CM, 1997, NATURE, V390, P580, DOI 10.1038/37551
   Funk RA, 2016, J VET INTERN MED, V30, P1300, DOI 10.1111/jvim.13973
   Gasmi S, 2017, Can Commun Dis Rep, V43, P194, DOI 10.14745/ccdr.v43i10a01
   Girard YA, 2009, APPL ENVIRON MICROB, V75, P7243, DOI 10.1128/AEM.01704-09
   Izac JR, 2017, VACCINE, V35, P3178, DOI 10.1016/j.vaccine.2017.04.079
   Jobe DA, 2003, CLIN DIAGN LAB IMMUN, V10, P573, DOI 10.1128/CDLI.10.4.573-578.2003
   Kumaran D, 2001, ACTA CRYSTALLOGR D, V57, P298, DOI 10.1107/S0907444900017546
   Kumaran D, 2001, EMBO J, V20, P971, DOI 10.1093/emboj/20.5.971
   LaFleur RL, 2009, CLIN VACCINE IMMUNOL, V16, P253, DOI 10.1128/CVI.00373-08
   Littman MP, 2018, J VET INTERN MED, V32, P887, DOI 10.1111/jvim.15085
   Lovrich SD, 2005, CLIN DIAGN LAB IMMUN, V12, P746, DOI 10.1128/CDLI.12.6.746-751.2005
   Lovrich SD, 2007, CLIN VACCINE IMMUNOL, V14, P635, DOI 10.1128/CVI.00431-06
   Mathiesen MJ, 1998, INFECT IMMUN, V66, P4073
   Miller DP, 2016, INFECT IMMUN, V84, P2051, DOI 10.1128/IAI.01542-15
   Miller DP, 2012, J BIOL CHEM, V287, P12715, DOI 10.1074/jbc.M112.339721
   Morshed MG, 2015, VECTOR-BORNE ZOONOT, V15, P701, DOI 10.1089/vbz.2015.1854
   Nelson CA, 2015, EMERG INFECT DIS, V21, P1625, DOI 10.3201/eid2109.150417
   Paules CI, 2018, NEW ENGL J MED, V379, P701, DOI 10.1056/NEJMp1807870
   PREACMURSIC V, 1992, INFECTION, V20, P342, DOI 10.1007/BF01710681
   Qiu WG, 2002, GENETICS, V160, P833
   Rhodes DVL, 2013, VET J, V198, P412, DOI 10.1016/j.tvjl.2013.07.019
   Rousselle JC, 1998, J INFECT DIS, V178, P733, DOI 10.1086/515382
   Schwan TG, 2003, BIOCHEM SOC T, V31, P108, DOI 10.1042/BST0310108
   Schwan TG, 2000, J CLIN MICROBIOL, V38, P382
   STEERE AC, 1983, NEW ENGL J MED, V308, P733, DOI 10.1056/NEJM198303313081301
   Stephenson N, 2016, EXP APPL ACAROL, V70, P239, DOI 10.1007/s10493-016-0068-8
   Tilly K, 2007, INFECT IMMUN, V75, P1517, DOI 10.1128/IAI.01725-06
   Tsao J, 2001, VECTOR-BORNE ZOONOT, V1, P65, DOI 10.1089/153036601750137705
   Wang GQ, 2002, J INFECT DIS, V186, P782, DOI 10.1086/343043
   Wang IN, 1999, GENETICS, V151, P15
   Xiang XW, 2017, FRONT CELL INFECT MI, V7, DOI 10.3389/fcimb.2017.00131
   2016, VET J, V218, P27
   1996, INFECT IMMUN, V64, P2234
   1999, INFECT IMMUN, V67, P5463
   2012, J PARASITOL, V98, P49
   2001, J BIOL CHEM, V276, P1001
NR 56
TC 2
Z9 2
U1 0
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD APR 17
PY 2019
VL 37
IS 17
BP 2401
EP 2407
DI 10.1016/j.vaccine.2019.02.007
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HV8UV
UT WOS:000466260500015
PM 30922701
OA Green Accepted, Green Published, Other Gold
DA 2020-05-12
ER

PT J
AU Wilson, SE
   Rosella, LC
   Wang, J
   Renaud, A
   Le Saux, N
   Crowcroft, NS
   Desai, S
   Harris, T
   Bolotin, S
   Gubbay, J
   Deeks, SL
AF Wilson, Sarah E.
   Rosella, Laura C.
   Wang, Jun
   Renaud, Ariane
   Le Saux, Nicole
   Crowcroft, Natasha S.
   Desai, Shalini
   Harris, Tara
   Bolotin, Shelly
   Gubbay, Jonathan
   Deeks, Shelley L.
TI Equity and impact: Ontario's infant rotavirus immunization program five
   years following implementation. A population-based cohort study
SO VACCINE
LA English
DT Article
DE Rotavirus; Immunization; Program impact; Equity; Hospitalization;
   Seasonality
ID GASTROENTERITIS HOSPITALIZATIONS; OLDER CHILDREN; VACCINE IMPACT;
   UNITED-STATES; DIARRHEA; SURVEILLANCE; DECREASE; OUTCOMES; ADULTS
AB Background: Ontario implemented a publicly-funded rotavirus (RV) immunization program in 2011. Our objectives were to evaluate its impact on hospitalizations and emergency department (ED) visits for acute gastroenteritis (AGE) five years after implementation.
   Methods: We performed a population-based longitudinal retrospective cohort study to identify hospitalizations and ED visits for RV-AGE and overall AGE in all age groups using ICD-10 codes between August 1, 2005 and March 31, 2016. A negative binomial regression model that included the effect of time was used to calculate rates, rate ratios (RRs) and 95% confidence intervals (Cis) for AGE before and after the program's implementation, after adjusting for age, seasonality and secular trends. We examined the seasonality of RV-AGE hospitalizations among children under five before and after the program and explored its equity impact.
   Results: Following program implementation, RV-AGE hospitalizations and ED visits among children under five years declined by 76% (RR 0.24, 95% CI 0.20-0.28) and 68% (RR 0.32, 95% CI 0.21-0.50), respectively. In addition, hospitalizations and ED visits for overall AGE declined by 38% (RR 0.62, 95% CI 0.59-0.65) and 26% (RR 0.74, 95% CI 0.73-0.76), respectively, among children under age five. Significant reductions in both outcomes were also found across a range of age-strata. In the pre-program period, the mean monthly hospitalization rate for RV-AGE among children residing in the most marginalized neighbourhoods was 33% higher than those residing in the least marginalized (RR 1.33, 95% CI 1.17-1.52), this disparity was not evident in the program period (RR 0.95, 95% CI 0.69-1.32). We found no evidence of a seasonal shift in rotavirus pediatric hospitalizations.
   Interpretation: The introduction of routine infant rotavirus immunization has had a substantial population impact in Ontario. Our study confirms herd effects and suggests the program may have reduced previous inequities in the burden of pediatric rotavirus hospitalizations. Crown Copyright (C) 2019 Published by Elsevier Ltd.
C1 [Wilson, Sarah E.; Rosella, Laura C.; Wang, Jun; Renaud, Ariane; Crowcroft, Natasha S.; Harris, Tara; Bolotin, Shelly; Gubbay, Jonathan; Deeks, Shelley L.] Publ Hlth Ontario, 480 Univ Ave,Suite 300, Toronto, ON M5G 1V2, Canada.
   [Wilson, Sarah E.; Rosella, Laura C.; Crowcroft, Natasha S.; Bolotin, Shelly; Deeks, Shelley L.] Univ Toronto, Dalla Lana Sch Publ Hlth, Toronto, ON, Canada.
   [Wilson, Sarah E.; Rosella, Laura C.; Wang, Jun; Crowcroft, Natasha S.] Inst Clin Evaluat Sci, Toronto, ON, Canada.
   [Le Saux, Nicole] Childrens Hosp Eastern Ontario, Div Infect Dis, Ottawa, ON, Canada.
   [Le Saux, Nicole] Univ Ottawa, Dept Pediat, Ottawa, ON, Canada.
   [Crowcroft, Natasha S.; Gubbay, Jonathan] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada.
   [Desai, Shalini] McMaster Univ, Dept Pediat, Hamilton, ON, Canada.
   [Gubbay, Jonathan] Hosp Sick Children, Dept Pediat, Toronto, ON, Canada.
   [Gubbay, Jonathan] Univ Toronto, Dept Pediat, Toronto, ON, Canada.
RP Wilson, SE (reprint author), Publ Hlth Ontario, 480 Univ Ave,Suite 300, Toronto, ON M5G 1V2, Canada.
EM sarah.wilson@oahpp.ca
RI Gubbay, Jonathan/Q-8580-2019
OI Gubbay, Jonathan/0000-0003-0026-3786; Crowcroft,
   Natasha/0000-0002-6761-8783
FU Public Health Ontario
FX This project was funded by Public Health Ontario.
CR Aliabadi N, 2015, MMWR-MORBID MORTAL W, V64, P337
   Bayard V, 2012, INT J INFECT DIS, V16, pE94, DOI 10.1016/j.ijid.2011.09.003
   Canadian Institute for Health Information, 2009, COD STAND VERS 2009
   Carmo DO, 2011, PLOS MED, V8
   Esona MD, 2014, HUM VACC IMMUNOTHER, V10, P25, DOI 10.4161/hv.26731
   Gastanaduy PA, 2013, JAMA-J AM MED ASSOC, V310, P851, DOI 10.1001/jama.2013.170800
   Gosselin V, 2016, CAN J PUBLIC HEALTH, V107, pE161, DOI [10.17269/cjph.107.5286, 10.17269/CJPH.107.5286]
   Hemming-Harlo M, 2016, PEDIATR INFECT DIS J, V35, P1304, DOI 10.1097/INF.0000000000001305
   Hsu VP, 2005, PEDIATRICS, V115, P78, DOI 10.1542/peds.2004-0860
   Hungerford D, 2018, BMC MED, V16, DOI 10.1186/s12916-017-0989-z
   Hungerford D, 2017, BMC INFECT DIS, V17, DOI 10.1186/s12879-017-2613-4
   Isabel S, 2018, VACCINE, V36, P2033, DOI 10.1016/j.vaccine.2018.02.064
   Jayasinghe S, 2013, VACCINE, V31, P967, DOI 10.1016/j.vaccine.2012.11.099
   Karafillakis E, 2015, VACCINE, V33, P2097, DOI 10.1016/j.vaccine.2015.03.016
   Lamberti LM, 2016, PEDIATR INFECT DIS J, V35, P992, DOI 10.1097/INF.0000000000001232
   Lopman BA, 2011, J INFECT DIS, V204, P980, DOI 10.1093/infdis/jir492
   Macartney KK, 2011, J PAEDIATR CHILD H, V47, P266, DOI 10.1111/j.1440-1754.2010.01953.x
   Matheson FI, 2012, CAN J PUBLIC HEALTH, V103, pS12, DOI 10.1007/BF03403823
   National Advisory Comittee on Immunization, 2010, CAN COMMUN DIS REP, V36, P1
   National Advisory Committee on Immunization (NACI), 2008, Can Commun Dis Rep, V34, P1
   National Advisory Committee on Immunization (NACI), 2010, UPD STAT US ROT VACC, V36
   Patel MM, 2007, PEDIATR INFECT DIS J, V26, P914, DOI 10.1097/INF.0b013e31812e52fd
   Pindyck T, 2018, EXPERT REV VACCINES, V17, P593, DOI 10.1080/14760584.2018.1489724
   Platts-Mills JA, 2017, CLIN INFECT DIS, V65, P1144, DOI 10.1093/cid/cix494
   Pockett RD, 2011, CURR MED RES OPIN, V27, P777, DOI 10.1185/03007995.2011.555757
   Pollard SL, 2015, VACCINE, V33, P3795, DOI 10.1016/j.vaccine.2015.06.064
   Public Health Agency of Canada, 2018, CAN PROV TERR ROUT C
   Richardson V, 2010, NEW ENGL J MED, V362, P299, DOI 10.1056/NEJMoa0905211
   Rosettie KL, 2018, AM J TROP MED HYG, V98, P1197, DOI 10.4269/ajtmh.17-0705
   Sabbe M, 2016, EUROSURVEILLANCE, V21, P19, DOI 10.2807/1560-7917.ES.2016.21.27.30273
   Shah MP, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0191429
   Tate JE, 2009, PEDIATRICS, V124, P465, DOI 10.1542/peds.2008-3528
   UK. Ministry of Housing Communities & Local Government, 2012, ENGL IND DEPR
   Wilson SE, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0192809
   Wilson SE, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154340
   Wilson Sarah E, 2015, BMC Res Notes, V8, P439, DOI 10.1186/s13104-015-1412-5
NR 36
TC 0
Z9 0
U1 0
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD APR 17
PY 2019
VL 37
IS 17
BP 2408
EP 2414
DI 10.1016/j.vaccine.2019.01.061
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HV8UV
UT WOS:000466260500016
PM 30765171
OA Other Gold
DA 2020-05-12
ER

PT J
AU Drury, G
   Jolliffe, S
   Mukhopadhyay, TK
AF Drury, Georgina
   Jolliffe, Siobhan
   Mukhopadhyay, Tarit K.
TI Process mapping of vaccines: Understanding the limitations in current
   response to emerging epidemic threats
SO VACCINE
LA English
DT Article
DE Emergency response; Priority pathogens; Development pipeline; Vaccine
   development tool
AB Vaccination remains the most successful and effective mechanism of pathogen control. However, their development and deployment in epidemic settings have been limited, and the 2015 Ebola outbreak in West Africa identified several bottlenecks linked to a lack of investment in pathogen research, infrastructure or regulation. Shortly after this outbreak, the UK Government established the UK Vaccine Network to ensure the UK is better prepared to respond to pathogens outbreaks of epidemic potential. As part of their work, the network commissioned the creation of a Vaccine Development Tool (http://www.vaccinedevelopment.org.ukJ ) to serve as a guide to the key stages in vaccine development. The tool also set out to capture the key, rate-limiting bottlenecks in the development of vaccines against emerging infectious disease such that corrective action could be taken, be it through research, funding, infrastructure and policy, both in the UK and internationally. The main research bottlenecks were related to understanding pathogen biology, identification of appropriate animal models and investment in the manufacturing sciences, especially into process development. Infrastructure gaps in GMP manufacturing and fill-finish were also identified and limitations in GMO regulation and regulatory and ethical approvals, especially for outbreak pathogens required new policy initiatives. The UK Vaccine Network has since begun work to correct for these limitations with a series of funding calls and development programmes. This paper seeks to summarise the Vaccine Development Tool and its key findings. (C) 2019 The Author(s). Published by Elsevier Ltd.
C1 [Drury, Georgina] Univ Birmingham, Coll Med & Dent Sci, Vincent Dr, Birmingham B15 2TT, W Midlands, England.
   [Mukhopadhyay, Tarit K.] UCL, Dept Biochem Engn, Bernard Katz Bldg,Gower St, London WC1E 7JE, England.
   [Jolliffe, Siobhan] Home Off, London SW1P 4DF, England.
RP Mukhopadhyay, TK (reprint author), UCL, Dept Biochem Engn, Bernard Katz Bldg,Gower St, London WC1E 7JE, England.
EM siobhan.jolliffe@homeoffice.gov.uk; ucbetkm@ucl.ac.uk
CR CAMACHO A, 2015, BMJ-BRIT MED J, V351, pH3740, DOI DOI 10.1136/HMJ.H3740
   Cox MMJ, 2011, J INVERTEBR PATHOL, V107, pS31, DOI 10.1016/j.jip.2011.05.003
   Friedrich MJ, 2018, JAMA-J AM MED ASSOC, V319, P1973, DOI 10.1001/jama.2018.5712
   Henao-Restrepo AM, 2015, LANCET, V386, P857, DOI 10.1016/S0140-6736(15)61117-5
   Lambe T, 2017, PHILOS T R SOC B, V372, DOI 10.1098/rstb.2016.0295
   Shrivastava SR, 2015, J RES MED SCI, V20, P107
   Sridhar Saranya, 2015, Ther Adv Vaccines, V3, P125, DOI 10.1177/2051013615611017
   World Health Organization, 2015, EMERGENCY
   2017, LANCET, V390, P451, DOI DOI 10.1016/S0140-6736(17)31370-3
   2017, HEALTH SECUR, V15, P41, DOI DOI 10.1089/HS20170006
   2017, VACCINE, V35, P3780, DOI DOI 10.1016/J.VACCINE.2017.05.032.
   2017, LANCET, V389, P233, DOI DOI 10.1016/50140-6736(17)30131-9
   2010, VET PATHOL, V47, P774, DOI DOI 10.1177/0300985810372506
   2015, J INFECT DIS, V211, P504
   2016, LANCET, V388, P460, DOI DOI 10.1016/S0140-6736(16131152-7
NR 15
TC 1
Z9 1
U1 1
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD APR 17
PY 2019
VL 37
IS 17
BP 2415
EP 2421
DI 10.1016/j.vaccine.2019.01.050
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HV8UV
UT WOS:000466260500017
PM 30910404
OA Other Gold, Green Published
DA 2020-05-12
ER

PT J
AU Dinc, G
   Arikan, A
AF Dinc, Gulten
   Arikan, Ayten
TI The interview with Robert Koch held by Huseyin Hulki and the Ottoman
   delegation on tuberculin therapy
SO VACCINE
LA English
DT Article
DE Huseyin Hulki; Robert Koch; Tuberculin therapy; History of tuberculosis;
   History of microbiology; History of vaccination
AB Robert Koch (1843-1910), who was one of the significant representatives of the golden age of microbiology, claimed to have discovered the tuberculin/vaccine therapy in 1890. During that era, the Ottoman Empire closely followed the important developments in the field of microbiology. For this reason, it was decided that a delegation should have been sent to Germany to observe the lecture "On Bacteriological Research" to be delivered by Koch on August 3, 1890 during the 10th International Congress of Medicine to be held in Berlin. The delegation travelled to Germany and carried out observations and met Koch in the meanwhile. Among the delegation sent to Berlin there was also Dr. Huseyin Hulki Bey, who graduated from the Military School of Medicine in 1885, and could speak French, Greek, Farsi and Arabic. One of the young professors of the medical school, Dr. H. Hulki gathered his memories on the trip to Berlin in a book after his return. In his book published under the title Berlin Memories (1892), he related the interview they held with Koch, the various medical centres they visited in Berlin, and the physicians they met there.
   This study aims to provide knowledge on the interview held with Koch in Berlin, and its reflections on the Ottoman medicine, in the light of Dr. H. Hulki's memories and other sources shedding light on the relations between Germany and Turkey in the 1890s. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Dinc, Gulten] Istanbul Univ Cerrahpasa, Cerrahpasa Med Fac, Dept Hist Med & Eth, TR-34098 Istanbul, Turkey.
   [Arikan, Ayten] Istanbul Yeni Yuzyil Univ, Fac Med, Dept Hist Med & Eth, TR-34001 Istanbul, Turkey.
RP Dinc, G (reprint author), Istanbul Univ Cerrahpasa, Cerrahpasa Tip Fak, Tip Tarihi & Etik Anabilim Dali, TR-34098 Istanbul, Turkey.
EM gdinc@istanbul.edu.tr
CR Barberis I, 2017, J Prev Med Hyg, V58, pE9
   Bettmann OL, 1962, PICTORIAL HIST MED
   Bey Huseyin Hulki, 1862, POLIKLINIK, V5, P1
   Blevins SM, 2010, INT J INFECT DIS, V14, pE744, DOI 10.1016/j.ijid.2009.12.003
   BURKE DS, 1993, VACCINE, V11, P795, DOI 10.1016/0264-410X(93)90354-Z
   Bursali Tahir, 1975, OSMANLI MUELLIFLERI, V3
   Cambau E, 2014, CLIN MICROBIOL INFEC, V20, P196, DOI 10.1111/1469-0691.12555
   Garrison FH, 1929, INTRO HIST MED
   Govsa IA, 1946, TURK MESHURLARI ANSI
   Huseyin Hulki, 1892, BERLIN HATIRATI, P1308
   Lagerkvist U., 2006, MIKROBIYOLOJININ ONC
   Munch R., 2015, ROBERT KOCH I GESCH
   Sehsuvaroglu BN, 1861, DERMATOLOJI DERGISI, V3
   Sehsuvaroglu BN, 1971, TIP FAK MEC, V34, P654
   Unver AS, 1939, TURK TIB TARIHI ARKI, V4, P47
   Unver AS, 1950, DIRIM, V3, P105
   Vilaplana C, 2010, MICROBES INFECT, V12, P99, DOI 10.1016/j.micinf.2009.10.006
NR 17
TC 0
Z9 0
U1 1
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD APR 17
PY 2019
VL 37
IS 17
BP 2422
EP 2425
DI 10.1016/j.vaccine.2019.03.038
PG 4
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HV8UV
UT WOS:000466260500018
PM 30922697
DA 2020-05-12
ER

PT J
AU Cashman, P
   Moberley, S
   Chee, K
   Stephenson, J
   Chaverot, S
   Martinelli, J
   Gadsden, T
   Bateman-Steel, C
   Redwood, L
   Howard, Z
   Ferson, MJ
   Durrheim, DN
AF Cashman, P.
   Moberley, S.
   Chee, K.
   Stephenson, J.
   Chaverot, S.
   Martinelli, J.
   Gadsden, T.
   Bateman-Steel, C.
   Redwood, L.
   Howard, Z.
   Ferson, M. J.
   Durrheim, D. N.
TI Participant centred safety surveillance of health care workers receiving
   influenza vaccination
SO VACCINE
LA English
DT Article
DE Active surveillance; Adverse events following immunisation; Mandatory
   vaccination; Staff Health Services
AB Following the introduction of mandatory influenza vaccination for staff working in high risk clinical areas in 2018, we conducted active surveillance for adverse events following immunisation utilising an automated online survey to vaccine recipients at three and 42 days post immunisation. Most participants 2285 (92%) agreed to participate; 515 (32%) staff reported any symptom and eight (1.6%) sought medical attention. The odds of having a reaction decreased with age by approximately 2% per year. The system was acceptable to staff, and the data demonstrated rates of reported symptoms within expected rates for influenza vaccines from clinical trials. Rates of medical attendance were similar to previous surveillance. Participant centred real-time safety surveillance proved useful in this staff influenza vaccination context, providing reassurance with expected rates and profile of common adverse events following staff influenza vaccination. (C) 2019 Published by Elsevier Ltd.
C1 [Cashman, P.; Moberley, S.; Stephenson, J.; Martinelli, J.] Hunter New England Populat Hlth, Newcastle, NSW, Australia.
   [Chee, K.; Chaverot, S.; Bateman-Steel, C.; Redwood, L.; Ferson, M. J.] South Eastern Sydney Local Hlth Dist, Publ Hlth Unit, Sydney, NSW, Australia.
   [Gadsden, T.] NSW Minist Hlth, 73 Miller St, Sydney, NSW 2060, Australia.
   [Bateman-Steel, C.] UNSW, Sch Social Sci, Sydney, NSW, Australia.
   [Howard, Z.; Durrheim, D. N.] Univ Newcastle, Callaghan, NSW, Australia.
   [Ferson, M. J.] Univ New South Wales, Sch Publ Hlth & Community Med, Sydney, NSW, Australia.
RP Cashman, P (reprint author), Hunter New England Populat Hlth, Newcastle, NSW, Australia.
EM patrick.cashman@hnehealth.nsw.gov.au
RI Howard, Zachary/W-8456-2019
OI Howard, Zachary/0000-0002-1542-5760; Gadsden,
   Thomas/0000-0002-9371-420X; Moberley, Sarah/0000-0002-6081-4482
FU National Centre for Immunisation Research and Surveillance; Australian
   Government Department of HealthAustralian GovernmentDepartment of Health
   & Ageing
FX We acknowledge the National Centre for Immunisation Research and
   Surveillance and the Australian Government Department of Health for
   their funding of AusVaxSafety. We acknowledge and thank the participants
   of Vaxtracker who freely gave their time to participate in vaccine
   safety surveillance. We also acknowledge Stephen Clarke for software and
   database development, and Staff Health Service Nurses who promoted and
   recruited participants into this program.
CR Armstrong PK, 2011, BMJ OPEN, V1, DOI 10.1136/bmjopen-2010-000016
   Australian Technical Advisory Group on Immunisation (ATAGI), 2018, AUSTR IMM HDB
   Cashman P, 2014, VACCINE, V32, P5503, DOI 10.1016/j.vaccine.2014.07.061
   Kelly HA, 2014, MED J AUSTRALIA, V201, P560, DOI 10.5694/mja14.01281
   Nohynek H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033536
   NSW Health, 2019, INF SHEET 1 RISK CAT
   NSW Health, 2018, OCC ASS SCREEN VACC
   Pillsbury AJ, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2018-023263
   Regan AK, 2015, VACCINE, V33, P6149, DOI 10.1016/j.vaccine.2015.10.005
   Sanofi Paseur, 2018, FLUQUADRI AUSTR PROD
   Seale H, 2011, MED J AUSTRALIA, V195, P336, DOI 10.5694/mja11.10067
NR 11
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD APR 24
PY 2019
VL 37
IS 18
BP 2427
EP 2429
DI 10.1016/j.vaccine.2019.02.082
PG 3
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HW3WD
UT WOS:000466622500001
PM 30930006
DA 2020-05-12
ER

PT J
AU Xin, H
   Glee, P
   Adams, A
   Mohiuddin, F
   Eberle, K
AF Xin, Hong
   Glee, Pati
   Adams, Abby
   Mohiuddin, Farhan
   Eberle, Karen
TI Design of a mimotope-peptide based double epitope vaccine against
   disseminated candidiasis
SO VACCINE
LA English
DT Article
DE Mimotope; Peptide vaccine; Antibody-mediated protection; Candida
   albicans; Candidiasis
ID IGG3 MONOCLONAL-ANTIBODY; PHAGE-DISPLAY; RISK-FACTORS; ALBICANS;
   PROTECTION; CANDIDEMIA; IGM; EPIDEMIOLOGY; INDUCE; MANNAN
AB Hematogenously disseminated candidiasis in humans is the third leading cause of nosocomial bloodstream infections in the US. There is no FDA approved antifungal vaccine or prophylactic/therapeutic antibody for use in humans. We first reported novel synthetic peptide and glycopeptide vaccines against Candida albicans cell surface epitopes that protect mice against disseminated candidiasis. We showed that antibodies specific for the peptide Fba (derived from C. albicans cell surface protein fructose bisphosphate aldolase) or for C albicans cell surface glycan epitope beta-1, 2-mannotriose [beta-(Man)(3)]) are both protective. This is an important step forward in vaccine design against disseminated candidiasis in humans. However, given the complexity of oligosaccharide synthesis, in this study we performed a new strategy for use of peptide mimotopes that structurally mimic the protective glycan epitope beta-(Man)(3) as surrogate immunogens that substitute for the glycan part of glycopeptide [beta-(Man)(3)-Fba] vaccine. All five selected mimotopes are immunogenic in mice and three mimotopes were able to induce protection in mice against disseminated candidiasis. Furthermore, immunization with three mimotope-peptide conjugate vaccines was also able to induce specific antibody responses, and importantly, protection against disseminated candidiasis in mice. Therefore, our new design of a mimotope-peptide based double epitope vaccine against candidiasis is a potential vaccine candidate that is economical to produce, highly efficacious and safe for use in humans. Published by Elsevier Ltd.
C1 [Xin, Hong; Adams, Abby; Eberle, Karen] LSUHSC, Dept MIP & Pediat, New Orleans, LA 70112 USA.
   [Glee, Pati] Ligocyte Pharmaceut Inc, Bozeman, MT 59718 USA.
   [Mohiuddin, Farhan] Loyola Univ, 6363 St Charles Ave, New Orleans, LA 70118 USA.
RP Xin, H (reprint author), LSUHSC, Room 6263,1901 Perdido St, New Orleans, LA 70112 USA.
EM hxin@lsuhsc.edu
FU National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [R21 AI13515];
   Louisiana State University Health Sciences Center (LSUHSC)
FX This research was supported by the National Institutes of Health Grant
   R21 AI13515. The author thanks the Louisiana State University Health
   Sciences Center (LSUHSC) for support of our research.
CR Abdi K, 2012, J IMMUNOL, V188, P5981, DOI 10.4049/jimmunol.1102868
   Alpan O, 2004, NAT IMMUNOL, V5, P615, DOI 10.1038/ni1077
   Astronomo DR, 2010, NAT REV DRUG DISCOV, V9
   Burritt JB, 1996, ANAL BIOCHEM, V238, P1, DOI 10.1006/abio.1996.0241
   BURRITT JB, 1995, J BIOL CHEM, V270, P16974, DOI 10.1074/jbc.270.28.16974
   CaesarTonThat TC, 1997, INFECT IMMUN, V65, P5354, DOI 10.1128/IAI.65.12.5354-5357.1997
   Cassone A, 2005, CURR MOL MED, V5, P377, DOI 10.2174/1566524054022549
   Charalambous BM, 2001, J MED MICROBIOL, V50, P937, DOI 10.1099/0022-1317-50-11-937
   Cutler JE, 2007, NAT REV MICROBIOL, V5, P13, DOI 10.1038/nrmicro1537
   Daniels Calvin C, 2016, J Pediatr Pharmacol Ther, V21, P27, DOI 10.5863/1551-6776-21.1.27
   DELEO FR, 1995, J BIOL CHEM, V270, P26246, DOI 10.1074/jbc.270.44.26246
   DELEO FR, 1995, P NATL ACAD SCI USA, V92, P7110, DOI 10.1073/pnas.92.15.7110
   Dimopoulos G, 2008, ANESTH ANALG, V106, P523, DOI 10.1213/ane.0b013e3181607262
   Foster SL, 2007, NATURE, V447, P972, DOI 10.1038/nature05836
   Gagne JJ, 2007, EXPERT OPIN PHARMACO, V8, P1643, DOI 10.1517/14656566.8.11.1643
   Han Y, 1997, INFECT IMMUN, V65, P4100, DOI 10.1128/IAI.65.10.4100-4107.1997
   Han Y, 1999, J INFECT DIS, V179, P1477, DOI 10.1086/314779
   Han Y, 2000, INFECT IMMUN, V68, P1649, DOI 10.1128/IAI.68.3.1649-1654.2000
   HAN YM, 1995, INFECT IMMUN, V63, P2714, DOI 10.1128/IAI.63.7.2714-2719.1995
   Han YM, 1997, J INFECT DIS, V175, P1169, DOI 10.1086/516455
   Han YM, 2001, J IMMUNOL, V167, P1550, DOI 10.4049/jimmunol.167.3.1550
   Krcmery V, 2002, J HOSP INFECT, V50, P243, DOI 10.1053/jhin.2001.1151
   Langenkamp A, 2000, NAT IMMUNOL, V1, P311, DOI 10.1038/79758
   Ma Y, 2008, INFECT IMMUN, V76, P1695, DOI 10.1128/IAI.01507-07
   MacLennan CA, 2013, SEMIN IMMUNOL, V25, P114, DOI 10.1016/j.smim.2013.05.004
   MENDENHALL MD, 1993, SCIENCE, V259, P216, DOI 10.1126/science.8421781
   Mochon AB, 2005, MED MYCOL, V43, P97, DOI 10.1080/13693780500035979
   Nitz M, 2002, J BIOL CHEM, V277, P3440, DOI 10.1074/jbc.M109274200
   Pappas PG, 2003, CLIN INFECT DIS, V37, P634, DOI 10.1086/376906
   Peri F, 2013, CHEM SOC REV, V42, P4543, DOI 10.1039/c2cs35422e
   PINCUS SH, 1988, J IMMUNOL, V140, P2779
   Spreghini E, 2008, ANTIMICROB AGENTS CH, V52, P513, DOI 10.1128/AAC.01447-07
   Varol C, 2007, J EXP MED, V204, P171, DOI 10.1084/jem.20061011
   Vassiliou E, 2004, J IMMUNOL, V173, P6955, DOI 10.4049/jimmunol.173.11.6955
   Viudes A, 2002, EUR J CLIN MICROBIOL, V21, P767, DOI 10.1007/s10096-002-0822-1
   Xin H, 2018, MED MYCOL
   XIN H, 2014, J VACCINES VACCIN, V9, DOI DOI 10.1371/JOURNAL.PONE.0085308
   Xin H, 2008, P NATL ACAD SCI USA, V105, P13526, DOI 10.1073/pnas.0803195105
   Xin H, 2006, INFECT IMMUN, V74, P4310, DOI 10.1128/IAI.00234-06
   Xin H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035106
   Xin H, 2011, CLIN VACCINE IMMUNOL, V18, P1656, DOI 10.1128/CVI.05215-11
   2006, SCIENCE, V311, P83, DOI DOI 10.1126/SCIENCE.1117729
   2002, J IMMUNOL METH, V262, P145
   1998, INFECT IMMUN, V66, P5771
NR 44
TC 1
Z9 1
U1 1
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD APR 24
PY 2019
VL 37
IS 18
BP 2430
EP 2438
DI 10.1016/j.vaccine.2019.03.061
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HW3WD
UT WOS:000466622500002
PM 30930005
OA Green Accepted
DA 2020-05-12
ER

PT J
AU Zheng, JZ
   Ou, ZF
   Xu, YL
   Xia, ZQ
   Lin, XF
   Jin, SS
   Liu, Y
   Wu, JM
AF Zheng, Juzeng
   Ou, Zhanfan
   Xu, Yilun
   Xia, ZiQiang
   Lin, Xianfan
   Jin, Sisi
   Liu, Yang
   Wu, Jinming
TI Hepatitis B virus-specific effector CD8(+) T cells are an important
   determinant of disease prognosis: A meta-analysis
SO VACCINE
LA English
DT Article
DE Specific CD8(+) T cell; Hepatitis B; Prognosis; Meta-analysis
ID HBV; INFECTION; CURE; INFLAMMATION; LYMPHOCYTES; CLEARANCE; RESPONSES;
   BLOCKADE
AB Background: Hepatitis B virus (HBV)-specific effector CD8(+) T cells are critical for viral clearance. To determine the effects of HBV-specific effector CD8(+) T cells on HBV infection, we performed a meta-analysis of the available literature.
   Methods: Electronic database searches identified appropriately designed studies that detected specific CD8(+) T cells in HBV-infected patients. Our main endpoints were the course of infection, seroconversion of HBV "e" antigen (HBeAg), the level of HBVDNA, and alanine aminotransferase (ALT) activity. We used a fixed/random model for analysis, according to the results of a heterogeneity test (P value of Q-squared, 12).
   Results: Our searches found five eligible articles. Pooled estimation of the reported results showed that levels of specific CD8(+) T cells were significantly higher in patients with acute hepatitis B than in patients with chronic hepatitis B (odds ratio [OR] = 76.30, 95% confidence interval [CI]: 15.37-378.70). With respect to chronic hepatitis B, patients with <10(7) copies/ml HBVDNA had higher levels of specific CD8(+) T cells relative to patients with >10(7) copies/ml HBVDNA, but the difference had no statistics significance (OR: 3.89, 95% CI: 0.71-21.33). Patients with negative HBeAg or positive anti-HBeAg antibody (anti-HBe) results had significantly higher levels of specific CD8(+) T cells versus patients with positive HBeAg results (OR: 5.82, 95% CI: 1.41-24.13). There were no significant associations between the levels of specific CD8(+) T cells and serum ALT activity (OR = 0.86, 95% CI: 0.01-74.15).
   Conclusion: HBV-specific effector CD8(+) T cells influence the disease activity in HBV-infected patients in various ways and determine prognosis by eliminating the virus. Therefore, efforts of studying HBV-specific effector CD8(+) T cells focused vaccine are potentially needed. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Zheng, Juzeng; Ou, Zhanfan; Xu, Yilun; Xia, ZiQiang; Lin, Xianfan; Jin, Sisi; Liu, Yang; Wu, Jinming] Wenzhou Med Univ, Affiliated Hosp 1, Dept Gastroenterol, Wenzhou 325000, Zhejiang, Peoples R China.
RP Wu, JM (reprint author), Wenzhou Med Univ, Affiliated Hosp 1, Dept Gastroenterol, Wenzhou 325000, Zhejiang, Peoples R China.
EM wzfydw@163.com
CR Aalaei-Andabili SH, 2012, VACCINE, V30, P5595, DOI 10.1016/j.vaccine.2012.06.063
   Allain JP, 2016, NAT REV GASTRO HEPAT, V13, P643, DOI 10.1038/nrgastro.2016.138
   Barnes E, 2015, MED MICROBIOL IMMUN, V204, P79, DOI 10.1007/s00430-014-0376-8
   Benechet AP, 2017, J HEPATOL, V66, P228, DOI 10.1016/j.jhep.2016.07.011
   Bengsch B, 2014, J HEPATOL, V61, P1212, DOI 10.1016/j.jhep.2014.07.005
   Bertoletti A, 2016, J HEPATOL, V64, pS71, DOI 10.1016/j.jhep.2016.01.026
   Bertoletti A, 2012, GUT, V61, P1754, DOI 10.1136/gutjnl-2011-301073
   Billioud G, 2016, J HEPATOL, V64, P781, DOI 10.1016/j.jhep.2015.11.032
   Cai DW, 2012, ANTIMICROB AGENTS CH, V56, P4277, DOI 10.1128/AAC.00473-12
   Chen JL, 2014, MOL THER, V22, P303, DOI 10.1038/mt.2013.212
   CHISARI FV, 1995, ANNU REV IMMUNOL, V13, P29, DOI 10.1146/annurev.immunol.13.1.29
   Dinney CM, 2015, J MICROBIOL, V53, P718, DOI 10.1007/s12275-015-5314-y
   Durantel D, 2016, J HEPATOL, V64, pS117, DOI 10.1016/j.jhep.2016.02.016
   El Sherbini A, 2014, DIGEST LIVER DIS, V46, P1103, DOI 10.1016/j.dld.2014.08.032
   Fabrizi F, 2012, VACCINE, V30, P2295, DOI 10.1016/j.vaccine.2012.01.064
   Fan Zhen-ping, 2004, Zhonghua Yi Xue Za Zhi, V84, P2073
   Fehlings M, 2018, J IMMUNOL METHODS, V453, P30, DOI 10.1016/j.jim.2017.09.010
   Feld JJ, 2007, ANTIVIR RES, V76, P168, DOI 10.1016/j.antiviral.2007.06.014
   Fioravanti J, 2017, J HEPATOL, V67, P543, DOI 10.1016/j.jhep.2017.04.020
   Fisicaro P, 2012, GASTROENTEROLOGY, V143, P1576, DOI 10.1053/j.gastro.2012.08.041
   Grimm D, 2011, HEPATOL INT, V5, P644, DOI 10.1007/s12072-011-9261-3
   Guidotti LG, 1996, IMMUNITY, V4, P25, DOI 10.1016/S1074-7613(00)80295-2
   Hong XP, 2017, HEPATOLOGY, V66, P2066, DOI 10.1002/hep.29479
   King TH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101904
   Kosinska AD, 2017, HEPATOLOGY, V66, P69, DOI 10.1002/hep.29155
   Lampertico P, 2015, J HEPATOL, V63, P1238, DOI 10.1016/j.jhep.2015.06.026
   Li S, 2017, JOVE-J VIS EXP, V127
   Liaw YF, 2009, HEPATOL INT, V3, P425, DOI 10.1007/s12072-009-9140-3
   LIU JINTAO, 2014, J CHINA HYDROLOGY, V01, P1
   Lucifora J, 2014, SCIENCE, V343, P1221, DOI 10.1126/science.1243462
   Maini MK, 2010, J HEPATOL, V52, P616, DOI 10.1016/j.jhep.2009.12.017
   Maini MK, 2000, J EXP MED, V191, P1269, DOI 10.1084/jem.191.8.1269
   Nassal M, 2015, GUT, V64, P1972, DOI 10.1136/gutjnl-2015-309809
   Nitschke K, 2016, DIGEST DIS, V34, P396, DOI 10.1159/000444555
   Nkongolo S, 2014, J HEPATOL, V60, P723, DOI 10.1016/j.jhep.2013.11.022
   Park JJ, 2016, GASTROENTEROLOGY, V150, P684, DOI 10.1053/j.gastro.2015.11.050
   Peng GP, 2011, J CLIN IMMUNOL, V31, P195, DOI 10.1007/s10875-010-9483-5
   Petersen J, 2016, J HEPATOL, V65, P835, DOI 10.1016/j.jhep.2016.05.043
   Petitti DB, 2001, STAT MED, V20, P3625, DOI 10.1002/sim.1091
   Phillips S, 2010, J IMMUNOL, V184, P287, DOI 10.4049/jimmunol.0902761
   Puntambekar SS, 2011, J VIROL, V85, P6702, DOI 10.1128/JVI.00200-11
   Revill P, 2016, NAT REV GASTRO HEPAT, V13, P239, DOI 10.1038/nrgastro.2016.7
   Schiffer JT, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/journal.pcbi.1003131
   Shimada N, 2003, J CLIN IMMUNOL, V23, P223, DOI 10.1023/A:1023366013858
   Sobao Y, 2002, J HEPATOL, V36, P105, DOI 10.1016/S0168-8278(01)00264-1
   Sprengers D, 2006, J MED VIROL, V78, P561, DOI 10.1002/jmv.20576
   Stray SJ, 2005, P NATL ACAD SCI USA, V102, P8138, DOI 10.1073/pnas.0409732102
   Sun J, 2009, NAT MED, V15, P277, DOI 10.1038/nm.1929
   Tan WG, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0181578
   Thimme R, 2003, J VIROL, V77, P68, DOI 10.1128/JVI.77.1.68-76.2003
   Trandem K, 2011, J IMMUNOL, V186, P3642, DOI 10.4049/jimmunol.1003292
   Webster GJM, 2004, J VIROL, V78, P5707, DOI 10.1128/JVI.78.11.5707-5719.2004
   Wherry EJ, 2011, PLOS PATHOG, V7
   Wisskirchen K, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0182936
   Xu HD, 2013, J INT MED RES, V41, P559, DOI 10.1177/0300060513483387
   Yang XX, 2009, J HUAZHONG U SCI-MED, V29, P567, DOI 10.1007/s11596-009-0508-3
   Zeisel MB, 2015, GUT, V64, P1314, DOI 10.1136/gutjnl-2014-308943
NR 57
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD APR 24
PY 2019
VL 37
IS 18
BP 2439
EP 2446
DI 10.1016/j.vaccine.2019.03.058
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HW3WD
UT WOS:000466622500003
PM 30935741
DA 2020-05-12
ER

PT J
AU Sawlwin, DC
   Jones, AG
   Albano, FR
AF Sawlwin, Daphne C.
   Jones, Alison Graves
   Albano, Frank R.
TI Modification of the vaccine manufacturing process improves the
   pyrogenicity profile of inactivated influenza vaccines in young children
SO VACCINE
LA English
DT Article
DE Febrile seizure; Fever; Inactivated influenza vaccines; Paediatrics;
   Quadrivalent influenza vaccine; Safety
ID UNITED-STATES; IMMUNIZATION PRACTICES; ADVISORY-COMMITTEE; SEASONAL
   INFLUENZA; ADVERSE EVENTS; SAFETY; IMMUNOGENICITY; RECOMMENDATIONS;
   PREVENTION; INFANTS
AB Background: There were increased reports of fevers and febrile reactions in young children (particularly children aged <5 years) receiving the Seqirus/CSL Southern Hemisphere 2010 trivalent inactivated influenza vaccine (IIV3). Modifying the vaccine manufacturing process by increasing the minimum concentration of splitting agent (sodium taurodeoxycholate [TDOC]) from 0.5% w/v to 1.5% w/v for all strains resolved this issue. The current analysis compared fever rates in three pediatric studies of Seqirus IIV3 (S-IIV3) or quadrivalent inactivated influenza vaccine (S-IIV4), prepared using the modified manufacturing process, with fever rates in three pediatric studies of historical (pre-2010) IIV3 formulations. The historical IIV3 formulations, S-IIV3, and S-IIV4 had 0/3, 2/3, and 4/4 vaccine strains split at 1.5% TDOC, respectively.
   Methods: For each study, fever rates (any grade and severe) were determined for the following age subgroups (as applicable), using the fever intensity grading system used in the S-IIV3/S-IIV4 studies: 6 months to <3 years; 3 to <5 years; 5 to <9 years; and 9 to <18 years.
   Results: For each age subgroup, the any grade and severe fever rates were lower in the S-IIV3/S-IIV4 studies than in the historical IIV3 formulation studies, with the greatest differences in fever rates observed in the youngest age groups. In the 6 months to <3 years group, the any grade fever rate was 7.0% (severe fever: 2.5%) in one S-IIV4 study compared with 38.7% to 40.0% (severe fever: 9.6% to 17.8%) in the historical IIV3 formulation studies. In the 3 to <5 years subgroup, the any grade fever rate was 4.9% (severe fever: 1.2%) in one S-IIV4 study compared with 34.1% to 36.0% (severe fever: 6.3% to 16.5%) in the historical IIV3 formulation studies.
   Conclusion: This analysis provides clinical evidence that the modified manufacturing process improved the fever profile across all pediatric age groups, in particular, in children aged <5 years. (C) 2019 Published by Elsevier Ltd.
C1 [Sawlwin, Daphne C.; Jones, Alison Graves] Seqirus Pty Ltd, Global Pharmacovigilance & Risk Management, 63 Poplar Rd, Parkville, Vic 3052, Australia.
   [Albano, Frank R.] Seqirus Pty Ltd, Clin Dev, Parkville, Vic, Australia.
RP Sawlwin, DC (reprint author), Seqirus Pty Ltd, Global Pharmacovigilance & Risk Management, 63 Poplar Rd, Parkville, Vic 3052, Australia.
EM Daphne.Sawlwin@seqirus.com; Alison.Graves-Jones@seqirus.com;
   Frank.Albano@seqirus.com
FU Seqirus Pty Ltd, Australia
FX The studies described in this manuscript were sponsored by Seqirus Pty
   Ltd, Australia, manufacturer/licensee of Afluria. Quadrivalent/Afluria
   Quad<SUP>TM</SUP>/Afluria Tetra<SUP>TM</SUP> (trademarks of Seqirus UK
   Limited or its affiliates). Medical writing assistance was provided by
   Justine Southby, PhD, CMPP, and Rebecca Lew, PhD, CMPP, of ProScribe
   -Envision Pharma Group, and was funded by Seqirus Pty Ltd, Australia.
   ProScribe's services complied with international guidelines for Good
   Publication Practice (GPP3).
CR Airey J, 2017, VACCINE, V35, P2745, DOI 10.1016/j.vaccine.2017.03.028
   [Anonymous], 2018, FLUV PROD INF
   Blyth CC, 2011, VACCINE, V29, P5107, DOI 10.1016/j.vaccine.2011.05.054
   Brady RC, 2014, VACCINE, V32, P7141, DOI 10.1016/j.vaccine.2014.10.024
   Center for Biologics Evaluation and Research, 2007, GUID IND TOX GRAD SC
   Centers for Disease Control and Prevention, CHILDH VACC FEBR SEI
   Cullen KA, 2016, MMWR SURVEILL SUMM, V65, P1, DOI 10.15585/mmwr.ss6502a1
   Grohskopf LA, 2017, MMWR RECOMM REP, V66, P3, DOI 10.15585/mmwr.rr6602a1
   Grohskopf LA, 2015, MMWR-MORBID MORTAL W, V64, P818, DOI [10.15585/mmwr.mm6430a3, 10.1111/ajt.13505]
   Halsey NA, 2015, VACCINE, V33, pF1, DOI 10.1016/j.vaccine.2015.10.080
   Lambert SB, 2013, INFLUENZA OTHER RESP, V7, P676, DOI 10.1111/irv.12107
   Neuzil KM, 2006, J INFECT DIS, V194, P1032, DOI 10.1086/507309
   Nolan T, 2009, INFLUENZA OTHER RESP, V3, P315, DOI 10.1111/j.1750-2659.2009.00108.x
   Rockman S, 2014, VACCINE, V32, P3861, DOI 10.1016/j.vaccine.2014.03.032
   Rockman S, 2014, VACCINE, V32, P3869, DOI 10.1016/j.vaccine.2014.03.035
   Statler VA, 2019, VACCINE, V37, P343, DOI 10.1016/j.vaccine.2018.07.036
   Therapeutic Goods Administration, 2010, INV FEBR REACT YOUNG
   Therapeutic Goods Administration, 2010, OV VACC REG SAF MON
   2010, MMWR, V59, P989
NR 19
TC 0
Z9 0
U1 1
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD APR 24
PY 2019
VL 37
IS 18
BP 2447
EP 2454
DI 10.1016/j.vaccine.2019.03.056
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HW3WD
UT WOS:000466622500004
PM 30935743
DA 2020-05-12
ER

PT J
AU Godi, A
   Panwar, K
   Haque, M
   Cocuzza, CE
   Andrews, N
   Southern, J
   Turner, P
   Miller, E
   Beddows, S
AF Godi, Anna
   Panwar, Kavita
   Haque, Mahmoud
   Cocuzza, Clementina E.
   Andrews, Nick
   Southern, Jo
   Turner, Paul
   Miller, Elizabeth
   Beddows, Simon
TI Durability of the neutralizing antibody response to vaccine and
   non-vaccine HPV types 7 years following immunization with either
   Cervarix (R) or Gardasil (R) vaccine
SO VACCINE
LA English
DT Article
DE Human papillomavirus; Vaccine; Antibody; Neutralization; Durability
ID HPV-16/18 AS04-ADJUVANTED VACCINE; COSTA-RICA VACCINE; HPV-6/11/16/18
   VACCINE; LONG-TERM; PAPILLOMAVIRUS; LEVEL; IMMUNOGENICITY; INFECTION;
   PROGRAMS; BIVALENT
AB Bivalent (Cervarix (R)) and quadrivalent (Gardasil (R)) Human Papillomavirus (HPV) vaccines demonstrate remarkable efficacy against the targeted genotypes, HPV16 and HPV18, but also a degree of cross-protection against non-vaccine incorporated genotypes, HPV31 and HPV45. These outcomes seem to be supported by observations that the HPV vaccines induce high titer neutralizing antibodies against vaccine types and lower responses against non-vaccine types. Few data are available on the robustness of the immune response against non-vaccine types. We examined the durability of vaccine and non-vaccine antibody responses in a follow up of a head-to-head study of 12-15 year old girls initially randomized to receive three doses of Cervarix (R) or Gardasil (R) vaccine. Neutralizing antibodies against both vaccine and non-vaccine types remained detectable up to 7 years following initial vaccination and a mixed effects model was used to predict the decline in antibody titers over a 15 year period. The decline in vaccine and non-vaccine type neutralizing antibody titers over the study period was estimated to be 30% every 5-7 years, with Cervarix (R) antibody titers expected to remain 3-4 fold higher than Gardasil (R) antibody titers over the long term. The antibody decline rates in those with an initial response to non-vaccine types were similar to that of vaccine types and are predicted to remain detectable for many years. Empirical data on the breadth, magnitude, specificity and durability of the immune response elicited by the HPV vaccines contribute to improving the evidence base supporting this important public health intervention. Crown Copyright (C) 2019 Published by Elsevier Ltd. All rights reserved.
C1 [Godi, Anna; Panwar, Kavita; Haque, Mahmoud; Beddows, Simon] Publ Hlth England, Virus Reference Dept, 61 Colindale Ave, London NW9 5EQ, England.
   [Southern, Jo; Miller, Elizabeth] Publ Hlth England, Immunisat & Countermeasures, London, England.
   [Cocuzza, Clementina E.] Univ Milano Bicocca, Dept Med & Surg, Monza, Italy.
   [Andrews, Nick] Publ Hlth England, Stat Modelling & Econ Dept, London, England.
   [Turner, Paul] Imperial Coll London, Paediat Sect, London, England.
RP Beddows, S (reprint author), Publ Hlth England, Virus Reference Dept, 61 Colindale Ave, London NW9 5EQ, England.
EM simon.beddows@phe.gov.uk
RI Cocuzza, Clementina Elvezia/AAE-2064-2019
OI Cocuzza, Clementina Elvezia/0000-0001-6166-1134; Beddows,
   Simon/0000-0002-6879-6215; Turner, Paul/0000-0001-9862-5161
FU National Institute for Health Research (NIHR) Policy Research Programme
   ("Vaccine Evaluation Consortium Phase II") [039/0031]
FX T This publication is independent research funded by the National
   Institute for Health Research (NIHR) Policy Research Programme ("Vaccine
   Evaluation Consortium Phase II", 039/0031). The views expressed in this
   publication are those of the author(s) and not necessarily those of the
   NHS, the National Institute for Health Research or the Department of
   Health and Social Care.
CR Artemchuk H, 2019, J INFECT DIS, V219, P582, DOI 10.1093/infdis/jiy545
   Beachler DC, 2016, J INFECT DIS, V213, P1444, DOI 10.1093/infdis/jiv753
   Bissett SL, 2017, VACCINE, V35, P3922, DOI 10.1016/j.vaccine.2017.06.028
   Bissett SL, 2016, SCI REP-UK, V6, DOI 10.1038/srep39730
   Bissett SL, 2012, CLIN VACCINE IMMUNOL, V19, P449, DOI 10.1128/CVI.05641-11
   Bruni L, 2016, LANCET GLOB HEALTH, V4, pE453, DOI 10.1016/S2214-109X(16)30099-7
   Draper E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061825
   Drolet M, 2015, LANCET INFECT DIS, V15, P565, DOI 10.1016/S1473-3099(14)71073-4
   Einstein MH, 2014, HUM VACC IMMUNOTHER, V10, P3435, DOI 10.4161/hv.36121
   Einstein MH, 2011, HUM VACCINES, V7, P1359, DOI 10.4161/hv.7.12.18282
   Ferris D, 2014, PEDIATRICS, V134, pE657, DOI 10.1542/peds.2013-4144
   Godi A, 2015, J GEN VIROL, V96, P1842, DOI 10.1099/vir.0.000121
   Herrero R, 2015, LANCET ONCOL, V16, pE206, DOI 10.1016/S1470-2045(14)70481-4
   Joura EA, 2015, NEW ENGL J MED, V372, P711, DOI 10.1056/NEJMoa1405044
   Kreimer AR, 2015, LANCET ONCOL, V16, P775, DOI 10.1016/S1470-2045(15)00047-9
   Lehtinen M, 2013, NAT REV CLIN ONCOL, V10, P400, DOI 10.1038/nrclinonc.2013.84
   Longet S, 2011, J VIROL, V85, P13253, DOI 10.1128/JVI.06093-11
   Mesher D, 2016, EMERG INFECT DIS, V22, P1732, DOI 10.3201/eid2210.160675
   Moscicki AB, 2012, VACCINE, V31, P234, DOI 10.1016/j.vaccine.2012.09.037
   Olsson SE, 2007, VACCINE, V25, P4931, DOI 10.1016/j.vaccine.2007.03.049
   Ryser M, 2019, EXPERT REV VACCINES, P1
   Safaeian M, 2013, CANCER PREV RES, V6, P1242, DOI 10.1158/1940-6207.CAPR-13-0203
   Scherer EM, 2016, EBIOMEDICINE, V10, P55, DOI 10.1016/j.ebiom.2016.06.042
   Schiller J, 2018, VACCINE, V36, P4768, DOI 10.1016/j.vaccine.2017.12.079
   Schiller JT, 2012, NAT REV MICROBIOL, V10, P681, DOI 10.1038/nrmicro2872
   Schwarz TF, 2017, CANCER MED-US, V6, P2723, DOI 10.1002/cam4.1155
   WHO, 2015, VACCINE, V33, P76, DOI 10.1016/j.vaccine.2014.05.040
   2015, CLIN VACCINE IMMUNOL, V22, P943, DOI DOI 10.1128/CVI.00133-15
NR 28
TC 1
Z9 1
U1 2
U2 6
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD APR 24
PY 2019
VL 37
IS 18
BP 2455
EP 2462
DI 10.1016/j.vaccine.2019.03.052
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HW3WD
UT WOS:000466622500005
PM 30926298
DA 2020-05-12
ER

PT J
AU Fumimoto, R
   Otsuka, N
   Sunagawa, T
   Tanaka-Taya, K
   Kamiya, H
   Kamachi, K
AF Fumimoto, Rei
   Otsuka, Nao
   Sunagawa, Tomimasa
   Tanaka-Taya, Keiko
   Kamiya, Hajime
   Kamachi, Kazunari
TI Age-related differences in antibody avidities to pertussis toxin and
   filamentous hemagglutinin in a healthy Japanese population
SO VACCINE
LA English
DT Article
DE Pertussis; Antibody avidity; Antibody titer; Pertussis toxin;
   Filamentous hemagglutinin; Acellular pertussis vaccine
ID WHOLE-CELL; BOOSTER VACCINATION; IGG; IMMUNIZATION; RESPONSES; IMMUNITY;
   SEROPREVALENCE; RESURGENCE; DIPHTHERIA; TETANUS
AB To gain insights into the current Japanese pertussis immunization schedule, we examined the distributions of antibody titers and avidities to pertussis toxin (PT) and filamentous hemagglutinin (FHA) in 460 Japanese healthy subjects (aged 1-60 years) based on age category. Our avidity enzyme-linked immunosorbent assays revealed that young children aged 1-2 years, which corresponded to ages after receiving primary and/or booster pertussis vaccinations, had relatively high-avidity anti-PT IgG (mean avidity index [Al], 40.5%) compared with other age groups (Al, 26.5-31.9%); however, they had relatively low-avidity anti-FHA IgG (Al, 41.8%). In contrast, children aged 3-6 years had both low-avidity anti-PT IgG (Al, 26.5%) and low-avidity anti-FHA IgG (Al, 40.4%). A significant age-related difference in anti-PT IgG avidity was observed between children aged 1-2 years and 3-6 years (P < 0.05); however, the difference in anti-FHA IgG avidity was not significant. The anti-PT IgG avidity was positively correlated with the antibody titer, especially among children aged 1-15 years (r(s) = 0.508-0.685; P < 0.01), indicating that the avidity of vaccine-induced anti-PT IgG decreases with decreasing IgG antibody titer to PT. Our findings strongly suggest that vaccine-induced anti-PT IgG avidity rapidly wanes after vaccination, but this is not observed for anti-FHA IgG avidity. Because children aged 3-6 years have both low-quantity and low-quality antibodies against PT, an additional booster vaccination with acellular pertussis vaccines is required for such children in Japan. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Fumimoto, Rei; Otsuka, Nao; Kamachi, Kazunari] Natl Inst Infect Dis, Dept Bacteriol 2, 4-7-1 Gakuen, Tokyo 2080011, Japan.
   [Fumimoto, Rei] St Marianna Univ, Sch Med, Dept Pediat, Kawasaki, Kanagawa, Japan.
   [Sunagawa, Tomimasa; Tanaka-Taya, Keiko; Kamiya, Hajime] Natl Inst Infect Dis, Infect Dis Surveillance Ctr, Tokyo, Japan.
RP Kamachi, K (reprint author), Natl Inst Infect Dis, Dept Bacteriol 2, 4-7-1 Gakuen, Tokyo 2080011, Japan.
EM kamachi@nih.go.jp
OI Kamachi, Kazunari/0000-0001-5259-1744
FU Ministry of Health, Labor, and Welfare of JapanMinistry of Health,
   Labour and Welfare, Japan [H29-Shinkou-Ippan-007]
FX This study was supported by a grant for Research on Emerging and
   Re-emerging Infectious Diseases from the Ministry of Health, Labor, and
   Welfare of Japan (H29-Shinkou-Ippan-007).
CR Abu Raya B, 2015, VACCINE, V33, P1948, DOI 10.1016/j.vaccine.2015.02.059
   Abu Sin M, 2009, PEDIATR INFECT DIS J, V28, P242, DOI 10.1097/INF.0b013e31818a5d69
   Almanzar G, 2013, J IMMUNOL METHODS, V387, P36, DOI 10.1016/j.jim.2012.09.008
   Anttila M, 1998, J INFECT DIS, V177, P1614, DOI 10.1086/515298
   Bamberger ES, 2008, EUR J PEDIATR, V167, P133, DOI 10.1007/s00431-007-0548-2
   BARENKAMP SJ, 1992, INFECT IMMUN, V60, P1302, DOI 10.1128/IAI.60.4.1302-1313.1992
   Barkoff AM, 2012, VACCINE, V30, P6897, DOI 10.1016/j.vaccine.2012.09.003
   Cabore RN, 2017, VIRULENCE, V8, P1245, DOI 10.1080/21505594.2017.1296998
   Campbell PT, 2015, VACCINE, V33, P5794, DOI 10.1016/j.vaccine.2015.09.025
   Cherry JD, 2012, NEW ENGL J MED, V367, P785, DOI 10.1056/NEJMp1209051
   Denoel PA, 2007, CLIN VACCINE IMMUNOL, V14, P1362, DOI 10.1128/CVI.00154-07
   Dominguez A, 2001, EPIDEMIOL INFECT, V126, P205, DOI 10.1017/S0950268801005325
   Guiso N, 2011, EUR J CLIN MICROBIOL, V30, P307, DOI 10.1007/s10096-010-1104-y
   Hallander HO, 2005, VACCINE, V23, P5359, DOI 10.1016/j.vaccine.2005.06.009
   HALLANDER HO, 1991, J INFECT DIS, V163, P1046, DOI 10.1093/infdis/163.5.1046
   Hendrikx LH, 2011, VACCINE, V30, P51, DOI 10.1016/j.vaccine.2011.10.048
   Hewlett EL, 2005, NEW ENGL J MED, V352, P1215, DOI 10.1056/NEJMcp041025
   Kilgore PE, 2016, CLIN MICROBIOL REV, V29, P449, DOI 10.1128/CMR.00083-15
   Konda T, 2002, VACCINE, V20, P1711, DOI 10.1016/S0264-410X(02)00045-2
   Loconsole D, 2018, PEDIATR INFECT DIS J, V37, pE126, DOI [10.1097/INF.0000000000001804, 10.1097/inf.0000000000001804]
   McGirr A, 2015, PEDIATRICS, V135, P331, DOI 10.1542/peds.2014-1729
   Miyaji Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077165
   Moriuchi T, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0181181
   NENCIONI L, 1991, INFECT IMMUN, V59, P625, DOI 10.1128/IAI.59.2.625-630.1991
   Pool V, 2018, VACCINE, V36, P2282, DOI 10.1016/j.vaccine.2018.03.029
   Prelog M, 2013, VACCINE, V31, P387, DOI 10.1016/j.vaccine.2012.10.105
   Riolo MA, 2013, VACCINE, V31, P5903, DOI 10.1016/j.vaccine.2013.09.020
   Saitoh A, 2018, VACCINE, V36, P4582, DOI 10.1016/j.vaccine.2018.01.092
   SCHLESINGER Y, 1992, JAMA-J AM MED ASSOC, V267, P1489, DOI 10.1001/jama.267.11.1489
   Schure RM, 2013, CLIN VACCINE IMMUNOL, V20, P1388, DOI 10.1128/CVI.00270-13
   Sheridan SL, 2014, EXPERT REV VACCINES, V13, P1081, DOI 10.1586/14760584.2014.944167
   Tartof SY, 2013, PEDIATRICS, V131, pE1047, DOI 10.1542/peds.2012-1928
   Van der Wielen M, 2003, VACCINE, V21, P2412, DOI 10.1016/S0264-410X(03)00062-8
   Vincent JM, 2000, CLIN INFECT DIS, V30, P534, DOI 10.1086/313707
   Wendelboe Aaron M, 2005, Pediatr Infect Dis J, V24, pS58, DOI 10.1097/01.inf.0000160914.59160.41
   Xu YH, 2014, HUM VACC IMMUNOTHER, V10, P192, DOI 10.4161/hv.26335
   2002, LANCET INFECT DIS, V2, P744
NR 37
TC 1
Z9 1
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD APR 24
PY 2019
VL 37
IS 18
BP 2463
EP 2469
DI 10.1016/j.vaccine.2019.03.055
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HW3WD
UT WOS:000466622500006
PM 30930008
DA 2020-05-12
ER

PT J
AU Andres, C
   Peremiquel-Trillas, P
   Gimferrer, L
   Pinana, M
   Codina, MG
   Rodrigo-Pendas, JA
   Campins-Marti, M
   Martin, MC
   Fuentes, F
   Rubio, S
   Pumarola, T
   Anton, A
AF Andres, Cristina
   Peremiquel-Trillas, Paula
   Gimferrer, Laura
   Pinana, Maria
   Gema Codina, Maria
   Angel Rodrigo-Pendas, Jose
   Campins-Marti, Magda
   Carmen Martin, Maria
   Fuentes, Francisco
   Rubio, Susana
   Pumarola, Tomas
   Anton, Andres
TI Molecular influenza surveillance at a tertiary university hospital
   during four consecutive seasons (2012-2016) in Catalonia, Spain
SO VACCINE
LA English
DT Article
DE Influenza viruses; Surveillance; Respiratory tract infection; Genetic
   diversity; Molecular epidemiology
ID AMINO-ACID SUBSTITUTION; HEMAGGLUTININ; VIRUSES; PATHOGENICITY;
   REPLICATION; RESISTANCE
AB Background: Influenza viruses (FLUV) are continuously evolving, which explain the occurrence of seasonal influenza epidemics and the need to review the vaccine strain composition annually. The aim is to describe the genetic diversity and clinical outcomes of FLUV detected at a tertiary university hospital in Barcelona (Spain) during the 2012-2016 seasons.
   Methods: The detection of FLUV from patients attended at the Emergency Department or admitted to the hospital was performed by either immunofluorescence or PCR-based assays. A specific real-time one-step multiplex RT-PCR was performed for influenza A (FLUAV) subtyping. The complete coding haemagglutinin domain 1 (HA1) and neuraminidase (NA) (2015-2016) protein sequences from a representative sampling were molecular characterised.
   Results: A total 1774 (66.1%) FLUAV and 910 (33.9%) influenza B (FLUBV) cases were laboratory-nfirmed. The hospitalisation rate was different between seasons, being the highest (81.4%) during the 2014-2015 season. FLUV were genetically close to vaccine strains except to the 2014-2015, in which most characterised A(H3N2) viruses belonged to a genetic group different from the vaccine strain. During the 2015-2016 season, B/Victoria-like viruses were the most predominant, but this component was not included in the trivalent vaccine used. Mutations D222G or D222N in HA1-domain were found in 3 A (H1N1)pdm09 strains from ICU-admitted cases. Three A(H1N1)pdm09 strains carried the NA H275Y (2) and S247N (1) mutations, respectively related to resistance or decreased susceptibility to oseltamivir.
   Conclusions: The circulation of drifted A(H3N2) strains during the 2014-2015 season was related to the high hospitalisation rate due to the mismatch with the vaccine strains. The predominance of a FLUBV lineage not included in the trivalent influenza vaccine during the 2015-2016 season highlights the need to use a tetravalent influenza vaccine. Virological surveillance of viral variants carrying protein changes that alter tropism and susceptibility to antivirals features should be strengthened in hospital settings. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Andres, Cristina; Gimferrer, Laura; Pinana, Maria; Gema Codina, Maria; Carmen Martin, Maria; Fuentes, Francisco; Rubio, Susana; Pumarola, Tomas; Anton, Andres] Univ Autonoma Barcelona, Hosp Univ Vall dHebron, Vall dHebron Res Inst, Resp Viruses Unit,Virol Sect,Microbiol Dept, Passeig Vall dHebron 119-129, Barcelona 08035, Spain.
   [Peremiquel-Trillas, Paula; Angel Rodrigo-Pendas, Jose; Campins-Marti, Magda] Univ Autonoma Barcelona, Hosp Univ Vall dHebron, Vall dHebron Res Inst, Prevent Med & Epidemiol Dept, Barcelona, Spain.
RP Pumarola, T (reprint author), Univ Autonoma Barcelona, Hosp Univ Vall dHebron, Vall dHebron Res Inst, Resp Viruses Unit,Virol Sect,Microbiol Dept, Passeig Vall dHebron 119-129, Barcelona 08035, Spain.
EM virusrespiratoris@vhebron.net
RI Pumarola, Tomas/AAB-5532-2019; Anton, Andres/B-3308-2011
OI Pumarola, Tomas/0000-0002-5171-7461; Anton, Andres/0000-0002-1476-0815;
   Rodrigo Pendas, Jose Angel/0000-0002-2383-9904; Peremiquel-Trillas,
   Paula/0000-0002-8636-1725
FU Fondo de Investigacion Sanitaria from the Spanish Ministry Science,
   Innovation and Universities [FIS PI08/0118, FIS PI11/01864, FIS
   PI14/01838]; Agenda d'Avaluacio de Tecnologia i Recerca Mediques (AATRM)
   [402/02/2008]; Catalan Association of Public Universities (ACUP)
   [2010ACUP_00437]; Spanish Network for the Research in Infectious
   Diseases [REIPI RD16/0016/0003]; European Regional Development Fund
   (ERDF)European Union (EU); Vail d'Hebron Research Institute
   (PREDVHIR-2013)
FX This work has been partially supported by Fondo de Investigacion
   Sanitaria (grants FIS PI08/0118, FIS PI11/01864, FIS PI14/01838) from
   the Spanish Ministry Science, Innovation and Universities; Agenda
   d'Avaluacio de Tecnologia i Recerca Mediques (AATRM) (grant
   402/02/2008); Catalan Association of Public Universities (ACUP) (grants
   2010ACUP_00437); the Spanish Network for the Research in Infectious
   Diseases (REIPI RD16/0016/0003); and the European Regional Development
   Fund (ERDF). Cristina Andres has been a recipient of a predoctoral
   fellowship from the Vail d'Hebron Research Institute (PREDVHIR-2013). We
   would like to acknowledge GISAID as we used their reference sequences.
CR Agencia de Salut Publica de Catalunya (ASPCAT). Generalitat de Catalunya, MAN VAC CAT, P166
   [Anonymous], 1999, PLA INF INF RESP AG
   [Anonymous], 2018, PLA ACT CAT ENF INF
   Anton A, 2016, CLIN MICROBIOL INFEC, V22, DOI 10.1016/j.cmi.2016.02.007
   Beaute J, 2015, EPIDEMIOL INFECT, V143, P2950, DOI 10.1017/S0950268814003422
   Bouvier NM, 2008, VACCINE, V26, pD49, DOI 10.1016/j.vaccine.2008.07.039
   Broberg EMA, 2016, EUROSURVEILLANCE, P30184
   Brownlee GG, 2001, PHILOS T ROY SOC B, V356, P1871, DOI 10.1098/rstb.2001.1001
   Corcioli F, 2014, VIRUS RES, V180, P39, DOI 10.1016/j.virusres.2013.12.010
   Edgar RC, 2004, NUCLEIC ACIDS RES, V32, P1792, DOI 10.1093/nar/gkh340
   Glaser L, 2005, J VIROL, V79, P11533, DOI 10.1128/JVI.79.17.11533-11536.2005
   Hurt AC, 2012, LANCET INFECT DIS, V12, P240, DOI 10.1016/S1473-3099(11)70318-8
   Instituto de Salud Carlos III (ISCIII), SIST VIG GRIP ESP
   LAMB RA, 1983, ANNU REV BIOCHEM, V52, P467, DOI 10.1146/annurev.bi.52.070183.002343
   Lin TW, 2009, VIROLOGY, V392, P73, DOI 10.1016/j.virol.2009.06.028
   Medina RA, 2011, NAT REV MICROBIOL, V9, P590, DOI 10.1038/nrmicro2613
   Nelson M, 2009, PLOS CURR, DOI [10.1371/currents.RRN1126, DOI 10.1371/CURRENTS.RRN1126]
   Nguyen HT, 2012, ANTIVIR THER, V17, P159, DOI 10.3851/IMP2067
   Perez-Ruiz Mercedes, 2012, Open Virol J, V6, P151, DOI 10.2174/1874357901206010151
   Munoz MP, 2011, VACCINE, V29, P5047, DOI 10.1016/j.vaccine.2011.04.067
   Schrauwen EJA, 2014, EUR J CLIN MICROBIOL, V33, P479, DOI 10.1007/s10096-013-1984-8
   Smith DJ, 2004, SCIENCE, V305, P371, DOI 10.1126/science.1097211
   Steinhauer DA, 1999, VIROLOGY, V258, P1, DOI 10.1006/viro.1999.9716
   Tamura K, 2011, MOL BIOL EVOL, V28, P2731, DOI 10.1093/molbev/msr121
   Terry BS, 2013, J MED DEVICES, V7, DOI 10.1115/1.4024477
   Tewawong N, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116302
   Vazquez-Perez JA, 2013, VIROL J, V10, DOI 10.1186/1743-422X-10-41
   Wie SH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062685
   World Health Organisation (WHO), WHO REC CAND VIR POT
   World Health Organization (WHO), 2016, REC COMP INFL VIR VA
   Xu LL, 2010, VIROL J, V7, DOI 10.1186/1743-422X-7-325
   Xu R, 2010, SCIENCE, V328, P357, DOI 10.1126/science.1186430
   2016, INFLUENZA OTHER RESP, V10, P525, DOI DOI 10.1111/IRV.12410
NR 33
TC 0
Z9 0
U1 1
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD APR 24
PY 2019
VL 37
IS 18
BP 2470
EP 2476
DI 10.1016/j.vaccine.2019.03.046
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HW3WD
UT WOS:000466622500007
PM 30926297
OA Green Published
DA 2020-05-12
ER

PT J
AU Findlow, H
   Tapia, MD
   Sow, SO
   Haidara, FC
   Coulibaly, F
   Keita, AM
   Diallo, F
   Doumbia, M
   Traore, A
   Schluterman, N
   Clark, DA
   Borrow, R
   Levine, MM
AF Findlow, H.
   Tapia, M. D.
   Sow, S. O.
   Haidara, F. C.
   Coulibaly, F.
   Keita, A. M.
   Diallo, F.
   Doumbia, M.
   Traore, A.
   Schluterman, N.
   Clark, D. A.
   Borrow, R.
   Levine, M. M.
TI Kinetics of maternally-derived serogroup A, C, Y and W-specific
   meningococcal immunoglobulin G in Malian women and infants
SO VACCINE
LA English
DT Article
DE Meningococcal; Maternal immunization; Vaccination
ID CAPSULAR POLYSACCHARIDE VACCINE; ANTIBODY; IMMUNIZATION; ASSIGNMENT;
   SERUM
AB A prospective, randomised, controlled observer-blind trial measuring the efficacy and immunogenicity of trivalent influenza vaccine (TIV) and the immunogenicity of quadrivalent meningococcal conjugate vaccine (MCV) in pregnant women and their infants up to 6 months of age was conducted in Mali. Here we reported the immunogenicity of MCV, which was used as a comparator vaccine to TIV, in this population. Third-trimester pregnant Malian women were randomized to receive TIV or MCV. Blood samples were collected from women prior to vaccination, 28 days post-vaccination, at delivery and 3 and 6 months post-delivery and from infants at birth and 3 and 6 months of age. Meningococcal-specific serogroup (Men) A,C, Y and W-specific antibodies were measured by enzyme linked immunosorbent assay in a randomly selected subset of 50 mother-infant pairs where the mother had received MCV. At birth, 94.0% (47/50) of infants had MenA specific IgG levels >= 2 mu g/mL decreasing to 72.9% and 30.4% at 3 and 6 months of age. For MenC, 81.3% (39/48) of infants had MenC specific IgG levels >= 2 mu g/mL at birth decreasing to 29.4% and 17.8% at 3 and 6 months of age. For MenY, 89.6% (43/48) of infants had MenY specific IgG levels >= 2 mu g/mL at birth decreasing to 64.6% and 62.5% at 3 and 6 months of age. For MenW, 89.6% (43/48) of infants had MenW specific IgG levels >= 2 mu g/ml at birth decreasing to 62.5% and 41.7% at 3 and 6 months of age.
   Maternal immunization with MCV conveyed protective levels of IgG at birth through to 3 months of age in the majority of infants. Crown Copyright (C) 2019 Published by Elsevier Ltd. All rights reserved.
C1 [Findlow, H.; Borrow, R.] Manchester Royal Infirm, Publ Hlth England, Vaccine Evaluat Unit, Manchester, Lancs, England.
   [Tapia, M. D.; Levine, M. M.] Univ Maryland, Sch Med, Ctr Vaccine Dev, Baltimore, MD 21201 USA.
   [Sow, S. O.; Haidara, F. C.; Coulibaly, F.; Keita, A. M.; Diallo, F.; Doumbia, M.; Traore, A.] Ctr Dev Vaccins, Bamako, Mali.
   [Schluterman, N.] Univ Maryland, Dept Epidemiol, Baltimore, MD 21201 USA.
   [Clark, D. A.] Emory Univ, Rollins Sch Publ Hlth, Dept Epidemiol, Atlanta, GA 30322 USA.
RP Findlow, H (reprint author), Manchester Royal Infirm, Publ Hlth England, Vaccine Evaluat Unit, Manchester, Lancs, England.
EM helenfindlow@hotmail.com
FU Bill and Melinda Gates Foundation - Sanofi Pasteur
FX Funding for the overall trial was from the Bill and Melinda Gates
   Foundation and this part of the work was funded by Sanofi Pasteur.
CR Amirthalingam G, 2014, LANCET, V384, P1521, DOI 10.1016/S0140-6736(14)60686-3
   CARLONE GM, 1992, J CLIN MICROBIOL, V30, P154, DOI 10.1128/JCM.30.1.154-159.1992
   Djingarey MH, 2015, CLIN INFECT DIS, V61, pS434, DOI 10.1093/cid/civ551
   Findlow H, 2006, CLIN VACCINE IMMUNOL, V13, P507, DOI 10.1128/CVI.13.4.507-510.2006
   GHEESLING LL, 1994, J CLIN MICROBIOL, V32, P1475, DOI 10.1128/JCM.32.6.1475-1482.1994
   HOLDER PK, 1995, CLIN DIAGN LAB IMMUN, V2, P132, DOI 10.1128/CDLI.2.2.132-137.1995
   Holme D, 2015, CLIN INFECT DIS, V61, pS563, DOI 10.1093/cid/civ505
   Joseph H, 2004, CLIN DIAGN LAB IMMUN, V11, P1, DOI 10.1128/CDLI.11.1.1-5.2004
   Karachaliou A, 2015, CLIN INFECT DIS, V61, pS594, DOI 10.1093/cid/civ508
   Lopes CRC, 2009, BRAZ J INFECT DIS, V13, P104, DOI 10.1590/S1413-86702009000200008
   Ohfuji S, 2018, J INFECT DIS, V217, P878, DOI 10.1093/infdis/jix629
   PELTOLA H, 1977, NEW ENGL J MED, V297, P686, DOI 10.1056/NEJM197709292971302
   SHAHID NS, 1995, LANCET, V346, P1252, DOI 10.1016/S0140-6736(95)91861-2
   Tapia MD, 2016, LANCET INFECT DIS, V16, P1026, DOI 10.1016/S1473-3099(16)30054-8
   Voysey M, 2017, VACCINE, V35, P5850, DOI 10.1016/j.vaccine.2017.09.002
   World Health Organization, 2007, MAT NEON TET EL MNTE
   2015, CLIN INFECT DIS, V60, P333, DOI DOI 10.1093/CID/CIU821
NR 17
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD APR 24
PY 2019
VL 37
IS 18
BP 2477
EP 2481
DI 10.1016/j.vaccine.2019.03.045
PG 5
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HW3WD
UT WOS:000466622500008
PM 30952500
OA Green Published, Other Gold
DA 2020-05-12
ER

PT J
AU Lopez-Fauqued, M
   Campora, L
   Delannois, F
   El Idrissi, M
   Oostvogels, L
   De Looze, FJ
   Diez-Domingo, J
   Heineman, TC
   Lal, H
   McElhaney, JE
   McNeil, SA
   Yeo, W
   Tavares-Da-Silva, F
   Ahonen, A
   Avelino-Silva, TJ
   Barba-Gomez, JF
   Berglund, J
   Cuixart, CB
   Caso, C
   Chlibek, R
   Choi, WS
   Cunningham, AL
   Desole, MG
   Eizenberg, P
   Esen, M
   Espie, E
   Gervais, P
   Ghesquiere, W
   Godeaux, O
   Gorfinkel, I
   Hui, DSC
   Hwang, SJ
   Korhonen, T
   Kovac, M
   Ledent, E
   Leung, E
   Levin, MJ
   Perez, SN
   Neto, JL
   Pauksens, K
   Poder, A
   de la Pinta, MLR
   Rombo, L
   Schwarz, TF
   Smetana, J
   Staniscia, T
   Tinoco, JC
   Toma, A
   Vastiau, I
   Vesikari, T
   Volpi, A
   Watanabe, D
   Weckx, LY
   Zahaf, T
AF Lopez-Fauqued, Marta
   Campora, Laura
   Delannois, Frederique
   El Idrissi, Mohamed
   Oostvogels, Lidia
   De Looze, Ferdinandus J.
   Diez-Domingo, Javier
   Heineman, Thomas C.
   Lal, Himal
   McElhaney, Janet E.
   McNeil, Shelly A.
   Yeo, Wilfred
   Tavares-Da-Silva, Fernanda
   Ahonen, Anitta
   Avelino-Silva, Thiago Junquera
   Fernando Barba-Gomez, Jose
   Berglund, Johan
   Brotons Cuixart, Carlos
   Caso, Covadonga
   Chlibek, Roman
   Choi, Won Suk
   Cunningham, Anthony L.
   Desole, Maria Guiseppina
   Eizenberg, Peter
   Esen, Meral
   Espie, Emmanuelle
   Gervais, Pierre
   Ghesquiere, Wayne
   Godeaux, Olivier
   Gorfinkel, Iris
   Hui, David Shu Cheong
   Hwang, Shinn-Jang
   Korhonen, Tiina
   Kovac, Martina
   Ledent, Edouard
   Leung, Edward
   Levin, Myron J.
   Narejos Perez, Silvia
   Neto, Jose Luiz
   Pauksens, Karlis
   Poder, Airi
   Rodriguez de la Pinta, Maria Luisa
   Rombo, Lars
   Schwarz, Tino F.
   Smetana, Jan
   Staniscia, Tommaso
   Tinoco, Juan Carlos
   Toma, Azhar
   Vastiau, Ilse
   Vesikari, Timo
   Volpi, Antonio
   Watanabe, Daisuke
   Weckx, Lily Yin
   Zahaf, Toufik
CA ZOE-Study Grp
TI Safety profile of the adjuvanted recombinant zoster vaccine: Pooled
   analysis of two large randomised phase 3 trials
SO VACCINE
LA English
DT Article
DE Varicella-zoster virus; Vaccine; Safety; Reactogenicity
ID SUBUNIT CANDIDATE VACCINE; HERPES-ZOSTER; OLDER; IMMUNOGENICITY; ADULTS;
   POPULATION; EFFICACY; AGE
AB Background: The ZOE-50 (NCT01165177) and ZOE-70 (NCT01165229) phase 3 clinical trials showed that the adjuvanted recombinant zoster vaccine (RZV) was >= 90% efficacious in preventing herpes zoster in adults. Here we present a comprehensive overview of the safety data from these studies.
   Methods: Adults aged >= 50 (ZOE-50) and >= 70 (ZOE-70) years were randomly vaccinated with RZV or placebo. Safety analyses were performed on the pooled total vaccinated cohort, consisting of participants receiving at least one dose of RZV or placebo. Solicited and unsolicited adverse events (AEs) were collected for 7 and 30 days after each vaccination, respectively. Serious AEs (SAEs) were collected from the first vaccination until 12 months post-last dose. Fatal AEs, vaccination-related SAEs, and potential immune-mediated diseases (pIMDs) were collected during the entire study period.
   Results: Safety was evaluated in 14,645 RZV and 14,660 placebo recipients. More RZV than placebo recipients reported unsolicited AEs (50.5% versus 32.0%); the difference was driven by transient injection site and solicited systemic reactions that were generally seen in the first week post-vaccination. The occurrence of overall SAEs (RZV: 10.1%; Placebo: 10.4%), fatal AEs (RZV: 4.3%; Placebo: 4.6%), and pIMDs (RZV: 1.2%; Placebo: 1.4%) was balanced between groups. The occurrence of possible exacerbations of pIMDs was rare and similar between groups. Overall, except for the expected local and systemic symptoms, the safety results were comparable between the RZV and Placebo groups irrespective of participant age, gender, or race.
   Conclusions: No safety concerns arose, supporting the favorable benefit-risk profile of RZV. (C) 2019 GlaxoSmithKline Biologicals SA. Published by Elsevier Ltd.
C1 [Lopez-Fauqued, Marta; Campora, Laura; Delannois, Frederique; Oostvogels, Lidia; Tavares-Da-Silva, Fernanda; Vastiau, Ilse] GSK, Ave Fleming 20, B-1300 Wavre, Belgium.
   [El Idrissi, Mohamed; Ledent, Edouard] GSK, Rixensart, Belgium.
   [De Looze, Ferdinandus J.] AusTrials Pty Ltd, Sherwood, Qld, Australia.
   [De Looze, Ferdinandus J.] Univ Queensland, Sch Med, Brisbane, Qld, Australia.
   [Diez-Domingo, Javier] Fdn Fomento Invest Sanitaria & Biomed, Vaccine Res Unit, Valencia, Spain.
   [Heineman, Thomas C.; Lal, Himal] GSK, King Of Prussia, PA USA.
   [McElhaney, Janet E.] Hlth Sci North Res Inst, Sudbury, ON, Canada.
   [McNeil, Shelly A.] Dalhousie Univ, Canadian Ctr Vaccinol, Halifax, NS, Canada.
   [McNeil, Shelly A.] Dalhousie Univ, IWK Hlth Ctr, Halifax, NS, Canada.
   [McNeil, Shelly A.] Dalhousie Univ, Nova Scotia Hlth Author, Halifax, NS, Canada.
   [Yeo, Wilfred] Univ Wollongong, Sch Med, Wollongong, NSW, Australia.
   [Ahonen, Anitta] Univ Tampere, Jarvenpaa Vaccine Clin, Tampere, Finland.
   [Avelino-Silva, Thiago Junquera] Univ Sao Paulo, Sch Med, Sao Paulo, Brazil.
   [Fernando Barba-Gomez, Jose] Inst Dermatol Jalisco, Guadalajara, Jalisco, Mexico.
   [Berglund, Johan] Blekinge Inst Technol, Karlskrona, Sweden.
   [Brotons Cuixart, Carlos] EAP Sardenya, Barcelona, Spain.
   [Caso, Covadonga] Hosp Clin San Carlos, Madrid, Spain.
   [Chlibek, Roman] Univ Def, Fac Mil Hlth Sci, Brno, Czech Republic.
   [Choi, Won Suk] Korea Univ, Coll Med, Seoul, South Korea.
   [Cunningham, Anthony L.] Univ Sydney, Westmead Inst Med Res, Sydney, NSW, Australia.
   [Desole, Maria Guiseppina] Serv Igiene Pubbl, Sassari, Italy.
   [Eizenberg, Peter] Doctors Ivanhoe, Ivanhoe, Australia.
   [Esen, Meral] Univ Clin Tubingen, Inst Tropenmed, Tubingen, Germany.
   [Espie, Emmanuelle; Godeaux, Olivier; Zahaf, Toufik] GSK, Brussels, Belgium.
   [Gervais, Pierre] Q&T Res Sherbrooke, Sherbrooke, PQ, Canada.
   [Ghesquiere, Wayne] Univ British Columbia, Vancouver, BC, Canada.
   [Gorfinkel, Iris] York Univ, N York, ON, Canada.
   [Hui, David Shu Cheong] Prince Wales Hosp, Hong Kong, Peoples R China.
   [Hwang, Shinn-Jang] Taipei Vet Gen Hosp, Taipei, Taiwan.
   [Hwang, Shinn-Jang] Natl Yang Ming Univ, Sch Med, Taipei, Taiwan.
   [Korhonen, Tiina] Univ Tampere, Sch Med, Vaccine Res Ctr, Tampere, Finland.
   [Kovac, Martina] GSK, New York, NY USA.
   [Leung, Edward] Hong Kong Assoc Gerontol, Hong Kong, Peoples R China.
   [Levin, Myron J.] Univ Colorado, Anschutz Med Campus, Aurora, CO USA.
   [Narejos Perez, Silvia] CAP Centelles, Centelles, Spain.
   [Neto, Jose Luiz] Inst AZ Pesquisa & Ensino, Curitiba, Parana, Brazil.
   [Pauksens, Karlis] Uppsala Univ Hosp, Uppsala, Sweden.
   [Poder, Airi] Kliiniliste Uuringute Keskus, Tartu, Estonia.
   [Rodriguez de la Pinta, Maria Luisa] Hosp Puerta de Hierro, Madrid, Spain.
   [Rombo, Lars] Uppsala Univ, Uppsala, Sweden.
   [Schwarz, Tino F.] Standort Juliusspital, Wurzburg, Germany.
   [Smetana, Jan] Univ Def, Fac Mil Hlth Sci, Brno, Czech Republic.
   [Staniscia, Tommaso] Univ G dAnnunzio, Chieti, Italy.
   [Tinoco, Juan Carlos] Hosp Gen Durango, Durango, Mexico.
   [Toma, Azhar] Manna Res, Toronto, ON, Canada.
   [Vesikari, Timo] Univ Tampere, Tampere, Finland.
   [Volpi, Antonio] AO Univ Policlin Tor Vergata, Rome, Italy.
   [Watanabe, Daisuke] Kobe Univ, Grad Sch Med, Kobe, Hyogo, Japan.
   [Weckx, Lily Yin] Univ Fed Sao Paulo, Sao Paulo, Brazil.
   [Oostvogels, Lidia] CureVac AG, Tubingen, Germany.
   [Heineman, Thomas C.] Halozyme Therapeut, San Diego, CA USA.
   [Lal, Himal] Pfizer Vaccine Inc, Collegeville, PA USA.
RP Campora, L (reprint author), GSK, Ave Fleming 20, B-1300 Wavre, Belgium.
EM marta.x.lopez-fauqed@gsk.com; laura.e.campora@gsk.com;
   frederique.x.delannois@gsk.com; mohamed.s.elidrissi@gsk.com;
   cornelia.oostvogels@orange.fr; f.delooze@trialworks.com.au;
   jdiezdomingo@gmail.com; tch3768@gmail.com; himallal@yahoo.com;
   jmcelhaney@hsnri.ca; Shelly.McNeil@nshealth.ca; wilf@uow.edu.au;
   fernanda.tavares@gsk.com
RI Hui, David SC/O-2754-2015; Avelino-Silva, Thiago J/J-8794-2013; Brotons,
   Carlos/AAG-8365-2020
OI Avelino-Silva, Thiago J/0000-0001-9347-0519; Brotons,
   Carlos/0000-0001-9388-6581; Smetana, Jan/0000-0002-4566-3356; WECKX,
   LILY/0000-0003-4949-3582; Yeo, Wilfred/0000-0001-9554-5203;
   Diez-Domingo, Javier/0000-0003-1008-3922; Lopez Fauqued,
   Marta/0000-0002-1337-7267
FU GlaxoSmithKline Biologicals SA, Rue de l'Institut 89, Rixensart, Belgium
FX The trials were funded by GlaxoSmithKline Biologicals SA, Rue de
   l'Institut 89, 1330 Rixensart, Belgium. GlaxoSmithKline Biologicals SA
   was involved in all stages of the conduct and analysis of the studies.
   GlaxoSmithKline Biologicals SA covered the costs associated with the
   development and the publishing of the present manuscript.
CR Agmon-Levin N, 2009, ISR MED ASSOC J, V11, P183
   Angelo MG, 2014, PHARMACOEPIDEM DR S, V23, P466, DOI 10.1002/pds.3554
   [Anonymous], LEAD CAUS DEATH MAL
   Biswal S, 2013, ECANCERMEDICALSCIENC, V7, DOI 10.3332/ecancer.2013.310
   Chlibek R, 2014, VACCINE, V32, P1745, DOI 10.1016/j.vaccine.2014.01.019
   Chlibek R, 2013, J INFECT DIS, V208, P1953, DOI 10.1093/infdis/jit365
   Crowson CS, 2011, ARTHRITIS RHEUM-US, V63, P633, DOI 10.1002/art.30155
   Cunningham AL, 2016, NEW ENGL J MED, V375, P1019, DOI 10.1056/NEJMoa1603800
   Da Silva FT, 2013, VACCINE, V31, P1870, DOI 10.1016/j.vaccine.2013.01.042
   Diamantopoulos AP, 2014, RHEUMATOLOGY, V53, P15
   Didierlaurent AM, 2014, J IMMUNOL, V193, P1920, DOI 10.4049/jimmunol.1400948
   Gencer S, 2003, J INFECTION, V47, P65, DOI 10.1016/S0163-4453(03)00044-6
   Gnann JW, 2002, NEW ENGL J MED, V347, P340, DOI 10.1056/NEJMcp1302674
   ICH, CLIN SAF DAT MAN DEF
   Israeli E, 2009, LUPUS, V18, P1217, DOI 10.1177/0961203309345724
   Johnson BH, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-1262-8
   Kawai K, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-004833
   Lal H, 2015, NEW ENGL J MED, V372, P2087, DOI 10.1056/NEJMoa1501184
   Leroux-Roels I, 2012, J INFECT DIS, V206, P1280, DOI 10.1093/infdis/jis497
   Perola O, 2005, EUR J CLIN MICROBIOL, V24, P766, DOI 10.1007/s10096-005-0045-3
   Prince MJ, 2015, LANCET, V385, P549, DOI 10.1016/S0140-6736(14)61347-7
   Rasch EK, 2003, ARTHRITIS RHEUM, V48, P917, DOI 10.1002/art.10897
   Salemi S, 2010, INT REV IMMUNOL, V29, P247, DOI 10.3109/08830181003746304
   Shoenfeld Y, 2011, J AUTOIMMUN, V36, P4, DOI 10.1016/j.jaut.2010.07.003
   Stadtmauer EA, 2014, BLOOD, V124, P2921, DOI 10.1182/blood-2014-04-573048
   Vanderpump MPJ, 2011, BRIT MED BULL, V99, P39, DOI 10.1093/bmb/ldr030
   Wraith DC, 2003, LANCET, V362, P1659, DOI 10.1016/S0140-6736(03)14802-7
   2015, DEMOGRAPHY, V52, P593, DOI DOI 10.1007/S13524-015-0372-7
NR 28
TC 2
Z9 2
U1 1
U2 6
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD APR 24
PY 2019
VL 37
IS 18
BP 2482
EP 2493
DI 10.1016/j.vaccine.2019.03.043
PG 12
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HW3WD
UT WOS:000466622500009
PM 30935742
OA Green Published, Other Gold
DA 2020-05-12
ER

PT J
AU Luyten, J
   Bruyneel, L
   van Hoek, AJ
AF Luyten, Jeroen
   Bruyneel, Luk
   van Hoek, Albert Jan
TI Assessing vaccine hesitancy in the UK population using a generalized
   vaccine hesitancy survey instrument
SO VACCINE
LA English
DT Article
DE Hesitancy; Skepticism; Vaccine hesitancy scale; Anti-vaccination
ID HERD-IMMUNITY; IMMUNIZATION; ATTITUDES; PROGRAMS; OPTIMISM; PARENTS;
   SCALE
AB Background: In many regions of the world, vaccine hesitancy has become an important concern to public health. A key part of any effective solution to it is to gain an in-depth understanding of the problem: its scope, who holds hesitant views and for which reasons.
   Methods: We adapt the original 10-item Vaccine Hesitancy Scale (VHS), which targets parental attitudes, to a more generic version that captures general attitudes to vaccination. We use this adapted VHS in a sample of 1402 British citizens, selected from a large online panel (N > 1,000,000) based on quota for age, gender, educational attainment and region (response rate 43%). The existence of VHS subscales is evaluated via exploratory and confirmatory factor analysis. We describe the extent of vaccine hesitancy in the sample, and use simple and multiple regression analysis to examine associations between respondent characteristics and vaccine hesitancy.
   Results: Despite ambiguities in defining hesitancy, we found that a substantial part of our sample held hesitant views about vaccination, particularly for those items reflecting aversion to risks of side effects. Four percent responded in a hesitant way to all ten items and ninety to at least one of the ten items. In line with recent studies in other populations, we identified two subscales within the VHS: lack of confidence in the need for vaccines and aversion to the risk of side effects. We found significant associations between hesitancy and various respondent characteristics but the predictive power of these associations remained limited.
   Conclusion: Our study suggests that whereas a substantial percentage of the British population is vaccine hesitant, these views are not clustered in typical demographic features. The small but important adaptation of the VHS to target general attitudes seems to result in highly similar psychometric characteristics as the original scale that exclusively targets parents. We provide suggestions for further validation of the VHS. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Luyten, Jeroen; Bruyneel, Luk] Katholieke Univ Leuven, Leuven Inst Healthcare, Kapucijnenvoer 35, B-3000 Leuven, Belgium.
   [van Hoek, Albert Jan] London Sch Hyg & Trop Med, Fac Epidemiol & Populat Hlth, Dept Infect Dis Epidemiol, Keppel St, London WC1E 7HT, England.
   [van Hoek, Albert Jan] Natl Inst Publ Hlth & Environm, Ctr Infect Dis, Antonie van Leeuwenhoeklaan 9, NL-3721 MA Bilthoven, Netherlands.
RP Luyten, J (reprint author), Katholieke Univ Leuven, Leuven Inst Healthcare, Kapucijnenvoer 35, B-3000 Leuven, Belgium.
EM jeroen.luyten@kuleuven.be
RI Bruyneel, Luk/V-6022-2019; Luyten, Jeroen/V-1124-2019
OI Bruyneel, Luk/0000-0003-1209-692X; Luyten, Jeroen/0000-0003-1770-6352;
   Luyten, Jeroen/0000-0001-6398-4025
FU National Institute for Health Research Health Protection Research Unit
   (NIHR HPRU) in immunisation at the London School of Hygiene & Tropical
   Medicine; Public Health England
FX AJvH received funding from the National Institute for Health Research
   Health Protection Research Unit (NIHR HPRU) in immunisation at the
   London School of Hygiene & Tropical Medicine in partnership with Public
   Health England. The views expressed are those of the authors and not
   necessarily those of the UK National Health Service, the UK NIHR, the UK
   Medical Research Council, the UK Department of Health or Public Health
   England.
CR Berger BE, 2010, HUM VACCINES, V6, P1016, DOI 10.4161/hv.6.12.13398
   Berndsen M, 2001, ACTA PSYCHOL, V108, P173, DOI 10.1016/S0001-6918(01)00029-4
   Brown KF, 2011, VACCINE, V29, P1700, DOI 10.1016/j.vaccine.2010.12.030
   Butler R, 2015, VACCINE, V33, P4176, DOI 10.1016/j.vaccine.2015.04.038
   Carver CS, 2010, CLIN PSYCHOL REV, V30, P879, DOI 10.1016/j.cpr.2010.01.006
   COOMBES R, 2017, BMJ-BRIT MED J, V359, DOI DOI 10.1136/BMJ.J4803
   Cooper LZ, 2008, PEDIATRICS, V122, P149, DOI 10.1542/peds.2008-0987
   Dawson A., 2009, ETHICS PREVENTION PU
   Dawson A, 2011, HEALTH AFFAIR, V30, P1029, DOI 10.1377/hlthaff.2011.0301
   Diekema DS, 2005, PEDIATRICS, V115, P1428, DOI 10.1542/peds.2005-0316
   Domek GJ, 2018, VACCINE, V36, P5273, DOI 10.1016/j.vaccine.2018.07.046
   Fine P, 2011, CLIN INFECT DIS, V52, P911, DOI 10.1093/cid/cir007
   Gilkey MB, 2014, VACCINE, V32, P6259, DOI 10.1016/j.vaccine.2014.09.007
   Hickler B, 2015, VACCINE, V33, P4155, DOI 10.1016/j.vaccine.2015.04.034
   Holt E, 2018, LANCET, V392, P724, DOI 10.1016/S0140-6736(18)32031-2
   Horne Z, 2015, P NATL ACAD SCI USA, V112, P10321, DOI 10.1073/pnas.1504019112
   Jarrett C, 2015, VACCINE, V33, P4180, DOI 10.1016/j.vaccine.2015.04.040
   King G, 2003, AM POLIT SCI REV, V97, P567, DOI 10.1017/S0003055403000881
   Larson HJ, 2015, VACCINE, V33, P4165, DOI 10.1016/j.vaccine.2015.04.037
   Luyten J, 2019, SOC JUSTICE RES, V32, P186, DOI 10.1007/s11211-019-00329-5
   Luyten J, 2019, SOC SCI MED, V228, P181, DOI 10.1016/j.socscimed.2019.03.025
   Luyten J, 2016, HEALTH AFFAIR, V35, P212, DOI 10.1377/hlthaff.2015.1088
   Luyten J, 2014, EUR J PUBLIC HEALTH, V24, P310, DOI 10.1093/eurpub/ckt080
   Luyten J, 2011, PUBLIC HEALTH ETH-UK, V4, P280, DOI 10.1093/phe/phr032
   MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036
   Martin LR, 2017, ANN BEHAV MED, V51, P652, DOI 10.1007/s12160-017-9888-y
   McRee AL, 2010, SEX TRANSM DIS, V37, P234, DOI 10.1097/OLQ.0b013e3181c37e15
   Meitinger K, 2017, PUBLIC OPIN QUART, V81, P447, DOI 10.1093/poq/nfx009
   Nadler JT, 2015, J GEN PSYCHOL, V142, P71, DOI 10.1080/00221309.2014.994590
   Opel DJ, 2011, HUM VACCINES, V7, P419, DOI 10.4161/hv.7.4.14120
   Orr C, 2017, CLIN PEDIATR, V56, P784, DOI 10.1177/0009922816687328
   Plotkin S, 2014, P NATL ACAD SCI USA, V111, P12283, DOI 10.1073/pnas.1400472111
   Salmon DA, 2006, LANCET, V367, P436, DOI 10.1016/S0140-6736(06)68144-0
   SCHEIER MF, 1994, J PERS SOC PSYCHOL, V67, P1063, DOI 10.1037/0022-3514.67.6.1063
   Schwartz JS, 2017, VACCINATION ETHICS P
   Shapiro GK, 2018, VACCINE, V36, P660, DOI 10.1016/j.vaccine.2017.12.043
   Shapiro GK, 2016, PAPILLOMAVIRUS RES, V2, P167, DOI 10.1016/j.pvr.2016.09.001
   Siddiqui M, 2013, HUM VACC IMMUNOTHER, V9, P2643, DOI 10.4161/hv.27243
   Verweij M, 2004, VACCINE, V22, P3122, DOI 10.1016/j.vaccine.2004.01.062
   WHO, 2018, 10 THREATS GLOB HLTH
   Zingg A, 2012, VACCINE, V30, P3771, DOI 10.1016/j.vaccine.2012.03.014
NR 41
TC 0
Z9 0
U1 6
U2 10
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD APR 24
PY 2019
VL 37
IS 18
BP 2494
EP 2501
DI 10.1016/j.vaccine.2019.03.041
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HW3WD
UT WOS:000466622500010
PM 30940484
DA 2020-05-12
ER

PT J
AU Pinto, LA
   Wilkin, TJ
   Kemp, TJ
   Abrahamsen, M
   Isaacs-Soriano, K
   Pan, YJ
   Webster-Cyriaque, J
   Palefsky, JM
   Giuliano, AR
AF Pinto, Ligia A.
   Wilkin, Timothy J.
   Kemp, Troy J.
   Abrahamsen, Martha
   Isaacs-Soriano, Kimberly
   Pan, Yuanji
   Webster-Cyriaque, Jennifer
   Palefsky, Joel M.
   Giuliano, Anna R.
TI Oral and systemic HPV antibody kinetics post-vaccination among
   HIV-positive and HIV-negative men
SO VACCINE
LA English
DT Article
DE HPV; HIV; Oral antibodies; HPV vaccine
ID HUMAN-PAPILLOMAVIRUS VACCINE; IMMUNOGENICITY; RESPONSES; CANCER; SAFETY;
   WOMEN; INFECTION; EFFICACY; AVIDITY; RISK
AB Duration and functional aspects of the oral and systemic antibody responses following HPV vaccination in HIV-negative (HIV-) and HIV-positive (HIV+) men are not well characterized. Oral and systemic HPV-16 and HPV-18-specific antibody levels were evaluated over 18-months of follow-up, in HIV+ and HIV- men. Sera and oral gargles from 147 HIV- men, ages 27-45 and 75 HIV+ men, ages 22-61, who received 3-doses of quadrivalent HPV vaccine were tested for HPV-16 and HPV-18 antibodies at Day 1, Month 7 (1 month post-dose 3), and Month 18 (12 months post-dose 3) and HPV avidity (Day 1, and Month 7) using L1-VLP ELISA.
   All individuals seroconverted, regardless of HIV-status, following 3-doses of vaccine for HPV-16 and HPV-18. Serum HPV-16 and HPV-18 antibody geometric mean levels were >2-fold lower in HIV+ compared to HIV- men at Month 7 (HPV-16: 808.5 versus 2119.8 EU/mL, and HPV-18: 285.8 versus 611.6 EU/mL, p < 0.001) but not significantly different at Month 18 (HPV-16: 281.8 versus 359.7 EU/mL, p = 0.145, and HPV-18: 120.2 versus 93.4 EU/mL, p = 0.372). Post-vaccination, only oral HPV-16 antibody levels at Month 7 were significantly different between HIV+ and HIV- men (127.7 versus 177.1 EU/mg of IgG, p = 0.008). Among baseline HPV-seronegative men, circulating levels of HPV-16 and HPV-18 antibodies were up to >3 fold lower in HIV+ men, at Months 7 and 18. In contrast, levels of HPV-16 and HPV-18 antibodies after vaccination were not inferior in baseline HPV-seropositive, HIV+ men. HPV-16 and HPV-18 avidity was lower among HIV+ compared to HIV- men at Month 7 (HPV-16: 1.95 M versus 2.12 M, p = 0.027; HPV-18: 1.50 M versus 1.72 M, p < 0.001).
   Although differences in peak antibody levels were observed between HIV+ and HIV- men following 3 doses of vaccine, plateau antibody levels were overall comparable, and avidity was relatively high for both groups. These data indicate that the vaccine induced antibody affinity maturation in both HIV+ and HIV- men and will likely result in long-term protective immune responses. (C) 2019 Published by Elsevier Ltd.
C1 [Pinto, Ligia A.; Kemp, Troy J.; Pan, Yuanji] Frederick Natl Lab Canc Res, HPV Immunol & HPV Serol Labs, Frederick, MD 21701 USA.
   [Wilkin, Timothy J.] Weill Cornell Med, Div Infect Dis, New York, NY USA.
   [Abrahamsen, Martha; Isaacs-Soriano, Kimberly; Giuliano, Anna R.] H Lee Moffitt Canc Ctr & Res Inst, Ctr Immunizat & Infect Res Canc, Tampa, FL USA.
   [Webster-Cyriaque, Jennifer] Univ N Carolina, Chapel Hill, NC 27515 USA.
   [Palefsky, Joel M.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
RP Pinto, LA (reprint author), Frederick Natl Lab Canc Res, HPV Immunol & HPV Serol Labs, Frederick, MD 21701 USA.
EM pintol@mail.nih.gov
OI Giuliano, Anna R/0000-0002-5440-8859
FU Investigator-Initiated Studies Program of Merck Sharp Dohme Corp; Miles
   for Moffitt program at the Moffitt Cancer Center in Tampa, Florida;
   National Cancer Institute, National Institutes of HealthUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Cancer Institute (NCI) [HHSN261200800001E]; National
   Cancer InstituteUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Cancer
   Institute (NCI) [UM1CA181255, AMC052]
FX This work was supported by a research grant from the
   Investigator-Initiated Studies Program of Merck Sharp & Dohme Corp [to
   A.R.G.]; Miles for Moffitt program at the Moffitt Cancer Center in
   Tampa, Florida; and this project has been funded in whole or in part
   with Federal funds from the National Cancer Institute, National
   Institutes of Health under Contract No. HHSN261200800001E. AMC052
   specimens were provided by AIDS and Cancer Specimen Resource, funded by
   the National Cancer Institute (UM1CA181255). The content of this
   publication does not necessarily reflect the views or policies of the
   Department of Health and Human Services, nor does mention of trade
   names, commercial products, or organizations imply endorsement by the
   U.S. Government. The opinions expressed in this paper are those of the
   authors and do not necessarily represent those of the funders. The
   funders of the study had no role in the design and conduct of the study;
   collection, management, analysis, and interpretation of the data; and
   preparation, review, or approval of the manuscript.
CR Bachmann MF, 1997, SCIENCE, V276, P2024, DOI 10.1126/science.276.5321.2024
   Beachler DC, 2014, ORAL ONCOL, V50, P1169, DOI 10.1016/j.oraloncology.2014.09.011
   Brophy J, 2018, PEDIATR INFECT DIS J, V37, P595, DOI [10.1097/INF.0000000000001874, 10.1097/inf.0000000000001874]
   Chaturvedi AK, 2011, J CLIN ONCOL, V29, P4294, DOI 10.1200/JCO.2011.36.4596
   Dauner JG, 2012, MOL CELL PROBE, V26, P73, DOI 10.1016/j.mcp.2012.01.002
   Dauner JG, 2010, VACCINE, V28, P5407, DOI 10.1016/j.vaccine.2010.06.018
   Delmas MC, 2000, AIDS, V14, P1775, DOI 10.1097/00002030-200008180-00013
   Giuliano AR, 2007, J INFECT DIS, V196, P1153, DOI 10.1086/521679
   Giuliano AR, 2011, NEW ENGL J MED, V364, P401, DOI 10.1056/NEJMoa0909537
   Guiguet M, 2009, LANCET ONCOL, V10, P1152, DOI 10.1016/S1470-2045(09)70282-7
   Herrin DM, 2014, HUM VACC IMMUNOTHER, V10, P3446, DOI 10.4161/hv.34408
   Jemal A, 2013, JNCI-J NATL CANCER I, V105, P175, DOI 10.1093/jnci/djs491
   Joura EA, 2008, VACCINE, V26, P6844, DOI 10.1016/j.vaccine.2008.09.073
   Kahn JA, 2013, CLIN INFECT DIS, V57, P735, DOI 10.1093/cid/cit319
   Kemp TJ, 2008, VACCINE, V26, P3608, DOI 10.1016/j.vaccine.2008.04.074
   Kojic EM, 2014, CLIN INFECT DIS, V59, P127, DOI 10.1093/cid/ciu238
   Kreimer AR, 2011, CANCER EPIDEM BIOMAR, V20, P172, DOI 10.1158/1055-9965.EPI-10-0682
   Money DM, 2016, VACCINE, V34, P4799, DOI 10.1016/j.vaccine.2016.08.016
   Moscicki AB, 2004, J INFECT DIS, V190, P1413, DOI 10.1086/424466
   Parmigiani A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079816
   Petersen PE, 2009, ORAL ONCOL, V45, P454, DOI 10.1016/j.oraloncology.2008.05.023
   Pinto LA, 2016, J INFECT DIS, V214, P1276, DOI 10.1093/infdis/jiw359
   Schiller JT, 2012, NAT REV MICROBIOL, V10, P681, DOI 10.1038/nrmicro2872
   Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387
   TAYAL SC, 1994, AIDS, V8, P558, DOI 10.1097/00002030-199404000-00024
   Viens LJ, 2016, MMWR-MORBID MORTAL W, V65, P661, DOI 10.15585/mmwr.mm6526a1
   Wilkin T, 2010, J INFECT DIS, V202, P1246, DOI 10.1086/656320
   Wilkin TJ, 2018, CLIN INFECT DIS
   2018, MMWR MORB MORTAL WKL, V67, P918
   2015, VACCINE, V33, P5640, DOI DOI 10.1016/J.VACCINE.2015.08.072
NR 30
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD APR 24
PY 2019
VL 37
IS 18
BP 2502
EP 2510
DI 10.1016/j.vaccine.2019.03.034
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HW3WD
UT WOS:000466622500011
PM 30940485
OA Green Accepted
DA 2020-05-12
ER

PT J
AU Mensah, K
   Heraud, JM
   Takahashi, S
   Winter, AK
   Metcalf, CJE
   Wesolowski, A
AF Mensah, K.
   Heraud, J. M.
   Takahashi, S.
   Winter, A. K.
   Metcalf, C. J. E.
   Wesolowski, A.
TI Seasonal gaps in measles vaccination coverage in Madagascar
SO VACCINE
LA English
DT Article
DE Vaccination; Measles; Madagascar; Healthcare access
ID HEALTH-CARE; BARRIERS; IMPACT; CAMPAIGNS
AB Introduction: Measles elimination depends on the successful deployment of measles containing vaccine. Vaccination programs often depend on a combination of routine and non-routine services, including supplementary immunization activities (SIAs) and vaccination weeks (VWs), that both aim to vaccinate all eligible children regardless of vaccination history or natural infection. Madagascar has used a combination of these activities to improve measles coverage. However, ongoing massive measles outbreak suggests that the country was in a "honeymoon" period and that coverage achieved needs to be re-evaluated. Although healthcare access is expected to vary seasonally in low resources settings, little evidence exists to quantify temporal fluctuations in routine vaccination, and interactions with other immunization activities.
   Methods: We used three data sources: national administrative data on measles vaccine delivery from 2013 to 2016, digitized vaccination cards from 49 health centers in 6 health districts, and a survey of health workers. Data were analyzed using linear regressions, analysis of variance, and t-tests.
   Findings: From 2013 to 2016, the footprint of SIAs and VWs is apparent, with more doses distributed during the relevant timeframes. Routine vaccination decreases in subsequent months, suggesting that additional activities may be interfering with routine services. The majority of missed vaccination opportunities occur during the rainy season. Health facility organization and shortage of vaccine contributed to vaccination gaps. Children born in June were the least likely to be vaccinated on time.
   Discussion: Evidence that routine vaccination coverage varies over the year and is diminished by other activities suggests that maintaining routine vaccination during SlAs and VWs is a key direction for strengthening immunization programs, ensuring population immunity and avoiding future outbreaks. (C) 2019 The Author(s). Published by Elsevier Ltd.
C1 [Mensah, K.; Takahashi, S.; Winter, A. K.; Metcalf, C. J. E.] Princeton Univ, Dept Ecol & Evolutionary Biol, Princeton, NJ 08544 USA.
   [Heraud, J. M.] Inst Pasteur Madagascar, Virol Unit, Antananarivo, Madagascar.
   [Metcalf, C. J. E.] Princeton Univ, Woodrow Wilson Sch Publ Affairs, Princeton, NJ 08544 USA.
   [Wesolowski, A.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD 21205 USA.
RP Mensah, K (reprint author), Princeton Univ, Dept Ecol & Evolutionary Biol, Princeton, NJ 08544 USA.; Wesolowski, A (reprint author), Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD 21205 USA.
EM kmensah@princeton.edu; awesolowski@jhu.edu
RI Heraud, Jean-Michel/AAD-8056-2019; Heraud, Jean-Michel/O-1464-2013
OI Heraud, Jean-Michel/0000-0003-1107-0859; Heraud,
   Jean-Michel/0000-0003-1107-0859; MENSAH, Keitly/0000-0003-0486-196X
FU BMGF [OPP1094793]; Wellcome Trust Sustaining Health [106866/Z/15/Z];
   Career Award at the Scientific Interface from the Burroughs Wellcome
   FundBurroughs Wellcome Fund; National Library of Medicine of the
   National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Library of
   Medicine (NLM) [Dp2LM013102]
FX CJEM, AKW and ST were supported by BMGF Grant #OPP1094793. CJEM, KM, APW
   were funded by Wellcome Trust Sustaining Health Grant (106866/Z/15/Z).
   APW is supported by a Career Award at the Scientific Interface from the
   Burroughs Wellcome Fund and by the National Library of Medicine of the
   National Institutes of Health under Award Number Dp2LM013102. The
   content is solely the responsibility of APW and does not necessarily
   represent the official views of the National Institutes of Health. We
   would like to thank Lieehar Andriamanalina, all the healthcare workers
   who participated to the study, Claude Kouadio, individuals from the
   Immunization program in Madagascar, the Metcalf Lab and individuals from
   the Virology Unit and the National Reference Laboratory for Measles at
   the Institut Pasteur de Madagascar in particular Richter
   Razafindratsimandresy and Soa Fy Andriamandimby.
CR Aaby P, 2014, CLIN INFECT DIS, V59, P484, DOI 10.1093/cid/ciu354
   [Anonymous], GLOB VACC ACT PLAN 2
   Blanford JI, 2012, INT J HEALTH GEOGR, V11, DOI 10.1186/1476-072X-11-24
   Bonu S, 2003, SOC SCI MED, V57, P1807, DOI 10.1016/S0277-9536(03)00056-X
   Carstensen B, 2007, STAT MED, V26, P3018, DOI 10.1002/sim.2764
   Clouston S, 2014, VACCINE, V32, P3533, DOI 10.1016/j.vaccine.2014.04.030
   Cutts FT, 1994, J INFECT DIS, P1
   Griffiths UK, 2011, J INFECT DIS, V204, pS78, DOI 10.1093/infdis/jir090
   Kashima S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038370
   Kreidl P, 2017, VACCINE, V35, P4836, DOI 10.1016/j.vaccine.2017.07.047
   MCLEAN AR, 1995, LANCET, V345, P272, DOI 10.1016/S0140-6736(95)90272-4
   Metcalf CJE, 2015, EPIDEMIOL INFECT, V143, P1457, DOI 10.1017/S0950268814001988
   Metcalf CJE, 2011, EPIDEMIOLOGY INFECT
   Ministere de la sante et du planning familial M, PLAN PLUR COMPL PROG
   Miyahara R, 2016, VACCINE, V34, P3335, DOI 10.1016/j.vaccine.2016.05.017
   Mounier-Jack S, 2016, HEALTH POLICY PLANN, V31, P1225, DOI 10.1093/heapol/czw054
   Munthali AC, 2019, DISABIL REHABIL, V41, P683, DOI 10.1080/09638288.2017.1404148
   Syed ST, 2013, J COMMUN HEALTH, V38, P976, DOI 10.1007/s10900-013-9681-1
   Tesarkova KH, 2018, SPRINGERBRIEF POPUL, P75, DOI 10.1007/978-3-319-67992-1_6
   Verguet S, 2013, J EPIDEMIOL COMMUN H, V67, P947, DOI 10.1136/jech-2012-202216
   Verguet S, 2012, VACCINE, V30, P1594, DOI 10.1016/j.vaccine.2011.12.123
   Vergunst R, 2015, GLOBAL HEALTH ACTION, V8, P1, DOI 10.3402/gha.v8.29003
   WHO, 2017, VACCINE
   Winter AK, 2018, AM J EPIDEMIOL, V187, P2219, DOI 10.1093/aje/kwy114
   Zimmerman RS, 2016, INTRO GLOBAL HLTH PR, P560
   2003, SOC SCI MED, V57, P1807, DOI DOI 10.1016/S0277-9536(03)00056-X
NR 26
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD APR 24
PY 2019
VL 37
IS 18
BP 2511
EP 2519
DI 10.1016/j.vaccine.2019.02.069
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HW3WD
UT WOS:000466622500012
PM 30940486
OA Green Published, Other Gold
DA 2020-05-12
ER

PT J
AU Arnold, LD
   Luong, L
   Rebmann, T
   Chang, JJ
AF Arnold, Lauren D.
   Luong, Lan
   Rebmann, Terri
   Chang, Jen Jen
TI Racial disparities in US maternal influenza vaccine uptake: Results from
   analysis of Pregnancy Risk Assessment Monitoring System (PRAMS) data,
   2012-2015
SO VACCINE
LA English
DT Article
DE Influenza vaccine; Pregnancy; Race/ethnicity; Disparities; PRAMS
ID UNITED-STATES; SEASONAL INFLUENZA; RACIAL/ETHNIC DISPARITIES; VIRUS
   INFECTION; PHASE 4; IMMUNIZATION; WOMEN; COVERAGE; RECOMMENDATIONS;
   PREDICTORS
AB Background: Pregnant women are at increased risk of hospitalization, serious complications, poor pregnancy outcomes, and mortality from influenza. Prior research suggests that there are racial/ethnic disparities in vaccination coverage and that a healthcare provider vaccination recommendation is associated with significantly higher vaccine uptake than without such a recommendation. The purpose of this study is to examine racial/ethnic disparities in healthcare providers' recommendations for pregnant women to receive the influenza vaccine and in vaccine uptake.
   Methods: This cross-sectional population-based study analyzed data from the Centers for Disease Control and Prevention's Pregnancy Risk Assessment Monitoring System (PRAMS) during 2012-2015 (n = 130161). Both healthcare provider recommendation and vaccine uptake were assessed dichotomously. Logistic regression was conducted to ascertain adjusted odds ratios and 95% confidence intervals, controlling for maternal age, marital status, education, prenatal care utilization, and smoking status.
   Results: Influenza vaccine uptake during pregnancy ranged from 39.1% among non-Hispanic (NH) Black women to 55.4% among NH Asian women. In the adjusted analysis, NH Black and NH Asian women had 19% (95% CI 0.75-0.86) and 34% (95% CI 0.61-0.72) decreased odds of receiving a provider recommendation for influenza vaccine during pregnancy, respectively, compared to NH White women. For influenza vaccine uptake, NH Black women were 30% less likely (95% CI 0.65-0.74) to receive influenza vaccine during pregnancy compared to NH White women.
   Conclusions: Our findings indicate that there are racial/ethnic disparities in healthcare provider recommendation and influenza vaccine uptake among pregnant women in the United States. Targeted efforts toward providers and interventions focusing on pregnant women may be warranted to reduce the disparity. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Arnold, Lauren D.; Luong, Lan; Rebmann, Terri; Chang, Jen Jen] St Louis Univ, Coll Publ Hlth & Social Justice, Dept Epidemiol & Biostat, 3545 Lafayette Ave, St Louis, MO 63104 USA.
RP Arnold, LD (reprint author), St Louis Univ, Coll Publ Hlth & Social Justice, 3545 Lafayette Ave, St Louis, MO 63104 USA.
EM lauren.arnold@slu.edu; lan.luong@slu.edu; terri.rebmann@slu.edu;
   Jenjen.chang@slu.edu
OI Rebmann, Terri/0000-0002-1338-8804
CR Ahluwalia IB, 2014, PUBLIC HEALTH REP, V129, P408, DOI 10.1177/003335491412900504
   Alexander GR, 1996, PUBLIC HEALTH REP, V111, P408
   Barber A, 2017, MMWR-MORBID MORTAL W, V66, P56, DOI 10.15585/mmwr.mm6602a4
   Bethancourt CN, 2017, CURR OPIN PEDIATR, V29, P737, DOI 10.1097/MOP.0000000000000553
   Budhwani H, 2016, PUBLIC HEALTH, V138, P146, DOI 10.1016/j.puhe.2016.04.003
   CDC, EST INFL ILLN MED VI
   Ding H, 2017, MMWR-MORBID MORTAL W, V66, P1016, DOI 10.15585/mmwr.mm6638a2
   Eick AA, 2011, ARCH PEDIAT ADOL MED, V165, P104, DOI 10.1001/archpediatrics.2010.192
   ENGLUND JA, 1993, J INFECT DIS, V168, P647, DOI 10.1093/infdis/168.3.647
   Fell DB, 2017, BJOG-INT J OBSTET GY, V124, P48, DOI 10.1111/1471-0528.14143
   Fell DB, 2017, VACCINE, V35, P5738, DOI 10.1016/j.vaccine.2017.08.037
   Fisher BM, 2011, AM J OBSTET GYNECOL, V204, pS107, DOI 10.1016/j.ajog.2011.02.041
   GREENLAND S, 1989, AM J PUBLIC HEALTH, V79, P340, DOI 10.2105/AJPH.79.3.340
   GREENLAND S, 1987, AM J EPIDEMIOL, V125, P761, DOI 10.1093/oxfordjournals.aje.a114593
   Grohskopf LA, 2017, MMWR RECOMM REP, V66, P3, DOI 10.15585/mmwr.rr6602a1
   Healy CM, 2015, VACCINE, V33, P5445, DOI 10.1016/j.vaccine.2015.08.028
   Henninger M, 2013, OBSTET GYNECOL, V121, P741, DOI 10.1097/AOG.0b013e3182878a5a
   Henninger ML, 2015, J WOMENS HEALTH, V24, P394, DOI 10.1089/jwh.2014.5105
   Lu PJ, 2018, VACCINE, V36, P890, DOI 10.1016/j.vaccine.2017.12.016
   Lu PJ, 2014, AM J INFECT CONTROL, V42, P763, DOI 10.1016/j.ajic.2014.03.021
   Luteijn JM, 2014, HUM REPROD, V29, P809, DOI 10.1093/humrep/det455
   Mertz D, 2017, VACCINE, V35, P521, DOI 10.1016/j.vaccine.2016.12.012
   Myers KL, 2016, VACCINE, V34, P3942, DOI 10.1016/j.vaccine.2016.06.042
   Nunes MC, 2016, JAMA PEDIATR, V170, P840, DOI 10.1001/jamapediatrics.2016.0921
   Osterman Michelle J K, 2018, Natl Vital Stat Rep, V67, P1
   Pierce M, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.d3214
   Putri WCWS, 2018, VACCINE, V36, P3960, DOI 10.1016/j.vaccine.2018.05.057
   Quinn SC, 2018, SSM-POPUL HLTH, V4, P25, DOI 10.1016/j.ssmph.2017.11.003
   Regan AK, 2016, PEDIATR INFECT DIS J, V35, P1097, DOI 10.1097/INF.0000000000001258
   Rothberg MB, 2008, AM J MED, V121, P258, DOI 10.1016/j.amjmed.2007.10.040
   Sakala IG, 2016, HUM VACC IMMUNOTHER, V12, P3065, DOI 10.1080/21645515.2016.1215392
   Stafford KA, 2013, J CANCER SURVIV, V7, P183, DOI 10.1007/s11764-012-0257-3
   Statistics NCfH, 2017, HLTH US CHARTB LONG
   Steinhoff MC, 2017, LANCET INFECT DIS, V17, P981, DOI 10.1016/S1473-3099(17)30252-9
   Tapia MD, 2016, LANCET INFECT DIS, V16, P1026, DOI 10.1016/S1473-3099(16)30054-8
   Thompson MG, 2014, CLIN INFECT DIS, V58, P449, DOI 10.1093/cid/cit750
   THOMPSON MG, 2018, CLIN INFECT DIS, P11, DOI DOI 10.1145/3193025.3193061
   World Health Organization, 2012, WEEKLY EPIDEMIOLOGIC, V47, P2012
   Yoo BK, 2011, AM J PREV MED, V40, P1, DOI 10.1016/j.amepre.2010.09.028
   Zaman K, 2008, NEW ENGL J MED, V359, P1555, DOI 10.1056/NEJMoa0708630
   Zou GY, 2004, AM J EPIDEMIOL, V159, P702, DOI 10.1093/aje/kwh090
   1996, PUBLIC HLTH REP, V111, P408
NR 42
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD APR 24
PY 2019
VL 37
IS 18
BP 2520
EP 2526
DI 10.1016/j.vaccine.2019.02.014
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HW3WD
UT WOS:000466622500013
PM 30928172
DA 2020-05-12
ER

PT J
AU Yu, GQ
   Jiang, YF
   Cheng, J
   Lei, ZG
AF Yu, Gangqiang
   Jiang, Yifan
   Cheng, Jun
   Lei, Zhigang
TI Structural effect on the vapor-liquid equilibrium of toluene-ionic
   liquid systems
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Vapor-liquid equilibrium (VLE); Ionic liquid (ILs); UNIFAC-Lei model;
   COSMO-RS model; Quantum chemistry calculation; Structural effect
ID VOLATILE ORGANIC-COMPOUNDS; EXTRACTIVE DISTILLATION;
   ACTIVITY-COEFFICIENTS; PHASE-EQUILIBRIA; BASIS-SETS; REMOVAL; VOCS;
   BINARY; PERVAPORATION; TEMPERATURE
AB The vapor-liquid equilibrium (VLE) of toluene-ionic liquid (IL) from short- to long-chain imidazolium-based ILs (i.e., [C4MIM](+), [C8MIM](+), [C10MIM](+), and [C12MIM](+)) with various anions (i.e., [BF4], [PF6], and [Tf2N]) was first measured under wide concentration and temperature ranges. These thermodynamic data are of great significance for an in-depth understanding with respect to capturing condensable gases with ILs. The UNIFAC-Lei model was applied to describe the VLE and successfully extended from short- to long-chain imidazolium-based ILs. For the ILs with relatively short alkyl side-chains on cations (e.g., [C4MIM](+) and [C8MIM](+)), the vapor pressure depends on the types of both anions and cations, while for the ILs with long alkyl side chains on cations (e.g., [C10MIM](+) and [C12MIM](+)), the vapor pressure is mainly dependent on the type of cations. Moreover, the COSMO-RS model and quantum chemistry calculations were used together to provide microscopic insights into the effect of IL structures on the VLE of toluene-IL systems. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Yu, Gangqiang; Jiang, Yifan; Cheng, Jun; Lei, Zhigang] Beijing Univ Chem Technol, State Key Lab Chem Resource Engn, Box 266, Beijing 100029, Peoples R China.
RP Lei, ZG (reprint author), Beijing Univ Chem Technol, State Key Lab Chem Resource Engn, Box 266, Beijing 100029, Peoples R China.
EM leizhg@mail.buct.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [U1862103]
FX This work is financially supported by the National Natural Science
   Foundation of China (No. U1862103).
CR Aguado S, 2004, J MEMBRANE SCI, V240, P159, DOI 10.1016/j.memsci.2004.05.004
   Ahmed I, 2017, ACS APPL MATER INTER, V9, P10276, DOI 10.1021/acsami.7b00859
   Alonso L, 2007, AICHE J, V53, P3108, DOI 10.1002/aic.11337
   Arce A, 2006, AICHE J, V52, P2089, DOI 10.1002/aic.10844
   Bedia J, 2013, AICHE J, V59, P1648, DOI 10.1002/aic.13926
   Bourgois D, 2009, CHEM ENG J, V145, P446, DOI 10.1016/j.cej.2008.04.038
   Chiang YC, 2001, CARBON, V39, P523, DOI 10.1016/S0008-6223(00)00161-5
   CLARK T, 1983, J COMPUT CHEM, V4, P294, DOI 10.1002/jcc.540040303
   Das D, 2004, CARBON, V42, P2949, DOI 10.1016/j.carbon.2004.07.008
   Figueroa JJ, 2012, PROCEDIA ENGINEER, V42, P1016, DOI 10.1016/j.proeng.2012.07.493
   FREDENSLUND A, 1975, AICHE J, V21, P1086, DOI 10.1002/aic.690210607
   Gallegos MV, 2017, CHEM ENG J, V313, P1099, DOI 10.1016/j.cej.2016.11.001
   Grimme S, 2010, J CHEM PHYS, V132, DOI 10.1063/1.3382344
   Han JL, 2018, AICHE J, V64, P606, DOI 10.1002/aic.15926
   HANSEN HK, 1991, IND ENG CHEM RES, V30, P2352, DOI 10.1021/ie00058a017
   HARIHARA.PC, 1973, THEOR CHIM ACTA, V28, P213, DOI 10.1007/BF00533485
   Heym F, 2010, CHEM ENG TECHNOL, V33, P1625, DOI 10.1002/ceat.201000146
   Itoh H, 2004, J AM CHEM SOC, V126, P3026, DOI 10.1021/ja039895g
   Kamal MS, 2016, ATMOS ENVIRON, V140, P117, DOI 10.1016/j.atmosenv.2016.05.031
   Kim HJ, 2002, ADV ENVIRON RES, V6, P255, DOI 10.1016/S1093-0191(01)00056-9
   KLAMT A, 1995, J PHYS CHEM-US, V99, P2224, DOI 10.1021/j100007a062
   Klamt A, 2012, PHYS CHEM CHEM PHYS, V14, P955, DOI 10.1039/c1cp22640a
   Kortunov PV, 2015, ENERG FUEL, V29, P5990, DOI 10.1021/acs.energyfuels.5b00876
   Lefebvre C, 2018, CHEMPHYSCHEM, V19, P724, DOI 10.1002/cphc.201701325
   Lei ZG, 2017, J MOL LIQ, V231, P272, DOI 10.1016/j.molliq.2017.01.110
   Lei ZG, 2014, AICHE J, V60, P3312, DOI 10.1002/aic.14537
   Lei ZG, 2009, IND ENG CHEM RES, V48, P2697, DOI 10.1021/ie801496e
   Liebert V, 2008, FLUID PHASE EQUILIBR, V268, P14, DOI 10.1016/j.fluid.2008.03.011
   Ling RJ, 2016, ACS APPL MATER INTER, V8, P32041, DOI 10.1021/acsami.6b11074
   Lu T, 2012, J COMPUT CHEM, V33, P580, DOI 10.1002/jcc.22885
   Lyu ZX, 2014, CHEM ENG SCI, V113, P45, DOI 10.1016/j.ces.2014.04.011
   Ma J, 2016, J MATER CHEM A, V4, P7281, DOI 10.1039/c6ta02611g
   MAZZARINO I, 1993, CATAL TODAY, V17, P335, DOI 10.1016/0920-5861(93)80037-2
   Meine N, 2010, GREEN CHEM, V12, P1711, DOI 10.1039/c0gc00091d
   MYERS JE, 1979, J CHEM THERMODYN, V11, P1019, DOI 10.1016/0021-9614(79)90132-0
   Nebig S, 2007, FLUID PHASE EQUILIBR, V258, P168, DOI 10.1016/j.fluid.2007.06.001
   Negadi L, 2009, J CHEM ENG DATA, V54, P2045, DOI 10.1021/je800888n
   Ngo HL, 2000, THERMOCHIM ACTA, V357, P97, DOI 10.1016/S0040-6031(00)00373-7
   Nishio M, 2011, PHYS CHEM CHEM PHYS, V13, P13873, DOI 10.1039/c1cp20404a
   Pandey LK, 2003, J MEMBRANE SCI, V227, P173, DOI 10.1016/j.memsci.2003.08.024
   PERDEW JP, 1986, PHYS REV B, V33, P8822, DOI 10.1103/PhysRevB.33.8822
   Pereiro AB, 2010, AICHE J, V56, P381, DOI 10.1002/aic.11937
   Reich R, 1998, J CHEM ENG DATA, V43, P299, DOI 10.1021/je970248c
   Roizard D, 2009, CHEM ENG SCI, V64, P1927, DOI 10.1016/j.ces.2009.01.014
   SCHAFER A, 1994, J CHEM PHYS, V100, P5829, DOI 10.1063/1.467146
   Sheldon R, 2001, CHEM COMMUN, P2399, DOI 10.1039/b107270f
   Solsona B, 2011, CHEM ENG J, V175, P271, DOI 10.1016/j.cej.2011.09.104
   STEPHENS PJ, 1994, J PHYS CHEM-US, V98, P11623, DOI 10.1021/j100096a001
   Torriero AAJ, 2009, J PHYS CHEM B, V113, P11222, DOI 10.1021/jp9046769
   Triolo A, 2006, J PHYS CHEM B, V110, P21357, DOI 10.1021/jp062895t
   Uragami T, 2001, MACROMOLECULES, V34, P6806, DOI 10.1021/ma010693j
   Wang WL, 2017, CHEM ENG J, V328, P353, DOI 10.1016/j.cej.2017.06.178
   Wilkes JS, 2002, GREEN CHEM, V4, P73, DOI 10.1039/b110838g
   Zhao DB, 2002, CATAL TODAY, V74, P157, DOI 10.1016/S0920-5861(01)00541-7
   Zhao XS, 1998, ENERG FUEL, V12, P1051, DOI 10.1021/ef980113s
   Zhao ZX, 2011, IND ENG CHEM RES, V50, P2254, DOI 10.1021/ie101414n
NR 56
TC 2
Z9 2
U1 5
U2 37
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD APR 28
PY 2019
VL 198
BP 1
EP 15
DI 10.1016/j.ces.2018.12.046
PG 15
WC Engineering, Chemical
SC Engineering
GA HL5YZ
UT WOS:000458810700001
DA 2020-05-12
ER

PT J
AU Chequer, L
   Bedrikovetsky, P
AF Chequer, L.
   Bedrikovetsky, P.
TI Suspension-colloidal flow accompanied by detachment of oversaturated and
   undersaturated fines in porous media
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Colloid; Fines migration; Particle detachment; Analytical model; Porous
   media; Mathematical model
ID TRANSPORT; MODEL; MIGRATION; DEPOSITION; BIOCOLLOIDS; ATTACHMENT;
   CONTACT; IMPACT; FIELD
AB Mechanical equilibrium of particles attached to rock during flow is defined as torque balance of attaching and detaching forces. Oversaturated state of fines means that detaching torque exceeds the attaching torque, and fines detach as the flow starts. In undersaturation, the attaching torque dominates the detaching torque, and fines mobilisation can occur only if there is either additional detaching torque or a weakening of the attaching torque. Preliminary laboratory tests determine the mechanical equilibrium velocity and salinity, to ensure that oversaturation or undersaturation can be readily reproduced in further corefloods. We formulate the basic governing equations and derive exact solutions for over and undersaturated cases. The exact solutions allow formulating the fingerprints for transport of oversaturated and undersaturated fines in porous media. The coreflood results reveal the characteristic features of the oversaturated case of fines migration. Moreover, the analytical modelling results are found to be in high agreement with the experimental data, under the typical values of the fitted model coefficients. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Chequer, L.; Bedrikovetsky, P.] Univ Adelaide, Australian Sch Petr, Adelaide, Australia.
RP Bedrikovetsky, P (reprint author), Univ Adelaide, Australian Sch Petr, Adelaide, Australia.
EM pavel@asp.adelaide.edu.au
OI Boechat Chequer, Larissa/0000-0003-0316-9170
FU CNPqNational Council for Scientific and Technological Development (CNPq)
FX The authors are grateful to Thomas Russell (The University of Adelaide)
   for fruitful discussions and close reading of the manuscript. L. Chequer
   acknowledges CNPq for financial support. Many thanks are due to David H.
   Levin (Murphy, NC, USA), who provided professional English-language
   editing of this article.
CR Al-Yaseri A, 2016, GEOPHYS PROSPECT, V64, P860, DOI 10.1111/1365-2478.12379
   Bacchin P, 2017, CHEM ENG SCI, V158, P208, DOI 10.1016/j.ces.2016.10.024
   Badalyan A, 2014, REV SCI INSTRUM, V85, DOI 10.1063/1.4861096
   Bear J., 2013, DYNAMICS FLUIDS PORO
   Bedrikovetsky P, 2008, TRANSPORT POROUS MED, V75, P335, DOI 10.1007/s11242-008-9228-6
   Bedrikovetsky P, 2013, MATH THEORY OIL GAS
   Bedrikovetsky P, 2011, TRANSPORT POROUS MED, V86, P383, DOI 10.1007/s11242-010-9626-4
   Bergendahl J, 2000, CHEM ENG SCI, V55, P1523, DOI 10.1016/S0009-2509(99)00422-4
   Borazjani S, 2017, APPL MATH MODEL, V44, P296, DOI 10.1016/j.apm.2016.12.023
   Bradford SA, 2013, LANGMUIR, V29, P6944, DOI 10.1021/la4011357
   Bradford SA, 2011, VADOSE ZONE J, V10, P252, DOI 10.2136/vzj2010.0064
   Bradford SA, 2009, ENVIRON SCI TECHNOL, V43, P6996, DOI 10.1021/es900840d
   Brady PV, 2015, ENERG FUEL, V29, P666, DOI 10.1021/ef502474a
   Chequer L, 2018, J PETROL SCI ENG, V165, P1054, DOI 10.1016/j.petrol.2018.01.012
   Chrysikopoulos CV, 2014, ENVIRON SCI TECHNOL, V48, P6805, DOI 10.1021/es501295n
   Coleman TF, 1996, SIAM J OPTIMIZ, V6, P418, DOI 10.1137/0806023
   Courant R., 1989, PARTIAL DIFFERENTIAL
   Derjaguin B.V., 1941, ACTA PHYSICOCHIM URS, V14, P633, DOI DOI 10.1016/0079-6816(93)90013-L
   DERJAGUIN BV, 1975, J COLLOID INTERF SCI, V53, P314, DOI 10.1016/0021-9797(75)90018-1
   Ding BB, 2018, CHEM ENG SCI, V175, P1, DOI 10.1016/j.ces.2017.09.033
   Elimelech M., 2013, PARTICLE DEPOSITION
   Israelachvili JN, 2011, INTERMOLECULAR AND SURFACE FORCES, 3RD EDITION, P1
   Joekar-Niasar V, 2016, IND ENG CHEM RES, V55, P6227, DOI 10.1021/acs.iecr.6b00842
   Katzourakis VE, 2018, WATER RESOUR RES, V54, P3841, DOI 10.1029/2017WR021996
   Katzourakis VE, 2017, GROUNDWATER, V55, P156, DOI 10.1111/gwat.12501
   Katzourakis VE, 2015, J CONTAM HYDROL, V181, P102, DOI 10.1016/j.jconhyd.2015.05.010
   Khilar K.C., 1998, MIGRATIONS FINES POR
   KHILAR KC, 1984, J COLLOID INTERF SCI, V101, P214, DOI 10.1016/0021-9797(84)90021-3
   KIA SF, 1987, J COLLOID INTERF SCI, V118, P158, DOI 10.1016/0021-9797(87)90444-9
   Landau L D, 1987, FLUID MECH
   Lazzari S, 2016, CHEM ENG SCI, V155, P469, DOI 10.1016/j.ces.2016.08.040
   Lin HK, 2009, PHYS REV E, V79, DOI 10.1103/PhysRevE.79.046321
   Logan J. D., 2008, INTRO NONLINEAR PART, V89
   Mahani H, 2015, SPE J, V20
   Marquez M, 2014, SPE PROD OPER, V29, P309, DOI 10.2118/165108-PA
   Mikolajczyk G, 2018, CHEM ENG SCI, V175, P257, DOI 10.1016/j.ces.2017.09.054
   Miranda R. M, 1993, SPE PROD OP S OKL CI, P271, DOI DOI 10.2118/25432-MS
   Oliveira MA, 2014, J PETROL SCI ENG, V122, P534, DOI 10.1016/j.petrol.2014.08.019
   ONEILL ME, 1968, CHEM ENG SCI, V23, P1293, DOI 10.1016/0009-2509(68)89039-6
   Pang ST, 1997, SPE FORMATION EVAL, V12, P194
   Polyanin A., 1994, METHODS MODELING EQU
   Polyanin A. D., 2007, HDB MATH ENG SCI
   Polyanin A. D., 2011, HDB NONLINEAR PARTIA
   SARKAR AK, 1990, J PETROL TECHNOL, V42, P646, DOI 10.2118/17437-PA
   Shampine L. F., 2005, Applied Numerical Analysis and Computational Mathematics, V2, P346, DOI 10.1002/anac.200510025
   Shampine LE, 2005, APPL MATH LETT, V18, P1134, DOI 10.1016/j.aml.2004.11.007
   Shapiro AA, 2008, CHEM ENG J, V142, P14, DOI 10.1016/j.cej.2007.11.006
   Shapiro AA, 2007, PHYSICA A, V375, P81, DOI 10.1016/j.physa.2006.08.033
   Shapiro AA, 2016, TRANSPORT POROUS MED, V112, P489, DOI 10.1007/s11242-016-0662-6
   Shapiro AA, 2015, TRANSPORT POROUS MED, V107, P335, DOI 10.1007/s11242-014-0442-0
   SHARMA MM, 1987, AICHE J, V33, P1636, DOI 10.1002/aic.690331007
   Thomas JM, 2010, CHEM ENG SCI, V65, P4285, DOI 10.1016/j.ces.2010.04.014
   Tikhonov A.N., 2013, EQUATIONS MATH PHYS
   Tufenkji N, 2005, LANGMUIR, V21, P841, DOI 10.1021/la048102g
   Xie Q, 2017, INT J GREENH GAS CON, V65, P32, DOI 10.1016/j.ijggc.2017.08.011
   You ZJ, 2015, GEOPHYS RES LETT, V42, P2852, DOI 10.1002/2015GL063986
   Yuan B, 2017, FUEL, V202, P380, DOI 10.1016/j.fuel.2017.04.004
   Yuan H., 2012, COLLOID TRANSPORT RE
   Yuan H, 2012, CHEM ENG J, V210, P63, DOI 10.1016/j.cej.2012.08.029
   Yuan H, 2010, CHEM ENG J, V162, P974, DOI 10.1016/j.cej.2010.07.003
   Zeinijahromi A, 2013, SPE J, V18, P518, DOI 10.2118/144009-PA
   Zeinijahromi A, 2012, J PETROL SCI ENG, V88-89, P125, DOI 10.1016/j.petrol.2012.02.002
   Zhang QL, 2017, CHEM ENG SCI, V168, P437, DOI 10.1016/j.ces.2017.04.038
   Zhou K, 2017, CHEM ENG SCI, V167, P288, DOI 10.1016/j.ces.2017.04.026
NR 64
TC 4
Z9 4
U1 1
U2 12
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD APR 28
PY 2019
VL 198
BP 16
EP 32
DI 10.1016/j.ces.2018.12.033
PG 17
WC Engineering, Chemical
SC Engineering
GA HL5YZ
UT WOS:000458810700002
DA 2020-05-12
ER

PT J
AU Kahrizi, M
   Kasiri, N
   Mohammadi, T
   Zhao, SF
AF Kahrizi, Mohammad
   Kasiri, Norollah
   Mohammadi, Toraj
   Zhao, Shuaifei
TI Introducing sorption coefficient through extended UNIQAC and
   Flory-Huggins models for improved flux prediction in forward osmosis
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Forward osmosis; Computational fluid dynamics; Sorption coefficient;
   Extended UNIQAC; Flory-Huggins
ID INTERNAL CONCENTRATION POLARIZATION; MASS-TRANSFER RESISTANCES; MEMBRANE
   EVAPORATION; WATER DESALINATION; AMINE SOLUTION; DRAW; TRANSPORT;
   SIMULATION; BEHAVIOR; FEED
AB A 2D computational fluid dynamic-based finite element model was developed to describe water flux and concentration polarization in forward osmosis (FO) under steady-state conditions. The extended UNIQAC equation in the feed and the Flory Huggins equation on the membrane side were solved simultaneously to calculate the activity coefficients of the diffusion components. The ratio of the feed component activity coefficient to that on the membrane surface was defined as the sorption coefficient. Employing the sorption coefficient led to a significantly improved accuracy of the developed model in estimating water flux. The membrane structural parameter determining internal concentration polarization (ICP) should be maintained at reasonable values. Otherwise, it may significantly increase the reverse salt flux and external concentration polarization (ECP) on the active layer. This suggests the tradeoffs between the membrane structural parameter and membrane selectivity, between ECP and ICP. Water fluxes were similar in counter-current and co-current flow modes. ICP had the most significant resistance to flow, reducing the water flux up to 75%. ECP on the feed side had a limited effect on FO water flux, particularly at high flow velocity. ECP on the draw side and reverse salt flux had negligible effects on FO water flux in our modeling. Our study provides important insights into developing high-performance FO membranes with reasonably low structural parameters and improving FO water flux by reducing the key limiting factor (e.g. ICP). (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Kahrizi, Mohammad; Kasiri, Norollah] IUST, Sch Chem Petr & Gas Engn, Comp Aided Proc Engn CAPE Lab, Tehran, Iran.
   [Mohammadi, Toraj] IUST, Sch Chem Petr & Gas Engn, Res & Technol Ctr Membrane Proc, Tehran, Iran.
   [Zhao, Shuaifei] Macquarie Univ, Dept Environm Sci, Sydney, NSW 2109, Australia.
RP Kasiri, N (reprint author), IUST, Sch Chem Petr & Gas Engn, Comp Aided Proc Engn CAPE Lab, Tehran, Iran.
EM m_kahrizi@alumni.iust.ac.ir; capepub@cape.iust.ac.ir;
   torajmohammadi@iust.ac.ir; shuaifei.zhao@mq.edu.au
RI Kasiri, Norollah/Q-1401-2019; /B-4935-2017; Mohammadi, Toraj/R-6407-2017
OI Kasiri, Norollah/0000-0003-2864-0176; /0000-0002-7727-6676; Mohammadi,
   Toraj/0000-0003-0455-3254
CR Achilli A, 2009, J MEMBRANE SCI, V343, P42, DOI 10.1016/j.memsci.2009.07.006
   Bui NN, 2015, J MEMBRANE SCI, V492, P289, DOI 10.1016/j.memsci.2015.02.001
   Cath TY, 2006, J MEMBRANE SCI, V281, P70, DOI 10.1016/j.memsci.2006.05.048
   Fosbol PL, 2013, ENRGY PROCED, V37, P844, DOI 10.1016/j.egypro.2013.05.177
   Gray GT, 2006, DESALINATION, V197, P1, DOI 10.1016/j.desal.2006.02.003
   Gruber MF, 2011, J MEMBRANE SCI, V379, P488, DOI 10.1016/j.memsci.2011.06.022
   Hamer W.J., 1972, J PHYS CHEM REF DATA, V1, P1047, DOI [DOI 10.1063/1.3253108, 10.1063/1.3253108]
   Jung DH, 2011, DESALINATION, V277, P83, DOI 10.1016/j.desal.2011.04.001
   KESSLER JO, 1976, DESALINATION, V18, P297, DOI 10.1016/S0011-9164(00)84119-3
   Li WY, 2011, J MEMBRANE SCI, V379, P307, DOI 10.1016/j.memsci.2011.05.074
   McCutcheon JR, 2007, AICHE J, V53, P1736, DOI 10.1002/aic.11197
   McCutcheon JR, 2006, J MEMBRANE SCI, V284, P237, DOI 10.1016/j.memsci.2006.07.049
   Meares P., 1966, EUR POLYM J, V2, P241
   Park M, 2013, J MEMBRANE SCI, V427, P10, DOI 10.1016/j.memsci.2012.09.045
   Phuntsho S, 2013, CHEM ENG J, V231, P484, DOI 10.1016/j.cej.2013.07.058
   Qasim M, 2015, DESALINATION, V374, P47, DOI 10.1016/j.desal.2015.07.016
   Sagiv A, 2015, J MEMBRANE SCI, V495, P198, DOI 10.1016/j.memsci.2015.08.022
   Sagiv A, 2014, J MEMBRANE SCI, V464, P161, DOI 10.1016/j.memsci.2014.04.001
   Sagiv A, 2011, J MEMBRANE SCI, V379, P86, DOI 10.1016/j.memsci.2011.05.042
   Sant'Anna V, 2012, J FOOD ENG, V111, P483, DOI 10.1016/j.jfoodeng.2012.01.032
   She QH, 2016, J MEMBRANE SCI, V499, P201, DOI 10.1016/j.memsci.2015.10.040
   SOLTANIEH M, 1981, CHEM ENG COMMUN, V12, P279, DOI 10.1080/00986448108910843
   Song LF, 2000, CHEM ENG COMMUN, V180, P145, DOI 10.1080/00986440008912206
   Suh C, 2013, J MEMBRANE SCI, V427, P365, DOI 10.1016/j.memsci.2012.08.033
   Suwaileh WA, 2018, DESALINATION, V436, P176, DOI 10.1016/j.desal.2018.01.035
   Tang CYY, 2010, J MEMBRANE SCI, V354, P123, DOI 10.1016/j.memsci.2010.02.059
   Tiraferri A, 2013, J MEMBRANE SCI, V444, P523, DOI 10.1016/j.memsci.2013.05.023
   Wang Y, 2018, PROCESSES, V6, DOI 10.3390/pr6090151
   Wang Y, 2018, RSC ADV, V8, P22469, DOI 10.1039/c8ra03166e
   Yong JS, 2012, J MEMBRANE SCI, V392, P9, DOI 10.1016/j.memsci.2011.11.020
   Yue MW, 2016, IND ENG CHEM RES, V55, P2615, DOI 10.1021/acs.iecr.6b00242
   Zhao SF, 2015, SEP PURIF TECHNOL, V146, P60, DOI 10.1016/j.seppur.2015.03.015
   Zhao SF, 2015, J MEMBRANE SCI, V473, P274, DOI 10.1016/j.memsci.2014.09.029
   Zhao SF, 2012, J MEMBRANE SCI, V396, P1, DOI 10.1016/j.memsci.2011.12.023
   Zhao SF, 2012, DESALINATION, V284, P175, DOI 10.1016/j.desal.2011.08.053
   Zhao SF, 2011, J MEMBRANE SCI, V382, P308, DOI 10.1016/j.memsci.2011.08.020
   Zhao SAF, 2011, J MEMBRANE SCI, V379, P459, DOI 10.1016/j.memsci.2011.06.021
NR 37
TC 2
Z9 2
U1 0
U2 12
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD APR 28
PY 2019
VL 198
BP 33
EP 42
DI 10.1016/j.ces.2018.11.056
PG 10
WC Engineering, Chemical
SC Engineering
GA HL5YZ
UT WOS:000458810700003
DA 2020-05-12
ER

PT J
AU Epiepang, FE
   Yang, X
   Li, JB
   Wei, YW
   Li, YS
   Yan, RT
AF Epiepang, Franklin E.
   Yang, Xiong
   Li, Jianbo
   Wei, Yuwei
   Li, Yingshu
   Yan, Ralph T.
TI Air separation sorbents: Mixed-cation zeolites with minimum lithium and
   silver
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Air separation; Li-LSX; Mixed-cation zeolites; LiSr-LSX; AgCa-LSX
ID FAUJASITE-TYPE FRAMEWORK; X-RAY; CRYSTAL-STRUCTURE; SORPTION COMPLEX;
   SUPERIOR ADSORBENT; ATMOSPHERIC GASES; ION-EXCHANGE; ADSORPTION;
   MOLECULES; POSITIONS
AB Mixed-cation LiSr-LSX, AgCa-LSX and AgSr-LSX containing minimum lithium and silver were prepared by exchanging small fractions of Li+ into Sr-LSX and Ag+ into Sr-LSX and Ca-LSX. To avoid diffusion of the Li+ into the inaccessible sites, the LiSr-LSX sample was exposed to a specifically derived dehydration condition. Similarly, the mixed-silver cation samples were treated to the selected condition post-ion-exchange to allow the Ag+ to migrate into SII+. Strong evidences were provided that significant fractions of the exchanged Li+ and Ag+ remained in SIII and SII+ respectively after comparisons of the N-2/O-2 adsorption isotherms and isosteric heats of adsorption of the mixed-cation and single-cation samples. Furthermore, the mixed-cation LiSr-LSX, AgCa-LSX and AgSr-LSX samples were compared against the single-cation Li-LSX sample based on their O-2 productivity performance via a PSA simulation model. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Epiepang, Franklin E.; Yang, Xiong; Yan, Ralph T.] Univ Michigan, Dept Chem Engn, Ann Arbor, MI 48109 USA.
   [Li, Jianbo; Wei, Yuwei] Luoyang Jianlong Micronano New Mat Co Ltd, Yanshi City 471900, Henan, Peoples R China.
   [Yang, Xiong; Li, Yingshu] Univ Sci & Technol Beijing, Sch Energy & Environm Engn, Beijing 100083, Peoples R China.
RP Yang, X; Yan, RT (reprint author), Univ Michigan, Dept Chem Engn, Ann Arbor, MI 48109 USA.
EM yangx@ustb.edu.cn; yang@umich.edu
FU NSFCNational Natural Science Foundation of China [51604016]; National
   Key R&D Program of China [2017YFC0806304]; Beijing Natural Science
   FoundationBeijing Natural Science Foundation [8174064]
FX The authors would like to express their gratitude to NSFC (Grant
   51604016), National Key R&D Program of China (No. 2017YFC0806304) and
   Beijing Natural Science Foundation (No. 8174064).
CR BENNETT JM, 1968, MATER RES BULL, V3, P633, DOI 10.1016/0025-5408(68)90112-8
   Breck D. W., 1984, ZEOLITE MOL SIEVES, P529
   Chao C. C., 1989, US Patent, Patent No. [4859217, 1989, 4,859, 217]
   Chao C. C., 1992, US Patent, Patent No. [5, 174, 979, 5174979, 5,174,979]
   Choi EY, 2002, J PHYS CHEM B, V106, P5827, DOI 10.1021/jp0140522
   Coe C. G, 1992, US Patent, Patent No. 5152813
   Coe C. G., 1995, U. S. Patent, Patent No. [5, 417, 957, 5417957, 5,417,957]
   Coe C. G., 1993, US Patent, Patent No. [1993,5,258,058, 5258058]
   Coe C. G., 1995, US Patent, Patent No. [5,419,891, 5419891]
   COSTENOBLE ML, 1978, J CHEM SOC FARAD T 1, V74, P477, DOI 10.1039/f19787400477
   COSTENOBLE ML, 1978, J CHEM SOC FARAD T 1, V74, P466, DOI 10.1039/f19787400466
   Epiepang FE, 2018, AICHE J, V64, P406, DOI 10.1002/aic.16032
   Epiepang FE, 2016, CHEM ENG SCI, V147, P100, DOI 10.1016/j.ces.2016.03.022
   Feuerstein M, 1998, MICROPOR MESOPOR MAT, V26, P27, DOI 10.1016/S1387-1811(98)00211-X
   Feuerstein M, 1998, CHEM MATER, V10, P2197, DOI 10.1021/cm980112d
   Frising T, 2008, MICROPOR MESOPOR MAT, V114, P27, DOI 10.1016/j.micromeso.2007.12.024
   HABGOOD HW, 1964, CAN J CHEM, V42, P2340, DOI 10.1139/v64-342
   HUANG YY, 1974, J CATAL, V32, P482, DOI 10.1016/0021-9517(74)90099-2
   Hutson ND, 2000, AICHE J, V46, P2305, DOI 10.1002/aic.690461121
   Hutson ND, 2000, CHEM MATER, V12, P3020, DOI 10.1021/cm000294n
   Hutson ND, 1999, AICHE J, V45, P724, DOI 10.1002/aic.690450407
   Hutson ND, 2000, IND ENG CHEM RES, V39, P1775, DOI 10.1021/ie990763z
   JACOBS PA, 1979, J CHEM SOC FARAD T 1, V75, P56, DOI 10.1039/f19797500056
   Jang SB, 1999, MICROPOR MESOPOR MAT, V28, P173, DOI 10.1016/S1387-1811(98)00299-6
   Jang SB, 1997, J PHYS CHEM B, V101, P3091, DOI 10.1021/jp9639612
   Maly KE, 2011, CHEM COMMUN, V47, P5163, DOI 10.1039/c1cc10866b
   Mertens FO, 2009, SURF SCI, V603, P1979, DOI 10.1016/j.susc.2008.10.054
   Mu B, 2011, ADSORPTION, V17, P777, DOI 10.1007/s10450-011-9328-4
   Mu B, 2010, J PHYS CHEM C, V114, P6464, DOI 10.1021/jp906417z
   Mulgundmath VP, 2012, CAN J CHEM ENG, V90, P730, DOI 10.1002/cjce.20592
   OLSON DH, 1968, J PHYS CHEM-US, V72, P4095, DOI 10.1021/j100858a025
   Palancher H, 2005, J APPL CRYSTALLOGR, V38, P370, DOI 10.1107/S0021889805000294
   Pichon C, 2005, STUD SURF SCI CATAL, V158, P789
   PLUTH JJ, 1973, MATER RES BULL, V8, P459, DOI 10.1016/0025-5408(73)90050-0
   PLUTH JJ, 1972, MATER RES BULL, V7, P1311, DOI 10.1016/0025-5408(72)90111-0
   Purewal J, 2012, J PHYS CHEM C, V116, P20199, DOI 10.1021/jp305524f
   Rege SU, 1997, IND ENG CHEM RES, V36, P5358, DOI 10.1021/ie9705214
   SHERRY HS, 1966, J PHYS CHEM-US, V70, P1158, DOI 10.1021/j100876a031
   Sircar S., 1985, US Patent, Patent No. [4,557,736, 4557736, 4,557, 736]
   SMOLIN YI, 1989, ACTA CRYSTALLOGR B, V45, P124, DOI 10.1107/S010876818801376X
   VITALE G, 1995, J PHYS CHEM-US, V99, P16087, DOI 10.1021/j100043a058
   Yang R T, 2003, ADSORBENTS FUNDAMENT
   Yang R.T., 1997, GAS SEPARATION ADSOR
   Yang X, 2018, CHEM ENG SCI, V178, P194, DOI 10.1016/j.ces.2017.12.039
   Yeom YH, 1998, J PHYS CHEM B, V102, P6071, DOI 10.1021/jp981437k
   Zhu XQ, 2017, ADSORPTION, V23, P175, DOI 10.1007/s10450-016-9843-4
NR 46
TC 0
Z9 0
U1 4
U2 12
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD APR 28
PY 2019
VL 198
BP 43
EP 51
DI 10.1016/j.ces.2018.12.048
PG 9
WC Engineering, Chemical
SC Engineering
GA HL5YZ
UT WOS:000458810700004
DA 2020-05-12
ER

PT J
AU Raimundo, PM
   Cloupet, A
   Cartellier, A
   Beneventi, D
   Augier, F
AF Raimundo, P. Maximiano
   Cloupet, A.
   Cartellier, A.
   Beneventi, D.
   Augier, F.
TI Hydrodynamics and scale-up of bubble columns in the heterogeneous
   regime: Comparison of bubble size, gas holdup and liquid velocity
   measured in 4 bubble columns from 0.15 m to 3 m in diameter
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Bubble column; Sauter diameter; Scale-up; Velocimetry; Heterogeneous
   regime; Experimental; Cross-correlation; Multiphase reactor; Clustering
ID CFD MODEL; FLOW; REACTORS; DESIGN
AB The development of CFD models coupled with Population Balance is a very promising topic concerning multiphase reactors. In the case of bubbly flows and bubble columns, a serious lack of local hydrodynamic characterizations still harms development and validation of relevant models. To fill partially this gap, a new bubble size measurement technique, previously introduced by Maximiano Raimundo et al. (2016), has been applied on a very wide range of bubble column diameters (from 0.15 m to 3 m) and superficial gas velocities (from 0.06 m/s to 0.35 m/s). Size measurements have been coupled with others concerning gas holdup and axial liquid velocity, in order to provide an experimental database allowing to clarify the scale-up rules and to assist future modelling works. Average bubble sizes have been measured as globally similar at every scale. Measured holdup and average liquid velocity confirm already reported behaviours at lower column diameters. Liquid velocity fluctuations also follow self-similar radial profiles and are proportional to the average liquid velocity at the centre of the column leading to a strong turbulence intensity. The fact that the quantity (gD)(1/2) appears as a natural velocity scale and the presence of strong gas-holdup gradients underline the similarity between bubble columns operated heterogeneous regime and free thermal convection in pipes. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Raimundo, P. Maximiano; Cloupet, A.; Augier, F.] IFP Energies Nouvelles, Rond Point Echangeur Solaize, F-69360 Solaize, France.
   [Raimundo, P. Maximiano; Cartellier, A.] Univ Grenoble Alpes, CNRS, Grenoble INP LEGI, F-38000 Grenoble, France.
   [Beneventi, D.] Ecole Francaise Papeterie & Ind Graph, INPG, BP 65, F-38402 St Martin Dheres, France.
   [Raimundo, P. Maximiano; Cartellier, A.] Univ Grenoble Alpes, Inst Engn, Grenoble, France.
RP Augier, F (reprint author), IFP Energies Nouvelles, Rond Point Echangeur Solaize, F-69360 Solaize, France.
EM Frederic.Augier@ifpen.fr
FU LabEx Tec 21 (Investissements d'Avenir)French National Research Agency
   (ANR) [ANR-11-LABX-0030]
FX LEGI and LGP2 laboratories are part of the LabEx Tec 21 (Investissements
   d'Avenir-Grant Agreement No. ANR-11-LABX-0030).
CR Besagni Giorgio, 2018, ChemEngineering, V2, DOI 10.3390/chemengineering2020013
   Besagni G, 2017, CHEM ENG SCI, V170, P270, DOI 10.1016/j.ces.2017.03.043
   Besagni G, 2017, INT J MULTIPHAS FLOW, V94, P53, DOI 10.1016/j.ijmultiphaseflow.2017.04.015
   Buffo A, 2013, INT J MULTIPHAS FLOW, V50, P41, DOI 10.1016/j.ijmultiphaseflow.2012.09.005
   Chaumat H, 2005, CHEM ENG SCI, V60, P5930, DOI 10.1016/j.ces.2005.04.026
   Clift R., 1978, BUBBLES DROPS PARTIC
   DECKWER WD, 1992, BUBBLE COLUMN REACTO
   Ferenc JS, 2007, PHYSICA A, V385, P518, DOI 10.1016/j.physa.2007.07.063
   Forret A, 2006, OIL GAS SCI TECHNOL, V61, P443, DOI 10.2516/ogst:2006044a
   Forret A, 2003, CHEM ENG SCI, V58, P719, DOI 10.1016/S0009-2509(02)00600-0
   Gemello L, 2018, CHEM ENG RES DES, V136, P846, DOI 10.1016/j.cherd.2018.06.026
   Gemello L, 2018, CHEM ENG SCI, V184, P93, DOI 10.1016/j.ces.2018.03.043
   Guan XP, 2016, IND ENG CHEM RES, V55, P3125, DOI 10.1021/acs.iecr.5b04015
   Guedon GR, 2017, CHEM ENG SCI, V161, P138, DOI 10.1016/j.ces.2016.12.015
   Jakobsen HA, 2005, IND ENG CHEM RES, V44, P5107, DOI 10.1021/ie049447x
   Joshi JB, 2001, CHEM ENG SCI, V56, P5893, DOI 10.1016/S0009-2509(01)00273-1
   Kantarci N, 2005, PROCESS BIOCHEM, V40, P2263, DOI 10.1016/j.procbio.2004.10.004
   Krishna R., 2001, T ICHEME A, V79
   Lehr F., 2004, AICHE J, V48, P2426
   McClure DD, 2017, CHEM ENG SCI, V170, P91, DOI 10.1016/j.ces.2016.12.066
   McClure DD, 2015, CHEM ENG SCI, V127, P189, DOI 10.1016/j.ces.2015.01.025
   McClure DD, 2014, CHEM ENG TECHNOL, V37, P131, DOI 10.1002/ceat.201300546
   MENZEL T, 1990, IND ENG CHEM RES, V29, P988, DOI 10.1021/ie00102a007
   Miyauchi T, 1970, KAGAKU KOGAKU, V34, P958
   Monchaux R, 2012, INT J MULTIPHAS FLOW, V40, P1, DOI 10.1016/j.ijmultiphaseflow.2011.12.001
   Nottenkaemper R., 1983, GER CHEM ENG, V6, P147
   Raimundo PM, 2016, CHEM ENG SCI, V155, P504, DOI 10.1016/j.ces.2016.08.041
   Riemann J., 1983, MEASURING TECHNIQUES
   Riquarts H.P, 1981, GER CHEM ENG, V4, P18
   ROELS JA, 1980, BIOTECHNOL BIOENG, V22, P2399, DOI 10.1002/bit.260221115
   Rollbusch P, 2015, CHEM ENG SCI, V126, P660, DOI 10.1016/j.ces.2014.11.061
   Rusaouen E, 2014, EUR PHYS J E, V37, DOI 10.1140/epje/i2014-14004-7
   Ruzicka MC, 2013, CHEM ENG RES DES, V91, P191, DOI 10.1016/j.cherd.2012.07.011
   Sanyal J, 2005, IND ENG CHEM RES, V44, P5063, DOI 10.1021/ie049555j
   Sasaki S, 2016, EXP THERM FLUID SCI, V72, P67, DOI 10.1016/j.expthermflusci.2015.10.027
   Schweitzer JH, 2001, CHEM ENG SCI, V56, P1103, DOI 10.1016/S0009-2509(00)00327-4
   Tisserand JC, 2010, NEW J PHYS, V12, DOI 10.1088/1367-2630/12/7/075024
   Xue J., 2004, THESIS
   Xue JL, 2008, AICHE J, V54, P350, DOI 10.1002/aic.11386
   Zehner P., 1986, INT CHEM ENG, V41, P1969
   ZUBER N, 1965, J HEAT TRANSF, V87, P453, DOI 10.1115/1.3689137
NR 41
TC 3
Z9 3
U1 6
U2 34
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD APR 28
PY 2019
VL 198
BP 52
EP 61
DI 10.1016/j.ces.2018.12.043
PG 10
WC Engineering, Chemical
SC Engineering
GA HL5YZ
UT WOS:000458810700005
DA 2020-05-12
ER

PT J
AU Wang, Q
   Cheng, ZL
AF Wang, Qing
   Cheng, Zhilin
TI A fractal model of water transport in shale reservoirs
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Apparent liquid permeability; Fractal model; Shale reservoirs;
   Mixed-wet; Nanoscale transport
ID ORGANIC-RICH SHALES; FAST MASS-TRANSPORT; GAS SLIPPAGE FACTOR;
   PERMEABILITY MODEL; POROUS-MEDIA; SPONTANEOUS IMBIBITION; LIQUID
   PERMEABILITY; CARBON NANOTUBES; FLOW ENHANCEMENT; SICHUAN BASIN
AB The investigation of water's flow behavior in nanoporous shale media is fundamental to the high-efficiency exploitation of shale gas reservoirs. Such an investigation can provide crucial theoretical foundations for the development of relevant techniques, such as hydraulic fracturing stimulation and reservoir productivity prospecting. Through the integration of the fractal model and nanoscale water transport mechanisms, this article presents an apparent liquid permeability (ALP) model of water flow in the mixed-wet shale matrix. This model incorporates various hydrodynamic features of water at the nanoscale and the pore structure characteristics of shale media. The ALP, the enhancement factor of the shale matrix, and the relative contributions of the organic and inorganic matter for the total ALP under different influencing factors were consequently analyzed. The results demonstrate that the wettability state of the inorganic matter has little effect on the ALP, and multilayer sticking that occurs in water transport leads to a slight decrease in the ALP. However, the ALP is very sensitive to the organic matter: when the organic nanopores become strongly hydrophobic, a dramatic increase in the ALP, resulting from a significant slip behavior, is observed. Additionally, shale's ALP increases or decreases, depending on the combined effects of the large-sized inorganic matter (generally larger than that of organic matter) and the more-hydrophobic organic matter. Furthermore, the structural parameters of shale media were studied. Thus, the developed model provides deeper insights into water transport in a shale matrix and a quantitative framework for future research. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Cheng, Zhilin] China Univ Petr, State Key Lab Petr Resources & Engn, Beijing 102249, Peoples R China.
   China Univ Petr, Sch Petr Engn, Beijing 102249, Peoples R China.
RP Cheng, ZL (reprint author), China Univ Petr, State Key Lab Petr Resources & Engn, Beijing 102249, Peoples R China.
EM zhilin_cheng1992@163.com
OI Cheng, Zhilin/0000-0002-7087-565X
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [51504265, 51474222, 51774298]; PetroChina
   Innovation Foundation [2017D-5007-0205]
FX The authors would like to thank National Natural Science Foundation of
   China (Grant No. 51504265, 51474222 and 51774298) and PetroChina
   Innovation Foundation (2017D-5007-0205) for the financial support.
CR Afsharpoor A, 2016, FUEL, V180, P580, DOI 10.1016/j.fuel.2016.04.078
   Akkutlu IY, 2012, SPE J, V17, P1002, DOI 10.2118/146422-PA
   Alibakhshi MA, 2016, SCI REP-UK, V6, DOI 10.1038/srep24936
   Ambrose RJ, 2012, SPE J, V17, P219, DOI 10.2118/131772-PA
   Anderson W. G, 1986, J PETROL TECHNOL, V38, P1124
   Barrat JL, 1999, PHYS REV LETT, V82, P4671, DOI 10.1103/PhysRevLett.82.4671
   Bohacs K., 2013, IPTC 2013 INT PETR T
   Cai JC, 2018, MAR PETROL GEOL, V98, P437, DOI 10.1016/j.marpetgeo.2018.08.040
   Cai JC, 2010, ENERG FUEL, V24, P1860, DOI 10.1021/ef901413p
   Calabro F, 2013, APPL MATH LETT, V26, P991, DOI 10.1016/j.aml.2013.05.004
   Chen J, 2014, FUEL, V129, P173, DOI 10.1016/j.fuel.2014.03.058
   Chen L, 2015, SCI REP-UK, V5, DOI 10.1038/srep08089
   Chen Z., 2014, UNC RES TECHN C DENV, P1079
   Cheng ZL, 2018, ENERG FUEL, V32, P6507, DOI 10.1021/acs.energyfuels.8b00394
   Collell J, 2015, J PHYS CHEM C, V119, P22587, DOI 10.1021/acs.jpcc.5b07242
   Curtis ME, 2012, INT J COAL GEOL, V103, P26, DOI 10.1016/j.coal.2012.08.004
   Curtis ME, 2012, AAPG BULL, V96, P665, DOI 10.1306/08151110188
   Engelder T, 2014, J UNCONV OIL GAS RES, V7, P33, DOI 10.1016/j.juogr.2014.03.002
   Falk K, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7949
   Gad-El-Hak M, 2006, HEAT TRANSFER ENG, V27, P13, DOI 10.1080/01457630500522305
   Geng LD, 2017, AICHE J, V63, P1430, DOI 10.1002/aic.15516
   Geng LD, 2016, J NAT GAS SCI ENG, V35, P593, DOI 10.1016/j.jngse.2016.08.033
   Ghanizadeh A, 2014, INT J COAL GEOL, V123, P20, DOI 10.1016/j.coal.2013.06.009
   Goertz MP, 2007, LANGMUIR, V23, P5491, DOI 10.1021/la062299q
   Holt JK, 2006, SCIENCE, V312, P1034, DOI 10.1126/science.1126298
   Howarth RW, 2011, NATURE, V477, P271, DOI 10.1038/477271a
   Huang DM, 2008, PHYS REV LETT, V101, DOI 10.1103/PhysRevLett.101.226101
   Huang L, 2018, APPL ENERG, V210, P28, DOI 10.1016/j.apenergy.2017.10.122
   Huang S, 2018, TRANSPORT POROUS MED, V121, P725, DOI 10.1007/s11242-017-0982-1
   Javadpour F, 2015, FUEL, V160, P549, DOI 10.1016/j.fuel.2015.08.017
   Joseph S, 2008, NANO LETT, V8, P452, DOI 10.1021/nl072385q
   Karniadakis G, 2006, MICROFLOWS NANOFLOWS
   Kuuskraa V, 2013, TECHNICALLY RECOVERA
   Li TD, 2007, PHYS REV B, V75, DOI 10.1103/PhysRevB.75.115415
   Liang MC, 2018, FRACTALS, V26, DOI 10.1142/S0218348X18500378
   Liu R., 2018, FRACT INTERDISCIP J
   Loucks RG, 2009, J SEDIMENT RES, V79, P848, DOI 10.2110/jsr.2009.092
   Majumder M, 2005, NATURE, V438, P44, DOI 10.1038/43844a
   Mandelbrot B.B., 1982, FRACTAL GEOMETRY NAT
   Mattia D, 2015, J MEMBRANE SCI, V475, P266, DOI 10.1016/j.memsci.2014.10.035
   Mattia D, 2012, MICROFLUID NANOFLUID, V13, P125, DOI 10.1007/s10404-012-0949-z
   Miao T., 2018, FRACT INTERDISCIP J
   Miao TJ, 2015, INT J HEAT MASS TRAN, V88, P814, DOI 10.1016/j.ijheatmasstransfer.2015.05.004
   Myers TG, 2011, MICROFLUID NANOFLUID, V10, P1141, DOI 10.1007/s10404-010-0752-7
   Nagayama G, 2004, INT J HEAT MASS TRAN, V47, P501, DOI 10.1016/j.ijheatmasstransfer.2003.07.013
   Nicot JP, 2014, ENVIRON SCI TECHNOL, V48, P2464, DOI 10.1021/es404050r
   Novlesky A., 2011, SHALE GAS MODELING W
   Sendner C, 2009, LANGMUIR, V25, P10768, DOI 10.1021/la901314b
   Shen YH, 2018, FRACTALS, V26, DOI 10.1142/S0218348X18400029
   Sheng GL, 2017, FRACTALS, V25, DOI 10.1142/S0218348X17400072
   Shi Y, 2018, COLLOID SURFACE A, V543, P64, DOI 10.1016/j.colsurfa.2017.12.052
   Sisan TB, 2011, MICROFLUID NANOFLUID, V11, P787, DOI 10.1007/s10404-011-0855-9
   Song WH, 2018, INT J HEAT MASS TRAN, V118, P948, DOI 10.1016/j.ijheatmasstransfer.2017.11.072
   Tao JB, 2018, CHEM ENG SCI, V192, P1252, DOI 10.1016/j.ces.2018.05.018
   Thomas JA, 2008, J CHEM PHYS, V128, DOI 10.1063/1.2837297
   Thomas JA, 2008, NANO LETT, V8, P2788, DOI 10.1021/nl8013617
   Thomas JA, 2010, INT J THERM SCI, V49, P281, DOI 10.1016/j.ijthermalsci.2009.07.008
   Thompson PA, 1997, NATURE, V389, P360, DOI 10.1038/38686
   Voronov RS, 2006, J CHEM PHYS, V124, DOI 10.1063/1.2194019
   Wang JJ, 2017, ENERG FUEL, V31, P205, DOI 10.1021/acs.energyfuels.6b02033
   Wang S, 2016, FUEL, V171, P74, DOI 10.1016/j.fuel.2015.12.071
   Wang Y, 2018, FRACTALS, V26, DOI 10.1142/S0218348X18400133
   Wu KL, 2017, P NATL ACAD SCI USA, V114, P3358, DOI 10.1073/pnas.1612608114
   Wu KL, 2016, INT J HEAT MASS TRAN, V93, P408, DOI 10.1016/j.ijheatmasstransfer.2015.10.003
   Wu KL, 2015, CHEM ENG J, V281, P813, DOI 10.1016/j.cej.2015.07.012
   Xiao BQ, 2017, J NANOSCI NANOTECHNO, V17, P6811, DOI 10.1166/jnn.2017.14502
   Xu P, 2017, FRACTALS, V25, DOI 10.1142/S0218348X1740014X
   Yang F, 2016, INT J COAL GEOL, V156, P12, DOI 10.1016/j.coal.2015.12.015
   Yang F, 2014, FUEL, V115, P378, DOI 10.1016/j.fuel.2013.07.040
   Yu B., 2014, TRANSPORT PHYS FRACT, P33
   Yu BM, 2005, CHINESE PHYS LETT, V22, P158, DOI 10.1088/0256-307X/22/1/045
   Yu BM, 2004, CHINESE PHYS LETT, V21, P1569, DOI 10.1088/0256-307X/21/8/044
   Yu BM, 2002, INT J HEAT MASS TRAN, V45, P2983, DOI 10.1016/S0017-9310(02)00014-5
   Yu BM, 2001, FRACTALS, V9, P365, DOI 10.1142/S0218348X01000804
   Yu BM, 2008, APPL MECH REV, V61, DOI 10.1115/1.2955849
   Yu BM, 2009, VADOSE ZONE J, V8, P177, DOI 10.2136/vzj2008.0015
   Zhang CF, 2018, J CONTROL SCI ENG, DOI 10.1155/2018/8676387
   Zhang Q, 2017, INT J HEAT MASS TRAN, V115, P224, DOI 10.1016/j.ijheatmasstransfer.2017.08.024
   Zhang T, 2018, CHEM ENG SCI, V187, P280, DOI 10.1016/j.ces.2018.05.016
   Zhao JL, 2018, INT J HEAT MASS TRAN, V125, P1131, DOI 10.1016/j.ijheatmasstransfer.2018.04.123
   Zhao JL, 2016, INT J HEAT MASS TRAN, V103, P1098, DOI 10.1016/j.ijheatmasstransfer.2016.08.026
   Zheng Q, 2013, CHEM ENG SCI, V87, P209, DOI 10.1016/j.ces.2012.10.019
   Zheng Q, 2012, J APPL PHYS, V111, DOI 10.1063/1.3679070
NR 83
TC 4
Z9 4
U1 11
U2 54
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD APR 28
PY 2019
VL 198
BP 62
EP 73
DI 10.1016/j.ces.2018.12.042
PG 12
WC Engineering, Chemical
SC Engineering
GA HL5YZ
UT WOS:000458810700006
DA 2020-05-12
ER

PT J
AU Feng, YN
   Weber, M
   Maletzko, C
   Chung, TS
AF Feng, Yingnan
   Weber, Martin
   Maletzko, Christian
   Chung, Tai-Shung
TI Fabrication of organic solvent nanofiltration membranes via facile
   bioinspired one-step modification
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Mussel-inspired coating; Organic solvent nanofiltration (OSN);
   Sulfonated polyphenylenesulfone (sPPSU); Membrane modification
ID THIN-FILM COMPOSITE; PORE-SIZE DISTRIBUTIONS; SEPARATION PERFORMANCE;
   POLYMER; ULTRAFILTRATION; CODEPOSITION; DEPOSITION; RETENTION;
   POLYIMIDE; CHEMISTRY
AB Since the mussel-inspired multifunctional coating was introduced in 2007, it has been utilized to modify membranes for a wide range of applications including ultrafiltration and nanofiltration. In this work, the effects of substrate pore size and coating conditions on the separation performance of organic solvent nanofiltration (OSN) membranes were investigated. By using sulfonated polyphenylenesulfone (sPPSU) as the substrate material and polyethyleneimine and pyrocatechol as the coating materials, OSN membranes can be fabricated if the pores of the sPPSU substrates are less than 12 nm in diameter (determined by the solute transport method). The coated membranes show rejections greater than 93% towards molecules with molecular weights larger than 645 g/mol and a permeance of 11.9 L m(-2)h(-1)bar(-1) in ethanol. The addition of epichlorohydrin in the coating solution can significantly enhance membrane rejections to small molecules. The fabricated membranes demonstrate good stability in 7-day tetracycline filtration tests. The 2-pass rejection can reach 96.2% to tetracycline for tetracycline/isopropanol solutions. The newly developed one-step facile coating method has great potential to fabricate membranes for OSN applications in the pharmaceutical industry. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Feng, Yingnan; Chung, Tai-Shung] Natl Univ Singapore, Dept Chem & Biomol Engn, Singapore 117585, Singapore.
   [Weber, Martin] BASF SE, Adv Mat & Syst Res, GM-B001, D-67056 Ludwigshafen, Germany.
   [Maletzko, Christian] BASF SE, Performance Mat, G PM PU-F206, D-67056 Ludwigshafen, Germany.
RP Chung, TS (reprint author), Natl Univ Singapore, Dept Chem & Biomol Engn, Singapore 117585, Singapore.
EM chencts@nus.edu.sg
RI Chung, Neal Tai-Shung/D-1183-2009
OI Chung, Neal Tai-Shung/0000-0003-3704-8609
FU National Research Foundation Singapore, SingaporeSingapore National
   Research Foundation [R-279-000-466-281]; BASF SE, Germany
   [R-279-000-411-597]
FX The authors would like to thank the National Research Foundation
   Singapore, Singapore for funding the work with the project entitled,
   Development of solvent resistant nanofiltration membranes for
   sustainable pharmaceutical and petrochemical manufacture,
   R-279-000-466-281. The authors would also like to express their
   gratitude to BASF SE, Germany for the financial support of the grant
   (R-279-000-411-597). The authors appreciate Dr. Yupan Tang for his
   valuable suggestion and Mr. Jian Chang, Mr. Dangchen Ma and Miss Zhuofan
   Gao for their generous help.
CR Aba NFD, 2015, J MEMBRANE SCI, V484, P87, DOI 10.1016/j.memsci.2015.03.001
   AIMAR P, 1990, J MEMBRANE SCI, V54, P321, DOI 10.1016/S0376-7388(00)80618-3
   Alfonsi K, 2008, GREEN CHEM, V10, P31, DOI 10.1039/b711717e
   Amirilargani M, 2016, CHEM ENG J, V289, P562, DOI 10.1016/j.cej.2015.12.062
   Bhanushali D, 2001, J MEMBRANE SCI, V189, P1, DOI 10.1016/S0376-7388(01)00356-8
   Blumenschein S, 2016, J MEMBRANE SCI, V510, P191, DOI 10.1016/j.memsci.2016.02.042
   Chau J, 2018, SEP PURIF TECHNOL, V199, P233, DOI 10.1016/j.seppur.2018.01.054
   Constable DJC, 2007, ORG PROCESS RES DEV, V11, P133, DOI 10.1021/op060170h
   Farahani MHDA, 2018, J MEMBRANE SCI, V548, P319, DOI 10.1016/j.memsci.2017.11.037
   Feng YN, 2018, J MEMBRANE SCI, V549, P550, DOI 10.1016/j.memsci.2017.12.048
   Han G, 2012, CHEM ENG SCI, V80, P219, DOI 10.1016/j.ces.2012.05.033
   HANSEN CM, 2000, HANSEN SOLUBILITY PA
   Hendrix K, 2013, J MEMBRANE SCI, V447, P96, DOI 10.1016/j.memsci.2013.07.006
   Hermans S, 2015, CURR OPIN CHEM ENG, V8, P45, DOI 10.1016/j.coche.2015.01.009
   Hosseinabadi SR, 2014, J MEMBRANE SCI, V454, P496, DOI 10.1016/j.memsci.2013.12.032
   Hung WL, 2016, J MEMBRANE SCI, V505, P70, DOI 10.1016/j.memsci.2016.01.021
   Jansen JC, 2013, J MEMBRANE SCI, V447, P107, DOI 10.1016/j.memsci.2013.07.009
   Karkhanechi H, 2018, POLYMER, V145, P310, DOI 10.1016/j.polymer.2018.04.074
   Kasemset S, 2017, J MEMBRANE SCI, V522, P100, DOI 10.1016/j.memsci.2016.07.016
   Kim JH, 2018, J MEMBRANE SCI, V550, P322, DOI 10.1016/j.memsci.2018.01.008
   Kosaraju PB, 2008, J MEMBRANE SCI, V321, P155, DOI 10.1016/j.memsci.2008.04.057
   Kotte MR, 2014, J MEMBRANE SCI, V450, P93, DOI 10.1016/j.memsci.2013.08.025
   Lee H, 2007, SCIENCE, V318, P426, DOI 10.1126/science.1147241
   Li MM, 2014, J MEMBRANE SCI, V459, P62, DOI 10.1016/j.memsci.2014.01.038
   Li XF, 2008, J MEMBRANE SCI, V324, P67, DOI 10.1016/j.memsci.2008.06.055
   Liu N, 2017, LANGMUIR, V33, P7380, DOI 10.1021/acs.langmuir.7b01281
   Lu T.-D., 2018, J MAT CHEM A
   Lv Y, 2015, J MEMBRANE SCI, V476, P50, DOI 10.1016/j.memsci.2014.11.024
   Marchetti P, 2014, CHEM REV, V114, P10735, DOI 10.1021/cr500006j
   Oatley-Radcliffe DL, 2017, J WATER PROCESS ENG, V19, P164, DOI 10.1016/j.jwpe.2017.07.026
   Perez-Manriquez L, 2015, REACT FUNCT POLYM, V86, P243, DOI 10.1016/j.reactfunctpolym.2014.09.015
   Peyravi M, 2012, J MEMBRANE SCI, V423, P225, DOI 10.1016/j.memsci.2012.08.019
   Schanze KS, 2018, ACS APPL MATER INTER, V10, P7521, DOI 10.1021/acsami.8b02929
   Singh S, 1998, J MEMBRANE SCI, V142, P111, DOI 10.1016/S0376-7388(97)00329-3
   Stawikowska J, 2013, CHEM ENG SCI, V97, P81, DOI 10.1016/j.ces.2013.03.054
   Sukma FM, 2018, J MEMBRANE SCI, V545, P329, DOI 10.1016/j.memsci.2017.09.080
   Sun SP, 2015, CHEM ENG SCI, V129, P232, DOI 10.1016/j.ces.2015.02.043
   Szekely G, 2014, GREEN CHEM, V16, P4440, DOI 10.1039/c4gc00701h
   Tanardi CR, 2016, MICROPOR MESOPOR MAT, V229, P106, DOI 10.1016/j.micromeso.2016.04.024
   Tashvigh AA, 2018, J MEMBRANE SCI, V545, P221, DOI 10.1016/j.memsci.2017.09.076
   Van der Bruggen B, 2002, WATER RES, V36, P1360, DOI 10.1016/S0043-1354(01)00318-9
   Viswanath D.S., 1989, DATA BOOK VISCOSITY
   Wang H, 2014, ACS APPL MATER INTER, V6, P5602, DOI 10.1021/am406052u
   Wang J, 2017, J MATER CHEM A, V5, P14847, DOI 10.1039/c7ta02661g
   Xing DY, 2014, GREEN CHEM, V16, P1383, DOI 10.1039/c3gc41634h
   Xu YC, 2016, CHEM ENG J, V303, P555, DOI 10.1016/j.cej.2016.06.024
   Xu YC, 2017, ACS SUSTAIN CHEM ENG, V5, P5520, DOI 10.1021/acssuschemeng.7b00871
   Xu YQ, 2017, IND ENG CHEM RES, V56, P11967, DOI 10.1021/acs.iecr.7b03409
   Yang XB, 2018, J MEMBRANE SCI, V549, P67, DOI 10.1016/j.memsci.2017.11.071
   Zeidler S, 2014, J MEMBRANE SCI, V470, P421, DOI 10.1016/j.memsci.2014.07.051
   Zhang C, 2017, ACS APPL MATER INTER, V9, P14437, DOI 10.1021/acsami.7b03115
NR 51
TC 3
Z9 3
U1 16
U2 101
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD APR 28
PY 2019
VL 198
BP 74
EP 84
DI 10.1016/j.ces.2019.01.008
PG 11
WC Engineering, Chemical
SC Engineering
GA HL5YZ
UT WOS:000458810700007
DA 2020-05-12
ER

PT J
AU Xue, ZC
   Guo, QH
   Gong, Y
   Wu, XX
   Wang, FC
   Yu, GS
AF Xue, Zhicun
   Guo, Qinghua
   Gong, Yan
   Wu, Xiaoxiang
   Wang, Fuchen
   Yu, Guangsuo
TI Detailed deposition characteristics around burner plane in an impinging
   entrained-flow coal gasifier
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Entrained-flow coal gasifier; Deposition behavior; Detachment;
   Classification; Statistical characteristics
ID HEAT-EXCHANGER TUBE; ASH DEPOSITION; PARTICLE DEPOSITION; FLAME
   CHARACTERISTICS; MODEL; COMBUSTION; SIMULATION; REACTOR
AB The droplets, coal particles and ash/slag particles generated in impinging flame, atomization and violent reaction at the burner plane lead to complex deposition characteristics in the impinging entrained-flow coal gasifier. To investigate the detailed deposition behaviors around burner plane, a new visualization system combined with high temperature endoscope and high speed camera was applied to capture the detailed process of deposition. With classification and statistical method, the CWS droplet and coal/ash/slag particle deposition behaviors as well as the detachment of adhered particles were discussed. The results show that the droplet deposition behaviors were divided into three types: deform and rebound without adherence, breakup and rebound without adherence and breakup with partial rebound and partial adherence. Over 50% of the droplets deform without any other behaviors. Only about 15% of the droplets adhere to the refractory wall. The particle deposition behaviors were divided into four types: rebound completely without breakup and adherence, adhere completely without breakup and rebound, breakup and rebound completely without adherence and breakup with partial rebound and partial adherence. The particles around the burner tend to rebound and the particles between the burners tend to adhere. Over 60% of the particles completely or partially adhere to the refractory wall and only a few particles break up. The detachment behaviors were divided into four types: detach completely, breakup and detach, detach after impact and multi-mode detach. Because of the low conversion degree of the particles around burner plane, the detach percentage of the adhered particles is relatively high and half of adhered particles detaches from the refractory wall completely. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Xue, Zhicun; Guo, Qinghua; Gong, Yan; Wu, Xiaoxiang; Wang, Fuchen; Yu, Guangsuo] East China Univ Sci & Technol, Key Lab Coal Gasificat & Energy Chem Engn, Minist Educ, Shanghai 200237, Peoples R China.
   [Yu, Guangsuo] Ningxia Univ, Sch Chem & Chem Engn, State Key Lab High Efficiency Coal Utilizat & Gre, Ningxia 750021, Peoples R China.
RP Gong, Y; Yu, GS (reprint author), East China Univ Sci & Technol, Key Lab Coal Gasificat & Energy Chem Engn, Minist Educ, Shanghai 200237, Peoples R China.
EM yangong@ecust.edu.cn; gsyu@ecust.edu.cn
RI Xue, Zhicun/AAD-9867-2020
FU National Key R&D Program of China [2017YFB0602601]; National Natural
   Science Foundation of ChinaNational Natural Science Foundation of China
   [21676091, 21761132034]
FX This work has been supported by the National Key R&D Program of China
   (2017YFB0602601) and the National Natural Science Foundation of China
   (21676091, 21761132034).
CR Barroso J, 2006, FUEL PROCESS TECHNOL, V87, P737, DOI 10.1016/j.fuproc.2006.02.004
   Borello D, 2013, APPL ENERG, V101, P413, DOI [10.1016/j.apenergy.2012.04.031, 10.1016/J.apenergy.2012.04.031]
   Fan JR, 2001, FUEL, V80, P645, DOI 10.1016/S0016-2361(00)00134-4
   Fan PX, 2014, ENERG FUEL, V28, P4895, DOI 10.1021/ef5007287
   Gong Y, 2017, APPL ENERG, V206, P1184, DOI 10.1016/j.apenergy.2017.10.037
   Gong Y, 2017, APPL ENERG, V205, P1091, DOI 10.1016/j.apenergy.2017.08.095
   Gong Y, 2015, CHEM ENG SCI, V138, P291, DOI 10.1016/j.ces.2015.08.013
   Gong Y, 2014, CHEM ENG SCI, V117, P93, DOI 10.1016/j.ces.2014.05.053
   Gong Y, 2013, IND ENG CHEM RES, V52, P3007, DOI 10.1021/ie3027857
   Gong Y, 2012, IND ENG CHEM RES, V51, P7828, DOI 10.1021/ie2028602
   Guo Q.H., 2018, J ENERGY I
   Higman C, 2008, GASIFICATION, 2ND EDITION, P1
   Higman C., 2014, GAS TECHN C OCT WASH
   Hosseini SB, 2017, APPL THERM ENG, V127, P330, DOI 10.1016/j.applthermaleng.2017.08.023
   Ichikawa K, 2004, FUEL, V83, P1009, DOI 10.1016/S0016-2361(03)00260-6
   Koyama S, 1996, FUEL, V75, P459, DOI 10.1016/0016-2361(95)00266-9
   Li SH, 2010, ENERG FUEL, V24, P1868, DOI 10.1021/ef901480e
   Liang QF, 2012, FUEL, V102, P491, DOI 10.1016/j.fuel.2012.06.092
   Luan C, 2014, FUEL, V119, P14, DOI 10.1016/j.fuel.2013.11.031
   Namkung H, 2017, FUEL PROCESS TECHNOL, V158, P206, DOI 10.1016/j.fuproc.2017.01.010
   Namkung H, 2014, FUEL, V117, P1274, DOI 10.1016/j.fuel.2013.07.028
   Ni JJ, 2014, ENERG FUEL, V25, P1004
   RICHARDS GH, 1993, ENERG FUEL, V7, P774, DOI 10.1021/ef00042a012
   Safronov D, 2017, FUEL PROCESS TECHNOL, V161, P62, DOI 10.1016/j.fuproc.2017.03.007
   Shimizu T, 2006, FUEL, V85, P170, DOI 10.1016/j.fuel.2005.03.033
   The Gasification & Syngas Technologies Council (GSTC), 2017, GAS PROC
   Troiano M, 2014, FUEL, V117, P1267, DOI 10.1016/j.fuel.2013.06.026
   Venturini P, 2012, APPL THERM ENG, V49, P131, DOI 10.1016/j.applthermaleng.2011.08.030
   WALSH PM, 1990, PROG ENERG COMBUST, V16, P327, DOI 10.1016/0360-1285(90)90042-2
   Wang HF, 1997, PROG ENERG COMBUST, V23, P267, DOI 10.1016/S0360-1285(97)00010-5
   Xue ZC, 2018, CHEM ENG SCI, V190, P248, DOI 10.1016/j.ces.2018.06.039
   Yan ZY, 2009, APPL ENERG, V86, P1359, DOI 10.1016/j.apenergy.2008.09.020
   Yu Z. H., 2011, U.S. Patent, Patent No. [7,862,632B2, 7862632]
   Zhang Q, 2017, AICHE J, V63, P2007, DOI 10.1002/aic.15555
NR 34
TC 2
Z9 2
U1 1
U2 14
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD APR 28
PY 2019
VL 198
BP 85
EP 97
DI 10.1016/j.ces.2019.01.016
PG 13
WC Engineering, Chemical
SC Engineering
GA HL5YZ
UT WOS:000458810700008
DA 2020-05-12
ER

PT J
AU Saeedipour, M
   Puttinger, S
   Doppelhammer, N
   Pirker, S
AF Saeedipour, Mahdi
   Puttinger, Stefan
   Doppelhammer, Nikolaus
   Pirker, Stefan
TI Investigation on turbulence in the vicinity of liquid-liquid interfaces
   Large eddy simulation and PIV experiment
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Large eddy simulation (LES); Volume of fluid method (VOF); Particle
   image velocimetry (PIV); Interfacial flow; Slag entrainment
ID SUBGRID SURFACE-TENSION; APPROXIMATE DECONVOLUTION;
   NUMERICAL-SIMULATION; MODEL; LES; ENTRAINMENT; DYNAMICS; FLOWS; SLAG
AB In this work, the turbulence in the vicinity of the liquid-liquid interfaces in an incompressible interfacial flow is investigated numerically and experimentally. A new large eddy simulation formulation is employed where all the subgrid scale (SGS) terms appearing in the filtered governing equations are closed by a volume of fluid-based Approximate Deconvolution Model (ADM-VOF) (Saeedipour et al., 2018). In this structural turbulence modelling approach, the SGS terms of stress tensor and surface tension in the Navier-Stokes equations, as well as the interface dynamics in the VOF transport equation, are mathematically reconstructed from the resolved scales. An oil-water benchmark experiment was designed for validation purposes where an oil layer is poured on the top of the water into which a submerged turbulent jet is injected and interacts with the oil-water interface. The interactions of the turbulence with the liquid-liquid interfaces are then studied by shadowgraphy visualization and time-resolved PIV measurement. Two sets of LES were performed using the ADM-VOF and a conventional LES model based on eddy-viscosity approach. The statistics of interfacial turbulence including velocity fluctuations and interface dynamics are analyzed and compared with the ones obtained from the experiment. The results reveal that in the interface vicinity the ADM-VOF approach, which reconstructs more turbulent scales and includes the SGS terms of turbulence-interface interactions, is of superior performance in predicting the energy spectra and statistics of turbulence. Far from the interface no particular difference between the LES models was observed. In addition, the temporal average of the interface motion as well as the evolution of the interfacial area is studied. While both models predict the averaged temporal evolution of the interface similarly, the ADM-VOF revealed its potentials for high fluctuating regions as it accounts for the effect of SGS term interface dynamics. This study provides a perspective for connecting the interfacial turbulence to metallurgical aspects of the continuous casting process. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Saeedipour, Mahdi; Puttinger, Stefan; Doppelhammer, Nikolaus; Pirker, Stefan] Johannes Kepler Univ Linz, Dept Particulate Flow Modelling, A-4040 Linz, Austria.
RP Saeedipour, M (reprint author), Johannes Kepler Univ Linz, Dept Particulate Flow Modelling, A-4040 Linz, Austria.
EM mahdi.saeedipour@jku.at
OI Doppelhammer, Nikolaus/0000-0002-2611-9216; Saeedipour,
   Mahdi/0000-0003-2441-6943
FU K1-MET GmbH; competence center for metallurgical research in Austria -
   Austrian Government
FX The authors gratefully acknowledge the funding support of K1-MET GmbH,
   the competence center for metallurgical research in Austria, which is
   partly funded by the Austrian Government.
CR Adrian R. J., 2011, PARTICLE IMAGE VELOC
   Aniszewski W, 2012, J COMPUT PHYS, V231, P7368, DOI 10.1016/j.jcp.2012.07.016
   Aniszewski W, 2016, J COMPUT PHYS, V327, P389, DOI 10.1016/j.jcp.2016.09.033
   BANERJEE S, 1968, IND ENG CHEM FUND, V7, P22, DOI 10.1021/i160025a004
   BRACKBILL JU, 1992, J COMPUT PHYS, V100, P335, DOI 10.1016/0021-9991(92)90240-Y
   Campos L., 2015, WIT T ENG SCI, V89, P439
   Campos L., 2015, NOTES NUMER FLUID ME, V135
   Campos L. C. B., 2017, THESIS
   Deshpande Suraj S., 2012, Computational Science and Discovery, V5, DOI 10.1088/1749-4699/5/1/014016
   GERMANO M, 1991, PHYS FLUIDS A-FLUID, V3, P1760, DOI 10.1063/1.857955
   Habisreutinger MA, 2007, J COMPUT PHYS, V224, P241, DOI 10.1016/j.jcp.2007.02.010
   Herrmann M, 2013, COMPUT FLUIDS, V87, P92, DOI 10.1016/j.compfluid.2013.02.008
   Hibbeler L, 2013, IRON STEEL TECHNOLOG, V10, P121
   HIRT CW, 1981, J COMPUT PHYS, V39, P201, DOI 10.1016/0021-9991(81)90145-5
   Huang A, 2015, STEEL RES INT, V86, P1447, DOI 10.1002/srin.201400373
   Iguchi M, 2000, ISIJ INT, V40, P685, DOI 10.2355/isijinternational.40.685
   Labourasse E, 2007, INT J MULTIPHAS FLOW, V33, P1, DOI 10.1016/j.ijmultiphaseflow.2006.05.010
   Lacanette D, 2006, PHYS FLUIDS, V18, DOI 10.1063/1.2186589
   Lakehal D, 2010, NUCL ENG DES, V240, P2096, DOI 10.1016/j.nucengdes.2009.11.030
   Larocque J, 2010, INT J HEAT FLUID FL, V31, P536, DOI 10.1016/j.ijheatfluidflow.2010.02.011
   Li Z., 2009, PHYS FLUIDS, V21
   Liovic P, 2007, INT J HEAT FLUID FL, V28, P127, DOI 10.1016/j.ijheatfluidflow.2006.03.003
   Liu ZQ, 2013, ISIJ INT, V53, P484, DOI 10.2355/isijinternational.53.484
   Lubin P, 2006, COAST ENG, V53, P631, DOI 10.1016/j.coastaleng.2006.01.001
   McCaslin J. O., 2014, TECH REP
   Mimouni S, 2017, NUCL ENG DES, V321, P118, DOI 10.1016/j.nucengdes.2016.12.009
   Puttinger S., 2017, 11 PAC S FLOW VIS IM
   Raffel M, 2007, EXP FLUID MECH, P1, DOI 10.1007/978-3-540-72308-0
   Roenby J., 2016, COMPUTATIONAL METHOD
   Saeedipour M., 2017, 12 INT C CFD OIL GAS
   Saeedipour M., 2018, INT J MULTIPHASE FLO
   Saeedipour M, 2017, INT J MULTIPHAS FLOW, V95, P71, DOI 10.1016/j.ijmultiphaseflow.2017.05.006
   Sagaut P., 1998, LARGE EDDY SIMULATIO
   Schneiderbauer S, 2018, PHYS FLUIDS, V30, DOI 10.1063/1.5017004
   Stolz S, 1999, PHYS FLUIDS, V11, P1699, DOI 10.1063/1.869867
   Stolz S, 2001, PHYS FLUIDS, V13, P997, DOI 10.1063/1.1350896
   Sulasalmi P, 2009, ISIJ INT, V49, P1661, DOI 10.2355/isijinternational.49.1661
   Trontin P, 2010, INT J MULTIPHAS FLOW, V36, P891, DOI 10.1016/j.ijmultiphaseflow.2010.08.003
   VAN LEER B, 1974, J COMPUT PHYS, V14, P361
   Vincent S, 2008, COMPUT FLUIDS, V37, P898, DOI 10.1016/j.compfluid.2007.02.017
   Vincent S., 2016, COMPUT FLUIDS
   Weller HG, 1998, COMPUT PHYS, V12, P620, DOI 10.1063/1.168744
   YOSHIZAWA A, 1985, J PHYS SOC JPN, V54, P2834, DOI 10.1143/JPSJ.54.2834
   Youngs D., 1982, NUMERICAL METHODS FL, P273, DOI DOI 10.1007/S11433-009-0265-0
NR 44
TC 1
Z9 1
U1 3
U2 24
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD APR 28
PY 2019
VL 198
BP 98
EP 107
DI 10.1016/j.ces.2018.12.040
PG 10
WC Engineering, Chemical
SC Engineering
GA HL5YZ
UT WOS:000458810700009
DA 2020-05-12
ER

PT J
AU Martinez, SM
   Di Lorenzo, M
AF Martinez, Sara Monasterio
   Di Lorenzo, Mirella
TI Electricity generation from untreated fresh digestate with a
   cost-effective array of floating microbial fuel cells
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Agri-food waste; Fresh digestate; Microbial fuel cells; Stack;
   Bioelectricity
ID COMPOSITE FOOD WASTE; ANAEROBIC-DIGESTION; WATER; BIOELECTRICITY;
   PERFORMANCE; ENERGY; POWER; BIOHYDROGEN; BIOMETHANE; ABSENCE
AB Over one billion tons of food waste is generated every year worldwide. This waste represents a substantial part of municipal solid waste and is usually incinerated. The effective integration of the anaerobic digester process with the microbial fuel cell technology is an ecofriendly and promising solution for the treatment of food waste, which leads to clean energy generation and by-products of industrial interest. In this context, we here report the development of a floating air-cathode microbial fuel cell device and demonstrate electricity generation from fresh digestate, directly collected from an anaerobic digester effluent with no pre-treatment, used as the electrolyte, fuel and source of electroactive bacteria. The floating fuel cells are characterised by a simple yet innovative design. No metal catalyst is used at the cathode, and the use of a membrane is not required thanks to a natural vertical stratification of microorganisms in the digestate that prevents oxygen diffusion to the anode. Both the wettability and the surface area of the anode are enhanced with a two-step pre-treatment, which enhances the electrochemical performance of the electrode, leading to an oxidation peak twice greater than the non-treated electrode. The individual microbial fuel cell unit generated a power peak of 0.043 +/- 0.001 mW, which increased linearly by connecting several units electrically in parallel in a stack and reached the value of 0.43 mW (corresponding to 51 +/- 2 mW m(-3)) with ten units. Considering the simplicity and affordability of the design proposed, which facilitates upscaling, this work paves the way for a promising and environmentally friendly alternative to food waste incineration. Crown Copyright (C) 2019 Published by Elsevier Ltd. All rights reserved.
C1 [Martinez, Sara Monasterio] Exergy Ltd, Off IV7 1st Floor,Cheetah Rd, Coventry CV1 2TL, W Midlands, England.
   [Martinez, Sara Monasterio; Di Lorenzo, Mirella] Univ Bath, Biosensors Bioelect & Biodevices Ctr C3Bio, Bath BA2 7AY, Avon, England.
   [Martinez, Sara Monasterio; Di Lorenzo, Mirella] Univ Bath, Dept Chem Engn, Bath BA2 7AY, Avon, England.
RP Di Lorenzo, M (reprint author), Univ Bath, Biosensors Bioelect & Biodevices Ctr C3Bio, Bath BA2 7AY, Avon, England.; Di Lorenzo, M (reprint author), Univ Bath, Dept Chem Engn, Bath BA2 7AY, Avon, England.
EM m.di.lorenzo@bath.ac.uk
OI Di Lorenzo, Mirella/0000-0002-1332-6347
FU European UnionEuropean Union (EU) [690142]
FX This work has been developed within the AgroCycle project, funded by the
   European Union's Horizon 2020 research and innovation programme under
   grant agreement No 690142. The authors would like also to thank: Ursula
   Potter and Diana Lednitzky for their help with the SEM imaging,
   Microscopy and Analysis Suite, University of Bath (UK); Wesley Wong from
   Wessex Water (UK) for kindly providing us the digestate used in this
   work.
CR Ahn Y, 2014, J POWER SOURCES, V249, P440, DOI 10.1016/j.jpowsour.2013.10.081
   Artyushkova K, 2015, BIOINTERPHASES, V10, DOI 10.1116/1.4913783
   Babauta J, 2012, BIOFOULING, V28, P789, DOI 10.1080/08927014.2012.710324
   Behera M, 2010, BIOELECTROCHEMISTRY, V79, P228, DOI 10.1016/j.bioelechem.2010.06.002
   Bethke CM, 2011, AM J SCI, V311, P183, DOI 10.2475/03.2011.01
   Bose D, 2018, ENERGY ENV SUSTAIN, P7, DOI 10.1007/978-981-10-7413-4_2
   Chae KJ, 2009, BIORESOURCE TECHNOL, V100, P3518, DOI 10.1016/j.biortech.2009.02.065
   Cheng SA, 2007, ELECTROCHEM COMMUN, V9, P492, DOI 10.1016/j.elecom.2006.10.023
   Chouler J, 2017, ELECTROCHIM ACTA, V231, P319, DOI 10.1016/j.electacta.2017.01.195
   Chouler J, 2016, ELECTROCHIM ACTA, V192, P89, DOI 10.1016/j.electacta.2016.01.112
   Costa A., 2015, ANAEROBIC DIGESTION, P15
   De Baere L, 2000, WATER SCI TECHNOL, V41, P283
   Di Lorenzo M, 2010, CHEM ENG J, V156, P40, DOI 10.1016/j.cej.2009.09.031
   Ding CM, 2015, ANGEW CHEM INT EDIT, V54, P1446, DOI 10.1002/anie.201409163
   FAO, 2018, FOOD LOSS WAST RED F, V26, P1240, DOI [10.1002/er.1419, DOI 10.1002/ER.1419]
   Feng YJ, 2010, J POWER SOURCES, V195, P1841, DOI 10.1016/j.jpowsour.2009.10.030
   Fradler KR, 2014, BIOCHEM ENG J, V85, P125, DOI 10.1016/j.bej.2014.02.008
   Gao A., 2017, ENERGY PROCEDIA, V105, P3915, DOI DOI 10.1016/J.EGYPR0.2017.03.811
   Goud RK, 2011, INT J HYDROGEN ENERG, V36, P6210, DOI 10.1016/j.ijhydene.2011.02.056
   Guo K, 2013, ENVIRON SCI TECHNOL, V47, P7563, DOI 10.1021/es400901u
   Heilmann J, 2006, WATER ENVIRON RES, V78, P531, DOI 10.2175/106143005X73046
   Holm-Nielsen JB, 2009, BIORESOURCE TECHNOL, V100, P5478, DOI 10.1016/j.biortech.2008.12.046
   Ieropoulos I, 2008, INT J ENERG RES, V32, P1228, DOI 10.1002/er.1419
   Ieropoulos I, 2017, INT J HYDROGEN ENERG, V42, P1783, DOI 10.1016/j.ijhydene.2016.11.083
   Ieropoulos IA, 2013, INT J HYDROGEN ENERG, V38, P492, DOI 10.1016/j.ijhydene.2012.09.062
   Karthikeyan OP, 2017, ENRGY PROCED, V136, P14, DOI 10.1016/j.egypro.2017.10.253
   Kim T, 2015, BIORESOURCE TECHNOL, V195, P217, DOI 10.1016/j.biortech.2015.06.009
   Ledezma P, 2013, BIORESOURCE TECHNOL, V134, P158, DOI 10.1016/j.biortech.2013.01.119
   Li H, 2016, BIORESOURCE TECHNOL, V205, P104, DOI 10.1016/j.biortech.2016.01.042
   Liu H, 2004, ENVIRON SCI TECHNOL, V38, P4040, DOI 10.1021/es0499344
   Logan BE, 2006, ENVIRON SCI TECHNOL, V40, P5181, DOI 10.1021/es0605016
   Lowy DA, 2006, BIOSENS BIOELECTRON, V21, P2058, DOI 10.1016/j.bios.2006.01.033
   Mateo S, 2019, ELECTROCHIM ACTA, V297, P297, DOI 10.1016/j.electacta.2018.11.193
   Min B, 2005, WATER RES, V39, P4961, DOI 10.1016/j.watres.2005.09.039
   Mohan SV, 2011, BIORESOURCE TECHNOL, V102, P7077, DOI 10.1016/j.biortech.2011.04.039
   Mohan SV, 2010, BIOCHEM ENG J, V51, P32, DOI 10.1016/j.bej.2010.04.012
   Mohan SV, 2010, BIORESOURCE TECHNOL, V101, P970, DOI 10.1016/j.biortech.2009.09.005
   Moqsud MA, 2014, WASTE MANAGE RES, V32, P124, DOI 10.1177/0734242X13517160
   Nastro R. A., 2015, GLOB CLEAN PROD C
   Park DH, 2003, BIOTECHNOL BIOENG, V81, P348, DOI 10.1002/bit.10501
   Pham TH, 2006, ENG LIFE SCI, V6, P285, DOI 10.1002/elsc.200620121
   Premier GC, 2013, RENEW ENERG, V49, P188, DOI 10.1016/j.renene.2012.01.035
   Press N. A., 2006, WASTE INCINERATION P, DOI [10.17226/5803, DOI 10.17226/5803]
   Rabaey K, 2005, TRENDS BIOTECHNOL, V23, P291, DOI 10.1016/j.tibtech.2005.04.008
   Reeb J., 1999, MOISTURE CONTENT OVE, P66, DOI [10.1016/j.apsusc.2013.11.072, DOI 10.1016/J.APSUSC.2013.11.072]
   Rice E. W., 2017, STANDARD METHODS EVA
   Rodrigo MA, 2007, J POWER SOURCES, V169, P198, DOI 10.1016/j.jpowsour.2007.01.054
   Sarjit A, 2015, AIMS BIOENG, V2, P404, DOI 10.3934/bioeng.2015.4.404
   Singh HM, 2019, BIOFUELS-UK, V10, P11, DOI 10.1080/17597269.2017.1413860
   Smith REG, 2015, J ELECTROANAL CHEM, V747, P29, DOI 10.1016/j.jelechem.2015.03.029
   Stenmarck A., 2000, ESTIMATES EUROPEAN F, DOI [10.13140/rg.2.1.4658.4721, DOI 10.13140/RG.2.1.4658.4721, 10.13140/RG.2.1.4658.4721]
   Stevens NPC, 2001, J PHYS CHEM A, V105, P9085, DOI 10.1021/jp0103878
   Thyberg KL, 2016, RESOUR CONSERV RECY, V106, P110, DOI 10.1016/j.resconrec.2015.11.016
   Wang X, 2009, ENVIRON SCI TECHNOL, V43, P6088, DOI 10.1021/es900391b
   Weld RJ, 2011, BIORESOURCE TECHNOL, V102, P842, DOI 10.1016/j.biortech.2010.09.002
   Yu ZS, 2018, BIORESOURCE TECHNOL, V255, P340, DOI 10.1016/j.biortech.2018.02.003
   Zhao F, 2009, CHEM SOC REV, V38, P1926, DOI 10.1039/b819866g
   Zielke E. A, 2006, ANALYSIS, V2
NR 58
TC 3
Z9 3
U1 2
U2 26
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD APR 28
PY 2019
VL 198
BP 108
EP 116
DI 10.1016/j.ces.2018.12.039
PG 9
WC Engineering, Chemical
SC Engineering
GA HL5YZ
UT WOS:000458810700010
DA 2020-05-12
ER

PT J
AU Penn, A
   Boyce, CM
   Conzelmann, N
   Bezinge, G
   Pruessmann, KP
   Muller, CR
AF Penn, Alexander
   Boyce, Christopher M.
   Conzelmann, Nicholas
   Bezinge, Gaetan
   Pruessmann, Klaas P.
   Muller, Christoph R.
TI Real-time magnetic resonance imaging of fluidized beds with internals
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Fluidized bed reactors; Magnetic resonance imaging; Multiphase flow;
   Internals; Gas bubbles; Defluidized hood
ID HEAT-TRANSFER; BUBBLE; OBJECTS; FLOW
AB The effect of internals on the fluidization dynamics in three-dimensional (3D) cylindrical fluidized beds was studied using real-time magnetic resonance imaging. Instantaneous snapshots of particle velocity and particle position were acquired for gas velocities U below and above the minimum fluidization velocity U-mf. Below U-mf, we found local fluidization and gas bubbling in areas adjacent to an inserted horizontal tube, likely caused by the gas locally exceeding U-mf as it flows around the insert. Above U-mf, the presence of the insert in the bed affected the fluidization dynamics. The wake region above the insert exhibited a lower average particle velocity and reduced velocity fluctuations as well as a substantially reduced number and size of gas bubbles as compared to a reference bed without internals. The extent of this wake region was found to be approximately as wide as the insert, and it extended from the top of the insert to the free surface of the bed. Moreover, the presence of internals also affected the regions below the insert by showing an increased rate of bubble formation directly below the inserted tube. The present work can provide relevant information on the design of fluidized beds with internals. Moreover, the data gathered in this work can be used to validate the accuracy of 3D numerical models of gas-solid systems. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Penn, Alexander; Pruessmann, Klaas P.] Swiss Fed Inst Technol, Inst Biomed Engn, Zurich, Switzerland.
   [Penn, Alexander; Pruessmann, Klaas P.] Univ Zurich, Zurich, Switzerland.
   [Penn, Alexander; Boyce, Christopher M.; Conzelmann, Nicholas; Bezinge, Gaetan; Muller, Christoph R.] Swiss Fed Inst Technol, Dept Mech & Proc Engn, Zurich, Switzerland.
   [Boyce, Christopher M.] Columbia Univ, Dept Chem Engn, New York, NY 10027 USA.
RP Penn, A (reprint author), Swiss Fed Inst Technol, Inst Biomed Engn, Zurich, Switzerland.; Penn, A (reprint author), Univ Zurich, Zurich, Switzerland.; Muller, CR (reprint author), Swiss Fed Inst Technol, Dept Mech & Proc Engn, Zurich, Switzerland.
EM apenn@ethz.ch; nuelchri@ethz.ch
RI Penn, Alexander/E-9692-2013; Muller, Christoph R/J-6025-2016
OI Penn, Alexander/0000-0001-5596-6310; Muller, Christoph
   R/0000-0003-2234-6902
FU Swiss National Science FoundationSwiss National Science Foundation
   (SNSF) [200021_153290]
FX This work was supported by the Swiss National Science Foundation under
   grant no. 200021_153290. The authors declare that they do not have any
   competing interests.
CR BASKAKOV AP, 1973, POWDER TECHNOL, V8, P273, DOI 10.1016/0032-5910(73)80092-0
   Boyce CM, 2018, AICHE J, V64, P2958, DOI 10.1002/aic.16036
   DARTON RC, 1977, T I CHEM ENG-LOND, V55, P274
   Franka NR, 2009, POWDER TECHNOL, V193, P69, DOI 10.1016/j.powtec.2009.02.008
   Fukushima E, 1999, ANNU REV FLUID MECH, V31, P95, DOI 10.1146/annurev.fluid.31.1.95
   GABOR JD, 1967, INT S FLUIDIZATION E, P230
   Gladden LF, 2007, CHEM ENG SCI, V62, P6969, DOI 10.1016/j.ces.2007.08.084
   Gladden LF, 2013, CURR OPIN CHEM ENG, V2, P331, DOI 10.1016/j.coche.2013.05.005
   GLASS DH, 1964, CHEM ENG SCI, V19, P1001, DOI 10.1016/0009-2509(64)85112-5
   HAGER WR, 1976, CHEM ENG SCI, V31, P657, DOI 10.1016/0009-2509(76)87008-X
   Kunii D., 1991, FLUIDIZATION ENG
   KUROSAKI Y, 1988, INT J HEAT MASS TRAN, V31, P349
   Laverman JA, 2008, CAN J CHEM ENG, V86, P523, DOI 10.1002/cjce.20054
   LEBIHAN D, 1986, RADIOLOGY, V161, P401, DOI 10.1148/radiology.161.2.3763909
   Muller CR, 2007, IND ENG CHEM RES, V46, P1642, DOI 10.1021/ie0611397
   Mueth DM, 2000, NATURE, V406, P385, DOI 10.1038/35019032
   NOACK R, 1970, CHEM-ING-TECH, V42, P371, DOI 10.1002/cite.330420610
   NOLL DC, 1991, IEEE T MED IMAGING, V10, P154, DOI 10.1109/42.79473
   Penn A, 2018, IND ENG CHEM RES, V57, P9674, DOI 10.1021/acs.iecr.8b00932
   Penn A, 2017, SCI ADV, V3, DOI 10.1126/sciadv.1701879
   Pruessmann KP, 1999, MAGNET RESON MED, V42, P952, DOI 10.1002/(SICI)1522-2594(199911)42:5<952::AID-MRM16>3.0.CO;2-S
   Rao P, 2013, POWDER TECHNOL, V243, P53, DOI 10.1016/j.powtec.2013.03.044
   Senadeera W, 2003, J FOOD ENG, V58, P277, DOI 10.1016/S0260-8774(02)00386-2
   STEHLING MK, 1991, SCIENCE, V254, P43, DOI 10.1126/science.1925560
   Van de Velden M, 2008, POWDER TECHNOL, V183, P290, DOI 10.1016/j.powtec.2007.07.027
   Verma V, 2014, AICHE J, V60, P1632, DOI 10.1002/aic.14393
   Werther J, 1999, POWDER TECHNOL, V102, P15, DOI 10.1016/S0032-5910(98)00202-2
   WERTHER J, 1977, CHEM-ING-TECH, V49, P777, DOI 10.1002/cite.330491003
   Werther J., 1973, INT J MULTIPHASE FLO, V1, P103
   Wu SY, 1998, POWDER TECHNOL, V98, P139, DOI 10.1016/S0032-5910(98)00026-6
   Yoshida M, 2010, ADV POWDER TECHNOL, V21, P69, DOI 10.1016/j.apt.2009.11.002
NR 31
TC 3
Z9 4
U1 2
U2 17
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD APR 28
PY 2019
VL 198
BP 117
EP 123
DI 10.1016/j.ces.2018.12.041
PG 7
WC Engineering, Chemical
SC Engineering
GA HL5YZ
UT WOS:000458810700011
DA 2020-05-12
ER

PT J
AU Qi, N
   Chen, GB
   Liang, C
   Guo, TK
   Liu, GL
   Zhang, K
AF Qi, Ning
   Chen, Guobin
   Liang, Chong
   Guo, Tiankui
   Liu, Guoliang
   Zhang, Kai
TI Numerical simulation and analysis of the influence of fracture geometry
   on wormhole propagation in carbonate reservoirs
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Acidification of large-scale carbonate reservoirs; Two-scale continuum
   model; Fracture geometry; Wormhole propagation; Step-by-step calculation
   method
ID REACTIVE DISSOLUTION; MODEL; FLOW
AB Wormholes can effectively connect the fracture system as the dominant channels when carbonate matrix is acidified, thereby increasing the distance of acidification. It is critical to clarify the wormhole propagation law in carbonate reservoirs so as to optimize the acidification design. Previous studies highlight the influences of matrix as well as single simple fracture on wormhole propagation. However, the works characterizing impacts of single and multiple fractures with different geometry are insufficient. In this paper, the two-scale continuum model and pseudo-fracture model were combined to study the worm-hole with different fractures. It was found that the fractures parallel to injection direction can concentrate fluids and thus accelerate the acid penetrating the formation, while the perpendicular ones will disperse fluids, thereby slowing down the breakthrough. The effect of straight fractures and arc fractures on wormholes are similar. When the inclination angle is less than 60 degrees, straight fracture and arc fracture can be regarded as parallel fracture of corresponding length. When the inclination angle is greater than 60 degrees, they can be regarded as superposition of parallel fracture and perpendicular fracture. As for the circular and polygonal fractures, only the parts near the outlet impact the subsequent wormhole propagation trajectories. The analysis of flow field shows that there is a control domain of about 3.L.cos(theta) around the fractures. When there is no intersection of control domains of multiple fractures, there is no interference between them. There is no need to consider all fractures in the formation. Based on this, the step-by-step calculation method proposed in this paper is suitable for acidizing large-scale formation with complex fracture network. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Qi, Ning; Chen, Guobin; Guo, Tiankui; Zhang, Kai] China Univ Petr, Sch Petr Engn, Qingdao 266580, Shandong, Peoples R China.
   [Liang, Chong; Liu, Guoliang] PetroChina, Res Inst Petr Explorat & Dev, Beijing 100083, Peoples R China.
RP Chen, GB; Zhang, K (reprint author), China Univ Petr, Sch Petr Engn, Qingdao 266580, Shandong, Peoples R China.
EM chenguobin@s.upc.edu.cn; zhangkai@upc.edu.cn
FU National Key Technologies Research and Development Program of
   ChinaNational Key Technology R&D Program [2017ZX005030005]; Shandong
   Provincial Natural Science Foundation, ChinaNatural Science Foundation
   of Shandong Province [ZR2017MEE073]; Fundamental Research Funds for the
   Central UniversitiesFundamental Research Funds for the Central
   Universities [14CX05019A]
FX This work was financially supported by the National Key Technologies
   Research and Development Program of China during the 13th Five-Year Plan
   Period (Project No. 2017ZX005030005), Shandong Provincial Natural
   Science Foundation, China (ZR2017MEE073), and the Fundamental Research
   Funds for the Central Universities (14CX05019A). Their sponsorship is
   gratefully acknowledged.
CR Buijse M, 2005, SOC PETROL ENG, DOI [10.2523/96892-MS, DOI 10.2523/96892-MS]
   Cohen CE, 2008, CHEM ENG SCI, V63, P3088, DOI 10.1016/j.ces.2008.03.021
   DACCORD G, 1993, CHEM ENG SCI, V48, P169, DOI 10.1016/0009-2509(93)80293-Y
   Dong C, 2002, SPE J, V7, P400, DOI 10.2118/81816-PA
   Fei Liu, 2017, Petroleum, V3, P438, DOI 10.1016/j.petlm.2017.05.007
   Fredd CN, 1998, AICHE J, V44, P1933, DOI 10.1002/aic.690440902
   Gupta N, 2001, CHEM ENG SCI, V56, P4771, DOI 10.1016/S0009-2509(01)00134-8
   HOEFNER ML, 1988, AICHE J, V34, P45, DOI 10.1002/aic.690340107
   Kalia N, 2007, CHEM ENG SCI, V62, P919, DOI 10.1016/j.ces.2006.10.021
   Kalia N, 2009, CHEM ENG SCI, V64, P376, DOI 10.1016/j.ces.2008.10.026
   Li YJ, 2016, NUCL SCI TECH, V27, DOI 10.1007/s41365-016-0130-6
   Liu PY, 2017, CHEM ENG SCI, V172, P143, DOI 10.1016/j.ces.2017.06.027
   Ma XF, 2017, J ENERG RESOUR-ASME, V139, DOI 10.1115/1.4035909
   Maheshwari P, 2013, CHEM ENG SCI, V90, P258, DOI 10.1016/j.ces.2012.12.032
   Panga MKR, 2005, AICHE J, V51, P3231, DOI 10.1002/aic.10574
   Ratnakar RR, 2013, CHEM ENG SCI, V90, P179, DOI 10.1016/j.ces.2012.12.019
   Samadi F, 2012, AIP CONF PROC, V1453, P167, DOI 10.1063/1.4711170
   Szymczak P, 2012, J FLUID MECH, V702, P239, DOI 10.1017/jfm.2012.174
   Wang Y., 2014, GEOPHYS PETROL, V53, P7, DOI [10.3969/j.issn.1000-1441.2014.06.014, DOI 10.3969/J.ISSN.1000-1441.2014.06.014]
   Zhang Y, 2014, TRANSPORT POROUS MED, V101, P99, DOI 10.1007/s11242-013-0233-z
NR 20
TC 0
Z9 0
U1 9
U2 24
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD APR 28
PY 2019
VL 198
BP 124
EP 143
DI 10.1016/j.ces.2018.12.047
PG 20
WC Engineering, Chemical
SC Engineering
GA HL5YZ
UT WOS:000458810700012
DA 2020-05-12
ER

PT J
AU Tang, YY
   Su, MJ
   Chu, GW
   Luo, Y
   Wang, YY
   Zhang, LL
   Chen, JF
AF Tang, Yuan-Yuan
   Su, Meng-Jun
   Chu, Guang-Wen
   Luo, Yong
   Wang, Yue-Yan
   Zhang, Liang-Liang
   Chen, Jian-Feng
TI Impact phenomena of liquid droplet passing through stainless steel wire
   mesh units
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Liquid droplet; Stainless steel wire mesh unit; Impaction; Spreading;
   Boundary
ID ROTATING PACKED-BED; WATER DROPLETS; MASS; SIZE
AB Investigating the behavior of droplets impacting on stainless steel wire mesh is of great importance. Previous studies focused on the impact phenomena of a whole wire mesh, without detailed function of each composing unit. In this work, the impact on two basic units of the single fiber and the intersection of two crossing fibers was systemically investigated. The dispersion processes of the droplets were recorded by a high-speed camera at various conditions of the droplet velocities, initial droplet sizes, and impacted object shapes. Three dripping modes of one-drop, double-drop, and ligament were observed when droplets impact on one single fiber. Two disintegration modes of four-part and two part were found with crossing fibers. Correlations of the maximum spreading length of the droplet on the fiber of wire mesh were proposed, and the predicted values were in a good agreement with the experimental values. The mathematical models of the boundaries between different modes were established based on the force analysis of the droplet impacting on the mesh units. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Tang, Yuan-Yuan; Su, Meng-Jun; Chu, Guang-Wen; Wang, Yue-Yan; Chen, Jian-Feng] Beijing Univ Chem Technol, Beijing Adv Innovat Ctr Soft Matter Sci & Engn, Beijing 100029, Peoples R China.
   [Tang, Yuan-Yuan; Su, Meng-Jun; Chu, Guang-Wen; Wang, Yue-Yan; Chen, Jian-Feng] Beijing Univ Chem Technol, State Key Lab Organ Inorgan Composites & Technol, Beijing 100029, Peoples R China.
   [Tang, Yuan-Yuan; Su, Meng-Jun; Chu, Guang-Wen; Luo, Yong; Wang, Yue-Yan; Zhang, Liang-Liang; Chen, Jian-Feng] Beijing Univ Chem Technol, Minist Educ High Grav Engn Technol, Res Ctr, Beijing 100029, Peoples R China.
RP Luo, Y (reprint author), Beijing Univ Chem Technol, State Key Lab Organ Inorgan Composites & Technol, Beijing 100029, Peoples R China.
EM luoyong@mail.buct.edu.cn
FU National Key Research and Development Program of China [2017YFA0206801];
   National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [21725601, 21676009, 21436001]
FX This work was supported by the National Key Research and Development
   Program of China (No. 2017YFA0206801) and the National Natural Science
   Foundation of China (Nos. 21725601, 21676009, and 21436001).
CR Almohammadi H, 2017, SOFT MATTER, V13, P2040, DOI 10.1039/c6sm02514e
   Bai H, 2010, ADV MATER, V22, P5521, DOI 10.1002/adma.201003169
   Bico J, 2002, COLLOID SURFACE A, V206, P41, DOI 10.1016/S0927-7757(02)00061-4
   BRYANT JE, 1988, J ECON ENTOMOL, V81, P130, DOI 10.1093/jee/81.1.130
   Chen QY, 2016, IND ENG CHEM RES, V55, P11606, DOI 10.1021/acs.iecr.6b02630
   Chu GW, 2015, CHEM ENG PROCESS, V90, P34, DOI 10.1016/j.cep.2015.02.007
   Contal P, 2004, J AEROSOL SCI, V35, P263, DOI 10.1016/j.jaerosci.2003.07.003
   Coulson J. M, 2000, CHEM ENG
   Estey RH, 2004, PHYTOPROTECTION, V85, P7, DOI 10.7202/008900ar
   Gilet T, 2010, EUR PHYS J E, V31, P253, DOI 10.1140/epje/i2010-10563-9
   Grishaev V, 2015, LANGMUIR, V31, P9833, DOI 10.1021/acs.langmuir.5b02162
   Hung LS, 2002, INT J MULTIPHAS FLOW, V28, P93, DOI 10.1016/S0301-9322(01)00061-1
   Hung LS, 1999, INT J MULTIPHAS FLOW, V25, P1545, DOI 10.1016/S0301-9322(98)00085-8
   Kim SG, 2016, PHYS FLUIDS, V28, DOI 10.1063/1.4945103
   Liang GT, 2016, INT J HEAT MASS TRAN, V101, P577, DOI 10.1016/j.ijheatmasstransfer.2016.05.062
   Liang GT, 2014, EXP THERM FLUID SCI, V52, P97, DOI 10.1016/j.expthermflusci.2013.09.001
   Liang GT, 2013, EXP THERM FLUID SCI, V51, P18, DOI 10.1016/j.expthermflusci.2013.06.012
   Lorenceau E, 2004, J COLLOID INTERF SCI, V279, P192, DOI 10.1016/j.jcis.2004.06.054
   Nuyttens D, 2009, T ASABE, V52, P1471, DOI 10.13031/2013.29127
   Park KC, 2013, LANGMUIR, V29, P13269, DOI 10.1021/la402409f
   Piroird K, 2009, J COLLOID INTERF SCI, V334, P70, DOI 10.1016/j.jcis.2009.03.004
   Ryu S, 2017, PHYS REV LETT, V118, DOI 10.1103/PhysRevLett.118.014501
   Sang L, 2017, CHEM ENG SCI, V170, P355, DOI 10.1016/j.ces.2016.12.041
   Sunol F, 2015, PHYS FLUIDS, V27, DOI 10.1063/1.4927365
   Thomas Z. F., 2013, INT J CHEM, V5, P113, DOI [10.5539/ijc.v5n4p113, DOI 10.5539/IJC.V5N4P113]
   Yeong YH, 2014, LANGMUIR, V30, P12027, DOI 10.1021/la502500z
   Zhang JP, 2017, CHEM ENG SCI, V170, P204, DOI 10.1016/j.ces.2017.03.058
   Zheng XH, 2016, CHEM ENG J, V285, P236, DOI 10.1016/j.cej.2015.09.083
   Zheng YM, 2010, NATURE, V463, P640, DOI 10.1038/nature08729
NR 29
TC 1
Z9 1
U1 5
U2 34
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD APR 28
PY 2019
VL 198
BP 144
EP 154
DI 10.1016/j.ces.2018.12.035
PG 11
WC Engineering, Chemical
SC Engineering
GA HL5YZ
UT WOS:000458810700013
DA 2020-05-12
ER

PT J
AU Shoyama, M
   Matsusaka, S
AF Shoyama, Mizuki
   Matsusaka, Shuji
TI Mechanism of disintegration of charged agglomerates in non-uniform
   electric field
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Particle electrification; Electric field; Chain agglomeration;
   Levitation; Rotation; Disintegration
ID PARTICLES; DISPERSION; VIBRATION; ELECTRIFICATION; ENHANCEMENT;
   LEVITATION; REMOVAL; SPHERES; SYSTEM
AB The mechanism of disintegration of agglomerates in a non-uniform electric field was studied experimentally and numerically. An external electric field was formed between an upper electrode made of wire mesh and a lower electrode comprising a metal plate. The dielectric particle layers on the lower electrode were charged by induction, and straight-chain agglomerates were formed on the surface of the particle layers by dipole interactions between the particles based on dielectric polarization. In the electric field, the charged agglomerates levitated under the influence of the Coulomb forces, and the charged agglomerates disintegrated with rotation when approaching the upper electrode. The experimental study and analysis of the numerical motion of the agglomerate showed that the charge distribution in the agglomerate generates torques around the centroid of the agglomerate in the non-uniform electric field around the upper electrode, and the centrifugal force acting on the rotating particles causes disintegration of the agglomerates. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Shoyama, Mizuki; Matsusaka, Shuji] Kyoto Univ, Dept Chem Engn, Kyoto 6158510, Japan.
RP Matsusaka, S (reprint author), Kyoto Univ, Dept Chem Engn, Kyoto 6158510, Japan.
EM matsu@cheme.kyoto-u.ac.jp
OI Matsusaka, Shuji/0000-0001-9048-929X
FU JSPS KAKENHIMinistry of Education, Culture, Sports, Science and
   Technology, Japan (MEXT)Japan Society for the Promotion of
   ScienceGrants-in-Aid for Scientific Research (KAKENHI) [JP17H03442]
FX This research was supported by JSPS KAKENHI Grant Number JP17H03442.
CR Adachi M, 2017, J ELECTROSTAT, V89, P88, DOI 10.1016/j.elstat.2017.08.003
   Calle CI, 2009, J ELECTROSTAT, V67, P89, DOI 10.1016/j.elstat.2009.02.012
   CHO AYH, 1964, J APPL PHYS, V35, P2561, DOI 10.1063/1.1713799
   Gotoh K, 2015, PARTICUL SCI TECHNOL, V33, P567, DOI 10.1080/02726351.2015.1060653
   HOLLMANN HE, 1950, J APPL PHYS, V21, P402, DOI 10.1063/1.1699674
   Hosseini M, 2012, CHINESE J CHEM ENG, V20, P654, DOI 10.1016/S1004-9541(11)60231-0
   ITOH T, 1994, J ELECTROSTAT, V32, P71, DOI 10.1016/0304-3886(94)90029-9
   Kacprzyk R, 2016, J ELECTROSTAT, V79, P33, DOI 10.1016/j.elstat.2015.12.001
   KASPER G, 1985, J AEROSOL SCI, V16, P535, DOI 10.1016/0021-8502(85)90006-0
   Kawamoto H, 2008, J ELECTROSTAT, V66, P220, DOI 10.1016/j.elstat.2008.01.002
   KLINGENBERG DJ, 1989, J CHEM PHYS, V91, P7888, DOI 10.1063/1.457256
   Kobayakawa M, 2015, CHEM ENG SCI, V123, P388, DOI 10.1016/j.ces.2014.11.046
   MASUDA H, 1994, ADV POWDER TECHNOL, V5, P205, DOI 10.1016/S0921-8831(08)60615-9
   Masuda H, 2009, ADV POWDER TECHNOL, V20, P113, DOI 10.1016/j.apt.2009.02.001
   MASUDA S, 1987, IEEE T IND APPL, V23, P474, DOI 10.1109/TIA.1987.4504934
   Mazumder MK, 2007, PARTICUL SCI TECHNOL, V25, P5, DOI 10.1080/02726350601146341
   Morgan H, 1997, J ELECTROSTAT, V42, P279, DOI 10.1016/S0304-3886(97)00159-9
   Nakajima Y, 2002, J ELECTROSTAT, V55, P203
   Ohtsuka S., 1997, KONA POWDER PART J, V15, P202
   Parthasarathy M, 1996, MAT SCI ENG R, V17, P57, DOI 10.1016/0927-796X(96)00191-X
   PEARCE CAR, 1954, BRIT J APPL PHYS, V5, P136, DOI 10.1088/0508-3443/5/4/304
   SEE H, 1991, J PHYS SOC JPN, V60, P2778, DOI 10.1143/JPSJ.60.2778
   Shoyama M, 2018, ADV POWDER TECHNOL, V29, P1960, DOI 10.1016/j.apt.2018.04.022
   Shoyama M, 2017, KAGAKU KOGAKU RONBUN, V43, P319, DOI 10.1252/kakoronbunshu.43.319
   Theerachaisupakij W, 2002, ADV POWDER TECHNOL, V13, P287, DOI 10.1163/156855202320252453
   WASHIZU M, 1994, IEEE IND APPLIC SOC, P1483, DOI 10.1109/IAS.1994.377621
   Wu Y, 2003, POWDER TECHNOL, V135, P59, DOI 10.1016/j.powtec.2003.08.004
   Zainuddin IM, 2012, PART PART SYST CHAR, V29, P8, DOI 10.1002/ppsc.201100052
NR 28
TC 1
Z9 1
U1 0
U2 5
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD APR 28
PY 2019
VL 198
BP 155
EP 164
DI 10.1016/j.ces.2018.12.055
PG 10
WC Engineering, Chemical
SC Engineering
GA HL5YZ
UT WOS:000458810700014
DA 2020-05-12
ER

PT J
AU Fariduddin, F
   Filot, IAW
   Zijlstra, B
   Hensen, EJM
AF Fariduddin, F.
   Filot, I. A. W.
   Zijlstra, B.
   Hensen, E. J. M.
TI Quantum-chemical-based microkinetics simulations of syngas conversion
   over MoS2(100) surface
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Synthesis gas; MoS2; Mechanism; Modelling; Kinetics
ID DENSITY-FUNCTIONAL THEORY; SYNTHESIS GAS CONVERSION; AB-INITIO; CO
   HYDROGENATION; SULFIDE CATALYSTS; MIXED ALCOHOLS; RH CATALYSTS; MOS2;
   SULFUR; METHANATION
AB MoS2 is a potential catalyst for the conversion of synthesis gas obtained from different carbon-containing feedstock into methane, hydrocarbons and alcohols. We performed a combined density functional theory and microkinetics simulation study of all relevant reaction pathways of CO and H-2 into methane, ethylene, ethane, formaldehyde, methanol, carbon dioxide and water at the bare and partially sulfided Mo-edge of MoS2(1 0 0). Reaction barriers were substantially lower for the 25% sulfur-covered Mo-edge in comparison to the bare Mo-edge. H-assisted CO dissociation is preferred over direct CO dissociation for both surfaces. Microkinetics simulations predict a negligible methanation rate for the bare Moedge, which contradicts experiment. The discrepancy stems from oxygen poisoning of the surface. Oxygen removal barriers are substantially lowered at a sulfur coverage of 25%. The resulting CO conversion rate and product distribution are in good agreement with reported experimental data. These simulations show how density functional theory combined with microkinetics simulations can predict performance of catalytic surface used in complex chemical reactions. (C) 2018 The Authors. Published by Elsevier Ltd.
C1 [Fariduddin, F.; Filot, I. A. W.; Zijlstra, B.; Hensen, E. J. M.] Eindhoven Univ Technol, Schuit Inst Catalysis, Lab Inorgan Mat Chem, POB 513, NL-5600 MB Eindhoven, Netherlands.
RP Hensen, EJM (reprint author), Eindhoven Univ Technol, Schuit Inst Catalysis, Lab Inorgan Mat Chem, POB 513, NL-5600 MB Eindhoven, Netherlands.
EM e.j.m.hensen@tue.nl
FU NWO-Top grant
FX We acknowledge NWO for providing access to the supercomputer facilities.
   EJMH acknowledges a NWO-Top grant for financial support.
CR Alfonso DR, 2013, J PHYS CHEM C, V117, P20562, DOI 10.1021/jp403828y
   ANDERSON AB, 1989, J CATAL, V119, P135, DOI 10.1016/0021-9517(89)90141-3
   ANDERSON RB, 1965, J CATAL, V4, P56, DOI 10.1016/0021-9517(65)90089-8
   Appl M, 1999, AMM PRINC IND PRACT, P135
   Bao J, 2009, TOP CATAL, V52, P789, DOI 10.1007/s11244-009-9200-x
   BARTHOLOMEW CH, 1982, ADV CATAL, V31, P135, DOI 10.1016/S0360-0564(08)60454-X
   BELL AT, 1981, CATAL REV, V23, P203, DOI 10.1080/03602458108068076
   BLOCHL PE, 1994, PHYS REV B, V50, P17953, DOI 10.1103/PhysRevB.50.17953
   Bollinger M. V., 2001, PHYS REV LETT, V87
   BROWN PN, 1989, SIAM J SCI STAT COMP, V10, P1038, DOI 10.1137/0910062
   Burch R, 1997, J CATAL, V165, P249, DOI 10.1006/jcat.1997.1482
   Byrne G. D., 1975, ACM Transactions on Mathematical Software, V1, P71, DOI 10.1145/355626.355636
   BYRNE GD, 1987, J COMPUT PHYS, V70, P1, DOI 10.1016/0021-9991(87)90001-5
   Charles N., 1991, HETEROGENEOUS CATALY, P454
   Chen J, 2002, CHEM COMMUN, P1722, DOI 10.1039/B205109e
   Chen YY, 2011, J MOL CATAL A-CHEM, V338, P44, DOI 10.1016/j.molcata.2011.01.024
   Chen YY, 2010, J MOL CATAL A-CHEM, V329, P77, DOI 10.1016/j.molcata.2010.06.021
   Chiang SW, 2012, ENERGIES, V5, P4147, DOI 10.3390/en5104147
   Chorkendorff I. B., 2017, CONCEPTS MODERN CATA
   DALLABETTA RA, 1975, J CATAL, V40, P173, DOI 10.1016/0021-9517(75)90244-4
   De Vita A., 1992, THESIS
   Dong X, 2009, CATAL TODAY, V147, P158, DOI 10.1016/j.cattod.2008.11.025
   Einstein A, 1913, ANN PHYS-BERLIN, V40, P551
   Filot IAW, 2015, ACS CATAL, V5, P5453, DOI 10.1021/acscatal.5b01391
   Filot IAW, 2014, ANGEW CHEM INT EDIT, V53, P12746, DOI 10.1002/anie.201406521
   FITZHARRIS WD, 1982, J CATAL, V76, P369, DOI 10.1016/0021-9517(82)90267-6
   FU YL, 1995, APPL CATAL A-GEN, V126, P273, DOI 10.1016/0926-860X(95)00059-3
   Hansen L. P., 2011, ANGEW CHEM, V123, P10335
   Helveg S, 2000, PHYS REV LETT, V84, P951, DOI 10.1103/PhysRevLett.84.951
   Henkelman G, 2000, J CHEM PHYS, V113, P9901, DOI 10.1063/1.1329672
   HOU P, 1983, J CATAL, V80, P280, DOI 10.1016/0021-9517(83)90253-1
   HOU PY, 1985, J CATAL, V93, P409, DOI 10.1016/0021-9517(85)90188-5
   Hu JL, 2007, CATAL TODAY, V120, P90, DOI 10.1016/j.cattod.2006.07.006
   Huang M, 2009, J PHYS CHEM C, V113, P5238, DOI 10.1021/jp807705y
   Jansen A. P. J., 2012, INTRO KINETIC M CARL
   Kim MY, 2013, CATAL COMMUN, V35, P68, DOI 10.1016/j.catcom.2013.02.004
   KITTEL C, 1966, INTRO SOLID STATE PH
   Koizumi N, 2004, J MOL CATAL A-CHEM, V207, P173, DOI 10.1016/S1381-1169(03)00497-7
   KRESSE G, 1994, PHYS REV B, V49, P14251, DOI 10.1103/PhysRevB.49.14251
   Kresse G, 1999, PHYS REV B, V59, P1758, DOI 10.1103/PhysRevB.59.1758
   Kresse G, 1996, COMP MATER SCI, V6, P15, DOI 10.1016/0927-0256(96)00008-0
   Lauritsen JV, 2007, NAT NANOTECHNOL, V2, P53, DOI 10.1038/nnano.2006.171
   LEE JS, 1994, APPL CATAL A-GEN, V110, P11, DOI 10.1016/0926-860X(94)80101-0
   Li YM, 1999, CATAL TODAY, V51, P25, DOI 10.1016/S0920-5861(99)00005-X
   Liu J, 2013, FUEL PROCESS TECHNOL, V110, P249, DOI 10.1016/j.fuproc.2013.01.003
   Liu YY, 2010, J JPN PETROL INST, V53, P153, DOI 10.1627/jpi.53.153
   LOGAN M, 1985, J CATAL, V94, P60, DOI 10.1016/0021-9517(85)90082-X
   Lu G, 1997, APPL CATAL A-GEN, V150, P243, DOI 10.1016/S0926-860X(96)00285-2
   Lund CRF, 1996, IND ENG CHEM RES, V35, P2531, DOI 10.1021/ie950608u
   MADON RJ, 1977, CATAL REV, V15, P69, DOI 10.1080/03602457708081722
   MONKHORST HJ, 1976, PHYS REV B, V13, P5188, DOI 10.1103/PhysRevB.13.5188
   Neiman M. L., 2004, MODELLING SYNGAS REA
   NIELSEN PEH, 1995, TOP CATAL, V2, P207
   OKUHARA T, 1977, J CATAL, V48, P229, DOI 10.1016/0021-9517(77)90094-X
   Perdew JP, 1996, PHYS REV LETT, V77, P3865, DOI 10.1103/PhysRevLett.77.3865
   Polyakov M, 2008, J CATAL, V256, P137, DOI 10.1016/j.jcat.2008.03.006
   Raybaud P, 2000, J CATAL, V189, P129, DOI 10.1006/jcat.1999.2698
   Remediakis IN, 2004, J PHYS CHEM B, V108, P14535, DOI 10.1021/jp0493374
   Ren J, 2006, SURF SCI, V600, P2329, DOI 10.1016/j.susc.2006.03.027
   Santos VP, 2013, ACS CATAL, V3, P1634, DOI 10.1021/cs4003518
   Schaaf T, 2014, ENERGY SUSTAIN SOC, V4, DOI 10.1186/s13705-014-0029-1
   Scheijen FJE, 2007, J PHYS CHEM C, V111, P13473, DOI 10.1021/jp072673a
   SCHOLZ GA, 1989, CAN J CHEM, V67, P862, DOI 10.1139/v89-133
   Shetty S, 2011, CATAL TODAY, V171, P168, DOI 10.1016/j.cattod.2011.04.006
   Shetty S, 2009, J AM CHEM SOC, V131, P12874, DOI 10.1021/ja9044482
   Shi XR, 2009, J MOL CATAL A-CHEM, V312, P7, DOI 10.1016/j.molcata.2009.06.025
   Shi XR, 2009, APPL CATAL A-GEN, V365, P62, DOI 10.1016/j.apcata.2009.05.050
   Sun XL, 2003, APPL CATAL A-GEN, V247, P133, DOI 10.1016/S0926-860X(03)00093-0
   Sun XC, 2013, APPL SURF SCI, V265, P720, DOI 10.1016/j.apsusc.2012.11.091
   TATSUMI T, 1984, CHEM LETT, P685, DOI 10.1246/cl.1984.685
   Travert A, 2001, CATAL TODAY, V70, P255, DOI 10.1016/S0920-5861(01)00422-9
   WOO HC, 1992, J CATAL, V138, P525, DOI 10.1016/0021-9517(92)90304-Z
   XIE YC, 1986, APPL CATAL, V27, P233
   Xu GW, 2006, CHEM ENG J, V121, P97, DOI 10.1016/j.cej.2006.05.010
   Xu X, 1987, CATAL TODAY, V2, P125, DOI DOI 10.1016/0920-5861(87)80002-0
   Zaman S, 2012, CATAL REV, V54, P41, DOI 10.1080/01614940.2012.627224
   Zeng T, 2005, J PHYS CHEM B, V109, P13704, DOI 10.1021/jp0518153
   Zeng T, 2005, J PHYS CHEM B, V109, P2846, DOI 10.1021/jp0466461
   ZHENG C, 1988, J AM CHEM SOC, V110, P749, DOI 10.1021/ja00211a015
NR 79
TC 2
Z9 2
U1 0
U2 9
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD APR 28
PY 2019
VL 198
BP 166
EP 183
DI 10.1016/j.ces.2018.10.040
PG 18
WC Engineering, Chemical
SC Engineering
GA HL5YZ
UT WOS:000458810700016
OA Other Gold, Green Published
DA 2020-05-12
ER

PT J
AU Sengar, A
   Kuipers, JAM
   van Santen, RA
   Padding, JT
AF Sengar, A.
   Kuipers, J. A. M.
   van Santen, R. A.
   Padding, J. T.
TI Towards a particle based approach for multiscale modeling of
   heterogeneous catalytic reactors
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Heterogenous catalysis; Multiscale modelling; Stochastic rotation
   dynamics; Multicomponent diffusion; Nonlinear reactions; Unsteady state
   modelling
ID MULTIPARTICLE COLLISION DYNAMICS; TRANSPORT-COEFFICIENTS; MESOSCOPIC
   MODEL; DIFFUSION; FLOW; DISPERSION; ADSORPTION
AB Particle based approaches are one of the recent modeling techniques to overcome the computational limitation in multiscale modeling of complex processes, for example a heterogeneous catalytic reactor. We propose an efficient model for a chemical reactor where hydrodynamics of the solvent is determined by Stochastic Rotation Dynamics and a reaction occurs over a catalytic surface where the reaction kinetics follows the mean-field assumption. We highlight the modeling techniques required to simulate such a system and then validate the model for its separate and combined components of convection, diffusion and reaction(s). A dimensionless analysis helps compare processes occurring at different scales. We determine the Reynolds number, Re, and the Damkohler numbers, Da and Da(L) in terms of key quantities. The approach is then used to analyse a reaction (a) following the Langmuir-Hinshelwood kinetics, (b) generating product particles with different self-diffusivity values as compared to the reactant particles. The model developed can further incorporate reactions occurring inside complex geometries (pore diffusion) and also be used to study complex reaction systems for which the mean-field assumption is no longer valid. (C) 2018 The Authors. Published by Elsevier Ltd.
C1 [Sengar, A.; Kuipers, J. A. M.] Eindhoven Univ Technol, Dept Chem Engn & Chem, POB 513, NL-5600 MB Eindhoven, Netherlands.
   [van Santen, R. A.] Eindhoven Univ Technol, Inst Complex Mol Syst, POB 513, NL-5600 MB Eindhoven, Netherlands.
   [Padding, J. T.] Delft Univ Technol, Proc & Energy Dept, Leeghwaterstr 39, NL-2628 CB Delft, Netherlands.
RP Sengar, A (reprint author), Eindhoven Univ Technol, Dept Chem Engn & Chem, POB 513, NL-5600 MB Eindhoven, Netherlands.
EM a.sengar@tue.nl; j.a.m.kuipers@tue.nl; r.a.v.santen@tue.nl;
   j.t.padding@tudelft.nl
FU Netherlands Center for Multi-scale Catalytic Energy Conversion (MCEC) -
   Netherlands Organization for Scientific Research, NWO
FX The work is part of the Netherlands Center for Multi-scale Catalytic
   Energy Conversion (MCEC), funded by the Netherlands Organization for
   Scientific Research, NWO.
CR Allahyarov E., 2002, PHYS REV E, V66, P1
   Alves MA, 2006, CHEM ENG SCI, V61, P1174, DOI 10.1016/j.ces.2005.08.017
   BERENDSEN HJC, 1991, NATO ADV SCI I E-APP, V205, P139
   Chen S, 1998, ANNU REV FLUID MECH, V30, P329, DOI 10.1146/annurev.fluid.30.1.329
   CHURCHILL SW, 1988, VISCOUS FLOWS PRACTI
   COLLINS FC, 1949, J COLL SCI IMP U TOK, V4, P425, DOI 10.1016/0095-8522(49)90023-9
   Delgado JMPQ, 2006, HEAT MASS TRANSFER, V42, P279, DOI 10.1007/s00231-005-0019-0
   Deprez L, 2017, SOFT MATTER, V13, P3532, DOI 10.1039/c7sm00123a
   Eigenberger G., 2008, HDB HETEROGENEOUS CA, P2075, DOI DOI 10.1002/9783527610044.HETCAT0111
   Gompper G, 2009, ADV POLYM SCI, V221, P1, DOI 10.1007/12_2008_5
   GUNN DJ, 1987, CHEM ENG SCI, V42, P363, DOI 10.1016/0009-2509(87)85066-2
   Huang MJ, 2016, SOFT MATTER, V12, P5581, DOI 10.1039/c6sm00830e
   Ihle T, 2003, PHYS REV E, V67, DOI 10.1103/PhysRevE.67.066705
   Ihle T, 2001, PHYS REV E, V63, part. no., DOI 10.1103/PhysRevE.63.020201
   Kikuchi N, 2003, J CHEM PHYS, V119, P6388, DOI 10.1063/1.1603721
   KLINKENBERG A, 1953, IND ENG CHEM, V45, P1202, DOI 10.1021/ie50522a024
   Kmiecik S, 2016, CHEM REV, V116, P7898, DOI 10.1021/acs.chemrev.6b00163
   Krishna R, 1997, CHEM ENG SCI, V52, P861, DOI 10.1016/S0009-2509(96)00458-7
   Kuroki M, 2009, J CHEM ENG JPN, V42, pS73, DOI 10.1252/jcej.08we256
   Lamura A, 2001, EUROPHYS LETT, V56, P319, DOI 10.1209/epl/i2001-00522-9
   Lanfrey PY, 2010, CHEM ENG SCI, V65, P1891, DOI 10.1016/j.ces.2009.11.011
   Levenspiel O., 1962, CHEM REACTION ENG
   Li Z, 2015, J CHEM PHYS, V143, DOI 10.1063/1.4923254
   Lu JT, 2018, CHEM ENG SCI, V176, P1, DOI 10.1016/j.ces.2017.10.018
   Malevanets A, 1999, J CHEM PHYS, V110, P8605, DOI 10.1063/1.478857
   Noguchi H, 2008, PHYS REV E, V78, DOI 10.1103/PhysRevE.78.016706
   Padding JT, 2006, PHYS REV E, V74, DOI 10.1103/PhysRevE.74.031402
   Pooley CM, 2005, J PHYS CHEM B, V109, P6505, DOI 10.1021/jp046040x
   Rohlf K, 2008, COMPUT PHYS COMMUN, V179, P132, DOI 10.1016/j.cpc.2008.01.027
   Salciccioli M, 2011, CHEM ENG SCI, V66, P4319, DOI 10.1016/j.ces.2011.05.050
   Sengar A, 2017, PHYS REV E, V96, DOI 10.1103/PhysRevE.96.022115
   Sheng N, 2004, POLYMER, V45, P487, DOI 10.1016/j.polymer.2003.10.100
   STEINHAUSER MO, 2007, COMPUTATIONAL MULTIS
   Taneda S., 1956, REP RES I APPL MECH, V4, P366
   TAYLOR R, 1993, MULTICOMPONENT MASS
   Tucci K, 2004, J CHEM PHYS, V120, P8262, DOI 10.1063/1.1690244
   Tuzel E, 2007, EPL-EUROPHYS LETT, V80, DOI 10.1209/0295-5075/80/40010
   Tuzel E, 2006, PHYS REV E, V74, DOI 10.1103/PhysRevE.74.056702
   Tuzel E, 2003, PHYS REV E, V68, DOI 10.1103/PhysRevE.68.036701
   Van de Ven-Lucassen IMJJ, 1998, MOL PHYS, V94, P495, DOI 10.1080/00268979809482342
   Vanson JM, 2015, SOFT MATTER, V11, P6125, DOI 10.1039/c5sm01348h
   Villemot F, 2014, J PHYS CHEM C, V118, P7423, DOI 10.1021/jp500037z
   Wehinger GD, 2015, CHEM ENG SCI, V122, P197, DOI 10.1016/j.ces.2014.09.007
NR 43
TC 4
Z9 4
U1 2
U2 11
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD APR 28
PY 2019
VL 198
BP 184
EP 197
DI 10.1016/j.ces.2018.10.038
PG 14
WC Engineering, Chemical
SC Engineering
GA HL5YZ
UT WOS:000458810700017
OA Green Published, Other Gold
DA 2020-05-12
ER

PT J
AU Ge, W
   Chang, Q
   Li, CX
   Wang, JW
AF Ge, Wei
   Chang, Qi
   Li, Chengxiang
   Wang, Junwu
TI Multiscale structures in particle-fluid systems: Characterization,
   modeling, and simulation
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Review
DE Multiscale structures; Mesoscale structures; Structure heterogeneity;
   Fluidization; Multiphase flow
ID DIRECT NUMERICAL-SIMULATION; GAS-SOLID FLOWS; IMMERSED BOUNDARY METHOD;
   LATTICE-BOLTZMANN SIMULATIONS; DISCRETE-ELEMENT METHOD; UNITED-ATOM
   DESCRIPTION; REACTIVE FORCE-FIELD; RAY COMPUTED-TOMOGRAPHY; AVERAGED
   2-FLUID MODEL; MASS-TRANSFER MODEL
AB This article reviews the general features of the multiscale structures in particle-fluid systems and the characterization, modeling, and simulation methods for these systems. The discussion focuses on the effects of mesoscale behavior, especially those present in process industries for materials and energy transformation and utilization. When there is substantial multiscale heterogeneity in these systems, local non-equilibrium and anisotropy generally lead to a lack of scale separation. Accurate and efficient simulation methods based on first principles and applied across different scales are highly desirable to reveal and quantify the complexities of these systems. Meanwhile, precisely designed experiments and exhaustive nonintrusive measurements are necessary to validate and expand the numerical findings. With this knowledge, rational mesoscale models can be established to provide multiscale simulation methods that do not need to fully reproduce the micro- and mesoscale details of the systems but can still take into account their effects on macroscales. Such multiscale methods are attractive for industrial applications but substantial effort in physical modeling and numerical implementation is still required before their widespread implementation. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Ge, Wei; Chang, Qi; Li, Chengxiang; Wang, Junwu] Chinese Acad Sci, Inst Proc Engn, State Key Lab Multiphase Complex Syst, Beijing 100190, Peoples R China.
   [Ge, Wei; Wang, Junwu] Univ Chinese Acad Sci, Sch Chem Engn, Beijing 100039, Peoples R China.
   [Ge, Wei; Chang, Qi] Collaborat Innovat Ctr Chem Sci & Engn Tianjin, Tianjin 300072, Peoples R China.
   [Chang, Qi] Tianjin Univ, Sch Chem Engn, Tianjin 300072, Peoples R China.
   [Li, Chengxiang] Dalian Natl Lab Clean Energy, Dalian 116023, Peoples R China.
RP Ge, W; Wang, JW (reprint author), Chinese Acad Sci, Inst Proc Engn, State Key Lab Multiphase Complex Syst, Beijing 100190, Peoples R China.; Ge, W; Wang, JW (reprint author), Univ Chinese Acad Sci, Sch Chem Engn, Beijing 100039, Peoples R China.; Ge, W (reprint author), Collaborat Innovat Ctr Chem Sci & Engn Tianjin, Tianjin 300072, Peoples R China.
EM wge@ipe.ac.cn; jwwang@ipe.ac.cn
RI Wang, Junwu/P-5040-2019; Wang, Junwu/C-6591-2009
OI Wang, Junwu/0000-0003-3988-1477; Wang, Junwu/0000-0003-3988-1477
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [91834303, 21821005]; Transformational Technologies
   for Clean Energy and Demonstration; Strategic Priority Research Program
   of the Chinese Academy of SciencesChinese Academy of Sciences
   [XDA21030700, XXH13506301]; Science Challenge Project [TZ2016001]; Key
   Research Program of Frontier Science, Chinese Academy of Sciences (CAS)
   [QYZDJ-SSW-JSC029]
FX This work was financially supported by the National Natural Science
   Foundation of China (grant no. 91834303 and 21821005), the
   "Transformational Technologies for Clean Energy and Demonstration", the
   Strategic Priority Research Program of the Chinese Academy of Sciences
   (grant no. XDA21030700 and XXH13506301), Science Challenge Project
   (grant no. TZ2016001), Key Research Program of Frontier Science, Chinese
   Academy of Sciences (CAS) (grant no. QYZDJ-SSW-JSC029). We thank Dr.
   Fanyong Meng, Dr. Limin Wang, Dr. Feiguo Chen, Dr. Wenlai Huang, Dr.
   Ying Ren, Mr. Shiwen Liu, and Ms. Xiaowen Liu for valuable discussions
   and providing some cited literature.
CR Abdulle A, 2012, ACTA NUMER, V21, P1, DOI 10.1017/S0962492912000025
   Agrawal K, 2001, J FLUID MECH, V445, P151, DOI 10.1017/S0022112001005663
   Agrawal K, 2013, CHEM ENG SCI, V95, P291, DOI 10.1016/j.ces.2013.03.017
   Ahmad S, 2010, INT COMMUN HEAT MASS, V37, P987, DOI 10.1016/j.icheatmasstransfer.2010.06.004
   Akkaya VR, 2015, MATH PROBL ENG, DOI 10.1155/2015/842837
   Alder B. J., 1956, MOL DYNAMICS ELECT C
   ALDER BJ, 1957, J CHEM PHYS, V27, P1208, DOI 10.1063/1.1743957
   Amirjalayer S, 2012, J PHYS CHEM C, V116, P4921, DOI 10.1021/jp211280m
   An XD, 2007, CHINA PART, V5, P305, DOI 10.1016/j.cpart.2007.07.001
   ANDERSON K, 1995, J FLUID MECH, V303, P327, DOI 10.1017/S0022112095004290
   ANDERSON TB, 1968, IND ENG CHEM FUND, V7, P12, DOI 10.1021/i160025a003
   ANDERSON TB, 1969, IND ENG CHEM FUND, V8, P137, DOI 10.1021/i160029a022
   ANDERSON TB, 1967, IND ENG CHEM FUND, V6, P527, DOI 10.1021/i160024a007
   Andrade JE, 2012, COMPUT METHOD APPL M, V241, P262, DOI 10.1016/j.cma.2012.06.012
   Andrews MJ, 1996, INT J MULTIPHAS FLOW, V22, P379, DOI 10.1016/0301-9322(95)00072-0
   Aranovich GL, 2007, MOL PHYS, V105, P1085, DOI 10.1080/00268970701348758
   Aranovich GL, 2009, PHYSICA A, V388, P3355, DOI 10.1016/j.physa.2009.05.012
   Aranovich GL, 2009, LANGMUIR, V25, P3577, DOI 10.1021/la803703h
   Aranovich GL, 2015, AICHE J, V61, P3138, DOI 10.1002/aic.14926
   Babich IV, 2003, FUEL, V82, P607, DOI 10.1016/S0016-2361(02)00324-1
   Balachandar S, 2010, ANNU REV FLUID MECH, V42, P111, DOI 10.1146/annurev.fluid.010908.165243
   BANHOLZER WF, 1987, IND ENG CHEM RES, V26, P763, DOI 10.1021/ie00064a025
   Bates SP, 1998, ADV CATAL, V42, P1, DOI 10.1016/S0360-0564(08)60627-6
   Beetstra R, 2007, AICHE J, V53, P489, DOI 10.1002/aic.11065
   Benyahia S, 2012, AICHE J, V58, P3589, DOI 10.1002/aic.13826
   Benyahia S, 2010, IND ENG CHEM RES, V49, P10588, DOI 10.1021/ie100662z
   BERGER MJ, 1989, J COMPUT PHYS, V82, P64, DOI 10.1016/0021-9991(89)90035-1
   Bergmann J, 2010, INT CONF SMART GRID, P131, DOI 10.1109/SMARTGRID.2010.5622032
   Bertei A, 2015, J POWER SOURCES, V279, P133, DOI 10.1016/j.jpowsour.2015.01.007
   Bieberle A, 2017, FLOW MEAS INSTRUM, V53, P180, DOI 10.1016/j.flowmeasinst.2016.04.004
   Bieberle M, 2016, CHEM ENG J, V285, P218, DOI 10.1016/j.cej.2015.10.003
   Bieberle M, 2012, CHEM ENG J, V189, P356, DOI 10.1016/j.cej.2012.02.028
   BIRD GA, 1963, PHYS FLUIDS, V6, P1518, DOI 10.1063/1.1710976
   BISWAS J, 1990, APPL CATAL, V63, P197, DOI 10.1016/S0166-9834(00)81716-9
   Blunt MJ, 2013, ADV WATER RESOUR, V51, P197, DOI 10.1016/j.advwatres.2012.03.003
   Blunt MJ, 2001, CURR OPIN COLLOID IN, V6, P197, DOI 10.1016/S1359-0294(01)00084-X
   Bogner S, 2015, INT J MULTIPHAS FLOW, V68, P71, DOI 10.1016/j.ijmultiphaseflow.2014.10.001
   Boujelben A, 2018, J PETROL SCI ENG, V165, P462, DOI 10.1016/j.petrol.2018.02.040
   Boulougouris GC, 1998, J PHYS CHEM B, V102, P1029, DOI 10.1021/jp972582l
   Brenner DW, 2000, PHYS STATUS SOLIDI B, V217, P23, DOI 10.1002/(SICI)1521-3951(200001)217:1<23::AID-PSSB23>3.0.CO;2-N
   BRENNER DW, 1990, PHYS REV B, V42, P9458, DOI 10.1103/PhysRevB.42.9458
   Brenner DW, 2002, J PHYS-CONDENS MAT, V14, P783, DOI 10.1088/0953-8984/14/4/312
   Brilliantov N V, 2010, KINETIC THEORY GRANU
   Budroni MA, 2017, CHAOS, V27, DOI 10.1063/1.4990740
   Buist KA, 2017, AICHE J, V63, P5335, DOI 10.1002/aic.15854
   Buist KA, 2014, AICHE J, V60, P3133, DOI 10.1002/aic.14512
   Busciglio A, 2008, CHEM ENG J, V140, P398, DOI 10.1016/j.cej.2007.11.015
   Cahyadi A, 2017, CHEM ENG SCI, V158, P70, DOI 10.1016/j.ces.2016.10.002
   CALLAGHAN PT, 1991, PRINCIPLES NUCL MAGN
   CAMPBELL CS, 1990, ANNU REV FLUID MECH, V22, P57, DOI 10.1146/annurev.fl.22.010190.000421
   Canelas RB, 2016, COMPUT PHYS COMMUN, V202, P131, DOI 10.1016/j.cpc.2016.01.006
   Capecelatro J, 2015, J FLUID MECH, V780, P578, DOI 10.1017/jfm.2015.459
   Capecelatro J, 2014, CHEM ENG J, V245, P295, DOI 10.1016/j.cej.2014.02.040
   Capecelatro J, 2013, J COMPUT PHYS, V238, P1, DOI 10.1016/j.jcp.2012.12.015
   CAR R, 1985, PHYS REV LETT, V55, P2471, DOI 10.1103/PhysRevLett.55.2471
   Charpentier JC, 2009, COMPUT CHEM ENG, V33, P936, DOI 10.1016/j.compchemeng.2008.11.007
   Chen B, 2001, J PHYS CHEM B, V105, P3093, DOI 10.1021/jp003882x
   Chen J., 2019, SELF CONSISTENT RESO
   Chen XZ, 2018, CHEM ENG SCI, V192, P864, DOI 10.1016/j.ces.2018.08.019
   [陈锡忠 Chen Xizhong], 2017, [中国粉体技术, China Powder Science and Technology], V23, P62
   Chen XZ, 2017, AICHE J, V63, P3681, DOI 10.1002/aic.15723
   Chen XZ, 2016, POWDER TECHNOL, V304, P177, DOI 10.1016/j.powtec.2016.08.017
   Chen XZ, 2015, PROCEDIA ENGINEER, V102, P661, DOI 10.1016/j.proeng.2015.01.160
   Chen XZ, 2014, POWDER TECHNOL, V254, P94, DOI 10.1016/j.powtec.2013.12.056
   CHEN YM, 1991, CHEM ENG SCI, V46, P2253, DOI 10.1016/0009-2509(91)85124-G
   Chenoweth K, 2008, J PHYS CHEM A, V112, P1040, DOI 10.1021/jp709896w
   Clift R., 1985, CONTINUOUS BUBBLING, P73
   Cloete JH, 2018, CHEM ENG SCI, V192, P906, DOI 10.1016/j.ces.2018.06.040
   Cocco R, 2010, POWDER TECHNOL, V203, P3, DOI 10.1016/j.powtec.2010.03.023
   Cocco RA, 2017, AICHE J, V63, P5361, DOI 10.1002/aic.15892
   Cohen Y, 2005, ANGEW CHEM INT EDIT, V44, P520, DOI 10.1002/anie.200300637
   Crowe C., 1998, MULTIPHASE FLOWS DRO
   CUNDALL PA, 1979, GEOTECHNIQUE, V29, P47, DOI 10.1680/geot.1979.29.1.47
   CURTISS CF, 1956, J CHEM PHYS, V24, P225, DOI 10.1063/1.1742459
   d'Humieres D, 2002, PHILOS T ROY SOC A, V360, P437, DOI 10.1098/rsta.2001.0955
   da Luz C, 2018, CHEM ENG SCI, V184, P285, DOI 10.1016/j.ces.2018.02.047
   da Silva JC, 2015, CHEMCATCHEM, V7, P413, DOI 10.1002/cctc.201402925
   Das S, 2018, CHEM ENG SCI, V191, P1, DOI 10.1016/j.ces.2018.04.061
   Davidson J. F., 1963, FLUIDIZED PARTICLES, P155
   de Martin L, 2014, CHEM ENG SCI, V112, P79, DOI 10.1016/j.ces.2014.03.024
   Deen NG, 2007, CHEM ENG SCI, V62, P28, DOI 10.1016/j.ces.2006.08.014
   Deen NG, 2002, CHEM ENG TECHNOL, V25, P97, DOI 10.1002/1521-4125(200201)25:1<97::AID-CEAT97>3.0.CO;2-7
   Deen NG, 2014, CHEM ENG SCI, V116, P710, DOI 10.1016/j.ces.2014.05.039
   Deng LJ, 2013, CHEM ENG SCI, V99, P89, DOI 10.1016/j.ces.2013.05.047
   DERJAGUIN BV, 1975, J COLLOID INTERF SCI, V53, P314, DOI 10.1016/0021-9797(75)90018-1
   Derksen JJ, 2007, J FLUID MECH, V587, P303, DOI 10.1017/S0022112007007094
   Desjardins O, 2008, J COMPUT PHYS, V227, P2514, DOI 10.1016/j.jcp.2007.10.026
   DING J, 1990, AICHE J, V36, P523, DOI 10.1002/aic.690360404
   Dobrohotoff PB, 2012, GRANUL MATTER, V14, P651, DOI 10.1007/s10035-012-0357-9
   DONEA J, 1982, COMPUT METHOD APPL M, V33, P689, DOI 10.1016/0045-7825(82)90128-1
   Dong WG, 2008, CHEM ENG SCI, V63, P2798, DOI 10.1016/j.ces.2008.01.038
   Dong WG, 2008, CHEM ENG SCI, V63, P2811, DOI 10.1016/j.ces.2008.01.039
   Du MJ, 2018, CHEM ENG J, V342, P386, DOI 10.1016/j.cej.2018.02.065
   Dubbeldam D, 2007, ANGEW CHEM INT EDIT, V46, P4496, DOI 10.1002/anie.200700218
   Dubrawski K, 2013, POWDER TECHNOL, V235, P203, DOI 10.1016/j.powtec.2012.10.031
   Dudukovic M. P., 1997, NONINVASIVE MONITORI
   Dudukovic MP, 2009, SCIENCE, V325, P698, DOI 10.1126/science.1174274
   Duru P, 2002, J FLUID MECH, V470, P359, DOI 10.1017/S0022112002002100
   Duru P, 2002, J FLUID MECH, V452, P371, DOI 10.1017/S0022112001007017
   Esteghamatian A, 2017, INT J MULTIPHAS FLOW, V92, P93, DOI 10.1016/j.ijmultiphaseflow.2017.03.002
   Fadlun EA, 2000, J COMPUT PHYS, V161, P35, DOI 10.1006/jcph.2000.6484
   Fan JH, 2004, CHEM ENG SCI, V59, P1863, DOI 10.1016/j.ces.2004.01.039
   Fang HJ, 2014, J MATER CHEM A, V2, P274, DOI 10.1039/c3ta13073h
   FANUCCI JB, 1981, PHYS FLUIDS, V24, P1944, DOI 10.1063/1.863291
   FANUCCI JB, 1979, J FLUID MECH, V94, P353, DOI 10.1017/S0022112079001063
   FATT I, 1956, T AM I MIN MET ENG, V207, P144
   Feng C, 2014, J ROCK MECH GEOTECH, V6, P26, DOI 10.1016/j.jrmge.2013.12.001
   Feng H., 2016, EFFECTS CLUSTERS FLU
   Ferellec JF, 2008, GEOMECH GEOENGIN, V3, P211, DOI 10.1080/17486020802253992
   Fischer F, 2008, MEAS SCI TECHNOL, V19, DOI 10.1088/0957-0233/19/9/094002
   Flekkoy EG, 1999, PHYS REV LETT, V83, P1775, DOI 10.1103/PhysRevLett.83.1775
   Fogler H. S., 2005, ELEMENTS CHEM REACTI
   FORTES AF, 1987, J FLUID MECH, V177, P467, DOI 10.1017/S0022112087001046
   Fox RO, 2008, J COMPUT PHYS, V227, P6313, DOI 10.1016/j.jcp.2008.03.014
   Fox RO, 2012, ANNU REV FLUID MECH, V44, P47, DOI 10.1146/annurev-fluid-120710-101118
   Freeman CM, 2011, TRANSPORT POROUS MED, V90, P253, DOI 10.1007/s11242-011-9761-6
   FRISCH U, 1986, PHYS REV LETT, V56, P1505, DOI 10.1103/PhysRevLett.56.1505
   Frust T, 2017, COMPUT PHYS COMMUN, V219, P353, DOI 10.1016/j.cpc.2017.05.025
   Fullmer WD, 2018, POWDER TECHNOL, V339, P760, DOI [10.1016/j.powtec.2018.08.044, 10.1016/J.powtec.2018.08.044]
   Fullmer WD, 2018, CHEM ENG SCI, V186, P84, DOI 10.1016/j.ces.2018.04.035
   Fullmer WD, 2017, J FLUID MECH, V823, P433, DOI 10.1017/jfm.2017.295
   Fullmer WD, 2017, ANNU REV FLUID MECH, V49, P485, DOI 10.1146/annurev-fluid-010816-060028
   Galindo-Torres SA, 2010, PHYS REV E, V82, DOI 10.1103/PhysRevE.82.056713
   Gao H, 2015, J PETROL SCI ENG, V133, P258, DOI 10.1016/j.petrol.2015.06.017
   Gao X, 2018, AICHE J, V64, P3565, DOI 10.1002/aic.16341
   Gao X, 2018, CHEM ENG SCI, V184, P33, DOI 10.1016/j.ces.2018.03.038
   Garz Oacute V., 2015, J NONLINEAR SCI NONE, V81, P497
   Ge W, 2003, CHEM ENG SCI, V58, P1565, DOI 10.1016/S0009-2509(02)00673-5
   Ge W, 2002, CHEM ENG SCI, V57, P3993, DOI 10.1016/S0009-2509(02)00234-8
   Ge W, 2001, CHINESE SCI BULL, V46, P1503, DOI 10.1007/BF02900568
   Ge W., 2008, P 9 INT C CIRC FLUID, P19
   Ge W., 1996, P 5 INT C CIRC FLUID, P260
   Ge W., 1998, THESIS
   Ge W, 2007, CHEM ENG SCI, V62, P3346, DOI 10.1016/j.ces.2007.02.049
   Ge W, 2017, REV CHEM ENG, V33, P551, DOI 10.1515/revce-2015-0079
   Ge W, 2015, CHEM ENG TECHNOL, V38, P575, DOI 10.1002/ceat.201400746
   Ge W, 2011, CHEM ENG SCI, V66, P4426, DOI 10.1016/j.ces.2011.05.029
   GELDART D, 1973, POWDER TECHNOL, V7, P285, DOI 10.1016/0032-5910(73)80037-3
   Geldart D, 1986, GAS FLUIDIZATION TEC
   Gidaspow D., 1994, MULTIPHASE FLOW FLUI
   Giesche H, 2006, PART PART SYST CHAR, V23, P9, DOI 10.1002/ppsc.200601009
   Gimelshein S, 2017, PHYS FLUIDS, V29, DOI 10.1063/1.4986529
   GINGOLD RA, 1977, MON NOT R ASTRON SOC, V181, P375, DOI 10.1093/mnras/181.3.375
   Ginn BT, 2004, J PHYS CHEM A, V108, P1325, DOI 10.1021/jp0358883
   Gladden LF, 2017, ANNU REV CHEM BIOMOL, V8, P227, DOI 10.1146/annurev-chembioeng-061114-123222
   GLANSDORFF P, 1971, THERMODYNAMICS STRUC
   Glasser BJ, 1998, PHYS REV LETT, V81, P1849, DOI 10.1103/PhysRevLett.81.1849
   Glasser BJ, 1997, J FLUID MECH, V334, P157, DOI 10.1017/S0022112096004351
   Glasser BJ, 1996, J FLUID MECH, V306, P183, DOI 10.1017/S0022112096001280
   Goldhirsch I, 2003, ANNU REV FLUID MECH, V35, P267, DOI 10.1146/annurev.fluid.35.101101.161114
   Goldhirsch I., 1993, Journal of Scientific Computing, V8, P1, DOI 10.1007/BF01060830
   GOLDHIRSCH I, 1993, PHYS REV LETT, V70, P1619, DOI 10.1103/PhysRevLett.70.1619
   Goldhirsch I., 1991, P JOINT DOE NSF WORK, P22
   Gonzalez R. G., 2016, J PHYS A, V50
   Gregg S.J., 1982, ADSORPTION SURFACE A
   Groot RD, 2003, J CHEM PHYS, V118, P11265, DOI 10.1063/1.1574800
   Groot RD, 1997, J CHEM PHYS, V107, P4423, DOI 10.1063/1.474784
   Guazzelli E, 2011, ANNU REV FLUID MECH, V43, P97, DOI 10.1146/annurev-fluid-122109-160736
   Guo Y, 2015, ANNU REV FLUID MECH, V47, P21, DOI 10.1146/annurev-fluid-010814-014644
   Han MZ, 2016, BIOPHYS CHEM, V209, P9, DOI 10.1016/j.bpc.2015.11.002
   Hancock BC, 2010, INT J PHARMACEUT, V384, P39, DOI 10.1016/j.ijpharm.2009.09.038
   Hansen N, 2010, CHEM ENG SCI, V65, P2472, DOI 10.1016/j.ces.2009.12.028
   Hansen N, 2009, J PHYS CHEM C, V113, P235, DOI 10.1021/jp8073046
   Hansen N, 2012, SOFT MATER, V10, P179, DOI 10.1080/1539445X.2011.599708
   Harris AT, 2002, POWDER TECHNOL, V127, P128, DOI 10.1016/S0032-5910(02)00114-6
   HARRIS JG, 1995, J PHYS CHEM-US, V99, P12021, DOI 10.1021/j100031a034
   Harris KM, 2006, J NEUROSCI, V26, P12101, DOI 10.1523/JNEUROSCI.3994-06.2006
   HASHIN Z, 1983, J APPL MECH-T ASME, V50, P481, DOI 10.1115/1.3167081
   HAZLETT RD, 1995, TRANSPORT POROUS MED, V20, P21, DOI 10.1007/BF00616924
   He L, 2017, INT J HEAT MASS TRAN, V114, P324, DOI 10.1016/j.ijheatmasstransfer.2017.06.068
   Heidebrecht P, 2011, CHEM ENG SCI, V66, P4389, DOI 10.1016/j.ces.2011.03.052
   Hernandez-Jimenez F, 2015, CHEM ENG SCI, V134, P57, DOI 10.1016/j.ces.2015.04.028
   Herrmann HJ, 1998, CONTINUUM MECH THERM, V10, P189, DOI 10.1007/s001610050089
   HETSRONI G, 1989, INT J MULTIPHAS FLOW, V15, P735, DOI 10.1016/0301-9322(89)90037-2
   HILL JR, 1995, J PHYS CHEM-US, V99, P9536, DOI 10.1021/j100023a036
   Hill RJ, 2001, J FLUID MECH, V448, P213, DOI 10.1017/S0022112001005948
   Holden D, 2012, J PHYS CHEM C, V116, P16639, DOI 10.1021/jp305129w
   Holland DJ, 2008, POWDER TECHNOL, V182, P171, DOI 10.1016/j.powtec.2007.06.030
   Holloway W, 2012, J FLUID MECH, V713, P27, DOI 10.1017/jfm.2012.425
   Holloway W, 2012, CHEM ENG SCI, V82, P132, DOI 10.1016/j.ces.2012.07.019
   Holloway W, 2010, AICHE J, V56, P1995, DOI 10.1002/aic.12127
   Hong K, 2016, POWDER TECHNOL, V296, P2, DOI 10.1016/j.powtec.2015.07.003
   Hong K, 2012, CHEM ENG SCI, V75, P376, DOI 10.1016/j.ces.2012.03.022
   HOOGERBRUGGE PJ, 1992, EUROPHYS LETT, V19, P155, DOI 10.1209/0295-5075/19/3/001
   Hoomans BPB, 1996, CHEM ENG SCI, V51, P99, DOI 10.1016/0009-2509(95)00271-5
   Hopkins MA, 2004, ENG COMPUTATION, V21, P422, DOI 10.1108/02644400410519866
   HOPKINS MA, 1991, PHYS FLUIDS A-FLUID, V3, P47, DOI 10.1063/1.857863
   HORIO M, 1994, CHEM ENG SCI, V49, P2413, DOI 10.1016/0009-2509(94)E0071-W
   Hou BL, 2010, CHEM ENG J, V163, P108, DOI 10.1016/j.cej.2010.07.028
   Hu HH, 1996, INT J MULTIPHAS FLOW, V22, P335, DOI 10.1016/0301-9322(95)00068-2
   Hu ZQ, 2012, J CHEM PHYS, V136, DOI 10.1063/1.4729314
   Huang WL, 2016, CHEM ENG SCI, V147, P83, DOI 10.1016/j.ces.2016.03.019
   Huang ZQ, 2017, POWDER TECHNOL, V321, P435, DOI 10.1016/j.powtec.2017.08.035
   Iddir H, 2005, AICHE J, V51, P1620, DOI 10.1002/aic.10429
   Igci Y, 2008, AICHE J, V54, P1431, DOI 10.1002/aic.11481
   Igci Y, 2011, IND ENG CHEM RES, V50, P13190, DOI 10.1021/ie200190q
   Ischenko AA, 2017, CHEM REV, V117, P11066, DOI 10.1021/acs.chemrev.6b00770
   Jackson R., 1977, TRANSPORT POROUS CAT
   Jackson R., 1963, T I CHEM ENG-LOND, V41, P13
   Jambunathan R, 2017, COMPUT FLUIDS, V149, P70, DOI 10.1016/j.compfluid.2017.02.020
   James JP, 2012, INT J HYDROGEN ENERG, V37, P18216, DOI 10.1016/j.ijhydene.2012.08.077
   Jeon JD, 2008, J MEMBRANE SCI, V309, P233, DOI 10.1016/j.memsci.2007.10.034
   Jia X, 2001, POWDER TECHNOL, V120, P175, DOI 10.1016/S0032-5910(01)00268-6
   Jiang Y., 2018, EMMS BASED SOL UNPUB
   Jiang Y., 2018, NETL WORKSH MULT FLO
   Jie OY, 1999, CHEM ENG SCI, V54, P5427
   Jobic H, 2015, J PHYS CHEM C, V119, P16115, DOI 10.1021/acs.jpcc.5b04259
   JOBIC H, 1994, J PHYS CHEM-US, V98, P4660, DOI 10.1021/j100068a029
   Joekar-Niasar V, 2012, CRIT REV ENV SCI TEC, V42, P1895, DOI 10.1080/10643389.2011.574101
   JOHNSON KL, 1971, PROC R SOC LON SER-A, V324, P301, DOI 10.1098/rspa.1971.0141
   Joshi JB, 2015, ANNU REV CHEM BIOMOL, V6, P347, DOI 10.1146/annurev-chembioeng-061114-123229
   Jun EJ, 2018, COMPUT FLUIDS, V166, P123, DOI 10.1016/j.compfluid.2018.02.005
   Jung J, 2005, IND ENG CHEM RES, V44, P1329, DOI 10.1021/ie0496838
   Kagermann D., 2013, SECURING FUTURE GERM
   Kalz KF, 2017, CHEMCATCHEM, V9, P17, DOI 10.1002/cctc.201600996
   Karakaya C, 2016, CHEM ENG SCI, V145, P299, DOI 10.1016/j.ces.2016.02.004
   Karge HG, 1996, APPL CATAL A-GEN, V146, P339, DOI 10.1016/S0926-860X(96)00175-5
   Karger J., 2012, DIFFUSION NANOPOROUS
   Karimipour S, 2011, POWDER TECHNOL, V205, P1, DOI 10.1016/j.powtec.2010.09.016
   Karniadakis G, 2006, MICROFLOWS NANOFLOWS
   Katayanagi Y, 2015, J POWER SOURCES, V280, P210, DOI 10.1016/j.jpowsour.2015.01.085
   KAZARI M, 1995, P 2 INT C MULT FLOW
   Keil FJ, 2012, TOP CURR CHEM, V307, P69, DOI 10.1007/128_2011_128
   Keil FJ, 1999, CATAL TODAY, V53, P245, DOI 10.1016/S0920-5861(99)00119-4
   Keil FJ, 2013, COMPUT MATH APPL, V65, P1674, DOI 10.1016/j.camwa.2012.11.023
   Ketcham RA, 2001, COMPUT GEOSCI-UK, V27, P381, DOI 10.1016/S0098-3004(00)00116-3
   Kikkinides ES, 2014, ADSORPTION, V20, P21, DOI 10.1007/s10450-013-9545-0
   Kim H, 2002, POWDER TECHNOL, V122, P83, DOI 10.1016/S0032-5910(01)00395-3
   Knowlton TM, 2005, POWDER TECHNOL, V150, P72, DOI 10.1016/j.powtec.2004.11.036
   Koch DL, 1999, J FLUID MECH, V400, P229, DOI 10.1017/S0022112099006485
   Koci P, 2006, CHEM ENG SCI, V61, P3240, DOI 10.1016/j.ces.2005.12.008
   Koci P, 2010, CHEM ENG SCI, V65, P412, DOI 10.1016/j.ces.2009.06.068
   KOELMAN JMVA, 1993, EUROPHYS LETT, V21, P363, DOI 10.1209/0295-5075/21/3/018
   Kong W, 2012, J POWER SOURCES, V206, P171, DOI 10.1016/j.jpowsour.2012.01.107
   Koornneef J, 2007, PROG ENERG COMBUST, V33, P19, DOI 10.1016/j.pecs.2006.07.001
   Koshizuka S, 1996, NUCL SCI ENG, V123, P421, DOI 10.13182/NSE96-A24205
   Kriebitzsch SHL, 2013, AICHE J, V59, P316, DOI 10.1002/aic.13804
   Kriebitzsch SHL, 2013, CHEM ENG SCI, V91, P1, DOI 10.1016/j.ces.2012.12.038
   KRISHNA R, 1993, CHEM ENG SCI, V48, P845, DOI 10.1016/0009-2509(93)80324-J
   Krishna R, 1997, CHEM ENG SCI, V52, P861, DOI 10.1016/S0009-2509(96)00458-7
   Kruggel-Emden H, 2014, CHEM ENG TECHNOL, V37, P847, DOI 10.1002/ceat.201300649
   Kubis AJ, 2004, METALL MATER TRANS A, V35A, P1935, DOI 10.1007/s11661-004-0142-4
   KUIPERS JAM, 1992, CHEM ENG SCI, V47, P1913, DOI 10.1016/0009-2509(92)80309-Z
   Kuwagi K, 2004, INT C FLUID ENG 11 I, V160, P243
   Kwon J, 2015, INT J MULTIPHAS FLOW, V72, P155, DOI 10.1016/j.ijmultiphaseflow.2015.02.004
   LADD AJC, 1994, J FLUID MECH, V271, P311, DOI 10.1017/S0022112094001783
   LADD AJC, 1994, J FLUID MECH, V271, P285, DOI 10.1017/S0022112094001771
   Lamari FD, 1998, J CHEM PHYS, V109, P4981, DOI 10.1063/1.477109
   Lane WA, 2016, CHEM ENG SCI, V151, P7, DOI 10.1016/j.ces.2016.05.005
   Launder B. E., 1974, Computer Methods in Applied Mechanics and Engineering, V3, P269, DOI 10.1016/0045-7825(74)90029-2
   Lemmens H., 2010, SPE RUSS OIL GAS C E
   Leon CALY, 1998, ADV COLLOID INTERFAC, V76, P341, DOI 10.1016/S0001-8686(98)00052-9
   LEONARD A, 1980, J COMPUT PHYS, V37, P289, DOI 10.1016/0021-9991(80)90040-6
   Leszczynski JS, 2002, POWDER TECHNOL, V128, P22, DOI 10.1016/S0032-5910(02)00150-X
   Li H, 2016, CHEM ENG SCI, V147, P1, DOI 10.1016/j.ces.2016.03.004
   LI HZ, 1991, POWDER TECHNOL, V66, P231, DOI 10.1016/0032-5910(91)80035-H
   Li J, 2005, CHEM ENG RES DES, V83, P574, DOI 10.1205/cherd.05093
   Li J, 2005, CHEM ENG SCI, V60, P1251, DOI 10.1016/j.ces.2004.09.083
   Li J, 2003, CHEM ENG SCI, V58, P711, DOI 10.1016/S0009-2509(02)00599-7
   Li J., 1988, MULTISCALE MODELING
   Li J., 1998, THESIS
   Li J., 1994, PARTICLE FLUID 2 PHA
   Li J., 1987, THESIS
   Li J., 2013, MULTISCALE MODELING
   Li JH, 1999, CHEM ENG SCI, V54, P1151, DOI 10.1016/S0009-2509(98)00409-6
   Li JH, 2000, POWDER TECHNOL, V111, P50, DOI 10.1016/S0032-5910(00)00238-2
   Li JH, 1998, CHEM ENG SCI, V53, P3367, DOI 10.1016/S0009-2509(98)00130-4
   Li JH, 2004, CHEM ENG SCI, V59, P1687, DOI 10.1016/j.ces.2004.01.025
   Li JH, 2003, CHEM ENG SCI, V58, P521, DOI 10.1016/S0009-2509(02)00577-8
   Li JH, 1996, CHEM ENG SCI, V51, P667
   Li JH, 2018, ANNU REV CHEM BIOMOL, V9, P41, DOI 10.1146/annurev-chembioeng-060817-084249
   Li JH, 2017, NATL SCI REV, V4, P787, DOI 10.1093/nsr/nwx124
   Li JH, 2018, CHEM ENG J, V333, P327, DOI 10.1016/j.cej.2017.09.162
   Li JH, 2016, CURR OPIN CHEM ENG, V13, P10, DOI 10.1016/j.coche.2016.07.008
   Li JH, 2015, CHEM ENG J, V278, P541, DOI 10.1016/j.cej.2014.10.005
   Li N, 2014, PHYS CHEM CHEM PHYS, V16, P10965, DOI 10.1039/c4cp00957f
   Li SH, 2005, SCI CHINA SER E, V48, P1, DOI 10.1360/04zze1
   Li SH, 2004, INT J ROCK MECH MIN, V41, P436, DOI 10.1016/j.ijrmms.2003.12.076
   Li TW, 2017, AICHE J, V63, P1203, DOI 10.1002/aic.15507
   Li XX, 2015, MOL SIMULAT, V41, P13, DOI 10.1080/08927022.2014.913789
   Li YP, 2017, LANGMUIR, V33, P11804, DOI 10.1021/acs.langmuir.7b02559
   Li YP, 2017, CHEM ENG J, V320, P458, DOI 10.1016/j.cej.2017.03.055
   Li Y, 2014, CHEM SOC REV, V43, P1543, DOI 10.1039/c3cs60296f
   LIAN GP, 1993, J COLLOID INTERF SCI, V161, P138, DOI 10.1006/jcis.1993.1452
   Liang J, 2017, ADV MATER, V29, DOI 10.1002/adma.201701139
   LIBERSKY LD, 1993, J COMPUT PHYS, V109, P67, DOI 10.1006/jcph.1993.1199
   LILLY DK, 1992, PHYS FLUIDS A-FLUID, V4, P633, DOI 10.1063/1.858280
   Lim KW, 2014, INT J NUMER ANAL MET, V38, P167, DOI 10.1002/nag.2203
   Lisal M, 2016, PHYS CHEM CHEM PHYS, V18, P16127, DOI 10.1039/c6cp00341a
   Liss ED, 2001, POWDER TECHNOL, V116, P116, DOI 10.1016/S0032-5910(00)00392-2
   Liu CF, 2015, CHEM ENG SCI, V122, P114, DOI 10.1016/j.ces.2014.09.002
   Liu H, 2016, J COMPUT CHEM, V37, P2634, DOI 10.1002/jcc.24495
   Liu J, 2014, J MOL GRAPH MODEL, V53, P13, DOI 10.1016/j.jmgm.2014.07.002
   Liu XW, 2017, AICHE J, V63, P3, DOI 10.1002/aic.15489
   Lowell S., 1991, POWDER SURFACE AREA
   Lu BN, 2013, AICHE J, V59, P1108, DOI 10.1002/aic.13917
   Lu BN, 2009, CHEM ENG SCI, V64, P3437, DOI 10.1016/j.ces.2009.04.024
   Lu G, 2015, CHEM ENG SCI, V127, P425, DOI 10.1016/j.ces.2014.11.050
   Lu LQ, 2016, CHEM ENG SCI, V155, P314, DOI 10.1016/j.ces.2016.08.013
   Lu LQ, 2016, IND ENG CHEM RES, V55, P10477, DOI 10.1021/acs.iecr.6b02688
   Lu LQ, 2014, CHEM ENG SCI, V120, P67, DOI 10.1016/j.ces.2014.08.004
   LUBACHEVSKY BD, 1991, J COMPUT PHYS, V94, P255, DOI 10.1016/0021-9991(91)90222-7
   LUCY LB, 1977, ASTRON J, V82, P1013, DOI 10.1086/112164
   LUN CKK, 1984, J FLUID MECH, V140, P223, DOI 10.1017/S0022112084000586
   Luo K, 2016, AICHE J, V62, P1917, DOI 10.1002/aic.15186
   Ma JS, 2006, CHEM ENG SCI, V61, P7096, DOI 10.1016/j.ces.2006.07.042
   Ma JS, 2009, CHEM ENG SCI, V64, P43, DOI 10.1016/j.ces.2008.09.005
   Ma SY, 2015, MACROMOLECULES, V48, P3112, DOI 10.1021/ma5026219
   Macia F, 2011, PROG THEOR PHYS, V125, P1091, DOI 10.1143/PTP.125.1091
   MacNeice P, 2000, COMPUT PHYS COMMUN, V126, P330, DOI 10.1016/S0010-4655(99)00501-9
   Mahdi RA, 2014, J COMPUT THEOR NANOS, V11, P1275, DOI 10.1166/jctn.2014.3494
   Mahoney MW, 2000, J CHEM PHYS, V112, P8910, DOI 10.1063/1.481505
   Malek K, 2003, J CHEM PHYS, V119, P2801, DOI 10.1063/1.1584652
   MARIN M, 1993, J COMPUT PHYS, V109, P306, DOI 10.1006/jcph.1993.1219
   Marin M, 1997, COMPUT PHYS COMMUN, V102, P81, DOI 10.1016/S0010-4655(97)00011-8
   Marks NA, 2001, PHYS REV B, V63, DOI 10.1103/PhysRevB.63.035401
   Martin MG, 1998, J PHYS CHEM B, V102, P2569, DOI 10.1021/jp972543+
   Martin MG, 1999, J PHYS CHEM B, V103, P4508, DOI 10.1021/jp984742e
   Mason E.A, 1983, GAS TRANSPORT POROUS
   Mathews JP, 2017, FUEL, V209, P10, DOI 10.1016/j.fuel.2017.07.079
   Mathiesen V, 2000, INT J MULTIPHAS FLOW, V26, P387, DOI 10.1016/S0301-9322(99)00027-0
   McMillan J, 2013, CHEM ENG SCI, V100, P39, DOI 10.1016/j.ces.2013.02.047
   MCNAMARA GR, 1988, PHYS REV LETT, V61, P2332, DOI 10.1103/PhysRevLett.61.2332
   McNaught AD, 1997, IUPAC COMPENDIUM CHE
   Mehrabadi M, 2015, J FLUID MECH, V770, P210, DOI 10.1017/jfm.2015.146
   Meng FY, 2009, POWDER TECHNOL, V194, P153, DOI 10.1016/j.powtec.2009.03.033
   Mignot Christophe, 2018, MICROSCOPY TODAY, V26, P12, DOI DOI 10.1017/S1551929518000482
   Mikami T, 1998, CHEM ENG SCI, V53, P1927, DOI 10.1016/S0009-2509(97)00325-4
   Milioli CC, 2013, AICHE J, V59, P3265, DOI 10.1002/aic.14130
   MINDLIN RD, 1953, J APPL MECH-T ASME, V20, P327
   Mitrano PP, 2014, J FLUID MECH, V738, DOI 10.1017/jfm.2013.602
   Mittal R, 2005, ANNU REV FLUID MECH, V37, P239, DOI 10.1146/annurev.fluid.37.061903.175743
   Mo Y., 2018, PARTICUOLOGY
   Mohamed KM, 2010, MICROFLUID NANOFLUID, V8, P283, DOI 10.1007/s10404-009-0529-z
   Mohd-Yusof J., 1997, COMBINED IMMERSED BO
   MOIN P, 1991, PHYS FLUIDS A-FLUID, V3, P2746, DOI 10.1063/1.858164
   Mokhtar MA, 2012, AICHE J, V58, P87, DOI 10.1002/aic.12568
   MONAGHAN JJ, 1995, COMPUT PHYS COMMUN, V87, P225, DOI 10.1016/0010-4655(94)00174-Z
   Moran JC, 2003, CHEM ENG SCI, V58, P1879, DOI 10.1016/S0009-2509(02)00684-X
   MORI S, 1975, AICHE J, V21, P109, DOI 10.1002/aic.690210114
   Morris JP, 1997, J COMPUT PHYS, V136, P214, DOI 10.1006/jcph.1997.5776
   Muller CR, 2007, IND ENG CHEM RES, V46, P1642, DOI 10.1021/ie0611397
   Muller-Plathe F, 2002, CHEMPHYSCHEM, V3, P754, DOI 10.1002/1439-7641(20020916)3:9<754::AID-CPHC754>3.0.CO;2-U
   Nagendra K, 2014, J COMPUT PHYS, V267, P225, DOI 10.1016/j.jcp.2014.02.045
   Newsome D, 2015, CHEM ENG SCI, V121, P300, DOI 10.1016/j.ces.2014.09.024
   Nguyen NQ, 2002, PHYS REV E, V66, DOI 10.1103/PhysRevE.66.046708
   NICHOLAS JB, 1991, J AM CHEM SOC, V113, P4792, DOI 10.1021/ja00013a012
   Nicolis G., 1977, SELF ORG NONEQUILIBR
   NICOLIS G, 1989, EXPLORING COMPLEXITY
   Ning Z, 1997, ADV POWDER TECHNOL, V8, P15, DOI 10.1016/S0921-8831(08)60477-X
   Noymer PD, 1998, CHEM ENG SCI, V53, P2859, DOI 10.1016/S0009-2509(98)00117-1
   O'Brien T.J., 1993, CIRCUL FLUID BED TEC, VIV, P367
   OConnell ST, 1995, PHYS REV E, V52, pR5792, DOI 10.1103/PhysRevE.52.R5792
   Ofori JY, 1996, IND ENG CHEM RES, V35, P1275, DOI 10.1021/ie9503252
   Oka S., 2003, FLUIDIZED BED COMBUS
   Okumura M, 2017, J ELECTROCHEM SOC, V164, pF928, DOI 10.1149/2.0581709jes
   Ory E., 2000, P ASME FED SUMM M NE
   Ouyang J, 1999, CHEM ENG SCI, V54, P2077, DOI 10.1016/S0009-2509(98)00413-8
   Ozel A, 2013, INT J MULTIPHAS FLOW, V55, P43, DOI 10.1016/j.ijmultiphaseflow.2013.04.002
   Pages G, 2017, ANALYST, V142, P3771, DOI 10.1039/c7an01031a
   Paquet E, 2015, BIOMED RES INT, DOI 10.1155/2015/183918
   PARKER DJ, 1993, NUCL INSTRUM METH A, V326, P592, DOI 10.1016/0168-9002(93)90864-E
   Parmentier JF, 2012, AICHE J, V58, P1084, DOI 10.1002/aic.12647
   Patankar NA, 2000, INT J MULTIPHAS FLOW, V26, P1509, DOI 10.1016/S0301-9322(99)00100-7
   Patil AV, 2015, CHEM ENG J, V259, P90, DOI 10.1016/j.cej.2014.07.107
   Pei CL, 2015, AICHE J, V61, P1792, DOI 10.1002/aic.14768
   Penn A, 2017, SCI ADV, V3, DOI 10.1126/sciadv.1701879
   Pereira JMC, 2014, CHEM ENG SCI, V117, P364, DOI 10.1016/j.ces.2014.06.028
   PESKIN CS, 1972, J COMPUT PHYS, V10, P252, DOI 10.1016/0021-9991(72)90065-4
   Pezeshki S, 2015, MOL SIMULAT, V41, P168, DOI 10.1080/08927022.2014.911870
   Picano F, 2015, J FLUID MECH, V764, P463, DOI 10.1017/jfm.2014.704
   Pope S. B., 2000, TURBULENT FLOWS
   Potapov AV, 2001, POWDER TECHNOL, V116, P204, DOI 10.1016/S0032-5910(00)00395-8
   Potoff JJ, 2001, AICHE J, V47, P1676, DOI 10.1002/aic.690470719
   Pournin L, 2005, GRANUL MATTER, V7, P119, DOI 10.1007/s10035-004-0188-4
   Prandtl L, 1925, Z ANGEW MATH MECH, V5, P136, DOI 10.1002/zamm.19250050212
   PRIGOGINE I, 1967, INTRO THERMODYNAMICS
   Prill T, 2013, J MICROSC-OXFORD, V250, P77, DOI 10.1111/jmi.12021
   Prill T, 2013, SCANNING, V35, P189, DOI 10.1002/sca.21047
   PURETZ J, 1984, P SOC PHOTO-OPT INST, V471, P38
   QIAN YH, 1992, EUROPHYS LETT, V17, P479, DOI 10.1209/0295-5075/17/6/001
   Radl S, 2014, CHEM ENG SCI, V117, P416, DOI 10.1016/j.ces.2014.07.011
   Raimondeau S, 2002, CHEM ENG J, V90, P3, DOI 10.1016/S1385-8947(02)00065-7
   RAPAPORT DC, 1980, J COMPUT PHYS, V34, P184, DOI 10.1016/0021-9991(80)90104-7
   Reh L., 2003, CHINA PART, V1, P185
   Ren W., 2005, HETEROGENEOUS MULTIS, P1
   Ren WQ, 2007, J COMPUT PHYS, V227, P1353, DOI 10.1016/j.jcp.2007.09.007
   Rezlerova E, 2017, LANGMUIR, V33, P11126, DOI 10.1021/acs.langmuir.7b01772
   Ritchie B. W., 2018, MNRAS, V323, P743
   Robinson M, 2014, INT J MULTIPHAS FLOW, V59, P121, DOI 10.1016/j.ijmultiphaseflow.2013.11.003
   Roldan Cuenya B, 2010, THIN SOLID FILMS, V518, P3127, DOI 10.1016/j.tsf.2010.01.018
   Roldughin VI, 2016, COLLOID J+, V78, P363, DOI 10.1134/S1061933X16030121
   Roldughin VI, 2011, ADV COLLOID INTERFAC, V168, P223, DOI 10.1016/j.cis.2011.04.001
   Rong LW, 2014, CHEM ENG SCI, V116, P508, DOI 10.1016/j.ces.2014.05.025
   Rong LW, 2013, CHEM ENG SCI, V99, P44, DOI 10.1016/j.ces.2013.05.036
   Rowe PN, 1997, CHEM ENG RES DES, V75, pS116, DOI 10.1016/S0263-8762(97)80009-3
   Rubinstein GJ, 2017, J FLUID MECH, V833, P599, DOI 10.1017/jfm.2017.705
   Rubinstein GJ, 2016, J FLUID MECH, V788, P576, DOI 10.1017/jfm.2015.679
   Rui N., 2017, MULT FLOW SCI WORKSH
   RUTHVEN DM, 1988, ACS SYM SER, V368, P362
   Sadeghi MA, 2017, CHEM ENG J, V330, P1002, DOI 10.1016/j.cej.2017.07.139
   Sagaut P., 2006, LARGE EDDY SIMULATIO
   Sakai M., 2008, J SOC POWDER TECHNOL, V45, P466
   Sakai M, 2014, CHEM ENG J, V244, P33, DOI 10.1016/j.cej.2014.01.029
   Sakai M, 2012, CHEM ENG J, V200, P663, DOI 10.1016/j.cej.2012.06.080
   Sakai M, 2009, CHEM ENG SCI, V64, P533, DOI 10.1016/j.ces.2008.10.003
   Sakano M., 2000, JPN J MULTIPHASE FLO, V14, P66
   Salciccioli M, 2011, CHEM ENG SCI, V66, P4319, DOI 10.1016/j.ces.2011.05.050
   Santarelli C, 2015, INT J MULTIPHAS FLOW, V75, P174, DOI 10.1016/j.ijmultiphaseflow.2015.05.007
   Sato N, 2016, J COMPUT PHYS, V321, P76, DOI 10.1016/j.jcp.2016.05.034
   Sato T, 2017, J NON-NEWTON FLUID, V241, P34, DOI 10.1016/j.jnnfm.2017.02.001
   Schluter S, 2014, WATER RESOUR RES, V50, P3615, DOI 10.1002/2014WR015256
   Schmid R, 2008, J AM CHEM SOC, V130, P12600, DOI 10.1021/ja804734g
   Schneider D, 2016, CHEM SOC REV, V45, P3439, DOI 10.1039/c5cs00715a
   Schneiderbauer S, 2018, AICHE J, V64, P1606, DOI 10.1002/aic.16141
   Schneiderbauer S, 2018, AICHE J, V64, P1591, DOI 10.1002/aic.16142
   Schneiderbauer S, 2017, AICHE J, V63, P3544, DOI 10.1002/aic.15684
   Schneiderbauer S, 2014, AICHE J, V60, P839, DOI 10.1002/aic.14321
   Senftle TP, 2016, NPJ COMPUT MATER, V2, DOI 10.1038/npjcompumats.2015.11
   Seville J. P. K., 1986, P FLUID 5
   Sevink GJA, 2014, SOFT MATTER, V10, P5129, DOI 10.1039/c4sm00297k
   Shaffer F, 2013, POWDER TECHNOL, V242, P86, DOI 10.1016/j.powtec.2013.01.012
   Shah MS, 2016, ANGEW CHEM INT EDIT, V55, P5938, DOI 10.1002/anie.201600612
   Sheikh B, 2018, COMPUT FLUIDS, V171, P15, DOI 10.1016/j.compfluid.2018.05.029
   Shen WJ, 2018, TRANSPORT POROUS MED, V123, P521, DOI 10.1007/s11242-017-0985-y
   Shen XJ, 2012, COMPUT THEOR CHEM, V990, P152, DOI 10.1016/j.comptc.2012.03.012
   Shi D., 2015, CHINA FINANCE EC REV, V3, P2196
   Shi YF, 2007, J CHEM PHYS, V127, DOI 10.1063/1.2779877
   Shi YF, 2015, MOL SIMULAT, V41, P3, DOI 10.1080/08927022.2014.918975
   Shi ZS, 2011, CHEM ENG SCI, V66, P5541, DOI 10.1016/j.ces.2011.07.020
   Sierakowski AJ, 2016, J COMPUT PHYS, V309, P164, DOI 10.1016/j.jcp.2015.12.057
   SINCLAIR JL, 1989, AICHE J, V35, P1473, DOI 10.1002/aic.690350908
   Smagorinsky J., 1963, MON WEATHER REV, V91, P99, DOI [10.1175/1520-0493(1963)091<0099:GCEWTP>2.3.CO;2, DOI 10.1175/1520-0493(1963)091<0099:GCEWTP>2.3.CO;2, 10.1175/1520-0493(1963)091, 10.1175/1520-0493(1963)091<less than>0099:GCEWTP<greater than>2.3.CO;2]
   Smit B, 2008, CHEM REV, V108, P4125, DOI 10.1021/cr8002642
   Snider DM, 2001, J COMPUT PHYS, V170, P523, DOI 10.1006/jcph.2001.6747
   Song FF, 2014, CHEM ENG SCI, V120, P112, DOI 10.1016/j.ces.2014.08.057
   Soong C.H., 1994, CIRCULATING FLUIDIZE, P615
   STEJSKAL EO, 1965, J CHEM PHYS, V42, P288, DOI 10.1063/1.1695690
   Stuart SJ, 2000, J CHEM PHYS, V112, P6472, DOI 10.1063/1.481208
   Su MZ, 2017, AICHE J, V63, P2588, DOI 10.1002/aic.15573
   Sun F, 2016, CHEM ENG SCI, V153, P87, DOI 10.1016/j.ces.2016.07.014
   Sun J., 2016, SCI TECHNOL, V27
   Sun R, 2015, INT J MULTIPHAS FLOW, V77, P142, DOI 10.1016/j.ijmultiphaseflow.2015.08.014
   Sun R, 2015, INT J MULTIPHAS FLOW, V72, P233, DOI 10.1016/j.ijmultiphaseflow.2015.02.014
   Sundaresan S, 2000, AICHE J, V46, P1102, DOI 10.1002/aic.690460602
   Sundaresan S, 2003, ANNU REV FLUID MECH, V35, P63, DOI 10.1146/annurev.fluid.35.101101.161151
   Sundaresan S, 2018, ANNU REV CHEM BIOMOL, V9, P61, DOI 10.1146/annurev-chembioeng-060817-084025
   Sungkorn R, 2012, PHYS FLUIDS, V24, DOI 10.1063/1.4770310
   Suwanwarangkul R, 2003, J POWER SOURCES, V122, P9, DOI 10.1016/S0378-7753(02)00724-3
   Syamlal M., 1993, DOEMETC951013
   Syamlal M., 1989, AICHE S SER, V85, P22
   Tahmasebi P, 2015, TRANSPORT POROUS MED, V110, P521, DOI 10.1007/s11242-015-0570-1
   Talmon Y, 2010, PHYS CHEM CHEM PHYS, V12, P5998, DOI 10.1039/b922060g
   Tan ML, 1998, PHYS REV LETT, V81, P3022, DOI 10.1103/PhysRevLett.81.3022
   Tanaka T., 1995, ASME FED, V228, P297
   Tang DX, 2004, SCI CHINA SER B, V47, P434, DOI 10.1360/04yb0020
   Tang Y, 2016, CHEM ENG SCI, V143, P166, DOI 10.1016/j.ces.2015.12.026
   Tang Y, 2015, AICHE J, V61, P688, DOI 10.1002/aic.14645
   Tang YL, 2016, AICHE J, V62, P1958, DOI 10.1002/aic.15197
   Tavassoli H, 2013, INT J MULTIPHAS FLOW, V57, P29, DOI 10.1016/j.ijmultiphaseflow.2013.06.009
   Tebianian S, 2016, CHEM ENG J, V306, P306, DOI 10.1016/j.cej.2016.07.058
   Tebianian S, 2016, POWDER TECHNOL, V296, P45, DOI 10.1016/j.powtec.2015.08.040
   Tebianian S, 2015, CHEM ENG SCI, V127, P310, DOI 10.1016/j.ces.2015.01.049
   Tenneti S, 2013, INT J HEAT MASS TRAN, V58, P471, DOI 10.1016/j.ijheatmasstransfer.2012.11.006
   Tenneti S, 2011, INT J MULTIPHAS FLOW, V37, P1072, DOI 10.1016/j.ijmultiphaseflow.2011.05.010
   TERSOFF J, 1988, PHYS REV LETT, V61, P2879, DOI 10.1103/PhysRevLett.61.2879
   Thabet A, 2018, CHEM ENG SCI, V187, P117, DOI 10.1016/j.ces.2018.04.054
   Thiele EW, 1939, IND ENG CHEM, V31, P916, DOI 10.1021/ie50355a027
   Thommes M, 2010, CHEM-ING-TECH, V82, P1059, DOI 10.1002/cite.201000064
   Tian YJ, 2017, CHEM ENG SCI, V171, P271, DOI 10.1016/j.ces.2017.05.037
   TING JM, 1993, INT J NUMER ANAL MET, V17, P603, DOI 10.1002/nag.1610170902
   Tomutsa L, 2007, SPE RESERV EVAL ENG, V10, P285, DOI 10.2118/99558-PA
   Tong ZB, 2010, CHEM ENG J, V164, P432, DOI 10.1016/j.cej.2009.11.027
   Tseng YH, 2003, J COMPUT PHYS, V192, P593, DOI 10.1016/j.jcp.2003.07.024
   Tseronis K, 2008, CHEM ENG SCI, V63, P5626, DOI 10.1016/j.ces.2008.07.037
   TSUJI Y, 1993, POWDER TECHNOL, V77, P79, DOI 10.1016/0032-5910(93)85010-7
   TSUO YP, 1990, AICHE J, V36, P885, DOI 10.1002/aic.690360610
   Uhlmann M, 2005, J COMPUT PHYS, V209, P448, DOI 10.1016/j.jcp.2005.03.017
   Uhlmann M, 2008, PHYS FLUIDS, V20, DOI 10.1063/1.2912459
   Ukrainczyk N, 2014, MODEL SIMUL MATER SC, V22, DOI 10.1088/0965-0393/22/3/035001
   Valverde JM, 2008, CHEM ENG J, V140, P296, DOI 10.1016/j.cej.2007.09.032
   Van den Akker HEA, 2010, IND ENG CHEM RES, V49, P10780, DOI 10.1021/ie1006382
   van der Hoef MA, 2008, ANNU REV FLUID MECH, V40, P47, DOI 10.1146/annurev.fluid.40.111406.102130
   Van der Hoef MA, 2005, J FLUID MECH, V528, P233, DOI 10.1017/S0022112004003295
   van Duin ACT, 2001, J PHYS CHEM A, V105, P9396, DOI 10.1021/jp004368u
   Vanduyfhuys L, 2012, J CHEM THEORY COMPUT, V8, P3217, DOI 10.1021/ct300172m
   Varas AEC, 2017, POWDER TECHNOL, V313, P402, DOI 10.1016/j.powtec.2017.01.055
   Varas AEC, 2017, CHEM ENG SCI, V169, P246, DOI 10.1016/j.ces.2016.08.030
   Vattipalli V, 2016, CHEM MATER, V28, P7852, DOI 10.1021/acs.chemmater.6b03308
   VELDSINK JW, 1995, CHEM ENG J BIOCH ENG, V57, P115, DOI 10.1016/0923-0467(94)02929-6
   Vu-Quoc L, 2000, COMPUT METHOD APPL M, V187, P483, DOI 10.1016/S0045-7825(99)00337-0
   Wachs A, 2009, COMPUT FLUIDS, V38, P1608, DOI 10.1016/j.compfluid.2009.01.005
   Wahab YA, 2015, SENSOR ACTUAT B-CHEM, V210, P602, DOI 10.1016/j.snb.2014.12.103
   Wang HF, 2018, AICHE J, V64, P2364, DOI 10.1002/aic.16163
   Wang JW, 2008, CHEM ENG SCI, V63, P3341, DOI 10.1016/j.ces.2008.03.041
   Wang JW, 2008, CHEM ENG SCI, V63, P2294, DOI 10.1016/j.ces.2008.01.021
   Wang JW, 2017, CHEM ENG SCI, V168, P11, DOI 10.1016/j.ces.2017.04.031
   Wang W., 2015, ADV CHEM ENG, V47, P193
   Wang ZL, 2009, INT J HEAT MASS TRAN, V52, P4510, DOI 10.1016/j.ijheatmasstransfer.2009.03.048
   Yuan S, 2012, FLOWS 30 AER SCI M E, V30, P373
   E W, 2007, COMMUN COMPUT PHYS, V2, P367
   Engquist B, 2003, PHYS REV B, V67
   Wang JW, 2008, CHEM ENG SCI, V63, P1553, DOI 10.1016/j.ces.2007.11.023
   Wang JW, 2016, AICHE J, V62, P2649, DOI 10.1002/aic.15244
   Wang JW, 2009, CHEM ENG SCI, V64, P622, DOI 10.1016/j.ces.2008.09.028
   Wang LM, 2017, POWDER TECHNOL, V319, P221, DOI 10.1016/j.powtec.2017.06.046
   Wang LM, 2016, CHEM ENG J, V300, P83, DOI 10.1016/j.cej.2016.04.115
   Wang LM, 2013, CHEM ENG SCI, V101, P228, DOI 10.1016/j.ces.2013.06.019
   Wang LN, 2005, CHEM ENG COMMUN, V192, P1636, DOI 10.1080/009864490896223
   Wang QG, 2015, CHEM ENG J, V260, P240, DOI 10.1016/j.cej.2014.08.052
   Wang SA, 2015, FUEL, V139, P646, DOI 10.1016/j.fuel.2014.09.027
   Wang S, 2014, CHEM ENG SCI, V116, P773, DOI 10.1016/j.ces.2014.05.046
   Wang T, 2018, CHEM SOC REV, V47, P6744, DOI 10.1039/c8cs00041g
   Wang W, 2004, CHINESE J CHEM ENG, V12, P335
   Wang W, 2007, CHEM ENG SCI, V62, P208, DOI 10.1016/j.ces.2006.08.017
   Wang YN, 2012, ENVIRON SCI TECHNOL, V46, P9995, DOI 10.1021/es301885m
   Warsito W, 2001, CHEM ENG SCI, V56, P6455, DOI 10.1016/S0009-2509(01)00234-2
   Washino K., 2007, J SOC POWDER TECHNOL, V44, P198
   Wen C.Y., 1966, CHEM ENG PROGR S SER, V62, P100, DOI DOI 10.1016/S0032-0633(98)00014-2
   White C, 2013, COMPUT FLUIDS, V71, P261, DOI 10.1016/j.compfluid.2012.10.023
   Wick CD, 2000, J PHYS CHEM B, V104, P8008, DOI 10.1021/jp001044x
   Wiggins C, 2017, NUCL INSTRUM METH A, V843, P22, DOI 10.1016/j.nima.2016.10.057
   WILHELM RH, 1948, CHEM ENG PROG, V44, P201
   Willett CD, 2000, LANGMUIR, V16, P9396, DOI 10.1021/la000657y
   Wippermann K, 2014, ELECTROCHIM ACTA, V141, P212, DOI 10.1016/j.electacta.2014.06.164
   Wirth R, 2009, CHEM GEOL, V261, P217, DOI 10.1016/j.chemgeo.2008.05.019
   Withers PJ, 2007, MATER TODAY, V10, P26, DOI 10.1016/S1369-7021(07)70305-X
   Xia JJ, 2014, INT J HEAT MASS TRAN, V75, P302, DOI 10.1016/j.ijheatmasstransfer.2014.03.048
   [肖海涛 Xiao Haitao], 2003, [化工学报, Journal of Chemical Industry and Engineering (China)], V54, P311
   Xie CY, 2017, ADV WATER RESOUR, V100, P26, DOI 10.1016/j.advwatres.2016.11.017
   Xiong QG, 2014, CONTINUUM MECH THERM, V26, P907, DOI 10.1007/s00161-014-0351-z
   Xiong QG, 2012, CHEM ENG SCI, V71, P422, DOI 10.1016/j.ces.2011.10.059
   Xiong QG, 2011, CHEM ENG SCI, V66, P1859, DOI 10.1016/j.ces.2011.01.033
   Xiong QG, 2010, CHEM ENG SCI, V65, P5356, DOI 10.1016/j.ces.2010.06.035
   Xiong QR, 2016, J CONTAM HYDROL, V192, P101, DOI 10.1016/j.jconhyd.2016.07.002
   Xu BH, 1997, CHEM ENG SCI, V52, P2785, DOI 10.1016/S0009-2509(97)00081-X
   Xu D, 2018, J CHEM PHYS, V148, DOI 10.1063/1.4999050
   Xu J, 2013, J BIOMOL STRUCT DYN, V31, P779, DOI 10.1080/07391102.2012.709461
   Xu M, 2007, CHEM ENG SCI, V62, P2302, DOI 10.1016/j.ces.2006.12.008
   Xu Y, 2010, FLOW TURBUL COMBUST, V85, P735, DOI 10.1007/s10494-010-9298-8
   Yang MJ, 2017, RENEW SUST ENERG REV, V74, P1346, DOI 10.1016/j.rser.2016.11.161
   Yang N, 2004, IND ENG CHEM RES, V43, P5548, DOI 10.1021/ie049773c
   Yang N, 2003, CHEM ENG J, V96, P71, DOI 10.1016/j.cej.2003.08.006
   YANG N, 2003, CHINA PART, V1, P38
   Yang N, 2007, CHEM ENG SCI, V62, P6978, DOI 10.1016/j.ces.2007.08.034
   Yang T, 2017, CRYSTENGCOMM, V19, P72, DOI 10.1039/c6ce02068b
   Yang T, 2016, CRYST GROWTH DES, V16, P2850, DOI 10.1021/acs.cgd.6b00171
   Yang T, 2015, CHEM ENG SCI, V138, P457, DOI 10.1016/j.ces.2015.08.017
   Ye GH, 2017, AICHE J, V63, P78, DOI 10.1002/aic.15415
   Ye M., 2015, ADV CHEM ENG, V47, P279
   Ye T, 1999, J COMPUT PHYS, V156, P209, DOI 10.1006/jcph.1999.6356
   Yerushalmi J., 1978, AICHE S SER, V174, P1
   Yuan DF, 2018, NAT CHEM, V10, P653, DOI 10.1038/s41557-018-0032-9
   Yue XP, 2006, LANGMUIR, V22, P3138, DOI 10.1021/la052843f
   Zabelok S, 2015, J COMPUT PHYS, V303, P455, DOI 10.1016/j.jcp.2015.10.003
   Zaidi AA, 2018, CHEM ENG RES DES, V132, P714, DOI 10.1016/j.cherd.2018.02.013
   Zaidi AA, 2014, ADV POWDER TECHNOL, V25, P1860, DOI 10.1016/j.apt.2014.07.019
   ZAIKIN AN, 1970, NATURE, V225, P535, DOI 10.1038/225535b0
   Zhang CL, 2016, MOL SIMULAT, V42, P1171, DOI 10.1080/08927022.2016.1154551
   Zhang DM, 1993, CHAOS, V3, P723, DOI 10.1063/1.165933
   Zhang JY, 2018, CHEM ENG SCI, V189, P212, DOI 10.1016/j.ces.2018.05.056
   Zhang JY, 2005, CHEM ENG SCI, V60, P3091, DOI 10.1016/j.ces.2004.11.057
   Zhang LL, 2013, J AM CHEM SOC, V135, P3722, DOI 10.1021/ja401129h
   Zhang MZ, 2010, MATER CONSTRUCC, V60, P7, DOI 10.3989/mc.2010.60810
   Zhang PF, 2017, J NANOSCI NANOTECHNO, V17, P6827, DOI 10.1166/jnn.2017.14518
   Zhang Q, 2009, PARTICUOLOGY, V7, P175, DOI 10.1016/j.partic.2009.01.013
   Zhang QB, 2017, POWDER TECHNOL, V315, P385, DOI 10.1016/j.powtec.2017.04.024
   Zhang Y, 2011, PARTICUOLOGY, V9, P365, DOI 10.1016/j.partic.2011.03.004
   Zhang Z, 2005, J COMPUT PHYS, V210, P292, DOI 10.1016/j.jcp.2005.04.009
   Zhao BD, 2018, CHEM ENG SCI, V177, P333, DOI 10.1016/j.ces.2017.11.047
   Zhao H., 2006, THESIS
   Zheng M, 2013, J MOL GRAPH MODEL, V41, P1, DOI 10.1016/j.jmgm.2013.02.001
   Zhong WQ, 2009, CHEM ENG TECHNOL, V32, P386, DOI 10.1002/ceat.200800516
   Zhou GF, 2014, CHEM ENG SCI, V116, P9, DOI 10.1016/j.ces.2014.04.025
   Zhou Q, 2015, PHYS FLUIDS, V27, DOI 10.1063/1.4927552
   Zhou Q, 2015, CHEM ENG SCI, V122, P637, DOI 10.1016/j.ces.2014.10.025
   Zhu HP, 2007, CHEM ENG SCI, V62, P3378, DOI 10.1016/j.ces.2006.12.089
   Zhu HP, 2008, CHEM ENG SCI, V63, P5728, DOI 10.1016/j.ces.2008.08.006
   Zhu KW, 2004, AICHE J, V50, P1729, DOI 10.1002/aic.10172
   Zhu LT, 2018, CHEM ENG SCI, V192, P759, DOI 10.1016/j.ces.2018.08.026
   ZOU B, 1994, POWDER TECHNOL, V78, P173, DOI 10.1016/0032-5910(93)02786-A
NR 581
TC 16
Z9 16
U1 27
U2 101
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD APR 28
PY 2019
VL 198
BP 198
EP 223
DI 10.1016/j.ces.2018.12.037
PG 26
WC Engineering, Chemical
SC Engineering
GA HL5YZ
UT WOS:000458810700018
DA 2020-05-12
ER

PT J
AU Partopour, B
   Troupel, A
   Dixon, AG
AF Partopour, Behnam
   Troupel, Alexandre
   Dixon, Anthony G.
TI Flux-dependent anisotropic pellet diffusivity in particle-resolved CFD
   simulations of fixed beds
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Resolved particle; Computational fluid dynamics; Effective diffusivity;
   Fixed bed; Porous catalyst
ID CATALYST PARTICLES; GASEOUS-DIFFUSION; ISOTHERMAL DIFFUSION; POROUS
   CATALYST; TRANSPORT; FLOW; OXIDATION; MODEL; MEDIA; HEAT
AB The implementation of multicomponent diffusion in porous catalyst particles into resolved-particle fixed bed computational fluid dynamics (CFD) presents challenges. Usually an isotropic effective diffusivity is employed for each species, which includes molecular diffusion, Knudsen diffusion and viscous flow. To obtain this quantity, constant and isotropic molar flux ratios are assumed. In fixed bed models, pellets composed of isotropic materials are situated in non-isotropic fluid-phase gradients in the bed, which call the assumptions into question. In this paper we present an extended model using a non-isotropic effective diffusivity tensor, which allows evaluation of the flux assumptions. The method is illustrated for resolved particle steady-state CFD simulations of ethylene oxidation in small test beds of spheres and four-hole cylinders. Comparisons to the original constant molar flux ratio model are made, which show that the flux changes affect reaction, species and temperature profiles in the particles, and are stronger in particles with longer diffusion paths. Larger differences between results from the two diffusion models are also seen when the effective diffusivity is decreased by reducing porosity and increasing tortuosity, typical of a reaction system where deactivation increases by carbon deposition. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Partopour, Behnam; Troupel, Alexandre; Dixon, Anthony G.] Worcester Polytech Inst, Dept Chem Engn, Worcester, MA 01609 USA.
   [Troupel, Alexandre] Siemens PLM Software, Lyon, France.
RP Dixon, AG (reprint author), Worcester Polytech Inst, Dept Chem Engn, Worcester, MA 01609 USA.
EM agdixon@wpi.edu
FU American Chemical Society Petroleum Research FundAmerican Chemical
   Society
FX Acknowledgment is made to the Donors of the American Chemical Society
   Petroleum Research Fund for support of this research. The sponsor played
   no role in the study design, in the collection, analysis and
   interpretation of data, in the writing of the report or in the decision
   to submit the article for publication.
CR Aris R., 1975, MATH THEORY DIFFUSIO
   BISCHOFF KB, 1968, CHEM ENG SCI, V23, P451, DOI 10.1016/0009-2509(68)87021-6
   Bufe A, 2017, CHEM-ING-TECH, V89, P1385, DOI 10.1002/cite.201700066
   Carman P.C., 1937, T I CHEM ENG-LOND, V15, P17, DOI [10.1016/S0263-8762(97)80003-2, DOI 10.1016/S0263-8762(97)80003-2]
   COPELOWITZ I, 1970, CHEM ENG SCI, V25, P885, DOI 10.1016/0009-2509(70)85123-5
   Coppens M.-O., 2009, DESIGN HETEROGENEOUS
   Dixon AG, 2012, IND ENG CHEM RES, V51, P15839, DOI 10.1021/ie202694m
   Dixon AG, 2010, IND ENG CHEM RES, V49, P9012, DOI 10.1021/ie100298q
   Donaubauer PJ, 2018, CHEM ENG SCI, V185, P282, DOI 10.1016/j.ces.2018.03.048
   Dong Y, 2016, CHEM ENG SCI, V142, P299, DOI 10.1016/j.ces.2015.12.004
   EVANS RB, 1962, J CHEM PHYS, V36, P1894, DOI 10.1063/1.1701287
   EVANS RB, 1961, J CHEM PHYS, V35, P2076, DOI 10.1063/1.1732211
   FENG C, 1973, IND ENG CHEM FUND, V12, P143, DOI 10.1021/i160046a001
   FOSTER RN, 1966, AICHE J, V12, P180, DOI 10.1002/aic.690120132
   FULLER EN, 1966, IND ENG CHEM, V58, P19, DOI 10.1021/ie50677a007
   Goll S, 2012, INT J HEAT MASS TRAN, V55, P480, DOI 10.1016/j.ijheatmasstransfer.2011.09.049
   HITE RH, 1977, CHEM ENG SCI, V32, P703, DOI 10.1016/0009-2509(77)80117-6
   HLAVACEK V, 1970, CHEM ENG SCI, V25, P1527, DOI 10.1016/0009-2509(70)85075-8
   Jackson R., 1977, TRANSPORT POROUS CAT
   JOHNSON MFL, 1965, J CATAL, V4, P248, DOI 10.1016/0021-9517(65)90015-1
   KAZA KR, 1980, CHEM ENG SCI, V35, P1179, DOI 10.1016/0009-2509(80)85108-6
   Keil F.J., 2012, MODELING SIMULATION
   Kerkhof PJAM, 1996, CHEM ENG J, V64, P319, DOI 10.1016/S0923-0467(96)03121-1
   Koci P, 2006, CHEM ENG SCI, V61, P3240, DOI 10.1016/j.ces.2005.12.008
   Lim JY, 2012, IND ENG CHEM RES, V51, P15901, DOI 10.1021/ie302528u
   Murthy JY, 1998, J HEAT TRANS-T ASME, V120, P583, DOI 10.1115/1.2824315
   Partopour Behnam, 2018, ChemEngineering, V2, DOI 10.3390/chemengineering2010002
   Partopour B, 2016, COMPUT CHEM ENG, V88, P126, DOI 10.1016/j.compchemeng.2016.02.015
   Pasaogullari U, 2007, J ELECTROCHEM SOC, V154, pB823, DOI 10.1149/1.2745714
   REYES S, 1985, CHEM ENG SCI, V40, P1723, DOI 10.1016/0009-2509(85)80034-8
   REYES SC, 1991, J CATAL, V129, P457, DOI 10.1016/0021-9517(91)90049-A
   Runstedtler A, 2006, CHEM ENG SCI, V61, P5021, DOI 10.1016/j.ces.2006.03.040
   SAHIMI M, 1990, CHEM ENG SCI, V45, P1443, DOI 10.1016/0009-2509(90)80001-U
   SCHNEIDER P, 1978, CHEM ENG SCI, V33, P1311, DOI 10.1016/0009-2509(78)85112-4
   SCHNITZLEIN K, 1988, COMPUT CHEM ENG, V12, P1157, DOI 10.1016/0098-1354(88)87037-6
   Solsvik J, 2013, CAN J CHEM ENG, V91, P66, DOI 10.1002/cjce.20680
   Stegelmann C, 2004, J CATAL, V221, P630, DOI 10.1016/j.jcat.2003.10.004
   STEWART WE, 1978, CHEM ENG SCI, V33, P547, DOI 10.1016/0009-2509(78)80016-5
   WAKAO N, 1962, CHEM ENG SCI, V17, P825, DOI 10.1016/0009-2509(62)87015-8
   Wehinger GD, 2017, COMPUT CHEM ENG, V101, P11, DOI 10.1016/j.compchemeng.2017.02.029
   WHEELER A, 1951, ADV CATAL, V3, P249, DOI 10.1016/S0360-0564(08)60109-1
   XU JG, 1989, AICHE J, V35, P97, DOI 10.1002/aic.690350110
   Young JB, 2005, INT J HEAT MASS TRAN, V48, P5338, DOI 10.1016/j.ijheatmasstransfer.2005.07.034
NR 43
TC 4
Z9 4
U1 1
U2 13
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD APR 28
PY 2019
VL 198
BP 224
EP 234
DI 10.1016/j.ces.2018.10.005
PG 11
WC Engineering, Chemical
SC Engineering
GA HL5YZ
UT WOS:000458810700019
DA 2020-05-12
ER

PT J
AU Geitenbeek, RG
   Salzmann, BBV
   Nieuwelink, AE
   Meijerink, A
   Weckhuysen, BM
AF Geitenbeek, Robin G.
   Salzmann, Bastiaan B., V
   Nieuwelink, Anne-Eva
   Meijerink, Andries
   Weckhuysen, Bert M.
TI Chemically and thermally stable lanthanide-doped Y2O3 nanoparticles for
   remote temperature sensing in catalytic environments
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Reaction temperature; Operando spectroscopy; Reactor bed; Lanthanides;
   Luminescence thermometry
ID LUMINESCENCE THERMOMETRY; REACTOR; METHANE
AB Luminescent nanoparticles have great potential for remote temperature sensing. Mapping of high temperature profiles under harsh conditions that are common in chemical reactors requires new thermally and chemically stable (nano)probes. Here, we report temperature dependent luminescence of Yb3+/Er3+-,Dy3+- and Eu3+-doped Y2O3 nanoparticles (NPs). We have deposited these lanthanide-doped Y2O3 NPs on alpha-Al2O3, a non-porous catalyst support material. The NPs are strongly adsorbed on the surface and no sintering was observed upon heating to 900 K for 12 h. The high chemical and thermal stability of Y2O3 makes these nanoprobes ideal for sensing in catalytic environments. A systematic study of the three types of luminescent NPs reveals that the temperature dependent luminescence of Yb3+/Er3+, Dy3+ and Eu3+ serves different temperature ranges: lower T regime (300-800 K, accuracy < 5 K) for Yb3+/Er3+, intermediate T for Dy3+(400-900 + K, accuracy < 15 K) and high T for Eu3+(550-900 + K, accuracy < 12 K). The superior thermal and chemical stability of the Y2O3/alpha-Al2O3 host in combination with different luminescent lanthanide dopants results in a robust system that can be tailored to monitor temperatures in different regimes with the highest possible sensitivity. (C) 2018 The Authors. Published by Elsevier Ltd.
C1 [Geitenbeek, Robin G.; Salzmann, Bastiaan B., V; Meijerink, Andries] Univ Utrecht, Debye Inst Nanomat Sci, Condensed Matter & Interfaces, Princetonpl 1, NL-3584 CC Utrecht, Netherlands.
   [Nieuwelink, Anne-Eva; Weckhuysen, Bert M.] Univ Utrecht, Debye Inst Nanomat Sci, Inorgan Chem & Catalysis, Univ Weg 99, NL-3584 CG Utrecht, Netherlands.
RP Meijerink, A (reprint author), Univ Utrecht, Debye Inst Nanomat Sci, Condensed Matter & Interfaces, Princetonpl 1, NL-3584 CC Utrecht, Netherlands.
EM A.Meijerink@uu.nl; B.M.Weckhuysen@uu.nl
FU Netherlands Center for Multiscale Catalytic Energy Conversion (MCEC), an
   NWO Gravitation programme - Ministry of Education, Culture and Science
   of the government of the Netherlands
FX This work was supported by the Netherlands Center for Multiscale
   Catalytic Energy Conversion (MCEC), an NWO Gravitation programme funded
   by the Ministry of Education, Culture and Science of the government of
   the Netherlands.
CR Aigouy L, 2005, APPL PHYS LETT, V87, DOI 10.1063/1.2123384
   Bar-Cohen A, 2009, MICROGRAVITY SCI TEC, V21, P351, DOI 10.1007/s12217-009-9162-4
   Benninger RKP, 2006, ANAL CHEM, V78, P2272, DOI 10.1021/ac051990f
   Brites CDS, 2012, NANOSCALE, V4, P4799, DOI 10.1039/c2nr30663h
   Fukushima S, 2016, OPT MATER EXPRESS, V6, P831, DOI 10.1364/OME.6.000831
   Geitenbeek RG, 2018, ACS CATAL, V8, P2397, DOI 10.1021/acscatal.7b04154
   Geitenbeek RG, 2017, J PHYS CHEM C, V121, P3503, DOI 10.1021/acs.jpcc.6b10279
   Haro-Gonzalez P, 2011, OPT MATER, V33, P742, DOI 10.1016/j.optmat.2010.11.026
   Hwang S, 2009, CHEM ENG COMMUN, V196, P616, DOI 10.1080/00986440802484465
   Jaque D, 2012, NANOSCALE, V4, P4301, DOI 10.1039/c2nr30764b
   Jundt DH, 1997, OPT LETT, V22, P1553, DOI 10.1364/OL.22.001553
   Kimmerle B, 2009, J PHYS CHEM C, V113, P3037, DOI 10.1021/jp810319v
   Koptyug IV, 2008, J AM CHEM SOC, V130, P10452, DOI 10.1021/ja802075m
   Li CR, 2007, CHEM PHYS LETT, V443, P426, DOI 10.1016/j.cplett.2007.06.081
   Li DY, 2012, OPT COMMUN, V285, P1925, DOI 10.1016/j.optcom.2011.12.075
   Low P, 2008, SMALL, V4, P908, DOI 10.1002/smll.200700581
   Mathews MD, 2004, J ALLOY COMPD, V377, P162, DOI 10.1016/j.jallcom.2003.12.043
   Mazidi SK, 2013, CHEM ENG TECHNOL, V36, P62, DOI 10.1002/ceat.201200268
   MENYUK N, 1972, APPL PHYS LETT, V21, P159, DOI 10.1063/1.1654325
   Okabe K, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1714
   Pandey A, 2013, APPL PHYS B-LASERS O, V113, P221, DOI 10.1007/s00340-013-5460-z
   Pompeo F, 2007, APPL CATAL A-GEN, V316, P175, DOI 10.1016/j.apcata.2006.09.007
   Rai VK, 2007, APPL PHYS B-LASERS O, V86, P333, DOI 10.1007/s00340-006-2445-1
   Rakov N, 2012, OPT COMMUN, V285, P1882, DOI 10.1016/j.optcom.2011.12.046
   Romero JJ, 2003, J APPL PHYS, V93, P3111, DOI 10.1063/1.1539911
   Simeone M, 2008, AICHE J, V54, P2689, DOI 10.1002/aic.11565
   Sohn S, 2004, POWDER TECHNOL, V142, P136, DOI 10.1016/j.powtec.2004.03.013
   Vetrone F, 2010, ACS NANO, V4, P3254, DOI 10.1021/nn100244a
   Wang F, 2009, CHEM SOC REV, V38, P976, DOI 10.1039/b809132n
   Xu X, 2015, ACS APPL MATER INTER, V7, P20813, DOI 10.1021/acsami.5b05876
   Yao W, 2007, CATAL LETT, V119, P185, DOI 10.1007/s10562-007-9220-8
   Yarulina I, 2016, CATAL SCI TECHNOL, V6, P5320, DOI 10.1039/c6cy00654j
NR 32
TC 6
Z9 6
U1 4
U2 36
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD APR 28
PY 2019
VL 198
BP 235
EP 240
DI 10.1016/j.ces.2018.10.004
PG 6
WC Engineering, Chemical
SC Engineering
GA HL5YZ
UT WOS:000458810700020
OA Other Gold
DA 2020-05-12
ER

PT J
AU Pirker, S
   Lichtenegger, T
AF Pirker, Stefan
   Lichtenegger, T.
TI Process control of through-flow reactor operation by real-time
   recurrence CFD (rCFD) simulations - Proof of concept
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Recurrence CFD; Real-time simulations; rCFD-based process control
ID BEDS
AB We resolve dynamic species transport in a turbulent through-flow reactor by means of recurrence CFD (rCFD). In order to incorporate rCFD into a process control loop, the existing real-time simulation methodology (Pirker and Lichtenegger, 2018) has been further developed significantly.
   First and foremost, we propose an interpolation methodology which enables the representation of intermediate pseudo-periodic flows in-between two recurrence databases. Interpolated rCFD predictions agree very well with corresponding full CFD results with respect to mean concentration, concentration histograms as well as spatial line profiles and temporal point monitors of concentration. We further apply interpolated rCFD to unsteadily varying through-flow conditions, achieving consistently good predictions. Next, we considered reactive and non-isothermal flow. Still, rCFD predictions agree very well with full CFD simulations with respect to the unsteadily evolving fields of species concentration and temperature. At the same time rCFD simulations run four orders of magnitude faster than corresponding full CFD simulations, yielding faster-than-real-time predictions of the evolving concentration fields.
   This paves the way towards a rCFD-based process control, such that (1) a recurrence database is selected based on process dynamics before (2) point probe of passive scalars are extrapolated by rCFD to high-resolution field data, which are (3) reduced to descriptive scalars, serving for (4) process actuation.
   We prove the feasibility of rCFD-based process control for (i) outflow concentration control and for (ii) local hot-spot suppression. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Pirker, Stefan] Johannes Kepler Univ Linz, Dept Particulate Flow Modelling, Linz, Austria.
   Johannes Kepler Univ Linz, Linz Inst Technol, Linz, Austria.
RP Pirker, S (reprint author), Johannes Kepler Univ Linz, Dept Particulate Flow Modelling, Linz, Austria.
EM stefan.pirker@jku.at
RI Lichtenegger, Thomas/AAB-6647-2019
OI Lichtenegger, Thomas/0000-0001-5577-6058
FU K1MET competence center; Linz Institute of Technology
   [LIT-2016-1-YOU-007, LIT-2017-3-SEE-008]
FX The authors acknowledge the financial support of the K1MET competence
   center and the Linz Institute of Technology (projects LIT-2016-1-YOU-007
   and LIT-2017-3-SEE-008).
CR Kieckhefen P., 2018, SIMULATION SPRAY COA
   Lichtenegger T, 2017, CHEM ENG SCI, V172, P310, DOI 10.1016/j.ces.2017.06.022
   Lichtenegger T, 2016, CHEM ENG SCI, V153, P394, DOI 10.1016/j.ces.2016.07.036
   Lichtenegger T, 2018, INT J MULTIPHAS FLOW, DOI [10.1016/j.ijmultiphasebow.2018.05.013, DOI 10.1016/J.IJMULTIPHASEBOW.2018.05.013]
   Llop MF, 2015, INT J MULTIPHAS FLOW, V73, P43, DOI 10.1016/j.ijmultiphaseflow.2015.03.003
   Pirker S, 2018, CHEM ENG SCI, V188, P65, DOI 10.1016/j.ces.2018.04.059
   Savari C, 2017, POWDER TECHNOL, V316, P148, DOI 10.1016/j.powtec.2016.12.075
   Seill P, 2017, V INTERNATIONAL CONFERENCE ON PARTICLE-BASED METHODS - FUNDAMENTALS AND APPLICATIONS (PARTICLES 2017), P57
   Tahmasebpour M, 2013, PARTICUOLOGY, V11, P647, DOI 10.1016/j.partic.2012.08.005
   Wang CH, 2012, POWDER TECHNOL, V219, P20, DOI 10.1016/j.powtec.2011.11.051
NR 10
TC 4
Z9 4
U1 0
U2 3
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD APR 28
PY 2019
VL 198
BP 241
EP 252
DI 10.1016/j.ces.2018.09.043
PG 12
WC Engineering, Chemical
SC Engineering
GA HL5YZ
UT WOS:000458810700021
DA 2020-05-12
ER

PT J
AU Huang, WL
   Li, JH
   Liu, ZC
   Zhou, J
   Ma, C
   Wen, LX
AF Huang, Wen Lai
   Li, Jinghai
   Liu, Zhicheng
   Zhou, Jian
   Ma, Chao
   Wen, Li-Xiong
TI Mesoscale distribution of adsorbates in ZSM-5 zeolite
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Mesoscale structure; Heterogeneous catalysis; Compromise in competition;
   Steady state; Zeolite; Channel utilization
ID SPATIOTEMPORAL SELF-ORGANIZATION; DIFFUSIVITY; ADLAYER
AB Complex distribution of adsorbates can emerge in heterogeneous catalysis due to the compromise among different mechanisms (showing different tendencies of structural evolution) associated with different processes. On two-dimensional catalyst surfaces, all the surfaces are exposed to the gas reservoir (and thus adsorption and desorption processes are accessible to all the surfaces), and we have investigated the effects of adsorption, desorption, diffusion, and reactions on the adlayer structure, and revealed the mechanisms (Huang and Li, 2016). However, in zeolites, only the entrances (or exits) of the pore channels are exposed to the gas reservoir (and thus adsorption and desorption processes are limited there), so the mesoscale behavior might be somewhat different. In this work we explore the influence of adsorption, desorption, diffusion, and reactions on the adsorbate distribution in the ZSM-5 zeolite using kinetic Monte Carlo simulations. Complex distributions of adsorbates (nonlinearly gradient, showing apparent adsorbate shells in some cases) have been revealed, and the channel utilization has been evaluated. The approach and results might be useful to catalyst design, especially determining the optimal thickness of zeolite on a catalyst particle (pellet), since the channel utilization is a measure of effective fraction of the catalyst and is correlated with the practical efficiency of catalysis. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Huang, Wen Lai; Li, Jinghai; Ma, Chao] Chinese Acad Sci, State Key Lab Multiphase Complex Syst, Inst Proc Engn, POB 353, Beijing 100190, Peoples R China.
   [Liu, Zhicheng; Zhou, Jian] SINOPEC, Shanghai Res Inst Petrochem Technol, Shanghai 201208, Peoples R China.
   [Ma, Chao; Wen, Li-Xiong] Beijing Univ Chem Technol, Coll Chem Engn, Beijing 100029, Peoples R China.
RP Huang, WL (reprint author), Chinese Acad Sci, State Key Lab Multiphase Complex Syst, Inst Proc Engn, POB 353, Beijing 100190, Peoples R China.
EM wlhuang@ipe.ac.cn
OI , Jinghai/0000-0002-5026-7104
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [91534104, 21878300, 91434102, 91334102]; State Key
   Laboratory of Multiphase Complex Systems in China [MPCS-2017-A-02];
   Research Center for Mesoscience at Institute of Process Engineering,
   Chinese Academy of Sciences [COM2015A002]; Shanghai Rising-Star Program
   [18QB1404500]
FX We appreciate the financial support from the National Natural Science
   Foundation of China (Grant Nos. 91534104, 21878300, 91434102, and
   91334102), the State Key Laboratory of Multiphase Complex Systems in
   China (Grant No. MPCS-2017-A-02), the Research Center for Mesoscience at
   Institute of Process Engineering, Chinese Academy of Sciences (Grant No.
   COM2015A002), and the Shanghai Rising-Star Program (Grant No.
   18QB1404500).
CR Battaile CC, 2008, COMPUT METHOD APPL M, V197, P3386, DOI 10.1016/j.cma.2008.03.010
   BORTZ AB, 1975, J COMPUT PHYS, V17, P10, DOI 10.1016/0021-9991(75)90060-1
   Dubbeldam D, 2003, J PHYS CHEM B, V107, P12138, DOI 10.1021/jp035200m
   Einstein A, 1905, ANN PHYS-BERLIN, V17, P549, DOI 10.1002/andp.19053220806
   ERTL G, 1991, SCIENCE, V254, P1750, DOI 10.1126/science.254.5039.1750
   FORD DM, 1995, J MEMBRANE SCI, V107, P47, DOI 10.1016/0376-7388(95)00101-H
   Huang WL, 2016, CHEM ENG SCI, V147, P83, DOI 10.1016/j.ces.2016.03.019
   Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5
   Krishna R, 2004, J PHYS CHEM B, V108, P14820, DOI 10.1021/jp0465682
   Krishna R, 2009, J PHYS CHEM C, V113, P19756, DOI 10.1021/jp906879d
   Li J, 2014, MESOSCIENCE PRINCIPL
   Ma CR, 2015, THESIS
   PLIMPTON S, 1995, J COMPUT PHYS, V117, P1, DOI 10.1006/jcph.1995.1039
   Sachs C, 2001, SCIENCE, V293, P1635, DOI 10.1126/science.1062883
   Shewmon P., 2016, DIFFUSION SOLIDS
   Smit B, 2008, CHEM REV, V108, P4125, DOI 10.1021/cr8002642
   Sun F, 2017, LANGMUIR, V33, P11582, DOI 10.1021/acs.langmuir.7b01930
   Sun F, 2016, CHEM ENG SCI, V153, P87, DOI 10.1016/j.ces.2016.07.014
   Wang Y, 2018, MICROPOR MESOPOR MAT, V258, P17, DOI 10.1016/j.micromeso.2017.08.052
   Wintterlin J, 1997, SCIENCE, V278, P1931, DOI 10.1126/science.278.5345.1931
   Zhou J, 2016, J CATAL, V340, P166, DOI 10.1016/j.jcat.2016.05.009
   Zhou J, 2014, RSC ADV, V4, P43752, DOI 10.1039/c4ra03986f
NR 22
TC 3
Z9 3
U1 3
U2 27
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD APR 28
PY 2019
VL 198
BP 253
EP 259
DI 10.1016/j.ces.2018.09.050
PG 7
WC Engineering, Chemical
SC Engineering
GA HL5YZ
UT WOS:000458810700022
DA 2020-05-12
ER

PT J
AU Gvozdic, B
   Dung, OY
   Almeras, E
   van Gils, DPM
   Lohse, D
   Huisman, SG
   Sun, C
AF Gvozdic, Biljana
   Dung, On-Yu
   Almeras, Elise
   van Gils, Dennis P. M.
   Lohse, Detlef
   Huisman, Sander G.
   Sun, Chao
TI Experimental investigation of heat transport in inhomogeneous bubbly
   flow
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Bubbly flows; Heat transfer; Bubble column; Experiments
ID NATURAL-CONVECTION; LIQUID VELOCITY; VERTICAL PLATE; REGIME;
   ENHANCEMENT; TURBULENCE; MOMENTUM; LAMINAR; WATER; LDA
AB In this work we study the heat transport in inhomogeneous bubbly flow. The experiments were performed in a rectangular bubble column heated from one side wall and cooled from the other, with millimetric bubbles introduced through one half of the injection section (close to the hot wall or close to the cold wall). We characterise the global heat transport while varying two parameters: the gas volume fraction alpha= 0.4-5.1%, and the Rayleigh number Ra-H= 4 x 10(9)- 2.2 x 10(10). As captured by imaging and characterised using Laser Doppler Anemometry (LDA), different flow regimes occur with increasing gas flow rates. In the generated inhomogeneous bubbly flow there are three main contributions to the mixing: (i) transport by the buoyancy driven recirculation, (ii) bubble induced turbulence (BIT) and (iii) shear-induced turbulence (SIT). The strength of these contributions and their interplay depends on the gas volume fraction which is reflected in the measured heat transport enhancement. We compare our results with the findings for heat transport in homogeneous bubbly flow from Gvozdic et al. (2018). We find that for the lower gas volume fractions (alpha < 4%), inhomogeneous bubbly injection results in better heat transport due to induced large-scale circulation. In contrast, for alpha > 4%, when the contribution of SIT becomes stronger, but so does the competition between all three contributions, the homogeneous injection is more efficient. (C) 2019 The Authors. Published by Elsevier Ltd.
C1 [Gvozdic, Biljana; Dung, On-Yu; Almeras, Elise; van Gils, Dennis P. M.; Lohse, Detlef; Huisman, Sander G.; Sun, Chao] Univ Twente, Fac Sci & Technol, JM Burgers Ctr Fluid Dynam, Phys Fluids Grp, POB 217, NL-7500 AE Enschede, Netherlands.
   [Gvozdic, Biljana; Dung, On-Yu; Almeras, Elise; van Gils, Dennis P. M.; Lohse, Detlef; Huisman, Sander G.; Sun, Chao] Univ Twente, Fac Sci & Technol, Max Planck Ctr Twente, POB 217, NL-7500 AE Enschede, Netherlands.
   [Almeras, Elise] CNRS INP UPS, UMR 5503, Lab Genie Chim, F-31106 Toulouse, France.
   [Sun, Chao] Tsinghua Univ, Ctr Combust Energy, Dept Energy & Power Engn, Key Lab Thermal Sci & Power Engn,Minist Educ, Beijing 100084, Peoples R China.
RP Huisman, SG (reprint author), Univ Twente, Fac Sci & Technol, JM Burgers Ctr Fluid Dynam, Phys Fluids Grp, POB 217, NL-7500 AE Enschede, Netherlands.; Huisman, SG; Sun, C (reprint author), Univ Twente, Fac Sci & Technol, Max Planck Ctr Twente, POB 217, NL-7500 AE Enschede, Netherlands.; Sun, C (reprint author), Tsinghua Univ, Ctr Combust Energy, Dept Energy & Power Engn, Key Lab Thermal Sci & Power Engn,Minist Educ, Beijing 100084, Peoples R China.
EM s.g.huisman@utwente.nl; chaosun@tsinghua.edu.cn
RI Lohse, Detlef/B-4915-2013; Huisman, Sander G/J-4178-2014; Sun,
   Chao/B-2743-2009
OI Lohse, Detlef/0000-0003-4138-2255; Sun, Chao/0000-0002-0930-6343; Dung,
   On-Yu/0000-0002-5002-1470
FU Natural Science Foundation of ChinaNational Natural Science Foundation
   of China [11672156]; Netherlands Center for Multiscale Catalytic Energy
   Conversion (MCEC), an NWO Gravitation Programme - Ministry of Education,
   Culture and Science of the government of The Netherlands
FX This work is part of the Industrial Partnership Programme i36 Dense
   Bubbly Flows that is carried out under an agreement between Akzo Nobel
   Chemicals International B.V., DSM Innovation Center B.V., SABIC Global
   Technologies B.V., Shell Global Solutions B.V., TATA Steel Nederland
   Technology B.V. and the Netherlands Organisation for Scientific Research
   (NWO). Chao Sun acknowledges the financial support from Natural Science
   Foundation of China under Grant No. 11672156. This work was also
   supported by The Netherlands Center for Multiscale Catalytic Energy
   Conversion (MCEC), an NWO Gravitation Programme funded by the Ministry
   of Education, Culture and Science of the government of The Netherlands.
CR Ahlers G, 2009, REV MOD PHYS, V81, P503, DOI 10.1103/RevModPhys.81.503
   Almeras E, 2016, CHEM ENG SCI, V140, P114, DOI 10.1016/j.ces.2015.10.010
   Almeras E, 2018, CHEM ENG SCI, V186, P52, DOI 10.1016/j.ces.2018.04.026
   Almeras E, 2015, J FLUID MECH, V776, P458, DOI 10.1017/jfm.2015.338
   BELMONTE A, 1994, PHYS REV E, V50, P269, DOI 10.1103/PhysRevE.50.269
   CARTELLIER A, 1990, REV SCI INSTRUM, V61, P874, DOI 10.1063/1.1141457
   Dabiri S, 2015, CHEM ENG SCI, V122, P106, DOI 10.1016/j.ces.2014.09.006
   Deen NG, 2013, CHEM ENG SCI, V102, P268, DOI 10.1016/j.ces.2013.08.025
   ELDER JW, 1965, J FLUID MECH, V23, P99, DOI 10.1017/S0022112065001258
   Groen JS, 1999, EXP FLUIDS, V27, P435, DOI 10.1007/s003480050369
   Gvozdic B, 2018, J FLUID MECH, V845, P226, DOI 10.1017/jfm.2018.213
   KIMURA S, 1984, J HEAT TRANS-T ASME, V106, P98, DOI 10.1115/1.3246666
   Kitagawa A, 2008, EXP FLUIDS, V45, P473, DOI 10.1007/s00348-008-0490-8
   Kitagawa A, 2013, CHEM ENG SCI, V99, P215, DOI 10.1016/j.ces.2013.05.027
   Kitagawa A, 2009, INT J HEAT FLUID FL, V30, P778, DOI 10.1016/j.ijheatfluidflow.2009.02.008
   Lohse D, 2010, ANNU REV FLUID MECH, V42, P335, DOI 10.1146/annurev.fluid.010908.165152
   MARKATOS NC, 1984, INT J HEAT MASS TRAN, V27, P755, DOI 10.1016/0017-9310(84)90145-5
   Mercado JM, 2010, J FLUID MECH, V650, P287, DOI 10.1017/S0022112009993570
   Mudde RF, 1997, CHEM ENG SCI, V52, P4217, DOI 10.1016/S0009-2509(97)88935-X
   Ng CS, 2017, J FLUID MECH, V825, P550, DOI 10.1017/jfm.2017.387
   Ng CS, 2015, J FLUID MECH, V764, P349, DOI 10.1017/jfm.2014.712
   Riboux G, 2010, J FLUID MECH, V643, P509, DOI 10.1017/S0022112009992084
   Risso F, 2002, J FLUID MECH, V453, P395, DOI [10.1017/S022112001006930, 10.1017/S0022112001006930]
   Roghair I, 2011, INT J MULTIPHAS FLOW, V37, P1093, DOI 10.1016/j.ijmultiphaseflow.2011.07.004
   Roig V, 1998, INT J MULTIPHAS FLOW, V24, P35, DOI 10.1016/S0301-9322(97)00046-3
   SATO Y, 1981, INT J MULTIPHAS FLOW, V7, P167, DOI 10.1016/0301-9322(81)90003-3
   SATO Y, 1981, INT J MULTIPHAS FLOW, V7, P179, DOI 10.1016/0301-9322(81)90004-5
   SEKOGUCHI K, 1980, B JSME, V23, P1625, DOI 10.1299/jsme1958.23.1625
   Shishkina O, 2016, J FLUID MECH, V790, DOI 10.1017/jfm.2016.55
   TOKUHIRO AT, 1994, INT J HEAT MASS TRAN, V37, P997, DOI 10.1016/0017-9310(94)90224-0
   Vial C, 2001, CHEM ENG SCI, V56, P1085, DOI 10.1016/S0009-2509(00)00325-0
   Wang F, 2018, J GEOPHYS RES-OCEANS, V123, P855, DOI 10.1002/2017JC013578
   Wang F, 2016, J GEOPHYS RES-OCEANS, V121, P7589, DOI 10.1002/2016JC012068
NR 33
TC 4
Z9 4
U1 1
U2 10
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD APR 28
PY 2019
VL 198
BP 260
EP 267
DI 10.1016/j.ces.2018.09.040
PG 8
WC Engineering, Chemical
SC Engineering
GA HL5YZ
UT WOS:000458810700023
OA Other Gold, Green Published, Green Accepted
DA 2020-05-12
ER

PT J
AU Vandewalle, LA
   Van de Vijver, R
   Van Geem, KM
   Marin, GB
AF Vandewalle, Laurien A.
   Van de Vijver, Ruben
   Van Geem, Kevin M.
   Marin, Guy B.
TI The role of mass and heat transfer in the design of novel reactors for
   oxidative coupling of methane
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Oxidative coupling of methane; Catalytic reactor design; Mass transfer
   limitations; Ignition; Autothermal operation
ID FLUIDIZED-BED REACTOR; TRANSPORT LIMITATIONS; GENERAL CRITERION;
   MEMBRANE REACTOR; TECHNOECONOMIC ANALYSIS; CORDIERITE MONOLITHS;
   CATALYTIC CONVERSION; STATISTICAL-ANALYSIS; BIFURCATION-ANALYSIS;
   DIAGNOSTIC-CRITERIA
AB Oxidative coupling of methane (OCM) is considered one of the most promising routes to directly convert methane into more valuable hydrocarbons. The uncertain economics related to the tradeoff between conversion and C-2 selectivities is the primary reason why OCM is currently not industrially applied. In the last decades, numerous studies have focused on developing a viable catalyst that has the potential to improve the low C-2 yields. But is the primary issue of OCM truly a catalyst problem? Because of the high exothermicity of the OCM process, thermal effects and path dependence are dominating in all OCM reactors of practical importance. Furthermore, irreducible diffusion limitations exist on the pellet scale. Understanding how to exploit these mass and heat transfer effects by reactor engineering is a prerequisite for the breakthrough of OCM. In this work an overview is given of criteria used to assess mass and heat transfer resistances, parametric sensitivity and runaway in catalytic packed bed reactors. The importance of mass transport limitations, runaway and/or ignition for OCM, either on the pellet scale or on the reactor scale, is shown in several examples. Both simple and advanced reactor concepts are discussed with a focus on their heat and mass transfer characteristics. Clear progress has been made in the past lustrum on all these fronts and it seems that research is on the verge of a real breakthrough to make OCM happen on an industrial scale. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Vandewalle, Laurien A.; Van de Vijver, Ruben; Van Geem, Kevin M.; Marin, Guy B.] Univ Ghent, Lab Chem Technol, Technol Pk 914, B-9052 Ghent, Belgium.
RP Van Geem, KM (reprint author), Univ Ghent, Lab Chem Technol, Technol Pk 914, B-9052 Ghent, Belgium.
EM Kevin.VanGeem@UGent.be
RI Van de Vijver, Ruben/C-2454-2018
OI Van de Vijver, Ruben/0000-0003-0605-8513
FU Fund for Scientific Research Flanders (FWO)FWO; Long Term Structural
   Methusalem Funding by the Flemish Government
FX Laurien A. Vandewalle gratefully acknowledges financial support from a
   doctoral fellowship from the Fund for Scientific Research Flanders
   (FWO). Ruben Van de Vijver acknowledges the Research Board of Ghent
   University (BOF). This work was also supported by the Long Term
   Structural Methusalem Funding by the Flemish Government.
CR Ahari JS, 2013, FUEL PROCESS TECHNOL, V115, P79, DOI 10.1016/j.fuproc.2013.04.006
   AIGLER JM, 1991, APPL CATAL, V70, P29
   Akehata T., 1961, CAN J CHEM ENG, V39, P127, DOI 10.1002/cjce.5450390306
   Alexiadis VI, 2014, APPL CATAL B-ENVIRON, V150, P496, DOI 10.1016/j.apcatb.2013.12.043
   Amghizar I, 2017, ENGINEERING-PRC, V3, P171, DOI 10.1016/J.ENG.2017.02.006
   ANDORF R, 1991, CAN J CHEM ENG, V69, P891, DOI 10.1002/cjce.5450690411
   ANNAPRAGADA AV, 1990, J CATAL, V123, P130, DOI 10.1016/0021-9517(90)90162-D
   Arndt S, 2011, TOP CATAL, V54, P1266, DOI 10.1007/s11244-011-9749-z
   Aseem A, 2018, CHEM ENG J, V331, P132, DOI 10.1016/j.cej.2017.08.093
   BALAKOTAIAH V, 1991, AICHE J, V37, P1780, DOI 10.1002/aic.690371203
   Balakotaiah V, 1999, CHEM ENG SCI, V54, P1725, DOI 10.1016/S0009-2509(99)00013-5
   BALAKOTAIAH V, 1995, CHEM ENG SCI, V50, P1149, DOI 10.1016/0009-2509(94)00463-2
   Balakotaiah V., 1996, CHEM ENG ED      FAL, V30, P234
   Balakotaiah V, 2014, CURR OPIN CHEM ENG, V5, P68, DOI 10.1016/j.coche.2014.05.002
   BENENATI RF, 1962, AICHE J, V8, P359, DOI 10.1002/aic.690080319
   Bhatia S, 2009, CHEM ENG J, V148, P525, DOI 10.1016/j.cej.2009.01.008
   BISCHOFF KB, 1967, CHEM ENG SCI, V22, P525, DOI 10.1016/0009-2509(67)80035-6
   Bracconi M, 2018, CHEM ENG PROCESS, V129, P181, DOI 10.1016/j.cep.2018.04.018
   CARBERRY JJ, 1961, AICHE J, V7, P350, DOI 10.1002/aic.690070239
   CARBERRY JJ, 1963, AICHE J, V9, P129, DOI 10.1002/aic.690090128
   Chaouki J, 1999, KOREAN J CHEM ENG, V16, P494, DOI 10.1007/BF02698274
   Chaouki J, 1999, CHEM ENG SCI, V54, P2039, DOI 10.1016/S0009-2509(98)00438-2
   CHEN Q, 1994, AICHE J, V40, P521, DOI 10.1002/aic.690400313
   Choudhary VR, 1998, J CHEM TECHNOL BIOT, V72, P125, DOI 10.1002/(SICI)1097-4660(199806)72:2<125::AID-JCTB880>3.0.CO;2-3
   Christoforatou EL, 1998, AICHE J, V44, P394, DOI 10.1002/aic.690440216
   Cizeron J. M., 2015, Reactors and systems for oxidative coupling of methane, Patent No. [US20150152025A1, 20150152025]
   CONWAY SJ, 1989, APPL CATAL, V56, P149, DOI 10.1016/S0166-9834(00)80165-7
   Couwenberg P. M, 1995, GAS PHASE CHAIN REAC, DOI [10.6100/IR428844, DOI 10.6100/IR428844]
   Couwenberg PM, 1996, IND ENG CHEM RES, V35, P3999, DOI 10.1021/ie9504617
   Couwenberg PM, 1996, IND ENG CHEM RES, V35, P415, DOI 10.1021/ie9502852
   Cruellas A, 2017, CATAL REV, V59, P234, DOI 10.1080/01614940.2017.1348085
   CYBULSKI A, 1994, CATAL REV, V36, P179, DOI 10.1080/01614949408013925
   DAUTZENBERG FM, 1992, CATAL TODAY, V13, P503, DOI 10.1016/0920-5861(92)80071-T
   De Wilde J, 2007, AICHE J, V53, P793, DOI 10.1002/aic.11139
   DELMAS H, 1988, CHEM ENG SCI, V43, P2281, DOI 10.1016/0009-2509(88)87116-1
   Deutschmann O., 2014, DETCHEM SOFTWARE PAC
   Deutschmann O., 2012, MODELING SIMULATION, DOI [10.1002/9783527639878, DOI 10.1002/9783527639878]
   Dommeti SMS, 1999, IND ENG CHEM RES, V38, P767, DOI 10.1021/ie980365g
   EDWARDS JH, 1992, METHANE CONVERSION O, P429
   Elkins TW, 2015, APPL CATAL A-GEN, V497, P96, DOI 10.1016/j.apcata.2015.02.040
   Fang X. P., 1992, J MOL CATAL, V6, P427
   FENG Y, 1991, J PHYS CHEM-US, V95, P6558, DOI 10.1021/j100170a035
   FINLAYSON BA, 1971, CHEM ENG SCI, V26, P1081, DOI 10.1016/0009-2509(71)80022-2
   FINLAYSON BA, 1974, CATAL REV, V10, P69, DOI 10.1080/01614947408079627
   Follmer G., 1989, CATAL TODAY, V4, P323
   Froment G. F., 2011, CHEM REACTOR ANAL DE
   FUJIMOTO K, 1991, STUD SURF SCI CATAL, V61, P525
   Geerts J. W. M. H, 1990, ETHYLENE SYNTHESIS D, DOI [10.6100/IR338278, DOI 10.6100/IR338278]
   GEERTS JWMH, 1990, J CHEM SOC CHEM COMM, P802, DOI 10.1039/c39900000802
   Giani L, 2005, IND ENG CHEM RES, V44, P9078, DOI 10.1021/ie050598p
   Giani L, 2005, IND ENG CHEM RES, V44, P4993, DOI 10.1021/ie0490886
   Godini HR, 2014, J IND ENG CHEM, V20, P1993, DOI 10.1016/j.jiec.2013.09.022
   Godini HR, 2012, IND ENG CHEM RES, V51, P7747, DOI 10.1021/ie202877r
   Godini HR, 2013, FUEL PROCESS TECHNOL, V106, P684, DOI 10.1016/j.fuproc.2012.10.002
   Gonzalez-Quiroga A, 2017, CHEM ENG J, V329, P198, DOI 10.1016/j.cej.2017.06.003
   GONZO EE, 1983, CATAL REV, V25, P119, DOI 10.1080/01614948308078875
   GOVINDARAO VMH, 1986, CHEM ENG SCI, V41, P533
   Groppi G, 2000, CHEM ENG SCI, V55, P2161, DOI 10.1016/S0009-2509(99)00440-6
   Gu T, 2016, CHEM ENG J, V284, P513, DOI 10.1016/j.cej.2015.09.005
   HINSON PG, 1991, J CHEM SOC CHEM COMM, P1430, DOI 10.1039/c39910001430
   Hiyoshi N, 2015, FUEL PROCESS TECHNOL, V133, P29, DOI 10.1016/j.fuproc.2015.01.003
   HLAVACEK V, 1970, CHEM ENG SCI, V25, P173, DOI 10.1016/0009-2509(70)85030-8
   Hoebink JHBJ, 1994, CHEM ENG SCI, V49, P5453, DOI 10.1016/0009-2509(94)00323-8
   HOEBINK JHBJ, 1995, CHEM ENG TECHNOL, V18, P12, DOI 10.1002/ceat.270180104
   Holst N, 2012, CHEM ENG TECHNOL, V35, P294, DOI 10.1002/ceat.201100473
   HUDGINS RR, 1968, CHEM ENG SCI, V23, P93, DOI 10.1016/0009-2509(68)87041-1
   ITO T, 1985, NATURE, V314, P721, DOI 10.1038/314721b0
   ITO T, 1985, J AM CHEM SOC, V107, P5062, DOI 10.1021/ja00304a008
   Jaso S, 2010, CHEM ENG SCI, V65, P6341, DOI 10.1016/j.ces.2010.08.019
   Jaso S., 2011, Method for oxidatively converting gaseous alkanes in a fluidized bed membrane reactor and a reactor for performing said method, Patent No. [WO2013017664A2, 2013017664]
   Jaso S, 2011, CHEM ENG J, V171, P255, DOI 10.1016/j.cej.2011.03.077
   Kaminsky M. P., 1997, U.S Patent, Patent No. [US5599510A, 5599510]
   Karakaya C, 2016, PROG ENERG COMBUST, V55, P60, DOI 10.1016/j.pecs.2016.04.003
   KATO K, 1969, CHEM ENG SCI, V24, P1351, DOI 10.1016/0009-2509(69)85055-4
   Kechagiopoulos PN, 2014, IND ENG CHEM RES, V53, P1825, DOI 10.1021/ie403160s
   Kee RJ, 2017, P COMBUST INST, V36, P51, DOI 10.1016/j.proci.2016.06.014
   Kiatkittipong W, 2005, CHEM ENG J, V115, P63, DOI 10.1016/j.cej.2005.09.018
   Kiwi-Minsker L, 2005, CATAL TODAY, V110, P2, DOI 10.1016/j.cattod.2005.09.011
   Knitter R, 2004, LAB CHIP, V4, P378, DOI 10.1039/b403361b
   Koirala R, 2014, APPL CATAL A-GEN, V484, P97, DOI 10.1016/j.apcata.2014.07.013
   Kondratenko EV, 2017, CATAL SCI TECHNOL, V7, P366, DOI 10.1039/c6cy01879c
   Kondratenko EV, 2015, CATAL SCI TECHNOL, V5, P1668, DOI 10.1039/c4cy01443j
   Kovacevic JZ, 2015, CHEM ENG SCI, V123, P220, DOI 10.1016/j.ces.2014.10.020
   Kubota H., 1969, J CHEM ENG JPN, V2, P238, DOI [10.1252/jcej.2.238, DOI 10.1252/JCEJ.2.238]
   Kunii D., 1969, FLUIDIZATION ENG
   LAFARGA D, 1994, CHEM ENG SCI, V49, P2005, DOI 10.1016/0009-2509(94)80083-9
   Lee JY, 2013, FUEL, V106, P851, DOI 10.1016/j.fuel.2013.01.026
   LEE JS, 1989, KOREAN J CHEM ENG, V6, P54, DOI 10.1007/BF02698112
   Lengyel I, 2018, CURR OPIN CHEM ENG, V21, P41, DOI 10.1016/j.coche.2018.02.013
   LEVAN T, 1993, J CATAL, V142, P18, DOI 10.1006/jcat.1993.1185
   Leyshon D. W., 1989, US Pat., Patent No. 4876409
   LIU SL, 1962, IND ENG CHEM FUND, V1, P200, DOI 10.1021/i160003a008
   Lomonosov VI, 2016, KINET CATAL+, V57, P647, DOI 10.1134/S0023158416050128
   Lomonosov VI, 2013, KINET CATAL+, V54, P451, DOI 10.1134/S0023158413040095
   Lu YP, 2000, J MEMBRANE SCI, V170, P27, DOI 10.1016/S0376-7388(99)00354-3
   Lunsford J.H., 1990, CATAL TODAY, V6, P235
   Lunsford JH, 2000, CATAL TODAY, V63, P165, DOI 10.1016/S0920-5861(00)00456-9
   LUSS D, 1968, AICHE J, V14, P211, DOI 10.1002/aic.690140204
   LUSS D, 1967, CHEM ENG SCI, V22, P253, DOI 10.1016/0009-2509(67)80113-1
   Maestri M, 2013, CATALYTICFOAM
   Maestri M, 2013, CHEM ENG SCI, V96, P106, DOI 10.1016/j.ces.2013.03.048
   Maffei T, 2016, CHEM ENG J, V283, P1392, DOI 10.1016/j.cej.2015.08.080
   Maurer S, 2014, CHEM ENG J, V252, P131, DOI 10.1016/j.cej.2014.04.083
   MEARS DE, 1971, J CATAL, V20, P127, DOI 10.1016/0021-9517(71)90073-X
   MEARS DE, 1971, IND ENG CHEM PROC DD, V10, P541, DOI 10.1021/i260040a020
   Michorczyk P, 2016, J MATER CHEM A, V4, P18753, DOI 10.1039/c6ta08629b
   Mleczko L, 1996, IND ENG CHEM RES, V35, P54, DOI 10.1021/ie950145s
   MLECZKO L, 1995, FUEL PROCESS TECHNOL, V42, P217, DOI 10.1016/0378-3820(94)00121-9
   Mleczko L, 1996, CAN J CHEM ENG, V74, P279, DOI 10.1002/cjce.5450740213
   Myrach P, 2010, CHEMCATCHEM, V2, P854, DOI 10.1002/cctc.201000083
   National Academies of Sciences Medicine and Engineering, 2016, P WORKSH, DOI [10.17226/23555, DOI 10.17226/23555]
   Niyogi K, 2017, POWDER TECHNOL, V305, P794, DOI 10.1016/j.powtec.2016.10.049
   Noon D, 2013, CHEMCATCHEM, V5, P146, DOI 10.1002/cctc.201200408
   NOZAKI T, 1992, CHEM ENG SCI, V47, P2945, DOI 10.1016/0009-2509(92)87156-K
   Obradovic A, 2016, CHEM ENG TECHNOL, V39, P1996, DOI 10.1002/ceat.201600216
   Oleson J. D., 1996, TECHNOLOGY VISION 20
   Olivier L, 2009, CATAL TODAY, V142, P34, DOI 10.1016/j.cattod.2009.01.009
   OTSUKA K, 1986, J CATAL, V100, P353, DOI 10.1016/0021-9517(86)90102-8
   Otsuka K, 1988, STUDIES SURF SCI CAT, V36, P383, DOI DOI 10.1016/S0167-2991(09)60529-2
   Pannek U, 1996, CHEM ENG SCI, V51, P3575, DOI 10.1016/0009-2509(96)00401-0
   Pannek U, 1998, CHEM ENG TECHNOL, V21, P811
   Patil DJ, 2003, INT J CHEM REACT ENG, V1, DOI 10.2202/1542-6580.1049
   PETERSEN EE, 1965, CHEM ENG SCI, V20, P587, DOI 10.1016/0009-2509(65)80024-0
   PETERSEN EE, 1965, CHEM REACTION ANAL
   Radaelli G, 2015, AICHE SPRING NAT M A
   Raja LL, 2000, CATAL TODAY, V59, P47, DOI 10.1016/S0920-5861(00)00271-6
   Salehi MS, 2016, IND ENG CHEM RES, V55, P3287, DOI 10.1021/acs.iecr.5b03292
   Salehi MS, 2016, IND ENG CHEM RES, V55, P1149, DOI 10.1021/acs.iecr.5b02433
   Salkuyeh YK, 2015, ENERG CONVERS MANAGE, V92, P406, DOI 10.1016/j.enconman.2014.12.081
   SANTOS A, 1994, STUD SURF SCI CATAL, V82, P387
   Sarsani S, 2017, CHEM ENG J, V328, P484, DOI 10.1016/j.cej.2017.07.002
   SCHAFFARCZYK S, 1993, CHEM-ING-TECH, V65, P743, DOI 10.1002/cite.330650617
   Schammel W. P., 2014, US Pat., Patent No. [20140107385A1, 20140107385]
   Scher E. C., 2015, Method for the oxidative coupling of methane in the presence of a nanowire catalyst, Patent No. [EP2853521A1, 2853521]
   SCHIEBISCH J, 1991, CHEM-ING-TECH, V63, P359, DOI 10.1002/cite.330630412
   Schlichting H., 2017, BOUNDARY LAYER THEOR, DOI [10.1007/978-3-662-52919-5, DOI 10.1007/978-3-662-52919-5]
   SCHWEER D, 1994, CATAL TODAY, V21, P357, DOI 10.1016/0920-5861(94)80157-6
   Serres T, 2012, CHEM ENG J, V213, P31, DOI 10.1016/j.cej.2012.09.061
   Simon U, 2012, CATAL COMMUN, V18, P132, DOI 10.1016/j.catcom.2011.11.021
   Sinev MY, 2009, J NAT GAS CHEM, V18, P273, DOI 10.1016/S1003-9953(08)60128-0
   Sollier BM, 2018, APPL CATAL A-GEN, V550, P113, DOI 10.1016/j.apcata.2017.10.023
   Sollier BM, 2017, APPL CATAL A-GEN, V532, P65, DOI 10.1016/j.apcata.2016.12.018
   Spallina V, 2017, ENERG CONVERS MANAGE, V154, P244, DOI 10.1016/j.enconman.2017.10.061
   Stansch Z, 1997, IND ENG CHEM RES, V36, P2568, DOI 10.1021/ie960562k
   STEWART WE, 1969, AICHE J, V15, P28, DOI 10.1002/aic.690150111
   Sun Z., 2018, CHEM ENG J
   Sun Z, 2018, CHEM ENG J, V343, P770, DOI 10.1016/j.cej.2018.02.004
   Tang LG, 2011, CATAL TODAY, V178, P172, DOI 10.1016/j.cattod.2011.07.014
   TAYLOR RP, 1991, IND ENG CHEM RES, V30, P1016, DOI 10.1021/ie00053a025
   Tezcan I, 2015, J CHEM TECHNOL BIOT, V90, P1827, DOI 10.1002/jctb.4493
   Thiruvenkataswamy P, 2016, J LOSS PREVENT PROC, V39, P74, DOI 10.1016/j.jlp.2015.11.019
   Thybaut JW, 2011, CATAL TODAY, V159, P29, DOI 10.1016/j.cattod.2010.09.002
   Tiemersma TP, 2012, CHEM ENG J, V203, P223, DOI 10.1016/j.cej.2012.07.021
   TJATJOPOULOS GJ, 1994, CATAL TODAY, V21, P387, DOI 10.1016/0920-5861(94)80160-6
   Tota A., 2007, MODELING PROCESS INT, P99, DOI DOI 10.1002/9783527610600
   Uzunoglu C, 2017, APPL CATAL A-GEN, V547, P22, DOI 10.1016/j.apcata.2017.08.020
   van Sint Annaland M, 2007, IND ENG CHEM RES, V46, P7513, DOI 10.1021/ie070638k
   Vandewalle L. A., 2017, AICHE ETHYL PROD C P
   Vandewalle LA, 2019, CHEM ENG SCI, V199, P635, DOI 10.1016/j.ces.2018.08.053
   Vatani A, 2014, J NAT GAS SCI ENG, V20, P347, DOI 10.1016/j.jngse.2014.07.005
   Visconti CG, 2018, METHANOL, P519, DOI DOI 10.1016/B978-0-444-63903-5.00019-4
   VOSKRESENSKAYA EN, 1995, CATAL REV, V37, P101, DOI 10.1080/01614949508007092
   Wang K, 2009, CATAL COMMUN, V10, P807, DOI 10.1016/j.catcom.2008.12.001
   WEISZ PB, 1954, ADV CATAL, V6, P143, DOI 10.1016/S0360-0564(08)60390-9
   WEISZ PB, 1962, CHEM ENG SCI, V17, P265, DOI 10.1016/0009-2509(62)85005-2
   West D. H, 2018, ISCRE 25 FLOR IT
   WESTERTERP KR, 1993, CHEM REACTOR DESIGN
   Wolf E. E, 1992, METHANE CONVERSION O, DOI [10.1007/978-94-015-7449-5, DOI 10.1007/978-94-015-7449-5]
   Xu G., 1997, Multi-stage fixed-bed reaction technology and device for methane oxidation coupling reaction, Patent No. [CN1146373A, 1146373]
   XU MT, 1991, CATAL LETT, V11, P295, DOI 10.1007/BF00764320
   YOUNG LC, 1973, IND ENG CHEM FUND, V12, P412, DOI 10.1021/i160048a004
   Yusuf R, 2005, CHEM ENG TECHNOL, V28, P13, DOI 10.1002/ceat.200407014
   Zarrinpashne S., 2011, Catalyst direct conversion of methane to ethane and ethylene, Patent No. [US 7902113 B2, 7902113]
   Zavyalova U, 2011, CHEMCATCHEM, V3, P1935, DOI 10.1002/cctc.201100186
   Zhang Zhao, 2014, Advanced Materials Research, V1004-1005, P648, DOI 10.4028/www.scientific.net/AMR.1004-1005.648
NR 175
TC 8
Z9 8
U1 10
U2 35
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD APR 28
PY 2019
VL 198
BP 268
EP 289
DI 10.1016/j.ces.2018.09.022
PG 22
WC Engineering, Chemical
SC Engineering
GA HL5YZ
UT WOS:000458810700024
DA 2020-05-12
ER

PT J
AU Boccardo, G
   Sethi, R
   Marchisio, DL
AF Boccardo, Gianluca
   Sethi, Rajandrea
   Marchisio, Daniele L.
TI Fine and ultrafine particle deposition in packed-bed catalytic reactors
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Catalytic reactors; Filtration; Particle deposition; Blender; OpenFOAM;
   QMOM
ID SINGLE-COLLECTOR EFFICIENCY; PREDICT COLLOIDAL RETENTION; POROUS-MEDIA;
   NUMERICAL-SIMULATION; PRESSURE-DROP; EXTENDING APPLICABILITY;
   CORRELATION EQUATIONS; CERAMIC FOAMS; MASS-TRANSFER; MOMENT METHOD
AB In this work we have performed an extensive CFD simulation campaign with the purpose of studying particle transport and deposition in different catalytic systems and under different conditions. Two types of geometric models representing different porous media were created. The first is a number of random packings of spheres created via rigid body simulations: this approach was tested in previous studies and was proved to result in realistic packings, validated in their geometric features and fluid dynamic behaviour. The second is a regular arrangement of spheres, which was also successfully employed in previous works to study fine particles dispersion.
   Using these random packings, simulations of particle deposition have been performed at different operating conditions. In the first part we calculated values of particle deposition efficiency and compared our results with the classical filtration theory, highlighting the criticalities in the use of the simplified models upon which the theory is based. In the second part we have studied the effect of polydisperse particle populations: this is also missing in the classical filtration theory, which always considers the transport of particles with uniform diameter. Thus, we have performed population balance modelling simulations for particle deposition, employing the quadrature method of moments (QMOM): as an accompanying technical addition, a study on the accuracy of the application of EQMOM in these systems is offered. Even more clearly in this case, the results show that the description of polydisperse populations has a very noticeable effect on the macro-scale description, which would dramatically improve the understanding of particle transport and deposition in filtration and catalytic processes. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Boccardo, Gianluca; Marchisio, Daniele L.] Politecn Torino, Dept Appl Sci & Technol, Turin, Italy.
   [Sethi, Rajandrea] Politecn Torino, Dept Environm Land & Infrastruct Engn, Turin, Italy.
RP Boccardo, G (reprint author), Politecn Torino, Dept Appl Sci & Technol, Turin, Italy.
EM gianluca.boccardo@polito.it
RI ; Marchisio, Daniele/I-2139-2013
OI BOCCARDO, GIANLUCA/0000-0003-1264-8237; Marchisio,
   Daniele/0000-0002-9104-0571
FU ISCRA initiative; HPC@POLITO
FX We acknowledge the CINECA award under the ISCRA initiative and
   HPC@POLITO (http://www.hpc.polito.it) for the availability of high
   performance computing resources and support. We also want to acknowledge
   the valuable contribution of Giuliana Giunta and Valeria Bizzarro to the
   present work.
CR Augier F, 2010, CHEM ENG SCI, V65, P1055, DOI 10.1016/j.ces.2009.09.059
   Bensaid S, 2009, CHEM ENG J, V154, P211, DOI 10.1016/j.cej.2009.03.043
   Bensaid S, 2010, CHEM ENG SCI, V65, P357, DOI 10.1016/j.ces.2009.06.051
   Biggs MJ, 2003, CHEM ENG SCI, V58, P1271, DOI 10.1016/S0009-2509(02)00555-9
   Boccardo G., 2017, J CONTAMIN HYDROL
   Boccardo G, 2015, CHEM ENG J, V279, P809, DOI 10.1016/j.cej.2015.05.032
   Boccardo G, 2014, J COLLOID INTERF SCI, V417, P227, DOI 10.1016/j.jcis.2013.11.007
   Cauda E, 2007, CHEM ENG SCI, V62, P5182, DOI 10.1016/j.ces.2006.12.048
   Crevacore E, 2016, PHYS REV E, V94, DOI 10.1103/PhysRevE.94.053118
   Crevacore E, 2016, CHEM ENGINEER TRANS, V47, P271, DOI 10.3303/CET1647046
   Ding BB, 2018, CHEM ENG SCI, V175, P1, DOI 10.1016/j.ces.2017.09.033
   Dixon AG, 2001, IND ENG CHEM RES, V40, P5246, DOI 10.1021/ie001035a
   ELIMELECH M, 1995, PARTICLE DEPOSITION
   Fino D, 2003, CHEM ENG SCI, V58, P951, DOI 10.1016/S0009-2509(02)00633-4
   Garrido GI, 2008, CHEM ENG SCI, V63, P5202, DOI 10.1016/j.ces.2008.06.015
   HAPPEL J, 1958, AICHE J, V4, P197, DOI 10.1002/aic.690040214
   Icardi M, 2014, PHYS REV E, V90, DOI 10.1103/PhysRevE.90.013032
   Jain D, 2015, CHEM ENG SCI, V137, P685, DOI 10.1016/j.ces.2015.07.025
   Jain D, 2013, CHEM ENG SCI, V100, P496, DOI 10.1016/j.ces.2013.02.060
   Johnson WP, 2013, WATER RESOUR RES, V49, P5328, DOI 10.1002/wrcr.20433
   Kolakaluri R, 2015, AICHE J, V61, P3594, DOI 10.1002/aic.14901
   Lacroix M, 2007, CHEM ENG SCI, V62, P3259, DOI 10.1016/j.ces.2007.03.027
   Laurent F, 2006, ESAIM-MATH MODEL NUM, V40, P431, DOI 10.1051/m2an:2006023
   Lejeune A, 2018, CHEM ENG SCI, V183, P240, DOI 10.1016/j.ces.2018.03.025
   LEVICH VG, 1962, PHYSICOCHEMICAL HYDR
   LOGAN BE, 1995, J ENVIRON ENG-ASCE, V121, P869, DOI 10.1061/(ASCE)0733-9372(1995)121:12(869)
   Ma HL, 2013, ENVIRON SCI TECHNOL, V47, P2272, DOI 10.1021/es304753r
   Madadi-Kandjani E, 2015, CHEM ENG SCI, V131, P323, DOI 10.1016/j.ces.2015.04.005
   Marchisio D.L, 2013, COMPUTATIONAL MODELS
   Massot M, 2010, SIAM J APPL MATH, V70, P3203, DOI 10.1137/080740027
   Messina F, 2016, WATER RESOUR RES, V52, P5492, DOI 10.1002/2016WR018592
   Messina F, 2015, J COLLOID INTERF SCI, V446, P185, DOI 10.1016/j.jcis.2015.01.024
   Mikolajczyk G, 2018, CHEM ENG SCI, V175, P257, DOI 10.1016/j.ces.2017.09.054
   Nelson KE, 2013, ENVIRON SCI TECHNOL, V47, P8078, DOI 10.1021/es401944q
   Nelson KE, 2011, WATER RESOUR RES, V47, DOI 10.1029/2010WR009587
   Partopour B, 2017, POWDER TECHNOL, V322, P258, DOI 10.1016/j.powtec.2017.09.009
   PAYATAKES AC, 1973, AICHE J, V19, P58, DOI 10.1002/aic.690190110
   Pazmino EF, 2011, ENVIRON SCI TECHNOL, V45, P10401, DOI 10.1021/es202203m
   PRIEVE DC, 1974, AICHE J, V20, P1178, DOI 10.1002/aic.690200618
   RAJAGOPALAN R, 1976, AICHE J, V22, P523, DOI 10.1002/aic.690220316
   Regulski W, 2015, CHEM ENG SCI, V137, P320, DOI 10.1016/j.ces.2015.06.043
   Segers QIE, 2013, CHEM ENG SCI, V100, P33, DOI 10.1016/j.ces.2013.01.001
   Tenneti S, 2011, INT J MULTIPHAS FLOW, V37, P1072, DOI 10.1016/j.ijmultiphaseflow.2011.05.010
   Tien C, 2013, GRANULAR FILTRATION
   Tufenkji N, 2004, ENVIRON SCI TECHNOL, V38, P529, DOI 10.1021/es034049r
   von Rickenbach J, 2015, CHEM ENG SCI, V138, P446, DOI 10.1016/j.ces.2015.08.020
   Yao K.M., 1968, THESIS
   YAO KM, 1971, ENVIRON SCI TECHNOL, V5, P1105, DOI 10.1021/es60058a005
   Yuan C, 2012, J AEROSOL SCI, V51, P1, DOI 10.1016/j.jaerosci.2012.04.003
NR 49
TC 5
Z9 5
U1 2
U2 11
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD APR 28
PY 2019
VL 198
BP 290
EP 304
DI 10.1016/j.ces.2018.09.024
PG 15
WC Engineering, Chemical
SC Engineering
GA HL5YZ
UT WOS:000458810700025
DA 2020-05-12
ER

PT J
AU Uslamin, EA
   Luna-Murillo, B
   Kosinov, N
   Bruijnincx, PCA
   Pidko, EA
   Weckhuysen, BM
   Hensen, EJM
AF Uslamin, Evgeny A.
   Luna-Murillo, Beatriz
   Kosinov, Nikolay
   Bruijnincx, Pieter C. A.
   Pidko, Evgeny A.
   Weckhuysen, Bert M.
   Hensen, Emiel J. M.
TI Gallium-promoted HZSM-5 zeolites as efficient catalysts for the
   aromatization of biomass-derived furans
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Biomass; Furanics; Aromatics; Zeolites; Ethylene
ID IN-SITU; ACIDIC PROPERTIES; FAST PYROLYSIS; ZSM-5; GA/ZSM-5; CRACKING;
   ACTIVATION; REACTIVITY; CONVERSION; CHEMISTRY
AB The development of novel technologies to convert renewable biomass feedstocks to fuels and chemicals is of increasing interest for making our chemical industry more sustainable. Plant biomass or its biomass-derived platform molecules are typically over-functionalized, requiring substantial modification to produce the chemicals currently demanded by industry. Furanic compounds are intermediates in the catalytic fast pyrolysis of lignocellulosic biomass or sugar dehydration and can in principle be further converted to aromatics. While upgrading of furanics by zeolite-catalysed aromatization typically results in a large loss of carbon due to coke deposition, carbon laydown can be mitigated by the addition of ethylene and by the modification of the zeolite with Lewis acid Ga sites. Here, we investigate the influence of the Ga loading on the physicochemical properties of Ga-modified HZSM-5 zeolite and its performance in the gas-phase aromatization of 2,5-dimethylfuran with ethylene. Characterization of the morphological, textural and acidic properties were carried out to understand the role of Bronsted and Lewis acid sites on the catalytic reaction. We demonstrate a crucial role of the dispersion of Ga-species and the resulting Lewis acidity of the Ga/ZSM-5 catalysts; and show means how to control both parameters by adjusting the synthesis method. (C) 2018 The Authors. Published by Elsevier Ltd.
C1 [Uslamin, Evgeny A.; Kosinov, Nikolay; Pidko, Evgeny A.; Hensen, Emiel J. M.] Eindhoven Univ Technol, Schuit Inst Catalysis, Lab Inorgan Mat Chem, Eindhoven, Netherlands.
   [Luna-Murillo, Beatriz; Bruijnincx, Pieter C. A.; Weckhuysen, Bert M.] Univ Utrecht, Debye Inst Nanomat Sci, Inorgan Chem & Catalysis Grp, Utrecht, Netherlands.
   [Pidko, Evgeny A.] Delft Univ Technol, Dept Chem Engn, Inorgan Syst Engn Grp, Van der Maasweg 9, NL-2629 HZ Delft, Netherlands.
RP Hensen, EJM (reprint author), Eindhoven Univ Technol, Schuit Inst Catalysis, Lab Inorgan Mat Chem, Eindhoven, Netherlands.; Weckhuysen, BM (reprint author), Univ Utrecht, Debye Inst Nanomat Sci, Inorgan Chem & Catalysis Grp, Utrecht, Netherlands.
EM B.M.Weckhuysen@uu.nl; E.J.M.Hensen@tue.nl
RI Pidko, Evgeny A./A-7811-2008; Uslamin, Evgeny A./AAE-2521-2020
OI Pidko, Evgeny A./0000-0001-9242-9901; Uslamin, Evgeny
   A./0000-0001-5454-9582
FU Netherlands Center for Multiscale Catalytic Energy Conversion (MCEC), an
   Nederlandse Organisatie voor Wetenschappelijk Onderzoek (NWO)
   Gravitation program - Ministry of Education, Culture and Science of the
   government of the Netherlands [501100003245]
FX This work was supported by the Netherlands Center for Multiscale
   Catalytic Energy Conversion; Funder ID 501100003245 (MCEC), an
   Nederlandse Organisatie voor Wetenschappelijk Onderzoek (NWO)
   Gravitation program funded by the Ministry of Education, Culture and
   Science of the government of the Netherlands.
CR Aramburo LR, 2013, CATAL SCI TECHNOL, V3, P1208, DOI 10.1039/c2cy20661g
   Aramburo LR, 2011, CHEM-EUR J, V17, P13773, DOI 10.1002/chem.201101361
   Bhan A, 2008, CATAL REV, V50, P19, DOI 10.1080/01614940701804745
   Bjorgen M, 2003, J AM CHEM SOC, V125, P15863, DOI 10.1021/ja037073d
   Buurmans ILC, 2012, CHEM-EUR J, V18, P1094, DOI 10.1002/chem.201102949
   Caeiro G, 2006, J MOL CATAL A-CHEM, V255, P131, DOI 10.1016/j.molcata.2006.03.068
   Carlson TR, 2009, TOP CATAL, V52, P241, DOI 10.1007/s11244-008-9160-6
   Cheng YT, 2012, GREEN CHEM, V14, P3114, DOI 10.1039/c2gc35767d
   Cheng YT, 2012, ANGEW CHEM INT EDIT, V51, P1387, DOI 10.1002/anie.201107390
   Cheng YT, 2011, ACS CATAL, V1, P611, DOI 10.1021/cs200103j
   Corma A, 2007, J CATAL, V247, P307, DOI 10.1016/j.jcat.2007.01.023
   DATKA J, 1992, J CATAL, V135, P186, DOI 10.1016/0021-9517(92)90279-Q
   EMEIS CA, 1993, J CATAL, V141, P347, DOI 10.1006/jcat.1993.1145
   Ennaert T, 2016, CHEM SOC REV, V45, P584, DOI 10.1039/c5cs00859j
   Fricke R, 2000, CHEM REV, V100, P2303, DOI 10.1021/cr9411637
   GUISNET M, 1992, APPL CATAL A-GEN, V89, P1, DOI 10.1016/0926-860X(92)80075-N
   Hagen A, 2000, CATAL REV, V42, P403, DOI 10.1081/CR-100101952
   Hensen EJM, 2005, CATAL LETT, V101, P79, DOI 10.1007/s10562-004-3753-x
   Hensen EJM, 2007, ANGEW CHEM INT EDIT, V46, P7273, DOI 10.1002/anie.200702463
   Kazansky VB, 2006, J PHYS CHEM B, V110, P7975, DOI 10.1021/jp055793w
   Kazansky VB, 2005, J CATAL, V233, P351, DOI 10.1016/j.jcat.2005.05.004
   Kazansky VB, 2004, J CATAL, V227, P263, DOI 10.1016/j.jcat.2004.07.021
   Kosinov N, 2017, J CATAL, V346, P125, DOI 10.1016/j.jcat.2016.12.006
   Kox MHF, 2008, CHEM-EUR J, V14, P1718, DOI 10.1002/chem.200701591
   Kubicka D, 2015, CATAL TODAY, V243, P10, DOI 10.1016/j.cattod.2014.07.043
   LALIK E, 1992, J PHYS CHEM-US, V96, P805, DOI 10.1021/j100181a051
   Lifshitz A, 1998, J PHYS CHEM A, V102, P10655, DOI 10.1021/jp982772b
   Luzgin MV, 2008, ANGEW CHEM INT EDIT, V47, P4559, DOI 10.1002/anie.200800317
   Parmon VN, 1999, CATAL TODAY, V51, P435, DOI 10.1016/S0920-5861(99)00032-2
   Pidko E. A, 2009, PHYS CHEM CHEM PHYS, V11, P2794, DOI [10.1039/b905015a, DOI 10.1039/B905015A]
   Pidko EA, 2006, J CATAL, V240, P73, DOI 10.1016/j.jcat.2006.03.011
   Pidko EA, 2012, P ROY SOC A-MATH PHY, V468, P2070, DOI 10.1098/rspa.2012.0057
   Qiu P, 1998, CATAL LETT, V52, P37, DOI 10.1023/A:1019046714762
   Rane N, 2008, MICROPOR MESOPOR MAT, V110, P279, DOI 10.1016/j.micromeso.2007.06.014
   Rane N, 2006, J CATAL, V239, P478, DOI 10.1016/j.jcat.2006.03.004
   Rezaei PS, 2014, APPL CATAL A-GEN, V469, P490, DOI 10.1016/j.apcata.2013.09.036
   Rohling RY, 2018, ACS CATAL, V8, P760, DOI [10.1021/acscatal.7b03343, 10.1021/acsatal.7b03343]
   Ramiro MSS, 2013, EDULEARN PROC, P161
   Sandoval-Diaz LE, 2015, MICROPOR MESOPOR MAT, V215, P229, DOI 10.1016/j.micromeso.2015.04.038
   Settle AE, 2017, GREEN CHEM, V19, P3468, DOI 10.1039/c7gc00992e
   Sheldon RA, 2014, GREEN CHEM, V16, P950, DOI [10.1039/c3gc41935e, 10.1039/C3GC41935E]
   Sprung C, 2015, J AM CHEM SOC, V137, P1916, DOI 10.1021/ja511381f
   TOPSOE NY, 1981, J CATAL, V70, P41, DOI 10.1016/0021-9517(81)90315-8
   Uslamin EA, 2018, GREEN CHEM, V20, P3818, DOI 10.1039/c8gc01528g
   van Bokhoven JA, 2004, J CATAL, V224, P50, DOI 10.1016/j.jcat.2004.02.003
   Van der Graaff W. N. P., 2016, ZEOLITES SUSTAINABLE, P347, DOI DOI 10.1007/978-3-662-47395-5
   Williams CL, 2012, ACS CATAL, V2, P935, DOI 10.1021/cs300011a
   WU EL, 1979, J PHYS CHEM-US, V83, P2777, DOI 10.1021/j100484a019
NR 48
TC 10
Z9 10
U1 7
U2 44
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD APR 28
PY 2019
VL 198
BP 305
EP 316
DI 10.1016/j.ces.2018.09.023
PG 12
WC Engineering, Chemical
SC Engineering
GA HL5YZ
UT WOS:000458810700026
OA Other Gold, Green Published
DA 2020-05-12
ER

PT J
AU Lu, JT
   Zhu, XJ
   Peters, EAJF
   Verzicco, R
   Lohse, D
   Kuipers, JAM
AF Lu, Jiangtao
   Zhu, Xiaojue
   Peters, E. A. J. F.
   Verzicco, Roberto
   Lohse, Detlef
   Kuipers, J. A. M.
TI Moving from momentum transfer to heat transfer - A comparative study of
   an advanced Graetz-Nusselt problem using immersed boundary methods
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Direct numerical simulation; Immersed boundary method;
   Continuous/discrete forcing method; Multiphase flow; Heat transfer;
   Mixed boundary conditions; Graetz-Nusselt problem
ID DIRECT NUMERICAL-SIMULATION; DISCRETIZED BOLTZMANN-EQUATION;
   MASS-TRANSFER; PARTICULATE SUSPENSIONS; INCOMPRESSIBLE FLOWS;
   PACKED-BEDS; FLUID; PARTICLE; SYSTEMS; LIQUID
AB In this paper two immersed boundary methods (IBM), specifically a continuous forcing method (CFM) and a discrete forcing method (DFM), are applied to perform direct numerical simulations (DNSs) of heat transfer problems in tubular fluid-particle systems. Both IBM models are built on the well-developed models utilized in momentum transfer studies, and have the capability to handle mixed boundary conditions at the particle surface as encountered in industrial applications with both active and passive particles.
   Following a thorough verification of both models for the classical Graetz-Nusselt problem, we subsequently apply them to study a much more advanced Graetz-Nusselt problem of more practical importance with a dense stationary array consisting of hundreds of particles randomly positioned inside a tube with adiabatic wall. The influence of particle sizes and fractional amount of passive particles is analyzed at varying Reynolds numbers, and the simulation results are compared between the two IBM models, finding good agreement. Our results thus qualify the two employed IBM modules for more complex applications. (C) 2018 The Authors. Published by Elsevier Ltd.
C1 [Lu, Jiangtao; Peters, E. A. J. F.; Kuipers, J. A. M.] Eindhoven Univ Technol, Dept Chem Engn & Chem, Multiphase Reactors Grp, NL-5600 MB Eindhoven, Netherlands.
   [Zhu, Xiaojue; Verzicco, Roberto; Lohse, Detlef] Univ Twente, MESA Inst, JM Burgers Ctr Fluid Dynam, Phys Fluids Grp, POB 217, Enschede, Netherlands.
   [Zhu, Xiaojue; Verzicco, Roberto; Lohse, Detlef] Univ Twente, MESA Inst, JM Burgers Ctr Fluid Dynam, Max Planck Ctr Twente Complex Fluid Dynam, POB 217, Enschede, Netherlands.
   [Verzicco, Roberto] Univ Roma Tor Vergata, Dipartimento Ingn Ind, Via Politecn 1, I-00133 Rome, Italy.
   [Lohse, Detlef] Max Planck Inst Dynam & Self Org, Fassberg 17, D-37077 Gottingen, Germany.
RP Peters, EAJF (reprint author), Eindhoven Univ Technol, Dept Chem Engn & Chem, Multiphase Reactors Grp, NL-5600 MB Eindhoven, Netherlands.
EM E.A.J.F.Peters@tue.nl
RI Peters, Frank/V-1293-2018; Lohse, Detlef/B-4915-2013
OI Peters, Frank/0000-0001-6099-3583; Lohse, Detlef/0000-0003-4138-2255;
   Lu, Jiangtao/0000-0003-3340-942X
FU research programme of the Foundation for Fundamental Research on Matter
   (FOM), Netherlands Organisation for Scientific Research (NWO);
   Netherlands Center for Multiscale Catalytic Energy Conversion (MCEC), an
   NWO Gravitation programme - Ministry of Education, Culture and Science
   of the government of the Netherlands; SURF Cooperative; PRACE
   [2016143351]; PRACE aisbl [14DECI005]
FX This work was supported by the research programme of the Foundation for
   Fundamental Research on Matter (FOM), which is part of the Netherlands
   Organisation for Scientific Research (NWO) and the Netherlands Center
   for Multiscale Catalytic Energy Conversion (MCEC), an NWO Gravitation
   programme funded by the Ministry of Education, Culture and Science of
   the government of the Netherlands.; Part of the simulations were carried
   out on the Dutch national e-infrastructure with the support of SURF
   Cooperative. We also acknowledge PRACE for awarding us access to Marconi
   at CINECA, Italy under PRACE project number 2016143351 and the DECI
   resource Fionn at ICHEC, Ireland with support from the PRACE aisbl under
   project number 14DECI005.
CR CHESSHIRE G, 1990, J COMPUT PHYS, V90, P1, DOI 10.1016/0021-9991(90)90196-8
   Das S, 2017, AICHE J, V63, P1152, DOI 10.1002/aic.15487
   Das S, 2017, CHEM ENG SCI, V160, P1, DOI 10.1016/j.ces.2016.11.008
   Deen NG, 2012, CHEM ENG SCI, V81, P329, DOI 10.1016/j.ces.2012.06.055
   Eppinger T, 2011, CHEM ENG J, V166, P324, DOI 10.1016/j.cej.2010.10.053
   Eshghinejadfard A, 2016, INT J HEAT FLUID FL, V60, P31, DOI 10.1016/j.ijheatfluidflow.2016.04.002
   Fadlun EA, 2000, J COMPUT PHYS, V161, P35, DOI 10.1006/jcph.2000.6484
   Feng ZG, 2009, INT J HEAT MASS TRAN, V52, P777, DOI 10.1016/j.ijheatmasstransfer.2008.07.023
   Giese M, 1998, AICHE J, V44, P484, DOI 10.1002/aic.690440225
   GOLDSTEIN D, 1993, J COMPUT PHYS, V105, P354, DOI 10.1006/jcph.1993.1081
   Graetz v.L, 1882, ANN PHYS, V254, P79, DOI DOI 10.1002/ANDP.18822540106
   GUNN DJ, 1978, INT J HEAT MASS TRAN, V21, P467, DOI 10.1016/0017-9310(78)90080-7
   Hu HH, 2001, J COMPUT PHYS, V169, P427, DOI 10.1006/jcph.2000.6592
   HUGHMARK GA, 1980, IND ENG CHEM FUND, V19, P198, DOI 10.1021/i160074a012
   Iaccarino G., 2003, Applied Mechanics Review, V56, P331, DOI 10.1115/1.1563627
   Kajishima T, 2011, HEAT TRANSF-ASIAN RE, V40, P387, DOI 10.1002/htj.20345
   Kim J, 2001, J COMPUT PHYS, V171, P132, DOI 10.1006/jcph.2001.6778
   KUMAR S, 1994, AICHE J, V40, P745, DOI 10.1002/aic.690400502
   KUNII D, 1967, INT J HEAT MASS TRAN, V10, P845
   LADD AJC, 1994, J FLUID MECH, V271, P311, DOI 10.1017/S0022112094001783
   LADD AJC, 1994, J FLUID MECH, V271, P285, DOI 10.1017/S0022112094001771
   Lu JT, 2018, IND ENG CHEM RES, V57, P4664, DOI 10.1021/acs.iecr.8b00268
   Lu JT, 2018, CHEM ENG SCI, V176, P1, DOI 10.1016/j.ces.2017.10.018
   Luo K, 2017, INT J HEAT MASS TRAN, V104, P98, DOI 10.1016/j.ijheatmasstransfer.2016.08.010
   Mittal R, 2008, J COMPUT PHYS, V227, P4825, DOI 10.1016/j.jcp.2008.01.028
   Mittal R, 2005, ANNU REV FLUID MECH, V37, P239, DOI 10.1146/annurev.fluid.37.061903.175743
   Mohd-Yusof J., 1997, ANN RES BRIEFS, P317
   Municchi F, 2017, INT J HEAT MASS TRAN, V111, P171, DOI 10.1016/j.ijheatmasstransfer.2017.03.122
   NELSON PA, 1975, CHEM ENG SCI, V30, P1, DOI 10.1016/0009-2509(75)85109-8
   Nusselt W, 1910, ABHANGIGKEIT WARMEUB
   Peskin CS, 2002, ACT NUMERIC, V11, P479, DOI 10.1017/S0962492902000077
   PESKIN CS, 1977, J COMPUT PHYS, V25, P220, DOI 10.1016/0021-9991(77)90100-0
   RAI MM, 1991, J COMPUT PHYS, V96, P15
   RANZ WE, 1952, CHEM ENG PROG, V48, P141
   Saiki EM, 1996, J COMPUT PHYS, V123, P450, DOI 10.1006/jcph.1996.0036
   SENGUPTA A, 1963, AICHE J, V9, P751
   Shah RK, 1978, LAMINAR FLOW FORCED
   Spandan V, 2017, J COMPUT PHYS, V348, P567, DOI 10.1016/j.jcp.2017.07.036
   Sun B, 2015, INT J HEAT MASS TRAN, V86, P898, DOI 10.1016/j.ijheatmasstransfer.2015.03.046
   Takeuchi S, 2010, INT J NUMER METH FL, V64, P1084, DOI 10.1002/fld.2272
   Tao L. N, 1961, J HEAT TRANSFER, V83, P466
   Tavassoli H, 2013, INT J MULTIPHAS FLOW, V57, P29, DOI 10.1016/j.ijmultiphaseflow.2013.06.009
   Tenneti S, 2013, INT J HEAT MASS TRAN, V58, P471, DOI 10.1016/j.ijheatmasstransfer.2012.11.006
   Tseng YH, 2003, J COMPUT PHYS, V192, P593, DOI 10.1016/j.jcp.2003.07.024
   TYAGI VP, 1966, J HEAT TRANSF, V88, P161, DOI 10.1115/1.3691501
   Udaykumar HS, 2001, J COMPUT PHYS, V174, P345, DOI 10.1006/jcph.2001.6916
   Uhlmann M, 2005, J COMPUT PHYS, V209, P448, DOI 10.1016/j.jcp.2005.03.017
   Van der Hoef MA, 2005, J FLUID MECH, V528, P233, DOI 10.1017/S0022112004003295
   van der Poel EP, 2015, COMPUT FLUIDS, V116, P10, DOI 10.1016/j.compfluid.2015.04.007
   Verzicco R, 1996, J COMPUT PHYS, V123, P402, DOI 10.1006/jcph.1996.0033
   Wang ZL, 2008, INT J MULTIPHAS FLOW, V34, P283, DOI 10.1016/j.ijmultiphaseflow.2007.10.004
   Xia JJ, 2014, INT J HEAT MASS TRAN, V75, P302, DOI 10.1016/j.ijheatmasstransfer.2014.03.048
   Xu S, 2006, J COMPUT PHYS, V216, P454, DOI 10.1016/j.jcp.2005.12.016
   Xu Y, 2013, CHEM ENG SCI, V104, P201, DOI 10.1016/j.ces.2013.09.023
   Zhu X., 2018, COMPUT PHYS COMMUN
NR 55
TC 6
Z9 5
U1 2
U2 20
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD APR 28
PY 2019
VL 198
BP 317
EP 333
DI 10.1016/j.ces.2018.08.046
PG 17
WC Engineering, Chemical
SC Engineering
GA HL5YZ
UT WOS:000458810700027
OA Other Gold
DA 2020-05-12
ER

PT J
AU Sulaiman, M
   Hammouti, A
   Climent, E
   Wachs, A
AF Sulaiman, Mostafa
   Hammouti, Abdelkader
   Climent, Eric
   Wachs, Anthony
TI Coupling the fictitious domain and sharp interface methods for the
   simulation of convective mass transfer around reactive particles:
   Towards a reactive Sherwood number correlation for dilute systems
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Sharp Interface Method; Catalyst particle; Mass transfer; Sherwood
   number; Chemical reaction; Thiele modulus
ID DIRECT NUMERICAL-SIMULATION; IMMERSED BOUNDARY METHOD; HEAT-TRANSFER;
   PARTICULATE FLOWS; EULERIAN APPROACH; PACKED-BED; CYLINDERS; EQUATION;
   CATALYST; CHANNEL
AB We suggest a reactive Sherwood number model for convective mass transfer around reactive particles in a dilute regime. The model is constructed with a simple external-internal coupling and is validated with Particle-Resolved Simulation (PRS). The PRS of reactive particle-fluid systems requires numerical methods able to handle efficiently sharp gradients of concentration and potential discontinuities of gradient concentrations at the fluid-particle interface. To simulate mass transfer from reactive catalyst beads immersed in a fluid flow, we coupled the Sharp Interface Method (SIM) to a Distributed Lagrange Multiplier/Fictions Domain (DLM/FD) two-phase flow solver. We evaluate the accuracy of our numerical method by comparison to analytic solutions and to generic test cases fully resolved by boundary fitted simulations. A previous theoretical model that couples the internal diffusion-reaction problem with the external advection-diffusion mass transfer in the fluid phase is extended to the configuration of three aligned spherical particles representative of a dilute particle-laden flow. Predictions of surface concentration, mass transfer coefficient and chemical effectiveness factor of catalyst particles are validated by DLM-FD/SIM simulations. We show that the model captures properly the effect of an internal first order chemical reaction on the overall respective reactive Sherwood number of each sphere depending on their relative positions. The proposed correlation for the reactive Sherwood number is based on an existing non-reactive Sherwood number correlation. The model can be later used in Euler/Lagrange or Euler/ Euler modelling of dilute reactive particle-laden flows. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Sulaiman, Mostafa; Hammouti, Abdelkader] IFP Energies Nouvelles, Fluid Mech Dept, Rondpoint Echangeur Solaize, BP 3, F-69360 Solaize, France.
   [Hammouti, Abdelkader] Univ Quebec, INRS ETE, 490 Rue Couronne, Quebec City, PQ G1K 9A9, Canada.
   [Climent, Eric] Univ Toulouse, CNRS, IMFT, Toulouse, France.
   [Wachs, Anthony] Univ British Columbia, Dept Math, 1984 Math Rd, Vancouver, BC V6T 1Z2, Canada.
   [Wachs, Anthony] Univ British Columbia, Dept Chem & Biol Engn, 2360 East Mall, Vancouver, BC V6T 1Z3, Canada.
RP Wachs, A (reprint author), Univ British Columbia, Dept Math, 1984 Math Rd, Vancouver, BC V6T 1Z2, Canada.
EM wachs@math.ubc.ca
OI wachs, anthony/0000-0002-8545-7688
CR Akiki G, 2017, J FLUID MECH, V813, P882, DOI 10.1017/jfm.2016.877
   Augier F, 2010, CHEM ENG SCI, V65, P1055, DOI 10.1016/j.ces.2009.09.059
   Augier F, 2010, CHEM ENG SCI, V65, P255, DOI 10.1016/j.ces.2009.06.027
   Calmet I, 1997, PHYS FLUIDS, V9, P438, DOI 10.1063/1.869138
   Clift R., 2005, BUBBLES DROPS PARTIC
   Dan C, 2010, INT J HEAT FLUID FL, V31, P1050, DOI 10.1016/j.ijheatfluidflow.2010.07.007
   Deen NG, 2014, CHEM ENG SCI, V116, P710, DOI 10.1016/j.ces.2014.05.039
   Dorai F, 2015, CHEM ENG SCI, V129, P180, DOI 10.1016/j.ces.2015.01.070
   Duarte F, 2004, COMPUT METHOD APPL M, V193, P4819, DOI 10.1016/j.cma.2004.05.003
   Fedkiw RP, 1999, J COMPUT PHYS, V152, P457, DOI 10.1006/jcph.1999.6136
   Feng ZG, 2000, INT J HEAT MASS TRAN, V43, P219, DOI 10.1016/S0017-9310(99)00133-7
   Furuta S, 2006, BIOMASS BIOENERG, V30, P870, DOI 10.1016/j.biombioe.2005.10.010
   Gibou F, 2003, J SCI COMPUT, V19, P183, DOI 10.1023/A:1025399807998
   Gibou F, 2002, J COMPUT PHYS, V176, P205, DOI 10.1006/jcph.2001.6977
   Gidaspow D., 1994, MULTIPHASE FLOW FLUI
   Glowinski R, 2001, J COMPUT PHYS, V169, P363, DOI 10.1006/jcph.2000.6542
   Glowinski R, 1999, INT J MULTIPHAS FLOW, V25, P755, DOI 10.1016/S0301-9322(98)00048-2
   GUNN DJ, 1978, INT J HEAT MASS TRAN, V21, P467, DOI 10.1016/0017-9310(78)90080-7
   Haroun Y, 2010, CHEM ENG SCI, V65, P2896, DOI 10.1016/j.ces.2010.01.012
   Hu HH, 2001, J COMPUT PHYS, V169, P427, DOI 10.1006/jcph.2000.6592
   Kapahi A, 2013, COMPUT FLUIDS, V83, P144, DOI 10.1016/j.compfluid.2012.06.024
   Khiabani RH, 2010, J HEAT TRANS-T ASME, V132, DOI 10.1115/1.4000860
   Kruggel-Emden H, 2016, POWDER TECHNOL, V294, P236, DOI 10.1016/j.powtec.2016.02.038
   Liu H, 2005, J COMPUT PHYS, V210, P32, DOI 10.1016/j.jcp.2005.03.032
   Liu XD, 2000, J COMPUT PHYS, V160, P151, DOI 10.1006/jcph.2000.6444
   Lu JT, 2018, CHEM ENG SCI, V176, P1, DOI 10.1016/j.ces.2017.10.018
   MAGNAUDET J, 1995, J FLUID MECH, V284, P97, DOI 10.1017/S0022112095000280
   Marella S, 2005, J COMPUT PHYS, V210, P1, DOI 10.1016/j.jcp.2005.03.031
   Maxwell J. C., 2005, ELEMENTARY TREATISE
   Montero C, 2018, FUEL PROCESS TECHNOL, V169, P207, DOI 10.1016/j.fuproc.2017.10.003
   Myungjoo Kang, 2000, Journal of Scientific Computing, V15, P323
   Rahmani M, 2014, PHYS FLUIDS, V26, DOI 10.1063/1.4892840
   RAMACHANDRAN RS, 1989, NUMER HEAT TR A-APPL, V15, P471, DOI 10.1080/10407788908944699
   RANZ WE, 1952, CHEM ENG PROG, V48, P141
   Romkes SJP, 2003, CHEM ENG J, V96, P3, DOI 10.1016/j.cej.2003.08.026
   Shao XM, 2012, INT J HEAT MASS TRAN, V55, P6775, DOI 10.1016/j.ijheatmasstransfer.2012.06.085
   Shi Y, 2011, POWDER TECHNOL, V210, P52, DOI 10.1016/j.powtec.2011.02.022
   Sulaiman M., 2018, CHEM ENG SCI, V65, P1055
   Sun B, 2015, INT J HEAT MASS TRAN, V86, P898, DOI 10.1016/j.ijheatmasstransfer.2015.03.046
   Sun B, 2016, J FLUID MECH, V798, P299, DOI 10.1017/jfm.2016.290
   Udaykumar HS, 2002, INT J HEAT MASS TRAN, V45, P4793, DOI 10.1016/S0017-9310(02)00194-1
   Uhlmann M, 2005, J COMPUT PHYS, V209, P448, DOI 10.1016/j.jcp.2005.03.017
   Wachs A, 2015, COMPUT FLUIDS, V115, P154, DOI 10.1016/j.compfluid.2015.04.006
   Wachs A, 2011, COMPUT CHEM ENG, V35, P2169, DOI 10.1016/j.compchemeng.2011.02.013
   WHITAKER S, 1972, AICHE J, V18, P361, DOI 10.1002/aic.690180219
   Xia JJ, 2014, INT J HEAT MASS TRAN, V75, P302, DOI 10.1016/j.ijheatmasstransfer.2014.03.048
   Yu ZS, 2006, J COMPUT PHYS, V217, P424, DOI 10.1016/j.jcp.2006.01.016
NR 47
TC 4
Z9 4
U1 6
U2 11
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD APR 28
PY 2019
VL 198
BP 334
EP 351
DI 10.1016/j.ces.2019.01.004
PG 18
WC Engineering, Chemical
SC Engineering
GA HL5YZ
UT WOS:000458810700028
OA Green Accepted
DA 2020-05-12
ER

PT J
AU Taucher, C
   Kollaritsch, H
   Dubischar, KL
AF Taucher, Christian
   Kollaritsch, Herwig
   Dubischar, Katrin L.
TI Persistence of the immune response after vaccination with the Japanese
   encephalitis vaccine, IXIARO (R) in healthy adults: A five year
   follow-up study
SO VACCINE
LA English
DT Article
DE Japanese encephalitis; Immunogenicity; Safety; Traveler; IC51; IXIARO
   (R); Seroprotection
ID IMMUNOGENICITY; SAFETY; IC51
AB Immunization with the Japanese encephalitis (JE) vaccine IXIARO (R) results in protective neutralizing antibody levels for one year. Since persistence of protective titer levels beyond one year was unknown, a 5 years follow-up study was conducted. Additionally, data were stratified to compare the persistence of protective neutralizing antibodies against JE in people with or without tick-borne encephalitis (TBE) vaccination.
   Four weeks after the primary series, the percentage of subjects with PRNT50 titer >= 1:10 in the intent-to-treat population was 99%; the rate after 5 years was 81.6%. By month 24, 36, 48 and 60, the percentages were still 90.7%, 91.7%, 90.1%, 85.9%, respectively in the population who had received TBE vaccine compared to 67.9%, 71.9%, 69.1%, 63.8% in the population who had not. No long-term safety concerns were identified.
   These data indicate that vaccination with IXIARO (R) is able to induce protective titers that persist up to 60 months after the primary immunization. (C) 2019 The Author(s). Published by Elsevier Ltd.
C1 [Taucher, Christian; Dubischar, Katrin L.] Valneva Austria GmbH, Campus Vienna Bioctr, Vienna, Austria.
   [Kollaritsch, Herwig] Med Univ Vienna, Inst Pathophysiol, Dept Specif Prophylaxis & Trop Med, Kinderspitalgasse 75, A-1090 Vienna, Austria.
RP Taucher, C (reprint author), Valneva Austria GmbH, Campus Vienna Bioctr 3, A-1030 Vienna, Austria.
EM christian.taucher@valneva.com
FU Valneva Austria GmbH
FX Valneva Austria GmbH was the funding source for this study.
CR Aerssens A, 2016, J TRAVEL MED, V23, DOI 10.1093/jtm/tav020
   [Anonymous], 2015, Wkly Epidemiol Rec, V90, P69
   Askling HH, 2012, VACCINE, V30, P499, DOI 10.1016/j.vaccine.2011.11.061
   Dubischar-Kastner K, 2010, VACCINE, V28, P5197, DOI 10.1016/j.vaccine.2010.05.069
   Eder S, 2011, VACCINE, V29, P2607, DOI 10.1016/j.vaccine.2011.01.058
   Hills SL, JAPANESE ENCEPHALITI
   Huang YJS, 2015, VECTOR-BORNE ZOONOT, V15, P709, DOI 10.1089/vbz.2015.1821
   Schuller E, 2008, VACCINE, V26, P4382, DOI 10.1016/j.vaccine.2008.05.081
   Tauber E, 2008, J INFECT DIS, V198, P493, DOI 10.1086/590116
   Tauber E, 2007, LANCET, V370, P1847, DOI 10.1016/S0140-6736(07)61780-2
NR 10
TC 2
Z9 2
U1 0
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAY 1
PY 2019
VL 37
IS 19
BP 2529
EP 2531
DI 10.1016/j.vaccine.2019.03.030
PG 3
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HV8QU
UT WOS:000466248800002
PM 30962094
OA Other Gold
DA 2020-05-12
ER

PT J
AU Chamberlain, AT
   Limaye, RJ
   O'Leary, ST
   Frew, PM
   Brewer, SE
   Spina, CI
   Ellingson, MK
   Dudley, MZ
   Orenstein, WA
   Donnelly, MA
   Riley, LE
   Ault, KA
   Salmon, DA
   Omer, SB
AF Chamberlain, A. T.
   Limaye, R. J.
   O'Leary, S. T.
   Frew, P. M.
   Brewer, S. E.
   Spina, C. I.
   Ellingson, M. K.
   Dudley, M. Z.
   Orenstein, W. A.
   Donnelly, M. A.
   Riley, L. E.
   Ault, K. A.
   Salmon, D. A.
   Omer, S. B.
TI Development and acceptability of a video-based vaccine promotion
   tutorial for obstetric care providers
SO VACCINE
LA English
DT Article
DE Maternal vaccination; Influenza; Tdap; Provider-patient communication;
   Vaccine hesitancy; Provider education
ID TDAP VACCINATION; PREGNANT-WOMEN; INFLUENZA; IMMUNIZATION; BEHAVIOR;
   PATIENT
AB A prenatal care provider's recommendation for maternal vaccines is one of the strongest predictors of vaccine acceptance during pregnancy. Aside from basic talking points, few resources exist to help obstetric care providers effectively navigate conversations with vaccine hesitant patients. This paper describes the development and acceptability of "VaxChat," an hour-long, evidence-based video tutorial aimed at improving obstetric care providers' ability to promote maternal vaccines. Between June and November 2017, 62 obstetric care providers registered to receive continuing medical education credit for viewing VaxChat. Of the post-tutorial responses received, over 90% said VaxChat increased their knowledge of what to say to vaccine hesitant patients, increased their confidence in addressing vaccinations with their pregnant patients, and will help them improve their practice culture regarding maternal vaccine promotion. Eighty percent intend to change how they approach vaccine conversations. These data suggest VaxChat may be a welcome complement to existing provider-to-patient talking points. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Chamberlain, A. T.; Omer, S. B.] Emory Univ, Rollins Sch Publ Hlth, Dept Epidemiol, 1518 Clifton Rd NE, Atlanta, GA 30322 USA.
   [Limaye, R. J.; Dudley, M. Z.; Salmon, D. A.] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Int Hlth, 615 N Wolfe St, Baltimore, MD 21205 USA.
   [Limaye, R. J.; Dudley, M. Z.; Salmon, D. A.] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Inst Vaccine Safety, 615 N Wolfe St, Baltimore, MD 21205 USA.
   [Limaye, R. J.] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Epidemiol, 615 N Wolfe St, Baltimore, MD 21205 USA.
   [O'Leary, S. T.; Brewer, S. E.; Spina, C. I.] Univ Colorado, Adult & Child Consortium Hlth Outcomes Res & Deli, Anschutz Med Campus, Aurora, CO 80045 USA.
   [O'Leary, S. T.; Brewer, S. E.; Spina, C. I.] Childrens Hosp, 13199 E Montview Blvd,Suite 300, Aurora, CO 80045 USA.
   [O'Leary, S. T.] Univ Colorado, Dept Pediat, Anschutz Med Campus,13123 E 16th Ave, Aurora, CO 80045 USA.
   [Frew, P. M.] Univ Nevada, Sch Community Hlth Sci, 4505 S Maryland Pkwy, Las Vegas, NV 89154 USA.
   [Ellingson, M. K.; Omer, S. B.] Emory Univ, Rollins Sch Publ Hlth, Hubert Dept Global Hlth, 1518 Clifton Rd NE, Atlanta, GA 30322 USA.
   [Orenstein, W. A.; Omer, S. B.] Emory Univ, Sch Med, Dept Pediat, 2015 Uppergate Dr, Atlanta, GA 30322 USA.
   [Orenstein, W. A.; Omer, S. B.] Emory Univ, Emory Vaccine Ctr, 201 Dowman Dr, Atlanta, GA 30322 USA.
   [Donnelly, M. A.] Univ Colorado, Sch Med, Dept Obstet & Gynecol, 12631 E 17th Ave,Acad Off 1,Room 4010, Aurora, CO 80045 USA.
   [Donnelly, M. A.] Denver Hlth Hosp Author, 777 Bannock St, Denver, CO 80204 USA.
   [Riley, L. E.] Cornell Univ, Weill Cornell Med, Dept Obstet & Gynecol, 156 William St 7th Floor, New York, NY 10038 USA.
   [Ault, K. A.] Univ Kansas, Sch Med, Dept Obstet & Gynecol, 3901 Rainbow Blvd, Kansas City, KS 66160 USA.
RP Chamberlain, AT (reprint author), Emory Univ, Rollins Sch Publ Hlth, Dept Epidemiol, 1518 Clifton Rd NE, Atlanta, GA 30322 USA.
EM Allison.Chamberlain@emory.edu
RI Brewer, Sarah/AAG-7535-2019; Chamberlain, Allison T./AAA-3835-2019;
   Frew, Paula/B-4774-2012
OI Chamberlain, Allison T./0000-0001-6009-537X; Brewer, Sarah
   E./0000-0003-0063-6626; Limaye, Rupali/0000-0002-3883-9720; Frew,
   Paula/0000-0002-3078-9124
FU National Institutes of Health, United StatesUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USA
   [R01AI110482]
FX This work was supported by the National Institutes of Health, United
   States [grant number R01AI110482 (All authors)]. The funder had no role
   in the design and conduct of the study; collection, management,
   analysis, or interpretation of the data; or preparation, review or
   approval of the manuscript.
CR American college of obstetricians and gynecologists, MAT IMM TOOLK
   [Anonymous], 2006, COMMUNICATION MED CA
   Beel E, 2013, HUMAN VACC IMMUNOTHE, V9
   Borrelli B, 2007, J ALLERGY CLIN IMMUN, V120, P1023, DOI 10.1016/j.jaci.2007.08.017
   Brewer NT, 2007, HEALTH PSYCHOL, V26, P136, DOI 10.1037/0278-6133.26.2.136
   Brewer NT, 2017, PEDIATRICS, V139, DOI 10.1542/peds.2016-1764
   Chamberlain AT, 2015, VACCINE, V33, P3571, DOI 10.1016/j.vaccine.2015.05.048
   Chapman GB, 2010, JAMA-J AM MED ASSOC, V304, P43, DOI 10.1001/jama.2010.892
   Cook J, 2011, DEBUNKING HDB
   Dempsey AF, 2018, JAMA PEDIAT, V172
   Ellingson MK, 2019, EXPERT REV VACCINES, V18, P191, DOI 10.1080/14760584.2019.1562907
   Haidt J, 2012, THE RIGHTEOUS MIND W
   Halpern SD, 2007, NEW ENGL J MED, V357, P1340, DOI 10.1056/NEJMsb071595
   Healy CM, 2015, VACCINE, V33, P5445, DOI 10.1016/j.vaccine.2015.08.028
   Hillen MA, 2013, PATIENT EDUC COUNS, V91, P295, DOI 10.1016/j.pec.2013.01.020
   Hovland CI, 1953, COMMUNICATION PERSUA
   Kahn KE, 2018, MMWR-MORBID MORTAL W, V67, P1055, DOI 10.15585/mmwr.mm6738a3
   Kahneman D, 2011, THINKING FAST SLOW
   Kharbanda EO, 2011, PREV MED, V52, P75, DOI 10.1016/j.ypmed.2010.10.009
   Marsh HA, 2014, MATERN CHILD HLTH J, V18, P1639, DOI 10.1007/s10995-013-1404-9
   Mazzoni SE, 2016, AM J OBSTET GYNECOL, V214, DOI 10.1016/j.ajog.2015.11.018
   Meharry PM, 2013, MATERN CHILD HLTH J, V17, P156, DOI 10.1007/s10995-012-0957-3
   Milkman KL, 2011, P NATL ACAD SCI USA, V108, P10415, DOI 10.1073/pnas.1103170108
   Miller R, 2002, MOTIVATIONAL INTERVI
   Moniz MH, 2013, J REPROD MED, V58, P383
   Nyhan B, 2014, PEDIATRICS, V133, pE835, DOI 10.1542/peds.2013-2365
   Omer SB, 2017, JAMA PEDIATR, V171, P929, DOI 10.1001/jamapediatrics.2017.2219
   Opel D, 2013, PEDIATRICS, V132, P1
   Orenstein WA, 2015, PUBLIC HEALTH REP, V130, P10
   Reno JE, 2018, J HEALTH COMMUN, V23, P313, DOI 10.1080/10810730.2018.1442530
   Sadique MZ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054149
   Taylor PJ, 2005, J APPL PSYCHOL, V90, P692, DOI 10.1037/0021-9010.90.4.692
   Thaler R. H., 2008, NUDGE IMPROVING DECI
   WITTE K, 1992, COMMUN MONOGR, V59, P329, DOI 10.1080/03637759209376276
   2019, OBSTET GYNECOL, V133, P40
NR 35
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAY 1
PY 2019
VL 37
IS 19
BP 2532
EP 2536
DI 10.1016/j.vaccine.2019.03.005
PG 5
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HV8QU
UT WOS:000466248800003
PM 30962093
OA Green Accepted
DA 2020-05-12
ER

PT J
AU Keersmaekers, N
   Ogunjimi, B
   Van Damme, P
   Beutels, P
   Hens, N
AF Keersmaekers, Nina
   Ogunjimi, Benson
   Van Damme, Pierre
   Beutels, Philippe
   Hens, Niel
TI An ODE-based mixed modelling approach for B- and T-cell dynamics induced
   by Varicella-Zoster Virus vaccines in adults shows higher T-cell
   proliferation with Shingrix than with Varilrix
SO VACCINE
LA English
DT Article
DE Mathematical models; Ordinary differential equations; Mixed effects;
   Varicella Zoster Virus vaccine; Herpes Zoster vaccine; B-cell dynamics;
   T-cell dynamics
AB Clinical trials covering the immunogenicity of a vaccine aim to study the longitudinal dynamics of certain immune cells after vaccination. The corresponding immunogenicity datasets are mainly analyzed by the use of statistical (mixed effects) models. This paper proposes the use of mathematical ordinary differential equation (ODE) models, combined with a mixed effects approach. ODE models are capable of translating underlying immunological post vaccination processes into mathematical formulas thereby enabling a testable data analysis. Mixed models include both population-averaged parameters (fixed effects) and individual-specific parameters (random effects) for dealing with inter- and intra-individual variability, respectively.
   This paper models B-cell and T-cell datasets of a phase I/II, open-label, randomized, parallel-group study (NCT00492648) in which the immunogenicity of a new Herpes Zoster vaccine (Shingrix) is compared with the original Varicella Zoster Virus vaccine (Varilrix).
   Since few significant correlations were found between the B-cell and T-cell datasets, each dataset was modeled separately. By following a general approach to both the formulation of several different models and the procedure of selecting the most suitable model, we were able to propose a mathematical ODE mixed-effects model for each dataset. As such, the use of ODE-based mixed effects models offers a suitable framework for handling longitudinal vaccine immunogenicity data. Moreover, this approach allows testing for differences in immunological processes between vaccines or schedules. We found that the Shingrix vaccination schedule led to a more pronounced proliferation of T-cells, without a difference in T-cell decay rate compared to the Varilrix vaccination schedule. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Keersmaekers, Nina; Ogunjimi, Benson; Beutels, Philippe; Hens, Niel] Univ Antwerp, Vaccine & Infect Dis Inst VAXINFECTIO, CHERMID, Antwerp, Belgium.
   [Keersmaekers, Nina; Ogunjimi, Benson; Van Damme, Pierre; Beutels, Philippe; Hens, Niel] Univ Antwerp, AUDACIS, Antwerp, Belgium.
   [Ogunjimi, Benson] Univ Antwerp, Vaccine & Infect Dis Inst VAXINFECTIO, ACTIV, Antwerp, Belgium.
   [Ogunjimi, Benson] Antwerp Univ Hosp, Dept Paediat, Edegem, Belgium.
   [Van Damme, Pierre] Univ Antwerp, Vaccine & Infect Dis Inst VAXINFECTIO, CEV, Antwerp, Belgium.
   [Hens, Niel] Hasselt Univ, Interuniv Inst Biostat & Stat Bioinformat, Diepenbeek, Belgium.
RP Keersmaekers, N (reprint author), Univ Antwerp, Vaccine & Infect Dis Inst VAXINFECTIO, CHERMID, Antwerp, Belgium.
EM nina.keersmaekers@uantwerp.be
RI Beutels, Philippe/A-1919-2010
OI Beutels, Philippe/0000-0001-5034-3595
FU University of Antwerp [BOF Concerted Research Action, Methusalem
   funding]; GSKGlaxoSmithKline; European Research Council (ERC) under the
   European UnionEuropean Research Council (ERC) [682540 - TransMID];
   Antwerp Study Centre for Infectious Diseases (BID); PfizerPfizer
FX This research was funded by the University of Antwerp [BOF Concerted
   Research Action, Methusalem funding], NH acknowledges support from the
   chair in evidence-based vaccinology sponsored by a gift from Pfizer
   (2009-2018) and GSK (2016) and from the European Research Council (ERC)
   under the European Union's Horizon 2020 research and innovation
   programme (grant agreement 682540 - TransMID). This research was
   supported by the Antwerp Study Centre for Infectious Diseases (BID). The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Andraud M, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002418
   Didierlaurent AM, 2017, EXPERT REV VACCINES, V16, P55, DOI 10.1080/14760584.2016.1213632
   Le D, 2015, FRONT CELL INFECT MI, V4, DOI 10.3389/fcimb.2014.00177
   Reshef DN, 2011, SCIENCE, V334, P1518, DOI 10.1126/science.1205438
   Van Herck K, 2000, J MED VIROL, V60, P1, DOI 10.1002/(SICI)1096-9071(200001)60:1&lt;1::AID-JMV1&gt;3.0.CO;2-H
   2007, J PHARMACOKINET PHAR, V34, P229, DOI DOI 10.1007/S10978-006-9043-Z
   2010, IMMUNOL REV, V236, P125, DOI DOI 10.1111/J.1600-065X.2010.00912.X
   2012, J INFECT DIS, V206, P1280, DOI DOI 10.1093/INFDIS/ISJ497
   2014, VACCINE, V32, P1507, DOI DOI 10.1016/J.VACCINE.2013.10.088
   2015, VACCINE, V33, P5723, DOI DOI 10.1016/J.VACCINE.2015.07.008
   2016, CLIN IMMUNOL, V169, P16, DOI DOI 10.1016/J.CLIM.2016.05.007
NR 11
TC 0
Z9 0
U1 2
U2 8
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAY 1
PY 2019
VL 37
IS 19
BP 2537
EP 2553
DI 10.1016/j.vaccine.2019.03.075
PG 17
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HV8QU
UT WOS:000466248800004
PM 30975567
DA 2020-05-12
ER

PT J
AU Kawade, A
   Babji, S
   Kamath, V
   Raut, A
   Kumar, CM
   Kundu, R
   Venkatramanan, P
   Lalwani, SK
   Bavdekar, A
   Juvekar, S
   Dayma, G
   Patil, R
   Kulkarni, M
   Hegde, A
   Nayak, D
   Garg, BS
   Gupta, S
   Jategaonkar, S
   Bedi, N
   Maliye, C
   Ganguly, N
   Uttam, KG
   Niyogi, P
   Palkar, S
   Hanumante, N
   Goyal, N
   Arya, A
   Aslam, M
   Paruiekar, V
   Dharmadhikari, A
   Gaikwad, D
   Zade, J
   Desai, S
   Kang, G
   Kulkarni, PS
AF Kawade, Anand
   Babji, Sudhir
   Kamath, Veena
   Raut, Abhishek
   Kumar, Chandra Mohan
   Kundu, Ritabrata
   Venkatramanan, Padmasani
   Lalwani, Sanjay K.
   Bavdekar, Ashish
   Juvekar, Sanjay
   Dayma, Girish
   Patil, Rakesh
   Kulkarni, Muralidhar
   Hegde, Asha
   Nayak, Dinesh
   Garg, B. S.
   Gupta, Subodh
   Jategaonkar, Smita
   Bedi, Nidhi
   Maliye, Chetna
   Ganguly, Nupur
   Uttam, Kheya Ghosh
   Niyogi, Prabal
   Palkar, Sonali
   Hanumante, Neeta
   Goyal, Nidhi
   Arya, Alok
   Aslam, Mohd.
   Paruiekar, Varsha
   Dharmadhikari, Abhijeet
   Gaikwad, Dutta
   Zade, Jagdish
   Desai, Sajjad
   Kang, Gagandeep
   Kulkarni, Prasad S.
TI Immunogenicity and lot-to-lot consistency of a ready to use liquid
   bovine-human reassortant pentavalent rotavirus vaccine (ROTASIIL -
   Liquid) in Indian infants
SO VACCINE
LA English
DT Article
DE Liquid Bovine-Human Reassortant; Pentavalent Rotavirus Vaccine
   (LBRV-PV); Lot-to-lot consistency; Immunogenicity; Safety
ID SAFETY; IMPACT; MORTALITY; EFFICACY; CHILDREN; TRIAL; COST
AB Background: A lyophilized bovine-human rotavirus reassortant pentavalent vaccine (BRV-PV, Rotasiil (R)) was licensed in 2016. A liquid formulation of this vaccine (LBRV-PV, Rotasiil - Liquid) was subsequently developed and was tested for non-inferiority to Rotasiil (R) and for lot-to-lot consistency.
   Methods: This Phase open II/III, randomized study was conducted at seven sites across India from November 2017 to June 2018. Participants were randomized into four arms; Lots A, B, and C of LBRV-PV and Rotasiil (R) in 1:1:1:1 ratio. Three doses of study vaccines were given at 6, 10, and 14 weeks of age. Blood samples were collected four weeks after the third dose to assess rotavirus IgA antibody levels. Non-inferiority of LBRV-PV to Rotasiil was proven if the lower limit two-sided 95% confidence interval (CI) of geometric mean concentration (GMC) ratio was at least 0.5. Lot-to-lot consistency was proven if 95% CI of the GMC ratios of three lots were between 0.5 and 2. Solicited reactions were collected by using diary cards.
   Results: Of the 1500 randomized infants, 1436 infants completed the study. The IgA GMC ratio of LBRV-PV to Rotasiil (R) was 1.19 (95% CI 0.96, 1.48). The corresponding IgA seropositivity rates were 60.41% (57.41, 63.35) and 52.75% (47.48, 57.97). The IgA GMC ratios among the three LBRV-PV lots were: Lot A versus Lot B: 1.34 (1.03, 1.75); Lot A versus Lot C: 1.22 (0.93, 1.60); and Lot B versus Lot C: 0.91 (0.69, 1.19). The 95% Cls for the GMC ratios were between 0.69 and 1.75. The incidence of solicited reactions was comparable across the four arms. Only one serious adverse event of gastroenteritis event in the Rotasiil (R) group was causally related.
   Conclusion: The immunological non-inferiority of LBRV-PV against Rotasiil as well as lot-to-lot consistency of LBRV-PV was demonstrated. LBRV-PV had safety profile similar to Rotasiil (R). (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Kawade, Anand; Babji, Sudhir; Bavdekar, Ashish; Juvekar, Sanjay; Dayma, Girish; Patil, Rakesh] KEM Hosp Res Ctr, Vadu Rural Hlth Program, Pune, Maharashtra, India.
   [Babji, Sudhir; Kang, Gagandeep] Christian Med Coll Vellore, Wellcome Trust Res Lab, Vellore, Tamil Nadu, India.
   [Kamath, Veena; Kulkarni, Muralidhar; Hegde, Asha; Nayak, Dinesh] Manipal Acad Higher Educ, Manipal, Karnataka, India.
   [Raut, Abhishek; Garg, B. S.; Gupta, Subodh; Jategaonkar, Smita; Maliye, Chetna] Mahatma Gandhi Inst Med Sci, Sevagram, India.
   [Kumar, Chandra Mohan; Bedi, Nidhi] Hamdard Inst Med Sci & Res, Delhi, India.
   [Kundu, Ritabrata; Ganguly, Nupur; Uttam, Kheya Ghosh; Niyogi, Prabal] Inst Child Hlth Kolkata, Kolkata, India.
   [Venkatramanan, Padmasani] Sri Ramachandra Med Ctr, Chennai, Tamil Nadu, India.
   [Lalwani, Sanjay K.; Palkar, Sonali; Hanumante, Neeta] Bharati Vidyapeeth Med Coll & Hosp, Pune, Maharashtra, India.
   [Goyal, Nidhi; Arya, Alok; Aslam, Mohd.] Soc Appl Studies, Ctr Hlth Res & Dev, Delhi, India.
   [Paruiekar, Varsha] DiagnoSearch Life Sci Pvt Ltd, Mumbai, Maharashtra, India.
   [Dharmadhikari, Abhijeet; Gaikwad, Dutta; Zade, Jagdish; Desai, Sajjad; Kulkarni, Prasad S.] Serum Inst India Pvt Ltd, 212-2 Hadapsar, Pune, Maharashtra, India.
RP Kulkarni, PS (reprint author), Serum Inst India Pvt Ltd, 212-2 Hadapsar, Pune, Maharashtra, India.
EM drpsk@seruminstitute.com
RI Raut, Abhishek/O-2936-2017
OI Raut, Abhishek/0000-0001-5671-5329
FU SIIPL
FX The study was funded by SIIPL.
CR Anil K, 2018, VACCINE, V36, P1542, DOI 10.1016/j.vaccine.2018.02.024
   [Anonymous], 2013, Wkly Epidemiol Rec, V88, P49
   Clinical considerations for evaluation of vaccines for prequalification, 2010, CLIN CONSIDERATIONS
   Desai S, 2018, VACCINE, V36, P5519, DOI 10.1016/j.vaccine.2018.07.064
   ELLA R, 2018, HUM VACC IMMUNOTHER, V15, P1
   Inchauste L, 2017, INT J INFECT DIS, V61, P79, DOI 10.1016/j.ijid.2017.06.006
   Isanaka S, 2017, NEW ENGL J MED, V376, P1121, DOI [10.1056/nejmoa1609462, 10.1056/NEJMoa1609462]
   Jonesteller CL, 2017, CLIN INFECT DIS, V65, P840, DOI 10.1093/cid/cix369
   Kulkarni PS, 2017, VACCINE, V35, P6228, DOI 10.1016/j.vaccine.2017.09.014
   Lokeshwar MR, 2013, HUM VACC IMMUNOTHER, V9, P172, DOI 10.4161/hv.22341
   Naik SP, 2017, VACCINE, V35, P2962, DOI 10.1016/j.vaccine.2017.04.025
   Narang A, 2009, HUM VACCINES, V5, P414, DOI 10.4161/hv.5.6.8176
   Paul A, 2014, VACCINE, V32, P3094, DOI 10.1016/j.vaccine.2014.03.013
   Pecenka C, 2017, VACCINE, V35, P3982, DOI 10.1016/j.vaccine.2017.05.087
   Paulo RLP, 2016, REV ASSOC MED BRAS, V62, P506, DOI 10.1590/1806-9282.62.06.506
   Rathi N, 2018, VACCINE, V36, P7943, DOI 10.1016/j.vaccine.2018.11.006
   SANTOS VS, 2016, INFECT DIS POVERTY, V5
   Tate JE, 2016, CLIN INFECT DIS, V62, pS96, DOI 10.1093/cid/civ1013
   Vesikari T, 2011, VACCINE, V29, P2079, DOI 10.1016/j.vaccine.2011.01.004
   Zade JK, 2014, VACCINE, V32, pA124, DOI 10.1016/j.vaccine.2014.03.003
NR 20
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAY 1
PY 2019
VL 37
IS 19
BP 2554
EP 2560
DI 10.1016/j.vaccine.2019.03.067
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HV8QU
UT WOS:000466248800005
PM 30955982
DA 2020-05-12
ER

PT J
AU El Sahly, HM
   Atmar, RL
   Patel, SM
   Bellamy, A
   Liu, LW
   Hong, WS
   Zhu, HC
   Guan, Y
   Keitel, WA
   Jackson, LA
   Campbell, JD
   Frey, SE
   Edwards, KM
   Keitel, WA
   Kotloff, KL
   Berry, AA
   Graham, I
   Atmar, RL
   Creech, B
   Thomsen, I
   Patel, SM
   Gutierrez, AF
   Anderson, EL
   El Sahly, HM
   Hill, H
   Noah, DL
   Bellamy, A
AF El Sahly, Hana M.
   Atmar, Robert L.
   Patel, Shital M.
   Bellamy, Abbie
   Liu, Liwei
   Hong, Wenshan
   Zhu, Huachen
   Guan, Yi
   Keitel, Wendy A.
   Jackson, Lisa A.
   Campbell, James D.
   Frey, Sharon E.
   Edwards, Kathryn M.
   Keitel, Wendy A.
   Kotloff, Karen L.
   Berry, Andrea A.
   Graham, Irene
   Atmar, Robert L.
   Creech, Buddy
   Thomsen, Isaac
   Patel, Shital M.
   Gutierrez, Andres F.
   Anderson, Edwin L.
   El Sahly, Hana M.
   Hill, Heather
   Noah, Diana L.
   Bellamy, Abbie
CA DMID 13-0033 Vaccine Study Grp
TI Safety and immunogenicity of an 8 year interval heterologous prime-boost
   influenza A/H7N7-H7N9 vaccination
SO VACCINE
LA English
DT Article
DE Influenza A/H7N9; Prime-boost; Vaccines; Pandemic; Avian; Influenza
ID 5 EPIDEMIC WAVES; ANTIBODY; RESPONSES; PATHOGENESIS; VIRUSES
AB Background: Influenza A/H7N9 viruses are undergoing antigenic drift since their emergence in 2013, and vaccination strategies are needed for pandemic preparedness. Two doses of adjuvanted monovalent inactivated influenza A/H7N9 vaccine (IIV1 A/H7N9) are needed for optimal serological responses. However, administering 2 doses in a pandemic setting might be challenging. We evaluated the immunogenicity of "boosting" with IIVI A/H7N9 in subjects "primed" 8 years previously with IIV1 A/H7N7.
   Methods: We administered 1 booster dose containing 45 mcg of IIVI A/H7N9 hemagglutinin to 17 recipients of 2 prior doses of IIV1 A/H7N7, and to 10 influenza A/H7-naive subjects. We tested their post-boosting sera for antibodies (Ab) against homologous influenza A/H7N9 using a hemagglutination inhibition assay; and compared their Ab titers to those in stored sera from recipients of AS03-adjuvanted IIVI A/H7N9 against 9 strains of influenza A/H7N9 viruses.
   Results: The percentage of subjects with Ab titers >= 40 on Days 9 and 29 post boosting, respectively, was 65% and 41% in primed subjects and 10% and 0% in unprimed subjects. The Ab titers in recipients of AS03-adjuvanted IIV1 A/H7N9 were higher than those in the prime-boost group against a panel of influenza A/H7N9 viruses, except for 2 highly pathogenic strains.
   Conclusions: Priming with IIVI A/H7 results in serological responses following a delayed boost with 1 dose of unadjuvanted IIV1 A/H7N9, despite lack of antibody response after the prime. Optimizing prime-boost approaches would benefit pandemic preparedness. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [El Sahly, Hana M.; Keitel, Wendy A.] Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA.
   [Atmar, Robert L.; Patel, Shital M.] Baylor Coll Med, Dept Med, Infect Dis Sect, Houston, TX 77030 USA.
   [Bellamy, Abbie] Emmes Corp, Rockville, MD USA.
   [Liu, Liwei; Hong, Wenshan; Zhu, Huachen; Guan, Yi] Shantou Univ, Coll Med, Joint Inst Virol Shantou Univ The Univ Hong Kong, Shantou, Guangdong, Peoples R China.
   [Guan, Yi] Univ Hong Kong, Sch Publ Hlth, State Key Lab Emerging Infect Dis, Hong Kong, Peoples R China.
RP El Sahly, HM (reprint author), Dept Mol Virol & Microbiol, One Baylor Plaza,BCM MS 280, Houston, TX 77030 USA.
EM hanae@bcm.edu
RI Zhu, Huachen/A-8252-2017
OI Zhu, Huachen/0000-0003-2711-0501; Patel, Shital/0000-0003-2828-6250;
   Guan, Yi/0000-0001-6057-9243
FU National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [HHSN2722013000151,
   HHSN272200800002C, HHSN272201500002C, HHSN272201400006C]; Hong Kong
   Research Grant CouncilHong Kong Research Grants Council [17127714];
   National Key Plan for Scientific Research and Development of China
   [2016YFD0500302]
FX Funding for this project was provided by the National Institutes of
   Health, contracts HHSN2722013000151, HHSN272200800002C,
   HHSN272201500002C, and HHSN272201400006C; Hong Kong Research Grant
   Council (17127714) and The National Key Plan for Scientific Research and
   Development of China (2016YFD0500302).
CR Babu TM, 2014, VACCINE, V32, P6798, DOI 10.1016/j.vaccine.2014.09.070
   Belser JA, 2013, NATURE, V501, P556, DOI 10.1038/nature12391
   Cheng W, 2018, INFLUENZA OTHER RESP, V12, P259, DOI 10.1111/irv.12532
   Couch RB, 2013, J INFECT DIS, V207, P974, DOI 10.1093/infdis/jis935
   Couch RB, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049704
   Ding X, 2017, INFECT GENET EVOL, V55, P269, DOI 10.1016/j.meegid.2017.09.027
   Galli G, 2009, P NATL ACAD SCI USA, V106, P7962, DOI 10.1073/pnas.0903181106
   Goji NA, 2008, J INFECT DIS, V198, P635, DOI 10.1086/590916
   Halliley JL, 2015, J INFECT DIS, V212, P1270, DOI 10.1093/infdis/jiv210
   Jackson LA, 2015, JAMA-J AM MED ASSOC, V314, P237, DOI 10.1001/jama.2015.7916
   Keitel WA, 2008, J INFECT DIS, V198, P1016, DOI 10.1086/591465
   Khurana S, 2013, J INFECT DIS, V208, P413, DOI 10.1093/infdis/jit178
   Mulligan MJ, 2014, JAMA-J AM MED ASSOC, V312, P1409, DOI 10.1001/jama.2014.12854
   Noah DL, 2009, CLIN VACCINE IMMUNOL, V16, P558, DOI 10.1128/CVI.00368-08
   Su S, 2017, TRENDS MICROBIOL, V25, P713, DOI 10.1016/j.tim.2017.06.008
   Treanor JJ, 2006, NEW ENGL J MED, V354, P1343, DOI 10.1056/NEJMoa055778
   Wan HQ, 2018, J VIROL, V92, DOI 10.1128/JVI.01588-17
   Wu HC, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0180763
   Zhu W, 2017, EURO SURVEILL, V22
NR 19
TC 1
Z9 1
U1 0
U2 5
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAY 1
PY 2019
VL 37
IS 19
BP 2561
EP 2568
DI 10.1016/j.vaccine.2019.03.071
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HV8QU
UT WOS:000466248800006
PM 30955980
DA 2020-05-12
ER

PT J
AU Lima, L
   Molina, MDF
   Pereira, BS
   Nadaf, MLA
   Nadaf, MIV
   Takano, OA
   Carneiro-Sampaio, M
   Palmeira, P
AF Lima, Laila
   Fortunato Molina, Mariela da Gama
   Pereira, Beatriz Sena
   Ale Nadaf, Marvin Lucas
   Valdomir Nadaf, Maria Isabel
   Takano, Olga Akiko
   Carneiro-Sampaio, Magda
   Palmeira, Patricia
TI Acquisition of specific antibodies and their influence on cell-mediated
   immune response in neonatal cord blood after maternal pertussis
   vaccination during pregnancy
SO VACCINE
LA English
DT Article
DE Bordetella pertussis; Tdap vaccine in pregnancy; IgG placental transfer;
   Neonatal T-cell response
ID BORDETELLA-PERTUSSIS; PLACENTAL-TRANSFER; WHOLE-CELL; IMMUNIZATION;
   INFANTS; PROTECTION; CYTOKINES
AB Maternal immunization with pertussis acellular vaccine (Tdap) is an intervention that provides protection to newborns. However, it has been reported that high maternal antibody levels may adversely affect the immune response of infants after active immunization. In this study, we evaluated neonatal passive acquisition of pertussis-specific antibodies and their influence on the neonatal cell-mediated immune response.
   Pregnant women were either vaccinated with Tdap vaccine (case group, n = 66) or received no vaccine (control group, n = 101). Whole-cell Bordetella pertussis (Bp), pertussis toxin (PT), filamentous hemagglutinin (FHA) and pertactin (PRN)-specific serum IgG were quantified in paired maternal-cord sera, and Bp- and PT-specific IgA were evaluated in colostrum by ELISA. Ex vivo neonatal blood lymphocyte responsiveness after Bp stimulation was assessed in case (n = 17) and control (n = 15) groups using flow cytometry to detect proliferation, cytokine production and activation phenotype of lymphocytes in the context of high specific IgG acquired after maternal vaccination.
   Anti-Bp, PT, FHA and PRN IgG concentrations in maternal and cord sera from case group were higher than those in control group with positive correlation indexes in both groups for all pertussis antigens. The control group presented higher placental transfer ratios of specific antibodies and, in the case group, vaccination between 26 and 31 gestation weeks was associated with the best placental transfer ratios. Specific IgA concentrations in colostrum were not affected by vaccine status. Whole blood assays revealed that newborns responded to Bp stimulation with higher expression of CD40L, CD69 and CD4(+) T cell proliferation compared to unstimulated cells, and a lower Thl response, while a preserved Th2 response compared to adults, but there were no differences between the neonatal groups for any of the studied parameters.
   Our results indicate that higher pertussis-specific IgG levels in newborn sera after maternal vaccination do not affect the neonatal ex vivo cell-mediated immune response. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Lima, Laila; Pereira, Beatriz Sena; Carneiro-Sampaio, Magda] Univ Sao Paulo, Fac Med, Dept Pediat, Sao Paulo, SP, Brazil.
   [Fortunato Molina, Mariela da Gama; Ale Nadaf, Marvin Lucas; Valdomir Nadaf, Maria Isabel; Takano, Olga Akiko] Univ Fed Mato Grosso, Dept Pediat, Cuiaba, MT, Brazil.
   [Palmeira, Patricia] Univ Sao Paulo, Fac Med, Hosp Clin, Dept Pediat,Lab Med Invest LIM 36, Sao Paulo, SP, Brazil.
RP Lima, L (reprint author), Univ Sao Paulo, Fac Med, Dept Pediat, Inst Crianca,LIM 36, Ave Dr Eneas Carvalho de Aguiar 647,5 Andar, BR-05403900 Sao Paulo, SP, Brazil.
EM lailalima@usp.br
RI TAKANO, OLGA AKIKO/AAA-8473-2019
FU FAPEMAT (Fundacao de Amparo a Pesquisa do Estado de Mato Grosso, MT,
   Brazil) [005/2015, 221674/2015]; CAPES (Coordenacao de Aperfeicoamento
   de Pessoal de Nivel Superior, Brazil)CAPES
FX Financial support was provided by FAPEMAT (Fundacao de Amparo a Pesquisa
   do Estado de Mato Grosso, MT, Brazil), Public announcement Universal
   005/2015, Grant 221674/2015 and by CAPES (Coordenacao de Aperfeicoamento
   de Pessoal de Nivel Superior, Brazil).
CR Abu Raya B, 2014, VACCINE, V32, P5632, DOI 10.1016/j.vaccine.2014.08.006
   Agarwal S, 2011, J HUM LACT, V27, P171, DOI 10.1177/0890334410395761
   Basha S, 2014, EXPERT REV CLIN IMMU, V10, P1171, DOI 10.1586/1744666X.2014.942288
   Boulton Jacqueline, 2013, Br J Nurs, V22, P1046
   Carbonetti NH, 2015, PATHOG DIS, V73, DOI 10.1093/femspd/ftv073
   Carollo M, 2012, VACCINE, V30, P1667, DOI 10.1016/j.vaccine.2011.12.104
   Denkinger CM, 2007, CELL IMMUNOL, V246, P46, DOI 10.1016/j.cellimm.2007.05.004
   Dirix V, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/795958
   Dubin PJ, 2008, IMMUNOL REV, V226, P160, DOI 10.1111/j.1600-065X.2008.00703.x
   Englund JA, 2007, J COMP PATHOL, V137, pS16, DOI 10.1016/j.jcpa.2007.04.006
   Goenka A, 2015, J INFECTION, V71, pS112, DOI 10.1016/j.jinf.2015.04.027
   Grondahl-Yli-Hannuksela K, 2016, VACCINE, V34, P341, DOI 10.1016/j.vaccine.2015.11.049
   Hoang HTT, 2016, VACCINE, V34, P151, DOI 10.1016/j.vaccine.2015.10.098
   Healy CM, 2007, PEDIATR INFECT DIS J, V26, P945, DOI 10.1097/INF.0b013e318156c18c
   Hodder SL, 2000, CLIN INFECT DIS, V31, P7, DOI 10.1086/313913
   Jones C, 2014, VACCINE, V32, P996, DOI 10.1016/j.vaccine.2013.11.104
   Le Doare K, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01269
   Maertens K, 2014, VACCINE, V32, P1786, DOI 10.1016/j.vaccine.2014.01.083
   Mattoo S, 2005, CLIN MICROBIOL REV, V18, P326, DOI 10.1128/CMR.18.2.326-382.2005
   McGuirk P, 2002, J EXP MED, V195, P221, DOI 10.1084/jem.20011288
   Mills KHG, 2001, MICROBES INFECT, V3, P655, DOI 10.1016/S1286-4579(01)01421-6
   Ministerio da Saude, 2015, B EPIDEMIOL, V46, P1
   Miyano Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064777
   Munoz FM, 2014, JAMA-J AM MED ASSOC, V311, P1760, DOI 10.1001/jama.2014.3633
   Nagao AT, 1998, SCAND J IMMUNOL, V47, P609
   Naidu MA, 2016, AM J OBSTET GYNECOL, V215, DOI 10.1016/j.ajog.2016.03.002
   Nieves DJ, 2016, MICROBIOL SPECTR, V4, DOI 10.1128/microbiolspec.EI10-0008-2015
   Niewiesk S, 2015, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00446
   Palazzo R, 2016, NEW MICROBIOL, V39, P35
   Palmeira P, 2016, REV ASSOC MED BRAS, V62, P584, DOI 10.1590/1806-9282.62.06.584
   Palmeira P, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/985646
   Pandolfi E, 2017, PEDIATR INFECT DIS J, V36, pE48, DOI 10.1097/INF.0000000000001418
   Plotkin SA, 2010, CLIN VACCINE IMMUNOL, V17, P1055, DOI 10.1128/CVI.00131-10
   Quinello C, 2010, SCAND J IMMUNOL, V72, P66, DOI 10.1111/j.1365-3083.2010.02410.x
   Raphael I, 2015, CYTOKINE, V74, P5, DOI 10.1016/j.cyto.2014.09.011
   Raya B. A., 2014, Vaccine, V32, P5787, DOI 10.1016/j.vaccine.2014.08.038
   Saso A, 2017, SEMIN IMMUNOPATHOL, V39, P627, DOI 10.1007/s00281-017-0654-9
   Shahid NS, 2002, VACCINE, V20, P2404, DOI 10.1016/S0264-410X(02)00061-0
   Siegrist CA, 2003, VACCINE, V21, P3406, DOI 10.1016/S0264-410X(03)00342-6
   Simister NE, 2003, VACCINE, V21, P3365, DOI 10.1016/S0264-410X(03)00334-7
   Smits K, 2013, VACCINE, V32, P111, DOI 10.1016/j.vaccine.2013.10.056
   Soares A, 2010, J IMMUNOL METHODS, V362, P43, DOI 10.1016/j.jim.2010.08.007
   Vermeulen F, 2010, CLIN VACCINE IMMUNOL, V17, P258, DOI 10.1128/CVI.00328-09
   WHICHER JT, 1983, CRC CR REV CL LAB SC, V18, P213
   WHO, 2016, VACC PREV DIS MON SY
   Winter K, 2012, J PEDIATR-US, V161, P1091, DOI 10.1016/j.jpeds.2012.05.041
   Wolfe DN, 2007, J INFECT DIS, V196, P1228, DOI 10.1086/521303
   2015, CLIN INFECT DIS, V60, P333
   2013, PEDIAT INFECT DIS J, V32, P1257
NR 49
TC 1
Z9 1
U1 0
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAY 1
PY 2019
VL 37
IS 19
BP 2569
EP 2579
DI 10.1016/j.vaccine.2019.03.070
PG 11
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HV8QU
UT WOS:000466248800007
PM 30955978
DA 2020-05-12
ER

PT J
AU Schartau, S
   Holt, DH
   Lutzen, T
   Rytter, D
   Molbak, K
AF Schartau, Sara
   Holt, Ditte Heering
   Lutzen, Tina
   Rytter, Dorte
   Molbak, Kare
TI On the contextual nature of vaccine safety monitoring: Adverse events
   reporting after HPV-vaccination in Denmark, 2015
SO VACCINE
LA English
DT Article
DE Adverse events following vaccination; HPV vaccine; Vaccine safety
   monitoring; Passive surveillance systems; Human papilloma virus
ID THEORETICAL DOMAINS FRAMEWORK
AB Background: In 2013-15, Denmark experienced an increase in reported suspected adverse events following vaccination (AEFI) against human papilloma virus (HPV). Dedicated centres ("One Access") were established in order to standardize management of patients who experienced medically unexplained physical symptoms after HPV vaccination. Since One Access was targeted patients with suspected AEFI after HPV vaccination, we used this opportunity to estimate completeness in AEFI reporting to the Danish Medicines Agency (DMA), and explore the topic of AEFI reporting from the perspective of physicians working at the centres to better understand health professionals' reporting behaviour.
   Methods: The study consisted of a quantitative and a qualitative part. In the quantitative analysis, we used the Danish civil registry number to merge a line-list of all One Access patients referred in 2015 with total number of patients who had reported suspected serious AEFI following HPV vaccination to the DMA in the years 2009-2015. We conducted four semi-structured interviews with doctors representing three out of five regions. The Theoretical Domains Framework together with empirical data from two clinical fieldtrips guided the formation of the qualitative study.
   Results: Among 1577 One Access patients, only 404 (26%) were reported to the DMA. We found significant regional differences in reporting completeness (p < 0.001) and differences between regions when looking at reporters' backgrounds (healthcare professionals vs non-professionals; p = 0.004). We identified several factors of importance for reporting behaviour amongst physicians, mainly under the domains of Knowledge, Motivation & Goals, and Environmental Context.
   Conclusions: Despite an official aim of homogenous case management, reporting of suspected AEFI was incomplete with large regional differences. The qualitative study corroborated that reporting behaviour was contextual. This observation represents an important caveat in interpreting data from AEFI reporting, in particular when these data are used for research or policymaking. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Schartau, Sara; Molbak, Kare] Statens Serum Inst, Div Infect Dis Preparedness, Copenhagen, Denmark.
   [Holt, Ditte Heering] Univ Southern Denmark, Natl Inst Publ Hlth, Odense, Denmark.
   [Lutzen, Tina; Rytter, Dorte] Aarhus Univ, Dept Publ Hlth, Aarhus, Denmark.
   [Molbak, Kare] Univ Copenhagen, Fac Hlth & Med Sci, Inst Vet & Anim Sci, Copenhagen, Denmark.
RP Molbak, K (reprint author), Statens Serum Inst, Div Infect Dis Preparedness, Copenhagen, Denmark.; Molbak, K (reprint author), Univ Copenhagen, Fac Hlth & Med Sci, Inst Vet & Anim Sci, Copenhagen, Denmark.
EM sara_schartau@hotmail.com; dihh@si-folke-sundhed.dk;
   tina.lutzen@ph.au.dk; dr@ph.au.dk; krm@ssi.dk
OI Lutzen, Tina/0000-0002-5384-2557
CR Brinth L., 2015, INT J VACCINES VACCI, V1, DOI [10.15406/ijvv.2015.01.00003, DOI 10.15406/ijvv.2015.01.00003, 10.15406/jvv.2015.01.00003]
   Brinth L, 2015, DAN MED J, V62
   Brinth LS, 2015, VACCINE, V33, P2602, DOI 10.1016/j.vaccine.2015.03.098
   Chandler RE, 2017, DRUG SAFETY, V40, P81, DOI 10.1007/s40264-016-0456-3
   Danish Medicines Agency, 2018, INTERACTIVE ADVERSE
   Duclos P, 1997, CAN FAM PHYSICIAN, V43, P1551
   Hansen P. R., 2018, PROGRAM
   Irujo M, 2007, DRUG SAFETY, V30, P1073, DOI 10.2165/00002018-200730110-00006
   Kingston MJ, 2004, MED J AUSTRALIA, V181, P36, DOI 10.5694/j.1326-5377.2004.tb06158.x
   LAZEN TH, 2017, CLIN EPIDEMIOL, V9, P465
   Leask J, 2009, VACCINE, V27, P5505, DOI 10.1016/j.vaccine.2009.06.102
   MALTERUD K, 2015, QUAL HEALTH RES
   Meranus D, 2012, PHARMACOEPIDEM DR S, V21, P269, DOI 10.1002/pds.2245
   Michie S, 2005, QUAL SAF HEALTH CARE, V14, P26, DOI 10.1136/qshc.2004.011155
   Mirbaha F, 2015, IMPLEMENT SCI, V10, DOI 10.1186/s13012-015-0302-5
   Molbak K, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0162520
   Parrella A, 2013, BMC HEALTH SERV RES, V13, DOI 10.1186/1472-6963-13-313
   Phillips CJ, 2015, J MULTIDISCIP HEALTH, V8, P139, DOI 10.2147/JMDH.S78458
   SHIMABUKURO TT, 2015, VACCINE, V7, P3
   *SUNDH, 2003, DOCUMENT IN DANISH, V6
   Sundhedsstyrelsen, 2016, WORKING PAPER
   Suppli CH, 2018, BMC PUBLIC HEALTH, V18, DOI 10.1186/s12889-018-6268-x
   TjOrnhOj-Thomsen T., 2008, RES METHODS PUBLIC H, P91
   WARING JJ, 2004, SOC SCI MED, V8, P55
   Weye N, 2018, EUR J PUBLIC HEALTH, V28, P1109, DOI 10.1093/eurpub/cky088
NR 25
TC 0
Z9 0
U1 2
U2 6
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAY 1
PY 2019
VL 37
IS 19
BP 2580
EP 2585
DI 10.1016/j.vaccine.2019.03.057
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HV8QU
UT WOS:000466248800008
PM 30967312
DA 2020-05-12
ER

PT J
AU Odutola, A
   Ota, MOC
   Antonio, M
   Ogundare, EO
   Saidu, Y
   Owiafe, PK
   Worwui, A
   Idoko, OT
   Owolabi, O
   Kampmann, B
   Greenwood, BM
   Alderson, M
   Traskine, M
   Swinnen, K
   Verlant, V
   Dobbelaere, K
   Borys, D
AF Odutola, Aderonke
   Ota, Martin O. C.
   Antonio, Martin
   Ogundare, Ezra O.
   Saidu, Yauba
   Owiafe, Patrick K.
   Worwui, Archibald
   Idoko, Olubukola T.
   Owolabi, Olumuyiwa
   Kampmann, Beate
   Greenwood, Brian M.
   Alderson, Mark
   Traskine, Magali
   Swinnen, Kristien
   Verlant, Vincent
   Dobbelaere, Kurt
   Borys, Dorota
TI Immunogenicity of pneumococcal conjugate vaccine formulations containing
   pneumococcal proteins, and immunogenicity and reactogenicity of
   co-administered routine vaccines - A phase II, randomised,
   observer-blind study in Gambian infants
SO VACCINE
LA English
DT Article
DE Streptococcus pneumoniae; Pneumococcal protein-containing vaccine;
   Immunogenicity; Pneumococcal serotype-specific polysaccharide;
   Paediatric vaccination
ID STREPTOCOCCUS-PNEUMONIAE; SAFETY; DISEASE
AB Background: Two conserved pneumococcal proteins, pneumolysin toxoid (dPly) and pneumococcal histidine triad protein D (PhtD), combined with 10 polysaccharide conjugates from the pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccine (PHiD-CV) in two investigational pneumococcal vaccine (PHiD-CV/dPly/PhtD) formulations were immunogenic and well-tolerated when administered to Gambian children. Here, we report immunogenicity of the polysaccharide conjugates, and immunogenicity and reactogenicity of co-administered routine vaccines.
   Methods: In this phase II, controlled, observer-blind, single-centre study, healthy infants aged 810 weeks were randomised (1:1:1:1:1:1) to six groups. Four groups received 3+0 schedule (2-3-4 months [M]) of PHiD-CV/dPly/PhtD (10 or 3014 of each protein), PHiD-CV, or 13-valent pneumococcal conjugate vaccine; and two groups received 2+1 schedule (2-4-9 M) of PHiD-CV/dPly/PhtD (30 mu g of each protein) or PHiD-CV. All infants received diphtheria-tetanus-whole cell pertussis-hepatitis B-Haemophilus influenzae type b (DTPw-HBV/Hib) and oral trivalent polio vaccines (OPV) at 2-3-4 M, and measles, yellow fever, and OPV vaccines at 9 M. We evaluated immune responses at 2-5-9-12 M; and reactogenicity 0-3 days post-vaccination.
   Results: 1200 infants were enrolled between June 2011 and May 2012; 1152 completed the study. 1 M post-primary vaccination, for each PHiD-CV serotype except 6B and 23F, >= 97.4% (3+0 schedule) and >= 96.4% (2+1 schedule) of infants had antibody concentrations >= 0.2 mu g/mL. Immune responses were comparable between groups within the same vaccination schedules. Observed antibody geometric mean concentrations (GMCs) increased by 1 M post-primary vaccination compared to pre-vaccination. In the following months, GMCs and opsonophagocytic activity titres waned, with an increase post-booster for the 2+1 schedule. Immune responses to protein D and, DTPw-HBV/Hib, OPV, measles, and yellow fever vaccines were not altered by co-administration with pneumococcal proteins. Reactogenicity of co-administered vaccines was comparable between groups and did not raise concerns.
   Conclusion: Immune responses to the 10 PHiD-CV polysaccharide conjugates-administered vaccines were not altered by addition of dPly and PhtD. (C) 2019 GlaxoSmithKline Biologicals SA. Published by Elsevier Ltd.
C1 [Odutola, Aderonke; Ota, Martin O. C.; Antonio, Martin; Ogundare, Ezra O.; Saidu, Yauba; Owiafe, Patrick K.; Worwui, Archibald; Idoko, Olubukola T.; Owolabi, Olumuyiwa; Kampmann, Beate] London Sch Hyg & Trop Med, Med Res Council Unit Gambia, Vaccines & Immun Theme, Banjul, Gambia.
   [Kampmann, Beate; Greenwood, Brian M.] London Sch Hyg & Trop Med, Fac Infect & Trop Dis, London, England.
   [Alderson, Mark] PATH, Seattle, WA USA.
   [Ota, Martin O. C.; Traskine, Magali; Swinnen, Kristien; Verlant, Vincent; Dobbelaere, Kurt; Borys, Dorota] GSK, Wavre, Belgium.
   [Saidu, Yauba] Clinton Hlth Access Initiat, Yaounde, Cameroon.
RP Odutola, A (reprint author), London Sch Hyg & Trop Med, Med Res Council Unit Gambia, Vaccines & Immun Theme, Banjul, Gambia.
EM aderonke.odutola@Ishtm.ac.uk; martin.x.ota@gsk.com; mantonio@mrc.gm;
   tundeyogundare@yahoo.com; ysaidu@clintonhealthaccess.org;
   pkowiafe@uhas.edu.gh; aworwui@mrc.gm; oidoko@mrc.gm; oowolabi@mrc.gm;
   bkampmann@mrc.gm; Brian.Greenwood@lshtm.ac.uk; malderson@path.org;
   magali.x.traskine@gsk.com; kristien.m.swinnen@gsk.com;
   vincent.verlant@gsk.com; dobbelaerekurt@gmail.com;
   dorota.d.borys@gsk.com
RI Ogundare, Ezra/AAM-8171-2020
OI Ogundare, Ezra/0000-0003-0082-0001
FU PATH, Seattle, USA; GlaxoSmithKline Biologicals SA,
   BelgiumGlaxoSmithKline
FX The study was funded by PATH, Seattle, USA, and GlaxoSmithKline
   Biologicals SA, Belgium. PATH was involved in the study design, data
   analysis, and data interpretation. GlaxoSmithKline Biologicals SA
   designed the study in collaboration with PATH, London School of Hygiene
   & Tropical Medicine (LSHTM), and the Medical Research Council (MRC)
   investigators, and coordinated collection, analysis, and interpretation
   of data.
CR Alderson MR, 2016, VACCINE, V34, P2959, DOI 10.1016/j.vaccine.2016.03.107
   Centers for Disease Control, 2017, GLOB PNEUM DIS VACC
   de Oliveira LH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166736
   Dicko A, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-882
   Domingues CMAS, 2014, LANCET RESP MED, V2, P464, DOI 10.1016/S2213-2600(14)70060-8
   Ginsburg AS, 2012, EXPERT REV VACCINES, V11, P279, DOI [10.1586/ERV.12.5, 10.1586/erv.12.5]
   IVAC, 2017, PNEUM CONJ VACC PCV
   Johnson HL, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000348
   Odutola A, 2016, HUM VACC IMMUNOTHER, V12, P393, DOI 10.1080/21645515.2015.1111496
   Odutola A, 2017, VACCINE, V35, P2531, DOI 10.1016/j.vaccine.2017.03.071
   Palmu AA, 2013, LANCET, V381, P214, DOI 10.1016/S0140-6736(12)61854-6
   Pilishvili T, 2010, J INFECT DIS, V201, P32, DOI 10.1086/648593
   Poolman JT, 2010, CLIN VACCINE IMMUNOL, V17, P134, DOI 10.1128/CVI.00289-09
   Prymula R, 2017, VACCINE, V35, P4603, DOI 10.1016/j.vaccine.2017.07.008
   Prymula R, 2014, VACCINE, V32, P3025, DOI 10.1016/j.vaccine.2014.03.066
   RomeroSteiner S, 1997, CLIN DIAGN LAB IMMUN, V4, P415, DOI 10.1128/CDLI.4.4.415-422.1997
   Seiberling M, 2012, VACCINE, V30, P7455, DOI 10.1016/j.vaccine.2012.10.080
   Sirima Sodiomon B, 2017, Pediatr Infect Dis J, V36, pe136, DOI 10.1097/INF.0000000000001518
   Tregnaghi MW, 2014, PLOS MED, V11, DOI 10.1371/journal.pmed.1001657
   Vesikari T, 2009, PEDIATR INFECT DIS J, V28, P563, DOI 10.1097/INF.0b013e31819d6394
   Whitney CG, 2003, NEW ENGL J MED, V348, P1737, DOI 10.1056/NEJMoa022823
   *WHO, 1993, [No title captured]
   World Health Organization, 2017, TABL 2 SUMM WHO POS
   World Health Organization, 2012, WKLY EPIDEMIOL REC, V87, P129
   World Health Organization, 2017, TABLE 1 SUMMARY OF W
   2013, VACCINE, V31, P327, DOI DOI 10.1016/J.VACCINE.2012.11.005
   2014, VACCINE, V32, P6838, DOI DOI 10.1016/JVACCINE2014020.57
   2014, LANCET RESP MED, V2, P717, DOI DOI 10.1016/52213-2600(14)70139-0
NR 28
TC 4
Z9 4
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAY 1
PY 2019
VL 37
IS 19
BP 2586
EP 2599
DI 10.1016/j.vaccine.2019.03.033
PG 14
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HV8QU
UT WOS:000466248800009
PM 30975570
OA Other Gold, Green Accepted
DA 2020-05-12
ER

PT J
AU Inoue, M
   Yonemura, T
   de Solom, R
   Yamaji, M
   Aizawa, M
   Knirsch, C
   Pride, MW
   Jansen, KU
   Gruber, W
   Webber, C
AF Inoue, Megumi
   Yonemura, Takuma
   de Solom, Richard
   Yamaji, Masako
   Aizawa, Masakazu
   Knirsch, Charles
   Pride, Michael W.
   Jansen, Kathrin U.
   Gruber, William
   Webber, Chris
TI A phase 1 randomized study assessing safety and immunogenicity of two
   3-dose regimens of a Clostridium difficile vaccine in healthy older
   Japanese adults
SO VACCINE
LA English
DT Article
DE Clostridium difficile infection; Older adults; Japan; Nosocomial
   diarrhea; Toxoid vaccine
ID INFECTION; TRANSPLANTATION; EPIDEMIOLOGY; DIAGNOSIS; THERAPY; BURDEN;
   TOXIN; CHINA
AB Background: Clostridium difficile infection (CDI) is a major global cause of nosocomial and community-acquired infections. Despite potentially severe or fatal complications and frequent recurrence, no preventive vaccine is currently available. This randomized, observer-blinded, placebo-controlled phase 1 study in older Japanese adults evaluated safety and immunogenicity of an investigational C difficile vaccine containing a mixture of genetically detoxified and chemically inactivated toxoids, A and B.
   Methods: Healthy Japanese adults aged 65 to 85 years were randomized in a 3:3:2 ratio to receive 100 or 200 mu g of C difficile vaccine or placebo, respectively, at 0, 1, and 6 months (month regimen) or 1, 8, and 30 days (day regimen). The primary objective was safety evaluation. Vaccine immunogenicity, the secondary objective, was determined by assessing toxin A- and toxin B-specific neutralizing antibody levels in human sera.
   Results: Local reactions were reported by up to 33.3% of subjects per dose in the month regimen; percentages were generally higher in the 200-mu g group. Such reactions were all mild or moderate in severity and generally transient. No adverse events in the month regimen led to subject withdrawal, and no serious adverse events were considered vaccine related. Further enrollment and dosing in the day regimen were discontinued after 3 subjects in the 100-mu g group reported severe redness after dose 2. In the month regimen study arm, immune responses as measured by toxin -neutralizing antibody geometric mean concentrations, geometric mean fold rises, and proportions of subjects achieving prespecified fold rises were generally higher in the 200-mu g group, peaked at month 7, and remained elevated at month 12.
   Conclusions: The C difficile vaccine candidate was safe, well tolerated, and immunogenic when administered to healthy older Japanese adults at 0, 1, and 6 months. Results support continued development of the vaccine for the prevention of CDI. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Inoue, Megumi] SOUSEIKAI PS Clin, Fukuoka, Fukuoka, Japan.
   [Yonemura, Takuma] SOUSEIKAI Sumida Hosp, Tokyo, Japan.
   [de Solom, Richard] Pfizer Australia, Sydney, NSW, Australia.
   [Yamaji, Masako; Aizawa, Masakazu] Pfizer R&D Japan GK, Tokyo, Japan.
   [Knirsch, Charles; Pride, Michael W.; Jansen, Kathrin U.; Gruber, William; Webber, Chris] Pfizer Inc, Pearl River, NY USA.
RP de Solom, R (reprint author), Pfizer Australia Pty Ltd, Level 15-18,151 Clarence St, Sydney, NSW 2000, Australia.
EM megumi.inoue8577@gmail.com; takuma-yonemura@Ita-med.com;
   richard.desolom@pfizer.com; masako.yamaji@pfizer.com;
   masakazu.aizawa@pfizer.com; charles.knirsch@pfizer.com;
   michael.pride@pfizer.com; kathrin.jansen@pfizer.com;
   bill.gruber@pfizer.com; chris.webber@pfizer.com
FU Pfizer Inc.Pfizer
FX This study was funded by Pfizer Inc.
CR Anderson AS, 2018, ANAEROBE 2018
   Barbut F., 2013, CLOSTRIDIUM DIFFICIL
   Bauer MP, 2011, LANCET, V377, P63, DOI 10.1016/S0140-6736(10)61266-4
   Cheng JW, 2016, SCI REP-UK, V6, DOI 10.1038/srep18834
   Choi HY, 2015, BIOMED RES INT, DOI 10.1155/2015/510386
   Deshpande A, 2012, CLIN GASTROENTEROL H, V10, P225, DOI 10.1016/j.cgh.2011.09.030
   Gerding DN, 2014, GUT MICROBES, V5, P15, DOI 10.4161/gmic.26854
   Gupta A, 2014, INFECT DRUG RESIST, V7, P63, DOI 10.2147/IDR.S46780
   Hikone M, 2015, CLIN EXP GASTROENTER, V8, P191, DOI 10.2147/CEG.S85007
   Ho J, 2017, EMERG INFECT DIS, V23, P1671, DOI 10.3201/eid2310.170797
   Honda H, 2014, ANAEROBE, V25, P5, DOI 10.1016/j.anaerobe.2013.10.004
   Japanese Association for Infectious Disease/Japanese Society of Chemotherapy, 2018, GUID TREATM CLOSTR C
   KELLY CP, 1994, NEW ENGL J MED, V330, P257, DOI 10.1056/NEJM199401273300406
   Kuehne SA, 2010, NATURE, V467, P711, DOI 10.1038/nature09397
   Leffler DA, 2015, NEW ENGL J MED, V372, P1539, DOI 10.1056/NEJMra1403772
   Lessa FC, 2015, NEW ENGL J MED, V372, P825, DOI [10.1056/NEJMoa1408913, 10.1056/NEJMc1505190]
   Louie TJ, 2011, NEW ENGL J MED, V364, P422, DOI 10.1056/NEJMoa0910812
   Mattila E, 2012, GASTROENTEROLOGY, V142, P490, DOI 10.1053/j.gastro.2011.11.037
   McDonald LC, 2007, INFECT CONT HOSP EP, V28, P140, DOI 10.1086/511798
   Mori N, 2015, J INFECT CHEMOTHER, V21, P718, DOI [10.1016/j.jiac.2015.06.009, 10.1016/j.jiac.2015.09.004]
   Rao K, 2015, INFECT DIS CLIN N AM, V29, P109, DOI 10.1016/j.idc.2014.11.009
   Riley TV, 2018, INFECT DIS THER, V7, P39, DOI 10.1007/s40121-018-0186-1
   Sheldon E, 2016, VACCINE, V34, P2082, DOI 10.1016/j.vaccine.2016.03.010
   Surawicz CM, 2013, AM J GASTROENTEROL, V108, P478, DOI 10.1038/ajg.2013.4
   U.S. Food and Drug Administration, 2016, ENF POL REG INV NEW
   van Nood E, 2013, NEW ENGL J MED, V368, P407, DOI 10.1056/NEJMoa1205037
   Verbeke F, 2017, BMC GASTROENTEROL, V17, DOI 10.1186/s12876-017-0687-5
   Weber DJ, 2010, AM J INFECT CONTROL, V38, pS25, DOI 10.1016/j.ajic.2010.04.196
   World Health Organization, 2015, AG HLTH
   2018, J INFECT CHEMOTHER, V24, P1, DOI DOI 10.1016/J.JIAC.2017.09.002
   2009, INFECT CONT HOSP EP, V30, P526, DOI DOI 10.1086/597507
NR 31
TC 0
Z9 0
U1 0
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAY 1
PY 2019
VL 37
IS 19
BP 2600
EP 2607
DI 10.1016/j.vaccine.2019.03.014
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HV8QU
UT WOS:000466248800010
PM 30962095
DA 2020-05-12
ER

PT J
AU Echevarria, D
   Gutfraind, A
   Boodram, B
   Layden, J
   Ozik, J
   Page, K
   Cotler, SJ
   Major, M
   Dahari, H
AF Echevarria, Desarae
   Gutfraind, Alexander
   Boodram, Basmattee
   Layden, Jennifer
   Ozik, Jonathan
   Page, Kimberly
   Cotler, Scott J.
   Major, Marian
   Dahari, Harel
TI Modeling indicates efficient vaccine-based interventions for the
   elimination of hepatitis C virus among persons who inject drugs in
   metropolitan Chicago
SO VACCINE
LA English
DT Article
DE Hepatitis C virus; Vaccine; Direct-acting antivirals; Mathematical
   modeling; Persons who inject drugs
ID HCV INFECTION; HIV-INFECTION; B VACCINATION; PEOPLE; RISK; PREVENTION;
   BEHAVIORS; IMMUNITY; YOUNG; METAANALYSIS
AB Background and aims: Persons who inject drugs (PWID) are at highest risk for acquiring and transmitting hepatitis C (HCV) infection. The recent availability of oral direct-acting antiviral (DAA) therapy with reported cure rates >90% can prevent HCV transmission, making HCV elimination an attainable goal among PWID. The World Health Organization (WHO) recently proposed a 90% reduction in HCV incidence as a key objective. However, given barriers to the use of DAAs in PWID, including cost, restricted access to DAAs, and risk of reinfection, combination strategies including the availability of effective vaccines are needed to eradicate HCV as a public health threat. This study aims to model the cost and efficacy of a dual modality approach using HCV vaccines combined with DAAs to reduce HCV incidence by 90% and prevalence by 50% in PWID populations.
   Methods: We developed a mathematical model that represents the HCV epidemic among PWID and calibrated it to empirical data from metropolitan Chicago, Illinois. Four medical interventions were considered: vaccination of HCV naive PWID, DAA treatment, DAA treatment followed by vaccination, and, a combination of vaccination and DAA treatment.
   Results: The combination of vaccination and DAAs is the lowest cost-expensive intervention for achieving the WHO target of 90% incidence reduction. The use of DAAs without a vaccine is much less cost-effective with the additional risk of reinfection after treatment. Vaccination of nave PWID alone, even when scaled-up to all reachable PWID, cannot achieve 90% reduction of incidence in high-prevalence populations due to infections occurring before vaccination. Similarly, the lowest cost-expensive way to halve prevalence in 15 years is through the combination of vaccination and DAAs.
   Conclusions: The modeling results underscore the importance of developing an effective HCV vaccine and augmenting DAAs with vaccines in HCV intervention strategies in order to achieve efficient reductions in incidence and prevalence. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Echevarria, Desarae; Gutfraind, Alexander; Cotler, Scott J.; Dahari, Harel] Loyola Univ Med Ctr, Dept Med, Div Hepatol, Program Expt & Theoret Modeling, Maywood, IL 60153 USA.
   [Gutfraind, Alexander] Univ Illinois, Sch Publ Hlth, Div Epidemiol & Biostat, Chicago, IL USA.
   [Boodram, Basmattee] Univ Illinois, Sch Publ Hlth, Community Hlth Sci, Chicago, IL USA.
   [Layden, Jennifer] Illinois Dept Publ Hlth, Hlth Protect Off, Chicago, IL USA.
   [Ozik, Jonathan] Univ Chicago, Consortium Adv Sci & Engn, Chicago, IL 60637 USA.
   [Ozik, Jonathan] Argonne Natl Lab, Decis & Infrastruct Sci, 9700 S Cass Ave, Argonne, IL 60439 USA.
   [Page, Kimberly] Univ New Mexico, Hlth Sci Ctr, Dept Internal Med, Div Epidemiol Biostat & Prevent Med, Albuquerque, NM 87131 USA.
   [Major, Marian] US FDA, Div Viral Prod, Ctr Biol Evaluat & Res, Silver Spring, MD USA.
RP Dahari, H (reprint author), Loyola Univ Med Ctr, Dept Med, Div Hepatol, Program Expt & Theoret Modeling, Maywood, IL 60153 USA.
EM hdahari@luc.edu
OI GUTFRAIND, ALEXANDER/0000-0002-3324-2220
FU U.S. National Institute of Health (NIH)United States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USA
   [R01-AI078881, R01-AI101229, R01-GM121600]
FX The research was supported in part by the U.S. National Institute of
   Health (NIH) grants R01-AI078881, R01-AI101229, and R01-GM121600. The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Andrews M., 2017, NAT PUBL RADIO
   [Anonymous], 2014, PRIOR AUTH SOV OTH M
   Armstrong GL, 2000, HEPATOLOGY, V31, P777, DOI 10.1002/hep.510310332
   Asher AK, 2016, SUBST USE MISUSE, V51, P1218, DOI 10.3109/10826084.2016.1161054
   Boodram B, 2018, J URBAN HEALTH, V95, P71, DOI 10.1007/s11524-017-0185-7
   Boodram B, 2010, DRUG ALCOHOL DEPEN, V111, P136, DOI 10.1016/j.drugalcdep.2010.04.003
   Boodram B, 2011, DRUG ALCOHOL DEPEN, V119, P166, DOI 10.1016/j.drugalcdep.2011.06.005
   Broz D, 2014, MMWR SURVEILL SUMM, V63, P1
   Bruggmann P, 2013, HEPATOLOGY, V58, P1523, DOI 10.1002/hep.26539
   Callendret B, 2012, GASTROENTEROLOGY, V142, P1384, DOI 10.1053/j.gastro.2012.02.010
   Campbell JV, 2007, DRUG ALCOHOL DEPEN, V91, pS64, DOI 10.1016/j.drugalcdep.2006.09.022
   CDC. Centers for Disease Control and Prevention, 2012, VIR HEP DRUG US
   Centers for Disease Control and Prevention (CDC), 2012, MMWR Morb Mortal Wkly Rep, V61, P133
   Cox A. L., 2016, Hepatitis C virus II: infection and disease, P325
   Cox AL, 2013, CLIN INFECT DIS, V57, pS46, DOI 10.1093/cid/cit329
   Dahari H, 2018, LANCET INFECT DIS, V18, P134, DOI 10.1016/S1473-3099(17)30678-3
   Dahari H, 2010, GASTROENTEROLOGY, V139, P965, DOI 10.1053/j.gastro.2010.05.077
   Day CA, 2016, J CLIN VIROL, V74, P66, DOI 10.1016/j.jcv.2015.11.031
   Echevarria D, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135901
   Epstein JM, 2009, NATURE, V460, P687, DOI 10.1038/460687a
   Fraser H, 2018, J HEPATOL, V68, P402, DOI 10.1016/j.jhep.2017.10.010
   GARFEIN RS, 2007, DRUG ALCOHOL DEPEN S, V91, pS
   Grebely J, 2017, NAT REV GASTRO HEPAT, V14, P641, DOI 10.1038/nrgastro.2017.106
   Gutfraind A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137993
   Hagan H, 2008, AM J EPIDEMIOL, V168, P1099, DOI 10.1093/aje/kwn237
   Hagan H, 2011, J INFECT DIS, V204, P74, DOI 10.1093/infdis/jir196
   Hahn JA, 2009, EPIDEMICS-NETH, V1, P47, DOI 10.1016/j.epidem.2008.10.002
   Hellard M, 2014, HEPATOLOGY, V59, P366, DOI 10.1002/hep.26623
   Hill A, 2014, SCIENCE, V345, P141, DOI 10.1126/science.1257737
   Hu YQ, 2008, AM J PREV MED, V35, P25, DOI 10.1016/j.amepre.2008.03.028
   Huo DZ, 2007, JAIDS-J ACQ IMM DEF, V45, P108, DOI 10.1097/QAI.0b013e318050d260
   Krahn MD, 2005, VACCINE, V23, P1549, DOI 10.1016/j.vaccine.2004.09.023
   Lauer GM, 2013, J INFECT DIS, V207, pS7, DOI 10.1093/infdis/jis762
   Lozano R, 2012, LANCET, V380, P2095, DOI 10.1016/S0140-6736(12)61728-0
   Lum PJ, 2005, SUBST USE MISUSE, V40, P1681, DOI 10.1080/10826080500222834
   Major M, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aao4496
   Martin NK, 2011, J HEPATOL, V54, P1137, DOI 10.1016/j.jhep.2010.08.029
   Martinello M, 2017, J VIRAL HEPATITIS, V24, P359, DOI 10.1111/jvh.12666
   Massad E, 2009, EPIDEMIOL INFECT, V137, P241, DOI 10.1017/S0950268808000873
   Midgard H, 2016, J HEPATOL, V64, P1020, DOI 10.1016/j.jhep.2016.01.001
   Missale G, 2012, GUT, V61, P1076, DOI 10.1136/gutjnl-2011-300515
   Mohd Hanafiah K, 2013, HEPATOLOGY, V57, P1333, DOI DOI 10.1002/HEP.26141
   Mondelli MU, 2015, GASTROENTEROLOGY, V149, P25, DOI 10.1053/j.gastro.2015.05.026
   Osburn WO, 2010, GASTROENTEROLOGY, V138, P315, DOI 10.1053/j.gastro.2009.09.017
   Roingeard P, 2016, LIVER INT, V36, P1076, DOI 10.1111/liv.13077
   Scott N, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0440-2
   Shiffman ML, 2014, CURR OPIN GASTROEN, V30, P217, DOI 10.1097/MOG.0000000000000062
   Simmons B, 2016, CLIN INFECT DIS, V62, P683, DOI 10.1093/cid/civ948
   Spiller MW, 2015, MMWR-MORBID MORTAL W, V64, P270
   Stone J, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0156213
   Strom BL, 2017, NATL STRATEGY ELIMIN
   Tempalski B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064789
   Thorpe LE, 2002, AM J EPIDEMIOL, V155, P645, DOI 10.1093/aje/155.7.645
   Walker CM, 2015, CURR OPIN IMMUNOL, V35, P137, DOI 10.1016/j.coi.2015.06.010
   WHO, 2016, COMBATING HEPATITIS
   Zelenev A, 2018, LANCET INFECT DIS, V18, P215, DOI 10.1016/S1473-3099(17)30676-X
   2015, J INFECT DIS, V212, P1407
   2006, ANN INTERN MED, V144, P705
NR 58
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAY 1
PY 2019
VL 37
IS 19
BP 2608
EP 2616
DI 10.1016/j.vaccine.2019.02.081
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HV8QU
UT WOS:000466248800011
PM 30962092
OA Green Accepted
DA 2020-05-12
ER

PT J
AU Crowcroft, NS
   Schwartz, KL
   Chen, C
   Johnson, C
   Li, Y
   Marchand-Austin, A
   Bolotin, S
   Jamieson, FB
   Drews, SJ
   Russell, ML
   Svenson, LW
   Simmonds, K
   Mahmud, SM
   Kwong, JC
AF Crowcroft, Natasha S.
   Schwartz, Kevin L.
   Chen, Cynthia
   Johnson, Caitlin
   Li, Ye
   Marchand-Austin, Alex
   Bolotin, Shelly
   Jamieson, Frances B.
   Drews, Steven J.
   Russell, Margaret L.
   Svenson, Lawrence W.
   Simmonds, Kimberley
   Mahmud, Salaheddin M.
   Kwong, Jeffrey C.
TI Pertussis vaccine effectiveness in a frequency matched population-based
   case-control Canadian Immunization Research Network study in Ontario,
   Canada 2009-2015
SO VACCINE
LA English
DT Article
DE Immunization; Pertussis; Vaccine effectiveness; Waning immunity
ID BURDEN
AB Background: Resurgences of pertussis have occurred in several high-income countries, often linked to waning of immunity from acellular pertussis vaccines. The degree of waning observed has varied by study design and setting. In Ontario, pertussis has not shown a substantial resurgence in the past decade. The routine immunization schedule comprises three priming doses in infancy, toddler and pre-school doses, and an adolescent dose at 14-16 years of age.
   Methods: We estimated pertussis vaccine effectiveness (VE) through a case-control study of 1335 cases statutorily reported to public health in Ontario and occurring between January 1,2009 and March 31, 2015, compared with 5340 randomly selected population controls, frequency-matched by age, primary-care provider and year of diagnosis. Pertussis cases met provincial confirmed or probable case definitions. We used multivariable logistic regression to estimate crude and adjusted odds ratios (aOR).
   Results: VE against pertussis was sustained between 92% (95% confidence interval (95%CI) 88-95%) in 2-3 year olds and 90% (95%CI: 80-95%) in 8-9 year olds, but fell rapidly to 49% (95%CI: 2-73%) in children 12-13 years of age. VE following the teenage booster given at 14-16 years in Ontario reached 76% (95%CI: 52-88%) in 14-16 year olds and 78% (95%CI: -31 to 96%) in those 16-22 years old. For children who were up-to-date with the immunization schedule, VE declined from 87% (95%CI: 84-90%) during the first year to 74% (95%CI: 63-82%) after 8 or more years following their last dose of immunization.
   Conclusions: VE is high during the first decade of life but then falls rapidly. Protection is not fully restored by the teenage booster. Our findings are consistent with the localized outbreaks we observe in high school children and underline the importance of additional policies to protect infants. Crown Copyright (C) 2019 Published by Elsevier Ltd.
C1 [Crowcroft, Natasha S.; Schwartz, Kevin L.; Chen, Cynthia; Johnson, Caitlin; Li, Ye; Marchand-Austin, Alex; Bolotin, Shelly; Jamieson, Frances B.; Kwong, Jeffrey C.] Publ Hlth Ontario, Toronto, ON, Canada.
   [Crowcroft, Natasha S.; Jamieson, Frances B.] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada.
   [Crowcroft, Natasha S.; Schwartz, Kevin L.; Li, Ye; Bolotin, Shelly; Kwong, Jeffrey C.] Univ Toronto, Dalla Lana Sch Publ Hlth, Toronto, ON, Canada.
   [Crowcroft, Natasha S.; Schwartz, Kevin L.; Kwong, Jeffrey C.] ICES, Toronto, ON, Canada.
   [Drews, Steven J.] ProvLab Alberta, Edmonton, AB, Canada.
   [Drews, Steven J.] Univ Alberta, Dept Lab Med & Pathol, Edmonton, AB, Canada.
   [Russell, Margaret L.] Univ Calgary, Cumming Sch Med, Calgary, AB, Canada.
   [Svenson, Lawrence W.; Simmonds, Kimberley] Alberta Hlth, Edmonton, AB, Canada.
   [Svenson, Lawrence W.] Univ Alberta, Div Prevent Med, Edmonton, AB, Canada.
   [Svenson, Lawrence W.; Simmonds, Kimberley] Univ Alberta, Sch Publ Hlth, Edmonton, AB, Canada.
   [Svenson, Lawrence W.; Simmonds, Kimberley] Univ Calgary, Community Hlth Sci, Calgary, AB, Canada.
   [Mahmud, Salaheddin M.] Univ Manitoba, Max Rady Coll Med, Vaccine & Drug Evaluat Ctr, Winnipeg, MB, Canada.
   [Kwong, Jeffrey C.] Univ Toronto, Dept Family & Community Med, Toronto, ON, Canada.
RP Crowcroft, NS (reprint author), Publ Hlth Ontario, Toronto, ON, Canada.
EM natasha.crowcroft@oahpp.ca
OI Crowcroft, Natasha/0000-0002-6761-8783; Marchand-Austin,
   Alex/0000-0001-5932-2037
FU Canadian Institutes of Health Research and Public Health Agency of
   Canada [CNF 137470]
FX This work was supported by the Canadian Institutes of Health Research
   and Public Health Agency of Canada (grant number CNF 137470).
CR Baxter R, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f4249
   Bolotin S, 2015, PATHOG DIS, V73, DOI 10.1093/femspd/ftv057
   Bolotin S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133209
   Brophy J, 2018, Can Commun Dis Rep, V44, P91, DOI 10.14745/ccdr.v44i34a04
   Choi YH, 2016, BMC MED, V14, DOI 10.1186/s12916-016-0665-8
   Crowcroft NS, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0195984
   Deeks S L, 2014, Can Commun Dis Rep, V40, P42
   FEUDTNER C, PEDIATRICS 2, V106, P205
   Feudtner C, 2014, BMC PEDIATR, V14, DOI 10.1186/1471-2431-14-199
   Finkelstein MM, 2004, CAN J PUBLIC HEALTH, V95, P90, DOI 10.1007/BF03405773
   Fox MP, 2005, INT J EPIDEMIOL, V34, P1370, DOI 10.1093/ije/dyi184
   Fulton TR, 2016, CLIN INFECT DIS, V62, P1100, DOI 10.1093/cid/ciw051
   Guthrie JL, 2010, J CLIN MICROBIOL, V48, P1435, DOI 10.1128/JCM.02417-09
   Klein NP, 2016, PEDIATRICS, V137, DOI 10.1542/peds.2015-3326
   Klein NP, 2013, PEDIATRICS, V131, pE1716, DOI 10.1542/peds.2012-3836
   Klein NP, 2012, NEW ENGL J MED, V367, P1012, DOI 10.1056/NEJMoa1200850
   Ministry of Health and Long-Term Care, 2016, PUBLICALLY FUNDED IM
   Ontario Agency for Health Protection and Promotion (Public Health Ontario), 2017, REP DIS TRENDS ONT
   Ontario Ministry of Health and Long Term Care, 2014, APP B PROV CAS DEF R
   Orenstein EW, 2007, INT J EPIDEMIOL, V36, P623, DOI 10.1093/ije/dym021
   Schwartz KL, 2016, CAN MED ASSOC J, V188, pE399, DOI 10.1503/cmaj.160193
   Sheridan SL, 2015, VACCINE, V33, P5027, DOI 10.1016/j.vaccine.2015.08.021
   van den Biggelaar AHJ, 2016, EXPERT REV VACCINES, V15, P69, DOI 10.1586/14760584.2016.1105136
   Wearing HJ, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000647
   Winter K, 2012, J PEDIATR-US, V161, P1091, DOI 10.1016/j.jpeds.2012.05.041
   World Health Organization, 2015, WKLY EPIDEMIOL REC, P433
   World Health Organization (WHO), 1991, WHO MEETING ON CASE
   World Health Organization (WHO), 2003, WHO REC STAND SURV S
   Yeung KHT, 2017, LANCET INFECT DIS, V17, P974, DOI 10.1016/S1473-3099(17)30390-0
NR 29
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAY 1
PY 2019
VL 37
IS 19
BP 2617
EP 2623
DI 10.1016/j.vaccine.2019.02.047
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HV8QU
UT WOS:000466248800012
PM 30967309
OA Other Gold
DA 2020-05-12
ER

PT J
AU Padilla-Quirarte, HO
   Badillo-Godinez, O
   Gutierrez-Xicotencatl, L
   Acevedo-Betancur, Y
   Luna-Andon, JD
   Montiel-Hernandez, JL
   Lopez-Guerrero, DV
   Esquivel-Guadarrama, F
AF Padilla-Quirarte, H. O.
   Badillo-Godinez, O.
   Gutierrez-Xicotencatl, L.
   Acevedo-Betancur, Y.
   Luna-Andon, J. D.
   Montiel-Hernandez, J. L.
   Lopez-Guerrero, D. V.
   Esquivel-Guadarrama, F.
TI Targeting M2e to DEC-205 induces an enhanced serum antibody-dependent
   heterosubtypic protection against influenza A virus infection
SO VACCINE
LA English
DT Article
DE Influenza; M2e; DEC-205; Dendritic cells; Heterosubtypic vaccine
ID EPSTEIN-BARR-VIRUS; DENDRITIC CELLS; EXTRACELLULAR DOMAIN;
   MONOCLONAL-ANTIBODY; MATRIX PROTEIN-2; RECEPTOR DEC-205; B-CELLS;
   ANTIGEN; VACCINE; HEMAGGLUTININ
AB The ectodomain of the influenza A virus (IAV) M2 protein (M2e) is highly conserved, and it represents a promising candidate for the development of an "universal vaccine". However, the low immunogenicity associated to M2e in a natural infection or in response to seasonal vaccines has led to explore new approaches to enhance it. In recent years, it has become clear that targeting antigens to dendritic cells (DC) is an efficient way to enhance immune responses against pathogens. In this work, the M2e peptide was chemically cross-linked to a monoclonal antibody (mAb) specific for DEC-205 (alpha-DEC-205:M2e), present on DC. BALB/c mice were inoculated subcutaneously (s.c.) three times with the conjugate equivalent to 1 mu g of M2e, in the presence of polyinosinic-polycytidylic acid (poly I:C) as adjuvant. As controls, other groups of mice were inoculated under the same conditions with M2e cross-linked to an isotype control mAb (isotype:M2e), 5 mu g of free M2e peptide, ovalbumin (OVA) cross-linked to the alpha-DEC-205 mAb (alpha-DEC-205:OVA) or poly I:C alone. Immunization with alpha-DEC-205-M2e induced high levels of serum antibodies (Abs) compared to isotype:M2e or to free M2e peptide, and in all cases IgG1 was predominant over IgG2a Abs. Furthermore, immunization with the alpha-DEC-205:M2e conjugate did not prevent morbidity, but it induced up to 76% protection against a heterosubtypic IAV lethal challenge. Contrasting with the 20 to 40% protection induced by isotype:M2e or by free M2e peptide. The protection induced by alpha-DEC-205:M2e conjugate was dependent on non-neutralizing serum Abs and independent of effector CD4(+) T cells. These results show that targeting M2e to DEC-205 is a very effective alternative to induce strong heterosubtypic protection against an IAV infection. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Padilla-Quirarte, H. O.; Acevedo-Betancur, Y.; Luna-Andon, J. D.; Esquivel-Guadarrama, F.] UAEM, Fac Med, LIV, Cuernavaca 63250, Morelos, Mexico.
   [Padilla-Quirarte, H. O.] UNAM, Inst Biotecnol, Cuernavaca, Morelos, Mexico.
   [Lopez-Guerrero, D. V.] UAEM, Fac Nutr, Cuernavaca, Morelos, Mexico.
   [Badillo-Godinez, O.; Gutierrez-Xicotencatl, L.] CISEI INSP, Cuernavaca, Morelos, Mexico.
   [Montiel-Hernandez, J. L.] UAEM, Fac Farm, Cuernavaca, Morelos, Mexico.
RP Esquivel-Guadarrama, F (reprint author), UAEM, Fac Med, LIV, Cuernavaca 63250, Morelos, Mexico.
EM fernando.esquivel@uaem.mx
OI Esquivel, Fernando/0000-0002-2962-0428; Badillo,
   Oscar/0000-0002-3840-9448
FU SEP-CONACYTConsejo Nacional de Ciencia y Tecnologia (CONACyT)
   [2015-01-257420]; SEP-PRODEP (Redes tematicas de colaboracion de CA,
   2015); CONACYTConsejo Nacional de Ciencia y Tecnologia (CONACyT)
   [375463]
FX We thank Gerardo Arreguin and Nancy Arias (Facultad de Medicina, UAEM),
   and Elizabeth Mata and Graciela Cabeza (Institute de Biotecnologia,
   UNAM) for the excellent animal house conditions. Carlos Arias for his
   neutral and critical point of view of the work. Erika Melchy and Carlos
   Mojica for their technical assistance in the flow cytometry assays. Juan
   Carlos Villegas-Garcia for technical assistance. This work was supported
   by grants from SEP-CONACYT (2015-01-257420) and SEP-PRODEP (Redes
   tematicas de colaboracion de CA, 2015). B.G.O is a Postdoctoral fellow
   of the Graduate Science Program, INSP, and was supported by CONACYT.
   P.Q.H.O is a Ph.D. student of the Biochemical Sciences Program,
   Institute de Biotecnologia, UNAM, and was supported by a CONACYT
   Scholarship (375463).
CR Amorim KNS, 2016, SCI REP-UK, V6, DOI 10.1038/srep39250
   Badillo-Godinez O, 2015, VACCINE, V33, P4228, DOI 10.1016/j.vaccine.2015.03.080
   Bonifaz L, 2002, J EXP MED, V196, P1627, DOI 10.1084/jem.20021598
   Bonifaz LC, 2004, J EXP MED, V199, P815, DOI 10.1084/jem.20032220
   Boscardin SB, 2006, J EXP MED, V203, P599, DOI 10.1084/jem.20051639
   Bozzacco L, 2010, EUR J IMMUNOL, V40, P36, DOI 10.1002/eji.200939748
   BROWN EG, 1990, J VIROL, V64, P4523, DOI 10.1128/JVI.64.9.4523-4533.1990
   Coconi-Linares N, 2013, VACCINE, V31, P2366, DOI 10.1016/j.vaccine.2013.03.009
   Deng L, 2015, VACCINES-BASEL, V3, P105, DOI 10.3390/vaccines3010105
   El Bakkouri K, 2011, J IMMUNOL, V186, P1022, DOI 10.4049/jimmunol.0902147
   Eliasson DG, 2018, MUCOSAL IMMUNOL, V11, P273, DOI 10.1038/mi.2017.14
   Eliasson DG, 2008, VACCINE, V26, P1243, DOI 10.1016/j.vaccine.2007.12.027
   Feng JQ, 2006, VIROL J, V3, DOI 10.1186/1743-422X-3-102
   Fiers W, 2009, VACCINE, V27, P6280, DOI 10.1016/j.vaccine.2009.07.007
   Gao X, 2013, ANTIVIR RES, V98, P4, DOI 10.1016/j.antiviral.2013.01.010
   Guo Y, 2017, MICROBES INFECT, V19, P641, DOI 10.1016/j.micinf.2017.08.010
   Gurer C, 2008, BLOOD, V112, P1231, DOI 10.1182/blood-2008-03-148072
   Henkel JR, 2000, J CELL BIOL, V148, P495, DOI 10.1083/jcb.148.3.495
   INABA K, 1995, CELL IMMUNOL, V163, P148, DOI 10.1006/cimm.1995.1109
   Iuliano AD, 2018, LANCET, V391, P1285, DOI 10.1016/S0140-6736(17)33293-2
   Jauregui-Zuniga D, 2017, RES VET SCI, V111, P55, DOI 10.1016/j.rvsc.2016.12.002
   Jegerlehner A, 2004, J IMMUNOL, V172, P5598, DOI 10.4049/jimmunol.172.9.5598
   Kamphorst AO, 2010, J IMMUNOL, V185, P3426, DOI 10.4049/jimmunol.1001205
   Lee YT, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0190868
   Leung CS, 2013, BLOOD, V121, P1584, DOI 10.1182/blood-2012-08-450775
   Maaske A, 2016, J CONTROL RELEASE, V237, P14, DOI 10.1016/j.jconrel.2016.06.043
   Macri C, 2016, CLIN TRANSL IMMUNOL, V5, DOI 10.1038/cti.2016.6
   Mozdzanowska K, 2003, VACCINE, V21, P2616, DOI 10.1016/S0264-410X(03)00040-9
   Narasaraju T, 2009, MICROBES INFECT, V11, P2, DOI 10.1016/j.micinf.2008.09.013
   Neirynck S, 1999, NAT MED, V5, P1157
   Pasqual G, 2015, METHODS MOL BIOL, V1291, P125, DOI 10.1007/978-1-4939-2498-1_10
   Petzold Cathleen, 2012, Rev Diabet Stud, V9, P305, DOI 10.1900/RDS.2012.9.305
   PINTO LH, 1992, CELL, V69, P517, DOI 10.1016/0092-8674(92)90452-I
   Ramakrishnan Muthannan Andavar, 2016, World J Virol, V5, P85, DOI 10.5501/wjv.v5.i2.85
   Rappazzo CG, 2016, VACCINE, V34, P1252, DOI 10.1016/j.vaccine.2016.01.028
   Schepens B, 2018, CURR OPIN IMMUNOL, V53, P22, DOI 10.1016/j.coi.2018.03.024
   Schotsaert M, 2013, MUCOSAL IMMUNOL, V6, P276, DOI 10.1038/mi.2012.69
   Shrimpton RE, 2009, MOL IMMUNOL, V46, P1229, DOI 10.1016/j.molimm.2008.11.016
   Simhadri VR, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124677
   Tao WQ, 2017, ANTIVIR RES, V141, P62, DOI 10.1016/j.antiviral.2017.01.021
   Tompkins SM, 2007, EMERG INFECT DIS, V13, P426, DOI 10.3201/eid1303.061125
   TREANOR JJ, 1990, J VIROL, V64, P1375, DOI 10.1128/JVI.64.3.1375-1377.1990
   Van den Hoecke S, 2017, J VIROL, V91, DOI 10.1128/JVI.02500-16
   Victora GD, 2010, CELL, V143, P592, DOI 10.1016/j.cell.2010.10.032
   Wadwa M, 2016, EUR J MICROBIOL IMMU, V6, P1, DOI 10.1556/1886.2015.00048
   Wu F, 2007, VACCINE, V25, P8868, DOI 10.1016/j.vaccine.2007.09.056
   1995, CELL IMMUNOL, V163, P157
   2017, BIOCH BIOPHYS RES CO, V493, P393
   2012, VACCINE, V30, P6359
   2014, J VIROL, V88, P325
   2015, J VIROL, V89, P3700
   2014, IMMUNOLOGY, V143, P300
NR 52
TC 0
Z9 0
U1 0
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAY 1
PY 2019
VL 37
IS 19
BP 2624
EP 2633
DI 10.1016/j.vaccine.2019.02.050
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HV8QU
UT WOS:000466248800013
PM 30955979
DA 2020-05-12
ER

PT J
AU Regan, AK
   Fielding, JE
   Chilver, MB
   Carville, KS
   Minney-Smith, CA
   Grant, KA
   Thomson, C
   Hahesy, T
   Deng, YM
   Stocks, N
   Sullivan, SG
AF Regan, Annette K.
   Fielding, James E.
   Chilver, Monique B.
   Carville, Kylie S.
   Minney-Smith, Cara A.
   Grant, Kristina A.
   Thomson, Chloe
   Hahesy, Trish
   Deng, Yi-Mo
   Stocks, Nigel
   Sullivan, Sheena G.
TI Intraseason decline in influenza vaccine effectiveness during the 2016
   southern hemisphere influenza season: A test-negative design study and
   phylogenetic assessment
SO VACCINE
LA English
DT Article
DE Influenza; Influenza vaccines; Test-negative design; Vaccine
   effectiveness; Case-control study
ID CIRCULATION
AB Background: We estimated the effectiveness of seasonal inactivated influenza vaccine and the potential influence of timing of immunization on vaccine effectiveness (VE) using data from the 2016 southern hemisphere influenza season.
   Methods: Data were pooled from three routine syndromic sentinel surveillance systems in general practices in Australia. Each system routinely collected specimens for influenza testing from patients presenting with influenza-like illness. Next generation sequencing was used to characterize viruses. Using a test negative design, VE was estimated based on the odds of vaccination among influenza-positive cases as compared to influenza-negative controls. Subgroup analyses were used to estimate VE by type, subtype and lineage, as well as age group and time between vaccination and symptom onset.
   Results: A total of 1085 patients tested for influenza in 2016 were included in the analysis, of whom 447 (41%) tested positive for influenza. The majority of detections were influenza A/H3N2 (74%). One-third (31%) of patients received the 2016 southern hemisphere formulation influenza vaccine. Overall, VE was estimated at 40% (95% CI: 18-56%). VE estimates were highest for patients immunized within two months prior to symptom onset (VE: 60%; 95% CI: 26-78%) and lowest for patients immunized >4 months prior to symptom onset (VE: 19%; 95% CI: -73-62%).
   Discussion: Overall, the 2016 influenza vaccine showed good protection against laboratory-confirmed infection among general practice patients. Results by duration of vaccination suggest a significant decline in effectiveness during the 2016 influenza season, indicating immunization close to influenza season offered optimal protection. Crown Copyright (C) 2019 Published by Elsevier Ltd. All rights reserved.
C1 [Regan, Annette K.] Texas A&M Univ, Sch Publ Hlth, 212 Adriance Dr, College Stn, TX 77843 USA.
   [Regan, Annette K.] Curtin Univ, Sch Publ Hlth, GPO Box U1987, Perth, WA 6845, Australia.
   [Regan, Annette K.; Thomson, Chloe] Dept Hlth Western Australia, Communicable Dis Control Directorate, 227 Stubbs Terrace, Shenton Pk, WA 6008, Australia.
   [Regan, Annette K.] Telethon Kids Inst, Wesfarmers Ctr Vaccines & Infect Dis, 15 Hosp Ave, Nedlands, WA 6008, Australia.
   [Fielding, James E.; Carville, Kylie S.; Grant, Kristina A.; Sullivan, Sheena G.] Victorian Infect Dis Reference Lab, 792 Elizabeth St, Melbourne, Vic 3000, Australia.
   [Fielding, James E.; Sullivan, Sheena G.] Univ Melbourne, Sch Populat & Global Hlth, Ctr Epidemiol & Biostat, 207 Bouverie St, Melbourne, Vic 3010, Australia.
   [Chilver, Monique B.; Stocks, Nigel] Univ Adelaide, Discipline Gen Practice, North Terrace, Adelaide, SA 5005, Australia.
   [Minney-Smith, Cara A.] PathWest Lab Med WA, Locked Bag 2009, Nedlands, WA 6909, Australia.
   [Hahesy, Trish] SA Pathol, Frome Rd, Adelaide, SA 5000, Australia.
   [Deng, Yi-Mo; Sullivan, Sheena G.] Peter Doherty Inst Infect & Immun, WHO Collaborating Ctr Reference & Res Influenza, 792 Elizabeth St, Melbourne, Vic 3000, Australia.
   [Sullivan, Sheena G.] Univ Calif Los Angeles, Fielding Sch Publ Hlth, 650 Charles E Young Dr South, Los Angeles, CA 90095 USA.
RP Regan, AK (reprint author), Texas A&M Univ, Sch Publ Hlth, 212 Adriance Lab Rd, College Stn, TX 77843 USA.
EM regan@tamhsc.edu
RI Regan, Annette/Q-9159-2016
OI Regan, Annette/0000-0002-3879-6193; Stocks, Nigel/0000-0002-9018-0361
FU Australian Government Department of Health (the Department); Victorian
   Government Department of Health and Human Services; Western Australian
   Government Department of HealthState Govt Western Australia; NHMRC Early
   Career FellowshipNational Health and Medical Research Council of
   Australia [GNT1138425]
FX The Australian Sentinel Practices Research Network and the WHO
   Collaborating Centre for Reference and Research on Influenza are
   supported by the Australian Government Department of Health (the
   Department). The opinions expressed in this paper are those of the
   authors, and do not necessarily represent the views of the Department.
   The Victorian Sentinel Practice Influenza Network is supported by the
   Victorian Government Department of Health and Human Services. The WA
   Sentinel Practices Network is supported by the Western Australian
   Government Department of Health. AKR was supported by a NHMRC Early
   Career Fellowship (GNT1138425).
CR Australian Government Department of Health, 2016, AUSTR INFL SURV REP
   Australian Technical Advisory Group on Immunisation (ATAGI), 2017, AUSTR IMM HDB
   Australian Technical Advisory Group on Immunisation (ATAGI), 2018, ATAGI ADV SEAS INFL
   Department of Health Western Australia, 2018, INFL IMM PROGR
   Ferdinands JM, 2017, CLIN INFECT DIS, V64, P544, DOI 10.1093/cid/ciw816
   Iuliano AD, 2018, LANCET, V391, P1285, DOI 10.1016/S0140-6736(17)33293-2
   Kissling E, 2016, EUROSURVEILLANCE, V21, P13, DOI 10.2807/1560-7917.ES.2016.21.16.30201
   Lewnard JA, 2018, AM J EPIDEMIOL, V187, P2686, DOI 10.1093/aje/kwy163
   Lipsitch M, 2018, CLIN INFECT DIS, DOI [10.1093/cid/civ773, DOI 10.1093/CID/CIV773]
   Pebody R, 2017, EUROSURVEILLANCE, V22, P10, DOI 10.2807/1560-7917.ES.2017.22.44.17-00306
   Queensland Health, 2018, 2018 INFL VACC GUID
   Skowronski DM, 2018, EUROSURVEILLANCE, V23, P2, DOI 10.2807/1560-7917.ES.2018.23.5.18-00035
   Sullivan Sheena G, 2016, Commun Dis Intell Q Rep, V40, pE351
   Treanor JJ, 2012, CLIN INFECT DIS, V55, P951, DOI 10.1093/cid/cis574
   Vilcu AM, 2018, CLIN MICROBIOL INFEC, V24, DOI 10.1016/j.cmi.2017.09.003
   World Health Organization, 2015, REC COMP INFL VIR VA
   Zhou B, 2017, J CLIN MICROBIOL, V55, P3492, DOI 10.1128/JCM.00957-17
   2015, J INFECT DIS, V211, P1529, DOI DOI 10.1093/INFDIS/JIU647
   2016, VACCINE, V34, P2164, DOI DOI 10.1016/J.VACCINE.2016.03.032
   2014, J INFECT DIS, V210, P126, DOI DOI 10.1093/INFDIS/JIU048
   2017, J INFECT DIS, V216, P1487, DOI DOI 10.1093/INFDIS/JIX526
   2018, EUR J PEDIATR, V177, P1009, DOI DOI 10.1007/S00431-018-3145-7
   2016, VACCINE, V34, P4905, DOI DOI 10.1016/J.VACCINE.2016.08.067
   2014, CLIN INFECT DIS, V58, P319, DOI DOI 10.1093/CID/CIT736
   2018, INFLUENZA OTHER RESP, V12, P423, DOI DOI 10.1111/IRV.12520
   2017, VACCINE, V35, P5799, DOI DOI 10.1016/J.VACCINE.2017.09.035
NR 26
TC 2
Z9 2
U1 0
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAY 1
PY 2019
VL 37
IS 19
BP 2634
EP 2641
DI 10.1016/j.vaccine.2019.02.027
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HV8QU
UT WOS:000466248800014
PM 30952499
DA 2020-05-12
ER

PT J
AU Gong, JH
   Yuan, H
   Gao, Z
   Hu, FQ
AF Gong, Jianhua
   Yuan, Hai
   Gao, Zhao
   Hu, Fengqi
TI Wasp venom and acute kidney injury: The mechanisms and therapeutic role
   of renal replacement therapy
SO TOXICON
LA English
DT Review
DE Wasp stings; Venom; Acute kidney injury; Renal replacement therapy
ID POLYBIA-PAULISTA HYMENOPTERA; STRUCTURAL-CHARACTERIZATION; FAILURE;
   MASTOPARAN; STINGS; RHABDOMYOLYSIS; PURIFICATION; INCREASES; NEPHRITIS;
   RECOVERY
AB Stinging accidents involving wasp venom are a notable cause of acute kidney injury (AKI) in Asia. However, very little attention has been paid to the understanding of the mechanisms involved in this type of AKI. The aims of this review are to explore the evidence for the mechanisms and the therapeutic role of renal replacement therapy of wasp venom and AKI. A systematic literature search was conducted using PubMed for the association among wasp venom and AKI. Wasp venom is a complex mixture of biologically active components, including enzymes, amines, and peptides. Wasp venom may induce local anaphylaxis reactions as well as systemic reactions such as AKI. AKI may develop as a result of direct nephrotoxic effects of the venom or secondary intravascular hemolysis and/or rhabdomyolysis. Histopathological features of renal biopsies predominantly include acute tubular necrosis and acute interstitial nephritis. Renal replacement therapy, which includes intermittent hemodialysis, hemoperfusion, plasmapheresis, continuous renal replacement therapy, and peritoneal dialysis, has been used to treat severe AKI cases induced by wasp stings. Continuous renal replacement therapy appears to provide more benefit than intermittent hemodialysis in the treatment of wasp sting-induced AKI. In this review, we summarize the existing evidence of the mechanisms and treatment for venom-induced AKI, with a particular emphasis on the role of renal replacement therapy in the management of severe AKI following massive wasp stings.
C1 [Gong, Jianhua; Yuan, Hai; Gao, Zhao; Hu, Fengqi] Hubei Univ Arts & Sci, Xiangyang Cent Hosp, Dept Nephrol, Affiliated Hosp, Xiangyang 441000, Hubei, Peoples R China.
RP Hu, FQ (reprint author), Hubei Univ Arts & Sci, Xiangyang Cent Hosp, Dept Nephrol, Affiliated Hosp, Xiangyang 441000, Hubei, Peoples R China.
EM hufengqi1@gmail.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [81300617]; Hubei Province Health and Family
   Planning Scientific Research Project [WJ2015Q038]
FX This work was funded by grants from the National Natural Science
   Foundation of China (81300617) and Hubei Province Health and Family
   Planning Scientific Research Project (WJ2015Q038).
CR Agarwal A, 2016, J AM SOC NEPHROL, V27, P1288, DOI 10.1681/ASN.2015070740
   Agarwal Vikas, 2005, Indian J Med Sci, V59, P117
   Bazon ML, 2017, TOXINS, V9, DOI 10.3390/toxins9090259
   Bich HNX, 2010, NEPHROL DIAL TRANSPL, V25, P1146, DOI 10.1093/ndt/gfp583
   Casale TB, 2014, NEW ENGL J MED, V370, P1432, DOI 10.1056/NEJMcp1302681
   Chao YW, 2004, AM J KIDNEY DIS, V43, DOI 10.1053/j.ajkd.2003.10.025
   D'Cruz S, 2008, NEPHROL DIAL TRANSPL, V23, P1754, DOI 10.1093/ndt/gfm855
   da Silva GB, 2017, REV INST MED TROP SP, V59, DOI [10.1590/S1678-9946201759025, 10.1590/s1678-9946201759025]
   Daniel S, 2002, BIOCHEMISTRY-US, V41, P9663, DOI 10.1021/bi025604p
   Dhanapriya J, 2016, CLIN KIDNEY J, V9, P201, DOI 10.1093/ckj/sfw004
   Dongol Y, 2013, EMJ NEPH, V10, P68
   EDDLESTONE GT, 1995, MOL PHARMACOL, V47, P787
   HABERMAN.E, 1972, SCIENCE, V177, P314, DOI 10.1126/science.177.4046.314
   Henriksen A, 2001, PROTEINS, V45, P438, DOI 10.1002/prot.1160
   Heung M, 2017, CRIT CARE CLIN, V33, P365, DOI 10.1016/j.ccc.2016.12.003
   Jacka MJ, 2005, CAN J ANAESTH, V52, P327, DOI 10.1007/BF03016071
   Konno K, 2016, TOXINS, V8, DOI 10.3390/toxins8040114
   Kumar V, 2013, RENAL FAILURE, V35, P170, DOI 10.3109/0886022X.2012.741467
   Li XD, 2015, AM J CASE REP, V16, P371, DOI 10.12659/AJCR.893734
   Liu G. J., 2017, COCHRANE DB SYST REV, V12
   Moreno M, 2015, TOXINS, V7, P1126, DOI 10.3390/toxins7041126
   Nandi M, 2012, PEDIATR NEPHROL, V27, P2315, DOI 10.1007/s00467-012-2250-5
   Natarajan G, 2016, KIDNEY INT, V89, P725, DOI 10.1016/j.kint.2015.12.013
   Petejova N, 2014, CRIT CARE, V18, DOI 10.1186/cc13897
   Przybilla B, 2012, DTSCH ARZTEBL INT, V109, P238, DOI 10.3238/arztebl.2012.0238
   Radhakrishnan H, 2014, INDIAN J CRIT CARE M, V18, P470, DOI 10.4103/0972-5229.136079
   Robinson SD, 2018, SCI ADV, V4, DOI 10.1126/sciadv.aau4640
   Rocha T, 2007, TOXICON, V50, P589, DOI 10.1016/j.toxicon.2007.05.003
   Rungsa P, 2018, TOXICON, V148, P74, DOI 10.1016/j.toxicon.2018.03.015
   Santos LD, 2007, TOXICON, V50, P923, DOI 10.1016/j.toxicon.2007.06.027
   Sharma Aman, 2006, BMC Nephrol, V7, P18, DOI 10.1186/1471-2369-7-18
   Sharmila RR, 2007, INDIAN J PEDIATR, V74, P1111, DOI 10.1007/s12098-007-0208-6
   Si XY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132708
   SITPRIJA V, 1972, LANCET, V1, P479
   Sookrung N, 2014, J PROTEOME RES, V13, P1336, DOI 10.1021/pr4009139
   Tauk B, 1999, AM J NEPHROL, V19, P70, DOI 10.1159/000013429
   Thiruventhiran T, 1999, NEPHROL DIAL TRANSPL, V14, P214, DOI 10.1093/ndt/14.1.214
   Vachvanichsanong P, 1997, PEDIATR NEPHROL, V11, P734, DOI 10.1007/s004670050377
   Vachvanichsanong P, 2009, EUR J PEDIATR, V168, P991, DOI 10.1007/s00431-008-0909-5
   Vikrant S, 2005, NEPHROLOGY, V10, P548, DOI 10.1111/j.1440-1797.2005.00482.x
   Vikrant S, 2017, CLIN KIDNEY J, V10, P532, DOI 10.1093/ckj/sfx010
   Vikrant S, 2017, KIDNEY INT, V92, P1288, DOI 10.1016/j.kint.2017.05.035
   Vikrant S, 2017, WILD ENVIRON MED, V28, P249, DOI 10.1016/j.wem.2017.05.007
   Walker AA, 2018, TOXICON, V154, P15, DOI 10.1016/j.toxicon.2018.09.004
   WINTER MC, 1992, AM J RESP CELL MOL, V6, P583, DOI 10.1165/ajrcmb/6.6.583
   Xie CH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083164
   Yang L, 2016, KIDNEY DIS-BASEL, V2, P95, DOI 10.1159/000441887
   Yuan H, 2016, BLOOD PURIFICAT, V42, P49, DOI 10.1159/000442740
   Zager RA, 1996, KIDNEY INT, V49, P314, DOI 10.1038/ki.1996.48
   Zhang L, 2013, CLIN J AM SOC NEPHRO, V8, P1850, DOI 10.2215/CJN.12081112
   Zhang L, 2010, BLOOD PURIFICAT, V30, P106, DOI 10.1159/000319600
   Zhang RB, 2001, AM J KIDNEY DIS, V38, part. no., DOI 10.1053/ajkd.2001.29289
   2012, TOXICON, V59, P163, DOI DOI 10.1016/J.TOXICON.2011.11.002
   2016, TOXICON, V113, P41, DOI DOI 10.1016/J.TOXICON.2016.02.005
   2018, TOXICON, V148, P172, DOI DOI 10.1016/J.TOXICON.2018.04.029
NR 55
TC 1
Z9 2
U1 1
U2 5
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD MAY
PY 2019
VL 163
BP 1
EP 7
DI 10.1016/j.toxicon.2019.03.008
PG 7
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA HY1QB
UT WOS:000467890600001
PM 30880185
DA 2020-05-12
ER

PT J
AU Moore, EC
   Porter, LM
   Ruha, AM
AF Moore, Elizabeth C.
   Porter, Lauren M.
   Ruha, Anne-Michelle
TI Rattlesnake venom-induced recurrent coagulopathy in first trimester
   pregnant women - Two Cases
SO TOXICON
LA English
DT Review
DE Antivenom; Rattlesnake; Pregnancy; Coagulopathy; Envenomation;
   Hemorrhage
ID IMMUNOGLOBULIN THERAPY; SNAKE ENVENOMATIONS; MANAGEMENT
AB Delayed or recurrent coagulopathy can occur up to 14 days after North American rattlesnake envenomation in patients that have been treated with Crotalidae Polyvalent Immune Fab (CroFab). There is little data in the literature characterizing the sequelae of North American rattlesnake envenomation in pregnancy and no previously published reports of recurrent coagulopathy in pregnancy.
   Case report We present 2 cases of first trimester pregnant women requiring readmission and retreatment with Crotalidae Polyvalent Immune Fab (CroFab) after developing recurrent/late coagulopathy following North American Rattlesnake Envenomation. Both patients were initially admitted and treated with CroFab following snakebite and discharged home without coagulopathy. One patient developed significant hypofibrinogenemia and subsequent hemorrhage after spontaneous abortion secondary to recurrent venom induced hypofibrinogenemia.
   Discussion: Pregnant women with recurrent or late coagulopathy may be at higher risk for hemorrhage and spontaneous abortion and require more frequent laboratory monitoring after initial hospitalization and treatment with antivenom. A lower threshold for re-treatment with CroFab may be warranted in patients with fibrinogen less than 100mg/dL even in the setting of a normal platelet count.
C1 [Moore, Elizabeth C.] Univ Southern Calif, Keck Sch Med, Div Med Toxicol, Dept Emergency Med, Los Angeles, CA 90033 USA.
   [Porter, Lauren M.; Ruha, Anne-Michelle] Univ Arizona, Coll Med, Banner Univ Med Ctr Phoenix, Dept Med Toxicol, Tucson, AZ 85721 USA.
RP Moore, EC (reprint author), Univ Southern Calif, Keck Sch Med, Div Med Toxicol, Dept Emergency Med, Los Angeles, CA 90033 USA.
EM elizabeth.moore@med.usc.edu
OI Moore, Elizabeth/0000-0002-7976-7241
CR Boyer LV, 2001, ANN EMERG MED, V37, P196, DOI 10.1067/mem.2001.113134
   Brown SA, 2013, CLIN TOXICOL, V51, P3, DOI 10.3109/15563650.2012.760127
   de Moerloose P, 2013, SEMIN THROMB HEMOST, V39, P585, DOI 10.1055/s-0033-1349222
   Lavonas EJ, 2011, BMC EMERG MED, V11, DOI 10.1186/1471-227X-11-2
   Lefkou E, 2008, OBSTET GYNAECOL REPR, V18, P217
   Pike GN, 2011, HEMATOL ONCOL CLIN N, V25, P359, DOI 10.1016/j.hoc.2011.01.007
   Seifert SA, 2001, ANN EMERG MED, V37, P189, DOI 10.1067/mem.2001.113135
   WINGERT WA, 1988, WESTERN J MED, V148, P37
   2010, WILDERNESS ENV MED, V21, P54, DOI DOI 10.1016/J.WEM.2009.12.025
   2014, ACAD EMERG MED, V21, P301, DOI DOI 10.1111/ACEM.12333
   2011, ANN EMERG MED, V57, P128, DOI DOI 10.1016/J.ANNEMERGMED.2010.06.550
   2011, HEMATOL ONCOL CLIN N, V25, P359, DOI DOI 10.1016/J.HOC.2011.01.007
   2011, CLIN TOXICOL, V49, P324, DOI DOI 10.3109/15563650.2011.566883
   2017, J MED TOXICOL, V13, P309, DOI DOI 10.1007/S13181-017-0633-5
   2011, TOXICON, V57, P53, DOI DOI 10.1016/J.TOXICON.2010.09.014
   1966, OBSTET GYNECOL, V27, P468
   2010, J REPROD MED, V55, P520
   2001, ACAD EMERG MED, V8, P177
   2009, CLIN TOXICOL, V47, P327, DOI DOI 10.1080/15563650902870277
   2005, CLIN TOXICOL, V43, P201, DOI DOI 10.1081/CLT-200053339
NR 20
TC 0
Z9 0
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD MAY
PY 2019
VL 163
BP 8
EP 11
DI 10.1016/j.toxicon.2019.03.006
PG 4
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA HY1QB
UT WOS:000467890600002
PM 30880187
DA 2020-05-12
ER

PT J
AU Diaz-Pena, LF
   Ramirez, R
   Cuellar-Balleza, L
   Aguilar, MB
   Lazcano-Perez, F
   Arreguin-Espinosa, R
   Ibarra-Alvarado, C
   Garcia-Arredondo, A
AF Fernando Diaz-Pena, Luis
   Ramirez, Raymundo
   Cuellar-Balleza, Luis
   Aguilar, Manuel B.
   Lazcano-Perez, Fernando
   Arreguin-Espinosa, Roberto
   Ibarra-Alvarado, Cesar
   Garcia-Arredondo, Alejandro
TI Rat aorta relaxation induced by the venom of Poecilotheria regalis
   involves the activation of the NO/cGMP pathway
SO TOXICON
LA English
DT Article
DE Poecilotheria regalis; Venom; Vasodilation; Nitric oxide; Endothelium
ID SPIDER; VASODILATION
AB Spider venoms are widely recognized as a new emerging source of potential research tools, pesticides, drug leads, and therapeutic agents. Some studies suggest that these venoms may contain interesting vasodilator compounds with potential therapeutic applications. In the present study, the vasodilator activity of the venom of Poecilotheria regalis was evaluated in isolated rat aortic rings. This venom induced an endothelium-dependent vasodilation [EC50 value was 5.52 (4.18-7.32) mu g protein/ml with an E-max = 103.4 +/- 3.8%]. While the percentage of vasodilation induced by the venom was significantly diminished in the presence of a nitric oxide synthase inhibitor (L-NAME), it remained unaltered in the presence of suramin, a P2-purinergic receptor antagonist. Moreover, the vasodilator activity of the venom was not affected after boiling bath incubation, but was significantly decreased under reducing conditions. Additionally, venom composition was analyzed by reversephase chromatography and MALDI-TOF mass spectrometry, and two fractions were obtained, referred to as peptidic and non-peptidic fractions. Interestingly, both fractions induced vasodilation in isolated rat aortic rings. The results of this study showed that the venom of P. regalis induces a concentration-dependent vasodilation in rat aorta that was endothelium-dependent and involves the activation of NO/cGMP pathway. These results suggest that the venom contains a combination of both peptidic and non-peptidic vasodilator components. This study provides pharmacological data that suggest that P. regalis venom may be an important source of peptidic and non-peptidic vasodilator compounds.
C1 [Fernando Diaz-Pena, Luis] Univ Autonoma Queretaro, Posgrad Ciencias Quim Biol, Fac Quim, Queretaro 76010, Mexico.
   [Ramirez, Raymundo; Ibarra-Alvarado, Cesar; Garcia-Arredondo, Alejandro] Univ Autonoma Queretaro, Dept Invest Quim & Farmacol Prod Nat, Fac Quim, Queretaro 76010, Mexico.
   [Cuellar-Balleza, Luis] Univ Autonoma Queretaro, Aracnario, Fac Ciencias Nat, Queretaro 76230, Mexico.
   [Aguilar, Manuel B.] Univ Nacl Autonoma Mexico, Lab Neurofarmacol Marina, Inst Neurobiol, Queretaro 76230, Mexico.
   [Lazcano-Perez, Fernando; Arreguin-Espinosa, Roberto] Univ Nacl Autonoma Mexico, Inst Quim, Mexico City 04510, DF, Mexico.
   [Lazcano-Perez, Fernando] Univ Autonoma Metropolitana, Dept Ciencias Salud, Campus Iztapalapa, Mexico City 09340, DF, Mexico.
RP Garcia-Arredondo, A (reprint author), Univ Autonoma Queretaro, Fac Quim, Ctr Univ S-N, Queretaro 76010, Mexico.
EM alejandro.gr@uaq.mx
FU National Council of Science and Technology (CONACYT)Consejo Nacional de
   Ciencia y Tecnologia (CONACyT) [CB-2013-01/223591]; Universidad Autonoma
   de Queretaro [FOFI-UAQ-2018/20501419122202]; CONACYTConsejo Nacional de
   Ciencia y Tecnologia (CONACyT)
FX This work was supported by grants CB-2013-01/223591 from the National
   Council of Science and Technology (CONACYT), and
   FOFI-UAQ-2018/20501419122202 from the Universidad Autonoma de Queretaro,
   to A. Garcia-Arredondo. L.F. Diaz-Pena and R. Ramirez acknowledge
   scholarships from CONACYT. The authors thank E. Garcia Rios, L. Rios
   Ruiz and L. Marquez Alonso for their help with the mass spectrometry
   analysis; and I. Guerrero Cardoso and J.E. de Jesus Lopez for their
   assistance in the evaluation of the vasodilator activity of other
   tarantula venoms.
CR Ahmed N, 2009, QJM-INT J MED, V102, P851, DOI 10.1093/qjmed/hcp128
   Andreev-Andrievskiy A, 2017, TOXICON, V138, P59, DOI 10.1016/j.toxicon.2017.08.013
   [Anonymous], 2018, WORLD SPID CAT VERS, DOI [10.24436/2, DOI 10.24436/2]
   CHAN TK, 1975, TOXICON, V13, P61, DOI 10.1016/0041-0101(75)90159-2
   Erlinge D, 2008, PURINERG SIGNAL, V4, P1, DOI 10.1007/s11302-007-9078-7
   Escoubas P, 2004, TOXICON, V43, P555, DOI 10.1016/j.toxicon.2004.02.007
   Forstermann U, 2012, EUR HEART J, V33, P829, DOI 10.1093/eurheartj/ehr304
   Fuchs J, 2014, TOXICON, V77, P73, DOI 10.1016/j.toxicon.2013.10.032
   Garcia-Arredondo A, 2016, J VENOM ANIM TOXINS, V22, DOI 10.1186/s40409-016-0087-2
   Hanrahan J. P, 2018, CLIN PHARM DRUG DEV, P1
   Herzig V, 2015, TOXINS, V7, P4366, DOI 10.3390/toxins7104366
   Holford M, 2018, SCIENCE, V361, P842, DOI 10.1126/science.aau7761
   Horta CC, 2013, TOXICON, V72, P102, DOI 10.1016/j.toxicon.2013.06.006
   King GF, 2013, ANNU REV ENTOMOL, V58, P475, DOI 10.1146/annurev-ento-120811-153650
   Koh CY, 2018, SEMIN THROMB HEMOST, V44, P691, DOI 10.1055/s-0038-1661384
   Ma BB, 2018, PEPTIDES, V99, P108, DOI 10.1016/j.peptides.2017.12.011
   McCmdden C. M, 2015, PLOS ONE, V10
   Pennington MW, 2018, BIOORGAN MED CHEM, V26, P2738, DOI 10.1016/j.bmc.2017.09.029
   Rattmann YD, 2008, TOXICON, V51, P363, DOI 10.1016/j.toxicon.2007.10.007
   Ravelli KG, 2017, TOXICON, V130, P29, DOI 10.1016/j.toxicon.2017.02.026
   Rocha-e-Silva TAA, 2009, TOXICON, V53, P153, DOI 10.1016/j.toxicon.2008.10.026
   Saez NJ, 2019, TOXICON, V158, P109, DOI 10.1016/j.toxicon.2018.11.298
   Sanchez FA, 2013, TISSUE BARRIERS, V1, DOI [10.4161/tisb.23896, 10.1161/CIRCRESAHA.112.274548]
   Schroeder FC, 2008, P NATL ACAD SCI USA, V105, P14283, DOI 10.1073/pnas.0806840105
   Smith J, 2015, RECONNECTING THE CITY: THE HISTORIC URBAN LANDSCAPE APPROACH AND THE FUTURE OF URBAN HERITAGE, P221
   SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7
   Thibeault S, 2010, MOL CELL, V39, P468, DOI 10.1016/j.molcel.2010.07.013
   Weinberg MLD, 2002, JPN J PHARMACOL, V88, P189, DOI 10.1254/jjp.88.189
   Wieling W, 2016, HEART RHYTHM, V13, P798, DOI 10.1016/j.hrthm.2015.11.023
   2017, TOXICON, V136, P34, DOI DOI 10.1016/J.TOXICON.2017.07.001
   2016, CURR MED CHEM, V23, P603, DOI DOI 10.2174/0929867323666160126142837
NR 31
TC 0
Z9 0
U1 2
U2 3
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD MAY
PY 2019
VL 163
BP 12
EP 18
DI 10.1016/j.toxicon.2019.03.010
PG 7
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA HY1QB
UT WOS:000467890600003
PM 30880186
DA 2020-05-12
ER

PT J
AU Kumara, H
   Seneviratne, N
   Jayaratne, DS
   Siribaddana, S
   Isbister, GK
   Silva, A
AF Kumara, Harendra
   Seneviratne, Nimal
   Jayaratne, Dilini S.
   Siribaddana, Sisira
   Isbister, Geoffrey K.
   Silva, Anjana
TI Severe coagulopathy in Merrem's hump-nosed pit viper (Hypnale hypnale)
   envenoming unresponsive to fresh frozen plasma: A case report
SO TOXICON
LA English
DT Review
DE H hypnale; Coagulopathy; Fresh frozen plasma; Cardiac arrest
ID RANDOMIZED CONTROLLED-TRIAL
AB The Merrem's hump-nosed viper (H. hypnale) causes many snakebites in South India and Sri Lanka. At present no antivenom is available for envenomings by this snake. A 42-year-old male bitten by a large H. hypnale, presented within 30 min of the bite and had a cardiac arrest soon after admission. This responded to standard advanced life support, but he had an unrecordably high international normalised ratio (INR), activated partial thromboplastin time and unrecordably low fibrinogen, consistent with a complete venom-induced consumption coagulopathy. In the absence of antivenom, a total of 1680ml of fresh frozen plasma (FFP) was transfused 5.5 and 16 h post-bite. The coagulopathy did not improve with the administration of FFP and a further elevation of D-Dimer after FFP suggested consumption of transfused clotting factors. The coagulopathy resolved after 72 h. The patient did not develop any bleeding complications, acute kidney injury or evidence of thrombotic microangiopathy and was discharged 8 days after the bite. This case suggests that early FFP for VICC in H. hypnale envenoming may worsen the coagulopathy in the absence of antivenom and cannot be recommended.
C1 [Kumara, Harendra] Univ Colombo, Post Grad Inst Med, Colombo 07, Sri Lanka.
   [Kumara, Harendra; Seneviratne, Nimal; Jayaratne, Dilini S.] Teaching Hosp, Anuradhapura 50000, Sri Lanka.
   [Siribaddana, Sisira; Silva, Anjana] Rajarata Univ Sri Lanka, Fac Med & Allied Sci, Saliyapura 50008, Sri Lanka.
   [Isbister, Geoffrey K.] Univ Newcastle, Clin Toxicol Res Grp, Sch Med & Publ Hlth, Callaghan, NSW, Australia.
   [Isbister, Geoffrey K.; Silva, Anjana] Univ Peradeniya, Fac Med, South Asian Clin Toxicol Res Collaborat, Peradeniya, Sri Lanka.
   [Silva, Anjana] Monash Univ, Fac Med Nursing & Hlth Sci, Dept Pharmacol, Monash Venom Grp, Clayton, Vic, Australia.
RP Silva, A (reprint author), Rajarata Univ Sri Lanka, Fac Med & Allied Sci, Saliyapura 50008, Sri Lanka.
EM nkanjanasilva@gmail.com
RI Siribaddana, Sisira/I-2295-2016; Silva, Anjana/AAB-7764-2019; Isbister,
   Geoffrey K/G-8052-2015
OI Siribaddana, Sisira/0000-0001-5821-2557; Silva,
   Anjana/0000-0002-9968-3707; Isbister, Geoffrey K/0000-0003-1519-7419
FU National Health and Medical Research Council (NHMRC), Australia: Centres
   for Research Excellence [1110343]
FX National Health and Medical Research Council (NHMRC), Australia: Centres
   for Research Excellence Grant No: 1110343.
CR Allen GE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0053188
   Chaisakul J, 2013, TOXICOL LETT, V221, P205, DOI 10.1016/j.toxlet.2013.06.235
   Chaisakul J, 2012, TOXICOL LETT, V213, P243, DOI 10.1016/j.toxlet.2012.06.015
   Isbister GK, 2017, J THROMB HAEMOST, V15, P645, DOI 10.1111/jth.13628
   Isbister GK, 2013, J THROMB HAEMOST, V11, P1310, DOI 10.1111/jth.12218
   Kasturiratne A., 2005, Southeast Asian Journal of Tropical Medicine and Public Health, V36, P733
   Maduwage K, 2013, CLIN TOXICOL, V51, P527, DOI 10.3109/15563650.2013.811589
   Maduwage K, 2013, TOXICON, V61, P11, DOI 10.1016/j.toxicon.2012.10.013
   Maduwage K, 2009, ZOOTAXA, P1
   Rathnayaka RMMKN, 2018, TOXICON, V148, P33, DOI 10.1016/j.toxicon.2018.03.014
   Sellahewa K. H., 2017, HUMP NOSED PIT VIPER
   Senanayake H., 2018, J MED CASE REP, V12, P12
   Shivanthan MC, 2014, J VENOM ANIM TOXINS, V20, DOI 10.1186/1678-9199-20-24
   Thillainathan Sharmila, 2015, BMC Res Notes, V8, P437, DOI 10.1186/s13104-015-1426-z
NR 14
TC 1
Z9 1
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD MAY
PY 2019
VL 163
BP 19
EP 22
DI 10.1016/j.toxicon.2019.03.015
PG 4
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA HY1QB
UT WOS:000467890600004
PM 30885617
DA 2020-05-12
ER

PT J
AU Dizaji, R
   Sharafi, A
   Pourahmad, J
   Abdollahifar, MA
   Vatanpour, H
   Hosseini, MJ
AF Dizaji, Rana
   Sharafi, Ali
   Pourahmad, Jalal
   Abdollahifar, Mohammad-Amin
   Vatanpour, Hossein
   Hosseini, Mir-Jamal
TI Induction of two independent immunological cell death signaling
   following hemoglobinuria -induced acute kidney injury: In vivo study
SO TOXICON
LA English
DT Article
DE Acute kidney injury (AKI); Hemiscorpius lepturus venom; Hemoglobinuria;
   Necroptosis; Ferroptosis
AB The main important clinical signs in acute kidney injury (AKI) after sever Hemiscorpius lepturus envenomation in patients is associated with proteinuria, hemolysis and hemoglobinuria. Unfortunately, our limited knowledge of molecular cell death mechanism in H. lepturus induced AKI restricts the development of desirable therapeutics. So, in the present study, the potential role of necroptosis and ferroptosis in H. lepturus induced AKI were investigated in male albino mice. The animals were administrated by SC injection of venom (1, 2.5, 5 and 10 mg/kg) based on LD50 determination. After 1 and 7 days, urinalysis, stereological assessments and gene expression of Ngal, Tnf-alpha, Tlr-4, Ripk3, Mlkl and Acsl4 were evaluated by real time PCR. Our data revealed that upregulation of renal Ngal expression is associated with the gene over expression of Tnf-alpha, Tlr-4, Ripk3 and Mlkl in venom treated kidneys. We observed that the Malondialdehyde (MDA) level was increased in dose-dependent manner similar to Acsl4 gene over expression suggesting a main role of ferroptosis in hemoglobinuria mediated AKI following envenomation. Moreover, transcriptional enhancement of Tlr-4and Tnf-alpha receptor can cause phosphorylation of Ripk3-Mlkl complex, collapse of membrane potential and DAMPs release which intensified the inflammation cytokines in kidney. Taken together, it supposes co-existence of two separate pathways of regulated necrosis and inflammatory environment provides a promising outlook in prevention and management of hemoglobinuria induced AKI following envenomation in clinical practice.
C1 [Dizaji, Rana; Pourahmad, Jalal; Vatanpour, Hossein] Shahid Beheshti Univ Med Sci, Fac Pharm, Dept Pharmacol, Tehran, Iran.
   [Dizaji, Rana; Pourahmad, Jalal; Vatanpour, Hossein] Shahid Beheshti Univ Med Sci, Fac Pharm, Dept Toxicol, Tehran, Iran.
   [Sharafi, Ali; Hosseini, Mir-Jamal] Zanjan Univ Med Sci, Zanjan Appl Pharmacol Res Ctr, Zanjan, Iran.
   [Sharafi, Ali] Zanjan Univ Med Sci, Zanjan Pharmaceut Biotechnol Res Ctr, Zanjan, Iran.
   [Abdollahifar, Mohammad-Amin] Shahid Beheshti Univ Med Sci, Dept Biol & Anat Sci, Tehran, Iran.
   [Hosseini, Mir-Jamal] Zanjan Univ Med Sci, Sch Pharm, Dept Pharmacol & Toxicol, Zanjan, Iran.
RP Vatanpour, H (reprint author), Shahid Beheshti Univ Med Sci, Fac Pharm, Dept Pharmacol, Tehran, Iran.; Vatanpour, H (reprint author), Shahid Beheshti Univ Med Sci, Fac Pharm, Dept Toxicol, Tehran, Iran.; Hosseini, MJ (reprint author), Zanjan Univ Med Sci, Zanjan Appl Pharmacol Res Ctr, Dept Pharmacol & Toxicol, Sch Pharm, POB 45139-56184, Zanjan, Iran.
EM vatanpour.hossein@gmail.com; jamal_hossini@yahoo.com
RI Sharafi, Ali/J-9647-2016; Dizaji, Rana/AAF-7540-2019
OI Sharafi, Ali/0000-0002-6012-1424; Dizaji, Rana/0000-0001-6812-3902;
   Hosseini, Mir-Jamal/0000-0002-4469-9488
FU Shahid Beheshti University of Medical Sciences [96/11/15/11462]; Zanjan
   Applied Pharmacology Research Center in Zanjan University of Medical
   Sciences
FX This work was supported by Shahid Beheshti University of Medical
   Sciences, Deputy of Research [Grant NO 96/11/15/11462, 2016] in
   collaboration with Zanjan Applied Pharmacology Research Center located
   in Zanjan University of Medical Sciences.
CR Deuel JW, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2015.392
   Dutra FF, 2014, P NATL ACAD SCI USA, V111, pE4110, DOI 10.1073/pnas.1405023111
   Homsi E, 2015, AM J PHYSIOL-RENAL, V308, pF1259, DOI 10.1152/ajprenal.00311.2014
   Kaiser William J, 2013, J BIOL CHEM JBC M, VM113
   Larsen R, 2012, FRONT PHARMACOL, V3, DOI 10.3389/fphar.2012.00077
   Mizuno Masashi, 2016, CNIDARIA PRESENT FUT
   Mulay Shrikant R., 2015, J AM SOC NEPHROL
   Nyengaard JR, 1999, J AM SOC NEPHROL, V10, P1100
   Valavi E, 2008, Indian J Nephrol, V18, P166, DOI 10.4103/0971-4065.45293
   Valavi E, 2016, SAUDI J KIDNEY DIS T, V27, P936, DOI 10.4103/1319-2442.190841
   Vanden Berghe T, 2014, NAT REV MOL CELL BIO, V15, P134, DOI 10.1038/nrm3737
   Wang S, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.37
   Weber K, 2018, COMMUN BIOL, V1, DOI 10.1038/s42003-017-0007-1
   Xie Y, 2016, CELL DEATH DIFFER, V23, P369, DOI 10.1038/cdd.2015.158
   Xu Y., 2015, J AM SOC NEPHROL
   Yang WS, 2016, TRENDS CELL BIOL, V26, P165, DOI 10.1016/j.tcb.2015.10.014
   Yang WS, 2014, CELL, V156, P317, DOI 10.1016/j.cell.2013.12.010
   2015, CLIN KIDNEY J, V8, P548, DOI DOI 10.1093/CKJ/SFV069
   2007, TOXICON, V50, P984, DOI DOI 10.1016/J.TOXICON.2007.07.018
   1999, BIOMETALS, V12, P353
   2012, BLOOD, V119, P2368, DOI DOI 10.1182/BLOOD-2011-08-375303
   2017, J AM SOC NEPHROL, V28, P218, DOI DOI 10.1681/ASN.2015121376
   2017, BIOMD ENVIRON SCI, V30, P581, DOI DOI 10.3967/BES2017.077
   2011, TOXICON, V58, P130, DOI DOI 10.1016/J.TOXICON.2011.05.016
   2013, GENE DEV, V27, P1640, DOI DOI 10.1101/GAD.223321.113
   2017, CELL MOL LIFE SCI, V74, P3631, DOI DOI 10.1007/S00018-017-2547-4
   2014, NAT CELL BIOL, V16, P1180, DOI DOI 10.1038/NCB3064
   2018, LAB INVEST, V98, P79, DOI DOI 10.1038/LABINVEST.2017.115
   2008, ANN REV PHARM TOXICO, V48, P463, DOI DOI 10.1146/ANNUREV.PHARMTOX.48.113006.094615
   2016, CELL RES, V26, P517, DOI DOI 10.1038/CR.2016.26
   2006, TOXICON, V48, P93, DOI DOI 10.1016/J.TOXICON.2006.04.017
   2008, ASIAN BIOMED, V2, P451
   2017, CELL, V171, P273, DOI DOI 10.1016/J.CELL.2017.09.021
   2013, P NATL ACAD SCI USA, V110, P1202, DOI DOI 10.1073/PNAS.1305538110
   2015, ACS CHEM BIOL, V10, P1604, DOI DOI 10.1021/ACSCHEMBIO.5B00245
   2007, J BIOL CHEM, V282, P2022, DOI DOI 10.1074/JBC.M610737200
   2014, P NATL ACAD SCI USA, V111, P1683, DOI DOI 10.1073/PNAS.1415518111
   2014, IMMUNITY, V41, P567, DOI DOI 10.1016/J.IMMUNI.2014.09.016
   2010, ANN REV PHARM TOXICO, V50, P323, DOI DOI 10.1146/ANNUREV.PHARMTOX.010909.105600
   2017, CELL RES, V27, P1081, DOI DOI 10.1038/CR.2017.75
   2014, MOL MED REP, V10, P719, DOI DOI 10.3892/MMR.2014.2234
   2014, NAT REV IMMUNOL, V14, P759, DOI DOI 10.1038/NRI3743
   2008, ANNU REV PATHMECHDIS, V3, P99, DOI DOI 10.1146/ANNUREV.PATHOL.3.121806.151456
   2017, NAT CHEM BIOL, V13, P91, DOI DOI 10.1038/NCHEMBIO.2239
   1977, ENV SCI TECHNOL, V11, P714
   2017, IMMUNOL CELL BIOL, V95, P152, DOI DOI 10.1038/ICB.2016.125
   2018, CURR OPIN IMMUNOL, V50, P14, DOI DOI 10.1016/J.COI.2017.10.005
   2011, NAT MED, V17, P216, DOI DOI 10.1038/NM.2290
   2016, NAT CHEM BIOL, V12, P497, DOI DOI 10.1038/NCHEMBIO.2079
   2012, CELL, V149, P1060, DOI DOI 10.1016/J.CELL.2012.03.042
   2018, P NATL ACAD SCI USA, V115, P4182, DOI DOI 10.1073/PNAS.1716578115
   1998, INT J DERMATOL, V37, P500
   2016, BIOCHEM BIOPH RES CO, V478, P1338, DOI DOI 10.1016/J.BBRC.2016.08.124
   2017, CELL DEATH DIFFER, V24, P1184, DOI DOI 10.1038/CDD.2017.65
NR 54
TC 2
Z9 2
U1 3
U2 5
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD MAY
PY 2019
VL 163
BP 23
EP 31
DI 10.1016/j.toxicon.2019.03.011
PG 9
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA HY1QB
UT WOS:000467890600005
PM 30890325
DA 2020-05-12
ER

PT J
AU Baum, RA
   Bronner, J
   Akpunonu, PDS
   Plott, J
   Bailey, AM
   Keyler, DE
AF Baum, R. A.
   Bronner, J.
   Akpunonu, P. D. S.
   Plott, J.
   Bailey, A. M.
   Keyler, D. E.
TI Crotalus durissus terrificus (viperidae; crotalinae) envenomation:
   Respiratory failure and treatment with antivipmyn TRI (R) antivenom
SO TOXICON
LA English
DT Article
DE Envenomation; C. d. terrificus; Antivenom; Antivipmyn TRI (R);
   Respiratory failure; United States
ID VENOM; COAGULOPATHY; SNAKEBITE; CROTOXIN; SERUM; MUSCLE
AB We report an envenomation to a professional herpetologist by a South American rattlesnake (Crotalus durissus terrificus) that resulted in respiratory failure, and therapeutic improvement following antivenom administration. A 56-year-old male was bitten on the left wrist by a Crotalus durissus terrificus (C. d. terrificus) while attempting to tube the snake for maintaining safe control while performing venom extraction. The patient was intubated due to rapidly ensuing respiratory failure and administration of Antivipmyn-TRI (R) was initiated while being transported via ambulance. The patient was admitted to the hospital unconscious and unresponsive. Mechanical ventilation was required until 5 h after completion of antivenom administration. No significant adverse effects were observed with antivenom administration. The patient was discharged approximately 55 h following envenomation. This is the first reported case in the United States of a patient following a C. d terrificus envenomation with consequent respiratory failure, and in which Antivipmyn-TRI (R) was successfully administered.
C1 [Baum, R. A.; Bailey, A. M.] Univ Kentucky HealthCare, Lexington, KY 40536 USA.
   [Baum, R. A.; Plott, J.; Bailey, A. M.] Univ Kentucky, Coll Pharm, Lexington, KY 40504 USA.
   [Bronner, J.; Akpunonu, P. D. S.] Univ Kentucky, Dept Emergency Med, Chandler Med Ctr, Lexington, KY 40536 USA.
   [Keyler, D. E.] Univ Minnesota, Dept Expt & Clin Pharmacol, 7-115 Weaver Densford Hall,308 Harvard St SE, Minneapolis, MN 55455 USA.
RP Keyler, DE (reprint author), Univ Minnesota, Dept Expt & Clin Pharmacol, 7-115 Weaver Densford Hall,308 Harvard St SE, Minneapolis, MN 55455 USA.
EM keyle001@umn.edu
OI Akpunonu, Peter/0000-0002-6968-686X
CR Amaral CFS, 1997, TOXICON, V35, P699, DOI 10.1016/S0041-0101(96)00181-X
   AMARAL CFS, 1991, REV INST MED TROP SP, V33, P251, DOI 10.1590/S0036-46651991000400002
   Boldrini-Franca J, 2010, J PROTEOMICS, V73, P1758, DOI 10.1016/j.jprot.2010.06.001
   Bucaretchi F, 2014, CLIN TOXICOL, V52, P639, DOI 10.3109/15563650.2014.913177
   Bucaretchi F, 2013, CLIN TOXICOL, V51, P505, DOI 10.3109/15563650.2013.802796
   CAMERON DL, 1978, BIOCHIM BIOPHYS ACTA, V532, P147, DOI 10.1016/0005-2795(78)90457-9
   CAMPBELL JA, 2004, VENOMOUS REPTILES W
   Cavalcante WLG, 2017, TOXICOL APPL PHARM, V334, P8, DOI 10.1016/j.taap.2017.08.021
   Churchman A, 2010, MED J AUSTRALIA, V193, P696, DOI 10.5694/j.1326-5377.2010.tb04108.x
   CUPO P, 1988, T ROY SOC TROP MED H, V82, P924, DOI 10.1016/0035-9203(88)90044-2
   de Siqueira J E, 1990, Arq Bras Cardiol, V54, P323
   Dijkman MA, 2016, CLIN TOXICOL, V54, P447, DOI 10.3109/15563650.2016.1156688
   EKENBACK K, 1985, J TOXICOL-CLIN TOXIC, V23, P357, DOI 10.3109/15563658508990645
   Faure G, 2017, TOXINOLOGY, P3, DOI 10.1007/978-94-007-6452-1_7
   Baudou FG, 2017, TOXICON, V140, P11, DOI 10.1016/j.toxicon.2017.10.009
   Georgieva D, 2010, J PROTEOME RES, V9, P2302, DOI 10.1021/pr901042p
   Isbister GK, 2013, MED J AUSTRALIA, V199, P763, DOI 10.5694/mja12.11172
   JORGE MT, 1992, REV INST MED TROP SP, V34, P347, DOI 10.1590/S0036-46651992000400013
   Laurence AS, 2000, BRIT J ANAESTH, V84, P763
   Lynch MJ, 2011, J MED TOXICOL, V7, P44, DOI 10.1007/s13181-010-0100-z
   MEBS D, 1983, TOXICON, V21, P393, DOI 10.1016/0041-0101(83)90096-X
   Nadaud A, 2019, ANAESTH CRIT CARE PA, V38, P193, DOI 10.1016/j.accpm.2018.06.004
   de Roodt A, 2016, TOXICON, V121, P22, DOI 10.1016/j.toxicon.2016.08.013
   Richardson WH, 2007, CLIN TOXICOL, V45, P472, DOI 10.1080/15563650701338187
   Sampaio SC, 2010, TOXICON, V55, P1045, DOI 10.1016/j.toxicon.2010.01.011
   Sano-Martins IS, 2001, QJM-INT J MED, V94, P551, DOI 10.1093/qjmed/94.10.551
   Teixeira-Araujo R, 2017, J VENOM ANIM TOXINS, V23, DOI 10.1186/s40409-017-0118-7
   Vale TC, 2013, REV SOC BRAS MED TRO, V46, P255, DOI 10.1590/0037-8682-1667-2013
   Williams KL, 2017, CLIN TOXICOL, V55, P326, DOI 10.1080/15563650.2017.1284334
   World Health Organisation, 2010, WHO GUID PROD CONTR, V141
   2013, TOXICON, V69, P75, DOI DOI 10.1016/J.TOXICON.2013.01.006
   2010, WILDERNESS ENVION ME, V21, P120
NR 32
TC 1
Z9 1
U1 0
U2 3
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD MAY
PY 2019
VL 163
BP 32
EP 35
DI 10.1016/j.toxicon.2019.03.009
PG 4
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA HY1QB
UT WOS:000467890600006
PM 30880190
DA 2020-05-12
ER

PT J
AU Duarte, RCF
   Rios, DRA
   Leite, PM
   Alves, LC
   Magalhaes, HPB
   Carvalho, MD
AF Figueiredo Duarte, Rita Carolina
   Alves Rios, Danyelle Romana
   Leite, Paula Mendonca
   Alves, Luan Carlos
   Barroso Magalhaes, Henrique Pimenta
   Carvalho, Maria das Gracas
TI Thrombin generation test for evaluating hemostatic effects of Brazilian
   snake venoms
SO TOXICON
LA English
DT Article
DE Thrombin generation test; Snake venom; Bothrops sp; Crotalus sp;
   Hemostatic changes; Hypercoagulability
AB Snake venoms as well as their components have been tested worldwide to find new molecules for prophylaxis and treatment of several pathologies or even for diagnostic purposes. It is widely known that snake venoms contain enzymes and non-enzymatic proteins that interfere with hemostasis leading to hemorrhage or even thrombosis. The treatment of snake envenoming and the development of new drugs. The thrombin generation test (TGT) is a highly sensitive tool for investigation of hemostatic changes, overlapping with existing coagulometric techniques. The aim of this study was to use TGT to evaluate in vitro hemostatic changes caused by venom of Brazilian snakes B. jararacussu, B. alternatus, B. moojeni and C. durissus terrificus in a normal pool of platelet-poor plasma, comparing results to those obtained by the classical coagulation assays, at the same concentrations of venom. B. moojeni venom showed to be more hypercoagulable, with a greater ability to activate coagulation, evidenced by increased values of Endogenous Thrombin Potential (ETP), even in the reactions in which the triggering reagent (tissue factor) was not added. On the other hand, the lowest ETP values were observed in plasma incubated with C. durissus terrificus venom. As a new finding of great importance, all venoms at the same concentrations assessed by TGT did not promote changes in a pool of platelet-poor plasma by classic coagulometric assays, such as prothrombin time (PT) and activated partial thromboplastin time (aPTT), whose results were within the reference range. Thus, TGT showed to be more sensitive than the coagulometric assays to evaluate the hemostatic effect of venom components in vitro. Our preliminary results indicate a potential role for TGT in improving the laboratory investigation of hemostatic changes due to snakebite. In addition, elucidation of hemostatic changes induced by different Brazilian snake venoms related to hypocoagulability or hypercoagulability represents an important approach to improving the treatment of snake envenoming and the development of new drugs.
C1 [Figueiredo Duarte, Rita Carolina; Leite, Paula Mendonca; Alves, Luan Carlos; Barroso Magalhaes, Henrique Pimenta; Carvalho, Maria das Gracas] Univ Fed Minas Gerais, Clin & Toxicol Dept, Fac Pharm, Belo Horizonte, MG, Brazil.
   [Alves Rios, Danyelle Romana] Univ Fed Sao Joao del Rei, Campus Ctr Oeste Dona Lindu, Sao Joao Del Rei, Brazil.
RP Carvalho, MD (reprint author), Univ Fed Minas Gerais, Clin & Toxicol Dept, Av Antonio Carlos 6627, BR-31270910 Belo Horizonte, MG, Brazil.
EM mgcarvalho@farmacia.ufmg.br
FU CNPq - BrazilNational Council for Scientific and Technological
   Development (CNPq) [426933/2016-8, 406537/2017-8]
FX This study was supported by CNPq - Brazil [grant number: 426933/2016-8
   and PDJ number 406537/2017-8].
CR Amorim FG, 2018, TOXINS, V10, DOI 10.3390/toxins10050177
   Berling I, 2015, TRANSFUS MED REV, V29, P82, DOI 10.1016/j.tmrv.2014.09.005
   Hemker HC, 2006, THROMB HAEMOSTASIS, V96, P553, DOI 10.1160/TH06-07-0408
   Hemker HC, 2003, PATHOPHYSIOL HAEMO T, V33, P4, DOI 10.1159/000071636
   Hoffman M, 2007, HEMATOL ONCOL CLIN N, V21, P1, DOI 10.1016/j.hoc.2006.11.004
   Kini R M, 2016, TOXINS, V8, pE284, DOI DOI 10.3390/T0XINS8100284
   Lister C, 2017, COMP BIOCHEM PHYS C, V202, P39, DOI 10.1016/j.cbpc.2017.07.005
   Lu Q, 2005, J THROMB HAEMOST, V3, P1791, DOI 10.1111/j.1538-7836.2005.01358.x
   McCleary RJR, 2013, THROMB RES, V132, P642, DOI 10.1016/j.thromres.2013.09.031
   O'Leary MA, 2010, J PHARMACOL TOX MET, V61, P27, DOI 10.1016/j.vascn.2009.06.004
   Perchuc AM, 2005, PATHOPHYSIOL HAEMO T, V34, P241, DOI 10.1159/000092431
   Rogalski A, 2017, TOXICOL LETT, V280, P159, DOI 10.1016/j.toxlet.2017.08.020
   Sajevic T, 2011, TOXICON, V57, P627, DOI 10.1016/j.toxicon.2011.01.006
   Sartim MA, 2016, ARCH TOXICOL, V90, P1261, DOI 10.1007/s00204-015-1533-6
   Sousa LF, 2018, TOXINS, V10, DOI 10.3390/toxins10100411
   Suntravat M, 2010, TOXICON, V56, P544, DOI 10.1016/j.toxicon.2010.05.012
   Yamashita KM, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002814
   2010, J PROTEOMICS, V73, P1758, DOI DOI 10.1016/J.JPROT.2010.06.001
   2018, TOXICOL LETT, V288, P119, DOI DOI 10.1016/J.TOXLET.2018.02.020
NR 19
TC 3
Z9 3
U1 1
U2 3
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD MAY
PY 2019
VL 163
BP 36
EP 43
DI 10.1016/j.toxicon.2019.03.012
PG 8
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA HY1QB
UT WOS:000467890600007
PM 30880188
DA 2020-05-12
ER

PT J
AU Fuchs, J
   Bessire, K
   Weiler, S
AF Fuchs, Joan
   Bessire, Karin
   Weiler, Stefan
TI A confirmed bite by a Beautiful Pit Viper (Trimeresurus venustus)
   resulting in local symptoms
SO TOXICON
LA English
DT Review
DE Trimeresurus venustus; Cryptelytrops venustus; Local symptoms;
   Coagulopathy
ID ALBOLABRIS; ENVENOMATION; THAILAND; MACROPS
AB This case report describes the effect of an envenomation by the Beautiful Pit Viper Trimeresurus venustus (or Cryptelytrops venustus), which is a green pit viper native to Thailand and Malaysia. A previously healthy 60-year-old snake breeder with no relevant medical history was bitten by his adult T. venustus in the third finger of his right hand while taking it out of the feeding box. The bite was painful and swelling progressed to include his whole hand within an hour after the bite. He was treated symptomatically with pre-emptive antibiotics and analgesics, never developed any hematological disorders such as coagulopathy and bleeding or disseminated intravascular coagulation and was discharged 26 hours after the bite.
   The clinical course in our patient matched two other well-documented cases reported to our Poisons Centre, and one further case presented as a conference-poster. All patients recovered with symptomatic therapy and never required antivenom. Therefore, bites by T. venustus seem to present with less severe symptoms compared to other Trimeresurus species.
C1 [Fuchs, Joan; Weiler, Stefan] Univ Zurich, Natl Poisons Informat Ctr, Tox Info Suisse, Associated Inst, Zurich, Switzerland.
   [Bessire, Karin] CHU Vaudois, Dept Emergency Med, Lausanne, Switzerland.
RP Fuchs, J (reprint author), Tox Info Suisse, Freiestr 16, CH-8032 Zurich, Switzerland.
EM joan.fuchs@toxinfo.ch
CR Chan J. C. N., 1993, Singapore Medical Journal, V34, P145
   Chan TYK, 2010, SE ASIAN J TROP MED, V41, P192
   Chanhome L, 2011, ASIAN BIOMED, V5, P311, DOI 10.5372/1905-7415.0503.043
   Chotenimitkhun R, 2008, CLIN TOXICOL, V46, P122, DOI 10.1080/15563650701266826
   Gowda R, 2018, J CELL BIOCHEM, V119, P5904, DOI 10.1002/jcb.26782
   Greene S, 2017, J EMERG MED, V53, pE115, DOI 10.1016/j.jemermed.2017.09.003
   HUTTON RA, 1990, T ROY SOC TROP MED H, V84, P866, DOI 10.1016/0035-9203(90)90111-Q
   Kerrigan KR, 1997, WORLD J SURG, V21, P369, DOI 10.1007/PL00012255
   Lavonas EJ, 2019, CLIN TOXICOL, V57, P144, DOI 10.1080/15563650.2018.1502445
   MAHASANDANA S, 1990, Southeast Asian Journal of Tropical Medicine and Public Health, V21, P225
   Malhotra A, 2004, HERPETOL J, V14, P21
   Pandey DP, 2019, WILD ENVIRON MED, V30, P79, DOI 10.1016/j.wem.2018.11.001
   Pham HX, 2018, CLIN TOXICOL, V56, P1121, DOI 10.1080/15563650.2018.1468447
   Rojnuckarin P, 1999, TOXICON, V37, P743, DOI 10.1016/S0041-0101(98)00214-1
   Suankratay C, 2002, WILD ENVIRON MED, V13, P256, DOI 10.1580/1080-6032(2002)013[0256:TAWLGP]2.0.CO;2
   Suteparuk S, 2016, 15 INT SCI C AS PAC, DOI [10.13140/RG.2.2.24829.26085, DOI 10.13140/RG.2.2.24829.26085]
   WARRELL DA, 1992, T ROY SOC TROP MED H, V86, P95, DOI 10.1016/0035-9203(92)90461-K
   Yang Janet Y. K., 2007, Hong Kong Medical Journal, V13, P392
   2017, TOXICON, V129, P95, DOI DOI 10.1016/J.TOXICON.2017.02.011
   2017, TOXICON, V137, P99, DOI DOI 10.1016/J.TOXICON.2017.07.017
NR 20
TC 0
Z9 0
U1 0
U2 2
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD MAY
PY 2019
VL 163
BP 44
EP 47
DI 10.1016/j.toxicon.2019.03.019
PG 4
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA HY1QB
UT WOS:000467890600008
PM 30902684
DA 2020-05-12
ER

PT J
AU Netzel, G
   Palmer, DG
   Masters, AM
   Tai, SY
   Allen, JG
   Fletcher, MT
AF Netzel, Gabriele
   Palmer, Dieter G.
   Masters, Anne M.
   Tai, Samantha Y.
   Allen, Jeremy G.
   Fletcher, Mary T.
TI Assessing the risk of residues of the toxin indospicine in bovine muscle
   and liver from north-west Australia
SO TOXICON
LA English
DT Article
DE Residue; Plant toxin; Beef; Indospicine; Indigofera
ID INDIGOFERA-SPICATA; AMINO-ACID; CAMEL MEAT; DOGS; RAT
AB Indospicine is a natural toxin occurring only in Indigofera plant species, including the Australian native species linnaei. These perennial legumes are resistant to drought and palatable to grazing livestock including cattle. Indospicine accumulates in the tissues (including muscle) of animals grazing Indigofera and these residues persist for several months after exposure. Dogs are particularly sensitive to indospicine with reports in past decades of hepatotoxicosis and mortalities in dogs after dietary exposure to indospicine-contaminated horse and camel meat. The risk for human consumption is not known, and the current study was undertaken to assess indospicine levels in cattle going to slaughter from divergent regions of Western Australia, and to predict the likelihood of significant residues being present. Muscle and corresponding liver samples from 776 cattle originating from the Kimberley and Pilbara Regions in the tropical north of the state, where I. linnaei is prevalent, and 640 cattle from the South West and South Coast Regions in the temperate south west of the state, where the plant is not known to occur, were collected at abattoirs over four seasons in 2015-2017. Indospicine levels were measured by LC-MS/MS and ranged from below detection to 3.63 mg/kg. No indospicine residues were detected in any of the animals originating from the South West and South Coast Regions. Prevalence of indospicine residues in cattle from the Kimberley Region was as high as 33% in spring and 91% in autumn, with positive animals being present in most consignments and on most properties. The average prevalence of indospicine residues from the Kimberley and Pilbara Regions throughout the survey period was 63%. @Risk best fit probability distributions showed ninety-fifth percentile (P95) indospicine concentrations of 0.54 mg/kg for muscle and 0.77 mg/kg for liver in cattle originating from the Kimberley and Pilbara Regions during the survey period. When considered with average Australian meat consumption data, the estimated consumer exposure from this P95 muscle was 0.32 mu g indospicine/kg bw/day, which compared favourably with our calculated provisional tolerable daily intake (PTDI) of 1.3 mu g indospicine/kg bw/day. However canine exposure is of potential concern, with active working dog exposure calculated to exceed this PTDI by a factor of 25, based on a P95 indospicine concentration of 0.54 mg/kg in muscle.
C1 [Netzel, Gabriele; Fletcher, Mary T.] Univ Queensland, Queensland Alliance Agr & Food Innovat, Hlth & Food Sci Precinct, 39 Kessels Rd, Coopers Plains, Qld 4108, Australia.
   [Palmer, Dieter G.; Masters, Anne M.; Tai, Samantha Y.; Allen, Jeremy G.] Dept Primary Ind & Reg Dev, South Perth, WA 6151, Australia.
RP Fletcher, MT (reprint author), Univ Queensland, Queensland Alliance Agr & Food Innovat, Hlth & Food Sci Precinct, 39 Kessels Rd, Coopers Plains, Qld 4108, Australia.
EM mary.fletcher@uq.edu.au
RI Netzel, Gabriele/M-3889-2013; Netzel, Gabi/AAL-1751-2020; Fletcher, Mary
   T./G-9584-2019
OI Netzel, Gabriele/0000-0003-1581-4851; Netzel, Gabi/0000-0002-5699-2622;
   Fletcher, Mary T./0000-0003-0189-3376
FU Biosecurity Research and Development Fund, part of the Boosting
   Biosecurity Defences project - Royalties for Regions; Department of
   Primary Industries and Regional Development (DPIRD) in Western Australia
FX This research was funded by The Biosecurity Research and Development
   Fund, part of the Boosting Biosecurity Defences project, supported by
   Royalties for Regions and the Department of Primary Industries and
   Regional Development (DPIRD) in Western Australia.
CR ABARES, 2017, AGR COMM STAT 2017
   Australian Bureau of Statistics, 2014, AUSTR HLTH SURV NUTR
   Australian Bureau of Statistics, 1995, NAT NUTR SURV FOODS
   CHRISTIE GS, 1969, BIOCHEM PHARMACOL, V18, P693, DOI 10.1016/0006-2952(69)90039-2
   CHRISTIE GS, 1975, J PATHOL, V117, P195, DOI 10.1002/path.1711170402
   CSIRO, 2009, WAT KIMB REG
   Du Puy D. J., 1993, Kew Bulletin, V48, P727, DOI 10.2307/4118850
   enHealth Council, 2012, ENV HLTH RISK ASS GU
   FitzGerald LM, 2011, AUST VET J, V89, P95, DOI 10.1111/j.1751-0813.2010.00684.x
   Fletcher M. T, 2013, INDOSPICINE ELUCIDAT, P45
   Fletcher MT, 2018, ANIM PROD SCI, V58, P568, DOI 10.1071/AN16394
   Fletcher MT, 2015, AGRICULTURE-BASEL, V5, P427, DOI 10.3390/agriculture5030427
   Goulding P. M, 2014, GEN REGIONS W AUSTR
   Gracie A, 2010, AGNOTE BIRDSVILLE DI
   HEGARTY MP, 1970, AUST J BIOL SCI, V23, P831, DOI 10.1071/BI9700831
   HEGARTY MP, 1988, AUST VET J, V65, P337, DOI 10.1111/j.1751-0813.1988.tb14259.x
   Instinct, 2014, RAW PET FOODS MEAT C
   Kelly W. R., 1992, Poisonous plants. Proceedings of the Third International Symposium., P126
   Lang CS, 2016, ORG BIOMOL CHEM, V14, P6826, DOI 10.1039/c6ob01187j
   Macarthur Veterinary Group, 2018, NORM WEIGHTS DOG BRE
   Nordfeldt S., 1952, HAWAII AGR EXPT STAT
   PEARN J H, 1970, British Journal of Experimental Pathology, V51, P34
   POWO, 2019, PLANTS WORLD ONL FAC
   Tan ETT, 2016, J AGR FOOD CHEM, V64, P8447, DOI 10.1021/acs.jafc.6b03499
   Tan ETT, 2016, J AGR FOOD CHEM, V64, P6613, DOI 10.1021/acs.jafc.6b02437
   Tan ETT, 2016, J AGR FOOD CHEM, V64, P6622, DOI 10.1021/acs.jafc.6b02707
   Tan ETT, 2014, J AGR FOOD CHEM, V62, P1974, DOI 10.1021/jf4052495
   WKC, 2012, COD WELF AUSTR LIV W
   Wong L, 2015, ECON MODEL, V49, P1, DOI 10.1016/j.econmod.2015.03.002
NR 29
TC 1
Z9 1
U1 4
U2 6
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD MAY
PY 2019
VL 163
BP 48
EP 58
DI 10.1016/j.toxicon.2019.03.007
PG 11
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA HY1QB
UT WOS:000467890600009
PM 30880189
DA 2020-05-12
ER

PT J
AU Paiva, ALB
   Mudadu, MA
   Pereira, EHT
   Marri, CA
   Guerra-Duarte, C
   Diniz, MRV
AF Paiva, Ana L. B.
   Mudadu, Mauricio A.
   Pereira, Elaine H. T.
   Marri, Camila A.
   Guerra-Duarte, Clara
   Diniz, Marcelo R., V
TI Transcriptome analysis of the spider Phoneutria pertyi venom glands
   reveals novel venom components for the genus Phoneutria
SO TOXICON
LA English
DT Article
DE Phoneutria; Venom glands; Transcriptome; Cysteine-rich toxin
ID ANTIMICROBIAL PEPTIDE; GLUTAMATE RELEASE; NIGRIVENTER; TOXIN;
   NEUROTOXIN; PH-ALPHA-1-BETA; PURIFICATION; WEB; IDENTIFICATION;
   HEMOCYTES
AB Phoneutria nigriventer spider venom has been studied for more than 40 years and several components with pharmacological potential have been described in it. However, studies on venoms from other species of the Phoneutria genus are scarce. In this work, a conventional cDNA library from the species Phoneutria pertyi venom glands was constructed, aiming to identify novel putative cysteine-rich peptide toxins for the genus Phoneutria. 296 unique sequences were identified and 51 sequences corresponded to putative cysteine-rich peptide toxins. Besides cysteine-rich peptide toxins, other putative venom components such as protease inhibitors, defensins and serine proteinases were identified. Furthermore, by manual curation of the sequences with no match at UniProt, we were able to identify glycine-rich proteins (GRP), a class of venom component never described in Phoneutria genus. This work describes the first complete sequences of toxins from the venom of P. pertyi and reveals that, despite most of the retrieved toxins show a high identity to toxins identified in Phoneutria genus, novel putative toxins remains to be described.
C1 [Paiva, Ana L. B.; Mudadu, Mauricio A.; Pereira, Elaine H. T.; Marri, Camila A.; Guerra-Duarte, Clara; Diniz, Marcelo R., V] Fundacao Ezequiel Dias, Diretoria Pesquisa & Desenvolvimento, Belo Horizonte, MG, Brazil.
   [Mudadu, Mauricio A.] Embrapa Informat Agr, Campinas, SP, Brazil.
RP Paiva, ALB (reprint author), Fundacao Ezequiel Dias, Rua Conde Pereira Carneiro,80 Gameleira, BR-30510010 Belo Horizonte, MG, Brazil.
EM analuiza.paiva@funed.mg.gov.br
RI de Alvarenga Mudadu, Mauricio/B-6524-2014; Duarte, Clara
   Guerra/H-1409-2012
OI de Alvarenga Mudadu, Mauricio/0000-0002-2767-2507; Duarte, Clara
   Guerra/0000-0002-7698-3811
FU FAPEMIGMinas Gerais State Research Foundation (FAPEMIG); CNPqNational
   Council for Scientific and Technological Development (CNPq); CAPESCAPES
FX We thank Mrs. Neiman Pereira for spiders maintenance and venom glands
   extraction. This work was supported by FAPEMIG, CNPq and CAPES.
CR Agostini RM, 2011, RETINA-J RET VIT DIS, V31, P1392, DOI 10.1097/IAE.0b013e318205b249
   Almeida AP, 2011, TOXICON, V57, P217, DOI 10.1016/j.toxicon.2010.11.013
   Almeida DD, 2012, BMC GENOMICS, V13, DOI 10.1186/1471-2164-13-362
   Antunes E, 2003, ANIMAIS PECONHENTOS, V1, P166
   Artimo P, 2012, NUCLEIC ACIDS RES, V40, pW597, DOI 10.1093/nar/gks400
   Baumann T, 2010, CELL MOL LIFE SCI, V67, P2787, DOI 10.1007/s00018-010-0364-0
   Blackledge TA, 2009, P NATL ACAD SCI USA, V106, P5229, DOI 10.1073/pnas.0901377106
   Chen J, 2015, INT J BIOL MACROMOL, V79, P504, DOI 10.1016/j.ijbiomac.2015.05.027
   Chen JJ, 2008, TOXICON, V52, P794, DOI 10.1016/j.toxicon.2008.08.003
   Chen Z, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082288
   Craik DJ, 2001, TOXICON, V39, P43, DOI 10.1016/S0041-0101(00)00160-4
   da Silva JF, 2015, TOXICON, V108, P53, DOI 10.1016/j.toxicon.2015.09.043
   de Figueiredo SG, 2001, TOXICON, V39, P309, DOI 10.1016/S0041-0101(00)00129-X
   De Lima M.E., 2015, SPIDER VENOMS, P1, DOI DOI 10.1007/978-94-007-6646-4
   de Lima ME, 2002, J INSECT PHYSIOL, V48, P53, DOI 10.1016/S0022-1910(01)00143-3
   de Oliveira UC, 2015, TOXICON, V95, P52, DOI 10.1016/j.toxicon.2014.12.013
   de Souza AH, 2013, CELL MOL NEUROBIOL, V33, P59, DOI 10.1007/s10571-012-9871-x
   Devaraja S, 2008, TOXICON, V52, P130, DOI 10.1016/j.toxicon.2008.04.168
   Devaraja S, 2011, TOXICON, V57, P248, DOI 10.1016/j.toxicon.2010.11.018
   Diniz M. R. V., 2018, OVERVIEW PHONEUTRIA, P1
   Pinheiro ACD, 2009, HIPPOCAMPUS, V19, P1123, DOI 10.1002/hipo.20580
   Emerich BL, 2016, TOXINS, V8, DOI 10.3390/toxins8040106
   Escoubas P, 2006, MOL DIVERS, V10, P545, DOI 10.1007/s11030-006-9050-4
   FIGUEIREDO SG, 1995, TOXICON, V33, P83, DOI 10.1016/0041-0101(94)00130-Z
   Fogaca AC, 2006, PEPTIDES, V27, P667, DOI 10.1016/j.peptides.2005.07.013
   Garb JE, 2018, CURR OPIN INSECT SCI, V25, P51, DOI 10.1016/j.cois.2017.11.005
   Green Michael R, 2016, Cold Spring Harb Protoc, V2016, DOI 10.1101/pdb.prot093344
   Gremski LH, 2010, MOL BIOSYST, V6, P2403, DOI 10.1039/c004118a
   Haney RA, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-366
   Huang Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082552
   Kozlov S, 2005, TOXICON, V46, P672, DOI 10.1016/j.toxicon.2005.07.009
   Kozlov SA, 2014, SCI DATA, V1, DOI 10.1038/sdata.2014.23
   Kuhn-Nentwig L, 2011, INSECT BIOCHEM MOLEC, V41, P891, DOI 10.1016/j.ibmb.2011.08.003
   Langenegger N, 2018, J BIOL CHEM, V293, P2079, DOI 10.1074/jbc.M117.810911
   Lorenzini DM, 2003, DEV COMP IMMUNOL, V27, P781, DOI 10.1016/S0145-305X(03)00058-2
   Lucas S. M, 2003, ANIMAIS PECONHENTOS, P141
   Martin-Moutot N, 2006, NEUROBIOL DIS, V22, P57, DOI 10.1016/j.nbd.2005.10.003
   Martins R, 2007, ZOOTAXA, P1
   Matavel A, 2002, FEBS LETT, V523, P219, DOI 10.1016/S0014-5793(02)02988-5
   Meng LX, 2016, J BIOL CHEM, V291, P7097, DOI 10.1074/jbc.M115.680611
   Nunes KP, 2008, TOXICON, V51, P1197, DOI 10.1016/j.toxicon.2008.02.010
   Oldrati V, 2016, MOL BIOSYST, V12, P3530, DOI 10.1039/c6mb00516k
   Paiva ALB, 2016, BIOCHIMIE, V121, P326, DOI 10.1016/j.biochi.2015.12.019
   Peigneur S, 2018, TOXICON, V151, P96, DOI 10.1016/j.toxicon.2018.07.008
   Peigneur S, 2012, MOL PHARMACOL, V82, P90, DOI 10.1124/mol.112.078188
   Pertea G, 2003, BIOINFORMATICS, V19, P651, DOI 10.1093/bioinformatics/btg034
   Pineda S. S., 2011, SPIDER TOXIN DATABAS, P7, DOI [10.1093/bioinformatics/xxxxx, DOI 10.1093/BIOINFORMATICS/XXXXX]
   Pineda SS, 2014, FUTURE MED CHEM, V6, P1699, DOI [10.4155/fmc.14.103, 10.4155/FMC.14.103]
   Postic G, 2018, NUCLEIC ACIDS RES, V46, pD454, DOI 10.1093/nar/gkx1084
   Rice P, 2000, TRENDS GENET, V16, P276, DOI 10.1016/S0168-9525(00)02024-2
   Richardson M, 2006, COMP BIOCHEM PHYS C, V142, P173, DOI 10.1016/j.cbpc.2005.09.010
   Rosa F, 2014, ANESTH ANALG, V119, P196, DOI 10.1213/ANE.0000000000000249
   Sachetto-Martins G, 2000, BBA-GENE STRUCT EXPR, V1492, P1, DOI 10.1016/S0167-4781(00)00064-6
   Saez NJ, 2010, TOXINS, V2, P2851, DOI 10.3390/toxins2122851
   Santibanez-Lopez CE, 2017, TOXICON, V133, P95, DOI 10.1016/j.toxicon.2017.05.002
   Santibanez-Lopez CE, 2016, TOXINS, V8, DOI 10.3390/toxins8120367
   Santos L. D., 2009, BROWN RECLUSE SPIDER, P933
   Shafee TMA, 2017, CELL MOL LIFE SCI, V74, P663, DOI 10.1007/s00018-016-2344-5
   SHIKATA Y, 1995, J BIOL CHEM, V270, P16719, DOI 10.1074/jbc.270.28.16719
   Sievers F, 2011, MOL SYST BIOL, V7, DOI 10.1038/msb.2011.75
   Silva AO, 2012, BIOCHIMIE, V94, P2756, DOI 10.1016/j.biochi.2012.08.016
   Tonello R, 2017, BRIT J PHARMACOL, V174, P57, DOI 10.1111/bph.13652
   Tonello R, 2014, J PAIN, V15, P619, DOI 10.1016/j.jpain.2014.02.007
   Undheim EAB, 2013, TOXINS, V5, P2488, DOI 10.3390/toxins5122488
   Veiga SS, 2000, TOXICON, V38, P825, DOI 10.1016/S0041-0101(99)00197-X
   Vieira LB, 2005, J PHARMACOL EXP THER, V314, P1370, DOI 10.1124/jpet.105.087023
   Vieira LB, 2003, NEUROCHEM INT, V42, P277, DOI 10.1016/S0197-0186(02)00130-4
   Vriens K, 2016, SCI REP-UK, V6, DOI 10.1038/srep32121
   Xu XX, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124925
   Yang S, 2014, INSECT BIOCHEM MOLEC, V47, P1, DOI 10.1016/j.ibmb.2014.01.007
   Zhang YQ, 2010, ZOOLOGY, V113, P10, DOI 10.1016/j.zool.2009.04.001
   Zhang Yun, 2015, Zoological Research, V36, P183, DOI 10.13918/j.issn.2095-8137.2015.4.183
   Zhu SY, 2014, MOL BIOL EVOL, V31, P546, DOI 10.1093/molbev/msu038
   Zobel-Thropp Pamela A, 2014, J Venom Res, V5, P33
   Zobel-Thropp PA, 2014, J PROTEOME RES, V13, P817, DOI 10.1021/pr400875s
   2008, PROTEIN PEPT LETT, V15, P700
NR 76
TC 2
Z9 2
U1 2
U2 5
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD MAY
PY 2019
VL 163
BP 59
EP 69
DI 10.1016/j.toxicon.2019.03.014
PG 11
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA HY1QB
UT WOS:000467890600010
PM 30902682
DA 2020-05-12
ER

PT J
AU de Medeiros, CR
   de Souza, SN
   Lara, AN
   Grego, KF
AF de Medeiros, Carlos Roberto
   de Souza, Solange Nogueira
   Lara, Amanda Nazareth
   Grego, Kathleen Fernandes
TI Use of infrared thermography in a case of systemic envenomation by the
   coral snake Micrurus frontalis (Dumeril et al., 1854) in Sao Paulo,
   Brazil
SO TOXICON
LA English
DT Review
DE Micrurus frontalis; Envenomation; Coral snake; Infrared thermography
ID PHOSPHOLIPASES A(2); FULVIUS-FULVIUS; BITES; VENOMS; ELAPIDAE; SPP.
AB Infrared thermography is a technique that quantifies the thermal (infrared) radiation emitted by an object and produces a high-resolution, digital thermal image of it. Medically, this technique is used to visualize the body's surface temperature distribution in a non-invasive, safe, and convenient fashion. However, to the best of our knowledge, the use of infrared thermography for assessing the systemic effects of envenomation by coral snakes has not been reported. In this case report, we describe the use of this technique in the management of a case of snakebite in Sao Paulo, Brazil. A 51-year-old woman was bitten on the back of the right hand by Micrurus frontalis, a species of coral snake, 10 min prior to her arrival at the hospital. Infrared imaging performed at admission revealed elevated temperatures at the bite site and in the elbow, as well as the preservation of a normal distal thermal gradient in both hands. A few minutes later, the patient developed muscle weakness in the upper limbs and in the eyelids, and infrared imaging showed an alteration of the thermal gradient in both hands, reflecting the systemic action of the venom. Following these observations, the patient was treated with the specific antivenom and was discharged 48 h post admission. At the two-week follow-up, the thermal image obtained showed no anomalies, indicating the recovery of the patient. Hence, infrared thermography can be very useful in the early identification of systemic neurotoxicity in cases of Micrurus snake bites, facilitating the decision to prescribe the antivenom.
C1 [de Medeiros, Carlos Roberto; de Souza, Solange Nogueira; Lara, Amanda Nazareth] Hosp Vital Brazil, Inst Butantan, Av Dr Vital Brasil 1500, BR-05503900 Sao Paulo, SP, Brazil.
   [Grego, Kathleen Fernandes] Inst Butantan, Lab Hetpetol, Av Dr Vital Brasil 1500, BR-05503900 Sao Paulo, SP, Brazil.
RP de Medeiros, CR (reprint author), Hosp Vital Brazil, Inst Butantan, Av Dr Vital Brasil 1500, BR-05503900 Sao Paulo, SP, Brazil.
EM carlos.medeiros@butantan.gov.br; solange.souza@butantan.gov.br;
   amandalara@yahoo.com; kathleen.grego@butantan.gov.br
RI Grego, Kathleen F/A-6394-2014; Lara, Amanda/AAA-9607-2019
OI Grego, Kathleen F/0000-0003-4769-5818; Lara, Amanda/0000-0002-4294-0282;
   Medeiros, Carlos Roberto de/0000-0001-9533-0819
CR Amuy E, 1997, TOXICON, V35, P1605, DOI 10.1016/S0041-0101(97)00045-7
   BARROS ACS, 1994, TOXICON, V32, P445, DOI 10.1016/0041-0101(94)90296-8
   Brasil Ministerio da Saude, 2017, INF SAUD EP MORB
   BRAZIL OV, 1987, REV I MED TROP, V29, P119, DOI 10.1590/S0036-46651987000300001
   Bucaretchi Fábio, 2006, Rev. Inst. Med. trop. S. Paulo, V48, P141, DOI 10.1590/S0036-46652006000300005
   Bucaretchi F, 2016, CLIN TOXICOL, V54, P222, DOI 10.3109/15563650.2015.1135337
   CAMPBELL JA, 1989, VENOMOUS REPTILES LA
   CAMPBELL JA, 2004, VENOMOUS REPTILES W, V1
   Cecchini AL, 2005, COMP BIOCHEM PHYS A, V140, P125, DOI 10.1016/j.cbpb.2004.11.012
   Charkoudian N, 2003, MAYO CLIN PROC, V78, P603, DOI 10.4065/78.5.603
   COELHO LK, 1992, HUM EXP TOXICOL, V11, P135, DOI 10.1177/096032719201100213
   da Silva NJ, 2001, COMP BIOCHEM PHYS C, V128, P425, DOI 10.1016/S1532-0456(00)00215-5
   de Medeiros CR, 2017, REV SOC BRAS MED TRO, V50, P260, DOI 10.1590/0037-8682-0390-2016
   de Roodt AR, 2004, J TOXICOL-CLIN TOXIC, V42, P171, DOI 10.1081/CLT-120030943
   DUMERIL AMC, 1854, ERPETOLOGIE GEN HIST, V9
   Fernandez ML, 2018, TOXICOL LETT, V286, P39, DOI 10.1016/j.toxlet.2017.11.037
   Francis BR, 1997, TOXICON, V35, P1193, DOI 10.1016/S0041-0101(97)00031-7
   Gurierrez J. M, 2016, COBRAS CORAIS BRASIL, P304
   GUTIERREZ JM, 1992, TOXICON, V30, P1299, DOI 10.1016/0041-0101(92)90446-C
   KITCHENS CS, 1987, JAMA-J AM MED ASSOC, V258, P1615, DOI 10.1001/jama.258.12.1615
   Lahiri BB, 2012, INFRARED PHYS TECHN, V55, P221, DOI 10.1016/j.infrared.2012.03.007
   Manock SR, 2008, T ROY SOC TROP MED H, V102, P1127, DOI 10.1016/j.trstmh.2008.03.026
   McCollough N. C., 1963, Journal of the Florida Medical Association, V49, P968
   Merla A, 2006, Conf Proc IEEE Eng Med Biol Soc, V2006, P224
   Nedel C. A, 1997, ENCONTRO NACL ACIDEN, P44
   Park Eun Sook, 1994, Yonsei Medical Journal, V35, P429
   PARRISH HM, 1967, AM J MED SCI, V253, P561
   Pergola P, 2000, EXERCISE SPORTS SCI
   PETTIGREW LC, 1985, NEUROLOGY, V35, P589, DOI 10.1212/WNL.35.4.589
   de Roodt AR, 2012, TOXICON, V59, P356, DOI 10.1016/j.toxicon.2011.11.009
   Ring EFJ, 2012, PHYSIOL MEAS, V33, pR33, DOI 10.1088/0967-3334/33/3/R33
   ROZE JA, 1996, CORAL SNAKES AM BIOL
   SLOWINSKI JB, 1995, J HERPETOL, V29, P325, DOI 10.2307/1564981
   Vital Brazil O, 1976, MEM I BUTANTAN SAO P, V40, P221
   Wood A, 2013, CLIN TOXICOL, V51, P783, DOI 10.3109/15563650.2013.828841
NR 35
TC 0
Z9 0
U1 2
U2 4
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD MAY
PY 2019
VL 163
BP 70
EP 73
DI 10.1016/j.toxicon.2019.03.016
PG 4
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA HY1QB
UT WOS:000467890600011
PM 30905699
DA 2020-05-12
ER

PT J
AU dos Santos, JM
   dos Santos, JC
   Marques, EE
   de Araujo, GC
   Seibert, CS
   Lopes-Ferreira, M
   Carla, L
AF dos Santos, Juliane Monteiro
   dos Santos, Janaina Cardoso
   Marques, Elineide Eugenio
   de Araujo, Gessi Carvalho
   Seibert, Carla Simone
   Lopes-Ferreira, Monica
   Carla, Lima
TI Stingray (Potamotrygon rex) maturity is associated with inflammatory
   capacity of the venom
SO TOXICON
LA English
DT Article
DE Stingray venom; Gender and maturity; Peptides; Proteins; Inflammation
ID BEHAVIOR; DIET
AB Several studies have been carried out with venom from sting and mucus of stingrays of marine or fluvial environments to compare the toxicity of their venom. However, studies demonstrating the existence of the influence of both sex and the maturation stage of stingrays on the variability of the toxic effects of venom are still scarce. Here, we investigated whether the sex and/or the stage maturation of the Potamotrygon rex stingray influence the toxic capacity of the venom to develop acute inflammation in mice. We carried out the main toxic activities in mice using venom from female or male of young and adult stingrays. Our results described here show that the nociception is mainly induced by venom from young female stingrays. In contrast, we observed the action of venom from both sex of adult stingrays in the induction of exudative phase of inflammatory process, including vascular leakage and neutrophil infiltration. Our data illustrate that the composition of the venom of P. rex is influenced by the stage of maturity of the stingray, modulating the production of peptides and proteins capable of acting on leukocytes-endothelial interactions and favoring neutrophil infiltration to the damage tissue.
C1 [dos Santos, Juliane Monteiro; dos Santos, Janaina Cardoso; Marques, Elineide Eugenio; de Araujo, Gessi Carvalho; Seibert, Carla Simone] Fed Univ Tocantins, Environm Sci, Campus Palmas, Palmas, Brazil.
   [Lopes-Ferreira, Monica; Carla, Lima] Butantan Inst, Immunoregulat Unit, Special Lab Appl Toxinol, Ctr Toxins Immuneresponse & Cell Signaling CEPID, Sao Paulo, Brazil.
RP Carla, L (reprint author), Butantan Inst, Immunoregulat Unit, Special Lab Appl Toxinol, Ctr Toxins Immuneresponse & Cell Signaling CEPID, Sao Paulo, Brazil.
EM carla.lima@butantan.gov.br
RI Center of Toxins, Immune-response/J-5731-2015; Lima, Carla/B-6750-2019
OI Lima, Carla/0000-0002-8161-966X
FU Sao Paulo Research Foundation-FapespFundacao de Amparo a Pesquisa do
   Estado de Sao Paulo (FAPESP) [2013/07467-1]; CNPqNational Council for
   Scientific and Technological Development (CNPq)
FX This study was supported by research grants from Sao Paulo Research
   Foundation-Fapesp (2013/07467-1), and CNPq. The funders had no role in
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Almeida MP, 2010, BRAZ J BIOL, V70, P155, DOI 10.1590/S1519-69842010000100022
   Araujo M. L. G., 2004, AC 20 INFORM, V8, P8
   Casewell NR, 2013, TRENDS ECOL EVOL, V28, P219, DOI 10.1016/j.tree.2012.10.020
   Conceicao K, 2009, PEPTIDES, V30, P2191, DOI 10.1016/j.peptides.2009.08.004
   Conceicao K, 2006, PEPTIDES, V27, P3039, DOI 10.1016/j.peptides.2006.09.002
   Daltry JC, 1996, NATURE, V379, P537, DOI 10.1038/379537a0
   de Roos AM, 2002, ECOL MONOGR, V72, P271, DOI 10.1890/0012-9615(2002)072[0271:ONSAFB]2.0.CO;2
   dos Santos JC, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-08395-y
   Evans RJ, 1996, J ACCID EMERG MED, V13, P224
   FENNER PJ, 1989, MED J AUSTRALIA, V151, P621, DOI 10.5694/j.1326-5377.1989.tb139631.x
   Fernandes G. R., 2016, SCI REP, V6, P21
   Neto DG, 2010, REV SOC BRAS MED TRO, V43, P82, DOI 10.1590/S0037-86822010000100018
   Garrone-Neto D, 2009, NEOTROP ICHTHYOL, V7, P113, DOI 10.1590/S1679-62252009000100015
   Gibbs HL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067220
   HUNSKAAR S, 1985, J NEUROSCI METH, V14, P69, DOI 10.1016/0165-0270(85)90116-5
   Lopes-Ferreira M, 2014, TOXICON, V90, P237, DOI 10.1016/j.toxicon.2014.08.007
   Magalhaes KW, 2006, TOXICON, V47, P575, DOI 10.1016/j.toxicon.2006.01.028
   Magalhaes MR, 2008, TOXICON, V51, P1060, DOI 10.1016/j.toxicon.2008.01.008
   Mehta D, 2006, PHYSIOL REV, V86, P279, DOI 10.1152/physrev.00012.2005
   Mittelbach GG, 2014, CAN J FISH AQUAT SCI, V71, P927, DOI 10.1139/cjfas-2013-0558
   Monteiro-dos-Santos J, 2011, INT IMMUNOPHARMACOL, V11, P1368, DOI 10.1016/j.intimp.2011.03.019
   Pedroso CM, 2007, TOXICON, V50, P688, DOI 10.1016/j.toxicon.2007.06.004
   Ramos AD, 2012, TOXICON, V59, P651, DOI 10.1016/j.toxicon.2012.02.002
   Rodriguez-Ravelo R, 2015, TOXICON, V107, P327, DOI 10.1016/j.toxicon.2015.06.026
   Rosa RS, 2010, CRC MAR BIOL SER, P241
   Rosa RS, 1985, THESIS COLL WILLIAM, P523
   Santos J. M., 2014, SCI AMAZON MAG, V3, P24
   Shibuya A, 2012, NEOTROP ICHTHYOL, V10, P189, DOI 10.1590/S1679-62252012000100018
   Silva F, 2018, TOXINS, V10, DOI 10.3390/toxins10120544
   von Reumont BM, 2018, TOXINS, V10, DOI 10.3390/toxins10070292
   Wood JN, 2012, CURR OPIN PHARMACOL, V12, P4, DOI 10.1016/j.coph.2011.10.013
   2015, TOXINS, V7, P2272, DOI DOI 10.3390/TOXINS7062272
   2012, NEOTROP ICHTHYOL, V10, P81
   2016, TOXICON, V115, P70, DOI DOI 10.1016/J.TOXICON.2016.02.022
NR 34
TC 0
Z9 0
U1 2
U2 5
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD MAY
PY 2019
VL 163
BP 74
EP 83
DI 10.1016/j.toxicon.2019.03.013
PG 10
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA HY1QB
UT WOS:000467890600012
PM 30898532
DA 2020-05-12
ER

PT J
AU Leiva, CL
   Cangelosi, A
   Mariconda, V
   Farace, M
   Geoghegan, P
   Brero, L
   Fernandez-Miyakawa, M
   Chacana, P
AF Leonidas Leiva, Carlos
   Cangelosi, Adriana
   Mariconda, Virginia
   Farace, Mariano
   Geoghegan, Patricia
   Brero, Luisa
   Fernandez-Miyakawa, Mariano
   Chacana, Pablo
TI IgY-based antivenom against Bothrops alternatus: Production and
   neutralization efficacy
SO TOXICON
LA English
DT Article
DE Bothrops alternatus; Snake venom; IgY antibody; Egg yolk; Snakebite;
   Venom neutralization
ID EGG-YOLK ANTIBODIES; LATIN-AMERICAN COUNTRIES; SNAKE ANTIVENOM;
   ADVERSE-REACTIONS; CAPRYLIC-ACID; PRECLINICAL ASSESSMENT; IMMUNOGLOBULIN
   IGY; VENOM; EQUINE; IMMUNIZATION
AB Antivenom for the treatment of bothropic snakebite is a priority for public health institutions from Latin America. An alternative to the conventional antivenom production is based on the use of egg yolk antibodies - IgY-technology - by immunizing laying hens. In this study, we produced, characterized and assessed the efficacy of IgY-based antivenoms against B. alternatus venom. Immunochemical studies (reactivity, avidity and antigen recognition pattern) as well as antivenom efficacy assays were performed. After the 3rd immunization, levels of specific IgY reached a maximum that was maintained throughout the observation period, while avidity indexes of the extracts increased after the successive immunizations. Furthermore, IgY against B. alternatus recognized protein complexes of the venom with high (> 40 kDa), medium (20-40 kDa) and low (< 20 kDa) molecular weights. IgY antivenoms obtained after 8 immunizations neutralized 35.65 mu g of B. alternatus venom per mg of antivenom, while specific activities values ranged from 0.28 to 0.42. In conclusion, we produced and characterized IgY antivenoms capable of neutralizing the lethal activity of B. alternatus venom at a preclinical level. Thus, IgY-technology may allow the production of effective and affordable antivenoms fulfilling the urgent needs of many countries where conventional manufacture is unable to provide enough availability of antivenoms.
C1 [Leonidas Leiva, Carlos; Farace, Mariano; Fernandez-Miyakawa, Mariano; Chacana, Pablo] Inst Nacl Tecnol Agr, Ctr Nacl Invest Agr, Inst Patobiol, Las Cabanas & Los Reseros S-N, Buenos Aires, DF, Argentina.
   [Leonidas Leiva, Carlos; Farace, Mariano; Fernandez-Miyakawa, Mariano] Consejo Nacl Invest Cient & Tecn, Av Rivadavia 1917, Caba, Argentina.
   [Cangelosi, Adriana; Mariconda, Virginia; Geoghegan, Patricia; Brero, Luisa] ANLIS Dr Carlos G Malbrdn, Ctr Nacl Control Calidad Biol, Av Velez Sarsfield 563, Caba, Argentina.
RP Leiva, CL (reprint author), Inst Nacl Tecnol Agr, Ctr Nacl Invest Agr, Inst Patobiol, Las Cabanas & Los Reseros S-N, Buenos Aires, DF, Argentina.; Leiva, CL (reprint author), Consejo Nacl Invest Cient & Tecn, Av Rivadavia 1917, Caba, Argentina.
EM leiva.carlos@inta.gob.ar; acangelosi2000@yahoo.com.ar;
   vmariconda@anlis.gov.ar; mariano_farace@hotmail.com;
   pgeoghegan@anlis.gov.ar; mlbrero@anlis.gov.ar;
   fernandezmiyakawa.m@inta.gob.ar; chacana.pablo@inta.gob.ar
OI Fernandez Miyakawa, Mariano Enrique/0000-0001-5251-4685; Leiva, Carlos
   Leonidas/0000-0001-9796-5092
FU Fondo Argentino Sectorial (FONARSEC) of the National Agency for Science
   and Technology Promotion-MinCyT [FITS Salud PPM03]
FX This work was supported by the Project FITS Salud PPM03 from the Fondo
   Argentino Sectorial (FONARSEC) of the National Agency for Science and
   Technology Promotion-MinCyT. We would like to thank Dr. Horacio Terzolo
   for his valuable comments to improve the manuscript, Dr. Natalia
   Casanova and Dr. Abimael Ortiz for their help in the analysis of data,
   Dr. Christian Dokmetjian and Dr. Matias Fingermann for the provision of
   venoms, and Mr. Ignacio de la Fuente for his help in the maintenance of
   the animals.
CR AKITA EM, 1992, J FOOD SCI, V57, P629, DOI 10.1111/j.1365-2621.1992.tb08058.x
   Alirol E, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003896
   Almeida CMC, 1998, VET REC, V143, P579, DOI 10.1136/vr.143.21.579
   Alvarenga LM, 2014, TOXINS, V6, P2541, DOI 10.3390/toxins6082541
   Amo A, 2010, J AGR FOOD CHEM, V58, P7453, DOI 10.1021/jf101403h
   Angulo Y, 1997, TOXICON, V35, P81, DOI 10.1016/S0041-0101(96)00077-3
   Bermudez-Mendez E, 2018, TOXINS, V10, DOI 10.3390/toxins10110452
   Campos C. M. T. de, 2003, Brazilian Journal of Veterinary Research and Animal Science, V40, P9
   Carlander D, 2001, UPSALA J MED SCI, V106, P189, DOI 10.3109/2000-1967-145
   Chacana P. A., 2004, Revista de Medicina Veterinaria (Buenos Aires), V85, P179
   Chalamaiah M, 2017, FOOD BIOSCI, V18, P38, DOI 10.1016/j.fbio.2017.04.002
   CHERONI AP, 1994, REV MED URUG, V10, P147
   Chippaux J. P., 1991, REPTILE VENOMS TOXIN, V5, P529
   Chippaux JP, 2017, J VENOM ANIM TOXINS, V23, DOI 10.1186/s40409-017-0127-6
   Chippaux JP, 2013, B ACAD NAT MED PARIS, V197, P993, DOI 10.1016/S0001-4079(19)31542-0
   de Almeida CMC, 2008, TOXICON, V52, P293, DOI 10.1016/j.toxicon.2008.05.022
   de Oliveira VC, 2011, TOXICON, V57, P680, DOI 10.1016/j.toxicon.2011.01.012
   da Rocha DG, 2017, EUR J PHARM SCI, V106, P404, DOI 10.1016/j.ejps.2017.05.069
   da Silva WD, 2011, TOXICON, V57, P1109, DOI 10.1016/j.toxicon.2011.03.022
   de Andrade FG, 2013, TOXICON, V66, P18, DOI 10.1016/j.toxicon.2013.01.018
   de Roodt A.R., 2004, ACTA TOXICOL ARGENT, V12, P29
   de Roodt Adolfo Rafael, 2010, Acta toxicol. argent., V18, P10
   De Roodt AR, 1998, TOXICON, V36, P1025, DOI 10.1016/S0041-0101(97)00111-6
   De Silva C, 2016, MOL IMMUNOL, V71, P152, DOI 10.1016/j.molimm.2016.02.005
   Diaz P, 2014, TOXICON, V90, P124, DOI 10.1016/j.toxicon.2014.07.021
   Dos-Santos MC, 2011, TOXICON, V57, P237, DOI 10.1016/j.toxicon.2010.11.016
   Duan HL, 2016, J VENOM ANIM TOXINS, V22, DOI 10.1186/s40409-016-0078-3
   Egea E, 2018, BIOMEDICA, V38, P232, DOI 10.7705/biomedica.v38i0.3689
   Egger M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019062
   Finney D. J., 1971, STAT METHODS BIOL AS, DOI [10.1080/03071020500393091, DOI 10.1080/03071020500393091]
   Fry BG, 2003, J TOXICOL-TOXIN REV, V22, P23, DOI 10.1081/TXR-120019018
   Baudou FG, 2017, TOXICON, V140, P11, DOI 10.1016/j.toxicon.2017.10.009
   GRUBER F.P., 2004, ALTEX, V21, P1
   Guevarra L., 2012, ACTA MED PHILIPP, V46
   GUTIERREZ JM, 1988, REV BIOL TROP, V36, P511
   Gutierrez JM, 2017, NAT REV DIS PRIMERS, V3, DOI [10.1038/nrdp.2017.79, 10.1038/nrdp.2017.63]
   Gutierrez Jose Maria, 2011, Inflammation & Allergy Drug Targets, V10, P369
   Herrera M, 2005, TOXICON, V46, P775, DOI 10.1016/j.toxicon.2005.08.004
   Hirai K, 2010, ACTA MED OKAYAMA, V64, P163
   Instituto Clodomiro Picado, 2007, DET ACT TOX VEN SERP
   Kasturiratne A, 2008, PLOS MED, V5, P1591, DOI 10.1371/journal.pmed.0050218
   Kazimierczuk K, 2005, ACTA BIOCHIM POL, V52, P261
   Kilkenny C, 2010, BRIT J PHARMACOL, V160, P1577, DOI 10.1111/j.1476-5381.2010.00872.x
   Knudsen C., 2018, TROP MED INFECT DIS, V3, P1, DOI [10.3390/tropicalmed3020000, DOI 10.3390/TROPICALMED3020000]
   Laborde H. F., 1989, REV MED URUG, V5, P20
   Lachmann PJ, 2012, EMERG MICROBES INFEC, V1, DOI 10.1038/emi.2012.2
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   Lanari LC, 2010, TOXICON, V55, P1415, DOI 10.1016/j.toxicon.2010.01.015
   Laustsen AH, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06086-4
   Laustsen AH, 2018, TOXICON, V146, P151, DOI 10.1016/j.toxicon.2018.03.004
   Laustsen AH, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005361
   Laustsen AH, 2017, PEERJ, V5, DOI 10.7717/peerj.2924
   Lee CH, 2016, APPL ENVIRON MICROB, V82, P6973, DOI 10.1128/AEM.01876-16
   Lee CH, 2016, APPL ENVIRON MICROB, V82, P71, DOI 10.1128/AEM.02608-15
   Sampaio LCL, 2014, VET PARASITOL, V204, P96, DOI 10.1016/j.vetpar.2014.05.032
   Leon G., 2011, INFLAM ALLERGY DRUG, V10, P1, DOI DOI 10.2174/187152811797200605
   Leon G, 2008, T ROY SOC TROP MED H, V102, P1115, DOI 10.1016/j.trstmh.2008.04.038
   Leon G, 2013, TOXICON, V76, P63, DOI 10.1016/j.toxicon.2013.09.010
   Lewin M, 2016, TOXINS, V8, DOI 10.3390/toxins8090248
   Marchand C, 2013, MABS-AUSTIN, V5, P633, DOI 10.4161/mabs.25613
   Gutierrez JM, 2007, CURR PHARM DESIGN, V13, P2935, DOI 10.2174/138161207782023784
   Gutierrez JM, 2017, TOXINS, V9, DOI 10.3390/toxins9050163
   Gutierrez JM, 2014, B WORLD HEALTH ORGAN, V92, P526, DOI 10.2471/BLT.13.132431
   Gutierrez JM, 2011, B MALARIOL SALUD AMB, V51, P1
   Gutierrez JM, 2009, TOXICON, V53, P625, DOI 10.1016/j.toxicon.2009.01.020
   Meenatchisundaram S, 2008, TOXICON, V52, P221, DOI 10.1016/j.toxicon.2008.04.179
   Mendoza Julio C, 2012, Rev. perú. med. exp. salud publica, V29, P69, DOI 10.1590/s1726-46342012000100010
   Morais V, 2006, J VENOM ANIM TOXINS, V12, P497, DOI 10.1590/S1678-91992006000300012
   Moreno Claudia, 2016, Bol Mal Salud Amb, V56, P192
   Moussa IM, 2012, SAUDI MED J, V33, P846
   Mudili V, 2015, SCI REP-UK, V5, DOI 10.1038/srep15151
   Navarro D, 2016, TOXICON, V120, P1, DOI 10.1016/j.toxicon.2016.06.018
   Ohler M, 2010, J PROTEOME RES, V9, P2422, DOI 10.1021/pr901128x
   Okamoto CK, 2017, TOXINS, V9, DOI 10.3390/toxins9030090
   Otero R, 1999, TOXICON, V37, P895, DOI 10.1016/S0041-0101(98)00220-7
   Otero-Patino R, 2012, TOXICON, V59, P344, DOI 10.1016/j.toxicon.2011.11.017
   Parma Y.R., 2012, FRONT CELL INFECT MI, V2, P1
   Pauly D, 2011, JOVE-J VIS EXP, DOI 10.3791/3084
   Queiroz GP, 2008, TOXICON, V52, P842, DOI 10.1016/j.toxicon.2008.10.002
   Rehault-Godbert S, 2013, J BIOL CHEM, V288, P17285, DOI 10.1074/jbc.M113.469759
   Riano-Umbarila L, 2019, TOXINS, V11, DOI 10.3390/toxins11010032
   Roncolato EC, 2013, J IMMUNOTOXICOL, V10, P160, DOI 10.3109/1547691X.2012.703253
   Roodt A. R. de, 1997, Revista de Medicina Veterinaria (Buenos Aires), V78, P220
   Saeed AFUH, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.00495
   Schade K, 2005, ATLA-ALTERN LAB ANIM, V33, P129, DOI 10.1177/026119290503300208
   Schade R., 2006, BIOACTIVE EGG COMPOU
   Scheske L, 2015, INT J HEALTH POLICY, V4, P447, DOI 10.15171/ijhpm.2015.75
   Segura A, 2010, TOXICON, V56, P980, DOI 10.1016/j.toxicon.2010.07.001
   Segura A, 2013, BIOLOGICALS, V41, P93, DOI 10.1016/j.biologicals.2012.11.001
   Sesarman A, 2008, BRIT J DERMATOL, V158, P463, DOI 10.1111/j.1365-2133.2007.08388.x
   Sevcik C, 2008, TOXICON, V51, P10, DOI 10.1016/j.toxicon.2007.06.009
   Sifi A, 2018, INT IMMUNOPHARMACOL, V61, P256, DOI 10.1016/j.intimp.2018.06.013
   Sousa LF, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002442
   Stanton D., 2018, BIOPROCESS INT, V16, pE3
   Theakston R. D. G., 2003, Toxicon, V41, P541, DOI 10.1016/S0041-0101(02)00393-8
   THEAKSTON RDG, 1983, B WORLD HEALTH ORGAN, V61, P949
   TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350
   Vazquez H, 2010, INT IMMUNOPHARMACOL, V10, P447, DOI 10.1016/j.intimp.2010.01.005
   Walczak M, 2015, BIOPOLYMERS, V104, P552, DOI 10.1002/bip.22695
   Wang Y., 2018, MOLECULES, V23, P1, DOI DOI 10.3390/MOLECULES23092334
   Witkowski PT, 2009, J IMMUNOL METHODS, V341, P146, DOI 10.1016/j.jim.2008.11.008
   World Health Organization, 1981, PROGR CHAR VEN STARD, V58
   World Health Organization, 2017, TECHNICAL REPORT SER
   You J, 2014, J APPL MICROBIOL, V117, P320, DOI 10.1111/jam.12525
   You ZR, 2014, HUM VACC IMMUNOTHER, V10, P2321, DOI 10.4161/hv.29433
   Yuan JW, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140615
   2010, TOXICON, V55, P739, DOI DOI 10.1016/J.TOXICON.2009.11.004
   2014, TOXICON, V85, P31, DOI DOI 10.1016/J.TOXICON.2014.04.006
NR 108
TC 2
Z9 2
U1 0
U2 3
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD MAY
PY 2019
VL 163
BP 84
EP 92
DI 10.1016/j.toxicon.2019.03.020
PG 9
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA HY1QB
UT WOS:000467890600013
PM 30914282
DA 2020-05-12
ER

PT J
AU Paz, RDR
   Altimira, PA
   Valverde, GC
   Martin, CB
AF Diaz-Romero Paz, Ricardo
   Avendano Altimira, Pilar
   Coloma Valverde, Gustavo
   Balhen Martin, Claudia
TI A Rare Case of Negative-Pressure Hydrocephalus: A Plausible Explanation
   and the Role of Transmantle Theory
SO WORLD NEUROSURGERY
LA English
DT Article
DE Arachnoid cyst; Hydrocephalus; Low-pressure; Negative-pressure;
   Transmantle pressure gradient
AB BACKGROUND: Negative-pressure hydrocephalus is a rare condition with the development of symptomatic hydrocephalus despite subnormal intracranial pressure (ICP). The etiology remains unclear. Some authors proposed that the differential pressure between the ventricular space and the subarachnoid space over cerebral convexity leads to the development of ventriculomegaly, namely as the transmantle pressure theory.
   CASE DESCRIPTION: A 49-year-old patient with a left Sylvian fissure arachnoid cyst underwent several surgeries including cystoperitoneal shunts and fenestrations of the cyst. The patient developed a cerebrospinal fluid fistula from the cranial wound was complicated by bacterial meningitis. Consequently, the shunt was removed, and external cyst drainage was placed. After 9 days, the patient developed acute hydrocephalus requiring external ventricular drainage (EVD). Two days later, after overdrainage of the external cyst drain, the patient suffered neurologic deterioration. The ICP measured by the EVD was -4 cm H2O, and a computed tomography scan demonstrated progression of the hydrocephalus. The external cyst drainage was shut off and the EVD level was adjusted to produce between 5 and 10 mL/hour of cerebrospinal fluid under a subatmospheric pressure set at -5 cm H2O, and gradually raised in increments of 1 cm every 3 days until a positive ICP occurred. Once clinical and radiographic stability was accomplished, a programmable ventriculoperitoneal shunt was inserted set to 30 mm H2O. A marked clinical and radiologic improvement was observed in the follow-up.
   CONCLUSIONS: This negative-pressure hydrocephalus case report supports the main role of the transmantle pressure theory. The subatmospheric EVD method and a low-pressure valve resulted in excellent clinical and radiographic outcomes.
C1 [Diaz-Romero Paz, Ricardo; Avendano Altimira, Pilar; Coloma Valverde, Gustavo] Hosp Insular Las Palmas, Dept Neurosurg, Plaza Doctor Pasteur, Las Palmas Gran Canaria, Spain.
   [Balhen Martin, Claudia] Hosp Perpetuo Socorro Leon & Castillo, Dept Radiol, Las Palmas Gran Canaria, Spain.
RP Paz, RDR (reprint author), Hosp Insular Las Palmas, Dept Neurosurg, Plaza Doctor Pasteur, Las Palmas Gran Canaria, Spain.
EM ricdrp@yahoo.com
CR Akins PT, 2011, NEUROCRIT CARE, V15, P461, DOI 10.1007/s12028-011-9543-6
   BANNISTER CM, 1972, ACTA NEUROCHIR, V27, P11, DOI 10.1007/BF01402168
   Clarke MJ, 2006, J NEUROSURG, V105, P475, DOI 10.3171/jns.2006.105.3.475
   CONNER ES, 1984, J NEUROSURG, V61, P322, DOI 10.3171/jns.1984.61.2.0322
   Dias MS, 1999, PEDIATR NEUROSURG, V30, P146, DOI 10.1159/000028783
   Filippidis AS, 2011, J NEUROSURG, V115, P1031, DOI 10.3171/2011.6.JNS101504
   FISHMAN RA, 1966, NEW ENGL J MED, V274, P466
   Galbarriatu L, 2013, ACTA NEUROCHIR, V155, P1981, DOI 10.1007/s00701-013-1819-5
   Hamilton MG, 2010, NEUROSURGERY, V67, P553, DOI 10.1227/01.NEU.0000387024.98553.65
   INGRAM TTS, 1971, DEV MED CHILD NEUROL, V13, P676
   Kalani MYS, 2013, J CLIN NEUROSCI, V20, P462, DOI 10.1016/j.jocn.2012.04.027
   Lin B-J, 2016, NEUROSURG QUART, V26, P256
   Owler BK, 2001, BRIT J NEUROSURG, V15, P353
   PANG DL, 1994, NEUROSURGERY, V35, P643, DOI 10.1227/00006123-199410000-00010
   Rekate HL, 2008, J NEUROSURG-PEDIATR, V2, P1, DOI 10.3171/PED/2008/2/7/001
   SHAPIRO K, 1987, J NEUROSURG, V67, P88, DOI 10.3171/jns.1987.67.1.0088
   SINGOUNAS EG, 1976, NEUROCHIRURGIA, V19, P22
   Stephensen H, 2002, NEUROSURGERY, V50, P763, DOI 10.1097/00006123-200204000-00016
   VASSILYADI M, 1995, J NEUROSURG, V83, P486, DOI 10.3171/jns.1995.83.3.0486
NR 19
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP 6
EP 9
DI 10.1016/j.wneu.2019.01.117
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700157
PM 30710718
DA 2020-05-12
ER

PT J
AU Tsuboki, S
   Kawano, T
   Ohmori, Y
   Amadatsu, T
   Mukasa, A
AF Tsuboki, Shimpei
   Kawano, Takayuki
   Ohmori, Yuki
   Amadatsu, Toshihiro
   Mukasa, Akitake
TI Surgical Treatment of Spontaneous Internal Carotid Artery Dissection
   with Abducent Nerve Palsy: Case Report and Review of Literature
SO WORLD NEUROSURGERY
LA English
DT Review
DE Abducent nerve palsy; Cavernous sinus; High-flow bypass; ICA dissection
AB BACKGROUND: Sixth-nerve palsy often develops as a result of trauma, neoplasm, or vascular disease affecting the pons. Less commonly, this palsy can be caused by pathology of the internal carotid artery in the cavernous sinus region. Here, we describe a rare case of spontaneous dissection of the internal carotid artery in the cavernous sinus accompanied by acute sixth nerve palsy that was successfully treated with surgery.
   CASE DESCRIPTION: An 18-year-old man presented suddenly and spontaneously with isolated abducent nerve palsy. His magnetic resonance angiography identified a dissection of the right internal carotid artery in the cavernous sinus. We successfully treated it with high-flow bypass and ligation of the internal carotid artery (ICA).
   CONCLUSIONS: Intracavernous ICA dissection is a possible cause of sixth nerve palsy. While most cases likely result from compromised arterial blood supply to the affected nerve, compression of the cranial nerves by the expanded artery can occur in some cases. Surgical treatment is a safe and effective option for relieving nerve compression after intracavernous ICA dissection.
C1 [Tsuboki, Shimpei; Kawano, Takayuki; Ohmori, Yuki; Amadatsu, Toshihiro; Mukasa, Akitake] Kumamoto Univ, Grad Sch Med Sci, Dept Neurosurg, Kumamoto, Japan.
RP Kawano, T (reprint author), Kumamoto Univ, Grad Sch Med Sci, Dept Neurosurg, Kumamoto, Japan.
EM tkawano-nsu@umin.net
OI Kawano, Takayuki/0000-0002-6885-4542
CR Baumgartner RW, 2001, NEUROLOGY, V57, P827, DOI 10.1212/WNL.57.5.827
   Bejot Y, 2014, INT J STROKE, V9, P879, DOI 10.1111/ijs.12154
   Biller J, 2014, STROKE, V45, P3155, DOI 10.1161/STR.0000000000000016
   Ducrocq X, 2000, REV NEUROL, V156, P520
   LAL V, 1994, COMPUT MED IMAG GRAP, V18, P381, DOI 10.1016/0895-6111(94)90009-4
   LAPRESLE J, 1986, BRAIN, V109, P207, DOI 10.1093/brain/109.1.207
   Lee VH, 2006, NEUROLOGY, V67, P1809, DOI 10.1212/01.wnl.0000244486.30455.71
   Lemesle M, 1998, CEPHALALGIA, V18, P112, DOI 10.1046/j.1468-2982.1998.1802112.x
   Leys D, 1997, EUR NEUROL, V37, P3, DOI 10.1159/000117396
   MADSEN PH, 1970, ACTA OPHTHALMOL, V48, P731
   MAITLAND CG, 1983, ARCH NEUROL-CHICAGO, V40, P448, DOI 10.1001/archneur.1983.04050070078022
   Mokri B, 1996, NEUROLOGY, V46, P356, DOI 10.1212/WNL.46.2.356
   SCHIEVINK WI, 1993, NEUROLOGY, V43, P1938, DOI 10.1212/WNL.43.10.1938
   Schievink WI, 2001, NEW ENGL J MED, V344, P898, DOI 10.1056/NEJM200103223441206
   STURZENEGGER M, 1995, J NEUROL, V242, P231, DOI 10.1007/BF00919596
   STURZENEGGER M, 1993, J NEUROL NEUROSUR PS, V56, P1191, DOI 10.1136/jnnp.56.11.1191
   Thanvi B, 2005, POSTGRAD MED J, V81, P383, DOI 10.1136/pgmj.2003.016774
   TROBE JD, 1978, ARCH OPHTHALMOL-CHIC, V96, P457, DOI 10.1001/archopht.1978.03910050233009
   Wei W, 2017, INT J GEOMECH, V17, DOI 10.1061/(ASCE)GM.1943-5622.0000669
   Wessels T, 2005, J NEUROL, V252, P453, DOI 10.1007/s00415-005-0673-7
   WILSON WB, 1989, ANN NEUROL, V25, P286, DOI 10.1002/ana.410250313
NR 21
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP 10
EP 14
DI 10.1016/j.wneu.2019.01.096
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700158
PM 30711658
DA 2020-05-12
ER

PT J
AU Somma, T
   Cappabianca, P
AF Somma, Teresa
   Cappabianca, Paolo
TI Women in Neurosurgery: A Young Italian Neurosurgeon's Perspective
SO WORLD NEUROSURGERY
LA English
DT Article
DE Neurosurgery; Women; Young perspective
ID GENDER
AB Several differences distinguish brain functioning and behavior of women and men. This article addresses how gender features influence the way one behaves in the workplace, in particular, in neurosurgery. Women experience impostor syndrome, which is a persistent fearing of impropriety, by tending to point out their own fears and express their flaws, underrating themselves. At the same time, women show more caution and more care for details than their male counterparts, emphasize teamwork and research, and show greater aptitude in surgical and medical practices. According to several authors, female neurosurgeons represent an important component for the future of the discipline and are essential to the field's growth. Nevertheless, young women feel a tension between the "women can have it all" movement and a realistic view of themselves as mothers, partners, employees, and leaders. As a young neurosurgeon, I think that our future is in our hands, it depends on our enthusiasm, on our energy but, above all, it will be bright, since we all are neurosurgeons.
C1 [Somma, Teresa; Cappabianca, Paolo] Univ Napoli Federico II, Div Neurosurg, Dept Neurosci & Reprod & Dent Sci, Naples, Italy.
RP Somma, T (reprint author), Univ Napoli Federico II, Div Neurosurg, Dept Neurosci & Reprod & Dent Sci, Naples, Italy.
EM teresa.somma85@gmail.com
CR Abosch A, 2018, J NEUROSURG, V129, P277, DOI 10.3171/2018.4.JNS172878
   Andrews NC, 2007, NEW ENGL J MED, V357, P1887, DOI 10.1056/NEJMp078198
   Benvenuti L., 2009, HEART LION HANDS WOM
   Benzil DL, 2008, J NEUROSURG, V109, P378, DOI 10.3171/JNS/2008/109/9/0378
   Bertakis KD, 2009, PATIENT EDUC COUNS, V76, P356, DOI 10.1016/j.pec.2009.07.022
   Cappabianca P, 2006, SURG NEUROL, V65, P35, DOI 10.1016/j.surneu.2005.05.002
   Carr PL, 1999, MAYO CLIN PROC, V74, P201, DOI 10.4065/74.2.201
   Corley J, 2018, WORLD NEUROSURG, V111, P130, DOI 10.1016/j.wneu.2017.12.086
   DOIDGE N, 2007, BRAIN CHANGES ITSELF
   Durham SR, 2018, J NEUROSURG, V129, P282, DOI 10.3171/2017.11.JNS171831
   Eagly AH, 2003, PSYCHOL BULL, V129, P569, DOI 10.1037/0033-2909.129.4.569
   Glaser E, 2012, INT J PSYCHOPHYSIOL, V85, P17, DOI 10.1016/j.ijpsycho.2012.01.007
   Hebb DO, 1949, ORG BEHAV
   Hojat M, 2002, AM J PSYCHIAT, V159, P1563, DOI 10.1176/appi.ajp.159.9.1563
   James W., 1890, PRINCIPLES PSYCHOL
   Keller TA, 2016, NEUROIMAGE, V125, P256, DOI 10.1016/j.neuroimage.2015.10.015
   Ngun TC, 2011, FRONT NEUROENDOCRIN, V32, P227, DOI 10.1016/j.yfrne.2010.10.001
   Pascual-Leone A, 2011, BRAIN TOPOGR, V24, P302, DOI 10.1007/s10548-011-0196-8
   Renfrow JJ, 2018, NEUROSURGERY, V82, P576, DOI 10.1093/neuros/nyx251
   Roter DL, 2002, JAMA-J AM MED ASSOC, V288, P756, DOI 10.1001/jama.288.6.756
   Sanchez C, 2018, BEHAV BRAIN RES, V351, P93, DOI 10.1016/j.bbr.2018.05.029
   Sandberg S, 2013, WOMEN WORK WILL LEAD
   1999, MAYO CLIN P, V74, P201
NR 23
TC 1
Z9 1
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP 15
EP 18
DI 10.1016/j.wneu.2019.01.059
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700159
PM 30684700
DA 2020-05-12
ER

PT J
AU Obi, M
   Onwuzulike, K
AF Obi, Megan
   Onwuzulike, Kaine
TI Neonatal Hyponatremia in the Setting of Untreated Progressive
   Hydrocephalus
SO WORLD NEUROSURGERY
LA English
DT Article
DE Hydrocephalus; Hyponatremia; Neonatal
ID INAPPROPRIATE SECRETION; INFANTS; HEMORRHAGE
AB BACKGROUND: Hyponatremia in the neonatal population is an uncommon occurrence and can be associated with significant increase in morbidity and mortality. In the neonatal population, it is typically associated with an excess of antidiuretic hormone and rarely has been found to be associated with hydrocephalus, short of being caused by the subsequent treatment of hydrocephalus.
   CASE DESCRIPTION: We present a case report of a patient with neonatal hydrocephalus, secondary to intraventricular hemorrhage in the setting of prematurity, treated at our institution, in whom sodium levels reached a nadir as head circumference peaked and subsequent treatment of hydrocephalus resolved the associated hyponatremia.
   CONCLUSIONS: Hydrocephalus secondary to intraventricular hemorrhage is a notable complication in the premature neonatal population. Physicians should be aware of its potential association with hyponatremia and consider early neurosurgical intervention when other etiologies of the electrolyte disturbance cannot be identified.
C1 [Obi, Megan] Case Western Reserve Sch Med, Cleveland, OH USA.
   [Onwuzulike, Kaine] Cleveland Clin Fdn, Dept Pediat Neurosurg, 9500 Euclid Ave, Cleveland, OH 44195 USA.
RP Onwuzulike, K (reprint author), Cleveland Clin Fdn, Dept Pediat Neurosurg, 9500 Euclid Ave, Cleveland, OH 44195 USA.
EM k.onwuzulike@gmail.com
CR Ahn SY, 2015, J KOREAN MED SCI, V30, pS52, DOI 10.3346/jkms.2015.30.S1.S52
   BRUNSVIG P F, 1990, Tidsskrift for den Norske Laegeforening, V110, P2367
   Caglar MK, 2006, NEUROL INDIA, V54, P109, DOI 10.4103/0028-3886.25145
   Chou CY, 2009, INT J CLIN PRACT, V63, P457, DOI 10.1111/j.1742-1241.2008.01925.x
   Garcia Segura A, 1994, An Med Interna, V11, P487
   Goldberg A, 2006, ARCH INTERN MED, V166, P781, DOI 10.1001/archinte.166.7.781
   Greenberg JH, 2015, AM J KIDNEY DIS, V65, P513, DOI 10.1053/j.ajkd.2014.10.024
   Jung KH, 2003, NEUROLOGY, V61, P554, DOI 10.1212/01.WNL.0000078196.83215.4D
   Kim JH, 2006, EUR NEUROL, V55, P39, DOI 10.1159/000091425
   Lang SS, 2012, J NEUROSURG-PEDIATR, V10, P39, DOI 10.3171/2012.4.PEDS1222
   MACMAHON P, 1983, ARCH DIS CHILD, V58, P385, DOI 10.1136/adc.58.5.385
   Marcialis MA, 2011, J MATERN-FETAL NEO M, V24, P75, DOI 10.3109/14767058.2011.607667
   Nagumo K, 1992, Rinsho Shinkeigaku, V32, P177
   PAPILE LA, 1978, J PEDIATR-US, V92, P529, DOI 10.1016/S0022-3476(78)80282-0
   PETERSON DT, 1975, ANN INTERN MED, V83, P675, DOI 10.7326/0003-4819-83-5-675_2
   Rafael Valdivia Lourdes, 2007, Rev. gastroenterol. Perú, V27, P37
   Reyes Dominguez A, 1996, An Med Interna, V13, P616
   Robinson S, 2012, J NEUROSURG-PEDIATR, V9, P242, DOI 10.3171/2011.12.PEDS11136
   Tamaoka A, 1986, Rinsho Shinkeigaku, V26, P1146
   Tenbrock K, 2003, ARCH DIS CHILD-FETAL, V88, P351
   Tully HM, 2014, EUR J MED GENET, V57, P359, DOI 10.1016/j.ejmg.2014.06.002
   Vaicys C, 2000, MINIM INVAS NEUROSUR, V43, P190, DOI 10.1055/s-2000-11371
   WISE BL, 1968, J NEUROSURG, V28, P429, DOI 10.3171/jns.1968.28.5.0429
   Yoshino M, 1999, INTERNAL MED, V38, P290, DOI 10.2169/internalmedicine.38.290
   Zieg J, 2014, ACTA PAEDIATR, V103, P1027, DOI 10.1111/apa.12705
NR 25
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP 19
EP 22
DI 10.1016/j.wneu.2019.01.124
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700160
PM 30716495
DA 2020-05-12
ER

PT J
AU Baro, V
   Landi, A
   Brigadoi, S
   Castellaro, M
   Moretto, M
   Anglani, M
   Ermani, M
   Causin, F
   Zanoletti, E
   Denaro, L
   Bertoldo, A
   d'Avella, D
AF Baro, Valentina
   Landi, Andrea
   Brigadoi, Sabrina
   Castellaro, Marco
   Moretto, Manuela
   Anglani, Mariagiulia
   Ermani, Mario
   Causin, Francesco
   Zanoletti, Elisabetta
   Denaro, Luca
   Bertoldo, Alessandra
   d'Avella, Domenico
TI Preoperative Prediction of Facial Nerve in Patients with Vestibular
   Schwannomas: The Role of Diffusion Tensor Imaging-A Systematic Review
SO WORLD NEUROSURGERY
LA English
DT Review
DE Diffusion tensor imaging; Facial nerve; Fiber tracking; Vestibular
   schwannoma
ID HEARING PRESERVATION SURGERY; EVIDENCE-BASED GUIDELINES;
   CARPAL-TUNNEL-SYNDROME; CRANIAL NERVES; RETROSIGMOID APPROACH; ACOUSTIC
   NEUROMAS; TRACTOGRAPHY; IDENTIFICATION; LOCATION; VISUALIZATION
AB In vestibular schwannoma surgery, the preservation of facial and cochlear nerves is of paramount concern regarding to their effect on patients' quality of life. The rate of nerve function preservation has increased with advancements in surgical technique and neuroimaging and the introduction of intraoperative neuromonitoring. The preoperative depiction of anatomical issues between the nerves and tumor could help in surgical planning. Many studies investigating advanced imaging for cranial nerves detection, in particular diffusion tensor imaging, have been reported in the past decade. A systematic review of the reported data evaluating preoperative facial nerve fiber tracking, followed by intraoperative verification, was conducted. Seventeen studies with 223 patients (mean age, 47.5 years; range 17-77; male/female ratio 1:1.4) met our inclusion criteria. Preoperative facial nerve fiber tracking was obtained for 214 patients (96%), and subsequent intraoperative verification revealed a correct prediction for 187 cases (85.5%). The results from the present review have confirmed that preoperative fiber tracking for facial nerve identification during large vestibular schwannoma surgery is valuable and reliable. However, the included studies were not comparable in terms of images, acquisitions, or postprocessing elaboration. Larger series and homogenous magnetic resonance imaging parameters are required to strengthen these findings.
C1 [Baro, Valentina; Landi, Andrea; Denaro, Luca; d'Avella, Domenico] Univ Padua, Sch Med, Dept Neurosci, Acad Neurosurg, Padua, Italy.
   [Anglani, Mariagiulia; Causin, Francesco] Univ Padua, Sch Med, Neuroradiol Unit, Padua, Italy.
   [Ermani, Mario] Univ Padua, Sch Med, Dept Neurosci, Padua, Italy.
   [Zanoletti, Elisabetta] Univ Padua, Sch Med, Dept Neurosci, Otolaryngol Unit, Padua, Italy.
   [Brigadoi, Sabrina] Univ Padua, Dept Dev Psychol, Padua, Italy.
   [Castellaro, Marco; Moretto, Manuela; Bertoldo, Alessandra] Univ Padua, Padua Neurosci Ctr, Padua, Italy.
   [Castellaro, Marco; Moretto, Manuela; Bertoldo, Alessandra] Univ Padua, Dept Informat Engn, Padua, Italy.
RP Baro, V (reprint author), Univ Padua, Sch Med, Dept Neurosci, Acad Neurosurg, Padua, Italy.
EM valentina.baro@unipd.it
RI Castellaro, Marco/AAE-2937-2019; Landi, Andrea/AAF-9826-2020; Moretto,
   Manuela/AAE-2949-2019
OI Castellaro, Marco/0000-0002-1203-2670; Moretto,
   Manuela/0000-0003-4178-1854; Landi, Andrea/0000-0002-7185-7779; Anglani,
   Mariagiulia/0000-0002-3989-4553; Brigadoi, Sabrina/0000-0003-3032-7381;
   BARO, VALENTINA/0000-0002-5642-4289
CR Bhimrao SK, 2016, OTOL NEUROTOL, V37, P1162, DOI 10.1097/MAO.0000000000001137
   Borkar SA, 2016, NEUROL INDIA, V64, P965, DOI 10.4103/0028-3886.190270
   Charpiot A, 2010, ACTA OTO-LARYNGOL, V130, P1249, DOI 10.3109/00016481003762316
   Chen DQ, 2011, NEUROSURGERY, V68, P1077, DOI 10.1227/NEU.0b013e31820c6cbe
   Chiou SY, 2017, NEURORADIOLOGY, V59, P893, DOI 10.1007/s00234-017-1869-0
   Choi KS, 2014, J KOREAN NEUROSURG S, V56, P11, DOI 10.3340/jkns.2014.56.1.11
   Dandinarasaiah M, 2019, OTOL NEUROTOL, V40, P226, DOI 10.1097/MAO.0000000000002068
   Dunn IF, 2018, NEUROSURGERY, V82, pE32, DOI 10.1093/neuros/nyx510
   Falcioni M, 2011, J NEUROSURG, V115, P820, DOI 10.3171/2011.5.JNS101597
   Fukuda M, 2008, J NEUROL NEUROSUR PS, V79, P1066, DOI 10.1136/jnnp.2007.130500
   Gerganov VM, 2011, J NEUROSURG, V115, P1087, DOI 10.3171/2011.7.JNS11495
   Hilly O, 2016, OTOL NEUROTOL, V37, P388, DOI 10.1097/MAO.0000000000000984
   Hiltunen J, 2005, CLIN NEUROPHYSIOL, V116, P2315, DOI 10.1016/j.clinph.2005.05.014
   Jones DK, 2013, NEUROIMAGE, V73, P239, DOI 10.1016/j.neuroimage.2012.06.081
   Khalil C, 2008, EUR RADIOL, V18, P2283, DOI 10.1007/s00330-008-0971-4
   Koerbel A, 2005, NEUROSURG FOCUS, V18, P310
   Koos WT, 1998, J NEUROSURG, V88, P506, DOI 10.3171/jns.1998.88.3.0506
   Li H, 2017, WORLD NEUROSURG, V107, P669, DOI 10.1016/j.wneu.2017.08.048
   Mazzoni A, 2011, ACTA OTORHINOLARYNGO, V31, P76
   Mazzoni A, 2018, OPER NEUROSURG, V14, P36, DOI 10.1093/ons/opx091
   Mikami T, 2005, NEUROSURG REV, V28, P261, DOI 10.1007/s10143-005-0394-5
   Roundy N, 2012, J NEUROSURG, V116, P697, DOI 10.3171/2011.12.JNS111404
   Samii M, 1997, NEUROSURGERY, V40, P684, DOI 10.1097/00006123-199704000-00006
   Samii M, 2013, SURG CEREBELLOPONTIN, P147
   Samii M, 2006, J NEUROSURG, V105, P527, DOI 10.3171/jns.2006.105.4.527
   Samii M, 2010, J NEUROSURG, V112, P860, DOI 10.3171/2009.7.JNS0989
   Sampath P, 2000, J NEUROSURG, V92, P70, DOI 10.3171/jns.2000.92.1.0070
   Sartoretti-Schefer S, 2000, AM J NEURORADIOL, V21, P810
   Satyarthee GD, 2017, WORLD NEUROSURG, V105, P1002, DOI 10.1016/j.wneu.2017.04.039
   Shigematsu Y, 1999, J COMPUT ASSIST TOMO, V23, P224, DOI 10.1097/00004728-199903000-00010
   Skorpil M, 2004, MAGN RESON IMAGING, V22, P743, DOI 10.1016/j.mri.2004.01.073
   Song F, 2016, J NEUROSURG, V125, P787, DOI 10.3171/2015.7.JNS142922
   Springborg JB, 2012, J NEUROL SURG PART B, V73, P168, DOI 10.1055/s-0032-1301403
   Stangerup SE, 2012, OTOLARYNG CLIN N AM, V45, P257, DOI 10.1016/j.otc.2011.12.008
   Taoka T, 2006, J MAGN RESON IMAGING, V24, P1005, DOI 10.1002/jmri.20725
   Ung N, 2016, J NEUROL SURG PART B, V77, P314, DOI 10.1055/s-0035-1566303
   Vivas EX, 2018, NEUROSURGERY, V82, pE44, DOI 10.1093/neuros/nyx513
   Wang CK, 2012, EUR J RADIOL, V81, P3378, DOI 10.1016/j.ejrad.2012.01.008
   Wei PH, 2015, ACTA NEUROCHIR, V157, P1239, DOI 10.1007/s00701-015-2431-7
   Yoshino M, 2015, J NEUROSURG, V123, P1480, DOI 10.3171/2014.11.JNS14988
   Yoshino M, 2015, ACTA NEUROCHIR, V157, P939, DOI 10.1007/s00701-015-2411-y
   Youssef AS, 2009, NEUROSURG FOCUS, V27, DOI 10.3171/2009.8.FOCUS09144
   Zhang YY, 2017, WORLD NEUROSURG, V99, P70, DOI 10.1016/j.wneu.2016.11.110
   Zhang YH, 2013, ACTA NEUROCHIR, V155, P1857, DOI 10.1007/s00701-013-1815-9
   Zolal A, 2017, WORLD NEUROSURG, V107, P47, DOI [10.1016/J.WNEU.2017.07.102, 10.1016/j.wneu.2017.07.102]
NR 45
TC 3
Z9 3
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP 24
EP 31
DI 10.1016/j.wneu.2019.01.099
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700161
PM 30708084
DA 2020-05-12
ER

PT J
AU Lyne, SB
   Polster, SP
   Fidai, S
   Pytel, P
   Yamini, B
AF Lyne, Sean B.
   Polster, Sean P.
   Fidai, Shiraz
   Pytel, Peter
   Yamini, Bakhtiar
TI Primary Sellar Paraganglioma: Case Report with Literature Review and
   Immunohistochemistry Resource
SO WORLD NEUROSURGERY
LA English
DT Review
DE Chromaffin; Glomus cell; Paraganglioma; Pathology; Pituitary adenoma;
   Sella
ID INTRASELLAR PARAGANGLIOMA; SUPRASELLAR PARAGANGLIOMA; HEAD;
   PHEOCHROMOCYTOMA; DIAGNOSIS; NECK
AB BACKGROUND: Differential diagnosis of sellar masses includes adenoma, meningioma, craniopharyngioma, and metastasis. Primary paraganglioma is seldom considered. We present a case of this unique pathology, review the relevant literature, and compile a compendium of immunohistochemical characteristics for use as a resource.
   CASE DESCRIPTION: A 73-year-old woman presented to the hospital with visual changes in her left hemifield. Noncontrast head computed tomography demonstrated a large sellar mass with suprasellar extension and displacement of the optic chiasm (diameter of 3.1 cm). Magnetic resonance imaging was unobtainable owing to an incompatible pacemaker. Computed tomography characterization was most consistent with a macroadenoma. Given the acute visual decline, surgical decompression via an endonasal transsphenoidal route was performed without complication. A diagnosis of paraganglioma was made based on histopathology. Following resection, the patient's visual field deficit improved. Computed tomography body imaging was negative for a metastatic origin.
   CONCLUSIONS: Paraganglioma is a rare but potential differential diagnosis to consider when evaluating sellar masses.
C1 [Lyne, Sean B.; Polster, Sean P.; Yamini, Bakhtiar] Univ Chicago Med & Biol Sci, Neurosurg Sect, Chicago, IL 60637 USA.
   [Fidai, Shiraz; Pytel, Peter] Univ Chicago Med & Biol Sci, Dept Pathol, Chicago, IL USA.
RP Yamini, B (reprint author), Univ Chicago Med & Biol Sci, Neurosurg Sect, Chicago, IL 60637 USA.
EM byamini@surgery.bsd.uchicago.edu
OI Polster, Sean/0000-0002-3229-5021
CR Albert A, 2011, CLIN NEUROL NEUROSUR, V113, P675, DOI 10.1016/j.clineuro.2011.04.002
   Baysal BE, 2002, J MED GENET, V39, P617, DOI 10.1136/jmg.39.9.617
   BILBAO JM, 1978, ARCH PATHOL LAB MED, V102, P95
   Boari N, 2006, ACTA NEUROCHIR, V148, P1311, DOI 10.1007/s00701-006-0895-1
   Boedeker CC, 2005, FAM CANCER, V4, P55, DOI 10.1007/s10689-004-2154-z
   Brink I, 2005, FAM CANCER, V4, P61, DOI 10.1007/s10689-004-2155-y
   Chaudhry NS, 2013, J CLIN NEUROSCI, V20, P1615, DOI 10.1016/j.jocn.2013.02.004
   Citow JS, 2011, NEUROSURGERY ORAL BO
   Colen TY, 2009, SKULL BASE-INTERD AP, V19, P377, DOI 10.1055/s-0029-1224771
   De Caro MLD, 1998, TUMORI J, V84, P408, DOI 10.1177/030089169808400319
   do Nascimento A, 2012, BRAIN PATHOL, V22, P869, DOI 10.1111/j.1750-3639.2012.00640.x
   FLINT EW, 1993, AM J NEURORADIOL, V14, P1191
   Gittleman H, 2014, J NEUROSURG, V121, P527, DOI 10.3171/2014.5.JNS131819
   Karlekar M, 2018, CLIN NUCL MED, V43, P591, DOI 10.1097/RLU.0000000000002157
   Kleinschmidt-DeMasters BK, 2015, ARCH PATHOL LAB MED, V139, P356, DOI 10.5858/arpa.2014-0020-OA
   Lee JH, 2002, CANCER, V94, P730, DOI 10.1002/cncr.10252
   Malec K, 2017, J CRANIO MAXILL SURG, V45, P127, DOI 10.1016/j.jcms.2016.10.003
   Mokry M, 1998, NEURORADIOLOGY, V40, P233, DOI 10.1007/s002340050573
   Naggara O, 2005, NEURORADIOLOGY, V47, P753, DOI 10.1007/s00234-005-1422-4
   Naik SM, 2013, INDIA J SURG ONCOL, V4, P305, DOI 10.1007/s13193-013-0249-4
   Ozum U, 2008, NEUROPATHOLOGY, V28, P547, DOI 10.1111/j.1440-1789.2008.00885.x
   Salame K, 2001, J NEURO-ONCOL, V54, P49, DOI 10.1023/A:1012535230135
   Sambaziotis D, 1999, ARCH PATHOL LAB MED, V123, P429
   Scheithauer BW, 1996, NEUROSURGERY, V38, P395, DOI 10.1097/00006123-199602000-00034
   Sinha S, 2008, J CLIN NEUROSCI, V15, P937, DOI 10.1016/j.jocn.2007.03.029
   Tischler AS, 2015, ENDOCR-RELAT CANCER, V22, pT123, DOI 10.1530/ERC-15-0261
   Voulgaris SG, 2006, CLIN NEUROPATHOL, V25, P221
   Wieneke JA, 2009, HEAD NECK PATHOL, V3, P303, DOI 10.1007/s12105-009-0130-5
   Yokoo H, 2003, CLIN NEUROPATHOL, V22, P222
   Zorlu F, 2005, J NEURO-ONCOL, V73, P265, DOI 10.1007/s11060-004-5673-4
NR 30
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP 32
EP 36
DI 10.1016/j.wneu.2019.01.094
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700162
PM 30703592
DA 2020-05-12
ER

PT J
AU Muram, S
   Yavin, D
   DuPlessis, S
AF Muram, Sandeep
   Yavin, Daniel
   DuPlessis, Stephan
TI Intrathecal Saline Infusion as an Effective Temporizing Measure in the
   Management of Spontaneous Intracranial Hypotension
SO WORLD NEUROSURGERY
LA English
DT Article
DE Intrathecal infusion; Spontaneous intracranial hypotension
AB BACKGROUND: Spontaneous intracranial hypotension (SIH) is a rare condition for which no optimal treatment guidelines have been determined. The most common presentation is orthostatic headaches, but patients can present with a variety of symptoms.
   CASE DESCRIPTION: We present a case of a 34-year-old man who developed progressive orthostatic headaches and bilateral subdural collections. His symptoms along with imaging of his brain and spine were consistent with SIH. Unfortunately, his symptoms continued to progress, and his level of consciousness became affected. The patient did not respond to either conservative management or epidural blood patching. As the result of his worsening condition, a lumbar drain was inserted for the intrathecal infusion of normal saline to prevent tonsillar herniation. Once the infusion was started, his level of consciousness improved. It was discovered that his cerebrospinal fluid leak was due to an osteophyte within his thoracic spine, which was eroding the dura. He underwent a costo-transversectomy with the removal of the osteophyte and repair of the dural defect. The patient had some improvement after this procedure, but he remained more somnolent than expected. On subsequent imaging, it was found that his subdural collections had increased slightly in size and it was decided to drain them. Both collections were released under high pressure, and he went on to make an excellent recovery.
   CONCLUSIONS: This case demonstrates that an intrathecal saline infusion can be used as an effective temporizing measure in patients with critical symptoms of SIH and it also alerts clinicians that low-pressure subdural collections can progress to subdural collections under high pressure.
C1 [Muram, Sandeep; Yavin, Daniel; DuPlessis, Stephan] Univ Calgary, Dept Neurosurg, Calgary, AB, Canada.
RP Muram, S (reprint author), Univ Calgary, Dept Neurosurg, Calgary, AB, Canada.
EM sandeep.muram@ucalgary.ca
CR Akkawi N, 2006, NEUROL SCI, V27, P63, DOI 10.1007/s10072-006-0566-2
   Beck J, 2019, NEUROSURGERY, V84, pE345, DOI 10.1093/neuros/nyy312
   Binder DK, 2002, NEUROSURGERY, V51, P830, DOI 10.1227/01.NEU.0000024286.95876.2F
   Davidson B, 2017, WORLD NEUROSURG, V101, P343, DOI 10.1016/j.wneu.2017.01.123
   Kim BW, 2011, J KOREAN NEUROSURG S, V50, P274, DOI 10.3340/jkns.2011.50.3.274
   Kranz PG, 2017, CURR PAIN HEADACHE R, V21, DOI 10.1007/s11916-017-0639-3
   Lasboo AA, 2008, AM J NEURORADIOL, V29, P1627, DOI 10.3174/ajnr.A1157
   Low JCM, 2017, WORLD NEUROSURG, V105, DOI 10.1016/j.wneu.2017.06.060
   Mokri Bahram, 2015, Continuum (Minneap Minn), V21, P1086, DOI 10.1212/CON.0000000000000193
   Mokri B, 2013, HEADACHE, V53, P1034, DOI 10.1111/head.12149
   O'Brien M, 2012, IRISH J MED SCI, V181, P171, DOI 10.1007/s11845-011-0766-5
   Pattichis A, 2016, J CLIN NEUROSCI, V34, P39, DOI 10.1016/j.jocn.2016.07.002
   Pleasure SJ, 1998, NEUROLOGY, V50, P1854, DOI 10.1212/WNL.50.6.1854
   Rouaud T, 2009, REV NEUROL-FRANCE, V165, P201, DOI 10.1016/j.neurol.2008.05.006
   Sartip K, 2016, CLIN NEUROL NEUROSUR, V143, P95, DOI 10.1016/j.clineuro.2016.02.017
   Sass C, 2013, NEUROCRIT CARE, V19, P116, DOI 10.1007/s12028-012-9783-0
   Schievink WI, 2016, J NEUROSURG-SPINE, V24, P960, DOI 10.3171/2015.10.SPINE15855
   Smith KA, 2016, J CLIN NEUROSCI, V25, P10, DOI 10.1016/j.jocn.2015.07.009
   Stephen Christopher D, 2016, Pract Neurol, V16, P146, DOI 10.1136/practneurol-2015-001231
   Witiw CD, 2012, EUR SPINE J, V4, P422
NR 20
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP 37
EP 41
DI 10.1016/j.wneu.2019.01.127
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700163
PM 30716492
DA 2020-05-12
ER

PT J
AU OuYang, M
   Huang, XF
   Wang, Y
AF OuYang, Mang
   Huang, Xiaofei
   Wang, Yang
TI Endovascular Treatment of Infectious Pseudoaneurysm of Internal Carotid
   Artery
SO WORLD NEUROSURGERY
LA English
DT Article
DE Digital subtraction angiography; Intracranial infectious aneurysm
ID ANEURYSM
AB BACKGROUND: Infectious pseudoaneurysm of the intracavernous carotid artery is rare, often caused by sphenoid sinusitis or transsphenoidal surgery. Management of intracranial infectious aneurysms (IIAs) remains a controversial topic lacking randomized controlled trials to guide clinical decision making.
   CASE DESCRIPTION: For this case, we used an antibiotic to treat the patient in the initial stage. Because IIAs enlarge rapidly, endovascular treatment was performed in the emergency department.
   CONCLUSIONS: Unfortunately, the patient died because the IIA recurred and ruptured. Therefore we speculated that stent-assisted coil placement for the treatment of ruptured infectious pseudoaneurysms of the internal carotid artery may not be safe.
C1 [OuYang, Mang; Huang, Xiaofei] Nanchang Univ, Coll Med, Dept Neurosurg, Nanchang, Jiangxi, Peoples R China.
   [OuYang, Mang; Huang, Xiaofei; Wang, Yang] Nanchang Univ, Affiliated Hosp 1, Nanchang, Jiangxi, Peoples R China.
RP Wang, Y (reprint author), Nanchang Univ, Affiliated Hosp 1, Nanchang, Jiangxi, Peoples R China.
EM 13970966877@163.com
OI OuYang, Mang/0000-0002-3208-5171
CR Cho YD, 2012, NEURORADIOLOGY, V54, P719, DOI 10.1007/s00234-011-0950-3
   Dusart A, 2013, ACTA NEUROL BELG, V113, P179, DOI 10.1007/s13760-012-0151-9
   MOLINARI GF, 1973, NEUROLOGY, V23, P325, DOI 10.1212/WNL.23.4.325
   Sugie M, 2009, J NEUROL SCI, V278, P115, DOI 10.1016/j.jns.2008.11.017
NR 4
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP 42
EP 43
DI 10.1016/j.wneu.2019.01.147
PG 2
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700164
PM 30731201
DA 2020-05-12
ER

PT J
AU Akeret, K
   Germans, M
   Sun, WH
   Kulcsar, Z
   Regli, L
AF Akeret, Kevin
   Germans, Menno
   Sun, Wenhua
   Kulcsar, Zsolt
   Regli, Luca
TI Subarachnoid Hemorrhage Due to Flow-Related Dissection of the
   Posterior-Inferior Cerebellar Artery Associated with a Distal
   Arteriovenous Malformation
SO WORLD NEUROSURGERY
LA English
DT Article
DE Brain arteriovenous malformation; Cerebral arteriovenous malformation;
   Dissection; Hemodynamics; Hyperdynamic flow; Intraventricular
   hemorrhage; Rheodynamics; Subarachnoid hemorrhage
ID ANEURYSMS
AB BACKGROUND: Cerebral arteriovenous malformations (CAVMs) are characterized by altered hemodynamics and associated with angioanatomic changes, such as aneurysms. We encountered a patient with a CAVM-associated dissection of the medial trunk of the posterior inferior cerebellar artery (PICA) instead of an aneurysm.
   CASE DESCRIPTION: We report the case of a 56-year-old male patient with spontaneous subarachnoid hemorrhage within the cisterna magna and fourth ventricle. Digital subtraction angiography revealed a cerebellar arteriovenous malformation located within the inferior semilunar lobule that did not anatomically match the bleeding pattern. The left PICA, serving as a primary feeding artery, showed a dissection of the proximal portion of the medial trunk with a precise anatomic association with the blood in the telovelotonsillar space. CAVM-induced hyperdynamic flow through the feeding vessel is the most plausible pathophysiologic explanation for the dissection. Complete microsurgical resection of the CAVM was performed, and 3-month follow-up digital subtraction angiography showed complete regression of the dissection, disappearance of irregularities, and significant caliber reduction of the medial PICA trunk.
   CONCLUSIONS: This is the first report of a hyperdynamic flow-related dissection of a CAVM-associated feeding vessel. Microsurgical resection of the CAVM allowed for spontaneous resolution of the dissected area by restoration of normal rheodynamics.
C1 [Akeret, Kevin; Germans, Menno; Sun, Wenhua; Regli, Luca] Univ Zurich, Univ Zurich Hosp, Dept Neurosurg, Zurich, Switzerland.
   [Akeret, Kevin; Germans, Menno; Sun, Wenhua; Kulcsar, Zsolt; Regli, Luca] Univ Zurich, Univ Zurich Hosp, Clin Neurosci Ctr, Zurich, Switzerland.
   [Kulcsar, Zsolt] Univ Zurich, Univ Zurich Hosp, Dept Neuroradiol, Zurich, Switzerland.
RP Akeret, K (reprint author), Univ Zurich, Univ Zurich Hosp, Dept Neurosurg, Zurich, Switzerland.; Akeret, K (reprint author), Univ Zurich, Univ Zurich Hosp, Clin Neurosci Ctr, Zurich, Switzerland.
EM kevin.akeret@gmx.ch
RI Germans, Menno/AAI-8211-2020
OI Kulcsar, Zsolt/0000-0002-6805-5150
CR AZZAM CJ, 1987, NEUROSURGERY, V21, P934, DOI 10.1227/00006123-198712000-00028
   Cordonnier C, 2008, J NEUROL NEUROSUR PS, V79, P47, DOI 10.1136/jnnp.2006.113753
   DOLENC V, 1978, J NEUROSURG, V49, P272, DOI 10.3171/jns.1978.49.2.0272
   DOLENC V, 1982, NEUROSURGERY, V11, P690, DOI 10.1227/00006123-198211000-00014
   Gross BA, 2013, CLIN NEUROL NEUROSUR, V115, P713, DOI 10.1016/j.clineuro.2012.08.008
   HODOZUKA A, 1991, Neurologia Medico-Chirurgica, V31, P966, DOI 10.2176/nmc.31.966
   Kim H, 2008, ACTA NEUROCHIR SUPPL, V105, P199
   KONDZIOLKA D, 1988, CAN J NEUROL SCI, V15, P130, DOI 10.1017/S0317167100027487
   LASJAUNIAS P, 1988, ACTA NEUROCHIR, V91, P29, DOI 10.1007/BF01400524
   Lawton MT, 2015, NAT REV DIS PRIMERS, V1, DOI 10.1038/nrdp.2015.8
   Lawton MT, 2010, NEUROSURGERY, V66, P702, DOI 10.1227/01.NEU.0000367555.16733.E1
   PATERSON JH, 1956, BRAIN, V79, P233, DOI 10.1093/brain/79.2.233
   SPETZLER RF, 1986, J NEUROSURG, V65, P476, DOI 10.3171/jns.1986.65.4.0476
   Thompson RC, 1998, NEUROSURGERY, V43, P202, DOI 10.1097/00006123-199808000-00006
   Westphal M, 2000, J NEUROSURG, V92, P995, DOI 10.3171/jns.2000.92.6.0995
   1998, NEUROSURGERY, V43, P202
NR 16
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP 44
EP 48
DI 10.1016/j.wneu.2019.01.148
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700165
PM 30721771
DA 2020-05-12
ER

PT J
AU Nakamizo, A
   Matsuo, S
   Amano, T
AF Nakamizo, Akira
   Matsuo, Satoshi
   Amano, Toshiyuki
TI Abducens Nerve Schwannoma: A Case Report and Literature Review
SO WORLD NEUROSURGERY
LA English
DT Review
DE 6th Cranial nerve; Abducens nerve; Neurinoma; Schwannoma
ID 6TH CRANIAL NERVES; CAVERNOUS SINUS; OCULOMOTOR NERVES; NEURINOMA;
   NEUROMA; 3RD
AB BACKGROUND: Abducens nerve function seldom shows complete recovery after removal of abducens nerve schwannoma. No cases with unclear course of the abducens nerve during surgery have been reported to achieve complete recovery of nerve function.
   CASE DESCRIPTION: We report the case of a 44-year-old woman who presented with occasional dysgeusia without abducens nerve paresis. Magnetic resonance imaging showed a solid tumor about 2 cm in diameter at the left cerebellopontine cistern. Cranial nerves except the abducens nerve appeared intact. The tumor was removed via suboccipital craniotomy. The abducens nerve was totally invisible on the surface of the tumor throughout the procedure. Only short segments of abducens nerve were identifiable at around Dorello's canal and the root exit zone. The tumor was resected by subcapsular dissection, and part of the tumor capsule was preserved as a scaffold for nerve generation, although whether any abducens nerve was included remained uncertain. Histopathologic examination confirmed World Health Organization grade I schwannoma. Postoperatively, the patient presented with complete left abducens nerve paresis and diplopia, but abducens nerve function began to improve 3 months later and had completely recovered within 16 months after surgery.
   CONCLUSIONS: This represents the first description of abducens nerve schwannoma in which the course of the abducens nerve was intraoperatively unclear but complete recovery was achieved. In such cases, intentional subcapsular dissection may potentiate functional recovery.
C1 [Nakamizo, Akira; Matsuo, Satoshi; Amano, Toshiyuki] Natl Hosp Org, Kyushu Med Ctr, Clin Res Inst, Dept Neurosurg, Fukuoka, Fukuoka, Japan.
RP Nakamizo, A (reprint author), Natl Hosp Org, Kyushu Med Ctr, Clin Res Inst, Dept Neurosurg, Fukuoka, Fukuoka, Japan.
EM nakamizo@ns.med.kyushu-u.ac.jp
RI Matsuo, Satoshi/AAE-3849-2020
OI Matsuo, Satoshi/0000-0002-2052-0471
CR Acharya R, 2003, NEUROL SCI, V24, P74, DOI 10.1007/s100720300076
   Beppu Takaaki, 1997, Neurologia Medico-Chirurgica, V37, P416, DOI 10.2176/nmc.37.416
   CELLI P, 1992, SURG NEUROL, V38, P216, DOI 10.1016/0090-3019(92)90172-J
   CHEN BH, 1981, NEUROSURGERY, V9, P64
   Chowdhury F, 2014, NEUROSURG QUART, V24, P40
   Erlich SA, 2009, CLIN NEUROL NEUROSUR, V111, P467, DOI 10.1016/j.clineuro.2009.01.001
   GINSBERG F, 1988, J COMPUT ASSIST TOMO, V12, P482, DOI 10.1097/00004728-198805010-00024
   HANSMAN ML, 1986, J COMPUT ASSIST TOMO, V10, P1030, DOI 10.1097/00004728-198611000-00026
   Ichimi Kazuyoshi, 1997, Neurologia Medico-Chirurgica, V37, P197, DOI 10.2176/nmc.37.197
   Kumar R, 2014, NEUROL INDIA, V62, P71, DOI [10.4103/0028-3886.128326, 10.4103/0028-3886.128355]
   Lanotte M, 1992, J Neurosurg Sci, V36, P233
   Lee SK, 2013, J KOREAN NEUROSURG S, V53, P374, DOI 10.3340/jkns.2013.53.6.374
   LEUNDA G, 1982, J NEUROSURG, V57, P563, DOI 10.3171/jns.1982.57.4.0563
   Li XJ, 2015, MASS SPECTROM LETT, V6, P1, DOI 10.5478/MSL.2015.6.1.1
   Mascarenhas L, 2004, ACTA NEUROCHIR, V146, P389, DOI 10.1007/s00701-003-0197-9
   Moses JE, 2011, NEUROL INDIA, V59, P471, DOI 10.4103/0028-3886.82743
   Nakagawa T, 2004, SURG NEUROL, V61, P559, DOI 10.1016/S0090-3019(03)00580-9
   Okada Y, 1997, NEUROSURGERY, V40, P608, DOI 10.1097/00006123-199703000-00035
   Park JH, 2009, NEUROSURG REV, V32, P375, DOI 10.1007/s10143-009-0203-7
   Sasaki T, 2002, J NEUROSURG, V97, P941, DOI 10.3171/jns.2002.97.4.0941
   SEKHAR LN, 1992, J NEUROSURG, V76, P935, DOI 10.3171/jns.1992.76.6.0935
   Shibao S, 2014, NEUROL MED-CHIR, V54, P331, DOI 10.2176/nmc.cr2012-0304
   Shono T, 2009, ACTA NEUROCHIR, V151, P733, DOI 10.1007/s00701-009-0312-7
   Suetake K, 1998, COMPUT MED IMAG GRAP, V22, P257, DOI 10.1016/S0895-6111(98)00023-8
   Sun H, 2017, WORLD NEUROSURG, V104, P883, DOI 10.1016/j.wneu.2017.04.146
   TUNG H, 1991, J NEUROSURG, V75, P638, DOI 10.3171/jns.1991.75.4.0638
   Vachata P, 2009, ACTA NEUROCHIR, V151, P1281, DOI 10.1007/s00701-009-0302-9
   Wang M, 2015, J CRANIOFAC SURG, V26, P589, DOI 10.1097/SCS.0000000000001520
   2001, J CLIN NEUROSCI, V8, P357
   2002, SURG NEUROL, V57, P183
NR 30
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAY
PY 2019
VL 125
BP 49
EP 54
DI 10.1016/j.wneu.2019.01.123
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HW2CX
UT WOS:000466491700166
PM 30716483
DA 2020-05-12
ER

EF